STUDYID|DOMAIN|USUBJID|RSSEQ|RSTESTCD|RSTEST|RSCAT|RSORRES|RSORRESU|RSSTRESC|RSSTRESN|RSSTRESU|RSMETHOD|RSLOBXFL|RSBLFL|RSDRVFL|RSEVAL|RSEVALID|RSACPTFL|VISITNUM|VISIT|VISITDY|TAETORD|EPOCH|RSDTC|RSDY|RSTPT|RSTPTNUM|RSELTM|RSTPTREF|RSRFTDTC|RSEVLINT|RSSTRTPT|RSSTTPT|RSENRTPT|RSENTPT
e|RS|35f5401f-575a-44dc-9141-8084716a5b70|1|NTERESP|Non-Target Enhancing Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|ug/kg|CA125 50% RESPONSE|1|cmH2O*s2/mL|RADIATION DOSIMETRY||||CLINICAL RESEARCH ASSOCIATE|INTERNIST|U|1|Visit_1|10|2|FOLLOW-UP|2020-10-20|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-21|P1Y2M10DT2H30M|BEFORE|2020-11-02|BEFORE|2020-12-11
e|RS|35f5401f-575a-44dc-9141-8084716a5b70|2|RDIORESP|Radiologic Response|MONTSERRAT CLL 1989|[?]|L/min/m2|ABSENT MORPHOLOGIC RESPONSE|1|10^9/dose|TOLUIDINE BLUE STAIN||Y||INVESTIGATOR|RATER|NA|1|Visit_1|10|3|TREATMENT|2020-10-20|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-21|P1Y2M10DT2H30M|BEFORE|2020-11-18|AFTER|2020-12-30
e|RS|35f5401f-575a-44dc-9141-8084716a5b70|3|MJPTHIND|Major Pathological Response Indicator|RECIST 1.0|[?]|PIXEL|CYTOGENETIC NO RESPONSE|1|APL U/mL|FARR ASSAY||Y||INVESTIGATOR|OPTOMETRIST|N|2|Visit_2|25|3|SCREENING|2020-11-04|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-16|P1Y2M10DT2H30M|BEFORE|2020-12-10|AFTER|2021-01-10
e|RS|35f5401f-575a-44dc-9141-8084716a5b70|4|MRDRESP|Minimal Residual Disease Response|BRUGGEMANN MRD 2010|||NED|1|PFU/animal|KARYOTYPING|||Y|CLINICAL RESEARCH ASSOCIATE|CLINICAL PATHOLOGIST|N|2|Visit_2|25|6|FOLLOW-UP|2020-11-04|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-16|P1Y2M10DT2H30M|BEFORE|2020-10-18|BEFORE|2021-01-14
e|RS|35f5401f-575a-44dc-9141-8084716a5b70|5|NEWLPROG|New Lesion Progression|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|||WORSENED|1|mEq/uL|ELISPOT|Y||Y|CLINICAL RESEARCH COORDINATOR|HEMATOLOGIST|N|3|Visit_3|40|5|SCREENING|2020-11-19|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-18|P1Y2M10DT2H30M|AFTER|2020-12-31|COINCIDENT|2021-01-04
e|RS|35f5401f-575a-44dc-9141-8084716a5b70|6|TRGRESP|Target Response|RECIST 1.1|[?]|10^3 copies/mL|MRD RELAPSE|1|mAmp|PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY|Y|||PARENT|NEUROLOGIST 2|NA|3|Visit_3|40|3|TREATMENT|2020-11-19|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-18|P1Y2M10DT2H30M|UNKNOWN|2020-12-12|BEFORE|2021-01-01
e|RS|35f5401f-575a-44dc-9141-8084716a5b70|7|NEWLPROG|New Lesion Progression|FAROOQUI SUPP CLL 2014|[?]|mL/min/mmHg|CYTOGENETIC MINIMAL RESPONSE|1|U/kg/day|SICKLE CELL SOLUBILITY TEST||||SPOUSE|MICROSCOPIST|NA|4|Visit_4|65|2|WASHOUT|2020-12-14|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-09|P1Y2M10DT2H30M|UNKNOWN|2020-12-30|AFTER|2021-01-09
e|RS|35f5401f-575a-44dc-9141-8084716a5b70|8|CLINRESP|Clinical Response|NCIWG CHESON CLL 1996|[?]|mL/kg/h|CYTOGENETIC CR|1|g/dL|PUPILLOMETRY||||SIBLING|PATHOLOGIST|U|4|Visit_4|65|7|TREATMENT|2020-12-14|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-09|P1Y2M10DT2H30M|UNKNOWN|2020-11-26|COINCIDENT|2021-01-16
e|RS|35f5401f-575a-44dc-9141-8084716a5b70|9|NEWLPROG|New Lesion Progression|HARTMAN PANCREATIC CANCER 2012|[?]|g/cage/day|UNFAVORABLE RESPONSE|1|mEq/mmol|PHOTOMETRY|Y|Y||HEALTH CARE PROFESSIONAL|ADJUDICATOR|N|5|Visit_5|90|6|TREATMENT|2021-01-08|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-14|P1Y2M10DT2H30M|UNKNOWN|2020-11-02|BEFORE|2020-11-10
e|RS|35f5401f-575a-44dc-9141-8084716a5b70|10|BONERESP|Bone Response|BRUGGEMANN MRD 2010|[?]|U/mL|PSEUDOPROGRESSION|1|mIU/L|IMMUNE REPERTOIRE DEEP SEQUENCING||Y||FAMILY MEMBER|PEDIATRIC NEUROLOGIST|NA|5|Visit_5|90|3|TREATMENT|2021-01-08|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-14|P1Y2M10DT2H30M|COINCIDENT|2021-01-03|COINCIDENT|2021-01-05
e|RS|8a863a88-67d8-4e50-bafa-c3146591f046|1|MOLRESP|Molecular Response|SCHWARZ CERVICAL CANCER 2009|[?]|DAYS|PSEUDOPROGRESSION|1|mCi/L|CT SCAN||||SPOUSE|READER 1|Y|1|Visit_1|10|7|TREATMENT|2020-12-29|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-18|P1Y2M10DT2H30M|UNKNOWN|2021-03-23|AFTER|2021-03-27
e|RS|8a863a88-67d8-4e50-bafa-c3146591f046|2|CYTORESP|Cytogenetic Response|EBMT BLADE MYELOMA 1998|[?]|mL/g/day|sCR|1|10^6/g|CALCOFLUOR WHITE STAIN||||SPOUSE|ADJUDICATOR 2|NA|1|Visit_1|10|1|TREATMENT|2020-12-29|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-18|P1Y2M10DT2H30M|UNKNOWN|2021-02-13|BEFORE|2021-02-14
e|RS|8a863a88-67d8-4e50-bafa-c3146591f046|3|MRDIND|Minimal Residual Disease Indicator|PALUMBO MULTIPLE MYELOMA 2009|||QUANTIFIABLE MRD POSITIVITY|1|PACK|DYNAMOMETRY|||Y|HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|N|2|Visit_2|25|7|TREATMENT|2021-01-13|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-09|P1Y2M10DT2H30M|UNKNOWN|2021-03-13|AFTER|2021-03-26
e|RS|8a863a88-67d8-4e50-bafa-c3146591f046|4|NTNERESP|Non-Target Non-Enhancing Response|DOHNER AML 2010|[?]|Antibody Unit|CYTOGENETIC PR|1|mmol/day|WESTERGREN||||HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|Y|2|Visit_2|25|6|WASHOUT|2021-01-13|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-09|P1Y2M10DT2H30M|AFTER|2021-02-07|ONGOING|2021-02-27
e|RS|8a863a88-67d8-4e50-bafa-c3146591f046|5|CLINRESP|Clinical Response|IWG CHESON AML 2003|[?]|mg/m2/h|TREATMENT FAILURE|1|ukat/10^12 RBC|SPECT/CT SCAN||||GUARDIAN|READER 2|U|3|Visit_3|40|4|TREATMENT|2021-01-28|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-15|P1Y2M10DT2H30M|UNKNOWN|2021-02-16|BEFORE|2021-03-14
e|RS|8a863a88-67d8-4e50-bafa-c3146591f046|6|SFTSRESP|Soft Tissue Response|DOHNER AML 2010|[?]|cmHg|sCR|1|GPS U|FLUORESCENT SPOT TEST||Y||HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|Y|3|Visit_3|40|2|WASHOUT|2021-01-28|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-15|P1Y2M10DT2H30M|BEFORE|2021-02-23|BEFORE|2021-03-23
e|RS|8a863a88-67d8-4e50-bafa-c3146591f046|7|MRDIND|Minimal Residual Disease Indicator|MRANO VAN DEN BENT GLIOMA 2011|[?]|U/kg/min|PSA PROGRESSION|1|cs|KINETIC MICROPARTICLE IMMUNOASSAY||||INTERVIEWER|DERMATOLOGIST|N|4|Visit_4|65|3|SCREENING|2021-02-22|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-29|P1Y2M10DT2H30M|AFTER|2021-01-07|COINCIDENT|2021-01-29
e|RS|8a863a88-67d8-4e50-bafa-c3146591f046|8|MJPTHIND|Major Pathological Response Indicator|UNSPECIFIED|[?]|CCID 50/mL|EQUIVOCAL|1|GPL U/mL|MICROBIAL CULTURE, LIQUID|Y|||NON-HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|NA|4|Visit_4|65|4|TREATMENT|2021-02-22|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-29|P1Y2M10DT2H30M|UNKNOWN|2021-03-08|BEFORE|2021-03-11
e|RS|8a863a88-67d8-4e50-bafa-c3146591f046|9|PATHRESP|Pathologic Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|Log10 ELISA unit|PMD|1|VIAL|PATHOLOGICAL EVALUATION||||NON-HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|NA|5|Visit_5|90|4|WASHOUT|2021-03-19|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-14|P1Y2M10DT2H30M|UNKNOWN|2021-02-25|BEFORE|2021-03-01
e|RS|8a863a88-67d8-4e50-bafa-c3146591f046|10|HEMARESP|Hematologic Response|GUPPY OVARIAN CANCER 2002|[?]|foz_us|QUANTIFIABLE MRD POSITIVITY|1|BOLUS|CHROMOGENIC ASSAY||||NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|U|5|Visit_5|90|3|TREATMENT|2021-03-19|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-14|P1Y2M10DT2H30M|COINCIDENT|2021-01-04|COINCIDENT|2021-03-11
e|RS|f8e8acef-d26d-40c0-9bf0-fe7ac24c9fea|1|CPRFSTAT|Clinical Performance Status|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|mmHg|cPR|1|mOsm/kg|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY|Y|Y||FRIEND|OPHTHALMOLOGIST|NA|1|Visit_1|10|4|WASHOUT|2020-08-03|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-20|P1Y2M10DT2H30M|COINCIDENT|2020-08-20|COINCIDENT|2020-10-08
e|RS|f8e8acef-d26d-40c0-9bf0-fe7ac24c9fea|2|MRPHRESP|Morphologic Response|NCCN ALL MRD 2014|[?]|10^3 CFU/mL|CYTOGENETIC PR|1|mJoule/cm2|TWO-COLOR MICROARRAY||||INVESTIGATOR|NEUROLOGIST 1|NA|1|Visit_1|10|7|TREATMENT|2020-08-03|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-20|P1Y2M10DT2H30M|UNKNOWN|2020-10-22|COINCIDENT|2020-10-31
e|RS|f8e8acef-d26d-40c0-9bf0-fe7ac24c9fea|3|CLINRESP|Clinical Response|IRANO 2015|||PD FROM PR|1|TROCHE|IMMUNOFLUORESCENT STAIN|||Y|GUARDIAN|RATER 1|U|2|Visit_2|25|7|WASHOUT|2020-08-18|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-30|P1Y2M10DT2H30M|UNKNOWN|2020-10-02|COINCIDENT|2020-10-18
e|RS|f8e8acef-d26d-40c0-9bf0-fe7ac24c9fea|4|NEWLPROG|New Lesion Progression|LEE LUNG CANCER 2011|[?]|10^12/L|PD/RELAPSE AFTER HI|1|Farad|ICP-MS||||FRIEND|NEUROLOGIST 1|NA|2|Visit_2|25|7|WASHOUT|2020-08-18|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-30|P1Y2M10DT2H30M|UNKNOWN|2020-10-21|COINCIDENT|2020-10-22
e|RS|f8e8acef-d26d-40c0-9bf0-fe7ac24c9fea|5|SFTSRESP|Soft Tissue Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|pmol/L|SMD|1|cmHg|CYSTOSCOPY||||ADJUDICATOR|MICROSCOPIST|NA|3|Visit_3|40|3|SCREENING|2020-09-02|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-29|P1Y2M10DT2H30M|BEFORE|2020-09-15|BEFORE|2020-10-29
e|RS|f8e8acef-d26d-40c0-9bf0-fe7ac24c9fea|6|METBRESP|Metabolic Response|RECICL|[?]|CAPFUL|NR|1|10^8 PFU|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|Y|||VENDOR|ADJUDICATOR|Y|3|Visit_3|40|3|SCREENING|2020-09-02|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-29|P1Y2M10DT2H30M|UNKNOWN|2020-10-22|ONGOING|2020-10-27
e|RS|f8e8acef-d26d-40c0-9bf0-fe7ac24c9fea|7|NTLWIND|Non-Target Lesion Worsening Indicator|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|/LPF|WORSENED|1|10^9 CFU|PHOTOMETRY||||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST|Y|4|Visit_4|65|5|TREATMENT|2020-09-27|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-31|P1Y2M10DT2H30M|BEFORE|2020-09-22|ONGOING|2020-09-30
e|RS|f8e8acef-d26d-40c0-9bf0-fe7ac24c9fea|8|HEMARESP|Hematologic Response|SCHER PROSTATE CANCER 2011|||MINOR PATHOLOGIC RESPONSE|1|C|TRANSMISSION ELECTRON MICROSCOPY|Y||Y|DOMESTIC PARTNER|MICROSCOPIST 1|NA|4|Visit_4|65|5|TREATMENT|2020-09-27|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-31|P1Y2M10DT2H30M|BEFORE|2020-09-21|AFTER|2020-10-23
e|RS|f8e8acef-d26d-40c0-9bf0-fe7ac24c9fea|9|BMIVLIND|Bone Marrow Involvement Indicator|CHOLLET BREAST CANCER 2002|||ABSENT MORPHOLOGIC RESPONSE|1|mL/cm|OPTICAL DENSITY MEASUREMENT|||Y|CLINICAL RESEARCH ASSOCIATE|PHYSIOTHERAPIST|U|5|Visit_5|90|7|TREATMENT|2020-10-22|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-08|P1Y2M10DT2H30M|AFTER|2020-10-14|AFTER|2020-10-25
e|RS|f8e8acef-d26d-40c0-9bf0-fe7ac24c9fea|10|MRPHRESP|Morphologic Response|SCHER PROSTATE CANCER 2011|[?]|dpm/0.5 mL|ABSENT MORPHOLOGIC RESPONSE|1|g/cm2|TRYPAN BLUE STAIN||Y||ADJUDICATOR|RADIOLOGIST 2|N|5|Visit_5|90|2|FOLLOW-UP|2020-10-22|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-08|P1Y2M10DT2H30M|COINCIDENT|2020-10-27|COINCIDENT|2020-10-29
e|RS|0558cb35-f542-4f9a-a7e7-18b1d71be69c|1|NTNERESP|Non-Target Non-Enhancing Response|CHOLLET BREAST CANCER 2002|[?]|umol/kg/min|PD|1|10^6 organisms/g|REVERSE TRANSCRIPTASE PCR||||STUDY SUBJECT|UROLOGIST|U|1|Visit_1|10|2|TREATMENT|2020-12-20|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-25|P1Y2M10DT2H30M|BEFORE|2020-12-16|BEFORE|2021-01-20
e|RS|0558cb35-f542-4f9a-a7e7-18b1d71be69c|2|CLINRESP|Clinical Response|BURCOMBE BREAST CANCER 2005|[?]|PELLET|MORPHOLOGIC LEUKEMIA-FREE STATE|1|um2|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY||||PROXY|ENDOCRINOLOGIST|N|1|Visit_1|10|1|TREATMENT|2020-12-20|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-25|P1Y2M10DT2H30M|COINCIDENT|2020-12-31|BEFORE|2021-01-02
e|RS|0558cb35-f542-4f9a-a7e7-18b1d71be69c|3|RDIORESP|Radiologic Response|NCIWG CHESON CLL 1996|[?]|min/day|HI-N|1|PIXELS/cm|OLIGO ACGH|Y|||SIBLING|FORENSIC PATHOLOGIST|U|2|Visit_2|25|1|FOLLOW-UP|2021-01-04|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-31|P1Y2M10DT2H30M|BEFORE|2021-02-11|AFTER|2021-03-02
e|RS|0558cb35-f542-4f9a-a7e7-18b1d71be69c|4|SFTSRESP|Soft Tissue Response|SCHWARZ CERVICAL CANCER 2009|||HI-E|1|log10 TCID 50/dose|INTERRUPTER TECHNIQUE|||Y|CAREGIVER|OPTOMETRIST|Y|2|Visit_2|25|3|TREATMENT|2021-01-04|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-31|P1Y2M10DT2H30M|AFTER|2021-03-16|ONGOING|2021-03-19
e|RS|0558cb35-f542-4f9a-a7e7-18b1d71be69c|5|PATHRESP|Pathologic Response|PERCIST|[?]|K|MOLECULAR CR|1|kg/cm|IMMUNOPRECIPITATION||||INDEPENDENT ASSESSOR|READER 3|Y|3|Visit_3|40|6|TREATMENT|2021-01-19|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-10|P1Y2M10DT2H30M|AFTER|2021-02-07|COINCIDENT|2021-02-27
e|RS|0558cb35-f542-4f9a-a7e7-18b1d71be69c|6|DRCRIND|Disease Recurrence Indicator|IRANO 2015|||NON-PD|1|APL U/mL|CISH|||Y|GUARDIAN|UROLOGIST|N|3|Visit_3|40|3|TREATMENT|2021-01-19|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-10|P1Y2M10DT2H30M|AFTER|2021-01-23|ONGOING|2021-02-03
e|RS|0558cb35-f542-4f9a-a7e7-18b1d71be69c|7|NEWLWIND|New Lesion Worsening Indicator|SHINDOH COLORECTAL CANCER 2013|[?]|APPLICATION|SD|1|10^6 CFU|IRON HEMATOXYLIN STAIN||||INDEPENDENT ASSESSOR|MICROSCOPIST|NA|4|Visit_4|65|4|TREATMENT|2021-02-13|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-22|P1Y2M10DT2H30M|AFTER|2021-01-01|BEFORE|2021-02-15
e|RS|0558cb35-f542-4f9a-a7e7-18b1d71be69c|8|BONERESP|Bone Response|EASL BRUIX LIVER CANCER 2001|[?]|DPM|SMD|1|Anson U|ORCHIDOMETERY||||CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 1|NA|4|Visit_4|65|3|TREATMENT|2021-02-13|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-22|P1Y2M10DT2H30M|BEFORE|2021-03-18|ONGOING|2021-03-19
e|RS|0558cb35-f542-4f9a-a7e7-18b1d71be69c|9|NEWLIND|New Lesion Indicator|HAMAOKA BREAST CANCER 2010|||PDu|1|g/g|NUCLEIC ACID SEQUENCING|||Y|INDEPENDENT ASSESSOR|INTERNIST|Y|5|Visit_5|90|1|WASHOUT|2021-03-10|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-22|P1Y2M10DT2H30M|AFTER|2021-01-08|BEFORE|2021-03-02
e|RS|0558cb35-f542-4f9a-a7e7-18b1d71be69c|10|NTLWIND|Non-Target Lesion Worsening Indicator|PCWG BUBLEY PROSTATE CANCER 1999|[?]|L/h|CYTOGENETIC NO RESPONSE|1|10^12 IU/L|PHASE-CONTRAST MRI|Y|Y||SIBLING|NEUROLOGIST 1|N|5|Visit_5|90|5|FOLLOW-UP|2021-03-10|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-22|P1Y2M10DT2H30M|UNKNOWN|2021-02-01|BEFORE|2021-03-10
e|RS|a9cf4d21-c2a8-4f32-b932-f05d2d317400|1|NTNERESP|Non-Target Non-Enhancing Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|usec|PR WITH LYMPHOCYTOSIS|1|log10 copies/mL|EPSILOMETER||||STUDY SUBJECT|RADIOLOGIST 2|NA|1|Visit_1|10|5|TREATMENT|2020-07-03|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-12|P1Y2M10DT2H30M|COINCIDENT|2020-07-27|COINCIDENT|2020-08-20
e|RS|a9cf4d21-c2a8-4f32-b932-f05d2d317400|2|BONERESP|Bone Response|MONTSERRAT CLL 1989|[?]|mL/animal|OPTIMAL MORPHOLOGIC RESPONSE|1|km/h|REAL-TIME POLYMERASE CHAIN REACTION ASSAY||Y||ADJUDICATOR|CARDIOLOGIST|NA|1|Visit_1|10|2|TREATMENT|2020-07-03|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-12|P1Y2M10DT2H30M|AFTER|2020-09-30|BEFORE|2020-10-01
e|RS|a9cf4d21-c2a8-4f32-b932-f05d2d317400|3|ANATRESP|Anatomic Response|AJCC V7|[?]|STEPS|FAVORABLE RESPONSE|1|mL/min/mmHg|HEMATOXYLIN AND EOSIN STAIN||||GUARDIAN|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|2|Visit_2|25|7|TREATMENT|2020-07-18|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-21|P1Y2M10DT2H30M|COINCIDENT|2020-06-29|BEFORE|2020-07-18
e|RS|a9cf4d21-c2a8-4f32-b932-f05d2d317400|4|SFTSRESP|Soft Tissue Response|KUKER LYMPHOMA 2005|[?]|GPL U/mL|TREATMENT FAILURE|1|DRUM|INDIA INK STAIN||Y||SPOUSE|ONCOLOGIST 1|NA|2|Visit_2|25|5|TREATMENT|2020-07-18|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-21|P1Y2M10DT2H30M|BEFORE|2020-06-25|ONGOING|2020-09-26
e|RS|a9cf4d21-c2a8-4f32-b932-f05d2d317400|5|METSIND|Metastatic Indicator|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|copies/ug|iCPD|1|Frames/s|MANUAL CLOT DETECTION||||ADJUDICATOR|OPTOMETRIST|NA|3|Visit_3|40|4|SCREENING|2020-08-02|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-21|P1Y2M10DT2H30M|UNKNOWN|2020-08-19|COINCIDENT|2020-09-07
e|RS|a9cf4d21-c2a8-4f32-b932-f05d2d317400|6|METSIND|Metastatic Indicator|RANO ELLINGSON 2017|||PD-CT|1|mL/g/min|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY||Y|Y|STUDY SUBJECT|DERMATOLOGIST|Y|3|Visit_3|40|7|TREATMENT|2020-08-02|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-21|P1Y2M10DT2H30M|AFTER|2020-08-19|AFTER|2020-09-04
e|RS|a9cf4d21-c2a8-4f32-b932-f05d2d317400|7|MRDRESP|Minimal Residual Disease Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|nmol/day|CYTOGENETIC NO RESPONSE|1|mOsm|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY||Y||CHILD|HEMATOLOGIST|NA|4|Visit_4|65|7|TREATMENT|2020-08-27|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-27|P1Y2M10DT2H30M|BEFORE|2020-09-11|ONGOING|2020-09-17
e|RS|a9cf4d21-c2a8-4f32-b932-f05d2d317400|8|SPLNRESP|Spleen Response|IWG CHESON MDS 2000|||MAJOR PATHOLOGIC RESPONSE|1|kDa|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY||Y|Y|CAREGIVER|ADJUDICATOR 2|Y|4|Visit_4|65|6|SCREENING|2020-08-27|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-27|P1Y2M10DT2H30M|AFTER|2020-09-28|COINCIDENT|2020-09-30
e|RS|a9cf4d21-c2a8-4f32-b932-f05d2d317400|9|MRPHRESP|Morphologic Response|AJCC V7|||MRD NEGATIVITY|1|mph|APPLANATION TONOMETRY|||Y|FRIEND|ADJUDICATOR 1|U|5|Visit_5|90|6|TREATMENT|2020-09-21|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-13|P1Y2M10DT2H30M|AFTER|2020-09-07|AFTER|2020-09-29
e|RS|a9cf4d21-c2a8-4f32-b932-f05d2d317400|10|TRGRESP|Target Response|NCIWG CHESON CLL 1996|[?]|gtt|CYTOGENETIC PR|1|10^10/L|TRANSVAGINAL ULTRASOUND||Y||GUARDIAN|FORENSIC PATHOLOGIST|Y|5|Visit_5|90|3|SCREENING|2020-09-21|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-13|P1Y2M10DT2H30M|COINCIDENT|2020-09-16|BEFORE|2020-09-18
e|RS|0389257f-50de-4a05-8f2a-69c068374337|1|MRDRESP|Minimal Residual Disease Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|||PARTIAL MORPHOLOGIC RESPONSE|1|mMU/mL|SIZE EXCLUSION CHROMATOGRAPHY|||Y|CAREGIVER|MICROSCOPIST 2|N|1|Visit_1|10|6|WASHOUT|2020-10-08|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-03|P1Y2M10DT2H30M|BEFORE|2020-10-15|ONGOING|2020-11-13
e|RS|0389257f-50de-4a05-8f2a-69c068374337|2|BONERESP|Bone Response|SACT|[?]|10^3 organisms/mL|MRD NEGATIVITY|1|mL/day|ELLA||||CAREGIVER|RATER 1|U|1|Visit_1|10|7|TREATMENT|2020-10-08|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-03|P1Y2M10DT2H30M|COINCIDENT|2020-10-17|ONGOING|2020-12-29
e|RS|0389257f-50de-4a05-8f2a-69c068374337|3|LIVRRESP|Liver Response|RANO|[?]|EIA unit|MOLECULAR MAJOR RESPONSE|1|cmH2O/mL|CELLULAR PROLIFERATION ASSAY||||SPOUSE|CARDIOLOGIST|Y|2|Visit_2|25|3|TREATMENT|2020-10-23|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-21|P1Y2M10DT2H30M|AFTER|2020-12-07|AFTER|2020-12-17
e|RS|0389257f-50de-4a05-8f2a-69c068374337|4|NEWLWIND|New Lesion Worsening Indicator|IWG CHESON MDS 2000|[?]|U/animal|TREATMENT FAILURE|1|fmol/g|IMMUNE REPERTOIRE DEEP SEQUENCING||||SIBLING|ADJUDICATOR 2|Y|2|Visit_2|25|3|TREATMENT|2020-10-23|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-21|P1Y2M10DT2H30M|BEFORE|2020-11-29|ONGOING|2020-12-22
e|RS|0389257f-50de-4a05-8f2a-69c068374337|5|SYMPTDTR|Symptomatic Deterioration|PETIT BREAST CANCER 2001|[?]|10^9/dose|WORSENED|1|kg/cm|KINETIC MICROPARTICLE IMMUNOASSAY||Y||SPOUSE|ONCOLOGIST 2|NA|3|Visit_3|40|1|WASHOUT|2020-11-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-21|P1Y2M10DT2H30M|COINCIDENT|2020-10-02|ONGOING|2021-01-01
e|RS|0389257f-50de-4a05-8f2a-69c068374337|6|PATHRESP|Pathologic Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|log10 copies/mL|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|mg/L|FARR ASSAY||||STUDY SUBJECT|UROLOGIST|N|3|Visit_3|40|4|TREATMENT|2020-11-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-21|P1Y2M10DT2H30M|COINCIDENT|2020-10-12|COINCIDENT|2020-12-08
e|RS|0389257f-50de-4a05-8f2a-69c068374337|7|CYTORESP|Cytogenetic Response|KUMAR IMWG 2016|[?]|Hz/s|CR-CT|1|mmAL|KNEMOMETRY||||CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 1|N|4|Visit_4|65|4|WASHOUT|2020-12-02|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-04|P1Y2M10DT2H30M|AFTER|2020-10-08|ONGOING|2020-11-28
e|RS|0389257f-50de-4a05-8f2a-69c068374337|8|NTLWIND|Non-Target Lesion Worsening Indicator|RAJKUMAR MYELOMA 2011|||MINOR PATHOLOGIC RESPONSE|1|ug/m2/h|RADIAL IMMUNODIFFUSION|Y||Y|PROXY|CLINICAL PATHOLOGIST|N|4|Visit_4|65|6|TREATMENT|2020-12-02|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-04|P1Y2M10DT2H30M|AFTER|2020-11-18|COINCIDENT|2020-11-25
e|RS|0389257f-50de-4a05-8f2a-69c068374337|9|HEMARESP|Hematologic Response|BLAZER COLORECTAL CANCER 2008|[?]|g/animal/wk|PR WITH LYMPHOCYTOSIS|1|ukat/10^12 RBC|IN VITRO GENE EXPRESSION ASSAY||||PROXY|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|5|Visit_5|90|5|SCREENING|2020-12-27|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-08|P1Y2M10DT2H30M|AFTER|2020-10-29|COINCIDENT|2020-12-02
e|RS|0389257f-50de-4a05-8f2a-69c068374337|10|NEWLPROG|New Lesion Progression|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|||PSEUDORESPONSE|1|s^-1(%O2)^-1|POLYSOMNOGRAPHY|Y||Y|FRIEND|ONCOLOGIST 1|Y|5|Visit_5|90|5|FOLLOW-UP|2020-12-27|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-08|P1Y2M10DT2H30M|BEFORE|2020-11-10|ONGOING|2020-11-30
e|RS|279ca0c7-7c4e-4cd7-a3b6-87bc5c037352|1|NTERESP|Non-Target Enhancing Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|KIT|PR-CT|1|/LPF|PANENDOSCOPY||Y||NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST|Y|1|Visit_1|10|2|TREATMENT|2020-12-15|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-20|P1Y2M10DT2H30M|UNKNOWN|2020-12-12|AFTER|2021-02-26
e|RS|279ca0c7-7c4e-4cd7-a3b6-87bc5c037352|2|BMIVLIND|Bone Marrow Involvement Indicator|KUKER LYMPHOMA 2005|[?]|L/s/kPa|STABLE|1|EU|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION||Y||INDEPENDENT ASSESSOR|NEUROLOGIST|NA|1|Visit_1|10|1|TREATMENT|2020-12-15|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-20|P1Y2M10DT2H30M|BEFORE|2021-03-04|BEFORE|2021-03-10
e|RS|279ca0c7-7c4e-4cd7-a3b6-87bc5c037352|3|SYMPTDTR|Symptomatic Deterioration|EBMT BLADE MYELOMA 1998|[?]|%|CYTOGENETIC PR|1|mg/kg/h|RADIOIMMUNOPRECIPITATION ASSAY||||DOMESTIC PARTNER|NEUROLOGIST 1|NA|2|Visit_2|25|4|WASHOUT|2020-12-30|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-24|P1Y2M10DT2H30M|BEFORE|2021-01-24|ONGOING|2021-02-06
e|RS|279ca0c7-7c4e-4cd7-a3b6-87bc5c037352|4|ANATRESP|Anatomic Response|IRANO 2015|||iCPD|1|PUFF|SISH||Y|Y|CHILD|MICROSCOPIST 1|Y|2|Visit_2|25|3|TREATMENT|2020-12-30|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-24|P1Y2M10DT2H30M|AFTER|2021-01-10|COINCIDENT|2021-01-28
e|RS|279ca0c7-7c4e-4cd7-a3b6-87bc5c037352|5|PATHRESP|Pathologic Response|GUILHOT CML 2007|[?]|dpm/0.5 mL|RELAPSED DISEASE FROM CR OR PR|1|Absorbance U|ELECTRONEUROGRAPHY||||CLINICAL RESEARCH COORDINATOR|READER 2|NA|3|Visit_3|40|5|TREATMENT|2021-01-14|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-16|P1Y2M10DT2H30M|COINCIDENT|2021-01-15|BEFORE|2021-01-31
e|RS|279ca0c7-7c4e-4cd7-a3b6-87bc5c037352|6|BONERESP|Bone Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|||UNFAVORABLE RESPONSE|1|10^6 U|ELECTRICAL IMPEDANCE MYOGRAPHY|||Y|ADJUDICATION COMMITTEE|CARDIOLOGIST|Y|3|Visit_3|40|4|TREATMENT|2021-01-14|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-16|P1Y2M10DT2H30M|BEFORE|2021-01-31|ONGOING|2021-02-12
e|RS|279ca0c7-7c4e-4cd7-a3b6-87bc5c037352|7|MJPTHIND|Major Pathological Response Indicator|PCWG BUBLEY PROSTATE CANCER 1999|||PD/RELAPSE AFTER HI|1|ppth|WEBER GREEN STAIN|Y||Y|CLINICAL RESEARCH COORDINATOR|INTERNIST|U|4|Visit_4|65|3|WASHOUT|2021-02-08|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-07|P1Y2M10DT2H30M|BEFORE|2020-12-14|ONGOING|2021-02-19
e|RS|279ca0c7-7c4e-4cd7-a3b6-87bc5c037352|8|BESTRESP|Best Overall Response|PETIT BREAST CANCER 2001|[?]|g/L|DISEASE TRANSFORMATION|1|mL/(min*100mL)|PET/CT SCAN WITHOUT CONTRAST||||CHILD|FORENSIC PATHOLOGIST|U|4|Visit_4|65|5|WASHOUT|2021-02-08|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-07|P1Y2M10DT2H30M|BEFORE|2021-02-07|COINCIDENT|2021-02-22
e|RS|279ca0c7-7c4e-4cd7-a3b6-87bc5c037352|9|MJPTHIND|Major Pathological Response Indicator|GUILHOT CML 2007|[?]|/2500 WBC|MRD RELAPSE|1|vp/dose|BIOPSY||||FRIEND|PHYSIOTHERAPIST|N|5|Visit_5|90|5|FOLLOW-UP|2021-03-05|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-25|P1Y2M10DT2H30M|BEFORE|2021-02-19|AFTER|2021-02-28
e|RS|279ca0c7-7c4e-4cd7-a3b6-87bc5c037352|10|NTNERESP|Non-Target Non-Enhancing Response|CHESON LYMPHOMA 2008|||RELAPSED DISEASE FROM CR|1|mAnson U/mL|CONTACT SPECULAR MICROSCOPY|||Y|ADJUDICATOR|HEMATOLOGIST|N|5|Visit_5|90|6|TREATMENT|2021-03-05|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-25|P1Y2M10DT2H30M|AFTER|2021-02-25|ONGOING|2021-03-08
e|RS|ca4e757f-268f-4f3f-b0d0-950bf9c26b08|1|OVRLRESP|Overall Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|MAC50|ABSENT MORPHOLOGIC RESPONSE|1|ugEq/L|X-RAY|Y|||FAMILY MEMBER|PATHOLOGIST 2|Y|1|Visit_1|10|2|FOLLOW-UP|2020-12-22|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-05|P1Y2M10DT2H30M|COINCIDENT|2021-02-21|ONGOING|2021-02-28
e|RS|ca4e757f-268f-4f3f-b0d0-950bf9c26b08|2|BMIVLIND|Bone Marrow Involvement Indicator|MURPHY PROSTATE CANCER 1980|||PR WITH LYMPHOCYTOSIS|1|uL/kg/day|SPIRAL CT|||Y|CHILD|MICROSCOPIST|N|1|Visit_1|10|7|WASHOUT|2020-12-22|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-05|P1Y2M10DT2H30M|BEFORE|2021-01-17|COINCIDENT|2021-01-31
e|RS|ca4e757f-268f-4f3f-b0d0-950bf9c26b08|3|TRGRESP|Target Response|UNSPECIFIED|[?]|L/s|iSD|1|NEBULE|FLOCCULATION, CHARCOAL ENHANCED||||CLINICAL STUDY SPONSOR|ONCOLOGIST 2|NA|2|Visit_2|25|3|FOLLOW-UP|2021-01-06|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-30|P1Y2M10DT2H30M|AFTER|2021-03-11|AFTER|2021-03-20
e|RS|ca4e757f-268f-4f3f-b0d0-950bf9c26b08|4|STRUSTAT|Steroid Use Status|PROTOCOL DEFINED RESPONSE CRITERIA|||iCR|1|mL/animal|PATHOLOGICAL EVALUATION||Y|Y|INTERVIEWER|RATER 2|N|2|Visit_2|25|5|TREATMENT|2021-01-06|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-30|P1Y2M10DT2H30M|BEFORE|2021-02-05|ONGOING|2021-02-20
e|RS|ca4e757f-268f-4f3f-b0d0-950bf9c26b08|5|TMRESP|Tumor Marker Response|CHESON MALIGNANT LYMPHOMA 2007|||iPR|1|PIXELS/cm|FLUORESCENCE ANGIOGRAPHY|Y||Y|FAMILY MEMBER|PATHOLOGIST|NA|3|Visit_3|40|1|TREATMENT|2021-01-21|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-26|P1Y2M10DT2H30M|COINCIDENT|2020-12-28|ONGOING|2021-03-07
e|RS|ca4e757f-268f-4f3f-b0d0-950bf9c26b08|6|NTNERESP|Non-Target Non-Enhancing Response|CHESON LYMPHOMA 2008|[?]|kg/cm|TREATMENT FAILURE|1|10^11/L|QUANTITATIVE ULTRASOUND||Y||CLINICAL STUDY SPONSOR|RATER 1|N|3|Visit_3|40|5|TREATMENT|2021-01-21|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-26|P1Y2M10DT2H30M|BEFORE|2021-01-29|ONGOING|2021-02-20
e|RS|ca4e757f-268f-4f3f-b0d0-950bf9c26b08|7|MRDRESP|Minimal Residual Disease Response|PETIT BREAST CANCER 2001|[?]|mL/cage|UNEQUIVOCAL|1|10^6/Ejaculate U|ELECTRICAL IMPEDANCE MYOGRAPHY||||CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 2|U|4|Visit_4|65|6|FOLLOW-UP|2021-02-15|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-09|P1Y2M10DT2H30M|AFTER|2021-02-17|COINCIDENT|2021-03-03
e|RS|ca4e757f-268f-4f3f-b0d0-950bf9c26b08|8|OVRLRESP|Overall Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|%(w/v)|RELAPSED DISEASE FROM CR|1|TROCHE|SINGLE-MOLECULE ARRAY||||VENDOR|INTERNIST|U|4|Visit_4|65|3|WASHOUT|2021-02-15|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-09|P1Y2M10DT2H30M|COINCIDENT|2021-03-05|AFTER|2021-03-11
e|RS|ca4e757f-268f-4f3f-b0d0-950bf9c26b08|9|MOLRESP|Molecular Response|MRECIST LENCIONI LIVER CANCER 2010|||STABLE|1|10^7/L|SPIROMETRY|||Y|DOMESTIC PARTNER|ADJUDICATOR 1|U|5|Visit_5|90|7|TREATMENT|2021-03-12|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-17|P1Y2M10DT2H30M|UNKNOWN|2021-01-31|AFTER|2021-02-01
e|RS|ca4e757f-268f-4f3f-b0d0-950bf9c26b08|10|TMRESP|Tumor Marker Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|mmHg/sec|CYTOGENETIC NO RESPONSE|1|pmol/L/h|PYROSEQUENCING||Y||ADJUDICATION COMMITTEE|RADIOLOGIST 2|NA|5|Visit_5|90|2|TREATMENT|2021-03-12|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-17|P1Y2M10DT2H30M|AFTER|2021-01-25|ONGOING|2021-01-29
e|RS|ad402b62-0625-431b-9bd7-ffd6124610f3|1|MNPTHIND|Minor Pathological Response Indicator|KUKER LYMPHOMA 2005|||ABSENT MORPHOLOGIC RESPONSE|1|P|BALLPOINT PEN TECHNIQUE|||Y|ADJUDICATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|1|Visit_1|10|6|WASHOUT|2020-09-25|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-13|P1Y2M10DT2H30M|UNKNOWN|2020-09-17|AFTER|2020-11-04
e|RS|ad402b62-0625-431b-9bd7-ffd6124610f3|2|MRDIND|Minimal Residual Disease Indicator|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|Linear ft*LB|NON-QUANTIFIABLE MRD POSITIVITY|1|uCi/kg|MICROARRAY||Y||SIGNIFICANT OTHER|MICROSCOPIST 2|Y|1|Visit_1|10|4|TREATMENT|2020-09-25|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-13|P1Y2M10DT2H30M|UNKNOWN|2020-09-19|AFTER|2020-10-14
e|RS|ad402b62-0625-431b-9bd7-ffd6124610f3|3|MRDIND|Minimal Residual Disease Indicator|KUKER LYMPHOMA 2005|[?]|kcal|iPR|1|/10^4|THERMAL IONIZATION MASS SPECTROMETRY||Y||PROXY|ONCOLOGIST|NA|2|Visit_2|25|3|TREATMENT|2020-10-10|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-16|P1Y2M10DT2H30M|AFTER|2020-12-06|BEFORE|2020-12-15
e|RS|ad402b62-0625-431b-9bd7-ffd6124610f3|4|MNPTHIND|Minor Pathological Response Indicator|DOHNER AML 2010|[?]|kIU|NON-PD|1|EP U|TARGETED GENOME SEQUENCING|Y|||SIGNIFICANT OTHER|DERMATOLOGIST|Y|2|Visit_2|25|1|FOLLOW-UP|2020-10-10|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-16|P1Y2M10DT2H30M|COINCIDENT|2020-10-31|AFTER|2020-12-20
e|RS|ad402b62-0625-431b-9bd7-ffd6124610f3|5|STRUSTAT|Steroid Use Status|FAROOQUI SUPP CLL 2014|[?]|mg/kg|PARTIAL MORPHOLOGIC RESPONSE|1|Farad|POLYGRAPHY||||VENDOR|ONCOLOGIST 1|N|3|Visit_3|40|7|FOLLOW-UP|2020-10-25|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-01|P1Y2M10DT2H30M|COINCIDENT|2020-09-27|BEFORE|2020-12-21
e|RS|ad402b62-0625-431b-9bd7-ffd6124610f3|6|STRUSTAT|Steroid Use Status|JACINTO CERVICAL CANCER 2007|[?]|kg/mol|RELAPSED DISEASE FROM CR OR PR|1|mol/g|FLUORESCENCE ANGIOGRAPHY|Y|Y||PARENT|INTERNIST|Y|3|Visit_3|40|2|WASHOUT|2020-10-25|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-01|P1Y2M10DT2H30M|COINCIDENT|2020-11-06|AFTER|2020-11-27
e|RS|ad402b62-0625-431b-9bd7-ffd6124610f3|7|DRCRIND|Disease Recurrence Indicator|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|kN/cm2|MR|1|cal|MAPH||Y||INTERVIEWER|ENDOCRINOLOGIST|U|4|Visit_4|65|5|SCREENING|2020-11-19|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-02|P1Y2M10DT2H30M|COINCIDENT|2020-11-17|AFTER|2020-12-06
e|RS|ad402b62-0625-431b-9bd7-ffd6124610f3|8|NTRGRESP|Non-target Response|RECIST 1.1|[?]|EU|PD|1|umol/mol|IRON HEMATOXYLIN STAIN|Y|||GUARDIAN|PHYSIOTHERAPIST|Y|4|Visit_4|65|2|SCREENING|2020-11-19|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-02|P1Y2M10DT2H30M|COINCIDENT|2020-10-20|BEFORE|2020-11-25
e|RS|ad402b62-0625-431b-9bd7-ffd6124610f3|9|BESTRESP|Best Overall Response|RECICL|||FAVORABLE RESPONSE|1|ugEq|COULOMETRIC TITRATION|||Y|CAREGIVER|READER 2|NA|5|Visit_5|90|7|TREATMENT|2020-12-14|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-10|P1Y2M10DT2H30M|BEFORE|2020-11-26|COINCIDENT|2020-12-19
e|RS|ad402b62-0625-431b-9bd7-ffd6124610f3|10|SPLNRESP|Spleen Response|CHESON NON-HODGKINS LYMPHOMA 1999|||HI-N|1|IU/L|KNEMOMETRY|||Y|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 1|NA|5|Visit_5|90|6|TREATMENT|2020-12-14|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-10|P1Y2M10DT2H30M|COINCIDENT|2020-11-24|COINCIDENT|2020-12-22
e|RS|d76b0f55-541c-491d-9162-4c133c9509f1|1|MRPHRESP|Morphologic Response|UNSPECIFIED|[?]|Mile|CYTOGENETIC MINOR RESPONSE|1|Mile|ETDRS EYE CHART|Y|Y||INTERVIEWER|CLINICAL PATHOLOGIST|Y|1|Visit_1|10|4|TREATMENT|2020-05-24|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-27|P1Y2M10DT2H30M|COINCIDENT|2020-05-30|BEFORE|2020-08-12
e|RS|d76b0f55-541c-491d-9162-4c133c9509f1|2|MRPHRESP|Morphologic Response|IWG CHESON AML 2003|||CHR|1|PFU/animal|RADIOIMMUNOPRECIPITATION ASSAY|||Y|CHILD|ONCOLOGIST|U|1|Visit_1|10|4|TREATMENT|2020-05-24|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-27|P1Y2M10DT2H30M|COINCIDENT|2020-06-06|BEFORE|2020-06-17
e|RS|d76b0f55-541c-491d-9162-4c133c9509f1|3|NEWLIND|New Lesion Indicator|IWG CHESON AML 2003|[?]|cg|CYTOGENETIC PR|1|MPS U|MICROBIAL CULTURE, LIQUID||Y||INTERVIEWER|NEUROLOGIST 1|NA|2|Visit_2|25|5|TREATMENT|2020-06-08|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-13|P1Y2M10DT2H30M|BEFORE|2020-06-30|COINCIDENT|2020-07-11
e|RS|d76b0f55-541c-491d-9162-4c133c9509f1|4|SYMPTDTR|Symptomatic Deterioration|EBMT BLADE MYELOMA 1998|[?]|mmol/min/kPa|TREATMENT FAILURE|1|L/kg|AUDIOMETRY||||CLINICAL STUDY SPONSOR|DERMATOLOGIST|Y|2|Visit_2|25|7|TREATMENT|2020-06-08|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-13|P1Y2M10DT2H30M|COINCIDENT|2020-06-27|BEFORE|2020-08-09
e|RS|d76b0f55-541c-491d-9162-4c133c9509f1|5|MOLRESP|Molecular Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|log10 TCID 50/dose|CA125 75% RESPONSE|1|ECL unit|ELLA||||FRIEND|PATHOLOGIST 1|N|3|Visit_3|40|7|TREATMENT|2020-06-23|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-20|P1Y2M10DT2H30M|BEFORE|2020-07-22|ONGOING|2020-08-08
e|RS|d76b0f55-541c-491d-9162-4c133c9509f1|6|SYMPTDTR|Symptomatic Deterioration|IWC HALLEK CLL 2008|||HI-N|1|U/g Hb|FLOW CYTOMETRY|Y||Y|CLINICAL RESEARCH COORDINATOR|READER|NA|3|Visit_3|40|7|FOLLOW-UP|2020-06-23|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-20|P1Y2M10DT2H30M|BEFORE|2020-08-16|COINCIDENT|2020-08-18
e|RS|d76b0f55-541c-491d-9162-4c133c9509f1|7|METSIND|Metastatic Indicator|WHO BREAST CANCER 2006|[?]|mg/m2/day|MOLECULAR CR|1|QUANTITY SUFFICIENT|ETDRS EYE CHART||||PARENT|MICROSCOPIST 3|Y|4|Visit_4|65|7|TREATMENT|2020-07-18|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-24|P1Y2M10DT2H30M|AFTER|2020-06-16|AFTER|2020-08-20
e|RS|d76b0f55-541c-491d-9162-4c133c9509f1|8|CYTORESP|Cytogenetic Response|SCHER PROSTATE CANCER 2011|[?]|Ci|CMR|1|%(w/w)|IVY INCISION METHOD||Y||STUDY SUBJECT|PHYSIOTHERAPIST|U|4|Visit_4|65|6|TREATMENT|2020-07-18|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-24|P1Y2M10DT2H30M|UNKNOWN|2020-05-21|COINCIDENT|2020-06-29
e|RS|d76b0f55-541c-491d-9162-4c133c9509f1|9|BMIVLIND|Bone Marrow Involvement Indicator|UNSPECIFIED|||NON-iCR/NON-iUPD|1|ukat/10^12 RBC|GEL ELECTROPHORESIS|||Y|HEALTH CARE PROFESSIONAL|READER 1|NA|5|Visit_5|90|3|TREATMENT|2020-08-12|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-18|P1Y2M10DT2H30M|AFTER|2020-08-16|BEFORE|2020-08-20
e|RS|d76b0f55-541c-491d-9162-4c133c9509f1|10|METSIND|Metastatic Indicator|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|10^3 CFU|EQUIVOCAL|1|APPLICATION|ELECTRONEUROGRAPHY||||SPOUSE|OPTOMETRIST|N|5|Visit_5|90|4|TREATMENT|2020-08-12|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-18|P1Y2M10DT2H30M|UNKNOWN|2020-07-17|ONGOING|2020-07-22
e|RS|146059d8-5652-41cd-b484-c6e5d8ea540f|1|NTRGRESP|Non-target Response|IWG CHESON MDS 2006|||WORSENED|1|mg/m2/day|CONTRAST ENHANCED MRI||Y|Y|SIGNIFICANT OTHER|INTERNIST|NA|1|Visit_1|10|1|WASHOUT|2020-08-26|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-03|P1Y2M10DT2H30M|COINCIDENT|2020-09-03|ONGOING|2020-09-15
e|RS|146059d8-5652-41cd-b484-c6e5d8ea540f|2|SPLNRESP|Spleen Response|KUKER LYMPHOMA 2005|||INCREASED|1|Bq/mL|FARR ASSAY|Y||Y|HEALTH CARE PROFESSIONAL|OPTOMETRIST|Y|1|Visit_1|10|4|FOLLOW-UP|2020-08-26|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-03|P1Y2M10DT2H30M|BEFORE|2020-10-12|COINCIDENT|2020-10-24
e|RS|146059d8-5652-41cd-b484-c6e5d8ea540f|3|TMRESP|Tumor Marker Response|DOHNER AML 2010|[?]|copies/uL|RELAPSED DISEASE|1|LB|DISK DIFFUSION||||SIGNIFICANT OTHER|ONCOLOGIST 2|NA|2|Visit_2|25|7|TREATMENT|2020-09-10|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-19|P1Y2M10DT2H30M|AFTER|2020-10-16|AFTER|2020-11-09
e|RS|146059d8-5652-41cd-b484-c6e5d8ea540f|4|CPRFSTAT|Clinical Performance Status|PCWG SCHER PROSTATE CANCER 2016|[?]|IU/dL|IMPROVED|1|um2|WHOLE EXOME SEQUENCING||||NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 1|Y|2|Visit_2|25|2|WASHOUT|2020-09-10|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-19|P1Y2M10DT2H30M|AFTER|2020-08-20|BEFORE|2020-11-08
e|RS|146059d8-5652-41cd-b484-c6e5d8ea540f|5|ANATRESP|Anatomic Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|pkat|PSEUDOPROGRESSION|1|U/kg/min|DOUBLE IMMUNODIFFUSION|Y|||PARENT|ADJUDICATOR 2|Y|3|Visit_3|40|5|SCREENING|2020-09-25|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-12|P1Y2M10DT2H30M|COINCIDENT|2020-10-07|AFTER|2020-11-16
e|RS|146059d8-5652-41cd-b484-c6e5d8ea540f|6|METSIND|Metastatic Indicator|AJCC V7|[?]|mL/cm3/min|CR-CT|1|U/cL|SNP ARRAY||||SIGNIFICANT OTHER|CARDIOLOGIST|U|3|Visit_3|40|3|TREATMENT|2020-09-25|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-12|P1Y2M10DT2H30M|BEFORE|2020-09-19|BEFORE|2020-10-25
e|RS|146059d8-5652-41cd-b484-c6e5d8ea540f|7|CYTORESP|Cytogenetic Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|dpm/mL|CMR|1|uL/mL|CONTRAST ENHANCED X-RAY|Y|||CLINICAL RESEARCH COORDINATOR|UROLOGIST|U|4|Visit_4|65|4|WASHOUT|2020-10-20|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-08|P1Y2M10DT2H30M|UNKNOWN|2020-10-12|AFTER|2020-10-30
e|RS|146059d8-5652-41cd-b484-c6e5d8ea540f|8|SYMPTDTR|Symptomatic Deterioration|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|nmol/kg/day|iCPD|1|mEq/uL|AUTOMATED COUNT||Y||SPOUSE|RADIOLOGIST 2|Y|4|Visit_4|65|7|WASHOUT|2020-10-20|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-08|P1Y2M10DT2H30M|COINCIDENT|2020-09-23|BEFORE|2020-10-16
e|RS|146059d8-5652-41cd-b484-c6e5d8ea540f|9|NEWLPROG|New Lesion Progression|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|PACKET|PR-CT|1|mV2/Hz|MICROBIAL BIOCHEMICAL IDENTIFICATION||||VENDOR|RADIOLOGIST|U|5|Visit_5|90|5|SCREENING|2020-11-14|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-04|P1Y2M10DT2H30M|UNKNOWN|2020-10-16|AFTER|2020-10-17
e|RS|146059d8-5652-41cd-b484-c6e5d8ea540f|10|BMIVLIND|Bone Marrow Involvement Indicator|CHESON CLL 2006|[?]|MET*min|NR|1|mg/mL/day|HPLC-UV||||ADJUDICATOR|ADJUDICATOR|N|5|Visit_5|90|4|SCREENING|2020-11-14|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-04|P1Y2M10DT2H30M|COINCIDENT|2020-08-27|BEFORE|2020-10-21
e|RS|3d5f1964-b65c-4a0a-bb5b-1689308754d8|1|MRPHRESP|Morphologic Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|Log10 ELISA unit/dose|pCR|1|mL|IRON HEMATOXYLIN STAIN|Y|||VENDOR|RADIOLOGIST 1|U|1|Visit_1|10|4|TREATMENT|2020-11-04|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-11|P1Y2M10DT2H30M|AFTER|2020-11-15|AFTER|2021-01-30
e|RS|3d5f1964-b65c-4a0a-bb5b-1689308754d8|2|SFTSRESP|Soft Tissue Response|SCHWARZ CERVICAL CANCER 2009|[?]|mIU/L|WORSENED|1|10^3 DNA copies/mL|TRANSESOPHAGEAL ECHOCARDIOGRAPHY||||VENDOR|MICROSCOPIST 2|NA|1|Visit_1|10|5|SCREENING|2020-11-04|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-11|P1Y2M10DT2H30M|UNKNOWN|2021-01-15|BEFORE|2021-01-29
e|RS|3d5f1964-b65c-4a0a-bb5b-1689308754d8|3|NEWLWIND|New Lesion Worsening Indicator|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|||SD-CT|1|log10 PFU/mL|SEQUENCING|Y||Y|ADJUDICATION COMMITTEE|READER|Y|2|Visit_2|25|5|TREATMENT|2020-11-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-12|P1Y2M10DT2H30M|AFTER|2020-11-22|AFTER|2020-12-12
e|RS|3d5f1964-b65c-4a0a-bb5b-1689308754d8|4|MJPTHIND|Major Pathological Response Indicator|CHESON NON-HODGKINS LYMPHOMA 1999|||PR-CT|1|BU|REFLECTANCE SPECTROSCOPY||Y|Y|CLINICAL STUDY SPONSOR|OPTOMETRIST|U|2|Visit_2|25|2|FOLLOW-UP|2020-11-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-12|P1Y2M10DT2H30M|AFTER|2021-01-07|AFTER|2021-01-26
e|RS|3d5f1964-b65c-4a0a-bb5b-1689308754d8|5|MNPTHIND|Minor Pathological Response Indicator|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|mmol/L|HI-P|1|um/day|REFRACTOMETRY||||CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 1|U|3|Visit_3|40|7|SCREENING|2020-12-04|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-13|P1Y2M10DT2H30M|BEFORE|2020-11-27|AFTER|2020-12-10
e|RS|3d5f1964-b65c-4a0a-bb5b-1689308754d8|6|HEMARESP|Hematologic Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|fraction of 1|NED|1|APL U|HIGH RESOLUTION MELT ANALYSIS||||DOMESTIC PARTNER|ADJUDICATOR 3|N|3|Visit_3|40|1|TREATMENT|2020-12-04|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-13|P1Y2M10DT2H30M|BEFORE|2021-01-05|BEFORE|2021-01-12
e|RS|3d5f1964-b65c-4a0a-bb5b-1689308754d8|7|METBRESP|Metabolic Response|LUGANO CLASSIFICATION|[?]|FFU|NOT ALL EVALUATED|1|mL*cmH2O|RADIAL IMMUNODIFFUSION||Y||PARENT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|4|Visit_4|65|6|TREATMENT|2020-12-29|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-04|P1Y2M10DT2H30M|AFTER|2021-01-01|BEFORE|2021-01-25
e|RS|3d5f1964-b65c-4a0a-bb5b-1689308754d8|8|ANATRESP|Anatomic Response|RECIST 1.0|[?]|steps/min|cPR|1|/10^4|TRICHROME STAIN||||HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|Y|4|Visit_4|65|1|TREATMENT|2020-12-29|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-04|P1Y2M10DT2H30M|COINCIDENT|2020-11-12|ONGOING|2021-01-11
e|RS|3d5f1964-b65c-4a0a-bb5b-1689308754d8|9|BESTRESP|Best Overall Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|lx|SD|1|HEP|HILLMEN COLOR CHART||Y||PARENT|ENDOCRINOLOGIST|N|5|Visit_5|90|6|TREATMENT|2021-01-23|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-02|P1Y2M10DT2H30M|UNKNOWN|2020-11-20|AFTER|2020-12-09
e|RS|3d5f1964-b65c-4a0a-bb5b-1689308754d8|10|MRDIND|Minimal Residual Disease Indicator|CHESON MALIGNANT LYMPHOMA 2007|[?]|NEEDLE GAUGE|PMD|1|nkat|REBOUND TONOMETRY|Y|||ADJUDICATION COMMITTEE|FORENSIC PATHOLOGIST|NA|5|Visit_5|90|1|FOLLOW-UP|2021-01-23|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-02|P1Y2M10DT2H30M|AFTER|2020-12-27|COINCIDENT|2021-01-29
e|RS|129dc836-068a-463e-b789-a0d05c60605d|1|PATHRESP|Pathologic Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|Tbsp|iCR|1|V|POLYGRAPHY||||STUDY SUBJECT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|1|Visit_1|10|7|WASHOUT|2020-07-06|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-08|P1Y2M10DT2H30M|BEFORE|2020-09-19|BEFORE|2020-09-21
e|RS|129dc836-068a-463e-b789-a0d05c60605d|2|MRDIND|Minimal Residual Disease Indicator|PCWG BUBLEY PROSTATE CANCER 1999|[?]|dpm/0.5 mL|NE|1|uCi|SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY||||ADJUDICATOR|CARDIOLOGIST|U|1|Visit_1|10|1|TREATMENT|2020-07-06|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-08|P1Y2M10DT2H30M|UNKNOWN|2020-09-03|COINCIDENT|2020-09-28
e|RS|129dc836-068a-463e-b789-a0d05c60605d|3|NEWLIND|New Lesion Indicator|SCHWARZ CERVICAL CANCER 2009|||CYTOGENETIC MINIMAL RESPONSE|1|U/m2/day|SPECTROPHOTOMETRY|||Y|GUARDIAN|OPTOMETRIST|U|2|Visit_2|25|5|SCREENING|2020-07-21|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-29|P1Y2M10DT2H30M|UNKNOWN|2020-09-02|COINCIDENT|2020-09-20
e|RS|129dc836-068a-463e-b789-a0d05c60605d|4|MRDIND|Minimal Residual Disease Indicator|CHOLLET BREAST CANCER 2002|[?]|ELISA unit|ABSENT MORPHOLOGIC RESPONSE|1|FEU|MICROBIAL CULTURE, SOLID||||CLINICAL STUDY SPONSOR|RATER 1|NA|2|Visit_2|25|7|TREATMENT|2020-07-21|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-29|P1Y2M10DT2H30M|UNKNOWN|2020-07-05|ONGOING|2020-07-19
e|RS|129dc836-068a-463e-b789-a0d05c60605d|5|NEWLWIND|New Lesion Worsening Indicator|RANO ELLINGSON 2017|[?]|uL/dose|INCREASED|1|pmol|TEST STRIP||Y||STUDY SUBJECT|OTOLARYNGOLOGIST|Y|3|Visit_3|40|1|FOLLOW-UP|2020-08-05|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-16|P1Y2M10DT2H30M|UNKNOWN|2020-08-13|COINCIDENT|2020-09-27
e|RS|129dc836-068a-463e-b789-a0d05c60605d|6|MRDIND|Minimal Residual Disease Indicator|FAROOQUI SUPP CLL 2014|||MORPHOLOGIC LEUKEMIA-FREE STATE|1|anti-Xa IU/mL|WHOLE GENOME SEQUENCING|Y||Y|CAREGIVER|ADJUDICATOR 3|N|3|Visit_3|40|7|TREATMENT|2020-08-05|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-16|P1Y2M10DT2H30M|BEFORE|2020-09-28|AFTER|2020-09-30
e|RS|129dc836-068a-463e-b789-a0d05c60605d|7|ANATRESP|Anatomic Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|pmol/day|MOLECULAR CR|1|dL|LC-FL||||INTERVIEWER|OPTOMETRIST|N|4|Visit_4|65|5|TREATMENT|2020-08-30|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-03|P1Y2M10DT2H30M|COINCIDENT|2020-09-28|COINCIDENT|2020-10-03
e|RS|129dc836-068a-463e-b789-a0d05c60605d|8|SFTSRESP|Soft Tissue Response|CHOI GIST 2008|[?]|PUFF|cCR|1|cP|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI||||CLINICAL STUDY SPONSOR|ADJUDICATOR 3|NA|4|Visit_4|65|5|WASHOUT|2020-08-30|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-03|P1Y2M10DT2H30M|UNKNOWN|2020-09-05|BEFORE|2020-09-17
e|RS|129dc836-068a-463e-b789-a0d05c60605d|9|NTLWIND|Non-Target Lesion Worsening Indicator|GCIG RUSTIN OVARIAN CANCER 2011|||EQUIVOCAL|1|L/min|URANYL ACETATE STAIN|||Y|SIBLING|RATER 2|NA|5|Visit_5|90|4|FOLLOW-UP|2020-09-24|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-12|P1Y2M10DT2H30M|COINCIDENT|2020-08-11|ONGOING|2020-08-20
e|RS|129dc836-068a-463e-b789-a0d05c60605d|10|RDIORESP|Radiologic Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|||iUPD|1|mL/animal|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|||Y|INTERVIEWER|NEUROLOGIST 1|Y|5|Visit_5|90|7|TREATMENT|2020-09-24|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-12|P1Y2M10DT2H30M|UNKNOWN|2020-07-27|ONGOING|2020-08-13
e|RS|9ef8a6d4-8326-4050-be85-e9f8983f55c1|1|SYMPTDTR|Symptomatic Deterioration|PCWG BUBLEY PROSTATE CANCER 1999|[?]|/mm|PR|1|vg/mL|VENTILATION PERFUSION LUNG SCAN||||CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST|Y|1|Visit_1|10|1|TREATMENT|2020-11-07|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-01|P1Y2M10DT2H30M|AFTER|2021-01-28|COINCIDENT|2021-02-03
e|RS|9ef8a6d4-8326-4050-be85-e9f8983f55c1|2|CYTORESP|Cytogenetic Response|CHESON CLL 2012|[?]|log10 CFU/g|cCR|1|mg/animal|ENZYMATIC COLORIMETRY||||ADJUDICATION COMMITTEE|OPTOMETRIST|N|1|Visit_1|10|4|TREATMENT|2020-11-07|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-01|P1Y2M10DT2H30M|UNKNOWN|2020-12-25|ONGOING|2021-01-21
e|RS|9ef8a6d4-8326-4050-be85-e9f8983f55c1|3|NEWLPROG|New Lesion Progression|CHESON LYMPHOMA 2008|[?]|CIGARETTE|NON-PD|1|PLUG|NUCLEAR RADIOLOGY||||INDEPENDENT ASSESSOR|UROLOGIST|U|2|Visit_2|25|2|TREATMENT|2020-11-22|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-28|P1Y2M10DT2H30M|AFTER|2020-12-25|BEFORE|2021-01-27
e|RS|9ef8a6d4-8326-4050-be85-e9f8983f55c1|4|NTLWIND|Non-Target Lesion Worsening Indicator|EASL BRUIX LIVER CANCER 2001|[?]|L/h|INDETERMINATE RESPONSE|1|IU/kg/h|DC SHEATH FLOW|Y|||INVESTIGATOR|ONCOLOGIST 1|Y|2|Visit_2|25|3|TREATMENT|2020-11-22|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-28|P1Y2M10DT2H30M|BEFORE|2021-01-29|ONGOING|2021-01-31
e|RS|9ef8a6d4-8326-4050-be85-e9f8983f55c1|5|NEWLPROG|New Lesion Progression|RANO|[?]|MHz|MORPHOLOGIC CR|1|mmol/s|SXA SCAN|Y|||DOMESTIC PARTNER|OPHTHALMOLOGIST|NA|3|Visit_3|40|7|FOLLOW-UP|2020-12-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-27|P1Y2M10DT2H30M|BEFORE|2021-01-04|ONGOING|2021-01-28
e|RS|9ef8a6d4-8326-4050-be85-e9f8983f55c1|6|RDIORESP|Radiologic Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|POUCH|NR|1|um2|PELLI-ROBSON EYE CHART||Y||ADJUDICATION COMMITTEE|NEUROLOGIST 1|U|3|Visit_3|40|7|TREATMENT|2020-12-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-27|P1Y2M10DT2H30M|AFTER|2020-11-23|ONGOING|2020-12-28
e|RS|9ef8a6d4-8326-4050-be85-e9f8983f55c1|7|MRDIND|Minimal Residual Disease Indicator|MRECIST BYRNE MESOTHELIOMA 2004|[?]|kg/cm2|PMR|1|IU/mg|FARR ASSAY|Y|||HEALTH CARE PROFESSIONAL|READER 2|U|4|Visit_4|65|7|SCREENING|2021-01-01|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-18|P1Y2M10DT2H30M|BEFORE|2021-01-03|BEFORE|2021-01-30
e|RS|9ef8a6d4-8326-4050-be85-e9f8983f55c1|8|CLINRESP|Clinical Response|PERCIST|[?]|U/g|INCREASED|1|/2500 WBC|CONTRAST ENHANCED PET/CT SCAN||||CLINICAL RESEARCH ASSOCIATE|READER 1|Y|4|Visit_4|65|7|TREATMENT|2021-01-01|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-18|P1Y2M10DT2H30M|UNKNOWN|2020-12-11|BEFORE|2021-01-09
e|RS|9ef8a6d4-8326-4050-be85-e9f8983f55c1|9|SFTSRESP|Soft Tissue Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|DAgU|mCR|1|BU/mL|IVY INCISION METHOD||||CHILD|PATHOLOGIST|Y|5|Visit_5|90|7|SCREENING|2021-01-26|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-28|P1Y2M10DT2H30M|COINCIDENT|2020-12-13|AFTER|2021-01-15
e|RS|9ef8a6d4-8326-4050-be85-e9f8983f55c1|10|PATHRESP|Pathologic Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|10^9 CFU/g|CYTOGENETIC MINIMAL RESPONSE|1|ug/L DDU|MICROBIAL CULTURE||||NON-HEALTH CARE PROFESSIONAL|DERMATOLOGIST|U|5|Visit_5|90|6|TREATMENT|2021-01-26|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-28|P1Y2M10DT2H30M|AFTER|2021-01-06|BEFORE|2021-01-24
e|RS|b91c4469-b3be-467f-8512-b73cf561e168|1|NTLWIND|Non-Target Lesion Worsening Indicator|DOHNER AML 2010|[?]|IU/mmol|IMMUNOPHENOTYPIC CR|1|10^7 CFU/mL|SPECULAR MICROSCOPY|Y|||PROXY|OPTOMETRIST|Y|1|Visit_1|10|5|SCREENING|2020-05-18|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-16|P1Y2M10DT2H30M|COINCIDENT|2020-05-17|AFTER|2020-06-01
e|RS|b91c4469-b3be-467f-8512-b73cf561e168|2|MRDRESP|Minimal Residual Disease Response|WOLCHOK SOLID TUMORS 2009|[?]|BOTTLE|PD/RELAPSE AFTER HI|1|IU/mL|INTERRUPTER TECHNIQUE|Y|||CLINICAL STUDY SPONSOR|NEUROLOGIST 2|NA|1|Visit_1|10|3|WASHOUT|2020-05-18|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-16|P1Y2M10DT2H30M|BEFORE|2020-06-13|COINCIDENT|2020-07-02
e|RS|b91c4469-b3be-467f-8512-b73cf561e168|3|METSIND|Metastatic Indicator|MASS|[?]|Hz|HI-P|1|10^6/g|CELL BASED BIOASSAY||Y||CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|2|Visit_2|25|5|SCREENING|2020-06-02|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-29|P1Y2M10DT2H30M|COINCIDENT|2020-07-31|ONGOING|2020-08-15
e|RS|b91c4469-b3be-467f-8512-b73cf561e168|4|MJPTHIND|Major Pathological Response Indicator|DOHNER AML 2010|[?]|mg/L FEU|SD|1|U/kg|SLOAN LETTER EYE CHART 1.25%||||SPOUSE|MICROSCOPIST 1|NA|2|Visit_2|25|4|WASHOUT|2020-06-02|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-29|P1Y2M10DT2H30M|UNKNOWN|2020-05-24|ONGOING|2020-07-05
e|RS|b91c4469-b3be-467f-8512-b73cf561e168|5|BONERESP|Bone Response|RAJKUMAR MYELOMA 2011|||PR WITH LYMPHOCYTOSIS|1|V|HPLC-UV|||Y|NON-HEALTH CARE PROFESSIONAL|CARDIOLOGIST|N|3|Visit_3|40|1|FOLLOW-UP|2020-06-17|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-16|P1Y2M10DT2H30M|COINCIDENT|2020-07-06|COINCIDENT|2020-08-03
e|RS|b91c4469-b3be-467f-8512-b73cf561e168|6|OVRLRESP|Overall Response|HAMAOKA BREAST CANCER 2010|||PSEUDOPROGRESSION|1|NEBULE|ECHOCARDIOGRAPHY|||Y|HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|NA|3|Visit_3|40|7|TREATMENT|2020-06-17|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-16|P1Y2M10DT2H30M|AFTER|2020-07-24|BEFORE|2020-08-08
e|RS|b91c4469-b3be-467f-8512-b73cf561e168|7|LIVRRESP|Liver Response|BLAZER COLORECTAL CANCER 2008|[?]|nm|CA125 50% RESPONSE|1|10^6 CFU/mL|SLIT LAMP PHOTOGRAPHY||||ADJUDICATION COMMITTEE|DEVELOPMENTAL PSYCHOLOGIST|N|4|Visit_4|65|4|SCREENING|2020-07-12|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-12|P1Y2M10DT2H30M|COINCIDENT|2020-06-06|COINCIDENT|2020-07-19
e|RS|b91c4469-b3be-467f-8512-b73cf561e168|8|TMRESP|Tumor Marker Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|uSiemens|NR|1|/VF|MICROBIAL BIOCHEMICAL IDENTIFICATION||||ADJUDICATOR|CLINICAL PATHOLOGIST|Y|4|Visit_4|65|2|FOLLOW-UP|2020-07-12|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-12|P1Y2M10DT2H30M|AFTER|2020-05-23|BEFORE|2020-06-27
e|RS|b91c4469-b3be-467f-8512-b73cf561e168|9|PATHRESP|Pathologic Response|IWG CHESON MDS 2006|[?]|VIRTUAL PIXEL|cPR|1|cg|RADIOGRAPHY|Y|||CHILD|ADJUDICATOR 2|Y|5|Visit_5|90|7|TREATMENT|2020-08-06|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-20|P1Y2M10DT2H30M|AFTER|2020-06-09|COINCIDENT|2020-06-30
e|RS|b91c4469-b3be-467f-8512-b73cf561e168|10|METSIND|Metastatic Indicator|KEAM BREAST CANCER 2013|[?]|/LPF|CYTOGENETIC NO RESPONSE|1|RNA copies/mL|DXA SCAN||||VENDOR|READER 2|NA|5|Visit_5|90|7|TREATMENT|2020-08-06|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-20|P1Y2M10DT2H30M|AFTER|2020-07-30|AFTER|2020-08-06
e|RS|3637e1e0-8c0c-45cc-b139-e812a589f940|1|NEWLIND|New Lesion Indicator|SACT|[?]|mEq|NE|1|mmol/L|CONTACT SPECULAR MICROSCOPY|Y|||CAREGIVER|INTERNIST|U|1|Visit_1|10|5|TREATMENT|2020-08-30|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-24|P1Y2M10DT2H30M|UNKNOWN|2020-08-23|COINCIDENT|2020-11-18
e|RS|3637e1e0-8c0c-45cc-b139-e812a589f940|2|ANATRESP|Anatomic Response|SCHER PROSTATE CANCER 2011|||QUANTIFIABLE MRD POSITIVITY|1|mCi/L|HIGH RESOLUTION MELT ANALYSIS|||Y|VENDOR|UROLOGIST|U|1|Visit_1|10|5|FOLLOW-UP|2020-08-30|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-24|P1Y2M10DT2H30M|BEFORE|2020-11-15|COINCIDENT|2020-11-26
e|RS|3637e1e0-8c0c-45cc-b139-e812a589f940|3|CPRFSTAT|Clinical Performance Status|DURIE MULTIPLE MYELOMA 2006|[?]|rpm|CRi|1|GBq|ISHIHARA COLOR PLATES|Y|Y||NON-HEALTH CARE PROFESSIONAL|READER|N|2|Visit_2|25|7|TREATMENT|2020-09-14|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-03|P1Y2M10DT2H30M|BEFORE|2020-10-08|AFTER|2020-11-16
e|RS|3637e1e0-8c0c-45cc-b139-e812a589f940|4|NEWLWIND|New Lesion Worsening Indicator|GCIG RUSTIN OVARIAN CANCER 2011|[?]|bel|QUANTIFIABLE MRD POSITIVITY|1|kV|IRON HEMATOXYLIN STAIN|Y|||FRIEND|RATER 1|NA|2|Visit_2|25|6|SCREENING|2020-09-14|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-03|P1Y2M10DT2H30M|UNKNOWN|2020-10-25|COINCIDENT|2020-10-31
e|RS|3637e1e0-8c0c-45cc-b139-e812a589f940|5|NEWLWIND|New Lesion Worsening Indicator|GUILHOT CML 2007|[?]|cmH2O/mL|CYTOGENETIC MINIMAL RESPONSE|1|Siemens|NEPHELOMETRY|Y|||SIGNIFICANT OTHER|ONCOLOGIST 2|Y|3|Visit_3|40|3|WASHOUT|2020-09-29|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-02|P1Y2M10DT2H30M|UNKNOWN|2020-11-15|ONGOING|2020-11-27
e|RS|3637e1e0-8c0c-45cc-b139-e812a589f940|6|HEMARESP|Hematologic Response|IWG CHESON MDS 2000|||MRD NEGATIVITY|1|g/U|FLOCCULATION, CHARCOAL ENHANCED|||Y|GUARDIAN|READER 3|U|3|Visit_3|40|3|SCREENING|2020-09-29|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-02|P1Y2M10DT2H30M|AFTER|2020-11-16|COINCIDENT|2020-11-22
e|RS|3637e1e0-8c0c-45cc-b139-e812a589f940|7|MRDIND|Minimal Residual Disease Indicator|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|nmol/L/h|RELAPSED DISEASE FROM CR|1|ppb|PHOTOMETRY||||DOMESTIC PARTNER|NEUROLOGIST|Y|4|Visit_4|65|6|FOLLOW-UP|2020-10-24|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-29|P1Y2M10DT2H30M|AFTER|2020-09-01|AFTER|2020-10-08
e|RS|3637e1e0-8c0c-45cc-b139-e812a589f940|8|LIVRRESP|Liver Response|CHESON CLL 2006|[?]|v/v|HI-E|1|mIU/L|RULER MEASUREMENT METHOD||||INDEPENDENT ASSESSOR|OPTOMETRIST|U|4|Visit_4|65|4|FOLLOW-UP|2020-10-24|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-29|P1Y2M10DT2H30M|BEFORE|2020-11-19|COINCIDENT|2020-11-27
e|RS|3637e1e0-8c0c-45cc-b139-e812a589f940|9|DRCRIND|Disease Recurrence Indicator|JUWEID NON-HODGKINS LYMPHOMA 2005|||PSEUDOPROGRESSION|1|mL/(min*100mL)|ACID FAST STAIN|Y||Y|STUDY SUBJECT|HEMATOLOGIST|N|5|Visit_5|90|6|WASHOUT|2020-11-18|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-19|P1Y2M10DT2H30M|AFTER|2020-09-14|BEFORE|2020-11-06
e|RS|3637e1e0-8c0c-45cc-b139-e812a589f940|10|CYTORESP|Cytogenetic Response|KUMAR IMWG 2016|[?]|CCID 50/mL|NON-CR/NON-PD|1|umol|TRANSESOPHAGEAL ECHOCARDIOGRAPHY|Y|||ADJUDICATION COMMITTEE|ADJUDICATOR 2|U|5|Visit_5|90|1|FOLLOW-UP|2020-11-18|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-19|P1Y2M10DT2H30M|AFTER|2020-11-06|BEFORE|2020-11-17
e|RS|23385974-5fcd-4c36-b9fa-2fbb3841f182|1|MNPTHIND|Minor Pathological Response Indicator|SACT|[?]|mL|ABSENT MORPHOLOGIC RESPONSE|1|Ci|IRON HEMATOXYLIN STAIN|Y|Y||FAMILY MEMBER|DERMATOLOGIST|U|1|Visit_1|10|5|SCREENING|2020-11-27|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-18|P1Y2M10DT2H30M|AFTER|2020-11-28|BEFORE|2021-01-25
e|RS|23385974-5fcd-4c36-b9fa-2fbb3841f182|2|LIVRRESP|Liver Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|||NON-PD|1|10^9 CFU/g|IMMUNOFLUORESCENT STAIN||Y|Y|CHILD|RATER 2|N|1|Visit_1|10|4|TREATMENT|2020-11-27|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-18|P1Y2M10DT2H30M|AFTER|2020-12-01|ONGOING|2020-12-22
e|RS|23385974-5fcd-4c36-b9fa-2fbb3841f182|3|MRDRESP|Minimal Residual Disease Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|kg/mol|mCR|1|GBq/g|CRYOSCOPY||||INVESTIGATOR|READER 1|NA|2|Visit_2|25|6|TREATMENT|2020-12-12|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-03|P1Y2M10DT2H30M|UNKNOWN|2020-12-16|COINCIDENT|2021-02-07
e|RS|23385974-5fcd-4c36-b9fa-2fbb3841f182|4|TMRESP|Tumor Marker Response|IRANO 2015|||QUANTIFIABLE MRD POSITIVITY|1|kN/cm2|SANGER SEQUENCING|||Y|SIBLING|PATHOLOGIST 2|Y|2|Visit_2|25|6|FOLLOW-UP|2020-12-12|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-03|P1Y2M10DT2H30M|UNKNOWN|2020-12-18|COINCIDENT|2021-01-08
e|RS|23385974-5fcd-4c36-b9fa-2fbb3841f182|5|NTLWIND|Non-Target Lesion Worsening Indicator|FAROOQUI SUPP CLL 2014|[?]|mmol/min/kPa/L|NR|1|CAPSULE|NEURAMINIDASE INHIBITION ASSAY||||DOMESTIC PARTNER|ADJUDICATOR 2|N|3|Visit_3|40|1|TREATMENT|2020-12-27|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-30|P1Y2M10DT2H30M|BEFORE|2020-11-19|BEFORE|2020-11-25
e|RS|23385974-5fcd-4c36-b9fa-2fbb3841f182|6|CPRFSTAT|Clinical Performance Status|MONTSERRAT CLL 1989|||PR|1|m3|REBOUND TONOMETRY|||Y|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 2|U|3|Visit_3|40|2|WASHOUT|2020-12-27|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-30|P1Y2M10DT2H30M|UNKNOWN|2021-01-30|COINCIDENT|2021-02-01
e|RS|23385974-5fcd-4c36-b9fa-2fbb3841f182|7|NEWLIND|New Lesion Indicator|JUWEID NON-HODGKINS LYMPHOMA 2005|||MOLECULAR CR|1|pg/dL|ANGIOGRAPHY|||Y|INDEPENDENT ASSESSOR|RATER 2|U|4|Visit_4|65|6|TREATMENT|2021-01-21|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-22|P1Y2M10DT2H30M|UNKNOWN|2020-12-19|AFTER|2021-02-13
e|RS|23385974-5fcd-4c36-b9fa-2fbb3841f182|8|BMIVLIND|Bone Marrow Involvement Indicator|RANO|[?]|damol/L|NON-iCR/NON-iUPD|1|10^3 organisms/mL|CAPILLARY ELECTROPHORESIS|Y|||SIBLING|MICROSCOPIST 1|U|4|Visit_4|65|1|FOLLOW-UP|2021-01-21|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-22|P1Y2M10DT2H30M|COINCIDENT|2020-12-01|COINCIDENT|2021-02-02
e|RS|23385974-5fcd-4c36-b9fa-2fbb3841f182|9|MJPTHIND|Major Pathological Response Indicator|TSUKASAKI LEUKEMIA LYMPHOMA 2009|||CYTOGENETIC MINOR RESPONSE|1|CAN|CORONARY ANGIOGRAPHY||Y|Y|GUARDIAN|INTERNIST|U|5|Visit_5|90|7|TREATMENT|2021-02-15|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-16|P1Y2M10DT2H30M|AFTER|2021-02-01|COINCIDENT|2021-02-08
e|RS|23385974-5fcd-4c36-b9fa-2fbb3841f182|10|BONERESP|Bone Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|ohm|UNEQUIVOCAL|1|IU/kg|PALPATION|Y|||STUDY SUBJECT|ONCOLOGIST 1|NA|5|Visit_5|90|3|TREATMENT|2021-02-15|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-16|P1Y2M10DT2H30M|BEFORE|2021-02-15|BEFORE|2021-02-16
e|RS|b76a836f-57ee-4e3d-89c4-31fdef04e5fe|1|MJPTHIND|Major Pathological Response Indicator|DURIE MULTIPLE MYELOMA 2006|[?]|cd|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|Ci/kg|SINGLE-SLICE SPIRAL CT||||PARENT|ADJUDICATOR 3|N|1|Visit_1|10|5|SCREENING|2020-12-06|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-20|P1Y2M10DT2H30M|UNKNOWN|2021-02-09|ONGOING|2021-02-25
e|RS|b76a836f-57ee-4e3d-89c4-31fdef04e5fe|2|MRDRESP|Minimal Residual Disease Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|10^6 CFU|PD|1|APS U|LAPAROSCOPY||||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST|Y|1|Visit_1|10|4|TREATMENT|2020-12-06|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-20|P1Y2M10DT2H30M|COINCIDENT|2021-02-20|BEFORE|2021-02-28
e|RS|b76a836f-57ee-4e3d-89c4-31fdef04e5fe|3|RDIORESP|Radiologic Response|KEAM BREAST CANCER 2013|||CR-CT|1|yd|MULTIPLE BREATH WASHOUT|||Y|CLINICAL RESEARCH ASSOCIATE|ENDOCRINOLOGIST|U|2|Visit_2|25|6|SCREENING|2020-12-21|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-28|P1Y2M10DT2H30M|COINCIDENT|2021-01-18|AFTER|2021-02-27
e|RS|b76a836f-57ee-4e3d-89c4-31fdef04e5fe|4|SPLNRESP|Spleen Response|PETIT BREAST CANCER 2001|[?]|nmol/g|EQUIVOCAL|1|mg/mL/min|VENTILATION PERFUSION LUNG SCAN||Y||INTERVIEWER|RATER 2|N|2|Visit_2|25|3|SCREENING|2020-12-21|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-28|P1Y2M10DT2H30M|AFTER|2021-02-27|AFTER|2021-03-03
e|RS|b76a836f-57ee-4e3d-89c4-31fdef04e5fe|5|BONERESP|Bone Response|iRECIST|[?]|gpELISA unit/mL|VGPR|1|CAPLET|CENTRIFUGATION||||CLINICAL STUDY SPONSOR|FORENSIC PATHOLOGIST|NA|3|Visit_3|40|3|TREATMENT|2021-01-05|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-17|P1Y2M10DT2H30M|UNKNOWN|2021-02-03|AFTER|2021-02-24
e|RS|b76a836f-57ee-4e3d-89c4-31fdef04e5fe|6|BONERESP|Bone Response|BURCOMBE BREAST CANCER 2005|[?]|g/animal/day|nPR|1|10^6/L|PULSE OXIMETRY|Y|Y||VENDOR|READER 3|NA|3|Visit_3|40|7|TREATMENT|2021-01-05|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-17|P1Y2M10DT2H30M|BEFORE|2021-03-05|BEFORE|2021-03-06
e|RS|b76a836f-57ee-4e3d-89c4-31fdef04e5fe|7|STRUSTAT|Steroid Use Status|MRANO VAN DEN BENT GLIOMA 2011|[?]|dpm/mg|VGPR|1|mm/2h|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY||||FAMILY MEMBER|OPTOMETRIST|Y|4|Visit_4|65|6|SCREENING|2021-01-30|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-02|P1Y2M10DT2H30M|AFTER|2021-01-30|ONGOING|2021-02-26
e|RS|b76a836f-57ee-4e3d-89c4-31fdef04e5fe|8|NEWLWIND|New Lesion Worsening Indicator|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|PELLET|FAVORABLE RESPONSE|1|dpm/mg|SPECTROPHOTOMETRY|Y|||CHILD|ADJUDICATOR 2|N|4|Visit_4|65|3|TREATMENT|2021-01-30|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-02|P1Y2M10DT2H30M|AFTER|2021-02-09|BEFORE|2021-02-28
e|RS|b76a836f-57ee-4e3d-89c4-31fdef04e5fe|9|RDIORESP|Radiologic Response|KUKER LYMPHOMA 2005|[?]|/4.0 mL|MORPHOLOGIC CRi|1|mEq/day|HPLC/IEX|Y|Y||CLINICAL RESEARCH ASSOCIATE|READER|NA|5|Visit_5|90|4|FOLLOW-UP|2021-02-24|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-21|P1Y2M10DT2H30M|BEFORE|2021-02-03|BEFORE|2021-02-11
e|RS|b76a836f-57ee-4e3d-89c4-31fdef04e5fe|10|RDIORESP|Radiologic Response|NCIWG CHESON CLL 1996|[?]|mL/m2/min|MORPHOLOGIC CRi|1|JAR|ARTERIAL SPIN LABELING FUNCTIONAL MRI|Y|||CLINICAL STUDY SPONSOR|ADJUDICATOR 2|N|5|Visit_5|90|4|SCREENING|2021-02-24|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-21|P1Y2M10DT2H30M|BEFORE|2020-12-02|BEFORE|2021-02-20
e|RS|f1327e16-08c6-4ef0-852e-13c095a94c00|1|HEMARESP|Hematologic Response|BURCOMBE BREAST CANCER 2005|[?]|GBq/ug|HI-P|1|sec|OPTICAL DENSITY MEASUREMENT||||CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|1|Visit_1|10|4|SCREENING|2020-05-26|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-21|P1Y2M10DT2H30M|BEFORE|2020-06-18|COINCIDENT|2020-08-17
e|RS|f1327e16-08c6-4ef0-852e-13c095a94c00|2|STRUSTAT|Steroid Use Status|GUILHOT CML 2007|[?]|IMPLANT|UNEQUIVOCAL|1|HOMEOPATHIC DILUTION|PALM METHOD||||PROXY|RADIOLOGIST|NA|1|Visit_1|10|4|SCREENING|2020-05-26|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-21|P1Y2M10DT2H30M|UNKNOWN|2020-08-08|ONGOING|2020-08-23
e|RS|f1327e16-08c6-4ef0-852e-13c095a94c00|3|SFTSRESP|Soft Tissue Response|MONTSERRAT CLL 1989|[?]|U/kg|HI-N|1|cpm|REFRACTOMETRY||Y||PARENT|PEDIATRIC NEUROLOGIST|NA|2|Visit_2|25|1|FOLLOW-UP|2020-06-10|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-29|P1Y2M10DT2H30M|BEFORE|2020-07-11|ONGOING|2020-07-15
e|RS|f1327e16-08c6-4ef0-852e-13c095a94c00|4|MRDIND|Minimal Residual Disease Indicator|PETIT BREAST CANCER 2001|[?]|K|NOT ALL EVALUATED|1|PELLET|MANUAL CLOT DETECTION||||INTERVIEWER|ONCOLOGIST 2|NA|2|Visit_2|25|4|WASHOUT|2020-06-10|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-29|P1Y2M10DT2H30M|UNKNOWN|2020-08-11|AFTER|2020-08-21
e|RS|f1327e16-08c6-4ef0-852e-13c095a94c00|5|BONERESP|Bone Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|cd*s/m2|ABSENT MORPHOLOGIC RESPONSE|1|mL/cage/day|PHYSICAL EXAMINATION||||CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST|N|3|Visit_3|40|6|TREATMENT|2020-06-25|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-11|P1Y2M10DT2H30M|COINCIDENT|2020-05-31|ONGOING|2020-07-20
e|RS|f1327e16-08c6-4ef0-852e-13c095a94c00|6|CLINRESP|Clinical Response|WOLCHOK SOLID TUMORS 2009|||iCR|1|Antibody Unit|GC/MS||Y|Y|DOMESTIC PARTNER|ADJUDICATOR 1|N|3|Visit_3|40|2|TREATMENT|2020-06-25|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-11|P1Y2M10DT2H30M|AFTER|2020-06-30|COINCIDENT|2020-07-22
e|RS|f1327e16-08c6-4ef0-852e-13c095a94c00|7|TRGRESP|Target Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|||PSEUDOPROGRESSION|1|CUP|FLUORESCENCE ANGIOGRAPHY|||Y|INTERVIEWER|ONCOLOGIST 1|U|4|Visit_4|65|4|TREATMENT|2020-07-20|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-05|P1Y2M10DT2H30M|UNKNOWN|2020-07-05|AFTER|2020-08-12
e|RS|f1327e16-08c6-4ef0-852e-13c095a94c00|8|SYMPTDTR|Symptomatic Deterioration|NCCN ALL MRD 2014|||NE|1|10^9 CFU|REFLECTANCE SPECTROSCOPY|Y|Y|Y|CLINICAL RESEARCH COORDINATOR|ENDOCRINOLOGIST|U|4|Visit_4|65|6|TREATMENT|2020-07-20|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-05|P1Y2M10DT2H30M|UNKNOWN|2020-08-23|ONGOING|2020-08-24
e|RS|f1327e16-08c6-4ef0-852e-13c095a94c00|9|SYMPTDTR|Symptomatic Deterioration|IWC HALLEK CLL 2008|[?]|msec|NON-CR/NON-PD|1|% INHIBITION|DIGITAL PCR ARRAY|Y|||CHILD|READER|NA|5|Visit_5|90|4|TREATMENT|2020-08-14|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-17|P1Y2M10DT2H30M|COINCIDENT|2020-06-27|AFTER|2020-07-21
e|RS|f1327e16-08c6-4ef0-852e-13c095a94c00|10|BESTRESP|Best Overall Response|PCWG SCHER PROSTATE CANCER 2016|[?]|BOLUS|PD/RELAPSE AFTER HI|1|U/g/day|TRANSVAGINAL ULTRASOUND||||PARENT|HEMATOLOGIST|NA|5|Visit_5|90|2|SCREENING|2020-08-14|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-17|P1Y2M10DT2H30M|UNKNOWN|2020-08-14|AFTER|2020-08-21
e|RS|52de3d1f-e750-49f3-9cfa-09ac97a5dd4b|1|STRUSTAT|Steroid Use Status|RECICL|[?]|mV2/Hz|MOLECULAR CR|1|PFU/dose|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY||||CHILD|PATHOLOGIST 2|Y|1|Visit_1|10|4|FOLLOW-UP|2021-01-15|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-20|P1Y2M10DT2H30M|UNKNOWN|2021-03-22|BEFORE|2021-04-05
e|RS|52de3d1f-e750-49f3-9cfa-09ac97a5dd4b|2|LIVRRESP|Liver Response|CHOI GIST 2008|[?]|CFU/g|MRD NEGATIVITY|1|10^4 CFU|MUGA|Y|||CHILD|PHYSIOTHERAPIST|U|1|Visit_1|10|4|WASHOUT|2021-01-15|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-20|P1Y2M10DT2H30M|COINCIDENT|2021-03-13|ONGOING|2021-03-19
e|RS|52de3d1f-e750-49f3-9cfa-09ac97a5dd4b|3|ANATRESP|Anatomic Response|RECIST 1.0|[?]|DROP|QUANTIFIABLE MRD POSITIVITY|1|h/wk|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE|Y|||HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|U|2|Visit_2|25|4|WASHOUT|2021-01-30|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-24|P1Y2M10DT2H30M|UNKNOWN|2021-02-22|AFTER|2021-03-18
e|RS|52de3d1f-e750-49f3-9cfa-09ac97a5dd4b|4|BESTRESP|Best Overall Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|mg/mL/day|PD FROM PR|1|mm2|GC/MS-EI||Y||NON-HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|Y|2|Visit_2|25|2|TREATMENT|2021-01-30|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-24|P1Y2M10DT2H30M|COINCIDENT|2021-03-23|COINCIDENT|2021-04-03
e|RS|52de3d1f-e750-49f3-9cfa-09ac97a5dd4b|5|SFTSRESP|Soft Tissue Response|PETIT BREAST CANCER 2001|[?]|ug/g/h|MR|1|nmol BCE/nmol|SINGLE-SLICE SPIRAL CT|Y|||STUDY SUBJECT|PATHOLOGIST 1|U|3|Visit_3|40|4|WASHOUT|2021-02-14|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-05|P1Y2M10DT2H30M|BEFORE|2021-03-13|ONGOING|2021-03-18
e|RS|52de3d1f-e750-49f3-9cfa-09ac97a5dd4b|6|PATHRESP|Pathologic Response|HAMAOKA BREAST CANCER 2010|||NR|1|U/g|MACRO BROTH DILUTION||Y|Y|INVESTIGATOR|RATER|N|3|Visit_3|40|6|FOLLOW-UP|2021-02-14|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-05|P1Y2M10DT2H30M|AFTER|2021-01-08|AFTER|2021-02-18
e|RS|52de3d1f-e750-49f3-9cfa-09ac97a5dd4b|7|CYTORESP|Cytogenetic Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|DIP|MORPHOLOGIC LEUKEMIA-FREE STATE|1|GLOBULE|LAPAROSCOPY||||PARENT|OPTOMETRIST|U|4|Visit_4|65|2|TREATMENT|2021-03-11|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-21|P1Y2M10DT2H30M|BEFORE|2021-04-11|COINCIDENT|2021-04-14
e|RS|52de3d1f-e750-49f3-9cfa-09ac97a5dd4b|8|MRDRESP|Minimal Residual Disease Response|CHESON LYMPHOMA 2008|||PARTIAL MORPHOLOGIC RESPONSE|1|hPa|KNEMOMETRY|||Y|CLINICAL STUDY SPONSOR|READER 2|U|4|Visit_4|65|6|TREATMENT|2021-03-11|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-21|P1Y2M10DT2H30M|COINCIDENT|2021-01-25|AFTER|2021-02-21
e|RS|52de3d1f-e750-49f3-9cfa-09ac97a5dd4b|9|CYTORESP|Cytogenetic Response|SCHER PROSTATE CANCER 2011|||RELAPSED DISEASE FROM CR|1|PACKAGE|TRANSESOPHAGEAL ECHOCARDIOGRAPHY|||Y|ADJUDICATOR|READER 1|NA|5|Visit_5|90|3|TREATMENT|2021-04-05|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-10|P1Y2M10DT2H30M|COINCIDENT|2021-02-28|AFTER|2021-03-27
e|RS|52de3d1f-e750-49f3-9cfa-09ac97a5dd4b|10|NTNERESP|Non-Target Non-Enhancing Response|LUGANO CLASSIFICATION|||HI-P|1|umol/L/min|MODIFIED ACID FAST STAIN|Y||Y|FRIEND|ADJUDICATOR|N|5|Visit_5|90|7|SCREENING|2021-04-05|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-10|P1Y2M10DT2H30M|COINCIDENT|2021-04-14|ONGOING|2021-04-15
e|RS|e8065021-c163-41c8-8a76-5f0c1c3a06c4|1|MRPHRESP|Morphologic Response|SCHWARZ CERVICAL CANCER 2009|[?]|ug/day|cPR|1|mU/L|DIGITAL PCR ARRAY|Y|Y||GUARDIAN|RATER 2|Y|1|Visit_1|10|2|TREATMENT|2020-12-08|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-06|P1Y2M10DT2H30M|COINCIDENT|2021-01-06|BEFORE|2021-02-13
e|RS|e8065021-c163-41c8-8a76-5f0c1c3a06c4|2|SPLNRESP|Spleen Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|AU/mL|sCR|1|PACKET|LEAD CITRATE STAIN||Y||INVESTIGATOR|RADIOLOGIST|Y|1|Visit_1|10|7|FOLLOW-UP|2020-12-08|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-06|P1Y2M10DT2H30M|AFTER|2021-01-01|AFTER|2021-01-10
e|RS|e8065021-c163-41c8-8a76-5f0c1c3a06c4|3|MNPTHIND|Minor Pathological Response Indicator|MONTSERRAT CLL 1989|[?]|BAU|RELAPSED DISEASE|1|CIGARETTE|POLYSOMNOGRAPHY||Y||DOMESTIC PARTNER|RADIOLOGIST|Y|2|Visit_2|25|7|TREATMENT|2020-12-23|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-16|P1Y2M10DT2H30M|AFTER|2021-03-02|BEFORE|2021-03-07
e|RS|e8065021-c163-41c8-8a76-5f0c1c3a06c4|4|MRDRESP|Minimal Residual Disease Response|PRINCE TCELL LYMPHOMA 2010|||CYTOGENETIC MINIMAL RESPONSE|1|mg/kg/dose|INFRARED SPECTROMETRY|||Y|CLINICAL RESEARCH COORDINATOR|OTOLARYNGOLOGIST|Y|2|Visit_2|25|6|TREATMENT|2020-12-23|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-16|P1Y2M10DT2H30M|UNKNOWN|2021-02-28|BEFORE|2021-03-01
e|RS|e8065021-c163-41c8-8a76-5f0c1c3a06c4|5|MRDRESP|Minimal Residual Disease Response|HARTMAN PANCREATIC CANCER 2012|[?]|Ci/uL|SD-CT|1|oz|PHASE-CONTRAST MRI||||CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 2|Y|3|Visit_3|40|1|TREATMENT|2021-01-07|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-27|P1Y2M10DT2H30M|UNKNOWN|2021-01-29|COINCIDENT|2021-02-25
e|RS|e8065021-c163-41c8-8a76-5f0c1c3a06c4|6|BMIVLIND|Bone Marrow Involvement Indicator|HARTMAN PANCREATIC CANCER 2012|[?]|mCi|iUPD|1|mCi/kg|POLYGRAPHY|Y|||CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 1|Y|3|Visit_3|40|2|SCREENING|2021-01-07|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-27|P1Y2M10DT2H30M|UNKNOWN|2020-12-18|ONGOING|2021-01-28
e|RS|e8065021-c163-41c8-8a76-5f0c1c3a06c4|7|SYMPTDTR|Symptomatic Deterioration|RECIST 1.1|[?]|gpELISA unit/mL|CRi|1|STEPS|VENTILATION PERFUSION LUNG SCAN||||INDEPENDENT ASSESSOR|ONCOLOGIST 1|U|4|Visit_4|65|5|WASHOUT|2021-02-01|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-28|P1Y2M10DT2H30M|BEFORE|2021-01-17|COINCIDENT|2021-02-21
e|RS|e8065021-c163-41c8-8a76-5f0c1c3a06c4|8|MRPHRESP|Morphologic Response|KUMAR IMWG 2016|||MRD PERSISTENCE|1|ug/mol|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|||Y|SPOUSE|ONCOLOGIST|NA|4|Visit_4|65|5|TREATMENT|2021-02-01|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-28|P1Y2M10DT2H30M|UNKNOWN|2021-02-12|AFTER|2021-03-02
e|RS|e8065021-c163-41c8-8a76-5f0c1c3a06c4|9|MOLRESP|Molecular Response|WHO BREAST CANCER 2006|[?]|cmol/L|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|ugEq|NUCLEIC ACID AMPLIFICATION TEST||||FAMILY MEMBER|CARDIOLOGIST|NA|5|Visit_5|90|4|TREATMENT|2021-02-26|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-10|P1Y2M10DT2H30M|COINCIDENT|2021-03-03|AFTER|2021-03-05
e|RS|e8065021-c163-41c8-8a76-5f0c1c3a06c4|10|MJPTHIND|Major Pathological Response Indicator|EBMT BLADE MYELOMA 1998|||CRi|1|g/m2|RAJI CELL EIA|||Y|CAREGIVER|OTOLARYNGOLOGIST|N|5|Visit_5|90|1|WASHOUT|2021-02-26|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-10|P1Y2M10DT2H30M|BEFORE|2021-03-02|BEFORE|2021-03-06
e|RS|854a9218-995e-47f4-87ab-e58d20f56d19|1|BMIVLIND|Bone Marrow Involvement Indicator|DURIE MULTIPLE MYELOMA 2006|||HI-E|1|%|STRESS ECHOCARDIOGRAPHY|||Y|CAREGIVER|NEUROLOGIST 1|U|1|Visit_1|10|4|SCREENING|2020-11-23|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-14|P1Y2M10DT2H30M|COINCIDENT|2020-11-18|COINCIDENT|2021-01-20
e|RS|854a9218-995e-47f4-87ab-e58d20f56d19|2|MOLRESP|Molecular Response|SACT|[?]|USP U|HI-P|1|mEq/mmol|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION||||CAREGIVER|NEUROLOGIST 2|NA|1|Visit_1|10|6|FOLLOW-UP|2020-11-23|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-14|P1Y2M10DT2H30M|AFTER|2021-01-14|AFTER|2021-02-07
e|RS|854a9218-995e-47f4-87ab-e58d20f56d19|3|MRPHRESP|Morphologic Response|KEAM BREAST CANCER 2013|[?]|PA|PD|1|log10 TCID 50/mL|FLUORESCENT LIFETIME IMAGING MICROSCOPY||||GUARDIAN|MICROSCOPIST|N|2|Visit_2|25|7|WASHOUT|2020-12-08|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-15|P1Y2M10DT2H30M|UNKNOWN|2020-12-30|COINCIDENT|2021-01-08
e|RS|854a9218-995e-47f4-87ab-e58d20f56d19|4|STRUSTAT|Steroid Use Status|IWG CHESON AML 2003|||MR|1|mL/kg/min|DISK DIFFUSION|Y||Y|INVESTIGATOR|MICROSCOPIST 2|NA|2|Visit_2|25|3|SCREENING|2020-12-08|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-15|P1Y2M10DT2H30M|AFTER|2020-11-25|ONGOING|2021-01-23
e|RS|854a9218-995e-47f4-87ab-e58d20f56d19|5|CYTORESP|Cytogenetic Response|IRANO 2015|[?]|g/animal/day|NON-QUANTIFIABLE MRD POSITIVITY|1|mL/kg/min|PH METER MEASUREMENT METHOD||Y||SIBLING|READER|N|3|Visit_3|40|3|FOLLOW-UP|2020-12-23|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-12|P1Y2M10DT2H30M|COINCIDENT|2020-12-01|COINCIDENT|2021-02-09
e|RS|854a9218-995e-47f4-87ab-e58d20f56d19|6|NTNERESP|Non-Target Non-Enhancing Response|EASL BRUIX LIVER CANCER 2001|[?]|breaths/min|HI-P|1|mg/kg/min|DUCTOGRAPHY||||STUDY SUBJECT|PATHOLOGIST|N|3|Visit_3|40|1|TREATMENT|2020-12-23|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-12|P1Y2M10DT2H30M|COINCIDENT|2020-12-29|COINCIDENT|2021-01-02
e|RS|854a9218-995e-47f4-87ab-e58d20f56d19|7|LIVRRESP|Liver Response|RAJKUMAR MYELOMA 2011|[?]|mL/g/day|CYTOGENETIC CR|1|ug/g/min|RADIOGRAPHY||||INDEPENDENT ASSESSOR|ADJUDICATOR 3|Y|4|Visit_4|65|7|FOLLOW-UP|2021-01-17|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-15|P1Y2M10DT2H30M|AFTER|2021-01-01|COINCIDENT|2021-02-02
e|RS|854a9218-995e-47f4-87ab-e58d20f56d19|8|NTRGRESP|Non-target Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|||iUPD|1|mCi/L|CYSTOSCOPY|Y||Y|SPOUSE|READER|U|4|Visit_4|65|6|FOLLOW-UP|2021-01-17|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-15|P1Y2M10DT2H30M|COINCIDENT|2021-02-12|ONGOING|2021-02-14
e|RS|854a9218-995e-47f4-87ab-e58d20f56d19|9|PATHRESP|Pathologic Response|BRUGGEMANN MRD 2010|[?]|keV|COMPLETE MRD RESPONSE|1|U/m2/day|POLYSOMNOGRAPHY||||CAREGIVER|ONCOLOGIST|N|5|Visit_5|90|6|WASHOUT|2021-02-11|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-25|P1Y2M10DT2H30M|BEFORE|2020-11-23|AFTER|2020-12-30
e|RS|854a9218-995e-47f4-87ab-e58d20f56d19|10|CLINRESP|Clinical Response|CHESON CLL 2006|[?]|U/dL|ABSENT MORPHOLOGIC RESPONSE|1|fmol/g|TOTAL BODY IRRADIATION|Y|||CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 2|U|5|Visit_5|90|3|SCREENING|2021-02-11|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-25|P1Y2M10DT2H30M|AFTER|2020-12-13|COINCIDENT|2021-02-02
e|RS|7865f4e0-11d8-45f7-b0d1-0fd7bb4c1311|1|LIVRRESP|Liver Response|SCHWARZ CERVICAL CANCER 2009|[?]|Bq/mg|MAJOR PATHOLOGIC RESPONSE|1|MET|LEAD CITRATE STAIN||||DOMESTIC PARTNER|MICROSCOPIST|U|1|Visit_1|10|5|TREATMENT|2020-06-21|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-19|P1Y2M10DT2H30M|AFTER|2020-07-25|ONGOING|2020-08-23
e|RS|7865f4e0-11d8-45f7-b0d1-0fd7bb4c1311|2|CYTORESP|Cytogenetic Response|CHOI GIST 2008|[?]|lm|SD|1|anti-Xa IU/mL|WESTERN BLOT||||FRIEND|ADJUDICATOR 1|NA|1|Visit_1|10|4|FOLLOW-UP|2020-06-21|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-19|P1Y2M10DT2H30M|UNKNOWN|2020-06-27|AFTER|2020-07-06
e|RS|7865f4e0-11d8-45f7-b0d1-0fd7bb4c1311|3|ANATRESP|Anatomic Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|||UNFAVORABLE RESPONSE|1|BP|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN|||Y|SIGNIFICANT OTHER|READER|NA|2|Visit_2|25|7|SCREENING|2020-07-06|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-25|P1Y2M10DT2H30M|COINCIDENT|2020-08-21|COINCIDENT|2020-09-17
e|RS|7865f4e0-11d8-45f7-b0d1-0fd7bb4c1311|4|BMIVLIND|Bone Marrow Involvement Indicator|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|ukat/10^12 RBC|MORPHOLOGIC CRi|1|QUANTITY SUFFICIENT|CELL BASED BIOASSAY|Y|Y||HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|Y|2|Visit_2|25|6|SCREENING|2020-07-06|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-25|P1Y2M10DT2H30M|AFTER|2020-08-04|AFTER|2020-08-22
e|RS|7865f4e0-11d8-45f7-b0d1-0fd7bb4c1311|5|RDIORESP|Radiologic Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|mL/m2/h|pCR|1|OI50|SLOAN LETTER EYE CHART 2.5%|Y|||CLINICAL STUDY SPONSOR|UROLOGIST|U|3|Visit_3|40|7|FOLLOW-UP|2020-07-21|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-22|P1Y2M10DT2H30M|AFTER|2020-06-22|COINCIDENT|2020-08-10
e|RS|7865f4e0-11d8-45f7-b0d1-0fd7bb4c1311|6|HEMARESP|Hematologic Response|RECIST 1.0|||COMPLETE MRD RESPONSE|1|10^6/L|ETDRS EYE CHART||Y|Y|DOMESTIC PARTNER|DERMATOLOGIST|Y|3|Visit_3|40|4|TREATMENT|2020-07-21|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-22|P1Y2M10DT2H30M|UNKNOWN|2020-07-05|ONGOING|2020-08-09
e|RS|7865f4e0-11d8-45f7-b0d1-0fd7bb4c1311|7|BONERESP|Bone Response|LUGANO CLASSIFICATION|[?]|IU/mmol|PD FROM PR|1|AgU/mL|QUANTITATIVE COMPUTED TOMOGRAPHY||||CLINICAL STUDY SPONSOR|PATHOLOGIST|NA|4|Visit_4|65|1|TREATMENT|2020-08-15|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-13|P1Y2M10DT2H30M|COINCIDENT|2020-08-07|ONGOING|2020-09-09
e|RS|7865f4e0-11d8-45f7-b0d1-0fd7bb4c1311|8|MNPTHIND|Minor Pathological Response Indicator|CHESON CLL 2006|[?]|STEPS|VGPR|1|fL|FLUORIMETRY||||PROXY|ENDOCRINOLOGIST|U|4|Visit_4|65|1|TREATMENT|2020-08-15|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-13|P1Y2M10DT2H30M|AFTER|2020-08-22|AFTER|2020-08-28
e|RS|7865f4e0-11d8-45f7-b0d1-0fd7bb4c1311|9|MRDIND|Minimal Residual Disease Indicator|HAMAOKA BREAST CANCER 2010|[?]|mL/(min*100mL)|CR|1|Roentgen|TELLER ACUITY CARDS|Y|Y||HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|U|5|Visit_5|90|3|TREATMENT|2020-09-09|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-01|P1Y2M10DT2H30M|BEFORE|2020-07-09|COINCIDENT|2020-07-11
e|RS|7865f4e0-11d8-45f7-b0d1-0fd7bb4c1311|10|SPLNRESP|Spleen Response|RECIST 1.0|||NR|1|Pack Year|AUSCULTATION|||Y|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|U|5|Visit_5|90|3|SCREENING|2020-09-09|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-01|P1Y2M10DT2H30M|BEFORE|2020-08-19|AFTER|2020-09-18
e|RS|08944dcd-a62d-4932-bb15-a8f15cc73229|1|NEWLIND|New Lesion Indicator|AJCC V7|[?]|ug/m2/day|INCREASED|1|10^7/L|SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY||||DOMESTIC PARTNER|ONCOLOGIST 1|Y|1|Visit_1|10|5|WASHOUT|2020-12-23|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-26|P1Y2M10DT2H30M|UNKNOWN|2021-02-26|AFTER|2021-02-27
e|RS|08944dcd-a62d-4932-bb15-a8f15cc73229|2|BONERESP|Bone Response|PERCIST|[?]|mg/kg/day|FAVORABLE RESPONSE|1|g/U|THICK SMEAR||Y||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 1|U|1|Visit_1|10|1|WASHOUT|2020-12-23|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-26|P1Y2M10DT2H30M|COINCIDENT|2021-02-02|AFTER|2021-02-22
e|RS|08944dcd-a62d-4932-bb15-a8f15cc73229|3|BESTRESP|Best Overall Response|MASS|||sCR|1|U/mg|CONTRAST ENHANCED SPIRAL CT SCAN|||Y|PARENT|UROLOGIST|NA|2|Visit_2|25|5|TREATMENT|2021-01-07|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-16|P1Y2M10DT2H30M|UNKNOWN|2021-02-05|BEFORE|2021-03-20
e|RS|08944dcd-a62d-4932-bb15-a8f15cc73229|4|TMRESP|Tumor Marker Response|CHOI GIST 2008|[?]|SACHET|PSA PROGRESSION|1|mmol/L|THICK SMEAR||||INDEPENDENT ASSESSOR|NEUROLOGIST|NA|2|Visit_2|25|2|FOLLOW-UP|2021-01-07|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-16|P1Y2M10DT2H30M|AFTER|2021-01-28|COINCIDENT|2021-02-09
e|RS|08944dcd-a62d-4932-bb15-a8f15cc73229|5|SFTSRESP|Soft Tissue Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|log10 PFU|EQUIVOCAL|1|fmol/L|WHOLE TRANSCRIPTOME SEQUENCING||||FRIEND|PHYSIOTHERAPIST|Y|3|Visit_3|40|3|FOLLOW-UP|2021-01-22|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-26|P1Y2M10DT2H30M|AFTER|2021-01-26|AFTER|2021-03-11
e|RS|08944dcd-a62d-4932-bb15-a8f15cc73229|6|CLINRESP|Clinical Response|SHINDOH COLORECTAL CANCER 2013|[?]|10^6 organisms/mg|NE|1|pmol/g|POLYSOMNOGRAPHY||||ADJUDICATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|3|Visit_3|40|3|SCREENING|2021-01-22|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-26|P1Y2M10DT2H30M|UNKNOWN|2021-02-02|ONGOING|2021-03-08
e|RS|08944dcd-a62d-4932-bb15-a8f15cc73229|7|LIVRRESP|Liver Response|NCIWG CHESON CLL 1996|[?]|MESF|MORPHOLOGIC CR|1|mL/breath|FLAME PHOTOMETRY||Y||CHILD|ADJUDICATOR 2|NA|4|Visit_4|65|3|TREATMENT|2021-02-16|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-08|P1Y2M10DT2H30M|BEFORE|2020-12-25|ONGOING|2021-02-05
e|RS|08944dcd-a62d-4932-bb15-a8f15cc73229|8|MRPHRESP|Morphologic Response|CHESON CLL 2012|||MRD RELAPSE|1|mV|TONOMETRY|||Y|INVESTIGATOR|CLINICAL PATHOLOGIST|Y|4|Visit_4|65|7|TREATMENT|2021-02-16|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-08|P1Y2M10DT2H30M|BEFORE|2021-02-19|BEFORE|2021-03-20
e|RS|08944dcd-a62d-4932-bb15-a8f15cc73229|9|SFTSRESP|Soft Tissue Response|LUGANO CLASSIFICATION|[?]|Anson U|PD-CT|1|%(w/w)|MASS SPECTROMETRY||||SIBLING|DEVELOPMENTAL PSYCHOLOGIST|Y|5|Visit_5|90|7|TREATMENT|2021-03-13|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-31|P1Y2M10DT2H30M|COINCIDENT|2021-01-15|COINCIDENT|2021-02-03
e|RS|08944dcd-a62d-4932-bb15-a8f15cc73229|10|CLINRESP|Clinical Response|DOHNER AML 2010|[?]|CAN|DISEASE TRANSFORMATION|1|TAMPON|LC-FL||||STUDY SUBJECT|MICROSCOPIST 2|N|5|Visit_5|90|2|TREATMENT|2021-03-13|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-31|P1Y2M10DT2H30M|UNKNOWN|2021-01-01|ONGOING|2021-01-28
e|RS|1d7df560-695a-41fe-9226-4cc206b05f48|1|MNPTHIND|Minor Pathological Response Indicator|WHO BREAST CANCER 2006|[?]|kg/cm2|iUPD|1|10^3 CFU/mL|INDIA INK STAIN||||ADJUDICATOR|PHYSIOTHERAPIST|U|1|Visit_1|10|1|WASHOUT|2020-12-09|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-13|P1Y2M10DT2H30M|UNKNOWN|2021-01-03|BEFORE|2021-01-15
e|RS|1d7df560-695a-41fe-9226-4cc206b05f48|2|BONERESP|Bone Response|HAMAOKA BREAST CANCER 2010|||sCR|1|KIT|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY|||Y|FRIEND|FORENSIC PATHOLOGIST|N|1|Visit_1|10|1|TREATMENT|2020-12-09|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-13|P1Y2M10DT2H30M|UNKNOWN|2020-12-12|ONGOING|2021-01-12
e|RS|1d7df560-695a-41fe-9226-4cc206b05f48|3|HEMARESP|Hematologic Response|RECICL|[?]|log EID 50/dose|PD/RELAPSE AFTER HI|1|mg/L FEU|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY||Y||CLINICAL RESEARCH ASSOCIATE|CARDIOLOGIST|NA|2|Visit_2|25|1|TREATMENT|2020-12-24|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-01|P1Y2M10DT2H30M|BEFORE|2020-12-25|ONGOING|2021-01-06
e|RS|1d7df560-695a-41fe-9226-4cc206b05f48|4|MRDIND|Minimal Residual Disease Indicator|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|||PD FROM PR|1|Watt|GC/MS-CI|||Y|HEALTH CARE PROFESSIONAL|UROLOGIST|N|2|Visit_2|25|4|WASHOUT|2020-12-24|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-01|P1Y2M10DT2H30M|COINCIDENT|2021-01-07|AFTER|2021-01-27
e|RS|1d7df560-695a-41fe-9226-4cc206b05f48|5|CYTORESP|Cytogenetic Response|RECICL|[?]|SACHET|CR|1|ug/L|REFRACTOMETRY||||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 2|U|3|Visit_3|40|2|WASHOUT|2021-01-08|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-06|P1Y2M10DT2H30M|AFTER|2021-03-06|ONGOING|2021-03-08
e|RS|1d7df560-695a-41fe-9226-4cc206b05f48|6|BMIVLIND|Bone Marrow Involvement Indicator|HARTMANN GERM CELL CANCER 2002|[?]|U/kg/min|COMPLETE MRD RESPONSE|1|CCID 50/mL|SLOAN LETTER EYE CHART 100%||||CLINICAL RESEARCH COORDINATOR|READER 1|U|3|Visit_3|40|4|SCREENING|2021-01-08|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-06|P1Y2M10DT2H30M|BEFORE|2021-02-09|AFTER|2021-02-26
e|RS|1d7df560-695a-41fe-9226-4cc206b05f48|7|MRDIND|Minimal Residual Disease Indicator|MRECIST LENCIONI LIVER CANCER 2010|[?]|Ci/kg|PSEUDORESPONSE|1|mEq|HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY||||CLINICAL STUDY SPONSOR|ADJUDICATOR 1|U|4|Visit_4|65|5|TREATMENT|2021-02-02|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-06|P1Y2M10DT2H30M|BEFORE|2021-02-02|ONGOING|2021-02-17
e|RS|1d7df560-695a-41fe-9226-4cc206b05f48|8|RDIORESP|Radiologic Response|iRECIST|[?]|10^9 CFU/g|MR|1|10^9 organisms/g|FLUORESCENT IMMUNOASSAY||Y||FRIEND|RADIOLOGIST 2|U|4|Visit_4|65|3|SCREENING|2021-02-02|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-06|P1Y2M10DT2H30M|AFTER|2020-12-30|AFTER|2021-01-01
e|RS|1d7df560-695a-41fe-9226-4cc206b05f48|9|BMIVLIND|Bone Marrow Involvement Indicator|iRECIST|[?]|mol/day|PDu|1|10^9 organisms/mg|MIGET||||FAMILY MEMBER|PATHOLOGIST 2|NA|5|Visit_5|90|4|WASHOUT|2021-02-27|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-25|P1Y2M10DT2H30M|UNKNOWN|2021-03-04|AFTER|2021-03-05
e|RS|1d7df560-695a-41fe-9226-4cc206b05f48|10|METSIND|Metastatic Indicator|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|DNA copies/ug|cCR|1|mg/m2/h|IODINE STAIN||Y||INTERVIEWER|MICROSCOPIST|N|5|Visit_5|90|5|TREATMENT|2021-02-27|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-25|P1Y2M10DT2H30M|AFTER|2021-02-04|ONGOING|2021-02-26
e|RS|12c802a8-862c-45a4-b12c-a6f920772534|1|MNPTHIND|Minor Pathological Response Indicator|AJCC V8|||NE|1|ppb|TEMPLATE INCISION METHOD|||Y|CLINICAL RESEARCH COORDINATOR|READER|U|1|Visit_1|10|4|FOLLOW-UP|2020-06-17|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-19|P1Y2M10DT2H30M|BEFORE|2020-07-18|COINCIDENT|2020-09-02
e|RS|12c802a8-862c-45a4-b12c-a6f920772534|2|OVRLRESP|Overall Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|10^7 CFU/mL|NED|1|kV|LC-FL|Y|Y||CAREGIVER|ADJUDICATOR|NA|1|Visit_1|10|2|FOLLOW-UP|2020-06-17|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-19|P1Y2M10DT2H30M|UNKNOWN|2020-06-13|BEFORE|2020-06-26
e|RS|12c802a8-862c-45a4-b12c-a6f920772534|3|MJPTHIND|Major Pathological Response Indicator|CHOI GIST 2008|||NR|1|mL/beat|PALM METHOD||Y|Y|NON-HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|U|2|Visit_2|25|5|WASHOUT|2020-07-02|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-31|P1Y2M10DT2H30M|BEFORE|2020-07-26|BEFORE|2020-08-09
e|RS|12c802a8-862c-45a4-b12c-a6f920772534|4|BESTRESP|Best Overall Response|NCCN ALL MRD 2014|||MORPHOLOGIC CR|1|mm/sec|CISH|||Y|HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|NA|2|Visit_2|25|6|WASHOUT|2020-07-02|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-31|P1Y2M10DT2H30M|UNKNOWN|2020-08-01|ONGOING|2020-08-06
e|RS|12c802a8-862c-45a4-b12c-a6f920772534|5|ANATRESP|Anatomic Response|PERCIST|||RELAPSED DISEASE FROM CR|1|mL/m2|ULTRASONOGRAPHIC ELASTOGRAPHY||Y|Y|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 3|U|3|Visit_3|40|2|TREATMENT|2020-07-17|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-02|P1Y2M10DT2H30M|COINCIDENT|2020-07-31|BEFORE|2020-08-24
e|RS|12c802a8-862c-45a4-b12c-a6f920772534|6|NTRGRESP|Non-target Response|JACINTO CERVICAL CANCER 2007|[?]|cd|MOLECULAR MAJOR RESPONSE|1|ukat|IMMUNOCHROMATOGRAPHY|Y|||CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 1|NA|3|Visit_3|40|6|FOLLOW-UP|2020-07-17|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-02|P1Y2M10DT2H30M|BEFORE|2020-07-16|BEFORE|2020-09-13
e|RS|12c802a8-862c-45a4-b12c-a6f920772534|7|NEWLPROG|New Lesion Progression|RECICL|||PSEUDORESPONSE|1|COAT|MULTIPLE BREATH WASHOUT||Y|Y|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR|N|4|Visit_4|65|1|SCREENING|2020-08-11|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-03|P1Y2M10DT2H30M|COINCIDENT|2020-06-23|ONGOING|2020-08-18
e|RS|12c802a8-862c-45a4-b12c-a6f920772534|8|METBRESP|Metabolic Response|RECICL|[?]|Mile|NOT ALL EVALUATED|1|ug/cm2|FLUORESCENT SPOT TEST||||CLINICAL STUDY SPONSOR|ENDOCRINOLOGIST|NA|4|Visit_4|65|2|WASHOUT|2020-08-11|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-03|P1Y2M10DT2H30M|AFTER|2020-08-15|ONGOING|2020-09-14
e|RS|12c802a8-862c-45a4-b12c-a6f920772534|9|SYMPTDTR|Symptomatic Deterioration|HARTMAN PANCREATIC CANCER 2012|[?]|nkat|IMPROVED|1|AU/mL|CONTRAST ENHANCED PET/CT SCAN||||PARENT|READER|N|5|Visit_5|90|7|TREATMENT|2020-09-05|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-15|P1Y2M10DT2H30M|COINCIDENT|2020-07-28|ONGOING|2020-08-20
e|RS|12c802a8-862c-45a4-b12c-a6f920772534|10|MRDRESP|Minimal Residual Disease Response|SCHWARZ CERVICAL CANCER 2009|[?]|WAFER|MINOR PATHOLOGIC RESPONSE|1|g/day|CONTRAST ENHANCED PET SCAN||||SPOUSE|PEDIATRIC NEUROLOGIST|Y|5|Visit_5|90|3|TREATMENT|2020-09-05|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-15|P1Y2M10DT2H30M|COINCIDENT|2020-07-25|ONGOING|2020-08-17
e|RS|1ac2ce3b-f73f-4a46-a8fe-ea44dfc635a3|1|MJPTHIND|Major Pathological Response Indicator|PRINCE TCELL LYMPHOMA 2010|[?]|mL/cage/day|CYTOGENETIC CR|1|mkat|CONTRAST ENHANCED X-RAY||||VENDOR|RADIOLOGIST|Y|1|Visit_1|10|2|WASHOUT|2020-11-23|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-20|P1Y2M10DT2H30M|UNKNOWN|2021-01-02|AFTER|2021-01-12
e|RS|1ac2ce3b-f73f-4a46-a8fe-ea44dfc635a3|2|MOLRESP|Molecular Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|F|HI-E|1|/HPF|SLIT LAMP PHOTOGRAPHY|Y|||FRIEND|OTOLARYNGOLOGIST|U|1|Visit_1|10|6|FOLLOW-UP|2020-11-23|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-20|P1Y2M10DT2H30M|AFTER|2020-11-19|BEFORE|2020-12-04
e|RS|1ac2ce3b-f73f-4a46-a8fe-ea44dfc635a3|3|OVRLRESP|Overall Response|CHESON LYMPHOMA 2008|||OPTIMAL MORPHOLOGIC RESPONSE|1|amol|KLEIHAUER-BETKE|||Y|DOMESTIC PARTNER|PEDIATRIC NEUROLOGIST|U|2|Visit_2|25|3|TREATMENT|2020-12-08|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-27|P1Y2M10DT2H30M|BEFORE|2021-02-17|COINCIDENT|2021-02-19
e|RS|1ac2ce3b-f73f-4a46-a8fe-ea44dfc635a3|4|NEWLIND|New Lesion Indicator|HARTMAN PANCREATIC CANCER 2012|[?]|mL/g/min|CHR|1|mmHg/sec|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|Y|||PARENT|ONCOLOGIST 1|U|2|Visit_2|25|6|WASHOUT|2020-12-08|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-27|P1Y2M10DT2H30M|BEFORE|2021-01-01|BEFORE|2021-01-31
e|RS|1ac2ce3b-f73f-4a46-a8fe-ea44dfc635a3|5|NTRGRESP|Non-target Response|DURIE MULTIPLE MYELOMA 2006|[?]|mMU/mL|NED|1|uCi/kg|SIZE EXCLUSION CHROMATOGRAPHY||||CLINICAL STUDY SPONSOR|CLINICAL PATHOLOGIST|Y|3|Visit_3|40|3|TREATMENT|2020-12-23|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-22|P1Y2M10DT2H30M|COINCIDENT|2020-11-30|BEFORE|2021-01-01
e|RS|1ac2ce3b-f73f-4a46-a8fe-ea44dfc635a3|6|MNPTHIND|Minor Pathological Response Indicator|BLAZER COLORECTAL CANCER 2008|[?]|mL/m2|EQUIVOCAL|1|10^6 IU/mL|NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY||||SPOUSE|CARDIOLOGIST|U|3|Visit_3|40|2|FOLLOW-UP|2020-12-23|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-22|P1Y2M10DT2H30M|BEFORE|2021-02-12|ONGOING|2021-02-18
e|RS|1ac2ce3b-f73f-4a46-a8fe-ea44dfc635a3|7|PATHRESP|Pathologic Response|CHOLLET BREAST CANCER 2002|[?]|nU/cL|MR|1|Gy/h|QUANTITATIVE ULTRASOUND||||VENDOR|PATHOLOGIST 1|N|4|Visit_4|65|3|TREATMENT|2021-01-17|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-10|P1Y2M10DT2H30M|UNKNOWN|2020-12-02|COINCIDENT|2020-12-24
e|RS|1ac2ce3b-f73f-4a46-a8fe-ea44dfc635a3|8|SFTSRESP|Soft Tissue Response|MONTSERRAT CLL 1989|[?]|km|NED|1|titer|TOTAL BODY RADIOGRAPHY||||INTERVIEWER|CARDIOLOGIST|N|4|Visit_4|65|7|SCREENING|2021-01-17|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-10|P1Y2M10DT2H30M|COINCIDENT|2020-12-17|COINCIDENT|2021-02-18
e|RS|1ac2ce3b-f73f-4a46-a8fe-ea44dfc635a3|9|NTNERESP|Non-Target Non-Enhancing Response|CHOLLET BREAST CANCER 2002|[?]|PACKET|INCREASED|1|Absorbance U/mL|CISH|Y|||CLINICAL STUDY SPONSOR|ADJUDICATOR 1|N|5|Visit_5|90|6|FOLLOW-UP|2021-02-11|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-09|P1Y2M10DT2H30M|BEFORE|2020-12-21|COINCIDENT|2021-01-16
e|RS|1ac2ce3b-f73f-4a46-a8fe-ea44dfc635a3|10|NTRGRESP|Non-target Response|RECIST 1.0|[?]|PACKAGE|NON-QUANTIFIABLE MRD POSITIVITY|1|s*kPa|KINETIC MICROPARTICLE IMMUNOASSAY|Y|||FRIEND|NEUROLOGIST 1|NA|5|Visit_5|90|2|TREATMENT|2021-02-11|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-09|P1Y2M10DT2H30M|AFTER|2021-01-17|COINCIDENT|2021-02-19
e|RS|6c1628af-ea1b-40ea-80fd-667bcfc29a4b|1|NTNERESP|Non-Target Non-Enhancing Response|BRUGGEMANN MRD 2010|[?]|10^5/L|RELAPSED DISEASE FROM CR OR PR|1|IU/kg/h|ELLA||||ADJUDICATOR|UROLOGIST|Y|1|Visit_1|10|3|TREATMENT|2020-08-16|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-08|P1Y2M10DT2H30M|UNKNOWN|2020-11-08|AFTER|2020-11-10
e|RS|6c1628af-ea1b-40ea-80fd-667bcfc29a4b|2|NEWLPROG|New Lesion Progression|MRECIST LENCIONI LIVER CANCER 2010|[?]|10^6/L|NR|1|cP|SCANNING ELECTRON MICROSCOPY||||STUDY SUBJECT|NEUROLOGIST 2|Y|1|Visit_1|10|6|TREATMENT|2020-08-16|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-08|P1Y2M10DT2H30M|UNKNOWN|2020-10-11|AFTER|2020-10-24
e|RS|6c1628af-ea1b-40ea-80fd-667bcfc29a4b|3|MNPTHIND|Minor Pathological Response Indicator|CHOI GIST 2008|[?]|cd|MORPHOLOGIC LEUKEMIA-FREE STATE|1|mL/mmHg|RAJI CELL RIA||||INDEPENDENT ASSESSOR|ONCOLOGIST|U|2|Visit_2|25|5|WASHOUT|2020-08-31|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-04|P1Y2M10DT2H30M|UNKNOWN|2020-09-05|AFTER|2020-11-04
e|RS|6c1628af-ea1b-40ea-80fd-667bcfc29a4b|4|MOLRESP|Molecular Response|KEAM BREAST CANCER 2013|||SD-CT|1|mg/h|HEMATOXYLIN AND EOSIN STAIN||Y|Y|FAMILY MEMBER|READER 3|NA|2|Visit_2|25|2|TREATMENT|2020-08-31|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-04|P1Y2M10DT2H30M|UNKNOWN|2020-10-05|COINCIDENT|2020-10-19
e|RS|6c1628af-ea1b-40ea-80fd-667bcfc29a4b|5|MRDRESP|Minimal Residual Disease Response|WOLCHOK SOLID TUMORS 2009|[?]|days/wk|NON-CR/NON-PD|1|10^3 RNA copies/mL|IMMUNOFIXATION ELECTROPHORESIS||||INTERVIEWER|OTOLARYNGOLOGIST|N|3|Visit_3|40|5|TREATMENT|2020-09-15|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-05|P1Y2M10DT2H30M|BEFORE|2020-10-17|BEFORE|2020-10-31
e|RS|6c1628af-ea1b-40ea-80fd-667bcfc29a4b|6|LIVRRESP|Liver Response|PCWG SCHER PROSTATE CANCER 2008|[?]|log EID 50/dose|CR|1|kN/cm2|TOLUIDINE BLUE STAIN||||SIGNIFICANT OTHER|PHYSIOTHERAPIST|U|3|Visit_3|40|1|FOLLOW-UP|2020-09-15|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-05|P1Y2M10DT2H30M|COINCIDENT|2020-11-05|AFTER|2020-11-08
e|RS|6c1628af-ea1b-40ea-80fd-667bcfc29a4b|7|NTNERESP|Non-Target Non-Enhancing Response|SCHWARZ CERVICAL CANCER 2009|[?]|Absorbance U|ABSENT MORPHOLOGIC RESPONSE|1|g/animal/day|IMMUNOASSAY||||FRIEND|PATHOLOGIST|NA|4|Visit_4|65|2|WASHOUT|2020-10-10|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-10|P1Y2M10DT2H30M|AFTER|2020-10-24|COINCIDENT|2020-11-08
e|RS|6c1628af-ea1b-40ea-80fd-667bcfc29a4b|8|MRDIND|Minimal Residual Disease Indicator|AJCC V8|[?]|Bq/mL|PMR|1|10^9 CFU/mL|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY||||FAMILY MEMBER|CLINICAL PATHOLOGIST|NA|4|Visit_4|65|4|SCREENING|2020-10-10|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-10|P1Y2M10DT2H30M|COINCIDENT|2020-08-25|AFTER|2020-09-30
e|RS|6c1628af-ea1b-40ea-80fd-667bcfc29a4b|9|METBRESP|Metabolic Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|ug/mL/h|PD FROM PR|1|PNU/mL|MULTIPLEXED BEAD BASED IMMUNOASSAY||||CHILD|PATHOLOGIST|NA|5|Visit_5|90|2|TREATMENT|2020-11-04|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-20|P1Y2M10DT2H30M|UNKNOWN|2020-10-18|ONGOING|2020-11-04
e|RS|6c1628af-ea1b-40ea-80fd-667bcfc29a4b|10|MJPTHIND|Major Pathological Response Indicator|GUILHOT CML 2007|[?]|ug/m2/day|PR|1|mOsm/L|CONTRAST ENHANCED X-RAY||||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|NA|5|Visit_5|90|1|TREATMENT|2020-11-04|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-20|P1Y2M10DT2H30M|BEFORE|2020-08-18|COINCIDENT|2020-08-26
e|RS|96114171-59a0-4543-b3ec-c7796ae8ee92|1|MNPTHIND|Minor Pathological Response Indicator|BRUGGEMANN MRD 2010|[?]|um|MOLECULAR CR|1|GPL U|ELISA||||SPOUSE|MICROSCOPIST 2|Y|1|Visit_1|10|6|FOLLOW-UP|2020-11-24|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-15|P1Y2M10DT2H30M|AFTER|2020-12-12|BEFORE|2021-01-14
e|RS|96114171-59a0-4543-b3ec-c7796ae8ee92|2|BMIVLIND|Bone Marrow Involvement Indicator|EASL BRUIX LIVER CANCER 2001|[?]|pt_us|pCR|1|mEq/uL|ECHOCARDIOGRAPHY||||INTERVIEWER|RATER|N|1|Visit_1|10|1|TREATMENT|2020-11-24|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-15|P1Y2M10DT2H30M|UNKNOWN|2020-12-31|AFTER|2021-01-21
e|RS|96114171-59a0-4543-b3ec-c7796ae8ee92|3|CPRFSTAT|Clinical Performance Status|SCHWARZ CERVICAL CANCER 2009|[?]|ug/L FEU|PSA PROGRESSION|1|mU/L|X-RAY||||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 1|U|2|Visit_2|25|5|WASHOUT|2020-12-09|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-03|P1Y2M10DT2H30M|UNKNOWN|2020-12-11|BEFORE|2021-01-10
e|RS|96114171-59a0-4543-b3ec-c7796ae8ee92|4|SPLNRESP|Spleen Response|DOHNER AML 2010|[?]|ELISA unit|TREATMENT FAILURE|1|% INHIBITION|MAGNETIC RESONANCE ANGIOGRAPHY|Y|||GUARDIAN|DERMATOLOGIST|NA|2|Visit_2|25|6|FOLLOW-UP|2020-12-09|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-03|P1Y2M10DT2H30M|BEFORE|2020-12-15|AFTER|2021-02-04
e|RS|96114171-59a0-4543-b3ec-c7796ae8ee92|5|TMRESP|Tumor Marker Response|PCWG BUBLEY PROSTATE CANCER 1999|||PSEUDORESPONSE|1|kPa/L/sec|MAGNETIC RESONANCE ANGIOGRAPHY|Y||Y|CAREGIVER|UROLOGIST|NA|3|Visit_3|40|4|TREATMENT|2020-12-24|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-16|P1Y2M10DT2H30M|COINCIDENT|2021-01-19|AFTER|2021-02-13
e|RS|96114171-59a0-4543-b3ec-c7796ae8ee92|6|CPRFSTAT|Clinical Performance Status|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|cmol|mCR|1|IU/kg|ELASTOGRAPHY|Y|||SPOUSE|CARDIOLOGIST|U|3|Visit_3|40|5|WASHOUT|2020-12-24|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-16|P1Y2M10DT2H30M|BEFORE|2020-12-05|BEFORE|2021-01-15
e|RS|96114171-59a0-4543-b3ec-c7796ae8ee92|7|BESTRESP|Best Overall Response|RAJKUMAR MYELOMA 2011|[?]|mEq/mL|CA125 50% RESPONSE|1|BU/mL|POLYGRAPHY|Y|||NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|Y|4|Visit_4|65|6|TREATMENT|2021-01-18|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-21|P1Y2M10DT2H30M|BEFORE|2021-01-03|AFTER|2021-01-14
e|RS|96114171-59a0-4543-b3ec-c7796ae8ee92|8|SFTSRESP|Soft Tissue Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|nmol/kg/day|SMD|1|10^5/L|SANGER SEQUENCING||||INTERVIEWER|RADIOLOGIST 2|N|4|Visit_4|65|4|SCREENING|2021-01-18|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-21|P1Y2M10DT2H30M|COINCIDENT|2021-01-09|AFTER|2021-02-08
e|RS|96114171-59a0-4543-b3ec-c7796ae8ee92|9|OVRLRESP|Overall Response|EBMT BLADE MYELOMA 1998|||CHR|1|WAFER|PET/MRI SCAN|||Y|CHILD|PATHOLOGIST 1|Y|5|Visit_5|90|6|TREATMENT|2021-02-12|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-15|P1Y2M10DT2H30M|BEFORE|2021-02-13|AFTER|2021-02-14
e|RS|96114171-59a0-4543-b3ec-c7796ae8ee92|10|TRGRESP|Target Response|BLAZER COLORECTAL CANCER 2008|[?]|m2|CR-CT|1|IU/g|IMMUNOASSAY||||CLINICAL STUDY SPONSOR|ONCOLOGIST|N|5|Visit_5|90|6|TREATMENT|2021-02-12|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-15|P1Y2M10DT2H30M|AFTER|2021-02-02|ONGOING|2021-02-05
e|RS|0070d42d-c864-4a83-a3c9-4c8ca7de51de|1|SPLNRESP|Spleen Response|RANO ELLINGSON 2017|[?]|mEq/ug|PD-CT|1|Anson U|SLIT LAMP PHOTOGRAPHY||||ADJUDICATION COMMITTEE|PEDIATRIC NEUROLOGIST|U|1|Visit_1|10|7|TREATMENT|2020-08-15|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-04|P1Y2M10DT2H30M|AFTER|2020-10-08|BEFORE|2020-10-13
e|RS|0070d42d-c864-4a83-a3c9-4c8ca7de51de|2|NTNERESP|Non-Target Non-Enhancing Response|CHESON CLL 2006|[?]|mg/kg/day|PD/RELAPSE AFTER HI|1|QUANTITY SUFFICIENT|MAGNETIC RESONANCE ELASTOGRAPHY||||DOMESTIC PARTNER|RADIOLOGIST 1|U|1|Visit_1|10|5|SCREENING|2020-08-15|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-04|P1Y2M10DT2H30M|COINCIDENT|2020-08-14|COINCIDENT|2020-09-18
e|RS|0070d42d-c864-4a83-a3c9-4c8ca7de51de|3|NEWLWIND|New Lesion Worsening Indicator|KUMAR IMWG 2016|[?]|VOXEL|RELAPSED DISEASE FROM CR|1|nmol BCE/L|ETDRS EYE CHART||||HEALTH CARE PROFESSIONAL|MICROSCOPIST|U|2|Visit_2|25|2|TREATMENT|2020-08-30|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-07|P1Y2M10DT2H30M|AFTER|2020-08-31|ONGOING|2020-09-20
e|RS|0070d42d-c864-4a83-a3c9-4c8ca7de51de|4|HEMARESP|Hematologic Response|WOLCHOK SOLID TUMORS 2009|[?]|U/animal|NON-CR/NON-PD|1|dmol|HILLMEN COLOR CHART|Y|||STUDY SUBJECT|OPHTHALMOLOGIST|Y|2|Visit_2|25|6|TREATMENT|2020-08-30|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-07|P1Y2M10DT2H30M|AFTER|2020-10-23|BEFORE|2020-10-27
e|RS|0070d42d-c864-4a83-a3c9-4c8ca7de51de|5|STRUSTAT|Steroid Use Status|CHOLLET BREAST CANCER 2002|[?]|10^6 IU|RELAPSED DISEASE FROM CR OR PR|1|BAU|PATHOLOGICAL EVALUATION||||DOMESTIC PARTNER|CARDIOLOGIST|U|3|Visit_3|40|2|TREATMENT|2020-09-14|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-16|P1Y2M10DT2H30M|BEFORE|2020-09-09|COINCIDENT|2020-09-21
e|RS|0070d42d-c864-4a83-a3c9-4c8ca7de51de|6|MRDIND|Minimal Residual Disease Indicator|MASS|[?]|umol/mol|iCR|1|kUSP|NUCLEIC ACID AMPLIFICATION TEST||||CLINICAL RESEARCH COORDINATOR|PEDIATRIC NEUROLOGIST|NA|3|Visit_3|40|2|WASHOUT|2020-09-14|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-16|P1Y2M10DT2H30M|UNKNOWN|2020-10-17|COINCIDENT|2020-10-27
e|RS|0070d42d-c864-4a83-a3c9-4c8ca7de51de|7|SFTSRESP|Soft Tissue Response|SCHWARZ CERVICAL CANCER 2009|||PD|1|umol/L/sec|FLOCCULATION, CHARCOAL ENHANCED||Y|Y|SIBLING|NEUROLOGIST|N|4|Visit_4|65|6|TREATMENT|2020-10-09|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-26|P1Y2M10DT2H30M|COINCIDENT|2020-08-28|AFTER|2020-10-05
e|RS|0070d42d-c864-4a83-a3c9-4c8ca7de51de|8|LIVRRESP|Liver Response|IWG CHESON MDS 2006|[?]|nmol/mL/min|SMD|1|mg/kg/min|AUSCULTATION|Y|||STUDY SUBJECT|READER 2|N|4|Visit_4|65|7|TREATMENT|2020-10-09|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-26|P1Y2M10DT2H30M|UNKNOWN|2020-09-18|BEFORE|2020-10-05
e|RS|0070d42d-c864-4a83-a3c9-4c8ca7de51de|9|NEWLIND|New Lesion Indicator|GUILHOT CML 2007|[?]|10^6 CFU|MAJOR PATHOLOGIC RESPONSE|1|LB|CINEANGIOGRAPHY||||CLINICAL RESEARCH ASSOCIATE|OPTOMETRIST|NA|5|Visit_5|90|5|WASHOUT|2020-11-03|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-08|P1Y2M10DT2H30M|COINCIDENT|2020-08-26|ONGOING|2020-09-08
e|RS|0070d42d-c864-4a83-a3c9-4c8ca7de51de|10|MNPTHIND|Minor Pathological Response Indicator|MASS|[?]|kg/cm|PD/RELAPSE AFTER HI|1|mL/kg/day|AURAMINE STAIN||||DOMESTIC PARTNER|ADJUDICATOR|N|5|Visit_5|90|1|TREATMENT|2020-11-03|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-08|P1Y2M10DT2H30M|UNKNOWN|2020-10-28|BEFORE|2020-11-11
e|RS|a2ec3389-6f5f-44a3-a6dd-f6177a805791|1|ANATRESP|Anatomic Response|HAMAOKA BREAST CANCER 2010|[?]|Shock Wave|MOLECULAR CR|1|mg/m2/h|ELECTROGASTROGRAPHY||||CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 2|NA|1|Visit_1|10|5|TREATMENT|2020-10-17|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-01|P1Y2M10DT2H30M|COINCIDENT|2021-01-10|ONGOING|2021-01-11
e|RS|a2ec3389-6f5f-44a3-a6dd-f6177a805791|2|NTRGRESP|Non-target Response|RECIST 1.1|[?]|uL/kg/day|COMPLETE MRD RESPONSE|1|kPa/L/sec|MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING||||CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 1|NA|1|Visit_1|10|5|TREATMENT|2020-10-17|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-01|P1Y2M10DT2H30M|COINCIDENT|2020-12-29|ONGOING|2021-01-06
e|RS|a2ec3389-6f5f-44a3-a6dd-f6177a805791|3|SPLNRESP|Spleen Response|CHESON NON-HODGKINS LYMPHOMA 1999|||HI-N|1|GPL U|ULTRASOUND|||Y|CHILD|ADJUDICATOR|Y|2|Visit_2|25|4|FOLLOW-UP|2020-11-01|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-10|P1Y2M10DT2H30M|UNKNOWN|2020-12-28|COINCIDENT|2021-01-06
e|RS|a2ec3389-6f5f-44a3-a6dd-f6177a805791|4|BMIVLIND|Bone Marrow Involvement Indicator|BRUGGEMANN MRD 2010|[?]|umol/h/mmol|PR WITH LYMPHOCYTOSIS|1|CONTAINER|FLOCCULATION, CHARCOAL ENHANCED||||CHILD|MICROSCOPIST 2|NA|2|Visit_2|25|6|WASHOUT|2020-11-01|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-10|P1Y2M10DT2H30M|AFTER|2020-11-29|ONGOING|2020-12-26
e|RS|a2ec3389-6f5f-44a3-a6dd-f6177a805791|5|MJPTHIND|Major Pathological Response Indicator|KUKER LYMPHOMA 2005|||CYTOGENETIC NO RESPONSE|1|uL/kg/day|DIFFUSION TENSOR MRI||Y|Y|INDEPENDENT ASSESSOR|RADIOLOGIST|N|3|Visit_3|40|4|SCREENING|2020-11-16|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-28|P1Y2M10DT2H30M|COINCIDENT|2020-11-10|AFTER|2020-12-06
e|RS|a2ec3389-6f5f-44a3-a6dd-f6177a805791|6|BONERESP|Bone Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|10^9/g|TREATMENT FAILURE|1|CUP|THICK SMEAR||||CLINICAL RESEARCH COORDINATOR|OPHTHALMOLOGIST|NA|3|Visit_3|40|5|TREATMENT|2020-11-16|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-28|P1Y2M10DT2H30M|BEFORE|2020-11-23|ONGOING|2020-12-06
e|RS|a2ec3389-6f5f-44a3-a6dd-f6177a805791|7|NTNERESP|Non-Target Non-Enhancing Response|RECIST 1.0|||PR|1|BEAM BREAKS|CLAUSS METHOD||Y|Y|DOMESTIC PARTNER|PATHOLOGIST 2|NA|4|Visit_4|65|3|TREATMENT|2020-12-11|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-20|P1Y2M10DT2H30M|BEFORE|2021-01-02|AFTER|2021-01-07
e|RS|a2ec3389-6f5f-44a3-a6dd-f6177a805791|8|MRDIND|Minimal Residual Disease Indicator|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|dpm/mg|PR|1|10^6 DNA copies/mL|FLOW CYTOMETRY||||SIBLING|ADJUDICATOR|N|4|Visit_4|65|6|SCREENING|2020-12-11|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-20|P1Y2M10DT2H30M|UNKNOWN|2021-01-14|BEFORE|2021-01-15
e|RS|a2ec3389-6f5f-44a3-a6dd-f6177a805791|9|NTERESP|Non-Target Enhancing Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|||MR|1|log EID 50/dose|MAGNETIC RESONANCE ENTEROGRAPHY||Y|Y|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 2|N|5|Visit_5|90|5|TREATMENT|2021-01-05|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-21|P1Y2M10DT2H30M|COINCIDENT|2020-12-31|BEFORE|2021-01-06
e|RS|a2ec3389-6f5f-44a3-a6dd-f6177a805791|10|SYMPTDTR|Symptomatic Deterioration|LUGANO CLASSIFICATION|[?]|copies/mL|iUPD|1|log10 TCID 50/uL|ENZYMATIC COLORIMETRY|Y|||CHILD|READER 2|U|5|Visit_5|90|2|WASHOUT|2021-01-05|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-21|P1Y2M10DT2H30M|UNKNOWN|2020-11-27|AFTER|2020-12-07
e|RS|cc562042-9641-460d-862e-d6923dd4207d|1|MRPHRESP|Morphologic Response|UNSPECIFIED|||CR-CT|1|10^6 organisms/mg|TARGETED GENOME SEQUENCING|Y||Y|STUDY SUBJECT|PEDIATRIC NEUROLOGIST|Y|1|Visit_1|10|4|WASHOUT|2020-05-27|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-17|P1Y2M10DT2H30M|COINCIDENT|2020-05-19|COINCIDENT|2020-07-23
e|RS|cc562042-9641-460d-862e-d6923dd4207d|2|CPRFSTAT|Clinical Performance Status|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|aMFI|UNFAVORABLE RESPONSE|1|ug/m2/h|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE||||CAREGIVER|READER 2|N|1|Visit_1|10|6|TREATMENT|2020-05-27|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-17|P1Y2M10DT2H30M|BEFORE|2020-06-13|AFTER|2020-08-20
e|RS|cc562042-9641-460d-862e-d6923dd4207d|3|MJPTHIND|Major Pathological Response Indicator|AJCC V7|[?]|Siemens|MOLECULAR MAJOR RESPONSE|1|kcal/day|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION||Y||PROXY|MICROSCOPIST|N|2|Visit_2|25|5|TREATMENT|2020-06-11|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-17|P1Y2M10DT2H30M|COINCIDENT|2020-08-24|ONGOING|2020-08-25
e|RS|cc562042-9641-460d-862e-d6923dd4207d|4|TRGRESP|Target Response|FAROOQUI SUPP CLL 2014|||DISEASE TRANSFORMATION|1|mg/kg/day|SISH|Y||Y|STUDY SUBJECT|RATER 2|Y|2|Visit_2|25|6|FOLLOW-UP|2020-06-11|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-17|P1Y2M10DT2H30M|COINCIDENT|2020-05-21|ONGOING|2020-06-28
e|RS|cc562042-9641-460d-862e-d6923dd4207d|5|TRGRESP|Target Response|CHESON NON-HODGKINS LYMPHOMA 1999|||MORPHOLOGIC CRi|1|gtt|PHOTOGRAPHY|||Y|VENDOR|ADJUDICATOR|NA|3|Visit_3|40|4|FOLLOW-UP|2020-06-26|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-03|P1Y2M10DT2H30M|UNKNOWN|2020-07-29|COINCIDENT|2020-08-16
e|RS|cc562042-9641-460d-862e-d6923dd4207d|6|NEWLPROG|New Lesion Progression|CHESON CLL 2006|[?]|mL/m2/h|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|ug/L FEU|MICROSCOPY||Y||INDEPENDENT ASSESSOR|ADJUDICATOR 3|Y|3|Visit_3|40|3|TREATMENT|2020-06-26|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-03|P1Y2M10DT2H30M|COINCIDENT|2020-08-19|ONGOING|2020-08-20
e|RS|cc562042-9641-460d-862e-d6923dd4207d|7|CLINRESP|Clinical Response|RECICL|[?]|pmol/10^10 cells|CYTOGENETIC NO RESPONSE|1|kg/cm|GC/MS-EI||||SPOUSE|CARDIOLOGIST|Y|4|Visit_4|65|3|TREATMENT|2020-07-21|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-14|P1Y2M10DT2H30M|UNKNOWN|2020-05-23|ONGOING|2020-06-29
e|RS|cc562042-9641-460d-862e-d6923dd4207d|8|CPRFSTAT|Clinical Performance Status|GCIG RUSTIN OVARIAN CANCER 2011|[?]|beats/min|IMMUNOPHENOTYPIC CR|1|Absorbance U|CLIP|Y|||PROXY|OPTOMETRIST|Y|4|Visit_4|65|7|TREATMENT|2020-07-21|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-14|P1Y2M10DT2H30M|COINCIDENT|2020-06-02|COINCIDENT|2020-06-17
e|RS|cc562042-9641-460d-862e-d6923dd4207d|9|MNPTHIND|Minor Pathological Response Indicator|CHOLLET BREAST CANCER 2002|[?]|10^6/hpf|PD-CT|1|mL/g/min|ELISA|Y|||STUDY SUBJECT|MICROSCOPIST 2|NA|5|Visit_5|90|4|TREATMENT|2020-08-15|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-04|P1Y2M10DT2H30M|COINCIDENT|2020-07-10|ONGOING|2020-07-28
e|RS|cc562042-9641-460d-862e-d6923dd4207d|10|NTERESP|Non-Target Enhancing Response|WHO BREAST CANCER 2006|[?]|Rad|UNFAVORABLE RESPONSE|1|m|CLIP||||ADJUDICATION COMMITTEE|ADJUDICATOR 2|N|5|Visit_5|90|6|TREATMENT|2020-08-15|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-04|P1Y2M10DT2H30M|COINCIDENT|2020-05-19|COINCIDENT|2020-06-24
e|RS|d0a4f2af-eb3c-4f04-b16d-b3ef5a8d0646|1|OVRLRESP|Overall Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|nkat/g Hb|PD/RELAPSE AFTER HI|1|10^6 CFU/g|BIOPSY||||CHILD|PEDIATRIC NEUROLOGIST|Y|1|Visit_1|10|7|TREATMENT|2020-07-30|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-27|P1Y2M10DT2H30M|UNKNOWN|2020-08-25|ONGOING|2020-09-19
e|RS|d0a4f2af-eb3c-4f04-b16d-b3ef5a8d0646|2|NTNERESP|Non-Target Non-Enhancing Response|IWG CHESON AML 2003|||PARTIAL MORPHOLOGIC RESPONSE|1|L/min|BAC ACGH|||Y|INDEPENDENT ASSESSOR|ADJUDICATOR 3|U|1|Visit_1|10|6|WASHOUT|2020-07-30|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-27|P1Y2M10DT2H30M|COINCIDENT|2020-09-05|COINCIDENT|2020-09-19
e|RS|d0a4f2af-eb3c-4f04-b16d-b3ef5a8d0646|3|SYMPTDTR|Symptomatic Deterioration|PERCIST|[?]|mg/h|NOT ALL EVALUATED|1|mL/g/min|CORONARY ANGIOGRAPHY||||VENDOR|MICROSCOPIST 2|Y|2|Visit_2|25|6|WASHOUT|2020-08-14|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-09|P1Y2M10DT2H30M|UNKNOWN|2020-07-23|AFTER|2020-08-20
e|RS|d0a4f2af-eb3c-4f04-b16d-b3ef5a8d0646|4|NEWLPROG|New Lesion Progression|EBMT BLADE MYELOMA 1998|[?]|IU/g|NED|1|WAFER|PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY|Y|||SIBLING|ADJUDICATOR 2|N|2|Visit_2|25|3|TREATMENT|2020-08-14|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-09|P1Y2M10DT2H30M|COINCIDENT|2020-07-30|BEFORE|2020-08-26
e|RS|d0a4f2af-eb3c-4f04-b16d-b3ef5a8d0646|5|NEWLWIND|New Lesion Worsening Indicator|MONTSERRAT CLL 1989|[?]|eq|CYTOGENETIC MINIMAL RESPONSE|1|ELISA unit|INDIRECT IMMUNOFLUORESCENCE||Y||VENDOR|ONCOLOGIST 1|U|3|Visit_3|40|5|TREATMENT|2020-08-29|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-29|P1Y2M10DT2H30M|COINCIDENT|2020-08-26|AFTER|2020-09-30
e|RS|d0a4f2af-eb3c-4f04-b16d-b3ef5a8d0646|6|MRDIND|Minimal Residual Disease Indicator|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|% INHIBITION|EQUIVOCAL|1|uL/mL|NUCLEIC ACID HYBRIDIZATION||||CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 1|N|3|Visit_3|40|1|WASHOUT|2020-08-29|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-29|P1Y2M10DT2H30M|AFTER|2020-07-25|COINCIDENT|2020-09-12
e|RS|d0a4f2af-eb3c-4f04-b16d-b3ef5a8d0646|7|NTNERESP|Non-Target Non-Enhancing Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|||PD-CT|1|mL/breath|PERIPHERAL ANGIOGRAPHY|Y||Y|INTERVIEWER|ADJUDICATOR 2|Y|4|Visit_4|65|3|FOLLOW-UP|2020-09-23|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-20|P1Y2M10DT2H30M|AFTER|2020-08-17|ONGOING|2020-09-11
e|RS|d0a4f2af-eb3c-4f04-b16d-b3ef5a8d0646|8|BMIVLIND|Bone Marrow Involvement Indicator|GCIG RUSTIN OVARIAN CANCER 2011|[?]|nsec|CR|1|/500 WBC|FLOW CYTOMETRY||||FRIEND|PEDIATRIC NEUROLOGIST|NA|4|Visit_4|65|4|TREATMENT|2020-09-23|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-20|P1Y2M10DT2H30M|BEFORE|2020-10-02|AFTER|2020-10-16
e|RS|d0a4f2af-eb3c-4f04-b16d-b3ef5a8d0646|9|MOLRESP|Molecular Response|FAROOQUI SUPP CLL 2014|[?]|mL/cm H2O|UNEQUIVOCAL|1|g/cage/wk|ANTIMICROBIAL COMBINATION TESTING||||CLINICAL STUDY SPONSOR|CARDIOLOGIST|Y|5|Visit_5|90|5|SCREENING|2020-10-18|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-19|P1Y2M10DT2H30M|UNKNOWN|2020-07-27|AFTER|2020-09-16
e|RS|d0a4f2af-eb3c-4f04-b16d-b3ef5a8d0646|10|MNPTHIND|Minor Pathological Response Indicator|HARTMAN PANCREATIC CANCER 2012|[?]|10^6 CFU/g|CYTOGENETIC CR|1|anti-Xa IU/mL|PELLI-ROBSON EYE CHART||||PARENT|PATHOLOGIST|Y|5|Visit_5|90|5|TREATMENT|2020-10-18|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-19|P1Y2M10DT2H30M|AFTER|2020-07-29|BEFORE|2020-09-19
e|RS|d90f2824-692e-403f-b1ca-5b6462c93a75|1|BONERESP|Bone Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|mL/kg/h|OPTIMAL MORPHOLOGIC RESPONSE|1|KIT|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN||Y||GUARDIAN|MICROSCOPIST 1|NA|1|Visit_1|10|7|WASHOUT|2020-07-15|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-31|P1Y2M10DT2H30M|AFTER|2020-09-01|COINCIDENT|2020-10-01
e|RS|d90f2824-692e-403f-b1ca-5b6462c93a75|2|BMIVLIND|Bone Marrow Involvement Indicator|PERCIST|[?]|TCID 50/dose|sCR|1|nmol/mol|CARDIAC THERMODILUTION|Y|||PROXY|ADJUDICATOR 3|N|1|Visit_1|10|1|SCREENING|2020-07-15|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-31|P1Y2M10DT2H30M|AFTER|2020-08-29|BEFORE|2020-10-03
e|RS|d90f2824-692e-403f-b1ca-5b6462c93a75|3|MNPTHIND|Minor Pathological Response Indicator|IWC HALLEK CLL 2008|||MORPHOLOGIC LEUKEMIA-FREE STATE|1|mmol/g|MAMMOGRAPHY|||Y|CHILD|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|2|Visit_2|25|2|TREATMENT|2020-07-30|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-17|P1Y2M10DT2H30M|BEFORE|2020-08-21|ONGOING|2020-10-01
e|RS|d90f2824-692e-403f-b1ca-5b6462c93a75|4|BMIVLIND|Bone Marrow Involvement Indicator|NCCN ALL MRD 2014|[?]|m3|SD|1|10^7 CFU|PAP STAIN||||CAREGIVER|READER 3|Y|2|Visit_2|25|2|TREATMENT|2020-07-30|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-17|P1Y2M10DT2H30M|COINCIDENT|2020-07-24|BEFORE|2020-08-02
e|RS|d90f2824-692e-403f-b1ca-5b6462c93a75|5|METSIND|Metastatic Indicator|RAJKUMAR MYELOMA 2011|[?]|Antibody Unit|PR|1|mL/m2/day|ELECTROGASTROGRAPHY||||SPOUSE|CLINICAL PATHOLOGIST|U|3|Visit_3|40|7|TREATMENT|2020-08-14|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-18|P1Y2M10DT2H30M|BEFORE|2020-08-29|AFTER|2020-09-24
e|RS|d90f2824-692e-403f-b1ca-5b6462c93a75|6|MOLRESP|Molecular Response|AJCC V7|[?]|mL/kg/h|SD-CT|1|pmol/dL|BALLPOINT PEN TECHNIQUE|Y|Y||FAMILY MEMBER|OPTOMETRIST|Y|3|Visit_3|40|5|TREATMENT|2020-08-14|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-18|P1Y2M10DT2H30M|BEFORE|2020-07-11|COINCIDENT|2020-08-09
e|RS|d90f2824-692e-403f-b1ca-5b6462c93a75|7|NTRGRESP|Non-target Response|PCWG BUBLEY PROSTATE CANCER 1999|||PMR|1|SACHET|WESTERN BLOT|||Y|PROXY|RADIOLOGIST 2|U|4|Visit_4|65|3|WASHOUT|2020-09-08|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-31|P1Y2M10DT2H30M|UNKNOWN|2020-09-15|ONGOING|2020-10-06
e|RS|d90f2824-692e-403f-b1ca-5b6462c93a75|8|NTLWIND|Non-Target Lesion Worsening Indicator|MRECIST LENCIONI LIVER CANCER 2010|[?]|mL/g/day|UNFAVORABLE RESPONSE|1|mg/g/h|ELECTROMYOGRAPHY|Y|||DOMESTIC PARTNER|MICROSCOPIST 2|N|4|Visit_4|65|1|TREATMENT|2020-09-08|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-31|P1Y2M10DT2H30M|BEFORE|2020-09-09|BEFORE|2020-09-12
e|RS|d90f2824-692e-403f-b1ca-5b6462c93a75|9|MRDIND|Minimal Residual Disease Indicator|RAJKUMAR MYELOMA 2011|[?]|vg/dose|NED|1|MASK|ACCELERATOR MASS SPECTROMETRY||Y||SIBLING|ADJUDICATOR|N|5|Visit_5|90|2|TREATMENT|2020-10-03|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-29|P1Y2M10DT2H30M|COINCIDENT|2020-08-13|BEFORE|2020-09-25
e|RS|d90f2824-692e-403f-b1ca-5b6462c93a75|10|MNPTHIND|Minor Pathological Response Indicator|KUKER LYMPHOMA 2005|||CA125 50% RESPONSE|1|PFU/dose|MUGA|||Y|INVESTIGATOR|READER 3|Y|5|Visit_5|90|1|TREATMENT|2020-10-03|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-29|P1Y2M10DT2H30M|BEFORE|2020-09-14|AFTER|2020-10-07
e|RS|ee0e55e1-6107-4a3c-85b4-cb48300153e8|1|NTERESP|Non-Target Enhancing Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|APS U|CR|1|10^3 CFU/mL|SISH||||FAMILY MEMBER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|1|Visit_1|10|2|FOLLOW-UP|2020-05-25|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-28|P1Y2M10DT2H30M|BEFORE|2020-06-28|BEFORE|2020-08-22
e|RS|ee0e55e1-6107-4a3c-85b4-cb48300153e8|2|STRUSTAT|Steroid Use Status|JACINTO CERVICAL CANCER 2007|[?]|10^4 CFU/mL|PSEUDORESPONSE|1|Antibody Unit|AURAMINE STAIN||||FAMILY MEMBER|ADJUDICATOR 3|U|1|Visit_1|10|3|FOLLOW-UP|2020-05-25|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-28|P1Y2M10DT2H30M|AFTER|2020-07-25|COINCIDENT|2020-08-06
e|RS|ee0e55e1-6107-4a3c-85b4-cb48300153e8|3|BESTRESP|Best Overall Response|EBMT BLADE MYELOMA 1998|||iSD|1|deg|TEMPLATE INCISION METHOD|||Y|CAREGIVER|INTERNIST|Y|2|Visit_2|25|1|TREATMENT|2020-06-09|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-27|P1Y2M10DT2H30M|UNKNOWN|2020-05-20|BEFORE|2020-06-23
e|RS|ee0e55e1-6107-4a3c-85b4-cb48300153e8|4|SFTSRESP|Soft Tissue Response|PERCIST|[?]|g/animal|PDu|1|kg/m2|ELECTROPHORESIS||||INVESTIGATOR|OTOLARYNGOLOGIST|Y|2|Visit_2|25|3|TREATMENT|2020-06-09|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-27|P1Y2M10DT2H30M|BEFORE|2020-07-31|BEFORE|2020-08-02
e|RS|ee0e55e1-6107-4a3c-85b4-cb48300153e8|5|NEWLWIND|New Lesion Worsening Indicator|KUKER LYMPHOMA 2005|[?]|U/10^12 RBC|PD|1|EIA unit|ICC||||ADJUDICATOR|MICROSCOPIST|NA|3|Visit_3|40|3|WASHOUT|2020-06-24|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-22|P1Y2M10DT2H30M|BEFORE|2020-08-10|AFTER|2020-08-16
e|RS|ee0e55e1-6107-4a3c-85b4-cb48300153e8|6|BESTRESP|Best Overall Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|P|NON-PD|1|umol/L/min|BALLPOINT PEN TECHNIQUE||||INVESTIGATOR|ADJUDICATOR 2|N|3|Visit_3|40|1|TREATMENT|2020-06-24|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-22|P1Y2M10DT2H30M|COINCIDENT|2020-07-05|ONGOING|2020-07-31
e|RS|ee0e55e1-6107-4a3c-85b4-cb48300153e8|7|MNPTHIND|Minor Pathological Response Indicator|IWC HALLEK CLL 2008|||MRD PERSISTENCE|1|copies/mL|FLUORESCENT SPOT TEST|||Y|VENDOR|RATER|N|4|Visit_4|65|4|SCREENING|2020-07-19|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-23|P1Y2M10DT2H30M|COINCIDENT|2020-06-26|COINCIDENT|2020-07-23
e|RS|ee0e55e1-6107-4a3c-85b4-cb48300153e8|8|PATHRESP|Pathologic Response|KUKER LYMPHOMA 2005|||CYTOGENETIC PR|1|/sec|CLAUSS METHOD|||Y|ADJUDICATOR|NEUROLOGIST 2|Y|4|Visit_4|65|3|WASHOUT|2020-07-19|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-23|P1Y2M10DT2H30M|COINCIDENT|2020-06-29|COINCIDENT|2020-07-05
e|RS|ee0e55e1-6107-4a3c-85b4-cb48300153e8|9|CYTORESP|Cytogenetic Response|BLAZER COLORECTAL CANCER 2008|||NON-iCR/NON-iUPD|1|uCi/L|MICROPARTICLE ENZYME IMMUNOASSAY||Y|Y|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 1|Y|5|Visit_5|90|6|TREATMENT|2020-08-13|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-06|P1Y2M10DT2H30M|AFTER|2020-06-15|AFTER|2020-08-15
e|RS|ee0e55e1-6107-4a3c-85b4-cb48300153e8|10|ANATRESP|Anatomic Response|iRECIST|[?]|uV*sec|MAJOR PATHOLOGIC RESPONSE|1|umol|CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|Y|||STUDY SUBJECT|RATER 1|N|5|Visit_5|90|7|TREATMENT|2020-08-13|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-06|P1Y2M10DT2H30M|UNKNOWN|2020-07-20|BEFORE|2020-08-17
e|RS|6aa37bb3-85aa-427f-9e56-a776257f1548|1|NEWLPROG|New Lesion Progression|FAROOQUI SUPP CLL 2014|||RELAPSED DISEASE FROM CR|1|mEq/kg|KLEIHAUER-BETKE|||Y|PARENT|INTERNIST|Y|1|Visit_1|10|5|TREATMENT|2020-11-14|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-22|P1Y2M10DT2H30M|AFTER|2020-11-08|AFTER|2021-01-02
e|RS|6aa37bb3-85aa-427f-9e56-a776257f1548|2|NTERESP|Non-Target Enhancing Response|UNSPECIFIED|[?]|v/v|NE|1|DRUM|ANALYTICAL ULTRACENTRIFUGATION||||PROXY|ADJUDICATOR 1|Y|1|Visit_1|10|1|WASHOUT|2020-11-14|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-22|P1Y2M10DT2H30M|COINCIDENT|2020-11-22|AFTER|2021-02-05
e|RS|6aa37bb3-85aa-427f-9e56-a776257f1548|3|TRGRESP|Target Response|GUPPY OVARIAN CANCER 2002|||INCREASED|1|LB|IMMUNOASSAY|Y||Y|FAMILY MEMBER|READER 2|U|2|Visit_2|25|6|WASHOUT|2020-11-29|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-16|P1Y2M10DT2H30M|BEFORE|2021-01-17|ONGOING|2021-01-20
e|RS|6aa37bb3-85aa-427f-9e56-a776257f1548|4|MRPHRESP|Morphologic Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|mL/g/min|FAVORABLE RESPONSE|1|K|DYNAMIC LIGHT SCATTERING||||FRIEND|DERMATOLOGIST|U|2|Visit_2|25|4|SCREENING|2020-11-29|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-16|P1Y2M10DT2H30M|UNKNOWN|2020-12-24|ONGOING|2021-02-07
e|RS|6aa37bb3-85aa-427f-9e56-a776257f1548|5|DRCRIND|Disease Recurrence Indicator|LEE LUNG CANCER 2011|[?]|g/mol|HI-P|1|umol/L/sec|ATOMIC ABSORPTION SPECTROMETRY|Y|||GUARDIAN|READER 3|U|3|Visit_3|40|5|SCREENING|2020-12-14|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-13|P1Y2M10DT2H30M|COINCIDENT|2020-11-16|ONGOING|2020-12-13
e|RS|6aa37bb3-85aa-427f-9e56-a776257f1548|6|BONERESP|Bone Response|SCHWARZ CERVICAL CANCER 2009|[?]|pmol/10^10 cells|RELAPSED DISEASE|1|ug/m2|SPECULAR MICROSCOPY|Y|Y||ADJUDICATION COMMITTEE|ONCOLOGIST 2|U|3|Visit_3|40|5|TREATMENT|2020-12-14|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-13|P1Y2M10DT2H30M|UNKNOWN|2020-11-25|BEFORE|2021-01-30
e|RS|6aa37bb3-85aa-427f-9e56-a776257f1548|7|NEWLIND|New Lesion Indicator|GUILHOT CML 2007|[?]|mL/h|CR-CT|1|10^3 CFU/mL|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY||||CHILD|ADJUDICATOR|Y|4|Visit_4|65|4|TREATMENT|2021-01-08|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-12|P1Y2M10DT2H30M|AFTER|2021-01-14|BEFORE|2021-01-24
e|RS|6aa37bb3-85aa-427f-9e56-a776257f1548|8|CPRFSTAT|Clinical Performance Status|iRECIST|[?]|U.CARR|HI-E|1|cy/cm|FLUORESCENCE ANGIOGRAPHY||||CAREGIVER|RADIOLOGIST 2|N|4|Visit_4|65|2|SCREENING|2021-01-08|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-12|P1Y2M10DT2H30M|BEFORE|2020-12-17|AFTER|2020-12-28
e|RS|6aa37bb3-85aa-427f-9e56-a776257f1548|9|NEWLIND|New Lesion Indicator|LEE LUNG CANCER 2011|[?]|psec|HI-E|1|cm/min|MASS SPECTROMETRY||||VENDOR|CARDIOLOGIST|NA|5|Visit_5|90|2|TREATMENT|2021-02-02|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-20|P1Y2M10DT2H30M|UNKNOWN|2020-11-12|COINCIDENT|2021-01-08
e|RS|6aa37bb3-85aa-427f-9e56-a776257f1548|10|MRPHRESP|Morphologic Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|||NON-iCR/NON-iUPD|1|/5x10^4 WBC|PANENDOSCOPY|||Y|INVESTIGATOR|PATHOLOGIST 2|Y|5|Visit_5|90|1|TREATMENT|2021-02-02|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-20|P1Y2M10DT2H30M|BEFORE|2021-01-13|COINCIDENT|2021-01-25
e|RS|592c5ea9-d4ca-4c3a-a836-6d88f2b93303|1|NEWLPROG|New Lesion Progression|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|yd|CYTOGENETIC MINOR RESPONSE|1|Gy|ERGOSPIROMETRY||||PROXY|READER 3|Y|1|Visit_1|10|1|SCREENING|2020-05-18|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-14|P1Y2M10DT2H30M|COINCIDENT|2020-06-27|ONGOING|2020-08-10
e|RS|592c5ea9-d4ca-4c3a-a836-6d88f2b93303|2|STRUSTAT|Steroid Use Status|BRUGGEMANN MRD 2010|[?]|g/kg/day|PD|1|Gy/min|HPLC/MS/MS||||DOMESTIC PARTNER|ONCOLOGIST 1|Y|1|Visit_1|10|3|TREATMENT|2020-05-18|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-14|P1Y2M10DT2H30M|UNKNOWN|2020-07-24|COINCIDENT|2020-08-10
e|RS|592c5ea9-d4ca-4c3a-a836-6d88f2b93303|3|PATHRESP|Pathologic Response|DOHNER AML 2010|||HI-N|1|10^5/hpf|DOUBLE IMMUNODIFFUSION|Y||Y|PROXY|RATER 2|N|2|Visit_2|25|2|TREATMENT|2020-06-02|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-15|P1Y2M10DT2H30M|BEFORE|2020-06-01|BEFORE|2020-08-07
e|RS|592c5ea9-d4ca-4c3a-a836-6d88f2b93303|4|MNPTHIND|Minor Pathological Response Indicator|IRANO 2015|[?]|DDU|mCR|1|mEq/uL|SMEAR||||STUDY SUBJECT|READER 1|N|2|Visit_2|25|5|FOLLOW-UP|2020-06-02|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-15|P1Y2M10DT2H30M|AFTER|2020-07-11|ONGOING|2020-07-27
e|RS|592c5ea9-d4ca-4c3a-a836-6d88f2b93303|5|MRPHRESP|Morphologic Response|RECIST 1.0|||WORSENED|1|dL|KINETIC CHROMOGENIC ASSAY||Y|Y|FRIEND|UROLOGIST|Y|3|Visit_3|40|1|TREATMENT|2020-06-17|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-22|P1Y2M10DT2H30M|UNKNOWN|2020-06-19|ONGOING|2020-07-22
e|RS|592c5ea9-d4ca-4c3a-a836-6d88f2b93303|6|MRDIND|Minimal Residual Disease Indicator|SACT|[?]|oz eq|WORSENED|1|%(w/v)|ACID FAST STAIN|Y|Y||SIGNIFICANT OTHER|FORENSIC PATHOLOGIST|Y|3|Visit_3|40|4|SCREENING|2020-06-17|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-22|P1Y2M10DT2H30M|COINCIDENT|2020-07-24|AFTER|2020-07-28
e|RS|592c5ea9-d4ca-4c3a-a836-6d88f2b93303|7|OVRLRESP|Overall Response|IWG CHESON MDS 2000|[?]|U/kg/h|NE|1|g/day|LASER CAPTURE MICRODISSECTION|Y|||SIGNIFICANT OTHER|RATER 1|NA|4|Visit_4|65|3|SCREENING|2020-07-12|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-26|P1Y2M10DT2H30M|UNKNOWN|2020-07-26|ONGOING|2020-08-03
e|RS|592c5ea9-d4ca-4c3a-a836-6d88f2b93303|8|NTRGRESP|Non-target Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|mg/mL/day|PR|1|fmol/L|SIZE EXCLUSION CHROMATOGRAPHY|Y|||PARENT|FORENSIC PATHOLOGIST|N|4|Visit_4|65|1|SCREENING|2020-07-12|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-26|P1Y2M10DT2H30M|BEFORE|2020-05-10|BEFORE|2020-06-14
e|RS|592c5ea9-d4ca-4c3a-a836-6d88f2b93303|9|NEWLWIND|New Lesion Worsening Indicator|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|uV|CYTOGENETIC MINOR RESPONSE|1|%|CELLULOSE TAPE||||INDEPENDENT ASSESSOR|ADJUDICATOR 2|U|5|Visit_5|90|4|SCREENING|2020-08-06|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-18|P1Y2M10DT2H30M|BEFORE|2020-07-02|COINCIDENT|2020-08-05
e|RS|592c5ea9-d4ca-4c3a-a836-6d88f2b93303|10|PATHRESP|Pathologic Response|EBMT BLADE MYELOMA 1998|[?]|10^3 organisms|SD|1|ppb|DYNAMIC LIGHT SCATTERING|Y|||VENDOR|RATER|Y|5|Visit_5|90|6|FOLLOW-UP|2020-08-06|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-18|P1Y2M10DT2H30M|AFTER|2020-07-30|BEFORE|2020-08-06
e|RS|940d4614-b41a-44d3-b878-6e19ee22f24b|1|ANATRESP|Anatomic Response|WOLCHOK SOLID TUMORS 2009|[?]|mmHg*min/L|HI-N|1|breaths/min|SXA SCAN|Y|||INTERVIEWER|RADIOLOGIST 1|U|1|Visit_1|10|1|TREATMENT|2020-07-06|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-17|P1Y2M10DT2H30M|COINCIDENT|2020-09-01|BEFORE|2020-09-18
e|RS|940d4614-b41a-44d3-b878-6e19ee22f24b|2|BESTRESP|Best Overall Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|10^6 organisms/mg|DECREASED|1|uEq/L|PHYSICAL EXAMINATION||||PARENT|MICROSCOPIST|NA|1|Visit_1|10|3|TREATMENT|2020-07-06|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-17|P1Y2M10DT2H30M|UNKNOWN|2020-07-10|ONGOING|2020-08-19
e|RS|940d4614-b41a-44d3-b878-6e19ee22f24b|3|NEWLIND|New Lesion Indicator|GUPPY OVARIAN CANCER 2002|||CYTOGENETIC PR|1|uL|ANTIMICROBIAL COMBINATION TESTING||Y|Y|INTERVIEWER|RATER|Y|2|Visit_2|25|3|SCREENING|2020-07-21|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-19|P1Y2M10DT2H30M|BEFORE|2020-07-29|ONGOING|2020-09-25
e|RS|940d4614-b41a-44d3-b878-6e19ee22f24b|4|METSIND|Metastatic Indicator|CHESON LYMPHOMA 2008|[?]|SCOOPFUL|iCPD|1|days/month|ANTIMICROBIAL COMBINATION TESTING|Y|Y||CHILD|RATER 1|Y|2|Visit_2|25|6|FOLLOW-UP|2020-07-21|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-19|P1Y2M10DT2H30M|COINCIDENT|2020-09-28|COINCIDENT|2020-10-02
e|RS|940d4614-b41a-44d3-b878-6e19ee22f24b|5|TRGRESP|Target Response|CHESON CLL 2006|[?]|F|DECREASED|1|kBq/uL|MICRONEUTRALIZATION ASSAY||||STUDY SUBJECT|RATER 1|U|3|Visit_3|40|5|TREATMENT|2020-08-05|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-26|P1Y2M10DT2H30M|AFTER|2020-07-23|AFTER|2020-08-19
e|RS|940d4614-b41a-44d3-b878-6e19ee22f24b|6|METSIND|Metastatic Indicator|IWG CHESON MDS 2006|[?]|BOWL|MORPHOLOGIC CR|1|P|MRS||Y||NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|NA|3|Visit_3|40|5|TREATMENT|2020-08-05|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-26|P1Y2M10DT2H30M|UNKNOWN|2020-09-30|COINCIDENT|2020-10-02
e|RS|940d4614-b41a-44d3-b878-6e19ee22f24b|7|BESTRESP|Best Overall Response|PCWG SCHER PROSTATE CANCER 2008|[?]|APL U/mL|RELAPSED DISEASE FROM CR|1|ECL unit|GRADIENT DIFFUSION|Y|||ADJUDICATION COMMITTEE|INTERNIST|Y|4|Visit_4|65|3|TREATMENT|2020-08-30|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-06|P1Y2M10DT2H30M|COINCIDENT|2020-09-25|AFTER|2020-09-29
e|RS|940d4614-b41a-44d3-b878-6e19ee22f24b|8|OVRLRESP|Overall Response|MURPHY PROSTATE CANCER 1980|[?]|mm/2h|CYTOGENETIC CR|1|PFU/mL|DYNAMOMETRY||||INTERVIEWER|PATHOLOGIST|U|4|Visit_4|65|3|FOLLOW-UP|2020-08-30|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-06|P1Y2M10DT2H30M|AFTER|2020-08-22|ONGOING|2020-08-28
e|RS|940d4614-b41a-44d3-b878-6e19ee22f24b|9|MRDIND|Minimal Residual Disease Indicator|WHO BREAST CANCER 2006|[?]|h/wk|COMPLETE MRD RESPONSE|1|umol/L/sec|RAJI CELL RIA||||GUARDIAN|RADIOLOGIST 1|N|5|Visit_5|90|7|WASHOUT|2020-09-24|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-23|P1Y2M10DT2H30M|AFTER|2020-08-24|ONGOING|2020-09-27
e|RS|940d4614-b41a-44d3-b878-6e19ee22f24b|10|DRCRIND|Disease Recurrence Indicator|iRECIST|||CYTOGENETIC NO RESPONSE|1|mL/(min*100mL)|TRANSTHORACIC ECHOCARDIOGRAPHY|||Y|FAMILY MEMBER|ADJUDICATOR 2|NA|5|Visit_5|90|3|SCREENING|2020-09-24|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-23|P1Y2M10DT2H30M|COINCIDENT|2020-07-14|COINCIDENT|2020-10-01
e|RS|e2edd4f0-926b-4514-bf3f-7449f248343f|1|BONERESP|Bone Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|PNU/mL|PD FROM PR|1|Linear ft*LB|FLOCCULATION||||INDEPENDENT ASSESSOR|FORENSIC PATHOLOGIST|Y|1|Visit_1|10|6|TREATMENT|2020-11-01|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-12|P1Y2M10DT2H30M|COINCIDENT|2021-01-15|BEFORE|2021-01-25
e|RS|e2edd4f0-926b-4514-bf3f-7449f248343f|2|SPLNRESP|Spleen Response|IWG CHESON MDS 2000|[?]|PIXELS/cm|MORPHOLOGIC CRi|1|mV*min|ALCIAN BLUE STAIN||||ADJUDICATION COMMITTEE|MICROSCOPIST 1|U|1|Visit_1|10|6|SCREENING|2020-11-01|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-12|P1Y2M10DT2H30M|COINCIDENT|2020-12-03|BEFORE|2021-01-22
e|RS|e2edd4f0-926b-4514-bf3f-7449f248343f|3|DRCRIND|Disease Recurrence Indicator|EBMT BLADE MYELOMA 1998|[?]|GBq/mg|CYTOGENETIC NO RESPONSE|1|PIXELS/cm|X-RAY FLUORESCENCE SPECTROMETRY||Y||PARENT|RATER|N|2|Visit_2|25|2|FOLLOW-UP|2020-11-16|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-05|P1Y2M10DT2H30M|UNKNOWN|2020-10-24|COINCIDENT|2020-12-18
e|RS|e2edd4f0-926b-4514-bf3f-7449f248343f|4|CPRFSTAT|Clinical Performance Status|KEAM BREAST CANCER 2013|||CYTOGENETIC PR|1|cd/m2|RULER MEASUREMENT METHOD|Y|Y|Y|FAMILY MEMBER|ADJUDICATOR 3|N|2|Visit_2|25|4|TREATMENT|2020-11-16|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-05|P1Y2M10DT2H30M|UNKNOWN|2020-12-03|COINCIDENT|2021-01-12
e|RS|e2edd4f0-926b-4514-bf3f-7449f248343f|5|NEWLIND|New Lesion Indicator|HARTMAN PANCREATIC CANCER 2012|[?]|umol|NE|1|APL U|MRI WITHOUT CONTRAST||Y||INVESTIGATOR|MICROSCOPIST 1|Y|3|Visit_3|40|2|TREATMENT|2020-12-01|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-16|P1Y2M10DT2H30M|AFTER|2020-11-16|AFTER|2021-01-06
e|RS|e2edd4f0-926b-4514-bf3f-7449f248343f|6|MRPHRESP|Morphologic Response|RANO ELLINGSON 2017|[?]|100 IU/mL|iUPD|1|cm/s|FARR ASSAY||Y||CAREGIVER|OTOLARYNGOLOGIST|N|3|Visit_3|40|5|TREATMENT|2020-12-01|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-16|P1Y2M10DT2H30M|AFTER|2021-01-20|ONGOING|2021-01-22
e|RS|e2edd4f0-926b-4514-bf3f-7449f248343f|7|MJPTHIND|Major Pathological Response Indicator|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|GLOBULE|CYTOGENETIC NO RESPONSE|1|um2|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY|Y|||CHILD|NEUROLOGIST 2|NA|4|Visit_4|65|7|SCREENING|2020-12-26|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-01|P1Y2M10DT2H30M|BEFORE|2021-01-12|AFTER|2021-01-17
e|RS|e2edd4f0-926b-4514-bf3f-7449f248343f|8|NEWLPROG|New Lesion Progression|IRANO 2015|[?]|APPLICATION|CA125 50% RESPONSE|1|um|PET/CT SCAN||||FAMILY MEMBER|READER 1|U|4|Visit_4|65|6|TREATMENT|2020-12-26|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-01|P1Y2M10DT2H30M|BEFORE|2021-01-04|COINCIDENT|2021-01-24
e|RS|e2edd4f0-926b-4514-bf3f-7449f248343f|9|NTLWIND|Non-Target Lesion Worsening Indicator|SCHER PROSTATE CANCER 2011|||HI-N|1|10^9 CFU/mL|FLUORESCENT LIFETIME IMAGING MICROSCOPY|Y||Y|VENDOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|5|Visit_5|90|5|WASHOUT|2021-01-20|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-18|P1Y2M10DT2H30M|BEFORE|2020-11-28|AFTER|2021-01-16
e|RS|e2edd4f0-926b-4514-bf3f-7449f248343f|10|TMRESP|Tumor Marker Response|SHINDOH COLORECTAL CANCER 2013|[?]|GPL U|UNEQUIVOCAL|1|AFU|HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY||Y||STUDY SUBJECT|READER 3|N|5|Visit_5|90|2|TREATMENT|2021-01-20|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-18|P1Y2M10DT2H30M|UNKNOWN|2020-12-07|BEFORE|2021-01-12
e|RS|215d711d-c98a-4f7b-ba41-d2c06ad70ddd|1|CLINRESP|Clinical Response|NCIWG CHESON CLL 1996|||NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|BE/mL|CONGO RED STAIN|||Y|DOMESTIC PARTNER|RADIOLOGIST 2|NA|1|Visit_1|10|7|SCREENING|2020-06-28|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-26|P1Y2M10DT2H30M|BEFORE|2020-07-28|ONGOING|2020-09-11
e|RS|215d711d-c98a-4f7b-ba41-d2c06ad70ddd|2|MOLRESP|Molecular Response|IRANO 2015|||TREATMENT FAILURE|1|mg/kg/dose|GRADIENT DIFFUSION|||Y|INVESTIGATOR|UROLOGIST|Y|1|Visit_1|10|6|TREATMENT|2020-06-28|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-26|P1Y2M10DT2H30M|BEFORE|2020-06-30|BEFORE|2020-08-05
e|RS|215d711d-c98a-4f7b-ba41-d2c06ad70ddd|3|CLINRESP|Clinical Response|BRUGGEMANN MRD 2010|[?]|P|NON-CR/NON-PD|1|mm2|MICROBIAL CULTURE, SOLID||||INVESTIGATOR|PATHOLOGIST 2|N|2|Visit_2|25|5|TREATMENT|2020-07-13|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-07|P1Y2M10DT2H30M|UNKNOWN|2020-07-16|AFTER|2020-09-04
e|RS|215d711d-c98a-4f7b-ba41-d2c06ad70ddd|4|MOLRESP|Molecular Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|SYRINGE|MINOR PATHOLOGIC RESPONSE|1|in2|ENDOSCOPY||||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 2|N|2|Visit_2|25|1|WASHOUT|2020-07-13|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-07|P1Y2M10DT2H30M|COINCIDENT|2020-09-19|COINCIDENT|2020-09-22
e|RS|215d711d-c98a-4f7b-ba41-d2c06ad70ddd|5|NEWLPROG|New Lesion Progression|AJCC V8|[?]|10^6/Ejaculate U|NON-iCR/NON-iUPD|1|uU/dL|VIRUS PLAQUE ASSAY||||DOMESTIC PARTNER|READER 3|U|3|Visit_3|40|3|TREATMENT|2020-07-28|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-01|P1Y2M10DT2H30M|BEFORE|2020-08-09|BEFORE|2020-09-04
e|RS|215d711d-c98a-4f7b-ba41-d2c06ad70ddd|6|RDIORESP|Radiologic Response|FAROOQUI SUPP CLL 2014|[?]|mmHg*min/L|PSA PROGRESSION|1|nmol/L/min|DYNAMIC CONTRAST ENHANCED MRI||||ADJUDICATOR|RADIOLOGIST|Y|3|Visit_3|40|1|TREATMENT|2020-07-28|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-01|P1Y2M10DT2H30M|COINCIDENT|2020-09-02|ONGOING|2020-09-19
e|RS|215d711d-c98a-4f7b-ba41-d2c06ad70ddd|7|NTNERESP|Non-Target Non-Enhancing Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|||CYTOGENETIC NO RESPONSE|1|uL|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI|||Y|ADJUDICATION COMMITTEE|PATHOLOGIST 2|U|4|Visit_4|65|2|TREATMENT|2020-08-22|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-18|P1Y2M10DT2H30M|COINCIDENT|2020-07-05|BEFORE|2020-08-01
e|RS|215d711d-c98a-4f7b-ba41-d2c06ad70ddd|8|RDIORESP|Radiologic Response|AJCC V7|[?]|cmol/L|NON-PD|1|VOXEL|DIFFUSION WEIGHTED MRI||||FRIEND|HEMATOLOGIST|Y|4|Visit_4|65|7|TREATMENT|2020-08-22|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-18|P1Y2M10DT2H30M|COINCIDENT|2020-07-26|ONGOING|2020-07-27
e|RS|215d711d-c98a-4f7b-ba41-d2c06ad70ddd|9|SYMPTDTR|Symptomatic Deterioration|AJCC V7|||CA125 75% RESPONSE|1|mg|CORONARY ANGIOGRAPHY|||Y|SIBLING|ONCOLOGIST 1|Y|5|Visit_5|90|5|TREATMENT|2020-09-16|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-12|P1Y2M10DT2H30M|BEFORE|2020-08-01|BEFORE|2020-08-31
e|RS|215d711d-c98a-4f7b-ba41-d2c06ad70ddd|10|OVRLRESP|Overall Response|FAROOQUI SUPP CLL 2014|[?]|cd/m2|PDu|1|ug/g/h|MODIFIED ACID FAST STAIN||||ADJUDICATOR|RATER 1|U|5|Visit_5|90|3|FOLLOW-UP|2020-09-16|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-12|P1Y2M10DT2H30M|COINCIDENT|2020-08-27|ONGOING|2020-09-16
e|RS|493a53ef-01ab-470c-9bbe-7c2aa48b946b|1|NTERESP|Non-Target Enhancing Response|CHOLLET BREAST CANCER 2002|||PARTIAL MORPHOLOGIC RESPONSE|1|%(w/w)|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION|||Y|STUDY SUBJECT|ADJUDICATOR 3|NA|1|Visit_1|10|6|TREATMENT|2020-07-13|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-25|P1Y2M10DT2H30M|BEFORE|2020-08-15|AFTER|2020-09-15
e|RS|493a53ef-01ab-470c-9bbe-7c2aa48b946b|2|ANATRESP|Anatomic Response|IWG CHESON MDS 2000|[?]|BAU/mL|CA125 75% RESPONSE|1|Ci/kg|PHOROPTER||||SIBLING|ENDOCRINOLOGIST|N|1|Visit_1|10|6|TREATMENT|2020-07-13|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-25|P1Y2M10DT2H30M|BEFORE|2020-08-09|COINCIDENT|2020-08-27
e|RS|493a53ef-01ab-470c-9bbe-7c2aa48b946b|3|NEWLIND|New Lesion Indicator|PRINCE TCELL LYMPHOMA 2010|[?]|g/L|STABLE|1|10^3/hpf|SIZE EXCLUSION CHROMATOGRAPHY||||CHILD|RADIOLOGIST 1|Y|2|Visit_2|25|4|FOLLOW-UP|2020-07-28|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-29|P1Y2M10DT2H30M|COINCIDENT|2020-09-25|COINCIDENT|2020-09-27
e|RS|493a53ef-01ab-470c-9bbe-7c2aa48b946b|4|TMRESP|Tumor Marker Response|BRUGGEMANN MRD 2010|[?]|RING|MINOR PATHOLOGIC RESPONSE|1|kcal/day|IN VITRO GENE EXPRESSION ASSAY||||INTERVIEWER|RADIOLOGIST 1|Y|2|Visit_2|25|5|TREATMENT|2020-07-28|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-29|P1Y2M10DT2H30M|AFTER|2020-07-19|COINCIDENT|2020-10-10
e|RS|493a53ef-01ab-470c-9bbe-7c2aa48b946b|5|LIVRRESP|Liver Response|KUMAR IMWG 2016|[?]|cm2|MORPHOLOGIC LEUKEMIA-FREE STATE|1|U/g|NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY||||CAREGIVER|NEUROLOGIST 2|NA|3|Visit_3|40|2|TREATMENT|2020-08-12|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-20|P1Y2M10DT2H30M|BEFORE|2020-09-21|COINCIDENT|2020-10-07
e|RS|493a53ef-01ab-470c-9bbe-7c2aa48b946b|6|NTNERESP|Non-Target Non-Enhancing Response|CHOI GIST 2008|[?]|Hounsfield Unit|SD|1|in2|IMMUNOASSAY||Y||INVESTIGATOR|ADJUDICATOR|N|3|Visit_3|40|2|TREATMENT|2020-08-12|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-20|P1Y2M10DT2H30M|BEFORE|2020-08-07|COINCIDENT|2020-10-10
e|RS|493a53ef-01ab-470c-9bbe-7c2aa48b946b|7|HEMARESP|Hematologic Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|g/m2/day|MORPHOLOGIC CR|1|m|EEG||||SIBLING|NEUROLOGIST 2|U|4|Visit_4|65|2|FOLLOW-UP|2020-09-06|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-22|P1Y2M10DT2H30M|BEFORE|2020-10-04|AFTER|2020-10-07
e|RS|493a53ef-01ab-470c-9bbe-7c2aa48b946b|8|NEWLWIND|New Lesion Worsening Indicator|BRUGGEMANN MRD 2010|[?]|EID 50/mL|NOT ALL EVALUATED|1|L/L|TURBIDIMETRY||||SIGNIFICANT OTHER|PATHOLOGIST 1|Y|4|Visit_4|65|5|FOLLOW-UP|2020-09-06|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-22|P1Y2M10DT2H30M|AFTER|2020-08-22|ONGOING|2020-09-16
e|RS|493a53ef-01ab-470c-9bbe-7c2aa48b946b|9|OVRLRESP|Overall Response|PRINCE TCELL LYMPHOMA 2010|||iCR|1|MASK|ELECTRICAL IMPEDANCE MYOGRAPHY|||Y|PROXY|READER 3|NA|5|Visit_5|90|3|TREATMENT|2020-10-01|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-04|P1Y2M10DT2H30M|BEFORE|2020-07-13|COINCIDENT|2020-07-22
e|RS|493a53ef-01ab-470c-9bbe-7c2aa48b946b|10|MRPHRESP|Morphologic Response|PCWG SCHER PROSTATE CANCER 2008|||CR|1|min*mg/mL|THIN SMEAR|||Y|FRIEND|RADIOLOGIST|Y|5|Visit_5|90|6|TREATMENT|2020-10-01|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-04|P1Y2M10DT2H30M|COINCIDENT|2020-10-06|BEFORE|2020-10-09
e|RS|ba33de14-b676-4389-a863-a7fa3edb8543|1|RDIORESP|Radiologic Response|CHOLLET BREAST CANCER 2002|||NOT ALL EVALUATED|1|mOsm/L|DYNAMIC CONTRAST ENHANCED MRI||Y|Y|INTERVIEWER|PATHOLOGIST|N|1|Visit_1|10|5|TREATMENT|2020-11-03|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-16|P1Y2M10DT2H30M|UNKNOWN|2020-11-24|ONGOING|2021-01-03
e|RS|ba33de14-b676-4389-a863-a7fa3edb8543|2|NTRGRESP|Non-target Response|CHESON CLL 2012|[?]|ug/m2/h|SD|1|mU/L|EEG||||PARENT|RATER 1|NA|1|Visit_1|10|2|TREATMENT|2020-11-03|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-16|P1Y2M10DT2H30M|BEFORE|2020-12-10|BEFORE|2021-01-18
e|RS|ba33de14-b676-4389-a863-a7fa3edb8543|3|DRCRIND|Disease Recurrence Indicator|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|MET*min|CMR|1|ft2|X-RAY FLUORESCENCE SPECTROMETRY||||FRIEND|RATER 2|N|2|Visit_2|25|7|TREATMENT|2020-11-18|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-18|P1Y2M10DT2H30M|COINCIDENT|2020-11-11|ONGOING|2020-11-24
e|RS|ba33de14-b676-4389-a863-a7fa3edb8543|4|TRGRESP|Target Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|cycle/min|ABSENT MORPHOLOGIC RESPONSE|1|KIT|REVERSE TRANSCRIPTASE PCR||||INTERVIEWER|ADJUDICATOR 3|Y|2|Visit_2|25|2|TREATMENT|2020-11-18|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-18|P1Y2M10DT2H30M|AFTER|2020-11-10|AFTER|2020-12-05
e|RS|ba33de14-b676-4389-a863-a7fa3edb8543|5|PATHRESP|Pathologic Response|IWG CHESON MDS 2000|||CYTOGENETIC PR|1|mL/h|IMMUNO-PET SCAN|||Y|CLINICAL RESEARCH COORDINATOR|READER 3|Y|3|Visit_3|40|6|SCREENING|2020-12-03|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-15|P1Y2M10DT2H30M|UNKNOWN|2020-12-18|COINCIDENT|2021-01-28
e|RS|ba33de14-b676-4389-a863-a7fa3edb8543|6|MRDRESP|Minimal Residual Disease Response|HAMAOKA BREAST CANCER 2010|||CYTOGENETIC NO RESPONSE|1|ppth|GC/FID|||Y|FAMILY MEMBER|UROLOGIST|U|3|Visit_3|40|1|TREATMENT|2020-12-03|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-15|P1Y2M10DT2H30M|AFTER|2021-01-28|COINCIDENT|2021-01-31
e|RS|ba33de14-b676-4389-a863-a7fa3edb8543|7|METBRESP|Metabolic Response|AJCC V8|[?]|10^6 organisms|HI-P|1|CCID 50/mL|QUANTITATIVE ULTRASOUND||||PROXY|ENDOCRINOLOGIST|Y|4|Visit_4|65|2|FOLLOW-UP|2020-12-28|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-08|P1Y2M10DT2H30M|UNKNOWN|2020-12-05|COINCIDENT|2020-12-14
e|RS|ba33de14-b676-4389-a863-a7fa3edb8543|8|BONERESP|Bone Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|NEEDLE GAUGE|CA125 75% RESPONSE|1|COAT|CINEANGIOGRAPHY||Y||VENDOR|FORENSIC PATHOLOGIST|NA|4|Visit_4|65|6|TREATMENT|2020-12-28|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-08|P1Y2M10DT2H30M|COINCIDENT|2021-01-01|ONGOING|2021-01-20
e|RS|ba33de14-b676-4389-a863-a7fa3edb8543|9|MRDRESP|Minimal Residual Disease Response|GUILHOT CML 2007|||CYTOGENETIC CR|1|dpm/0.5 mL|IMMUNOFLUORESCENT STAIN|||Y|CLINICAL STUDY SPONSOR|OPHTHALMOLOGIST|N|5|Visit_5|90|7|SCREENING|2021-01-22|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-25|P1Y2M10DT2H30M|BEFORE|2020-12-13|ONGOING|2021-01-19
e|RS|ba33de14-b676-4389-a863-a7fa3edb8543|10|LIVRRESP|Liver Response|WOLCHOK SOLID TUMORS 2009|[?]|SYRINGE|PD-CT|1|/7.5 mL|WRIGHT STAIN||||NON-HEALTH CARE PROFESSIONAL|CARDIOLOGIST|NA|5|Visit_5|90|1|TREATMENT|2021-01-22|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-25|P1Y2M10DT2H30M|AFTER|2020-12-26|BEFORE|2021-01-25
e|RS|24801f05-79be-433d-8124-85580bc14c4f|1|CYTORESP|Cytogenetic Response|SCHER PROSTATE CANCER 2011|[?]|mL/min|IMMUNOPHENOTYPIC CR|1|fraction of 1|MAPH||Y||FRIEND|READER 1|NA|1|Visit_1|10|7|FOLLOW-UP|2020-09-09|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-05|P1Y2M10DT2H30M|AFTER|2020-10-01|AFTER|2020-10-25
e|RS|24801f05-79be-433d-8124-85580bc14c4f|2|HEMARESP|Hematologic Response|CHESON LYMPHOMA 2008|||pCR|1|log10 CCID 50/dose|MICROBIAL BIOCHEMICAL IDENTIFICATION|Y|Y|Y|INVESTIGATOR|NEUROLOGIST|Y|1|Visit_1|10|3|SCREENING|2020-09-09|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-05|P1Y2M10DT2H30M|UNKNOWN|2020-09-16|BEFORE|2020-09-27
e|RS|24801f05-79be-433d-8124-85580bc14c4f|3|NTLWIND|Non-Target Lesion Worsening Indicator|NCIWG CHESON CLL 1996|[?]|BE/mL|iSD|1|EU|SMEAR||||NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST|Y|2|Visit_2|25|7|WASHOUT|2020-09-24|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-01|P1Y2M10DT2H30M|BEFORE|2020-10-10|COINCIDENT|2020-11-21
e|RS|24801f05-79be-433d-8124-85580bc14c4f|4|ANATRESP|Anatomic Response|BLAZER COLORECTAL CANCER 2008|||CR-CT|1|SBE/mL|TOTAL BODY RADIOGRAPHY|Y|Y|Y|ADJUDICATION COMMITTEE|RATER 1|U|2|Visit_2|25|3|TREATMENT|2020-09-24|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-01|P1Y2M10DT2H30M|AFTER|2020-09-27|COINCIDENT|2020-10-23
e|RS|24801f05-79be-433d-8124-85580bc14c4f|5|METSIND|Metastatic Indicator|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|pmol/10^10 cells|PD FROM PR|1|IU/g|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS||||CAREGIVER|ONCOLOGIST 2|N|3|Visit_3|40|1|TREATMENT|2020-10-09|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-08|P1Y2M10DT2H30M|UNKNOWN|2020-09-01|BEFORE|2020-10-02
e|RS|24801f05-79be-433d-8124-85580bc14c4f|6|CPRFSTAT|Clinical Performance Status|RANO ELLINGSON 2017|[?]|uV2|CYTOGENETIC MINOR RESPONSE|1|10^3 CFU|LASER CAPTURE MICRODISSECTION||Y||SPOUSE|PATHOLOGIST 2|U|3|Visit_3|40|2|TREATMENT|2020-10-09|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-08|P1Y2M10DT2H30M|AFTER|2020-11-19|AFTER|2020-11-29
e|RS|24801f05-79be-433d-8124-85580bc14c4f|7|STRUSTAT|Steroid Use Status|GUILHOT CML 2007|||CR|1|GBq/mg|HPLC-UV|||Y|DOMESTIC PARTNER|UROLOGIST|N|4|Visit_4|65|3|WASHOUT|2020-11-03|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-24|P1Y2M10DT2H30M|UNKNOWN|2020-12-02|AFTER|2020-12-07
e|RS|24801f05-79be-433d-8124-85580bc14c4f|8|SYMPTDTR|Symptomatic Deterioration|RANO ELLINGSON 2017|[?]|mEq/day|iCPD|1|MBq|REFRACTOMETRY|Y|||FAMILY MEMBER|ONCOLOGIST 1|Y|4|Visit_4|65|4|TREATMENT|2020-11-03|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-24|P1Y2M10DT2H30M|BEFORE|2020-11-26|ONGOING|2020-12-07
e|RS|24801f05-79be-433d-8124-85580bc14c4f|9|OVRLRESP|Overall Response|LEE LUNG CANCER 2011|[?]|U/m2|pCR|1|mm/min|HIGH LEVEL AMINOGLYCOSIDE SCREEN||||CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 2|U|5|Visit_5|90|3|FOLLOW-UP|2020-11-28|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-23|P1Y2M10DT2H30M|UNKNOWN|2020-09-04|BEFORE|2020-09-27
e|RS|24801f05-79be-433d-8124-85580bc14c4f|10|SPLNRESP|Spleen Response|RANO|[?]|/10^5|WORSENED|1|10^8 PFU|COMPLEMENT FIXATION|Y|||PROXY|PHYSIOTHERAPIST|NA|5|Visit_5|90|5|SCREENING|2020-11-28|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-23|P1Y2M10DT2H30M|UNKNOWN|2020-11-30|COINCIDENT|2020-12-01
e|RS|02df80f9-2337-4abd-9452-41cd83dec8ba|1|NEWLIND|New Lesion Indicator|GCIG RUSTIN OVARIAN CANCER 2011|[?]|MET*h|WORSENED|1|IU/day|DIFFUSION WEIGHTED MRI||Y||ADJUDICATION COMMITTEE|NEUROLOGIST 1|Y|1|Visit_1|10|3|SCREENING|2020-08-04|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-04|P1Y2M10DT2H30M|COINCIDENT|2020-08-10|COINCIDENT|2020-10-15
e|RS|02df80f9-2337-4abd-9452-41cd83dec8ba|2|DRCRIND|Disease Recurrence Indicator|CHESON CLL 2006|[?]|tuberculin unit|iCR|1|ug|STRESS ECHOCARDIOGRAPHY||||CLINICAL RESEARCH COORDINATOR|ONCOLOGIST|Y|1|Visit_1|10|4|TREATMENT|2020-08-04|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-04|P1Y2M10DT2H30M|BEFORE|2020-10-23|BEFORE|2020-10-26
e|RS|02df80f9-2337-4abd-9452-41cd83dec8ba|3|TMRESP|Tumor Marker Response|JACINTO CERVICAL CANCER 2007|[?]|KALLIKREIN INHIBITOR UNIT|EQUIVOCAL|1|atm|LISSAMINE GREEN STAIN||||SIBLING|ADJUDICATOR 2|NA|2|Visit_2|25|5|TREATMENT|2020-08-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-26|P1Y2M10DT2H30M|UNKNOWN|2020-10-20|BEFORE|2020-10-21
e|RS|02df80f9-2337-4abd-9452-41cd83dec8ba|4|NEWLPROG|New Lesion Progression|DOHNER AML 2010|[?]|PUFF|SD|1|mg/m2/day|CORONARY ANGIOGRAPHY||Y||FRIEND|RADIOLOGIST 2|U|2|Visit_2|25|2|TREATMENT|2020-08-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-26|P1Y2M10DT2H30M|BEFORE|2020-10-17|ONGOING|2020-10-23
e|RS|02df80f9-2337-4abd-9452-41cd83dec8ba|5|MRDRESP|Minimal Residual Disease Response|JACINTO CERVICAL CANCER 2007|[?]|10^4 CFU/mL|CYTOGENETIC CR|1|LB|SPIRAL CT SCAN WITHOUT CONTRAST||||PROXY|RATER 1|N|3|Visit_3|40|1|TREATMENT|2020-09-03|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-28|P1Y2M10DT2H30M|UNKNOWN|2020-08-12|BEFORE|2020-09-25
e|RS|02df80f9-2337-4abd-9452-41cd83dec8ba|6|MRDRESP|Minimal Residual Disease Response|KUKER LYMPHOMA 2005|||PARTIAL MORPHOLOGIC RESPONSE|1|uL|DARK FIELD MICROSCOPY||Y|Y|SIBLING|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|3|Visit_3|40|3|WASHOUT|2020-09-03|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-28|P1Y2M10DT2H30M|BEFORE|2020-07-28|ONGOING|2020-09-30
e|RS|02df80f9-2337-4abd-9452-41cd83dec8ba|7|ANATRESP|Anatomic Response|NCCN ALL MRD 2014|[?]|uV|PSA PROGRESSION|1|10^3 CFU|NEURAMINIDASE INHIBITION ASSAY||Y||VENDOR|UROLOGIST|Y|4|Visit_4|65|6|FOLLOW-UP|2020-09-28|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-30|P1Y2M10DT2H30M|AFTER|2020-09-05|ONGOING|2020-10-08
e|RS|02df80f9-2337-4abd-9452-41cd83dec8ba|8|MRPHRESP|Morphologic Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|umol/mol|PMR|1|PFU/mL|AGAR PROPORTION||||SIGNIFICANT OTHER|NEUROLOGIST|U|4|Visit_4|65|2|SCREENING|2020-09-28|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-30|P1Y2M10DT2H30M|COINCIDENT|2020-09-29|BEFORE|2020-10-01
e|RS|02df80f9-2337-4abd-9452-41cd83dec8ba|9|BONERESP|Bone Response|iRECIST|[?]|cmol|MRD PERSISTENCE|1|umol|BETA LACTAMASE||||INTERVIEWER|MICROSCOPIST 1|U|5|Visit_5|90|5|TREATMENT|2020-10-23|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-29|P1Y2M10DT2H30M|COINCIDENT|2020-08-12|ONGOING|2020-10-27
e|RS|02df80f9-2337-4abd-9452-41cd83dec8ba|10|METBRESP|Metabolic Response|HAMAOKA BREAST CANCER 2010|[?]|kPa|MRD RELAPSE|1|ft3|CELL CYTOTOXICITY NEUTRALIZATION ASSAY||||ADJUDICATION COMMITTEE|RADIOLOGIST|NA|5|Visit_5|90|6|TREATMENT|2020-10-23|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-29|P1Y2M10DT2H30M|COINCIDENT|2020-07-30|AFTER|2020-10-22
e|RS|d9eea93b-f9f9-466c-aa8a-a250baff18ef|1|DRCRIND|Disease Recurrence Indicator|MURPHY PROSTATE CANCER 1980|||RELAPSED DISEASE FROM CR|1|Newton|TRANSTHORACIC ECHOCARDIOGRAPHY|||Y|CLINICAL STUDY SPONSOR|RADIOLOGIST|Y|1|Visit_1|10|6|TREATMENT|2020-08-03|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-17|P1Y2M10DT2H30M|UNKNOWN|2020-09-14|AFTER|2020-10-27
e|RS|d9eea93b-f9f9-466c-aa8a-a250baff18ef|2|NEWLPROG|New Lesion Progression|IRANO 2015|[?]|uEq|CR|1|NEBULE|CALCOFLUOR WHITE STAIN||Y||CAREGIVER|RADIOLOGIST 1|N|1|Visit_1|10|4|TREATMENT|2020-08-03|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-17|P1Y2M10DT2H30M|BEFORE|2020-10-20|AFTER|2020-10-26
e|RS|d9eea93b-f9f9-466c-aa8a-a250baff18ef|3|NTLWIND|Non-Target Lesion Worsening Indicator|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|||PR|1|umol/day|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|Y||Y|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 2|N|2|Visit_2|25|7|TREATMENT|2020-08-18|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-20|P1Y2M10DT2H30M|UNKNOWN|2020-08-21|COINCIDENT|2020-08-22
e|RS|d9eea93b-f9f9-466c-aa8a-a250baff18ef|4|OVRLRESP|Overall Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|/mm|STABLE|1|PFU/dose|NUCLEIC ACID SEQUENCING||||SIBLING|OPTOMETRIST|Y|2|Visit_2|25|2|TREATMENT|2020-08-18|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-20|P1Y2M10DT2H30M|BEFORE|2020-08-14|AFTER|2020-10-17
e|RS|d9eea93b-f9f9-466c-aa8a-a250baff18ef|5|PATHRESP|Pathologic Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|vg/dose|CRi|1|mg/m2/day|AGAR PROPORTION|Y|||CAREGIVER|MICROSCOPIST 2|NA|3|Visit_3|40|2|WASHOUT|2020-09-02|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-12|P1Y2M10DT2H30M|COINCIDENT|2020-09-20|COINCIDENT|2020-09-29
e|RS|d9eea93b-f9f9-466c-aa8a-a250baff18ef|6|MRDRESP|Minimal Residual Disease Response|BLAZER COLORECTAL CANCER 2008|[?]|mmHg/sec|pCR|1|mmol/L|SCINTIGRAPHY|Y|||ADJUDICATION COMMITTEE|NEUROLOGIST 1|N|3|Visit_3|40|1|TREATMENT|2020-09-02|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-12|P1Y2M10DT2H30M|UNKNOWN|2020-10-05|AFTER|2020-10-30
e|RS|d9eea93b-f9f9-466c-aa8a-a250baff18ef|7|NEWLPROG|New Lesion Progression|PALUMBO MULTIPLE MYELOMA 2009|[?]|10^6 CFU/g|sCR|1|10^9/dose|ORCHIDOMETERY||Y||CAREGIVER|CLINICAL PATHOLOGIST|U|4|Visit_4|65|5|TREATMENT|2020-09-27|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-05|P1Y2M10DT2H30M|AFTER|2020-10-25|COINCIDENT|2020-10-29
e|RS|d9eea93b-f9f9-466c-aa8a-a250baff18ef|8|OVRLRESP|Overall Response|IRANO 2015|[?]|mCi|MR|1|Frames/s|MAGNETIC RESONANCE ENTEROGRAPHY||Y||DOMESTIC PARTNER|RADIOLOGIST 2|N|4|Visit_4|65|1|FOLLOW-UP|2020-09-27|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-05|P1Y2M10DT2H30M|COINCIDENT|2020-09-08|ONGOING|2020-10-20
e|RS|d9eea93b-f9f9-466c-aa8a-a250baff18ef|9|DRCRIND|Disease Recurrence Indicator|HARTMAN PANCREATIC CANCER 2012|[?]|pptr|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|mph|POLYMERASE CHAIN REACTION||||CAREGIVER|INTERNIST|NA|5|Visit_5|90|4|TREATMENT|2020-10-22|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-22|P1Y2M10DT2H30M|AFTER|2020-08-06|COINCIDENT|2020-08-28
e|RS|d9eea93b-f9f9-466c-aa8a-a250baff18ef|10|NTNERESP|Non-Target Non-Enhancing Response|MRECIST BYRNE MESOTHELIOMA 2004|||iCPD|1|U/10^12 RBC|KNEMOMETRY|Y||Y|DOMESTIC PARTNER|RADIOLOGIST|Y|5|Visit_5|90|2|WASHOUT|2020-10-22|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-22|P1Y2M10DT2H30M|BEFORE|2020-08-06|AFTER|2020-10-12
e|RS|35a59f6a-2712-4d1b-a954-f1418d4b9168|1|STRUSTAT|Steroid Use Status|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|||OPTIMAL MORPHOLOGIC RESPONSE|1|U/m2|RADIATION DOSIMETRY|||Y|SPOUSE|CARDIOLOGIST|N|1|Visit_1|10|7|WASHOUT|2020-11-05|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-24|P1Y2M10DT2H30M|COINCIDENT|2020-12-23|ONGOING|2021-01-16
e|RS|35a59f6a-2712-4d1b-a954-f1418d4b9168|2|MNPTHIND|Minor Pathological Response Indicator|BLAZER COLORECTAL CANCER 2008|[?]|BOX|CYTOGENETIC MINOR RESPONSE|1|U/kg|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY|Y|||CLINICAL STUDY SPONSOR|ONCOLOGIST 2|N|1|Visit_1|10|2|WASHOUT|2020-11-05|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-24|P1Y2M10DT2H30M|COINCIDENT|2021-01-14|AFTER|2021-01-16
e|RS|35a59f6a-2712-4d1b-a954-f1418d4b9168|3|NEWLIND|New Lesion Indicator|RECICL|[?]|cd*s/m2|SMD|1|LENS|LANDOLT RING||||SIBLING|UROLOGIST|U|2|Visit_2|25|3|TREATMENT|2020-11-20|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-20|P1Y2M10DT2H30M|BEFORE|2021-01-06|COINCIDENT|2021-01-09
e|RS|35a59f6a-2712-4d1b-a954-f1418d4b9168|4|NTLWIND|Non-Target Lesion Worsening Indicator|CHOI GIST 2008|[?]|kcal|CYTOGENETIC MINIMAL RESPONSE|1|RNA copies/mL|CALCULATION||||CLINICAL RESEARCH ASSOCIATE|CARDIOLOGIST|NA|2|Visit_2|25|6|TREATMENT|2020-11-20|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-20|P1Y2M10DT2H30M|COINCIDENT|2020-12-11|COINCIDENT|2021-01-23
e|RS|35a59f6a-2712-4d1b-a954-f1418d4b9168|5|MRDIND|Minimal Residual Disease Indicator|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|log10 TCID 50/mL|PD|1|pm|BALLPOINT PEN TECHNIQUE||Y||CAREGIVER|OPHTHALMOLOGIST|Y|3|Visit_3|40|4|WASHOUT|2020-12-05|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-07|P1Y2M10DT2H30M|COINCIDENT|2020-12-05|AFTER|2020-12-08
e|RS|35a59f6a-2712-4d1b-a954-f1418d4b9168|6|METBRESP|Metabolic Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|mg/g/h|UNFAVORABLE RESPONSE|1|umol/day|CISH|Y|||FAMILY MEMBER|OPHTHALMOLOGIST|N|3|Visit_3|40|3|WASHOUT|2020-12-05|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-07|P1Y2M10DT2H30M|UNKNOWN|2020-11-29|ONGOING|2021-01-06
e|RS|35a59f6a-2712-4d1b-a954-f1418d4b9168|7|NTERESP|Non-Target Enhancing Response|RECIST 1.1|[?]|nmol/L/min|MOLECULAR MAJOR RESPONSE|1|pmol/g|DARK FIELD MICROSCOPY||||SPOUSE|RATER|NA|4|Visit_4|65|5|WASHOUT|2020-12-30|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-14|P1Y2M10DT2H30M|UNKNOWN|2020-11-20|ONGOING|2021-01-30
e|RS|35a59f6a-2712-4d1b-a954-f1418d4b9168|8|TRGRESP|Target Response|NCCN ALL MRD 2014|||OPTIMAL MORPHOLOGIC RESPONSE|1|cpm|FLUORESCENT MICROSCOPY|||Y|PARENT|RADIOLOGIST|U|4|Visit_4|65|4|SCREENING|2020-12-30|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-14|P1Y2M10DT2H30M|COINCIDENT|2020-11-05|COINCIDENT|2020-11-29
e|RS|35a59f6a-2712-4d1b-a954-f1418d4b9168|9|NTERESP|Non-Target Enhancing Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|MPL U/mL|CYTOGENETIC MINIMAL RESPONSE|1|pg/cell|POLYMERASE CHAIN REACTION||||INDEPENDENT ASSESSOR|NEUROLOGIST 1|Y|5|Visit_5|90|2|TREATMENT|2021-01-24|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-14|P1Y2M10DT2H30M|BEFORE|2020-11-29|ONGOING|2020-12-19
e|RS|35a59f6a-2712-4d1b-a954-f1418d4b9168|10|MJPTHIND|Major Pathological Response Indicator|EBMT BLADE MYELOMA 1998|[?]|U|CYTOGENETIC PR|1|Weber|PERCUSSION||||INTERVIEWER|RADIOLOGIST 2|NA|5|Visit_5|90|7|WASHOUT|2021-01-24|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-14|P1Y2M10DT2H30M|AFTER|2021-01-05|COINCIDENT|2021-01-06
e|RS|ecfa7c81-fd68-4b8c-8305-65e1ecbff67f|1|ANATRESP|Anatomic Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|10^12 IU/L|cPR|1|10^5/hpf|MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING||||SPOUSE|UROLOGIST|Y|1|Visit_1|10|4|TREATMENT|2020-11-10|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-14|P1Y2M10DT2H30M|AFTER|2020-12-01|ONGOING|2020-12-22
e|RS|ecfa7c81-fd68-4b8c-8305-65e1ecbff67f|2|SYMPTDTR|Symptomatic Deterioration|SHINDOH COLORECTAL CANCER 2013|||CR-CT|1|mg/m2|MAGNETIC RESONANCE ANGIOGRAPHY|||Y|GUARDIAN|DEVELOPMENTAL PSYCHOLOGIST|U|1|Visit_1|10|1|TREATMENT|2020-11-10|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-14|P1Y2M10DT2H30M|UNKNOWN|2021-01-10|COINCIDENT|2021-02-07
e|RS|ecfa7c81-fd68-4b8c-8305-65e1ecbff67f|3|PATHRESP|Pathologic Response|PCWG SCHER PROSTATE CANCER 2008|[?]|JAR|DECREASED|1|L/min/m2|PLETHYSMOGRAPHY||||HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|Y|2|Visit_2|25|4|FOLLOW-UP|2020-11-25|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-13|P1Y2M10DT2H30M|UNKNOWN|2020-11-22|ONGOING|2020-12-03
e|RS|ecfa7c81-fd68-4b8c-8305-65e1ecbff67f|4|STRUSTAT|Steroid Use Status|BURCOMBE BREAST CANCER 2005|[?]|umol/day|CMR|1|log10 PFU/mL|CELL OF ORIGIN ASSAY||||INDEPENDENT ASSESSOR|PATHOLOGIST|NA|2|Visit_2|25|4|WASHOUT|2020-11-25|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-13|P1Y2M10DT2H30M|UNKNOWN|2021-01-07|AFTER|2021-01-17
e|RS|ecfa7c81-fd68-4b8c-8305-65e1ecbff67f|5|TMRESP|Tumor Marker Response|HARTMANN GERM CELL CANCER 2002|[?]|umol/L/h|MORPHOLOGIC CRi|1|kBq|NEURAMINIDASE INHIBITION ASSAY||||PARENT|CARDIOLOGIST|U|3|Visit_3|40|6|TREATMENT|2020-12-10|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-25|P1Y2M10DT2H30M|BEFORE|2021-01-20|AFTER|2021-01-25
e|RS|ecfa7c81-fd68-4b8c-8305-65e1ecbff67f|6|MJPTHIND|Major Pathological Response Indicator|IWG CHESON AML 2003|[?]|mg/h|NON-CR/NON-PD|1|uL/kg/day|HPLC-FL||||FAMILY MEMBER|DEVELOPMENTAL PSYCHOLOGIST|NA|3|Visit_3|40|6|FOLLOW-UP|2020-12-10|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-25|P1Y2M10DT2H30M|UNKNOWN|2020-12-25|COINCIDENT|2021-01-29
e|RS|ecfa7c81-fd68-4b8c-8305-65e1ecbff67f|7|NTERESP|Non-Target Enhancing Response|PETIT BREAST CANCER 2001|||HI-N|1|COAT|TRANSMISSION ELECTRON MICROSCOPY|||Y|INDEPENDENT ASSESSOR|MICROSCOPIST 1|Y|4|Visit_4|65|3|TREATMENT|2021-01-04|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-10|P1Y2M10DT2H30M|AFTER|2020-11-08|BEFORE|2021-02-01
e|RS|ecfa7c81-fd68-4b8c-8305-65e1ecbff67f|8|MJPTHIND|Major Pathological Response Indicator|MONTSERRAT CLL 1989|[?]|mL/dL|pCR|1|%(w/w)|DARK FIELD MICROSCOPY||||HEALTH CARE PROFESSIONAL|OPTOMETRIST|U|4|Visit_4|65|2|WASHOUT|2021-01-04|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-10|P1Y2M10DT2H30M|BEFORE|2020-11-29|COINCIDENT|2021-01-09
e|RS|ecfa7c81-fd68-4b8c-8305-65e1ecbff67f|9|NTERESP|Non-Target Enhancing Response|RANO|[?]|TROCHE|VGPR|1|mmol/min/kPa/L|MAGNETIC RESONANCE ANGIOGRAPHY||||CLINICAL RESEARCH COORDINATOR|OTOLARYNGOLOGIST|N|5|Visit_5|90|7|TREATMENT|2021-01-29|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-30|P1Y2M10DT2H30M|AFTER|2021-01-30|COINCIDENT|2021-02-05
e|RS|ecfa7c81-fd68-4b8c-8305-65e1ecbff67f|10|NEWLWIND|New Lesion Worsening Indicator|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|||SD-CT|1|ft3|IMMUNOFIXATION ELECTROPHORESIS|||Y|NON-HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|Y|5|Visit_5|90|2|FOLLOW-UP|2021-01-29|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-30|P1Y2M10DT2H30M|AFTER|2020-12-14|BEFORE|2021-01-30
e|RS|7fa3d0ff-fd49-4114-bebe-1c27765f01b8|1|OVRLRESP|Overall Response|RECIST 1.0|[?]|uL|nPR|1|atm|BIOIMPEDANCE SPECTROSCOPY||||NON-HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|U|1|Visit_1|10|7|SCREENING|2020-05-13|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-11|P1Y2M10DT2H30M|BEFORE|2020-07-15|BEFORE|2020-07-21
e|RS|7fa3d0ff-fd49-4114-bebe-1c27765f01b8|2|LIVRRESP|Liver Response|NCCN ALL MRD 2014|[?]|Ci/mg|MOLECULAR MAJOR RESPONSE|1|Bq/kg|SICKLE CELL SOLUBILITY TEST||||SIBLING|MICROSCOPIST 1|Y|1|Visit_1|10|1|WASHOUT|2020-05-13|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-11|P1Y2M10DT2H30M|BEFORE|2020-05-11|AFTER|2020-07-02
e|RS|7fa3d0ff-fd49-4114-bebe-1c27765f01b8|3|CYTORESP|Cytogenetic Response|HARTMANN GERM CELL CANCER 2002|[?]|TABLET|iUPD|1|/LPF|LASER CAPTURE MICRODISSECTION|Y|Y||GUARDIAN|MICROSCOPIST 1|U|2|Visit_2|25|4|TREATMENT|2020-05-28|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-08|P1Y2M10DT2H30M|UNKNOWN|2020-07-12|AFTER|2020-08-07
e|RS|7fa3d0ff-fd49-4114-bebe-1c27765f01b8|4|NEWLPROG|New Lesion Progression|NCCN ALL MRD 2014|[?]|HOMEOPATHIC DILUTION|DISEASE TRANSFORMATION|1|SFC/10^6 PBMC|HPLC/MS||||CAREGIVER|RADIOLOGIST|U|2|Visit_2|25|7|TREATMENT|2020-05-28|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-08|P1Y2M10DT2H30M|COINCIDENT|2020-06-15|AFTER|2020-08-06
e|RS|7fa3d0ff-fd49-4114-bebe-1c27765f01b8|5|CYTORESP|Cytogenetic Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|DIP|PD|1|ugEq/L|CONTRAST ENHANCED PET/CT SCAN|Y|||SIBLING|NEUROLOGIST 2|U|3|Visit_3|40|6|WASHOUT|2020-06-12|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-07|P1Y2M10DT2H30M|AFTER|2020-05-30|COINCIDENT|2020-06-24
e|RS|7fa3d0ff-fd49-4114-bebe-1c27765f01b8|6|SYMPTDTR|Symptomatic Deterioration|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|nmol BCE/mmol|CYTOGENETIC PR|1|Hz|BRDU CELLULAR PROLIFERATION ASSAY||||GUARDIAN|DERMATOLOGIST|NA|3|Visit_3|40|2|SCREENING|2020-06-12|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-07|P1Y2M10DT2H30M|UNKNOWN|2020-08-02|ONGOING|2020-08-07
e|RS|7fa3d0ff-fd49-4114-bebe-1c27765f01b8|7|BONERESP|Bone Response|PCWG SCHER PROSTATE CANCER 2016|[?]|MET*h|SD-CT|1|100 IU/mL|ETDRS EYE CHART||||CAREGIVER|RATER 2|Y|4|Visit_4|65|2|TREATMENT|2020-07-07|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-12|P1Y2M10DT2H30M|UNKNOWN|2020-07-16|AFTER|2020-08-07
e|RS|7fa3d0ff-fd49-4114-bebe-1c27765f01b8|8|MRDRESP|Minimal Residual Disease Response|CHOI GIST 2008|||NE|1|umol/h/mmol|RAJI CELL EIA|||Y|GUARDIAN|ADJUDICATOR|U|4|Visit_4|65|1|FOLLOW-UP|2020-07-07|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-12|P1Y2M10DT2H30M|AFTER|2020-05-23|BEFORE|2020-06-11
e|RS|7fa3d0ff-fd49-4114-bebe-1c27765f01b8|9|SFTSRESP|Soft Tissue Response|DURIE MULTIPLE MYELOMA 2006|[?]|fmol|iCPD|1|10^6 DNA copies/mL|WRIGHT-GIEMSA STAIN||||VENDOR|INTERNIST|U|5|Visit_5|90|6|TREATMENT|2020-08-01|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-01|P1Y2M10DT2H30M|COINCIDENT|2020-06-10|BEFORE|2020-07-12
e|RS|7fa3d0ff-fd49-4114-bebe-1c27765f01b8|10|ANATRESP|Anatomic Response|EBMT BLADE MYELOMA 1998|||PR WITH LYMPHOCYTOSIS|1|mL/kg/day|LANDOLT RING||Y|Y|INTERVIEWER|DERMATOLOGIST|U|5|Visit_5|90|5|SCREENING|2020-08-01|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-01|P1Y2M10DT2H30M|AFTER|2020-06-14|BEFORE|2020-06-26
e|RS|d041952e-4aa6-4b37-9cec-127adce2eabb|1|TMRESP|Tumor Marker Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|||FAVORABLE RESPONSE|1|%/min|AUTOREFRACTION|||Y|DOMESTIC PARTNER|PEDIATRIC NEUROLOGIST|N|1|Visit_1|10|4|TREATMENT|2020-10-09|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-07|P1Y2M10DT2H30M|UNKNOWN|2020-12-17|ONGOING|2020-12-23
e|RS|d041952e-4aa6-4b37-9cec-127adce2eabb|2|NEWLIND|New Lesion Indicator|NCIWG CHESON CLL 1996|[?]|PATCH|CA125 50% RESPONSE|1|RATIO|MICROBIAL CULTURE, LIQUID||||VENDOR|PATHOLOGIST|NA|1|Visit_1|10|6|FOLLOW-UP|2020-10-09|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-07|P1Y2M10DT2H30M|COINCIDENT|2020-10-30|BEFORE|2020-12-09
e|RS|d041952e-4aa6-4b37-9cec-127adce2eabb|3|MRDIND|Minimal Residual Disease Indicator|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|ft|pCR|1|Enzyme U/g Hb|ELECTROCHEMILUMINESCENCE||||CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 1|Y|2|Visit_2|25|4|SCREENING|2020-10-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-25|P1Y2M10DT2H30M|AFTER|2020-11-19|AFTER|2020-11-24
e|RS|d041952e-4aa6-4b37-9cec-127adce2eabb|4|SYMPTDTR|Symptomatic Deterioration|LEE LUNG CANCER 2011|[?]|h/wk|CR-CT|1|F|BRDU CELLULAR PROLIFERATION ASSAY||||FRIEND|PATHOLOGIST 2|U|2|Visit_2|25|6|TREATMENT|2020-10-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-25|P1Y2M10DT2H30M|AFTER|2020-12-18|ONGOING|2021-01-01
e|RS|d041952e-4aa6-4b37-9cec-127adce2eabb|5|MNPTHIND|Minor Pathological Response Indicator|KUMAR IMWG 2016|[?]|YEARS|STABLE|1|cmH2O*s/mL|HPLC/IEX||||PROXY|CARDIOLOGIST|U|3|Visit_3|40|5|SCREENING|2020-11-08|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-04|P1Y2M10DT2H30M|AFTER|2020-11-11|AFTER|2020-12-18
e|RS|d041952e-4aa6-4b37-9cec-127adce2eabb|6|METBRESP|Metabolic Response|AJCC V8|[?]|/40 HPFs|NOT ALL EVALUATED|1|RING|CARDIAC THERMODILUTION|Y|||VENDOR|PATHOLOGIST 2|Y|3|Visit_3|40|3|TREATMENT|2020-11-08|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-04|P1Y2M10DT2H30M|UNKNOWN|2020-11-11|COINCIDENT|2020-11-24
e|RS|d041952e-4aa6-4b37-9cec-127adce2eabb|7|NTERESP|Non-Target Enhancing Response|RAJKUMAR MYELOMA 2011|||STABLE|1|Log10 ELISA unit|PLAQUE REDUCTION NEUTRALIZATION ASSAY|||Y|FAMILY MEMBER|READER 3|U|4|Visit_4|65|3|FOLLOW-UP|2020-12-03|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-29|P1Y2M10DT2H30M|UNKNOWN|2020-12-14|AFTER|2020-12-27
e|RS|d041952e-4aa6-4b37-9cec-127adce2eabb|8|NTRGRESP|Non-target Response|CHOLLET BREAST CANCER 2002|||iCPD|1|Linear ft*LB|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY|Y||Y|SPOUSE|ADJUDICATOR 3|N|4|Visit_4|65|1|WASHOUT|2020-12-03|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-29|P1Y2M10DT2H30M|COINCIDENT|2020-11-30|ONGOING|2020-12-11
e|RS|d041952e-4aa6-4b37-9cec-127adce2eabb|9|NEWLWIND|New Lesion Worsening Indicator|PERCIST|[?]|L/h|CRi|1|MET*h|DIFFUSION TENSOR MRI||||GUARDIAN|PATHOLOGIST 2|U|5|Visit_5|90|7|SCREENING|2020-12-28|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-18|P1Y2M10DT2H30M|AFTER|2020-10-12|AFTER|2020-11-23
e|RS|d041952e-4aa6-4b37-9cec-127adce2eabb|10|MJPTHIND|Major Pathological Response Indicator|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|km|MR|1|ag|SPECULAR MICROSCOPY||Y||CLINICAL STUDY SPONSOR|RADIOLOGIST 1|N|5|Visit_5|90|5|TREATMENT|2020-12-28|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-18|P1Y2M10DT2H30M|UNKNOWN|2020-11-10|BEFORE|2020-12-29
e|RS|7f0ceec0-eda9-40ea-b2e8-90ba6bf3d115|1|MJPTHIND|Major Pathological Response Indicator|BURCOMBE BREAST CANCER 2005|[?]|BAU|VGPR|1|/mm|CAPILLARY ELECTROPHORESIS||||STUDY SUBJECT|ONCOLOGIST|N|1|Visit_1|10|1|TREATMENT|2020-06-09|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-05|P1Y2M10DT2H30M|BEFORE|2020-06-17|COINCIDENT|2020-08-02
e|RS|7f0ceec0-eda9-40ea-b2e8-90ba6bf3d115|2|METSIND|Metastatic Indicator|PCWG SCHER PROSTATE CANCER 2008|||MRD NEGATIVITY|1|MBq|SPIRAL CT|||Y|HEALTH CARE PROFESSIONAL|READER|U|1|Visit_1|10|6|SCREENING|2020-06-09|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-05|P1Y2M10DT2H30M|BEFORE|2020-06-04|COINCIDENT|2020-08-10
e|RS|7f0ceec0-eda9-40ea-b2e8-90ba6bf3d115|3|SYMPTDTR|Symptomatic Deterioration|NCCN ALL MRD 2014|||EQUIVOCAL|1|mm/h|MOUSE PROTECTION ASSAY||Y|Y|PROXY|UROLOGIST|Y|2|Visit_2|25|7|WASHOUT|2020-06-24|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-28|P1Y2M10DT2H30M|COINCIDENT|2020-06-28|AFTER|2020-07-14
e|RS|7f0ceec0-eda9-40ea-b2e8-90ba6bf3d115|4|BMIVLIND|Bone Marrow Involvement Indicator|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|Joule|iCPD|1|Bq/kg|PET SCAN||||INDEPENDENT ASSESSOR|READER 2|N|2|Visit_2|25|4|FOLLOW-UP|2020-06-24|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-28|P1Y2M10DT2H30M|AFTER|2020-07-06|AFTER|2020-08-14
e|RS|7f0ceec0-eda9-40ea-b2e8-90ba6bf3d115|5|NEWLIND|New Lesion Indicator|FAROOQUI SUPP CLL 2014|[?]|mm/h|NE|1|amp|MAGNETIC RESONANCE ANGIOGRAPHY||||VENDOR|RADIOLOGIST 2|U|3|Visit_3|40|5|WASHOUT|2020-07-09|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-05|P1Y2M10DT2H30M|COINCIDENT|2020-06-12|BEFORE|2020-06-19
e|RS|7f0ceec0-eda9-40ea-b2e8-90ba6bf3d115|6|OVRLRESP|Overall Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|umol/L/h|OPTIMAL MORPHOLOGIC RESPONSE|1|mL/dose|DYNAMOMETRY||||CLINICAL RESEARCH ASSOCIATE|PHYSIOTHERAPIST|U|3|Visit_3|40|7|SCREENING|2020-07-09|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-05|P1Y2M10DT2H30M|BEFORE|2020-06-09|COINCIDENT|2020-06-26
e|RS|7f0ceec0-eda9-40ea-b2e8-90ba6bf3d115|7|TRGRESP|Target Response|RANO ELLINGSON 2017|||SMD|1|C|BIOPSY|Y|Y|Y|VENDOR|CLINICAL PATHOLOGIST|U|4|Visit_4|65|1|SCREENING|2020-08-03|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-20|P1Y2M10DT2H30M|AFTER|2020-06-03|BEFORE|2020-08-15
e|RS|7f0ceec0-eda9-40ea-b2e8-90ba6bf3d115|8|MRDRESP|Minimal Residual Disease Response|WHO BREAST CANCER 2006|||PARTIAL MORPHOLOGIC RESPONSE|1|DPM|VENTILATION PERFUSION LUNG SCAN|||Y|SIGNIFICANT OTHER|RADIOLOGIST 2|U|4|Visit_4|65|3|WASHOUT|2020-08-03|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-20|P1Y2M10DT2H30M|AFTER|2020-06-27|AFTER|2020-08-15
e|RS|7f0ceec0-eda9-40ea-b2e8-90ba6bf3d115|9|MRDIND|Minimal Residual Disease Indicator|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|/10^5|STABLE|1|YEARS|HPLC/MS/MS||Y||HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|N|5|Visit_5|90|2|SCREENING|2020-08-28|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-02|P1Y2M10DT2H30M|UNKNOWN|2020-08-28|COINCIDENT|2020-08-29
e|RS|7f0ceec0-eda9-40ea-b2e8-90ba6bf3d115|10|LIVRRESP|Liver Response|LUGANO CLASSIFICATION|[?]|log10 TCID 50/mL|PMD|1|BOTTLE|PHOTOMETRIC CLOT DETECTION||||ADJUDICATOR|OPTOMETRIST|U|5|Visit_5|90|3|WASHOUT|2020-08-28|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-02|P1Y2M10DT2H30M|BEFORE|2020-07-30|AFTER|2020-08-27
e|RS|9fc393da-4665-4be5-a869-856c45ddcf13|1|PATHRESP|Pathologic Response|PRINCE TCELL LYMPHOMA 2010|[?]|cm H2O|STABLE|1|CAPSULE|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI||||DOMESTIC PARTNER|RADIOLOGIST|NA|1|Visit_1|10|1|SCREENING|2020-06-18|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-07|P1Y2M10DT2H30M|AFTER|2020-07-20|COINCIDENT|2020-08-18
e|RS|9fc393da-4665-4be5-a869-856c45ddcf13|2|NEWLIND|New Lesion Indicator|PCWG SCHER PROSTATE CANCER 2016|||PSEUDOPROGRESSION|1|BOLUS|PLETHYSMOGRAPHY|||Y|NON-HEALTH CARE PROFESSIONAL|UROLOGIST|NA|1|Visit_1|10|1|WASHOUT|2020-06-18|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-07|P1Y2M10DT2H30M|UNKNOWN|2020-08-14|AFTER|2020-09-02
e|RS|9fc393da-4665-4be5-a869-856c45ddcf13|3|SYMPTDTR|Symptomatic Deterioration|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|MnFI|CYTOGENETIC NO RESPONSE|1|cm/s|AGAR DILUTION||Y||VENDOR|OPTOMETRIST|U|2|Visit_2|25|6|FOLLOW-UP|2020-07-03|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-16|P1Y2M10DT2H30M|BEFORE|2020-08-26|COINCIDENT|2020-09-10
e|RS|9fc393da-4665-4be5-a869-856c45ddcf13|4|NTNERESP|Non-Target Non-Enhancing Response|AJCC V7|||PD|1|mmol/min/kPa/L|ORCHIDOMETERY|||Y|CAREGIVER|READER 3|Y|2|Visit_2|25|5|TREATMENT|2020-07-03|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-16|P1Y2M10DT2H30M|AFTER|2020-07-01|COINCIDENT|2020-07-31
e|RS|9fc393da-4665-4be5-a869-856c45ddcf13|5|TMRESP|Tumor Marker Response|BRUGGEMANN MRD 2010|||MR|1|um2|FLUORESCENT ENZYME IMMUNOASSAY|||Y|CHILD|ONCOLOGIST 1|Y|3|Visit_3|40|5|WASHOUT|2020-07-18|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-12|P1Y2M10DT2H30M|AFTER|2020-06-17|AFTER|2020-08-05
e|RS|9fc393da-4665-4be5-a869-856c45ddcf13|6|PATHRESP|Pathologic Response|RECIST 1.0|||PD FROM PR|1|mL/cm|TRICHROME STAIN|Y||Y|SIBLING|RATER 2|N|3|Visit_3|40|7|WASHOUT|2020-07-18|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-12|P1Y2M10DT2H30M|AFTER|2020-07-24|BEFORE|2020-08-07
e|RS|9fc393da-4665-4be5-a869-856c45ddcf13|7|OVRLRESP|Overall Response|KUMAR IMWG 2016|[?]|mL/cm3/min|CA125 75% RESPONSE|1|KALLIKREIN INHIBITOR UNIT|GC/MS/MS||||FRIEND|DEVELOPMENTAL PSYCHOLOGIST|NA|4|Visit_4|65|3|TREATMENT|2020-08-12|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-09|P1Y2M10DT2H30M|COINCIDENT|2020-07-25|ONGOING|2020-07-28
e|RS|9fc393da-4665-4be5-a869-856c45ddcf13|8|SYMPTDTR|Symptomatic Deterioration|EBMT BLADE MYELOMA 1998|[?]|mEq/mL|HI-E|1|pmol/g|WESTERGREN||||INTERVIEWER|HEMATOLOGIST|Y|4|Visit_4|65|6|TREATMENT|2020-08-12|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-09|P1Y2M10DT2H30M|COINCIDENT|2020-08-19|BEFORE|2020-09-08
e|RS|9fc393da-4665-4be5-a869-856c45ddcf13|9|MRPHRESP|Morphologic Response|iRECIST|[?]|uL/mL|PMR|1|kg|DC SHEATH FLOW|Y|Y||STUDY SUBJECT|NEUROLOGIST|U|5|Visit_5|90|3|FOLLOW-UP|2020-09-06|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-08|P1Y2M10DT2H30M|UNKNOWN|2020-06-16|COINCIDENT|2020-07-08
e|RS|9fc393da-4665-4be5-a869-856c45ddcf13|10|METSIND|Metastatic Indicator|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|L/s/kPa|CA125 75% RESPONSE|1|10^9/L|CYSTOMETRY||||SIBLING|RADIOLOGIST 1|Y|5|Visit_5|90|3|FOLLOW-UP|2020-09-06|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-08|P1Y2M10DT2H30M|COINCIDENT|2020-06-11|COINCIDENT|2020-08-19
e|RS|cddc1541-4de9-45e7-bb61-15a2d5baca6f|1|CPRFSTAT|Clinical Performance Status|IWG CHESON AML 2003|||HI-P|1|/LPF|CALCOFLUOR WHITE STAIN|Y||Y|HEALTH CARE PROFESSIONAL|UROLOGIST|U|1|Visit_1|10|2|FOLLOW-UP|2021-01-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-14|P1Y2M10DT2H30M|UNKNOWN|2021-04-09|AFTER|2021-04-10
e|RS|cddc1541-4de9-45e7-bb61-15a2d5baca6f|2|OVRLRESP|Overall Response|HAMAOKA BREAST CANCER 2010|[?]|titer|RELAPSED DISEASE|1|mg/g/min|CELL OF ORIGIN ASSAY||||VENDOR|PHYSIOTHERAPIST|U|1|Visit_1|10|1|WASHOUT|2021-01-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-14|P1Y2M10DT2H30M|AFTER|2021-03-09|ONGOING|2021-03-21
e|RS|cddc1541-4de9-45e7-bb61-15a2d5baca6f|3|SPLNRESP|Spleen Response|HAMAOKA BREAST CANCER 2010|[?]|mg/kg/day|COMPLETE MRD RESPONSE|1|mmol|GC/MS-EI|Y|||HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|Y|2|Visit_2|25|2|TREATMENT|2021-02-03|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-06|P1Y2M10DT2H30M|BEFORE|2021-02-03|ONGOING|2021-02-24
e|RS|cddc1541-4de9-45e7-bb61-15a2d5baca6f|4|CPRFSTAT|Clinical Performance Status|MRANO VAN DEN BENT GLIOMA 2011|[?]|ug/min|CYTOGENETIC MINOR RESPONSE|1|nmol/L/h|MACRO BROTH DILUTION||||INDEPENDENT ASSESSOR|ADJUDICATOR 1|Y|2|Visit_2|25|7|WASHOUT|2021-02-03|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-06|P1Y2M10DT2H30M|AFTER|2021-04-09|AFTER|2021-04-14
e|RS|cddc1541-4de9-45e7-bb61-15a2d5baca6f|5|BMIVLIND|Bone Marrow Involvement Indicator|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|1/(s*kPa)|WORSENED|1|FFU|LC-FL|Y|Y||DOMESTIC PARTNER|FORENSIC PATHOLOGIST|N|3|Visit_3|40|7|TREATMENT|2021-02-18|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-08|P1Y2M10DT2H30M|BEFORE|2021-02-16|ONGOING|2021-03-15
e|RS|cddc1541-4de9-45e7-bb61-15a2d5baca6f|6|METBRESP|Metabolic Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|h/wk|CYTOGENETIC NO RESPONSE|1|uCi/L|PERFUSION MRI||Y||FAMILY MEMBER|NEUROLOGIST 1|NA|3|Visit_3|40|6|SCREENING|2021-02-18|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-08|P1Y2M10DT2H30M|UNKNOWN|2021-04-13|AFTER|2021-04-15
e|RS|cddc1541-4de9-45e7-bb61-15a2d5baca6f|7|MRDRESP|Minimal Residual Disease Response|HAMAOKA BREAST CANCER 2010|[?]|vp/mL|MINOR PATHOLOGIC RESPONSE|1|cm|CONFOCAL MICROSCOPY||||ADJUDICATOR|READER|N|4|Visit_4|65|6|FOLLOW-UP|2021-03-15|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-22|P1Y2M10DT2H30M|BEFORE|2021-02-17|BEFORE|2021-03-17
e|RS|cddc1541-4de9-45e7-bb61-15a2d5baca6f|8|BMIVLIND|Bone Marrow Involvement Indicator|PCWG SCHER PROSTATE CANCER 2016|||OPTIMAL MORPHOLOGIC RESPONSE|1|yd|SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY||Y|Y|CHILD|FORENSIC PATHOLOGIST|NA|4|Visit_4|65|1|TREATMENT|2021-03-15|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-22|P1Y2M10DT2H30M|BEFORE|2021-03-26|COINCIDENT|2021-04-14
e|RS|cddc1541-4de9-45e7-bb61-15a2d5baca6f|9|MRDRESP|Minimal Residual Disease Response|PRINCE TCELL LYMPHOMA 2010|||pCR|1|v/v|CAPILLARY ELECTROPHORESIS|||Y|SPOUSE|NEUROLOGIST 1|U|5|Visit_5|90|2|TREATMENT|2021-04-09|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-15|P1Y2M10DT2H30M|UNKNOWN|2021-02-26|BEFORE|2021-03-08
e|RS|cddc1541-4de9-45e7-bb61-15a2d5baca6f|10|NTNERESP|Non-Target Non-Enhancing Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|||VGPR|1|cup eq|FLOW MICROSCOPY|Y||Y|PARENT|NEUROLOGIST 1|Y|5|Visit_5|90|4|TREATMENT|2021-04-09|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-15|P1Y2M10DT2H30M|UNKNOWN|2021-02-15|BEFORE|2021-02-20
e|RS|303c6dbe-59f9-4016-baa1-8506c0c1ee09|1|NEWLPROG|New Lesion Progression|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|JAR|DECREASED|1|foz_us|FLOW MICROSCOPY|Y|Y||CAREGIVER|ADJUDICATOR 3|NA|1|Visit_1|10|4|TREATMENT|2020-12-26|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-28|P1Y2M10DT2H30M|UNKNOWN|2021-03-25|COINCIDENT|2021-03-26
e|RS|303c6dbe-59f9-4016-baa1-8506c0c1ee09|2|METSIND|Metastatic Indicator|PALUMBO MULTIPLE MYELOMA 2009|[?]|mmol/min/kPa/L|RELAPSED DISEASE FROM CR|1|mg/m2/h|URANYL ACETATE STAIN||||PARENT|RATER 2|U|1|Visit_1|10|3|WASHOUT|2020-12-26|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-28|P1Y2M10DT2H30M|COINCIDENT|2020-12-19|ONGOING|2021-02-17
e|RS|303c6dbe-59f9-4016-baa1-8506c0c1ee09|3|BMIVLIND|Bone Marrow Involvement Indicator|IWG CHESON MDS 2000|[?]|Gy|pCR|1|dmol|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY||||GUARDIAN|FORENSIC PATHOLOGIST|N|2|Visit_2|25|6|SCREENING|2021-01-10|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-23|P1Y2M10DT2H30M|AFTER|2021-01-10|BEFORE|2021-01-15
e|RS|303c6dbe-59f9-4016-baa1-8506c0c1ee09|4|SPLNRESP|Spleen Response|AJCC V7|||PR|1|fmol/g|POLYSOMNOGRAPHY|||Y|SIBLING|PATHOLOGIST|NA|2|Visit_2|25|2|SCREENING|2021-01-10|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-23|P1Y2M10DT2H30M|COINCIDENT|2021-03-13|COINCIDENT|2021-03-21
e|RS|303c6dbe-59f9-4016-baa1-8506c0c1ee09|5|NTERESP|Non-Target Enhancing Response|SACT|||CYTOGENETIC CR|1|m3|MAPH||Y|Y|CLINICAL STUDY SPONSOR|OPTOMETRIST|N|3|Visit_3|40|1|SCREENING|2021-01-25|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-06|P1Y2M10DT2H30M|COINCIDENT|2021-03-07|ONGOING|2021-03-15
e|RS|303c6dbe-59f9-4016-baa1-8506c0c1ee09|6|CPRFSTAT|Clinical Performance Status|MONTSERRAT CLL 1989|[?]|cal|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|MPL U|PERIPHERAL ANGIOGRAPHY||||STUDY SUBJECT|READER 1|NA|3|Visit_3|40|6|FOLLOW-UP|2021-01-25|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-06|P1Y2M10DT2H30M|BEFORE|2020-12-20|ONGOING|2021-03-05
e|RS|303c6dbe-59f9-4016-baa1-8506c0c1ee09|7|SFTSRESP|Soft Tissue Response|MRECIST LENCIONI LIVER CANCER 2010|||COMPLETE MRD RESPONSE|1|CAPLET|LC-FL|||Y|INTERVIEWER|PATHOLOGIST|N|4|Visit_4|65|2|TREATMENT|2021-02-19|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-26|P1Y2M10DT2H30M|BEFORE|2021-02-19|COINCIDENT|2021-03-02
e|RS|303c6dbe-59f9-4016-baa1-8506c0c1ee09|8|NEWLIND|New Lesion Indicator|CHESON CLL 2012|[?]|U/m2|INCREASED|1|ug/m2/h|CENTRIFUGATION||||VENDOR|ENDOCRINOLOGIST|Y|4|Visit_4|65|1|TREATMENT|2021-02-19|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-26|P1Y2M10DT2H30M|AFTER|2021-02-24|AFTER|2021-03-05
e|RS|303c6dbe-59f9-4016-baa1-8506c0c1ee09|9|CYTORESP|Cytogenetic Response|IRANO 2015|||CHR|1|kIU|TEST STRIP|||Y|INDEPENDENT ASSESSOR|ONCOLOGIST 2|N|5|Visit_5|90|1|TREATMENT|2021-03-16|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-11|P1Y2M10DT2H30M|BEFORE|2021-01-22|ONGOING|2021-03-11
e|RS|303c6dbe-59f9-4016-baa1-8506c0c1ee09|10|METSIND|Metastatic Indicator|MRECIST LENCIONI LIVER CANCER 2010|[?]|ft3|PMR|1|umol/min|PULSE OXIMETRY|Y|||FRIEND|OTOLARYNGOLOGIST|NA|5|Visit_5|90|3|TREATMENT|2021-03-16|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-11|P1Y2M10DT2H30M|AFTER|2021-01-21|COINCIDENT|2021-01-27
e|RS|fee3c810-3d76-4db4-9272-6b4e8fd14088|1|MOLRESP|Molecular Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|PIXELS/in|NOT ALL EVALUATED|1|Ci/L|ELLA||||CLINICAL RESEARCH COORDINATOR|PHYSIOTHERAPIST|U|1|Visit_1|10|2|TREATMENT|2020-12-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-11|P1Y2M10DT2H30M|UNKNOWN|2020-12-21|AFTER|2021-02-06
e|RS|fee3c810-3d76-4db4-9272-6b4e8fd14088|2|TMRESP|Tumor Marker Response|PCWG SCHER PROSTATE CANCER 2008|||PSEUDOPROGRESSION|1|dpm/mg|SPIRAL CT SCAN WITHOUT CONTRAST|||Y|ADJUDICATION COMMITTEE|NEUROLOGIST 1|Y|1|Visit_1|10|6|TREATMENT|2020-12-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-11|P1Y2M10DT2H30M|BEFORE|2021-01-03|ONGOING|2021-02-04
e|RS|fee3c810-3d76-4db4-9272-6b4e8fd14088|3|MRPHRESP|Morphologic Response|IWG CHESON MDS 2000|[?]|cal|nPR|1|um|SPIROMETRY||||HEALTH CARE PROFESSIONAL|DERMATOLOGIST|NA|2|Visit_2|25|2|FOLLOW-UP|2020-12-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-09|P1Y2M10DT2H30M|UNKNOWN|2021-01-04|AFTER|2021-01-30
e|RS|fee3c810-3d76-4db4-9272-6b4e8fd14088|4|NTERESP|Non-Target Enhancing Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|||UNEQUIVOCAL|1|CONTAINER|MIGET|||Y|INDEPENDENT ASSESSOR|FORENSIC PATHOLOGIST|Y|2|Visit_2|25|1|FOLLOW-UP|2020-12-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-09|P1Y2M10DT2H30M|COINCIDENT|2020-12-23|COINCIDENT|2021-03-11
e|RS|fee3c810-3d76-4db4-9272-6b4e8fd14088|5|BMIVLIND|Bone Marrow Involvement Indicator|RANO ELLINGSON 2017|[?]|Newton|MRD NEGATIVITY|1|Newton|CHROMOGENIC ASSAY|Y|||NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|U|3|Visit_3|40|6|FOLLOW-UP|2021-01-14|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-05|P1Y2M10DT2H30M|UNKNOWN|2020-12-30|AFTER|2021-02-07
e|RS|fee3c810-3d76-4db4-9272-6b4e8fd14088|6|STRUSTAT|Steroid Use Status|JACINTO CERVICAL CANCER 2007|[?]|Hounsfield Unit|NON-CR/NON-PD|1|ms2|HEMATOXYLIN AND EOSIN STAIN||Y||ADJUDICATION COMMITTEE|RATER|NA|3|Visit_3|40|1|FOLLOW-UP|2021-01-14|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-05|P1Y2M10DT2H30M|AFTER|2021-03-13|COINCIDENT|2021-03-14
e|RS|fee3c810-3d76-4db4-9272-6b4e8fd14088|7|LIVRRESP|Liver Response|CHESON CLL 2006|[?]|Linear ft*LB|NED|1|MET*min|IMMUNE REPERTOIRE DEEP SEQUENCING||||SPOUSE|PATHOLOGIST 1|U|4|Visit_4|65|2|FOLLOW-UP|2021-02-08|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-17|P1Y2M10DT2H30M|UNKNOWN|2020-12-12|ONGOING|2021-02-26
e|RS|fee3c810-3d76-4db4-9272-6b4e8fd14088|8|SFTSRESP|Soft Tissue Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|||SMD|1|PACKET|QUANTITATIVE PERIPHERAL ANGIOGRAPHY|||Y|PROXY|ADJUDICATOR 3|U|4|Visit_4|65|6|SCREENING|2021-02-08|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-17|P1Y2M10DT2H30M|UNKNOWN|2021-01-04|COINCIDENT|2021-02-13
e|RS|fee3c810-3d76-4db4-9272-6b4e8fd14088|9|MRDRESP|Minimal Residual Disease Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|||pCR|1|Bq/ug|NUCLEIC ACID AMPLIFICATION TEST|Y||Y|INDEPENDENT ASSESSOR|MICROSCOPIST 2|N|5|Visit_5|90|5|WASHOUT|2021-03-05|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-05|P1Y2M10DT2H30M|UNKNOWN|2021-03-09|AFTER|2021-03-10
e|RS|fee3c810-3d76-4db4-9272-6b4e8fd14088|10|BESTRESP|Best Overall Response|HARTMAN PANCREATIC CANCER 2012|[?]|ft2|PR-CT|1|breaths/30s|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY||||PARENT|RADIOLOGIST 2|Y|5|Visit_5|90|3|TREATMENT|2021-03-05|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-05|P1Y2M10DT2H30M|BEFORE|2020-12-30|BEFORE|2021-03-09
e|RS|d5125e6c-2ab6-4286-8ce0-0011f1e08fbb|1|NEWLWIND|New Lesion Worsening Indicator|IWG CHESON MDS 2000|[?]|cm2|IMMUNOPHENOTYPIC CR|1|BOLUS|IMMUNO-PET SCAN|Y|||GUARDIAN|MICROSCOPIST 2|N|1|Visit_1|10|2|FOLLOW-UP|2020-07-08|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-26|P1Y2M10DT2H30M|AFTER|2020-07-19|BEFORE|2020-09-19
e|RS|d5125e6c-2ab6-4286-8ce0-0011f1e08fbb|2|TMRESP|Tumor Marker Response|SHINDOH COLORECTAL CANCER 2013|[?]|Ci/mg|PR-CT|1|10^9 CFU|DYNAMOMETRY||||NON-HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|N|1|Visit_1|10|1|FOLLOW-UP|2020-07-08|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-26|P1Y2M10DT2H30M|UNKNOWN|2020-07-13|AFTER|2020-09-03
e|RS|d5125e6c-2ab6-4286-8ce0-0011f1e08fbb|3|MOLRESP|Molecular Response|BURCOMBE BREAST CANCER 2005|||ABSENT MORPHOLOGIC RESPONSE|1|nm|THICK SMEAR||Y|Y|ADJUDICATION COMMITTEE|FORENSIC PATHOLOGIST|NA|2|Visit_2|25|5|FOLLOW-UP|2020-07-23|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-10|P1Y2M10DT2H30M|COINCIDENT|2020-08-13|AFTER|2020-10-04
e|RS|d5125e6c-2ab6-4286-8ce0-0011f1e08fbb|4|NTERESP|Non-Target Enhancing Response|LEE LUNG CANCER 2011|[?]|log EID 50/dose|PD-CT|1|10^9 CFU/mL|RIA||||FRIEND|READER|U|2|Visit_2|25|4|TREATMENT|2020-07-23|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-10|P1Y2M10DT2H30M|UNKNOWN|2020-08-20|COINCIDENT|2020-09-16
e|RS|d5125e6c-2ab6-4286-8ce0-0011f1e08fbb|5|CLINRESP|Clinical Response|MACDONALD GLIOMA 1990|||MRD PERSISTENCE|1|mg/kg/min|AUDIOMETRY||Y|Y|PROXY|READER|NA|3|Visit_3|40|1|TREATMENT|2020-08-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-04|P1Y2M10DT2H30M|COINCIDENT|2020-07-11|ONGOING|2020-08-05
e|RS|d5125e6c-2ab6-4286-8ce0-0011f1e08fbb|6|HEMARESP|Hematologic Response|RANO ELLINGSON 2017|[?]|dmol|PR-CT|1|mm3/mm2/year|CAPILLARY ELECTROPHORESIS||||STUDY SUBJECT|HEMATOLOGIST|U|3|Visit_3|40|2|TREATMENT|2020-08-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-04|P1Y2M10DT2H30M|AFTER|2020-07-28|AFTER|2020-09-27
e|RS|d5125e6c-2ab6-4286-8ce0-0011f1e08fbb|7|NTNERESP|Non-Target Non-Enhancing Response|RANO|[?]|cmol|CYTOGENETIC CR|1|eq|CT SCAN||||CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 2|NA|4|Visit_4|65|6|SCREENING|2020-09-01|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-12|P1Y2M10DT2H30M|UNKNOWN|2020-07-10|COINCIDENT|2020-09-17
e|RS|d5125e6c-2ab6-4286-8ce0-0011f1e08fbb|8|METBRESP|Metabolic Response|RECIST 1.0|||CYTOGENETIC CR|1|HOMEOPATHIC DILUTION|PHASE-CONTRAST MRI|||Y|PARENT|PEDIATRIC NEUROLOGIST|NA|4|Visit_4|65|3|WASHOUT|2020-09-01|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-12|P1Y2M10DT2H30M|UNKNOWN|2020-09-17|COINCIDENT|2020-09-18
e|RS|d5125e6c-2ab6-4286-8ce0-0011f1e08fbb|9|SFTSRESP|Soft Tissue Response|BRUGGEMANN MRD 2010|||CYTOGENETIC MINIMAL RESPONSE|1|10^3 CFU|TONOMETRY||Y|Y|DOMESTIC PARTNER|ADJUDICATOR 2|NA|5|Visit_5|90|6|WASHOUT|2020-09-26|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-19|P1Y2M10DT2H30M|AFTER|2020-09-28|COINCIDENT|2020-10-03
e|RS|d5125e6c-2ab6-4286-8ce0-0011f1e08fbb|10|NTLWIND|Non-Target Lesion Worsening Indicator|SACT|[?]|U/L|iUPD|1|genEq/mL|AUTOREFRACTION|Y|Y||CAREGIVER|MICROSCOPIST|Y|5|Visit_5|90|3|TREATMENT|2020-09-26|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-19|P1Y2M10DT2H30M|BEFORE|2020-09-15|BEFORE|2020-09-19
e|RS|2e6e4c1d-4976-4f32-bd2e-8db09440f7b3|1|SPLNRESP|Spleen Response|AJCC V8|||CRi|1|MPS U|MALDI|||Y|FRIEND|ONCOLOGIST|NA|1|Visit_1|10|2|FOLLOW-UP|2020-08-01|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-22|P1Y2M10DT2H30M|BEFORE|2020-10-20|BEFORE|2020-10-25
e|RS|2e6e4c1d-4976-4f32-bd2e-8db09440f7b3|2|MJPTHIND|Major Pathological Response Indicator|MURPHY PROSTATE CANCER 1980|||NE|1|mU/L|FLUORESCENT LIFETIME IMAGING MICROSCOPY|||Y|ADJUDICATION COMMITTEE|ENDOCRINOLOGIST|U|1|Visit_1|10|3|WASHOUT|2020-08-01|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-22|P1Y2M10DT2H30M|BEFORE|2020-07-24|COINCIDENT|2020-10-12
e|RS|2e6e4c1d-4976-4f32-bd2e-8db09440f7b3|3|MRPHRESP|Morphologic Response|DOHNER AML 2010|[?]|/day|NOT ALL EVALUATED|1|ug/m2/day|PERCUSSION||||SIGNIFICANT OTHER|ADJUDICATOR|NA|2|Visit_2|25|3|TREATMENT|2020-08-16|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-11|P1Y2M10DT2H30M|UNKNOWN|2020-10-21|BEFORE|2020-10-24
e|RS|2e6e4c1d-4976-4f32-bd2e-8db09440f7b3|4|SFTSRESP|Soft Tissue Response|HAMAOKA BREAST CANCER 2010|||PD|1|nkat|KINETIC CHROMOGENIC ASSAY|Y||Y|CAREGIVER|MICROSCOPIST|Y|2|Visit_2|25|2|TREATMENT|2020-08-16|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-11|P1Y2M10DT2H30M|AFTER|2020-10-23|BEFORE|2020-10-29
e|RS|2e6e4c1d-4976-4f32-bd2e-8db09440f7b3|5|MRDIND|Minimal Residual Disease Indicator|KEAM BREAST CANCER 2013|[?]|dyn|UNEQUIVOCAL|1|Osm|HEMOCYTOMETRY||||NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST|U|3|Visit_3|40|4|TREATMENT|2020-08-31|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-07|P1Y2M10DT2H30M|AFTER|2020-09-15|BEFORE|2020-10-06
e|RS|2e6e4c1d-4976-4f32-bd2e-8db09440f7b3|6|SPLNRESP|Spleen Response|GUPPY OVARIAN CANCER 2002|[?]|PFU/animal|CYTOGENETIC MINIMAL RESPONSE|1|BOX|ELISPOT||||SPOUSE|READER 1|Y|3|Visit_3|40|7|FOLLOW-UP|2020-08-31|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-07|P1Y2M10DT2H30M|AFTER|2020-08-02|BEFORE|2020-10-22
e|RS|2e6e4c1d-4976-4f32-bd2e-8db09440f7b3|7|NTLWIND|Non-Target Lesion Worsening Indicator|SACT|||CYTOGENETIC PR|1|10^9 organisms|HILLMEN COLOR CHART|||Y|CAREGIVER|DERMATOLOGIST|N|4|Visit_4|65|4|WASHOUT|2020-09-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-20|P1Y2M10DT2H30M|AFTER|2020-09-08|BEFORE|2020-10-15
e|RS|2e6e4c1d-4976-4f32-bd2e-8db09440f7b3|8|NTERESP|Non-Target Enhancing Response|BURCOMBE BREAST CANCER 2005|[?]|log10 CFU/g|PMR|1|mEq/mmol|FLUORESCEIN STAIN||||PROXY|PATHOLOGIST|U|4|Visit_4|65|6|TREATMENT|2020-09-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-20|P1Y2M10DT2H30M|UNKNOWN|2020-07-30|BEFORE|2020-10-28
e|RS|2e6e4c1d-4976-4f32-bd2e-8db09440f7b3|9|OVRLRESP|Overall Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|IU/g|MRD PERSISTENCE|1|ug/m2/h|URANYL ACETATE STAIN||||NON-HEALTH CARE PROFESSIONAL|OPTOMETRIST|NA|5|Visit_5|90|6|FOLLOW-UP|2020-10-20|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-27|P1Y2M10DT2H30M|COINCIDENT|2020-08-26|ONGOING|2020-10-11
e|RS|2e6e4c1d-4976-4f32-bd2e-8db09440f7b3|10|ANATRESP|Anatomic Response|IWC HALLEK CLL 2008|[?]|CAPLET|cCR|1|mmol/min/kPa|SICKLE CELL SOLUBILITY TEST|Y|||VENDOR|INTERNIST|U|5|Visit_5|90|5|TREATMENT|2020-10-20|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-27|P1Y2M10DT2H30M|AFTER|2020-08-09|ONGOING|2020-09-12
e|RS|47fad45a-9a4c-47ee-a863-089d979523b5|1|NEWLPROG|New Lesion Progression|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|||SD|1|U/L|SICKLE CELL SOLUBILITY TEST|||Y|DOMESTIC PARTNER|MICROSCOPIST|N|1|Visit_1|10|2|TREATMENT|2020-10-07|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-21|P1Y2M10DT2H30M|BEFORE|2020-12-07|BEFORE|2021-01-04
e|RS|47fad45a-9a4c-47ee-a863-089d979523b5|2|MRDRESP|Minimal Residual Disease Response|HARTMANN GERM CELL CANCER 2002|[?]|mCi/kg|NE|1|10^9 organisms/mg|TURBIDIMETRY||Y||CAREGIVER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|1|Visit_1|10|5|FOLLOW-UP|2020-10-07|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-21|P1Y2M10DT2H30M|BEFORE|2020-10-15|BEFORE|2020-12-18
e|RS|47fad45a-9a4c-47ee-a863-089d979523b5|3|MRDRESP|Minimal Residual Disease Response|BLAZER COLORECTAL CANCER 2008|||HI-N|1|mV|MICROBIAL CONCENTRATION|Y||Y|ADJUDICATION COMMITTEE|RATER|U|2|Visit_2|25|2|TREATMENT|2020-10-22|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-27|P1Y2M10DT2H30M|AFTER|2020-12-19|AFTER|2020-12-25
e|RS|47fad45a-9a4c-47ee-a863-089d979523b5|4|MJPTHIND|Major Pathological Response Indicator|IWC HALLEK CLL 2008|[?]|fraction of 1|MAJOR PATHOLOGIC RESPONSE|1|BLOCKS|ZIEHL NEELSEN ACID FAST STAIN||||ADJUDICATION COMMITTEE|RATER 1|N|2|Visit_2|25|3|TREATMENT|2020-10-22|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-27|P1Y2M10DT2H30M|COINCIDENT|2021-01-02|BEFORE|2021-01-03
e|RS|47fad45a-9a4c-47ee-a863-089d979523b5|5|ANATRESP|Anatomic Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|ft2|NON-PD|1|PACKET|MICROBIAL CONCENTRATION||||CAREGIVER|RATER|U|3|Visit_3|40|6|TREATMENT|2020-11-06|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-17|P1Y2M10DT2H30M|BEFORE|2020-10-18|COINCIDENT|2020-11-02
e|RS|47fad45a-9a4c-47ee-a863-089d979523b5|6|METSIND|Metastatic Indicator|DOHNER AML 2010|[?]|pmol/10^10 cells|UNEQUIVOCAL|1|mg/kg/week|REVERSE TRANSCRIPTASE PCR||Y||SIGNIFICANT OTHER|DERMATOLOGIST|U|3|Visit_3|40|7|SCREENING|2020-11-06|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-17|P1Y2M10DT2H30M|UNKNOWN|2020-10-18|BEFORE|2020-12-08
e|RS|47fad45a-9a4c-47ee-a863-089d979523b5|7|MNPTHIND|Minor Pathological Response Indicator|CHESON NON-HODGKINS LYMPHOMA 1999|||NOT ALL EVALUATED|1|PFU/animal|ICC|Y|Y|Y|CLINICAL RESEARCH ASSOCIATE|ENDOCRINOLOGIST|U|4|Visit_4|65|7|FOLLOW-UP|2020-12-01|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-30|P1Y2M10DT2H30M|BEFORE|2020-12-18|COINCIDENT|2020-12-24
e|RS|47fad45a-9a4c-47ee-a863-089d979523b5|8|HEMARESP|Hematologic Response|IRANO 2015|[?]|KALLIKREIN INHIBITOR UNIT|PD FROM PR|1|nmol BCE/nmol|ELLA||||SIGNIFICANT OTHER|DEVELOPMENTAL PSYCHOLOGIST|NA|4|Visit_4|65|5|TREATMENT|2020-12-01|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-30|P1Y2M10DT2H30M|BEFORE|2020-11-02|COINCIDENT|2020-12-03
e|RS|47fad45a-9a4c-47ee-a863-089d979523b5|9|RDIORESP|Radiologic Response|MURPHY PROSTATE CANCER 1980|[?]|IU|MRD RELAPSE|1|PLUG|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION||||INVESTIGATOR|NEUROLOGIST|NA|5|Visit_5|90|1|TREATMENT|2020-12-26|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-17|P1Y2M10DT2H30M|BEFORE|2020-12-07|BEFORE|2020-12-08
e|RS|47fad45a-9a4c-47ee-a863-089d979523b5|10|OVRLRESP|Overall Response|KEAM BREAST CANCER 2013|[?]|EID 50/dose|PSA PROGRESSION|1|nmol/kg/day|IRON HEMATOXYLIN STAIN||||CLINICAL RESEARCH COORDINATOR|ONCOLOGIST|NA|5|Visit_5|90|6|WASHOUT|2020-12-26|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-17|P1Y2M10DT2H30M|UNKNOWN|2020-12-14|AFTER|2020-12-28
e|RS|317b8b6d-9638-44a3-816f-7f3fca1e01a3|1|MOLRESP|Molecular Response|AJCC V7|[?]|damol/L|sCR|1|mAmp|ROMANOWSKY STAIN||Y||GUARDIAN|RATER 2|NA|1|Visit_1|10|4|TREATMENT|2020-05-23|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-06|P1Y2M10DT2H30M|AFTER|2020-08-15|COINCIDENT|2020-08-17
e|RS|317b8b6d-9638-44a3-816f-7f3fca1e01a3|2|MRDRESP|Minimal Residual Disease Response|GUILHOT CML 2007|[?]|mmAL|CYTOGENETIC MINOR RESPONSE|1|Ci/kg|COULOMETRIC TITRATION||||DOMESTIC PARTNER|FORENSIC PATHOLOGIST|NA|1|Visit_1|10|3|FOLLOW-UP|2020-05-23|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-06|P1Y2M10DT2H30M|BEFORE|2020-07-20|BEFORE|2020-07-26
e|RS|317b8b6d-9638-44a3-816f-7f3fca1e01a3|3|OVRLRESP|Overall Response|IWC HALLEK CLL 2008|[?]|mmol/g|NR|1|kg/mol|WHOLE GENOME SEQUENCING||Y||VENDOR|MICROSCOPIST|Y|2|Visit_2|25|5|FOLLOW-UP|2020-06-07|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-07|P1Y2M10DT2H30M|UNKNOWN|2020-08-14|AFTER|2020-08-19
e|RS|317b8b6d-9638-44a3-816f-7f3fca1e01a3|4|METBRESP|Metabolic Response|IWG CHESON MDS 2000|[?]|mg/m2/h|PSEUDORESPONSE|1|mEq/day|SPECT/CT SCAN||||INTERVIEWER|MICROSCOPIST 1|U|2|Visit_2|25|7|FOLLOW-UP|2020-06-07|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-07|P1Y2M10DT2H30M|UNKNOWN|2020-07-24|ONGOING|2020-08-14
e|RS|317b8b6d-9638-44a3-816f-7f3fca1e01a3|5|PATHRESP|Pathologic Response|MASS|[?]|mL/g/day|IMPROVED|1|nmol/L|ELLA||Y||FRIEND|READER|NA|3|Visit_3|40|5|SCREENING|2020-06-22|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-03|P1Y2M10DT2H30M|BEFORE|2020-05-27|COINCIDENT|2020-08-19
e|RS|317b8b6d-9638-44a3-816f-7f3fca1e01a3|6|PATHRESP|Pathologic Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|/mm2|PARTIAL MORPHOLOGIC RESPONSE|1|log10 IU/mL|ELISA||||PROXY|OTOLARYNGOLOGIST|NA|3|Visit_3|40|2|WASHOUT|2020-06-22|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-03|P1Y2M10DT2H30M|UNKNOWN|2020-05-30|ONGOING|2020-08-16
e|RS|317b8b6d-9638-44a3-816f-7f3fca1e01a3|7|MOLRESP|Molecular Response|PRINCE TCELL LYMPHOMA 2010|||INDETERMINATE RESPONSE|1|LOZENGE|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|||Y|SPOUSE|RADIOLOGIST 2|NA|4|Visit_4|65|1|WASHOUT|2020-07-17|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-28|P1Y2M10DT2H30M|COINCIDENT|2020-06-21|AFTER|2020-07-23
e|RS|317b8b6d-9638-44a3-816f-7f3fca1e01a3|8|CPRFSTAT|Clinical Performance Status|BRUGGEMANN MRD 2010|[?]|kg/cm2|PSEUDORESPONSE|1|P|MALDI|Y|||HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|N|4|Visit_4|65|1|TREATMENT|2020-07-17|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-28|P1Y2M10DT2H30M|UNKNOWN|2020-06-29|BEFORE|2020-07-02
e|RS|317b8b6d-9638-44a3-816f-7f3fca1e01a3|9|METSIND|Metastatic Indicator|WOLCHOK SOLID TUMORS 2009|[?]|BAR|sCR|1|ug/min|ENZYMATIC ULTRACENTRIFUGATION||||CLINICAL RESEARCH COORDINATOR|RATER|Y|5|Visit_5|90|5|TREATMENT|2020-08-11|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-16|P1Y2M10DT2H30M|BEFORE|2020-06-05|AFTER|2020-08-02
e|RS|317b8b6d-9638-44a3-816f-7f3fca1e01a3|10|NEWLWIND|New Lesion Worsening Indicator|PALUMBO MULTIPLE MYELOMA 2009|[?]|mV*min|iCPD|1|10^3/hpf|BRDU CELLULAR PROLIFERATION ASSAY||Y||SPOUSE|OTOLARYNGOLOGIST|N|5|Visit_5|90|4|TREATMENT|2020-08-11|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-16|P1Y2M10DT2H30M|COINCIDENT|2020-07-04|COINCIDENT|2020-08-18
e|RS|3bad8e12-9a92-4227-a3f6-b3eac8fa57ec|1|NEWLPROG|New Lesion Progression|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|anti-Xa IU|CYTOGENETIC PR|1|s^-1(%O2)^-1|U-HPLC/MS/MS||||INDEPENDENT ASSESSOR|READER 3|U|1|Visit_1|10|2|WASHOUT|2020-07-10|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-18|P1Y2M10DT2H30M|UNKNOWN|2020-10-07|COINCIDENT|2020-10-08
e|RS|3bad8e12-9a92-4227-a3f6-b3eac8fa57ec|2|CLINRESP|Clinical Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|ug/g/day|PR|1|ug/L FEU|IMPEDANCE CONDUCTIVITY||||DOMESTIC PARTNER|ADJUDICATOR 2|Y|1|Visit_1|10|7|TREATMENT|2020-07-10|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-18|P1Y2M10DT2H30M|AFTER|2020-08-13|ONGOING|2020-10-06
e|RS|3bad8e12-9a92-4227-a3f6-b3eac8fa57ec|3|NTNERESP|Non-Target Non-Enhancing Response|CHESON CLL 2006|||SD|1|ft3|ENZYMATIC SPECTROPHOTOMETRY|||Y|FRIEND|ENDOCRINOLOGIST|N|2|Visit_2|25|3|SCREENING|2020-07-25|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-09|P1Y2M10DT2H30M|UNKNOWN|2020-09-10|ONGOING|2020-09-27
e|RS|3bad8e12-9a92-4227-a3f6-b3eac8fa57ec|4|SPLNRESP|Spleen Response|CHESON LYMPHOMA 2008|[?]|MESF|SMD|1|mg/h|FARNSWORTH-MUNSELL 100 HUE TEST||||STUDY SUBJECT|READER|N|2|Visit_2|25|2|TREATMENT|2020-07-25|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-09|P1Y2M10DT2H30M|AFTER|2020-08-05|BEFORE|2020-08-25
e|RS|3bad8e12-9a92-4227-a3f6-b3eac8fa57ec|5|CPRFSTAT|Clinical Performance Status|CHESON CLL 2012|||CYTOGENETIC NO RESPONSE|1|anti-Xa IU|LIGHT SCATTERING SPECTROSCOPY|||Y|ADJUDICATION COMMITTEE|OTOLARYNGOLOGIST|N|3|Visit_3|40|3|SCREENING|2020-08-09|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-12|P1Y2M10DT2H30M|COINCIDENT|2020-09-26|COINCIDENT|2020-10-04
e|RS|3bad8e12-9a92-4227-a3f6-b3eac8fa57ec|6|CYTORESP|Cytogenetic Response|GUPPY OVARIAN CANCER 2002|[?]|WAFER|MORPHOLOGIC CRi|1|DIP|KARYOTYPING||Y||SPOUSE|OPTOMETRIST|N|3|Visit_3|40|4|TREATMENT|2020-08-09|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-12|P1Y2M10DT2H30M|BEFORE|2020-08-28|ONGOING|2020-09-14
e|RS|3bad8e12-9a92-4227-a3f6-b3eac8fa57ec|7|BESTRESP|Best Overall Response|DOHNER AML 2010|[?]|% INHIBITION|cCR|1|ng|MICROBIAL CONCENTRATION||Y||STUDY SUBJECT|ADJUDICATOR 2|U|4|Visit_4|65|2|SCREENING|2020-09-03|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-04|P1Y2M10DT2H30M|COINCIDENT|2020-08-21|COINCIDENT|2020-08-30
e|RS|3bad8e12-9a92-4227-a3f6-b3eac8fa57ec|8|STRUSTAT|Steroid Use Status|PRINCE TCELL LYMPHOMA 2010|[?]|ugEq/L|PD/RELAPSE AFTER HI|1|mg/kg/h|DIGITAL PCR ARRAY||||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|N|4|Visit_4|65|2|TREATMENT|2020-09-03|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-04|P1Y2M10DT2H30M|AFTER|2020-08-13|BEFORE|2020-09-12
e|RS|3bad8e12-9a92-4227-a3f6-b3eac8fa57ec|9|NEWLPROG|New Lesion Progression|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|||RELAPSED DISEASE|1|ug/min|MICRODENSITOMETRY|||Y|FAMILY MEMBER|READER 1|U|5|Visit_5|90|1|TREATMENT|2020-09-28|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-03|P1Y2M10DT2H30M|COINCIDENT|2020-09-20|COINCIDENT|2020-09-26
e|RS|3bad8e12-9a92-4227-a3f6-b3eac8fa57ec|10|MRDRESP|Minimal Residual Disease Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|PIXELS/cm|SMD|1|umol/L/sec|ELECTROPHORESIS|Y|||GUARDIAN|ADJUDICATOR 2|U|5|Visit_5|90|2|SCREENING|2020-09-28|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-03|P1Y2M10DT2H30M|UNKNOWN|2020-07-13|BEFORE|2020-08-13
e|RS|e7cee930-54f6-482e-b782-01aed0f0db06|1|NEWLPROG|New Lesion Progression|EASL BRUIX LIVER CANCER 2001|[?]|Bq/g|UNEQUIVOCAL|1|kHz|ENDOSCOPY||||NON-HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|Y|1|Visit_1|10|2|FOLLOW-UP|2021-01-07|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-01|P1Y2M10DT2H30M|UNKNOWN|2021-02-22|AFTER|2021-03-22
e|RS|e7cee930-54f6-482e-b782-01aed0f0db06|2|METBRESP|Metabolic Response|WOLCHOK SOLID TUMORS 2009|[?]|Ci/mL|MOLECULAR MAJOR RESPONSE|1|/7.5 mL|MRI||||SIGNIFICANT OTHER|MICROSCOPIST 1|N|1|Visit_1|10|6|SCREENING|2021-01-07|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-01|P1Y2M10DT2H30M|AFTER|2021-02-26|COINCIDENT|2021-03-04
e|RS|e7cee930-54f6-482e-b782-01aed0f0db06|3|ANATRESP|Anatomic Response|RAJKUMAR MYELOMA 2011|[?]|MHz|MOLECULAR MAJOR RESPONSE|1|PRESSOR UNITS|LIGHT MICROSCOPY||Y||NON-HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|NA|2|Visit_2|25|6|TREATMENT|2021-01-22|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-02|P1Y2M10DT2H30M|BEFORE|2021-01-06|ONGOING|2021-04-01
e|RS|e7cee930-54f6-482e-b782-01aed0f0db06|4|MRPHRESP|Morphologic Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|PACK|OPTIMAL MORPHOLOGIC RESPONSE|1|mmol/min/kPa|MRI|Y|||FRIEND|MICROSCOPIST 3|Y|2|Visit_2|25|5|TREATMENT|2021-01-22|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-02|P1Y2M10DT2H30M|COINCIDENT|2021-01-25|ONGOING|2021-03-04
e|RS|e7cee930-54f6-482e-b782-01aed0f0db06|5|BMIVLIND|Bone Marrow Involvement Indicator|KEAM BREAST CANCER 2013|[?]|CARTRIDGE|CA125 75% RESPONSE|1|mg2/dL2|LISSAMINE GREEN STAIN||Y||DOMESTIC PARTNER|DEVELOPMENTAL PSYCHOLOGIST|N|3|Visit_3|40|5|WASHOUT|2021-02-06|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-29|P1Y2M10DT2H30M|AFTER|2021-03-06|ONGOING|2021-03-24
e|RS|e7cee930-54f6-482e-b782-01aed0f0db06|6|STRUSTAT|Steroid Use Status|KUMAR IMWG 2016|[?]|umol/L|NON-QUANTIFIABLE MRD POSITIVITY|1|EIA unit|POLYMERASE CHAIN REACTION||||GUARDIAN|READER 3|Y|3|Visit_3|40|4|TREATMENT|2021-02-06|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-29|P1Y2M10DT2H30M|UNKNOWN|2021-01-19|COINCIDENT|2021-03-24
e|RS|e7cee930-54f6-482e-b782-01aed0f0db06|7|METBRESP|Metabolic Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|BU|IMMUNOPHENOTYPIC CR|1|cycle/min|LIQUID SCINTILLATION COUNTING||Y||INVESTIGATOR|RATER 1|Y|4|Visit_4|65|6|TREATMENT|2021-03-03|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-07|P1Y2M10DT2H30M|UNKNOWN|2021-02-27|COINCIDENT|2021-03-02
e|RS|e7cee930-54f6-482e-b782-01aed0f0db06|8|NTNERESP|Non-Target Non-Enhancing Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|ug/m2/h|HI-E|1|Frames/s|ELECTROGASTROGRAPHY|Y|||INDEPENDENT ASSESSOR|ADJUDICATOR 2|NA|4|Visit_4|65|4|SCREENING|2021-03-03|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-07|P1Y2M10DT2H30M|COINCIDENT|2021-01-07|AFTER|2021-02-09
e|RS|e7cee930-54f6-482e-b782-01aed0f0db06|9|CPRFSTAT|Clinical Performance Status|KUMAR IMWG 2016|[?]|kBq/uL|pCR|1|Ci/ug|TRICHROME STAIN||||SIBLING|MICROSCOPIST 3|Y|5|Visit_5|90|3|TREATMENT|2021-03-28|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-22|P1Y2M10DT2H30M|UNKNOWN|2021-01-27|BEFORE|2021-02-11
e|RS|e7cee930-54f6-482e-b782-01aed0f0db06|10|NTERESP|Non-Target Enhancing Response|LUGANO CLASSIFICATION|||CR|1|dpm/mg|GC/MS/MS|||Y|GUARDIAN|PHYSIOTHERAPIST|U|5|Visit_5|90|2|TREATMENT|2021-03-28|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-22|P1Y2M10DT2H30M|AFTER|2021-04-02|BEFORE|2021-04-04
e|RS|4f0e0353-bd4b-45ee-9e21-40489b5f8d2f|1|RDIORESP|Radiologic Response|IWC HALLEK CLL 2008|[?]|scm|NON-QUANTIFIABLE MRD POSITIVITY|1|SCOOPFUL|JAEGER EYE CHART|Y|Y||CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST|N|1|Visit_1|10|7|TREATMENT|2021-01-21|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-17|P1Y2M10DT2H30M|AFTER|2021-04-20|COINCIDENT|2021-04-21
e|RS|4f0e0353-bd4b-45ee-9e21-40489b5f8d2f|2|SPLNRESP|Spleen Response|CHOLLET BREAST CANCER 2002|[?]|kg/mol|cCR|1|mmAL|SLOAN LETTER EYE CHART 1.25%||||DOMESTIC PARTNER|OPHTHALMOLOGIST|N|1|Visit_1|10|1|WASHOUT|2021-01-21|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-17|P1Y2M10DT2H30M|COINCIDENT|2021-03-29|BEFORE|2021-04-09
e|RS|4f0e0353-bd4b-45ee-9e21-40489b5f8d2f|3|HEMARESP|Hematologic Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|eq|CA125 50% RESPONSE|1|umol/L/h|PET/CT SCAN||||INVESTIGATOR|ENDOCRINOLOGIST|Y|2|Visit_2|25|2|WASHOUT|2021-02-05|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-05|P1Y2M10DT2H30M|AFTER|2021-04-05|ONGOING|2021-04-11
e|RS|4f0e0353-bd4b-45ee-9e21-40489b5f8d2f|4|BMIVLIND|Bone Marrow Involvement Indicator|WOLCHOK SOLID TUMORS 2009|[?]|Bq/uL|DECREASED|1|/h|DNA MICROARRAY|Y|||NON-HEALTH CARE PROFESSIONAL|RATER|NA|2|Visit_2|25|7|FOLLOW-UP|2021-02-05|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-05|P1Y2M10DT2H30M|COINCIDENT|2021-03-10|AFTER|2021-04-07
e|RS|4f0e0353-bd4b-45ee-9e21-40489b5f8d2f|5|RDIORESP|Radiologic Response|CHOI GIST 2008|[?]|genEq/mL|MINOR PATHOLOGIC RESPONSE|1|dyn|AURAMINE STAIN||Y||GUARDIAN|READER 2|N|3|Visit_3|40|2|FOLLOW-UP|2021-02-20|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-10|P1Y2M10DT2H30M|BEFORE|2021-03-22|AFTER|2021-04-02
e|RS|4f0e0353-bd4b-45ee-9e21-40489b5f8d2f|6|NTRGRESP|Non-target Response|NCCN ALL MRD 2014|[?]|FIU|iCR|1|mg|MULTIPLE BREATH WASHOUT||||HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|N|3|Visit_3|40|3|WASHOUT|2021-02-20|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-10|P1Y2M10DT2H30M|BEFORE|2021-02-10|AFTER|2021-03-23
e|RS|4f0e0353-bd4b-45ee-9e21-40489b5f8d2f|7|METBRESP|Metabolic Response|EASL BRUIX LIVER CANCER 2001|[?]|pg/dL|NR|1|mOsm/L|GEL ELECTROPHORESIS||Y||FAMILY MEMBER|OTOLARYNGOLOGIST|U|4|Visit_4|65|5|TREATMENT|2021-03-17|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-20|P1Y2M10DT2H30M|AFTER|2021-03-13|BEFORE|2021-03-22
e|RS|4f0e0353-bd4b-45ee-9e21-40489b5f8d2f|8|TMRESP|Tumor Marker Response|EASL BRUIX LIVER CANCER 2001|||STABLE|1|mIU/L|CELL BASED BIOASSAY|||Y|INDEPENDENT ASSESSOR|ADJUDICATOR 3|Y|4|Visit_4|65|5|WASHOUT|2021-03-17|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-20|P1Y2M10DT2H30M|UNKNOWN|2021-03-30|AFTER|2021-04-06
e|RS|4f0e0353-bd4b-45ee-9e21-40489b5f8d2f|9|NTERESP|Non-Target Enhancing Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|||OPTIMAL MORPHOLOGIC RESPONSE|1|mV2/Hz|CINEANGIOGRAPHY|Y||Y|SPOUSE|RADIOLOGIST 1|N|5|Visit_5|90|7|FOLLOW-UP|2021-04-11|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-29|P1Y2M10DT2H30M|BEFORE|2021-03-08|AFTER|2021-03-30
e|RS|4f0e0353-bd4b-45ee-9e21-40489b5f8d2f|10|STRUSTAT|Steroid Use Status|GUPPY OVARIAN CANCER 2002|[?]|10^6 IU|PD/RELAPSE AFTER HI|1|pL|SPECT/CT SCAN||||FAMILY MEMBER|DERMATOLOGIST|NA|5|Visit_5|90|2|TREATMENT|2021-04-11|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-29|P1Y2M10DT2H30M|BEFORE|2021-01-15|COINCIDENT|2021-02-09
e|RS|f754ae7d-0776-41c0-988c-8cf2879d85da|1|MRDIND|Minimal Residual Disease Indicator|IWG CHESON MDS 2006|[?]|mL/animal|UNEQUIVOCAL|1|cGy|GC/MS-CI||||NON-HEALTH CARE PROFESSIONAL|UROLOGIST|U|1|Visit_1|10|5|TREATMENT|2020-09-17|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-29|P1Y2M10DT2H30M|UNKNOWN|2020-11-26|AFTER|2020-12-02
e|RS|f754ae7d-0776-41c0-988c-8cf2879d85da|2|SYMPTDTR|Symptomatic Deterioration|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|mg/g/h|sCR|1|g/cm2|PLAQUE REDUCTION NEUTRALIZATION ASSAY|Y|Y||VENDOR|READER|NA|1|Visit_1|10|7|WASHOUT|2020-09-17|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-29|P1Y2M10DT2H30M|COINCIDENT|2020-12-13|COINCIDENT|2020-12-14
e|RS|f754ae7d-0776-41c0-988c-8cf2879d85da|3|MNPTHIND|Minor Pathological Response Indicator|RECICL|[?]|cd/m2|PD FROM PR|1|dL|MIGET||||NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|U|2|Visit_2|25|4|TREATMENT|2020-10-02|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-19|P1Y2M10DT2H30M|UNKNOWN|2020-12-01|BEFORE|2020-12-13
e|RS|f754ae7d-0776-41c0-988c-8cf2879d85da|4|CPRFSTAT|Clinical Performance Status|PETIT BREAST CANCER 2001|[?]|L/day|CYTOGENETIC PR|1|STEPS|RYAN BLUE STAIN||||VENDOR|NEUROLOGIST 2|N|2|Visit_2|25|2|TREATMENT|2020-10-02|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-19|P1Y2M10DT2H30M|COINCIDENT|2020-12-14|ONGOING|2020-12-15
e|RS|f754ae7d-0776-41c0-988c-8cf2879d85da|5|HEMARESP|Hematologic Response|KEAM BREAST CANCER 2013|[?]|MASK|MORPHOLOGIC LEUKEMIA-FREE STATE|1|MASK|MRI||Y||SPOUSE|CLINICAL PATHOLOGIST|U|3|Visit_3|40|7|WASHOUT|2020-10-17|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-17|P1Y2M10DT2H30M|UNKNOWN|2020-09-26|ONGOING|2020-11-29
e|RS|f754ae7d-0776-41c0-988c-8cf2879d85da|6|MOLRESP|Molecular Response|HAMAOKA BREAST CANCER 2010|[?]|RFU|NE|1|mL/m2/h|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY||||STUDY SUBJECT|ONCOLOGIST 1|Y|3|Visit_3|40|4|WASHOUT|2020-10-17|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-17|P1Y2M10DT2H30M|UNKNOWN|2020-11-16|AFTER|2020-12-12
e|RS|f754ae7d-0776-41c0-988c-8cf2879d85da|7|NTERESP|Non-Target Enhancing Response|AJCC V7|[?]|cs|MORPHOLOGIC LEUKEMIA-FREE STATE|1|Gy|TOTAL BODY IRRADIATION|Y|||DOMESTIC PARTNER|ONCOLOGIST 1|N|4|Visit_4|65|3|TREATMENT|2020-11-11|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-02|P1Y2M10DT2H30M|UNKNOWN|2020-09-18|COINCIDENT|2020-11-01
e|RS|f754ae7d-0776-41c0-988c-8cf2879d85da|8|TMRESP|Tumor Marker Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|g/m2|NON-PD|1|LENS|WHOLE TRANSCRIPTOME SEQUENCING||||INVESTIGATOR|RATER 2|U|4|Visit_4|65|5|WASHOUT|2020-11-11|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-02|P1Y2M10DT2H30M|UNKNOWN|2020-12-05|AFTER|2020-12-12
e|RS|f754ae7d-0776-41c0-988c-8cf2879d85da|9|PATHRESP|Pathologic Response|PCWG SCHER PROSTATE CANCER 2016|[?]|RATIO|PSEUDORESPONSE|1|dpm/0.5 mL|ZIEHL NEELSEN ACID FAST STAIN||||SIGNIFICANT OTHER|PATHOLOGIST 2|U|5|Visit_5|90|1|FOLLOW-UP|2020-12-06|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-06|P1Y2M10DT2H30M|COINCIDENT|2020-09-19|COINCIDENT|2020-11-08
e|RS|f754ae7d-0776-41c0-988c-8cf2879d85da|10|LIVRRESP|Liver Response|MURPHY PROSTATE CANCER 1980|||iCR|1|mL/h|HEMAGGLUTINATION ASSAY|Y||Y|PARENT|RADIOLOGIST|U|5|Visit_5|90|5|TREATMENT|2020-12-06|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-06|P1Y2M10DT2H30M|UNKNOWN|2020-09-16|AFTER|2020-10-08
e|RS|8a8d8c31-ae36-4a64-90da-ba5eb473e420|1|MNPTHIND|Minor Pathological Response Indicator|RECICL|[?]|mU/g|PR WITH LYMPHOCYTOSIS|1|BU|SPECT/CT SCAN||Y||ADJUDICATION COMMITTEE|READER 3|N|1|Visit_1|10|3|TREATMENT|2020-06-25|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-20|P1Y2M10DT2H30M|COINCIDENT|2020-07-15|BEFORE|2020-09-14
e|RS|8a8d8c31-ae36-4a64-90da-ba5eb473e420|2|PATHRESP|Pathologic Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|nCi|SD-CT|1|/HPF|SNP ARRAY||||INVESTIGATOR|DEVELOPMENTAL PSYCHOLOGIST|Y|1|Visit_1|10|1|TREATMENT|2020-06-25|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-20|P1Y2M10DT2H30M|COINCIDENT|2020-09-18|COINCIDENT|2020-09-19
e|RS|8a8d8c31-ae36-4a64-90da-ba5eb473e420|3|NEWLPROG|New Lesion Progression|MRECIST BYRNE MESOTHELIOMA 2004|[?]|tsp|CRi|1|10^4/L|IMMUNOFLUORESCENT STAIN||||INTERVIEWER|PATHOLOGIST 1|U|2|Visit_2|25|4|WASHOUT|2020-07-10|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-04|P1Y2M10DT2H30M|COINCIDENT|2020-06-28|ONGOING|2020-08-30
e|RS|8a8d8c31-ae36-4a64-90da-ba5eb473e420|4|RDIORESP|Radiologic Response|AJCC V8|[?]|cmH2O/mL|MR|1|Anson U|TRANSMISSION ELECTRON MICROSCOPY||||CAREGIVER|NEUROLOGIST|NA|2|Visit_2|25|2|FOLLOW-UP|2020-07-10|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-04|P1Y2M10DT2H30M|COINCIDENT|2020-08-03|ONGOING|2020-09-08
e|RS|8a8d8c31-ae36-4a64-90da-ba5eb473e420|5|NTERESP|Non-Target Enhancing Response|NCIWG CHESON CLL 1996|[?]|log10 PFU|NE|1|ug/kg/day|TONOMETRY||||SIBLING|CARDIOLOGIST|Y|3|Visit_3|40|2|WASHOUT|2020-07-25|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-17|P1Y2M10DT2H30M|AFTER|2020-07-18|BEFORE|2020-08-31
e|RS|8a8d8c31-ae36-4a64-90da-ba5eb473e420|6|MJPTHIND|Major Pathological Response Indicator|HARTMAN PANCREATIC CANCER 2012|[?]|10^6 IU/mL|EQUIVOCAL|1|U|DISK DIFFUSION||||INTERVIEWER|MICROSCOPIST 1|NA|3|Visit_3|40|6|TREATMENT|2020-07-25|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-17|P1Y2M10DT2H30M|COINCIDENT|2020-09-12|COINCIDENT|2020-09-17
e|RS|8a8d8c31-ae36-4a64-90da-ba5eb473e420|7|OVRLRESP|Overall Response|SCHWARZ CERVICAL CANCER 2009|[?]|USP U|CR|1|GPL U/mL|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY||Y||NON-HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|Y|4|Visit_4|65|1|TREATMENT|2020-08-19|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-05|P1Y2M10DT2H30M|COINCIDENT|2020-06-22|BEFORE|2020-08-17
e|RS|8a8d8c31-ae36-4a64-90da-ba5eb473e420|8|CYTORESP|Cytogenetic Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|mL/kg|OPTIMAL MORPHOLOGIC RESPONSE|1|10^9 organisms|POLYGRAPHY||||GUARDIAN|OTOLARYNGOLOGIST|NA|4|Visit_4|65|3|TREATMENT|2020-08-19|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-05|P1Y2M10DT2H30M|BEFORE|2020-07-20|AFTER|2020-08-26
e|RS|8a8d8c31-ae36-4a64-90da-ba5eb473e420|9|MJPTHIND|Major Pathological Response Indicator|BLAZER COLORECTAL CANCER 2008|||COMPLETE MRD RESPONSE|1|/10^5|PET/SPECT SCAN|Y|Y|Y|SPOUSE|ADJUDICATOR 2|NA|5|Visit_5|90|6|TREATMENT|2020-09-13|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-13|P1Y2M10DT2H30M|BEFORE|2020-08-20|ONGOING|2020-09-10
e|RS|8a8d8c31-ae36-4a64-90da-ba5eb473e420|10|NTRGRESP|Non-target Response|CHESON CLL 2006|[?]|rpm|MINOR PATHOLOGIC RESPONSE|1|hPa|GC/MS/MS|Y|||GUARDIAN|RATER 2|Y|5|Visit_5|90|4|TREATMENT|2020-09-13|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-13|P1Y2M10DT2H30M|COINCIDENT|2020-07-03|COINCIDENT|2020-07-25
e|RS|482e40c9-2908-4269-b93c-61c311e9fde3|1|CPRFSTAT|Clinical Performance Status|DURIE MULTIPLE MYELOMA 2006|||HI-E|1|Ci/uL|PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY|||Y|PARENT|MICROSCOPIST 1|NA|1|Visit_1|10|3|FOLLOW-UP|2020-07-16|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-06|P1Y2M10DT2H30M|AFTER|2020-10-10|BEFORE|2020-10-12
e|RS|482e40c9-2908-4269-b93c-61c311e9fde3|2|NEWLWIND|New Lesion Worsening Indicator|RANO ELLINGSON 2017|[?]|/40 HPFs|PD|1|mL/day|AUSCULTATION||||SIBLING|PATHOLOGIST|Y|1|Visit_1|10|4|TREATMENT|2020-07-16|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-06|P1Y2M10DT2H30M|UNKNOWN|2020-07-17|ONGOING|2020-10-07
e|RS|482e40c9-2908-4269-b93c-61c311e9fde3|3|HEMARESP|Hematologic Response|AJCC V7|[?]|mL/beat|CHR|1|sec|OBSERVATION||Y||PROXY|RATER 1|NA|2|Visit_2|25|3|TREATMENT|2020-07-31|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-04|P1Y2M10DT2H30M|UNKNOWN|2020-08-28|ONGOING|2020-08-31
e|RS|482e40c9-2908-4269-b93c-61c311e9fde3|4|MRDRESP|Minimal Residual Disease Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|||NE|1|TUBE|DUCTOGRAPHY|||Y|CHILD|NEUROLOGIST|Y|2|Visit_2|25|5|FOLLOW-UP|2020-07-31|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-04|P1Y2M10DT2H30M|UNKNOWN|2020-08-12|BEFORE|2020-08-30
e|RS|482e40c9-2908-4269-b93c-61c311e9fde3|5|RDIORESP|Radiologic Response|SCHER PROSTATE CANCER 2011|[?]|APL U|nPR|1|GBq|FLUORESCENCE ANGIOGRAPHY||||CHILD|PEDIATRIC NEUROLOGIST|NA|3|Visit_3|40|7|TREATMENT|2020-08-15|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-25|P1Y2M10DT2H30M|BEFORE|2020-07-22|AFTER|2020-08-09
e|RS|482e40c9-2908-4269-b93c-61c311e9fde3|6|MOLRESP|Molecular Response|CHOI GIST 2008|[?]|cm/s|CR|1|/2000 RBC|ALCIAN BLUE STAIN||||PROXY|PATHOLOGIST 2|Y|3|Visit_3|40|7|FOLLOW-UP|2020-08-15|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-25|P1Y2M10DT2H30M|UNKNOWN|2020-08-03|AFTER|2020-09-28
e|RS|482e40c9-2908-4269-b93c-61c311e9fde3|7|MNPTHIND|Minor Pathological Response Indicator|CHESON CLL 2012|[?]|Shock Wave|IMMUNOPHENOTYPIC CR|1|Henry|DARK FIELD MICROSCOPY||Y||SIBLING|RADIOLOGIST 1|Y|4|Visit_4|65|7|SCREENING|2020-09-09|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-13|P1Y2M10DT2H30M|AFTER|2020-10-11|COINCIDENT|2020-10-13
e|RS|482e40c9-2908-4269-b93c-61c311e9fde3|8|LIVRRESP|Liver Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|/sec|DECREASED|1|%(w/v)|EEG||||STUDY SUBJECT|RATER 2|NA|4|Visit_4|65|3|SCREENING|2020-09-09|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-13|P1Y2M10DT2H30M|BEFORE|2020-08-13|AFTER|2020-08-14
e|RS|482e40c9-2908-4269-b93c-61c311e9fde3|9|DRCRIND|Disease Recurrence Indicator|NCIWG CHESON CLL 1996|[?]|mm3/mm2/year|NON-QUANTIFIABLE MRD POSITIVITY|1|nmol/L/min|NEXT GENERATION TARGETED SEQUENCING||||CLINICAL STUDY SPONSOR|ADJUDICATOR|Y|5|Visit_5|90|3|TREATMENT|2020-10-04|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-15|P1Y2M10DT2H30M|BEFORE|2020-09-27|AFTER|2020-10-05
e|RS|482e40c9-2908-4269-b93c-61c311e9fde3|10|MJPTHIND|Major Pathological Response Indicator|MRANO VAN DEN BENT GLIOMA 2011|[?]|mmol/min/kPa|SMD|1|Torr|CONTRAST ENHANCED MRI|Y|||ADJUDICATION COMMITTEE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5|Visit_5|90|1|TREATMENT|2020-10-04|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-15|P1Y2M10DT2H30M|AFTER|2020-07-16|COINCIDENT|2020-08-12
e|RS|f7cfb281-0556-4316-9373-65edf63c4b23|1|LIVRRESP|Liver Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|pt_br|COMPLETE MRD RESPONSE|1|Log10 ELISA unit|MALDI||Y||PROXY|PEDIATRIC NEUROLOGIST|N|1|Visit_1|10|2|TREATMENT|2020-06-29|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-17|P1Y2M10DT2H30M|UNKNOWN|2020-07-05|AFTER|2020-07-30
e|RS|f7cfb281-0556-4316-9373-65edf63c4b23|2|NEWLPROG|New Lesion Progression|SCHWARZ CERVICAL CANCER 2009|[?]|mL/m2/day|CA125 75% RESPONSE|1|pg/dL|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY|Y|||INVESTIGATOR|NEUROLOGIST 1|NA|1|Visit_1|10|5|WASHOUT|2020-06-29|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-17|P1Y2M10DT2H30M|UNKNOWN|2020-06-25|AFTER|2020-08-12
e|RS|f7cfb281-0556-4316-9373-65edf63c4b23|3|NTERESP|Non-Target Enhancing Response|SACT|[?]|CFU/g|UNFAVORABLE RESPONSE|1|EID 50/mL|ACCELERATOR MASS SPECTROMETRY||||INTERVIEWER|RATER|Y|2|Visit_2|25|2|SCREENING|2020-07-14|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-02|P1Y2M10DT2H30M|BEFORE|2020-09-26|BEFORE|2020-09-27
e|RS|f7cfb281-0556-4316-9373-65edf63c4b23|4|PATHRESP|Pathologic Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|cup eq|EQUIVOCAL|1|10^6/g|DYNAMOMETRY||||INVESTIGATOR|PATHOLOGIST 1|Y|2|Visit_2|25|3|WASHOUT|2020-07-14|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-02|P1Y2M10DT2H30M|COINCIDENT|2020-07-17|BEFORE|2020-07-19
e|RS|f7cfb281-0556-4316-9373-65edf63c4b23|5|METBRESP|Metabolic Response|HAMAOKA BREAST CANCER 2010|[?]|mmol/day|mCR|1|cm/s|HEMAGGLUTINATION ASSAY||||ADJUDICATION COMMITTEE|CLINICAL PATHOLOGIST|N|3|Visit_3|40|2|SCREENING|2020-07-29|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-01|P1Y2M10DT2H30M|COINCIDENT|2020-08-20|AFTER|2020-09-19
e|RS|f7cfb281-0556-4316-9373-65edf63c4b23|6|MRDRESP|Minimal Residual Disease Response|HAMAOKA BREAST CANCER 2010|||MRD RELAPSE|1|nsec|SPECT SCAN|||Y|VENDOR|OPHTHALMOLOGIST|Y|3|Visit_3|40|2|TREATMENT|2020-07-29|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-01|P1Y2M10DT2H30M|COINCIDENT|2020-08-14|BEFORE|2020-09-12
e|RS|f7cfb281-0556-4316-9373-65edf63c4b23|7|NEWLPROG|New Lesion Progression|SACT|[?]|ft3|IMPROVED|1|APL U|CYSTOSCOPY||||GUARDIAN|OPTOMETRIST|Y|4|Visit_4|65|6|TREATMENT|2020-08-23|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-16|P1Y2M10DT2H30M|UNKNOWN|2020-06-29|ONGOING|2020-08-07
e|RS|f7cfb281-0556-4316-9373-65edf63c4b23|8|BONERESP|Bone Response|IWG CHESON AML 2003|[?]|nmol/L/min|CYTOGENETIC MINOR RESPONSE|1|mg/dL|IMMUNOCHEMILUMINOMETRIC ASSAY||||HEALTH CARE PROFESSIONAL|ONCOLOGIST|NA|4|Visit_4|65|5|TREATMENT|2020-08-23|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-16|P1Y2M10DT2H30M|AFTER|2020-09-17|BEFORE|2020-09-19
e|RS|f7cfb281-0556-4316-9373-65edf63c4b23|9|CYTORESP|Cytogenetic Response|SACT|||PD FROM PR|1|cs|WESTERGREN|||Y|CLINICAL STUDY SPONSOR|READER 3|N|5|Visit_5|90|6|SCREENING|2020-09-17|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-03|P1Y2M10DT2H30M|COINCIDENT|2020-07-27|AFTER|2020-09-26
e|RS|f7cfb281-0556-4316-9373-65edf63c4b23|10|CLINRESP|Clinical Response|DURIE MULTIPLE MYELOMA 2006|[?]|MnFI|MRD PERSISTENCE|1|g/animal|DYNAMOMETRY||||PARENT|FORENSIC PATHOLOGIST|Y|5|Visit_5|90|6|TREATMENT|2020-09-17|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-03|P1Y2M10DT2H30M|COINCIDENT|2020-08-04|ONGOING|2020-08-29
e|RS|e0b03cb9-aa73-48c8-b05b-4a506ecf077b|1|CYTORESP|Cytogenetic Response|RECICL|[?]|mg/mL/min|ABSENT MORPHOLOGIC RESPONSE|1|Joule|ACID FAST STAIN||||INTERVIEWER|PATHOLOGIST 2|U|1|Visit_1|10|3|TREATMENT|2021-01-10|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-27|P1Y2M10DT2H30M|COINCIDENT|2021-03-09|AFTER|2021-03-19
e|RS|e0b03cb9-aa73-48c8-b05b-4a506ecf077b|2|ANATRESP|Anatomic Response|IWC HALLEK CLL 2008|[?]|g/kg/day|STABLE|1|kHz|HEMOCYTOMETRY||Y||CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|1|Visit_1|10|1|WASHOUT|2021-01-10|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-27|P1Y2M10DT2H30M|BEFORE|2021-02-14|COINCIDENT|2021-04-04
e|RS|e0b03cb9-aa73-48c8-b05b-4a506ecf077b|3|METSIND|Metastatic Indicator|SHINDOH COLORECTAL CANCER 2013|||PD/RELAPSE AFTER HI|1|cs|PHYSICAL EXAMINATION|Y||Y|GUARDIAN|ONCOLOGIST 2|NA|2|Visit_2|25|7|TREATMENT|2021-01-25|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-23|P1Y2M10DT2H30M|UNKNOWN|2021-02-24|ONGOING|2021-03-17
e|RS|e0b03cb9-aa73-48c8-b05b-4a506ecf077b|4|MRDRESP|Minimal Residual Disease Response|UNSPECIFIED|[?]|/10^5|MINOR PATHOLOGIC RESPONSE|1|cd|MUGA||Y||PROXY|READER 2|NA|2|Visit_2|25|3|SCREENING|2021-01-25|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-23|P1Y2M10DT2H30M|BEFORE|2021-04-02|AFTER|2021-04-06
e|RS|e0b03cb9-aa73-48c8-b05b-4a506ecf077b|5|LIVRRESP|Liver Response|HAMAOKA BREAST CANCER 2010|[?]|Tesla|PR-CT|1|mL/mmHg/min/L|WRIGHT STAIN||Y||ADJUDICATION COMMITTEE|RADIOLOGIST 2|Y|3|Visit_3|40|3|WASHOUT|2021-02-09|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-08|P1Y2M10DT2H30M|AFTER|2021-01-18|ONGOING|2021-03-16
e|RS|e0b03cb9-aa73-48c8-b05b-4a506ecf077b|6|NTNERESP|Non-Target Non-Enhancing Response|PRINCE TCELL LYMPHOMA 2010|[?]|mkat|NON-PD|1|CAPLET|WHOLE EXOME SEQUENCING||Y||CAREGIVER|READER|Y|3|Visit_3|40|6|TREATMENT|2021-02-09|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-08|P1Y2M10DT2H30M|AFTER|2021-03-15|COINCIDENT|2021-03-24
e|RS|e0b03cb9-aa73-48c8-b05b-4a506ecf077b|7|MRPHRESP|Morphologic Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|L|mCR|1|uIU/L|CELL BASED BIOASSAY||Y||CAREGIVER|READER 2|U|4|Visit_4|65|6|TREATMENT|2021-03-06|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-27|P1Y2M10DT2H30M|AFTER|2021-03-26|AFTER|2021-04-04
e|RS|e0b03cb9-aa73-48c8-b05b-4a506ecf077b|8|SFTSRESP|Soft Tissue Response|SCHER PROSTATE CANCER 2011|[?]|10^3 copies/mL|RELAPSED DISEASE FROM CR|1|Bq/g|COLORIMETRY||||NON-HEALTH CARE PROFESSIONAL|READER|Y|4|Visit_4|65|6|SCREENING|2021-03-06|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-27|P1Y2M10DT2H30M|AFTER|2021-03-04|COINCIDENT|2021-03-14
e|RS|e0b03cb9-aa73-48c8-b05b-4a506ecf077b|9|NTRGRESP|Non-target Response|MACDONALD GLIOMA 1990|[?]|Gravitational Unit|MRD NEGATIVITY|1|PRESSOR UNITS|PERCUSSION|Y|||CLINICAL RESEARCH ASSOCIATE|CARDIOLOGIST|Y|5|Visit_5|90|1|TREATMENT|2021-03-31|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-05|P1Y2M10DT2H30M|UNKNOWN|2021-01-21|COINCIDENT|2021-03-09
e|RS|e0b03cb9-aa73-48c8-b05b-4a506ecf077b|10|SPLNRESP|Spleen Response|UNSPECIFIED|[?]|/day|PR|1|m/sec|CONTRAST ENHANCED X-RAY|Y|||HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|U|5|Visit_5|90|6|TREATMENT|2021-03-31|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-05|P1Y2M10DT2H30M|COINCIDENT|2021-01-15|AFTER|2021-01-28
e|RS|9ed8a578-a82a-423a-81ca-ee87f98d62f7|1|LIVRRESP|Liver Response|HARTMAN PANCREATIC CANCER 2012|[?]|BLOCKS|iPR|1|mU|COMPUTERIZED CORNEAL TOPOGRAPHY||||SIBLING|ADJUDICATOR 3|NA|1|Visit_1|10|4|FOLLOW-UP|2020-09-02|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-12|P1Y2M10DT2H30M|BEFORE|2020-09-10|AFTER|2020-09-21
e|RS|9ed8a578-a82a-423a-81ca-ee87f98d62f7|2|NTNERESP|Non-Target Non-Enhancing Response|LUGANO CLASSIFICATION|[?]|m/sec2|MR|1|%/s|CRYOSCOPY|Y|||FRIEND|READER 1|NA|1|Visit_1|10|3|TREATMENT|2020-09-02|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-12|P1Y2M10DT2H30M|COINCIDENT|2020-09-15|COINCIDENT|2020-11-03
e|RS|9ed8a578-a82a-423a-81ca-ee87f98d62f7|3|NTLWIND|Non-Target Lesion Worsening Indicator|PCWG BUBLEY PROSTATE CANCER 1999|[?]|mL/dose|RELAPSED DISEASE FROM CR OR PR|1|DNA copies/ug|THICK SMEAR||||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 1|U|2|Visit_2|25|7|FOLLOW-UP|2020-09-17|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-20|P1Y2M10DT2H30M|BEFORE|2020-11-21|ONGOING|2020-11-24
e|RS|9ed8a578-a82a-423a-81ca-ee87f98d62f7|4|NEWLWIND|New Lesion Worsening Indicator|WOLCHOK SOLID TUMORS 2009|||RELAPSED DISEASE FROM CR|1|L/min|RADIAL IMMUNODIFFUSION|Y||Y|VENDOR|OTOLARYNGOLOGIST|NA|2|Visit_2|25|4|TREATMENT|2020-09-17|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-20|P1Y2M10DT2H30M|BEFORE|2020-10-05|ONGOING|2020-11-27
e|RS|9ed8a578-a82a-423a-81ca-ee87f98d62f7|5|BMIVLIND|Bone Marrow Involvement Indicator|AJCC V8|||CMR|1|uCi/kg|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY|Y||Y|SPOUSE|MICROSCOPIST 3|Y|3|Visit_3|40|6|SCREENING|2020-10-02|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-12|P1Y2M10DT2H30M|BEFORE|2020-08-26|ONGOING|2020-10-16
e|RS|9ed8a578-a82a-423a-81ca-ee87f98d62f7|6|MOLRESP|Molecular Response|DURIE MULTIPLE MYELOMA 2006|[?]|tsp|iCPD|1|nmol|FLUORESCENCE ANGIOGRAPHY||||SPOUSE|ADJUDICATOR 3|U|3|Visit_3|40|4|FOLLOW-UP|2020-10-02|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-12|P1Y2M10DT2H30M|BEFORE|2020-10-20|COINCIDENT|2020-11-14
e|RS|9ed8a578-a82a-423a-81ca-ee87f98d62f7|7|ANATRESP|Anatomic Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|cd*s/m2|NOT ALL EVALUATED|1|FIU|PERIODIC ACID SCHIFF STAIN|Y|||PROXY|READER 2|U|4|Visit_4|65|3|TREATMENT|2020-10-27|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-19|P1Y2M10DT2H30M|UNKNOWN|2020-09-06|AFTER|2020-10-31
e|RS|9ed8a578-a82a-423a-81ca-ee87f98d62f7|8|CLINRESP|Clinical Response|FAROOQUI SUPP CLL 2014|[?]|m2|EQUIVOCAL|1|g/cm2|LIGHT MICROSCOPY||||NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST|Y|4|Visit_4|65|5|SCREENING|2020-10-27|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-19|P1Y2M10DT2H30M|AFTER|2020-11-25|AFTER|2020-11-29
e|RS|9ed8a578-a82a-423a-81ca-ee87f98d62f7|9|PATHRESP|Pathologic Response|RECICL|||CYTOGENETIC PR|1|PFU|IMMUNOASSAY||Y|Y|CLINICAL STUDY SPONSOR|FORENSIC PATHOLOGIST|Y|5|Visit_5|90|3|FOLLOW-UP|2020-11-21|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-31|P1Y2M10DT2H30M|UNKNOWN|2020-10-29|COINCIDENT|2020-11-08
e|RS|9ed8a578-a82a-423a-81ca-ee87f98d62f7|10|MJPTHIND|Major Pathological Response Indicator|SCHER PROSTATE CANCER 2011|||NON-iCR/NON-iUPD|1|vp/mL|ELLA|||Y|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST|N|5|Visit_5|90|2|FOLLOW-UP|2020-11-21|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-31|P1Y2M10DT2H30M|BEFORE|2020-08-29|BEFORE|2020-11-20
e|RS|2214af46-1072-4328-bf3d-f4fe9cd97d9b|1|SFTSRESP|Soft Tissue Response|NCCN ALL MRD 2014|[?]|SYRINGE|FAVORABLE RESPONSE|1|IU/g Hb|PET/CT SCAN||||INTERVIEWER|PATHOLOGIST 1|N|1|Visit_1|10|3|FOLLOW-UP|2020-10-18|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-06|P1Y2M10DT2H30M|UNKNOWN|2020-12-30|BEFORE|2021-01-05
e|RS|2214af46-1072-4328-bf3d-f4fe9cd97d9b|2|MNPTHIND|Minor Pathological Response Indicator|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|damol/L|MR|1|mL/min/mmHg|ELISA||||CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 2|Y|1|Visit_1|10|2|SCREENING|2020-10-18|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-06|P1Y2M10DT2H30M|COINCIDENT|2020-10-14|ONGOING|2020-12-24
e|RS|2214af46-1072-4328-bf3d-f4fe9cd97d9b|3|PATHRESP|Pathologic Response|PCWG SCHER PROSTATE CANCER 2008|[?]|cpm|CR|1|BOWL|MICRO BROTH DILUTION||||DOMESTIC PARTNER|RADIOLOGIST 1|NA|2|Visit_2|25|3|FOLLOW-UP|2020-11-02|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-03|P1Y2M10DT2H30M|AFTER|2021-01-02|COINCIDENT|2021-01-11
e|RS|2214af46-1072-4328-bf3d-f4fe9cd97d9b|4|MRPHRESP|Morphologic Response|FAROOQUI SUPP CLL 2014|[?]|log EID 50/dose|VGPR|1|AgU/mL|WRIGHT STAIN||||DOMESTIC PARTNER|FORENSIC PATHOLOGIST|Y|2|Visit_2|25|6|TREATMENT|2020-11-02|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-03|P1Y2M10DT2H30M|COINCIDENT|2020-11-27|ONGOING|2020-12-29
e|RS|2214af46-1072-4328-bf3d-f4fe9cd97d9b|5|PATHRESP|Pathologic Response|CHOI GIST 2008|[?]|BOWL|MRD NEGATIVITY|1|g/m2|SPECT/CT SCAN||Y||VENDOR|NEUROLOGIST 1|Y|3|Visit_3|40|6|TREATMENT|2020-11-17|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-25|P1Y2M10DT2H30M|UNKNOWN|2020-12-24|BEFORE|2020-12-27
e|RS|2214af46-1072-4328-bf3d-f4fe9cd97d9b|6|PATHRESP|Pathologic Response|JACINTO CERVICAL CANCER 2007|[?]|ppth|HI-N|1|mEq/ug|MULTIPLEXED BEAD BASED IMMUNOASSAY||||SIBLING|READER|N|3|Visit_3|40|5|TREATMENT|2020-11-17|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-25|P1Y2M10DT2H30M|AFTER|2020-12-22|BEFORE|2021-01-13
e|RS|2214af46-1072-4328-bf3d-f4fe9cd97d9b|7|CPRFSTAT|Clinical Performance Status|HARTMANN GERM CELL CANCER 2002|[?]|10^7 TCID 50/dose|MORPHOLOGIC CR|1|cmH2O*s/mL|ULTRASONOGRAPHIC ELASTOGRAPHY||||CLINICAL STUDY SPONSOR|INTERNIST|NA|4|Visit_4|65|7|TREATMENT|2020-12-12|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-02|P1Y2M10DT2H30M|AFTER|2020-12-22|BEFORE|2021-01-11
e|RS|2214af46-1072-4328-bf3d-f4fe9cd97d9b|8|NTERESP|Non-Target Enhancing Response|BURCOMBE BREAST CANCER 2005|||IMPROVED|1|USP U|FLOW MICROSCOPY|||Y|CHILD|OPTOMETRIST|N|4|Visit_4|65|7|WASHOUT|2020-12-12|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-02|P1Y2M10DT2H30M|AFTER|2020-11-28|BEFORE|2020-12-13
e|RS|2214af46-1072-4328-bf3d-f4fe9cd97d9b|9|CLINRESP|Clinical Response|IWG CHESON MDS 2000|[?]|GBq/g|PMR|1|U/m2/day|CHROMATOGRAPHY||||STUDY SUBJECT|PATHOLOGIST 2|NA|5|Visit_5|90|7|TREATMENT|2021-01-06|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-15|P1Y2M10DT2H30M|COINCIDENT|2020-11-01|BEFORE|2020-11-24
e|RS|2214af46-1072-4328-bf3d-f4fe9cd97d9b|10|TRGRESP|Target Response|DURIE MULTIPLE MYELOMA 2006|[?]|10^6/L|pCR|1|nmol BCE/L|ANTIMICROBIAL COMBINATION TESTING||||ADJUDICATOR|NEUROLOGIST 2|N|5|Visit_5|90|4|SCREENING|2021-01-06|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-15|P1Y2M10DT2H30M|BEFORE|2020-12-29|AFTER|2021-01-04
e|RS|7e56eb43-62a6-45ac-9476-1d0655595a04|1|METSIND|Metastatic Indicator|MRECIST BYRNE MESOTHELIOMA 2004|[?]|CYLINDER|MOLECULAR MAJOR RESPONSE|1|mg/m2/h|TWO-COLOR MICROARRAY||||VENDOR|READER|NA|1|Visit_1|10|4|TREATMENT|2021-01-24|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-31|P1Y2M10DT2H30M|AFTER|2021-03-06|AFTER|2021-04-22
e|RS|7e56eb43-62a6-45ac-9476-1d0655595a04|2|PATHRESP|Pathologic Response|PRINCE TCELL LYMPHOMA 2010|[?]|Gy|SD|1|vg/kg|CISH||Y||FAMILY MEMBER|NEUROLOGIST 2|Y|1|Visit_1|10|4|WASHOUT|2021-01-24|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-31|P1Y2M10DT2H30M|UNKNOWN|2021-02-16|AFTER|2021-02-23
e|RS|7e56eb43-62a6-45ac-9476-1d0655595a04|3|SPLNRESP|Spleen Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|IU/mmol|CYTOGENETIC MINIMAL RESPONSE|1|ft2|MULTI-SLICE SPIRAL CT|Y|||INDEPENDENT ASSESSOR|MICROSCOPIST|Y|2|Visit_2|25|3|SCREENING|2021-02-08|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-10|P1Y2M10DT2H30M|UNKNOWN|2021-04-04|COINCIDENT|2021-04-07
e|RS|7e56eb43-62a6-45ac-9476-1d0655595a04|4|CPRFSTAT|Clinical Performance Status|RANO ELLINGSON 2017|[?]|kat|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|Bq/uL|TRANSMISSION ELECTRON MICROSCOPY|Y|||STUDY SUBJECT|ADJUDICATOR|Y|2|Visit_2|25|1|SCREENING|2021-02-08|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-10|P1Y2M10DT2H30M|BEFORE|2021-01-27|AFTER|2021-03-15
e|RS|7e56eb43-62a6-45ac-9476-1d0655595a04|5|BMIVLIND|Bone Marrow Involvement Indicator|MASS|[?]|Gauss|RELAPSED DISEASE FROM CR OR PR|1|/mm|MODIFIED ACID FAST STAIN|Y|||ADJUDICATOR|DERMATOLOGIST|U|3|Visit_3|40|6|TREATMENT|2021-02-23|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-26|P1Y2M10DT2H30M|UNKNOWN|2021-02-17|COINCIDENT|2021-03-14
e|RS|7e56eb43-62a6-45ac-9476-1d0655595a04|6|MOLRESP|Molecular Response|HARTMANN GERM CELL CANCER 2002|[?]|/month|CYTOGENETIC MINOR RESPONSE|1|CAPLET|CHROMOGENIC ASSAY|Y|Y||FAMILY MEMBER|OPTOMETRIST|N|3|Visit_3|40|7|WASHOUT|2021-02-23|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-26|P1Y2M10DT2H30M|UNKNOWN|2021-03-07|AFTER|2021-03-31
e|RS|7e56eb43-62a6-45ac-9476-1d0655595a04|7|CLINRESP|Clinical Response|SCHER PROSTATE CANCER 2011|||PD FROM PR|1|mmol/min/kPa|SPECTROPHOTOMETRY|||Y|CAREGIVER|DERMATOLOGIST|NA|4|Visit_4|65|5|TREATMENT|2021-03-20|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-17|P1Y2M10DT2H30M|COINCIDENT|2021-02-17|BEFORE|2021-04-21
e|RS|7e56eb43-62a6-45ac-9476-1d0655595a04|8|MNPTHIND|Minor Pathological Response Indicator|IWC HALLEK CLL 2008|[?]|IU/day|CA125 75% RESPONSE|1|USP U|ANTIBIOTIC AGAR SCREEN||||FRIEND|ADJUDICATOR 2|Y|4|Visit_4|65|4|SCREENING|2021-03-20|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-17|P1Y2M10DT2H30M|UNKNOWN|2021-04-23|ONGOING|2021-04-24
e|RS|7e56eb43-62a6-45ac-9476-1d0655595a04|9|NEWLIND|New Lesion Indicator|MASS|[?]|L/day|FAVORABLE RESPONSE|1|hr/day|CONTRAST ENHANCED SPIRAL CT SCAN|Y|||ADJUDICATOR|OTOLARYNGOLOGIST|U|5|Visit_5|90|7|FOLLOW-UP|2021-04-14|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-17|P1Y2M10DT2H30M|AFTER|2021-01-29|ONGOING|2021-02-17
e|RS|7e56eb43-62a6-45ac-9476-1d0655595a04|10|HEMARESP|Hematologic Response|EASL BRUIX LIVER CANCER 2001|||iUPD|1|SACHET|CYSTOSCOPY|Y|Y|Y|CLINICAL STUDY SPONSOR|ADJUDICATOR|Y|5|Visit_5|90|7|TREATMENT|2021-04-14|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-17|P1Y2M10DT2H30M|BEFORE|2021-01-25|AFTER|2021-04-08
e|RS|73a8e85a-0b5f-496b-b164-afc4d1f02de2|1|ANATRESP|Anatomic Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|mm/h|SD|1|Bq/L|MICROSCOPY||||PROXY|MICROSCOPIST|Y|1|Visit_1|10|1|FOLLOW-UP|2020-06-29|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-23|P1Y2M10DT2H30M|COINCIDENT|2020-09-18|AFTER|2020-09-22
e|RS|73a8e85a-0b5f-496b-b164-afc4d1f02de2|2|NEWLWIND|New Lesion Worsening Indicator|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|U/L|VGPR|1|pmol|REAL-TIME POLYMERASE CHAIN REACTION ASSAY||||HEALTH CARE PROFESSIONAL|ONCOLOGIST|Y|1|Visit_1|10|5|FOLLOW-UP|2020-06-29|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-23|P1Y2M10DT2H30M|BEFORE|2020-08-18|AFTER|2020-08-23
e|RS|73a8e85a-0b5f-496b-b164-afc4d1f02de2|3|CLINRESP|Clinical Response|AJCC V7|[?]|ppth|CYTOGENETIC CR|1|uCi/kg|DYNAMIC CONTRAST ENHANCED MRI|Y|||CAREGIVER|READER 3|U|2|Visit_2|25|6|TREATMENT|2020-07-14|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-06|P1Y2M10DT2H30M|BEFORE|2020-07-15|BEFORE|2020-07-31
e|RS|73a8e85a-0b5f-496b-b164-afc4d1f02de2|4|NEWLPROG|New Lesion Progression|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|mmol/min/kPa|CR-CT|1|10^6 organisms|GIEMSA STAIN||Y||INTERVIEWER|HEMATOLOGIST|U|2|Visit_2|25|7|TREATMENT|2020-07-14|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-06|P1Y2M10DT2H30M|BEFORE|2020-08-05|COINCIDENT|2020-09-02
e|RS|73a8e85a-0b5f-496b-b164-afc4d1f02de2|5|SYMPTDTR|Symptomatic Deterioration|CHESON NON-HODGKINS LYMPHOMA 1999|||CR|1|/MBP|ROMANOWSKY STAIN|Y||Y|CLINICAL STUDY SPONSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|3|Visit_3|40|6|TREATMENT|2020-07-29|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-30|P1Y2M10DT2H30M|BEFORE|2020-08-27|AFTER|2020-09-13
e|RS|73a8e85a-0b5f-496b-b164-afc4d1f02de2|6|METBRESP|Metabolic Response|MURPHY PROSTATE CANCER 1980|[?]|L/kg|NOT ALL EVALUATED|1|mOsm|PELLI-ROBSON EYE CHART||Y||SIGNIFICANT OTHER|HEMATOLOGIST|N|3|Visit_3|40|7|TREATMENT|2020-07-29|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-30|P1Y2M10DT2H30M|AFTER|2020-06-21|ONGOING|2020-08-05
e|RS|73a8e85a-0b5f-496b-b164-afc4d1f02de2|7|OVRLRESP|Overall Response|CHOLLET BREAST CANCER 2002|[?]|Hz|IMMUNOPHENOTYPIC CR|1|nmol/mL/min|WHOLE EXOME SEQUENCING||||SIGNIFICANT OTHER|MICROSCOPIST 3|U|4|Visit_4|65|1|TREATMENT|2020-08-23|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-29|P1Y2M10DT2H30M|AFTER|2020-07-25|AFTER|2020-09-20
e|RS|73a8e85a-0b5f-496b-b164-afc4d1f02de2|8|CLINRESP|Clinical Response|CHOLLET BREAST CANCER 2002|[?]|amu|INCREASED|1|pg/cell|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY||||PROXY|HEMATOLOGIST|N|4|Visit_4|65|4|TREATMENT|2020-08-23|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-29|P1Y2M10DT2H30M|BEFORE|2020-09-15|BEFORE|2020-09-17
e|RS|73a8e85a-0b5f-496b-b164-afc4d1f02de2|9|MRDRESP|Minimal Residual Disease Response|SCHWARZ CERVICAL CANCER 2009|[?]|Gy|CYTOGENETIC MINOR RESPONSE|1|kV|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY||Y||CHILD|ADJUDICATOR 1|Y|5|Visit_5|90|6|SCREENING|2020-09-17|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-31|P1Y2M10DT2H30M|UNKNOWN|2020-07-03|ONGOING|2020-09-14
e|RS|73a8e85a-0b5f-496b-b164-afc4d1f02de2|10|MRPHRESP|Morphologic Response|AJCC V8|||UNEQUIVOCAL|1|mol|ANTIMICROBIAL COMBINATION TESTING|||Y|GUARDIAN|ONCOLOGIST 2|NA|5|Visit_5|90|2|SCREENING|2020-09-17|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-31|P1Y2M10DT2H30M|COINCIDENT|2020-06-26|AFTER|2020-09-15
e|RS|84f74359-c79b-4f1c-8119-a4993b071973|1|MOLRESP|Molecular Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|||PR-CT|1|Antibody Unit|INDIA INK STAIN|Y|Y|Y|FRIEND|OPHTHALMOLOGIST|U|1|Visit_1|10|6|TREATMENT|2020-05-12|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-23|P1Y2M10DT2H30M|COINCIDENT|2020-08-06|ONGOING|2020-08-07
e|RS|84f74359-c79b-4f1c-8119-a4993b071973|2|RDIORESP|Radiologic Response|MACDONALD GLIOMA 1990|||RELAPSED DISEASE|1|copies/mL|ELECTRONEUROGRAPHY||Y|Y|VENDOR|PHYSIOTHERAPIST|U|1|Visit_1|10|3|TREATMENT|2020-05-12|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-23|P1Y2M10DT2H30M|AFTER|2020-07-07|AFTER|2020-07-25
e|RS|84f74359-c79b-4f1c-8119-a4993b071973|3|MRDIND|Minimal Residual Disease Indicator|KEAM BREAST CANCER 2013|[?]|10^6 organisms/mL|NON-PD|1|tsp|HEMATOXYLIN AND EOSIN STAIN|Y|||SPOUSE|DEVELOPMENTAL PSYCHOLOGIST|NA|2|Visit_2|25|5|TREATMENT|2020-05-27|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-07|P1Y2M10DT2H30M|UNKNOWN|2020-06-01|ONGOING|2020-07-30
e|RS|84f74359-c79b-4f1c-8119-a4993b071973|4|NEWLPROG|New Lesion Progression|LUGANO CLASSIFICATION|||CYTOGENETIC PR|1|Sv|MICROBIAL CULTURE|Y||Y|INDEPENDENT ASSESSOR|MICROSCOPIST 3|U|2|Visit_2|25|1|FOLLOW-UP|2020-05-27|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-07|P1Y2M10DT2H30M|UNKNOWN|2020-06-24|COINCIDENT|2020-07-02
e|RS|84f74359-c79b-4f1c-8119-a4993b071973|5|CPRFSTAT|Clinical Performance Status|PRINCE TCELL LYMPHOMA 2010|[?]|mg/m2/day|sCR|1|U/kg/min|WESTERN BLOT||||PARENT|MICROSCOPIST 3|Y|3|Visit_3|40|1|FOLLOW-UP|2020-06-11|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-01|P1Y2M10DT2H30M|AFTER|2020-08-03|ONGOING|2020-08-04
e|RS|84f74359-c79b-4f1c-8119-a4993b071973|6|TMRESP|Tumor Marker Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|cmH2O/mL|PR WITH LYMPHOCYTOSIS|1|JAR|PAP STAIN||||VENDOR|DERMATOLOGIST|Y|3|Visit_3|40|6|TREATMENT|2020-06-11|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-01|P1Y2M10DT2H30M|BEFORE|2020-06-14|ONGOING|2020-07-25
e|RS|84f74359-c79b-4f1c-8119-a4993b071973|7|MRDIND|Minimal Residual Disease Indicator|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|mm3/mm2/year|NR|1|mL/(min*100mL)|WESTERN BLOT||Y||ADJUDICATION COMMITTEE|INTERNIST|NA|4|Visit_4|65|1|TREATMENT|2020-07-06|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-04|P1Y2M10DT2H30M|BEFORE|2020-07-16|ONGOING|2020-07-28
e|RS|84f74359-c79b-4f1c-8119-a4993b071973|8|METBRESP|Metabolic Response|CHESON CLL 2012|[?]|TRACE|iSD|1|mmol/L|SNP ARRAY||||HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|N|4|Visit_4|65|4|TREATMENT|2020-07-06|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-04|P1Y2M10DT2H30M|COINCIDENT|2020-07-20|COINCIDENT|2020-07-31
e|RS|84f74359-c79b-4f1c-8119-a4993b071973|9|BMIVLIND|Bone Marrow Involvement Indicator|FAROOQUI SUPP CLL 2014|||PSEUDOPROGRESSION|1|LOZENGE|MIGET|Y||Y|INDEPENDENT ASSESSOR|ADJUDICATOR|U|5|Visit_5|90|4|WASHOUT|2020-07-31|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-02|P1Y2M10DT2H30M|COINCIDENT|2020-06-14|ONGOING|2020-07-18
e|RS|84f74359-c79b-4f1c-8119-a4993b071973|10|NTERESP|Non-Target Enhancing Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|nU/cL|PD/RELAPSE AFTER HI|1|STEPS|NUCLEAR RADIOLOGY||Y||PROXY|ENDOCRINOLOGIST|N|5|Visit_5|90|3|SCREENING|2020-07-31|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-02|P1Y2M10DT2H30M|BEFORE|2020-06-27|COINCIDENT|2020-07-10
e|RS|d6ff71b7-6a5f-415f-8267-15c9c1f5585c|1|NEWLWIND|New Lesion Worsening Indicator|UNSPECIFIED|||MRD RELAPSE|1|mmol/min/kPa/L|PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY|||Y|FRIEND|MICROSCOPIST 1|U|1|Visit_1|10|3|TREATMENT|2020-11-06|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-30|P1Y2M10DT2H30M|AFTER|2021-01-13|BEFORE|2021-02-01
e|RS|d6ff71b7-6a5f-415f-8267-15c9c1f5585c|2|MRDRESP|Minimal Residual Disease Response|CHESON CLL 2012|[?]|/500 WBC|PSEUDORESPONSE|1|KALLIKREIN INHIBITOR UNIT|MICROBIAL CULTURE, SOLID||Y||STUDY SUBJECT|HEMATOLOGIST|NA|1|Visit_1|10|2|TREATMENT|2020-11-06|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-30|P1Y2M10DT2H30M|BEFORE|2020-12-16|BEFORE|2021-02-02
e|RS|d6ff71b7-6a5f-415f-8267-15c9c1f5585c|3|PATHRESP|Pathologic Response|CHOLLET BREAST CANCER 2002|||PD FROM PR|1|L/h/m2|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|||Y|SPOUSE|HEMATOLOGIST|N|2|Visit_2|25|5|TREATMENT|2020-11-21|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-07|P1Y2M10DT2H30M|UNKNOWN|2020-11-12|ONGOING|2021-01-06
e|RS|d6ff71b7-6a5f-415f-8267-15c9c1f5585c|4|TRGRESP|Target Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|mL/kg|PMD|1|mL/min/1.73m2|WHOLE TRANSCRIPTOME SEQUENCING|Y|||CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST|Y|2|Visit_2|25|4|TREATMENT|2020-11-21|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-07|P1Y2M10DT2H30M|COINCIDENT|2021-01-20|BEFORE|2021-01-27
e|RS|d6ff71b7-6a5f-415f-8267-15c9c1f5585c|5|BESTRESP|Best Overall Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|||INDETERMINATE RESPONSE|1|VOXEL|MAPH||Y|Y|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST|U|3|Visit_3|40|7|TREATMENT|2020-12-06|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-19|P1Y2M10DT2H30M|BEFORE|2020-11-05|AFTER|2020-11-28
e|RS|d6ff71b7-6a5f-415f-8267-15c9c1f5585c|6|MJPTHIND|Major Pathological Response Indicator|PERCIST|[?]|PFU/dose|HI-E|1|NEBULE|MODIFIED ACID FAST STAIN|Y|||FAMILY MEMBER|MICROSCOPIST|Y|3|Visit_3|40|6|SCREENING|2020-12-06|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-19|P1Y2M10DT2H30M|UNKNOWN|2020-11-03|COINCIDENT|2020-12-04
e|RS|d6ff71b7-6a5f-415f-8267-15c9c1f5585c|7|NEWLIND|New Lesion Indicator|JACINTO CERVICAL CANCER 2007|[?]|ug/dL|VGPR|1|MET*min|PHOTOGRAPHY||Y||STUDY SUBJECT|MICROSCOPIST 2|NA|4|Visit_4|65|3|FOLLOW-UP|2020-12-31|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-15|P1Y2M10DT2H30M|COINCIDENT|2020-12-22|COINCIDENT|2021-02-01
e|RS|d6ff71b7-6a5f-415f-8267-15c9c1f5585c|8|SYMPTDTR|Symptomatic Deterioration|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|/MBP|NR|1|JDF Unit|CAPILLARY ELECTROPHORESIS|Y|||CLINICAL RESEARCH COORDINATOR|UROLOGIST|Y|4|Visit_4|65|7|TREATMENT|2020-12-31|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-15|P1Y2M10DT2H30M|AFTER|2020-11-10|COINCIDENT|2020-12-20
e|RS|d6ff71b7-6a5f-415f-8267-15c9c1f5585c|9|SFTSRESP|Soft Tissue Response|AJCC V8|||EQUIVOCAL|1|U/L|PLAQUE REDUCTION NEUTRALIZATION ASSAY|Y||Y|ADJUDICATOR|PATHOLOGIST|N|5|Visit_5|90|6|FOLLOW-UP|2021-01-25|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-12|P1Y2M10DT2H30M|BEFORE|2020-11-27|AFTER|2020-12-10
e|RS|d6ff71b7-6a5f-415f-8267-15c9c1f5585c|10|METSIND|Metastatic Indicator|IWG CHESON MDS 2000|[?]|uEq/L|UNEQUIVOCAL|1|mL/dose|PEAK FLOWMETRY||||ADJUDICATION COMMITTEE|READER|U|5|Visit_5|90|4|SCREENING|2021-01-25|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-12|P1Y2M10DT2H30M|BEFORE|2020-11-29|ONGOING|2021-01-10
e|RS|cd0c969e-61c6-4c65-ac19-4ee247f5009a|1|PATHRESP|Pathologic Response|PCWG SCHER PROSTATE CANCER 2008|[?]|AgU/mL|STABLE|1|breaths/min|RADIOIMMUNOPRECIPITATION ASSAY|Y|||SIGNIFICANT OTHER|UROLOGIST|U|1|Visit_1|10|1|FOLLOW-UP|2020-09-09|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-26|P1Y2M10DT2H30M|COINCIDENT|2020-10-09|ONGOING|2020-10-24
e|RS|cd0c969e-61c6-4c65-ac19-4ee247f5009a|2|MRDIND|Minimal Residual Disease Indicator|UNSPECIFIED|[?]|PIPE|HI-N|1|APS U|COLORIMETRY||||STUDY SUBJECT|OPTOMETRIST|N|1|Visit_1|10|5|SCREENING|2020-09-09|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-26|P1Y2M10DT2H30M|UNKNOWN|2020-09-01|COINCIDENT|2020-10-27
e|RS|cd0c969e-61c6-4c65-ac19-4ee247f5009a|3|TMRESP|Tumor Marker Response|BLAZER COLORECTAL CANCER 2008|||UNFAVORABLE RESPONSE|1|VIAL|SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY|||Y|SIBLING|INTERNIST|U|2|Visit_2|25|6|TREATMENT|2020-09-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-21|P1Y2M10DT2H30M|BEFORE|2020-11-05|ONGOING|2020-11-25
e|RS|cd0c969e-61c6-4c65-ac19-4ee247f5009a|4|NEWLIND|New Lesion Indicator|IWG CHESON MDS 2000|[?]|cy/cm|MORPHOLOGIC LEUKEMIA-FREE STATE|1|ELISA unit/mL|FORCED OSCILLATION TECHNIQUE|Y|||INTERVIEWER|READER|NA|2|Visit_2|25|4|FOLLOW-UP|2020-09-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-21|P1Y2M10DT2H30M|UNKNOWN|2020-09-05|COINCIDENT|2020-11-24
e|RS|cd0c969e-61c6-4c65-ac19-4ee247f5009a|5|MRPHRESP|Morphologic Response|PRINCE TCELL LYMPHOMA 2010|[?]|BISCUIT|CA125 50% RESPONSE|1|APL U|CONTRAST ENHANCED PET/CT SCAN||||CLINICAL RESEARCH ASSOCIATE|ENDOCRINOLOGIST|Y|3|Visit_3|40|4|FOLLOW-UP|2020-10-09|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-26|P1Y2M10DT2H30M|UNKNOWN|2020-09-12|COINCIDENT|2020-10-21
e|RS|cd0c969e-61c6-4c65-ac19-4ee247f5009a|6|MNPTHIND|Minor Pathological Response Indicator|HARTMANN GERM CELL CANCER 2002|[?]|EP U|COMPLETE MRD RESPONSE|1|PELLET|CHROMOGENIC ASSAY||||INVESTIGATOR|ADJUDICATOR 2|NA|3|Visit_3|40|6|FOLLOW-UP|2020-10-09|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-26|P1Y2M10DT2H30M|UNKNOWN|2020-11-21|BEFORE|2020-12-04
e|RS|cd0c969e-61c6-4c65-ac19-4ee247f5009a|7|NTNERESP|Non-Target Non-Enhancing Response|NCIWG CHESON CLL 1996|||RELAPSED DISEASE|1|mg/m2/min|BRDU CELLULAR PROLIFERATION ASSAY||Y|Y|CLINICAL RESEARCH COORDINATOR|READER 2|NA|4|Visit_4|65|3|TREATMENT|2020-11-03|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-06|P1Y2M10DT2H30M|BEFORE|2020-10-30|AFTER|2020-11-17
e|RS|cd0c969e-61c6-4c65-ac19-4ee247f5009a|8|OVRLRESP|Overall Response|IWG CHESON MDS 2000|[?]|km/h|ABSENT MORPHOLOGIC RESPONSE|1|EP U|IMMUNOFLUORESCENT STAIN|Y|||CHILD|PHYSIOTHERAPIST|Y|4|Visit_4|65|4|FOLLOW-UP|2020-11-03|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-06|P1Y2M10DT2H30M|UNKNOWN|2020-11-22|AFTER|2020-11-28
e|RS|cd0c969e-61c6-4c65-ac19-4ee247f5009a|9|BMIVLIND|Bone Marrow Involvement Indicator|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|GPS U|STABLE|1|mph|U-HPLC/MS/MS||||FRIEND|DEVELOPMENTAL PSYCHOLOGIST|NA|5|Visit_5|90|6|WASHOUT|2020-11-28|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-02|P1Y2M10DT2H30M|COINCIDENT|2020-11-23|ONGOING|2020-12-05
e|RS|cd0c969e-61c6-4c65-ac19-4ee247f5009a|10|PATHRESP|Pathologic Response|NCIWG CHESON CLL 1996|[?]|ngEq/L|MRD NEGATIVITY|1|foz_us|NUCLEIC ACID BASED METHOD|Y|||CHILD|RADIOLOGIST|NA|5|Visit_5|90|7|SCREENING|2020-11-28|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-02|P1Y2M10DT2H30M|COINCIDENT|2020-12-07|AFTER|2020-12-08
e|RS|1fff484d-0a68-42cd-8eff-bc4fe4da945c|1|MRPHRESP|Morphologic Response|IWG CHESON MDS 2006|[?]|anti-Xa IU/mL|CYTOGENETIC PR|1|RATIO|PALPATION||||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST|N|1|Visit_1|10|3|SCREENING|2021-01-28|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-25|P1Y2M10DT2H30M|BEFORE|2021-04-15|AFTER|2021-04-19
e|RS|1fff484d-0a68-42cd-8eff-bc4fe4da945c|2|BESTRESP|Best Overall Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|||NOT ALL EVALUATED|1|ug/L FEU|COULOMETRIC TITRATION|Y|Y|Y|STUDY SUBJECT|ENDOCRINOLOGIST|Y|1|Visit_1|10|4|TREATMENT|2021-01-28|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-25|P1Y2M10DT2H30M|UNKNOWN|2021-04-26|AFTER|2021-04-27
e|RS|1fff484d-0a68-42cd-8eff-bc4fe4da945c|3|MRDIND|Minimal Residual Disease Indicator|BRUGGEMANN MRD 2010|[?]|mg/dose|MORPHOLOGIC CRi|1|rpm|GC/MS||||STUDY SUBJECT|DERMATOLOGIST|N|2|Visit_2|25|2|SCREENING|2021-02-12|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-09|P1Y2M10DT2H30M|BEFORE|2021-02-26|BEFORE|2021-04-20
e|RS|1fff484d-0a68-42cd-8eff-bc4fe4da945c|4|PATHRESP|Pathologic Response|SCHER PROSTATE CANCER 2011|[?]|ug/m2/min|STABLE|1|CFU/g|CENTRIFUGATION||Y||ADJUDICATOR|CARDIOLOGIST|U|2|Visit_2|25|5|TREATMENT|2021-02-12|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-09|P1Y2M10DT2H30M|AFTER|2021-02-24|ONGOING|2021-04-09
e|RS|1fff484d-0a68-42cd-8eff-bc4fe4da945c|5|NEWLWIND|New Lesion Worsening Indicator|CHESON LYMPHOMA 2008|[?]|MASK|EQUIVOCAL|1|pg/L|HPLC/MS/MS||||VENDOR|MICROSCOPIST 3|NA|3|Visit_3|40|7|FOLLOW-UP|2021-02-27|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-02|P1Y2M10DT2H30M|COINCIDENT|2021-01-22|AFTER|2021-04-08
e|RS|1fff484d-0a68-42cd-8eff-bc4fe4da945c|6|NTRGRESP|Non-target Response|CHESON CLL 2006|[?]|ng|UNFAVORABLE RESPONSE|1|aMFI|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION||||DOMESTIC PARTNER|HEMATOLOGIST|N|3|Visit_3|40|2|SCREENING|2021-02-27|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-02|P1Y2M10DT2H30M|BEFORE|2021-01-28|BEFORE|2021-03-11
e|RS|1fff484d-0a68-42cd-8eff-bc4fe4da945c|7|CPRFSTAT|Clinical Performance Status|MACDONALD GLIOMA 1990|[?]|mL/animal/day|HI-N|1|mU|COULOMETRIC TITRATION||||PARENT|PATHOLOGIST 2|U|4|Visit_4|65|5|TREATMENT|2021-03-24|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-20|P1Y2M10DT2H30M|BEFORE|2021-03-31|COINCIDENT|2021-04-03
e|RS|1fff484d-0a68-42cd-8eff-bc4fe4da945c|8|METBRESP|Metabolic Response|CHESON CLL 2012|[?]|BOX|PR WITH LYMPHOCYTOSIS|1|GBq/g|HEMAGGLUTINATION INHIBITION ASSAY|Y|Y||FAMILY MEMBER|NEUROLOGIST 2|U|4|Visit_4|65|5|SCREENING|2021-03-24|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-20|P1Y2M10DT2H30M|AFTER|2021-03-06|BEFORE|2021-03-21
e|RS|1fff484d-0a68-42cd-8eff-bc4fe4da945c|9|NEWLPROG|New Lesion Progression|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|amol|HI-P|1|/LPF|ISHIHARA COLOR PLATES||||SIGNIFICANT OTHER|PHYSIOTHERAPIST|N|5|Visit_5|90|3|TREATMENT|2021-04-18|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-08|P1Y2M10DT2H30M|AFTER|2021-01-24|ONGOING|2021-03-08
e|RS|1fff484d-0a68-42cd-8eff-bc4fe4da945c|10|RDIORESP|Radiologic Response|EASL BRUIX LIVER CANCER 2001|[?]|SPRAY|iSD|1|10^8/L|CLOT DETECTION|Y|Y||ADJUDICATION COMMITTEE|ADJUDICATOR 2|NA|5|Visit_5|90|4|SCREENING|2021-04-18|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-08|P1Y2M10DT2H30M|AFTER|2021-04-22|COINCIDENT|2021-04-23
e|RS|e2c20e9a-0ac5-4907-96de-472bee70bd79|1|MRPHRESP|Morphologic Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|mL/s|iPR|1|U/kg/min|INDIA INK STAIN||||VENDOR|ADJUDICATOR 1|Y|1|Visit_1|10|7|TREATMENT|2020-12-04|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-10|P1Y2M10DT2H30M|UNKNOWN|2021-02-10|BEFORE|2021-02-27
e|RS|e2c20e9a-0ac5-4907-96de-472bee70bd79|2|STRUSTAT|Steroid Use Status|GUPPY OVARIAN CANCER 2002|||RELAPSED DISEASE FROM CR OR PR|1|mg/dL|HEMOCYTOMETRY|Y|Y|Y|CAREGIVER|ENDOCRINOLOGIST|N|1|Visit_1|10|2|TREATMENT|2020-12-04|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-10|P1Y2M10DT2H30M|COINCIDENT|2020-12-27|BEFORE|2021-01-19
e|RS|e2c20e9a-0ac5-4907-96de-472bee70bd79|3|BMIVLIND|Bone Marrow Involvement Indicator|HAMAOKA BREAST CANCER 2010|[?]|Absorbance U/min|NON-CR/NON-PD|1|mg/day|PET/CT SCAN||||DOMESTIC PARTNER|MICROSCOPIST 2|U|2|Visit_2|25|4|FOLLOW-UP|2020-12-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-04|P1Y2M10DT2H30M|BEFORE|2020-12-09|COINCIDENT|2021-02-25
e|RS|e2c20e9a-0ac5-4907-96de-472bee70bd79|4|METSIND|Metastatic Indicator|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|Joule|HI-P|1|LB|HEMOCYTOMETRY||||INTERVIEWER|ADJUDICATOR 3|NA|2|Visit_2|25|3|WASHOUT|2020-12-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-04|P1Y2M10DT2H30M|AFTER|2021-01-18|COINCIDENT|2021-02-07
e|RS|e2c20e9a-0ac5-4907-96de-472bee70bd79|5|SYMPTDTR|Symptomatic Deterioration|JACINTO CERVICAL CANCER 2007|[?]|CONTAINER|IMMUNOPHENOTYPIC CR|1|AFU|ELASTOGRAPHY||||SPOUSE|PEDIATRIC NEUROLOGIST|NA|3|Visit_3|40|3|WASHOUT|2021-01-03|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-12|P1Y2M10DT2H30M|UNKNOWN|2021-01-16|AFTER|2021-01-24
e|RS|e2c20e9a-0ac5-4907-96de-472bee70bd79|6|NTNERESP|Non-Target Non-Enhancing Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|pg|PR|1|um2|X-RAY|Y|||INDEPENDENT ASSESSOR|PATHOLOGIST|U|3|Visit_3|40|5|TREATMENT|2021-01-03|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-12|P1Y2M10DT2H30M|UNKNOWN|2021-01-17|BEFORE|2021-02-14
e|RS|e2c20e9a-0ac5-4907-96de-472bee70bd79|7|MRPHRESP|Morphologic Response|CHOI GIST 2008|[?]|mL/kg|UNEQUIVOCAL|1|vg/kg|SMEAR||||SPOUSE|ONCOLOGIST 1|Y|4|Visit_4|65|7|TREATMENT|2021-01-28|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-22|P1Y2M10DT2H30M|UNKNOWN|2020-12-20|BEFORE|2021-01-30
e|RS|e2c20e9a-0ac5-4907-96de-472bee70bd79|8|LIVRRESP|Liver Response|BRUGGEMANN MRD 2010|[?]|umol/L|DECREASED|1|AU/mL|SICKLE CELL SOLUBILITY TEST||||CAREGIVER|MICROSCOPIST|Y|4|Visit_4|65|6|SCREENING|2021-01-28|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-22|P1Y2M10DT2H30M|UNKNOWN|2021-01-15|COINCIDENT|2021-01-31
e|RS|e2c20e9a-0ac5-4907-96de-472bee70bd79|9|BONERESP|Bone Response|HARTMANN GERM CELL CANCER 2002|[?]|pmol/g|MOLECULAR CR|1|Bq/g|ICC||||SIBLING|RATER|Y|5|Visit_5|90|5|SCREENING|2021-02-22|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-16|P1Y2M10DT2H30M|AFTER|2021-01-23|COINCIDENT|2021-02-11
e|RS|e2c20e9a-0ac5-4907-96de-472bee70bd79|10|NEWLPROG|New Lesion Progression|RECIST 1.1|[?]|umol/L/h|MAJOR PATHOLOGIC RESPONSE|1|pmol/day|PLAQUE REDUCTION NEUTRALIZATION ASSAY||Y||FAMILY MEMBER|DEVELOPMENTAL PSYCHOLOGIST|NA|5|Visit_5|90|7|TREATMENT|2021-02-22|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-16|P1Y2M10DT2H30M|BEFORE|2021-02-24|BEFORE|2021-02-26
e|RS|6064ca8c-b723-4d05-914a-bb547d86fcc5|1|BESTRESP|Best Overall Response|AJCC V8|[?]|10^6 CFU/mL|COMPLETE MRD RESPONSE|1|%(w/v)|MUGA||Y||HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|Y|1|Visit_1|10|6|TREATMENT|2020-06-02|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-27|P1Y2M10DT2H30M|BEFORE|2020-06-22|AFTER|2020-08-06
e|RS|6064ca8c-b723-4d05-914a-bb547d86fcc5|2|PATHRESP|Pathologic Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|umol/dL|iCPD|1|mOsm/kg|ISHIHARA COLOR PLATES||||FAMILY MEMBER|MICROSCOPIST|Y|1|Visit_1|10|3|SCREENING|2020-06-02|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-27|P1Y2M10DT2H30M|COINCIDENT|2020-08-01|BEFORE|2020-08-24
e|RS|6064ca8c-b723-4d05-914a-bb547d86fcc5|3|BONERESP|Bone Response|PERCIST|[?]|BAR|PD FROM PR|1|cal|AUTOREFRACTION||||ADJUDICATOR|PATHOLOGIST 2|N|2|Visit_2|25|6|TREATMENT|2020-06-17|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-09|P1Y2M10DT2H30M|AFTER|2020-07-07|BEFORE|2020-08-09
e|RS|6064ca8c-b723-4d05-914a-bb547d86fcc5|4|NTLWIND|Non-Target Lesion Worsening Indicator|LUGANO CLASSIFICATION|[?]|/LSQN|MINOR PATHOLOGIC RESPONSE|1|10^11/L|IODINE STAIN||||SIGNIFICANT OTHER|NEUROLOGIST 1|NA|2|Visit_2|25|4|TREATMENT|2020-06-17|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-09|P1Y2M10DT2H30M|COINCIDENT|2020-05-30|COINCIDENT|2020-06-23
e|RS|6064ca8c-b723-4d05-914a-bb547d86fcc5|5|SYMPTDTR|Symptomatic Deterioration|RANO|[?]|10^4/L|PMR|1|mg/kg|INDIRECT IMMUNOFLUORESCENCE||||FRIEND|MICROSCOPIST 3|NA|3|Visit_3|40|1|SCREENING|2020-07-02|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-05|P1Y2M10DT2H30M|COINCIDENT|2020-07-03|BEFORE|2020-07-27
e|RS|6064ca8c-b723-4d05-914a-bb547d86fcc5|6|METBRESP|Metabolic Response|IWG CHESON AML 2003|[?]|DAgU/mL|PD/RELAPSE AFTER HI|1|C|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS||||FRIEND|CLINICAL PATHOLOGIST|U|3|Visit_3|40|7|FOLLOW-UP|2020-07-02|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-05|P1Y2M10DT2H30M|UNKNOWN|2020-08-24|AFTER|2020-08-26
e|RS|6064ca8c-b723-4d05-914a-bb547d86fcc5|7|MRPHRESP|Morphologic Response|NCIWG CHESON CLL 1996|[?]|dpm/mL|CYTOGENETIC PR|1|BOWL|GC/MS-CI||||DOMESTIC PARTNER|NEUROLOGIST 1|Y|4|Visit_4|65|2|WASHOUT|2020-07-27|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-09|P1Y2M10DT2H30M|AFTER|2020-08-07|ONGOING|2020-08-22
e|RS|6064ca8c-b723-4d05-914a-bb547d86fcc5|8|BESTRESP|Best Overall Response|PRINCE TCELL LYMPHOMA 2010|||NON-PD|1|ug/L FEU|CELL CYTOTOXICITY NEUTRALIZATION ASSAY|Y||Y|INVESTIGATOR|PATHOLOGIST 2|N|4|Visit_4|65|4|TREATMENT|2020-07-27|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-09|P1Y2M10DT2H30M|BEFORE|2020-07-09|AFTER|2020-08-13
e|RS|6064ca8c-b723-4d05-914a-bb547d86fcc5|9|MRDRESP|Minimal Residual Disease Response|PCWG SCHER PROSTATE CANCER 2008|||QUANTIFIABLE MRD POSITIVITY|1|mL/m2|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY|Y||Y|VENDOR|ADJUDICATOR|Y|5|Visit_5|90|7|TREATMENT|2020-08-21|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-03|P1Y2M10DT2H30M|BEFORE|2020-07-16|ONGOING|2020-08-27
e|RS|6064ca8c-b723-4d05-914a-bb547d86fcc5|10|TRGRESP|Target Response|WHO BREAST CANCER 2006|[?]|tsp eq|PSA PROGRESSION|1|rpm|CHROMOGENIC ASSAY|Y|||SIBLING|RATER 2|Y|5|Visit_5|90|6|FOLLOW-UP|2020-08-21|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-03|P1Y2M10DT2H30M|COINCIDENT|2020-07-20|ONGOING|2020-07-31
e|RS|8effbbff-acda-4718-89f1-e30a418f6bae|1|CPRFSTAT|Clinical Performance Status|AJCC V7|[?]|log EID 50/dose|MOLECULAR CR|1|nkat/g Hb|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS||||CHILD|HEMATOLOGIST|NA|1|Visit_1|10|3|TREATMENT|2020-11-06|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-21|P1Y2M10DT2H30M|BEFORE|2021-01-28|BEFORE|2021-02-02
e|RS|8effbbff-acda-4718-89f1-e30a418f6bae|2|CYTORESP|Cytogenetic Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|GLOBULE|NON-PD|1|U/m2/min|ACID FAST STAIN|Y|||STUDY SUBJECT|ONCOLOGIST|N|1|Visit_1|10|7|TREATMENT|2020-11-06|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-21|P1Y2M10DT2H30M|COINCIDENT|2020-11-08|COINCIDENT|2021-01-06
e|RS|8effbbff-acda-4718-89f1-e30a418f6bae|3|LIVRRESP|Liver Response|AJCC V7|[?]|AFU|PMD|1|Farad|STRESS ECHOCARDIOGRAPHY||||CHILD|OTOLARYNGOLOGIST|U|2|Visit_2|25|3|FOLLOW-UP|2020-11-21|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-16|P1Y2M10DT2H30M|COINCIDENT|2021-01-05|BEFORE|2021-02-01
e|RS|8effbbff-acda-4718-89f1-e30a418f6bae|4|NEWLPROG|New Lesion Progression|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|||PDu|1|MHz|LASER CAPTURE MICRODISSECTION|||Y|CLINICAL RESEARCH ASSOCIATE|RATER 2|Y|2|Visit_2|25|2|WASHOUT|2020-11-21|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-16|P1Y2M10DT2H30M|COINCIDENT|2020-11-07|AFTER|2021-01-07
e|RS|8effbbff-acda-4718-89f1-e30a418f6bae|5|NTERESP|Non-Target Enhancing Response|SACT|[?]|ms2|CMR|1|U/m2/min|PERIODIC ACID SCHIFF STAIN||||VENDOR|RADIOLOGIST 1|U|3|Visit_3|40|6|WASHOUT|2020-12-06|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-20|P1Y2M10DT2H30M|AFTER|2020-10-29|BEFORE|2020-11-27
e|RS|8effbbff-acda-4718-89f1-e30a418f6bae|6|NTLWIND|Non-Target Lesion Worsening Indicator|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|mkat|iPR|1|mCi/kg|IMMUNOBLOT|Y|||SPOUSE|ADJUDICATOR|Y|3|Visit_3|40|1|TREATMENT|2020-12-06|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-20|P1Y2M10DT2H30M|COINCIDENT|2021-01-14|BEFORE|2021-01-29
e|RS|8effbbff-acda-4718-89f1-e30a418f6bae|7|NEWLIND|New Lesion Indicator|KEAM BREAST CANCER 2013|[?]|mmHg*min/L|PD FROM PR|1|APL U|SPIROMETRY||Y||FRIEND|MICROSCOPIST 1|U|4|Visit_4|65|5|TREATMENT|2020-12-31|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-30|P1Y2M10DT2H30M|COINCIDENT|2020-10-31|BEFORE|2020-12-29
e|RS|8effbbff-acda-4718-89f1-e30a418f6bae|8|ANATRESP|Anatomic Response|AJCC V8|[?]|Coulomb|HI-N|1|TRANSDUCING UNIT/mL|EIA||||SIBLING|READER 3|N|4|Visit_4|65|6|WASHOUT|2020-12-31|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-30|P1Y2M10DT2H30M|BEFORE|2020-12-09|ONGOING|2021-01-12
e|RS|8effbbff-acda-4718-89f1-e30a418f6bae|9|NTRGRESP|Non-target Response|BURCOMBE BREAST CANCER 2005|[?]|log10 TCID 50/mL|CA125 50% RESPONSE|1|/MBP|DYNAMIC LIGHT SCATTERING||||SIGNIFICANT OTHER|UROLOGIST|U|5|Visit_5|90|1|FOLLOW-UP|2021-01-25|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-22|P1Y2M10DT2H30M|COINCIDENT|2021-01-10|AFTER|2021-01-24
e|RS|8effbbff-acda-4718-89f1-e30a418f6bae|10|MJPTHIND|Major Pathological Response Indicator|PCWG SCHER PROSTATE CANCER 2008|[?]|cmHg|NON-iCR/NON-iUPD|1|mEq/mL|MAPH||||STUDY SUBJECT|RADIOLOGIST 1|N|5|Visit_5|90|7|FOLLOW-UP|2021-01-25|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-22|P1Y2M10DT2H30M|COINCIDENT|2020-11-18|ONGOING|2020-12-12
e|RS|859b16a5-f6a2-40cc-8e01-18c112b1969e|1|HEMARESP|Hematologic Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|dpm/mL|RELAPSED DISEASE|1|uEq/L|FLUORESCENT LIFETIME IMAGING MICROSCOPY||Y||PARENT|READER 1|U|1|Visit_1|10|6|TREATMENT|2020-08-18|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-22|P1Y2M10DT2H30M|BEFORE|2020-08-15|COINCIDENT|2020-10-17
e|RS|859b16a5-f6a2-40cc-8e01-18c112b1969e|2|HEMARESP|Hematologic Response|PRINCE TCELL LYMPHOMA 2010|[?]|10^5/hpf|IMPROVED|1|Gy|PEAK FLOWMETRY|Y|Y||HEALTH CARE PROFESSIONAL|UROLOGIST|N|1|Visit_1|10|6|TREATMENT|2020-08-18|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-22|P1Y2M10DT2H30M|AFTER|2020-11-13|BEFORE|2020-11-15
e|RS|859b16a5-f6a2-40cc-8e01-18c112b1969e|3|MJPTHIND|Major Pathological Response Indicator|BURCOMBE BREAST CANCER 2005|[?]|mCi/L|UNFAVORABLE RESPONSE|1|mmol|X-RAY FLUORESCENCE SPECTROMETRY||||ADJUDICATOR|ONCOLOGIST|NA|2|Visit_2|25|3|TREATMENT|2020-09-02|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-10|P1Y2M10DT2H30M|AFTER|2020-10-18|COINCIDENT|2020-11-04
e|RS|859b16a5-f6a2-40cc-8e01-18c112b1969e|4|METSIND|Metastatic Indicator|SHINDOH COLORECTAL CANCER 2013|[?]|ug/g/h|SMD|1|uL/kg/day|CONTRAST ENHANCED PET/CT SCAN||Y||STUDY SUBJECT|PHYSIOTHERAPIST|N|2|Visit_2|25|6|TREATMENT|2020-09-02|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-10|P1Y2M10DT2H30M|COINCIDENT|2020-10-04|BEFORE|2020-10-15
e|RS|859b16a5-f6a2-40cc-8e01-18c112b1969e|5|MNPTHIND|Minor Pathological Response Indicator|CHESON MALIGNANT LYMPHOMA 2007|||NON-QUANTIFIABLE MRD POSITIVITY|1|10^3 RNA copies/mL|AUDIOMETRY|Y||Y|ADJUDICATION COMMITTEE|OTOLARYNGOLOGIST|NA|3|Visit_3|40|5|SCREENING|2020-09-17|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-22|P1Y2M10DT2H30M|BEFORE|2020-09-18|ONGOING|2020-11-07
e|RS|859b16a5-f6a2-40cc-8e01-18c112b1969e|6|HEMARESP|Hematologic Response|RANO ELLINGSON 2017|||PR WITH LYMPHOCYTOSIS|1|U/g/day|WHOLE TRANSCRIPTOME SEQUENCING|||Y|PROXY|MICROSCOPIST 3|N|3|Visit_3|40|2|TREATMENT|2020-09-17|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-22|P1Y2M10DT2H30M|COINCIDENT|2020-11-01|BEFORE|2020-11-10
e|RS|859b16a5-f6a2-40cc-8e01-18c112b1969e|7|ANATRESP|Anatomic Response|EBMT BLADE MYELOMA 1998|[?]|dmol|PMR|1|cpm|ULTRASONOGRAPHIC ELASTOGRAPHY|Y|Y||INTERVIEWER|OTOLARYNGOLOGIST|NA|4|Visit_4|65|6|TREATMENT|2020-10-12|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-29|P1Y2M10DT2H30M|BEFORE|2020-11-15|ONGOING|2020-11-16
e|RS|859b16a5-f6a2-40cc-8e01-18c112b1969e|8|OVRLRESP|Overall Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|||RELAPSED DISEASE|1|Ci/mL|POLYGRAPHY|||Y|ADJUDICATOR|NEUROLOGIST 1|NA|4|Visit_4|65|5|WASHOUT|2020-10-12|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-29|P1Y2M10DT2H30M|COINCIDENT|2020-10-10|BEFORE|2020-10-19
e|RS|859b16a5-f6a2-40cc-8e01-18c112b1969e|9|SFTSRESP|Soft Tissue Response|HARTMANN GERM CELL CANCER 2002|||MAJOR PATHOLOGIC RESPONSE|1|cL|ACID FAST STAIN|||Y|CAREGIVER|ADJUDICATOR 3|Y|5|Visit_5|90|4|TREATMENT|2020-11-06|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-26|P1Y2M10DT2H30M|AFTER|2020-10-26|COINCIDENT|2020-11-01
e|RS|859b16a5-f6a2-40cc-8e01-18c112b1969e|10|NTNERESP|Non-Target Non-Enhancing Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|||CA125 50% RESPONSE|1|TCID 50/dose|CALIPER MEASUREMENT METHOD|||Y|INDEPENDENT ASSESSOR|ONCOLOGIST 1|NA|5|Visit_5|90|7|TREATMENT|2020-11-06|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-26|P1Y2M10DT2H30M|COINCIDENT|2020-09-28|ONGOING|2020-09-30
e|RS|36b457ef-4cf6-4043-a836-49368ebf3f1c|1|MRDIND|Minimal Residual Disease Indicator|MRECIST LENCIONI LIVER CANCER 2010|[?]|MET*h|CRi|1|in2|AGAR PROPORTION|Y|Y||ADJUDICATION COMMITTEE|PATHOLOGIST 2|U|1|Visit_1|10|1|SCREENING|2020-08-16|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-25|P1Y2M10DT2H30M|UNKNOWN|2020-09-22|ONGOING|2020-10-15
e|RS|36b457ef-4cf6-4043-a836-49368ebf3f1c|2|NTRGRESP|Non-target Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|mCi/kg|CYTOGENETIC NO RESPONSE|1|ug/m2/h|IMMUNOCHROMATOGRAPHY||Y||ADJUDICATION COMMITTEE|HEMATOLOGIST|NA|1|Visit_1|10|7|FOLLOW-UP|2020-08-16|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-25|P1Y2M10DT2H30M|COINCIDENT|2020-09-23|AFTER|2020-11-02
e|RS|36b457ef-4cf6-4043-a836-49368ebf3f1c|3|CYTORESP|Cytogenetic Response|MRECIST BYRNE MESOTHELIOMA 2004|||MOLECULAR CR|1|TRANSDUCING UNIT/mL|MS/MS||Y|Y|ADJUDICATOR|RADIOLOGIST 2|Y|2|Visit_2|25|5|SCREENING|2020-08-31|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-19|P1Y2M10DT2H30M|AFTER|2020-10-25|ONGOING|2020-11-07
e|RS|36b457ef-4cf6-4043-a836-49368ebf3f1c|4|MRDIND|Minimal Residual Disease Indicator|BURCOMBE BREAST CANCER 2005|[?]|sec|CYTOGENETIC MINIMAL RESPONSE|1|ng/dL|PERFUSION MRI||||SPOUSE|ADJUDICATOR 1|N|2|Visit_2|25|6|SCREENING|2020-08-31|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-19|P1Y2M10DT2H30M|UNKNOWN|2020-08-20|AFTER|2020-10-29
e|RS|36b457ef-4cf6-4043-a836-49368ebf3f1c|5|DRCRIND|Disease Recurrence Indicator|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|umol/L/min|PDu|1|kcal|KARYOTYPING||Y||PROXY|PATHOLOGIST|U|3|Visit_3|40|4|TREATMENT|2020-09-15|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-07|P1Y2M10DT2H30M|BEFORE|2020-11-08|AFTER|2020-11-10
e|RS|36b457ef-4cf6-4043-a836-49368ebf3f1c|6|NTNERESP|Non-Target Non-Enhancing Response|RAJKUMAR MYELOMA 2011|[?]|10^3 CFU|SMD|1|fL|SMEAR||||CHILD|PATHOLOGIST 1|N|3|Visit_3|40|1|FOLLOW-UP|2020-09-15|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-07|P1Y2M10DT2H30M|AFTER|2020-10-17|ONGOING|2020-11-10
e|RS|36b457ef-4cf6-4043-a836-49368ebf3f1c|7|METBRESP|Metabolic Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|10^8 PFU|NOT ALL EVALUATED|1|ft|SPECULAR MICROSCOPY||||VENDOR|RATER|N|4|Visit_4|65|6|TREATMENT|2020-10-10|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-09|P1Y2M10DT2H30M|UNKNOWN|2020-10-15|AFTER|2020-10-27
e|RS|36b457ef-4cf6-4043-a836-49368ebf3f1c|8|DRCRIND|Disease Recurrence Indicator|GCIG RUSTIN OVARIAN CANCER 2011|[?]|mph|PD/RELAPSE AFTER HI|1|psi|MICROBIAL CONCENTRATION||||GUARDIAN|READER 2|Y|4|Visit_4|65|5|TREATMENT|2020-10-10|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-09|P1Y2M10DT2H30M|BEFORE|2020-08-24|ONGOING|2020-09-21
e|RS|36b457ef-4cf6-4043-a836-49368ebf3f1c|9|SYMPTDTR|Symptomatic Deterioration|CHOLLET BREAST CANCER 2002|[?]|mL/min/mmHg|CYTOGENETIC PR|1|/200 HPFs|FISH||||INTERVIEWER|READER 3|Y|5|Visit_5|90|7|TREATMENT|2020-11-04|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-29|P1Y2M10DT2H30M|COINCIDENT|2020-11-11|COINCIDENT|2020-11-12
e|RS|36b457ef-4cf6-4043-a836-49368ebf3f1c|10|SYMPTDTR|Symptomatic Deterioration|CHESON LYMPHOMA 2008|[?]|RFU|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|RNA copies/mL|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE|Y|||SIBLING|OPHTHALMOLOGIST|N|5|Visit_5|90|2|FOLLOW-UP|2020-11-04|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-29|P1Y2M10DT2H30M|AFTER|2020-08-26|COINCIDENT|2020-10-22
e|RS|31f33e38-bba6-4c8a-b563-14afaabae5d7|1|MOLRESP|Molecular Response|BURCOMBE BREAST CANCER 2005|[?]|ug/g/h|iPR|1|%/s|FISH||||CLINICAL RESEARCH COORDINATOR|RADIOLOGIST|N|1|Visit_1|10|1|FOLLOW-UP|2020-07-01|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-05|P1Y2M10DT2H30M|AFTER|2020-07-17|ONGOING|2020-09-01
e|RS|31f33e38-bba6-4c8a-b563-14afaabae5d7|2|MRDRESP|Minimal Residual Disease Response|RECICL|||DISEASE TRANSFORMATION|1|log10 TCID 50/mL|HPLC/IEX|Y||Y|GUARDIAN|PATHOLOGIST 1|Y|1|Visit_1|10|4|FOLLOW-UP|2020-07-01|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-05|P1Y2M10DT2H30M|UNKNOWN|2020-07-28|BEFORE|2020-09-01
e|RS|31f33e38-bba6-4c8a-b563-14afaabae5d7|3|BESTRESP|Best Overall Response|KUKER LYMPHOMA 2005|||MRD NEGATIVITY|1|CONTAINER|HEMAGGLUTINATION ASSAY|Y||Y|CHILD|RATER|NA|2|Visit_2|25|6|WASHOUT|2020-07-16|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-30|P1Y2M10DT2H30M|BEFORE|2020-08-11|COINCIDENT|2020-09-28
e|RS|31f33e38-bba6-4c8a-b563-14afaabae5d7|4|NEWLIND|New Lesion Indicator|MACDONALD GLIOMA 1990|||FAVORABLE RESPONSE|1|umol/mg/min|CONTACT SPECULAR MICROSCOPY|||Y|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|NA|2|Visit_2|25|7|WASHOUT|2020-07-16|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-30|P1Y2M10DT2H30M|COINCIDENT|2020-09-26|COINCIDENT|2020-09-27
e|RS|31f33e38-bba6-4c8a-b563-14afaabae5d7|5|DRCRIND|Disease Recurrence Indicator|GUILHOT CML 2007|[?]|Sv|COMPLETE MRD RESPONSE|1|kHz|QUANTITATIVE ULTRASOUND||||FAMILY MEMBER|INTERNIST|NA|3|Visit_3|40|4|TREATMENT|2020-07-31|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-11|P1Y2M10DT2H30M|COINCIDENT|2020-08-02|AFTER|2020-09-05
e|RS|31f33e38-bba6-4c8a-b563-14afaabae5d7|6|TRGRESP|Target Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|EU|MAJOR PATHOLOGIC RESPONSE|1|ft2|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS||Y||FAMILY MEMBER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|3|Visit_3|40|4|SCREENING|2020-07-31|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-11|P1Y2M10DT2H30M|AFTER|2020-09-23|AFTER|2020-09-26
e|RS|31f33e38-bba6-4c8a-b563-14afaabae5d7|7|RDIORESP|Radiologic Response|BLAZER COLORECTAL CANCER 2008|[?]|/kg|DECREASED|1|bel|LIGHT SCATTERING SPECTROSCOPY|Y|Y||SIBLING|DEVELOPMENTAL PSYCHOLOGIST|N|4|Visit_4|65|2|FOLLOW-UP|2020-08-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-22|P1Y2M10DT2H30M|AFTER|2020-06-28|COINCIDENT|2020-07-17
e|RS|31f33e38-bba6-4c8a-b563-14afaabae5d7|8|SPLNRESP|Spleen Response|BURCOMBE BREAST CANCER 2005|[?]|mEq/ug|DECREASED|1|Pa|SINGLE-MOLECULE ARRAY||||STUDY SUBJECT|OTOLARYNGOLOGIST|U|4|Visit_4|65|1|WASHOUT|2020-08-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-22|P1Y2M10DT2H30M|BEFORE|2020-07-15|BEFORE|2020-08-21
e|RS|31f33e38-bba6-4c8a-b563-14afaabae5d7|9|HEMARESP|Hematologic Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|/mm2|CYTOGENETIC PR|1|h*%|REVERSE TRANSCRIPTASE PCR|Y|||ADJUDICATION COMMITTEE|PATHOLOGIST 1|Y|5|Visit_5|90|2|WASHOUT|2020-09-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-26|P1Y2M10DT2H30M|UNKNOWN|2020-06-25|COINCIDENT|2020-08-25
e|RS|31f33e38-bba6-4c8a-b563-14afaabae5d7|10|TRGRESP|Target Response|KUKER LYMPHOMA 2005|[?]|g/L|NED|1|CCID 50/mL|WHOLE GENOME SEQUENCING||||CLINICAL STUDY SPONSOR|MICROSCOPIST|NA|5|Visit_5|90|3|TREATMENT|2020-09-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-26|P1Y2M10DT2H30M|AFTER|2020-08-18|COINCIDENT|2020-09-21
e|RS|6794dffe-333b-425b-8883-26f6e5ba0797|1|STRUSTAT|Steroid Use Status|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|dyn|CYTOGENETIC PR|1|cg|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN|Y|||NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|U|1|Visit_1|10|7|TREATMENT|2020-07-09|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-29|P1Y2M10DT2H30M|BEFORE|2020-10-03|BEFORE|2020-10-06
e|RS|6794dffe-333b-425b-8883-26f6e5ba0797|2|STRUSTAT|Steroid Use Status|CHESON MALIGNANT LYMPHOMA 2007|||NON-CR/NON-PD|1|mEq/g|IMMUNORADIOMETRIC ASSAY||Y|Y|HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|Y|1|Visit_1|10|5|WASHOUT|2020-07-09|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-29|P1Y2M10DT2H30M|COINCIDENT|2020-07-31|AFTER|2020-10-03
e|RS|6794dffe-333b-425b-8883-26f6e5ba0797|3|PATHRESP|Pathologic Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|mEq/mmol|MRD NEGATIVITY|1|DNA copies/ug|QUANTITATIVE PERIPHERAL ANGIOGRAPHY|Y|||FRIEND|CLINICAL PATHOLOGIST|N|2|Visit_2|25|6|TREATMENT|2020-07-24|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-23|P1Y2M10DT2H30M|AFTER|2020-10-01|ONGOING|2020-10-02
e|RS|6794dffe-333b-425b-8883-26f6e5ba0797|4|MOLRESP|Molecular Response|DURIE MULTIPLE MYELOMA 2006|[?]|Tbsp|SMD|1|Coulomb|APPLANATION TONOMETRY||||ADJUDICATOR|NEUROLOGIST|U|2|Visit_2|25|1|WASHOUT|2020-07-24|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-23|P1Y2M10DT2H30M|BEFORE|2020-09-04|AFTER|2020-10-02
e|RS|6794dffe-333b-425b-8883-26f6e5ba0797|5|PATHRESP|Pathologic Response|NCIWG CHESON CLL 1996|||MORPHOLOGIC CR|1|dmol|BALLPOINT PEN TECHNIQUE|||Y|INVESTIGATOR|PATHOLOGIST|U|3|Visit_3|40|7|FOLLOW-UP|2020-08-08|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-08|P1Y2M10DT2H30M|AFTER|2020-08-03|COINCIDENT|2020-08-12
e|RS|6794dffe-333b-425b-8883-26f6e5ba0797|6|MRDIND|Minimal Residual Disease Indicator|LUGANO CLASSIFICATION|[?]|L/h/m2|IMPROVED|1|mU|ULTRASONOGRAPHIC ELASTOGRAPHY||Y||CLINICAL RESEARCH COORDINATOR|READER 3|NA|3|Visit_3|40|7|WASHOUT|2020-08-08|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-08|P1Y2M10DT2H30M|UNKNOWN|2020-09-04|COINCIDENT|2020-09-14
e|RS|6794dffe-333b-425b-8883-26f6e5ba0797|7|NEWLWIND|New Lesion Worsening Indicator|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|VIAL|NOT ALL EVALUATED|1|10^12 IU/L|TEST STRIP||Y||CLINICAL RESEARCH ASSOCIATE|RATER|U|4|Visit_4|65|2|SCREENING|2020-09-02|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-12|P1Y2M10DT2H30M|AFTER|2020-08-01|BEFORE|2020-09-18
e|RS|6794dffe-333b-425b-8883-26f6e5ba0797|8|NTRGRESP|Non-target Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|mm|FAVORABLE RESPONSE|1|ug/mL/h|COULOMETRIC TITRATION|Y|||ADJUDICATION COMMITTEE|READER 3|Y|4|Visit_4|65|5|FOLLOW-UP|2020-09-02|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-12|P1Y2M10DT2H30M|COINCIDENT|2020-09-21|BEFORE|2020-09-29
e|RS|6794dffe-333b-425b-8883-26f6e5ba0797|9|NEWLPROG|New Lesion Progression|CHOI GIST 2008|[?]|dyn|CR-CT|1|/10^3|ACCELERATOR MASS SPECTROMETRY|Y|||DOMESTIC PARTNER|ENDOCRINOLOGIST|N|5|Visit_5|90|6|SCREENING|2020-09-27|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-09|P1Y2M10DT2H30M|UNKNOWN|2020-08-12|AFTER|2020-09-27
e|RS|6794dffe-333b-425b-8883-26f6e5ba0797|10|NEWLIND|New Lesion Indicator|GUILHOT CML 2007|[?]|ng|SMD|1|cP|CINEANGIOGRAPHY||||STUDY SUBJECT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5|Visit_5|90|3|TREATMENT|2020-09-27|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-09|P1Y2M10DT2H30M|BEFORE|2020-09-11|AFTER|2020-09-24
e|RS|d7d9a12d-6bb1-44a2-a008-6a5bae013d40|1|BMIVLIND|Bone Marrow Involvement Indicator|RECICL|[?]|PIXEL|CRi|1|nkat|LC-FL||||STUDY SUBJECT|READER 1|U|1|Visit_1|10|6|TREATMENT|2020-06-07|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-20|P1Y2M10DT2H30M|COINCIDENT|2020-08-11|BEFORE|2020-08-27
e|RS|d7d9a12d-6bb1-44a2-a008-6a5bae013d40|2|DRCRIND|Disease Recurrence Indicator|MRECIST BYRNE MESOTHELIOMA 2004|[?]|10^3 organisms/mL|PR WITH LYMPHOCYTOSIS|1|mg/m2/day|AURAMINE STAIN||||PARENT|PATHOLOGIST 1|U|1|Visit_1|10|6|WASHOUT|2020-06-07|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-20|P1Y2M10DT2H30M|UNKNOWN|2020-07-31|BEFORE|2020-08-18
e|RS|d7d9a12d-6bb1-44a2-a008-6a5bae013d40|3|MOLRESP|Molecular Response|HARTMAN PANCREATIC CANCER 2012|[?]|ug/g/day|CR|1|ug/kg|AGAR DILUTION|Y|||SIGNIFICANT OTHER|NEUROLOGIST|Y|2|Visit_2|25|7|SCREENING|2020-06-22|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-22|P1Y2M10DT2H30M|BEFORE|2020-08-25|BEFORE|2020-08-26
e|RS|d7d9a12d-6bb1-44a2-a008-6a5bae013d40|4|RDIORESP|Radiologic Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|BISCUIT|iCR|1|nmol/L/min|ELECTRONEUROGRAPHY||Y||SIBLING|READER 2|N|2|Visit_2|25|4|FOLLOW-UP|2020-06-22|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-22|P1Y2M10DT2H30M|BEFORE|2020-07-18|AFTER|2020-08-03
e|RS|d7d9a12d-6bb1-44a2-a008-6a5bae013d40|5|NTLWIND|Non-Target Lesion Worsening Indicator|WHO BREAST CANCER 2006|[?]|fL|MRD NEGATIVITY|1|in|INFRARED SPECTROMETRY||||STUDY SUBJECT|DERMATOLOGIST|Y|3|Visit_3|40|6|TREATMENT|2020-07-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-06|P1Y2M10DT2H30M|BEFORE|2020-08-05|ONGOING|2020-08-18
e|RS|d7d9a12d-6bb1-44a2-a008-6a5bae013d40|6|BONERESP|Bone Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|kg/L|cPR|1|Osm|CENTRIFUGATION||Y||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|N|3|Visit_3|40|4|TREATMENT|2020-07-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-06|P1Y2M10DT2H30M|AFTER|2020-07-29|COINCIDENT|2020-08-09
e|RS|d7d9a12d-6bb1-44a2-a008-6a5bae013d40|7|NTLWIND|Non-Target Lesion Worsening Indicator|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|POUCH|TREATMENT FAILURE|1|mL/dL|FLAME PHOTOMETRY||||PROXY|RADIOLOGIST|U|4|Visit_4|65|6|SCREENING|2020-08-01|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-18|P1Y2M10DT2H30M|UNKNOWN|2020-07-06|COINCIDENT|2020-07-14
e|RS|d7d9a12d-6bb1-44a2-a008-6a5bae013d40|8|LIVRRESP|Liver Response|SCHWARZ CERVICAL CANCER 2009|[?]|ug/mL/h|SD-CT|1|DISK|MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY||||INVESTIGATOR|READER|U|4|Visit_4|65|6|TREATMENT|2020-08-01|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-18|P1Y2M10DT2H30M|AFTER|2020-06-22|COINCIDENT|2020-07-23
e|RS|d7d9a12d-6bb1-44a2-a008-6a5bae013d40|9|CLINRESP|Clinical Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|USP U|nPR|1|AMPULE|IMPULSE OSCILLOMETRY||||VENDOR|RADIOLOGIST 2|N|5|Visit_5|90|6|SCREENING|2020-08-26|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-24|P1Y2M10DT2H30M|UNKNOWN|2020-06-13|AFTER|2020-06-30
e|RS|d7d9a12d-6bb1-44a2-a008-6a5bae013d40|10|NTRGRESP|Non-target Response|MONTSERRAT CLL 1989|[?]|ug/animal|CYTOGENETIC CR|1|mol/mL|MEDIASTINOSCOPY||||CAREGIVER|CARDIOLOGIST|Y|5|Visit_5|90|3|TREATMENT|2020-08-26|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-24|P1Y2M10DT2H30M|UNKNOWN|2020-06-22|BEFORE|2020-08-04
e|RS|45897452-8f5a-458d-9a43-13237460ba48|1|NEWLIND|New Lesion Indicator|SCHWARZ CERVICAL CANCER 2009|[?]|/2500 WBC|MINOR PATHOLOGIC RESPONSE|1|kUSP|TOTAL BODY IRRADIATION|Y|||FRIEND|READER|NA|1|Visit_1|10|3|SCREENING|2020-11-11|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-08|P1Y2M10DT2H30M|UNKNOWN|2021-01-20|AFTER|2021-02-01
e|RS|45897452-8f5a-458d-9a43-13237460ba48|2|MJPTHIND|Major Pathological Response Indicator|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|gpELISA unit/mL|MOLECULAR MAJOR RESPONSE|1|MET|ELECTROMYOGRAPHY||||FAMILY MEMBER|NEUROLOGIST|N|1|Visit_1|10|4|SCREENING|2020-11-11|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-08|P1Y2M10DT2H30M|BEFORE|2020-12-16|ONGOING|2020-12-30
e|RS|45897452-8f5a-458d-9a43-13237460ba48|3|CYTORESP|Cytogenetic Response|BRUGGEMANN MRD 2010|||pCR|1|Bq/g|TRANSVAGINAL ULTRASOUND|||Y|CAREGIVER|READER|Y|2|Visit_2|25|7|SCREENING|2020-11-26|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-19|P1Y2M10DT2H30M|COINCIDENT|2020-11-16|COINCIDENT|2020-12-30
e|RS|45897452-8f5a-458d-9a43-13237460ba48|4|SYMPTDTR|Symptomatic Deterioration|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|||PR WITH LYMPHOCYTOSIS|1|mmol/day|PHOTOMETRY|||Y|DOMESTIC PARTNER|ADJUDICATOR|N|2|Visit_2|25|4|TREATMENT|2020-11-26|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-19|P1Y2M10DT2H30M|UNKNOWN|2021-01-29|BEFORE|2021-02-04
e|RS|45897452-8f5a-458d-9a43-13237460ba48|5|MRPHRESP|Morphologic Response|PERCIST|[?]|MBq|NON-PD|1|Enzyme U/m2|COMPUTERIZED CORNEAL TOPOGRAPHY||Y||SPOUSE|FORENSIC PATHOLOGIST|U|3|Visit_3|40|5|TREATMENT|2020-12-11|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-20|P1Y2M10DT2H30M|COINCIDENT|2021-01-23|COINCIDENT|2021-02-05
e|RS|45897452-8f5a-458d-9a43-13237460ba48|6|SFTSRESP|Soft Tissue Response|CHOI GIST 2008|[?]|%/s|NON-CR/NON-PD|1|pg/cell|SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY|Y|||INDEPENDENT ASSESSOR|OPTOMETRIST|N|3|Visit_3|40|7|TREATMENT|2020-12-11|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-20|P1Y2M10DT2H30M|COINCIDENT|2021-01-08|AFTER|2021-02-02
e|RS|45897452-8f5a-458d-9a43-13237460ba48|7|CPRFSTAT|Clinical Performance Status|KUKER LYMPHOMA 2005|||MRD PERSISTENCE|1|BU|DUCTOGRAPHY|Y||Y|HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|4|Visit_4|65|2|TREATMENT|2021-01-05|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-25|P1Y2M10DT2H30M|BEFORE|2021-01-23|BEFORE|2021-02-05
e|RS|45897452-8f5a-458d-9a43-13237460ba48|8|TRGRESP|Target Response|AJCC V7|[?]|P|PD FROM PR|1|ukat/L|IMMUNOCHROMATOGRAPHY||||FRIEND|ONCOLOGIST 2|NA|4|Visit_4|65|6|WASHOUT|2021-01-05|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-25|P1Y2M10DT2H30M|BEFORE|2020-12-18|COINCIDENT|2021-01-26
e|RS|45897452-8f5a-458d-9a43-13237460ba48|9|STRUSTAT|Steroid Use Status|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|/mm2|RELAPSED DISEASE|1|10^4/L|PHASE CONTRAST MICROSCOPY|Y|||DOMESTIC PARTNER|OPTOMETRIST|N|5|Visit_5|90|1|SCREENING|2021-01-30|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-05|P1Y2M10DT2H30M|BEFORE|2020-11-07|BEFORE|2020-12-26
e|RS|45897452-8f5a-458d-9a43-13237460ba48|10|CLINRESP|Clinical Response|PCWG SCHER PROSTATE CANCER 2008|[?]|BAU/mL|sCR|1|SFC/10^6 PBMC|NUCLEIC ACID SEQUENCING|Y|||ADJUDICATOR|MICROSCOPIST 2|Y|5|Visit_5|90|7|TREATMENT|2021-01-30|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-05|P1Y2M10DT2H30M|BEFORE|2020-12-05|BEFORE|2021-01-19
e|RS|16eb981f-2118-4658-a83f-93d925c410c9|1|BMIVLIND|Bone Marrow Involvement Indicator|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|cmH2O/mL|VGPR|1|L|MALDI-TOF|Y|||PROXY|ADJUDICATOR|N|1|Visit_1|10|7|WASHOUT|2020-12-16|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-15|P1Y2M10DT2H30M|AFTER|2021-01-03|AFTER|2021-02-06
e|RS|16eb981f-2118-4658-a83f-93d925c410c9|2|NTERESP|Non-Target Enhancing Response|PCWG SCHER PROSTATE CANCER 2016|[?]|mCi/kg|NON-PD|1|cup eq|GEL ELECTROPHORESIS||||GUARDIAN|READER 1|NA|1|Visit_1|10|5|TREATMENT|2020-12-16|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-15|P1Y2M10DT2H30M|BEFORE|2021-02-08|AFTER|2021-02-28
e|RS|16eb981f-2118-4658-a83f-93d925c410c9|3|SYMPTDTR|Symptomatic Deterioration|IWG CHESON MDS 2000|[?]|ug/L|NR|1|HEP|TWO-COLOR MICROARRAY||Y||GUARDIAN|ONCOLOGIST|N|2|Visit_2|25|1|TREATMENT|2020-12-31|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-26|P1Y2M10DT2H30M|AFTER|2021-03-02|AFTER|2021-03-09
e|RS|16eb981f-2118-4658-a83f-93d925c410c9|4|CYTORESP|Cytogenetic Response|IWG CHESON AML 2003|[?]|Weber|PSEUDORESPONSE|1|AgU/mL|TWO-COLOR MICROARRAY||||HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|N|2|Visit_2|25|2|FOLLOW-UP|2020-12-31|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-26|P1Y2M10DT2H30M|COINCIDENT|2020-12-20|ONGOING|2021-03-01
e|RS|16eb981f-2118-4658-a83f-93d925c410c9|5|SYMPTDTR|Symptomatic Deterioration|SCHER PROSTATE CANCER 2011|[?]|pkat|INDETERMINATE RESPONSE|1|mg/mL/min|RYAN BLUE STAIN||Y||DOMESTIC PARTNER|OPTOMETRIST|U|3|Visit_3|40|2|WASHOUT|2021-01-15|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-21|P1Y2M10DT2H30M|COINCIDENT|2021-03-06|COINCIDENT|2021-03-07
e|RS|16eb981f-2118-4658-a83f-93d925c410c9|6|MNPTHIND|Minor Pathological Response Indicator|HAMAOKA BREAST CANCER 2010|[?]|mL/animal/day|HI-P|1|Torr|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY||||ADJUDICATOR|PATHOLOGIST 1|Y|3|Visit_3|40|3|TREATMENT|2021-01-15|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-21|P1Y2M10DT2H30M|AFTER|2020-12-31|ONGOING|2021-02-21
e|RS|16eb981f-2118-4658-a83f-93d925c410c9|7|RDIORESP|Radiologic Response|WHO BREAST CANCER 2006|[?]|U/mg|CHR|1|U.CARR|RADIATION DOSIMETRY||||DOMESTIC PARTNER|OPTOMETRIST|Y|4|Visit_4|65|5|WASHOUT|2021-02-09|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-01|P1Y2M10DT2H30M|AFTER|2021-02-01|ONGOING|2021-03-05
e|RS|16eb981f-2118-4658-a83f-93d925c410c9|8|ANATRESP|Anatomic Response|MACDONALD GLIOMA 1990|[?]|keV|RELAPSED DISEASE FROM CR|1|10^9 organisms/g|DYNAMIC LIGHT SCATTERING|Y|||INTERVIEWER|ADJUDICATOR 3|NA|4|Visit_4|65|4|FOLLOW-UP|2021-02-09|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-01|P1Y2M10DT2H30M|COINCIDENT|2021-01-14|COINCIDENT|2021-02-04
e|RS|16eb981f-2118-4658-a83f-93d925c410c9|9|OVRLRESP|Overall Response|IWC HALLEK CLL 2008|||iUPD|1|mmAL|TRANSVAGINAL ULTRASOUND||Y|Y|HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|N|5|Visit_5|90|7|FOLLOW-UP|2021-03-06|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-23|P1Y2M10DT2H30M|UNKNOWN|2021-01-07|COINCIDENT|2021-01-18
e|RS|16eb981f-2118-4658-a83f-93d925c410c9|10|BESTRESP|Best Overall Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|||STABLE|1|BOLUS|BAC ACGH||Y|Y|CAREGIVER|OTOLARYNGOLOGIST|N|5|Visit_5|90|6|SCREENING|2021-03-06|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-23|P1Y2M10DT2H30M|UNKNOWN|2020-12-10|AFTER|2021-02-28
e|RS|3f3ade8a-e27b-4f20-8b4d-69c7bae520c1|1|LIVRRESP|Liver Response|MACDONALD GLIOMA 1990|[?]|mL/dL|IMMUNOPHENOTYPIC CR|1|LB|MANUAL CLOT DETECTION|Y|||ADJUDICATOR|NEUROLOGIST 2|U|1|Visit_1|10|7|TREATMENT|2021-01-11|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-13|P1Y2M10DT2H30M|COINCIDENT|2021-03-02|BEFORE|2021-03-13
e|RS|3f3ade8a-e27b-4f20-8b4d-69c7bae520c1|2|NTRGRESP|Non-target Response|RANO ELLINGSON 2017|[?]|copies/ug|HI-N|1|oz|MAMMOGRAPHY||Y||VENDOR|CLINICAL PATHOLOGIST|NA|1|Visit_1|10|7|TREATMENT|2021-01-11|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-13|P1Y2M10DT2H30M|UNKNOWN|2021-02-07|AFTER|2021-03-07
e|RS|3f3ade8a-e27b-4f20-8b4d-69c7bae520c1|3|NTERESP|Non-Target Enhancing Response|SACT|[?]|ag|ABSENT MORPHOLOGIC RESPONSE|1|umol|SPECTROPHOTOMETRY||||INVESTIGATOR|READER 2|NA|2|Visit_2|25|2|TREATMENT|2021-01-26|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-29|P1Y2M10DT2H30M|AFTER|2021-02-08|COINCIDENT|2021-04-01
e|RS|3f3ade8a-e27b-4f20-8b4d-69c7bae520c1|4|LIVRRESP|Liver Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|COAT|HI-P|1|/ms|MICROSCOPY||||NON-HEALTH CARE PROFESSIONAL|DERMATOLOGIST|NA|2|Visit_2|25|7|SCREENING|2021-01-26|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-29|P1Y2M10DT2H30M|AFTER|2021-01-17|AFTER|2021-01-31
e|RS|3f3ade8a-e27b-4f20-8b4d-69c7bae520c1|5|SPLNRESP|Spleen Response|PCWG SCHER PROSTATE CANCER 2008|[?]|kDa|CA125 75% RESPONSE|1|psec|JAEGER EYE CHART|Y|||INDEPENDENT ASSESSOR|PEDIATRIC NEUROLOGIST|NA|3|Visit_3|40|3|SCREENING|2021-02-10|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-20|P1Y2M10DT2H30M|BEFORE|2021-03-14|AFTER|2021-03-28
e|RS|3f3ade8a-e27b-4f20-8b4d-69c7bae520c1|6|NTERESP|Non-Target Enhancing Response|MONTSERRAT CLL 1989|[?]|IU/kg/h|UNEQUIVOCAL|1|ug/kg/day|CONTRAST ENHANCED MRI|Y|||FRIEND|RADIOLOGIST|NA|3|Visit_3|40|3|SCREENING|2021-02-10|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-20|P1Y2M10DT2H30M|COINCIDENT|2021-04-02|ONGOING|2021-04-10
e|RS|3f3ade8a-e27b-4f20-8b4d-69c7bae520c1|7|MNPTHIND|Minor Pathological Response Indicator|iRECIST|[?]|TROCHE|sCR|1|mAmp|BIOIMPEDANCE SPECTROSCOPY||||VENDOR|MICROSCOPIST 2|N|4|Visit_4|65|4|WASHOUT|2021-03-07|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-13|P1Y2M10DT2H30M|BEFORE|2021-01-25|AFTER|2021-02-27
e|RS|3f3ade8a-e27b-4f20-8b4d-69c7bae520c1|8|SPLNRESP|Spleen Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|nmol/L/h|MORPHOLOGIC CR|1|AU/mL|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION|Y|||FRIEND|NEUROLOGIST 1|N|4|Visit_4|65|7|TREATMENT|2021-03-07|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-13|P1Y2M10DT2H30M|COINCIDENT|2021-02-05|COINCIDENT|2021-02-11
e|RS|3f3ade8a-e27b-4f20-8b4d-69c7bae520c1|9|METBRESP|Metabolic Response|RANO|[?]|P|sCR|1|10^3 CFU|GC/MS/MS|Y|||SIGNIFICANT OTHER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|5|Visit_5|90|4|TREATMENT|2021-04-01|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-25|P1Y2M10DT2H30M|BEFORE|2021-03-31|AFTER|2021-04-03
e|RS|3f3ade8a-e27b-4f20-8b4d-69c7bae520c1|10|BONERESP|Bone Response|AJCC V8|[?]|uL/dose|NON-QUANTIFIABLE MRD POSITIVITY|1|10^9/dose|TRANSCRIPTION-MEDIATED AMPLIFICATION||||CHILD|UROLOGIST|NA|5|Visit_5|90|2|FOLLOW-UP|2021-04-01|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-25|P1Y2M10DT2H30M|COINCIDENT|2021-02-28|AFTER|2021-03-30
e|RS|d99a6a66-accf-4a8e-b696-b6d5b4ce249c|1|NEWLPROG|New Lesion Progression|MRANO VAN DEN BENT GLIOMA 2011|[?]|RFU|COMPLETE MRD RESPONSE|1|nmol BCE/nmol|ACID FAST STAIN||||STUDY SUBJECT|PEDIATRIC NEUROLOGIST|U|1|Visit_1|10|4|TREATMENT|2021-01-29|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-23|P1Y2M10DT2H30M|COINCIDENT|2021-03-18|BEFORE|2021-04-19
e|RS|d99a6a66-accf-4a8e-b696-b6d5b4ce249c|2|NEWLIND|New Lesion Indicator|MRECIST LENCIONI LIVER CANCER 2010|||PD/RELAPSE AFTER HI|1|nU/cL|NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY|Y||Y|CLINICAL RESEARCH ASSOCIATE|RATER|N|1|Visit_1|10|3|SCREENING|2021-01-29|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-23|P1Y2M10DT2H30M|COINCIDENT|2021-02-28|AFTER|2021-03-20
e|RS|d99a6a66-accf-4a8e-b696-b6d5b4ce249c|3|OVRLRESP|Overall Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|10^7 TCID 50/dose|MAJOR PATHOLOGIC RESPONSE|1|10^6 IU/mL|TRANSTHORACIC ECHOCARDIOGRAPHY||Y||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|Y|2|Visit_2|25|6|TREATMENT|2021-02-13|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-01|P1Y2M10DT2H30M|UNKNOWN|2021-03-18|BEFORE|2021-04-13
e|RS|d99a6a66-accf-4a8e-b696-b6d5b4ce249c|4|OVRLRESP|Overall Response|iRECIST|[?]|PA|COMPLETE MRD RESPONSE|1|ug/L/h|ULTRASONOGRAPHIC ELASTOGRAPHY|Y|Y||INDEPENDENT ASSESSOR|PHYSIOTHERAPIST|NA|2|Visit_2|25|3|TREATMENT|2021-02-13|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-01|P1Y2M10DT2H30M|AFTER|2021-03-21|COINCIDENT|2021-04-12
e|RS|d99a6a66-accf-4a8e-b696-b6d5b4ce249c|5|BONERESP|Bone Response|LEE LUNG CANCER 2011|||MOLECULAR MAJOR RESPONSE|1|VIRTUAL PIXEL|PALPATION|||Y|INVESTIGATOR|READER 2|N|3|Visit_3|40|2|FOLLOW-UP|2021-02-28|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-20|P1Y2M10DT2H30M|AFTER|2021-02-04|AFTER|2021-03-30
e|RS|d99a6a66-accf-4a8e-b696-b6d5b4ce249c|6|BONERESP|Bone Response|IWG CHESON MDS 2006|||CYTOGENETIC NO RESPONSE|1|EVENTS|GC/MS-EI|||Y|FRIEND|NEUROLOGIST 1|Y|3|Visit_3|40|4|TREATMENT|2021-02-28|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-20|P1Y2M10DT2H30M|UNKNOWN|2021-03-19|COINCIDENT|2021-03-29
e|RS|d99a6a66-accf-4a8e-b696-b6d5b4ce249c|7|DRCRIND|Disease Recurrence Indicator|HARTMANN GERM CELL CANCER 2002|[?]|pg/dL|PMD|1|g/cage/wk|MICRONEUTRALIZATION ASSAY|Y|||INTERVIEWER|PATHOLOGIST 1|U|4|Visit_4|65|7|SCREENING|2021-03-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-24|P1Y2M10DT2H30M|AFTER|2021-04-01|BEFORE|2021-04-26
e|RS|d99a6a66-accf-4a8e-b696-b6d5b4ce249c|8|ANATRESP|Anatomic Response|MASS|[?]|pg/cell|sCR|1|mm/min|ELASTOGRAPHY|Y|||STUDY SUBJECT|DEVELOPMENTAL PSYCHOLOGIST|U|4|Visit_4|65|4|WASHOUT|2021-03-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-24|P1Y2M10DT2H30M|COINCIDENT|2021-04-02|ONGOING|2021-04-20
e|RS|d99a6a66-accf-4a8e-b696-b6d5b4ce249c|9|NTERESP|Non-Target Enhancing Response|CHOI GIST 2008|[?]|Hz/s|PR WITH LYMPHOCYTOSIS|1|mEq/g|FLAME PHOTOMETRY||||CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 2|NA|5|Visit_5|90|2|FOLLOW-UP|2021-04-19|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-26|P1Y2M10DT2H30M|AFTER|2021-04-07|ONGOING|2021-04-12
e|RS|d99a6a66-accf-4a8e-b696-b6d5b4ce249c|10|MRPHRESP|Morphologic Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|U/g/h|MR|1|mg/kg/week|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION||Y||FRIEND|HEMATOLOGIST|Y|5|Visit_5|90|3|FOLLOW-UP|2021-04-19|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-26|P1Y2M10DT2H30M|UNKNOWN|2021-03-03|COINCIDENT|2021-04-04
e|RS|874f491c-5d55-4738-86b7-b1200b16d106|1|OVRLRESP|Overall Response|HARTMAN PANCREATIC CANCER 2012|[?]|g/kg/day|iCR|1|mL/cage/wk|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|Y|||INTERVIEWER|CLINICAL PATHOLOGIST|N|1|Visit_1|10|7|TREATMENT|2021-01-08|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-31|P1Y2M10DT2H30M|BEFORE|2021-01-10|COINCIDENT|2021-03-13
e|RS|874f491c-5d55-4738-86b7-b1200b16d106|2|NTNERESP|Non-Target Non-Enhancing Response|FAROOQUI SUPP CLL 2014|[?]|mL/kg/day|UNFAVORABLE RESPONSE|1|U/kg/day|SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|Y|Y||PARENT|MICROSCOPIST 2|Y|1|Visit_1|10|1|TREATMENT|2021-01-08|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-31|P1Y2M10DT2H30M|UNKNOWN|2021-03-02|COINCIDENT|2021-03-09
e|RS|874f491c-5d55-4738-86b7-b1200b16d106|3|METBRESP|Metabolic Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|Enzyme U|WORSENED|1|pptr|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY||||FRIEND|PATHOLOGIST 2|N|2|Visit_2|25|5|TREATMENT|2021-01-23|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-03|P1Y2M10DT2H30M|AFTER|2021-02-15|AFTER|2021-03-28
e|RS|874f491c-5d55-4738-86b7-b1200b16d106|4|METSIND|Metastatic Indicator|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|ng|sCR|1|kBq/uL|ALCIAN BLUE STAIN||||CHILD|FORENSIC PATHOLOGIST|NA|2|Visit_2|25|2|FOLLOW-UP|2021-01-23|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-03|P1Y2M10DT2H30M|UNKNOWN|2021-01-08|BEFORE|2021-02-26
e|RS|874f491c-5d55-4738-86b7-b1200b16d106|5|TRGRESP|Target Response|CHOI GIST 2008|[?]|Antibody Unit|UNEQUIVOCAL|1|mEq/ug|PHASE CONTRAST MICROSCOPY||||FRIEND|PATHOLOGIST 1|NA|3|Visit_3|40|6|FOLLOW-UP|2021-02-07|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-29|P1Y2M10DT2H30M|COINCIDENT|2020-12-31|AFTER|2021-01-04
e|RS|874f491c-5d55-4738-86b7-b1200b16d106|6|MRPHRESP|Morphologic Response|PRINCE TCELL LYMPHOMA 2010|||OPTIMAL MORPHOLOGIC RESPONSE|1|Pa|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY|Y|Y|Y|CHILD|ADJUDICATOR 2|Y|3|Visit_3|40|4|WASHOUT|2021-02-07|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-29|P1Y2M10DT2H30M|COINCIDENT|2021-01-20|AFTER|2021-02-19
e|RS|874f491c-5d55-4738-86b7-b1200b16d106|7|OVRLRESP|Overall Response|BRUGGEMANN MRD 2010|[?]|tuberculin unit/mL|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|uU/dL|COMPUTERIZED CORNEAL TOPOGRAPHY||Y||CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 3|U|4|Visit_4|65|6|FOLLOW-UP|2021-03-04|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-12|P1Y2M10DT2H30M|AFTER|2021-01-02|COINCIDENT|2021-03-31
e|RS|874f491c-5d55-4738-86b7-b1200b16d106|8|MRPHRESP|Morphologic Response|RAJKUMAR MYELOMA 2011|[?]|CAPFUL|TREATMENT FAILURE|1|BOX|DOPPLER ULTRASOUND||||GUARDIAN|DERMATOLOGIST|N|4|Visit_4|65|6|TREATMENT|2021-03-04|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-12|P1Y2M10DT2H30M|UNKNOWN|2021-01-25|COINCIDENT|2021-03-03
e|RS|874f491c-5d55-4738-86b7-b1200b16d106|9|NEWLIND|New Lesion Indicator|LUGANO CLASSIFICATION|||CR|1|10^9 CFU|HEMATOXYLIN AND EOSIN STAIN|||Y|INDEPENDENT ASSESSOR|READER 1|N|5|Visit_5|90|3|TREATMENT|2021-03-29|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-23|P1Y2M10DT2H30M|UNKNOWN|2021-03-06|AFTER|2021-03-22
e|RS|874f491c-5d55-4738-86b7-b1200b16d106|10|MOLRESP|Molecular Response|AJCC V8|[?]|fraction of 1|sCR|1|/month|HIGH RESOLUTION CT||||PARENT|DERMATOLOGIST|U|5|Visit_5|90|7|SCREENING|2021-03-29|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-23|P1Y2M10DT2H30M|COINCIDENT|2021-03-17|COINCIDENT|2021-03-19
e|RS|281ccdef-794c-49ad-9616-6f6f68dd4543|1|METBRESP|Metabolic Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|IU/mL|HI-N|1|CCID 50/dose|ICC|Y|||GUARDIAN|PATHOLOGIST 1|Y|1|Visit_1|10|6|TREATMENT|2020-06-04|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-03|P1Y2M10DT2H30M|AFTER|2020-06-01|BEFORE|2020-09-01
e|RS|281ccdef-794c-49ad-9616-6f6f68dd4543|2|NTRGRESP|Non-target Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|10^3 CFU/g|UNEQUIVOCAL|1|Absorbance U/min|PERFUSION MRI||||STUDY SUBJECT|FORENSIC PATHOLOGIST|N|1|Visit_1|10|4|WASHOUT|2020-06-04|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-03|P1Y2M10DT2H30M|BEFORE|2020-07-16|BEFORE|2020-08-09
e|RS|281ccdef-794c-49ad-9616-6f6f68dd4543|3|SPLNRESP|Spleen Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|10^3 organisms/mL|CA125 75% RESPONSE|1|AU/mL|KNEMOMETRY||||CLINICAL STUDY SPONSOR|MICROSCOPIST 2|Y|2|Visit_2|25|5|FOLLOW-UP|2020-06-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-05|P1Y2M10DT2H30M|COINCIDENT|2020-08-11|BEFORE|2020-08-24
e|RS|281ccdef-794c-49ad-9616-6f6f68dd4543|4|MRDIND|Minimal Residual Disease Indicator|JACINTO CERVICAL CANCER 2007|[?]|Absorbance U/mL|FAVORABLE RESPONSE|1|/100 WBC|DUCTOGRAPHY||||HEALTH CARE PROFESSIONAL|RATER 1|N|2|Visit_2|25|4|FOLLOW-UP|2020-06-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-05|P1Y2M10DT2H30M|COINCIDENT|2020-08-12|COINCIDENT|2020-08-30
e|RS|281ccdef-794c-49ad-9616-6f6f68dd4543|5|BONERESP|Bone Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|days/month|PR|1|cmol/L|POLYGRAPHY|Y|||FRIEND|RATER 2|U|3|Visit_3|40|2|FOLLOW-UP|2020-07-04|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-15|P1Y2M10DT2H30M|BEFORE|2020-05-30|BEFORE|2020-07-20
e|RS|281ccdef-794c-49ad-9616-6f6f68dd4543|6|MJPTHIND|Major Pathological Response Indicator|NCIWG CHESON CLL 1996|[?]|log10 CCID 50/dose|INDETERMINATE RESPONSE|1|Coulomb|CONFOCAL MICROSCOPY|Y|||CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST|Y|3|Visit_3|40|3|WASHOUT|2020-07-04|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-15|P1Y2M10DT2H30M|UNKNOWN|2020-07-11|BEFORE|2020-08-15
e|RS|281ccdef-794c-49ad-9616-6f6f68dd4543|7|CLINRESP|Clinical Response|PROTOCOL DEFINED RESPONSE CRITERIA|||RELAPSED DISEASE FROM CR OR PR|1|ukat/10^12 RBC|FLUORESCENT LIFETIME IMAGING MICROSCOPY|Y||Y|GUARDIAN|ENDOCRINOLOGIST|U|4|Visit_4|65|5|TREATMENT|2020-07-29|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-20|P1Y2M10DT2H30M|BEFORE|2020-07-26|ONGOING|2020-08-17
e|RS|281ccdef-794c-49ad-9616-6f6f68dd4543|8|SPLNRESP|Spleen Response|CHOLLET BREAST CANCER 2002|||OPTIMAL MORPHOLOGIC RESPONSE|1|10^3 CFU|DROPLET DIGITAL PCR|||Y|ADJUDICATOR|PATHOLOGIST|NA|4|Visit_4|65|7|SCREENING|2020-07-29|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-20|P1Y2M10DT2H30M|BEFORE|2020-07-05|BEFORE|2020-07-13
e|RS|281ccdef-794c-49ad-9616-6f6f68dd4543|9|MJPTHIND|Major Pathological Response Indicator|IWC HALLEK CLL 2008|[?]|mL/min|IMMUNOPHENOTYPIC CR|1|mmHg/sec|INTERRUPTER TECHNIQUE||||CLINICAL STUDY SPONSOR|NEUROLOGIST 2|N|5|Visit_5|90|3|TREATMENT|2020-08-23|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-23|P1Y2M10DT2H30M|BEFORE|2020-08-19|COINCIDENT|2020-08-25
e|RS|281ccdef-794c-49ad-9616-6f6f68dd4543|10|PATHRESP|Pathologic Response|MASS|||TREATMENT FAILURE|1|MASK|CAPILLARY ELECTROPHORESIS||Y|Y|ADJUDICATION COMMITTEE|RATER 1|N|5|Visit_5|90|1|TREATMENT|2020-08-23|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-23|P1Y2M10DT2H30M|BEFORE|2020-06-03|COINCIDENT|2020-08-10
e|RS|b1179e10-e8fe-472c-a511-d6d460571857|1|SFTSRESP|Soft Tissue Response|HAMAOKA BREAST CANCER 2010|||iCPD|1|mJoule/cm2|SCANNING ELECTRON MICROSCOPY||Y|Y|FAMILY MEMBER|RADIOLOGIST 1|NA|1|Visit_1|10|2|TREATMENT|2020-08-02|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-26|P1Y2M10DT2H30M|AFTER|2020-09-01|ONGOING|2020-10-26
e|RS|b1179e10-e8fe-472c-a511-d6d460571857|2|PATHRESP|Pathologic Response|KEAM BREAST CANCER 2013|||STABLE|1|L/h/m2|CALCULATION|||Y|DOMESTIC PARTNER|ADJUDICATOR 3|Y|1|Visit_1|10|3|SCREENING|2020-08-02|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-26|P1Y2M10DT2H30M|UNKNOWN|2020-09-23|COINCIDENT|2020-10-29
e|RS|b1179e10-e8fe-472c-a511-d6d460571857|3|TMRESP|Tumor Marker Response|JACINTO CERVICAL CANCER 2007|[?]|mol/L|PMR|1|mL/kg/h|JAEGER EYE CHART||||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 2|U|2|Visit_2|25|7|TREATMENT|2020-08-17|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-22|P1Y2M10DT2H30M|UNKNOWN|2020-08-24|AFTER|2020-09-03
e|RS|b1179e10-e8fe-472c-a511-d6d460571857|4|LIVRRESP|Liver Response|MURPHY PROSTATE CANCER 1980|[?]|BLOCKS|PD/RELAPSE AFTER HI|1|psec|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY|Y|Y||INVESTIGATOR|INTERNIST|NA|2|Visit_2|25|4|WASHOUT|2020-08-17|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-22|P1Y2M10DT2H30M|UNKNOWN|2020-09-10|AFTER|2020-10-21
e|RS|b1179e10-e8fe-472c-a511-d6d460571857|5|DRCRIND|Disease Recurrence Indicator|HARTMAN PANCREATIC CANCER 2012|||WORSENED|1|mCi/kg|IMMUNOCHROMATOGRAPHY|Y||Y|INVESTIGATOR|PHYSIOTHERAPIST|NA|3|Visit_3|40|4|TREATMENT|2020-09-01|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-31|P1Y2M10DT2H30M|UNKNOWN|2020-07-26|BEFORE|2020-10-04
e|RS|b1179e10-e8fe-472c-a511-d6d460571857|6|STRUSTAT|Steroid Use Status|PCWG SCHER PROSTATE CANCER 2016|[?]|umol/h/mmol|HI-P|1|mg/kg/h|BRDU CELLULAR PROLIFERATION ASSAY||||PROXY|ONCOLOGIST|NA|3|Visit_3|40|5|TREATMENT|2020-09-01|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-31|P1Y2M10DT2H30M|BEFORE|2020-08-13|AFTER|2020-10-14
e|RS|b1179e10-e8fe-472c-a511-d6d460571857|7|BMIVLIND|Bone Marrow Involvement Indicator|CHESON LYMPHOMA 2008|[?]|mL/g/min|MORPHOLOGIC CR|1|mL/cm H2O|NUCLEIC ACID BASED METHOD|Y|||INTERVIEWER|RADIOLOGIST 1|NA|4|Visit_4|65|2|WASHOUT|2020-09-26|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-24|P1Y2M10DT2H30M|UNKNOWN|2020-10-13|AFTER|2020-10-15
e|RS|b1179e10-e8fe-472c-a511-d6d460571857|8|METBRESP|Metabolic Response|IRANO 2015|||PR|1|10^6 CFU|HEMATOXYLIN AND EOSIN STAIN|||Y|INVESTIGATOR|CARDIOLOGIST|NA|4|Visit_4|65|1|TREATMENT|2020-09-26|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-24|P1Y2M10DT2H30M|AFTER|2020-07-25|ONGOING|2020-10-27
e|RS|b1179e10-e8fe-472c-a511-d6d460571857|9|MRPHRESP|Morphologic Response|LEE LUNG CANCER 2011|[?]|C|HI-E|1|CONTAINER|DYNAMIC CONTRAST ENHANCED MRI|Y|||FRIEND|MICROSCOPIST|N|5|Visit_5|90|1|FOLLOW-UP|2020-10-21|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-19|P1Y2M10DT2H30M|BEFORE|2020-09-29|AFTER|2020-10-29
e|RS|b1179e10-e8fe-472c-a511-d6d460571857|10|BMIVLIND|Bone Marrow Involvement Indicator|IWG CHESON AML 2003|||RELAPSED DISEASE|1|BOTTLE|OPHTHALMOSCOPY|Y|Y|Y|DOMESTIC PARTNER|ONCOLOGIST|NA|5|Visit_5|90|2|TREATMENT|2020-10-21|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-19|P1Y2M10DT2H30M|COINCIDENT|2020-10-13|ONGOING|2020-10-25
e|RS|6362cf42-f286-4151-bdf7-38fcc5639eed|1|RDIORESP|Radiologic Response|CHESON CLL 2012|||MRD NEGATIVITY|1|kBq/uL|NON-INVASIVE DIELECTRIC SENSING|Y|Y|Y|PARENT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|1|Visit_1|10|7|TREATMENT|2020-09-07|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-24|P1Y2M10DT2H30M|COINCIDENT|2020-11-25|ONGOING|2020-12-02
e|RS|6362cf42-f286-4151-bdf7-38fcc5639eed|2|MNPTHIND|Minor Pathological Response Indicator|RANO|[?]|Mile|COMPLETE MRD RESPONSE|1|MPS U|MS/MS|Y|||CLINICAL STUDY SPONSOR|DEVELOPMENTAL PSYCHOLOGIST|N|1|Visit_1|10|7|FOLLOW-UP|2020-09-07|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-24|P1Y2M10DT2H30M|UNKNOWN|2020-11-06|BEFORE|2020-11-29
e|RS|6362cf42-f286-4151-bdf7-38fcc5639eed|3|TMRESP|Tumor Marker Response|RECICL|[?]|um2|cCR|1|um/s|TURBIDIMETRY|Y|Y||DOMESTIC PARTNER|NEUROLOGIST 1|NA|2|Visit_2|25|5|TREATMENT|2020-09-22|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-08|P1Y2M10DT2H30M|UNKNOWN|2020-10-23|ONGOING|2020-11-22
e|RS|6362cf42-f286-4151-bdf7-38fcc5639eed|4|NTLWIND|Non-Target Lesion Worsening Indicator|IWG CHESON MDS 2006|||MORPHOLOGIC CRi|1|psec|ACRIDINE ORANGE STAIN|||Y|SIBLING|MICROSCOPIST|N|2|Visit_2|25|1|SCREENING|2020-09-22|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-08|P1Y2M10DT2H30M|AFTER|2020-09-25|ONGOING|2020-09-26
e|RS|6362cf42-f286-4151-bdf7-38fcc5639eed|5|NEWLIND|New Lesion Indicator|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|||MINOR PATHOLOGIC RESPONSE|1|mL/mmHg|MULTI-SLICE SPIRAL CT|||Y|CHILD|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|3|Visit_3|40|3|TREATMENT|2020-10-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-08|P1Y2M10DT2H30M|AFTER|2020-09-06|COINCIDENT|2020-11-29
e|RS|6362cf42-f286-4151-bdf7-38fcc5639eed|6|MNPTHIND|Minor Pathological Response Indicator|DURIE MULTIPLE MYELOMA 2006|[?]|mV|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|Absorbance U/min|INFRARED SPECTROMETRY|Y|||CLINICAL RESEARCH COORDINATOR|HEMATOLOGIST|Y|3|Visit_3|40|4|TREATMENT|2020-10-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-08|P1Y2M10DT2H30M|AFTER|2020-10-21|ONGOING|2020-12-05
e|RS|6362cf42-f286-4151-bdf7-38fcc5639eed|7|CPRFSTAT|Clinical Performance Status|LEE LUNG CANCER 2011|[?]|Gy/min|EQUIVOCAL|1|kBq/uL|DIFFUSION WEIGHTED MRI||||CLINICAL STUDY SPONSOR|RATER|U|4|Visit_4|65|7|WASHOUT|2020-11-01|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-05|P1Y2M10DT2H30M|UNKNOWN|2020-11-03|COINCIDENT|2020-11-25
e|RS|6362cf42-f286-4151-bdf7-38fcc5639eed|8|SFTSRESP|Soft Tissue Response|MONTSERRAT CLL 1989|[?]|Enzyme U|UNEQUIVOCAL|1|TABLET|IMMUNOTURBIDIMETRY||||ADJUDICATOR|ENDOCRINOLOGIST|U|4|Visit_4|65|6|TREATMENT|2020-11-01|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-05|P1Y2M10DT2H30M|COINCIDENT|2020-11-15|BEFORE|2020-12-02
e|RS|6362cf42-f286-4151-bdf7-38fcc5639eed|9|DRCRIND|Disease Recurrence Indicator|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|10^6/g|CA125 75% RESPONSE|1|DAYS|ENZYMATIC COLORIMETRY||||HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|5|Visit_5|90|6|TREATMENT|2020-11-26|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-13|P1Y2M10DT2H30M|BEFORE|2020-09-27|COINCIDENT|2020-10-14
e|RS|6362cf42-f286-4151-bdf7-38fcc5639eed|10|MNPTHIND|Minor Pathological Response Indicator|GCIG RUSTIN OVARIAN CANCER 2011|[?]|YEARS|TREATMENT FAILURE|1|10^11/L|MYELOPEROXIDASE STAIN|Y|||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST|U|5|Visit_5|90|5|WASHOUT|2020-11-26|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-13|P1Y2M10DT2H30M|UNKNOWN|2020-09-16|ONGOING|2020-11-14
e|RS|8e28e3ab-0060-43f7-b033-c16bd77c0e29|1|METBRESP|Metabolic Response|RECIST 1.1|[?]|vp/dose|MOLECULAR CR|1|BOTTLE|IRON HEMATOXYLIN STAIN||||INVESTIGATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|1|Visit_1|10|7|FOLLOW-UP|2020-11-30|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-22|P1Y2M10DT2H30M|BEFORE|2021-01-07|COINCIDENT|2021-01-27
e|RS|8e28e3ab-0060-43f7-b033-c16bd77c0e29|2|PATHRESP|Pathologic Response|WOLCHOK SOLID TUMORS 2009|[?]|CFU/mL|MRD NEGATIVITY|1|uIU/dL|ANTIMICROBIAL COMBINATION TESTING||||INTERVIEWER|DERMATOLOGIST|N|1|Visit_1|10|6|TREATMENT|2020-11-30|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-22|P1Y2M10DT2H30M|AFTER|2020-12-27|AFTER|2021-01-15
e|RS|8e28e3ab-0060-43f7-b033-c16bd77c0e29|3|MJPTHIND|Major Pathological Response Indicator|IWG CHESON MDS 2006|[?]|DNA copies/mL|CR-CT|1|10^11/L|WEBER GREEN STAIN||||HEALTH CARE PROFESSIONAL|RATER|Y|2|Visit_2|25|4|FOLLOW-UP|2020-12-15|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-22|P1Y2M10DT2H30M|AFTER|2021-01-14|AFTER|2021-01-23
e|RS|8e28e3ab-0060-43f7-b033-c16bd77c0e29|4|RDIORESP|Radiologic Response|LEE LUNG CANCER 2011|[?]|mEq/dL|mCR|1|g/cage/wk|FORCED OSCILLATION TECHNIQUE||||NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST|NA|2|Visit_2|25|2|TREATMENT|2020-12-15|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-22|P1Y2M10DT2H30M|BEFORE|2021-01-18|AFTER|2021-02-24
e|RS|8e28e3ab-0060-43f7-b033-c16bd77c0e29|5|METSIND|Metastatic Indicator|UNSPECIFIED|[?]|/VF|NON-PD|1|/ms|REBOUND TONOMETRY|Y|||ADJUDICATOR|HEMATOLOGIST|U|3|Visit_3|40|5|TREATMENT|2020-12-30|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-07|P1Y2M10DT2H30M|BEFORE|2021-02-13|ONGOING|2021-02-19
e|RS|8e28e3ab-0060-43f7-b033-c16bd77c0e29|6|MRDRESP|Minimal Residual Disease Response|RECIST 1.0|[?]|mOsm/L|HI-E|1|VIAL|ENZYMATIC COLORIMETRY||||CLINICAL STUDY SPONSOR|OTOLARYNGOLOGIST|Y|3|Visit_3|40|3|SCREENING|2020-12-30|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-07|P1Y2M10DT2H30M|UNKNOWN|2020-11-23|AFTER|2021-02-24
e|RS|8e28e3ab-0060-43f7-b033-c16bd77c0e29|7|MRPHRESP|Morphologic Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|||cPR|1|mN|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN|||Y|SIBLING|READER 1|NA|4|Visit_4|65|2|FOLLOW-UP|2021-01-24|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-29|P1Y2M10DT2H30M|BEFORE|2020-11-23|AFTER|2020-12-25
e|RS|8e28e3ab-0060-43f7-b033-c16bd77c0e29|8|LIVRRESP|Liver Response|SCHWARZ CERVICAL CANCER 2009|[?]|HEP|VGPR|1|mm/h|PLETHYSMOGRAPHY||||SIBLING|NEUROLOGIST 1|Y|4|Visit_4|65|2|SCREENING|2021-01-24|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-29|P1Y2M10DT2H30M|UNKNOWN|2021-01-08|COINCIDENT|2021-01-13
e|RS|8e28e3ab-0060-43f7-b033-c16bd77c0e29|9|NEWLPROG|New Lesion Progression|LUGANO CLASSIFICATION|[?]|U/g/h|MORPHOLOGIC LEUKEMIA-FREE STATE|1|mm/sec|MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY||||GUARDIAN|DERMATOLOGIST|Y|5|Visit_5|90|6|TREATMENT|2021-02-18|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-07|P1Y2M10DT2H30M|BEFORE|2020-12-09|COINCIDENT|2020-12-16
e|RS|8e28e3ab-0060-43f7-b033-c16bd77c0e29|10|OVRLRESP|Overall Response|MONTSERRAT CLL 1989|||CYTOGENETIC NO RESPONSE|1|nmol/kg/day|TARGETED GENOME SEQUENCING|||Y|SIGNIFICANT OTHER|RADIOLOGIST 1|N|5|Visit_5|90|3|TREATMENT|2021-02-18|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-07|P1Y2M10DT2H30M|COINCIDENT|2020-12-16|BEFORE|2021-01-24
e|RS|d0f0a002-b5cd-468a-98ff-e0eeaa5969e7|1|DRCRIND|Disease Recurrence Indicator|KEAM BREAST CANCER 2013|||PMD|1|g/kg|THIN SMEAR||Y|Y|INVESTIGATOR|READER 3|Y|1|Visit_1|10|4|TREATMENT|2020-06-27|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-30|P1Y2M10DT2H30M|BEFORE|2020-09-22|ONGOING|2020-09-23
e|RS|d0f0a002-b5cd-468a-98ff-e0eeaa5969e7|2|BMIVLIND|Bone Marrow Involvement Indicator|NCCN ALL MRD 2014|[?]|PACKET|RELAPSED DISEASE FROM CR|1|STEPS|SXA SCAN||Y||INVESTIGATOR|MICROSCOPIST 3|NA|1|Visit_1|10|1|SCREENING|2020-06-27|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-30|P1Y2M10DT2H30M|AFTER|2020-07-21|AFTER|2020-08-25
e|RS|d0f0a002-b5cd-468a-98ff-e0eeaa5969e7|3|DRCRIND|Disease Recurrence Indicator|MRANO VAN DEN BENT GLIOMA 2011|[?]|GBq|STABLE|1|cycle/min|CONFOCAL MICROSCOPY||||FRIEND|READER|U|2|Visit_2|25|7|TREATMENT|2020-07-12|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-30|P1Y2M10DT2H30M|AFTER|2020-09-03|COINCIDENT|2020-09-17
e|RS|d0f0a002-b5cd-468a-98ff-e0eeaa5969e7|4|MNPTHIND|Minor Pathological Response Indicator|HARTMANN GERM CELL CANCER 2002|[?]|PFU/dose|OPTIMAL MORPHOLOGIC RESPONSE|1|mL/cage/wk|SLOAN LETTER EYE CHART 100%|Y|||INDEPENDENT ASSESSOR|RATER|U|2|Visit_2|25|2|TREATMENT|2020-07-12|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-30|P1Y2M10DT2H30M|BEFORE|2020-07-27|BEFORE|2020-08-08
e|RS|d0f0a002-b5cd-468a-98ff-e0eeaa5969e7|5|DRCRIND|Disease Recurrence Indicator|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|mL/mmHg/min/L|PARTIAL MORPHOLOGIC RESPONSE|1|umol/L/h|MODIFIED ACID FAST STAIN||Y||PARENT|PATHOLOGIST 2|Y|3|Visit_3|40|4|WASHOUT|2020-07-27|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-20|P1Y2M10DT2H30M|AFTER|2020-09-05|ONGOING|2020-09-24
e|RS|d0f0a002-b5cd-468a-98ff-e0eeaa5969e7|6|METSIND|Metastatic Indicator|NCIWG CHESON CLL 1996|[?]|mg/day|CR|1|mg/m2|PLETHYSMOGRAPHY||Y||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 3|U|3|Visit_3|40|3|TREATMENT|2020-07-27|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-20|P1Y2M10DT2H30M|COINCIDENT|2020-08-14|ONGOING|2020-09-22
e|RS|d0f0a002-b5cd-468a-98ff-e0eeaa5969e7|7|STRUSTAT|Steroid Use Status|IWG CHESON MDS 2000|[?]|mmHg/sec|PR-CT|1|dpm/0.5 mL|OPTICAL MAPPING||||PARENT|PATHOLOGIST|Y|4|Visit_4|65|5|FOLLOW-UP|2020-08-21|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-28|P1Y2M10DT2H30M|AFTER|2020-06-29|ONGOING|2020-07-10
e|RS|d0f0a002-b5cd-468a-98ff-e0eeaa5969e7|8|METBRESP|Metabolic Response|UNSPECIFIED|[?]|mmol/mol|PDu|1|MBq/uL|ELECTROPHORESIS|Y|||FAMILY MEMBER|MICROSCOPIST 1|U|4|Visit_4|65|1|SCREENING|2020-08-21|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-28|P1Y2M10DT2H30M|BEFORE|2020-09-09|AFTER|2020-09-19
e|RS|d0f0a002-b5cd-468a-98ff-e0eeaa5969e7|9|TMRESP|Tumor Marker Response|iRECIST|||HI-E|1|ft3|APPLANATION TONOMETRY||Y|Y|ADJUDICATION COMMITTEE|READER|Y|5|Visit_5|90|1|TREATMENT|2020-09-15|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-07|P1Y2M10DT2H30M|BEFORE|2020-06-28|COINCIDENT|2020-07-14
e|RS|d0f0a002-b5cd-468a-98ff-e0eeaa5969e7|10|MJPTHIND|Major Pathological Response Indicator|IWG CHESON AML 2003|[?]|nmol|INCREASED|1|U/10^12 RBC|MULTIPLEXED BEAD BASED IMMUNOASSAY|Y|||CLINICAL RESEARCH ASSOCIATE|OPHTHALMOLOGIST|NA|5|Visit_5|90|1|SCREENING|2020-09-15|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-07|P1Y2M10DT2H30M|AFTER|2020-06-29|ONGOING|2020-07-04
e|RS|0c1fcd0e-847b-4bf1-82c1-5d749742cc5b|1|METSIND|Metastatic Indicator|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|g/kg|INDETERMINATE RESPONSE|1|mL/dose|CALCOFLUOR WHITE STAIN|Y|Y||INTERVIEWER|NEUROLOGIST 2|Y|1|Visit_1|10|1|SCREENING|2020-06-22|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-06|P1Y2M10DT2H30M|BEFORE|2020-08-26|COINCIDENT|2020-09-02
e|RS|0c1fcd0e-847b-4bf1-82c1-5d749742cc5b|2|DRCRIND|Disease Recurrence Indicator|CHESON CLL 2006|[?]|mEq/g|SMD|1|ms2|MRI||Y||CAREGIVER|CARDIOLOGIST|NA|1|Visit_1|10|6|FOLLOW-UP|2020-06-22|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-06|P1Y2M10DT2H30M|BEFORE|2020-08-18|COINCIDENT|2020-09-17
e|RS|0c1fcd0e-847b-4bf1-82c1-5d749742cc5b|3|TRGRESP|Target Response|HAMAOKA BREAST CANCER 2010|[?]|U/g|INCREASED|1|mL/cage|SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY|Y|||CHILD|PATHOLOGIST 1|NA|2|Visit_2|25|4|TREATMENT|2020-07-07|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-29|P1Y2M10DT2H30M|BEFORE|2020-09-06|ONGOING|2020-09-13
e|RS|0c1fcd0e-847b-4bf1-82c1-5d749742cc5b|4|NTNERESP|Non-Target Non-Enhancing Response|IWC HALLEK CLL 2008|||CYTOGENETIC NO RESPONSE|1|10^6 IU/mL|ARTERIAL SPIN LABELING FUNCTIONAL MRI||Y|Y|HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|U|2|Visit_2|25|2|TREATMENT|2020-07-07|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-29|P1Y2M10DT2H30M|COINCIDENT|2020-09-11|COINCIDENT|2020-09-16
e|RS|0c1fcd0e-847b-4bf1-82c1-5d749742cc5b|5|MRPHRESP|Morphologic Response|IWG CHESON AML 2003|[?]|IU/L|iCPD|1|MESF|CHROMOGENIC ASSAY||||CLINICAL RESEARCH ASSOCIATE|READER 3|N|3|Visit_3|40|2|SCREENING|2020-07-22|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-13|P1Y2M10DT2H30M|BEFORE|2020-08-20|BEFORE|2020-09-08
e|RS|0c1fcd0e-847b-4bf1-82c1-5d749742cc5b|6|METBRESP|Metabolic Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|||NED|1|copies/mL|CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|||Y|FAMILY MEMBER|RATER 2|NA|3|Visit_3|40|1|SCREENING|2020-07-22|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-13|P1Y2M10DT2H30M|UNKNOWN|2020-07-16|ONGOING|2020-09-01
e|RS|0c1fcd0e-847b-4bf1-82c1-5d749742cc5b|7|BONERESP|Bone Response|LEE LUNG CANCER 2011|[?]|mL/cm|PSEUDOPROGRESSION|1|uIU/dL|NEXT GENERATION SEQUENCING||||SIBLING|NEUROLOGIST 2|U|4|Visit_4|65|1|TREATMENT|2020-08-16|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-08|P1Y2M10DT2H30M|AFTER|2020-08-30|COINCIDENT|2020-09-03
e|RS|0c1fcd0e-847b-4bf1-82c1-5d749742cc5b|8|NTLWIND|Non-Target Lesion Worsening Indicator|PCWG SCHER PROSTATE CANCER 2008|[?]|BAG|PSA PROGRESSION|1|mEq/ug|SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY||||FRIEND|PEDIATRIC NEUROLOGIST|U|4|Visit_4|65|2|FOLLOW-UP|2020-08-16|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-08|P1Y2M10DT2H30M|UNKNOWN|2020-07-19|COINCIDENT|2020-08-21
e|RS|0c1fcd0e-847b-4bf1-82c1-5d749742cc5b|9|SYMPTDTR|Symptomatic Deterioration|UNSPECIFIED|[?]|dL|PD/RELAPSE AFTER HI|1|mL/s|NON-INVASIVE DIELECTRIC SENSING||Y||PROXY|CLINICAL PATHOLOGIST|N|5|Visit_5|90|5|TREATMENT|2020-09-10|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-17|P1Y2M10DT2H30M|AFTER|2020-08-19|AFTER|2020-09-11
e|RS|0c1fcd0e-847b-4bf1-82c1-5d749742cc5b|10|MJPTHIND|Major Pathological Response Indicator|SACT|[?]|m/sec|PR|1|hr/day|SLOAN LETTER EYE CHART 2.5%||||FRIEND|READER 2|U|5|Visit_5|90|4|TREATMENT|2020-09-10|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-17|P1Y2M10DT2H30M|BEFORE|2020-08-01|AFTER|2020-09-14
e|RS|43880587-c397-402d-886b-9b666e3fe455|1|MRDRESP|Minimal Residual Disease Response|RANO ELLINGSON 2017|||SD-CT|1|/LSQN|ETDRS EYE CHART|Y||Y|FRIEND|ADJUDICATOR|Y|1|Visit_1|10|4|FOLLOW-UP|2020-07-21|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-20|P1Y2M10DT2H30M|UNKNOWN|2020-09-29|COINCIDENT|2020-10-16
e|RS|43880587-c397-402d-886b-9b666e3fe455|2|HEMARESP|Hematologic Response|CHESON CLL 2006|[?]|ug/g/min|FAVORABLE RESPONSE|1|/HPF|TOTAL BODY RADIOGRAPHY||||CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL PSYCHOLOGIST|N|1|Visit_1|10|3|TREATMENT|2020-07-21|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-20|P1Y2M10DT2H30M|COINCIDENT|2020-07-21|AFTER|2020-09-03
e|RS|43880587-c397-402d-886b-9b666e3fe455|3|CYTORESP|Cytogenetic Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|nCi|CA125 75% RESPONSE|1|RNA copies/mL|HPLC/IEX||Y||SIBLING|READER 3|U|2|Visit_2|25|2|SCREENING|2020-08-05|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-13|P1Y2M10DT2H30M|AFTER|2020-10-18|COINCIDENT|2020-10-19
e|RS|43880587-c397-402d-886b-9b666e3fe455|4|BONERESP|Bone Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|ug/kg|nPR|1|kUSP|ANTIMICROBIAL COMBINATION TESTING||||ADJUDICATOR|ENDOCRINOLOGIST|U|2|Visit_2|25|5|WASHOUT|2020-08-05|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-13|P1Y2M10DT2H30M|UNKNOWN|2020-07-26|COINCIDENT|2020-07-29
e|RS|43880587-c397-402d-886b-9b666e3fe455|5|SPLNRESP|Spleen Response|RECIST 1.1|[?]|Arbitrary U|CYTOGENETIC MINOR RESPONSE|1|PIXELS/cm|HIGH RESOLUTION CT|Y|||FAMILY MEMBER|UROLOGIST|N|3|Visit_3|40|3|FOLLOW-UP|2020-08-20|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-26|P1Y2M10DT2H30M|COINCIDENT|2020-09-09|COINCIDENT|2020-10-02
e|RS|43880587-c397-402d-886b-9b666e3fe455|6|MNPTHIND|Minor Pathological Response Indicator|MURPHY PROSTATE CANCER 1980|[?]|Osm|MRD PERSISTENCE|1|genEq|LISSAMINE GREEN STAIN|Y|Y||VENDOR|READER|Y|3|Visit_3|40|1|TREATMENT|2020-08-20|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-26|P1Y2M10DT2H30M|AFTER|2020-08-29|AFTER|2020-09-26
e|RS|43880587-c397-402d-886b-9b666e3fe455|7|NEWLPROG|New Lesion Progression|SHINDOH COLORECTAL CANCER 2013|[?]|PACKAGE|SD-CT|1|mL/min/mmHg|MANUAL CLOT DETECTION|Y|||GUARDIAN|PATHOLOGIST 2|U|4|Visit_4|65|4|SCREENING|2020-09-14|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-21|P1Y2M10DT2H30M|COINCIDENT|2020-08-08|BEFORE|2020-08-28
e|RS|43880587-c397-402d-886b-9b666e3fe455|8|MRPHRESP|Morphologic Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|cL|sCR|1|PIXELS/cm|SISH||||SIBLING|OPHTHALMOLOGIST|U|4|Visit_4|65|7|TREATMENT|2020-09-14|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-21|P1Y2M10DT2H30M|UNKNOWN|2020-08-04|COINCIDENT|2020-10-14
e|RS|43880587-c397-402d-886b-9b666e3fe455|9|NTLWIND|Non-Target Lesion Worsening Indicator|PERCIST|[?]|U/mmol|CYTOGENETIC PR|1|APPLICATION|JAFFE REACTION||||DOMESTIC PARTNER|READER 1|NA|5|Visit_5|90|6|WASHOUT|2020-10-09|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-08|P1Y2M10DT2H30M|COINCIDENT|2020-09-01|ONGOING|2020-10-02
e|RS|43880587-c397-402d-886b-9b666e3fe455|10|SYMPTDTR|Symptomatic Deterioration|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|mol/mL|CYTOGENETIC PR|1|U/g/h|SLOAN LETTER EYE CHART 100%||||PARENT|ONCOLOGIST 2|NA|5|Visit_5|90|3|FOLLOW-UP|2020-10-09|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-08|P1Y2M10DT2H30M|COINCIDENT|2020-10-03|COINCIDENT|2020-10-10
e|RS|807f83d2-9364-4ee4-855d-304f3e252555|1|LIVRRESP|Liver Response|iRECIST|[?]|OD Unit|NON-QUANTIFIABLE MRD POSITIVITY|1|VOXEL|NUCLEIC ACID HYBRIDIZATION|Y|||FRIEND|DEVELOPMENTAL PSYCHOLOGIST|U|1|Visit_1|10|5|SCREENING|2020-05-14|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-28|P1Y2M10DT2H30M|UNKNOWN|2020-06-24|BEFORE|2020-07-14
e|RS|807f83d2-9364-4ee4-855d-304f3e252555|2|BESTRESP|Best Overall Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|||WORSENED|1|BOX|PERFUSION MRI|||Y|DOMESTIC PARTNER|RADIOLOGIST|U|1|Visit_1|10|3|FOLLOW-UP|2020-05-14|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-28|P1Y2M10DT2H30M|AFTER|2020-06-12|AFTER|2020-06-21
e|RS|807f83d2-9364-4ee4-855d-304f3e252555|3|STRUSTAT|Steroid Use Status|IWG CHESON MDS 2006|[?]|mJoule/cm2|MORPHOLOGIC CRi|1|PRESSOR UNITS|REAL-TIME POLYMERASE CHAIN REACTION ASSAY||||STUDY SUBJECT|PATHOLOGIST 1|NA|2|Visit_2|25|2|FOLLOW-UP|2020-05-29|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-30|P1Y2M10DT2H30M|COINCIDENT|2020-07-11|AFTER|2020-07-14
e|RS|807f83d2-9364-4ee4-855d-304f3e252555|4|NEWLWIND|New Lesion Worsening Indicator|PCWG BUBLEY PROSTATE CANCER 1999|[?]|Ci|nPR|1|umol/h/mmol|ROMANOWSKY STAIN|Y|Y||CLINICAL RESEARCH COORDINATOR|CLINICAL PATHOLOGIST|NA|2|Visit_2|25|3|TREATMENT|2020-05-29|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-30|P1Y2M10DT2H30M|AFTER|2020-06-21|BEFORE|2020-06-25
e|RS|807f83d2-9364-4ee4-855d-304f3e252555|5|NTRGRESP|Non-target Response|WHO BREAST CANCER 2006|||MORPHOLOGIC LEUKEMIA-FREE STATE|1|mL/cm H2O|AUTOREFRACTION|||Y|CAREGIVER|ENDOCRINOLOGIST|N|3|Visit_3|40|3|WASHOUT|2020-06-13|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-03|P1Y2M10DT2H30M|BEFORE|2020-06-10|COINCIDENT|2020-07-11
e|RS|807f83d2-9364-4ee4-855d-304f3e252555|6|BONERESP|Bone Response|GUILHOT CML 2007|[?]|mL/animal/day|HI-P|1|U/g Hb|FLOCCULATION, CHARCOAL ENHANCED||||INDEPENDENT ASSESSOR|CLINICAL PATHOLOGIST|U|3|Visit_3|40|3|TREATMENT|2020-06-13|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-03|P1Y2M10DT2H30M|AFTER|2020-07-02|BEFORE|2020-07-19
e|RS|807f83d2-9364-4ee4-855d-304f3e252555|7|NTERESP|Non-Target Enhancing Response|MACDONALD GLIOMA 1990|[?]|COAT|NON-QUANTIFIABLE MRD POSITIVITY|1|nsec|FUNDUS PHOTOGRAPHY|Y|||CAREGIVER|PATHOLOGIST 2|U|4|Visit_4|65|3|TREATMENT|2020-07-08|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-30|P1Y2M10DT2H30M|AFTER|2020-05-28|AFTER|2020-07-08
e|RS|807f83d2-9364-4ee4-855d-304f3e252555|8|MRPHRESP|Morphologic Response|IRANO 2015|[?]|cmol|CR|1|mmol/g|MICRODENSITOMETRY||||SPOUSE|OTOLARYNGOLOGIST|N|4|Visit_4|65|1|TREATMENT|2020-07-08|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-30|P1Y2M10DT2H30M|UNKNOWN|2020-06-23|COINCIDENT|2020-07-27
e|RS|807f83d2-9364-4ee4-855d-304f3e252555|9|MNPTHIND|Minor Pathological Response Indicator|PCWG SCHER PROSTATE CANCER 2016|[?]|foz_us|MORPHOLOGIC LEUKEMIA-FREE STATE|1|mV2/Hz|NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY||||FAMILY MEMBER|RADIOLOGIST 1|U|5|Visit_5|90|6|TREATMENT|2020-08-02|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-12|P1Y2M10DT2H30M|UNKNOWN|2020-07-18|BEFORE|2020-08-11
e|RS|807f83d2-9364-4ee4-855d-304f3e252555|10|STRUSTAT|Steroid Use Status|NCCN ALL MRD 2014|||PD-CT|1|mg/L|SANGER SEQUENCING|||Y|INDEPENDENT ASSESSOR|ONCOLOGIST 2|N|5|Visit_5|90|1|FOLLOW-UP|2020-08-02|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-12|P1Y2M10DT2H30M|COINCIDENT|2020-06-09|AFTER|2020-07-01
e|RS|45dd95cd-857f-4cbd-89d7-640a8ed74fd8|1|BESTRESP|Best Overall Response|SACT|[?]|/40 HPFs|cPR|1|nmol BCE/nmol|PHOTOMETRIC CLOT DETECTION||||CLINICAL STUDY SPONSOR|DEVELOPMENTAL PSYCHOLOGIST|U|1|Visit_1|10|5|TREATMENT|2020-12-09|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-26|P1Y2M10DT2H30M|AFTER|2020-12-23|ONGOING|2021-02-10
e|RS|45dd95cd-857f-4cbd-89d7-640a8ed74fd8|2|HEMARESP|Hematologic Response|IWG CHESON MDS 2000|[?]|EP U|MORPHOLOGIC CR|1|mmol|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS||||PARENT|ONCOLOGIST|Y|1|Visit_1|10|4|TREATMENT|2020-12-09|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-26|P1Y2M10DT2H30M|AFTER|2020-12-24|COINCIDENT|2021-01-15
e|RS|45dd95cd-857f-4cbd-89d7-640a8ed74fd8|3|NEWLPROG|New Lesion Progression|PCWG BUBLEY PROSTATE CANCER 1999|||CYTOGENETIC MINIMAL RESPONSE|1|ELISA unit|TRANSMISSION ELECTRON MICROSCOPY|||Y|CHILD|PATHOLOGIST|Y|2|Visit_2|25|5|SCREENING|2020-12-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-02|P1Y2M10DT2H30M|COINCIDENT|2021-01-07|ONGOING|2021-01-23
e|RS|45dd95cd-857f-4cbd-89d7-640a8ed74fd8|4|CPRFSTAT|Clinical Performance Status|CHOLLET BREAST CANCER 2002|[?]|pg/dL|SD-CT|1|cal|SANGER SEQUENCING|Y|Y||INVESTIGATOR|ONCOLOGIST|NA|2|Visit_2|25|7|TREATMENT|2020-12-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-02|P1Y2M10DT2H30M|UNKNOWN|2021-03-05|ONGOING|2021-03-08
e|RS|45dd95cd-857f-4cbd-89d7-640a8ed74fd8|5|TRGRESP|Target Response|HARTMAN PANCREATIC CANCER 2012|[?]|ukat/L|iSD|1|/h|SXA SCAN||Y||FAMILY MEMBER|RATER 2|Y|3|Visit_3|40|6|FOLLOW-UP|2021-01-08|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-16|P1Y2M10DT2H30M|UNKNOWN|2021-02-09|BEFORE|2021-02-27
e|RS|45dd95cd-857f-4cbd-89d7-640a8ed74fd8|6|LIVRRESP|Liver Response|PROTOCOL DEFINED RESPONSE CRITERIA|||PSEUDORESPONSE|1|PIPE|COMPUTERIZED CORNEAL TOPOGRAPHY|||Y|SIBLING|HEMATOLOGIST|NA|3|Visit_3|40|3|TREATMENT|2021-01-08|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-16|P1Y2M10DT2H30M|UNKNOWN|2021-03-05|ONGOING|2021-03-07
e|RS|45dd95cd-857f-4cbd-89d7-640a8ed74fd8|7|SPLNRESP|Spleen Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|mmHg/sec|iCR|1|dpm/mg|SURFACE PLASMON RESONANCE||||SIGNIFICANT OTHER|OPTOMETRIST|U|4|Visit_4|65|7|FOLLOW-UP|2021-02-02|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-20|P1Y2M10DT2H30M|BEFORE|2021-01-15|BEFORE|2021-01-29
e|RS|45dd95cd-857f-4cbd-89d7-640a8ed74fd8|8|NTRGRESP|Non-target Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|||TREATMENT FAILURE|1|ug/L/h|MICRODENSITOMETRY|||Y|INTERVIEWER|ONCOLOGIST 2|NA|4|Visit_4|65|5|TREATMENT|2021-02-02|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-20|P1Y2M10DT2H30M|AFTER|2021-02-16|AFTER|2021-02-25
e|RS|45dd95cd-857f-4cbd-89d7-640a8ed74fd8|9|DRCRIND|Disease Recurrence Indicator|CHESON CLL 2012|[?]|U/kg/h|IMPROVED|1|CIGARETTE|MYELOPEROXIDASE STAIN||||VENDOR|RATER|NA|5|Visit_5|90|1|FOLLOW-UP|2021-02-27|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-27|P1Y2M10DT2H30M|UNKNOWN|2021-03-06|BEFORE|2021-03-08
e|RS|45dd95cd-857f-4cbd-89d7-640a8ed74fd8|10|MNPTHIND|Minor Pathological Response Indicator|MONTSERRAT CLL 1989|||CRi|1|mol/mol|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI|||Y|INTERVIEWER|READER 3|NA|5|Visit_5|90|6|WASHOUT|2021-02-27|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-27|P1Y2M10DT2H30M|UNKNOWN|2021-01-24|COINCIDENT|2021-02-04
e|RS|81c33633-6ade-45fe-a78e-0e853d8aa9c2|1|DRCRIND|Disease Recurrence Indicator|PETIT BREAST CANCER 2001|[?]|mg/dose|FAVORABLE RESPONSE|1|mol/L|REFLECTANCE SPECTROSCOPY||Y||NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|N|1|Visit_1|10|4|TREATMENT|2020-08-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-26|P1Y2M10DT2H30M|AFTER|2020-10-27|ONGOING|2020-11-03
e|RS|81c33633-6ade-45fe-a78e-0e853d8aa9c2|2|NTLWIND|Non-Target Lesion Worsening Indicator|UNSPECIFIED|[?]|kg/L|CHR|1|Bq/uL|GRAM STAIN||Y||INVESTIGATOR|RADIOLOGIST 1|U|1|Visit_1|10|4|TREATMENT|2020-08-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-26|P1Y2M10DT2H30M|COINCIDENT|2020-08-29|COINCIDENT|2020-10-04
e|RS|81c33633-6ade-45fe-a78e-0e853d8aa9c2|3|NTLWIND|Non-Target Lesion Worsening Indicator|MASS|[?]|L/h|NED|1|Mile|ROMANOWSKY STAIN|Y|||CAREGIVER|RADIOLOGIST|N|2|Visit_2|25|1|TREATMENT|2020-08-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-19|P1Y2M10DT2H30M|UNKNOWN|2020-11-04|BEFORE|2020-11-08
e|RS|81c33633-6ade-45fe-a78e-0e853d8aa9c2|4|LIVRRESP|Liver Response|IWG CHESON MDS 2006|||NR|1|IU/dL|NUCLEIC ACID AMPLIFICATION TEST|||Y|PROXY|ENDOCRINOLOGIST|N|2|Visit_2|25|7|SCREENING|2020-08-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-19|P1Y2M10DT2H30M|COINCIDENT|2020-08-14|AFTER|2020-11-11
e|RS|81c33633-6ade-45fe-a78e-0e853d8aa9c2|5|MNPTHIND|Minor Pathological Response Indicator|IWG CHESON AML 2003|[?]|m|PMR|1|ug/kg/h|MACRO BROTH DILUTION||||FRIEND|NEUROLOGIST|NA|3|Visit_3|40|1|FOLLOW-UP|2020-09-14|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-29|P1Y2M10DT2H30M|AFTER|2020-11-12|COINCIDENT|2020-11-13
e|RS|81c33633-6ade-45fe-a78e-0e853d8aa9c2|6|MRDIND|Minimal Residual Disease Indicator|HARTMAN PANCREATIC CANCER 2012|[?]|10^4 CFU|HI-P|1|mg/g/h|GC/MS||||CAREGIVER|PHYSIOTHERAPIST|Y|3|Visit_3|40|7|FOLLOW-UP|2020-09-14|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-29|P1Y2M10DT2H30M|COINCIDENT|2020-10-19|COINCIDENT|2020-10-31
e|RS|81c33633-6ade-45fe-a78e-0e853d8aa9c2|7|DRCRIND|Disease Recurrence Indicator|CHOLLET BREAST CANCER 2002|[?]|TROCHE|QUANTIFIABLE MRD POSITIVITY|1|g/animal|CONTRAST ENHANCED X-RAY|Y|||INVESTIGATOR|ADJUDICATOR|U|4|Visit_4|65|1|SCREENING|2020-10-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-03|P1Y2M10DT2H30M|BEFORE|2020-09-04|BEFORE|2020-10-17
e|RS|81c33633-6ade-45fe-a78e-0e853d8aa9c2|8|NTERESP|Non-Target Enhancing Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|IU/g Hb|CA125 50% RESPONSE|1|U/g/day|REFRACTOMETRY||||FRIEND|OPHTHALMOLOGIST|U|4|Visit_4|65|2|TREATMENT|2020-10-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-03|P1Y2M10DT2H30M|UNKNOWN|2020-10-12|ONGOING|2020-10-19
e|RS|81c33633-6ade-45fe-a78e-0e853d8aa9c2|9|TRGRESP|Target Response|AJCC V7|[?]|Hz/s|MOLECULAR CR|1|U/g Hb|REFRACTOMETRY|Y|||ADJUDICATION COMMITTEE|FORENSIC PATHOLOGIST|NA|5|Visit_5|90|2|WASHOUT|2020-11-03|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-25|P1Y2M10DT2H30M|BEFORE|2020-10-31|ONGOING|2020-11-04
e|RS|81c33633-6ade-45fe-a78e-0e853d8aa9c2|10|SFTSRESP|Soft Tissue Response|CHOLLET BREAST CANCER 2002|[?]|mmol/mol|MRD NEGATIVITY|1|mL/cage/wk|CYSTOSCOPY|Y|||VENDOR|READER 2|U|5|Visit_5|90|7|FOLLOW-UP|2020-11-03|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-25|P1Y2M10DT2H30M|AFTER|2020-11-09|ONGOING|2020-11-12
e|RS|62f3a2a8-f181-4d95-a9b3-a94cd71594a3|1|MRDRESP|Minimal Residual Disease Response|IWG CHESON AML 2003|[?]|pL|CMR|1|L/L|MS/MS||||FRIEND|READER 1|U|1|Visit_1|10|3|TREATMENT|2020-08-01|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-31|P1Y2M10DT2H30M|BEFORE|2020-08-26|BEFORE|2020-09-21
e|RS|62f3a2a8-f181-4d95-a9b3-a94cd71594a3|2|SYMPTDTR|Symptomatic Deterioration|RECICL|[?]|U/mg|WORSENED|1|km/h|RADIAL IMMUNODIFFUSION||Y||VENDOR|FORENSIC PATHOLOGIST|NA|1|Visit_1|10|2|SCREENING|2020-08-01|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-31|P1Y2M10DT2H30M|UNKNOWN|2020-08-09|COINCIDENT|2020-09-12
e|RS|62f3a2a8-f181-4d95-a9b3-a94cd71594a3|3|NTNERESP|Non-Target Non-Enhancing Response|CHESON CLL 2012|[?]|ms/mmHg|COMPLETE MRD RESPONSE|1|pg/L|CONFOCAL MICROSCOPY|Y|||VENDOR|ADJUDICATOR|Y|2|Visit_2|25|7|SCREENING|2020-08-16|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-10|P1Y2M10DT2H30M|BEFORE|2020-09-25|ONGOING|2020-10-24
e|RS|62f3a2a8-f181-4d95-a9b3-a94cd71594a3|4|TRGRESP|Target Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|pmol/L/h|PDu|1|10^6 organisms/mg|ENZYMATIC SPECTROPHOTOMETRY||Y||INTERVIEWER|NEUROLOGIST 1|N|2|Visit_2|25|2|TREATMENT|2020-08-16|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-10|P1Y2M10DT2H30M|AFTER|2020-08-07|ONGOING|2020-08-22
e|RS|62f3a2a8-f181-4d95-a9b3-a94cd71594a3|5|DRCRIND|Disease Recurrence Indicator|KEAM BREAST CANCER 2013|[?]|/10^5|CA125 50% RESPONSE|1|mL/kg|LC/MS/MS||Y||ADJUDICATOR|RATER 2|N|3|Visit_3|40|4|TREATMENT|2020-08-31|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-09|P1Y2M10DT2H30M|UNKNOWN|2020-08-13|ONGOING|2020-09-05
e|RS|62f3a2a8-f181-4d95-a9b3-a94cd71594a3|6|NEWLPROG|New Lesion Progression|RANO|[?]|kBq/uL|DECREASED|1|VIRTUAL PIXEL|ELECTROCHEMILUMINESCENCE||||INVESTIGATOR|DERMATOLOGIST|U|3|Visit_3|40|3|SCREENING|2020-08-31|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-09|P1Y2M10DT2H30M|UNKNOWN|2020-08-14|ONGOING|2020-10-20
e|RS|62f3a2a8-f181-4d95-a9b3-a94cd71594a3|7|LIVRRESP|Liver Response|HAMAOKA BREAST CANCER 2010|||RELAPSED DISEASE|1|SPRAY|ELECTRICAL IMPEDANCE MYOGRAPHY|||Y|INDEPENDENT ASSESSOR|RADIOLOGIST|NA|4|Visit_4|65|1|WASHOUT|2020-09-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-16|P1Y2M10DT2H30M|UNKNOWN|2020-10-03|AFTER|2020-10-13
e|RS|62f3a2a8-f181-4d95-a9b3-a94cd71594a3|8|MRPHRESP|Morphologic Response|CHOLLET BREAST CANCER 2002|[?]|U/mL|PMD|1|F|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN|Y|||ADJUDICATOR|DEVELOPMENTAL PSYCHOLOGIST|U|4|Visit_4|65|4|FOLLOW-UP|2020-09-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-16|P1Y2M10DT2H30M|BEFORE|2020-07-30|COINCIDENT|2020-10-15
e|RS|62f3a2a8-f181-4d95-a9b3-a94cd71594a3|9|OVRLRESP|Overall Response|PCWG SCHER PROSTATE CANCER 2008|[?]|10^6/L|MORPHOLOGIC CRi|1|m/sec|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY||||CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 1|NA|5|Visit_5|90|6|TREATMENT|2020-10-20|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-22|P1Y2M10DT2H30M|BEFORE|2020-08-27|AFTER|2020-09-12
e|RS|62f3a2a8-f181-4d95-a9b3-a94cd71594a3|10|CLINRESP|Clinical Response|BLAZER COLORECTAL CANCER 2008|[?]|ohm|cPR|1|Bq/mL|ENZYMATIC SPECTROPHOTOMETRY||||CLINICAL STUDY SPONSOR|NEUROLOGIST 1|U|5|Visit_5|90|7|TREATMENT|2020-10-20|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-22|P1Y2M10DT2H30M|BEFORE|2020-10-07|BEFORE|2020-10-22
e|RS|7d6e9afe-919e-481a-87d5-bbaf7ca2ec6c|1|NEWLIND|New Lesion Indicator|HAMAOKA BREAST CANCER 2010|[?]|log10 CFU/mL|SMD|1|mL/kg|MICROBIAL CONCENTRATION||||CHILD|READER 1|NA|1|Visit_1|10|1|TREATMENT|2020-09-01|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-05|P1Y2M10DT2H30M|COINCIDENT|2020-11-23|BEFORE|2020-11-28
e|RS|7d6e9afe-919e-481a-87d5-bbaf7ca2ec6c|2|ANATRESP|Anatomic Response|PRINCE TCELL LYMPHOMA 2010|[?]|tuberculin unit/mL|RELAPSED DISEASE FROM CR|1|Newton|KNEMOMETRY||||PROXY|MICROSCOPIST 1|U|1|Visit_1|10|2|FOLLOW-UP|2020-09-01|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-05|P1Y2M10DT2H30M|AFTER|2020-09-19|COINCIDENT|2020-10-03
e|RS|7d6e9afe-919e-481a-87d5-bbaf7ca2ec6c|3|NTERESP|Non-Target Enhancing Response|RANO ELLINGSON 2017|[?]|Ci|NE|1|g/dL|OPHTHALMOSCOPY||||CAREGIVER|ADJUDICATOR 2|NA|2|Visit_2|25|7|TREATMENT|2020-09-16|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-29|P1Y2M10DT2H30M|BEFORE|2020-09-19|AFTER|2020-10-15
e|RS|7d6e9afe-919e-481a-87d5-bbaf7ca2ec6c|4|SYMPTDTR|Symptomatic Deterioration|CHOLLET BREAST CANCER 2002|[?]|pt_us|MAJOR PATHOLOGIC RESPONSE|1|%(v/v)|U-HPLC/MS/MS|Y|Y||SIGNIFICANT OTHER|PATHOLOGIST|NA|2|Visit_2|25|4|TREATMENT|2020-09-16|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-29|P1Y2M10DT2H30M|AFTER|2020-09-14|BEFORE|2020-09-15
e|RS|7d6e9afe-919e-481a-87d5-bbaf7ca2ec6c|5|ANATRESP|Anatomic Response|PETIT BREAST CANCER 2001|[?]|DNA copies/mL|MINOR PATHOLOGIC RESPONSE|1|DAYS|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY||Y||CAREGIVER|RADIOLOGIST 1|U|3|Visit_3|40|3|SCREENING|2020-10-01|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-18|P1Y2M10DT2H30M|UNKNOWN|2020-11-02|ONGOING|2020-11-19
e|RS|7d6e9afe-919e-481a-87d5-bbaf7ca2ec6c|6|HEMARESP|Hematologic Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|||SD-CT|1|cm H2O|PAP STAIN||Y|Y|ADJUDICATION COMMITTEE|DERMATOLOGIST|N|3|Visit_3|40|7|TREATMENT|2020-10-01|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-18|P1Y2M10DT2H30M|COINCIDENT|2020-09-15|BEFORE|2020-09-18
e|RS|7d6e9afe-919e-481a-87d5-bbaf7ca2ec6c|7|SPLNRESP|Spleen Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|mEq/ug|iSD|1|BISCUIT|INDIA INK STAIN||||DOMESTIC PARTNER|ONCOLOGIST 1|NA|4|Visit_4|65|3|TREATMENT|2020-10-26|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-24|P1Y2M10DT2H30M|BEFORE|2020-09-24|COINCIDENT|2020-10-22
e|RS|7d6e9afe-919e-481a-87d5-bbaf7ca2ec6c|8|NEWLPROG|New Lesion Progression|MRECIST BYRNE MESOTHELIOMA 2004|[?]|Tbsp|iUPD|1|/mm|CYSTOSCOPY|Y|Y||HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|U|4|Visit_4|65|3|SCREENING|2020-10-26|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-24|P1Y2M10DT2H30M|AFTER|2020-09-24|BEFORE|2020-10-04
e|RS|7d6e9afe-919e-481a-87d5-bbaf7ca2ec6c|9|NEWLWIND|New Lesion Worsening Indicator|HARTMANN GERM CELL CANCER 2002|[?]|10^7 PFU|INCREASED|1|Log10 ELISA unit|COMPLEMENT FIXATION||||PARENT|ADJUDICATOR 2|N|5|Visit_5|90|1|TREATMENT|2020-11-20|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-10|P1Y2M10DT2H30M|BEFORE|2020-10-24|ONGOING|2020-11-19
e|RS|7d6e9afe-919e-481a-87d5-bbaf7ca2ec6c|10|MRPHRESP|Morphologic Response|MACDONALD GLIOMA 1990|[?]|CAN|VGPR|1|Linear ft*LB|ELECTROMYOGRAPHY|Y|||CAREGIVER|MICROSCOPIST 3|NA|5|Visit_5|90|1|TREATMENT|2020-11-20|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-10|P1Y2M10DT2H30M|COINCIDENT|2020-09-08|AFTER|2020-11-18
e|RS|84ccf2f8-8b9d-486c-8aad-a11bc45ed4f5|1|MRDIND|Minimal Residual Disease Indicator|GUILHOT CML 2007|[?]|mV*min|NON-QUANTIFIABLE MRD POSITIVITY|1|mL/min/1.73m2|CALCOFLUOR WHITE STAIN||||INVESTIGATOR|PATHOLOGIST 2|NA|1|Visit_1|10|5|FOLLOW-UP|2021-01-27|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-07|P1Y2M10DT2H30M|UNKNOWN|2021-03-24|BEFORE|2021-04-05
e|RS|84ccf2f8-8b9d-486c-8aad-a11bc45ed4f5|2|BESTRESP|Best Overall Response|MRECIST BYRNE MESOTHELIOMA 2004|||FAVORABLE RESPONSE|1|mL/m2/min|SEQUENCING|||Y|PROXY|ADJUDICATOR 1|Y|1|Visit_1|10|4|FOLLOW-UP|2021-01-27|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-07|P1Y2M10DT2H30M|BEFORE|2021-01-26|AFTER|2021-02-25
e|RS|84ccf2f8-8b9d-486c-8aad-a11bc45ed4f5|3|NTRGRESP|Non-target Response|MONTSERRAT CLL 1989|[?]|Mile|WORSENED|1|mg/mL/day|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION||||CAREGIVER|CARDIOLOGIST|Y|2|Visit_2|25|1|TREATMENT|2021-02-11|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-24|P1Y2M10DT2H30M|COINCIDENT|2021-03-07|COINCIDENT|2021-03-17
e|RS|84ccf2f8-8b9d-486c-8aad-a11bc45ed4f5|4|STRUSTAT|Steroid Use Status|AJCC V8|[?]|cm H2O|INCREASED|1|L/min|PYROSEQUENCING||||CLINICAL STUDY SPONSOR|ADJUDICATOR 1|NA|2|Visit_2|25|4|FOLLOW-UP|2021-02-11|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-24|P1Y2M10DT2H30M|COINCIDENT|2021-02-15|BEFORE|2021-04-26
e|RS|84ccf2f8-8b9d-486c-8aad-a11bc45ed4f5|5|ANATRESP|Anatomic Response|SCHER PROSTATE CANCER 2011|[?]|pmol/dL|PMR|1|MHz|REVERSE TRANSCRIPTASE PCR||||CLINICAL RESEARCH COORDINATOR|READER 3|U|3|Visit_3|40|1|WASHOUT|2021-02-26|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-23|P1Y2M10DT2H30M|UNKNOWN|2021-02-08|COINCIDENT|2021-04-21
e|RS|84ccf2f8-8b9d-486c-8aad-a11bc45ed4f5|6|MOLRESP|Molecular Response|HAMAOKA BREAST CANCER 2010|||UNEQUIVOCAL|1|mg/kg/dose|NEURAMINIDASE INHIBITION ASSAY|||Y|PARENT|DERMATOLOGIST|NA|3|Visit_3|40|2|FOLLOW-UP|2021-02-26|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-23|P1Y2M10DT2H30M|AFTER|2021-04-20|AFTER|2021-04-22
e|RS|84ccf2f8-8b9d-486c-8aad-a11bc45ed4f5|7|DRCRIND|Disease Recurrence Indicator|CHESON MALIGNANT LYMPHOMA 2007|[?]|DROP|IMMUNOPHENOTYPIC CR|1|EVENTS|MRI||||FAMILY MEMBER|CARDIOLOGIST|Y|4|Visit_4|65|6|FOLLOW-UP|2021-03-23|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-26|P1Y2M10DT2H30M|AFTER|2021-02-10|COINCIDENT|2021-03-03
e|RS|84ccf2f8-8b9d-486c-8aad-a11bc45ed4f5|8|NTERESP|Non-Target Enhancing Response|CHOI GIST 2008|||MORPHOLOGIC LEUKEMIA-FREE STATE|1|fmol/L|SICKLE CELL SOLUBILITY TEST|||Y|GUARDIAN|INTERNIST|N|4|Visit_4|65|7|FOLLOW-UP|2021-03-23|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-26|P1Y2M10DT2H30M|COINCIDENT|2021-02-08|COINCIDENT|2021-04-07
e|RS|84ccf2f8-8b9d-486c-8aad-a11bc45ed4f5|9|NTNERESP|Non-Target Non-Enhancing Response|CHESON CLL 2006|[?]|/7.5 mL|ABSENT MORPHOLOGIC RESPONSE|1|vg/mL|IMMUNOTURBIDIMETRY||||FRIEND|MICROSCOPIST 2|N|5|Visit_5|90|3|SCREENING|2021-04-17|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-22|P1Y2M10DT2H30M|AFTER|2021-03-23|AFTER|2021-03-30
e|RS|84ccf2f8-8b9d-486c-8aad-a11bc45ed4f5|10|MOLRESP|Molecular Response|HAMAOKA BREAST CANCER 2010|[?]|10^8 PFU|COMPLETE MRD RESPONSE|1|anti-Xa IU|DOPPLER ULTRASOUND||||INVESTIGATOR|NEUROLOGIST|N|5|Visit_5|90|1|TREATMENT|2021-04-17|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-22|P1Y2M10DT2H30M|BEFORE|2021-03-26|BEFORE|2021-04-17
e|RS|21740641-69bb-49a9-a86d-2444914f6d12|1|CYTORESP|Cytogenetic Response|GUILHOT CML 2007|[?]|pmol/dL|MOLECULAR MAJOR RESPONSE|1|FIU|DROPLET DIGITAL PCR||||FAMILY MEMBER|ONCOLOGIST 2|N|1|Visit_1|10|6|TREATMENT|2020-05-17|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-07|P1Y2M10DT2H30M|AFTER|2020-07-09|COINCIDENT|2020-07-29
e|RS|21740641-69bb-49a9-a86d-2444914f6d12|2|SFTSRESP|Soft Tissue Response|HARTMAN PANCREATIC CANCER 2012|[?]|breaths/30s|sCR|1|mg/min|FLUOROSCOPY||||DOMESTIC PARTNER|PATHOLOGIST|U|1|Visit_1|10|7|TREATMENT|2020-05-17|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-07|P1Y2M10DT2H30M|UNKNOWN|2020-06-17|AFTER|2020-06-24
e|RS|21740641-69bb-49a9-a86d-2444914f6d12|3|MRDIND|Minimal Residual Disease Indicator|HARTMAN PANCREATIC CANCER 2012|||NON-CR/NON-PD|1|Ci/ug|HEMOCYTOMETRY|||Y|SIBLING|READER 2|N|2|Visit_2|25|6|TREATMENT|2020-06-01|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-11|P1Y2M10DT2H30M|BEFORE|2020-05-11|COINCIDENT|2020-08-11
e|RS|21740641-69bb-49a9-a86d-2444914f6d12|4|METSIND|Metastatic Indicator|JACINTO CERVICAL CANCER 2007|[?]|10^9 CFU|HI-P|1|ug/kg/min|REVERSE TRANSCRIPTASE PCR||Y||NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|U|2|Visit_2|25|6|TREATMENT|2020-06-01|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-11|P1Y2M10DT2H30M|COINCIDENT|2020-05-23|AFTER|2020-06-25
e|RS|21740641-69bb-49a9-a86d-2444914f6d12|5|TMRESP|Tumor Marker Response|KUMAR IMWG 2016|[?]|Tesla|STABLE|1|uIU/dL|CALIPER MEASUREMENT METHOD||||SPOUSE|READER 3|U|3|Visit_3|40|3|TREATMENT|2020-06-16|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-09|P1Y2M10DT2H30M|AFTER|2020-08-12|BEFORE|2020-08-13
e|RS|21740641-69bb-49a9-a86d-2444914f6d12|6|MRPHRESP|Morphologic Response|MACDONALD GLIOMA 1990|[?]|pkat|WORSENED|1|pkat/L|FLUORESCEIN STAIN||||PROXY|PHYSIOTHERAPIST|Y|3|Visit_3|40|2|FOLLOW-UP|2020-06-16|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-09|P1Y2M10DT2H30M|COINCIDENT|2020-08-11|AFTER|2020-08-14
e|RS|21740641-69bb-49a9-a86d-2444914f6d12|7|SPLNRESP|Spleen Response|UNSPECIFIED|||MOLECULAR MAJOR RESPONSE|1|10^4/hpf|GRAM STAIN|||Y|FAMILY MEMBER|UROLOGIST|N|4|Visit_4|65|2|TREATMENT|2020-07-11|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-28|P1Y2M10DT2H30M|UNKNOWN|2020-06-13|COINCIDENT|2020-06-22
e|RS|21740641-69bb-49a9-a86d-2444914f6d12|8|CYTORESP|Cytogenetic Response|RANO|[?]|nmol/day|MAJOR PATHOLOGIC RESPONSE|1|10^7 CFU|CISH|Y|||NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|NA|4|Visit_4|65|1|TREATMENT|2020-07-11|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-28|P1Y2M10DT2H30M|UNKNOWN|2020-07-25|ONGOING|2020-08-01
e|RS|21740641-69bb-49a9-a86d-2444914f6d12|9|BMIVLIND|Bone Marrow Involvement Indicator|HAMAOKA BREAST CANCER 2010|[?]|10^3 organisms|STABLE|1|mm/min|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|Y|||ADJUDICATOR|ONCOLOGIST 2|U|5|Visit_5|90|7|TREATMENT|2020-08-05|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-16|P1Y2M10DT2H30M|BEFORE|2020-08-08|BEFORE|2020-08-09
e|RS|21740641-69bb-49a9-a86d-2444914f6d12|10|SYMPTDTR|Symptomatic Deterioration|DURIE MULTIPLE MYELOMA 2006|||PD FROM PR|1|uV2|AURAMINE STAIN|Y||Y|STUDY SUBJECT|OTOLARYNGOLOGIST|Y|5|Visit_5|90|3|WASHOUT|2020-08-05|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-16|P1Y2M10DT2H30M|BEFORE|2020-07-12|COINCIDENT|2020-08-11
e|RS|c3984f41-30a0-49a4-a8bd-f36fad4621a8|1|SYMPTDTR|Symptomatic Deterioration|NCIWG CHESON CLL 1996|[?]|Ci/kg|INDETERMINATE RESPONSE|1|mL/g/min|FORCED OSCILLATION TECHNIQUE||||ADJUDICATION COMMITTEE|ADJUDICATOR 1|U|1|Visit_1|10|6|SCREENING|2020-06-18|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-06|P1Y2M10DT2H30M|UNKNOWN|2020-06-18|BEFORE|2020-08-12
e|RS|c3984f41-30a0-49a4-a8bd-f36fad4621a8|2|NEWLPROG|New Lesion Progression|WOLCHOK SOLID TUMORS 2009|[?]|g/animal/day|MRD RELAPSE|1|dpm/mL|CLINICAL EVALUATION||||INTERVIEWER|MICROSCOPIST 2|Y|1|Visit_1|10|1|SCREENING|2020-06-18|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-06|P1Y2M10DT2H30M|AFTER|2020-08-25|ONGOING|2020-08-30
e|RS|c3984f41-30a0-49a4-a8bd-f36fad4621a8|3|OVRLRESP|Overall Response|NCIWG CHESON CLL 1996|[?]|10^9 CFU|MAJOR PATHOLOGIC RESPONSE|1|dram|PHOTOGRAPHY||Y||SIGNIFICANT OTHER|ADJUDICATOR 1|U|2|Visit_2|25|7|TREATMENT|2020-07-03|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-19|P1Y2M10DT2H30M|UNKNOWN|2020-08-20|COINCIDENT|2020-09-14
e|RS|c3984f41-30a0-49a4-a8bd-f36fad4621a8|4|MOLRESP|Molecular Response|PERCIST|[?]|10^4/hpf|CA125 50% RESPONSE|1|pt_us|IMMUNOTURBIDIMETRY|Y|||PROXY|RATER|Y|2|Visit_2|25|1|TREATMENT|2020-07-03|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-19|P1Y2M10DT2H30M|AFTER|2020-07-03|COINCIDENT|2020-08-28
e|RS|c3984f41-30a0-49a4-a8bd-f36fad4621a8|5|LIVRRESP|Liver Response|CHOI GIST 2008|||RELAPSED DISEASE FROM CR|1|/cmH2O|SXA SCAN|Y|Y|Y|GUARDIAN|RATER 1|Y|3|Visit_3|40|6|TREATMENT|2020-07-18|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-13|P1Y2M10DT2H30M|BEFORE|2020-07-22|AFTER|2020-08-30
e|RS|c3984f41-30a0-49a4-a8bd-f36fad4621a8|6|LIVRRESP|Liver Response|IRANO 2015|[?]|g/m2|PD/RELAPSE AFTER HI|1|v/v|DYNAMIC LIGHT SCATTERING||||SIGNIFICANT OTHER|RATER 2|U|3|Visit_3|40|4|TREATMENT|2020-07-18|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-13|P1Y2M10DT2H30M|UNKNOWN|2020-08-30|ONGOING|2020-08-31
e|RS|c3984f41-30a0-49a4-a8bd-f36fad4621a8|7|RDIORESP|Radiologic Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|pmol|NOT ALL EVALUATED|1|L/s|HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY||||VENDOR|OPHTHALMOLOGIST|NA|4|Visit_4|65|4|TREATMENT|2020-08-12|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-08|P1Y2M10DT2H30M|COINCIDENT|2020-07-19|COINCIDENT|2020-09-04
e|RS|c3984f41-30a0-49a4-a8bd-f36fad4621a8|8|NTERESP|Non-Target Enhancing Response|CHESON LYMPHOMA 2008|[?]|cd/m2|MAJOR PATHOLOGIC RESPONSE|1|ug/kg/min|PALPATION||Y||GUARDIAN|MICROSCOPIST 1|NA|4|Visit_4|65|7|TREATMENT|2020-08-12|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-08|P1Y2M10DT2H30M|AFTER|2020-08-23|BEFORE|2020-08-27
e|RS|c3984f41-30a0-49a4-a8bd-f36fad4621a8|9|MJPTHIND|Major Pathological Response Indicator|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|DIP|CHR|1|foz_br|ORCHIDOMETERY||||FRIEND|ADJUDICATOR|Y|5|Visit_5|90|6|WASHOUT|2020-09-06|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-08|P1Y2M10DT2H30M|UNKNOWN|2020-07-16|AFTER|2020-08-30
e|RS|c3984f41-30a0-49a4-a8bd-f36fad4621a8|10|TMRESP|Tumor Marker Response|BRUGGEMANN MRD 2010|[?]|dL|CYTOGENETIC MINOR RESPONSE|1|/mm2|NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY|Y|||SPOUSE|PATHOLOGIST 1|NA|5|Visit_5|90|2|TREATMENT|2020-09-06|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-08|P1Y2M10DT2H30M|AFTER|2020-07-11|ONGOING|2020-07-14
e|RS|1ae9a175-fd7a-4215-adc4-ce6bd220f94d|1|CYTORESP|Cytogenetic Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|10^9/L|iUPD|1|Gy/h|ULTRASONOGRAPHIC ELASTOGRAPHY||Y||PROXY|INTERNIST|NA|1|Visit_1|10|6|SCREENING|2021-01-21|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-03|P1Y2M10DT2H30M|UNKNOWN|2021-02-22|AFTER|2021-04-17
e|RS|1ae9a175-fd7a-4215-adc4-ce6bd220f94d|2|BMIVLIND|Bone Marrow Involvement Indicator|RECIST 1.1|[?]|ug|PSEUDOPROGRESSION|1|cal|POTENTIOMETRY||Y||FRIEND|ADJUDICATOR|Y|1|Visit_1|10|5|FOLLOW-UP|2021-01-21|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-03|P1Y2M10DT2H30M|COINCIDENT|2021-04-11|COINCIDENT|2021-04-14
e|RS|1ae9a175-fd7a-4215-adc4-ce6bd220f94d|3|NTERESP|Non-Target Enhancing Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|days/month|PR|1|mU|MICROBIAL BIOCHEMICAL IDENTIFICATION||||STUDY SUBJECT|OPHTHALMOLOGIST|N|2|Visit_2|25|3|TREATMENT|2021-02-05|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-28|P1Y2M10DT2H30M|UNKNOWN|2021-03-28|AFTER|2021-04-12
e|RS|1ae9a175-fd7a-4215-adc4-ce6bd220f94d|4|BONERESP|Bone Response|SCHWARZ CERVICAL CANCER 2009|[?]|Enzyme U/m2|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|U/mmol|CLIP SEQUENCING||||PROXY|OTOLARYNGOLOGIST|NA|2|Visit_2|25|5|SCREENING|2021-02-05|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-28|P1Y2M10DT2H30M|AFTER|2021-02-11|COINCIDENT|2021-04-20
e|RS|1ae9a175-fd7a-4215-adc4-ce6bd220f94d|5|RDIORESP|Radiologic Response|AJCC V8|[?]|mg/L FEU|PDu|1|cmHg|NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY||||FAMILY MEMBER|RADIOLOGIST 1|NA|3|Visit_3|40|6|FOLLOW-UP|2021-02-20|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-16|P1Y2M10DT2H30M|COINCIDENT|2021-03-26|BEFORE|2021-03-29
e|RS|1ae9a175-fd7a-4215-adc4-ce6bd220f94d|6|STRUSTAT|Steroid Use Status|JACINTO CERVICAL CANCER 2007|[?]|10^6 organisms/g|MOLECULAR MAJOR RESPONSE|1|uEq/L|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY||||SIGNIFICANT OTHER|NEUROLOGIST 1|U|3|Visit_3|40|6|TREATMENT|2021-02-20|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-16|P1Y2M10DT2H30M|BEFORE|2021-03-27|COINCIDENT|2021-04-07
e|RS|1ae9a175-fd7a-4215-adc4-ce6bd220f94d|7|ANATRESP|Anatomic Response|RECIST 1.1|||CR|1|Absorbance U/mL|JAEGER EYE CHART|||Y|ADJUDICATION COMMITTEE|MICROSCOPIST|U|4|Visit_4|65|6|TREATMENT|2021-03-17|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-05|P1Y2M10DT2H30M|COINCIDENT|2021-02-23|COINCIDENT|2021-03-22
e|RS|1ae9a175-fd7a-4215-adc4-ce6bd220f94d|8|MRDRESP|Minimal Residual Disease Response|DOHNER AML 2010|||MRD PERSISTENCE|1|ug/L DDU|MICRODENSITOMETRY|||Y|PARENT|INTERNIST|N|4|Visit_4|65|4|TREATMENT|2021-03-17|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-05|P1Y2M10DT2H30M|COINCIDENT|2021-03-16|COINCIDENT|2021-03-18
e|RS|1ae9a175-fd7a-4215-adc4-ce6bd220f94d|9|OVRLRESP|Overall Response|MONTSERRAT CLL 1989|||NON-CR/NON-PD|1|IU/mL|MULTIPLE BREATH WASHOUT|||Y|STUDY SUBJECT|MICROSCOPIST|U|5|Visit_5|90|4|FOLLOW-UP|2021-04-11|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-05|P1Y2M10DT2H30M|BEFORE|2021-02-22|BEFORE|2021-03-22
e|RS|1ae9a175-fd7a-4215-adc4-ce6bd220f94d|10|BESTRESP|Best Overall Response|RECICL|[?]|USP U|CYTOGENETIC MINIMAL RESPONSE|1|10^6/hpf|INDIA INK STAIN||||FRIEND|DEVELOPMENTAL PSYCHOLOGIST|N|5|Visit_5|90|1|TREATMENT|2021-04-11|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-05|P1Y2M10DT2H30M|BEFORE|2021-01-28|COINCIDENT|2021-04-16
e|RS|0f85b859-187d-4c6b-8873-33c0f18d3e3c|1|ANATRESP|Anatomic Response|CHOLLET BREAST CANCER 2002|||CYTOGENETIC CR|1|/100 HPFs|X-RAY FLUORESCENCE SPECTROMETRY|Y|Y|Y|HEALTH CARE PROFESSIONAL|RADIOLOGIST|N|1|Visit_1|10|1|SCREENING|2020-07-24|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-12|P1Y2M10DT2H30M|BEFORE|2020-08-10|COINCIDENT|2020-09-15
e|RS|0f85b859-187d-4c6b-8873-33c0f18d3e3c|2|TMRESP|Tumor Marker Response|PRINCE TCELL LYMPHOMA 2010|[?]|10^3 organisms/mL|RELAPSED DISEASE FROM CR OR PR|1|10^3 organisms/mL|LUXOL FAST BLUE AND CRESYL VIOLET STAIN||||CLINICAL STUDY SPONSOR|RADIOLOGIST 2|U|1|Visit_1|10|5|TREATMENT|2020-07-24|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-12|P1Y2M10DT2H30M|COINCIDENT|2020-07-25|BEFORE|2020-09-05
e|RS|0f85b859-187d-4c6b-8873-33c0f18d3e3c|3|NTLWIND|Non-Target Lesion Worsening Indicator|IWG CHESON MDS 2006|||CR-CT|1|mg/kg/day|ATOMIC ABSORPTION SPECTROMETRY||Y|Y|INVESTIGATOR|READER 1|Y|2|Visit_2|25|3|TREATMENT|2020-08-08|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-23|P1Y2M10DT2H30M|UNKNOWN|2020-10-19|ONGOING|2020-10-21
e|RS|0f85b859-187d-4c6b-8873-33c0f18d3e3c|4|TRGRESP|Target Response|IWG CHESON AML 2003|||DECREASED|1|gpELISA unit/mL|REFLECTANCE SPECTROSCOPY|||Y|ADJUDICATION COMMITTEE|MICROSCOPIST 3|U|2|Visit_2|25|5|TREATMENT|2020-08-08|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-23|P1Y2M10DT2H30M|AFTER|2020-09-03|AFTER|2020-09-04
e|RS|0f85b859-187d-4c6b-8873-33c0f18d3e3c|5|METSIND|Metastatic Indicator|HARTMAN PANCREATIC CANCER 2012|||CR-CT|1|cm/s|SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY|||Y|CHILD|PATHOLOGIST 1|Y|3|Visit_3|40|2|TREATMENT|2020-08-23|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-27|P1Y2M10DT2H30M|COINCIDENT|2020-09-07|ONGOING|2020-09-27
e|RS|0f85b859-187d-4c6b-8873-33c0f18d3e3c|6|LIVRRESP|Liver Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|lm|iSD|1|kDa|RIA||Y||ADJUDICATOR|ADJUDICATOR 2|NA|3|Visit_3|40|5|FOLLOW-UP|2020-08-23|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-27|P1Y2M10DT2H30M|COINCIDENT|2020-08-01|ONGOING|2020-10-13
e|RS|0f85b859-187d-4c6b-8873-33c0f18d3e3c|7|NEWLPROG|New Lesion Progression|KUKER LYMPHOMA 2005|[?]|10^3 organisms|WORSENED|1|DISK|ENZYMATIC SPECTROPHOTOMETRY||||CLINICAL RESEARCH ASSOCIATE|OPHTHALMOLOGIST|U|4|Visit_4|65|7|TREATMENT|2020-09-17|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-05|P1Y2M10DT2H30M|BEFORE|2020-09-21|ONGOING|2020-10-06
e|RS|0f85b859-187d-4c6b-8873-33c0f18d3e3c|8|MOLRESP|Molecular Response|FAROOQUI SUPP CLL 2014|[?]|ug/min|CMR|1|V|FLUORESCENT LIFETIME IMAGING MICROSCOPY||Y||ADJUDICATOR|INTERNIST|Y|4|Visit_4|65|7|TREATMENT|2020-09-17|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-05|P1Y2M10DT2H30M|BEFORE|2020-07-25|AFTER|2020-08-27
e|RS|0f85b859-187d-4c6b-8873-33c0f18d3e3c|9|MOLRESP|Molecular Response|PCWG SCHER PROSTATE CANCER 2008|||NED|1|mmAL|PERIPHERAL ANGIOGRAPHY|||Y|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 1|N|5|Visit_5|90|6|FOLLOW-UP|2020-10-12|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-12|P1Y2M10DT2H30M|AFTER|2020-07-18|ONGOING|2020-07-31
e|RS|0f85b859-187d-4c6b-8873-33c0f18d3e3c|10|CYTORESP|Cytogenetic Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|||sCR|1|/200 HPFs|SLIT LAMP PHOTOGRAPHY|||Y|SIGNIFICANT OTHER|PEDIATRIC NEUROLOGIST|NA|5|Visit_5|90|6|TREATMENT|2020-10-12|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-12|P1Y2M10DT2H30M|AFTER|2020-10-07|COINCIDENT|2020-10-11
e|RS|5e383a9d-dc97-4352-8add-d55a1a566b9f|1|SPLNRESP|Spleen Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|mm2|iCPD|1|10^9 organisms/g|GRAM STAIN||||SPOUSE|ADJUDICATOR 2|Y|1|Visit_1|10|2|FOLLOW-UP|2020-09-27|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-30|P1Y2M10DT2H30M|AFTER|2020-12-12|ONGOING|2020-12-15
e|RS|5e383a9d-dc97-4352-8add-d55a1a566b9f|2|SYMPTDTR|Symptomatic Deterioration|MRECIST BYRNE MESOTHELIOMA 2004|||INDETERMINATE RESPONSE|1|mm2|FLUORIMETRY|||Y|ADJUDICATION COMMITTEE|ADJUDICATOR 3|N|1|Visit_1|10|4|FOLLOW-UP|2020-09-27|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-30|P1Y2M10DT2H30M|COINCIDENT|2020-12-11|COINCIDENT|2020-12-14
e|RS|5e383a9d-dc97-4352-8add-d55a1a566b9f|3|MJPTHIND|Major Pathological Response Indicator|CHESON CLL 2012|[?]|IU/mg|CA125 75% RESPONSE|1|MPS U|MICRO BROTH DILUTION||Y||HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|N|2|Visit_2|25|4|TREATMENT|2020-10-12|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-11|P1Y2M10DT2H30M|BEFORE|2020-12-02|COINCIDENT|2020-12-07
e|RS|5e383a9d-dc97-4352-8add-d55a1a566b9f|4|NEWLIND|New Lesion Indicator|RECICL|[?]|log10 PFU|PD/RELAPSE AFTER HI|1|CCID 50/mL|PET/CT SCAN||Y||SIGNIFICANT OTHER|MICROSCOPIST 2|N|2|Visit_2|25|3|TREATMENT|2020-10-12|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-11|P1Y2M10DT2H30M|AFTER|2020-11-14|COINCIDENT|2020-12-23
e|RS|5e383a9d-dc97-4352-8add-d55a1a566b9f|5|BESTRESP|Best Overall Response|MURPHY PROSTATE CANCER 1980|||NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|/day|KARYOTYPING|||Y|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST|Y|3|Visit_3|40|4|TREATMENT|2020-10-27|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-23|P1Y2M10DT2H30M|COINCIDENT|2020-11-10|ONGOING|2020-11-12
e|RS|5e383a9d-dc97-4352-8add-d55a1a566b9f|6|MOLRESP|Molecular Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|C|IMMUNOPHENOTYPIC CR|1|P|TRANSCRIPTION-MEDIATED AMPLIFICATION|Y|||ADJUDICATOR|ADJUDICATOR|U|3|Visit_3|40|1|WASHOUT|2020-10-27|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-23|P1Y2M10DT2H30M|UNKNOWN|2020-12-01|ONGOING|2020-12-20
e|RS|5e383a9d-dc97-4352-8add-d55a1a566b9f|7|METBRESP|Metabolic Response|RECICL|[?]|Shock Wave|DISEASE TRANSFORMATION|1|MET*min|QUANTITATIVE CORONARY ANGIOGRAPHY|Y|||DOMESTIC PARTNER|HEMATOLOGIST|U|4|Visit_4|65|5|SCREENING|2020-11-21|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-27|P1Y2M10DT2H30M|COINCIDENT|2020-09-22|AFTER|2020-10-12
e|RS|5e383a9d-dc97-4352-8add-d55a1a566b9f|8|CLINRESP|Clinical Response|SCHWARZ CERVICAL CANCER 2009|[?]|10^3 CFU/g|CYTOGENETIC MINIMAL RESPONSE|1|ELISA unit|AUDIOMETRY||Y||INDEPENDENT ASSESSOR|NEUROLOGIST|U|4|Visit_4|65|7|TREATMENT|2020-11-21|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-27|P1Y2M10DT2H30M|BEFORE|2020-12-17|BEFORE|2020-12-22
e|RS|5e383a9d-dc97-4352-8add-d55a1a566b9f|9|CPRFSTAT|Clinical Performance Status|DOHNER AML 2010|[?]|fraction of 1|iPR|1|BOWL|JAFFE REACTION||||DOMESTIC PARTNER|UROLOGIST|NA|5|Visit_5|90|7|TREATMENT|2020-12-16|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-20|P1Y2M10DT2H30M|COINCIDENT|2020-11-07|BEFORE|2020-11-13
e|RS|5e383a9d-dc97-4352-8add-d55a1a566b9f|10|MNPTHIND|Minor Pathological Response Indicator|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|U/kg/day|MRD RELAPSE|1|nmol BCE/nmol|AUSCULTATION||||ADJUDICATION COMMITTEE|UROLOGIST|NA|5|Visit_5|90|3|TREATMENT|2020-12-16|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-20|P1Y2M10DT2H30M|BEFORE|2020-09-22|AFTER|2020-11-14
e|RS|3eda746b-fb97-4950-a528-1d4ae5d3653a|1|MJPTHIND|Major Pathological Response Indicator|CHESON LYMPHOMA 2008|[?]|Bq/mg|CYTOGENETIC CR|1|AU/mL|CINEANGIOGRAPHY||||GUARDIAN|FORENSIC PATHOLOGIST|Y|1|Visit_1|10|3|TREATMENT|2020-06-13|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-05|P1Y2M10DT2H30M|COINCIDENT|2020-06-29|ONGOING|2020-07-22
e|RS|3eda746b-fb97-4950-a528-1d4ae5d3653a|2|NTERESP|Non-Target Enhancing Response|CHOI GIST 2008|||ABSENT MORPHOLOGIC RESPONSE|1|APL U|REAL-TIME POLYMERASE CHAIN REACTION ASSAY|||Y|STUDY SUBJECT|UROLOGIST|U|1|Visit_1|10|6|WASHOUT|2020-06-13|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-05|P1Y2M10DT2H30M|COINCIDENT|2020-06-08|AFTER|2020-07-27
e|RS|3eda746b-fb97-4950-a528-1d4ae5d3653a|3|HEMARESP|Hematologic Response|GUPPY OVARIAN CANCER 2002|[?]|cm2|OPTIMAL MORPHOLOGIC RESPONSE|1|mg/m2|ELECTROGASTROGRAPHY||Y||ADJUDICATION COMMITTEE|ADJUDICATOR 1|Y|2|Visit_2|25|6|FOLLOW-UP|2020-06-28|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-31|P1Y2M10DT2H30M|COINCIDENT|2020-07-25|ONGOING|2020-08-08
e|RS|3eda746b-fb97-4950-a528-1d4ae5d3653a|4|BESTRESP|Best Overall Response|RANO|[?]|mL/h|NON-CR/NON-PD|1|fmol/g|PELLI-ROBSON EYE CHART|Y|||ADJUDICATION COMMITTEE|READER 2|Y|2|Visit_2|25|3|TREATMENT|2020-06-28|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-31|P1Y2M10DT2H30M|AFTER|2020-07-22|ONGOING|2020-08-14
e|RS|3eda746b-fb97-4950-a528-1d4ae5d3653a|5|OVRLRESP|Overall Response|GUILHOT CML 2007|||PMR|1|umol/mol|ACRIDINE ORANGE STAIN|||Y|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|U|3|Visit_3|40|6|TREATMENT|2020-07-13|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-23|P1Y2M10DT2H30M|COINCIDENT|2020-07-31|ONGOING|2020-08-27
e|RS|3eda746b-fb97-4950-a528-1d4ae5d3653a|6|SYMPTDTR|Symptomatic Deterioration|GUILHOT CML 2007|||CA125 75% RESPONSE|1|EID 50/mL|SNELLEN EYE CHART|||Y|FAMILY MEMBER|RADIOLOGIST 2|Y|3|Visit_3|40|5|TREATMENT|2020-07-13|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-23|P1Y2M10DT2H30M|COINCIDENT|2020-07-21|COINCIDENT|2020-08-09
e|RS|3eda746b-fb97-4950-a528-1d4ae5d3653a|7|NTERESP|Non-Target Enhancing Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|ug/m2|PSEUDORESPONSE|1|rpm|TRIPLE-PHASE MRI SCAN||||CAREGIVER|ADJUDICATOR 1|NA|4|Visit_4|65|3|FOLLOW-UP|2020-08-07|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-24|P1Y2M10DT2H30M|AFTER|2020-07-13|BEFORE|2020-08-10
e|RS|3eda746b-fb97-4950-a528-1d4ae5d3653a|8|CLINRESP|Clinical Response|RECIST 1.1|[?]|fmol/L|iCR|1|bel|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY||||CAREGIVER|RATER 2|Y|4|Visit_4|65|3|TREATMENT|2020-08-07|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-24|P1Y2M10DT2H30M|BEFORE|2020-08-22|AFTER|2020-09-06
e|RS|3eda746b-fb97-4950-a528-1d4ae5d3653a|9|CYTORESP|Cytogenetic Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|genEq|IMMUNOPHENOTYPIC CR|1|kDa|INDIRECT IMMUNOFLUORESCENCE|Y|||SIBLING|NEUROLOGIST 2|N|5|Visit_5|90|2|FOLLOW-UP|2020-09-01|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-30|P1Y2M10DT2H30M|AFTER|2020-07-24|COINCIDENT|2020-08-09
e|RS|3eda746b-fb97-4950-a528-1d4ae5d3653a|10|ANATRESP|Anatomic Response|DURIE MULTIPLE MYELOMA 2006|[?]|U/m2|iPR|1|mL/kg/h|GIEMSA STAIN|Y|||FAMILY MEMBER|RATER|U|5|Visit_5|90|2|WASHOUT|2020-09-01|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-30|P1Y2M10DT2H30M|BEFORE|2020-07-22|ONGOING|2020-08-30
e|RS|a3b72841-3401-4dcc-9d06-75438b408d0b|1|STRUSTAT|Steroid Use Status|RAJKUMAR MYELOMA 2011|[?]|CUP|iSD|1|/mm2|INTRAVASCULAR ULTRASOUND||Y||CAREGIVER|PEDIATRIC NEUROLOGIST|Y|1|Visit_1|10|3|FOLLOW-UP|2020-11-05|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-28|P1Y2M10DT2H30M|UNKNOWN|2020-11-21|COINCIDENT|2020-11-26
e|RS|a3b72841-3401-4dcc-9d06-75438b408d0b|2|NTERESP|Non-Target Enhancing Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|||CR|1|10^3 copies/mL|HPLC-UV|||Y|CLINICAL RESEARCH COORDINATOR|READER 3|Y|1|Visit_1|10|1|TREATMENT|2020-11-05|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-28|P1Y2M10DT2H30M|UNKNOWN|2020-11-21|BEFORE|2020-11-29
e|RS|a3b72841-3401-4dcc-9d06-75438b408d0b|3|LIVRRESP|Liver Response|SCHWARZ CERVICAL CANCER 2009|[?]|mg/m2/day|MRD RELAPSE|1|cm|URANYL ACETATE STAIN||||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 1|N|2|Visit_2|25|2|SCREENING|2020-11-20|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-12|P1Y2M10DT2H30M|COINCIDENT|2020-12-20|COINCIDENT|2021-01-28
e|RS|a3b72841-3401-4dcc-9d06-75438b408d0b|4|STRUSTAT|Steroid Use Status|EASL BRUIX LIVER CANCER 2001|||DECREASED|1|DDU|PUPILLOMETRY|||Y|NON-HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|N|2|Visit_2|25|1|TREATMENT|2020-11-20|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-12|P1Y2M10DT2H30M|COINCIDENT|2020-11-14|ONGOING|2021-01-04
e|RS|a3b72841-3401-4dcc-9d06-75438b408d0b|5|SPLNRESP|Spleen Response|SHINDOH COLORECTAL CANCER 2013|[?]|deg2|PD|1|oz|JAFFE REACTION||Y||HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|U|3|Visit_3|40|1|TREATMENT|2020-12-05|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-04|P1Y2M10DT2H30M|UNKNOWN|2021-01-22|ONGOING|2021-01-23
e|RS|a3b72841-3401-4dcc-9d06-75438b408d0b|6|SYMPTDTR|Symptomatic Deterioration|SCHWARZ CERVICAL CANCER 2009|[?]|Gy|PDu|1|mEq/kg|MALDI|Y|||FAMILY MEMBER|OPTOMETRIST|Y|3|Visit_3|40|1|TREATMENT|2020-12-05|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-04|P1Y2M10DT2H30M|UNKNOWN|2021-01-17|ONGOING|2021-01-21
e|RS|a3b72841-3401-4dcc-9d06-75438b408d0b|7|MJPTHIND|Major Pathological Response Indicator|MURPHY PROSTATE CANCER 1980|[?]|/40 HPFs|PD/RELAPSE AFTER HI|1|P|INFRARED SPECTROMETRY|Y|||NON-HEALTH CARE PROFESSIONAL|RATER|NA|4|Visit_4|65|4|TREATMENT|2020-12-30|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-13|P1Y2M10DT2H30M|AFTER|2020-12-29|ONGOING|2021-01-26
e|RS|a3b72841-3401-4dcc-9d06-75438b408d0b|8|MJPTHIND|Major Pathological Response Indicator|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|10^9 organisms/g|SD-CT|1|cP|HPLC/MS/MS||||FAMILY MEMBER|READER 3|Y|4|Visit_4|65|5|TREATMENT|2020-12-30|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-13|P1Y2M10DT2H30M|COINCIDENT|2020-11-29|COINCIDENT|2020-12-24
e|RS|a3b72841-3401-4dcc-9d06-75438b408d0b|9|SPLNRESP|Spleen Response|GCIG RUSTIN OVARIAN CANCER 2011|||CR|1|10^3 organisms/g|MYELOPEROXIDASE STAIN|||Y|FRIEND|DERMATOLOGIST|N|5|Visit_5|90|7|TREATMENT|2021-01-24|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-01|P1Y2M10DT2H30M|UNKNOWN|2020-11-07|AFTER|2020-12-14
e|RS|a3b72841-3401-4dcc-9d06-75438b408d0b|10|MRDRESP|Minimal Residual Disease Response|SACT|[?]|mL/h|CR|1|EVENTS|SICKLE CELL SOLUBILITY TEST|Y|Y||SIBLING|ADJUDICATOR 2|U|5|Visit_5|90|4|WASHOUT|2021-01-24|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-01|P1Y2M10DT2H30M|UNKNOWN|2021-01-23|COINCIDENT|2021-01-26
e|RS|4393406e-bda5-42e4-a752-a8121004b7ef|1|CPRFSTAT|Clinical Performance Status|RECIST 1.1|[?]|g/dL|UNFAVORABLE RESPONSE|1|SPRAY|HIGH RESOLUTION MELT ANALYSIS||||GUARDIAN|ADJUDICATOR 3|Y|1|Visit_1|10|5|FOLLOW-UP|2020-10-28|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-31|P1Y2M10DT2H30M|UNKNOWN|2020-11-09|ONGOING|2020-11-13
e|RS|4393406e-bda5-42e4-a752-a8121004b7ef|2|DRCRIND|Disease Recurrence Indicator|KUMAR IMWG 2016|||VGPR|1|mol/mol|SLIT LAMP PHOTOGRAPHY||Y|Y|FAMILY MEMBER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|1|Visit_1|10|2|TREATMENT|2020-10-28|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-31|P1Y2M10DT2H30M|BEFORE|2021-01-18|BEFORE|2021-01-21
e|RS|4393406e-bda5-42e4-a752-a8121004b7ef|3|NTRGRESP|Non-target Response|SCHWARZ CERVICAL CANCER 2009|||NOT ALL EVALUATED|1|mL/animal/day|MEDIASTINOSCOPY|||Y|GUARDIAN|OPHTHALMOLOGIST|U|2|Visit_2|25|3|TREATMENT|2020-11-12|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-13|P1Y2M10DT2H30M|AFTER|2021-01-03|COINCIDENT|2021-01-12
e|RS|4393406e-bda5-42e4-a752-a8121004b7ef|4|TRGRESP|Target Response|RECIST 1.1|||NOT ALL EVALUATED|1|L/kg|BALLPOINT PEN TECHNIQUE|||Y|CLINICAL RESEARCH ASSOCIATE|READER 1|NA|2|Visit_2|25|7|FOLLOW-UP|2020-11-12|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-13|P1Y2M10DT2H30M|AFTER|2020-11-25|BEFORE|2020-12-26
e|RS|4393406e-bda5-42e4-a752-a8121004b7ef|5|HEMARESP|Hematologic Response|RAJKUMAR MYELOMA 2011|[?]|PLUG|RELAPSED DISEASE FROM CR OR PR|1|/cmH2O|TRIPLE-PHASE MRI SCAN|Y|||CHILD|READER 3|NA|3|Visit_3|40|1|SCREENING|2020-11-27|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-06|P1Y2M10DT2H30M|COINCIDENT|2020-12-02|COINCIDENT|2021-01-16
e|RS|4393406e-bda5-42e4-a752-a8121004b7ef|6|ANATRESP|Anatomic Response|MACDONALD GLIOMA 1990|||SD|1|VIRTUAL PIXEL|THIN SMEAR|||Y|HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|Y|3|Visit_3|40|7|WASHOUT|2020-11-27|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-06|P1Y2M10DT2H30M|BEFORE|2020-11-08|COINCIDENT|2020-12-11
e|RS|4393406e-bda5-42e4-a752-a8121004b7ef|7|MNPTHIND|Minor Pathological Response Indicator|NCCN ALL MRD 2014|[?]|Arbitrary U|MRD NEGATIVITY|1|ppth|MYELOPEROXIDASE STAIN|Y|Y||PARENT|MICROSCOPIST 2|U|4|Visit_4|65|1|WASHOUT|2020-12-22|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-28|P1Y2M10DT2H30M|BEFORE|2020-11-29|ONGOING|2021-01-17
e|RS|4393406e-bda5-42e4-a752-a8121004b7ef|8|PATHRESP|Pathologic Response|CHOI GIST 2008|[?]|GBq/mg|iPR|1|mL/h|ICP-MS|Y|||FAMILY MEMBER|CLINICAL PATHOLOGIST|NA|4|Visit_4|65|5|WASHOUT|2020-12-22|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-28|P1Y2M10DT2H30M|COINCIDENT|2021-01-10|BEFORE|2021-01-24
e|RS|4393406e-bda5-42e4-a752-a8121004b7ef|9|TRGRESP|Target Response|WHO BREAST CANCER 2006|[?]|Ci/mg|PR-CT|1|mL/kg/h|PERIODIC ACID SCHIFF STAIN||||VENDOR|CARDIOLOGIST|NA|5|Visit_5|90|4|SCREENING|2021-01-16|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-23|P1Y2M10DT2H30M|UNKNOWN|2021-01-25|AFTER|2021-01-26
e|RS|4393406e-bda5-42e4-a752-a8121004b7ef|10|HEMARESP|Hematologic Response|CHESON CLL 2006|[?]|Enzyme U|iCR|1|U/mg|HANSEL STAIN|Y|Y||INDEPENDENT ASSESSOR|ADJUDICATOR 1|NA|5|Visit_5|90|3|WASHOUT|2021-01-16|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-23|P1Y2M10DT2H30M|AFTER|2020-12-24|COINCIDENT|2021-01-11
e|RS|d70f5903-3d94-422b-8f69-212f015b54c9|1|NEWLWIND|New Lesion Worsening Indicator|MRECIST LENCIONI LIVER CANCER 2010|||OPTIMAL MORPHOLOGIC RESPONSE|1|eq|CRYOSCOPY||Y|Y|PROXY|PATHOLOGIST 2|U|1|Visit_1|10|7|FOLLOW-UP|2020-05-19|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-05|P1Y2M10DT2H30M|UNKNOWN|2020-07-05|ONGOING|2020-07-12
e|RS|d70f5903-3d94-422b-8f69-212f015b54c9|2|PATHRESP|Pathologic Response|DURIE MULTIPLE MYELOMA 2006|[?]|psi|PARTIAL MORPHOLOGIC RESPONSE|1|VOXEL|TONOMETRY|Y|||FAMILY MEMBER|PHYSIOTHERAPIST|N|1|Visit_1|10|5|SCREENING|2020-05-19|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-05|P1Y2M10DT2H30M|AFTER|2020-08-12|COINCIDENT|2020-08-13
e|RS|d70f5903-3d94-422b-8f69-212f015b54c9|3|NTRGRESP|Non-target Response|HARTMANN GERM CELL CANCER 2002|[?]|atm|CYTOGENETIC MINIMAL RESPONSE|1|nmol/mol|RADIOIMMUNOPRECIPITATION ASSAY||Y||SIBLING|MICROSCOPIST 2|NA|2|Visit_2|25|7|TREATMENT|2020-06-03|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-14|P1Y2M10DT2H30M|BEFORE|2020-05-31|COINCIDENT|2020-08-04
e|RS|d70f5903-3d94-422b-8f69-212f015b54c9|4|METSIND|Metastatic Indicator|BRUGGEMANN MRD 2010|[?]|TRANSDUCING UNIT|ABSENT MORPHOLOGIC RESPONSE|1|10^9 CFU/g|JAEGER EYE CHART|Y|||INTERVIEWER|HEMATOLOGIST|Y|2|Visit_2|25|1|WASHOUT|2020-06-03|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-14|P1Y2M10DT2H30M|UNKNOWN|2020-07-22|ONGOING|2020-07-24
e|RS|d70f5903-3d94-422b-8f69-212f015b54c9|5|CPRFSTAT|Clinical Performance Status|SCHWARZ CERVICAL CANCER 2009|||iPR|1|IU/g|LAPAROSCOPY|Y|Y|Y|SPOUSE|NEUROLOGIST 1|Y|3|Visit_3|40|3|SCREENING|2020-06-18|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-15|P1Y2M10DT2H30M|COINCIDENT|2020-05-23|AFTER|2020-06-13
e|RS|d70f5903-3d94-422b-8f69-212f015b54c9|6|MRDIND|Minimal Residual Disease Indicator|TSUKASAKI LEUKEMIA LYMPHOMA 2009|||MRD NEGATIVITY|1|DRUM|COMPUTERIZED CORNEAL TOPOGRAPHY|||Y|SIBLING|OTOLARYNGOLOGIST|U|3|Visit_3|40|4|TREATMENT|2020-06-18|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-15|P1Y2M10DT2H30M|AFTER|2020-05-31|COINCIDENT|2020-06-08
e|RS|d70f5903-3d94-422b-8f69-212f015b54c9|7|CYTORESP|Cytogenetic Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|mg/g/h|INCREASED|1|g/L|MECHANICAL CLOT DETECTION||||CLINICAL STUDY SPONSOR|RATER 1|NA|4|Visit_4|65|2|TREATMENT|2020-07-13|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-23|P1Y2M10DT2H30M|COINCIDENT|2020-08-07|COINCIDENT|2020-08-09
e|RS|d70f5903-3d94-422b-8f69-212f015b54c9|8|CLINRESP|Clinical Response|IWG CHESON MDS 2000|[?]|F|CYTOGENETIC PR|1|PA|NEURAMINIDASE INHIBITION ASSAY||||INTERVIEWER|ONCOLOGIST 2|N|4|Visit_4|65|3|SCREENING|2020-07-13|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-23|P1Y2M10DT2H30M|BEFORE|2020-06-08|BEFORE|2020-06-23
e|RS|d70f5903-3d94-422b-8f69-212f015b54c9|9|BMIVLIND|Bone Marrow Involvement Indicator|LEE LUNG CANCER 2011|[?]|mm/2h|MRD PERSISTENCE|1|SQU/mL|TRANSCRIPTION-MEDIATED AMPLIFICATION||||CAREGIVER|READER 2|U|5|Visit_5|90|5|TREATMENT|2020-08-07|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-02|P1Y2M10DT2H30M|BEFORE|2020-07-09|COINCIDENT|2020-07-23
e|RS|d70f5903-3d94-422b-8f69-212f015b54c9|10|NTNERESP|Non-Target Non-Enhancing Response|CHOLLET BREAST CANCER 2002|[?]|ug/dL|iUPD|1|uV*sec|POLYGRAPHY||||GUARDIAN|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|5|Visit_5|90|5|FOLLOW-UP|2020-08-07|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-02|P1Y2M10DT2H30M|UNKNOWN|2020-07-02|BEFORE|2020-08-01
e|RS|ef772266-faf1-4904-8ac3-19cbc3ea7d36|1|NTERESP|Non-Target Enhancing Response|RANO ELLINGSON 2017|[?]|/5x10^4 WBC|MORPHOLOGIC LEUKEMIA-FREE STATE|1|umol/h/mmol|IMMUNOTURBIDIMETRY||Y||CLINICAL STUDY SPONSOR|UROLOGIST|Y|1|Visit_1|10|4|TREATMENT|2021-01-06|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-25|P1Y2M10DT2H30M|AFTER|2021-02-18|ONGOING|2021-03-26
e|RS|ef772266-faf1-4904-8ac3-19cbc3ea7d36|2|CYTORESP|Cytogenetic Response|SHINDOH COLORECTAL CANCER 2013|[?]|cL|PD-CT|1|10^3 RNA copies/mL|TRANSCRIPTION-MEDIATED AMPLIFICATION||||PROXY|FORENSIC PATHOLOGIST|U|1|Visit_1|10|2|TREATMENT|2021-01-06|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-25|P1Y2M10DT2H30M|UNKNOWN|2021-02-25|BEFORE|2021-03-21
e|RS|ef772266-faf1-4904-8ac3-19cbc3ea7d36|3|MNPTHIND|Minor Pathological Response Indicator|LUGANO CLASSIFICATION|[?]|mm2|MRD PERSISTENCE|1|ug/animal|GC/MS-CI||Y||CLINICAL RESEARCH ASSOCIATE|RATER 1|N|2|Visit_2|25|5|TREATMENT|2021-01-21|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-05|P1Y2M10DT2H30M|UNKNOWN|2021-02-07|BEFORE|2021-04-03
e|RS|ef772266-faf1-4904-8ac3-19cbc3ea7d36|4|LIVRRESP|Liver Response|KEAM BREAST CANCER 2013|[?]|cGy|PR-CT|1|EID 50/mL|ELECTRONEUROGRAPHY|Y|||PARENT|FORENSIC PATHOLOGIST|NA|2|Visit_2|25|3|TREATMENT|2021-01-21|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-05|P1Y2M10DT2H30M|BEFORE|2021-01-06|COINCIDENT|2021-03-08
e|RS|ef772266-faf1-4904-8ac3-19cbc3ea7d36|5|METBRESP|Metabolic Response|LUGANO CLASSIFICATION|[?]|mL/m2|IMPROVED|1|FIU|FLOCCULATION||||FAMILY MEMBER|ONCOLOGIST|U|3|Visit_3|40|7|TREATMENT|2021-02-05|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-24|P1Y2M10DT2H30M|COINCIDENT|2021-02-09|ONGOING|2021-03-17
e|RS|ef772266-faf1-4904-8ac3-19cbc3ea7d36|6|NEWLWIND|New Lesion Worsening Indicator|GUPPY OVARIAN CANCER 2002|[?]|TABLET|ABSENT MORPHOLOGIC RESPONSE|1|mg/m2/day|INTRAVASCULAR ULTRASOUND||Y||SPOUSE|ADJUDICATOR|NA|3|Visit_3|40|6|WASHOUT|2021-02-05|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-24|P1Y2M10DT2H30M|BEFORE|2021-02-17|COINCIDENT|2021-03-14
e|RS|ef772266-faf1-4904-8ac3-19cbc3ea7d36|7|ANATRESP|Anatomic Response|RANO ELLINGSON 2017|[?]|APS U|DECREASED|1|pmol/L/h|PHYSICAL EXAMINATION|Y|||CAREGIVER|NEUROLOGIST 2|U|4|Visit_4|65|2|SCREENING|2021-03-02|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-04|P1Y2M10DT2H30M|AFTER|2021-03-29|ONGOING|2021-03-30
e|RS|ef772266-faf1-4904-8ac3-19cbc3ea7d36|8|METBRESP|Metabolic Response|MACDONALD GLIOMA 1990|[?]|10^4 CFU/mL|HI-P|1|DIP|PHOROPTER||||FRIEND|OPTOMETRIST|Y|4|Visit_4|65|3|SCREENING|2021-03-02|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-04|P1Y2M10DT2H30M|COINCIDENT|2021-01-12|COINCIDENT|2021-03-03
e|RS|ef772266-faf1-4904-8ac3-19cbc3ea7d36|9|SFTSRESP|Soft Tissue Response|HARTMANN GERM CELL CANCER 2002|[?]|mL/dose|CYTOGENETIC CR|1|IU/g|MASS SPECTROMETRY||||INVESTIGATOR|PHYSIOTHERAPIST|N|5|Visit_5|90|7|TREATMENT|2021-03-27|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-03|P1Y2M10DT2H30M|BEFORE|2021-01-13|ONGOING|2021-02-05
e|RS|ef772266-faf1-4904-8ac3-19cbc3ea7d36|10|NTLWIND|Non-Target Lesion Worsening Indicator|IWC HALLEK CLL 2008|[?]|lx|EQUIVOCAL|1|mCi/kg|RYAN BLUE STAIN|Y|Y||SPOUSE|ADJUDICATOR 3|U|5|Visit_5|90|3|TREATMENT|2021-03-27|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-03|P1Y2M10DT2H30M|COINCIDENT|2021-01-07|ONGOING|2021-02-05
e|RS|c0f9c36c-1ae5-4f80-b936-0afe3f661746|1|MRDIND|Minimal Residual Disease Indicator|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|mL/100g/min|pCR|1|V/sec|ENDPOINT DILUTION ASSAY||||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 3|U|1|Visit_1|10|3|TREATMENT|2020-07-14|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-22|P1Y2M10DT2H30M|COINCIDENT|2020-07-13|AFTER|2020-09-06
e|RS|c0f9c36c-1ae5-4f80-b936-0afe3f661746|2|MRDIND|Minimal Residual Disease Indicator|KEAM BREAST CANCER 2013|[?]|ug/kg/h|PR WITH LYMPHOCYTOSIS|1|CIGARETTE|CLIP||||FAMILY MEMBER|MICROSCOPIST 1|Y|1|Visit_1|10|6|SCREENING|2020-07-14|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-22|P1Y2M10DT2H30M|BEFORE|2020-07-18|ONGOING|2020-09-10
e|RS|c0f9c36c-1ae5-4f80-b936-0afe3f661746|3|TRGRESP|Target Response|SCHER PROSTATE CANCER 2011|[?]|cm/min|FAVORABLE RESPONSE|1|hPa|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION||||FRIEND|NEUROLOGIST 2|NA|2|Visit_2|25|1|TREATMENT|2020-07-29|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-31|P1Y2M10DT2H30M|BEFORE|2020-08-20|ONGOING|2020-10-04
e|RS|c0f9c36c-1ae5-4f80-b936-0afe3f661746|4|MRPHRESP|Morphologic Response|MONTSERRAT CLL 1989|[?]|ft|IMMUNOPHENOTYPIC CR|1|TABLET|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS||||SPOUSE|ONCOLOGIST 2|NA|2|Visit_2|25|3|TREATMENT|2020-07-29|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-31|P1Y2M10DT2H30M|BEFORE|2020-07-23|AFTER|2020-10-06
e|RS|c0f9c36c-1ae5-4f80-b936-0afe3f661746|5|LIVRRESP|Liver Response|RECIST 1.1|[?]|breaths/30s|EQUIVOCAL|1|U/animal|ANTIMICROBIAL COMBINATION TESTING||||FAMILY MEMBER|OPHTHALMOLOGIST|U|3|Visit_3|40|2|TREATMENT|2020-08-13|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-18|P1Y2M10DT2H30M|BEFORE|2020-09-15|AFTER|2020-09-19
e|RS|c0f9c36c-1ae5-4f80-b936-0afe3f661746|6|HEMARESP|Hematologic Response|CHOI GIST 2008|[?]|10^6 U|ABSENT MORPHOLOGIC RESPONSE|1|mg/m2|POPULATION SEQUENCING||Y||CLINICAL RESEARCH ASSOCIATE|FORENSIC PATHOLOGIST|NA|3|Visit_3|40|3|FOLLOW-UP|2020-08-13|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-18|P1Y2M10DT2H30M|BEFORE|2020-08-02|BEFORE|2020-09-14
e|RS|c0f9c36c-1ae5-4f80-b936-0afe3f661746|7|MJPTHIND|Major Pathological Response Indicator|MRECIST LENCIONI LIVER CANCER 2010|[?]|U/kg|PD FROM PR|1|mIU/L|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY||||HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|4|Visit_4|65|3|TREATMENT|2020-09-07|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-21|P1Y2M10DT2H30M|BEFORE|2020-09-22|COINCIDENT|2020-10-09
e|RS|c0f9c36c-1ae5-4f80-b936-0afe3f661746|8|METSIND|Metastatic Indicator|SHINDOH COLORECTAL CANCER 2013|[?]|/mm|NON-CR/NON-PD|1|mEq/mL|IMMUNOASSAY||Y||ADJUDICATION COMMITTEE|RADIOLOGIST 2|Y|4|Visit_4|65|1|SCREENING|2020-09-07|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-21|P1Y2M10DT2H30M|UNKNOWN|2020-09-24|ONGOING|2020-09-29
e|RS|c0f9c36c-1ae5-4f80-b936-0afe3f661746|9|MRDRESP|Minimal Residual Disease Response|CHESON CLL 2012|[?]|AFU|PARTIAL MORPHOLOGIC RESPONSE|1|h/wk|DISK DIFFUSION||||STUDY SUBJECT|MICROSCOPIST 3|Y|5|Visit_5|90|6|TREATMENT|2020-10-02|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-21|P1Y2M10DT2H30M|UNKNOWN|2020-10-04|ONGOING|2020-10-05
e|RS|c0f9c36c-1ae5-4f80-b936-0afe3f661746|10|DRCRIND|Disease Recurrence Indicator|HARTMANN GERM CELL CANCER 2002|[?]|CYLINDER|IMPROVED|1|mg/m2/day|CORONARY ANGIOGRAPHY||||STUDY SUBJECT|PATHOLOGIST 2|U|5|Visit_5|90|4|FOLLOW-UP|2020-10-02|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-21|P1Y2M10DT2H30M|AFTER|2020-08-15|BEFORE|2020-09-02
e|RS|f17b5630-e782-4135-8a50-4a9bb2fe63b1|1|NTRGRESP|Non-target Response|AJCC V7|[?]|IU/mL|SMD|1|/100 HPFs|HILLMEN COLOR CHART||||CAREGIVER|RADIOLOGIST 2|NA|1|Visit_1|10|5|TREATMENT|2020-11-29|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-31|P1Y2M10DT2H30M|UNKNOWN|2021-02-14|BEFORE|2021-02-23
e|RS|f17b5630-e782-4135-8a50-4a9bb2fe63b1|2|CLINRESP|Clinical Response|KEAM BREAST CANCER 2013|[?]|CIGARETTE|MORPHOLOGIC CRi|1|PACKET|SXA SCAN||||SIGNIFICANT OTHER|READER 3|Y|1|Visit_1|10|5|TREATMENT|2020-11-29|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-31|P1Y2M10DT2H30M|COINCIDENT|2021-02-08|ONGOING|2021-02-26
e|RS|f17b5630-e782-4135-8a50-4a9bb2fe63b1|3|PATHRESP|Pathologic Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|10^6 CFU|PSEUDORESPONSE|1|/10^3|U-HPLC/MS/MS||||VENDOR|OTOLARYNGOLOGIST|N|2|Visit_2|25|7|WASHOUT|2020-12-14|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-16|P1Y2M10DT2H30M|AFTER|2020-11-30|BEFORE|2020-12-06
e|RS|f17b5630-e782-4135-8a50-4a9bb2fe63b1|4|SPLNRESP|Spleen Response|HARTMANN GERM CELL CANCER 2002|[?]|TUBE|MR|1|mV/sec|HILLMEN COLOR CHART||Y||SPOUSE|MICROSCOPIST|N|2|Visit_2|25|2|TREATMENT|2020-12-14|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-16|P1Y2M10DT2H30M|BEFORE|2021-02-23|COINCIDENT|2021-02-25
e|RS|f17b5630-e782-4135-8a50-4a9bb2fe63b1|5|MNPTHIND|Minor Pathological Response Indicator|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|MBq/uL|iUPD|1|mmHg/L/min|INTRAVASCULAR ULTRASOUND|Y|||INTERVIEWER|PATHOLOGIST|NA|3|Visit_3|40|5|SCREENING|2020-12-29|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-19|P1Y2M10DT2H30M|COINCIDENT|2021-01-14|ONGOING|2021-02-10
e|RS|f17b5630-e782-4135-8a50-4a9bb2fe63b1|6|SFTSRESP|Soft Tissue Response|WOLCHOK SOLID TUMORS 2009|||CR|1|APS U|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|||Y|INDEPENDENT ASSESSOR|PATHOLOGIST|Y|3|Visit_3|40|3|WASHOUT|2020-12-29|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-19|P1Y2M10DT2H30M|AFTER|2020-12-15|AFTER|2020-12-25
e|RS|f17b5630-e782-4135-8a50-4a9bb2fe63b1|7|MJPTHIND|Major Pathological Response Indicator|CHESON CLL 2012|||INCREASED|1|MnFI|OBSERVATION||Y|Y|CAREGIVER|NEUROLOGIST 2|Y|4|Visit_4|65|4|TREATMENT|2021-01-23|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-14|P1Y2M10DT2H30M|COINCIDENT|2021-02-23|AFTER|2021-02-25
e|RS|f17b5630-e782-4135-8a50-4a9bb2fe63b1|8|CLINRESP|Clinical Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|SACHET|PDu|1|pg/cell|PULSE OXIMETRY||||CHILD|ADJUDICATOR 2|N|4|Visit_4|65|3|TREATMENT|2021-01-23|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-14|P1Y2M10DT2H30M|COINCIDENT|2020-12-15|BEFORE|2021-01-29
e|RS|f17b5630-e782-4135-8a50-4a9bb2fe63b1|9|MRPHRESP|Morphologic Response|IWG CHESON MDS 2006|||MORPHOLOGIC CRi|1|CFU/mL|CALCULATION|||Y|NON-HEALTH CARE PROFESSIONAL|UROLOGIST|U|5|Visit_5|90|4|TREATMENT|2021-02-17|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-03|P1Y2M10DT2H30M|BEFORE|2021-01-10|ONGOING|2021-02-24
e|RS|f17b5630-e782-4135-8a50-4a9bb2fe63b1|10|SFTSRESP|Soft Tissue Response|SCHER PROSTATE CANCER 2011|[?]|10^9 CFU|PSEUDOPROGRESSION|1|mol/g|PANENDOSCOPY||Y||SIBLING|CARDIOLOGIST|NA|5|Visit_5|90|3|WASHOUT|2021-02-17|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-03|P1Y2M10DT2H30M|BEFORE|2021-01-09|ONGOING|2021-02-06
e|RS|8bdb40c9-1e44-45ae-bf08-81ea635fd762|1|DRCRIND|Disease Recurrence Indicator|BLAZER COLORECTAL CANCER 2008|[?]|Bq/uL|PARTIAL MORPHOLOGIC RESPONSE|1|Newton|TARGETED TRANSCRIPTOME SEQUENCING||||DOMESTIC PARTNER|ONCOLOGIST|N|1|Visit_1|10|6|SCREENING|2021-01-02|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-20|P1Y2M10DT2H30M|UNKNOWN|2021-03-15|ONGOING|2021-03-27
e|RS|8bdb40c9-1e44-45ae-bf08-81ea635fd762|2|MRPHRESP|Morphologic Response|PCWG SCHER PROSTATE CANCER 2008|[?]|DAgU/mL|MINOR PATHOLOGIC RESPONSE|1|mg/kg/dose|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY||||INTERVIEWER|PATHOLOGIST 1|Y|1|Visit_1|10|4|FOLLOW-UP|2021-01-02|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-20|P1Y2M10DT2H30M|COINCIDENT|2021-01-19|ONGOING|2021-01-22
e|RS|8bdb40c9-1e44-45ae-bf08-81ea635fd762|3|BMIVLIND|Bone Marrow Involvement Indicator|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|mg/m2/min|MR|1|mkat|FLUORIMETRY||Y||ADJUDICATION COMMITTEE|CLINICAL PATHOLOGIST|NA|2|Visit_2|25|3|TREATMENT|2021-01-17|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-28|P1Y2M10DT2H30M|UNKNOWN|2021-01-14|BEFORE|2021-02-20
e|RS|8bdb40c9-1e44-45ae-bf08-81ea635fd762|4|ANATRESP|Anatomic Response|FAROOQUI SUPP CLL 2014|[?]|beats/min|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|nU/cL|MACRO BROTH DILUTION||Y||GUARDIAN|ADJUDICATOR 2|NA|2|Visit_2|25|5|TREATMENT|2021-01-17|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-28|P1Y2M10DT2H30M|AFTER|2021-02-21|ONGOING|2021-03-29
e|RS|8bdb40c9-1e44-45ae-bf08-81ea635fd762|5|HEMARESP|Hematologic Response|IWC HALLEK CLL 2008|[?]|mol/g|IMPROVED|1|pkat/L|WRIGHT-GIEMSA STAIN||||NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|NA|3|Visit_3|40|2|WASHOUT|2021-02-01|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-10|P1Y2M10DT2H30M|COINCIDENT|2021-03-11|BEFORE|2021-03-14
e|RS|8bdb40c9-1e44-45ae-bf08-81ea635fd762|6|METBRESP|Metabolic Response|PCWG SCHER PROSTATE CANCER 2008|||STABLE|1|mL/min/mmHg|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY|Y||Y|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|NA|3|Visit_3|40|1|FOLLOW-UP|2021-02-01|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-10|P1Y2M10DT2H30M|AFTER|2021-03-12|ONGOING|2021-03-16
e|RS|8bdb40c9-1e44-45ae-bf08-81ea635fd762|7|NEWLWIND|New Lesion Worsening Indicator|iRECIST|||PSEUDOPROGRESSION|1|GBq/g|WESTERGREN|||Y|ADJUDICATOR|NEUROLOGIST|NA|4|Visit_4|65|3|FOLLOW-UP|2021-02-26|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-15|P1Y2M10DT2H30M|BEFORE|2021-01-26|ONGOING|2021-03-26
e|RS|8bdb40c9-1e44-45ae-bf08-81ea635fd762|8|SFTSRESP|Soft Tissue Response|HAMAOKA BREAST CANCER 2010|[?]|BAU/mL|cCR|1|dpm/mL|FLOCCULATION||||SIBLING|RADIOLOGIST 2|Y|4|Visit_4|65|2|TREATMENT|2021-02-26|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-15|P1Y2M10DT2H30M|AFTER|2021-02-18|AFTER|2021-02-24
e|RS|8bdb40c9-1e44-45ae-bf08-81ea635fd762|9|STRUSTAT|Steroid Use Status|PALUMBO MULTIPLE MYELOMA 2009|[?]|kHz|PD/RELAPSE AFTER HI|1|mg|LINE PROBE ASSAY|Y|||HEALTH CARE PROFESSIONAL|READER 2|U|5|Visit_5|90|6|WASHOUT|2021-03-23|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-15|P1Y2M10DT2H30M|AFTER|2021-01-25|AFTER|2021-03-05
e|RS|8bdb40c9-1e44-45ae-bf08-81ea635fd762|10|MOLRESP|Molecular Response|EASL BRUIX LIVER CANCER 2001|||CMR|1|TABLET|BIOPSY|||Y|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|NA|5|Visit_5|90|4|TREATMENT|2021-03-23|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-15|P1Y2M10DT2H30M|BEFORE|2021-03-11|BEFORE|2021-03-17
e|RS|c010dfcb-c1bb-4b4f-b58c-f4986ee86384|1|MOLRESP|Molecular Response|iRECIST|[?]|SACHET|HI-P|1|kV|NEPHELOMETRY||||FAMILY MEMBER|ONCOLOGIST 1|N|1|Visit_1|10|7|SCREENING|2021-01-16|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-22|P1Y2M10DT2H30M|BEFORE|2021-03-13|ONGOING|2021-04-12
e|RS|c010dfcb-c1bb-4b4f-b58c-f4986ee86384|2|PATHRESP|Pathologic Response|WOLCHOK SOLID TUMORS 2009|[?]|fraction of 1|cCR|1|g|ELECTROCHEMILUMINESCENCE IMMUNOASSAY||||FAMILY MEMBER|READER 3|U|1|Visit_1|10|4|SCREENING|2021-01-16|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-22|P1Y2M10DT2H30M|AFTER|2021-01-29|ONGOING|2021-03-18
e|RS|c010dfcb-c1bb-4b4f-b58c-f4986ee86384|3|TRGRESP|Target Response|MURPHY PROSTATE CANCER 1980|||UNFAVORABLE RESPONSE|1|dpm/0.5 mL|HIGH RESOLUTION MELT ANALYSIS|||Y|INVESTIGATOR|READER 2|Y|2|Visit_2|25|1|TREATMENT|2021-01-31|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-11|P1Y2M10DT2H30M|COINCIDENT|2021-01-10|AFTER|2021-02-09
e|RS|c010dfcb-c1bb-4b4f-b58c-f4986ee86384|4|MRDRESP|Minimal Residual Disease Response|KUMAR IMWG 2016|[?]|mm3/mm2/year|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|g/U|VIRUS PLAQUE ASSAY||||PARENT|OPTOMETRIST|NA|2|Visit_2|25|7|TREATMENT|2021-01-31|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-11|P1Y2M10DT2H30M|UNKNOWN|2021-03-23|AFTER|2021-04-05
e|RS|c010dfcb-c1bb-4b4f-b58c-f4986ee86384|5|NEWLWIND|New Lesion Worsening Indicator|IRANO 2015|[?]|RFU|RELAPSED DISEASE FROM CR OR PR|1|IU/mg|NO INFORMATION||||SIGNIFICANT OTHER|NEUROLOGIST 2|U|3|Visit_3|40|4|TREATMENT|2021-02-15|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-09|P1Y2M10DT2H30M|AFTER|2021-03-16|ONGOING|2021-03-31
e|RS|c010dfcb-c1bb-4b4f-b58c-f4986ee86384|6|TRGRESP|Target Response|MASS|[?]|BOTTLE|QUANTIFIABLE MRD POSITIVITY|1|uL/mL|ISHIHARA COLOR PLATES|Y|||FRIEND|PATHOLOGIST 1|U|3|Visit_3|40|5|TREATMENT|2021-02-15|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-09|P1Y2M10DT2H30M|AFTER|2021-02-22|ONGOING|2021-03-14
e|RS|c010dfcb-c1bb-4b4f-b58c-f4986ee86384|7|NEWLPROG|New Lesion Progression|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|DAYS|MOLECULAR MAJOR RESPONSE|1|mg|RADIATION DOSIMETRY||||CLINICAL STUDY SPONSOR|HEMATOLOGIST|U|4|Visit_4|65|5|TREATMENT|2021-03-12|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-17|P1Y2M10DT2H30M|COINCIDENT|2021-02-05|COINCIDENT|2021-03-02
e|RS|c010dfcb-c1bb-4b4f-b58c-f4986ee86384|8|MJPTHIND|Major Pathological Response Indicator|GUPPY OVARIAN CANCER 2002|[?]|mol/g|CA125 50% RESPONSE|1|MPL U/mL|TOLUIDINE BLUE STAIN||||SIBLING|PATHOLOGIST 2|Y|4|Visit_4|65|5|TREATMENT|2021-03-12|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-17|P1Y2M10DT2H30M|COINCIDENT|2021-03-28|ONGOING|2021-04-15
e|RS|c010dfcb-c1bb-4b4f-b58c-f4986ee86384|9|NTNERESP|Non-Target Non-Enhancing Response|KUKER LYMPHOMA 2005|[?]|um/s|UNFAVORABLE RESPONSE|1|uL/dose|NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY|Y|Y||SIGNIFICANT OTHER|OTOLARYNGOLOGIST|N|5|Visit_5|90|1|FOLLOW-UP|2021-04-06|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-24|P1Y2M10DT2H30M|COINCIDENT|2021-02-16|COINCIDENT|2021-03-04
e|RS|c010dfcb-c1bb-4b4f-b58c-f4986ee86384|10|BESTRESP|Best Overall Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|ppm|ABSENT MORPHOLOGIC RESPONSE|1|ngEq/L|CALIPER MEASUREMENT METHOD||||FAMILY MEMBER|FORENSIC PATHOLOGIST|Y|5|Visit_5|90|1|FOLLOW-UP|2021-04-06|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-24|P1Y2M10DT2H30M|COINCIDENT|2021-03-17|COINCIDENT|2021-04-07
e|RS|296f8314-5a07-47b5-8796-31afe709b379|1|METSIND|Metastatic Indicator|KEAM BREAST CANCER 2013|[?]|ug/cm2|PR|1|mN|PHOROPTER||||ADJUDICATOR|READER 1|U|1|Visit_1|10|5|WASHOUT|2020-07-08|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-12|P1Y2M10DT2H30M|UNKNOWN|2020-09-10|AFTER|2020-09-14
e|RS|296f8314-5a07-47b5-8796-31afe709b379|2|MRPHRESP|Morphologic Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|AMPULE|QUANTIFIABLE MRD POSITIVITY|1|MASK|WHOLE GENOME SEQUENCING||||SIBLING|OPTOMETRIST|U|1|Visit_1|10|2|SCREENING|2020-07-08|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-12|P1Y2M10DT2H30M|UNKNOWN|2020-09-04|BEFORE|2020-09-24
e|RS|296f8314-5a07-47b5-8796-31afe709b379|3|MRDIND|Minimal Residual Disease Indicator|DURIE MULTIPLE MYELOMA 2006|||CYTOGENETIC CR|1|hr/day|MALDI||Y|Y|VENDOR|NEUROLOGIST 2|Y|2|Visit_2|25|5|TREATMENT|2020-07-23|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-25|P1Y2M10DT2H30M|UNKNOWN|2020-08-11|AFTER|2020-08-18
e|RS|296f8314-5a07-47b5-8796-31afe709b379|4|ANATRESP|Anatomic Response|iRECIST|[?]|g/g/day|PSEUDOPROGRESSION|1|10^6 CFU/mL|CISH||||PROXY|ADJUDICATOR 2|NA|2|Visit_2|25|7|FOLLOW-UP|2020-07-23|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-25|P1Y2M10DT2H30M|UNKNOWN|2020-09-26|BEFORE|2020-10-02
e|RS|296f8314-5a07-47b5-8796-31afe709b379|5|TMRESP|Tumor Marker Response|CHESON CLL 2006|[?]|Pack Year|QUANTIFIABLE MRD POSITIVITY|1|pt_br|RULER MEASUREMENT METHOD||||STUDY SUBJECT|ONCOLOGIST|NA|3|Visit_3|40|4|FOLLOW-UP|2020-08-07|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-04|P1Y2M10DT2H30M|UNKNOWN|2020-07-01|BEFORE|2020-09-12
e|RS|296f8314-5a07-47b5-8796-31afe709b379|6|BONERESP|Bone Response|CHESON CLL 2006|[?]|SCOOPFUL|OPTIMAL MORPHOLOGIC RESPONSE|1|Bq/kg|MICROBIAL BIOCHEMICAL IDENTIFICATION|Y|||SIGNIFICANT OTHER|MICROSCOPIST 3|NA|3|Visit_3|40|1|TREATMENT|2020-08-07|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-04|P1Y2M10DT2H30M|UNKNOWN|2020-07-05|AFTER|2020-08-30
e|RS|296f8314-5a07-47b5-8796-31afe709b379|7|NTRGRESP|Non-target Response|RECICL|[?]|SUPPOSITORY|nPR|1|AMPULE|CONTRAST ENHANCED SPIRAL CT SCAN||||INVESTIGATOR|PHYSIOTHERAPIST|NA|4|Visit_4|65|4|WASHOUT|2020-09-01|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-13|P1Y2M10DT2H30M|COINCIDENT|2020-08-09|BEFORE|2020-09-21
e|RS|296f8314-5a07-47b5-8796-31afe709b379|8|BMIVLIND|Bone Marrow Involvement Indicator|CHESON CLL 2012|[?]|mAnson U/mL|PARTIAL MORPHOLOGIC RESPONSE|1|Ci/uL|MRS||||SIBLING|ADJUDICATOR 3|U|4|Visit_4|65|5|FOLLOW-UP|2020-09-01|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-13|P1Y2M10DT2H30M|UNKNOWN|2020-08-21|ONGOING|2020-10-04
e|RS|296f8314-5a07-47b5-8796-31afe709b379|9|NEWLPROG|New Lesion Progression|AJCC V8|[?]|U/mL|UNFAVORABLE RESPONSE|1|mL/g/min|OSCILLOMETRY||Y||CLINICAL STUDY SPONSOR|RADIOLOGIST|U|5|Visit_5|90|5|FOLLOW-UP|2020-09-26|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-10|P1Y2M10DT2H30M|AFTER|2020-08-27|BEFORE|2020-09-19
e|RS|296f8314-5a07-47b5-8796-31afe709b379|10|NTERESP|Non-Target Enhancing Response|BURCOMBE BREAST CANCER 2005|||DISEASE TRANSFORMATION|1|mm/sec|CELLULAR PROLIFERATION ASSAY|Y|Y|Y|ADJUDICATION COMMITTEE|MICROSCOPIST|NA|5|Visit_5|90|5|TREATMENT|2020-09-26|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-10|P1Y2M10DT2H30M|COINCIDENT|2020-09-28|COINCIDENT|2020-10-05
e|RS|ae1e4047-f4d7-47fa-a5f6-974f9a9c2a48|1|NTLWIND|Non-Target Lesion Worsening Indicator|HARTMANN GERM CELL CANCER 2002|[?]|m3|CR|1|h/wk|WHOLE GENOME SEQUENCING||||CAREGIVER|MICROSCOPIST 3|N|1|Visit_1|10|4|TREATMENT|2020-12-13|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-18|P1Y2M10DT2H30M|UNKNOWN|2021-02-09|AFTER|2021-02-23
e|RS|ae1e4047-f4d7-47fa-a5f6-974f9a9c2a48|2|CLINRESP|Clinical Response|MURPHY PROSTATE CANCER 1980|[?]|ug/kg/h|CR-CT|1|BAR|COMPUTERIZED CORNEAL TOPOGRAPHY||||FRIEND|RATER 1|N|1|Visit_1|10|7|TREATMENT|2020-12-13|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-18|P1Y2M10DT2H30M|UNKNOWN|2020-12-20|ONGOING|2021-01-23
e|RS|ae1e4047-f4d7-47fa-a5f6-974f9a9c2a48|3|NTERESP|Non-Target Enhancing Response|BLAZER COLORECTAL CANCER 2008|||MORPHOLOGIC CR|1|AMPULE|DOUBLE IMMUNODIFFUSION|Y||Y|INDEPENDENT ASSESSOR|RATER|Y|2|Visit_2|25|5|WASHOUT|2020-12-28|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-13|P1Y2M10DT2H30M|BEFORE|2020-12-20|BEFORE|2021-01-23
e|RS|ae1e4047-f4d7-47fa-a5f6-974f9a9c2a48|4|CLINRESP|Clinical Response|DOHNER AML 2010|[?]|mL/s|MOLECULAR MAJOR RESPONSE|1|Ci/uL|WHOLE TRANSCRIPTOME SEQUENCING||||CLINICAL STUDY SPONSOR|INTERNIST|Y|2|Visit_2|25|7|TREATMENT|2020-12-28|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-13|P1Y2M10DT2H30M|BEFORE|2021-02-02|AFTER|2021-03-02
e|RS|ae1e4047-f4d7-47fa-a5f6-974f9a9c2a48|5|MOLRESP|Molecular Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|QUANTITY SUFFICIENT|PD FROM PR|1|LB|SMEAR|Y|||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 2|N|3|Visit_3|40|2|FOLLOW-UP|2021-01-12|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-10|P1Y2M10DT2H30M|BEFORE|2021-02-15|ONGOING|2021-02-17
e|RS|ae1e4047-f4d7-47fa-a5f6-974f9a9c2a48|6|TRGRESP|Target Response|RECICL|[?]|mU/L|PMR|1|TRACE|DARK FIELD MICROSCOPY||Y||SIBLING|RADIOLOGIST 1|N|3|Visit_3|40|7|TREATMENT|2021-01-12|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-10|P1Y2M10DT2H30M|AFTER|2021-01-03|AFTER|2021-01-16
e|RS|ae1e4047-f4d7-47fa-a5f6-974f9a9c2a48|7|HEMARESP|Hematologic Response|NCIWG CHESON CLL 1996|[?]|%(w/v)|OPTIMAL MORPHOLOGIC RESPONSE|1|mEq/kg|MRI WITHOUT CONTRAST|Y|Y||SIBLING|RADIOLOGIST|NA|4|Visit_4|65|7|TREATMENT|2021-02-06|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-03|P1Y2M10DT2H30M|COINCIDENT|2021-02-01|ONGOING|2021-03-02
e|RS|ae1e4047-f4d7-47fa-a5f6-974f9a9c2a48|8|TMRESP|Tumor Marker Response|SCHWARZ CERVICAL CANCER 2009|||UNFAVORABLE RESPONSE|1|/500 WBC|FLUORESCENT IMMUNOASSAY|||Y|ADJUDICATOR|PHYSIOTHERAPIST|U|4|Visit_4|65|5|TREATMENT|2021-02-06|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-03|P1Y2M10DT2H30M|UNKNOWN|2021-02-27|ONGOING|2021-03-04
e|RS|ae1e4047-f4d7-47fa-a5f6-974f9a9c2a48|9|RDIORESP|Radiologic Response|RANO ELLINGSON 2017|||sCR|1|mL/sec/1.73m2|CELLULAR PROLIFERATION ASSAY|||Y|HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|N|5|Visit_5|90|2|SCREENING|2021-03-03|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-06|P1Y2M10DT2H30M|BEFORE|2021-02-18|ONGOING|2021-02-20
e|RS|ae1e4047-f4d7-47fa-a5f6-974f9a9c2a48|10|NEWLPROG|New Lesion Progression|MURPHY PROSTATE CANCER 1980|||PSA PROGRESSION|1|mgEq|NUCLEIC ACID AMPLIFICATION TEST|||Y|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|N|5|Visit_5|90|1|SCREENING|2021-03-03|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-06|P1Y2M10DT2H30M|BEFORE|2021-03-05|ONGOING|2021-03-09
e|RS|b06043ae-8251-4df8-ab6d-0ceb269c1a42|1|TMRESP|Tumor Marker Response|DOHNER AML 2010|[?]|mL/animal|MINOR PATHOLOGIC RESPONSE|1|Ci/kg|SLIT LAMP||Y||CAREGIVER|RADIOLOGIST|Y|1|Visit_1|10|5|SCREENING|2021-01-25|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-01|P1Y2M10DT2H30M|AFTER|2021-04-19|AFTER|2021-04-23
e|RS|b06043ae-8251-4df8-ab6d-0ceb269c1a42|2|TRGRESP|Target Response|AJCC V8|[?]|mL/min/1.73m2|CR|1|nm|HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY||||CLINICAL STUDY SPONSOR|PATHOLOGIST 1|N|1|Visit_1|10|4|TREATMENT|2021-01-25|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-01|P1Y2M10DT2H30M|UNKNOWN|2021-03-17|AFTER|2021-03-28
e|RS|b06043ae-8251-4df8-ab6d-0ceb269c1a42|3|NTLWIND|Non-Target Lesion Worsening Indicator|GUILHOT CML 2007|[?]|umol/min|MORPHOLOGIC LEUKEMIA-FREE STATE|1|mL/(min*100mL)|DNA MICROARRAY|Y|||PARENT|PATHOLOGIST 2|Y|2|Visit_2|25|6|SCREENING|2021-02-09|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-27|P1Y2M10DT2H30M|BEFORE|2021-03-11|AFTER|2021-04-06
e|RS|b06043ae-8251-4df8-ab6d-0ceb269c1a42|4|LIVRRESP|Liver Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|ug/kg/min|PD-CT|1|pkat|POTENTIOMETRY|Y|||PROXY|READER|N|2|Visit_2|25|5|WASHOUT|2021-02-09|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-27|P1Y2M10DT2H30M|COINCIDENT|2021-04-03|ONGOING|2021-04-13
e|RS|b06043ae-8251-4df8-ab6d-0ceb269c1a42|5|OVRLRESP|Overall Response|SACT|[?]|mL/dose|PD/RELAPSE AFTER HI|1|log10 PFU/mL|ENZYMATIC SPECTROPHOTOMETRY||Y||ADJUDICATOR|DEVELOPMENTAL PSYCHOLOGIST|Y|3|Visit_3|40|7|TREATMENT|2021-02-24|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-04|P1Y2M10DT2H30M|UNKNOWN|2021-01-22|COINCIDENT|2021-02-15
e|RS|b06043ae-8251-4df8-ab6d-0ceb269c1a42|6|SYMPTDTR|Symptomatic Deterioration|PALUMBO MULTIPLE MYELOMA 2009|||QUANTIFIABLE MRD POSITIVITY|1|log10 copies/mL|MYELOPEROXIDASE STAIN|||Y|SIGNIFICANT OTHER|MICROSCOPIST 3|U|3|Visit_3|40|5|WASHOUT|2021-02-24|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-04|P1Y2M10DT2H30M|UNKNOWN|2021-01-28|ONGOING|2021-03-06
e|RS|b06043ae-8251-4df8-ab6d-0ceb269c1a42|7|MJPTHIND|Major Pathological Response Indicator|GCIG RUSTIN OVARIAN CANCER 2011|[?]|L/min/m2|CYTOGENETIC CR|1|mL/min|QUANTITATIVE COMPUTED TOMOGRAPHY|Y|Y||NON-HEALTH CARE PROFESSIONAL|READER 1|N|4|Visit_4|65|3|FOLLOW-UP|2021-03-21|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-16|P1Y2M10DT2H30M|UNKNOWN|2021-03-18|AFTER|2021-03-24
e|RS|b06043ae-8251-4df8-ab6d-0ceb269c1a42|8|HEMARESP|Hematologic Response|DURIE MULTIPLE MYELOMA 2006|[?]|mV/sec|PSA PROGRESSION|1|NEBULE|CONTACT SPECULAR MICROSCOPY||Y||CAREGIVER|OPTOMETRIST|Y|4|Visit_4|65|2|TREATMENT|2021-03-21|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-16|P1Y2M10DT2H30M|AFTER|2021-01-25|COINCIDENT|2021-04-22
e|RS|b06043ae-8251-4df8-ab6d-0ceb269c1a42|9|BMIVLIND|Bone Marrow Involvement Indicator|HARTMAN PANCREATIC CANCER 2012|||CR-CT|1|nmol/L/h|SISH|Y|Y|Y|FRIEND|DEVELOPMENTAL PSYCHOLOGIST|NA|5|Visit_5|90|4|FOLLOW-UP|2021-04-15|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-23|P1Y2M10DT2H30M|UNKNOWN|2021-04-09|AFTER|2021-04-11
e|RS|b06043ae-8251-4df8-ab6d-0ceb269c1a42|10|NTERESP|Non-Target Enhancing Response|GUILHOT CML 2007|||NR|1|10^3 copies/mL|ACRIDINE ORANGE STAIN|||Y|SIBLING|ADJUDICATOR 1|Y|5|Visit_5|90|3|TREATMENT|2021-04-15|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-23|P1Y2M10DT2H30M|AFTER|2021-01-27|AFTER|2021-02-11
e|RS|d4fb5b9e-e244-4818-be3d-dbb57faacd43|1|NTERESP|Non-Target Enhancing Response|SCHER PROSTATE CANCER 2011|[?]|mL/dL|PSEUDORESPONSE|1|ppb|SLOAN LETTER EYE CHART 2.5%||||FRIEND|NEUROLOGIST|Y|1|Visit_1|10|1|TREATMENT|2020-11-07|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-03|P1Y2M10DT2H30M|AFTER|2020-12-13|COINCIDENT|2021-01-11
e|RS|d4fb5b9e-e244-4818-be3d-dbb57faacd43|2|MRDIND|Minimal Residual Disease Indicator|FAROOQUI SUPP CLL 2014|[?]|mg/cm2|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|YEARS|TEMPLATE INCISION METHOD||||CHILD|PATHOLOGIST|NA|1|Visit_1|10|6|WASHOUT|2020-11-07|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-03|P1Y2M10DT2H30M|BEFORE|2021-01-30|BEFORE|2021-01-31
e|RS|d4fb5b9e-e244-4818-be3d-dbb57faacd43|3|MRDIND|Minimal Residual Disease Indicator|EBMT BLADE MYELOMA 1998|[?]|mol/g|CMR|1|gpELISA unit/mL|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE||||CLINICAL RESEARCH COORDINATOR|NEUROLOGIST|N|2|Visit_2|25|5|WASHOUT|2020-11-22|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-04|P1Y2M10DT2H30M|UNKNOWN|2020-12-03|BEFORE|2021-01-17
e|RS|d4fb5b9e-e244-4818-be3d-dbb57faacd43|4|NEWLPROG|New Lesion Progression|IWG CHESON AML 2003|||iUPD|1|DAgU|TONOMETRY|||Y|NON-HEALTH CARE PROFESSIONAL|RATER 2|U|2|Visit_2|25|6|TREATMENT|2020-11-22|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-04|P1Y2M10DT2H30M|COINCIDENT|2021-01-04|COINCIDENT|2021-01-21
e|RS|d4fb5b9e-e244-4818-be3d-dbb57faacd43|5|RDIORESP|Radiologic Response|PETIT BREAST CANCER 2001|[?]|fmol|MORPHOLOGIC CRi|1|g/animal/wk|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY||||STUDY SUBJECT|READER 2|Y|3|Visit_3|40|5|TREATMENT|2020-12-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-18|P1Y2M10DT2H30M|BEFORE|2020-11-22|BEFORE|2020-12-02
e|RS|d4fb5b9e-e244-4818-be3d-dbb57faacd43|6|NEWLWIND|New Lesion Worsening Indicator|DURIE MULTIPLE MYELOMA 2006|[?]|mL/animal/day|cPR|1|PIPE|DXA SCAN|Y|||INDEPENDENT ASSESSOR|READER 3|NA|3|Visit_3|40|1|FOLLOW-UP|2020-12-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-18|P1Y2M10DT2H30M|BEFORE|2020-11-06|ONGOING|2021-01-20
e|RS|d4fb5b9e-e244-4818-be3d-dbb57faacd43|7|CPRFSTAT|Clinical Performance Status|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|mmol/mol|VGPR|1|%(w/w)|PERFUSION MRI||||CLINICAL STUDY SPONSOR|CLINICAL PATHOLOGIST|U|4|Visit_4|65|4|TREATMENT|2021-01-01|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-25|P1Y2M10DT2H30M|UNKNOWN|2021-01-29|COINCIDENT|2021-02-01
e|RS|d4fb5b9e-e244-4818-be3d-dbb57faacd43|8|NEWLPROG|New Lesion Progression|RANO ELLINGSON 2017|||NOT ALL EVALUATED|1|Enzyme U|MASS SPECTROMETRY|Y||Y|ADJUDICATOR|MICROSCOPIST 1|U|4|Visit_4|65|3|FOLLOW-UP|2021-01-01|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-25|P1Y2M10DT2H30M|UNKNOWN|2020-11-12|COINCIDENT|2020-11-28
e|RS|d4fb5b9e-e244-4818-be3d-dbb57faacd43|9|DRCRIND|Disease Recurrence Indicator|JACINTO CERVICAL CANCER 2007|||OPTIMAL MORPHOLOGIC RESPONSE|1|mEq/g|NUCLEIC ACID HYBRIDIZATION|||Y|CHILD|MICROSCOPIST 3|Y|5|Visit_5|90|5|TREATMENT|2021-01-26|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-30|P1Y2M10DT2H30M|COINCIDENT|2020-12-03|BEFORE|2020-12-10
e|RS|d4fb5b9e-e244-4818-be3d-dbb57faacd43|10|TMRESP|Tumor Marker Response|DOHNER AML 2010|[?]|mol/g|NE|1|10^7/L|GC/MS/MS||Y||SPOUSE|ADJUDICATOR|NA|5|Visit_5|90|6|TREATMENT|2021-01-26|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-30|P1Y2M10DT2H30M|BEFORE|2021-01-22|BEFORE|2021-01-29
e|RS|7e6cbcf1-7175-4b46-b82f-32189cfcf6bb|1|CLINRESP|Clinical Response|PALUMBO MULTIPLE MYELOMA 2009|||NON-PD|1|pmol/g|SPECTROPHOTOMETRY|||Y|INTERVIEWER|ADJUDICATOR 3|U|1|Visit_1|10|6|FOLLOW-UP|2020-07-13|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-28|P1Y2M10DT2H30M|BEFORE|2020-08-04|COINCIDENT|2020-09-12
e|RS|7e6cbcf1-7175-4b46-b82f-32189cfcf6bb|2|CPRFSTAT|Clinical Performance Status|IWG CHESON AML 2003|[?]|ft|pCR|1|IU/L|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY|Y|||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST|U|1|Visit_1|10|6|TREATMENT|2020-07-13|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-28|P1Y2M10DT2H30M|AFTER|2020-10-03|COINCIDENT|2020-10-10
e|RS|7e6cbcf1-7175-4b46-b82f-32189cfcf6bb|3|MNPTHIND|Minor Pathological Response Indicator|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|TRACE|PD|1|dpm/100mg|LAPAROSCOPY||||DOMESTIC PARTNER|READER 1|U|2|Visit_2|25|2|WASHOUT|2020-07-28|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-11|P1Y2M10DT2H30M|COINCIDENT|2020-07-10|COINCIDENT|2020-07-30
e|RS|7e6cbcf1-7175-4b46-b82f-32189cfcf6bb|4|NTLWIND|Non-Target Lesion Worsening Indicator|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|mL/cage/wk|HI-N|1|MAC50|AUTOREFRACTION||||STUDY SUBJECT|DEVELOPMENTAL PSYCHOLOGIST|NA|2|Visit_2|25|7|TREATMENT|2020-07-28|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-11|P1Y2M10DT2H30M|UNKNOWN|2020-10-03|AFTER|2020-10-05
e|RS|7e6cbcf1-7175-4b46-b82f-32189cfcf6bb|5|TMRESP|Tumor Marker Response|PERCIST|[?]|mph|UNEQUIVOCAL|1|HOMEOPATHIC DILUTION|DIGITAL PCR ARRAY||||CLINICAL STUDY SPONSOR|ADJUDICATOR 1|Y|3|Visit_3|40|1|TREATMENT|2020-08-12|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-10|P1Y2M10DT2H30M|BEFORE|2020-09-14|ONGOING|2020-09-30
e|RS|7e6cbcf1-7175-4b46-b82f-32189cfcf6bb|6|OVRLRESP|Overall Response|RAJKUMAR MYELOMA 2011|[?]|mOsm/L|IMMUNOPHENOTYPIC CR|1|ft|SMEAR|Y|Y||FRIEND|ADJUDICATOR 2|U|3|Visit_3|40|4|FOLLOW-UP|2020-08-12|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-10|P1Y2M10DT2H30M|BEFORE|2020-07-13|AFTER|2020-07-15
e|RS|7e6cbcf1-7175-4b46-b82f-32189cfcf6bb|7|MRDRESP|Minimal Residual Disease Response|SCHWARZ CERVICAL CANCER 2009|[?]|10^9/g|OPTIMAL MORPHOLOGIC RESPONSE|1|cm|CYSTOMETRY||||PROXY|CARDIOLOGIST|NA|4|Visit_4|65|2|TREATMENT|2020-09-06|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-13|P1Y2M10DT2H30M|UNKNOWN|2020-07-26|COINCIDENT|2020-08-27
e|RS|7e6cbcf1-7175-4b46-b82f-32189cfcf6bb|8|MRDIND|Minimal Residual Disease Indicator|PCWG SCHER PROSTATE CANCER 2016|[?]|ppb|FAVORABLE RESPONSE|1|mV*min|PERCUSSION||||CAREGIVER|PATHOLOGIST|NA|4|Visit_4|65|7|TREATMENT|2020-09-06|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-13|P1Y2M10DT2H30M|COINCIDENT|2020-07-08|ONGOING|2020-09-13
e|RS|7e6cbcf1-7175-4b46-b82f-32189cfcf6bb|9|SYMPTDTR|Symptomatic Deterioration|RANO ELLINGSON 2017|[?]|days/wk|NON-PD|1|mL/kg/day|MRS||||FAMILY MEMBER|READER 3|NA|5|Visit_5|90|4|TREATMENT|2020-10-01|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-12|P1Y2M10DT2H30M|UNKNOWN|2020-07-31|AFTER|2020-08-17
e|RS|7e6cbcf1-7175-4b46-b82f-32189cfcf6bb|10|BONERESP|Bone Response|DOHNER AML 2010|[?]|m|MRD NEGATIVITY|1|uCi/kg|TRYPAN BLUE STAIN||Y||INVESTIGATOR|NEUROLOGIST|N|5|Visit_5|90|5|TREATMENT|2020-10-01|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-12|P1Y2M10DT2H30M|UNKNOWN|2020-08-15|AFTER|2020-09-07
e|RS|26e6a3e9-7e84-4c99-b1b9-0608b6d73512|1|MOLRESP|Molecular Response|KUMAR IMWG 2016|[?]|mEq/kg|CA125 75% RESPONSE|1|um/s|CELL CYTOTOXICITY NEUTRALIZATION ASSAY||||SIGNIFICANT OTHER|PATHOLOGIST 2|Y|1|Visit_1|10|1|WASHOUT|2021-01-14|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-01|P1Y2M10DT2H30M|COINCIDENT|2021-01-12|BEFORE|2021-02-16
e|RS|26e6a3e9-7e84-4c99-b1b9-0608b6d73512|2|TMRESP|Tumor Marker Response|CHOI GIST 2008|[?]|Hz/s|MINOR PATHOLOGIC RESPONSE|1|nkat/L|CONGO RED STAIN||Y||GUARDIAN|ADJUDICATOR 2|N|1|Visit_1|10|4|WASHOUT|2021-01-14|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-01|P1Y2M10DT2H30M|AFTER|2021-03-02|AFTER|2021-03-08
e|RS|26e6a3e9-7e84-4c99-b1b9-0608b6d73512|3|MJPTHIND|Major Pathological Response Indicator|GUPPY OVARIAN CANCER 2002|[?]|Log10 ELISA unit/dose|MRD RELAPSE|1|PELLET|X-RAY FLUORESCENCE SPECTROMETRY||||CAREGIVER|PATHOLOGIST 1|N|2|Visit_2|25|1|TREATMENT|2021-01-29|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-11|P1Y2M10DT2H30M|AFTER|2021-03-02|ONGOING|2021-04-02
e|RS|26e6a3e9-7e84-4c99-b1b9-0608b6d73512|4|NTLWIND|Non-Target Lesion Worsening Indicator|RECIST 1.1|[?]|grain|CR-CT|1|10^12 IU/L|DC SHEATH FLOW||Y||NON-HEALTH CARE PROFESSIONAL|READER|U|2|Visit_2|25|7|TREATMENT|2021-01-29|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-11|P1Y2M10DT2H30M|AFTER|2021-01-10|BEFORE|2021-02-04
e|RS|26e6a3e9-7e84-4c99-b1b9-0608b6d73512|5|STRUSTAT|Steroid Use Status|IWG CHESON MDS 2006|[?]|mm/min|DECREASED|1|BAG|CONGO RED STAIN||||CLINICAL RESEARCH COORDINATOR|PHYSIOTHERAPIST|U|3|Visit_3|40|7|FOLLOW-UP|2021-02-13|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-02|P1Y2M10DT2H30M|COINCIDENT|2021-03-12|COINCIDENT|2021-04-01
e|RS|26e6a3e9-7e84-4c99-b1b9-0608b6d73512|6|PATHRESP|Pathologic Response|RANO|[?]|U/g|SD-CT|1|ng|CELLULOSE TAPE||Y||INDEPENDENT ASSESSOR|READER 1|U|3|Visit_3|40|2|SCREENING|2021-02-13|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-02|P1Y2M10DT2H30M|AFTER|2021-02-02|ONGOING|2021-02-15
e|RS|26e6a3e9-7e84-4c99-b1b9-0608b6d73512|7|RDIORESP|Radiologic Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|h/wk|COMPLETE MRD RESPONSE|1|DNA copies/mL|CALCULATION||||DOMESTIC PARTNER|RATER 1|NA|4|Visit_4|65|7|WASHOUT|2021-03-10|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-28|P1Y2M10DT2H30M|AFTER|2021-03-02|BEFORE|2021-03-07
e|RS|26e6a3e9-7e84-4c99-b1b9-0608b6d73512|8|TMRESP|Tumor Marker Response|RANO|||cPR|1|RATIO|SLIT LAMP|Y||Y|INDEPENDENT ASSESSOR|ONCOLOGIST 2|U|4|Visit_4|65|6|TREATMENT|2021-03-10|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-28|P1Y2M10DT2H30M|BEFORE|2021-01-16|AFTER|2021-04-03
e|RS|26e6a3e9-7e84-4c99-b1b9-0608b6d73512|9|NTNERESP|Non-Target Non-Enhancing Response|EASL BRUIX LIVER CANCER 2001|[?]|MET|CYTOGENETIC NO RESPONSE|1|BU|KINYOUN STAIN||||GUARDIAN|RADIOLOGIST 1|Y|5|Visit_5|90|1|TREATMENT|2021-04-04|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-16|P1Y2M10DT2H30M|BEFORE|2021-03-29|ONGOING|2021-04-08
e|RS|26e6a3e9-7e84-4c99-b1b9-0608b6d73512|10|MRDRESP|Minimal Residual Disease Response|PALUMBO MULTIPLE MYELOMA 2009|||DECREASED|1|g/g/day|HPLC/MS|Y||Y|CAREGIVER|MICROSCOPIST 3|Y|5|Visit_5|90|6|SCREENING|2021-04-04|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-16|P1Y2M10DT2H30M|BEFORE|2021-01-23|AFTER|2021-03-03
e|RS|b1215705-4c22-43bd-aa65-58bd8745f081|1|MJPTHIND|Major Pathological Response Indicator|PCWG SCHER PROSTATE CANCER 2016|[?]|ks|PR-CT|1|nmol/L/h|PET/MRI SCAN||||PARENT|CARDIOLOGIST|N|1|Visit_1|10|3|SCREENING|2020-07-15|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-11|P1Y2M10DT2H30M|UNKNOWN|2020-08-23|BEFORE|2020-09-15
e|RS|b1215705-4c22-43bd-aa65-58bd8745f081|2|OVRLRESP|Overall Response|GUPPY OVARIAN CANCER 2002|[?]|mmol2/L2|iSD|1|10^9 CFU/g|MICROBIAL CONCENTRATION||||HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|Y|1|Visit_1|10|4|TREATMENT|2020-07-15|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-11|P1Y2M10DT2H30M|BEFORE|2020-10-06|BEFORE|2020-10-08
e|RS|b1215705-4c22-43bd-aa65-58bd8745f081|3|NTLWIND|Non-Target Lesion Worsening Indicator|SHINDOH COLORECTAL CANCER 2013|[?]|L/h|iSD|1|dpm/mg|CRYOSCOPY||||ADJUDICATOR|ADJUDICATOR 2|U|2|Visit_2|25|4|WASHOUT|2020-07-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-19|P1Y2M10DT2H30M|BEFORE|2020-09-03|AFTER|2020-09-23
e|RS|b1215705-4c22-43bd-aa65-58bd8745f081|4|NEWLPROG|New Lesion Progression|BLAZER COLORECTAL CANCER 2008|||MINOR PATHOLOGIC RESPONSE|1|TAMPON|POLYMERASE CHAIN REACTION|||Y|STUDY SUBJECT|DERMATOLOGIST|N|2|Visit_2|25|2|FOLLOW-UP|2020-07-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-19|P1Y2M10DT2H30M|COINCIDENT|2020-10-03|COINCIDENT|2020-10-11
e|RS|b1215705-4c22-43bd-aa65-58bd8745f081|5|CLINRESP|Clinical Response|PERCIST|[?]|Ci/L|cPR|1|mL/s/m2|CELLULAR PROLIFERATION ASSAY|Y|||SIBLING|NEUROLOGIST|N|3|Visit_3|40|6|TREATMENT|2020-08-14|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-04|P1Y2M10DT2H30M|COINCIDENT|2020-08-09|BEFORE|2020-09-22
e|RS|b1215705-4c22-43bd-aa65-58bd8745f081|6|BESTRESP|Best Overall Response|UNSPECIFIED|[?]|/month|CA125 75% RESPONSE|1|mL/cage|TOLUIDINE BLUE STAIN||Y||STUDY SUBJECT|PEDIATRIC NEUROLOGIST|N|3|Visit_3|40|5|SCREENING|2020-08-14|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-04|P1Y2M10DT2H30M|UNKNOWN|2020-08-04|AFTER|2020-10-07
e|RS|b1215705-4c22-43bd-aa65-58bd8745f081|7|MJPTHIND|Major Pathological Response Indicator|MURPHY PROSTATE CANCER 1980|[?]|Arbitrary U|VGPR|1|mL/min/1.73m2|SLOAN LETTER EYE CHART 100%||||CHILD|OPHTHALMOLOGIST|N|4|Visit_4|65|1|WASHOUT|2020-09-08|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-02|P1Y2M10DT2H30M|BEFORE|2020-07-24|AFTER|2020-10-06
e|RS|b1215705-4c22-43bd-aa65-58bd8745f081|8|NTNERESP|Non-Target Non-Enhancing Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|||sCR|1|HEP|ISHIHARA COLOR PLATES|Y|Y|Y|ADJUDICATION COMMITTEE|ONCOLOGIST|N|4|Visit_4|65|7|FOLLOW-UP|2020-09-08|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-02|P1Y2M10DT2H30M|UNKNOWN|2020-09-23|ONGOING|2020-09-25
e|RS|b1215705-4c22-43bd-aa65-58bd8745f081|9|NEWLIND|New Lesion Indicator|BLAZER COLORECTAL CANCER 2008|||EQUIVOCAL|1|mL/animal/wk|HIGH RESOLUTION CT|||Y|STUDY SUBJECT|DEVELOPMENTAL PSYCHOLOGIST|Y|5|Visit_5|90|2|FOLLOW-UP|2020-10-03|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-22|P1Y2M10DT2H30M|AFTER|2020-09-11|AFTER|2020-10-10
e|RS|b1215705-4c22-43bd-aa65-58bd8745f081|10|BONERESP|Bone Response|PCWG SCHER PROSTATE CANCER 2016|[?]|mL/m2/h|iPR|1|cal|SLOAN LETTER EYE CHART 100%||||ADJUDICATOR|READER 2|U|5|Visit_5|90|4|SCREENING|2020-10-03|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-22|P1Y2M10DT2H30M|BEFORE|2020-10-06|AFTER|2020-10-10
e|RS|b99c6528-af4e-42f5-8d2d-18943b57d55a|1|PATHRESP|Pathologic Response|NCCN ALL MRD 2014|||pCR|1|pg/cell|BALLPOINT PEN TECHNIQUE|||Y|ADJUDICATION COMMITTEE|MICROSCOPIST|U|1|Visit_1|10|3|TREATMENT|2020-10-25|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-13|P1Y2M10DT2H30M|BEFORE|2020-12-31|AFTER|2021-01-16
e|RS|b99c6528-af4e-42f5-8d2d-18943b57d55a|2|STRUSTAT|Steroid Use Status|CHESON CLL 2006|[?]|BOTTLE|MAJOR PATHOLOGIC RESPONSE|1|mmol/day|CLIP||||SIGNIFICANT OTHER|OTOLARYNGOLOGIST|Y|1|Visit_1|10|3|FOLLOW-UP|2020-10-25|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-13|P1Y2M10DT2H30M|COINCIDENT|2020-12-03|ONGOING|2021-01-09
e|RS|b99c6528-af4e-42f5-8d2d-18943b57d55a|3|NEWLWIND|New Lesion Worsening Indicator|KUMAR IMWG 2016|||CYTOGENETIC CR|1|U/g Hb|MOUSE PROTECTION ASSAY||Y|Y|VENDOR|INTERNIST|N|2|Visit_2|25|5|TREATMENT|2020-11-09|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-08|P1Y2M10DT2H30M|UNKNOWN|2020-12-20|BEFORE|2021-01-11
e|RS|b99c6528-af4e-42f5-8d2d-18943b57d55a|4|NTERESP|Non-Target Enhancing Response|CHOLLET BREAST CANCER 2002|[?]|PACK|iPR|1|ohm|MICROBIAL BIOCHEMICAL IDENTIFICATION||||GUARDIAN|RADIOLOGIST 2|NA|2|Visit_2|25|7|TREATMENT|2020-11-09|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-08|P1Y2M10DT2H30M|BEFORE|2020-11-10|COINCIDENT|2020-12-06
e|RS|b99c6528-af4e-42f5-8d2d-18943b57d55a|5|CPRFSTAT|Clinical Performance Status|DURIE MULTIPLE MYELOMA 2006|[?]|GPL U/mL|PD FROM PR|1|fmol/L/sec|QUANTITATIVE PERIPHERAL ANGIOGRAPHY||||INVESTIGATOR|ADJUDICATOR 2|U|3|Visit_3|40|4|TREATMENT|2020-11-24|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-15|P1Y2M10DT2H30M|UNKNOWN|2021-01-13|ONGOING|2021-01-20
e|RS|b99c6528-af4e-42f5-8d2d-18943b57d55a|6|MNPTHIND|Minor Pathological Response Indicator|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|h/wk|RELAPSED DISEASE FROM CR|1|POINT|ELISA||||INDEPENDENT ASSESSOR|NEUROLOGIST|N|3|Visit_3|40|7|FOLLOW-UP|2020-11-24|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-15|P1Y2M10DT2H30M|UNKNOWN|2020-11-26|COINCIDENT|2020-12-24
e|RS|b99c6528-af4e-42f5-8d2d-18943b57d55a|7|CLINRESP|Clinical Response|EBMT BLADE MYELOMA 1998|[?]|log10 CFU/g|ABSENT MORPHOLOGIC RESPONSE|1|ka_u/dL|GC/MS/MS||||CLINICAL STUDY SPONSOR|NEUROLOGIST 2|U|4|Visit_4|65|5|SCREENING|2020-12-19|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-11|P1Y2M10DT2H30M|COINCIDENT|2020-11-08|AFTER|2020-11-19
e|RS|b99c6528-af4e-42f5-8d2d-18943b57d55a|8|CYTORESP|Cytogenetic Response|FAROOQUI SUPP CLL 2014|[?]|mL/cm H2O|MOLECULAR CR|1|amp|PHOTOMETRIC CLOT DETECTION||||HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|Y|4|Visit_4|65|3|SCREENING|2020-12-19|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-11|P1Y2M10DT2H30M|COINCIDENT|2020-12-19|AFTER|2021-01-08
e|RS|b99c6528-af4e-42f5-8d2d-18943b57d55a|9|MRDRESP|Minimal Residual Disease Response|PCWG SCHER PROSTATE CANCER 2008|[?]|mV|STABLE|1|EU|HEMATOXYLIN AND EOSIN STAIN|Y|||FAMILY MEMBER|PATHOLOGIST 1|NA|5|Visit_5|90|7|TREATMENT|2021-01-13|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-08|P1Y2M10DT2H30M|AFTER|2020-10-31|AFTER|2020-11-11
e|RS|b99c6528-af4e-42f5-8d2d-18943b57d55a|10|CYTORESP|Cytogenetic Response|WHO BREAST CANCER 2006|||NON-iCR/NON-iUPD|1|ug/g/min|CONTRAST ENHANCED SPIRAL CT SCAN|||Y|CLINICAL RESEARCH ASSOCIATE|RATER|N|5|Visit_5|90|7|SCREENING|2021-01-13|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-08|P1Y2M10DT2H30M|UNKNOWN|2020-12-26|AFTER|2021-01-13
e|RS|6848e438-51ca-4a7d-8f81-26c375969a64|1|DRCRIND|Disease Recurrence Indicator|HAMAOKA BREAST CANCER 2010|[?]|cal|iCPD|1|U/mL|WHOLE GENOME SEQUENCING|Y|||FRIEND|PATHOLOGIST 2|U|1|Visit_1|10|4|SCREENING|2020-11-12|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-12|P1Y2M10DT2H30M|COINCIDENT|2020-12-11|COINCIDENT|2021-02-07
e|RS|6848e438-51ca-4a7d-8f81-26c375969a64|2|METBRESP|Metabolic Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|QUANTITY SUFFICIENT|PMD|1|K|WRIGHT STAIN||||FAMILY MEMBER|NEUROLOGIST|NA|1|Visit_1|10|6|SCREENING|2020-11-12|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-12|P1Y2M10DT2H30M|UNKNOWN|2020-12-21|ONGOING|2021-01-03
e|RS|6848e438-51ca-4a7d-8f81-26c375969a64|3|MRDRESP|Minimal Residual Disease Response|iRECIST|||CYTOGENETIC NO RESPONSE|1|uOsm|NUCLEAR RADIOLOGY|Y||Y|VENDOR|RATER 2|Y|2|Visit_2|25|4|TREATMENT|2020-11-27|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-14|P1Y2M10DT2H30M|AFTER|2020-11-21|AFTER|2020-12-03
e|RS|6848e438-51ca-4a7d-8f81-26c375969a64|4|NEWLIND|New Lesion Indicator|WHO BREAST CANCER 2006|[?]|cm|PSEUDOPROGRESSION|1|umol/min|KNEMOMETRY|Y|Y||VENDOR|ENDOCRINOLOGIST|N|2|Visit_2|25|2|TREATMENT|2020-11-27|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-14|P1Y2M10DT2H30M|BEFORE|2020-11-16|BEFORE|2021-01-08
e|RS|6848e438-51ca-4a7d-8f81-26c375969a64|5|METBRESP|Metabolic Response|KEAM BREAST CANCER 2013|[?]|Enzyme U/g Hb|UNFAVORABLE RESPONSE|1|IU|TEMPLATE INCISION METHOD||||FRIEND|ENDOCRINOLOGIST|NA|3|Visit_3|40|2|SCREENING|2020-12-12|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-25|P1Y2M10DT2H30M|COINCIDENT|2020-11-11|BEFORE|2020-12-31
e|RS|6848e438-51ca-4a7d-8f81-26c375969a64|6|HEMARESP|Hematologic Response|GCIG RUSTIN OVARIAN CANCER 2011|||nPR|1|10^3 CFU/mL|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION|||Y|CLINICAL STUDY SPONSOR|RADIOLOGIST|NA|3|Visit_3|40|1|TREATMENT|2020-12-12|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-25|P1Y2M10DT2H30M|UNKNOWN|2020-12-21|BEFORE|2021-01-12
e|RS|6848e438-51ca-4a7d-8f81-26c375969a64|7|MOLRESP|Molecular Response|CHESON CLL 2012|||RELAPSED DISEASE|1|YEARS|BALLPOINT PEN TECHNIQUE|Y||Y|PARENT|MICROSCOPIST|N|4|Visit_4|65|3|TREATMENT|2021-01-06|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-16|P1Y2M10DT2H30M|AFTER|2020-12-31|AFTER|2021-02-07
e|RS|6848e438-51ca-4a7d-8f81-26c375969a64|8|MRDRESP|Minimal Residual Disease Response|CHOI GIST 2008|[?]|mCi/L|RELAPSED DISEASE|1|mkat|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN||||CHILD|PEDIATRIC NEUROLOGIST|U|4|Visit_4|65|4|TREATMENT|2021-01-06|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-16|P1Y2M10DT2H30M|AFTER|2021-02-02|AFTER|2021-02-06
e|RS|6848e438-51ca-4a7d-8f81-26c375969a64|9|ANATRESP|Anatomic Response|BLAZER COLORECTAL CANCER 2008|||PMR|1|mAmp|DXA SCAN||Y|Y|STUDY SUBJECT|MICROSCOPIST 3|U|5|Visit_5|90|5|FOLLOW-UP|2021-01-31|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-15|P1Y2M10DT2H30M|COINCIDENT|2021-01-27|BEFORE|2021-02-05
e|RS|6848e438-51ca-4a7d-8f81-26c375969a64|10|ANATRESP|Anatomic Response|NCIWG CHESON CLL 1996|[?]|damol/L|EQUIVOCAL|1|cmH2O*s2/mL|TRANSVAGINAL ULTRASOUND||||FRIEND|ADJUDICATOR 3|Y|5|Visit_5|90|1|TREATMENT|2021-01-31|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-15|P1Y2M10DT2H30M|UNKNOWN|2020-12-08|COINCIDENT|2020-12-25
e|RS|a6e11c33-7905-42d2-bda9-671d756d4c51|1|NTERESP|Non-Target Enhancing Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|Gy/min|CYTOGENETIC NO RESPONSE|1|mL/dose|PERIPHERAL ANGIOGRAPHY|Y|Y||ADJUDICATOR|READER 1|NA|1|Visit_1|10|7|TREATMENT|2020-08-06|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-10|P1Y2M10DT2H30M|COINCIDENT|2020-09-10|COINCIDENT|2020-10-02
e|RS|a6e11c33-7905-42d2-bda9-671d756d4c51|2|SFTSRESP|Soft Tissue Response|SCHWARZ CERVICAL CANCER 2009|[?]|pg/dL|DECREASED|1|10^11/L|OSCILLOMETRY||||INDEPENDENT ASSESSOR|READER 1|U|1|Visit_1|10|5|TREATMENT|2020-08-06|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-10|P1Y2M10DT2H30M|COINCIDENT|2020-10-01|ONGOING|2020-10-17
e|RS|a6e11c33-7905-42d2-bda9-671d756d4c51|3|ANATRESP|Anatomic Response|IWC HALLEK CLL 2008|[?]|m2|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|ukat|GC/MS-EI|Y|||CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 1|N|2|Visit_2|25|1|WASHOUT|2020-08-21|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-17|P1Y2M10DT2H30M|UNKNOWN|2020-10-31|AFTER|2020-11-01
e|RS|a6e11c33-7905-42d2-bda9-671d756d4c51|4|METBRESP|Metabolic Response|LEE LUNG CANCER 2011|||EQUIVOCAL|1|kBq/uL|CHROMOGENIC ASSAY|||Y|FRIEND|NEUROLOGIST|N|2|Visit_2|25|2|TREATMENT|2020-08-21|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-17|P1Y2M10DT2H30M|UNKNOWN|2020-08-09|AFTER|2020-10-14
e|RS|a6e11c33-7905-42d2-bda9-671d756d4c51|5|RDIORESP|Radiologic Response|BLAZER COLORECTAL CANCER 2008|||CR|1|SACHET|CAPILLARY ELECTROPHORESIS|||Y|STUDY SUBJECT|RATER 2|NA|3|Visit_3|40|2|TREATMENT|2020-09-05|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-29|P1Y2M10DT2H30M|AFTER|2020-10-29|ONGOING|2020-11-01
e|RS|a6e11c33-7905-42d2-bda9-671d756d4c51|6|ANATRESP|Anatomic Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|10^6/g|OPTIMAL MORPHOLOGIC RESPONSE|1|dmol|COMPLEMENT FIXATION|Y|Y||PARENT|OPTOMETRIST|Y|3|Visit_3|40|3|TREATMENT|2020-09-05|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-29|P1Y2M10DT2H30M|BEFORE|2020-08-07|AFTER|2020-09-07
e|RS|a6e11c33-7905-42d2-bda9-671d756d4c51|7|DRCRIND|Disease Recurrence Indicator|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|||WORSENED|1|um/day|IMMUNOCHROMATOGRAPHY||Y|Y|PARENT|HEMATOLOGIST|N|4|Visit_4|65|7|WASHOUT|2020-09-30|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-28|P1Y2M10DT2H30M|UNKNOWN|2020-08-02|ONGOING|2020-08-03
e|RS|a6e11c33-7905-42d2-bda9-671d756d4c51|8|OVRLRESP|Overall Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|uCi/L|sCR|1|DISK|IMMUNOCHROMATOGRAPHY||||DOMESTIC PARTNER|READER 1|U|4|Visit_4|65|6|TREATMENT|2020-09-30|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-28|P1Y2M10DT2H30M|AFTER|2020-10-06|BEFORE|2020-10-14
e|RS|a6e11c33-7905-42d2-bda9-671d756d4c51|9|OVRLRESP|Overall Response|RANO|[?]|LENS|NON-QUANTIFIABLE MRD POSITIVITY|1|10^6 organisms/mg|CALIPER MEASUREMENT METHOD||||PROXY|RATER 1|NA|5|Visit_5|90|2|TREATMENT|2020-10-25|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-19|P1Y2M10DT2H30M|COINCIDENT|2020-11-03|ONGOING|2020-11-04
e|RS|a6e11c33-7905-42d2-bda9-671d756d4c51|10|TMRESP|Tumor Marker Response|CHESON CLL 2012|[?]|BU/mL|NON-CR/NON-PD|1|%(v/v)|ELISPOT||||SIBLING|DERMATOLOGIST|N|5|Visit_5|90|1|SCREENING|2020-10-25|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-19|P1Y2M10DT2H30M|BEFORE|2020-10-12|BEFORE|2020-10-31
e|RS|441d3bc1-c95e-4e52-bd1b-7713f3a2cd8c|1|NTERESP|Non-Target Enhancing Response|IRANO 2015|||cCR|1|mm|OPTICAL DENSITY MEASUREMENT|||Y|SIGNIFICANT OTHER|RATER|Y|1|Visit_1|10|4|TREATMENT|2020-11-12|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-07|P1Y2M10DT2H30M|BEFORE|2020-11-28|BEFORE|2020-12-15
e|RS|441d3bc1-c95e-4e52-bd1b-7713f3a2cd8c|2|BMIVLIND|Bone Marrow Involvement Indicator|KEAM BREAST CANCER 2013|[?]|IU/dL|FAVORABLE RESPONSE|1|mL/animal/day|DOUBLE IMMUNODIFFUSION||Y||VENDOR|CLINICAL PATHOLOGIST|N|1|Visit_1|10|1|TREATMENT|2020-11-12|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-07|P1Y2M10DT2H30M|BEFORE|2021-01-24|COINCIDENT|2021-02-04
e|RS|441d3bc1-c95e-4e52-bd1b-7713f3a2cd8c|3|TMRESP|Tumor Marker Response|LUGANO CLASSIFICATION|[?]|mL/100g/min|TREATMENT FAILURE|1|HOURS|HPLC-UV|Y|||INTERVIEWER|PATHOLOGIST 2|Y|2|Visit_2|25|7|TREATMENT|2020-11-27|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-27|P1Y2M10DT2H30M|UNKNOWN|2020-12-21|ONGOING|2021-01-17
e|RS|441d3bc1-c95e-4e52-bd1b-7713f3a2cd8c|4|SFTSRESP|Soft Tissue Response|SACT|[?]|HEP|STABLE|1|10^6/Ejaculate U|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY||||FAMILY MEMBER|HEMATOLOGIST|N|2|Visit_2|25|1|WASHOUT|2020-11-27|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-27|P1Y2M10DT2H30M|COINCIDENT|2020-12-28|ONGOING|2021-02-02
e|RS|441d3bc1-c95e-4e52-bd1b-7713f3a2cd8c|5|TMRESP|Tumor Marker Response|AJCC V8|[?]|uCi/L|PD FROM PR|1|IU|ECHOCARDIOGRAPHY||||ADJUDICATOR|CLINICAL PATHOLOGIST|N|3|Visit_3|40|6|WASHOUT|2020-12-12|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-03|P1Y2M10DT2H30M|BEFORE|2021-01-08|BEFORE|2021-01-13
e|RS|441d3bc1-c95e-4e52-bd1b-7713f3a2cd8c|6|SFTSRESP|Soft Tissue Response|RAJKUMAR MYELOMA 2011|[?]|Mile|iCPD|1|Absorbance U/mL|PHOTOGRAPHY|Y|||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST|U|3|Visit_3|40|2|SCREENING|2020-12-12|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-03|P1Y2M10DT2H30M|UNKNOWN|2021-01-26|COINCIDENT|2021-01-29
e|RS|441d3bc1-c95e-4e52-bd1b-7713f3a2cd8c|7|CPRFSTAT|Clinical Performance Status|EBMT BLADE MYELOMA 1998|||STABLE|1|g/dL|IMPULSE OSCILLOMETRY|||Y|PROXY|ADJUDICATOR 1|Y|4|Visit_4|65|7|WASHOUT|2021-01-06|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-03|P1Y2M10DT2H30M|AFTER|2021-02-09|BEFORE|2021-02-10
e|RS|441d3bc1-c95e-4e52-bd1b-7713f3a2cd8c|8|NEWLWIND|New Lesion Worsening Indicator|SACT|||MOLECULAR CR|1|cd/m2|CYSTOSCOPY||Y|Y|SIBLING|READER 2|Y|4|Visit_4|65|3|WASHOUT|2021-01-06|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-03|P1Y2M10DT2H30M|UNKNOWN|2020-12-03|BEFORE|2021-01-07
e|RS|441d3bc1-c95e-4e52-bd1b-7713f3a2cd8c|9|CPRFSTAT|Clinical Performance Status|WOLCHOK SOLID TUMORS 2009|[?]|mV/sec|COMPLETE MRD RESPONSE|1|g/U|IMMUNE REPERTOIRE DEEP SEQUENCING|Y|Y||PARENT|READER 1|Y|5|Visit_5|90|7|TREATMENT|2021-01-31|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-05|P1Y2M10DT2H30M|COINCIDENT|2020-11-23|ONGOING|2021-02-06
e|RS|441d3bc1-c95e-4e52-bd1b-7713f3a2cd8c|10|MNPTHIND|Minor Pathological Response Indicator|EASL BRUIX LIVER CANCER 2001|[?]|umol/day|PD/RELAPSE AFTER HI|1|um2|APPLANATION TONOMETRY||||FRIEND|MICROSCOPIST 3|NA|5|Visit_5|90|5|TREATMENT|2021-01-31|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-05|P1Y2M10DT2H30M|UNKNOWN|2020-12-05|AFTER|2021-01-02
e|RS|8ef37b54-b463-43a4-879f-3ad653c4fef4|1|CPRFSTAT|Clinical Performance Status|PETIT BREAST CANCER 2001|[?]|uL/dose|MRD PERSISTENCE|1|uSiemens|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION||Y||SPOUSE|HEMATOLOGIST|N|1|Visit_1|10|6|SCREENING|2020-09-11|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-20|P1Y2M10DT2H30M|COINCIDENT|2020-09-17|BEFORE|2020-10-25
e|RS|8ef37b54-b463-43a4-879f-3ad653c4fef4|2|MOLRESP|Molecular Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|ug/g/h|CA125 75% RESPONSE|1|ECL unit|MICROBIAL CONCENTRATION||||PARENT|PATHOLOGIST 1|U|1|Visit_1|10|7|WASHOUT|2020-09-11|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-20|P1Y2M10DT2H30M|BEFORE|2020-09-20|AFTER|2020-11-19
e|RS|8ef37b54-b463-43a4-879f-3ad653c4fef4|3|PATHRESP|Pathologic Response|RANO ELLINGSON 2017|[?]|WEEKS|NON-QUANTIFIABLE MRD POSITIVITY|1|mOsm/kg|GRAM STAIN||||FAMILY MEMBER|DERMATOLOGIST|N|2|Visit_2|25|2|TREATMENT|2020-09-26|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-27|P1Y2M10DT2H30M|UNKNOWN|2020-09-26|ONGOING|2020-11-01
e|RS|8ef37b54-b463-43a4-879f-3ad653c4fef4|4|METBRESP|Metabolic Response|WOLCHOK SOLID TUMORS 2009|[?]|MPS U|IMPROVED|1|10^6/Ejaculate U|TURBIDIMETRY||||SPOUSE|CARDIOLOGIST|U|2|Visit_2|25|2|WASHOUT|2020-09-26|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-27|P1Y2M10DT2H30M|AFTER|2020-11-02|ONGOING|2020-11-26
e|RS|8ef37b54-b463-43a4-879f-3ad653c4fef4|5|NTLWIND|Non-Target Lesion Worsening Indicator|EASL BRUIX LIVER CANCER 2001|[?]|ngEq/L|RELAPSED DISEASE|1|min/day|GC/MS/MS||||HEALTH CARE PROFESSIONAL|UROLOGIST|Y|3|Visit_3|40|6|TREATMENT|2020-10-11|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-26|P1Y2M10DT2H30M|BEFORE|2020-10-14|BEFORE|2020-10-22
e|RS|8ef37b54-b463-43a4-879f-3ad653c4fef4|6|CYTORESP|Cytogenetic Response|EASL BRUIX LIVER CANCER 2001|[?]|uEq/L|RELAPSED DISEASE FROM CR|1|gtt|LIQUID SCINTILLATION COUNTING||||INTERVIEWER|MICROSCOPIST 2|U|3|Visit_3|40|3|FOLLOW-UP|2020-10-11|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-26|P1Y2M10DT2H30M|UNKNOWN|2020-09-22|AFTER|2020-10-01
e|RS|8ef37b54-b463-43a4-879f-3ad653c4fef4|7|BONERESP|Bone Response|JACINTO CERVICAL CANCER 2007|[?]|mg/cm2|CHR|1|10^6 organisms/mL|SPIRAL CT||||FRIEND|RATER 1|NA|4|Visit_4|65|3|WASHOUT|2020-11-05|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-09|P1Y2M10DT2H30M|AFTER|2020-11-29|BEFORE|2020-12-08
e|RS|8ef37b54-b463-43a4-879f-3ad653c4fef4|8|CLINRESP|Clinical Response|PCWG BUBLEY PROSTATE CANCER 1999|||sCR|1|10^6 organisms/mL|SPIROMETRY|||Y|FAMILY MEMBER|RATER 1|Y|4|Visit_4|65|2|WASHOUT|2020-11-05|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-09|P1Y2M10DT2H30M|BEFORE|2020-10-06|COINCIDENT|2020-10-14
e|RS|8ef37b54-b463-43a4-879f-3ad653c4fef4|9|NTLWIND|Non-Target Lesion Worsening Indicator|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|umol/L/min|SD|1|10^6 U|TONOMETRY||||STUDY SUBJECT|ADJUDICATOR 3|Y|5|Visit_5|90|3|TREATMENT|2020-11-30|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-05|P1Y2M10DT2H30M|AFTER|2020-11-29|BEFORE|2020-12-01
e|RS|8ef37b54-b463-43a4-879f-3ad653c4fef4|10|METBRESP|Metabolic Response|CHESON CLL 2006|[?]|ug|WORSENED|1|nmol/L|CALIPER MEASUREMENT METHOD||Y||FAMILY MEMBER|READER 3|N|5|Visit_5|90|5|SCREENING|2020-11-30|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-05|P1Y2M10DT2H30M|UNKNOWN|2020-11-28|COINCIDENT|2020-12-02
e|RS|cf10035c-4d44-4512-810b-c267d1c8821b|1|METBRESP|Metabolic Response|IRANO 2015|[?]|ms2|INDETERMINATE RESPONSE|1|10^4/hpf|FLUORESCEIN STAIN||||STUDY SUBJECT|RATER|NA|1|Visit_1|10|4|TREATMENT|2020-05-27|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-04|P1Y2M10DT2H30M|UNKNOWN|2020-07-01|AFTER|2020-08-01
e|RS|cf10035c-4d44-4512-810b-c267d1c8821b|2|STRUSTAT|Steroid Use Status|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|||MORPHOLOGIC CRi|1|STEPS|IMPEDANCE CONDUCTIVITY|||Y|ADJUDICATOR|ONCOLOGIST 2|NA|1|Visit_1|10|4|FOLLOW-UP|2020-05-27|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-04|P1Y2M10DT2H30M|BEFORE|2020-07-20|BEFORE|2020-08-05
e|RS|cf10035c-4d44-4512-810b-c267d1c8821b|3|BMIVLIND|Bone Marrow Involvement Indicator|GUPPY OVARIAN CANCER 2002|[?]|pmol/10^10 cells|COMPLETE MRD RESPONSE|1|cal|ERGOSPIROMETRY||||INVESTIGATOR|RATER|N|2|Visit_2|25|3|TREATMENT|2020-06-11|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-24|P1Y2M10DT2H30M|COINCIDENT|2020-05-19|BEFORE|2020-07-03
e|RS|cf10035c-4d44-4512-810b-c267d1c8821b|4|MNPTHIND|Minor Pathological Response Indicator|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|CYLINDER|NR|1|ug/g/h|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY||||SPOUSE|ADJUDICATOR 1|U|2|Visit_2|25|2|TREATMENT|2020-06-11|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-24|P1Y2M10DT2H30M|UNKNOWN|2020-07-15|COINCIDENT|2020-08-20
e|RS|cf10035c-4d44-4512-810b-c267d1c8821b|5|STRUSTAT|Steroid Use Status|HARTMAN PANCREATIC CANCER 2012|[?]|/month|cCR|1|MPS U|AURAMINE STAIN||||CAREGIVER|UROLOGIST|Y|3|Visit_3|40|7|WASHOUT|2020-06-26|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-14|P1Y2M10DT2H30M|BEFORE|2020-05-25|ONGOING|2020-08-18
e|RS|cf10035c-4d44-4512-810b-c267d1c8821b|6|CLINRESP|Clinical Response|PERCIST|[?]|EID 50/mL|HI-P|1|mCi|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS||||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST|Y|3|Visit_3|40|2|TREATMENT|2020-06-26|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-14|P1Y2M10DT2H30M|UNKNOWN|2020-05-22|ONGOING|2020-05-27
e|RS|cf10035c-4d44-4512-810b-c267d1c8821b|7|NTNERESP|Non-Target Non-Enhancing Response|UNSPECIFIED|||WORSENED|1|mL/m2/h|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY||Y|Y|SIBLING|ADJUDICATOR 3|U|4|Visit_4|65|6|SCREENING|2020-07-21|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-04|P1Y2M10DT2H30M|UNKNOWN|2020-06-24|ONGOING|2020-07-27
e|RS|cf10035c-4d44-4512-810b-c267d1c8821b|8|TRGRESP|Target Response|DURIE MULTIPLE MYELOMA 2006|[?]|uV*sec|NON-QUANTIFIABLE MRD POSITIVITY|1|ohm|DIGITAL PCR||Y||CAREGIVER|READER 3|NA|4|Visit_4|65|4|SCREENING|2020-07-21|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-04|P1Y2M10DT2H30M|AFTER|2020-06-04|AFTER|2020-06-06
e|RS|cf10035c-4d44-4512-810b-c267d1c8821b|9|NTLWIND|Non-Target Lesion Worsening Indicator|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|GBq/ug|MRD PERSISTENCE|1|/h|MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY||||CLINICAL RESEARCH ASSOCIATE|INTERNIST|N|5|Visit_5|90|3|FOLLOW-UP|2020-08-15|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-23|P1Y2M10DT2H30M|UNKNOWN|2020-05-20|BEFORE|2020-08-09
e|RS|cf10035c-4d44-4512-810b-c267d1c8821b|10|NEWLWIND|New Lesion Worsening Indicator|HARTMAN PANCREATIC CANCER 2012|[?]|ukat|pCR|1|IU|ERGOSPIROMETRY|Y|||STUDY SUBJECT|RATER|N|5|Visit_5|90|5|FOLLOW-UP|2020-08-15|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-23|P1Y2M10DT2H30M|COINCIDENT|2020-07-18|AFTER|2020-08-13
e|RS|f24e5ff9-ebe2-4dfe-88ed-1705eb410c9b|1|BMIVLIND|Bone Marrow Involvement Indicator|MURPHY PROSTATE CANCER 1980|[?]|copies/ug|PD|1|10^9 organisms/g|FARNSWORTH-MUNSELL 100 HUE TEST||Y||SIBLING|CLINICAL PATHOLOGIST|Y|1|Visit_1|10|3|WASHOUT|2020-08-01|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-19|P1Y2M10DT2H30M|AFTER|2020-09-26|AFTER|2020-10-23
e|RS|f24e5ff9-ebe2-4dfe-88ed-1705eb410c9b|2|PATHRESP|Pathologic Response|NCCN ALL MRD 2014|[?]|kUSP|HI-P|1|mmHg|CENTRIFUGATION||||FAMILY MEMBER|DERMATOLOGIST|Y|1|Visit_1|10|6|SCREENING|2020-08-01|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-19|P1Y2M10DT2H30M|BEFORE|2020-09-19|BEFORE|2020-09-26
e|RS|f24e5ff9-ebe2-4dfe-88ed-1705eb410c9b|3|NEWLWIND|New Lesion Worsening Indicator|PRINCE TCELL LYMPHOMA 2010|[?]|MASK|IMMUNOPHENOTYPIC CR|1|mEq/mL|ISHIHARA COLOR PLATES||Y||FAMILY MEMBER|ADJUDICATOR 2|Y|2|Visit_2|25|4|TREATMENT|2020-08-16|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-01|P1Y2M10DT2H30M|COINCIDENT|2020-09-15|BEFORE|2020-09-26
e|RS|f24e5ff9-ebe2-4dfe-88ed-1705eb410c9b|4|HEMARESP|Hematologic Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|QUANTITY SUFFICIENT|PD FROM PR|1|MBq/uL|HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY||||SIGNIFICANT OTHER|PEDIATRIC NEUROLOGIST|NA|2|Visit_2|25|7|TREATMENT|2020-08-16|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-01|P1Y2M10DT2H30M|UNKNOWN|2020-08-02|AFTER|2020-08-22
e|RS|f24e5ff9-ebe2-4dfe-88ed-1705eb410c9b|5|BESTRESP|Best Overall Response|CHOLLET BREAST CANCER 2002|[?]|PNU/mL|RELAPSED DISEASE FROM CR OR PR|1|L/min/m2|NON-INVASIVE DIELECTRIC SENSING|Y|||CHILD|CARDIOLOGIST|U|3|Visit_3|40|3|SCREENING|2020-08-31|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-08|P1Y2M10DT2H30M|COINCIDENT|2020-07-27|COINCIDENT|2020-08-08
e|RS|f24e5ff9-ebe2-4dfe-88ed-1705eb410c9b|6|STRUSTAT|Steroid Use Status|SCHWARZ CERVICAL CANCER 2009|[?]|mL/(min*100mL)|NON-CR/NON-PD|1|cg|SPIROMETRY|Y|||PARENT|MICROSCOPIST|U|3|Visit_3|40|7|TREATMENT|2020-08-31|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-08|P1Y2M10DT2H30M|BEFORE|2020-10-08|COINCIDENT|2020-10-28
e|RS|f24e5ff9-ebe2-4dfe-88ed-1705eb410c9b|7|BMIVLIND|Bone Marrow Involvement Indicator|HAMAOKA BREAST CANCER 2010|[?]|mEq/ug|MORPHOLOGIC CRi|1|10^6 organisms/mg|BIOIMPEDANCE SPECTROSCOPY||||PARENT|PHYSIOTHERAPIST|U|4|Visit_4|65|5|TREATMENT|2020-09-25|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-30|P1Y2M10DT2H30M|COINCIDENT|2020-07-25|COINCIDENT|2020-08-04
e|RS|f24e5ff9-ebe2-4dfe-88ed-1705eb410c9b|8|MJPTHIND|Major Pathological Response Indicator|NCCN ALL MRD 2014|[?]|Newton|INDETERMINATE RESPONSE|1|log10 TCID 50/dose|HPLC/IEX||Y||FRIEND|OTOLARYNGOLOGIST|N|4|Visit_4|65|2|TREATMENT|2020-09-25|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-30|P1Y2M10DT2H30M|AFTER|2020-10-25|AFTER|2020-10-29
e|RS|f24e5ff9-ebe2-4dfe-88ed-1705eb410c9b|9|OVRLRESP|Overall Response|PCWG BUBLEY PROSTATE CANCER 1999|||QUANTIFIABLE MRD POSITIVITY|1|P|SPIROMETRY||Y|Y|PROXY|ONCOLOGIST 1|NA|5|Visit_5|90|1|TREATMENT|2020-10-20|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-29|P1Y2M10DT2H30M|COINCIDENT|2020-08-02|COINCIDENT|2020-08-04
e|RS|f24e5ff9-ebe2-4dfe-88ed-1705eb410c9b|10|LIVRRESP|Liver Response|CHOLLET BREAST CANCER 2002|[?]|10^4 CFU/mL|NE|1|ka_u/dL|PET/SPECT SCAN||||PARENT|MICROSCOPIST 3|NA|5|Visit_5|90|6|TREATMENT|2020-10-20|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-29|P1Y2M10DT2H30M|AFTER|2020-08-15|COINCIDENT|2020-09-24
e|RS|a1e0035a-3328-4966-8664-82e53a44eb59|1|SPLNRESP|Spleen Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|nmol|NED|1|MdFI|BAC ACGH|Y|||FRIEND|MICROSCOPIST 3|Y|1|Visit_1|10|6|TREATMENT|2020-08-10|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-09|P1Y2M10DT2H30M|UNKNOWN|2020-09-06|COINCIDENT|2020-10-01
e|RS|a1e0035a-3328-4966-8664-82e53a44eb59|2|MRPHRESP|Morphologic Response|AJCC V7|[?]|mN|pCR|1|dpm/mL|FARR ASSAY|Y|||HEALTH CARE PROFESSIONAL|RADIOLOGIST|Y|1|Visit_1|10|1|WASHOUT|2020-08-10|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-09|P1Y2M10DT2H30M|COINCIDENT|2020-10-03|BEFORE|2020-11-03
e|RS|a1e0035a-3328-4966-8664-82e53a44eb59|3|DRCRIND|Disease Recurrence Indicator|SACT|||MRD PERSISTENCE|1|DAYS|PLETHYSMOGRAPHY|Y||Y|GUARDIAN|UROLOGIST|N|2|Visit_2|25|3|SCREENING|2020-08-25|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-15|P1Y2M10DT2H30M|AFTER|2020-10-22|AFTER|2020-11-01
e|RS|a1e0035a-3328-4966-8664-82e53a44eb59|4|DRCRIND|Disease Recurrence Indicator|KEAM BREAST CANCER 2013|[?]|INHALATION|PSA PROGRESSION|1|MBP|INCISION-INDUCED BLEEDING METHOD||Y||NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|NA|2|Visit_2|25|1|SCREENING|2020-08-25|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-15|P1Y2M10DT2H30M|BEFORE|2020-08-14|ONGOING|2020-09-16
e|RS|a1e0035a-3328-4966-8664-82e53a44eb59|5|NEWLWIND|New Lesion Worsening Indicator|BURCOMBE BREAST CANCER 2005|||iCR|1|mEq/ug|URANYL ACETATE STAIN|||Y|ADJUDICATION COMMITTEE|CARDIOLOGIST|N|3|Visit_3|40|2|SCREENING|2020-09-09|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-28|P1Y2M10DT2H30M|COINCIDENT|2020-09-09|AFTER|2020-09-14
e|RS|a1e0035a-3328-4966-8664-82e53a44eb59|6|LIVRRESP|Liver Response|MURPHY PROSTATE CANCER 1980|[?]|km/h|mCR|1|L/day|LIGHT SCATTERING SPECTROSCOPY||||VENDOR|CARDIOLOGIST|U|3|Visit_3|40|5|WASHOUT|2020-09-09|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-28|P1Y2M10DT2H30M|BEFORE|2020-08-19|BEFORE|2020-09-08
e|RS|a1e0035a-3328-4966-8664-82e53a44eb59|7|MOLRESP|Molecular Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|mmol/g|INDETERMINATE RESPONSE|1|U/g/h|NUCLEAR RADIOLOGY||Y||SPOUSE|NEUROLOGIST 2|NA|4|Visit_4|65|5|TREATMENT|2020-10-04|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-08|P1Y2M10DT2H30M|UNKNOWN|2020-09-19|COINCIDENT|2020-10-10
e|RS|a1e0035a-3328-4966-8664-82e53a44eb59|8|MJPTHIND|Major Pathological Response Indicator|SACT|[?]|%/s|CR-CT|1|foz_br|FLOCCULATION, CHARCOAL ENHANCED||||HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|U|4|Visit_4|65|3|FOLLOW-UP|2020-10-04|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-08|P1Y2M10DT2H30M|COINCIDENT|2020-10-30|BEFORE|2020-11-07
e|RS|a1e0035a-3328-4966-8664-82e53a44eb59|9|BESTRESP|Best Overall Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|/LPF|NED|1|USP U|RAJI CELL RIA||Y||STUDY SUBJECT|OPTOMETRIST|U|5|Visit_5|90|4|TREATMENT|2020-10-29|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-12|P1Y2M10DT2H30M|UNKNOWN|2020-08-25|COINCIDENT|2020-10-19
e|RS|a1e0035a-3328-4966-8664-82e53a44eb59|10|HEMARESP|Hematologic Response|NCCN ALL MRD 2014|[?]|mg/kg/week|EQUIVOCAL|1|Joule|MUGA||||FRIEND|READER 2|U|5|Visit_5|90|6|TREATMENT|2020-10-29|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-12|P1Y2M10DT2H30M|COINCIDENT|2020-08-10|ONGOING|2020-08-29
e|RS|771377fd-724f-4056-b2ea-84e1adab1f47|1|NTNERESP|Non-Target Non-Enhancing Response|SACT|||CA125 50% RESPONSE|1|log10 TCID 50/uL|HPLC/MS/MS|||Y|PROXY|RATER 1|Y|1|Visit_1|10|1|TREATMENT|2020-11-08|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-22|P1Y2M10DT2H30M|UNKNOWN|2020-11-23|BEFORE|2020-12-03
e|RS|771377fd-724f-4056-b2ea-84e1adab1f47|2|SPLNRESP|Spleen Response|iRECIST|[?]|grain|NR|1|ukat|THIN SMEAR||Y||SIGNIFICANT OTHER|OPHTHALMOLOGIST|N|1|Visit_1|10|6|TREATMENT|2020-11-08|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-22|P1Y2M10DT2H30M|UNKNOWN|2020-11-15|BEFORE|2020-12-23
e|RS|771377fd-724f-4056-b2ea-84e1adab1f47|3|SFTSRESP|Soft Tissue Response|SCHWARZ CERVICAL CANCER 2009|||SD-CT|1|Newton|CARDIAC THERMODILUTION|||Y|PARENT|ADJUDICATOR|N|2|Visit_2|25|1|TREATMENT|2020-11-23|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-18|P1Y2M10DT2H30M|COINCIDENT|2020-12-06|COINCIDENT|2020-12-22
e|RS|771377fd-724f-4056-b2ea-84e1adab1f47|4|BMIVLIND|Bone Marrow Involvement Indicator|PCWG BUBLEY PROSTATE CANCER 1999|[?]|Gy/min|CMR|1|umol/day|IMMUNOBLOT||||CLINICAL RESEARCH COORDINATOR|OTOLARYNGOLOGIST|N|2|Visit_2|25|3|FOLLOW-UP|2020-11-23|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-18|P1Y2M10DT2H30M|BEFORE|2020-11-20|BEFORE|2021-01-29
e|RS|771377fd-724f-4056-b2ea-84e1adab1f47|5|NEWLIND|New Lesion Indicator|KEAM BREAST CANCER 2013|[?]|STEPS|NOT ALL EVALUATED|1|g/m2/day|JAFFE REACTION||||CAREGIVER|DEVELOPMENTAL PSYCHOLOGIST|N|3|Visit_3|40|3|WASHOUT|2020-12-08|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-29|P1Y2M10DT2H30M|UNKNOWN|2021-01-08|COINCIDENT|2021-01-28
e|RS|771377fd-724f-4056-b2ea-84e1adab1f47|6|MOLRESP|Molecular Response|PCWG SCHER PROSTATE CANCER 2008|[?]|deg/s|sCR|1|/100 WBC|CLIP SEQUENCING||Y||CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 1|U|3|Visit_3|40|4|TREATMENT|2020-12-08|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-29|P1Y2M10DT2H30M|AFTER|2020-12-05|BEFORE|2021-01-15
e|RS|771377fd-724f-4056-b2ea-84e1adab1f47|7|RDIORESP|Radiologic Response|AJCC V7|||MOLECULAR CR|1|MESF|NON-INVASIVE DIELECTRIC SENSING|Y||Y|SPOUSE|ADJUDICATOR 3|Y|4|Visit_4|65|7|SCREENING|2021-01-02|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-17|P1Y2M10DT2H30M|AFTER|2021-01-05|ONGOING|2021-02-03
e|RS|771377fd-724f-4056-b2ea-84e1adab1f47|8|ANATRESP|Anatomic Response|SCHWARZ CERVICAL CANCER 2009|[?]|SQU/mL|DECREASED|1|mL/beat|FLUORESCEIN STAIN|Y|||SPOUSE|ADJUDICATOR|N|4|Visit_4|65|7|TREATMENT|2021-01-02|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-17|P1Y2M10DT2H30M|COINCIDENT|2021-01-27|ONGOING|2021-01-28
e|RS|771377fd-724f-4056-b2ea-84e1adab1f47|9|SPLNRESP|Spleen Response|NCCN ALL MRD 2014|[?]|cg|INCREASED|1|pmol/10^10 cells|REAL-TIME POLYMERASE CHAIN REACTION ASSAY||||VENDOR|READER 2|Y|5|Visit_5|90|1|FOLLOW-UP|2021-01-27|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-14|P1Y2M10DT2H30M|BEFORE|2021-01-17|COINCIDENT|2021-01-27
e|RS|771377fd-724f-4056-b2ea-84e1adab1f47|10|MRDRESP|Minimal Residual Disease Response|BURCOMBE BREAST CANCER 2005|[?]|dram|RELAPSED DISEASE FROM CR|1|mL/animal|RADIOGRAPHY|Y|||INVESTIGATOR|FORENSIC PATHOLOGIST|U|5|Visit_5|90|5|FOLLOW-UP|2021-01-27|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-14|P1Y2M10DT2H30M|UNKNOWN|2021-01-03|BEFORE|2021-01-31
e|RS|8e3ae12f-e4d8-4bcd-b444-979496e0cfe1|1|CPRFSTAT|Clinical Performance Status|DURIE MULTIPLE MYELOMA 2006|[?]|ug/m2/h|CA125 75% RESPONSE|1|Ci/mL|BETA LACTAMASE||||ADJUDICATOR|OTOLARYNGOLOGIST|N|1|Visit_1|10|5|TREATMENT|2020-08-23|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-15|P1Y2M10DT2H30M|COINCIDENT|2020-09-22|BEFORE|2020-10-21
e|RS|8e3ae12f-e4d8-4bcd-b444-979496e0cfe1|2|NTRGRESP|Non-target Response|PCWG SCHER PROSTATE CANCER 2016|[?]|cmHg|PARTIAL MORPHOLOGIC RESPONSE|1|mL/kg/day|PHYSICAL EXAMINATION|Y|Y||ADJUDICATION COMMITTEE|NEUROLOGIST 1|N|1|Visit_1|10|2|TREATMENT|2020-08-23|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-15|P1Y2M10DT2H30M|COINCIDENT|2020-09-06|BEFORE|2020-11-03
e|RS|8e3ae12f-e4d8-4bcd-b444-979496e0cfe1|3|CYTORESP|Cytogenetic Response|CHESON CLL 2006|[?]|IU/dL|RELAPSED DISEASE FROM CR OR PR|1|vg/kg|NO INFORMATION|Y|Y||VENDOR|RADIOLOGIST 2|NA|2|Visit_2|25|5|WASHOUT|2020-09-07|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-04|P1Y2M10DT2H30M|BEFORE|2020-09-24|BEFORE|2020-11-02
e|RS|8e3ae12f-e4d8-4bcd-b444-979496e0cfe1|4|MRPHRESP|Morphologic Response|SHINDOH COLORECTAL CANCER 2013|[?]|deg2|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|U/g/day|PALM METHOD||||CLINICAL STUDY SPONSOR|RADIOLOGIST|NA|2|Visit_2|25|3|TREATMENT|2020-09-07|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-04|P1Y2M10DT2H30M|BEFORE|2020-10-04|ONGOING|2020-10-19
e|RS|8e3ae12f-e4d8-4bcd-b444-979496e0cfe1|5|NTNERESP|Non-Target Non-Enhancing Response|RAJKUMAR MYELOMA 2011|[?]|mL/beat|DISEASE TRANSFORMATION|1|CAN|INFRARED SPECTROMETRY||Y||HEALTH CARE PROFESSIONAL|CARDIOLOGIST|N|3|Visit_3|40|5|WASHOUT|2020-09-22|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-01|P1Y2M10DT2H30M|BEFORE|2020-09-04|ONGOING|2020-09-27
e|RS|8e3ae12f-e4d8-4bcd-b444-979496e0cfe1|6|CPRFSTAT|Clinical Performance Status|DOHNER AML 2010|[?]|pg/dL|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|mL/kg/h|NEXT GENERATION TARGETED SEQUENCING||||SIGNIFICANT OTHER|RATER 1|N|3|Visit_3|40|4|SCREENING|2020-09-22|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-01|P1Y2M10DT2H30M|UNKNOWN|2020-08-29|ONGOING|2020-10-04
e|RS|8e3ae12f-e4d8-4bcd-b444-979496e0cfe1|7|RDIORESP|Radiologic Response|NCCN ALL MRD 2014|||iPR|1|LOZENGE|MICROBIAL CULTURE||Y|Y|HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|U|4|Visit_4|65|5|TREATMENT|2020-10-17|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-25|P1Y2M10DT2H30M|AFTER|2020-10-16|BEFORE|2020-10-26
e|RS|8e3ae12f-e4d8-4bcd-b444-979496e0cfe1|8|TRGRESP|Target Response|HARTMAN PANCREATIC CANCER 2012|||CYTOGENETIC MINIMAL RESPONSE|1|/month|TRIPLE-PHASE MRI SCAN||Y|Y|CAREGIVER|MICROSCOPIST|N|4|Visit_4|65|3|TREATMENT|2020-10-17|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-25|P1Y2M10DT2H30M|UNKNOWN|2020-10-22|AFTER|2020-10-25
e|RS|8e3ae12f-e4d8-4bcd-b444-979496e0cfe1|9|PATHRESP|Pathologic Response|CHESON CLL 2012|||OPTIMAL MORPHOLOGIC RESPONSE|1|TAMPON|INTERRUPTER TECHNIQUE|Y|Y|Y|INTERVIEWER|ADJUDICATOR|Y|5|Visit_5|90|3|FOLLOW-UP|2020-11-11|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-25|P1Y2M10DT2H30M|AFTER|2020-10-12|COINCIDENT|2020-10-18
e|RS|8e3ae12f-e4d8-4bcd-b444-979496e0cfe1|10|CPRFSTAT|Clinical Performance Status|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|mL/g/h|CHR|1|kg/cm|MALDI|Y|||PARENT|RADIOLOGIST 1|Y|5|Visit_5|90|4|TREATMENT|2020-11-11|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-25|P1Y2M10DT2H30M|UNKNOWN|2020-08-17|ONGOING|2020-10-11
e|RS|3aea0861-8f67-4717-93ce-c1e322f151d9|1|CYTORESP|Cytogenetic Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|g/U|CYTOGENETIC MINOR RESPONSE|1|AU/mL|ECHOCARDIOGRAPHY||||CLINICAL STUDY SPONSOR|MICROSCOPIST 2|Y|1|Visit_1|10|7|TREATMENT|2020-08-14|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-30|P1Y2M10DT2H30M|UNKNOWN|2020-08-20|ONGOING|2020-11-02
e|RS|3aea0861-8f67-4717-93ce-c1e322f151d9|2|MOLRESP|Molecular Response|GUILHOT CML 2007|||mCR|1|IU/day|FLUORESCENT SPOT TEST|Y|Y|Y|GUARDIAN|RATER 1|U|1|Visit_1|10|2|FOLLOW-UP|2020-08-14|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-30|P1Y2M10DT2H30M|BEFORE|2020-09-10|ONGOING|2020-11-04
e|RS|3aea0861-8f67-4717-93ce-c1e322f151d9|3|STRUSTAT|Steroid Use Status|SACT|[?]|uIU/dL|PD|1|ppm|HEMATOXYLIN AND EOSIN STAIN||Y||SIGNIFICANT OTHER|PATHOLOGIST 1|NA|2|Visit_2|25|2|WASHOUT|2020-08-29|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-14|P1Y2M10DT2H30M|AFTER|2020-10-23|ONGOING|2020-11-10
e|RS|3aea0861-8f67-4717-93ce-c1e322f151d9|4|MRDRESP|Minimal Residual Disease Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|mmol2/L2|FAVORABLE RESPONSE|1|km/h|SINGLE-SLICE SPIRAL CT|Y|||PROXY|OTOLARYNGOLOGIST|NA|2|Visit_2|25|1|TREATMENT|2020-08-29|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-14|P1Y2M10DT2H30M|BEFORE|2020-09-23|AFTER|2020-10-08
e|RS|3aea0861-8f67-4717-93ce-c1e322f151d9|5|MOLRESP|Molecular Response|CHESON CLL 2012|[?]|WAFER|FAVORABLE RESPONSE|1|ukat/10^12 RBC|POLYSOMNOGRAPHY||Y||NON-HEALTH CARE PROFESSIONAL|READER 3|NA|3|Visit_3|40|1|TREATMENT|2020-09-13|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-20|P1Y2M10DT2H30M|UNKNOWN|2020-11-07|AFTER|2020-11-08
e|RS|3aea0861-8f67-4717-93ce-c1e322f151d9|6|NEWLIND|New Lesion Indicator|KUMAR IMWG 2016|[?]|um2|VGPR|1|mg/animal|CLAUSS METHOD||||PROXY|NEUROLOGIST 2|NA|3|Visit_3|40|5|WASHOUT|2020-09-13|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-20|P1Y2M10DT2H30M|COINCIDENT|2020-10-16|BEFORE|2020-10-20
e|RS|3aea0861-8f67-4717-93ce-c1e322f151d9|7|HEMARESP|Hematologic Response|NCIWG CHESON CLL 1996|||RELAPSED DISEASE|1|BU|GC/MS/MS|Y||Y|SPOUSE|ONCOLOGIST 2|U|4|Visit_4|65|4|TREATMENT|2020-10-08|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-18|P1Y2M10DT2H30M|COINCIDENT|2020-09-26|AFTER|2020-10-04
e|RS|3aea0861-8f67-4717-93ce-c1e322f151d9|8|SFTSRESP|Soft Tissue Response|CHESON CLL 2006|[?]|ug/L FEU|sCR|1|IU/dL|BRDU CELLULAR PROLIFERATION ASSAY|Y|Y||INTERVIEWER|ONCOLOGIST 2|U|4|Visit_4|65|7|TREATMENT|2020-10-08|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-18|P1Y2M10DT2H30M|COINCIDENT|2020-10-20|COINCIDENT|2020-10-26
e|RS|3aea0861-8f67-4717-93ce-c1e322f151d9|9|MRPHRESP|Morphologic Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|Bq/mg|MR|1|cm/s|NEXT GENERATION TARGETED SEQUENCING||Y||PROXY|RATER 1|NA|5|Visit_5|90|2|TREATMENT|2020-11-02|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-17|P1Y2M10DT2H30M|AFTER|2020-09-29|COINCIDENT|2020-11-05
e|RS|3aea0861-8f67-4717-93ce-c1e322f151d9|10|MRDIND|Minimal Residual Disease Indicator|IWC HALLEK CLL 2008|||cPR|1|nmol/mL/min|MICROBIAL CULTURE, SOLID||Y|Y|ADJUDICATOR|NEUROLOGIST 1|Y|5|Visit_5|90|3|FOLLOW-UP|2020-11-02|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-17|P1Y2M10DT2H30M|COINCIDENT|2020-08-25|ONGOING|2020-09-08
e|RS|4fbe2ae7-4b86-4706-845c-d1f22f1a822f|1|DRCRIND|Disease Recurrence Indicator|SACT|[?]|/100 WBC|MRD PERSISTENCE|1|%(w/w)|ELISPOT||||FRIEND|PATHOLOGIST 1|U|1|Visit_1|10|1|TREATMENT|2020-10-05|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-02|P1Y2M10DT2H30M|BEFORE|2020-10-19|ONGOING|2020-11-14
e|RS|4fbe2ae7-4b86-4706-845c-d1f22f1a822f|2|OVRLRESP|Overall Response|SACT|||PD FROM PR|1|ohm|ATOMIC ABSORPTION SPECTROMETRY|||Y|INVESTIGATOR|READER|Y|1|Visit_1|10|1|FOLLOW-UP|2020-10-05|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-02|P1Y2M10DT2H30M|UNKNOWN|2020-12-05|COINCIDENT|2020-12-14
e|RS|4fbe2ae7-4b86-4706-845c-d1f22f1a822f|3|LIVRRESP|Liver Response|IWG CHESON MDS 2000|[?]|mg/kg|CYTOGENETIC NO RESPONSE|1|keV|HPLC||Y||ADJUDICATOR|NEUROLOGIST 1|Y|2|Visit_2|25|1|FOLLOW-UP|2020-10-20|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-18|P1Y2M10DT2H30M|AFTER|2020-12-04|ONGOING|2020-12-06
e|RS|4fbe2ae7-4b86-4706-845c-d1f22f1a822f|4|MRDRESP|Minimal Residual Disease Response|MURPHY PROSTATE CANCER 1980|||MAJOR PATHOLOGIC RESPONSE|1|mmol/mol|REAL-TIME POLYMERASE CHAIN REACTION ASSAY||Y|Y|SPOUSE|ONCOLOGIST 2|N|2|Visit_2|25|1|TREATMENT|2020-10-20|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-18|P1Y2M10DT2H30M|BEFORE|2020-10-14|AFTER|2020-11-21
e|RS|4fbe2ae7-4b86-4706-845c-d1f22f1a822f|5|SPLNRESP|Spleen Response|LUGANO CLASSIFICATION|||SD|1|vp/dose|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY|Y|Y|Y|HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|Y|3|Visit_3|40|5|TREATMENT|2020-11-04|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-03|P1Y2M10DT2H30M|BEFORE|2020-11-26|COINCIDENT|2020-12-02
e|RS|4fbe2ae7-4b86-4706-845c-d1f22f1a822f|6|BONERESP|Bone Response|SACT|[?]|mg/kg|CYTOGENETIC CR|1|10^6 RNA copies/mL|QUANTITATIVE CORONARY ANGIOGRAPHY||Y||INDEPENDENT ASSESSOR|RATER|NA|3|Visit_3|40|6|FOLLOW-UP|2020-11-04|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-03|P1Y2M10DT2H30M|AFTER|2020-10-12|COINCIDENT|2020-11-20
e|RS|4fbe2ae7-4b86-4706-845c-d1f22f1a822f|7|STRUSTAT|Steroid Use Status|WHO BREAST CANCER 2006|[?]|DNA copies/mL|CYTOGENETIC MINOR RESPONSE|1|RFU|CONGO RED STAIN||||INVESTIGATOR|DERMATOLOGIST|N|4|Visit_4|65|2|TREATMENT|2020-11-29|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-26|P1Y2M10DT2H30M|UNKNOWN|2020-10-06|ONGOING|2020-10-19
e|RS|4fbe2ae7-4b86-4706-845c-d1f22f1a822f|8|MJPTHIND|Major Pathological Response Indicator|RAJKUMAR MYELOMA 2011|[?]|NEEDLE GAUGE|FAVORABLE RESPONSE|1|Shock Wave|PELLI-ROBSON EYE CHART||||FRIEND|READER|N|4|Visit_4|65|7|TREATMENT|2020-11-29|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-26|P1Y2M10DT2H30M|COINCIDENT|2020-11-04|BEFORE|2020-12-02
e|RS|4fbe2ae7-4b86-4706-845c-d1f22f1a822f|9|HEMARESP|Hematologic Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|vg/mL|pCR|1|umol/L|CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY||||STUDY SUBJECT|RADIOLOGIST|N|5|Visit_5|90|5|TREATMENT|2020-12-24|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-09|P1Y2M10DT2H30M|COINCIDENT|2021-01-01|COINCIDENT|2021-01-02
e|RS|4fbe2ae7-4b86-4706-845c-d1f22f1a822f|10|NTRGRESP|Non-target Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|amp|CRi|1|kV|IMMUNOFLUORESCENT STAIN||Y||GUARDIAN|ONCOLOGIST 2|Y|5|Visit_5|90|3|TREATMENT|2020-12-24|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-09|P1Y2M10DT2H30M|UNKNOWN|2020-12-16|AFTER|2020-12-21
e|RS|ec63ad33-0411-4d12-af68-e2cda3a3f1ac|1|SYMPTDTR|Symptomatic Deterioration|PCWG SCHER PROSTATE CANCER 2016|[?]|WEEKS|PMD|1|log EID 50/dose|DROPLET DIGITAL PCR||Y||CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|1|Visit_1|10|4|WASHOUT|2020-12-30|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-02|P1Y2M10DT2H30M|AFTER|2021-01-24|COINCIDENT|2021-02-26
e|RS|ec63ad33-0411-4d12-af68-e2cda3a3f1ac|2|NTERESP|Non-Target Enhancing Response|HAMAOKA BREAST CANCER 2010|[?]|mL/cm|INDETERMINATE RESPONSE|1|ELISA unit/mL|SNELLEN EYE CHART|Y|||ADJUDICATION COMMITTEE|ADJUDICATOR 2|NA|1|Visit_1|10|6|FOLLOW-UP|2020-12-30|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-02|P1Y2M10DT2H30M|AFTER|2021-01-04|AFTER|2021-01-30
e|RS|ec63ad33-0411-4d12-af68-e2cda3a3f1ac|3|METBRESP|Metabolic Response|PETIT BREAST CANCER 2001|||NON-iCR/NON-iUPD|1|pg/dL|MRI WITHOUT CONTRAST|Y|Y|Y|CLINICAL STUDY SPONSOR|INTERNIST|N|2|Visit_2|25|7|SCREENING|2021-01-14|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-01|P1Y2M10DT2H30M|AFTER|2021-01-09|AFTER|2021-01-13
e|RS|ec63ad33-0411-4d12-af68-e2cda3a3f1ac|4|NEWLWIND|New Lesion Worsening Indicator|NCCN ALL MRD 2014|[?]|/VF|CYTOGENETIC MINIMAL RESPONSE|1|Bq/kg|PYROSEQUENCING||||PROXY|DERMATOLOGIST|U|2|Visit_2|25|2|TREATMENT|2021-01-14|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-01|P1Y2M10DT2H30M|AFTER|2021-02-23|COINCIDENT|2021-03-04
e|RS|ec63ad33-0411-4d12-af68-e2cda3a3f1ac|5|STRUSTAT|Steroid Use Status|AJCC V7|[?]|mEq/kg|COMPLETE MRD RESPONSE|1|mg/cm2|RADIAL IMMUNODIFFUSION||Y||ADJUDICATION COMMITTEE|MICROSCOPIST 1|NA|3|Visit_3|40|1|SCREENING|2021-01-29|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-19|P1Y2M10DT2H30M|COINCIDENT|2021-02-04|ONGOING|2021-02-10
e|RS|ec63ad33-0411-4d12-af68-e2cda3a3f1ac|6|BESTRESP|Best Overall Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|10^3 organisms/g|NON-iCR/NON-iUPD|1|dL|BETA LACTAMASE||||STUDY SUBJECT|PATHOLOGIST 2|U|3|Visit_3|40|2|TREATMENT|2021-01-29|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-19|P1Y2M10DT2H30M|UNKNOWN|2021-01-28|ONGOING|2021-03-10
e|RS|ec63ad33-0411-4d12-af68-e2cda3a3f1ac|7|NTLWIND|Non-Target Lesion Worsening Indicator|FAROOQUI SUPP CLL 2014|||iCR|1|kg/cm2|OSCILLOMETRY|||Y|INDEPENDENT ASSESSOR|OTOLARYNGOLOGIST|N|4|Visit_4|65|4|WASHOUT|2021-02-23|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-08|P1Y2M10DT2H30M|UNKNOWN|2021-02-15|COINCIDENT|2021-03-10
e|RS|ec63ad33-0411-4d12-af68-e2cda3a3f1ac|8|DRCRIND|Disease Recurrence Indicator|PALUMBO MULTIPLE MYELOMA 2009|||iPR|1|mm3/mm2/year|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY||Y|Y|CHILD|PATHOLOGIST 2|N|4|Visit_4|65|1|FOLLOW-UP|2021-02-23|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-08|P1Y2M10DT2H30M|UNKNOWN|2021-01-04|COINCIDENT|2021-01-17
e|RS|ec63ad33-0411-4d12-af68-e2cda3a3f1ac|9|MJPTHIND|Major Pathological Response Indicator|PCWG SCHER PROSTATE CANCER 2016|[?]|ng/mol|VGPR|1|dL|ULTRASONOGRAPHIC ELASTOGRAPHY||||GUARDIAN|ADJUDICATOR|NA|5|Visit_5|90|7|WASHOUT|2021-03-20|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-26|P1Y2M10DT2H30M|COINCIDENT|2021-02-19|AFTER|2021-03-04
e|RS|ec63ad33-0411-4d12-af68-e2cda3a3f1ac|10|METBRESP|Metabolic Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|mN|OPTIMAL MORPHOLOGIC RESPONSE|1|10^9/L|GC/FID||||VENDOR|ONCOLOGIST 1|U|5|Visit_5|90|3|WASHOUT|2021-03-20|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-26|P1Y2M10DT2H30M|COINCIDENT|2021-01-12|COINCIDENT|2021-03-11
e|RS|39f51bd8-5edc-4434-92d4-7d8b683a6c32|1|OVRLRESP|Overall Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|/LSQN|NR|1|mg/mol|HEMAGGLUTINATION INHIBITION ASSAY|Y|Y||DOMESTIC PARTNER|FORENSIC PATHOLOGIST|Y|1|Visit_1|10|5|FOLLOW-UP|2020-09-19|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-20|P1Y2M10DT2H30M|UNKNOWN|2020-10-02|AFTER|2020-11-27
e|RS|39f51bd8-5edc-4434-92d4-7d8b683a6c32|2|NTERESP|Non-Target Enhancing Response|CHESON CLL 2012|[?]|tsp eq|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|JAR|WESTERN BLOT||||SIGNIFICANT OTHER|ADJUDICATOR 2|N|1|Visit_1|10|5|FOLLOW-UP|2020-09-19|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-20|P1Y2M10DT2H30M|UNKNOWN|2020-11-06|BEFORE|2020-11-11
e|RS|39f51bd8-5edc-4434-92d4-7d8b683a6c32|3|PATHRESP|Pathologic Response|RANO|[?]|g/cm2|HI-P|1|kg|RADIATION DOSIMETRY||Y||INDEPENDENT ASSESSOR|RATER|NA|2|Visit_2|25|4|TREATMENT|2020-10-04|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-09|P1Y2M10DT2H30M|UNKNOWN|2020-11-13|ONGOING|2020-12-15
e|RS|39f51bd8-5edc-4434-92d4-7d8b683a6c32|4|BESTRESP|Best Overall Response|RECIST 1.0|[?]|/MBP|IMPROVED|1|U/g Hb|FLUORESCENT SPOT TEST||||STUDY SUBJECT|ONCOLOGIST 2|NA|2|Visit_2|25|6|WASHOUT|2020-10-04|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-09|P1Y2M10DT2H30M|AFTER|2020-11-25|BEFORE|2020-11-26
e|RS|39f51bd8-5edc-4434-92d4-7d8b683a6c32|5|BESTRESP|Best Overall Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|U/kg/h|RELAPSED DISEASE|1|breaths/30s|PHASE CONTRAST MICROSCOPY||Y||PARENT|ADJUDICATOR|NA|3|Visit_3|40|5|FOLLOW-UP|2020-10-19|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-14|P1Y2M10DT2H30M|UNKNOWN|2020-12-14|AFTER|2020-12-16
e|RS|39f51bd8-5edc-4434-92d4-7d8b683a6c32|6|SFTSRESP|Soft Tissue Response|KUMAR IMWG 2016|[?]|WEEKS|SD-CT|1|BU|WRIGHT-GIEMSA STAIN||||CAREGIVER|DERMATOLOGIST|U|3|Visit_3|40|2|TREATMENT|2020-10-19|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-14|P1Y2M10DT2H30M|AFTER|2020-11-21|COINCIDENT|2020-12-15
e|RS|39f51bd8-5edc-4434-92d4-7d8b683a6c32|7|TMRESP|Tumor Marker Response|WOLCHOK SOLID TUMORS 2009|[?]|pt_br|NR|1|dpm/mL|HPLC||||CLINICAL STUDY SPONSOR|PATHOLOGIST 1|Y|4|Visit_4|65|6|FOLLOW-UP|2020-11-13|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-23|P1Y2M10DT2H30M|AFTER|2020-10-19|COINCIDENT|2020-11-16
e|RS|39f51bd8-5edc-4434-92d4-7d8b683a6c32|8|BESTRESP|Best Overall Response|IWC HALLEK CLL 2008|[?]|ng/mol|MAJOR PATHOLOGIC RESPONSE|1|Gy/min|HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY||||CAREGIVER|ADJUDICATOR 2|NA|4|Visit_4|65|3|SCREENING|2020-11-13|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-23|P1Y2M10DT2H30M|AFTER|2020-11-17|ONGOING|2020-12-11
e|RS|39f51bd8-5edc-4434-92d4-7d8b683a6c32|9|STRUSTAT|Steroid Use Status|DURIE MULTIPLE MYELOMA 2006|[?]|breaths/min|PSA PROGRESSION|1|mPa|MICROBIAL BIOCHEMICAL IDENTIFICATION||||DOMESTIC PARTNER|OPTOMETRIST|Y|5|Visit_5|90|7|FOLLOW-UP|2020-12-08|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-20|P1Y2M10DT2H30M|COINCIDENT|2020-11-09|ONGOING|2020-12-16
e|RS|39f51bd8-5edc-4434-92d4-7d8b683a6c32|10|CPRFSTAT|Clinical Performance Status|JACINTO CERVICAL CANCER 2007|[?]|U/g Hb|MORPHOLOGIC LEUKEMIA-FREE STATE|1|ukat/10^12 RBC|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION||||INVESTIGATOR|OPHTHALMOLOGIST|NA|5|Visit_5|90|2|FOLLOW-UP|2020-12-08|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-20|P1Y2M10DT2H30M|UNKNOWN|2020-10-13|COINCIDENT|2020-11-25
e|RS|80565a22-8cec-46a2-abd7-91daf0767035|1|NTLWIND|Non-Target Lesion Worsening Indicator|CHESON LYMPHOMA 2008|[?]|amol|SD-CT|1|Pa|CISH||||CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 2|N|1|Visit_1|10|1|TREATMENT|2021-01-28|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-24|P1Y2M10DT2H30M|UNKNOWN|2021-03-23|BEFORE|2021-04-18
e|RS|80565a22-8cec-46a2-abd7-91daf0767035|2|METBRESP|Metabolic Response|IWG CHESON AML 2003|||NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|h*%|INDIRECT IMMUNOFLUORESCENCE|||Y|INTERVIEWER|RADIOLOGIST|U|1|Visit_1|10|4|TREATMENT|2021-01-28|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-24|P1Y2M10DT2H30M|UNKNOWN|2021-03-25|BEFORE|2021-04-11
e|RS|80565a22-8cec-46a2-abd7-91daf0767035|3|NTERESP|Non-Target Enhancing Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|/day|CA125 75% RESPONSE|1|nmol BCE/nmol|FLOW MICROSCOPY|Y|||GUARDIAN|ADJUDICATOR|U|2|Visit_2|25|6|TREATMENT|2021-02-12|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-04|P1Y2M10DT2H30M|UNKNOWN|2021-04-15|AFTER|2021-04-17
e|RS|80565a22-8cec-46a2-abd7-91daf0767035|4|ANATRESP|Anatomic Response|PCWG SCHER PROSTATE CANCER 2008|||MRD RELAPSE|1|Bq/mL|GC/MS/MS|||Y|SIGNIFICANT OTHER|RADIOLOGIST 2|Y|2|Visit_2|25|1|FOLLOW-UP|2021-02-12|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-04|P1Y2M10DT2H30M|COINCIDENT|2021-04-16|ONGOING|2021-04-25
e|RS|80565a22-8cec-46a2-abd7-91daf0767035|5|NTLWIND|Non-Target Lesion Worsening Indicator|RANO ELLINGSON 2017|[?]|aMFI|iUPD|1|DISK|DOUBLE IMMUNODIFFUSION||||GUARDIAN|UROLOGIST|Y|3|Visit_3|40|1|WASHOUT|2021-02-27|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-20|P1Y2M10DT2H30M|AFTER|2021-03-06|ONGOING|2021-04-03
e|RS|80565a22-8cec-46a2-abd7-91daf0767035|6|NTRGRESP|Non-target Response|GUILHOT CML 2007|||HI-E|1|g/g/day|NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY|||Y|SPOUSE|CARDIOLOGIST|N|3|Visit_3|40|6|TREATMENT|2021-02-27|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-20|P1Y2M10DT2H30M|COINCIDENT|2021-04-25|COINCIDENT|2021-04-26
e|RS|80565a22-8cec-46a2-abd7-91daf0767035|7|MNPTHIND|Minor Pathological Response Indicator|MRANO VAN DEN BENT GLIOMA 2011|||MRD RELAPSE|1|mg2/dL2|IMMUNODIFFUSION|||Y|VENDOR|RADIOLOGIST 2|Y|4|Visit_4|65|7|FOLLOW-UP|2021-03-24|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-24|P1Y2M10DT2H30M|AFTER|2021-03-20|ONGOING|2021-04-18
e|RS|80565a22-8cec-46a2-abd7-91daf0767035|8|STRUSTAT|Steroid Use Status|KUMAR IMWG 2016|[?]|dram|iCR|1|g/cage/day|HIGH RESOLUTION MELT ANALYSIS|Y|||SPOUSE|MICROSCOPIST 1|Y|4|Visit_4|65|5|FOLLOW-UP|2021-03-24|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-24|P1Y2M10DT2H30M|UNKNOWN|2021-03-21|AFTER|2021-04-27
e|RS|80565a22-8cec-46a2-abd7-91daf0767035|9|METBRESP|Metabolic Response|CHESON CLL 2012|||SD|1|mg/animal|HEMAGGLUTINATION INHIBITION ASSAY|||Y|FRIEND|READER 2|Y|5|Visit_5|90|5|WASHOUT|2021-04-18|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-26|P1Y2M10DT2H30M|COINCIDENT|2021-03-05|BEFORE|2021-04-07
e|RS|80565a22-8cec-46a2-abd7-91daf0767035|10|BESTRESP|Best Overall Response|RECIST 1.0|||CYTOGENETIC CR|1|ug/L|SNELLEN EYE CHART|||Y|NON-HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|NA|5|Visit_5|90|3|FOLLOW-UP|2021-04-18|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-26|P1Y2M10DT2H30M|BEFORE|2021-04-09|ONGOING|2021-04-10
e|RS|585a254e-c36b-44cf-b8a9-335fb98e0fd2|1|NEWLPROG|New Lesion Progression|EBMT BLADE MYELOMA 1998|[?]|/10^4|MAJOR PATHOLOGIC RESPONSE|1|mV/sec|INTERRUPTER TECHNIQUE||||INTERVIEWER|RATER|U|1|Visit_1|10|2|TREATMENT|2020-10-19|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-23|P1Y2M10DT2H30M|COINCIDENT|2020-11-20|BEFORE|2020-11-26
e|RS|585a254e-c36b-44cf-b8a9-335fb98e0fd2|2|SPLNRESP|Spleen Response|DOHNER AML 2010|[?]|ug/kg|MINOR PATHOLOGIC RESPONSE|1|BEAM BREAKS|LANDOLT RING|Y|Y||CHILD|ENDOCRINOLOGIST|NA|1|Visit_1|10|3|FOLLOW-UP|2020-10-19|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-23|P1Y2M10DT2H30M|UNKNOWN|2020-12-10|COINCIDENT|2021-01-03
e|RS|585a254e-c36b-44cf-b8a9-335fb98e0fd2|3|CYTORESP|Cytogenetic Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|Bq/L|STABLE|1|/wk|POLYMERASE CHAIN REACTION||||CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 2|NA|2|Visit_2|25|2|FOLLOW-UP|2020-11-03|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-29|P1Y2M10DT2H30M|COINCIDENT|2020-10-30|COINCIDENT|2020-12-14
e|RS|585a254e-c36b-44cf-b8a9-335fb98e0fd2|4|NEWLIND|New Lesion Indicator|RANO|||QUANTIFIABLE MRD POSITIVITY|1|mg/kg|SLIT LAMP|||Y|INTERVIEWER|ONCOLOGIST|U|2|Visit_2|25|6|WASHOUT|2020-11-03|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-29|P1Y2M10DT2H30M|AFTER|2021-01-09|BEFORE|2021-01-11
e|RS|585a254e-c36b-44cf-b8a9-335fb98e0fd2|5|BONERESP|Bone Response|RECICL|[?]|kUSP|NON-PD|1|uCi|FORCED OSCILLATION TECHNIQUE||||INTERVIEWER|ONCOLOGIST 1|N|3|Visit_3|40|7|TREATMENT|2020-11-18|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-28|P1Y2M10DT2H30M|AFTER|2020-11-19|COINCIDENT|2020-12-11
e|RS|585a254e-c36b-44cf-b8a9-335fb98e0fd2|6|NTERESP|Non-Target Enhancing Response|HARTMANN GERM CELL CANCER 2002|[?]|Ci/kg|iCPD|1|g/g|KINETIC CHROMOGENIC ASSAY||Y||ADJUDICATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|3|Visit_3|40|1|TREATMENT|2020-11-18|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-28|P1Y2M10DT2H30M|COINCIDENT|2021-01-16|ONGOING|2021-01-17
e|RS|585a254e-c36b-44cf-b8a9-335fb98e0fd2|7|SFTSRESP|Soft Tissue Response|RANO ELLINGSON 2017|||STABLE|1|km|LISSAMINE GREEN STAIN|||Y|INDEPENDENT ASSESSOR|INTERNIST|U|4|Visit_4|65|5|SCREENING|2020-12-13|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-26|P1Y2M10DT2H30M|BEFORE|2020-12-09|AFTER|2021-01-01
e|RS|585a254e-c36b-44cf-b8a9-335fb98e0fd2|8|CPRFSTAT|Clinical Performance Status|WHO BREAST CANCER 2006|[?]|kat|PR|1|fraction of 1|DISK DIFFUSION||||FAMILY MEMBER|OTOLARYNGOLOGIST|Y|4|Visit_4|65|7|FOLLOW-UP|2020-12-13|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-26|P1Y2M10DT2H30M|COINCIDENT|2020-10-25|BEFORE|2020-11-28
e|RS|585a254e-c36b-44cf-b8a9-335fb98e0fd2|9|NTRGRESP|Non-target Response|AJCC V7|[?]|/10^4|PSA PROGRESSION|1|POINT|ENDOSCOPY||||CAREGIVER|RATER 1|Y|5|Visit_5|90|4|TREATMENT|2021-01-07|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-03|P1Y2M10DT2H30M|COINCIDENT|2020-11-26|AFTER|2021-01-16
e|RS|585a254e-c36b-44cf-b8a9-335fb98e0fd2|10|NTNERESP|Non-Target Non-Enhancing Response|DURIE MULTIPLE MYELOMA 2006|[?]|fg|UNFAVORABLE RESPONSE|1|TABLET|CONTRAST ENHANCED SPIRAL CT SCAN|Y|||CLINICAL STUDY SPONSOR|READER 1|Y|5|Visit_5|90|6|SCREENING|2021-01-07|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-03|P1Y2M10DT2H30M|AFTER|2020-10-28|COINCIDENT|2020-12-18
e|RS|9ee3632d-4e99-4a46-b0b9-237467d97ca0|1|NTLWIND|Non-Target Lesion Worsening Indicator|RAJKUMAR MYELOMA 2011|[?]|/10^3|CYTOGENETIC MINIMAL RESPONSE|1|/cmH2O|PHASE-CONTRAST MRI|Y|||INDEPENDENT ASSESSOR|FORENSIC PATHOLOGIST|NA|1|Visit_1|10|5|TREATMENT|2020-09-09|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-02|P1Y2M10DT2H30M|BEFORE|2020-09-25|ONGOING|2020-11-02
e|RS|9ee3632d-4e99-4a46-b0b9-237467d97ca0|2|NTERESP|Non-Target Enhancing Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|ag|NON-iCR/NON-iUPD|1|IU/mg|JAFFE REACTION||||INVESTIGATOR|OTOLARYNGOLOGIST|Y|1|Visit_1|10|3|TREATMENT|2020-09-09|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-02|P1Y2M10DT2H30M|BEFORE|2020-11-04|COINCIDENT|2020-11-27
e|RS|9ee3632d-4e99-4a46-b0b9-237467d97ca0|3|SYMPTDTR|Symptomatic Deterioration|RAJKUMAR MYELOMA 2011|[?]|nmol/L/min|PMR|1|mmol|OPHTHALMOSCOPY||||NON-HEALTH CARE PROFESSIONAL|READER 3|Y|2|Visit_2|25|1|WASHOUT|2020-09-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-06|P1Y2M10DT2H30M|COINCIDENT|2020-11-02|ONGOING|2020-12-03
e|RS|9ee3632d-4e99-4a46-b0b9-237467d97ca0|4|OVRLRESP|Overall Response|NCIWG CHESON CLL 1996|[?]|ELISA unit/dose|PMD|1|ug/L DDU|SLOAN LETTER EYE CHART 1.25%|Y|||PARENT|PATHOLOGIST 1|N|2|Visit_2|25|6|SCREENING|2020-09-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-06|P1Y2M10DT2H30M|AFTER|2020-09-12|BEFORE|2020-12-02
e|RS|9ee3632d-4e99-4a46-b0b9-237467d97ca0|5|MRPHRESP|Morphologic Response|FAROOQUI SUPP CLL 2014|[?]|/LPF|NON-QUANTIFIABLE MRD POSITIVITY|1|BU|IHC||||PROXY|ONCOLOGIST 1|N|3|Visit_3|40|6|TREATMENT|2020-10-09|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-26|P1Y2M10DT2H30M|AFTER|2020-10-03|ONGOING|2020-12-02
e|RS|9ee3632d-4e99-4a46-b0b9-237467d97ca0|6|RDIORESP|Radiologic Response|RAJKUMAR MYELOMA 2011|[?]|L/h|CMR|1|dyn|CONGO RED STAIN|Y|||CLINICAL RESEARCH ASSOCIATE|READER 1|NA|3|Visit_3|40|1|TREATMENT|2020-10-09|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-26|P1Y2M10DT2H30M|AFTER|2020-10-18|AFTER|2020-12-03
e|RS|9ee3632d-4e99-4a46-b0b9-237467d97ca0|7|HEMARESP|Hematologic Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|10^6/g|PSEUDORESPONSE|1|uU/dL|KNEMOMETRY||Y||INDEPENDENT ASSESSOR|DEVELOPMENTAL PSYCHOLOGIST|N|4|Visit_4|65|6|TREATMENT|2020-11-03|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-02|P1Y2M10DT2H30M|UNKNOWN|2020-11-09|AFTER|2020-11-23
e|RS|9ee3632d-4e99-4a46-b0b9-237467d97ca0|8|ANATRESP|Anatomic Response|MRECIST LENCIONI LIVER CANCER 2010|||iCR|1|mL/min/mmHg|NUCLEIC ACID HYBRIDIZATION|||Y|CHILD|DEVELOPMENTAL PSYCHOLOGIST|U|4|Visit_4|65|5|TREATMENT|2020-11-03|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-02|P1Y2M10DT2H30M|BEFORE|2020-09-12|ONGOING|2020-09-20
e|RS|9ee3632d-4e99-4a46-b0b9-237467d97ca0|9|BMIVLIND|Bone Marrow Involvement Indicator|WOLCHOK SOLID TUMORS 2009|[?]|umol/min|iCPD|1|CARTRIDGE|CONTRAST ENHANCED PET/CT SCAN|Y|||HEALTH CARE PROFESSIONAL|RATER 1|NA|5|Visit_5|90|5|TREATMENT|2020-11-28|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-21|P1Y2M10DT2H30M|COINCIDENT|2020-10-30|COINCIDENT|2020-11-09
e|RS|9ee3632d-4e99-4a46-b0b9-237467d97ca0|10|MJPTHIND|Major Pathological Response Indicator|AJCC V8|[?]|AU/mL|HI-E|1|BOLUS|RADIOIMMUNOPRECIPITATION ASSAY||||ADJUDICATOR|READER|NA|5|Visit_5|90|1|WASHOUT|2020-11-28|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-21|P1Y2M10DT2H30M|COINCIDENT|2020-09-18|BEFORE|2020-10-17
e|RS|be576e43-f39f-4e7b-9df3-e3a3e1f52d7d|1|TMRESP|Tumor Marker Response|LEE LUNG CANCER 2011|[?]|Pa|SD|1|IU/kg|ATOMIC ABSORPTION SPECTROMETRY|Y|||SPOUSE|ONCOLOGIST 1|U|1|Visit_1|10|7|WASHOUT|2020-06-16|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-08|P1Y2M10DT2H30M|AFTER|2020-07-26|AFTER|2020-08-27
e|RS|be576e43-f39f-4e7b-9df3-e3a3e1f52d7d|2|OVRLRESP|Overall Response|IWC HALLEK CLL 2008|[?]|mOsm|PSA PROGRESSION|1|mL/cage/day|DYNAMIC LIGHT SCATTERING|Y|||CLINICAL RESEARCH COORDINATOR|DERMATOLOGIST|U|1|Visit_1|10|2|WASHOUT|2020-06-16|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-08|P1Y2M10DT2H30M|BEFORE|2020-09-10|ONGOING|2020-09-13
e|RS|be576e43-f39f-4e7b-9df3-e3a3e1f52d7d|3|RDIORESP|Radiologic Response|SCHWARZ CERVICAL CANCER 2009|[?]|ppm|MRD NEGATIVITY|1|mL/mmHg|HPLC/MS/MS||||INVESTIGATOR|ADJUDICATOR 1|NA|2|Visit_2|25|2|TREATMENT|2020-07-01|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-29|P1Y2M10DT2H30M|BEFORE|2020-07-11|AFTER|2020-09-07
e|RS|be576e43-f39f-4e7b-9df3-e3a3e1f52d7d|4|MOLRESP|Molecular Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|10^3 organisms|NR|1|log10 PFU/mL|CLOT DETECTION||||HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|U|2|Visit_2|25|3|WASHOUT|2020-07-01|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-29|P1Y2M10DT2H30M|UNKNOWN|2020-07-14|COINCIDENT|2020-09-11
e|RS|be576e43-f39f-4e7b-9df3-e3a3e1f52d7d|5|ANATRESP|Anatomic Response|BRUGGEMANN MRD 2010|||TREATMENT FAILURE|1|dram|TOLUIDINE BLUE STAIN|||Y|CHILD|OTOLARYNGOLOGIST|U|3|Visit_3|40|1|TREATMENT|2020-07-16|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-22|P1Y2M10DT2H30M|UNKNOWN|2020-08-21|AFTER|2020-09-09
e|RS|be576e43-f39f-4e7b-9df3-e3a3e1f52d7d|6|PATHRESP|Pathologic Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|||VGPR|1|10^3 organisms/mL|CISH|||Y|INVESTIGATOR|ADJUDICATOR 3|U|3|Visit_3|40|1|WASHOUT|2020-07-16|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-22|P1Y2M10DT2H30M|COINCIDENT|2020-07-20|COINCIDENT|2020-08-16
e|RS|be576e43-f39f-4e7b-9df3-e3a3e1f52d7d|7|MRDRESP|Minimal Residual Disease Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|psi|VGPR|1|MASK|MAMMOGRAPHY||||DOMESTIC PARTNER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|4|Visit_4|65|4|WASHOUT|2020-08-10|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-17|P1Y2M10DT2H30M|BEFORE|2020-06-27|AFTER|2020-07-02
e|RS|be576e43-f39f-4e7b-9df3-e3a3e1f52d7d|8|METBRESP|Metabolic Response|PCWG SCHER PROSTATE CANCER 2008|[?]|/10^3|CRi|1|MESF|MS/MS||||CLINICAL STUDY SPONSOR|PATHOLOGIST 2|U|4|Visit_4|65|3|SCREENING|2020-08-10|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-17|P1Y2M10DT2H30M|BEFORE|2020-06-22|AFTER|2020-09-05
e|RS|be576e43-f39f-4e7b-9df3-e3a3e1f52d7d|9|NTRGRESP|Non-target Response|UNSPECIFIED|||MORPHOLOGIC LEUKEMIA-FREE STATE|1|Hounsfield Unit|LIGHT MICROSCOPY|Y||Y|STUDY SUBJECT|READER 3|U|5|Visit_5|90|6|SCREENING|2020-09-04|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-28|P1Y2M10DT2H30M|UNKNOWN|2020-07-17|BEFORE|2020-08-24
e|RS|be576e43-f39f-4e7b-9df3-e3a3e1f52d7d|10|METSIND|Metastatic Indicator|CHESON MALIGNANT LYMPHOMA 2007|||CYTOGENETIC NO RESPONSE|1|Absorbance U/min|NON-INVASIVE DIELECTRIC SENSING|||Y|PROXY|PATHOLOGIST 2|N|5|Visit_5|90|6|TREATMENT|2020-09-04|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-28|P1Y2M10DT2H30M|COINCIDENT|2020-06-29|COINCIDENT|2020-09-12
e|RS|34b2090b-13ac-4fb2-8d87-eca2839a62f2|1|MNPTHIND|Minor Pathological Response Indicator|JACINTO CERVICAL CANCER 2007|||DECREASED|1|U|ROMANOWSKY STAIN|||Y|ADJUDICATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|1|Visit_1|10|3|TREATMENT|2020-06-07|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-01|P1Y2M10DT2H30M|AFTER|2020-06-26|BEFORE|2020-08-31
e|RS|34b2090b-13ac-4fb2-8d87-eca2839a62f2|2|MNPTHIND|Minor Pathological Response Indicator|PCWG BUBLEY PROSTATE CANCER 1999|[?]|mAmp|MORPHOLOGIC CR|1|CUP|WESTERGREN||||FAMILY MEMBER|MICROSCOPIST 1|NA|1|Visit_1|10|6|TREATMENT|2020-06-07|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-01|P1Y2M10DT2H30M|UNKNOWN|2020-07-06|BEFORE|2020-07-17
e|RS|34b2090b-13ac-4fb2-8d87-eca2839a62f2|3|MRDIND|Minimal Residual Disease Indicator|IRANO 2015|[?]|/2000 RBC|MOLECULAR CR|1|U/mmol|LEAD CITRATE STAIN|Y|||CAREGIVER|RADIOLOGIST 1|N|2|Visit_2|25|2|TREATMENT|2020-06-22|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-18|P1Y2M10DT2H30M|COINCIDENT|2020-08-07|BEFORE|2020-08-26
e|RS|34b2090b-13ac-4fb2-8d87-eca2839a62f2|4|TMRESP|Tumor Marker Response|RECICL|[?]|mmHg*min/L|RELAPSED DISEASE FROM CR|1|kV|NEXT GENERATION TARGETED SEQUENCING|Y|||CLINICAL STUDY SPONSOR|RATER 1|Y|2|Visit_2|25|7|FOLLOW-UP|2020-06-22|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-18|P1Y2M10DT2H30M|UNKNOWN|2020-06-24|BEFORE|2020-08-06
e|RS|34b2090b-13ac-4fb2-8d87-eca2839a62f2|5|METSIND|Metastatic Indicator|MACDONALD GLIOMA 1990|[?]|COAT|CYTOGENETIC MINOR RESPONSE|1|m/sec2|EEG||Y||INVESTIGATOR|FORENSIC PATHOLOGIST|N|3|Visit_3|40|4|SCREENING|2020-07-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-17|P1Y2M10DT2H30M|COINCIDENT|2020-07-09|ONGOING|2020-07-13
e|RS|34b2090b-13ac-4fb2-8d87-eca2839a62f2|6|METBRESP|Metabolic Response|iRECIST|[?]|mL/cage/day|INCREASED|1|copies/mL|TRANSVAGINAL ULTRASOUND||||HEALTH CARE PROFESSIONAL|HEMATOLOGIST|NA|3|Visit_3|40|4|SCREENING|2020-07-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-17|P1Y2M10DT2H30M|BEFORE|2020-08-15|AFTER|2020-08-28
e|RS|34b2090b-13ac-4fb2-8d87-eca2839a62f2|7|NEWLIND|New Lesion Indicator|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|amol|DECREASED|1|g/mol|AUTOREFRACTION||Y||PROXY|PATHOLOGIST 1|N|4|Visit_4|65|7|WASHOUT|2020-08-01|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-08|P1Y2M10DT2H30M|BEFORE|2020-07-28|AFTER|2020-08-27
e|RS|34b2090b-13ac-4fb2-8d87-eca2839a62f2|8|RDIORESP|Radiologic Response|RECIST 1.1|[?]|ms2|PSEUDORESPONSE|1|10^9/dose|STATIC PERIMETRY||||GUARDIAN|MICROSCOPIST 2|U|4|Visit_4|65|6|SCREENING|2020-08-01|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-08|P1Y2M10DT2H30M|UNKNOWN|2020-05-31|COINCIDENT|2020-07-16
e|RS|34b2090b-13ac-4fb2-8d87-eca2839a62f2|9|NEWLWIND|New Lesion Worsening Indicator|PCWG BUBLEY PROSTATE CANCER 1999|[?]|10^10/L|MINOR PATHOLOGIC RESPONSE|1|g/L|REFLECTANCE SPECTROSCOPY||||INVESTIGATOR|NEUROLOGIST|NA|5|Visit_5|90|5|WASHOUT|2020-08-26|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-20|P1Y2M10DT2H30M|COINCIDENT|2020-08-30|COINCIDENT|2020-08-31
e|RS|34b2090b-13ac-4fb2-8d87-eca2839a62f2|10|METBRESP|Metabolic Response|RANO ELLINGSON 2017|[?]|/HPF|PD/RELAPSE AFTER HI|1|V|MUGA||||CAREGIVER|OPTOMETRIST|Y|5|Visit_5|90|6|FOLLOW-UP|2020-08-26|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-20|P1Y2M10DT2H30M|BEFORE|2020-07-28|COINCIDENT|2020-08-06
e|RS|bfc19b4b-51bb-4056-9195-8bd2db53a497|1|MOLRESP|Molecular Response|BRUGGEMANN MRD 2010|[?]|kcal|iCPD|1|log10 PFU|CHROMATOGRAPHY||||FRIEND|NEUROLOGIST|N|1|Visit_1|10|2|TREATMENT|2020-07-26|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-25|P1Y2M10DT2H30M|UNKNOWN|2020-10-22|COINCIDENT|2020-10-23
e|RS|bfc19b4b-51bb-4056-9195-8bd2db53a497|2|MRDIND|Minimal Residual Disease Indicator|RAJKUMAR MYELOMA 2011|[?]|pg/cell|IMPROVED|1|10^5/L|RADIOIMMUNOPRECIPITATION ASSAY|Y|||FAMILY MEMBER|ADJUDICATOR 1|U|1|Visit_1|10|2|FOLLOW-UP|2020-07-26|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-25|P1Y2M10DT2H30M|AFTER|2020-08-20|AFTER|2020-09-19
e|RS|bfc19b4b-51bb-4056-9195-8bd2db53a497|3|MRDRESP|Minimal Residual Disease Response|RECIST 1.0|[?]|mL|cPR|1|10^6 CFU/mL|SIZE EXCLUSION CHROMATOGRAPHY|Y|||HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|N|2|Visit_2|25|5|TREATMENT|2020-08-10|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-05|P1Y2M10DT2H30M|COINCIDENT|2020-09-08|ONGOING|2020-10-03
e|RS|bfc19b4b-51bb-4056-9195-8bd2db53a497|4|TRGRESP|Target Response|CHESON CLL 2006|[?]|BISCUIT|PSA PROGRESSION|1|IU/mmol|HPLC/MS||||STUDY SUBJECT|INTERNIST|U|2|Visit_2|25|3|TREATMENT|2020-08-10|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-05|P1Y2M10DT2H30M|BEFORE|2020-10-11|ONGOING|2020-10-15
e|RS|bfc19b4b-51bb-4056-9195-8bd2db53a497|5|METBRESP|Metabolic Response|PCWG SCHER PROSTATE CANCER 2016|||STABLE|1|ELISA unit/mL|X-RAY FLUORESCENCE SPECTROMETRY|||Y|STUDY SUBJECT|ONCOLOGIST 1|N|3|Visit_3|40|3|TREATMENT|2020-08-25|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-11|P1Y2M10DT2H30M|COINCIDENT|2020-09-15|COINCIDENT|2020-10-21
e|RS|bfc19b4b-51bb-4056-9195-8bd2db53a497|6|CYTORESP|Cytogenetic Response|RANO ELLINGSON 2017|[?]|deg|PD-CT|1|dL|NUCLEIC ACID SEQUENCING||Y||PARENT|MICROSCOPIST 1|Y|3|Visit_3|40|1|TREATMENT|2020-08-25|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-11|P1Y2M10DT2H30M|AFTER|2020-10-17|COINCIDENT|2020-10-23
e|RS|bfc19b4b-51bb-4056-9195-8bd2db53a497|7|BMIVLIND|Bone Marrow Involvement Indicator|MACDONALD GLIOMA 1990|||PARTIAL MORPHOLOGIC RESPONSE|1|mV|FUNDUS PHOTOGRAPHY||Y|Y|SIGNIFICANT OTHER|MICROSCOPIST 2|U|4|Visit_4|65|4|TREATMENT|2020-09-19|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-29|P1Y2M10DT2H30M|COINCIDENT|2020-09-16|ONGOING|2020-10-11
e|RS|bfc19b4b-51bb-4056-9195-8bd2db53a497|8|MOLRESP|Molecular Response|MONTSERRAT CLL 1989|[?]|min|FAVORABLE RESPONSE|1|ug|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION||||GUARDIAN|ENDOCRINOLOGIST|N|4|Visit_4|65|3|TREATMENT|2020-09-19|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-29|P1Y2M10DT2H30M|AFTER|2020-10-18|AFTER|2020-10-23
e|RS|bfc19b4b-51bb-4056-9195-8bd2db53a497|9|NEWLPROG|New Lesion Progression|LEE LUNG CANCER 2011|[?]|Ci/ug|IMMUNOPHENOTYPIC CR|1|mg/kg|HPLC-FL|Y|||HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|N|5|Visit_5|90|2|SCREENING|2020-10-14|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-25|P1Y2M10DT2H30M|AFTER|2020-10-06|AFTER|2020-10-15
e|RS|bfc19b4b-51bb-4056-9195-8bd2db53a497|10|SYMPTDTR|Symptomatic Deterioration|AJCC V8|[?]|Henry|PD-CT|1|JAR|COLORIMETRY|Y|Y||CLINICAL RESEARCH COORDINATOR|ENDOCRINOLOGIST|U|5|Visit_5|90|1|TREATMENT|2020-10-14|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-25|P1Y2M10DT2H30M|AFTER|2020-08-31|AFTER|2020-10-15
e|RS|8620aadd-f97d-4bc1-9466-7e5a96ccc66f|1|CYTORESP|Cytogenetic Response|AJCC V8|||iPR|1|10^11/L|AUSCULTATION|Y||Y|ADJUDICATION COMMITTEE|RADIOLOGIST|U|1|Visit_1|10|6|TREATMENT|2020-09-21|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-19|P1Y2M10DT2H30M|AFTER|2020-10-02|AFTER|2020-10-15
e|RS|8620aadd-f97d-4bc1-9466-7e5a96ccc66f|2|METSIND|Metastatic Indicator|RANO|||PR WITH LYMPHOCYTOSIS|1|nmol/kg/day|INDIRECT IMMUNOFLUORESCENCE|||Y|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|N|1|Visit_1|10|1|TREATMENT|2020-09-21|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-19|P1Y2M10DT2H30M|COINCIDENT|2020-11-28|BEFORE|2020-12-05
e|RS|8620aadd-f97d-4bc1-9466-7e5a96ccc66f|3|CPRFSTAT|Clinical Performance Status|HAMAOKA BREAST CANCER 2010|||PMD|1|OD Unit|HPLC-FL|||Y|CAREGIVER|RATER 1|N|2|Visit_2|25|7|TREATMENT|2020-10-06|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-29|P1Y2M10DT2H30M|UNKNOWN|2020-09-14|ONGOING|2020-11-19
e|RS|8620aadd-f97d-4bc1-9466-7e5a96ccc66f|4|NTLWIND|Non-Target Lesion Worsening Indicator|MACDONALD GLIOMA 1990|[?]|mEq/g|pCR|1|foz_br|DIFFUSION WEIGHTED MRI||||DOMESTIC PARTNER|MICROSCOPIST 3|N|2|Visit_2|25|6|TREATMENT|2020-10-06|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-29|P1Y2M10DT2H30M|AFTER|2020-11-20|BEFORE|2020-12-09
e|RS|8620aadd-f97d-4bc1-9466-7e5a96ccc66f|5|CPRFSTAT|Clinical Performance Status|BURCOMBE BREAST CANCER 2005|[?]|10^6 copies/mL|nPR|1|Gy/min|SIZE EXCLUSION CHROMATOGRAPHY||||HEALTH CARE PROFESSIONAL|CARDIOLOGIST|N|3|Visit_3|40|6|SCREENING|2020-10-21|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-12|P1Y2M10DT2H30M|AFTER|2020-12-05|ONGOING|2020-12-19
e|RS|8620aadd-f97d-4bc1-9466-7e5a96ccc66f|6|MJPTHIND|Major Pathological Response Indicator|WHO BREAST CANCER 2006|[?]|umol|NON-PD|1|USP U|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION||||CAREGIVER|READER 2|Y|3|Visit_3|40|5|TREATMENT|2020-10-21|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-12|P1Y2M10DT2H30M|AFTER|2020-12-08|COINCIDENT|2020-12-13
e|RS|8620aadd-f97d-4bc1-9466-7e5a96ccc66f|7|BMIVLIND|Bone Marrow Involvement Indicator|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|kBq/uL|HI-P|1|um2|NON-INVASIVE DIELECTRIC SENSING||||CLINICAL RESEARCH COORDINATOR|RATER|U|4|Visit_4|65|3|TREATMENT|2020-11-15|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-13|P1Y2M10DT2H30M|UNKNOWN|2020-10-10|AFTER|2020-10-13
e|RS|8620aadd-f97d-4bc1-9466-7e5a96ccc66f|8|METBRESP|Metabolic Response|HAMAOKA BREAST CANCER 2010|[?]|L/day|CMR|1|ug/m2/min|RADIATION DOSIMETRY||||FRIEND|ADJUDICATOR 2|NA|4|Visit_4|65|4|TREATMENT|2020-11-15|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-13|P1Y2M10DT2H30M|COINCIDENT|2020-10-11|AFTER|2020-12-05
e|RS|8620aadd-f97d-4bc1-9466-7e5a96ccc66f|9|MJPTHIND|Major Pathological Response Indicator|CHOLLET BREAST CANCER 2002|||MOLECULAR MAJOR RESPONSE|1|GBq/ug|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY||Y|Y|DOMESTIC PARTNER|DERMATOLOGIST|Y|5|Visit_5|90|4|TREATMENT|2020-12-10|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-02|P1Y2M10DT2H30M|UNKNOWN|2020-11-01|COINCIDENT|2020-11-29
e|RS|8620aadd-f97d-4bc1-9466-7e5a96ccc66f|10|MJPTHIND|Major Pathological Response Indicator|LUGANO CLASSIFICATION|[?]|v/v|NR|1|kUSP|THERMAL IONIZATION MASS SPECTROMETRY||||CLINICAL STUDY SPONSOR|NEUROLOGIST 2|N|5|Visit_5|90|7|FOLLOW-UP|2020-12-10|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-02|P1Y2M10DT2H30M|UNKNOWN|2020-09-29|COINCIDENT|2020-11-26
e|RS|64a70103-14bf-42f4-808b-fbdecec8bd4f|1|NTLWIND|Non-Target Lesion Worsening Indicator|SCHWARZ CERVICAL CANCER 2009|||MRD PERSISTENCE|1|mg/kg/dose|MRS|||Y|CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 1|N|1|Visit_1|10|6|TREATMENT|2020-09-09|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-27|P1Y2M10DT2H30M|AFTER|2020-11-09|ONGOING|2020-11-15
e|RS|64a70103-14bf-42f4-808b-fbdecec8bd4f|2|MNPTHIND|Minor Pathological Response Indicator|RECIST 1.0|[?]|mEq|PR|1|mL/cm H2O|THIN SMEAR|Y|||INDEPENDENT ASSESSOR|OTOLARYNGOLOGIST|NA|1|Visit_1|10|5|TREATMENT|2020-09-09|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-27|P1Y2M10DT2H30M|UNKNOWN|2020-10-08|AFTER|2020-10-30
e|RS|64a70103-14bf-42f4-808b-fbdecec8bd4f|3|CPRFSTAT|Clinical Performance Status|CHOLLET BREAST CANCER 2002|||nPR|1|pg/L|MUGA|Y|Y|Y|VENDOR|ADJUDICATOR 1|NA|2|Visit_2|25|4|WASHOUT|2020-09-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-03|P1Y2M10DT2H30M|COINCIDENT|2020-11-07|COINCIDENT|2020-11-21
e|RS|64a70103-14bf-42f4-808b-fbdecec8bd4f|4|MNPTHIND|Minor Pathological Response Indicator|RECIST 1.0|[?]|10^4/hpf|CA125 50% RESPONSE|1|Coulomb|URANYL ACETATE STAIN|Y|Y||SIBLING|OTOLARYNGOLOGIST|Y|2|Visit_2|25|6|TREATMENT|2020-09-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-03|P1Y2M10DT2H30M|AFTER|2020-10-15|AFTER|2020-10-18
e|RS|64a70103-14bf-42f4-808b-fbdecec8bd4f|5|NEWLIND|New Lesion Indicator|CHESON CLL 2012|[?]|PA|NOT ALL EVALUATED|1|10^5/hpf|HEMAGGLUTINATION ASSAY||||SIBLING|RATER 1|Y|3|Visit_3|40|4|WASHOUT|2020-10-09|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-12|P1Y2M10DT2H30M|UNKNOWN|2020-09-30|AFTER|2020-10-29
e|RS|64a70103-14bf-42f4-808b-fbdecec8bd4f|6|SFTSRESP|Soft Tissue Response|IWG CHESON MDS 2006|[?]|L/min/m2|COMPLETE MRD RESPONSE|1|lx|COULOMETRIC TITRATION||Y||GUARDIAN|PATHOLOGIST|Y|3|Visit_3|40|7|TREATMENT|2020-10-09|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-12|P1Y2M10DT2H30M|COINCIDENT|2020-09-06|COINCIDENT|2020-10-23
e|RS|64a70103-14bf-42f4-808b-fbdecec8bd4f|7|CPRFSTAT|Clinical Performance Status|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|||PARTIAL MORPHOLOGIC RESPONSE|1|g/cm2|CELL BASED BIOASSAY|Y|Y|Y|PARENT|RADIOLOGIST|N|4|Visit_4|65|6|WASHOUT|2020-11-03|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-22|P1Y2M10DT2H30M|AFTER|2020-10-04|ONGOING|2020-10-07
e|RS|64a70103-14bf-42f4-808b-fbdecec8bd4f|8|NTLWIND|Non-Target Lesion Worsening Indicator|NCIWG CHESON CLL 1996|[?]|MBq/uL|NON-iCR/NON-iUPD|1|SQU/mL|IMMUNOASSAY||||DOMESTIC PARTNER|RATER|N|4|Visit_4|65|6|TREATMENT|2020-11-03|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-22|P1Y2M10DT2H30M|COINCIDENT|2020-11-09|ONGOING|2020-12-04
e|RS|64a70103-14bf-42f4-808b-fbdecec8bd4f|9|MOLRESP|Molecular Response|KUMAR IMWG 2016|[?]|g/m2/day|PR WITH LYMPHOCYTOSIS|1|HOMEOPATHIC DILUTION|PET/CT SCAN||Y||DOMESTIC PARTNER|HEMATOLOGIST|N|5|Visit_5|90|3|WASHOUT|2020-11-28|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-08|P1Y2M10DT2H30M|UNKNOWN|2020-09-19|ONGOING|2020-11-11
e|RS|64a70103-14bf-42f4-808b-fbdecec8bd4f|10|MRDIND|Minimal Residual Disease Indicator|PRINCE TCELL LYMPHOMA 2010|||cCR|1|ngEq/L|ARTERIAL SPIN LABELING FUNCTIONAL MRI|Y||Y|INTERVIEWER|DEVELOPMENTAL PSYCHOLOGIST|U|5|Visit_5|90|7|FOLLOW-UP|2020-11-28|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-08|P1Y2M10DT2H30M|UNKNOWN|2020-09-17|AFTER|2020-10-27
e|RS|00f3949b-b14a-47c5-942c-2ab71e03e40f|1|PATHRESP|Pathologic Response|SACT|[?]|tuberculin unit/mL|EQUIVOCAL|1|cs|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY||||ADJUDICATION COMMITTEE|NEUROLOGIST 1|Y|1|Visit_1|10|5|TREATMENT|2021-01-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-26|P1Y2M10DT2H30M|COINCIDENT|2021-03-07|AFTER|2021-04-04
e|RS|00f3949b-b14a-47c5-942c-2ab71e03e40f|2|SYMPTDTR|Symptomatic Deterioration|CHESON MALIGNANT LYMPHOMA 2007|[?]|NEBULE|NOT ALL EVALUATED|1|10^6/g|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS||||CAREGIVER|OTOLARYNGOLOGIST|Y|1|Visit_1|10|2|WASHOUT|2021-01-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-26|P1Y2M10DT2H30M|COINCIDENT|2021-03-02|ONGOING|2021-03-17
e|RS|00f3949b-b14a-47c5-942c-2ab71e03e40f|3|METSIND|Metastatic Indicator|WHO BREAST CANCER 2006|[?]|nL|DECREASED|1|cs|SPIRAL CT|Y|||SPOUSE|CLINICAL PATHOLOGIST|N|2|Visit_2|25|4|FOLLOW-UP|2021-02-03|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-02|P1Y2M10DT2H30M|UNKNOWN|2021-04-09|AFTER|2021-04-10
e|RS|00f3949b-b14a-47c5-942c-2ab71e03e40f|4|BONERESP|Bone Response|PRINCE TCELL LYMPHOMA 2010|[?]|cmol/L|IMMUNOPHENOTYPIC CR|1|mL/cage|KARYOTYPING||||CAREGIVER|PHYSIOTHERAPIST|N|2|Visit_2|25|1|TREATMENT|2021-02-03|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-02|P1Y2M10DT2H30M|AFTER|2021-03-20|BEFORE|2021-03-25
e|RS|00f3949b-b14a-47c5-942c-2ab71e03e40f|5|MOLRESP|Molecular Response|GUPPY OVARIAN CANCER 2002|||CYTOGENETIC MINOR RESPONSE|1|BU|CLAUSS METHOD|Y|Y|Y|INDEPENDENT ASSESSOR|RATER 2|Y|3|Visit_3|40|6|TREATMENT|2021-02-18|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-22|P1Y2M10DT2H30M|BEFORE|2021-04-11|AFTER|2021-04-16
e|RS|00f3949b-b14a-47c5-942c-2ab71e03e40f|6|BMIVLIND|Bone Marrow Involvement Indicator|PCWG SCHER PROSTATE CANCER 2008|[?]|ug/g/day|EQUIVOCAL|1|IU/g Hb|SMEAR||||PROXY|RADIOLOGIST 1|U|3|Visit_3|40|7|FOLLOW-UP|2021-02-18|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-22|P1Y2M10DT2H30M|AFTER|2021-02-15|BEFORE|2021-02-28
e|RS|00f3949b-b14a-47c5-942c-2ab71e03e40f|7|NTNERESP|Non-Target Non-Enhancing Response|SHINDOH COLORECTAL CANCER 2013|[?]|g/cage|NED|1|10^6/Ejaculate U|PERCUSSION||||INDEPENDENT ASSESSOR|PHYSIOTHERAPIST|U|4|Visit_4|65|4|SCREENING|2021-03-15|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-21|P1Y2M10DT2H30M|AFTER|2021-03-22|BEFORE|2021-03-28
e|RS|00f3949b-b14a-47c5-942c-2ab71e03e40f|8|NEWLIND|New Lesion Indicator|DURIE MULTIPLE MYELOMA 2006|[?]|mol/mL|STABLE|1|nCi|COLORIMETRY||||PARENT|RATER|Y|4|Visit_4|65|2|TREATMENT|2021-03-15|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-21|P1Y2M10DT2H30M|BEFORE|2021-03-11|AFTER|2021-04-15
e|RS|00f3949b-b14a-47c5-942c-2ab71e03e40f|9|SYMPTDTR|Symptomatic Deterioration|KUMAR IMWG 2016|[?]|psi|INDETERMINATE RESPONSE|1|BEAM BREAKS|TRICHROME STAIN||||FAMILY MEMBER|OPTOMETRIST|U|5|Visit_5|90|4|TREATMENT|2021-04-09|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-20|P1Y2M10DT2H30M|UNKNOWN|2021-04-06|AFTER|2021-04-16
e|RS|00f3949b-b14a-47c5-942c-2ab71e03e40f|10|SFTSRESP|Soft Tissue Response|GUILHOT CML 2007|[?]|nm|NON-CR/NON-PD|1|Absorbance U|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE||||SIGNIFICANT OTHER|READER|N|5|Visit_5|90|1|FOLLOW-UP|2021-04-09|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-20|P1Y2M10DT2H30M|BEFORE|2021-01-30|COINCIDENT|2021-03-02
e|RS|bf3676e3-b1aa-48cc-b5ae-ac6427d2b7d6|1|TMRESP|Tumor Marker Response|PALUMBO MULTIPLE MYELOMA 2009|||SD-CT|1|kat|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY||Y|Y|HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|Y|1|Visit_1|10|4|TREATMENT|2020-12-27|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-23|P1Y2M10DT2H30M|AFTER|2021-02-21|COINCIDENT|2021-03-04
e|RS|bf3676e3-b1aa-48cc-b5ae-ac6427d2b7d6|2|OVRLRESP|Overall Response|MACDONALD GLIOMA 1990|||ABSENT MORPHOLOGIC RESPONSE|1|U/dL|CINEANGIOGRAPHY|||Y|ADJUDICATOR|OPHTHALMOLOGIST|Y|1|Visit_1|10|2|TREATMENT|2020-12-27|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-23|P1Y2M10DT2H30M|UNKNOWN|2021-03-11|COINCIDENT|2021-03-17
e|RS|bf3676e3-b1aa-48cc-b5ae-ac6427d2b7d6|3|DRCRIND|Disease Recurrence Indicator|RECIST 1.1|||MRD NEGATIVITY|1|10^9 CFU/g|SEQUENCING|||Y|INVESTIGATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|2|Visit_2|25|4|WASHOUT|2021-01-11|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-01|P1Y2M10DT2H30M|BEFORE|2020-12-27|BEFORE|2021-02-19
e|RS|bf3676e3-b1aa-48cc-b5ae-ac6427d2b7d6|4|HEMARESP|Hematologic Response|FAROOQUI SUPP CLL 2014|[?]|U/m2/day|UNFAVORABLE RESPONSE|1|ug/cm2|MAGNETIC RESONANCE ENTEROGRAPHY||||ADJUDICATOR|ADJUDICATOR 1|Y|2|Visit_2|25|3|WASHOUT|2021-01-11|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-01|P1Y2M10DT2H30M|BEFORE|2021-02-06|AFTER|2021-02-22
e|RS|bf3676e3-b1aa-48cc-b5ae-ac6427d2b7d6|5|DRCRIND|Disease Recurrence Indicator|MASS|[?]|Ci/kg|iPR|1|mg/cm2|LIGHT MICROSCOPY||||INDEPENDENT ASSESSOR|PATHOLOGIST 2|U|3|Visit_3|40|6|TREATMENT|2021-01-26|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-14|P1Y2M10DT2H30M|COINCIDENT|2021-03-13|AFTER|2021-03-25
e|RS|bf3676e3-b1aa-48cc-b5ae-ac6427d2b7d6|6|LIVRRESP|Liver Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|U/animal|HI-N|1|Anson U|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION||Y||SIBLING|PATHOLOGIST 2|U|3|Visit_3|40|5|TREATMENT|2021-01-26|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-14|P1Y2M10DT2H30M|BEFORE|2021-02-27|BEFORE|2021-03-12
e|RS|bf3676e3-b1aa-48cc-b5ae-ac6427d2b7d6|7|BESTRESP|Best Overall Response|IWC HALLEK CLL 2008|[?]|mL/m2|MINOR PATHOLOGIC RESPONSE|1|copies/uL|FLUORESCENT IMMUNOASSAY||||SIBLING|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|4|Visit_4|65|7|TREATMENT|2021-02-20|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-03|P1Y2M10DT2H30M|AFTER|2021-03-22|ONGOING|2021-03-26
e|RS|bf3676e3-b1aa-48cc-b5ae-ac6427d2b7d6|8|NEWLPROG|New Lesion Progression|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|10^9/dose|CA125 50% RESPONSE|1|PRESSOR UNITS|NEPHELOMETRY||||DOMESTIC PARTNER|OPHTHALMOLOGIST|NA|4|Visit_4|65|7|TREATMENT|2021-02-20|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-03|P1Y2M10DT2H30M|AFTER|2021-02-26|AFTER|2021-03-09
e|RS|bf3676e3-b1aa-48cc-b5ae-ac6427d2b7d6|9|CYTORESP|Cytogenetic Response|WOLCHOK SOLID TUMORS 2009|[?]|mOsm/L|IMPROVED|1|Bq/mg|AUTOMATED COUNT||||INDEPENDENT ASSESSOR|ENDOCRINOLOGIST|NA|5|Visit_5|90|5|FOLLOW-UP|2021-03-17|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-01|P1Y2M10DT2H30M|BEFORE|2021-03-17|BEFORE|2021-03-21
e|RS|bf3676e3-b1aa-48cc-b5ae-ac6427d2b7d6|10|BONERESP|Bone Response|KEAM BREAST CANCER 2013|||SMD|1|fmol/L|CONGO RED STAIN|||Y|STUDY SUBJECT|RATER 1|NA|5|Visit_5|90|2|WASHOUT|2021-03-17|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-01|P1Y2M10DT2H30M|AFTER|2021-03-14|AFTER|2021-03-17
e|RS|c0d878ab-28d2-4c98-b1a9-26cd3fd3fd1e|1|METBRESP|Metabolic Response|JACINTO CERVICAL CANCER 2007|[?]|CCID 50/mL|CYTOGENETIC NO RESPONSE|1|PA|MYELOPEROXIDASE STAIN||Y||VENDOR|DERMATOLOGIST|Y|1|Visit_1|10|2|SCREENING|2020-07-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-24|P1Y2M10DT2H30M|UNKNOWN|2020-09-28|AFTER|2020-10-04
e|RS|c0d878ab-28d2-4c98-b1a9-26cd3fd3fd1e|2|STRUSTAT|Steroid Use Status|NCCN ALL MRD 2014|||INDETERMINATE RESPONSE|1|cd/m2|GC/MS|||Y|ADJUDICATION COMMITTEE|DEVELOPMENTAL PSYCHOLOGIST|NA|1|Visit_1|10|1|WASHOUT|2020-07-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-24|P1Y2M10DT2H30M|AFTER|2020-08-08|BEFORE|2020-08-18
e|RS|c0d878ab-28d2-4c98-b1a9-26cd3fd3fd1e|3|SYMPTDTR|Symptomatic Deterioration|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|BLOCKS|IMPROVED|1|mIU/L|BETA LACTAMASE||||FRIEND|ENDOCRINOLOGIST|NA|2|Visit_2|25|3|WASHOUT|2020-08-03|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-12|P1Y2M10DT2H30M|COINCIDENT|2020-10-03|COINCIDENT|2020-10-12
e|RS|c0d878ab-28d2-4c98-b1a9-26cd3fd3fd1e|4|TMRESP|Tumor Marker Response|MACDONALD GLIOMA 1990|[?]|10^10/L|MRD PERSISTENCE|1|dpm/100mg|INTRAVASCULAR ULTRASOUND|Y|||CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 1|N|2|Visit_2|25|4|TREATMENT|2020-08-03|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-12|P1Y2M10DT2H30M|COINCIDENT|2020-07-25|AFTER|2020-08-26
e|RS|c0d878ab-28d2-4c98-b1a9-26cd3fd3fd1e|5|LIVRRESP|Liver Response|SCHWARZ CERVICAL CANCER 2009|[?]|PELLET|EQUIVOCAL|1|PA|MECHANICAL CLOT DETECTION||||ADJUDICATOR|DEVELOPMENTAL PSYCHOLOGIST|U|3|Visit_3|40|2|TREATMENT|2020-08-18|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-10|P1Y2M10DT2H30M|COINCIDENT|2020-08-01|BEFORE|2020-09-22
e|RS|c0d878ab-28d2-4c98-b1a9-26cd3fd3fd1e|6|PATHRESP|Pathologic Response|HARTMAN PANCREATIC CANCER 2012|||CYTOGENETIC MINOR RESPONSE|1|10^6/L|PHOTOGRAPHY|||Y|STUDY SUBJECT|NEUROLOGIST 2|U|3|Visit_3|40|7|TREATMENT|2020-08-18|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-10|P1Y2M10DT2H30M|COINCIDENT|2020-09-13|AFTER|2020-10-13
e|RS|c0d878ab-28d2-4c98-b1a9-26cd3fd3fd1e|7|MRDRESP|Minimal Residual Disease Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|umol/L|NR|1|mU/L|AUTOREFRACTION||Y||PARENT|RADIOLOGIST 1|U|4|Visit_4|65|4|TREATMENT|2020-09-12|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-13|P1Y2M10DT2H30M|AFTER|2020-07-20|COINCIDENT|2020-09-03
e|RS|c0d878ab-28d2-4c98-b1a9-26cd3fd3fd1e|8|NTRGRESP|Non-target Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|log10 PFU/mL|MOLECULAR MAJOR RESPONSE|1|IU/L|EPSILOMETER||Y||CLINICAL STUDY SPONSOR|PEDIATRIC NEUROLOGIST|Y|4|Visit_4|65|1|TREATMENT|2020-09-12|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-13|P1Y2M10DT2H30M|BEFORE|2020-09-15|COINCIDENT|2020-10-10
e|RS|c0d878ab-28d2-4c98-b1a9-26cd3fd3fd1e|9|MRDRESP|Minimal Residual Disease Response|HAMAOKA BREAST CANCER 2010|||CR-CT|1|U/g/min|DUCTOGRAPHY|Y|Y|Y|HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|U|5|Visit_5|90|3|TREATMENT|2020-10-07|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-22|P1Y2M10DT2H30M|COINCIDENT|2020-09-03|ONGOING|2020-10-01
e|RS|c0d878ab-28d2-4c98-b1a9-26cd3fd3fd1e|10|MRDRESP|Minimal Residual Disease Response|HARTMAN PANCREATIC CANCER 2012|[?]|10^9 organisms/mL|PR-CT|1|GBq/ug|SLIT LAMP|Y|||CHILD|INTERNIST|NA|5|Visit_5|90|2|WASHOUT|2020-10-07|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-22|P1Y2M10DT2H30M|AFTER|2020-07-23|COINCIDENT|2020-09-17
e|RS|44ca1fe6-76d2-4a94-9854-1ddbde638803|1|OVRLRESP|Overall Response|PERCIST|[?]|kg/L|UNFAVORABLE RESPONSE|1|Ci/uL|ELASTOGRAPHY|Y|||ADJUDICATOR|READER 2|Y|1|Visit_1|10|1|SCREENING|2020-07-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-24|P1Y2M10DT2H30M|BEFORE|2020-07-23|ONGOING|2020-08-18
e|RS|44ca1fe6-76d2-4a94-9854-1ddbde638803|2|METSIND|Metastatic Indicator|RANO ELLINGSON 2017|[?]|pptr|QUANTIFIABLE MRD POSITIVITY|1|usec|EEG||||SIGNIFICANT OTHER|ADJUDICATOR 1|NA|1|Visit_1|10|2|FOLLOW-UP|2020-07-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-24|P1Y2M10DT2H30M|COINCIDENT|2020-07-28|COINCIDENT|2020-10-08
e|RS|44ca1fe6-76d2-4a94-9854-1ddbde638803|3|NTNERESP|Non-Target Non-Enhancing Response|PCWG SCHER PROSTATE CANCER 2008|[?]|10^3 CFU|MOLECULAR CR|1|CFU/g|ELECTROPHORESIS||||HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|N|2|Visit_2|25|1|FOLLOW-UP|2020-08-03|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-18|P1Y2M10DT2H30M|BEFORE|2020-08-04|BEFORE|2020-09-16
e|RS|44ca1fe6-76d2-4a94-9854-1ddbde638803|4|SPLNRESP|Spleen Response|JACINTO CERVICAL CANCER 2007|[?]|Enzyme U/L|MOLECULAR CR|1|AgU/mL|HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY|Y|||DOMESTIC PARTNER|RATER 1|NA|2|Visit_2|25|1|FOLLOW-UP|2020-08-03|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-18|P1Y2M10DT2H30M|UNKNOWN|2020-10-09|AFTER|2020-10-16
e|RS|44ca1fe6-76d2-4a94-9854-1ddbde638803|5|TMRESP|Tumor Marker Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|ng/dL|PMR|1|mOsm|SPECT/CT SCAN||||CLINICAL STUDY SPONSOR|NEUROLOGIST 2|Y|3|Visit_3|40|4|TREATMENT|2020-08-18|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-30|P1Y2M10DT2H30M|AFTER|2020-10-06|ONGOING|2020-10-14
e|RS|44ca1fe6-76d2-4a94-9854-1ddbde638803|6|ANATRESP|Anatomic Response|SCHWARZ CERVICAL CANCER 2009|[?]|dpm/mg|INCREASED|1|FIU|MICRONEUTRALIZATION ASSAY||||CHILD|DEVELOPMENTAL PSYCHOLOGIST|NA|3|Visit_3|40|2|TREATMENT|2020-08-18|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-30|P1Y2M10DT2H30M|BEFORE|2020-08-13|AFTER|2020-09-01
e|RS|44ca1fe6-76d2-4a94-9854-1ddbde638803|7|MRPHRESP|Morphologic Response|GUILHOT CML 2007|||cCR|1|cm/min|HIGH LEVEL AMINOGLYCOSIDE SCREEN||Y|Y|NON-HEALTH CARE PROFESSIONAL|READER|U|4|Visit_4|65|3|SCREENING|2020-09-12|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-14|P1Y2M10DT2H30M|AFTER|2020-10-15|COINCIDENT|2020-10-16
e|RS|44ca1fe6-76d2-4a94-9854-1ddbde638803|8|MRDIND|Minimal Residual Disease Indicator|PRINCE TCELL LYMPHOMA 2010|[?]|km/h|PD-CT|1|log10 CFU/mL|AUDIOMETRY||||PROXY|HEMATOLOGIST|Y|4|Visit_4|65|7|FOLLOW-UP|2020-09-12|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-14|P1Y2M10DT2H30M|BEFORE|2020-09-10|ONGOING|2020-10-15
e|RS|44ca1fe6-76d2-4a94-9854-1ddbde638803|9|MRDRESP|Minimal Residual Disease Response|NCCN ALL MRD 2014|[?]|ug/m2/h|PMR|1|mg/dL|DOPPLER ULTRASOUND||||STUDY SUBJECT|ONCOLOGIST 1|N|5|Visit_5|90|5|WASHOUT|2020-10-07|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-20|P1Y2M10DT2H30M|COINCIDENT|2020-08-25|AFTER|2020-09-08
e|RS|44ca1fe6-76d2-4a94-9854-1ddbde638803|10|CLINRESP|Clinical Response|RANO|[?]|10^6/g|NON-CR/NON-PD|1|U/dL|AUDIOMETRY||Y||STUDY SUBJECT|UROLOGIST|Y|5|Visit_5|90|2|TREATMENT|2020-10-07|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-20|P1Y2M10DT2H30M|AFTER|2020-08-09|ONGOING|2020-10-04
e|RS|edc935ed-3b94-43fa-9b7f-facf6eb6780e|1|STRUSTAT|Steroid Use Status|RANO ELLINGSON 2017|[?]|keV|cPR|1|mEq/kg|IMMUNOPRECIPITATION|Y|||VENDOR|OPTOMETRIST|Y|1|Visit_1|10|5|TREATMENT|2020-12-04|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-16|P1Y2M10DT2H30M|AFTER|2021-02-24|BEFORE|2021-02-26
e|RS|edc935ed-3b94-43fa-9b7f-facf6eb6780e|2|MOLRESP|Molecular Response|WOLCHOK SOLID TUMORS 2009|[?]|Frames/s|PDu|1|NEEDLE GAUGE|TONOMETRY||Y||GUARDIAN|INTERNIST|NA|1|Visit_1|10|1|FOLLOW-UP|2020-12-04|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-16|P1Y2M10DT2H30M|AFTER|2021-01-14|AFTER|2021-02-16
e|RS|edc935ed-3b94-43fa-9b7f-facf6eb6780e|3|NEWLIND|New Lesion Indicator|SHINDOH COLORECTAL CANCER 2013|[?]|umol/L/sec|VGPR|1|ukat/10^12 RBC|INFRARED SPECTROMETRY||||ADJUDICATOR|NEUROLOGIST 1|NA|2|Visit_2|25|7|TREATMENT|2020-12-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-11|P1Y2M10DT2H30M|BEFORE|2020-12-27|COINCIDENT|2021-01-28
e|RS|edc935ed-3b94-43fa-9b7f-facf6eb6780e|4|DRCRIND|Disease Recurrence Indicator|BLAZER COLORECTAL CANCER 2008|[?]|kPa/L/sec|pCR|1|CIGARETTE|SCANNING ELECTRON MICROSCOPY||||CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL PSYCHOLOGIST|U|2|Visit_2|25|7|FOLLOW-UP|2020-12-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-11|P1Y2M10DT2H30M|BEFORE|2021-02-17|ONGOING|2021-02-23
e|RS|edc935ed-3b94-43fa-9b7f-facf6eb6780e|5|SYMPTDTR|Symptomatic Deterioration|IRANO 2015|[?]|ng/day|NR|1|U/g|FORCED OSCILLATION TECHNIQUE|Y|||FAMILY MEMBER|CLINICAL PATHOLOGIST|Y|3|Visit_3|40|3|TREATMENT|2021-01-03|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-06|P1Y2M10DT2H30M|AFTER|2020-12-09|AFTER|2021-01-19
e|RS|edc935ed-3b94-43fa-9b7f-facf6eb6780e|6|METSIND|Metastatic Indicator|LUGANO CLASSIFICATION|[?]|Ci/mL|PDu|1|mol/g|CONTRAST ENHANCED SPIRAL CT SCAN|Y|||ADJUDICATOR|RADIOLOGIST 2|N|3|Visit_3|40|1|TREATMENT|2021-01-03|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-06|P1Y2M10DT2H30M|BEFORE|2021-02-21|BEFORE|2021-02-24
e|RS|edc935ed-3b94-43fa-9b7f-facf6eb6780e|7|SYMPTDTR|Symptomatic Deterioration|BLAZER COLORECTAL CANCER 2008|[?]|deg2|NED|1|ppm|WESTERGREN||Y||FAMILY MEMBER|RATER 1|U|4|Visit_4|65|5|SCREENING|2021-01-28|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-02|P1Y2M10DT2H30M|COINCIDENT|2020-11-27|AFTER|2021-01-25
e|RS|edc935ed-3b94-43fa-9b7f-facf6eb6780e|8|BESTRESP|Best Overall Response|KEAM BREAST CANCER 2013|||MOLECULAR CR|1|mm/sec|QUANTITATIVE PERIPHERAL ANGIOGRAPHY|||Y|CHILD|RATER|N|4|Visit_4|65|2|FOLLOW-UP|2021-01-28|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-02|P1Y2M10DT2H30M|UNKNOWN|2020-12-16|AFTER|2021-01-01
e|RS|edc935ed-3b94-43fa-9b7f-facf6eb6780e|9|DRCRIND|Disease Recurrence Indicator|DOHNER AML 2010|[?]|ug/day|CR|1|MASK|APPLANATION TONOMETRY||Y||SPOUSE|CLINICAL PATHOLOGIST|N|5|Visit_5|90|1|SCREENING|2021-02-22|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-20|P1Y2M10DT2H30M|AFTER|2021-01-12|COINCIDENT|2021-01-15
e|RS|edc935ed-3b94-43fa-9b7f-facf6eb6780e|10|SPLNRESP|Spleen Response|LEE LUNG CANCER 2011|[?]|mg/m2/h|PR|1|V/sec|BIOIMPEDANCE SPECTROSCOPY||||INVESTIGATOR|PHYSIOTHERAPIST|NA|5|Visit_5|90|1|FOLLOW-UP|2021-02-22|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-20|P1Y2M10DT2H30M|COINCIDENT|2020-11-27|BEFORE|2020-12-24
e|RS|f997ad2a-e9b1-4341-96d5-caef4bcb7196|1|NEWLWIND|New Lesion Worsening Indicator|MASS|[?]|m3|SD|1|mEq/day|RADIOIMMUNOPRECIPITATION ASSAY||Y||CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 2|NA|1|Visit_1|10|6|WASHOUT|2020-06-08|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-31|P1Y2M10DT2H30M|AFTER|2020-08-23|ONGOING|2020-09-03
e|RS|f997ad2a-e9b1-4341-96d5-caef4bcb7196|2|MRDRESP|Minimal Residual Disease Response|GCIG RUSTIN OVARIAN CANCER 2011|||DISEASE TRANSFORMATION|1|DISK|SNP ARRAY|||Y|SIGNIFICANT OTHER|MICROSCOPIST 2|NA|1|Visit_1|10|6|TREATMENT|2020-06-08|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-31|P1Y2M10DT2H30M|UNKNOWN|2020-08-31|AFTER|2020-09-04
e|RS|f997ad2a-e9b1-4341-96d5-caef4bcb7196|3|NEWLIND|New Lesion Indicator|RECIST 1.1|[?]|/100 HPFs|MORPHOLOGIC CR|1|cd|ENZYMATIC SPECTROPHOTOMETRY||||CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 2|N|2|Visit_2|25|6|WASHOUT|2020-06-23|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-18|P1Y2M10DT2H30M|UNKNOWN|2020-07-05|COINCIDENT|2020-08-23
e|RS|f997ad2a-e9b1-4341-96d5-caef4bcb7196|4|HEMARESP|Hematologic Response|WOLCHOK SOLID TUMORS 2009|[?]|m2|MORPHOLOGIC LEUKEMIA-FREE STATE|1|mPa|INTERRUPTER TECHNIQUE||||STUDY SUBJECT|INTERNIST|N|2|Visit_2|25|3|SCREENING|2020-06-23|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-18|P1Y2M10DT2H30M|AFTER|2020-06-10|ONGOING|2020-08-28
e|RS|f997ad2a-e9b1-4341-96d5-caef4bcb7196|5|BMIVLIND|Bone Marrow Involvement Indicator|KEAM BREAST CANCER 2013|[?]|ukat/10^12 RBC|PD/RELAPSE AFTER HI|1|mMU/mL|PET SCAN||||INTERVIEWER|OPHTHALMOLOGIST|U|3|Visit_3|40|7|SCREENING|2020-07-08|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-24|P1Y2M10DT2H30M|UNKNOWN|2020-08-26|ONGOING|2020-08-31
e|RS|f997ad2a-e9b1-4341-96d5-caef4bcb7196|6|ANATRESP|Anatomic Response|IWG CHESON AML 2003|||CYTOGENETIC CR|1|kg/L|SPECTROPHOTOMETRY|Y||Y|CAREGIVER|RADIOLOGIST|U|3|Visit_3|40|2|WASHOUT|2020-07-08|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-24|P1Y2M10DT2H30M|BEFORE|2020-07-29|BEFORE|2020-08-16
e|RS|f997ad2a-e9b1-4341-96d5-caef4bcb7196|7|SPLNRESP|Spleen Response|AJCC V8|[?]|BOLUS|QUANTIFIABLE MRD POSITIVITY|1|cmH2O/mL|WHOLE GENOME SEQUENCING||Y||VENDOR|READER 1|Y|4|Visit_4|65|3|TREATMENT|2020-08-02|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-10|P1Y2M10DT2H30M|BEFORE|2020-06-22|BEFORE|2020-07-30
e|RS|f997ad2a-e9b1-4341-96d5-caef4bcb7196|8|TRGRESP|Target Response|IWG CHESON AML 2003|||MR|1|U/kg|ECHOCARDIOGRAPHY||Y|Y|FAMILY MEMBER|PEDIATRIC NEUROLOGIST|NA|4|Visit_4|65|3|FOLLOW-UP|2020-08-02|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-10|P1Y2M10DT2H30M|UNKNOWN|2020-06-15|BEFORE|2020-08-07
e|RS|f997ad2a-e9b1-4341-96d5-caef4bcb7196|9|NEWLPROG|New Lesion Progression|SACT|[?]|ukat|PSEUDOPROGRESSION|1|ug/L FEU|ELISPOT||||DOMESTIC PARTNER|NEUROLOGIST|NA|5|Visit_5|90|5|TREATMENT|2020-08-27|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-17|P1Y2M10DT2H30M|COINCIDENT|2020-09-01|BEFORE|2020-09-03
e|RS|f997ad2a-e9b1-4341-96d5-caef4bcb7196|10|RDIORESP|Radiologic Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|10^3 organisms/g|EQUIVOCAL|1|10^5/hpf|ELECTROMYOGRAPHY||Y||SIBLING|NEUROLOGIST 1|NA|5|Visit_5|90|7|TREATMENT|2020-08-27|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-17|P1Y2M10DT2H30M|AFTER|2020-08-13|BEFORE|2020-08-24
e|RS|5a56874f-10e4-4cd0-842f-19552a04d1bd|1|NEWLWIND|New Lesion Worsening Indicator|IRANO 2015|[?]|mmol/day|PD-CT|1|PFU/dose|SANGER SEQUENCING||Y||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 3|Y|1|Visit_1|10|5|SCREENING|2020-06-20|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-18|P1Y2M10DT2H30M|UNKNOWN|2020-08-25|ONGOING|2020-09-16
e|RS|5a56874f-10e4-4cd0-842f-19552a04d1bd|2|MRDRESP|Minimal Residual Disease Response|RANO ELLINGSON 2017|[?]|mmol2/L2|HI-E|1|cL|SINGLE-SLICE SPIRAL CT||Y||SPOUSE|OTOLARYNGOLOGIST|Y|1|Visit_1|10|4|TREATMENT|2020-06-20|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-18|P1Y2M10DT2H30M|BEFORE|2020-08-04|BEFORE|2020-08-16
e|RS|5a56874f-10e4-4cd0-842f-19552a04d1bd|3|MOLRESP|Molecular Response|JUWEID NON-HODGKINS LYMPHOMA 2005|||iCR|1|g|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY|||Y|NON-HEALTH CARE PROFESSIONAL|HEMATOLOGIST|Y|2|Visit_2|25|3|TREATMENT|2020-07-05|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-11|P1Y2M10DT2H30M|BEFORE|2020-08-02|ONGOING|2020-09-09
e|RS|5a56874f-10e4-4cd0-842f-19552a04d1bd|4|SFTSRESP|Soft Tissue Response|RANO ELLINGSON 2017|||NOT ALL EVALUATED|1|mL/s/m2|COULOMETRIC TITRATION|Y||Y|SIBLING|READER|U|2|Visit_2|25|3|SCREENING|2020-07-05|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-11|P1Y2M10DT2H30M|COINCIDENT|2020-08-09|BEFORE|2020-09-08
e|RS|5a56874f-10e4-4cd0-842f-19552a04d1bd|5|RDIORESP|Radiologic Response|NCIWG CHESON CLL 1996|||MORPHOLOGIC CRi|1|dB|MICROSCOPY||Y|Y|CAREGIVER|NEUROLOGIST 1|NA|3|Visit_3|40|6|WASHOUT|2020-07-20|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-11|P1Y2M10DT2H30M|AFTER|2020-07-01|BEFORE|2020-09-13
e|RS|5a56874f-10e4-4cd0-842f-19552a04d1bd|6|SFTSRESP|Soft Tissue Response|MRECIST LENCIONI LIVER CANCER 2010|||MOLECULAR MAJOR RESPONSE|1|CCID 50/dose|SIZE EXCLUSION CHROMATOGRAPHY|||Y|PROXY|NEUROLOGIST 1|U|3|Visit_3|40|4|SCREENING|2020-07-20|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-11|P1Y2M10DT2H30M|BEFORE|2020-08-20|BEFORE|2020-08-28
e|RS|5a56874f-10e4-4cd0-842f-19552a04d1bd|7|RDIORESP|Radiologic Response|FAROOQUI SUPP CLL 2014|[?]|log10 TCID 50/dose|QUANTIFIABLE MRD POSITIVITY|1|NEEDLE GAUGE|ICP-MS||||INDEPENDENT ASSESSOR|PATHOLOGIST|NA|4|Visit_4|65|6|SCREENING|2020-08-14|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-31|P1Y2M10DT2H30M|COINCIDENT|2020-07-07|COINCIDENT|2020-08-31
e|RS|5a56874f-10e4-4cd0-842f-19552a04d1bd|8|CLINRESP|Clinical Response|CHESON LYMPHOMA 2008|||INCREASED|1|pmol|KARYOTYPING|||Y|DOMESTIC PARTNER|PATHOLOGIST 2|U|4|Visit_4|65|4|SCREENING|2020-08-14|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-31|P1Y2M10DT2H30M|BEFORE|2020-07-05|COINCIDENT|2020-07-23
e|RS|5a56874f-10e4-4cd0-842f-19552a04d1bd|9|METSIND|Metastatic Indicator|RAJKUMAR MYELOMA 2011|[?]|kg|iSD|1|mg/mL/day|ELISA||||INTERVIEWER|UROLOGIST|U|5|Visit_5|90|4|TREATMENT|2020-09-08|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-27|P1Y2M10DT2H30M|AFTER|2020-07-30|COINCIDENT|2020-08-25
e|RS|5a56874f-10e4-4cd0-842f-19552a04d1bd|10|NEWLIND|New Lesion Indicator|PALUMBO MULTIPLE MYELOMA 2009|[?]|ECL unit|MR|1|/500 WBC|SCINTIGRAPHY||||STUDY SUBJECT|READER|Y|5|Visit_5|90|6|FOLLOW-UP|2020-09-08|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-27|P1Y2M10DT2H30M|UNKNOWN|2020-06-22|AFTER|2020-09-08
e|RS|f1d4ebe5-fc72-447b-8872-67e971ff471b|1|STRUSTAT|Steroid Use Status|LUGANO CLASSIFICATION|[?]|mg/min|NON-QUANTIFIABLE MRD POSITIVITY|1|ug/L/h|RIA||||CHILD|CLINICAL PATHOLOGIST|U|1|Visit_1|10|7|SCREENING|2020-11-08|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-23|P1Y2M10DT2H30M|BEFORE|2020-12-08|COINCIDENT|2020-12-20
e|RS|f1d4ebe5-fc72-447b-8872-67e971ff471b|2|MJPTHIND|Major Pathological Response Indicator|RECICL|[?]|DDU|EQUIVOCAL|1|AFU|SINGLE-SLICE SPIRAL CT||Y||INVESTIGATOR|RATER 2|N|1|Visit_1|10|3|TREATMENT|2020-11-08|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-23|P1Y2M10DT2H30M|BEFORE|2020-12-25|COINCIDENT|2021-02-03
e|RS|f1d4ebe5-fc72-447b-8872-67e971ff471b|3|OVRLRESP|Overall Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|U/cL|CA125 75% RESPONSE|1|10^6/g|MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY||Y||INTERVIEWER|MICROSCOPIST 3|Y|2|Visit_2|25|4|TREATMENT|2020-11-23|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-03|P1Y2M10DT2H30M|BEFORE|2020-12-29|COINCIDENT|2021-02-03
e|RS|f1d4ebe5-fc72-447b-8872-67e971ff471b|4|BMIVLIND|Bone Marrow Involvement Indicator|SCHWARZ CERVICAL CANCER 2009|||MR|1|mm/2h|MAGNETIC RESONANCE ENTEROGRAPHY|||Y|FAMILY MEMBER|ADJUDICATOR 1|N|2|Visit_2|25|2|TREATMENT|2020-11-23|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-03|P1Y2M10DT2H30M|UNKNOWN|2021-01-16|AFTER|2021-01-21
e|RS|f1d4ebe5-fc72-447b-8872-67e971ff471b|5|METSIND|Metastatic Indicator|GCIG RUSTIN OVARIAN CANCER 2011|[?]|BOWL|TREATMENT FAILURE|1|foz_us|SNP ARRAY||Y||DOMESTIC PARTNER|NEUROLOGIST|U|3|Visit_3|40|5|SCREENING|2020-12-08|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-29|P1Y2M10DT2H30M|AFTER|2021-01-10|ONGOING|2021-01-17
e|RS|f1d4ebe5-fc72-447b-8872-67e971ff471b|6|BMIVLIND|Bone Marrow Involvement Indicator|SCHWARZ CERVICAL CANCER 2009|[?]|DIP|MAJOR PATHOLOGIC RESPONSE|1|mm/h|SINGLE-MOLECULE ARRAY||||FRIEND|PEDIATRIC NEUROLOGIST|U|3|Visit_3|40|7|TREATMENT|2020-12-08|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-29|P1Y2M10DT2H30M|UNKNOWN|2021-01-23|BEFORE|2021-01-24
e|RS|f1d4ebe5-fc72-447b-8872-67e971ff471b|7|MJPTHIND|Major Pathological Response Indicator|WOLCHOK SOLID TUMORS 2009|[?]|/wk|NON-iCR/NON-iUPD|1|pg|TEST STRIP|Y|||INDEPENDENT ASSESSOR|OTOLARYNGOLOGIST|N|4|Visit_4|65|7|TREATMENT|2021-01-02|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-26|P1Y2M10DT2H30M|COINCIDENT|2020-12-19|BEFORE|2021-01-07
e|RS|f1d4ebe5-fc72-447b-8872-67e971ff471b|8|METSIND|Metastatic Indicator|RANO|[?]|Ci/L|SD|1|10^9 organisms/g|IHC||||SIGNIFICANT OTHER|ADJUDICATOR|N|4|Visit_4|65|5|SCREENING|2021-01-02|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-26|P1Y2M10DT2H30M|AFTER|2020-12-31|BEFORE|2021-01-30
e|RS|f1d4ebe5-fc72-447b-8872-67e971ff471b|9|METSIND|Metastatic Indicator|PCWG BUBLEY PROSTATE CANCER 1999|[?]|GBq/ug|NON-QUANTIFIABLE MRD POSITIVITY|1|mL/g/min|DC SHEATH FLOW|Y|||SIGNIFICANT OTHER|MICROSCOPIST|N|5|Visit_5|90|3|TREATMENT|2021-01-27|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-02|P1Y2M10DT2H30M|COINCIDENT|2020-12-03|BEFORE|2021-01-25
e|RS|f1d4ebe5-fc72-447b-8872-67e971ff471b|10|BONERESP|Bone Response|WHO BREAST CANCER 2006|[?]|deg/s|CYTOGENETIC NO RESPONSE|1|pmol/dL|IMMUNOCHEMILUMINOMETRIC ASSAY||||NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|Y|5|Visit_5|90|6|TREATMENT|2021-01-27|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-02|P1Y2M10DT2H30M|BEFORE|2020-12-10|COINCIDENT|2021-02-03
e|RS|2a141b73-e336-4701-9067-8d51d532596b|1|CYTORESP|Cytogenetic Response|KUKER LYMPHOMA 2005|[?]|BOLUS|ABSENT MORPHOLOGIC RESPONSE|1|g/kg/day|COMPUTERIZED CORNEAL TOPOGRAPHY|Y|||CLINICAL STUDY SPONSOR|MICROSCOPIST|Y|1|Visit_1|10|5|FOLLOW-UP|2020-06-12|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-09|P1Y2M10DT2H30M|COINCIDENT|2020-06-27|ONGOING|2020-07-07
e|RS|2a141b73-e336-4701-9067-8d51d532596b|2|HEMARESP|Hematologic Response|CHESON MALIGNANT LYMPHOMA 2007|||iPR|1|mL/kg/day|FARR ASSAY|||Y|PROXY|ADJUDICATOR|Y|1|Visit_1|10|2|TREATMENT|2020-06-12|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-09|P1Y2M10DT2H30M|BEFORE|2020-07-30|ONGOING|2020-08-04
e|RS|2a141b73-e336-4701-9067-8d51d532596b|3|MRDRESP|Minimal Residual Disease Response|RANO ELLINGSON 2017|[?]|GBq/mg|NON-iCR/NON-iUPD|1|Sv|SPECULAR MICROSCOPY||||STUDY SUBJECT|OTOLARYNGOLOGIST|Y|2|Visit_2|25|1|TREATMENT|2020-06-27|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-07|P1Y2M10DT2H30M|COINCIDENT|2020-07-03|AFTER|2020-08-07
e|RS|2a141b73-e336-4701-9067-8d51d532596b|4|RDIORESP|Radiologic Response|MURPHY PROSTATE CANCER 1980|[?]|EU|NON-QUANTIFIABLE MRD POSITIVITY|1|mg/dose|ALCIAN BLUE STAIN||||PROXY|READER 1|Y|2|Visit_2|25|5|SCREENING|2020-06-27|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-07|P1Y2M10DT2H30M|UNKNOWN|2020-06-10|BEFORE|2020-07-11
e|RS|2a141b73-e336-4701-9067-8d51d532596b|5|TMRESP|Tumor Marker Response|KEAM BREAST CANCER 2013|[?]|SUPPOSITORY|PARTIAL MORPHOLOGIC RESPONSE|1|psi|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION||||STUDY SUBJECT|ADJUDICATOR 2|Y|3|Visit_3|40|4|FOLLOW-UP|2020-07-12|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-10|P1Y2M10DT2H30M|AFTER|2020-09-01|AFTER|2020-09-09
e|RS|2a141b73-e336-4701-9067-8d51d532596b|6|NEWLPROG|New Lesion Progression|SCHER PROSTATE CANCER 2011|[?]|Bq/uL|PR WITH LYMPHOCYTOSIS|1|nU/cL|AUTOREFRACTION||||NON-HEALTH CARE PROFESSIONAL|OPTOMETRIST|Y|3|Visit_3|40|5|WASHOUT|2020-07-12|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-10|P1Y2M10DT2H30M|BEFORE|2020-07-28|ONGOING|2020-08-31
e|RS|2a141b73-e336-4701-9067-8d51d532596b|7|BONERESP|Bone Response|HARTMANN GERM CELL CANCER 2002|[?]|mol/day|CA125 50% RESPONSE|1|10^10/L|HPLC/IEX||||CHILD|PATHOLOGIST|NA|4|Visit_4|65|1|SCREENING|2020-08-06|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-08|P1Y2M10DT2H30M|BEFORE|2020-08-15|ONGOING|2020-08-23
e|RS|2a141b73-e336-4701-9067-8d51d532596b|8|BESTRESP|Best Overall Response|FAROOQUI SUPP CLL 2014|||STABLE|1|s/h|IODINE STAIN|||Y|CAREGIVER|MICROSCOPIST|Y|4|Visit_4|65|7|TREATMENT|2020-08-06|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-08|P1Y2M10DT2H30M|AFTER|2020-08-02|COINCIDENT|2020-08-15
e|RS|2a141b73-e336-4701-9067-8d51d532596b|9|OVRLRESP|Overall Response|LUGANO CLASSIFICATION|[?]|10^7 TCID 50/dose|PMR|1|IU/g|INCISION-INDUCED BLEEDING METHOD||Y||PROXY|ONCOLOGIST 1|NA|5|Visit_5|90|4|TREATMENT|2020-08-31|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-05|P1Y2M10DT2H30M|COINCIDENT|2020-07-29|COINCIDENT|2020-08-13
e|RS|2a141b73-e336-4701-9067-8d51d532596b|10|SFTSRESP|Soft Tissue Response|PETIT BREAST CANCER 2001|||CYTOGENETIC CR|1|g/g/day|URANYL ACETATE STAIN|Y||Y|ADJUDICATION COMMITTEE|HEMATOLOGIST|Y|5|Visit_5|90|3|TREATMENT|2020-08-31|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-05|P1Y2M10DT2H30M|BEFORE|2020-08-11|ONGOING|2020-09-01
e|RS|4adf9a2c-3c43-4289-8156-1a109791580c|1|MRDRESP|Minimal Residual Disease Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|MBq|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|DRINK|RADIOGRAPHY||Y||STUDY SUBJECT|PATHOLOGIST 1|NA|1|Visit_1|10|6|TREATMENT|2020-11-22|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-30|P1Y2M10DT2H30M|BEFORE|2020-12-22|BEFORE|2020-12-28
e|RS|4adf9a2c-3c43-4289-8156-1a109791580c|2|TRGRESP|Target Response|RAJKUMAR MYELOMA 2011|[?]|TRANSDUCING UNIT|ABSENT MORPHOLOGIC RESPONSE|1|10^6 organisms/mL|PALM METHOD||||CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 1|NA|1|Visit_1|10|5|FOLLOW-UP|2020-11-22|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-30|P1Y2M10DT2H30M|AFTER|2021-01-11|BEFORE|2021-01-21
e|RS|4adf9a2c-3c43-4289-8156-1a109791580c|3|NTERESP|Non-Target Enhancing Response|AJCC V7|[?]|U|TREATMENT FAILURE|1|mU/L|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION||||SIGNIFICANT OTHER|ONCOLOGIST 2|U|2|Visit_2|25|7|TREATMENT|2020-12-07|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-01|P1Y2M10DT2H30M|BEFORE|2020-11-25|BEFORE|2021-01-12
e|RS|4adf9a2c-3c43-4289-8156-1a109791580c|4|NEWLWIND|New Lesion Worsening Indicator|MRECIST LENCIONI LIVER CANCER 2010|[?]|lx|cCR|1|10^7 CFU|KINYOUN STAIN||||DOMESTIC PARTNER|NEUROLOGIST 2|U|2|Visit_2|25|5|TREATMENT|2020-12-07|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-01|P1Y2M10DT2H30M|UNKNOWN|2021-01-03|ONGOING|2021-01-17
e|RS|4adf9a2c-3c43-4289-8156-1a109791580c|5|MOLRESP|Molecular Response|CHESON LYMPHOMA 2008|[?]|mg/L|PR|1|cd|POPULATION SEQUENCING||||SIGNIFICANT OTHER|OTOLARYNGOLOGIST|N|3|Visit_3|40|3|SCREENING|2020-12-22|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-07|P1Y2M10DT2H30M|COINCIDENT|2021-01-15|ONGOING|2021-01-28
e|RS|4adf9a2c-3c43-4289-8156-1a109791580c|6|MRDRESP|Minimal Residual Disease Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|kBq/uL|PMR|1|INHALATION|CONTRAST ENHANCED PET SCAN||||DOMESTIC PARTNER|MICROSCOPIST|N|3|Visit_3|40|7|FOLLOW-UP|2020-12-22|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-07|P1Y2M10DT2H30M|AFTER|2021-02-17|ONGOING|2021-02-18
e|RS|4adf9a2c-3c43-4289-8156-1a109791580c|7|NEWLWIND|New Lesion Worsening Indicator|PCWG SCHER PROSTATE CANCER 2016|||pCR|1|dpm/mL|CLIP||Y|Y|CAREGIVER|NEUROLOGIST 1|N|4|Visit_4|65|3|WASHOUT|2021-01-16|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-14|P1Y2M10DT2H30M|BEFORE|2020-11-22|AFTER|2020-12-24
e|RS|4adf9a2c-3c43-4289-8156-1a109791580c|8|NEWLWIND|New Lesion Worsening Indicator|JACINTO CERVICAL CANCER 2007|[?]|/100 WBC|NOT ALL EVALUATED|1|ELISA unit/mL|PET/MRI SCAN|Y|Y||INDEPENDENT ASSESSOR|NEUROLOGIST 1|Y|4|Visit_4|65|1|WASHOUT|2021-01-16|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-14|P1Y2M10DT2H30M|AFTER|2021-02-08|COINCIDENT|2021-02-18
e|RS|4adf9a2c-3c43-4289-8156-1a109791580c|9|STRUSTAT|Steroid Use Status|MURPHY PROSTATE CANCER 1980|[?]|/2000 RBC|CYTOGENETIC MINIMAL RESPONSE|1|g/g/day|IMMUNOPRECIPITATION||||SIGNIFICANT OTHER|MICROSCOPIST 1|Y|5|Visit_5|90|5|TREATMENT|2021-02-10|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-04|P1Y2M10DT2H30M|BEFORE|2020-11-26|BEFORE|2021-01-26
e|RS|4adf9a2c-3c43-4289-8156-1a109791580c|10|MRDIND|Minimal Residual Disease Indicator|iRECIST|[?]|mEq/mmol|RELAPSED DISEASE FROM CR OR PR|1|10^4 CFU/mL|U-HPLC/MS/MS||Y||FRIEND|PEDIATRIC NEUROLOGIST|NA|5|Visit_5|90|5|WASHOUT|2021-02-10|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-04|P1Y2M10DT2H30M|UNKNOWN|2021-01-05|AFTER|2021-02-02
e|RS|1781d0c2-60c1-49df-98ed-e7dbc63e5b40|1|NEWLPROG|New Lesion Progression|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|mL/breath|NED|1|kcal|PULMONARY ANGIOGRAPHY|Y|||CAREGIVER|ADJUDICATOR|NA|1|Visit_1|10|7|FOLLOW-UP|2020-05-23|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-20|P1Y2M10DT2H30M|AFTER|2020-06-22|COINCIDENT|2020-07-19
e|RS|1781d0c2-60c1-49df-98ed-e7dbc63e5b40|2|MRDRESP|Minimal Residual Disease Response|PCWG SCHER PROSTATE CANCER 2016|[?]|cy/cm|WORSENED|1|U/animal|WHOLE EXOME SEQUENCING||||SIGNIFICANT OTHER|RATER 1|Y|1|Visit_1|10|5|FOLLOW-UP|2020-05-23|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-20|P1Y2M10DT2H30M|COINCIDENT|2020-08-08|BEFORE|2020-08-19
e|RS|1781d0c2-60c1-49df-98ed-e7dbc63e5b40|3|SFTSRESP|Soft Tissue Response|PRINCE TCELL LYMPHOMA 2010|[?]|10^6 U|MOLECULAR CR|1|mm|TELLER ACUITY CARDS||||VENDOR|ADJUDICATOR 3|N|2|Visit_2|25|5|FOLLOW-UP|2020-06-07|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-17|P1Y2M10DT2H30M|AFTER|2020-06-15|COINCIDENT|2020-08-02
e|RS|1781d0c2-60c1-49df-98ed-e7dbc63e5b40|4|NTLWIND|Non-Target Lesion Worsening Indicator|MRECIST LENCIONI LIVER CANCER 2010|[?]|/5x10^4 WBC|NON-QUANTIFIABLE MRD POSITIVITY|1|pt_br|PYROSEQUENCING||||DOMESTIC PARTNER|OPHTHALMOLOGIST|U|2|Visit_2|25|3|TREATMENT|2020-06-07|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-17|P1Y2M10DT2H30M|BEFORE|2020-06-15|ONGOING|2020-07-09
e|RS|1781d0c2-60c1-49df-98ed-e7dbc63e5b40|5|DRCRIND|Disease Recurrence Indicator|MRECIST BYRNE MESOTHELIOMA 2004|[?]|foz_br|NED|1|mkat|RADIOGRAPHY||||PROXY|RADIOLOGIST|NA|3|Visit_3|40|3|TREATMENT|2020-06-22|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-01|P1Y2M10DT2H30M|UNKNOWN|2020-07-20|COINCIDENT|2020-07-21
e|RS|1781d0c2-60c1-49df-98ed-e7dbc63e5b40|6|HEMARESP|Hematologic Response|PRINCE TCELL LYMPHOMA 2010|||WORSENED|1|cg|U-HPLC/MS/MS||Y|Y|INDEPENDENT ASSESSOR|CLINICAL PATHOLOGIST|Y|3|Visit_3|40|5|TREATMENT|2020-06-22|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-01|P1Y2M10DT2H30M|UNKNOWN|2020-08-01|ONGOING|2020-08-09
e|RS|1781d0c2-60c1-49df-98ed-e7dbc63e5b40|7|STRUSTAT|Steroid Use Status|TSUKASAKI LEUKEMIA LYMPHOMA 2009|||PR WITH LYMPHOCYTOSIS|1|cmH2O*s2/mL|LASER CAPTURE MICRODISSECTION|||Y|VENDOR|ONCOLOGIST 1|N|4|Visit_4|65|3|SCREENING|2020-07-17|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-30|P1Y2M10DT2H30M|COINCIDENT|2020-07-13|COINCIDENT|2020-07-27
e|RS|1781d0c2-60c1-49df-98ed-e7dbc63e5b40|8|MRDRESP|Minimal Residual Disease Response|RAJKUMAR MYELOMA 2011|||CYTOGENETIC NO RESPONSE|1|U/m2|SPIRAL CT SCAN WITHOUT CONTRAST||Y|Y|VENDOR|HEMATOLOGIST|U|4|Visit_4|65|5|WASHOUT|2020-07-17|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-30|P1Y2M10DT2H30M|UNKNOWN|2020-07-24|BEFORE|2020-08-11
e|RS|1781d0c2-60c1-49df-98ed-e7dbc63e5b40|9|MRPHRESP|Morphologic Response|CHESON CLL 2012|[?]|DIP|WORSENED|1|mL/cage|LIGHT MICROSCOPY||||INVESTIGATOR|CARDIOLOGIST|NA|5|Visit_5|90|1|FOLLOW-UP|2020-08-11|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-13|P1Y2M10DT2H30M|UNKNOWN|2020-07-20|COINCIDENT|2020-08-01
e|RS|1781d0c2-60c1-49df-98ed-e7dbc63e5b40|10|MRDIND|Minimal Residual Disease Indicator|BLAZER COLORECTAL CANCER 2008|[?]|mg/kg/dose|NOT ALL EVALUATED|1|LENS|MICRONEUTRALIZATION ASSAY|Y|||HEALTH CARE PROFESSIONAL|READER 1|U|5|Visit_5|90|5|TREATMENT|2020-08-11|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-13|P1Y2M10DT2H30M|AFTER|2020-07-10|ONGOING|2020-07-20
e|RS|1b2eda86-2d2c-4fdc-a88e-409ea5180603|1|MJPTHIND|Major Pathological Response Indicator|UNSPECIFIED|[?]|mL/animal/wk|iPR|1|mg/animal|DROPLET DIGITAL PCR||||INVESTIGATOR|INTERNIST|Y|1|Visit_1|10|3|TREATMENT|2020-05-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-10|P1Y2M10DT2H30M|UNKNOWN|2020-06-08|AFTER|2020-06-29
e|RS|1b2eda86-2d2c-4fdc-a88e-409ea5180603|2|ANATRESP|Anatomic Response|IWG CHESON AML 2003|[?]|ugEq|iPR|1|BE/mL|PUPILLOMETRY|Y|||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 3|U|1|Visit_1|10|6|FOLLOW-UP|2020-05-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-10|P1Y2M10DT2H30M|BEFORE|2020-08-16|AFTER|2020-08-17
e|RS|1b2eda86-2d2c-4fdc-a88e-409ea5180603|3|MNPTHIND|Minor Pathological Response Indicator|CHESON MALIGNANT LYMPHOMA 2007|||UNEQUIVOCAL|1|beats/min|INCISION-INDUCED BLEEDING METHOD|||Y|INDEPENDENT ASSESSOR|MICROSCOPIST 1|Y|2|Visit_2|25|5|TREATMENT|2020-06-03|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-19|P1Y2M10DT2H30M|AFTER|2020-06-03|BEFORE|2020-08-16
e|RS|1b2eda86-2d2c-4fdc-a88e-409ea5180603|4|CPRFSTAT|Clinical Performance Status|IRANO 2015|[?]|umol/L/min|NOT ALL EVALUATED|1|ug/m2/h|NUCLEIC ACID BASED METHOD||||GUARDIAN|PATHOLOGIST 1|NA|2|Visit_2|25|6|TREATMENT|2020-06-03|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-19|P1Y2M10DT2H30M|COINCIDENT|2020-05-15|AFTER|2020-07-06
e|RS|1b2eda86-2d2c-4fdc-a88e-409ea5180603|5|NTERESP|Non-Target Enhancing Response|RANO ELLINGSON 2017|[?]|MBP|MR|1|L/min|CLOT DETECTION||||INVESTIGATOR|ADJUDICATOR 2|Y|3|Visit_3|40|7|TREATMENT|2020-06-18|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-04|P1Y2M10DT2H30M|AFTER|2020-06-01|COINCIDENT|2020-07-26
e|RS|1b2eda86-2d2c-4fdc-a88e-409ea5180603|6|NEWLWIND|New Lesion Worsening Indicator|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|mg/mL/min|CMR|1|mg/kg/day|MIGET||||CHILD|ADJUDICATOR 3|NA|3|Visit_3|40|4|TREATMENT|2020-06-18|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-04|P1Y2M10DT2H30M|BEFORE|2020-06-27|BEFORE|2020-08-12
e|RS|1b2eda86-2d2c-4fdc-a88e-409ea5180603|7|MRPHRESP|Morphologic Response|GUILHOT CML 2007|[?]|ug/kg/h|PR-CT|1|IU/day|REVERSE TRANSCRIPTASE PCR|Y|||FRIEND|INTERNIST|N|4|Visit_4|65|2|TREATMENT|2020-07-13|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-12|P1Y2M10DT2H30M|UNKNOWN|2020-08-12|ONGOING|2020-08-15
e|RS|1b2eda86-2d2c-4fdc-a88e-409ea5180603|8|MRDIND|Minimal Residual Disease Indicator|HARTMANN GERM CELL CANCER 2002|[?]|cs|PD/RELAPSE AFTER HI|1|m/sec2|CELL OF ORIGIN ASSAY||||FAMILY MEMBER|OPTOMETRIST|U|4|Visit_4|65|3|WASHOUT|2020-07-13|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-12|P1Y2M10DT2H30M|COINCIDENT|2020-08-03|BEFORE|2020-08-07
e|RS|1b2eda86-2d2c-4fdc-a88e-409ea5180603|9|RDIORESP|Radiologic Response|iRECIST|[?]|TABLET|INDETERMINATE RESPONSE|1|m/sec2|ETDRS EYE CHART||||CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 2|Y|5|Visit_5|90|7|FOLLOW-UP|2020-08-07|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-29|P1Y2M10DT2H30M|AFTER|2020-05-11|COINCIDENT|2020-06-13
e|RS|1b2eda86-2d2c-4fdc-a88e-409ea5180603|10|BESTRESP|Best Overall Response|AJCC V8|[?]|Henry|mCR|1|um/day|BIOIMPEDANCE SPECTROSCOPY||||CAREGIVER|ONCOLOGIST 1|N|5|Visit_5|90|6|TREATMENT|2020-08-07|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-29|P1Y2M10DT2H30M|COINCIDENT|2020-07-13|AFTER|2020-07-27
e|RS|fc02184a-dfba-4964-be3a-cfa5f5d7200e|1|METSIND|Metastatic Indicator|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|DRUM|MRD NEGATIVITY|1|MESF|TWO-COLOR MICROARRAY||||INTERVIEWER|INTERNIST|Y|1|Visit_1|10|5|TREATMENT|2020-05-26|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-31|P1Y2M10DT2H30M|BEFORE|2020-08-09|AFTER|2020-08-23
e|RS|fc02184a-dfba-4964-be3a-cfa5f5d7200e|2|TRGRESP|Target Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|log10 CFU/g|MRD PERSISTENCE|1|log10 CCID 50/dose|RAJI CELL RIA||||CAREGIVER|MICROSCOPIST 1|U|1|Visit_1|10|3|SCREENING|2020-05-26|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-31|P1Y2M10DT2H30M|BEFORE|2020-06-28|COINCIDENT|2020-08-23
e|RS|fc02184a-dfba-4964-be3a-cfa5f5d7200e|3|SPLNRESP|Spleen Response|PCWG SCHER PROSTATE CANCER 2008|[?]|dpm/0.5 mL|MR|1|ug/h|MICRONEUTRALIZATION ASSAY|Y|||DOMESTIC PARTNER|FORENSIC PATHOLOGIST|NA|2|Visit_2|25|3|FOLLOW-UP|2020-06-10|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-24|P1Y2M10DT2H30M|AFTER|2020-08-11|COINCIDENT|2020-08-20
e|RS|fc02184a-dfba-4964-be3a-cfa5f5d7200e|4|MRDRESP|Minimal Residual Disease Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|CONTAINER|NON-CR/NON-PD|1|Sv|GEL ELECTROPHORESIS||||HEALTH CARE PROFESSIONAL|RATER|N|2|Visit_2|25|5|WASHOUT|2020-06-10|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-24|P1Y2M10DT2H30M|COINCIDENT|2020-07-09|ONGOING|2020-08-12
e|RS|fc02184a-dfba-4964-be3a-cfa5f5d7200e|5|MOLRESP|Molecular Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|uL/dose|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|CONTAINER|HPLC||||CHILD|RATER 1|U|3|Visit_3|40|1|SCREENING|2020-06-25|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-07|P1Y2M10DT2H30M|BEFORE|2020-06-16|BEFORE|2020-07-23
e|RS|fc02184a-dfba-4964-be3a-cfa5f5d7200e|6|NEWLWIND|New Lesion Worsening Indicator|NCCN ALL MRD 2014|||CYTOGENETIC CR|1|10^5/L|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|||Y|SIGNIFICANT OTHER|UROLOGIST|NA|3|Visit_3|40|6|FOLLOW-UP|2020-06-25|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-07|P1Y2M10DT2H30M|COINCIDENT|2020-05-18|COINCIDENT|2020-08-10
e|RS|fc02184a-dfba-4964-be3a-cfa5f5d7200e|7|MRDIND|Minimal Residual Disease Indicator|NCCN ALL MRD 2014|[?]|mg/dL|NR|1|RATIO|WHOLE EXOME SEQUENCING|Y|Y||INVESTIGATOR|RATER|U|4|Visit_4|65|3|SCREENING|2020-07-20|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-02|P1Y2M10DT2H30M|COINCIDENT|2020-07-17|COINCIDENT|2020-08-09
e|RS|fc02184a-dfba-4964-be3a-cfa5f5d7200e|8|METBRESP|Metabolic Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|Frames/s|RELAPSED DISEASE FROM CR OR PR|1|days/month|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY|Y|||CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 1|NA|4|Visit_4|65|6|TREATMENT|2020-07-20|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-02|P1Y2M10DT2H30M|COINCIDENT|2020-06-29|ONGOING|2020-07-02
e|RS|fc02184a-dfba-4964-be3a-cfa5f5d7200e|9|SFTSRESP|Soft Tissue Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|U/m2|IMMUNOPHENOTYPIC CR|1|Farad|HEMAGGLUTINATION INHIBITION ASSAY||||ADJUDICATOR|NEUROLOGIST 2|NA|5|Visit_5|90|3|WASHOUT|2020-08-14|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-13|P1Y2M10DT2H30M|BEFORE|2020-08-22|ONGOING|2020-08-23
e|RS|fc02184a-dfba-4964-be3a-cfa5f5d7200e|10|SFTSRESP|Soft Tissue Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|10^3 RNA copies/mL|NED|1|mL/kg|PELLI-ROBSON EYE CHART||Y||FAMILY MEMBER|ONCOLOGIST 2|U|5|Visit_5|90|1|TREATMENT|2020-08-14|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-13|P1Y2M10DT2H30M|COINCIDENT|2020-06-04|AFTER|2020-06-17
e|RS|37c59cfa-b952-4d16-a675-5e3b3a2e0288|1|CPRFSTAT|Clinical Performance Status|GCIG RUSTIN OVARIAN CANCER 2011|[?]|pmol|PSEUDOPROGRESSION|1|mOsm/kg|IMMUNOBLOT||||PROXY|ONCOLOGIST|NA|1|Visit_1|10|7|FOLLOW-UP|2020-05-29|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-14|P1Y2M10DT2H30M|COINCIDENT|2020-07-22|COINCIDENT|2020-07-23
e|RS|37c59cfa-b952-4d16-a675-5e3b3a2e0288|2|NTLWIND|Non-Target Lesion Worsening Indicator|RECIST 1.1|[?]|umol/day|cPR|1|dB|OSCILLOMETRY||||GUARDIAN|RATER 2|U|1|Visit_1|10|7|FOLLOW-UP|2020-05-29|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-14|P1Y2M10DT2H30M|COINCIDENT|2020-06-17|AFTER|2020-08-22
e|RS|37c59cfa-b952-4d16-a675-5e3b3a2e0288|3|NEWLWIND|New Lesion Worsening Indicator|CHESON MALIGNANT LYMPHOMA 2007|||CA125 50% RESPONSE|1|mmol/g|RIA||Y|Y|SIBLING|OPHTHALMOLOGIST|Y|2|Visit_2|25|2|FOLLOW-UP|2020-06-13|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-24|P1Y2M10DT2H30M|UNKNOWN|2020-07-27|BEFORE|2020-08-22
e|RS|37c59cfa-b952-4d16-a675-5e3b3a2e0288|4|MRDIND|Minimal Residual Disease Indicator|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|cmH2O*s2/mL|NOT ALL EVALUATED|1|dpm/0.5 mL|SLIT LAMP||||INTERVIEWER|RATER 1|N|2|Visit_2|25|4|SCREENING|2020-06-13|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-24|P1Y2M10DT2H30M|BEFORE|2020-08-22|ONGOING|2020-08-23
e|RS|37c59cfa-b952-4d16-a675-5e3b3a2e0288|5|SPLNRESP|Spleen Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|AMPULE|CYTOGENETIC CR|1|U/mmol|PERCUSSION||Y||FAMILY MEMBER|READER|NA|3|Visit_3|40|4|TREATMENT|2020-06-28|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-20|P1Y2M10DT2H30M|UNKNOWN|2020-07-04|BEFORE|2020-08-22
e|RS|37c59cfa-b952-4d16-a675-5e3b3a2e0288|6|SYMPTDTR|Symptomatic Deterioration|WHO BREAST CANCER 2006|[?]|um|PMR|1|U/mL|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS||||CHILD|NEUROLOGIST|N|3|Visit_3|40|3|FOLLOW-UP|2020-06-28|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-20|P1Y2M10DT2H30M|AFTER|2020-08-02|AFTER|2020-08-20
e|RS|37c59cfa-b952-4d16-a675-5e3b3a2e0288|7|SFTSRESP|Soft Tissue Response|IWG CHESON MDS 2006|[?]|g/cm2|RELAPSED DISEASE FROM CR|1|%/min|FLAME PHOTOMETRY||Y||CLINICAL STUDY SPONSOR|CARDIOLOGIST|Y|4|Visit_4|65|7|TREATMENT|2020-07-23|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-26|P1Y2M10DT2H30M|COINCIDENT|2020-06-17|AFTER|2020-07-16
e|RS|37c59cfa-b952-4d16-a675-5e3b3a2e0288|8|CPRFSTAT|Clinical Performance Status|MRECIST BYRNE MESOTHELIOMA 2004|||MORPHOLOGIC CRi|1|mL/mmHg|ELECTROCHEMILUMINESCENCE|||Y|GUARDIAN|ADJUDICATOR 1|Y|4|Visit_4|65|1|SCREENING|2020-07-23|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-26|P1Y2M10DT2H30M|BEFORE|2020-06-16|AFTER|2020-07-27
e|RS|37c59cfa-b952-4d16-a675-5e3b3a2e0288|9|ANATRESP|Anatomic Response|CHOI GIST 2008|||mCR|1|mL/g/day|MANUAL COUNT|Y|Y|Y|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 1|U|5|Visit_5|90|3|TREATMENT|2020-08-17|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-18|P1Y2M10DT2H30M|COINCIDENT|2020-08-22|AFTER|2020-08-23
e|RS|37c59cfa-b952-4d16-a675-5e3b3a2e0288|10|TMRESP|Tumor Marker Response|PRINCE TCELL LYMPHOMA 2010|[?]|JDF Unit|VGPR|1|L/s/kPa|ACRIDINE ORANGE STAIN|Y|||ADJUDICATION COMMITTEE|DEVELOPMENTAL PSYCHOLOGIST|Y|5|Visit_5|90|4|SCREENING|2020-08-17|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-18|P1Y2M10DT2H30M|UNKNOWN|2020-06-19|ONGOING|2020-07-24
e|RS|11130b2c-e9fd-4a50-87ee-5dfa19199eba|1|CLINRESP|Clinical Response|MASS|[?]|ELISA unit/mL|NON-iCR/NON-iUPD|1|pmol/10^10 cells|SLOAN LETTER EYE CHART 100%|Y|Y||DOMESTIC PARTNER|READER|N|1|Visit_1|10|7|TREATMENT|2020-12-03|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-14|P1Y2M10DT2H30M|AFTER|2021-01-09|AFTER|2021-02-05
e|RS|11130b2c-e9fd-4a50-87ee-5dfa19199eba|2|BMIVLIND|Bone Marrow Involvement Indicator|RECIST 1.1|||pCR|1|MBq/uL|PALM METHOD|||Y|INDEPENDENT ASSESSOR|PATHOLOGIST 2|U|1|Visit_1|10|7|TREATMENT|2020-12-03|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-14|P1Y2M10DT2H30M|AFTER|2020-12-13|COINCIDENT|2020-12-29
e|RS|11130b2c-e9fd-4a50-87ee-5dfa19199eba|3|NTNERESP|Non-Target Non-Enhancing Response|BLAZER COLORECTAL CANCER 2008|||MRD RELAPSE|1|mL/cm H2O|STATIC PERIMETRY||Y|Y|INVESTIGATOR|READER 3|NA|2|Visit_2|25|5|TREATMENT|2020-12-18|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-01|P1Y2M10DT2H30M|COINCIDENT|2020-12-06|COINCIDENT|2021-01-21
e|RS|11130b2c-e9fd-4a50-87ee-5dfa19199eba|4|MRDIND|Minimal Residual Disease Indicator|JACINTO CERVICAL CANCER 2007|[?]|deg|NON-PD|1|KIT|MUGA||||STUDY SUBJECT|PHYSIOTHERAPIST|N|2|Visit_2|25|1|TREATMENT|2020-12-18|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-01|P1Y2M10DT2H30M|COINCIDENT|2020-12-31|ONGOING|2021-02-27
e|RS|11130b2c-e9fd-4a50-87ee-5dfa19199eba|5|SPLNRESP|Spleen Response|IWG CHESON AML 2003|[?]|/min|PD|1|mU|MICROBIAL CULTURE|Y|Y||ADJUDICATION COMMITTEE|ONCOLOGIST 2|U|3|Visit_3|40|4|TREATMENT|2021-01-02|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-14|P1Y2M10DT2H30M|AFTER|2020-12-06|AFTER|2021-02-16
e|RS|11130b2c-e9fd-4a50-87ee-5dfa19199eba|6|NEWLIND|New Lesion Indicator|IWG CHESON MDS 2000|[?]|10^6 organisms/mL|ABSENT MORPHOLOGIC RESPONSE|1|titer|CAPILLARY ELECTROPHORESIS|Y|Y||ADJUDICATION COMMITTEE|ADJUDICATOR 1|U|3|Visit_3|40|7|TREATMENT|2021-01-02|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-14|P1Y2M10DT2H30M|BEFORE|2021-02-04|ONGOING|2021-02-23
e|RS|11130b2c-e9fd-4a50-87ee-5dfa19199eba|7|MOLRESP|Molecular Response|DOHNER AML 2010|||VGPR|1|IU/mmol|GRADIENT DIFFUSION|||Y|SIGNIFICANT OTHER|CARDIOLOGIST|Y|4|Visit_4|65|3|FOLLOW-UP|2021-01-27|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-03|P1Y2M10DT2H30M|UNKNOWN|2020-12-30|ONGOING|2021-02-26
e|RS|11130b2c-e9fd-4a50-87ee-5dfa19199eba|8|PATHRESP|Pathologic Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|mL/m2/h|cPR|1|min|NUCLEIC ACID BASED METHOD|Y|Y||SPOUSE|READER 3|N|4|Visit_4|65|3|TREATMENT|2021-01-27|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-03|P1Y2M10DT2H30M|UNKNOWN|2021-02-04|ONGOING|2021-02-22
e|RS|11130b2c-e9fd-4a50-87ee-5dfa19199eba|9|DRCRIND|Disease Recurrence Indicator|SCHER PROSTATE CANCER 2011|[?]|ppb|IMMUNOPHENOTYPIC CR|1|U|QUANTITATIVE CORONARY ANGIOGRAPHY||||INVESTIGATOR|MICROSCOPIST 1|Y|5|Visit_5|90|1|FOLLOW-UP|2021-02-21|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-16|P1Y2M10DT2H30M|UNKNOWN|2021-02-04|BEFORE|2021-02-14
e|RS|11130b2c-e9fd-4a50-87ee-5dfa19199eba|10|SFTSRESP|Soft Tissue Response|RANO|[?]|mEq/ug|cPR|1|kBq/uL|PEAK FLOWMETRY||||PARENT|READER 2|NA|5|Visit_5|90|2|FOLLOW-UP|2021-02-21|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-16|P1Y2M10DT2H30M|UNKNOWN|2021-01-03|COINCIDENT|2021-01-14
e|RS|08e4310f-f868-4858-a321-f33a21a771e8|1|TRGRESP|Target Response|PERCIST|[?]|s/h|cPR|1|umol/kg/min|TRIPLE-PHASE SPIRAL CT SCAN||||GUARDIAN|ONCOLOGIST 1|NA|1|Visit_1|10|1|TREATMENT|2020-05-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-22|P1Y2M10DT2H30M|AFTER|2020-05-29|AFTER|2020-06-21
e|RS|08e4310f-f868-4858-a321-f33a21a771e8|2|TMRESP|Tumor Marker Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|SUPPOSITORY|VGPR|1|BAU|HANSEL STAIN||Y||CAREGIVER|ONCOLOGIST 1|Y|1|Visit_1|10|2|TREATMENT|2020-05-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-22|P1Y2M10DT2H30M|AFTER|2020-07-17|COINCIDENT|2020-07-30
e|RS|08e4310f-f868-4858-a321-f33a21a771e8|3|CYTORESP|Cytogenetic Response|DOHNER AML 2010|||UNFAVORABLE RESPONSE|1|U/g/min|SINGLE-MOLECULE ARRAY|||Y|SIGNIFICANT OTHER|READER 1|Y|2|Visit_2|25|7|TREATMENT|2020-05-30|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-14|P1Y2M10DT2H30M|BEFORE|2020-05-23|BEFORE|2020-06-25
e|RS|08e4310f-f868-4858-a321-f33a21a771e8|4|NEWLWIND|New Lesion Worsening Indicator|KUKER LYMPHOMA 2005|[?]|BAR|NOT ALL EVALUATED|1|PFU/mL|MALDI||Y||INTERVIEWER|RADIOLOGIST|N|2|Visit_2|25|1|WASHOUT|2020-05-30|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-14|P1Y2M10DT2H30M|AFTER|2020-06-25|AFTER|2020-07-27
e|RS|08e4310f-f868-4858-a321-f33a21a771e8|5|CPRFSTAT|Clinical Performance Status|DURIE MULTIPLE MYELOMA 2006|[?]|MnFI|ABSENT MORPHOLOGIC RESPONSE|1|Hz|SLOAN LETTER EYE CHART 2.5%||||PARENT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|3|Visit_3|40|4|WASHOUT|2020-06-14|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-09|P1Y2M10DT2H30M|UNKNOWN|2020-06-13|BEFORE|2020-07-09
e|RS|08e4310f-f868-4858-a321-f33a21a771e8|6|SYMPTDTR|Symptomatic Deterioration|MACDONALD GLIOMA 1990|[?]|mL/breath|RELAPSED DISEASE|1|Bq/L|U-HPLC/MS/MS||||PARENT|HEMATOLOGIST|U|3|Visit_3|40|4|TREATMENT|2020-06-14|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-09|P1Y2M10DT2H30M|COINCIDENT|2020-06-14|COINCIDENT|2020-07-31
e|RS|08e4310f-f868-4858-a321-f33a21a771e8|7|BESTRESP|Best Overall Response|PETIT BREAST CANCER 2001|[?]|mEq/day|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|pkat/L|GC/FID||||FAMILY MEMBER|PEDIATRIC NEUROLOGIST|Y|4|Visit_4|65|1|TREATMENT|2020-07-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-21|P1Y2M10DT2H30M|BEFORE|2020-05-25|COINCIDENT|2020-07-30
e|RS|08e4310f-f868-4858-a321-f33a21a771e8|8|CLINRESP|Clinical Response|UNSPECIFIED|[?]|U/m2|PD FROM PR|1|g/cage/wk|FLUORESCENT LIFETIME IMAGING MICROSCOPY||||CLINICAL RESEARCH COORDINATOR|RATER|NA|4|Visit_4|65|6|TREATMENT|2020-07-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-21|P1Y2M10DT2H30M|COINCIDENT|2020-06-30|AFTER|2020-07-22
e|RS|08e4310f-f868-4858-a321-f33a21a771e8|9|METBRESP|Metabolic Response|IRANO 2015|||NR|1|mJoule/cm2|NEXT GENERATION SEQUENCING|Y||Y|PARENT|READER|NA|5|Visit_5|90|7|TREATMENT|2020-08-03|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-14|P1Y2M10DT2H30M|UNKNOWN|2020-07-24|BEFORE|2020-07-26
e|RS|08e4310f-f868-4858-a321-f33a21a771e8|10|ANATRESP|Anatomic Response|DOHNER AML 2010|[?]|mV*min|IMMUNOPHENOTYPIC CR|1|mmol/kg|MICROBIAL CONCENTRATION||Y||PROXY|MICROSCOPIST 3|N|5|Visit_5|90|2|TREATMENT|2020-08-03|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-14|P1Y2M10DT2H30M|COINCIDENT|2020-07-30|ONGOING|2020-08-03
e|RS|29edf133-8b5b-46d5-bf7a-f75af4658417|1|HEMARESP|Hematologic Response|CHOI GIST 2008|||MAJOR PATHOLOGIC RESPONSE|1|nmol BCE/L|PEAK FLOWMETRY|||Y|CLINICAL RESEARCH COORDINATOR|UROLOGIST|N|1|Visit_1|10|4|SCREENING|2020-08-22|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-08|P1Y2M10DT2H30M|COINCIDENT|2020-09-26|COINCIDENT|2020-10-28
e|RS|29edf133-8b5b-46d5-bf7a-f75af4658417|2|HEMARESP|Hematologic Response|iRECIST|[?]|Anson U|PD|1|U/m2/day|NON-CONTACT SPECULAR MICROSCOPY||Y||DOMESTIC PARTNER|CARDIOLOGIST|U|1|Visit_1|10|6|WASHOUT|2020-08-22|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-08|P1Y2M10DT2H30M|COINCIDENT|2020-11-07|AFTER|2020-11-08
e|RS|29edf133-8b5b-46d5-bf7a-f75af4658417|3|CYTORESP|Cytogenetic Response|SHINDOH COLORECTAL CANCER 2013|||mCR|1|hr/day|ENZYMATIC SPECTROPHOTOMETRY|||Y|FRIEND|ADJUDICATOR|Y|2|Visit_2|25|5|TREATMENT|2020-09-06|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-25|P1Y2M10DT2H30M|AFTER|2020-10-04|AFTER|2020-10-29
e|RS|29edf133-8b5b-46d5-bf7a-f75af4658417|4|NTRGRESP|Non-target Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|||RELAPSED DISEASE FROM CR OR PR|1|nmol/L|POPULATION SEQUENCING|||Y|CLINICAL STUDY SPONSOR|UROLOGIST|NA|2|Visit_2|25|1|WASHOUT|2020-09-06|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-25|P1Y2M10DT2H30M|UNKNOWN|2020-10-19|AFTER|2020-10-23
e|RS|29edf133-8b5b-46d5-bf7a-f75af4658417|5|MJPTHIND|Major Pathological Response Indicator|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|ug/kg/min|CYTOGENETIC PR|1|%/min|NUCLEIC ACID BASED METHOD||||DOMESTIC PARTNER|CARDIOLOGIST|U|3|Visit_3|40|3|WASHOUT|2020-09-21|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-26|P1Y2M10DT2H30M|BEFORE|2020-10-21|AFTER|2020-10-26
e|RS|29edf133-8b5b-46d5-bf7a-f75af4658417|6|SYMPTDTR|Symptomatic Deterioration|MURPHY PROSTATE CANCER 1980|[?]|vg/kg|PD-CT|1|deg/s|MULTIPLEXED BEAD BASED IMMUNOASSAY||||DOMESTIC PARTNER|ADJUDICATOR 2|N|3|Visit_3|40|1|FOLLOW-UP|2020-09-21|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-26|P1Y2M10DT2H30M|COINCIDENT|2020-11-19|COINCIDENT|2020-11-20
e|RS|29edf133-8b5b-46d5-bf7a-f75af4658417|7|HEMARESP|Hematologic Response|KEAM BREAST CANCER 2013|||PMR|1|U/g Hb|CALIPER MEASUREMENT METHOD|||Y|SIBLING|PATHOLOGIST 1|Y|4|Visit_4|65|3|TREATMENT|2020-10-16|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-29|P1Y2M10DT2H30M|COINCIDENT|2020-10-10|BEFORE|2020-11-05
e|RS|29edf133-8b5b-46d5-bf7a-f75af4658417|8|MOLRESP|Molecular Response|DOHNER AML 2010|[?]|uV|CYTOGENETIC MINOR RESPONSE|1|cm/min|STATIC PERIMETRY||||CHILD|ONCOLOGIST 2|U|4|Visit_4|65|7|WASHOUT|2020-10-16|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-29|P1Y2M10DT2H30M|COINCIDENT|2020-09-25|AFTER|2020-09-29
e|RS|29edf133-8b5b-46d5-bf7a-f75af4658417|9|BONERESP|Bone Response|HAMAOKA BREAST CANCER 2010|[?]|CONTAINER|iCR|1|ft3|NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY||||GUARDIAN|MICROSCOPIST 3|U|5|Visit_5|90|1|FOLLOW-UP|2020-11-10|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-18|P1Y2M10DT2H30M|COINCIDENT|2020-09-20|AFTER|2020-11-14
e|RS|29edf133-8b5b-46d5-bf7a-f75af4658417|10|BONERESP|Bone Response|LUGANO CLASSIFICATION|||FAVORABLE RESPONSE|1|Ejaculate U|MANUAL CLOT DETECTION||Y|Y|FRIEND|ENDOCRINOLOGIST|N|5|Visit_5|90|2|FOLLOW-UP|2020-11-10|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-18|P1Y2M10DT2H30M|BEFORE|2020-08-18|AFTER|2020-11-18
e|RS|49756233-e18f-4187-8d48-3b6b4fa7e5c2|1|ANATRESP|Anatomic Response|KUKER LYMPHOMA 2005|[?]|h*%|INDETERMINATE RESPONSE|1|mg/animal|IMMUNOPRECIPITATION|Y|||SIBLING|NEUROLOGIST 1|NA|1|Visit_1|10|1|FOLLOW-UP|2020-08-09|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-12|P1Y2M10DT2H30M|BEFORE|2020-10-12|ONGOING|2020-10-18
e|RS|49756233-e18f-4187-8d48-3b6b4fa7e5c2|2|SFTSRESP|Soft Tissue Response|BURCOMBE BREAST CANCER 2005|[?]|/5x10^4 WBC|SMD|1|10^6 copies/mL|NEPHELOMETRY|Y|||INVESTIGATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|1|Visit_1|10|4|TREATMENT|2020-08-09|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-12|P1Y2M10DT2H30M|COINCIDENT|2020-09-23|COINCIDENT|2020-09-24
e|RS|49756233-e18f-4187-8d48-3b6b4fa7e5c2|3|NEWLIND|New Lesion Indicator|WOLCHOK SOLID TUMORS 2009|[?]|days/month|sCR|1|BP|POLYGRAPHY||||CLINICAL RESEARCH COORDINATOR|OTOLARYNGOLOGIST|NA|2|Visit_2|25|2|WASHOUT|2020-08-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-10|P1Y2M10DT2H30M|UNKNOWN|2020-09-06|BEFORE|2020-09-19
e|RS|49756233-e18f-4187-8d48-3b6b4fa7e5c2|4|MJPTHIND|Major Pathological Response Indicator|PCWG BUBLEY PROSTATE CANCER 1999|[?]|g/g|EQUIVOCAL|1|sec|WESTERGREN||||CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST|N|2|Visit_2|25|5|TREATMENT|2020-08-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-10|P1Y2M10DT2H30M|BEFORE|2020-08-20|BEFORE|2020-09-27
e|RS|49756233-e18f-4187-8d48-3b6b4fa7e5c2|5|BESTRESP|Best Overall Response|AJCC V7|[?]|STRIP|SD|1|10^6/g|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY|Y|||CLINICAL STUDY SPONSOR|OTOLARYNGOLOGIST|N|3|Visit_3|40|7|SCREENING|2020-09-08|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-19|P1Y2M10DT2H30M|UNKNOWN|2020-10-17|AFTER|2020-11-02
e|RS|49756233-e18f-4187-8d48-3b6b4fa7e5c2|6|NEWLWIND|New Lesion Worsening Indicator|RAJKUMAR MYELOMA 2011|||PR|1|mmol/day|DISK DIFFUSION|||Y|INVESTIGATOR|RADIOLOGIST 1|Y|3|Visit_3|40|3|TREATMENT|2020-09-08|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-19|P1Y2M10DT2H30M|COINCIDENT|2020-09-02|ONGOING|2020-10-22
e|RS|49756233-e18f-4187-8d48-3b6b4fa7e5c2|7|TRGRESP|Target Response|RAJKUMAR MYELOMA 2011|||CYTOGENETIC MINOR RESPONSE|1|anti-Xa IU|GC/MS|||Y|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST|NA|4|Visit_4|65|6|FOLLOW-UP|2020-10-03|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-14|P1Y2M10DT2H30M|AFTER|2020-09-14|COINCIDENT|2020-11-01
e|RS|49756233-e18f-4187-8d48-3b6b4fa7e5c2|8|SPLNRESP|Spleen Response|KUMAR IMWG 2016|||IMMUNOPHENOTYPIC CR|1|days/month|MICRONEUTRALIZATION ASSAY|||Y|HEALTH CARE PROFESSIONAL|READER 1|NA|4|Visit_4|65|1|SCREENING|2020-10-03|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-14|P1Y2M10DT2H30M|COINCIDENT|2020-10-04|ONGOING|2020-11-04
e|RS|49756233-e18f-4187-8d48-3b6b4fa7e5c2|9|MJPTHIND|Major Pathological Response Indicator|SCHWARZ CERVICAL CANCER 2009|||ABSENT MORPHOLOGIC RESPONSE|1|uL/kg/day|ELECTROCHEMILUMINESCENCE IMMUNOASSAY||Y|Y|SIGNIFICANT OTHER|NEUROLOGIST|Y|5|Visit_5|90|5|TREATMENT|2020-10-28|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-13|P1Y2M10DT2H30M|BEFORE|2020-09-04|ONGOING|2020-10-16
e|RS|49756233-e18f-4187-8d48-3b6b4fa7e5c2|10|LIVRRESP|Liver Response|MRECIST BYRNE MESOTHELIOMA 2004|||iCPD|1|F|SPECT/CT SCAN||Y|Y|INTERVIEWER|READER 3|NA|5|Visit_5|90|6|WASHOUT|2020-10-28|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-13|P1Y2M10DT2H30M|UNKNOWN|2020-09-08|ONGOING|2020-09-10
e|RS|7a046104-7215-4708-9d85-66683ceb8fe8|1|SFTSRESP|Soft Tissue Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|||PARTIAL MORPHOLOGIC RESPONSE|1|EVENTS|HILLMEN COLOR CHART|||Y|ADJUDICATOR|INTERNIST|Y|1|Visit_1|10|2|TREATMENT|2020-10-16|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-15|P1Y2M10DT2H30M|BEFORE|2020-10-17|BEFORE|2020-12-13
e|RS|7a046104-7215-4708-9d85-66683ceb8fe8|2|BONERESP|Bone Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|||CYTOGENETIC MINIMAL RESPONSE|1|mg/mL/min|WRIGHT-GIEMSA STAIN|Y||Y|PARENT|NEUROLOGIST|U|1|Visit_1|10|7|TREATMENT|2020-10-16|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-15|P1Y2M10DT2H30M|UNKNOWN|2020-10-29|ONGOING|2020-12-10
e|RS|7a046104-7215-4708-9d85-66683ceb8fe8|3|SPLNRESP|Spleen Response|KUKER LYMPHOMA 2005|[?]|g/m2|MORPHOLOGIC CRi|1|foz_us|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY|Y|||INVESTIGATOR|READER 2|Y|2|Visit_2|25|7|TREATMENT|2020-10-31|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-16|P1Y2M10DT2H30M|UNKNOWN|2020-12-21|COINCIDENT|2021-01-09
e|RS|7a046104-7215-4708-9d85-66683ceb8fe8|4|NTRGRESP|Non-target Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|uL/kg/day|MORPHOLOGIC CR|1|Gauss|PERIPHERAL ANGIOGRAPHY|Y|||ADJUDICATION COMMITTEE|ADJUDICATOR 2|N|2|Visit_2|25|1|WASHOUT|2020-10-31|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-16|P1Y2M10DT2H30M|UNKNOWN|2020-11-13|BEFORE|2020-12-24
e|RS|7a046104-7215-4708-9d85-66683ceb8fe8|5|TRGRESP|Target Response|CHESON CLL 2012|[?]|kg/m2|ABSENT MORPHOLOGIC RESPONSE|1|mg/mL/day|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION||Y||FAMILY MEMBER|ADJUDICATOR 2|U|3|Visit_3|40|7|TREATMENT|2020-11-15|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-29|P1Y2M10DT2H30M|BEFORE|2020-10-18|COINCIDENT|2020-11-26
e|RS|7a046104-7215-4708-9d85-66683ceb8fe8|6|METSIND|Metastatic Indicator|EASL BRUIX LIVER CANCER 2001|||MRD RELAPSE|1|s^-1(%O2)^-1|WRIGHT STAIN||Y|Y|DOMESTIC PARTNER|RADIOLOGIST|U|3|Visit_3|40|2|TREATMENT|2020-11-15|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-29|P1Y2M10DT2H30M|UNKNOWN|2021-01-09|BEFORE|2021-01-11
e|RS|7a046104-7215-4708-9d85-66683ceb8fe8|7|MRPHRESP|Morphologic Response|EASL BRUIX LIVER CANCER 2001|[?]|umol/mol|iCR|1|MET*min|POTENTIOMETRY|Y|||ADJUDICATION COMMITTEE|ADJUDICATOR|U|4|Visit_4|65|1|SCREENING|2020-12-10|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-09|P1Y2M10DT2H30M|COINCIDENT|2021-01-12|BEFORE|2021-01-13
e|RS|7a046104-7215-4708-9d85-66683ceb8fe8|8|METBRESP|Metabolic Response|AJCC V7|||PD/RELAPSE AFTER HI|1|fmol/g|PALPATION|||Y|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST|U|4|Visit_4|65|7|WASHOUT|2020-12-10|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-09|P1Y2M10DT2H30M|COINCIDENT|2020-12-13|BEFORE|2020-12-21
e|RS|7a046104-7215-4708-9d85-66683ceb8fe8|9|MOLRESP|Molecular Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|10^6 IU/mL|FAVORABLE RESPONSE|1|Enzyme U/L|THERMAL IONIZATION MASS SPECTROMETRY||||CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL PSYCHOLOGIST|NA|5|Visit_5|90|5|TREATMENT|2021-01-04|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-29|P1Y2M10DT2H30M|AFTER|2020-12-02|BEFORE|2020-12-23
e|RS|7a046104-7215-4708-9d85-66683ceb8fe8|10|HEMARESP|Hematologic Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|tuberculin unit/mL|IMPROVED|1|PFU|FLUORESCENT MICROSCOPY||||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 3|NA|5|Visit_5|90|1|SCREENING|2021-01-04|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-29|P1Y2M10DT2H30M|AFTER|2021-01-08|COINCIDENT|2021-01-12
e|RS|6a22373a-8b46-4b5a-94b2-fee3bcd59dda|1|MJPTHIND|Major Pathological Response Indicator|GUILHOT CML 2007|[?]|nmol/L/min|SD-CT|1|ELISA unit|GC/MS-EI||||INVESTIGATOR|RATER 1|Y|1|Visit_1|10|7|TREATMENT|2021-01-26|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-07|P1Y2M10DT2H30M|COINCIDENT|2021-02-05|COINCIDENT|2021-02-25
e|RS|6a22373a-8b46-4b5a-94b2-fee3bcd59dda|2|TRGRESP|Target Response|IWG CHESON AML 2003|||NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|PIPE|REVERSE TRANSCRIPTASE PCR|||Y|NON-HEALTH CARE PROFESSIONAL|INTERNIST|NA|1|Visit_1|10|2|SCREENING|2021-01-26|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-07|P1Y2M10DT2H30M|UNKNOWN|2021-02-19|BEFORE|2021-02-28
e|RS|6a22373a-8b46-4b5a-94b2-fee3bcd59dda|3|SYMPTDTR|Symptomatic Deterioration|RANO ELLINGSON 2017|[?]|uU/dL|INCREASED|1|CYLINDER|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE||||PROXY|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|2|Visit_2|25|7|FOLLOW-UP|2021-02-10|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-03|P1Y2M10DT2H30M|COINCIDENT|2021-03-07|COINCIDENT|2021-04-16
e|RS|6a22373a-8b46-4b5a-94b2-fee3bcd59dda|4|OVRLRESP|Overall Response|BLAZER COLORECTAL CANCER 2008|||CYTOGENETIC PR|1|10^12 IU/L|LISSAMINE GREEN STAIN||Y|Y|INVESTIGATOR|RATER|NA|2|Visit_2|25|2|TREATMENT|2021-02-10|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-03|P1Y2M10DT2H30M|BEFORE|2021-01-25|BEFORE|2021-02-03
e|RS|6a22373a-8b46-4b5a-94b2-fee3bcd59dda|5|BESTRESP|Best Overall Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|dpm/0.5 mL|FAVORABLE RESPONSE|1|/kg|PLAQUE REDUCTION NEUTRALIZATION ASSAY||Y||CLINICAL RESEARCH ASSOCIATE|RATER 2|U|3|Visit_3|40|7|TREATMENT|2021-02-25|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-30|P1Y2M10DT2H30M|UNKNOWN|2021-01-30|BEFORE|2021-02-22
e|RS|6a22373a-8b46-4b5a-94b2-fee3bcd59dda|6|CYTORESP|Cytogenetic Response|RECIST 1.1|[?]|dpm/100mg|iUPD|1|U/g/h|WRIGHT-GIEMSA STAIN||Y||SPOUSE|ADJUDICATOR 3|NA|3|Visit_3|40|4|FOLLOW-UP|2021-02-25|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-30|P1Y2M10DT2H30M|COINCIDENT|2021-03-07|ONGOING|2021-04-06
e|RS|6a22373a-8b46-4b5a-94b2-fee3bcd59dda|7|DRCRIND|Disease Recurrence Indicator|GCIG RUSTIN OVARIAN CANCER 2011|[?]|MPS U|QUANTIFIABLE MRD POSITIVITY|1|uU/L|SPECT/CT SCAN|Y|||CHILD|RADIOLOGIST|U|4|Visit_4|65|3|TREATMENT|2021-03-22|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-21|P1Y2M10DT2H30M|COINCIDENT|2021-03-15|AFTER|2021-03-23
e|RS|6a22373a-8b46-4b5a-94b2-fee3bcd59dda|8|OVRLRESP|Overall Response|UNSPECIFIED|[?]|eq|EQUIVOCAL|1|umol/day|DOPPLER ULTRASOUND|Y|||INVESTIGATOR|OTOLARYNGOLOGIST|U|4|Visit_4|65|5|TREATMENT|2021-03-22|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-21|P1Y2M10DT2H30M|AFTER|2021-04-24|BEFORE|2021-04-25
e|RS|6a22373a-8b46-4b5a-94b2-fee3bcd59dda|9|STRUSTAT|Steroid Use Status|RANO ELLINGSON 2017|[?]|umol|PSA PROGRESSION|1|uV|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|Y|Y||CLINICAL RESEARCH COORDINATOR|PATHOLOGIST|N|5|Visit_5|90|4|FOLLOW-UP|2021-04-16|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-28|P1Y2M10DT2H30M|COINCIDENT|2021-01-26|COINCIDENT|2021-02-06
e|RS|6a22373a-8b46-4b5a-94b2-fee3bcd59dda|10|NTNERESP|Non-Target Non-Enhancing Response|SCHER PROSTATE CANCER 2011|[?]|TCID 50/dose|iCPD|1|log10 CCID 50/dose|DIGITAL PCR ARRAY||Y||CLINICAL STUDY SPONSOR|ONCOLOGIST 2|NA|5|Visit_5|90|1|TREATMENT|2021-04-16|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-28|P1Y2M10DT2H30M|AFTER|2021-04-12|ONGOING|2021-04-18
e|RS|bcbe7d50-2ebe-483a-9d71-dce4094f864e|1|MRPHRESP|Morphologic Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|mg/h|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|DISK|CONTRAST ENHANCED SPIRAL CT SCAN|Y|||GUARDIAN|INTERNIST|U|1|Visit_1|10|6|TREATMENT|2020-05-25|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-21|P1Y2M10DT2H30M|COINCIDENT|2020-06-18|AFTER|2020-07-06
e|RS|bcbe7d50-2ebe-483a-9d71-dce4094f864e|2|ANATRESP|Anatomic Response|BLAZER COLORECTAL CANCER 2008|[?]|mEq/day|PD/RELAPSE AFTER HI|1|amu|FLOCCULATION, CHARCOAL ENHANCED||||NON-HEALTH CARE PROFESSIONAL|READER 1|U|1|Visit_1|10|2|TREATMENT|2020-05-25|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-21|P1Y2M10DT2H30M|BEFORE|2020-05-26|COINCIDENT|2020-06-14
e|RS|bcbe7d50-2ebe-483a-9d71-dce4094f864e|3|NEWLIND|New Lesion Indicator|MURPHY PROSTATE CANCER 1980|||SD-CT|1|ug/L DDU|ALCIAN BLUE STAIN||Y|Y|FAMILY MEMBER|PEDIATRIC NEUROLOGIST|U|2|Visit_2|25|6|WASHOUT|2020-06-09|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-08|P1Y2M10DT2H30M|BEFORE|2020-07-06|AFTER|2020-07-23
e|RS|bcbe7d50-2ebe-483a-9d71-dce4094f864e|4|MRDRESP|Minimal Residual Disease Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|HEP|HI-N|1|uU/L|PH METER MEASUREMENT METHOD||Y||CHILD|PATHOLOGIST|NA|2|Visit_2|25|2|TREATMENT|2020-06-09|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-08|P1Y2M10DT2H30M|COINCIDENT|2020-06-04|COINCIDENT|2020-07-22
e|RS|bcbe7d50-2ebe-483a-9d71-dce4094f864e|5|BONERESP|Bone Response|LUGANO CLASSIFICATION|[?]|/2000 RBC|CYTOGENETIC PR|1|GPS U|PANENDOSCOPY|Y|||GUARDIAN|FORENSIC PATHOLOGIST|U|3|Visit_3|40|3|SCREENING|2020-06-24|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-08|P1Y2M10DT2H30M|UNKNOWN|2020-08-18|BEFORE|2020-08-22
e|RS|bcbe7d50-2ebe-483a-9d71-dce4094f864e|6|NTNERESP|Non-Target Non-Enhancing Response|CHESON CLL 2012|[?]|/h|RELAPSED DISEASE FROM CR|1|10^6 copies/mL|ACRIDINE ORANGE STAIN||||SIGNIFICANT OTHER|READER 3|Y|3|Visit_3|40|4|WASHOUT|2020-06-24|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-08|P1Y2M10DT2H30M|COINCIDENT|2020-05-23|BEFORE|2020-07-14
e|RS|bcbe7d50-2ebe-483a-9d71-dce4094f864e|7|DRCRIND|Disease Recurrence Indicator|PCWG SCHER PROSTATE CANCER 2016|[?]|SFC/10^6 PBMC|QUANTIFIABLE MRD POSITIVITY|1|uV*sec|EPSILOMETER||||ADJUDICATOR|MICROSCOPIST 1|N|4|Visit_4|65|4|SCREENING|2020-07-19|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-22|P1Y2M10DT2H30M|BEFORE|2020-07-10|ONGOING|2020-08-06
e|RS|bcbe7d50-2ebe-483a-9d71-dce4094f864e|8|CYTORESP|Cytogenetic Response|KUMAR IMWG 2016|[?]|EID 50/mL|STABLE|1|VIRTUAL PIXEL|MRS||||GUARDIAN|ADJUDICATOR 1|N|4|Visit_4|65|1|FOLLOW-UP|2020-07-19|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-22|P1Y2M10DT2H30M|UNKNOWN|2020-07-07|AFTER|2020-08-13
e|RS|bcbe7d50-2ebe-483a-9d71-dce4094f864e|9|DRCRIND|Disease Recurrence Indicator|BRUGGEMANN MRD 2010|[?]|mOsm/L|NOT ALL EVALUATED|1|KALLIKREIN INHIBITOR UNIT|CYSTOSCOPY||||VENDOR|READER 1|N|5|Visit_5|90|1|TREATMENT|2020-08-13|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-14|P1Y2M10DT2H30M|COINCIDENT|2020-05-22|AFTER|2020-05-28
e|RS|bcbe7d50-2ebe-483a-9d71-dce4094f864e|10|CPRFSTAT|Clinical Performance Status|PCWG SCHER PROSTATE CANCER 2016|||MRD PERSISTENCE|1|F|ERGOSPIROMETRY||Y|Y|INTERVIEWER|ADJUDICATOR 2|U|5|Visit_5|90|6|TREATMENT|2020-08-13|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-14|P1Y2M10DT2H30M|BEFORE|2020-08-21|AFTER|2020-08-22
e|RS|2550ba24-7bcf-41e2-9eae-536e13d4b345|1|CYTORESP|Cytogenetic Response|IWC HALLEK CLL 2008|[?]|uCi/L|MORPHOLOGIC CRi|1|mL/g/min|NEXT GENERATION TARGETED SEQUENCING||||ADJUDICATION COMMITTEE|ONCOLOGIST|N|1|Visit_1|10|3|TREATMENT|2021-01-20|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-17|P1Y2M10DT2H30M|AFTER|2021-03-10|ONGOING|2021-04-05
e|RS|2550ba24-7bcf-41e2-9eae-536e13d4b345|2|NTERESP|Non-Target Enhancing Response|HARTMAN PANCREATIC CANCER 2012|||PMR|1|mg/kg/h|WHOLE TRANSCRIPTOME SEQUENCING|Y||Y|DOMESTIC PARTNER|PATHOLOGIST|N|1|Visit_1|10|4|TREATMENT|2021-01-20|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-17|P1Y2M10DT2H30M|AFTER|2021-01-27|BEFORE|2021-03-03
e|RS|2550ba24-7bcf-41e2-9eae-536e13d4b345|3|NEWLWIND|New Lesion Worsening Indicator|CHOLLET BREAST CANCER 2002|[?]|kg/cm2|DECREASED|1|L/L|CONTRAST ENHANCED PET/CT SCAN||||FRIEND|CLINICAL PATHOLOGIST|N|2|Visit_2|25|4|FOLLOW-UP|2021-02-04|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-24|P1Y2M10DT2H30M|BEFORE|2021-03-18|ONGOING|2021-03-22
e|RS|2550ba24-7bcf-41e2-9eae-536e13d4b345|4|TRGRESP|Target Response|NCCN ALL MRD 2014|[?]|pkat/L|CYTOGENETIC CR|1|in|STRESS ECHOCARDIOGRAPHY||||INVESTIGATOR|MICROSCOPIST 2|N|2|Visit_2|25|6|TREATMENT|2021-02-04|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-24|P1Y2M10DT2H30M|BEFORE|2021-04-07|BEFORE|2021-04-09
e|RS|2550ba24-7bcf-41e2-9eae-536e13d4b345|5|MOLRESP|Molecular Response|BLAZER COLORECTAL CANCER 2008|[?]|sec|HI-E|1|tsp eq|GC/FID||Y||SIBLING|MICROSCOPIST 1|NA|3|Visit_3|40|1|TREATMENT|2021-02-19|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-16|P1Y2M10DT2H30M|UNKNOWN|2021-02-28|BEFORE|2021-04-03
e|RS|2550ba24-7bcf-41e2-9eae-536e13d4b345|6|NTERESP|Non-Target Enhancing Response|NCIWG CHESON CLL 1996|||NOT ALL EVALUATED|1|kN/cm2|CLOT DETECTION|||Y|ADJUDICATION COMMITTEE|OPTOMETRIST|N|3|Visit_3|40|5|TREATMENT|2021-02-19|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-16|P1Y2M10DT2H30M|COINCIDENT|2021-04-18|ONGOING|2021-04-19
e|RS|2550ba24-7bcf-41e2-9eae-536e13d4b345|7|MRDIND|Minimal Residual Disease Indicator|KUKER LYMPHOMA 2005|||SD-CT|1|nkat/L|PHOROPTER|||Y|CLINICAL RESEARCH COORDINATOR|OTOLARYNGOLOGIST|NA|4|Visit_4|65|1|SCREENING|2021-03-16|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-11|P1Y2M10DT2H30M|COINCIDENT|2021-01-22|AFTER|2021-03-29
e|RS|2550ba24-7bcf-41e2-9eae-536e13d4b345|8|SFTSRESP|Soft Tissue Response|RECIST 1.0|||HI-P|1|EID 50/dose|ECHOCARDIOGRAPHY|||Y|INDEPENDENT ASSESSOR|INTERNIST|N|4|Visit_4|65|3|SCREENING|2021-03-16|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-11|P1Y2M10DT2H30M|AFTER|2021-01-16|COINCIDENT|2021-03-11
e|RS|2550ba24-7bcf-41e2-9eae-536e13d4b345|9|TRGRESP|Target Response|MRANO VAN DEN BENT GLIOMA 2011|||CR|1|ug/g/h|DNA MICROARRAY|Y||Y|HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|Y|5|Visit_5|90|3|WASHOUT|2021-04-10|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-05|P1Y2M10DT2H30M|AFTER|2021-02-08|ONGOING|2021-04-12
e|RS|2550ba24-7bcf-41e2-9eae-536e13d4b345|10|CPRFSTAT|Clinical Performance Status|AJCC V8|||PDu|1|APPLICATION|CYSTOSCOPY|Y||Y|INDEPENDENT ASSESSOR|RATER 1|N|5|Visit_5|90|1|TREATMENT|2021-04-10|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-05|P1Y2M10DT2H30M|COINCIDENT|2021-01-20|BEFORE|2021-03-30
e|RS|aeec3c61-c825-482e-b77e-a9b8e0bb1f68|1|BMIVLIND|Bone Marrow Involvement Indicator|MRANO VAN DEN BENT GLIOMA 2011|[?]|mg/kg/day|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|BP|SLIT LAMP PHOTOGRAPHY|Y|Y||FRIEND|ONCOLOGIST 1|U|1|Visit_1|10|1|SCREENING|2020-08-14|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-04|P1Y2M10DT2H30M|BEFORE|2020-08-20|BEFORE|2020-10-11
e|RS|aeec3c61-c825-482e-b77e-a9b8e0bb1f68|2|DRCRIND|Disease Recurrence Indicator|WOLCHOK SOLID TUMORS 2009|||RELAPSED DISEASE FROM CR OR PR|1|g/m2|ZIEHL NEELSEN ACID FAST STAIN|||Y|VENDOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|1|Visit_1|10|4|SCREENING|2020-08-14|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-04|P1Y2M10DT2H30M|AFTER|2020-10-27|COINCIDENT|2020-10-28
e|RS|aeec3c61-c825-482e-b77e-a9b8e0bb1f68|3|HEMARESP|Hematologic Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|/MBP|NON-CR/NON-PD|1|ag|CLAUSS METHOD|Y|Y||ADJUDICATION COMMITTEE|MICROSCOPIST 3|NA|2|Visit_2|25|5|FOLLOW-UP|2020-08-29|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-10|P1Y2M10DT2H30M|BEFORE|2020-08-27|COINCIDENT|2020-09-04
e|RS|aeec3c61-c825-482e-b77e-a9b8e0bb1f68|4|NTNERESP|Non-Target Non-Enhancing Response|SCHWARZ CERVICAL CANCER 2009|[?]|vp/mL|NON-PD|1|GBq/g|THICK SMEAR||||INVESTIGATOR|RADIOLOGIST 2|NA|2|Visit_2|25|7|TREATMENT|2020-08-29|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-10|P1Y2M10DT2H30M|BEFORE|2020-09-21|COINCIDENT|2020-10-14
e|RS|aeec3c61-c825-482e-b77e-a9b8e0bb1f68|5|MRDRESP|Minimal Residual Disease Response|IWG CHESON MDS 2000|[?]|aMFI|NR|1|ug/m2/min|FLUORESCENCE ANGIOGRAPHY||||GUARDIAN|MICROSCOPIST 3|Y|3|Visit_3|40|2|TREATMENT|2020-09-13|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-12|P1Y2M10DT2H30M|BEFORE|2020-09-11|BEFORE|2020-09-30
e|RS|aeec3c61-c825-482e-b77e-a9b8e0bb1f68|6|TMRESP|Tumor Marker Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|genEq|SD|1|mm|KINETIC CHROMOGENIC ASSAY||Y||PROXY|CARDIOLOGIST|N|3|Visit_3|40|7|WASHOUT|2020-09-13|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-12|P1Y2M10DT2H30M|COINCIDENT|2020-08-21|COINCIDENT|2020-11-11
e|RS|aeec3c61-c825-482e-b77e-a9b8e0bb1f68|7|HEMARESP|Hematologic Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|ug/h|pCR|1|CCID 50/mL|ENDOSCOPY||||CAREGIVER|NEUROLOGIST 1|U|4|Visit_4|65|1|TREATMENT|2020-10-08|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-29|P1Y2M10DT2H30M|AFTER|2020-11-02|COINCIDENT|2020-11-11
e|RS|aeec3c61-c825-482e-b77e-a9b8e0bb1f68|8|NTLWIND|Non-Target Lesion Worsening Indicator|MRECIST LENCIONI LIVER CANCER 2010|[?]|Ci/mL|PR WITH LYMPHOCYTOSIS|1|10^3 organisms/g|NUCLEIC ACID BASED METHOD||||CLINICAL STUDY SPONSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|4|Visit_4|65|5|TREATMENT|2020-10-08|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-29|P1Y2M10DT2H30M|AFTER|2020-10-24|BEFORE|2020-10-29
e|RS|aeec3c61-c825-482e-b77e-a9b8e0bb1f68|9|BESTRESP|Best Overall Response|SACT|[?]|Enzyme U/L|pCR|1|Enzyme U/m2|CARDIAC THERMODILUTION|Y|Y||SIGNIFICANT OTHER|OTOLARYNGOLOGIST|Y|5|Visit_5|90|4|TREATMENT|2020-11-02|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-23|P1Y2M10DT2H30M|AFTER|2020-09-11|AFTER|2020-10-20
e|RS|aeec3c61-c825-482e-b77e-a9b8e0bb1f68|10|ANATRESP|Anatomic Response|IWC HALLEK CLL 2008|[?]|mU/g|CYTOGENETIC CR|1|km/h|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|Y|||HEALTH CARE PROFESSIONAL|NEUROLOGIST|NA|5|Visit_5|90|3|SCREENING|2020-11-02|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-23|P1Y2M10DT2H30M|AFTER|2020-09-03|ONGOING|2020-10-07
e|RS|6ec23671-252e-4dc9-b919-88254fce68a5|1|MJPTHIND|Major Pathological Response Indicator|MRECIST LENCIONI LIVER CANCER 2010|||PR|1|/LSQN|SPECT/CT SCAN|||Y|INDEPENDENT ASSESSOR|RADIOLOGIST|NA|1|Visit_1|10|3|WASHOUT|2020-07-28|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-14|P1Y2M10DT2H30M|AFTER|2020-08-25|BEFORE|2020-09-18
e|RS|6ec23671-252e-4dc9-b919-88254fce68a5|2|PATHRESP|Pathologic Response|EBMT BLADE MYELOMA 1998|[?]|/MBP|PSA PROGRESSION|1|cy/cm|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN||||INDEPENDENT ASSESSOR|OPTOMETRIST|Y|1|Visit_1|10|6|TREATMENT|2020-07-28|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-14|P1Y2M10DT2H30M|AFTER|2020-09-27|BEFORE|2020-10-12
e|RS|6ec23671-252e-4dc9-b919-88254fce68a5|3|MNPTHIND|Minor Pathological Response Indicator|BURCOMBE BREAST CANCER 2005|||MRD RELAPSE|1|ug/L|CELLULOSE TAPE|Y|Y|Y|SIBLING|OPHTHALMOLOGIST|Y|2|Visit_2|25|3|WASHOUT|2020-08-12|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-20|P1Y2M10DT2H30M|AFTER|2020-09-09|ONGOING|2020-10-05
e|RS|6ec23671-252e-4dc9-b919-88254fce68a5|4|BMIVLIND|Bone Marrow Involvement Indicator|SACT|[?]|umol|iPR|1|IU/dL|CHROMATOGRAPHY||||CHILD|CLINICAL PATHOLOGIST|U|2|Visit_2|25|1|TREATMENT|2020-08-12|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-20|P1Y2M10DT2H30M|BEFORE|2020-08-06|ONGOING|2020-09-25
e|RS|6ec23671-252e-4dc9-b919-88254fce68a5|5|STRUSTAT|Steroid Use Status|IWG CHESON MDS 2006|[?]|g/cage/wk|OPTIMAL MORPHOLOGIC RESPONSE|1|/MBP|HEMATOXYLIN AND EOSIN STAIN|Y|||ADJUDICATION COMMITTEE|MICROSCOPIST|U|3|Visit_3|40|4|FOLLOW-UP|2020-08-27|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-11|P1Y2M10DT2H30M|AFTER|2020-09-08|COINCIDENT|2020-10-17
e|RS|6ec23671-252e-4dc9-b919-88254fce68a5|6|MRDRESP|Minimal Residual Disease Response|PRINCE TCELL LYMPHOMA 2010|[?]|mmHg/L/min|MRD RELAPSE|1|dmol|BIOPSY|Y|||FAMILY MEMBER|NEUROLOGIST 1|N|3|Visit_3|40|1|FOLLOW-UP|2020-08-27|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-11|P1Y2M10DT2H30M|BEFORE|2020-09-15|AFTER|2020-09-19
e|RS|6ec23671-252e-4dc9-b919-88254fce68a5|7|STRUSTAT|Steroid Use Status|RAJKUMAR MYELOMA 2011|||iCR|1|mg/kg/h|CYSTOSCOPY||Y|Y|ADJUDICATOR|RATER 1|NA|4|Visit_4|65|2|WASHOUT|2020-09-21|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-04|P1Y2M10DT2H30M|BEFORE|2020-09-04|AFTER|2020-09-26
e|RS|6ec23671-252e-4dc9-b919-88254fce68a5|8|RDIORESP|Radiologic Response|IRANO 2015|[?]|cmol/L|COMPLETE MRD RESPONSE|1|pmol/L/h|CONTRAST ENHANCED SPIRAL CT SCAN|Y|||PROXY|MICROSCOPIST 1|N|4|Visit_4|65|2|TREATMENT|2020-09-21|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-04|P1Y2M10DT2H30M|UNKNOWN|2020-08-30|COINCIDENT|2020-10-06
e|RS|6ec23671-252e-4dc9-b919-88254fce68a5|9|NEWLWIND|New Lesion Worsening Indicator|PERCIST|||CYTOGENETIC NO RESPONSE|1|mg/cm2|ANTIBIOTIC AGAR SCREEN|||Y|INTERVIEWER|CLINICAL PATHOLOGIST|U|5|Visit_5|90|2|TREATMENT|2020-10-16|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-18|P1Y2M10DT2H30M|AFTER|2020-09-27|AFTER|2020-10-10
e|RS|6ec23671-252e-4dc9-b919-88254fce68a5|10|BONERESP|Bone Response|JACINTO CERVICAL CANCER 2007|[?]|COAT|RELAPSED DISEASE FROM CR OR PR|1|10^4/hpf|BALLPOINT PEN TECHNIQUE|Y|||GUARDIAN|PEDIATRIC NEUROLOGIST|Y|5|Visit_5|90|5|TREATMENT|2020-10-16|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-18|P1Y2M10DT2H30M|AFTER|2020-08-14|AFTER|2020-10-15
e|RS|db59e5e1-ccda-480b-8955-da5157e16c4a|1|TMRESP|Tumor Marker Response|SCHER PROSTATE CANCER 2011|[?]|cmH2O/mL|DECREASED|1|tuberculin unit|ROMANOWSKY STAIN||||FAMILY MEMBER|RATER|Y|1|Visit_1|10|6|TREATMENT|2020-05-14|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-04|P1Y2M10DT2H30M|COINCIDENT|2020-08-05|AFTER|2020-08-11
e|RS|db59e5e1-ccda-480b-8955-da5157e16c4a|2|BONERESP|Bone Response|PALUMBO MULTIPLE MYELOMA 2009|||UNFAVORABLE RESPONSE|1|10^5/hpf|INTRAVASCULAR ULTRASOUND||Y|Y|ADJUDICATOR|MICROSCOPIST 2|N|1|Visit_1|10|7|FOLLOW-UP|2020-05-14|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-04|P1Y2M10DT2H30M|COINCIDENT|2020-06-01|BEFORE|2020-06-14
e|RS|db59e5e1-ccda-480b-8955-da5157e16c4a|3|BONERESP|Bone Response|DOHNER AML 2010|[?]|cm2|INCREASED|1|HOURS|CARDIAC THERMODILUTION|Y|||CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 2|Y|2|Visit_2|25|5|TREATMENT|2020-05-29|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-28|P1Y2M10DT2H30M|UNKNOWN|2020-06-01|ONGOING|2020-07-24
e|RS|db59e5e1-ccda-480b-8955-da5157e16c4a|4|ANATRESP|Anatomic Response|IWG CHESON MDS 2000|[?]|h/wk|ABSENT MORPHOLOGIC RESPONSE|1|Bq/mg|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY||||STUDY SUBJECT|FORENSIC PATHOLOGIST|NA|2|Visit_2|25|5|SCREENING|2020-05-29|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-28|P1Y2M10DT2H30M|COINCIDENT|2020-07-07|COINCIDENT|2020-08-11
e|RS|db59e5e1-ccda-480b-8955-da5157e16c4a|5|MRDRESP|Minimal Residual Disease Response|IRANO 2015|[?]|uCi/L|iCR|1|CCID 50/mL|LAPAROSCOPY||||CLINICAL STUDY SPONSOR|MICROSCOPIST 1|N|3|Visit_3|40|2|TREATMENT|2020-06-13|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-17|P1Y2M10DT2H30M|UNKNOWN|2020-06-25|AFTER|2020-06-29
e|RS|db59e5e1-ccda-480b-8955-da5157e16c4a|6|NTLWIND|Non-Target Lesion Worsening Indicator|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|g/L|mCR|1|U/m2|MS/MS||||DOMESTIC PARTNER|OPTOMETRIST|NA|3|Visit_3|40|3|FOLLOW-UP|2020-06-13|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-17|P1Y2M10DT2H30M|UNKNOWN|2020-07-16|BEFORE|2020-07-21
e|RS|db59e5e1-ccda-480b-8955-da5157e16c4a|7|BONERESP|Bone Response|MURPHY PROSTATE CANCER 1980|[?]|pmol/dL|MRD NEGATIVITY|1|10^5/L|MAGNETIC RESONANCE ELASTOGRAPHY||||NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|N|4|Visit_4|65|5|TREATMENT|2020-07-08|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-24|P1Y2M10DT2H30M|AFTER|2020-08-07|AFTER|2020-08-08
e|RS|db59e5e1-ccda-480b-8955-da5157e16c4a|8|OVRLRESP|Overall Response|RECIST 1.1|[?]|10^3 CFU/g|iCPD|1|ng/mol|CYSTOMETRY||Y||FAMILY MEMBER|RATER 1|NA|4|Visit_4|65|7|TREATMENT|2020-07-08|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-24|P1Y2M10DT2H30M|COINCIDENT|2020-05-08|BEFORE|2020-06-24
e|RS|db59e5e1-ccda-480b-8955-da5157e16c4a|9|MJPTHIND|Major Pathological Response Indicator|RAJKUMAR MYELOMA 2011|[?]|ppb|MRD NEGATIVITY|1|Gauss|SICKLE CELL SOLUBILITY TEST||||DOMESTIC PARTNER|HEMATOLOGIST|NA|5|Visit_5|90|6|FOLLOW-UP|2020-08-02|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-22|P1Y2M10DT2H30M|COINCIDENT|2020-06-17|COINCIDENT|2020-08-01
e|RS|db59e5e1-ccda-480b-8955-da5157e16c4a|10|CYTORESP|Cytogenetic Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|km/h|PR-CT|1|g/m2/day|ANTIBIOTIC AGAR SCREEN||||PARENT|PATHOLOGIST 1|NA|5|Visit_5|90|7|FOLLOW-UP|2020-08-02|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-22|P1Y2M10DT2H30M|COINCIDENT|2020-06-03|BEFORE|2020-07-26
e|RS|1dce856e-b7cb-4899-b27f-87ab8d918df4|1|TMRESP|Tumor Marker Response|PRINCE TCELL LYMPHOMA 2010|||SMD|1|ug/L DDU|ELASTOGRAPHY|||Y|SPOUSE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|1|Visit_1|10|1|TREATMENT|2020-09-12|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-11|P1Y2M10DT2H30M|BEFORE|2020-09-17|COINCIDENT|2020-09-24
e|RS|1dce856e-b7cb-4899-b27f-87ab8d918df4|2|BESTRESP|Best Overall Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|U/m2/day|CA125 75% RESPONSE|1|10^3 CFU/mL|VIRUS PLAQUE ASSAY|Y|||VENDOR|PEDIATRIC NEUROLOGIST|Y|1|Visit_1|10|5|WASHOUT|2020-09-12|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-11|P1Y2M10DT2H30M|AFTER|2020-09-08|COINCIDENT|2020-11-24
e|RS|1dce856e-b7cb-4899-b27f-87ab8d918df4|3|STRUSTAT|Steroid Use Status|AJCC V7|||RELAPSED DISEASE|1|mg/day|CONTRAST ENHANCED CT SCAN|||Y|DOMESTIC PARTNER|ONCOLOGIST 2|Y|2|Visit_2|25|1|FOLLOW-UP|2020-09-27|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-22|P1Y2M10DT2H30M|BEFORE|2020-09-11|AFTER|2020-11-25
e|RS|1dce856e-b7cb-4899-b27f-87ab8d918df4|4|HEMARESP|Hematologic Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|||NR|1|KALLIKREIN INHIBITOR UNIT|MAGNETIC RESONANCE ENTEROGRAPHY|||Y|FRIEND|DEVELOPMENTAL PSYCHOLOGIST|Y|2|Visit_2|25|2|SCREENING|2020-09-27|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-22|P1Y2M10DT2H30M|AFTER|2020-11-01|COINCIDENT|2020-11-04
e|RS|1dce856e-b7cb-4899-b27f-87ab8d918df4|5|NEWLIND|New Lesion Indicator|WHO BREAST CANCER 2006|[?]|min|PD|1|Enzyme U/m2|AUSCULTATION||||SIGNIFICANT OTHER|NEUROLOGIST|U|3|Visit_3|40|7|TREATMENT|2020-10-12|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-27|P1Y2M10DT2H30M|BEFORE|2020-11-04|AFTER|2020-11-10
e|RS|1dce856e-b7cb-4899-b27f-87ab8d918df4|6|NTERESP|Non-Target Enhancing Response|DURIE MULTIPLE MYELOMA 2006|[?]|gtt|CMR|1|g/animal/wk|PAP STAIN||||ADJUDICATOR|NEUROLOGIST|N|3|Visit_3|40|6|TREATMENT|2020-10-12|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-27|P1Y2M10DT2H30M|AFTER|2020-11-17|BEFORE|2020-12-07
e|RS|1dce856e-b7cb-4899-b27f-87ab8d918df4|7|NEWLWIND|New Lesion Worsening Indicator|IRANO 2015|[?]|atm|INDETERMINATE RESPONSE|1|Roentgen|CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY||||ADJUDICATOR|ONCOLOGIST|NA|4|Visit_4|65|3|WASHOUT|2020-11-06|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-23|P1Y2M10DT2H30M|AFTER|2020-09-21|AFTER|2020-10-18
e|RS|1dce856e-b7cb-4899-b27f-87ab8d918df4|8|STRUSTAT|Steroid Use Status|PCWG SCHER PROSTATE CANCER 2008|[?]|TCID 50/dose|HI-N|1|lx|MOUSE PROTECTION ASSAY||||CHILD|CARDIOLOGIST|U|4|Visit_4|65|5|TREATMENT|2020-11-06|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-23|P1Y2M10DT2H30M|BEFORE|2020-11-03|BEFORE|2020-12-07
e|RS|1dce856e-b7cb-4899-b27f-87ab8d918df4|9|PATHRESP|Pathologic Response|WHO BREAST CANCER 2006|||MOLECULAR MAJOR RESPONSE|1|AFU|LIGHT MICROSCOPY|||Y|PROXY|MICROSCOPIST 2|Y|5|Visit_5|90|5|WASHOUT|2020-12-01|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-05|P1Y2M10DT2H30M|COINCIDENT|2020-10-24|COINCIDENT|2020-11-09
e|RS|1dce856e-b7cb-4899-b27f-87ab8d918df4|10|BESTRESP|Best Overall Response|CHESON CLL 2012|[?]|10^6 organisms/mL|PDu|1|DIP|BRDU CELLULAR PROLIFERATION ASSAY|Y|Y||CAREGIVER|ADJUDICATOR 3|N|5|Visit_5|90|2|TREATMENT|2020-12-01|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-05|P1Y2M10DT2H30M|BEFORE|2020-09-14|ONGOING|2020-12-08
e|RS|7449180b-e226-4e97-a059-8760f6523f77|1|STRUSTAT|Steroid Use Status|SHINDOH COLORECTAL CANCER 2013|[?]|PIXEL|pCR|1|cm H2O|MAMMOGRAPHY||||SIBLING|ONCOLOGIST 1|N|1|Visit_1|10|2|TREATMENT|2020-07-04|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-11|P1Y2M10DT2H30M|BEFORE|2020-08-15|AFTER|2020-09-28
e|RS|7449180b-e226-4e97-a059-8760f6523f77|2|HEMARESP|Hematologic Response|RECICL|[?]|CYLINDER|UNEQUIVOCAL|1|dpm/mg|PHOTOMETRY||||NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST|Y|1|Visit_1|10|3|SCREENING|2020-07-04|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-11|P1Y2M10DT2H30M|UNKNOWN|2020-08-07|BEFORE|2020-09-13
e|RS|7449180b-e226-4e97-a059-8760f6523f77|3|BESTRESP|Best Overall Response|LUGANO CLASSIFICATION|[?]|BOX|PR|1|mL/(min*100mL)|GC/FID||||VENDOR|FORENSIC PATHOLOGIST|Y|2|Visit_2|25|5|WASHOUT|2020-07-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-28|P1Y2M10DT2H30M|BEFORE|2020-07-29|COINCIDENT|2020-09-03
e|RS|7449180b-e226-4e97-a059-8760f6523f77|4|SPLNRESP|Spleen Response|MACDONALD GLIOMA 1990|||SD-CT|1|mg/m2/h|SPECT/CT SCAN|||Y|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 2|N|2|Visit_2|25|6|SCREENING|2020-07-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-28|P1Y2M10DT2H30M|COINCIDENT|2020-07-23|AFTER|2020-09-18
e|RS|7449180b-e226-4e97-a059-8760f6523f77|5|CYTORESP|Cytogenetic Response|HARTMAN PANCREATIC CANCER 2012|[?]|/LPF|CHR|1|SYRINGE|ANALYTICAL ULTRACENTRIFUGATION||||CAREGIVER|NEUROLOGIST 2|N|3|Visit_3|40|2|TREATMENT|2020-08-03|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-30|P1Y2M10DT2H30M|COINCIDENT|2020-09-06|COINCIDENT|2020-09-16
e|RS|7449180b-e226-4e97-a059-8760f6523f77|6|METBRESP|Metabolic Response|RANO|||NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|g/animal/wk|HIGH RESOLUTION CT||Y|Y|FAMILY MEMBER|CLINICAL PATHOLOGIST|N|3|Visit_3|40|7|TREATMENT|2020-08-03|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-30|P1Y2M10DT2H30M|AFTER|2020-07-08|COINCIDENT|2020-08-01
e|RS|7449180b-e226-4e97-a059-8760f6523f77|7|METBRESP|Metabolic Response|NCIWG CHESON CLL 1996|[?]|APPLICATION|IMMUNOPHENOTYPIC CR|1|ks|KINYOUN STAIN||||SIGNIFICANT OTHER|MICROSCOPIST 1|U|4|Visit_4|65|4|WASHOUT|2020-08-28|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-07|P1Y2M10DT2H30M|AFTER|2020-07-02|COINCIDENT|2020-07-16
e|RS|7449180b-e226-4e97-a059-8760f6523f77|8|CPRFSTAT|Clinical Performance Status|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|||HI-P|1|10^7 CFU|PALPATION||Y|Y|PARENT|READER|U|4|Visit_4|65|4|TREATMENT|2020-08-28|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-07|P1Y2M10DT2H30M|AFTER|2020-07-27|COINCIDENT|2020-09-23
e|RS|7449180b-e226-4e97-a059-8760f6523f77|9|SYMPTDTR|Symptomatic Deterioration|IRANO 2015|[?]|mg/mol|PR|1|amu|LIGHT SCATTERING SPECTROSCOPY||||NON-HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|U|5|Visit_5|90|7|WASHOUT|2020-09-22|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-08|P1Y2M10DT2H30M|COINCIDENT|2020-09-29|COINCIDENT|2020-10-01
e|RS|7449180b-e226-4e97-a059-8760f6523f77|10|NEWLWIND|New Lesion Worsening Indicator|RANO|[?]|RFU|iCR|1|DPM|OLIGO ACGH||Y||FAMILY MEMBER|OPTOMETRIST|N|5|Visit_5|90|7|FOLLOW-UP|2020-09-22|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-08|P1Y2M10DT2H30M|COINCIDENT|2020-07-26|COINCIDENT|2020-08-28
e|RS|f077c497-b0f0-4a20-b448-608b0cc6ab36|1|NTERESP|Non-Target Enhancing Response|PRINCE TCELL LYMPHOMA 2010|[?]|/LSQN|PD-CT|1|NFIU|AURAMINE STAIN|Y|Y||GUARDIAN|INTERNIST|NA|1|Visit_1|10|3|TREATMENT|2020-06-08|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-09|P1Y2M10DT2H30M|AFTER|2020-06-01|COINCIDENT|2020-07-17
e|RS|f077c497-b0f0-4a20-b448-608b0cc6ab36|2|TRGRESP|Target Response|MACDONALD GLIOMA 1990|[?]|10^9 CFU/g|RELAPSED DISEASE FROM CR OR PR|1|mg/min|MODIFIED ACID FAST STAIN|Y|||FRIEND|HEMATOLOGIST|Y|1|Visit_1|10|1|TREATMENT|2020-06-08|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-09|P1Y2M10DT2H30M|COINCIDENT|2020-07-30|COINCIDENT|2020-08-29
e|RS|f077c497-b0f0-4a20-b448-608b0cc6ab36|3|NTNERESP|Non-Target Non-Enhancing Response|PRINCE TCELL LYMPHOMA 2010|[?]|mL/animal/wk|DECREASED|1|kBq|HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY||||CLINICAL RESEARCH ASSOCIATE|RATER 2|NA|2|Visit_2|25|7|TREATMENT|2020-06-23|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-30|P1Y2M10DT2H30M|UNKNOWN|2020-06-25|COINCIDENT|2020-08-06
e|RS|f077c497-b0f0-4a20-b448-608b0cc6ab36|4|MRDIND|Minimal Residual Disease Indicator|GUPPY OVARIAN CANCER 2002|||NON-iCR/NON-iUPD|1|uEq/L|MOUSE PROTECTION ASSAY|||Y|HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|N|2|Visit_2|25|4|SCREENING|2020-06-23|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-30|P1Y2M10DT2H30M|AFTER|2020-08-26|AFTER|2020-09-05
e|RS|f077c497-b0f0-4a20-b448-608b0cc6ab36|5|CYTORESP|Cytogenetic Response|MURPHY PROSTATE CANCER 1980|[?]|10^3/hpf|MINOR PATHOLOGIC RESPONSE|1|TAMPON|CONFOCAL MICROSCOPY|Y|||DOMESTIC PARTNER|PHYSIOTHERAPIST|U|3|Visit_3|40|6|TREATMENT|2020-07-08|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-13|P1Y2M10DT2H30M|BEFORE|2020-07-07|ONGOING|2020-08-10
e|RS|f077c497-b0f0-4a20-b448-608b0cc6ab36|6|SPLNRESP|Spleen Response|DOHNER AML 2010|[?]|psi|CA125 75% RESPONSE|1|mg/L|HANSEL STAIN||||HEALTH CARE PROFESSIONAL|OPTOMETRIST|Y|3|Visit_3|40|1|TREATMENT|2020-07-08|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-13|P1Y2M10DT2H30M|BEFORE|2020-08-20|COINCIDENT|2020-08-28
e|RS|f077c497-b0f0-4a20-b448-608b0cc6ab36|7|NEWLPROG|New Lesion Progression|NCIWG CHESON CLL 1996|[?]|MET*min|iSD|1|m3|SLOAN LETTER EYE CHART 100%||||CHILD|ONCOLOGIST|U|4|Visit_4|65|5|FOLLOW-UP|2020-08-02|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-01|P1Y2M10DT2H30M|BEFORE|2020-07-16|BEFORE|2020-08-15
e|RS|f077c497-b0f0-4a20-b448-608b0cc6ab36|8|NTNERESP|Non-Target Non-Enhancing Response|CHOI GIST 2008|[?]|nmol|IMMUNOPHENOTYPIC CR|1|Bq/kg|SCANNING ELECTRON MICROSCOPY||||ADJUDICATION COMMITTEE|FORENSIC PATHOLOGIST|N|4|Visit_4|65|4|FOLLOW-UP|2020-08-02|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-01|P1Y2M10DT2H30M|UNKNOWN|2020-08-01|COINCIDENT|2020-08-24
e|RS|f077c497-b0f0-4a20-b448-608b0cc6ab36|9|MRDIND|Minimal Residual Disease Indicator|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|Hz/s|PMR|1|oz eq|SCANNING ELECTRON MICROSCOPY||||STUDY SUBJECT|NEUROLOGIST|Y|5|Visit_5|90|5|TREATMENT|2020-08-27|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-03|P1Y2M10DT2H30M|BEFORE|2020-07-15|BEFORE|2020-08-16
e|RS|f077c497-b0f0-4a20-b448-608b0cc6ab36|10|CPRFSTAT|Clinical Performance Status|RECICL|[?]|TUBE|PSEUDOPROGRESSION|1|mg/kg/day|PHASE CONTRAST MICROSCOPY||||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|NA|5|Visit_5|90|7|SCREENING|2020-08-27|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-03|P1Y2M10DT2H30M|UNKNOWN|2020-07-27|BEFORE|2020-08-01
e|RS|172f12c6-0d7f-4e9b-be14-b64b94a26f9a|1|ANATRESP|Anatomic Response|KEAM BREAST CANCER 2013|[?]|Absorbance U/mL|SD-CT|1|nm|MICROARRAY||||INVESTIGATOR|READER 1|NA|1|Visit_1|10|7|TREATMENT|2020-06-12|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-29|P1Y2M10DT2H30M|UNKNOWN|2020-07-04|BEFORE|2020-08-17
e|RS|172f12c6-0d7f-4e9b-be14-b64b94a26f9a|2|CLINRESP|Clinical Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|||NR|1|Shock Wave|MASS SPECTROMETRY|||Y|SIGNIFICANT OTHER|MICROSCOPIST 2|NA|1|Visit_1|10|3|SCREENING|2020-06-12|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-29|P1Y2M10DT2H30M|AFTER|2020-07-27|AFTER|2020-08-26
e|RS|172f12c6-0d7f-4e9b-be14-b64b94a26f9a|3|SFTSRESP|Soft Tissue Response|RAJKUMAR MYELOMA 2011|[?]|usec|EQUIVOCAL|1|PATCH|VENTILATION PERFUSION LUNG SCAN||||CLINICAL RESEARCH COORDINATOR|RATER|N|2|Visit_2|25|4|WASHOUT|2020-06-27|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-20|P1Y2M10DT2H30M|BEFORE|2020-08-23|AFTER|2020-08-28
e|RS|172f12c6-0d7f-4e9b-be14-b64b94a26f9a|4|NEWLIND|New Lesion Indicator|CHESON CLL 2012|||RELAPSED DISEASE|1|usec|CALCULATION|||Y|VENDOR|OTOLARYNGOLOGIST|NA|2|Visit_2|25|3|TREATMENT|2020-06-27|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-20|P1Y2M10DT2H30M|BEFORE|2020-06-27|ONGOING|2020-07-14
e|RS|172f12c6-0d7f-4e9b-be14-b64b94a26f9a|5|SFTSRESP|Soft Tissue Response|WOLCHOK SOLID TUMORS 2009|[?]|mOsm|WORSENED|1|anti-Xa IU|MICROBIAL CONCENTRATION||||PARENT|ONCOLOGIST|Y|3|Visit_3|40|4|TREATMENT|2020-07-12|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-11|P1Y2M10DT2H30M|BEFORE|2020-08-19|COINCIDENT|2020-08-23
e|RS|172f12c6-0d7f-4e9b-be14-b64b94a26f9a|6|NTRGRESP|Non-target Response|PCWG SCHER PROSTATE CANCER 2016|[?]|Frames/s|STABLE|1|min*mg/mL|TRANSVAGINAL ULTRASOUND||||ADJUDICATION COMMITTEE|INTERNIST|N|3|Visit_3|40|4|WASHOUT|2020-07-12|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-11|P1Y2M10DT2H30M|UNKNOWN|2020-08-14|AFTER|2020-09-03
e|RS|172f12c6-0d7f-4e9b-be14-b64b94a26f9a|7|SYMPTDTR|Symptomatic Deterioration|PETIT BREAST CANCER 2001|[?]|mol/mL|INDETERMINATE RESPONSE|1|g/kg|TWO-COLOR MICROARRAY||Y||SIGNIFICANT OTHER|PEDIATRIC NEUROLOGIST|U|4|Visit_4|65|3|TREATMENT|2020-08-06|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-26|P1Y2M10DT2H30M|AFTER|2020-08-31|AFTER|2020-09-04
e|RS|172f12c6-0d7f-4e9b-be14-b64b94a26f9a|8|MRPHRESP|Morphologic Response|RECIST 1.1|[?]|HOMEOPATHIC DILUTION|DECREASED|1|mIU/L|PULSE OXIMETRY||||HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|U|4|Visit_4|65|7|FOLLOW-UP|2020-08-06|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-26|P1Y2M10DT2H30M|UNKNOWN|2020-08-09|AFTER|2020-08-28
e|RS|172f12c6-0d7f-4e9b-be14-b64b94a26f9a|9|LIVRRESP|Liver Response|AJCC V7|[?]|mV|VGPR|1|mCi/kg|GC/MS/MS||||ADJUDICATION COMMITTEE|ONCOLOGIST|N|5|Visit_5|90|4|TREATMENT|2020-08-31|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-26|P1Y2M10DT2H30M|UNKNOWN|2020-07-21|BEFORE|2020-09-07
e|RS|172f12c6-0d7f-4e9b-be14-b64b94a26f9a|10|RDIORESP|Radiologic Response|AJCC V7|[?]|ks|CA125 75% RESPONSE|1|kV|HEMATOXYLIN AND EOSIN STAIN||||INDEPENDENT ASSESSOR|RATER 2|Y|5|Visit_5|90|1|WASHOUT|2020-08-31|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-26|P1Y2M10DT2H30M|UNKNOWN|2020-08-16|ONGOING|2020-09-08
e|RS|3f7c46ac-fe30-4ef3-a581-99c064a85efa|1|CLINRESP|Clinical Response|NCIWG CHESON CLL 1996|||NED|1|mPa|ACCELERATOR MASS SPECTROMETRY|||Y|SPOUSE|NEUROLOGIST 2|U|1|Visit_1|10|6|TREATMENT|2021-01-11|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-02|P1Y2M10DT2H30M|UNKNOWN|2021-03-23|AFTER|2021-04-01
e|RS|3f7c46ac-fe30-4ef3-a581-99c064a85efa|2|TMRESP|Tumor Marker Response|LEE LUNG CANCER 2011|||UNEQUIVOCAL|1|umol|JAEGER EYE CHART||Y|Y|PROXY|PEDIATRIC NEUROLOGIST|Y|1|Visit_1|10|2|TREATMENT|2021-01-11|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-02|P1Y2M10DT2H30M|COINCIDENT|2021-03-29|COINCIDENT|2021-03-31
e|RS|3f7c46ac-fe30-4ef3-a581-99c064a85efa|3|MJPTHIND|Major Pathological Response Indicator|EUROPEAN LEUKEMIANET BACCARANI CML 2006|||PMR|1|cg|FLAME PHOTOMETRY||Y|Y|SPOUSE|PATHOLOGIST 2|U|2|Visit_2|25|6|SCREENING|2021-01-26|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-15|P1Y2M10DT2H30M|UNKNOWN|2021-03-18|AFTER|2021-04-04
e|RS|3f7c46ac-fe30-4ef3-a581-99c064a85efa|4|METBRESP|Metabolic Response|IRANO 2015|[?]|U/10^12 RBC|MRD PERSISTENCE|1|DIP|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY||||ADJUDICATION COMMITTEE|PATHOLOGIST 1|NA|2|Visit_2|25|6|TREATMENT|2021-01-26|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-15|P1Y2M10DT2H30M|BEFORE|2021-01-29|COINCIDENT|2021-02-25
e|RS|3f7c46ac-fe30-4ef3-a581-99c064a85efa|5|NTRGRESP|Non-target Response|RECICL|[?]|cm/min|PSEUDORESPONSE|1|U/kg/h|LINE PROBE ASSAY|Y|||CHILD|ONCOLOGIST 1|Y|3|Visit_3|40|5|FOLLOW-UP|2021-02-10|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-02|P1Y2M10DT2H30M|UNKNOWN|2021-02-27|BEFORE|2021-03-05
e|RS|3f7c46ac-fe30-4ef3-a581-99c064a85efa|6|SYMPTDTR|Symptomatic Deterioration|PCWG BUBLEY PROSTATE CANCER 1999|||VGPR|1|cm2|CISH|||Y|STUDY SUBJECT|ADJUDICATOR|NA|3|Visit_3|40|6|TREATMENT|2021-02-10|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-02|P1Y2M10DT2H30M|AFTER|2021-01-30|AFTER|2021-02-03
e|RS|3f7c46ac-fe30-4ef3-a581-99c064a85efa|7|CLINRESP|Clinical Response|SCHWARZ CERVICAL CANCER 2009|[?]|cycle/min|mCR|1|mV|MALDI-TOF|Y|Y||INVESTIGATOR|PHYSIOTHERAPIST|U|4|Visit_4|65|2|TREATMENT|2021-03-07|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-07|P1Y2M10DT2H30M|AFTER|2021-04-01|ONGOING|2021-04-09
e|RS|3f7c46ac-fe30-4ef3-a581-99c064a85efa|8|BONERESP|Bone Response|CHOI GIST 2008|||MRD PERSISTENCE|1|g/L|MALDI-TOF|Y|Y|Y|VENDOR|DEVELOPMENTAL PSYCHOLOGIST|U|4|Visit_4|65|5|FOLLOW-UP|2021-03-07|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-07|P1Y2M10DT2H30M|AFTER|2021-03-22|BEFORE|2021-03-26
e|RS|3f7c46ac-fe30-4ef3-a581-99c064a85efa|9|SFTSRESP|Soft Tissue Response|HARTMAN PANCREATIC CANCER 2012|||QUANTIFIABLE MRD POSITIVITY|1|nmol/kg/day|DNA MICROARRAY|Y||Y|CLINICAL STUDY SPONSOR|RATER 1|Y|5|Visit_5|90|3|FOLLOW-UP|2021-04-01|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-29|P1Y2M10DT2H30M|UNKNOWN|2021-03-31|COINCIDENT|2021-04-10
e|RS|3f7c46ac-fe30-4ef3-a581-99c064a85efa|10|ANATRESP|Anatomic Response|IWG CHESON MDS 2000|[?]|pmol/L|MORPHOLOGIC LEUKEMIA-FREE STATE|1|PHERESIS UNIT|IRON HEMATOXYLIN STAIN||||PROXY|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|5|Visit_5|90|7|TREATMENT|2021-04-01|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-29|P1Y2M10DT2H30M|BEFORE|2021-03-23|COINCIDENT|2021-04-04
e|RS|8d944400-df75-4ec7-8fb4-239eb0f6de9d|1|ANATRESP|Anatomic Response|RECIST 1.0|[?]|cmol/L|MRD PERSISTENCE|1|bel|PHASE CONTRAST MICROSCOPY||Y||FRIEND|ADJUDICATOR 3|U|1|Visit_1|10|1|TREATMENT|2020-09-22|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-29|P1Y2M10DT2H30M|COINCIDENT|2020-10-27|ONGOING|2020-12-10
e|RS|8d944400-df75-4ec7-8fb4-239eb0f6de9d|2|NTNERESP|Non-Target Non-Enhancing Response|CHESON MALIGNANT LYMPHOMA 2007|||CA125 75% RESPONSE|1|cd*s/m2|LIQUID SCINTILLATION COUNTING|||Y|VENDOR|READER 2|U|1|Visit_1|10|3|WASHOUT|2020-09-22|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-29|P1Y2M10DT2H30M|AFTER|2020-11-20|ONGOING|2020-12-16
e|RS|8d944400-df75-4ec7-8fb4-239eb0f6de9d|3|MRPHRESP|Morphologic Response|GUILHOT CML 2007|[?]|APS U|PD/RELAPSE AFTER HI|1|PNU/mL|ANTIBIOTIC AGAR SCREEN||||CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 1|Y|2|Visit_2|25|6|TREATMENT|2020-10-07|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-07|P1Y2M10DT2H30M|COINCIDENT|2020-12-12|BEFORE|2020-12-20
e|RS|8d944400-df75-4ec7-8fb4-239eb0f6de9d|4|DRCRIND|Disease Recurrence Indicator|BURCOMBE BREAST CANCER 2005|[?]|mCi|INCREASED|1|Ci/kg|TRIPLE-PHASE SPIRAL CT SCAN|Y|||ADJUDICATION COMMITTEE|DERMATOLOGIST|Y|2|Visit_2|25|3|TREATMENT|2020-10-07|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-07|P1Y2M10DT2H30M|UNKNOWN|2020-11-19|ONGOING|2020-12-17
e|RS|8d944400-df75-4ec7-8fb4-239eb0f6de9d|5|SFTSRESP|Soft Tissue Response|PCWG SCHER PROSTATE CANCER 2016|[?]|g/animal|cPR|1|/500 WBC|U-HPLC/MS/MS||||CLINICAL STUDY SPONSOR|PATHOLOGIST|Y|3|Visit_3|40|3|TREATMENT|2020-10-22|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-10|P1Y2M10DT2H30M|AFTER|2020-11-25|AFTER|2020-12-13
e|RS|8d944400-df75-4ec7-8fb4-239eb0f6de9d|6|BMIVLIND|Bone Marrow Involvement Indicator|CHESON MALIGNANT LYMPHOMA 2007|[?]|mL/min/mmHg|PMR|1|U/kg/min|CLIP||||STUDY SUBJECT|MICROSCOPIST|U|3|Visit_3|40|7|TREATMENT|2020-10-22|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-10|P1Y2M10DT2H30M|AFTER|2020-10-02|ONGOING|2020-10-06
e|RS|8d944400-df75-4ec7-8fb4-239eb0f6de9d|7|OVRLRESP|Overall Response|CHESON NON-HODGKINS LYMPHOMA 1999|||MORPHOLOGIC CRi|1|pg/dL|LAPAROSCOPY||Y|Y|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 1|N|4|Visit_4|65|7|TREATMENT|2020-11-16|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-03|P1Y2M10DT2H30M|COINCIDENT|2020-10-18|COINCIDENT|2020-10-29
e|RS|8d944400-df75-4ec7-8fb4-239eb0f6de9d|8|RDIORESP|Radiologic Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|g/day|CYTOGENETIC PR|1|LOZENGE|HEMATOXYLIN AND EOSIN STAIN||||NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST|U|4|Visit_4|65|7|TREATMENT|2020-11-16|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-03|P1Y2M10DT2H30M|COINCIDENT|2020-11-02|BEFORE|2020-11-18
e|RS|8d944400-df75-4ec7-8fb4-239eb0f6de9d|9|MJPTHIND|Major Pathological Response Indicator|HARTMANN GERM CELL CANCER 2002|[?]|10^9 organisms/mg|DISEASE TRANSFORMATION|1|10^9 organisms/mL|ACRIDINE ORANGE STAIN|Y|||CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 2|Y|5|Visit_5|90|5|TREATMENT|2020-12-11|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-11|P1Y2M10DT2H30M|UNKNOWN|2020-11-13|COINCIDENT|2020-12-20
e|RS|8d944400-df75-4ec7-8fb4-239eb0f6de9d|10|OVRLRESP|Overall Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|MPS U|PSEUDOPROGRESSION|1|Rad|CALIPER MEASUREMENT METHOD||||CLINICAL RESEARCH COORDINATOR|PHYSIOTHERAPIST|U|5|Visit_5|90|3|WASHOUT|2020-12-11|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-11|P1Y2M10DT2H30M|BEFORE|2020-12-05|AFTER|2020-12-20
e|RS|7b201f93-bd8c-4507-a7b7-27a02e364647|1|TRGRESP|Target Response|MASS|[?]|Enzyme U/m2|nPR|1|L/L|WEBER GREEN STAIN||||SPOUSE|RADIOLOGIST 2|U|1|Visit_1|10|7|WASHOUT|2020-12-23|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-28|P1Y2M10DT2H30M|AFTER|2021-03-11|BEFORE|2021-03-19
e|RS|7b201f93-bd8c-4507-a7b7-27a02e364647|2|NTNERESP|Non-Target Non-Enhancing Response|IWG CHESON MDS 2006|[?]|10^3 DNA copies/mL|DECREASED|1|uIU/dL|IMMUNOPRECIPITATION||||NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|1|Visit_1|10|1|TREATMENT|2020-12-23|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-28|P1Y2M10DT2H30M|UNKNOWN|2021-01-21|COINCIDENT|2021-02-28
e|RS|7b201f93-bd8c-4507-a7b7-27a02e364647|3|DRCRIND|Disease Recurrence Indicator|RANO ELLINGSON 2017|||nPR|1|cmHg|TELLER ACUITY CARDS||Y|Y|INDEPENDENT ASSESSOR|CARDIOLOGIST|U|2|Visit_2|25|7|WASHOUT|2021-01-07|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-11|P1Y2M10DT2H30M|AFTER|2021-01-10|BEFORE|2021-03-21
e|RS|7b201f93-bd8c-4507-a7b7-27a02e364647|4|NTLWIND|Non-Target Lesion Worsening Indicator|PCWG SCHER PROSTATE CANCER 2008|||DECREASED|1|10^5/L|EPSILOMETER|||Y|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|N|2|Visit_2|25|6|SCREENING|2021-01-07|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-11|P1Y2M10DT2H30M|UNKNOWN|2021-02-03|AFTER|2021-03-05
e|RS|7b201f93-bd8c-4507-a7b7-27a02e364647|5|SFTSRESP|Soft Tissue Response|IRANO 2015|[?]|HOMEOPATHIC DILUTION|PARTIAL MORPHOLOGIC RESPONSE|1|cm/min|IMMUNE REPERTOIRE DEEP SEQUENCING||Y||INVESTIGATOR|RADIOLOGIST|NA|3|Visit_3|40|6|WASHOUT|2021-01-22|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-03|P1Y2M10DT2H30M|COINCIDENT|2021-01-17|ONGOING|2021-03-16
e|RS|7b201f93-bd8c-4507-a7b7-27a02e364647|6|NEWLWIND|New Lesion Worsening Indicator|EASL BRUIX LIVER CANCER 2001|[?]|mg/animal|CA125 75% RESPONSE|1|Watt|HEMOCYTOMETRY||Y||ADJUDICATOR|UROLOGIST|NA|3|Visit_3|40|3|WASHOUT|2021-01-22|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-03|P1Y2M10DT2H30M|BEFORE|2020-12-21|ONGOING|2021-02-23
e|RS|7b201f93-bd8c-4507-a7b7-27a02e364647|7|MRDIND|Minimal Residual Disease Indicator|PRINCE TCELL LYMPHOMA 2010|[?]|ug/dose|PSEUDORESPONSE|1|U/g/min|CENTRIFUGATION||Y||SPOUSE|ADJUDICATOR 2|N|4|Visit_4|65|3|TREATMENT|2021-02-16|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-05|P1Y2M10DT2H30M|COINCIDENT|2021-01-20|BEFORE|2021-03-17
e|RS|7b201f93-bd8c-4507-a7b7-27a02e364647|8|RDIORESP|Radiologic Response|EASL BRUIX LIVER CANCER 2001|[?]|Log10 ELISA unit|CYTOGENETIC PR|1|mg2/dL2|RADIAL IMMUNODIFFUSION||||FAMILY MEMBER|NEUROLOGIST|N|4|Visit_4|65|1|SCREENING|2021-02-16|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-05|P1Y2M10DT2H30M|UNKNOWN|2021-03-11|ONGOING|2021-03-17
e|RS|7b201f93-bd8c-4507-a7b7-27a02e364647|9|NTLWIND|Non-Target Lesion Worsening Indicator|EUROPEAN LEUKEMIANET BACCARANI CML 2006|||MORPHOLOGIC LEUKEMIA-FREE STATE|1|EIA unit|TARGETED TRANSCRIPTOME SEQUENCING|Y||Y|PARENT|DEVELOPMENTAL PSYCHOLOGIST|N|5|Visit_5|90|2|TREATMENT|2021-03-13|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-19|P1Y2M10DT2H30M|COINCIDENT|2021-02-25|BEFORE|2021-03-16
e|RS|7b201f93-bd8c-4507-a7b7-27a02e364647|10|MRDRESP|Minimal Residual Disease Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|BU/mL|PD/RELAPSE AFTER HI|1|pmol/g|EEG|Y|Y||DOMESTIC PARTNER|READER 2|U|5|Visit_5|90|1|WASHOUT|2021-03-13|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-19|P1Y2M10DT2H30M|COINCIDENT|2021-01-07|AFTER|2021-02-28
e|RS|fbc3f1fc-c3e7-4db5-8156-77ba9a459073|1|METBRESP|Metabolic Response|IWG CHESON MDS 2006|[?]|mL/breath|PD FROM PR|1|ft2|REAL-TIME POLYMERASE CHAIN REACTION ASSAY|Y|||GUARDIAN|PATHOLOGIST 1|U|1|Visit_1|10|2|TREATMENT|2020-08-05|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-23|P1Y2M10DT2H30M|BEFORE|2020-09-29|AFTER|2020-10-01
e|RS|fbc3f1fc-c3e7-4db5-8156-77ba9a459073|2|NEWLWIND|New Lesion Worsening Indicator|BLAZER COLORECTAL CANCER 2008|[?]|SYRINGE|MORPHOLOGIC CRi|1|RING|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY|Y|Y||HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|U|1|Visit_1|10|2|WASHOUT|2020-08-05|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-23|P1Y2M10DT2H30M|AFTER|2020-11-01|COINCIDENT|2020-11-02
e|RS|fbc3f1fc-c3e7-4db5-8156-77ba9a459073|3|CLINRESP|Clinical Response|SCHWARZ CERVICAL CANCER 2009|[?]|copies/ug|CRi|1|ug/animal|ELASTOGRAPHY||||CLINICAL STUDY SPONSOR|PATHOLOGIST|U|2|Visit_2|25|3|FOLLOW-UP|2020-08-20|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-31|P1Y2M10DT2H30M|COINCIDENT|2020-09-29|COINCIDENT|2020-10-05
e|RS|fbc3f1fc-c3e7-4db5-8156-77ba9a459073|4|NEWLWIND|New Lesion Worsening Indicator|GUILHOT CML 2007|[?]|damol/L|CA125 75% RESPONSE|1|mg/kg/min|RULER MEASUREMENT METHOD||||SIGNIFICANT OTHER|PHYSIOTHERAPIST|N|2|Visit_2|25|3|SCREENING|2020-08-20|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-31|P1Y2M10DT2H30M|AFTER|2020-08-01|ONGOING|2020-08-10
e|RS|fbc3f1fc-c3e7-4db5-8156-77ba9a459073|5|MRDIND|Minimal Residual Disease Indicator|SHINDOH COLORECTAL CANCER 2013|[?]|ug/g/day|SD-CT|1|mPa|IN VITRO GENE EXPRESSION ASSAY|Y|||INDEPENDENT ASSESSOR|RATER 2|U|3|Visit_3|40|3|WASHOUT|2020-09-04|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-29|P1Y2M10DT2H30M|UNKNOWN|2020-10-18|BEFORE|2020-10-24
e|RS|fbc3f1fc-c3e7-4db5-8156-77ba9a459073|6|CYTORESP|Cytogenetic Response|CHOLLET BREAST CANCER 2002|[?]|mm3/mm2/year|iSD|1|GBq|NUCLEAR RADIOLOGY||||DOMESTIC PARTNER|DERMATOLOGIST|U|3|Visit_3|40|7|WASHOUT|2020-09-04|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-29|P1Y2M10DT2H30M|AFTER|2020-09-18|BEFORE|2020-10-10
e|RS|fbc3f1fc-c3e7-4db5-8156-77ba9a459073|7|BONERESP|Bone Response|KUMAR IMWG 2016|[?]|bel|UNEQUIVOCAL|1|psi|TELLER ACUITY CARDS|Y|||INTERVIEWER|DERMATOLOGIST|NA|4|Visit_4|65|1|SCREENING|2020-09-29|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-02|P1Y2M10DT2H30M|AFTER|2020-09-22|AFTER|2020-10-12
e|RS|fbc3f1fc-c3e7-4db5-8156-77ba9a459073|8|MRDIND|Minimal Residual Disease Indicator|KUKER LYMPHOMA 2005|[?]|U/dL|RELAPSED DISEASE FROM CR|1|SFC/10^6 PBMC|FLUORESCENCE ANGIOGRAPHY|Y|||CLINICAL RESEARCH COORDINATOR|READER|U|4|Visit_4|65|3|SCREENING|2020-09-29|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-02|P1Y2M10DT2H30M|COINCIDENT|2020-09-22|COINCIDENT|2020-10-10
e|RS|fbc3f1fc-c3e7-4db5-8156-77ba9a459073|9|HEMARESP|Hematologic Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|deg|CA125 75% RESPONSE|1|Enzyme U/g Hb|IMPULSE OSCILLOMETRY||Y||CLINICAL STUDY SPONSOR|ONCOLOGIST 1|NA|5|Visit_5|90|3|FOLLOW-UP|2020-10-24|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-05|P1Y2M10DT2H30M|BEFORE|2020-09-03|AFTER|2020-11-02
e|RS|fbc3f1fc-c3e7-4db5-8156-77ba9a459073|10|MNPTHIND|Minor Pathological Response Indicator|KUKER LYMPHOMA 2005|||MR|1|DROP|SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY||Y|Y|NON-HEALTH CARE PROFESSIONAL|CARDIOLOGIST|U|5|Visit_5|90|6|TREATMENT|2020-10-24|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-05|P1Y2M10DT2H30M|UNKNOWN|2020-11-01|BEFORE|2020-11-02
e|RS|3611b798-9b3d-4173-b23e-3017939847e0|1|TMRESP|Tumor Marker Response|PRINCE TCELL LYMPHOMA 2010|[?]|/2500 WBC|MORPHOLOGIC CRi|1|umol/L/min|AUTOMATED COUNT||Y||STUDY SUBJECT|PATHOLOGIST 2|N|1|Visit_1|10|5|TREATMENT|2020-08-03|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-15|P1Y2M10DT2H30M|COINCIDENT|2020-09-12|ONGOING|2020-09-29
e|RS|3611b798-9b3d-4173-b23e-3017939847e0|2|DRCRIND|Disease Recurrence Indicator|KUKER LYMPHOMA 2005|[?]|MPL U/mL|PARTIAL MORPHOLOGIC RESPONSE|1|kcal|POTENTIOMETRY|Y|||INTERVIEWER|RATER 2|N|1|Visit_1|10|5|TREATMENT|2020-08-03|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-15|P1Y2M10DT2H30M|BEFORE|2020-08-21|COINCIDENT|2020-09-19
e|RS|3611b798-9b3d-4173-b23e-3017939847e0|3|HEMARESP|Hematologic Response|SACT|||CYTOGENETIC CR|1|CAPFUL|HIGH RESOLUTION CT|Y||Y|PARENT|HEMATOLOGIST|Y|2|Visit_2|25|4|TREATMENT|2020-08-18|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-11|P1Y2M10DT2H30M|AFTER|2020-08-07|ONGOING|2020-10-11
e|RS|3611b798-9b3d-4173-b23e-3017939847e0|4|MNPTHIND|Minor Pathological Response Indicator|RAJKUMAR MYELOMA 2011|[?]|U/g Hb|SD|1|ng/L|MULTIPLE BREATH WASHOUT||||CLINICAL STUDY SPONSOR|MICROSCOPIST 1|Y|2|Visit_2|25|3|SCREENING|2020-08-18|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-11|P1Y2M10DT2H30M|AFTER|2020-08-21|AFTER|2020-09-08
e|RS|3611b798-9b3d-4173-b23e-3017939847e0|5|BESTRESP|Best Overall Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|mL/h|iCPD|1|lx|DIFFUSION WEIGHTED MRI||Y||INVESTIGATOR|RADIOLOGIST 1|Y|3|Visit_3|40|3|TREATMENT|2020-09-02|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-13|P1Y2M10DT2H30M|UNKNOWN|2020-08-03|AFTER|2020-09-27
e|RS|3611b798-9b3d-4173-b23e-3017939847e0|6|NTRGRESP|Non-target Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|kg/cm|NR|1|nmol/L/min|MICROBIAL CULTURE|Y|||ADJUDICATION COMMITTEE|OPHTHALMOLOGIST|N|3|Visit_3|40|2|WASHOUT|2020-09-02|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-13|P1Y2M10DT2H30M|COINCIDENT|2020-08-12|ONGOING|2020-10-14
e|RS|3611b798-9b3d-4173-b23e-3017939847e0|7|LIVRRESP|Liver Response|CHESON LYMPHOMA 2008|[?]|MESF|CR-CT|1|ft|CT SCAN WITHOUT CONTRAST|Y|||SIBLING|CARDIOLOGIST|U|4|Visit_4|65|6|FOLLOW-UP|2020-09-27|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-06|P1Y2M10DT2H30M|AFTER|2020-08-23|COINCIDENT|2020-10-12
e|RS|3611b798-9b3d-4173-b23e-3017939847e0|8|METSIND|Metastatic Indicator|LUGANO CLASSIFICATION|[?]|steps/min|iCR|1|cL|IMMUNOTURBIDIMETRY||Y||FRIEND|READER 3|Y|4|Visit_4|65|6|TREATMENT|2020-09-27|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-06|P1Y2M10DT2H30M|AFTER|2020-10-07|ONGOING|2020-10-14
e|RS|3611b798-9b3d-4173-b23e-3017939847e0|9|SPLNRESP|Spleen Response|AJCC V8|[?]|GBq|NOT ALL EVALUATED|1|kHz|OPTICAL DENSITY MEASUREMENT|Y|||PROXY|READER|U|5|Visit_5|90|1|TREATMENT|2020-10-22|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-26|P1Y2M10DT2H30M|BEFORE|2020-09-01|BEFORE|2020-10-16
e|RS|3611b798-9b3d-4173-b23e-3017939847e0|10|NTLWIND|Non-Target Lesion Worsening Indicator|LUGANO CLASSIFICATION|||OPTIMAL MORPHOLOGIC RESPONSE|1|/day|WRIGHT-GIEMSA STAIN||Y|Y|ADJUDICATOR|DEVELOPMENTAL PSYCHOLOGIST|N|5|Visit_5|90|3|TREATMENT|2020-10-22|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-26|P1Y2M10DT2H30M|BEFORE|2020-08-11|BEFORE|2020-09-15
e|RS|f651799b-9723-4c2c-88d1-de2f347e9a69|1|MRDRESP|Minimal Residual Disease Response|MASS|[?]|mL/kg/day|CYTOGENETIC PR|1|mol|MEDIASTINOSCOPY||Y||INVESTIGATOR|MICROSCOPIST 2|Y|1|Visit_1|10|7|WASHOUT|2020-06-24|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-09|P1Y2M10DT2H30M|AFTER|2020-06-29|BEFORE|2020-08-13
e|RS|f651799b-9723-4c2c-88d1-de2f347e9a69|2|NTLWIND|Non-Target Lesion Worsening Indicator|MRECIST LENCIONI LIVER CANCER 2010|||FAVORABLE RESPONSE|1|PFU/dose|ENZYMATIC ULTRACENTRIFUGATION||Y|Y|PROXY|ONCOLOGIST 1|NA|1|Visit_1|10|6|TREATMENT|2020-06-24|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-09|P1Y2M10DT2H30M|BEFORE|2020-07-07|ONGOING|2020-09-15
e|RS|f651799b-9723-4c2c-88d1-de2f347e9a69|3|NTERESP|Non-Target Enhancing Response|PRINCE TCELL LYMPHOMA 2010|[?]|JDF Unit|SD-CT|1|ug/g/day|CT SCAN||||DOMESTIC PARTNER|RADIOLOGIST 1|NA|2|Visit_2|25|5|TREATMENT|2020-07-09|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-10|P1Y2M10DT2H30M|BEFORE|2020-09-07|COINCIDENT|2020-09-10
e|RS|f651799b-9723-4c2c-88d1-de2f347e9a69|4|PATHRESP|Pathologic Response|MONTSERRAT CLL 1989|[?]|mL/s|CYTOGENETIC NO RESPONSE|1|cs|CLOT DETECTION||||SIBLING|ONCOLOGIST 1|N|2|Visit_2|25|4|TREATMENT|2020-07-09|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-10|P1Y2M10DT2H30M|BEFORE|2020-07-21|ONGOING|2020-09-04
e|RS|f651799b-9723-4c2c-88d1-de2f347e9a69|5|PATHRESP|Pathologic Response|IWG CHESON MDS 2000|[?]|10^6 copies/mL|nPR|1|ug/kg/day|ISHIHARA COLOR PLATES||Y||SIGNIFICANT OTHER|RADIOLOGIST|U|3|Visit_3|40|2|FOLLOW-UP|2020-07-24|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-19|P1Y2M10DT2H30M|COINCIDENT|2020-08-23|ONGOING|2020-08-28
e|RS|f651799b-9723-4c2c-88d1-de2f347e9a69|6|NEWLIND|New Lesion Indicator|PALUMBO MULTIPLE MYELOMA 2009|[?]|oz eq|PSA PROGRESSION|1|C|DUKE INCISION METHOD|Y|||CLINICAL STUDY SPONSOR|READER 2|U|3|Visit_3|40|1|TREATMENT|2020-07-24|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-19|P1Y2M10DT2H30M|COINCIDENT|2020-08-25|AFTER|2020-09-18
e|RS|f651799b-9723-4c2c-88d1-de2f347e9a69|7|NTNERESP|Non-Target Non-Enhancing Response|IRANO 2015|[?]|hPa|PARTIAL MORPHOLOGIC RESPONSE|1|CFU/mL|IMMUNOPRECIPITATION||||ADJUDICATOR|UROLOGIST|U|4|Visit_4|65|5|TREATMENT|2020-08-18|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-05|P1Y2M10DT2H30M|AFTER|2020-06-29|BEFORE|2020-08-13
e|RS|f651799b-9723-4c2c-88d1-de2f347e9a69|8|NEWLPROG|New Lesion Progression|SCHER PROSTATE CANCER 2011|[?]|mg/mL/min|MORPHOLOGIC LEUKEMIA-FREE STATE|1|damol/L|AUTOREFRACTION||||SPOUSE|READER 1|NA|4|Visit_4|65|6|SCREENING|2020-08-18|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-05|P1Y2M10DT2H30M|BEFORE|2020-07-12|ONGOING|2020-08-04
e|RS|f651799b-9723-4c2c-88d1-de2f347e9a69|9|CPRFSTAT|Clinical Performance Status|RECICL|[?]|dyn|CA125 75% RESPONSE|1|ft3|PLAQUE REDUCTION NEUTRALIZATION ASSAY||||CLINICAL STUDY SPONSOR|ENDOCRINOLOGIST|U|5|Visit_5|90|3|FOLLOW-UP|2020-09-12|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-02|P1Y2M10DT2H30M|BEFORE|2020-08-29|AFTER|2020-09-08
e|RS|f651799b-9723-4c2c-88d1-de2f347e9a69|10|NEWLIND|New Lesion Indicator|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|10^9 organisms/g|DECREASED|1|ug/m2|TRYPAN BLUE STAIN||||DOMESTIC PARTNER|DERMATOLOGIST|N|5|Visit_5|90|2|FOLLOW-UP|2020-09-12|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-02|P1Y2M10DT2H30M|COINCIDENT|2020-09-14|ONGOING|2020-09-18
e|RS|51c6f0e2-6a67-40cd-aac8-fd4cd0188b42|1|OVRLRESP|Overall Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|10^6 organisms/g|RELAPSED DISEASE|1|mL/animal/wk|MRS||||FRIEND|MICROSCOPIST|N|1|Visit_1|10|4|TREATMENT|2020-10-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-21|P1Y2M10DT2H30M|AFTER|2021-01-07|COINCIDENT|2021-01-13
e|RS|51c6f0e2-6a67-40cd-aac8-fd4cd0188b42|2|BESTRESP|Best Overall Response|JACINTO CERVICAL CANCER 2007|[?]|cy/cm|PSEUDOPROGRESSION|1|mL/mmHg/min/L|CONFOCAL MICROSCOPY||||CHILD|ADJUDICATOR|NA|1|Visit_1|10|4|TREATMENT|2020-10-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-21|P1Y2M10DT2H30M|AFTER|2020-12-26|ONGOING|2021-01-05
e|RS|51c6f0e2-6a67-40cd-aac8-fd4cd0188b42|3|MRDRESP|Minimal Residual Disease Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|kUSP|iCPD|1|Frames/s|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY||Y||INTERVIEWER|RATER 1|NA|2|Visit_2|25|4|TREATMENT|2020-11-03|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-14|P1Y2M10DT2H30M|COINCIDENT|2020-12-28|ONGOING|2021-01-07
e|RS|51c6f0e2-6a67-40cd-aac8-fd4cd0188b42|4|CLINRESP|Clinical Response|CHESON MALIGNANT LYMPHOMA 2007|||UNFAVORABLE RESPONSE|1|mg/kg/min|QUANTITATIVE CORONARY ANGIOGRAPHY|||Y|GUARDIAN|MICROSCOPIST 1|U|2|Visit_2|25|2|TREATMENT|2020-11-03|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-14|P1Y2M10DT2H30M|COINCIDENT|2020-11-01|AFTER|2020-12-15
e|RS|51c6f0e2-6a67-40cd-aac8-fd4cd0188b42|5|NTRGRESP|Non-target Response|KUKER LYMPHOMA 2005|[?]|10^6 organisms/g|NON-PD|1|uV*sec|WESTERN BLOT||Y||ADJUDICATOR|DEVELOPMENTAL PSYCHOLOGIST|Y|3|Visit_3|40|3|TREATMENT|2020-11-18|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-17|P1Y2M10DT2H30M|UNKNOWN|2020-12-26|AFTER|2021-01-09
e|RS|51c6f0e2-6a67-40cd-aac8-fd4cd0188b42|6|RDIORESP|Radiologic Response|MONTSERRAT CLL 1989|[?]|mmHg/L/min|FAVORABLE RESPONSE|1|PFU/dose|ANTIMICROBIAL COMBINATION TESTING||||NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR|Y|3|Visit_3|40|4|WASHOUT|2020-11-18|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-17|P1Y2M10DT2H30M|UNKNOWN|2020-12-11|BEFORE|2021-01-05
e|RS|51c6f0e2-6a67-40cd-aac8-fd4cd0188b42|7|NEWLPROG|New Lesion Progression|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|mg/kg/day|PD-CT|1|pt_br|PANENDOSCOPY||||INTERVIEWER|MICROSCOPIST 2|NA|4|Visit_4|65|4|WASHOUT|2020-12-13|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-15|P1Y2M10DT2H30M|AFTER|2020-10-16|AFTER|2020-11-29
e|RS|51c6f0e2-6a67-40cd-aac8-fd4cd0188b42|8|NEWLPROG|New Lesion Progression|PRINCE TCELL LYMPHOMA 2010|[?]|ng/mol|CYTOGENETIC MINOR RESPONSE|1|nsec|VENTILATION PERFUSION LUNG SCAN||||FAMILY MEMBER|FORENSIC PATHOLOGIST|NA|4|Visit_4|65|7|TREATMENT|2020-12-13|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-15|P1Y2M10DT2H30M|UNKNOWN|2020-11-26|ONGOING|2021-01-12
e|RS|51c6f0e2-6a67-40cd-aac8-fd4cd0188b42|9|CYTORESP|Cytogenetic Response|GUILHOT CML 2007|[?]|Farad|cPR|1|IU/g|GC/MS||||HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|Y|5|Visit_5|90|3|TREATMENT|2021-01-07|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-13|P1Y2M10DT2H30M|BEFORE|2020-10-31|AFTER|2020-11-29
e|RS|51c6f0e2-6a67-40cd-aac8-fd4cd0188b42|10|NEWLPROG|New Lesion Progression|KUKER LYMPHOMA 2005|[?]|mg/kg/min|HI-E|1|PA|MACRO BROTH DILUTION||||SIGNIFICANT OTHER|UROLOGIST|Y|5|Visit_5|90|4|TREATMENT|2021-01-07|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-13|P1Y2M10DT2H30M|UNKNOWN|2020-12-25|COINCIDENT|2020-12-30
e|RS|29b16c31-df0e-493c-a777-46113b904879|1|SFTSRESP|Soft Tissue Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|mL/g/day|MINOR PATHOLOGIC RESPONSE|1|cpm|GC/MS||||ADJUDICATOR|OTOLARYNGOLOGIST|Y|1|Visit_1|10|7|SCREENING|2020-06-07|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-04|P1Y2M10DT2H30M|BEFORE|2020-07-27|BEFORE|2020-09-01
e|RS|29b16c31-df0e-493c-a777-46113b904879|2|NEWLPROG|New Lesion Progression|UNSPECIFIED|[?]|mL/m2/min|IMMUNOPHENOTYPIC CR|1|msec|CLAUSS METHOD||||PARENT|PATHOLOGIST 1|N|1|Visit_1|10|7|WASHOUT|2020-06-07|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-04|P1Y2M10DT2H30M|AFTER|2020-07-09|BEFORE|2020-07-28
e|RS|29b16c31-df0e-493c-a777-46113b904879|3|SYMPTDTR|Symptomatic Deterioration|EASL BRUIX LIVER CANCER 2001|[?]|10^6 CFU/g|FAVORABLE RESPONSE|1|cal|MICROBIAL CULTURE, SOLID||||FAMILY MEMBER|RADIOLOGIST|Y|2|Visit_2|25|6|TREATMENT|2020-06-22|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-09|P1Y2M10DT2H30M|UNKNOWN|2020-07-01|BEFORE|2020-08-20
e|RS|29b16c31-df0e-493c-a777-46113b904879|4|MJPTHIND|Major Pathological Response Indicator|IWG CHESON MDS 2006|[?]|ppm|QUANTIFIABLE MRD POSITIVITY|1|cy/cm|ELECTROPHORESIS|Y|||PROXY|MICROSCOPIST 3|N|2|Visit_2|25|5|SCREENING|2020-06-22|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-09|P1Y2M10DT2H30M|UNKNOWN|2020-09-02|AFTER|2020-09-03
e|RS|29b16c31-df0e-493c-a777-46113b904879|5|BESTRESP|Best Overall Response|CHOLLET BREAST CANCER 2002|||IMMUNOPHENOTYPIC CR|1|vp/mL|SPIRAL CT|||Y|CLINICAL RESEARCH COORDINATOR|DERMATOLOGIST|U|3|Visit_3|40|2|TREATMENT|2020-07-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-16|P1Y2M10DT2H30M|UNKNOWN|2020-08-09|ONGOING|2020-08-22
e|RS|29b16c31-df0e-493c-a777-46113b904879|6|BESTRESP|Best Overall Response|DURIE MULTIPLE MYELOMA 2006|[?]|mL/animal/day|PSEUDORESPONSE|1|nmol|MAGNETIC RESONANCE ANGIOGRAPHY||Y||FAMILY MEMBER|DERMATOLOGIST|U|3|Visit_3|40|5|TREATMENT|2020-07-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-16|P1Y2M10DT2H30M|BEFORE|2020-07-12|AFTER|2020-07-29
e|RS|29b16c31-df0e-493c-a777-46113b904879|7|MRPHRESP|Morphologic Response|FAROOQUI SUPP CLL 2014|||iCR|1|amp|CLIP SEQUENCING|||Y|CHILD|OPHTHALMOLOGIST|Y|4|Visit_4|65|1|TREATMENT|2020-08-01|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-06|P1Y2M10DT2H30M|BEFORE|2020-07-10|ONGOING|2020-07-28
e|RS|29b16c31-df0e-493c-a777-46113b904879|8|NTLWIND|Non-Target Lesion Worsening Indicator|FAROOQUI SUPP CLL 2014|[?]|MBq|INCREASED|1|/10^5|MRI WITHOUT CONTRAST||||ADJUDICATION COMMITTEE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|4|Visit_4|65|3|SCREENING|2020-08-01|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-06|P1Y2M10DT2H30M|COINCIDENT|2020-06-17|AFTER|2020-08-10
e|RS|29b16c31-df0e-493c-a777-46113b904879|9|MJPTHIND|Major Pathological Response Indicator|NCIWG CHESON CLL 1996|||TREATMENT FAILURE|1|log10 CCID 50/dose|TRIPLE-PHASE SPIRAL CT SCAN|||Y|INDEPENDENT ASSESSOR|CLINICAL PATHOLOGIST|U|5|Visit_5|90|7|TREATMENT|2020-08-26|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-21|P1Y2M10DT2H30M|AFTER|2020-07-30|COINCIDENT|2020-08-06
e|RS|29b16c31-df0e-493c-a777-46113b904879|10|ANATRESP|Anatomic Response|RANO ELLINGSON 2017|[?]|U/L|PMR|1|ELISA unit|NO INFORMATION||||INVESTIGATOR|CARDIOLOGIST|N|5|Visit_5|90|6|SCREENING|2020-08-26|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-21|P1Y2M10DT2H30M|UNKNOWN|2020-08-29|COINCIDENT|2020-09-04
e|RS|56b7d8fb-23b2-4f0a-9bc6-8e6621937251|1|SFTSRESP|Soft Tissue Response|DOHNER AML 2010|||SD-CT|1|AU/mL|JAFFE REACTION|||Y|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|NA|1|Visit_1|10|7|TREATMENT|2020-07-31|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-02|P1Y2M10DT2H30M|COINCIDENT|2020-10-11|AFTER|2020-10-21
e|RS|56b7d8fb-23b2-4f0a-9bc6-8e6621937251|2|MNPTHIND|Minor Pathological Response Indicator|CHESON CLL 2006|||PSEUDORESPONSE|1|mL/100g/min|MRS|||Y|SIGNIFICANT OTHER|HEMATOLOGIST|NA|1|Visit_1|10|4|TREATMENT|2020-07-31|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-02|P1Y2M10DT2H30M|COINCIDENT|2020-08-02|COINCIDENT|2020-10-23
e|RS|56b7d8fb-23b2-4f0a-9bc6-8e6621937251|3|STRUSTAT|Steroid Use Status|IWG CHESON MDS 2006|[?]|SUPPOSITORY|CA125 75% RESPONSE|1|IU/dL|AUTOREFRACTION|Y|||INTERVIEWER|PATHOLOGIST 1|U|2|Visit_2|25|1|WASHOUT|2020-08-15|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-27|P1Y2M10DT2H30M|AFTER|2020-08-09|BEFORE|2020-09-14
e|RS|56b7d8fb-23b2-4f0a-9bc6-8e6621937251|4|MRPHRESP|Morphologic Response|FAROOQUI SUPP CLL 2014|[?]|BEAM BREAKS|RELAPSED DISEASE FROM CR|1|10^7 CFU|INCISION-INDUCED BLEEDING METHOD||Y||ADJUDICATOR|OPHTHALMOLOGIST|N|2|Visit_2|25|7|SCREENING|2020-08-15|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-27|P1Y2M10DT2H30M|UNKNOWN|2020-10-26|COINCIDENT|2020-10-27
e|RS|56b7d8fb-23b2-4f0a-9bc6-8e6621937251|5|METSIND|Metastatic Indicator|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|mJoule/cm2|cPR|1|mEq/L|IODINE STAIN||||INVESTIGATOR|UROLOGIST|U|3|Visit_3|40|5|SCREENING|2020-08-30|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-29|P1Y2M10DT2H30M|UNKNOWN|2020-07-23|ONGOING|2020-08-13
e|RS|56b7d8fb-23b2-4f0a-9bc6-8e6621937251|6|METBRESP|Metabolic Response|MURPHY PROSTATE CANCER 1980|||HI-P|1|foz_us|FLOW CYTOMETRY|||Y|CLINICAL RESEARCH COORDINATOR|ENDOCRINOLOGIST|Y|3|Visit_3|40|3|SCREENING|2020-08-30|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-29|P1Y2M10DT2H30M|BEFORE|2020-10-09|ONGOING|2020-10-27
e|RS|56b7d8fb-23b2-4f0a-9bc6-8e6621937251|7|CPRFSTAT|Clinical Performance Status|HARTMAN PANCREATIC CANCER 2012|||MRD RELAPSE|1|gMFI|ENDOSCOPY||Y|Y|CLINICAL RESEARCH COORDINATOR|INTERNIST|Y|4|Visit_4|65|6|TREATMENT|2020-09-24|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-25|P1Y2M10DT2H30M|AFTER|2020-08-30|AFTER|2020-10-12
e|RS|56b7d8fb-23b2-4f0a-9bc6-8e6621937251|8|CYTORESP|Cytogenetic Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|PACKET|iCPD|1|Weber|TRIPLE-PHASE MRI SCAN||||CHILD|PATHOLOGIST 1|U|4|Visit_4|65|3|TREATMENT|2020-09-24|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-25|P1Y2M10DT2H30M|BEFORE|2020-07-27|AFTER|2020-10-03
e|RS|56b7d8fb-23b2-4f0a-9bc6-8e6621937251|9|HEMARESP|Hematologic Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|log10 CCID 50/dose|PSEUDORESPONSE|1|/2000 RBC|NEPHELOMETRY||||SIGNIFICANT OTHER|RATER 2|U|5|Visit_5|90|7|TREATMENT|2020-10-19|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-02|P1Y2M10DT2H30M|AFTER|2020-10-23|COINCIDENT|2020-10-28
e|RS|56b7d8fb-23b2-4f0a-9bc6-8e6621937251|10|BESTRESP|Best Overall Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|10^6 U|INDETERMINATE RESPONSE|1|cm2|DIGITAL PCR ARRAY||||SPOUSE|RADIOLOGIST 2|U|5|Visit_5|90|7|WASHOUT|2020-10-19|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-02|P1Y2M10DT2H30M|UNKNOWN|2020-09-29|ONGOING|2020-10-14
e|RS|118914c8-9f6a-47c8-b427-296a99547756|1|STRUSTAT|Steroid Use Status|SCHWARZ CERVICAL CANCER 2009|[?]|10^3 organisms/g|CHR|1|/500 WBC|ANALYTICAL ULTRACENTRIFUGATION||||ADJUDICATION COMMITTEE|ADJUDICATOR 1|Y|1|Visit_1|10|4|TREATMENT|2020-10-25|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-11|P1Y2M10DT2H30M|BEFORE|2021-01-21|ONGOING|2021-01-22
e|RS|118914c8-9f6a-47c8-b427-296a99547756|2|NTERESP|Non-Target Enhancing Response|MURPHY PROSTATE CANCER 1980|[?]|10^4 CFU|WORSENED|1|HEP|NUCLEAR RADIOLOGY||Y||GUARDIAN|OPHTHALMOLOGIST|U|1|Visit_1|10|6|SCREENING|2020-10-25|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-11|P1Y2M10DT2H30M|UNKNOWN|2021-01-07|ONGOING|2021-01-15
e|RS|118914c8-9f6a-47c8-b427-296a99547756|3|SFTSRESP|Soft Tissue Response|IWG CHESON MDS 2006|[?]|10^9 organisms|HI-P|1|U/g/min|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE||||SIGNIFICANT OTHER|CLINICAL PATHOLOGIST|NA|2|Visit_2|25|3|TREATMENT|2020-11-09|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-26|P1Y2M10DT2H30M|COINCIDENT|2020-12-04|BEFORE|2020-12-16
e|RS|118914c8-9f6a-47c8-b427-296a99547756|4|NEWLPROG|New Lesion Progression|IWG CHESON AML 2003|[?]|%(w/w)|PSA PROGRESSION|1|mmol/kg|MECHANICAL CLOT DETECTION||Y||VENDOR|MICROSCOPIST|Y|2|Visit_2|25|5|FOLLOW-UP|2020-11-09|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-26|P1Y2M10DT2H30M|UNKNOWN|2020-10-22|ONGOING|2020-11-24
e|RS|118914c8-9f6a-47c8-b427-296a99547756|5|NTERESP|Non-Target Enhancing Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|HEP|DECREASED|1|mL/kg/day|IN SITU HYBRIDIZATION||Y||PROXY|NEUROLOGIST 2|N|3|Visit_3|40|6|TREATMENT|2020-11-24|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-18|P1Y2M10DT2H30M|AFTER|2020-11-17|ONGOING|2020-12-06
e|RS|118914c8-9f6a-47c8-b427-296a99547756|6|RDIORESP|Radiologic Response|WHO BREAST CANCER 2006|[?]|uEq|MRD NEGATIVITY|1|1/(s*kPa)|GC/MS-CI||||PARENT|PATHOLOGIST 1|U|3|Visit_3|40|2|TREATMENT|2020-11-24|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-18|P1Y2M10DT2H30M|COINCIDENT|2020-12-27|BEFORE|2021-01-06
e|RS|118914c8-9f6a-47c8-b427-296a99547756|7|CLINRESP|Clinical Response|KEAM BREAST CANCER 2013|||UNEQUIVOCAL|1|umol/mg/min|DC SHEATH FLOW|||Y|INTERVIEWER|PATHOLOGIST 1|NA|4|Visit_4|65|3|TREATMENT|2020-12-19|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-28|P1Y2M10DT2H30M|COINCIDENT|2020-12-30|ONGOING|2021-01-02
e|RS|118914c8-9f6a-47c8-b427-296a99547756|8|BESTRESP|Best Overall Response|IWG CHESON MDS 2006|[?]|BOX|PDu|1|EID 50/mL|PET/MRI SCAN||||PROXY|UROLOGIST|N|4|Visit_4|65|5|TREATMENT|2020-12-19|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-28|P1Y2M10DT2H30M|BEFORE|2020-11-26|AFTER|2020-12-20
e|RS|118914c8-9f6a-47c8-b427-296a99547756|9|NTERESP|Non-Target Enhancing Response|NCCN ALL MRD 2014|[?]|mL/dose|MRD PERSISTENCE|1|pmol|TEST STRIP||Y||SPOUSE|MICROSCOPIST|U|5|Visit_5|90|7|TREATMENT|2021-01-13|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-02|P1Y2M10DT2H30M|UNKNOWN|2020-11-15|BEFORE|2021-01-17
e|RS|118914c8-9f6a-47c8-b427-296a99547756|10|NEWLIND|New Lesion Indicator|SCHWARZ CERVICAL CANCER 2009|[?]|mL/day|PD FROM PR|1|ks|MICROBIAL CULTURE, SOLID||||SPOUSE|ONCOLOGIST|Y|5|Visit_5|90|3|FOLLOW-UP|2021-01-13|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-02|P1Y2M10DT2H30M|BEFORE|2021-01-17|ONGOING|2021-01-22
e|RS|9b936ec9-01d9-4626-8d6d-83f3a1aefd96|1|NTERESP|Non-Target Enhancing Response|EASL BRUIX LIVER CANCER 2001|||PSA PROGRESSION|1|10^6 organisms/mL|CLIP SEQUENCING|Y||Y|INTERVIEWER|ONCOLOGIST|NA|1|Visit_1|10|4|WASHOUT|2020-12-09|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-23|P1Y2M10DT2H30M|COINCIDENT|2021-02-03|COINCIDENT|2021-02-07
e|RS|9b936ec9-01d9-4626-8d6d-83f3a1aefd96|2|MOLRESP|Molecular Response|GUPPY OVARIAN CANCER 2002|[?]|V/sec|CMR|1|10^12/L|LANDOLT RING||Y||CAREGIVER|MICROSCOPIST 1|NA|1|Visit_1|10|4|SCREENING|2020-12-09|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-23|P1Y2M10DT2H30M|BEFORE|2020-12-12|ONGOING|2021-02-17
e|RS|9b936ec9-01d9-4626-8d6d-83f3a1aefd96|3|ANATRESP|Anatomic Response|EASL BRUIX LIVER CANCER 2001|[?]|Bq/mg|VGPR|1|ug/g/h|WEBER GREEN STAIN||Y||NON-HEALTH CARE PROFESSIONAL|HEMATOLOGIST|N|2|Visit_2|25|6|TREATMENT|2020-12-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-08|P1Y2M10DT2H30M|UNKNOWN|2021-03-06|AFTER|2021-03-08
e|RS|9b936ec9-01d9-4626-8d6d-83f3a1aefd96|4|NEWLPROG|New Lesion Progression|MRANO VAN DEN BENT GLIOMA 2011|[?]|RATIO|PD FROM PR|1|GBq/g|HPLC/IEX||||CAREGIVER|DERMATOLOGIST|NA|2|Visit_2|25|2|WASHOUT|2020-12-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-08|P1Y2M10DT2H30M|UNKNOWN|2020-12-03|BEFORE|2021-01-22
e|RS|9b936ec9-01d9-4626-8d6d-83f3a1aefd96|5|SFTSRESP|Soft Tissue Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|Tbsp|CMR|1|dB|DYNAMIC CONTRAST ENHANCED MRI||||FRIEND|ADJUDICATOR 1|N|3|Visit_3|40|6|SCREENING|2021-01-08|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-01|P1Y2M10DT2H30M|COINCIDENT|2021-02-14|COINCIDENT|2021-02-24
e|RS|9b936ec9-01d9-4626-8d6d-83f3a1aefd96|6|MNPTHIND|Minor Pathological Response Indicator|CHESON LYMPHOMA 2008|[?]|10^6 DNA copies/mL|iUPD|1|mEq/mmol|HPLC/MS||||CHILD|OPTOMETRIST|N|3|Visit_3|40|1|FOLLOW-UP|2021-01-08|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-01|P1Y2M10DT2H30M|UNKNOWN|2020-12-07|COINCIDENT|2021-03-01
e|RS|9b936ec9-01d9-4626-8d6d-83f3a1aefd96|7|ANATRESP|Anatomic Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|cmol/L|MAJOR PATHOLOGIC RESPONSE|1|Bq|IN SITU HYBRIDIZATION||||CHILD|ADJUDICATOR 3|Y|4|Visit_4|65|3|SCREENING|2021-02-02|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-12|P1Y2M10DT2H30M|AFTER|2020-12-16|ONGOING|2021-01-21
e|RS|9b936ec9-01d9-4626-8d6d-83f3a1aefd96|8|METBRESP|Metabolic Response|PROTOCOL DEFINED RESPONSE CRITERIA|||MORPHOLOGIC CRi|1|ug/dL|QUANTITATIVE CORONARY ANGIOGRAPHY|||Y|ADJUDICATION COMMITTEE|MICROSCOPIST 1|Y|4|Visit_4|65|3|TREATMENT|2021-02-02|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-12|P1Y2M10DT2H30M|BEFORE|2020-12-06|BEFORE|2021-01-13
e|RS|9b936ec9-01d9-4626-8d6d-83f3a1aefd96|9|LIVRRESP|Liver Response|DURIE MULTIPLE MYELOMA 2006|[?]|mL/kg/min|HI-N|1|MnFI|IMMUNOTURBIDIMETRY|Y|||GUARDIAN|ADJUDICATOR 1|N|5|Visit_5|90|1|TREATMENT|2021-02-27|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-07|P1Y2M10DT2H30M|COINCIDENT|2020-12-29|COINCIDENT|2021-01-15
e|RS|9b936ec9-01d9-4626-8d6d-83f3a1aefd96|10|SYMPTDTR|Symptomatic Deterioration|LUGANO CLASSIFICATION|||INDETERMINATE RESPONSE|1|amp|SURFACE PLASMON RESONANCE|Y||Y|PROXY|ONCOLOGIST 2|NA|5|Visit_5|90|7|TREATMENT|2021-02-27|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-07|P1Y2M10DT2H30M|AFTER|2020-12-03|ONGOING|2021-02-08
e|RS|571cbffe-c3e1-4f18-a9f7-cf11a4058f2c|1|NTNERESP|Non-Target Non-Enhancing Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|mJoule/cm2|QUANTIFIABLE MRD POSITIVITY|1|Hounsfield Unit|SEQUENCING||||SIGNIFICANT OTHER|FORENSIC PATHOLOGIST|U|1|Visit_1|10|1|TREATMENT|2021-01-08|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-16|P1Y2M10DT2H30M|BEFORE|2021-03-10|BEFORE|2021-03-27
e|RS|571cbffe-c3e1-4f18-a9f7-cf11a4058f2c|2|CLINRESP|Clinical Response|RECIST 1.1|[?]|cycle/min|cCR|1|umol/day|RYAN BLUE STAIN||||CHILD|RATER 2|Y|1|Visit_1|10|7|TREATMENT|2021-01-08|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-16|P1Y2M10DT2H30M|UNKNOWN|2021-03-04|AFTER|2021-03-08
e|RS|571cbffe-c3e1-4f18-a9f7-cf11a4058f2c|3|CLINRESP|Clinical Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|10^3/hpf|cPR|1|BISCUIT|CONTRAST ENHANCED SPIRAL CT SCAN||||INTERVIEWER|UROLOGIST|N|2|Visit_2|25|3|WASHOUT|2021-01-23|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-06|P1Y2M10DT2H30M|COINCIDENT|2021-01-10|ONGOING|2021-04-03
e|RS|571cbffe-c3e1-4f18-a9f7-cf11a4058f2c|4|MJPTHIND|Major Pathological Response Indicator|DOHNER AML 2010|||FAVORABLE RESPONSE|1|kg/cm2|DARK FIELD MICROSCOPY|||Y|CHILD|RADIOLOGIST 2|N|2|Visit_2|25|6|SCREENING|2021-01-23|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-06|P1Y2M10DT2H30M|AFTER|2021-02-13|BEFORE|2021-03-17
e|RS|571cbffe-c3e1-4f18-a9f7-cf11a4058f2c|5|BMIVLIND|Bone Marrow Involvement Indicator|DURIE MULTIPLE MYELOMA 2006|[?]|10^4/L|MRD RELAPSE|1|10^6 U|IMMUNOASSAY||Y||INVESTIGATOR|ENDOCRINOLOGIST|Y|3|Visit_3|40|2|TREATMENT|2021-02-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-09|P1Y2M10DT2H30M|AFTER|2021-03-16|ONGOING|2021-04-04
e|RS|571cbffe-c3e1-4f18-a9f7-cf11a4058f2c|6|MRPHRESP|Morphologic Response|BLAZER COLORECTAL CANCER 2008|[?]|10^9/g|MINOR PATHOLOGIC RESPONSE|1|uV|RULER MEASUREMENT METHOD||||SPOUSE|HEMATOLOGIST|NA|3|Visit_3|40|6|WASHOUT|2021-02-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-09|P1Y2M10DT2H30M|BEFORE|2021-02-16|BEFORE|2021-03-19
e|RS|571cbffe-c3e1-4f18-a9f7-cf11a4058f2c|7|NTERESP|Non-Target Enhancing Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|APL U/mL|CHR|1|mL/dL|SLOAN LETTER EYE CHART 1.25%||Y||NON-HEALTH CARE PROFESSIONAL|READER|U|4|Visit_4|65|6|FOLLOW-UP|2021-03-04|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-28|P1Y2M10DT2H30M|AFTER|2021-01-08|COINCIDENT|2021-03-11
e|RS|571cbffe-c3e1-4f18-a9f7-cf11a4058f2c|8|OVRLRESP|Overall Response|WHO BREAST CANCER 2006|||IMPROVED|1|K|WHOLE GENOME SEQUENCING|||Y|INDEPENDENT ASSESSOR|NEUROLOGIST 1|N|4|Visit_4|65|5|FOLLOW-UP|2021-03-04|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-28|P1Y2M10DT2H30M|AFTER|2021-03-07|AFTER|2021-03-15
e|RS|571cbffe-c3e1-4f18-a9f7-cf11a4058f2c|9|METSIND|Metastatic Indicator|HARTMANN GERM CELL CANCER 2002|[?]|CARTRIDGE|HI-P|1|log10 copies/mL|CINEANGIOGRAPHY||Y||SIGNIFICANT OTHER|PATHOLOGIST 2|N|5|Visit_5|90|5|TREATMENT|2021-03-29|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-26|P1Y2M10DT2H30M|UNKNOWN|2021-03-12|ONGOING|2021-04-03
e|RS|571cbffe-c3e1-4f18-a9f7-cf11a4058f2c|10|MOLRESP|Molecular Response|CHESON CLL 2012|||CYTOGENETIC PR|1|ug|TRICHROME STAIN|||Y|CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5|Visit_5|90|4|TREATMENT|2021-03-29|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-26|P1Y2M10DT2H30M|AFTER|2021-01-17|BEFORE|2021-03-11
e|RS|7a5ae465-03b9-4006-a29e-94822ed857aa|1|CPRFSTAT|Clinical Performance Status|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|mg/mol|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|ks|MULTIPLE BREATH WASHOUT|Y|||DOMESTIC PARTNER|RATER 1|N|1|Visit_1|10|7|WASHOUT|2020-07-02|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-13|P1Y2M10DT2H30M|AFTER|2020-07-08|ONGOING|2020-07-11
e|RS|7a5ae465-03b9-4006-a29e-94822ed857aa|2|SYMPTDTR|Symptomatic Deterioration|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|mg/mL/day|CYTOGENETIC PR|1|USP U|THICK SMEAR||Y||DOMESTIC PARTNER|MICROSCOPIST 2|Y|1|Visit_1|10|1|TREATMENT|2020-07-02|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-13|P1Y2M10DT2H30M|BEFORE|2020-08-20|ONGOING|2020-09-17
e|RS|7a5ae465-03b9-4006-a29e-94822ed857aa|3|DRCRIND|Disease Recurrence Indicator|BURCOMBE BREAST CANCER 2005|||sCR|1|POUCH|SLOAN LETTER EYE CHART 1.25%||Y|Y|INVESTIGATOR|MICROSCOPIST 3|N|2|Visit_2|25|6|TREATMENT|2020-07-17|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-30|P1Y2M10DT2H30M|UNKNOWN|2020-09-03|BEFORE|2020-09-17
e|RS|7a5ae465-03b9-4006-a29e-94822ed857aa|4|NTERESP|Non-Target Enhancing Response|IRANO 2015|[?]|MBq/uL|VGPR|1|MPS U|IMPEDANCE CONDUCTIVITY||Y||INDEPENDENT ASSESSOR|ADJUDICATOR 1|U|2|Visit_2|25|2|SCREENING|2020-07-17|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-30|P1Y2M10DT2H30M|BEFORE|2020-06-27|BEFORE|2020-07-28
e|RS|7a5ae465-03b9-4006-a29e-94822ed857aa|5|METBRESP|Metabolic Response|AJCC V7|[?]|PIXELS/cm|iCPD|1|10^3/hpf|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY||||FAMILY MEMBER|RATER|N|3|Visit_3|40|5|TREATMENT|2020-08-01|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-21|P1Y2M10DT2H30M|COINCIDENT|2020-07-05|ONGOING|2020-07-21
e|RS|7a5ae465-03b9-4006-a29e-94822ed857aa|6|SFTSRESP|Soft Tissue Response|SHINDOH COLORECTAL CANCER 2013|[?]|mg/kg/week|INCREASED|1|TRANSDUCING UNIT|CLIP SEQUENCING||Y||NON-HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|N|3|Visit_3|40|7|FOLLOW-UP|2020-08-01|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-21|P1Y2M10DT2H30M|AFTER|2020-07-14|ONGOING|2020-09-21
e|RS|7a5ae465-03b9-4006-a29e-94822ed857aa|7|OVRLRESP|Overall Response|JACINTO CERVICAL CANCER 2007|[?]|nmol/day|PSEUDOPROGRESSION|1|ELISA unit/mL|PELLI-ROBSON EYE CHART||||ADJUDICATION COMMITTEE|PATHOLOGIST 1|Y|4|Visit_4|65|2|SCREENING|2020-08-26|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-21|P1Y2M10DT2H30M|COINCIDENT|2020-08-22|AFTER|2020-09-01
e|RS|7a5ae465-03b9-4006-a29e-94822ed857aa|8|MNPTHIND|Minor Pathological Response Indicator|GUPPY OVARIAN CANCER 2002|[?]|MET*min|PSA PROGRESSION|1|TCID 50/dose|ELISA||||ADJUDICATION COMMITTEE|NEUROLOGIST|U|4|Visit_4|65|4|TREATMENT|2020-08-26|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-21|P1Y2M10DT2H30M|AFTER|2020-08-21|BEFORE|2020-09-25
e|RS|7a5ae465-03b9-4006-a29e-94822ed857aa|9|MRDIND|Minimal Residual Disease Indicator|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|mmol/kg|NR|1|10^6/hpf|AURAMINE STAIN||||SIBLING|MICROSCOPIST 2|Y|5|Visit_5|90|7|TREATMENT|2020-09-20|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-12|P1Y2M10DT2H30M|COINCIDENT|2020-08-31|AFTER|2020-09-18
e|RS|7a5ae465-03b9-4006-a29e-94822ed857aa|10|NTNERESP|Non-Target Non-Enhancing Response|MURPHY PROSTATE CANCER 1980|[?]|mL/kg/h|CR|1|cy/cm|TEST STRIP|Y|||HEALTH CARE PROFESSIONAL|RADIOLOGIST|NA|5|Visit_5|90|6|TREATMENT|2020-09-20|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-12|P1Y2M10DT2H30M|BEFORE|2020-09-05|BEFORE|2020-09-25
e|RS|179801c9-6c40-4d58-b8a6-6f2cee9c9d58|1|MRPHRESP|Morphologic Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|||INCREASED|1|mmol|MICROBIAL CULTURE||Y|Y|PROXY|READER 2|Y|1|Visit_1|10|5|TREATMENT|2020-09-22|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-14|P1Y2M10DT2H30M|BEFORE|2020-10-21|AFTER|2020-12-18
e|RS|179801c9-6c40-4d58-b8a6-6f2cee9c9d58|2|NTERESP|Non-Target Enhancing Response|MACDONALD GLIOMA 1990|||RELAPSED DISEASE FROM CR|1|Pa|IMMUNOBLOT|||Y|CAREGIVER|CARDIOLOGIST|Y|1|Visit_1|10|7|TREATMENT|2020-09-22|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-14|P1Y2M10DT2H30M|UNKNOWN|2020-12-06|AFTER|2020-12-10
e|RS|179801c9-6c40-4d58-b8a6-6f2cee9c9d58|3|METSIND|Metastatic Indicator|CHOI GIST 2008|[?]|mkat|iCPD|1|/VF|CONGO RED STAIN||||CLINICAL STUDY SPONSOR|READER 2|NA|2|Visit_2|25|7|SCREENING|2020-10-07|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-06|P1Y2M10DT2H30M|AFTER|2020-10-02|COINCIDENT|2020-10-08
e|RS|179801c9-6c40-4d58-b8a6-6f2cee9c9d58|4|SFTSRESP|Soft Tissue Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|um2|PR|1|cL|ELISPOT||||SIGNIFICANT OTHER|RATER|N|2|Visit_2|25|6|TREATMENT|2020-10-07|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-06|P1Y2M10DT2H30M|UNKNOWN|2020-12-12|BEFORE|2020-12-20
e|RS|179801c9-6c40-4d58-b8a6-6f2cee9c9d58|5|MRPHRESP|Morphologic Response|PCWG SCHER PROSTATE CANCER 2016|[?]|kat|CYTOGENETIC CR|1|10^3/L|ENDPOINT DILUTION ASSAY||||SIBLING|PHYSIOTHERAPIST|N|3|Visit_3|40|3|TREATMENT|2020-10-22|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-15|P1Y2M10DT2H30M|UNKNOWN|2020-10-31|BEFORE|2020-12-17
e|RS|179801c9-6c40-4d58-b8a6-6f2cee9c9d58|6|LIVRRESP|Liver Response|NCCN ALL MRD 2014|[?]|10^8 PFU|CA125 50% RESPONSE|1|mOsm/kg|IMMUNOCHROMATOGRAPHY||||SIBLING|NEUROLOGIST|NA|3|Visit_3|40|5|SCREENING|2020-10-22|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-15|P1Y2M10DT2H30M|UNKNOWN|2020-09-29|ONGOING|2020-10-13
e|RS|179801c9-6c40-4d58-b8a6-6f2cee9c9d58|7|NTRGRESP|Non-target Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|||NR|1|mL/animal/wk|IMMUNODIFFUSION|Y||Y|DOMESTIC PARTNER|CLINICAL PATHOLOGIST|Y|4|Visit_4|65|2|WASHOUT|2020-11-16|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-15|P1Y2M10DT2H30M|AFTER|2020-12-19|ONGOING|2020-12-20
e|RS|179801c9-6c40-4d58-b8a6-6f2cee9c9d58|8|NEWLPROG|New Lesion Progression|CHESON CLL 2006|[?]|ug/L|cCR|1|mCi/L|TELLER ACUITY CARDS|Y|||SIBLING|UROLOGIST|U|4|Visit_4|65|6|WASHOUT|2020-11-16|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-15|P1Y2M10DT2H30M|COINCIDENT|2020-10-24|AFTER|2020-11-23
e|RS|179801c9-6c40-4d58-b8a6-6f2cee9c9d58|9|BONERESP|Bone Response|PCWG SCHER PROSTATE CANCER 2008|[?]|JDF Unit|PARTIAL MORPHOLOGIC RESPONSE|1|Bq/kg|ECHOCARDIOGRAPHY|Y|Y||INVESTIGATOR|OPTOMETRIST|N|5|Visit_5|90|2|TREATMENT|2020-12-11|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-24|P1Y2M10DT2H30M|BEFORE|2020-09-27|COINCIDENT|2020-10-06
e|RS|179801c9-6c40-4d58-b8a6-6f2cee9c9d58|10|SPLNRESP|Spleen Response|GUILHOT CML 2007|||PMD|1|U/g/day|FUNDUS PHOTOGRAPHY|||Y|CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 2|NA|5|Visit_5|90|6|FOLLOW-UP|2020-12-11|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-24|P1Y2M10DT2H30M|UNKNOWN|2020-10-24|AFTER|2020-11-24
e|RS|2e4cd860-734a-40b0-bde5-ca08297415a9|1|BONERESP|Bone Response|PERCIST|[?]|PA|NE|1|mL/kg|MAGNETIC RESONANCE ENTEROGRAPHY||||HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|N|1|Visit_1|10|6|TREATMENT|2020-11-25|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-03|P1Y2M10DT2H30M|COINCIDENT|2020-12-12|BEFORE|2021-01-24
e|RS|2e4cd860-734a-40b0-bde5-ca08297415a9|2|NTLWIND|Non-Target Lesion Worsening Indicator|KUMAR IMWG 2016|[?]|mJoule/cm2|iCR|1|BISCUIT|HANSEL STAIN||||INDEPENDENT ASSESSOR|PATHOLOGIST 2|NA|1|Visit_1|10|6|WASHOUT|2020-11-25|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-03|P1Y2M10DT2H30M|UNKNOWN|2021-01-19|ONGOING|2021-01-31
e|RS|2e4cd860-734a-40b0-bde5-ca08297415a9|3|RDIORESP|Radiologic Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|/wk|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|ukat|FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY||||CLINICAL STUDY SPONSOR|RADIOLOGIST 1|Y|2|Visit_2|25|6|TREATMENT|2020-12-10|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-06|P1Y2M10DT2H30M|BEFORE|2020-12-18|BEFORE|2021-02-19
e|RS|2e4cd860-734a-40b0-bde5-ca08297415a9|4|NEWLIND|New Lesion Indicator|CHESON CLL 2012|[?]|g/cm2|CYTOGENETIC CR|1|uEq|LASER CAPTURE MICRODISSECTION||||VENDOR|OPHTHALMOLOGIST|U|2|Visit_2|25|7|TREATMENT|2020-12-10|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-06|P1Y2M10DT2H30M|UNKNOWN|2021-01-08|ONGOING|2021-01-26
e|RS|2e4cd860-734a-40b0-bde5-ca08297415a9|5|DRCRIND|Disease Recurrence Indicator|HARTMAN PANCREATIC CANCER 2012|[?]|g/dL|EQUIVOCAL|1|Mile|SLIT LAMP PHOTOGRAPHY|Y|||CLINICAL STUDY SPONSOR|MICROSCOPIST 2|NA|3|Visit_3|40|1|TREATMENT|2020-12-25|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-30|P1Y2M10DT2H30M|BEFORE|2021-02-04|BEFORE|2021-02-11
e|RS|2e4cd860-734a-40b0-bde5-ca08297415a9|6|ANATRESP|Anatomic Response|LUGANO CLASSIFICATION|[?]|uV2|iCPD|1|mg/cm2|SLIT LAMP PHOTOGRAPHY||Y||CLINICAL RESEARCH COORDINATOR|READER 2|NA|3|Visit_3|40|2|TREATMENT|2020-12-25|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-30|P1Y2M10DT2H30M|COINCIDENT|2021-02-22|ONGOING|2021-02-23
e|RS|2e4cd860-734a-40b0-bde5-ca08297415a9|7|NEWLWIND|New Lesion Worsening Indicator|IWG CHESON MDS 2000|[?]|/month|iCR|1|mU/L|GC/MS||||INVESTIGATOR|ONCOLOGIST|Y|4|Visit_4|65|6|TREATMENT|2021-01-19|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-14|P1Y2M10DT2H30M|COINCIDENT|2021-01-22|ONGOING|2021-02-16
e|RS|2e4cd860-734a-40b0-bde5-ca08297415a9|8|SYMPTDTR|Symptomatic Deterioration|PCWG SCHER PROSTATE CANCER 2008|[?]|breaths/min|PSEUDOPROGRESSION|1|deg2|IMMUNODIFFUSION||||CHILD|INTERNIST|N|4|Visit_4|65|4|TREATMENT|2021-01-19|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-14|P1Y2M10DT2H30M|COINCIDENT|2021-01-20|BEFORE|2021-01-24
e|RS|2e4cd860-734a-40b0-bde5-ca08297415a9|9|BONERESP|Bone Response|SCHER PROSTATE CANCER 2011|||MINOR PATHOLOGIC RESPONSE|1|10^6 organisms/g|MALDI||Y|Y|PARENT|ENDOCRINOLOGIST|N|5|Visit_5|90|5|SCREENING|2021-02-13|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-29|P1Y2M10DT2H30M|BEFORE|2021-01-28|ONGOING|2021-02-04
e|RS|2e4cd860-734a-40b0-bde5-ca08297415a9|10|RDIORESP|Radiologic Response|AJCC V8|[?]|log10 TCID 50/dose|PD|1|g/cm2|PERFUSION MRI||||CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 2|U|5|Visit_5|90|5|FOLLOW-UP|2021-02-13|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-29|P1Y2M10DT2H30M|COINCIDENT|2021-02-12|COINCIDENT|2021-02-22
e|RS|3f1854fb-d14e-4699-888b-d5042fa9327c|1|NEWLPROG|New Lesion Progression|LUGANO CLASSIFICATION|[?]|mEq/day|CR-CT|1|Bq/ug|PHYSICAL EXAMINATION||||CLINICAL STUDY SPONSOR|RADIOLOGIST 1|N|1|Visit_1|10|6|TREATMENT|2020-08-04|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-23|P1Y2M10DT2H30M|BEFORE|2020-10-15|COINCIDENT|2020-10-25
e|RS|3f1854fb-d14e-4699-888b-d5042fa9327c|2|MJPTHIND|Major Pathological Response Indicator|NCCN ALL MRD 2014|[?]|10^6/L|CYTOGENETIC PR|1|DIOPTER|PERFUSION MRI|Y|||ADJUDICATION COMMITTEE|PHYSIOTHERAPIST|U|1|Visit_1|10|4|FOLLOW-UP|2020-08-04|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-23|P1Y2M10DT2H30M|BEFORE|2020-10-06|AFTER|2020-10-18
e|RS|3f1854fb-d14e-4699-888b-d5042fa9327c|3|NTERESP|Non-Target Enhancing Response|MONTSERRAT CLL 1989|[?]|10^6/Ejaculate U|CYTOGENETIC PR|1|U/g|IODINE STAIN||||SIBLING|NEUROLOGIST 1|U|2|Visit_2|25|1|TREATMENT|2020-08-19|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-16|P1Y2M10DT2H30M|BEFORE|2020-10-02|BEFORE|2020-10-15
e|RS|3f1854fb-d14e-4699-888b-d5042fa9327c|4|NEWLPROG|New Lesion Progression|CHOI GIST 2008|[?]|dpm/100mg|QUANTIFIABLE MRD POSITIVITY|1|MPL U/mL|DIRECT SEQUENCING|Y|||VENDOR|ONCOLOGIST|NA|2|Visit_2|25|4|FOLLOW-UP|2020-08-19|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-16|P1Y2M10DT2H30M|UNKNOWN|2020-09-27|AFTER|2020-10-31
e|RS|3f1854fb-d14e-4699-888b-d5042fa9327c|5|METSIND|Metastatic Indicator|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|PACKET|DECREASED|1|uU/L|DYNAMIC LIGHT SCATTERING|Y|||ADJUDICATOR|READER 3|NA|3|Visit_3|40|6|SCREENING|2020-09-03|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-03|P1Y2M10DT2H30M|UNKNOWN|2020-08-02|AFTER|2020-09-30
e|RS|3f1854fb-d14e-4699-888b-d5042fa9327c|6|MNPTHIND|Minor Pathological Response Indicator|CHESON LYMPHOMA 2008|[?]|kg/cm|EQUIVOCAL|1|U/kg/h|NEPHELOMETRY|Y|||GUARDIAN|OPTOMETRIST|U|3|Visit_3|40|2|TREATMENT|2020-09-03|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-03|P1Y2M10DT2H30M|BEFORE|2020-08-07|BEFORE|2020-09-15
e|RS|3f1854fb-d14e-4699-888b-d5042fa9327c|7|NEWLPROG|New Lesion Progression|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|CFU/g|RELAPSED DISEASE|1|U/m2/min|MULTI-SLICE SPIRAL CT|Y|||VENDOR|NEUROLOGIST 2|NA|4|Visit_4|65|3|TREATMENT|2020-09-28|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-27|P1Y2M10DT2H30M|UNKNOWN|2020-10-12|ONGOING|2020-10-25
e|RS|3f1854fb-d14e-4699-888b-d5042fa9327c|8|METSIND|Metastatic Indicator|iRECIST|||iSD|1|gtt|HEMOCYTOMETRY|Y||Y|CHILD|PATHOLOGIST|Y|4|Visit_4|65|2|TREATMENT|2020-09-28|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-27|P1Y2M10DT2H30M|AFTER|2020-09-17|BEFORE|2020-09-28
e|RS|3f1854fb-d14e-4699-888b-d5042fa9327c|9|CLINRESP|Clinical Response|LEE LUNG CANCER 2011|[?]|/kg|STABLE|1|/LSQN|ERGOSPIROMETRY||||ADJUDICATOR|NEUROLOGIST 2|Y|5|Visit_5|90|7|FOLLOW-UP|2020-10-23|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-07|P1Y2M10DT2H30M|COINCIDENT|2020-10-03|COINCIDENT|2020-10-26
e|RS|3f1854fb-d14e-4699-888b-d5042fa9327c|10|BONERESP|Bone Response|KEAM BREAST CANCER 2013|[?]|mL/day|NED|1|mg/dose|IMPULSE OSCILLOMETRY||||DOMESTIC PARTNER|RATER 2|Y|5|Visit_5|90|2|TREATMENT|2020-10-23|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-07|P1Y2M10DT2H30M|BEFORE|2020-08-29|ONGOING|2020-10-10
e|RS|f6e37eba-e224-47f3-baa0-59dfdfb47b70|1|NEWLIND|New Lesion Indicator|GUPPY OVARIAN CANCER 2002|[?]|kBq|HI-P|1|mg/mol|LISSAMINE GREEN STAIN|Y|||INDEPENDENT ASSESSOR|PEDIATRIC NEUROLOGIST|Y|1|Visit_1|10|6|TREATMENT|2020-12-10|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-01|P1Y2M10DT2H30M|BEFORE|2021-01-31|ONGOING|2021-02-06
e|RS|f6e37eba-e224-47f3-baa0-59dfdfb47b70|2|ANATRESP|Anatomic Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|DNA copies/ug|MORPHOLOGIC LEUKEMIA-FREE STATE|1|mg/kg/dose|HPLC/IEX||Y||SPOUSE|UROLOGIST|N|1|Visit_1|10|4|TREATMENT|2020-12-10|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-01|P1Y2M10DT2H30M|BEFORE|2020-12-13|ONGOING|2020-12-17
e|RS|f6e37eba-e224-47f3-baa0-59dfdfb47b70|3|LIVRRESP|Liver Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|ECL unit|PMD|1|ug/dose|NEXT GENERATION SEQUENCING||||HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|NA|2|Visit_2|25|2|WASHOUT|2020-12-25|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-06|P1Y2M10DT2H30M|BEFORE|2021-02-24|AFTER|2021-03-02
e|RS|f6e37eba-e224-47f3-baa0-59dfdfb47b70|4|MRDRESP|Minimal Residual Disease Response|NCIWG CHESON CLL 1996|[?]|m/sec2|DECREASED|1|nmol/kg/day|MOUSE PROTECTION ASSAY||||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR|Y|2|Visit_2|25|3|SCREENING|2020-12-25|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-06|P1Y2M10DT2H30M|AFTER|2021-02-23|COINCIDENT|2021-03-03
e|RS|f6e37eba-e224-47f3-baa0-59dfdfb47b70|5|NTERESP|Non-Target Enhancing Response|UNSPECIFIED|[?]|dram|FAVORABLE RESPONSE|1|mEq/L|CYSTOSCOPY|Y|Y||NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|N|3|Visit_3|40|4|SCREENING|2021-01-09|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-23|P1Y2M10DT2H30M|UNKNOWN|2021-03-07|ONGOING|2021-03-09
e|RS|f6e37eba-e224-47f3-baa0-59dfdfb47b70|6|RDIORESP|Radiologic Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|mL/animal/day|MORPHOLOGIC CR|1|CAN|ELECTROPHORESIS|Y|||FRIEND|OTOLARYNGOLOGIST|Y|3|Visit_3|40|6|TREATMENT|2021-01-09|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-23|P1Y2M10DT2H30M|COINCIDENT|2020-12-21|BEFORE|2021-01-29
e|RS|f6e37eba-e224-47f3-baa0-59dfdfb47b70|7|SFTSRESP|Soft Tissue Response|DOHNER AML 2010|[?]|mL/(min*100mL)|CYTOGENETIC CR|1|tsp eq|IHC||||CLINICAL STUDY SPONSOR|ONCOLOGIST|N|4|Visit_4|65|5|WASHOUT|2021-02-03|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-05|P1Y2M10DT2H30M|BEFORE|2021-02-22|AFTER|2021-02-23
e|RS|f6e37eba-e224-47f3-baa0-59dfdfb47b70|8|SFTSRESP|Soft Tissue Response|RECIST 1.0|[?]|mg/m2|PMR|1|BP|FLUORESCENT MICROSCOPY||||HEALTH CARE PROFESSIONAL|MICROSCOPIST|Y|4|Visit_4|65|3|FOLLOW-UP|2021-02-03|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-05|P1Y2M10DT2H30M|UNKNOWN|2020-12-16|COINCIDENT|2021-02-07
e|RS|f6e37eba-e224-47f3-baa0-59dfdfb47b70|9|TRGRESP|Target Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|WAFER|sCR|1|Hz|HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY||||STUDY SUBJECT|READER 1|N|5|Visit_5|90|1|TREATMENT|2021-02-28|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-20|P1Y2M10DT2H30M|COINCIDENT|2021-01-12|BEFORE|2021-01-29
e|RS|f6e37eba-e224-47f3-baa0-59dfdfb47b70|10|NTERESP|Non-Target Enhancing Response|CHOLLET BREAST CANCER 2002|||PR WITH LYMPHOCYTOSIS|1|10^5/L|LC/MS|||Y|SIBLING|OPHTHALMOLOGIST|N|5|Visit_5|90|1|TREATMENT|2021-02-28|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-20|P1Y2M10DT2H30M|COINCIDENT|2020-12-15|BEFORE|2021-02-11
e|RS|8298b45d-16ff-42ef-8404-0f3ce628f9e5|1|MRDIND|Minimal Residual Disease Indicator|HARTMANN GERM CELL CANCER 2002|||SD-CT|1|nmol BCE/nmol|CELLULAR PROLIFERATION ASSAY|||Y|STUDY SUBJECT|RATER 1|U|1|Visit_1|10|1|SCREENING|2020-07-31|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-24|P1Y2M10DT2H30M|COINCIDENT|2020-10-27|ONGOING|2020-10-28
e|RS|8298b45d-16ff-42ef-8404-0f3ce628f9e5|2|BESTRESP|Best Overall Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|kg/cm|CA125 50% RESPONSE|1|Rad|X-RAY||||SIBLING|RATER 2|N|1|Visit_1|10|5|TREATMENT|2020-07-31|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-24|P1Y2M10DT2H30M|BEFORE|2020-08-18|COINCIDENT|2020-09-17
e|RS|8298b45d-16ff-42ef-8404-0f3ce628f9e5|3|TMRESP|Tumor Marker Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|mg/m2/day|NE|1|/10^4|MICROARRAY|Y|||INVESTIGATOR|INTERNIST|N|2|Visit_2|25|7|TREATMENT|2020-08-15|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-21|P1Y2M10DT2H30M|UNKNOWN|2020-10-23|BEFORE|2020-10-28
e|RS|8298b45d-16ff-42ef-8404-0f3ce628f9e5|4|TRGRESP|Target Response|KUKER LYMPHOMA 2005|[?]|g/animal|NED|1|GBq/mg|MAGNETIC RESONANCE ELASTOGRAPHY|Y|||NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST|Y|2|Visit_2|25|3|FOLLOW-UP|2020-08-15|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-21|P1Y2M10DT2H30M|COINCIDENT|2020-10-16|AFTER|2020-10-28
e|RS|8298b45d-16ff-42ef-8404-0f3ce628f9e5|5|TRGRESP|Target Response|CHOLLET BREAST CANCER 2002|[?]|U/g/min|UNEQUIVOCAL|1|AU/mL|PET SCAN||||INTERVIEWER|READER 1|NA|3|Visit_3|40|4|TREATMENT|2020-08-30|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-04|P1Y2M10DT2H30M|BEFORE|2020-10-05|COINCIDENT|2020-10-21
e|RS|8298b45d-16ff-42ef-8404-0f3ce628f9e5|6|MRDIND|Minimal Residual Disease Indicator|MRECIST BYRNE MESOTHELIOMA 2004|[?]|ag|PD/RELAPSE AFTER HI|1|mL/min|BIOIMPEDANCE SPECTROSCOPY||||GUARDIAN|ADJUDICATOR 2|N|3|Visit_3|40|7|WASHOUT|2020-08-30|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-04|P1Y2M10DT2H30M|UNKNOWN|2020-10-04|ONGOING|2020-10-22
e|RS|8298b45d-16ff-42ef-8404-0f3ce628f9e5|7|NEWLWIND|New Lesion Worsening Indicator|NCCN ALL MRD 2014|[?]|mkat|DECREASED|1|10^6 organisms/g|GIEMSA STAIN|Y|||CAREGIVER|READER 3|NA|4|Visit_4|65|4|FOLLOW-UP|2020-09-24|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-18|P1Y2M10DT2H30M|COINCIDENT|2020-10-24|ONGOING|2020-10-25
e|RS|8298b45d-16ff-42ef-8404-0f3ce628f9e5|8|SFTSRESP|Soft Tissue Response|SHINDOH COLORECTAL CANCER 2013|[?]|mol/day|VGPR|1|lm|AMSLER GRID|Y|||GUARDIAN|ADJUDICATOR 3|NA|4|Visit_4|65|7|FOLLOW-UP|2020-09-24|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-18|P1Y2M10DT2H30M|AFTER|2020-09-26|ONGOING|2020-10-20
e|RS|8298b45d-16ff-42ef-8404-0f3ce628f9e5|9|RDIORESP|Radiologic Response|CHOLLET BREAST CANCER 2002|[?]|nmol BCE/mmol|iPR|1|DAgU/mL|LASER CAPTURE MICRODISSECTION|Y|Y||PARENT|RATER 1|NA|5|Visit_5|90|4|TREATMENT|2020-10-19|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-23|P1Y2M10DT2H30M|BEFORE|2020-10-07|ONGOING|2020-10-23
e|RS|8298b45d-16ff-42ef-8404-0f3ce628f9e5|10|CPRFSTAT|Clinical Performance Status|CHESON CLL 2006|[?]|in|MR|1|TABLET|ORCHIDOMETERY|Y|||INDEPENDENT ASSESSOR|PEDIATRIC NEUROLOGIST|Y|5|Visit_5|90|3|TREATMENT|2020-10-19|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-23|P1Y2M10DT2H30M|UNKNOWN|2020-08-12|BEFORE|2020-08-29
e|RS|ee5c6623-5cb4-4f18-99b0-6373328abc1d|1|MNPTHIND|Minor Pathological Response Indicator|SHINDOH COLORECTAL CANCER 2013|[?]|mg/m2/h|MINOR PATHOLOGIC RESPONSE|1|umol/mg/min|SLOAN LETTER EYE CHART 1.25%||||CAREGIVER|ADJUDICATOR 1|N|1|Visit_1|10|1|TREATMENT|2020-06-11|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-04|P1Y2M10DT2H30M|AFTER|2020-08-02|AFTER|2020-09-06
e|RS|ee5c6623-5cb4-4f18-99b0-6373328abc1d|2|BMIVLIND|Bone Marrow Involvement Indicator|RANO ELLINGSON 2017|[?]|Ci/mL|PD-CT|1|vg/kg|NEPHELOMETRY||||SPOUSE|MICROSCOPIST 1|NA|1|Visit_1|10|6|TREATMENT|2020-06-11|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-04|P1Y2M10DT2H30M|AFTER|2020-06-17|AFTER|2020-07-15
e|RS|ee5c6623-5cb4-4f18-99b0-6373328abc1d|3|MOLRESP|Molecular Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|cd|iPR|1|mmol/L|FLUORESCENCE ANGIOGRAPHY||||CHILD|RATER 1|NA|2|Visit_2|25|7|TREATMENT|2020-06-26|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-22|P1Y2M10DT2H30M|BEFORE|2020-08-16|ONGOING|2020-09-05
e|RS|ee5c6623-5cb4-4f18-99b0-6373328abc1d|4|TRGRESP|Target Response|GUPPY OVARIAN CANCER 2002|||sCR|1|uOsm|REBOUND TONOMETRY|||Y|SIGNIFICANT OTHER|RADIOLOGIST 2|NA|2|Visit_2|25|5|SCREENING|2020-06-26|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-22|P1Y2M10DT2H30M|AFTER|2020-07-24|AFTER|2020-09-06
e|RS|ee5c6623-5cb4-4f18-99b0-6373328abc1d|5|STRUSTAT|Steroid Use Status|RANO|[?]|cd|CRi|1|pmol/day|PHASE CONTRAST MICROSCOPY|Y|||INVESTIGATOR|INTERNIST|U|3|Visit_3|40|4|FOLLOW-UP|2020-07-11|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-20|P1Y2M10DT2H30M|UNKNOWN|2020-06-16|COINCIDENT|2020-07-20
e|RS|ee5c6623-5cb4-4f18-99b0-6373328abc1d|6|SYMPTDTR|Symptomatic Deterioration|RANO|||PD|1|cd|GC/FID|Y|Y|Y|FRIEND|RADIOLOGIST|NA|3|Visit_3|40|3|FOLLOW-UP|2020-07-11|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-20|P1Y2M10DT2H30M|BEFORE|2020-06-06|AFTER|2020-08-31
e|RS|ee5c6623-5cb4-4f18-99b0-6373328abc1d|7|MRDIND|Minimal Residual Disease Indicator|SHINDOH COLORECTAL CANCER 2013|[?]|m/sec2|mCR|1|mm3/mm2/year|LIGHT SCATTERING SPECTROSCOPY||||CLINICAL STUDY SPONSOR|ONCOLOGIST|Y|4|Visit_4|65|2|SCREENING|2020-08-05|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-07|P1Y2M10DT2H30M|UNKNOWN|2020-09-04|COINCIDENT|2020-09-08
e|RS|ee5c6623-5cb4-4f18-99b0-6373328abc1d|8|NEWLPROG|New Lesion Progression|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|log10 TCID 50/mL|QUANTIFIABLE MRD POSITIVITY|1|10^9 CFU|ACID FAST STAIN|Y|||PARENT|RATER 1|U|4|Visit_4|65|2|TREATMENT|2020-08-05|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-07|P1Y2M10DT2H30M|BEFORE|2020-08-08|ONGOING|2020-08-21
e|RS|ee5c6623-5cb4-4f18-99b0-6373328abc1d|9|CLINRESP|Clinical Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|usec|NON-iCR/NON-iUPD|1|BAU/mL|IN VITRO GENE EXPRESSION ASSAY||Y||CHILD|DEVELOPMENTAL PSYCHOLOGIST|Y|5|Visit_5|90|3|SCREENING|2020-08-30|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-30|P1Y2M10DT2H30M|UNKNOWN|2020-08-22|AFTER|2020-09-08
e|RS|ee5c6623-5cb4-4f18-99b0-6373328abc1d|10|MNPTHIND|Minor Pathological Response Indicator|FAROOQUI SUPP CLL 2014|||INCREASED|1|keV|IMMUNOASSAY|Y||Y|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR|U|5|Visit_5|90|1|TREATMENT|2020-08-30|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-30|P1Y2M10DT2H30M|UNKNOWN|2020-09-05|AFTER|2020-09-07
e|RS|f8d6576b-b300-4c5f-8f5a-6bb35250d576|1|MRDIND|Minimal Residual Disease Indicator|MASS|[?]|ug/g/min|nPR|1|copies/mL|MS/MS|Y|||ADJUDICATOR|READER|U|1|Visit_1|10|3|TREATMENT|2020-06-25|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-17|P1Y2M10DT2H30M|AFTER|2020-09-11|BEFORE|2020-09-13
e|RS|f8d6576b-b300-4c5f-8f5a-6bb35250d576|2|METSIND|Metastatic Indicator|CHOLLET BREAST CANCER 2002|[?]|/10^3|PSA PROGRESSION|1|/500 WBC|FLUORESCENT LIFETIME IMAGING MICROSCOPY||Y||FRIEND|OPHTHALMOLOGIST|Y|1|Visit_1|10|7|FOLLOW-UP|2020-06-25|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-17|P1Y2M10DT2H30M|COINCIDENT|2020-09-11|BEFORE|2020-09-18
e|RS|f8d6576b-b300-4c5f-8f5a-6bb35250d576|3|NTERESP|Non-Target Enhancing Response|MACDONALD GLIOMA 1990|[?]|log10 IU/mL|RELAPSED DISEASE|1|log10 CFU/mL|STRESS ECHOCARDIOGRAPHY||||FAMILY MEMBER|RATER 1|N|2|Visit_2|25|3|SCREENING|2020-07-10|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-06|P1Y2M10DT2H30M|COINCIDENT|2020-07-12|ONGOING|2020-08-16
e|RS|f8d6576b-b300-4c5f-8f5a-6bb35250d576|4|BESTRESP|Best Overall Response|MONTSERRAT CLL 1989|||MRD PERSISTENCE|1|log10 TCID 50/mL|MRI||Y|Y|ADJUDICATOR|NEUROLOGIST 1|U|2|Visit_2|25|1|FOLLOW-UP|2020-07-10|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-06|P1Y2M10DT2H30M|BEFORE|2020-06-25|AFTER|2020-07-29
e|RS|f8d6576b-b300-4c5f-8f5a-6bb35250d576|5|MRPHRESP|Morphologic Response|SACT|[?]|min|PDu|1|mm/2h|RAJI CELL EIA||||VENDOR|ADJUDICATOR|U|3|Visit_3|40|7|WASHOUT|2020-07-25|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-08|P1Y2M10DT2H30M|BEFORE|2020-07-07|COINCIDENT|2020-07-12
e|RS|f8d6576b-b300-4c5f-8f5a-6bb35250d576|6|MRDIND|Minimal Residual Disease Indicator|PRINCE TCELL LYMPHOMA 2010|[?]|/10^5|CYTOGENETIC CR|1|JAR|LAPAROSCOPY||||GUARDIAN|RATER 2|Y|3|Visit_3|40|5|TREATMENT|2020-07-25|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-08|P1Y2M10DT2H30M|BEFORE|2020-07-16|BEFORE|2020-07-19
e|RS|f8d6576b-b300-4c5f-8f5a-6bb35250d576|7|PATHRESP|Pathologic Response|WOLCHOK SOLID TUMORS 2009|[?]|/mm2|iUPD|1|KALLIKREIN INHIBITOR UNIT|NUCLEIC ACID SEQUENCING||Y||STUDY SUBJECT|READER|NA|4|Visit_4|65|3|TREATMENT|2020-08-19|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-14|P1Y2M10DT2H30M|COINCIDENT|2020-07-05|BEFORE|2020-08-31
e|RS|f8d6576b-b300-4c5f-8f5a-6bb35250d576|8|ANATRESP|Anatomic Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|L/min|SD|1|cd|MAGNETIC RESONANCE ELASTOGRAPHY|Y|||ADJUDICATION COMMITTEE|ONCOLOGIST 2|Y|4|Visit_4|65|1|TREATMENT|2020-08-19|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-14|P1Y2M10DT2H30M|COINCIDENT|2020-09-12|COINCIDENT|2020-09-19
e|RS|f8d6576b-b300-4c5f-8f5a-6bb35250d576|9|RDIORESP|Radiologic Response|JUWEID NON-HODGKINS LYMPHOMA 2005|||CYTOGENETIC PR|1|IU/g|TOTAL BODY IRRADIATION||Y|Y|CHILD|HEMATOLOGIST|Y|5|Visit_5|90|1|SCREENING|2020-09-13|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-05|P1Y2M10DT2H30M|COINCIDENT|2020-07-12|COINCIDENT|2020-07-24
e|RS|f8d6576b-b300-4c5f-8f5a-6bb35250d576|10|SYMPTDTR|Symptomatic Deterioration|RANO ELLINGSON 2017|[?]|mEq/ug|DECREASED|1|10^3 CFU/g|CONFOCAL MICROSCOPY||||NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|NA|5|Visit_5|90|4|TREATMENT|2020-09-13|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-05|P1Y2M10DT2H30M|UNKNOWN|2020-07-07|BEFORE|2020-07-22
e|RS|8635a6b3-d16e-432c-90bf-53f1494dbe5e|1|BESTRESP|Best Overall Response|LEE LUNG CANCER 2011|||IMMUNOPHENOTYPIC CR|1|Henry|KINETIC MICROPARTICLE IMMUNOASSAY|||Y|SIGNIFICANT OTHER|ENDOCRINOLOGIST|NA|1|Visit_1|10|7|SCREENING|2020-10-26|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-20|P1Y2M10DT2H30M|BEFORE|2020-11-13|COINCIDENT|2020-12-18
e|RS|8635a6b3-d16e-432c-90bf-53f1494dbe5e|2|ANATRESP|Anatomic Response|JACINTO CERVICAL CANCER 2007|[?]|um/day|MRD RELAPSE|1|/5x10^4 WBC|ELECTROMYOGRAPHY||||INTERVIEWER|MICROSCOPIST|Y|1|Visit_1|10|2|WASHOUT|2020-10-26|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-20|P1Y2M10DT2H30M|COINCIDENT|2021-01-23|COINCIDENT|2021-01-24
e|RS|8635a6b3-d16e-432c-90bf-53f1494dbe5e|3|TRGRESP|Target Response|SCHWARZ CERVICAL CANCER 2009|[?]|psi|NON-iCR/NON-iUPD|1|mm/sec|QUANTITATIVE PERIPHERAL ANGIOGRAPHY||||INVESTIGATOR|DERMATOLOGIST|N|2|Visit_2|25|6|TREATMENT|2020-11-10|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-23|P1Y2M10DT2H30M|AFTER|2021-01-19|ONGOING|2021-01-22
e|RS|8635a6b3-d16e-432c-90bf-53f1494dbe5e|4|HEMARESP|Hematologic Response|SHINDOH COLORECTAL CANCER 2013|||INDETERMINATE RESPONSE|1|10^11/L|CONFOCAL MICROSCOPY||Y|Y|SPOUSE|ONCOLOGIST 1|NA|2|Visit_2|25|6|TREATMENT|2020-11-10|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-23|P1Y2M10DT2H30M|UNKNOWN|2020-11-25|AFTER|2020-12-24
e|RS|8635a6b3-d16e-432c-90bf-53f1494dbe5e|5|LIVRRESP|Liver Response|JUWEID NON-HODGKINS LYMPHOMA 2005|||PR-CT|1|ug/L DDU|HEMAGGLUTINATION ASSAY|||Y|SIGNIFICANT OTHER|INTERNIST|U|3|Visit_3|40|2|WASHOUT|2020-11-25|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-16|P1Y2M10DT2H30M|COINCIDENT|2020-12-11|ONGOING|2021-01-07
e|RS|8635a6b3-d16e-432c-90bf-53f1494dbe5e|6|MRDRESP|Minimal Residual Disease Response|AJCC V8|||CA125 50% RESPONSE|1|ug/animal|MRI|||Y|CHILD|ENDOCRINOLOGIST|N|3|Visit_3|40|5|FOLLOW-UP|2020-11-25|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-16|P1Y2M10DT2H30M|AFTER|2020-12-19|COINCIDENT|2021-01-23
e|RS|8635a6b3-d16e-432c-90bf-53f1494dbe5e|7|CYTORESP|Cytogenetic Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|100 IU/mL|FAVORABLE RESPONSE|1|nmol|FLUORIMETRY|Y|||STUDY SUBJECT|OPHTHALMOLOGIST|N|4|Visit_4|65|7|TREATMENT|2020-12-20|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-30|P1Y2M10DT2H30M|COINCIDENT|2020-11-24|ONGOING|2021-01-19
e|RS|8635a6b3-d16e-432c-90bf-53f1494dbe5e|8|MNPTHIND|Minor Pathological Response Indicator|WOLCHOK SOLID TUMORS 2009|[?]|mL/min/mmHg|EQUIVOCAL|1|/mm|CT SCAN||||INDEPENDENT ASSESSOR|ADJUDICATOR|Y|4|Visit_4|65|4|TREATMENT|2020-12-20|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-30|P1Y2M10DT2H30M|BEFORE|2020-10-19|COINCIDENT|2020-12-07
e|RS|8635a6b3-d16e-432c-90bf-53f1494dbe5e|9|BMIVLIND|Bone Marrow Involvement Indicator|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|g/L|PD|1|mgEq|CINEANGIOGRAPHY||||SIGNIFICANT OTHER|RADIOLOGIST 1|Y|5|Visit_5|90|3|TREATMENT|2021-01-14|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-02|P1Y2M10DT2H30M|BEFORE|2020-12-02|ONGOING|2020-12-07
e|RS|8635a6b3-d16e-432c-90bf-53f1494dbe5e|10|MNPTHIND|Minor Pathological Response Indicator|iRECIST|||CA125 75% RESPONSE|1|Hz|HPLC-UV|||Y|CLINICAL STUDY SPONSOR|MICROSCOPIST 3|Y|5|Visit_5|90|5|WASHOUT|2021-01-14|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-02|P1Y2M10DT2H30M|BEFORE|2021-01-20|AFTER|2021-01-21
e|RS|2cda4297-410a-49e4-949c-deb3dc4c6656|1|NEWLWIND|New Lesion Worsening Indicator|SHINDOH COLORECTAL CANCER 2013|[?]|PRESSOR UNITS|WORSENED|1|AFU|MASS SPECTROMETRY||||NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|Y|1|Visit_1|10|7|FOLLOW-UP|2020-06-20|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-23|P1Y2M10DT2H30M|UNKNOWN|2020-08-17|BEFORE|2020-09-05
e|RS|2cda4297-410a-49e4-949c-deb3dc4c6656|2|METBRESP|Metabolic Response|KUMAR IMWG 2016|||CA125 50% RESPONSE|1|lx|CLIP||Y|Y|FRIEND|DEVELOPMENTAL PSYCHOLOGIST|U|1|Visit_1|10|6|SCREENING|2020-06-20|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-23|P1Y2M10DT2H30M|BEFORE|2020-06-29|AFTER|2020-07-25
e|RS|2cda4297-410a-49e4-949c-deb3dc4c6656|3|MJPTHIND|Major Pathological Response Indicator|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|copies/ug|MORPHOLOGIC LEUKEMIA-FREE STATE|1|mL/cm H2O|NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY||||NON-HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|U|2|Visit_2|25|2|TREATMENT|2020-07-05|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-08|P1Y2M10DT2H30M|AFTER|2020-07-16|COINCIDENT|2020-08-20
e|RS|2cda4297-410a-49e4-949c-deb3dc4c6656|4|BONERESP|Bone Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|fmol/g|CR-CT|1|10^3 organisms/mL|REFRACTOMETRY||||VENDOR|CLINICAL PATHOLOGIST|N|2|Visit_2|25|3|WASHOUT|2020-07-05|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-08|P1Y2M10DT2H30M|COINCIDENT|2020-06-14|AFTER|2020-09-03
e|RS|2cda4297-410a-49e4-949c-deb3dc4c6656|5|NTLWIND|Non-Target Lesion Worsening Indicator|IWG CHESON MDS 2000|[?]|mg/day|CYTOGENETIC MINOR RESPONSE|1|nmol/L|MODIFIED ACID FAST STAIN||Y||FRIEND|ONCOLOGIST|NA|3|Visit_3|40|7|FOLLOW-UP|2020-07-20|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-24|P1Y2M10DT2H30M|UNKNOWN|2020-06-27|AFTER|2020-09-07
e|RS|2cda4297-410a-49e4-949c-deb3dc4c6656|6|NEWLIND|New Lesion Indicator|HARTMAN PANCREATIC CANCER 2012|[?]|mg/dose|PARTIAL MORPHOLOGIC RESPONSE|1|/2500 WBC|IMMUNOTURBIDIMETRY|Y|||PROXY|MICROSCOPIST|N|3|Visit_3|40|1|TREATMENT|2020-07-20|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-24|P1Y2M10DT2H30M|AFTER|2020-08-13|AFTER|2020-09-02
e|RS|2cda4297-410a-49e4-949c-deb3dc4c6656|7|MRPHRESP|Morphologic Response|RANO ELLINGSON 2017|[?]|pL|IMMUNOPHENOTYPIC CR|1|g/U|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION||||INTERVIEWER|READER 2|N|4|Visit_4|65|3|TREATMENT|2020-08-14|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-14|P1Y2M10DT2H30M|BEFORE|2020-08-15|ONGOING|2020-08-27
e|RS|2cda4297-410a-49e4-949c-deb3dc4c6656|8|METBRESP|Metabolic Response|DURIE MULTIPLE MYELOMA 2006|[?]|mg/dose|ABSENT MORPHOLOGIC RESPONSE|1|Roentgen|TRYPAN BLUE STAIN||||CLINICAL RESEARCH COORDINATOR|PEDIATRIC NEUROLOGIST|NA|4|Visit_4|65|5|TREATMENT|2020-08-14|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-14|P1Y2M10DT2H30M|COINCIDENT|2020-08-04|AFTER|2020-09-07
e|RS|2cda4297-410a-49e4-949c-deb3dc4c6656|9|SPLNRESP|Spleen Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|||PD FROM PR|1|mL/g/h|SCINTIGRAPHY|||Y|CLINICAL RESEARCH ASSOCIATE|READER 1|NA|5|Visit_5|90|2|TREATMENT|2020-09-08|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-13|P1Y2M10DT2H30M|BEFORE|2020-07-23|AFTER|2020-08-10
e|RS|2cda4297-410a-49e4-949c-deb3dc4c6656|10|MOLRESP|Molecular Response|IWG CHESON MDS 2000|||cCR|1|IMPLANT|MULTIPLE BREATH WASHOUT|||Y|CHILD|INTERNIST|NA|5|Visit_5|90|6|TREATMENT|2020-09-08|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-13|P1Y2M10DT2H30M|BEFORE|2020-09-09|ONGOING|2020-09-10
e|RS|a74b51fe-34f5-4c8f-971f-d42e15f9cf41|1|SPLNRESP|Spleen Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|GPL U/mL|CYTOGENETIC MINOR RESPONSE|1|mg/mol|INDIRECT IMMUNOFLUORESCENCE||||NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|N|1|Visit_1|10|4|WASHOUT|2021-01-29|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-21|P1Y2M10DT2H30M|COINCIDENT|2021-04-24|AFTER|2021-04-26
e|RS|a74b51fe-34f5-4c8f-971f-d42e15f9cf41|2|NTRGRESP|Non-target Response|KUKER LYMPHOMA 2005|[?]|umol/L|CR|1|U/m2/h|WRIGHT-GIEMSA STAIN|Y|||VENDOR|INTERNIST|NA|1|Visit_1|10|6|SCREENING|2021-01-29|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-21|P1Y2M10DT2H30M|AFTER|2021-04-21|AFTER|2021-04-28
e|RS|a74b51fe-34f5-4c8f-971f-d42e15f9cf41|3|BESTRESP|Best Overall Response|WOLCHOK SOLID TUMORS 2009|[?]|/min|MOLECULAR CR|1|10^6/g|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY||||INTERVIEWER|OTOLARYNGOLOGIST|NA|2|Visit_2|25|1|WASHOUT|2021-02-13|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-07|P1Y2M10DT2H30M|UNKNOWN|2021-03-07|COINCIDENT|2021-03-16
e|RS|a74b51fe-34f5-4c8f-971f-d42e15f9cf41|4|LIVRRESP|Liver Response|PETIT BREAST CANCER 2001|[?]|ppb|UNFAVORABLE RESPONSE|1|mEq/L|MRI WITHOUT CONTRAST||Y||VENDOR|MICROSCOPIST 3|Y|2|Visit_2|25|6|TREATMENT|2021-02-13|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-07|P1Y2M10DT2H30M|UNKNOWN|2021-02-11|ONGOING|2021-04-20
e|RS|a74b51fe-34f5-4c8f-971f-d42e15f9cf41|5|NEWLIND|New Lesion Indicator|PRINCE TCELL LYMPHOMA 2010|[?]|SFC/10^6 PBMC|QUANTIFIABLE MRD POSITIVITY|1|uL/dose|MICROBIAL BIOCHEMICAL IDENTIFICATION||Y||PARENT|PHYSIOTHERAPIST|NA|3|Visit_3|40|7|FOLLOW-UP|2021-02-28|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-28|P1Y2M10DT2H30M|AFTER|2021-01-29|ONGOING|2021-04-26
e|RS|a74b51fe-34f5-4c8f-971f-d42e15f9cf41|6|SPLNRESP|Spleen Response|BRUGGEMANN MRD 2010|[?]|uEq|RELAPSED DISEASE|1|IU/mL|ULTRASOUND||||CHILD|PATHOLOGIST 2|N|3|Visit_3|40|7|FOLLOW-UP|2021-02-28|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-28|P1Y2M10DT2H30M|UNKNOWN|2021-02-15|BEFORE|2021-03-22
e|RS|a74b51fe-34f5-4c8f-971f-d42e15f9cf41|7|CLINRESP|Clinical Response|KUMAR IMWG 2016|[?]|DISK|MORPHOLOGIC CR|1|bel|MRI WITHOUT CONTRAST|Y|||PROXY|PATHOLOGIST|N|4|Visit_4|65|6|SCREENING|2021-03-25|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-27|P1Y2M10DT2H30M|UNKNOWN|2021-03-30|ONGOING|2021-04-18
e|RS|a74b51fe-34f5-4c8f-971f-d42e15f9cf41|8|CLINRESP|Clinical Response|PCWG SCHER PROSTATE CANCER 2016|||PR-CT|1|FIU|AURAMINE STAIN|Y||Y|SIBLING|RATER 2|N|4|Visit_4|65|3|TREATMENT|2021-03-25|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-27|P1Y2M10DT2H30M|BEFORE|2021-02-18|COINCIDENT|2021-03-12
e|RS|a74b51fe-34f5-4c8f-971f-d42e15f9cf41|9|NEWLWIND|New Lesion Worsening Indicator|IWG CHESON AML 2003|[?]|mmHg/L/min|PSEUDORESPONSE|1|PIXEL|NON-INVASIVE DIELECTRIC SENSING||||SIBLING|MICROSCOPIST|NA|5|Visit_5|90|4|TREATMENT|2021-04-19|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-04|P1Y2M10DT2H30M|BEFORE|2021-02-08|COINCIDENT|2021-02-21
e|RS|a74b51fe-34f5-4c8f-971f-d42e15f9cf41|10|BONERESP|Bone Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|||IMPROVED|1|ukat/L|MULTI-SLICE SPIRAL CT||Y|Y|PARENT|ADJUDICATOR|N|5|Visit_5|90|5|FOLLOW-UP|2021-04-19|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-04|P1Y2M10DT2H30M|COINCIDENT|2021-02-08|ONGOING|2021-02-24
e|RS|9e82141b-e2b9-42c7-b813-b79bda2bd216|1|BESTRESP|Best Overall Response|RAJKUMAR MYELOMA 2011|[?]|MONTHS|EQUIVOCAL|1|pmol/g|PALM METHOD||||CHILD|NEUROLOGIST|N|1|Visit_1|10|7|SCREENING|2020-05-31|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-14|P1Y2M10DT2H30M|UNKNOWN|2020-07-01|ONGOING|2020-08-26
e|RS|9e82141b-e2b9-42c7-b813-b79bda2bd216|2|NTNERESP|Non-Target Non-Enhancing Response|GCIG RUSTIN OVARIAN CANCER 2011|||CHR|1|pg|FARNSWORTH-MUNSELL 100 HUE TEST||Y|Y|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST|N|1|Visit_1|10|7|SCREENING|2020-05-31|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-14|P1Y2M10DT2H30M|AFTER|2020-08-17|BEFORE|2020-08-22
e|RS|9e82141b-e2b9-42c7-b813-b79bda2bd216|3|BESTRESP|Best Overall Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|/mm2|HI-P|1|pkat|DIGITAL PCR ARRAY||||INVESTIGATOR|PEDIATRIC NEUROLOGIST|NA|2|Visit_2|25|4|SCREENING|2020-06-15|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-06|P1Y2M10DT2H30M|COINCIDENT|2020-07-12|COINCIDENT|2020-08-25
e|RS|9e82141b-e2b9-42c7-b813-b79bda2bd216|4|MJPTHIND|Major Pathological Response Indicator|CHOI GIST 2008|||sCR|1|deg/mm|ISHIHARA COLOR PLATES|||Y|INDEPENDENT ASSESSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|2|Visit_2|25|4|SCREENING|2020-06-15|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-06|P1Y2M10DT2H30M|AFTER|2020-06-30|ONGOING|2020-08-04
e|RS|9e82141b-e2b9-42c7-b813-b79bda2bd216|5|NTRGRESP|Non-target Response|BURCOMBE BREAST CANCER 2005|[?]|nU/cL|cPR|1|CUP|FORCED OSCILLATION TECHNIQUE||||CHILD|MICROSCOPIST 2|Y|3|Visit_3|40|5|WASHOUT|2020-06-30|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-18|P1Y2M10DT2H30M|AFTER|2020-07-28|BEFORE|2020-08-10
e|RS|9e82141b-e2b9-42c7-b813-b79bda2bd216|6|NEWLWIND|New Lesion Worsening Indicator|MURPHY PROSTATE CANCER 1980|[?]|/mm|FAVORABLE RESPONSE|1|EU|PLAQUE REDUCTION NEUTRALIZATION ASSAY||||ADJUDICATION COMMITTEE|PATHOLOGIST 1|U|3|Visit_3|40|3|TREATMENT|2020-06-30|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-18|P1Y2M10DT2H30M|COINCIDENT|2020-07-28|BEFORE|2020-08-18
e|RS|9e82141b-e2b9-42c7-b813-b79bda2bd216|7|STRUSTAT|Steroid Use Status|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|/ms|iUPD|1|g/L|CONTRAST ENHANCED PET/CT SCAN||Y||INTERVIEWER|UROLOGIST|U|4|Visit_4|65|2|SCREENING|2020-07-25|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-21|P1Y2M10DT2H30M|COINCIDENT|2020-07-12|AFTER|2020-07-19
e|RS|9e82141b-e2b9-42c7-b813-b79bda2bd216|8|SPLNRESP|Spleen Response|WHO BREAST CANCER 2006|||HI-E|1|sec|ELECTROGASTROGRAPHY|Y||Y|PARENT|MICROSCOPIST 3|NA|4|Visit_4|65|4|TREATMENT|2020-07-25|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-21|P1Y2M10DT2H30M|AFTER|2020-08-14|ONGOING|2020-08-21
e|RS|9e82141b-e2b9-42c7-b813-b79bda2bd216|9|CYTORESP|Cytogenetic Response|SCHWARZ CERVICAL CANCER 2009|[?]|TROCHE|MRD NEGATIVITY|1|cup eq|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION||Y||PROXY|MICROSCOPIST 3|N|5|Visit_5|90|6|TREATMENT|2020-08-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-31|P1Y2M10DT2H30M|BEFORE|2020-08-16|BEFORE|2020-08-21
e|RS|9e82141b-e2b9-42c7-b813-b79bda2bd216|10|MRPHRESP|Morphologic Response|FAROOQUI SUPP CLL 2014|[?]|s^-1(%O2)^-1|PD FROM PR|1|mg/g/h|MRS||||INVESTIGATOR|RATER 1|N|5|Visit_5|90|3|TREATMENT|2020-08-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-31|P1Y2M10DT2H30M|BEFORE|2020-06-05|AFTER|2020-06-06
e|RS|4b432c61-c620-4c5e-8aad-411facc0f4db|1|METSIND|Metastatic Indicator|KUKER LYMPHOMA 2005|[?]|/10^5|IMMUNOPHENOTYPIC CR|1|EID 50/dose|PHOTOGRAPHY||Y||CAREGIVER|ADJUDICATOR 1|NA|1|Visit_1|10|7|TREATMENT|2020-09-14|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-27|P1Y2M10DT2H30M|AFTER|2020-12-02|ONGOING|2020-12-08
e|RS|4b432c61-c620-4c5e-8aad-411facc0f4db|2|STRUSTAT|Steroid Use Status|PRINCE TCELL LYMPHOMA 2010|[?]|mg/cm2|PD-CT|1|DAgU|CARDIAC THERMODILUTION|Y|||ADJUDICATOR|ADJUDICATOR 1|U|1|Visit_1|10|3|WASHOUT|2020-09-14|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-27|P1Y2M10DT2H30M|UNKNOWN|2020-11-08|COINCIDENT|2020-11-10
e|RS|4b432c61-c620-4c5e-8aad-411facc0f4db|3|BMIVLIND|Bone Marrow Involvement Indicator|PALUMBO MULTIPLE MYELOMA 2009|[?]|/VF|PSA PROGRESSION|1|mL/g/h|LASER CAPTURE MICRODISSECTION|Y|Y||INDEPENDENT ASSESSOR|DERMATOLOGIST|N|2|Visit_2|25|7|WASHOUT|2020-09-29|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-15|P1Y2M10DT2H30M|AFTER|2020-09-21|AFTER|2020-11-12
e|RS|4b432c61-c620-4c5e-8aad-411facc0f4db|4|MRPHRESP|Morphologic Response|KUKER LYMPHOMA 2005|[?]|TUBE|CYTOGENETIC NO RESPONSE|1|mol/L|CONFOCAL MICROSCOPY||||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST|NA|2|Visit_2|25|5|TREATMENT|2020-09-29|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-15|P1Y2M10DT2H30M|COINCIDENT|2020-11-13|BEFORE|2020-12-01
e|RS|4b432c61-c620-4c5e-8aad-411facc0f4db|5|MRDRESP|Minimal Residual Disease Response|MURPHY PROSTATE CANCER 1980|[?]|nCi|IMMUNOPHENOTYPIC CR|1|Newton|LIGHT SCATTERING SPECTROSCOPY||||NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|N|3|Visit_3|40|4|TREATMENT|2020-10-14|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-18|P1Y2M10DT2H30M|BEFORE|2020-10-18|COINCIDENT|2020-12-05
e|RS|4b432c61-c620-4c5e-8aad-411facc0f4db|6|NTRGRESP|Non-target Response|FAROOQUI SUPP CLL 2014|[?]|g/kg/day|HI-E|1|ka_u/dL|CONTRAST ENHANCED PET/CT SCAN||||DOMESTIC PARTNER|RADIOLOGIST 1|U|3|Visit_3|40|6|WASHOUT|2020-10-14|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-18|P1Y2M10DT2H30M|BEFORE|2020-11-21|COINCIDENT|2020-12-12
e|RS|4b432c61-c620-4c5e-8aad-411facc0f4db|7|CPRFSTAT|Clinical Performance Status|BURCOMBE BREAST CANCER 2005|||NR|1|kBq/uL|OPTICAL MAPPING|||Y|CLINICAL RESEARCH ASSOCIATE|DERMATOLOGIST|U|4|Visit_4|65|6|FOLLOW-UP|2020-11-08|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-04|P1Y2M10DT2H30M|BEFORE|2020-10-23|AFTER|2020-11-02
e|RS|4b432c61-c620-4c5e-8aad-411facc0f4db|8|OVRLRESP|Overall Response|KEAM BREAST CANCER 2013|[?]|K|SD|1|dB|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION||||GUARDIAN|RATER 2|N|4|Visit_4|65|3|FOLLOW-UP|2020-11-08|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-04|P1Y2M10DT2H30M|BEFORE|2020-10-01|BEFORE|2020-12-05
e|RS|4b432c61-c620-4c5e-8aad-411facc0f4db|9|LIVRRESP|Liver Response|SACT|[?]|days/month|CR-CT|1|mAnson U/mL|ANTIMICROBIAL COMBINATION TESTING||Y||CLINICAL RESEARCH COORDINATOR|RATER 2|N|5|Visit_5|90|4|TREATMENT|2020-12-03|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-28|P1Y2M10DT2H30M|UNKNOWN|2020-11-04|AFTER|2020-11-28
e|RS|4b432c61-c620-4c5e-8aad-411facc0f4db|10|CPRFSTAT|Clinical Performance Status|CHOI GIST 2008|[?]|V|CHR|1|hPa|TONOMETRY||Y||ADJUDICATION COMMITTEE|FORENSIC PATHOLOGIST|NA|5|Visit_5|90|7|SCREENING|2020-12-03|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-28|P1Y2M10DT2H30M|AFTER|2020-11-15|COINCIDENT|2020-12-02
e|RS|1a1e6863-26da-4b5d-b82a-5703e3e9056e|1|NEWLPROG|New Lesion Progression|WHO BREAST CANCER 2006|[?]|aMFI|iCR|1|U/m2/min|HPLC||||INDEPENDENT ASSESSOR|READER 1|Y|1|Visit_1|10|1|FOLLOW-UP|2020-12-26|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-03|P1Y2M10DT2H30M|COINCIDENT|2021-03-19|ONGOING|2021-03-21
e|RS|1a1e6863-26da-4b5d-b82a-5703e3e9056e|2|NEWLIND|New Lesion Indicator|HAMAOKA BREAST CANCER 2010|||CYTOGENETIC MINOR RESPONSE|1|kat|LINE PROBE ASSAY||Y|Y|CAREGIVER|READER|NA|1|Visit_1|10|6|TREATMENT|2020-12-26|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-03|P1Y2M10DT2H30M|UNKNOWN|2021-01-01|BEFORE|2021-02-12
e|RS|1a1e6863-26da-4b5d-b82a-5703e3e9056e|3|BONERESP|Bone Response|EASL BRUIX LIVER CANCER 2001|[?]|ks|MORPHOLOGIC LEUKEMIA-FREE STATE|1|breaths/min|X-RAY FLUORESCENCE SPECTROMETRY|Y|Y||SPOUSE|RADIOLOGIST 1|Y|2|Visit_2|25|7|TREATMENT|2021-01-10|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-28|P1Y2M10DT2H30M|AFTER|2021-02-12|COINCIDENT|2021-03-13
e|RS|1a1e6863-26da-4b5d-b82a-5703e3e9056e|4|NEWLWIND|New Lesion Worsening Indicator|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|PFU|mCR|1|PRESSOR UNITS|AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT||Y||CLINICAL RESEARCH COORDINATOR|UROLOGIST|NA|2|Visit_2|25|6|TREATMENT|2021-01-10|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-28|P1Y2M10DT2H30M|AFTER|2021-02-13|ONGOING|2021-02-24
e|RS|1a1e6863-26da-4b5d-b82a-5703e3e9056e|5|MRDIND|Minimal Residual Disease Indicator|IWG CHESON MDS 2000|[?]|GBq/ug|WORSENED|1|PFU/animal|TRICHROME STAIN||||SIBLING|PHYSIOTHERAPIST|NA|3|Visit_3|40|3|WASHOUT|2021-01-25|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-14|P1Y2M10DT2H30M|AFTER|2021-01-29|BEFORE|2021-02-10
e|RS|1a1e6863-26da-4b5d-b82a-5703e3e9056e|6|RDIORESP|Radiologic Response|LEE LUNG CANCER 2011|||PR|1|mL/dL|DARK FIELD MICROSCOPY|||Y|HEALTH CARE PROFESSIONAL|PATHOLOGIST|NA|3|Visit_3|40|1|TREATMENT|2021-01-25|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-14|P1Y2M10DT2H30M|AFTER|2021-03-18|BEFORE|2021-03-25
e|RS|1a1e6863-26da-4b5d-b82a-5703e3e9056e|7|METBRESP|Metabolic Response|LUGANO CLASSIFICATION|||CYTOGENETIC NO RESPONSE|1|umol/min|LASER CAPTURE MICRODISSECTION|Y||Y|FAMILY MEMBER|READER 1|Y|4|Visit_4|65|6|TREATMENT|2021-02-19|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-14|P1Y2M10DT2H30M|UNKNOWN|2021-02-05|COINCIDENT|2021-02-16
e|RS|1a1e6863-26da-4b5d-b82a-5703e3e9056e|8|METSIND|Metastatic Indicator|PRINCE TCELL LYMPHOMA 2010|[?]|10^9 organisms|PR-CT|1|nkat|OPHTHALMOSCOPY||||PARENT|MICROSCOPIST 2|N|4|Visit_4|65|4|TREATMENT|2021-02-19|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-14|P1Y2M10DT2H30M|AFTER|2021-01-17|COINCIDENT|2021-03-13
e|RS|1a1e6863-26da-4b5d-b82a-5703e3e9056e|9|NEWLPROG|New Lesion Progression|MRECIST LENCIONI LIVER CANCER 2010|[?]|ug/m2/h|cCR|1|g/kg|SNELLEN EYE CHART||||INVESTIGATOR|ONCOLOGIST|Y|5|Visit_5|90|7|WASHOUT|2021-03-16|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-20|P1Y2M10DT2H30M|AFTER|2021-01-15|AFTER|2021-03-04
e|RS|1a1e6863-26da-4b5d-b82a-5703e3e9056e|10|TRGRESP|Target Response|IWG CHESON AML 2003|[?]|BU|nPR|1|umol/L/sec|AUTOREFRACTION||||INDEPENDENT ASSESSOR|MICROSCOPIST 3|NA|5|Visit_5|90|3|FOLLOW-UP|2021-03-16|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-20|P1Y2M10DT2H30M|BEFORE|2021-02-15|ONGOING|2021-02-20
e|RS|8c8053d1-adae-4d45-870e-cf4ad2475c74|1|DRCRIND|Disease Recurrence Indicator|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|ng/L|sCR|1|dmol|IMMUNOCHROMATOGRAPHY||Y||SPOUSE|ONCOLOGIST|U|1|Visit_1|10|1|SCREENING|2020-05-11|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-26|P1Y2M10DT2H30M|AFTER|2020-07-09|AFTER|2020-07-23
e|RS|8c8053d1-adae-4d45-870e-cf4ad2475c74|2|NTERESP|Non-Target Enhancing Response|GUPPY OVARIAN CANCER 2002|[?]|PRESSOR UNITS|FAVORABLE RESPONSE|1|fraction of 1|IMMUNOTURBIDIMETRY|Y|Y||HEALTH CARE PROFESSIONAL|READER 1|Y|1|Visit_1|10|7|FOLLOW-UP|2020-05-11|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-26|P1Y2M10DT2H30M|BEFORE|2020-06-16|AFTER|2020-07-07
e|RS|8c8053d1-adae-4d45-870e-cf4ad2475c74|3|ANATRESP|Anatomic Response|RANO|[?]|Ci/L|IMMUNOPHENOTYPIC CR|1|RFU|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS||Y||PARENT|ADJUDICATOR 3|U|2|Visit_2|25|7|TREATMENT|2020-05-26|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-26|P1Y2M10DT2H30M|BEFORE|2020-07-26|ONGOING|2020-08-01
e|RS|8c8053d1-adae-4d45-870e-cf4ad2475c74|4|MOLRESP|Molecular Response|CHOI GIST 2008|[?]|TROCHE|CR-CT|1|BU/mL|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS||||STUDY SUBJECT|MICROSCOPIST|Y|2|Visit_2|25|4|WASHOUT|2020-05-26|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-26|P1Y2M10DT2H30M|AFTER|2020-06-18|ONGOING|2020-07-29
e|RS|8c8053d1-adae-4d45-870e-cf4ad2475c74|5|MRDRESP|Minimal Residual Disease Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|10^9 organisms/mg|RELAPSED DISEASE FROM CR|1|GPL U|JAFFE REACTION||||INTERVIEWER|PATHOLOGIST 1|Y|3|Visit_3|40|6|SCREENING|2020-06-10|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-29|P1Y2M10DT2H30M|AFTER|2020-06-10|COINCIDENT|2020-07-11
e|RS|8c8053d1-adae-4d45-870e-cf4ad2475c74|6|MRPHRESP|Morphologic Response|PRINCE TCELL LYMPHOMA 2010|[?]|mL/kg/day|PMR|1|ugEq|PERIPHERAL ANGIOGRAPHY||Y||FAMILY MEMBER|CLINICAL PATHOLOGIST|U|3|Visit_3|40|3|TREATMENT|2020-06-10|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-29|P1Y2M10DT2H30M|COINCIDENT|2020-07-20|BEFORE|2020-07-29
e|RS|8c8053d1-adae-4d45-870e-cf4ad2475c74|7|RDIORESP|Radiologic Response|GCIG RUSTIN OVARIAN CANCER 2011|||PARTIAL MORPHOLOGIC RESPONSE|1|vp/dose|JAFFE REACTION|||Y|CLINICAL RESEARCH ASSOCIATE|ENDOCRINOLOGIST|NA|4|Visit_4|65|1|TREATMENT|2020-07-05|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-16|P1Y2M10DT2H30M|UNKNOWN|2020-06-05|AFTER|2020-07-20
e|RS|8c8053d1-adae-4d45-870e-cf4ad2475c74|8|MOLRESP|Molecular Response|IWG CHESON MDS 2006|||HI-E|1|KALLIKREIN INHIBITOR UNIT|DIGITAL PCR ARRAY|||Y|DOMESTIC PARTNER|RATER 2|U|4|Visit_4|65|1|TREATMENT|2020-07-05|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-16|P1Y2M10DT2H30M|AFTER|2020-07-15|ONGOING|2020-08-03
e|RS|8c8053d1-adae-4d45-870e-cf4ad2475c74|9|HEMARESP|Hematologic Response|BURCOMBE BREAST CANCER 2005|[?]|GBq|iCPD|1|PIPE|FLUORESCENCE ANGIOGRAPHY||||NON-HEALTH CARE PROFESSIONAL|READER|U|5|Visit_5|90|7|TREATMENT|2020-07-30|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-11|P1Y2M10DT2H30M|UNKNOWN|2020-06-14|ONGOING|2020-06-29
e|RS|8c8053d1-adae-4d45-870e-cf4ad2475c74|10|BONERESP|Bone Response|AJCC V8|[?]|MPS U|DECREASED|1|10^3 DNA copies/mL|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION||Y||NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST|U|5|Visit_5|90|1|FOLLOW-UP|2020-07-30|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-11|P1Y2M10DT2H30M|UNKNOWN|2020-07-15|BEFORE|2020-07-25
e|RS|c3b911a8-116e-4940-80a2-7128db004f4a|1|NTRGRESP|Non-target Response|IWG CHESON MDS 2000|[?]|10^9 organisms/mg|CR-CT|1|ug/m2|CELL BASED BIOASSAY||||FAMILY MEMBER|CARDIOLOGIST|N|1|Visit_1|10|2|WASHOUT|2020-11-19|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-24|P1Y2M10DT2H30M|UNKNOWN|2020-11-24|COINCIDENT|2020-12-01
e|RS|c3b911a8-116e-4940-80a2-7128db004f4a|2|NTERESP|Non-Target Enhancing Response|PRINCE TCELL LYMPHOMA 2010|[?]|U/g Hb|HI-E|1|APL U/mL|POPULATION SEQUENCING||Y||SIBLING|NEUROLOGIST 2|Y|1|Visit_1|10|6|TREATMENT|2020-11-19|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-24|P1Y2M10DT2H30M|COINCIDENT|2020-12-29|ONGOING|2021-02-03
e|RS|c3b911a8-116e-4940-80a2-7128db004f4a|3|DRCRIND|Disease Recurrence Indicator|SACT|||MAJOR PATHOLOGIC RESPONSE|1|Mile|MAGNETIC RESONANCE ELASTOGRAPHY|Y||Y|HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|N|2|Visit_2|25|3|TREATMENT|2020-12-04|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-10|P1Y2M10DT2H30M|BEFORE|2021-02-04|AFTER|2021-02-07
e|RS|c3b911a8-116e-4940-80a2-7128db004f4a|4|CLINRESP|Clinical Response|RANO ELLINGSON 2017|[?]|U/L|CMR|1|10^9 CFU|CLINICAL EVALUATION||||SPOUSE|MICROSCOPIST|NA|2|Visit_2|25|1|TREATMENT|2020-12-04|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-10|P1Y2M10DT2H30M|BEFORE|2020-11-23|BEFORE|2020-12-11
e|RS|c3b911a8-116e-4940-80a2-7128db004f4a|5|MRPHRESP|Morphologic Response|FAROOQUI SUPP CLL 2014|||PR|1|U/10^12 RBC|MULTIPLE BREATH WASHOUT|||Y|DOMESTIC PARTNER|PHYSIOTHERAPIST|U|3|Visit_3|40|2|TREATMENT|2020-12-19|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-30|P1Y2M10DT2H30M|AFTER|2020-12-20|AFTER|2021-01-04
e|RS|c3b911a8-116e-4940-80a2-7128db004f4a|6|NEWLWIND|New Lesion Worsening Indicator|BLAZER COLORECTAL CANCER 2008|[?]|uL/dose|CA125 75% RESPONSE|1|deg2|KLEIHAUER-BETKE||||CLINICAL STUDY SPONSOR|RADIOLOGIST 1|NA|3|Visit_3|40|6|WASHOUT|2020-12-19|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-30|P1Y2M10DT2H30M|UNKNOWN|2020-12-13|COINCIDENT|2021-02-03
e|RS|c3b911a8-116e-4940-80a2-7128db004f4a|7|NTERESP|Non-Target Enhancing Response|SACT|[?]|PRESSOR UNITS|ABSENT MORPHOLOGIC RESPONSE|1|/5x10^4 WBC|EEG|Y|||FAMILY MEMBER|MICROSCOPIST 1|NA|4|Visit_4|65|3|TREATMENT|2021-01-13|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-15|P1Y2M10DT2H30M|BEFORE|2020-11-11|ONGOING|2020-12-30
e|RS|c3b911a8-116e-4940-80a2-7128db004f4a|8|MNPTHIND|Minor Pathological Response Indicator|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|umol/L/sec|MRD PERSISTENCE|1|cm/s|HEMAGGLUTINATION ASSAY||||INVESTIGATOR|READER 2|NA|4|Visit_4|65|4|TREATMENT|2021-01-13|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-15|P1Y2M10DT2H30M|AFTER|2021-01-16|BEFORE|2021-02-10
e|RS|c3b911a8-116e-4940-80a2-7128db004f4a|9|METBRESP|Metabolic Response|PCWG BUBLEY PROSTATE CANCER 1999|||PDu|1|pptr|DIFFUSION WEIGHTED MRI|||Y|GUARDIAN|RATER|U|5|Visit_5|90|6|TREATMENT|2021-02-07|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-22|P1Y2M10DT2H30M|COINCIDENT|2020-12-15|ONGOING|2021-01-09
e|RS|c3b911a8-116e-4940-80a2-7128db004f4a|10|CYTORESP|Cytogenetic Response|CHOLLET BREAST CANCER 2002|[?]|PFU|INDETERMINATE RESPONSE|1|g/mol|PELLI-ROBSON EYE CHART|Y|||SIGNIFICANT OTHER|NEUROLOGIST 1|Y|5|Visit_5|90|2|WASHOUT|2021-02-07|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-22|P1Y2M10DT2H30M|BEFORE|2020-11-28|AFTER|2020-12-19
e|RS|401d66ba-bc00-4495-ba5d-796068dd1fd6|1|MJPTHIND|Major Pathological Response Indicator|RECIST 1.0|[?]|ka_u/dL|TREATMENT FAILURE|1|nmol/mol|ISHIHARA COLOR PLATES||||INTERVIEWER|MICROSCOPIST 3|N|1|Visit_1|10|5|TREATMENT|2020-06-11|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-18|P1Y2M10DT2H30M|COINCIDENT|2020-08-20|BEFORE|2020-09-04
e|RS|401d66ba-bc00-4495-ba5d-796068dd1fd6|2|PATHRESP|Pathologic Response|PETIT BREAST CANCER 2001|[?]|mg/m2|HI-E|1|uCi/kg|CALIPER MEASUREMENT METHOD||||ADJUDICATION COMMITTEE|ONCOLOGIST 1|U|1|Visit_1|10|6|TREATMENT|2020-06-11|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-18|P1Y2M10DT2H30M|COINCIDENT|2020-06-24|ONGOING|2020-07-26
e|RS|401d66ba-bc00-4495-ba5d-796068dd1fd6|3|TRGRESP|Target Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|||CR|1|OD Unit|FLUORESCENT MICROSCOPY|Y||Y|PROXY|HEMATOLOGIST|Y|2|Visit_2|25|1|WASHOUT|2020-06-26|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-18|P1Y2M10DT2H30M|COINCIDENT|2020-07-22|AFTER|2020-09-03
e|RS|401d66ba-bc00-4495-ba5d-796068dd1fd6|4|CLINRESP|Clinical Response|CHOLLET BREAST CANCER 2002|[?]|WAFER|PD FROM PR|1|mL/cm3/min|MICROBIAL CULTURE|Y|||NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|Y|2|Visit_2|25|3|FOLLOW-UP|2020-06-26|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-18|P1Y2M10DT2H30M|AFTER|2020-06-15|COINCIDENT|2020-08-04
e|RS|401d66ba-bc00-4495-ba5d-796068dd1fd6|5|NTRGRESP|Non-target Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|s/h|TREATMENT FAILURE|1|mmHg*min/L|MICROSCOPY|Y|||CHILD|RADIOLOGIST 2|NA|3|Visit_3|40|3|FOLLOW-UP|2020-07-11|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-15|P1Y2M10DT2H30M|COINCIDENT|2020-07-28|BEFORE|2020-08-15
e|RS|401d66ba-bc00-4495-ba5d-796068dd1fd6|6|MJPTHIND|Major Pathological Response Indicator|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|PNU/mL|CA125 50% RESPONSE|1|mV|MIGET||Y||CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST|Y|3|Visit_3|40|3|FOLLOW-UP|2020-07-11|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-15|P1Y2M10DT2H30M|COINCIDENT|2020-07-28|COINCIDENT|2020-09-04
e|RS|401d66ba-bc00-4495-ba5d-796068dd1fd6|7|HEMARESP|Hematologic Response|BURCOMBE BREAST CANCER 2005|[?]|U/animal|MORPHOLOGIC LEUKEMIA-FREE STATE|1|cm H2O|MODIFIED ACID FAST STAIN||||INTERVIEWER|OPTOMETRIST|Y|4|Visit_4|65|7|TREATMENT|2020-08-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-07|P1Y2M10DT2H30M|BEFORE|2020-07-11|ONGOING|2020-09-02
e|RS|401d66ba-bc00-4495-ba5d-796068dd1fd6|8|BONERESP|Bone Response|CHESON CLL 2012|[?]|10^6 CFU|PD FROM PR|1|L/h/m2|PAP STAIN||||INVESTIGATOR|RADIOLOGIST 2|U|4|Visit_4|65|2|FOLLOW-UP|2020-08-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-07|P1Y2M10DT2H30M|COINCIDENT|2020-06-30|BEFORE|2020-07-24
e|RS|401d66ba-bc00-4495-ba5d-796068dd1fd6|9|ANATRESP|Anatomic Response|PRINCE TCELL LYMPHOMA 2010|[?]|grain|NON-QUANTIFIABLE MRD POSITIVITY|1|log10 TCID 50/mL|TRICHROME STAIN|Y|||SIBLING|DERMATOLOGIST|N|5|Visit_5|90|5|WASHOUT|2020-08-30|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-26|P1Y2M10DT2H30M|BEFORE|2020-07-15|AFTER|2020-08-11
e|RS|401d66ba-bc00-4495-ba5d-796068dd1fd6|10|OVRLRESP|Overall Response|EBMT BLADE MYELOMA 1998|[?]|Gy/min|CHR|1|kg/cm2|X-RAY|Y|||INTERVIEWER|NEUROLOGIST|U|5|Visit_5|90|2|TREATMENT|2020-08-30|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-26|P1Y2M10DT2H30M|AFTER|2020-08-30|COINCIDENT|2020-09-03
e|RS|f8113725-4deb-48a1-876a-ba168a6d2cee|1|BMIVLIND|Bone Marrow Involvement Indicator|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|LOZENGE|INCREASED|1|mg/kg/min|FUNDUS PHOTOGRAPHY||||STUDY SUBJECT|NEUROLOGIST|N|1|Visit_1|10|4|SCREENING|2021-01-22|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-31|P1Y2M10DT2H30M|UNKNOWN|2021-03-11|BEFORE|2021-03-30
e|RS|f8113725-4deb-48a1-876a-ba168a6d2cee|2|CPRFSTAT|Clinical Performance Status|HAMAOKA BREAST CANCER 2010|[?]|PACKET|IMMUNOPHENOTYPIC CR|1|mL/100g/min|PHASE-CONTRAST MRI||||FAMILY MEMBER|CLINICAL PATHOLOGIST|N|1|Visit_1|10|1|TREATMENT|2021-01-22|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-31|P1Y2M10DT2H30M|BEFORE|2021-04-19|AFTER|2021-04-21
e|RS|f8113725-4deb-48a1-876a-ba168a6d2cee|3|MNPTHIND|Minor Pathological Response Indicator|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|||nPR|1|CIGAR|SPIRAL CT SCAN WITHOUT CONTRAST|||Y|SIGNIFICANT OTHER|NEUROLOGIST 2|U|2|Visit_2|25|6|TREATMENT|2021-02-06|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-18|P1Y2M10DT2H30M|COINCIDENT|2021-02-02|COINCIDENT|2021-03-21
e|RS|f8113725-4deb-48a1-876a-ba168a6d2cee|4|HEMARESP|Hematologic Response|RECIST 1.1|[?]|mL/min/mmHg|DISEASE TRANSFORMATION|1|mmHg|LASER CAPTURE MICRODISSECTION|Y|||GUARDIAN|RATER|Y|2|Visit_2|25|3|TREATMENT|2021-02-06|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-18|P1Y2M10DT2H30M|AFTER|2021-02-22|COINCIDENT|2021-02-26
e|RS|f8113725-4deb-48a1-876a-ba168a6d2cee|5|MRDRESP|Minimal Residual Disease Response|AJCC V8|[?]|mmHg/L/min|STABLE|1|mgEq|DIFFUSION WEIGHTED MRI||Y||FAMILY MEMBER|DERMATOLOGIST|U|3|Visit_3|40|7|FOLLOW-UP|2021-02-21|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-06|P1Y2M10DT2H30M|COINCIDENT|2021-04-03|BEFORE|2021-04-19
e|RS|f8113725-4deb-48a1-876a-ba168a6d2cee|6|CPRFSTAT|Clinical Performance Status|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|Siemens|MOLECULAR MAJOR RESPONSE|1|uV*sec|SLOAN LETTER EYE CHART 2.5%||||ADJUDICATOR|ONCOLOGIST 2|NA|3|Visit_3|40|6|TREATMENT|2021-02-21|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-06|P1Y2M10DT2H30M|UNKNOWN|2021-01-27|AFTER|2021-03-03
e|RS|f8113725-4deb-48a1-876a-ba168a6d2cee|7|TMRESP|Tumor Marker Response|MURPHY PROSTATE CANCER 1980|||nPR|1|genEq|PHASE CONTRAST MICROSCOPY|||Y|GUARDIAN|ADJUDICATOR 1|N|4|Visit_4|65|4|TREATMENT|2021-03-18|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-17|P1Y2M10DT2H30M|UNKNOWN|2021-03-22|BEFORE|2021-03-29
e|RS|f8113725-4deb-48a1-876a-ba168a6d2cee|8|NTRGRESP|Non-target Response|CHOLLET BREAST CANCER 2002|[?]|F|UNEQUIVOCAL|1|m3|PET/MRI SCAN||||CHILD|RATER 1|Y|4|Visit_4|65|3|FOLLOW-UP|2021-03-18|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-17|P1Y2M10DT2H30M|COINCIDENT|2021-03-02|ONGOING|2021-04-05
e|RS|f8113725-4deb-48a1-876a-ba168a6d2cee|9|MRDRESP|Minimal Residual Disease Response|CHESON LYMPHOMA 2008|||CR|1|s*kPa|FORCED OSCILLATION TECHNIQUE|||Y|DOMESTIC PARTNER|RADIOLOGIST 1|NA|5|Visit_5|90|1|WASHOUT|2021-04-12|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-12|P1Y2M10DT2H30M|AFTER|2021-04-09|BEFORE|2021-04-18
e|RS|f8113725-4deb-48a1-876a-ba168a6d2cee|10|NTNERESP|Non-Target Non-Enhancing Response|AJCC V7|||EQUIVOCAL|1|mg/g/h|WESTERN BLOT|Y||Y|NON-HEALTH CARE PROFESSIONAL|READER 1|Y|5|Visit_5|90|7|TREATMENT|2021-04-12|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-12|P1Y2M10DT2H30M|BEFORE|2021-02-08|ONGOING|2021-02-23
e|RS|f056c174-b6da-4df6-bf95-2e31911939fb|1|NTERESP|Non-Target Enhancing Response|MACDONALD GLIOMA 1990|[?]|deg/mm|UNFAVORABLE RESPONSE|1|vg/dose|PANENDOSCOPY||Y||CAREGIVER|DERMATOLOGIST|NA|1|Visit_1|10|5|TREATMENT|2020-12-16|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-15|P1Y2M10DT2H30M|AFTER|2020-12-12|COINCIDENT|2020-12-27
e|RS|f056c174-b6da-4df6-bf95-2e31911939fb|2|MJPTHIND|Major Pathological Response Indicator|SACT|[?]|nL|MOLECULAR MAJOR RESPONSE|1|mV|IMMUNOBLOT||||INVESTIGATOR|INTERNIST|U|1|Visit_1|10|3|WASHOUT|2020-12-16|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-15|P1Y2M10DT2H30M|COINCIDENT|2021-01-20|ONGOING|2021-03-13
e|RS|f056c174-b6da-4df6-bf95-2e31911939fb|3|RDIORESP|Radiologic Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|||WORSENED|1|ug/mol|MICROBIAL CONCENTRATION|Y|Y|Y|FAMILY MEMBER|DERMATOLOGIST|Y|2|Visit_2|25|5|TREATMENT|2020-12-31|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-27|P1Y2M10DT2H30M|UNKNOWN|2021-02-27|BEFORE|2021-03-11
e|RS|f056c174-b6da-4df6-bf95-2e31911939fb|4|OVRLRESP|Overall Response|MONTSERRAT CLL 1989|[?]|U/kg/day|UNEQUIVOCAL|1|kV|NON-INVASIVE DIELECTRIC SENSING|Y|||CAREGIVER|RADIOLOGIST|U|2|Visit_2|25|6|FOLLOW-UP|2020-12-31|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-27|P1Y2M10DT2H30M|AFTER|2021-01-11|COINCIDENT|2021-02-04
e|RS|f056c174-b6da-4df6-bf95-2e31911939fb|5|MJPTHIND|Major Pathological Response Indicator|IWG CHESON MDS 2000|||FAVORABLE RESPONSE|1|log10 copies/mL|BRDU CELLULAR PROLIFERATION ASSAY|||Y|SPOUSE|READER 1|N|3|Visit_3|40|4|FOLLOW-UP|2021-01-15|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-28|P1Y2M10DT2H30M|COINCIDENT|2021-03-03|BEFORE|2021-03-04
e|RS|f056c174-b6da-4df6-bf95-2e31911939fb|6|MRPHRESP|Morphologic Response|UNSPECIFIED|||NON-iCR/NON-iUPD|1|ugEq/L|SLOAN LETTER EYE CHART 1.25%|||Y|VENDOR|PATHOLOGIST|NA|3|Visit_3|40|6|TREATMENT|2021-01-15|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-28|P1Y2M10DT2H30M|COINCIDENT|2021-03-12|AFTER|2021-03-15
e|RS|f056c174-b6da-4df6-bf95-2e31911939fb|7|BESTRESP|Best Overall Response|PALUMBO MULTIPLE MYELOMA 2009|||MOLECULAR MAJOR RESPONSE|1|mg/kg/min|CLIP|Y|Y|Y|INVESTIGATOR|CARDIOLOGIST|N|4|Visit_4|65|7|FOLLOW-UP|2021-02-09|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-09|P1Y2M10DT2H30M|UNKNOWN|2020-12-10|ONGOING|2021-03-01
e|RS|f056c174-b6da-4df6-bf95-2e31911939fb|8|DRCRIND|Disease Recurrence Indicator|DURIE MULTIPLE MYELOMA 2006|[?]|umol/L/h|ABSENT MORPHOLOGIC RESPONSE|1|mg2/dL2|LYMPHANGIOGRAPHY||||HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|NA|4|Visit_4|65|5|TREATMENT|2021-02-09|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-09|P1Y2M10DT2H30M|COINCIDENT|2021-01-08|BEFORE|2021-02-08
e|RS|f056c174-b6da-4df6-bf95-2e31911939fb|9|BONERESP|Bone Response|RANO ELLINGSON 2017|||SMD|1|mL/cm|FLAME PHOTOMETRY||Y|Y|CHILD|ADJUDICATOR 3|NA|5|Visit_5|90|1|TREATMENT|2021-03-06|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-02|P1Y2M10DT2H30M|COINCIDENT|2021-02-10|AFTER|2021-02-14
e|RS|f056c174-b6da-4df6-bf95-2e31911939fb|10|NTRGRESP|Non-target Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|||MRD RELAPSE|1|Bq|NUCLEAR RADIOLOGY||Y|Y|VENDOR|HEMATOLOGIST|N|5|Visit_5|90|2|TREATMENT|2021-03-06|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-02|P1Y2M10DT2H30M|BEFORE|2020-12-14|ONGOING|2021-02-12
e|RS|b265eb9f-88e1-42d8-83a5-4bc40e46ab54|1|HEMARESP|Hematologic Response|SACT|||PD/RELAPSE AFTER HI|1|DIOPTER|ANGIOGRAPHY|||Y|PROXY|PATHOLOGIST 2|N|1|Visit_1|10|4|TREATMENT|2020-09-16|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-05|P1Y2M10DT2H30M|AFTER|2020-12-13|ONGOING|2020-12-14
e|RS|b265eb9f-88e1-42d8-83a5-4bc40e46ab54|2|CPRFSTAT|Clinical Performance Status|EBMT BLADE MYELOMA 1998|||CHR|1|eq|HEMAGGLUTINATION ASSAY|||Y|INVESTIGATOR|PEDIATRIC NEUROLOGIST|NA|1|Visit_1|10|1|SCREENING|2020-09-16|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-05|P1Y2M10DT2H30M|UNKNOWN|2020-11-15|ONGOING|2020-12-06
e|RS|b265eb9f-88e1-42d8-83a5-4bc40e46ab54|3|NEWLPROG|New Lesion Progression|CHOI GIST 2008|[?]|g/kg/day|iCPD|1|km/h|ROMANOWSKY STAIN|Y|||PROXY|MICROSCOPIST|U|2|Visit_2|25|3|TREATMENT|2020-10-01|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-29|P1Y2M10DT2H30M|BEFORE|2020-09-11|COINCIDENT|2020-11-26
e|RS|b265eb9f-88e1-42d8-83a5-4bc40e46ab54|4|SYMPTDTR|Symptomatic Deterioration|SCHWARZ CERVICAL CANCER 2009|||pCR|1|g/animal/wk|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|||Y|CLINICAL RESEARCH ASSOCIATE|OTOLARYNGOLOGIST|U|2|Visit_2|25|5|FOLLOW-UP|2020-10-01|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-29|P1Y2M10DT2H30M|UNKNOWN|2020-09-14|COINCIDENT|2020-11-02
e|RS|b265eb9f-88e1-42d8-83a5-4bc40e46ab54|5|METBRESP|Metabolic Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|FIU|nPR|1|GPL U|TRANSVAGINAL ULTRASOUND||||PROXY|ENDOCRINOLOGIST|NA|3|Visit_3|40|6|TREATMENT|2020-10-16|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-26|P1Y2M10DT2H30M|AFTER|2020-10-04|COINCIDENT|2020-12-04
e|RS|b265eb9f-88e1-42d8-83a5-4bc40e46ab54|6|NTLWIND|Non-Target Lesion Worsening Indicator|CHESON CLL 2012|||UNFAVORABLE RESPONSE|1|P|FLUORIMETRY|Y|Y|Y|CLINICAL STUDY SPONSOR|DERMATOLOGIST|NA|3|Visit_3|40|1|TREATMENT|2020-10-16|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-26|P1Y2M10DT2H30M|COINCIDENT|2020-12-02|COINCIDENT|2020-12-03
e|RS|b265eb9f-88e1-42d8-83a5-4bc40e46ab54|7|NEWLPROG|New Lesion Progression|IWG CHESON AML 2003|[?]|BISCUIT|PR-CT|1|mol|MICRO BROTH DILUTION||Y||ADJUDICATOR|NEUROLOGIST 1|Y|4|Visit_4|65|7|TREATMENT|2020-11-10|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-08|P1Y2M10DT2H30M|COINCIDENT|2020-09-09|AFTER|2020-11-13
e|RS|b265eb9f-88e1-42d8-83a5-4bc40e46ab54|8|MRDIND|Minimal Residual Disease Indicator|CHESON CLL 2006|[?]|pmol/g|CR-CT|1|Enzyme U/L|NUCLEIC ACID HYBRIDIZATION||||CLINICAL STUDY SPONSOR|INTERNIST|Y|4|Visit_4|65|2|WASHOUT|2020-11-10|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-08|P1Y2M10DT2H30M|UNKNOWN|2020-09-30|ONGOING|2020-10-15
e|RS|b265eb9f-88e1-42d8-83a5-4bc40e46ab54|9|NTLWIND|Non-Target Lesion Worsening Indicator|IWG CHESON MDS 2000|||MORPHOLOGIC CR|1|10^9/g|ELECTRONEUROGRAPHY|Y||Y|CAREGIVER|DEVELOPMENTAL PSYCHOLOGIST|U|5|Visit_5|90|7|WASHOUT|2020-12-05|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-08|P1Y2M10DT2H30M|UNKNOWN|2020-10-21|COINCIDENT|2020-10-25
e|RS|b265eb9f-88e1-42d8-83a5-4bc40e46ab54|10|MRDRESP|Minimal Residual Disease Response|RAJKUMAR MYELOMA 2011|[?]|mL/g/min|PSEUDORESPONSE|1|Bq/ug|DC SHEATH FLOW||||PARENT|RATER 2|U|5|Visit_5|90|4|TREATMENT|2020-12-05|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-08|P1Y2M10DT2H30M|AFTER|2020-09-22|AFTER|2020-11-03
e|RS|57b7f30f-5f2a-425d-8bf2-fd5915cac481|1|MNPTHIND|Minor Pathological Response Indicator|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|U/g/h|NON-iCR/NON-iUPD|1|mph|MICROSCOPY|Y|||GUARDIAN|NEUROLOGIST 2|N|1|Visit_1|10|2|TREATMENT|2021-01-18|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-07|P1Y2M10DT2H30M|BEFORE|2021-03-14|BEFORE|2021-04-06
e|RS|57b7f30f-5f2a-425d-8bf2-fd5915cac481|2|BONERESP|Bone Response|AJCC V7|[?]|in2|MORPHOLOGIC LEUKEMIA-FREE STATE|1|g/m2|IMMUNOBLOT||||CHILD|RADIOLOGIST|U|1|Visit_1|10|5|TREATMENT|2021-01-18|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-07|P1Y2M10DT2H30M|BEFORE|2021-02-03|ONGOING|2021-04-08
e|RS|57b7f30f-5f2a-425d-8bf2-fd5915cac481|3|METSIND|Metastatic Indicator|WHO BREAST CANCER 2006|[?]|SFC/10^6 PBMC|INDETERMINATE RESPONSE|1|mAnson U/mL|MAMMOGRAPHY||||INTERVIEWER|MICROSCOPIST 2|N|2|Visit_2|25|1|TREATMENT|2021-02-02|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-24|P1Y2M10DT2H30M|UNKNOWN|2021-01-27|COINCIDENT|2021-02-08
e|RS|57b7f30f-5f2a-425d-8bf2-fd5915cac481|4|METBRESP|Metabolic Response|UNSPECIFIED|[?]|pmol/10^10 cells|MRD PERSISTENCE|1|g/kg|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY|Y|||INTERVIEWER|ADJUDICATOR 2|N|2|Visit_2|25|7|FOLLOW-UP|2021-02-02|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-24|P1Y2M10DT2H30M|BEFORE|2021-03-10|AFTER|2021-03-15
e|RS|57b7f30f-5f2a-425d-8bf2-fd5915cac481|5|HEMARESP|Hematologic Response|AJCC V7|[?]|mL/kg/day|PSA PROGRESSION|1|g/kg/day|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI|Y|||INDEPENDENT ASSESSOR|DERMATOLOGIST|Y|3|Visit_3|40|1|FOLLOW-UP|2021-02-17|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-10|P1Y2M10DT2H30M|UNKNOWN|2021-04-13|BEFORE|2021-04-15
e|RS|57b7f30f-5f2a-425d-8bf2-fd5915cac481|6|NTNERESP|Non-Target Non-Enhancing Response|MURPHY PROSTATE CANCER 1980|[?]|dpm/mL|HI-N|1|ELISA unit/mL|PANENDOSCOPY||||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 3|Y|3|Visit_3|40|6|TREATMENT|2021-02-17|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-10|P1Y2M10DT2H30M|BEFORE|2021-04-05|COINCIDENT|2021-04-14
e|RS|57b7f30f-5f2a-425d-8bf2-fd5915cac481|7|HEMARESP|Hematologic Response|UNSPECIFIED|[?]|ppth|NON-PD|1|rpm|HPLC-FL|Y|||VENDOR|MICROSCOPIST|U|4|Visit_4|65|7|TREATMENT|2021-03-14|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-17|P1Y2M10DT2H30M|COINCIDENT|2021-01-15|COINCIDENT|2021-04-01
e|RS|57b7f30f-5f2a-425d-8bf2-fd5915cac481|8|LIVRRESP|Liver Response|BLAZER COLORECTAL CANCER 2008|[?]|kHz|IMMUNOPHENOTYPIC CR|1|MnFI|MANUAL COUNT|Y|||PROXY|ONCOLOGIST 2|N|4|Visit_4|65|4|TREATMENT|2021-03-14|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-17|P1Y2M10DT2H30M|AFTER|2021-02-28|AFTER|2021-03-28
e|RS|57b7f30f-5f2a-425d-8bf2-fd5915cac481|9|STRUSTAT|Steroid Use Status|EASL BRUIX LIVER CANCER 2001|[?]|mL/g/h|PR WITH LYMPHOCYTOSIS|1|LB|RULER MEASUREMENT METHOD||||INDEPENDENT ASSESSOR|READER|N|5|Visit_5|90|4|TREATMENT|2021-04-08|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-10|P1Y2M10DT2H30M|UNKNOWN|2021-03-22|COINCIDENT|2021-03-28
e|RS|57b7f30f-5f2a-425d-8bf2-fd5915cac481|10|OVRLRESP|Overall Response|IWG CHESON MDS 2006|||FAVORABLE RESPONSE|1|10^10/L|GIEMSA STAIN|Y|Y|Y|STUDY SUBJECT|NEUROLOGIST 1|U|5|Visit_5|90|7|TREATMENT|2021-04-08|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-10|P1Y2M10DT2H30M|BEFORE|2021-01-19|ONGOING|2021-02-02
e|RS|02d9a74a-abc8-4b47-a4d4-a196d339f621|1|OVRLRESP|Overall Response|CHESON CLL 2006|||iPR|1|uL/mL|TRANSESOPHAGEAL ECHOCARDIOGRAPHY|||Y|DOMESTIC PARTNER|NEUROLOGIST 2|NA|1|Visit_1|10|6|TREATMENT|2020-09-14|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-31|P1Y2M10DT2H30M|COINCIDENT|2020-10-06|AFTER|2020-12-01
e|RS|02d9a74a-abc8-4b47-a4d4-a196d339f621|2|MJPTHIND|Major Pathological Response Indicator|HARTMANN GERM CELL CANCER 2002|[?]|Bq|FAVORABLE RESPONSE|1|mol|COMPLEMENT FIXATION||||INDEPENDENT ASSESSOR|NEUROLOGIST 2|N|1|Visit_1|10|1|SCREENING|2020-09-14|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-31|P1Y2M10DT2H30M|BEFORE|2020-09-30|COINCIDENT|2020-11-06
e|RS|02d9a74a-abc8-4b47-a4d4-a196d339f621|3|BONERESP|Bone Response|GUPPY OVARIAN CANCER 2002|[?]|mL/animal|QUANTIFIABLE MRD POSITIVITY|1|10^6 CFU/mL|TELLER ACUITY CARDS|Y|||GUARDIAN|RATER 1|U|2|Visit_2|25|5|SCREENING|2020-09-29|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-27|P1Y2M10DT2H30M|UNKNOWN|2020-11-04|AFTER|2020-12-09
e|RS|02d9a74a-abc8-4b47-a4d4-a196d339f621|4|TRGRESP|Target Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|s/h|CA125 75% RESPONSE|1|genEq|FARNSWORTH-MUNSELL 100 HUE TEST||||SPOUSE|PHYSIOTHERAPIST|U|2|Visit_2|25|3|TREATMENT|2020-09-29|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-27|P1Y2M10DT2H30M|BEFORE|2020-10-24|COINCIDENT|2020-12-10
e|RS|02d9a74a-abc8-4b47-a4d4-a196d339f621|5|MRDIND|Minimal Residual Disease Indicator|SCHWARZ CERVICAL CANCER 2009|[?]|mL/(min*100mL)|PD|1|log10 CCID 50/dose|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS||||FRIEND|READER|N|3|Visit_3|40|4|TREATMENT|2020-10-14|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-08|P1Y2M10DT2H30M|COINCIDENT|2020-11-27|AFTER|2020-12-04
e|RS|02d9a74a-abc8-4b47-a4d4-a196d339f621|6|NTRGRESP|Non-target Response|RECIST 1.1|[?]|TAMPON|HI-N|1|GLOBULE|SURFACE PLASMON RESONANCE|Y|||FRIEND|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|3|Visit_3|40|5|TREATMENT|2020-10-14|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-08|P1Y2M10DT2H30M|UNKNOWN|2020-09-09|AFTER|2020-12-12
e|RS|02d9a74a-abc8-4b47-a4d4-a196d339f621|7|LIVRRESP|Liver Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|uV*sec|PMD|1|10^9/dose|TRANSESOPHAGEAL ECHOCARDIOGRAPHY||Y||SIBLING|ONCOLOGIST|NA|4|Visit_4|65|2|SCREENING|2020-11-08|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-17|P1Y2M10DT2H30M|AFTER|2020-10-02|COINCIDENT|2020-10-25
e|RS|02d9a74a-abc8-4b47-a4d4-a196d339f621|8|ANATRESP|Anatomic Response|GUPPY OVARIAN CANCER 2002|[?]|mg/h|COMPLETE MRD RESPONSE|1|Gy/min|CLINICAL EVALUATION|Y|||INVESTIGATOR|INTERNIST|N|4|Visit_4|65|6|WASHOUT|2020-11-08|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-17|P1Y2M10DT2H30M|BEFORE|2020-11-03|BEFORE|2020-11-15
e|RS|02d9a74a-abc8-4b47-a4d4-a196d339f621|9|NEWLPROG|New Lesion Progression|RECIST 1.1|||MRD RELAPSE|1|mL/animal|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY|||Y|DOMESTIC PARTNER|RATER|U|5|Visit_5|90|7|SCREENING|2020-12-03|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-08|P1Y2M10DT2H30M|AFTER|2020-09-23|BEFORE|2020-12-12
e|RS|02d9a74a-abc8-4b47-a4d4-a196d339f621|10|SPLNRESP|Spleen Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|ng/dL|HI-E|1|RFU|RIA||||DOMESTIC PARTNER|NEUROLOGIST 1|U|5|Visit_5|90|1|WASHOUT|2020-12-03|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-08|P1Y2M10DT2H30M|COINCIDENT|2020-10-13|COINCIDENT|2020-11-12
e|RS|81480f83-206f-40c0-a5a4-f75b31cda363|1|MRDIND|Minimal Residual Disease Indicator|KUKER LYMPHOMA 2005|[?]|FEU|COMPLETE MRD RESPONSE|1|ng|DNA MICROARRAY||Y||FRIEND|CLINICAL PATHOLOGIST|NA|1|Visit_1|10|5|WASHOUT|2020-11-22|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-06|P1Y2M10DT2H30M|COINCIDENT|2020-12-22|COINCIDENT|2021-01-02
e|RS|81480f83-206f-40c0-a5a4-f75b31cda363|2|METSIND|Metastatic Indicator|PCWG SCHER PROSTATE CANCER 2016|[?]|CARTRIDGE|VGPR|1|vp/dose|ELECTROCHEMILUMINESCENCE|Y|||SIBLING|MICROSCOPIST 2|N|1|Visit_1|10|5|TREATMENT|2020-11-22|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-06|P1Y2M10DT2H30M|AFTER|2020-11-18|COINCIDENT|2021-02-06
e|RS|81480f83-206f-40c0-a5a4-f75b31cda363|3|ANATRESP|Anatomic Response|BURCOMBE BREAST CANCER 2005|[?]|10^3 DNA copies/mL|PMD|1|U/L|QUANTITATIVE CORONARY ANGIOGRAPHY||||INTERVIEWER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|2|Visit_2|25|1|SCREENING|2020-12-07|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-18|P1Y2M10DT2H30M|COINCIDENT|2021-01-23|BEFORE|2021-01-28
e|RS|81480f83-206f-40c0-a5a4-f75b31cda363|4|NTNERESP|Non-Target Non-Enhancing Response|BURCOMBE BREAST CANCER 2005|||SMD|1|dpm/mL|NEXT GENERATION SEQUENCING||Y|Y|GUARDIAN|NEUROLOGIST 1|U|2|Visit_2|25|1|TREATMENT|2020-12-07|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-18|P1Y2M10DT2H30M|BEFORE|2020-12-21|ONGOING|2021-01-26
e|RS|81480f83-206f-40c0-a5a4-f75b31cda363|5|PATHRESP|Pathologic Response|BRUGGEMANN MRD 2010|||HI-E|1|Hz/s|FLUORESCENT MICROSCOPY|Y||Y|STUDY SUBJECT|RADIOLOGIST 2|N|3|Visit_3|40|2|TREATMENT|2020-12-22|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-25|P1Y2M10DT2H30M|UNKNOWN|2020-12-03|BEFORE|2020-12-08
e|RS|81480f83-206f-40c0-a5a4-f75b31cda363|6|NTRGRESP|Non-target Response|SCHER PROSTATE CANCER 2011|[?]|10^9 CFU/mL|HI-N|1|PHERESIS UNIT|SISH||||CLINICAL STUDY SPONSOR|ADJUDICATOR 3|Y|3|Visit_3|40|6|SCREENING|2020-12-22|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-25|P1Y2M10DT2H30M|UNKNOWN|2020-11-29|AFTER|2021-02-11
e|RS|81480f83-206f-40c0-a5a4-f75b31cda363|7|NTERESP|Non-Target Enhancing Response|IRANO 2015|||MORPHOLOGIC CR|1|Anson U|DIRECT SEQUENCING||Y|Y|CLINICAL STUDY SPONSOR|RADIOLOGIST|N|4|Visit_4|65|6|SCREENING|2021-01-16|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-09|P1Y2M10DT2H30M|AFTER|2020-12-01|AFTER|2021-01-15
e|RS|81480f83-206f-40c0-a5a4-f75b31cda363|8|MJPTHIND|Major Pathological Response Indicator|IWC HALLEK CLL 2008|[?]|BU|pCR|1|ug/day|KARYOTYPING||||ADJUDICATION COMMITTEE|READER|N|4|Visit_4|65|2|TREATMENT|2021-01-16|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-09|P1Y2M10DT2H30M|BEFORE|2021-01-28|AFTER|2021-01-29
e|RS|81480f83-206f-40c0-a5a4-f75b31cda363|9|HEMARESP|Hematologic Response|DOHNER AML 2010|[?]|Log10 ELISA unit|DISEASE TRANSFORMATION|1|lx|ENZYMATIC COLORIMETRY||||CLINICAL RESEARCH ASSOCIATE|RATER 2|N|5|Visit_5|90|3|TREATMENT|2021-02-10|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-04|P1Y2M10DT2H30M|COINCIDENT|2021-01-28|ONGOING|2021-01-30
e|RS|81480f83-206f-40c0-a5a4-f75b31cda363|10|MRDRESP|Minimal Residual Disease Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|APS U|CMR|1|DROP|CRYOSCOPY|Y|||FRIEND|MICROSCOPIST 1|N|5|Visit_5|90|2|TREATMENT|2021-02-10|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-04|P1Y2M10DT2H30M|UNKNOWN|2021-01-15|ONGOING|2021-02-17
e|RS|2b183b69-3ed8-4356-b9e2-0988128de3f2|1|SYMPTDTR|Symptomatic Deterioration|JACINTO CERVICAL CANCER 2007|[?]|Ci/mg|STABLE|1|10^6 IU|FLUOROSCOPY||||STUDY SUBJECT|RADIOLOGIST|U|1|Visit_1|10|4|SCREENING|2020-10-16|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-19|P1Y2M10DT2H30M|BEFORE|2020-12-14|ONGOING|2021-01-13
e|RS|2b183b69-3ed8-4356-b9e2-0988128de3f2|2|ANATRESP|Anatomic Response|CHOLLET BREAST CANCER 2002|[?]|/500 WBC|EQUIVOCAL|1|mL/m2/day|SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY||Y||CHILD|READER|N|1|Visit_1|10|1|SCREENING|2020-10-16|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-19|P1Y2M10DT2H30M|BEFORE|2020-12-24|BEFORE|2021-01-08
e|RS|2b183b69-3ed8-4356-b9e2-0988128de3f2|3|NTRGRESP|Non-target Response|SHINDOH COLORECTAL CANCER 2013|[?]|mg/L FEU|CR|1|ug/dose|TRIPLE-PHASE SPIRAL CT SCAN||||INTERVIEWER|NEUROLOGIST 2|U|2|Visit_2|25|1|TREATMENT|2020-10-31|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-24|P1Y2M10DT2H30M|UNKNOWN|2020-11-10|BEFORE|2020-12-07
e|RS|2b183b69-3ed8-4356-b9e2-0988128de3f2|4|SYMPTDTR|Symptomatic Deterioration|GUPPY OVARIAN CANCER 2002|||UNEQUIVOCAL|1|mL/m2/h|LASER CAPTURE MICRODISSECTION|||Y|CLINICAL RESEARCH ASSOCIATE|PEDIATRIC NEUROLOGIST|U|2|Visit_2|25|7|FOLLOW-UP|2020-10-31|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-24|P1Y2M10DT2H30M|AFTER|2020-12-03|AFTER|2021-01-07
e|RS|2b183b69-3ed8-4356-b9e2-0988128de3f2|5|SPLNRESP|Spleen Response|KUKER LYMPHOMA 2005|[?]|CUP|PSEUDOPROGRESSION|1|/cmH2O|SCANNING ELECTRON MICROSCOPY||||CHILD|ADJUDICATOR 1|U|3|Visit_3|40|1|SCREENING|2020-11-15|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-12|P1Y2M10DT2H30M|COINCIDENT|2020-12-12|COINCIDENT|2020-12-28
e|RS|2b183b69-3ed8-4356-b9e2-0988128de3f2|6|CLINRESP|Clinical Response|RECICL|[?]|genEq|PSEUDORESPONSE|1|/LPF|URANYL ACETATE STAIN|Y|Y||CLINICAL RESEARCH ASSOCIATE|HEMATOLOGIST|U|3|Visit_3|40|2|WASHOUT|2020-11-15|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-12|P1Y2M10DT2H30M|BEFORE|2020-10-24|COINCIDENT|2020-10-31
e|RS|2b183b69-3ed8-4356-b9e2-0988128de3f2|7|MRDIND|Minimal Residual Disease Indicator|SCHER PROSTATE CANCER 2011|[?]|MBq|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|PRESSOR UNITS|PEAK FLOWMETRY||||PARENT|INTERNIST|NA|4|Visit_4|65|1|WASHOUT|2020-12-10|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-22|P1Y2M10DT2H30M|AFTER|2021-01-05|ONGOING|2021-01-13
e|RS|2b183b69-3ed8-4356-b9e2-0988128de3f2|8|MNPTHIND|Minor Pathological Response Indicator|MASS|[?]|PFU/dose|NON-CR/NON-PD|1|DAYS|INTRAVASCULAR ULTRASOUND||||INDEPENDENT ASSESSOR|NEUROLOGIST 2|Y|4|Visit_4|65|6|FOLLOW-UP|2020-12-10|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-22|P1Y2M10DT2H30M|COINCIDENT|2020-10-29|COINCIDENT|2020-11-02
e|RS|2b183b69-3ed8-4356-b9e2-0988128de3f2|9|SYMPTDTR|Symptomatic Deterioration|MASS|[?]|Siemens|iCR|1|10^3/L|SLOAN LETTER EYE CHART 2.5%||||CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST|NA|5|Visit_5|90|5|FOLLOW-UP|2021-01-04|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-30|P1Y2M10DT2H30M|COINCIDENT|2020-12-25|AFTER|2021-01-13
e|RS|2b183b69-3ed8-4356-b9e2-0988128de3f2|10|NEWLIND|New Lesion Indicator|EBMT BLADE MYELOMA 1998|[?]|RNA copies/mL|NON-QUANTIFIABLE MRD POSITIVITY|1|mg/m2/min|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY||||INVESTIGATOR|ENDOCRINOLOGIST|NA|5|Visit_5|90|7|WASHOUT|2021-01-04|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-30|P1Y2M10DT2H30M|COINCIDENT|2020-12-18|BEFORE|2021-01-08
e|RS|6ed8a749-81c0-4998-817d-efc86cfaa091|1|MRDIND|Minimal Residual Disease Indicator|AJCC V8|||INCREASED|1|10^7/L|LYMPHANGIOGRAPHY||Y|Y|HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|Y|1|Visit_1|10|1|TREATMENT|2020-06-05|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-13|P1Y2M10DT2H30M|AFTER|2020-06-21|BEFORE|2020-07-27
e|RS|6ed8a749-81c0-4998-817d-efc86cfaa091|2|MRPHRESP|Morphologic Response|PERCIST|[?]|mmol/kg|CA125 50% RESPONSE|1|mAnson U/mL|WRIGHT STAIN||Y||FAMILY MEMBER|ADJUDICATOR|Y|1|Visit_1|10|1|TREATMENT|2020-06-05|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-13|P1Y2M10DT2H30M|UNKNOWN|2020-07-08|ONGOING|2020-07-15
e|RS|6ed8a749-81c0-4998-817d-efc86cfaa091|3|NTERESP|Non-Target Enhancing Response|PCWG SCHER PROSTATE CANCER 2008|||CYTOGENETIC MINOR RESPONSE|1|PFU|FLAME PHOTOMETRY||Y|Y|SIGNIFICANT OTHER|ENDOCRINOLOGIST|N|2|Visit_2|25|7|TREATMENT|2020-06-20|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-15|P1Y2M10DT2H30M|UNKNOWN|2020-08-02|AFTER|2020-08-06
e|RS|6ed8a749-81c0-4998-817d-efc86cfaa091|4|BONERESP|Bone Response|iRECIST|[?]|s^-1(%O2)^-1|MOLECULAR CR|1|10^11/L|FLUORIMETRY||||SIBLING|CARDIOLOGIST|NA|2|Visit_2|25|2|TREATMENT|2020-06-20|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-15|P1Y2M10DT2H30M|COINCIDENT|2020-08-19|ONGOING|2020-08-30
e|RS|6ed8a749-81c0-4998-817d-efc86cfaa091|5|MRPHRESP|Morphologic Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|%|HI-N|1|U/m2/min|CHROMOGENIC ASSAY|Y|||CHILD|PATHOLOGIST 2|U|3|Visit_3|40|7|TREATMENT|2020-07-05|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-22|P1Y2M10DT2H30M|BEFORE|2020-07-22|COINCIDENT|2020-08-18
e|RS|6ed8a749-81c0-4998-817d-efc86cfaa091|6|STRUSTAT|Steroid Use Status|FAROOQUI SUPP CLL 2014|||MRD PERSISTENCE|1|mL/cage|PALM METHOD||Y|Y|INDEPENDENT ASSESSOR|RADIOLOGIST 1|NA|3|Visit_3|40|3|TREATMENT|2020-07-05|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-22|P1Y2M10DT2H30M|AFTER|2020-06-11|BEFORE|2020-06-22
e|RS|6ed8a749-81c0-4998-817d-efc86cfaa091|7|CYTORESP|Cytogenetic Response|KEAM BREAST CANCER 2013|[?]|TRANSDUCING UNIT/mL|PMD|1|GPL U|POLYMERASE CHAIN REACTION||||SIGNIFICANT OTHER|RADIOLOGIST 1|NA|4|Visit_4|65|3|TREATMENT|2020-07-30|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-02|P1Y2M10DT2H30M|BEFORE|2020-06-04|AFTER|2020-08-28
e|RS|6ed8a749-81c0-4998-817d-efc86cfaa091|8|MNPTHIND|Minor Pathological Response Indicator|iRECIST|[?]|mg/m2/day|PSA PROGRESSION|1|pm|ENZYMATIC ULTRACENTRIFUGATION||||PARENT|RATER 2|Y|4|Visit_4|65|3|SCREENING|2020-07-30|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-02|P1Y2M10DT2H30M|COINCIDENT|2020-08-29|BEFORE|2020-08-30
e|RS|6ed8a749-81c0-4998-817d-efc86cfaa091|9|METBRESP|Metabolic Response|BRUGGEMANN MRD 2010|[?]|mm3/mm2/year|VGPR|1|USP U|DOPPLER ULTRASOUND||||CLINICAL RESEARCH COORDINATOR|RATER|N|5|Visit_5|90|6|TREATMENT|2020-08-24|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-17|P1Y2M10DT2H30M|UNKNOWN|2020-07-02|BEFORE|2020-07-19
e|RS|6ed8a749-81c0-4998-817d-efc86cfaa091|10|TMRESP|Tumor Marker Response|EBMT BLADE MYELOMA 1998|||SD|1|tsp|VENTILATION PERFUSION LUNG SCAN|||Y|SIGNIFICANT OTHER|ADJUDICATOR 3|Y|5|Visit_5|90|7|WASHOUT|2020-08-24|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-17|P1Y2M10DT2H30M|AFTER|2020-06-22|BEFORE|2020-08-26
e|RS|b0f061e5-5dc0-422d-8d96-e7b1af8bda6b|1|ANATRESP|Anatomic Response|IWC HALLEK CLL 2008|[?]|Bq/ug|iUPD|1|EID 50/mL|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY||||FAMILY MEMBER|ONCOLOGIST 1|U|1|Visit_1|10|1|SCREENING|2021-01-18|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-08|P1Y2M10DT2H30M|BEFORE|2021-04-08|COINCIDENT|2021-04-10
e|RS|b0f061e5-5dc0-422d-8d96-e7b1af8bda6b|2|METBRESP|Metabolic Response|SCHWARZ CERVICAL CANCER 2009|[?]|cm/min|FAVORABLE RESPONSE|1|U/cL|MYELOPEROXIDASE STAIN||Y||DOMESTIC PARTNER|CARDIOLOGIST|U|1|Visit_1|10|4|SCREENING|2021-01-18|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-08|P1Y2M10DT2H30M|COINCIDENT|2021-01-11|AFTER|2021-03-04
e|RS|b0f061e5-5dc0-422d-8d96-e7b1af8bda6b|3|NTRGRESP|Non-target Response|PROTOCOL DEFINED RESPONSE CRITERIA|||iSD|1|uU/dL|ELLA|||Y|NON-HEALTH CARE PROFESSIONAL|READER 3|Y|2|Visit_2|25|4|WASHOUT|2021-02-02|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-30|P1Y2M10DT2H30M|AFTER|2021-03-18|ONGOING|2021-04-07
e|RS|b0f061e5-5dc0-422d-8d96-e7b1af8bda6b|4|MRDRESP|Minimal Residual Disease Response|IWC HALLEK CLL 2008|||RELAPSED DISEASE FROM CR OR PR|1|mm/2h|ELECTROCHEMILUMINESCENCE|||Y|SPOUSE|CARDIOLOGIST|NA|2|Visit_2|25|2|TREATMENT|2021-02-02|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-30|P1Y2M10DT2H30M|AFTER|2021-02-22|AFTER|2021-03-11
e|RS|b0f061e5-5dc0-422d-8d96-e7b1af8bda6b|5|CYTORESP|Cytogenetic Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|mEq/mmol|DISEASE TRANSFORMATION|1|mL/beat|IMMUNORADIOMETRIC ASSAY|Y|||FAMILY MEMBER|ONCOLOGIST 1|N|3|Visit_3|40|3|TREATMENT|2021-02-17|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-19|P1Y2M10DT2H30M|COINCIDENT|2021-04-14|ONGOING|2021-04-15
e|RS|b0f061e5-5dc0-422d-8d96-e7b1af8bda6b|6|MNPTHIND|Minor Pathological Response Indicator|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|anti-Xa IU/mL|PR|1|%|MRI WITHOUT CONTRAST||||INTERVIEWER|READER 1|Y|3|Visit_3|40|4|TREATMENT|2021-02-17|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-19|P1Y2M10DT2H30M|BEFORE|2021-02-04|AFTER|2021-04-04
e|RS|b0f061e5-5dc0-422d-8d96-e7b1af8bda6b|7|BONERESP|Bone Response|RANO|[?]|/4.0 mL|PMD|1|nm|MALDI||||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 1|NA|4|Visit_4|65|1|FOLLOW-UP|2021-03-14|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-13|P1Y2M10DT2H30M|UNKNOWN|2021-01-30|ONGOING|2021-02-18
e|RS|b0f061e5-5dc0-422d-8d96-e7b1af8bda6b|8|BESTRESP|Best Overall Response|EBMT BLADE MYELOMA 1998|[?]|L/s|CYTOGENETIC NO RESPONSE|1|Enzyme U/L|ARTERIAL SPIN LABELING FUNCTIONAL MRI||||DOMESTIC PARTNER|RADIOLOGIST|N|4|Visit_4|65|4|FOLLOW-UP|2021-03-14|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-13|P1Y2M10DT2H30M|COINCIDENT|2021-03-27|ONGOING|2021-03-28
e|RS|b0f061e5-5dc0-422d-8d96-e7b1af8bda6b|9|BONERESP|Bone Response|MONTSERRAT CLL 1989|[?]|mEq/g|CYTOGENETIC PR|1|titer|ATOMIC ABSORPTION SPECTROMETRY||||DOMESTIC PARTNER|PATHOLOGIST 1|Y|5|Visit_5|90|3|FOLLOW-UP|2021-04-08|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-12|P1Y2M10DT2H30M|UNKNOWN|2021-02-01|COINCIDENT|2021-02-04
e|RS|b0f061e5-5dc0-422d-8d96-e7b1af8bda6b|10|BMIVLIND|Bone Marrow Involvement Indicator|MASS|[?]|cy/cm|NE|1|Osm|MICROSCOPY||Y||CLINICAL RESEARCH ASSOCIATE|INTERNIST|NA|5|Visit_5|90|5|WASHOUT|2021-04-08|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-12|P1Y2M10DT2H30M|AFTER|2021-03-22|ONGOING|2021-04-08
e|RS|e6162980-e240-4924-a13a-dde28b2345cd|1|METSIND|Metastatic Indicator|CHOI GIST 2008|[?]|mL*cmH2O|pCR|1|PIXELS/in|SXA SCAN||Y||HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|U|1|Visit_1|10|3|TREATMENT|2020-08-11|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-22|P1Y2M10DT2H30M|UNKNOWN|2020-09-09|BEFORE|2020-09-18
e|RS|e6162980-e240-4924-a13a-dde28b2345cd|2|BONERESP|Bone Response|IWC HALLEK CLL 2008|[?]|% INHIBITION|PD-CT|1|10^6 RNA copies/mL|BETA LACTAMASE||Y||SIGNIFICANT OTHER|ONCOLOGIST 1|Y|1|Visit_1|10|7|WASHOUT|2020-08-11|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-22|P1Y2M10DT2H30M|AFTER|2020-09-06|AFTER|2020-10-02
e|RS|e6162980-e240-4924-a13a-dde28b2345cd|3|NTERESP|Non-Target Enhancing Response|JUWEID NON-HODGKINS LYMPHOMA 2005|||PSEUDORESPONSE|1|U/kg|FLUORESCENCE ANGIOGRAPHY||Y|Y|NON-HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|Y|2|Visit_2|25|6|WASHOUT|2020-08-26|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-21|P1Y2M10DT2H30M|AFTER|2020-10-29|COINCIDENT|2020-11-08
e|RS|e6162980-e240-4924-a13a-dde28b2345cd|4|OVRLRESP|Overall Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|U.CARR|EQUIVOCAL|1|kg|PALPATION||Y||CHILD|DEVELOPMENTAL PSYCHOLOGIST|NA|2|Visit_2|25|1|TREATMENT|2020-08-26|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-21|P1Y2M10DT2H30M|BEFORE|2020-09-20|AFTER|2020-10-27
e|RS|e6162980-e240-4924-a13a-dde28b2345cd|5|SPLNRESP|Spleen Response|UNSPECIFIED|[?]|ppb|EQUIVOCAL|1|cup eq|REFLECTANCE SPECTROSCOPY|Y|Y||FAMILY MEMBER|OTOLARYNGOLOGIST|NA|3|Visit_3|40|5|TREATMENT|2020-09-10|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-17|P1Y2M10DT2H30M|UNKNOWN|2020-08-03|BEFORE|2020-09-06
e|RS|e6162980-e240-4924-a13a-dde28b2345cd|6|PATHRESP|Pathologic Response|MASS|[?]|mg/mL/day|pCR|1|mg/g/min|PHOROPTER||||GUARDIAN|NEUROLOGIST 2|N|3|Visit_3|40|1|TREATMENT|2020-09-10|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-17|P1Y2M10DT2H30M|COINCIDENT|2020-10-16|AFTER|2020-11-07
e|RS|e6162980-e240-4924-a13a-dde28b2345cd|7|NTLWIND|Non-Target Lesion Worsening Indicator|PCWG SCHER PROSTATE CANCER 2016|[?]|kBq|PDu|1|10^3 CFU/mL|RADIOGRAPHY|Y|||HEALTH CARE PROFESSIONAL|ADJUDICATOR 1|Y|4|Visit_4|65|7|TREATMENT|2020-10-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-18|P1Y2M10DT2H30M|COINCIDENT|2020-09-29|COINCIDENT|2020-10-22
e|RS|e6162980-e240-4924-a13a-dde28b2345cd|8|METBRESP|Metabolic Response|RAJKUMAR MYELOMA 2011|[?]|10^7 PFU|iCPD|1|pm|RYAN BLUE STAIN||||FRIEND|ADJUDICATOR 2|NA|4|Visit_4|65|5|FOLLOW-UP|2020-10-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-18|P1Y2M10DT2H30M|COINCIDENT|2020-08-07|COINCIDENT|2020-10-03
e|RS|e6162980-e240-4924-a13a-dde28b2345cd|9|NEWLWIND|New Lesion Worsening Indicator|KEAM BREAST CANCER 2013|[?]|dB|PSEUDOPROGRESSION|1|L/day|IMMUNOASSAY||Y||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|U|5|Visit_5|90|4|TREATMENT|2020-10-30|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-21|P1Y2M10DT2H30M|UNKNOWN|2020-09-11|COINCIDENT|2020-10-27
e|RS|e6162980-e240-4924-a13a-dde28b2345cd|10|NEWLIND|New Lesion Indicator|WHO BREAST CANCER 2006|[?]|msec|PR WITH LYMPHOCYTOSIS|1|mL/h|FLUORESCENT IMMUNOASSAY||||SIGNIFICANT OTHER|READER 2|Y|5|Visit_5|90|3|TREATMENT|2020-10-30|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-21|P1Y2M10DT2H30M|BEFORE|2020-09-01|BEFORE|2020-09-18
e|RS|3dc9c666-8be3-4cfa-88d4-b18647e08d00|1|CYTORESP|Cytogenetic Response|CHESON CLL 2006|[?]|mg/g/min|NON-QUANTIFIABLE MRD POSITIVITY|1|mg/min|MICRONEUTRALIZATION ASSAY|Y|Y||GUARDIAN|READER 1|N|1|Visit_1|10|1|SCREENING|2020-06-13|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-25|P1Y2M10DT2H30M|UNKNOWN|2020-08-01|ONGOING|2020-08-07
e|RS|3dc9c666-8be3-4cfa-88d4-b18647e08d00|2|MRPHRESP|Morphologic Response|EASL BRUIX LIVER CANCER 2001|||MORPHOLOGIC CRi|1|Torr|CINEANGIOGRAPHY|||Y|CLINICAL RESEARCH COORDINATOR|RATER 1|N|1|Visit_1|10|2|TREATMENT|2020-06-13|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-25|P1Y2M10DT2H30M|COINCIDENT|2020-06-08|AFTER|2020-08-17
e|RS|3dc9c666-8be3-4cfa-88d4-b18647e08d00|3|NTLWIND|Non-Target Lesion Worsening Indicator|HAMAOKA BREAST CANCER 2010|[?]|pmol|PD FROM PR|1|mg2/dL2|WHOLE TRANSCRIPTOME SEQUENCING|Y|||VENDOR|ADJUDICATOR 1|Y|2|Visit_2|25|5|WASHOUT|2020-06-28|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-17|P1Y2M10DT2H30M|AFTER|2020-07-24|BEFORE|2020-07-26
e|RS|3dc9c666-8be3-4cfa-88d4-b18647e08d00|4|BMIVLIND|Bone Marrow Involvement Indicator|NCCN ALL MRD 2014|[?]|vp/mL|CR-CT|1|PFU/animal|TEMPLATE INCISION METHOD|Y|||ADJUDICATOR|PHYSIOTHERAPIST|N|2|Visit_2|25|5|WASHOUT|2020-06-28|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-17|P1Y2M10DT2H30M|BEFORE|2020-08-16|COINCIDENT|2020-09-03
e|RS|3dc9c666-8be3-4cfa-88d4-b18647e08d00|5|CPRFSTAT|Clinical Performance Status|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|mmol/L|QUANTIFIABLE MRD POSITIVITY|1|APL U/mL|DIGITAL PCR ARRAY|Y|||INDEPENDENT ASSESSOR|ADJUDICATOR 2|U|3|Visit_3|40|3|SCREENING|2020-07-13|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-12|P1Y2M10DT2H30M|BEFORE|2020-09-10|ONGOING|2020-09-11
e|RS|3dc9c666-8be3-4cfa-88d4-b18647e08d00|6|SFTSRESP|Soft Tissue Response|KUMAR IMWG 2016|[?]|Linear ft*LB|CA125 50% RESPONSE|1|PACKAGE|SPECT/CT SCAN||||PARENT|READER 3|Y|3|Visit_3|40|4|FOLLOW-UP|2020-07-13|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-12|P1Y2M10DT2H30M|UNKNOWN|2020-07-09|BEFORE|2020-08-23
e|RS|3dc9c666-8be3-4cfa-88d4-b18647e08d00|7|NTLWIND|Non-Target Lesion Worsening Indicator|PCWG BUBLEY PROSTATE CANCER 1999|[?]|Anson U|MRD RELAPSE|1|log10 copies/mL|SLOAN LETTER EYE CHART 2.5%||||INDEPENDENT ASSESSOR|NEUROLOGIST|Y|4|Visit_4|65|7|TREATMENT|2020-08-07|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-30|P1Y2M10DT2H30M|AFTER|2020-09-02|ONGOING|2020-09-04
e|RS|3dc9c666-8be3-4cfa-88d4-b18647e08d00|8|PATHRESP|Pathologic Response|MONTSERRAT CLL 1989|[?]|AU/mL|HI-P|1|mL/h|OPTICAL DENSITY MEASUREMENT||||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR|Y|4|Visit_4|65|7|WASHOUT|2020-08-07|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-30|P1Y2M10DT2H30M|AFTER|2020-08-16|COINCIDENT|2020-08-31
e|RS|3dc9c666-8be3-4cfa-88d4-b18647e08d00|9|TRGRESP|Target Response|AJCC V8|[?]|FEU|DECREASED|1|foz_us|DOPPLER ULTRASOUND||||CHILD|CLINICAL PATHOLOGIST|Y|5|Visit_5|90|3|FOLLOW-UP|2020-09-01|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-29|P1Y2M10DT2H30M|BEFORE|2020-08-25|BEFORE|2020-09-02
e|RS|3dc9c666-8be3-4cfa-88d4-b18647e08d00|10|ANATRESP|Anatomic Response|RANO ELLINGSON 2017|[?]|IMPLANT|NED|1|BAU/mL|MODIFIED ACID FAST STAIN|Y|||SIBLING|READER 3|U|5|Visit_5|90|5|WASHOUT|2020-09-01|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-29|P1Y2M10DT2H30M|UNKNOWN|2020-07-28|AFTER|2020-09-03
e|RS|6aed5c2d-d5b1-4969-9a8a-14a79a839dbc|1|NTNERESP|Non-Target Non-Enhancing Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|cP|CMR|1|ug/mL/h|CHROMOGENIC ASSAY||||FAMILY MEMBER|ENDOCRINOLOGIST|U|1|Visit_1|10|5|FOLLOW-UP|2021-01-23|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-18|P1Y2M10DT2H30M|UNKNOWN|2021-04-05|ONGOING|2021-04-16
e|RS|6aed5c2d-d5b1-4969-9a8a-14a79a839dbc|2|NTERESP|Non-Target Enhancing Response|SCHWARZ CERVICAL CANCER 2009|[?]|U/mmol|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|kg/cm|X-RAY FLUORESCENCE SPECTROMETRY||Y||FAMILY MEMBER|READER|N|1|Visit_1|10|6|FOLLOW-UP|2021-01-23|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-18|P1Y2M10DT2H30M|BEFORE|2021-01-31|BEFORE|2021-03-26
e|RS|6aed5c2d-d5b1-4969-9a8a-14a79a839dbc|3|METSIND|Metastatic Indicator|PCWG SCHER PROSTATE CANCER 2016|[?]|uCi/kg|CR|1|copies/uL|HPLC||Y||CLINICAL RESEARCH COORDINATOR|DERMATOLOGIST|NA|2|Visit_2|25|6|SCREENING|2021-02-07|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-05|P1Y2M10DT2H30M|AFTER|2021-03-07|BEFORE|2021-03-24
e|RS|6aed5c2d-d5b1-4969-9a8a-14a79a839dbc|4|CLINRESP|Clinical Response|LUGANO CLASSIFICATION|[?]|dpm/0.5 mL|RELAPSED DISEASE|1|mL/(min*100mL)|DIRECT SEQUENCING|Y|Y||VENDOR|MICROSCOPIST 2|U|2|Visit_2|25|3|TREATMENT|2021-02-07|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-05|P1Y2M10DT2H30M|BEFORE|2021-02-06|COINCIDENT|2021-03-01
e|RS|6aed5c2d-d5b1-4969-9a8a-14a79a839dbc|5|STRUSTAT|Steroid Use Status|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|pmol/10^9 cells|PARTIAL MORPHOLOGIC RESPONSE|1|mEq/mmol|DISK DIFFUSION|Y|Y||PARENT|OPHTHALMOLOGIST|Y|3|Visit_3|40|3|TREATMENT|2021-02-22|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-19|P1Y2M10DT2H30M|COINCIDENT|2021-02-20|BEFORE|2021-03-31
e|RS|6aed5c2d-d5b1-4969-9a8a-14a79a839dbc|6|CPRFSTAT|Clinical Performance Status|BRUGGEMANN MRD 2010|||mCR|1|BEAM BREAKS|REBOUND TONOMETRY|Y||Y|CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|3|Visit_3|40|2|TREATMENT|2021-02-22|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-19|P1Y2M10DT2H30M|BEFORE|2021-03-21|ONGOING|2021-03-26
e|RS|6aed5c2d-d5b1-4969-9a8a-14a79a839dbc|7|PATHRESP|Pathologic Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|||CA125 75% RESPONSE|1|nmol/g|AUTOREFRACTION|||Y|ADJUDICATOR|NEUROLOGIST 2|NA|4|Visit_4|65|2|WASHOUT|2021-03-19|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-02|P1Y2M10DT2H30M|BEFORE|2021-03-16|ONGOING|2021-04-17
e|RS|6aed5c2d-d5b1-4969-9a8a-14a79a839dbc|8|NTERESP|Non-Target Enhancing Response|LEE LUNG CANCER 2011|[?]|mmHg/L/min|RELAPSED DISEASE FROM CR|1|ug/mol|CAPILLARY ELECTROPHORESIS||||FRIEND|PHYSIOTHERAPIST|Y|4|Visit_4|65|5|TREATMENT|2021-03-19|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-02|P1Y2M10DT2H30M|COINCIDENT|2021-03-11|COINCIDENT|2021-04-15
e|RS|6aed5c2d-d5b1-4969-9a8a-14a79a839dbc|9|SYMPTDTR|Symptomatic Deterioration|GUPPY OVARIAN CANCER 2002|[?]|pmol/10^10 cells|OPTIMAL MORPHOLOGIC RESPONSE|1|IU|ELISPOT||||SIGNIFICANT OTHER|CARDIOLOGIST|N|5|Visit_5|90|7|FOLLOW-UP|2021-04-13|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-06|P1Y2M10DT2H30M|COINCIDENT|2021-02-21|BEFORE|2021-03-04
e|RS|6aed5c2d-d5b1-4969-9a8a-14a79a839dbc|10|NEWLWIND|New Lesion Worsening Indicator|HARTMANN GERM CELL CANCER 2002|[?]|anti-Xa IU/mL|PARTIAL MORPHOLOGIC RESPONSE|1|mMU/mL|CT SCAN WITHOUT CONTRAST|Y|||CHILD|RATER 2|Y|5|Visit_5|90|4|TREATMENT|2021-04-13|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-06|P1Y2M10DT2H30M|UNKNOWN|2021-03-04|AFTER|2021-04-13
e|RS|b3da6961-98dc-4f83-9cf4-dbc7f4a91c61|1|ANATRESP|Anatomic Response|LEE LUNG CANCER 2011|[?]|uSiemens|OPTIMAL MORPHOLOGIC RESPONSE|1|Ejaculate U|MS/MS||||INVESTIGATOR|READER 1|NA|1|Visit_1|10|1|SCREENING|2020-11-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-25|P1Y2M10DT2H30M|AFTER|2021-02-07|AFTER|2021-02-09
e|RS|b3da6961-98dc-4f83-9cf4-dbc7f4a91c61|2|NEWLPROG|New Lesion Progression|MRANO VAN DEN BENT GLIOMA 2011|[?]|uIU/L|SD|1|/2000 RBC|CLOT DETECTION||||NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST|U|1|Visit_1|10|5|WASHOUT|2020-11-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-25|P1Y2M10DT2H30M|COINCIDENT|2021-01-09|ONGOING|2021-02-12
e|RS|b3da6961-98dc-4f83-9cf4-dbc7f4a91c61|3|OVRLRESP|Overall Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|um2|cPR|1|U/g Hb|MIGET||||INVESTIGATOR|OPTOMETRIST|U|2|Visit_2|25|4|WASHOUT|2020-12-04|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-20|P1Y2M10DT2H30M|COINCIDENT|2020-11-24|COINCIDENT|2021-02-04
e|RS|b3da6961-98dc-4f83-9cf4-dbc7f4a91c61|4|HEMARESP|Hematologic Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|CCID 50/dose|HI-E|1|uV*sec|CONTRAST ENHANCED MRI||||PARENT|OPHTHALMOLOGIST|U|2|Visit_2|25|4|WASHOUT|2020-12-04|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-20|P1Y2M10DT2H30M|COINCIDENT|2020-12-03|BEFORE|2021-01-07
e|RS|b3da6961-98dc-4f83-9cf4-dbc7f4a91c61|5|SFTSRESP|Soft Tissue Response|iRECIST|[?]|kg/m2|SMD|1|mg/L FEU|COMPUTERIZED CORNEAL TOPOGRAPHY|Y|||INVESTIGATOR|ONCOLOGIST 2|N|3|Visit_3|40|1|TREATMENT|2020-12-19|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-07|P1Y2M10DT2H30M|UNKNOWN|2020-11-17|ONGOING|2020-12-02
e|RS|b3da6961-98dc-4f83-9cf4-dbc7f4a91c61|6|NEWLPROG|New Lesion Progression|HAMAOKA BREAST CANCER 2010|[?]|U/L|STABLE|1|LOZENGE|ANGIOGRAPHY||Y||CHILD|PATHOLOGIST|Y|3|Visit_3|40|5|TREATMENT|2020-12-19|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-07|P1Y2M10DT2H30M|AFTER|2021-01-07|BEFORE|2021-01-27
e|RS|b3da6961-98dc-4f83-9cf4-dbc7f4a91c61|7|SPLNRESP|Spleen Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|POINT|PD/RELAPSE AFTER HI|1|pm|GC/MS-CI||||FAMILY MEMBER|DERMATOLOGIST|U|4|Visit_4|65|6|TREATMENT|2021-01-13|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-14|P1Y2M10DT2H30M|UNKNOWN|2020-11-14|AFTER|2020-11-27
e|RS|b3da6961-98dc-4f83-9cf4-dbc7f4a91c61|8|NEWLWIND|New Lesion Worsening Indicator|JACINTO CERVICAL CANCER 2007|[?]|mol/L|iCR|1|mol/mol|MS/MS|Y|||SPOUSE|ADJUDICATOR|U|4|Visit_4|65|4|TREATMENT|2021-01-13|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-14|P1Y2M10DT2H30M|BEFORE|2021-01-31|COINCIDENT|2021-02-03
e|RS|b3da6961-98dc-4f83-9cf4-dbc7f4a91c61|9|MRDIND|Minimal Residual Disease Indicator|SHINDOH COLORECTAL CANCER 2013|[?]|RFU|MAJOR PATHOLOGIC RESPONSE|1|Joule|SICKLE CELL SOLUBILITY TEST||||INVESTIGATOR|READER 3|NA|5|Visit_5|90|6|TREATMENT|2021-02-07|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-14|P1Y2M10DT2H30M|AFTER|2020-11-26|AFTER|2021-01-06
e|RS|b3da6961-98dc-4f83-9cf4-dbc7f4a91c61|10|HEMARESP|Hematologic Response|CHESON CLL 2006|[?]|MET|TREATMENT FAILURE|1|damol/L|TRANSCRIPTION-MEDIATED AMPLIFICATION|Y|||FRIEND|FORENSIC PATHOLOGIST|N|5|Visit_5|90|7|TREATMENT|2021-02-07|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-14|P1Y2M10DT2H30M|COINCIDENT|2021-02-13|AFTER|2021-02-16
e|RS|2738b933-c71d-4239-a093-6b4aa7cc41df|1|MRPHRESP|Morphologic Response|BLAZER COLORECTAL CANCER 2008|||iCR|1|10^9/L|PALM METHOD|Y||Y|SIBLING|RATER 2|NA|1|Visit_1|10|4|FOLLOW-UP|2020-05-28|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-12|P1Y2M10DT2H30M|COINCIDENT|2020-06-01|COINCIDENT|2020-07-26
e|RS|2738b933-c71d-4239-a093-6b4aa7cc41df|2|PATHRESP|Pathologic Response|PROTOCOL DEFINED RESPONSE CRITERIA|||PD|1|DAYS|GEL ELECTROPHORESIS|||Y|SIGNIFICANT OTHER|ONCOLOGIST|Y|1|Visit_1|10|6|TREATMENT|2020-05-28|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-12|P1Y2M10DT2H30M|UNKNOWN|2020-08-17|AFTER|2020-08-20
e|RS|2738b933-c71d-4239-a093-6b4aa7cc41df|3|BONERESP|Bone Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|10^9 organisms/mg|mCR|1|DISK|TRYPAN BLUE STAIN||||SIBLING|ONCOLOGIST 1|N|2|Visit_2|25|1|TREATMENT|2020-06-12|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-08|P1Y2M10DT2H30M|UNKNOWN|2020-07-31|BEFORE|2020-08-12
e|RS|2738b933-c71d-4239-a093-6b4aa7cc41df|4|NTRGRESP|Non-target Response|BLAZER COLORECTAL CANCER 2008|[?]|cm|PMR|1|VOXEL|LIQUID SCINTILLATION COUNTING||||INVESTIGATOR|ADJUDICATOR 1|NA|2|Visit_2|25|2|SCREENING|2020-06-12|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-08|P1Y2M10DT2H30M|COINCIDENT|2020-08-04|BEFORE|2020-08-22
e|RS|2738b933-c71d-4239-a093-6b4aa7cc41df|5|OVRLRESP|Overall Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|||nPR|1|MBq|IMMUNOCHEMILUMINOMETRIC ASSAY|||Y|CLINICAL STUDY SPONSOR|PATHOLOGIST|Y|3|Visit_3|40|4|TREATMENT|2020-06-27|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-13|P1Y2M10DT2H30M|AFTER|2020-08-03|COINCIDENT|2020-08-13
e|RS|2738b933-c71d-4239-a093-6b4aa7cc41df|6|SYMPTDTR|Symptomatic Deterioration|DOHNER AML 2010|||SD-CT|1|RING|DIFFUSION WEIGHTED MRI||Y|Y|INVESTIGATOR|MICROSCOPIST 2|Y|3|Visit_3|40|2|FOLLOW-UP|2020-06-27|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-13|P1Y2M10DT2H30M|UNKNOWN|2020-05-24|BEFORE|2020-06-02
e|RS|2738b933-c71d-4239-a093-6b4aa7cc41df|7|OVRLRESP|Overall Response|SHINDOH COLORECTAL CANCER 2013|[?]|mg/dose|UNFAVORABLE RESPONSE|1|CIGARETTE|FUNDUS PHOTOGRAPHY||||STUDY SUBJECT|ADJUDICATOR 1|U|4|Visit_4|65|2|TREATMENT|2020-07-22|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-09|P1Y2M10DT2H30M|COINCIDENT|2020-07-27|ONGOING|2020-07-29
e|RS|2738b933-c71d-4239-a093-6b4aa7cc41df|8|BESTRESP|Best Overall Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|mEq/g|QUANTIFIABLE MRD POSITIVITY|1|10^9 organisms/mg|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY||||SIBLING|PATHOLOGIST 1|U|4|Visit_4|65|1|TREATMENT|2020-07-22|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-09|P1Y2M10DT2H30M|COINCIDENT|2020-07-18|BEFORE|2020-08-23
e|RS|2738b933-c71d-4239-a093-6b4aa7cc41df|9|NEWLWIND|New Lesion Worsening Indicator|RANO ELLINGSON 2017|[?]|CIGARETTE|VGPR|1|mol/mol|DIFFUSION WEIGHTED MRI|Y|||GUARDIAN|INTERNIST|U|5|Visit_5|90|1|FOLLOW-UP|2020-08-16|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-27|P1Y2M10DT2H30M|COINCIDENT|2020-06-15|ONGOING|2020-06-26
e|RS|2738b933-c71d-4239-a093-6b4aa7cc41df|10|NEWLWIND|New Lesion Worsening Indicator|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|s^-1(%O2)^-1|CYTOGENETIC NO RESPONSE|1|mol/L|AMSLER GRID|Y|||SIBLING|READER 3|NA|5|Visit_5|90|3|TREATMENT|2020-08-16|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-27|P1Y2M10DT2H30M|BEFORE|2020-06-03|BEFORE|2020-07-10
e|RS|68b9ff4e-9694-4545-a752-4d3ac0e89fda|1|METBRESP|Metabolic Response|MASS|[?]|U/g/day|PMR|1|10^6 CFU/mL|POPULATION SEQUENCING||Y||PARENT|ONCOLOGIST|NA|1|Visit_1|10|5|TREATMENT|2021-01-08|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-25|P1Y2M10DT2H30M|UNKNOWN|2021-03-14|ONGOING|2021-03-27
e|RS|68b9ff4e-9694-4545-a752-4d3ac0e89fda|2|NTNERESP|Non-Target Non-Enhancing Response|CHESON CLL 2012|[?]|LOZENGE|cCR|1|nmol/g|CT SCAN WITHOUT CONTRAST|Y|||CLINICAL STUDY SPONSOR|RATER 2|Y|1|Visit_1|10|5|TREATMENT|2021-01-08|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-25|P1Y2M10DT2H30M|COINCIDENT|2021-03-05|COINCIDENT|2021-03-14
e|RS|68b9ff4e-9694-4545-a752-4d3ac0e89fda|3|ANATRESP|Anatomic Response|MRECIST LENCIONI LIVER CANCER 2010|||PMR|1|mg/animal|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY|||Y|ADJUDICATION COMMITTEE|READER 2|N|2|Visit_2|25|5|TREATMENT|2021-01-23|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-25|P1Y2M10DT2H30M|AFTER|2021-04-02|BEFORE|2021-04-03
e|RS|68b9ff4e-9694-4545-a752-4d3ac0e89fda|4|METBRESP|Metabolic Response|PERCIST|||INCREASED|1|log10 TCID 50/dose|NUCLEAR RADIOLOGY|||Y|CHILD|INTERNIST|Y|2|Visit_2|25|6|WASHOUT|2021-01-23|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-25|P1Y2M10DT2H30M|BEFORE|2021-03-13|AFTER|2021-03-25
e|RS|68b9ff4e-9694-4545-a752-4d3ac0e89fda|5|METBRESP|Metabolic Response|BURCOMBE BREAST CANCER 2005|[?]|AU/mL|NON-CR/NON-PD|1|USP U|ENDPOINT DILUTION ASSAY||Y||ADJUDICATION COMMITTEE|INTERNIST|NA|3|Visit_3|40|1|WASHOUT|2021-02-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-03|P1Y2M10DT2H30M|UNKNOWN|2021-04-07|BEFORE|2021-04-08
e|RS|68b9ff4e-9694-4545-a752-4d3ac0e89fda|6|DRCRIND|Disease Recurrence Indicator|PCWG SCHER PROSTATE CANCER 2016|[?]|Newton|HI-N|1|mL/animal/day|PULSE OXIMETRY||Y||FRIEND|MICROSCOPIST 1|Y|3|Visit_3|40|3|WASHOUT|2021-02-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-03|P1Y2M10DT2H30M|AFTER|2021-02-01|ONGOING|2021-03-14
e|RS|68b9ff4e-9694-4545-a752-4d3ac0e89fda|7|METSIND|Metastatic Indicator|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|ug/h|PMD|1|IU/L|BETA LACTAMASE||||SIGNIFICANT OTHER|OTOLARYNGOLOGIST|Y|4|Visit_4|65|7|WASHOUT|2021-03-04|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-05|P1Y2M10DT2H30M|UNKNOWN|2021-01-15|BEFORE|2021-02-15
e|RS|68b9ff4e-9694-4545-a752-4d3ac0e89fda|8|PATHRESP|Pathologic Response|HARTMANN GERM CELL CANCER 2002|[?]|Anson U|cCR|1|ug/h|GRADIENT DIFFUSION||Y||CLINICAL STUDY SPONSOR|PATHOLOGIST 1|NA|4|Visit_4|65|6|TREATMENT|2021-03-04|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-05|P1Y2M10DT2H30M|BEFORE|2021-03-13|COINCIDENT|2021-04-07
e|RS|68b9ff4e-9694-4545-a752-4d3ac0e89fda|9|CLINRESP|Clinical Response|AJCC V8|[?]|cup eq|iCPD|1|pmol/g|CALCULATION|Y|Y||HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|Y|5|Visit_5|90|1|TREATMENT|2021-03-29|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-08|P1Y2M10DT2H30M|UNKNOWN|2021-03-30|ONGOING|2021-04-01
e|RS|68b9ff4e-9694-4545-a752-4d3ac0e89fda|10|STRUSTAT|Steroid Use Status|BLAZER COLORECTAL CANCER 2008|[?]|deg|RELAPSED DISEASE|1|CIGARETTE|AURAMINE STAIN||||INDEPENDENT ASSESSOR|CARDIOLOGIST|U|5|Visit_5|90|4|TREATMENT|2021-03-29|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-08|P1Y2M10DT2H30M|UNKNOWN|2021-02-27|AFTER|2021-03-08
e|RS|0f0ec179-5100-4a3d-9f93-54140aca7d30|1|RDIORESP|Radiologic Response|PRINCE TCELL LYMPHOMA 2010|[?]|U/mmol|iSD|1|cm/s|ELECTROGASTROGRAPHY||||VENDOR|OTOLARYNGOLOGIST|U|1|Visit_1|10|7|TREATMENT|2020-08-25|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-30|P1Y2M10DT2H30M|AFTER|2020-11-09|ONGOING|2020-11-14
e|RS|0f0ec179-5100-4a3d-9f93-54140aca7d30|2|NTRGRESP|Non-target Response|PERCIST|[?]|mmAL|FAVORABLE RESPONSE|1|uV*sec|PH METER MEASUREMENT METHOD||||ADJUDICATION COMMITTEE|ONCOLOGIST 1|U|1|Visit_1|10|6|TREATMENT|2020-08-25|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-30|P1Y2M10DT2H30M|BEFORE|2020-09-10|ONGOING|2020-10-20
e|RS|0f0ec179-5100-4a3d-9f93-54140aca7d30|3|MRDRESP|Minimal Residual Disease Response|RANO ELLINGSON 2017|[?]|amol|PR|1|mg/g/min|MICROBIAL BIOCHEMICAL IDENTIFICATION||||DOMESTIC PARTNER|UROLOGIST|N|2|Visit_2|25|6|TREATMENT|2020-09-09|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-26|P1Y2M10DT2H30M|BEFORE|2020-09-09|COINCIDENT|2020-11-02
e|RS|0f0ec179-5100-4a3d-9f93-54140aca7d30|4|LIVRRESP|Liver Response|AJCC V8|[?]|tuberculin unit|MORPHOLOGIC CR|1|pmol/L|LEAD CITRATE STAIN||Y||PARENT|RATER|NA|2|Visit_2|25|7|TREATMENT|2020-09-09|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-26|P1Y2M10DT2H30M|COINCIDENT|2020-11-14|AFTER|2020-11-17
e|RS|0f0ec179-5100-4a3d-9f93-54140aca7d30|5|CLINRESP|Clinical Response|RAJKUMAR MYELOMA 2011|[?]|mg/m2/h|SD|1|U/dL|INCISION-INDUCED BLEEDING METHOD||||CLINICAL RESEARCH ASSOCIATE|PHYSIOTHERAPIST|NA|3|Visit_3|40|4|TREATMENT|2020-09-24|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-18|P1Y2M10DT2H30M|AFTER|2020-11-03|AFTER|2020-11-16
e|RS|0f0ec179-5100-4a3d-9f93-54140aca7d30|6|SPLNRESP|Spleen Response|FAROOQUI SUPP CLL 2014|[?]|GBq/ug|MOLECULAR MAJOR RESPONSE|1|mL/kg/min|LC/MS||Y||CLINICAL STUDY SPONSOR|ADJUDICATOR 1|NA|3|Visit_3|40|5|SCREENING|2020-09-24|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-18|P1Y2M10DT2H30M|COINCIDENT|2020-08-26|COINCIDENT|2020-10-10
e|RS|0f0ec179-5100-4a3d-9f93-54140aca7d30|7|CPRFSTAT|Clinical Performance Status|HARTMAN PANCREATIC CANCER 2012|||MORPHOLOGIC CR|1|MASK|MECHANICAL CLOT DETECTION|||Y|INTERVIEWER|PHYSIOTHERAPIST|NA|4|Visit_4|65|5|TREATMENT|2020-10-19|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-27|P1Y2M10DT2H30M|COINCIDENT|2020-11-19|ONGOING|2020-11-20
e|RS|0f0ec179-5100-4a3d-9f93-54140aca7d30|8|SPLNRESP|Spleen Response|EASL BRUIX LIVER CANCER 2001|[?]|ug/m2/min|CHR|1|pmol/g|FLUORESCENT LIFETIME IMAGING MICROSCOPY||||INTERVIEWER|FORENSIC PATHOLOGIST|Y|4|Visit_4|65|6|TREATMENT|2020-10-19|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-27|P1Y2M10DT2H30M|COINCIDENT|2020-11-18|BEFORE|2020-11-20
e|RS|0f0ec179-5100-4a3d-9f93-54140aca7d30|9|MRDIND|Minimal Residual Disease Indicator|HARTMAN PANCREATIC CANCER 2012|[?]|nm|CR-CT|1|/200 HPFs|CONGO RED STAIN||||HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|U|5|Visit_5|90|5|TREATMENT|2020-11-13|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-01|P1Y2M10DT2H30M|COINCIDENT|2020-11-09|ONGOING|2020-11-16
e|RS|0f0ec179-5100-4a3d-9f93-54140aca7d30|10|SFTSRESP|Soft Tissue Response|LEE LUNG CANCER 2011|[?]|RNA copies/mL|CYTOGENETIC MINIMAL RESPONSE|1|ug/g/h|NUCLEIC ACID BASED METHOD||Y||PARENT|RADIOLOGIST|N|5|Visit_5|90|2|WASHOUT|2020-11-13|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-01|P1Y2M10DT2H30M|UNKNOWN|2020-10-18|AFTER|2020-10-20
e|RS|6affe43d-e455-40af-8478-dc38019e89e1|1|METBRESP|Metabolic Response|EBMT BLADE MYELOMA 1998|[?]|HOURS|PD-CT|1|vg/kg|CALIPER MEASUREMENT METHOD||||INDEPENDENT ASSESSOR|MICROSCOPIST 2|Y|1|Visit_1|10|1|TREATMENT|2020-06-17|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-15|P1Y2M10DT2H30M|BEFORE|2020-08-07|BEFORE|2020-09-03
e|RS|6affe43d-e455-40af-8478-dc38019e89e1|2|CYTORESP|Cytogenetic Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|mL|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|/500 WBC|ENZYMATIC SPECTROPHOTOMETRY|Y|||GUARDIAN|MICROSCOPIST 3|Y|1|Visit_1|10|7|TREATMENT|2020-06-17|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-15|P1Y2M10DT2H30M|AFTER|2020-09-12|AFTER|2020-09-14
e|RS|6affe43d-e455-40af-8478-dc38019e89e1|3|CLINRESP|Clinical Response|DOHNER AML 2010|[?]|cal|MOLECULAR MAJOR RESPONSE|1|10^4/hpf|LISSAMINE GREEN STAIN||Y||STUDY SUBJECT|READER 1|NA|2|Visit_2|25|3|TREATMENT|2020-07-02|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-25|P1Y2M10DT2H30M|BEFORE|2020-06-09|BEFORE|2020-07-10
e|RS|6affe43d-e455-40af-8478-dc38019e89e1|4|METBRESP|Metabolic Response|BLAZER COLORECTAL CANCER 2008|||CR-CT|1|foz_br|NEPHELOMETRY|||Y|GUARDIAN|PATHOLOGIST 1|U|2|Visit_2|25|7|TREATMENT|2020-07-02|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-25|P1Y2M10DT2H30M|AFTER|2020-08-21|BEFORE|2020-08-30
e|RS|6affe43d-e455-40af-8478-dc38019e89e1|5|NEWLWIND|New Lesion Worsening Indicator|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|BISCUIT|PR WITH LYMPHOCYTOSIS|1|uU/L|DROPLET DIGITAL PCR||||INVESTIGATOR|ENDOCRINOLOGIST|Y|3|Visit_3|40|1|TREATMENT|2020-07-17|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-24|P1Y2M10DT2H30M|UNKNOWN|2020-08-03|BEFORE|2020-08-07
e|RS|6affe43d-e455-40af-8478-dc38019e89e1|6|MRDIND|Minimal Residual Disease Indicator|KUMAR IMWG 2016|||CYTOGENETIC PR|1|10^3 RNA copies/mL|RAJI CELL RIA|||Y|INVESTIGATOR|ADJUDICATOR 3|N|3|Visit_3|40|3|SCREENING|2020-07-17|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-24|P1Y2M10DT2H30M|UNKNOWN|2020-06-28|BEFORE|2020-08-22
e|RS|6affe43d-e455-40af-8478-dc38019e89e1|7|METBRESP|Metabolic Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|nmol/kg/day|VGPR|1|%(v/v)|PET/CT SCAN||||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 1|N|4|Visit_4|65|1|SCREENING|2020-08-11|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-15|P1Y2M10DT2H30M|COINCIDENT|2020-08-05|ONGOING|2020-09-06
e|RS|6affe43d-e455-40af-8478-dc38019e89e1|8|BMIVLIND|Bone Marrow Involvement Indicator|KUKER LYMPHOMA 2005|[?]|anti-Xa IU|nPR|1|Absorbance U/mL|CISH|Y|||CLINICAL RESEARCH COORDINATOR|RATER|NA|4|Visit_4|65|6|TREATMENT|2020-08-11|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-15|P1Y2M10DT2H30M|BEFORE|2020-07-10|BEFORE|2020-08-05
e|RS|6affe43d-e455-40af-8478-dc38019e89e1|9|SPLNRESP|Spleen Response|CHESON CLL 2006|[?]|U/animal|mCR|1|ppth|EEG||||GUARDIAN|ONCOLOGIST 2|U|5|Visit_5|90|5|FOLLOW-UP|2020-09-05|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-01|P1Y2M10DT2H30M|UNKNOWN|2020-07-21|BEFORE|2020-08-13
e|RS|6affe43d-e455-40af-8478-dc38019e89e1|10|NEWLPROG|New Lesion Progression|GUPPY OVARIAN CANCER 2002|[?]|BOTTLE|VGPR|1|cm/s|INDIA INK STAIN||||SIBLING|PATHOLOGIST 1|N|5|Visit_5|90|5|TREATMENT|2020-09-05|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-01|P1Y2M10DT2H30M|BEFORE|2020-07-25|ONGOING|2020-08-16
e|RS|1c090c96-0a6c-45dd-b862-0aa3d9d579cb|1|STRUSTAT|Steroid Use Status|PCWG BUBLEY PROSTATE CANCER 1999|[?]|Antibody Unit|PR-CT|1|bel|CLOT DETECTION||||INDEPENDENT ASSESSOR|NEUROLOGIST 2|Y|1|Visit_1|10|4|FOLLOW-UP|2020-06-07|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-29|P1Y2M10DT2H30M|BEFORE|2020-05-30|COINCIDENT|2020-06-19
e|RS|1c090c96-0a6c-45dd-b862-0aa3d9d579cb|2|MOLRESP|Molecular Response|HAMAOKA BREAST CANCER 2010|||NR|1|APL U|AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT|||Y|STUDY SUBJECT|MICROSCOPIST 3|N|1|Visit_1|10|7|TREATMENT|2020-06-07|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-29|P1Y2M10DT2H30M|AFTER|2020-07-07|ONGOING|2020-08-25
e|RS|1c090c96-0a6c-45dd-b862-0aa3d9d579cb|3|MNPTHIND|Minor Pathological Response Indicator|WOLCHOK SOLID TUMORS 2009|||PD-CT|1|PRESSOR UNITS|SCINTIGRAPHY|Y||Y|SIBLING|INTERNIST|N|2|Visit_2|25|5|TREATMENT|2020-06-22|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-21|P1Y2M10DT2H30M|BEFORE|2020-07-29|COINCIDENT|2020-08-30
e|RS|1c090c96-0a6c-45dd-b862-0aa3d9d579cb|4|SPLNRESP|Spleen Response|RECIST 1.0|[?]|cmH2O*s/mL|PMR|1|mL*cmH2O|TONOMETRY||Y||FRIEND|RADIOLOGIST 1|NA|2|Visit_2|25|7|FOLLOW-UP|2020-06-22|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-21|P1Y2M10DT2H30M|UNKNOWN|2020-09-02|COINCIDENT|2020-09-04
e|RS|1c090c96-0a6c-45dd-b862-0aa3d9d579cb|5|NTERESP|Non-Target Enhancing Response|IWG CHESON MDS 2000|[?]|GLOBULE|MRD RELAPSE|1|mg/m2/day|CONTRAST ENHANCED CT SCAN||Y||STUDY SUBJECT|PATHOLOGIST 1|U|3|Visit_3|40|4|TREATMENT|2020-07-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-28|P1Y2M10DT2H30M|AFTER|2020-06-28|BEFORE|2020-09-04
e|RS|1c090c96-0a6c-45dd-b862-0aa3d9d579cb|6|MOLRESP|Molecular Response|PETIT BREAST CANCER 2001|[?]|/10^4|PSEUDOPROGRESSION|1|/LPF|KNEMOMETRY||||SIBLING|OTOLARYNGOLOGIST|N|3|Visit_3|40|6|WASHOUT|2020-07-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-28|P1Y2M10DT2H30M|UNKNOWN|2020-06-11|ONGOING|2020-08-03
e|RS|1c090c96-0a6c-45dd-b862-0aa3d9d579cb|7|NTRGRESP|Non-target Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|10^7 PFU|EQUIVOCAL|1|mg/m2/min|COMPUTERIZED CORNEAL TOPOGRAPHY|Y|||PARENT|NEUROLOGIST|NA|4|Visit_4|65|2|FOLLOW-UP|2020-08-01|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-18|P1Y2M10DT2H30M|BEFORE|2020-08-04|ONGOING|2020-08-05
e|RS|1c090c96-0a6c-45dd-b862-0aa3d9d579cb|8|NEWLPROG|New Lesion Progression|LEE LUNG CANCER 2011|||iSD|1|cup eq|SCANNING ELECTRON MICROSCOPY|||Y|CAREGIVER|RATER|N|4|Visit_4|65|6|WASHOUT|2020-08-01|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-18|P1Y2M10DT2H30M|AFTER|2020-06-13|BEFORE|2020-08-30
e|RS|1c090c96-0a6c-45dd-b862-0aa3d9d579cb|9|BMIVLIND|Bone Marrow Involvement Indicator|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|BLOCKS|NR|1|mg/m2/day|RAJI CELL EIA|Y|||ADJUDICATOR|READER 2|NA|5|Visit_5|90|2|TREATMENT|2020-08-26|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-07|P1Y2M10DT2H30M|BEFORE|2020-06-27|BEFORE|2020-08-22
e|RS|1c090c96-0a6c-45dd-b862-0aa3d9d579cb|10|CYTORESP|Cytogenetic Response|PRINCE TCELL LYMPHOMA 2010|[?]|10^3 organisms/g|UNFAVORABLE RESPONSE|1|nCi|TRANSESOPHAGEAL ECHOCARDIOGRAPHY||||SIGNIFICANT OTHER|RATER 1|NA|5|Visit_5|90|7|WASHOUT|2020-08-26|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-07|P1Y2M10DT2H30M|UNKNOWN|2020-08-20|COINCIDENT|2020-08-26
e|RS|e0258c95-7bcc-4b54-895c-f290a1364b5c|1|NEWLWIND|New Lesion Worsening Indicator|CHOI GIST 2008|||SD|1|m|SXA SCAN||Y|Y|SPOUSE|PATHOLOGIST 1|NA|1|Visit_1|10|1|TREATMENT|2020-12-27|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-19|P1Y2M10DT2H30M|AFTER|2021-01-03|AFTER|2021-02-14
e|RS|e0258c95-7bcc-4b54-895c-f290a1364b5c|2|MRDIND|Minimal Residual Disease Indicator|NCIWG CHESON CLL 1996|[?]|U/g Hb|IMMUNOPHENOTYPIC CR|1|rpm|IVY INCISION METHOD||Y||NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|U|1|Visit_1|10|6|TREATMENT|2020-12-27|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-19|P1Y2M10DT2H30M|UNKNOWN|2021-02-01|COINCIDENT|2021-02-24
e|RS|e0258c95-7bcc-4b54-895c-f290a1364b5c|3|SPLNRESP|Spleen Response|JACINTO CERVICAL CANCER 2007|[?]|nmol BCE/nmol|TREATMENT FAILURE|1|SFC/10^6 PBMC|PHOTOGRAPHY|Y|Y||INTERVIEWER|PEDIATRIC NEUROLOGIST|N|2|Visit_2|25|5|FOLLOW-UP|2021-01-11|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-03|P1Y2M10DT2H30M|UNKNOWN|2021-02-21|BEFORE|2021-02-23
e|RS|e0258c95-7bcc-4b54-895c-f290a1364b5c|4|TMRESP|Tumor Marker Response|IWG CHESON AML 2003|[?]|U/dL|INDETERMINATE RESPONSE|1|g/U|FARNSWORTH-MUNSELL 100 HUE TEST||||INDEPENDENT ASSESSOR|MICROSCOPIST 3|Y|2|Visit_2|25|1|FOLLOW-UP|2021-01-11|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-03|P1Y2M10DT2H30M|COINCIDENT|2021-02-27|BEFORE|2021-03-21
e|RS|e0258c95-7bcc-4b54-895c-f290a1364b5c|5|BONERESP|Bone Response|MACDONALD GLIOMA 1990|[?]|cmH2O/mL|PR WITH LYMPHOCYTOSIS|1|L/day|DIRECT SEQUENCING||Y||DOMESTIC PARTNER|ADJUDICATOR 3|U|3|Visit_3|40|7|TREATMENT|2021-01-26|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-12|P1Y2M10DT2H30M|BEFORE|2021-02-23|AFTER|2021-03-03
e|RS|e0258c95-7bcc-4b54-895c-f290a1364b5c|6|MRDIND|Minimal Residual Disease Indicator|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|mg/animal|MORPHOLOGIC CRi|1|mg/L|DNA MICROARRAY||||ADJUDICATION COMMITTEE|HEMATOLOGIST|NA|3|Visit_3|40|2|TREATMENT|2021-01-26|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-12|P1Y2M10DT2H30M|AFTER|2021-01-16|BEFORE|2021-01-19
e|RS|e0258c95-7bcc-4b54-895c-f290a1364b5c|7|HEMARESP|Hematologic Response|RECIST 1.1|[?]|log10 TCID 50/uL|sCR|1|Linear ft*LB|FLUORESCEIN STAIN||||FRIEND|ONCOLOGIST|U|4|Visit_4|65|7|FOLLOW-UP|2021-02-20|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-21|P1Y2M10DT2H30M|BEFORE|2021-03-23|BEFORE|2021-03-26
e|RS|e0258c95-7bcc-4b54-895c-f290a1364b5c|8|OVRLRESP|Overall Response|SCHER PROSTATE CANCER 2011|[?]|10^7 CFU/mL|SD-CT|1|KIT|VENTILATION PERFUSION LUNG SCAN|Y|||ADJUDICATION COMMITTEE|READER 2|U|4|Visit_4|65|4|FOLLOW-UP|2021-02-20|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-21|P1Y2M10DT2H30M|AFTER|2021-02-02|AFTER|2021-03-01
e|RS|e0258c95-7bcc-4b54-895c-f290a1364b5c|9|BONERESP|Bone Response|BLAZER COLORECTAL CANCER 2008|||PR-CT|1|APL U/mL|RAJI CELL RIA|||Y|PARENT|RADIOLOGIST 2|U|5|Visit_5|90|5|FOLLOW-UP|2021-03-17|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-27|P1Y2M10DT2H30M|UNKNOWN|2020-12-29|ONGOING|2021-03-17
e|RS|e0258c95-7bcc-4b54-895c-f290a1364b5c|10|MRPHRESP|Morphologic Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|AFU|STABLE|1|/2000 RBC|DISK DIFFUSION||||INVESTIGATOR|PATHOLOGIST 1|N|5|Visit_5|90|2|TREATMENT|2021-03-17|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-27|P1Y2M10DT2H30M|BEFORE|2021-02-03|AFTER|2021-03-22
e|RS|7218f9ae-0119-4633-a8d3-7d98b2ae1671|1|NTNERESP|Non-Target Non-Enhancing Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|fmol|WORSENED|1|10^11/L|ANTIMICROBIAL COMBINATION TESTING||||ADJUDICATOR|RATER|NA|1|Visit_1|10|5|FOLLOW-UP|2021-01-13|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-07|P1Y2M10DT2H30M|AFTER|2021-02-21|BEFORE|2021-04-09
e|RS|7218f9ae-0119-4633-a8d3-7d98b2ae1671|2|MOLRESP|Molecular Response|FAROOQUI SUPP CLL 2014|||PD-CT|1|/100 HPFs|CELL CYTOTOXICITY NEUTRALIZATION ASSAY|||Y|NON-HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|U|1|Visit_1|10|6|WASHOUT|2021-01-13|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-07|P1Y2M10DT2H30M|AFTER|2021-03-25|ONGOING|2021-04-10
e|RS|7218f9ae-0119-4633-a8d3-7d98b2ae1671|3|SPLNRESP|Spleen Response|CHESON CLL 2012|||RELAPSED DISEASE FROM CR OR PR|1|um|HPLC/MS/MS|||Y|INDEPENDENT ASSESSOR|READER 1|Y|2|Visit_2|25|3|SCREENING|2021-01-28|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-26|P1Y2M10DT2H30M|AFTER|2021-02-28|COINCIDENT|2021-04-02
e|RS|7218f9ae-0119-4633-a8d3-7d98b2ae1671|4|METBRESP|Metabolic Response|FAROOQUI SUPP CLL 2014|[?]|Hounsfield Unit|CR-CT|1|mol/g|SLIT LAMP PHOTOGRAPHY||||SIBLING|RADIOLOGIST 2|U|2|Visit_2|25|2|FOLLOW-UP|2021-01-28|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-26|P1Y2M10DT2H30M|UNKNOWN|2021-03-10|AFTER|2021-03-23
e|RS|7218f9ae-0119-4633-a8d3-7d98b2ae1671|5|SPLNRESP|Spleen Response|RANO ELLINGSON 2017|[?]|gtt|PD|1|mN|MAPH||Y||CLINICAL STUDY SPONSOR|RADIOLOGIST 1|Y|3|Visit_3|40|2|WASHOUT|2021-02-12|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-08|P1Y2M10DT2H30M|BEFORE|2021-03-15|ONGOING|2021-04-02
e|RS|7218f9ae-0119-4633-a8d3-7d98b2ae1671|6|MNPTHIND|Minor Pathological Response Indicator|CHESON CLL 2006|[?]|mg/L|CYTOGENETIC NO RESPONSE|1|genEq/mL|PALPATION||||SIGNIFICANT OTHER|RATER 2|NA|3|Visit_3|40|1|WASHOUT|2021-02-12|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-08|P1Y2M10DT2H30M|UNKNOWN|2021-01-17|AFTER|2021-04-10
e|RS|7218f9ae-0119-4633-a8d3-7d98b2ae1671|7|TRGRESP|Target Response|RANO ELLINGSON 2017|[?]|mmol/day|PMR|1|EVENTS|FLUORESCENT LIFETIME IMAGING MICROSCOPY|Y|Y||HEALTH CARE PROFESSIONAL|DERMATOLOGIST|Y|4|Visit_4|65|2|SCREENING|2021-03-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-05|P1Y2M10DT2H30M|AFTER|2021-04-09|BEFORE|2021-04-11
e|RS|7218f9ae-0119-4633-a8d3-7d98b2ae1671|8|NEWLPROG|New Lesion Progression|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|||mCR|1|GPL U|MIGET||Y|Y|INTERVIEWER|READER 1|N|4|Visit_4|65|4|TREATMENT|2021-03-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-05|P1Y2M10DT2H30M|UNKNOWN|2021-02-20|AFTER|2021-03-22
e|RS|7218f9ae-0119-4633-a8d3-7d98b2ae1671|9|CYTORESP|Cytogenetic Response|MONTSERRAT CLL 1989|||PSEUDOPROGRESSION|1|BAU|AUTOREFRACTION||Y|Y|INTERVIEWER|HEMATOLOGIST|Y|5|Visit_5|90|5|TREATMENT|2021-04-03|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-05|P1Y2M10DT2H30M|UNKNOWN|2021-01-05|AFTER|2021-01-24
e|RS|7218f9ae-0119-4633-a8d3-7d98b2ae1671|10|NEWLIND|New Lesion Indicator|WHO BREAST CANCER 2006|[?]|/month|CYTOGENETIC PR|1|OI50|DUKE INCISION METHOD|Y|Y||FRIEND|RATER 2|Y|5|Visit_5|90|5|WASHOUT|2021-04-03|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-05|P1Y2M10DT2H30M|BEFORE|2021-03-05|COINCIDENT|2021-04-08
e|RS|f8c938ff-21c8-4d0b-9335-08d2865543ab|1|SYMPTDTR|Symptomatic Deterioration|AJCC V7|[?]|cm|STABLE|1|mg/day|X-RAY FLUORESCENCE SPECTROMETRY|Y|||INDEPENDENT ASSESSOR|HEMATOLOGIST|U|1|Visit_1|10|2|TREATMENT|2020-05-11|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-06|P1Y2M10DT2H30M|COINCIDENT|2020-05-13|ONGOING|2020-07-21
e|RS|f8c938ff-21c8-4d0b-9335-08d2865543ab|2|MRPHRESP|Morphologic Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|Coulomb|NR|1|s/h|CLAUSS METHOD|Y|||PROXY|ADJUDICATOR|Y|1|Visit_1|10|7|TREATMENT|2020-05-11|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-06|P1Y2M10DT2H30M|AFTER|2020-05-17|BEFORE|2020-07-03
e|RS|f8c938ff-21c8-4d0b-9335-08d2865543ab|3|NEWLWIND|New Lesion Worsening Indicator|BRUGGEMANN MRD 2010|[?]|Joule|MRD PERSISTENCE|1|SFC/10^6 PBMC|LIQUID SCINTILLATION COUNTING|Y|Y||PROXY|PATHOLOGIST 2|U|2|Visit_2|25|5|TREATMENT|2020-05-26|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-30|P1Y2M10DT2H30M|AFTER|2020-06-21|COINCIDENT|2020-08-08
e|RS|f8c938ff-21c8-4d0b-9335-08d2865543ab|4|BONERESP|Bone Response|PROTOCOL DEFINED RESPONSE CRITERIA|||MORPHOLOGIC LEUKEMIA-FREE STATE|1|mCi|PERFUSION MRI|||Y|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST|U|2|Visit_2|25|3|TREATMENT|2020-05-26|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-30|P1Y2M10DT2H30M|AFTER|2020-07-29|ONGOING|2020-07-31
e|RS|f8c938ff-21c8-4d0b-9335-08d2865543ab|5|ANATRESP|Anatomic Response|BURCOMBE BREAST CANCER 2005|[?]|/h|PR WITH LYMPHOCYTOSIS|1|MASK|PHOROPTER||||HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|U|3|Visit_3|40|7|FOLLOW-UP|2020-06-10|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-21|P1Y2M10DT2H30M|UNKNOWN|2020-07-22|COINCIDENT|2020-08-05
e|RS|f8c938ff-21c8-4d0b-9335-08d2865543ab|6|SPLNRESP|Spleen Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|kg/m2|CA125 50% RESPONSE|1|P|ELASTOGRAPHY||Y||SPOUSE|NEUROLOGIST|Y|3|Visit_3|40|6|WASHOUT|2020-06-10|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-21|P1Y2M10DT2H30M|BEFORE|2020-05-26|ONGOING|2020-05-30
e|RS|f8c938ff-21c8-4d0b-9335-08d2865543ab|7|MRPHRESP|Morphologic Response|KEAM BREAST CANCER 2013|[?]|BLOCKS|cPR|1|pmol/L|SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|Y|Y||CAREGIVER|READER|N|4|Visit_4|65|4|FOLLOW-UP|2020-07-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-30|P1Y2M10DT2H30M|COINCIDENT|2020-06-18|ONGOING|2020-07-14
e|RS|f8c938ff-21c8-4d0b-9335-08d2865543ab|8|MRDIND|Minimal Residual Disease Indicator|HARTMAN PANCREATIC CANCER 2012|[?]|psi|NON-PD|1|10^9 CFU|ZIEHL NEELSEN ACID FAST STAIN||Y||HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|Y|4|Visit_4|65|4|TREATMENT|2020-07-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-30|P1Y2M10DT2H30M|AFTER|2020-05-27|BEFORE|2020-07-06
e|RS|f8c938ff-21c8-4d0b-9335-08d2865543ab|9|METBRESP|Metabolic Response|GUPPY OVARIAN CANCER 2002|[?]|nmol/mol|CYTOGENETIC MINOR RESPONSE|1|s/h|TRANSTHORACIC ECHOCARDIOGRAPHY||Y||HEALTH CARE PROFESSIONAL|RADIOLOGIST|NA|5|Visit_5|90|1|SCREENING|2020-07-30|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-25|P1Y2M10DT2H30M|AFTER|2020-06-19|AFTER|2020-06-26
e|RS|f8c938ff-21c8-4d0b-9335-08d2865543ab|10|NEWLIND|New Lesion Indicator|iRECIST|||CRi|1|U/g Hb|LISSAMINE GREEN STAIN||Y|Y|DOMESTIC PARTNER|CARDIOLOGIST|N|5|Visit_5|90|2|WASHOUT|2020-07-30|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-25|P1Y2M10DT2H30M|COINCIDENT|2020-06-23|BEFORE|2020-07-20
e|RS|7176f852-7392-4636-800f-3aad48e93065|1|NEWLWIND|New Lesion Worsening Indicator|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|nkat/L|PSEUDOPROGRESSION|1|fmol/g|NEXT GENERATION TARGETED SEQUENCING|Y|Y||CHILD|READER|NA|1|Visit_1|10|5|TREATMENT|2021-01-16|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-03|P1Y2M10DT2H30M|AFTER|2021-02-24|COINCIDENT|2021-03-22
e|RS|7176f852-7392-4636-800f-3aad48e93065|2|TMRESP|Tumor Marker Response|IWG CHESON MDS 2006|||nPR|1|ug|HPLC/MS/MS|||Y|HEALTH CARE PROFESSIONAL|UROLOGIST|N|1|Visit_1|10|4|TREATMENT|2021-01-16|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-03|P1Y2M10DT2H30M|UNKNOWN|2021-01-25|COINCIDENT|2021-04-02
e|RS|7176f852-7392-4636-800f-3aad48e93065|3|NEWLIND|New Lesion Indicator|KEAM BREAST CANCER 2013|||CRi|1|mCi|TRIPLE-PHASE SPIRAL CT SCAN|||Y|ADJUDICATION COMMITTEE|ADJUDICATOR 3|U|2|Visit_2|25|1|WASHOUT|2021-01-31|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-01|P1Y2M10DT2H30M|AFTER|2021-03-05|COINCIDENT|2021-04-11
e|RS|7176f852-7392-4636-800f-3aad48e93065|4|NEWLIND|New Lesion Indicator|IRANO 2015|[?]|vg/mL|PSEUDORESPONSE|1|10^4/L|ELECTROPHORESIS||||SIBLING|READER 1|NA|2|Visit_2|25|4|FOLLOW-UP|2021-01-31|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-01|P1Y2M10DT2H30M|AFTER|2021-04-07|ONGOING|2021-04-14
e|RS|7176f852-7392-4636-800f-3aad48e93065|5|ANATRESP|Anatomic Response|BURCOMBE BREAST CANCER 2005|[?]|10^6 CFU|sCR|1|RNA copies/mL|LYMPHANGIOGRAPHY||||INTERVIEWER|MICROSCOPIST 2|Y|3|Visit_3|40|3|WASHOUT|2021-02-15|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-07|P1Y2M10DT2H30M|COINCIDENT|2021-03-10|BEFORE|2021-04-02
e|RS|7176f852-7392-4636-800f-3aad48e93065|6|RDIORESP|Radiologic Response|IRANO 2015|||FAVORABLE RESPONSE|1|QUANTITY SUFFICIENT|VENTILATION PERFUSION LUNG SCAN|||Y|INDEPENDENT ASSESSOR|ONCOLOGIST 1|N|3|Visit_3|40|5|TREATMENT|2021-02-15|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-07|P1Y2M10DT2H30M|BEFORE|2021-03-18|COINCIDENT|2021-04-12
e|RS|7176f852-7392-4636-800f-3aad48e93065|7|SYMPTDTR|Symptomatic Deterioration|HARTMANN GERM CELL CANCER 2002|[?]|10^3 organisms|MOLECULAR MAJOR RESPONSE|1|cd/m2|DYNAMIC CONTRAST ENHANCED MRI||Y||CLINICAL RESEARCH ASSOCIATE|UROLOGIST|U|4|Visit_4|65|1|SCREENING|2021-03-12|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-22|P1Y2M10DT2H30M|COINCIDENT|2021-02-13|BEFORE|2021-04-05
e|RS|7176f852-7392-4636-800f-3aad48e93065|8|ANATRESP|Anatomic Response|FAROOQUI SUPP CLL 2014|||CRi|1|/2500 WBC|CONTRAST ENHANCED SPIRAL CT SCAN|||Y|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 3|NA|4|Visit_4|65|2|FOLLOW-UP|2021-03-12|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-22|P1Y2M10DT2H30M|UNKNOWN|2021-02-21|COINCIDENT|2021-03-20
e|RS|7176f852-7392-4636-800f-3aad48e93065|9|CLINRESP|Clinical Response|CHOLLET BREAST CANCER 2002|[?]|PACK|CA125 50% RESPONSE|1|%(w/w)|GC/MS-EI||Y||CLINICAL STUDY SPONSOR|ADJUDICATOR 3|NA|5|Visit_5|90|7|FOLLOW-UP|2021-04-06|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-10|P1Y2M10DT2H30M|AFTER|2021-03-20|BEFORE|2021-03-22
e|RS|7176f852-7392-4636-800f-3aad48e93065|10|CYTORESP|Cytogenetic Response|JACINTO CERVICAL CANCER 2007|[?]|IU|TREATMENT FAILURE|1|copies/mL|FLUOROSCOPY||Y||VENDOR|ADJUDICATOR|N|5|Visit_5|90|6|WASHOUT|2021-04-06|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-10|P1Y2M10DT2H30M|UNKNOWN|2021-03-31|ONGOING|2021-04-07
e|RS|753d5d9d-ec84-46f5-a933-b18b8e3a6b0e|1|MOLRESP|Molecular Response|PALUMBO MULTIPLE MYELOMA 2009|||HI-N|1|KIT|ENZYMATIC COLORIMETRY|||Y|PARENT|FORENSIC PATHOLOGIST|N|1|Visit_1|10|5|TREATMENT|2020-10-08|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-13|P1Y2M10DT2H30M|UNKNOWN|2020-11-02|AFTER|2020-11-06
e|RS|753d5d9d-ec84-46f5-a933-b18b8e3a6b0e|2|METBRESP|Metabolic Response|CHESON NON-HODGKINS LYMPHOMA 1999|||OPTIMAL MORPHOLOGIC RESPONSE|1|pkat/L|THICK SMEAR|||Y|VENDOR|ONCOLOGIST|N|1|Visit_1|10|4|TREATMENT|2020-10-08|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-13|P1Y2M10DT2H30M|AFTER|2020-12-07|BEFORE|2021-01-05
e|RS|753d5d9d-ec84-46f5-a933-b18b8e3a6b0e|3|NEWLPROG|New Lesion Progression|WOLCHOK SOLID TUMORS 2009|[?]|nmol/L|PDu|1|s/h|HPLC-UV|Y|||SIBLING|READER|Y|2|Visit_2|25|7|TREATMENT|2020-10-23|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-12|P1Y2M10DT2H30M|AFTER|2020-11-07|COINCIDENT|2020-12-21
e|RS|753d5d9d-ec84-46f5-a933-b18b8e3a6b0e|4|METBRESP|Metabolic Response|HARTMAN PANCREATIC CANCER 2012|[?]|DAYS|SD-CT|1|mL/g/h|DIFFUSION WEIGHTED MRI||||CHILD|ONCOLOGIST 2|U|2|Visit_2|25|6|TREATMENT|2020-10-23|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-12|P1Y2M10DT2H30M|AFTER|2020-11-30|BEFORE|2020-12-06
e|RS|753d5d9d-ec84-46f5-a933-b18b8e3a6b0e|5|SYMPTDTR|Symptomatic Deterioration|MONTSERRAT CLL 1989|||PMR|1|kV|TRICHROME STAIN|||Y|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|NA|3|Visit_3|40|1|SCREENING|2020-11-07|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-19|P1Y2M10DT2H30M|UNKNOWN|2020-11-01|AFTER|2020-11-26
e|RS|753d5d9d-ec84-46f5-a933-b18b8e3a6b0e|6|NEWLWIND|New Lesion Worsening Indicator|GUILHOT CML 2007|[?]|dmol|CA125 50% RESPONSE|1|BOX|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY||||INTERVIEWER|PATHOLOGIST|U|3|Visit_3|40|3|FOLLOW-UP|2020-11-07|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-19|P1Y2M10DT2H30M|UNKNOWN|2020-12-14|ONGOING|2021-01-01
e|RS|753d5d9d-ec84-46f5-a933-b18b8e3a6b0e|7|TMRESP|Tumor Marker Response|RANO|||CYTOGENETIC CR|1|pptr|AUDIOMETRY|Y|Y|Y|HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|4|Visit_4|65|7|TREATMENT|2020-12-02|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-13|P1Y2M10DT2H30M|BEFORE|2020-12-18|ONGOING|2020-12-30
e|RS|753d5d9d-ec84-46f5-a933-b18b8e3a6b0e|8|MJPTHIND|Major Pathological Response Indicator|MRANO VAN DEN BENT GLIOMA 2011|||iCR|1|ft3|IMMUNOBLOT|Y||Y|PARENT|RATER 1|NA|4|Visit_4|65|1|TREATMENT|2020-12-02|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-13|P1Y2M10DT2H30M|UNKNOWN|2020-12-20|COINCIDENT|2020-12-21
e|RS|753d5d9d-ec84-46f5-a933-b18b8e3a6b0e|9|NEWLWIND|New Lesion Worsening Indicator|DURIE MULTIPLE MYELOMA 2006|[?]|in2|MINOR PATHOLOGIC RESPONSE|1|10^4/L|COLORIMETRY||Y||PARENT|RATER 2|N|5|Visit_5|90|5|WASHOUT|2020-12-27|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-29|P1Y2M10DT2H30M|UNKNOWN|2020-10-30|AFTER|2020-11-09
e|RS|753d5d9d-ec84-46f5-a933-b18b8e3a6b0e|10|NTNERESP|Non-Target Non-Enhancing Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|||PMR|1|mL/mmHg|NEPHELOMETRY|||Y|CHILD|MICROSCOPIST 1|N|5|Visit_5|90|6|TREATMENT|2020-12-27|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-29|P1Y2M10DT2H30M|AFTER|2020-10-18|COINCIDENT|2020-12-18
e|RS|69e41d6b-57f7-48b0-be7a-29fca953f8d9|1|NTERESP|Non-Target Enhancing Response|GUPPY OVARIAN CANCER 2002|[?]|JDF Unit|NON-PD|1|Log10 ELISA unit|WESTERN BLOT||||GUARDIAN|CLINICAL PATHOLOGIST|Y|1|Visit_1|10|3|WASHOUT|2020-10-28|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-13|P1Y2M10DT2H30M|UNKNOWN|2021-01-04|ONGOING|2021-01-11
e|RS|69e41d6b-57f7-48b0-be7a-29fca953f8d9|2|METBRESP|Metabolic Response|BRUGGEMANN MRD 2010|||PSEUDORESPONSE|1|10^9 organisms/mL|COULOMETRIC TITRATION|||Y|SIBLING|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|1|Visit_1|10|7|WASHOUT|2020-10-28|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-13|P1Y2M10DT2H30M|COINCIDENT|2021-01-06|BEFORE|2021-01-13
e|RS|69e41d6b-57f7-48b0-be7a-29fca953f8d9|3|NTRGRESP|Non-target Response|JACINTO CERVICAL CANCER 2007|[?]|PUFF|SMD|1|uSiemens|LIGHT MICROSCOPY||||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 1|N|2|Visit_2|25|2|SCREENING|2020-11-12|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-17|P1Y2M10DT2H30M|AFTER|2020-10-26|COINCIDENT|2020-12-11
e|RS|69e41d6b-57f7-48b0-be7a-29fca953f8d9|4|OVRLRESP|Overall Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|L/h|cCR|1|uCi/kg|ELECTROGASTROGRAPHY|Y|Y||HEALTH CARE PROFESSIONAL|PATHOLOGIST|N|2|Visit_2|25|6|TREATMENT|2020-11-12|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-17|P1Y2M10DT2H30M|BEFORE|2020-12-13|ONGOING|2021-01-04
e|RS|69e41d6b-57f7-48b0-be7a-29fca953f8d9|5|NEWLIND|New Lesion Indicator|CHOLLET BREAST CANCER 2002|[?]|Roentgen|NON-QUANTIFIABLE MRD POSITIVITY|1|PUFF|CELL OF ORIGIN ASSAY||||DOMESTIC PARTNER|READER 2|U|3|Visit_3|40|6|TREATMENT|2020-11-27|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-21|P1Y2M10DT2H30M|COINCIDENT|2021-01-04|COINCIDENT|2021-01-08
e|RS|69e41d6b-57f7-48b0-be7a-29fca953f8d9|6|NTNERESP|Non-Target Non-Enhancing Response|EBMT BLADE MYELOMA 1998|[?]|10^6 CFU|RELAPSED DISEASE|1|mg/kg/week|HEMAGGLUTINATION INHIBITION ASSAY||||INTERVIEWER|ADJUDICATOR 2|N|3|Visit_3|40|5|TREATMENT|2020-11-27|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-21|P1Y2M10DT2H30M|AFTER|2020-11-07|COINCIDENT|2020-12-25
e|RS|69e41d6b-57f7-48b0-be7a-29fca953f8d9|7|STRUSTAT|Steroid Use Status|WHO BREAST CANCER 2006|[?]|L/kg|RELAPSED DISEASE FROM CR OR PR|1|nmol|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION||||FAMILY MEMBER|NEUROLOGIST 2|Y|4|Visit_4|65|1|TREATMENT|2020-12-22|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-25|P1Y2M10DT2H30M|COINCIDENT|2021-01-09|COINCIDENT|2021-01-22
e|RS|69e41d6b-57f7-48b0-be7a-29fca953f8d9|8|DRCRIND|Disease Recurrence Indicator|HAMAOKA BREAST CANCER 2010|||CHR|1|MET*h|MIGET|||Y|SPOUSE|READER 1|NA|4|Visit_4|65|6|TREATMENT|2020-12-22|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-25|P1Y2M10DT2H30M|COINCIDENT|2021-01-15|BEFORE|2021-01-18
e|RS|69e41d6b-57f7-48b0-be7a-29fca953f8d9|9|SFTSRESP|Soft Tissue Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|||cCR|1|STRIP|FORCED OSCILLATION TECHNIQUE|Y|Y|Y|CLINICAL STUDY SPONSOR|PHYSIOTHERAPIST|Y|5|Visit_5|90|2|TREATMENT|2021-01-16|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-27|P1Y2M10DT2H30M|COINCIDENT|2020-12-07|ONGOING|2021-01-24
e|RS|69e41d6b-57f7-48b0-be7a-29fca953f8d9|10|MRDIND|Minimal Residual Disease Indicator|GCIG RUSTIN OVARIAN CANCER 2011|[?]|cup eq|CR-CT|1|SQU/mL|MULTI-SLICE SPIRAL CT||||SIGNIFICANT OTHER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|5|Visit_5|90|3|SCREENING|2021-01-16|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-27|P1Y2M10DT2H30M|UNKNOWN|2021-01-19|BEFORE|2021-01-21
e|RS|a38eb4fc-2422-4d4a-a435-58ae9bf42589|1|METBRESP|Metabolic Response|AJCC V7|[?]|km/h|MRD PERSISTENCE|1|10^4 CFU|GEL ELECTROPHORESIS|Y|||INDEPENDENT ASSESSOR|RADIOLOGIST|N|1|Visit_1|10|6|TREATMENT|2020-11-23|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-28|P1Y2M10DT2H30M|BEFORE|2020-12-10|BEFORE|2020-12-13
e|RS|a38eb4fc-2422-4d4a-a435-58ae9bf42589|2|MJPTHIND|Major Pathological Response Indicator|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|||DECREASED|1|eq|MOUSE PROTECTION ASSAY|Y||Y|SIBLING|RADIOLOGIST 2|Y|1|Visit_1|10|4|TREATMENT|2020-11-23|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-28|P1Y2M10DT2H30M|BEFORE|2021-02-08|COINCIDENT|2021-02-20
e|RS|a38eb4fc-2422-4d4a-a435-58ae9bf42589|3|NTERESP|Non-Target Enhancing Response|AJCC V8|[?]|/ms|MORPHOLOGIC LEUKEMIA-FREE STATE|1|U.CARR|CINEANGIOGRAPHY||Y||CHILD|READER 1|N|2|Visit_2|25|6|SCREENING|2020-12-08|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-15|P1Y2M10DT2H30M|AFTER|2021-01-14|BEFORE|2021-02-09
e|RS|a38eb4fc-2422-4d4a-a435-58ae9bf42589|4|NTRGRESP|Non-target Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|Gauss|CR-CT|1|foz_us|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY||Y||HEALTH CARE PROFESSIONAL|RATER 2|Y|2|Visit_2|25|7|WASHOUT|2020-12-08|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-15|P1Y2M10DT2H30M|UNKNOWN|2021-01-22|ONGOING|2021-02-08
e|RS|a38eb4fc-2422-4d4a-a435-58ae9bf42589|5|PATHRESP|Pathologic Response|IWG CHESON MDS 2006|[?]|kHz|iUPD|1|hr/day|MICROPARTICLE ENZYME IMMUNOASSAY||Y||CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR|NA|3|Visit_3|40|7|TREATMENT|2020-12-23|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-03|P1Y2M10DT2H30M|COINCIDENT|2021-02-15|BEFORE|2021-02-20
e|RS|a38eb4fc-2422-4d4a-a435-58ae9bf42589|6|METBRESP|Metabolic Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|mL/m2/min|MRD RELAPSE|1|Frames/s|PULSE OXIMETRY||||INVESTIGATOR|ONCOLOGIST|Y|3|Visit_3|40|5|SCREENING|2020-12-23|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-03|P1Y2M10DT2H30M|BEFORE|2021-02-09|COINCIDENT|2021-02-10
e|RS|a38eb4fc-2422-4d4a-a435-58ae9bf42589|7|CLINRESP|Clinical Response|LEE LUNG CANCER 2011|[?]|aMFI|MR|1|mkat|TRANSESOPHAGEAL ECHOCARDIOGRAPHY||||DOMESTIC PARTNER|ENDOCRINOLOGIST|NA|4|Visit_4|65|3|WASHOUT|2021-01-17|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-11|P1Y2M10DT2H30M|BEFORE|2020-12-19|ONGOING|2020-12-27
e|RS|a38eb4fc-2422-4d4a-a435-58ae9bf42589|8|NTLWIND|Non-Target Lesion Worsening Indicator|CHESON CLL 2012|[?]|10^11/L|NON-PD|1|TROCHE|ANGIOGRAPHY||||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 3|U|4|Visit_4|65|3|TREATMENT|2021-01-17|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-11|P1Y2M10DT2H30M|UNKNOWN|2021-02-07|AFTER|2021-02-11
e|RS|a38eb4fc-2422-4d4a-a435-58ae9bf42589|9|CYTORESP|Cytogenetic Response|RECIST 1.1|[?]|mm2|FAVORABLE RESPONSE|1|oz eq|AUSCULTATION|Y|||STUDY SUBJECT|INTERNIST|U|5|Visit_5|90|6|FOLLOW-UP|2021-02-11|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-17|P1Y2M10DT2H30M|BEFORE|2021-02-03|BEFORE|2021-02-08
e|RS|a38eb4fc-2422-4d4a-a435-58ae9bf42589|10|CPRFSTAT|Clinical Performance Status|PETIT BREAST CANCER 2001|[?]|Gauss|UNFAVORABLE RESPONSE|1|10^3 CFU/g|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY||||NON-HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|Y|5|Visit_5|90|4|TREATMENT|2021-02-11|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-17|P1Y2M10DT2H30M|COINCIDENT|2020-12-26|COINCIDENT|2021-01-01
e|RS|12ae2530-f9f6-4e7d-9daa-fdfaacb1c747|1|CLINRESP|Clinical Response|MACDONALD GLIOMA 1990|[?]|mL/cm|RELAPSED DISEASE|1|mOsm/L|EEG||||DOMESTIC PARTNER|ONCOLOGIST|U|1|Visit_1|10|6|WASHOUT|2020-09-26|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-04|P1Y2M10DT2H30M|BEFORE|2020-10-16|ONGOING|2020-12-17
e|RS|12ae2530-f9f6-4e7d-9daa-fdfaacb1c747|2|MJPTHIND|Major Pathological Response Indicator|PCWG SCHER PROSTATE CANCER 2008|||PR|1|10^4/hpf|HEMOCYTOMETRY|Y||Y|NON-HEALTH CARE PROFESSIONAL|READER|Y|1|Visit_1|10|4|FOLLOW-UP|2020-09-26|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-04|P1Y2M10DT2H30M|AFTER|2020-11-10|AFTER|2020-12-22
e|RS|12ae2530-f9f6-4e7d-9daa-fdfaacb1c747|3|SFTSRESP|Soft Tissue Response|CHOLLET BREAST CANCER 2002|[?]|Absorbance U/min|FAVORABLE RESPONSE|1|WEEKS|TOLUIDINE BLUE STAIN||Y||SIBLING|ADJUDICATOR 2|NA|2|Visit_2|25|7|WASHOUT|2020-10-11|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-23|P1Y2M10DT2H30M|COINCIDENT|2020-11-04|ONGOING|2020-12-13
e|RS|12ae2530-f9f6-4e7d-9daa-fdfaacb1c747|4|SYMPTDTR|Symptomatic Deterioration|PROTOCOL DEFINED RESPONSE CRITERIA|||CYTOGENETIC MINOR RESPONSE|1|BOWL|PULMONARY ANGIOGRAPHY|||Y|DOMESTIC PARTNER|ENDOCRINOLOGIST|NA|2|Visit_2|25|5|WASHOUT|2020-10-11|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-23|P1Y2M10DT2H30M|UNKNOWN|2020-09-24|BEFORE|2020-12-17
e|RS|12ae2530-f9f6-4e7d-9daa-fdfaacb1c747|5|NTERESP|Non-Target Enhancing Response|iRECIST|[?]|CARTRIDGE|NR|1|ks|COULOMETRIC TITRATION||||INTERVIEWER|NEUROLOGIST 2|Y|3|Visit_3|40|2|WASHOUT|2020-10-26|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-25|P1Y2M10DT2H30M|COINCIDENT|2020-11-02|ONGOING|2020-11-22
e|RS|12ae2530-f9f6-4e7d-9daa-fdfaacb1c747|6|NTERESP|Non-Target Enhancing Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|||PR|1|/sec|OSCILLOMETRY|||Y|SIGNIFICANT OTHER|RADIOLOGIST 2|N|3|Visit_3|40|2|FOLLOW-UP|2020-10-26|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-25|P1Y2M10DT2H30M|COINCIDENT|2020-11-29|AFTER|2020-12-10
e|RS|12ae2530-f9f6-4e7d-9daa-fdfaacb1c747|7|METBRESP|Metabolic Response|EASL BRUIX LIVER CANCER 2001|[?]|aMFI|CA125 75% RESPONSE|1|mol/g|MANUAL COUNT|Y|Y||VENDOR|PEDIATRIC NEUROLOGIST|N|4|Visit_4|65|6|FOLLOW-UP|2020-11-20|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-05|P1Y2M10DT2H30M|BEFORE|2020-11-27|ONGOING|2020-12-03
e|RS|12ae2530-f9f6-4e7d-9daa-fdfaacb1c747|8|STRUSTAT|Steroid Use Status|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|PLUG|iCPD|1|10^9 organisms/mL|TOTAL BODY IRRADIATION||||PARENT|RADIOLOGIST 2|U|4|Visit_4|65|7|TREATMENT|2020-11-20|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-05|P1Y2M10DT2H30M|BEFORE|2020-10-02|ONGOING|2020-11-12
e|RS|12ae2530-f9f6-4e7d-9daa-fdfaacb1c747|9|CYTORESP|Cytogenetic Response|PETIT BREAST CANCER 2001|||PSA PROGRESSION|1|10^4/L|FLUORIMETRY|||Y|STUDY SUBJECT|OTOLARYNGOLOGIST|N|5|Visit_5|90|2|TREATMENT|2020-12-15|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-07|P1Y2M10DT2H30M|UNKNOWN|2020-11-09|ONGOING|2020-12-17
e|RS|12ae2530-f9f6-4e7d-9daa-fdfaacb1c747|10|MOLRESP|Molecular Response|WOLCHOK SOLID TUMORS 2009|[?]|DIOPTER|COMPLETE MRD RESPONSE|1|Newton|POLYSOMNOGRAPHY||||VENDOR|PATHOLOGIST 1|Y|5|Visit_5|90|2|FOLLOW-UP|2020-12-15|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-07|P1Y2M10DT2H30M|COINCIDENT|2020-12-04|ONGOING|2020-12-06
e|RS|29e42c28-c2f8-4c27-9a6d-12f0d5fa4ab3|1|BESTRESP|Best Overall Response|FAROOQUI SUPP CLL 2014|[?]|cpm|OPTIMAL MORPHOLOGIC RESPONSE|1|FIU|MIGET||||INTERVIEWER|OTOLARYNGOLOGIST|N|1|Visit_1|10|1|TREATMENT|2021-01-01|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-22|P1Y2M10DT2H30M|BEFORE|2021-03-06|COINCIDENT|2021-03-19
e|RS|29e42c28-c2f8-4c27-9a6d-12f0d5fa4ab3|2|RDIORESP|Radiologic Response|IWG CHESON AML 2003|||PD/RELAPSE AFTER HI|1|g/cage/day|CLIP|||Y|SPOUSE|RADIOLOGIST|N|1|Visit_1|10|5|TREATMENT|2021-01-01|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-22|P1Y2M10DT2H30M|AFTER|2021-03-08|COINCIDENT|2021-03-19
e|RS|29e42c28-c2f8-4c27-9a6d-12f0d5fa4ab3|3|NTLWIND|Non-Target Lesion Worsening Indicator|BLAZER COLORECTAL CANCER 2008|[?]|umol/mg/min|CRi|1|um|TONOMETRY||||ADJUDICATOR|HEMATOLOGIST|N|2|Visit_2|25|4|FOLLOW-UP|2021-01-16|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-15|P1Y2M10DT2H30M|UNKNOWN|2021-02-22|BEFORE|2021-03-23
e|RS|29e42c28-c2f8-4c27-9a6d-12f0d5fa4ab3|4|STRUSTAT|Steroid Use Status|EBMT BLADE MYELOMA 1998|[?]|nkat|iUPD|1|Absorbance U/mL|MS/MS||||CLINICAL STUDY SPONSOR|CLINICAL PATHOLOGIST|Y|2|Visit_2|25|1|FOLLOW-UP|2021-01-16|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-15|P1Y2M10DT2H30M|UNKNOWN|2021-03-15|ONGOING|2021-03-25
e|RS|29e42c28-c2f8-4c27-9a6d-12f0d5fa4ab3|5|MRDRESP|Minimal Residual Disease Response|HARTMAN PANCREATIC CANCER 2012|[?]|RATIO|CR-CT|1|Watt|NEXT GENERATION SEQUENCING||||HEALTH CARE PROFESSIONAL|INTERNIST|U|3|Visit_3|40|3|TREATMENT|2021-01-31|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-20|P1Y2M10DT2H30M|BEFORE|2021-02-09|AFTER|2021-03-20
e|RS|29e42c28-c2f8-4c27-9a6d-12f0d5fa4ab3|6|RDIORESP|Radiologic Response|RECIST 1.0|||PSEUDORESPONSE|1|NFIU|ARTERIAL SPIN LABELING FUNCTIONAL MRI|||Y|GUARDIAN|ENDOCRINOLOGIST|Y|3|Visit_3|40|6|TREATMENT|2021-01-31|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-20|P1Y2M10DT2H30M|BEFORE|2021-02-27|BEFORE|2021-03-03
e|RS|29e42c28-c2f8-4c27-9a6d-12f0d5fa4ab3|7|METBRESP|Metabolic Response|RECICL|||CMR|1|cy/cm|FLUORESCENT MICROSCOPY|||Y|GUARDIAN|OTOLARYNGOLOGIST|N|4|Visit_4|65|5|FOLLOW-UP|2021-02-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-11|P1Y2M10DT2H30M|COINCIDENT|2021-01-31|COINCIDENT|2021-03-06
e|RS|29e42c28-c2f8-4c27-9a6d-12f0d5fa4ab3|8|MOLRESP|Molecular Response|PRINCE TCELL LYMPHOMA 2010|[?]|Ci|UNFAVORABLE RESPONSE|1|10^9/L|NUCLEIC ACID HYBRIDIZATION||Y||HEALTH CARE PROFESSIONAL|READER 2|U|4|Visit_4|65|7|WASHOUT|2021-02-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-11|P1Y2M10DT2H30M|AFTER|2021-02-10|AFTER|2021-03-13
e|RS|29e42c28-c2f8-4c27-9a6d-12f0d5fa4ab3|9|LIVRRESP|Liver Response|GCIG RUSTIN OVARIAN CANCER 2011|||INDETERMINATE RESPONSE|1|10^3 RNA copies/mL|MAGNETIC RESONANCE ANGIOGRAPHY||Y|Y|STUDY SUBJECT|MICROSCOPIST 3|NA|5|Visit_5|90|1|TREATMENT|2021-03-22|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-29|P1Y2M10DT2H30M|UNKNOWN|2021-03-25|AFTER|2021-03-26
e|RS|29e42c28-c2f8-4c27-9a6d-12f0d5fa4ab3|10|MRPHRESP|Morphologic Response|KUKER LYMPHOMA 2005|[?]|VIRTUAL PIXEL|CA125 75% RESPONSE|1|mg/L FEU|IMMUNOCHROMATOGRAPHY|Y|||CHILD|READER|N|5|Visit_5|90|5|TREATMENT|2021-03-22|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-29|P1Y2M10DT2H30M|COINCIDENT|2021-01-21|AFTER|2021-03-18
e|RS|dd518f55-0280-445d-a29f-10f09b21fd53|1|NTRGRESP|Non-target Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|nmol/g|sCR|1|nCi|HEMAGGLUTINATION ASSAY|Y|||FAMILY MEMBER|PEDIATRIC NEUROLOGIST|N|1|Visit_1|10|4|TREATMENT|2020-05-18|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-09|P1Y2M10DT2H30M|BEFORE|2020-08-06|ONGOING|2020-08-15
e|RS|dd518f55-0280-445d-a29f-10f09b21fd53|2|HEMARESP|Hematologic Response|PERCIST|[?]|kPa|CR-CT|1|Gauss|ANALYTICAL ULTRACENTRIFUGATION||Y||CHILD|RATER 1|Y|1|Visit_1|10|6|TREATMENT|2020-05-18|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-09|P1Y2M10DT2H30M|AFTER|2020-05-24|AFTER|2020-07-31
e|RS|dd518f55-0280-445d-a29f-10f09b21fd53|3|MOLRESP|Molecular Response|KUKER LYMPHOMA 2005|[?]|COAT|CA125 75% RESPONSE|1|vg/dose|FLUORESCENT MICROSCOPY||Y||FAMILY MEMBER|FORENSIC PATHOLOGIST|N|2|Visit_2|25|6|TREATMENT|2020-06-02|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-27|P1Y2M10DT2H30M|UNKNOWN|2020-06-03|ONGOING|2020-07-05
e|RS|dd518f55-0280-445d-a29f-10f09b21fd53|4|MJPTHIND|Major Pathological Response Indicator|DOHNER AML 2010|[?]|g/animal|OPTIMAL MORPHOLOGIC RESPONSE|1|CUP|OPTICAL MAPPING||Y||SPOUSE|RATER 1|N|2|Visit_2|25|4|TREATMENT|2020-06-02|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-27|P1Y2M10DT2H30M|BEFORE|2020-05-29|BEFORE|2020-07-25
e|RS|dd518f55-0280-445d-a29f-10f09b21fd53|5|ANATRESP|Anatomic Response|LEE LUNG CANCER 2011|||CYTOGENETIC MINIMAL RESPONSE|1|pmol/L|MICROBIAL CONCENTRATION|Y||Y|SIGNIFICANT OTHER|ADJUDICATOR|Y|3|Visit_3|40|5|WASHOUT|2020-06-17|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-15|P1Y2M10DT2H30M|COINCIDENT|2020-05-12|AFTER|2020-07-27
e|RS|dd518f55-0280-445d-a29f-10f09b21fd53|6|DRCRIND|Disease Recurrence Indicator|RANO ELLINGSON 2017|[?]|lx|CRi|1|/MBP|BAC ACGH|Y|||INVESTIGATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|3|Visit_3|40|4|WASHOUT|2020-06-17|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-15|P1Y2M10DT2H30M|AFTER|2020-06-26|BEFORE|2020-07-05
e|RS|dd518f55-0280-445d-a29f-10f09b21fd53|7|MRDIND|Minimal Residual Disease Indicator|CHOI GIST 2008|[?]|mL*cmH2O|RELAPSED DISEASE|1|Gy|IMPEDANCE CONDUCTIVITY|Y|Y||CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|4|Visit_4|65|5|TREATMENT|2020-07-12|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-03|P1Y2M10DT2H30M|BEFORE|2020-06-01|BEFORE|2020-06-02
e|RS|dd518f55-0280-445d-a29f-10f09b21fd53|8|MOLRESP|Molecular Response|LEE LUNG CANCER 2011|[?]|U/mL|CRi|1|kcal|MODIFIED ACID FAST STAIN||||CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 2|NA|4|Visit_4|65|4|SCREENING|2020-07-12|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-03|P1Y2M10DT2H30M|AFTER|2020-06-03|BEFORE|2020-08-07
e|RS|dd518f55-0280-445d-a29f-10f09b21fd53|9|CLINRESP|Clinical Response|CHOI GIST 2008|[?]|Ci/kg|iSD|1|DPM|INTRAVASCULAR ULTRASOUND||Y||CHILD|CLINICAL PATHOLOGIST|N|5|Visit_5|90|5|WASHOUT|2020-08-06|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-17|P1Y2M10DT2H30M|AFTER|2020-05-14|BEFORE|2020-08-11
e|RS|dd518f55-0280-445d-a29f-10f09b21fd53|10|NTNERESP|Non-Target Non-Enhancing Response|DURIE MULTIPLE MYELOMA 2006|[?]|Henry|PARTIAL MORPHOLOGIC RESPONSE|1|steps/min|DUCTOGRAPHY|Y|||INDEPENDENT ASSESSOR|MICROSCOPIST 3|U|5|Visit_5|90|2|TREATMENT|2020-08-06|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-17|P1Y2M10DT2H30M|BEFORE|2020-07-15|ONGOING|2020-08-10
e|RS|49a972da-dfad-438e-b5bc-26ee6b955a59|1|MRDRESP|Minimal Residual Disease Response|SACT|[?]|mL/cage/day|CA125 50% RESPONSE|1|pg/L|TRICHROME STAIN|Y|||SIGNIFICANT OTHER|CLINICAL PATHOLOGIST|U|1|Visit_1|10|2|TREATMENT|2020-06-24|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-01|P1Y2M10DT2H30M|BEFORE|2020-07-03|ONGOING|2020-08-20
e|RS|49a972da-dfad-438e-b5bc-26ee6b955a59|2|MRDIND|Minimal Residual Disease Indicator|PRINCE TCELL LYMPHOMA 2010|[?]|kBq/uL|UNFAVORABLE RESPONSE|1|ug/day|CRYOSCOPY|Y|Y||INDEPENDENT ASSESSOR|ADJUDICATOR 1|NA|1|Visit_1|10|5|TREATMENT|2020-06-24|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-01|P1Y2M10DT2H30M|UNKNOWN|2020-07-31|ONGOING|2020-08-03
e|RS|49a972da-dfad-438e-b5bc-26ee6b955a59|3|NEWLIND|New Lesion Indicator|PALUMBO MULTIPLE MYELOMA 2009|[?]|10^6 organisms|SD-CT|1|IU/mL|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION||Y||CLINICAL STUDY SPONSOR|DEVELOPMENTAL PSYCHOLOGIST|N|2|Visit_2|25|6|TREATMENT|2020-07-09|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-12|P1Y2M10DT2H30M|UNKNOWN|2020-08-17|BEFORE|2020-08-21
e|RS|49a972da-dfad-438e-b5bc-26ee6b955a59|4|MRPHRESP|Morphologic Response|PCWG SCHER PROSTATE CANCER 2016|||CYTOGENETIC MINIMAL RESPONSE|1|mmHg|HPLC/MS|||Y|STUDY SUBJECT|ENDOCRINOLOGIST|Y|2|Visit_2|25|6|TREATMENT|2020-07-09|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-12|P1Y2M10DT2H30M|BEFORE|2020-08-19|COINCIDENT|2020-09-07
e|RS|49a972da-dfad-438e-b5bc-26ee6b955a59|5|NEWLWIND|New Lesion Worsening Indicator|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|||PSEUDOPROGRESSION|1|atm|FLUORESCENCE ANGIOGRAPHY||Y|Y|VENDOR|RADIOLOGIST 1|U|3|Visit_3|40|3|TREATMENT|2020-07-24|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-31|P1Y2M10DT2H30M|BEFORE|2020-06-29|ONGOING|2020-08-25
e|RS|49a972da-dfad-438e-b5bc-26ee6b955a59|6|SFTSRESP|Soft Tissue Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|CYLINDER|CHR|1|h/wk|HPLC-UV||||HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|NA|3|Visit_3|40|3|TREATMENT|2020-07-24|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-31|P1Y2M10DT2H30M|BEFORE|2020-08-30|BEFORE|2020-09-14
e|RS|49a972da-dfad-438e-b5bc-26ee6b955a59|7|PATHRESP|Pathologic Response|iRECIST|[?]|IU/g Hb|CA125 50% RESPONSE|1|VIRTUAL PIXEL|FLUOROSCOPY|Y|||SPOUSE|ONCOLOGIST|Y|4|Visit_4|65|1|TREATMENT|2020-08-18|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-13|P1Y2M10DT2H30M|BEFORE|2020-08-21|BEFORE|2020-08-25
e|RS|49a972da-dfad-438e-b5bc-26ee6b955a59|8|MRDRESP|Minimal Residual Disease Response|AJCC V8|||HI-N|1|mV*min|PERFUSION MRI|Y||Y|NON-HEALTH CARE PROFESSIONAL|DERMATOLOGIST|U|4|Visit_4|65|5|TREATMENT|2020-08-18|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-13|P1Y2M10DT2H30M|BEFORE|2020-09-03|BEFORE|2020-09-04
e|RS|49a972da-dfad-438e-b5bc-26ee6b955a59|9|NEWLIND|New Lesion Indicator|IWG CHESON MDS 2000|[?]|/MBP|sCR|1|10^9 organisms/mL|ELECTRONEUROGRAPHY||||CHILD|NEUROLOGIST|NA|5|Visit_5|90|6|TREATMENT|2020-09-12|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-19|P1Y2M10DT2H30M|AFTER|2020-07-29|BEFORE|2020-09-19
e|RS|49a972da-dfad-438e-b5bc-26ee6b955a59|10|LIVRRESP|Liver Response|NCIWG CHESON CLL 1996|||MAJOR PATHOLOGIC RESPONSE|1|/VF|ELECTRICAL IMPEDANCE MYOGRAPHY|||Y|CLINICAL RESEARCH COORDINATOR|INTERNIST|Y|5|Visit_5|90|4|SCREENING|2020-09-12|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-19|P1Y2M10DT2H30M|UNKNOWN|2020-08-12|ONGOING|2020-08-28
e|RS|502a42a7-2ed6-46b9-9b10-728f849334b6|1|LIVRRESP|Liver Response|KUKER LYMPHOMA 2005|[?]|mOsm/kg|TREATMENT FAILURE|1|g/mol|MALDI|Y|Y||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|Y|1|Visit_1|10|5|FOLLOW-UP|2020-11-21|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-29|P1Y2M10DT2H30M|UNKNOWN|2021-01-12|BEFORE|2021-01-26
e|RS|502a42a7-2ed6-46b9-9b10-728f849334b6|2|BESTRESP|Best Overall Response|CHESON CLL 2012|[?]|POINT|CMR|1|10^4 CFU|TRICHROME STAIN||Y||NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|Y|1|Visit_1|10|4|TREATMENT|2020-11-21|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-29|P1Y2M10DT2H30M|BEFORE|2020-12-31|ONGOING|2021-02-05
e|RS|502a42a7-2ed6-46b9-9b10-728f849334b6|3|CPRFSTAT|Clinical Performance Status|LEE LUNG CANCER 2011|||PD FROM PR|1|IU/mg|GRAM STAIN||Y|Y|SIBLING|RADIOLOGIST 1|U|2|Visit_2|25|2|SCREENING|2020-12-06|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-15|P1Y2M10DT2H30M|COINCIDENT|2021-01-11|ONGOING|2021-02-17
e|RS|502a42a7-2ed6-46b9-9b10-728f849334b6|4|SPLNRESP|Spleen Response|EBMT BLADE MYELOMA 1998|[?]|mm3/mm2/year|MOLECULAR MAJOR RESPONSE|1|uL/kg/day|FLOCCULATION, CHARCOAL ENHANCED||Y||INDEPENDENT ASSESSOR|CARDIOLOGIST|Y|2|Visit_2|25|5|TREATMENT|2020-12-06|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-15|P1Y2M10DT2H30M|COINCIDENT|2021-01-17|ONGOING|2021-01-21
e|RS|502a42a7-2ed6-46b9-9b10-728f849334b6|5|RDIORESP|Radiologic Response|IRANO 2015|[?]|pm|NON-CR/NON-PD|1|CCID 50/dose|ALCIAN BLUE STAIN||Y||FRIEND|READER 1|U|3|Visit_3|40|1|WASHOUT|2020-12-21|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-13|P1Y2M10DT2H30M|AFTER|2021-01-29|BEFORE|2021-02-10
e|RS|502a42a7-2ed6-46b9-9b10-728f849334b6|6|MNPTHIND|Minor Pathological Response Indicator|MONTSERRAT CLL 1989|[?]|CONTAINER|VGPR|1|U/dL|SPIRAL CT SCAN WITHOUT CONTRAST||||INDEPENDENT ASSESSOR|RATER|NA|3|Visit_3|40|5|TREATMENT|2020-12-21|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-13|P1Y2M10DT2H30M|AFTER|2021-02-07|COINCIDENT|2021-02-11
e|RS|502a42a7-2ed6-46b9-9b10-728f849334b6|7|NTNERESP|Non-Target Non-Enhancing Response|BLAZER COLORECTAL CANCER 2008|||iPR|1|%/s|TARGETED GENOME SEQUENCING|Y||Y|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR|Y|4|Visit_4|65|1|TREATMENT|2021-01-15|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-19|P1Y2M10DT2H30M|UNKNOWN|2020-12-15|BEFORE|2021-01-01
e|RS|502a42a7-2ed6-46b9-9b10-728f849334b6|8|NEWLWIND|New Lesion Worsening Indicator|DURIE MULTIPLE MYELOMA 2006|[?]|ppth|MAJOR PATHOLOGIC RESPONSE|1|L/s/kPa|ELECTROCHEMILUMINESCENCE IMMUNOASSAY||||CAREGIVER|ADJUDICATOR|NA|4|Visit_4|65|2|TREATMENT|2021-01-15|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-19|P1Y2M10DT2H30M|UNKNOWN|2020-12-19|ONGOING|2021-01-27
e|RS|502a42a7-2ed6-46b9-9b10-728f849334b6|9|CLINRESP|Clinical Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|ug/mL/h|PR-CT|1|ka_u/dL|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY||||CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 1|U|5|Visit_5|90|1|SCREENING|2021-02-09|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-06|P1Y2M10DT2H30M|AFTER|2020-11-26|COINCIDENT|2020-12-28
e|RS|502a42a7-2ed6-46b9-9b10-728f849334b6|10|MNPTHIND|Minor Pathological Response Indicator|DURIE MULTIPLE MYELOMA 2006|[?]|min/day|pCR|1|Ejaculate U|FLUORIMETRY|Y|||INVESTIGATOR|CLINICAL PATHOLOGIST|NA|5|Visit_5|90|3|TREATMENT|2021-02-09|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-06|P1Y2M10DT2H30M|UNKNOWN|2020-12-31|AFTER|2021-01-03
e|RS|61cce2a8-16d6-4cb3-91fc-71f1f2f02551|1|METSIND|Metastatic Indicator|PETIT BREAST CANCER 2001|[?]|kPa/L/sec|MR|1|Henry|MICRO BROTH DILUTION||||ADJUDICATION COMMITTEE|HEMATOLOGIST|N|1|Visit_1|10|7|SCREENING|2020-10-26|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-17|P1Y2M10DT2H30M|UNKNOWN|2021-01-23|BEFORE|2021-01-24
e|RS|61cce2a8-16d6-4cb3-91fc-71f1f2f02551|2|NTERESP|Non-Target Enhancing Response|LEE LUNG CANCER 2011|[?]|/sec|PD|1|%|GC/MS/MS||||INTERVIEWER|RADIOLOGIST 1|N|1|Visit_1|10|7|WASHOUT|2020-10-26|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-17|P1Y2M10DT2H30M|UNKNOWN|2020-11-18|ONGOING|2020-11-25
e|RS|61cce2a8-16d6-4cb3-91fc-71f1f2f02551|3|LIVRRESP|Liver Response|MACDONALD GLIOMA 1990|[?]|FIU|CYTOGENETIC CR|1|U/dL|IMMUNE REPERTOIRE DEEP SEQUENCING||||INTERVIEWER|ADJUDICATOR 2|Y|2|Visit_2|25|1|TREATMENT|2020-11-10|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-04|P1Y2M10DT2H30M|COINCIDENT|2020-12-21|AFTER|2021-01-15
e|RS|61cce2a8-16d6-4cb3-91fc-71f1f2f02551|4|CPRFSTAT|Clinical Performance Status|KUKER LYMPHOMA 2005|||INDETERMINATE RESPONSE|1|nmol/g|ROMANOWSKY STAIN|||Y|CAREGIVER|OTOLARYNGOLOGIST|NA|2|Visit_2|25|3|TREATMENT|2020-11-10|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-04|P1Y2M10DT2H30M|COINCIDENT|2020-10-22|ONGOING|2020-11-02
e|RS|61cce2a8-16d6-4cb3-91fc-71f1f2f02551|5|BMIVLIND|Bone Marrow Involvement Indicator|IWC HALLEK CLL 2008|||COMPLETE MRD RESPONSE|1|10^6 organisms/mg|KINETIC MICROPARTICLE IMMUNOASSAY||Y|Y|ADJUDICATION COMMITTEE|READER|N|3|Visit_3|40|3|FOLLOW-UP|2020-11-25|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-02|P1Y2M10DT2H30M|COINCIDENT|2021-01-06|AFTER|2021-01-14
e|RS|61cce2a8-16d6-4cb3-91fc-71f1f2f02551|6|METSIND|Metastatic Indicator|CHESON CLL 2006|[?]|um/day|MRD NEGATIVITY|1|g/g|MOUSE PROTECTION ASSAY||Y||INDEPENDENT ASSESSOR|RADIOLOGIST 2|Y|3|Visit_3|40|1|WASHOUT|2020-11-25|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-02|P1Y2M10DT2H30M|AFTER|2020-12-02|COINCIDENT|2020-12-05
e|RS|61cce2a8-16d6-4cb3-91fc-71f1f2f02551|7|MRDRESP|Minimal Residual Disease Response|RECICL|[?]|10^3 CFU|SD-CT|1|g|DIRECT SEQUENCING||||GUARDIAN|RADIOLOGIST|N|4|Visit_4|65|7|TREATMENT|2020-12-20|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-15|P1Y2M10DT2H30M|BEFORE|2020-12-07|BEFORE|2020-12-08
e|RS|61cce2a8-16d6-4cb3-91fc-71f1f2f02551|8|NTNERESP|Non-Target Non-Enhancing Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|10^6 IU/mL|SD-CT|1|Pa|COLORIMETRY|Y|||VENDOR|OPHTHALMOLOGIST|Y|4|Visit_4|65|2|TREATMENT|2020-12-20|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-15|P1Y2M10DT2H30M|AFTER|2021-01-12|AFTER|2021-01-22
e|RS|61cce2a8-16d6-4cb3-91fc-71f1f2f02551|9|METBRESP|Metabolic Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|||RELAPSED DISEASE FROM CR|1|Hounsfield Unit|TRANSESOPHAGEAL ECHOCARDIOGRAPHY|Y|Y|Y|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|U|5|Visit_5|90|7|WASHOUT|2021-01-14|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-21|P1Y2M10DT2H30M|BEFORE|2021-01-08|COINCIDENT|2021-01-18
e|RS|61cce2a8-16d6-4cb3-91fc-71f1f2f02551|10|CYTORESP|Cytogenetic Response|IWG CHESON AML 2003|[?]|PIXEL|PR WITH LYMPHOCYTOSIS|1|mAnson U/mL|MAGNETIC RESONANCE ANGIOGRAPHY||||CHILD|OTOLARYNGOLOGIST|Y|5|Visit_5|90|5|FOLLOW-UP|2021-01-14|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-21|P1Y2M10DT2H30M|COINCIDENT|2021-01-23|AFTER|2021-01-24
e|RS|40c048ea-d637-426b-8afe-2da3a6961528|1|RDIORESP|Radiologic Response|PCWG SCHER PROSTATE CANCER 2008|[?]|sec|CRi|1|OI50|MICROBIAL CULTURE||Y||FAMILY MEMBER|DEVELOPMENTAL PSYCHOLOGIST|Y|1|Visit_1|10|6|TREATMENT|2020-07-13|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-23|P1Y2M10DT2H30M|BEFORE|2020-08-13|AFTER|2020-08-20
e|RS|40c048ea-d637-426b-8afe-2da3a6961528|2|LIVRRESP|Liver Response|PERCIST|[?]|copies/ug|NON-iCR/NON-iUPD|1|g/g|HIGH RESOLUTION MELT ANALYSIS||||STUDY SUBJECT|NEUROLOGIST 1|NA|1|Visit_1|10|4|TREATMENT|2020-07-13|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-23|P1Y2M10DT2H30M|COINCIDENT|2020-09-06|AFTER|2020-10-07
e|RS|40c048ea-d637-426b-8afe-2da3a6961528|3|NTRGRESP|Non-target Response|HARTMAN PANCREATIC CANCER 2012|||NR|1|mg/mL/day|WRIGHT STAIN|||Y|SIGNIFICANT OTHER|READER|Y|2|Visit_2|25|2|TREATMENT|2020-07-28|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-03|P1Y2M10DT2H30M|UNKNOWN|2020-07-17|BEFORE|2020-09-15
e|RS|40c048ea-d637-426b-8afe-2da3a6961528|4|ANATRESP|Anatomic Response|GUPPY OVARIAN CANCER 2002|[?]|%/min|RELAPSED DISEASE|1|ukat/10^12 RBC|ENZYMATIC COLORIMETRY||Y||CHILD|DERMATOLOGIST|NA|2|Visit_2|25|6|WASHOUT|2020-07-28|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-03|P1Y2M10DT2H30M|UNKNOWN|2020-07-20|ONGOING|2020-08-04
e|RS|40c048ea-d637-426b-8afe-2da3a6961528|5|STRUSTAT|Steroid Use Status|SHINDOH COLORECTAL CANCER 2013|[?]|AgU/mL|SD-CT|1|10^7 PFU|POPULATION SEQUENCING||Y||VENDOR|ADJUDICATOR 3|NA|3|Visit_3|40|6|TREATMENT|2020-08-12|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-24|P1Y2M10DT2H30M|BEFORE|2020-07-07|COINCIDENT|2020-09-22
e|RS|40c048ea-d637-426b-8afe-2da3a6961528|6|CYTORESP|Cytogenetic Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|/7.5 mL|PR|1|Log10 ELISA unit|MRI||||FAMILY MEMBER|PATHOLOGIST 1|NA|3|Visit_3|40|1|FOLLOW-UP|2020-08-12|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-24|P1Y2M10DT2H30M|COINCIDENT|2020-07-15|COINCIDENT|2020-07-17
e|RS|40c048ea-d637-426b-8afe-2da3a6961528|7|DRCRIND|Disease Recurrence Indicator|FAROOQUI SUPP CLL 2014|[?]|keV|CR|1|uL/dose|MICROBIAL CULTURE|Y|Y||VENDOR|RADIOLOGIST 2|NA|4|Visit_4|65|4|WASHOUT|2020-09-06|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-04|P1Y2M10DT2H30M|UNKNOWN|2020-09-20|ONGOING|2020-10-08
e|RS|40c048ea-d637-426b-8afe-2da3a6961528|8|DRCRIND|Disease Recurrence Indicator|GCIG RUSTIN OVARIAN CANCER 2011|[?]|mL|DECREASED|1|mg/mL/day|CORONARY ANGIOGRAPHY||||PROXY|MICROSCOPIST 3|NA|4|Visit_4|65|7|TREATMENT|2020-09-06|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-04|P1Y2M10DT2H30M|UNKNOWN|2020-09-05|COINCIDENT|2020-09-16
e|RS|40c048ea-d637-426b-8afe-2da3a6961528|9|MJPTHIND|Major Pathological Response Indicator|KEAM BREAST CANCER 2013|[?]|mol/mol|IMMUNOPHENOTYPIC CR|1|ug/kg/day|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY||Y||SPOUSE|INTERNIST|U|5|Visit_5|90|2|TREATMENT|2020-10-01|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-07|P1Y2M10DT2H30M|UNKNOWN|2020-08-25|AFTER|2020-09-11
e|RS|40c048ea-d637-426b-8afe-2da3a6961528|10|MRDIND|Minimal Residual Disease Indicator|LEE LUNG CANCER 2011|[?]|Bq/kg|MRD PERSISTENCE|1|SACHET|ULTRASOUND||Y||NON-HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|N|5|Visit_5|90|7|WASHOUT|2020-10-01|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-07|P1Y2M10DT2H30M|COINCIDENT|2020-08-12|AFTER|2020-09-17
e|RS|4d03b209-bd53-47f5-8251-f9fb2074bc38|1|LIVRRESP|Liver Response|HARTMAN PANCREATIC CANCER 2012|[?]|deg|FAVORABLE RESPONSE|1|mCi/L|MRS||||INDEPENDENT ASSESSOR|PEDIATRIC NEUROLOGIST|Y|1|Visit_1|10|7|FOLLOW-UP|2021-01-02|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-13|P1Y2M10DT2H30M|BEFORE|2021-03-12|ONGOING|2021-03-17
e|RS|4d03b209-bd53-47f5-8251-f9fb2074bc38|2|ANATRESP|Anatomic Response|SCHER PROSTATE CANCER 2011|||pCR|1|DAYS|PULSE OXIMETRY||Y|Y|HEALTH CARE PROFESSIONAL|READER 3|Y|1|Visit_1|10|3|TREATMENT|2021-01-02|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-13|P1Y2M10DT2H30M|UNKNOWN|2021-02-17|ONGOING|2021-03-20
e|RS|4d03b209-bd53-47f5-8251-f9fb2074bc38|3|METSIND|Metastatic Indicator|IWG CHESON AML 2003|[?]|fraction of 1|PD/RELAPSE AFTER HI|1|amu|SLIT LAMP PHOTOGRAPHY||||FRIEND|OTOLARYNGOLOGIST|NA|2|Visit_2|25|1|TREATMENT|2021-01-17|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-18|P1Y2M10DT2H30M|COINCIDENT|2021-02-20|AFTER|2021-03-19
e|RS|4d03b209-bd53-47f5-8251-f9fb2074bc38|4|MRPHRESP|Morphologic Response|KUMAR IMWG 2016|[?]|BLOCKS|iSD|1|yd|GEL ELECTROPHORESIS|Y|Y||ADJUDICATOR|DEVELOPMENTAL PSYCHOLOGIST|U|2|Visit_2|25|2|FOLLOW-UP|2021-01-17|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-18|P1Y2M10DT2H30M|AFTER|2021-02-17|BEFORE|2021-03-27
e|RS|4d03b209-bd53-47f5-8251-f9fb2074bc38|5|NTRGRESP|Non-target Response|BLAZER COLORECTAL CANCER 2008|[?]|Gravitational Unit|PD FROM PR|1|mg/m2/h|INFRARED SPECTROMETRY||||INVESTIGATOR|ENDOCRINOLOGIST|NA|3|Visit_3|40|3|FOLLOW-UP|2021-02-01|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-03|P1Y2M10DT2H30M|BEFORE|2021-03-31|BEFORE|2021-04-01
e|RS|4d03b209-bd53-47f5-8251-f9fb2074bc38|6|SFTSRESP|Soft Tissue Response|WHO BREAST CANCER 2006|[?]|10^3 CFU/g|HI-E|1|uL/dose|SNP ARRAY||||SPOUSE|RATER 2|Y|3|Visit_3|40|1|TREATMENT|2021-02-01|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-03|P1Y2M10DT2H30M|UNKNOWN|2021-02-24|AFTER|2021-03-13
e|RS|4d03b209-bd53-47f5-8251-f9fb2074bc38|7|BESTRESP|Best Overall Response|PETIT BREAST CANCER 2001|[?]|10^4 CFU/mL|CR|1|MnFI|POTENTIOMETRY||Y||FAMILY MEMBER|RATER 1|U|4|Visit_4|65|7|TREATMENT|2021-02-26|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-25|P1Y2M10DT2H30M|COINCIDENT|2021-02-07|COINCIDENT|2021-03-30
e|RS|4d03b209-bd53-47f5-8251-f9fb2074bc38|8|TMRESP|Tumor Marker Response|WHO BREAST CANCER 2006|[?]|g/kg|DECREASED|1|mL/cm H2O|NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY|Y|||SIBLING|PATHOLOGIST 1|U|4|Visit_4|65|6|FOLLOW-UP|2021-02-26|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-25|P1Y2M10DT2H30M|COINCIDENT|2021-01-04|COINCIDENT|2021-01-12
e|RS|4d03b209-bd53-47f5-8251-f9fb2074bc38|9|METSIND|Metastatic Indicator|SCHWARZ CERVICAL CANCER 2009|[?]|MPL U|DISEASE TRANSFORMATION|1|min/day|PH METER MEASUREMENT METHOD||||SPOUSE|FORENSIC PATHOLOGIST|N|5|Visit_5|90|2|FOLLOW-UP|2021-03-23|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-01|P1Y2M10DT2H30M|UNKNOWN|2021-02-09|AFTER|2021-03-22
e|RS|4d03b209-bd53-47f5-8251-f9fb2074bc38|10|METSIND|Metastatic Indicator|SHINDOH COLORECTAL CANCER 2013|[?]|mV/sec|iSD|1|U/g/h|TOTAL BODY RADIOGRAPHY||||GUARDIAN|READER 2|U|5|Visit_5|90|3|TREATMENT|2021-03-23|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-01|P1Y2M10DT2H30M|COINCIDENT|2021-03-05|ONGOING|2021-03-18
e|RS|35f01eda-1acb-4700-8285-c8cd4b69b524|1|LIVRRESP|Liver Response|EBMT BLADE MYELOMA 1998|[?]|log10 PFU|UNFAVORABLE RESPONSE|1|mph|FREEZING POINT DEPRESSION||||INTERVIEWER|READER 1|Y|1|Visit_1|10|3|WASHOUT|2020-09-30|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-16|P1Y2M10DT2H30M|BEFORE|2020-10-10|ONGOING|2020-11-27
e|RS|35f01eda-1acb-4700-8285-c8cd4b69b524|2|RDIORESP|Radiologic Response|GUILHOT CML 2007|[?]|oz eq|EQUIVOCAL|1|g/m2|OBSERVATION||||CLINICAL RESEARCH COORDINATOR|RATER 2|Y|1|Visit_1|10|7|SCREENING|2020-09-30|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-16|P1Y2M10DT2H30M|COINCIDENT|2020-12-13|ONGOING|2020-12-27
e|RS|35f01eda-1acb-4700-8285-c8cd4b69b524|3|MRDRESP|Minimal Residual Disease Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|TABLET|EQUIVOCAL|1|mOsm|ELECTROCHEMILUMINESCENCE IMMUNOASSAY||||NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|NA|2|Visit_2|25|5|TREATMENT|2020-10-15|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-11|P1Y2M10DT2H30M|AFTER|2020-11-26|AFTER|2020-12-09
e|RS|35f01eda-1acb-4700-8285-c8cd4b69b524|4|ANATRESP|Anatomic Response|AJCC V8|[?]|kUSP|PDu|1|mm2|HPLC-UV||||CLINICAL RESEARCH ASSOCIATE|CARDIOLOGIST|NA|2|Visit_2|25|2|TREATMENT|2020-10-15|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-11|P1Y2M10DT2H30M|COINCIDENT|2020-12-18|AFTER|2020-12-27
e|RS|35f01eda-1acb-4700-8285-c8cd4b69b524|5|MRPHRESP|Morphologic Response|KUKER LYMPHOMA 2005|||CR-CT|1|BAR|KARYOTYPING|||Y|DOMESTIC PARTNER|PATHOLOGIST|U|3|Visit_3|40|6|TREATMENT|2020-10-30|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-24|P1Y2M10DT2H30M|BEFORE|2020-12-24|AFTER|2020-12-27
e|RS|35f01eda-1acb-4700-8285-c8cd4b69b524|6|STRUSTAT|Steroid Use Status|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|PACK|PSA PROGRESSION|1|cmol|ALCIAN BLUE STAIN||||CLINICAL STUDY SPONSOR|RADIOLOGIST|U|3|Visit_3|40|6|SCREENING|2020-10-30|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-24|P1Y2M10DT2H30M|UNKNOWN|2020-10-28|BEFORE|2020-12-01
e|RS|35f01eda-1acb-4700-8285-c8cd4b69b524|7|SFTSRESP|Soft Tissue Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|||NOT ALL EVALUATED|1|GPS U|CONTRAST ENHANCED SPIRAL CT SCAN|||Y|FAMILY MEMBER|PATHOLOGIST 1|N|4|Visit_4|65|2|SCREENING|2020-11-24|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-19|P1Y2M10DT2H30M|BEFORE|2020-12-02|ONGOING|2020-12-03
e|RS|35f01eda-1acb-4700-8285-c8cd4b69b524|8|LIVRRESP|Liver Response|MRECIST BYRNE MESOTHELIOMA 2004|||PARTIAL MORPHOLOGIC RESPONSE|1|nCi|CALCULATION|||Y|INTERVIEWER|ADJUDICATOR 1|Y|4|Visit_4|65|4|TREATMENT|2020-11-24|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-19|P1Y2M10DT2H30M|AFTER|2020-11-08|COINCIDENT|2020-11-10
e|RS|35f01eda-1acb-4700-8285-c8cd4b69b524|9|SYMPTDTR|Symptomatic Deterioration|MRECIST BYRNE MESOTHELIOMA 2004|[?]|ug/L DDU|NR|1|ms/mmHg|ISHIHARA COLOR PLATES||||CAREGIVER|READER 2|Y|5|Visit_5|90|6|WASHOUT|2020-12-19|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-19|P1Y2M10DT2H30M|BEFORE|2020-11-13|ONGOING|2020-12-23
e|RS|35f01eda-1acb-4700-8285-c8cd4b69b524|10|MRPHRESP|Morphologic Response|EBMT BLADE MYELOMA 1998|[?]|DROP|PSEUDORESPONSE|1|mL/beat|WRIGHT STAIN|Y|||CAREGIVER|RATER 2|U|5|Visit_5|90|2|TREATMENT|2020-12-19|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-19|P1Y2M10DT2H30M|COINCIDENT|2020-11-21|AFTER|2020-12-25
e|RS|9df97277-7d07-4020-bae0-dfa982f21c8d|1|BONERESP|Bone Response|IWC HALLEK CLL 2008|||CA125 75% RESPONSE|1|Sv|FISH|||Y|CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|1|Visit_1|10|5|WASHOUT|2020-11-02|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-15|P1Y2M10DT2H30M|BEFORE|2021-01-18|AFTER|2021-01-28
e|RS|9df97277-7d07-4020-bae0-dfa982f21c8d|2|METSIND|Metastatic Indicator|MRANO VAN DEN BENT GLIOMA 2011|[?]|GBq/ug|NON-iCR/NON-iUPD|1|log10 TCID 50/uL|OPHTHALMOSCOPY||||INDEPENDENT ASSESSOR|OPHTHALMOLOGIST|NA|1|Visit_1|10|5|SCREENING|2020-11-02|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-15|P1Y2M10DT2H30M|BEFORE|2020-12-12|BEFORE|2021-01-24
e|RS|9df97277-7d07-4020-bae0-dfa982f21c8d|3|PATHRESP|Pathologic Response|IWC HALLEK CLL 2008|[?]|Tesla|SD|1|Newton|SMEAR||||CHILD|ONCOLOGIST 2|N|2|Visit_2|25|1|FOLLOW-UP|2020-11-17|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-19|P1Y2M10DT2H30M|COINCIDENT|2021-01-20|COINCIDENT|2021-01-24
e|RS|9df97277-7d07-4020-bae0-dfa982f21c8d|4|SFTSRESP|Soft Tissue Response|LEE LUNG CANCER 2011|[?]|log10 PFU/mL|CA125 75% RESPONSE|1|mL/day|PALPATION||Y||ADJUDICATOR|MICROSCOPIST 3|NA|2|Visit_2|25|7|TREATMENT|2020-11-17|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-19|P1Y2M10DT2H30M|AFTER|2021-01-16|AFTER|2021-01-26
e|RS|9df97277-7d07-4020-bae0-dfa982f21c8d|5|CYTORESP|Cytogenetic Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|cmHg|COMPLETE MRD RESPONSE|1|mL/s|MYELOPEROXIDASE STAIN||Y||FRIEND|DERMATOLOGIST|Y|3|Visit_3|40|6|FOLLOW-UP|2020-12-02|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-28|P1Y2M10DT2H30M|COINCIDENT|2021-01-08|AFTER|2021-01-28
e|RS|9df97277-7d07-4020-bae0-dfa982f21c8d|6|NTERESP|Non-Target Enhancing Response|SCHWARZ CERVICAL CANCER 2009|[?]|ng/day|PSEUDORESPONSE|1|mEq/dL|NEXT GENERATION TARGETED SEQUENCING||||ADJUDICATION COMMITTEE|DEVELOPMENTAL PSYCHOLOGIST|NA|3|Visit_3|40|6|FOLLOW-UP|2020-12-02|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-28|P1Y2M10DT2H30M|COINCIDENT|2020-11-06|ONGOING|2021-01-16
e|RS|9df97277-7d07-4020-bae0-dfa982f21c8d|7|OVRLRESP|Overall Response|IWG CHESON MDS 2006|||RELAPSED DISEASE FROM CR OR PR|1|deg/mm|ORCHIDOMETERY|||Y|SIGNIFICANT OTHER|CLINICAL PATHOLOGIST|Y|4|Visit_4|65|1|TREATMENT|2020-12-27|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-11|P1Y2M10DT2H30M|UNKNOWN|2020-12-17|COINCIDENT|2021-01-27
e|RS|9df97277-7d07-4020-bae0-dfa982f21c8d|8|OVRLRESP|Overall Response|DURIE MULTIPLE MYELOMA 2006|[?]|mL/beat|QUANTIFIABLE MRD POSITIVITY|1|mm/h|MICROSCOPY||||INTERVIEWER|MICROSCOPIST 1|NA|4|Visit_4|65|3|TREATMENT|2020-12-27|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-11|P1Y2M10DT2H30M|BEFORE|2021-01-22|ONGOING|2021-01-29
e|RS|9df97277-7d07-4020-bae0-dfa982f21c8d|9|PATHRESP|Pathologic Response|RAJKUMAR MYELOMA 2011|[?]|Farad|MRD NEGATIVITY|1|cmH2O*s2/mL|MICROBIAL CULTURE, LIQUID||||INVESTIGATOR|PEDIATRIC NEUROLOGIST|Y|5|Visit_5|90|2|TREATMENT|2021-01-21|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-07|P1Y2M10DT2H30M|COINCIDENT|2020-11-18|COINCIDENT|2021-01-27
e|RS|9df97277-7d07-4020-bae0-dfa982f21c8d|10|SFTSRESP|Soft Tissue Response|DURIE MULTIPLE MYELOMA 2006|[?]|Bq/g|PSA PROGRESSION|1|L/kg|OPTICAL DENSITY MEASUREMENT||Y||INVESTIGATOR|MICROSCOPIST 2|Y|5|Visit_5|90|6|SCREENING|2021-01-21|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-07|P1Y2M10DT2H30M|UNKNOWN|2021-01-20|AFTER|2021-01-21
e|RS|d1b522d5-557a-4361-a9da-292aa601fbc3|1|OVRLRESP|Overall Response|AJCC V7|[?]|cm2|MOLECULAR MAJOR RESPONSE|1|mol/mol|CALIPER MEASUREMENT METHOD|Y|||INVESTIGATOR|CLINICAL PATHOLOGIST|N|1|Visit_1|10|6|TREATMENT|2020-10-09|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-11|P1Y2M10DT2H30M|AFTER|2020-11-13|COINCIDENT|2020-12-20
e|RS|d1b522d5-557a-4361-a9da-292aa601fbc3|2|NTERESP|Non-Target Enhancing Response|LUGANO CLASSIFICATION|[?]|10^6 IU/mL|INDETERMINATE RESPONSE|1|GLOBULE|QUANTITATIVE ULTRASOUND|Y|||SIGNIFICANT OTHER|MICROSCOPIST|Y|1|Visit_1|10|6|WASHOUT|2020-10-09|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-11|P1Y2M10DT2H30M|COINCIDENT|2020-11-01|BEFORE|2020-12-19
e|RS|d1b522d5-557a-4361-a9da-292aa601fbc3|3|CPRFSTAT|Clinical Performance Status|RANO ELLINGSON 2017|[?]|MBP|MAJOR PATHOLOGIC RESPONSE|1|mL/kg|QUANTITATIVE ULTRASOUND|Y|||FAMILY MEMBER|MICROSCOPIST|N|2|Visit_2|25|1|FOLLOW-UP|2020-10-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-17|P1Y2M10DT2H30M|COINCIDENT|2021-01-02|ONGOING|2021-01-04
e|RS|d1b522d5-557a-4361-a9da-292aa601fbc3|4|NTLWIND|Non-Target Lesion Worsening Indicator|GUILHOT CML 2007|[?]|g/day|STABLE|1|tuberculin unit/mL|LIGHT MICROSCOPY|Y|||SPOUSE|PATHOLOGIST|N|2|Visit_2|25|1|SCREENING|2020-10-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-17|P1Y2M10DT2H30M|AFTER|2020-10-04|ONGOING|2020-12-04
e|RS|d1b522d5-557a-4361-a9da-292aa601fbc3|5|OVRLRESP|Overall Response|PRINCE TCELL LYMPHOMA 2010|[?]|PFU/mL|mCR|1|Bq/mg|REFLECTANCE SPECTROSCOPY|Y|||CLINICAL STUDY SPONSOR|DERMATOLOGIST|N|3|Visit_3|40|6|TREATMENT|2020-11-08|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-15|P1Y2M10DT2H30M|COINCIDENT|2020-10-24|BEFORE|2020-12-12
e|RS|d1b522d5-557a-4361-a9da-292aa601fbc3|6|NEWLIND|New Lesion Indicator|IWG CHESON MDS 2006|||MRD PERSISTENCE|1|ug/m2/h|OPTICAL COHERENCE TOMOGRAPHY|||Y|SIGNIFICANT OTHER|CARDIOLOGIST|U|3|Visit_3|40|4|FOLLOW-UP|2020-11-08|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-15|P1Y2M10DT2H30M|BEFORE|2021-01-03|ONGOING|2021-01-06
e|RS|d1b522d5-557a-4361-a9da-292aa601fbc3|7|SPLNRESP|Spleen Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|||iPR|1|Log10 ELISA unit/dose|PET/CT SCAN WITHOUT CONTRAST||Y|Y|CAREGIVER|RADIOLOGIST 1|Y|4|Visit_4|65|3|TREATMENT|2020-12-03|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-02|P1Y2M10DT2H30M|BEFORE|2020-11-12|AFTER|2021-01-05
e|RS|d1b522d5-557a-4361-a9da-292aa601fbc3|8|MJPTHIND|Major Pathological Response Indicator|MASS|[?]|mol/mg|PD/RELAPSE AFTER HI|1|days/month|HANSEL STAIN||Y||GUARDIAN|MICROSCOPIST 1|N|4|Visit_4|65|2|SCREENING|2020-12-03|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-02|P1Y2M10DT2H30M|AFTER|2020-11-08|COINCIDENT|2020-12-05
e|RS|d1b522d5-557a-4361-a9da-292aa601fbc3|9|NEWLPROG|New Lesion Progression|IRANO 2015|[?]|Enzyme U/L|PMD|1|DAYS|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION|Y|Y||ADJUDICATION COMMITTEE|FORENSIC PATHOLOGIST|Y|5|Visit_5|90|6|TREATMENT|2020-12-28|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-17|P1Y2M10DT2H30M|BEFORE|2020-11-10|BEFORE|2020-12-16
e|RS|d1b522d5-557a-4361-a9da-292aa601fbc3|10|SPLNRESP|Spleen Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|mL/min|SD-CT|1|BAU|GRADIENT DIFFUSION||||PARENT|READER 3|U|5|Visit_5|90|6|WASHOUT|2020-12-28|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-17|P1Y2M10DT2H30M|UNKNOWN|2021-01-01|COINCIDENT|2021-01-05
e|RS|c6343fe8-6005-4fe8-b3e6-cfcb56c2d360|1|CPRFSTAT|Clinical Performance Status|JACINTO CERVICAL CANCER 2007|[?]|mg/min|PMD|1|fmol/L/sec|INTRAVASCULAR ULTRASOUND||||VENDOR|READER 2|U|1|Visit_1|10|3|TREATMENT|2020-07-27|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-21|P1Y2M10DT2H30M|BEFORE|2020-08-20|BEFORE|2020-10-06
e|RS|c6343fe8-6005-4fe8-b3e6-cfcb56c2d360|2|TMRESP|Tumor Marker Response|EASL BRUIX LIVER CANCER 2001|||MORPHOLOGIC LEUKEMIA-FREE STATE|1|TRANSDUCING UNIT/mL|EIA||Y|Y|VENDOR|RATER|NA|1|Visit_1|10|3|TREATMENT|2020-07-27|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-21|P1Y2M10DT2H30M|BEFORE|2020-10-10|BEFORE|2020-10-14
e|RS|c6343fe8-6005-4fe8-b3e6-cfcb56c2d360|3|MRDRESP|Minimal Residual Disease Response|IWC HALLEK CLL 2008|||PD-CT|1|mL/g/min|CISH|Y||Y|CLINICAL STUDY SPONSOR|MICROSCOPIST|N|2|Visit_2|25|6|TREATMENT|2020-08-11|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-08|P1Y2M10DT2H30M|BEFORE|2020-09-14|AFTER|2020-09-16
e|RS|c6343fe8-6005-4fe8-b3e6-cfcb56c2d360|4|PATHRESP|Pathologic Response|iRECIST|[?]|%(w/w)|iCPD|1|nmol BCE/L|IMMUNOBLOT||||GUARDIAN|NEUROLOGIST|U|2|Visit_2|25|4|SCREENING|2020-08-11|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-08|P1Y2M10DT2H30M|COINCIDENT|2020-08-20|ONGOING|2020-09-23
e|RS|c6343fe8-6005-4fe8-b3e6-cfcb56c2d360|5|NEWLWIND|New Lesion Worsening Indicator|WOLCHOK SOLID TUMORS 2009|[?]|U/animal|MOLECULAR MAJOR RESPONSE|1|uIU/dL|POLYMERASE CHAIN REACTION||Y||INDEPENDENT ASSESSOR|FORENSIC PATHOLOGIST|U|3|Visit_3|40|7|WASHOUT|2020-08-26|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-10|P1Y2M10DT2H30M|BEFORE|2020-08-24|COINCIDENT|2020-09-24
e|RS|c6343fe8-6005-4fe8-b3e6-cfcb56c2d360|6|MRPHRESP|Morphologic Response|KUKER LYMPHOMA 2005|||IMMUNOPHENOTYPIC CR|1|in2|IVY INCISION METHOD|||Y|VENDOR|ONCOLOGIST 1|N|3|Visit_3|40|4|WASHOUT|2020-08-26|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-10|P1Y2M10DT2H30M|AFTER|2020-10-09|ONGOING|2020-10-14
e|RS|c6343fe8-6005-4fe8-b3e6-cfcb56c2d360|7|SPLNRESP|Spleen Response|NCIWG CHESON CLL 1996|[?]|mEq/g|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|/sec|GEL ELECTROPHORESIS|Y|Y||INVESTIGATOR|RADIOLOGIST 1|N|4|Visit_4|65|6|TREATMENT|2020-09-20|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-21|P1Y2M10DT2H30M|UNKNOWN|2020-08-12|ONGOING|2020-09-11
e|RS|c6343fe8-6005-4fe8-b3e6-cfcb56c2d360|8|SPLNRESP|Spleen Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|10^3/L|MORPHOLOGIC CRi|1|TRANSDUCING UNIT/mL|DOUBLE IMMUNODIFFUSION||Y||SIGNIFICANT OTHER|MICROSCOPIST|N|4|Visit_4|65|6|WASHOUT|2020-09-20|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-21|P1Y2M10DT2H30M|UNKNOWN|2020-10-16|COINCIDENT|2020-10-17
e|RS|c6343fe8-6005-4fe8-b3e6-cfcb56c2d360|9|TMRESP|Tumor Marker Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|scm|INCREASED|1|nCi|CARDIAC THERMODILUTION||||STUDY SUBJECT|PHYSIOTHERAPIST|NA|5|Visit_5|90|5|TREATMENT|2020-10-15|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-01|P1Y2M10DT2H30M|UNKNOWN|2020-10-09|COINCIDENT|2020-10-15
e|RS|c6343fe8-6005-4fe8-b3e6-cfcb56c2d360|10|SPLNRESP|Spleen Response|RANO|||CRi|1|ag|IMMUNORADIOMETRIC ASSAY|Y||Y|INTERVIEWER|INTERNIST|U|5|Visit_5|90|2|SCREENING|2020-10-15|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-01|P1Y2M10DT2H30M|BEFORE|2020-10-22|BEFORE|2020-10-23
e|RS|da2d0844-3608-4927-9103-cb7c52dd2c96|1|MRDIND|Minimal Residual Disease Indicator|DOHNER AML 2010|[?]|kIU|SMD|1|V/sec|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY||Y||INDEPENDENT ASSESSOR|INTERNIST|Y|1|Visit_1|10|5|WASHOUT|2021-01-26|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-28|P1Y2M10DT2H30M|AFTER|2021-01-25|COINCIDENT|2021-02-15
e|RS|da2d0844-3608-4927-9103-cb7c52dd2c96|2|RDIORESP|Radiologic Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|10^9/L|MORPHOLOGIC CR|1|cd|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY|Y|Y||INVESTIGATOR|MICROSCOPIST|Y|1|Visit_1|10|6|TREATMENT|2021-01-26|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-28|P1Y2M10DT2H30M|AFTER|2021-04-07|BEFORE|2021-04-21
e|RS|da2d0844-3608-4927-9103-cb7c52dd2c96|3|STRUSTAT|Steroid Use Status|CHESON CLL 2006|[?]|mL/cage/wk|HI-E|1|DROP|HILLMEN COLOR CHART||Y||SIGNIFICANT OTHER|ADJUDICATOR 2|NA|2|Visit_2|25|4|TREATMENT|2021-02-10|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-24|P1Y2M10DT2H30M|COINCIDENT|2021-03-07|BEFORE|2021-04-23
e|RS|da2d0844-3608-4927-9103-cb7c52dd2c96|4|NTLWIND|Non-Target Lesion Worsening Indicator|AJCC V7|[?]|mg/m2/min|iUPD|1|mL/animal|GC/MS-EI||Y||CHILD|OPTOMETRIST|N|2|Visit_2|25|6|TREATMENT|2021-02-10|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-24|P1Y2M10DT2H30M|UNKNOWN|2021-02-19|ONGOING|2021-04-05
e|RS|da2d0844-3608-4927-9103-cb7c52dd2c96|5|MRDIND|Minimal Residual Disease Indicator|EBMT BLADE MYELOMA 1998|[?]|10^7 TCID 50/dose|iCR|1|fraction of 1|PERIODIC ACID SCHIFF STAIN||Y||FAMILY MEMBER|ONCOLOGIST 1|Y|3|Visit_3|40|7|FOLLOW-UP|2021-02-25|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-16|P1Y2M10DT2H30M|BEFORE|2021-04-24|BEFORE|2021-04-25
e|RS|da2d0844-3608-4927-9103-cb7c52dd2c96|6|BONERESP|Bone Response|HAMAOKA BREAST CANCER 2010|[?]|kg/cm2|iCR|1|nkat|SPECULAR MICROSCOPY|Y|||HEALTH CARE PROFESSIONAL|CARDIOLOGIST|NA|3|Visit_3|40|3|TREATMENT|2021-02-25|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-16|P1Y2M10DT2H30M|COINCIDENT|2021-02-19|BEFORE|2021-03-12
e|RS|da2d0844-3608-4927-9103-cb7c52dd2c96|7|TRGRESP|Target Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|Gy|MRD PERSISTENCE|1|10^6/Ejaculate U|HANSEL STAIN|Y|Y||CAREGIVER|ADJUDICATOR 1|NA|4|Visit_4|65|2|FOLLOW-UP|2021-03-22|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-07|P1Y2M10DT2H30M|COINCIDENT|2021-04-03|ONGOING|2021-04-10
e|RS|da2d0844-3608-4927-9103-cb7c52dd2c96|8|NTLWIND|Non-Target Lesion Worsening Indicator|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|RING|CYTOGENETIC NO RESPONSE|1|U/10^12 RBC|SCINTIGRAPHY||||SIBLING|UROLOGIST|U|4|Visit_4|65|2|TREATMENT|2021-03-22|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-07|P1Y2M10DT2H30M|BEFORE|2021-04-05|ONGOING|2021-04-25
e|RS|da2d0844-3608-4927-9103-cb7c52dd2c96|9|SYMPTDTR|Symptomatic Deterioration|GCIG RUSTIN OVARIAN CANCER 2011|[?]|U/g/min|PARTIAL MORPHOLOGIC RESPONSE|1|mL/kg/min|MICROBIAL BIOCHEMICAL IDENTIFICATION|Y|||HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|Y|5|Visit_5|90|4|TREATMENT|2021-04-16|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-03|P1Y2M10DT2H30M|COINCIDENT|2021-03-12|AFTER|2021-04-11
e|RS|da2d0844-3608-4927-9103-cb7c52dd2c96|10|DRCRIND|Disease Recurrence Indicator|SACT|||CRi|1|copies/mL|MICROBIAL CULTURE, SOLID|||Y|NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|N|5|Visit_5|90|1|FOLLOW-UP|2021-04-16|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-03|P1Y2M10DT2H30M|UNKNOWN|2021-04-03|BEFORE|2021-04-13
e|RS|30b6f8a7-4512-462d-a162-45c3dad853e5|1|TRGRESP|Target Response|PCWG SCHER PROSTATE CANCER 2008|[?]|AMPULE|PD FROM PR|1|mm/h|PAP STAIN||Y||FAMILY MEMBER|INTERNIST|Y|1|Visit_1|10|7|WASHOUT|2020-12-02|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-23|P1Y2M10DT2H30M|BEFORE|2021-01-15|COINCIDENT|2021-01-16
e|RS|30b6f8a7-4512-462d-a162-45c3dad853e5|2|PATHRESP|Pathologic Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|CCID 50/dose|SMD|1|Gy/min|POPULATION SEQUENCING||||ADJUDICATOR|FORENSIC PATHOLOGIST|U|1|Visit_1|10|6|SCREENING|2020-12-02|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-23|P1Y2M10DT2H30M|COINCIDENT|2021-01-05|COINCIDENT|2021-01-24
e|RS|30b6f8a7-4512-462d-a162-45c3dad853e5|3|ANATRESP|Anatomic Response|RANO ELLINGSON 2017|||iUPD|1|BAU/mL|PULMONARY ANGIOGRAPHY|||Y|SIBLING|READER 2|Y|2|Visit_2|25|4|FOLLOW-UP|2020-12-17|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-01|P1Y2M10DT2H30M|COINCIDENT|2020-12-06|AFTER|2021-02-28
e|RS|30b6f8a7-4512-462d-a162-45c3dad853e5|4|SFTSRESP|Soft Tissue Response|NCIWG CHESON CLL 1996|[?]|10^7/L|QUANTIFIABLE MRD POSITIVITY|1|YEARS|OPHTHALMOSCOPY||Y||STUDY SUBJECT|NEUROLOGIST 1|U|2|Visit_2|25|7|WASHOUT|2020-12-17|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-01|P1Y2M10DT2H30M|AFTER|2021-02-16|BEFORE|2021-02-18
e|RS|30b6f8a7-4512-462d-a162-45c3dad853e5|5|BONERESP|Bone Response|NCIWG CHESON CLL 1996|[?]|U/L|RELAPSED DISEASE|1|mol/mol|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION||Y||GUARDIAN|PATHOLOGIST 1|N|3|Visit_3|40|7|SCREENING|2021-01-01|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-18|P1Y2M10DT2H30M|AFTER|2021-01-08|COINCIDENT|2021-01-19
e|RS|30b6f8a7-4512-462d-a162-45c3dad853e5|6|SYMPTDTR|Symptomatic Deterioration|iRECIST|[?]|BOLUS|NOT ALL EVALUATED|1|kHz|ENZYMATIC COLORIMETRY||Y||CAREGIVER|RATER 2|NA|3|Visit_3|40|6|TREATMENT|2021-01-01|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-18|P1Y2M10DT2H30M|BEFORE|2021-01-23|BEFORE|2021-01-26
e|RS|30b6f8a7-4512-462d-a162-45c3dad853e5|7|MOLRESP|Molecular Response|MONTSERRAT CLL 1989|[?]|grain|VGPR|1|g/mol|TARGETED GENOME SEQUENCING||||VENDOR|ENDOCRINOLOGIST|N|4|Visit_4|65|6|TREATMENT|2021-01-26|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-25|P1Y2M10DT2H30M|UNKNOWN|2021-02-11|AFTER|2021-02-17
e|RS|30b6f8a7-4512-462d-a162-45c3dad853e5|8|METSIND|Metastatic Indicator|CHESON LYMPHOMA 2008|[?]|g|NON-iCR/NON-iUPD|1|/wk|HPLC||||HEALTH CARE PROFESSIONAL|OPTOMETRIST|NA|4|Visit_4|65|5|TREATMENT|2021-01-26|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-25|P1Y2M10DT2H30M|AFTER|2021-01-31|BEFORE|2021-02-18
e|RS|30b6f8a7-4512-462d-a162-45c3dad853e5|9|DRCRIND|Disease Recurrence Indicator|KUKER LYMPHOMA 2005|[?]|BAU|UNEQUIVOCAL|1|L/day|MICROBIAL CULTURE, SOLID|Y|||SIBLING|MICROSCOPIST 1|U|5|Visit_5|90|1|TREATMENT|2021-02-20|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-24|P1Y2M10DT2H30M|BEFORE|2020-12-29|AFTER|2021-01-25
e|RS|30b6f8a7-4512-462d-a162-45c3dad853e5|10|SFTSRESP|Soft Tissue Response|NCIWG CHESON CLL 1996|[?]|mg/mL/min|NE|1|/HPF|CLOT DETECTION||||ADJUDICATOR|ONCOLOGIST 2|Y|5|Visit_5|90|6|TREATMENT|2021-02-20|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-24|P1Y2M10DT2H30M|COINCIDENT|2021-01-18|BEFORE|2021-02-14
e|RS|1a3808b9-6004-4133-8f59-49905d04655e|1|NTRGRESP|Non-target Response|BLAZER COLORECTAL CANCER 2008|[?]|L/L|pCR|1|vp/mL|TARGETED TRANSCRIPTOME SEQUENCING|Y|Y||CAREGIVER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|1|Visit_1|10|3|SCREENING|2020-11-07|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-24|P1Y2M10DT2H30M|UNKNOWN|2021-01-17|COINCIDENT|2021-01-23
e|RS|1a3808b9-6004-4133-8f59-49905d04655e|2|PATHRESP|Pathologic Response|MONTSERRAT CLL 1989|||PARTIAL MORPHOLOGIC RESPONSE|1|Gy|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION|||Y|CLINICAL RESEARCH COORDINATOR|PEDIATRIC NEUROLOGIST|U|1|Visit_1|10|4|WASHOUT|2020-11-07|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-24|P1Y2M10DT2H30M|BEFORE|2021-01-18|COINCIDENT|2021-01-19
e|RS|1a3808b9-6004-4133-8f59-49905d04655e|3|SFTSRESP|Soft Tissue Response|LEE LUNG CANCER 2011|||EQUIVOCAL|1|ohm|HPLC-UV|||Y|PROXY|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|2|Visit_2|25|4|FOLLOW-UP|2020-11-22|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-17|P1Y2M10DT2H30M|COINCIDENT|2020-11-09|COINCIDENT|2021-01-01
e|RS|1a3808b9-6004-4133-8f59-49905d04655e|4|TMRESP|Tumor Marker Response|AJCC V7|[?]|mm|SD|1|%/min|CELL CYTOTOXICITY NEUTRALIZATION ASSAY|Y|||INDEPENDENT ASSESSOR|INTERNIST|N|2|Visit_2|25|7|TREATMENT|2020-11-22|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-17|P1Y2M10DT2H30M|AFTER|2021-01-14|AFTER|2021-01-26
e|RS|1a3808b9-6004-4133-8f59-49905d04655e|5|CYTORESP|Cytogenetic Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|in2|CYTOGENETIC MINIMAL RESPONSE|1|mL/cm H2O|CONTACT SPECULAR MICROSCOPY|Y|Y||SIBLING|PATHOLOGIST 1|NA|3|Visit_3|40|2|SCREENING|2020-12-07|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-01|P1Y2M10DT2H30M|AFTER|2020-12-29|BEFORE|2021-01-23
e|RS|1a3808b9-6004-4133-8f59-49905d04655e|6|BMIVLIND|Bone Marrow Involvement Indicator|WHO BREAST CANCER 2006|[?]|mEq/uL|CYTOGENETIC MINOR RESPONSE|1|BP|TOLUIDINE BLUE STAIN||||CLINICAL STUDY SPONSOR|PEDIATRIC NEUROLOGIST|NA|3|Visit_3|40|2|TREATMENT|2020-12-07|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-01|P1Y2M10DT2H30M|BEFORE|2020-11-27|ONGOING|2020-11-30
e|RS|1a3808b9-6004-4133-8f59-49905d04655e|7|BMIVLIND|Bone Marrow Involvement Indicator|SCHER PROSTATE CANCER 2011|[?]|ug|ABSENT MORPHOLOGIC RESPONSE|1|cd|SCINTIGRAPHY||Y||ADJUDICATOR|RADIOLOGIST|N|4|Visit_4|65|5|FOLLOW-UP|2021-01-01|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-07|P1Y2M10DT2H30M|UNKNOWN|2020-12-10|COINCIDENT|2020-12-15
e|RS|1a3808b9-6004-4133-8f59-49905d04655e|8|METSIND|Metastatic Indicator|DOHNER AML 2010|[?]|U/m2/h|EQUIVOCAL|1|10^9/g|EPSILOMETER||||CAREGIVER|OPTOMETRIST|U|4|Visit_4|65|3|SCREENING|2021-01-01|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-07|P1Y2M10DT2H30M|UNKNOWN|2020-12-13|AFTER|2020-12-26
e|RS|1a3808b9-6004-4133-8f59-49905d04655e|9|NTNERESP|Non-Target Non-Enhancing Response|CHESON CLL 2006|[?]|ft2|NE|1|gMFI|SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY||Y||ADJUDICATOR|ENDOCRINOLOGIST|N|5|Visit_5|90|2|SCREENING|2021-01-26|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-25|P1Y2M10DT2H30M|BEFORE|2020-12-31|ONGOING|2021-01-31
e|RS|1a3808b9-6004-4133-8f59-49905d04655e|10|ANATRESP|Anatomic Response|MONTSERRAT CLL 1989|[?]|genEq|CRi|1|log10 CFU/g|INDIA INK STAIN||||CLINICAL RESEARCH ASSOCIATE|READER|NA|5|Visit_5|90|5|FOLLOW-UP|2021-01-26|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-25|P1Y2M10DT2H30M|COINCIDENT|2020-11-11|ONGOING|2021-01-13
e|RS|5c91894d-c756-4ade-9fc4-2a64d4acc53f|1|NEWLIND|New Lesion Indicator|MURPHY PROSTATE CANCER 1980|[?]|10^7 PFU|PSEUDOPROGRESSION|1|DAYS|NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY||||ADJUDICATION COMMITTEE|HEMATOLOGIST|N|1|Visit_1|10|2|FOLLOW-UP|2021-01-19|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-07|P1Y2M10DT2H30M|UNKNOWN|2021-02-24|AFTER|2021-03-25
e|RS|5c91894d-c756-4ade-9fc4-2a64d4acc53f|2|METSIND|Metastatic Indicator|PCWG SCHER PROSTATE CANCER 2016|[?]|10^7/L|SMD|1|DAgU/mL|DROPLET DIGITAL PCR|Y|Y||DOMESTIC PARTNER|PATHOLOGIST|Y|1|Visit_1|10|5|SCREENING|2021-01-19|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-07|P1Y2M10DT2H30M|COINCIDENT|2021-02-20|ONGOING|2021-04-04
e|RS|5c91894d-c756-4ade-9fc4-2a64d4acc53f|3|MRDIND|Minimal Residual Disease Indicator|GUILHOT CML 2007|||CYTOGENETIC CR|1|mV/sec|DIGITAL PCR|||Y|ADJUDICATION COMMITTEE|FORENSIC PATHOLOGIST|NA|2|Visit_2|25|2|TREATMENT|2021-02-03|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-25|P1Y2M10DT2H30M|UNKNOWN|2021-01-22|AFTER|2021-03-10
e|RS|5c91894d-c756-4ade-9fc4-2a64d4acc53f|4|HEMARESP|Hematologic Response|IRANO 2015|[?]|g/animal/wk|PSEUDOPROGRESSION|1|ug/mL/h|HILLMEN COLOR CHART||||FAMILY MEMBER|ONCOLOGIST 2|NA|2|Visit_2|25|1|TREATMENT|2021-02-03|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-25|P1Y2M10DT2H30M|AFTER|2021-04-10|AFTER|2021-04-18
e|RS|5c91894d-c756-4ade-9fc4-2a64d4acc53f|5|NEWLPROG|New Lesion Progression|WOLCHOK SOLID TUMORS 2009|[?]|ELISA unit/mL|MRD NEGATIVITY|1|BU/mL|FLOW CYTOMETRY|Y|||SIGNIFICANT OTHER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|3|Visit_3|40|4|FOLLOW-UP|2021-02-18|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-04|P1Y2M10DT2H30M|BEFORE|2021-03-13|AFTER|2021-04-02
e|RS|5c91894d-c756-4ade-9fc4-2a64d4acc53f|6|ANATRESP|Anatomic Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|s^-1(%O2)^-1|DECREASED|1|/VF|IMMUNOCHEMILUMINOMETRIC ASSAY||||GUARDIAN|OTOLARYNGOLOGIST|NA|3|Visit_3|40|4|FOLLOW-UP|2021-02-18|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-04|P1Y2M10DT2H30M|COINCIDENT|2021-03-02|BEFORE|2021-03-10
e|RS|5c91894d-c756-4ade-9fc4-2a64d4acc53f|7|METBRESP|Metabolic Response|HARTMANN GERM CELL CANCER 2002|[?]|cd|MOLECULAR MAJOR RESPONSE|1|aMFI|TRICHROME STAIN||Y||VENDOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|4|Visit_4|65|7|WASHOUT|2021-03-15|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-01|P1Y2M10DT2H30M|UNKNOWN|2021-02-26|ONGOING|2021-03-15
e|RS|5c91894d-c756-4ade-9fc4-2a64d4acc53f|8|MRPHRESP|Morphologic Response|CHESON LYMPHOMA 2008|[?]|/MBP|PSA PROGRESSION|1|mg/mol|MULTI-SLICE SPIRAL CT||||CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST|Y|4|Visit_4|65|5|TREATMENT|2021-03-15|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-01|P1Y2M10DT2H30M|UNKNOWN|2021-04-18|COINCIDENT|2021-04-19
e|RS|5c91894d-c756-4ade-9fc4-2a64d4acc53f|9|METSIND|Metastatic Indicator|GUPPY OVARIAN CANCER 2002|||CRi|1|uV*sec|CYSTOMETRY||Y|Y|ADJUDICATION COMMITTEE|CARDIOLOGIST|NA|5|Visit_5|90|2|FOLLOW-UP|2021-04-09|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-06|P1Y2M10DT2H30M|COINCIDENT|2021-04-14|BEFORE|2021-04-15
e|RS|5c91894d-c756-4ade-9fc4-2a64d4acc53f|10|PATHRESP|Pathologic Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|YEARS|NED|1|CAPLET|FLOW CYTOMETRY||||ADJUDICATION COMMITTEE|PATHOLOGIST|Y|5|Visit_5|90|5|TREATMENT|2021-04-09|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-06|P1Y2M10DT2H30M|UNKNOWN|2021-03-13|COINCIDENT|2021-03-20
e|RS|cc9d17ea-ec8b-46bb-af7d-ad19da3cfb20|1|MOLRESP|Molecular Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|days/wk|ABSENT MORPHOLOGIC RESPONSE|1|ug/kg|NUCLEIC ACID BASED METHOD|Y|Y||CLINICAL STUDY SPONSOR|READER 2|N|1|Visit_1|10|6|WASHOUT|2020-07-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-08|P1Y2M10DT2H30M|BEFORE|2020-10-11|ONGOING|2020-10-12
e|RS|cc9d17ea-ec8b-46bb-af7d-ad19da3cfb20|2|MJPTHIND|Major Pathological Response Indicator|PETIT BREAST CANCER 2001|[?]|Absorbance U|cPR|1|10^3/L|OLIGO ACGH||||HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|N|1|Visit_1|10|6|TREATMENT|2020-07-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-08|P1Y2M10DT2H30M|AFTER|2020-08-18|COINCIDENT|2020-10-05
e|RS|cc9d17ea-ec8b-46bb-af7d-ad19da3cfb20|3|TRGRESP|Target Response|RECIST 1.0|[?]|nmol|PD/RELAPSE AFTER HI|1|mL/animal/day|ELECTROGASTROGRAPHY||||GUARDIAN|ADJUDICATOR|NA|2|Visit_2|25|5|FOLLOW-UP|2020-07-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-29|P1Y2M10DT2H30M|BEFORE|2020-10-12|AFTER|2020-10-13
e|RS|cc9d17ea-ec8b-46bb-af7d-ad19da3cfb20|4|METBRESP|Metabolic Response|KEAM BREAST CANCER 2013|[?]|nm|HI-P|1|10^5/L|ANALYTICAL ULTRACENTRIFUGATION||||FAMILY MEMBER|MICROSCOPIST 3|N|2|Visit_2|25|7|FOLLOW-UP|2020-07-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-29|P1Y2M10DT2H30M|UNKNOWN|2020-09-02|COINCIDENT|2020-10-10
e|RS|cc9d17ea-ec8b-46bb-af7d-ad19da3cfb20|5|NTRGRESP|Non-target Response|UNSPECIFIED|[?]|tsp|SD|1|U|FLUORESCENT ENZYME IMMUNOASSAY||||SPOUSE|CARDIOLOGIST|N|3|Visit_3|40|2|FOLLOW-UP|2020-08-14|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-02|P1Y2M10DT2H30M|BEFORE|2020-08-27|ONGOING|2020-09-13
e|RS|cc9d17ea-ec8b-46bb-af7d-ad19da3cfb20|6|NTNERESP|Non-Target Non-Enhancing Response|AJCC V7|[?]|cal|DISEASE TRANSFORMATION|1|10^3 DNA copies/mL|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|Y|||FRIEND|PEDIATRIC NEUROLOGIST|Y|3|Visit_3|40|6|SCREENING|2020-08-14|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-02|P1Y2M10DT2H30M|UNKNOWN|2020-08-01|BEFORE|2020-08-20
e|RS|cc9d17ea-ec8b-46bb-af7d-ad19da3cfb20|7|BONERESP|Bone Response|KUMAR IMWG 2016|[?]|NEEDLE GAUGE|CR|1|nmol|CONTACT SPECULAR MICROSCOPY||||PARENT|PEDIATRIC NEUROLOGIST|NA|4|Visit_4|65|7|WASHOUT|2020-09-08|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-24|P1Y2M10DT2H30M|BEFORE|2020-09-19|BEFORE|2020-10-09
e|RS|cc9d17ea-ec8b-46bb-af7d-ad19da3cfb20|8|NTNERESP|Non-Target Non-Enhancing Response|CHOI GIST 2008|||CMR|1|10^6 organisms|PLAQUE REDUCTION NEUTRALIZATION ASSAY|Y||Y|FRIEND|PATHOLOGIST 1|Y|4|Visit_4|65|1|SCREENING|2020-09-08|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-24|P1Y2M10DT2H30M|COINCIDENT|2020-08-24|BEFORE|2020-10-06
e|RS|cc9d17ea-ec8b-46bb-af7d-ad19da3cfb20|9|NEWLWIND|New Lesion Worsening Indicator|CHESON CLL 2012|[?]|mL/m2|SD|1|kBq/uL|NUCLEIC ACID BASED METHOD||Y||FAMILY MEMBER|PATHOLOGIST 1|Y|5|Visit_5|90|6|SCREENING|2020-10-03|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-27|P1Y2M10DT2H30M|BEFORE|2020-08-24|ONGOING|2020-08-28
e|RS|cc9d17ea-ec8b-46bb-af7d-ad19da3cfb20|10|CLINRESP|Clinical Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|dyn|NON-iCR/NON-iUPD|1|V/sec|DOUBLE IMMUNODIFFUSION||||NON-HEALTH CARE PROFESSIONAL|INTERNIST|NA|5|Visit_5|90|7|SCREENING|2020-10-03|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-27|P1Y2M10DT2H30M|COINCIDENT|2020-07-27|ONGOING|2020-09-03
e|RS|4a6cff44-d7c3-410f-afe0-a11ae0e8872b|1|NEWLIND|New Lesion Indicator|SHINDOH COLORECTAL CANCER 2013|[?]|JAR|MORPHOLOGIC CR|1|/month|PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY||||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 2|NA|1|Visit_1|10|1|SCREENING|2020-09-15|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-13|P1Y2M10DT2H30M|BEFORE|2020-10-24|ONGOING|2020-11-11
e|RS|4a6cff44-d7c3-410f-afe0-a11ae0e8872b|2|TRGRESP|Target Response|EASL BRUIX LIVER CANCER 2001|[?]|pL|INDETERMINATE RESPONSE|1|tuberculin unit/mL|COMPLEMENT FIXATION||||CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 1|U|1|Visit_1|10|4|TREATMENT|2020-09-15|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-13|P1Y2M10DT2H30M|AFTER|2020-10-18|AFTER|2020-11-26
e|RS|4a6cff44-d7c3-410f-afe0-a11ae0e8872b|3|RDIORESP|Radiologic Response|SCHER PROSTATE CANCER 2011|||CRi|1|mEq/mmol|MANUAL COUNT|Y|Y|Y|HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|NA|2|Visit_2|25|4|TREATMENT|2020-09-30|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-12|P1Y2M10DT2H30M|COINCIDENT|2020-10-08|AFTER|2020-12-01
e|RS|4a6cff44-d7c3-410f-afe0-a11ae0e8872b|4|CLINRESP|Clinical Response|SCHWARZ CERVICAL CANCER 2009|[?]|copies/ug|PD-CT|1|cm H2O|MECHANICAL CLOT DETECTION||||CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR|NA|2|Visit_2|25|5|TREATMENT|2020-09-30|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-12|P1Y2M10DT2H30M|BEFORE|2020-10-09|ONGOING|2020-12-09
e|RS|4a6cff44-d7c3-410f-afe0-a11ae0e8872b|5|MRDRESP|Minimal Residual Disease Response|CHESON LYMPHOMA 2008|[?]|mL/animal/day|INCREASED|1|10^7/L|NEPHELOMETRY||||SPOUSE|RADIOLOGIST 1|U|3|Visit_3|40|7|TREATMENT|2020-10-15|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-25|P1Y2M10DT2H30M|UNKNOWN|2020-11-11|AFTER|2020-12-11
e|RS|4a6cff44-d7c3-410f-afe0-a11ae0e8872b|6|NEWLPROG|New Lesion Progression|MRECIST LENCIONI LIVER CANCER 2010|||PR WITH LYMPHOCYTOSIS|1|mg/m2/h|PLAQUE REDUCTION NEUTRALIZATION ASSAY|Y||Y|VENDOR|MICROSCOPIST 2|U|3|Visit_3|40|6|TREATMENT|2020-10-15|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-25|P1Y2M10DT2H30M|UNKNOWN|2020-12-12|AFTER|2020-12-13
e|RS|4a6cff44-d7c3-410f-afe0-a11ae0e8872b|7|NEWLWIND|New Lesion Worsening Indicator|HARTMANN GERM CELL CANCER 2002|[?]|Bq/mg|SMD|1|/HPF|X-RAY FLUORESCENCE SPECTROMETRY||Y||SIGNIFICANT OTHER|READER 3|U|4|Visit_4|65|7|SCREENING|2020-11-09|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-19|P1Y2M10DT2H30M|BEFORE|2020-10-28|COINCIDENT|2020-11-26
e|RS|4a6cff44-d7c3-410f-afe0-a11ae0e8872b|8|SPLNRESP|Spleen Response|AJCC V8|[?]|SACHET|MORPHOLOGIC LEUKEMIA-FREE STATE|1|nmol/kg/day|POLYMERASE CHAIN REACTION||Y||CHILD|NEUROLOGIST|Y|4|Visit_4|65|6|TREATMENT|2020-11-09|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-19|P1Y2M10DT2H30M|AFTER|2020-11-15|BEFORE|2020-11-20
e|RS|4a6cff44-d7c3-410f-afe0-a11ae0e8872b|9|BMIVLIND|Bone Marrow Involvement Indicator|PCWG SCHER PROSTATE CANCER 2016|||PR WITH LYMPHOCYTOSIS|1|AU/mL|HPLC/IEX|||Y|SPOUSE|ONCOLOGIST 2|NA|5|Visit_5|90|4|TREATMENT|2020-12-04|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-08|P1Y2M10DT2H30M|BEFORE|2020-09-18|ONGOING|2020-11-26
e|RS|4a6cff44-d7c3-410f-afe0-a11ae0e8872b|10|CPRFSTAT|Clinical Performance Status|PCWG SCHER PROSTATE CANCER 2016|||TREATMENT FAILURE|1|APL U/mL|ENZYMATIC SPECTROPHOTOMETRY|||Y|GUARDIAN|RADIOLOGIST|Y|5|Visit_5|90|5|WASHOUT|2020-12-04|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-08|P1Y2M10DT2H30M|UNKNOWN|2020-11-12|COINCIDENT|2020-11-13
e|RS|35fd3f79-60b3-4101-ab79-952ca0e8f1ce|1|BONERESP|Bone Response|WHO BREAST CANCER 2006|[?]|g/L|NON-CR/NON-PD|1|PUFF|CALCULATION||||VENDOR|MICROSCOPIST 2|N|1|Visit_1|10|1|FOLLOW-UP|2020-06-10|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-04|P1Y2M10DT2H30M|COINCIDENT|2020-06-02|ONGOING|2020-07-14
e|RS|35fd3f79-60b3-4101-ab79-952ca0e8f1ce|2|CLINRESP|Clinical Response|CHOI GIST 2008|[?]|cm|iUPD|1|bel|TRYPAN BLUE STAIN||||SIGNIFICANT OTHER|ONCOLOGIST|U|1|Visit_1|10|6|TREATMENT|2020-06-10|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-04|P1Y2M10DT2H30M|COINCIDENT|2020-08-19|ONGOING|2020-08-22
e|RS|35fd3f79-60b3-4101-ab79-952ca0e8f1ce|3|CLINRESP|Clinical Response|CHESON NON-HODGKINS LYMPHOMA 1999|||iCR|1|nmol/L/min|CRYOSCOPY|||Y|VENDOR|PEDIATRIC NEUROLOGIST|Y|2|Visit_2|25|2|WASHOUT|2020-06-25|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-11|P1Y2M10DT2H30M|BEFORE|2020-09-05|BEFORE|2020-09-07
e|RS|35fd3f79-60b3-4101-ab79-952ca0e8f1ce|4|LIVRRESP|Liver Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|U/g/min|iCPD|1|cs|GC/MS/MS||||PROXY|MICROSCOPIST 1|Y|2|Visit_2|25|5|FOLLOW-UP|2020-06-25|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-11|P1Y2M10DT2H30M|UNKNOWN|2020-07-25|COINCIDENT|2020-08-06
e|RS|35fd3f79-60b3-4101-ab79-952ca0e8f1ce|5|NTERESP|Non-Target Enhancing Response|KUKER LYMPHOMA 2005|[?]|kBq/uL|SD-CT|1|keV|SLIT LAMP||||CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 2|N|3|Visit_3|40|7|TREATMENT|2020-07-10|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-17|P1Y2M10DT2H30M|BEFORE|2020-07-28|ONGOING|2020-08-09
e|RS|35fd3f79-60b3-4101-ab79-952ca0e8f1ce|6|BESTRESP|Best Overall Response|MASS|[?]|nmol/L|PR|1|KIT|TOTAL BODY RADIOGRAPHY||||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR|NA|3|Visit_3|40|1|TREATMENT|2020-07-10|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-17|P1Y2M10DT2H30M|BEFORE|2020-07-04|ONGOING|2020-09-02
e|RS|35fd3f79-60b3-4101-ab79-952ca0e8f1ce|7|MRDIND|Minimal Residual Disease Indicator|DOHNER AML 2010|||PSEUDOPROGRESSION|1|min/day|CLIP||Y|Y|HEALTH CARE PROFESSIONAL|READER|U|4|Visit_4|65|4|FOLLOW-UP|2020-08-04|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-17|P1Y2M10DT2H30M|UNKNOWN|2020-06-02|COINCIDENT|2020-08-10
e|RS|35fd3f79-60b3-4101-ab79-952ca0e8f1ce|8|METSIND|Metastatic Indicator|CHESON LYMPHOMA 2008|[?]|CAPLET|NON-PD|1|Tesla|FLUORESCENT IMMUNOASSAY||||VENDOR|MICROSCOPIST 3|N|4|Visit_4|65|2|TREATMENT|2020-08-04|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-17|P1Y2M10DT2H30M|COINCIDENT|2020-08-21|ONGOING|2020-09-06
e|RS|35fd3f79-60b3-4101-ab79-952ca0e8f1ce|9|TRGRESP|Target Response|MACDONALD GLIOMA 1990|[?]|NEEDLE GAUGE|MRD PERSISTENCE|1|mm/2h|CHROMATOGRAPHY||||NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|NA|5|Visit_5|90|7|TREATMENT|2020-08-29|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-08|P1Y2M10DT2H30M|BEFORE|2020-07-06|ONGOING|2020-07-13
e|RS|35fd3f79-60b3-4101-ab79-952ca0e8f1ce|10|NEWLIND|New Lesion Indicator|KUKER LYMPHOMA 2005|[?]|/MBP|CRi|1|TAMPON|PLETHYSMOGRAPHY||||SPOUSE|RADIOLOGIST 2|U|5|Visit_5|90|4|TREATMENT|2020-08-29|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-08|P1Y2M10DT2H30M|AFTER|2020-06-28|ONGOING|2020-08-20
e|RS|37610314-f803-4ffa-a584-ebfe09267a0d|1|BESTRESP|Best Overall Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|m2|PD FROM PR|1|Roentgen|BAC ACGH||||PROXY|READER 3|NA|1|Visit_1|10|6|TREATMENT|2020-06-30|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-26|P1Y2M10DT2H30M|AFTER|2020-08-28|AFTER|2020-09-14
e|RS|37610314-f803-4ffa-a584-ebfe09267a0d|2|METSIND|Metastatic Indicator|WOLCHOK SOLID TUMORS 2009|||TREATMENT FAILURE|1|/kg|MYELOPEROXIDASE STAIN|||Y|DOMESTIC PARTNER|HEMATOLOGIST|N|1|Visit_1|10|2|TREATMENT|2020-06-30|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-26|P1Y2M10DT2H30M|AFTER|2020-09-26|BEFORE|2020-09-27
e|RS|37610314-f803-4ffa-a584-ebfe09267a0d|3|NTLWIND|Non-Target Lesion Worsening Indicator|IRANO 2015|||SMD|1|dyn|RYAN BLUE STAIN|||Y|PARENT|NEUROLOGIST 1|Y|2|Visit_2|25|6|TREATMENT|2020-07-15|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-24|P1Y2M10DT2H30M|AFTER|2020-06-26|COINCIDENT|2020-08-11
e|RS|37610314-f803-4ffa-a584-ebfe09267a0d|4|NEWLWIND|New Lesion Worsening Indicator|DOHNER AML 2010|[?]|MBP|CMR|1|cg|HANSEL STAIN|Y|||CLINICAL STUDY SPONSOR|READER|U|2|Visit_2|25|1|WASHOUT|2020-07-15|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-24|P1Y2M10DT2H30M|AFTER|2020-07-31|BEFORE|2020-09-10
e|RS|37610314-f803-4ffa-a584-ebfe09267a0d|5|CLINRESP|Clinical Response|SCHWARZ CERVICAL CANCER 2009|[?]|gtt|CA125 75% RESPONSE|1|mg/mol|FUNCTIONAL MRI||||SIGNIFICANT OTHER|RADIOLOGIST|U|3|Visit_3|40|4|WASHOUT|2020-07-30|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-06|P1Y2M10DT2H30M|UNKNOWN|2020-09-08|BEFORE|2020-09-17
e|RS|37610314-f803-4ffa-a584-ebfe09267a0d|6|NTERESP|Non-Target Enhancing Response|RANO ELLINGSON 2017|[?]|BEAM BREAKS|PD-CT|1|10^9 CFU/g|FORCED OSCILLATION TECHNIQUE||||PROXY|INTERNIST|Y|3|Visit_3|40|2|TREATMENT|2020-07-30|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-06|P1Y2M10DT2H30M|COINCIDENT|2020-07-29|BEFORE|2020-08-01
e|RS|37610314-f803-4ffa-a584-ebfe09267a0d|7|METSIND|Metastatic Indicator|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|ks|PD/RELAPSE AFTER HI|1|ug/dL|FARR ASSAY||||STUDY SUBJECT|PATHOLOGIST 2|N|4|Visit_4|65|5|WASHOUT|2020-08-24|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-12|P1Y2M10DT2H30M|AFTER|2020-08-08|BEFORE|2020-09-15
e|RS|37610314-f803-4ffa-a584-ebfe09267a0d|8|MOLRESP|Molecular Response|PCWG SCHER PROSTATE CANCER 2016|[?]|10^6 CFU|UNFAVORABLE RESPONSE|1|oz eq|FLUORESCENT MICROSCOPY||Y||SPOUSE|ADJUDICATOR 1|NA|4|Visit_4|65|2|SCREENING|2020-08-24|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-12|P1Y2M10DT2H30M|COINCIDENT|2020-09-06|ONGOING|2020-09-16
e|RS|37610314-f803-4ffa-a584-ebfe09267a0d|9|TMRESP|Tumor Marker Response|KEAM BREAST CANCER 2013|[?]|APL U/mL|HI-P|1|ngEq/L|AURAMINE STAIN||||CLINICAL STUDY SPONSOR|RATER 1|U|5|Visit_5|90|5|TREATMENT|2020-09-18|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-07|P1Y2M10DT2H30M|COINCIDENT|2020-06-24|COINCIDENT|2020-09-14
e|RS|37610314-f803-4ffa-a584-ebfe09267a0d|10|NEWLPROG|New Lesion Progression|PCWG SCHER PROSTATE CANCER 2016|[?]|uEq|PDu|1|U/cL|MACRO BROTH DILUTION|Y|||DOMESTIC PARTNER|ENDOCRINOLOGIST|N|5|Visit_5|90|4|FOLLOW-UP|2020-09-18|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-07|P1Y2M10DT2H30M|UNKNOWN|2020-08-10|AFTER|2020-09-25
e|RS|760ec5ce-3ae7-4268-9f76-b83085ad3754|1|RDIORESP|Radiologic Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|U/g/min|HI-N|1|kIU|PLAQUE REDUCTION NEUTRALIZATION ASSAY||||INTERVIEWER|RATER|N|1|Visit_1|10|5|SCREENING|2020-09-24|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-18|P1Y2M10DT2H30M|UNKNOWN|2020-12-07|BEFORE|2020-12-15
e|RS|760ec5ce-3ae7-4268-9f76-b83085ad3754|2|BMIVLIND|Bone Marrow Involvement Indicator|FAROOQUI SUPP CLL 2014|[?]|/ms|NON-iCR/NON-iUPD|1|IMPLANT|INDIA INK STAIN||||CLINICAL RESEARCH ASSOCIATE|INTERNIST|NA|1|Visit_1|10|4|SCREENING|2020-09-24|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-18|P1Y2M10DT2H30M|BEFORE|2020-10-13|AFTER|2020-12-03
e|RS|760ec5ce-3ae7-4268-9f76-b83085ad3754|3|NEWLIND|New Lesion Indicator|SACT|[?]|hPa|PDu|1|umol|VENTILATION PERFUSION LUNG SCAN|Y|||CHILD|UROLOGIST|U|2|Visit_2|25|3|WASHOUT|2020-10-09|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-03|P1Y2M10DT2H30M|COINCIDENT|2020-12-04|AFTER|2020-12-06
e|RS|760ec5ce-3ae7-4268-9f76-b83085ad3754|4|MRDIND|Minimal Residual Disease Indicator|HARTMAN PANCREATIC CANCER 2012|[?]|10^4/hpf|RELAPSED DISEASE|1|cm/min|MICROBIAL CULTURE, LIQUID||Y||PROXY|PHYSIOTHERAPIST|U|2|Visit_2|25|5|TREATMENT|2020-10-09|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-03|P1Y2M10DT2H30M|COINCIDENT|2020-11-13|AFTER|2020-12-09
e|RS|760ec5ce-3ae7-4268-9f76-b83085ad3754|5|NTRGRESP|Non-target Response|CHOI GIST 2008|[?]|ms2|iCPD|1|EU|HPLC/IEX||||FRIEND|PATHOLOGIST 1|N|3|Visit_3|40|4|SCREENING|2020-10-24|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-15|P1Y2M10DT2H30M|COINCIDENT|2020-12-03|BEFORE|2020-12-16
e|RS|760ec5ce-3ae7-4268-9f76-b83085ad3754|6|PATHRESP|Pathologic Response|DOHNER AML 2010|[?]|tsp eq|IMMUNOPHENOTYPIC CR|1|Bq|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS|Y|||SPOUSE|RADIOLOGIST|Y|3|Visit_3|40|6|WASHOUT|2020-10-24|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-15|P1Y2M10DT2H30M|COINCIDENT|2020-10-01|ONGOING|2020-11-07
e|RS|760ec5ce-3ae7-4268-9f76-b83085ad3754|7|TMRESP|Tumor Marker Response|CHESON CLL 2006|[?]|10^6 RNA copies/mL|DECREASED|1|mg/animal|TRICHROME STAIN||||FAMILY MEMBER|RATER 1|NA|4|Visit_4|65|6|TREATMENT|2020-11-18|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-17|P1Y2M10DT2H30M|AFTER|2020-10-31|AFTER|2020-11-30
e|RS|760ec5ce-3ae7-4268-9f76-b83085ad3754|8|TMRESP|Tumor Marker Response|CHESON LYMPHOMA 2008|[?]|CUP|MORPHOLOGIC CRi|1|MONTHS|U-HPLC/MS/MS||Y||PROXY|ADJUDICATOR 1|NA|4|Visit_4|65|2|WASHOUT|2020-11-18|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-17|P1Y2M10DT2H30M|BEFORE|2020-10-18|AFTER|2020-11-01
e|RS|760ec5ce-3ae7-4268-9f76-b83085ad3754|9|TRGRESP|Target Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|nmol/g|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|ug/kg/day|NUCLEIC ACID AMPLIFICATION TEST||||CLINICAL STUDY SPONSOR|RADIOLOGIST 1|Y|5|Visit_5|90|7|TREATMENT|2020-12-13|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-01|P1Y2M10DT2H30M|AFTER|2020-09-30|AFTER|2020-11-06
e|RS|760ec5ce-3ae7-4268-9f76-b83085ad3754|10|SFTSRESP|Soft Tissue Response|DOHNER AML 2010|[?]|Bq/mL|WORSENED|1|grain|INFRARED SPECTROMETRY||Y||SIBLING|READER 1|N|5|Visit_5|90|3|TREATMENT|2020-12-13|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-01|P1Y2M10DT2H30M|COINCIDENT|2020-10-21|AFTER|2020-12-04
e|RS|13773a62-50b1-4b2a-a5c7-ec0e0245a97e|1|BMIVLIND|Bone Marrow Involvement Indicator|PRINCE TCELL LYMPHOMA 2010|||CHR|1|mL/cm3/min|POTENTIOMETRY|Y|Y|Y|CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST|N|1|Visit_1|10|1|TREATMENT|2020-06-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-09|P1Y2M10DT2H30M|UNKNOWN|2020-08-23|COINCIDENT|2020-09-12
e|RS|13773a62-50b1-4b2a-a5c7-ec0e0245a97e|2|SPLNRESP|Spleen Response|RECIST 1.0|[?]|10^7/L|PD FROM PR|1|K|VIRUS PLAQUE ASSAY|Y|||SIBLING|RADIOLOGIST 1|U|1|Visit_1|10|2|SCREENING|2020-06-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-09|P1Y2M10DT2H30M|UNKNOWN|2020-07-13|ONGOING|2020-08-17
e|RS|13773a62-50b1-4b2a-a5c7-ec0e0245a97e|3|BMIVLIND|Bone Marrow Involvement Indicator|RANO ELLINGSON 2017|[?]|/ms|PSA PROGRESSION|1|min/day|REFRACTOMETRY|Y|||FAMILY MEMBER|ONCOLOGIST 2|N|2|Visit_2|25|5|WASHOUT|2020-06-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-26|P1Y2M10DT2H30M|UNKNOWN|2020-07-28|BEFORE|2020-08-16
e|RS|13773a62-50b1-4b2a-a5c7-ec0e0245a97e|4|MJPTHIND|Major Pathological Response Indicator|SACT|[?]|/200 HPFs|CA125 75% RESPONSE|1|APL U|GC/MS/MS||||DOMESTIC PARTNER|PEDIATRIC NEUROLOGIST|Y|2|Visit_2|25|3|TREATMENT|2020-06-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-26|P1Y2M10DT2H30M|UNKNOWN|2020-06-07|BEFORE|2020-08-15
e|RS|13773a62-50b1-4b2a-a5c7-ec0e0245a97e|5|NTNERESP|Non-Target Non-Enhancing Response|BURCOMBE BREAST CANCER 2005|[?]|mmHg|MRD NEGATIVITY|1|mOsm|IMMUNE REPERTOIRE DEEP SEQUENCING||||CLINICAL STUDY SPONSOR|RADIOLOGIST|NA|3|Visit_3|40|3|TREATMENT|2020-07-15|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-09|P1Y2M10DT2H30M|BEFORE|2020-07-17|AFTER|2020-07-18
e|RS|13773a62-50b1-4b2a-a5c7-ec0e0245a97e|6|TMRESP|Tumor Marker Response|HARTMANN GERM CELL CANCER 2002|[?]|/min|CR|1|mOsm|SPIROMETRY||||CLINICAL STUDY SPONSOR|RADIOLOGIST|NA|3|Visit_3|40|1|SCREENING|2020-07-15|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-09|P1Y2M10DT2H30M|BEFORE|2020-06-19|BEFORE|2020-07-01
e|RS|13773a62-50b1-4b2a-a5c7-ec0e0245a97e|7|NEWLIND|New Lesion Indicator|GUILHOT CML 2007|[?]|Gravitational Unit|WORSENED|1|ug/g/h|OLIGO ACGH||||GUARDIAN|NEUROLOGIST 2|NA|4|Visit_4|65|6|SCREENING|2020-08-09|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-17|P1Y2M10DT2H30M|BEFORE|2020-08-04|BEFORE|2020-08-09
e|RS|13773a62-50b1-4b2a-a5c7-ec0e0245a97e|8|SYMPTDTR|Symptomatic Deterioration|IWG CHESON AML 2003|[?]|log10 IU/mL|RELAPSED DISEASE FROM CR OR PR|1|Gravitational Unit|COMPUTERIZED CORNEAL TOPOGRAPHY||||STUDY SUBJECT|RATER 1|N|4|Visit_4|65|1|TREATMENT|2020-08-09|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-17|P1Y2M10DT2H30M|UNKNOWN|2020-06-13|COINCIDENT|2020-07-23
e|RS|13773a62-50b1-4b2a-a5c7-ec0e0245a97e|9|MRDIND|Minimal Residual Disease Indicator|IWG CHESON MDS 2000|[?]|NFIU|PD/RELAPSE AFTER HI|1|10^11/L|ORCHIDOMETERY||||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST|U|5|Visit_5|90|2|FOLLOW-UP|2020-09-03|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-25|P1Y2M10DT2H30M|COINCIDENT|2020-08-08|ONGOING|2020-08-24
e|RS|13773a62-50b1-4b2a-a5c7-ec0e0245a97e|10|BESTRESP|Best Overall Response|PALUMBO MULTIPLE MYELOMA 2009|||COMPLETE MRD RESPONSE|1|Ci/mg|SANGER SEQUENCING|||Y|CHILD|NEUROLOGIST 1|U|5|Visit_5|90|1|WASHOUT|2020-09-03|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-25|P1Y2M10DT2H30M|AFTER|2020-07-26|BEFORE|2020-08-10
e|RS|d0a9940e-a75f-4fcc-8d0c-5a8dae7d9344|1|MRDIND|Minimal Residual Disease Indicator|LUGANO CLASSIFICATION|[?]|VOXEL|HI-P|1|Absorbance U/min|ANTIBIOTIC AGAR SCREEN||||PROXY|PEDIATRIC NEUROLOGIST|N|1|Visit_1|10|5|FOLLOW-UP|2021-01-24|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-27|P1Y2M10DT2H30M|AFTER|2021-04-14|AFTER|2021-04-23
e|RS|d0a9940e-a75f-4fcc-8d0c-5a8dae7d9344|2|MRDRESP|Minimal Residual Disease Response|LEE LUNG CANCER 2011|[?]|/LPF|iPR|1|mEq/day|CINEANGIOGRAPHY|Y|||STUDY SUBJECT|ENDOCRINOLOGIST|NA|1|Visit_1|10|4|TREATMENT|2021-01-24|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-27|P1Y2M10DT2H30M|BEFORE|2021-01-26|COINCIDENT|2021-04-21
e|RS|d0a9940e-a75f-4fcc-8d0c-5a8dae7d9344|3|ANATRESP|Anatomic Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|mol/g|CYTOGENETIC NO RESPONSE|1|log10 PFU/mL|RULER MEASUREMENT METHOD||Y||STUDY SUBJECT|DERMATOLOGIST|U|2|Visit_2|25|6|WASHOUT|2021-02-08|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-14|P1Y2M10DT2H30M|AFTER|2021-04-12|ONGOING|2021-04-23
e|RS|d0a9940e-a75f-4fcc-8d0c-5a8dae7d9344|4|TRGRESP|Target Response|NCCN ALL MRD 2014|[?]|mL/kg|NON-CR/NON-PD|1|nU/cL|FLUORIMETRY||||INTERVIEWER|ADJUDICATOR 3|U|2|Visit_2|25|5|TREATMENT|2021-02-08|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-14|P1Y2M10DT2H30M|COINCIDENT|2021-02-09|BEFORE|2021-04-08
e|RS|d0a9940e-a75f-4fcc-8d0c-5a8dae7d9344|5|SPLNRESP|Spleen Response|SHINDOH COLORECTAL CANCER 2013|[?]|dpm/mg|NE|1|pmol/10^9 cells|FLAME PHOTOMETRY||||SIBLING|ADJUDICATOR 3|Y|3|Visit_3|40|7|TREATMENT|2021-02-23|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-02|P1Y2M10DT2H30M|COINCIDENT|2021-02-09|BEFORE|2021-03-04
e|RS|d0a9940e-a75f-4fcc-8d0c-5a8dae7d9344|6|SPLNRESP|Spleen Response|CHESON CLL 2012|[?]|10^11/L|PR-CT|1|IMPLANT|SANGER SEQUENCING|Y|||FAMILY MEMBER|RADIOLOGIST 2|Y|3|Visit_3|40|5|TREATMENT|2021-02-23|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-02|P1Y2M10DT2H30M|UNKNOWN|2021-03-29|ONGOING|2021-04-11
e|RS|d0a9940e-a75f-4fcc-8d0c-5a8dae7d9344|7|BMIVLIND|Bone Marrow Involvement Indicator|NCIWG CHESON CLL 1996|[?]|/h|PMR|1|mL/breath|HIGH RESOLUTION MELT ANALYSIS||Y||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 1|NA|4|Visit_4|65|4|FOLLOW-UP|2021-03-20|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-13|P1Y2M10DT2H30M|COINCIDENT|2021-02-23|AFTER|2021-04-12
e|RS|d0a9940e-a75f-4fcc-8d0c-5a8dae7d9344|8|MRPHRESP|Morphologic Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|cm|CYTOGENETIC MINOR RESPONSE|1|pg|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY||||DOMESTIC PARTNER|ADJUDICATOR 2|Y|4|Visit_4|65|6|WASHOUT|2021-03-20|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-13|P1Y2M10DT2H30M|AFTER|2021-03-05|AFTER|2021-03-26
e|RS|d0a9940e-a75f-4fcc-8d0c-5a8dae7d9344|9|NTLWIND|Non-Target Lesion Worsening Indicator|KUKER LYMPHOMA 2005|[?]|gpELISA unit/mL|MRD NEGATIVITY|1|mol/mg|CLAUSS METHOD||Y||ADJUDICATOR|ADJUDICATOR|U|5|Visit_5|90|5|TREATMENT|2021-04-14|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-01|P1Y2M10DT2H30M|COINCIDENT|2021-02-10|BEFORE|2021-03-23
e|RS|d0a9940e-a75f-4fcc-8d0c-5a8dae7d9344|10|OVRLRESP|Overall Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|L|COMPLETE MRD RESPONSE|1|10^7/L|PET/CT SCAN||||NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|NA|5|Visit_5|90|1|SCREENING|2021-04-14|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-01|P1Y2M10DT2H30M|BEFORE|2021-01-17|ONGOING|2021-02-02
e|RS|8f0ff98a-fd19-4c9f-87ec-96200ced0f82|1|DRCRIND|Disease Recurrence Indicator|iRECIST|||TREATMENT FAILURE|1|mCi|GIEMSA STAIN|||Y|CAREGIVER|NEUROLOGIST 2|Y|1|Visit_1|10|2|TREATMENT|2020-11-13|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-06|P1Y2M10DT2H30M|UNKNOWN|2020-12-30|COINCIDENT|2021-02-08
e|RS|8f0ff98a-fd19-4c9f-87ec-96200ced0f82|2|SYMPTDTR|Symptomatic Deterioration|FAROOQUI SUPP CLL 2014|||NON-CR/NON-PD|1|ug|DOPPLER ULTRASOUND||Y|Y|STUDY SUBJECT|MICROSCOPIST|U|1|Visit_1|10|6|WASHOUT|2020-11-13|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-06|P1Y2M10DT2H30M|COINCIDENT|2021-02-08|AFTER|2021-02-10
e|RS|8f0ff98a-fd19-4c9f-87ec-96200ced0f82|3|NTRGRESP|Non-target Response|RECICL|[?]|mL/animal/day|iPR|1|GPL U|WRIGHT-GIEMSA STAIN||||CLINICAL RESEARCH ASSOCIATE|READER|NA|2|Visit_2|25|2|TREATMENT|2020-11-28|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-22|P1Y2M10DT2H30M|AFTER|2020-11-30|AFTER|2021-01-10
e|RS|8f0ff98a-fd19-4c9f-87ec-96200ced0f82|4|SPLNRESP|Spleen Response|PERCIST|[?]|mg/m2/min|sCR|1|nmol/day|IMMUNODIFFUSION||||CAREGIVER|ADJUDICATOR|N|2|Visit_2|25|3|TREATMENT|2020-11-28|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-22|P1Y2M10DT2H30M|AFTER|2021-01-07|ONGOING|2021-02-10
e|RS|8f0ff98a-fd19-4c9f-87ec-96200ced0f82|5|BESTRESP|Best Overall Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|U/g/h|RELAPSED DISEASE|1|10^3 copies/mL|CONTRAST ENHANCED MRI||Y||SPOUSE|RADIOLOGIST 2|N|3|Visit_3|40|6|TREATMENT|2020-12-13|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-31|P1Y2M10DT2H30M|UNKNOWN|2020-11-27|COINCIDENT|2021-01-30
e|RS|8f0ff98a-fd19-4c9f-87ec-96200ced0f82|6|STRUSTAT|Steroid Use Status|DURIE MULTIPLE MYELOMA 2006|||DECREASED|1|days/wk|MICROBIAL CULTURE, LIQUID|||Y|INDEPENDENT ASSESSOR|PATHOLOGIST|U|3|Visit_3|40|7|SCREENING|2020-12-13|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-31|P1Y2M10DT2H30M|AFTER|2020-12-06|AFTER|2021-02-03
e|RS|8f0ff98a-fd19-4c9f-87ec-96200ced0f82|7|SFTSRESP|Soft Tissue Response|MACDONALD GLIOMA 1990|[?]|aMFI|PSEUDOPROGRESSION|1|PLUG|ISHIHARA COLOR PLATES||||VENDOR|OPHTHALMOLOGIST|N|4|Visit_4|65|5|FOLLOW-UP|2021-01-07|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-25|P1Y2M10DT2H30M|BEFORE|2021-01-09|ONGOING|2021-01-25
e|RS|8f0ff98a-fd19-4c9f-87ec-96200ced0f82|8|NTNERESP|Non-Target Non-Enhancing Response|LUGANO CLASSIFICATION|[?]|FEU|MAJOR PATHOLOGIC RESPONSE|1|g/animal|TRANSESOPHAGEAL ECHOCARDIOGRAPHY|Y|Y||FAMILY MEMBER|HEMATOLOGIST|NA|4|Visit_4|65|4|TREATMENT|2021-01-07|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-25|P1Y2M10DT2H30M|COINCIDENT|2020-11-17|AFTER|2021-01-19
e|RS|8f0ff98a-fd19-4c9f-87ec-96200ced0f82|9|MRPHRESP|Morphologic Response|RECIST 1.1|||nPR|1|uL|CONGO RED STAIN|||Y|CLINICAL STUDY SPONSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|5|Visit_5|90|7|TREATMENT|2021-02-01|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-16|P1Y2M10DT2H30M|AFTER|2021-01-06|AFTER|2021-02-01
e|RS|8f0ff98a-fd19-4c9f-87ec-96200ced0f82|10|NTNERESP|Non-Target Non-Enhancing Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|VIAL|QUANTIFIABLE MRD POSITIVITY|1|AgU/mL|BIOIMPEDANCE SPECTROSCOPY||||SPOUSE|RATER|U|5|Visit_5|90|5|TREATMENT|2021-02-01|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-16|P1Y2M10DT2H30M|COINCIDENT|2021-01-02|ONGOING|2021-02-03
e|RS|d7b41e15-6725-4433-8a35-72629e342b47|1|ANATRESP|Anatomic Response|RECIST 1.1|[?]|10^9/dose|OPTIMAL MORPHOLOGIC RESPONSE|1|10^6 organisms/g|MULTI-SLICE SPIRAL CT||||INDEPENDENT ASSESSOR|UROLOGIST|N|1|Visit_1|10|1|FOLLOW-UP|2020-09-14|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-10|P1Y2M10DT2H30M|BEFORE|2020-10-25|ONGOING|2020-11-01
e|RS|d7b41e15-6725-4433-8a35-72629e342b47|2|ANATRESP|Anatomic Response|BRUGGEMANN MRD 2010|||PD-CT|1|g/U|HEMAGGLUTINATION INHIBITION ASSAY||Y|Y|ADJUDICATION COMMITTEE|RADIOLOGIST 2|Y|1|Visit_1|10|4|SCREENING|2020-09-14|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-10|P1Y2M10DT2H30M|BEFORE|2020-12-03|COINCIDENT|2020-12-07
e|RS|d7b41e15-6725-4433-8a35-72629e342b47|3|LIVRRESP|Liver Response|iRECIST|||DISEASE TRANSFORMATION|1|pmol/L/h|CONFOCAL MICROSCOPY|Y||Y|CHILD|ONCOLOGIST 1|Y|2|Visit_2|25|6|WASHOUT|2020-09-29|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-05|P1Y2M10DT2H30M|COINCIDENT|2020-11-21|ONGOING|2020-12-06
e|RS|d7b41e15-6725-4433-8a35-72629e342b47|4|METBRESP|Metabolic Response|EASL BRUIX LIVER CANCER 2001|||MR|1|cL|TARGETED TRANSCRIPTOME SEQUENCING|Y|Y|Y|CHILD|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|2|Visit_2|25|2|FOLLOW-UP|2020-09-29|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-05|P1Y2M10DT2H30M|AFTER|2020-09-24|BEFORE|2020-09-29
e|RS|d7b41e15-6725-4433-8a35-72629e342b47|5|NTLWIND|Non-Target Lesion Worsening Indicator|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|ug/kg|MORPHOLOGIC LEUKEMIA-FREE STATE|1|mL/cage|CALCOFLUOR WHITE STAIN||||ADJUDICATOR|PATHOLOGIST 2|NA|3|Visit_3|40|6|SCREENING|2020-10-14|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-16|P1Y2M10DT2H30M|COINCIDENT|2020-11-06|AFTER|2020-11-22
e|RS|d7b41e15-6725-4433-8a35-72629e342b47|6|MNPTHIND|Minor Pathological Response Indicator|MASS|[?]|%|CA125 50% RESPONSE|1|cal|IRON HEMATOXYLIN STAIN||||DOMESTIC PARTNER|RADIOLOGIST|U|3|Visit_3|40|1|TREATMENT|2020-10-14|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-16|P1Y2M10DT2H30M|AFTER|2020-10-27|COINCIDENT|2020-11-19
e|RS|d7b41e15-6725-4433-8a35-72629e342b47|7|CLINRESP|Clinical Response|WHO BREAST CANCER 2006|[?]|SQU/mL|PD FROM PR|1|cycle/min|KLEIHAUER-BETKE||||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 3|U|4|Visit_4|65|6|SCREENING|2020-11-08|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-06|P1Y2M10DT2H30M|COINCIDENT|2020-09-20|AFTER|2020-11-29
e|RS|d7b41e15-6725-4433-8a35-72629e342b47|8|NEWLIND|New Lesion Indicator|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|IU/g Hb|PR-CT|1|10^6/hpf|ENDPOINT DILUTION ASSAY||Y||SPOUSE|NEUROLOGIST 2|N|4|Visit_4|65|1|TREATMENT|2020-11-08|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-06|P1Y2M10DT2H30M|UNKNOWN|2020-11-06|AFTER|2020-11-24
e|RS|d7b41e15-6725-4433-8a35-72629e342b47|9|MJPTHIND|Major Pathological Response Indicator|HARTMAN PANCREATIC CANCER 2012|||DECREASED|1|Ci/mg|MEDIASTINOSCOPY|||Y|INTERVIEWER|OPTOMETRIST|U|5|Visit_5|90|6|SCREENING|2020-12-03|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-18|P1Y2M10DT2H30M|UNKNOWN|2020-10-07|AFTER|2020-10-12
e|RS|d7b41e15-6725-4433-8a35-72629e342b47|10|CPRFSTAT|Clinical Performance Status|PALUMBO MULTIPLE MYELOMA 2009|[?]|WEEKS|INDETERMINATE RESPONSE|1|m2|OPTICAL COHERENCE TOMOGRAPHY|Y|Y||VENDOR|NEUROLOGIST 2|NA|5|Visit_5|90|6|FOLLOW-UP|2020-12-03|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-18|P1Y2M10DT2H30M|UNKNOWN|2020-11-19|ONGOING|2020-12-06
e|RS|aeddc1ed-545c-405e-b1f7-08131961f5ff|1|DRCRIND|Disease Recurrence Indicator|JACINTO CERVICAL CANCER 2007|||CR-CT|1|PIXELS/cm|REVERSE TRANSCRIPTASE PCR|||Y|SIGNIFICANT OTHER|RATER 2|Y|1|Visit_1|10|1|TREATMENT|2020-10-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-16|P1Y2M10DT2H30M|BEFORE|2020-10-14|ONGOING|2020-12-08
e|RS|aeddc1ed-545c-405e-b1f7-08131961f5ff|2|BESTRESP|Best Overall Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|mEq/uL|DISEASE TRANSFORMATION|1|10^9/L|OPTICAL MAPPING||||CLINICAL STUDY SPONSOR|PATHOLOGIST|NA|1|Visit_1|10|6|TREATMENT|2020-10-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-16|P1Y2M10DT2H30M|COINCIDENT|2020-11-07|ONGOING|2021-01-10
e|RS|aeddc1ed-545c-405e-b1f7-08131961f5ff|3|TMRESP|Tumor Marker Response|MACDONALD GLIOMA 1990|[?]|pmol/10^10 cells|CHR|1|Ci/L|AUSCULTATION|Y|||DOMESTIC PARTNER|NEUROLOGIST 1|U|2|Visit_2|25|6|SCREENING|2020-10-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-05|P1Y2M10DT2H30M|AFTER|2020-11-15|ONGOING|2020-12-14
e|RS|aeddc1ed-545c-405e-b1f7-08131961f5ff|4|NEWLWIND|New Lesion Worsening Indicator|MRECIST BYRNE MESOTHELIOMA 2004|||CYTOGENETIC PR|1|ug/kg/day|FLOW MICROSCOPY|||Y|PROXY|PATHOLOGIST 2|N|2|Visit_2|25|3|SCREENING|2020-10-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-05|P1Y2M10DT2H30M|BEFORE|2020-11-16|AFTER|2020-12-20
e|RS|aeddc1ed-545c-405e-b1f7-08131961f5ff|5|HEMARESP|Hematologic Response|KEAM BREAST CANCER 2013|[?]|NFIU|NR|1|mEq/mL|MRS||||SPOUSE|ADJUDICATOR 1|NA|3|Visit_3|40|1|TREATMENT|2020-11-14|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-07|P1Y2M10DT2H30M|AFTER|2020-11-27|BEFORE|2020-12-08
e|RS|aeddc1ed-545c-405e-b1f7-08131961f5ff|6|TRGRESP|Target Response|CHESON NON-HODGKINS LYMPHOMA 1999|||CHR|1|L/h|CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|||Y|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 2|NA|3|Visit_3|40|2|TREATMENT|2020-11-14|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-07|P1Y2M10DT2H30M|COINCIDENT|2020-11-04|COINCIDENT|2020-12-24
e|RS|aeddc1ed-545c-405e-b1f7-08131961f5ff|7|CPRFSTAT|Clinical Performance Status|KUKER LYMPHOMA 2005|[?]|10^3 organisms/g|SD|1|uV2|WHOLE GENOME SEQUENCING||Y||PROXY|DERMATOLOGIST|U|4|Visit_4|65|6|TREATMENT|2020-12-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-05|P1Y2M10DT2H30M|UNKNOWN|2020-10-10|AFTER|2021-01-12
e|RS|aeddc1ed-545c-405e-b1f7-08131961f5ff|8|CLINRESP|Clinical Response|CHOLLET BREAST CANCER 2002|[?]|10^6/hpf|pCR|1|L/s/kPa|NUCLEIC ACID BASED METHOD|Y|||STUDY SUBJECT|RATER 1|Y|4|Visit_4|65|5|TREATMENT|2020-12-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-05|P1Y2M10DT2H30M|UNKNOWN|2020-11-16|ONGOING|2021-01-06
e|RS|aeddc1ed-545c-405e-b1f7-08131961f5ff|9|PATHRESP|Pathologic Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|log10 CFU/g|NOT ALL EVALUATED|1|Log10 ELISA unit/dose|TELLER ACUITY CARDS|Y|Y||PARENT|READER 1|NA|5|Visit_5|90|5|FOLLOW-UP|2021-01-03|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-05|P1Y2M10DT2H30M|AFTER|2021-01-12|ONGOING|2021-01-13
e|RS|aeddc1ed-545c-405e-b1f7-08131961f5ff|10|MOLRESP|Molecular Response|PERCIST|[?]|cpm|PR|1|pt_us|IMMUNOPRECIPITATION||||GUARDIAN|RADIOLOGIST 2|N|5|Visit_5|90|6|SCREENING|2021-01-03|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-05|P1Y2M10DT2H30M|AFTER|2020-11-24|BEFORE|2020-12-19
e|RS|3effe272-6a68-4163-a4f3-bd269af6061c|1|DRCRIND|Disease Recurrence Indicator|PRINCE TCELL LYMPHOMA 2010|||CR-CT|1|K|ELECTROCHEMILUMINESCENCE IMMUNOASSAY|||Y|ADJUDICATOR|ENDOCRINOLOGIST|N|1|Visit_1|10|1|SCREENING|2021-01-15|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-29|P1Y2M10DT2H30M|COINCIDENT|2021-03-12|BEFORE|2021-04-02
e|RS|3effe272-6a68-4163-a4f3-bd269af6061c|2|SFTSRESP|Soft Tissue Response|MONTSERRAT CLL 1989|[?]|10^9/L|PD|1|Pa|MICROBIAL CONCENTRATION||Y||CHILD|ADJUDICATOR 3|NA|1|Visit_1|10|2|SCREENING|2021-01-15|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-29|P1Y2M10DT2H30M|AFTER|2021-01-24|ONGOING|2021-02-23
e|RS|3effe272-6a68-4163-a4f3-bd269af6061c|3|ANATRESP|Anatomic Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|U/dL|MINOR PATHOLOGIC RESPONSE|1|PFU/mL|ISHIHARA COLOR PLATES||||CLINICAL RESEARCH COORDINATOR|FORENSIC PATHOLOGIST|Y|2|Visit_2|25|7|TREATMENT|2021-01-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-23|P1Y2M10DT2H30M|BEFORE|2021-02-15|ONGOING|2021-03-27
e|RS|3effe272-6a68-4163-a4f3-bd269af6061c|4|BMIVLIND|Bone Marrow Involvement Indicator|MURPHY PROSTATE CANCER 1980|[?]|L/h|CYTOGENETIC MINOR RESPONSE|1|ug/L|DC SHEATH FLOW||Y||CAREGIVER|RADIOLOGIST|Y|2|Visit_2|25|6|SCREENING|2021-01-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-23|P1Y2M10DT2H30M|UNKNOWN|2021-03-29|BEFORE|2021-04-09
e|RS|3effe272-6a68-4163-a4f3-bd269af6061c|5|NEWLWIND|New Lesion Worsening Indicator|PCWG SCHER PROSTATE CANCER 2016|||cPR|1|um/s|TURBIDIMETRY|||Y|NON-HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|NA|3|Visit_3|40|6|TREATMENT|2021-02-14|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-02|P1Y2M10DT2H30M|AFTER|2021-01-30|AFTER|2021-02-12
e|RS|3effe272-6a68-4163-a4f3-bd269af6061c|6|DRCRIND|Disease Recurrence Indicator|IRANO 2015|||NON-CR/NON-PD|1|10^12 IU/L|HPLC-FL|||Y|DOMESTIC PARTNER|RATER|Y|3|Visit_3|40|7|TREATMENT|2021-02-14|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-02|P1Y2M10DT2H30M|AFTER|2021-03-17|AFTER|2021-04-03
e|RS|3effe272-6a68-4163-a4f3-bd269af6061c|7|NEWLWIND|New Lesion Worsening Indicator|AJCC V7|||CYTOGENETIC MINIMAL RESPONSE|1|TAMPON|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI|Y||Y|CHILD|RATER|Y|4|Visit_4|65|3|WASHOUT|2021-03-11|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-21|P1Y2M10DT2H30M|AFTER|2021-01-31|COINCIDENT|2021-02-16
e|RS|3effe272-6a68-4163-a4f3-bd269af6061c|8|CYTORESP|Cytogenetic Response|MONTSERRAT CLL 1989|[?]|10^3 CFU/mL|PSEUDOPROGRESSION|1|GPL U|RADIAL IMMUNODIFFUSION||Y||FAMILY MEMBER|HEMATOLOGIST|Y|4|Visit_4|65|5|SCREENING|2021-03-11|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-21|P1Y2M10DT2H30M|UNKNOWN|2021-04-14|BEFORE|2021-04-15
e|RS|3effe272-6a68-4163-a4f3-bd269af6061c|9|MNPTHIND|Minor Pathological Response Indicator|KEAM BREAST CANCER 2013|[?]|ag|PDu|1|ug/m2|SLIT LAMP PHOTOGRAPHY||||CHILD|FORENSIC PATHOLOGIST|NA|5|Visit_5|90|7|WASHOUT|2021-04-05|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-04|P1Y2M10DT2H30M|COINCIDENT|2021-02-06|COINCIDENT|2021-03-31
e|RS|3effe272-6a68-4163-a4f3-bd269af6061c|10|MRDRESP|Minimal Residual Disease Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|U/animal|PARTIAL MORPHOLOGIC RESPONSE|1|BLOCKS|PH METER MEASUREMENT METHOD||Y||SIBLING|ADJUDICATOR|U|5|Visit_5|90|6|SCREENING|2021-04-05|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-04|P1Y2M10DT2H30M|UNKNOWN|2021-01-17|AFTER|2021-02-28
e|RS|8153c765-a92a-4b0f-9ef3-6ca925337f54|1|CPRFSTAT|Clinical Performance Status|MONTSERRAT CLL 1989|[?]|mJoule/cm2|COMPLETE MRD RESPONSE|1|TCID 50/dose|CALIPER MEASUREMENT METHOD|Y|Y||INVESTIGATOR|PEDIATRIC NEUROLOGIST|U|1|Visit_1|10|6|TREATMENT|2020-09-29|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-03|P1Y2M10DT2H30M|UNKNOWN|2020-10-12|BEFORE|2020-12-24
e|RS|8153c765-a92a-4b0f-9ef3-6ca925337f54|2|BESTRESP|Best Overall Response|AJCC V7|[?]|Bq|PR|1|DIOPTER|COMPLEMENT FIXATION||||PROXY|MICROSCOPIST 1|U|1|Visit_1|10|7|TREATMENT|2020-09-29|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-03|P1Y2M10DT2H30M|BEFORE|2020-10-19|AFTER|2020-11-06
e|RS|8153c765-a92a-4b0f-9ef3-6ca925337f54|3|METSIND|Metastatic Indicator|WOLCHOK SOLID TUMORS 2009|[?]|10^6 CFU/g|CHR|1|deg2|WHOLE EXOME SEQUENCING|Y|Y||HEALTH CARE PROFESSIONAL|UROLOGIST|U|2|Visit_2|25|7|WASHOUT|2020-10-14|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-15|P1Y2M10DT2H30M|UNKNOWN|2020-12-17|BEFORE|2020-12-26
e|RS|8153c765-a92a-4b0f-9ef3-6ca925337f54|4|BMIVLIND|Bone Marrow Involvement Indicator|LEE LUNG CANCER 2011|[?]|FEU|QUANTIFIABLE MRD POSITIVITY|1|min/day|WEBER GREEN STAIN||||FRIEND|OPTOMETRIST|NA|2|Visit_2|25|7|FOLLOW-UP|2020-10-14|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-15|P1Y2M10DT2H30M|COINCIDENT|2020-12-21|BEFORE|2020-12-25
e|RS|8153c765-a92a-4b0f-9ef3-6ca925337f54|5|PATHRESP|Pathologic Response|EBMT BLADE MYELOMA 1998|[?]|uCi|SMD|1|mL/dose|SINGLE-SLICE SPIRAL CT||||ADJUDICATOR|RATER|U|3|Visit_3|40|6|SCREENING|2020-10-29|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-22|P1Y2M10DT2H30M|AFTER|2020-11-27|AFTER|2020-12-02
e|RS|8153c765-a92a-4b0f-9ef3-6ca925337f54|6|NEWLWIND|New Lesion Worsening Indicator|BRUGGEMANN MRD 2010|[?]|mCi/L|CA125 50% RESPONSE|1|WAFER|ULTRASONOGRAPHIC ELASTOGRAPHY||Y||SIGNIFICANT OTHER|RATER 1|N|3|Visit_3|40|4|TREATMENT|2020-10-29|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-22|P1Y2M10DT2H30M|UNKNOWN|2020-12-21|COINCIDENT|2020-12-26
e|RS|8153c765-a92a-4b0f-9ef3-6ca925337f54|7|NEWLWIND|New Lesion Worsening Indicator|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|||iUPD|1|ug/min|IMMUNOFLUORESCENT STAIN||Y|Y|SIGNIFICANT OTHER|RADIOLOGIST 1|Y|4|Visit_4|65|4|FOLLOW-UP|2020-11-23|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-04|P1Y2M10DT2H30M|COINCIDENT|2020-12-16|COINCIDENT|2020-12-26
e|RS|8153c765-a92a-4b0f-9ef3-6ca925337f54|8|SYMPTDTR|Symptomatic Deterioration|PCWG SCHER PROSTATE CANCER 2016|[?]|mmol|NON-PD|1|Rad|WHOLE GENOME SEQUENCING||Y||CLINICAL STUDY SPONSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|4|Visit_4|65|7|TREATMENT|2020-11-23|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-04|P1Y2M10DT2H30M|COINCIDENT|2020-12-14|BEFORE|2020-12-19
e|RS|8153c765-a92a-4b0f-9ef3-6ca925337f54|9|SYMPTDTR|Symptomatic Deterioration|BLAZER COLORECTAL CANCER 2008|[?]|EU|iCR|1|mMU/mL|AGAR PROPORTION||||SPOUSE|HEMATOLOGIST|N|5|Visit_5|90|6|FOLLOW-UP|2020-12-18|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-20|P1Y2M10DT2H30M|BEFORE|2020-12-07|BEFORE|2020-12-09
e|RS|8153c765-a92a-4b0f-9ef3-6ca925337f54|10|BMIVLIND|Bone Marrow Involvement Indicator|KUMAR IMWG 2016|[?]|10^6 organisms|HI-E|1|U/mg|APPLANATION TONOMETRY||||NON-HEALTH CARE PROFESSIONAL|RATER|Y|5|Visit_5|90|1|SCREENING|2020-12-18|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-20|P1Y2M10DT2H30M|UNKNOWN|2020-12-04|COINCIDENT|2020-12-23
e|RS|8d27cdcf-768e-4630-95b5-da554f6f3b56|1|RDIORESP|Radiologic Response|IRANO 2015|[?]|mm/min|cCR|1|USP U|SMEAR||||CLINICAL STUDY SPONSOR|PATHOLOGIST|U|1|Visit_1|10|2|FOLLOW-UP|2020-10-30|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-11|P1Y2M10DT2H30M|AFTER|2020-12-27|AFTER|2021-01-04
e|RS|8d27cdcf-768e-4630-95b5-da554f6f3b56|2|CPRFSTAT|Clinical Performance Status|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|kBq/uL|CR-CT|1|pmol/dL|PET/CT SCAN||Y||INTERVIEWER|PATHOLOGIST|N|1|Visit_1|10|6|TREATMENT|2020-10-30|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-11|P1Y2M10DT2H30M|COINCIDENT|2020-10-28|BEFORE|2020-11-01
e|RS|8d27cdcf-768e-4630-95b5-da554f6f3b56|3|NTNERESP|Non-Target Non-Enhancing Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|cm H2O|MINOR PATHOLOGIC RESPONSE|1|U|ENZYMATIC COLORIMETRY||||PROXY|ONCOLOGIST 2|N|2|Visit_2|25|7|SCREENING|2020-11-14|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-08|P1Y2M10DT2H30M|COINCIDENT|2020-11-18|COINCIDENT|2020-12-19
e|RS|8d27cdcf-768e-4630-95b5-da554f6f3b56|4|METSIND|Metastatic Indicator|EUROPEAN LEUKEMIANET BACCARANI CML 2006|||PD/RELAPSE AFTER HI|1|kcal|TOTAL BODY IRRADIATION|||Y|CLINICAL RESEARCH ASSOCIATE|OPHTHALMOLOGIST|Y|2|Visit_2|25|2|TREATMENT|2020-11-14|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-08|P1Y2M10DT2H30M|AFTER|2020-12-21|BEFORE|2021-01-08
e|RS|8d27cdcf-768e-4630-95b5-da554f6f3b56|5|CLINRESP|Clinical Response|BRUGGEMANN MRD 2010|||PSA PROGRESSION|1|SACHET|ALCIAN BLUE STAIN||Y|Y|FRIEND|PHYSIOTHERAPIST|Y|3|Visit_3|40|2|WASHOUT|2020-11-29|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-22|P1Y2M10DT2H30M|UNKNOWN|2020-12-23|ONGOING|2021-01-07
e|RS|8d27cdcf-768e-4630-95b5-da554f6f3b56|6|HEMARESP|Hematologic Response|SHINDOH COLORECTAL CANCER 2013|[?]|amol|WORSENED|1|ug/g/h|CALCULATION||||STUDY SUBJECT|RADIOLOGIST 2|U|3|Visit_3|40|4|TREATMENT|2020-11-29|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-22|P1Y2M10DT2H30M|UNKNOWN|2021-01-26|COINCIDENT|2021-01-27
e|RS|8d27cdcf-768e-4630-95b5-da554f6f3b56|7|SPLNRESP|Spleen Response|SACT|[?]|mN|nPR|1|POUCH|MICROARRAY||||HEALTH CARE PROFESSIONAL|READER 3|NA|4|Visit_4|65|4|TREATMENT|2020-12-24|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-29|P1Y2M10DT2H30M|BEFORE|2020-10-27|COINCIDENT|2020-10-29
e|RS|8d27cdcf-768e-4630-95b5-da554f6f3b56|8|MJPTHIND|Major Pathological Response Indicator|UNSPECIFIED|[?]|uCi|UNFAVORABLE RESPONSE|1|mmol/kg|LINE PROBE ASSAY||||CAREGIVER|ONCOLOGIST|Y|4|Visit_4|65|4|TREATMENT|2020-12-24|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-29|P1Y2M10DT2H30M|BEFORE|2020-12-24|ONGOING|2020-12-30
e|RS|8d27cdcf-768e-4630-95b5-da554f6f3b56|9|TRGRESP|Target Response|NCCN ALL MRD 2014|[?]|kPa/L/sec|CYTOGENETIC PR|1|mL/kg/h|WRIGHT-GIEMSA STAIN||Y||ADJUDICATOR|ENDOCRINOLOGIST|Y|5|Visit_5|90|7|TREATMENT|2021-01-18|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-23|P1Y2M10DT2H30M|AFTER|2021-01-04|ONGOING|2021-01-26
e|RS|8d27cdcf-768e-4630-95b5-da554f6f3b56|10|MRDRESP|Minimal Residual Disease Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|IU/g Hb|MRD NEGATIVITY|1|dram|NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY||||CLINICAL RESEARCH ASSOCIATE|CLINICAL PATHOLOGIST|N|5|Visit_5|90|6|TREATMENT|2021-01-18|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-23|P1Y2M10DT2H30M|COINCIDENT|2020-10-28|COINCIDENT|2020-12-20
e|RS|5c2791ff-aaf6-413f-9827-6e97e2273388|1|ANATRESP|Anatomic Response|KUMAR IMWG 2016|[?]|BE/mL|nPR|1|/LPF|JAFFE REACTION||||FRIEND|RADIOLOGIST 1|Y|1|Visit_1|10|3|TREATMENT|2020-09-06|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-05|P1Y2M10DT2H30M|COINCIDENT|2020-10-04|BEFORE|2020-10-11
e|RS|5c2791ff-aaf6-413f-9827-6e97e2273388|2|NTLWIND|Non-Target Lesion Worsening Indicator|RAJKUMAR MYELOMA 2011|||MR|1|% INHIBITION|ENDPOINT DILUTION ASSAY|Y||Y|ADJUDICATOR|RATER 2|Y|1|Visit_1|10|1|TREATMENT|2020-09-06|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-05|P1Y2M10DT2H30M|COINCIDENT|2020-11-04|COINCIDENT|2020-12-04
e|RS|5c2791ff-aaf6-413f-9827-6e97e2273388|3|NTERESP|Non-Target Enhancing Response|LUGANO CLASSIFICATION|||WORSENED|1|dmol|ANGIOGRAPHY|Y||Y|HEALTH CARE PROFESSIONAL|NEUROLOGIST|U|2|Visit_2|25|1|TREATMENT|2020-09-21|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-10|P1Y2M10DT2H30M|AFTER|2020-11-06|AFTER|2020-12-01
e|RS|5c2791ff-aaf6-413f-9827-6e97e2273388|4|NTERESP|Non-Target Enhancing Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|m2|iSD|1|DIOPTER|ICP-MS||||INDEPENDENT ASSESSOR|OPHTHALMOLOGIST|NA|2|Visit_2|25|3|TREATMENT|2020-09-21|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-10|P1Y2M10DT2H30M|COINCIDENT|2020-09-12|AFTER|2020-09-13
e|RS|5c2791ff-aaf6-413f-9827-6e97e2273388|5|NTRGRESP|Non-target Response|RECIST 1.0|[?]|uIU/dL|SD|1|L/day|CARDIAC THERMODILUTION||Y||STUDY SUBJECT|RADIOLOGIST|NA|3|Visit_3|40|6|FOLLOW-UP|2020-10-06|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-14|P1Y2M10DT2H30M|BEFORE|2020-11-24|COINCIDENT|2020-11-30
e|RS|5c2791ff-aaf6-413f-9827-6e97e2273388|6|ANATRESP|Anatomic Response|RANO ELLINGSON 2017|[?]|/min|nPR|1|APL U|MICROSCOPY|Y|||SIBLING|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|3|Visit_3|40|4|WASHOUT|2020-10-06|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-14|P1Y2M10DT2H30M|COINCIDENT|2020-09-07|AFTER|2020-10-18
e|RS|5c2791ff-aaf6-413f-9827-6e97e2273388|7|NTRGRESP|Non-target Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|mkat|MRD RELAPSE|1|10^9/g|U-HPLC/MS/MS|Y|||FRIEND|READER 3|N|4|Visit_4|65|5|TREATMENT|2020-10-31|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-30|P1Y2M10DT2H30M|AFTER|2020-09-03|COINCIDENT|2020-09-07
e|RS|5c2791ff-aaf6-413f-9827-6e97e2273388|8|PATHRESP|Pathologic Response|iRECIST|[?]|mL|QUANTIFIABLE MRD POSITIVITY|1|MPL U|SEQUENCING|Y|||FAMILY MEMBER|RADIOLOGIST 2|Y|4|Visit_4|65|7|TREATMENT|2020-10-31|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-30|P1Y2M10DT2H30M|AFTER|2020-10-18|COINCIDENT|2020-10-19
e|RS|5c2791ff-aaf6-413f-9827-6e97e2273388|9|CPRFSTAT|Clinical Performance Status|MRANO VAN DEN BENT GLIOMA 2011|||CYTOGENETIC MINOR RESPONSE|1|uOsm|BALLPOINT PEN TECHNIQUE|||Y|INTERVIEWER|MICROSCOPIST|Y|5|Visit_5|90|5|SCREENING|2020-11-25|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-10|P1Y2M10DT2H30M|COINCIDENT|2020-11-19|COINCIDENT|2020-11-29
e|RS|5c2791ff-aaf6-413f-9827-6e97e2273388|10|MNPTHIND|Minor Pathological Response Indicator|IRANO 2015|[?]|mL/animal/wk|PMR|1|PIPE|CONTRAST ENHANCED CT SCAN|Y|||STUDY SUBJECT|READER 1|U|5|Visit_5|90|7|SCREENING|2020-11-25|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-10|P1Y2M10DT2H30M|AFTER|2020-09-17|COINCIDENT|2020-09-26
e|RS|b336d8c2-7bca-404e-aea3-5148d559ea99|1|MJPTHIND|Major Pathological Response Indicator|NCIWG CHESON CLL 1996|[?]|ug/L FEU|SD|1|days/wk|SCINTIGRAPHY||||HEALTH CARE PROFESSIONAL|INTERNIST|N|1|Visit_1|10|6|WASHOUT|2020-09-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-22|P1Y2M10DT2H30M|BEFORE|2020-10-05|ONGOING|2020-11-03
e|RS|b336d8c2-7bca-404e-aea3-5148d559ea99|2|TMRESP|Tumor Marker Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|EP U|WORSENED|1|dpm/mL|JAFFE REACTION||||INVESTIGATOR|PATHOLOGIST|Y|1|Visit_1|10|6|FOLLOW-UP|2020-09-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-22|P1Y2M10DT2H30M|AFTER|2020-10-03|BEFORE|2020-10-21
e|RS|b336d8c2-7bca-404e-aea3-5148d559ea99|3|DRCRIND|Disease Recurrence Indicator|KEAM BREAST CANCER 2013|[?]|mL/kg/h|CHR|1|IU/g|BRDU CELLULAR PROLIFERATION ASSAY||||ADJUDICATION COMMITTEE|MICROSCOPIST 3|N|2|Visit_2|25|6|SCREENING|2020-10-04|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-08|P1Y2M10DT2H30M|UNKNOWN|2020-11-30|COINCIDENT|2020-12-02
e|RS|b336d8c2-7bca-404e-aea3-5148d559ea99|4|BESTRESP|Best Overall Response|IWG CHESON MDS 2000|[?]|IU/dL|mCR|1|mL/cage/wk|REAL-TIME POLYMERASE CHAIN REACTION ASSAY||Y||PROXY|READER|NA|2|Visit_2|25|2|SCREENING|2020-10-04|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-08|P1Y2M10DT2H30M|BEFORE|2020-12-11|ONGOING|2020-12-12
e|RS|b336d8c2-7bca-404e-aea3-5148d559ea99|5|NEWLWIND|New Lesion Worsening Indicator|MURPHY PROSTATE CANCER 1980|[?]|1/(s*kPa)|MRD PERSISTENCE|1|CCID 50/mL|ELECTROGASTROGRAPHY||||ADJUDICATOR|FORENSIC PATHOLOGIST|U|3|Visit_3|40|3|FOLLOW-UP|2020-10-19|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-31|P1Y2M10DT2H30M|AFTER|2020-12-03|COINCIDENT|2020-12-11
e|RS|b336d8c2-7bca-404e-aea3-5148d559ea99|6|NEWLIND|New Lesion Indicator|KEAM BREAST CANCER 2013|[?]|ms2|CMR|1|kg/cm|MYELOPEROXIDASE STAIN||||VENDOR|PATHOLOGIST 1|NA|3|Visit_3|40|3|TREATMENT|2020-10-19|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-31|P1Y2M10DT2H30M|UNKNOWN|2020-09-23|BEFORE|2020-10-07
e|RS|b336d8c2-7bca-404e-aea3-5148d559ea99|7|LIVRRESP|Liver Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|ppm|NED|1|ug/dL|DYNAMIC CONTRAST ENHANCED MRI||||HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|U|4|Visit_4|65|7|SCREENING|2020-11-13|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-03|P1Y2M10DT2H30M|COINCIDENT|2020-10-17|AFTER|2020-11-07
e|RS|b336d8c2-7bca-404e-aea3-5148d559ea99|8|RDIORESP|Radiologic Response|PCWG SCHER PROSTATE CANCER 2008|[?]|10^3 DNA copies/mL|FAVORABLE RESPONSE|1|mCi/kg|HILLMEN COLOR CHART||||HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|U|4|Visit_4|65|6|TREATMENT|2020-11-13|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-03|P1Y2M10DT2H30M|BEFORE|2020-10-09|AFTER|2020-10-18
e|RS|b336d8c2-7bca-404e-aea3-5148d559ea99|9|ANATRESP|Anatomic Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|||MORPHOLOGIC CR|1|CAPSULE|FARR ASSAY|Y||Y|CLINICAL STUDY SPONSOR|READER 2|NA|5|Visit_5|90|7|TREATMENT|2020-12-08|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-14|P1Y2M10DT2H30M|AFTER|2020-11-10|COINCIDENT|2020-12-13
e|RS|b336d8c2-7bca-404e-aea3-5148d559ea99|10|PATHRESP|Pathologic Response|HAMAOKA BREAST CANCER 2010|[?]|L/min/m2|INCREASED|1|CCID 50/dose|TRIPLE-PHASE MRI SCAN||Y||CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 1|NA|5|Visit_5|90|3|TREATMENT|2020-12-08|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-14|P1Y2M10DT2H30M|AFTER|2020-09-26|ONGOING|2020-11-07
e|RS|702b2f8f-63b9-44c1-a46d-1a41bc837c32|1|CPRFSTAT|Clinical Performance Status|GUPPY OVARIAN CANCER 2002|[?]|PACK|MORPHOLOGIC CRi|1|ug/mol|FLUORESCENCE ANGIOGRAPHY|Y|||PARENT|READER|NA|1|Visit_1|10|6|WASHOUT|2020-06-17|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-30|P1Y2M10DT2H30M|COINCIDENT|2020-06-25|ONGOING|2020-07-12
e|RS|702b2f8f-63b9-44c1-a46d-1a41bc837c32|2|BONERESP|Bone Response|BRUGGEMANN MRD 2010|[?]|KIT|IMMUNOPHENOTYPIC CR|1|10^6 CFU/mL|ELECTRICAL IMPEDANCE MYOGRAPHY||Y||SPOUSE|MICROSCOPIST 1|NA|1|Visit_1|10|2|TREATMENT|2020-06-17|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-30|P1Y2M10DT2H30M|BEFORE|2020-08-01|AFTER|2020-08-15
e|RS|702b2f8f-63b9-44c1-a46d-1a41bc837c32|3|NEWLIND|New Lesion Indicator|GUILHOT CML 2007|||NOT ALL EVALUATED|1|%/min|PLAQUE REDUCTION NEUTRALIZATION ASSAY|||Y|PROXY|ADJUDICATOR 1|N|2|Visit_2|25|5|TREATMENT|2020-07-02|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-18|P1Y2M10DT2H30M|COINCIDENT|2020-07-20|AFTER|2020-09-04
e|RS|702b2f8f-63b9-44c1-a46d-1a41bc837c32|4|NTLWIND|Non-Target Lesion Worsening Indicator|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|mm/h|NOT ALL EVALUATED|1|Gy/min|FUNCTIONAL MRI||||SPOUSE|CARDIOLOGIST|N|2|Visit_2|25|6|TREATMENT|2020-07-02|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-18|P1Y2M10DT2H30M|UNKNOWN|2020-06-18|COINCIDENT|2020-07-21
e|RS|702b2f8f-63b9-44c1-a46d-1a41bc837c32|5|PATHRESP|Pathologic Response|DURIE MULTIPLE MYELOMA 2006|||sCR|1|SUPPOSITORY|WHOLE TRANSCRIPTOME SEQUENCING|||Y|GUARDIAN|ONCOLOGIST|U|3|Visit_3|40|2|WASHOUT|2020-07-17|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-07|P1Y2M10DT2H30M|COINCIDENT|2020-07-17|ONGOING|2020-09-08
e|RS|702b2f8f-63b9-44c1-a46d-1a41bc837c32|6|METBRESP|Metabolic Response|HARTMANN GERM CELL CANCER 2002|[?]|ng/dL|NON-QUANTIFIABLE MRD POSITIVITY|1|damol/L|COMPUTERIZED CORNEAL TOPOGRAPHY||||SIBLING|RATER 2|N|3|Visit_3|40|7|FOLLOW-UP|2020-07-17|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-07|P1Y2M10DT2H30M|COINCIDENT|2020-07-08|BEFORE|2020-07-27
e|RS|702b2f8f-63b9-44c1-a46d-1a41bc837c32|7|BONERESP|Bone Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|Hz/s|PR|1|sec|LASER CAPTURE MICRODISSECTION|Y|||SIGNIFICANT OTHER|NEUROLOGIST|U|4|Visit_4|65|7|TREATMENT|2020-08-11|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-12|P1Y2M10DT2H30M|COINCIDENT|2020-09-02|BEFORE|2020-09-05
e|RS|702b2f8f-63b9-44c1-a46d-1a41bc837c32|8|RDIORESP|Radiologic Response|NCIWG CHESON CLL 1996|[?]|10^6 organisms|CYTOGENETIC PR|1|U/10^12 RBC|FLOW MICROSCOPY||||CHILD|READER 1|NA|4|Visit_4|65|6|FOLLOW-UP|2020-08-11|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-12|P1Y2M10DT2H30M|COINCIDENT|2020-08-05|BEFORE|2020-09-10
e|RS|702b2f8f-63b9-44c1-a46d-1a41bc837c32|9|HEMARESP|Hematologic Response|JACINTO CERVICAL CANCER 2007|[?]|Coulomb|DECREASED|1|BOWL|FLUORIMETRY||||FAMILY MEMBER|CARDIOLOGIST|NA|5|Visit_5|90|4|TREATMENT|2020-09-05|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-17|P1Y2M10DT2H30M|BEFORE|2020-09-09|COINCIDENT|2020-09-10
e|RS|702b2f8f-63b9-44c1-a46d-1a41bc837c32|10|TRGRESP|Target Response|WHO BREAST CANCER 2006|[?]|umol|PARTIAL MORPHOLOGIC RESPONSE|1|LB|SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY|Y|||INVESTIGATOR|RADIOLOGIST 1|U|5|Visit_5|90|6|TREATMENT|2020-09-05|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-17|P1Y2M10DT2H30M|COINCIDENT|2020-07-17|AFTER|2020-07-20
e|RS|1261eee1-f073-4419-b0b7-28abd0ec1513|1|MJPTHIND|Major Pathological Response Indicator|BRUGGEMANN MRD 2010|[?]|Enzyme U/L|PMR|1|/2000 RBC|IODINE STAIN||||FAMILY MEMBER|PATHOLOGIST|N|1|Visit_1|10|3|FOLLOW-UP|2020-10-01|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-26|P1Y2M10DT2H30M|UNKNOWN|2020-11-09|BEFORE|2020-11-18
e|RS|1261eee1-f073-4419-b0b7-28abd0ec1513|2|MNPTHIND|Minor Pathological Response Indicator|AJCC V8|[?]|U/g Hb|NON-CR/NON-PD|1|umol/day|PANENDOSCOPY|Y|Y||STUDY SUBJECT|RADIOLOGIST 1|NA|1|Visit_1|10|3|WASHOUT|2020-10-01|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-26|P1Y2M10DT2H30M|BEFORE|2020-10-29|AFTER|2020-12-17
e|RS|1261eee1-f073-4419-b0b7-28abd0ec1513|3|MNPTHIND|Minor Pathological Response Indicator|AJCC V8|[?]|umol|iCR|1|Newton|CONTRAST ENHANCED MRI||||FAMILY MEMBER|READER 1|U|2|Visit_2|25|6|FOLLOW-UP|2020-10-16|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-07|P1Y2M10DT2H30M|COINCIDENT|2020-12-14|AFTER|2020-12-20
e|RS|1261eee1-f073-4419-b0b7-28abd0ec1513|4|SYMPTDTR|Symptomatic Deterioration|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|10^9/g|NON-PD|1|mg|POPULATION SEQUENCING||||FRIEND|ONCOLOGIST|Y|2|Visit_2|25|3|TREATMENT|2020-10-16|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-07|P1Y2M10DT2H30M|BEFORE|2020-12-18|BEFORE|2020-12-21
e|RS|1261eee1-f073-4419-b0b7-28abd0ec1513|5|MRDRESP|Minimal Residual Disease Response|RECICL|||NED|1|lm|ELASTOGRAPHY|Y||Y|CLINICAL RESEARCH COORDINATOR|READER 1|Y|3|Visit_3|40|1|FOLLOW-UP|2020-10-31|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-29|P1Y2M10DT2H30M|BEFORE|2020-11-03|COINCIDENT|2020-11-08
e|RS|1261eee1-f073-4419-b0b7-28abd0ec1513|6|CLINRESP|Clinical Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|ug/L DDU|CA125 50% RESPONSE|1|mm/sec|IMPEDANCE CONDUCTIVITY||Y||FRIEND|PEDIATRIC NEUROLOGIST|NA|3|Visit_3|40|2|TREATMENT|2020-10-31|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-29|P1Y2M10DT2H30M|AFTER|2020-10-02|COINCIDENT|2020-11-02
e|RS|1261eee1-f073-4419-b0b7-28abd0ec1513|7|LIVRRESP|Liver Response|PCWG SCHER PROSTATE CANCER 2008|||NON-QUANTIFIABLE MRD POSITIVITY|1|10^3 CFU|ELLA|||Y|ADJUDICATION COMMITTEE|NEUROLOGIST 2|U|4|Visit_4|65|5|FOLLOW-UP|2020-11-25|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-24|P1Y2M10DT2H30M|COINCIDENT|2020-12-19|COINCIDENT|2020-12-25
e|RS|1261eee1-f073-4419-b0b7-28abd0ec1513|8|STRUSTAT|Steroid Use Status|MRECIST LENCIONI LIVER CANCER 2010|[?]|psi|QUANTIFIABLE MRD POSITIVITY|1|SYRINGE|AGAR PROPORTION||||PROXY|NEUROLOGIST|U|4|Visit_4|65|1|FOLLOW-UP|2020-11-25|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-24|P1Y2M10DT2H30M|AFTER|2020-11-02|COINCIDENT|2020-11-19
e|RS|1261eee1-f073-4419-b0b7-28abd0ec1513|9|SPLNRESP|Spleen Response|iRECIST|[?]|L|MRD PERSISTENCE|1|cd/m2|COMPUTERIZED CORNEAL TOPOGRAPHY||||FRIEND|RATER|N|5|Visit_5|90|3|TREATMENT|2020-12-20|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-12|P1Y2M10DT2H30M|COINCIDENT|2020-12-12|AFTER|2020-12-23
e|RS|1261eee1-f073-4419-b0b7-28abd0ec1513|10|SFTSRESP|Soft Tissue Response|KUKER LYMPHOMA 2005|[?]|log10 TCID 50/uL|HI-E|1|pmol/10^9 cells|ECHOCARDIOGRAPHY|Y|||NON-HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|U|5|Visit_5|90|4|WASHOUT|2020-12-20|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-12|P1Y2M10DT2H30M|BEFORE|2020-11-27|AFTER|2020-12-24
e|RS|46eefdf3-c314-4e61-963c-ce7f48c636e5|1|CPRFSTAT|Clinical Performance Status|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|BU/mL|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|POUCH|GC/MS|Y|Y||HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|Y|1|Visit_1|10|6|FOLLOW-UP|2020-12-29|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-31|P1Y2M10DT2H30M|COINCIDENT|2021-01-20|COINCIDENT|2021-02-18
e|RS|46eefdf3-c314-4e61-963c-ce7f48c636e5|2|NEWLIND|New Lesion Indicator|KUMAR IMWG 2016|[?]|EVENTS|RELAPSED DISEASE|1|DRUM|TURBIDIMETRY|Y|||PROXY|ONCOLOGIST|N|1|Visit_1|10|7|TREATMENT|2020-12-29|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-31|P1Y2M10DT2H30M|AFTER|2021-03-06|COINCIDENT|2021-03-16
e|RS|46eefdf3-c314-4e61-963c-ce7f48c636e5|3|NEWLPROG|New Lesion Progression|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|tuberculin unit/mL|PDu|1|10^5/hpf|PYROSEQUENCING||||PROXY|PATHOLOGIST 1|N|2|Visit_2|25|6|TREATMENT|2021-01-13|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-21|P1Y2M10DT2H30M|BEFORE|2021-03-13|COINCIDENT|2021-03-17
e|RS|46eefdf3-c314-4e61-963c-ce7f48c636e5|4|STRUSTAT|Steroid Use Status|EASL BRUIX LIVER CANCER 2001|[?]|deg|MORPHOLOGIC LEUKEMIA-FREE STATE|1|kPa|DC SHEATH FLOW||||GUARDIAN|INTERNIST|NA|2|Visit_2|25|7|TREATMENT|2021-01-13|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-21|P1Y2M10DT2H30M|COINCIDENT|2021-01-11|AFTER|2021-02-02
e|RS|46eefdf3-c314-4e61-963c-ce7f48c636e5|5|HEMARESP|Hematologic Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|mL/min|PSEUDOPROGRESSION|1|mL/beat|KLEIHAUER-BETKE||Y||GUARDIAN|READER 2|Y|3|Visit_3|40|5|TREATMENT|2021-01-28|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-24|P1Y2M10DT2H30M|AFTER|2021-01-12|AFTER|2021-03-10
e|RS|46eefdf3-c314-4e61-963c-ce7f48c636e5|6|NTRGRESP|Non-target Response|EBMT BLADE MYELOMA 1998|[?]|DDU|PR|1|10^6 CFU|INTERRUPTER TECHNIQUE||Y||ADJUDICATION COMMITTEE|PHYSIOTHERAPIST|Y|3|Visit_3|40|5|FOLLOW-UP|2021-01-28|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-24|P1Y2M10DT2H30M|AFTER|2021-03-26|BEFORE|2021-03-28
e|RS|46eefdf3-c314-4e61-963c-ce7f48c636e5|7|METSIND|Metastatic Indicator|EBMT BLADE MYELOMA 1998|[?]|TRANSDUCING UNIT|sCR|1|oz|IMMUNO-PET SCAN||||INDEPENDENT ASSESSOR|RATER 2|N|4|Visit_4|65|3|SCREENING|2021-02-22|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-06|P1Y2M10DT2H30M|AFTER|2021-01-25|AFTER|2021-03-16
e|RS|46eefdf3-c314-4e61-963c-ce7f48c636e5|8|CLINRESP|Clinical Response|MURPHY PROSTATE CANCER 1980|[?]|cmH2O*s/mL|PR WITH LYMPHOCYTOSIS|1|U/g/h|MS/MS||||FRIEND|RATER|N|4|Visit_4|65|4|FOLLOW-UP|2021-02-22|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-06|P1Y2M10DT2H30M|UNKNOWN|2021-01-19|COINCIDENT|2021-03-08
e|RS|46eefdf3-c314-4e61-963c-ce7f48c636e5|9|BMIVLIND|Bone Marrow Involvement Indicator|SHINDOH COLORECTAL CANCER 2013|||OPTIMAL MORPHOLOGIC RESPONSE|1|L/h/m2|VIRUS PLAQUE ASSAY|||Y|FAMILY MEMBER|FORENSIC PATHOLOGIST|N|5|Visit_5|90|2|TREATMENT|2021-03-19|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-18|P1Y2M10DT2H30M|BEFORE|2021-01-12|ONGOING|2021-01-27
e|RS|46eefdf3-c314-4e61-963c-ce7f48c636e5|10|METBRESP|Metabolic Response|RECIST 1.0|[?]|mL/(min*100mL)|MORPHOLOGIC CR|1|mg/g/h|VENTILATION PERFUSION LUNG SCAN||Y||SIBLING|ONCOLOGIST 1|N|5|Visit_5|90|1|FOLLOW-UP|2021-03-19|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-18|P1Y2M10DT2H30M|UNKNOWN|2021-02-20|COINCIDENT|2021-03-17
e|RS|f632159b-8c91-4f0d-81cb-e5b9195588c9|1|METBRESP|Metabolic Response|KUMAR IMWG 2016|||IMMUNOPHENOTYPIC CR|1|nU/cL|HPLC|Y|Y|Y|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 1|N|1|Visit_1|10|1|FOLLOW-UP|2021-01-12|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-25|P1Y2M10DT2H30M|UNKNOWN|2021-03-02|COINCIDENT|2021-04-07
e|RS|f632159b-8c91-4f0d-81cb-e5b9195588c9|2|MNPTHIND|Minor Pathological Response Indicator|AJCC V8|[?]|mL/100g/min|CA125 50% RESPONSE|1|mAmp|NEXT GENERATION SEQUENCING|Y|||NON-HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|N|1|Visit_1|10|6|SCREENING|2021-01-12|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-25|P1Y2M10DT2H30M|UNKNOWN|2021-03-27|AFTER|2021-04-05
e|RS|f632159b-8c91-4f0d-81cb-e5b9195588c9|3|MRPHRESP|Morphologic Response|HAMAOKA BREAST CANCER 2010|||CHR|1|log10 copies/mL|TRANSESOPHAGEAL ECHOCARDIOGRAPHY|||Y|ADJUDICATOR|NEUROLOGIST|N|2|Visit_2|25|2|TREATMENT|2021-01-27|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-20|P1Y2M10DT2H30M|AFTER|2021-01-11|ONGOING|2021-04-05
e|RS|f632159b-8c91-4f0d-81cb-e5b9195588c9|4|BESTRESP|Best Overall Response|KEAM BREAST CANCER 2013|[?]|10^4 CFU/mL|PMD|1|g/animal/day|VIRUS PLAQUE ASSAY|Y|||HEALTH CARE PROFESSIONAL|ONCOLOGIST|N|2|Visit_2|25|5|FOLLOW-UP|2021-01-27|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-20|P1Y2M10DT2H30M|COINCIDENT|2021-01-17|AFTER|2021-01-30
e|RS|f632159b-8c91-4f0d-81cb-e5b9195588c9|5|DRCRIND|Disease Recurrence Indicator|BURCOMBE BREAST CANCER 2005|[?]|IU/dL|MINOR PATHOLOGIC RESPONSE|1|L/s|CONTRAST ENHANCED MRI|Y|||STUDY SUBJECT|READER|U|3|Visit_3|40|3|TREATMENT|2021-02-11|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-16|P1Y2M10DT2H30M|COINCIDENT|2021-01-13|COINCIDENT|2021-04-08
e|RS|f632159b-8c91-4f0d-81cb-e5b9195588c9|6|TMRESP|Tumor Marker Response|RANO ELLINGSON 2017|[?]|pmol/g|MINOR PATHOLOGIC RESPONSE|1|/2000 RBC|QUANTITATIVE PERIPHERAL ANGIOGRAPHY||||HEALTH CARE PROFESSIONAL|RATER 2|U|3|Visit_3|40|7|SCREENING|2021-02-11|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-16|P1Y2M10DT2H30M|UNKNOWN|2021-02-11|COINCIDENT|2021-02-25
e|RS|f632159b-8c91-4f0d-81cb-e5b9195588c9|7|MRPHRESP|Morphologic Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|/VF|iPR|1|ug/mL/h|RADIOIMMUNOPRECIPITATION ASSAY|Y|||FRIEND|CLINICAL PATHOLOGIST|Y|4|Visit_4|65|7|TREATMENT|2021-03-08|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-07|P1Y2M10DT2H30M|BEFORE|2021-02-15|ONGOING|2021-03-10
e|RS|f632159b-8c91-4f0d-81cb-e5b9195588c9|8|NEWLWIND|New Lesion Worsening Indicator|PCWG BUBLEY PROSTATE CANCER 1999|[?]|Ci/ug|INCREASED|1|pg/dL|PHOTOMETRIC CLOT DETECTION|Y|||STUDY SUBJECT|PEDIATRIC NEUROLOGIST|NA|4|Visit_4|65|6|WASHOUT|2021-03-08|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-07|P1Y2M10DT2H30M|BEFORE|2021-03-14|BEFORE|2021-03-28
e|RS|f632159b-8c91-4f0d-81cb-e5b9195588c9|9|CPRFSTAT|Clinical Performance Status|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|/7.5 mL|CRi|1|mm/h|APPLANATION TONOMETRY|Y|||HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5|Visit_5|90|3|WASHOUT|2021-04-02|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-23|P1Y2M10DT2H30M|AFTER|2021-03-06|AFTER|2021-04-03
e|RS|f632159b-8c91-4f0d-81cb-e5b9195588c9|10|MRPHRESP|Morphologic Response|PERCIST|[?]|/200 HPFs|PR WITH LYMPHOCYTOSIS|1|lm|INCISION-INDUCED BLEEDING METHOD|Y|Y||CHILD|OPTOMETRIST|NA|5|Visit_5|90|7|FOLLOW-UP|2021-04-02|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-23|P1Y2M10DT2H30M|AFTER|2021-04-11|COINCIDENT|2021-04-12
e|RS|898a9d2f-338b-41bf-8ac0-c4a025481349|1|STRUSTAT|Steroid Use Status|HAMAOKA BREAST CANCER 2010|||RELAPSED DISEASE|1|cL|PALPATION|Y|Y|Y|CHILD|MICROSCOPIST 3|N|1|Visit_1|10|3|SCREENING|2020-05-24|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-15|P1Y2M10DT2H30M|BEFORE|2020-07-07|COINCIDENT|2020-08-09
e|RS|898a9d2f-338b-41bf-8ac0-c4a025481349|2|METBRESP|Metabolic Response|BURCOMBE BREAST CANCER 2005|[?]|log10 TCID 50/mL|CR-CT|1|mL/s|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY||Y||SIGNIFICANT OTHER|PATHOLOGIST 1|U|1|Visit_1|10|4|SCREENING|2020-05-24|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-15|P1Y2M10DT2H30M|BEFORE|2020-07-28|ONGOING|2020-08-05
e|RS|898a9d2f-338b-41bf-8ac0-c4a025481349|3|SYMPTDTR|Symptomatic Deterioration|CHESON LYMPHOMA 2008|[?]|mL/mmHg|NON-CR/NON-PD|1|U/m2/h|OPTICAL DENSITY MEASUREMENT|Y|||PROXY|ONCOLOGIST 1|N|2|Visit_2|25|5|TREATMENT|2020-06-08|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-16|P1Y2M10DT2H30M|AFTER|2020-06-20|AFTER|2020-07-01
e|RS|898a9d2f-338b-41bf-8ac0-c4a025481349|4|MJPTHIND|Major Pathological Response Indicator|PCWG SCHER PROSTATE CANCER 2008|[?]|GPL U|PSEUDORESPONSE|1|kIU|CYSTOMETRY|Y|||SIBLING|UROLOGIST|U|2|Visit_2|25|4|SCREENING|2020-06-08|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-16|P1Y2M10DT2H30M|COINCIDENT|2020-08-02|COINCIDENT|2020-08-19
e|RS|898a9d2f-338b-41bf-8ac0-c4a025481349|5|PATHRESP|Pathologic Response|CHOLLET BREAST CANCER 2002|[?]|mV|MORPHOLOGIC CR|1|pg|LAPAROSCOPY||||SIBLING|ONCOLOGIST|N|3|Visit_3|40|3|WASHOUT|2020-06-23|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-21|P1Y2M10DT2H30M|AFTER|2020-07-02|AFTER|2020-07-24
e|RS|898a9d2f-338b-41bf-8ac0-c4a025481349|6|SPLNRESP|Spleen Response|GUPPY OVARIAN CANCER 2002|[?]|GBq/ug|cPR|1|L/h|TWO-COLOR MICROARRAY||Y||ADJUDICATION COMMITTEE|DEVELOPMENTAL PSYCHOLOGIST|Y|3|Visit_3|40|4|TREATMENT|2020-06-23|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-21|P1Y2M10DT2H30M|BEFORE|2020-05-19|ONGOING|2020-08-06
e|RS|898a9d2f-338b-41bf-8ac0-c4a025481349|7|BMIVLIND|Bone Marrow Involvement Indicator|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|||UNFAVORABLE RESPONSE|1|BOLUS|GC/MS/MS|||Y|FRIEND|CLINICAL PATHOLOGIST|Y|4|Visit_4|65|6|SCREENING|2020-07-18|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-10|P1Y2M10DT2H30M|COINCIDENT|2020-06-06|ONGOING|2020-07-28
e|RS|898a9d2f-338b-41bf-8ac0-c4a025481349|8|STRUSTAT|Steroid Use Status|RECIST 1.0|[?]|keV|MR|1|10^6 IU/mL|ELECTROCHEMILUMINESCENCE IMMUNOASSAY|Y|Y||FRIEND|ONCOLOGIST|N|4|Visit_4|65|2|TREATMENT|2020-07-18|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-10|P1Y2M10DT2H30M|BEFORE|2020-07-17|BEFORE|2020-08-19
e|RS|898a9d2f-338b-41bf-8ac0-c4a025481349|9|MRDIND|Minimal Residual Disease Indicator|IWG CHESON MDS 2006|[?]|umol/L/min|MOLECULAR CR|1|mAnson U/mL|GRADIENT DIFFUSION||||CAREGIVER|DEVELOPMENTAL PSYCHOLOGIST|NA|5|Visit_5|90|7|TREATMENT|2020-08-12|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-23|P1Y2M10DT2H30M|UNKNOWN|2020-07-19|BEFORE|2020-08-09
e|RS|898a9d2f-338b-41bf-8ac0-c4a025481349|10|DRCRIND|Disease Recurrence Indicator|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|DRINK|MORPHOLOGIC CRi|1|IU/kg/h|ACRIDINE ORANGE STAIN|Y|||SIBLING|NEUROLOGIST|N|5|Visit_5|90|5|TREATMENT|2020-08-12|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-23|P1Y2M10DT2H30M|BEFORE|2020-07-22|BEFORE|2020-07-30
e|RS|db3824aa-375d-4e40-a14b-af0e4460914e|1|NEWLWIND|New Lesion Worsening Indicator|SHINDOH COLORECTAL CANCER 2013|[?]|C|MRD NEGATIVITY|1|L/h/m2|CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|Y|Y||SIBLING|ONCOLOGIST 1|U|1|Visit_1|10|3|FOLLOW-UP|2020-05-20|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-27|P1Y2M10DT2H30M|BEFORE|2020-06-19|COINCIDENT|2020-08-13
e|RS|db3824aa-375d-4e40-a14b-af0e4460914e|2|MJPTHIND|Major Pathological Response Indicator|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|10^9 CFU/g|CR-CT|1|log10 IU/mL|CONTRAST ENHANCED MRI||||CLINICAL RESEARCH COORDINATOR|NEUROLOGIST|NA|1|Visit_1|10|2|FOLLOW-UP|2020-05-20|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-27|P1Y2M10DT2H30M|AFTER|2020-07-15|COINCIDENT|2020-07-31
e|RS|db3824aa-375d-4e40-a14b-af0e4460914e|3|NTLWIND|Non-Target Lesion Worsening Indicator|CHESON LYMPHOMA 2008|[?]|10^3 CFU/mL|PARTIAL MORPHOLOGIC RESPONSE|1|U/m2/day|AMSLER GRID||||CAREGIVER|ONCOLOGIST|NA|2|Visit_2|25|2|WASHOUT|2020-06-04|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-07|P1Y2M10DT2H30M|AFTER|2020-05-21|ONGOING|2020-05-31
e|RS|db3824aa-375d-4e40-a14b-af0e4460914e|4|MNPTHIND|Minor Pathological Response Indicator|CHESON LYMPHOMA 2008|[?]|cm/s|OPTIMAL MORPHOLOGIC RESPONSE|1|lx|BRDU CELLULAR PROLIFERATION ASSAY|Y|Y||PROXY|ONCOLOGIST 2|Y|2|Visit_2|25|2|WASHOUT|2020-06-04|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-07|P1Y2M10DT2H30M|AFTER|2020-06-21|AFTER|2020-08-06
e|RS|db3824aa-375d-4e40-a14b-af0e4460914e|5|METSIND|Metastatic Indicator|JACINTO CERVICAL CANCER 2007|[?]|mL/100g/min|PSEUDORESPONSE|1|g/g/day|PERIPHERAL ANGIOGRAPHY|Y|||SPOUSE|DEVELOPMENTAL PSYCHOLOGIST|N|3|Visit_3|40|2|TREATMENT|2020-06-19|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-04|P1Y2M10DT2H30M|BEFORE|2020-05-29|COINCIDENT|2020-06-08
e|RS|db3824aa-375d-4e40-a14b-af0e4460914e|6|NTRGRESP|Non-target Response|AJCC V8|||iCPD|1|mL/kg|MICROBIAL CULTURE, SOLID|||Y|VENDOR|FORENSIC PATHOLOGIST|U|3|Visit_3|40|4|TREATMENT|2020-06-19|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-04|P1Y2M10DT2H30M|BEFORE|2020-05-27|ONGOING|2020-08-02
e|RS|db3824aa-375d-4e40-a14b-af0e4460914e|7|DRCRIND|Disease Recurrence Indicator|CHESON CLL 2012|||MORPHOLOGIC CR|1|km|SPECULAR MICROSCOPY|Y||Y|PARENT|RATER 1|U|4|Visit_4|65|2|SCREENING|2020-07-14|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-02|P1Y2M10DT2H30M|UNKNOWN|2020-05-27|AFTER|2020-07-15
e|RS|db3824aa-375d-4e40-a14b-af0e4460914e|8|PATHRESP|Pathologic Response|WHO BREAST CANCER 2006|[?]|GPS U|CR-CT|1|kPa/L/sec|DOUBLE IMMUNODIFFUSION|Y|||CAREGIVER|NEUROLOGIST 2|NA|4|Visit_4|65|5|FOLLOW-UP|2020-07-14|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-02|P1Y2M10DT2H30M|COINCIDENT|2020-08-10|ONGOING|2020-08-15
e|RS|db3824aa-375d-4e40-a14b-af0e4460914e|9|MRDRESP|Minimal Residual Disease Response|LEE LUNG CANCER 2011|[?]|damol/L|PMR|1|fL|MULTIPLEXED BEAD BASED IMMUNOASSAY||Y||CLINICAL RESEARCH ASSOCIATE|DERMATOLOGIST|U|5|Visit_5|90|1|TREATMENT|2020-08-08|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-02|P1Y2M10DT2H30M|COINCIDENT|2020-08-07|BEFORE|2020-08-08
e|RS|db3824aa-375d-4e40-a14b-af0e4460914e|10|NTLWIND|Non-Target Lesion Worsening Indicator|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|||sCR|1|ug/kg/day|SPIROMETRY|||Y|CLINICAL STUDY SPONSOR|DEVELOPMENTAL PSYCHOLOGIST|NA|5|Visit_5|90|4|FOLLOW-UP|2020-08-08|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-02|P1Y2M10DT2H30M|COINCIDENT|2020-05-18|ONGOING|2020-07-20
e|RS|0ea6be64-32f8-4e10-b993-687ea200e4e9|1|TMRESP|Tumor Marker Response|EBMT BLADE MYELOMA 1998|[?]|/200 HPFs|CR-CT|1|uIU/L|STATIC PERIMETRY||Y||INTERVIEWER|DEVELOPMENTAL PSYCHOLOGIST|N|1|Visit_1|10|4|SCREENING|2021-01-28|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-28|P1Y2M10DT2H30M|BEFORE|2021-03-08|BEFORE|2021-03-10
e|RS|0ea6be64-32f8-4e10-b993-687ea200e4e9|2|LIVRRESP|Liver Response|UNSPECIFIED|[?]|10^9/dose|QUANTIFIABLE MRD POSITIVITY|1|10^11/L|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY|Y|||FAMILY MEMBER|PATHOLOGIST|N|1|Visit_1|10|5|TREATMENT|2021-01-28|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-28|P1Y2M10DT2H30M|COINCIDENT|2021-04-27|AFTER|2021-04-28
e|RS|0ea6be64-32f8-4e10-b993-687ea200e4e9|3|SYMPTDTR|Symptomatic Deterioration|SCHER PROSTATE CANCER 2011|||CR|1|10^3 CFU|LYMPHANGIOGRAPHY|||Y|INDEPENDENT ASSESSOR|RATER 2|N|2|Visit_2|25|3|TREATMENT|2021-02-12|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-12|P1Y2M10DT2H30M|COINCIDENT|2021-01-31|COINCIDENT|2021-04-11
e|RS|0ea6be64-32f8-4e10-b993-687ea200e4e9|4|SFTSRESP|Soft Tissue Response|GUILHOT CML 2007|[?]|kDa|iPR|1|U.CARR|NON-INVASIVE DIELECTRIC SENSING||||GUARDIAN|DERMATOLOGIST|NA|2|Visit_2|25|5|TREATMENT|2021-02-12|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-12|P1Y2M10DT2H30M|BEFORE|2021-03-07|COINCIDENT|2021-03-19
e|RS|0ea6be64-32f8-4e10-b993-687ea200e4e9|5|MRDRESP|Minimal Residual Disease Response|EASL BRUIX LIVER CANCER 2001|[?]|um/s|CRi|1|IU/day|FLUORESCENT ENZYME IMMUNOASSAY||||SIBLING|RATER|Y|3|Visit_3|40|4|TREATMENT|2021-02-27|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-19|P1Y2M10DT2H30M|AFTER|2021-04-27|AFTER|2021-04-28
e|RS|0ea6be64-32f8-4e10-b993-687ea200e4e9|6|RDIORESP|Radiologic Response|GUPPY OVARIAN CANCER 2002|[?]|FIU|CR-CT|1|ug/cm2|STATIC PERIMETRY||||VENDOR|CARDIOLOGIST|Y|3|Visit_3|40|1|TREATMENT|2021-02-27|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-19|P1Y2M10DT2H30M|BEFORE|2021-03-05|AFTER|2021-03-06
e|RS|0ea6be64-32f8-4e10-b993-687ea200e4e9|7|OVRLRESP|Overall Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|lx|PDu|1|/HPF|MICROARRAY||||CHILD|ONCOLOGIST 1|Y|4|Visit_4|65|7|FOLLOW-UP|2021-03-24|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-27|P1Y2M10DT2H30M|AFTER|2021-02-13|ONGOING|2021-04-19
e|RS|0ea6be64-32f8-4e10-b993-687ea200e4e9|8|SYMPTDTR|Symptomatic Deterioration|IWC HALLEK CLL 2008|[?]|ug/L|COMPLETE MRD RESPONSE|1|nkat/g Hb|STRESS ECHOCARDIOGRAPHY||||STUDY SUBJECT|MICROSCOPIST 2|N|4|Visit_4|65|5|TREATMENT|2021-03-24|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-27|P1Y2M10DT2H30M|UNKNOWN|2021-04-09|COINCIDENT|2021-04-18
e|RS|0ea6be64-32f8-4e10-b993-687ea200e4e9|9|RDIORESP|Radiologic Response|GUPPY OVARIAN CANCER 2002|[?]|Coulomb|CR-CT|1|pkat/L|ELECTROMYOGRAPHY||||SIGNIFICANT OTHER|ADJUDICATOR 3|NA|5|Visit_5|90|6|TREATMENT|2021-04-18|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-03|P1Y2M10DT2H30M|BEFORE|2021-04-12|COINCIDENT|2021-04-25
e|RS|0ea6be64-32f8-4e10-b993-687ea200e4e9|10|STRUSTAT|Steroid Use Status|SHINDOH COLORECTAL CANCER 2013|[?]|kBq|PD FROM PR|1|log10 CFU/mL|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION||||CHILD|ADJUDICATOR 3|Y|5|Visit_5|90|7|FOLLOW-UP|2021-04-18|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-03|P1Y2M10DT2H30M|AFTER|2021-01-24|ONGOING|2021-04-08
e|RS|18504c4e-41c8-4c1a-a479-d179ccd318e3|1|TRGRESP|Target Response|EBMT BLADE MYELOMA 1998|||DISEASE TRANSFORMATION|1|uV*sec|FISH|Y||Y|CLINICAL STUDY SPONSOR|RADIOLOGIST 1|N|1|Visit_1|10|6|WASHOUT|2020-06-22|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-07|P1Y2M10DT2H30M|COINCIDENT|2020-09-16|AFTER|2020-09-18
e|RS|18504c4e-41c8-4c1a-a479-d179ccd318e3|2|LIVRRESP|Liver Response|HARTMAN PANCREATIC CANCER 2012|||PSEUDORESPONSE|1|/VF|SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY||Y|Y|SIBLING|PEDIATRIC NEUROLOGIST|U|1|Visit_1|10|6|WASHOUT|2020-06-22|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-07|P1Y2M10DT2H30M|COINCIDENT|2020-07-28|COINCIDENT|2020-08-19
e|RS|18504c4e-41c8-4c1a-a479-d179ccd318e3|3|METSIND|Metastatic Indicator|MRANO VAN DEN BENT GLIOMA 2011|||MOLECULAR CR|1|cmHg|FLUORESCENT SPOT TEST|||Y|CHILD|ENDOCRINOLOGIST|NA|2|Visit_2|25|3|WASHOUT|2020-07-07|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-12|P1Y2M10DT2H30M|AFTER|2020-07-29|AFTER|2020-07-31
e|RS|18504c4e-41c8-4c1a-a479-d179ccd318e3|4|MRDIND|Minimal Residual Disease Indicator|LEE LUNG CANCER 2011|||QUANTIFIABLE MRD POSITIVITY|1|ECL unit|MICROBIAL CULTURE, LIQUID||Y|Y|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|Y|2|Visit_2|25|6|SCREENING|2020-07-07|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-12|P1Y2M10DT2H30M|COINCIDENT|2020-09-16|ONGOING|2020-09-17
e|RS|18504c4e-41c8-4c1a-a479-d179ccd318e3|5|METBRESP|Metabolic Response|CHESON CLL 2012|[?]|L/h/m2|DECREASED|1|mL/kg|IODINE STAIN||Y||PARENT|MICROSCOPIST 3|NA|3|Visit_3|40|7|WASHOUT|2020-07-22|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-06|P1Y2M10DT2H30M|AFTER|2020-06-29|ONGOING|2020-08-02
e|RS|18504c4e-41c8-4c1a-a479-d179ccd318e3|6|MRDRESP|Minimal Residual Disease Response|RAJKUMAR MYELOMA 2011|[?]|/2500 WBC|mCR|1|vp/mL|ENDOSCOPY|Y|||VENDOR|NEUROLOGIST|Y|3|Visit_3|40|4|TREATMENT|2020-07-22|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-06|P1Y2M10DT2H30M|AFTER|2020-09-01|ONGOING|2020-09-17
e|RS|18504c4e-41c8-4c1a-a479-d179ccd318e3|7|BESTRESP|Best Overall Response|WOLCHOK SOLID TUMORS 2009|||MRD NEGATIVITY|1|ag|FREEZING POINT DEPRESSION||Y|Y|SIGNIFICANT OTHER|OPTOMETRIST|NA|4|Visit_4|65|2|TREATMENT|2020-08-16|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-17|P1Y2M10DT2H30M|BEFORE|2020-06-17|COINCIDENT|2020-09-14
e|RS|18504c4e-41c8-4c1a-a479-d179ccd318e3|8|NEWLPROG|New Lesion Progression|KUKER LYMPHOMA 2005|[?]|foz_us|RELAPSED DISEASE FROM CR|1|bel|REAL-TIME POLYMERASE CHAIN REACTION ASSAY||||CHILD|OPHTHALMOLOGIST|Y|4|Visit_4|65|6|FOLLOW-UP|2020-08-16|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-17|P1Y2M10DT2H30M|UNKNOWN|2020-07-09|BEFORE|2020-08-19
e|RS|18504c4e-41c8-4c1a-a479-d179ccd318e3|9|NEWLPROG|New Lesion Progression|EASL BRUIX LIVER CANCER 2001|[?]|mEq/dL|MOLECULAR CR|1|IU/mmol|NEXT GENERATION TARGETED SEQUENCING||||NON-HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|Y|5|Visit_5|90|3|TREATMENT|2020-09-10|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-19|P1Y2M10DT2H30M|UNKNOWN|2020-06-25|COINCIDENT|2020-09-14
e|RS|18504c4e-41c8-4c1a-a479-d179ccd318e3|10|SYMPTDTR|Symptomatic Deterioration|NCCN ALL MRD 2014|||HI-N|1|pptr|IMMUNODIFFUSION|||Y|DOMESTIC PARTNER|RADIOLOGIST 1|Y|5|Visit_5|90|2|FOLLOW-UP|2020-09-10|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-19|P1Y2M10DT2H30M|UNKNOWN|2020-09-11|BEFORE|2020-09-15
e|RS|7f211d8a-7478-4082-8d95-4ace9ceee919|1|CLINRESP|Clinical Response|BRUGGEMANN MRD 2010|[?]|psi|OPTIMAL MORPHOLOGIC RESPONSE|1|mL/min/1.73m2|IMPEDANCE CONDUCTIVITY||||PARENT|PATHOLOGIST 1|Y|1|Visit_1|10|3|WASHOUT|2020-08-19|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-23|P1Y2M10DT2H30M|UNKNOWN|2020-10-20|BEFORE|2020-11-15
e|RS|7f211d8a-7478-4082-8d95-4ace9ceee919|2|NTLWIND|Non-Target Lesion Worsening Indicator|GCIG RUSTIN OVARIAN CANCER 2011|[?]|cmHg|PD-CT|1|cmH2O*s2/mL|SEQUENCING||||SIGNIFICANT OTHER|UROLOGIST|Y|1|Visit_1|10|1|TREATMENT|2020-08-19|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-23|P1Y2M10DT2H30M|COINCIDENT|2020-10-09|ONGOING|2020-10-27
e|RS|7f211d8a-7478-4082-8d95-4ace9ceee919|3|LIVRRESP|Liver Response|HARTMAN PANCREATIC CANCER 2012|[?]|mmAL|cPR|1|mg/dose|URANYL ACETATE STAIN|Y|||SIGNIFICANT OTHER|READER 3|N|2|Visit_2|25|1|TREATMENT|2020-09-03|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-26|P1Y2M10DT2H30M|COINCIDENT|2020-09-03|BEFORE|2020-09-25
e|RS|7f211d8a-7478-4082-8d95-4ace9ceee919|4|SFTSRESP|Soft Tissue Response|LEE LUNG CANCER 2011|[?]|mL/kg/h|PD|1|EU|IMMUNOFIXATION ELECTROPHORESIS||Y||CLINICAL STUDY SPONSOR|CLINICAL PATHOLOGIST|NA|2|Visit_2|25|1|TREATMENT|2020-09-03|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-26|P1Y2M10DT2H30M|UNKNOWN|2020-11-03|BEFORE|2020-11-10
e|RS|7f211d8a-7478-4082-8d95-4ace9ceee919|5|SPLNRESP|Spleen Response|CHESON CLL 2006|||PD|1|uIU/L|FREEZING POINT DEPRESSION|Y||Y|HEALTH CARE PROFESSIONAL|CARDIOLOGIST|NA|3|Visit_3|40|2|SCREENING|2020-09-18|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-27|P1Y2M10DT2H30M|COINCIDENT|2020-08-16|ONGOING|2020-10-25
e|RS|7f211d8a-7478-4082-8d95-4ace9ceee919|6|BESTRESP|Best Overall Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|10^6 DNA copies/mL|cCR|1|10^12/L|STRESS ECHOCARDIOGRAPHY||||GUARDIAN|RATER|Y|3|Visit_3|40|6|FOLLOW-UP|2020-09-18|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-27|P1Y2M10DT2H30M|AFTER|2020-10-03|AFTER|2020-11-06
e|RS|7f211d8a-7478-4082-8d95-4ace9ceee919|7|NTRGRESP|Non-target Response|JUWEID NON-HODGKINS LYMPHOMA 2005|||MORPHOLOGIC CR|1|mg/m2/h|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY||Y|Y|SPOUSE|PATHOLOGIST 1|N|4|Visit_4|65|6|TREATMENT|2020-10-13|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-05|P1Y2M10DT2H30M|BEFORE|2020-10-04|ONGOING|2020-10-06
e|RS|7f211d8a-7478-4082-8d95-4ace9ceee919|8|NEWLWIND|New Lesion Worsening Indicator|RAJKUMAR MYELOMA 2011|||WORSENED|1|POUCH|PULSE OXIMETRY|||Y|ADJUDICATOR|OTOLARYNGOLOGIST|Y|4|Visit_4|65|4|WASHOUT|2020-10-13|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-05|P1Y2M10DT2H30M|UNKNOWN|2020-11-10|COINCIDENT|2020-11-16
e|RS|7f211d8a-7478-4082-8d95-4ace9ceee919|9|MRDIND|Minimal Residual Disease Indicator|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|min|INDETERMINATE RESPONSE|1|BOTTLE|ANTIMICROBIAL COMBINATION TESTING|Y|||SIGNIFICANT OTHER|PATHOLOGIST 2|Y|5|Visit_5|90|7|SCREENING|2020-11-07|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-24|P1Y2M10DT2H30M|AFTER|2020-10-02|BEFORE|2020-11-13
e|RS|7f211d8a-7478-4082-8d95-4ace9ceee919|10|BONERESP|Bone Response|RANO|[?]|mg/min|MOLECULAR MAJOR RESPONSE|1|mV*min|FREEZING POINT DEPRESSION|Y|||PARENT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5|Visit_5|90|2|FOLLOW-UP|2020-11-07|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-24|P1Y2M10DT2H30M|AFTER|2020-11-10|AFTER|2020-11-11
e|RS|0739e140-bcac-4df9-9629-bd0748d1fdd6|1|MNPTHIND|Minor Pathological Response Indicator|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|mm/sec|SD|1|EID 50/dose|CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|Y|||SIGNIFICANT OTHER|READER 2|NA|1|Visit_1|10|7|TREATMENT|2020-10-09|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-24|P1Y2M10DT2H30M|BEFORE|2020-12-09|AFTER|2020-12-14
e|RS|0739e140-bcac-4df9-9629-bd0748d1fdd6|2|BMIVLIND|Bone Marrow Involvement Indicator|AJCC V8|[?]|10^3 organisms/g|PMR|1|deg|ENZYMATIC SPECTROPHOTOMETRY||||ADJUDICATION COMMITTEE|MICROSCOPIST|Y|1|Visit_1|10|4|TREATMENT|2020-10-09|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-24|P1Y2M10DT2H30M|AFTER|2020-12-12|BEFORE|2020-12-15
e|RS|0739e140-bcac-4df9-9629-bd0748d1fdd6|3|NTNERESP|Non-Target Non-Enhancing Response|HARTMANN GERM CELL CANCER 2002|[?]|ELISA unit/mL|sCR|1|mL/cage/wk|VIRUS PLAQUE ASSAY||||CHILD|PATHOLOGIST|N|2|Visit_2|25|1|FOLLOW-UP|2020-10-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-30|P1Y2M10DT2H30M|AFTER|2020-11-28|ONGOING|2020-12-01
e|RS|0739e140-bcac-4df9-9629-bd0748d1fdd6|4|RDIORESP|Radiologic Response|MASS|||PD-CT|1|Gy/min|EPSILOMETER|Y||Y|CHILD|DERMATOLOGIST|U|2|Visit_2|25|7|TREATMENT|2020-10-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-30|P1Y2M10DT2H30M|AFTER|2020-11-27|COINCIDENT|2020-12-30
e|RS|0739e140-bcac-4df9-9629-bd0748d1fdd6|5|RDIORESP|Radiologic Response|AJCC V7|||NED|1|kg|ALCIAN BLUE STAIN|Y||Y|INDEPENDENT ASSESSOR|FORENSIC PATHOLOGIST|Y|3|Visit_3|40|6|FOLLOW-UP|2020-11-08|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-23|P1Y2M10DT2H30M|COINCIDENT|2020-11-28|BEFORE|2021-01-04
e|RS|0739e140-bcac-4df9-9629-bd0748d1fdd6|6|MNPTHIND|Minor Pathological Response Indicator|SCHWARZ CERVICAL CANCER 2009|[?]|nkat/L|NON-QUANTIFIABLE MRD POSITIVITY|1|dL|QUANTITATIVE ULTRASOUND||||DOMESTIC PARTNER|READER 3|Y|3|Visit_3|40|7|TREATMENT|2020-11-08|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-23|P1Y2M10DT2H30M|COINCIDENT|2020-10-11|AFTER|2020-12-14
e|RS|0739e140-bcac-4df9-9629-bd0748d1fdd6|7|LIVRRESP|Liver Response|GCIG RUSTIN OVARIAN CANCER 2011|||PD-CT|1|mEq/mL|POLYSOMNOGRAPHY||Y|Y|ADJUDICATOR|READER 2|N|4|Visit_4|65|5|FOLLOW-UP|2020-12-03|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-13|P1Y2M10DT2H30M|BEFORE|2021-01-03|COINCIDENT|2021-01-04
e|RS|0739e140-bcac-4df9-9629-bd0748d1fdd6|8|BONERESP|Bone Response|GCIG RUSTIN OVARIAN CANCER 2011|||CYTOGENETIC NO RESPONSE|1|PLUG|GC/MS/MS||Y|Y|INDEPENDENT ASSESSOR|PHYSIOTHERAPIST|Y|4|Visit_4|65|5|TREATMENT|2020-12-03|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-13|P1Y2M10DT2H30M|COINCIDENT|2020-11-14|ONGOING|2020-11-29
e|RS|0739e140-bcac-4df9-9629-bd0748d1fdd6|9|MRPHRESP|Morphologic Response|EASL BRUIX LIVER CANCER 2001|[?]|g/m2/day|MAJOR PATHOLOGIC RESPONSE|1|/40 HPFs|PET/CT SCAN WITHOUT CONTRAST|Y|||PARENT|ONCOLOGIST 2|Y|5|Visit_5|90|2|WASHOUT|2020-12-28|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-23|P1Y2M10DT2H30M|COINCIDENT|2020-11-11|AFTER|2020-11-19
e|RS|0739e140-bcac-4df9-9629-bd0748d1fdd6|10|BESTRESP|Best Overall Response|MURPHY PROSTATE CANCER 1980|[?]|mMU/mL|ABSENT MORPHOLOGIC RESPONSE|1|/40 HPFs|TELLER ACUITY CARDS||||NON-HEALTH CARE PROFESSIONAL|OPTOMETRIST|NA|5|Visit_5|90|2|WASHOUT|2020-12-28|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-23|P1Y2M10DT2H30M|BEFORE|2020-11-12|AFTER|2020-11-26
e|RS|4d44daf5-8ebc-4d4f-aa33-e8ab9f5442e0|1|BMIVLIND|Bone Marrow Involvement Indicator|MRECIST LENCIONI LIVER CANCER 2010|||CR|1|DAgU|MULTIPLEXED BEAD BASED IMMUNOASSAY|||Y|SIBLING|RATER|NA|1|Visit_1|10|3|WASHOUT|2020-12-21|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-01|P1Y2M10DT2H30M|BEFORE|2020-12-19|ONGOING|2021-02-23
e|RS|4d44daf5-8ebc-4d4f-aa33-e8ab9f5442e0|2|NEWLWIND|New Lesion Worsening Indicator|PALUMBO MULTIPLE MYELOMA 2009|[?]|nmol/mL/min|mCR|1|mL/mmHg/min/L|EPSILOMETER|Y|||ADJUDICATION COMMITTEE|PATHOLOGIST 1|Y|1|Visit_1|10|3|TREATMENT|2020-12-21|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-01|P1Y2M10DT2H30M|AFTER|2021-03-18|AFTER|2021-03-19
e|RS|4d44daf5-8ebc-4d4f-aa33-e8ab9f5442e0|3|MRDRESP|Minimal Residual Disease Response|JACINTO CERVICAL CANCER 2007|[?]|mL/m2/h|COMPLETE MRD RESPONSE|1|umol/h/mmol|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY||||SIGNIFICANT OTHER|PATHOLOGIST|Y|2|Visit_2|25|1|TREATMENT|2021-01-05|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-06|P1Y2M10DT2H30M|BEFORE|2021-02-13|ONGOING|2021-02-18
e|RS|4d44daf5-8ebc-4d4f-aa33-e8ab9f5442e0|4|MJPTHIND|Major Pathological Response Indicator|CHESON LYMPHOMA 2008|[?]|mL/mmHg|CA125 50% RESPONSE|1|cm2|FLAME PHOTOMETRY|Y|||INVESTIGATOR|ADJUDICATOR 2|Y|2|Visit_2|25|3|TREATMENT|2021-01-05|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-06|P1Y2M10DT2H30M|BEFORE|2021-01-09|COINCIDENT|2021-02-06
e|RS|4d44daf5-8ebc-4d4f-aa33-e8ab9f5442e0|5|METBRESP|Metabolic Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|mmol/min/kPa|HI-P|1|MET|HPLC-UV||||ADJUDICATOR|NEUROLOGIST 2|N|3|Visit_3|40|3|TREATMENT|2021-01-20|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-02|P1Y2M10DT2H30M|BEFORE|2021-02-26|AFTER|2021-03-12
e|RS|4d44daf5-8ebc-4d4f-aa33-e8ab9f5442e0|6|LIVRRESP|Liver Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|10^5/L|CR|1|IU/mg|ELASTOGRAPHY||Y||CAREGIVER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|3|Visit_3|40|3|SCREENING|2021-01-20|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-02|P1Y2M10DT2H30M|UNKNOWN|2021-02-08|AFTER|2021-03-19
e|RS|4d44daf5-8ebc-4d4f-aa33-e8ab9f5442e0|7|CPRFSTAT|Clinical Performance Status|EASL BRUIX LIVER CANCER 2001|[?]|U/kg/day|iSD|1|10^7 CFU|LISSAMINE GREEN STAIN||Y||ADJUDICATOR|PHYSIOTHERAPIST|N|4|Visit_4|65|7|TREATMENT|2021-02-14|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-01|P1Y2M10DT2H30M|COINCIDENT|2021-02-21|ONGOING|2021-03-17
e|RS|4d44daf5-8ebc-4d4f-aa33-e8ab9f5442e0|8|HEMARESP|Hematologic Response|WOLCHOK SOLID TUMORS 2009|[?]|10^3/L|CA125 50% RESPONSE|1|nmol/L|IMMUNO-PET SCAN||||PROXY|PHYSIOTHERAPIST|U|4|Visit_4|65|7|TREATMENT|2021-02-14|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-01|P1Y2M10DT2H30M|BEFORE|2021-01-22|AFTER|2021-02-22
e|RS|4d44daf5-8ebc-4d4f-aa33-e8ab9f5442e0|9|PATHRESP|Pathologic Response|IRANO 2015|[?]|pg/dL|cCR|1|L/kg|JAFFE REACTION||||FAMILY MEMBER|PEDIATRIC NEUROLOGIST|Y|5|Visit_5|90|7|SCREENING|2021-03-11|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-26|P1Y2M10DT2H30M|COINCIDENT|2021-02-18|BEFORE|2021-03-01
e|RS|4d44daf5-8ebc-4d4f-aa33-e8ab9f5442e0|10|TRGRESP|Target Response|KEAM BREAST CANCER 2013|[?]|cycle/min|sCR|1|MET|GC/MS-CI||||DOMESTIC PARTNER|ADJUDICATOR|N|5|Visit_5|90|6|TREATMENT|2021-03-11|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-26|P1Y2M10DT2H30M|BEFORE|2021-02-27|AFTER|2021-03-08
e|RS|f24b931a-2cdd-4432-a1dd-69c7286f4690|1|NTRGRESP|Non-target Response|RAJKUMAR MYELOMA 2011|||PD/RELAPSE AFTER HI|1|ka_u/dL|PET SCAN|Y||Y|DOMESTIC PARTNER|ONCOLOGIST 1|N|1|Visit_1|10|1|TREATMENT|2020-05-15|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-18|P1Y2M10DT2H30M|AFTER|2020-07-14|ONGOING|2020-07-26
e|RS|f24b931a-2cdd-4432-a1dd-69c7286f4690|2|NTRGRESP|Non-target Response|IWG CHESON AML 2003|[?]|10^6/L|iCPD|1|g/g|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION||||INTERVIEWER|NEUROLOGIST 2|Y|1|Visit_1|10|3|FOLLOW-UP|2020-05-15|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-18|P1Y2M10DT2H30M|AFTER|2020-08-11|COINCIDENT|2020-08-12
e|RS|f24b931a-2cdd-4432-a1dd-69c7286f4690|3|SPLNRESP|Spleen Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|amu|PD/RELAPSE AFTER HI|1|% INHIBITION|DIRECT SEQUENCING||Y||CLINICAL STUDY SPONSOR|OPHTHALMOLOGIST|N|2|Visit_2|25|4|TREATMENT|2020-05-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-14|P1Y2M10DT2H30M|UNKNOWN|2020-08-08|ONGOING|2020-08-12
e|RS|f24b931a-2cdd-4432-a1dd-69c7286f4690|4|LIVRRESP|Liver Response|CHESON NON-HODGKINS LYMPHOMA 1999|||MRD NEGATIVITY|1|AgU/mL|QUANTITATIVE CORONARY ANGIOGRAPHY|Y||Y|ADJUDICATION COMMITTEE|CARDIOLOGIST|U|2|Visit_2|25|1|FOLLOW-UP|2020-05-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-14|P1Y2M10DT2H30M|UNKNOWN|2020-08-07|AFTER|2020-08-08
e|RS|f24b931a-2cdd-4432-a1dd-69c7286f4690|5|STRUSTAT|Steroid Use Status|MASS|[?]|mg/mL/min|IMPROVED|1|mol/mol|PUPILLOMETRY||Y||SPOUSE|MICROSCOPIST|NA|3|Visit_3|40|3|TREATMENT|2020-06-14|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-29|P1Y2M10DT2H30M|AFTER|2020-07-30|AFTER|2020-08-07
e|RS|f24b931a-2cdd-4432-a1dd-69c7286f4690|6|NTERESP|Non-Target Enhancing Response|AJCC V8|[?]|cm/s|WORSENED|1|deg|ELECTRICAL IMPEDANCE MYOGRAPHY||||PARENT|DERMATOLOGIST|N|3|Visit_3|40|1|TREATMENT|2020-06-14|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-29|P1Y2M10DT2H30M|BEFORE|2020-05-28|BEFORE|2020-08-06
e|RS|f24b931a-2cdd-4432-a1dd-69c7286f4690|7|BMIVLIND|Bone Marrow Involvement Indicator|BURCOMBE BREAST CANCER 2005|||PR|1|vg/dose|IMMUNOCHEMILUMINOMETRIC ASSAY|||Y|CLINICAL RESEARCH COORDINATOR|CARDIOLOGIST|U|4|Visit_4|65|3|TREATMENT|2020-07-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-17|P1Y2M10DT2H30M|AFTER|2020-05-25|ONGOING|2020-06-18
e|RS|f24b931a-2cdd-4432-a1dd-69c7286f4690|8|MRDIND|Minimal Residual Disease Indicator|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|ug/mL/h|SMD|1|10^10/L|ELISPOT||||CHILD|READER 2|Y|4|Visit_4|65|2|TREATMENT|2020-07-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-17|P1Y2M10DT2H30M|BEFORE|2020-07-20|AFTER|2020-08-08
e|RS|f24b931a-2cdd-4432-a1dd-69c7286f4690|9|HEMARESP|Hematologic Response|WHO BREAST CANCER 2006|[?]|mm3/mm2/year|cPR|1|PLUG|PHOTOMETRIC CLOT DETECTION|Y|||INDEPENDENT ASSESSOR|NEUROLOGIST 1|U|5|Visit_5|90|3|TREATMENT|2020-08-03|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-02|P1Y2M10DT2H30M|UNKNOWN|2020-07-28|BEFORE|2020-08-09
e|RS|f24b931a-2cdd-4432-a1dd-69c7286f4690|10|DRCRIND|Disease Recurrence Indicator|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|mEq/day|CA125 50% RESPONSE|1|pt_us|AUTOREFRACTION||||CAREGIVER|PEDIATRIC NEUROLOGIST|N|5|Visit_5|90|6|WASHOUT|2020-08-03|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-02|P1Y2M10DT2H30M|COINCIDENT|2020-05-10|COINCIDENT|2020-07-08
e|RS|d394120d-7630-4fcf-a336-482599d88296|1|TMRESP|Tumor Marker Response|NCIWG CHESON CLL 1996|[?]|mOsm/L|PMD|1|cmHg|IMPULSE OSCILLOMETRY||||CLINICAL STUDY SPONSOR|RATER 2|Y|1|Visit_1|10|3|FOLLOW-UP|2021-01-22|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-02|P1Y2M10DT2H30M|COINCIDENT|2021-01-18|AFTER|2021-02-09
e|RS|d394120d-7630-4fcf-a336-482599d88296|2|BESTRESP|Best Overall Response|SCHWARZ CERVICAL CANCER 2009|[?]|Watt|SD-CT|1|um/s|PERIODIC ACID SCHIFF STAIN|Y|Y||ADJUDICATOR|INTERNIST|Y|1|Visit_1|10|6|SCREENING|2021-01-22|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-02|P1Y2M10DT2H30M|BEFORE|2021-01-25|BEFORE|2021-02-05
e|RS|d394120d-7630-4fcf-a336-482599d88296|3|PATHRESP|Pathologic Response|PERCIST|[?]|pkat/L|PD-CT|1|MASK|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE||||CLINICAL RESEARCH COORDINATOR|RATER 2|U|2|Visit_2|25|5|TREATMENT|2021-02-06|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-01|P1Y2M10DT2H30M|COINCIDENT|2021-02-26|BEFORE|2021-03-05
e|RS|d394120d-7630-4fcf-a336-482599d88296|4|NTLWIND|Non-Target Lesion Worsening Indicator|CHOLLET BREAST CANCER 2002|[?]|/month|HI-E|1|NEEDLE GAUGE|PH METER MEASUREMENT METHOD||||CLINICAL RESEARCH COORDINATOR|RADIOLOGIST|N|2|Visit_2|25|1|WASHOUT|2021-02-06|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-01|P1Y2M10DT2H30M|COINCIDENT|2021-01-17|COINCIDENT|2021-02-05
e|RS|d394120d-7630-4fcf-a336-482599d88296|5|NTNERESP|Non-Target Non-Enhancing Response|DURIE MULTIPLE MYELOMA 2006|||PSEUDOPROGRESSION|1|10^3/hpf|QUANTITATIVE CORONARY ANGIOGRAPHY|||Y|SPOUSE|READER|NA|3|Visit_3|40|2|TREATMENT|2021-02-21|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-22|P1Y2M10DT2H30M|AFTER|2021-04-01|BEFORE|2021-04-03
e|RS|d394120d-7630-4fcf-a336-482599d88296|6|TRGRESP|Target Response|RANO ELLINGSON 2017|[?]|m/sec|NR|1|Bq/uL|HPLC-UV||||CHILD|UROLOGIST|Y|3|Visit_3|40|6|TREATMENT|2021-02-21|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-22|P1Y2M10DT2H30M|COINCIDENT|2021-04-15|ONGOING|2021-04-16
e|RS|d394120d-7630-4fcf-a336-482599d88296|7|STRUSTAT|Steroid Use Status|CHESON NON-HODGKINS LYMPHOMA 1999|||INDETERMINATE RESPONSE|1|GBq/ug|ANGIOGRAPHY|Y||Y|SIBLING|READER 1|U|4|Visit_4|65|6|TREATMENT|2021-03-18|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-12|P1Y2M10DT2H30M|COINCIDENT|2021-03-12|ONGOING|2021-04-05
e|RS|d394120d-7630-4fcf-a336-482599d88296|8|NTERESP|Non-Target Enhancing Response|MRECIST BYRNE MESOTHELIOMA 2004|||CA125 50% RESPONSE|1|mEq/L|PATHOLOGICAL EVALUATION|||Y|CHILD|RATER 2|U|4|Visit_4|65|4|TREATMENT|2021-03-18|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-12|P1Y2M10DT2H30M|AFTER|2021-01-31|ONGOING|2021-02-19
e|RS|d394120d-7630-4fcf-a336-482599d88296|9|SYMPTDTR|Symptomatic Deterioration|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|mg/kg|MRD RELAPSE|1|dmol|LISSAMINE GREEN STAIN||||NON-HEALTH CARE PROFESSIONAL|CARDIOLOGIST|NA|5|Visit_5|90|1|WASHOUT|2021-04-12|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-17|P1Y2M10DT2H30M|UNKNOWN|2021-03-14|ONGOING|2021-04-07
e|RS|d394120d-7630-4fcf-a336-482599d88296|10|MRDRESP|Minimal Residual Disease Response|PCWG SCHER PROSTATE CANCER 2008|[?]|Bq/mL|MOLECULAR CR|1|cmol|AUTOMATED COUNT||||PARENT|INTERNIST|NA|5|Visit_5|90|3|TREATMENT|2021-04-12|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-17|P1Y2M10DT2H30M|UNKNOWN|2021-01-16|ONGOING|2021-02-18
e|RS|bcda1d95-58ed-4991-9395-0b98efc1d9a1|1|OVRLRESP|Overall Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|ug/g/day|iCR|1|Pack Year|ELISA||||INVESTIGATOR|MICROSCOPIST 3|Y|1|Visit_1|10|6|SCREENING|2020-10-21|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-29|P1Y2M10DT2H30M|UNKNOWN|2020-11-14|ONGOING|2021-01-06
e|RS|bcda1d95-58ed-4991-9395-0b98efc1d9a1|2|LIVRRESP|Liver Response|BLAZER COLORECTAL CANCER 2008|[?]|mmol|CHR|1|10^5/hpf|FUNDUS PHOTOGRAPHY||||INDEPENDENT ASSESSOR|OTOLARYNGOLOGIST|NA|1|Visit_1|10|1|FOLLOW-UP|2020-10-21|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-29|P1Y2M10DT2H30M|AFTER|2020-10-18|ONGOING|2020-11-18
e|RS|bcda1d95-58ed-4991-9395-0b98efc1d9a1|3|RDIORESP|Radiologic Response|GUILHOT CML 2007|[?]|GBq|CHR|1|mg/kg|WHOLE GENOME SEQUENCING||||FAMILY MEMBER|OPHTHALMOLOGIST|NA|2|Visit_2|25|3|WASHOUT|2020-11-05|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-21|P1Y2M10DT2H30M|BEFORE|2021-01-17|COINCIDENT|2021-01-18
e|RS|bcda1d95-58ed-4991-9395-0b98efc1d9a1|4|MRDRESP|Minimal Residual Disease Response|DURIE MULTIPLE MYELOMA 2006|[?]|U/m2/min|MRD RELAPSE|1|nmol BCE/mmol|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY||||CAREGIVER|CARDIOLOGIST|Y|2|Visit_2|25|5|TREATMENT|2020-11-05|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-21|P1Y2M10DT2H30M|BEFORE|2020-12-28|ONGOING|2021-01-16
e|RS|bcda1d95-58ed-4991-9395-0b98efc1d9a1|5|LIVRRESP|Liver Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|mg/animal|IMPROVED|1|COAT|LASER CAPTURE MICRODISSECTION||||SIBLING|MICROSCOPIST 3|Y|3|Visit_3|40|2|SCREENING|2020-11-20|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-06|P1Y2M10DT2H30M|COINCIDENT|2020-12-28|ONGOING|2021-01-02
e|RS|bcda1d95-58ed-4991-9395-0b98efc1d9a1|6|DRCRIND|Disease Recurrence Indicator|PCWG SCHER PROSTATE CANCER 2008|[?]|h*%|iPR|1|ft3|IN SITU HYBRIDIZATION||||ADJUDICATION COMMITTEE|RATER 1|NA|3|Visit_3|40|6|TREATMENT|2020-11-20|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-06|P1Y2M10DT2H30M|AFTER|2020-11-23|BEFORE|2020-11-29
e|RS|bcda1d95-58ed-4991-9395-0b98efc1d9a1|7|BESTRESP|Best Overall Response|CHESON LYMPHOMA 2008|[?]|10^3 organisms|STABLE|1|bel|STRESS ECHOCARDIOGRAPHY||||HEALTH CARE PROFESSIONAL|RATER 2|Y|4|Visit_4|65|1|WASHOUT|2020-12-15|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-13|P1Y2M10DT2H30M|BEFORE|2020-11-11|BEFORE|2020-12-11
e|RS|bcda1d95-58ed-4991-9395-0b98efc1d9a1|8|HEMARESP|Hematologic Response|UNSPECIFIED|||PD|1|g/g|SPECT/CT SCAN||Y|Y|CLINICAL RESEARCH COORDINATOR|FORENSIC PATHOLOGIST|Y|4|Visit_4|65|4|FOLLOW-UP|2020-12-15|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-13|P1Y2M10DT2H30M|AFTER|2020-11-12|AFTER|2020-11-13
e|RS|bcda1d95-58ed-4991-9395-0b98efc1d9a1|9|MNPTHIND|Minor Pathological Response Indicator|DOHNER AML 2010|||PDu|1|IU/mg|TWO-COLOR MICROARRAY|||Y|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|N|5|Visit_5|90|2|TREATMENT|2021-01-09|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-21|P1Y2M10DT2H30M|AFTER|2020-12-25|COINCIDENT|2021-01-15
e|RS|bcda1d95-58ed-4991-9395-0b98efc1d9a1|10|SYMPTDTR|Symptomatic Deterioration|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|U/kg/day|pCR|1|mEq/dL|ENDOSCOPY|Y|||INVESTIGATOR|FORENSIC PATHOLOGIST|NA|5|Visit_5|90|4|SCREENING|2021-01-09|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-21|P1Y2M10DT2H30M|AFTER|2021-01-11|BEFORE|2021-01-12
e|RS|6999bd5c-0790-42b8-a4ff-e538776b0fb0|1|BESTRESP|Best Overall Response|HARTMANN GERM CELL CANCER 2002|[?]|mg/L|MR|1|mg/m2/h|QUANTITATIVE CORONARY ANGIOGRAPHY||Y||CLINICAL RESEARCH COORDINATOR|RADIOLOGIST|NA|1|Visit_1|10|7|TREATMENT|2020-08-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-27|P1Y2M10DT2H30M|AFTER|2020-10-15|ONGOING|2020-11-05
e|RS|6999bd5c-0790-42b8-a4ff-e538776b0fb0|2|SYMPTDTR|Symptomatic Deterioration|IWG CHESON MDS 2006|[?]|C|MORPHOLOGIC LEUKEMIA-FREE STATE|1|Pack Year|MICROPARTICLE ENZYME IMMUNOASSAY||||CAREGIVER|NEUROLOGIST|NA|1|Visit_1|10|2|TREATMENT|2020-08-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-27|P1Y2M10DT2H30M|BEFORE|2020-08-29|ONGOING|2020-10-02
e|RS|6999bd5c-0790-42b8-a4ff-e538776b0fb0|3|MNPTHIND|Minor Pathological Response Indicator|RECIST 1.0|||RELAPSED DISEASE FROM CR OR PR|1|log EID 50/dose|ATOMIC ABSORPTION SPECTROMETRY|Y||Y|CAREGIVER|PATHOLOGIST|NA|2|Visit_2|25|4|SCREENING|2020-08-30|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-16|P1Y2M10DT2H30M|UNKNOWN|2020-10-08|ONGOING|2020-11-06
e|RS|6999bd5c-0790-42b8-a4ff-e538776b0fb0|4|MNPTHIND|Minor Pathological Response Indicator|MRECIST LENCIONI LIVER CANCER 2010|[?]|grain|iCR|1|mol|HPLC/MS/MS||||CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR|NA|2|Visit_2|25|7|TREATMENT|2020-08-30|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-16|P1Y2M10DT2H30M|UNKNOWN|2020-08-23|ONGOING|2020-10-16
e|RS|6999bd5c-0790-42b8-a4ff-e538776b0fb0|5|MRDRESP|Minimal Residual Disease Response|RAJKUMAR MYELOMA 2011|[?]|BAU|pCR|1|MBq|ELECTROGASTROGRAPHY||||SPOUSE|INTERNIST|Y|3|Visit_3|40|4|TREATMENT|2020-09-14|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-06|P1Y2M10DT2H30M|BEFORE|2020-09-11|BEFORE|2020-10-08
e|RS|6999bd5c-0790-42b8-a4ff-e538776b0fb0|6|NTRGRESP|Non-target Response|JACINTO CERVICAL CANCER 2007|||CA125 50% RESPONSE|1|10^6 IU|DNA MICROARRAY|||Y|GUARDIAN|OPTOMETRIST|U|3|Visit_3|40|1|TREATMENT|2020-09-14|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-06|P1Y2M10DT2H30M|UNKNOWN|2020-11-01|ONGOING|2020-11-10
e|RS|6999bd5c-0790-42b8-a4ff-e538776b0fb0|7|MOLRESP|Molecular Response|NCCN ALL MRD 2014|[?]|g/g|CYTOGENETIC NO RESPONSE|1|10^6 organisms/mg|MAGNETIC RESONANCE ANGIOGRAPHY||||GUARDIAN|PHYSIOTHERAPIST|U|4|Visit_4|65|2|TREATMENT|2020-10-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-21|P1Y2M10DT2H30M|AFTER|2020-11-08|AFTER|2020-11-10
e|RS|6999bd5c-0790-42b8-a4ff-e538776b0fb0|8|NEWLPROG|New Lesion Progression|KEAM BREAST CANCER 2013|[?]|OI50|OPTIMAL MORPHOLOGIC RESPONSE|1|U/g Hb|QUANTITATIVE CORONARY ANGIOGRAPHY|Y|||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 1|U|4|Visit_4|65|6|TREATMENT|2020-10-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-21|P1Y2M10DT2H30M|BEFORE|2020-08-13|ONGOING|2020-08-27
e|RS|6999bd5c-0790-42b8-a4ff-e538776b0fb0|9|MRPHRESP|Morphologic Response|AJCC V7|[?]|DNA copies/ug|iSD|1|mL/s|WRIGHT STAIN||Y||ADJUDICATION COMMITTEE|ADJUDICATOR|U|5|Visit_5|90|4|SCREENING|2020-11-03|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-31|P1Y2M10DT2H30M|UNKNOWN|2020-11-08|ONGOING|2020-11-10
e|RS|6999bd5c-0790-42b8-a4ff-e538776b0fb0|10|CLINRESP|Clinical Response|CHESON LYMPHOMA 2008|[?]|STEPS|PARTIAL MORPHOLOGIC RESPONSE|1|uL|CENTRIFUGATION||Y||CHILD|READER 3|Y|5|Visit_5|90|6|TREATMENT|2020-11-03|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-31|P1Y2M10DT2H30M|BEFORE|2020-11-06|AFTER|2020-11-12
e|RS|5934d59a-b0f4-4377-a3c3-00d434d3ddfd|1|SFTSRESP|Soft Tissue Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|NEEDLE GAUGE|HI-E|1|cL|PHOTOMETRIC CLOT DETECTION||||CLINICAL STUDY SPONSOR|ONCOLOGIST 1|U|1|Visit_1|10|4|FOLLOW-UP|2020-12-21|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-23|P1Y2M10DT2H30M|COINCIDENT|2021-01-29|AFTER|2021-02-18
e|RS|5934d59a-b0f4-4377-a3c3-00d434d3ddfd|2|LIVRRESP|Liver Response|PRINCE TCELL LYMPHOMA 2010|[?]|Torr|CMR|1|pmol/L/h|TRANSMISSION ELECTRON MICROSCOPY||||CLINICAL STUDY SPONSOR|OPHTHALMOLOGIST|U|1|Visit_1|10|6|TREATMENT|2020-12-21|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-23|P1Y2M10DT2H30M|AFTER|2021-01-15|BEFORE|2021-01-25
e|RS|5934d59a-b0f4-4377-a3c3-00d434d3ddfd|3|METBRESP|Metabolic Response|RAJKUMAR MYELOMA 2011|[?]|ppth|MORPHOLOGIC CRi|1|mol/day|MEDIASTINOSCOPY||||DOMESTIC PARTNER|RATER 1|U|2|Visit_2|25|4|SCREENING|2021-01-05|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-17|P1Y2M10DT2H30M|COINCIDENT|2021-01-30|COINCIDENT|2021-03-17
e|RS|5934d59a-b0f4-4377-a3c3-00d434d3ddfd|4|MRDIND|Minimal Residual Disease Indicator|CHESON CLL 2012|||MORPHOLOGIC LEUKEMIA-FREE STATE|1|cmol/L|CAPILLARY ELECTROPHORESIS||Y|Y|GUARDIAN|RATER 1|Y|2|Visit_2|25|5|FOLLOW-UP|2021-01-05|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-17|P1Y2M10DT2H30M|UNKNOWN|2020-12-25|COINCIDENT|2021-01-03
e|RS|5934d59a-b0f4-4377-a3c3-00d434d3ddfd|5|MOLRESP|Molecular Response|MURPHY PROSTATE CANCER 1980|[?]|PA|UNFAVORABLE RESPONSE|1|mL/beat|FLUORESCENT MICROSCOPY||Y||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|Y|3|Visit_3|40|5|FOLLOW-UP|2021-01-20|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-10|P1Y2M10DT2H30M|AFTER|2020-12-26|BEFORE|2021-02-09
e|RS|5934d59a-b0f4-4377-a3c3-00d434d3ddfd|6|BMIVLIND|Bone Marrow Involvement Indicator|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|L/h|NE|1|mL*cmH2O|SCANNING ELECTRON MICROSCOPY||Y||FAMILY MEMBER|RATER 1|NA|3|Visit_3|40|7|TREATMENT|2021-01-20|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-10|P1Y2M10DT2H30M|AFTER|2020-12-14|AFTER|2020-12-18
e|RS|5934d59a-b0f4-4377-a3c3-00d434d3ddfd|7|CLINRESP|Clinical Response|KUMAR IMWG 2016|[?]|copies/mL|PMR|1|kN/cm2|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|Y|||FAMILY MEMBER|MICROSCOPIST 3|NA|4|Visit_4|65|2|TREATMENT|2021-02-14|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-08|P1Y2M10DT2H30M|AFTER|2021-02-06|AFTER|2021-02-10
e|RS|5934d59a-b0f4-4377-a3c3-00d434d3ddfd|8|HEMARESP|Hematologic Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|nmol BCE/mmol|NR|1|mL/animal|CONTRAST ENHANCED SPIRAL CT SCAN||Y||STUDY SUBJECT|RADIOLOGIST 2|U|4|Visit_4|65|3|FOLLOW-UP|2021-02-14|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-08|P1Y2M10DT2H30M|COINCIDENT|2021-02-17|COINCIDENT|2021-03-08
e|RS|5934d59a-b0f4-4377-a3c3-00d434d3ddfd|9|RDIORESP|Radiologic Response|MURPHY PROSTATE CANCER 1980|[?]|mEq/mL|MRD RELAPSE|1|mL/min/mmHg|MULTI-SLICE SPIRAL CT||||SPOUSE|MICROSCOPIST 2|NA|5|Visit_5|90|2|WASHOUT|2021-03-11|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-16|P1Y2M10DT2H30M|UNKNOWN|2021-02-17|AFTER|2021-03-14
e|RS|5934d59a-b0f4-4377-a3c3-00d434d3ddfd|10|STRUSTAT|Steroid Use Status|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|cmH2O/mL|COMPLETE MRD RESPONSE|1|mL/s|ELECTROMYOGRAPHY|Y|||CLINICAL RESEARCH ASSOCIATE|CLINICAL PATHOLOGIST|NA|5|Visit_5|90|2|WASHOUT|2021-03-11|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-16|P1Y2M10DT2H30M|COINCIDENT|2021-02-26|COINCIDENT|2021-03-06
e|RS|59b0fee3-2294-448e-9837-38bd6b5c794b|1|MOLRESP|Molecular Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|cmH2O/mL|MAJOR PATHOLOGIC RESPONSE|1|EID 50/mL|ARTERIAL SPIN LABELING FUNCTIONAL MRI|Y|Y||INTERVIEWER|PATHOLOGIST 2|NA|1|Visit_1|10|2|WASHOUT|2021-01-01|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-24|P1Y2M10DT2H30M|BEFORE|2021-02-17|COINCIDENT|2021-03-24
e|RS|59b0fee3-2294-448e-9837-38bd6b5c794b|2|TRGRESP|Target Response|RECICL|||NED|1|10^7/L|INDIA INK STAIN|||Y|STUDY SUBJECT|INTERNIST|NA|1|Visit_1|10|6|SCREENING|2021-01-01|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-24|P1Y2M10DT2H30M|AFTER|2021-03-12|BEFORE|2021-03-19
e|RS|59b0fee3-2294-448e-9837-38bd6b5c794b|3|ANATRESP|Anatomic Response|MONTSERRAT CLL 1989|[?]|PA|NE|1|hPa|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY||||CLINICAL STUDY SPONSOR|DERMATOLOGIST|U|2|Visit_2|25|5|WASHOUT|2021-01-16|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-14|P1Y2M10DT2H30M|AFTER|2021-01-02|BEFORE|2021-01-07
e|RS|59b0fee3-2294-448e-9837-38bd6b5c794b|4|LIVRRESP|Liver Response|MRECIST LENCIONI LIVER CANCER 2010|||CYTOGENETIC PR|1|GPL U|TRANSCRIPTION-MEDIATED AMPLIFICATION|||Y|CLINICAL STUDY SPONSOR|ADJUDICATOR 1|U|2|Visit_2|25|6|TREATMENT|2021-01-16|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-14|P1Y2M10DT2H30M|AFTER|2020-12-31|COINCIDENT|2021-01-20
e|RS|59b0fee3-2294-448e-9837-38bd6b5c794b|5|NTERESP|Non-Target Enhancing Response|iRECIST|[?]|cmol/L|mCR|1|pmol/L|PUPILLOMETRY||Y||ADJUDICATION COMMITTEE|PEDIATRIC NEUROLOGIST|N|3|Visit_3|40|7|TREATMENT|2021-01-31|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-13|P1Y2M10DT2H30M|BEFORE|2021-01-03|ONGOING|2021-03-06
e|RS|59b0fee3-2294-448e-9837-38bd6b5c794b|6|NTNERESP|Non-Target Non-Enhancing Response|IWC HALLEK CLL 2008|[?]|IMPLANT|MOLECULAR MAJOR RESPONSE|1|SQU/mL|QUANTITATIVE ULTRASOUND||||SIBLING|ONCOLOGIST 2|Y|3|Visit_3|40|3|TREATMENT|2021-01-31|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-13|P1Y2M10DT2H30M|COINCIDENT|2021-01-03|BEFORE|2021-01-22
e|RS|59b0fee3-2294-448e-9837-38bd6b5c794b|7|NTRGRESP|Non-target Response|PRINCE TCELL LYMPHOMA 2010|[?]|m/sec2|NON-CR/NON-PD|1|pt_br|VIRUS PLAQUE ASSAY|Y|Y||HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|N|4|Visit_4|65|6|WASHOUT|2021-02-25|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-22|P1Y2M10DT2H30M|COINCIDENT|2021-03-07|ONGOING|2021-03-27
e|RS|59b0fee3-2294-448e-9837-38bd6b5c794b|8|OVRLRESP|Overall Response|IWG CHESON MDS 2000|[?]|steps/min|COMPLETE MRD RESPONSE|1|mOsm/L|CONTRAST ENHANCED SPIRAL CT SCAN|Y|||FRIEND|OPHTHALMOLOGIST|N|4|Visit_4|65|4|SCREENING|2021-02-25|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-22|P1Y2M10DT2H30M|UNKNOWN|2021-02-23|ONGOING|2021-03-24
e|RS|59b0fee3-2294-448e-9837-38bd6b5c794b|9|NTRGRESP|Non-target Response|HARTMANN GERM CELL CANCER 2002|||PR|1|ug/L FEU|PH METER MEASUREMENT METHOD|Y|Y|Y|STUDY SUBJECT|MICROSCOPIST 1|NA|5|Visit_5|90|3|SCREENING|2021-03-22|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-27|P1Y2M10DT2H30M|AFTER|2021-02-08|COINCIDENT|2021-03-16
e|RS|59b0fee3-2294-448e-9837-38bd6b5c794b|10|MRDIND|Minimal Residual Disease Indicator|KEAM BREAST CANCER 2013|[?]|Anson U|MORPHOLOGIC LEUKEMIA-FREE STATE|1|foz_br|IODINE STAIN|Y|||STUDY SUBJECT|RATER 1|Y|5|Visit_5|90|1|TREATMENT|2021-03-22|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-27|P1Y2M10DT2H30M|BEFORE|2020-12-24|ONGOING|2021-03-21
e|RS|d9bdb1e3-4630-423f-be01-4873bce30422|1|NEWLIND|New Lesion Indicator|IWG CHESON MDS 2000|[?]|10^3 CFU/mL|CR-CT|1|mL/min/mmHg|PULMONARY ANGIOGRAPHY||||VENDOR|READER 3|N|1|Visit_1|10|2|TREATMENT|2020-12-22|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-07|P1Y2M10DT2H30M|BEFORE|2020-12-28|BEFORE|2021-03-01
e|RS|d9bdb1e3-4630-423f-be01-4873bce30422|2|HEMARESP|Hematologic Response|GUPPY OVARIAN CANCER 2002|||RELAPSED DISEASE|1|10^6 organisms/mL|OSCILLOMETRY|||Y|VENDOR|ONCOLOGIST 1|N|1|Visit_1|10|5|TREATMENT|2020-12-22|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-07|P1Y2M10DT2H30M|AFTER|2021-01-09|AFTER|2021-02-20
e|RS|d9bdb1e3-4630-423f-be01-4873bce30422|3|CLINRESP|Clinical Response|LEE LUNG CANCER 2011|[?]|CYLINDER|QUANTIFIABLE MRD POSITIVITY|1|mkat|TURBIDIMETRY||||PROXY|CARDIOLOGIST|U|2|Visit_2|25|1|TREATMENT|2021-01-06|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-20|P1Y2M10DT2H30M|UNKNOWN|2021-01-31|COINCIDENT|2021-02-18
e|RS|d9bdb1e3-4630-423f-be01-4873bce30422|4|DRCRIND|Disease Recurrence Indicator|HARTMANN GERM CELL CANCER 2002|||EQUIVOCAL|1|ECL unit|PERIPHERAL ANGIOGRAPHY|Y||Y|SIBLING|NEUROLOGIST 1|Y|2|Visit_2|25|3|WASHOUT|2021-01-06|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-20|P1Y2M10DT2H30M|BEFORE|2021-02-16|AFTER|2021-03-17
e|RS|d9bdb1e3-4630-423f-be01-4873bce30422|5|DRCRIND|Disease Recurrence Indicator|CHOI GIST 2008|||cCR|1|MBq|CALCOFLUOR WHITE STAIN|Y||Y|SIBLING|PATHOLOGIST|Y|3|Visit_3|40|6|FOLLOW-UP|2021-01-21|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-20|P1Y2M10DT2H30M|AFTER|2021-02-09|BEFORE|2021-03-06
e|RS|d9bdb1e3-4630-423f-be01-4873bce30422|6|TRGRESP|Target Response|MASS|[?]|ug/m2/day|mCR|1|mL/m2|EPSILOMETER||||INDEPENDENT ASSESSOR|ADJUDICATOR|NA|3|Visit_3|40|4|SCREENING|2021-01-21|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-20|P1Y2M10DT2H30M|BEFORE|2021-03-10|COINCIDENT|2021-03-19
e|RS|d9bdb1e3-4630-423f-be01-4873bce30422|7|MNPTHIND|Minor Pathological Response Indicator|IWC HALLEK CLL 2008|[?]|kat|nPR|1|cmol/L|ELECTROMYOGRAPHY||||FRIEND|RATER|NA|4|Visit_4|65|4|SCREENING|2021-02-15|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-29|P1Y2M10DT2H30M|COINCIDENT|2020-12-22|ONGOING|2020-12-29
e|RS|d9bdb1e3-4630-423f-be01-4873bce30422|8|NTNERESP|Non-Target Non-Enhancing Response|IWC HALLEK CLL 2008|[?]|AFU|MOLECULAR MAJOR RESPONSE|1|uCi|LC-FL||||CLINICAL RESEARCH ASSOCIATE|RATER 2|Y|4|Visit_4|65|3|WASHOUT|2021-02-15|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-29|P1Y2M10DT2H30M|BEFORE|2021-02-15|AFTER|2021-03-03
e|RS|d9bdb1e3-4630-423f-be01-4873bce30422|9|HEMARESP|Hematologic Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|||MR|1|mm/min|SINGLE-SLICE SPIRAL CT||Y|Y|DOMESTIC PARTNER|DERMATOLOGIST|U|5|Visit_5|90|6|TREATMENT|2021-03-12|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-08|P1Y2M10DT2H30M|UNKNOWN|2021-01-28|AFTER|2021-03-20
e|RS|d9bdb1e3-4630-423f-be01-4873bce30422|10|MOLRESP|Molecular Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|mL/cage/day|PR|1|mCi|POLYSOMNOGRAPHY||||INVESTIGATOR|MICROSCOPIST 3|N|5|Visit_5|90|6|TREATMENT|2021-03-12|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-08|P1Y2M10DT2H30M|UNKNOWN|2021-03-02|AFTER|2021-03-19
e|RS|7a2e5851-3c3e-46b4-876f-7dd6c8005f9a|1|NEWLIND|New Lesion Indicator|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|/5x10^4 WBC|NED|1|Tbsp|ELECTROCHEMILUMINESCENCE IMMUNOASSAY|Y|||SPOUSE|INTERNIST|NA|1|Visit_1|10|2|TREATMENT|2020-06-25|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-14|P1Y2M10DT2H30M|UNKNOWN|2020-07-12|AFTER|2020-08-21
e|RS|7a2e5851-3c3e-46b4-876f-7dd6c8005f9a|2|STRUSTAT|Steroid Use Status|SACT|[?]|DDU|iSD|1|nmol/kg/day|WESTERGREN||Y||INVESTIGATOR|MICROSCOPIST 1|N|1|Visit_1|10|1|TREATMENT|2020-06-25|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-14|P1Y2M10DT2H30M|UNKNOWN|2020-08-19|BEFORE|2020-09-09
e|RS|7a2e5851-3c3e-46b4-876f-7dd6c8005f9a|3|MOLRESP|Molecular Response|PERCIST|[?]|umol/h/mmol|CMR|1|10^9 CFU/g|LIGHT MICROSCOPY||||INTERVIEWER|NEUROLOGIST|Y|2|Visit_2|25|2|TREATMENT|2020-07-10|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-15|P1Y2M10DT2H30M|COINCIDENT|2020-07-05|ONGOING|2020-07-30
e|RS|7a2e5851-3c3e-46b4-876f-7dd6c8005f9a|4|MRDIND|Minimal Residual Disease Indicator|DURIE MULTIPLE MYELOMA 2006|[?]|%/s|PD-CT|1|RNA copies/mL|ENZYMATIC COLORIMETRY|Y|||STUDY SUBJECT|MICROSCOPIST 1|NA|2|Visit_2|25|5|TREATMENT|2020-07-10|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-15|P1Y2M10DT2H30M|BEFORE|2020-07-13|BEFORE|2020-07-21
e|RS|7a2e5851-3c3e-46b4-876f-7dd6c8005f9a|5|METSIND|Metastatic Indicator|KEAM BREAST CANCER 2013|[?]|10^3/hpf|OPTIMAL MORPHOLOGIC RESPONSE|1|mg/dose|VENTILATION PERFUSION LUNG SCAN||Y||CLINICAL STUDY SPONSOR|PEDIATRIC NEUROLOGIST|NA|3|Visit_3|40|6|TREATMENT|2020-07-25|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-18|P1Y2M10DT2H30M|BEFORE|2020-07-18|BEFORE|2020-09-11
e|RS|7a2e5851-3c3e-46b4-876f-7dd6c8005f9a|6|METSIND|Metastatic Indicator|KUMAR IMWG 2016|[?]|/2500 WBC|PSEUDOPROGRESSION|1|Enzyme U|OPTICAL MAPPING|Y|||CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR|N|3|Visit_3|40|4|WASHOUT|2020-07-25|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-18|P1Y2M10DT2H30M|COINCIDENT|2020-08-15|BEFORE|2020-09-17
e|RS|7a2e5851-3c3e-46b4-876f-7dd6c8005f9a|7|BONERESP|Bone Response|CHESON CLL 2006|[?]|USP U|PD/RELAPSE AFTER HI|1|Gy|NUCLEIC ACID SEQUENCING|Y|||SIBLING|NEUROLOGIST 1|N|4|Visit_4|65|7|SCREENING|2020-08-19|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-23|P1Y2M10DT2H30M|AFTER|2020-09-21|AFTER|2020-09-22
e|RS|7a2e5851-3c3e-46b4-876f-7dd6c8005f9a|8|PATHRESP|Pathologic Response|HARTMANN GERM CELL CANCER 2002|[?]|ug/min|NON-PD|1|cm H2O|HPLC/MS/MS|Y|||ADJUDICATOR|MICROSCOPIST|NA|4|Visit_4|65|4|TREATMENT|2020-08-19|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-23|P1Y2M10DT2H30M|COINCIDENT|2020-06-17|BEFORE|2020-09-13
e|RS|7a2e5851-3c3e-46b4-876f-7dd6c8005f9a|9|MNPTHIND|Minor Pathological Response Indicator|RAJKUMAR MYELOMA 2011|[?]|ug/m2|HI-P|1|RNA copies/mL|TRANSCRIPTION-MEDIATED AMPLIFICATION||||CLINICAL STUDY SPONSOR|READER|Y|5|Visit_5|90|5|SCREENING|2020-09-13|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-13|P1Y2M10DT2H30M|COINCIDENT|2020-09-08|BEFORE|2020-09-21
e|RS|7a2e5851-3c3e-46b4-876f-7dd6c8005f9a|10|HEMARESP|Hematologic Response|PRINCE TCELL LYMPHOMA 2010|||HI-E|1|CAPFUL|ZIEHL NEELSEN ACID FAST STAIN|||Y|SPOUSE|OPTOMETRIST|NA|5|Visit_5|90|2|TREATMENT|2020-09-13|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-13|P1Y2M10DT2H30M|UNKNOWN|2020-06-29|AFTER|2020-07-18
e|RS|5546d86b-6a12-4b5f-b66f-8d85ba4691e6|1|CYTORESP|Cytogenetic Response|SHINDOH COLORECTAL CANCER 2013|[?]|uOsm|NON-iCR/NON-iUPD|1|msec|WHOLE GENOME SEQUENCING||Y||INDEPENDENT ASSESSOR|OPTOMETRIST|Y|1|Visit_1|10|5|TREATMENT|2020-08-04|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-15|P1Y2M10DT2H30M|UNKNOWN|2020-09-11|ONGOING|2020-10-11
e|RS|5546d86b-6a12-4b5f-b66f-8d85ba4691e6|2|HEMARESP|Hematologic Response|DURIE MULTIPLE MYELOMA 2006|[?]|MPL U/mL|NON-iCR/NON-iUPD|1|mPa|MAGNETIC RESONANCE ENTEROGRAPHY|Y|||CHILD|ONCOLOGIST 2|NA|1|Visit_1|10|7|FOLLOW-UP|2020-08-04|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-15|P1Y2M10DT2H30M|AFTER|2020-08-13|BEFORE|2020-10-08
e|RS|5546d86b-6a12-4b5f-b66f-8d85ba4691e6|3|TRGRESP|Target Response|CHESON CLL 2006|[?]|bel|iCPD|1|10^7 PFU|PULMONARY ANGIOGRAPHY||Y||FRIEND|OPTOMETRIST|NA|2|Visit_2|25|2|WASHOUT|2020-08-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-30|P1Y2M10DT2H30M|UNKNOWN|2020-09-14|BEFORE|2020-09-28
e|RS|5546d86b-6a12-4b5f-b66f-8d85ba4691e6|4|BMIVLIND|Bone Marrow Involvement Indicator|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|/mm|MRD NEGATIVITY|1|umol/L/sec|LIQUID SCINTILLATION COUNTING||||HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|U|2|Visit_2|25|6|SCREENING|2020-08-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-30|P1Y2M10DT2H30M|AFTER|2020-08-29|BEFORE|2020-08-31
e|RS|5546d86b-6a12-4b5f-b66f-8d85ba4691e6|5|SYMPTDTR|Symptomatic Deterioration|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|cGy|ABSENT MORPHOLOGIC RESPONSE|1|damol/L|PHASE-CONTRAST MRI||||CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 1|Y|3|Visit_3|40|2|WASHOUT|2020-09-03|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-25|P1Y2M10DT2H30M|BEFORE|2020-07-29|ONGOING|2020-10-22
e|RS|5546d86b-6a12-4b5f-b66f-8d85ba4691e6|6|NTLWIND|Non-Target Lesion Worsening Indicator|KUMAR IMWG 2016|[?]|/500 WBC|MRD PERSISTENCE|1|deg/mm|GRAM STAIN||||ADJUDICATION COMMITTEE|OTOLARYNGOLOGIST|U|3|Visit_3|40|5|TREATMENT|2020-09-03|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-25|P1Y2M10DT2H30M|UNKNOWN|2020-07-29|ONGOING|2020-08-11
e|RS|5546d86b-6a12-4b5f-b66f-8d85ba4691e6|7|MRPHRESP|Morphologic Response|RAJKUMAR MYELOMA 2011|||CRi|1|kg/L|DIGITAL PCR|||Y|INTERVIEWER|ONCOLOGIST 2|NA|4|Visit_4|65|5|FOLLOW-UP|2020-09-28|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-10|P1Y2M10DT2H30M|COINCIDENT|2020-08-05|AFTER|2020-09-30
e|RS|5546d86b-6a12-4b5f-b66f-8d85ba4691e6|8|BMIVLIND|Bone Marrow Involvement Indicator|CHOI GIST 2008|[?]|mg/m2/min|MOLECULAR MAJOR RESPONSE|1|pmol/10^10 cells|QUANTITATIVE CORONARY ANGIOGRAPHY||||SIBLING|ADJUDICATOR|N|4|Visit_4|65|1|TREATMENT|2020-09-28|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-10|P1Y2M10DT2H30M|BEFORE|2020-10-23|BEFORE|2020-10-29
e|RS|5546d86b-6a12-4b5f-b66f-8d85ba4691e6|9|DRCRIND|Disease Recurrence Indicator|BRUGGEMANN MRD 2010|[?]|U/10^12 RBC|NON-iCR/NON-iUPD|1|mV*min|FLUORESCENCE ANGIOGRAPHY||Y||DOMESTIC PARTNER|INTERNIST|U|5|Visit_5|90|4|SCREENING|2020-10-23|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-29|P1Y2M10DT2H30M|COINCIDENT|2020-10-07|COINCIDENT|2020-10-12
e|RS|5546d86b-6a12-4b5f-b66f-8d85ba4691e6|10|NTLWIND|Non-Target Lesion Worsening Indicator|CHESON CLL 2006|[?]|mmol2/L2|CMR|1|mg/L|MICROBIAL CONCENTRATION||Y||STUDY SUBJECT|MICROSCOPIST|U|5|Visit_5|90|1|FOLLOW-UP|2020-10-23|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-29|P1Y2M10DT2H30M|COINCIDENT|2020-08-08|BEFORE|2020-08-28
e|RS|933c3a61-59a0-4cfb-ae17-45bc48229323|1|MJPTHIND|Major Pathological Response Indicator|HARTMANN GERM CELL CANCER 2002|[?]|10^6 CFU|CA125 75% RESPONSE|1|Ci/kg|DIGITAL PCR||||FAMILY MEMBER|RATER|Y|1|Visit_1|10|4|SCREENING|2020-09-09|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-20|P1Y2M10DT2H30M|COINCIDENT|2020-10-13|ONGOING|2020-12-06
e|RS|933c3a61-59a0-4cfb-ae17-45bc48229323|2|NTRGRESP|Non-target Response|IWG CHESON AML 2003|[?]|10^3 organisms/g|PD-CT|1|mmol|TRANSMISSION ELECTRON MICROSCOPY|Y|Y||SIBLING|FORENSIC PATHOLOGIST|N|1|Visit_1|10|4|TREATMENT|2020-09-09|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-20|P1Y2M10DT2H30M|UNKNOWN|2020-10-23|ONGOING|2020-11-22
e|RS|933c3a61-59a0-4cfb-ae17-45bc48229323|3|NTERESP|Non-Target Enhancing Response|RANO ELLINGSON 2017|[?]|nL|MRD PERSISTENCE|1|Coulomb|CRYOSCOPY|Y|||SPOUSE|ONCOLOGIST|U|2|Visit_2|25|4|FOLLOW-UP|2020-09-24|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-01|P1Y2M10DT2H30M|AFTER|2020-11-28|AFTER|2020-12-03
e|RS|933c3a61-59a0-4cfb-ae17-45bc48229323|4|ANATRESP|Anatomic Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|BISCUIT|IMMUNOPHENOTYPIC CR|1|10^6/g|TOTAL BODY IRRADIATION||||INVESTIGATOR|MICROSCOPIST 3|N|2|Visit_2|25|2|FOLLOW-UP|2020-09-24|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-01|P1Y2M10DT2H30M|AFTER|2020-09-12|ONGOING|2020-11-07
e|RS|933c3a61-59a0-4cfb-ae17-45bc48229323|5|OVRLRESP|Overall Response|MONTSERRAT CLL 1989|[?]|mL/s|MRD RELAPSE|1|GBq|SINGLE-MOLECULE ARRAY||||NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|NA|3|Visit_3|40|3|FOLLOW-UP|2020-10-09|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-12|P1Y2M10DT2H30M|BEFORE|2020-09-15|COINCIDENT|2020-11-25
e|RS|933c3a61-59a0-4cfb-ae17-45bc48229323|6|TMRESP|Tumor Marker Response|SCHWARZ CERVICAL CANCER 2009|[?]|vg/dose|MAJOR PATHOLOGIC RESPONSE|1|CFU/g|IMMUNOFLUORESCENT STAIN||||PARENT|READER 1|Y|3|Visit_3|40|5|WASHOUT|2020-10-09|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-12|P1Y2M10DT2H30M|UNKNOWN|2020-09-22|BEFORE|2020-10-21
e|RS|933c3a61-59a0-4cfb-ae17-45bc48229323|7|ANATRESP|Anatomic Response|WHO BREAST CANCER 2006|[?]|mg/kg/h|CYTOGENETIC MINIMAL RESPONSE|1|uIU/dL|GIEMSA STAIN|Y|Y||SIGNIFICANT OTHER|ONCOLOGIST|N|4|Visit_4|65|5|TREATMENT|2020-11-03|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-30|P1Y2M10DT2H30M|AFTER|2020-12-05|AFTER|2020-12-06
e|RS|933c3a61-59a0-4cfb-ae17-45bc48229323|8|DRCRIND|Disease Recurrence Indicator|PCWG BUBLEY PROSTATE CANCER 1999|[?]|mmol/kg|PDu|1|PNU/mL|CLIP SEQUENCING||Y||ADJUDICATOR|INTERNIST|N|4|Visit_4|65|1|TREATMENT|2020-11-03|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-30|P1Y2M10DT2H30M|COINCIDENT|2020-09-08|ONGOING|2020-10-11
e|RS|933c3a61-59a0-4cfb-ae17-45bc48229323|9|METSIND|Metastatic Indicator|KUKER LYMPHOMA 2005|[?]|10^5/L|PSA PROGRESSION|1|mg/h|TARGETED GENOME SEQUENCING||||DOMESTIC PARTNER|ONCOLOGIST 1|Y|5|Visit_5|90|2|SCREENING|2020-11-28|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-27|P1Y2M10DT2H30M|AFTER|2020-10-26|AFTER|2020-11-18
e|RS|933c3a61-59a0-4cfb-ae17-45bc48229323|10|SFTSRESP|Soft Tissue Response|DOHNER AML 2010|[?]|/HPF|NOT ALL EVALUATED|1|/min|TURBIDIMETRY|Y|||CLINICAL STUDY SPONSOR|CLINICAL PATHOLOGIST|NA|5|Visit_5|90|2|TREATMENT|2020-11-28|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-27|P1Y2M10DT2H30M|COINCIDENT|2020-11-10|COINCIDENT|2020-11-13
e|RS|58d871e3-ef99-48da-ab12-fdfdc2e01da6|1|TMRESP|Tumor Marker Response|IRANO 2015|[?]|VOXEL|SD-CT|1|/VF|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION||||SIBLING|NEUROLOGIST|N|1|Visit_1|10|3|TREATMENT|2020-10-26|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-06|P1Y2M10DT2H30M|UNKNOWN|2020-11-03|COINCIDENT|2021-01-22
e|RS|58d871e3-ef99-48da-ab12-fdfdc2e01da6|2|PATHRESP|Pathologic Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|kcal|INDETERMINATE RESPONSE|1|MONTHS|POLYSOMNOGRAPHY|Y|||CHILD|READER 3|NA|1|Visit_1|10|2|WASHOUT|2020-10-26|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-06|P1Y2M10DT2H30M|UNKNOWN|2021-01-06|ONGOING|2021-01-21
e|RS|58d871e3-ef99-48da-ab12-fdfdc2e01da6|3|BESTRESP|Best Overall Response|JUWEID NON-HODGKINS LYMPHOMA 2005|||PD FROM PR|1|ppth|MEDIASTINOSCOPY|||Y|INDEPENDENT ASSESSOR|UROLOGIST|U|2|Visit_2|25|2|TREATMENT|2020-11-10|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-15|P1Y2M10DT2H30M|AFTER|2020-12-17|COINCIDENT|2020-12-29
e|RS|58d871e3-ef99-48da-ab12-fdfdc2e01da6|4|MOLRESP|Molecular Response|EASL BRUIX LIVER CANCER 2001|[?]|mL/m2/h|CA125 75% RESPONSE|1|titer|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY|Y|Y||FRIEND|PEDIATRIC NEUROLOGIST|U|2|Visit_2|25|7|FOLLOW-UP|2020-11-10|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-15|P1Y2M10DT2H30M|BEFORE|2020-11-23|AFTER|2020-12-01
e|RS|58d871e3-ef99-48da-ab12-fdfdc2e01da6|5|MNPTHIND|Minor Pathological Response Indicator|SHINDOH COLORECTAL CANCER 2013|[?]|ugEq|PSEUDORESPONSE|1|uL/kg/day|MEDIASTINOSCOPY||||CAREGIVER|RATER 2|N|3|Visit_3|40|7|TREATMENT|2020-11-25|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-02|P1Y2M10DT2H30M|BEFORE|2020-10-25|ONGOING|2020-10-31
e|RS|58d871e3-ef99-48da-ab12-fdfdc2e01da6|6|DRCRIND|Disease Recurrence Indicator|iRECIST|[?]|SFC/10^6 PBMC|MRD PERSISTENCE|1|km/h|DOPPLER ULTRASOUND||||CLINICAL STUDY SPONSOR|OPTOMETRIST|Y|3|Visit_3|40|1|WASHOUT|2020-11-25|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-02|P1Y2M10DT2H30M|BEFORE|2020-12-08|AFTER|2020-12-11
e|RS|58d871e3-ef99-48da-ab12-fdfdc2e01da6|7|MNPTHIND|Minor Pathological Response Indicator|DOHNER AML 2010|[?]|L/h/m2|SD|1|cal|KINYOUN STAIN||||ADJUDICATOR|RATER 1|U|4|Visit_4|65|4|FOLLOW-UP|2020-12-20|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-28|P1Y2M10DT2H30M|AFTER|2021-01-08|AFTER|2021-01-12
e|RS|58d871e3-ef99-48da-ab12-fdfdc2e01da6|8|NEWLIND|New Lesion Indicator|RECIST 1.0|[?]|mL/kg/h|CR-CT|1|OI50|CONTRAST ENHANCED MRI||||ADJUDICATOR|NEUROLOGIST|N|4|Visit_4|65|2|WASHOUT|2020-12-20|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-28|P1Y2M10DT2H30M|COINCIDENT|2021-01-13|COINCIDENT|2021-01-18
e|RS|58d871e3-ef99-48da-ab12-fdfdc2e01da6|9|METBRESP|Metabolic Response|LUGANO CLASSIFICATION|||CYTOGENETIC CR|1|Gravitational Unit|PULSE OXIMETRY|Y||Y|PARENT|READER|U|5|Visit_5|90|2|TREATMENT|2021-01-14|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-03|P1Y2M10DT2H30M|UNKNOWN|2020-12-02|COINCIDENT|2020-12-28
e|RS|58d871e3-ef99-48da-ab12-fdfdc2e01da6|10|CPRFSTAT|Clinical Performance Status|IWG CHESON MDS 2000|||PR-CT|1|U/cL|MICROSCOPY|||Y|CLINICAL STUDY SPONSOR|ADJUDICATOR 2|NA|5|Visit_5|90|6|FOLLOW-UP|2021-01-14|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-03|P1Y2M10DT2H30M|UNKNOWN|2021-01-14|ONGOING|2021-01-17
e|RS|ac66129e-3244-4cd8-a235-43b4bfb7dace|1|MRDIND|Minimal Residual Disease Indicator|GUPPY OVARIAN CANCER 2002|[?]|usec|QUANTIFIABLE MRD POSITIVITY|1|mol/mg|NEXT GENERATION TARGETED SEQUENCING||||FRIEND|ONCOLOGIST 2|Y|1|Visit_1|10|6|TREATMENT|2020-10-29|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-31|P1Y2M10DT2H30M|COINCIDENT|2021-01-22|ONGOING|2021-01-23
e|RS|ac66129e-3244-4cd8-a235-43b4bfb7dace|2|ANATRESP|Anatomic Response|EBMT BLADE MYELOMA 1998|[?]|mL/mmHg/min/L|ABSENT MORPHOLOGIC RESPONSE|1|mEq|ACRIDINE ORANGE STAIN||||CAREGIVER|NEUROLOGIST 2|NA|1|Visit_1|10|3|WASHOUT|2020-10-29|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-31|P1Y2M10DT2H30M|UNKNOWN|2021-01-09|COINCIDENT|2021-01-17
e|RS|ac66129e-3244-4cd8-a235-43b4bfb7dace|3|PATHRESP|Pathologic Response|EASL BRUIX LIVER CANCER 2001|[?]|CFU/g|MORPHOLOGIC CRi|1|amu|DIGITAL PCR ARRAY||Y||SIBLING|DERMATOLOGIST|N|2|Visit_2|25|6|TREATMENT|2020-11-13|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-30|P1Y2M10DT2H30M|COINCIDENT|2020-12-24|AFTER|2020-12-31
e|RS|ac66129e-3244-4cd8-a235-43b4bfb7dace|4|RDIORESP|Radiologic Response|UNSPECIFIED|[?]|Osm|IMMUNOPHENOTYPIC CR|1|/cmH2O|INDIA INK STAIN||||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 3|N|2|Visit_2|25|1|TREATMENT|2020-11-13|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-30|P1Y2M10DT2H30M|BEFORE|2021-01-23|BEFORE|2021-01-24
e|RS|ac66129e-3244-4cd8-a235-43b4bfb7dace|5|MJPTHIND|Major Pathological Response Indicator|HAMAOKA BREAST CANCER 2010|||MINOR PATHOLOGIC RESPONSE|1|IU/L|ELECTROMYOGRAPHY|Y||Y|INDEPENDENT ASSESSOR|RATER 1|N|3|Visit_3|40|1|WASHOUT|2020-11-28|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-07|P1Y2M10DT2H30M|AFTER|2021-01-03|ONGOING|2021-01-26
e|RS|ac66129e-3244-4cd8-a235-43b4bfb7dace|6|RDIORESP|Radiologic Response|WOLCHOK SOLID TUMORS 2009|[?]|Coulomb|MORPHOLOGIC CR|1|WAFER|DUKE INCISION METHOD||||SIBLING|DEVELOPMENTAL PSYCHOLOGIST|U|3|Visit_3|40|2|TREATMENT|2020-11-28|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-07|P1Y2M10DT2H30M|COINCIDENT|2020-12-30|COINCIDENT|2021-01-06
e|RS|ac66129e-3244-4cd8-a235-43b4bfb7dace|7|METSIND|Metastatic Indicator|DURIE MULTIPLE MYELOMA 2006|[?]|ms/mmHg|PD|1|IU/L|GC/FID|Y|Y||CAREGIVER|OTOLARYNGOLOGIST|U|4|Visit_4|65|4|FOLLOW-UP|2020-12-23|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-10|P1Y2M10DT2H30M|COINCIDENT|2020-11-04|COINCIDENT|2020-12-16
e|RS|ac66129e-3244-4cd8-a235-43b4bfb7dace|8|NTNERESP|Non-Target Non-Enhancing Response|BURCOMBE BREAST CANCER 2005|[?]|beats/min|CRi|1|PA|LEAD CITRATE STAIN||||CLINICAL RESEARCH COORDINATOR|RATER 2|NA|4|Visit_4|65|5|TREATMENT|2020-12-23|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-10|P1Y2M10DT2H30M|BEFORE|2020-12-02|COINCIDENT|2020-12-04
e|RS|ac66129e-3244-4cd8-a235-43b4bfb7dace|9|HEMARESP|Hematologic Response|JACINTO CERVICAL CANCER 2007|||QUANTIFIABLE MRD POSITIVITY|1|L/s|LYMPHANGIOGRAPHY||Y|Y|ADJUDICATION COMMITTEE|MICROSCOPIST 3|N|5|Visit_5|90|4|WASHOUT|2021-01-17|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-07|P1Y2M10DT2H30M|COINCIDENT|2020-11-25|ONGOING|2020-12-05
e|RS|ac66129e-3244-4cd8-a235-43b4bfb7dace|10|MOLRESP|Molecular Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|||MAJOR PATHOLOGIC RESPONSE|1|mmol|MICROBIAL CONCENTRATION|||Y|VENDOR|READER 3|U|5|Visit_5|90|4|WASHOUT|2021-01-17|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-07|P1Y2M10DT2H30M|BEFORE|2020-12-13|COINCIDENT|2021-01-17
e|RS|2f2297c4-ed0a-45c2-bbd9-13c945abb67b|1|LIVRRESP|Liver Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|mmol/min/kPa/L|EQUIVOCAL|1|mEq/L|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS||||CLINICAL RESEARCH ASSOCIATE|RATER 2|U|1|Visit_1|10|2|TREATMENT|2020-09-02|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-05|P1Y2M10DT2H30M|BEFORE|2020-11-25|AFTER|2020-11-26
e|RS|2f2297c4-ed0a-45c2-bbd9-13c945abb67b|2|SPLNRESP|Spleen Response|WOLCHOK SOLID TUMORS 2009|[?]|log10 TCID 50/dose|CHR|1|SUPPOSITORY|FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY||||VENDOR|CARDIOLOGIST|Y|1|Visit_1|10|1|TREATMENT|2020-09-02|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-05|P1Y2M10DT2H30M|COINCIDENT|2020-11-15|AFTER|2020-11-29
e|RS|2f2297c4-ed0a-45c2-bbd9-13c945abb67b|3|SFTSRESP|Soft Tissue Response|JACINTO CERVICAL CANCER 2007|||PD-CT|1|10^3 organisms|NEURAMINIDASE INHIBITION ASSAY|||Y|INDEPENDENT ASSESSOR|READER 1|NA|2|Visit_2|25|5|SCREENING|2020-09-17|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-26|P1Y2M10DT2H30M|BEFORE|2020-09-27|ONGOING|2020-10-29
e|RS|2f2297c4-ed0a-45c2-bbd9-13c945abb67b|4|ANATRESP|Anatomic Response|GUPPY OVARIAN CANCER 2002|[?]|TRANSDUCING UNIT/mL|iCPD|1|cup eq|FUNCTIONAL MRI||||ADJUDICATOR|CARDIOLOGIST|Y|2|Visit_2|25|1|TREATMENT|2020-09-17|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-26|P1Y2M10DT2H30M|UNKNOWN|2020-11-19|ONGOING|2020-11-28
e|RS|2f2297c4-ed0a-45c2-bbd9-13c945abb67b|5|MNPTHIND|Minor Pathological Response Indicator|CHOLLET BREAST CANCER 2002|[?]|DRUM|CHR|1|scm|DXA SCAN|Y|||FAMILY MEMBER|ONCOLOGIST 1|N|3|Visit_3|40|6|TREATMENT|2020-10-02|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-29|P1Y2M10DT2H30M|BEFORE|2020-10-21|ONGOING|2020-10-28
e|RS|2f2297c4-ed0a-45c2-bbd9-13c945abb67b|6|BESTRESP|Best Overall Response|IWG CHESON MDS 2006|[?]|%(w/v)|NON-PD|1|SYRINGE|NEXT GENERATION TARGETED SEQUENCING||Y||CLINICAL STUDY SPONSOR|ONCOLOGIST|U|3|Visit_3|40|7|TREATMENT|2020-10-02|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-29|P1Y2M10DT2H30M|AFTER|2020-11-20|BEFORE|2020-11-27
e|RS|2f2297c4-ed0a-45c2-bbd9-13c945abb67b|7|TMRESP|Tumor Marker Response|FAROOQUI SUPP CLL 2014|[?]|PIPE|DECREASED|1|mAmp|QUANTITATIVE ULTRASOUND||||FRIEND|READER 2|Y|4|Visit_4|65|3|TREATMENT|2020-10-27|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-28|P1Y2M10DT2H30M|UNKNOWN|2020-09-04|ONGOING|2020-10-28
e|RS|2f2297c4-ed0a-45c2-bbd9-13c945abb67b|8|SYMPTDTR|Symptomatic Deterioration|IRANO 2015|[?]|U/g/day|STABLE|1|10^6 CFU|MICROBIAL CONCENTRATION||||FRIEND|CARDIOLOGIST|NA|4|Visit_4|65|7|TREATMENT|2020-10-27|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-28|P1Y2M10DT2H30M|UNKNOWN|2020-10-03|AFTER|2020-11-29
e|RS|2f2297c4-ed0a-45c2-bbd9-13c945abb67b|9|TMRESP|Tumor Marker Response|CHESON MALIGNANT LYMPHOMA 2007|||PMR|1|uV|DISK DIFFUSION|||Y|SIBLING|RATER|NA|5|Visit_5|90|2|WASHOUT|2020-11-21|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-02|P1Y2M10DT2H30M|COINCIDENT|2020-09-02|AFTER|2020-09-26
e|RS|2f2297c4-ed0a-45c2-bbd9-13c945abb67b|10|NTNERESP|Non-Target Non-Enhancing Response|AJCC V7|[?]|INHALATION|RELAPSED DISEASE|1|breaths/30s|OPTICAL MAPPING|Y|||DOMESTIC PARTNER|ADJUDICATOR|Y|5|Visit_5|90|5|TREATMENT|2020-11-21|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-02|P1Y2M10DT2H30M|BEFORE|2020-10-16|AFTER|2020-11-29
e|RS|3d59a754-10bb-4847-93ea-433b43265a2f|1|STRUSTAT|Steroid Use Status|HARTMAN PANCREATIC CANCER 2012|[?]|U/kg|MINOR PATHOLOGIC RESPONSE|1|Ci|ZIEHL NEELSEN ACID FAST STAIN|Y|||SIBLING|ENDOCRINOLOGIST|U|1|Visit_1|10|5|TREATMENT|2020-10-24|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-14|P1Y2M10DT2H30M|COINCIDENT|2020-12-29|COINCIDENT|2021-01-07
e|RS|3d59a754-10bb-4847-93ea-433b43265a2f|2|LIVRRESP|Liver Response|IWG CHESON AML 2003|[?]|%/s|SD-CT|1|mV2/Hz|OSCILLOMETRY||||DOMESTIC PARTNER|ADJUDICATOR 2|U|1|Visit_1|10|7|TREATMENT|2020-10-24|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-14|P1Y2M10DT2H30M|BEFORE|2020-11-26|COINCIDENT|2021-01-15
e|RS|3d59a754-10bb-4847-93ea-433b43265a2f|3|SYMPTDTR|Symptomatic Deterioration|RECICL|[?]|mU/g|iPR|1|g/cage/wk|DOPPLER ULTRASOUND||||SPOUSE|ONCOLOGIST 2|U|2|Visit_2|25|5|TREATMENT|2020-11-08|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-27|P1Y2M10DT2H30M|UNKNOWN|2020-11-30|BEFORE|2020-12-31
e|RS|3d59a754-10bb-4847-93ea-433b43265a2f|4|CPRFSTAT|Clinical Performance Status|CHESON CLL 2006|[?]|PELLET|IMPROVED|1|tuberculin unit|TOTAL BODY RADIOGRAPHY||||INTERVIEWER|OTOLARYNGOLOGIST|NA|2|Visit_2|25|3|TREATMENT|2020-11-08|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-27|P1Y2M10DT2H30M|UNKNOWN|2020-10-26|ONGOING|2021-01-03
e|RS|3d59a754-10bb-4847-93ea-433b43265a2f|5|MRPHRESP|Morphologic Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|PFU/mL|sCR|1|ug/day|ACRIDINE ORANGE STAIN||Y||DOMESTIC PARTNER|NEUROLOGIST|U|3|Visit_3|40|5|TREATMENT|2020-11-23|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-25|P1Y2M10DT2H30M|COINCIDENT|2021-01-20|ONGOING|2021-01-21
e|RS|3d59a754-10bb-4847-93ea-433b43265a2f|6|MOLRESP|Molecular Response|DOHNER AML 2010|||iCR|1|Hz|LANDOLT RING|||Y|INDEPENDENT ASSESSOR|CLINICAL PATHOLOGIST|NA|3|Visit_3|40|3|FOLLOW-UP|2020-11-23|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-25|P1Y2M10DT2H30M|COINCIDENT|2021-01-08|AFTER|2021-01-12
e|RS|3d59a754-10bb-4847-93ea-433b43265a2f|7|CLINRESP|Clinical Response|RANO|[?]|ohm|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|uV*sec|CONTRAST ENHANCED CT SCAN||||CLINICAL RESEARCH COORDINATOR|PEDIATRIC NEUROLOGIST|NA|4|Visit_4|65|1|TREATMENT|2020-12-18|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-30|P1Y2M10DT2H30M|AFTER|2021-01-11|AFTER|2021-01-18
e|RS|3d59a754-10bb-4847-93ea-433b43265a2f|8|PATHRESP|Pathologic Response|HARTMANN GERM CELL CANCER 2002|[?]|nkat/L|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|mMU/mL|FISH|Y|||NON-HEALTH CARE PROFESSIONAL|UROLOGIST|U|4|Visit_4|65|4|FOLLOW-UP|2020-12-18|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-30|P1Y2M10DT2H30M|UNKNOWN|2020-12-20|COINCIDENT|2021-01-14
e|RS|3d59a754-10bb-4847-93ea-433b43265a2f|9|METSIND|Metastatic Indicator|LEE LUNG CANCER 2011|[?]|mmol/g|CA125 50% RESPONSE|1|kg/cm2|DYNAMIC CONTRAST ENHANCED MRI||||ADJUDICATOR|ADJUDICATOR|NA|5|Visit_5|90|1|WASHOUT|2021-01-12|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-25|P1Y2M10DT2H30M|UNKNOWN|2020-12-19|ONGOING|2021-01-09
e|RS|3d59a754-10bb-4847-93ea-433b43265a2f|10|MNPTHIND|Minor Pathological Response Indicator|GCIG RUSTIN OVARIAN CANCER 2011|[?]|Pack Year|QUANTIFIABLE MRD POSITIVITY|1|uOsm|ARTERIAL SPIN LABELING FUNCTIONAL MRI||||NON-HEALTH CARE PROFESSIONAL|READER 2|NA|5|Visit_5|90|5|FOLLOW-UP|2021-01-12|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-25|P1Y2M10DT2H30M|UNKNOWN|2020-10-16|COINCIDENT|2020-12-24
e|RS|0d3d37a5-2215-4b28-b6f7-7256abcdd97e|1|TMRESP|Tumor Marker Response|KUKER LYMPHOMA 2005|[?]|MdFI|NON-PD|1|mL/min/mmHg|CELL CYTOTOXICITY NEUTRALIZATION ASSAY||||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|NA|1|Visit_1|10|4|SCREENING|2021-01-20|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-12|P1Y2M10DT2H30M|COINCIDENT|2021-04-09|BEFORE|2021-04-16
e|RS|0d3d37a5-2215-4b28-b6f7-7256abcdd97e|2|MOLRESP|Molecular Response|BRUGGEMANN MRD 2010|[?]|INHALATION|CHR|1|nmol BCE/nmol|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY||||ADJUDICATION COMMITTEE|ONCOLOGIST 2|NA|1|Visit_1|10|3|TREATMENT|2021-01-20|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-12|P1Y2M10DT2H30M|UNKNOWN|2021-04-17|BEFORE|2021-04-18
e|RS|0d3d37a5-2215-4b28-b6f7-7256abcdd97e|3|TMRESP|Tumor Marker Response|IWG CHESON AML 2003|[?]|mg/L FEU|TREATMENT FAILURE|1|U/mmol|ACRIDINE ORANGE STAIN|Y|Y||PARENT|ADJUDICATOR 1|N|2|Visit_2|25|7|FOLLOW-UP|2021-02-04|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-24|P1Y2M10DT2H30M|COINCIDENT|2021-04-19|COINCIDENT|2021-04-20
e|RS|0d3d37a5-2215-4b28-b6f7-7256abcdd97e|4|SPLNRESP|Spleen Response|GUPPY OVARIAN CANCER 2002|[?]|m2|PD/RELAPSE AFTER HI|1|ppm|FLUORESCENT MICROSCOPY||Y||NON-HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|U|2|Visit_2|25|4|WASHOUT|2021-02-04|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-24|P1Y2M10DT2H30M|BEFORE|2021-02-04|ONGOING|2021-02-08
e|RS|0d3d37a5-2215-4b28-b6f7-7256abcdd97e|5|SYMPTDTR|Symptomatic Deterioration|RANO ELLINGSON 2017|[?]|vg/dose|STABLE|1|CARTRIDGE|VIRUS PLAQUE ASSAY||||CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 1|NA|3|Visit_3|40|1|SCREENING|2021-02-19|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-12|P1Y2M10DT2H30M|BEFORE|2021-02-08|BEFORE|2021-03-31
e|RS|0d3d37a5-2215-4b28-b6f7-7256abcdd97e|6|METBRESP|Metabolic Response|LEE LUNG CANCER 2011|||VGPR|1|g/animal|COULOMETRIC TITRATION|||Y|STUDY SUBJECT|READER 2|NA|3|Visit_3|40|3|SCREENING|2021-02-19|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-12|P1Y2M10DT2H30M|COINCIDENT|2021-02-02|BEFORE|2021-03-16
e|RS|0d3d37a5-2215-4b28-b6f7-7256abcdd97e|7|TMRESP|Tumor Marker Response|RANO|[?]|mmol2/L2|CYTOGENETIC PR|1|Sv|MECHANICAL CLOT DETECTION||||CLINICAL RESEARCH ASSOCIATE|READER 1|N|4|Visit_4|65|4|TREATMENT|2021-03-16|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-16|P1Y2M10DT2H30M|COINCIDENT|2021-01-13|BEFORE|2021-03-17
e|RS|0d3d37a5-2215-4b28-b6f7-7256abcdd97e|8|MRPHRESP|Morphologic Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|MAC50|MINOR PATHOLOGIC RESPONSE|1|IU/mg|INCISION-INDUCED BLEEDING METHOD|Y|||STUDY SUBJECT|ADJUDICATOR 2|U|4|Visit_4|65|7|FOLLOW-UP|2021-03-16|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-16|P1Y2M10DT2H30M|UNKNOWN|2021-01-29|COINCIDENT|2021-02-09
e|RS|0d3d37a5-2215-4b28-b6f7-7256abcdd97e|9|MNPTHIND|Minor Pathological Response Indicator|LUGANO CLASSIFICATION|[?]|MBq/uL|QUANTIFIABLE MRD POSITIVITY|1|mL/kg/h|PH METER MEASUREMENT METHOD||||ADJUDICATION COMMITTEE|RADIOLOGIST|NA|5|Visit_5|90|1|TREATMENT|2021-04-10|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-05|P1Y2M10DT2H30M|AFTER|2021-02-25|COINCIDENT|2021-04-01
e|RS|0d3d37a5-2215-4b28-b6f7-7256abcdd97e|10|OVRLRESP|Overall Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|DRUM|CYTOGENETIC MINIMAL RESPONSE|1|mL/g/h|OLIGO ACGH|Y|||PROXY|ADJUDICATOR 2|NA|5|Visit_5|90|1|FOLLOW-UP|2021-04-10|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-05|P1Y2M10DT2H30M|COINCIDENT|2021-01-30|AFTER|2021-02-18
e|RS|89209495-c485-4eb7-b858-8dc5490d2b64|1|TMRESP|Tumor Marker Response|SCHER PROSTATE CANCER 2011|[?]|Tbsp|PSEUDORESPONSE|1|L/h|PH METER MEASUREMENT METHOD|Y|Y||PROXY|RATER 2|N|1|Visit_1|10|1|TREATMENT|2020-09-07|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-03|P1Y2M10DT2H30M|COINCIDENT|2020-10-05|BEFORE|2020-11-05
e|RS|89209495-c485-4eb7-b858-8dc5490d2b64|2|BESTRESP|Best Overall Response|IWG CHESON MDS 2000|[?]|ug/g/min|MRD PERSISTENCE|1|lx|SPIRAL CT||||HEALTH CARE PROFESSIONAL|READER 3|U|1|Visit_1|10|4|TREATMENT|2020-09-07|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-03|P1Y2M10DT2H30M|BEFORE|2020-09-09|AFTER|2020-09-24
e|RS|89209495-c485-4eb7-b858-8dc5490d2b64|3|SYMPTDTR|Symptomatic Deterioration|PETIT BREAST CANCER 2001|[?]|RNA copies/mL|ABSENT MORPHOLOGIC RESPONSE|1|mL|RADIOIMMUNOPRECIPITATION ASSAY|Y|||PROXY|ONCOLOGIST 2|U|2|Visit_2|25|4|TREATMENT|2020-09-22|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-30|P1Y2M10DT2H30M|UNKNOWN|2020-09-05|AFTER|2020-11-12
e|RS|89209495-c485-4eb7-b858-8dc5490d2b64|4|HEMARESP|Hematologic Response|BURCOMBE BREAST CANCER 2005|[?]|10^3/hpf|RELAPSED DISEASE FROM CR|1|Bq|NO INFORMATION||||FAMILY MEMBER|MICROSCOPIST 1|Y|2|Visit_2|25|7|WASHOUT|2020-09-22|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-30|P1Y2M10DT2H30M|AFTER|2020-09-18|ONGOING|2020-10-05
e|RS|89209495-c485-4eb7-b858-8dc5490d2b64|5|ANATRESP|Anatomic Response|KUKER LYMPHOMA 2005|[?]|um/s|RELAPSED DISEASE FROM CR OR PR|1|cL|IMMUNODIFFUSION|Y|||FRIEND|ADJUDICATOR 1|NA|3|Visit_3|40|7|SCREENING|2020-10-07|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-17|P1Y2M10DT2H30M|COINCIDENT|2020-11-08|ONGOING|2020-11-09
e|RS|89209495-c485-4eb7-b858-8dc5490d2b64|6|BMIVLIND|Bone Marrow Involvement Indicator|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|U/kg/min|HI-E|1|cmHg|IMMUNOPRECIPITATION|Y|||CLINICAL STUDY SPONSOR|NEUROLOGIST 2|U|3|Visit_3|40|1|TREATMENT|2020-10-07|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-17|P1Y2M10DT2H30M|COINCIDENT|2020-10-13|AFTER|2020-10-17
e|RS|89209495-c485-4eb7-b858-8dc5490d2b64|7|MRDRESP|Minimal Residual Disease Response|WOLCHOK SOLID TUMORS 2009|||UNEQUIVOCAL|1|g/dL|CLIP SEQUENCING||Y|Y|CAREGIVER|PATHOLOGIST|U|4|Visit_4|65|6|TREATMENT|2020-11-01|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-18|P1Y2M10DT2H30M|UNKNOWN|2020-11-23|BEFORE|2020-12-05
e|RS|89209495-c485-4eb7-b858-8dc5490d2b64|8|STRUSTAT|Steroid Use Status|EASL BRUIX LIVER CANCER 2001|[?]|FFU|MOLECULAR MAJOR RESPONSE|1|TROCHE|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY||||HEALTH CARE PROFESSIONAL|PATHOLOGIST|N|4|Visit_4|65|4|SCREENING|2020-11-01|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-18|P1Y2M10DT2H30M|COINCIDENT|2020-09-29|COINCIDENT|2020-10-26
e|RS|89209495-c485-4eb7-b858-8dc5490d2b64|9|LIVRRESP|Liver Response|PCWG SCHER PROSTATE CANCER 2016|[?]|lm|PR WITH LYMPHOCYTOSIS|1|mL/m2/min|TOTAL BODY IRRADIATION||||CLINICAL STUDY SPONSOR|PATHOLOGIST 1|NA|5|Visit_5|90|3|TREATMENT|2020-11-26|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-26|P1Y2M10DT2H30M|AFTER|2020-09-16|BEFORE|2020-11-14
e|RS|89209495-c485-4eb7-b858-8dc5490d2b64|10|BONERESP|Bone Response|KEAM BREAST CANCER 2013|[?]|pmol/L/h|CHR|1|ka_u/dL|URANYL ACETATE STAIN||||SIGNIFICANT OTHER|MICROSCOPIST 1|U|5|Visit_5|90|5|FOLLOW-UP|2020-11-26|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-26|P1Y2M10DT2H30M|AFTER|2020-10-30|ONGOING|2020-12-01
e|RS|d80522bb-f146-4270-a6e1-326fde50d9ca|1|MJPTHIND|Major Pathological Response Indicator|IWG CHESON AML 2003|[?]|L/day|STABLE|1|Osm|PET/SPECT SCAN||||VENDOR|ADJUDICATOR 3|U|1|Visit_1|10|6|FOLLOW-UP|2020-12-31|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-08|P1Y2M10DT2H30M|UNKNOWN|2021-01-18|AFTER|2021-01-23
e|RS|d80522bb-f146-4270-a6e1-326fde50d9ca|2|PATHRESP|Pathologic Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|psi|CYTOGENETIC CR|1|pkat/L|PERIPHERAL ANGIOGRAPHY||||FAMILY MEMBER|MICROSCOPIST 1|N|1|Visit_1|10|7|SCREENING|2020-12-31|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-08|P1Y2M10DT2H30M|UNKNOWN|2021-03-26|AFTER|2021-03-28
e|RS|d80522bb-f146-4270-a6e1-326fde50d9ca|3|NTLWIND|Non-Target Lesion Worsening Indicator|IWG CHESON MDS 2000|||PSEUDOPROGRESSION|1|/month|EIA|||Y|CLINICAL STUDY SPONSOR|ADJUDICATOR 1|NA|2|Visit_2|25|4|WASHOUT|2021-01-15|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-25|P1Y2M10DT2H30M|COINCIDENT|2021-03-12|COINCIDENT|2021-03-28
e|RS|d80522bb-f146-4270-a6e1-326fde50d9ca|4|STRUSTAT|Steroid Use Status|CHESON CLL 2012|||CA125 50% RESPONSE|1|10^8 PFU|IMMUNOTURBIDIMETRY|||Y|VENDOR|CLINICAL PATHOLOGIST|NA|2|Visit_2|25|3|TREATMENT|2021-01-15|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-25|P1Y2M10DT2H30M|COINCIDENT|2021-01-02|AFTER|2021-03-13
e|RS|d80522bb-f146-4270-a6e1-326fde50d9ca|5|MOLRESP|Molecular Response|BRUGGEMANN MRD 2010|||mCR|1|APS U|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI|||Y|GUARDIAN|FORENSIC PATHOLOGIST|NA|3|Visit_3|40|7|FOLLOW-UP|2021-01-30|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-21|P1Y2M10DT2H30M|COINCIDENT|2021-02-27|BEFORE|2021-03-14
e|RS|d80522bb-f146-4270-a6e1-326fde50d9ca|6|PATHRESP|Pathologic Response|SCHER PROSTATE CANCER 2011|[?]|CAPFUL|PR|1|m2|U-HPLC/MS/MS||||SPOUSE|FORENSIC PATHOLOGIST|Y|3|Visit_3|40|5|WASHOUT|2021-01-30|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-21|P1Y2M10DT2H30M|COINCIDENT|2021-01-09|COINCIDENT|2021-02-10
e|RS|d80522bb-f146-4270-a6e1-326fde50d9ca|7|CPRFSTAT|Clinical Performance Status|BRUGGEMANN MRD 2010|[?]|g|iPR|1|g/cage/day|WRIGHT STAIN||||STUDY SUBJECT|OPTOMETRIST|NA|4|Visit_4|65|5|TREATMENT|2021-02-24|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-31|P1Y2M10DT2H30M|UNKNOWN|2021-02-19|BEFORE|2021-02-27
e|RS|d80522bb-f146-4270-a6e1-326fde50d9ca|8|NEWLPROG|New Lesion Progression|IWG CHESON MDS 2006|||CA125 75% RESPONSE|1|ng/day|CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|||Y|INVESTIGATOR|NEUROLOGIST 1|N|4|Visit_4|65|3|TREATMENT|2021-02-24|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-31|P1Y2M10DT2H30M|COINCIDENT|2021-03-11|BEFORE|2021-03-22
e|RS|d80522bb-f146-4270-a6e1-326fde50d9ca|9|SFTSRESP|Soft Tissue Response|LUGANO CLASSIFICATION|[?]|AU/mL|VGPR|1|IU/L|CONTRAST ENHANCED CT SCAN||||PARENT|READER 1|N|5|Visit_5|90|2|SCREENING|2021-03-21|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-22|P1Y2M10DT2H30M|BEFORE|2021-02-09|ONGOING|2021-03-20
e|RS|d80522bb-f146-4270-a6e1-326fde50d9ca|10|MRDRESP|Minimal Residual Disease Response|CHESON CLL 2012|[?]|BOWL|PR|1|uL|AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT|Y|||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 3|N|5|Visit_5|90|1|WASHOUT|2021-03-21|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-22|P1Y2M10DT2H30M|COINCIDENT|2021-01-21|AFTER|2021-02-01
e|RS|3982a462-95f6-4e71-93e5-9df777770067|1|BMIVLIND|Bone Marrow Involvement Indicator|PRINCE TCELL LYMPHOMA 2010|[?]|/HPF|MOLECULAR CR|1|DNA copies/ug|MICROBIAL CULTURE||||ADJUDICATOR|RATER 2|NA|1|Visit_1|10|7|TREATMENT|2020-12-25|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-24|P1Y2M10DT2H30M|AFTER|2021-03-13|ONGOING|2021-03-14
e|RS|3982a462-95f6-4e71-93e5-9df777770067|2|TMRESP|Tumor Marker Response|BURCOMBE BREAST CANCER 2005|[?]|mg/L FEU|UNEQUIVOCAL|1|mol/L|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY||||CLINICAL STUDY SPONSOR|ADJUDICATOR 3|U|1|Visit_1|10|7|TREATMENT|2020-12-25|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-24|P1Y2M10DT2H30M|BEFORE|2021-01-11|COINCIDENT|2021-03-06
e|RS|3982a462-95f6-4e71-93e5-9df777770067|3|BONERESP|Bone Response|IWG CHESON MDS 2006|[?]|km/h|PD-CT|1|Hz|QUANTITATIVE CORONARY ANGIOGRAPHY|Y|||CLINICAL STUDY SPONSOR|CLINICAL PATHOLOGIST|NA|2|Visit_2|25|5|FOLLOW-UP|2021-01-09|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-16|P1Y2M10DT2H30M|UNKNOWN|2021-01-05|BEFORE|2021-03-06
e|RS|3982a462-95f6-4e71-93e5-9df777770067|4|NTERESP|Non-Target Enhancing Response|IWG CHESON MDS 2006|[?]|kV|QUANTIFIABLE MRD POSITIVITY|1|grain|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY||Y||SIBLING|PATHOLOGIST 2|N|2|Visit_2|25|7|SCREENING|2021-01-09|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-16|P1Y2M10DT2H30M|COINCIDENT|2021-01-31|COINCIDENT|2021-02-12
e|RS|3982a462-95f6-4e71-93e5-9df777770067|5|DRCRIND|Disease Recurrence Indicator|MRECIST BYRNE MESOTHELIOMA 2004|[?]|anti-Xa IU/mL|STABLE|1|g/dL|PULMONARY ANGIOGRAPHY|Y|||GUARDIAN|ADJUDICATOR 2|Y|3|Visit_3|40|3|FOLLOW-UP|2021-01-24|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-20|P1Y2M10DT2H30M|BEFORE|2021-03-13|COINCIDENT|2021-03-19
e|RS|3982a462-95f6-4e71-93e5-9df777770067|6|NTRGRESP|Non-target Response|DOHNER AML 2010|[?]|log10 TCID 50/dose|COMPLETE MRD RESPONSE|1|CONTAINER|DYNAMIC CONTRAST ENHANCED MRI||||DOMESTIC PARTNER|READER 1|Y|3|Visit_3|40|1|SCREENING|2021-01-24|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-20|P1Y2M10DT2H30M|COINCIDENT|2021-01-27|ONGOING|2021-01-29
e|RS|3982a462-95f6-4e71-93e5-9df777770067|7|NTRGRESP|Non-target Response|IWG CHESON MDS 2000|[?]|%(w/w)|MRD PERSISTENCE|1|NFIU|NUCLEIC ACID SEQUENCING||Y||ADJUDICATION COMMITTEE|CARDIOLOGIST|N|4|Visit_4|65|3|SCREENING|2021-02-18|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-05|P1Y2M10DT2H30M|UNKNOWN|2021-01-27|BEFORE|2021-02-17
e|RS|3982a462-95f6-4e71-93e5-9df777770067|8|MRDRESP|Minimal Residual Disease Response|RANO|||FAVORABLE RESPONSE|1|ppm|PHOTOMETRIC CLOT DETECTION|||Y|CHILD|READER 3|Y|4|Visit_4|65|4|TREATMENT|2021-02-18|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-05|P1Y2M10DT2H30M|COINCIDENT|2021-03-04|BEFORE|2021-03-18
e|RS|3982a462-95f6-4e71-93e5-9df777770067|9|MNPTHIND|Minor Pathological Response Indicator|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|mL/g/h|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|Hz|ELECTROCHEMILUMINESCENCE||||SIBLING|RATER 1|U|5|Visit_5|90|3|SCREENING|2021-03-15|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-29|P1Y2M10DT2H30M|UNKNOWN|2021-03-12|BEFORE|2021-03-18
e|RS|3982a462-95f6-4e71-93e5-9df777770067|10|DRCRIND|Disease Recurrence Indicator|CHESON LYMPHOMA 2008|||STABLE|1|NEEDLE GAUGE|ELECTROCHEMILUMINESCENCE|Y||Y|CHILD|READER 2|N|5|Visit_5|90|3|FOLLOW-UP|2021-03-15|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-29|P1Y2M10DT2H30M|AFTER|2021-03-20|COINCIDENT|2021-03-22
e|RS|f3a3a6ca-2344-4cee-a6a5-59beee9304df|1|LIVRRESP|Liver Response|WHO BREAST CANCER 2006|[?]|mm/sec|OPTIMAL MORPHOLOGIC RESPONSE|1|Coulomb|RAJI CELL EIA||||PARENT|ONCOLOGIST 2|NA|1|Visit_1|10|3|FOLLOW-UP|2020-11-09|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-11|P1Y2M10DT2H30M|UNKNOWN|2020-11-17|AFTER|2020-12-15
e|RS|f3a3a6ca-2344-4cee-a6a5-59beee9304df|2|MRDRESP|Minimal Residual Disease Response|BURCOMBE BREAST CANCER 2005|||NON-CR/NON-PD|1|m/sec2|ACRIDINE ORANGE STAIN|Y||Y|CHILD|ADJUDICATOR 2|NA|1|Visit_1|10|2|WASHOUT|2020-11-09|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-11|P1Y2M10DT2H30M|BEFORE|2020-12-05|COINCIDENT|2020-12-08
e|RS|f3a3a6ca-2344-4cee-a6a5-59beee9304df|3|MRDRESP|Minimal Residual Disease Response|RAJKUMAR MYELOMA 2011|||CYTOGENETIC MINOR RESPONSE|1|mL/breath|PERIPHERAL ANGIOGRAPHY|||Y|INTERVIEWER|RADIOLOGIST|N|2|Visit_2|25|3|TREATMENT|2020-11-24|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-08|P1Y2M10DT2H30M|UNKNOWN|2020-11-17|BEFORE|2021-02-06
e|RS|f3a3a6ca-2344-4cee-a6a5-59beee9304df|4|HEMARESP|Hematologic Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|Coulomb|RELAPSED DISEASE FROM CR|1|mmHg/sec|AUTOMATED COUNT||||CHILD|RADIOLOGIST|Y|2|Visit_2|25|5|FOLLOW-UP|2020-11-24|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-08|P1Y2M10DT2H30M|BEFORE|2020-11-20|AFTER|2021-01-23
e|RS|f3a3a6ca-2344-4cee-a6a5-59beee9304df|5|ANATRESP|Anatomic Response|CHOLLET BREAST CANCER 2002|[?]|10^7 CFU|ABSENT MORPHOLOGIC RESPONSE|1|POINT|DIGITAL PCR||||SIBLING|HEMATOLOGIST|NA|3|Visit_3|40|7|FOLLOW-UP|2020-12-09|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-20|P1Y2M10DT2H30M|AFTER|2020-11-06|AFTER|2020-11-24
e|RS|f3a3a6ca-2344-4cee-a6a5-59beee9304df|6|OVRLRESP|Overall Response|PCWG SCHER PROSTATE CANCER 2008|[?]|10^6 U|STABLE|1|GPL U/mL|ELECTROMYOGRAPHY|Y|||CLINICAL RESEARCH COORDINATOR|ENDOCRINOLOGIST|N|3|Visit_3|40|5|WASHOUT|2020-12-09|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-20|P1Y2M10DT2H30M|AFTER|2020-12-03|COINCIDENT|2021-01-02
e|RS|f3a3a6ca-2344-4cee-a6a5-59beee9304df|7|NTNERESP|Non-Target Non-Enhancing Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|min|PARTIAL MORPHOLOGIC RESPONSE|1|/10^4|PHOTOMETRIC CLOT DETECTION||Y||CHILD|HEMATOLOGIST|Y|4|Visit_4|65|3|TREATMENT|2021-01-03|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-05|P1Y2M10DT2H30M|AFTER|2020-11-28|COINCIDENT|2020-12-16
e|RS|f3a3a6ca-2344-4cee-a6a5-59beee9304df|8|NTLWIND|Non-Target Lesion Worsening Indicator|EBMT BLADE MYELOMA 1998|||INCREASED|1|mmol/s|SLOAN LETTER EYE CHART 1.25%||Y|Y|INDEPENDENT ASSESSOR|RADIOLOGIST|N|4|Visit_4|65|2|SCREENING|2021-01-03|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-05|P1Y2M10DT2H30M|UNKNOWN|2021-01-29|AFTER|2021-02-01
e|RS|f3a3a6ca-2344-4cee-a6a5-59beee9304df|9|LIVRRESP|Liver Response|RECIST 1.1|[?]|uCi|IMMUNOPHENOTYPIC CR|1|CONTAINER|KINYOUN STAIN||Y||PROXY|CARDIOLOGIST|NA|5|Visit_5|90|5|FOLLOW-UP|2021-01-28|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-16|P1Y2M10DT2H30M|UNKNOWN|2020-11-13|COINCIDENT|2021-02-02
e|RS|f3a3a6ca-2344-4cee-a6a5-59beee9304df|10|NEWLIND|New Lesion Indicator|DURIE MULTIPLE MYELOMA 2006|[?]|cpm|cPR|1|TROCHE|PULSE OXIMETRY||||ADJUDICATION COMMITTEE|MICROSCOPIST 3|Y|5|Visit_5|90|3|TREATMENT|2021-01-28|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-16|P1Y2M10DT2H30M|BEFORE|2020-12-05|BEFORE|2021-01-30
e|RS|175cfd82-a6fe-463b-81e5-07ae9e1253db|1|HEMARESP|Hematologic Response|PETIT BREAST CANCER 2001|||STABLE|1|10^3/hpf|CONTRAST ENHANCED PET SCAN|Y||Y|SIGNIFICANT OTHER|PATHOLOGIST 1|N|1|Visit_1|10|3|WASHOUT|2020-05-26|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-15|P1Y2M10DT2H30M|AFTER|2020-06-30|ONGOING|2020-07-23
e|RS|175cfd82-a6fe-463b-81e5-07ae9e1253db|2|SPLNRESP|Spleen Response|AJCC V8|[?]|mg/m2/h|NON-CR/NON-PD|1|anti-Xa IU|LIGHT MICROSCOPY|Y|||CAREGIVER|ONCOLOGIST 1|U|1|Visit_1|10|1|FOLLOW-UP|2020-05-26|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-15|P1Y2M10DT2H30M|AFTER|2020-05-26|COINCIDENT|2020-06-12
e|RS|175cfd82-a6fe-463b-81e5-07ae9e1253db|3|NEWLPROG|New Lesion Progression|CHOI GIST 2008|||iCPD|1|10^12 IU/L|RYAN BLUE STAIN|||Y|HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|NA|2|Visit_2|25|7|SCREENING|2020-06-10|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-25|P1Y2M10DT2H30M|BEFORE|2020-08-19|ONGOING|2020-08-21
e|RS|175cfd82-a6fe-463b-81e5-07ae9e1253db|4|TRGRESP|Target Response|PETIT BREAST CANCER 2001|[?]|10^6/hpf|STABLE|1|CIGAR|GC/MS/MS||||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 2|Y|2|Visit_2|25|5|TREATMENT|2020-06-10|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-25|P1Y2M10DT2H30M|COINCIDENT|2020-07-29|COINCIDENT|2020-07-31
e|RS|175cfd82-a6fe-463b-81e5-07ae9e1253db|5|NEWLWIND|New Lesion Worsening Indicator|CHOLLET BREAST CANCER 2002|[?]|10^9 organisms|CYTOGENETIC MINOR RESPONSE|1|Ci/L|ETDRS EYE CHART||||PARENT|ONCOLOGIST 2|NA|3|Visit_3|40|3|WASHOUT|2020-06-25|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-18|P1Y2M10DT2H30M|AFTER|2020-05-19|BEFORE|2020-06-05
e|RS|175cfd82-a6fe-463b-81e5-07ae9e1253db|6|MRPHRESP|Morphologic Response|PERCIST|||PR WITH LYMPHOCYTOSIS|1|kcal/day|TOLUIDINE BLUE STAIN|Y||Y|SIGNIFICANT OTHER|CARDIOLOGIST|NA|3|Visit_3|40|1|SCREENING|2020-06-25|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-18|P1Y2M10DT2H30M|AFTER|2020-07-02|AFTER|2020-07-12
e|RS|175cfd82-a6fe-463b-81e5-07ae9e1253db|7|MJPTHIND|Major Pathological Response Indicator|RECIST 1.1|[?]|PUFF|PR|1|amol|PHOTOMETRY||||PARENT|MICROSCOPIST 2|U|4|Visit_4|65|3|TREATMENT|2020-07-20|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-10|P1Y2M10DT2H30M|AFTER|2020-06-18|ONGOING|2020-07-25
e|RS|175cfd82-a6fe-463b-81e5-07ae9e1253db|8|NTERESP|Non-Target Enhancing Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|genEq|cCR|1|s^-1(%O2)^-1|QUANTITATIVE ULTRASOUND||||ADJUDICATOR|ONCOLOGIST|U|4|Visit_4|65|5|FOLLOW-UP|2020-07-20|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-10|P1Y2M10DT2H30M|BEFORE|2020-08-04|AFTER|2020-08-08
e|RS|175cfd82-a6fe-463b-81e5-07ae9e1253db|9|METSIND|Metastatic Indicator|PALUMBO MULTIPLE MYELOMA 2009|||DECREASED|1|umol/mg/min|STATIC PERIMETRY|Y||Y|GUARDIAN|MICROSCOPIST 1|U|5|Visit_5|90|1|SCREENING|2020-08-14|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-09|P1Y2M10DT2H30M|UNKNOWN|2020-07-26|AFTER|2020-07-29
e|RS|175cfd82-a6fe-463b-81e5-07ae9e1253db|10|LIVRRESP|Liver Response|iRECIST|[?]|/month|CR|1|fmol/L|FUNCTIONAL MRI|Y|Y||NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|Y|5|Visit_5|90|7|FOLLOW-UP|2020-08-14|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-09|P1Y2M10DT2H30M|BEFORE|2020-07-04|ONGOING|2020-07-24
e|RS|e19b469c-40d5-4506-8233-a86bebde880d|1|SYMPTDTR|Symptomatic Deterioration|RECIST 1.1|[?]|EP U|WORSENED|1|mg/mL/day|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|Y|||CHILD|READER 2|Y|1|Visit_1|10|4|TREATMENT|2021-01-22|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-21|P1Y2M10DT2H30M|UNKNOWN|2021-02-19|COINCIDENT|2021-04-15
e|RS|e19b469c-40d5-4506-8233-a86bebde880d|2|HEMARESP|Hematologic Response|RECIST 1.0|[?]|AMPULE|CYTOGENETIC CR|1|U/m2|PATHOLOGICAL EVALUATION||||PARENT|OPHTHALMOLOGIST|NA|1|Visit_1|10|2|TREATMENT|2021-01-22|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-21|P1Y2M10DT2H30M|COINCIDENT|2021-03-03|ONGOING|2021-03-25
e|RS|e19b469c-40d5-4506-8233-a86bebde880d|3|METBRESP|Metabolic Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|||CYTOGENETIC CR|1|ka_u/dL|SXA SCAN|||Y|INTERVIEWER|ONCOLOGIST 2|U|2|Visit_2|25|4|TREATMENT|2021-02-06|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-11|P1Y2M10DT2H30M|UNKNOWN|2021-03-18|COINCIDENT|2021-03-19
e|RS|e19b469c-40d5-4506-8233-a86bebde880d|4|OVRLRESP|Overall Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|pg/L|PSA PROGRESSION|1|U/m2/h|GRAM STAIN||||GUARDIAN|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|2|Visit_2|25|7|TREATMENT|2021-02-06|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-11|P1Y2M10DT2H30M|UNKNOWN|2021-02-12|AFTER|2021-03-30
e|RS|e19b469c-40d5-4506-8233-a86bebde880d|5|HEMARESP|Hematologic Response|PROTOCOL DEFINED RESPONSE CRITERIA|||TREATMENT FAILURE|1|Sv|RAJI CELL RIA|||Y|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 2|U|3|Visit_3|40|4|SCREENING|2021-02-21|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-08|P1Y2M10DT2H30M|BEFORE|2021-04-06|COINCIDENT|2021-04-09
e|RS|e19b469c-40d5-4506-8233-a86bebde880d|6|CLINRESP|Clinical Response|GUILHOT CML 2007|[?]|10^10/L|HI-E|1|MAC50|MAMMOGRAPHY||||ADJUDICATOR|MICROSCOPIST 3|Y|3|Visit_3|40|4|SCREENING|2021-02-21|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-08|P1Y2M10DT2H30M|BEFORE|2021-03-23|AFTER|2021-04-11
e|RS|e19b469c-40d5-4506-8233-a86bebde880d|7|MRPHRESP|Morphologic Response|DOHNER AML 2010|[?]|U/g Hb|CYTOGENETIC MINOR RESPONSE|1|kg/L|LC/MS/MS||||GUARDIAN|OPTOMETRIST|NA|4|Visit_4|65|5|SCREENING|2021-03-18|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-01|P1Y2M10DT2H30M|AFTER|2021-03-24|COINCIDENT|2021-04-09
e|RS|e19b469c-40d5-4506-8233-a86bebde880d|8|METBRESP|Metabolic Response|RECIST 1.0|||HI-P|1|rpm|FLUORESCENT IMMUNOASSAY|Y||Y|CLINICAL STUDY SPONSOR|READER|Y|4|Visit_4|65|1|SCREENING|2021-03-18|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-01|P1Y2M10DT2H30M|UNKNOWN|2021-02-06|COINCIDENT|2021-02-16
e|RS|e19b469c-40d5-4506-8233-a86bebde880d|9|NTNERESP|Non-Target Non-Enhancing Response|RECICL|||pCR|1|BAU/mL|CONTRAST ENHANCED SPIRAL CT SCAN|||Y|CLINICAL STUDY SPONSOR|PEDIATRIC NEUROLOGIST|Y|5|Visit_5|90|3|TREATMENT|2021-04-12|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-14|P1Y2M10DT2H30M|UNKNOWN|2021-04-01|AFTER|2021-04-21
e|RS|e19b469c-40d5-4506-8233-a86bebde880d|10|NTLWIND|Non-Target Lesion Worsening Indicator|LEE LUNG CANCER 2011|[?]|Torr|IMPROVED|1|10^11/L|MEDIASTINOSCOPY||Y||CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 1|NA|5|Visit_5|90|7|TREATMENT|2021-04-12|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-14|P1Y2M10DT2H30M|COINCIDENT|2021-03-25|ONGOING|2021-04-06
e|RS|f280a4a5-9826-4d77-adf1-992284cb3314|1|BESTRESP|Best Overall Response|WOLCHOK SOLID TUMORS 2009|[?]|nmol/kg/day|UNFAVORABLE RESPONSE|1|10^9 CFU/g|MANUAL CLOT DETECTION||Y||STUDY SUBJECT|PATHOLOGIST 2|N|1|Visit_1|10|2|TREATMENT|2020-12-19|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-01|P1Y2M10DT2H30M|AFTER|2021-02-15|BEFORE|2021-03-03
e|RS|f280a4a5-9826-4d77-adf1-992284cb3314|2|DRCRIND|Disease Recurrence Indicator|SHINDOH COLORECTAL CANCER 2013|||PD-CT|1|AgU/mL|CONFOCAL MICROSCOPY|||Y|INVESTIGATOR|OPTOMETRIST|N|1|Visit_1|10|5|SCREENING|2020-12-19|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-01|P1Y2M10DT2H30M|COINCIDENT|2021-02-18|AFTER|2021-02-19
e|RS|f280a4a5-9826-4d77-adf1-992284cb3314|3|MJPTHIND|Major Pathological Response Indicator|KEAM BREAST CANCER 2013|[?]|Siemens|HI-E|1|nmol/mol|PHYSICAL EXAMINATION||||ADJUDICATION COMMITTEE|UROLOGIST|N|2|Visit_2|25|4|WASHOUT|2021-01-03|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-04|P1Y2M10DT2H30M|COINCIDENT|2021-02-14|ONGOING|2021-03-18
e|RS|f280a4a5-9826-4d77-adf1-992284cb3314|4|NTLWIND|Non-Target Lesion Worsening Indicator|LUGANO CLASSIFICATION|||iUPD|1|PHERESIS UNIT|OSCILLOMETRY||Y|Y|INTERVIEWER|NEUROLOGIST|U|2|Visit_2|25|6|TREATMENT|2021-01-03|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-04|P1Y2M10DT2H30M|COINCIDENT|2021-03-14|BEFORE|2021-03-18
e|RS|f280a4a5-9826-4d77-adf1-992284cb3314|5|NEWLPROG|New Lesion Progression|MRECIST LENCIONI LIVER CANCER 2010|[?]|atm|RELAPSED DISEASE FROM CR OR PR|1|/7.5 mL|STATIC PERIMETRY||||INDEPENDENT ASSESSOR|RATER 1|NA|3|Visit_3|40|5|TREATMENT|2021-01-18|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-26|P1Y2M10DT2H30M|BEFORE|2021-02-25|BEFORE|2021-03-15
e|RS|f280a4a5-9826-4d77-adf1-992284cb3314|6|BMIVLIND|Bone Marrow Involvement Indicator|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|Bq/g|PMR|1|DAgU|MUGA||||DOMESTIC PARTNER|READER 1|Y|3|Visit_3|40|7|TREATMENT|2021-01-18|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-26|P1Y2M10DT2H30M|AFTER|2020-12-29|COINCIDENT|2021-01-06
e|RS|f280a4a5-9826-4d77-adf1-992284cb3314|7|MOLRESP|Molecular Response|SHINDOH COLORECTAL CANCER 2013|||CMR|1|mol/g|SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY|Y|Y|Y|GUARDIAN|RADIOLOGIST 2|U|4|Visit_4|65|4|SCREENING|2021-02-12|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-11|P1Y2M10DT2H30M|UNKNOWN|2020-12-11|AFTER|2021-01-24
e|RS|f280a4a5-9826-4d77-adf1-992284cb3314|8|CLINRESP|Clinical Response|JACINTO CERVICAL CANCER 2007|[?]|gpELISA unit/mL|NON-QUANTIFIABLE MRD POSITIVITY|1|Gauss|WEBER GREEN STAIN||||FAMILY MEMBER|UROLOGIST|NA|4|Visit_4|65|7|WASHOUT|2021-02-12|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-11|P1Y2M10DT2H30M|UNKNOWN|2021-01-27|ONGOING|2021-01-29
e|RS|f280a4a5-9826-4d77-adf1-992284cb3314|9|NTNERESP|Non-Target Non-Enhancing Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|/2000 RBC|DISEASE TRANSFORMATION|1|10^7 TCID 50/dose|ETDRS EYE CHART|Y|||PARENT|MICROSCOPIST 1|N|5|Visit_5|90|4|FOLLOW-UP|2021-03-09|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-31|P1Y2M10DT2H30M|BEFORE|2020-12-31|COINCIDENT|2021-01-14
e|RS|f280a4a5-9826-4d77-adf1-992284cb3314|10|SFTSRESP|Soft Tissue Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|P|MORPHOLOGIC CRi|1|ng/mol|COULOMETRIC TITRATION||Y||HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|NA|5|Visit_5|90|2|TREATMENT|2021-03-09|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-31|P1Y2M10DT2H30M|BEFORE|2021-01-15|BEFORE|2021-02-24
e|RS|82840929-7800-4254-b60a-8af4786664f6|1|MNPTHIND|Minor Pathological Response Indicator|BURCOMBE BREAST CANCER 2005|[?]|KIT|MOLECULAR MAJOR RESPONSE|1|mEq/ug|MICROBIAL CULTURE||||CHILD|DEVELOPMENTAL PSYCHOLOGIST|U|1|Visit_1|10|7|TREATMENT|2020-06-04|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-10|P1Y2M10DT2H30M|BEFORE|2020-07-19|AFTER|2020-08-22
e|RS|82840929-7800-4254-b60a-8af4786664f6|2|MRPHRESP|Morphologic Response|NCIWG CHESON CLL 1996|[?]|mph|UNEQUIVOCAL|1|g/dL|PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY||||PARENT|CARDIOLOGIST|U|1|Visit_1|10|4|TREATMENT|2020-06-04|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-10|P1Y2M10DT2H30M|BEFORE|2020-08-01|BEFORE|2020-08-29
e|RS|82840929-7800-4254-b60a-8af4786664f6|3|MOLRESP|Molecular Response|IWG CHESON MDS 2006|||iUPD|1|mmol|CINEANGIOGRAPHY|||Y|ADJUDICATOR|PATHOLOGIST|Y|2|Visit_2|25|5|SCREENING|2020-06-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-24|P1Y2M10DT2H30M|BEFORE|2020-08-24|AFTER|2020-09-01
e|RS|82840929-7800-4254-b60a-8af4786664f6|4|CYTORESP|Cytogenetic Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|g/U|iPR|1|/500 WBC|ETDRS EYE CHART||||DOMESTIC PARTNER|NEUROLOGIST 2|Y|2|Visit_2|25|2|FOLLOW-UP|2020-06-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-24|P1Y2M10DT2H30M|AFTER|2020-06-20|AFTER|2020-07-23
e|RS|82840929-7800-4254-b60a-8af4786664f6|5|NEWLPROG|New Lesion Progression|FAROOQUI SUPP CLL 2014|[?]|mV*min|iUPD|1|ks|NEPHELOMETRY||||FAMILY MEMBER|PEDIATRIC NEUROLOGIST|NA|3|Visit_3|40|5|WASHOUT|2020-07-04|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-21|P1Y2M10DT2H30M|AFTER|2020-06-20|ONGOING|2020-07-17
e|RS|82840929-7800-4254-b60a-8af4786664f6|6|NEWLIND|New Lesion Indicator|FAROOQUI SUPP CLL 2014|[?]|ELISA unit|PARTIAL MORPHOLOGIC RESPONSE|1|ug/mol|PULMONARY ANGIOGRAPHY||||VENDOR|MICROSCOPIST 2|NA|3|Visit_3|40|7|SCREENING|2020-07-04|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-21|P1Y2M10DT2H30M|AFTER|2020-05-28|COINCIDENT|2020-07-05
e|RS|82840929-7800-4254-b60a-8af4786664f6|7|MJPTHIND|Major Pathological Response Indicator|PCWG BUBLEY PROSTATE CANCER 1999|[?]|mg/m2|MR|1|Bq/g|X-RAY FLUORESCENCE SPECTROMETRY||Y||VENDOR|RATER 1|Y|4|Visit_4|65|1|TREATMENT|2020-07-29|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-23|P1Y2M10DT2H30M|COINCIDENT|2020-07-08|ONGOING|2020-08-16
e|RS|82840929-7800-4254-b60a-8af4786664f6|8|TRGRESP|Target Response|CHESON CLL 2012|[?]|FFU|PD-CT|1|EU|MIGET||||INVESTIGATOR|ADJUDICATOR 3|N|4|Visit_4|65|5|WASHOUT|2020-07-29|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-23|P1Y2M10DT2H30M|AFTER|2020-07-19|AFTER|2020-08-10
e|RS|82840929-7800-4254-b60a-8af4786664f6|9|DRCRIND|Disease Recurrence Indicator|NCIWG CHESON CLL 1996|[?]|g/m2/day|CR-CT|1|mg/m2/h|SLOAN LETTER EYE CHART 100%||||CHILD|ONCOLOGIST 1|Y|5|Visit_5|90|4|SCREENING|2020-08-23|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-15|P1Y2M10DT2H30M|COINCIDENT|2020-06-29|BEFORE|2020-08-27
e|RS|82840929-7800-4254-b60a-8af4786664f6|10|BMIVLIND|Bone Marrow Involvement Indicator|PRINCE TCELL LYMPHOMA 2010|[?]|g/animal/day|iUPD|1|mEq/mmol|WESTERN BLOT||||SPOUSE|RATER|Y|5|Visit_5|90|5|SCREENING|2020-08-23|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-15|P1Y2M10DT2H30M|AFTER|2020-09-01|ONGOING|2020-09-02
e|RS|dae25bdb-38fd-4852-9a9a-7627368e9497|1|LIVRRESP|Liver Response|CHESON NON-HODGKINS LYMPHOMA 1999|||UNFAVORABLE RESPONSE|1|U/dL|MICROPARTICLE ENZYME IMMUNOASSAY|Y||Y|SIGNIFICANT OTHER|DEVELOPMENTAL PSYCHOLOGIST|N|1|Visit_1|10|4|TREATMENT|2020-09-02|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-24|P1Y2M10DT2H30M|AFTER|2020-11-11|ONGOING|2020-11-21
e|RS|dae25bdb-38fd-4852-9a9a-7627368e9497|2|RDIORESP|Radiologic Response|CHESON CLL 2006|[?]|10^9 CFU|MRD RELAPSE|1|mEq/mmol|PHOTOMETRY||||CLINICAL STUDY SPONSOR|ENDOCRINOLOGIST|NA|1|Visit_1|10|3|TREATMENT|2020-09-02|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-24|P1Y2M10DT2H30M|AFTER|2020-09-01|BEFORE|2020-11-15
e|RS|dae25bdb-38fd-4852-9a9a-7627368e9497|3|NEWLPROG|New Lesion Progression|CHOLLET BREAST CANCER 2002|||MORPHOLOGIC LEUKEMIA-FREE STATE|1|umol/L/min|RADIOIMMUNOPRECIPITATION ASSAY|||Y|SIBLING|CLINICAL PATHOLOGIST|U|2|Visit_2|25|7|TREATMENT|2020-09-17|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-19|P1Y2M10DT2H30M|BEFORE|2020-11-22|BEFORE|2020-11-24
e|RS|dae25bdb-38fd-4852-9a9a-7627368e9497|4|CLINRESP|Clinical Response|NCIWG CHESON CLL 1996|||MORPHOLOGIC CR|1|VIRTUAL PIXEL|PHASE CONTRAST MICROSCOPY|||Y|SIGNIFICANT OTHER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|2|Visit_2|25|2|FOLLOW-UP|2020-09-17|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-19|P1Y2M10DT2H30M|UNKNOWN|2020-11-12|BEFORE|2020-11-30
e|RS|dae25bdb-38fd-4852-9a9a-7627368e9497|5|MJPTHIND|Major Pathological Response Indicator|CHOI GIST 2008|[?]|keV|CR-CT|1|/40 HPFs|RADIOIMMUNOPRECIPITATION ASSAY||||CLINICAL STUDY SPONSOR|ONCOLOGIST|N|3|Visit_3|40|5|TREATMENT|2020-10-02|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-10|P1Y2M10DT2H30M|AFTER|2020-09-26|ONGOING|2020-11-01
e|RS|dae25bdb-38fd-4852-9a9a-7627368e9497|6|NTRGRESP|Non-target Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|fmol|PDu|1|DRUM|IMMUNOASSAY||||INDEPENDENT ASSESSOR|READER 2|U|3|Visit_3|40|5|TREATMENT|2020-10-02|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-10|P1Y2M10DT2H30M|COINCIDENT|2020-10-22|COINCIDENT|2020-10-30
e|RS|dae25bdb-38fd-4852-9a9a-7627368e9497|7|LIVRRESP|Liver Response|IWG CHESON AML 2003|[?]|BOTTLE|CA125 50% RESPONSE|1|Absorbance U/min|MICRODENSITOMETRY||||SIGNIFICANT OTHER|ADJUDICATOR 1|Y|4|Visit_4|65|5|WASHOUT|2020-10-27|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-14|P1Y2M10DT2H30M|BEFORE|2020-10-30|ONGOING|2020-11-18
e|RS|dae25bdb-38fd-4852-9a9a-7627368e9497|8|HEMARESP|Hematologic Response|HAMAOKA BREAST CANCER 2010|||PD|1|CAPFUL|CLIP SEQUENCING|||Y|FRIEND|NEUROLOGIST|U|4|Visit_4|65|5|SCREENING|2020-10-27|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-14|P1Y2M10DT2H30M|UNKNOWN|2020-10-10|ONGOING|2020-10-29
e|RS|dae25bdb-38fd-4852-9a9a-7627368e9497|9|NTLWIND|Non-Target Lesion Worsening Indicator|HAMAOKA BREAST CANCER 2010|[?]|m2|OPTIMAL MORPHOLOGIC RESPONSE|1|10^3 organisms|SCANNING ELECTRON MICROSCOPY||||SIGNIFICANT OTHER|DEVELOPMENTAL PSYCHOLOGIST|Y|5|Visit_5|90|7|TREATMENT|2020-11-21|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-03|P1Y2M10DT2H30M|AFTER|2020-10-13|BEFORE|2020-11-17
e|RS|dae25bdb-38fd-4852-9a9a-7627368e9497|10|TRGRESP|Target Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|Bq/mL|INDETERMINATE RESPONSE|1|nkat/g Hb|WEBER GREEN STAIN||||CLINICAL STUDY SPONSOR|ADJUDICATOR 2|U|5|Visit_5|90|6|TREATMENT|2020-11-21|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-03|P1Y2M10DT2H30M|BEFORE|2020-11-07|ONGOING|2020-11-12
e|RS|9e009737-cd77-4b96-a4af-e9731ef7e9d0|1|MNPTHIND|Minor Pathological Response Indicator|CHESON CLL 2012|[?]|APS U|SMD|1|nkat/L|MICROBIAL BIOCHEMICAL IDENTIFICATION||Y||PROXY|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|1|Visit_1|10|4|TREATMENT|2020-10-05|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-22|P1Y2M10DT2H30M|BEFORE|2020-11-21|AFTER|2020-12-16
e|RS|9e009737-cd77-4b96-a4af-e9731ef7e9d0|2|CPRFSTAT|Clinical Performance Status|MACDONALD GLIOMA 1990|[?]|kBq|SD-CT|1|Ejaculate U|PERIPHERAL ANGIOGRAPHY||||FAMILY MEMBER|RATER 1|N|1|Visit_1|10|7|SCREENING|2020-10-05|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-22|P1Y2M10DT2H30M|COINCIDENT|2020-11-07|AFTER|2020-11-21
e|RS|9e009737-cd77-4b96-a4af-e9731ef7e9d0|3|BONERESP|Bone Response|HARTMANN GERM CELL CANCER 2002|[?]|BAR|UNEQUIVOCAL|1|gpELISA unit/mL|LANDOLT RING||Y||INVESTIGATOR|OPTOMETRIST|Y|2|Visit_2|25|3|TREATMENT|2020-10-20|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-06|P1Y2M10DT2H30M|UNKNOWN|2020-12-08|BEFORE|2020-12-27
e|RS|9e009737-cd77-4b96-a4af-e9731ef7e9d0|4|NTRGRESP|Non-target Response|PRINCE TCELL LYMPHOMA 2010|[?]|mol/mg|PR|1|mol/mol|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION||||STUDY SUBJECT|UROLOGIST|U|2|Visit_2|25|5|SCREENING|2020-10-20|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-06|P1Y2M10DT2H30M|UNKNOWN|2020-12-29|ONGOING|2021-01-02
e|RS|9e009737-cd77-4b96-a4af-e9731ef7e9d0|5|NTLWIND|Non-Target Lesion Worsening Indicator|CHESON NON-HODGKINS LYMPHOMA 1999|||TREATMENT FAILURE|1|ug/m2/day|IMMUNOCHEMILUMINOMETRIC ASSAY|||Y|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 1|Y|3|Visit_3|40|7|WASHOUT|2020-11-04|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-05|P1Y2M10DT2H30M|BEFORE|2020-10-15|AFTER|2020-12-10
e|RS|9e009737-cd77-4b96-a4af-e9731ef7e9d0|6|MRDIND|Minimal Residual Disease Indicator|UNSPECIFIED|[?]|mkat|cPR|1|Weber|PHOTOMETRY||||NON-HEALTH CARE PROFESSIONAL|RATER|N|3|Visit_3|40|3|TREATMENT|2020-11-04|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-05|P1Y2M10DT2H30M|UNKNOWN|2020-11-01|BEFORE|2020-11-14
e|RS|9e009737-cd77-4b96-a4af-e9731ef7e9d0|7|NTRGRESP|Non-target Response|IWG CHESON MDS 2000|[?]|nmol/L/min|NR|1|ug/dL|IMMUNOPRECIPITATION|Y|||HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|U|4|Visit_4|65|6|FOLLOW-UP|2020-11-29|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-15|P1Y2M10DT2H30M|COINCIDENT|2020-10-19|AFTER|2020-11-01
e|RS|9e009737-cd77-4b96-a4af-e9731ef7e9d0|8|BMIVLIND|Bone Marrow Involvement Indicator|LUGANO CLASSIFICATION|[?]|DAYS|SMD|1|U/L|CALCOFLUOR WHITE STAIN||||SPOUSE|ADJUDICATOR 3|Y|4|Visit_4|65|6|FOLLOW-UP|2020-11-29|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-15|P1Y2M10DT2H30M|AFTER|2020-10-23|ONGOING|2020-12-23
e|RS|9e009737-cd77-4b96-a4af-e9731ef7e9d0|9|BESTRESP|Best Overall Response|EBMT BLADE MYELOMA 1998|[?]|VIRTUAL PIXEL|MRD RELAPSE|1|10^6/L|MICRONEUTRALIZATION ASSAY||||STUDY SUBJECT|ADJUDICATOR 1|NA|5|Visit_5|90|6|TREATMENT|2020-12-24|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-04|P1Y2M10DT2H30M|COINCIDENT|2020-11-25|AFTER|2020-12-16
e|RS|9e009737-cd77-4b96-a4af-e9731ef7e9d0|10|MOLRESP|Molecular Response|CHESON CLL 2012|[?]|/VF|iSD|1|1/(s*kPa)|MAMMOGRAPHY||||STUDY SUBJECT|NEUROLOGIST 2|NA|5|Visit_5|90|2|TREATMENT|2020-12-24|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-04|P1Y2M10DT2H30M|COINCIDENT|2020-10-17|AFTER|2020-11-30
e|RS|e7468d01-71b3-47c4-9715-62fe143364cb|1|BMIVLIND|Bone Marrow Involvement Indicator|BLAZER COLORECTAL CANCER 2008|[?]|mL/cm H2O|nPR|1|kV|INDIA INK STAIN|Y|||INDEPENDENT ASSESSOR|RADIOLOGIST 2|Y|1|Visit_1|10|3|FOLLOW-UP|2020-10-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-31|P1Y2M10DT2H30M|AFTER|2020-11-22|BEFORE|2020-12-08
e|RS|e7468d01-71b3-47c4-9715-62fe143364cb|2|BMIVLIND|Bone Marrow Involvement Indicator|SCHER PROSTATE CANCER 2011|[?]|ppth|PARTIAL MORPHOLOGIC RESPONSE|1|fmol/g|LIGHT MICROSCOPY||||DOMESTIC PARTNER|MICROSCOPIST|NA|1|Visit_1|10|7|WASHOUT|2020-10-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-31|P1Y2M10DT2H30M|BEFORE|2020-12-26|ONGOING|2021-01-05
e|RS|e7468d01-71b3-47c4-9715-62fe143364cb|3|METBRESP|Metabolic Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|mEq/ug|CYTOGENETIC MINIMAL RESPONSE|1|Log10 ELISA unit/dose|STRESS ECHOCARDIOGRAPHY||Y||CLINICAL RESEARCH ASSOCIATE|READER 3|Y|2|Visit_2|25|3|SCREENING|2020-10-30|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-18|P1Y2M10DT2H30M|COINCIDENT|2020-12-27|AFTER|2021-01-09
e|RS|e7468d01-71b3-47c4-9715-62fe143364cb|4|MJPTHIND|Major Pathological Response Indicator|CHOI GIST 2008|[?]|kcal/day|mCR|1|g/cage|AGAR DILUTION||||VENDOR|RATER 2|N|2|Visit_2|25|3|WASHOUT|2020-10-30|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-18|P1Y2M10DT2H30M|UNKNOWN|2020-12-13|BEFORE|2020-12-14
e|RS|e7468d01-71b3-47c4-9715-62fe143364cb|5|HEMARESP|Hematologic Response|SACT|[?]|TROCHE|PR|1|Hz|PAP STAIN||||VENDOR|READER|Y|3|Visit_3|40|3|FOLLOW-UP|2020-11-14|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-09|P1Y2M10DT2H30M|UNKNOWN|2020-10-13|AFTER|2020-11-07
e|RS|e7468d01-71b3-47c4-9715-62fe143364cb|6|SPLNRESP|Spleen Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|g|iCPD|1|uEq|LINE PROBE ASSAY||||SIBLING|UROLOGIST|N|3|Visit_3|40|3|TREATMENT|2020-11-14|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-09|P1Y2M10DT2H30M|COINCIDENT|2020-10-18|BEFORE|2020-10-27
e|RS|e7468d01-71b3-47c4-9715-62fe143364cb|7|PATHRESP|Pathologic Response|BLAZER COLORECTAL CANCER 2008|[?]|g/L|MRD NEGATIVITY|1|Ci/L|U-HPLC/MS/MS||||CAREGIVER|MICROSCOPIST 1|N|4|Visit_4|65|5|FOLLOW-UP|2020-12-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-25|P1Y2M10DT2H30M|UNKNOWN|2020-10-18|AFTER|2020-12-29
e|RS|e7468d01-71b3-47c4-9715-62fe143364cb|8|MRPHRESP|Morphologic Response|SHINDOH COLORECTAL CANCER 2013|||INDETERMINATE RESPONSE|1|mmol/min/kPa/L|IN VITRO GENE EXPRESSION ASSAY|||Y|STUDY SUBJECT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|4|Visit_4|65|2|TREATMENT|2020-12-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-25|P1Y2M10DT2H30M|COINCIDENT|2020-12-05|COINCIDENT|2021-01-10
e|RS|e7468d01-71b3-47c4-9715-62fe143364cb|9|BESTRESP|Best Overall Response|EBMT BLADE MYELOMA 1998|[?]|g|PSA PROGRESSION|1|10^9 organisms|TARGETED TRANSCRIPTOME SEQUENCING||||NON-HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|N|5|Visit_5|90|1|FOLLOW-UP|2021-01-03|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-18|P1Y2M10DT2H30M|COINCIDENT|2020-12-16|AFTER|2021-01-07
e|RS|e7468d01-71b3-47c4-9715-62fe143364cb|10|HEMARESP|Hematologic Response|NCIWG CHESON CLL 1996|[?]|BEAM BREAKS|mCR|1|U/mg|MASS SPECTROMETRY||||ADJUDICATOR|ONCOLOGIST 1|Y|5|Visit_5|90|7|TREATMENT|2021-01-03|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-18|P1Y2M10DT2H30M|BEFORE|2021-01-09|ONGOING|2021-01-12
e|RS|6a021859-1b18-4eb5-9548-0e32c0c1edf7|1|OVRLRESP|Overall Response|SACT|[?]|grain|PARTIAL MORPHOLOGIC RESPONSE|1|IU|PERCUSSION||||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 3|U|1|Visit_1|10|4|TREATMENT|2020-05-18|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-11|P1Y2M10DT2H30M|AFTER|2020-06-10|BEFORE|2020-07-23
e|RS|6a021859-1b18-4eb5-9548-0e32c0c1edf7|2|NTLWIND|Non-Target Lesion Worsening Indicator|RECIST 1.0|[?]|Roentgen|MAJOR PATHOLOGIC RESPONSE|1|Bq/L|MAGNETIC RESONANCE ENTEROGRAPHY|Y|Y||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 1|U|1|Visit_1|10|1|FOLLOW-UP|2020-05-18|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-11|P1Y2M10DT2H30M|COINCIDENT|2020-05-16|AFTER|2020-06-22
e|RS|6a021859-1b18-4eb5-9548-0e32c0c1edf7|3|METBRESP|Metabolic Response|MRECIST LENCIONI LIVER CANCER 2010|||NON-iCR/NON-iUPD|1|kHz|IMMUNOFLUORESCENT STAIN|Y||Y|DOMESTIC PARTNER|READER 1|N|2|Visit_2|25|1|TREATMENT|2020-06-02|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-14|P1Y2M10DT2H30M|UNKNOWN|2020-06-10|COINCIDENT|2020-07-01
e|RS|6a021859-1b18-4eb5-9548-0e32c0c1edf7|4|TMRESP|Tumor Marker Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|mL/cm|CYTOGENETIC CR|1|mm/2h|SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY||||SIBLING|INTERNIST|Y|2|Visit_2|25|6|WASHOUT|2020-06-02|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-14|P1Y2M10DT2H30M|UNKNOWN|2020-07-09|BEFORE|2020-08-07
e|RS|6a021859-1b18-4eb5-9548-0e32c0c1edf7|5|TRGRESP|Target Response|RECIST 1.1|[?]|mol/g|NR|1|APPLICATION|CONTACT SPECULAR MICROSCOPY||||SPOUSE|MICROSCOPIST 1|U|3|Visit_3|40|5|TREATMENT|2020-06-17|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-15|P1Y2M10DT2H30M|AFTER|2020-08-01|COINCIDENT|2020-08-02
e|RS|6a021859-1b18-4eb5-9548-0e32c0c1edf7|6|ANATRESP|Anatomic Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|tsp|INDETERMINATE RESPONSE|1|10^9 CFU|X-RAY||||INTERVIEWER|OTOLARYNGOLOGIST|Y|3|Visit_3|40|3|TREATMENT|2020-06-17|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-15|P1Y2M10DT2H30M|BEFORE|2020-07-15|BEFORE|2020-07-25
e|RS|6a021859-1b18-4eb5-9548-0e32c0c1edf7|7|BONERESP|Bone Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|vp/mL|MOLECULAR CR|1|/sec|ELASTOGRAPHY||||SIGNIFICANT OTHER|PATHOLOGIST|Y|4|Visit_4|65|6|TREATMENT|2020-07-12|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-17|P1Y2M10DT2H30M|COINCIDENT|2020-07-16|BEFORE|2020-07-25
e|RS|6a021859-1b18-4eb5-9548-0e32c0c1edf7|8|NEWLIND|New Lesion Indicator|MURPHY PROSTATE CANCER 1980|[?]|m3|iPR|1|10^4/L|RADIAL IMMUNODIFFUSION|Y|Y||HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|Y|4|Visit_4|65|2|FOLLOW-UP|2020-07-12|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-17|P1Y2M10DT2H30M|UNKNOWN|2020-07-23|AFTER|2020-07-24
e|RS|6a021859-1b18-4eb5-9548-0e32c0c1edf7|9|DRCRIND|Disease Recurrence Indicator|SCHWARZ CERVICAL CANCER 2009|||CYTOGENETIC NO RESPONSE|1|%|IMMUNOFIXATION ELECTROPHORESIS||Y|Y|SIBLING|READER 3|N|5|Visit_5|90|5|TREATMENT|2020-08-06|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-21|P1Y2M10DT2H30M|BEFORE|2020-05-14|AFTER|2020-06-30
e|RS|6a021859-1b18-4eb5-9548-0e32c0c1edf7|10|NTERESP|Non-Target Enhancing Response|BLAZER COLORECTAL CANCER 2008|||mCR|1|U/g/h|AUDIOMETRY|||Y|INVESTIGATOR|ENDOCRINOLOGIST|Y|5|Visit_5|90|7|TREATMENT|2020-08-06|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-21|P1Y2M10DT2H30M|AFTER|2020-07-02|BEFORE|2020-08-03
e|RS|eb409ec5-4c02-41c8-a11f-03d990818c2a|1|CPRFSTAT|Clinical Performance Status|WOLCHOK SOLID TUMORS 2009|[?]|umol/mg/min|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|10^3 organisms|SEQUENCING|Y|||GUARDIAN|ONCOLOGIST|N|1|Visit_1|10|4|TREATMENT|2020-12-09|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-20|P1Y2M10DT2H30M|AFTER|2021-02-25|ONGOING|2021-03-01
e|RS|eb409ec5-4c02-41c8-a11f-03d990818c2a|2|NTERESP|Non-Target Enhancing Response|IWG CHESON AML 2003|[?]|PLUG|PD/RELAPSE AFTER HI|1|uEq|HPLC/MS||||GUARDIAN|CARDIOLOGIST|N|1|Visit_1|10|5|TREATMENT|2020-12-09|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-20|P1Y2M10DT2H30M|COINCIDENT|2021-01-19|AFTER|2021-02-23
e|RS|eb409ec5-4c02-41c8-a11f-03d990818c2a|3|NEWLWIND|New Lesion Worsening Indicator|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|10^6 copies/mL|PR-CT|1|10^9/L|OBSERVATION||||HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|U|2|Visit_2|25|3|SCREENING|2020-12-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-01|P1Y2M10DT2H30M|COINCIDENT|2020-12-13|AFTER|2021-02-04
e|RS|eb409ec5-4c02-41c8-a11f-03d990818c2a|4|NEWLIND|New Lesion Indicator|KEAM BREAST CANCER 2013|[?]|10^9 organisms/g|CYTOGENETIC CR|1|uCi/L|HANSEL STAIN||||CAREGIVER|PATHOLOGIST 1|U|2|Visit_2|25|3|TREATMENT|2020-12-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-01|P1Y2M10DT2H30M|COINCIDENT|2021-01-31|COINCIDENT|2021-02-19
e|RS|eb409ec5-4c02-41c8-a11f-03d990818c2a|5|NTERESP|Non-Target Enhancing Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|CCID 50/dose|PSEUDORESPONSE|1|ugEq|PATHOLOGICAL EVALUATION||||STUDY SUBJECT|ADJUDICATOR 3|N|3|Visit_3|40|1|FOLLOW-UP|2021-01-08|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-21|P1Y2M10DT2H30M|UNKNOWN|2021-01-13|COINCIDENT|2021-01-29
e|RS|eb409ec5-4c02-41c8-a11f-03d990818c2a|6|STRUSTAT|Steroid Use Status|PRINCE TCELL LYMPHOMA 2010|[?]|kHz|MINOR PATHOLOGIC RESPONSE|1|RING|MICROPARTICLE ENZYME IMMUNOASSAY|Y|Y||CHILD|PATHOLOGIST 2|NA|3|Visit_3|40|3|SCREENING|2021-01-08|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-21|P1Y2M10DT2H30M|BEFORE|2020-12-21|COINCIDENT|2021-02-18
e|RS|eb409ec5-4c02-41c8-a11f-03d990818c2a|7|SFTSRESP|Soft Tissue Response|MASS|||ABSENT MORPHOLOGIC RESPONSE|1|10^6 DNA copies/mL|MULTI-SLICE SPIRAL CT|||Y|CHILD|READER 1|Y|4|Visit_4|65|6|FOLLOW-UP|2021-02-02|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-08|P1Y2M10DT2H30M|COINCIDENT|2021-01-09|COINCIDENT|2021-02-02
e|RS|eb409ec5-4c02-41c8-a11f-03d990818c2a|8|NEWLIND|New Lesion Indicator|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|mCi|UNFAVORABLE RESPONSE|1|foz_us|OPTICAL DENSITY MEASUREMENT||||VENDOR|RADIOLOGIST 1|N|4|Visit_4|65|6|SCREENING|2021-02-02|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-08|P1Y2M10DT2H30M|AFTER|2021-01-26|ONGOING|2021-02-02
e|RS|eb409ec5-4c02-41c8-a11f-03d990818c2a|9|MJPTHIND|Major Pathological Response Indicator|CHOLLET BREAST CANCER 2002|[?]|dpm/mL|MRD RELAPSE|1|log10 CFU/g|SANGER SEQUENCING||||PROXY|CARDIOLOGIST|NA|5|Visit_5|90|4|FOLLOW-UP|2021-02-27|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-01|P1Y2M10DT2H30M|COINCIDENT|2020-12-15|ONGOING|2021-01-28
e|RS|eb409ec5-4c02-41c8-a11f-03d990818c2a|10|BONERESP|Bone Response|RECIST 1.1|||TREATMENT FAILURE|1|amol|PYROSEQUENCING|||Y|INTERVIEWER|ONCOLOGIST|N|5|Visit_5|90|5|SCREENING|2021-02-27|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-01|P1Y2M10DT2H30M|COINCIDENT|2021-02-13|COINCIDENT|2021-02-14
e|RS|2178f542-809d-4306-84e4-26d3b3b370b0|1|SYMPTDTR|Symptomatic Deterioration|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|U/L|SD|1|10^12/L|PHOTOMETRIC CLOT DETECTION|Y|||CAREGIVER|CLINICAL PATHOLOGIST|U|1|Visit_1|10|1|TREATMENT|2020-11-06|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-18|P1Y2M10DT2H30M|BEFORE|2021-01-25|AFTER|2021-02-02
e|RS|2178f542-809d-4306-84e4-26d3b3b370b0|2|BONERESP|Bone Response|JACINTO CERVICAL CANCER 2007|[?]|MPL U|RELAPSED DISEASE FROM CR|1|mL/animal/day|LEAD CITRATE STAIN||||DOMESTIC PARTNER|READER 2|N|1|Visit_1|10|6|TREATMENT|2020-11-06|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-18|P1Y2M10DT2H30M|AFTER|2020-12-12|BEFORE|2021-01-20
e|RS|2178f542-809d-4306-84e4-26d3b3b370b0|3|MOLRESP|Molecular Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|L/s|NON-CR/NON-PD|1|dB|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION|Y|||VENDOR|FORENSIC PATHOLOGIST|N|2|Visit_2|25|2|SCREENING|2020-11-21|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-07|P1Y2M10DT2H30M|COINCIDENT|2020-12-06|COINCIDENT|2021-01-11
e|RS|2178f542-809d-4306-84e4-26d3b3b370b0|4|BESTRESP|Best Overall Response|CHOLLET BREAST CANCER 2002|||pCR|1|log10 TCID 50/dose|THICK SMEAR|||Y|CAREGIVER|PHYSIOTHERAPIST|Y|2|Visit_2|25|7|WASHOUT|2020-11-21|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-07|P1Y2M10DT2H30M|COINCIDENT|2021-01-07|AFTER|2021-01-22
e|RS|2178f542-809d-4306-84e4-26d3b3b370b0|5|MRDIND|Minimal Residual Disease Indicator|FAROOQUI SUPP CLL 2014|[?]|cmH2O*s/mL|SMD|1|pmol/10^9 cells|PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY||||NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|NA|3|Visit_3|40|4|SCREENING|2020-12-06|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-30|P1Y2M10DT2H30M|BEFORE|2020-12-22|COINCIDENT|2021-01-23
e|RS|2178f542-809d-4306-84e4-26d3b3b370b0|6|NTNERESP|Non-Target Non-Enhancing Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|||NE|1|/MBP|PERIPHERAL ANGIOGRAPHY|||Y|SIBLING|READER|N|3|Visit_3|40|4|FOLLOW-UP|2020-12-06|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-30|P1Y2M10DT2H30M|UNKNOWN|2020-12-26|AFTER|2021-01-09
e|RS|2178f542-809d-4306-84e4-26d3b3b370b0|7|SFTSRESP|Soft Tissue Response|HARTMAN PANCREATIC CANCER 2012|[?]|cy/cm|MOLECULAR CR|1|mL/animal|ENZYMATIC ULTRACENTRIFUGATION||||FAMILY MEMBER|PEDIATRIC NEUROLOGIST|N|4|Visit_4|65|3|TREATMENT|2020-12-31|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-14|P1Y2M10DT2H30M|COINCIDENT|2020-12-08|BEFORE|2021-01-16
e|RS|2178f542-809d-4306-84e4-26d3b3b370b0|8|METSIND|Metastatic Indicator|GUPPY OVARIAN CANCER 2002|[?]|mL/s|UNEQUIVOCAL|1|mL/m2/day|MICRODENSITOMETRY||||GUARDIAN|MICROSCOPIST 3|Y|4|Visit_4|65|6|SCREENING|2020-12-31|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-14|P1Y2M10DT2H30M|COINCIDENT|2021-01-21|COINCIDENT|2021-01-27
e|RS|2178f542-809d-4306-84e4-26d3b3b370b0|9|CLINRESP|Clinical Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|MET*min|SD-CT|1|MBq/uL|QUANTITATIVE ULTRASOUND|Y|||CHILD|RADIOLOGIST|N|5|Visit_5|90|7|TREATMENT|2021-01-25|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-29|P1Y2M10DT2H30M|COINCIDENT|2020-11-19|ONGOING|2020-12-10
e|RS|2178f542-809d-4306-84e4-26d3b3b370b0|10|MNPTHIND|Minor Pathological Response Indicator|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|PIXEL|NON-iCR/NON-iUPD|1|s/h|CONTRAST ENHANCED MRI||Y||INVESTIGATOR|ONCOLOGIST 1|N|5|Visit_5|90|1|TREATMENT|2021-01-25|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-29|P1Y2M10DT2H30M|AFTER|2020-12-31|BEFORE|2021-01-26
e|RS|da7423fb-461e-43a6-bcb9-aa87051bda0a|1|METBRESP|Metabolic Response|PRINCE TCELL LYMPHOMA 2010|[?]|FINGERTIP UNIT|CYTOGENETIC NO RESPONSE|1|cmol|CLAUSS METHOD|Y|Y||ADJUDICATOR|READER 2|NA|1|Visit_1|10|7|TREATMENT|2020-10-04|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-19|P1Y2M10DT2H30M|COINCIDENT|2020-12-28|ONGOING|2020-12-30
e|RS|da7423fb-461e-43a6-bcb9-aa87051bda0a|2|MRDIND|Minimal Residual Disease Indicator|IRANO 2015|||SD-CT|1|eq|PLAQUE REDUCTION NEUTRALIZATION ASSAY|||Y|FRIEND|NEUROLOGIST 1|NA|1|Visit_1|10|2|SCREENING|2020-10-04|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-19|P1Y2M10DT2H30M|BEFORE|2020-10-17|COINCIDENT|2020-12-28
e|RS|da7423fb-461e-43a6-bcb9-aa87051bda0a|3|SFTSRESP|Soft Tissue Response|WOLCHOK SOLID TUMORS 2009|[?]|cm H2O|OPTIMAL MORPHOLOGIC RESPONSE|1|U/kg/min|HANSEL STAIN||||CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 2|NA|2|Visit_2|25|5|WASHOUT|2020-10-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-28|P1Y2M10DT2H30M|AFTER|2020-12-31|AFTER|2021-01-01
e|RS|da7423fb-461e-43a6-bcb9-aa87051bda0a|4|MRDIND|Minimal Residual Disease Indicator|AJCC V8|[?]|10^3 organisms|MRD RELAPSE|1|umol/min|IN SITU HYBRIDIZATION|Y|||CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST|NA|2|Visit_2|25|1|TREATMENT|2020-10-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-28|P1Y2M10DT2H30M|BEFORE|2020-11-09|ONGOING|2020-11-12
e|RS|da7423fb-461e-43a6-bcb9-aa87051bda0a|5|LIVRRESP|Liver Response|IWG CHESON MDS 2000|[?]|mg/m2/day|PSA PROGRESSION|1|deg|PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY||||PARENT|OTOLARYNGOLOGIST|Y|3|Visit_3|40|3|TREATMENT|2020-11-03|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-02|P1Y2M10DT2H30M|BEFORE|2020-11-12|AFTER|2020-12-13
e|RS|da7423fb-461e-43a6-bcb9-aa87051bda0a|6|STRUSTAT|Steroid Use Status|PCWG SCHER PROSTATE CANCER 2016|[?]|mg/min|CRi|1|10^4 CFU/mL|CT SCAN||||VENDOR|UROLOGIST|Y|3|Visit_3|40|7|TREATMENT|2020-11-03|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-02|P1Y2M10DT2H30M|UNKNOWN|2020-10-11|AFTER|2020-12-02
e|RS|da7423fb-461e-43a6-bcb9-aa87051bda0a|7|LIVRRESP|Liver Response|RECIST 1.0|[?]|pmol/L/h|TREATMENT FAILURE|1|HEP|MANUAL CLOT DETECTION||Y||SIGNIFICANT OTHER|ENDOCRINOLOGIST|U|4|Visit_4|65|7|TREATMENT|2020-11-28|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-04|P1Y2M10DT2H30M|COINCIDENT|2020-10-16|AFTER|2020-12-31
e|RS|da7423fb-461e-43a6-bcb9-aa87051bda0a|8|HEMARESP|Hematologic Response|MONTSERRAT CLL 1989|[?]|ug/day|CA125 75% RESPONSE|1|pmol/L|MRS|Y|||SPOUSE|PHYSIOTHERAPIST|U|4|Visit_4|65|7|SCREENING|2020-11-28|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-04|P1Y2M10DT2H30M|COINCIDENT|2020-10-27|COINCIDENT|2020-11-15
e|RS|da7423fb-461e-43a6-bcb9-aa87051bda0a|9|MNPTHIND|Minor Pathological Response Indicator|GUILHOT CML 2007|[?]|tsp|IMMUNOPHENOTYPIC CR|1|MET*min|MS/MS||Y||SIGNIFICANT OTHER|RATER 1|U|5|Visit_5|90|1|WASHOUT|2020-12-23|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-18|P1Y2M10DT2H30M|COINCIDENT|2020-11-28|COINCIDENT|2020-12-27
e|RS|da7423fb-461e-43a6-bcb9-aa87051bda0a|10|RDIORESP|Radiologic Response|PCWG SCHER PROSTATE CANCER 2016|[?]|gpELISA unit/mL|QUANTIFIABLE MRD POSITIVITY|1|umol/kg/min|NUCLEIC ACID SEQUENCING||Y||SIBLING|NEUROLOGIST 2|NA|5|Visit_5|90|5|WASHOUT|2020-12-23|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-18|P1Y2M10DT2H30M|UNKNOWN|2020-12-09|COINCIDENT|2020-12-15
e|RS|40e4c69f-6115-4f0e-8555-45b12b222801|1|MOLRESP|Molecular Response|NCIWG CHESON CLL 1996|[?]|umol/L/min|CYTOGENETIC MINIMAL RESPONSE|1|m3|WHOLE EXOME SEQUENCING||||INTERVIEWER|RADIOLOGIST 2|Y|1|Visit_1|10|5|WASHOUT|2021-01-30|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-29|P1Y2M10DT2H30M|BEFORE|2021-03-11|AFTER|2021-03-15
e|RS|40e4c69f-6115-4f0e-8555-45b12b222801|2|MNPTHIND|Minor Pathological Response Indicator|DOHNER AML 2010|[?]|mV/sec|PD/RELAPSE AFTER HI|1|uV*sec|CT SCAN WITHOUT CONTRAST||||STUDY SUBJECT|MICROSCOPIST|NA|1|Visit_1|10|4|TREATMENT|2021-01-30|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-29|P1Y2M10DT2H30M|UNKNOWN|2021-02-22|ONGOING|2021-03-01
e|RS|40e4c69f-6115-4f0e-8555-45b12b222801|3|NEWLPROG|New Lesion Progression|SCHWARZ CERVICAL CANCER 2009|[?]|pt_br|NON-QUANTIFIABLE MRD POSITIVITY|1|U|THIN SMEAR||||PROXY|PATHOLOGIST 1|NA|2|Visit_2|25|4|TREATMENT|2021-02-14|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-18|P1Y2M10DT2H30M|AFTER|2021-04-06|BEFORE|2021-04-23
e|RS|40e4c69f-6115-4f0e-8555-45b12b222801|4|NTERESP|Non-Target Enhancing Response|KEAM BREAST CANCER 2013|||NON-CR/NON-PD|1|U/10^12 RBC|ELECTROGASTROGRAPHY|Y||Y|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|NA|2|Visit_2|25|4|TREATMENT|2021-02-14|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-18|P1Y2M10DT2H30M|UNKNOWN|2021-03-30|ONGOING|2021-04-21
e|RS|40e4c69f-6115-4f0e-8555-45b12b222801|5|CYTORESP|Cytogenetic Response|IWG CHESON AML 2003|[?]|10^6 IU|MRD PERSISTENCE|1|mN|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY||||INDEPENDENT ASSESSOR|NEUROLOGIST 2|N|3|Visit_3|40|6|FOLLOW-UP|2021-03-01|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-03|P1Y2M10DT2H30M|COINCIDENT|2021-02-04|COINCIDENT|2021-02-20
e|RS|40e4c69f-6115-4f0e-8555-45b12b222801|6|NTNERESP|Non-Target Non-Enhancing Response|LUGANO CLASSIFICATION|[?]|umol/L/h|PD-CT|1|SFC/10^6 PBMC|FLUORESCENT IMMUNOASSAY||||CLINICAL STUDY SPONSOR|NEUROLOGIST 2|NA|3|Visit_3|40|1|TREATMENT|2021-03-01|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-03|P1Y2M10DT2H30M|AFTER|2021-04-08|BEFORE|2021-04-15
e|RS|40e4c69f-6115-4f0e-8555-45b12b222801|7|METBRESP|Metabolic Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|cmol/L|RELAPSED DISEASE|1|uEq|PET SCAN|Y|||SIGNIFICANT OTHER|NEUROLOGIST 1|NA|4|Visit_4|65|4|FOLLOW-UP|2021-03-26|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-20|P1Y2M10DT2H30M|AFTER|2021-04-21|COINCIDENT|2021-04-29
e|RS|40e4c69f-6115-4f0e-8555-45b12b222801|8|HEMARESP|Hematologic Response|WHO BREAST CANCER 2006|[?]|mL/min/1.73m2|MINOR PATHOLOGIC RESPONSE|1|mL|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS||Y||CAREGIVER|UROLOGIST|NA|4|Visit_4|65|5|SCREENING|2021-03-26|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-20|P1Y2M10DT2H30M|UNKNOWN|2021-04-05|COINCIDENT|2021-04-27
e|RS|40e4c69f-6115-4f0e-8555-45b12b222801|9|BESTRESP|Best Overall Response|PCWG BUBLEY PROSTATE CANCER 1999|||SD|1|pmol/10^10 cells|TRANSTHORACIC ECHOCARDIOGRAPHY|Y||Y|SIGNIFICANT OTHER|PATHOLOGIST 2|Y|5|Visit_5|90|5|SCREENING|2021-04-20|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-27|P1Y2M10DT2H30M|AFTER|2021-04-19|COINCIDENT|2021-04-26
e|RS|40e4c69f-6115-4f0e-8555-45b12b222801|10|SYMPTDTR|Symptomatic Deterioration|SHINDOH COLORECTAL CANCER 2013|[?]|Gy/min|CHR|1|U/g/day|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE||||INVESTIGATOR|FORENSIC PATHOLOGIST|N|5|Visit_5|90|5|TREATMENT|2021-04-20|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-27|P1Y2M10DT2H30M|UNKNOWN|2021-02-19|ONGOING|2021-03-17
e|RS|1307d7f6-acb6-4096-a907-08345548a82b|1|NTERESP|Non-Target Enhancing Response|iRECIST|[?]|cm/s|PDu|1|s/h|RAJI CELL RIA||||INTERVIEWER|READER 2|N|1|Visit_1|10|3|FOLLOW-UP|2020-05-28|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-18|P1Y2M10DT2H30M|AFTER|2020-05-28|ONGOING|2020-06-12
e|RS|1307d7f6-acb6-4096-a907-08345548a82b|2|OVRLRESP|Overall Response|PERCIST|[?]|PATCH|iSD|1|/10^5|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION||Y||PARENT|ADJUDICATOR 1|U|1|Visit_1|10|6|SCREENING|2020-05-28|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-18|P1Y2M10DT2H30M|BEFORE|2020-08-02|ONGOING|2020-08-05
e|RS|1307d7f6-acb6-4096-a907-08345548a82b|3|CYTORESP|Cytogenetic Response|IWC HALLEK CLL 2008|[?]|min/day|NON-iCR/NON-iUPD|1|Absorbance U/mL|ROMANOWSKY STAIN||Y||INTERVIEWER|INTERNIST|NA|2|Visit_2|25|4|TREATMENT|2020-06-12|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-26|P1Y2M10DT2H30M|BEFORE|2020-07-17|BEFORE|2020-07-23
e|RS|1307d7f6-acb6-4096-a907-08345548a82b|4|MRPHRESP|Morphologic Response|MACDONALD GLIOMA 1990|||iPR|1|OD Unit|IMMUNOFIXATION ELECTROPHORESIS|||Y|CLINICAL STUDY SPONSOR|FORENSIC PATHOLOGIST|NA|2|Visit_2|25|1|TREATMENT|2020-06-12|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-26|P1Y2M10DT2H30M|COINCIDENT|2020-05-30|COINCIDENT|2020-07-19
e|RS|1307d7f6-acb6-4096-a907-08345548a82b|5|OVRLRESP|Overall Response|RECIST 1.0|[?]|g/day|CYTOGENETIC MINIMAL RESPONSE|1|kUSP|TRICHROME STAIN||||SIGNIFICANT OTHER|RATER 2|U|3|Visit_3|40|6|FOLLOW-UP|2020-06-27|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-25|P1Y2M10DT2H30M|BEFORE|2020-07-15|ONGOING|2020-07-18
e|RS|1307d7f6-acb6-4096-a907-08345548a82b|6|MNPTHIND|Minor Pathological Response Indicator|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|10^6 organisms/mL|FAVORABLE RESPONSE|1|mg|TWO-COLOR MICROARRAY|Y|||CLINICAL RESEARCH COORDINATOR|OTOLARYNGOLOGIST|N|3|Visit_3|40|6|FOLLOW-UP|2020-06-27|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-25|P1Y2M10DT2H30M|AFTER|2020-07-27|BEFORE|2020-08-08
e|RS|1307d7f6-acb6-4096-a907-08345548a82b|7|ANATRESP|Anatomic Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|10^4/L|CYTOGENETIC CR|1|L/min|SNELLEN EYE CHART|Y|||INTERVIEWER|ENDOCRINOLOGIST|Y|4|Visit_4|65|1|WASHOUT|2020-07-22|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-29|P1Y2M10DT2H30M|COINCIDENT|2020-05-26|COINCIDENT|2020-06-16
e|RS|1307d7f6-acb6-4096-a907-08345548a82b|8|CYTORESP|Cytogenetic Response|SHINDOH COLORECTAL CANCER 2013|||STABLE|1|10^9 organisms|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI||Y|Y|FRIEND|PHYSIOTHERAPIST|U|4|Visit_4|65|2|WASHOUT|2020-07-22|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-29|P1Y2M10DT2H30M|COINCIDENT|2020-07-24|COINCIDENT|2020-08-23
e|RS|1307d7f6-acb6-4096-a907-08345548a82b|9|OVRLRESP|Overall Response|RANO ELLINGSON 2017|[?]|ag|MORPHOLOGIC LEUKEMIA-FREE STATE|1|g/mol|MRI|Y|||FRIEND|OPHTHALMOLOGIST|U|5|Visit_5|90|2|TREATMENT|2020-08-16|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-23|P1Y2M10DT2H30M|AFTER|2020-06-04|AFTER|2020-08-05
e|RS|1307d7f6-acb6-4096-a907-08345548a82b|10|CYTORESP|Cytogenetic Response|HARTMANN GERM CELL CANCER 2002|[?]|ohm|mCR|1|mm/2h|PALPATION||||DOMESTIC PARTNER|CARDIOLOGIST|NA|5|Visit_5|90|3|TREATMENT|2020-08-16|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-23|P1Y2M10DT2H30M|AFTER|2020-06-24|COINCIDENT|2020-07-29
e|RS|bac23835-1120-43b2-9d99-694bef97f44b|1|NEWLIND|New Lesion Indicator|CHESON CLL 2012|[?]|cup eq|MINOR PATHOLOGIC RESPONSE|1|Ci/mg|MACRO BROTH DILUTION||||INVESTIGATOR|RADIOLOGIST|Y|1|Visit_1|10|6|TREATMENT|2020-05-21|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-16|P1Y2M10DT2H30M|AFTER|2020-06-28|ONGOING|2020-08-07
e|RS|bac23835-1120-43b2-9d99-694bef97f44b|2|NTLWIND|Non-Target Lesion Worsening Indicator|GUILHOT CML 2007|[?]|Arbitrary U|NR|1|Henry|PHOTOMETRIC CLOT DETECTION||||PROXY|MICROSCOPIST 1|U|1|Visit_1|10|4|TREATMENT|2020-05-21|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-16|P1Y2M10DT2H30M|COINCIDENT|2020-06-22|COINCIDENT|2020-08-14
e|RS|bac23835-1120-43b2-9d99-694bef97f44b|3|BONERESP|Bone Response|MRECIST LENCIONI LIVER CANCER 2010|||RELAPSED DISEASE|1|mmHg*min/L|MICRO BROTH DILUTION||Y|Y|INDEPENDENT ASSESSOR|OTOLARYNGOLOGIST|U|2|Visit_2|25|5|FOLLOW-UP|2020-06-05|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-05|P1Y2M10DT2H30M|UNKNOWN|2020-06-17|ONGOING|2020-06-20
e|RS|bac23835-1120-43b2-9d99-694bef97f44b|4|SPLNRESP|Spleen Response|PCWG SCHER PROSTATE CANCER 2016|[?]|PNU/mL|CYTOGENETIC CR|1|10^6 IU/mL|KNEMOMETRY||||CLINICAL RESEARCH COORDINATOR|CLINICAL PATHOLOGIST|NA|2|Visit_2|25|6|SCREENING|2020-06-05|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-05|P1Y2M10DT2H30M|BEFORE|2020-07-26|COINCIDENT|2020-08-07
e|RS|bac23835-1120-43b2-9d99-694bef97f44b|5|NTRGRESP|Non-target Response|WHO BREAST CANCER 2006|[?]|BOX|PD|1|U/dL|CELLULAR PROLIFERATION ASSAY||Y||SIGNIFICANT OTHER|NEUROLOGIST 2|NA|3|Visit_3|40|6|TREATMENT|2020-06-20|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-23|P1Y2M10DT2H30M|COINCIDENT|2020-06-03|BEFORE|2020-06-25
e|RS|bac23835-1120-43b2-9d99-694bef97f44b|6|LIVRRESP|Liver Response|NCCN ALL MRD 2014|[?]|mmol2/L2|MORPHOLOGIC CRi|1|cm|APPLANATION TONOMETRY||Y||CLINICAL RESEARCH COORDINATOR|NEUROLOGIST|N|3|Visit_3|40|2|TREATMENT|2020-06-20|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-23|P1Y2M10DT2H30M|BEFORE|2020-07-08|COINCIDENT|2020-07-09
e|RS|bac23835-1120-43b2-9d99-694bef97f44b|7|CYTORESP|Cytogenetic Response|GUILHOT CML 2007|[?]|beats/min|CRi|1|mL/m2|FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY||||CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 2|NA|4|Visit_4|65|4|SCREENING|2020-07-15|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-15|P1Y2M10DT2H30M|UNKNOWN|2020-06-30|BEFORE|2020-07-01
e|RS|bac23835-1120-43b2-9d99-694bef97f44b|8|NTLWIND|Non-Target Lesion Worsening Indicator|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|Coulomb|PD FROM PR|1|cd|MICROPARTICLE ENZYME IMMUNOASSAY||||NON-HEALTH CARE PROFESSIONAL|CARDIOLOGIST|N|4|Visit_4|65|1|FOLLOW-UP|2020-07-15|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-15|P1Y2M10DT2H30M|AFTER|2020-05-23|AFTER|2020-07-10
e|RS|bac23835-1120-43b2-9d99-694bef97f44b|9|NEWLIND|New Lesion Indicator|MRANO VAN DEN BENT GLIOMA 2011|[?]|mIU/L|MR|1|nkat/L|DYNAMIC LIGHT SCATTERING||||CHILD|FORENSIC PATHOLOGIST|U|5|Visit_5|90|7|TREATMENT|2020-08-09|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-18|P1Y2M10DT2H30M|AFTER|2020-05-29|ONGOING|2020-06-15
e|RS|bac23835-1120-43b2-9d99-694bef97f44b|10|NEWLPROG|New Lesion Progression|PRINCE TCELL LYMPHOMA 2010|[?]|deg2|IMPROVED|1|damol/L|ELLA|Y|||PROXY|RADIOLOGIST|U|5|Visit_5|90|3|TREATMENT|2020-08-09|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-18|P1Y2M10DT2H30M|UNKNOWN|2020-07-27|BEFORE|2020-08-03
e|RS|8cf8f8a1-5c55-4f82-b6bc-109acdf5b514|1|NEWLWIND|New Lesion Worsening Indicator|SCHWARZ CERVICAL CANCER 2009|[?]|msec|NR|1|10^6 IU|PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY||Y||INDEPENDENT ASSESSOR|NEUROLOGIST|N|1|Visit_1|10|4|FOLLOW-UP|2020-09-24|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-15|P1Y2M10DT2H30M|BEFORE|2020-10-21|AFTER|2020-12-01
e|RS|8cf8f8a1-5c55-4f82-b6bc-109acdf5b514|2|STRUSTAT|Steroid Use Status|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|ug/h|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|pmol/day|HEMOCYTOMETRY||||INTERVIEWER|ONCOLOGIST|U|1|Visit_1|10|2|SCREENING|2020-09-24|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-15|P1Y2M10DT2H30M|BEFORE|2020-10-14|AFTER|2020-12-03
e|RS|8cf8f8a1-5c55-4f82-b6bc-109acdf5b514|3|MRDIND|Minimal Residual Disease Indicator|CHESON MALIGNANT LYMPHOMA 2007|[?]|CUP|NON-iCR/NON-iUPD|1|Enzyme U/g Hb|ENDOSCOPY||Y||FAMILY MEMBER|READER 1|NA|2|Visit_2|25|7|TREATMENT|2020-10-09|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-25|P1Y2M10DT2H30M|UNKNOWN|2020-09-29|BEFORE|2020-11-23
e|RS|8cf8f8a1-5c55-4f82-b6bc-109acdf5b514|4|NEWLWIND|New Lesion Worsening Indicator|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|DAgU|CHR|1|IU/kg|RADIATION DOSIMETRY||||GUARDIAN|HEMATOLOGIST|NA|2|Visit_2|25|3|TREATMENT|2020-10-09|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-25|P1Y2M10DT2H30M|COINCIDENT|2020-10-31|BEFORE|2020-11-08
e|RS|8cf8f8a1-5c55-4f82-b6bc-109acdf5b514|5|STRUSTAT|Steroid Use Status|IWG CHESON MDS 2006|[?]|hr/day|OPTIMAL MORPHOLOGIC RESPONSE|1|INHALATION|PHOTOMETRY||||CLINICAL RESEARCH ASSOCIATE|FORENSIC PATHOLOGIST|U|3|Visit_3|40|2|FOLLOW-UP|2020-10-24|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-24|P1Y2M10DT2H30M|UNKNOWN|2020-09-25|AFTER|2020-12-11
e|RS|8cf8f8a1-5c55-4f82-b6bc-109acdf5b514|6|PATHRESP|Pathologic Response|LUGANO CLASSIFICATION|||HI-P|1|pmol/10^9 cells|HPLC-FL|||Y|PARENT|PEDIATRIC NEUROLOGIST|NA|3|Visit_3|40|7|WASHOUT|2020-10-24|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-24|P1Y2M10DT2H30M|UNKNOWN|2020-10-08|BEFORE|2020-10-29
e|RS|8cf8f8a1-5c55-4f82-b6bc-109acdf5b514|7|STRUSTAT|Steroid Use Status|PRINCE TCELL LYMPHOMA 2010|[?]|mL*cmH2O|PARTIAL MORPHOLOGIC RESPONSE|1|hr/day|MICROBIAL CULTURE||||SIGNIFICANT OTHER|ADJUDICATOR|Y|4|Visit_4|65|7|TREATMENT|2020-11-18|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-11|P1Y2M10DT2H30M|BEFORE|2020-12-02|AFTER|2020-12-19
e|RS|8cf8f8a1-5c55-4f82-b6bc-109acdf5b514|8|ANATRESP|Anatomic Response|UNSPECIFIED|[?]|EU|iSD|1|Ci/ug|MULTI-SLICE SPIRAL CT|Y|||HEALTH CARE PROFESSIONAL|RATER 2|NA|4|Visit_4|65|3|TREATMENT|2020-11-18|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-11|P1Y2M10DT2H30M|AFTER|2020-10-28|AFTER|2020-10-29
e|RS|8cf8f8a1-5c55-4f82-b6bc-109acdf5b514|9|NTERESP|Non-Target Enhancing Response|KUKER LYMPHOMA 2005|||CYTOGENETIC PR|1|mph|TRIPLE-PHASE SPIRAL CT SCAN|||Y|STUDY SUBJECT|MICROSCOPIST 2|Y|5|Visit_5|90|6|FOLLOW-UP|2020-12-13|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-18|P1Y2M10DT2H30M|BEFORE|2020-10-26|COINCIDENT|2020-12-02
e|RS|8cf8f8a1-5c55-4f82-b6bc-109acdf5b514|10|NEWLIND|New Lesion Indicator|MURPHY PROSTATE CANCER 1980|[?]|TRACE|PSEUDORESPONSE|1|10^6 IU/mL|IMMUNOFIXATION ELECTROPHORESIS||Y||STUDY SUBJECT|RATER|Y|5|Visit_5|90|4|FOLLOW-UP|2020-12-13|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-18|P1Y2M10DT2H30M|UNKNOWN|2020-10-23|BEFORE|2020-11-07
e|RS|14cd64f5-f3c8-47a4-b40e-9c5090890870|1|MOLRESP|Molecular Response|BLAZER COLORECTAL CANCER 2008|[?]|10^7 CFU|NON-iCR/NON-iUPD|1|MPL U/mL|IMMUNO-PET SCAN||||SIGNIFICANT OTHER|READER 2|Y|1|Visit_1|10|3|TREATMENT|2020-09-24|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-21|P1Y2M10DT2H30M|BEFORE|2020-11-02|ONGOING|2020-12-10
e|RS|14cd64f5-f3c8-47a4-b40e-9c5090890870|2|SYMPTDTR|Symptomatic Deterioration|MURPHY PROSTATE CANCER 1980|[?]|CARTRIDGE|PD FROM PR|1|10^6/L|SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY||Y||CLINICAL STUDY SPONSOR|OTOLARYNGOLOGIST|N|1|Visit_1|10|7|TREATMENT|2020-09-24|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-21|P1Y2M10DT2H30M|COINCIDENT|2020-11-04|BEFORE|2020-12-11
e|RS|14cd64f5-f3c8-47a4-b40e-9c5090890870|3|HEMARESP|Hematologic Response|FAROOQUI SUPP CLL 2014|[?]|nmol BCE/mmol|HI-N|1|umol/mg/min|ELECTROGASTROGRAPHY|Y|Y||INVESTIGATOR|PATHOLOGIST 2|NA|2|Visit_2|25|3|WASHOUT|2020-10-09|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-17|P1Y2M10DT2H30M|UNKNOWN|2020-11-02|COINCIDENT|2020-12-21
e|RS|14cd64f5-f3c8-47a4-b40e-9c5090890870|4|BONERESP|Bone Response|LUGANO CLASSIFICATION|[?]|mCi/kg|IMMUNOPHENOTYPIC CR|1|PIXELS/in|PULMONARY ANGIOGRAPHY||||PROXY|NEUROLOGIST|NA|2|Visit_2|25|5|WASHOUT|2020-10-09|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-17|P1Y2M10DT2H30M|UNKNOWN|2020-11-04|BEFORE|2020-12-13
e|RS|14cd64f5-f3c8-47a4-b40e-9c5090890870|5|METBRESP|Metabolic Response|EBMT BLADE MYELOMA 1998|[?]|pt_us|nPR|1|EID 50/dose|MICROBIAL CULTURE, LIQUID||||PROXY|MICROSCOPIST 2|Y|3|Visit_3|40|3|SCREENING|2020-10-24|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-12|P1Y2M10DT2H30M|AFTER|2020-10-15|BEFORE|2020-11-06
e|RS|14cd64f5-f3c8-47a4-b40e-9c5090890870|6|BMIVLIND|Bone Marrow Involvement Indicator|LEE LUNG CANCER 2011|[?]|mg/day|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|10^8/L|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION|Y|||ADJUDICATOR|ONCOLOGIST 2|Y|3|Visit_3|40|5|TREATMENT|2020-10-24|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-12|P1Y2M10DT2H30M|COINCIDENT|2020-10-27|BEFORE|2020-11-06
e|RS|14cd64f5-f3c8-47a4-b40e-9c5090890870|7|CLINRESP|Clinical Response|EASL BRUIX LIVER CANCER 2001|[?]|cm H2O|DISEASE TRANSFORMATION|1|mEq/L|PET/MRI SCAN||||CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 1|NA|4|Visit_4|65|6|WASHOUT|2020-11-18|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-16|P1Y2M10DT2H30M|COINCIDENT|2020-09-19|AFTER|2020-11-16
e|RS|14cd64f5-f3c8-47a4-b40e-9c5090890870|8|NEWLWIND|New Lesion Worsening Indicator|IWC HALLEK CLL 2008|[?]|ukat/L|iUPD|1|P|GIEMSA STAIN||||GUARDIAN|RADIOLOGIST 2|NA|4|Visit_4|65|6|TREATMENT|2020-11-18|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-16|P1Y2M10DT2H30M|BEFORE|2020-10-20|ONGOING|2020-10-21
e|RS|14cd64f5-f3c8-47a4-b40e-9c5090890870|9|SPLNRESP|Spleen Response|KEAM BREAST CANCER 2013|||CA125 75% RESPONSE|1|CAPSULE|IODINE STAIN|Y||Y|VENDOR|READER 3|Y|5|Visit_5|90|3|WASHOUT|2020-12-13|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-27|P1Y2M10DT2H30M|UNKNOWN|2020-12-18|AFTER|2020-12-19
e|RS|14cd64f5-f3c8-47a4-b40e-9c5090890870|10|SYMPTDTR|Symptomatic Deterioration|PETIT BREAST CANCER 2001|[?]|kHz|COMPLETE MRD RESPONSE|1|10^7 PFU|WESTERN BLOT||||FRIEND|PATHOLOGIST 1|N|5|Visit_5|90|7|FOLLOW-UP|2020-12-13|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-27|P1Y2M10DT2H30M|COINCIDENT|2020-12-07|AFTER|2020-12-09
e|RS|ca4a06be-5e6a-4220-9854-e5fe02b384af|1|NEWLWIND|New Lesion Worsening Indicator|MASS|[?]|nL|SD-CT|1|nmol|NUCLEIC ACID AMPLIFICATION TEST|Y|Y||SPOUSE|RADIOLOGIST|U|1|Visit_1|10|3|TREATMENT|2020-10-03|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-24|P1Y2M10DT2H30M|COINCIDENT|2020-12-23|BEFORE|2020-12-31
e|RS|ca4a06be-5e6a-4220-9854-e5fe02b384af|2|NEWLIND|New Lesion Indicator|KUKER LYMPHOMA 2005|[?]|Enzyme U/L|VGPR|1|cd|SPIRAL CT SCAN WITHOUT CONTRAST||||PARENT|READER 3|N|1|Visit_1|10|4|TREATMENT|2020-10-03|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-24|P1Y2M10DT2H30M|COINCIDENT|2020-10-11|COINCIDENT|2020-10-19
e|RS|ca4a06be-5e6a-4220-9854-e5fe02b384af|3|CPRFSTAT|Clinical Performance Status|GUILHOT CML 2007|[?]|DPM|MAJOR PATHOLOGIC RESPONSE|1|L/min|PHOROPTER||Y||INTERVIEWER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|2|Visit_2|25|7|TREATMENT|2020-10-18|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-29|P1Y2M10DT2H30M|UNKNOWN|2020-11-08|COINCIDENT|2020-11-23
e|RS|ca4a06be-5e6a-4220-9854-e5fe02b384af|4|HEMARESP|Hematologic Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|Joule|iPR|1|Tesla|GC/MS|Y|||CLINICAL STUDY SPONSOR|DERMATOLOGIST|U|2|Visit_2|25|3|TREATMENT|2020-10-18|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-29|P1Y2M10DT2H30M|UNKNOWN|2020-11-20|ONGOING|2020-11-30
e|RS|ca4a06be-5e6a-4220-9854-e5fe02b384af|5|DRCRIND|Disease Recurrence Indicator|SCHWARZ CERVICAL CANCER 2009|[?]|K|MR|1|dyn|GRADIENT DIFFUSION|Y|||PARENT|HEMATOLOGIST|NA|3|Visit_3|40|3|WASHOUT|2020-11-02|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-21|P1Y2M10DT2H30M|UNKNOWN|2020-09-25|ONGOING|2020-12-09
e|RS|ca4a06be-5e6a-4220-9854-e5fe02b384af|6|SYMPTDTR|Symptomatic Deterioration|PETIT BREAST CANCER 2001|[?]|mL/g/min|STABLE|1|mL/animal|SCANNING ELECTRON MICROSCOPY||||HEALTH CARE PROFESSIONAL|OPTOMETRIST|U|3|Visit_3|40|4|TREATMENT|2020-11-02|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-21|P1Y2M10DT2H30M|BEFORE|2020-12-23|ONGOING|2020-12-26
e|RS|ca4a06be-5e6a-4220-9854-e5fe02b384af|7|SFTSRESP|Soft Tissue Response|PRINCE TCELL LYMPHOMA 2010|[?]|mg/m2/min|IMPROVED|1|Bq/L|COMPUTERIZED CORNEAL TOPOGRAPHY||||CAREGIVER|UROLOGIST|N|4|Visit_4|65|7|TREATMENT|2020-11-27|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-25|P1Y2M10DT2H30M|BEFORE|2020-12-06|COINCIDENT|2020-12-31
e|RS|ca4a06be-5e6a-4220-9854-e5fe02b384af|8|MJPTHIND|Major Pathological Response Indicator|CHESON CLL 2012|[?]|umol/L|PARTIAL MORPHOLOGIC RESPONSE|1|10^6/L|CELLULOSE TAPE||||INDEPENDENT ASSESSOR|MICROSCOPIST 2|U|4|Visit_4|65|5|TREATMENT|2020-11-27|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-25|P1Y2M10DT2H30M|AFTER|2020-10-10|AFTER|2020-10-12
e|RS|ca4a06be-5e6a-4220-9854-e5fe02b384af|9|MJPTHIND|Major Pathological Response Indicator|GUPPY OVARIAN CANCER 2002|[?]|ug/L DDU|CR|1|/h|PET/CT SCAN||||ADJUDICATION COMMITTEE|RATER 1|U|5|Visit_5|90|6|SCREENING|2020-12-22|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-20|P1Y2M10DT2H30M|UNKNOWN|2020-11-21|ONGOING|2020-11-26
e|RS|ca4a06be-5e6a-4220-9854-e5fe02b384af|10|MRPHRESP|Morphologic Response|AJCC V7|[?]|kPa/L/sec|iCR|1|mL/cage|FLUORESCENT IMMUNOASSAY||||HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|Y|5|Visit_5|90|5|TREATMENT|2020-12-22|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-20|P1Y2M10DT2H30M|AFTER|2020-09-27|BEFORE|2020-11-08
e|RS|55504c69-a659-402b-a0cb-95ab4e08c086|1|MRPHRESP|Morphologic Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|||NON-PD|1|ft3|IMMUNOCHEMILUMINOMETRIC ASSAY|||Y|PROXY|RADIOLOGIST|Y|1|Visit_1|10|5|TREATMENT|2021-01-14|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-25|P1Y2M10DT2H30M|COINCIDENT|2021-02-19|ONGOING|2021-02-21
e|RS|55504c69-a659-402b-a0cb-95ab4e08c086|2|HEMARESP|Hematologic Response|RANO ELLINGSON 2017|[?]|PIPE|SMD|1|pg|NUCLEIC ACID AMPLIFICATION TEST|Y|Y||SIGNIFICANT OTHER|DEVELOPMENTAL PSYCHOLOGIST|U|1|Visit_1|10|5|TREATMENT|2021-01-14|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-25|P1Y2M10DT2H30M|COINCIDENT|2021-03-06|AFTER|2021-03-25
e|RS|55504c69-a659-402b-a0cb-95ab4e08c086|3|METBRESP|Metabolic Response|AJCC V7|[?]|DRUM|PDu|1|% INHIBITION|DARK FIELD MICROSCOPY||||INDEPENDENT ASSESSOR|NEUROLOGIST|Y|2|Visit_2|25|1|TREATMENT|2021-01-29|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-09|P1Y2M10DT2H30M|COINCIDENT|2021-01-12|AFTER|2021-02-07
e|RS|55504c69-a659-402b-a0cb-95ab4e08c086|4|CPRFSTAT|Clinical Performance Status|CHESON LYMPHOMA 2008|[?]|mm2|PD/RELAPSE AFTER HI|1|Gy/min|IRON HEMATOXYLIN STAIN||||PARENT|DERMATOLOGIST|NA|2|Visit_2|25|6|SCREENING|2021-01-29|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-09|P1Y2M10DT2H30M|AFTER|2021-02-12|BEFORE|2021-03-01
e|RS|55504c69-a659-402b-a0cb-95ab4e08c086|5|MRPHRESP|Morphologic Response|FAROOQUI SUPP CLL 2014|[?]|g/animal/wk|HI-E|1|ng/L|SPIRAL CT||Y||PROXY|UROLOGIST|N|3|Visit_3|40|4|TREATMENT|2021-02-13|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-06|P1Y2M10DT2H30M|AFTER|2021-02-26|ONGOING|2021-04-05
e|RS|55504c69-a659-402b-a0cb-95ab4e08c086|6|NTLWIND|Non-Target Lesion Worsening Indicator|PALUMBO MULTIPLE MYELOMA 2009|[?]|mL/h|COMPLETE MRD RESPONSE|1|cm/min|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY||||STUDY SUBJECT|ADJUDICATOR 2|Y|3|Visit_3|40|4|WASHOUT|2021-02-13|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-06|P1Y2M10DT2H30M|AFTER|2021-03-15|BEFORE|2021-04-05
e|RS|55504c69-a659-402b-a0cb-95ab4e08c086|7|SPLNRESP|Spleen Response|JACINTO CERVICAL CANCER 2007|[?]|mL/g/min|TREATMENT FAILURE|1|nmol BCE/mmol|LIGHT MICROSCOPY||Y||CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 1|U|4|Visit_4|65|7|TREATMENT|2021-03-10|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-22|P1Y2M10DT2H30M|COINCIDENT|2021-04-08|AFTER|2021-04-10
e|RS|55504c69-a659-402b-a0cb-95ab4e08c086|8|NTERESP|Non-Target Enhancing Response|PCWG SCHER PROSTATE CANCER 2008|||PSA PROGRESSION|1|umol/h/mmol|CONTRAST ENHANCED PET SCAN|Y|Y|Y|NON-HEALTH CARE PROFESSIONAL|READER 1|U|4|Visit_4|65|6|TREATMENT|2021-03-10|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-22|P1Y2M10DT2H30M|BEFORE|2021-03-03|COINCIDENT|2021-03-19
e|RS|55504c69-a659-402b-a0cb-95ab4e08c086|9|LIVRRESP|Liver Response|IRANO 2015|||CYTOGENETIC MINIMAL RESPONSE|1|10^9 CFU|FISH|||Y|PARENT|INTERNIST|NA|5|Visit_5|90|7|FOLLOW-UP|2021-04-04|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-18|P1Y2M10DT2H30M|UNKNOWN|2021-01-29|ONGOING|2021-03-13
e|RS|55504c69-a659-402b-a0cb-95ab4e08c086|10|HEMARESP|Hematologic Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|bel|IMMUNOPHENOTYPIC CR|1|um/day|TRANSTHORACIC ECHOCARDIOGRAPHY||Y||INTERVIEWER|RADIOLOGIST|N|5|Visit_5|90|3|TREATMENT|2021-04-04|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-18|P1Y2M10DT2H30M|COINCIDENT|2021-02-14|BEFORE|2021-04-10
e|RS|bffa468a-a27b-4e87-a60d-b5787a03c6f6|1|RDIORESP|Radiologic Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|umol|MORPHOLOGIC LEUKEMIA-FREE STATE|1|10^6 DNA copies/mL|TRANSVAGINAL ULTRASOUND||||SIGNIFICANT OTHER|CLINICAL PATHOLOGIST|NA|1|Visit_1|10|3|FOLLOW-UP|2020-11-30|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-14|P1Y2M10DT2H30M|COINCIDENT|2020-12-12|AFTER|2021-02-07
e|RS|bffa468a-a27b-4e87-a60d-b5787a03c6f6|2|MJPTHIND|Major Pathological Response Indicator|HARTMAN PANCREATIC CANCER 2012|[?]|s^-1(%O2)^-1|CA125 50% RESPONSE|1|g/kg|HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY||||DOMESTIC PARTNER|PEDIATRIC NEUROLOGIST|Y|1|Visit_1|10|7|TREATMENT|2020-11-30|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-14|P1Y2M10DT2H30M|AFTER|2021-01-13|COINCIDENT|2021-01-30
e|RS|bffa468a-a27b-4e87-a60d-b5787a03c6f6|3|OVRLRESP|Overall Response|KEAM BREAST CANCER 2013|[?]|ppth|PDu|1|vg/dose|SLOAN LETTER EYE CHART 100%||||DOMESTIC PARTNER|RATER 1|N|2|Visit_2|25|5|TREATMENT|2020-12-15|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-22|P1Y2M10DT2H30M|UNKNOWN|2021-01-15|AFTER|2021-02-13
e|RS|bffa468a-a27b-4e87-a60d-b5787a03c6f6|4|CYTORESP|Cytogenetic Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|CUP|COMPLETE MRD RESPONSE|1|umol/mg/min|GC/MS-EI|Y|Y||PARENT|PHYSIOTHERAPIST|U|2|Visit_2|25|3|FOLLOW-UP|2020-12-15|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-22|P1Y2M10DT2H30M|AFTER|2021-02-13|COINCIDENT|2021-02-17
e|RS|bffa468a-a27b-4e87-a60d-b5787a03c6f6|5|MRDIND|Minimal Residual Disease Indicator|CHESON CLL 2012|[?]|DAgU|SD-CT|1|/100 HPFs|RYAN BLUE STAIN||||ADJUDICATOR|READER 2|U|3|Visit_3|40|4|TREATMENT|2020-12-30|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-04|P1Y2M10DT2H30M|BEFORE|2020-12-03|BEFORE|2021-01-12
e|RS|bffa468a-a27b-4e87-a60d-b5787a03c6f6|6|STRUSTAT|Steroid Use Status|NCIWG CHESON CLL 1996|[?]|mL*cmH2O|PARTIAL MORPHOLOGIC RESPONSE|1|Hounsfield Unit|ECHOCARDIOGRAPHY||Y||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|Y|3|Visit_3|40|3|TREATMENT|2020-12-30|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-04|P1Y2M10DT2H30M|BEFORE|2021-01-10|ONGOING|2021-02-06
e|RS|bffa468a-a27b-4e87-a60d-b5787a03c6f6|7|NTNERESP|Non-Target Non-Enhancing Response|AJCC V8|||CMR|1|min*mg/mL|PHOTOMETRIC CLOT DETECTION|||Y|VENDOR|READER 1|NA|4|Visit_4|65|5|FOLLOW-UP|2021-01-24|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-01|P1Y2M10DT2H30M|AFTER|2020-12-28|AFTER|2021-02-15
e|RS|bffa468a-a27b-4e87-a60d-b5787a03c6f6|8|TRGRESP|Target Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|||IMMUNOPHENOTYPIC CR|1|/min|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY|||Y|SIBLING|READER 3|NA|4|Visit_4|65|6|WASHOUT|2021-01-24|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-01|P1Y2M10DT2H30M|COINCIDENT|2021-01-21|BEFORE|2021-02-26
e|RS|bffa468a-a27b-4e87-a60d-b5787a03c6f6|9|METSIND|Metastatic Indicator|RECICL|||SD-CT|1|Bq/L|TRYPAN BLUE STAIN|||Y|SPOUSE|RATER 2|NA|5|Visit_5|90|5|TREATMENT|2021-02-18|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-03|P1Y2M10DT2H30M|UNKNOWN|2021-02-04|COINCIDENT|2021-02-06
e|RS|bffa468a-a27b-4e87-a60d-b5787a03c6f6|10|BESTRESP|Best Overall Response|PETIT BREAST CANCER 2001|[?]|APS U|iCPD|1|log EID 50/dose|DIFFUSION TENSOR MRI|Y|||FAMILY MEMBER|ONCOLOGIST 2|NA|5|Visit_5|90|1|TREATMENT|2021-02-18|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-03|P1Y2M10DT2H30M|BEFORE|2020-12-27|BEFORE|2021-02-09
e|RS|2e25aa76-914f-41e3-82ce-7c56ba2f6271|1|TMRESP|Tumor Marker Response|CHESON CLL 2006|[?]|SPRAY|COMPLETE MRD RESPONSE|1|EID 50/dose|FLOCCULATION, CHARCOAL ENHANCED||||FAMILY MEMBER|PATHOLOGIST 2|N|1|Visit_1|10|1|FOLLOW-UP|2020-12-11|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-07|P1Y2M10DT2H30M|BEFORE|2021-01-04|COINCIDENT|2021-02-16
e|RS|2e25aa76-914f-41e3-82ce-7c56ba2f6271|2|MRDRESP|Minimal Residual Disease Response|WHO BREAST CANCER 2006|[?]|pmol/g|RELAPSED DISEASE FROM CR OR PR|1|10^9 organisms/g|BAC ACGH||||PROXY|ENDOCRINOLOGIST|U|1|Visit_1|10|6|TREATMENT|2020-12-11|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-07|P1Y2M10DT2H30M|COINCIDENT|2020-12-30|COINCIDENT|2021-02-11
e|RS|2e25aa76-914f-41e3-82ce-7c56ba2f6271|3|MRPHRESP|Morphologic Response|MASS|[?]|umol/kg/min|IMMUNOPHENOTYPIC CR|1|Ci/kg|ENZYMATIC COLORIMETRY|Y|||PARENT|CLINICAL PATHOLOGIST|NA|2|Visit_2|25|4|TREATMENT|2020-12-26|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-25|P1Y2M10DT2H30M|UNKNOWN|2021-01-31|BEFORE|2021-03-05
e|RS|2e25aa76-914f-41e3-82ce-7c56ba2f6271|4|TMRESP|Tumor Marker Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|pmol/g|PARTIAL MORPHOLOGIC RESPONSE|1|Pack Year|EPSILOMETER||||CLINICAL STUDY SPONSOR|RADIOLOGIST 1|U|2|Visit_2|25|1|SCREENING|2020-12-26|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-25|P1Y2M10DT2H30M|AFTER|2021-02-09|BEFORE|2021-02-11
e|RS|2e25aa76-914f-41e3-82ce-7c56ba2f6271|5|MRPHRESP|Morphologic Response|EASL BRUIX LIVER CANCER 2001|||cPR|1|mol|NON-CONTACT SPECULAR MICROSCOPY|Y||Y|GUARDIAN|CARDIOLOGIST|Y|3|Visit_3|40|7|TREATMENT|2021-01-10|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-22|P1Y2M10DT2H30M|UNKNOWN|2020-12-25|COINCIDENT|2020-12-28
e|RS|2e25aa76-914f-41e3-82ce-7c56ba2f6271|6|TRGRESP|Target Response|PCWG SCHER PROSTATE CANCER 2016|[?]|mm|NE|1|titer|ELECTRONEUROGRAPHY||||PROXY|RATER 2|Y|3|Visit_3|40|4|TREATMENT|2021-01-10|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-22|P1Y2M10DT2H30M|COINCIDENT|2021-02-21|BEFORE|2021-02-23
e|RS|2e25aa76-914f-41e3-82ce-7c56ba2f6271|7|TRGRESP|Target Response|IWG CHESON MDS 2006|[?]|Absorbance U/min|CHR|1|IU/mg|MEDIASTINOSCOPY||||FAMILY MEMBER|MICROSCOPIST 3|N|4|Visit_4|65|4|TREATMENT|2021-02-04|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-20|P1Y2M10DT2H30M|BEFORE|2021-02-08|COINCIDENT|2021-02-25
e|RS|2e25aa76-914f-41e3-82ce-7c56ba2f6271|8|SYMPTDTR|Symptomatic Deterioration|RANO ELLINGSON 2017|[?]|U/kg/min|NON-iCR/NON-iUPD|1|ng/L|COULOMETRIC TITRATION||||STUDY SUBJECT|READER|Y|4|Visit_4|65|6|TREATMENT|2021-02-04|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-20|P1Y2M10DT2H30M|BEFORE|2020-12-09|BEFORE|2020-12-25
e|RS|2e25aa76-914f-41e3-82ce-7c56ba2f6271|9|BMIVLIND|Bone Marrow Involvement Indicator|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|||PR|1|g/animal/wk|WHOLE TRANSCRIPTOME SEQUENCING|Y||Y|CHILD|MICROSCOPIST|U|5|Visit_5|90|3|TREATMENT|2021-03-01|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-15|P1Y2M10DT2H30M|AFTER|2021-01-19|AFTER|2021-02-04
e|RS|2e25aa76-914f-41e3-82ce-7c56ba2f6271|10|NTRGRESP|Non-target Response|IRANO 2015|||CA125 75% RESPONSE|1|mL/kg/day|CT SCAN WITHOUT CONTRAST|||Y|HEALTH CARE PROFESSIONAL|PATHOLOGIST|NA|5|Visit_5|90|6|TREATMENT|2021-03-01|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-15|P1Y2M10DT2H30M|UNKNOWN|2021-01-31|ONGOING|2021-02-11
e|RS|12c24fff-080b-4889-a455-ff55d5c0536c|1|NTNERESP|Non-Target Non-Enhancing Response|IWG CHESON AML 2003|[?]|cm H2O|SD-CT|1|mL/kg/day|REBOUND TONOMETRY||||STUDY SUBJECT|RATER 1|Y|1|Visit_1|10|2|FOLLOW-UP|2021-01-27|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-24|P1Y2M10DT2H30M|BEFORE|2021-02-07|ONGOING|2021-02-08
e|RS|12c24fff-080b-4889-a455-ff55d5c0536c|2|NEWLWIND|New Lesion Worsening Indicator|SHINDOH COLORECTAL CANCER 2013|[?]|ELISA unit|PMR|1|BAU|REAL-TIME POLYMERASE CHAIN REACTION ASSAY||Y||GUARDIAN|READER|NA|1|Visit_1|10|6|SCREENING|2021-01-27|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-24|P1Y2M10DT2H30M|AFTER|2021-02-16|AFTER|2021-03-10
e|RS|12c24fff-080b-4889-a455-ff55d5c0536c|3|CPRFSTAT|Clinical Performance Status|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|pmol/10^10 cells|RELAPSED DISEASE FROM CR|1|Ci/mL|DROPLET DIGITAL PCR||Y||PARENT|RADIOLOGIST 1|Y|2|Visit_2|25|1|SCREENING|2021-02-11|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-03|P1Y2M10DT2H30M|UNKNOWN|2021-04-20|AFTER|2021-04-24
e|RS|12c24fff-080b-4889-a455-ff55d5c0536c|4|BMIVLIND|Bone Marrow Involvement Indicator|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|||DECREASED|1|mg/g/h|JAFFE REACTION|||Y|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST|N|2|Visit_2|25|4|TREATMENT|2021-02-11|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-03|P1Y2M10DT2H30M|UNKNOWN|2021-02-28|ONGOING|2021-03-12
e|RS|12c24fff-080b-4889-a455-ff55d5c0536c|5|TRGRESP|Target Response|EASL BRUIX LIVER CANCER 2001|[?]|vg/kg|NOT ALL EVALUATED|1|mg|MICROARRAY||||STUDY SUBJECT|MICROSCOPIST 1|U|3|Visit_3|40|4|FOLLOW-UP|2021-02-26|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-10|P1Y2M10DT2H30M|UNKNOWN|2021-04-15|BEFORE|2021-04-26
e|RS|12c24fff-080b-4889-a455-ff55d5c0536c|6|BONERESP|Bone Response|PERCIST|||MORPHOLOGIC CRi|1|APL U/mL|PET/MRI SCAN|||Y|ADJUDICATION COMMITTEE|ADJUDICATOR 2|N|3|Visit_3|40|5|WASHOUT|2021-02-26|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-10|P1Y2M10DT2H30M|BEFORE|2021-04-22|BEFORE|2021-04-23
e|RS|12c24fff-080b-4889-a455-ff55d5c0536c|7|NEWLIND|New Lesion Indicator|PALUMBO MULTIPLE MYELOMA 2009|[?]|PIPE|RELAPSED DISEASE FROM CR OR PR|1|mg/m2/day|INFRARED SPECTROMETRY|Y|Y||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST|U|4|Visit_4|65|2|WASHOUT|2021-03-23|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-14|P1Y2M10DT2H30M|BEFORE|2021-02-26|BEFORE|2021-04-14
e|RS|12c24fff-080b-4889-a455-ff55d5c0536c|8|OVRLRESP|Overall Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|||iCPD|1|lx|ISHIHARA COLOR PLATES|||Y|STUDY SUBJECT|MICROSCOPIST 3|N|4|Visit_4|65|5|FOLLOW-UP|2021-03-23|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-14|P1Y2M10DT2H30M|UNKNOWN|2021-02-03|BEFORE|2021-04-23
e|RS|12c24fff-080b-4889-a455-ff55d5c0536c|9|CYTORESP|Cytogenetic Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|U/m2|NOT ALL EVALUATED|1|uIU/dL|INTERRUPTER TECHNIQUE||||INDEPENDENT ASSESSOR|MICROSCOPIST 3|NA|5|Visit_5|90|2|WASHOUT|2021-04-17|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-24|P1Y2M10DT2H30M|BEFORE|2021-04-19|BEFORE|2021-04-25
e|RS|12c24fff-080b-4889-a455-ff55d5c0536c|10|BMIVLIND|Bone Marrow Involvement Indicator|IWG CHESON MDS 2000|||iCPD|1|uIU/L|RADIATION DOSIMETRY|||Y|VENDOR|RADIOLOGIST 2|Y|5|Visit_5|90|5|WASHOUT|2021-04-17|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-24|P1Y2M10DT2H30M|UNKNOWN|2021-02-26|BEFORE|2021-03-04
e|RS|aecfe062-4e0d-4c91-8b67-1f304c5765ae|1|CYTORESP|Cytogenetic Response|KEAM BREAST CANCER 2013|[?]|SCOOPFUL|PDu|1|cd/m2|X-RAY FLUORESCENCE SPECTROMETRY||||DOMESTIC PARTNER|RADIOLOGIST 1|U|1|Visit_1|10|4|WASHOUT|2021-01-21|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-12|P1Y2M10DT2H30M|BEFORE|2021-03-23|BEFORE|2021-03-31
e|RS|aecfe062-4e0d-4c91-8b67-1f304c5765ae|2|SPLNRESP|Spleen Response|LUGANO CLASSIFICATION|[?]|10^5/L|STABLE|1|vp/mL|GC/MS||||FRIEND|RATER 1|N|1|Visit_1|10|2|WASHOUT|2021-01-21|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-12|P1Y2M10DT2H30M|BEFORE|2021-01-30|AFTER|2021-02-09
e|RS|aecfe062-4e0d-4c91-8b67-1f304c5765ae|3|CPRFSTAT|Clinical Performance Status|BRUGGEMANN MRD 2010|[?]|P|CYTOGENETIC CR|1|mg/dL|FLOCCULATION, CHARCOAL ENHANCED||||SIBLING|ADJUDICATOR 1|U|2|Visit_2|25|5|TREATMENT|2021-02-05|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-08|P1Y2M10DT2H30M|COINCIDENT|2021-01-26|BEFORE|2021-01-28
e|RS|aecfe062-4e0d-4c91-8b67-1f304c5765ae|4|CPRFSTAT|Clinical Performance Status|KUMAR IMWG 2016|[?]|aMFI|COMPLETE MRD RESPONSE|1|h*%|PHOTOMETRIC CLOT DETECTION||||NON-HEALTH CARE PROFESSIONAL|READER 3|U|2|Visit_2|25|5|TREATMENT|2021-02-05|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-08|P1Y2M10DT2H30M|COINCIDENT|2021-03-18|AFTER|2021-04-09
e|RS|aecfe062-4e0d-4c91-8b67-1f304c5765ae|5|BESTRESP|Best Overall Response|MRECIST LENCIONI LIVER CANCER 2010|||NON-CR/NON-PD|1|ug/dL|ELLA|Y||Y|FRIEND|RADIOLOGIST 1|N|3|Visit_3|40|7|WASHOUT|2021-02-20|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-18|P1Y2M10DT2H30M|BEFORE|2021-01-15|COINCIDENT|2021-02-13
e|RS|aecfe062-4e0d-4c91-8b67-1f304c5765ae|6|MRPHRESP|Morphologic Response|PCWG SCHER PROSTATE CANCER 2008|[?]|U/cL|NR|1|kcal/day|WHOLE GENOME SEQUENCING||||INDEPENDENT ASSESSOR|PEDIATRIC NEUROLOGIST|U|3|Visit_3|40|1|SCREENING|2021-02-20|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-18|P1Y2M10DT2H30M|BEFORE|2021-02-16|ONGOING|2021-04-01
e|RS|aecfe062-4e0d-4c91-8b67-1f304c5765ae|7|DRCRIND|Disease Recurrence Indicator|BLAZER COLORECTAL CANCER 2008|[?]|cd|PD/RELAPSE AFTER HI|1|ug/dL|TEMPLATE INCISION METHOD||||GUARDIAN|ADJUDICATOR 2|NA|4|Visit_4|65|4|TREATMENT|2021-03-17|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-22|P1Y2M10DT2H30M|BEFORE|2021-03-08|ONGOING|2021-03-27
e|RS|aecfe062-4e0d-4c91-8b67-1f304c5765ae|8|MJPTHIND|Major Pathological Response Indicator|AJCC V7|||FAVORABLE RESPONSE|1|/LPF|ELECTROMYOGRAPHY|||Y|SIBLING|PATHOLOGIST 2|NA|4|Visit_4|65|2|TREATMENT|2021-03-17|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-22|P1Y2M10DT2H30M|AFTER|2021-03-29|AFTER|2021-04-04
e|RS|aecfe062-4e0d-4c91-8b67-1f304c5765ae|9|NTRGRESP|Non-target Response|SHINDOH COLORECTAL CANCER 2013|[?]|mg/kg/h|CYTOGENETIC NO RESPONSE|1|ppth|HEMATOXYLIN AND EOSIN STAIN||||INVESTIGATOR|PEDIATRIC NEUROLOGIST|NA|5|Visit_5|90|7|TREATMENT|2021-04-11|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-21|P1Y2M10DT2H30M|UNKNOWN|2021-03-20|BEFORE|2021-03-28
e|RS|aecfe062-4e0d-4c91-8b67-1f304c5765ae|10|MJPTHIND|Major Pathological Response Indicator|BLAZER COLORECTAL CANCER 2008|[?]|PACK|VGPR|1|Arbitrary U|SCINTIGRAPHY||||GUARDIAN|PHYSIOTHERAPIST|Y|5|Visit_5|90|7|SCREENING|2021-04-11|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-21|P1Y2M10DT2H30M|COINCIDENT|2021-01-21|ONGOING|2021-04-14
e|RS|05a142dc-a779-44cb-ab2e-f961676a3940|1|MRDIND|Minimal Residual Disease Indicator|FAROOQUI SUPP CLL 2014|[?]|ppm|NON-PD|1|MPS U|DYNAMIC LIGHT SCATTERING||||CAREGIVER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|1|Visit_1|10|2|SCREENING|2020-11-18|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-20|P1Y2M10DT2H30M|COINCIDENT|2021-02-13|AFTER|2021-02-15
e|RS|05a142dc-a779-44cb-ab2e-f961676a3940|2|RDIORESP|Radiologic Response|EBMT BLADE MYELOMA 1998|[?]|dmol|WORSENED|1|mmol/kg|CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|Y|||FAMILY MEMBER|NEUROLOGIST 2|U|1|Visit_1|10|6|TREATMENT|2020-11-18|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-20|P1Y2M10DT2H30M|BEFORE|2020-12-19|ONGOING|2021-02-12
e|RS|05a142dc-a779-44cb-ab2e-f961676a3940|3|NEWLWIND|New Lesion Worsening Indicator|MACDONALD GLIOMA 1990|[?]|PFU|QUANTIFIABLE MRD POSITIVITY|1|mg/min|IMMUNOPRECIPITATION|Y|Y||NON-HEALTH CARE PROFESSIONAL|CARDIOLOGIST|N|2|Visit_2|25|2|TREATMENT|2020-12-03|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-14|P1Y2M10DT2H30M|AFTER|2021-02-04|ONGOING|2021-02-14
e|RS|05a142dc-a779-44cb-ab2e-f961676a3940|4|PATHRESP|Pathologic Response|BURCOMBE BREAST CANCER 2005|[?]|mg|PD FROM PR|1|mL|RADIATION DOSIMETRY||||PARENT|RADIOLOGIST|Y|2|Visit_2|25|1|TREATMENT|2020-12-03|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-14|P1Y2M10DT2H30M|AFTER|2021-01-05|COINCIDENT|2021-02-10
e|RS|05a142dc-a779-44cb-ab2e-f961676a3940|5|BONERESP|Bone Response|DURIE MULTIPLE MYELOMA 2006|[?]|ug/m2/h|iPR|1|CIGAR|CELLULOSE TAPE||||GUARDIAN|PATHOLOGIST 1|U|3|Visit_3|40|2|TREATMENT|2020-12-18|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-09|P1Y2M10DT2H30M|BEFORE|2020-11-10|AFTER|2021-01-23
e|RS|05a142dc-a779-44cb-ab2e-f961676a3940|6|CLINRESP|Clinical Response|GUILHOT CML 2007|[?]|umol/L/h|SD-CT|1|log10 PFU/mL|PET/MRI SCAN|Y|||SPOUSE|ADJUDICATOR 3|Y|3|Visit_3|40|7|TREATMENT|2020-12-18|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-09|P1Y2M10DT2H30M|COINCIDENT|2021-01-29|COINCIDENT|2021-02-13
e|RS|05a142dc-a779-44cb-ab2e-f961676a3940|7|NEWLIND|New Lesion Indicator|MACDONALD GLIOMA 1990|[?]|g/cm2|RELAPSED DISEASE|1|PFU|DROPLET DIGITAL PCR|Y|||PARENT|CARDIOLOGIST|NA|4|Visit_4|65|4|FOLLOW-UP|2021-01-12|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-17|P1Y2M10DT2H30M|COINCIDENT|2021-01-19|BEFORE|2021-01-20
e|RS|05a142dc-a779-44cb-ab2e-f961676a3940|8|HEMARESP|Hematologic Response|iRECIST|[?]|L/day|PSEUDORESPONSE|1|scm|MAGNETIC RESONANCE ENTEROGRAPHY||||INDEPENDENT ASSESSOR|PEDIATRIC NEUROLOGIST|N|4|Visit_4|65|3|TREATMENT|2021-01-12|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-17|P1Y2M10DT2H30M|COINCIDENT|2021-02-10|AFTER|2021-02-14
e|RS|05a142dc-a779-44cb-ab2e-f961676a3940|9|CLINRESP|Clinical Response|DOHNER AML 2010|||NON-iCR/NON-iUPD|1|GPL U/mL|CALCOFLUOR WHITE STAIN||Y|Y|CAREGIVER|RADIOLOGIST 1|NA|5|Visit_5|90|4|SCREENING|2021-02-06|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-27|P1Y2M10DT2H30M|UNKNOWN|2021-02-12|BEFORE|2021-02-13
e|RS|05a142dc-a779-44cb-ab2e-f961676a3940|10|SFTSRESP|Soft Tissue Response|CHESON CLL 2012|||UNEQUIVOCAL|1|mg/L FEU|CONFOCAL MICROSCOPY|||Y|GUARDIAN|UROLOGIST|Y|5|Visit_5|90|7|WASHOUT|2021-02-06|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-27|P1Y2M10DT2H30M|AFTER|2020-12-20|COINCIDENT|2021-01-02
e|RS|498524c5-08c4-41a4-af81-876ab2452f64|1|SFTSRESP|Soft Tissue Response|EASL BRUIX LIVER CANCER 2001|[?]|GBq|TREATMENT FAILURE|1|BLOCKS|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY||Y||INDEPENDENT ASSESSOR|OPTOMETRIST|U|1|Visit_1|10|5|SCREENING|2020-12-09|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-04|P1Y2M10DT2H30M|COINCIDENT|2021-01-05|AFTER|2021-01-08
e|RS|498524c5-08c4-41a4-af81-876ab2452f64|2|TMRESP|Tumor Marker Response|BRUGGEMANN MRD 2010|[?]|ug/h|PR-CT|1|mm/h|FUNCTIONAL MRI||||INVESTIGATOR|UROLOGIST|N|1|Visit_1|10|7|TREATMENT|2020-12-09|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-04|P1Y2M10DT2H30M|COINCIDENT|2020-12-17|ONGOING|2020-12-25
e|RS|498524c5-08c4-41a4-af81-876ab2452f64|3|MJPTHIND|Major Pathological Response Indicator|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|EP U|CYTOGENETIC MINIMAL RESPONSE|1|copies/uL|WRIGHT STAIN||||FRIEND|OPTOMETRIST|Y|2|Visit_2|25|1|TREATMENT|2020-12-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-15|P1Y2M10DT2H30M|BEFORE|2021-02-03|AFTER|2021-02-04
e|RS|498524c5-08c4-41a4-af81-876ab2452f64|4|CYTORESP|Cytogenetic Response|MONTSERRAT CLL 1989|||NON-PD|1|mL/dose|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|Y|Y|Y|INVESTIGATOR|MICROSCOPIST 1|NA|2|Visit_2|25|7|FOLLOW-UP|2020-12-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-15|P1Y2M10DT2H30M|BEFORE|2021-01-12|AFTER|2021-03-06
e|RS|498524c5-08c4-41a4-af81-876ab2452f64|5|RDIORESP|Radiologic Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|10^5/L|HI-P|1|RATIO|SPECULAR MICROSCOPY||||ADJUDICATION COMMITTEE|ENDOCRINOLOGIST|U|3|Visit_3|40|6|TREATMENT|2021-01-08|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-01|P1Y2M10DT2H30M|COINCIDENT|2021-01-04|ONGOING|2021-01-14
e|RS|498524c5-08c4-41a4-af81-876ab2452f64|6|BONERESP|Bone Response|IWG CHESON MDS 2000|[?]|USP U|NED|1|/10^4|PYROSEQUENCING||Y||ADJUDICATOR|RADIOLOGIST|NA|3|Visit_3|40|3|SCREENING|2021-01-08|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-01|P1Y2M10DT2H30M|BEFORE|2021-01-25|COINCIDENT|2021-02-09
e|RS|498524c5-08c4-41a4-af81-876ab2452f64|7|RDIORESP|Radiologic Response|WHO BREAST CANCER 2006|||MRD RELAPSE|1|ng/L|POPULATION SEQUENCING|||Y|INVESTIGATOR|NEUROLOGIST 2|NA|4|Visit_4|65|1|SCREENING|2021-02-02|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-13|P1Y2M10DT2H30M|AFTER|2020-12-26|AFTER|2021-02-06
e|RS|498524c5-08c4-41a4-af81-876ab2452f64|8|CLINRESP|Clinical Response|FAROOQUI SUPP CLL 2014|[?]|pmol/10^10 cells|MOLECULAR CR|1|CONTAINER|MALDI-TOF||||FAMILY MEMBER|MICROSCOPIST 3|NA|4|Visit_4|65|6|FOLLOW-UP|2021-02-02|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-13|P1Y2M10DT2H30M|COINCIDENT|2021-03-02|COINCIDENT|2021-03-06
e|RS|498524c5-08c4-41a4-af81-876ab2452f64|9|CPRFSTAT|Clinical Performance Status|MRECIST LENCIONI LIVER CANCER 2010|[?]|cup eq|PR-CT|1|PFU/mL|PLETHYSMOGRAPHY||||STUDY SUBJECT|ADJUDICATOR|NA|5|Visit_5|90|2|TREATMENT|2021-02-27|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-09|P1Y2M10DT2H30M|BEFORE|2021-01-12|BEFORE|2021-03-02
e|RS|498524c5-08c4-41a4-af81-876ab2452f64|10|MRPHRESP|Morphologic Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|Ci/kg|CYTOGENETIC PR|1|ug/L/h|ARTERIAL SPIN LABELING FUNCTIONAL MRI||||GUARDIAN|RADIOLOGIST|Y|5|Visit_5|90|3|TREATMENT|2021-02-27|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-09|P1Y2M10DT2H30M|AFTER|2021-02-21|COINCIDENT|2021-02-22
e|RS|93490930-01cd-470e-81a3-bcd7a140ccc1|1|NTLWIND|Non-Target Lesion Worsening Indicator|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|||iCR|1|Enzyme U|KINYOUN STAIN|||Y|INDEPENDENT ASSESSOR|MICROSCOPIST 2|NA|1|Visit_1|10|3|TREATMENT|2020-11-17|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-26|P1Y2M10DT2H30M|AFTER|2021-01-21|AFTER|2021-02-03
e|RS|93490930-01cd-470e-81a3-bcd7a140ccc1|2|RDIORESP|Radiologic Response|IWG CHESON AML 2003|[?]|mV2/Hz|PDu|1|lx|CELLULAR PROLIFERATION ASSAY|Y|||PARENT|ONCOLOGIST 2|U|1|Visit_1|10|2|TREATMENT|2020-11-17|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-26|P1Y2M10DT2H30M|AFTER|2020-12-04|COINCIDENT|2021-02-02
e|RS|93490930-01cd-470e-81a3-bcd7a140ccc1|3|ANATRESP|Anatomic Response|CHESON CLL 2006|||EQUIVOCAL|1|fmol/g|NEPHELOMETRY|||Y|NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|Y|2|Visit_2|25|4|SCREENING|2020-12-02|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-20|P1Y2M10DT2H30M|COINCIDENT|2021-02-10|COINCIDENT|2021-02-12
e|RS|93490930-01cd-470e-81a3-bcd7a140ccc1|4|NEWLPROG|New Lesion Progression|RANO ELLINGSON 2017|[?]|/2000 RBC|INCREASED|1|CIGARETTE|TRIPLE-PHASE MRI SCAN||||CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 1|NA|2|Visit_2|25|1|SCREENING|2020-12-02|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-20|P1Y2M10DT2H30M|UNKNOWN|2021-02-01|AFTER|2021-02-02
e|RS|93490930-01cd-470e-81a3-bcd7a140ccc1|5|BMIVLIND|Bone Marrow Involvement Indicator|BURCOMBE BREAST CANCER 2005|[?]|mL/m2|CHR|1|10^6/L|HEMOCYTOMETRY|Y|Y||SIBLING|NEUROLOGIST 2|Y|3|Visit_3|40|4|FOLLOW-UP|2020-12-17|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-14|P1Y2M10DT2H30M|BEFORE|2020-12-15|COINCIDENT|2020-12-31
e|RS|93490930-01cd-470e-81a3-bcd7a140ccc1|6|SPLNRESP|Spleen Response|BLAZER COLORECTAL CANCER 2008|[?]|cal|UNEQUIVOCAL|1|/month|FARR ASSAY||Y||CHILD|READER 1|N|3|Visit_3|40|4|FOLLOW-UP|2020-12-17|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-14|P1Y2M10DT2H30M|AFTER|2020-12-02|COINCIDENT|2021-01-14
e|RS|93490930-01cd-470e-81a3-bcd7a140ccc1|7|ANATRESP|Anatomic Response|PERCIST|[?]|ug/kg/h|RELAPSED DISEASE FROM CR|1|nm|CT SCAN WITHOUT CONTRAST||||FAMILY MEMBER|READER 2|N|4|Visit_4|65|7|TREATMENT|2021-01-11|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-22|P1Y2M10DT2H30M|UNKNOWN|2021-01-12|BEFORE|2021-01-24
e|RS|93490930-01cd-470e-81a3-bcd7a140ccc1|8|MOLRESP|Molecular Response|HAMAOKA BREAST CANCER 2010|[?]|10^3 organisms/mL|iPR|1|CFU/g|MICROBIAL CULTURE, SOLID||||CAREGIVER|RATER 2|N|4|Visit_4|65|2|FOLLOW-UP|2021-01-11|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-22|P1Y2M10DT2H30M|COINCIDENT|2020-11-10|BEFORE|2021-01-20
e|RS|93490930-01cd-470e-81a3-bcd7a140ccc1|9|DRCRIND|Disease Recurrence Indicator|GUILHOT CML 2007|[?]|LB|FAVORABLE RESPONSE|1|umol/min|ELECTROPHORESIS||||CHILD|MICROSCOPIST|N|5|Visit_5|90|2|FOLLOW-UP|2021-02-05|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-18|P1Y2M10DT2H30M|COINCIDENT|2020-12-09|COINCIDENT|2020-12-31
e|RS|93490930-01cd-470e-81a3-bcd7a140ccc1|10|NTERESP|Non-Target Enhancing Response|MONTSERRAT CLL 1989|||INDETERMINATE RESPONSE|1|mg/m2|HILLMEN COLOR CHART|Y||Y|GUARDIAN|CARDIOLOGIST|N|5|Visit_5|90|7|TREATMENT|2021-02-05|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-18|P1Y2M10DT2H30M|UNKNOWN|2021-01-04|BEFORE|2021-01-22
e|RS|fd588c97-c57f-432f-81a0-a116a017c5dd|1|METSIND|Metastatic Indicator|UNSPECIFIED|[?]|mL/cm H2O|MRD RELAPSE|1|g/g|OPTICAL COHERENCE TOMOGRAPHY||||DOMESTIC PARTNER|READER 1|U|1|Visit_1|10|1|TREATMENT|2020-06-03|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-19|P1Y2M10DT2H30M|BEFORE|2020-07-22|BEFORE|2020-07-29
e|RS|fd588c97-c57f-432f-81a0-a116a017c5dd|2|MRDIND|Minimal Residual Disease Indicator|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|uEq|MRD RELAPSE|1|V/sec|SNP ARRAY||||HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|N|1|Visit_1|10|4|SCREENING|2020-06-03|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-19|P1Y2M10DT2H30M|COINCIDENT|2020-07-25|ONGOING|2020-08-18
e|RS|fd588c97-c57f-432f-81a0-a116a017c5dd|3|STRUSTAT|Steroid Use Status|EBMT BLADE MYELOMA 1998|||HI-E|1|g/m2/day|EIA|||Y|SIGNIFICANT OTHER|MICROSCOPIST 1|NA|2|Visit_2|25|4|WASHOUT|2020-06-18|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-20|P1Y2M10DT2H30M|UNKNOWN|2020-06-01|AFTER|2020-08-08
e|RS|fd588c97-c57f-432f-81a0-a116a017c5dd|4|MRDRESP|Minimal Residual Disease Response|PERCIST|[?]|mmol/kg|MRD PERSISTENCE|1|uSiemens|MICROBIAL CULTURE, LIQUID||||HEALTH CARE PROFESSIONAL|READER|Y|2|Visit_2|25|2|SCREENING|2020-06-18|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-20|P1Y2M10DT2H30M|BEFORE|2020-06-10|ONGOING|2020-07-30
e|RS|fd588c97-c57f-432f-81a0-a116a017c5dd|5|BONERESP|Bone Response|BURCOMBE BREAST CANCER 2005|[?]|COAT|NON-CR/NON-PD|1|mEq/mL|LINE PROBE ASSAY|Y|||SIBLING|NEUROLOGIST 2|Y|3|Visit_3|40|1|TREATMENT|2020-07-03|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-23|P1Y2M10DT2H30M|AFTER|2020-06-13|COINCIDENT|2020-08-19
e|RS|fd588c97-c57f-432f-81a0-a116a017c5dd|6|TMRESP|Tumor Marker Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|10^6 organisms/mL|STABLE|1|gMFI|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS||Y||SPOUSE|READER|NA|3|Visit_3|40|6|SCREENING|2020-07-03|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-23|P1Y2M10DT2H30M|AFTER|2020-07-30|AFTER|2020-08-04
e|RS|fd588c97-c57f-432f-81a0-a116a017c5dd|7|MOLRESP|Molecular Response|PALUMBO MULTIPLE MYELOMA 2009|||CYTOGENETIC MINOR RESPONSE|1|TUBE|TRYPAN BLUE STAIN|Y|Y|Y|FRIEND|OPHTHALMOLOGIST|U|4|Visit_4|65|3|TREATMENT|2020-07-28|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-28|P1Y2M10DT2H30M|BEFORE|2020-07-19|COINCIDENT|2020-08-02
e|RS|fd588c97-c57f-432f-81a0-a116a017c5dd|8|SYMPTDTR|Symptomatic Deterioration|CHOI GIST 2008|||MORPHOLOGIC CR|1|Watt|SINGLE-SLICE SPIRAL CT|||Y|PROXY|RADIOLOGIST|Y|4|Visit_4|65|3|TREATMENT|2020-07-28|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-28|P1Y2M10DT2H30M|COINCIDENT|2020-06-08|BEFORE|2020-08-29
e|RS|fd588c97-c57f-432f-81a0-a116a017c5dd|9|NEWLIND|New Lesion Indicator|IRANO 2015|[?]|uCi/kg|PD-CT|1|U/m2/day|TRANSCRIPTION-MEDIATED AMPLIFICATION|Y|||FRIEND|ADJUDICATOR 3|U|5|Visit_5|90|6|WASHOUT|2020-08-22|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-08|P1Y2M10DT2H30M|BEFORE|2020-08-18|ONGOING|2020-08-30
e|RS|fd588c97-c57f-432f-81a0-a116a017c5dd|10|LIVRRESP|Liver Response|KEAM BREAST CANCER 2013|[?]|GLOBULE|SD-CT|1|uIU/L|MS/MS||Y||CAREGIVER|RADIOLOGIST 1|N|5|Visit_5|90|7|TREATMENT|2020-08-22|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-08|P1Y2M10DT2H30M|COINCIDENT|2020-08-04|BEFORE|2020-08-15
e|RS|18028efc-33b9-4741-a47a-8fdac0a90e6e|1|HEMARESP|Hematologic Response|CHOLLET BREAST CANCER 2002|||cCR|1|VIRTUAL PIXEL|IMMUNE REPERTOIRE DEEP SEQUENCING||Y|Y|SIBLING|RATER 2|U|1|Visit_1|10|3|TREATMENT|2020-12-22|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-18|P1Y2M10DT2H30M|AFTER|2021-01-24|BEFORE|2021-02-13
e|RS|18028efc-33b9-4741-a47a-8fdac0a90e6e|2|SFTSRESP|Soft Tissue Response|BRUGGEMANN MRD 2010|[?]|10^6/L|MRD RELAPSE|1|vg/mL|AGAR DILUTION|Y|Y||SIGNIFICANT OTHER|OTOLARYNGOLOGIST|U|1|Visit_1|10|5|FOLLOW-UP|2020-12-22|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-18|P1Y2M10DT2H30M|BEFORE|2020-12-25|AFTER|2021-01-08
e|RS|18028efc-33b9-4741-a47a-8fdac0a90e6e|3|MNPTHIND|Minor Pathological Response Indicator|LEE LUNG CANCER 2011|[?]|mg/m2/day|PR WITH LYMPHOCYTOSIS|1|CYLINDER|PHOTOGRAPHY||||GUARDIAN|ENDOCRINOLOGIST|NA|2|Visit_2|25|7|WASHOUT|2021-01-06|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-07|P1Y2M10DT2H30M|AFTER|2021-03-06|AFTER|2021-03-18
e|RS|18028efc-33b9-4741-a47a-8fdac0a90e6e|4|ANATRESP|Anatomic Response|RANO|[?]|pm|PD-CT|1|U/g/h|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY||||DOMESTIC PARTNER|ONCOLOGIST|Y|2|Visit_2|25|4|TREATMENT|2021-01-06|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-07|P1Y2M10DT2H30M|COINCIDENT|2020-12-26|COINCIDENT|2021-01-31
e|RS|18028efc-33b9-4741-a47a-8fdac0a90e6e|5|BESTRESP|Best Overall Response|IWG CHESON AML 2003|[?]|mm/h|MAJOR PATHOLOGIC RESPONSE|1|Antibody Unit|PHYSICAL EXAMINATION||Y||HEALTH CARE PROFESSIONAL|READER 2|NA|3|Visit_3|40|1|TREATMENT|2021-01-21|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-08|P1Y2M10DT2H30M|UNKNOWN|2021-02-09|AFTER|2021-03-04
e|RS|18028efc-33b9-4741-a47a-8fdac0a90e6e|6|CYTORESP|Cytogenetic Response|SACT|[?]|BLOCKS|PD/RELAPSE AFTER HI|1|umol/mg/min|CLAUSS METHOD||||ADJUDICATION COMMITTEE|PATHOLOGIST|U|3|Visit_3|40|2|TREATMENT|2021-01-21|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-08|P1Y2M10DT2H30M|AFTER|2020-12-18|COINCIDENT|2021-02-11
e|RS|18028efc-33b9-4741-a47a-8fdac0a90e6e|7|CYTORESP|Cytogenetic Response|RAJKUMAR MYELOMA 2011|[?]|DAgU/mL|iCPD|1|ppm|ELLA|Y|||SIGNIFICANT OTHER|INTERNIST|NA|4|Visit_4|65|5|FOLLOW-UP|2021-02-15|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-08|P1Y2M10DT2H30M|BEFORE|2021-02-18|COINCIDENT|2021-02-19
e|RS|18028efc-33b9-4741-a47a-8fdac0a90e6e|8|MNPTHIND|Minor Pathological Response Indicator|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|U.CARR|NOT ALL EVALUATED|1|min*mg/mL|HPLC-FL||||GUARDIAN|CARDIOLOGIST|NA|4|Visit_4|65|6|TREATMENT|2021-02-15|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-08|P1Y2M10DT2H30M|AFTER|2021-02-18|COINCIDENT|2021-03-04
e|RS|18028efc-33b9-4741-a47a-8fdac0a90e6e|9|MOLRESP|Molecular Response|RAJKUMAR MYELOMA 2011|[?]|mL/m2/min|UNEQUIVOCAL|1|/LSQN|MICROSCOPY|Y|||SIGNIFICANT OTHER|CLINICAL PATHOLOGIST|N|5|Visit_5|90|6|TREATMENT|2021-03-12|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-06|P1Y2M10DT2H30M|BEFORE|2020-12-31|BEFORE|2021-01-16
e|RS|18028efc-33b9-4741-a47a-8fdac0a90e6e|10|STRUSTAT|Steroid Use Status|KEAM BREAST CANCER 2013|[?]|DPM|SD|1|10^3/L|MUGA||||DOMESTIC PARTNER|READER 3|N|5|Visit_5|90|5|SCREENING|2021-03-12|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-06|P1Y2M10DT2H30M|AFTER|2021-03-03|AFTER|2021-03-06
e|RS|ec47a40e-dd7f-47ee-b571-d91ce72c1cf1|1|OVRLRESP|Overall Response|AJCC V7|||UNEQUIVOCAL|1|umol/h/mmol|U-HPLC/MS/MS|||Y|INDEPENDENT ASSESSOR|MICROSCOPIST 1|U|1|Visit_1|10|3|TREATMENT|2020-06-04|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-29|P1Y2M10DT2H30M|COINCIDENT|2020-08-29|COINCIDENT|2020-09-01
e|RS|ec47a40e-dd7f-47ee-b571-d91ce72c1cf1|2|NEWLWIND|New Lesion Worsening Indicator|GUILHOT CML 2007|[?]|V/sec|CYTOGENETIC MINIMAL RESPONSE|1|vg/kg|BIOPSY|Y|||INTERVIEWER|OPHTHALMOLOGIST|N|1|Visit_1|10|7|WASHOUT|2020-06-04|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-29|P1Y2M10DT2H30M|AFTER|2020-08-08|AFTER|2020-08-26
e|RS|ec47a40e-dd7f-47ee-b571-d91ce72c1cf1|3|MRPHRESP|Morphologic Response|GUILHOT CML 2007|[?]|pmol/dL|CR-CT|1|L/h/m2|DYNAMIC LIGHT SCATTERING||Y||FRIEND|RADIOLOGIST 2|Y|2|Visit_2|25|7|WASHOUT|2020-06-19|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-01|P1Y2M10DT2H30M|BEFORE|2020-08-31|ONGOING|2020-09-01
e|RS|ec47a40e-dd7f-47ee-b571-d91ce72c1cf1|4|SPLNRESP|Spleen Response|IWG CHESON MDS 2006|[?]|Coulomb|NON-CR/NON-PD|1|mmol/g|CONGO RED STAIN||||SIGNIFICANT OTHER|OTOLARYNGOLOGIST|Y|2|Visit_2|25|7|FOLLOW-UP|2020-06-19|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-01|P1Y2M10DT2H30M|BEFORE|2020-07-02|COINCIDENT|2020-07-04
e|RS|ec47a40e-dd7f-47ee-b571-d91ce72c1cf1|5|BMIVLIND|Bone Marrow Involvement Indicator|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|RATIO|INDETERMINATE RESPONSE|1|DRINK|HEMAGGLUTINATION INHIBITION ASSAY||Y||CAREGIVER|READER|U|3|Visit_3|40|1|SCREENING|2020-07-04|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-27|P1Y2M10DT2H30M|COINCIDENT|2020-06-24|COINCIDENT|2020-07-10
e|RS|ec47a40e-dd7f-47ee-b571-d91ce72c1cf1|6|BESTRESP|Best Overall Response|SACT|||PR WITH LYMPHOCYTOSIS|1|BAR|IMPEDANCE CONDUCTIVITY|||Y|HEALTH CARE PROFESSIONAL|RATER 1|U|3|Visit_3|40|4|TREATMENT|2020-07-04|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-27|P1Y2M10DT2H30M|BEFORE|2020-08-15|BEFORE|2020-08-18
e|RS|ec47a40e-dd7f-47ee-b571-d91ce72c1cf1|7|CLINRESP|Clinical Response|RECICL|[?]|Newton|CYTOGENETIC CR|1|keV|MULTIPLEXED BEAD BASED IMMUNOASSAY||||INDEPENDENT ASSESSOR|RATER 1|N|4|Visit_4|65|4|FOLLOW-UP|2020-07-29|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-16|P1Y2M10DT2H30M|AFTER|2020-07-26|AFTER|2020-08-11
e|RS|ec47a40e-dd7f-47ee-b571-d91ce72c1cf1|8|NEWLIND|New Lesion Indicator|SHINDOH COLORECTAL CANCER 2013|||UNEQUIVOCAL|1|Mile|SEQUENCING|Y|Y|Y|PARENT|MICROSCOPIST|Y|4|Visit_4|65|1|TREATMENT|2020-07-29|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-16|P1Y2M10DT2H30M|AFTER|2020-09-01|COINCIDENT|2020-09-02
e|RS|ec47a40e-dd7f-47ee-b571-d91ce72c1cf1|9|RDIORESP|Radiologic Response|LEE LUNG CANCER 2011|[?]|DAgU|MRD NEGATIVITY|1|s*kPa|MICROSCOPY||Y||ADJUDICATOR|PEDIATRIC NEUROLOGIST|Y|5|Visit_5|90|4|SCREENING|2020-08-23|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-20|P1Y2M10DT2H30M|UNKNOWN|2020-06-04|COINCIDENT|2020-08-17
e|RS|ec47a40e-dd7f-47ee-b571-d91ce72c1cf1|10|DRCRIND|Disease Recurrence Indicator|PRINCE TCELL LYMPHOMA 2010|[?]|PA|PD-CT|1|cycle/min|ULTRASOUND||Y||INDEPENDENT ASSESSOR|READER 2|U|5|Visit_5|90|3|TREATMENT|2020-08-23|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-20|P1Y2M10DT2H30M|BEFORE|2020-06-09|ONGOING|2020-06-22
e|RS|08fccce4-64bf-431e-81b0-a96566e77df6|1|SYMPTDTR|Symptomatic Deterioration|LUGANO CLASSIFICATION|[?]|m/sec|MINOR PATHOLOGIC RESPONSE|1|mEq|DUKE INCISION METHOD||||FRIEND|ONCOLOGIST 1|Y|1|Visit_1|10|2|TREATMENT|2021-01-20|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-12|P1Y2M10DT2H30M|COINCIDENT|2021-02-24|COINCIDENT|2021-04-06
e|RS|08fccce4-64bf-431e-81b0-a96566e77df6|2|ANATRESP|Anatomic Response|MURPHY PROSTATE CANCER 1980|||CYTOGENETIC NO RESPONSE|1|ag|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|||Y|HEALTH CARE PROFESSIONAL|READER 2|NA|1|Visit_1|10|6|SCREENING|2021-01-20|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-12|P1Y2M10DT2H30M|COINCIDENT|2021-02-03|COINCIDENT|2021-04-08
e|RS|08fccce4-64bf-431e-81b0-a96566e77df6|3|LIVRRESP|Liver Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|uCi/L|COMPLETE MRD RESPONSE|1|/4.0 mL|DC SHEATH FLOW|Y|||FRIEND|READER|U|2|Visit_2|25|1|TREATMENT|2021-02-04|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-27|P1Y2M10DT2H30M|AFTER|2021-03-13|BEFORE|2021-04-12
e|RS|08fccce4-64bf-431e-81b0-a96566e77df6|4|MRDIND|Minimal Residual Disease Indicator|BRUGGEMANN MRD 2010|[?]|log10 TCID 50/uL|DECREASED|1|Shock Wave|LC/MS/MS|Y|||SIBLING|DEVELOPMENTAL PSYCHOLOGIST|N|2|Visit_2|25|5|SCREENING|2021-02-04|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-27|P1Y2M10DT2H30M|AFTER|2021-03-23|BEFORE|2021-04-05
e|RS|08fccce4-64bf-431e-81b0-a96566e77df6|5|MOLRESP|Molecular Response|WHO BREAST CANCER 2006|[?]|10^6 organisms/mL|ABSENT MORPHOLOGIC RESPONSE|1|Antibody Unit|CALIPER MEASUREMENT METHOD||||INDEPENDENT ASSESSOR|FORENSIC PATHOLOGIST|Y|3|Visit_3|40|7|TREATMENT|2021-02-19|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-07|P1Y2M10DT2H30M|COINCIDENT|2021-03-01|COINCIDENT|2021-03-31
e|RS|08fccce4-64bf-431e-81b0-a96566e77df6|6|HEMARESP|Hematologic Response|RANO|[?]|g/day|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|mg/kg|LYMPHANGIOGRAPHY|Y|Y||PROXY|ADJUDICATOR 2|N|3|Visit_3|40|4|TREATMENT|2021-02-19|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-07|P1Y2M10DT2H30M|BEFORE|2021-04-11|COINCIDENT|2021-04-12
e|RS|08fccce4-64bf-431e-81b0-a96566e77df6|7|LIVRRESP|Liver Response|GUPPY OVARIAN CANCER 2002|[?]|/200 HPFs|MRD RELAPSE|1|ukat|SISH||||ADJUDICATOR|PATHOLOGIST 1|Y|4|Visit_4|65|2|TREATMENT|2021-03-16|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-13|P1Y2M10DT2H30M|UNKNOWN|2021-02-24|ONGOING|2021-03-27
e|RS|08fccce4-64bf-431e-81b0-a96566e77df6|8|NTNERESP|Non-Target Non-Enhancing Response|GUPPY OVARIAN CANCER 2002|[?]|C|MINOR PATHOLOGIC RESPONSE|1|CONTAINER|NON-CONTACT SPECULAR MICROSCOPY||Y||SIGNIFICANT OTHER|CARDIOLOGIST|Y|4|Visit_4|65|2|TREATMENT|2021-03-16|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-13|P1Y2M10DT2H30M|COINCIDENT|2021-01-14|BEFORE|2021-03-08
e|RS|08fccce4-64bf-431e-81b0-a96566e77df6|9|HEMARESP|Hematologic Response|GCIG RUSTIN OVARIAN CANCER 2011|||PR-CT|1|ms2|LASER CAPTURE MICRODISSECTION|||Y|INVESTIGATOR|MICROSCOPIST|Y|5|Visit_5|90|3|TREATMENT|2021-04-10|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-12|P1Y2M10DT2H30M|BEFORE|2021-03-09|ONGOING|2021-03-15
e|RS|08fccce4-64bf-431e-81b0-a96566e77df6|10|METSIND|Metastatic Indicator|HAMAOKA BREAST CANCER 2010|[?]|JAR|PR|1|mL/sec/1.73m2|QUANTITATIVE PERIPHERAL ANGIOGRAPHY||||INDEPENDENT ASSESSOR|RATER|NA|5|Visit_5|90|6|TREATMENT|2021-04-10|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-12|P1Y2M10DT2H30M|COINCIDENT|2021-03-27|COINCIDENT|2021-03-28
e|RS|0354fab5-5636-4504-8345-af060ad4c90c|1|ANATRESP|Anatomic Response|IWG CHESON AML 2003|[?]|mg/day|MORPHOLOGIC LEUKEMIA-FREE STATE|1|mol/L|CRYOSCOPY||||CLINICAL STUDY SPONSOR|PHYSIOTHERAPIST|N|1|Visit_1|10|4|TREATMENT|2021-01-23|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-25|P1Y2M10DT2H30M|BEFORE|2021-03-13|ONGOING|2021-04-16
e|RS|0354fab5-5636-4504-8345-af060ad4c90c|2|NTERESP|Non-Target Enhancing Response|AJCC V8|||IMPROVED|1|pmol/g|TURBIDIMETRY|Y|Y|Y|GUARDIAN|RADIOLOGIST 2|Y|1|Visit_1|10|3|FOLLOW-UP|2021-01-23|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-25|P1Y2M10DT2H30M|COINCIDENT|2021-04-01|ONGOING|2021-04-16
e|RS|0354fab5-5636-4504-8345-af060ad4c90c|3|NTERESP|Non-Target Enhancing Response|KUKER LYMPHOMA 2005|[?]|RNA copies/mL|MOLECULAR MAJOR RESPONSE|1|uL/kg/day|ELECTRICAL IMPEDANCE MYOGRAPHY||||HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|Y|2|Visit_2|25|2|TREATMENT|2021-02-07|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-10|P1Y2M10DT2H30M|COINCIDENT|2021-02-18|ONGOING|2021-04-14
e|RS|0354fab5-5636-4504-8345-af060ad4c90c|4|MJPTHIND|Major Pathological Response Indicator|AJCC V7|[?]|DROP|DISEASE TRANSFORMATION|1|ug/h|MAPH||||CAREGIVER|READER 1|N|2|Visit_2|25|6|TREATMENT|2021-02-07|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-10|P1Y2M10DT2H30M|AFTER|2021-03-11|BEFORE|2021-04-10
e|RS|0354fab5-5636-4504-8345-af060ad4c90c|5|MJPTHIND|Major Pathological Response Indicator|AJCC V8|||MRD PERSISTENCE|1|ug/kg/min|SLOAN LETTER EYE CHART 100%|||Y|SPOUSE|ONCOLOGIST 2|U|3|Visit_3|40|1|TREATMENT|2021-02-22|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-05|P1Y2M10DT2H30M|COINCIDENT|2021-04-06|ONGOING|2021-04-21
e|RS|0354fab5-5636-4504-8345-af060ad4c90c|6|NTNERESP|Non-Target Non-Enhancing Response|RANO ELLINGSON 2017|[?]|g/g|PD/RELAPSE AFTER HI|1|PLUG|OLIGO ACGH|Y|Y||SPOUSE|ONCOLOGIST|N|3|Visit_3|40|7|SCREENING|2021-02-22|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-05|P1Y2M10DT2H30M|UNKNOWN|2021-02-03|COINCIDENT|2021-03-20
e|RS|0354fab5-5636-4504-8345-af060ad4c90c|7|PATHRESP|Pathologic Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|ug/dL|sCR|1|mL/s/m2|MICRO BROTH DILUTION||Y||FAMILY MEMBER|HEMATOLOGIST|N|4|Visit_4|65|1|SCREENING|2021-03-19|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-07|P1Y2M10DT2H30M|BEFORE|2021-03-10|AFTER|2021-03-25
e|RS|0354fab5-5636-4504-8345-af060ad4c90c|8|BMIVLIND|Bone Marrow Involvement Indicator|KEAM BREAST CANCER 2013|||UNFAVORABLE RESPONSE|1|DIP|CLOT DETECTION||Y|Y|HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|Y|4|Visit_4|65|6|TREATMENT|2021-03-19|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-07|P1Y2M10DT2H30M|AFTER|2021-03-24|BEFORE|2021-04-16
e|RS|0354fab5-5636-4504-8345-af060ad4c90c|9|METBRESP|Metabolic Response|HAMAOKA BREAST CANCER 2010|[?]|bel|MRD PERSISTENCE|1|fmol/L/sec|AUSCULTATION||||SIBLING|READER|N|5|Visit_5|90|4|TREATMENT|2021-04-13|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-17|P1Y2M10DT2H30M|AFTER|2021-04-12|ONGOING|2021-04-13
e|RS|0354fab5-5636-4504-8345-af060ad4c90c|10|CLINRESP|Clinical Response|DOHNER AML 2010|||PSEUDOPROGRESSION|1|DRUM|FLUORESCENT IMMUNOASSAY|||Y|VENDOR|RATER 2|U|5|Visit_5|90|3|WASHOUT|2021-04-13|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-17|P1Y2M10DT2H30M|AFTER|2021-03-06|COINCIDENT|2021-04-16
e|RS|f4f1a53a-d621-4f75-b44e-96b959aed03d|1|BESTRESP|Best Overall Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|pg/cell|nPR|1|uCi/L|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY|Y|||ADJUDICATOR|NEUROLOGIST|U|1|Visit_1|10|2|FOLLOW-UP|2021-01-09|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-06|P1Y2M10DT2H30M|BEFORE|2021-03-06|BEFORE|2021-03-27
e|RS|f4f1a53a-d621-4f75-b44e-96b959aed03d|2|NTNERESP|Non-Target Non-Enhancing Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|mmol2/L2|CYTOGENETIC MINOR RESPONSE|1|mkat|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE||Y||CAREGIVER|PEDIATRIC NEUROLOGIST|Y|1|Visit_1|10|5|TREATMENT|2021-01-09|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-06|P1Y2M10DT2H30M|AFTER|2021-02-08|AFTER|2021-04-03
e|RS|f4f1a53a-d621-4f75-b44e-96b959aed03d|3|TMRESP|Tumor Marker Response|NCCN ALL MRD 2014|[?]|g/L|HI-E|1|PIXELS/cm|MOUSE PROTECTION ASSAY||||CAREGIVER|ONCOLOGIST|Y|2|Visit_2|25|6|FOLLOW-UP|2021-01-24|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-28|P1Y2M10DT2H30M|COINCIDENT|2021-04-05|COINCIDENT|2021-04-07
e|RS|f4f1a53a-d621-4f75-b44e-96b959aed03d|4|RDIORESP|Radiologic Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|mEq/uL|DISEASE TRANSFORMATION|1|mOsm/kg|DIFFUSION WEIGHTED MRI||||FRIEND|ADJUDICATOR|Y|2|Visit_2|25|7|WASHOUT|2021-01-24|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-28|P1Y2M10DT2H30M|COINCIDENT|2021-01-06|AFTER|2021-01-24
e|RS|f4f1a53a-d621-4f75-b44e-96b959aed03d|5|ANATRESP|Anatomic Response|SCHWARZ CERVICAL CANCER 2009|||CA125 75% RESPONSE|1|in2|PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY|||Y|SPOUSE|OTOLARYNGOLOGIST|U|3|Visit_3|40|4|TREATMENT|2021-02-08|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-18|P1Y2M10DT2H30M|COINCIDENT|2021-02-19|AFTER|2021-03-03
e|RS|f4f1a53a-d621-4f75-b44e-96b959aed03d|6|CPRFSTAT|Clinical Performance Status|CHESON CLL 2012|||NON-CR/NON-PD|1|mg/mL/min|TONOMETRY|||Y|SIBLING|ADJUDICATOR 1|Y|3|Visit_3|40|7|FOLLOW-UP|2021-02-08|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-18|P1Y2M10DT2H30M|BEFORE|2021-03-06|AFTER|2021-03-20
e|RS|f4f1a53a-d621-4f75-b44e-96b959aed03d|7|CLINRESP|Clinical Response|PERCIST|[?]|/VF|CA125 75% RESPONSE|1|DISK|WHOLE GENOME SEQUENCING||Y||ADJUDICATION COMMITTEE|ONCOLOGIST 1|NA|4|Visit_4|65|4|SCREENING|2021-03-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-27|P1Y2M10DT2H30M|COINCIDENT|2021-01-19|BEFORE|2021-02-19
e|RS|f4f1a53a-d621-4f75-b44e-96b959aed03d|8|SYMPTDTR|Symptomatic Deterioration|DOHNER AML 2010|[?]|/sec|RELAPSED DISEASE FROM CR|1|/MBP|TRANSVAGINAL ULTRASOUND||||SPOUSE|DERMATOLOGIST|NA|4|Visit_4|65|1|SCREENING|2021-03-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-27|P1Y2M10DT2H30M|AFTER|2021-02-12|BEFORE|2021-03-21
e|RS|f4f1a53a-d621-4f75-b44e-96b959aed03d|9|METSIND|Metastatic Indicator|GUPPY OVARIAN CANCER 2002|[?]|Henry|CA125 75% RESPONSE|1|mL/100g/min|MULTI-SLICE SPIRAL CT||Y||INVESTIGATOR|ADJUDICATOR 3|NA|5|Visit_5|90|7|SCREENING|2021-03-30|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-18|P1Y2M10DT2H30M|COINCIDENT|2021-01-28|ONGOING|2021-02-22
e|RS|f4f1a53a-d621-4f75-b44e-96b959aed03d|10|STRUSTAT|Steroid Use Status|CHESON CLL 2006|[?]|damol/L|DECREASED|1|PIPE|VENTILATION PERFUSION LUNG SCAN|Y|||HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|U|5|Visit_5|90|5|FOLLOW-UP|2021-03-30|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-18|P1Y2M10DT2H30M|UNKNOWN|2021-02-21|BEFORE|2021-03-31
e|RS|ed392c1a-0167-4ee9-b208-8b0c8d314bb4|1|BONERESP|Bone Response|AJCC V7|[?]|foz_us|MORPHOLOGIC CRi|1|/LPF|ELISA||Y||FRIEND|FORENSIC PATHOLOGIST|Y|1|Visit_1|10|7|WASHOUT|2020-10-01|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-10|P1Y2M10DT2H30M|COINCIDENT|2020-11-22|COINCIDENT|2020-12-14
e|RS|ed392c1a-0167-4ee9-b208-8b0c8d314bb4|2|BONERESP|Bone Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|mL/dL|INCREASED|1|ft2|CLIP SEQUENCING||||CLINICAL RESEARCH COORDINATOR|PEDIATRIC NEUROLOGIST|N|1|Visit_1|10|1|WASHOUT|2020-10-01|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-10|P1Y2M10DT2H30M|AFTER|2020-11-13|BEFORE|2020-12-04
e|RS|ed392c1a-0167-4ee9-b208-8b0c8d314bb4|3|DRCRIND|Disease Recurrence Indicator|SCHWARZ CERVICAL CANCER 2009|||MR|1|mEq/g|ALCIAN BLUE STAIN|Y||Y|STUDY SUBJECT|CARDIOLOGIST|U|2|Visit_2|25|6|TREATMENT|2020-10-16|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-29|P1Y2M10DT2H30M|UNKNOWN|2020-12-27|BEFORE|2020-12-29
e|RS|ed392c1a-0167-4ee9-b208-8b0c8d314bb4|4|OVRLRESP|Overall Response|PETIT BREAST CANCER 2001|[?]|/kg|FAVORABLE RESPONSE|1|MESF|QUANTITATIVE ULTRASOUND||Y||VENDOR|OTOLARYNGOLOGIST|NA|2|Visit_2|25|4|TREATMENT|2020-10-16|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-29|P1Y2M10DT2H30M|UNKNOWN|2020-12-02|AFTER|2020-12-24
e|RS|ed392c1a-0167-4ee9-b208-8b0c8d314bb4|5|NTRGRESP|Non-target Response|LUGANO CLASSIFICATION|[?]|IU/g|CYTOGENETIC MINOR RESPONSE|1|mg/cm2|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY||||ADJUDICATION COMMITTEE|ADJUDICATOR 1|NA|3|Visit_3|40|1|TREATMENT|2020-10-31|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-29|P1Y2M10DT2H30M|BEFORE|2020-10-30|ONGOING|2020-12-27
e|RS|ed392c1a-0167-4ee9-b208-8b0c8d314bb4|6|BONERESP|Bone Response|LUGANO CLASSIFICATION|[?]|dpm/mL|CYTOGENETIC PR|1|mL/cm|HPLC-UV||||PROXY|DERMATOLOGIST|N|3|Visit_3|40|5|TREATMENT|2020-10-31|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-29|P1Y2M10DT2H30M|COINCIDENT|2020-09-24|COINCIDENT|2020-11-10
e|RS|ed392c1a-0167-4ee9-b208-8b0c8d314bb4|7|NEWLWIND|New Lesion Worsening Indicator|NCIWG CHESON CLL 1996|[?]|uEq|INDETERMINATE RESPONSE|1|mL/g/day|CELLULAR PROLIFERATION ASSAY||||FRIEND|CARDIOLOGIST|U|4|Visit_4|65|6|TREATMENT|2020-11-25|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-17|P1Y2M10DT2H30M|UNKNOWN|2020-11-14|ONGOING|2020-12-19
e|RS|ed392c1a-0167-4ee9-b208-8b0c8d314bb4|8|NTRGRESP|Non-target Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|mCi/kg|DECREASED|1|mmol/g|IRON HEMATOXYLIN STAIN||||ADJUDICATOR|ONCOLOGIST|N|4|Visit_4|65|7|WASHOUT|2020-11-25|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-17|P1Y2M10DT2H30M|BEFORE|2020-12-22|COINCIDENT|2020-12-28
e|RS|ed392c1a-0167-4ee9-b208-8b0c8d314bb4|9|MRDIND|Minimal Residual Disease Indicator|RECICL|||PD-CT|1|/10^4|ANGIOGRAPHY|||Y|STUDY SUBJECT|MICROSCOPIST 3|Y|5|Visit_5|90|7|TREATMENT|2020-12-20|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-12|P1Y2M10DT2H30M|BEFORE|2020-11-04|COINCIDENT|2020-11-11
e|RS|ed392c1a-0167-4ee9-b208-8b0c8d314bb4|10|TRGRESP|Target Response|GUILHOT CML 2007|||INDETERMINATE RESPONSE|1|LENS|GC/MS/MS||Y|Y|DOMESTIC PARTNER|MICROSCOPIST 2|U|5|Visit_5|90|7|SCREENING|2020-12-20|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-12|P1Y2M10DT2H30M|UNKNOWN|2020-11-15|BEFORE|2020-12-15
e|RS|679423a4-92cf-4a93-8277-282f9b43f2ed|1|NTLWIND|Non-Target Lesion Worsening Indicator|CHOLLET BREAST CANCER 2002|[?]|msec|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|mL/sec/1.73m2|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS||||HEALTH CARE PROFESSIONAL|UROLOGIST|U|1|Visit_1|10|3|TREATMENT|2020-08-03|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-07|P1Y2M10DT2H30M|AFTER|2020-09-26|COINCIDENT|2020-10-09
e|RS|679423a4-92cf-4a93-8277-282f9b43f2ed|2|MRDRESP|Minimal Residual Disease Response|EASL BRUIX LIVER CANCER 2001|[?]|PHERESIS UNIT|HI-E|1|mL/kg|GC/FID|Y|||ADJUDICATION COMMITTEE|ADJUDICATOR 1|U|1|Visit_1|10|3|TREATMENT|2020-08-03|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-07|P1Y2M10DT2H30M|COINCIDENT|2020-09-10|COINCIDENT|2020-10-03
e|RS|679423a4-92cf-4a93-8277-282f9b43f2ed|3|MRDIND|Minimal Residual Disease Indicator|EASL BRUIX LIVER CANCER 2001|||MRD NEGATIVITY|1|mmHg|CLOT DETECTION|Y||Y|SPOUSE|RATER 1|Y|2|Visit_2|25|1|WASHOUT|2020-08-18|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-10|P1Y2M10DT2H30M|BEFORE|2020-09-25|ONGOING|2020-10-14
e|RS|679423a4-92cf-4a93-8277-282f9b43f2ed|4|MRDIND|Minimal Residual Disease Indicator|BURCOMBE BREAST CANCER 2005|[?]|FEU|MRD RELAPSE|1|U/m2/day|TRANSTHORACIC ECHOCARDIOGRAPHY|Y|Y||VENDOR|MICROSCOPIST 3|NA|2|Visit_2|25|4|SCREENING|2020-08-18|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-10|P1Y2M10DT2H30M|UNKNOWN|2020-08-04|BEFORE|2020-09-01
e|RS|679423a4-92cf-4a93-8277-282f9b43f2ed|5|PATHRESP|Pathologic Response|CHOI GIST 2008|||OPTIMAL MORPHOLOGIC RESPONSE|1|m2|IMMUNOPRECIPITATION|||Y|HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|N|3|Visit_3|40|7|WASHOUT|2020-09-02|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-14|P1Y2M10DT2H30M|COINCIDENT|2020-07-28|AFTER|2020-10-06
e|RS|679423a4-92cf-4a93-8277-282f9b43f2ed|6|ANATRESP|Anatomic Response|SACT|[?]|pmol/g|UNFAVORABLE RESPONSE|1|genEq/mL|BIOPSY||||CAREGIVER|ADJUDICATOR 2|NA|3|Visit_3|40|6|FOLLOW-UP|2020-09-02|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-14|P1Y2M10DT2H30M|UNKNOWN|2020-07-30|AFTER|2020-10-24
e|RS|679423a4-92cf-4a93-8277-282f9b43f2ed|7|MOLRESP|Molecular Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|mEq/uL|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|U/m2/min|PHYSICAL EXAMINATION||||FAMILY MEMBER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|4|Visit_4|65|5|TREATMENT|2020-09-27|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-23|P1Y2M10DT2H30M|BEFORE|2020-09-19|COINCIDENT|2020-10-11
e|RS|679423a4-92cf-4a93-8277-282f9b43f2ed|8|NEWLIND|New Lesion Indicator|GUILHOT CML 2007|[?]|mL/g/h|MOLECULAR MAJOR RESPONSE|1|deg/mm|HEMAGGLUTINATION INHIBITION ASSAY||||SIBLING|READER 3|N|4|Visit_4|65|4|FOLLOW-UP|2020-09-27|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-23|P1Y2M10DT2H30M|BEFORE|2020-10-17|ONGOING|2020-10-23
e|RS|679423a4-92cf-4a93-8277-282f9b43f2ed|9|MOLRESP|Molecular Response|JACINTO CERVICAL CANCER 2007|[?]|nkat/L|STABLE|1|mmol/kg|AMSLER GRID||||NON-HEALTH CARE PROFESSIONAL|HEMATOLOGIST|NA|5|Visit_5|90|7|TREATMENT|2020-10-22|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-20|P1Y2M10DT2H30M|BEFORE|2020-08-11|ONGOING|2020-10-08
e|RS|679423a4-92cf-4a93-8277-282f9b43f2ed|10|RDIORESP|Radiologic Response|CHESON MALIGNANT LYMPHOMA 2007|||MR|1|g/m2/day|RULER MEASUREMENT METHOD|Y||Y|CAREGIVER|NEUROLOGIST 2|U|5|Visit_5|90|1|TREATMENT|2020-10-22|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-20|P1Y2M10DT2H30M|AFTER|2020-08-01|BEFORE|2020-08-23
e|RS|fb686cda-337b-46aa-b67b-790414201d9a|1|MRDRESP|Minimal Residual Disease Response|IWG CHESON MDS 2000|[?]|dpm/mL|NED|1|Ci/ug|MAPH||||PARENT|OPHTHALMOLOGIST|Y|1|Visit_1|10|1|TREATMENT|2020-05-26|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-01|P1Y2M10DT2H30M|COINCIDENT|2020-05-26|COINCIDENT|2020-06-28
e|RS|fb686cda-337b-46aa-b67b-790414201d9a|2|SPLNRESP|Spleen Response|SCHWARZ CERVICAL CANCER 2009|[?]|mL/g/h|cPR|1|ug/g/min|CT SCAN WITHOUT CONTRAST||Y||NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|Y|1|Visit_1|10|3|TREATMENT|2020-05-26|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-01|P1Y2M10DT2H30M|AFTER|2020-07-13|AFTER|2020-07-16
e|RS|fb686cda-337b-46aa-b67b-790414201d9a|3|SFTSRESP|Soft Tissue Response|WHO BREAST CANCER 2006|[?]|mEq/dL|PDu|1|ng/day|IMPULSE OSCILLOMETRY||||SIGNIFICANT OTHER|READER|N|2|Visit_2|25|5|TREATMENT|2020-06-10|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-08|P1Y2M10DT2H30M|COINCIDENT|2020-07-27|AFTER|2020-08-06
e|RS|fb686cda-337b-46aa-b67b-790414201d9a|4|BONERESP|Bone Response|MONTSERRAT CLL 1989|[?]|ng/mol|iSD|1|cmH2O*s/mL|DIFFUSION TENSOR MRI||||INDEPENDENT ASSESSOR|OPHTHALMOLOGIST|Y|2|Visit_2|25|5|FOLLOW-UP|2020-06-10|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-08|P1Y2M10DT2H30M|COINCIDENT|2020-08-02|ONGOING|2020-08-13
e|RS|fb686cda-337b-46aa-b67b-790414201d9a|5|MRPHRESP|Morphologic Response|FAROOQUI SUPP CLL 2014|[?]|MHz|PD FROM PR|1|%(w/w)|RIA||||SIGNIFICANT OTHER|READER 2|Y|3|Visit_3|40|5|TREATMENT|2020-06-25|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-13|P1Y2M10DT2H30M|AFTER|2020-06-22|AFTER|2020-06-23
e|RS|fb686cda-337b-46aa-b67b-790414201d9a|6|BMIVLIND|Bone Marrow Involvement Indicator|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|mEq/mL|EQUIVOCAL|1|mm2|MUGA|Y|||ADJUDICATOR|DERMATOLOGIST|Y|3|Visit_3|40|1|SCREENING|2020-06-25|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-13|P1Y2M10DT2H30M|COINCIDENT|2020-06-18|ONGOING|2020-07-04
e|RS|fb686cda-337b-46aa-b67b-790414201d9a|7|CYTORESP|Cytogenetic Response|EBMT BLADE MYELOMA 1998|[?]|umol/L/min|cPR|1|/day|LC/MS||Y||HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|U|4|Visit_4|65|4|TREATMENT|2020-07-20|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-10|P1Y2M10DT2H30M|BEFORE|2020-06-16|AFTER|2020-07-18
e|RS|fb686cda-337b-46aa-b67b-790414201d9a|8|LIVRRESP|Liver Response|iRECIST|||nPR|1|uCi|EEG||Y|Y|DOMESTIC PARTNER|ADJUDICATOR 2|U|4|Visit_4|65|7|TREATMENT|2020-07-20|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-10|P1Y2M10DT2H30M|COINCIDENT|2020-07-20|ONGOING|2020-08-14
e|RS|fb686cda-337b-46aa-b67b-790414201d9a|9|RDIORESP|Radiologic Response|CHESON LYMPHOMA 2008|[?]|mAnson U/mL|RELAPSED DISEASE FROM CR OR PR|1|pm|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION||||HEALTH CARE PROFESSIONAL|ONCOLOGIST|NA|5|Visit_5|90|6|SCREENING|2020-08-14|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-23|P1Y2M10DT2H30M|UNKNOWN|2020-06-13|AFTER|2020-08-12
e|RS|fb686cda-337b-46aa-b67b-790414201d9a|10|NTLWIND|Non-Target Lesion Worsening Indicator|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|GPL U|mCR|1|pL|CYSTOSCOPY|Y|||GUARDIAN|NEUROLOGIST|U|5|Visit_5|90|3|TREATMENT|2020-08-14|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-23|P1Y2M10DT2H30M|BEFORE|2020-08-16|BEFORE|2020-08-23
e|RS|98d3c31c-8b79-4d8a-a39e-21b0a3fa653b|1|MRPHRESP|Morphologic Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|ukat/L|VGPR|1|fg|OSCILLOMETRY||Y||ADJUDICATOR|RATER 2|NA|1|Visit_1|10|4|FOLLOW-UP|2020-10-05|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-04|P1Y2M10DT2H30M|UNKNOWN|2020-11-20|BEFORE|2020-12-09
e|RS|98d3c31c-8b79-4d8a-a39e-21b0a3fa653b|2|NTRGRESP|Non-target Response|CHESON NON-HODGKINS LYMPHOMA 1999|||UNFAVORABLE RESPONSE|1|g/dL|NUCLEIC ACID HYBRIDIZATION|Y||Y|ADJUDICATOR|NEUROLOGIST 2|Y|1|Visit_1|10|2|TREATMENT|2020-10-05|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-04|P1Y2M10DT2H30M|COINCIDENT|2020-12-16|COINCIDENT|2020-12-22
e|RS|98d3c31c-8b79-4d8a-a39e-21b0a3fa653b|3|CYTORESP|Cytogenetic Response|HAMAOKA BREAST CANCER 2010|[?]|log10 CCID 50/dose|MORPHOLOGIC CRi|1|DAgU|QUANTITATIVE PERIPHERAL ANGIOGRAPHY||||FAMILY MEMBER|READER 3|NA|2|Visit_2|25|3|FOLLOW-UP|2020-10-20|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-26|P1Y2M10DT2H30M|UNKNOWN|2020-11-22|BEFORE|2020-12-16
e|RS|98d3c31c-8b79-4d8a-a39e-21b0a3fa653b|4|NTRGRESP|Non-target Response|HARTMAN PANCREATIC CANCER 2012|[?]|mmol|SD|1|DRUM|CYSTOSCOPY||||INDEPENDENT ASSESSOR|ADJUDICATOR 1|N|2|Visit_2|25|3|SCREENING|2020-10-20|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-26|P1Y2M10DT2H30M|COINCIDENT|2020-10-10|AFTER|2020-10-13
e|RS|98d3c31c-8b79-4d8a-a39e-21b0a3fa653b|5|BONERESP|Bone Response|GUPPY OVARIAN CANCER 2002|[?]|ug/kg/day|nPR|1|nCi|BIOPSY||Y||PARENT|MICROSCOPIST 3|Y|3|Visit_3|40|1|TREATMENT|2020-11-04|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-02|P1Y2M10DT2H30M|COINCIDENT|2020-12-03|ONGOING|2020-12-17
e|RS|98d3c31c-8b79-4d8a-a39e-21b0a3fa653b|6|STRUSTAT|Steroid Use Status|AJCC V8|[?]|lx|CYTOGENETIC PR|1|mm/sec|INCISION-INDUCED BLEEDING METHOD|Y|||PARENT|NEUROLOGIST 2|Y|3|Visit_3|40|7|FOLLOW-UP|2020-11-04|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-02|P1Y2M10DT2H30M|UNKNOWN|2020-09-28|COINCIDENT|2020-10-07
e|RS|98d3c31c-8b79-4d8a-a39e-21b0a3fa653b|7|CLINRESP|Clinical Response|IWC HALLEK CLL 2008|[?]|TROCHE|UNEQUIVOCAL|1|mg/g/h|MICROSCOPY||Y||FAMILY MEMBER|PHYSIOTHERAPIST|U|4|Visit_4|65|6|TREATMENT|2020-11-29|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-25|P1Y2M10DT2H30M|BEFORE|2020-10-25|ONGOING|2020-12-28
e|RS|98d3c31c-8b79-4d8a-a39e-21b0a3fa653b|8|NTNERESP|Non-Target Non-Enhancing Response|PRINCE TCELL LYMPHOMA 2010|[?]|kN/cm2|iCR|1|kPa/L/sec|DIFFUSION TENSOR MRI||Y||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|U|4|Visit_4|65|1|TREATMENT|2020-11-29|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-25|P1Y2M10DT2H30M|UNKNOWN|2020-12-05|AFTER|2020-12-22
e|RS|98d3c31c-8b79-4d8a-a39e-21b0a3fa653b|9|CPRFSTAT|Clinical Performance Status|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|SBE/mL|CYTOGENETIC NO RESPONSE|1|mL/s/m2|COLORIMETRY||Y||CLINICAL STUDY SPONSOR|PATHOLOGIST 1|NA|5|Visit_5|90|2|TREATMENT|2020-12-24|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-25|P1Y2M10DT2H30M|COINCIDENT|2020-12-06|COINCIDENT|2020-12-28
e|RS|98d3c31c-8b79-4d8a-a39e-21b0a3fa653b|10|NTERESP|Non-Target Enhancing Response|IWG CHESON MDS 2000|[?]|mg/mol|NON-CR/NON-PD|1|m3|SCANNING ELECTRON MICROSCOPY|Y|||SIGNIFICANT OTHER|PHYSIOTHERAPIST|N|5|Visit_5|90|7|WASHOUT|2020-12-24|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-25|P1Y2M10DT2H30M|COINCIDENT|2020-10-08|BEFORE|2020-12-29
e|RS|92d7a180-9353-41f8-93e2-ebcee32a1c63|1|NEWLPROG|New Lesion Progression|PCWG BUBLEY PROSTATE CANCER 1999|[?]|h*%|PARTIAL MORPHOLOGIC RESPONSE|1|log10 CCID 50/dose|CONTRAST ENHANCED PET/CT SCAN||Y||FAMILY MEMBER|CLINICAL PATHOLOGIST|NA|1|Visit_1|10|4|TREATMENT|2020-12-06|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-14|P1Y2M10DT2H30M|UNKNOWN|2021-02-22|AFTER|2021-02-27
e|RS|92d7a180-9353-41f8-93e2-ebcee32a1c63|2|NTNERESP|Non-Target Non-Enhancing Response|CHOI GIST 2008|[?]|kPa|CYTOGENETIC CR|1|/10^5|IHC|Y|||CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 1|NA|1|Visit_1|10|6|TREATMENT|2020-12-06|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-14|P1Y2M10DT2H30M|COINCIDENT|2021-02-23|COINCIDENT|2021-03-03
e|RS|92d7a180-9353-41f8-93e2-ebcee32a1c63|3|NEWLPROG|New Lesion Progression|SHINDOH COLORECTAL CANCER 2013|[?]|HOURS|CA125 50% RESPONSE|1|uL/dose|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY||||NON-HEALTH CARE PROFESSIONAL|HEMATOLOGIST|NA|2|Visit_2|25|7|FOLLOW-UP|2020-12-21|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-04|P1Y2M10DT2H30M|AFTER|2021-02-06|BEFORE|2021-03-05
e|RS|92d7a180-9353-41f8-93e2-ebcee32a1c63|4|NTLWIND|Non-Target Lesion Worsening Indicator|JUWEID NON-HODGKINS LYMPHOMA 2005|||MRD PERSISTENCE|1|mm3/mm2/year|PANENDOSCOPY||Y|Y|ADJUDICATOR|RADIOLOGIST|Y|2|Visit_2|25|7|TREATMENT|2020-12-21|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-04|P1Y2M10DT2H30M|AFTER|2021-01-13|ONGOING|2021-03-03
e|RS|92d7a180-9353-41f8-93e2-ebcee32a1c63|5|DRCRIND|Disease Recurrence Indicator|IWC HALLEK CLL 2008|||SMD|1|mCi|VENTILATION PERFUSION LUNG SCAN|||Y|CLINICAL STUDY SPONSOR|OPTOMETRIST|NA|3|Visit_3|40|2|WASHOUT|2021-01-05|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-21|P1Y2M10DT2H30M|AFTER|2020-12-01|COINCIDENT|2020-12-13
e|RS|92d7a180-9353-41f8-93e2-ebcee32a1c63|6|NTRGRESP|Non-target Response|PCWG SCHER PROSTATE CANCER 2016|[?]|m/sec2|INCREASED|1|uCi|BIOPSY||||FRIEND|ONCOLOGIST 2|U|3|Visit_3|40|1|FOLLOW-UP|2021-01-05|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-21|P1Y2M10DT2H30M|AFTER|2021-01-15|AFTER|2021-02-20
e|RS|92d7a180-9353-41f8-93e2-ebcee32a1c63|7|HEMARESP|Hematologic Response|PERCIST|[?]|PELLET|NE|1|nmol/g|SXA SCAN||||SIBLING|ONCOLOGIST 2|NA|4|Visit_4|65|6|WASHOUT|2021-01-30|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-23|P1Y2M10DT2H30M|AFTER|2020-12-16|COINCIDENT|2021-02-06
e|RS|92d7a180-9353-41f8-93e2-ebcee32a1c63|8|BMIVLIND|Bone Marrow Involvement Indicator|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|||CRi|1|cmH2O*s/mL|KINETIC CHROMOGENIC ASSAY|Y||Y|CLINICAL RESEARCH COORDINATOR|CARDIOLOGIST|Y|4|Visit_4|65|6|FOLLOW-UP|2021-01-30|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-23|P1Y2M10DT2H30M|AFTER|2020-12-03|ONGOING|2020-12-17
e|RS|92d7a180-9353-41f8-93e2-ebcee32a1c63|9|TRGRESP|Target Response|MACDONALD GLIOMA 1990|||NE|1|PIXEL|HPLC/MS|||Y|CLINICAL RESEARCH ASSOCIATE|OPTOMETRIST|N|5|Visit_5|90|4|TREATMENT|2021-02-24|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-09|P1Y2M10DT2H30M|UNKNOWN|2021-01-08|BEFORE|2021-02-25
e|RS|92d7a180-9353-41f8-93e2-ebcee32a1c63|10|SFTSRESP|Soft Tissue Response|SACT|||MRD PERSISTENCE|1|/wk|ATOMIC ABSORPTION SPECTROMETRY|||Y|CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|5|Visit_5|90|6|TREATMENT|2021-02-24|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-09|P1Y2M10DT2H30M|AFTER|2021-01-07|AFTER|2021-02-11
e|RS|5da18fbc-1274-4cb3-bb6b-b57872b9815b|1|SYMPTDTR|Symptomatic Deterioration|GUILHOT CML 2007|[?]|ng/L|NR|1|ug/L DDU|PANENDOSCOPY||||NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|NA|1|Visit_1|10|4|FOLLOW-UP|2020-10-17|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-31|P1Y2M10DT2H30M|COINCIDENT|2020-12-08|ONGOING|2021-01-08
e|RS|5da18fbc-1274-4cb3-bb6b-b57872b9815b|2|STRUSTAT|Steroid Use Status|MRECIST LENCIONI LIVER CANCER 2010|[?]|/LSQN|PMR|1|mm|AUDIOMETRY||||GUARDIAN|ONCOLOGIST 2|Y|1|Visit_1|10|1|WASHOUT|2020-10-17|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-31|P1Y2M10DT2H30M|UNKNOWN|2020-12-21|COINCIDENT|2021-01-09
e|RS|5da18fbc-1274-4cb3-bb6b-b57872b9815b|3|NTLWIND|Non-Target Lesion Worsening Indicator|BRUGGEMANN MRD 2010|[?]|bel|UNFAVORABLE RESPONSE|1|pt_us|BAC ACGH||||STUDY SUBJECT|MICROSCOPIST 3|Y|2|Visit_2|25|7|SCREENING|2020-11-01|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-18|P1Y2M10DT2H30M|BEFORE|2020-12-12|BEFORE|2020-12-13
e|RS|5da18fbc-1274-4cb3-bb6b-b57872b9815b|4|ANATRESP|Anatomic Response|BURCOMBE BREAST CANCER 2005|[?]|IU/L|iSD|1|mL/g/min|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION||||GUARDIAN|MICROSCOPIST 3|Y|2|Visit_2|25|4|SCREENING|2020-11-01|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-18|P1Y2M10DT2H30M|AFTER|2020-12-22|AFTER|2021-01-11
e|RS|5da18fbc-1274-4cb3-bb6b-b57872b9815b|5|TRGRESP|Target Response|LUGANO CLASSIFICATION|[?]|CAN|MOLECULAR MAJOR RESPONSE|1|kcal|INCISION-INDUCED BLEEDING METHOD||||ADJUDICATOR|DEVELOPMENTAL PSYCHOLOGIST|N|3|Visit_3|40|4|TREATMENT|2020-11-16|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-22|P1Y2M10DT2H30M|BEFORE|2021-01-11|BEFORE|2021-01-14
e|RS|5da18fbc-1274-4cb3-bb6b-b57872b9815b|6|MRDIND|Minimal Residual Disease Indicator|MRECIST LENCIONI LIVER CANCER 2010|||PD FROM PR|1|vg/mL|NEPHELOMETRY|||Y|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|Y|3|Visit_3|40|5|FOLLOW-UP|2020-11-16|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-22|P1Y2M10DT2H30M|COINCIDENT|2020-10-11|ONGOING|2021-01-13
e|RS|5da18fbc-1274-4cb3-bb6b-b57872b9815b|7|ANATRESP|Anatomic Response|PETIT BREAST CANCER 2001|[?]|kcal|VGPR|1|10^6 CFU/g|RYAN BLUE STAIN||||CLINICAL RESEARCH ASSOCIATE|RATER 2|U|4|Visit_4|65|1|TREATMENT|2020-12-11|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-19|P1Y2M10DT2H30M|AFTER|2020-11-07|ONGOING|2020-12-31
e|RS|5da18fbc-1274-4cb3-bb6b-b57872b9815b|8|BESTRESP|Best Overall Response|RECIST 1.1|[?]|ug/m2|MOLECULAR MAJOR RESPONSE|1|dram|FUNDUS PHOTOGRAPHY||||SPOUSE|NEUROLOGIST 2|N|4|Visit_4|65|7|TREATMENT|2020-12-11|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-19|P1Y2M10DT2H30M|BEFORE|2020-11-03|AFTER|2020-11-09
e|RS|5da18fbc-1274-4cb3-bb6b-b57872b9815b|9|ANATRESP|Anatomic Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|mOsm|CYTOGENETIC PR|1|mg/min|OPTICAL COHERENCE TOMOGRAPHY||||CLINICAL STUDY SPONSOR|MICROSCOPIST 1|NA|5|Visit_5|90|4|WASHOUT|2021-01-05|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-11|P1Y2M10DT2H30M|AFTER|2020-12-21|AFTER|2021-01-14
e|RS|5da18fbc-1274-4cb3-bb6b-b57872b9815b|10|LIVRRESP|Liver Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|Ci/kg|MRD NEGATIVITY|1|mCi|DOPPLER ULTRASOUND||Y||ADJUDICATOR|UROLOGIST|U|5|Visit_5|90|2|TREATMENT|2021-01-05|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-11|P1Y2M10DT2H30M|AFTER|2020-12-07|AFTER|2021-01-06
e|RS|aca1ac29-8b75-4362-a3fd-f42d77f9ffc0|1|BONERESP|Bone Response|WOLCHOK SOLID TUMORS 2009|[?]|10^6 CFU/mL|PR WITH LYMPHOCYTOSIS|1|10^4/L|SLOAN LETTER EYE CHART 100%||||FAMILY MEMBER|OTOLARYNGOLOGIST|N|1|Visit_1|10|5|TREATMENT|2020-11-21|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-31|P1Y2M10DT2H30M|AFTER|2020-12-17|COINCIDENT|2021-01-17
e|RS|aca1ac29-8b75-4362-a3fd-f42d77f9ffc0|2|OVRLRESP|Overall Response|AJCC V8|[?]|mol/L|CRi|1|U/g/h|NEPHELOMETRY||||CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 1|U|1|Visit_1|10|2|FOLLOW-UP|2020-11-21|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-31|P1Y2M10DT2H30M|COINCIDENT|2021-02-11|COINCIDENT|2021-02-13
e|RS|aca1ac29-8b75-4362-a3fd-f42d77f9ffc0|3|NEWLWIND|New Lesion Worsening Indicator|EBMT BLADE MYELOMA 1998|||HI-N|1|PIXELS/in|WESTERGREN|||Y|ADJUDICATOR|ADJUDICATOR 3|Y|2|Visit_2|25|6|FOLLOW-UP|2020-12-06|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-02|P1Y2M10DT2H30M|UNKNOWN|2020-11-20|ONGOING|2020-12-18
e|RS|aca1ac29-8b75-4362-a3fd-f42d77f9ffc0|4|PATHRESP|Pathologic Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|uCi|EQUIVOCAL|1|nkat/L|PHASE-CONTRAST MRI|Y|||CHILD|NEUROLOGIST|N|2|Visit_2|25|2|TREATMENT|2020-12-06|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-02|P1Y2M10DT2H30M|UNKNOWN|2021-02-14|ONGOING|2021-02-15
e|RS|aca1ac29-8b75-4362-a3fd-f42d77f9ffc0|5|OVRLRESP|Overall Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|mL/cage|MR|1|cm/s|MASS SPECTROMETRY||Y||PARENT|OTOLARYNGOLOGIST|N|3|Visit_3|40|1|TREATMENT|2020-12-21|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-29|P1Y2M10DT2H30M|AFTER|2021-02-07|ONGOING|2021-02-16
e|RS|aca1ac29-8b75-4362-a3fd-f42d77f9ffc0|6|NEWLWIND|New Lesion Worsening Indicator|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|||EQUIVOCAL|1|gMFI|SPIRAL CT|||Y|FAMILY MEMBER|ENDOCRINOLOGIST|NA|3|Visit_3|40|3|WASHOUT|2020-12-21|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-29|P1Y2M10DT2H30M|COINCIDENT|2020-12-13|AFTER|2021-01-17
e|RS|aca1ac29-8b75-4362-a3fd-f42d77f9ffc0|7|MRDIND|Minimal Residual Disease Indicator|EBMT BLADE MYELOMA 1998|||CYTOGENETIC CR|1|um/s|ANALYTICAL ULTRACENTRIFUGATION|||Y|STUDY SUBJECT|RATER 1|Y|4|Visit_4|65|4|WASHOUT|2021-01-15|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-13|P1Y2M10DT2H30M|AFTER|2021-01-17|AFTER|2021-01-25
e|RS|aca1ac29-8b75-4362-a3fd-f42d77f9ffc0|8|SFTSRESP|Soft Tissue Response|RANO|[?]|USP U|SD|1|SBE/mL|ICC||||PROXY|READER 2|U|4|Visit_4|65|1|TREATMENT|2021-01-15|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-13|P1Y2M10DT2H30M|AFTER|2020-12-07|COINCIDENT|2021-02-12
e|RS|aca1ac29-8b75-4362-a3fd-f42d77f9ffc0|9|SFTSRESP|Soft Tissue Response|RANO|[?]|Enzyme U|CR-CT|1|CCID 50/dose|MUGA||||SIGNIFICANT OTHER|OPHTHALMOLOGIST|U|5|Visit_5|90|5|WASHOUT|2021-02-09|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-10|P1Y2M10DT2H30M|COINCIDENT|2020-11-15|AFTER|2020-12-19
e|RS|aca1ac29-8b75-4362-a3fd-f42d77f9ffc0|10|DRCRIND|Disease Recurrence Indicator|WHO BREAST CANCER 2006|[?]|WEEKS|MOLECULAR CR|1|uIU/L|GC/MS/MS|Y|||VENDOR|PHYSIOTHERAPIST|U|5|Visit_5|90|4|WASHOUT|2021-02-09|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-10|P1Y2M10DT2H30M|COINCIDENT|2021-02-04|BEFORE|2021-02-11
e|RS|4a195822-d646-4b22-a3b9-f6642442474d|1|HEMARESP|Hematologic Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|g|CYTOGENETIC CR|1|Pack Year|APPLANATION TONOMETRY|Y|Y||DOMESTIC PARTNER|RADIOLOGIST 1|Y|1|Visit_1|10|4|FOLLOW-UP|2020-07-25|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-25|P1Y2M10DT2H30M|AFTER|2020-08-14|BEFORE|2020-10-17
e|RS|4a195822-d646-4b22-a3b9-f6642442474d|2|HEMARESP|Hematologic Response|RECICL|[?]|days/wk|CA125 75% RESPONSE|1|TCID 50/dose|IMMUNODIFFUSION|Y|Y||INTERVIEWER|NEUROLOGIST 1|N|1|Visit_1|10|2|WASHOUT|2020-07-25|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-25|P1Y2M10DT2H30M|BEFORE|2020-08-15|AFTER|2020-10-07
e|RS|4a195822-d646-4b22-a3b9-f6642442474d|3|TRGRESP|Target Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|Enzyme U/m2|CMR|1|uIU/L|PET/SPECT SCAN||Y||PARENT|DEVELOPMENTAL PSYCHOLOGIST|N|2|Visit_2|25|7|TREATMENT|2020-08-09|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-03|P1Y2M10DT2H30M|BEFORE|2020-08-13|COINCIDENT|2020-09-28
e|RS|4a195822-d646-4b22-a3b9-f6642442474d|4|OVRLRESP|Overall Response|GUPPY OVARIAN CANCER 2002|||cPR|1|mm2|ANGIOGRAPHY|||Y|INDEPENDENT ASSESSOR|RATER 2|NA|2|Visit_2|25|1|TREATMENT|2020-08-09|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-03|P1Y2M10DT2H30M|COINCIDENT|2020-07-17|ONGOING|2020-09-25
e|RS|4a195822-d646-4b22-a3b9-f6642442474d|5|CPRFSTAT|Clinical Performance Status|MURPHY PROSTATE CANCER 1980|[?]|/kg|PD/RELAPSE AFTER HI|1|umol/h/mmol|HPLC-UV||Y||CLINICAL RESEARCH COORDINATOR|CARDIOLOGIST|NA|3|Visit_3|40|6|TREATMENT|2020-08-24|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-20|P1Y2M10DT2H30M|BEFORE|2020-08-28|COINCIDENT|2020-09-05
e|RS|4a195822-d646-4b22-a3b9-f6642442474d|6|SYMPTDTR|Symptomatic Deterioration|LEE LUNG CANCER 2011|[?]|10^10/L|PD FROM PR|1|tuberculin unit/mL|GEL ELECTROPHORESIS||||ADJUDICATOR|PATHOLOGIST 1|Y|3|Visit_3|40|6|TREATMENT|2020-08-24|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-20|P1Y2M10DT2H30M|UNKNOWN|2020-07-26|COINCIDENT|2020-09-03
e|RS|4a195822-d646-4b22-a3b9-f6642442474d|7|NEWLPROG|New Lesion Progression|CHESON CLL 2006|||NED|1|nmol/L/h|RIA|||Y|NON-HEALTH CARE PROFESSIONAL|RATER 1|U|4|Visit_4|65|2|TREATMENT|2020-09-18|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-23|P1Y2M10DT2H30M|AFTER|2020-09-05|AFTER|2020-10-20
e|RS|4a195822-d646-4b22-a3b9-f6642442474d|8|BESTRESP|Best Overall Response|IRANO 2015|[?]|nmol/mL/min|RELAPSED DISEASE|1|m3|AUDIOMETRY||||INDEPENDENT ASSESSOR|DERMATOLOGIST|N|4|Visit_4|65|7|TREATMENT|2020-09-18|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-23|P1Y2M10DT2H30M|BEFORE|2020-08-24|BEFORE|2020-08-25
e|RS|4a195822-d646-4b22-a3b9-f6642442474d|9|STRUSTAT|Steroid Use Status|iRECIST|[?]|grain|mCR|1|ug/kg/min|WHOLE GENOME SEQUENCING||||SPOUSE|NEUROLOGIST 1|N|5|Visit_5|90|1|SCREENING|2020-10-13|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-11|P1Y2M10DT2H30M|UNKNOWN|2020-10-06|BEFORE|2020-10-07
e|RS|4a195822-d646-4b22-a3b9-f6642442474d|10|CYTORESP|Cytogenetic Response|EASL BRUIX LIVER CANCER 2001|[?]|mg/g/h|PR|1|/100 WBC|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS||||CHILD|ONCOLOGIST 1|NA|5|Visit_5|90|5|WASHOUT|2020-10-13|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-11|P1Y2M10DT2H30M|UNKNOWN|2020-10-06|ONGOING|2020-10-19
e|RS|515808c1-fda7-43bb-91dc-28e2d4e308cd|1|SYMPTDTR|Symptomatic Deterioration|HARTMAN PANCREATIC CANCER 2012|[?]|EP U|TREATMENT FAILURE|1|mg/L|HIGH RESOLUTION MELT ANALYSIS||||CLINICAL RESEARCH COORDINATOR|PHYSIOTHERAPIST|Y|1|Visit_1|10|2|TREATMENT|2020-09-07|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-06|P1Y2M10DT2H30M|AFTER|2020-10-18|BEFORE|2020-11-14
e|RS|515808c1-fda7-43bb-91dc-28e2d4e308cd|2|METBRESP|Metabolic Response|PERCIST|||MOLECULAR MAJOR RESPONSE|1|g/g|SLOAN LETTER EYE CHART 2.5%|Y||Y|STUDY SUBJECT|PATHOLOGIST|N|1|Visit_1|10|2|TREATMENT|2020-09-07|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-06|P1Y2M10DT2H30M|AFTER|2020-09-16|ONGOING|2020-10-31
e|RS|515808c1-fda7-43bb-91dc-28e2d4e308cd|3|LIVRRESP|Liver Response|IWG CHESON MDS 2006|[?]|Ci/kg|HI-E|1|mL/dL|PERIODIC ACID SCHIFF STAIN||Y||GUARDIAN|FORENSIC PATHOLOGIST|Y|2|Visit_2|25|7|TREATMENT|2020-09-22|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-25|P1Y2M10DT2H30M|AFTER|2020-09-11|AFTER|2020-11-27
e|RS|515808c1-fda7-43bb-91dc-28e2d4e308cd|4|METBRESP|Metabolic Response|IWG CHESON MDS 2006|[?]|mV2/Hz|iUPD|1|cmH2O/mL|LANDOLT RING||||CHILD|ADJUDICATOR 3|Y|2|Visit_2|25|4|TREATMENT|2020-09-22|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-25|P1Y2M10DT2H30M|AFTER|2020-10-09|ONGOING|2020-10-30
e|RS|515808c1-fda7-43bb-91dc-28e2d4e308cd|5|CLINRESP|Clinical Response|NCIWG CHESON CLL 1996|[?]|APPLICATION|DISEASE TRANSFORMATION|1|COAT|LASER CAPTURE MICRODISSECTION||||STUDY SUBJECT|READER 2|N|3|Visit_3|40|4|WASHOUT|2020-10-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-04|P1Y2M10DT2H30M|AFTER|2020-11-16|COINCIDENT|2020-12-02
e|RS|515808c1-fda7-43bb-91dc-28e2d4e308cd|6|MNPTHIND|Minor Pathological Response Indicator|CHESON LYMPHOMA 2008|[?]|dpm/mL|PD FROM PR|1|AU/mL|FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY||||ADJUDICATION COMMITTEE|READER 2|U|3|Visit_3|40|3|TREATMENT|2020-10-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-04|P1Y2M10DT2H30M|BEFORE|2020-11-09|BEFORE|2020-12-02
e|RS|515808c1-fda7-43bb-91dc-28e2d4e308cd|7|BESTRESP|Best Overall Response|SHINDOH COLORECTAL CANCER 2013|[?]|mL/g/min|iSD|1|mL/kg|IMMUNORADIOMETRIC ASSAY||||SIGNIFICANT OTHER|ADJUDICATOR 1|NA|4|Visit_4|65|3|FOLLOW-UP|2020-11-01|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-15|P1Y2M10DT2H30M|COINCIDENT|2020-08-31|BEFORE|2020-09-05
e|RS|515808c1-fda7-43bb-91dc-28e2d4e308cd|8|BESTRESP|Best Overall Response|PETIT BREAST CANCER 2001|||PD|1|um/day|REVERSE TRANSCRIPTASE PCR|||Y|ADJUDICATION COMMITTEE|ADJUDICATOR 2|Y|4|Visit_4|65|1|TREATMENT|2020-11-01|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-15|P1Y2M10DT2H30M|COINCIDENT|2020-09-15|ONGOING|2020-09-19
e|RS|515808c1-fda7-43bb-91dc-28e2d4e308cd|9|OVRLRESP|Overall Response|GUILHOT CML 2007|[?]|ELISA unit|HI-E|1|PNU/mL|LIQUID SCINTILLATION COUNTING||Y||SIBLING|RADIOLOGIST 2|Y|5|Visit_5|90|7|TREATMENT|2020-11-26|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-09|P1Y2M10DT2H30M|UNKNOWN|2020-11-30|COINCIDENT|2020-12-05
e|RS|515808c1-fda7-43bb-91dc-28e2d4e308cd|10|HEMARESP|Hematologic Response|PCWG SCHER PROSTATE CANCER 2008|[?]|mL*cmH2O|MINOR PATHOLOGIC RESPONSE|1|mkat|INTERRUPTER TECHNIQUE||||PROXY|RADIOLOGIST|U|5|Visit_5|90|4|TREATMENT|2020-11-26|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-09|P1Y2M10DT2H30M|UNKNOWN|2020-09-03|AFTER|2020-09-19
e|RS|18461665-388d-403b-90e4-2b42fcb4a01a|1|MJPTHIND|Major Pathological Response Indicator|KUKER LYMPHOMA 2005|[?]|SCOOPFUL|EQUIVOCAL|1|kHz|ACRIDINE ORANGE STAIN||Y||CLINICAL RESEARCH COORDINATOR|UROLOGIST|N|1|Visit_1|10|5|WASHOUT|2020-10-03|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-06|P1Y2M10DT2H30M|COINCIDENT|2020-12-09|AFTER|2020-12-18
e|RS|18461665-388d-403b-90e4-2b42fcb4a01a|2|MRDIND|Minimal Residual Disease Indicator|BRUGGEMANN MRD 2010|||DISEASE TRANSFORMATION|1|ug/g/min|OSCILLOMETRY|||Y|FRIEND|PATHOLOGIST 2|N|1|Visit_1|10|1|TREATMENT|2020-10-03|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-06|P1Y2M10DT2H30M|COINCIDENT|2020-12-05|ONGOING|2020-12-24
e|RS|18461665-388d-403b-90e4-2b42fcb4a01a|3|ANATRESP|Anatomic Response|RECICL|[?]|IMPLANT|PSEUDORESPONSE|1|1/(s*kPa)|TRANSTHORACIC ECHOCARDIOGRAPHY|Y|||STUDY SUBJECT|RATER 1|U|2|Visit_2|25|7|SCREENING|2020-10-18|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-06|P1Y2M10DT2H30M|BEFORE|2020-12-20|COINCIDENT|2020-12-25
e|RS|18461665-388d-403b-90e4-2b42fcb4a01a|4|OVRLRESP|Overall Response|RECICL|[?]|AgU/mL|MINOR PATHOLOGIC RESPONSE|1|PATCH|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY|Y|||PROXY|OTOLARYNGOLOGIST|Y|2|Visit_2|25|7|TREATMENT|2020-10-18|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-06|P1Y2M10DT2H30M|BEFORE|2020-11-23|COINCIDENT|2020-11-29
e|RS|18461665-388d-403b-90e4-2b42fcb4a01a|5|NTERESP|Non-Target Enhancing Response|LUGANO CLASSIFICATION|[?]|AMPULE|DISEASE TRANSFORMATION|1|g/m2/day|MALDI-TOF||||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR|U|3|Visit_3|40|4|WASHOUT|2020-11-02|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-10|P1Y2M10DT2H30M|BEFORE|2020-11-29|BEFORE|2020-12-15
e|RS|18461665-388d-403b-90e4-2b42fcb4a01a|6|MRDIND|Minimal Residual Disease Indicator|CHOI GIST 2008|||PR-CT|1|mU/L|KINETIC MICROPARTICLE IMMUNOASSAY||Y|Y|NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|3|Visit_3|40|4|FOLLOW-UP|2020-11-02|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-10|P1Y2M10DT2H30M|AFTER|2020-12-24|ONGOING|2020-12-31
e|RS|18461665-388d-403b-90e4-2b42fcb4a01a|7|DRCRIND|Disease Recurrence Indicator|GUPPY OVARIAN CANCER 2002|[?]|mg/L|sCR|1|MONTHS|SCINTIGRAPHY||||HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|NA|4|Visit_4|65|3|WASHOUT|2020-11-27|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-19|P1Y2M10DT2H30M|BEFORE|2020-11-15|AFTER|2020-12-28
e|RS|18461665-388d-403b-90e4-2b42fcb4a01a|8|METBRESP|Metabolic Response|RECICL|[?]|mL/kg/min|DISEASE TRANSFORMATION|1|days/wk|MICROPARTICLE ENZYME IMMUNOASSAY||Y||ADJUDICATION COMMITTEE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|4|Visit_4|65|2|TREATMENT|2020-11-27|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-19|P1Y2M10DT2H30M|COINCIDENT|2020-12-01|BEFORE|2020-12-11
e|RS|18461665-388d-403b-90e4-2b42fcb4a01a|9|MJPTHIND|Major Pathological Response Indicator|HAMAOKA BREAST CANCER 2010|[?]|usec|MOLECULAR CR|1|ms2|VIRUS PLAQUE ASSAY||Y||CLINICAL RESEARCH COORDINATOR|READER|NA|5|Visit_5|90|4|WASHOUT|2020-12-22|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-19|P1Y2M10DT2H30M|COINCIDENT|2020-10-30|AFTER|2020-12-17
e|RS|18461665-388d-403b-90e4-2b42fcb4a01a|10|SFTSRESP|Soft Tissue Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|ukat/L|CYTOGENETIC PR|1|L/s/kPa|NUCLEIC ACID SEQUENCING|Y|||CLINICAL RESEARCH ASSOCIATE|RATER 1|N|5|Visit_5|90|2|WASHOUT|2020-12-22|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-19|P1Y2M10DT2H30M|COINCIDENT|2020-12-22|ONGOING|2020-12-31
e|RS|c3d2c2f3-6f3e-4671-b17b-47e6809bcca0|1|NEWLIND|New Lesion Indicator|GUILHOT CML 2007|[?]|CARTRIDGE|MAJOR PATHOLOGIC RESPONSE|1|nmol/g|DIGITAL PCR||Y||CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 3|U|1|Visit_1|10|5|TREATMENT|2020-08-14|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-16|P1Y2M10DT2H30M|COINCIDENT|2020-10-02|BEFORE|2020-11-11
e|RS|c3d2c2f3-6f3e-4671-b17b-47e6809bcca0|2|NTNERESP|Non-Target Non-Enhancing Response|RECIST 1.1|[?]|10^3/L|PR-CT|1|um/day|IMMUNORADIOMETRIC ASSAY||||CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 1|Y|1|Visit_1|10|4|FOLLOW-UP|2020-08-14|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-16|P1Y2M10DT2H30M|AFTER|2020-08-20|ONGOING|2020-09-28
e|RS|c3d2c2f3-6f3e-4671-b17b-47e6809bcca0|3|PATHRESP|Pathologic Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|mmHg/sec|NED|1|g/day|LANDOLT RING||||SPOUSE|UROLOGIST|N|2|Visit_2|25|4|FOLLOW-UP|2020-08-29|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-18|P1Y2M10DT2H30M|BEFORE|2020-10-20|AFTER|2020-10-22
e|RS|c3d2c2f3-6f3e-4671-b17b-47e6809bcca0|4|BONERESP|Bone Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|INHALATION|PSEUDORESPONSE|1|mV|SICKLE CELL SOLUBILITY TEST|Y|||ADJUDICATION COMMITTEE|DERMATOLOGIST|NA|2|Visit_2|25|3|TREATMENT|2020-08-29|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-18|P1Y2M10DT2H30M|UNKNOWN|2020-09-12|COINCIDENT|2020-10-29
e|RS|c3d2c2f3-6f3e-4671-b17b-47e6809bcca0|5|BESTRESP|Best Overall Response|MACDONALD GLIOMA 1990|[?]|IU/kg/h|MR|1|cm/min|PULMONARY ANGIOGRAPHY||||PROXY|HEMATOLOGIST|N|3|Visit_3|40|1|TREATMENT|2020-09-13|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-08|P1Y2M10DT2H30M|BEFORE|2020-08-11|BEFORE|2020-09-27
e|RS|c3d2c2f3-6f3e-4671-b17b-47e6809bcca0|6|METSIND|Metastatic Indicator|NCIWG CHESON CLL 1996|[?]|mEq/mL|VGPR|1|m|IN SITU HYBRIDIZATION||||INDEPENDENT ASSESSOR|MICROSCOPIST 3|N|3|Visit_3|40|6|SCREENING|2020-09-13|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-08|P1Y2M10DT2H30M|AFTER|2020-08-22|COINCIDENT|2020-09-11
e|RS|c3d2c2f3-6f3e-4671-b17b-47e6809bcca0|7|MRDRESP|Minimal Residual Disease Response|MACDONALD GLIOMA 1990|[?]|Farad|CYTOGENETIC NO RESPONSE|1|mkat|NEXT GENERATION TARGETED SEQUENCING||||INDEPENDENT ASSESSOR|CLINICAL PATHOLOGIST|N|4|Visit_4|65|1|TREATMENT|2020-10-08|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-17|P1Y2M10DT2H30M|AFTER|2020-08-31|AFTER|2020-09-15
e|RS|c3d2c2f3-6f3e-4671-b17b-47e6809bcca0|8|NTNERESP|Non-Target Non-Enhancing Response|MACDONALD GLIOMA 1990|[?]|g/mol|PD FROM PR|1|mL/m2|MICRODENSITOMETRY||Y||ADJUDICATOR|MICROSCOPIST 3|U|4|Visit_4|65|5|FOLLOW-UP|2020-10-08|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-17|P1Y2M10DT2H30M|UNKNOWN|2020-09-14|AFTER|2020-09-16
e|RS|c3d2c2f3-6f3e-4671-b17b-47e6809bcca0|9|MRDIND|Minimal Residual Disease Indicator|MRANO VAN DEN BENT GLIOMA 2011|[?]|IU|NOT ALL EVALUATED|1|LOZENGE|FLOW MICROSCOPY||||FAMILY MEMBER|INTERNIST|U|5|Visit_5|90|2|TREATMENT|2020-11-02|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-06|P1Y2M10DT2H30M|BEFORE|2020-10-11|AFTER|2020-10-23
e|RS|c3d2c2f3-6f3e-4671-b17b-47e6809bcca0|10|NEWLIND|New Lesion Indicator|HARTMAN PANCREATIC CANCER 2012|||PSEUDOPROGRESSION|1|EID 50/dose|ORCHIDOMETERY||Y|Y|HEALTH CARE PROFESSIONAL|RATER 2|NA|5|Visit_5|90|4|TREATMENT|2020-11-02|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-06|P1Y2M10DT2H30M|COINCIDENT|2020-09-29|AFTER|2020-10-19
e|RS|e3ce1661-1b72-4835-88d1-5a6d3655b674|1|TMRESP|Tumor Marker Response|RAJKUMAR MYELOMA 2011|[?]|um/day|PSEUDOPROGRESSION|1|APL U/mL|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS||||NON-HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|Y|1|Visit_1|10|4|FOLLOW-UP|2020-08-12|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-05|P1Y2M10DT2H30M|COINCIDENT|2020-08-04|ONGOING|2020-10-19
e|RS|e3ce1661-1b72-4835-88d1-5a6d3655b674|2|METSIND|Metastatic Indicator|RANO|[?]|kHz|STABLE|1|ug/g/h|IMPEDANCE CONDUCTIVITY||Y||PROXY|RATER 1|U|1|Visit_1|10|3|FOLLOW-UP|2020-08-12|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-05|P1Y2M10DT2H30M|COINCIDENT|2020-11-03|BEFORE|2020-11-06
e|RS|e3ce1661-1b72-4835-88d1-5a6d3655b674|3|NEWLWIND|New Lesion Worsening Indicator|PETIT BREAST CANCER 2001|[?]|10^6 CFU/g|INDETERMINATE RESPONSE|1|Hz/s|OPTICAL DENSITY MEASUREMENT||||VENDOR|HEMATOLOGIST|U|2|Visit_2|25|3|TREATMENT|2020-08-27|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-25|P1Y2M10DT2H30M|COINCIDENT|2020-09-30|BEFORE|2020-10-30
e|RS|e3ce1661-1b72-4835-88d1-5a6d3655b674|4|CYTORESP|Cytogenetic Response|SCHER PROSTATE CANCER 2011|||mCR|1|log10 TCID 50/mL|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY|Y||Y|FAMILY MEMBER|PEDIATRIC NEUROLOGIST|N|2|Visit_2|25|4|TREATMENT|2020-08-27|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-25|P1Y2M10DT2H30M|AFTER|2020-09-14|ONGOING|2020-10-05
e|RS|e3ce1661-1b72-4835-88d1-5a6d3655b674|5|TMRESP|Tumor Marker Response|NCIWG CHESON CLL 1996|[?]|mAnson U/mL|HI-N|1|mol|MAGNETIC RESONANCE ELASTOGRAPHY||Y||CHILD|ONCOLOGIST 1|Y|3|Visit_3|40|5|TREATMENT|2020-09-11|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-07|P1Y2M10DT2H30M|BEFORE|2020-10-25|AFTER|2020-10-31
e|RS|e3ce1661-1b72-4835-88d1-5a6d3655b674|6|CLINRESP|Clinical Response|IRANO 2015|[?]|vp/mL|WORSENED|1|/4.0 mL|CONTRAST ENHANCED SPIRAL CT SCAN||||ADJUDICATOR|OPTOMETRIST|Y|3|Visit_3|40|6|TREATMENT|2020-09-11|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-07|P1Y2M10DT2H30M|AFTER|2020-09-10|COINCIDENT|2020-09-15
e|RS|e3ce1661-1b72-4835-88d1-5a6d3655b674|7|MNPTHIND|Minor Pathological Response Indicator|PETIT BREAST CANCER 2001|[?]|V|NON-iCR/NON-iUPD|1|FIU|PET/SPECT SCAN||||PARENT|ENDOCRINOLOGIST|U|4|Visit_4|65|7|TREATMENT|2020-10-06|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-10|P1Y2M10DT2H30M|COINCIDENT|2020-09-14|ONGOING|2020-09-27
e|RS|e3ce1661-1b72-4835-88d1-5a6d3655b674|8|SFTSRESP|Soft Tissue Response|RECIST 1.0|||DISEASE TRANSFORMATION|1|kcal|HIGH RESOLUTION MELT ANALYSIS|||Y|CHILD|MICROSCOPIST 3|NA|4|Visit_4|65|2|SCREENING|2020-10-06|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-10|P1Y2M10DT2H30M|UNKNOWN|2020-08-10|COINCIDENT|2020-10-19
e|RS|e3ce1661-1b72-4835-88d1-5a6d3655b674|9|BESTRESP|Best Overall Response|IWG CHESON MDS 2000|[?]|nL|PDu|1|10^6 organisms/mg|PEAK FLOWMETRY||||GUARDIAN|CLINICAL PATHOLOGIST|N|5|Visit_5|90|7|WASHOUT|2020-10-31|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-15|P1Y2M10DT2H30M|BEFORE|2020-10-06|BEFORE|2020-10-09
e|RS|e3ce1661-1b72-4835-88d1-5a6d3655b674|10|PATHRESP|Pathologic Response|RECICL|||cPR|1|Roentgen|INDIA INK STAIN|||Y|VENDOR|MICROSCOPIST 1|U|5|Visit_5|90|6|SCREENING|2020-10-31|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-15|P1Y2M10DT2H30M|UNKNOWN|2020-08-08|AFTER|2020-09-26
e|RS|240844e9-3dda-438e-81b2-8f6aa4e0427e|1|SPLNRESP|Spleen Response|PERCIST|[?]|PNU/mL|CA125 50% RESPONSE|1|pkat|ETDRS EYE CHART||Y||HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|Y|1|Visit_1|10|2|TREATMENT|2020-12-09|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-05|P1Y2M10DT2H30M|BEFORE|2021-02-20|ONGOING|2021-03-04
e|RS|240844e9-3dda-438e-81b2-8f6aa4e0427e|2|HEMARESP|Hematologic Response|CHESON LYMPHOMA 2008|||PSA PROGRESSION|1|um|IMMUNOCHEMILUMINOMETRIC ASSAY|||Y|STUDY SUBJECT|CLINICAL PATHOLOGIST|NA|1|Visit_1|10|6|TREATMENT|2020-12-09|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-05|P1Y2M10DT2H30M|AFTER|2020-12-08|COINCIDENT|2021-01-07
e|RS|240844e9-3dda-438e-81b2-8f6aa4e0427e|3|BMIVLIND|Bone Marrow Involvement Indicator|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|mL/(min*100mL)|NE|1|mAnson U/mL|GC/MS/MS||Y||PARENT|RADIOLOGIST 1|N|2|Visit_2|25|1|TREATMENT|2020-12-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-04|P1Y2M10DT2H30M|AFTER|2021-01-18|BEFORE|2021-02-09
e|RS|240844e9-3dda-438e-81b2-8f6aa4e0427e|4|MNPTHIND|Minor Pathological Response Indicator|UNSPECIFIED|||IMPROVED|1|mL/min/mmHg|LYMPHANGIOGRAPHY|||Y|INVESTIGATOR|RATER|U|2|Visit_2|25|7|TREATMENT|2020-12-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-04|P1Y2M10DT2H30M|UNKNOWN|2021-01-01|COINCIDENT|2021-03-04
e|RS|240844e9-3dda-438e-81b2-8f6aa4e0427e|5|DRCRIND|Disease Recurrence Indicator|GUILHOT CML 2007|[?]|WAFER|VGPR|1|10^9/L|TELLER ACUITY CARDS||||SIGNIFICANT OTHER|ONCOLOGIST 2|NA|3|Visit_3|40|6|FOLLOW-UP|2021-01-08|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-24|P1Y2M10DT2H30M|UNKNOWN|2021-02-18|ONGOING|2021-02-24
e|RS|240844e9-3dda-438e-81b2-8f6aa4e0427e|6|MRDIND|Minimal Residual Disease Indicator|RECICL|||PR WITH LYMPHOCYTOSIS|1|EID 50/mL|SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY|||Y|ADJUDICATION COMMITTEE|ADJUDICATOR 3|NA|3|Visit_3|40|6|TREATMENT|2021-01-08|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-24|P1Y2M10DT2H30M|BEFORE|2021-02-04|AFTER|2021-02-25
e|RS|240844e9-3dda-438e-81b2-8f6aa4e0427e|7|HEMARESP|Hematologic Response|MASS|[?]|VIAL|INCREASED|1|cycle/min|NUCLEIC ACID BASED METHOD||||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 3|NA|4|Visit_4|65|2|TREATMENT|2021-02-02|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-10|P1Y2M10DT2H30M|AFTER|2021-03-03|COINCIDENT|2021-03-08
e|RS|240844e9-3dda-438e-81b2-8f6aa4e0427e|8|CPRFSTAT|Clinical Performance Status|RECICL|[?]|g/L|PSEUDOPROGRESSION|1|MET*h|MACRO BROTH DILUTION|Y|Y||ADJUDICATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|4|Visit_4|65|3|TREATMENT|2021-02-02|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-10|P1Y2M10DT2H30M|COINCIDENT|2021-02-12|COINCIDENT|2021-02-28
e|RS|240844e9-3dda-438e-81b2-8f6aa4e0427e|9|PATHRESP|Pathologic Response|PETIT BREAST CANCER 2001|[?]|mg/min|MAJOR PATHOLOGIC RESPONSE|1|aMFI|MICROBIAL CULTURE, SOLID||||DOMESTIC PARTNER|NEUROLOGIST 2|Y|5|Visit_5|90|4|TREATMENT|2021-02-27|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-02|P1Y2M10DT2H30M|BEFORE|2021-01-20|BEFORE|2021-02-03
e|RS|240844e9-3dda-438e-81b2-8f6aa4e0427e|10|LIVRRESP|Liver Response|HAMAOKA BREAST CANCER 2010|[?]|mol|PD/RELAPSE AFTER HI|1|10^5/L|MICRODENSITOMETRY||||CLINICAL STUDY SPONSOR|ONCOLOGIST|NA|5|Visit_5|90|3|SCREENING|2021-02-27|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-02|P1Y2M10DT2H30M|BEFORE|2021-02-18|AFTER|2021-03-02
e|RS|fccf5c5d-deb6-4f13-a485-afcda3556578|1|TMRESP|Tumor Marker Response|MASS|[?]|EID 50/mL|MORPHOLOGIC CRi|1|nL|MIGET||||CLINICAL RESEARCH COORDINATOR|UROLOGIST|U|1|Visit_1|10|2|TREATMENT|2020-08-04|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-28|P1Y2M10DT2H30M|UNKNOWN|2020-07-30|ONGOING|2020-10-28
e|RS|fccf5c5d-deb6-4f13-a485-afcda3556578|2|NTLWIND|Non-Target Lesion Worsening Indicator|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|um/s|CRi|1|cd|DNA MICROARRAY||Y||VENDOR|READER 3|Y|1|Visit_1|10|7|WASHOUT|2020-08-04|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-28|P1Y2M10DT2H30M|AFTER|2020-09-04|AFTER|2020-10-02
e|RS|fccf5c5d-deb6-4f13-a485-afcda3556578|3|RDIORESP|Radiologic Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|Bq/mL|PMR|1|mmHg/L/min|AUTOMATED COUNT||||INDEPENDENT ASSESSOR|ADJUDICATOR|U|2|Visit_2|25|1|TREATMENT|2020-08-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-17|P1Y2M10DT2H30M|BEFORE|2020-09-18|COINCIDENT|2020-10-07
e|RS|fccf5c5d-deb6-4f13-a485-afcda3556578|4|NTLWIND|Non-Target Lesion Worsening Indicator|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|mJoule/cm2|mCR|1|dpm/mL|IMMUNOTURBIDIMETRY||||INVESTIGATOR|ONCOLOGIST 1|NA|2|Visit_2|25|3|SCREENING|2020-08-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-17|P1Y2M10DT2H30M|COINCIDENT|2020-09-29|BEFORE|2020-10-04
e|RS|fccf5c5d-deb6-4f13-a485-afcda3556578|5|TMRESP|Tumor Marker Response|AJCC V8|||NED|1|Tbsp|NEURAMINIDASE INHIBITION ASSAY|Y||Y|ADJUDICATION COMMITTEE|PATHOLOGIST|NA|3|Visit_3|40|7|TREATMENT|2020-09-03|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-09|P1Y2M10DT2H30M|COINCIDENT|2020-09-24|COINCIDENT|2020-10-19
e|RS|fccf5c5d-deb6-4f13-a485-afcda3556578|6|DRCRIND|Disease Recurrence Indicator|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|TRACE|CYTOGENETIC MINOR RESPONSE|1|Hz/s|FLOW CYTOMETRY|Y|||INTERVIEWER|PEDIATRIC NEUROLOGIST|U|3|Visit_3|40|4|TREATMENT|2020-09-03|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-09|P1Y2M10DT2H30M|UNKNOWN|2020-08-17|BEFORE|2020-09-23
e|RS|fccf5c5d-deb6-4f13-a485-afcda3556578|7|NEWLIND|New Lesion Indicator|RAJKUMAR MYELOMA 2011|[?]|g/kg/day|RELAPSED DISEASE FROM CR OR PR|1|MET|COLORIMETRY||||CLINICAL RESEARCH ASSOCIATE|PEDIATRIC NEUROLOGIST|N|4|Visit_4|65|6|TREATMENT|2020-09-28|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-12|P1Y2M10DT2H30M|BEFORE|2020-10-30|ONGOING|2020-11-01
e|RS|fccf5c5d-deb6-4f13-a485-afcda3556578|8|MJPTHIND|Major Pathological Response Indicator|IWC HALLEK CLL 2008|[?]|CIGAR|iCPD|1|Bq/kg|ISHIHARA COLOR PLATES||||CHILD|MICROSCOPIST 2|U|4|Visit_4|65|4|TREATMENT|2020-09-28|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-12|P1Y2M10DT2H30M|AFTER|2020-08-31|AFTER|2020-09-23
e|RS|fccf5c5d-deb6-4f13-a485-afcda3556578|9|CYTORESP|Cytogenetic Response|IWC HALLEK CLL 2008|||HI-N|1|mL/kg/min|PUPILLOMETRY|Y||Y|CLINICAL STUDY SPONSOR|PHYSIOTHERAPIST|Y|5|Visit_5|90|5|FOLLOW-UP|2020-10-23|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-14|P1Y2M10DT2H30M|BEFORE|2020-08-24|COINCIDENT|2020-09-29
e|RS|fccf5c5d-deb6-4f13-a485-afcda3556578|10|METBRESP|Metabolic Response|HAMAOKA BREAST CANCER 2010|[?]|mg/kg/dose|RELAPSED DISEASE FROM CR|1|Bq/L|SPECT/CT SCAN||||VENDOR|ADJUDICATOR|U|5|Visit_5|90|3|TREATMENT|2020-10-23|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-14|P1Y2M10DT2H30M|UNKNOWN|2020-09-29|AFTER|2020-10-18
e|RS|94620ed0-1ae8-4fa5-a629-9210860b0be9|1|MRDIND|Minimal Residual Disease Indicator|IWG CHESON MDS 2000|[?]|kPa|QUANTIFIABLE MRD POSITIVITY|1|PFU|SISH|Y|||SPOUSE|PEDIATRIC NEUROLOGIST|U|1|Visit_1|10|6|TREATMENT|2020-08-04|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-09|P1Y2M10DT2H30M|AFTER|2020-08-31|AFTER|2020-09-16
e|RS|94620ed0-1ae8-4fa5-a629-9210860b0be9|2|TMRESP|Tumor Marker Response|IWG CHESON MDS 2006|[?]|nCi|WORSENED|1|umol/h/mmol|ELECTROCHEMILUMINESCENCE||Y||INTERVIEWER|ADJUDICATOR 3|Y|1|Visit_1|10|5|WASHOUT|2020-08-04|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-09|P1Y2M10DT2H30M|AFTER|2020-09-26|BEFORE|2020-10-20
e|RS|94620ed0-1ae8-4fa5-a629-9210860b0be9|3|CYTORESP|Cytogenetic Response|WOLCHOK SOLID TUMORS 2009|[?]|U/cL|SMD|1|nsec|ANALYTICAL ULTRACENTRIFUGATION|Y|||SPOUSE|RATER|N|2|Visit_2|25|6|TREATMENT|2020-08-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-15|P1Y2M10DT2H30M|UNKNOWN|2020-10-22|BEFORE|2020-10-31
e|RS|94620ed0-1ae8-4fa5-a629-9210860b0be9|4|STRUSTAT|Steroid Use Status|KEAM BREAST CANCER 2013|||MOLECULAR MAJOR RESPONSE|1|pmol/10^9 cells|SINGLE-SLICE SPIRAL CT|||Y|CAREGIVER|ENDOCRINOLOGIST|U|2|Visit_2|25|6|TREATMENT|2020-08-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-15|P1Y2M10DT2H30M|COINCIDENT|2020-10-05|ONGOING|2020-10-24
e|RS|94620ed0-1ae8-4fa5-a629-9210860b0be9|5|MNPTHIND|Minor Pathological Response Indicator|KUMAR IMWG 2016|[?]|IMPLANT|MRD NEGATIVITY|1|mg/dL|NEXT GENERATION SEQUENCING|Y|||CLINICAL RESEARCH COORDINATOR|READER 1|U|3|Visit_3|40|1|TREATMENT|2020-09-03|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-18|P1Y2M10DT2H30M|UNKNOWN|2020-09-04|ONGOING|2020-10-27
e|RS|94620ed0-1ae8-4fa5-a629-9210860b0be9|6|BESTRESP|Best Overall Response|LUGANO CLASSIFICATION|[?]|GPL U|MOLECULAR MAJOR RESPONSE|1|steps/min|ULTRASONOGRAPHIC ELASTOGRAPHY||||HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|Y|3|Visit_3|40|2|TREATMENT|2020-09-03|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-18|P1Y2M10DT2H30M|UNKNOWN|2020-09-30|COINCIDENT|2020-10-17
e|RS|94620ed0-1ae8-4fa5-a629-9210860b0be9|7|BONERESP|Bone Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|fmol/g|CYTOGENETIC MINIMAL RESPONSE|1|DROP|KNEMOMETRY|Y|||CLINICAL STUDY SPONSOR|DEVELOPMENTAL PSYCHOLOGIST|Y|4|Visit_4|65|3|WASHOUT|2020-09-28|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-21|P1Y2M10DT2H30M|UNKNOWN|2020-09-04|COINCIDENT|2020-09-05
e|RS|94620ed0-1ae8-4fa5-a629-9210860b0be9|8|SYMPTDTR|Symptomatic Deterioration|FAROOQUI SUPP CLL 2014|||CYTOGENETIC MINIMAL RESPONSE|1|mL/sec/1.73m2|IHC|||Y|SIBLING|ADJUDICATOR 3|NA|4|Visit_4|65|7|TREATMENT|2020-09-28|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-21|P1Y2M10DT2H30M|BEFORE|2020-09-05|ONGOING|2020-10-02
e|RS|94620ed0-1ae8-4fa5-a629-9210860b0be9|9|SYMPTDTR|Symptomatic Deterioration|MRANO VAN DEN BENT GLIOMA 2011|||OPTIMAL MORPHOLOGIC RESPONSE|1|Enzyme U/m2|CYSTOMETRY|Y||Y|VENDOR|PEDIATRIC NEUROLOGIST|U|5|Visit_5|90|2|TREATMENT|2020-10-23|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-23|P1Y2M10DT2H30M|AFTER|2020-10-09|BEFORE|2020-10-17
e|RS|94620ed0-1ae8-4fa5-a629-9210860b0be9|10|NEWLPROG|New Lesion Progression|PRINCE TCELL LYMPHOMA 2010|||CR-CT|1|10^9/g|NUCLEAR RADIOLOGY|||Y|ADJUDICATOR|READER|U|5|Visit_5|90|5|TREATMENT|2020-10-23|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-23|P1Y2M10DT2H30M|BEFORE|2020-08-27|COINCIDENT|2020-10-17
e|RS|9c3b6912-19be-435c-87fc-781a08efb847|1|CPRFSTAT|Clinical Performance Status|PROTOCOL DEFINED RESPONSE CRITERIA|||MORPHOLOGIC CR|1|10^6 CFU/mL|APPLANATION TONOMETRY|||Y|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|N|1|Visit_1|10|1|TREATMENT|2021-01-22|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-25|P1Y2M10DT2H30M|AFTER|2021-03-30|COINCIDENT|2021-04-12
e|RS|9c3b6912-19be-435c-87fc-781a08efb847|2|NTERESP|Non-Target Enhancing Response|IWG CHESON AML 2003|[?]|INHALATION|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|pg/L|ECHOCARDIOGRAPHY||||FRIEND|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|1|Visit_1|10|6|WASHOUT|2021-01-22|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-25|P1Y2M10DT2H30M|COINCIDENT|2021-03-12|AFTER|2021-04-21
e|RS|9c3b6912-19be-435c-87fc-781a08efb847|3|TRGRESP|Target Response|LUGANO CLASSIFICATION|||CMR|1|mg/g/h|NUCLEIC ACID HYBRIDIZATION|||Y|HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|2|Visit_2|25|7|FOLLOW-UP|2021-02-06|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-09|P1Y2M10DT2H30M|UNKNOWN|2021-03-11|COINCIDENT|2021-03-22
e|RS|9c3b6912-19be-435c-87fc-781a08efb847|4|METBRESP|Metabolic Response|RECIST 1.1|[?]|s^-1(%O2)^-1|CYTOGENETIC MINOR RESPONSE|1|ug/min|IMMUNOASSAY||Y||HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|Y|2|Visit_2|25|4|SCREENING|2021-02-06|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-09|P1Y2M10DT2H30M|AFTER|2021-04-07|COINCIDENT|2021-04-17
e|RS|9c3b6912-19be-435c-87fc-781a08efb847|5|CYTORESP|Cytogenetic Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|% INHIBITION|DISEASE TRANSFORMATION|1|L/min/m2|LC/MS||||VENDOR|ADJUDICATOR 1|NA|3|Visit_3|40|1|TREATMENT|2021-02-21|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-04|P1Y2M10DT2H30M|BEFORE|2021-04-09|BEFORE|2021-04-11
e|RS|9c3b6912-19be-435c-87fc-781a08efb847|6|NEWLWIND|New Lesion Worsening Indicator|CHOI GIST 2008|[?]|psi|mCR|1|COAT|ICC||||INTERVIEWER|HEMATOLOGIST|NA|3|Visit_3|40|1|TREATMENT|2021-02-21|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-04|P1Y2M10DT2H30M|UNKNOWN|2021-02-10|BEFORE|2021-04-04
e|RS|9c3b6912-19be-435c-87fc-781a08efb847|7|BMIVLIND|Bone Marrow Involvement Indicator|AJCC V7|||WORSENED|1|Pa|WEBER GREEN STAIN||Y|Y|ADJUDICATION COMMITTEE|RADIOLOGIST 1|Y|4|Visit_4|65|1|FOLLOW-UP|2021-03-18|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-17|P1Y2M10DT2H30M|UNKNOWN|2021-01-16|BEFORE|2021-01-21
e|RS|9c3b6912-19be-435c-87fc-781a08efb847|8|MJPTHIND|Major Pathological Response Indicator|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|||MORPHOLOGIC CR|1|atm|RYAN BLUE STAIN|Y||Y|SIGNIFICANT OTHER|PEDIATRIC NEUROLOGIST|Y|4|Visit_4|65|7|SCREENING|2021-03-18|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-17|P1Y2M10DT2H30M|AFTER|2021-04-20|AFTER|2021-04-21
e|RS|9c3b6912-19be-435c-87fc-781a08efb847|9|NTLWIND|Non-Target Lesion Worsening Indicator|SCHWARZ CERVICAL CANCER 2009|[?]|BAG|MINOR PATHOLOGIC RESPONSE|1|oz|IMMUNOPRECIPITATION||||PROXY|RATER 2|N|5|Visit_5|90|2|TREATMENT|2021-04-12|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-07|P1Y2M10DT2H30M|UNKNOWN|2021-03-15|COINCIDENT|2021-04-21
e|RS|9c3b6912-19be-435c-87fc-781a08efb847|10|MRDRESP|Minimal Residual Disease Response|MASS|[?]|/LSQN|SMD|1|lx|PUPILLOMETRY||Y||ADJUDICATION COMMITTEE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|5|Visit_5|90|1|SCREENING|2021-04-12|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-07|P1Y2M10DT2H30M|AFTER|2021-01-21|COINCIDENT|2021-01-31
e|RS|171a6d85-ba2e-45da-b31b-01651b26e890|1|SPLNRESP|Spleen Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|/100 WBC|iPR|1|m2|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY|Y|||STUDY SUBJECT|ONCOLOGIST|NA|1|Visit_1|10|1|FOLLOW-UP|2020-08-02|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-18|P1Y2M10DT2H30M|COINCIDENT|2020-08-31|BEFORE|2020-09-05
e|RS|171a6d85-ba2e-45da-b31b-01651b26e890|2|MOLRESP|Molecular Response|RECIST 1.0|[?]|mMU/mL|MRD PERSISTENCE|1|10^6 organisms|PYROSEQUENCING|Y|||INTERVIEWER|DEVELOPMENTAL PSYCHOLOGIST|N|1|Visit_1|10|3|FOLLOW-UP|2020-08-02|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-18|P1Y2M10DT2H30M|COINCIDENT|2020-08-31|ONGOING|2020-10-28
e|RS|171a6d85-ba2e-45da-b31b-01651b26e890|3|NTNERESP|Non-Target Non-Enhancing Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|Hz|ABSENT MORPHOLOGIC RESPONSE|1|mph|NUCLEAR RADIOLOGY||||SIGNIFICANT OTHER|ONCOLOGIST|U|2|Visit_2|25|7|FOLLOW-UP|2020-08-17|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-11|P1Y2M10DT2H30M|AFTER|2020-07-28|BEFORE|2020-09-20
e|RS|171a6d85-ba2e-45da-b31b-01651b26e890|4|DRCRIND|Disease Recurrence Indicator|IWG CHESON AML 2003|[?]|USP U|MORPHOLOGIC CR|1|mL/h|DXA SCAN|Y|Y||CLINICAL RESEARCH COORDINATOR|FORENSIC PATHOLOGIST|NA|2|Visit_2|25|7|TREATMENT|2020-08-17|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-11|P1Y2M10DT2H30M|BEFORE|2020-09-11|COINCIDENT|2020-10-02
e|RS|171a6d85-ba2e-45da-b31b-01651b26e890|5|PATHRESP|Pathologic Response|SCHER PROSTATE CANCER 2011|[?]|mEq/ug|OPTIMAL MORPHOLOGIC RESPONSE|1|mg/g/h|SINGLE-SLICE SPIRAL CT||Y||SPOUSE|NEUROLOGIST 1|N|3|Visit_3|40|5|FOLLOW-UP|2020-09-01|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-18|P1Y2M10DT2H30M|AFTER|2020-07-26|AFTER|2020-08-31
e|RS|171a6d85-ba2e-45da-b31b-01651b26e890|6|SYMPTDTR|Symptomatic Deterioration|PROTOCOL DEFINED RESPONSE CRITERIA|||NON-QUANTIFIABLE MRD POSITIVITY|1|MBq/uL|AGAR DILUTION|||Y|VENDOR|CLINICAL PATHOLOGIST|Y|3|Visit_3|40|7|TREATMENT|2020-09-01|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-18|P1Y2M10DT2H30M|BEFORE|2020-09-08|BEFORE|2020-09-30
e|RS|171a6d85-ba2e-45da-b31b-01651b26e890|7|MNPTHIND|Minor Pathological Response Indicator|RECIST 1.0|[?]|cmH2O*s/mL|DISEASE TRANSFORMATION|1|%(v/v)|GEL ELECTROPHORESIS||Y||CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 1|NA|4|Visit_4|65|1|TREATMENT|2020-09-26|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-28|P1Y2M10DT2H30M|AFTER|2020-10-26|BEFORE|2020-10-29
e|RS|171a6d85-ba2e-45da-b31b-01651b26e890|8|CPRFSTAT|Clinical Performance Status|HARTMANN GERM CELL CANCER 2002|||mCR|1|cpm|JAEGER EYE CHART|||Y|STUDY SUBJECT|RADIOLOGIST 1|U|4|Visit_4|65|2|TREATMENT|2020-09-26|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-28|P1Y2M10DT2H30M|AFTER|2020-08-04|BEFORE|2020-08-08
e|RS|171a6d85-ba2e-45da-b31b-01651b26e890|9|MNPTHIND|Minor Pathological Response Indicator|AJCC V8|[?]|BISCUIT|iCR|1|Absorbance U/min|LUXOL FAST BLUE AND CRESYL VIOLET STAIN||||NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|N|5|Visit_5|90|1|WASHOUT|2020-10-21|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-18|P1Y2M10DT2H30M|COINCIDENT|2020-10-12|AFTER|2020-10-20
e|RS|171a6d85-ba2e-45da-b31b-01651b26e890|10|MOLRESP|Molecular Response|RANO ELLINGSON 2017|[?]|km|PR WITH LYMPHOCYTOSIS|1|vp/mL|PERIODIC ACID SCHIFF STAIN||||CLINICAL RESEARCH COORDINATOR|PEDIATRIC NEUROLOGIST|N|5|Visit_5|90|1|FOLLOW-UP|2020-10-21|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-18|P1Y2M10DT2H30M|BEFORE|2020-10-09|AFTER|2020-10-26
e|RS|a8338164-1bb5-4474-9432-4d5a81ab30d8|1|STRUSTAT|Steroid Use Status|JACINTO CERVICAL CANCER 2007|||NON-PD|1|DRUM|LYMPHANGIOGRAPHY|||Y|INVESTIGATOR|ADJUDICATOR 2|U|1|Visit_1|10|7|WASHOUT|2020-12-10|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-16|P1Y2M10DT2H30M|COINCIDENT|2021-01-15|ONGOING|2021-01-21
e|RS|a8338164-1bb5-4474-9432-4d5a81ab30d8|2|NTRGRESP|Non-target Response|PCWG SCHER PROSTATE CANCER 2016|[?]|mmHg|COMPLETE MRD RESPONSE|1|L/L|EIA|Y|||STUDY SUBJECT|ONCOLOGIST|N|1|Visit_1|10|7|TREATMENT|2020-12-10|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-16|P1Y2M10DT2H30M|COINCIDENT|2020-12-12|BEFORE|2021-02-14
e|RS|a8338164-1bb5-4474-9432-4d5a81ab30d8|3|MRPHRESP|Morphologic Response|PRINCE TCELL LYMPHOMA 2010|||NON-iCR/NON-iUPD|1|10^6/hpf|ELECTROCHEMILUMINESCENCE IMMUNOASSAY|Y||Y|FAMILY MEMBER|ONCOLOGIST 2|NA|2|Visit_2|25|4|TREATMENT|2020-12-25|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-27|P1Y2M10DT2H30M|COINCIDENT|2021-03-05|COINCIDENT|2021-03-08
e|RS|a8338164-1bb5-4474-9432-4d5a81ab30d8|4|STRUSTAT|Steroid Use Status|MASS|||NON-iCR/NON-iUPD|1|ppm|REBOUND TONOMETRY||Y|Y|CHILD|HEMATOLOGIST|Y|2|Visit_2|25|5|TREATMENT|2020-12-25|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-27|P1Y2M10DT2H30M|BEFORE|2021-01-25|COINCIDENT|2021-03-08
e|RS|a8338164-1bb5-4474-9432-4d5a81ab30d8|5|NTERESP|Non-Target Enhancing Response|SACT|[?]|CFU/g|DISEASE TRANSFORMATION|1|keV|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|Y|Y||VENDOR|PATHOLOGIST|Y|3|Visit_3|40|6|WASHOUT|2021-01-09|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-07|P1Y2M10DT2H30M|BEFORE|2021-01-27|ONGOING|2021-03-09
e|RS|a8338164-1bb5-4474-9432-4d5a81ab30d8|6|TRGRESP|Target Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|||PR WITH LYMPHOCYTOSIS|1|Bq/ug|POLYMERASE CHAIN REACTION|||Y|CAREGIVER|MICROSCOPIST|NA|3|Visit_3|40|2|FOLLOW-UP|2021-01-09|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-07|P1Y2M10DT2H30M|UNKNOWN|2020-12-21|COINCIDENT|2021-01-12
e|RS|a8338164-1bb5-4474-9432-4d5a81ab30d8|7|NTRGRESP|Non-target Response|PCWG SCHER PROSTATE CANCER 2008|[?]|breaths/min|iCPD|1|WEEKS|PET/MRI SCAN|Y|||PARENT|PHYSIOTHERAPIST|NA|4|Visit_4|65|4|TREATMENT|2021-02-03|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-23|P1Y2M10DT2H30M|AFTER|2021-02-12|AFTER|2021-03-08
e|RS|a8338164-1bb5-4474-9432-4d5a81ab30d8|8|CLINRESP|Clinical Response|CHESON LYMPHOMA 2008|||DECREASED|1|mL/m2/min|RIA|Y|Y|Y|INDEPENDENT ASSESSOR|READER 1|NA|4|Visit_4|65|5|SCREENING|2021-02-03|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-23|P1Y2M10DT2H30M|BEFORE|2020-12-31|BEFORE|2021-02-16
e|RS|a8338164-1bb5-4474-9432-4d5a81ab30d8|9|BONERESP|Bone Response|PCWG SCHER PROSTATE CANCER 2016|[?]|SUPPOSITORY|IMMUNOPHENOTYPIC CR|1|cmHg|INCISION-INDUCED BLEEDING METHOD||||GUARDIAN|RATER 1|Y|5|Visit_5|90|7|SCREENING|2021-02-28|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-21|P1Y2M10DT2H30M|BEFORE|2020-12-12|BEFORE|2021-03-01
e|RS|a8338164-1bb5-4474-9432-4d5a81ab30d8|10|RDIORESP|Radiologic Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|||PD FROM PR|1|g/cage|RADIATION DOSIMETRY||Y|Y|INDEPENDENT ASSESSOR|HEMATOLOGIST|Y|5|Visit_5|90|6|TREATMENT|2021-02-28|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-21|P1Y2M10DT2H30M|COINCIDENT|2021-01-09|ONGOING|2021-01-31
e|RS|6d64077e-1f18-4bd6-ba86-53d90121f7a9|1|SYMPTDTR|Symptomatic Deterioration|CHOI GIST 2008|||PARTIAL MORPHOLOGIC RESPONSE|1|GBq/mg|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY|Y||Y|FAMILY MEMBER|NEUROLOGIST|Y|1|Visit_1|10|6|WASHOUT|2020-06-17|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-12|P1Y2M10DT2H30M|UNKNOWN|2020-07-20|BEFORE|2020-09-02
e|RS|6d64077e-1f18-4bd6-ba86-53d90121f7a9|2|BONERESP|Bone Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|deg/s|RELAPSED DISEASE|1|DPM|DYNAMIC LIGHT SCATTERING||||VENDOR|RATER 2|Y|1|Visit_1|10|6|SCREENING|2020-06-17|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-12|P1Y2M10DT2H30M|COINCIDENT|2020-07-09|ONGOING|2020-07-30
e|RS|6d64077e-1f18-4bd6-ba86-53d90121f7a9|3|NTNERESP|Non-Target Non-Enhancing Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|/VF|RELAPSED DISEASE FROM CR OR PR|1|SCOOPFUL|HEMAGGLUTINATION INHIBITION ASSAY|Y|||NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|Y|2|Visit_2|25|6|WASHOUT|2020-07-02|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-10|P1Y2M10DT2H30M|COINCIDENT|2020-08-04|ONGOING|2020-08-27
e|RS|6d64077e-1f18-4bd6-ba86-53d90121f7a9|4|TMRESP|Tumor Marker Response|MURPHY PROSTATE CANCER 1980|[?]|10^4 CFU/mL|PD/RELAPSE AFTER HI|1|STEPS|HIGH RESOLUTION CT||||FAMILY MEMBER|MICROSCOPIST|NA|2|Visit_2|25|1|TREATMENT|2020-07-02|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-10|P1Y2M10DT2H30M|COINCIDENT|2020-06-23|ONGOING|2020-08-04
e|RS|6d64077e-1f18-4bd6-ba86-53d90121f7a9|5|HEMARESP|Hematologic Response|KEAM BREAST CANCER 2013|[?]|pptr|MOLECULAR MAJOR RESPONSE|1|EU|ANTIBIOTIC AGAR SCREEN|Y|||INVESTIGATOR|ENDOCRINOLOGIST|N|3|Visit_3|40|5|TREATMENT|2020-07-17|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-26|P1Y2M10DT2H30M|BEFORE|2020-07-14|BEFORE|2020-07-28
e|RS|6d64077e-1f18-4bd6-ba86-53d90121f7a9|6|NEWLWIND|New Lesion Worsening Indicator|RANO ELLINGSON 2017|||MOLECULAR CR|1|m3|DROPLET DIGITAL PCR|Y||Y|NON-HEALTH CARE PROFESSIONAL|UROLOGIST|N|3|Visit_3|40|1|TREATMENT|2020-07-17|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-26|P1Y2M10DT2H30M|COINCIDENT|2020-06-29|ONGOING|2020-08-26
e|RS|6d64077e-1f18-4bd6-ba86-53d90121f7a9|7|MOLRESP|Molecular Response|SACT|[?]|mgEq|MORPHOLOGIC LEUKEMIA-FREE STATE|1|kUSP|FLOW CYTOMETRY||Y||ADJUDICATION COMMITTEE|READER 2|Y|4|Visit_4|65|4|TREATMENT|2020-08-11|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-07|P1Y2M10DT2H30M|BEFORE|2020-07-10|BEFORE|2020-07-27
e|RS|6d64077e-1f18-4bd6-ba86-53d90121f7a9|8|SYMPTDTR|Symptomatic Deterioration|GCIG RUSTIN OVARIAN CANCER 2011|[?]|mL/g/h|iSD|1|TCID 50/dose|SURFACE PLASMON RESONANCE|Y|||INTERVIEWER|OPTOMETRIST|NA|4|Visit_4|65|2|WASHOUT|2020-08-11|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-07|P1Y2M10DT2H30M|BEFORE|2020-06-26|ONGOING|2020-07-27
e|RS|6d64077e-1f18-4bd6-ba86-53d90121f7a9|9|METBRESP|Metabolic Response|CHESON NON-HODGKINS LYMPHOMA 1999|||CYTOGENETIC CR|1|yd|IMMUNOASSAY|Y||Y|PROXY|INTERNIST|Y|5|Visit_5|90|3|FOLLOW-UP|2020-09-05|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-08|P1Y2M10DT2H30M|COINCIDENT|2020-07-04|AFTER|2020-07-10
e|RS|6d64077e-1f18-4bd6-ba86-53d90121f7a9|10|MOLRESP|Molecular Response|KUMAR IMWG 2016|[?]|ug/mol|iSD|1|/2000 RBC|DYNAMIC LIGHT SCATTERING|Y|Y||GUARDIAN|ADJUDICATOR|N|5|Visit_5|90|5|TREATMENT|2020-09-05|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-08|P1Y2M10DT2H30M|UNKNOWN|2020-08-25|COINCIDENT|2020-09-01
e|RS|91d08486-3db7-4c71-a63f-fd060f4ae1a4|1|MJPTHIND|Major Pathological Response Indicator|WOLCHOK SOLID TUMORS 2009|[?]|10^5/L|PD FROM PR|1|10^12 IU/L|NUCLEIC ACID HYBRIDIZATION|Y|Y||FRIEND|CARDIOLOGIST|NA|1|Visit_1|10|1|TREATMENT|2020-12-25|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-11|P1Y2M10DT2H30M|BEFORE|2021-01-20|COINCIDENT|2021-02-13
e|RS|91d08486-3db7-4c71-a63f-fd060f4ae1a4|2|MOLRESP|Molecular Response|IWG CHESON AML 2003|[?]|V/sec|PSEUDORESPONSE|1|mL/breath|ELISA||||CLINICAL RESEARCH COORDINATOR|OPTOMETRIST|U|1|Visit_1|10|5|TREATMENT|2020-12-25|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-11|P1Y2M10DT2H30M|BEFORE|2021-02-21|COINCIDENT|2021-02-26
e|RS|91d08486-3db7-4c71-a63f-fd060f4ae1a4|3|MNPTHIND|Minor Pathological Response Indicator|HARTMAN PANCREATIC CANCER 2012|[?]|SACHET|PD|1|/cmH2O|LIQUID SCINTILLATION COUNTING||||HEALTH CARE PROFESSIONAL|CARDIOLOGIST|NA|2|Visit_2|25|6|TREATMENT|2021-01-09|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-22|P1Y2M10DT2H30M|BEFORE|2021-02-06|ONGOING|2021-02-08
e|RS|91d08486-3db7-4c71-a63f-fd060f4ae1a4|4|BMIVLIND|Bone Marrow Involvement Indicator|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|dB|iUPD|1|DNA copies/ug|MULTI-SLICE SPIRAL CT||||PROXY|PATHOLOGIST|N|2|Visit_2|25|6|TREATMENT|2021-01-09|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-22|P1Y2M10DT2H30M|UNKNOWN|2021-03-10|COINCIDENT|2021-03-15
e|RS|91d08486-3db7-4c71-a63f-fd060f4ae1a4|5|SPLNRESP|Spleen Response|GCIG RUSTIN OVARIAN CANCER 2011|||PMD|1|mg/L|ENDOSCOPY|||Y|NON-HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|NA|3|Visit_3|40|7|TREATMENT|2021-01-24|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-24|P1Y2M10DT2H30M|COINCIDENT|2020-12-24|AFTER|2021-01-03
e|RS|91d08486-3db7-4c71-a63f-fd060f4ae1a4|6|NTRGRESP|Non-target Response|CHOI GIST 2008|||MRD NEGATIVITY|1|mmHg/L/min|TRANSESOPHAGEAL ECHOCARDIOGRAPHY|||Y|SIBLING|ADJUDICATOR 3|N|3|Visit_3|40|5|TREATMENT|2021-01-24|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-24|P1Y2M10DT2H30M|BEFORE|2021-01-15|AFTER|2021-01-24
e|RS|91d08486-3db7-4c71-a63f-fd060f4ae1a4|7|METBRESP|Metabolic Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|||RELAPSED DISEASE FROM CR|1|umol/day|STRESS ECHOCARDIOGRAPHY|||Y|STUDY SUBJECT|RATER|N|4|Visit_4|65|3|TREATMENT|2021-02-18|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-25|P1Y2M10DT2H30M|COINCIDENT|2021-03-21|BEFORE|2021-03-24
e|RS|91d08486-3db7-4c71-a63f-fd060f4ae1a4|8|TRGRESP|Target Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|cg|iPR|1|MPL U|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY||||FRIEND|ONCOLOGIST|N|4|Visit_4|65|1|FOLLOW-UP|2021-02-18|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-25|P1Y2M10DT2H30M|BEFORE|2021-01-20|COINCIDENT|2021-01-30
e|RS|91d08486-3db7-4c71-a63f-fd060f4ae1a4|9|MRDIND|Minimal Residual Disease Indicator|JACINTO CERVICAL CANCER 2007|[?]|10^9/g|STABLE|1|cy/cm|CONTRAST ENHANCED X-RAY||||CAREGIVER|RATER 1|Y|5|Visit_5|90|7|TREATMENT|2021-03-15|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-20|P1Y2M10DT2H30M|BEFORE|2021-01-23|ONGOING|2021-01-29
e|RS|91d08486-3db7-4c71-a63f-fd060f4ae1a4|10|CLINRESP|Clinical Response|PCWG SCHER PROSTATE CANCER 2008|||CRi|1|ug/m2/h|LEAD CITRATE STAIN||Y|Y|STUDY SUBJECT|OPHTHALMOLOGIST|U|5|Visit_5|90|4|SCREENING|2021-03-15|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-20|P1Y2M10DT2H30M|BEFORE|2021-01-15|AFTER|2021-02-20
e|RS|f44ad5ae-71d0-462e-8d57-b5f8fffaf2da|1|DRCRIND|Disease Recurrence Indicator|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|uOsm|PR|1|pg/L|CELL OF ORIGIN ASSAY||Y||SIGNIFICANT OTHER|ADJUDICATOR 2|U|1|Visit_1|10|5|TREATMENT|2020-08-14|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-27|P1Y2M10DT2H30M|UNKNOWN|2020-08-15|AFTER|2020-10-27
e|RS|f44ad5ae-71d0-462e-8d57-b5f8fffaf2da|2|MOLRESP|Molecular Response|CHESON LYMPHOMA 2008|||MOLECULAR CR|1|U/g|QUANTITATIVE COMPUTED TOMOGRAPHY|||Y|CAREGIVER|ADJUDICATOR 1|U|1|Visit_1|10|6|SCREENING|2020-08-14|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-27|P1Y2M10DT2H30M|BEFORE|2020-10-14|AFTER|2020-10-31
e|RS|f44ad5ae-71d0-462e-8d57-b5f8fffaf2da|3|METBRESP|Metabolic Response|RECIST 1.0|[?]|m2|PSEUDOPROGRESSION|1|mV|MYELOPEROXIDASE STAIN|Y|||FRIEND|ADJUDICATOR 1|Y|2|Visit_2|25|2|TREATMENT|2020-08-29|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-13|P1Y2M10DT2H30M|BEFORE|2020-09-04|ONGOING|2020-10-05
e|RS|f44ad5ae-71d0-462e-8d57-b5f8fffaf2da|4|MRDIND|Minimal Residual Disease Indicator|EASL BRUIX LIVER CANCER 2001|[?]|gpELISA unit/mL|iPR|1|10^3/L|MICRO BROTH DILUTION|Y|||INTERVIEWER|RATER 1|NA|2|Visit_2|25|4|TREATMENT|2020-08-29|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-13|P1Y2M10DT2H30M|BEFORE|2020-08-26|ONGOING|2020-08-29
e|RS|f44ad5ae-71d0-462e-8d57-b5f8fffaf2da|5|PATHRESP|Pathologic Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|mPa|CR-CT|1|STEPS|PERCUSSION||||FRIEND|ONCOLOGIST 2|U|3|Visit_3|40|6|TREATMENT|2020-09-13|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-05|P1Y2M10DT2H30M|UNKNOWN|2020-08-09|ONGOING|2020-09-06
e|RS|f44ad5ae-71d0-462e-8d57-b5f8fffaf2da|6|SYMPTDTR|Symptomatic Deterioration|CHESON NON-HODGKINS LYMPHOMA 1999|||PSEUDORESPONSE|1|Ci/g|WESTERGREN|||Y|SIGNIFICANT OTHER|OPTOMETRIST|N|3|Visit_3|40|7|WASHOUT|2020-09-13|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-05|P1Y2M10DT2H30M|COINCIDENT|2020-09-10|COINCIDENT|2020-09-29
e|RS|f44ad5ae-71d0-462e-8d57-b5f8fffaf2da|7|RDIORESP|Radiologic Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|L/min/m2|CRi|1|mg/kg/day|ENZYMATIC SPECTROPHOTOMETRY||||NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|U|4|Visit_4|65|2|WASHOUT|2020-10-08|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-13|P1Y2M10DT2H30M|BEFORE|2020-08-23|BEFORE|2020-10-14
e|RS|f44ad5ae-71d0-462e-8d57-b5f8fffaf2da|8|MOLRESP|Molecular Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|amp|CYTOGENETIC MINIMAL RESPONSE|1|PACKAGE|CELL OF ORIGIN ASSAY||||FRIEND|MICROSCOPIST 2|NA|4|Visit_4|65|7|WASHOUT|2020-10-08|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-13|P1Y2M10DT2H30M|AFTER|2020-08-28|AFTER|2020-10-15
e|RS|f44ad5ae-71d0-462e-8d57-b5f8fffaf2da|9|MOLRESP|Molecular Response|MACDONALD GLIOMA 1990|[?]|mL/dL|UNEQUIVOCAL|1|Pack Year|BIOIMPEDANCE SPECTROSCOPY||||PROXY|MICROSCOPIST 3|N|5|Visit_5|90|1|SCREENING|2020-11-02|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-25|P1Y2M10DT2H30M|COINCIDENT|2020-10-03|COINCIDENT|2020-11-08
e|RS|f44ad5ae-71d0-462e-8d57-b5f8fffaf2da|10|STRUSTAT|Steroid Use Status|KUMAR IMWG 2016|[?]|log10 CCID 50/dose|MRD PERSISTENCE|1|WAFER|SPECT/CT SCAN|Y|Y||HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|Y|5|Visit_5|90|6|FOLLOW-UP|2020-11-02|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-25|P1Y2M10DT2H30M|UNKNOWN|2020-10-25|BEFORE|2020-11-01
e|RS|7b8a488a-ffd8-45bd-9b6d-8c16b1f24997|1|SFTSRESP|Soft Tissue Response|BURCOMBE BREAST CANCER 2005|[?]|mg/dose|IMMUNOPHENOTYPIC CR|1|JAR|MS/MS||||CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 2|U|1|Visit_1|10|6|TREATMENT|2021-01-09|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-07|P1Y2M10DT2H30M|UNKNOWN|2021-01-06|AFTER|2021-03-22
e|RS|7b8a488a-ffd8-45bd-9b6d-8c16b1f24997|2|MOLRESP|Molecular Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|U/animal|NON-iCR/NON-iUPD|1|cd/m2|CONTRAST ENHANCED X-RAY||||CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR|NA|1|Visit_1|10|5|FOLLOW-UP|2021-01-09|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-07|P1Y2M10DT2H30M|COINCIDENT|2021-03-29|COINCIDENT|2021-04-02
e|RS|7b8a488a-ffd8-45bd-9b6d-8c16b1f24997|3|MJPTHIND|Major Pathological Response Indicator|RAJKUMAR MYELOMA 2011|[?]|vg/kg|RELAPSED DISEASE|1|anti-Xa IU/mL|KLEIHAUER-BETKE|Y|||ADJUDICATION COMMITTEE|FORENSIC PATHOLOGIST|Y|2|Visit_2|25|6|TREATMENT|2021-01-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-07|P1Y2M10DT2H30M|UNKNOWN|2021-03-07|AFTER|2021-03-28
e|RS|7b8a488a-ffd8-45bd-9b6d-8c16b1f24997|4|SPLNRESP|Spleen Response|HARTMANN GERM CELL CANCER 2002|[?]|Anson U|FAVORABLE RESPONSE|1|mL/min|ELISPOT|Y|||PROXY|HEMATOLOGIST|NA|2|Visit_2|25|5|TREATMENT|2021-01-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-07|P1Y2M10DT2H30M|AFTER|2021-03-06|AFTER|2021-04-03
e|RS|7b8a488a-ffd8-45bd-9b6d-8c16b1f24997|5|METSIND|Metastatic Indicator|EBMT BLADE MYELOMA 1998|[?]|in2|HI-N|1|cal|VIRUS PLAQUE ASSAY||||INTERVIEWER|ADJUDICATOR|NA|3|Visit_3|40|2|TREATMENT|2021-02-08|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-02|P1Y2M10DT2H30M|COINCIDENT|2021-04-08|AFTER|2021-04-09
e|RS|7b8a488a-ffd8-45bd-9b6d-8c16b1f24997|6|MRDIND|Minimal Residual Disease Indicator|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|||iCPD|1|TABLET|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|||Y|GUARDIAN|RATER 2|U|3|Visit_3|40|5|WASHOUT|2021-02-08|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-02|P1Y2M10DT2H30M|BEFORE|2021-03-30|ONGOING|2021-04-07
e|RS|7b8a488a-ffd8-45bd-9b6d-8c16b1f24997|7|METSIND|Metastatic Indicator|LEE LUNG CANCER 2011|[?]|mPa|SD|1|mm/2h|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION||Y||CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|4|Visit_4|65|6|TREATMENT|2021-03-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-09|P1Y2M10DT2H30M|BEFORE|2021-04-02|ONGOING|2021-04-03
e|RS|7b8a488a-ffd8-45bd-9b6d-8c16b1f24997|8|RDIORESP|Radiologic Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|ug/g/day|IMPROVED|1|vg/mL|LISSAMINE GREEN STAIN||||STUDY SUBJECT|DERMATOLOGIST|NA|4|Visit_4|65|4|FOLLOW-UP|2021-03-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-09|P1Y2M10DT2H30M|UNKNOWN|2021-02-24|BEFORE|2021-03-04
e|RS|7b8a488a-ffd8-45bd-9b6d-8c16b1f24997|9|TMRESP|Tumor Marker Response|RAJKUMAR MYELOMA 2011|||VGPR|1|mU/g|PULMONARY ANGIOGRAPHY|Y||Y|FRIEND|HEMATOLOGIST|N|5|Visit_5|90|2|FOLLOW-UP|2021-03-30|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-17|P1Y2M10DT2H30M|BEFORE|2021-01-29|AFTER|2021-03-20
e|RS|7b8a488a-ffd8-45bd-9b6d-8c16b1f24997|10|MRPHRESP|Morphologic Response|CHESON LYMPHOMA 2008|||CYTOGENETIC PR|1|steps/min|GIEMSA STAIN|||Y|STUDY SUBJECT|MICROSCOPIST 3|N|5|Visit_5|90|5|FOLLOW-UP|2021-03-30|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-17|P1Y2M10DT2H30M|COINCIDENT|2021-03-23|AFTER|2021-04-07
e|RS|87998e13-813a-464d-935c-d5513cd0db5e|1|MJPTHIND|Major Pathological Response Indicator|RANO|[?]|mmol/s|PR|1|s^-1(%O2)^-1|NEXT GENERATION SEQUENCING||Y||DOMESTIC PARTNER|MICROSCOPIST 1|U|1|Visit_1|10|7|SCREENING|2020-08-31|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-04|P1Y2M10DT2H30M|UNKNOWN|2020-10-01|COINCIDENT|2020-10-13
e|RS|87998e13-813a-464d-935c-d5513cd0db5e|2|SYMPTDTR|Symptomatic Deterioration|NCIWG CHESON CLL 1996|[?]|days/wk|PMD|1|log10 CCID 50/dose|DYNAMIC LIGHT SCATTERING||||GUARDIAN|ADJUDICATOR 3|Y|1|Visit_1|10|5|WASHOUT|2020-08-31|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-04|P1Y2M10DT2H30M|BEFORE|2020-09-07|ONGOING|2020-11-13
e|RS|87998e13-813a-464d-935c-d5513cd0db5e|3|NEWLIND|New Lesion Indicator|LEE LUNG CANCER 2011|||NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|ug/kg/min|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY||Y|Y|INDEPENDENT ASSESSOR|RADIOLOGIST 1|N|2|Visit_2|25|4|WASHOUT|2020-09-15|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-22|P1Y2M10DT2H30M|BEFORE|2020-10-14|AFTER|2020-11-05
e|RS|87998e13-813a-464d-935c-d5513cd0db5e|4|CLINRESP|Clinical Response|LEE LUNG CANCER 2011|[?]|Enzyme U/m2|cCR|1|FINGERTIP UNIT|SPIROMETRY||||STUDY SUBJECT|ENDOCRINOLOGIST|N|2|Visit_2|25|2|WASHOUT|2020-09-15|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-22|P1Y2M10DT2H30M|BEFORE|2020-08-28|COINCIDENT|2020-09-12
e|RS|87998e13-813a-464d-935c-d5513cd0db5e|5|NTNERESP|Non-Target Non-Enhancing Response|BURCOMBE BREAST CANCER 2005|||NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|uEq/L|PHOTOMETRY||Y|Y|HEALTH CARE PROFESSIONAL|OPTOMETRIST|N|3|Visit_3|40|6|FOLLOW-UP|2020-09-30|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-31|P1Y2M10DT2H30M|AFTER|2020-09-19|ONGOING|2020-09-20
e|RS|87998e13-813a-464d-935c-d5513cd0db5e|6|MOLRESP|Molecular Response|AJCC V7|[?]|mL/animal/wk|IMPROVED|1|fg|REAL-TIME POLYMERASE CHAIN REACTION ASSAY||Y||SIGNIFICANT OTHER|DERMATOLOGIST|U|3|Visit_3|40|7|TREATMENT|2020-09-30|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-31|P1Y2M10DT2H30M|AFTER|2020-10-26|COINCIDENT|2020-11-17
e|RS|87998e13-813a-464d-935c-d5513cd0db5e|7|CPRFSTAT|Clinical Performance Status|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|FEU|CHR|1|K|TELLER ACUITY CARDS||Y||SPOUSE|ONCOLOGIST 1|NA|4|Visit_4|65|7|WASHOUT|2020-10-25|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-03|P1Y2M10DT2H30M|BEFORE|2020-10-23|COINCIDENT|2020-11-16
e|RS|87998e13-813a-464d-935c-d5513cd0db5e|8|NEWLWIND|New Lesion Worsening Indicator|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|APPLICATION|FAVORABLE RESPONSE|1|AMPULE|HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY||||INTERVIEWER|PEDIATRIC NEUROLOGIST|NA|4|Visit_4|65|7|SCREENING|2020-10-25|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-03|P1Y2M10DT2H30M|COINCIDENT|2020-10-30|AFTER|2020-11-13
e|RS|87998e13-813a-464d-935c-d5513cd0db5e|9|CYTORESP|Cytogenetic Response|FAROOQUI SUPP CLL 2014|[?]|nmol|iSD|1|/100 HPFs|INDIA INK STAIN||||FAMILY MEMBER|READER 3|Y|5|Visit_5|90|2|TREATMENT|2020-11-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-01|P1Y2M10DT2H30M|UNKNOWN|2020-10-22|ONGOING|2020-11-07
e|RS|87998e13-813a-464d-935c-d5513cd0db5e|10|SYMPTDTR|Symptomatic Deterioration|KEAM BREAST CANCER 2013|[?]|U/m2/day|STABLE|1|mmAL|IMMUNO-PET SCAN||||CAREGIVER|ONCOLOGIST|Y|5|Visit_5|90|5|SCREENING|2020-11-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-01|P1Y2M10DT2H30M|COINCIDENT|2020-10-31|COINCIDENT|2020-11-24
e|RS|7812e96e-ea53-4eb0-8160-d4118c567c9d|1|BESTRESP|Best Overall Response|iRECIST|[?]|ft2|PD FROM PR|1|EU|IMMUNODIFFUSION||Y||INTERVIEWER|OTOLARYNGOLOGIST|Y|1|Visit_1|10|6|WASHOUT|2021-01-27|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-05|P1Y2M10DT2H30M|UNKNOWN|2021-03-12|ONGOING|2021-03-30
e|RS|7812e96e-ea53-4eb0-8160-d4118c567c9d|2|SFTSRESP|Soft Tissue Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|g/animal/day|pCR|1|log EID 50/dose|SICKLE CELL SOLUBILITY TEST|Y|||INVESTIGATOR|ADJUDICATOR 3|NA|1|Visit_1|10|6|WASHOUT|2021-01-27|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-05|P1Y2M10DT2H30M|AFTER|2021-04-09|ONGOING|2021-04-14
e|RS|7812e96e-ea53-4eb0-8160-d4118c567c9d|3|NTERESP|Non-Target Enhancing Response|PERCIST|||CA125 50% RESPONSE|1|U/m2/h|SICKLE CELL SOLUBILITY TEST|||Y|HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|Y|2|Visit_2|25|1|TREATMENT|2021-02-11|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-28|P1Y2M10DT2H30M|UNKNOWN|2021-02-14|BEFORE|2021-04-11
e|RS|7812e96e-ea53-4eb0-8160-d4118c567c9d|4|ANATRESP|Anatomic Response|HAMAOKA BREAST CANCER 2010|||PSA PROGRESSION|1|Gauss|ULTRASONOGRAPHIC ELASTOGRAPHY|Y||Y|ADJUDICATION COMMITTEE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|2|Visit_2|25|7|SCREENING|2021-02-11|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-28|P1Y2M10DT2H30M|UNKNOWN|2021-01-27|COINCIDENT|2021-04-24
e|RS|7812e96e-ea53-4eb0-8160-d4118c567c9d|5|CYTORESP|Cytogenetic Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|msec|iCR|1|mEq/day|LIQUID SCINTILLATION COUNTING||||ADJUDICATION COMMITTEE|MICROSCOPIST 3|Y|3|Visit_3|40|6|FOLLOW-UP|2021-02-26|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-23|P1Y2M10DT2H30M|BEFORE|2021-04-23|AFTER|2021-04-26
e|RS|7812e96e-ea53-4eb0-8160-d4118c567c9d|6|HEMARESP|Hematologic Response|RECICL|[?]|mU|CYTOGENETIC CR|1|APL U|FORCED OSCILLATION TECHNIQUE||||VENDOR|RATER 1|N|3|Visit_3|40|6|FOLLOW-UP|2021-02-26|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-23|P1Y2M10DT2H30M|COINCIDENT|2021-04-04|COINCIDENT|2021-04-07
e|RS|7812e96e-ea53-4eb0-8160-d4118c567c9d|7|NTERESP|Non-Target Enhancing Response|SCHWARZ CERVICAL CANCER 2009|[?]|DRINK|MORPHOLOGIC CR|1|PACK|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY||||SPOUSE|RATER 2|NA|4|Visit_4|65|6|FOLLOW-UP|2021-03-23|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-11|P1Y2M10DT2H30M|BEFORE|2021-04-15|BEFORE|2021-04-24
e|RS|7812e96e-ea53-4eb0-8160-d4118c567c9d|8|NEWLWIND|New Lesion Worsening Indicator|MASS|[?]|EID 50/dose|RELAPSED DISEASE FROM CR OR PR|1|ug/kg/h|LYMPHANGIOGRAPHY||||FRIEND|RATER 2|NA|4|Visit_4|65|3|TREATMENT|2021-03-23|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-11|P1Y2M10DT2H30M|UNKNOWN|2021-04-24|COINCIDENT|2021-04-26
e|RS|7812e96e-ea53-4eb0-8160-d4118c567c9d|9|CYTORESP|Cytogenetic Response|HAMAOKA BREAST CANCER 2010|[?]|BISCUIT|PDu|1|10^8 PFU|DARK FIELD MICROSCOPY|Y|||SIBLING|ADJUDICATOR 1|N|5|Visit_5|90|1|TREATMENT|2021-04-17|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-18|P1Y2M10DT2H30M|BEFORE|2021-03-03|ONGOING|2021-03-11
e|RS|7812e96e-ea53-4eb0-8160-d4118c567c9d|10|BESTRESP|Best Overall Response|JACINTO CERVICAL CANCER 2007|[?]|MET*h|sCR|1|dB|U-HPLC/MS/MS||||GUARDIAN|RADIOLOGIST 2|N|5|Visit_5|90|5|WASHOUT|2021-04-17|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-18|P1Y2M10DT2H30M|BEFORE|2021-03-16|AFTER|2021-04-18
e|RS|f9c6c448-0e3d-421f-a63f-be4aeb965256|1|METBRESP|Metabolic Response|WOLCHOK SOLID TUMORS 2009|||TREATMENT FAILURE|1|genEq|QUANTITATIVE COMPUTED TOMOGRAPHY|Y||Y|INVESTIGATOR|PEDIATRIC NEUROLOGIST|Y|1|Visit_1|10|4|TREATMENT|2020-11-08|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-04|P1Y2M10DT2H30M|AFTER|2020-12-21|AFTER|2021-01-01
e|RS|f9c6c448-0e3d-421f-a63f-be4aeb965256|2|SFTSRESP|Soft Tissue Response|NCIWG CHESON CLL 1996|||iSD|1|pmol|TOLUIDINE BLUE STAIN|||Y|VENDOR|READER 3|U|1|Visit_1|10|2|WASHOUT|2020-11-08|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-04|P1Y2M10DT2H30M|UNKNOWN|2020-12-15|AFTER|2021-01-03
e|RS|f9c6c448-0e3d-421f-a63f-be4aeb965256|3|LIVRRESP|Liver Response|KEAM BREAST CANCER 2013|[?]|mg/mL/day|VGPR|1|mm/min|ELLA|Y|Y||INVESTIGATOR|FORENSIC PATHOLOGIST|Y|2|Visit_2|25|4|TREATMENT|2020-11-23|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-04|P1Y2M10DT2H30M|UNKNOWN|2020-12-20|AFTER|2021-01-03
e|RS|f9c6c448-0e3d-421f-a63f-be4aeb965256|4|METBRESP|Metabolic Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|TRACE|PD|1|dpm/0.5 mL|MEDIASTINOSCOPY||||INTERVIEWER|MICROSCOPIST|NA|2|Visit_2|25|1|SCREENING|2020-11-23|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-04|P1Y2M10DT2H30M|AFTER|2021-02-03|COINCIDENT|2021-02-04
e|RS|f9c6c448-0e3d-421f-a63f-be4aeb965256|5|OVRLRESP|Overall Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|foz_br|PR|1|EID 50/dose|APPLANATION TONOMETRY||||SIBLING|UROLOGIST|N|3|Visit_3|40|6|TREATMENT|2020-12-08|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-11|P1Y2M10DT2H30M|AFTER|2020-12-02|BEFORE|2021-01-11
e|RS|f9c6c448-0e3d-421f-a63f-be4aeb965256|6|TMRESP|Tumor Marker Response|PCWG SCHER PROSTATE CANCER 2008|||SMD|1|psec|NEPHELOMETRY||Y|Y|FAMILY MEMBER|MICROSCOPIST 1|N|3|Visit_3|40|6|SCREENING|2020-12-08|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-11|P1Y2M10DT2H30M|UNKNOWN|2020-12-13|BEFORE|2021-01-11
e|RS|f9c6c448-0e3d-421f-a63f-be4aeb965256|7|PATHRESP|Pathologic Response|SHINDOH COLORECTAL CANCER 2013|[?]|10^6 DNA copies/mL|HI-N|1|cy/cm|WRIGHT STAIN||||HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|U|4|Visit_4|65|2|TREATMENT|2021-01-02|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-21|P1Y2M10DT2H30M|COINCIDENT|2020-12-06|ONGOING|2021-01-24
e|RS|f9c6c448-0e3d-421f-a63f-be4aeb965256|8|SFTSRESP|Soft Tissue Response|CHESON NON-HODGKINS LYMPHOMA 1999|||PR|1|mEq|PHASE CONTRAST MICROSCOPY||Y|Y|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR|NA|4|Visit_4|65|2|TREATMENT|2021-01-02|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-21|P1Y2M10DT2H30M|BEFORE|2020-12-01|BEFORE|2021-01-28
e|RS|f9c6c448-0e3d-421f-a63f-be4aeb965256|9|MJPTHIND|Major Pathological Response Indicator|CHOLLET BREAST CANCER 2002|[?]|Antibody Unit|CA125 50% RESPONSE|1|ug/L/h|NON-CONTACT SPECULAR MICROSCOPY||||SIGNIFICANT OTHER|READER|Y|5|Visit_5|90|3|WASHOUT|2021-01-27|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-09|P1Y2M10DT2H30M|BEFORE|2020-11-04|BEFORE|2020-12-31
e|RS|f9c6c448-0e3d-421f-a63f-be4aeb965256|10|BMIVLIND|Bone Marrow Involvement Indicator|MASS|||IMPROVED|1|mEq/ug|LC/MS|||Y|PARENT|ADJUDICATOR 1|Y|5|Visit_5|90|3|TREATMENT|2021-01-27|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-09|P1Y2M10DT2H30M|BEFORE|2021-01-26|ONGOING|2021-01-27
e|RS|e8da815a-b53c-46f4-a546-e8553152719f|1|NEWLPROG|New Lesion Progression|DURIE MULTIPLE MYELOMA 2006|[?]|10^3 CFU/mL|RELAPSED DISEASE|1|mL*cmH2O|PHOTOMETRY||||VENDOR|ONCOLOGIST 2|NA|1|Visit_1|10|5|TREATMENT|2020-12-27|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-07|P1Y2M10DT2H30M|AFTER|2021-01-24|BEFORE|2021-01-28
e|RS|e8da815a-b53c-46f4-a546-e8553152719f|2|MOLRESP|Molecular Response|PCWG SCHER PROSTATE CANCER 2008|[?]|cmol/L|MR|1|STEPS|X-RAY FLUORESCENCE SPECTROMETRY||||VENDOR|ADJUDICATOR 2|NA|1|Visit_1|10|6|TREATMENT|2020-12-27|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-07|P1Y2M10DT2H30M|COINCIDENT|2021-03-16|AFTER|2021-03-20
e|RS|e8da815a-b53c-46f4-a546-e8553152719f|3|CPRFSTAT|Clinical Performance Status|IWG CHESON MDS 2006|[?]|kDa|cPR|1|ng/dL|PET/CT SCAN WITHOUT CONTRAST||||INDEPENDENT ASSESSOR|RATER 1|N|2|Visit_2|25|4|TREATMENT|2021-01-11|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-24|P1Y2M10DT2H30M|COINCIDENT|2021-02-20|COINCIDENT|2021-03-01
e|RS|e8da815a-b53c-46f4-a546-e8553152719f|4|NTERESP|Non-Target Enhancing Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|MPS U|iCPD|1|Ci|CORONARY ANGIOGRAPHY||||ADJUDICATOR|CLINICAL PATHOLOGIST|N|2|Visit_2|25|6|FOLLOW-UP|2021-01-11|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-24|P1Y2M10DT2H30M|UNKNOWN|2021-01-26|COINCIDENT|2021-01-29
e|RS|e8da815a-b53c-46f4-a546-e8553152719f|5|CPRFSTAT|Clinical Performance Status|RECIST 1.0|[?]|10^6 IU/mL|MRD RELAPSE|1|mmol2/L2|MAPH||||PARENT|RATER|Y|3|Visit_3|40|6|TREATMENT|2021-01-26|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-09|P1Y2M10DT2H30M|AFTER|2021-03-20|ONGOING|2021-03-23
e|RS|e8da815a-b53c-46f4-a546-e8553152719f|6|MRPHRESP|Morphologic Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|IU/mg|QUANTIFIABLE MRD POSITIVITY|1|uU/dL|TARGETED TRANSCRIPTOME SEQUENCING||||VENDOR|ADJUDICATOR 2|N|3|Visit_3|40|7|SCREENING|2021-01-26|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-09|P1Y2M10DT2H30M|BEFORE|2021-01-10|COINCIDENT|2021-03-01
e|RS|e8da815a-b53c-46f4-a546-e8553152719f|7|MRPHRESP|Morphologic Response|MRECIST BYRNE MESOTHELIOMA 2004|||WORSENED|1|mg/L FEU|TARGETED TRANSCRIPTOME SEQUENCING|||Y|FAMILY MEMBER|ADJUDICATOR 2|Y|4|Visit_4|65|2|SCREENING|2021-02-20|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-16|P1Y2M10DT2H30M|COINCIDENT|2020-12-24|AFTER|2021-02-17
e|RS|e8da815a-b53c-46f4-a546-e8553152719f|8|MNPTHIND|Minor Pathological Response Indicator|FAROOQUI SUPP CLL 2014|[?]|PIPE|cCR|1|10^9 organisms/g|PERIODIC ACID SCHIFF STAIN||Y||PROXY|ADJUDICATOR 2|N|4|Visit_4|65|7|WASHOUT|2021-02-20|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-16|P1Y2M10DT2H30M|BEFORE|2021-02-22|COINCIDENT|2021-03-21
e|RS|e8da815a-b53c-46f4-a546-e8553152719f|9|LIVRRESP|Liver Response|RECIST 1.0|[?]|mmol/min/kPa|MORPHOLOGIC LEUKEMIA-FREE STATE|1|ug/mL/h|HPLC-UV||||NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST|NA|5|Visit_5|90|6|TREATMENT|2021-03-17|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-22|P1Y2M10DT2H30M|UNKNOWN|2021-01-09|BEFORE|2021-02-11
e|RS|e8da815a-b53c-46f4-a546-e8553152719f|10|METSIND|Metastatic Indicator|DOHNER AML 2010|||CR|1|ks|PALPATION|||Y|INVESTIGATOR|ADJUDICATOR 1|U|5|Visit_5|90|6|TREATMENT|2021-03-17|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-22|P1Y2M10DT2H30M|COINCIDENT|2021-02-13|BEFORE|2021-03-25
e|RS|701d794b-07b4-4394-a2a4-d31a9f5b743a|1|MRDIND|Minimal Residual Disease Indicator|EUROPEAN LEUKEMIANET BACCARANI CML 2006|||PR WITH LYMPHOCYTOSIS|1|mJoule/cm2|CELL CYTOTOXICITY NEUTRALIZATION ASSAY|||Y|CLINICAL STUDY SPONSOR|ADJUDICATOR|N|1|Visit_1|10|6|FOLLOW-UP|2021-01-29|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-21|P1Y2M10DT2H30M|BEFORE|2021-03-19|BEFORE|2021-04-08
e|RS|701d794b-07b4-4394-a2a4-d31a9f5b743a|2|BESTRESP|Best Overall Response|MRANO VAN DEN BENT GLIOMA 2011|||INDETERMINATE RESPONSE|1|LENS|MRI WITHOUT CONTRAST||Y|Y|CHILD|RATER|U|1|Visit_1|10|3|WASHOUT|2021-01-29|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-21|P1Y2M10DT2H30M|COINCIDENT|2021-02-23|AFTER|2021-03-18
e|RS|701d794b-07b4-4394-a2a4-d31a9f5b743a|3|BONERESP|Bone Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|mg/dL|MAJOR PATHOLOGIC RESPONSE|1|umol|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION||||INDEPENDENT ASSESSOR|NEUROLOGIST 2|Y|2|Visit_2|25|4|WASHOUT|2021-02-13|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-15|P1Y2M10DT2H30M|COINCIDENT|2021-04-13|ONGOING|2021-04-14
e|RS|701d794b-07b4-4394-a2a4-d31a9f5b743a|4|MNPTHIND|Minor Pathological Response Indicator|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|nU/cL|COMPLETE MRD RESPONSE|1|kg/mol|PHOTOMETRIC CLOT DETECTION||||SIGNIFICANT OTHER|PATHOLOGIST 1|NA|2|Visit_2|25|3|TREATMENT|2021-02-13|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-15|P1Y2M10DT2H30M|BEFORE|2021-02-01|AFTER|2021-02-11
e|RS|701d794b-07b4-4394-a2a4-d31a9f5b743a|5|CPRFSTAT|Clinical Performance Status|JACINTO CERVICAL CANCER 2007|[?]|MAC50|MRD PERSISTENCE|1|PRESSOR UNITS|LC-FL||||FAMILY MEMBER|RADIOLOGIST|U|3|Visit_3|40|6|FOLLOW-UP|2021-02-28|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-07|P1Y2M10DT2H30M|UNKNOWN|2021-02-09|AFTER|2021-02-12
e|RS|701d794b-07b4-4394-a2a4-d31a9f5b743a|6|BONERESP|Bone Response|CHESON LYMPHOMA 2008|[?]|mL/kg/min|cCR|1|Farad|IMMUNOTURBIDIMETRY||||SPOUSE|PATHOLOGIST 1|NA|3|Visit_3|40|2|TREATMENT|2021-02-28|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-07|P1Y2M10DT2H30M|AFTER|2021-03-14|COINCIDENT|2021-04-18
e|RS|701d794b-07b4-4394-a2a4-d31a9f5b743a|7|METSIND|Metastatic Indicator|SACT|[?]|umol/L/h|CR|1|mg/kg/min|SCINTIGRAPHY|Y|||INVESTIGATOR|OPHTHALMOLOGIST|Y|4|Visit_4|65|4|FOLLOW-UP|2021-03-25|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-18|P1Y2M10DT2H30M|COINCIDENT|2021-03-31|ONGOING|2021-04-10
e|RS|701d794b-07b4-4394-a2a4-d31a9f5b743a|8|BONERESP|Bone Response|PETIT BREAST CANCER 2001|[?]|amu|CYTOGENETIC MINIMAL RESPONSE|1|U/kg/min|FLOW MICROSCOPY||||CAREGIVER|MICROSCOPIST 3|NA|4|Visit_4|65|6|TREATMENT|2021-03-25|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-18|P1Y2M10DT2H30M|UNKNOWN|2021-01-24|AFTER|2021-04-25
e|RS|701d794b-07b4-4394-a2a4-d31a9f5b743a|9|NEWLPROG|New Lesion Progression|RECICL|[?]|MnFI|MAJOR PATHOLOGIC RESPONSE|1|APPLICATION|LEAD CITRATE STAIN||Y||ADJUDICATION COMMITTEE|ADJUDICATOR|U|5|Visit_5|90|2|TREATMENT|2021-04-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-26|P1Y2M10DT2H30M|UNKNOWN|2021-03-13|BEFORE|2021-04-23
e|RS|701d794b-07b4-4394-a2a4-d31a9f5b743a|10|NTLWIND|Non-Target Lesion Worsening Indicator|MACDONALD GLIOMA 1990|[?]|dpm/mL|CHR|1|psec|CONTRAST ENHANCED PET SCAN||||PROXY|CARDIOLOGIST|NA|5|Visit_5|90|5|TREATMENT|2021-04-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-26|P1Y2M10DT2H30M|AFTER|2021-04-28|AFTER|2021-04-29
e|RS|45a9c2a7-3f0e-4bed-ac5b-e9ef5ba4fffd|1|SPLNRESP|Spleen Response|WOLCHOK SOLID TUMORS 2009|[?]|SFC/10^6 PBMC|SD|1|ug/L/h|KINETIC MICROPARTICLE IMMUNOASSAY||||FAMILY MEMBER|RATER|Y|1|Visit_1|10|5|WASHOUT|2020-12-25|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-15|P1Y2M10DT2H30M|UNKNOWN|2021-03-22|ONGOING|2021-03-24
e|RS|45a9c2a7-3f0e-4bed-ac5b-e9ef5ba4fffd|2|MNPTHIND|Minor Pathological Response Indicator|HAMAOKA BREAST CANCER 2010|[?]|m/sec2|SD|1|cmH2O/mL|INDIA INK STAIN||||CLINICAL RESEARCH COORDINATOR|ONCOLOGIST|Y|1|Visit_1|10|5|FOLLOW-UP|2020-12-25|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-15|P1Y2M10DT2H30M|BEFORE|2021-01-26|AFTER|2021-03-12
e|RS|45a9c2a7-3f0e-4bed-ac5b-e9ef5ba4fffd|3|TRGRESP|Target Response|CHOI GIST 2008|[?]|mg/kg/week|sCR|1|grain|MEDIASTINOSCOPY||||INVESTIGATOR|PATHOLOGIST 1|U|2|Visit_2|25|6|SCREENING|2021-01-09|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-29|P1Y2M10DT2H30M|COINCIDENT|2021-03-09|BEFORE|2021-03-14
e|RS|45a9c2a7-3f0e-4bed-ac5b-e9ef5ba4fffd|4|BONERESP|Bone Response|RECIST 1.1|[?]|GBq/mg|PSEUDOPROGRESSION|1|ukat/10^12 RBC|TARGETED GENOME SEQUENCING||Y||DOMESTIC PARTNER|DEVELOPMENTAL PSYCHOLOGIST|N|2|Visit_2|25|4|TREATMENT|2021-01-09|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-29|P1Y2M10DT2H30M|COINCIDENT|2021-02-19|AFTER|2021-03-12
e|RS|45a9c2a7-3f0e-4bed-ac5b-e9ef5ba4fffd|5|SPLNRESP|Spleen Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|IU|CA125 50% RESPONSE|1|% INHIBITION|CELL OF ORIGIN ASSAY|Y|Y||DOMESTIC PARTNER|DERMATOLOGIST|NA|3|Visit_3|40|2|FOLLOW-UP|2021-01-24|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-06|P1Y2M10DT2H30M|BEFORE|2021-03-09|AFTER|2021-03-11
e|RS|45a9c2a7-3f0e-4bed-ac5b-e9ef5ba4fffd|6|SFTSRESP|Soft Tissue Response|MACDONALD GLIOMA 1990|[?]|LOZENGE|COMPLETE MRD RESPONSE|1|K|COLORIMETRY||||CHILD|ONCOLOGIST|Y|3|Visit_3|40|2|WASHOUT|2021-01-24|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-06|P1Y2M10DT2H30M|BEFORE|2021-02-07|BEFORE|2021-02-15
e|RS|45a9c2a7-3f0e-4bed-ac5b-e9ef5ba4fffd|7|MOLRESP|Molecular Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|g/m2|MRD NEGATIVITY|1|PLUG|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION|Y|||FRIEND|RADIOLOGIST 1|U|4|Visit_4|65|6|FOLLOW-UP|2021-02-18|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-22|P1Y2M10DT2H30M|COINCIDENT|2021-03-24|COINCIDENT|2021-03-25
e|RS|45a9c2a7-3f0e-4bed-ac5b-e9ef5ba4fffd|8|METBRESP|Metabolic Response|KEAM BREAST CANCER 2013|[?]|cm2|PSEUDORESPONSE|1|kg/m2|THIN SMEAR|Y|||CLINICAL STUDY SPONSOR|OPTOMETRIST|U|4|Visit_4|65|7|SCREENING|2021-02-18|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-22|P1Y2M10DT2H30M|COINCIDENT|2021-02-08|COINCIDENT|2021-02-16
e|RS|45a9c2a7-3f0e-4bed-ac5b-e9ef5ba4fffd|9|BMIVLIND|Bone Marrow Involvement Indicator|BLAZER COLORECTAL CANCER 2008|||pCR|1|10^6 DNA copies/mL|DNA MICROARRAY|||Y|STUDY SUBJECT|RADIOLOGIST|Y|5|Visit_5|90|1|FOLLOW-UP|2021-03-15|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-25|P1Y2M10DT2H30M|BEFORE|2021-02-12|AFTER|2021-03-11
e|RS|45a9c2a7-3f0e-4bed-ac5b-e9ef5ba4fffd|10|HEMARESP|Hematologic Response|RECIST 1.1|[?]|mEq/dL|SD-CT|1|WAFER|FLUORIMETRY|Y|||NON-HEALTH CARE PROFESSIONAL|OPTOMETRIST|NA|5|Visit_5|90|1|SCREENING|2021-03-15|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-25|P1Y2M10DT2H30M|COINCIDENT|2021-03-24|BEFORE|2021-03-25
e|RS|060a73b7-19d8-4a73-9976-6bbc8a83a6d5|1|DRCRIND|Disease Recurrence Indicator|HARTMAN PANCREATIC CANCER 2012|||MRD NEGATIVITY|1|10^4/hpf|CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|||Y|STUDY SUBJECT|OPHTHALMOLOGIST|U|1|Visit_1|10|4|WASHOUT|2020-08-10|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-08|P1Y2M10DT2H30M|COINCIDENT|2020-08-11|AFTER|2020-09-20
e|RS|060a73b7-19d8-4a73-9976-6bbc8a83a6d5|2|METBRESP|Metabolic Response|MONTSERRAT CLL 1989|[?]|cL|STABLE|1|Bq/uL|TURBIDIMETRY||Y||FRIEND|PATHOLOGIST|U|1|Visit_1|10|3|TREATMENT|2020-08-10|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-08|P1Y2M10DT2H30M|COINCIDENT|2020-08-24|COINCIDENT|2020-09-22
e|RS|060a73b7-19d8-4a73-9976-6bbc8a83a6d5|3|MRDIND|Minimal Residual Disease Indicator|TSUKASAKI LEUKEMIA LYMPHOMA 2009|||PD/RELAPSE AFTER HI|1|10^4 CFU|ZIEHL NEELSEN ACID FAST STAIN||Y|Y|CAREGIVER|OTOLARYNGOLOGIST|U|2|Visit_2|25|4|TREATMENT|2020-08-25|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-10|P1Y2M10DT2H30M|UNKNOWN|2020-09-28|BEFORE|2020-10-02
e|RS|060a73b7-19d8-4a73-9976-6bbc8a83a6d5|4|NEWLPROG|New Lesion Progression|MONTSERRAT CLL 1989|[?]|PIXEL|IMPROVED|1|ug/m2/min|BIOPSY||||CAREGIVER|MICROSCOPIST 2|N|2|Visit_2|25|7|TREATMENT|2020-08-25|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-10|P1Y2M10DT2H30M|AFTER|2020-09-17|BEFORE|2020-10-18
e|RS|060a73b7-19d8-4a73-9976-6bbc8a83a6d5|5|NTERESP|Non-Target Enhancing Response|MASS|||NON-QUANTIFIABLE MRD POSITIVITY|1|mL/s|HIGH RESOLUTION CT||Y|Y|HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|NA|3|Visit_3|40|7|FOLLOW-UP|2020-09-09|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-30|P1Y2M10DT2H30M|BEFORE|2020-09-06|ONGOING|2020-11-07
e|RS|060a73b7-19d8-4a73-9976-6bbc8a83a6d5|6|ANATRESP|Anatomic Response|JACINTO CERVICAL CANCER 2007|[?]|MET|NED|1|10^3 organisms/mL|TRANSESOPHAGEAL ECHOCARDIOGRAPHY||||INTERVIEWER|PATHOLOGIST|NA|3|Visit_3|40|6|SCREENING|2020-09-09|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-30|P1Y2M10DT2H30M|UNKNOWN|2020-08-12|BEFORE|2020-08-24
e|RS|060a73b7-19d8-4a73-9976-6bbc8a83a6d5|7|SFTSRESP|Soft Tissue Response|AJCC V7|||EQUIVOCAL|1|g/mol|ATOMIC ABSORPTION SPECTROMETRY|||Y|INVESTIGATOR|READER|U|4|Visit_4|65|5|WASHOUT|2020-10-04|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-12|P1Y2M10DT2H30M|COINCIDENT|2020-09-29|BEFORE|2020-10-18
e|RS|060a73b7-19d8-4a73-9976-6bbc8a83a6d5|8|MRDIND|Minimal Residual Disease Indicator|GCIG RUSTIN OVARIAN CANCER 2011|[?]|APL U/mL|ABSENT MORPHOLOGIC RESPONSE|1|uL/kg/day|IMMUNODIFFUSION|Y|||SPOUSE|READER|NA|4|Visit_4|65|5|TREATMENT|2020-10-04|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-12|P1Y2M10DT2H30M|BEFORE|2020-08-19|COINCIDENT|2020-09-01
e|RS|060a73b7-19d8-4a73-9976-6bbc8a83a6d5|9|METBRESP|Metabolic Response|PALUMBO MULTIPLE MYELOMA 2009|||iUPD|1|MPS U|ENZYMATIC COLORIMETRY|Y||Y|STUDY SUBJECT|ADJUDICATOR 2|Y|5|Visit_5|90|3|SCREENING|2020-10-29|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-12|P1Y2M10DT2H30M|AFTER|2020-10-31|ONGOING|2020-11-06
e|RS|060a73b7-19d8-4a73-9976-6bbc8a83a6d5|10|TRGRESP|Target Response|SACT|[?]|GBq/g|PD FROM PR|1|P|REVERSE TRANSCRIPTASE PCR||||CLINICAL RESEARCH COORDINATOR|RADIOLOGIST|Y|5|Visit_5|90|7|FOLLOW-UP|2020-10-29|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-12|P1Y2M10DT2H30M|COINCIDENT|2020-09-03|ONGOING|2020-09-13
e|RS|fe8b11f0-70b9-4c5e-8075-6cdb4dd95c5a|1|BESTRESP|Best Overall Response|WHO BREAST CANCER 2006|[?]|eq|CYTOGENETIC NO RESPONSE|1|Log10 ELISA unit|DIFFUSION WEIGHTED MRI|Y|||VENDOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|1|Visit_1|10|4|TREATMENT|2021-01-02|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-07|P1Y2M10DT2H30M|BEFORE|2021-02-16|AFTER|2021-02-21
e|RS|fe8b11f0-70b9-4c5e-8075-6cdb4dd95c5a|2|MRDRESP|Minimal Residual Disease Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|mg/kg/week|OPTIMAL MORPHOLOGIC RESPONSE|1|ECL unit|IMPEDANCE CONDUCTIVITY||||SIGNIFICANT OTHER|NEUROLOGIST 1|Y|1|Visit_1|10|6|WASHOUT|2021-01-02|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-07|P1Y2M10DT2H30M|BEFORE|2021-02-22|COINCIDENT|2021-03-01
e|RS|fe8b11f0-70b9-4c5e-8075-6cdb4dd95c5a|3|MNPTHIND|Minor Pathological Response Indicator|MACDONALD GLIOMA 1990|[?]|mL/100g/min|nPR|1|RATIO|NEPHELOMETRY||||PROXY|CARDIOLOGIST|Y|2|Visit_2|25|7|TREATMENT|2021-01-17|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-23|P1Y2M10DT2H30M|UNKNOWN|2021-01-06|BEFORE|2021-01-13
e|RS|fe8b11f0-70b9-4c5e-8075-6cdb4dd95c5a|4|TMRESP|Tumor Marker Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|ppm|VGPR|1|TUBE|POPULATION SEQUENCING|Y|||PARENT|READER|NA|2|Visit_2|25|1|TREATMENT|2021-01-17|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-23|P1Y2M10DT2H30M|BEFORE|2021-03-25|COINCIDENT|2021-04-01
e|RS|fe8b11f0-70b9-4c5e-8075-6cdb4dd95c5a|5|METBRESP|Metabolic Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|||NOT ALL EVALUATED|1|vp/dose|BRDU CELLULAR PROLIFERATION ASSAY|Y||Y|CLINICAL STUDY SPONSOR|MICROSCOPIST 3|Y|3|Visit_3|40|1|TREATMENT|2021-02-01|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-14|P1Y2M10DT2H30M|COINCIDENT|2021-02-21|COINCIDENT|2021-03-05
e|RS|fe8b11f0-70b9-4c5e-8075-6cdb4dd95c5a|6|CPRFSTAT|Clinical Performance Status|PRINCE TCELL LYMPHOMA 2010|[?]|/wk|SD|1|pt_us|EIA|Y|||PARENT|NEUROLOGIST|U|3|Visit_3|40|5|TREATMENT|2021-02-01|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-14|P1Y2M10DT2H30M|UNKNOWN|2021-02-20|BEFORE|2021-03-23
e|RS|fe8b11f0-70b9-4c5e-8075-6cdb4dd95c5a|7|ANATRESP|Anatomic Response|IRANO 2015|||PD FROM PR|1|dram|FORCED OSCILLATION TECHNIQUE|||Y|CAREGIVER|DEVELOPMENTAL PSYCHOLOGIST|U|4|Visit_4|65|1|FOLLOW-UP|2021-02-26|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-18|P1Y2M10DT2H30M|BEFORE|2021-01-17|AFTER|2021-03-10
e|RS|fe8b11f0-70b9-4c5e-8075-6cdb4dd95c5a|8|CYTORESP|Cytogenetic Response|CHOLLET BREAST CANCER 2002|[?]|ppb|CR|1|/mm|MICROSCOPY|Y|||SIBLING|INTERNIST|U|4|Visit_4|65|5|WASHOUT|2021-02-26|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-18|P1Y2M10DT2H30M|COINCIDENT|2021-03-21|BEFORE|2021-03-29
e|RS|fe8b11f0-70b9-4c5e-8075-6cdb4dd95c5a|9|MRDRESP|Minimal Residual Disease Response|GUPPY OVARIAN CANCER 2002|[?]|Log10 ELISA unit|CR-CT|1|cm/s|TOLUIDINE BLUE STAIN||||NON-HEALTH CARE PROFESSIONAL|READER 1|NA|5|Visit_5|90|2|WASHOUT|2021-03-23|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-02|P1Y2M10DT2H30M|AFTER|2021-02-09|ONGOING|2021-03-15
e|RS|fe8b11f0-70b9-4c5e-8075-6cdb4dd95c5a|10|BESTRESP|Best Overall Response|WHO BREAST CANCER 2006|||CA125 75% RESPONSE|1|mg/mL/min|GRAM STAIN|||Y|INDEPENDENT ASSESSOR|PATHOLOGIST 2|N|5|Visit_5|90|1|FOLLOW-UP|2021-03-23|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-02|P1Y2M10DT2H30M|COINCIDENT|2021-03-07|AFTER|2021-03-12
e|RS|bb2487c3-cc05-48f8-9031-0e433c07e3d6|1|NEWLWIND|New Lesion Worsening Indicator|KUKER LYMPHOMA 2005|[?]|Siemens|TREATMENT FAILURE|1|titer|INTERRUPTER TECHNIQUE||Y||HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|Y|1|Visit_1|10|3|WASHOUT|2020-11-29|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-29|P1Y2M10DT2H30M|AFTER|2021-02-21|COINCIDENT|2021-02-24
e|RS|bb2487c3-cc05-48f8-9031-0e433c07e3d6|2|MRDRESP|Minimal Residual Disease Response|CHESON CLL 2012|[?]|Ci/g|NON-CR/NON-PD|1|fmol/g|LUXOL FAST BLUE AND CRESYL VIOLET STAIN|Y|||PARENT|OTOLARYNGOLOGIST|U|1|Visit_1|10|2|WASHOUT|2020-11-29|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-29|P1Y2M10DT2H30M|COINCIDENT|2020-12-14|AFTER|2021-01-04
e|RS|bb2487c3-cc05-48f8-9031-0e433c07e3d6|3|NEWLIND|New Lesion Indicator|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|lm|MOLECULAR MAJOR RESPONSE|1|Farad|SURFACE PLASMON RESONANCE||||INVESTIGATOR|PATHOLOGIST 2|Y|2|Visit_2|25|6|TREATMENT|2020-12-14|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-02|P1Y2M10DT2H30M|COINCIDENT|2020-12-30|BEFORE|2021-02-13
e|RS|bb2487c3-cc05-48f8-9031-0e433c07e3d6|4|METBRESP|Metabolic Response|AJCC V8|[?]|ug/m2/h|NED|1|mkat|IN SITU HYBRIDIZATION||Y||CHILD|ONCOLOGIST|NA|2|Visit_2|25|6|WASHOUT|2020-12-14|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-02|P1Y2M10DT2H30M|AFTER|2020-12-30|BEFORE|2021-01-06
e|RS|bb2487c3-cc05-48f8-9031-0e433c07e3d6|5|NTERESP|Non-Target Enhancing Response|IWG CHESON MDS 2000|[?]|g/cage/day|PD-CT|1|10^5/L|TRICHROME STAIN|Y|||STUDY SUBJECT|OTOLARYNGOLOGIST|NA|3|Visit_3|40|2|TREATMENT|2020-12-29|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-11|P1Y2M10DT2H30M|BEFORE|2020-12-09|COINCIDENT|2020-12-12
e|RS|bb2487c3-cc05-48f8-9031-0e433c07e3d6|6|MJPTHIND|Major Pathological Response Indicator|PALUMBO MULTIPLE MYELOMA 2009|||IMMUNOPHENOTYPIC CR|1|mV*min|PHYSICAL EXAMINATION|||Y|CLINICAL STUDY SPONSOR|MICROSCOPIST|NA|3|Visit_3|40|6|TREATMENT|2020-12-29|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-11|P1Y2M10DT2H30M|AFTER|2021-01-14|BEFORE|2021-01-24
e|RS|bb2487c3-cc05-48f8-9031-0e433c07e3d6|7|MNPTHIND|Minor Pathological Response Indicator|PCWG BUBLEY PROSTATE CANCER 1999|[?]|/10^4|PDu|1|mL/cage/wk|SLIT LAMP PHOTOGRAPHY||||CLINICAL RESEARCH ASSOCIATE|PHYSIOTHERAPIST|N|4|Visit_4|65|1|TREATMENT|2021-01-23|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-26|P1Y2M10DT2H30M|COINCIDENT|2021-02-12|COINCIDENT|2021-02-15
e|RS|bb2487c3-cc05-48f8-9031-0e433c07e3d6|8|SYMPTDTR|Symptomatic Deterioration|PCWG BUBLEY PROSTATE CANCER 1999|[?]|BOLUS|QUANTIFIABLE MRD POSITIVITY|1|anti-Xa IU|COMPUTERIZED CORNEAL TOPOGRAPHY||||GUARDIAN|CLINICAL PATHOLOGIST|U|4|Visit_4|65|2|TREATMENT|2021-01-23|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-26|P1Y2M10DT2H30M|UNKNOWN|2021-02-05|COINCIDENT|2021-02-25
e|RS|bb2487c3-cc05-48f8-9031-0e433c07e3d6|9|CLINRESP|Clinical Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|ngEq/L|CA125 75% RESPONSE|1|min/day|KINYOUN STAIN||||CHILD|DERMATOLOGIST|U|5|Visit_5|90|7|TREATMENT|2021-02-17|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-18|P1Y2M10DT2H30M|UNKNOWN|2021-02-21|ONGOING|2021-02-24
e|RS|bb2487c3-cc05-48f8-9031-0e433c07e3d6|10|METSIND|Metastatic Indicator|PALUMBO MULTIPLE MYELOMA 2009|[?]|uOsm|IMPROVED|1|10^9 CFU/g|AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT|Y|||PROXY|PHYSIOTHERAPIST|Y|5|Visit_5|90|1|TREATMENT|2021-02-17|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-18|P1Y2M10DT2H30M|COINCIDENT|2021-02-26|AFTER|2021-02-27
e|RS|2661da18-b539-49d8-ac80-9da03c127d21|1|NEWLWIND|New Lesion Worsening Indicator|CHESON LYMPHOMA 2008|[?]|TCID 50/dose|NOT ALL EVALUATED|1|DAYS|PALM METHOD||||ADJUDICATION COMMITTEE|ONCOLOGIST|U|1|Visit_1|10|5|TREATMENT|2020-07-26|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-08|P1Y2M10DT2H30M|BEFORE|2020-08-23|AFTER|2020-10-18
e|RS|2661da18-b539-49d8-ac80-9da03c127d21|2|BONERESP|Bone Response|EASL BRUIX LIVER CANCER 2001|[?]|Bq/g|CA125 75% RESPONSE|1|/2500 WBC|FORCED OSCILLATION TECHNIQUE||Y||SIGNIFICANT OTHER|ADJUDICATOR 1|NA|1|Visit_1|10|6|TREATMENT|2020-07-26|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-08|P1Y2M10DT2H30M|AFTER|2020-10-09|AFTER|2020-10-12
e|RS|2661da18-b539-49d8-ac80-9da03c127d21|3|DRCRIND|Disease Recurrence Indicator|iRECIST|[?]|10^6/Ejaculate U|CYTOGENETIC MINOR RESPONSE|1|mg/dose|LIQUID SCINTILLATION COUNTING||||STUDY SUBJECT|OTOLARYNGOLOGIST|U|2|Visit_2|25|7|WASHOUT|2020-08-10|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-14|P1Y2M10DT2H30M|AFTER|2020-08-31|AFTER|2020-09-15
e|RS|2661da18-b539-49d8-ac80-9da03c127d21|4|LIVRRESP|Liver Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|BAR|PMR|1|h/wk|KNEMOMETRY|Y|||FAMILY MEMBER|ONCOLOGIST 2|N|2|Visit_2|25|1|FOLLOW-UP|2020-08-10|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-14|P1Y2M10DT2H30M|COINCIDENT|2020-09-20|ONGOING|2020-10-05
e|RS|2661da18-b539-49d8-ac80-9da03c127d21|5|DRCRIND|Disease Recurrence Indicator|PCWG SCHER PROSTATE CANCER 2016|||CHR|1|10^9 CFU/g|DROPLET DIGITAL PCR||Y|Y|CHILD|CARDIOLOGIST|Y|3|Visit_3|40|1|WASHOUT|2020-08-25|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-12|P1Y2M10DT2H30M|AFTER|2020-07-20|COINCIDENT|2020-10-16
e|RS|2661da18-b539-49d8-ac80-9da03c127d21|6|MOLRESP|Molecular Response|SCHER PROSTATE CANCER 2011|[?]|days/wk|NON-iCR/NON-iUPD|1|Absorbance U/min|CORONARY ANGIOGRAPHY||||DOMESTIC PARTNER|RATER|Y|3|Visit_3|40|4|TREATMENT|2020-08-25|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-12|P1Y2M10DT2H30M|COINCIDENT|2020-10-16|COINCIDENT|2020-10-19
e|RS|2661da18-b539-49d8-ac80-9da03c127d21|7|CPRFSTAT|Clinical Performance Status|CHOLLET BREAST CANCER 2002|[?]|%/min|CMR|1|Ci/kg|SINGLE-MOLECULE ARRAY|Y|||DOMESTIC PARTNER|UROLOGIST|NA|4|Visit_4|65|1|SCREENING|2020-09-19|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-20|P1Y2M10DT2H30M|COINCIDENT|2020-09-08|ONGOING|2020-09-20
e|RS|2661da18-b539-49d8-ac80-9da03c127d21|8|MRDIND|Minimal Residual Disease Indicator|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|||CMR|1|breaths/min|WEBER GREEN STAIN||Y|Y|HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|NA|4|Visit_4|65|2|TREATMENT|2020-09-19|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-20|P1Y2M10DT2H30M|BEFORE|2020-10-09|COINCIDENT|2020-10-13
e|RS|2661da18-b539-49d8-ac80-9da03c127d21|9|CLINRESP|Clinical Response|CHOLLET BREAST CANCER 2002|||CYTOGENETIC MINOR RESPONSE|1|min*mg/mL|LIGHT SCATTERING SPECTROSCOPY|||Y|CLINICAL STUDY SPONSOR|MICROSCOPIST 1|U|5|Visit_5|90|7|SCREENING|2020-10-14|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-19|P1Y2M10DT2H30M|AFTER|2020-09-11|ONGOING|2020-10-09
e|RS|2661da18-b539-49d8-ac80-9da03c127d21|10|NEWLPROG|New Lesion Progression|NCCN ALL MRD 2014|||PMR|1|PA|ANALYTICAL ULTRACENTRIFUGATION|||Y|PARENT|READER 3|U|5|Visit_5|90|6|SCREENING|2020-10-14|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-19|P1Y2M10DT2H30M|COINCIDENT|2020-07-19|ONGOING|2020-10-02
e|RS|f1835786-c567-4235-9bd1-f7ffcec12741|1|SPLNRESP|Spleen Response|RANO|[?]|U/m2|COMPLETE MRD RESPONSE|1|BE/mL|SICKLE CELL SOLUBILITY TEST||||NON-HEALTH CARE PROFESSIONAL|RATER|U|1|Visit_1|10|5|TREATMENT|2020-08-06|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-06|P1Y2M10DT2H30M|COINCIDENT|2020-11-03|ONGOING|2020-11-04
e|RS|f1835786-c567-4235-9bd1-f7ffcec12741|2|HEMARESP|Hematologic Response|MACDONALD GLIOMA 1990|[?]|kPa/L/sec|PMD|1|PIXEL|PET/CT SCAN||||SIBLING|RATER 2|N|1|Visit_1|10|3|WASHOUT|2020-08-06|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-06|P1Y2M10DT2H30M|UNKNOWN|2020-10-17|ONGOING|2020-10-24
e|RS|f1835786-c567-4235-9bd1-f7ffcec12741|3|LIVRRESP|Liver Response|FAROOQUI SUPP CLL 2014|[?]|g/cage/wk|NR|1|Ejaculate U|QUANTITATIVE CORONARY ANGIOGRAPHY|Y|||NON-HEALTH CARE PROFESSIONAL|INTERNIST|N|2|Visit_2|25|1|TREATMENT|2020-08-21|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-01|P1Y2M10DT2H30M|COINCIDENT|2020-09-11|COINCIDENT|2020-10-15
e|RS|f1835786-c567-4235-9bd1-f7ffcec12741|4|MJPTHIND|Major Pathological Response Indicator|PCWG BUBLEY PROSTATE CANCER 1999|[?]|hPa|HI-N|1|cm/s|INTERRUPTER TECHNIQUE|Y|Y||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 1|Y|2|Visit_2|25|6|TREATMENT|2020-08-21|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-01|P1Y2M10DT2H30M|UNKNOWN|2020-10-04|BEFORE|2020-10-22
e|RS|f1835786-c567-4235-9bd1-f7ffcec12741|5|STRUSTAT|Steroid Use Status|PERCIST|[?]|mAmp|PD|1|oz|INTERRUPTER TECHNIQUE||||NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|U|3|Visit_3|40|5|TREATMENT|2020-09-05|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-08|P1Y2M10DT2H30M|AFTER|2020-10-24|ONGOING|2020-11-01
e|RS|f1835786-c567-4235-9bd1-f7ffcec12741|6|MOLRESP|Molecular Response|KEAM BREAST CANCER 2013|[?]|mol/mg|PR|1|/MBP|OPTICAL DENSITY MEASUREMENT||||INDEPENDENT ASSESSOR|PATHOLOGIST|Y|3|Visit_3|40|7|TREATMENT|2020-09-05|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-08|P1Y2M10DT2H30M|AFTER|2020-09-28|AFTER|2020-10-02
e|RS|f1835786-c567-4235-9bd1-f7ffcec12741|7|NTNERESP|Non-Target Non-Enhancing Response|WOLCHOK SOLID TUMORS 2009|[?]|ms2|CHR|1|uL/dose|LASER CAPTURE MICRODISSECTION||||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|NA|4|Visit_4|65|4|WASHOUT|2020-09-30|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-30|P1Y2M10DT2H30M|BEFORE|2020-10-26|ONGOING|2020-11-01
e|RS|f1835786-c567-4235-9bd1-f7ffcec12741|8|OVRLRESP|Overall Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|mm3/mm2/year|CA125 50% RESPONSE|1|10^3 organisms|RADIAL IMMUNODIFFUSION||||ADJUDICATION COMMITTEE|DERMATOLOGIST|U|4|Visit_4|65|7|TREATMENT|2020-09-30|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-30|P1Y2M10DT2H30M|COINCIDENT|2020-10-24|BEFORE|2020-11-03
e|RS|f1835786-c567-4235-9bd1-f7ffcec12741|9|NEWLPROG|New Lesion Progression|MRECIST BYRNE MESOTHELIOMA 2004|[?]|MPS U|CYTOGENETIC MINIMAL RESPONSE|1|log EID 50/dose|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN||Y||PROXY|ADJUDICATOR 3|U|5|Visit_5|90|6|FOLLOW-UP|2020-10-25|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-01|P1Y2M10DT2H30M|UNKNOWN|2020-08-24|ONGOING|2020-09-28
e|RS|f1835786-c567-4235-9bd1-f7ffcec12741|10|BESTRESP|Best Overall Response|IRANO 2015|||PD|1|10^7 TCID 50/dose|AUDIOMETRY|||Y|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST|Y|5|Visit_5|90|4|FOLLOW-UP|2020-10-25|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-01|P1Y2M10DT2H30M|BEFORE|2020-10-08|AFTER|2020-10-13
e|RS|019eb415-1da3-40fa-b4ba-b1f381ec3cac|1|TMRESP|Tumor Marker Response|RECIST 1.1|[?]|EVENTS|NON-iCR/NON-iUPD|1|pmol|TRICHROME STAIN||||DOMESTIC PARTNER|NEUROLOGIST 2|N|1|Visit_1|10|7|FOLLOW-UP|2020-07-10|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-05|P1Y2M10DT2H30M|COINCIDENT|2020-08-09|ONGOING|2020-10-03
e|RS|019eb415-1da3-40fa-b4ba-b1f381ec3cac|2|RDIORESP|Radiologic Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|KALLIKREIN INHIBITOR UNIT|CYTOGENETIC CR|1|SQU/mL|TOLUIDINE BLUE STAIN||||CLINICAL RESEARCH COORDINATOR|OPTOMETRIST|N|1|Visit_1|10|4|WASHOUT|2020-07-10|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-05|P1Y2M10DT2H30M|COINCIDENT|2020-08-05|AFTER|2020-09-14
e|RS|019eb415-1da3-40fa-b4ba-b1f381ec3cac|3|NTLWIND|Non-Target Lesion Worsening Indicator|MRANO VAN DEN BENT GLIOMA 2011|[?]|U/10^12 RBC|MINOR PATHOLOGIC RESPONSE|1|/4.0 mL|TWO-COLOR MICROARRAY||||VENDOR|ADJUDICATOR|N|2|Visit_2|25|7|FOLLOW-UP|2020-07-25|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-20|P1Y2M10DT2H30M|COINCIDENT|2020-08-21|COINCIDENT|2020-10-06
e|RS|019eb415-1da3-40fa-b4ba-b1f381ec3cac|4|CLINRESP|Clinical Response|PCWG SCHER PROSTATE CANCER 2016|[?]|cd/m2|PSA PROGRESSION|1|mL/cm H2O|INDIRECT IMMUNOFLUORESCENCE||||SIGNIFICANT OTHER|RATER 2|U|2|Visit_2|25|5|WASHOUT|2020-07-25|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-20|P1Y2M10DT2H30M|BEFORE|2020-07-18|ONGOING|2020-07-19
e|RS|019eb415-1da3-40fa-b4ba-b1f381ec3cac|5|BMIVLIND|Bone Marrow Involvement Indicator|MASS|||PD|1|CAPSULE|WHOLE EXOME SEQUENCING|||Y|PARENT|RATER|Y|3|Visit_3|40|3|TREATMENT|2020-08-09|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-06|P1Y2M10DT2H30M|UNKNOWN|2020-08-05|COINCIDENT|2020-08-18
e|RS|019eb415-1da3-40fa-b4ba-b1f381ec3cac|6|CPRFSTAT|Clinical Performance Status|NCIWG CHESON CLL 1996|[?]|/sec|PSEUDOPROGRESSION|1|10^6 organisms/mL|DIGITAL PCR ARRAY||||PARENT|PHYSIOTHERAPIST|Y|3|Visit_3|40|3|FOLLOW-UP|2020-08-09|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-06|P1Y2M10DT2H30M|BEFORE|2020-07-30|BEFORE|2020-09-07
e|RS|019eb415-1da3-40fa-b4ba-b1f381ec3cac|7|RDIORESP|Radiologic Response|CHESON LYMPHOMA 2008|||MINOR PATHOLOGIC RESPONSE|1|nCi|DNA MICROARRAY||Y|Y|SIBLING|ONCOLOGIST 2|U|4|Visit_4|65|6|FOLLOW-UP|2020-09-03|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-06|P1Y2M10DT2H30M|AFTER|2020-08-19|BEFORE|2020-08-20
e|RS|019eb415-1da3-40fa-b4ba-b1f381ec3cac|8|MRDIND|Minimal Residual Disease Indicator|UNSPECIFIED|[?]|umol/L|PMR|1|mg/min|WHOLE EXOME SEQUENCING||||FAMILY MEMBER|READER|NA|4|Visit_4|65|1|WASHOUT|2020-09-03|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-06|P1Y2M10DT2H30M|AFTER|2020-09-13|AFTER|2020-09-22
e|RS|019eb415-1da3-40fa-b4ba-b1f381ec3cac|9|METBRESP|Metabolic Response|FAROOQUI SUPP CLL 2014|[?]|uV|PR-CT|1|LOZENGE|RYAN BLUE STAIN|Y|Y||CHILD|OPTOMETRIST|NA|5|Visit_5|90|3|WASHOUT|2020-09-28|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-26|P1Y2M10DT2H30M|COINCIDENT|2020-07-15|ONGOING|2020-07-26
e|RS|019eb415-1da3-40fa-b4ba-b1f381ec3cac|10|ANATRESP|Anatomic Response|SACT|[?]|log10 CFU/mL|HI-E|1|cg|FORCED OSCILLATION TECHNIQUE||||CHILD|DERMATOLOGIST|N|5|Visit_5|90|2|TREATMENT|2020-09-28|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-26|P1Y2M10DT2H30M|BEFORE|2020-07-02|COINCIDENT|2020-08-03
e|RS|2506c6e2-018f-4300-b3b5-44ff8d6e13df|1|MRDRESP|Minimal Residual Disease Response|RAJKUMAR MYELOMA 2011|[?]|km|cPR|1|/min|FLOW MICROSCOPY||||GUARDIAN|READER 3|N|1|Visit_1|10|3|SCREENING|2020-07-23|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-01|P1Y2M10DT2H30M|UNKNOWN|2020-09-23|COINCIDENT|2020-09-27
e|RS|2506c6e2-018f-4300-b3b5-44ff8d6e13df|2|CLINRESP|Clinical Response|GUILHOT CML 2007|[?]|Gy/min|PR-CT|1|V|FLUORESCENT ENZYME IMMUNOASSAY||||PROXY|PEDIATRIC NEUROLOGIST|N|1|Visit_1|10|3|FOLLOW-UP|2020-07-23|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-01|P1Y2M10DT2H30M|AFTER|2020-09-22|BEFORE|2020-10-03
e|RS|2506c6e2-018f-4300-b3b5-44ff8d6e13df|3|NTLWIND|Non-Target Lesion Worsening Indicator|CHESON CLL 2012|[?]|mg|RELAPSED DISEASE|1|10^3/L|CALIPER MEASUREMENT METHOD||Y||SIGNIFICANT OTHER|RADIOLOGIST 1|Y|2|Visit_2|25|7|TREATMENT|2020-08-07|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-30|P1Y2M10DT2H30M|BEFORE|2020-09-13|ONGOING|2020-09-30
e|RS|2506c6e2-018f-4300-b3b5-44ff8d6e13df|4|ANATRESP|Anatomic Response|KEAM BREAST CANCER 2013|||CA125 50% RESPONSE|1|ohm|PHASE CONTRAST MICROSCOPY|Y|Y|Y|ADJUDICATOR|ONCOLOGIST 1|NA|2|Visit_2|25|4|TREATMENT|2020-08-07|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-30|P1Y2M10DT2H30M|UNKNOWN|2020-08-27|COINCIDENT|2020-08-28
e|RS|2506c6e2-018f-4300-b3b5-44ff8d6e13df|5|ANATRESP|Anatomic Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|10^4/hpf|NON-QUANTIFIABLE MRD POSITIVITY|1|PHERESIS UNIT|SPECT SCAN||||NON-HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|Y|3|Visit_3|40|1|FOLLOW-UP|2020-08-22|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-10|P1Y2M10DT2H30M|BEFORE|2020-10-20|AFTER|2020-10-21
e|RS|2506c6e2-018f-4300-b3b5-44ff8d6e13df|6|MOLRESP|Molecular Response|PCWG SCHER PROSTATE CANCER 2016|[?]|umol/dL|PD FROM PR|1|mg/g/h|CHROMOGENIC ASSAY|Y|Y||HEALTH CARE PROFESSIONAL|RADIOLOGIST|Y|3|Visit_3|40|5|TREATMENT|2020-08-22|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-10|P1Y2M10DT2H30M|AFTER|2020-09-24|ONGOING|2020-09-25
e|RS|2506c6e2-018f-4300-b3b5-44ff8d6e13df|7|NEWLPROG|New Lesion Progression|SHINDOH COLORECTAL CANCER 2013|||NON-QUANTIFIABLE MRD POSITIVITY|1|Ci/L|PYROSEQUENCING||Y|Y|PROXY|RATER|NA|4|Visit_4|65|7|TREATMENT|2020-09-16|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-12|P1Y2M10DT2H30M|AFTER|2020-09-24|COINCIDENT|2020-10-02
e|RS|2506c6e2-018f-4300-b3b5-44ff8d6e13df|8|MJPTHIND|Major Pathological Response Indicator|BRUGGEMANN MRD 2010|[?]|mg/m2|NON-PD|1|NFIU|PERIODIC ACID SCHIFF STAIN||||SIBLING|OTOLARYNGOLOGIST|N|4|Visit_4|65|5|TREATMENT|2020-09-16|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-12|P1Y2M10DT2H30M|BEFORE|2020-07-30|BEFORE|2020-08-25
e|RS|2506c6e2-018f-4300-b3b5-44ff8d6e13df|9|NTRGRESP|Non-target Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|PIXELS/cm|PD|1|uL/dose|CELL OF ORIGIN ASSAY||||CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL PSYCHOLOGIST|Y|5|Visit_5|90|7|FOLLOW-UP|2020-10-11|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-04|P1Y2M10DT2H30M|UNKNOWN|2020-10-03|BEFORE|2020-10-09
e|RS|2506c6e2-018f-4300-b3b5-44ff8d6e13df|10|CYTORESP|Cytogenetic Response|PRINCE TCELL LYMPHOMA 2010|[?]|mL/dL|CMR|1|QUANTITY SUFFICIENT|PLAQUE REDUCTION NEUTRALIZATION ASSAY||||CAREGIVER|RATER 1|U|5|Visit_5|90|3|FOLLOW-UP|2020-10-11|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-04|P1Y2M10DT2H30M|BEFORE|2020-09-21|COINCIDENT|2020-10-06
e|RS|65c439f8-9658-4ac5-9eae-0837182a90fd|1|DRCRIND|Disease Recurrence Indicator|BLAZER COLORECTAL CANCER 2008|[?]|uL|CA125 50% RESPONSE|1|/LSQN|ICP-MS||Y||INTERVIEWER|RATER 1|Y|1|Visit_1|10|5|SCREENING|2020-06-04|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-26|P1Y2M10DT2H30M|BEFORE|2020-08-11|BEFORE|2020-08-26
e|RS|65c439f8-9658-4ac5-9eae-0837182a90fd|2|SFTSRESP|Soft Tissue Response|SCHER PROSTATE CANCER 2011|[?]|IU|MOLECULAR CR|1|g/cage/day|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION||Y||INDEPENDENT ASSESSOR|INTERNIST|Y|1|Visit_1|10|1|FOLLOW-UP|2020-06-04|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-26|P1Y2M10DT2H30M|BEFORE|2020-08-31|ONGOING|2020-09-01
e|RS|65c439f8-9658-4ac5-9eae-0837182a90fd|3|NTLWIND|Non-Target Lesion Worsening Indicator|KUKER LYMPHOMA 2005|[?]|dpm/mg|SD|1|mg/m2/h|QUANTITATIVE COMPUTED TOMOGRAPHY||||DOMESTIC PARTNER|READER|NA|2|Visit_2|25|5|SCREENING|2020-06-19|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-27|P1Y2M10DT2H30M|COINCIDENT|2020-07-22|COINCIDENT|2020-08-02
e|RS|65c439f8-9658-4ac5-9eae-0837182a90fd|4|OVRLRESP|Overall Response|IWG CHESON MDS 2000|[?]|mCi/kg|CMR|1|mg/m2/min|PERFUSION MRI|Y|||NON-HEALTH CARE PROFESSIONAL|INTERNIST|NA|2|Visit_2|25|1|TREATMENT|2020-06-19|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-27|P1Y2M10DT2H30M|UNKNOWN|2020-08-05|BEFORE|2020-08-13
e|RS|65c439f8-9658-4ac5-9eae-0837182a90fd|5|MJPTHIND|Major Pathological Response Indicator|CHESON CLL 2012|||MORPHOLOGIC CR|1|mEq|PET SCAN||Y|Y|GUARDIAN|ADJUDICATOR 3|U|3|Visit_3|40|6|TREATMENT|2020-07-04|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-02|P1Y2M10DT2H30M|COINCIDENT|2020-08-17|COINCIDENT|2020-08-27
e|RS|65c439f8-9658-4ac5-9eae-0837182a90fd|6|NEWLIND|New Lesion Indicator|AJCC V8|||CA125 75% RESPONSE|1|mg/L|MICROBIAL BIOCHEMICAL IDENTIFICATION|||Y|SIBLING|ONCOLOGIST 1|NA|3|Visit_3|40|6|WASHOUT|2020-07-04|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-02|P1Y2M10DT2H30M|COINCIDENT|2020-08-03|AFTER|2020-09-01
e|RS|65c439f8-9658-4ac5-9eae-0837182a90fd|7|PATHRESP|Pathologic Response|RANO ELLINGSON 2017|[?]|eq|PSEUDORESPONSE|1|IU/g|BIOPSY|Y|Y||CAREGIVER|OTOLARYNGOLOGIST|Y|4|Visit_4|65|6|SCREENING|2020-07-29|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-23|P1Y2M10DT2H30M|AFTER|2020-05-31|BEFORE|2020-07-09
e|RS|65c439f8-9658-4ac5-9eae-0837182a90fd|8|PATHRESP|Pathologic Response|KEAM BREAST CANCER 2013|[?]|Absorbance U/mL|PR WITH LYMPHOCYTOSIS|1|mL/kg/min|CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY||||CAREGIVER|READER|U|4|Visit_4|65|1|TREATMENT|2020-07-29|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-23|P1Y2M10DT2H30M|COINCIDENT|2020-06-17|ONGOING|2020-07-25
e|RS|65c439f8-9658-4ac5-9eae-0837182a90fd|9|SFTSRESP|Soft Tissue Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|||UNEQUIVOCAL|1|/cmH2O|WRIGHT-GIEMSA STAIN|||Y|VENDOR|PATHOLOGIST 1|U|5|Visit_5|90|6|TREATMENT|2020-08-23|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-21|P1Y2M10DT2H30M|AFTER|2020-08-28|ONGOING|2020-09-01
e|RS|65c439f8-9658-4ac5-9eae-0837182a90fd|10|NTERESP|Non-Target Enhancing Response|FAROOQUI SUPP CLL 2014|[?]|fmol/L|INCREASED|1|Antibody Unit|SURFACE PLASMON RESONANCE||||SIGNIFICANT OTHER|ONCOLOGIST|Y|5|Visit_5|90|5|WASHOUT|2020-08-23|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-21|P1Y2M10DT2H30M|COINCIDENT|2020-06-19|COINCIDENT|2020-08-17
e|RS|5b73ad4c-bb28-47d1-a2f6-8508444059a5|1|MRDRESP|Minimal Residual Disease Response|CHESON CLL 2006|[?]|log EID 50/dose|HI-E|1|dpm/mg|MOUSE PROTECTION ASSAY||||CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 2|N|1|Visit_1|10|6|SCREENING|2020-06-12|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-24|P1Y2M10DT2H30M|BEFORE|2020-07-15|ONGOING|2020-08-18
e|RS|5b73ad4c-bb28-47d1-a2f6-8508444059a5|2|HEMARESP|Hematologic Response|AJCC V7|[?]|SPRAY|HI-N|1|ug/m2/day|ORCHIDOMETERY||||FRIEND|CLINICAL PATHOLOGIST|NA|1|Visit_1|10|5|FOLLOW-UP|2020-06-12|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-24|P1Y2M10DT2H30M|COINCIDENT|2020-07-31|COINCIDENT|2020-09-06
e|RS|5b73ad4c-bb28-47d1-a2f6-8508444059a5|3|OVRLRESP|Overall Response|CHESON CLL 2012|[?]|beats/min|CR-CT|1|QUANTITY SUFFICIENT|ELECTROCHEMILUMINESCENCE||Y||SIBLING|DERMATOLOGIST|Y|2|Visit_2|25|1|TREATMENT|2020-06-27|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-13|P1Y2M10DT2H30M|UNKNOWN|2020-06-27|AFTER|2020-07-28
e|RS|5b73ad4c-bb28-47d1-a2f6-8508444059a5|4|CYTORESP|Cytogenetic Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|/h|WORSENED|1|EID 50/dose|ULTRASONOGRAPHIC ELASTOGRAPHY||||CLINICAL STUDY SPONSOR|ADJUDICATOR|Y|2|Visit_2|25|1|TREATMENT|2020-06-27|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-13|P1Y2M10DT2H30M|AFTER|2020-09-01|ONGOING|2020-09-02
e|RS|5b73ad4c-bb28-47d1-a2f6-8508444059a5|5|DRCRIND|Disease Recurrence Indicator|MACDONALD GLIOMA 1990|||MORPHOLOGIC CR|1|ng|PET/CT SCAN WITHOUT CONTRAST|||Y|SIGNIFICANT OTHER|HEMATOLOGIST|NA|3|Visit_3|40|4|TREATMENT|2020-07-12|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-31|P1Y2M10DT2H30M|AFTER|2020-09-03|ONGOING|2020-09-05
e|RS|5b73ad4c-bb28-47d1-a2f6-8508444059a5|6|OVRLRESP|Overall Response|CHESON CLL 2012|[?]|yd|NE|1|mEq/g|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION|Y|||SIBLING|PATHOLOGIST 2|U|3|Visit_3|40|5|FOLLOW-UP|2020-07-12|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-31|P1Y2M10DT2H30M|AFTER|2020-08-24|COINCIDENT|2020-09-08
e|RS|5b73ad4c-bb28-47d1-a2f6-8508444059a5|7|METBRESP|Metabolic Response|PCWG SCHER PROSTATE CANCER 2016|[?]|DAgU/mL|NON-QUANTIFIABLE MRD POSITIVITY|1|mL/kg/day|CALCULATION||||ADJUDICATOR|MICROSCOPIST 2|U|4|Visit_4|65|4|TREATMENT|2020-08-06|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-25|P1Y2M10DT2H30M|AFTER|2020-06-05|COINCIDENT|2020-07-26
e|RS|5b73ad4c-bb28-47d1-a2f6-8508444059a5|8|METSIND|Metastatic Indicator|RANO ELLINGSON 2017|[?]|Henry|QUANTIFIABLE MRD POSITIVITY|1|mL/g/day|IMMUNOBLOT||||GUARDIAN|RATER|NA|4|Visit_4|65|3|SCREENING|2020-08-06|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-25|P1Y2M10DT2H30M|BEFORE|2020-06-20|COINCIDENT|2020-08-24
e|RS|5b73ad4c-bb28-47d1-a2f6-8508444059a5|9|NTRGRESP|Non-target Response|KEAM BREAST CANCER 2013|[?]|L/L|QUANTIFIABLE MRD POSITIVITY|1|fg|BIOPSY||||FAMILY MEMBER|NEUROLOGIST 2|U|5|Visit_5|90|1|SCREENING|2020-08-31|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-30|P1Y2M10DT2H30M|COINCIDENT|2020-08-19|ONGOING|2020-09-03
e|RS|5b73ad4c-bb28-47d1-a2f6-8508444059a5|10|SYMPTDTR|Symptomatic Deterioration|KEAM BREAST CANCER 2013|||pCR|1|10^6 CFU/mL|PERIODIC ACID SCHIFF STAIN|Y|Y|Y|FRIEND|NEUROLOGIST 2|U|5|Visit_5|90|7|WASHOUT|2020-08-31|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-30|P1Y2M10DT2H30M|COINCIDENT|2020-07-14|AFTER|2020-07-30
e|RS|16dcaefa-701c-4863-b010-8ac640aeb55a|1|NTNERESP|Non-Target Non-Enhancing Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|ng/mol|NON-QUANTIFIABLE MRD POSITIVITY|1|mg/kg/day|CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY||||INDEPENDENT ASSESSOR|PEDIATRIC NEUROLOGIST|NA|1|Visit_1|10|6|SCREENING|2020-06-17|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-24|P1Y2M10DT2H30M|AFTER|2020-07-18|COINCIDENT|2020-08-03
e|RS|16dcaefa-701c-4863-b010-8ac640aeb55a|2|RDIORESP|Radiologic Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|||NON-PD|1|fmol/L|NEPHELOMETRY|||Y|PROXY|RATER 2|U|1|Visit_1|10|2|SCREENING|2020-06-17|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-24|P1Y2M10DT2H30M|BEFORE|2020-07-11|BEFORE|2020-08-18
e|RS|16dcaefa-701c-4863-b010-8ac640aeb55a|3|ANATRESP|Anatomic Response|UNSPECIFIED|[?]|U/m2/h|STABLE|1|10^7 PFU|CLAUSS METHOD|Y|||DOMESTIC PARTNER|HEMATOLOGIST|Y|2|Visit_2|25|7|WASHOUT|2020-07-02|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-13|P1Y2M10DT2H30M|UNKNOWN|2020-06-25|BEFORE|2020-07-25
e|RS|16dcaefa-701c-4863-b010-8ac640aeb55a|4|NTRGRESP|Non-target Response|GCIG RUSTIN OVARIAN CANCER 2011|||COMPLETE MRD RESPONSE|1|10^5/hpf|NEXT GENERATION SEQUENCING|||Y|SIBLING|PATHOLOGIST 1|NA|2|Visit_2|25|5|WASHOUT|2020-07-02|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-13|P1Y2M10DT2H30M|COINCIDENT|2020-07-01|BEFORE|2020-07-20
e|RS|16dcaefa-701c-4863-b010-8ac640aeb55a|5|SYMPTDTR|Symptomatic Deterioration|UNSPECIFIED|[?]|/min|CYTOGENETIC NO RESPONSE|1|pkat/L|SPIRAL CT||Y||CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 1|U|3|Visit_3|40|3|TREATMENT|2020-07-17|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-22|P1Y2M10DT2H30M|BEFORE|2020-06-26|AFTER|2020-08-09
e|RS|16dcaefa-701c-4863-b010-8ac640aeb55a|6|MRDRESP|Minimal Residual Disease Response|MONTSERRAT CLL 1989|[?]|V|sCR|1|cycle/min|FLOCCULATION, CHARCOAL ENHANCED||||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 1|U|3|Visit_3|40|5|TREATMENT|2020-07-17|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-22|P1Y2M10DT2H30M|BEFORE|2020-06-17|BEFORE|2020-08-13
e|RS|16dcaefa-701c-4863-b010-8ac640aeb55a|7|TMRESP|Tumor Marker Response|NCIWG CHESON CLL 1996|[?]|10^9 CFU|UNEQUIVOCAL|1|vg/dose|IODINE STAIN||||INDEPENDENT ASSESSOR|PEDIATRIC NEUROLOGIST|N|4|Visit_4|65|7|TREATMENT|2020-08-11|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-09|P1Y2M10DT2H30M|BEFORE|2020-08-24|ONGOING|2020-09-09
e|RS|16dcaefa-701c-4863-b010-8ac640aeb55a|8|PATHRESP|Pathologic Response|BURCOMBE BREAST CANCER 2005|||PR WITH LYMPHOCYTOSIS|1|umol/min|HPLC/MS|||Y|CHILD|MICROSCOPIST 3|N|4|Visit_4|65|6|TREATMENT|2020-08-11|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-09|P1Y2M10DT2H30M|COINCIDENT|2020-08-17|BEFORE|2020-09-11
e|RS|16dcaefa-701c-4863-b010-8ac640aeb55a|9|TRGRESP|Target Response|MACDONALD GLIOMA 1990|[?]|dmol|MAJOR PATHOLOGIC RESPONSE|1|g/animal/day|DIFFUSION WEIGHTED MRI||||ADJUDICATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5|Visit_5|90|4|TREATMENT|2020-09-05|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-05|P1Y2M10DT2H30M|COINCIDENT|2020-07-05|ONGOING|2020-08-28
e|RS|16dcaefa-701c-4863-b010-8ac640aeb55a|10|CYTORESP|Cytogenetic Response|RANO ELLINGSON 2017|||PARTIAL MORPHOLOGIC RESPONSE|1|g/dL|TRICHROME STAIN|Y||Y|HEALTH CARE PROFESSIONAL|OPTOMETRIST|N|5|Visit_5|90|5|TREATMENT|2020-09-05|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-05|P1Y2M10DT2H30M|BEFORE|2020-07-11|COINCIDENT|2020-08-09
e|RS|4c19e870-9195-41d8-9c8a-8a54bb428732|1|TMRESP|Tumor Marker Response|SACT|||MAJOR PATHOLOGIC RESPONSE|1|mCi/L|IMMUNE REPERTOIRE DEEP SEQUENCING||Y|Y|NON-HEALTH CARE PROFESSIONAL|READER 1|N|1|Visit_1|10|1|FOLLOW-UP|2020-08-03|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-29|P1Y2M10DT2H30M|BEFORE|2020-08-31|AFTER|2020-09-27
e|RS|4c19e870-9195-41d8-9c8a-8a54bb428732|2|CLINRESP|Clinical Response|HAMAOKA BREAST CANCER 2010|[?]|deg2|NON-PD|1|QUANTITY SUFFICIENT|DIFFUSION TENSOR MRI||||FAMILY MEMBER|ENDOCRINOLOGIST|NA|1|Visit_1|10|1|TREATMENT|2020-08-03|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-29|P1Y2M10DT2H30M|UNKNOWN|2020-10-15|AFTER|2020-10-26
e|RS|4c19e870-9195-41d8-9c8a-8a54bb428732|3|NTNERESP|Non-Target Non-Enhancing Response|LUGANO CLASSIFICATION|[?]|uL|sCR|1|mg/m2/h|LEAD CITRATE STAIN||Y||DOMESTIC PARTNER|RADIOLOGIST 1|NA|2|Visit_2|25|5|TREATMENT|2020-08-18|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-01|P1Y2M10DT2H30M|COINCIDENT|2020-08-22|ONGOING|2020-09-05
e|RS|4c19e870-9195-41d8-9c8a-8a54bb428732|4|NEWLPROG|New Lesion Progression|CHOI GIST 2008|[?]|vg/mL|COMPLETE MRD RESPONSE|1|Henry|NUCLEIC ACID HYBRIDIZATION|Y|||STUDY SUBJECT|RATER|U|2|Visit_2|25|5|FOLLOW-UP|2020-08-18|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-01|P1Y2M10DT2H30M|BEFORE|2020-08-07|ONGOING|2020-09-27
e|RS|4c19e870-9195-41d8-9c8a-8a54bb428732|5|OVRLRESP|Overall Response|PRINCE TCELL LYMPHOMA 2010|||HI-N|1|mg/animal|INFRARED SPECTROMETRY|Y||Y|FRIEND|OTOLARYNGOLOGIST|NA|3|Visit_3|40|6|FOLLOW-UP|2020-09-02|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-31|P1Y2M10DT2H30M|BEFORE|2020-09-25|AFTER|2020-10-30
e|RS|4c19e870-9195-41d8-9c8a-8a54bb428732|6|BESTRESP|Best Overall Response|HARTMAN PANCREATIC CANCER 2012|[?]|mmHg*min/L|iUPD|1|YEARS|FUNDUS PHOTOGRAPHY||Y||FAMILY MEMBER|PHYSIOTHERAPIST|Y|3|Visit_3|40|2|TREATMENT|2020-09-02|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-31|P1Y2M10DT2H30M|BEFORE|2020-10-15|BEFORE|2020-10-16
e|RS|4c19e870-9195-41d8-9c8a-8a54bb428732|7|BONERESP|Bone Response|CHESON CLL 2006|[?]|nmol BCE/L|MORPHOLOGIC CRi|1|ng|PET SCAN||||FAMILY MEMBER|ENDOCRINOLOGIST|U|4|Visit_4|65|1|TREATMENT|2020-09-27|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-06|P1Y2M10DT2H30M|COINCIDENT|2020-09-14|COINCIDENT|2020-10-03
e|RS|4c19e870-9195-41d8-9c8a-8a54bb428732|8|HEMARESP|Hematologic Response|RANO|[?]|GPL U/mL|DECREASED|1|m/sec|MASS SPECTROMETRY|Y|||HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|Y|4|Visit_4|65|4|TREATMENT|2020-09-27|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-06|P1Y2M10DT2H30M|COINCIDENT|2020-07-30|ONGOING|2020-10-03
e|RS|4c19e870-9195-41d8-9c8a-8a54bb428732|9|BMIVLIND|Bone Marrow Involvement Indicator|HAMAOKA BREAST CANCER 2010|||PMR|1|10^7 TCID 50/dose|MICROSCOPY|||Y|CAREGIVER|ADJUDICATOR 1|U|5|Visit_5|90|5|TREATMENT|2020-10-22|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-13|P1Y2M10DT2H30M|COINCIDENT|2020-10-04|ONGOING|2020-10-10
e|RS|4c19e870-9195-41d8-9c8a-8a54bb428732|10|METSIND|Metastatic Indicator|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|/2000 RBC|MRD PERSISTENCE|1|STRIP|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY||||PARENT|ONCOLOGIST|N|5|Visit_5|90|1|SCREENING|2020-10-22|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-13|P1Y2M10DT2H30M|BEFORE|2020-09-21|ONGOING|2020-09-22
e|RS|7682184f-0801-4315-9c5f-116f7321a2b0|1|BMIVLIND|Bone Marrow Involvement Indicator|IWG CHESON AML 2003|[?]|deg/mm|PD FROM PR|1|ug/h|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY||Y||SPOUSE|RATER 2|N|1|Visit_1|10|4|FOLLOW-UP|2020-12-22|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-23|P1Y2M10DT2H30M|COINCIDENT|2021-01-22|COINCIDENT|2021-03-12
e|RS|7682184f-0801-4315-9c5f-116f7321a2b0|2|MOLRESP|Molecular Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|NEBULE|CYTOGENETIC MINOR RESPONSE|1|U/g Hb|KARYOTYPING||Y||INDEPENDENT ASSESSOR|NEUROLOGIST|NA|1|Visit_1|10|1|TREATMENT|2020-12-22|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-23|P1Y2M10DT2H30M|BEFORE|2021-03-08|ONGOING|2021-03-20
e|RS|7682184f-0801-4315-9c5f-116f7321a2b0|3|BESTRESP|Best Overall Response|AJCC V7|[?]|mmol/mol|PMD|1|um2|MULTIPLEXED BEAD BASED IMMUNOASSAY||||SPOUSE|OPTOMETRIST|U|2|Visit_2|25|6|FOLLOW-UP|2021-01-06|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-31|P1Y2M10DT2H30M|BEFORE|2020-12-18|AFTER|2021-03-07
e|RS|7682184f-0801-4315-9c5f-116f7321a2b0|4|TRGRESP|Target Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|mL/100g/min|INCREASED|1|LB|MECHANICAL CLOT DETECTION||Y||PROXY|CARDIOLOGIST|Y|2|Visit_2|25|2|TREATMENT|2021-01-06|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-31|P1Y2M10DT2H30M|COINCIDENT|2021-01-12|COINCIDENT|2021-01-16
e|RS|7682184f-0801-4315-9c5f-116f7321a2b0|5|MRDRESP|Minimal Residual Disease Response|DURIE MULTIPLE MYELOMA 2006|||IMPROVED|1|vg/dose|TOLUIDINE BLUE STAIN|||Y|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 1|NA|3|Visit_3|40|3|TREATMENT|2021-01-21|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-20|P1Y2M10DT2H30M|UNKNOWN|2021-02-26|ONGOING|2021-03-15
e|RS|7682184f-0801-4315-9c5f-116f7321a2b0|6|NEWLWIND|New Lesion Worsening Indicator|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|||MOLECULAR CR|1|DAYS|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|||Y|PROXY|ENDOCRINOLOGIST|NA|3|Visit_3|40|2|SCREENING|2021-01-21|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-20|P1Y2M10DT2H30M|UNKNOWN|2021-02-16|COINCIDENT|2021-03-12
e|RS|7682184f-0801-4315-9c5f-116f7321a2b0|7|SFTSRESP|Soft Tissue Response|IWC HALLEK CLL 2008|||iSD|1|Bq/L|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|||Y|PARENT|ONCOLOGIST 2|U|4|Visit_4|65|1|TREATMENT|2021-02-15|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-11|P1Y2M10DT2H30M|AFTER|2021-01-11|AFTER|2021-03-11
e|RS|7682184f-0801-4315-9c5f-116f7321a2b0|8|STRUSTAT|Steroid Use Status|AJCC V8|[?]|um2|iCR|1|nkat|NEPHELOMETRY|Y|||SIGNIFICANT OTHER|PHYSIOTHERAPIST|N|4|Visit_4|65|7|SCREENING|2021-02-15|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-11|P1Y2M10DT2H30M|BEFORE|2021-01-22|ONGOING|2021-02-26
e|RS|7682184f-0801-4315-9c5f-116f7321a2b0|9|CYTORESP|Cytogenetic Response|GUPPY OVARIAN CANCER 2002|[?]|kN/cm2|iSD|1|10^6 organisms/mg|FLOCCULATION, CHARCOAL ENHANCED||Y||ADJUDICATOR|RADIOLOGIST 2|NA|5|Visit_5|90|3|TREATMENT|2021-03-12|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-29|P1Y2M10DT2H30M|AFTER|2021-01-11|COINCIDENT|2021-03-05
e|RS|7682184f-0801-4315-9c5f-116f7321a2b0|10|SFTSRESP|Soft Tissue Response|CHESON MALIGNANT LYMPHOMA 2007|||CRi|1|mmol/mol|TRIPLE-PHASE MRI SCAN|||Y|DOMESTIC PARTNER|READER|N|5|Visit_5|90|6|SCREENING|2021-03-12|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-29|P1Y2M10DT2H30M|AFTER|2021-01-31|COINCIDENT|2021-03-13
e|RS|c40f9cb3-b597-4614-8ba5-d40849030ff9|1|ANATRESP|Anatomic Response|UNSPECIFIED|[?]|10^4/L|CA125 75% RESPONSE|1|TRACE|CARDIAC THERMODILUTION|Y|||INDEPENDENT ASSESSOR|PEDIATRIC NEUROLOGIST|NA|1|Visit_1|10|3|TREATMENT|2020-12-12|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-17|P1Y2M10DT2H30M|BEFORE|2021-03-06|COINCIDENT|2021-03-08
e|RS|c40f9cb3-b597-4614-8ba5-d40849030ff9|2|MRDIND|Minimal Residual Disease Indicator|CHESON CLL 2006|[?]|CAN|PD FROM PR|1|10^11/L|KNEMOMETRY||Y||INVESTIGATOR|ONCOLOGIST|U|1|Visit_1|10|3|SCREENING|2020-12-12|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-17|P1Y2M10DT2H30M|COINCIDENT|2021-02-23|BEFORE|2021-03-04
e|RS|c40f9cb3-b597-4614-8ba5-d40849030ff9|3|NTLWIND|Non-Target Lesion Worsening Indicator|IWC HALLEK CLL 2008|[?]|U.CARR|PARTIAL MORPHOLOGIC RESPONSE|1|10^6 IU/mL|IMPEDANCE CONDUCTIVITY||||PARENT|OPTOMETRIST|NA|2|Visit_2|25|5|WASHOUT|2020-12-27|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-22|P1Y2M10DT2H30M|AFTER|2021-03-06|AFTER|2021-03-07
e|RS|c40f9cb3-b597-4614-8ba5-d40849030ff9|4|NEWLPROG|New Lesion Progression|JACINTO CERVICAL CANCER 2007|[?]|10^9 organisms/mL|MOLECULAR CR|1|/500 WBC|DARK FIELD MICROSCOPY||||HEALTH CARE PROFESSIONAL|UROLOGIST|U|2|Visit_2|25|3|WASHOUT|2020-12-27|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-22|P1Y2M10DT2H30M|AFTER|2020-12-11|ONGOING|2021-03-04
e|RS|c40f9cb3-b597-4614-8ba5-d40849030ff9|5|OVRLRESP|Overall Response|SCHER PROSTATE CANCER 2011|||ABSENT MORPHOLOGIC RESPONSE|1|ukat/L|BAC ACGH|Y||Y|SPOUSE|READER 3|Y|3|Visit_3|40|7|SCREENING|2021-01-11|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-13|P1Y2M10DT2H30M|AFTER|2021-03-08|BEFORE|2021-03-10
e|RS|c40f9cb3-b597-4614-8ba5-d40849030ff9|6|RDIORESP|Radiologic Response|SACT|[?]|cy/cm|PSA PROGRESSION|1|10^3/hpf|CELL BASED BIOASSAY||Y||INDEPENDENT ASSESSOR|FORENSIC PATHOLOGIST|Y|3|Visit_3|40|3|FOLLOW-UP|2021-01-11|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-13|P1Y2M10DT2H30M|COINCIDENT|2021-02-12|COINCIDENT|2021-03-10
e|RS|c40f9cb3-b597-4614-8ba5-d40849030ff9|7|METBRESP|Metabolic Response|LUGANO CLASSIFICATION|||TREATMENT FAILURE|1|TROCHE|DYNAMOMETRY||Y|Y|FRIEND|MICROSCOPIST 3|Y|4|Visit_4|65|5|SCREENING|2021-02-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-12|P1Y2M10DT2H30M|BEFORE|2021-01-31|BEFORE|2021-02-06
e|RS|c40f9cb3-b597-4614-8ba5-d40849030ff9|8|NTLWIND|Non-Target Lesion Worsening Indicator|FAROOQUI SUPP CLL 2014|[?]|Antibody Unit|INDETERMINATE RESPONSE|1|ms/mmHg|IODINE STAIN|Y|||SPOUSE|NEUROLOGIST 1|N|4|Visit_4|65|4|SCREENING|2021-02-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-12|P1Y2M10DT2H30M|AFTER|2020-12-28|COINCIDENT|2021-01-16
e|RS|c40f9cb3-b597-4614-8ba5-d40849030ff9|9|SFTSRESP|Soft Tissue Response|iRECIST|[?]|MESF|cCR|1|dL|DYNAMIC CONTRAST ENHANCED MRI|Y|||FAMILY MEMBER|NEUROLOGIST 1|Y|5|Visit_5|90|4|SCREENING|2021-03-02|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-21|P1Y2M10DT2H30M|BEFORE|2021-01-15|BEFORE|2021-02-24
e|RS|c40f9cb3-b597-4614-8ba5-d40849030ff9|10|MRDIND|Minimal Residual Disease Indicator|AJCC V7|[?]|mgEq|RELAPSED DISEASE FROM CR OR PR|1|CAN|MASS SPECTROMETRY||Y||INVESTIGATOR|NEUROLOGIST|NA|5|Visit_5|90|5|TREATMENT|2021-03-02|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-21|P1Y2M10DT2H30M|UNKNOWN|2021-01-26|COINCIDENT|2021-02-27
e|RS|5e850a5f-cfce-4bdd-a8f2-22996b8a6a64|1|OVRLRESP|Overall Response|RAJKUMAR MYELOMA 2011|[?]|10^6 organisms/g|CHR|1|10^3 organisms/mL|CELL OF ORIGIN ASSAY||Y||DOMESTIC PARTNER|RATER 2|Y|1|Visit_1|10|1|FOLLOW-UP|2020-09-09|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-02|P1Y2M10DT2H30M|AFTER|2020-10-02|BEFORE|2020-11-20
e|RS|5e850a5f-cfce-4bdd-a8f2-22996b8a6a64|2|RDIORESP|Radiologic Response|JACINTO CERVICAL CANCER 2007|[?]|uL/mL|CYTOGENETIC NO RESPONSE|1|L/day|FLOW CYTOMETRY||||CLINICAL RESEARCH ASSOCIATE|OPHTHALMOLOGIST|N|1|Visit_1|10|7|WASHOUT|2020-09-09|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-02|P1Y2M10DT2H30M|UNKNOWN|2020-10-21|AFTER|2020-11-19
e|RS|5e850a5f-cfce-4bdd-a8f2-22996b8a6a64|3|NEWLWIND|New Lesion Worsening Indicator|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|VOXEL|PD-CT|1|m/sec|DIFFUSION WEIGHTED MRI||||FRIEND|MICROSCOPIST|N|2|Visit_2|25|7|TREATMENT|2020-09-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-10|P1Y2M10DT2H30M|COINCIDENT|2020-09-30|BEFORE|2020-10-13
e|RS|5e850a5f-cfce-4bdd-a8f2-22996b8a6a64|4|CLINRESP|Clinical Response|KUKER LYMPHOMA 2005|[?]|mCi/kg|HI-E|1|foz_us|BETA LACTAMASE||||FRIEND|READER|Y|2|Visit_2|25|4|TREATMENT|2020-09-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-10|P1Y2M10DT2H30M|BEFORE|2020-12-02|COINCIDENT|2020-12-06
e|RS|5e850a5f-cfce-4bdd-a8f2-22996b8a6a64|5|MRPHRESP|Morphologic Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|lm|NED|1|MBP|AURAMINE STAIN||Y||CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 1|U|3|Visit_3|40|1|WASHOUT|2020-10-09|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-25|P1Y2M10DT2H30M|BEFORE|2020-10-01|AFTER|2020-12-03
e|RS|5e850a5f-cfce-4bdd-a8f2-22996b8a6a64|6|NTERESP|Non-Target Enhancing Response|CHESON CLL 2006|[?]|dmol|MORPHOLOGIC CR|1|mol|ENDPOINT DILUTION ASSAY||||NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST|Y|3|Visit_3|40|2|TREATMENT|2020-10-09|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-25|P1Y2M10DT2H30M|BEFORE|2020-10-05|AFTER|2020-12-04
e|RS|5e850a5f-cfce-4bdd-a8f2-22996b8a6a64|7|NEWLWIND|New Lesion Worsening Indicator|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|||SD|1|mL/mmHg|CYSTOMETRY|||Y|PARENT|OPTOMETRIST|Y|4|Visit_4|65|6|TREATMENT|2020-11-03|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-04|P1Y2M10DT2H30M|BEFORE|2020-12-04|AFTER|2020-12-07
e|RS|5e850a5f-cfce-4bdd-a8f2-22996b8a6a64|8|METBRESP|Metabolic Response|MRECIST LENCIONI LIVER CANCER 2010|||INCREASED|1|mL/breath|PERCUSSION|||Y|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 3|N|4|Visit_4|65|4|SCREENING|2020-11-03|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-04|P1Y2M10DT2H30M|UNKNOWN|2020-09-03|AFTER|2020-11-18
e|RS|5e850a5f-cfce-4bdd-a8f2-22996b8a6a64|9|PATHRESP|Pathologic Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|PFU/dose|CYTOGENETIC CR|1|/10^3|MICROBIAL CULTURE, LIQUID||||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST|NA|5|Visit_5|90|5|SCREENING|2020-11-28|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-03|P1Y2M10DT2H30M|UNKNOWN|2020-11-03|AFTER|2020-11-30
e|RS|5e850a5f-cfce-4bdd-a8f2-22996b8a6a64|10|BESTRESP|Best Overall Response|BLAZER COLORECTAL CANCER 2008|[?]|DNA copies/mL|CA125 50% RESPONSE|1|dyn|CONTRAST ENHANCED MRI|Y|||FRIEND|CLINICAL PATHOLOGIST|Y|5|Visit_5|90|6|TREATMENT|2020-11-28|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-03|P1Y2M10DT2H30M|BEFORE|2020-11-27|ONGOING|2020-12-02
e|RS|c9308aa7-f38f-4b54-a919-d3f893b18cd1|1|LIVRRESP|Liver Response|MURPHY PROSTATE CANCER 1980|[?]|kg/cm2|RELAPSED DISEASE FROM CR|1|mJoule/cm2|CLAUSS METHOD||||HEALTH CARE PROFESSIONAL|UROLOGIST|NA|1|Visit_1|10|2|TREATMENT|2020-11-07|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-16|P1Y2M10DT2H30M|UNKNOWN|2020-11-16|COINCIDENT|2020-12-26
e|RS|c9308aa7-f38f-4b54-a919-d3f893b18cd1|2|METSIND|Metastatic Indicator|BLAZER COLORECTAL CANCER 2008|[?]|umol/dL|PSEUDORESPONSE|1|Enzyme U|IHC|Y|||SIGNIFICANT OTHER|MICROSCOPIST 2|N|1|Visit_1|10|1|FOLLOW-UP|2020-11-07|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-16|P1Y2M10DT2H30M|COINCIDENT|2020-11-16|BEFORE|2020-12-05
e|RS|c9308aa7-f38f-4b54-a919-d3f893b18cd1|3|BONERESP|Bone Response|BURCOMBE BREAST CANCER 2005|||RELAPSED DISEASE|1|QUANTITY SUFFICIENT|MRI WITHOUT CONTRAST|||Y|CHILD|RATER 1|N|2|Visit_2|25|6|TREATMENT|2020-11-22|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-16|P1Y2M10DT2H30M|BEFORE|2020-11-21|BEFORE|2021-01-23
e|RS|c9308aa7-f38f-4b54-a919-d3f893b18cd1|4|MOLRESP|Molecular Response|SCHER PROSTATE CANCER 2011|[?]|ug/L/h|NED|1|mg/g/min|REFRACTOMETRY||Y||PARENT|READER 3|N|2|Visit_2|25|6|FOLLOW-UP|2020-11-22|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-16|P1Y2M10DT2H30M|COINCIDENT|2020-12-30|COINCIDENT|2021-01-23
e|RS|c9308aa7-f38f-4b54-a919-d3f893b18cd1|5|LIVRRESP|Liver Response|PETIT BREAST CANCER 2001|[?]|msec|iSD|1|mOsm/kg|OPHTHALMOSCOPY||||VENDOR|RATER 2|Y|3|Visit_3|40|2|TREATMENT|2020-12-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-05|P1Y2M10DT2H30M|BEFORE|2021-01-18|ONGOING|2021-01-25
e|RS|c9308aa7-f38f-4b54-a919-d3f893b18cd1|6|DRCRIND|Disease Recurrence Indicator|RANO ELLINGSON 2017|[?]|L/kg|FAVORABLE RESPONSE|1|10^6 DNA copies/mL|SIZE EXCLUSION CHROMATOGRAPHY||||CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|3|Visit_3|40|2|FOLLOW-UP|2020-12-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-05|P1Y2M10DT2H30M|COINCIDENT|2021-01-01|BEFORE|2021-02-04
e|RS|c9308aa7-f38f-4b54-a919-d3f893b18cd1|7|TMRESP|Tumor Marker Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|Bq/ug|PD FROM PR|1|Ci/g|BALLPOINT PEN TECHNIQUE|Y|||CAREGIVER|NEUROLOGIST 2|U|4|Visit_4|65|7|WASHOUT|2021-01-01|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-31|P1Y2M10DT2H30M|BEFORE|2020-12-31|COINCIDENT|2021-01-31
e|RS|c9308aa7-f38f-4b54-a919-d3f893b18cd1|8|LIVRRESP|Liver Response|KUKER LYMPHOMA 2005|[?]|kBq|nPR|1|dpm/0.5 mL|ELISA|Y|||ADJUDICATOR|NEUROLOGIST 2|Y|4|Visit_4|65|4|TREATMENT|2021-01-01|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-31|P1Y2M10DT2H30M|COINCIDENT|2020-12-28|ONGOING|2021-01-25
e|RS|c9308aa7-f38f-4b54-a919-d3f893b18cd1|9|TMRESP|Tumor Marker Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|||FAVORABLE RESPONSE|1|L/L|CRYOSCOPY|Y||Y|INTERVIEWER|ADJUDICATOR 3|Y|5|Visit_5|90|7|TREATMENT|2021-01-26|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-18|P1Y2M10DT2H30M|AFTER|2021-01-11|ONGOING|2021-01-31
e|RS|c9308aa7-f38f-4b54-a919-d3f893b18cd1|10|MRDIND|Minimal Residual Disease Indicator|RECIST 1.0|||PSEUDOPROGRESSION|1|10^3 copies/mL|GC/MS-EI|||Y|DOMESTIC PARTNER|NEUROLOGIST 1|N|5|Visit_5|90|6|TREATMENT|2021-01-26|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-18|P1Y2M10DT2H30M|COINCIDENT|2020-11-17|ONGOING|2020-11-27
e|RS|e7cfb803-a0be-4020-9982-e0c3cdd90cd1|1|TRGRESP|Target Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|DRUM|WORSENED|1|fmol/L|FLOCCULATION, CHARCOAL ENHANCED||||PARENT|RATER|Y|1|Visit_1|10|6|SCREENING|2020-08-22|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-21|P1Y2M10DT2H30M|UNKNOWN|2020-10-12|COINCIDENT|2020-11-19
e|RS|e7cfb803-a0be-4020-9982-e0c3cdd90cd1|2|MRPHRESP|Morphologic Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|titer|HI-P|1|mmol/min/kPa|SPECTROPHOTOMETRY||Y||SIBLING|RATER|Y|1|Visit_1|10|3|TREATMENT|2020-08-22|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-21|P1Y2M10DT2H30M|COINCIDENT|2020-08-20|AFTER|2020-11-05
e|RS|e7cfb803-a0be-4020-9982-e0c3cdd90cd1|3|RDIORESP|Radiologic Response|EBMT BLADE MYELOMA 1998|[?]|mm3/mm2/year|CYTOGENETIC NO RESPONSE|1|Bq/g|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION||||PARENT|CARDIOLOGIST|N|2|Visit_2|25|4|TREATMENT|2020-09-06|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-05|P1Y2M10DT2H30M|COINCIDENT|2020-08-14|AFTER|2020-11-13
e|RS|e7cfb803-a0be-4020-9982-e0c3cdd90cd1|4|PATHRESP|Pathologic Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|umol/mg/min|MOLECULAR CR|1|/10^5|NON-CONTACT SPECULAR MICROSCOPY||Y||VENDOR|ENDOCRINOLOGIST|N|2|Visit_2|25|7|TREATMENT|2020-09-06|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-05|P1Y2M10DT2H30M|BEFORE|2020-08-18|BEFORE|2020-10-02
e|RS|e7cfb803-a0be-4020-9982-e0c3cdd90cd1|5|NEWLPROG|New Lesion Progression|IWG CHESON MDS 2006|[?]|PA|SMD|1|mOsm/L|CINEANGIOGRAPHY||||INDEPENDENT ASSESSOR|CARDIOLOGIST|U|3|Visit_3|40|3|FOLLOW-UP|2020-09-21|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-25|P1Y2M10DT2H30M|UNKNOWN|2020-08-14|ONGOING|2020-11-17
e|RS|e7cfb803-a0be-4020-9982-e0c3cdd90cd1|6|METBRESP|Metabolic Response|EBMT BLADE MYELOMA 1998|[?]|ug/h|iCR|1|days/month|KARYOTYPING|Y|Y||CLINICAL RESEARCH ASSOCIATE|UROLOGIST|U|3|Visit_3|40|7|TREATMENT|2020-09-21|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-25|P1Y2M10DT2H30M|UNKNOWN|2020-10-26|BEFORE|2020-10-29
e|RS|e7cfb803-a0be-4020-9982-e0c3cdd90cd1|7|DRCRIND|Disease Recurrence Indicator|RANO|||HI-P|1|vg/mL|SEQUENCING|Y||Y|STUDY SUBJECT|RATER|N|4|Visit_4|65|3|SCREENING|2020-10-16|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-25|P1Y2M10DT2H30M|UNKNOWN|2020-10-30|AFTER|2020-11-10
e|RS|e7cfb803-a0be-4020-9982-e0c3cdd90cd1|8|BMIVLIND|Bone Marrow Involvement Indicator|PETIT BREAST CANCER 2001|||DISEASE TRANSFORMATION|1|m3|TOTAL BODY IRRADIATION|Y||Y|SIGNIFICANT OTHER|RATER|Y|4|Visit_4|65|3|TREATMENT|2020-10-16|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-25|P1Y2M10DT2H30M|UNKNOWN|2020-08-27|ONGOING|2020-11-17
e|RS|e7cfb803-a0be-4020-9982-e0c3cdd90cd1|9|TMRESP|Tumor Marker Response|MURPHY PROSTATE CANCER 1980|||ABSENT MORPHOLOGIC RESPONSE|1|mL/cm H2O|SPECTROPHOTOMETRY|||Y|SIGNIFICANT OTHER|MICROSCOPIST 2|N|5|Visit_5|90|1|TREATMENT|2020-11-10|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-27|P1Y2M10DT2H30M|UNKNOWN|2020-10-25|BEFORE|2020-11-10
e|RS|e7cfb803-a0be-4020-9982-e0c3cdd90cd1|10|NTLWIND|Non-Target Lesion Worsening Indicator|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|grain|NE|1|10^9 CFU/g|MAGNETIC RESONANCE ANGIOGRAPHY|Y|||CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 1|Y|5|Visit_5|90|7|FOLLOW-UP|2020-11-10|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-27|P1Y2M10DT2H30M|BEFORE|2020-08-23|AFTER|2020-10-26
e|RS|3da865e8-9680-4112-b6d3-1f5763cfdaae|1|HEMARESP|Hematologic Response|RECIST 1.1|||HI-P|1|HEP|PERIPHERAL ANGIOGRAPHY|Y||Y|FRIEND|DERMATOLOGIST|N|1|Visit_1|10|4|FOLLOW-UP|2021-01-20|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-19|P1Y2M10DT2H30M|UNKNOWN|2021-02-25|BEFORE|2021-03-19
e|RS|3da865e8-9680-4112-b6d3-1f5763cfdaae|2|MNPTHIND|Minor Pathological Response Indicator|PRINCE TCELL LYMPHOMA 2010|[?]|P|RELAPSED DISEASE|1|vg/dose|MULTIPLEXED BEAD BASED IMMUNOASSAY||||PARENT|READER 1|N|1|Visit_1|10|4|TREATMENT|2021-01-20|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-19|P1Y2M10DT2H30M|COINCIDENT|2021-01-20|BEFORE|2021-04-03
e|RS|3da865e8-9680-4112-b6d3-1f5763cfdaae|3|CYTORESP|Cytogenetic Response|RANO|[?]|umol/L/min|SD|1|U/m2/day|IMMUNOPRECIPITATION||Y||VENDOR|DERMATOLOGIST|Y|2|Visit_2|25|6|FOLLOW-UP|2021-02-04|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-16|P1Y2M10DT2H30M|AFTER|2021-04-03|COINCIDENT|2021-04-18
e|RS|3da865e8-9680-4112-b6d3-1f5763cfdaae|4|MJPTHIND|Major Pathological Response Indicator|EBMT BLADE MYELOMA 1998|[?]|L/s|SD-CT|1|fmol/L/sec|FLUORIMETRY||||NON-HEALTH CARE PROFESSIONAL|READER|N|2|Visit_2|25|7|TREATMENT|2021-02-04|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-16|P1Y2M10DT2H30M|UNKNOWN|2021-03-16|COINCIDENT|2021-03-24
e|RS|3da865e8-9680-4112-b6d3-1f5763cfdaae|5|NEWLWIND|New Lesion Worsening Indicator|IWG CHESON MDS 2006|||PD|1|TRANSDUCING UNIT/mL|CLIP||Y|Y|SPOUSE|CLINICAL PATHOLOGIST|N|3|Visit_3|40|7|WASHOUT|2021-02-19|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-12|P1Y2M10DT2H30M|UNKNOWN|2021-04-07|COINCIDENT|2021-04-13
e|RS|3da865e8-9680-4112-b6d3-1f5763cfdaae|6|OVRLRESP|Overall Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|IU/mL|IMMUNOPHENOTYPIC CR|1|mPa|CINEANGIOGRAPHY||||CLINICAL RESEARCH COORDINATOR|UROLOGIST|U|3|Visit_3|40|2|FOLLOW-UP|2021-02-19|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-12|P1Y2M10DT2H30M|BEFORE|2021-04-11|ONGOING|2021-04-17
e|RS|3da865e8-9680-4112-b6d3-1f5763cfdaae|7|MRDIND|Minimal Residual Disease Indicator|CHESON CLL 2012|[?]|nkat/L|OPTIMAL MORPHOLOGIC RESPONSE|1|mL/min/1.73m2|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI||||INDEPENDENT ASSESSOR|RADIOLOGIST|U|4|Visit_4|65|2|TREATMENT|2021-03-16|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-30|P1Y2M10DT2H30M|AFTER|2021-02-02|BEFORE|2021-02-26
e|RS|3da865e8-9680-4112-b6d3-1f5763cfdaae|8|PATHRESP|Pathologic Response|UNSPECIFIED|[?]|beats/min|PARTIAL MORPHOLOGIC RESPONSE|1|mIU/L|RIA|Y|||INDEPENDENT ASSESSOR|UROLOGIST|U|4|Visit_4|65|1|WASHOUT|2021-03-16|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-30|P1Y2M10DT2H30M|UNKNOWN|2021-02-16|COINCIDENT|2021-02-26
e|RS|3da865e8-9680-4112-b6d3-1f5763cfdaae|9|METSIND|Metastatic Indicator|LEE LUNG CANCER 2011|[?]|ug/m2|mCR|1|%(v/v)|THICK SMEAR|Y|||GUARDIAN|RADIOLOGIST|Y|5|Visit_5|90|5|SCREENING|2021-04-10|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-14|P1Y2M10DT2H30M|COINCIDENT|2021-02-23|ONGOING|2021-03-21
e|RS|3da865e8-9680-4112-b6d3-1f5763cfdaae|10|NEWLPROG|New Lesion Progression|PETIT BREAST CANCER 2001|[?]|nmol/kg/day|SD|1|uCi/L|PELLI-ROBSON EYE CHART||||ADJUDICATION COMMITTEE|OPHTHALMOLOGIST|NA|5|Visit_5|90|2|SCREENING|2021-04-10|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-14|P1Y2M10DT2H30M|COINCIDENT|2021-04-02|BEFORE|2021-04-07
e|RS|60afc3a3-56b7-4988-9006-e12f3bc1097c|1|NTLWIND|Non-Target Lesion Worsening Indicator|CHESON CLL 2006|||RELAPSED DISEASE FROM CR|1|BU|CARDIAC THERMODILUTION|||Y|INDEPENDENT ASSESSOR|MICROSCOPIST 1|NA|1|Visit_1|10|6|TREATMENT|2020-08-16|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-17|P1Y2M10DT2H30M|COINCIDENT|2020-09-17|ONGOING|2020-11-13
e|RS|60afc3a3-56b7-4988-9006-e12f3bc1097c|2|CLINRESP|Clinical Response|EASL BRUIX LIVER CANCER 2001|[?]|mg/L|PD FROM PR|1|Ci|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY||Y||INTERVIEWER|RADIOLOGIST 2|N|1|Visit_1|10|3|TREATMENT|2020-08-16|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-17|P1Y2M10DT2H30M|BEFORE|2020-09-05|BEFORE|2020-10-17
e|RS|60afc3a3-56b7-4988-9006-e12f3bc1097c|3|MNPTHIND|Minor Pathological Response Indicator|MASS|||DECREASED|1|F|SEQUENCING|Y|Y|Y|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR|N|2|Visit_2|25|3|TREATMENT|2020-08-31|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-12|P1Y2M10DT2H30M|COINCIDENT|2020-10-04|BEFORE|2020-10-12
e|RS|60afc3a3-56b7-4988-9006-e12f3bc1097c|4|MOLRESP|Molecular Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|pptr|CR-CT|1|DNA copies/mL|URANYL ACETATE STAIN||||ADJUDICATOR|OPTOMETRIST|Y|2|Visit_2|25|5|SCREENING|2020-08-31|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-12|P1Y2M10DT2H30M|COINCIDENT|2020-08-21|BEFORE|2020-10-10
e|RS|60afc3a3-56b7-4988-9006-e12f3bc1097c|5|NEWLWIND|New Lesion Worsening Indicator|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|uL/kg/day|CMR|1|umol/dL|IN SITU HYBRIDIZATION|Y|Y||HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|N|3|Visit_3|40|7|SCREENING|2020-09-15|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-05|P1Y2M10DT2H30M|COINCIDENT|2020-10-12|AFTER|2020-10-30
e|RS|60afc3a3-56b7-4988-9006-e12f3bc1097c|6|HEMARESP|Hematologic Response|SCHWARZ CERVICAL CANCER 2009|[?]|Gy|PSEUDOPROGRESSION|1|mPa|DIRECT SEQUENCING||||SPOUSE|ONCOLOGIST 2|N|3|Visit_3|40|3|WASHOUT|2020-09-15|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-05|P1Y2M10DT2H30M|UNKNOWN|2020-09-19|ONGOING|2020-10-25
e|RS|60afc3a3-56b7-4988-9006-e12f3bc1097c|7|BONERESP|Bone Response|CHESON CLL 2006|[?]|mm|CMR|1|mEq/mmol|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION||Y||FAMILY MEMBER|READER 3|N|4|Visit_4|65|7|FOLLOW-UP|2020-10-10|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-15|P1Y2M10DT2H30M|AFTER|2020-09-10|ONGOING|2020-10-28
e|RS|60afc3a3-56b7-4988-9006-e12f3bc1097c|8|BONERESP|Bone Response|GUILHOT CML 2007|||MORPHOLOGIC LEUKEMIA-FREE STATE|1|/10^4|FLUOROSCOPY|Y||Y|ADJUDICATOR|PATHOLOGIST 2|U|4|Visit_4|65|7|TREATMENT|2020-10-10|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-15|P1Y2M10DT2H30M|BEFORE|2020-08-27|BEFORE|2020-09-16
e|RS|60afc3a3-56b7-4988-9006-e12f3bc1097c|9|NEWLWIND|New Lesion Worsening Indicator|CHESON CLL 2012|||PMR|1|g/cage|MIGET|||Y|FAMILY MEMBER|READER 3|NA|5|Visit_5|90|4|FOLLOW-UP|2020-11-04|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-11|P1Y2M10DT2H30M|UNKNOWN|2020-09-18|AFTER|2020-10-26
e|RS|60afc3a3-56b7-4988-9006-e12f3bc1097c|10|NEWLIND|New Lesion Indicator|EASL BRUIX LIVER CANCER 2001|[?]|Hz|PR WITH LYMPHOCYTOSIS|1|Ci/kg|ELASTOGRAPHY|Y|||CLINICAL STUDY SPONSOR|HEMATOLOGIST|U|5|Visit_5|90|2|TREATMENT|2020-11-04|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-11|P1Y2M10DT2H30M|AFTER|2020-09-01|ONGOING|2020-10-28
e|RS|440119fb-ad46-4348-b236-8e2979c7bf2e|1|CPRFSTAT|Clinical Performance Status|AJCC V8|[?]|Ci/L|nPR|1|g/animal/day|ZIEHL NEELSEN ACID FAST STAIN||||INVESTIGATOR|RATER|U|1|Visit_1|10|6|TREATMENT|2020-12-16|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-09|P1Y2M10DT2H30M|COINCIDENT|2020-12-24|AFTER|2021-02-08
e|RS|440119fb-ad46-4348-b236-8e2979c7bf2e|2|SFTSRESP|Soft Tissue Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|||INCREASED|1|tsp|WHOLE EXOME SEQUENCING|Y||Y|PARENT|ONCOLOGIST 1|N|1|Visit_1|10|4|SCREENING|2020-12-16|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-09|P1Y2M10DT2H30M|AFTER|2020-12-13|ONGOING|2020-12-18
e|RS|440119fb-ad46-4348-b236-8e2979c7bf2e|3|METBRESP|Metabolic Response|RANO|[?]|V|MINOR PATHOLOGIC RESPONSE|1|kPa/L/sec|CONTRAST ENHANCED SPIRAL CT SCAN|Y|||VENDOR|CARDIOLOGIST|Y|2|Visit_2|25|3|SCREENING|2020-12-31|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-04|P1Y2M10DT2H30M|BEFORE|2021-03-09|COINCIDENT|2021-03-14
e|RS|440119fb-ad46-4348-b236-8e2979c7bf2e|4|OVRLRESP|Overall Response|WOLCHOK SOLID TUMORS 2009|[?]|Mile|IMPROVED|1|Mile|THIN SMEAR|Y|||NON-HEALTH CARE PROFESSIONAL|INTERNIST|Y|2|Visit_2|25|2|TREATMENT|2020-12-31|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-04|P1Y2M10DT2H30M|UNKNOWN|2021-01-07|AFTER|2021-01-17
e|RS|440119fb-ad46-4348-b236-8e2979c7bf2e|5|CYTORESP|Cytogenetic Response|HARTMANN GERM CELL CANCER 2002|||CYTOGENETIC MINIMAL RESPONSE|1|genEq/mL|ECHOCARDIOGRAPHY|||Y|FAMILY MEMBER|MICROSCOPIST 1|Y|3|Visit_3|40|6|TREATMENT|2021-01-15|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-28|P1Y2M10DT2H30M|UNKNOWN|2021-02-22|COINCIDENT|2021-03-11
e|RS|440119fb-ad46-4348-b236-8e2979c7bf2e|6|NTERESP|Non-Target Enhancing Response|UNSPECIFIED|||cCR|1|ug/g/min|WEBER GREEN STAIN|Y|Y|Y|SIBLING|ONCOLOGIST 1|Y|3|Visit_3|40|2|TREATMENT|2021-01-15|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-28|P1Y2M10DT2H30M|BEFORE|2021-01-07|BEFORE|2021-02-17
e|RS|440119fb-ad46-4348-b236-8e2979c7bf2e|7|BONERESP|Bone Response|CHOLLET BREAST CANCER 2002|[?]|umol/mg/min|RELAPSED DISEASE FROM CR OR PR|1|mL/dL|HPLC/IEX||||INDEPENDENT ASSESSOR|RATER|U|4|Visit_4|65|7|SCREENING|2021-02-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-12|P1Y2M10DT2H30M|AFTER|2021-02-24|COINCIDENT|2021-03-08
e|RS|440119fb-ad46-4348-b236-8e2979c7bf2e|8|CLINRESP|Clinical Response|LEE LUNG CANCER 2011|[?]|g/L|UNEQUIVOCAL|1|IU|HILLMEN COLOR CHART||||VENDOR|RATER 1|NA|4|Visit_4|65|2|WASHOUT|2021-02-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-12|P1Y2M10DT2H30M|BEFORE|2021-02-15|AFTER|2021-02-16
e|RS|440119fb-ad46-4348-b236-8e2979c7bf2e|9|BESTRESP|Best Overall Response|RAJKUMAR MYELOMA 2011|[?]|dyn|PD|1|AU/mL|CONGO RED STAIN||||INVESTIGATOR|FORENSIC PATHOLOGIST|U|5|Visit_5|90|7|SCREENING|2021-03-06|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-03|P1Y2M10DT2H30M|COINCIDENT|2021-02-21|BEFORE|2021-02-25
e|RS|440119fb-ad46-4348-b236-8e2979c7bf2e|10|NTRGRESP|Non-target Response|MURPHY PROSTATE CANCER 1980|||PDu|1|QUANTITY SUFFICIENT|HPLC/MS/MS|Y|Y|Y|INDEPENDENT ASSESSOR|CLINICAL PATHOLOGIST|Y|5|Visit_5|90|2|SCREENING|2021-03-06|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-03|P1Y2M10DT2H30M|BEFORE|2021-02-12|COINCIDENT|2021-03-07
e|RS|af45a9de-c8aa-4602-8e3b-d16998740ebd|1|DRCRIND|Disease Recurrence Indicator|RECICL|[?]|L/day|PSEUDOPROGRESSION|1|anti-Xa IU|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION|Y|||PARENT|READER 2|Y|1|Visit_1|10|5|FOLLOW-UP|2020-06-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-19|P1Y2M10DT2H30M|AFTER|2020-07-19|ONGOING|2020-09-07
e|RS|af45a9de-c8aa-4602-8e3b-d16998740ebd|2|BESTRESP|Best Overall Response|PCWG SCHER PROSTATE CANCER 2016|[?]|Shock Wave|NON-CR/NON-PD|1|DROP|NUCLEIC ACID SEQUENCING||||STUDY SUBJECT|ADJUDICATOR|U|1|Visit_1|10|6|SCREENING|2020-06-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-19|P1Y2M10DT2H30M|AFTER|2020-07-30|ONGOING|2020-08-15
e|RS|af45a9de-c8aa-4602-8e3b-d16998740ebd|3|SFTSRESP|Soft Tissue Response|RECIST 1.0|[?]|g/day|PR WITH LYMPHOCYTOSIS|1|Joule|COLORIMETRY||||STUDY SUBJECT|ADJUDICATOR|N|2|Visit_2|25|3|TREATMENT|2020-06-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-03|P1Y2M10DT2H30M|BEFORE|2020-06-12|COINCIDENT|2020-06-30
e|RS|af45a9de-c8aa-4602-8e3b-d16998740ebd|4|NTNERESP|Non-Target Non-Enhancing Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|mCi/kg|RELAPSED DISEASE FROM CR|1|APPLICATION|DISK DIFFUSION|Y|||SIBLING|CARDIOLOGIST|N|2|Visit_2|25|4|FOLLOW-UP|2020-06-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-03|P1Y2M10DT2H30M|COINCIDENT|2020-07-16|ONGOING|2020-07-30
e|RS|af45a9de-c8aa-4602-8e3b-d16998740ebd|5|STRUSTAT|Steroid Use Status|EBMT BLADE MYELOMA 1998|[?]|kBq|CR|1|mIU/L|MRI WITHOUT CONTRAST||||CAREGIVER|FORENSIC PATHOLOGIST|N|3|Visit_3|40|3|TREATMENT|2020-07-15|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-19|P1Y2M10DT2H30M|AFTER|2020-06-28|BEFORE|2020-07-15
e|RS|af45a9de-c8aa-4602-8e3b-d16998740ebd|6|METBRESP|Metabolic Response|AJCC V7|[?]|BE/mL|CMR|1|mg/kg/min|DNA MICROARRAY||||FAMILY MEMBER|ADJUDICATOR|U|3|Visit_3|40|1|TREATMENT|2020-07-15|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-19|P1Y2M10DT2H30M|COINCIDENT|2020-07-13|ONGOING|2020-08-29
e|RS|af45a9de-c8aa-4602-8e3b-d16998740ebd|7|RDIORESP|Radiologic Response|NCIWG CHESON CLL 1996|||NED|1|10^9/dose|GRAM STAIN|||Y|SIGNIFICANT OTHER|NEUROLOGIST 1|U|4|Visit_4|65|1|WASHOUT|2020-08-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-10|P1Y2M10DT2H30M|UNKNOWN|2020-09-12|BEFORE|2020-09-13
e|RS|af45a9de-c8aa-4602-8e3b-d16998740ebd|8|MRDRESP|Minimal Residual Disease Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|mCi/kg|NON-iCR/NON-iUPD|1|ks|PHOROPTER|Y|||CLINICAL RESEARCH ASSOCIATE|CLINICAL PATHOLOGIST|NA|4|Visit_4|65|1|TREATMENT|2020-08-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-10|P1Y2M10DT2H30M|BEFORE|2020-08-07|BEFORE|2020-09-09
e|RS|af45a9de-c8aa-4602-8e3b-d16998740ebd|9|METBRESP|Metabolic Response|IWG CHESON MDS 2000|[?]|g/animal/wk|MRD PERSISTENCE|1|U/g Hb|MALDI||||SIBLING|RATER 1|U|5|Visit_5|90|1|SCREENING|2020-09-03|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-08|P1Y2M10DT2H30M|COINCIDENT|2020-09-02|BEFORE|2020-09-05
e|RS|af45a9de-c8aa-4602-8e3b-d16998740ebd|10|SFTSRESP|Soft Tissue Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|kIU|CHR|1|L/h|ATOMIC ABSORPTION SPECTROMETRY||||CAREGIVER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5|Visit_5|90|5|TREATMENT|2020-09-03|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-08|P1Y2M10DT2H30M|AFTER|2020-06-16|ONGOING|2020-08-14
e|RS|23306866-3fcb-418d-861b-de3bd779260d|1|BESTRESP|Best Overall Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|pmol/L|pCR|1|copies/ug|TWO-COLOR MICROARRAY||Y||ADJUDICATOR|NEUROLOGIST 1|N|1|Visit_1|10|1|FOLLOW-UP|2020-07-25|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-31|P1Y2M10DT2H30M|AFTER|2020-07-25|COINCIDENT|2020-08-03
e|RS|23306866-3fcb-418d-861b-de3bd779260d|2|METSIND|Metastatic Indicator|SCHER PROSTATE CANCER 2011|||UNFAVORABLE RESPONSE|1|Anson U|CELL OF ORIGIN ASSAY|||Y|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 1|N|1|Visit_1|10|1|TREATMENT|2020-07-25|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-31|P1Y2M10DT2H30M|UNKNOWN|2020-10-16|COINCIDENT|2020-10-22
e|RS|23306866-3fcb-418d-861b-de3bd779260d|3|BMIVLIND|Bone Marrow Involvement Indicator|PETIT BREAST CANCER 2001|[?]|U/kg/h|HI-N|1|TRANSDUCING UNIT|MICROBIAL CULTURE, LIQUID||||VENDOR|MICROSCOPIST|Y|2|Visit_2|25|3|WASHOUT|2020-08-09|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-09|P1Y2M10DT2H30M|UNKNOWN|2020-09-23|BEFORE|2020-09-29
e|RS|23306866-3fcb-418d-861b-de3bd779260d|4|NEWLIND|New Lesion Indicator|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|mmol/min/kPa|PDu|1|mg/g/min|STRESS ECHOCARDIOGRAPHY|Y|||FRIEND|NEUROLOGIST 1|NA|2|Visit_2|25|7|TREATMENT|2020-08-09|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-09|P1Y2M10DT2H30M|AFTER|2020-09-25|ONGOING|2020-09-29
e|RS|23306866-3fcb-418d-861b-de3bd779260d|5|SFTSRESP|Soft Tissue Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|BOX|cPR|1|mg/m2/day|AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT||||CLINICAL RESEARCH COORDINATOR|CARDIOLOGIST|NA|3|Visit_3|40|1|TREATMENT|2020-08-24|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-09|P1Y2M10DT2H30M|UNKNOWN|2020-08-19|BEFORE|2020-09-08
e|RS|23306866-3fcb-418d-861b-de3bd779260d|6|CYTORESP|Cytogenetic Response|BRUGGEMANN MRD 2010|||MAJOR PATHOLOGIC RESPONSE|1|PA|SPECT SCAN||Y|Y|STUDY SUBJECT|DERMATOLOGIST|N|3|Visit_3|40|3|FOLLOW-UP|2020-08-24|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-09|P1Y2M10DT2H30M|COINCIDENT|2020-09-04|AFTER|2020-09-29
e|RS|23306866-3fcb-418d-861b-de3bd779260d|7|RDIORESP|Radiologic Response|LEE LUNG CANCER 2011|[?]|m3|PD|1|foz_us|IN SITU HYBRIDIZATION||||CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL PSYCHOLOGIST|Y|4|Visit_4|65|1|SCREENING|2020-09-18|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-26|P1Y2M10DT2H30M|AFTER|2020-10-17|AFTER|2020-10-22
e|RS|23306866-3fcb-418d-861b-de3bd779260d|8|NTNERESP|Non-Target Non-Enhancing Response|KEAM BREAST CANCER 2013|[?]|pkat|OPTIMAL MORPHOLOGIC RESPONSE|1|mol/mg|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY||||CLINICAL RESEARCH ASSOCIATE|CARDIOLOGIST|Y|4|Visit_4|65|7|SCREENING|2020-09-18|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-26|P1Y2M10DT2H30M|UNKNOWN|2020-08-22|AFTER|2020-08-25
e|RS|23306866-3fcb-418d-861b-de3bd779260d|9|NEWLWIND|New Lesion Worsening Indicator|BRUGGEMANN MRD 2010|[?]|mL/cm H2O|MRD PERSISTENCE|1|Bq/uL|AGAR PROPORTION||||VENDOR|HEMATOLOGIST|Y|5|Visit_5|90|3|FOLLOW-UP|2020-10-13|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-15|P1Y2M10DT2H30M|AFTER|2020-10-04|COINCIDENT|2020-10-18
e|RS|23306866-3fcb-418d-861b-de3bd779260d|10|NTLWIND|Non-Target Lesion Worsening Indicator|DOHNER AML 2010|[?]|10^3 organisms|CYTOGENETIC MINIMAL RESPONSE|1|g/animal/wk|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION||||STUDY SUBJECT|PATHOLOGIST 1|N|5|Visit_5|90|6|FOLLOW-UP|2020-10-13|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-15|P1Y2M10DT2H30M|COINCIDENT|2020-07-23|ONGOING|2020-10-21
e|RS|144d2eb9-d79a-4a61-91f5-6a807832d8ca|1|NTRGRESP|Non-target Response|DOHNER AML 2010|[?]|ug/m2|NE|1|100 IU/mL|CELL BASED BIOASSAY||||FAMILY MEMBER|OTOLARYNGOLOGIST|Y|1|Visit_1|10|7|WASHOUT|2020-08-04|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-24|P1Y2M10DT2H30M|BEFORE|2020-08-02|AFTER|2020-10-31
e|RS|144d2eb9-d79a-4a61-91f5-6a807832d8ca|2|NTRGRESP|Non-target Response|CHOI GIST 2008|[?]|EVENTS|ABSENT MORPHOLOGIC RESPONSE|1|%(w/w)|SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|Y|||INTERVIEWER|RADIOLOGIST|U|1|Visit_1|10|4|FOLLOW-UP|2020-08-04|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-24|P1Y2M10DT2H30M|BEFORE|2020-08-25|ONGOING|2020-10-04
e|RS|144d2eb9-d79a-4a61-91f5-6a807832d8ca|3|BONERESP|Bone Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|mg/dose|iCR|1|pmol/10^10 cells|LINE PROBE ASSAY|Y|||GUARDIAN|OPTOMETRIST|N|2|Visit_2|25|6|TREATMENT|2020-08-19|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-28|P1Y2M10DT2H30M|UNKNOWN|2020-07-28|BEFORE|2020-09-02
e|RS|144d2eb9-d79a-4a61-91f5-6a807832d8ca|4|PATHRESP|Pathologic Response|MRECIST LENCIONI LIVER CANCER 2010|||cCR|1|deg/s|CONTRAST ENHANCED CT SCAN|Y|Y|Y|STUDY SUBJECT|HEMATOLOGIST|NA|2|Visit_2|25|1|SCREENING|2020-08-19|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-28|P1Y2M10DT2H30M|BEFORE|2020-09-15|BEFORE|2020-10-27
e|RS|144d2eb9-d79a-4a61-91f5-6a807832d8ca|5|ANATRESP|Anatomic Response|GUPPY OVARIAN CANCER 2002|[?]|v/v|DISEASE TRANSFORMATION|1|mmol/g|IMMUNOBLOT||Y||INVESTIGATOR|RADIOLOGIST 1|Y|3|Visit_3|40|5|TREATMENT|2020-09-03|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-27|P1Y2M10DT2H30M|BEFORE|2020-09-30|AFTER|2020-10-08
e|RS|144d2eb9-d79a-4a61-91f5-6a807832d8ca|6|MNPTHIND|Minor Pathological Response Indicator|WOLCHOK SOLID TUMORS 2009|[?]|mmol/mol|PSEUDORESPONSE|1|cd|REFLECTANCE SPECTROSCOPY||||DOMESTIC PARTNER|ADJUDICATOR 3|U|3|Visit_3|40|1|FOLLOW-UP|2020-09-03|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-27|P1Y2M10DT2H30M|UNKNOWN|2020-08-03|ONGOING|2020-09-17
e|RS|144d2eb9-d79a-4a61-91f5-6a807832d8ca|7|SFTSRESP|Soft Tissue Response|IWG CHESON MDS 2000|[?]|Coulomb|CA125 50% RESPONSE|1|uEq|HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY||||SPOUSE|ADJUDICATOR|NA|4|Visit_4|65|3|TREATMENT|2020-09-28|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-23|P1Y2M10DT2H30M|COINCIDENT|2020-09-26|AFTER|2020-10-22
e|RS|144d2eb9-d79a-4a61-91f5-6a807832d8ca|8|METBRESP|Metabolic Response|WHO BREAST CANCER 2006|[?]|mL/animal/wk|cCR|1|nmol BCE/nmol|AUSCULTATION||||INVESTIGATOR|READER 2|N|4|Visit_4|65|2|TREATMENT|2020-09-28|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-23|P1Y2M10DT2H30M|AFTER|2020-07-31|ONGOING|2020-08-25
e|RS|144d2eb9-d79a-4a61-91f5-6a807832d8ca|9|CLINRESP|Clinical Response|DOHNER AML 2010|||NE|1|min|LINE PROBE ASSAY|||Y|PROXY|PEDIATRIC NEUROLOGIST|N|5|Visit_5|90|5|FOLLOW-UP|2020-10-23|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-25|P1Y2M10DT2H30M|UNKNOWN|2020-07-30|ONGOING|2020-09-09
e|RS|144d2eb9-d79a-4a61-91f5-6a807832d8ca|10|SYMPTDTR|Symptomatic Deterioration|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|g/m2|cCR|1|ng/dL|ENZYMATIC ULTRACENTRIFUGATION|Y|||CHILD|HEMATOLOGIST|U|5|Visit_5|90|6|FOLLOW-UP|2020-10-23|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-25|P1Y2M10DT2H30M|AFTER|2020-09-12|ONGOING|2020-10-14
e|RS|92855d33-eee6-449f-a9e6-c06a1532571f|1|CYTORESP|Cytogenetic Response|AJCC V7|[?]|fmol/g|ABSENT MORPHOLOGIC RESPONSE|1|damol/L|CLAUSS METHOD||||PARENT|NEUROLOGIST 1|U|1|Visit_1|10|2|FOLLOW-UP|2020-11-29|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-20|P1Y2M10DT2H30M|COINCIDENT|2021-02-19|ONGOING|2021-02-25
e|RS|92855d33-eee6-449f-a9e6-c06a1532571f|2|MRPHRESP|Morphologic Response|FAROOQUI SUPP CLL 2014|[?]|ukat/10^12 RBC|CYTOGENETIC NO RESPONSE|1|dyn|THERMAL IONIZATION MASS SPECTROMETRY||||CAREGIVER|READER|Y|1|Visit_1|10|1|SCREENING|2020-11-29|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-20|P1Y2M10DT2H30M|COINCIDENT|2021-02-11|AFTER|2021-02-12
e|RS|92855d33-eee6-449f-a9e6-c06a1532571f|3|PATHRESP|Pathologic Response|IWC HALLEK CLL 2008|[?]|log10 TCID 50/dose|RELAPSED DISEASE FROM CR OR PR|1|mg/g/min|PH METER MEASUREMENT METHOD|Y|||ADJUDICATOR|UROLOGIST|Y|2|Visit_2|25|4|TREATMENT|2020-12-14|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-27|P1Y2M10DT2H30M|AFTER|2020-12-03|ONGOING|2021-02-09
e|RS|92855d33-eee6-449f-a9e6-c06a1532571f|4|PATHRESP|Pathologic Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|mmHg*min/L|PSA PROGRESSION|1|usec|CELL OF ORIGIN ASSAY||Y||PROXY|DEVELOPMENTAL PSYCHOLOGIST|NA|2|Visit_2|25|7|SCREENING|2020-12-14|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-27|P1Y2M10DT2H30M|COINCIDENT|2021-01-27|ONGOING|2021-02-19
e|RS|92855d33-eee6-449f-a9e6-c06a1532571f|5|TRGRESP|Target Response|CHESON CLL 2012|[?]|mU|HI-N|1|10^3 DNA copies/mL|FLOW CYTOMETRY||||DOMESTIC PARTNER|ADJUDICATOR 2|Y|3|Visit_3|40|2|TREATMENT|2020-12-29|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-03|P1Y2M10DT2H30M|UNKNOWN|2021-01-20|AFTER|2021-01-28
e|RS|92855d33-eee6-449f-a9e6-c06a1532571f|6|NEWLPROG|New Lesion Progression|KUKER LYMPHOMA 2005|[?]|mgEq|MINOR PATHOLOGIC RESPONSE|1|10^3 CFU/mL|MAGNETIC RESONANCE ANGIOGRAPHY||||PROXY|RATER|N|3|Visit_3|40|3|FOLLOW-UP|2020-12-29|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-03|P1Y2M10DT2H30M|BEFORE|2020-12-12|AFTER|2021-02-26
e|RS|92855d33-eee6-449f-a9e6-c06a1532571f|7|SYMPTDTR|Symptomatic Deterioration|PRINCE TCELL LYMPHOMA 2010|||CYTOGENETIC CR|1|g/kg|POLYGRAPHY||Y|Y|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 1|Y|4|Visit_4|65|4|TREATMENT|2021-01-23|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-30|P1Y2M10DT2H30M|UNKNOWN|2021-02-05|ONGOING|2021-02-15
e|RS|92855d33-eee6-449f-a9e6-c06a1532571f|8|STRUSTAT|Steroid Use Status|SHINDOH COLORECTAL CANCER 2013|[?]|10^9 CFU/mL|DISEASE TRANSFORMATION|1|AFU|AUTOREFRACTION||Y||FAMILY MEMBER|PHYSIOTHERAPIST|Y|4|Visit_4|65|2|SCREENING|2021-01-23|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-30|P1Y2M10DT2H30M|BEFORE|2020-11-27|COINCIDENT|2021-01-24
e|RS|92855d33-eee6-449f-a9e6-c06a1532571f|9|NEWLPROG|New Lesion Progression|PRINCE TCELL LYMPHOMA 2010|||CA125 75% RESPONSE|1|cg|RADIATION DOSIMETRY|Y||Y|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 1|Y|5|Visit_5|90|4|SCREENING|2021-02-17|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-04|P1Y2M10DT2H30M|COINCIDENT|2021-01-05|COINCIDENT|2021-02-03
e|RS|92855d33-eee6-449f-a9e6-c06a1532571f|10|METBRESP|Metabolic Response|LEE LUNG CANCER 2011|[?]|DAgU|PR WITH LYMPHOCYTOSIS|1|psec|IMPULSE OSCILLOMETRY||||INTERVIEWER|RADIOLOGIST 2|NA|5|Visit_5|90|2|WASHOUT|2021-02-17|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-04|P1Y2M10DT2H30M|AFTER|2021-02-07|AFTER|2021-02-08
e|RS|0204e2fc-bc80-44cd-a749-90c1bf21a2bb|1|CLINRESP|Clinical Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|BOX|TREATMENT FAILURE|1|kPa/L/sec|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION||||CAREGIVER|MICROSCOPIST 3|N|1|Visit_1|10|6|TREATMENT|2021-01-29|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-26|P1Y2M10DT2H30M|AFTER|2021-02-16|COINCIDENT|2021-03-27
e|RS|0204e2fc-bc80-44cd-a749-90c1bf21a2bb|2|NEWLIND|New Lesion Indicator|IWC HALLEK CLL 2008|[?]|pmol/day|CYTOGENETIC PR|1|cP|WRIGHT STAIN||||INTERVIEWER|RATER|U|1|Visit_1|10|1|FOLLOW-UP|2021-01-29|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-26|P1Y2M10DT2H30M|UNKNOWN|2021-04-21|AFTER|2021-04-27
e|RS|0204e2fc-bc80-44cd-a749-90c1bf21a2bb|3|MRDIND|Minimal Residual Disease Indicator|SACT|[?]|Ci/L|INDETERMINATE RESPONSE|1|cs|LIGHT MICROSCOPY|Y|||NON-HEALTH CARE PROFESSIONAL|RATER 1|NA|2|Visit_2|25|5|TREATMENT|2021-02-13|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-23|P1Y2M10DT2H30M|UNKNOWN|2021-04-03|AFTER|2021-04-19
e|RS|0204e2fc-bc80-44cd-a749-90c1bf21a2bb|4|BESTRESP|Best Overall Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|LOZENGE|CR-CT|1|mm3/mm2/year|IMMUNOBLOT||||CHILD|CARDIOLOGIST|Y|2|Visit_2|25|2|TREATMENT|2021-02-13|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-23|P1Y2M10DT2H30M|AFTER|2021-03-04|ONGOING|2021-04-21
e|RS|0204e2fc-bc80-44cd-a749-90c1bf21a2bb|5|OVRLRESP|Overall Response|MACDONALD GLIOMA 1990|[?]|uIU/dL|ABSENT MORPHOLOGIC RESPONSE|1|ppm|SNELLEN EYE CHART||||DOMESTIC PARTNER|PEDIATRIC NEUROLOGIST|Y|3|Visit_3|40|5|TREATMENT|2021-02-28|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-27|P1Y2M10DT2H30M|AFTER|2021-04-01|BEFORE|2021-04-16
e|RS|0204e2fc-bc80-44cd-a749-90c1bf21a2bb|6|TRGRESP|Target Response|GUPPY OVARIAN CANCER 2002|[?]|kcal/day|HI-N|1|MET|NON-CONTACT SPECULAR MICROSCOPY|Y|||VENDOR|MICROSCOPIST|U|3|Visit_3|40|3|TREATMENT|2021-02-28|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-27|P1Y2M10DT2H30M|BEFORE|2021-04-03|COINCIDENT|2021-04-07
e|RS|0204e2fc-bc80-44cd-a749-90c1bf21a2bb|7|BMIVLIND|Bone Marrow Involvement Indicator|HARTMAN PANCREATIC CANCER 2012|||UNFAVORABLE RESPONSE|1|Ejaculate U|LC/MS|||Y|ADJUDICATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|4|Visit_4|65|6|FOLLOW-UP|2021-03-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-06|P1Y2M10DT2H30M|BEFORE|2021-04-16|BEFORE|2021-04-23
e|RS|0204e2fc-bc80-44cd-a749-90c1bf21a2bb|8|MRDIND|Minimal Residual Disease Indicator|SCHER PROSTATE CANCER 2011|[?]|10^9/L|pCR|1|umol/L|ANALYTICAL ULTRACENTRIFUGATION||||VENDOR|DEVELOPMENTAL PSYCHOLOGIST|U|4|Visit_4|65|7|WASHOUT|2021-03-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-06|P1Y2M10DT2H30M|BEFORE|2021-02-27|COINCIDENT|2021-03-24
e|RS|0204e2fc-bc80-44cd-a749-90c1bf21a2bb|9|MJPTHIND|Major Pathological Response Indicator|UNSPECIFIED|[?]|INHALATION|CRi|1|g/animal/day|HIGH RESOLUTION MELT ANALYSIS||Y||INDEPENDENT ASSESSOR|CARDIOLOGIST|Y|5|Visit_5|90|7|SCREENING|2021-04-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-27|P1Y2M10DT2H30M|BEFORE|2021-02-25|AFTER|2021-04-26
e|RS|0204e2fc-bc80-44cd-a749-90c1bf21a2bb|10|NEWLWIND|New Lesion Worsening Indicator|MACDONALD GLIOMA 1990|||MRD NEGATIVITY|1|gpELISA unit/mL|BETA LACTAMASE|||Y|PARENT|ADJUDICATOR 2|U|5|Visit_5|90|2|FOLLOW-UP|2021-04-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-27|P1Y2M10DT2H30M|UNKNOWN|2021-03-16|COINCIDENT|2021-03-17
e|RS|40cb9bc3-abec-4158-bdee-becdeceba727|1|TRGRESP|Target Response|KUMAR IMWG 2016|[?]|Linear ft*LB|IMPROVED|1|dpm/mL|DROPLET DIGITAL PCR||||ADJUDICATOR|READER 3|N|1|Visit_1|10|3|WASHOUT|2020-10-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-11|P1Y2M10DT2H30M|BEFORE|2020-11-01|AFTER|2020-11-09
e|RS|40cb9bc3-abec-4158-bdee-becdeceba727|2|HEMARESP|Hematologic Response|RANO ELLINGSON 2017|[?]|Newton|iSD|1|mEq/mmol|TRANSESOPHAGEAL ECHOCARDIOGRAPHY||Y||INTERVIEWER|ONCOLOGIST|Y|1|Visit_1|10|5|WASHOUT|2020-10-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-11|P1Y2M10DT2H30M|COINCIDENT|2020-11-20|ONGOING|2020-11-26
e|RS|40cb9bc3-abec-4158-bdee-becdeceba727|3|SYMPTDTR|Symptomatic Deterioration|IRANO 2015|||CRi|1|MnFI|SINGLE-SLICE SPIRAL CT|||Y|CLINICAL STUDY SPONSOR|ADJUDICATOR 1|Y|2|Visit_2|25|7|SCREENING|2020-11-03|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-21|P1Y2M10DT2H30M|COINCIDENT|2021-01-15|COINCIDENT|2021-01-16
e|RS|40cb9bc3-abec-4158-bdee-becdeceba727|4|PATHRESP|Pathologic Response|NCIWG CHESON CLL 1996|[?]|TAMPON|cPR|1|g/cage|HPLC-FL|Y|Y||CAREGIVER|DEVELOPMENTAL PSYCHOLOGIST|U|2|Visit_2|25|6|TREATMENT|2020-11-03|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-21|P1Y2M10DT2H30M|UNKNOWN|2020-10-11|ONGOING|2021-01-14
e|RS|40cb9bc3-abec-4158-bdee-becdeceba727|5|SFTSRESP|Soft Tissue Response|SCHWARZ CERVICAL CANCER 2009|[?]|log10 CFU/g|CR-CT|1|10^5/L|IMMUNOBLOT|Y|Y||ADJUDICATION COMMITTEE|PHYSIOTHERAPIST|NA|3|Visit_3|40|3|TREATMENT|2020-11-18|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-01|P1Y2M10DT2H30M|AFTER|2020-12-16|BEFORE|2020-12-18
e|RS|40cb9bc3-abec-4158-bdee-becdeceba727|6|NTNERESP|Non-Target Non-Enhancing Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|fg|RELAPSED DISEASE|1|STRIP|REBOUND TONOMETRY||||INTERVIEWER|CARDIOLOGIST|N|3|Visit_3|40|4|SCREENING|2020-11-18|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-01|P1Y2M10DT2H30M|AFTER|2020-11-20|BEFORE|2020-12-13
e|RS|40cb9bc3-abec-4158-bdee-becdeceba727|7|CPRFSTAT|Clinical Performance Status|CHESON CLL 2012|[?]|uV2|CYTOGENETIC NO RESPONSE|1|U/mL|POLYSOMNOGRAPHY||Y||GUARDIAN|RADIOLOGIST 2|N|4|Visit_4|65|1|FOLLOW-UP|2020-12-13|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-20|P1Y2M10DT2H30M|COINCIDENT|2020-12-24|COINCIDENT|2020-12-30
e|RS|40cb9bc3-abec-4158-bdee-becdeceba727|8|CPRFSTAT|Clinical Performance Status|SCHER PROSTATE CANCER 2011|||EQUIVOCAL|1|TAMPON|LISSAMINE GREEN STAIN|||Y|PARENT|OPTOMETRIST|U|4|Visit_4|65|2|FOLLOW-UP|2020-12-13|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-20|P1Y2M10DT2H30M|BEFORE|2020-11-09|BEFORE|2020-12-08
e|RS|40cb9bc3-abec-4158-bdee-becdeceba727|9|TMRESP|Tumor Marker Response|HARTMAN PANCREATIC CANCER 2012|[?]|nmol/mL/min|PR-CT|1|Ci/uL|LISSAMINE GREEN STAIN||||ADJUDICATOR|PEDIATRIC NEUROLOGIST|U|5|Visit_5|90|3|FOLLOW-UP|2021-01-07|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-23|P1Y2M10DT2H30M|COINCIDENT|2021-01-13|ONGOING|2021-01-14
e|RS|40cb9bc3-abec-4158-bdee-becdeceba727|10|SFTSRESP|Soft Tissue Response|PERCIST|[?]|BAU|EQUIVOCAL|1|MET|DNA MICROARRAY|Y|||CLINICAL STUDY SPONSOR|NEUROLOGIST|NA|5|Visit_5|90|5|WASHOUT|2021-01-07|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-23|P1Y2M10DT2H30M|BEFORE|2020-11-08|ONGOING|2021-01-05
e|RS|f4dbdcd5-52ca-498c-b72a-1c0209c9a286|1|MJPTHIND|Major Pathological Response Indicator|DOHNER AML 2010|[?]|COAT|MRD NEGATIVITY|1|GBq/mg|IN SITU HYBRIDIZATION||||SIGNIFICANT OTHER|RATER|NA|1|Visit_1|10|1|SCREENING|2020-10-17|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-19|P1Y2M10DT2H30M|AFTER|2021-01-05|ONGOING|2021-01-07
e|RS|f4dbdcd5-52ca-498c-b72a-1c0209c9a286|2|MRDIND|Minimal Residual Disease Indicator|CHOI GIST 2008|[?]|10^9/dose|CHR|1|mol/g|FREEZING POINT DEPRESSION||||CLINICAL STUDY SPONSOR|PATHOLOGIST|U|1|Visit_1|10|6|TREATMENT|2020-10-17|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-19|P1Y2M10DT2H30M|BEFORE|2021-01-10|AFTER|2021-01-11
e|RS|f4dbdcd5-52ca-498c-b72a-1c0209c9a286|3|NTERESP|Non-Target Enhancing Response|IRANO 2015|[?]|ug/L DDU|WORSENED|1|tsp eq|DYNAMIC CONTRAST ENHANCED MRI||Y||SIBLING|PATHOLOGIST|U|2|Visit_2|25|1|TREATMENT|2020-11-01|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-20|P1Y2M10DT2H30M|AFTER|2020-11-04|AFTER|2020-12-24
e|RS|f4dbdcd5-52ca-498c-b72a-1c0209c9a286|4|TRGRESP|Target Response|HARTMAN PANCREATIC CANCER 2012|[?]|mIU/L|MORPHOLOGIC CR|1|cGy|SANGER SEQUENCING||||HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|NA|2|Visit_2|25|7|WASHOUT|2020-11-01|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-20|P1Y2M10DT2H30M|UNKNOWN|2020-12-04|COINCIDENT|2020-12-09
e|RS|f4dbdcd5-52ca-498c-b72a-1c0209c9a286|5|MRDRESP|Minimal Residual Disease Response|PCWG SCHER PROSTATE CANCER 2008|[?]|PFU/mL|CR-CT|1|mm/sec|CHROMOGENIC ASSAY||||VENDOR|MICROSCOPIST|Y|3|Visit_3|40|2|SCREENING|2020-11-16|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-14|P1Y2M10DT2H30M|BEFORE|2020-10-21|BEFORE|2020-11-05
e|RS|f4dbdcd5-52ca-498c-b72a-1c0209c9a286|6|NEWLPROG|New Lesion Progression|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|RNA copies/mL|CYTOGENETIC PR|1|pg/dL|TRIPLE-PHASE SPIRAL CT SCAN||||ADJUDICATION COMMITTEE|RATER 2|NA|3|Visit_3|40|5|WASHOUT|2020-11-16|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-14|P1Y2M10DT2H30M|BEFORE|2020-10-11|BEFORE|2020-10-28
e|RS|f4dbdcd5-52ca-498c-b72a-1c0209c9a286|7|CLINRESP|Clinical Response|RECIST 1.0|[?]|pmol/10^9 cells|HI-E|1|BISCUIT|CONTRAST ENHANCED PET/CT SCAN||Y||CAREGIVER|RADIOLOGIST|NA|4|Visit_4|65|2|SCREENING|2020-12-11|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-27|P1Y2M10DT2H30M|UNKNOWN|2021-01-07|BEFORE|2021-01-08
e|RS|f4dbdcd5-52ca-498c-b72a-1c0209c9a286|8|SFTSRESP|Soft Tissue Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|||PDu|1|DRINK|LANDOLT RING|Y||Y|CLINICAL RESEARCH ASSOCIATE|OTOLARYNGOLOGIST|Y|4|Visit_4|65|6|WASHOUT|2020-12-11|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-27|P1Y2M10DT2H30M|AFTER|2021-01-01|COINCIDENT|2021-01-12
e|RS|f4dbdcd5-52ca-498c-b72a-1c0209c9a286|9|NTERESP|Non-Target Enhancing Response|MURPHY PROSTATE CANCER 1980|[?]|nU/cL|cPR|1|10^4/hpf|MALDI|Y|||CLINICAL RESEARCH ASSOCIATE|FORENSIC PATHOLOGIST|NA|5|Visit_5|90|7|TREATMENT|2021-01-05|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-14|P1Y2M10DT2H30M|BEFORE|2020-11-11|COINCIDENT|2020-12-04
e|RS|f4dbdcd5-52ca-498c-b72a-1c0209c9a286|10|OVRLRESP|Overall Response|IWG CHESON MDS 2000|[?]|g/kg/day|NON-CR/NON-PD|1|MBq|HEMAGGLUTINATION INHIBITION ASSAY|Y|||SPOUSE|OPHTHALMOLOGIST|U|5|Visit_5|90|4|TREATMENT|2021-01-05|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-14|P1Y2M10DT2H30M|AFTER|2020-11-29|BEFORE|2020-12-10
e|RS|616b284a-3fed-4009-bafe-7da10acd537e|1|MJPTHIND|Major Pathological Response Indicator|LEE LUNG CANCER 2011|[?]|mg/cm2|iPR|1|nmol BCE/mmol|DUCTOGRAPHY|Y|||SIGNIFICANT OTHER|OPTOMETRIST|Y|1|Visit_1|10|3|TREATMENT|2020-09-03|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-08|P1Y2M10DT2H30M|AFTER|2020-10-20|BEFORE|2020-10-30
e|RS|616b284a-3fed-4009-bafe-7da10acd537e|2|NTRGRESP|Non-target Response|PRINCE TCELL LYMPHOMA 2010|||PR WITH LYMPHOCYTOSIS|1|kg/L|LAPAROSCOPY|||Y|PROXY|CLINICAL PATHOLOGIST|N|1|Visit_1|10|7|WASHOUT|2020-09-03|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-08|P1Y2M10DT2H30M|UNKNOWN|2020-10-06|ONGOING|2020-11-25
e|RS|616b284a-3fed-4009-bafe-7da10acd537e|3|NEWLWIND|New Lesion Worsening Indicator|BURCOMBE BREAST CANCER 2005|[?]|Ci/mg|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|ug/kg/day|MRI WITHOUT CONTRAST||Y||DOMESTIC PARTNER|PEDIATRIC NEUROLOGIST|U|2|Visit_2|25|5|TREATMENT|2020-09-18|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-05|P1Y2M10DT2H30M|AFTER|2020-11-09|COINCIDENT|2020-11-11
e|RS|616b284a-3fed-4009-bafe-7da10acd537e|4|METSIND|Metastatic Indicator|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|Anson U|CYTOGENETIC MINIMAL RESPONSE|1|mIU/L|RAJI CELL RIA||||FAMILY MEMBER|ONCOLOGIST 1|N|2|Visit_2|25|3|SCREENING|2020-09-18|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-05|P1Y2M10DT2H30M|COINCIDENT|2020-11-09|BEFORE|2020-11-17
e|RS|616b284a-3fed-4009-bafe-7da10acd537e|5|SFTSRESP|Soft Tissue Response|AJCC V7|[?]|Ci/uL|iUPD|1|Bq/g|REVERSE TRANSCRIPTASE PCR||Y||CLINICAL STUDY SPONSOR|NEUROLOGIST|NA|3|Visit_3|40|7|TREATMENT|2020-10-03|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-27|P1Y2M10DT2H30M|UNKNOWN|2020-09-25|ONGOING|2020-10-03
e|RS|616b284a-3fed-4009-bafe-7da10acd537e|6|DRCRIND|Disease Recurrence Indicator|TSUKASAKI LEUKEMIA LYMPHOMA 2009|||CA125 50% RESPONSE|1|U/m2/h|PET/SPECT SCAN||Y|Y|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 2|N|3|Visit_3|40|7|TREATMENT|2020-10-03|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-27|P1Y2M10DT2H30M|UNKNOWN|2020-10-04|COINCIDENT|2020-11-27
e|RS|616b284a-3fed-4009-bafe-7da10acd537e|7|PATHRESP|Pathologic Response|PETIT BREAST CANCER 2001|[?]|copies/ug|PDu|1|10^3 organisms/mL|MRI||||STUDY SUBJECT|RATER 2|NA|4|Visit_4|65|7|TREATMENT|2020-10-28|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-31|P1Y2M10DT2H30M|COINCIDENT|2020-09-21|BEFORE|2020-10-20
e|RS|616b284a-3fed-4009-bafe-7da10acd537e|8|METSIND|Metastatic Indicator|KEAM BREAST CANCER 2013|[?]|%|iCPD|1|eq|URANYL ACETATE STAIN||Y||PROXY|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|4|Visit_4|65|6|TREATMENT|2020-10-28|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-31|P1Y2M10DT2H30M|BEFORE|2020-11-26|AFTER|2020-11-28
e|RS|616b284a-3fed-4009-bafe-7da10acd537e|9|RDIORESP|Radiologic Response|UNSPECIFIED|[?]|10^4 CFU|CHR|1|SUPPOSITORY|IMPULSE OSCILLOMETRY|Y|Y||NON-HEALTH CARE PROFESSIONAL|READER|N|5|Visit_5|90|2|TREATMENT|2020-11-22|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-19|P1Y2M10DT2H30M|BEFORE|2020-10-15|COINCIDENT|2020-11-20
e|RS|616b284a-3fed-4009-bafe-7da10acd537e|10|MRPHRESP|Morphologic Response|EASL BRUIX LIVER CANCER 2001|||PSEUDORESPONSE|1|10^3 CFU/g|TRANSMISSION ELECTRON MICROSCOPY|||Y|HEALTH CARE PROFESSIONAL|OPTOMETRIST|NA|5|Visit_5|90|2|FOLLOW-UP|2020-11-22|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-19|P1Y2M10DT2H30M|BEFORE|2020-09-02|COINCIDENT|2020-09-20
e|RS|d39b53da-187f-4da6-9614-2bd301e9ad05|1|NTNERESP|Non-Target Non-Enhancing Response|PRINCE TCELL LYMPHOMA 2010|||WORSENED|1|PRESSOR UNITS|CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY||Y|Y|SPOUSE|NEUROLOGIST 2|Y|1|Visit_1|10|6|WASHOUT|2020-10-02|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-04|P1Y2M10DT2H30M|COINCIDENT|2020-11-19|COINCIDENT|2020-11-27
e|RS|d39b53da-187f-4da6-9614-2bd301e9ad05|2|MRDIND|Minimal Residual Disease Indicator|MRECIST BYRNE MESOTHELIOMA 2004|[?]|uL/mL|cPR|1|APS U|FUNCTIONAL MRI|Y|||CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 1|Y|1|Visit_1|10|3|TREATMENT|2020-10-02|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-04|P1Y2M10DT2H30M|AFTER|2020-11-16|COINCIDENT|2020-11-22
e|RS|d39b53da-187f-4da6-9614-2bd301e9ad05|3|HEMARESP|Hematologic Response|BLAZER COLORECTAL CANCER 2008|||CA125 75% RESPONSE|1|10^4/L|SINGLE-MOLECULE ARRAY|Y||Y|GUARDIAN|READER 3|N|2|Visit_2|25|6|TREATMENT|2020-10-17|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-27|P1Y2M10DT2H30M|COINCIDENT|2020-09-27|COINCIDENT|2020-11-10
e|RS|d39b53da-187f-4da6-9614-2bd301e9ad05|4|HEMARESP|Hematologic Response|HARTMANN GERM CELL CANCER 2002|||iSD|1|mm/2h|FLOW MICROSCOPY|Y|Y|Y|ADJUDICATION COMMITTEE|PATHOLOGIST|Y|2|Visit_2|25|4|WASHOUT|2020-10-17|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-27|P1Y2M10DT2H30M|UNKNOWN|2020-11-28|BEFORE|2020-12-24
e|RS|d39b53da-187f-4da6-9614-2bd301e9ad05|5|NTLWIND|Non-Target Lesion Worsening Indicator|EASL BRUIX LIVER CANCER 2001|[?]|mL/(min*100mL)|OPTIMAL MORPHOLOGIC RESPONSE|1|umol/min|FLUORESCENT IMMUNOASSAY|Y|Y||ADJUDICATION COMMITTEE|ENDOCRINOLOGIST|N|3|Visit_3|40|4|TREATMENT|2020-11-01|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-09|P1Y2M10DT2H30M|UNKNOWN|2020-12-15|BEFORE|2020-12-27
e|RS|d39b53da-187f-4da6-9614-2bd301e9ad05|6|MNPTHIND|Minor Pathological Response Indicator|PETIT BREAST CANCER 2001|[?]|POINT|MORPHOLOGIC CR|1|pmol/L|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY||||NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|3|Visit_3|40|3|SCREENING|2020-11-01|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-09|P1Y2M10DT2H30M|COINCIDENT|2020-12-09|COINCIDENT|2020-12-18
e|RS|d39b53da-187f-4da6-9614-2bd301e9ad05|7|MOLRESP|Molecular Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|||CHR|1|Roentgen|IMMUNOASSAY|Y||Y|GUARDIAN|DERMATOLOGIST|Y|4|Visit_4|65|3|TREATMENT|2020-11-26|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-16|P1Y2M10DT2H30M|COINCIDENT|2020-12-01|ONGOING|2020-12-21
e|RS|d39b53da-187f-4da6-9614-2bd301e9ad05|8|PATHRESP|Pathologic Response|CHESON CLL 2012|[?]|mAnson U/mL|MR|1|/500 WBC|ACRIDINE ORANGE STAIN|Y|||SIBLING|NEUROLOGIST 1|NA|4|Visit_4|65|7|TREATMENT|2020-11-26|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-16|P1Y2M10DT2H30M|COINCIDENT|2020-12-23|ONGOING|2020-12-29
e|RS|d39b53da-187f-4da6-9614-2bd301e9ad05|9|TMRESP|Tumor Marker Response|PRINCE TCELL LYMPHOMA 2010|[?]|mg/kg/dose|PD FROM PR|1|HEP|POLYGRAPHY||||FRIEND|RADIOLOGIST|U|5|Visit_5|90|3|SCREENING|2020-12-21|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-11|P1Y2M10DT2H30M|BEFORE|2020-11-23|AFTER|2020-12-27
e|RS|d39b53da-187f-4da6-9614-2bd301e9ad05|10|MOLRESP|Molecular Response|RECICL|[?]|MHz|PDu|1|SBE/mL|ULTRASOUND||||FRIEND|ONCOLOGIST 2|N|5|Visit_5|90|4|TREATMENT|2020-12-21|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-11|P1Y2M10DT2H30M|UNKNOWN|2020-10-06|AFTER|2020-12-13
e|RS|c2a43fc4-83c4-4522-b3b2-d4cb1a92a4b7|1|NEWLPROG|New Lesion Progression|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|Osm|COMPLETE MRD RESPONSE|1|uCi|CYSTOSCOPY|Y|||FAMILY MEMBER|OTOLARYNGOLOGIST|N|1|Visit_1|10|5|FOLLOW-UP|2020-12-04|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-28|P1Y2M10DT2H30M|UNKNOWN|2020-12-31|BEFORE|2021-01-14
e|RS|c2a43fc4-83c4-4522-b3b2-d4cb1a92a4b7|2|HEMARESP|Hematologic Response|JACINTO CERVICAL CANCER 2007|[?]|10^4/hpf|MRD PERSISTENCE|1|DDU|MRI|Y|||INDEPENDENT ASSESSOR|ENDOCRINOLOGIST|Y|1|Visit_1|10|3|FOLLOW-UP|2020-12-04|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-28|P1Y2M10DT2H30M|UNKNOWN|2021-02-22|COINCIDENT|2021-02-27
e|RS|c2a43fc4-83c4-4522-b3b2-d4cb1a92a4b7|3|MNPTHIND|Minor Pathological Response Indicator|PERCIST|[?]|mOsm/kg|NE|1|kN/cm2|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION||||NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST|U|2|Visit_2|25|2|TREATMENT|2020-12-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-01|P1Y2M10DT2H30M|UNKNOWN|2021-01-06|COINCIDENT|2021-01-23
e|RS|c2a43fc4-83c4-4522-b3b2-d4cb1a92a4b7|4|NTERESP|Non-Target Enhancing Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|mJoule/cm2|CR|1|mL/m2/h|ELECTROCHEMILUMINESCENCE||||GUARDIAN|INTERNIST|Y|2|Visit_2|25|7|FOLLOW-UP|2020-12-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-01|P1Y2M10DT2H30M|AFTER|2021-01-16|BEFORE|2021-02-20
e|RS|c2a43fc4-83c4-4522-b3b2-d4cb1a92a4b7|5|ANATRESP|Anatomic Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|deg/s|NON-iCR/NON-iUPD|1|CYLINDER|MICROSCOPY||||ADJUDICATOR|RADIOLOGIST 1|Y|3|Visit_3|40|5|SCREENING|2021-01-03|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-17|P1Y2M10DT2H30M|AFTER|2021-01-23|AFTER|2021-02-06
e|RS|c2a43fc4-83c4-4522-b3b2-d4cb1a92a4b7|6|MRDIND|Minimal Residual Disease Indicator|CHESON LYMPHOMA 2008|||MINOR PATHOLOGIC RESPONSE|1|Bq/ug|HEMAGGLUTINATION ASSAY||Y|Y|ADJUDICATOR|PATHOLOGIST 1|NA|3|Visit_3|40|3|FOLLOW-UP|2021-01-03|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-17|P1Y2M10DT2H30M|AFTER|2021-03-02|COINCIDENT|2021-03-03
e|RS|c2a43fc4-83c4-4522-b3b2-d4cb1a92a4b7|7|STRUSTAT|Steroid Use Status|AJCC V7|[?]|in|IMMUNOPHENOTYPIC CR|1|VIAL|TRANSCRIPTION-MEDIATED AMPLIFICATION||Y||INTERVIEWER|NEUROLOGIST 1|N|4|Visit_4|65|6|SCREENING|2021-01-28|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-29|P1Y2M10DT2H30M|COINCIDENT|2020-12-22|COINCIDENT|2021-01-22
e|RS|c2a43fc4-83c4-4522-b3b2-d4cb1a92a4b7|8|PATHRESP|Pathologic Response|NCIWG CHESON CLL 1996|[?]|Enzyme U/L|INDETERMINATE RESPONSE|1|ug/mol|DISK DIFFUSION||||NON-HEALTH CARE PROFESSIONAL|RATER 1|U|4|Visit_4|65|1|TREATMENT|2021-01-28|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-29|P1Y2M10DT2H30M|BEFORE|2021-01-02|AFTER|2021-02-28
e|RS|c2a43fc4-83c4-4522-b3b2-d4cb1a92a4b7|9|CYTORESP|Cytogenetic Response|PCWG SCHER PROSTATE CANCER 2016|[?]|PATCH|ABSENT MORPHOLOGIC RESPONSE|1|U/mg|DIRECT SEQUENCING||||ADJUDICATOR|INTERNIST|NA|5|Visit_5|90|7|TREATMENT|2021-02-22|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-08|P1Y2M10DT2H30M|UNKNOWN|2020-12-19|COINCIDENT|2021-01-30
e|RS|c2a43fc4-83c4-4522-b3b2-d4cb1a92a4b7|10|METSIND|Metastatic Indicator|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|||CYTOGENETIC PR|1|mL/cage|STRESS ECHOCARDIOGRAPHY|||Y|PROXY|ADJUDICATOR 2|Y|5|Visit_5|90|2|TREATMENT|2021-02-22|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-08|P1Y2M10DT2H30M|BEFORE|2020-12-08|BEFORE|2020-12-12
e|RS|e51cf168-af89-44d9-9e56-14785071f6b0|1|NTLWIND|Non-Target Lesion Worsening Indicator|MASS|||PMD|1|SYRINGE|IN VITRO GENE EXPRESSION ASSAY|||Y|FRIEND|ADJUDICATOR|NA|1|Visit_1|10|7|FOLLOW-UP|2020-11-27|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-12|P1Y2M10DT2H30M|BEFORE|2021-01-30|BEFORE|2021-02-07
e|RS|e51cf168-af89-44d9-9e56-14785071f6b0|2|NTERESP|Non-Target Enhancing Response|MURPHY PROSTATE CANCER 1980|[?]|10^6 RNA copies/mL|STABLE|1|mN|INDIA INK STAIN|Y|||DOMESTIC PARTNER|RADIOLOGIST 1|NA|1|Visit_1|10|3|TREATMENT|2020-11-27|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-12|P1Y2M10DT2H30M|AFTER|2021-02-19|BEFORE|2021-02-20
e|RS|e51cf168-af89-44d9-9e56-14785071f6b0|3|SPLNRESP|Spleen Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|10^5/L|MOLECULAR MAJOR RESPONSE|1|U/m2/min|LAPAROSCOPY|Y|||CHILD|MICROSCOPIST 3|Y|2|Visit_2|25|3|WASHOUT|2020-12-12|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-25|P1Y2M10DT2H30M|BEFORE|2020-12-15|AFTER|2021-02-01
e|RS|e51cf168-af89-44d9-9e56-14785071f6b0|4|ANATRESP|Anatomic Response|DOHNER AML 2010|[?]|K|PR WITH LYMPHOCYTOSIS|1|uCi/L|REVERSE TRANSCRIPTASE PCR|Y|||SIBLING|RATER 1|Y|2|Visit_2|25|3|TREATMENT|2020-12-12|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-25|P1Y2M10DT2H30M|BEFORE|2020-11-22|BEFORE|2021-02-02
e|RS|e51cf168-af89-44d9-9e56-14785071f6b0|5|BESTRESP|Best Overall Response|GUPPY OVARIAN CANCER 2002|||CHR|1|PFU/mL|SNELLEN EYE CHART|||Y|INDEPENDENT ASSESSOR|ADJUDICATOR 3|U|3|Visit_3|40|5|TREATMENT|2020-12-27|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-18|P1Y2M10DT2H30M|AFTER|2020-11-29|ONGOING|2021-01-25
e|RS|e51cf168-af89-44d9-9e56-14785071f6b0|6|BONERESP|Bone Response|HARTMAN PANCREATIC CANCER 2012|[?]|BP|UNFAVORABLE RESPONSE|1|mg/cm2|SISH||||INTERVIEWER|ONCOLOGIST 1|N|3|Visit_3|40|3|TREATMENT|2020-12-27|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-18|P1Y2M10DT2H30M|BEFORE|2020-12-27|AFTER|2021-01-19
e|RS|e51cf168-af89-44d9-9e56-14785071f6b0|7|NEWLIND|New Lesion Indicator|DURIE MULTIPLE MYELOMA 2006|[?]|IU/mL|iCR|1|mg/m2/min|ACRIDINE ORANGE STAIN||||VENDOR|PEDIATRIC NEUROLOGIST|N|4|Visit_4|65|1|FOLLOW-UP|2021-01-21|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-19|P1Y2M10DT2H30M|UNKNOWN|2021-01-07|BEFORE|2021-01-18
e|RS|e51cf168-af89-44d9-9e56-14785071f6b0|8|CYTORESP|Cytogenetic Response|EBMT BLADE MYELOMA 1998|[?]|nmol BCE/nmol|FAVORABLE RESPONSE|1|PUFF|SANGER SEQUENCING||||GUARDIAN|FORENSIC PATHOLOGIST|Y|4|Visit_4|65|7|TREATMENT|2021-01-21|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-19|P1Y2M10DT2H30M|UNKNOWN|2021-01-03|COINCIDENT|2021-02-17
e|RS|e51cf168-af89-44d9-9e56-14785071f6b0|9|OVRLRESP|Overall Response|DURIE MULTIPLE MYELOMA 2006|[?]|PLUG|SMD|1|mph|FLUORESCEIN STAIN||||HEALTH CARE PROFESSIONAL|RATER 1|Y|5|Visit_5|90|1|SCREENING|2021-02-15|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-13|P1Y2M10DT2H30M|UNKNOWN|2021-02-03|COINCIDENT|2021-02-11
e|RS|e51cf168-af89-44d9-9e56-14785071f6b0|10|MRDRESP|Minimal Residual Disease Response|IWG CHESON MDS 2000|[?]|GBq/g|HI-N|1|ms2|SPECT SCAN||||CLINICAL RESEARCH ASSOCIATE|HEMATOLOGIST|N|5|Visit_5|90|4|TREATMENT|2021-02-15|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-13|P1Y2M10DT2H30M|AFTER|2021-01-30|BEFORE|2021-02-03
e|RS|8416f8c6-d0e4-43fc-9a66-6a916e853e87|1|NTRGRESP|Non-target Response|PERCIST|[?]|pmol/L|SMD|1|10^7 CFU/mL|CARDIAC THERMODILUTION||Y||VENDOR|ONCOLOGIST 1|Y|1|Visit_1|10|6|FOLLOW-UP|2020-06-13|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-13|P1Y2M10DT2H30M|BEFORE|2020-08-20|BEFORE|2020-09-06
e|RS|8416f8c6-d0e4-43fc-9a66-6a916e853e87|2|TRGRESP|Target Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|Siemens|CYTOGENETIC PR|1|/40 HPFs|ELECTRONEUROGRAPHY||||CLINICAL STUDY SPONSOR|ADJUDICATOR 2|U|1|Visit_1|10|5|FOLLOW-UP|2020-06-13|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-13|P1Y2M10DT2H30M|BEFORE|2020-09-02|ONGOING|2020-09-09
e|RS|8416f8c6-d0e4-43fc-9a66-6a916e853e87|3|CPRFSTAT|Clinical Performance Status|GCIG RUSTIN OVARIAN CANCER 2011|[?]|pm|MORPHOLOGIC CR|1|mL/breath|OPTICAL COHERENCE TOMOGRAPHY||||ADJUDICATOR|PATHOLOGIST|Y|2|Visit_2|25|3|TREATMENT|2020-06-28|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-11|P1Y2M10DT2H30M|COINCIDENT|2020-06-06|ONGOING|2020-08-26
e|RS|8416f8c6-d0e4-43fc-9a66-6a916e853e87|4|SFTSRESP|Soft Tissue Response|BLAZER COLORECTAL CANCER 2008|[?]|Ci/kg|PD FROM PR|1|genEq/mL|LIGHT MICROSCOPY||||STUDY SUBJECT|NEUROLOGIST 1|N|2|Visit_2|25|2|FOLLOW-UP|2020-06-28|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-11|P1Y2M10DT2H30M|UNKNOWN|2020-08-15|ONGOING|2020-08-23
e|RS|8416f8c6-d0e4-43fc-9a66-6a916e853e87|5|MRPHRESP|Morphologic Response|WOLCHOK SOLID TUMORS 2009|[?]|mL/min/1.73m2|RELAPSED DISEASE FROM CR|1|mmol/mol|RAJI CELL EIA||Y||INDEPENDENT ASSESSOR|PHYSIOTHERAPIST|U|3|Visit_3|40|5|SCREENING|2020-07-13|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-29|P1Y2M10DT2H30M|UNKNOWN|2020-08-29|ONGOING|2020-09-04
e|RS|8416f8c6-d0e4-43fc-9a66-6a916e853e87|6|ANATRESP|Anatomic Response|WHO BREAST CANCER 2006|[?]|mAnson U/mL|NE|1|IMPLANT|RYAN BLUE STAIN||||ADJUDICATION COMMITTEE|READER 2|N|3|Visit_3|40|1|SCREENING|2020-07-13|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-29|P1Y2M10DT2H30M|COINCIDENT|2020-06-06|BEFORE|2020-06-26
e|RS|8416f8c6-d0e4-43fc-9a66-6a916e853e87|7|OVRLRESP|Overall Response|AJCC V7|[?]|JAR|UNEQUIVOCAL|1|mL/m2/day|SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|Y|Y||PARENT|CLINICAL PATHOLOGIST|Y|4|Visit_4|65|6|TREATMENT|2020-08-07|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-24|P1Y2M10DT2H30M|UNKNOWN|2020-09-06|ONGOING|2020-09-10
e|RS|8416f8c6-d0e4-43fc-9a66-6a916e853e87|8|NTNERESP|Non-Target Non-Enhancing Response|WHO BREAST CANCER 2006|[?]|Torr|DISEASE TRANSFORMATION|1|mL/m2|ECHOCARDIOGRAPHY||||ADJUDICATOR|PATHOLOGIST 1|NA|4|Visit_4|65|6|SCREENING|2020-08-07|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-24|P1Y2M10DT2H30M|UNKNOWN|2020-07-31|ONGOING|2020-08-20
e|RS|8416f8c6-d0e4-43fc-9a66-6a916e853e87|9|METSIND|Metastatic Indicator|FAROOQUI SUPP CLL 2014|[?]|hr/day|iUPD|1|MnFI|RADIOIMMUNOPRECIPITATION ASSAY||Y||VENDOR|ENDOCRINOLOGIST|U|5|Visit_5|90|5|FOLLOW-UP|2020-09-01|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-09|P1Y2M10DT2H30M|UNKNOWN|2020-08-19|COINCIDENT|2020-08-23
e|RS|8416f8c6-d0e4-43fc-9a66-6a916e853e87|10|TRGRESP|Target Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|SYRINGE|RELAPSED DISEASE FROM CR|1|IU/g Hb|CYSTOMETRY||||DOMESTIC PARTNER|OPHTHALMOLOGIST|Y|5|Visit_5|90|2|TREATMENT|2020-09-01|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-09|P1Y2M10DT2H30M|UNKNOWN|2020-07-07|AFTER|2020-08-18
e|RS|a110e924-90a1-4e84-b47a-410f800fa201|1|SPLNRESP|Spleen Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|/MBP|HI-N|1|fmol|IN VITRO GENE EXPRESSION ASSAY||||NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|U|1|Visit_1|10|7|TREATMENT|2020-10-29|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-07|P1Y2M10DT2H30M|AFTER|2020-12-14|ONGOING|2020-12-17
e|RS|a110e924-90a1-4e84-b47a-410f800fa201|2|NTERESP|Non-Target Enhancing Response|MURPHY PROSTATE CANCER 1980|||IMPROVED|1|kg/cm|SPIRAL CT|||Y|SIGNIFICANT OTHER|MICROSCOPIST 3|N|1|Visit_1|10|1|TREATMENT|2020-10-29|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-07|P1Y2M10DT2H30M|COINCIDENT|2020-11-12|ONGOING|2021-01-10
e|RS|a110e924-90a1-4e84-b47a-410f800fa201|3|OVRLRESP|Overall Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|dL|CMR|1|mEq/day|GIEMSA STAIN|Y|||NON-HEALTH CARE PROFESSIONAL|INTERNIST|Y|2|Visit_2|25|1|FOLLOW-UP|2020-11-13|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-20|P1Y2M10DT2H30M|AFTER|2020-11-07|COINCIDENT|2020-12-29
e|RS|a110e924-90a1-4e84-b47a-410f800fa201|4|ANATRESP|Anatomic Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|CAPFUL|cCR|1|kg|FLUORESCENT MICROSCOPY||||SPOUSE|PATHOLOGIST|Y|2|Visit_2|25|4|TREATMENT|2020-11-13|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-20|P1Y2M10DT2H30M|AFTER|2021-01-22|AFTER|2021-01-25
e|RS|a110e924-90a1-4e84-b47a-410f800fa201|5|MJPTHIND|Major Pathological Response Indicator|MACDONALD GLIOMA 1990|[?]|NFIU|pCR|1|g/kg|SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|Y|||PROXY|OTOLARYNGOLOGIST|Y|3|Visit_3|40|3|TREATMENT|2020-11-28|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-07|P1Y2M10DT2H30M|AFTER|2020-11-27|BEFORE|2020-12-30
e|RS|a110e924-90a1-4e84-b47a-410f800fa201|6|LIVRRESP|Liver Response|IWG CHESON MDS 2006|[?]|/HPF|WORSENED|1|10^6 DNA copies/mL|KARYOTYPING||Y||NON-HEALTH CARE PROFESSIONAL|READER 3|Y|3|Visit_3|40|1|SCREENING|2020-11-28|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-07|P1Y2M10DT2H30M|AFTER|2020-10-29|AFTER|2020-11-12
e|RS|a110e924-90a1-4e84-b47a-410f800fa201|7|BMIVLIND|Bone Marrow Involvement Indicator|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|10^6 DNA copies/mL|cPR|1|g/cage/wk|PERIODIC ACID SCHIFF STAIN||||DOMESTIC PARTNER|NEUROLOGIST 2|U|4|Visit_4|65|1|SCREENING|2020-12-23|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-22|P1Y2M10DT2H30M|UNKNOWN|2020-12-20|COINCIDENT|2021-01-26
e|RS|a110e924-90a1-4e84-b47a-410f800fa201|8|DRCRIND|Disease Recurrence Indicator|NCIWG CHESON CLL 1996|[?]|log10 PFU|VGPR|1|log10 IU/mL|FLOW MICROSCOPY||||FRIEND|OTOLARYNGOLOGIST|N|4|Visit_4|65|2|TREATMENT|2020-12-23|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-22|P1Y2M10DT2H30M|AFTER|2020-11-02|AFTER|2020-12-30
e|RS|a110e924-90a1-4e84-b47a-410f800fa201|9|SYMPTDTR|Symptomatic Deterioration|KUKER LYMPHOMA 2005|||ABSENT MORPHOLOGIC RESPONSE|1|FINGERTIP UNIT|MANUAL COUNT|||Y|SPOUSE|CLINICAL PATHOLOGIST|Y|5|Visit_5|90|5|WASHOUT|2021-01-17|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-30|P1Y2M10DT2H30M|COINCIDENT|2021-01-01|COINCIDENT|2021-01-17
e|RS|a110e924-90a1-4e84-b47a-410f800fa201|10|CPRFSTAT|Clinical Performance Status|RANO ELLINGSON 2017|[?]|AFU|CYTOGENETIC NO RESPONSE|1|ELISA unit/mL|DIGITAL PCR||||FAMILY MEMBER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5|Visit_5|90|3|TREATMENT|2021-01-17|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-30|P1Y2M10DT2H30M|UNKNOWN|2020-11-03|BEFORE|2020-11-07
e|RS|40681cb8-5d49-4e1d-b893-f5fad62a0885|1|NTRGRESP|Non-target Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|KALLIKREIN INHIBITOR UNIT|CA125 50% RESPONSE|1|deg/s|CALCOFLUOR WHITE STAIN||||CAREGIVER|PATHOLOGIST 1|NA|1|Visit_1|10|6|FOLLOW-UP|2020-08-08|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-02|P1Y2M10DT2H30M|UNKNOWN|2020-09-09|BEFORE|2020-10-14
e|RS|40681cb8-5d49-4e1d-b893-f5fad62a0885|2|NTRGRESP|Non-target Response|JUWEID NON-HODGKINS LYMPHOMA 2005|||MORPHOLOGIC CR|1|L/day|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY|Y||Y|HEALTH CARE PROFESSIONAL|CARDIOLOGIST|NA|1|Visit_1|10|6|FOLLOW-UP|2020-08-08|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-02|P1Y2M10DT2H30M|AFTER|2020-09-03|COINCIDENT|2020-10-09
e|RS|40681cb8-5d49-4e1d-b893-f5fad62a0885|3|NEWLWIND|New Lesion Worsening Indicator|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|HEP|nPR|1|mAmp|IMMUNOFLUORESCENT STAIN||Y||HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|2|Visit_2|25|5|TREATMENT|2020-08-23|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-21|P1Y2M10DT2H30M|COINCIDENT|2020-09-11|ONGOING|2020-10-01
e|RS|40681cb8-5d49-4e1d-b893-f5fad62a0885|4|PATHRESP|Pathologic Response|WHO BREAST CANCER 2006|[?]|FINGERTIP UNIT|PD FROM PR|1|g/animal/day|RAJI CELL EIA||||CAREGIVER|ENDOCRINOLOGIST|Y|2|Visit_2|25|1|SCREENING|2020-08-23|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-21|P1Y2M10DT2H30M|UNKNOWN|2020-08-09|ONGOING|2020-10-23
e|RS|40681cb8-5d49-4e1d-b893-f5fad62a0885|5|BONERESP|Bone Response|CHESON LYMPHOMA 2008|[?]|10^6 DNA copies/mL|NR|1|U/m2/min|WRIGHT-GIEMSA STAIN||||CHILD|FORENSIC PATHOLOGIST|Y|3|Visit_3|40|3|TREATMENT|2020-09-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-05|P1Y2M10DT2H30M|AFTER|2020-10-10|ONGOING|2020-10-13
e|RS|40681cb8-5d49-4e1d-b893-f5fad62a0885|6|STRUSTAT|Steroid Use Status|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|BAG|VGPR|1|Arbitrary U|OLIGO ACGH||Y||CLINICAL RESEARCH COORDINATOR|CLINICAL PATHOLOGIST|NA|3|Visit_3|40|6|WASHOUT|2020-09-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-05|P1Y2M10DT2H30M|BEFORE|2020-10-17|BEFORE|2020-10-28
e|RS|40681cb8-5d49-4e1d-b893-f5fad62a0885|7|NTLWIND|Non-Target Lesion Worsening Indicator|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|ug/min|iUPD|1|g/animal/day|ANALYTICAL ULTRACENTRIFUGATION||||SIBLING|READER|Y|4|Visit_4|65|5|TREATMENT|2020-10-02|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-10|P1Y2M10DT2H30M|COINCIDENT|2020-10-27|BEFORE|2020-11-05
e|RS|40681cb8-5d49-4e1d-b893-f5fad62a0885|8|MRDIND|Minimal Residual Disease Indicator|FAROOQUI SUPP CLL 2014|[?]|MET*h|HI-N|1|NEBULE|PHASE CONTRAST MICROSCOPY||Y||NON-HEALTH CARE PROFESSIONAL|RATER|Y|4|Visit_4|65|3|TREATMENT|2020-10-02|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-10|P1Y2M10DT2H30M|UNKNOWN|2020-10-08|ONGOING|2020-11-03
e|RS|40681cb8-5d49-4e1d-b893-f5fad62a0885|9|MNPTHIND|Minor Pathological Response Indicator|SACT|[?]|L/h|NED|1|s*kPa|ECHOCARDIOGRAPHY|Y|Y||SIGNIFICANT OTHER|MICROSCOPIST 2|U|5|Visit_5|90|6|FOLLOW-UP|2020-10-27|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-23|P1Y2M10DT2H30M|AFTER|2020-09-08|BEFORE|2020-11-03
e|RS|40681cb8-5d49-4e1d-b893-f5fad62a0885|10|BONERESP|Bone Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|mL/cm3/min|MINOR PATHOLOGIC RESPONSE|1|STRIP|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|Y|||SPOUSE|DEVELOPMENTAL PSYCHOLOGIST|NA|5|Visit_5|90|2|SCREENING|2020-10-27|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-23|P1Y2M10DT2H30M|AFTER|2020-10-02|AFTER|2020-10-12
e|RS|7a7dd1e0-46b7-4a46-bbde-601c5ee3ceeb|1|TRGRESP|Target Response|MRECIST BYRNE MESOTHELIOMA 2004|||NON-CR/NON-PD|1|STRIP|SANGER SEQUENCING|||Y|INTERVIEWER|READER 3|U|1|Visit_1|10|5|FOLLOW-UP|2020-12-17|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-26|P1Y2M10DT2H30M|UNKNOWN|2021-02-25|BEFORE|2021-03-07
e|RS|7a7dd1e0-46b7-4a46-bbde-601c5ee3ceeb|2|RDIORESP|Radiologic Response|RANO ELLINGSON 2017|[?]|/wk|CA125 50% RESPONSE|1|ukat/L|PH METER MEASUREMENT METHOD|Y|||SIGNIFICANT OTHER|ENDOCRINOLOGIST|Y|1|Visit_1|10|7|WASHOUT|2020-12-17|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-26|P1Y2M10DT2H30M|BEFORE|2021-02-14|BEFORE|2021-02-20
e|RS|7a7dd1e0-46b7-4a46-bbde-601c5ee3ceeb|3|MRPHRESP|Morphologic Response|AJCC V7|[?]|pmol/10^10 cells|PR-CT|1|nmol/L/h|PULMONARY ANGIOGRAPHY||||INDEPENDENT ASSESSOR|READER 2|N|2|Visit_2|25|1|SCREENING|2021-01-01|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-19|P1Y2M10DT2H30M|COINCIDENT|2021-01-25|ONGOING|2021-03-10
e|RS|7a7dd1e0-46b7-4a46-bbde-601c5ee3ceeb|4|TRGRESP|Target Response|SACT|[?]|nmol/kg/day|SMD|1|log10 CFU/g|FARR ASSAY|Y|||CHILD|PHYSIOTHERAPIST|Y|2|Visit_2|25|6|SCREENING|2021-01-01|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-19|P1Y2M10DT2H30M|UNKNOWN|2020-12-17|COINCIDENT|2021-03-14
e|RS|7a7dd1e0-46b7-4a46-bbde-601c5ee3ceeb|5|NEWLIND|New Lesion Indicator|RECIST 1.0|||EQUIVOCAL|1|ug/mL/h|CLINICAL EVALUATION|Y||Y|FAMILY MEMBER|RATER 2|Y|3|Visit_3|40|5|WASHOUT|2021-01-16|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-10|P1Y2M10DT2H30M|COINCIDENT|2020-12-22|COINCIDENT|2021-03-13
e|RS|7a7dd1e0-46b7-4a46-bbde-601c5ee3ceeb|6|MNPTHIND|Minor Pathological Response Indicator|IRANO 2015|[?]|min/day|NED|1|Absorbance U/mL|MICROBIAL CULTURE, LIQUID||||SIGNIFICANT OTHER|UROLOGIST|NA|3|Visit_3|40|6|TREATMENT|2021-01-16|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-10|P1Y2M10DT2H30M|BEFORE|2020-12-21|COINCIDENT|2021-01-27
e|RS|7a7dd1e0-46b7-4a46-bbde-601c5ee3ceeb|7|METBRESP|Metabolic Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|Ci/L|INDETERMINATE RESPONSE|1|breaths/30s|DARK FIELD MICROSCOPY||||SPOUSE|NEUROLOGIST 2|NA|4|Visit_4|65|2|WASHOUT|2021-02-10|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-06|P1Y2M10DT2H30M|UNKNOWN|2021-01-19|COINCIDENT|2021-01-28
e|RS|7a7dd1e0-46b7-4a46-bbde-601c5ee3ceeb|8|SYMPTDTR|Symptomatic Deterioration|RECIST 1.0|[?]|Pack Year|STABLE|1|um|AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT||||INVESTIGATOR|READER 2|NA|4|Visit_4|65|4|TREATMENT|2021-02-10|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-06|P1Y2M10DT2H30M|BEFORE|2021-01-30|ONGOING|2021-03-08
e|RS|7a7dd1e0-46b7-4a46-bbde-601c5ee3ceeb|9|MRDRESP|Minimal Residual Disease Response|SCHWARZ CERVICAL CANCER 2009|||PR WITH LYMPHOCYTOSIS|1|nmol/L/h|SPECT SCAN|Y||Y|CHILD|RADIOLOGIST 2|U|5|Visit_5|90|3|FOLLOW-UP|2021-03-07|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-13|P1Y2M10DT2H30M|COINCIDENT|2021-02-14|COINCIDENT|2021-03-06
e|RS|7a7dd1e0-46b7-4a46-bbde-601c5ee3ceeb|10|METBRESP|Metabolic Response|GUILHOT CML 2007|[?]|Coulomb|CA125 50% RESPONSE|1|pm|SLOAN LETTER EYE CHART 1.25%||||INTERVIEWER|READER 2|U|5|Visit_5|90|4|TREATMENT|2021-03-07|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-13|P1Y2M10DT2H30M|AFTER|2020-12-30|ONGOING|2021-01-21
e|RS|96e65c5c-723c-42d9-8e88-0bcb600e9f88|1|MRDRESP|Minimal Residual Disease Response|EBMT BLADE MYELOMA 1998|[?]|ug/min|NON-PD|1|10^6 organisms|HEMOCYTOMETRY||||CLINICAL STUDY SPONSOR|ADJUDICATOR|U|1|Visit_1|10|2|SCREENING|2020-09-10|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-29|P1Y2M10DT2H30M|AFTER|2020-09-06|ONGOING|2020-09-26
e|RS|96e65c5c-723c-42d9-8e88-0bcb600e9f88|2|SPLNRESP|Spleen Response|MURPHY PROSTATE CANCER 1980|[?]|CAPSULE|COMPLETE MRD RESPONSE|1|10^6 DNA copies/mL|ICC|Y|Y||SPOUSE|ONCOLOGIST 1|N|1|Visit_1|10|7|TREATMENT|2020-09-10|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-29|P1Y2M10DT2H30M|BEFORE|2020-11-26|AFTER|2020-12-06
e|RS|96e65c5c-723c-42d9-8e88-0bcb600e9f88|3|TMRESP|Tumor Marker Response|IWG CHESON MDS 2000|[?]|nm|iCPD|1|ug/h|CONTRAST ENHANCED PET SCAN||||STUDY SUBJECT|PATHOLOGIST 1|U|2|Visit_2|25|1|TREATMENT|2020-09-25|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-10|P1Y2M10DT2H30M|COINCIDENT|2020-09-16|COINCIDENT|2020-10-26
e|RS|96e65c5c-723c-42d9-8e88-0bcb600e9f88|4|NTRGRESP|Non-target Response|PRINCE TCELL LYMPHOMA 2010|[?]|/h|pCR|1|pmol|FLUORESCENT MICROSCOPY||||VENDOR|RADIOLOGIST 1|N|2|Visit_2|25|7|TREATMENT|2020-09-25|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-10|P1Y2M10DT2H30M|AFTER|2020-11-30|COINCIDENT|2020-12-02
e|RS|96e65c5c-723c-42d9-8e88-0bcb600e9f88|5|NEWLIND|New Lesion Indicator|KEAM BREAST CANCER 2013|[?]|MBq|PMR|1|mCi/kg|CELL BASED BIOASSAY||||INVESTIGATOR|UROLOGIST|Y|3|Visit_3|40|3|TREATMENT|2020-10-10|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-02|P1Y2M10DT2H30M|UNKNOWN|2020-10-07|BEFORE|2020-10-21
e|RS|96e65c5c-723c-42d9-8e88-0bcb600e9f88|6|HEMARESP|Hematologic Response|JACINTO CERVICAL CANCER 2007|[?]|gpELISA unit/mL|MAJOR PATHOLOGIC RESPONSE|1|OD Unit|CALCOFLUOR WHITE STAIN|Y|||CAREGIVER|READER|U|3|Visit_3|40|1|TREATMENT|2020-10-10|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-02|P1Y2M10DT2H30M|BEFORE|2020-09-29|ONGOING|2020-12-02
e|RS|96e65c5c-723c-42d9-8e88-0bcb600e9f88|7|NTERESP|Non-Target Enhancing Response|IRANO 2015|[?]|Watt|cCR|1|V|PHYSICAL EXAMINATION||||PROXY|OTOLARYNGOLOGIST|U|4|Visit_4|65|6|TREATMENT|2020-11-04|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-04|P1Y2M10DT2H30M|COINCIDENT|2020-11-28|BEFORE|2020-12-04
e|RS|96e65c5c-723c-42d9-8e88-0bcb600e9f88|8|BONERESP|Bone Response|KUKER LYMPHOMA 2005|[?]|ug/m2/h|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|ug/dL|DOPPLER ULTRASOUND||||INDEPENDENT ASSESSOR|ADJUDICATOR 2|U|4|Visit_4|65|7|SCREENING|2020-11-04|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-04|P1Y2M10DT2H30M|BEFORE|2020-09-24|COINCIDENT|2020-12-04
e|RS|96e65c5c-723c-42d9-8e88-0bcb600e9f88|9|BONERESP|Bone Response|MONTSERRAT CLL 1989|[?]|TRANSDUCING UNIT/mL|PR-CT|1|TABLET|MECHANICAL CLOT DETECTION||||CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 2|Y|5|Visit_5|90|7|FOLLOW-UP|2020-11-29|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-18|P1Y2M10DT2H30M|COINCIDENT|2020-10-29|AFTER|2020-11-20
e|RS|96e65c5c-723c-42d9-8e88-0bcb600e9f88|10|NTLWIND|Non-Target Lesion Worsening Indicator|RECICL|||IMMUNOPHENOTYPIC CR|1|RFU|AUTOMATED COUNT|Y||Y|PARENT|NEUROLOGIST|NA|5|Visit_5|90|3|TREATMENT|2020-11-29|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-18|P1Y2M10DT2H30M|COINCIDENT|2020-09-23|ONGOING|2020-10-08
e|RS|eaf1edbe-1848-4614-b7b1-dcbcba5f0a15|1|SYMPTDTR|Symptomatic Deterioration|LEE LUNG CANCER 2011|[?]|10^3 DNA copies/mL|MRD NEGATIVITY|1|pg/cell|IMMUNODIFFUSION||||SIBLING|PATHOLOGIST 1|N|1|Visit_1|10|7|TREATMENT|2020-07-12|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-03|P1Y2M10DT2H30M|BEFORE|2020-09-30|BEFORE|2020-10-08
e|RS|eaf1edbe-1848-4614-b7b1-dcbcba5f0a15|2|ANATRESP|Anatomic Response|CHOLLET BREAST CANCER 2002|[?]|10^6 DNA copies/mL|NON-iCR/NON-iUPD|1|ug/mol|TARGETED TRANSCRIPTOME SEQUENCING|Y|||PARENT|CARDIOLOGIST|U|1|Visit_1|10|5|WASHOUT|2020-07-12|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-03|P1Y2M10DT2H30M|AFTER|2020-08-20|COINCIDENT|2020-09-07
e|RS|eaf1edbe-1848-4614-b7b1-dcbcba5f0a15|3|MOLRESP|Molecular Response|MACDONALD GLIOMA 1990|[?]|log10 CFU/g|IMMUNOPHENOTYPIC CR|1|mV|FLUORESCENT ENZYME IMMUNOASSAY|Y|||HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|2|Visit_2|25|2|FOLLOW-UP|2020-07-27|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-14|P1Y2M10DT2H30M|COINCIDENT|2020-09-15|BEFORE|2020-10-03
e|RS|eaf1edbe-1848-4614-b7b1-dcbcba5f0a15|4|PATHRESP|Pathologic Response|iRECIST|||PD/RELAPSE AFTER HI|1|10^12 IU/L|JAEGER EYE CHART||Y|Y|NON-HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|NA|2|Visit_2|25|4|WASHOUT|2020-07-27|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-14|P1Y2M10DT2H30M|UNKNOWN|2020-07-13|BEFORE|2020-10-04
e|RS|eaf1edbe-1848-4614-b7b1-dcbcba5f0a15|5|BESTRESP|Best Overall Response|HARTMANN GERM CELL CANCER 2002|[?]|10^3 copies/mL|UNEQUIVOCAL|1|kN/cm2|COMPUTERIZED CORNEAL TOPOGRAPHY|Y|||HEALTH CARE PROFESSIONAL|ONCOLOGIST|Y|3|Visit_3|40|6|TREATMENT|2020-08-11|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-11|P1Y2M10DT2H30M|UNKNOWN|2020-08-01|BEFORE|2020-09-18
e|RS|eaf1edbe-1848-4614-b7b1-dcbcba5f0a15|6|NEWLPROG|New Lesion Progression|RAJKUMAR MYELOMA 2011|[?]|L|FAVORABLE RESPONSE|1|RFU|ULTRASONOGRAPHIC ELASTOGRAPHY||||FRIEND|OPHTHALMOLOGIST|Y|3|Visit_3|40|4|TREATMENT|2020-08-11|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-11|P1Y2M10DT2H30M|AFTER|2020-08-19|AFTER|2020-09-11
e|RS|eaf1edbe-1848-4614-b7b1-dcbcba5f0a15|7|RDIORESP|Radiologic Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|Bq/L|iPR|1|Gy|CONTRAST ENHANCED SPIRAL CT SCAN||||VENDOR|RADIOLOGIST 2|N|4|Visit_4|65|2|TREATMENT|2020-09-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-07|P1Y2M10DT2H30M|AFTER|2020-08-25|COINCIDENT|2020-09-10
e|RS|eaf1edbe-1848-4614-b7b1-dcbcba5f0a15|8|METBRESP|Metabolic Response|BLAZER COLORECTAL CANCER 2008|[?]|tuberculin unit/mL|DISEASE TRANSFORMATION|1|mCi/L|FLAME PHOTOMETRY||||PARENT|OPTOMETRIST|N|4|Visit_4|65|3|TREATMENT|2020-09-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-07|P1Y2M10DT2H30M|COINCIDENT|2020-07-28|COINCIDENT|2020-08-24
e|RS|eaf1edbe-1848-4614-b7b1-dcbcba5f0a15|9|NTLWIND|Non-Target Lesion Worsening Indicator|SCHER PROSTATE CANCER 2011|[?]|umol/min|PD/RELAPSE AFTER HI|1|dB|EEG||||SIBLING|MICROSCOPIST 2|NA|5|Visit_5|90|6|SCREENING|2020-09-30|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-12|P1Y2M10DT2H30M|UNKNOWN|2020-09-13|COINCIDENT|2020-10-04
e|RS|eaf1edbe-1848-4614-b7b1-dcbcba5f0a15|10|NTLWIND|Non-Target Lesion Worsening Indicator|RECIST 1.1|[?]|m/sec|cPR|1|ug/animal|OBSERVATION||||SIBLING|READER 1|U|5|Visit_5|90|7|SCREENING|2020-09-30|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-12|P1Y2M10DT2H30M|AFTER|2020-09-16|COINCIDENT|2020-10-05
e|RS|f81742a2-5250-43d7-a6e2-8fcb1625a114|1|CPRFSTAT|Clinical Performance Status|IWC HALLEK CLL 2008|[?]|log10 IU/mL|DISEASE TRANSFORMATION|1|mg2/dL2|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY|Y|||VENDOR|NEUROLOGIST|Y|1|Visit_1|10|5|TREATMENT|2020-05-30|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-14|P1Y2M10DT2H30M|COINCIDENT|2020-06-06|ONGOING|2020-07-14
e|RS|f81742a2-5250-43d7-a6e2-8fcb1625a114|2|METBRESP|Metabolic Response|KUMAR IMWG 2016|[?]|ug/day|SMD|1|10^6/L|CONTRAST ENHANCED X-RAY|Y|||INVESTIGATOR|ONCOLOGIST 1|NA|1|Visit_1|10|3|SCREENING|2020-05-30|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-14|P1Y2M10DT2H30M|AFTER|2020-07-31|ONGOING|2020-08-11
e|RS|f81742a2-5250-43d7-a6e2-8fcb1625a114|3|TRGRESP|Target Response|KUMAR IMWG 2016|||RELAPSED DISEASE FROM CR OR PR|1|/day|KARYOTYPING|Y||Y|HEALTH CARE PROFESSIONAL|OPTOMETRIST|N|2|Visit_2|25|3|FOLLOW-UP|2020-06-14|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-13|P1Y2M10DT2H30M|AFTER|2020-05-25|ONGOING|2020-05-30
e|RS|f81742a2-5250-43d7-a6e2-8fcb1625a114|4|NTERESP|Non-Target Enhancing Response|CHOLLET BREAST CANCER 2002|[?]|mol/mg|DECREASED|1|Anson U|MACRO BROTH DILUTION||Y||FAMILY MEMBER|RATER 2|Y|2|Visit_2|25|7|TREATMENT|2020-06-14|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-13|P1Y2M10DT2H30M|AFTER|2020-06-26|BEFORE|2020-07-29
e|RS|f81742a2-5250-43d7-a6e2-8fcb1625a114|5|STRUSTAT|Steroid Use Status|EBMT BLADE MYELOMA 1998|[?]|PIXEL|nPR|1|VIAL|ACRIDINE ORANGE STAIN|Y|||CLINICAL RESEARCH COORDINATOR|RADIOLOGIST|Y|3|Visit_3|40|6|TREATMENT|2020-06-29|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-17|P1Y2M10DT2H30M|BEFORE|2020-08-01|COINCIDENT|2020-08-10
e|RS|f81742a2-5250-43d7-a6e2-8fcb1625a114|6|NTLWIND|Non-Target Lesion Worsening Indicator|KEAM BREAST CANCER 2013|[?]|g/cage|CMR|1|10^6 organisms|NON-CONTACT SPECULAR MICROSCOPY||||ADJUDICATION COMMITTEE|OTOLARYNGOLOGIST|N|3|Visit_3|40|2|TREATMENT|2020-06-29|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-17|P1Y2M10DT2H30M|COINCIDENT|2020-07-18|AFTER|2020-08-12
e|RS|f81742a2-5250-43d7-a6e2-8fcb1625a114|7|SPLNRESP|Spleen Response|WHO BREAST CANCER 2006|[?]|ug/cm2|PD/RELAPSE AFTER HI|1|Bq/L|PLETHYSMOGRAPHY|Y|Y||GUARDIAN|NEUROLOGIST 1|U|4|Visit_4|65|5|WASHOUT|2020-07-24|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-03|P1Y2M10DT2H30M|BEFORE|2020-07-22|AFTER|2020-08-17
e|RS|f81742a2-5250-43d7-a6e2-8fcb1625a114|8|BESTRESP|Best Overall Response|SCHWARZ CERVICAL CANCER 2009|[?]|MnFI|CYTOGENETIC MINIMAL RESPONSE|1|Gauss|WRIGHT STAIN|Y|||PROXY|HEMATOLOGIST|U|4|Visit_4|65|7|TREATMENT|2020-07-24|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-03|P1Y2M10DT2H30M|BEFORE|2020-05-25|COINCIDENT|2020-08-09
e|RS|f81742a2-5250-43d7-a6e2-8fcb1625a114|9|MOLRESP|Molecular Response|RANO ELLINGSON 2017|||UNFAVORABLE RESPONSE|1|dpm/mg|ELASTOGRAPHY||Y|Y|FRIEND|READER 2|NA|5|Visit_5|90|5|WASHOUT|2020-08-18|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-25|P1Y2M10DT2H30M|UNKNOWN|2020-07-25|AFTER|2020-07-29
e|RS|f81742a2-5250-43d7-a6e2-8fcb1625a114|10|ANATRESP|Anatomic Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|ug|MAJOR PATHOLOGIC RESPONSE|1|STEPS|ANTIMICROBIAL COMBINATION TESTING||Y||VENDOR|UROLOGIST|Y|5|Visit_5|90|6|TREATMENT|2020-08-18|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-25|P1Y2M10DT2H30M|COINCIDENT|2020-05-28|AFTER|2020-08-03
e|RS|c6bad1d0-3514-4f98-b229-d093a94dfbc4|1|TRGRESP|Target Response|RAJKUMAR MYELOMA 2011|[?]|cd/m2|HI-E|1|10^4/hpf|APPLANATION TONOMETRY||||CHILD|MICROSCOPIST 1|U|1|Visit_1|10|3|TREATMENT|2020-06-24|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-18|P1Y2M10DT2H30M|UNKNOWN|2020-07-14|ONGOING|2020-07-26
e|RS|c6bad1d0-3514-4f98-b229-d093a94dfbc4|2|MOLRESP|Molecular Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|g/cage/wk|MRD NEGATIVITY|1|TUBE|HEMATOXYLIN AND EOSIN STAIN||||SIGNIFICANT OTHER|OPTOMETRIST|Y|1|Visit_1|10|3|TREATMENT|2020-06-24|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-18|P1Y2M10DT2H30M|UNKNOWN|2020-07-20|COINCIDENT|2020-07-24
e|RS|c6bad1d0-3514-4f98-b229-d093a94dfbc4|3|DRCRIND|Disease Recurrence Indicator|KUMAR IMWG 2016|[?]|s^-1(%O2)^-1|MAJOR PATHOLOGIC RESPONSE|1|/min|ACRIDINE ORANGE STAIN||||FRIEND|MICROSCOPIST|Y|2|Visit_2|25|6|TREATMENT|2020-07-09|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-16|P1Y2M10DT2H30M|AFTER|2020-07-21|BEFORE|2020-07-31
e|RS|c6bad1d0-3514-4f98-b229-d093a94dfbc4|4|TMRESP|Tumor Marker Response|HAMAOKA BREAST CANCER 2010|[?]|usec|PD-CT|1|HEP|POTENTIOMETRY|Y|||PARENT|ONCOLOGIST 1|Y|2|Visit_2|25|4|WASHOUT|2020-07-09|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-16|P1Y2M10DT2H30M|AFTER|2020-08-15|AFTER|2020-09-21
e|RS|c6bad1d0-3514-4f98-b229-d093a94dfbc4|5|MRDIND|Minimal Residual Disease Indicator|HARTMANN GERM CELL CANCER 2002|[?]|Enzyme U/L|MINOR PATHOLOGIC RESPONSE|1|LB|REVERSE TRANSCRIPTASE PCR||Y||SPOUSE|MICROSCOPIST|NA|3|Visit_3|40|3|TREATMENT|2020-07-24|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-19|P1Y2M10DT2H30M|UNKNOWN|2020-07-05|AFTER|2020-08-04
e|RS|c6bad1d0-3514-4f98-b229-d093a94dfbc4|6|MOLRESP|Molecular Response|JUWEID NON-HODGKINS LYMPHOMA 2005|||pCR|1|cm|BALLPOINT PEN TECHNIQUE|||Y|FAMILY MEMBER|MICROSCOPIST 1|Y|3|Visit_3|40|7|FOLLOW-UP|2020-07-24|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-19|P1Y2M10DT2H30M|BEFORE|2020-07-28|ONGOING|2020-08-25
e|RS|c6bad1d0-3514-4f98-b229-d093a94dfbc4|7|CPRFSTAT|Clinical Performance Status|PETIT BREAST CANCER 2001|[?]|g/m2/day|CYTOGENETIC MINOR RESPONSE|1|cs|NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY|Y|||NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|NA|4|Visit_4|65|1|SCREENING|2020-08-18|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-24|P1Y2M10DT2H30M|COINCIDENT|2020-08-30|ONGOING|2020-09-15
e|RS|c6bad1d0-3514-4f98-b229-d093a94dfbc4|8|METBRESP|Metabolic Response|RANO ELLINGSON 2017|||MRD NEGATIVITY|1|min/day|ELECTRONEUROGRAPHY|||Y|INTERVIEWER|MICROSCOPIST 1|U|4|Visit_4|65|5|TREATMENT|2020-08-18|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-24|P1Y2M10DT2H30M|AFTER|2020-06-23|AFTER|2020-07-30
e|RS|c6bad1d0-3514-4f98-b229-d093a94dfbc4|9|MOLRESP|Molecular Response|RECICL|[?]|cmol|iCPD|1|ppb|AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT||||GUARDIAN|READER 1|NA|5|Visit_5|90|1|FOLLOW-UP|2020-09-12|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-30|P1Y2M10DT2H30M|COINCIDENT|2020-08-28|ONGOING|2020-09-12
e|RS|c6bad1d0-3514-4f98-b229-d093a94dfbc4|10|HEMARESP|Hematologic Response|RANO|||MRD RELAPSE|1|HOURS|PH METER MEASUREMENT METHOD|||Y|CAREGIVER|ADJUDICATOR 2|NA|5|Visit_5|90|7|FOLLOW-UP|2020-09-12|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-30|P1Y2M10DT2H30M|COINCIDENT|2020-08-12|AFTER|2020-09-19
e|RS|84d68bcc-dc7a-4366-9630-40ce8885351d|1|RDIORESP|Radiologic Response|PERCIST|[?]|IU/kg|iCR|1|genEq|POLYSOMNOGRAPHY||||FRIEND|ADJUDICATOR 3|U|1|Visit_1|10|4|TREATMENT|2020-06-16|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-26|P1Y2M10DT2H30M|COINCIDENT|2020-08-28|BEFORE|2020-09-01
e|RS|84d68bcc-dc7a-4366-9630-40ce8885351d|2|CYTORESP|Cytogenetic Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|U/kg/h|ABSENT MORPHOLOGIC RESPONSE|1|nmol/day|DOUBLE IMMUNODIFFUSION|Y|Y||CLINICAL STUDY SPONSOR|RADIOLOGIST 2|Y|1|Visit_1|10|4|FOLLOW-UP|2020-06-16|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-26|P1Y2M10DT2H30M|COINCIDENT|2020-07-06|BEFORE|2020-08-16
e|RS|84d68bcc-dc7a-4366-9630-40ce8885351d|3|RDIORESP|Radiologic Response|DURIE MULTIPLE MYELOMA 2006|[?]|Ci/L|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|10^4 CFU|MICRODENSITOMETRY||||FRIEND|PATHOLOGIST|N|2|Visit_2|25|5|WASHOUT|2020-07-01|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-01|P1Y2M10DT2H30M|AFTER|2020-08-22|BEFORE|2020-09-02
e|RS|84d68bcc-dc7a-4366-9630-40ce8885351d|4|TRGRESP|Target Response|MURPHY PROSTATE CANCER 1980|||PR-CT|1|amu|DIFFUSION WEIGHTED MRI||Y|Y|SIBLING|RADIOLOGIST 2|Y|2|Visit_2|25|6|WASHOUT|2020-07-01|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-01|P1Y2M10DT2H30M|COINCIDENT|2020-07-26|COINCIDENT|2020-08-30
e|RS|84d68bcc-dc7a-4366-9630-40ce8885351d|5|MRDRESP|Minimal Residual Disease Response|UNSPECIFIED|[?]|FIU|iPR|1|mol/mL|MAPH||Y||STUDY SUBJECT|READER 1|Y|3|Visit_3|40|1|SCREENING|2020-07-16|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-28|P1Y2M10DT2H30M|AFTER|2020-08-10|ONGOING|2020-09-03
e|RS|84d68bcc-dc7a-4366-9630-40ce8885351d|6|NEWLIND|New Lesion Indicator|SCHWARZ CERVICAL CANCER 2009|[?]|mEq/kg|RELAPSED DISEASE|1|DPM|MULTIPLE BREATH WASHOUT|Y|||DOMESTIC PARTNER|CLINICAL PATHOLOGIST|NA|3|Visit_3|40|4|WASHOUT|2020-07-16|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-28|P1Y2M10DT2H30M|UNKNOWN|2020-09-01|BEFORE|2020-09-12
e|RS|84d68bcc-dc7a-4366-9630-40ce8885351d|7|MRDIND|Minimal Residual Disease Indicator|SCHWARZ CERVICAL CANCER 2009|[?]|Ci/mL|MRD RELAPSE|1|TUBE|GC/FID||Y||SIBLING|RATER 2|Y|4|Visit_4|65|5|TREATMENT|2020-08-10|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-27|P1Y2M10DT2H30M|BEFORE|2020-06-24|BEFORE|2020-07-04
e|RS|84d68bcc-dc7a-4366-9630-40ce8885351d|8|NTERESP|Non-Target Enhancing Response|SCHWARZ CERVICAL CANCER 2009|[?]|CAPFUL|MAJOR PATHOLOGIC RESPONSE|1|nU/cL|CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|Y|||DOMESTIC PARTNER|READER 2|U|4|Visit_4|65|2|SCREENING|2020-08-10|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-27|P1Y2M10DT2H30M|BEFORE|2020-08-25|ONGOING|2020-08-30
e|RS|84d68bcc-dc7a-4366-9630-40ce8885351d|9|MRDRESP|Minimal Residual Disease Response|IWC HALLEK CLL 2008|||TREATMENT FAILURE|1|MnFI|NEPHELOMETRY|||Y|INTERVIEWER|PEDIATRIC NEUROLOGIST|NA|5|Visit_5|90|4|FOLLOW-UP|2020-09-04|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-07|P1Y2M10DT2H30M|AFTER|2020-08-03|AFTER|2020-09-13
e|RS|84d68bcc-dc7a-4366-9630-40ce8885351d|10|SYMPTDTR|Symptomatic Deterioration|UNSPECIFIED|||nPR|1|anti-Xa IU|HEMAGGLUTINATION ASSAY||Y|Y|FRIEND|ONCOLOGIST|U|5|Visit_5|90|6|TREATMENT|2020-09-04|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-07|P1Y2M10DT2H30M|AFTER|2020-07-11|AFTER|2020-09-02
e|RS|517f3930-5202-4e0a-b3e1-85ed4bd7e117|1|MNPTHIND|Minor Pathological Response Indicator|SCHER PROSTATE CANCER 2011|[?]|IU/mg|IMMUNOPHENOTYPIC CR|1|Anson U|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|Y|||STUDY SUBJECT|PATHOLOGIST 2|NA|1|Visit_1|10|1|TREATMENT|2021-01-08|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-07|P1Y2M10DT2H30M|COINCIDENT|2021-02-26|COINCIDENT|2021-03-09
e|RS|517f3930-5202-4e0a-b3e1-85ed4bd7e117|2|SPLNRESP|Spleen Response|GUPPY OVARIAN CANCER 2002|[?]|umol/mg/min|CA125 50% RESPONSE|1|um2|EEG||Y||FRIEND|ADJUDICATOR|Y|1|Visit_1|10|4|TREATMENT|2021-01-08|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-07|P1Y2M10DT2H30M|COINCIDENT|2021-03-28|COINCIDENT|2021-04-06
e|RS|517f3930-5202-4e0a-b3e1-85ed4bd7e117|3|NTNERESP|Non-Target Non-Enhancing Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|||PD FROM PR|1|uSiemens|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|Y||Y|CLINICAL STUDY SPONSOR|NEUROLOGIST 1|Y|2|Visit_2|25|1|SCREENING|2021-01-23|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-26|P1Y2M10DT2H30M|AFTER|2021-03-26|ONGOING|2021-04-03
e|RS|517f3930-5202-4e0a-b3e1-85ed4bd7e117|4|CPRFSTAT|Clinical Performance Status|CHOI GIST 2008|[?]|Mile|INCREASED|1|GPS U|FLOCCULATION, CHARCOAL ENHANCED|Y|||CLINICAL RESEARCH ASSOCIATE|READER 3|NA|2|Visit_2|25|3|TREATMENT|2021-01-23|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-26|P1Y2M10DT2H30M|BEFORE|2021-03-28|AFTER|2021-03-29
e|RS|517f3930-5202-4e0a-b3e1-85ed4bd7e117|5|CLINRESP|Clinical Response|DURIE MULTIPLE MYELOMA 2006|[?]|mL/g/min|NON-PD|1|g/animal|REBOUND TONOMETRY||||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST|N|3|Visit_3|40|1|SCREENING|2021-02-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-03|P1Y2M10DT2H30M|BEFORE|2021-03-10|AFTER|2021-04-06
e|RS|517f3930-5202-4e0a-b3e1-85ed4bd7e117|6|METBRESP|Metabolic Response|PCWG SCHER PROSTATE CANCER 2008|||CA125 50% RESPONSE|1|mmol/g|LUXOL FAST BLUE AND CRESYL VIOLET STAIN|||Y|CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|3|Visit_3|40|3|FOLLOW-UP|2021-02-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-03|P1Y2M10DT2H30M|AFTER|2021-03-15|AFTER|2021-03-18
e|RS|517f3930-5202-4e0a-b3e1-85ed4bd7e117|7|OVRLRESP|Overall Response|BRUGGEMANN MRD 2010|[?]|uOsm|PD FROM PR|1|%/s|DISK DIFFUSION||Y||SPOUSE|OPTOMETRIST|Y|4|Visit_4|65|7|TREATMENT|2021-03-04|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-21|P1Y2M10DT2H30M|BEFORE|2021-01-05|ONGOING|2021-02-22
e|RS|517f3930-5202-4e0a-b3e1-85ed4bd7e117|8|CLINRESP|Clinical Response|HARTMAN PANCREATIC CANCER 2012|[?]|DNA copies/mL|COMPLETE MRD RESPONSE|1|ug|ICC|Y|||CLINICAL RESEARCH ASSOCIATE|READER 2|Y|4|Visit_4|65|4|TREATMENT|2021-03-04|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-21|P1Y2M10DT2H30M|AFTER|2021-01-30|AFTER|2021-03-12
e|RS|517f3930-5202-4e0a-b3e1-85ed4bd7e117|9|DRCRIND|Disease Recurrence Indicator|BRUGGEMANN MRD 2010|[?]|10^4/hpf|CHR|1|kIU|POTENTIOMETRY||Y||VENDOR|READER 1|U|5|Visit_5|90|5|WASHOUT|2021-03-29|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-12|P1Y2M10DT2H30M|UNKNOWN|2021-01-28|ONGOING|2021-03-31
e|RS|517f3930-5202-4e0a-b3e1-85ed4bd7e117|10|STRUSTAT|Steroid Use Status|RECIST 1.0|||iUPD|1|mmol/min/kPa|QUANTITATIVE PERIPHERAL ANGIOGRAPHY|||Y|INTERVIEWER|MICROSCOPIST 2|N|5|Visit_5|90|6|TREATMENT|2021-03-29|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-12|P1Y2M10DT2H30M|AFTER|2021-02-09|AFTER|2021-03-26
e|RS|edd73650-27bb-474f-bab7-d2c3d57b2dc4|1|MRPHRESP|Morphologic Response|JUWEID NON-HODGKINS LYMPHOMA 2005|||COMPLETE MRD RESPONSE|1|g/day|CHROMOGENIC ASSAY|||Y|FAMILY MEMBER|NEUROLOGIST 1|NA|1|Visit_1|10|4|FOLLOW-UP|2020-12-21|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-20|P1Y2M10DT2H30M|BEFORE|2021-03-06|AFTER|2021-03-14
e|RS|edd73650-27bb-474f-bab7-d2c3d57b2dc4|2|MJPTHIND|Major Pathological Response Indicator|KUMAR IMWG 2016|||mCR|1|Bq/uL|MYELOPEROXIDASE STAIN|||Y|PROXY|OPTOMETRIST|Y|1|Visit_1|10|6|TREATMENT|2020-12-21|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-20|P1Y2M10DT2H30M|BEFORE|2021-02-02|BEFORE|2021-03-14
e|RS|edd73650-27bb-474f-bab7-d2c3d57b2dc4|3|DRCRIND|Disease Recurrence Indicator|CHESON LYMPHOMA 2008|||PSA PROGRESSION|1|Bq/uL|GC/MS|||Y|VENDOR|PATHOLOGIST 2|N|2|Visit_2|25|4|FOLLOW-UP|2021-01-05|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-01|P1Y2M10DT2H30M|UNKNOWN|2021-02-15|COINCIDENT|2021-03-20
e|RS|edd73650-27bb-474f-bab7-d2c3d57b2dc4|4|MRDIND|Minimal Residual Disease Indicator|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|uL/kg/day|MOLECULAR CR|1|JDF Unit|SINGLE-MOLECULE ARRAY||||CHILD|OPHTHALMOLOGIST|NA|2|Visit_2|25|7|TREATMENT|2021-01-05|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-01|P1Y2M10DT2H30M|COINCIDENT|2021-03-08|AFTER|2021-03-18
e|RS|edd73650-27bb-474f-bab7-d2c3d57b2dc4|5|OVRLRESP|Overall Response|PETIT BREAST CANCER 2001|||UNEQUIVOCAL|1|/wk|MICRODENSITOMETRY|||Y|CLINICAL RESEARCH COORDINATOR|RATER 2|U|3|Visit_3|40|5|WASHOUT|2021-01-20|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-15|P1Y2M10DT2H30M|AFTER|2020-12-19|COINCIDENT|2021-02-11
e|RS|edd73650-27bb-474f-bab7-d2c3d57b2dc4|6|NTERESP|Non-Target Enhancing Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|MBq|SMD|1|PACKAGE|MANUAL COUNT||Y||DOMESTIC PARTNER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|3|Visit_3|40|6|TREATMENT|2021-01-20|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-15|P1Y2M10DT2H30M|COINCIDENT|2021-03-12|COINCIDENT|2021-03-13
e|RS|edd73650-27bb-474f-bab7-d2c3d57b2dc4|7|SYMPTDTR|Symptomatic Deterioration|MONTSERRAT CLL 1989|[?]|kN/cm2|NED|1|ug/mL/h|IMMUNORADIOMETRIC ASSAY||||CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 3|U|4|Visit_4|65|2|TREATMENT|2021-02-14|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-16|P1Y2M10DT2H30M|BEFORE|2021-02-23|AFTER|2021-03-10
e|RS|edd73650-27bb-474f-bab7-d2c3d57b2dc4|8|BESTRESP|Best Overall Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|FINGERTIP UNIT|PR-CT|1|APS U|MAGNETIC RESONANCE ELASTOGRAPHY||||DOMESTIC PARTNER|CLINICAL PATHOLOGIST|N|4|Visit_4|65|5|TREATMENT|2021-02-14|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-16|P1Y2M10DT2H30M|UNKNOWN|2021-03-10|COINCIDENT|2021-03-13
e|RS|edd73650-27bb-474f-bab7-d2c3d57b2dc4|9|NEWLPROG|New Lesion Progression|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|mg/g/h|CA125 75% RESPONSE|1|copies/ug|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE||Y||DOMESTIC PARTNER|RATER 1|NA|5|Visit_5|90|1|TREATMENT|2021-03-11|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-07|P1Y2M10DT2H30M|COINCIDENT|2020-12-15|ONGOING|2021-02-25
e|RS|edd73650-27bb-474f-bab7-d2c3d57b2dc4|10|MNPTHIND|Minor Pathological Response Indicator|CHOLLET BREAST CANCER 2002|||UNEQUIVOCAL|1|/4.0 mL|DOUBLE IMMUNODIFFUSION|||Y|CAREGIVER|PATHOLOGIST 2|Y|5|Visit_5|90|1|TREATMENT|2021-03-11|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-07|P1Y2M10DT2H30M|AFTER|2021-03-08|BEFORE|2021-03-20
e|RS|98737dfa-0058-4420-a515-38526f01f90d|1|NTNERESP|Non-Target Non-Enhancing Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|/10^3|INCREASED|1|ft3|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY||||GUARDIAN|NEUROLOGIST 1|Y|1|Visit_1|10|1|FOLLOW-UP|2020-09-09|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-25|P1Y2M10DT2H30M|BEFORE|2020-09-15|COINCIDENT|2020-12-06
e|RS|98737dfa-0058-4420-a515-38526f01f90d|2|MOLRESP|Molecular Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|cm|IMPROVED|1|Enzyme U|ELISPOT||||SPOUSE|MICROSCOPIST|N|1|Visit_1|10|5|SCREENING|2020-09-09|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-25|P1Y2M10DT2H30M|UNKNOWN|2020-09-14|COINCIDENT|2020-10-24
e|RS|98737dfa-0058-4420-a515-38526f01f90d|3|NTNERESP|Non-Target Non-Enhancing Response|CHESON CLL 2012|[?]|mmol/day|CYTOGENETIC NO RESPONSE|1|ng/L|SXA SCAN|Y|Y||VENDOR|DEVELOPMENTAL PSYCHOLOGIST|NA|2|Visit_2|25|5|SCREENING|2020-09-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-10|P1Y2M10DT2H30M|UNKNOWN|2020-11-13|ONGOING|2020-12-02
e|RS|98737dfa-0058-4420-a515-38526f01f90d|4|PATHRESP|Pathologic Response|PCWG SCHER PROSTATE CANCER 2016|||CR|1|dram|RAJI CELL EIA|||Y|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 1|N|2|Visit_2|25|3|WASHOUT|2020-09-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-10|P1Y2M10DT2H30M|BEFORE|2020-09-21|ONGOING|2020-11-03
e|RS|98737dfa-0058-4420-a515-38526f01f90d|5|MRDRESP|Minimal Residual Disease Response|JUWEID NON-HODGKINS LYMPHOMA 2005|||PSA PROGRESSION|1|10^9/dose|STATIC PERIMETRY|||Y|FRIEND|DERMATOLOGIST|NA|3|Visit_3|40|5|WASHOUT|2020-10-09|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-31|P1Y2M10DT2H30M|UNKNOWN|2020-11-17|BEFORE|2020-11-27
e|RS|98737dfa-0058-4420-a515-38526f01f90d|6|TRGRESP|Target Response|SHINDOH COLORECTAL CANCER 2013|[?]|MnFI|NOT ALL EVALUATED|1|FFU|OLIGO ACGH|Y|||PARENT|MICROSCOPIST 1|U|3|Visit_3|40|2|TREATMENT|2020-10-09|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-31|P1Y2M10DT2H30M|UNKNOWN|2020-11-03|COINCIDENT|2020-11-23
e|RS|98737dfa-0058-4420-a515-38526f01f90d|7|NTLWIND|Non-Target Lesion Worsening Indicator|HARTMAN PANCREATIC CANCER 2012|[?]|cal|CA125 75% RESPONSE|1|dyn|PLETHYSMOGRAPHY||||FAMILY MEMBER|NEUROLOGIST|U|4|Visit_4|65|1|WASHOUT|2020-11-03|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-18|P1Y2M10DT2H30M|COINCIDENT|2020-10-11|AFTER|2020-10-23
e|RS|98737dfa-0058-4420-a515-38526f01f90d|8|NEWLWIND|New Lesion Worsening Indicator|DOHNER AML 2010|||PR WITH LYMPHOCYTOSIS|1|CONTAINER|POTENTIOMETRY||Y|Y|HEALTH CARE PROFESSIONAL|ADJUDICATOR 1|N|4|Visit_4|65|1|TREATMENT|2020-11-03|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-18|P1Y2M10DT2H30M|BEFORE|2020-11-02|COINCIDENT|2020-11-09
e|RS|98737dfa-0058-4420-a515-38526f01f90d|9|CPRFSTAT|Clinical Performance Status|KUMAR IMWG 2016|[?]|g/cage|CMR|1|ug/day|BETA LACTAMASE||||VENDOR|NEUROLOGIST 1|U|5|Visit_5|90|5|TREATMENT|2020-11-28|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-18|P1Y2M10DT2H30M|AFTER|2020-10-12|AFTER|2020-10-14
e|RS|98737dfa-0058-4420-a515-38526f01f90d|10|NEWLWIND|New Lesion Worsening Indicator|RECIST 1.1|[?]|pmol/dL|PMR|1|GPL U/mL|ELASTOGRAPHY||||CLINICAL RESEARCH COORDINATOR|PEDIATRIC NEUROLOGIST|U|5|Visit_5|90|3|TREATMENT|2020-11-28|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-18|P1Y2M10DT2H30M|AFTER|2020-09-14|BEFORE|2020-10-18
e|RS|e713c631-cdd8-428f-a3a6-0195f6fb80b4|1|CYTORESP|Cytogenetic Response|IWG CHESON MDS 2006|||NON-CR/NON-PD|1|mm3/mm2/year|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE|||Y|GUARDIAN|PHYSIOTHERAPIST|N|1|Visit_1|10|2|TREATMENT|2020-10-03|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-15|P1Y2M10DT2H30M|UNKNOWN|2020-12-12|AFTER|2020-12-26
e|RS|e713c631-cdd8-428f-a3a6-0195f6fb80b4|2|RDIORESP|Radiologic Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|L/day|NE|1|L/L|FLOW MICROSCOPY||Y||GUARDIAN|MICROSCOPIST|NA|1|Visit_1|10|2|WASHOUT|2020-10-03|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-15|P1Y2M10DT2H30M|UNKNOWN|2020-12-26|ONGOING|2020-12-31
e|RS|e713c631-cdd8-428f-a3a6-0195f6fb80b4|3|SPLNRESP|Spleen Response|RECIST 1.0|[?]|pg/L|HI-P|1|JAR|MRI||||INVESTIGATOR|OPTOMETRIST|Y|2|Visit_2|25|7|TREATMENT|2020-10-18|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-26|P1Y2M10DT2H30M|COINCIDENT|2020-12-04|COINCIDENT|2020-12-10
e|RS|e713c631-cdd8-428f-a3a6-0195f6fb80b4|4|NEWLPROG|New Lesion Progression|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|kg/mol|VGPR|1|ug/m2/day|CALCOFLUOR WHITE STAIN||||VENDOR|ENDOCRINOLOGIST|NA|2|Visit_2|25|1|WASHOUT|2020-10-18|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-26|P1Y2M10DT2H30M|COINCIDENT|2020-11-22|COINCIDENT|2020-11-28
e|RS|e713c631-cdd8-428f-a3a6-0195f6fb80b4|5|HEMARESP|Hematologic Response|WOLCHOK SOLID TUMORS 2009|[?]|pm|PR|1|GPL U|LIQUID SCINTILLATION COUNTING||Y||ADJUDICATION COMMITTEE|NEUROLOGIST|N|3|Visit_3|40|1|WASHOUT|2020-11-02|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-19|P1Y2M10DT2H30M|AFTER|2020-10-01|BEFORE|2020-12-20
e|RS|e713c631-cdd8-428f-a3a6-0195f6fb80b4|6|SPLNRESP|Spleen Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|||CYTOGENETIC MINOR RESPONSE|1|10^9 CFU|MASS SPECTROMETRY||Y|Y|PARENT|PEDIATRIC NEUROLOGIST|Y|3|Visit_3|40|2|FOLLOW-UP|2020-11-02|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-19|P1Y2M10DT2H30M|AFTER|2020-10-21|COINCIDENT|2020-12-27
e|RS|e713c631-cdd8-428f-a3a6-0195f6fb80b4|7|SYMPTDTR|Symptomatic Deterioration|MRANO VAN DEN BENT GLIOMA 2011|||PD-CT|1|kcal|KARYOTYPING|||Y|INTERVIEWER|CLINICAL PATHOLOGIST|U|4|Visit_4|65|3|SCREENING|2020-11-27|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-18|P1Y2M10DT2H30M|AFTER|2020-12-04|AFTER|2020-12-05
e|RS|e713c631-cdd8-428f-a3a6-0195f6fb80b4|8|HEMARESP|Hematologic Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|||MOLECULAR CR|1|10^6 RNA copies/mL|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|||Y|INTERVIEWER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|4|Visit_4|65|2|SCREENING|2020-11-27|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-18|P1Y2M10DT2H30M|UNKNOWN|2020-11-08|BEFORE|2020-12-07
e|RS|e713c631-cdd8-428f-a3a6-0195f6fb80b4|9|NEWLWIND|New Lesion Worsening Indicator|MASS|[?]|nmol/kg/day|CRi|1|Roentgen|ICC||||INTERVIEWER|PATHOLOGIST 2|U|5|Visit_5|90|3|WASHOUT|2020-12-22|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-04|P1Y2M10DT2H30M|AFTER|2020-10-11|AFTER|2020-12-15
e|RS|e713c631-cdd8-428f-a3a6-0195f6fb80b4|10|MRDRESP|Minimal Residual Disease Response|PERCIST|[?]|copies/uL|cCR|1|kat|LUXOL FAST BLUE AND CRESYL VIOLET STAIN||||HEALTH CARE PROFESSIONAL|UROLOGIST|Y|5|Visit_5|90|5|SCREENING|2020-12-22|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-04|P1Y2M10DT2H30M|BEFORE|2020-10-08|AFTER|2020-11-01
e|RS|a3964bed-1273-4bce-bbb4-b8d768b30aa3|1|TRGRESP|Target Response|SCHWARZ CERVICAL CANCER 2009|||iCPD|1|mg/m2/min|LISSAMINE GREEN STAIN||Y|Y|INTERVIEWER|MICROSCOPIST 3|Y|1|Visit_1|10|3|SCREENING|2020-09-20|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-06|P1Y2M10DT2H30M|UNKNOWN|2020-10-13|ONGOING|2020-10-27
e|RS|a3964bed-1273-4bce-bbb4-b8d768b30aa3|2|METSIND|Metastatic Indicator|EBMT BLADE MYELOMA 1998|[?]|U/dL|HI-N|1|mPa|ORCHIDOMETERY||Y||SIGNIFICANT OTHER|PATHOLOGIST 1|NA|1|Visit_1|10|5|TREATMENT|2020-09-20|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-06|P1Y2M10DT2H30M|COINCIDENT|2020-10-29|AFTER|2020-12-17
e|RS|a3964bed-1273-4bce-bbb4-b8d768b30aa3|3|NEWLPROG|New Lesion Progression|KEAM BREAST CANCER 2013|[?]|GPL U/mL|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|pmol/L/h|GIEMSA STAIN||||PARENT|MICROSCOPIST 1|NA|2|Visit_2|25|7|TREATMENT|2020-10-05|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-02|P1Y2M10DT2H30M|AFTER|2020-12-07|BEFORE|2020-12-17
e|RS|a3964bed-1273-4bce-bbb4-b8d768b30aa3|4|RDIORESP|Radiologic Response|GUILHOT CML 2007|||MOLECULAR MAJOR RESPONSE|1|log EID 50/dose|HEMAGGLUTINATION INHIBITION ASSAY|Y||Y|PROXY|MICROSCOPIST 1|Y|2|Visit_2|25|6|FOLLOW-UP|2020-10-05|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-02|P1Y2M10DT2H30M|AFTER|2020-10-30|AFTER|2020-12-14
e|RS|a3964bed-1273-4bce-bbb4-b8d768b30aa3|5|LIVRRESP|Liver Response|CHESON LYMPHOMA 2008|[?]|Hz/s|IMMUNOPHENOTYPIC CR|1|g/day|IVY INCISION METHOD||||VENDOR|CARDIOLOGIST|Y|3|Visit_3|40|5|SCREENING|2020-10-20|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-22|P1Y2M10DT2H30M|COINCIDENT|2020-10-04|ONGOING|2020-10-29
e|RS|a3964bed-1273-4bce-bbb4-b8d768b30aa3|6|ANATRESP|Anatomic Response|EBMT BLADE MYELOMA 1998|||CYTOGENETIC NO RESPONSE|1|BOWL|INCISION-INDUCED BLEEDING METHOD|||Y|FAMILY MEMBER|DERMATOLOGIST|Y|3|Visit_3|40|1|TREATMENT|2020-10-20|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-22|P1Y2M10DT2H30M|COINCIDENT|2020-10-30|COINCIDENT|2020-11-24
e|RS|a3964bed-1273-4bce-bbb4-b8d768b30aa3|7|MOLRESP|Molecular Response|DURIE MULTIPLE MYELOMA 2006|[?]|Pack Year|PD/RELAPSE AFTER HI|1|10^9 CFU|ATOMIC ABSORPTION SPECTROMETRY||||GUARDIAN|ONCOLOGIST 2|N|4|Visit_4|65|3|FOLLOW-UP|2020-11-14|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-13|P1Y2M10DT2H30M|UNKNOWN|2020-12-12|BEFORE|2020-12-16
e|RS|a3964bed-1273-4bce-bbb4-b8d768b30aa3|8|NEWLIND|New Lesion Indicator|AJCC V7|[?]|fmol/L/sec|MR|1|U/m2/day|KINYOUN STAIN|Y|Y||CLINICAL STUDY SPONSOR|ADJUDICATOR 1|NA|4|Visit_4|65|5|FOLLOW-UP|2020-11-14|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-13|P1Y2M10DT2H30M|UNKNOWN|2020-10-04|COINCIDENT|2020-12-16
e|RS|a3964bed-1273-4bce-bbb4-b8d768b30aa3|9|MRPHRESP|Morphologic Response|SACT|||IMMUNOPHENOTYPIC CR|1|mL/min|ZIEHL NEELSEN ACID FAST STAIN|||Y|FAMILY MEMBER|INTERNIST|N|5|Visit_5|90|4|TREATMENT|2020-12-09|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-02|P1Y2M10DT2H30M|COINCIDENT|2020-10-27|AFTER|2020-10-29
e|RS|a3964bed-1273-4bce-bbb4-b8d768b30aa3|10|BESTRESP|Best Overall Response|MASS|[?]|kg/cm2|HI-N|1|ug/m2|EIA||||SIBLING|MICROSCOPIST|Y|5|Visit_5|90|7|TREATMENT|2020-12-09|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-02|P1Y2M10DT2H30M|BEFORE|2020-12-16|AFTER|2020-12-18
e|RS|b77116ca-2b32-411f-a0ff-fa70d74eb4bd|1|METSIND|Metastatic Indicator|MONTSERRAT CLL 1989|||IMMUNOPHENOTYPIC CR|1|U|NUCLEIC ACID SEQUENCING||Y|Y|GUARDIAN|ENDOCRINOLOGIST|U|1|Visit_1|10|7|SCREENING|2020-12-21|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-04|P1Y2M10DT2H30M|COINCIDENT|2021-03-06|COINCIDENT|2021-03-08
e|RS|b77116ca-2b32-411f-a0ff-fa70d74eb4bd|2|BESTRESP|Best Overall Response|WHO BREAST CANCER 2006|[?]|nmol BCE/L|HI-N|1|um2|DNA MICROARRAY||||FAMILY MEMBER|NEUROLOGIST|NA|1|Visit_1|10|3|TREATMENT|2020-12-21|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-04|P1Y2M10DT2H30M|AFTER|2021-01-27|BEFORE|2021-02-15
e|RS|b77116ca-2b32-411f-a0ff-fa70d74eb4bd|3|BONERESP|Bone Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|ug/animal|CA125 75% RESPONSE|1|10^8/L|PEAK FLOWMETRY|Y|||SPOUSE|READER 2|N|2|Visit_2|25|7|TREATMENT|2021-01-05|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-21|P1Y2M10DT2H30M|BEFORE|2021-02-06|AFTER|2021-02-17
e|RS|b77116ca-2b32-411f-a0ff-fa70d74eb4bd|4|HEMARESP|Hematologic Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|mol/mg|PD/RELAPSE AFTER HI|1|10^6 organisms/mg|LIGHT SCATTERING SPECTROSCOPY|Y|||CLINICAL RESEARCH COORDINATOR|OTOLARYNGOLOGIST|U|2|Visit_2|25|1|SCREENING|2021-01-05|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-21|P1Y2M10DT2H30M|AFTER|2021-03-02|AFTER|2021-03-14
e|RS|b77116ca-2b32-411f-a0ff-fa70d74eb4bd|5|CLINRESP|Clinical Response|IWG CHESON MDS 2000|[?]|kHz|INDETERMINATE RESPONSE|1|log10 TCID 50/mL|NUCLEIC ACID HYBRIDIZATION||||HEALTH CARE PROFESSIONAL|RATER 1|NA|3|Visit_3|40|5|TREATMENT|2021-01-20|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-24|P1Y2M10DT2H30M|COINCIDENT|2021-01-21|BEFORE|2021-02-08
e|RS|b77116ca-2b32-411f-a0ff-fa70d74eb4bd|6|DRCRIND|Disease Recurrence Indicator|HAMAOKA BREAST CANCER 2010|[?]|mg/mol|CR|1|Roentgen|KINYOUN STAIN|Y|||SIBLING|OPHTHALMOLOGIST|NA|3|Visit_3|40|6|FOLLOW-UP|2021-01-20|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-24|P1Y2M10DT2H30M|BEFORE|2021-01-07|BEFORE|2021-01-12
e|RS|b77116ca-2b32-411f-a0ff-fa70d74eb4bd|7|PATHRESP|Pathologic Response|HARTMANN GERM CELL CANCER 2002|[?]|FINGERTIP UNIT|CYTOGENETIC CR|1|Bq/mL|LC-FL||||DOMESTIC PARTNER|PATHOLOGIST 2|N|4|Visit_4|65|3|TREATMENT|2021-02-14|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-05|P1Y2M10DT2H30M|COINCIDENT|2021-02-09|ONGOING|2021-03-14
e|RS|b77116ca-2b32-411f-a0ff-fa70d74eb4bd|8|RDIORESP|Radiologic Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|Log10 ELISA unit/dose|WORSENED|1|U/mg|CLINICAL EVALUATION||Y||NON-HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|Y|4|Visit_4|65|1|TREATMENT|2021-02-14|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-05|P1Y2M10DT2H30M|BEFORE|2021-01-28|COINCIDENT|2021-02-03
e|RS|b77116ca-2b32-411f-a0ff-fa70d74eb4bd|9|TRGRESP|Target Response|SCHWARZ CERVICAL CANCER 2009|[?]|mL/m2/min|cCR|1|mol/mL|DC SHEATH FLOW|Y|Y||FRIEND|PATHOLOGIST 2|NA|5|Visit_5|90|4|WASHOUT|2021-03-11|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-01|P1Y2M10DT2H30M|AFTER|2021-01-11|COINCIDENT|2021-02-13
e|RS|b77116ca-2b32-411f-a0ff-fa70d74eb4bd|10|NTLWIND|Non-Target Lesion Worsening Indicator|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|||iCR|1|APS U|PUPILLOMETRY|||Y|CLINICAL RESEARCH ASSOCIATE|CLINICAL PATHOLOGIST|U|5|Visit_5|90|4|TREATMENT|2021-03-11|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-01|P1Y2M10DT2H30M|AFTER|2020-12-28|BEFORE|2021-02-17
e|RS|cedc258a-b0e3-4590-afe1-9ed2b6ba28bc|1|NTERESP|Non-Target Enhancing Response|MACDONALD GLIOMA 1990|[?]|mg/kg|MORPHOLOGIC CR|1|EID 50/dose|OPTICAL DENSITY MEASUREMENT||||CHILD|OPTOMETRIST|U|1|Visit_1|10|1|TREATMENT|2020-06-09|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-12|P1Y2M10DT2H30M|AFTER|2020-08-25|COINCIDENT|2020-09-02
e|RS|cedc258a-b0e3-4590-afe1-9ed2b6ba28bc|2|TRGRESP|Target Response|HARTMANN GERM CELL CANCER 2002|[?]|APPLICATION|PD FROM PR|1|USP U|DIRECT SEQUENCING||||NON-HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|N|1|Visit_1|10|5|TREATMENT|2020-06-09|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-12|P1Y2M10DT2H30M|BEFORE|2020-08-31|AFTER|2020-09-05
e|RS|cedc258a-b0e3-4590-afe1-9ed2b6ba28bc|3|NTLWIND|Non-Target Lesion Worsening Indicator|RANO|||PR|1|IU/L|ENDOSCOPY|||Y|ADJUDICATION COMMITTEE|ONCOLOGIST 2|Y|2|Visit_2|25|1|TREATMENT|2020-06-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-13|P1Y2M10DT2H30M|COINCIDENT|2020-09-03|ONGOING|2020-09-06
e|RS|cedc258a-b0e3-4590-afe1-9ed2b6ba28bc|4|STRUSTAT|Steroid Use Status|CHESON LYMPHOMA 2008|[?]|mL/100g/min|PMR|1|mg/dL|TOLUIDINE BLUE STAIN||||PROXY|NEUROLOGIST 1|NA|2|Visit_2|25|1|TREATMENT|2020-06-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-13|P1Y2M10DT2H30M|COINCIDENT|2020-06-27|AFTER|2020-09-05
e|RS|cedc258a-b0e3-4590-afe1-9ed2b6ba28bc|5|HEMARESP|Hematologic Response|WOLCHOK SOLID TUMORS 2009|[?]|g/mol|PSA PROGRESSION|1|mg/kg/week|SEQUENCING||||CAREGIVER|READER 2|Y|3|Visit_3|40|6|TREATMENT|2020-07-09|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-11|P1Y2M10DT2H30M|BEFORE|2020-07-17|BEFORE|2020-09-05
e|RS|cedc258a-b0e3-4590-afe1-9ed2b6ba28bc|6|OVRLRESP|Overall Response|CHESON CLL 2006|[?]|log10 TCID 50/dose|DECREASED|1|NFIU|TRANSTHORACIC ECHOCARDIOGRAPHY|Y|Y||FAMILY MEMBER|ADJUDICATOR 2|N|3|Visit_3|40|5|WASHOUT|2020-07-09|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-11|P1Y2M10DT2H30M|BEFORE|2020-07-19|BEFORE|2020-08-21
e|RS|cedc258a-b0e3-4590-afe1-9ed2b6ba28bc|7|NTERESP|Non-Target Enhancing Response|MASS|[?]|days/wk|MOLECULAR MAJOR RESPONSE|1|PNU/mL|TRANSESOPHAGEAL ECHOCARDIOGRAPHY||Y||FRIEND|MICROSCOPIST 2|U|4|Visit_4|65|1|TREATMENT|2020-08-03|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-12|P1Y2M10DT2H30M|BEFORE|2020-06-16|AFTER|2020-07-02
e|RS|cedc258a-b0e3-4590-afe1-9ed2b6ba28bc|8|NEWLWIND|New Lesion Worsening Indicator|RECIST 1.0|[?]|Weber|DECREASED|1|Bq/uL|IMMUNOFIXATION ELECTROPHORESIS||||INVESTIGATOR|DERMATOLOGIST|N|4|Visit_4|65|1|SCREENING|2020-08-03|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-12|P1Y2M10DT2H30M|BEFORE|2020-09-03|BEFORE|2020-09-04
e|RS|cedc258a-b0e3-4590-afe1-9ed2b6ba28bc|9|MJPTHIND|Major Pathological Response Indicator|CHOI GIST 2008|||CRi|1|Antibody Unit|HPLC/IEX|||Y|DOMESTIC PARTNER|DERMATOLOGIST|U|5|Visit_5|90|7|TREATMENT|2020-08-28|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-28|P1Y2M10DT2H30M|AFTER|2020-08-15|BEFORE|2020-08-23
e|RS|cedc258a-b0e3-4590-afe1-9ed2b6ba28bc|10|NTERESP|Non-Target Enhancing Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|mm3/mm2/year|PSA PROGRESSION|1|U/kg/min|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION||||GUARDIAN|RATER 1|U|5|Visit_5|90|1|SCREENING|2020-08-28|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-28|P1Y2M10DT2H30M|AFTER|2020-06-19|COINCIDENT|2020-08-09
e|RS|597ff319-c16e-4aae-a7d9-ed2bc25684dc|1|NTERESP|Non-Target Enhancing Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|log10 copies/mL|OPTIMAL MORPHOLOGIC RESPONSE|1|mmol|PELLI-ROBSON EYE CHART||||INTERVIEWER|ADJUDICATOR 2|N|1|Visit_1|10|5|TREATMENT|2020-05-28|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-13|P1Y2M10DT2H30M|AFTER|2020-07-15|AFTER|2020-07-21
e|RS|597ff319-c16e-4aae-a7d9-ed2bc25684dc|2|MRDIND|Minimal Residual Disease Indicator|KEAM BREAST CANCER 2013|||SD-CT|1|10^3 DNA copies/mL|AUTOREFRACTION|Y||Y|SIGNIFICANT OTHER|NEUROLOGIST|U|1|Visit_1|10|3|WASHOUT|2020-05-28|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-13|P1Y2M10DT2H30M|COINCIDENT|2020-07-07|AFTER|2020-07-19
e|RS|597ff319-c16e-4aae-a7d9-ed2bc25684dc|3|SFTSRESP|Soft Tissue Response|RECICL|[?]|pmol/g|CYTOGENETIC MINOR RESPONSE|1|nmol/L|GEL ELECTROPHORESIS|Y|||SPOUSE|MICROSCOPIST 1|Y|2|Visit_2|25|6|SCREENING|2020-06-12|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-13|P1Y2M10DT2H30M|AFTER|2020-07-25|ONGOING|2020-08-09
e|RS|597ff319-c16e-4aae-a7d9-ed2bc25684dc|4|OVRLRESP|Overall Response|CHOI GIST 2008|[?]|AFU|MORPHOLOGIC CR|1|mL/cage|TRANSTHORACIC ECHOCARDIOGRAPHY||||PROXY|RATER 1|Y|2|Visit_2|25|1|SCREENING|2020-06-12|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-13|P1Y2M10DT2H30M|COINCIDENT|2020-07-20|AFTER|2020-07-30
e|RS|597ff319-c16e-4aae-a7d9-ed2bc25684dc|5|TMRESP|Tumor Marker Response|AJCC V8|||RELAPSED DISEASE FROM CR OR PR|1|kPa/L/sec|MRI|Y||Y|INVESTIGATOR|PEDIATRIC NEUROLOGIST|N|3|Visit_3|40|5|TREATMENT|2020-06-27|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-03|P1Y2M10DT2H30M|BEFORE|2020-07-12|AFTER|2020-08-22
e|RS|597ff319-c16e-4aae-a7d9-ed2bc25684dc|6|NEWLPROG|New Lesion Progression|CHOLLET BREAST CANCER 2002|[?]|mg/g/h|PMR|1|mph|CORONARY ANGIOGRAPHY|Y|||INVESTIGATOR|READER 3|NA|3|Visit_3|40|3|SCREENING|2020-06-27|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-03|P1Y2M10DT2H30M|UNKNOWN|2020-07-28|BEFORE|2020-08-09
e|RS|597ff319-c16e-4aae-a7d9-ed2bc25684dc|7|MJPTHIND|Major Pathological Response Indicator|CHESON MALIGNANT LYMPHOMA 2007|[?]|nmol BCE/L|TREATMENT FAILURE|1|mL/kg/day|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS||||PARENT|ENDOCRINOLOGIST|U|4|Visit_4|65|2|TREATMENT|2020-07-22|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-10|P1Y2M10DT2H30M|BEFORE|2020-08-16|COINCIDENT|2020-08-17
e|RS|597ff319-c16e-4aae-a7d9-ed2bc25684dc|8|NTRGRESP|Non-target Response|PCWG SCHER PROSTATE CANCER 2008|[?]|kg/mol|PD/RELAPSE AFTER HI|1|g/U|ENDPOINT DILUTION ASSAY|Y|||ADJUDICATION COMMITTEE|DERMATOLOGIST|Y|4|Visit_4|65|1|SCREENING|2020-07-22|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-10|P1Y2M10DT2H30M|AFTER|2020-08-17|AFTER|2020-08-22
e|RS|597ff319-c16e-4aae-a7d9-ed2bc25684dc|9|LIVRRESP|Liver Response|RECIST 1.1|[?]|U/g|RELAPSED DISEASE FROM CR OR PR|1|Absorbance U/min|FLUORESCENT IMMUNOASSAY||||SIBLING|ADJUDICATOR 1|Y|5|Visit_5|90|1|FOLLOW-UP|2020-08-16|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-07|P1Y2M10DT2H30M|UNKNOWN|2020-05-20|ONGOING|2020-07-25
e|RS|597ff319-c16e-4aae-a7d9-ed2bc25684dc|10|MOLRESP|Molecular Response|BURCOMBE BREAST CANCER 2005|||INDETERMINATE RESPONSE|1|/kg|IMMUNOCHROMATOGRAPHY|Y|Y|Y|INDEPENDENT ASSESSOR|MICROSCOPIST 3|U|5|Visit_5|90|7|TREATMENT|2020-08-16|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-07|P1Y2M10DT2H30M|COINCIDENT|2020-07-04|AFTER|2020-08-18
e|RS|7d845e3e-8bd1-4647-a3e8-352a52b585cb|1|NEWLWIND|New Lesion Worsening Indicator|CHOLLET BREAST CANCER 2002|[?]|V|STABLE|1|uIU/dL|CT SCAN WITHOUT CONTRAST|Y|||INTERVIEWER|PATHOLOGIST 2|N|1|Visit_1|10|4|TREATMENT|2020-11-08|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-25|P1Y2M10DT2H30M|UNKNOWN|2020-12-06|BEFORE|2021-01-03
e|RS|7d845e3e-8bd1-4647-a3e8-352a52b585cb|2|SPLNRESP|Spleen Response|MONTSERRAT CLL 1989|[?]|g/dL|MINOR PATHOLOGIC RESPONSE|1|%/min|LYMPHANGIOGRAPHY|Y|||SIBLING|ADJUDICATOR 2|NA|1|Visit_1|10|6|SCREENING|2020-11-08|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-25|P1Y2M10DT2H30M|BEFORE|2021-02-05|BEFORE|2021-02-06
e|RS|7d845e3e-8bd1-4647-a3e8-352a52b585cb|3|MNPTHIND|Minor Pathological Response Indicator|SCHER PROSTATE CANCER 2011|[?]|/wk|PR|1|L/h|LC-FL||Y||ADJUDICATOR|RADIOLOGIST 1|NA|2|Visit_2|25|3|TREATMENT|2020-11-23|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-19|P1Y2M10DT2H30M|BEFORE|2021-01-18|BEFORE|2021-01-20
e|RS|7d845e3e-8bd1-4647-a3e8-352a52b585cb|4|RDIORESP|Radiologic Response|DURIE MULTIPLE MYELOMA 2006|[?]|breaths/min|mCR|1|kg/cm|FUNCTIONAL MRI||||ADJUDICATOR|CLINICAL PATHOLOGIST|Y|2|Visit_2|25|2|TREATMENT|2020-11-23|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-19|P1Y2M10DT2H30M|UNKNOWN|2021-01-18|AFTER|2021-01-25
e|RS|7d845e3e-8bd1-4647-a3e8-352a52b585cb|5|CYTORESP|Cytogenetic Response|NCCN ALL MRD 2014|[?]|dpm/mg|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|mg/m2/day|MODIFIED ACID FAST STAIN||Y||PARENT|MICROSCOPIST|U|3|Visit_3|40|5|FOLLOW-UP|2020-12-08|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-12|P1Y2M10DT2H30M|BEFORE|2021-01-03|ONGOING|2021-01-08
e|RS|7d845e3e-8bd1-4647-a3e8-352a52b585cb|6|STRUSTAT|Steroid Use Status|RANO|||RELAPSED DISEASE FROM CR OR PR|1|/7.5 mL|BAC ACGH||Y|Y|VENDOR|OTOLARYNGOLOGIST|U|3|Visit_3|40|1|TREATMENT|2020-12-08|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-12|P1Y2M10DT2H30M|AFTER|2020-12-21|ONGOING|2021-01-01
e|RS|7d845e3e-8bd1-4647-a3e8-352a52b585cb|7|MRDIND|Minimal Residual Disease Indicator|BURCOMBE BREAST CANCER 2005|[?]|TUBE|MORPHOLOGIC LEUKEMIA-FREE STATE|1|mg/min|REFRACTOMETRY|Y|||SIGNIFICANT OTHER|ONCOLOGIST 1|NA|4|Visit_4|65|4|TREATMENT|2021-01-02|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-19|P1Y2M10DT2H30M|COINCIDENT|2020-12-04|AFTER|2021-01-16
e|RS|7d845e3e-8bd1-4647-a3e8-352a52b585cb|8|NTLWIND|Non-Target Lesion Worsening Indicator|UNSPECIFIED|[?]|Gy/h|IMPROVED|1|mL/h|DIFFUSION WEIGHTED MRI||||VENDOR|FORENSIC PATHOLOGIST|N|4|Visit_4|65|7|TREATMENT|2021-01-02|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-19|P1Y2M10DT2H30M|AFTER|2021-02-03|BEFORE|2021-02-05
e|RS|7d845e3e-8bd1-4647-a3e8-352a52b585cb|9|NTERESP|Non-Target Enhancing Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|um|NON-QUANTIFIABLE MRD POSITIVITY|1|Gy|FLUORESCEIN STAIN||||HEALTH CARE PROFESSIONAL|ONCOLOGIST|NA|5|Visit_5|90|7|SCREENING|2021-01-27|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-25|P1Y2M10DT2H30M|BEFORE|2020-11-10|BEFORE|2021-01-26
e|RS|7d845e3e-8bd1-4647-a3e8-352a52b585cb|10|SPLNRESP|Spleen Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|||SD-CT|1|ug/kg/h|CLIP||Y|Y|PROXY|OTOLARYNGOLOGIST|Y|5|Visit_5|90|6|SCREENING|2021-01-27|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-25|P1Y2M10DT2H30M|AFTER|2020-12-15|ONGOING|2021-01-14
e|RS|7e9f4283-f90b-4f74-939c-b42648e8373c|1|STRUSTAT|Steroid Use Status|BLAZER COLORECTAL CANCER 2008|||CYTOGENETIC PR|1|mg/L FEU|LC-FL|Y||Y|FRIEND|PATHOLOGIST 2|U|1|Visit_1|10|1|TREATMENT|2020-12-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-26|P1Y2M10DT2H30M|UNKNOWN|2020-12-20|AFTER|2021-02-20
e|RS|7e9f4283-f90b-4f74-939c-b42648e8373c|2|NTNERESP|Non-Target Non-Enhancing Response|RANO ELLINGSON 2017|||INCREASED|1|mEq/g|SLOAN LETTER EYE CHART 100%|||Y|SIGNIFICANT OTHER|ADJUDICATOR|U|1|Visit_1|10|1|TREATMENT|2020-12-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-26|P1Y2M10DT2H30M|BEFORE|2020-12-27|AFTER|2021-01-21
e|RS|7e9f4283-f90b-4f74-939c-b42648e8373c|3|SYMPTDTR|Symptomatic Deterioration|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|BLOCKS|SD|1|PA|MECHANICAL CLOT DETECTION|Y|||FAMILY MEMBER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|2|Visit_2|25|5|TREATMENT|2020-12-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-30|P1Y2M10DT2H30M|BEFORE|2021-01-30|BEFORE|2021-03-06
e|RS|7e9f4283-f90b-4f74-939c-b42648e8373c|4|DRCRIND|Disease Recurrence Indicator|JACINTO CERVICAL CANCER 2007|||NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|tuberculin unit|PUPILLOMETRY||Y|Y|ADJUDICATION COMMITTEE|MICROSCOPIST 1|U|2|Visit_2|25|7|TREATMENT|2020-12-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-30|P1Y2M10DT2H30M|AFTER|2021-02-15|ONGOING|2021-03-13
e|RS|7e9f4283-f90b-4f74-939c-b42648e8373c|5|ANATRESP|Anatomic Response|RECICL|||QUANTIFIABLE MRD POSITIVITY|1|100 IU/mL|POTENTIOMETRY|||Y|STUDY SUBJECT|CLINICAL PATHOLOGIST|NA|3|Visit_3|40|4|TREATMENT|2021-01-14|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-11|P1Y2M10DT2H30M|UNKNOWN|2021-01-06|COINCIDENT|2021-02-03
e|RS|7e9f4283-f90b-4f74-939c-b42648e8373c|6|TRGRESP|Target Response|AJCC V7|||CR|1|U/kg|TOTAL BODY RADIOGRAPHY|||Y|FRIEND|ADJUDICATOR 2|NA|3|Visit_3|40|5|TREATMENT|2021-01-14|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-11|P1Y2M10DT2H30M|UNKNOWN|2021-01-15|AFTER|2021-03-07
e|RS|7e9f4283-f90b-4f74-939c-b42648e8373c|7|HEMARESP|Hematologic Response|WHO BREAST CANCER 2006|[?]|umol/h/mmol|SD-CT|1|mmol/L|IODINE STAIN||||CLINICAL STUDY SPONSOR|ONCOLOGIST 2|U|4|Visit_4|65|4|SCREENING|2021-02-08|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-16|P1Y2M10DT2H30M|COINCIDENT|2021-01-06|ONGOING|2021-03-11
e|RS|7e9f4283-f90b-4f74-939c-b42648e8373c|8|NEWLPROG|New Lesion Progression|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|MHz|PR|1|10^6 CFU/g|ICC||||ADJUDICATOR|ADJUDICATOR 1|Y|4|Visit_4|65|7|TREATMENT|2021-02-08|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-16|P1Y2M10DT2H30M|BEFORE|2021-03-09|COINCIDENT|2021-03-11
e|RS|7e9f4283-f90b-4f74-939c-b42648e8373c|9|SYMPTDTR|Symptomatic Deterioration|MRANO VAN DEN BENT GLIOMA 2011|[?]|ppm|NON-CR/NON-PD|1|g/L|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI||||CAREGIVER|MICROSCOPIST 1|Y|5|Visit_5|90|5|TREATMENT|2021-03-05|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-16|P1Y2M10DT2H30M|UNKNOWN|2021-01-19|ONGOING|2021-01-23
e|RS|7e9f4283-f90b-4f74-939c-b42648e8373c|10|NEWLWIND|New Lesion Worsening Indicator|FAROOQUI SUPP CLL 2014|||iSD|1|log10 IU/mL|MASS SPECTROMETRY|||Y|STUDY SUBJECT|ADJUDICATOR|N|5|Visit_5|90|1|TREATMENT|2021-03-05|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-16|P1Y2M10DT2H30M|UNKNOWN|2021-01-09|BEFORE|2021-01-31
e|RS|20a637e6-83d2-4a86-9ecc-8ddb0523997f|1|NTRGRESP|Non-target Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|in|CR|1|nkat/g Hb|SEQUENCING|Y|||CAREGIVER|READER 3|NA|1|Visit_1|10|7|FOLLOW-UP|2020-10-31|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-09|P1Y2M10DT2H30M|COINCIDENT|2020-11-10|ONGOING|2021-01-08
e|RS|20a637e6-83d2-4a86-9ecc-8ddb0523997f|2|BMIVLIND|Bone Marrow Involvement Indicator|LUGANO CLASSIFICATION|[?]|CCID 50/mL|NON-PD|1|mol/mL|FLUORESCENT IMMUNOASSAY|Y|||FRIEND|DERMATOLOGIST|N|1|Visit_1|10|5|SCREENING|2020-10-31|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-09|P1Y2M10DT2H30M|COINCIDENT|2021-01-10|ONGOING|2021-01-25
e|RS|20a637e6-83d2-4a86-9ecc-8ddb0523997f|3|DRCRIND|Disease Recurrence Indicator|CHOLLET BREAST CANCER 2002|||NOT ALL EVALUATED|1|psi|HEMATOXYLIN AND EOSIN STAIN|||Y|CLINICAL STUDY SPONSOR|ENDOCRINOLOGIST|Y|2|Visit_2|25|1|SCREENING|2020-11-15|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-03|P1Y2M10DT2H30M|AFTER|2020-12-29|COINCIDENT|2021-01-18
e|RS|20a637e6-83d2-4a86-9ecc-8ddb0523997f|4|METSIND|Metastatic Indicator|CHOI GIST 2008|[?]|Absorbance U/min|CRi|1|MPL U/mL|HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY|Y|Y||PROXY|RADIOLOGIST 2|N|2|Visit_2|25|6|TREATMENT|2020-11-15|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-03|P1Y2M10DT2H30M|UNKNOWN|2020-11-27|ONGOING|2021-01-13
e|RS|20a637e6-83d2-4a86-9ecc-8ddb0523997f|5|NTRGRESP|Non-target Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|||COMPLETE MRD RESPONSE|1|MPL U/mL|POLYMERASE CHAIN REACTION|||Y|INDEPENDENT ASSESSOR|CLINICAL PATHOLOGIST|N|3|Visit_3|40|7|TREATMENT|2020-11-30|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-21|P1Y2M10DT2H30M|COINCIDENT|2020-12-31|COINCIDENT|2021-01-08
e|RS|20a637e6-83d2-4a86-9ecc-8ddb0523997f|6|NTLWIND|Non-Target Lesion Worsening Indicator|PCWG SCHER PROSTATE CANCER 2016|[?]|ug/mol|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|U/g/day|DIFFUSION WEIGHTED MRI|Y|Y||CLINICAL RESEARCH COORDINATOR|READER 2|NA|3|Visit_3|40|1|WASHOUT|2020-11-30|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-21|P1Y2M10DT2H30M|AFTER|2021-01-09|BEFORE|2021-01-22
e|RS|20a637e6-83d2-4a86-9ecc-8ddb0523997f|7|DRCRIND|Disease Recurrence Indicator|PCWG SCHER PROSTATE CANCER 2016|[?]|/7.5 mL|CYTOGENETIC CR|1|/200 HPFs|REFRACTOMETRY||||PARENT|READER 3|Y|4|Visit_4|65|5|SCREENING|2020-12-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-05|P1Y2M10DT2H30M|AFTER|2021-01-08|ONGOING|2021-01-15
e|RS|20a637e6-83d2-4a86-9ecc-8ddb0523997f|8|NTERESP|Non-Target Enhancing Response|HARTMANN GERM CELL CANCER 2002|[?]|ng|EQUIVOCAL|1|m/sec2|FLUORESCEIN STAIN||||DOMESTIC PARTNER|PATHOLOGIST 2|U|4|Visit_4|65|7|SCREENING|2020-12-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-05|P1Y2M10DT2H30M|UNKNOWN|2020-11-22|ONGOING|2021-01-10
e|RS|20a637e6-83d2-4a86-9ecc-8ddb0523997f|9|MRDRESP|Minimal Residual Disease Response|KUMAR IMWG 2016|||CR-CT|1|uOsm|IODINE STAIN|Y|Y|Y|DOMESTIC PARTNER|ONCOLOGIST 2|NA|5|Visit_5|90|5|TREATMENT|2021-01-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-09|P1Y2M10DT2H30M|COINCIDENT|2020-10-25|COINCIDENT|2021-01-19
e|RS|20a637e6-83d2-4a86-9ecc-8ddb0523997f|10|NEWLIND|New Lesion Indicator|IWG CHESON AML 2003|[?]|10^5/L|PD/RELAPSE AFTER HI|1|cmH2O/mL|BETA LACTAMASE||Y||CHILD|ONCOLOGIST 2|N|5|Visit_5|90|7|TREATMENT|2021-01-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-09|P1Y2M10DT2H30M|COINCIDENT|2020-12-21|AFTER|2021-01-22
e|RS|29b5d32c-0c0e-42b2-8dfd-ff92a7a6229e|1|MRDRESP|Minimal Residual Disease Response|FAROOQUI SUPP CLL 2014|[?]|mmol/L|DISEASE TRANSFORMATION|1|PFU|STRESS ECHOCARDIOGRAPHY||Y||ADJUDICATOR|NEUROLOGIST 1|NA|1|Visit_1|10|3|TREATMENT|2020-05-16|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-12|P1Y2M10DT2H30M|COINCIDENT|2020-05-23|ONGOING|2020-06-14
e|RS|29b5d32c-0c0e-42b2-8dfd-ff92a7a6229e|2|MJPTHIND|Major Pathological Response Indicator|iRECIST|[?]|CIGAR|PD-CT|1|fmol|SINGLE-SLICE SPIRAL CT||Y||CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|1|Visit_1|10|5|TREATMENT|2020-05-16|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-12|P1Y2M10DT2H30M|COINCIDENT|2020-06-10|BEFORE|2020-06-14
e|RS|29b5d32c-0c0e-42b2-8dfd-ff92a7a6229e|3|SFTSRESP|Soft Tissue Response|BURCOMBE BREAST CANCER 2005|[?]|10^6 CFU/g|mCR|1|mmol/kg|VIRUS PLAQUE ASSAY||Y||SIGNIFICANT OTHER|READER|Y|2|Visit_2|25|6|SCREENING|2020-05-31|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-06|P1Y2M10DT2H30M|COINCIDENT|2020-06-08|AFTER|2020-06-17
e|RS|29b5d32c-0c0e-42b2-8dfd-ff92a7a6229e|4|NTNERESP|Non-Target Non-Enhancing Response|PRINCE TCELL LYMPHOMA 2010|[?]|DNA copies/ug|HI-N|1|10^9 organisms/mg|ETDRS EYE CHART||||CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 2|NA|2|Visit_2|25|1|SCREENING|2020-05-31|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-06|P1Y2M10DT2H30M|BEFORE|2020-06-21|ONGOING|2020-07-28
e|RS|29b5d32c-0c0e-42b2-8dfd-ff92a7a6229e|5|CLINRESP|Clinical Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|nCi|nPR|1|U/animal|PERFUSION MRI||Y||CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 2|N|3|Visit_3|40|4|WASHOUT|2020-06-15|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-09|P1Y2M10DT2H30M|COINCIDENT|2020-05-20|BEFORE|2020-07-02
e|RS|29b5d32c-0c0e-42b2-8dfd-ff92a7a6229e|6|MJPTHIND|Major Pathological Response Indicator|GUILHOT CML 2007|[?]|Newton|MAJOR PATHOLOGIC RESPONSE|1|GBq|HPLC/MS||Y||ADJUDICATOR|RATER 1|Y|3|Visit_3|40|7|FOLLOW-UP|2020-06-15|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-09|P1Y2M10DT2H30M|BEFORE|2020-07-10|COINCIDENT|2020-07-29
e|RS|29b5d32c-0c0e-42b2-8dfd-ff92a7a6229e|7|MRDIND|Minimal Residual Disease Indicator|RECIST 1.1|[?]|GPS U|PSEUDORESPONSE|1|10^6 copies/mL|X-RAY FLUORESCENCE SPECTROMETRY|Y|||VENDOR|RADIOLOGIST 1|N|4|Visit_4|65|6|SCREENING|2020-07-10|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-10|P1Y2M10DT2H30M|BEFORE|2020-06-10|AFTER|2020-07-13
e|RS|29b5d32c-0c0e-42b2-8dfd-ff92a7a6229e|8|ANATRESP|Anatomic Response|RECIST 1.1|[?]|BAU/mL|PD FROM PR|1|kN/cm2|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY||Y||VENDOR|READER|U|4|Visit_4|65|7|TREATMENT|2020-07-10|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-10|P1Y2M10DT2H30M|BEFORE|2020-07-24|ONGOING|2020-07-28
e|RS|29b5d32c-0c0e-42b2-8dfd-ff92a7a6229e|9|MRDIND|Minimal Residual Disease Indicator|EUROPEAN LEUKEMIANET BACCARANI CML 2006|||SD-CT|1|amol|DXA SCAN|||Y|CHILD|RADIOLOGIST 1|NA|5|Visit_5|90|4|TREATMENT|2020-08-04|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-13|P1Y2M10DT2H30M|COINCIDENT|2020-08-11|COINCIDENT|2020-08-12
e|RS|29b5d32c-0c0e-42b2-8dfd-ff92a7a6229e|10|MRDIND|Minimal Residual Disease Indicator|SHINDOH COLORECTAL CANCER 2013|||iCR|1|mm/sec|RADIOGRAPHY||Y|Y|CLINICAL STUDY SPONSOR|READER 2|NA|5|Visit_5|90|7|SCREENING|2020-08-04|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-13|P1Y2M10DT2H30M|BEFORE|2020-07-07|COINCIDENT|2020-08-04
e|RS|595aa95c-4378-47c1-96e9-5512d08fb653|1|STRUSTAT|Steroid Use Status|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|||iSD|1|umol|ELASTOGRAPHY|||Y|HEALTH CARE PROFESSIONAL|RATER 1|Y|1|Visit_1|10|6|TREATMENT|2020-08-23|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-04|P1Y2M10DT2H30M|UNKNOWN|2020-10-26|ONGOING|2020-11-05
e|RS|595aa95c-4378-47c1-96e9-5512d08fb653|2|NTRGRESP|Non-target Response|NCCN ALL MRD 2014|[?]|SUPPOSITORY|CRi|1|mmHg|SMEAR||||PROXY|RATER 2|NA|1|Visit_1|10|6|SCREENING|2020-08-23|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-04|P1Y2M10DT2H30M|UNKNOWN|2020-09-05|AFTER|2020-11-16
e|RS|595aa95c-4378-47c1-96e9-5512d08fb653|3|MRDIND|Minimal Residual Disease Indicator|PETIT BREAST CANCER 2001|[?]|pt_br|INCREASED|1|/500 WBC|FLUORESCENCE ANGIOGRAPHY||Y||SIGNIFICANT OTHER|MICROSCOPIST 2|N|2|Visit_2|25|1|TREATMENT|2020-09-07|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-14|P1Y2M10DT2H30M|UNKNOWN|2020-08-20|BEFORE|2020-08-30
e|RS|595aa95c-4378-47c1-96e9-5512d08fb653|4|OVRLRESP|Overall Response|PETIT BREAST CANCER 2001|[?]|mL/g/day|iCPD|1|TCID 50/dose|PERFUSION MRI|Y|||SIGNIFICANT OTHER|ADJUDICATOR 3|U|2|Visit_2|25|6|SCREENING|2020-09-07|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-14|P1Y2M10DT2H30M|BEFORE|2020-11-02|ONGOING|2020-11-04
e|RS|595aa95c-4378-47c1-96e9-5512d08fb653|5|BMIVLIND|Bone Marrow Involvement Indicator|MRECIST LENCIONI LIVER CANCER 2010|[?]|ECL unit|mCR|1|DAgU|GRAM STAIN|Y|||VENDOR|NEUROLOGIST 1|Y|3|Visit_3|40|4|TREATMENT|2020-09-22|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-18|P1Y2M10DT2H30M|COINCIDENT|2020-09-27|ONGOING|2020-11-05
e|RS|595aa95c-4378-47c1-96e9-5512d08fb653|6|METBRESP|Metabolic Response|HAMAOKA BREAST CANCER 2010|[?]|PFU/dose|CMR|1|dpm/mg|SPECT SCAN||||ADJUDICATION COMMITTEE|UROLOGIST|NA|3|Visit_3|40|4|TREATMENT|2020-09-22|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-18|P1Y2M10DT2H30M|AFTER|2020-11-05|AFTER|2020-11-14
e|RS|595aa95c-4378-47c1-96e9-5512d08fb653|7|TMRESP|Tumor Marker Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|AgU/mL|WORSENED|1|dL|PET/CT SCAN WITHOUT CONTRAST||||PARENT|MICROSCOPIST 1|Y|4|Visit_4|65|3|TREATMENT|2020-10-17|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-07|P1Y2M10DT2H30M|BEFORE|2020-11-08|COINCIDENT|2020-11-10
e|RS|595aa95c-4378-47c1-96e9-5512d08fb653|8|DRCRIND|Disease Recurrence Indicator|KEAM BREAST CANCER 2013|[?]|g/day|PSA PROGRESSION|1|10^3 organisms|FLUORESCENT MICROSCOPY||||STUDY SUBJECT|PATHOLOGIST 2|Y|4|Visit_4|65|4|FOLLOW-UP|2020-10-17|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-07|P1Y2M10DT2H30M|UNKNOWN|2020-10-30|BEFORE|2020-11-18
e|RS|595aa95c-4378-47c1-96e9-5512d08fb653|9|MRPHRESP|Morphologic Response|GUILHOT CML 2007|[?]|vg/kg|PR|1|TRANSDUCING UNIT/mL|MEDIASTINOSCOPY||||STUDY SUBJECT|PEDIATRIC NEUROLOGIST|Y|5|Visit_5|90|2|WASHOUT|2020-11-11|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-30|P1Y2M10DT2H30M|COINCIDENT|2020-11-15|AFTER|2020-11-18
e|RS|595aa95c-4378-47c1-96e9-5512d08fb653|10|ANATRESP|Anatomic Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|||MORPHOLOGIC CR|1|WEEKS|ECHOCARDIOGRAPHY|Y||Y|VENDOR|ADJUDICATOR 3|NA|5|Visit_5|90|1|WASHOUT|2020-11-11|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-30|P1Y2M10DT2H30M|AFTER|2020-09-16|BEFORE|2020-11-05
e|RS|b528dc24-e791-41b1-95b3-fc0be18da47f|1|BESTRESP|Best Overall Response|PROTOCOL DEFINED RESPONSE CRITERIA|||iCPD|1|dpm/mg|IMMUNOTURBIDIMETRY|||Y|FAMILY MEMBER|READER 2|NA|1|Visit_1|10|7|WASHOUT|2020-12-27|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-23|P1Y2M10DT2H30M|AFTER|2021-01-27|BEFORE|2021-02-23
e|RS|b528dc24-e791-41b1-95b3-fc0be18da47f|2|RDIORESP|Radiologic Response|IWG CHESON MDS 2000|[?]|Bq/uL|CRi|1|BOWL|NO INFORMATION||||CHILD|ADJUDICATOR 3|N|1|Visit_1|10|4|TREATMENT|2020-12-27|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-23|P1Y2M10DT2H30M|AFTER|2021-02-02|BEFORE|2021-03-06
e|RS|b528dc24-e791-41b1-95b3-fc0be18da47f|3|METBRESP|Metabolic Response|FAROOQUI SUPP CLL 2014|[?]|log10 TCID 50/uL|PR|1|mg/day|FARR ASSAY|Y|||CLINICAL RESEARCH COORDINATOR|RADIOLOGIST|U|2|Visit_2|25|5|TREATMENT|2021-01-11|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-20|P1Y2M10DT2H30M|COINCIDENT|2021-01-08|COINCIDENT|2021-02-26
e|RS|b528dc24-e791-41b1-95b3-fc0be18da47f|4|DRCRIND|Disease Recurrence Indicator|RANO|[?]|pm|NED|1|ug/min|IMMUNODIFFUSION||||NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|N|2|Visit_2|25|6|TREATMENT|2021-01-11|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-20|P1Y2M10DT2H30M|UNKNOWN|2021-02-28|ONGOING|2021-03-18
e|RS|b528dc24-e791-41b1-95b3-fc0be18da47f|5|HEMARESP|Hematologic Response|SCHWARZ CERVICAL CANCER 2009|[?]|mCi|iCPD|1|10^6 RNA copies/mL|ZIEHL NEELSEN ACID FAST STAIN||||STUDY SUBJECT|MICROSCOPIST 3|U|3|Visit_3|40|7|SCREENING|2021-01-26|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-01|P1Y2M10DT2H30M|UNKNOWN|2020-12-28|ONGOING|2021-03-25
e|RS|b528dc24-e791-41b1-95b3-fc0be18da47f|6|CPRFSTAT|Clinical Performance Status|NCIWG CHESON CLL 1996|[?]|cL|PSEUDORESPONSE|1|cy/cm|INDIRECT IMMUNOFLUORESCENCE|Y|Y||INDEPENDENT ASSESSOR|OPHTHALMOLOGIST|Y|3|Visit_3|40|5|WASHOUT|2021-01-26|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-01|P1Y2M10DT2H30M|COINCIDENT|2021-03-02|AFTER|2021-03-12
e|RS|b528dc24-e791-41b1-95b3-fc0be18da47f|7|MOLRESP|Molecular Response|MRECIST BYRNE MESOTHELIOMA 2004|||PDu|1|mL/beat|PH METER MEASUREMENT METHOD||Y|Y|SIBLING|HEMATOLOGIST|N|4|Visit_4|65|2|SCREENING|2021-02-20|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-12|P1Y2M10DT2H30M|UNKNOWN|2021-01-15|BEFORE|2021-03-16
e|RS|b528dc24-e791-41b1-95b3-fc0be18da47f|8|HEMARESP|Hematologic Response|iRECIST|[?]|PNU/mL|MORPHOLOGIC LEUKEMIA-FREE STATE|1|dram|DOUBLE IMMUNODIFFUSION||Y||DOMESTIC PARTNER|PEDIATRIC NEUROLOGIST|U|4|Visit_4|65|5|TREATMENT|2021-02-20|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-12|P1Y2M10DT2H30M|COINCIDENT|2020-12-24|ONGOING|2021-03-12
e|RS|b528dc24-e791-41b1-95b3-fc0be18da47f|9|ANATRESP|Anatomic Response|CHOLLET BREAST CANCER 2002|[?]|10^9 organisms/g|iUPD|1|PATCH|HEMAGGLUTINATION INHIBITION ASSAY|Y|||CLINICAL STUDY SPONSOR|ADJUDICATOR 2|NA|5|Visit_5|90|4|TREATMENT|2021-03-17|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-11|P1Y2M10DT2H30M|AFTER|2021-01-31|AFTER|2021-02-05
e|RS|b528dc24-e791-41b1-95b3-fc0be18da47f|10|NEWLIND|New Lesion Indicator|AJCC V8|[?]|U.CARR|mCR|1|DRUM|CELLULOSE TAPE||||SIBLING|MICROSCOPIST 1|Y|5|Visit_5|90|5|FOLLOW-UP|2021-03-17|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-11|P1Y2M10DT2H30M|BEFORE|2021-03-21|BEFORE|2021-03-25
e|RS|7a43c892-0e7f-4f33-9130-e175e475531f|1|CPRFSTAT|Clinical Performance Status|SCHER PROSTATE CANCER 2011|[?]|foz_br|MAJOR PATHOLOGIC RESPONSE|1|PIXEL|ULTRASONOGRAPHIC ELASTOGRAPHY||||GUARDIAN|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|1|Visit_1|10|1|SCREENING|2020-05-17|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-28|P1Y2M10DT2H30M|AFTER|2020-05-27|BEFORE|2020-07-21
e|RS|7a43c892-0e7f-4f33-9130-e175e475531f|2|ANATRESP|Anatomic Response|RECIST 1.0|[?]|MnFI|PD FROM PR|1|mL/mmHg|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS||Y||ADJUDICATOR|MICROSCOPIST 1|Y|1|Visit_1|10|7|TREATMENT|2020-05-17|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-28|P1Y2M10DT2H30M|UNKNOWN|2020-08-12|BEFORE|2020-08-13
e|RS|7a43c892-0e7f-4f33-9130-e175e475531f|3|NTNERESP|Non-Target Non-Enhancing Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|eq|PR|1|NEEDLE GAUGE|MOUSE PROTECTION ASSAY|Y|Y||CAREGIVER|READER 2|Y|2|Visit_2|25|4|TREATMENT|2020-06-01|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-09|P1Y2M10DT2H30M|BEFORE|2020-07-16|COINCIDENT|2020-07-19
e|RS|7a43c892-0e7f-4f33-9130-e175e475531f|4|OVRLRESP|Overall Response|BRUGGEMANN MRD 2010|[?]|dB|PMR|1|ppth|CHROMATOGRAPHY|Y|Y||ADJUDICATOR|MICROSCOPIST 3|Y|2|Visit_2|25|4|TREATMENT|2020-06-01|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-09|P1Y2M10DT2H30M|COINCIDENT|2020-08-03|AFTER|2020-08-14
e|RS|7a43c892-0e7f-4f33-9130-e175e475531f|5|SFTSRESP|Soft Tissue Response|SHINDOH COLORECTAL CANCER 2013|[?]|uV*sec|CYTOGENETIC CR|1|mg2/dL2|REBOUND TONOMETRY|Y|||STUDY SUBJECT|INTERNIST|U|3|Visit_3|40|2|FOLLOW-UP|2020-06-16|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-23|P1Y2M10DT2H30M|AFTER|2020-05-18|AFTER|2020-07-14
e|RS|7a43c892-0e7f-4f33-9130-e175e475531f|6|TRGRESP|Target Response|JACINTO CERVICAL CANCER 2007|[?]|mEq/dL|mCR|1|uU/dL|MICROBIAL CULTURE|Y|||CHILD|READER|Y|3|Visit_3|40|3|TREATMENT|2020-06-16|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-23|P1Y2M10DT2H30M|COINCIDENT|2020-05-09|AFTER|2020-05-11
e|RS|7a43c892-0e7f-4f33-9130-e175e475531f|7|METSIND|Metastatic Indicator|AJCC V8|||PMD|1|oz eq|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|Y||Y|FRIEND|PEDIATRIC NEUROLOGIST|Y|4|Visit_4|65|1|TREATMENT|2020-07-11|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-15|P1Y2M10DT2H30M|UNKNOWN|2020-05-22|AFTER|2020-07-11
e|RS|7a43c892-0e7f-4f33-9130-e175e475531f|8|NEWLPROG|New Lesion Progression|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|/VF|HI-E|1|kUSP|TWO-COLOR MICROARRAY|Y|||CLINICAL STUDY SPONSOR|OPTOMETRIST|N|4|Visit_4|65|7|WASHOUT|2020-07-11|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-15|P1Y2M10DT2H30M|UNKNOWN|2020-05-14|ONGOING|2020-07-07
e|RS|7a43c892-0e7f-4f33-9130-e175e475531f|9|SYMPTDTR|Symptomatic Deterioration|iRECIST|||PSEUDOPROGRESSION|1|/40 HPFs|HEMOCYTOMETRY|Y||Y|CLINICAL RESEARCH ASSOCIATE|RATER|NA|5|Visit_5|90|1|TREATMENT|2020-08-05|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-23|P1Y2M10DT2H30M|AFTER|2020-07-22|ONGOING|2020-08-01
e|RS|7a43c892-0e7f-4f33-9130-e175e475531f|10|LIVRRESP|Liver Response|RECIST 1.1|[?]|MPL U/mL|mCR|1|pmol/L/h|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION||||CLINICAL STUDY SPONSOR|NEUROLOGIST 2|NA|5|Visit_5|90|4|WASHOUT|2020-08-05|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-23|P1Y2M10DT2H30M|COINCIDENT|2020-07-24|BEFORE|2020-08-03
e|RS|8cce3de1-e56d-4c2c-9b45-cdf1f226dc5e|1|MNPTHIND|Minor Pathological Response Indicator|IWC HALLEK CLL 2008|[?]|pmol/L|EQUIVOCAL|1|IMPLANT|PANENDOSCOPY||Y||FRIEND|READER|Y|1|Visit_1|10|7|FOLLOW-UP|2020-12-10|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-27|P1Y2M10DT2H30M|AFTER|2021-01-08|AFTER|2021-03-03
e|RS|8cce3de1-e56d-4c2c-9b45-cdf1f226dc5e|2|TRGRESP|Target Response|RANO|||UNFAVORABLE RESPONSE|1|Tbsp|ICP-MS|Y||Y|CLINICAL STUDY SPONSOR|DERMATOLOGIST|NA|1|Visit_1|10|7|SCREENING|2020-12-10|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-27|P1Y2M10DT2H30M|BEFORE|2020-12-25|COINCIDENT|2021-01-27
e|RS|8cce3de1-e56d-4c2c-9b45-cdf1f226dc5e|3|CPRFSTAT|Clinical Performance Status|MACDONALD GLIOMA 1990|[?]|m/sec|MRD NEGATIVITY|1|PFU|SCINTIGRAPHY||||STUDY SUBJECT|OPTOMETRIST|U|2|Visit_2|25|6|TREATMENT|2020-12-25|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-16|P1Y2M10DT2H30M|COINCIDENT|2021-03-09|COINCIDENT|2021-03-10
e|RS|8cce3de1-e56d-4c2c-9b45-cdf1f226dc5e|4|SFTSRESP|Soft Tissue Response|HAMAOKA BREAST CANCER 2010|||PARTIAL MORPHOLOGIC RESPONSE|1|CCID 50/mL|IMMUNO-PET SCAN|Y||Y|FAMILY MEMBER|READER 2|Y|2|Visit_2|25|3|TREATMENT|2020-12-25|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-16|P1Y2M10DT2H30M|COINCIDENT|2020-12-07|AFTER|2021-02-13
e|RS|8cce3de1-e56d-4c2c-9b45-cdf1f226dc5e|5|SPLNRESP|Spleen Response|AJCC V8|[?]|ug/kg/h|CMR|1|umol/mg/min|MANUAL CLOT DETECTION|Y|||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR|N|3|Visit_3|40|3|TREATMENT|2021-01-09|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-30|P1Y2M10DT2H30M|AFTER|2021-01-13|BEFORE|2021-02-11
e|RS|8cce3de1-e56d-4c2c-9b45-cdf1f226dc5e|6|CYTORESP|Cytogenetic Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|BOWL|NON-PD|1|breaths/min|CALIPER MEASUREMENT METHOD||||CLINICAL STUDY SPONSOR|OTOLARYNGOLOGIST|N|3|Visit_3|40|6|TREATMENT|2021-01-09|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-30|P1Y2M10DT2H30M|COINCIDENT|2021-02-21|BEFORE|2021-03-01
e|RS|8cce3de1-e56d-4c2c-9b45-cdf1f226dc5e|7|TRGRESP|Target Response|MURPHY PROSTATE CANCER 1980|||RELAPSED DISEASE|1|DDU|MODIFIED ACID FAST STAIN|Y||Y|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 2|NA|4|Visit_4|65|3|SCREENING|2021-02-03|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-17|P1Y2M10DT2H30M|COINCIDENT|2020-12-06|ONGOING|2021-02-11
e|RS|8cce3de1-e56d-4c2c-9b45-cdf1f226dc5e|8|MRPHRESP|Morphologic Response|IRANO 2015|[?]|mg/kg|DISEASE TRANSFORMATION|1|m3|FLOCCULATION, CHARCOAL ENHANCED||||FRIEND|DEVELOPMENTAL PSYCHOLOGIST|Y|4|Visit_4|65|3|SCREENING|2021-02-03|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-17|P1Y2M10DT2H30M|AFTER|2020-12-09|COINCIDENT|2021-01-19
e|RS|8cce3de1-e56d-4c2c-9b45-cdf1f226dc5e|9|NTERESP|Non-Target Enhancing Response|IWG CHESON MDS 2006|[?]|mg/L FEU|PSEUDOPROGRESSION|1|kg/mol|SPECTROPHOTOMETRY||Y||CLINICAL STUDY SPONSOR|CARDIOLOGIST|Y|5|Visit_5|90|4|SCREENING|2021-02-28|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-01|P1Y2M10DT2H30M|AFTER|2020-12-27|AFTER|2021-03-06
e|RS|8cce3de1-e56d-4c2c-9b45-cdf1f226dc5e|10|NEWLIND|New Lesion Indicator|PETIT BREAST CANCER 2001|[?]|ug/g/h|MINOR PATHOLOGIC RESPONSE|1|um/day|ELISPOT||||STUDY SUBJECT|RATER 2|Y|5|Visit_5|90|3|WASHOUT|2021-02-28|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-01|P1Y2M10DT2H30M|BEFORE|2021-01-18|COINCIDENT|2021-01-31
e|RS|bde9096e-9ab9-45fe-8e96-1ec9762824a0|1|OVRLRESP|Overall Response|IWC HALLEK CLL 2008|||QUANTIFIABLE MRD POSITIVITY|1|DAgU|MANUAL COUNT|||Y|HEALTH CARE PROFESSIONAL|RATER 1|U|1|Visit_1|10|7|TREATMENT|2020-08-27|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-19|P1Y2M10DT2H30M|UNKNOWN|2020-10-05|ONGOING|2020-10-16
e|RS|bde9096e-9ab9-45fe-8e96-1ec9762824a0|2|SPLNRESP|Spleen Response|GUILHOT CML 2007|||NON-iCR/NON-iUPD|1|/cmH2O|WHOLE TRANSCRIPTOME SEQUENCING||Y|Y|ADJUDICATION COMMITTEE|RADIOLOGIST 1|N|1|Visit_1|10|7|TREATMENT|2020-08-27|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-19|P1Y2M10DT2H30M|AFTER|2020-10-20|COINCIDENT|2020-11-10
e|RS|bde9096e-9ab9-45fe-8e96-1ec9762824a0|3|TMRESP|Tumor Marker Response|RANO|[?]|cm/min|MORPHOLOGIC CR|1|ppm|ALCIAN BLUE STAIN||||STUDY SUBJECT|RADIOLOGIST 2|Y|2|Visit_2|25|2|WASHOUT|2020-09-11|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-18|P1Y2M10DT2H30M|BEFORE|2020-10-31|AFTER|2020-11-20
e|RS|bde9096e-9ab9-45fe-8e96-1ec9762824a0|4|MRPHRESP|Morphologic Response|RANO|[?]|steps/min|iCR|1|COAT|LISSAMINE GREEN STAIN||||PROXY|ADJUDICATOR 1|NA|2|Visit_2|25|6|SCREENING|2020-09-11|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-18|P1Y2M10DT2H30M|BEFORE|2020-08-29|COINCIDENT|2020-11-19
e|RS|bde9096e-9ab9-45fe-8e96-1ec9762824a0|5|MRPHRESP|Morphologic Response|IWG CHESON MDS 2006|[?]|mL/animal/day|UNFAVORABLE RESPONSE|1|gpELISA unit/mL|POLYGRAPHY||||ADJUDICATION COMMITTEE|UROLOGIST|Y|3|Visit_3|40|1|SCREENING|2020-09-26|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-20|P1Y2M10DT2H30M|AFTER|2020-09-03|BEFORE|2020-10-28
e|RS|bde9096e-9ab9-45fe-8e96-1ec9762824a0|6|PATHRESP|Pathologic Response|SHINDOH COLORECTAL CANCER 2013|[?]|U/dL|sCR|1|Linear ft*LB|DIGITAL PCR ARRAY|Y|Y||ADJUDICATION COMMITTEE|ADJUDICATOR 1|U|3|Visit_3|40|5|FOLLOW-UP|2020-09-26|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-20|P1Y2M10DT2H30M|BEFORE|2020-11-15|BEFORE|2020-11-17
e|RS|bde9096e-9ab9-45fe-8e96-1ec9762824a0|7|STRUSTAT|Steroid Use Status|MACDONALD GLIOMA 1990|[?]|mg/min|PSEUDORESPONSE|1|log10 CCID 50/dose|ZIEHL NEELSEN ACID FAST STAIN||||PARENT|RATER|NA|4|Visit_4|65|1|TREATMENT|2020-10-21|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-16|P1Y2M10DT2H30M|COINCIDENT|2020-08-28|AFTER|2020-09-01
e|RS|bde9096e-9ab9-45fe-8e96-1ec9762824a0|8|SPLNRESP|Spleen Response|RAJKUMAR MYELOMA 2011|||iCR|1|log10 copies/mL|COLORIMETRY|||Y|STUDY SUBJECT|ADJUDICATOR 3|NA|4|Visit_4|65|5|TREATMENT|2020-10-21|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-16|P1Y2M10DT2H30M|UNKNOWN|2020-11-02|ONGOING|2020-11-20
e|RS|bde9096e-9ab9-45fe-8e96-1ec9762824a0|9|SPLNRESP|Spleen Response|PERCIST|||PSEUDOPROGRESSION|1|ug/day|ENZYMATIC COLORIMETRY|||Y|GUARDIAN|RADIOLOGIST 2|Y|5|Visit_5|90|2|TREATMENT|2020-11-15|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-30|P1Y2M10DT2H30M|BEFORE|2020-11-15|ONGOING|2020-11-16
e|RS|bde9096e-9ab9-45fe-8e96-1ec9762824a0|10|BESTRESP|Best Overall Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|mg/g/h|STABLE|1|10^9 CFU/g|ELECTRONEUROGRAPHY||||SIBLING|RATER 2|N|5|Visit_5|90|7|WASHOUT|2020-11-15|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-30|P1Y2M10DT2H30M|UNKNOWN|2020-08-19|AFTER|2020-09-06
e|RS|ea7907aa-811e-48ec-9fc6-ab8affde8913|1|STRUSTAT|Steroid Use Status|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|L/L|cCR|1|Newton|MRI||||ADJUDICATOR|ONCOLOGIST|N|1|Visit_1|10|1|SCREENING|2020-06-28|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-10|P1Y2M10DT2H30M|AFTER|2020-08-17|AFTER|2020-08-23
e|RS|ea7907aa-811e-48ec-9fc6-ab8affde8913|2|NTRGRESP|Non-target Response|RANO ELLINGSON 2017|[?]|ft2|MORPHOLOGIC CRi|1|umol/day|GC/FID|Y|||FRIEND|RATER 2|Y|1|Visit_1|10|7|SCREENING|2020-06-28|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-10|P1Y2M10DT2H30M|BEFORE|2020-08-22|AFTER|2020-09-13
e|RS|ea7907aa-811e-48ec-9fc6-ab8affde8913|3|DRCRIND|Disease Recurrence Indicator|IWG CHESON AML 2003|[?]|nmol/kg/day|PMD|1|%(w/w)|PALM METHOD||||VENDOR|INTERNIST|Y|2|Visit_2|25|4|FOLLOW-UP|2020-07-13|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-26|P1Y2M10DT2H30M|AFTER|2020-09-16|AFTER|2020-09-21
e|RS|ea7907aa-811e-48ec-9fc6-ab8affde8913|4|BESTRESP|Best Overall Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|||OPTIMAL MORPHOLOGIC RESPONSE|1|10^3 CFU/g|PET/CT SCAN WITHOUT CONTRAST|||Y|INDEPENDENT ASSESSOR|ADJUDICATOR|Y|2|Visit_2|25|4|TREATMENT|2020-07-13|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-26|P1Y2M10DT2H30M|BEFORE|2020-08-17|BEFORE|2020-09-14
e|RS|ea7907aa-811e-48ec-9fc6-ab8affde8913|5|BONERESP|Bone Response|PETIT BREAST CANCER 2001|[?]|kPa|NE|1|mm2|PANENDOSCOPY|Y|Y||ADJUDICATION COMMITTEE|FORENSIC PATHOLOGIST|U|3|Visit_3|40|7|TREATMENT|2020-07-28|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-24|P1Y2M10DT2H30M|AFTER|2020-09-21|BEFORE|2020-09-22
e|RS|ea7907aa-811e-48ec-9fc6-ab8affde8913|6|MOLRESP|Molecular Response|UNSPECIFIED|[?]|dL|iUPD|1|mL/g/min|CRYOSCOPY||||PARENT|MICROSCOPIST 2|U|3|Visit_3|40|3|TREATMENT|2020-07-28|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-24|P1Y2M10DT2H30M|AFTER|2020-08-26|COINCIDENT|2020-09-01
e|RS|ea7907aa-811e-48ec-9fc6-ab8affde8913|7|NTRGRESP|Non-target Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|kat|STABLE|1|PUFF|FUNCTIONAL MRI|Y|||SIGNIFICANT OTHER|RATER|U|4|Visit_4|65|7|SCREENING|2020-08-22|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-21|P1Y2M10DT2H30M|COINCIDENT|2020-07-19|BEFORE|2020-09-06
e|RS|ea7907aa-811e-48ec-9fc6-ab8affde8913|8|NEWLPROG|New Lesion Progression|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|Enzyme U/L|MOLECULAR CR|1|ELISA unit/dose|SPECT SCAN||Y||CLINICAL STUDY SPONSOR|RADIOLOGIST|N|4|Visit_4|65|5|FOLLOW-UP|2020-08-22|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-21|P1Y2M10DT2H30M|BEFORE|2020-07-19|AFTER|2020-08-19
e|RS|ea7907aa-811e-48ec-9fc6-ab8affde8913|9|MRDIND|Minimal Residual Disease Indicator|LUGANO CLASSIFICATION|||UNEQUIVOCAL|1|in2|MUGA|||Y|FRIEND|READER 2|NA|5|Visit_5|90|7|SCREENING|2020-09-16|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-01|P1Y2M10DT2H30M|UNKNOWN|2020-06-27|AFTER|2020-08-02
e|RS|ea7907aa-811e-48ec-9fc6-ab8affde8913|10|NTRGRESP|Non-target Response|CHESON CLL 2012|[?]|mOsm|PR WITH LYMPHOCYTOSIS|1|/h|PET SCAN||||INVESTIGATOR|NEUROLOGIST 2|Y|5|Visit_5|90|7|TREATMENT|2020-09-16|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-01|P1Y2M10DT2H30M|BEFORE|2020-07-11|ONGOING|2020-09-23
e|RS|3aa9935c-943d-406a-bb6e-fc067fa8a487|1|HEMARESP|Hematologic Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|SBE/mL|CRi|1|ft|BRDU CELLULAR PROLIFERATION ASSAY||Y||DOMESTIC PARTNER|PATHOLOGIST 2|U|1|Visit_1|10|6|TREATMENT|2020-08-27|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-01|P1Y2M10DT2H30M|BEFORE|2020-09-03|BEFORE|2020-10-20
e|RS|3aa9935c-943d-406a-bb6e-fc067fa8a487|2|NTNERESP|Non-Target Non-Enhancing Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|dyn|MORPHOLOGIC CR|1|/500 WBC|SICKLE CELL SOLUBILITY TEST||||PARENT|PATHOLOGIST 1|N|1|Visit_1|10|2|WASHOUT|2020-08-27|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-01|P1Y2M10DT2H30M|COINCIDENT|2020-09-24|AFTER|2020-10-12
e|RS|3aa9935c-943d-406a-bb6e-fc067fa8a487|3|MJPTHIND|Major Pathological Response Indicator|PCWG BUBLEY PROSTATE CANCER 1999|[?]|umol/mol|NED|1|10^7 CFU|FLUORESCENT MICROSCOPY||||PROXY|RATER 1|N|2|Visit_2|25|3|FOLLOW-UP|2020-09-11|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-10|P1Y2M10DT2H30M|AFTER|2020-11-05|ONGOING|2020-11-21
e|RS|3aa9935c-943d-406a-bb6e-fc067fa8a487|4|MRDRESP|Minimal Residual Disease Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|anti-Xa IU|CMR|1|pL|IMMUNOBLOT||||SIGNIFICANT OTHER|ADJUDICATOR 2|N|2|Visit_2|25|5|TREATMENT|2020-09-11|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-10|P1Y2M10DT2H30M|BEFORE|2020-11-03|ONGOING|2020-11-16
e|RS|3aa9935c-943d-406a-bb6e-fc067fa8a487|5|CPRFSTAT|Clinical Performance Status|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|Ci/mL|QUANTIFIABLE MRD POSITIVITY|1|BEAM BREAKS|FLOW MICROSCOPY||||INTERVIEWER|ADJUDICATOR 1|N|3|Visit_3|40|1|SCREENING|2020-09-26|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-27|P1Y2M10DT2H30M|BEFORE|2020-11-04|COINCIDENT|2020-11-17
e|RS|3aa9935c-943d-406a-bb6e-fc067fa8a487|6|NEWLWIND|New Lesion Worsening Indicator|RECICL|[?]|MET*min|iUPD|1|pmol/day|MRI||Y||CHILD|ADJUDICATOR 1|N|3|Visit_3|40|5|TREATMENT|2020-09-26|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-27|P1Y2M10DT2H30M|COINCIDENT|2020-09-10|COINCIDENT|2020-09-17
e|RS|3aa9935c-943d-406a-bb6e-fc067fa8a487|7|ANATRESP|Anatomic Response|EBMT BLADE MYELOMA 1998|[?]|KALLIKREIN INHIBITOR UNIT|NON-PD|1|umol|CONTRAST ENHANCED PET SCAN||||ADJUDICATOR|OPHTHALMOLOGIST|U|4|Visit_4|65|4|FOLLOW-UP|2020-10-21|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-21|P1Y2M10DT2H30M|UNKNOWN|2020-10-25|COINCIDENT|2020-11-16
e|RS|3aa9935c-943d-406a-bb6e-fc067fa8a487|8|MRDRESP|Minimal Residual Disease Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|||NE|1|mL/kg/day|TOTAL BODY RADIOGRAPHY|Y||Y|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|NA|4|Visit_4|65|2|WASHOUT|2020-10-21|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-21|P1Y2M10DT2H30M|BEFORE|2020-11-09|ONGOING|2020-11-10
e|RS|3aa9935c-943d-406a-bb6e-fc067fa8a487|9|CPRFSTAT|Clinical Performance Status|JACINTO CERVICAL CANCER 2007|||PSEUDORESPONSE|1|nkat|AURAMINE STAIN|Y|Y|Y|DOMESTIC PARTNER|RADIOLOGIST 2|U|5|Visit_5|90|3|TREATMENT|2020-11-15|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-24|P1Y2M10DT2H30M|AFTER|2020-10-08|AFTER|2020-11-03
e|RS|3aa9935c-943d-406a-bb6e-fc067fa8a487|10|TMRESP|Tumor Marker Response|MASS|[?]|umol/L|iCR|1|ppb|CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY||||ADJUDICATOR|INTERNIST|NA|5|Visit_5|90|4|WASHOUT|2020-11-15|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-24|P1Y2M10DT2H30M|BEFORE|2020-10-02|AFTER|2020-10-19
e|RS|0cac2007-ca12-45ba-9b1c-70f753232f05|1|LIVRRESP|Liver Response|IWC HALLEK CLL 2008|[?]|/5x10^4 WBC|INDETERMINATE RESPONSE|1|/wk|REFLECTANCE SPECTROSCOPY|Y|||SIBLING|RADIOLOGIST|U|1|Visit_1|10|1|TREATMENT|2020-12-01|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-09|P1Y2M10DT2H30M|BEFORE|2021-01-03|COINCIDENT|2021-02-07
e|RS|0cac2007-ca12-45ba-9b1c-70f753232f05|2|MNPTHIND|Minor Pathological Response Indicator|PERCIST|||sCR|1|TAMPON|ELECTROGASTROGRAPHY|||Y|CLINICAL STUDY SPONSOR|OPHTHALMOLOGIST|U|1|Visit_1|10|7|FOLLOW-UP|2020-12-01|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-09|P1Y2M10DT2H30M|COINCIDENT|2021-02-05|BEFORE|2021-02-23
e|RS|0cac2007-ca12-45ba-9b1c-70f753232f05|3|MRPHRESP|Morphologic Response|IWG CHESON AML 2003|[?]|ug/kg/h|PR WITH LYMPHOCYTOSIS|1|mL/cm|STATIC PERIMETRY||||GUARDIAN|CLINICAL PATHOLOGIST|NA|2|Visit_2|25|1|SCREENING|2020-12-16|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-30|P1Y2M10DT2H30M|BEFORE|2020-12-01|AFTER|2021-01-31
e|RS|0cac2007-ca12-45ba-9b1c-70f753232f05|4|NEWLPROG|New Lesion Progression|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|V/sec|PR WITH LYMPHOCYTOSIS|1|breaths/min|POLYGRAPHY||||CLINICAL STUDY SPONSOR|READER 1|NA|2|Visit_2|25|3|TREATMENT|2020-12-16|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-30|P1Y2M10DT2H30M|AFTER|2021-01-21|ONGOING|2021-02-26
e|RS|0cac2007-ca12-45ba-9b1c-70f753232f05|5|RDIORESP|Radiologic Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|mg2/dL2|HI-N|1|log10 PFU|STRESS ECHOCARDIOGRAPHY||||VENDOR|OPTOMETRIST|Y|3|Visit_3|40|5|TREATMENT|2020-12-31|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-22|P1Y2M10DT2H30M|COINCIDENT|2020-12-19|BEFORE|2021-01-17
e|RS|0cac2007-ca12-45ba-9b1c-70f753232f05|6|MNPTHIND|Minor Pathological Response Indicator|CHESON CLL 2006|||CA125 75% RESPONSE|1|CIGAR|IN SITU HYBRIDIZATION|Y||Y|GUARDIAN|PATHOLOGIST 2|N|3|Visit_3|40|7|TREATMENT|2020-12-31|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-22|P1Y2M10DT2H30M|COINCIDENT|2021-01-09|COINCIDENT|2021-01-17
e|RS|0cac2007-ca12-45ba-9b1c-70f753232f05|7|TRGRESP|Target Response|CHESON CLL 2012|[?]|mEq/day|PSEUDOPROGRESSION|1|SFC/10^6 PBMC|ELECTROPHORESIS|Y|Y||DOMESTIC PARTNER|ADJUDICATOR 2|Y|4|Visit_4|65|4|TREATMENT|2021-01-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-29|P1Y2M10DT2H30M|AFTER|2021-02-16|AFTER|2021-02-19
e|RS|0cac2007-ca12-45ba-9b1c-70f753232f05|8|NTNERESP|Non-Target Non-Enhancing Response|MACDONALD GLIOMA 1990|[?]|nkat|CA125 50% RESPONSE|1|foz_us|FLUORESCENT SPOT TEST||||NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|NA|4|Visit_4|65|7|TREATMENT|2021-01-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-29|P1Y2M10DT2H30M|COINCIDENT|2020-12-21|AFTER|2021-02-12
e|RS|0cac2007-ca12-45ba-9b1c-70f753232f05|9|CPRFSTAT|Clinical Performance Status|RANO|[?]|Siemens|CRi|1|cg|CLOT DETECTION|Y|||NON-HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|Y|5|Visit_5|90|6|FOLLOW-UP|2021-02-19|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-16|P1Y2M10DT2H30M|UNKNOWN|2021-02-20|COINCIDENT|2021-02-23
e|RS|0cac2007-ca12-45ba-9b1c-70f753232f05|10|MRDRESP|Minimal Residual Disease Response|AJCC V8|[?]|DNA copies/mL|RELAPSED DISEASE|1|IU/L|POLYMERASE CHAIN REACTION||||FAMILY MEMBER|PEDIATRIC NEUROLOGIST|Y|5|Visit_5|90|2|TREATMENT|2021-02-19|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-16|P1Y2M10DT2H30M|AFTER|2020-12-26|BEFORE|2021-02-09
e|RS|2339e91a-b93e-426f-9b60-3d3b6969268d|1|NTNERESP|Non-Target Non-Enhancing Response|PETIT BREAST CANCER 2001|||SD|1|Bq/ug|HEMAGGLUTINATION ASSAY|||Y|NON-HEALTH CARE PROFESSIONAL|HEMATOLOGIST|U|1|Visit_1|10|6|SCREENING|2020-07-07|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-02|P1Y2M10DT2H30M|AFTER|2020-09-13|ONGOING|2020-09-19
e|RS|2339e91a-b93e-426f-9b60-3d3b6969268d|2|CPRFSTAT|Clinical Performance Status|MASS|[?]|DAYS|SMD|1|ng/L|CELLULOSE TAPE||||INTERVIEWER|READER 1|N|1|Visit_1|10|4|FOLLOW-UP|2020-07-07|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-02|P1Y2M10DT2H30M|UNKNOWN|2020-10-02|ONGOING|2020-10-04
e|RS|2339e91a-b93e-426f-9b60-3d3b6969268d|3|METBRESP|Metabolic Response|iRECIST|[?]|min*mg/mL|cPR|1|L/day|SPECT SCAN||||VENDOR|ADJUDICATOR 1|N|2|Visit_2|25|3|TREATMENT|2020-07-22|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-02|P1Y2M10DT2H30M|AFTER|2020-07-18|BEFORE|2020-09-23
e|RS|2339e91a-b93e-426f-9b60-3d3b6969268d|4|NTRGRESP|Non-target Response|CHESON LYMPHOMA 2008|||PD-CT|1|mV*min|TRANSVAGINAL ULTRASOUND|Y||Y|SIGNIFICANT OTHER|OPTOMETRIST|N|2|Visit_2|25|2|TREATMENT|2020-07-22|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-02|P1Y2M10DT2H30M|AFTER|2020-08-09|BEFORE|2020-09-19
e|RS|2339e91a-b93e-426f-9b60-3d3b6969268d|5|METSIND|Metastatic Indicator|RAJKUMAR MYELOMA 2011|||NON-QUANTIFIABLE MRD POSITIVITY|1|APL U/mL|IN VITRO GENE EXPRESSION ASSAY|||Y|PARENT|PATHOLOGIST 1|Y|3|Visit_3|40|3|WASHOUT|2020-08-06|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-31|P1Y2M10DT2H30M|BEFORE|2020-08-04|BEFORE|2020-08-20
e|RS|2339e91a-b93e-426f-9b60-3d3b6969268d|6|STRUSTAT|Steroid Use Status|RECIST 1.1|[?]|DDU|PR-CT|1|mEq/mmol|NEXT GENERATION TARGETED SEQUENCING|Y|Y||SIBLING|NEUROLOGIST|Y|3|Visit_3|40|6|SCREENING|2020-08-06|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-31|P1Y2M10DT2H30M|UNKNOWN|2020-09-29|COINCIDENT|2020-10-03
e|RS|2339e91a-b93e-426f-9b60-3d3b6969268d|7|NTERESP|Non-Target Enhancing Response|CHESON NON-HODGKINS LYMPHOMA 1999|||ABSENT MORPHOLOGIC RESPONSE|1|10^6 IU|CONGO RED STAIN|||Y|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 1|U|4|Visit_4|65|2|TREATMENT|2020-08-31|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-08|P1Y2M10DT2H30M|COINCIDENT|2020-09-09|COINCIDENT|2020-09-22
e|RS|2339e91a-b93e-426f-9b60-3d3b6969268d|8|BMIVLIND|Bone Marrow Involvement Indicator|HARTMAN PANCREATIC CANCER 2012|[?]|fg|cPR|1|CYLINDER|ICP-MS||Y||VENDOR|RATER 1|NA|4|Visit_4|65|7|TREATMENT|2020-08-31|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-08|P1Y2M10DT2H30M|UNKNOWN|2020-09-18|ONGOING|2020-09-30
e|RS|2339e91a-b93e-426f-9b60-3d3b6969268d|9|STRUSTAT|Steroid Use Status|AJCC V7|[?]|lx|INDETERMINATE RESPONSE|1|kV|MULTIPLEXED BEAD BASED IMMUNOASSAY|Y|||ADJUDICATION COMMITTEE|INTERNIST|U|5|Visit_5|90|1|TREATMENT|2020-09-25|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-14|P1Y2M10DT2H30M|BEFORE|2020-07-04|COINCIDENT|2020-08-05
e|RS|2339e91a-b93e-426f-9b60-3d3b6969268d|10|NEWLWIND|New Lesion Worsening Indicator|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|PIPE|PSA PROGRESSION|1|10^9 CFU/g|ORCHIDOMETERY|Y|||SIBLING|MICROSCOPIST 3|U|5|Visit_5|90|2|SCREENING|2020-09-25|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-14|P1Y2M10DT2H30M|AFTER|2020-09-11|BEFORE|2020-09-22
e|RS|0d09e35b-e864-4492-a341-21c71d92b551|1|METBRESP|Metabolic Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|10^3 organisms/mL|MAJOR PATHOLOGIC RESPONSE|1|dyn|CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY||||GUARDIAN|RATER|N|1|Visit_1|10|3|FOLLOW-UP|2020-10-30|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-23|P1Y2M10DT2H30M|BEFORE|2021-01-17|ONGOING|2021-01-23
e|RS|0d09e35b-e864-4492-a341-21c71d92b551|2|BONERESP|Bone Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|ppm|CYTOGENETIC NO RESPONSE|1|uOsm|CELL CYTOTOXICITY NEUTRALIZATION ASSAY||||INDEPENDENT ASSESSOR|ENDOCRINOLOGIST|N|1|Visit_1|10|3|TREATMENT|2020-10-30|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-23|P1Y2M10DT2H30M|COINCIDENT|2020-11-20|BEFORE|2020-12-25
e|RS|0d09e35b-e864-4492-a341-21c71d92b551|3|STRUSTAT|Steroid Use Status|RECICL|[?]|/MBP|IMPROVED|1|mol|PET/SPECT SCAN||||FAMILY MEMBER|RADIOLOGIST 2|U|2|Visit_2|25|7|TREATMENT|2020-11-14|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-31|P1Y2M10DT2H30M|BEFORE|2021-01-25|AFTER|2021-01-26
e|RS|0d09e35b-e864-4492-a341-21c71d92b551|4|BMIVLIND|Bone Marrow Involvement Indicator|CHESON LYMPHOMA 2008|[?]|kg/cm|RELAPSED DISEASE FROM CR|1|DRINK|TRICHROME STAIN||||FAMILY MEMBER|CLINICAL PATHOLOGIST|U|2|Visit_2|25|4|TREATMENT|2020-11-14|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-31|P1Y2M10DT2H30M|BEFORE|2021-01-20|ONGOING|2021-01-22
e|RS|0d09e35b-e864-4492-a341-21c71d92b551|5|DRCRIND|Disease Recurrence Indicator|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|hPa|CA125 50% RESPONSE|1|MBq/uL|WRIGHT-GIEMSA STAIN||||INTERVIEWER|NEUROLOGIST 1|U|3|Visit_3|40|1|FOLLOW-UP|2020-11-29|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-09|P1Y2M10DT2H30M|BEFORE|2020-11-01|COINCIDENT|2020-11-15
e|RS|0d09e35b-e864-4492-a341-21c71d92b551|6|MNPTHIND|Minor Pathological Response Indicator|AJCC V7|[?]|mEq/dL|iCR|1|mL/g/min|AUTOMATED COUNT||||HEALTH CARE PROFESSIONAL|INTERNIST|Y|3|Visit_3|40|6|SCREENING|2020-11-29|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-09|P1Y2M10DT2H30M|BEFORE|2021-01-06|ONGOING|2021-01-19
e|RS|0d09e35b-e864-4492-a341-21c71d92b551|7|ANATRESP|Anatomic Response|BLAZER COLORECTAL CANCER 2008|[?]|10^8/L|COMPLETE MRD RESPONSE|1|Frames/s|CONGO RED STAIN||Y||GUARDIAN|OPTOMETRIST|N|4|Visit_4|65|4|WASHOUT|2020-12-24|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-13|P1Y2M10DT2H30M|UNKNOWN|2020-12-16|AFTER|2021-01-24
e|RS|0d09e35b-e864-4492-a341-21c71d92b551|8|MOLRESP|Molecular Response|MONTSERRAT CLL 1989|||MRD RELAPSE|1|titer|PANENDOSCOPY|||Y|HEALTH CARE PROFESSIONAL|NEUROLOGIST|U|4|Visit_4|65|6|TREATMENT|2020-12-24|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-13|P1Y2M10DT2H30M|COINCIDENT|2021-01-25|COINCIDENT|2021-01-26
e|RS|0d09e35b-e864-4492-a341-21c71d92b551|9|NTRGRESP|Non-target Response|SACT|[?]|umol/L/sec|NOT ALL EVALUATED|1|PIXELS/in|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY||||VENDOR|MICROSCOPIST 3|NA|5|Visit_5|90|5|TREATMENT|2021-01-18|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-26|P1Y2M10DT2H30M|UNKNOWN|2020-12-04|COINCIDENT|2020-12-13
e|RS|0d09e35b-e864-4492-a341-21c71d92b551|10|DRCRIND|Disease Recurrence Indicator|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|||QUANTIFIABLE MRD POSITIVITY|1|ECL unit|MAGNETIC RESONANCE ELASTOGRAPHY|Y||Y|CLINICAL RESEARCH COORDINATOR|OPTOMETRIST|N|5|Visit_5|90|6|TREATMENT|2021-01-18|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-26|P1Y2M10DT2H30M|COINCIDENT|2020-10-26|BEFORE|2021-01-01
e|RS|0f8b5d32-6c34-4ea3-bab7-816c1d755ffd|1|MOLRESP|Molecular Response|LEE LUNG CANCER 2011|[?]|dB|RELAPSED DISEASE FROM CR OR PR|1|atm|MECHANICAL CLOT DETECTION||Y||ADJUDICATION COMMITTEE|FORENSIC PATHOLOGIST|NA|1|Visit_1|10|4|FOLLOW-UP|2020-06-05|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-08|P1Y2M10DT2H30M|AFTER|2020-06-16|AFTER|2020-08-17
e|RS|0f8b5d32-6c34-4ea3-bab7-816c1d755ffd|2|HEMARESP|Hematologic Response|MASS|||PD-CT|1|PIXELS/in|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS||Y|Y|INVESTIGATOR|PATHOLOGIST|Y|1|Visit_1|10|5|TREATMENT|2020-06-05|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-08|P1Y2M10DT2H30M|AFTER|2020-08-01|AFTER|2020-08-23
e|RS|0f8b5d32-6c34-4ea3-bab7-816c1d755ffd|3|MRDRESP|Minimal Residual Disease Response|BURCOMBE BREAST CANCER 2005|[?]|GPS U|CMR|1|10^3 CFU/g|LYMPHANGIOGRAPHY|Y|||CLINICAL RESEARCH COORDINATOR|RATER 1|U|2|Visit_2|25|3|SCREENING|2020-06-20|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-07|P1Y2M10DT2H30M|COINCIDENT|2020-06-05|ONGOING|2020-06-06
e|RS|0f8b5d32-6c34-4ea3-bab7-816c1d755ffd|4|NEWLWIND|New Lesion Worsening Indicator|AJCC V8|[?]|Linear ft*LB|NON-QUANTIFIABLE MRD POSITIVITY|1|DPM|MRI||||STUDY SUBJECT|ONCOLOGIST|NA|2|Visit_2|25|3|TREATMENT|2020-06-20|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-07|P1Y2M10DT2H30M|UNKNOWN|2020-07-14|COINCIDENT|2020-08-24
e|RS|0f8b5d32-6c34-4ea3-bab7-816c1d755ffd|5|PATHRESP|Pathologic Response|RECIST 1.0|||PR-CT|1|vg/kg|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY|Y||Y|GUARDIAN|PATHOLOGIST 1|NA|3|Visit_3|40|4|TREATMENT|2020-07-05|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-11|P1Y2M10DT2H30M|BEFORE|2020-08-29|ONGOING|2020-08-30
e|RS|0f8b5d32-6c34-4ea3-bab7-816c1d755ffd|6|CYTORESP|Cytogenetic Response|PERCIST|[?]|kg/cm|CRi|1|uU/dL|LC/MS|Y|||VENDOR|READER 1|N|3|Visit_3|40|5|TREATMENT|2020-07-05|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-11|P1Y2M10DT2H30M|UNKNOWN|2020-07-23|BEFORE|2020-07-27
e|RS|0f8b5d32-6c34-4ea3-bab7-816c1d755ffd|7|OVRLRESP|Overall Response|RANO|[?]|mm3/mm2/year|NE|1|umol/L/sec|ECHOCARDIOGRAPHY||||DOMESTIC PARTNER|DERMATOLOGIST|Y|4|Visit_4|65|7|WASHOUT|2020-07-30|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-02|P1Y2M10DT2H30M|BEFORE|2020-08-20|BEFORE|2020-08-31
e|RS|0f8b5d32-6c34-4ea3-bab7-816c1d755ffd|8|MJPTHIND|Major Pathological Response Indicator|NCIWG CHESON CLL 1996|[?]|nmol/day|mCR|1|10^3 organisms|IMMUNOPRECIPITATION||||STUDY SUBJECT|OPTOMETRIST|NA|4|Visit_4|65|5|WASHOUT|2020-07-30|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-02|P1Y2M10DT2H30M|BEFORE|2020-08-13|ONGOING|2020-08-30
e|RS|0f8b5d32-6c34-4ea3-bab7-816c1d755ffd|9|LIVRRESP|Liver Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|MBq|CHR|1|mL/mmHg/min/L|ANALYTICAL ULTRACENTRIFUGATION|Y|||SIBLING|NEUROLOGIST 1|U|5|Visit_5|90|5|TREATMENT|2020-08-24|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-14|P1Y2M10DT2H30M|COINCIDENT|2020-08-19|BEFORE|2020-08-20
e|RS|0f8b5d32-6c34-4ea3-bab7-816c1d755ffd|10|CLINRESP|Clinical Response|KUKER LYMPHOMA 2005|[?]|/200 HPFs|HI-E|1|ag|IHC||||NON-HEALTH CARE PROFESSIONAL|OPTOMETRIST|N|5|Visit_5|90|1|FOLLOW-UP|2020-08-24|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-14|P1Y2M10DT2H30M|UNKNOWN|2020-06-19|ONGOING|2020-08-25
e|RS|0a5b1036-cd00-4221-b218-ee2664e5a43e|1|STRUSTAT|Steroid Use Status|PCWG BUBLEY PROSTATE CANCER 1999|[?]|AMPULE|NON-QUANTIFIABLE MRD POSITIVITY|1|10^7/L|PHASE CONTRAST MICROSCOPY||||PARENT|NEUROLOGIST|Y|1|Visit_1|10|6|WASHOUT|2021-01-02|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-31|P1Y2M10DT2H30M|AFTER|2021-01-30|ONGOING|2021-03-13
e|RS|0a5b1036-cd00-4221-b218-ee2664e5a43e|2|MRDIND|Minimal Residual Disease Indicator|MURPHY PROSTATE CANCER 1980|||nPR|1|BOWL|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|||Y|INDEPENDENT ASSESSOR|RATER|NA|1|Visit_1|10|7|TREATMENT|2021-01-02|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-31|P1Y2M10DT2H30M|UNKNOWN|2021-03-02|BEFORE|2021-04-01
e|RS|0a5b1036-cd00-4221-b218-ee2664e5a43e|3|OVRLRESP|Overall Response|JACINTO CERVICAL CANCER 2007|||MOLECULAR MAJOR RESPONSE|1|kHz|JAEGER EYE CHART|Y||Y|PROXY|RATER 2|U|2|Visit_2|25|1|TREATMENT|2021-01-17|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-06|P1Y2M10DT2H30M|BEFORE|2021-02-24|COINCIDENT|2021-03-08
e|RS|0a5b1036-cd00-4221-b218-ee2664e5a43e|4|STRUSTAT|Steroid Use Status|FAROOQUI SUPP CLL 2014|[?]|mL/g/min|CA125 75% RESPONSE|1|DRINK|LASER CAPTURE MICRODISSECTION||||FRIEND|MICROSCOPIST 2|U|2|Visit_2|25|2|FOLLOW-UP|2021-01-17|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-06|P1Y2M10DT2H30M|AFTER|2021-01-14|BEFORE|2021-02-18
e|RS|0a5b1036-cd00-4221-b218-ee2664e5a43e|5|CYTORESP|Cytogenetic Response|RECIST 1.0|[?]|IU/kg/h|INCREASED|1|10^3 RNA copies/mL|REVERSE TRANSCRIPTASE PCR|Y|||CAREGIVER|CARDIOLOGIST|U|3|Visit_3|40|4|SCREENING|2021-02-01|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-12|P1Y2M10DT2H30M|COINCIDENT|2021-03-16|ONGOING|2021-03-22
e|RS|0a5b1036-cd00-4221-b218-ee2664e5a43e|6|NTRGRESP|Non-target Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|10^8/L|ABSENT MORPHOLOGIC RESPONSE|1|ug/g/min|PET/MRI SCAN||||HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|Y|3|Visit_3|40|3|FOLLOW-UP|2021-02-01|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-12|P1Y2M10DT2H30M|UNKNOWN|2021-01-02|BEFORE|2021-02-19
e|RS|0a5b1036-cd00-4221-b218-ee2664e5a43e|7|CYTORESP|Cytogenetic Response|MACDONALD GLIOMA 1990|[?]|/2000 RBC|HI-N|1|TROCHE|IMMUNOTURBIDIMETRY||||NON-HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|NA|4|Visit_4|65|3|TREATMENT|2021-02-26|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-04|P1Y2M10DT2H30M|COINCIDENT|2021-02-09|COINCIDENT|2021-03-19
e|RS|0a5b1036-cd00-4221-b218-ee2664e5a43e|8|METSIND|Metastatic Indicator|RAJKUMAR MYELOMA 2011|[?]|TROCHE|PD|1|umol/h/mmol|MANUAL CLOT DETECTION||||PARENT|PATHOLOGIST 2|Y|4|Visit_4|65|1|WASHOUT|2021-02-26|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-04|P1Y2M10DT2H30M|BEFORE|2021-03-29|COINCIDENT|2021-03-30
e|RS|0a5b1036-cd00-4221-b218-ee2664e5a43e|9|METSIND|Metastatic Indicator|PCWG SCHER PROSTATE CANCER 2016|[?]|L/min|mCR|1|Hz/s|WHOLE EXOME SEQUENCING||Y||CLINICAL STUDY SPONSOR|RADIOLOGIST 1|NA|5|Visit_5|90|1|TREATMENT|2021-03-23|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-15|P1Y2M10DT2H30M|COINCIDENT|2021-03-19|BEFORE|2021-03-23
e|RS|0a5b1036-cd00-4221-b218-ee2664e5a43e|10|TRGRESP|Target Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|10^9 CFU/g|NE|1|pt_br|MICRO BROTH DILUTION||Y||FRIEND|INTERNIST|N|5|Visit_5|90|7|TREATMENT|2021-03-23|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-15|P1Y2M10DT2H30M|UNKNOWN|2021-01-05|ONGOING|2021-04-01
e|RS|a4f74465-7abc-4cc2-a0be-25d1c802af8c|1|CLINRESP|Clinical Response|SCHWARZ CERVICAL CANCER 2009|[?]|AU/mL|PD-CT|1|ELISA unit|IMMUNOTURBIDIMETRY||Y||INTERVIEWER|RATER|N|1|Visit_1|10|1|TREATMENT|2020-09-30|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-03|P1Y2M10DT2H30M|BEFORE|2020-11-07|BEFORE|2020-12-21
e|RS|a4f74465-7abc-4cc2-a0be-25d1c802af8c|2|CPRFSTAT|Clinical Performance Status|KUKER LYMPHOMA 2005|[?]|kcal|CMR|1|Bq/L|AGAR PROPORTION||||CHILD|DERMATOLOGIST|U|1|Visit_1|10|1|TREATMENT|2020-09-30|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-03|P1Y2M10DT2H30M|BEFORE|2020-09-30|COINCIDENT|2020-10-12
e|RS|a4f74465-7abc-4cc2-a0be-25d1c802af8c|3|MRPHRESP|Morphologic Response|CHOI GIST 2008|[?]|ppm|cPR|1|breaths/min|ORCHIDOMETERY||||STUDY SUBJECT|RADIOLOGIST|Y|2|Visit_2|25|1|WASHOUT|2020-10-15|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-09|P1Y2M10DT2H30M|BEFORE|2020-11-28|COINCIDENT|2020-12-18
e|RS|a4f74465-7abc-4cc2-a0be-25d1c802af8c|4|MRDRESP|Minimal Residual Disease Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|Absorbance U|iPR|1|PFU/animal|POLYGRAPHY|Y|||INDEPENDENT ASSESSOR|OTOLARYNGOLOGIST|NA|2|Visit_2|25|7|TREATMENT|2020-10-15|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-09|P1Y2M10DT2H30M|UNKNOWN|2020-12-25|ONGOING|2020-12-27
e|RS|a4f74465-7abc-4cc2-a0be-25d1c802af8c|5|MRPHRESP|Morphologic Response|SCHER PROSTATE CANCER 2011|||CR|1|L|DARK FIELD MICROSCOPY|||Y|GUARDIAN|PHYSIOTHERAPIST|U|3|Visit_3|40|1|TREATMENT|2020-10-30|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-15|P1Y2M10DT2H30M|UNKNOWN|2020-10-17|BEFORE|2020-11-29
e|RS|a4f74465-7abc-4cc2-a0be-25d1c802af8c|6|MRPHRESP|Morphologic Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|kat|NOT ALL EVALUATED|1|dpm/mg|DIRECT SEQUENCING||||CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST|NA|3|Visit_3|40|7|SCREENING|2020-10-30|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-15|P1Y2M10DT2H30M|UNKNOWN|2020-12-21|COINCIDENT|2020-12-25
e|RS|a4f74465-7abc-4cc2-a0be-25d1c802af8c|7|NEWLWIND|New Lesion Worsening Indicator|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|mgEq|UNEQUIVOCAL|1|JDF Unit|FUNDUS PHOTOGRAPHY|Y|||CAREGIVER|ONCOLOGIST|U|4|Visit_4|65|2|FOLLOW-UP|2020-11-24|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-28|P1Y2M10DT2H30M|BEFORE|2020-12-24|BEFORE|2020-12-26
e|RS|a4f74465-7abc-4cc2-a0be-25d1c802af8c|8|MRDIND|Minimal Residual Disease Indicator|SCHER PROSTATE CANCER 2011|[?]|dpm/100mg|PSEUDOPROGRESSION|1|dmol|MALDI||Y||GUARDIAN|CLINICAL PATHOLOGIST|Y|4|Visit_4|65|3|TREATMENT|2020-11-24|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-28|P1Y2M10DT2H30M|COINCIDENT|2020-10-27|ONGOING|2020-12-12
e|RS|a4f74465-7abc-4cc2-a0be-25d1c802af8c|9|ANATRESP|Anatomic Response|IRANO 2015|[?]|RFU|HI-P|1|10^3/L|FUNCTIONAL MRI||||ADJUDICATOR|PATHOLOGIST 1|Y|5|Visit_5|90|3|WASHOUT|2020-12-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-18|P1Y2M10DT2H30M|AFTER|2020-10-08|AFTER|2020-10-16
e|RS|a4f74465-7abc-4cc2-a0be-25d1c802af8c|10|BESTRESP|Best Overall Response|HARTMANN GERM CELL CANCER 2002|||PR WITH LYMPHOCYTOSIS|1|uIU/L|KINYOUN STAIN|Y||Y|HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|U|5|Visit_5|90|5|TREATMENT|2020-12-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-18|P1Y2M10DT2H30M|AFTER|2020-12-23|BEFORE|2020-12-26
e|RS|2d38f416-c40c-41a1-a4be-bcbfa4a97ad9|1|METBRESP|Metabolic Response|BRUGGEMANN MRD 2010|[?]|cd/m2|PD-CT|1|in2|IHC||Y||ADJUDICATOR|PEDIATRIC NEUROLOGIST|N|1|Visit_1|10|2|TREATMENT|2020-11-12|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-27|P1Y2M10DT2H30M|AFTER|2020-11-26|COINCIDENT|2021-01-10
e|RS|2d38f416-c40c-41a1-a4be-bcbfa4a97ad9|2|NEWLIND|New Lesion Indicator|GCIG RUSTIN OVARIAN CANCER 2011|||iCPD|1|umol/min|APPLANATION TONOMETRY|||Y|FAMILY MEMBER|FORENSIC PATHOLOGIST|NA|1|Visit_1|10|3|TREATMENT|2020-11-12|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-27|P1Y2M10DT2H30M|COINCIDENT|2020-12-18|ONGOING|2021-02-05
e|RS|2d38f416-c40c-41a1-a4be-bcbfa4a97ad9|3|BMIVLIND|Bone Marrow Involvement Indicator|MRECIST BYRNE MESOTHELIOMA 2004|[?]|nmol BCE/nmol|CMR|1|10^4/L|NO INFORMATION|Y|||CLINICAL STUDY SPONSOR|DEVELOPMENTAL PSYCHOLOGIST|NA|2|Visit_2|25|7|WASHOUT|2020-11-27|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-15|P1Y2M10DT2H30M|BEFORE|2021-01-17|BEFORE|2021-02-05
e|RS|2d38f416-c40c-41a1-a4be-bcbfa4a97ad9|4|BONERESP|Bone Response|CHESON LYMPHOMA 2008|||MOLECULAR MAJOR RESPONSE|1|km|FLAME PHOTOMETRY|Y||Y|CLINICAL STUDY SPONSOR|READER|NA|2|Visit_2|25|7|WASHOUT|2020-11-27|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-15|P1Y2M10DT2H30M|COINCIDENT|2020-11-15|AFTER|2021-01-06
e|RS|2d38f416-c40c-41a1-a4be-bcbfa4a97ad9|5|TMRESP|Tumor Marker Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|pmol|iPR|1|in|THIN SMEAR||Y||SIBLING|ADJUDICATOR 1|NA|3|Visit_3|40|2|SCREENING|2020-12-12|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-20|P1Y2M10DT2H30M|UNKNOWN|2021-01-26|BEFORE|2021-02-05
e|RS|2d38f416-c40c-41a1-a4be-bcbfa4a97ad9|6|MRDRESP|Minimal Residual Disease Response|CHOI GIST 2008|[?]|PIXELS/cm|QUANTIFIABLE MRD POSITIVITY|1|Tesla|AUDIOMETRY|Y|||PROXY|PATHOLOGIST 1|U|3|Visit_3|40|4|TREATMENT|2020-12-12|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-20|P1Y2M10DT2H30M|BEFORE|2020-11-15|AFTER|2020-12-05
e|RS|2d38f416-c40c-41a1-a4be-bcbfa4a97ad9|7|MRPHRESP|Morphologic Response|CHOI GIST 2008|[?]|Gy/h|PD|1|umol/L/sec|AUTOREFRACTION|Y|||INVESTIGATOR|MICROSCOPIST|N|4|Visit_4|65|2|TREATMENT|2021-01-06|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-23|P1Y2M10DT2H30M|BEFORE|2020-12-22|ONGOING|2021-01-21
e|RS|2d38f416-c40c-41a1-a4be-bcbfa4a97ad9|8|NTERESP|Non-Target Enhancing Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|||NOT ALL EVALUATED|1|/40 HPFs|AUSCULTATION|||Y|PROXY|ADJUDICATOR|U|4|Visit_4|65|2|TREATMENT|2021-01-06|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-23|P1Y2M10DT2H30M|BEFORE|2020-12-26|COINCIDENT|2021-01-09
e|RS|2d38f416-c40c-41a1-a4be-bcbfa4a97ad9|9|CLINRESP|Clinical Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|BAG|iUPD|1|Bq/mL|AURAMINE STAIN||Y||VENDOR|FORENSIC PATHOLOGIST|Y|5|Visit_5|90|7|FOLLOW-UP|2021-01-31|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-05|P1Y2M10DT2H30M|AFTER|2020-12-09|BEFORE|2020-12-28
e|RS|2d38f416-c40c-41a1-a4be-bcbfa4a97ad9|10|MJPTHIND|Major Pathological Response Indicator|MRECIST LENCIONI LIVER CANCER 2010|[?]|10^7 CFU|SD-CT|1|dpm/mL|WEBER GREEN STAIN||Y||NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|Y|5|Visit_5|90|5|TREATMENT|2021-01-31|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-05|P1Y2M10DT2H30M|COINCIDENT|2021-01-05|AFTER|2021-02-03
e|RS|e7262592-01e8-4cb3-b967-ec1037505e81|1|PATHRESP|Pathologic Response|LEE LUNG CANCER 2011|||PMD|1|10^4 CFU/mL|LC-FL|||Y|GUARDIAN|ONCOLOGIST 2|NA|1|Visit_1|10|4|TREATMENT|2020-09-12|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-24|P1Y2M10DT2H30M|UNKNOWN|2020-10-02|AFTER|2020-10-21
e|RS|e7262592-01e8-4cb3-b967-ec1037505e81|2|DRCRIND|Disease Recurrence Indicator|AJCC V8|[?]|cm/s|TREATMENT FAILURE|1|copies/mL|LIGHT SCATTERING SPECTROSCOPY||||DOMESTIC PARTNER|FORENSIC PATHOLOGIST|NA|1|Visit_1|10|7|TREATMENT|2020-09-12|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-24|P1Y2M10DT2H30M|AFTER|2020-11-14|AFTER|2020-11-27
e|RS|e7262592-01e8-4cb3-b967-ec1037505e81|3|BESTRESP|Best Overall Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|m/sec2|CYTOGENETIC CR|1|umol|DXA SCAN||Y||SIBLING|RATER 1|U|2|Visit_2|25|5|SCREENING|2020-09-27|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-23|P1Y2M10DT2H30M|UNKNOWN|2020-09-25|ONGOING|2020-11-01
e|RS|e7262592-01e8-4cb3-b967-ec1037505e81|4|METSIND|Metastatic Indicator|MACDONALD GLIOMA 1990|[?]|cg|PARTIAL MORPHOLOGIC RESPONSE|1|yd|GC/FID||||CHILD|RATER 1|U|2|Visit_2|25|1|WASHOUT|2020-09-27|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-23|P1Y2M10DT2H30M|AFTER|2020-09-11|AFTER|2020-10-15
e|RS|e7262592-01e8-4cb3-b967-ec1037505e81|5|HEMARESP|Hematologic Response|AJCC V7|[?]|grain|mCR|1|ug/g/h|FLUORESCENT ENZYME IMMUNOASSAY|Y|Y||CAREGIVER|MICROSCOPIST|N|3|Visit_3|40|1|TREATMENT|2020-10-12|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-28|P1Y2M10DT2H30M|COINCIDENT|2020-09-06|ONGOING|2020-12-04
e|RS|e7262592-01e8-4cb3-b967-ec1037505e81|6|DRCRIND|Disease Recurrence Indicator|SCHWARZ CERVICAL CANCER 2009|[?]|mL/cm|STABLE|1|10^8/L|TWO-COLOR MICROARRAY||||CLINICAL RESEARCH COORDINATOR|RATER 1|N|3|Visit_3|40|4|TREATMENT|2020-10-12|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-28|P1Y2M10DT2H30M|UNKNOWN|2020-11-05|AFTER|2020-11-08
e|RS|e7262592-01e8-4cb3-b967-ec1037505e81|7|SPLNRESP|Spleen Response|UNSPECIFIED|||iCR|1|damol/L|IMPULSE OSCILLOMETRY|||Y|GUARDIAN|NEUROLOGIST|NA|4|Visit_4|65|4|FOLLOW-UP|2020-11-06|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-08|P1Y2M10DT2H30M|AFTER|2020-10-13|AFTER|2020-11-29
e|RS|e7262592-01e8-4cb3-b967-ec1037505e81|8|BMIVLIND|Bone Marrow Involvement Indicator|MURPHY PROSTATE CANCER 1980|||NON-iCR/NON-iUPD|1|10^4 CFU/mL|REAL-TIME POLYMERASE CHAIN REACTION ASSAY|||Y|CHILD|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|4|Visit_4|65|5|WASHOUT|2020-11-06|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-08|P1Y2M10DT2H30M|BEFORE|2020-12-05|COINCIDENT|2020-12-10
e|RS|e7262592-01e8-4cb3-b967-ec1037505e81|9|NEWLPROG|New Lesion Progression|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|||IMPROVED|1|PLUG|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY|Y||Y|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST|N|5|Visit_5|90|7|TREATMENT|2020-12-01|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-04|P1Y2M10DT2H30M|BEFORE|2020-12-03|COINCIDENT|2020-12-04
e|RS|e7262592-01e8-4cb3-b967-ec1037505e81|10|CLINRESP|Clinical Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|ug/day|PR WITH LYMPHOCYTOSIS|1|10^6 organisms/g|FORCED OSCILLATION TECHNIQUE||||FAMILY MEMBER|ONCOLOGIST|Y|5|Visit_5|90|5|TREATMENT|2020-12-01|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-04|P1Y2M10DT2H30M|BEFORE|2020-09-29|ONGOING|2020-11-13
e|RS|bf150829-1b25-418a-9bc6-61716984387c|1|SPLNRESP|Spleen Response|RECIST 1.1|||PR WITH LYMPHOCYTOSIS|1|10^9 CFU|TRYPAN BLUE STAIN|||Y|INTERVIEWER|NEUROLOGIST 2|N|1|Visit_1|10|3|TREATMENT|2020-06-15|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-01|P1Y2M10DT2H30M|UNKNOWN|2020-08-17|BEFORE|2020-08-23
e|RS|bf150829-1b25-418a-9bc6-61716984387c|2|MRDRESP|Minimal Residual Disease Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|mV2/Hz|iPR|1|Henry|FARNSWORTH-MUNSELL 100 HUE TEST||||CLINICAL RESEARCH ASSOCIATE|RATER 1|NA|1|Visit_1|10|3|TREATMENT|2020-06-15|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-01|P1Y2M10DT2H30M|UNKNOWN|2020-06-22|BEFORE|2020-07-19
e|RS|bf150829-1b25-418a-9bc6-61716984387c|3|NTLWIND|Non-Target Lesion Worsening Indicator|PCWG BUBLEY PROSTATE CANCER 1999|[?]|mmHg/L/min|PMD|1|ug/dose|SIZE EXCLUSION CHROMATOGRAPHY||||CAREGIVER|MICROSCOPIST 2|Y|2|Visit_2|25|6|SCREENING|2020-06-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-09|P1Y2M10DT2H30M|UNKNOWN|2020-06-12|COINCIDENT|2020-08-14
e|RS|bf150829-1b25-418a-9bc6-61716984387c|4|MRDIND|Minimal Residual Disease Indicator|CHESON LYMPHOMA 2008|[?]|BU|INCREASED|1|m/sec2|FLUORIMETRY||Y||HEALTH CARE PROFESSIONAL|READER 2|U|2|Visit_2|25|5|TREATMENT|2020-06-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-09|P1Y2M10DT2H30M|AFTER|2020-08-12|BEFORE|2020-08-25
e|RS|bf150829-1b25-418a-9bc6-61716984387c|5|TMRESP|Tumor Marker Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|||cCR|1|Rad|ELECTROCHEMILUMINESCENCE|||Y|PARENT|MICROSCOPIST|NA|3|Visit_3|40|1|TREATMENT|2020-07-15|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-17|P1Y2M10DT2H30M|BEFORE|2020-08-07|COINCIDENT|2020-09-04
e|RS|bf150829-1b25-418a-9bc6-61716984387c|6|MNPTHIND|Minor Pathological Response Indicator|HAMAOKA BREAST CANCER 2010|||iCPD|1|mol/g|IMMUNORADIOMETRIC ASSAY||Y|Y|PARENT|INTERNIST|N|3|Visit_3|40|6|TREATMENT|2020-07-15|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-17|P1Y2M10DT2H30M|BEFORE|2020-08-06|BEFORE|2020-08-22
e|RS|bf150829-1b25-418a-9bc6-61716984387c|7|HEMARESP|Hematologic Response|EASL BRUIX LIVER CANCER 2001|[?]|10^3 CFU/g|iSD|1|mkat|WRIGHT-GIEMSA STAIN||||CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 1|N|4|Visit_4|65|1|FOLLOW-UP|2020-08-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-06|P1Y2M10DT2H30M|AFTER|2020-06-12|BEFORE|2020-07-04
e|RS|bf150829-1b25-418a-9bc6-61716984387c|8|BMIVLIND|Bone Marrow Involvement Indicator|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|Ci/ug|NON-CR/NON-PD|1|g/animal|HEMOCYTOMETRY||||FAMILY MEMBER|MICROSCOPIST 1|Y|4|Visit_4|65|5|TREATMENT|2020-08-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-06|P1Y2M10DT2H30M|UNKNOWN|2020-07-09|BEFORE|2020-07-19
e|RS|bf150829-1b25-418a-9bc6-61716984387c|9|NEWLIND|New Lesion Indicator|MASS|[?]|U/g|MRD NEGATIVITY|1|cup eq|PERCUSSION||||ADJUDICATION COMMITTEE|ADJUDICATOR 1|N|5|Visit_5|90|3|WASHOUT|2020-09-03|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-03|P1Y2M10DT2H30M|UNKNOWN|2020-06-20|COINCIDENT|2020-09-04
e|RS|bf150829-1b25-418a-9bc6-61716984387c|10|NTLWIND|Non-Target Lesion Worsening Indicator|BRUGGEMANN MRD 2010|[?]|mEq/mmol|CA125 50% RESPONSE|1|mph|ELECTRICAL IMPEDANCE MYOGRAPHY||||CLINICAL STUDY SPONSOR|OPHTHALMOLOGIST|U|5|Visit_5|90|6|TREATMENT|2020-09-03|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-03|P1Y2M10DT2H30M|COINCIDENT|2020-09-02|ONGOING|2020-09-07
e|RS|5c1cc260-97a0-493c-bc11-57f31ffd7455|1|NTNERESP|Non-Target Non-Enhancing Response|GUPPY OVARIAN CANCER 2002|||iSD|1|deg2|ULTRASOUND|||Y|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 1|Y|1|Visit_1|10|2|SCREENING|2020-09-06|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-02|P1Y2M10DT2H30M|UNKNOWN|2020-09-03|ONGOING|2020-10-01
e|RS|5c1cc260-97a0-493c-bc11-57f31ffd7455|2|MRPHRESP|Morphologic Response|EASL BRUIX LIVER CANCER 2001|[?]|mm/min|PR-CT|1|BP|PERIODIC ACID SCHIFF STAIN||||INDEPENDENT ASSESSOR|DEVELOPMENTAL PSYCHOLOGIST|U|1|Visit_1|10|2|WASHOUT|2020-09-06|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-02|P1Y2M10DT2H30M|BEFORE|2020-10-01|COINCIDENT|2020-10-24
e|RS|5c1cc260-97a0-493c-bc11-57f31ffd7455|3|STRUSTAT|Steroid Use Status|GUPPY OVARIAN CANCER 2002|[?]|mL/min|sCR|1|g/dL|APPLANATION TONOMETRY||||SIBLING|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|2|Visit_2|25|4|TREATMENT|2020-09-21|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-23|P1Y2M10DT2H30M|AFTER|2020-08-29|BEFORE|2020-09-11
e|RS|5c1cc260-97a0-493c-bc11-57f31ffd7455|4|TRGRESP|Target Response|SACT|[?]|/100 HPFs|CA125 75% RESPONSE|1|HOURS|CELL BASED BIOASSAY|Y|||FAMILY MEMBER|PATHOLOGIST 1|Y|2|Visit_2|25|3|TREATMENT|2020-09-21|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-23|P1Y2M10DT2H30M|UNKNOWN|2020-11-29|AFTER|2020-12-04
e|RS|5c1cc260-97a0-493c-bc11-57f31ffd7455|5|NEWLIND|New Lesion Indicator|LEE LUNG CANCER 2011|[?]|mg/m2/min|EQUIVOCAL|1|10^9/g|SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY|Y|||CAREGIVER|ADJUDICATOR 1|N|3|Visit_3|40|3|TREATMENT|2020-10-06|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-07|P1Y2M10DT2H30M|BEFORE|2020-10-12|AFTER|2020-11-09
e|RS|5c1cc260-97a0-493c-bc11-57f31ffd7455|6|LIVRRESP|Liver Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|GPL U|PARTIAL MORPHOLOGIC RESPONSE|1|RING|MICRONEUTRALIZATION ASSAY||||HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|Y|3|Visit_3|40|7|WASHOUT|2020-10-06|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-07|P1Y2M10DT2H30M|COINCIDENT|2020-10-31|COINCIDENT|2020-12-03
e|RS|5c1cc260-97a0-493c-bc11-57f31ffd7455|7|SPLNRESP|Spleen Response|MACDONALD GLIOMA 1990|||NR|1|Weber|IMMUNOTURBIDIMETRY|Y||Y|PARENT|ADJUDICATOR 3|Y|4|Visit_4|65|7|TREATMENT|2020-10-31|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-12|P1Y2M10DT2H30M|COINCIDENT|2020-09-06|AFTER|2020-10-29
e|RS|5c1cc260-97a0-493c-bc11-57f31ffd7455|8|MNPTHIND|Minor Pathological Response Indicator|PRINCE TCELL LYMPHOMA 2010|[?]|ug/dL|MRD RELAPSE|1|U/dL|BALLPOINT PEN TECHNIQUE|Y|||INDEPENDENT ASSESSOR|PATHOLOGIST 2|Y|4|Visit_4|65|2|FOLLOW-UP|2020-10-31|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-12|P1Y2M10DT2H30M|COINCIDENT|2020-11-19|AFTER|2020-11-25
e|RS|5c1cc260-97a0-493c-bc11-57f31ffd7455|9|PATHRESP|Pathologic Response|WOLCHOK SOLID TUMORS 2009|[?]|PIXELS/cm|NON-iCR/NON-iUPD|1|cpm|IODINE STAIN||||DOMESTIC PARTNER|NEUROLOGIST|Y|5|Visit_5|90|7|TREATMENT|2020-11-25|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-06|P1Y2M10DT2H30M|BEFORE|2020-11-17|COINCIDENT|2020-11-18
e|RS|5c1cc260-97a0-493c-bc11-57f31ffd7455|10|NEWLIND|New Lesion Indicator|PALUMBO MULTIPLE MYELOMA 2009|||NOT ALL EVALUATED|1|MASK|PLETHYSMOGRAPHY|||Y|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 2|N|5|Visit_5|90|4|TREATMENT|2020-11-25|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-06|P1Y2M10DT2H30M|UNKNOWN|2020-09-08|COINCIDENT|2020-10-22
e|RS|cca2835b-ca8d-4db6-89b4-9f2855968a8a|1|MOLRESP|Molecular Response|CHOI GIST 2008|[?]|uU/L|QUANTIFIABLE MRD POSITIVITY|1|tuberculin unit|FLOCCULATION, CHARCOAL ENHANCED||||SIBLING|ADJUDICATOR 2|Y|1|Visit_1|10|4|TREATMENT|2020-07-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-17|P1Y2M10DT2H30M|AFTER|2020-07-20|BEFORE|2020-09-09
e|RS|cca2835b-ca8d-4db6-89b4-9f2855968a8a|2|PATHRESP|Pathologic Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|PIXELS/in|CYTOGENETIC NO RESPONSE|1|ugEq|ARTERIAL SPIN LABELING FUNCTIONAL MRI|Y|||PARENT|NEUROLOGIST 1|Y|1|Visit_1|10|1|SCREENING|2020-07-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-17|P1Y2M10DT2H30M|COINCIDENT|2020-08-21|ONGOING|2020-10-08
e|RS|cca2835b-ca8d-4db6-89b4-9f2855968a8a|3|NEWLPROG|New Lesion Progression|MURPHY PROSTATE CANCER 1980|[?]|pg|UNEQUIVOCAL|1|mg/m2/min|EEG||||INTERVIEWER|OPHTHALMOLOGIST|U|2|Visit_2|25|5|SCREENING|2020-08-03|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-06|P1Y2M10DT2H30M|UNKNOWN|2020-09-18|COINCIDENT|2020-10-05
e|RS|cca2835b-ca8d-4db6-89b4-9f2855968a8a|4|CYTORESP|Cytogenetic Response|IRANO 2015|[?]|days/wk|MORPHOLOGIC LEUKEMIA-FREE STATE|1|10^6 CFU/g|TARGETED TRANSCRIPTOME SEQUENCING||||INDEPENDENT ASSESSOR|ONCOLOGIST|Y|2|Visit_2|25|3|WASHOUT|2020-08-03|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-06|P1Y2M10DT2H30M|AFTER|2020-09-25|ONGOING|2020-09-26
e|RS|cca2835b-ca8d-4db6-89b4-9f2855968a8a|5|TRGRESP|Target Response|DOHNER AML 2010|[?]|IU/kg/h|MORPHOLOGIC CR|1|CFU/mL|GC/FID||||SIGNIFICANT OTHER|CARDIOLOGIST|U|3|Visit_3|40|2|SCREENING|2020-08-18|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-17|P1Y2M10DT2H30M|COINCIDENT|2020-08-03|ONGOING|2020-09-26
e|RS|cca2835b-ca8d-4db6-89b4-9f2855968a8a|6|SPLNRESP|Spleen Response|IWG CHESON MDS 2000|[?]|cmol/L|RELAPSED DISEASE FROM CR|1|1/(s*kPa)|PHYSICAL EXAMINATION||||NON-HEALTH CARE PROFESSIONAL|CARDIOLOGIST|N|3|Visit_3|40|3|TREATMENT|2020-08-18|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-17|P1Y2M10DT2H30M|BEFORE|2020-08-21|COINCIDENT|2020-10-02
e|RS|cca2835b-ca8d-4db6-89b4-9f2855968a8a|7|SYMPTDTR|Symptomatic Deterioration|BLAZER COLORECTAL CANCER 2008|[?]|ug/L DDU|UNFAVORABLE RESPONSE|1|uV2|WEBER GREEN STAIN||Y||FAMILY MEMBER|MICROSCOPIST 3|Y|4|Visit_4|65|6|TREATMENT|2020-09-12|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-24|P1Y2M10DT2H30M|BEFORE|2020-10-03|BEFORE|2020-10-16
e|RS|cca2835b-ca8d-4db6-89b4-9f2855968a8a|8|CYTORESP|Cytogenetic Response|CHESON LYMPHOMA 2008|[?]|SPRAY|CMR|1|km/h|MOUSE PROTECTION ASSAY||||DOMESTIC PARTNER|READER 1|U|4|Visit_4|65|2|TREATMENT|2020-09-12|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-24|P1Y2M10DT2H30M|UNKNOWN|2020-09-17|AFTER|2020-10-08
e|RS|cca2835b-ca8d-4db6-89b4-9f2855968a8a|9|RDIORESP|Radiologic Response|IWG CHESON MDS 2006|[?]|MPL U/mL|MORPHOLOGIC CR|1|ELISA unit/mL|CELL OF ORIGIN ASSAY|Y|||FRIEND|RADIOLOGIST 1|N|5|Visit_5|90|1|SCREENING|2020-10-07|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-08|P1Y2M10DT2H30M|AFTER|2020-08-16|AFTER|2020-08-24
e|RS|cca2835b-ca8d-4db6-89b4-9f2855968a8a|10|BMIVLIND|Bone Marrow Involvement Indicator|MRANO VAN DEN BENT GLIOMA 2011|[?]|mm3/mm2/year|EQUIVOCAL|1|mL/cm3/min|NEXT GENERATION TARGETED SEQUENCING||||DOMESTIC PARTNER|READER 2|N|5|Visit_5|90|4|WASHOUT|2020-10-07|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-08|P1Y2M10DT2H30M|BEFORE|2020-09-04|AFTER|2020-09-25
e|RS|420e3ac1-ba3f-4baf-bcfb-121c0fdc947e|1|TRGRESP|Target Response|iRECIST|[?]|V|SD|1|umol/kg/min|QUANTITATIVE COMPUTED TOMOGRAPHY||Y||CHILD|NEUROLOGIST 2|Y|1|Visit_1|10|2|SCREENING|2020-10-07|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-25|P1Y2M10DT2H30M|COINCIDENT|2020-11-16|AFTER|2020-12-21
e|RS|420e3ac1-ba3f-4baf-bcfb-121c0fdc947e|2|NTRGRESP|Non-target Response|IWG CHESON AML 2003|[?]|g/dL|SD-CT|1|TAMPON|THICK SMEAR|Y|||PROXY|CARDIOLOGIST|N|1|Visit_1|10|5|TREATMENT|2020-10-07|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-25|P1Y2M10DT2H30M|BEFORE|2020-12-09|COINCIDENT|2020-12-11
e|RS|420e3ac1-ba3f-4baf-bcfb-121c0fdc947e|3|MRDRESP|Minimal Residual Disease Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|MPL U|QUANTIFIABLE MRD POSITIVITY|1|mU/L|GC/FID||||PROXY|MICROSCOPIST 1|U|2|Visit_2|25|5|TREATMENT|2020-10-22|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-21|P1Y2M10DT2H30M|BEFORE|2020-10-20|ONGOING|2020-12-17
e|RS|420e3ac1-ba3f-4baf-bcfb-121c0fdc947e|4|METBRESP|Metabolic Response|FAROOQUI SUPP CLL 2014|[?]|MAC50|PMD|1|IMPLANT|INCISION-INDUCED BLEEDING METHOD||||CLINICAL RESEARCH COORDINATOR|UROLOGIST|NA|2|Visit_2|25|7|TREATMENT|2020-10-22|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-21|P1Y2M10DT2H30M|UNKNOWN|2020-12-06|AFTER|2020-12-15
e|RS|420e3ac1-ba3f-4baf-bcfb-121c0fdc947e|5|NEWLPROG|New Lesion Progression|IWC HALLEK CLL 2008|||CA125 75% RESPONSE|1|CUP|NEXT GENERATION TARGETED SEQUENCING|||Y|CLINICAL RESEARCH COORDINATOR|READER 2|NA|3|Visit_3|40|7|FOLLOW-UP|2020-11-06|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-08|P1Y2M10DT2H30M|AFTER|2020-12-15|AFTER|2020-12-24
e|RS|420e3ac1-ba3f-4baf-bcfb-121c0fdc947e|6|TRGRESP|Target Response|WHO BREAST CANCER 2006|||TREATMENT FAILURE|1|uOsm|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY|||Y|INTERVIEWER|READER 3|N|3|Visit_3|40|7|FOLLOW-UP|2020-11-06|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-08|P1Y2M10DT2H30M|COINCIDENT|2020-11-11|BEFORE|2020-11-16
e|RS|420e3ac1-ba3f-4baf-bcfb-121c0fdc947e|7|TMRESP|Tumor Marker Response|HARTMAN PANCREATIC CANCER 2012|[?]|dL|PSEUDORESPONSE|1|Rad|RADIATION DOSIMETRY||||NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|N|4|Visit_4|65|5|FOLLOW-UP|2020-12-01|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-24|P1Y2M10DT2H30M|UNKNOWN|2020-10-22|COINCIDENT|2020-12-07
e|RS|420e3ac1-ba3f-4baf-bcfb-121c0fdc947e|8|CLINRESP|Clinical Response|CHESON CLL 2006|[?]|kHz|NON-iCR/NON-iUPD|1|MPL U/mL|NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY||||CLINICAL STUDY SPONSOR|CLINICAL PATHOLOGIST|U|4|Visit_4|65|4|TREATMENT|2020-12-01|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-24|P1Y2M10DT2H30M|AFTER|2020-12-20|AFTER|2020-12-24
e|RS|420e3ac1-ba3f-4baf-bcfb-121c0fdc947e|9|HEMARESP|Hematologic Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|Hz|cCR|1|nmol/mol|CORONARY ANGIOGRAPHY||||NON-HEALTH CARE PROFESSIONAL|RATER|NA|5|Visit_5|90|5|FOLLOW-UP|2020-12-26|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-24|P1Y2M10DT2H30M|BEFORE|2020-12-12|BEFORE|2020-12-29
e|RS|420e3ac1-ba3f-4baf-bcfb-121c0fdc947e|10|MRPHRESP|Morphologic Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|BLOCKS|sCR|1|pmol/L|REBOUND TONOMETRY||||INTERVIEWER|RATER 1|Y|5|Visit_5|90|3|TREATMENT|2020-12-26|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-24|P1Y2M10DT2H30M|UNKNOWN|2020-11-09|BEFORE|2020-11-29
e|RS|74cd0a4f-f9fe-4df9-93b8-7832512d0828|1|OVRLRESP|Overall Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|L/h/m2|cCR|1|BOLUS|MAPH||||VENDOR|READER|N|1|Visit_1|10|5|TREATMENT|2020-05-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-18|P1Y2M10DT2H30M|UNKNOWN|2020-06-15|AFTER|2020-06-19
e|RS|74cd0a4f-f9fe-4df9-93b8-7832512d0828|2|MRDRESP|Minimal Residual Disease Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|mEq/g|PD-CT|1|10^7/L|STATIC PERIMETRY||||STUDY SUBJECT|MICROSCOPIST 2|N|1|Visit_1|10|6|FOLLOW-UP|2020-05-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-18|P1Y2M10DT2H30M|AFTER|2020-07-22|AFTER|2020-08-01
e|RS|74cd0a4f-f9fe-4df9-93b8-7832512d0828|3|RDIORESP|Radiologic Response|CHESON CLL 2012|[?]|genEq/mL|PSEUDOPROGRESSION|1|10^9 CFU/g|LIGHT MICROSCOPY||||ADJUDICATION COMMITTEE|ONCOLOGIST|Y|2|Visit_2|25|2|FOLLOW-UP|2020-05-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-12|P1Y2M10DT2H30M|COINCIDENT|2020-07-31|ONGOING|2020-08-07
e|RS|74cd0a4f-f9fe-4df9-93b8-7832512d0828|4|CLINRESP|Clinical Response|iRECIST|[?]|nmol/mL/min|NR|1|PA|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY||||SPOUSE|DERMATOLOGIST|N|2|Visit_2|25|3|FOLLOW-UP|2020-05-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-12|P1Y2M10DT2H30M|AFTER|2020-07-14|COINCIDENT|2020-07-25
e|RS|74cd0a4f-f9fe-4df9-93b8-7832512d0828|5|NTLWIND|Non-Target Lesion Worsening Indicator|KUMAR IMWG 2016|[?]|ug/m2/day|QUANTIFIABLE MRD POSITIVITY|1|mMU/mL|BIOPSY||||CLINICAL RESEARCH ASSOCIATE|READER 3|Y|3|Visit_3|40|7|TREATMENT|2020-06-14|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-25|P1Y2M10DT2H30M|UNKNOWN|2020-05-21|BEFORE|2020-06-30
e|RS|74cd0a4f-f9fe-4df9-93b8-7832512d0828|6|NTRGRESP|Non-target Response|LEE LUNG CANCER 2011|||CRi|1|g/mol|CINEANGIOGRAPHY||Y|Y|HEALTH CARE PROFESSIONAL|RATER 2|NA|3|Visit_3|40|7|TREATMENT|2020-06-14|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-25|P1Y2M10DT2H30M|COINCIDENT|2020-06-15|AFTER|2020-07-12
e|RS|74cd0a4f-f9fe-4df9-93b8-7832512d0828|7|SYMPTDTR|Symptomatic Deterioration|GUILHOT CML 2007|||PMR|1|FIU|AGAR PROPORTION||Y|Y|STUDY SUBJECT|MICROSCOPIST|U|4|Visit_4|65|7|SCREENING|2020-07-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-06|P1Y2M10DT2H30M|UNKNOWN|2020-07-24|AFTER|2020-08-04
e|RS|74cd0a4f-f9fe-4df9-93b8-7832512d0828|8|LIVRRESP|Liver Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|U/mg|CYTOGENETIC CR|1|dpm/100mg|PLAQUE REDUCTION NEUTRALIZATION ASSAY|Y|||ADJUDICATOR|PATHOLOGIST 2|NA|4|Visit_4|65|4|TREATMENT|2020-07-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-06|P1Y2M10DT2H30M|BEFORE|2020-07-16|AFTER|2020-07-30
e|RS|74cd0a4f-f9fe-4df9-93b8-7832512d0828|9|OVRLRESP|Overall Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|ukat/L|SMD|1|10^5/L|IMMUNOPRECIPITATION||||FAMILY MEMBER|RADIOLOGIST|U|5|Visit_5|90|5|TREATMENT|2020-08-03|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-09|P1Y2M10DT2H30M|BEFORE|2020-06-09|ONGOING|2020-06-15
e|RS|74cd0a4f-f9fe-4df9-93b8-7832512d0828|10|MJPTHIND|Major Pathological Response Indicator|HAMAOKA BREAST CANCER 2010|||UNEQUIVOCAL|1|uV|INCISION-INDUCED BLEEDING METHOD|Y||Y|ADJUDICATION COMMITTEE|RATER 1|NA|5|Visit_5|90|4|WASHOUT|2020-08-03|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-09|P1Y2M10DT2H30M|UNKNOWN|2020-07-22|AFTER|2020-08-02
e|RS|09238251-feaf-45a9-b295-dfed9a75fbb2|1|TMRESP|Tumor Marker Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|APL U|CR-CT|1|ug/m2/h|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION|Y|||CHILD|PATHOLOGIST 1|NA|1|Visit_1|10|6|WASHOUT|2020-06-26|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-13|P1Y2M10DT2H30M|BEFORE|2020-08-15|COINCIDENT|2020-09-07
e|RS|09238251-feaf-45a9-b295-dfed9a75fbb2|2|CYTORESP|Cytogenetic Response|CHESON MALIGNANT LYMPHOMA 2007|||sCR|1|nsec|SNELLEN EYE CHART|||Y|CLINICAL RESEARCH ASSOCIATE|RATER|U|1|Visit_1|10|7|TREATMENT|2020-06-26|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-13|P1Y2M10DT2H30M|COINCIDENT|2020-06-25|AFTER|2020-07-14
e|RS|09238251-feaf-45a9-b295-dfed9a75fbb2|3|MRDRESP|Minimal Residual Disease Response|EASL BRUIX LIVER CANCER 2001|[?]|mol/day|MOLECULAR CR|1|BOWL|CALIPER MEASUREMENT METHOD||||DOMESTIC PARTNER|NEUROLOGIST|U|2|Visit_2|25|2|TREATMENT|2020-07-11|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-13|P1Y2M10DT2H30M|BEFORE|2020-06-18|BEFORE|2020-07-02
e|RS|09238251-feaf-45a9-b295-dfed9a75fbb2|4|STRUSTAT|Steroid Use Status|WOLCHOK SOLID TUMORS 2009|[?]|HEP|ABSENT MORPHOLOGIC RESPONSE|1|h*%|KARYOTYPING||||STUDY SUBJECT|MICROSCOPIST 1|Y|2|Visit_2|25|1|FOLLOW-UP|2020-07-11|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-13|P1Y2M10DT2H30M|BEFORE|2020-08-18|ONGOING|2020-08-27
e|RS|09238251-feaf-45a9-b295-dfed9a75fbb2|5|LIVRRESP|Liver Response|HARTMANN GERM CELL CANCER 2002|[?]|TUBE|PMD|1|IU/day|ELISA||Y||SPOUSE|RATER 2|NA|3|Visit_3|40|4|TREATMENT|2020-07-26|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-26|P1Y2M10DT2H30M|BEFORE|2020-06-20|ONGOING|2020-08-04
e|RS|09238251-feaf-45a9-b295-dfed9a75fbb2|6|OVRLRESP|Overall Response|IWG CHESON MDS 2000|[?]|L/h/m2|PARTIAL MORPHOLOGIC RESPONSE|1|pmol/g|ENDPOINT DILUTION ASSAY||||PARENT|NEUROLOGIST|U|3|Visit_3|40|5|TREATMENT|2020-07-26|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-26|P1Y2M10DT2H30M|AFTER|2020-09-20|COINCIDENT|2020-09-23
e|RS|09238251-feaf-45a9-b295-dfed9a75fbb2|7|SPLNRESP|Spleen Response|LEE LUNG CANCER 2011|[?]|WEEKS|MAJOR PATHOLOGIC RESPONSE|1|TROCHE|TONOMETRY||||FRIEND|ADJUDICATOR 2|N|4|Visit_4|65|2|TREATMENT|2020-08-20|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-09|P1Y2M10DT2H30M|BEFORE|2020-07-22|AFTER|2020-08-06
e|RS|09238251-feaf-45a9-b295-dfed9a75fbb2|8|NTLWIND|Non-Target Lesion Worsening Indicator|DURIE MULTIPLE MYELOMA 2006|[?]|BU/mL|iCR|1|fg|SPIROMETRY|Y|||VENDOR|DEVELOPMENTAL PSYCHOLOGIST|NA|4|Visit_4|65|3|FOLLOW-UP|2020-08-20|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-09|P1Y2M10DT2H30M|UNKNOWN|2020-06-22|ONGOING|2020-09-03
e|RS|09238251-feaf-45a9-b295-dfed9a75fbb2|9|TMRESP|Tumor Marker Response|CHESON CLL 2006|[?]|usec|PARTIAL MORPHOLOGIC RESPONSE|1|/mm2|PLETHYSMOGRAPHY||||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST|N|5|Visit_5|90|4|SCREENING|2020-09-14|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-24|P1Y2M10DT2H30M|UNKNOWN|2020-07-04|ONGOING|2020-09-23
e|RS|09238251-feaf-45a9-b295-dfed9a75fbb2|10|CPRFSTAT|Clinical Performance Status|PRINCE TCELL LYMPHOMA 2010|||PARTIAL MORPHOLOGIC RESPONSE|1|fmol/L/sec|TELLER ACUITY CARDS||Y|Y|PARENT|READER 1|N|5|Visit_5|90|3|TREATMENT|2020-09-14|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-24|P1Y2M10DT2H30M|AFTER|2020-08-22|AFTER|2020-08-23
e|RS|3e896568-85dc-4a14-ba41-eb3575940a9d|1|TMRESP|Tumor Marker Response|BURCOMBE BREAST CANCER 2005|||HI-P|1|Bq/L|QUANTITATIVE COMPUTED TOMOGRAPHY|Y||Y|DOMESTIC PARTNER|PHYSIOTHERAPIST|NA|1|Visit_1|10|2|SCREENING|2021-01-26|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-23|P1Y2M10DT2H30M|BEFORE|2021-02-11|ONGOING|2021-02-15
e|RS|3e896568-85dc-4a14-ba41-eb3575940a9d|2|SYMPTDTR|Symptomatic Deterioration|LEE LUNG CANCER 2011|||MOLECULAR MAJOR RESPONSE|1|ug/kg/h|SNP ARRAY|Y||Y|HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|U|1|Visit_1|10|1|FOLLOW-UP|2021-01-26|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-23|P1Y2M10DT2H30M|BEFORE|2021-02-27|AFTER|2021-03-16
e|RS|3e896568-85dc-4a14-ba41-eb3575940a9d|3|MNPTHIND|Minor Pathological Response Indicator|KEAM BREAST CANCER 2013|[?]|EID 50/dose|MOLECULAR MAJOR RESPONSE|1|pmol/dL|TEST STRIP||Y||ADJUDICATOR|PATHOLOGIST 2|NA|2|Visit_2|25|6|TREATMENT|2021-02-10|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-04|P1Y2M10DT2H30M|BEFORE|2021-03-13|COINCIDENT|2021-04-17
e|RS|3e896568-85dc-4a14-ba41-eb3575940a9d|4|NTNERESP|Non-Target Non-Enhancing Response|HARTMAN PANCREATIC CANCER 2012|[?]|g/cage/wk|TREATMENT FAILURE|1|kHz|WRIGHT STAIN|Y|||PROXY|NEUROLOGIST 1|U|2|Visit_2|25|5|SCREENING|2021-02-10|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-04|P1Y2M10DT2H30M|BEFORE|2021-01-20|ONGOING|2021-02-14
e|RS|3e896568-85dc-4a14-ba41-eb3575940a9d|5|NEWLPROG|New Lesion Progression|WHO BREAST CANCER 2006|||SD|1|OI50|WEBER GREEN STAIN||Y|Y|CHILD|OPHTHALMOLOGIST|Y|3|Visit_3|40|3|WASHOUT|2021-02-25|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-24|P1Y2M10DT2H30M|UNKNOWN|2021-02-08|ONGOING|2021-04-24
e|RS|3e896568-85dc-4a14-ba41-eb3575940a9d|6|MRDIND|Minimal Residual Disease Indicator|NCIWG CHESON CLL 1996|[?]|kg/m2|MRD PERSISTENCE|1|PLUG|ELASTOGRAPHY|Y|||GUARDIAN|PATHOLOGIST|Y|3|Visit_3|40|4|SCREENING|2021-02-25|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-24|P1Y2M10DT2H30M|UNKNOWN|2021-03-07|ONGOING|2021-04-23
e|RS|3e896568-85dc-4a14-ba41-eb3575940a9d|7|NTLWIND|Non-Target Lesion Worsening Indicator|PCWG SCHER PROSTATE CANCER 2016|||VGPR|1|pmol/10^10 cells|FLUORESCENCE ANGIOGRAPHY|||Y|FAMILY MEMBER|READER 3|N|4|Visit_4|65|2|WASHOUT|2021-03-22|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-17|P1Y2M10DT2H30M|COINCIDENT|2021-04-10|BEFORE|2021-04-18
e|RS|3e896568-85dc-4a14-ba41-eb3575940a9d|8|METSIND|Metastatic Indicator|CHESON MALIGNANT LYMPHOMA 2007|[?]|ELISA unit|IMMUNOPHENOTYPIC CR|1|m|HEMATOXYLIN AND EOSIN STAIN|Y|Y||CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL PSYCHOLOGIST|Y|4|Visit_4|65|7|FOLLOW-UP|2021-03-22|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-17|P1Y2M10DT2H30M|UNKNOWN|2021-02-21|ONGOING|2021-04-08
e|RS|3e896568-85dc-4a14-ba41-eb3575940a9d|9|METSIND|Metastatic Indicator|iRECIST|||CA125 75% RESPONSE|1|Rad|HPLC-UV|Y||Y|ADJUDICATION COMMITTEE|DEVELOPMENTAL PSYCHOLOGIST|U|5|Visit_5|90|7|TREATMENT|2021-04-16|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-28|P1Y2M10DT2H30M|UNKNOWN|2021-02-19|ONGOING|2021-04-20
e|RS|3e896568-85dc-4a14-ba41-eb3575940a9d|10|STRUSTAT|Steroid Use Status|MASS|[?]|IU/mL|TREATMENT FAILURE|1|mL/dL|MICROARRAY||||FAMILY MEMBER|ADJUDICATOR 3|N|5|Visit_5|90|2|SCREENING|2021-04-16|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-28|P1Y2M10DT2H30M|COINCIDENT|2021-03-27|AFTER|2021-04-24
e|RS|7e759204-4cf5-49fb-9d9e-82e0199c7ccc|1|TRGRESP|Target Response|BRUGGEMANN MRD 2010|[?]|PACK|NON-PD|1|U/g Hb|POLYMERASE CHAIN REACTION||||HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|NA|1|Visit_1|10|1|FOLLOW-UP|2020-10-22|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-13|P1Y2M10DT2H30M|COINCIDENT|2020-10-26|BEFORE|2020-11-27
e|RS|7e759204-4cf5-49fb-9d9e-82e0199c7ccc|2|NTERESP|Non-Target Enhancing Response|iRECIST|[?]|mEq/ug|nPR|1|dpm/mL|HIGH LEVEL AMINOGLYCOSIDE SCREEN||||PARENT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|1|Visit_1|10|1|SCREENING|2020-10-22|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-13|P1Y2M10DT2H30M|UNKNOWN|2020-12-11|COINCIDENT|2020-12-28
e|RS|7e759204-4cf5-49fb-9d9e-82e0199c7ccc|3|HEMARESP|Hematologic Response|EASL BRUIX LIVER CANCER 2001|[?]|foz_us|IMMUNOPHENOTYPIC CR|1|mL/sec/1.73m2|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION||||CLINICAL STUDY SPONSOR|ADJUDICATOR 3|N|2|Visit_2|25|7|TREATMENT|2020-11-06|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-02|P1Y2M10DT2H30M|UNKNOWN|2020-11-24|AFTER|2021-01-07
e|RS|7e759204-4cf5-49fb-9d9e-82e0199c7ccc|4|SPLNRESP|Spleen Response|SACT|[?]|ms/mmHg|IMMUNOPHENOTYPIC CR|1|SYRINGE|SICKLE CELL SOLUBILITY TEST||Y||SIBLING|RATER 1|U|2|Visit_2|25|6|TREATMENT|2020-11-06|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-02|P1Y2M10DT2H30M|BEFORE|2020-11-30|COINCIDENT|2021-01-02
e|RS|7e759204-4cf5-49fb-9d9e-82e0199c7ccc|5|MJPTHIND|Major Pathological Response Indicator|SHINDOH COLORECTAL CANCER 2013|[?]|10^3/hpf|NOT ALL EVALUATED|1|mmol/min/kPa|QUANTITATIVE PERIPHERAL ANGIOGRAPHY|Y|||FAMILY MEMBER|RADIOLOGIST|U|3|Visit_3|40|6|WASHOUT|2020-11-21|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-28|P1Y2M10DT2H30M|AFTER|2020-11-01|BEFORE|2021-01-07
e|RS|7e759204-4cf5-49fb-9d9e-82e0199c7ccc|6|OVRLRESP|Overall Response|PCWG SCHER PROSTATE CANCER 2016|[?]|SFC/10^6 PBMC|MORPHOLOGIC CRi|1|log10 TCID 50/uL|LIGHT SCATTERING SPECTROSCOPY||||FAMILY MEMBER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|3|Visit_3|40|4|TREATMENT|2020-11-21|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-28|P1Y2M10DT2H30M|BEFORE|2020-12-02|ONGOING|2020-12-31
e|RS|7e759204-4cf5-49fb-9d9e-82e0199c7ccc|7|DRCRIND|Disease Recurrence Indicator|CHOLLET BREAST CANCER 2002|||PD-CT|1|km|AGAR DILUTION|Y|Y|Y|FRIEND|DERMATOLOGIST|NA|4|Visit_4|65|2|FOLLOW-UP|2020-12-16|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-21|P1Y2M10DT2H30M|COINCIDENT|2020-12-10|COINCIDENT|2021-01-03
e|RS|7e759204-4cf5-49fb-9d9e-82e0199c7ccc|8|TRGRESP|Target Response|MURPHY PROSTATE CANCER 1980|[?]|U/g|UNFAVORABLE RESPONSE|1|ug/g/h|CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY||||ADJUDICATION COMMITTEE|MICROSCOPIST 1|U|4|Visit_4|65|7|TREATMENT|2020-12-16|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-21|P1Y2M10DT2H30M|BEFORE|2020-12-03|BEFORE|2020-12-07
e|RS|7e759204-4cf5-49fb-9d9e-82e0199c7ccc|9|MRPHRESP|Morphologic Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|steps/min|NON-QUANTIFIABLE MRD POSITIVITY|1|g/animal/wk|OSCILLOMETRY|Y|||ADJUDICATION COMMITTEE|HEMATOLOGIST|Y|5|Visit_5|90|7|TREATMENT|2021-01-10|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-13|P1Y2M10DT2H30M|AFTER|2020-11-26|AFTER|2020-12-19
e|RS|7e759204-4cf5-49fb-9d9e-82e0199c7ccc|10|TRGRESP|Target Response|IWC HALLEK CLL 2008|[?]|Enzyme U|PMR|1|mkat|CONTRAST ENHANCED PET/CT SCAN||||FRIEND|RADIOLOGIST 2|Y|5|Visit_5|90|5|TREATMENT|2021-01-10|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-13|P1Y2M10DT2H30M|AFTER|2021-01-07|ONGOING|2021-01-13
e|RS|725c5a91-72b0-4b2c-a51a-d1006303373e|1|MJPTHIND|Major Pathological Response Indicator|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|10^9/dose|DISEASE TRANSFORMATION|1|Pack Year|INFRARED SPECTROMETRY||||ADJUDICATION COMMITTEE|PHYSIOTHERAPIST|NA|1|Visit_1|10|3|TREATMENT|2020-11-23|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-26|P1Y2M10DT2H30M|BEFORE|2021-02-09|AFTER|2021-02-11
e|RS|725c5a91-72b0-4b2c-a51a-d1006303373e|2|HEMARESP|Hematologic Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|/sec|MRD RELAPSE|1|cmol/L|AGAR DILUTION||||CHILD|ENDOCRINOLOGIST|N|1|Visit_1|10|3|SCREENING|2020-11-23|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-26|P1Y2M10DT2H30M|UNKNOWN|2020-12-23|BEFORE|2021-01-08
e|RS|725c5a91-72b0-4b2c-a51a-d1006303373e|3|NTNERESP|Non-Target Non-Enhancing Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|mOsm|sCR|1|uCi/kg|SPECT/CT SCAN||Y||CLINICAL STUDY SPONSOR|ENDOCRINOLOGIST|NA|2|Visit_2|25|3|TREATMENT|2020-12-08|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-21|P1Y2M10DT2H30M|BEFORE|2021-02-12|AFTER|2021-02-19
e|RS|725c5a91-72b0-4b2c-a51a-d1006303373e|4|HEMARESP|Hematologic Response|iRECIST|[?]|mL/breath|OPTIMAL MORPHOLOGIC RESPONSE|1|ugEq|NO INFORMATION|Y|||HEALTH CARE PROFESSIONAL|RATER|N|2|Visit_2|25|2|WASHOUT|2020-12-08|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-21|P1Y2M10DT2H30M|AFTER|2020-12-13|AFTER|2021-01-14
e|RS|725c5a91-72b0-4b2c-a51a-d1006303373e|5|MJPTHIND|Major Pathological Response Indicator|SCHWARZ CERVICAL CANCER 2009|[?]|Farad|PSA PROGRESSION|1|tuberculin unit/mL|IMMUNOBLOT||||ADJUDICATOR|RADIOLOGIST 2|Y|3|Visit_3|40|6|WASHOUT|2020-12-23|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-29|P1Y2M10DT2H30M|COINCIDENT|2020-11-19|AFTER|2020-12-07
e|RS|725c5a91-72b0-4b2c-a51a-d1006303373e|6|CLINRESP|Clinical Response|LUGANO CLASSIFICATION|[?]|1/(s*kPa)|COMPLETE MRD RESPONSE|1|mL/dL|MALDI-TOF||||SPOUSE|RADIOLOGIST 2|NA|3|Visit_3|40|4|TREATMENT|2020-12-23|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-29|P1Y2M10DT2H30M|COINCIDENT|2021-01-13|ONGOING|2021-01-24
e|RS|725c5a91-72b0-4b2c-a51a-d1006303373e|7|CLINRESP|Clinical Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|Ci/uL|CYTOGENETIC CR|1|/200 HPFs|NEPHELOMETRY||||GUARDIAN|RADIOLOGIST 1|U|4|Visit_4|65|5|WASHOUT|2021-01-17|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-08|P1Y2M10DT2H30M|BEFORE|2021-01-02|ONGOING|2021-02-15
e|RS|725c5a91-72b0-4b2c-a51a-d1006303373e|8|TRGRESP|Target Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|||DECREASED|1|ugEq|ARTERIAL SPIN LABELING FUNCTIONAL MRI|Y||Y|CAREGIVER|HEMATOLOGIST|NA|4|Visit_4|65|1|WASHOUT|2021-01-17|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-08|P1Y2M10DT2H30M|AFTER|2020-12-12|AFTER|2020-12-29
e|RS|725c5a91-72b0-4b2c-a51a-d1006303373e|9|MRPHRESP|Morphologic Response|GUPPY OVARIAN CANCER 2002|[?]|mg/min|cPR|1|foz_us|NON-INVASIVE DIELECTRIC SENSING||Y||VENDOR|READER 3|Y|5|Visit_5|90|3|SCREENING|2021-02-11|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-17|P1Y2M10DT2H30M|BEFORE|2021-01-14|COINCIDENT|2021-01-25
e|RS|725c5a91-72b0-4b2c-a51a-d1006303373e|10|BMIVLIND|Bone Marrow Involvement Indicator|MONTSERRAT CLL 1989|[?]|ft|CA125 75% RESPONSE|1|PACK|CELLULOSE TAPE||||INTERVIEWER|READER 2|U|5|Visit_5|90|5|SCREENING|2021-02-11|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-17|P1Y2M10DT2H30M|UNKNOWN|2020-12-15|AFTER|2020-12-16
e|RS|5bf5b31d-a59d-46b7-8f8f-97919d449565|1|MNPTHIND|Minor Pathological Response Indicator|MACDONALD GLIOMA 1990|[?]|mmol/g|PD|1|ug/L/h|MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY||||INDEPENDENT ASSESSOR|ENDOCRINOLOGIST|NA|1|Visit_1|10|5|TREATMENT|2021-01-01|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-22|P1Y2M10DT2H30M|UNKNOWN|2021-03-03|ONGOING|2021-03-21
e|RS|5bf5b31d-a59d-46b7-8f8f-97919d449565|2|CPRFSTAT|Clinical Performance Status|GCIG RUSTIN OVARIAN CANCER 2011|[?]|SQU/mL|NOT ALL EVALUATED|1|Newton|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY||||FRIEND|OTOLARYNGOLOGIST|U|1|Visit_1|10|3|TREATMENT|2021-01-01|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-22|P1Y2M10DT2H30M|AFTER|2021-03-23|ONGOING|2021-03-26
e|RS|5bf5b31d-a59d-46b7-8f8f-97919d449565|3|MJPTHIND|Major Pathological Response Indicator|KUMAR IMWG 2016|[?]|PFU|RELAPSED DISEASE|1|g/g/day|ARTERIAL SPIN LABELING FUNCTIONAL MRI|Y|Y||CLINICAL RESEARCH COORDINATOR|READER 2|N|2|Visit_2|25|4|TREATMENT|2021-01-16|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-14|P1Y2M10DT2H30M|UNKNOWN|2021-03-08|BEFORE|2021-03-20
e|RS|5bf5b31d-a59d-46b7-8f8f-97919d449565|4|MOLRESP|Molecular Response|PRINCE TCELL LYMPHOMA 2010|[?]|mU|MORPHOLOGIC CR|1|kHz|STRESS ECHOCARDIOGRAPHY|Y|||SIBLING|READER 3|U|2|Visit_2|25|3|TREATMENT|2021-01-16|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-14|P1Y2M10DT2H30M|UNKNOWN|2021-02-26|COINCIDENT|2021-03-05
e|RS|5bf5b31d-a59d-46b7-8f8f-97919d449565|5|NTNERESP|Non-Target Non-Enhancing Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|ug/mL/h|ABSENT MORPHOLOGIC RESPONSE|1|mg/m2/h|RADIOGRAPHY||||SPOUSE|READER 1|NA|3|Visit_3|40|3|WASHOUT|2021-01-31|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-26|P1Y2M10DT2H30M|AFTER|2021-02-05|AFTER|2021-02-14
e|RS|5bf5b31d-a59d-46b7-8f8f-97919d449565|6|NTRGRESP|Non-target Response|PALUMBO MULTIPLE MYELOMA 2009|||PARTIAL MORPHOLOGIC RESPONSE|1|mol/L|MASS SPECTROMETRY|||Y|CLINICAL RESEARCH ASSOCIATE|OTOLARYNGOLOGIST|U|3|Visit_3|40|6|TREATMENT|2021-01-31|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-26|P1Y2M10DT2H30M|BEFORE|2021-01-10|ONGOING|2021-02-22
e|RS|5bf5b31d-a59d-46b7-8f8f-97919d449565|7|TMRESP|Tumor Marker Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|umol|NOT ALL EVALUATED|1|CAN|DIFFUSION TENSOR MRI||Y||PROXY|OTOLARYNGOLOGIST|N|4|Visit_4|65|5|TREATMENT|2021-02-25|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-13|P1Y2M10DT2H30M|COINCIDENT|2021-02-25|AFTER|2021-03-07
e|RS|5bf5b31d-a59d-46b7-8f8f-97919d449565|8|MRPHRESP|Morphologic Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|mL/animal/day|PR-CT|1|umol/L/min|OBSERVATION||Y||FRIEND|NEUROLOGIST 2|NA|4|Visit_4|65|7|FOLLOW-UP|2021-02-25|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-13|P1Y2M10DT2H30M|BEFORE|2021-03-27|BEFORE|2021-03-31
e|RS|5bf5b31d-a59d-46b7-8f8f-97919d449565|9|TMRESP|Tumor Marker Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|||NON-QUANTIFIABLE MRD POSITIVITY|1|L/s/kPa|RIA|||Y|INDEPENDENT ASSESSOR|ADJUDICATOR|N|5|Visit_5|90|2|FOLLOW-UP|2021-03-22|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-14|P1Y2M10DT2H30M|AFTER|2021-01-23|COINCIDENT|2021-01-27
e|RS|5bf5b31d-a59d-46b7-8f8f-97919d449565|10|NEWLIND|New Lesion Indicator|RECICL|[?]|mMU/mL|RELAPSED DISEASE|1|cs|CAPILLARY ELECTROPHORESIS||||INDEPENDENT ASSESSOR|READER 3|Y|5|Visit_5|90|3|FOLLOW-UP|2021-03-22|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-14|P1Y2M10DT2H30M|UNKNOWN|2021-03-12|AFTER|2021-03-17
e|RS|7fc35880-1672-4e64-ba3b-aa3f1e42764b|1|CLINRESP|Clinical Response|JACINTO CERVICAL CANCER 2007|[?]|Bq/ug|nPR|1|kBq/uL|REAL-TIME POLYMERASE CHAIN REACTION ASSAY||||HEALTH CARE PROFESSIONAL|OPTOMETRIST|NA|1|Visit_1|10|4|TREATMENT|2020-05-26|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-17|P1Y2M10DT2H30M|AFTER|2020-08-06|AFTER|2020-08-09
e|RS|7fc35880-1672-4e64-ba3b-aa3f1e42764b|2|HEMARESP|Hematologic Response|NCIWG CHESON CLL 1996|[?]|pmol|PDu|1|mMU/mL|TRANSVAGINAL ULTRASOUND|Y|Y||ADJUDICATOR|MICROSCOPIST 3|U|1|Visit_1|10|6|SCREENING|2020-05-26|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-17|P1Y2M10DT2H30M|BEFORE|2020-06-27|COINCIDENT|2020-07-18
e|RS|7fc35880-1672-4e64-ba3b-aa3f1e42764b|3|LIVRRESP|Liver Response|iRECIST|||MRD RELAPSE|1|psi|REFRACTOMETRY||Y|Y|FRIEND|ADJUDICATOR 2|N|2|Visit_2|25|2|SCREENING|2020-06-10|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-06|P1Y2M10DT2H30M|BEFORE|2020-07-31|ONGOING|2020-08-08
e|RS|7fc35880-1672-4e64-ba3b-aa3f1e42764b|4|NEWLWIND|New Lesion Worsening Indicator|CHESON CLL 2006|[?]|gpELISA unit/mL|PD-CT|1|msec|KLEIHAUER-BETKE|Y|||ADJUDICATION COMMITTEE|PHYSIOTHERAPIST|U|2|Visit_2|25|3|SCREENING|2020-06-10|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-06|P1Y2M10DT2H30M|AFTER|2020-05-26|COINCIDENT|2020-07-15
e|RS|7fc35880-1672-4e64-ba3b-aa3f1e42764b|5|CPRFSTAT|Clinical Performance Status|MRANO VAN DEN BENT GLIOMA 2011|[?]|log10 CFU/mL|MRD NEGATIVITY|1|K|PHOTOGRAPHY||Y||PROXY|CLINICAL PATHOLOGIST|U|3|Visit_3|40|1|TREATMENT|2020-06-25|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-14|P1Y2M10DT2H30M|UNKNOWN|2020-07-28|BEFORE|2020-08-01
e|RS|7fc35880-1672-4e64-ba3b-aa3f1e42764b|6|MRPHRESP|Morphologic Response|MACDONALD GLIOMA 1990|[?]|10^5/hpf|MOLECULAR MAJOR RESPONSE|1|CARTRIDGE|BRDU CELLULAR PROLIFERATION ASSAY||||CHILD|CARDIOLOGIST|NA|3|Visit_3|40|3|TREATMENT|2020-06-25|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-14|P1Y2M10DT2H30M|UNKNOWN|2020-06-26|COINCIDENT|2020-07-12
e|RS|7fc35880-1672-4e64-ba3b-aa3f1e42764b|7|NEWLPROG|New Lesion Progression|CHOLLET BREAST CANCER 2002|[?]|cal|RELAPSED DISEASE FROM CR OR PR|1|pmol/10^10 cells|CLINICAL EVALUATION||||VENDOR|MICROSCOPIST 3|NA|4|Visit_4|65|6|WASHOUT|2020-07-20|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-06|P1Y2M10DT2H30M|COINCIDENT|2020-05-26|BEFORE|2020-07-16
e|RS|7fc35880-1672-4e64-ba3b-aa3f1e42764b|8|TRGRESP|Target Response|AJCC V7|||HI-N|1|uV2|SLIT LAMP|||Y|FRIEND|MICROSCOPIST 2|N|4|Visit_4|65|2|FOLLOW-UP|2020-07-20|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-06|P1Y2M10DT2H30M|UNKNOWN|2020-07-05|ONGOING|2020-07-27
e|RS|7fc35880-1672-4e64-ba3b-aa3f1e42764b|9|BMIVLIND|Bone Marrow Involvement Indicator|PRINCE TCELL LYMPHOMA 2010|[?]|PATCH|RELAPSED DISEASE FROM CR OR PR|1|Gravitational Unit|CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|Y|||CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 1|NA|5|Visit_5|90|1|TREATMENT|2020-08-14|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-24|P1Y2M10DT2H30M|COINCIDENT|2020-08-06|AFTER|2020-08-09
e|RS|7fc35880-1672-4e64-ba3b-aa3f1e42764b|10|CYTORESP|Cytogenetic Response|CHOLLET BREAST CANCER 2002|||IMPROVED|1|log10 TCID 50/uL|NUCLEIC ACID AMPLIFICATION TEST|||Y|INVESTIGATOR|FORENSIC PATHOLOGIST|N|5|Visit_5|90|7|TREATMENT|2020-08-14|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-24|P1Y2M10DT2H30M|UNKNOWN|2020-07-30|BEFORE|2020-08-16
e|RS|f093c85b-c6bc-414d-a6e3-a8dcb33226ff|1|NEWLWIND|New Lesion Worsening Indicator|RANO ELLINGSON 2017|||NON-PD|1|mIU/L|PANENDOSCOPY|||Y|CLINICAL STUDY SPONSOR|NEUROLOGIST 1|N|1|Visit_1|10|7|SCREENING|2020-10-14|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-16|P1Y2M10DT2H30M|COINCIDENT|2021-01-05|COINCIDENT|2021-01-07
e|RS|f093c85b-c6bc-414d-a6e3-a8dcb33226ff|2|METBRESP|Metabolic Response|IWG CHESON MDS 2000|||ABSENT MORPHOLOGIC RESPONSE|1|pg/cell|MEDIASTINOSCOPY||Y|Y|SIBLING|ADJUDICATOR|Y|1|Visit_1|10|4|TREATMENT|2020-10-14|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-16|P1Y2M10DT2H30M|UNKNOWN|2020-10-24|BEFORE|2020-12-15
e|RS|f093c85b-c6bc-414d-a6e3-a8dcb33226ff|3|NTERESP|Non-Target Enhancing Response|HARTMANN GERM CELL CANCER 2002|[?]|mm/min|PSEUDOPROGRESSION|1|BOWL|ELECTRICAL IMPEDANCE MYOGRAPHY||Y||STUDY SUBJECT|MICROSCOPIST 2|Y|2|Visit_2|25|3|FOLLOW-UP|2020-10-29|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-21|P1Y2M10DT2H30M|AFTER|2020-11-28|ONGOING|2020-12-05
e|RS|f093c85b-c6bc-414d-a6e3-a8dcb33226ff|4|NTERESP|Non-Target Enhancing Response|iRECIST|[?]|GBq/g|iSD|1|uCi/L|HEMOCYTOMETRY||Y||ADJUDICATOR|CLINICAL PATHOLOGIST|Y|2|Visit_2|25|7|TREATMENT|2020-10-29|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-21|P1Y2M10DT2H30M|COINCIDENT|2020-12-05|COINCIDENT|2021-01-07
e|RS|f093c85b-c6bc-414d-a6e3-a8dcb33226ff|5|METSIND|Metastatic Indicator|RANO ELLINGSON 2017|[?]|10^7 PFU|MORPHOLOGIC CRi|1|VOXEL|FLUORESCENT SPOT TEST||Y||PARENT|OPHTHALMOLOGIST|U|3|Visit_3|40|6|SCREENING|2020-11-13|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-28|P1Y2M10DT2H30M|AFTER|2020-10-30|AFTER|2020-11-07
e|RS|f093c85b-c6bc-414d-a6e3-a8dcb33226ff|6|CYTORESP|Cytogenetic Response|CHESON MALIGNANT LYMPHOMA 2007|||CYTOGENETIC NO RESPONSE|1|Antibody Unit|HEMATOXYLIN AND EOSIN STAIN||Y|Y|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST|N|3|Visit_3|40|2|FOLLOW-UP|2020-11-13|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-28|P1Y2M10DT2H30M|UNKNOWN|2020-10-21|ONGOING|2020-11-18
e|RS|f093c85b-c6bc-414d-a6e3-a8dcb33226ff|7|NTNERESP|Non-Target Non-Enhancing Response|CHOLLET BREAST CANCER 2002|[?]|F|CA125 75% RESPONSE|1|BOTTLE|FLUORESCEIN STAIN||||DOMESTIC PARTNER|RADIOLOGIST|N|4|Visit_4|65|5|TREATMENT|2020-12-08|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-26|P1Y2M10DT2H30M|AFTER|2020-12-17|COINCIDENT|2020-12-27
e|RS|f093c85b-c6bc-414d-a6e3-a8dcb33226ff|8|NEWLIND|New Lesion Indicator|PCWG SCHER PROSTATE CANCER 2008|[?]|umol/L|DECREASED|1|1/(s*kPa)|HPLC|Y|Y||CLINICAL RESEARCH ASSOCIATE|READER 3|Y|4|Visit_4|65|2|TREATMENT|2020-12-08|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-26|P1Y2M10DT2H30M|BEFORE|2020-11-08|COINCIDENT|2020-12-27
e|RS|f093c85b-c6bc-414d-a6e3-a8dcb33226ff|9|NEWLIND|New Lesion Indicator|LUGANO CLASSIFICATION|||RELAPSED DISEASE FROM CR OR PR|1|BE/mL|HANSEL STAIN||Y|Y|SPOUSE|READER 2|NA|5|Visit_5|90|7|TREATMENT|2021-01-02|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-18|P1Y2M10DT2H30M|COINCIDENT|2021-01-11|BEFORE|2021-01-12
e|RS|f093c85b-c6bc-414d-a6e3-a8dcb33226ff|10|MNPTHIND|Minor Pathological Response Indicator|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|mL|CYTOGENETIC PR|1|MASK|IHC||Y||FRIEND|CARDIOLOGIST|NA|5|Visit_5|90|7|TREATMENT|2021-01-02|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-18|P1Y2M10DT2H30M|COINCIDENT|2020-12-19|BEFORE|2020-12-27
e|RS|f8878ffd-67af-414c-b346-596dbec640cf|1|NEWLPROG|New Lesion Progression|AJCC V8|[?]|Bq/mL|CYTOGENETIC CR|1|log10 copies/mL|PEAK FLOWMETRY||||ADJUDICATOR|NEUROLOGIST 2|U|1|Visit_1|10|7|SCREENING|2021-01-04|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-07|P1Y2M10DT2H30M|AFTER|2021-04-02|COINCIDENT|2021-04-03
e|RS|f8878ffd-67af-414c-b346-596dbec640cf|2|DRCRIND|Disease Recurrence Indicator|RAJKUMAR MYELOMA 2011|[?]|ppm|MOLECULAR CR|1|cmol|IMMUNOFIXATION ELECTROPHORESIS||||INVESTIGATOR|PATHOLOGIST|NA|1|Visit_1|10|3|TREATMENT|2021-01-04|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-07|P1Y2M10DT2H30M|BEFORE|2021-03-30|AFTER|2021-04-02
e|RS|f8878ffd-67af-414c-b346-596dbec640cf|3|NTNERESP|Non-Target Non-Enhancing Response|WOLCHOK SOLID TUMORS 2009|||CRi|1|CAPFUL|SNP ARRAY|||Y|FRIEND|RADIOLOGIST 1|U|2|Visit_2|25|2|FOLLOW-UP|2021-01-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-10|P1Y2M10DT2H30M|COINCIDENT|2021-03-03|AFTER|2021-03-22
e|RS|f8878ffd-67af-414c-b346-596dbec640cf|4|MRDRESP|Minimal Residual Disease Response|SHINDOH COLORECTAL CANCER 2013|[?]|vg/mL|cPR|1|U/g/day|MAGNETIC RESONANCE ANGIOGRAPHY||||ADJUDICATION COMMITTEE|READER 1|NA|2|Visit_2|25|5|WASHOUT|2021-01-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-10|P1Y2M10DT2H30M|BEFORE|2021-03-05|ONGOING|2021-04-01
e|RS|f8878ffd-67af-414c-b346-596dbec640cf|5|METSIND|Metastatic Indicator|MASS|[?]|U/mg|INCREASED|1|10^6 organisms|CONTRAST ENHANCED PET/CT SCAN||||FRIEND|INTERNIST|N|3|Visit_3|40|7|TREATMENT|2021-02-03|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-07|P1Y2M10DT2H30M|COINCIDENT|2021-01-08|BEFORE|2021-02-02
e|RS|f8878ffd-67af-414c-b346-596dbec640cf|6|NEWLIND|New Lesion Indicator|HAMAOKA BREAST CANCER 2010|||HI-P|1|Weber|MAMMOGRAPHY|||Y|SPOUSE|READER 2|Y|3|Visit_3|40|3|SCREENING|2021-02-03|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-07|P1Y2M10DT2H30M|UNKNOWN|2021-03-01|ONGOING|2021-03-25
e|RS|f8878ffd-67af-414c-b346-596dbec640cf|7|DRCRIND|Disease Recurrence Indicator|UNSPECIFIED|[?]|beats/min|HI-N|1|mL/m2/h|PET/CT SCAN WITHOUT CONTRAST|Y|||SIBLING|RADIOLOGIST|Y|4|Visit_4|65|1|TREATMENT|2021-02-28|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-29|P1Y2M10DT2H30M|UNKNOWN|2021-02-19|COINCIDENT|2021-02-27
e|RS|f8878ffd-67af-414c-b346-596dbec640cf|8|MRPHRESP|Morphologic Response|KUMAR IMWG 2016|[?]|U/g|PD/RELAPSE AFTER HI|1|10^9 CFU/mL|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|Y|||NON-HEALTH CARE PROFESSIONAL|READER 1|NA|4|Visit_4|65|3|TREATMENT|2021-02-28|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-29|P1Y2M10DT2H30M|COINCIDENT|2021-02-15|AFTER|2021-03-02
e|RS|f8878ffd-67af-414c-b346-596dbec640cf|9|BESTRESP|Best Overall Response|CHOI GIST 2008|[?]|mol/L|MOLECULAR MAJOR RESPONSE|1|mPa|CONTACT SPECULAR MICROSCOPY||||CLINICAL STUDY SPONSOR|NEUROLOGIST|N|5|Visit_5|90|6|TREATMENT|2021-03-25|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-17|P1Y2M10DT2H30M|BEFORE|2021-01-03|BEFORE|2021-01-15
e|RS|f8878ffd-67af-414c-b346-596dbec640cf|10|SFTSRESP|Soft Tissue Response|DOHNER AML 2010|||CRi|1|mU|RADIOGRAPHY|||Y|FRIEND|ONCOLOGIST 1|N|5|Visit_5|90|4|TREATMENT|2021-03-25|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-17|P1Y2M10DT2H30M|BEFORE|2021-03-30|BEFORE|2021-04-03
e|RS|d8212248-cd8c-4404-8ad8-2c89c05bee9e|1|PATHRESP|Pathologic Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|OD Unit|SMD|1|mg/kg/dose|ACRIDINE ORANGE STAIN||||CAREGIVER|RADIOLOGIST|Y|1|Visit_1|10|5|TREATMENT|2020-05-11|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-28|P1Y2M10DT2H30M|COINCIDENT|2020-07-04|AFTER|2020-07-06
e|RS|d8212248-cd8c-4404-8ad8-2c89c05bee9e|2|TMRESP|Tumor Marker Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|kUSP|HI-P|1|RATIO|FUNDUS PHOTOGRAPHY||Y||INTERVIEWER|OPTOMETRIST|U|1|Visit_1|10|1|TREATMENT|2020-05-11|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-28|P1Y2M10DT2H30M|COINCIDENT|2020-07-10|BEFORE|2020-07-15
e|RS|d8212248-cd8c-4404-8ad8-2c89c05bee9e|3|HEMARESP|Hematologic Response|GUPPY OVARIAN CANCER 2002|[?]|mm/sec|CYTOGENETIC NO RESPONSE|1|10^9/g|ELECTRONEUROGRAPHY||Y||CAREGIVER|ADJUDICATOR 2|U|2|Visit_2|25|4|TREATMENT|2020-05-26|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-29|P1Y2M10DT2H30M|AFTER|2020-07-03|COINCIDENT|2020-07-23
e|RS|d8212248-cd8c-4404-8ad8-2c89c05bee9e|4|BMIVLIND|Bone Marrow Involvement Indicator|PCWG BUBLEY PROSTATE CANCER 1999|||NON-CR/NON-PD|1|fg|WESTERGREN|Y||Y|NON-HEALTH CARE PROFESSIONAL|UROLOGIST|Y|2|Visit_2|25|6|TREATMENT|2020-05-26|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-29|P1Y2M10DT2H30M|BEFORE|2020-07-29|ONGOING|2020-08-08
e|RS|d8212248-cd8c-4404-8ad8-2c89c05bee9e|5|NTLWIND|Non-Target Lesion Worsening Indicator|RANO|[?]|LOZENGE|CYTOGENETIC PR|1|g/m2/day|KARYOTYPING|Y|||CHILD|INTERNIST|U|3|Visit_3|40|3|FOLLOW-UP|2020-06-10|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-11|P1Y2M10DT2H30M|UNKNOWN|2020-05-31|BEFORE|2020-06-25
e|RS|d8212248-cd8c-4404-8ad8-2c89c05bee9e|6|PATHRESP|Pathologic Response|SACT|[?]|mMU/mL|ABSENT MORPHOLOGIC RESPONSE|1|ug/kg/day|SLOAN LETTER EYE CHART 2.5%||||CAREGIVER|READER 3|U|3|Visit_3|40|1|WASHOUT|2020-06-10|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-11|P1Y2M10DT2H30M|AFTER|2020-08-01|COINCIDENT|2020-08-05
e|RS|d8212248-cd8c-4404-8ad8-2c89c05bee9e|7|LIVRRESP|Liver Response|CHESON CLL 2012|||MORPHOLOGIC LEUKEMIA-FREE STATE|1|PIXEL|PET SCAN|||Y|CLINICAL STUDY SPONSOR|MICROSCOPIST|N|4|Visit_4|65|1|SCREENING|2020-07-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-26|P1Y2M10DT2H30M|AFTER|2020-05-22|BEFORE|2020-06-06
e|RS|d8212248-cd8c-4404-8ad8-2c89c05bee9e|8|RDIORESP|Radiologic Response|RAJKUMAR MYELOMA 2011|[?]|fmol/L/sec|QUANTIFIABLE MRD POSITIVITY|1|AgU/mL|HPLC/MS/MS||||INDEPENDENT ASSESSOR|FORENSIC PATHOLOGIST|NA|4|Visit_4|65|7|SCREENING|2020-07-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-26|P1Y2M10DT2H30M|COINCIDENT|2020-07-11|AFTER|2020-07-25
e|RS|d8212248-cd8c-4404-8ad8-2c89c05bee9e|9|TRGRESP|Target Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|g/cage/day|CYTOGENETIC MINOR RESPONSE|1|ug/mL/h|BALLPOINT PEN TECHNIQUE||||ADJUDICATOR|PEDIATRIC NEUROLOGIST|Y|5|Visit_5|90|7|TREATMENT|2020-07-30|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-12|P1Y2M10DT2H30M|BEFORE|2020-06-12|BEFORE|2020-07-23
e|RS|d8212248-cd8c-4404-8ad8-2c89c05bee9e|10|CYTORESP|Cytogenetic Response|CHOLLET BREAST CANCER 2002|[?]|uCi|DECREASED|1|Ci/mL|SLOAN LETTER EYE CHART 1.25%||Y||GUARDIAN|MICROSCOPIST|NA|5|Visit_5|90|2|TREATMENT|2020-07-30|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-12|P1Y2M10DT2H30M|BEFORE|2020-07-17|ONGOING|2020-07-30
e|RS|ea9c56ad-d69c-47c2-b486-65ce91e1f60d|1|MOLRESP|Molecular Response|HARTMAN PANCREATIC CANCER 2012|[?]|CAN|HI-P|1|10^6 CFU/mL|PEAK FLOWMETRY||||STUDY SUBJECT|CARDIOLOGIST|U|1|Visit_1|10|6|SCREENING|2020-07-02|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-12|P1Y2M10DT2H30M|COINCIDENT|2020-08-03|COINCIDENT|2020-09-04
e|RS|ea9c56ad-d69c-47c2-b486-65ce91e1f60d|2|MRPHRESP|Morphologic Response|CHESON CLL 2006|[?]|lm|CA125 75% RESPONSE|1|g/g|STRESS ECHOCARDIOGRAPHY||||SIBLING|RADIOLOGIST|N|1|Visit_1|10|6|TREATMENT|2020-07-02|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-12|P1Y2M10DT2H30M|UNKNOWN|2020-09-03|COINCIDENT|2020-09-20
e|RS|ea9c56ad-d69c-47c2-b486-65ce91e1f60d|3|STRUSTAT|Steroid Use Status|BLAZER COLORECTAL CANCER 2008|[?]|SUPPOSITORY|sCR|1|ug/cm2|ELLA||Y||SPOUSE|READER 1|NA|2|Visit_2|25|7|SCREENING|2020-07-17|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-26|P1Y2M10DT2H30M|BEFORE|2020-07-06|ONGOING|2020-09-04
e|RS|ea9c56ad-d69c-47c2-b486-65ce91e1f60d|4|BMIVLIND|Bone Marrow Involvement Indicator|RECIST 1.0|[?]|10^9 organisms|NOT ALL EVALUATED|1|SYRINGE|MECHANICAL CLOT DETECTION||Y||VENDOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|2|Visit_2|25|2|WASHOUT|2020-07-17|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-26|P1Y2M10DT2H30M|COINCIDENT|2020-06-30|COINCIDENT|2020-09-28
e|RS|ea9c56ad-d69c-47c2-b486-65ce91e1f60d|5|BESTRESP|Best Overall Response|HAMAOKA BREAST CANCER 2010|||UNFAVORABLE RESPONSE|1|PACK|DARK FIELD MICROSCOPY|||Y|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|U|3|Visit_3|40|5|TREATMENT|2020-08-01|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-21|P1Y2M10DT2H30M|COINCIDENT|2020-08-27|BEFORE|2020-09-05
e|RS|ea9c56ad-d69c-47c2-b486-65ce91e1f60d|6|HEMARESP|Hematologic Response|WHO BREAST CANCER 2006|[?]|mEq/L|MRD NEGATIVITY|1|VIRTUAL PIXEL|AUSCULTATION||||HEALTH CARE PROFESSIONAL|RATER 1|N|3|Visit_3|40|2|WASHOUT|2020-08-01|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-21|P1Y2M10DT2H30M|COINCIDENT|2020-06-27|BEFORE|2020-09-27
e|RS|ea9c56ad-d69c-47c2-b486-65ce91e1f60d|7|NTRGRESP|Non-target Response|AJCC V7|[?]|g/g|MOLECULAR CR|1|mEq/L|DNA MICROARRAY||||STUDY SUBJECT|RATER 1|NA|4|Visit_4|65|5|TREATMENT|2020-08-26|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-06|P1Y2M10DT2H30M|UNKNOWN|2020-08-23|ONGOING|2020-09-15
e|RS|ea9c56ad-d69c-47c2-b486-65ce91e1f60d|8|NTNERESP|Non-Target Non-Enhancing Response|MRANO VAN DEN BENT GLIOMA 2011|||IMMUNOPHENOTYPIC CR|1|mOsm/L|LISSAMINE GREEN STAIN|||Y|PROXY|ADJUDICATOR 3|U|4|Visit_4|65|3|TREATMENT|2020-08-26|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-06|P1Y2M10DT2H30M|BEFORE|2020-07-16|BEFORE|2020-07-17
e|RS|ea9c56ad-d69c-47c2-b486-65ce91e1f60d|9|NEWLWIND|New Lesion Worsening Indicator|LEE LUNG CANCER 2011|[?]|mL/m2|PDu|1|uCi/kg|GRAM STAIN||||CLINICAL STUDY SPONSOR|PATHOLOGIST 2|N|5|Visit_5|90|5|TREATMENT|2020-09-20|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-13|P1Y2M10DT2H30M|UNKNOWN|2020-09-14|COINCIDENT|2020-09-19
e|RS|ea9c56ad-d69c-47c2-b486-65ce91e1f60d|10|CYTORESP|Cytogenetic Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|m2|RELAPSED DISEASE|1|s*kPa|ERGOSPIROMETRY||||ADJUDICATOR|READER 3|NA|5|Visit_5|90|3|FOLLOW-UP|2020-09-20|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-13|P1Y2M10DT2H30M|UNKNOWN|2020-08-29|AFTER|2020-09-08
e|RS|b832144e-88c4-4ad6-b173-abac7802a36c|1|PATHRESP|Pathologic Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|10^4/hpf|MORPHOLOGIC LEUKEMIA-FREE STATE|1|mol/g|ELECTROPHORESIS||||FRIEND|DEVELOPMENTAL PSYCHOLOGIST|NA|1|Visit_1|10|4|TREATMENT|2021-01-14|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-23|P1Y2M10DT2H30M|BEFORE|2021-01-26|COINCIDENT|2021-03-16
e|RS|b832144e-88c4-4ad6-b173-abac7802a36c|2|PATHRESP|Pathologic Response|GUILHOT CML 2007|[?]|L/min|HI-E|1|Bq/mL|HILLMEN COLOR CHART|Y|Y||INTERVIEWER|OTOLARYNGOLOGIST|NA|1|Visit_1|10|6|TREATMENT|2021-01-14|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-23|P1Y2M10DT2H30M|UNKNOWN|2021-03-01|BEFORE|2021-04-06
e|RS|b832144e-88c4-4ad6-b173-abac7802a36c|3|NEWLPROG|New Lesion Progression|EASL BRUIX LIVER CANCER 2001|||CYTOGENETIC PR|1|kHz|GRAM STAIN|Y||Y|DOMESTIC PARTNER|DERMATOLOGIST|N|2|Visit_2|25|2|TREATMENT|2021-01-29|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-17|P1Y2M10DT2H30M|AFTER|2021-04-06|BEFORE|2021-04-07
e|RS|b832144e-88c4-4ad6-b173-abac7802a36c|4|STRUSTAT|Steroid Use Status|FAROOQUI SUPP CLL 2014|[?]|g/m2|CA125 50% RESPONSE|1|/mm2|PERCUSSION||||SPOUSE|HEMATOLOGIST|U|2|Visit_2|25|7|TREATMENT|2021-01-29|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-17|P1Y2M10DT2H30M|UNKNOWN|2021-01-09|AFTER|2021-04-05
e|RS|b832144e-88c4-4ad6-b173-abac7802a36c|5|BMIVLIND|Bone Marrow Involvement Indicator|EBMT BLADE MYELOMA 1998|||iUPD|1|U/dL|PET/CT SCAN|||Y|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST|N|3|Visit_3|40|2|TREATMENT|2021-02-13|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-18|P1Y2M10DT2H30M|AFTER|2021-03-12|ONGOING|2021-03-28
e|RS|b832144e-88c4-4ad6-b173-abac7802a36c|6|NEWLWIND|New Lesion Worsening Indicator|PRINCE TCELL LYMPHOMA 2010|[?]|ug/min|MORPHOLOGIC CR|1|kUSP|MRI||||CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST|N|3|Visit_3|40|1|TREATMENT|2021-02-13|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-18|P1Y2M10DT2H30M|AFTER|2021-04-01|COINCIDENT|2021-04-13
e|RS|b832144e-88c4-4ad6-b173-abac7802a36c|7|MOLRESP|Molecular Response|MASS|[?]|fraction of 1|iUPD|1|pmol/L|FLUORIMETRY|Y|||FAMILY MEMBER|CLINICAL PATHOLOGIST|N|4|Visit_4|65|3|TREATMENT|2021-03-10|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-28|P1Y2M10DT2H30M|UNKNOWN|2021-01-15|BEFORE|2021-02-04
e|RS|b832144e-88c4-4ad6-b173-abac7802a36c|8|OVRLRESP|Overall Response|EASL BRUIX LIVER CANCER 2001|[?]|ngEq/L|NON-QUANTIFIABLE MRD POSITIVITY|1|PELLET|COMPUTERIZED CORNEAL TOPOGRAPHY|Y|Y||ADJUDICATOR|CARDIOLOGIST|N|4|Visit_4|65|1|FOLLOW-UP|2021-03-10|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-28|P1Y2M10DT2H30M|COINCIDENT|2021-02-22|COINCIDENT|2021-04-13
e|RS|b832144e-88c4-4ad6-b173-abac7802a36c|9|MNPTHIND|Minor Pathological Response Indicator|WHO BREAST CANCER 2006|||NED|1|10^6 CFU/g|ELISA|Y|Y|Y|HEALTH CARE PROFESSIONAL|DERMATOLOGIST|NA|5|Visit_5|90|4|TREATMENT|2021-04-04|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-18|P1Y2M10DT2H30M|COINCIDENT|2021-03-09|ONGOING|2021-04-01
e|RS|b832144e-88c4-4ad6-b173-abac7802a36c|10|TRGRESP|Target Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|BAU/mL|SD-CT|1|mm2|SLOAN LETTER EYE CHART 100%||||FAMILY MEMBER|READER|N|5|Visit_5|90|6|TREATMENT|2021-04-04|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-18|P1Y2M10DT2H30M|BEFORE|2021-01-10|BEFORE|2021-02-01
e|RS|6acacd87-c487-401c-8888-76ccf97b640d|1|NEWLPROG|New Lesion Progression|GUPPY OVARIAN CANCER 2002|[?]|10^4/L|MORPHOLOGIC LEUKEMIA-FREE STATE|1|U/m2/day|GIEMSA STAIN||||SPOUSE|READER 1|N|1|Visit_1|10|5|TREATMENT|2020-05-25|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-07|P1Y2M10DT2H30M|COINCIDENT|2020-07-13|AFTER|2020-08-09
e|RS|6acacd87-c487-401c-8888-76ccf97b640d|2|HEMARESP|Hematologic Response|CHESON CLL 2006|||MORPHOLOGIC CRi|1|L/day|AGAR PROPORTION|||Y|FAMILY MEMBER|ADJUDICATOR 3|NA|1|Visit_1|10|5|TREATMENT|2020-05-25|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-07|P1Y2M10DT2H30M|UNKNOWN|2020-06-16|ONGOING|2020-07-13
e|RS|6acacd87-c487-401c-8888-76ccf97b640d|3|SYMPTDTR|Symptomatic Deterioration|KEAM BREAST CANCER 2013|||PR|1|/500 WBC|THERMAL IONIZATION MASS SPECTROMETRY||Y|Y|NON-HEALTH CARE PROFESSIONAL|READER|Y|2|Visit_2|25|5|FOLLOW-UP|2020-06-09|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-28|P1Y2M10DT2H30M|UNKNOWN|2020-07-23|AFTER|2020-08-18
e|RS|6acacd87-c487-401c-8888-76ccf97b640d|4|MRPHRESP|Morphologic Response|JACINTO CERVICAL CANCER 2007|||IMPROVED|1|um/day|DROPLET DIGITAL PCR||Y|Y|ADJUDICATOR|OPTOMETRIST|Y|2|Visit_2|25|2|TREATMENT|2020-06-09|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-28|P1Y2M10DT2H30M|COINCIDENT|2020-08-22|AFTER|2020-08-23
e|RS|6acacd87-c487-401c-8888-76ccf97b640d|5|OVRLRESP|Overall Response|PETIT BREAST CANCER 2001|[?]|U/mmol|RELAPSED DISEASE FROM CR|1|amu|REVERSE TRANSCRIPTASE PCR|Y|||INVESTIGATOR|NEUROLOGIST 2|NA|3|Visit_3|40|7|TREATMENT|2020-06-24|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-03|P1Y2M10DT2H30M|COINCIDENT|2020-05-31|COINCIDENT|2020-07-05
e|RS|6acacd87-c487-401c-8888-76ccf97b640d|6|HEMARESP|Hematologic Response|GUPPY OVARIAN CANCER 2002|[?]|mmol/min/kPa/L|WORSENED|1|Ci/uL|MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY||||CLINICAL RESEARCH ASSOCIATE|PEDIATRIC NEUROLOGIST|U|3|Visit_3|40|1|SCREENING|2020-06-24|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-03|P1Y2M10DT2H30M|UNKNOWN|2020-08-18|ONGOING|2020-08-21
e|RS|6acacd87-c487-401c-8888-76ccf97b640d|7|NEWLPROG|New Lesion Progression|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|ag|CR|1|mEq/mmol|OLIGO ACGH|Y|Y||SIGNIFICANT OTHER|RADIOLOGIST 1|U|4|Visit_4|65|4|TREATMENT|2020-07-19|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-20|P1Y2M10DT2H30M|UNKNOWN|2020-05-20|BEFORE|2020-07-01
e|RS|6acacd87-c487-401c-8888-76ccf97b640d|8|SPLNRESP|Spleen Response|PETIT BREAST CANCER 2001|[?]|BOTTLE|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|U/animal|PERIPHERAL ANGIOGRAPHY||||ADJUDICATOR|READER|N|4|Visit_4|65|1|TREATMENT|2020-07-19|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-20|P1Y2M10DT2H30M|BEFORE|2020-08-10|ONGOING|2020-08-13
e|RS|6acacd87-c487-401c-8888-76ccf97b640d|9|METBRESP|Metabolic Response|EASL BRUIX LIVER CANCER 2001|||HI-P|1|mL/mmHg/min/L|PLAQUE REDUCTION NEUTRALIZATION ASSAY|||Y|CLINICAL STUDY SPONSOR|READER 1|NA|5|Visit_5|90|7|TREATMENT|2020-08-13|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-09|P1Y2M10DT2H30M|AFTER|2020-07-24|AFTER|2020-08-09
e|RS|6acacd87-c487-401c-8888-76ccf97b640d|10|METSIND|Metastatic Indicator|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|h/wk|MORPHOLOGIC CR|1|10^3 CFU/g|PHASE-CONTRAST MRI||||CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 1|Y|5|Visit_5|90|1|WASHOUT|2020-08-13|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-09|P1Y2M10DT2H30M|UNKNOWN|2020-05-20|ONGOING|2020-05-24
e|RS|3e9b342f-56c3-45cb-9b9f-5b6e5f555bdf|1|MRDRESP|Minimal Residual Disease Response|JACINTO CERVICAL CANCER 2007|[?]|BAU|SD-CT|1|m/sec|ELASTOGRAPHY||Y||ADJUDICATOR|OTOLARYNGOLOGIST|NA|1|Visit_1|10|5|FOLLOW-UP|2020-07-16|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-01|P1Y2M10DT2H30M|AFTER|2020-07-16|AFTER|2020-08-23
e|RS|3e9b342f-56c3-45cb-9b9f-5b6e5f555bdf|2|NTLWIND|Non-Target Lesion Worsening Indicator|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|kat|CYTOGENETIC CR|1|g|TOTAL BODY IRRADIATION||||HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|U|1|Visit_1|10|4|TREATMENT|2020-07-16|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-01|P1Y2M10DT2H30M|AFTER|2020-08-25|AFTER|2020-10-08
e|RS|3e9b342f-56c3-45cb-9b9f-5b6e5f555bdf|3|BMIVLIND|Bone Marrow Involvement Indicator|PROTOCOL DEFINED RESPONSE CRITERIA|||RELAPSED DISEASE FROM CR OR PR|1|Pack Year|SPIRAL CT|Y||Y|CLINICAL RESEARCH COORDINATOR|OPTOMETRIST|NA|2|Visit_2|25|5|WASHOUT|2020-07-31|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-28|P1Y2M10DT2H30M|UNKNOWN|2020-07-31|BEFORE|2020-09-09
e|RS|3e9b342f-56c3-45cb-9b9f-5b6e5f555bdf|4|HEMARESP|Hematologic Response|BLAZER COLORECTAL CANCER 2008|[?]|m2|HI-E|1|mEq/mmol|FLUORESCENT LIFETIME IMAGING MICROSCOPY||||PROXY|ENDOCRINOLOGIST|U|2|Visit_2|25|3|FOLLOW-UP|2020-07-31|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-28|P1Y2M10DT2H30M|BEFORE|2020-07-23|AFTER|2020-10-08
e|RS|3e9b342f-56c3-45cb-9b9f-5b6e5f555bdf|5|MNPTHIND|Minor Pathological Response Indicator|EASL BRUIX LIVER CANCER 2001|[?]|Bq/mg|VGPR|1|kat|MAPH||||PARENT|CARDIOLOGIST|Y|3|Visit_3|40|3|SCREENING|2020-08-15|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-25|P1Y2M10DT2H30M|BEFORE|2020-07-27|BEFORE|2020-07-30
e|RS|3e9b342f-56c3-45cb-9b9f-5b6e5f555bdf|6|METSIND|Metastatic Indicator|MRECIST LENCIONI LIVER CANCER 2010|||CR|1|U/dL|AMSLER GRID|||Y|PARENT|OPTOMETRIST|U|3|Visit_3|40|2|SCREENING|2020-08-15|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-25|P1Y2M10DT2H30M|AFTER|2020-10-08|BEFORE|2020-10-10
e|RS|3e9b342f-56c3-45cb-9b9f-5b6e5f555bdf|7|MNPTHIND|Minor Pathological Response Indicator|NCIWG CHESON CLL 1996|[?]|GBq/ug|mCR|1|ukat/10^12 RBC|CONTACT SPECULAR MICROSCOPY||||SPOUSE|RADIOLOGIST 2|NA|4|Visit_4|65|3|TREATMENT|2020-09-09|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-26|P1Y2M10DT2H30M|UNKNOWN|2020-07-22|ONGOING|2020-08-07
e|RS|3e9b342f-56c3-45cb-9b9f-5b6e5f555bdf|8|NTLWIND|Non-Target Lesion Worsening Indicator|SHINDOH COLORECTAL CANCER 2013|||sCR|1|JAR|HPLC|||Y|ADJUDICATION COMMITTEE|PATHOLOGIST 2|NA|4|Visit_4|65|7|WASHOUT|2020-09-09|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-26|P1Y2M10DT2H30M|BEFORE|2020-09-15|AFTER|2020-09-19
e|RS|3e9b342f-56c3-45cb-9b9f-5b6e5f555bdf|9|MRDIND|Minimal Residual Disease Indicator|RANO|[?]|mmol/day|MRD RELAPSE|1|copies/uL|STRESS ECHOCARDIOGRAPHY||Y||INTERVIEWER|ADJUDICATOR|N|5|Visit_5|90|7|TREATMENT|2020-10-04|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-29|P1Y2M10DT2H30M|UNKNOWN|2020-09-21|BEFORE|2020-09-29
e|RS|3e9b342f-56c3-45cb-9b9f-5b6e5f555bdf|10|METSIND|Metastatic Indicator|IWG CHESON MDS 2006|[?]|msec|pCR|1|g/g/day|PHOTOMETRIC CLOT DETECTION||||CHILD|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5|Visit_5|90|3|TREATMENT|2020-10-04|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-29|P1Y2M10DT2H30M|AFTER|2020-07-08|BEFORE|2020-07-18
e|RS|73988e01-56c0-4b31-84e2-c23ce0bac5ac|1|TMRESP|Tumor Marker Response|BURCOMBE BREAST CANCER 2005|[?]|deg2|STABLE|1|10^7 CFU/mL|OLIGO ACGH|Y|Y||SIGNIFICANT OTHER|UROLOGIST|Y|1|Visit_1|10|3|TREATMENT|2021-01-03|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-18|P1Y2M10DT2H30M|AFTER|2021-03-17|AFTER|2021-03-31
e|RS|73988e01-56c0-4b31-84e2-c23ce0bac5ac|2|MRDRESP|Minimal Residual Disease Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|km|CYTOGENETIC CR|1|mL/kg/min|MAPH||||INTERVIEWER|CLINICAL PATHOLOGIST|U|1|Visit_1|10|5|WASHOUT|2021-01-03|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-18|P1Y2M10DT2H30M|COINCIDENT|2021-01-01|COINCIDENT|2021-01-24
e|RS|73988e01-56c0-4b31-84e2-c23ce0bac5ac|3|LIVRRESP|Liver Response|MASS|[?]|mU|EQUIVOCAL|1|nmol/day|TWO-COLOR MICROARRAY||||SIGNIFICANT OTHER|DEVELOPMENTAL PSYCHOLOGIST|NA|2|Visit_2|25|2|TREATMENT|2021-01-18|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-24|P1Y2M10DT2H30M|BEFORE|2021-03-03|AFTER|2021-03-13
e|RS|73988e01-56c0-4b31-84e2-c23ce0bac5ac|4|CYTORESP|Cytogenetic Response|KUMAR IMWG 2016|||ABSENT MORPHOLOGIC RESPONSE|1|yd|MOUSE PROTECTION ASSAY|Y|Y|Y|GUARDIAN|ADJUDICATOR 3|NA|2|Visit_2|25|3|TREATMENT|2021-01-18|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-24|P1Y2M10DT2H30M|COINCIDENT|2021-03-28|BEFORE|2021-03-30
e|RS|73988e01-56c0-4b31-84e2-c23ce0bac5ac|5|OVRLRESP|Overall Response|MASS|[?]|dmol|PR|1|KALLIKREIN INHIBITOR UNIT|TARGETED GENOME SEQUENCING||||CAREGIVER|MICROSCOPIST 2|Y|3|Visit_3|40|5|SCREENING|2021-02-02|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-26|P1Y2M10DT2H30M|COINCIDENT|2021-03-27|BEFORE|2021-04-02
e|RS|73988e01-56c0-4b31-84e2-c23ce0bac5ac|6|NTLWIND|Non-Target Lesion Worsening Indicator|MRECIST BYRNE MESOTHELIOMA 2004|[?]|BOTTLE|PMD|1|log10 CCID 50/dose|MYELOPEROXIDASE STAIN||||PROXY|PATHOLOGIST 1|NA|3|Visit_3|40|5|TREATMENT|2021-02-02|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-26|P1Y2M10DT2H30M|AFTER|2021-01-24|AFTER|2021-02-13
e|RS|73988e01-56c0-4b31-84e2-c23ce0bac5ac|7|BONERESP|Bone Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|IU/g Hb|STABLE|1|ugEq|SIZE EXCLUSION CHROMATOGRAPHY|Y|||HEALTH CARE PROFESSIONAL|MICROSCOPIST|N|4|Visit_4|65|2|WASHOUT|2021-02-27|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-01|P1Y2M10DT2H30M|BEFORE|2021-01-20|ONGOING|2021-02-11
e|RS|73988e01-56c0-4b31-84e2-c23ce0bac5ac|8|CPRFSTAT|Clinical Performance Status|MONTSERRAT CLL 1989|[?]|cal|SMD|1|in2|HEMATOXYLIN AND EOSIN STAIN||||CLINICAL RESEARCH ASSOCIATE|READER 3|NA|4|Visit_4|65|6|SCREENING|2021-02-27|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-01|P1Y2M10DT2H30M|COINCIDENT|2021-03-12|BEFORE|2021-03-21
e|RS|73988e01-56c0-4b31-84e2-c23ce0bac5ac|9|STRUSTAT|Steroid Use Status|BRUGGEMANN MRD 2010|[?]|Absorbance U/mL|QUANTIFIABLE MRD POSITIVITY|1|mm/sec|PET/CT SCAN||||CHILD|RADIOLOGIST 1|Y|5|Visit_5|90|7|TREATMENT|2021-03-24|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-26|P1Y2M10DT2H30M|COINCIDENT|2021-03-26|COINCIDENT|2021-04-02
e|RS|73988e01-56c0-4b31-84e2-c23ce0bac5ac|10|BMIVLIND|Bone Marrow Involvement Indicator|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|||CYTOGENETIC MINOR RESPONSE|1|ELISA unit/mL|MECHANICAL CLOT DETECTION||Y|Y|CHILD|ENDOCRINOLOGIST|U|5|Visit_5|90|5|FOLLOW-UP|2021-03-24|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-26|P1Y2M10DT2H30M|UNKNOWN|2020-12-28|BEFORE|2021-01-04
e|RS|0670f6a3-18c9-4027-91c1-56f5555589a8|1|BONERESP|Bone Response|IWG CHESON AML 2003|[?]|cL|sCR|1|psi|HPLC/MS||||INTERVIEWER|READER 1|NA|1|Visit_1|10|6|FOLLOW-UP|2020-05-13|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-07|P1Y2M10DT2H30M|AFTER|2020-07-27|COINCIDENT|2020-07-31
e|RS|0670f6a3-18c9-4027-91c1-56f5555589a8|2|NTNERESP|Non-Target Non-Enhancing Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|aMFI|DECREASED|1|/HPF|MICRO BROTH DILUTION|Y|||ADJUDICATION COMMITTEE|DERMATOLOGIST|N|1|Visit_1|10|3|SCREENING|2020-05-13|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-07|P1Y2M10DT2H30M|UNKNOWN|2020-06-09|COINCIDENT|2020-07-30
e|RS|0670f6a3-18c9-4027-91c1-56f5555589a8|3|CYTORESP|Cytogenetic Response|RAJKUMAR MYELOMA 2011|[?]|Gy/h|TREATMENT FAILURE|1|pL|FREEZING POINT DEPRESSION||||STUDY SUBJECT|RADIOLOGIST|Y|2|Visit_2|25|2|WASHOUT|2020-05-28|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-09|P1Y2M10DT2H30M|BEFORE|2020-05-17|AFTER|2020-07-31
e|RS|0670f6a3-18c9-4027-91c1-56f5555589a8|4|NEWLWIND|New Lesion Worsening Indicator|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|Weber|MINOR PATHOLOGIC RESPONSE|1|uV*sec|CONTRAST ENHANCED MRI|Y|Y||CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|2|Visit_2|25|3|TREATMENT|2020-05-28|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-09|P1Y2M10DT2H30M|COINCIDENT|2020-07-28|BEFORE|2020-08-05
e|RS|0670f6a3-18c9-4027-91c1-56f5555589a8|5|BESTRESP|Best Overall Response|PERCIST|[?]|ngEq/L|EQUIVOCAL|1|scm|PELLI-ROBSON EYE CHART|Y|||DOMESTIC PARTNER|NEUROLOGIST|Y|3|Visit_3|40|3|WASHOUT|2020-06-12|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-21|P1Y2M10DT2H30M|BEFORE|2020-07-17|AFTER|2020-07-21
e|RS|0670f6a3-18c9-4027-91c1-56f5555589a8|6|LIVRRESP|Liver Response|WOLCHOK SOLID TUMORS 2009|[?]|HOMEOPATHIC DILUTION|HI-P|1|ppm|POPULATION SEQUENCING||||FRIEND|ADJUDICATOR 2|N|3|Visit_3|40|2|SCREENING|2020-06-12|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-21|P1Y2M10DT2H30M|COINCIDENT|2020-08-08|AFTER|2020-08-09
e|RS|0670f6a3-18c9-4027-91c1-56f5555589a8|7|CPRFSTAT|Clinical Performance Status|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|PACKAGE|INCREASED|1|BP|ARTERIAL SPIN LABELING FUNCTIONAL MRI|Y|||FAMILY MEMBER|RADIOLOGIST 1|N|4|Visit_4|65|5|TREATMENT|2020-07-07|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-09|P1Y2M10DT2H30M|AFTER|2020-05-14|COINCIDENT|2020-07-26
e|RS|0670f6a3-18c9-4027-91c1-56f5555589a8|8|MOLRESP|Molecular Response|UNSPECIFIED|[?]|ELISA unit/mL|PD FROM PR|1|Enzyme U/L|SLIT LAMP PHOTOGRAPHY||Y||SIGNIFICANT OTHER|OPTOMETRIST|Y|4|Visit_4|65|5|WASHOUT|2020-07-07|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-09|P1Y2M10DT2H30M|UNKNOWN|2020-06-13|AFTER|2020-07-02
e|RS|0670f6a3-18c9-4027-91c1-56f5555589a8|9|NTERESP|Non-Target Enhancing Response|FAROOQUI SUPP CLL 2014|[?]|Bq/g|UNEQUIVOCAL|1|Weber|PET/SPECT SCAN||Y||CLINICAL STUDY SPONSOR|PHYSIOTHERAPIST|N|5|Visit_5|90|5|SCREENING|2020-08-01|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-10|P1Y2M10DT2H30M|BEFORE|2020-05-21|AFTER|2020-07-27
e|RS|0670f6a3-18c9-4027-91c1-56f5555589a8|10|CLINRESP|Clinical Response|RECIST 1.0|[?]|nkat/L|PDu|1|ug/m2|MYELOPEROXIDASE STAIN|Y|||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 2|N|5|Visit_5|90|6|SCREENING|2020-08-01|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-10|P1Y2M10DT2H30M|AFTER|2020-06-22|ONGOING|2020-07-15
e|RS|59179734-8784-4a88-aa6b-51b6082ffc1b|1|NTLWIND|Non-Target Lesion Worsening Indicator|SCHER PROSTATE CANCER 2011|[?]|ug/kg/h|iCR|1|g/cage/day|DOPPLER ULTRASOUND||||VENDOR|RATER|Y|1|Visit_1|10|3|TREATMENT|2020-08-11|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-21|P1Y2M10DT2H30M|BEFORE|2020-08-20|COINCIDENT|2020-10-04
e|RS|59179734-8784-4a88-aa6b-51b6082ffc1b|2|ANATRESP|Anatomic Response|CHOLLET BREAST CANCER 2002|||PDu|1|DNA copies/mL|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION|Y||Y|STUDY SUBJECT|OTOLARYNGOLOGIST|NA|1|Visit_1|10|5|FOLLOW-UP|2020-08-11|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-21|P1Y2M10DT2H30M|AFTER|2020-09-18|BEFORE|2020-10-23
e|RS|59179734-8784-4a88-aa6b-51b6082ffc1b|3|MNPTHIND|Minor Pathological Response Indicator|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|ohm|CMR|1|mg/h|TONOMETRY||||CLINICAL RESEARCH COORDINATOR|READER 1|NA|2|Visit_2|25|4|TREATMENT|2020-08-26|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-13|P1Y2M10DT2H30M|COINCIDENT|2020-10-08|ONGOING|2020-10-27
e|RS|59179734-8784-4a88-aa6b-51b6082ffc1b|4|NTRGRESP|Non-target Response|MONTSERRAT CLL 1989|[?]|POINT|iPR|1|tuberculin unit/mL|TONOMETRY|Y|||CHILD|RADIOLOGIST 2|U|2|Visit_2|25|1|TREATMENT|2020-08-26|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-13|P1Y2M10DT2H30M|COINCIDENT|2020-09-06|COINCIDENT|2020-09-20
e|RS|59179734-8784-4a88-aa6b-51b6082ffc1b|5|MRDIND|Minimal Residual Disease Indicator|GUILHOT CML 2007|[?]|10^6 CFU/mL|NED|1|cal|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION||Y||CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 2|Y|3|Visit_3|40|5|SCREENING|2020-09-10|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-15|P1Y2M10DT2H30M|BEFORE|2020-09-09|ONGOING|2020-10-26
e|RS|59179734-8784-4a88-aa6b-51b6082ffc1b|6|CPRFSTAT|Clinical Performance Status|SACT|||iSD|1|COAT|CONTRAST ENHANCED CT SCAN|||Y|CLINICAL RESEARCH COORDINATOR|READER 3|Y|3|Visit_3|40|3|SCREENING|2020-09-10|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-15|P1Y2M10DT2H30M|UNKNOWN|2020-10-04|COINCIDENT|2020-11-06
e|RS|59179734-8784-4a88-aa6b-51b6082ffc1b|7|ANATRESP|Anatomic Response|KUMAR IMWG 2016|[?]|cy/cm|cCR|1|10^4/hpf|NUCLEIC ACID HYBRIDIZATION||||INVESTIGATOR|PATHOLOGIST|U|4|Visit_4|65|2|TREATMENT|2020-10-05|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-04|P1Y2M10DT2H30M|BEFORE|2020-09-17|AFTER|2020-10-12
e|RS|59179734-8784-4a88-aa6b-51b6082ffc1b|8|NEWLIND|New Lesion Indicator|IRANO 2015|[?]|/2000 RBC|MORPHOLOGIC CR|1|APPLICATION|FLUORESCENCE ANGIOGRAPHY||||HEALTH CARE PROFESSIONAL|OPTOMETRIST|Y|4|Visit_4|65|5|TREATMENT|2020-10-05|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-04|P1Y2M10DT2H30M|UNKNOWN|2020-11-08|COINCIDENT|2020-11-09
e|RS|59179734-8784-4a88-aa6b-51b6082ffc1b|9|CYTORESP|Cytogenetic Response|RAJKUMAR MYELOMA 2011|[?]|pmol/g|RELAPSED DISEASE FROM CR|1|%/s|SPECT/CT SCAN|Y|Y||SIGNIFICANT OTHER|MICROSCOPIST 3|NA|5|Visit_5|90|1|TREATMENT|2020-10-30|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-07|P1Y2M10DT2H30M|UNKNOWN|2020-10-15|COINCIDENT|2020-11-03
e|RS|59179734-8784-4a88-aa6b-51b6082ffc1b|10|OVRLRESP|Overall Response|CHESON CLL 2006|[?]|mN|UNEQUIVOCAL|1|umol/L/sec|CORONARY ANGIOGRAPHY||Y||DOMESTIC PARTNER|RATER 2|U|5|Visit_5|90|2|FOLLOW-UP|2020-10-30|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-07|P1Y2M10DT2H30M|UNKNOWN|2020-11-05|ONGOING|2020-11-08
e|RS|ef21c401-3b32-478b-9a7d-e25ccc3e3c60|1|NTRGRESP|Non-target Response|RECIST 1.0|[?]|gtt|UNEQUIVOCAL|1|L/s/kPa|PULSE OXIMETRY|Y|||CHILD|MICROSCOPIST|U|1|Visit_1|10|5|TREATMENT|2020-08-22|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-16|P1Y2M10DT2H30M|BEFORE|2020-09-11|BEFORE|2020-11-06
e|RS|ef21c401-3b32-478b-9a7d-e25ccc3e3c60|2|RDIORESP|Radiologic Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|/day|MINOR PATHOLOGIC RESPONSE|1|/day|STATIC PERIMETRY||Y||VENDOR|PATHOLOGIST 2|N|1|Visit_1|10|2|TREATMENT|2020-08-22|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-16|P1Y2M10DT2H30M|BEFORE|2020-10-30|COINCIDENT|2020-11-10
e|RS|ef21c401-3b32-478b-9a7d-e25ccc3e3c60|3|ANATRESP|Anatomic Response|HARTMAN PANCREATIC CANCER 2012|||MOLECULAR CR|1|s/h|MALDI-TOF||Y|Y|VENDOR|PATHOLOGIST 2|NA|2|Visit_2|25|3|WASHOUT|2020-09-06|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-04|P1Y2M10DT2H30M|COINCIDENT|2020-10-26|AFTER|2020-10-31
e|RS|ef21c401-3b32-478b-9a7d-e25ccc3e3c60|4|HEMARESP|Hematologic Response|MASS|[?]|mCi|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|log10 CFU/g|OSCILLOMETRY||||DOMESTIC PARTNER|PATHOLOGIST|NA|2|Visit_2|25|4|WASHOUT|2020-09-06|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-04|P1Y2M10DT2H30M|COINCIDENT|2020-10-21|BEFORE|2020-11-07
e|RS|ef21c401-3b32-478b-9a7d-e25ccc3e3c60|5|TMRESP|Tumor Marker Response|AJCC V7|[?]|ugEq|NE|1|/cmH2O|MRS||||HEALTH CARE PROFESSIONAL|PATHOLOGIST|NA|3|Visit_3|40|2|WASHOUT|2020-09-21|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-16|P1Y2M10DT2H30M|COINCIDENT|2020-08-23|AFTER|2020-11-10
e|RS|ef21c401-3b32-478b-9a7d-e25ccc3e3c60|6|NTNERESP|Non-Target Non-Enhancing Response|SCHER PROSTATE CANCER 2011|[?]|cm/min|IMMUNOPHENOTYPIC CR|1|pmol/10^9 cells|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY||||CLINICAL RESEARCH COORDINATOR|HEMATOLOGIST|N|3|Visit_3|40|3|TREATMENT|2020-09-21|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-16|P1Y2M10DT2H30M|BEFORE|2020-09-17|AFTER|2020-10-15
e|RS|ef21c401-3b32-478b-9a7d-e25ccc3e3c60|7|STRUSTAT|Steroid Use Status|IWG CHESON MDS 2006|[?]|cmH2O*s2/mL|IMPROVED|1|dyn|REAL-TIME POLYMERASE CHAIN REACTION ASSAY||||ADJUDICATOR|DERMATOLOGIST|NA|4|Visit_4|65|2|WASHOUT|2020-10-16|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-15|P1Y2M10DT2H30M|AFTER|2020-11-03|AFTER|2020-11-05
e|RS|ef21c401-3b32-478b-9a7d-e25ccc3e3c60|8|MNPTHIND|Minor Pathological Response Indicator|IWG CHESON MDS 2006|[?]|amp|NON-CR/NON-PD|1|mL|PLETHYSMOGRAPHY||Y||CAREGIVER|FORENSIC PATHOLOGIST|Y|4|Visit_4|65|5|WASHOUT|2020-10-16|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-15|P1Y2M10DT2H30M|AFTER|2020-11-08|AFTER|2020-11-09
e|RS|ef21c401-3b32-478b-9a7d-e25ccc3e3c60|9|MRPHRESP|Morphologic Response|CHESON CLL 2012|[?]|10^3 CFU/mL|NE|1|cm/s|LYMPHANGIOGRAPHY|Y|||CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST|Y|5|Visit_5|90|7|TREATMENT|2020-11-10|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-30|P1Y2M10DT2H30M|COINCIDENT|2020-10-06|AFTER|2020-11-13
e|RS|ef21c401-3b32-478b-9a7d-e25ccc3e3c60|10|LIVRRESP|Liver Response|CHESON CLL 2006|[?]|Frames/s|iCR|1|PFU/dose|QUANTITATIVE COMPUTED TOMOGRAPHY||Y||CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 1|N|5|Visit_5|90|3|SCREENING|2020-11-10|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-30|P1Y2M10DT2H30M|BEFORE|2020-09-03|COINCIDENT|2020-10-10
e|RS|01c642f8-48ef-4375-aa2b-d0940b74e580|1|SYMPTDTR|Symptomatic Deterioration|MACDONALD GLIOMA 1990|||NE|1|mL/cage/day|MODIFIED ACID FAST STAIN|||Y|CLINICAL STUDY SPONSOR|INTERNIST|Y|1|Visit_1|10|1|SCREENING|2020-09-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-26|P1Y2M10DT2H30M|COINCIDENT|2020-11-17|AFTER|2020-11-22
e|RS|01c642f8-48ef-4375-aa2b-d0940b74e580|2|STRUSTAT|Steroid Use Status|IWG CHESON MDS 2006|[?]|LB|PARTIAL MORPHOLOGIC RESPONSE|1|10^7/L|GC/MS-CI|Y|||INVESTIGATOR|OPTOMETRIST|N|1|Visit_1|10|6|SCREENING|2020-09-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-26|P1Y2M10DT2H30M|UNKNOWN|2020-10-24|COINCIDENT|2020-11-20
e|RS|01c642f8-48ef-4375-aa2b-d0940b74e580|3|NEWLWIND|New Lesion Worsening Indicator|SHINDOH COLORECTAL CANCER 2013|[?]|nmol/mL/min|NED|1|copies/ug|CINEANGIOGRAPHY||||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 1|N|2|Visit_2|25|3|FOLLOW-UP|2020-10-04|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-25|P1Y2M10DT2H30M|BEFORE|2020-12-14|BEFORE|2020-12-15
e|RS|01c642f8-48ef-4375-aa2b-d0940b74e580|4|MNPTHIND|Minor Pathological Response Indicator|RAJKUMAR MYELOMA 2011|[?]|mg/kg/dose|iUPD|1|PHERESIS UNIT|FLUORESCEIN STAIN||||CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 2|U|2|Visit_2|25|3|SCREENING|2020-10-04|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-25|P1Y2M10DT2H30M|AFTER|2020-10-21|AFTER|2020-10-23
e|RS|01c642f8-48ef-4375-aa2b-d0940b74e580|5|BONERESP|Bone Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|oz eq|iPR|1|BOX|HANSEL STAIN||||FAMILY MEMBER|READER 1|Y|3|Visit_3|40|5|SCREENING|2020-10-19|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-25|P1Y2M10DT2H30M|AFTER|2020-12-05|ONGOING|2020-12-08
e|RS|01c642f8-48ef-4375-aa2b-d0940b74e580|6|DRCRIND|Disease Recurrence Indicator|RANO ELLINGSON 2017|[?]|/LSQN|CRi|1|cmH2O*s/mL|COMPLEMENT FIXATION||||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 2|U|3|Visit_3|40|3|TREATMENT|2020-10-19|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-25|P1Y2M10DT2H30M|BEFORE|2020-09-14|COINCIDENT|2020-11-11
e|RS|01c642f8-48ef-4375-aa2b-d0940b74e580|7|NTRGRESP|Non-target Response|RAJKUMAR MYELOMA 2011|[?]|%(v/v)|PD FROM PR|1|IU/L|STRESS ECHOCARDIOGRAPHY||Y||SIGNIFICANT OTHER|OPHTHALMOLOGIST|NA|4|Visit_4|65|1|TREATMENT|2020-11-13|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-19|P1Y2M10DT2H30M|BEFORE|2020-09-24|ONGOING|2020-10-04
e|RS|01c642f8-48ef-4375-aa2b-d0940b74e580|8|MJPTHIND|Major Pathological Response Indicator|PCWG BUBLEY PROSTATE CANCER 1999|[?]|mU|NE|1|DIP|LIQUID SCINTILLATION COUNTING||||HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|N|4|Visit_4|65|4|WASHOUT|2020-11-13|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-19|P1Y2M10DT2H30M|UNKNOWN|2020-09-15|AFTER|2020-10-21
e|RS|01c642f8-48ef-4375-aa2b-d0940b74e580|9|SPLNRESP|Spleen Response|FAROOQUI SUPP CLL 2014|||MOLECULAR MAJOR RESPONSE|1|kg/cm2|LINE PROBE ASSAY|||Y|SIBLING|PEDIATRIC NEUROLOGIST|U|5|Visit_5|90|1|SCREENING|2020-12-08|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-25|P1Y2M10DT2H30M|COINCIDENT|2020-10-23|BEFORE|2020-12-05
e|RS|01c642f8-48ef-4375-aa2b-d0940b74e580|10|NEWLPROG|New Lesion Progression|MASS|||NON-QUANTIFIABLE MRD POSITIVITY|1|mol/mg|PET/SPECT SCAN|||Y|SIGNIFICANT OTHER|PHYSIOTHERAPIST|NA|5|Visit_5|90|3|TREATMENT|2020-12-08|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-25|P1Y2M10DT2H30M|COINCIDENT|2020-10-10|BEFORE|2020-10-29
e|RS|c0e7028c-6f5c-410a-afde-e56af2177983|1|RDIORESP|Radiologic Response|LEE LUNG CANCER 2011|[?]|mEq/L|IMMUNOPHENOTYPIC CR|1|BEAM BREAKS|MICROARRAY||||PROXY|ONCOLOGIST 2|Y|1|Visit_1|10|3|FOLLOW-UP|2020-07-06|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-06|P1Y2M10DT2H30M|UNKNOWN|2020-08-10|ONGOING|2020-08-18
e|RS|c0e7028c-6f5c-410a-afde-e56af2177983|2|NEWLIND|New Lesion Indicator|MACDONALD GLIOMA 1990|||CYTOGENETIC CR|1|amp|CONTRAST ENHANCED PET SCAN||Y|Y|DOMESTIC PARTNER|ONCOLOGIST|Y|1|Visit_1|10|1|SCREENING|2020-07-06|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-06|P1Y2M10DT2H30M|BEFORE|2020-08-26|COINCIDENT|2020-09-18
e|RS|c0e7028c-6f5c-410a-afde-e56af2177983|3|METBRESP|Metabolic Response|PCWG SCHER PROSTATE CANCER 2016|[?]|pL|EQUIVOCAL|1|breaths/30s|LC/MS||||VENDOR|READER 2|NA|2|Visit_2|25|6|TREATMENT|2020-07-21|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-13|P1Y2M10DT2H30M|UNKNOWN|2020-09-15|BEFORE|2020-09-21
e|RS|c0e7028c-6f5c-410a-afde-e56af2177983|4|MOLRESP|Molecular Response|EBMT BLADE MYELOMA 1998|[?]|kHz|CR|1|POINT|MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING||||CLINICAL STUDY SPONSOR|ONCOLOGIST 1|U|2|Visit_2|25|3|FOLLOW-UP|2020-07-21|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-13|P1Y2M10DT2H30M|AFTER|2020-07-13|ONGOING|2020-09-17
e|RS|c0e7028c-6f5c-410a-afde-e56af2177983|5|HEMARESP|Hematologic Response|KEAM BREAST CANCER 2013|[?]|Hz/s|MINOR PATHOLOGIC RESPONSE|1|fmol|HPLC/MS/MS||||FRIEND|PHYSIOTHERAPIST|U|3|Visit_3|40|1|TREATMENT|2020-08-05|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-07|P1Y2M10DT2H30M|BEFORE|2020-08-17|COINCIDENT|2020-09-25
e|RS|c0e7028c-6f5c-410a-afde-e56af2177983|6|SYMPTDTR|Symptomatic Deterioration|AJCC V7|||DECREASED|1|ug/m2/h|NUCLEAR RADIOLOGY|||Y|ADJUDICATOR|RATER 2|U|3|Visit_3|40|2|TREATMENT|2020-08-05|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-07|P1Y2M10DT2H30M|COINCIDENT|2020-07-24|AFTER|2020-09-05
e|RS|c0e7028c-6f5c-410a-afde-e56af2177983|7|MOLRESP|Molecular Response|SCHWARZ CERVICAL CANCER 2009|[?]|JDF Unit|sCR|1|mL/h|LANDOLT RING||||NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST|N|4|Visit_4|65|4|TREATMENT|2020-08-30|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-06|P1Y2M10DT2H30M|BEFORE|2020-07-10|BEFORE|2020-07-21
e|RS|c0e7028c-6f5c-410a-afde-e56af2177983|8|RDIORESP|Radiologic Response|FAROOQUI SUPP CLL 2014|[?]|cm2|pCR|1|mmHg/L/min|QUANTITATIVE PERIPHERAL ANGIOGRAPHY|Y|||FRIEND|PHYSIOTHERAPIST|U|4|Visit_4|65|5|SCREENING|2020-08-30|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-06|P1Y2M10DT2H30M|AFTER|2020-08-11|AFTER|2020-08-23
e|RS|c0e7028c-6f5c-410a-afde-e56af2177983|9|OVRLRESP|Overall Response|EASL BRUIX LIVER CANCER 2001|||iUPD|1|VIRTUAL PIXEL|SISH|||Y|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 2|Y|5|Visit_5|90|2|TREATMENT|2020-09-24|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-15|P1Y2M10DT2H30M|COINCIDENT|2020-09-02|ONGOING|2020-09-30
e|RS|c0e7028c-6f5c-410a-afde-e56af2177983|10|PATHRESP|Pathologic Response|CHESON LYMPHOMA 2008|[?]|mCi/L|SD|1|U/mmol|PULSE OXIMETRY||||HEALTH CARE PROFESSIONAL|READER 2|Y|5|Visit_5|90|6|FOLLOW-UP|2020-09-24|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-15|P1Y2M10DT2H30M|AFTER|2020-09-15|AFTER|2020-10-02
e|RS|eba928ed-9434-4e75-b49d-169298f966e1|1|TRGRESP|Target Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|mL*cmH2O|MOLECULAR CR|1|h*%|TRANSESOPHAGEAL ECHOCARDIOGRAPHY||||DOMESTIC PARTNER|RATER 2|Y|1|Visit_1|10|3|FOLLOW-UP|2020-08-12|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-15|P1Y2M10DT2H30M|UNKNOWN|2020-09-15|BEFORE|2020-10-02
e|RS|eba928ed-9434-4e75-b49d-169298f966e1|2|MRDIND|Minimal Residual Disease Indicator|MASS|||CMR|1|dB|MALDI-TOF|Y||Y|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|Y|1|Visit_1|10|6|SCREENING|2020-08-12|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-15|P1Y2M10DT2H30M|AFTER|2020-08-29|COINCIDENT|2020-09-03
e|RS|eba928ed-9434-4e75-b49d-169298f966e1|3|BESTRESP|Best Overall Response|PCWG SCHER PROSTATE CANCER 2008|[?]|MESF|NON-iCR/NON-iUPD|1|BOLUS|CARDIAC THERMODILUTION|Y|||FRIEND|MICROSCOPIST|U|2|Visit_2|25|1|SCREENING|2020-08-27|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-08|P1Y2M10DT2H30M|AFTER|2020-08-29|COINCIDENT|2020-09-10
e|RS|eba928ed-9434-4e75-b49d-169298f966e1|4|MRDIND|Minimal Residual Disease Indicator|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|mm/sec|PR-CT|1|10^3 copies/mL|PHOTOGRAPHY||||VENDOR|ADJUDICATOR 3|NA|2|Visit_2|25|6|FOLLOW-UP|2020-08-27|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-08|P1Y2M10DT2H30M|AFTER|2020-08-31|BEFORE|2020-09-27
e|RS|eba928ed-9434-4e75-b49d-169298f966e1|5|NTNERESP|Non-Target Non-Enhancing Response|WOLCHOK SOLID TUMORS 2009|[?]|mol/L|PMD|1|EIA unit|SICKLE CELL SOLUBILITY TEST||||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 1|N|3|Visit_3|40|6|FOLLOW-UP|2020-09-11|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-02|P1Y2M10DT2H30M|AFTER|2020-08-30|BEFORE|2020-10-27
e|RS|eba928ed-9434-4e75-b49d-169298f966e1|6|NTERESP|Non-Target Enhancing Response|HAMAOKA BREAST CANCER 2010|[?]|PACKAGE|RELAPSED DISEASE|1|in|OPTICAL COHERENCE TOMOGRAPHY|Y|Y||FAMILY MEMBER|DEVELOPMENTAL PSYCHOLOGIST|U|3|Visit_3|40|6|SCREENING|2020-09-11|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-02|P1Y2M10DT2H30M|AFTER|2020-09-02|AFTER|2020-09-28
e|RS|eba928ed-9434-4e75-b49d-169298f966e1|7|NTRGRESP|Non-target Response|CHESON LYMPHOMA 2008|[?]|mL/cage|INCREASED|1|kg/L|ENZYMATIC ULTRACENTRIFUGATION||||FAMILY MEMBER|ADJUDICATOR|NA|4|Visit_4|65|4|TREATMENT|2020-10-06|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-15|P1Y2M10DT2H30M|BEFORE|2020-08-19|ONGOING|2020-10-07
e|RS|eba928ed-9434-4e75-b49d-169298f966e1|8|BESTRESP|Best Overall Response|HAMAOKA BREAST CANCER 2010|[?]|10^9 organisms|iSD|1|mL/kg|MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY||Y||SPOUSE|NEUROLOGIST 2|Y|4|Visit_4|65|2|TREATMENT|2020-10-06|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-15|P1Y2M10DT2H30M|UNKNOWN|2020-10-15|BEFORE|2020-10-29
e|RS|eba928ed-9434-4e75-b49d-169298f966e1|9|NEWLIND|New Lesion Indicator|RANO|[?]|KALLIKREIN INHIBITOR UNIT|HI-P|1|C|ZIEHL NEELSEN ACID FAST STAIN||||FAMILY MEMBER|OPHTHALMOLOGIST|U|5|Visit_5|90|3|FOLLOW-UP|2020-10-31|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-08|P1Y2M10DT2H30M|UNKNOWN|2020-10-10|AFTER|2020-10-11
e|RS|eba928ed-9434-4e75-b49d-169298f966e1|10|METSIND|Metastatic Indicator|PALUMBO MULTIPLE MYELOMA 2009|[?]|g/cm2|PD/RELAPSE AFTER HI|1|umol/mg/min|MANUAL COUNT||||CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST|Y|5|Visit_5|90|1|TREATMENT|2020-10-31|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-08|P1Y2M10DT2H30M|AFTER|2020-08-15|AFTER|2020-10-23
e|RS|4772aa80-2097-4867-a549-b6f9b140f141|1|NTNERESP|Non-Target Non-Enhancing Response|RECICL|[?]|umol/kg/min|PR WITH LYMPHOCYTOSIS|1|APS U|ETDRS EYE CHART||||ADJUDICATION COMMITTEE|NEUROLOGIST|N|1|Visit_1|10|2|TREATMENT|2020-07-12|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-19|P1Y2M10DT2H30M|BEFORE|2020-10-04|COINCIDENT|2020-10-09
e|RS|4772aa80-2097-4867-a549-b6f9b140f141|2|MOLRESP|Molecular Response|LUGANO CLASSIFICATION|[?]|%/s|NON-PD|1|rpm|FUNCTIONAL MRI||Y||CLINICAL STUDY SPONSOR|PHYSIOTHERAPIST|Y|1|Visit_1|10|6|FOLLOW-UP|2020-07-12|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-19|P1Y2M10DT2H30M|BEFORE|2020-08-06|AFTER|2020-09-18
e|RS|4772aa80-2097-4867-a549-b6f9b140f141|3|TRGRESP|Target Response|HAMAOKA BREAST CANCER 2010|[?]|LB|NR|1|TRACE|SPIRAL CT|Y|||ADJUDICATOR|UROLOGIST|Y|2|Visit_2|25|4|TREATMENT|2020-07-27|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-16|P1Y2M10DT2H30M|AFTER|2020-10-02|COINCIDENT|2020-10-08
e|RS|4772aa80-2097-4867-a549-b6f9b140f141|4|MRDRESP|Minimal Residual Disease Response|DOHNER AML 2010|[?]|/kg|CYTOGENETIC MINOR RESPONSE|1|mm/min|WHOLE GENOME SEQUENCING||Y||PARENT|ONCOLOGIST|NA|2|Visit_2|25|4|TREATMENT|2020-07-27|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-16|P1Y2M10DT2H30M|COINCIDENT|2020-08-14|COINCIDENT|2020-09-29
e|RS|4772aa80-2097-4867-a549-b6f9b140f141|5|HEMARESP|Hematologic Response|SHINDOH COLORECTAL CANCER 2013|[?]|PACKAGE|MOLECULAR MAJOR RESPONSE|1|mL/beat|MODIFIED ACID FAST STAIN||||CHILD|RATER|U|3|Visit_3|40|4|SCREENING|2020-08-11|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-31|P1Y2M10DT2H30M|UNKNOWN|2020-08-14|BEFORE|2020-08-29
e|RS|4772aa80-2097-4867-a549-b6f9b140f141|6|METSIND|Metastatic Indicator|GUPPY OVARIAN CANCER 2002|||WORSENED|1|BOLUS|PHOTOMETRIC CLOT DETECTION|||Y|GUARDIAN|MICROSCOPIST 3|NA|3|Visit_3|40|3|TREATMENT|2020-08-11|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-31|P1Y2M10DT2H30M|BEFORE|2020-09-13|AFTER|2020-10-07
e|RS|4772aa80-2097-4867-a549-b6f9b140f141|7|MNPTHIND|Minor Pathological Response Indicator|MASS|[?]|fmol|DECREASED|1|g/g/day|CYSTOSCOPY||||CAREGIVER|FORENSIC PATHOLOGIST|U|4|Visit_4|65|2|SCREENING|2020-09-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-01|P1Y2M10DT2H30M|UNKNOWN|2020-07-24|AFTER|2020-08-08
e|RS|4772aa80-2097-4867-a549-b6f9b140f141|8|TRGRESP|Target Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|ppth|VGPR|1|log10 CFU/mL|COMPUTERIZED CORNEAL TOPOGRAPHY|Y|||SPOUSE|ONCOLOGIST 2|U|4|Visit_4|65|3|SCREENING|2020-09-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-01|P1Y2M10DT2H30M|BEFORE|2020-08-18|COINCIDENT|2020-09-03
e|RS|4772aa80-2097-4867-a549-b6f9b140f141|9|MNPTHIND|Minor Pathological Response Indicator|CHESON LYMPHOMA 2008|[?]|Antibody Unit|pCR|1|IU/mL|PYROSEQUENCING||||STUDY SUBJECT|READER 2|Y|5|Visit_5|90|6|TREATMENT|2020-09-30|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-30|P1Y2M10DT2H30M|BEFORE|2020-08-16|ONGOING|2020-09-23
e|RS|4772aa80-2097-4867-a549-b6f9b140f141|10|HEMARESP|Hematologic Response|IWG CHESON AML 2003|||CYTOGENETIC MINIMAL RESPONSE|1|mEq/ug|SICKLE CELL SOLUBILITY TEST|||Y|INTERVIEWER|READER|N|5|Visit_5|90|4|TREATMENT|2020-09-30|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-30|P1Y2M10DT2H30M|COINCIDENT|2020-07-11|ONGOING|2020-08-28
e|RS|74acb1a5-6dab-4b9e-ac7b-d242bdd44d26|1|NEWLIND|New Lesion Indicator|EBMT BLADE MYELOMA 1998|[?]|BP|CR-CT|1|VOXEL|BIOPSY||||SIGNIFICANT OTHER|OPHTHALMOLOGIST|N|1|Visit_1|10|1|TREATMENT|2020-06-07|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-11|P1Y2M10DT2H30M|AFTER|2020-06-10|BEFORE|2020-07-26
e|RS|74acb1a5-6dab-4b9e-ac7b-d242bdd44d26|2|BMIVLIND|Bone Marrow Involvement Indicator|KUMAR IMWG 2016|[?]|in|TREATMENT FAILURE|1|mmHg/sec|IN SITU HYBRIDIZATION|Y|||GUARDIAN|UROLOGIST|N|1|Visit_1|10|6|WASHOUT|2020-06-07|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-11|P1Y2M10DT2H30M|UNKNOWN|2020-08-06|BEFORE|2020-08-18
e|RS|74acb1a5-6dab-4b9e-ac7b-d242bdd44d26|3|BONERESP|Bone Response|CHOI GIST 2008|[?]|mol/mg|CR-CT|1|eq|RULER MEASUREMENT METHOD||||VENDOR|READER 1|N|2|Visit_2|25|2|WASHOUT|2020-06-22|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-20|P1Y2M10DT2H30M|AFTER|2020-06-05|BEFORE|2020-06-11
e|RS|74acb1a5-6dab-4b9e-ac7b-d242bdd44d26|4|LIVRRESP|Liver Response|KUKER LYMPHOMA 2005|[?]|ft|UNFAVORABLE RESPONSE|1|/2000 RBC|WHOLE GENOME SEQUENCING||||PROXY|INTERNIST|NA|2|Visit_2|25|3|WASHOUT|2020-06-22|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-20|P1Y2M10DT2H30M|AFTER|2020-08-10|AFTER|2020-08-30
e|RS|74acb1a5-6dab-4b9e-ac7b-d242bdd44d26|5|STRUSTAT|Steroid Use Status|KUKER LYMPHOMA 2005|[?]|pmol/day|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|100 IU/mL|NUCLEIC ACID AMPLIFICATION TEST|Y|Y||INVESTIGATOR|ADJUDICATOR|NA|3|Visit_3|40|3|SCREENING|2020-07-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-16|P1Y2M10DT2H30M|BEFORE|2020-07-09|COINCIDENT|2020-07-31
e|RS|74acb1a5-6dab-4b9e-ac7b-d242bdd44d26|6|NEWLPROG|New Lesion Progression|DOHNER AML 2010|[?]|mL/m2/min|EQUIVOCAL|1|Ci/mL|TRANSMISSION ELECTRON MICROSCOPY|Y|Y||INTERVIEWER|READER 3|NA|3|Visit_3|40|2|TREATMENT|2020-07-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-16|P1Y2M10DT2H30M|AFTER|2020-06-13|ONGOING|2020-08-27
e|RS|74acb1a5-6dab-4b9e-ac7b-d242bdd44d26|7|NTRGRESP|Non-target Response|KEAM BREAST CANCER 2013|[?]|cm/s|DECREASED|1|log10 CFU/mL|PAP STAIN||||HEALTH CARE PROFESSIONAL|READER|Y|4|Visit_4|65|1|WASHOUT|2020-08-01|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-20|P1Y2M10DT2H30M|COINCIDENT|2020-07-22|COINCIDENT|2020-08-30
e|RS|74acb1a5-6dab-4b9e-ac7b-d242bdd44d26|8|SFTSRESP|Soft Tissue Response|LUGANO CLASSIFICATION|[?]|nsec|PSA PROGRESSION|1|Gy|ENZYMATIC SPECTROPHOTOMETRY||||ADJUDICATOR|OPHTHALMOLOGIST|U|4|Visit_4|65|6|WASHOUT|2020-08-01|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-20|P1Y2M10DT2H30M|BEFORE|2020-08-24|COINCIDENT|2020-09-02
e|RS|74acb1a5-6dab-4b9e-ac7b-d242bdd44d26|9|LIVRRESP|Liver Response|IRANO 2015|[?]|IU/day|PR-CT|1|/2500 WBC|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY|Y|||FAMILY MEMBER|ADJUDICATOR 1|Y|5|Visit_5|90|3|TREATMENT|2020-08-26|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-20|P1Y2M10DT2H30M|COINCIDENT|2020-06-14|AFTER|2020-06-29
e|RS|74acb1a5-6dab-4b9e-ac7b-d242bdd44d26|10|RDIORESP|Radiologic Response|MURPHY PROSTATE CANCER 1980|[?]|mg/g/h|CA125 50% RESPONSE|1|pm|PERCUSSION||Y||CHILD|READER 3|N|5|Visit_5|90|4|SCREENING|2020-08-26|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-20|P1Y2M10DT2H30M|BEFORE|2020-08-08|COINCIDENT|2020-08-23
e|RS|4d8dd0d0-407d-4374-8345-c11f30603273|1|RDIORESP|Radiologic Response|GUILHOT CML 2007|[?]|10^3/L|CYTOGENETIC MINIMAL RESPONSE|1|mmol/mol|APPLANATION TONOMETRY||||CLINICAL STUDY SPONSOR|NEUROLOGIST 1|N|1|Visit_1|10|4|TREATMENT|2021-01-01|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-15|P1Y2M10DT2H30M|UNKNOWN|2021-02-01|COINCIDENT|2021-02-12
e|RS|4d8dd0d0-407d-4374-8345-c11f30603273|2|ANATRESP|Anatomic Response|IWC HALLEK CLL 2008|[?]|HOMEOPATHIC DILUTION|iCR|1|kg/cm|ISHIHARA COLOR PLATES||||GUARDIAN|MICROSCOPIST 1|U|1|Visit_1|10|4|TREATMENT|2021-01-01|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-15|P1Y2M10DT2H30M|UNKNOWN|2020-12-29|AFTER|2021-01-14
e|RS|4d8dd0d0-407d-4374-8345-c11f30603273|3|NEWLIND|New Lesion Indicator|iRECIST|||PR|1|pg/dL|DOPPLER ULTRASOUND|||Y|ADJUDICATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|2|Visit_2|25|2|TREATMENT|2021-01-16|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-19|P1Y2M10DT2H30M|BEFORE|2021-03-18|ONGOING|2021-03-31
e|RS|4d8dd0d0-407d-4374-8345-c11f30603273|4|ANATRESP|Anatomic Response|CHOLLET BREAST CANCER 2002|[?]|amol|CR-CT|1|mg/m2/h|SPIROMETRY||||INVESTIGATOR|OTOLARYNGOLOGIST|Y|2|Visit_2|25|3|SCREENING|2021-01-16|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-19|P1Y2M10DT2H30M|AFTER|2021-03-06|ONGOING|2021-03-13
e|RS|4d8dd0d0-407d-4374-8345-c11f30603273|5|CLINRESP|Clinical Response|RANO ELLINGSON 2017|[?]|/kg|CA125 50% RESPONSE|1|STEPS|CELLULAR PROLIFERATION ASSAY||Y||VENDOR|ENDOCRINOLOGIST|N|3|Visit_3|40|2|WASHOUT|2021-01-31|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-18|P1Y2M10DT2H30M|UNKNOWN|2021-01-29|COINCIDENT|2021-03-26
e|RS|4d8dd0d0-407d-4374-8345-c11f30603273|6|HEMARESP|Hematologic Response|GUPPY OVARIAN CANCER 2002|[?]|BOLUS|CR|1|mkat|FLOCCULATION, CHARCOAL ENHANCED||||CHILD|RADIOLOGIST 1|N|3|Visit_3|40|2|SCREENING|2021-01-31|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-18|P1Y2M10DT2H30M|UNKNOWN|2021-01-02|ONGOING|2021-02-06
e|RS|4d8dd0d0-407d-4374-8345-c11f30603273|7|HEMARESP|Hematologic Response|WHO BREAST CANCER 2006|[?]|/4.0 mL|INCREASED|1|P|STATIC PERIMETRY||||INDEPENDENT ASSESSOR|RADIOLOGIST|Y|4|Visit_4|65|6|TREATMENT|2021-02-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-10|P1Y2M10DT2H30M|AFTER|2021-01-07|AFTER|2021-01-16
e|RS|4d8dd0d0-407d-4374-8345-c11f30603273|8|MRPHRESP|Morphologic Response|RECICL|[?]|PELLET|CR-CT|1|kg/mol|CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|Y|||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 3|NA|4|Visit_4|65|6|TREATMENT|2021-02-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-10|P1Y2M10DT2H30M|UNKNOWN|2021-01-10|COINCIDENT|2021-03-17
e|RS|4d8dd0d0-407d-4374-8345-c11f30603273|9|BESTRESP|Best Overall Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|CAPSULE|IMMUNOPHENOTYPIC CR|1|cup eq|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|Y|Y||FRIEND|OTOLARYNGOLOGIST|N|5|Visit_5|90|3|TREATMENT|2021-03-22|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-06|P1Y2M10DT2H30M|COINCIDENT|2021-03-25|AFTER|2021-03-30
e|RS|4d8dd0d0-407d-4374-8345-c11f30603273|10|MJPTHIND|Major Pathological Response Indicator|HAMAOKA BREAST CANCER 2010|||NON-CR/NON-PD|1|g|CONTRAST ENHANCED PET/CT SCAN|||Y|INDEPENDENT ASSESSOR|MICROSCOPIST 3|NA|5|Visit_5|90|6|FOLLOW-UP|2021-03-22|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-06|P1Y2M10DT2H30M|AFTER|2021-01-01|AFTER|2021-03-08
e|RS|6996077b-556a-47b9-bbff-20c1b4df35ea|1|LIVRRESP|Liver Response|PETIT BREAST CANCER 2001|[?]|mCi|PSEUDOPROGRESSION|1|m2|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY||Y||ADJUDICATION COMMITTEE|READER 2|Y|1|Visit_1|10|2|TREATMENT|2020-06-08|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-03|P1Y2M10DT2H30M|AFTER|2020-06-27|ONGOING|2020-07-14
e|RS|6996077b-556a-47b9-bbff-20c1b4df35ea|2|BONERESP|Bone Response|MONTSERRAT CLL 1989|||PD-CT|1|Arbitrary U|POLYMERASE CHAIN REACTION||Y|Y|PARENT|CARDIOLOGIST|NA|1|Visit_1|10|2|TREATMENT|2020-06-08|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-03|P1Y2M10DT2H30M|AFTER|2020-07-06|COINCIDENT|2020-08-30
e|RS|6996077b-556a-47b9-bbff-20c1b4df35ea|3|SYMPTDTR|Symptomatic Deterioration|KUMAR IMWG 2016|[?]|pmol/L/h|iUPD|1|Ci/kg|POPULATION SEQUENCING||||ADJUDICATOR|FORENSIC PATHOLOGIST|NA|2|Visit_2|25|6|SCREENING|2020-06-23|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-14|P1Y2M10DT2H30M|BEFORE|2020-07-15|ONGOING|2020-08-24
e|RS|6996077b-556a-47b9-bbff-20c1b4df35ea|4|NTNERESP|Non-Target Non-Enhancing Response|PETIT BREAST CANCER 2001|[?]|IU/kg|NR|1|10^9 organisms/mg|DIGITAL PCR ARRAY|Y|Y||ADJUDICATOR|ADJUDICATOR 1|Y|2|Visit_2|25|5|WASHOUT|2020-06-23|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-14|P1Y2M10DT2H30M|BEFORE|2020-08-05|ONGOING|2020-08-23
e|RS|6996077b-556a-47b9-bbff-20c1b4df35ea|5|MJPTHIND|Major Pathological Response Indicator|RECIST 1.0|[?]|L|UNEQUIVOCAL|1|umol/mg/min|ANGIOGRAPHY|Y|||INTERVIEWER|READER 3|N|3|Visit_3|40|7|TREATMENT|2020-07-08|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-01|P1Y2M10DT2H30M|BEFORE|2020-07-31|COINCIDENT|2020-08-08
e|RS|6996077b-556a-47b9-bbff-20c1b4df35ea|6|BONERESP|Bone Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|mL/beat|NON-PD|1|Absorbance U/mL|ELECTROCHEMILUMINESCENCE||Y||CLINICAL RESEARCH ASSOCIATE|READER 2|NA|3|Visit_3|40|3|TREATMENT|2020-07-08|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-01|P1Y2M10DT2H30M|UNKNOWN|2020-08-08|ONGOING|2020-08-18
e|RS|6996077b-556a-47b9-bbff-20c1b4df35ea|7|BONERESP|Bone Response|LEE LUNG CANCER 2011|[?]|mL/mmHg/min/L|PSA PROGRESSION|1|RFU|IMMUNOPRECIPITATION||||INDEPENDENT ASSESSOR|MICROSCOPIST 3|NA|4|Visit_4|65|6|WASHOUT|2020-08-02|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-08|P1Y2M10DT2H30M|COINCIDENT|2020-08-30|AFTER|2020-09-05
e|RS|6996077b-556a-47b9-bbff-20c1b4df35ea|8|LIVRRESP|Liver Response|GUPPY OVARIAN CANCER 2002|[?]|min/day|CYTOGENETIC MINOR RESPONSE|1|TRANSDUCING UNIT/mL|WEBER GREEN STAIN|Y|||FRIEND|ENDOCRINOLOGIST|NA|4|Visit_4|65|3|TREATMENT|2020-08-02|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-08|P1Y2M10DT2H30M|COINCIDENT|2020-07-11|COINCIDENT|2020-08-14
e|RS|6996077b-556a-47b9-bbff-20c1b4df35ea|9|MJPTHIND|Major Pathological Response Indicator|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|MnFI|PDu|1|pmol/10^9 cells|ATOMIC ABSORPTION SPECTROMETRY||||CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR|U|5|Visit_5|90|2|WASHOUT|2020-08-27|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-26|P1Y2M10DT2H30M|COINCIDENT|2020-07-02|ONGOING|2020-07-18
e|RS|6996077b-556a-47b9-bbff-20c1b4df35ea|10|ANATRESP|Anatomic Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|log10 PFU/mL|CYTOGENETIC CR|1|cL|IMMUNOBLOT||||CAREGIVER|PATHOLOGIST 2|Y|5|Visit_5|90|3|TREATMENT|2020-08-27|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-26|P1Y2M10DT2H30M|BEFORE|2020-07-08|COINCIDENT|2020-09-01
e|RS|d79d31c5-d51a-46a7-b22c-20d6d483f46e|1|DRCRIND|Disease Recurrence Indicator|PCWG BUBLEY PROSTATE CANCER 1999|[?]|STEPS|cPR|1|mmol/min/kPa|CHROMOGENIC ASSAY||Y||ADJUDICATOR|ADJUDICATOR 2|U|1|Visit_1|10|1|SCREENING|2020-10-23|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-02|P1Y2M10DT2H30M|COINCIDENT|2020-10-15|COINCIDENT|2020-10-28
e|RS|d79d31c5-d51a-46a7-b22c-20d6d483f46e|2|MOLRESP|Molecular Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|kat|NR|1|tsp eq|DIRECT SEQUENCING||||HEALTH CARE PROFESSIONAL|RADIOLOGIST|N|1|Visit_1|10|1|TREATMENT|2020-10-23|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-02|P1Y2M10DT2H30M|BEFORE|2020-11-17|AFTER|2021-01-03
e|RS|d79d31c5-d51a-46a7-b22c-20d6d483f46e|3|NTRGRESP|Non-target Response|EBMT BLADE MYELOMA 1998|[?]|cs|CR|1|ug/h|DYNAMIC LIGHT SCATTERING|Y|Y||HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|NA|2|Visit_2|25|4|FOLLOW-UP|2020-11-07|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-10|P1Y2M10DT2H30M|COINCIDENT|2020-12-06|AFTER|2020-12-10
e|RS|d79d31c5-d51a-46a7-b22c-20d6d483f46e|4|LIVRRESP|Liver Response|SACT|[?]|uU/dL|PARTIAL MORPHOLOGIC RESPONSE|1|oz eq|EIA||||ADJUDICATOR|NEUROLOGIST 2|Y|2|Visit_2|25|6|WASHOUT|2020-11-07|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-10|P1Y2M10DT2H30M|COINCIDENT|2020-10-16|ONGOING|2020-10-28
e|RS|d79d31c5-d51a-46a7-b22c-20d6d483f46e|5|MRDIND|Minimal Residual Disease Indicator|PCWG SCHER PROSTATE CANCER 2016|[?]|/10^5|MOLECULAR MAJOR RESPONSE|1|ug/kg/h|CELL OF ORIGIN ASSAY||||SIBLING|NEUROLOGIST 2|U|3|Visit_3|40|2|TREATMENT|2020-11-22|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-16|P1Y2M10DT2H30M|BEFORE|2020-12-06|BEFORE|2020-12-11
e|RS|d79d31c5-d51a-46a7-b22c-20d6d483f46e|6|HEMARESP|Hematologic Response|BURCOMBE BREAST CANCER 2005|[?]|10^7 CFU|NOT ALL EVALUATED|1|pm|GIEMSA STAIN||Y||GUARDIAN|MICROSCOPIST 1|N|3|Visit_3|40|4|TREATMENT|2020-11-22|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-16|P1Y2M10DT2H30M|UNKNOWN|2020-12-04|ONGOING|2020-12-14
e|RS|d79d31c5-d51a-46a7-b22c-20d6d483f46e|7|OVRLRESP|Overall Response|KUKER LYMPHOMA 2005|[?]|foz_us|COMPLETE MRD RESPONSE|1|/2000 RBC|IN VITRO GENE EXPRESSION ASSAY||||GUARDIAN|ONCOLOGIST|U|4|Visit_4|65|1|FOLLOW-UP|2020-12-17|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-24|P1Y2M10DT2H30M|BEFORE|2021-01-18|COINCIDENT|2021-01-20
e|RS|d79d31c5-d51a-46a7-b22c-20d6d483f46e|8|NTERESP|Non-Target Enhancing Response|KUMAR IMWG 2016|[?]|10^6 U|CR-CT|1|SYRINGE|TARGETED TRANSCRIPTOME SEQUENCING||Y||INDEPENDENT ASSESSOR|READER 1|Y|4|Visit_4|65|5|SCREENING|2020-12-17|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-24|P1Y2M10DT2H30M|BEFORE|2020-12-22|BEFORE|2021-01-20
e|RS|d79d31c5-d51a-46a7-b22c-20d6d483f46e|9|NTLWIND|Non-Target Lesion Worsening Indicator|KEAM BREAST CANCER 2013|[?]|pmol/10^9 cells|FAVORABLE RESPONSE|1|fraction of 1|CONTRAST ENHANCED CT SCAN||||DOMESTIC PARTNER|ADJUDICATOR 2|N|5|Visit_5|90|6|TREATMENT|2021-01-11|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-26|P1Y2M10DT2H30M|COINCIDENT|2021-01-17|COINCIDENT|2021-01-19
e|RS|d79d31c5-d51a-46a7-b22c-20d6d483f46e|10|RDIORESP|Radiologic Response|KEAM BREAST CANCER 2013|[?]|/2500 WBC|iPR|1|Tesla|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY||||ADJUDICATION COMMITTEE|CARDIOLOGIST|N|5|Visit_5|90|3|TREATMENT|2021-01-11|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-26|P1Y2M10DT2H30M|COINCIDENT|2020-11-16|ONGOING|2020-11-29
e|RS|738d539e-a810-4207-8904-fc6a5d055424|1|MNPTHIND|Minor Pathological Response Indicator|EBMT BLADE MYELOMA 1998|[?]|mL/(min*100mL)|MORPHOLOGIC CR|1|ugEq/L|LAPAROSCOPY||||DOMESTIC PARTNER|INTERNIST|U|1|Visit_1|10|3|TREATMENT|2021-01-08|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-01|P1Y2M10DT2H30M|AFTER|2021-04-04|BEFORE|2021-04-05
e|RS|738d539e-a810-4207-8904-fc6a5d055424|2|DRCRIND|Disease Recurrence Indicator|RECIST 1.1|||pCR|1|copies/ug|RYAN BLUE STAIN|||Y|STUDY SUBJECT|PATHOLOGIST|U|1|Visit_1|10|6|SCREENING|2021-01-08|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-01|P1Y2M10DT2H30M|AFTER|2021-01-07|COINCIDENT|2021-02-24
e|RS|738d539e-a810-4207-8904-fc6a5d055424|3|SFTSRESP|Soft Tissue Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|PHERESIS UNIT|PSEUDORESPONSE|1|/2000 RBC|RAJI CELL EIA||||INVESTIGATOR|RATER 1|N|2|Visit_2|25|4|TREATMENT|2021-01-23|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-11|P1Y2M10DT2H30M|AFTER|2021-02-19|COINCIDENT|2021-04-01
e|RS|738d539e-a810-4207-8904-fc6a5d055424|4|NTLWIND|Non-Target Lesion Worsening Indicator|BRUGGEMANN MRD 2010|[?]|cm/min|pCR|1|BISCUIT|DOPPLER ULTRASOUND||||STUDY SUBJECT|ENDOCRINOLOGIST|N|2|Visit_2|25|4|TREATMENT|2021-01-23|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-11|P1Y2M10DT2H30M|BEFORE|2021-03-24|AFTER|2021-03-29
e|RS|738d539e-a810-4207-8904-fc6a5d055424|5|TMRESP|Tumor Marker Response|RECICL|[?]|cm/s|CYTOGENETIC CR|1|PACKET|DIRECT SEQUENCING|Y|Y||GUARDIAN|ADJUDICATOR 2|Y|3|Visit_3|40|5|SCREENING|2021-02-07|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-05|P1Y2M10DT2H30M|AFTER|2021-03-24|ONGOING|2021-03-25
e|RS|738d539e-a810-4207-8904-fc6a5d055424|6|MNPTHIND|Minor Pathological Response Indicator|CHESON LYMPHOMA 2008|||PD|1|Frames/s|ULTRASOUND|||Y|FRIEND|ADJUDICATOR|N|3|Visit_3|40|7|SCREENING|2021-02-07|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-05|P1Y2M10DT2H30M|UNKNOWN|2021-02-01|ONGOING|2021-03-22
e|RS|738d539e-a810-4207-8904-fc6a5d055424|7|MRPHRESP|Morphologic Response|IWG CHESON AML 2003|[?]|mg/mL/day|TREATMENT FAILURE|1|PIXELS/in|FLOW CYTOMETRY||||NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|N|4|Visit_4|65|5|FOLLOW-UP|2021-03-04|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-22|P1Y2M10DT2H30M|COINCIDENT|2021-01-11|BEFORE|2021-01-16
e|RS|738d539e-a810-4207-8904-fc6a5d055424|8|METBRESP|Metabolic Response|EBMT BLADE MYELOMA 1998|[?]|mmol/mol|PD|1|tsp|MRI||Y||CLINICAL STUDY SPONSOR|READER 1|N|4|Visit_4|65|5|WASHOUT|2021-03-04|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-22|P1Y2M10DT2H30M|BEFORE|2021-04-04|AFTER|2021-04-06
e|RS|738d539e-a810-4207-8904-fc6a5d055424|9|BMIVLIND|Bone Marrow Involvement Indicator|RANO ELLINGSON 2017|[?]|dmol|MOLECULAR MAJOR RESPONSE|1|mg/mL/min|MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING||||CLINICAL RESEARCH ASSOCIATE|HEMATOLOGIST|U|5|Visit_5|90|1|TREATMENT|2021-03-29|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-17|P1Y2M10DT2H30M|COINCIDENT|2021-02-21|BEFORE|2021-03-02
e|RS|738d539e-a810-4207-8904-fc6a5d055424|10|METBRESP|Metabolic Response|RAJKUMAR MYELOMA 2011|[?]|Newton|UNFAVORABLE RESPONSE|1|mg/kg/dose|PET/SPECT SCAN||||SIBLING|PATHOLOGIST|N|5|Visit_5|90|3|TREATMENT|2021-03-29|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-17|P1Y2M10DT2H30M|AFTER|2021-02-21|BEFORE|2021-03-07
e|RS|95e3cff6-3c61-4e31-97ff-cfcbe1cab4f7|1|MJPTHIND|Major Pathological Response Indicator|NCCN ALL MRD 2014|[?]|10^6 organisms|NON-QUANTIFIABLE MRD POSITIVITY|1|NEEDLE GAUGE|OLIGO ACGH||Y||INVESTIGATOR|OPTOMETRIST|U|1|Visit_1|10|4|FOLLOW-UP|2020-08-11|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-22|P1Y2M10DT2H30M|UNKNOWN|2020-09-29|COINCIDENT|2020-10-16
e|RS|95e3cff6-3c61-4e31-97ff-cfcbe1cab4f7|2|LIVRRESP|Liver Response|IWG CHESON MDS 2000|||INCREASED|1|nkat/L|IMMUNO-PET SCAN|||Y|SIGNIFICANT OTHER|ADJUDICATOR|Y|1|Visit_1|10|4|FOLLOW-UP|2020-08-11|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-22|P1Y2M10DT2H30M|AFTER|2020-10-04|AFTER|2020-10-07
e|RS|95e3cff6-3c61-4e31-97ff-cfcbe1cab4f7|3|NTRGRESP|Non-target Response|LEE LUNG CANCER 2011|[?]|mIU/L|sCR|1|U/mg|QUANTITATIVE ULTRASOUND||||INVESTIGATOR|READER 1|N|2|Visit_2|25|4|WASHOUT|2020-08-26|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-01|P1Y2M10DT2H30M|BEFORE|2020-09-08|ONGOING|2020-09-14
e|RS|95e3cff6-3c61-4e31-97ff-cfcbe1cab4f7|4|MRDIND|Minimal Residual Disease Indicator|HAMAOKA BREAST CANCER 2010|[?]|CFU/g|MR|1|vp/dose|RADIAL IMMUNODIFFUSION|Y|||HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|N|2|Visit_2|25|1|SCREENING|2020-08-26|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-01|P1Y2M10DT2H30M|COINCIDENT|2020-09-22|ONGOING|2020-10-28
e|RS|95e3cff6-3c61-4e31-97ff-cfcbe1cab4f7|5|NEWLWIND|New Lesion Worsening Indicator|MONTSERRAT CLL 1989|[?]|TABLET|NR|1|deg2|FLUORIMETRY||||VENDOR|CARDIOLOGIST|N|3|Visit_3|40|3|TREATMENT|2020-09-10|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-13|P1Y2M10DT2H30M|UNKNOWN|2020-09-13|COINCIDENT|2020-09-28
e|RS|95e3cff6-3c61-4e31-97ff-cfcbe1cab4f7|6|DRCRIND|Disease Recurrence Indicator|HARTMANN GERM CELL CANCER 2002|[?]|vg/kg|NON-CR/NON-PD|1|GBq|PET/CT SCAN WITHOUT CONTRAST||||GUARDIAN|CARDIOLOGIST|U|3|Visit_3|40|5|TREATMENT|2020-09-10|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-13|P1Y2M10DT2H30M|BEFORE|2020-10-30|ONGOING|2020-11-06
e|RS|95e3cff6-3c61-4e31-97ff-cfcbe1cab4f7|7|BONERESP|Bone Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|genEq|PR|1|dram|CISH|Y|||DOMESTIC PARTNER|ADJUDICATOR|N|4|Visit_4|65|2|TREATMENT|2020-10-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-17|P1Y2M10DT2H30M|COINCIDENT|2020-10-26|ONGOING|2020-11-05
e|RS|95e3cff6-3c61-4e31-97ff-cfcbe1cab4f7|8|MJPTHIND|Major Pathological Response Indicator|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|||SMD|1|Absorbance U/mL|TELLER ACUITY CARDS||Y|Y|SPOUSE|OPHTHALMOLOGIST|N|4|Visit_4|65|3|TREATMENT|2020-10-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-17|P1Y2M10DT2H30M|COINCIDENT|2020-10-11|AFTER|2020-10-26
e|RS|95e3cff6-3c61-4e31-97ff-cfcbe1cab4f7|9|RDIORESP|Radiologic Response|NCIWG CHESON CLL 1996|[?]|APL U|iUPD|1|uCi/kg|SEQUENCING||||GUARDIAN|RADIOLOGIST 2|Y|5|Visit_5|90|1|TREATMENT|2020-10-30|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-27|P1Y2M10DT2H30M|UNKNOWN|2020-08-23|COINCIDENT|2020-10-04
e|RS|95e3cff6-3c61-4e31-97ff-cfcbe1cab4f7|10|SPLNRESP|Spleen Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|MBq|nPR|1|U/g/h|CALCOFLUOR WHITE STAIN|Y|||HEALTH CARE PROFESSIONAL|READER 1|NA|5|Visit_5|90|7|SCREENING|2020-10-30|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-27|P1Y2M10DT2H30M|BEFORE|2020-09-20|AFTER|2020-10-20
e|RS|20841d37-0444-4d1d-b934-1e805cdacdaf|1|NTNERESP|Non-Target Non-Enhancing Response|IWG CHESON MDS 2006|[?]|U/L|TREATMENT FAILURE|1|/mm2|SPECT/CT SCAN|Y|Y||STUDY SUBJECT|ENDOCRINOLOGIST|N|1|Visit_1|10|4|FOLLOW-UP|2020-11-22|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-19|P1Y2M10DT2H30M|BEFORE|2020-12-10|AFTER|2021-01-08
e|RS|20841d37-0444-4d1d-b934-1e805cdacdaf|2|NEWLIND|New Lesion Indicator|HARTMAN PANCREATIC CANCER 2012|[?]|APPLICATION|SMD|1|mg/cm2|LINE PROBE ASSAY||Y||FAMILY MEMBER|READER 3|Y|1|Visit_1|10|7|SCREENING|2020-11-22|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-19|P1Y2M10DT2H30M|AFTER|2020-11-30|BEFORE|2021-01-09
e|RS|20841d37-0444-4d1d-b934-1e805cdacdaf|3|CLINRESP|Clinical Response|IWG CHESON MDS 2000|[?]|g/day|CYTOGENETIC NO RESPONSE|1|pmol/10^9 cells|HPLC||||CHILD|CLINICAL PATHOLOGIST|U|2|Visit_2|25|2|FOLLOW-UP|2020-12-07|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-24|P1Y2M10DT2H30M|COINCIDENT|2021-02-11|BEFORE|2021-02-18
e|RS|20841d37-0444-4d1d-b934-1e805cdacdaf|4|CYTORESP|Cytogenetic Response|MASS|||mCR|1|BAG|FUNDUS PHOTOGRAPHY||Y|Y|SIGNIFICANT OTHER|RADIOLOGIST|N|2|Visit_2|25|3|SCREENING|2020-12-07|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-24|P1Y2M10DT2H30M|AFTER|2020-12-24|AFTER|2021-02-12
e|RS|20841d37-0444-4d1d-b934-1e805cdacdaf|5|NEWLPROG|New Lesion Progression|EASL BRUIX LIVER CANCER 2001|[?]|COAT|SMD|1|MBq/uL|GRADIENT DIFFUSION||||VENDOR|RATER|Y|3|Visit_3|40|7|FOLLOW-UP|2020-12-22|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-15|P1Y2M10DT2H30M|BEFORE|2021-01-15|BEFORE|2021-02-14
e|RS|20841d37-0444-4d1d-b934-1e805cdacdaf|6|MJPTHIND|Major Pathological Response Indicator|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|mmol/s|nPR|1|GBq|POPULATION SEQUENCING||||ADJUDICATOR|ONCOLOGIST 2|N|3|Visit_3|40|6|SCREENING|2020-12-22|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-15|P1Y2M10DT2H30M|BEFORE|2020-12-09|AFTER|2020-12-14
e|RS|20841d37-0444-4d1d-b934-1e805cdacdaf|7|METSIND|Metastatic Indicator|WHO BREAST CANCER 2006|||STABLE|1|uEq|DUCTOGRAPHY||Y|Y|INTERVIEWER|ADJUDICATOR 3|NA|4|Visit_4|65|1|SCREENING|2021-01-16|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-23|P1Y2M10DT2H30M|UNKNOWN|2020-11-17|ONGOING|2020-11-18
e|RS|20841d37-0444-4d1d-b934-1e805cdacdaf|8|PATHRESP|Pathologic Response|MACDONALD GLIOMA 1990|||EQUIVOCAL|1|pg/dL|PET SCAN||Y|Y|HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|NA|4|Visit_4|65|6|SCREENING|2021-01-16|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-23|P1Y2M10DT2H30M|UNKNOWN|2021-02-05|COINCIDENT|2021-02-15
e|RS|20841d37-0444-4d1d-b934-1e805cdacdaf|9|HEMARESP|Hematologic Response|NCIWG CHESON CLL 1996|[?]|/HPF|TREATMENT FAILURE|1|log10 CFU/g|CLINICAL EVALUATION||||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 2|Y|5|Visit_5|90|2|FOLLOW-UP|2021-02-10|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-26|P1Y2M10DT2H30M|COINCIDENT|2021-01-18|AFTER|2021-01-19
e|RS|20841d37-0444-4d1d-b934-1e805cdacdaf|10|NTRGRESP|Non-target Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|mOsm/L|PSA PROGRESSION|1|mL/s|VENTILATION PERFUSION LUNG SCAN||Y||CHILD|NEUROLOGIST|U|5|Visit_5|90|5|TREATMENT|2021-02-10|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-26|P1Y2M10DT2H30M|AFTER|2021-01-08|ONGOING|2021-02-17
e|RS|a96323a5-4d4f-4ea4-b3da-89b8cca46ee0|1|MRPHRESP|Morphologic Response|DURIE MULTIPLE MYELOMA 2006|[?]|log10 PFU/mL|FAVORABLE RESPONSE|1|Ejaculate U|MASS SPECTROMETRY||||NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|NA|1|Visit_1|10|3|TREATMENT|2020-11-01|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-22|P1Y2M10DT2H30M|UNKNOWN|2020-12-17|ONGOING|2020-12-19
e|RS|a96323a5-4d4f-4ea4-b3da-89b8cca46ee0|2|NEWLWIND|New Lesion Worsening Indicator|FAROOQUI SUPP CLL 2014|[?]|amp|NE|1|%/s|RAJI CELL EIA|Y|||CLINICAL STUDY SPONSOR|ADJUDICATOR 1|Y|1|Visit_1|10|4|TREATMENT|2020-11-01|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-22|P1Y2M10DT2H30M|BEFORE|2021-01-06|ONGOING|2021-01-19
e|RS|a96323a5-4d4f-4ea4-b3da-89b8cca46ee0|3|MOLRESP|Molecular Response|PCWG SCHER PROSTATE CANCER 2016|[?]|nkat/L|cCR|1|DISK|AUDIOMETRY||||INTERVIEWER|ONCOLOGIST 2|Y|2|Visit_2|25|7|TREATMENT|2020-11-16|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-25|P1Y2M10DT2H30M|UNKNOWN|2021-01-23|COINCIDENT|2021-01-27
e|RS|a96323a5-4d4f-4ea4-b3da-89b8cca46ee0|4|CYTORESP|Cytogenetic Response|KUKER LYMPHOMA 2005|[?]|mOsm|pCR|1|10^6 IU|MICRO BROTH DILUTION|Y|||INDEPENDENT ASSESSOR|MICROSCOPIST 2|N|2|Visit_2|25|3|TREATMENT|2020-11-16|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-25|P1Y2M10DT2H30M|AFTER|2020-11-09|AFTER|2021-01-08
e|RS|a96323a5-4d4f-4ea4-b3da-89b8cca46ee0|5|MRPHRESP|Morphologic Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|mL/day|MORPHOLOGIC CRi|1|mCi/kg|MACRO BROTH DILUTION||||INTERVIEWER|MICROSCOPIST 2|Y|3|Visit_3|40|2|TREATMENT|2020-12-01|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-12|P1Y2M10DT2H30M|UNKNOWN|2020-11-30|COINCIDENT|2021-01-27
e|RS|a96323a5-4d4f-4ea4-b3da-89b8cca46ee0|6|SYMPTDTR|Symptomatic Deterioration|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|mL/cm3/min|COMPLETE MRD RESPONSE|1|10^6/L|REFRACTOMETRY||Y||VENDOR|NEUROLOGIST|NA|3|Visit_3|40|5|TREATMENT|2020-12-01|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-12|P1Y2M10DT2H30M|BEFORE|2020-12-20|AFTER|2020-12-24
e|RS|a96323a5-4d4f-4ea4-b3da-89b8cca46ee0|7|MOLRESP|Molecular Response|PCWG SCHER PROSTATE CANCER 2008|||PD|1|U/cL|DROPLET DIGITAL PCR|||Y|CLINICAL STUDY SPONSOR|CARDIOLOGIST|Y|4|Visit_4|65|3|WASHOUT|2020-12-26|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-06|P1Y2M10DT2H30M|UNKNOWN|2020-11-22|ONGOING|2020-11-28
e|RS|a96323a5-4d4f-4ea4-b3da-89b8cca46ee0|8|NTLWIND|Non-Target Lesion Worsening Indicator|IWG CHESON AML 2003|[?]|damol/L|NE|1|10^3 CFU/mL|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|Y|Y||CLINICAL RESEARCH ASSOCIATE|HEMATOLOGIST|N|4|Visit_4|65|5|TREATMENT|2020-12-26|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-06|P1Y2M10DT2H30M|COINCIDENT|2021-01-26|AFTER|2021-01-27
e|RS|a96323a5-4d4f-4ea4-b3da-89b8cca46ee0|9|TMRESP|Tumor Marker Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|log10 PFU/mL|INDETERMINATE RESPONSE|1|nU/cL|ELECTROPHORESIS|Y|||CAREGIVER|HEMATOLOGIST|NA|5|Visit_5|90|3|FOLLOW-UP|2021-01-20|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-03|P1Y2M10DT2H30M|BEFORE|2021-01-17|BEFORE|2021-01-28
e|RS|a96323a5-4d4f-4ea4-b3da-89b8cca46ee0|10|METSIND|Metastatic Indicator|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|umol/mg/min|RELAPSED DISEASE FROM CR OR PR|1|U/kg/day|AURAMINE STAIN|Y|||PROXY|OTOLARYNGOLOGIST|Y|5|Visit_5|90|5|SCREENING|2021-01-20|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-03|P1Y2M10DT2H30M|AFTER|2020-12-18|ONGOING|2021-01-08
e|RS|d74682f1-824e-449d-bdf1-db517d8fdf2e|1|TMRESP|Tumor Marker Response|IRANO 2015|||CA125 50% RESPONSE|1|PACKAGE|CLAUSS METHOD|Y||Y|VENDOR|RADIOLOGIST 2|U|1|Visit_1|10|7|SCREENING|2020-08-08|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-01|P1Y2M10DT2H30M|COINCIDENT|2020-09-04|COINCIDENT|2020-11-03
e|RS|d74682f1-824e-449d-bdf1-db517d8fdf2e|2|CPRFSTAT|Clinical Performance Status|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|10^3 CFU/g|PMD|1|PFU|GRADIENT DIFFUSION|Y|||SPOUSE|OPHTHALMOLOGIST|N|1|Visit_1|10|4|TREATMENT|2020-08-08|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-01|P1Y2M10DT2H30M|BEFORE|2020-10-31|BEFORE|2020-11-02
e|RS|d74682f1-824e-449d-bdf1-db517d8fdf2e|3|STRUSTAT|Steroid Use Status|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|||MRD PERSISTENCE|1|/h|SPECULAR MICROSCOPY|||Y|DOMESTIC PARTNER|ADJUDICATOR 3|U|2|Visit_2|25|3|SCREENING|2020-08-23|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-21|P1Y2M10DT2H30M|AFTER|2020-08-18|BEFORE|2020-08-25
e|RS|d74682f1-824e-449d-bdf1-db517d8fdf2e|4|NEWLWIND|New Lesion Worsening Indicator|PERCIST|[?]|ug/animal|NON-PD|1|/5x10^4 WBC|ENZYMATIC ULTRACENTRIFUGATION||||HEALTH CARE PROFESSIONAL|READER 1|N|2|Visit_2|25|5|WASHOUT|2020-08-23|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-21|P1Y2M10DT2H30M|AFTER|2020-10-14|BEFORE|2020-11-02
e|RS|d74682f1-824e-449d-bdf1-db517d8fdf2e|5|MRDIND|Minimal Residual Disease Indicator|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|Bq/L|CR-CT|1|Pa|RADIOIMMUNOPRECIPITATION ASSAY||Y||GUARDIAN|MICROSCOPIST|U|3|Visit_3|40|7|WASHOUT|2020-09-07|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-14|P1Y2M10DT2H30M|AFTER|2020-08-06|COINCIDENT|2020-10-04
e|RS|d74682f1-824e-449d-bdf1-db517d8fdf2e|6|OVRLRESP|Overall Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|L/s|STABLE|1|VIAL|IMMUNOBLOT||||CLINICAL STUDY SPONSOR|RADIOLOGIST 2|U|3|Visit_3|40|1|SCREENING|2020-09-07|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-14|P1Y2M10DT2H30M|COINCIDENT|2020-09-30|AFTER|2020-10-30
e|RS|d74682f1-824e-449d-bdf1-db517d8fdf2e|7|ANATRESP|Anatomic Response|IWC HALLEK CLL 2008|||CR|1|MAC50|LC/MS/MS|Y||Y|DOMESTIC PARTNER|MICROSCOPIST 1|NA|4|Visit_4|65|2|TREATMENT|2020-10-02|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-07|P1Y2M10DT2H30M|COINCIDENT|2020-08-26|AFTER|2020-10-19
e|RS|d74682f1-824e-449d-bdf1-db517d8fdf2e|8|MRPHRESP|Morphologic Response|SHINDOH COLORECTAL CANCER 2013|[?]|deg2|IMMUNOPHENOTYPIC CR|1|kDa|SCINTIGRAPHY|Y|||VENDOR|RADIOLOGIST|U|4|Visit_4|65|5|FOLLOW-UP|2020-10-02|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-07|P1Y2M10DT2H30M|AFTER|2020-08-17|BEFORE|2020-09-21
e|RS|d74682f1-824e-449d-bdf1-db517d8fdf2e|9|DRCRIND|Disease Recurrence Indicator|SACT|[?]|nU/cL|STABLE|1|AFU|SCINTIGRAPHY|Y|||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 2|U|5|Visit_5|90|3|SCREENING|2020-10-27|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-12|P1Y2M10DT2H30M|AFTER|2020-10-21|COINCIDENT|2020-11-03
e|RS|d74682f1-824e-449d-bdf1-db517d8fdf2e|10|NTERESP|Non-Target Enhancing Response|PCWG SCHER PROSTATE CANCER 2008|[?]|U/kg|MORPHOLOGIC CRi|1|g/animal/day|ENDPOINT DILUTION ASSAY||||STUDY SUBJECT|MICROSCOPIST 3|N|5|Visit_5|90|5|WASHOUT|2020-10-27|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-12|P1Y2M10DT2H30M|COINCIDENT|2020-08-18|ONGOING|2020-08-23
e|RS|a3c226dc-d8f4-4fbc-b840-f1dc1b2680dd|1|METBRESP|Metabolic Response|SCHER PROSTATE CANCER 2011|[?]|GBq/mg|TREATMENT FAILURE|1|mmol/g|MRS||||INVESTIGATOR|FORENSIC PATHOLOGIST|NA|1|Visit_1|10|2|WASHOUT|2020-12-07|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-19|P1Y2M10DT2H30M|AFTER|2021-01-12|ONGOING|2021-02-18
e|RS|a3c226dc-d8f4-4fbc-b840-f1dc1b2680dd|2|SFTSRESP|Soft Tissue Response|WHO BREAST CANCER 2006|[?]|mEq/mL|PSA PROGRESSION|1|/LPF|ANALYTICAL ULTRACENTRIFUGATION|Y|||ADJUDICATOR|ONCOLOGIST 1|NA|1|Visit_1|10|7|WASHOUT|2020-12-07|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-19|P1Y2M10DT2H30M|UNKNOWN|2021-02-09|COINCIDENT|2021-02-13
e|RS|a3c226dc-d8f4-4fbc-b840-f1dc1b2680dd|3|METSIND|Metastatic Indicator|GCIG RUSTIN OVARIAN CANCER 2011|[?]|nkat|EQUIVOCAL|1|ug/animal|ARTERIAL SPIN LABELING FUNCTIONAL MRI||Y||FRIEND|RATER|U|2|Visit_2|25|3|TREATMENT|2020-12-22|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-23|P1Y2M10DT2H30M|AFTER|2020-12-24|AFTER|2021-01-16
e|RS|a3c226dc-d8f4-4fbc-b840-f1dc1b2680dd|4|TMRESP|Tumor Marker Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|psi|CA125 50% RESPONSE|1|10^3/L|SEQUENCING||||GUARDIAN|READER 3|Y|2|Visit_2|25|6|FOLLOW-UP|2020-12-22|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-23|P1Y2M10DT2H30M|UNKNOWN|2020-12-12|BEFORE|2020-12-26
e|RS|a3c226dc-d8f4-4fbc-b840-f1dc1b2680dd|5|SFTSRESP|Soft Tissue Response|AJCC V7|||iCR|1|cs|FLUORESCEIN STAIN|||Y|SIBLING|NEUROLOGIST 1|NA|3|Visit_3|40|6|FOLLOW-UP|2021-01-06|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-12|P1Y2M10DT2H30M|UNKNOWN|2021-02-13|ONGOING|2021-02-28
e|RS|a3c226dc-d8f4-4fbc-b840-f1dc1b2680dd|6|DRCRIND|Disease Recurrence Indicator|UNSPECIFIED|||TREATMENT FAILURE|1|amp|MICROBIAL CULTURE, LIQUID|Y||Y|SPOUSE|INTERNIST|NA|3|Visit_3|40|6|TREATMENT|2021-01-06|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-12|P1Y2M10DT2H30M|AFTER|2020-12-02|AFTER|2020-12-03
e|RS|a3c226dc-d8f4-4fbc-b840-f1dc1b2680dd|7|CLINRESP|Clinical Response|SCHWARZ CERVICAL CANCER 2009|[?]|CUP|NOT ALL EVALUATED|1|tsp eq|MRI WITHOUT CONTRAST||||INDEPENDENT ASSESSOR|RATER|Y|4|Visit_4|65|4|TREATMENT|2021-01-31|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-04|P1Y2M10DT2H30M|AFTER|2020-12-16|ONGOING|2021-02-09
e|RS|a3c226dc-d8f4-4fbc-b840-f1dc1b2680dd|8|CLINRESP|Clinical Response|CHESON CLL 2006|||PR-CT|1|fmol/L|NON-INVASIVE DIELECTRIC SENSING|||Y|VENDOR|NEUROLOGIST 1|NA|4|Visit_4|65|5|TREATMENT|2021-01-31|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-04|P1Y2M10DT2H30M|AFTER|2021-03-03|ONGOING|2021-03-05
e|RS|a3c226dc-d8f4-4fbc-b840-f1dc1b2680dd|9|MRDIND|Minimal Residual Disease Indicator|PALUMBO MULTIPLE MYELOMA 2009|[?]|CIGARETTE|FAVORABLE RESPONSE|1|IU/g Hb|DUKE INCISION METHOD||Y||HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|NA|5|Visit_5|90|2|FOLLOW-UP|2021-02-25|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-30|P1Y2M10DT2H30M|COINCIDENT|2021-01-26|AFTER|2021-02-26
e|RS|a3c226dc-d8f4-4fbc-b840-f1dc1b2680dd|10|CPRFSTAT|Clinical Performance Status|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|ug/kg|PMD|1|CARTRIDGE|MULTI-SLICE SPIRAL CT|Y|||GUARDIAN|OPHTHALMOLOGIST|NA|5|Visit_5|90|1|FOLLOW-UP|2021-02-25|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-30|P1Y2M10DT2H30M|BEFORE|2021-01-18|AFTER|2021-01-30
e|RS|33cc0c60-b4f3-4b6c-9c7f-a4b0f536b0ac|1|NTRGRESP|Non-target Response|IWG CHESON AML 2003|[?]|copies/mL|CRi|1|Bq/mL|MAGNETIC RESONANCE ELASTOGRAPHY||||INTERVIEWER|NEUROLOGIST 1|U|1|Visit_1|10|2|SCREENING|2020-07-02|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-25|P1Y2M10DT2H30M|COINCIDENT|2020-08-06|AFTER|2020-09-08
e|RS|33cc0c60-b4f3-4b6c-9c7f-a4b0f536b0ac|2|METSIND|Metastatic Indicator|PCWG SCHER PROSTATE CANCER 2016|[?]|mU|iCR|1|PACKET|THIN SMEAR||||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST|U|1|Visit_1|10|7|TREATMENT|2020-07-02|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-25|P1Y2M10DT2H30M|AFTER|2020-09-07|BEFORE|2020-09-17
e|RS|33cc0c60-b4f3-4b6c-9c7f-a4b0f536b0ac|3|NTLWIND|Non-Target Lesion Worsening Indicator|SCHER PROSTATE CANCER 2011|[?]|mg/kg/week|cCR|1|PELLET|ANTIBIOTIC AGAR SCREEN||||INTERVIEWER|MICROSCOPIST 1|N|2|Visit_2|25|6|TREATMENT|2020-07-17|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-22|P1Y2M10DT2H30M|UNKNOWN|2020-07-10|ONGOING|2020-09-17
e|RS|33cc0c60-b4f3-4b6c-9c7f-a4b0f536b0ac|4|NEWLPROG|New Lesion Progression|SCHER PROSTATE CANCER 2011|[?]|dmol|PSEUDORESPONSE|1|fmol/g|TWO-COLOR MICROARRAY|Y|Y||CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST|Y|2|Visit_2|25|6|TREATMENT|2020-07-17|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-22|P1Y2M10DT2H30M|BEFORE|2020-09-25|ONGOING|2020-09-29
e|RS|33cc0c60-b4f3-4b6c-9c7f-a4b0f536b0ac|5|MRPHRESP|Morphologic Response|CHESON LYMPHOMA 2008|[?]|Ci|MR|1|ugEq|LUXOL FAST BLUE AND CRESYL VIOLET STAIN|Y|||INVESTIGATOR|ADJUDICATOR|Y|3|Visit_3|40|5|WASHOUT|2020-08-01|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-30|P1Y2M10DT2H30M|BEFORE|2020-07-09|COINCIDENT|2020-07-23
e|RS|33cc0c60-b4f3-4b6c-9c7f-a4b0f536b0ac|6|NEWLIND|New Lesion Indicator|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|SFC/10^6 PBMC|OPTIMAL MORPHOLOGIC RESPONSE|1|ngEq/L|PET/CT SCAN WITHOUT CONTRAST|Y|||CLINICAL STUDY SPONSOR|PATHOLOGIST 2|U|3|Visit_3|40|6|TREATMENT|2020-08-01|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-30|P1Y2M10DT2H30M|COINCIDENT|2020-08-16|COINCIDENT|2020-09-22
e|RS|33cc0c60-b4f3-4b6c-9c7f-a4b0f536b0ac|7|MRPHRESP|Morphologic Response|AJCC V7|[?]|10^6 RNA copies/mL|PD|1|MBP|INFRARED SPECTROMETRY||||GUARDIAN|PATHOLOGIST|U|4|Visit_4|65|3|TREATMENT|2020-08-26|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-09|P1Y2M10DT2H30M|BEFORE|2020-09-04|COINCIDENT|2020-09-20
e|RS|33cc0c60-b4f3-4b6c-9c7f-a4b0f536b0ac|8|CYTORESP|Cytogenetic Response|LUGANO CLASSIFICATION|[?]|umol/L/sec|NON-PD|1|SPRAY|SCANNING ELECTRON MICROSCOPY||||GUARDIAN|ADJUDICATOR 3|NA|4|Visit_4|65|7|TREATMENT|2020-08-26|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-09|P1Y2M10DT2H30M|BEFORE|2020-08-09|ONGOING|2020-09-11
e|RS|33cc0c60-b4f3-4b6c-9c7f-a4b0f536b0ac|9|LIVRRESP|Liver Response|WHO BREAST CANCER 2006|[?]|nmol/mL/min|INCREASED|1|dmol|IMMUNOASSAY||||INTERVIEWER|PATHOLOGIST 1|NA|5|Visit_5|90|6|WASHOUT|2020-09-20|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-19|P1Y2M10DT2H30M|COINCIDENT|2020-07-06|BEFORE|2020-08-02
e|RS|33cc0c60-b4f3-4b6c-9c7f-a4b0f536b0ac|10|RDIORESP|Radiologic Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|/mm|PD|1|cup eq|WHOLE GENOME SEQUENCING||Y||CHILD|READER|NA|5|Visit_5|90|1|WASHOUT|2020-09-20|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-19|P1Y2M10DT2H30M|UNKNOWN|2020-07-14|BEFORE|2020-08-27
e|RS|94c7f1e8-9703-4376-9cb2-6a1344dbf8cd|1|PATHRESP|Pathologic Response|EBMT BLADE MYELOMA 1998|||NR|1|fL|NO INFORMATION|Y||Y|SPOUSE|OTOLARYNGOLOGIST|U|1|Visit_1|10|7|TREATMENT|2020-11-17|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-03|P1Y2M10DT2H30M|UNKNOWN|2020-11-11|BEFORE|2021-02-01
e|RS|94c7f1e8-9703-4376-9cb2-6a1344dbf8cd|2|NTNERESP|Non-Target Non-Enhancing Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|mL/g/day|CHR|1|10^3 RNA copies/mL|PET SCAN||||INTERVIEWER|READER 3|U|1|Visit_1|10|6|SCREENING|2020-11-17|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-03|P1Y2M10DT2H30M|BEFORE|2021-01-09|BEFORE|2021-02-12
e|RS|94c7f1e8-9703-4376-9cb2-6a1344dbf8cd|3|TRGRESP|Target Response|MURPHY PROSTATE CANCER 1980|||MORPHOLOGIC CRi|1|gtt|HPLC/MS/MS|||Y|DOMESTIC PARTNER|ONCOLOGIST 1|Y|2|Visit_2|25|7|FOLLOW-UP|2020-12-02|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-16|P1Y2M10DT2H30M|BEFORE|2020-12-11|COINCIDENT|2021-01-15
e|RS|94c7f1e8-9703-4376-9cb2-6a1344dbf8cd|4|BESTRESP|Best Overall Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|||INDETERMINATE RESPONSE|1|AMPULE|ULTRASOUND|Y|Y|Y|FAMILY MEMBER|PATHOLOGIST|Y|2|Visit_2|25|3|WASHOUT|2020-12-02|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-16|P1Y2M10DT2H30M|BEFORE|2020-12-13|AFTER|2021-01-17
e|RS|94c7f1e8-9703-4376-9cb2-6a1344dbf8cd|5|NEWLIND|New Lesion Indicator|CHOLLET BREAST CANCER 2002|[?]|mEq/day|MORPHOLOGIC CRi|1|lm|URANYL ACETATE STAIN||Y||VENDOR|PHYSIOTHERAPIST|Y|3|Visit_3|40|1|TREATMENT|2020-12-17|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-05|P1Y2M10DT2H30M|BEFORE|2021-02-03|BEFORE|2021-02-09
e|RS|94c7f1e8-9703-4376-9cb2-6a1344dbf8cd|6|SPLNRESP|Spleen Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|ug/mol|MAJOR PATHOLOGIC RESPONSE|1|IU/mmol|QUANTITATIVE CORONARY ANGIOGRAPHY||||CLINICAL RESEARCH COORDINATOR|PHYSIOTHERAPIST|N|3|Visit_3|40|1|WASHOUT|2020-12-17|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-05|P1Y2M10DT2H30M|BEFORE|2020-12-20|BEFORE|2021-01-06
e|RS|94c7f1e8-9703-4376-9cb2-6a1344dbf8cd|7|DRCRIND|Disease Recurrence Indicator|CHESON NON-HODGKINS LYMPHOMA 1999|||CYTOGENETIC PR|1|/kg|AMSLER GRID|||Y|CAREGIVER|HEMATOLOGIST|Y|4|Visit_4|65|6|TREATMENT|2021-01-11|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-18|P1Y2M10DT2H30M|AFTER|2020-11-19|ONGOING|2020-12-26
e|RS|94c7f1e8-9703-4376-9cb2-6a1344dbf8cd|8|CLINRESP|Clinical Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|MONTHS|CR|1|ug/g/min|ELECTROCHEMILUMINESCENCE||||INVESTIGATOR|READER 1|N|4|Visit_4|65|4|WASHOUT|2021-01-11|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-18|P1Y2M10DT2H30M|AFTER|2021-02-07|BEFORE|2021-02-12
e|RS|94c7f1e8-9703-4376-9cb2-6a1344dbf8cd|9|BMIVLIND|Bone Marrow Involvement Indicator|MONTSERRAT CLL 1989|[?]|BISCUIT|pCR|1|CCID 50/dose|RADIOIMMUNOPRECIPITATION ASSAY||||NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|N|5|Visit_5|90|1|SCREENING|2021-02-05|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-10|P1Y2M10DT2H30M|BEFORE|2020-12-11|COINCIDENT|2021-01-25
e|RS|94c7f1e8-9703-4376-9cb2-6a1344dbf8cd|10|NEWLWIND|New Lesion Worsening Indicator|DURIE MULTIPLE MYELOMA 2006|[?]|10^9 organisms/mg|DISEASE TRANSFORMATION|1|mL/mmHg|CONTRAST ENHANCED SPIRAL CT SCAN|Y|||DOMESTIC PARTNER|RATER 2|Y|5|Visit_5|90|3|FOLLOW-UP|2021-02-05|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-10|P1Y2M10DT2H30M|UNKNOWN|2020-12-06|BEFORE|2020-12-22
e|RS|20abe0d2-bbe5-422b-b9a7-ae645928b0bf|1|NTLWIND|Non-Target Lesion Worsening Indicator|IWG CHESON AML 2003|[?]|g/dL|MORPHOLOGIC CR|1|mEq/mmol|IODINE STAIN||||INVESTIGATOR|MICROSCOPIST 1|Y|1|Visit_1|10|1|FOLLOW-UP|2020-10-27|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-07|P1Y2M10DT2H30M|AFTER|2020-11-26|AFTER|2021-01-19
e|RS|20abe0d2-bbe5-422b-b9a7-ae645928b0bf|2|NTERESP|Non-Target Enhancing Response|NCIWG CHESON CLL 1996|[?]|V/sec|VGPR|1|vp/mL|ULTRASONOGRAPHIC ELASTOGRAPHY||||INTERVIEWER|CARDIOLOGIST|NA|1|Visit_1|10|4|WASHOUT|2020-10-27|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-07|P1Y2M10DT2H30M|AFTER|2021-01-09|COINCIDENT|2021-01-15
e|RS|20abe0d2-bbe5-422b-b9a7-ae645928b0bf|3|CYTORESP|Cytogenetic Response|IWC HALLEK CLL 2008|||RELAPSED DISEASE FROM CR OR PR|1|kPa|HEMAGGLUTINATION ASSAY|||Y|DOMESTIC PARTNER|ENDOCRINOLOGIST|Y|2|Visit_2|25|7|SCREENING|2020-11-11|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-30|P1Y2M10DT2H30M|COINCIDENT|2021-01-09|COINCIDENT|2021-01-15
e|RS|20abe0d2-bbe5-422b-b9a7-ae645928b0bf|4|MRDIND|Minimal Residual Disease Indicator|HARTMANN GERM CELL CANCER 2002|[?]|vp/dose|CHR|1|m3|LASER CAPTURE MICRODISSECTION||||SPOUSE|RADIOLOGIST|Y|2|Visit_2|25|4|SCREENING|2020-11-11|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-30|P1Y2M10DT2H30M|COINCIDENT|2020-10-22|COINCIDENT|2020-11-14
e|RS|20abe0d2-bbe5-422b-b9a7-ae645928b0bf|5|LIVRRESP|Liver Response|SACT|[?]|dmol|CA125 50% RESPONSE|1|P|DC SHEATH FLOW||||INDEPENDENT ASSESSOR|ADJUDICATOR|Y|3|Visit_3|40|2|TREATMENT|2020-11-26|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-11|P1Y2M10DT2H30M|COINCIDENT|2021-01-12|ONGOING|2021-01-23
e|RS|20abe0d2-bbe5-422b-b9a7-ae645928b0bf|6|NTNERESP|Non-Target Non-Enhancing Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|/40 HPFs|NED|1|um/s|NEURAMINIDASE INHIBITION ASSAY||||ADJUDICATOR|PEDIATRIC NEUROLOGIST|Y|3|Visit_3|40|4|FOLLOW-UP|2020-11-26|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-11|P1Y2M10DT2H30M|UNKNOWN|2021-01-06|ONGOING|2021-01-15
e|RS|20abe0d2-bbe5-422b-b9a7-ae645928b0bf|7|CLINRESP|Clinical Response|RECICL|[?]|BP|INCREASED|1|cm/s|CLOT DETECTION||Y||FRIEND|OPHTHALMOLOGIST|U|4|Visit_4|65|3|TREATMENT|2020-12-21|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-09|P1Y2M10DT2H30M|BEFORE|2020-12-18|ONGOING|2020-12-24
e|RS|20abe0d2-bbe5-422b-b9a7-ae645928b0bf|8|NTLWIND|Non-Target Lesion Worsening Indicator|UNSPECIFIED|[?]|TRACE|ABSENT MORPHOLOGIC RESPONSE|1|g/mol|U-HPLC/MS/MS||||PARENT|RATER|Y|4|Visit_4|65|1|TREATMENT|2020-12-21|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-09|P1Y2M10DT2H30M|AFTER|2021-01-05|BEFORE|2021-01-16
e|RS|20abe0d2-bbe5-422b-b9a7-ae645928b0bf|9|MRPHRESP|Morphologic Response|CHESON CLL 2006|[?]|/sec|STABLE|1|ug/h|LINE PROBE ASSAY||Y||SPOUSE|ONCOLOGIST 1|N|5|Visit_5|90|6|FOLLOW-UP|2021-01-15|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-20|P1Y2M10DT2H30M|UNKNOWN|2020-12-05|BEFORE|2021-01-17
e|RS|20abe0d2-bbe5-422b-b9a7-ae645928b0bf|10|NTERESP|Non-Target Enhancing Response|CHESON LYMPHOMA 2008|[?]|USP U|FAVORABLE RESPONSE|1|NEEDLE GAUGE|CALIPER MEASUREMENT METHOD||Y||FRIEND|RADIOLOGIST 1|N|5|Visit_5|90|3|FOLLOW-UP|2021-01-15|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-20|P1Y2M10DT2H30M|COINCIDENT|2021-01-23|BEFORE|2021-01-24
e|RS|b5644705-65e9-4d9b-9f5c-f8f62d26e257|1|NTNERESP|Non-Target Non-Enhancing Response|RECIST 1.1|[?]|MET*min|MOLECULAR MAJOR RESPONSE|1|yd|MICROPARTICLE ENZYME IMMUNOASSAY|Y|Y||CLINICAL STUDY SPONSOR|READER 2|N|1|Visit_1|10|1|TREATMENT|2020-12-24|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-17|P1Y2M10DT2H30M|AFTER|2021-01-21|ONGOING|2021-02-26
e|RS|b5644705-65e9-4d9b-9f5c-f8f62d26e257|2|RDIORESP|Radiologic Response|RECICL|[?]|PACKAGE|CR|1|fmol/L|PHOROPTER||||CLINICAL RESEARCH ASSOCIATE|PEDIATRIC NEUROLOGIST|NA|1|Visit_1|10|2|WASHOUT|2020-12-24|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-17|P1Y2M10DT2H30M|UNKNOWN|2021-01-18|COINCIDENT|2021-03-19
e|RS|b5644705-65e9-4d9b-9f5c-f8f62d26e257|3|CLINRESP|Clinical Response|MURPHY PROSTATE CANCER 1980|[?]|U/kg/min|IMMUNOPHENOTYPIC CR|1|nmol/mol|OPHTHALMOSCOPY||||ADJUDICATION COMMITTEE|CARDIOLOGIST|N|2|Visit_2|25|4|TREATMENT|2021-01-08|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-10|P1Y2M10DT2H30M|COINCIDENT|2021-02-18|AFTER|2021-02-27
e|RS|b5644705-65e9-4d9b-9f5c-f8f62d26e257|4|CLINRESP|Clinical Response|WOLCHOK SOLID TUMORS 2009|||HI-P|1|INHALATION|EEG|||Y|HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|Y|2|Visit_2|25|7|SCREENING|2021-01-08|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-10|P1Y2M10DT2H30M|AFTER|2021-01-23|BEFORE|2021-03-02
e|RS|b5644705-65e9-4d9b-9f5c-f8f62d26e257|5|OVRLRESP|Overall Response|CHESON LYMPHOMA 2008|[?]|mL/kg/h|PR-CT|1|GBq|QUANTITATIVE PERIPHERAL ANGIOGRAPHY|Y|Y||SIBLING|RATER 2|U|3|Visit_3|40|4|TREATMENT|2021-01-23|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-06|P1Y2M10DT2H30M|UNKNOWN|2021-02-21|AFTER|2021-02-27
e|RS|b5644705-65e9-4d9b-9f5c-f8f62d26e257|6|ANATRESP|Anatomic Response|HARTMANN GERM CELL CANCER 2002|[?]|BAG|iCR|1|min|RADIOGRAPHY||||FRIEND|NEUROLOGIST 2|Y|3|Visit_3|40|7|WASHOUT|2021-01-23|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-06|P1Y2M10DT2H30M|BEFORE|2021-02-23|ONGOING|2021-03-18
e|RS|b5644705-65e9-4d9b-9f5c-f8f62d26e257|7|CYTORESP|Cytogenetic Response|BURCOMBE BREAST CANCER 2005|[?]|GLOBULE|MOLECULAR MAJOR RESPONSE|1|BAU/mL|CONTRAST ENHANCED PET SCAN||Y||FRIEND|NEUROLOGIST 1|NA|4|Visit_4|65|5|TREATMENT|2021-02-17|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-23|P1Y2M10DT2H30M|UNKNOWN|2021-01-06|BEFORE|2021-03-08
e|RS|b5644705-65e9-4d9b-9f5c-f8f62d26e257|8|BMIVLIND|Bone Marrow Involvement Indicator|RAJKUMAR MYELOMA 2011|[?]|aMFI|VGPR|1|TABLET|LASER CAPTURE MICRODISSECTION|Y|Y||HEALTH CARE PROFESSIONAL|DERMATOLOGIST|Y|4|Visit_4|65|4|WASHOUT|2021-02-17|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-23|P1Y2M10DT2H30M|COINCIDENT|2021-01-18|COINCIDENT|2021-02-16
e|RS|b5644705-65e9-4d9b-9f5c-f8f62d26e257|9|MRDIND|Minimal Residual Disease Indicator|CHESON LYMPHOMA 2008|||DISEASE TRANSFORMATION|1|ug/h|IMMUNOASSAY||Y|Y|SIGNIFICANT OTHER|RATER|N|5|Visit_5|90|7|TREATMENT|2021-03-14|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-30|P1Y2M10DT2H30M|BEFORE|2021-01-30|COINCIDENT|2021-02-14
e|RS|b5644705-65e9-4d9b-9f5c-f8f62d26e257|10|MRDIND|Minimal Residual Disease Indicator|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|||sCR|1|POUCH|PET SCAN|||Y|CHILD|OPTOMETRIST|U|5|Visit_5|90|1|TREATMENT|2021-03-14|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-30|P1Y2M10DT2H30M|BEFORE|2020-12-23|BEFORE|2021-02-01
e|RS|ec82f59b-197a-4ccc-b5e5-d91627a86a27|1|STRUSTAT|Steroid Use Status|RECIST 1.1|||MORPHOLOGIC CR|1|mOsm/kg|DROPLET DIGITAL PCR|||Y|INVESTIGATOR|NEUROLOGIST 2|Y|1|Visit_1|10|2|TREATMENT|2020-05-16|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-12|P1Y2M10DT2H30M|UNKNOWN|2020-05-26|AFTER|2020-05-29
e|RS|ec82f59b-197a-4ccc-b5e5-d91627a86a27|2|NTERESP|Non-Target Enhancing Response|IRANO 2015|[?]|JAR|CR-CT|1|damol/L|PUPILLOMETRY|Y|Y||NON-HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|N|1|Visit_1|10|4|FOLLOW-UP|2020-05-16|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-12|P1Y2M10DT2H30M|AFTER|2020-05-14|AFTER|2020-07-18
e|RS|ec82f59b-197a-4ccc-b5e5-d91627a86a27|3|BESTRESP|Best Overall Response|AJCC V8|[?]|BP|NON-QUANTIFIABLE MRD POSITIVITY|1|ppth|CHROMATOGRAPHY||||ADJUDICATION COMMITTEE|CLINICAL PATHOLOGIST|NA|2|Visit_2|25|4|FOLLOW-UP|2020-05-31|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-31|P1Y2M10DT2H30M|COINCIDENT|2020-05-23|COINCIDENT|2020-06-14
e|RS|ec82f59b-197a-4ccc-b5e5-d91627a86a27|4|MRPHRESP|Morphologic Response|BURCOMBE BREAST CANCER 2005|[?]|mmol/L|CHR|1|10^6 IU/mL|PERIODIC ACID SCHIFF STAIN|Y|||PARENT|RATER 1|Y|2|Visit_2|25|2|WASHOUT|2020-05-31|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-31|P1Y2M10DT2H30M|COINCIDENT|2020-08-03|ONGOING|2020-08-11
e|RS|ec82f59b-197a-4ccc-b5e5-d91627a86a27|5|BMIVLIND|Bone Marrow Involvement Indicator|HARTMANN GERM CELL CANCER 2002|[?]|AgU/mL|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|WEEKS|SIZE EXCLUSION CHROMATOGRAPHY||||INTERVIEWER|PEDIATRIC NEUROLOGIST|NA|3|Visit_3|40|6|TREATMENT|2020-06-15|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-21|P1Y2M10DT2H30M|COINCIDENT|2020-06-21|ONGOING|2020-08-05
e|RS|ec82f59b-197a-4ccc-b5e5-d91627a86a27|6|CYTORESP|Cytogenetic Response|IRANO 2015|||NON-CR/NON-PD|1|PFU|TONOMETRY||Y|Y|INTERVIEWER|ADJUDICATOR|U|3|Visit_3|40|4|WASHOUT|2020-06-15|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-21|P1Y2M10DT2H30M|COINCIDENT|2020-07-06|ONGOING|2020-07-30
e|RS|ec82f59b-197a-4ccc-b5e5-d91627a86a27|7|NTLWIND|Non-Target Lesion Worsening Indicator|HARTMANN GERM CELL CANCER 2002|[?]|nU/cL|MORPHOLOGIC LEUKEMIA-FREE STATE|1|log10 TCID 50/mL|WHOLE TRANSCRIPTOME SEQUENCING||||VENDOR|NEUROLOGIST|U|4|Visit_4|65|1|WASHOUT|2020-07-10|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-16|P1Y2M10DT2H30M|BEFORE|2020-05-25|ONGOING|2020-08-13
e|RS|ec82f59b-197a-4ccc-b5e5-d91627a86a27|8|CPRFSTAT|Clinical Performance Status|PERCIST|[?]|Torr|MINOR PATHOLOGIC RESPONSE|1|mL/mmHg/min/L|AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT||Y||STUDY SUBJECT|MICROSCOPIST 3|N|4|Visit_4|65|6|TREATMENT|2020-07-10|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-16|P1Y2M10DT2H30M|COINCIDENT|2020-05-21|COINCIDENT|2020-07-07
e|RS|ec82f59b-197a-4ccc-b5e5-d91627a86a27|9|LIVRRESP|Liver Response|KEAM BREAST CANCER 2013|[?]|log10 TCID 50/dose|CA125 50% RESPONSE|1|mL/sec/1.73m2|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION||||HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|N|5|Visit_5|90|5|FOLLOW-UP|2020-08-04|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-16|P1Y2M10DT2H30M|AFTER|2020-07-16|AFTER|2020-08-06
e|RS|ec82f59b-197a-4ccc-b5e5-d91627a86a27|10|ANATRESP|Anatomic Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|TCID 50/dose|iCPD|1|10^3 organisms/mL|AGAR DILUTION||Y||PROXY|OPTOMETRIST|Y|5|Visit_5|90|5|TREATMENT|2020-08-04|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-16|P1Y2M10DT2H30M|AFTER|2020-06-10|BEFORE|2020-08-01
e|RS|527fd604-110f-47b1-bd8b-b1de2f5b0d29|1|CPRFSTAT|Clinical Performance Status|HARTMANN GERM CELL CANCER 2002|[?]|ug/m2/day|pCR|1|nkat/g Hb|CHROMATOGRAPHY||Y||SIGNIFICANT OTHER|MICROSCOPIST 1|NA|1|Visit_1|10|4|FOLLOW-UP|2020-11-29|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-03|P1Y2M10DT2H30M|AFTER|2020-12-09|BEFORE|2021-02-08
e|RS|527fd604-110f-47b1-bd8b-b1de2f5b0d29|2|BESTRESP|Best Overall Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|mOsm/kg|SD-CT|1|TABLET|FARNSWORTH-MUNSELL 100 HUE TEST|Y|Y||FRIEND|ONCOLOGIST 2|U|1|Visit_1|10|3|FOLLOW-UP|2020-11-29|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-03|P1Y2M10DT2H30M|COINCIDENT|2021-01-18|BEFORE|2021-01-28
e|RS|527fd604-110f-47b1-bd8b-b1de2f5b0d29|3|MRPHRESP|Morphologic Response|BLAZER COLORECTAL CANCER 2008|[?]|GBq/mg|MRD RELAPSE|1|psi|KARYOTYPING||||SPOUSE|NEUROLOGIST 2|NA|2|Visit_2|25|7|SCREENING|2020-12-14|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-14|P1Y2M10DT2H30M|UNKNOWN|2021-02-01|AFTER|2021-02-22
e|RS|527fd604-110f-47b1-bd8b-b1de2f5b0d29|4|NTNERESP|Non-Target Non-Enhancing Response|PETIT BREAST CANCER 2001|||QUANTIFIABLE MRD POSITIVITY|1|kg/cm2|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY|||Y|FRIEND|RADIOLOGIST 2|U|2|Visit_2|25|6|TREATMENT|2020-12-14|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-14|P1Y2M10DT2H30M|UNKNOWN|2020-12-26|ONGOING|2021-01-04
e|RS|527fd604-110f-47b1-bd8b-b1de2f5b0d29|5|NEWLIND|New Lesion Indicator|LUGANO CLASSIFICATION|||CR|1|10^4 CFU/mL|NEURAMINIDASE INHIBITION ASSAY|Y|Y|Y|PROXY|READER 1|NA|3|Visit_3|40|5|FOLLOW-UP|2020-12-29|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-19|P1Y2M10DT2H30M|AFTER|2020-12-30|ONGOING|2021-01-06
e|RS|527fd604-110f-47b1-bd8b-b1de2f5b0d29|6|MRPHRESP|Morphologic Response|EASL BRUIX LIVER CANCER 2001|[?]|/10^4|CA125 50% RESPONSE|1|Hounsfield Unit|CONTACT SPECULAR MICROSCOPY|Y|||STUDY SUBJECT|MICROSCOPIST 2|N|3|Visit_3|40|6|TREATMENT|2020-12-29|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-19|P1Y2M10DT2H30M|COINCIDENT|2020-11-24|AFTER|2020-12-10
e|RS|527fd604-110f-47b1-bd8b-b1de2f5b0d29|7|SFTSRESP|Soft Tissue Response|UNSPECIFIED|[?]|EVENTS|SMD|1|ohm|OPTICAL COHERENCE TOMOGRAPHY||||PROXY|RATER|NA|4|Visit_4|65|5|TREATMENT|2021-01-23|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-15|P1Y2M10DT2H30M|AFTER|2021-01-24|COINCIDENT|2021-02-03
e|RS|527fd604-110f-47b1-bd8b-b1de2f5b0d29|8|BMIVLIND|Bone Marrow Involvement Indicator|HARTMANN GERM CELL CANCER 2002|[?]|DDU|MAJOR PATHOLOGIC RESPONSE|1|CAPLET|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION||||INTERVIEWER|PATHOLOGIST 2|Y|4|Visit_4|65|7|TREATMENT|2021-01-23|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-15|P1Y2M10DT2H30M|COINCIDENT|2021-02-03|AFTER|2021-02-26
e|RS|527fd604-110f-47b1-bd8b-b1de2f5b0d29|9|NTERESP|Non-Target Enhancing Response|IRANO 2015|[?]|QUANTITY SUFFICIENT|CYTOGENETIC CR|1|nL|FLUORESCENT SPOT TEST||||CLINICAL STUDY SPONSOR|RADIOLOGIST 1|NA|5|Visit_5|90|7|WASHOUT|2021-02-17|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-29|P1Y2M10DT2H30M|COINCIDENT|2021-01-10|AFTER|2021-01-27
e|RS|527fd604-110f-47b1-bd8b-b1de2f5b0d29|10|MNPTHIND|Minor Pathological Response Indicator|HAMAOKA BREAST CANCER 2010|[?]|mL/animal|CR|1|mL/cage|MEDIASTINOSCOPY|Y|||GUARDIAN|RATER 1|NA|5|Visit_5|90|1|TREATMENT|2021-02-17|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-29|P1Y2M10DT2H30M|AFTER|2021-01-24|BEFORE|2021-02-19
e|RS|1e1de453-920a-4132-b2f7-6335ee81ec83|1|NEWLPROG|New Lesion Progression|AJCC V8|[?]|uL/mL|NE|1|MBP|SLOAN LETTER EYE CHART 2.5%||||INDEPENDENT ASSESSOR|ONCOLOGIST 2|N|1|Visit_1|10|3|TREATMENT|2020-10-22|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-14|P1Y2M10DT2H30M|UNKNOWN|2020-10-14|AFTER|2020-11-01
e|RS|1e1de453-920a-4132-b2f7-6335ee81ec83|2|NEWLPROG|New Lesion Progression|SACT|||PD/RELAPSE AFTER HI|1|HOURS|IMPEDANCE CONDUCTIVITY|||Y|NON-HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|U|1|Visit_1|10|6|FOLLOW-UP|2020-10-22|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-14|P1Y2M10DT2H30M|AFTER|2021-01-03|AFTER|2021-01-05
e|RS|1e1de453-920a-4132-b2f7-6335ee81ec83|3|NEWLPROG|New Lesion Progression|RECICL|[?]|SFC/10^6 PBMC|PD FROM PR|1|IU/kg/h|MAGNETIC RESONANCE ANGIOGRAPHY|Y|||ADJUDICATION COMMITTEE|RADIOLOGIST 1|Y|2|Visit_2|25|2|TREATMENT|2020-11-06|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-12|P1Y2M10DT2H30M|UNKNOWN|2020-11-07|COINCIDENT|2020-11-29
e|RS|1e1de453-920a-4132-b2f7-6335ee81ec83|4|NEWLPROG|New Lesion Progression|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|||PSEUDORESPONSE|1|copies/ug|CLIP SEQUENCING|||Y|ADJUDICATOR|RATER 2|Y|2|Visit_2|25|3|TREATMENT|2020-11-06|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-12|P1Y2M10DT2H30M|UNKNOWN|2020-12-05|ONGOING|2020-12-31
e|RS|1e1de453-920a-4132-b2f7-6335ee81ec83|5|MJPTHIND|Major Pathological Response Indicator|PERCIST|[?]|TABLET|OPTIMAL MORPHOLOGIC RESPONSE|1|g/cage|DIFFUSION TENSOR MRI|Y|||VENDOR|NEUROLOGIST|Y|3|Visit_3|40|2|TREATMENT|2020-11-21|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-06|P1Y2M10DT2H30M|AFTER|2020-10-26|ONGOING|2020-12-01
e|RS|1e1de453-920a-4132-b2f7-6335ee81ec83|6|NTRGRESP|Non-target Response|RANO|[?]|ug/g/h|MRD RELAPSE|1|mmHg*min/L|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY|Y|||FAMILY MEMBER|RATER 1|Y|3|Visit_3|40|6|TREATMENT|2020-11-21|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-06|P1Y2M10DT2H30M|UNKNOWN|2020-10-26|AFTER|2020-12-05
e|RS|1e1de453-920a-4132-b2f7-6335ee81ec83|7|SFTSRESP|Soft Tissue Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|ELISA unit/mL|PMR|1|BU|TURBIDIMETRY||||INVESTIGATOR|RATER 1|U|4|Visit_4|65|1|TREATMENT|2020-12-16|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-03|P1Y2M10DT2H30M|BEFORE|2020-11-17|COINCIDENT|2021-01-10
e|RS|1e1de453-920a-4132-b2f7-6335ee81ec83|8|STRUSTAT|Steroid Use Status|AJCC V7|[?]|mg/m2/min|sCR|1|ng/mol|ELLA||||ADJUDICATOR|ENDOCRINOLOGIST|N|4|Visit_4|65|6|SCREENING|2020-12-16|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-03|P1Y2M10DT2H30M|UNKNOWN|2020-10-26|AFTER|2020-12-18
e|RS|1e1de453-920a-4132-b2f7-6335ee81ec83|9|NTNERESP|Non-Target Non-Enhancing Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|10^3 organisms/mL|NON-CR/NON-PD|1|um/s|SLIT LAMP|Y|||CAREGIVER|READER 1|U|5|Visit_5|90|6|FOLLOW-UP|2021-01-10|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-23|P1Y2M10DT2H30M|AFTER|2020-11-21|ONGOING|2020-12-31
e|RS|1e1de453-920a-4132-b2f7-6335ee81ec83|10|LIVRRESP|Liver Response|MONTSERRAT CLL 1989|[?]|cGy|MOLECULAR CR|1|MPS U|AUSCULTATION||||GUARDIAN|RADIOLOGIST 2|U|5|Visit_5|90|3|TREATMENT|2021-01-10|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-23|P1Y2M10DT2H30M|BEFORE|2020-11-20|ONGOING|2020-12-17
e|RS|e553ad8e-96f4-4cb0-a005-51e9b64513b7|1|NEWLIND|New Lesion Indicator|GUILHOT CML 2007|||cCR|1|lm|MULTIPLEXED BEAD BASED IMMUNOASSAY|Y||Y|CLINICAL STUDY SPONSOR|PEDIATRIC NEUROLOGIST|U|1|Visit_1|10|4|TREATMENT|2020-06-29|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-12|P1Y2M10DT2H30M|COINCIDENT|2020-09-14|AFTER|2020-09-17
e|RS|e553ad8e-96f4-4cb0-a005-51e9b64513b7|2|NEWLWIND|New Lesion Worsening Indicator|BRUGGEMANN MRD 2010|[?]|mL/m2/h|mCR|1|pptr|SINGLE-MOLECULE ARRAY|Y|||VENDOR|RADIOLOGIST|U|1|Visit_1|10|6|SCREENING|2020-06-29|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-12|P1Y2M10DT2H30M|BEFORE|2020-07-26|ONGOING|2020-08-24
e|RS|e553ad8e-96f4-4cb0-a005-51e9b64513b7|3|MJPTHIND|Major Pathological Response Indicator|MACDONALD GLIOMA 1990|[?]|mmHg/L/min|MRD PERSISTENCE|1|uSiemens|ICP-MS||||PROXY|NEUROLOGIST 2|N|2|Visit_2|25|7|WASHOUT|2020-07-14|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-21|P1Y2M10DT2H30M|COINCIDENT|2020-08-15|ONGOING|2020-09-06
e|RS|e553ad8e-96f4-4cb0-a005-51e9b64513b7|4|BESTRESP|Best Overall Response|KUKER LYMPHOMA 2005|||CA125 75% RESPONSE|1|KIT|SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY|||Y|VENDOR|ADJUDICATOR 3|U|2|Visit_2|25|4|TREATMENT|2020-07-14|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-21|P1Y2M10DT2H30M|COINCIDENT|2020-07-27|COINCIDENT|2020-08-30
e|RS|e553ad8e-96f4-4cb0-a005-51e9b64513b7|5|METSIND|Metastatic Indicator|BLAZER COLORECTAL CANCER 2008|[?]|cup eq|EQUIVOCAL|1|uCi/kg|GC/FID|Y|||INDEPENDENT ASSESSOR|NEUROLOGIST 1|N|3|Visit_3|40|7|TREATMENT|2020-07-29|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-20|P1Y2M10DT2H30M|AFTER|2020-09-16|COINCIDENT|2020-09-23
e|RS|e553ad8e-96f4-4cb0-a005-51e9b64513b7|6|ANATRESP|Anatomic Response|FAROOQUI SUPP CLL 2014|[?]|steps/min|MRD RELAPSE|1|uIU/dL|BIOIMPEDANCE SPECTROSCOPY|Y|||STUDY SUBJECT|MICROSCOPIST 1|Y|3|Visit_3|40|4|FOLLOW-UP|2020-07-29|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-20|P1Y2M10DT2H30M|BEFORE|2020-08-16|BEFORE|2020-09-05
e|RS|e553ad8e-96f4-4cb0-a005-51e9b64513b7|7|NTRGRESP|Non-target Response|iRECIST|[?]|IU/g|CR-CT|1|PIXEL|ROMANOWSKY STAIN|Y|Y||INTERVIEWER|READER 3|Y|4|Visit_4|65|3|TREATMENT|2020-08-23|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-21|P1Y2M10DT2H30M|BEFORE|2020-07-24|BEFORE|2020-08-26
e|RS|e553ad8e-96f4-4cb0-a005-51e9b64513b7|8|PATHRESP|Pathologic Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|nmol/kg/day|WORSENED|1|CUP|GC/FID||||CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 2|U|4|Visit_4|65|5|SCREENING|2020-08-23|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-21|P1Y2M10DT2H30M|COINCIDENT|2020-08-18|COINCIDENT|2020-08-27
e|RS|e553ad8e-96f4-4cb0-a005-51e9b64513b7|9|TRGRESP|Target Response|KEAM BREAST CANCER 2013|[?]|/month|QUANTIFIABLE MRD POSITIVITY|1|HEP|ELECTRICAL IMPEDANCE MYOGRAPHY|Y|||ADJUDICATION COMMITTEE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|5|Visit_5|90|7|SCREENING|2020-09-17|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-30|P1Y2M10DT2H30M|AFTER|2020-09-22|AFTER|2020-09-26
e|RS|e553ad8e-96f4-4cb0-a005-51e9b64513b7|10|METBRESP|Metabolic Response|PERCIST|[?]|nmol|CA125 75% RESPONSE|1|ug/g/min|TOTAL BODY RADIOGRAPHY||||FAMILY MEMBER|MICROSCOPIST 1|Y|5|Visit_5|90|2|TREATMENT|2020-09-17|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-30|P1Y2M10DT2H30M|AFTER|2020-09-01|BEFORE|2020-09-24
e|RS|9bd9a8ad-dafd-46e0-a51c-c086ca4e9c0c|1|OVRLRESP|Overall Response|IRANO 2015|[?]|deg2|MR|1|U/mL|MICROBIAL CULTURE, SOLID||||CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 1|N|1|Visit_1|10|6|WASHOUT|2020-12-16|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-03|P1Y2M10DT2H30M|BEFORE|2021-01-11|AFTER|2021-02-09
e|RS|9bd9a8ad-dafd-46e0-a51c-c086ca4e9c0c|2|MJPTHIND|Major Pathological Response Indicator|PCWG SCHER PROSTATE CANCER 2016|[?]|mV2/Hz|OPTIMAL MORPHOLOGIC RESPONSE|1|U/cL|FLUORESCENT IMMUNOASSAY|Y|||SIBLING|ONCOLOGIST 1|U|1|Visit_1|10|5|TREATMENT|2020-12-16|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-03|P1Y2M10DT2H30M|UNKNOWN|2021-03-06|ONGOING|2021-03-11
e|RS|9bd9a8ad-dafd-46e0-a51c-c086ca4e9c0c|3|TMRESP|Tumor Marker Response|BRUGGEMANN MRD 2010|[?]|Antibody Unit|NON-CR/NON-PD|1|SBE/mL|MEDIASTINOSCOPY|Y|Y||CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 1|Y|2|Visit_2|25|2|FOLLOW-UP|2020-12-31|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-05|P1Y2M10DT2H30M|UNKNOWN|2021-03-14|BEFORE|2021-03-15
e|RS|9bd9a8ad-dafd-46e0-a51c-c086ca4e9c0c|4|OVRLRESP|Overall Response|BLAZER COLORECTAL CANCER 2008|[?]|MONTHS|CYTOGENETIC NO RESPONSE|1|dmol|SIZE EXCLUSION CHROMATOGRAPHY||Y||STUDY SUBJECT|MICROSCOPIST 2|Y|2|Visit_2|25|5|TREATMENT|2020-12-31|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-05|P1Y2M10DT2H30M|COINCIDENT|2021-01-01|ONGOING|2021-01-17
e|RS|9bd9a8ad-dafd-46e0-a51c-c086ca4e9c0c|5|BMIVLIND|Bone Marrow Involvement Indicator|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|ECL unit|DECREASED|1|umol|MOUSE PROTECTION ASSAY|Y|||PROXY|INTERNIST|NA|3|Visit_3|40|1|TREATMENT|2021-01-15|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-13|P1Y2M10DT2H30M|COINCIDENT|2021-01-20|BEFORE|2021-02-14
e|RS|9bd9a8ad-dafd-46e0-a51c-c086ca4e9c0c|6|NTNERESP|Non-Target Non-Enhancing Response|NCCN ALL MRD 2014|[?]|Gy|EQUIVOCAL|1|CAPSULE|PATHOLOGICAL EVALUATION||||INVESTIGATOR|ENDOCRINOLOGIST|Y|3|Visit_3|40|4|TREATMENT|2021-01-15|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-13|P1Y2M10DT2H30M|AFTER|2021-02-14|ONGOING|2021-02-20
e|RS|9bd9a8ad-dafd-46e0-a51c-c086ca4e9c0c|7|BONERESP|Bone Response|RECICL|[?]|log10 PFU|MORPHOLOGIC CRi|1|DPM|ULTRASOUND||||CAREGIVER|READER 1|N|4|Visit_4|65|1|TREATMENT|2021-02-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-05|P1Y2M10DT2H30M|UNKNOWN|2021-03-09|COINCIDENT|2021-03-14
e|RS|9bd9a8ad-dafd-46e0-a51c-c086ca4e9c0c|8|NTNERESP|Non-Target Non-Enhancing Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|dpm/0.5 mL|ABSENT MORPHOLOGIC RESPONSE|1|Frames/s|DOUBLE IMMUNODIFFUSION|Y|||DOMESTIC PARTNER|RATER 2|U|4|Visit_4|65|5|SCREENING|2021-02-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-05|P1Y2M10DT2H30M|COINCIDENT|2021-01-18|BEFORE|2021-03-15
e|RS|9bd9a8ad-dafd-46e0-a51c-c086ca4e9c0c|9|OVRLRESP|Overall Response|PCWG SCHER PROSTATE CANCER 2008|[?]|mV*min|NED|1|GPL U|ISHIHARA COLOR PLATES||||GUARDIAN|RADIOLOGIST|NA|5|Visit_5|90|6|TREATMENT|2021-03-06|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-09|P1Y2M10DT2H30M|COINCIDENT|2021-01-15|BEFORE|2021-02-22
e|RS|9bd9a8ad-dafd-46e0-a51c-c086ca4e9c0c|10|NEWLPROG|New Lesion Progression|IWG CHESON AML 2003|||iCR|1|GBq/ug|PULMONARY ANGIOGRAPHY|Y||Y|SPOUSE|MICROSCOPIST 2|NA|5|Visit_5|90|6|TREATMENT|2021-03-06|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-09|P1Y2M10DT2H30M|COINCIDENT|2020-12-10|ONGOING|2021-01-19
e|RS|c041c7ce-8c14-49cd-a2b2-e7e18b5bc579|1|TRGRESP|Target Response|BRUGGEMANN MRD 2010|[?]|mEq/mmol|CA125 75% RESPONSE|1|10^6/L|ROMANOWSKY STAIN||Y||STUDY SUBJECT|RATER 1|NA|1|Visit_1|10|7|TREATMENT|2020-06-09|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-29|P1Y2M10DT2H30M|UNKNOWN|2020-06-10|BEFORE|2020-07-23
e|RS|c041c7ce-8c14-49cd-a2b2-e7e18b5bc579|2|NEWLPROG|New Lesion Progression|LEE LUNG CANCER 2011|[?]|GBq|UNFAVORABLE RESPONSE|1|PELLET|WESTERN BLOT||||GUARDIAN|PATHOLOGIST|NA|1|Visit_1|10|1|TREATMENT|2020-06-09|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-29|P1Y2M10DT2H30M|BEFORE|2020-06-19|ONGOING|2020-08-17
e|RS|c041c7ce-8c14-49cd-a2b2-e7e18b5bc579|3|ANATRESP|Anatomic Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|/mm2|MORPHOLOGIC CR|1|/5x10^4 WBC|GEL ELECTROPHORESIS|Y|Y||VENDOR|READER 1|N|2|Visit_2|25|3|FOLLOW-UP|2020-06-24|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-02|P1Y2M10DT2H30M|UNKNOWN|2020-09-03|COINCIDENT|2020-09-06
e|RS|c041c7ce-8c14-49cd-a2b2-e7e18b5bc579|4|NEWLIND|New Lesion Indicator|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|/month|NON-iCR/NON-iUPD|1|L/min|PANENDOSCOPY|Y|||PROXY|PATHOLOGIST|U|2|Visit_2|25|1|TREATMENT|2020-06-24|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-02|P1Y2M10DT2H30M|COINCIDENT|2020-06-29|BEFORE|2020-08-26
e|RS|c041c7ce-8c14-49cd-a2b2-e7e18b5bc579|5|HEMARESP|Hematologic Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|10^3 CFU/mL|CYTOGENETIC CR|1|DNA copies/mL|MOUSE PROTECTION ASSAY|Y|||SIBLING|READER 1|U|3|Visit_3|40|7|WASHOUT|2020-07-09|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-14|P1Y2M10DT2H30M|UNKNOWN|2020-09-01|COINCIDENT|2020-09-06
e|RS|c041c7ce-8c14-49cd-a2b2-e7e18b5bc579|6|METSIND|Metastatic Indicator|SCHER PROSTATE CANCER 2011|[?]|umol/h/mmol|mCR|1|YEARS|FLAME PHOTOMETRY||||SPOUSE|OPTOMETRIST|NA|3|Visit_3|40|3|WASHOUT|2020-07-09|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-14|P1Y2M10DT2H30M|COINCIDENT|2020-08-10|COINCIDENT|2020-08-14
e|RS|c041c7ce-8c14-49cd-a2b2-e7e18b5bc579|7|LIVRRESP|Liver Response|RECICL|[?]|nmol/L|MOLECULAR MAJOR RESPONSE|1|CCID 50/dose|NEPHELOMETRY|Y|||FAMILY MEMBER|INTERNIST|NA|4|Visit_4|65|4|TREATMENT|2020-08-03|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-28|P1Y2M10DT2H30M|BEFORE|2020-06-21|COINCIDENT|2020-07-28
e|RS|c041c7ce-8c14-49cd-a2b2-e7e18b5bc579|8|ANATRESP|Anatomic Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|sec|EQUIVOCAL|1|10^8/L|MACRO BROTH DILUTION||Y||INVESTIGATOR|MICROSCOPIST 2|Y|4|Visit_4|65|4|TREATMENT|2020-08-03|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-28|P1Y2M10DT2H30M|BEFORE|2020-06-07|AFTER|2020-07-25
e|RS|c041c7ce-8c14-49cd-a2b2-e7e18b5bc579|9|DRCRIND|Disease Recurrence Indicator|CHESON CLL 2006|[?]|umol/h/mmol|DISEASE TRANSFORMATION|1|anti-Xa IU|ETDRS EYE CHART|Y|||PARENT|DEVELOPMENTAL PSYCHOLOGIST|U|5|Visit_5|90|3|FOLLOW-UP|2020-08-28|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-29|P1Y2M10DT2H30M|UNKNOWN|2020-09-04|BEFORE|2020-09-05
e|RS|c041c7ce-8c14-49cd-a2b2-e7e18b5bc579|10|LIVRRESP|Liver Response|RANO ELLINGSON 2017|||CYTOGENETIC MINIMAL RESPONSE|1|CAPLET|MICROSCOPY|||Y|CLINICAL RESEARCH ASSOCIATE|READER|U|5|Visit_5|90|7|SCREENING|2020-08-28|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-29|P1Y2M10DT2H30M|COINCIDENT|2020-07-16|AFTER|2020-08-05
e|RS|2c9752be-9479-4c18-bb2c-19ffa8dfec3a|1|PATHRESP|Pathologic Response|HAMAOKA BREAST CANCER 2010|[?]|Hounsfield Unit|NON-CR/NON-PD|1|BE/mL|CLIP||||INTERVIEWER|RADIOLOGIST|N|1|Visit_1|10|2|TREATMENT|2020-10-29|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-06|P1Y2M10DT2H30M|COINCIDENT|2021-01-18|COINCIDENT|2021-01-25
e|RS|2c9752be-9479-4c18-bb2c-19ffa8dfec3a|2|TRGRESP|Target Response|PRINCE TCELL LYMPHOMA 2010|[?]|/200 HPFs|MR|1|s^-1(%O2)^-1|DOUBLE IMMUNODIFFUSION||Y||PARENT|PATHOLOGIST 1|U|1|Visit_1|10|4|FOLLOW-UP|2020-10-29|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-06|P1Y2M10DT2H30M|BEFORE|2020-11-16|BEFORE|2020-11-17
e|RS|2c9752be-9479-4c18-bb2c-19ffa8dfec3a|3|NTLWIND|Non-Target Lesion Worsening Indicator|MRANO VAN DEN BENT GLIOMA 2011|[?]|Ci/ug|IMMUNOPHENOTYPIC CR|1|IU|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|Y|Y||PARENT|RATER 1|N|2|Visit_2|25|5|FOLLOW-UP|2020-11-13|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-02|P1Y2M10DT2H30M|UNKNOWN|2020-12-04|BEFORE|2020-12-07
e|RS|2c9752be-9479-4c18-bb2c-19ffa8dfec3a|4|NTERESP|Non-Target Enhancing Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|vp/mL|CA125 75% RESPONSE|1|/200 HPFs|PHOTOMETRIC CLOT DETECTION||||ADJUDICATION COMMITTEE|ONCOLOGIST|N|2|Visit_2|25|3|TREATMENT|2020-11-13|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-02|P1Y2M10DT2H30M|COINCIDENT|2020-12-10|ONGOING|2021-01-18
e|RS|2c9752be-9479-4c18-bb2c-19ffa8dfec3a|5|CLINRESP|Clinical Response|HARTMAN PANCREATIC CANCER 2012|||STABLE|1|C|AURAMINE STAIN|Y||Y|STUDY SUBJECT|DERMATOLOGIST|U|3|Visit_3|40|2|TREATMENT|2020-11-28|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-17|P1Y2M10DT2H30M|UNKNOWN|2021-01-17|AFTER|2021-01-26
e|RS|2c9752be-9479-4c18-bb2c-19ffa8dfec3a|6|OVRLRESP|Overall Response|HARTMAN PANCREATIC CANCER 2012|||MRD PERSISTENCE|1|mL/cage/wk|SMEAR||Y|Y|DOMESTIC PARTNER|RATER|NA|3|Visit_3|40|6|TREATMENT|2020-11-28|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-17|P1Y2M10DT2H30M|AFTER|2020-10-28|ONGOING|2020-11-27
e|RS|2c9752be-9479-4c18-bb2c-19ffa8dfec3a|7|ANATRESP|Anatomic Response|GUPPY OVARIAN CANCER 2002|[?]|10^6 organisms|PR|1|km|PEAK FLOWMETRY||||FAMILY MEMBER|RATER 2|U|4|Visit_4|65|1|WASHOUT|2020-12-23|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-25|P1Y2M10DT2H30M|COINCIDENT|2021-01-22|BEFORE|2021-01-24
e|RS|2c9752be-9479-4c18-bb2c-19ffa8dfec3a|8|SPLNRESP|Spleen Response|SHINDOH COLORECTAL CANCER 2013|[?]|U/mL|HI-P|1|ELISA unit|CLIP||||SIBLING|HEMATOLOGIST|Y|4|Visit_4|65|4|TREATMENT|2020-12-23|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-25|P1Y2M10DT2H30M|UNKNOWN|2021-01-01|ONGOING|2021-01-26
e|RS|2c9752be-9479-4c18-bb2c-19ffa8dfec3a|9|MRDRESP|Minimal Residual Disease Response|RECIST 1.1|[?]|ug/m2/day|pCR|1|m2|SLIT LAMP||||CAREGIVER|READER 1|Y|5|Visit_5|90|1|TREATMENT|2021-01-17|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-06|P1Y2M10DT2H30M|UNKNOWN|2020-10-26|COINCIDENT|2021-01-19
e|RS|2c9752be-9479-4c18-bb2c-19ffa8dfec3a|10|MJPTHIND|Major Pathological Response Indicator|AJCC V7|[?]|10^6 DNA copies/mL|iSD|1|kg/m2|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY||||VENDOR|PATHOLOGIST|NA|5|Visit_5|90|2|SCREENING|2021-01-17|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-06|P1Y2M10DT2H30M|COINCIDENT|2020-12-07|AFTER|2021-01-12
e|RS|083f3f2b-c66c-4a98-95c6-fc2bbceecf7e|1|NTLWIND|Non-Target Lesion Worsening Indicator|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|||IMPROVED|1|copies/uL|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION||Y|Y|INVESTIGATOR|READER 2|Y|1|Visit_1|10|1|SCREENING|2020-12-24|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-03|P1Y2M10DT2H30M|COINCIDENT|2020-12-26|AFTER|2021-01-04
e|RS|083f3f2b-c66c-4a98-95c6-fc2bbceecf7e|2|SFTSRESP|Soft Tissue Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|10^9/L|RELAPSED DISEASE FROM CR OR PR|1|umol/kg/min|HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY|Y|Y||CLINICAL RESEARCH ASSOCIATE|READER 3|N|1|Visit_1|10|4|FOLLOW-UP|2020-12-24|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-03|P1Y2M10DT2H30M|BEFORE|2021-01-05|BEFORE|2021-02-22
e|RS|083f3f2b-c66c-4a98-95c6-fc2bbceecf7e|3|MJPTHIND|Major Pathological Response Indicator|HARTMANN GERM CELL CANCER 2002|||PSEUDORESPONSE|1|SPRAY|KARYOTYPING|||Y|STUDY SUBJECT|RADIOLOGIST 2|NA|2|Visit_2|25|6|WASHOUT|2021-01-08|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-23|P1Y2M10DT2H30M|BEFORE|2021-01-13|COINCIDENT|2021-01-14
e|RS|083f3f2b-c66c-4a98-95c6-fc2bbceecf7e|4|STRUSTAT|Steroid Use Status|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|Joule|ABSENT MORPHOLOGIC RESPONSE|1|TAMPON|OPTICAL COHERENCE TOMOGRAPHY||||CHILD|OTOLARYNGOLOGIST|Y|2|Visit_2|25|1|TREATMENT|2021-01-08|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-23|P1Y2M10DT2H30M|BEFORE|2021-02-08|ONGOING|2021-02-22
e|RS|083f3f2b-c66c-4a98-95c6-fc2bbceecf7e|5|NTRGRESP|Non-target Response|IRANO 2015|||IMMUNOPHENOTYPIC CR|1|mL/kg/day|MAPH|Y|Y|Y|SIGNIFICANT OTHER|MICROSCOPIST 2|Y|3|Visit_3|40|5|WASHOUT|2021-01-23|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-13|P1Y2M10DT2H30M|AFTER|2021-03-22|COINCIDENT|2021-03-23
e|RS|083f3f2b-c66c-4a98-95c6-fc2bbceecf7e|6|BESTRESP|Best Overall Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|ug/m2|PD-CT|1|10^7 TCID 50/dose|HEMAGGLUTINATION ASSAY|Y|||CLINICAL STUDY SPONSOR|ADJUDICATOR 1|N|3|Visit_3|40|3|SCREENING|2021-01-23|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-13|P1Y2M10DT2H30M|AFTER|2021-01-28|ONGOING|2021-02-12
e|RS|083f3f2b-c66c-4a98-95c6-fc2bbceecf7e|7|MOLRESP|Molecular Response|AJCC V7|[?]|grain|MINOR PATHOLOGIC RESPONSE|1|g/m2/day|KINETIC CHROMOGENIC ASSAY||||SIGNIFICANT OTHER|RADIOLOGIST 2|NA|4|Visit_4|65|5|TREATMENT|2021-02-17|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-04|P1Y2M10DT2H30M|UNKNOWN|2021-03-17|BEFORE|2021-03-21
e|RS|083f3f2b-c66c-4a98-95c6-fc2bbceecf7e|8|MRDRESP|Minimal Residual Disease Response|DURIE MULTIPLE MYELOMA 2006|[?]|genEq|PD|1|10^8 PFU|MAMMOGRAPHY||||CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 1|U|4|Visit_4|65|2|SCREENING|2021-02-17|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-04|P1Y2M10DT2H30M|UNKNOWN|2020-12-21|ONGOING|2021-01-30
e|RS|083f3f2b-c66c-4a98-95c6-fc2bbceecf7e|9|NTNERESP|Non-Target Non-Enhancing Response|KUMAR IMWG 2016|[?]|10^6 organisms/mL|NED|1|mL/animal/wk|ENDOSCOPY||||SPOUSE|RATER|U|5|Visit_5|90|5|TREATMENT|2021-03-14|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-13|P1Y2M10DT2H30M|BEFORE|2021-01-04|ONGOING|2021-03-03
e|RS|083f3f2b-c66c-4a98-95c6-fc2bbceecf7e|10|HEMARESP|Hematologic Response|PERCIST|[?]|pmol/10^9 cells|PD|1|10^8/L|MICROSCOPY||||ADJUDICATOR|MICROSCOPIST 3|Y|5|Visit_5|90|7|FOLLOW-UP|2021-03-14|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-13|P1Y2M10DT2H30M|BEFORE|2021-02-24|COINCIDENT|2021-03-06
e|RS|ad04ec90-9fd5-49f2-ae23-264273eb0a24|1|METBRESP|Metabolic Response|JACINTO CERVICAL CANCER 2007|[?]|C|PR|1|keV|HPLC/MS/MS||||INVESTIGATOR|HEMATOLOGIST|Y|1|Visit_1|10|3|SCREENING|2020-10-17|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-27|P1Y2M10DT2H30M|AFTER|2020-12-25|BEFORE|2021-01-02
e|RS|ad04ec90-9fd5-49f2-ae23-264273eb0a24|2|DRCRIND|Disease Recurrence Indicator|CHESON CLL 2006|[?]|Arbitrary U|NED|1|/kg|CONTRAST ENHANCED PET/CT SCAN||||PROXY|NEUROLOGIST|U|1|Visit_1|10|2|SCREENING|2020-10-17|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-27|P1Y2M10DT2H30M|BEFORE|2020-12-16|BEFORE|2020-12-22
e|RS|ad04ec90-9fd5-49f2-ae23-264273eb0a24|3|PATHRESP|Pathologic Response|CHOLLET BREAST CANCER 2002|||EQUIVOCAL|1|U/g/day|RYAN BLUE STAIN||Y|Y|ADJUDICATION COMMITTEE|MICROSCOPIST 1|NA|2|Visit_2|25|6|TREATMENT|2020-11-01|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-13|P1Y2M10DT2H30M|AFTER|2020-12-27|ONGOING|2021-01-01
e|RS|ad04ec90-9fd5-49f2-ae23-264273eb0a24|4|NEWLWIND|New Lesion Worsening Indicator|CHESON MALIGNANT LYMPHOMA 2007|[?]|% INHIBITION|NED|1|/10^3|MECHANICAL CLOT DETECTION||||GUARDIAN|ONCOLOGIST 1|N|2|Visit_2|25|3|TREATMENT|2020-11-01|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-13|P1Y2M10DT2H30M|COINCIDENT|2020-12-02|ONGOING|2020-12-25
e|RS|ad04ec90-9fd5-49f2-ae23-264273eb0a24|5|MRPHRESP|Morphologic Response|BURCOMBE BREAST CANCER 2005|[?]|10^6 U|NON-QUANTIFIABLE MRD POSITIVITY|1|U/10^12 RBC|FLOW MICROSCOPY||||PARENT|ONCOLOGIST 2|N|3|Visit_3|40|3|TREATMENT|2020-11-16|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-07|P1Y2M10DT2H30M|COINCIDENT|2020-12-31|AFTER|2021-01-07
e|RS|ad04ec90-9fd5-49f2-ae23-264273eb0a24|6|NTLWIND|Non-Target Lesion Worsening Indicator|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|vp/mL|NE|1|BU|MICROARRAY||||VENDOR|NEUROLOGIST 1|NA|3|Visit_3|40|2|SCREENING|2020-11-16|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-07|P1Y2M10DT2H30M|BEFORE|2020-12-29|COINCIDENT|2021-01-05
e|RS|ad04ec90-9fd5-49f2-ae23-264273eb0a24|7|PATHRESP|Pathologic Response|HARTMAN PANCREATIC CANCER 2012|[?]|cd|NOT ALL EVALUATED|1|kg/cm2|INTERRUPTER TECHNIQUE||||VENDOR|PATHOLOGIST 2|Y|4|Visit_4|65|3|SCREENING|2020-12-11|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-19|P1Y2M10DT2H30M|BEFORE|2020-12-06|AFTER|2020-12-25
e|RS|ad04ec90-9fd5-49f2-ae23-264273eb0a24|8|PATHRESP|Pathologic Response|HARTMAN PANCREATIC CANCER 2012|[?]|tuberculin unit/mL|cPR|1|mL/g/min|MOUSE PROTECTION ASSAY||||CHILD|RATER 2|U|4|Visit_4|65|6|TREATMENT|2020-12-11|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-19|P1Y2M10DT2H30M|UNKNOWN|2020-11-18|AFTER|2020-12-30
e|RS|ad04ec90-9fd5-49f2-ae23-264273eb0a24|9|MRDRESP|Minimal Residual Disease Response|CHESON CLL 2012|[?]|/wk|PARTIAL MORPHOLOGIC RESPONSE|1|Ci|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION||||VENDOR|INTERNIST|NA|5|Visit_5|90|3|WASHOUT|2021-01-05|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-25|P1Y2M10DT2H30M|COINCIDENT|2020-12-20|AFTER|2020-12-22
e|RS|ad04ec90-9fd5-49f2-ae23-264273eb0a24|10|MRDRESP|Minimal Residual Disease Response|RANO|[?]|g/animal/wk|CR-CT|1|SCOOPFUL|X-RAY FLUORESCENCE SPECTROMETRY||||FAMILY MEMBER|NEUROLOGIST 2|Y|5|Visit_5|90|3|TREATMENT|2021-01-05|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-25|P1Y2M10DT2H30M|AFTER|2020-11-22|ONGOING|2020-12-13
e|RS|a1d203ef-7ee1-4373-988a-370532bae2b1|1|MNPTHIND|Minor Pathological Response Indicator|IRANO 2015|[?]|psec|MOLECULAR CR|1|/2500 WBC|TURBIDIMETRY||||INTERVIEWER|ADJUDICATOR 1|NA|1|Visit_1|10|2|SCREENING|2021-01-28|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-13|P1Y2M10DT2H30M|UNKNOWN|2021-03-30|ONGOING|2021-04-06
e|RS|a1d203ef-7ee1-4373-988a-370532bae2b1|2|ANATRESP|Anatomic Response|PCWG SCHER PROSTATE CANCER 2008|[?]|/VF|MRD NEGATIVITY|1|kg/L|PHASE-CONTRAST MRI||||PROXY|UROLOGIST|Y|1|Visit_1|10|6|TREATMENT|2021-01-28|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-13|P1Y2M10DT2H30M|AFTER|2021-02-26|BEFORE|2021-03-04
e|RS|a1d203ef-7ee1-4373-988a-370532bae2b1|3|TRGRESP|Target Response|HAMAOKA BREAST CANCER 2010|||iPR|1|U/g|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|||Y|INDEPENDENT ASSESSOR|ADJUDICATOR 2|N|2|Visit_2|25|1|TREATMENT|2021-02-12|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-06|P1Y2M10DT2H30M|COINCIDENT|2021-04-24|AFTER|2021-04-25
e|RS|a1d203ef-7ee1-4373-988a-370532bae2b1|4|NTLWIND|Non-Target Lesion Worsening Indicator|PRINCE TCELL LYMPHOMA 2010|||CYTOGENETIC PR|1|10^7 PFU|PET/CT SCAN|||Y|FRIEND|ADJUDICATOR 3|U|2|Visit_2|25|6|FOLLOW-UP|2021-02-12|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-06|P1Y2M10DT2H30M|COINCIDENT|2021-03-04|COINCIDENT|2021-03-23
e|RS|a1d203ef-7ee1-4373-988a-370532bae2b1|5|MRPHRESP|Morphologic Response|RANO ELLINGSON 2017|[?]|FEU|SD-CT|1|BAG|CONTRAST ENHANCED X-RAY||||PARENT|NEUROLOGIST|U|3|Visit_3|40|1|TREATMENT|2021-02-27|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-08|P1Y2M10DT2H30M|UNKNOWN|2021-01-23|AFTER|2021-04-21
e|RS|a1d203ef-7ee1-4373-988a-370532bae2b1|6|CYTORESP|Cytogenetic Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|VIAL|DECREASED|1|Absorbance U/mL|PATHOLOGICAL EVALUATION|Y|||ADJUDICATOR|ADJUDICATOR 1|Y|3|Visit_3|40|6|FOLLOW-UP|2021-02-27|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-08|P1Y2M10DT2H30M|UNKNOWN|2021-03-13|BEFORE|2021-04-09
e|RS|a1d203ef-7ee1-4373-988a-370532bae2b1|7|CLINRESP|Clinical Response|EASL BRUIX LIVER CANCER 2001|||MORPHOLOGIC CR|1|COAT|SCANNING ELECTRON MICROSCOPY|||Y|INVESTIGATOR|INTERNIST|U|4|Visit_4|65|6|TREATMENT|2021-03-24|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-21|P1Y2M10DT2H30M|BEFORE|2021-04-04|COINCIDENT|2021-04-23
e|RS|a1d203ef-7ee1-4373-988a-370532bae2b1|8|CPRFSTAT|Clinical Performance Status|MACDONALD GLIOMA 1990|[?]|log10 IU/mL|COMPLETE MRD RESPONSE|1|SFC/10^6 PBMC|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY||||PROXY|NEUROLOGIST 1|U|4|Visit_4|65|3|FOLLOW-UP|2021-03-24|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-21|P1Y2M10DT2H30M|UNKNOWN|2021-04-19|COINCIDENT|2021-04-26
e|RS|a1d203ef-7ee1-4373-988a-370532bae2b1|9|NTERESP|Non-Target Enhancing Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|||MRD PERSISTENCE|1|genEq/mL|SPIROMETRY|||Y|CAREGIVER|ONCOLOGIST 1|Y|5|Visit_5|90|5|TREATMENT|2021-04-18|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-27|P1Y2M10DT2H30M|UNKNOWN|2021-03-23|COINCIDENT|2021-04-01
e|RS|a1d203ef-7ee1-4373-988a-370532bae2b1|10|MNPTHIND|Minor Pathological Response Indicator|RANO ELLINGSON 2017|[?]|MET*min|UNFAVORABLE RESPONSE|1|ug/mol|ISHIHARA COLOR PLATES||||CAREGIVER|RATER 2|U|5|Visit_5|90|3|SCREENING|2021-04-18|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-27|P1Y2M10DT2H30M|COINCIDENT|2021-03-16|ONGOING|2021-04-01
e|RS|4389d158-cb51-4779-b19a-f38dbef0806a|1|PATHRESP|Pathologic Response|IWC HALLEK CLL 2008|||ABSENT MORPHOLOGIC RESPONSE|1|mL/100g/min|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY||Y|Y|CHILD|READER|NA|1|Visit_1|10|3|WASHOUT|2020-06-22|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-30|P1Y2M10DT2H30M|BEFORE|2020-08-15|ONGOING|2020-08-17
e|RS|4389d158-cb51-4779-b19a-f38dbef0806a|2|MRDIND|Minimal Residual Disease Indicator|CHOI GIST 2008|[?]|L/day|PR-CT|1|ug/L FEU|MULTIPLE BREATH WASHOUT||||ADJUDICATION COMMITTEE|PATHOLOGIST 1|N|1|Visit_1|10|4|TREATMENT|2020-06-22|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-30|P1Y2M10DT2H30M|COINCIDENT|2020-09-05|AFTER|2020-09-09
e|RS|4389d158-cb51-4779-b19a-f38dbef0806a|3|NEWLIND|New Lesion Indicator|GUILHOT CML 2007|||TREATMENT FAILURE|1|BLOCKS|CONFOCAL MICROSCOPY|Y||Y|INTERVIEWER|READER 1|U|2|Visit_2|25|3|TREATMENT|2020-07-07|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-03|P1Y2M10DT2H30M|COINCIDENT|2020-08-23|BEFORE|2020-09-04
e|RS|4389d158-cb51-4779-b19a-f38dbef0806a|4|RDIORESP|Radiologic Response|IWG CHESON MDS 2000|[?]|mV|NON-CR/NON-PD|1|ug/L|CISH||Y||ADJUDICATOR|ENDOCRINOLOGIST|Y|2|Visit_2|25|6|TREATMENT|2020-07-07|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-03|P1Y2M10DT2H30M|COINCIDENT|2020-08-19|BEFORE|2020-08-24
e|RS|4389d158-cb51-4779-b19a-f38dbef0806a|5|SFTSRESP|Soft Tissue Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|%(w/w)|OPTIMAL MORPHOLOGIC RESPONSE|1|V|REAL-TIME POLYMERASE CHAIN REACTION ASSAY||||INTERVIEWER|ENDOCRINOLOGIST|U|3|Visit_3|40|3|WASHOUT|2020-07-22|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-13|P1Y2M10DT2H30M|BEFORE|2020-06-25|ONGOING|2020-07-16
e|RS|4389d158-cb51-4779-b19a-f38dbef0806a|6|RDIORESP|Radiologic Response|MRANO VAN DEN BENT GLIOMA 2011|||PD|1|10^5/hpf|ACID FAST STAIN|Y||Y|INDEPENDENT ASSESSOR|RADIOLOGIST|U|3|Visit_3|40|3|SCREENING|2020-07-22|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-13|P1Y2M10DT2H30M|UNKNOWN|2020-06-30|BEFORE|2020-07-29
e|RS|4389d158-cb51-4779-b19a-f38dbef0806a|7|METSIND|Metastatic Indicator|IRANO 2015|||RELAPSED DISEASE FROM CR|1|dram|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|||Y|CAREGIVER|OTOLARYNGOLOGIST|NA|4|Visit_4|65|3|FOLLOW-UP|2020-08-16|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-02|P1Y2M10DT2H30M|COINCIDENT|2020-08-11|BEFORE|2020-09-02
e|RS|4389d158-cb51-4779-b19a-f38dbef0806a|8|MRDIND|Minimal Residual Disease Indicator|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|Roentgen|iCPD|1|lm|REVERSE TRANSCRIPTASE PCR||||PARENT|READER 3|U|4|Visit_4|65|4|FOLLOW-UP|2020-08-16|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-02|P1Y2M10DT2H30M|BEFORE|2020-07-08|BEFORE|2020-08-22
e|RS|4389d158-cb51-4779-b19a-f38dbef0806a|9|CYTORESP|Cytogenetic Response|iRECIST|||SD-CT|1|mL/cm H2O|MANUAL COUNT|Y||Y|FRIEND|READER 2|NA|5|Visit_5|90|5|WASHOUT|2020-09-10|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-07|P1Y2M10DT2H30M|COINCIDENT|2020-08-10|COINCIDENT|2020-08-16
e|RS|4389d158-cb51-4779-b19a-f38dbef0806a|10|LIVRRESP|Liver Response|UNSPECIFIED|[?]|ukat/10^12 RBC|PR WITH LYMPHOCYTOSIS|1|gMFI|SLOAN LETTER EYE CHART 2.5%|Y|Y||NON-HEALTH CARE PROFESSIONAL|UROLOGIST|Y|5|Visit_5|90|7|TREATMENT|2020-09-10|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-07|P1Y2M10DT2H30M|AFTER|2020-08-18|COINCIDENT|2020-08-24
e|RS|3a973b7a-3583-4383-b59e-3dab51b511bd|1|STRUSTAT|Steroid Use Status|PERCIST|[?]|IU/L|IMPROVED|1|mmol|GC/MS||||FRIEND|MICROSCOPIST|U|1|Visit_1|10|2|TREATMENT|2021-01-19|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-22|P1Y2M10DT2H30M|BEFORE|2021-02-21|BEFORE|2021-03-02
e|RS|3a973b7a-3583-4383-b59e-3dab51b511bd|2|NTLWIND|Non-Target Lesion Worsening Indicator|DURIE MULTIPLE MYELOMA 2006|[?]|TABLET|CYTOGENETIC NO RESPONSE|1|mg/kg/min|IN VITRO GENE EXPRESSION ASSAY|Y|||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST|NA|1|Visit_1|10|2|FOLLOW-UP|2021-01-19|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-22|P1Y2M10DT2H30M|UNKNOWN|2021-01-28|BEFORE|2021-03-26
e|RS|3a973b7a-3583-4383-b59e-3dab51b511bd|3|NTRGRESP|Non-target Response|EASL BRUIX LIVER CANCER 2001|[?]|/2000 RBC|INDETERMINATE RESPONSE|1|cd/m2|PH METER MEASUREMENT METHOD||||PROXY|FORENSIC PATHOLOGIST|U|2|Visit_2|25|3|WASHOUT|2021-02-03|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-03|P1Y2M10DT2H30M|BEFORE|2021-02-10|COINCIDENT|2021-03-19
e|RS|3a973b7a-3583-4383-b59e-3dab51b511bd|4|MNPTHIND|Minor Pathological Response Indicator|GCIG RUSTIN OVARIAN CANCER 2011|||MRD NEGATIVITY|1|CAN|PAP STAIN|||Y|PROXY|ONCOLOGIST|Y|2|Visit_2|25|1|TREATMENT|2021-02-03|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-03|P1Y2M10DT2H30M|AFTER|2021-03-22|COINCIDENT|2021-04-13
e|RS|3a973b7a-3583-4383-b59e-3dab51b511bd|5|NEWLWIND|New Lesion Worsening Indicator|DOHNER AML 2010|[?]|deg|mCR|1|10^12/L|HEMOCYTOMETRY||||DOMESTIC PARTNER|PATHOLOGIST 2|NA|3|Visit_3|40|2|WASHOUT|2021-02-18|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-22|P1Y2M10DT2H30M|BEFORE|2021-02-08|ONGOING|2021-04-03
e|RS|3a973b7a-3583-4383-b59e-3dab51b511bd|6|LIVRRESP|Liver Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|/10^5|PMD|1|uSiemens|INTERRUPTER TECHNIQUE||||HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|NA|3|Visit_3|40|7|SCREENING|2021-02-18|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-22|P1Y2M10DT2H30M|UNKNOWN|2021-04-07|ONGOING|2021-04-11
e|RS|3a973b7a-3583-4383-b59e-3dab51b511bd|7|ANATRESP|Anatomic Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|ppb|CR-CT|1|amol|KNEMOMETRY||Y||GUARDIAN|OTOLARYNGOLOGIST|U|4|Visit_4|65|4|FOLLOW-UP|2021-03-15|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-14|P1Y2M10DT2H30M|COINCIDENT|2021-03-19|COINCIDENT|2021-03-26
e|RS|3a973b7a-3583-4383-b59e-3dab51b511bd|8|CPRFSTAT|Clinical Performance Status|PERCIST|[?]|uU/dL|PD/RELAPSE AFTER HI|1|Ci/L|PUPILLOMETRY||||SIGNIFICANT OTHER|RADIOLOGIST 1|N|4|Visit_4|65|6|FOLLOW-UP|2021-03-15|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-14|P1Y2M10DT2H30M|UNKNOWN|2021-03-24|COINCIDENT|2021-04-17
e|RS|3a973b7a-3583-4383-b59e-3dab51b511bd|9|MJPTHIND|Major Pathological Response Indicator|UNSPECIFIED|[?]|COAT|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|mL/dL|AGAR PROPORTION|Y|||INVESTIGATOR|CARDIOLOGIST|NA|5|Visit_5|90|5|WASHOUT|2021-04-09|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-29|P1Y2M10DT2H30M|AFTER|2021-03-17|ONGOING|2021-03-27
e|RS|3a973b7a-3583-4383-b59e-3dab51b511bd|10|NEWLWIND|New Lesion Worsening Indicator|PCWG SCHER PROSTATE CANCER 2016|[?]|dL|MOLECULAR MAJOR RESPONSE|1|mU/g|CONTRAST ENHANCED X-RAY||||CLINICAL RESEARCH ASSOCIATE|OTOLARYNGOLOGIST|N|5|Visit_5|90|7|SCREENING|2021-04-09|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-29|P1Y2M10DT2H30M|COINCIDENT|2021-02-01|BEFORE|2021-02-17
e|RS|d283591c-2085-459e-94f2-d3eb6b81aea7|1|MOLRESP|Molecular Response|RANO ELLINGSON 2017|||nPR|1|%(w/v)|PYROSEQUENCING|Y|Y|Y|HEALTH CARE PROFESSIONAL|READER|U|1|Visit_1|10|1|WASHOUT|2020-09-28|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-02|P1Y2M10DT2H30M|BEFORE|2020-10-26|BEFORE|2020-11-02
e|RS|d283591c-2085-459e-94f2-d3eb6b81aea7|2|SYMPTDTR|Symptomatic Deterioration|IWG CHESON AML 2003|[?]|DPM|MORPHOLOGIC LEUKEMIA-FREE STATE|1|ug/L FEU|MICRODENSITOMETRY|Y|||INDEPENDENT ASSESSOR|PATHOLOGIST 1|U|1|Visit_1|10|4|TREATMENT|2020-09-28|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-02|P1Y2M10DT2H30M|AFTER|2020-12-23|COINCIDENT|2020-12-25
e|RS|d283591c-2085-459e-94f2-d3eb6b81aea7|3|NEWLPROG|New Lesion Progression|IWG CHESON MDS 2000|||cCR|1|g|PULSE OXIMETRY|||Y|DOMESTIC PARTNER|MICROSCOPIST 3|N|2|Visit_2|25|3|FOLLOW-UP|2020-10-13|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-23|P1Y2M10DT2H30M|UNKNOWN|2020-10-27|ONGOING|2020-12-26
e|RS|d283591c-2085-459e-94f2-d3eb6b81aea7|4|MRDIND|Minimal Residual Disease Indicator|RECICL|[?]|tuberculin unit/mL|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|MHz|CONTRAST ENHANCED X-RAY||Y||CAREGIVER|READER 3|NA|2|Visit_2|25|5|TREATMENT|2020-10-13|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-23|P1Y2M10DT2H30M|COINCIDENT|2020-10-11|BEFORE|2020-11-22
e|RS|d283591c-2085-459e-94f2-d3eb6b81aea7|5|NTERESP|Non-Target Enhancing Response|HAMAOKA BREAST CANCER 2010|[?]|g/U|NON-QUANTIFIABLE MRD POSITIVITY|1|beats/min|ARTERIAL SPIN LABELING FUNCTIONAL MRI|Y|||INDEPENDENT ASSESSOR|READER 1|Y|3|Visit_3|40|3|FOLLOW-UP|2020-10-28|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-01|P1Y2M10DT2H30M|BEFORE|2020-11-24|AFTER|2020-12-08
e|RS|d283591c-2085-459e-94f2-d3eb6b81aea7|6|HEMARESP|Hematologic Response|IRANO 2015|[?]|ms2|MOLECULAR CR|1|/40 HPFs|LC/MS/MS|Y|||VENDOR|NEUROLOGIST 2|Y|3|Visit_3|40|5|WASHOUT|2020-10-28|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-01|P1Y2M10DT2H30M|COINCIDENT|2020-11-28|AFTER|2020-12-21
e|RS|d283591c-2085-459e-94f2-d3eb6b81aea7|7|NEWLWIND|New Lesion Worsening Indicator|SACT|[?]|amp|CRi|1|EVENTS|RAJI CELL EIA||||PROXY|ENDOCRINOLOGIST|U|4|Visit_4|65|3|WASHOUT|2020-11-22|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-23|P1Y2M10DT2H30M|COINCIDENT|2020-10-16|ONGOING|2020-12-16
e|RS|d283591c-2085-459e-94f2-d3eb6b81aea7|8|TMRESP|Tumor Marker Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|ELISA unit/dose|QUANTIFIABLE MRD POSITIVITY|1|U/m2/h|FLAME PHOTOMETRY||Y||GUARDIAN|READER|Y|4|Visit_4|65|4|SCREENING|2020-11-22|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-23|P1Y2M10DT2H30M|BEFORE|2020-10-22|BEFORE|2020-11-03
e|RS|d283591c-2085-459e-94f2-d3eb6b81aea7|9|PATHRESP|Pathologic Response|DURIE MULTIPLE MYELOMA 2006|[?]|log10 CCID 50/dose|PMR|1|BOTTLE|GC/MS||||FRIEND|FORENSIC PATHOLOGIST|U|5|Visit_5|90|5|TREATMENT|2020-12-17|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-28|P1Y2M10DT2H30M|BEFORE|2020-11-10|AFTER|2020-11-24
e|RS|d283591c-2085-459e-94f2-d3eb6b81aea7|10|CLINRESP|Clinical Response|IRANO 2015|[?]|mCi/L|SMD|1|min*mg/mL|NEXT GENERATION TARGETED SEQUENCING||||CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 1|Y|5|Visit_5|90|5|TREATMENT|2020-12-17|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-28|P1Y2M10DT2H30M|UNKNOWN|2020-10-29|ONGOING|2020-11-07
e|RS|da31f695-9f6a-46b2-8002-5c1c21b55cf3|1|CPRFSTAT|Clinical Performance Status|MRECIST BYRNE MESOTHELIOMA 2004|[?]|SBE/mL|CMR|1|um|DYNAMIC CONTRAST ENHANCED MRI||||CLINICAL RESEARCH COORDINATOR|DERMATOLOGIST|U|1|Visit_1|10|6|SCREENING|2020-10-01|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-12|P1Y2M10DT2H30M|COINCIDENT|2020-10-01|AFTER|2020-10-04
e|RS|da31f695-9f6a-46b2-8002-5c1c21b55cf3|2|DRCRIND|Disease Recurrence Indicator|DURIE MULTIPLE MYELOMA 2006|[?]|uIU/dL|PARTIAL MORPHOLOGIC RESPONSE|1|Ci|ULTRASOUND||||HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|N|1|Visit_1|10|1|SCREENING|2020-10-01|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-12|P1Y2M10DT2H30M|BEFORE|2020-11-15|COINCIDENT|2020-12-16
e|RS|da31f695-9f6a-46b2-8002-5c1c21b55cf3|3|NTNERESP|Non-Target Non-Enhancing Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|||PARTIAL MORPHOLOGIC RESPONSE|1|anti-Xa IU|GIEMSA STAIN|Y||Y|PROXY|CLINICAL PATHOLOGIST|U|2|Visit_2|25|4|TREATMENT|2020-10-16|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-30|P1Y2M10DT2H30M|UNKNOWN|2020-11-13|BEFORE|2020-11-22
e|RS|da31f695-9f6a-46b2-8002-5c1c21b55cf3|4|SPLNRESP|Spleen Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|uU/L|PMR|1|Ejaculate U|MICROBIAL BIOCHEMICAL IDENTIFICATION||Y||INVESTIGATOR|DEVELOPMENTAL PSYCHOLOGIST|Y|2|Visit_2|25|7|SCREENING|2020-10-16|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-30|P1Y2M10DT2H30M|UNKNOWN|2020-12-17|AFTER|2020-12-26
e|RS|da31f695-9f6a-46b2-8002-5c1c21b55cf3|5|TMRESP|Tumor Marker Response|AJCC V7|||HI-P|1|cpm|APPLANATION TONOMETRY|||Y|FAMILY MEMBER|ADJUDICATOR 3|N|3|Visit_3|40|6|TREATMENT|2020-10-31|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-03|P1Y2M10DT2H30M|AFTER|2020-09-23|ONGOING|2020-11-20
e|RS|da31f695-9f6a-46b2-8002-5c1c21b55cf3|6|NEWLWIND|New Lesion Worsening Indicator|EASL BRUIX LIVER CANCER 2001|[?]|mL/g/day|PDu|1|copies/uL|IN SITU HYBRIDIZATION||Y||SIBLING|RATER 1|N|3|Visit_3|40|6|TREATMENT|2020-10-31|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-03|P1Y2M10DT2H30M|UNKNOWN|2020-12-20|BEFORE|2020-12-27
e|RS|da31f695-9f6a-46b2-8002-5c1c21b55cf3|7|STRUSTAT|Steroid Use Status|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|m/sec2|sCR|1|lm|PUPILLOMETRY||||SIGNIFICANT OTHER|INTERNIST|Y|4|Visit_4|65|3|TREATMENT|2020-11-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-15|P1Y2M10DT2H30M|AFTER|2020-12-21|ONGOING|2020-12-22
e|RS|da31f695-9f6a-46b2-8002-5c1c21b55cf3|8|MNPTHIND|Minor Pathological Response Indicator|RECIST 1.1|[?]|tuberculin unit/mL|PD-CT|1|C|NEXT GENERATION SEQUENCING||Y||FAMILY MEMBER|PEDIATRIC NEUROLOGIST|NA|4|Visit_4|65|2|TREATMENT|2020-11-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-15|P1Y2M10DT2H30M|UNKNOWN|2020-12-04|COINCIDENT|2020-12-21
e|RS|da31f695-9f6a-46b2-8002-5c1c21b55cf3|9|TMRESP|Tumor Marker Response|iRECIST|[?]|ug/L/h|MRD NEGATIVITY|1|10^3 DNA copies/mL|MAPH|Y|||SPOUSE|READER 1|N|5|Visit_5|90|5|TREATMENT|2020-12-20|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-10|P1Y2M10DT2H30M|UNKNOWN|2020-10-13|ONGOING|2020-11-19
e|RS|da31f695-9f6a-46b2-8002-5c1c21b55cf3|10|STRUSTAT|Steroid Use Status|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|10^6 copies/mL|IMMUNOPHENOTYPIC CR|1|pmol/g|INDIA INK STAIN||Y||DOMESTIC PARTNER|DERMATOLOGIST|Y|5|Visit_5|90|2|FOLLOW-UP|2020-12-20|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-10|P1Y2M10DT2H30M|AFTER|2020-12-18|AFTER|2020-12-24
e|RS|4cd63e56-3d93-403a-8011-3b4fcf26e445|1|NEWLPROG|New Lesion Progression|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|||OPTIMAL MORPHOLOGIC RESPONSE|1|mEq/day|HANSEL STAIN|||Y|GUARDIAN|PATHOLOGIST|NA|1|Visit_1|10|3|FOLLOW-UP|2020-12-27|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-03|P1Y2M10DT2H30M|UNKNOWN|2021-01-24|COINCIDENT|2021-02-09
e|RS|4cd63e56-3d93-403a-8011-3b4fcf26e445|2|NTNERESP|Non-Target Non-Enhancing Response|IWG CHESON MDS 2006|[?]|nmol BCE/mmol|QUANTIFIABLE MRD POSITIVITY|1|mL/day|HPLC-UV|Y|||STUDY SUBJECT|ADJUDICATOR 1|NA|1|Visit_1|10|6|TREATMENT|2020-12-27|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-03|P1Y2M10DT2H30M|COINCIDENT|2021-01-26|AFTER|2021-02-09
e|RS|4cd63e56-3d93-403a-8011-3b4fcf26e445|3|CPRFSTAT|Clinical Performance Status|PRINCE TCELL LYMPHOMA 2010|[?]|mm/sec|MRD RELAPSE|1|uCi/L|PANENDOSCOPY||||CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 2|N|2|Visit_2|25|6|SCREENING|2021-01-11|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-20|P1Y2M10DT2H30M|UNKNOWN|2021-03-24|AFTER|2021-03-25
e|RS|4cd63e56-3d93-403a-8011-3b4fcf26e445|4|BMIVLIND|Bone Marrow Involvement Indicator|SCHWARZ CERVICAL CANCER 2009|[?]|DDU|VGPR|1|U/kg/h|SLOAN LETTER EYE CHART 2.5%||||PROXY|FORENSIC PATHOLOGIST|NA|2|Visit_2|25|3|FOLLOW-UP|2021-01-11|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-20|P1Y2M10DT2H30M|UNKNOWN|2021-03-01|AFTER|2021-03-19
e|RS|4cd63e56-3d93-403a-8011-3b4fcf26e445|5|DRCRIND|Disease Recurrence Indicator|MRANO VAN DEN BENT GLIOMA 2011|[?]|vp/dose|INDETERMINATE RESPONSE|1|ug/kg/day|CLOT DETECTION||||CLINICAL STUDY SPONSOR|READER 3|NA|3|Visit_3|40|2|FOLLOW-UP|2021-01-26|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-07|P1Y2M10DT2H30M|UNKNOWN|2021-03-06|ONGOING|2021-03-11
e|RS|4cd63e56-3d93-403a-8011-3b4fcf26e445|6|MRDIND|Minimal Residual Disease Indicator|PETIT BREAST CANCER 2001|[?]|DNA copies/mL|RELAPSED DISEASE|1|mmHg/L/min|FLUORESCEIN STAIN||||SPOUSE|PATHOLOGIST 2|U|3|Visit_3|40|2|FOLLOW-UP|2021-01-26|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-07|P1Y2M10DT2H30M|AFTER|2021-01-20|BEFORE|2021-02-01
e|RS|4cd63e56-3d93-403a-8011-3b4fcf26e445|7|MRDIND|Minimal Residual Disease Indicator|CHOLLET BREAST CANCER 2002|[?]|mmol/s|CR-CT|1|beats/min|REBOUND TONOMETRY||||INTERVIEWER|DEVELOPMENTAL PSYCHOLOGIST|Y|4|Visit_4|65|6|WASHOUT|2021-02-20|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-21|P1Y2M10DT2H30M|BEFORE|2021-02-17|COINCIDENT|2021-03-18
e|RS|4cd63e56-3d93-403a-8011-3b4fcf26e445|8|BESTRESP|Best Overall Response|BLAZER COLORECTAL CANCER 2008|[?]|mg/cm2|RELAPSED DISEASE|1|ag|POLYGRAPHY|Y|Y||CAREGIVER|OTOLARYNGOLOGIST|NA|4|Visit_4|65|1|SCREENING|2021-02-20|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-21|P1Y2M10DT2H30M|UNKNOWN|2021-01-20|BEFORE|2021-02-21
e|RS|4cd63e56-3d93-403a-8011-3b4fcf26e445|9|TRGRESP|Target Response|KUMAR IMWG 2016|||CMR|1|FIU|GC/MS/MS||Y|Y|INDEPENDENT ASSESSOR|PHYSIOTHERAPIST|N|5|Visit_5|90|6|TREATMENT|2021-03-17|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-31|P1Y2M10DT2H30M|COINCIDENT|2021-02-06|COINCIDENT|2021-02-07
e|RS|4cd63e56-3d93-403a-8011-3b4fcf26e445|10|ANATRESP|Anatomic Response|BRUGGEMANN MRD 2010|[?]|cm H2O|CR-CT|1|ms/mmHg|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS||||FAMILY MEMBER|DERMATOLOGIST|U|5|Visit_5|90|1|FOLLOW-UP|2021-03-17|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-31|P1Y2M10DT2H30M|BEFORE|2021-01-28|COINCIDENT|2021-01-29
e|RS|379e3838-eef8-45a4-bd0b-5b8b3ec3e204|1|BMIVLIND|Bone Marrow Involvement Indicator|MURPHY PROSTATE CANCER 1980|[?]|g/animal/day|CYTOGENETIC CR|1|nmol BCE/nmol|IMMUNOFLUORESCENT STAIN||Y||DOMESTIC PARTNER|RATER 2|NA|1|Visit_1|10|3|SCREENING|2020-05-23|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-03|P1Y2M10DT2H30M|AFTER|2020-06-10|COINCIDENT|2020-06-19
e|RS|379e3838-eef8-45a4-bd0b-5b8b3ec3e204|2|DRCRIND|Disease Recurrence Indicator|AJCC V8|[?]|mEq/mmol|CYTOGENETIC NO RESPONSE|1|fmol/g|ELLA||||CAREGIVER|READER 1|N|1|Visit_1|10|5|TREATMENT|2020-05-23|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-03|P1Y2M10DT2H30M|BEFORE|2020-07-17|BEFORE|2020-07-27
e|RS|379e3838-eef8-45a4-bd0b-5b8b3ec3e204|3|NTNERESP|Non-Target Non-Enhancing Response|CHOI GIST 2008|[?]|uOsm|SD|1|MBq/uL|CHROMOGENIC ASSAY||Y||HEALTH CARE PROFESSIONAL|ADJUDICATOR 1|U|2|Visit_2|25|5|SCREENING|2020-06-07|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-17|P1Y2M10DT2H30M|UNKNOWN|2020-06-23|AFTER|2020-06-27
e|RS|379e3838-eef8-45a4-bd0b-5b8b3ec3e204|4|HEMARESP|Hematologic Response|LEE LUNG CANCER 2011|[?]|cmol|iCR|1|HEP|PANENDOSCOPY||||DOMESTIC PARTNER|PATHOLOGIST 1|N|2|Visit_2|25|4|WASHOUT|2020-06-07|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-17|P1Y2M10DT2H30M|BEFORE|2020-06-23|AFTER|2020-08-09
e|RS|379e3838-eef8-45a4-bd0b-5b8b3ec3e204|5|OVRLRESP|Overall Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|ug/L FEU|NON-QUANTIFIABLE MRD POSITIVITY|1|mCi|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|Y|||PARENT|RATER|U|3|Visit_3|40|7|WASHOUT|2020-06-22|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-18|P1Y2M10DT2H30M|AFTER|2020-06-01|COINCIDENT|2020-06-22
e|RS|379e3838-eef8-45a4-bd0b-5b8b3ec3e204|6|LIVRRESP|Liver Response|RAJKUMAR MYELOMA 2011|[?]|10^11/L|CYTOGENETIC MINIMAL RESPONSE|1|10^6/Ejaculate U|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION|Y|||ADJUDICATION COMMITTEE|PHYSIOTHERAPIST|N|3|Visit_3|40|1|WASHOUT|2020-06-22|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-18|P1Y2M10DT2H30M|BEFORE|2020-05-23|AFTER|2020-05-26
e|RS|379e3838-eef8-45a4-bd0b-5b8b3ec3e204|7|OVRLRESP|Overall Response|RECICL|||NE|1|mg/L FEU|NUCLEAR RADIOLOGY||Y|Y|PARENT|ONCOLOGIST 1|Y|4|Visit_4|65|2|TREATMENT|2020-07-17|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-02|P1Y2M10DT2H30M|AFTER|2020-06-08|BEFORE|2020-07-25
e|RS|379e3838-eef8-45a4-bd0b-5b8b3ec3e204|8|MJPTHIND|Major Pathological Response Indicator|IRANO 2015|[?]|L/h/m2|VGPR|1|pmol/dL|MIGET||||SPOUSE|ADJUDICATOR 3|Y|4|Visit_4|65|1|TREATMENT|2020-07-17|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-02|P1Y2M10DT2H30M|AFTER|2020-06-21|BEFORE|2020-07-02
e|RS|379e3838-eef8-45a4-bd0b-5b8b3ec3e204|9|METSIND|Metastatic Indicator|IRANO 2015|||NED|1|um|ENZYMATIC ULTRACENTRIFUGATION||Y|Y|ADJUDICATOR|OPTOMETRIST|N|5|Visit_5|90|7|TREATMENT|2020-08-11|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-11|P1Y2M10DT2H30M|COINCIDENT|2020-07-17|BEFORE|2020-08-04
e|RS|379e3838-eef8-45a4-bd0b-5b8b3ec3e204|10|TRGRESP|Target Response|MONTSERRAT CLL 1989|[?]|Absorbance U/min|iSD|1|Absorbance U|DOPPLER ULTRASOUND||||SIBLING|RATER|Y|5|Visit_5|90|2|TREATMENT|2020-08-11|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-11|P1Y2M10DT2H30M|UNKNOWN|2020-07-31|ONGOING|2020-08-16
e|RS|f31bab3b-3624-44a5-a62f-f8cf9055eec4|1|HEMARESP|Hematologic Response|NCIWG CHESON CLL 1996|[?]|g/U|PR-CT|1|VOXEL|PHOTOMETRIC CLOT DETECTION||||CLINICAL STUDY SPONSOR|READER|Y|1|Visit_1|10|3|TREATMENT|2020-08-09|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-29|P1Y2M10DT2H30M|COINCIDENT|2020-10-30|BEFORE|2020-11-05
e|RS|f31bab3b-3624-44a5-a62f-f8cf9055eec4|2|MOLRESP|Molecular Response|FAROOQUI SUPP CLL 2014|[?]|Shock Wave|cCR|1|Roentgen|MAGNETIC RESONANCE ANGIOGRAPHY||||CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 2|Y|1|Visit_1|10|2|TREATMENT|2020-08-09|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-29|P1Y2M10DT2H30M|AFTER|2020-08-15|ONGOING|2020-08-25
e|RS|f31bab3b-3624-44a5-a62f-f8cf9055eec4|3|SPLNRESP|Spleen Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|U/g|CYTOGENETIC CR|1|mV|STATIC PERIMETRY||||CLINICAL RESEARCH COORDINATOR|PHYSIOTHERAPIST|Y|2|Visit_2|25|2|FOLLOW-UP|2020-08-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-12|P1Y2M10DT2H30M|COINCIDENT|2020-09-12|COINCIDENT|2020-09-15
e|RS|f31bab3b-3624-44a5-a62f-f8cf9055eec4|4|STRUSTAT|Steroid Use Status|KEAM BREAST CANCER 2013|[?]|IU/day|cPR|1|Absorbance U/mL|HPLC-FL||||CAREGIVER|UROLOGIST|N|2|Visit_2|25|6|SCREENING|2020-08-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-12|P1Y2M10DT2H30M|UNKNOWN|2020-08-04|AFTER|2020-08-19
e|RS|f31bab3b-3624-44a5-a62f-f8cf9055eec4|5|METBRESP|Metabolic Response|HARTMAN PANCREATIC CANCER 2012|[?]|ug/mL/h|PD-CT|1|Antibody Unit|SICKLE CELL SOLUBILITY TEST||||CHILD|PEDIATRIC NEUROLOGIST|U|3|Visit_3|40|6|FOLLOW-UP|2020-09-08|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-26|P1Y2M10DT2H30M|AFTER|2020-09-30|COINCIDENT|2020-10-02
e|RS|f31bab3b-3624-44a5-a62f-f8cf9055eec4|6|SYMPTDTR|Symptomatic Deterioration|CHOI GIST 2008|||IMPROVED|1|Ci/ug|PHYSICAL EXAMINATION|||Y|SIBLING|PHYSIOTHERAPIST|U|3|Visit_3|40|2|FOLLOW-UP|2020-09-08|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-26|P1Y2M10DT2H30M|COINCIDENT|2020-09-12|ONGOING|2020-10-08
e|RS|f31bab3b-3624-44a5-a62f-f8cf9055eec4|7|MOLRESP|Molecular Response|JACINTO CERVICAL CANCER 2007|[?]|ng/L|IMMUNOPHENOTYPIC CR|1|U/cL|BETA LACTAMASE|Y|||PARENT|READER 1|N|4|Visit_4|65|1|FOLLOW-UP|2020-10-03|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-19|P1Y2M10DT2H30M|BEFORE|2020-08-13|BEFORE|2020-08-22
e|RS|f31bab3b-3624-44a5-a62f-f8cf9055eec4|8|PATHRESP|Pathologic Response|BURCOMBE BREAST CANCER 2005|[?]|ng/day|PD|1|cmol/L|PHYSICAL EXAMINATION||||ADJUDICATION COMMITTEE|RATER 2|NA|4|Visit_4|65|5|WASHOUT|2020-10-03|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-19|P1Y2M10DT2H30M|COINCIDENT|2020-10-25|AFTER|2020-10-28
e|RS|f31bab3b-3624-44a5-a62f-f8cf9055eec4|9|CPRFSTAT|Clinical Performance Status|CHOI GIST 2008|[?]|ugEq/L|CYTOGENETIC CR|1|anti-Xa IU|TRIPLE-PHASE MRI SCAN|Y|||STUDY SUBJECT|ONCOLOGIST 2|U|5|Visit_5|90|7|TREATMENT|2020-10-28|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-31|P1Y2M10DT2H30M|AFTER|2020-11-06|COINCIDENT|2020-11-07
e|RS|f31bab3b-3624-44a5-a62f-f8cf9055eec4|10|CPRFSTAT|Clinical Performance Status|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|||NOT ALL EVALUATED|1|mol/L|GRADIENT DIFFUSION|||Y|INDEPENDENT ASSESSOR|DERMATOLOGIST|Y|5|Visit_5|90|3|WASHOUT|2020-10-28|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-31|P1Y2M10DT2H30M|UNKNOWN|2020-08-01|COINCIDENT|2020-09-19
e|RS|0b5675aa-4ec0-4548-9a0b-a13f8de89883|1|METSIND|Metastatic Indicator|NCCN ALL MRD 2014|[?]|umol|SD-CT|1|IU/L|FLUORIMETRY||||CAREGIVER|MICROSCOPIST 1|Y|1|Visit_1|10|3|WASHOUT|2020-06-28|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-20|P1Y2M10DT2H30M|BEFORE|2020-07-17|COINCIDENT|2020-09-20
e|RS|0b5675aa-4ec0-4548-9a0b-a13f8de89883|2|BONERESP|Bone Response|EASL BRUIX LIVER CANCER 2001|[?]|Bq/uL|QUANTIFIABLE MRD POSITIVITY|1|kPa/L/sec|MICROPARTICLE ENZYME IMMUNOASSAY||||INVESTIGATOR|DERMATOLOGIST|Y|1|Visit_1|10|3|WASHOUT|2020-06-28|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-20|P1Y2M10DT2H30M|COINCIDENT|2020-09-13|BEFORE|2020-09-24
e|RS|0b5675aa-4ec0-4548-9a0b-a13f8de89883|3|DRCRIND|Disease Recurrence Indicator|IWG CHESON AML 2003|[?]|PACKET|RELAPSED DISEASE FROM CR OR PR|1|pmol/day|SICKLE CELL SOLUBILITY TEST||||NON-HEALTH CARE PROFESSIONAL|UROLOGIST|N|2|Visit_2|25|7|SCREENING|2020-07-13|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-16|P1Y2M10DT2H30M|UNKNOWN|2020-08-06|COINCIDENT|2020-09-06
e|RS|0b5675aa-4ec0-4548-9a0b-a13f8de89883|4|CYTORESP|Cytogenetic Response|BLAZER COLORECTAL CANCER 2008|[?]|ug/L|PR WITH LYMPHOCYTOSIS|1|kUSP|SMEAR|Y|||ADJUDICATION COMMITTEE|RATER|Y|2|Visit_2|25|3|WASHOUT|2020-07-13|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-16|P1Y2M10DT2H30M|BEFORE|2020-06-21|ONGOING|2020-07-09
e|RS|0b5675aa-4ec0-4548-9a0b-a13f8de89883|5|SFTSRESP|Soft Tissue Response|GUILHOT CML 2007|[?]|MET*h|MRD RELAPSE|1|g/day|VENTILATION PERFUSION LUNG SCAN||||HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|3|Visit_3|40|6|TREATMENT|2020-07-28|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-19|P1Y2M10DT2H30M|BEFORE|2020-08-04|ONGOING|2020-08-08
e|RS|0b5675aa-4ec0-4548-9a0b-a13f8de89883|6|SPLNRESP|Spleen Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|K|CYTOGENETIC MINIMAL RESPONSE|1|10^3 organisms|IMMUNOASSAY||||VENDOR|UROLOGIST|U|3|Visit_3|40|2|TREATMENT|2020-07-28|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-19|P1Y2M10DT2H30M|AFTER|2020-07-19|AFTER|2020-07-26
e|RS|0b5675aa-4ec0-4548-9a0b-a13f8de89883|7|NTERESP|Non-Target Enhancing Response|KUKER LYMPHOMA 2005|||CRi|1|U/dL|ICP-MS|Y||Y|CLINICAL RESEARCH ASSOCIATE|READER 1|U|4|Visit_4|65|7|TREATMENT|2020-08-22|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-03|P1Y2M10DT2H30M|UNKNOWN|2020-08-02|COINCIDENT|2020-08-04
e|RS|0b5675aa-4ec0-4548-9a0b-a13f8de89883|8|CPRFSTAT|Clinical Performance Status|DURIE MULTIPLE MYELOMA 2006|||SD|1|nL|FLUOROSCOPY|||Y|NON-HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|U|4|Visit_4|65|3|TREATMENT|2020-08-22|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-03|P1Y2M10DT2H30M|BEFORE|2020-06-25|BEFORE|2020-09-25
e|RS|0b5675aa-4ec0-4548-9a0b-a13f8de89883|9|NEWLWIND|New Lesion Worsening Indicator|DURIE MULTIPLE MYELOMA 2006|[?]|ug/kg|CYTOGENETIC MINOR RESPONSE|1|/5x10^4 WBC|FLUORESCENT LIFETIME IMAGING MICROSCOPY||||SIBLING|OPHTHALMOLOGIST|NA|5|Visit_5|90|4|TREATMENT|2020-09-16|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-09|P1Y2M10DT2H30M|UNKNOWN|2020-09-15|AFTER|2020-09-25
e|RS|0b5675aa-4ec0-4548-9a0b-a13f8de89883|10|NTNERESP|Non-Target Non-Enhancing Response|MRANO VAN DEN BENT GLIOMA 2011|||NE|1|GPS U|X-RAY|||Y|FRIEND|MICROSCOPIST 3|U|5|Visit_5|90|7|SCREENING|2020-09-16|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-09|P1Y2M10DT2H30M|AFTER|2020-08-20|COINCIDENT|2020-08-29
e|RS|9bdf9856-3b2a-43db-b369-3e13868ef413|1|CPRFSTAT|Clinical Performance Status|RECIST 1.1|||PR WITH LYMPHOCYTOSIS|1|DIP|SCANNING ELECTRON MICROSCOPY|||Y|FRIEND|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|1|Visit_1|10|2|WASHOUT|2021-01-23|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-01|P1Y2M10DT2H30M|COINCIDENT|2021-03-16|COINCIDENT|2021-04-18
e|RS|9bdf9856-3b2a-43db-b369-3e13868ef413|2|NTRGRESP|Non-target Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|10^9 CFU/g|CMR|1|U/mL|OLIGO ACGH||Y||VENDOR|RATER 1|N|1|Visit_1|10|6|WASHOUT|2021-01-23|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-01|P1Y2M10DT2H30M|COINCIDENT|2021-03-12|BEFORE|2021-03-24
e|RS|9bdf9856-3b2a-43db-b369-3e13868ef413|3|NEWLPROG|New Lesion Progression|EBMT BLADE MYELOMA 1998|[?]|mPa|CA125 50% RESPONSE|1|uV|WESTERN BLOT|Y|||INTERVIEWER|ONCOLOGIST 2|Y|2|Visit_2|25|6|TREATMENT|2021-02-07|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-06|P1Y2M10DT2H30M|BEFORE|2021-01-24|AFTER|2021-04-06
e|RS|9bdf9856-3b2a-43db-b369-3e13868ef413|4|NTLWIND|Non-Target Lesion Worsening Indicator|RANO ELLINGSON 2017|[?]|CAPFUL|iUPD|1|mmol/g|TRANSMISSION ELECTRON MICROSCOPY||||SPOUSE|READER 2|U|2|Visit_2|25|3|TREATMENT|2021-02-07|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-06|P1Y2M10DT2H30M|UNKNOWN|2021-03-21|AFTER|2021-03-26
e|RS|9bdf9856-3b2a-43db-b369-3e13868ef413|5|HEMARESP|Hematologic Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|mmol/min/kPa|PDu|1|Pack Year|MAGNETIC RESONANCE ENTEROGRAPHY|Y|||CLINICAL RESEARCH ASSOCIATE|READER|N|3|Visit_3|40|7|TREATMENT|2021-02-22|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-21|P1Y2M10DT2H30M|AFTER|2021-03-29|ONGOING|2021-04-11
e|RS|9bdf9856-3b2a-43db-b369-3e13868ef413|6|BONERESP|Bone Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|/HPF|iSD|1|CFU/g|TARGETED TRANSCRIPTOME SEQUENCING||Y||CHILD|RADIOLOGIST|Y|3|Visit_3|40|1|TREATMENT|2021-02-22|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-21|P1Y2M10DT2H30M|BEFORE|2021-02-14|COINCIDENT|2021-04-09
e|RS|9bdf9856-3b2a-43db-b369-3e13868ef413|7|SPLNRESP|Spleen Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|AgU/mL|SMD|1|g/kg|SIZE EXCLUSION CHROMATOGRAPHY||||CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 1|Y|4|Visit_4|65|3|TREATMENT|2021-03-19|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-31|P1Y2M10DT2H30M|BEFORE|2021-03-16|ONGOING|2021-03-26
e|RS|9bdf9856-3b2a-43db-b369-3e13868ef413|8|LIVRRESP|Liver Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|mU/g|CYTOGENETIC MINIMAL RESPONSE|1|mEq/L|PHASE-CONTRAST MRI||Y||SIBLING|MICROSCOPIST 2|NA|4|Visit_4|65|1|TREATMENT|2021-03-19|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-31|P1Y2M10DT2H30M|UNKNOWN|2021-03-07|BEFORE|2021-03-19
e|RS|9bdf9856-3b2a-43db-b369-3e13868ef413|9|CYTORESP|Cytogenetic Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|vg/kg|FAVORABLE RESPONSE|1|mg/g/h|PHASE CONTRAST MICROSCOPY||||CLINICAL STUDY SPONSOR|MICROSCOPIST 3|U|5|Visit_5|90|2|TREATMENT|2021-04-13|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-16|P1Y2M10DT2H30M|UNKNOWN|2021-01-29|AFTER|2021-02-06
e|RS|9bdf9856-3b2a-43db-b369-3e13868ef413|10|NTERESP|Non-Target Enhancing Response|CHESON CLL 2012|[?]|mmol/min/kPa/L|NOT ALL EVALUATED|1|mg/day|SURFACE PLASMON RESONANCE||Y||SIBLING|RADIOLOGIST 1|U|5|Visit_5|90|6|TREATMENT|2021-04-13|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-16|P1Y2M10DT2H30M|AFTER|2021-04-10|COINCIDENT|2021-04-13
e|RS|5cc53922-60c0-4bce-8d4a-bc59e9203d63|1|DRCRIND|Disease Recurrence Indicator|MRANO VAN DEN BENT GLIOMA 2011|[?]|ug/m2/min|iCPD|1|FINGERTIP UNIT|CONFOCAL MICROSCOPY|Y|||STUDY SUBJECT|ADJUDICATOR 1|U|1|Visit_1|10|2|TREATMENT|2020-12-28|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-17|P1Y2M10DT2H30M|COINCIDENT|2021-01-20|AFTER|2021-02-02
e|RS|5cc53922-60c0-4bce-8d4a-bc59e9203d63|2|CPRFSTAT|Clinical Performance Status|DOHNER AML 2010|[?]|kcal/day|mCR|1|POUCH|HPLC/MS/MS||||CLINICAL STUDY SPONSOR|OPHTHALMOLOGIST|Y|1|Visit_1|10|3|TREATMENT|2020-12-28|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-17|P1Y2M10DT2H30M|AFTER|2021-03-20|BEFORE|2021-03-26
e|RS|5cc53922-60c0-4bce-8d4a-bc59e9203d63|3|MNPTHIND|Minor Pathological Response Indicator|SCHWARZ CERVICAL CANCER 2009|||DISEASE TRANSFORMATION|1|mL/breath|ELISA|||Y|FRIEND|ADJUDICATOR|NA|2|Visit_2|25|2|TREATMENT|2021-01-12|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-03|P1Y2M10DT2H30M|BEFORE|2021-02-28|AFTER|2021-03-10
e|RS|5cc53922-60c0-4bce-8d4a-bc59e9203d63|4|LIVRRESP|Liver Response|SCHER PROSTATE CANCER 2011|[?]|ukat/10^12 RBC|RELAPSED DISEASE FROM CR OR PR|1|10^6 U|REBOUND TONOMETRY||Y||CLINICAL RESEARCH ASSOCIATE|READER 3|U|2|Visit_2|25|6|TREATMENT|2021-01-12|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-03|P1Y2M10DT2H30M|UNKNOWN|2021-03-01|COINCIDENT|2021-03-17
e|RS|5cc53922-60c0-4bce-8d4a-bc59e9203d63|5|NEWLWIND|New Lesion Worsening Indicator|LEE LUNG CANCER 2011|||PARTIAL MORPHOLOGIC RESPONSE|1|/sec|QUANTITATIVE ULTRASOUND||Y|Y|FAMILY MEMBER|CARDIOLOGIST|Y|3|Visit_3|40|7|TREATMENT|2021-01-27|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-16|P1Y2M10DT2H30M|AFTER|2021-03-05|BEFORE|2021-03-12
e|RS|5cc53922-60c0-4bce-8d4a-bc59e9203d63|6|MRDIND|Minimal Residual Disease Indicator|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|mg/animal|DECREASED|1|BOX|ELECTROCHEMILUMINESCENCE IMMUNOASSAY|Y|||CLINICAL RESEARCH ASSOCIATE|PEDIATRIC NEUROLOGIST|N|3|Visit_3|40|5|WASHOUT|2021-01-27|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-16|P1Y2M10DT2H30M|COINCIDENT|2021-01-20|BEFORE|2021-02-05
e|RS|5cc53922-60c0-4bce-8d4a-bc59e9203d63|7|NEWLWIND|New Lesion Worsening Indicator|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|h*%|MORPHOLOGIC CR|1|BAR|MALDI-TOF|Y|||FRIEND|READER 2|Y|4|Visit_4|65|2|FOLLOW-UP|2021-02-21|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-24|P1Y2M10DT2H30M|AFTER|2021-03-26|AFTER|2021-03-27
e|RS|5cc53922-60c0-4bce-8d4a-bc59e9203d63|8|OVRLRESP|Overall Response|RANO ELLINGSON 2017|||UNEQUIVOCAL|1|mg/kg/week|HEMATOXYLIN AND EOSIN STAIN|||Y|VENDOR|OPTOMETRIST|Y|4|Visit_4|65|4|SCREENING|2021-02-21|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-24|P1Y2M10DT2H30M|COINCIDENT|2020-12-25|COINCIDENT|2021-03-26
e|RS|5cc53922-60c0-4bce-8d4a-bc59e9203d63|9|NTNERESP|Non-Target Non-Enhancing Response|RANO|[?]|KALLIKREIN INHIBITOR UNIT|NON-iCR/NON-iUPD|1|mg/g/min|POLYSOMNOGRAPHY||||NON-HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|N|5|Visit_5|90|3|WASHOUT|2021-03-18|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-10|P1Y2M10DT2H30M|UNKNOWN|2021-01-01|COINCIDENT|2021-01-29
e|RS|5cc53922-60c0-4bce-8d4a-bc59e9203d63|10|ANATRESP|Anatomic Response|AJCC V7|[?]|Bq/mg|SMD|1|CAN|SMEAR||||FRIEND|PATHOLOGIST|NA|5|Visit_5|90|2|TREATMENT|2021-03-18|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-10|P1Y2M10DT2H30M|UNKNOWN|2021-01-04|AFTER|2021-03-03
e|RS|ae4761e8-2ede-43b6-8ec4-40c97add3cfa|1|NEWLIND|New Lesion Indicator|WOLCHOK SOLID TUMORS 2009|[?]|U/L|EQUIVOCAL|1|nmol/kg/day|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS||||ADJUDICATION COMMITTEE|ONCOLOGIST|N|1|Visit_1|10|4|WASHOUT|2020-12-29|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-08|P1Y2M10DT2H30M|UNKNOWN|2021-03-23|BEFORE|2021-03-28
e|RS|ae4761e8-2ede-43b6-8ec4-40c97add3cfa|2|BESTRESP|Best Overall Response|SCHER PROSTATE CANCER 2011|[?]|g/cm2|iCPD|1|tsp eq|GC/MS/MS||||PARENT|NEUROLOGIST|U|1|Visit_1|10|4|TREATMENT|2020-12-29|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-08|P1Y2M10DT2H30M|UNKNOWN|2021-01-21|BEFORE|2021-03-03
e|RS|ae4761e8-2ede-43b6-8ec4-40c97add3cfa|3|HEMARESP|Hematologic Response|LEE LUNG CANCER 2011|[?]|mL/cm H2O|CYTOGENETIC MINIMAL RESPONSE|1|/wk|LIGHT MICROSCOPY|Y|||ADJUDICATION COMMITTEE|RATER 2|U|2|Visit_2|25|1|FOLLOW-UP|2021-01-13|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-17|P1Y2M10DT2H30M|COINCIDENT|2021-01-03|AFTER|2021-01-28
e|RS|ae4761e8-2ede-43b6-8ec4-40c97add3cfa|4|RDIORESP|Radiologic Response|RECIST 1.0|[?]|ukat/L|IMPROVED|1|mm/sec|MASS SPECTROMETRY|Y|||SPOUSE|PATHOLOGIST 1|Y|2|Visit_2|25|2|TREATMENT|2021-01-13|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-17|P1Y2M10DT2H30M|UNKNOWN|2021-01-28|ONGOING|2021-03-19
e|RS|ae4761e8-2ede-43b6-8ec4-40c97add3cfa|5|CYTORESP|Cytogenetic Response|CHESON CLL 2012|[?]|mEq/uL|IMPROVED|1|/10^4|MICROPARTICLE ENZYME IMMUNOASSAY||||STUDY SUBJECT|CLINICAL PATHOLOGIST|N|3|Visit_3|40|2|TREATMENT|2021-01-28|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-03|P1Y2M10DT2H30M|UNKNOWN|2020-12-23|BEFORE|2021-01-31
e|RS|ae4761e8-2ede-43b6-8ec4-40c97add3cfa|6|NTRGRESP|Non-target Response|DOHNER AML 2010|[?]|IU/mmol|CYTOGENETIC MINIMAL RESPONSE|1|Joule|TELLER ACUITY CARDS||||CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR|NA|3|Visit_3|40|7|SCREENING|2021-01-28|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-03|P1Y2M10DT2H30M|BEFORE|2021-02-01|AFTER|2021-03-22
e|RS|ae4761e8-2ede-43b6-8ec4-40c97add3cfa|7|RDIORESP|Radiologic Response|IWG CHESON AML 2003|[?]|mg/mol|CYTOGENETIC MINIMAL RESPONSE|1|mgEq|HPLC/MS||||CLINICAL STUDY SPONSOR|CLINICAL PATHOLOGIST|N|4|Visit_4|65|1|TREATMENT|2021-02-22|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-23|P1Y2M10DT2H30M|BEFORE|2021-02-11|AFTER|2021-03-14
e|RS|ae4761e8-2ede-43b6-8ec4-40c97add3cfa|8|METBRESP|Metabolic Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|Pa|PARTIAL MORPHOLOGIC RESPONSE|1|BAU/mL|DYNAMIC CONTRAST ENHANCED MRI||||ADJUDICATOR|READER 1|NA|4|Visit_4|65|2|WASHOUT|2021-02-22|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-23|P1Y2M10DT2H30M|AFTER|2021-02-15|ONGOING|2021-03-20
e|RS|ae4761e8-2ede-43b6-8ec4-40c97add3cfa|9|SFTSRESP|Soft Tissue Response|LEE LUNG CANCER 2011|[?]|mCi/kg|CR-CT|1|mEq/uL|SLOAN LETTER EYE CHART 1.25%||Y||INVESTIGATOR|OTOLARYNGOLOGIST|U|5|Visit_5|90|2|TREATMENT|2021-03-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-03|P1Y2M10DT2H30M|COINCIDENT|2021-02-03|BEFORE|2021-03-09
e|RS|ae4761e8-2ede-43b6-8ec4-40c97add3cfa|10|BESTRESP|Best Overall Response|GCIG RUSTIN OVARIAN CANCER 2011|||CYTOGENETIC CR|1|ng/L|DOUBLE IMMUNODIFFUSION||Y|Y|INTERVIEWER|ONCOLOGIST 1|N|5|Visit_5|90|7|TREATMENT|2021-03-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-03|P1Y2M10DT2H30M|AFTER|2021-03-12|ONGOING|2021-03-13
e|RS|066281d3-27b8-439f-8340-f59115f646ef|1|SPLNRESP|Spleen Response|NCIWG CHESON CLL 1996|||PMR|1|pmol/10^10 cells|AGAR PROPORTION|||Y|FRIEND|READER 2|U|1|Visit_1|10|4|FOLLOW-UP|2020-10-21|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-07|P1Y2M10DT2H30M|AFTER|2021-01-05|COINCIDENT|2021-01-09
e|RS|066281d3-27b8-439f-8340-f59115f646ef|2|LIVRRESP|Liver Response|RECIST 1.0|[?]|breaths/min|mCR|1|mL/mmHg|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY||||SIBLING|RATER 2|U|1|Visit_1|10|5|TREATMENT|2020-10-21|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-07|P1Y2M10DT2H30M|BEFORE|2020-10-22|AFTER|2020-11-09
e|RS|066281d3-27b8-439f-8340-f59115f646ef|3|CLINRESP|Clinical Response|KUMAR IMWG 2016|[?]|uU/dL|EQUIVOCAL|1|amp|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE|Y|||PARENT|HEMATOLOGIST|NA|2|Visit_2|25|5|SCREENING|2020-11-05|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-06|P1Y2M10DT2H30M|BEFORE|2020-11-08|AFTER|2020-12-12
e|RS|066281d3-27b8-439f-8340-f59115f646ef|4|DRCRIND|Disease Recurrence Indicator|KUKER LYMPHOMA 2005|||SD-CT|1|Coulomb|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|||Y|PARENT|MICROSCOPIST 1|U|2|Visit_2|25|3|SCREENING|2020-11-05|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-06|P1Y2M10DT2H30M|COINCIDENT|2021-01-02|ONGOING|2021-01-16
e|RS|066281d3-27b8-439f-8340-f59115f646ef|5|NEWLIND|New Lesion Indicator|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|/ms|RELAPSED DISEASE FROM CR OR PR|1|mL/day|MIGET||Y||ADJUDICATOR|HEMATOLOGIST|N|3|Visit_3|40|6|TREATMENT|2020-11-20|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-01|P1Y2M10DT2H30M|UNKNOWN|2020-10-28|AFTER|2020-11-20
e|RS|066281d3-27b8-439f-8340-f59115f646ef|6|DRCRIND|Disease Recurrence Indicator|PCWG SCHER PROSTATE CANCER 2008|||PD-CT|1|L/kg|PERIPHERAL ANGIOGRAPHY|||Y|NON-HEALTH CARE PROFESSIONAL|RATER 1|N|3|Visit_3|40|4|SCREENING|2020-11-20|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-01|P1Y2M10DT2H30M|BEFORE|2020-11-05|COINCIDENT|2020-12-21
e|RS|066281d3-27b8-439f-8340-f59115f646ef|7|MRDRESP|Minimal Residual Disease Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|mV2/Hz|NON-QUANTIFIABLE MRD POSITIVITY|1|OI50|PLAQUE REDUCTION NEUTRALIZATION ASSAY||||SIBLING|NEUROLOGIST 1|NA|4|Visit_4|65|3|FOLLOW-UP|2020-12-15|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-23|P1Y2M10DT2H30M|AFTER|2020-10-20|AFTER|2020-11-07
e|RS|066281d3-27b8-439f-8340-f59115f646ef|8|CLINRESP|Clinical Response|SCHER PROSTATE CANCER 2011|[?]|mg/day|iSD|1|CIGARETTE|CALCOFLUOR WHITE STAIN||||SIBLING|PATHOLOGIST 2|U|4|Visit_4|65|6|SCREENING|2020-12-15|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-23|P1Y2M10DT2H30M|UNKNOWN|2020-12-14|BEFORE|2020-12-22
e|RS|066281d3-27b8-439f-8340-f59115f646ef|9|MNPTHIND|Minor Pathological Response Indicator|HAMAOKA BREAST CANCER 2010|[?]|RATIO|cPR|1|CCID 50/mL|PH METER MEASUREMENT METHOD||||VENDOR|PATHOLOGIST|N|5|Visit_5|90|1|SCREENING|2021-01-09|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-12|P1Y2M10DT2H30M|AFTER|2020-12-13|AFTER|2020-12-16
e|RS|066281d3-27b8-439f-8340-f59115f646ef|10|CLINRESP|Clinical Response|CHOI GIST 2008|[?]|Ci|EQUIVOCAL|1|PIXELS/in|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI||||NON-HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|NA|5|Visit_5|90|7|TREATMENT|2021-01-09|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-12|P1Y2M10DT2H30M|AFTER|2020-11-12|AFTER|2021-01-10
e|RS|d23cc47e-da96-4042-a69f-60097beaef0e|1|METBRESP|Metabolic Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|Watt|DISEASE TRANSFORMATION|1|mL/100g/min|IMMUNODIFFUSION|Y|||VENDOR|READER|N|1|Visit_1|10|2|TREATMENT|2021-01-21|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-17|P1Y2M10DT2H30M|UNKNOWN|2021-02-26|BEFORE|2021-04-03
e|RS|d23cc47e-da96-4042-a69f-60097beaef0e|2|BMIVLIND|Bone Marrow Involvement Indicator|JACINTO CERVICAL CANCER 2007|[?]|uL/mL|nPR|1|pmol/10^10 cells|KNEMOMETRY||||ADJUDICATION COMMITTEE|HEMATOLOGIST|Y|1|Visit_1|10|7|FOLLOW-UP|2021-01-21|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-17|P1Y2M10DT2H30M|UNKNOWN|2021-04-15|COINCIDENT|2021-04-16
e|RS|d23cc47e-da96-4042-a69f-60097beaef0e|3|BONERESP|Bone Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|log10 TCID 50/dose|PSEUDORESPONSE|1|nkat|FARR ASSAY|Y|||CLINICAL STUDY SPONSOR|OPHTHALMOLOGIST|NA|2|Visit_2|25|3|FOLLOW-UP|2021-02-05|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-05|P1Y2M10DT2H30M|COINCIDENT|2021-02-27|AFTER|2021-03-06
e|RS|d23cc47e-da96-4042-a69f-60097beaef0e|4|CPRFSTAT|Clinical Performance Status|DURIE MULTIPLE MYELOMA 2006|[?]|100 IU/mL|IMMUNOPHENOTYPIC CR|1|mCi/L|NUCLEAR RADIOLOGY||Y||PARENT|MICROSCOPIST 3|NA|2|Visit_2|25|5|TREATMENT|2021-02-05|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-05|P1Y2M10DT2H30M|COINCIDENT|2021-02-12|BEFORE|2021-02-26
e|RS|d23cc47e-da96-4042-a69f-60097beaef0e|5|NTERESP|Non-Target Enhancing Response|DURIE MULTIPLE MYELOMA 2006|||MORPHOLOGIC CRi|1|MPS U|HIGH RESOLUTION MELT ANALYSIS|||Y|SIBLING|PATHOLOGIST|U|3|Visit_3|40|3|WASHOUT|2021-02-20|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-02|P1Y2M10DT2H30M|AFTER|2021-02-07|BEFORE|2021-03-26
e|RS|d23cc47e-da96-4042-a69f-60097beaef0e|6|BESTRESP|Best Overall Response|BLAZER COLORECTAL CANCER 2008|[?]|g/cage/day|MAJOR PATHOLOGIC RESPONSE|1|10^7 PFU|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY||Y||CAREGIVER|INTERNIST|NA|3|Visit_3|40|4|TREATMENT|2021-02-20|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-02|P1Y2M10DT2H30M|BEFORE|2021-03-08|AFTER|2021-03-23
e|RS|d23cc47e-da96-4042-a69f-60097beaef0e|7|SPLNRESP|Spleen Response|RAJKUMAR MYELOMA 2011|[?]|Absorbance U|MAJOR PATHOLOGIC RESPONSE|1|U/cL|SISH||||FAMILY MEMBER|PATHOLOGIST|U|4|Visit_4|65|3|SCREENING|2021-03-17|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-31|P1Y2M10DT2H30M|UNKNOWN|2021-02-02|BEFORE|2021-04-10
e|RS|d23cc47e-da96-4042-a69f-60097beaef0e|8|BONERESP|Bone Response|UNSPECIFIED|[?]|kPa|INCREASED|1|10^3 organisms/mL|NEXT GENERATION TARGETED SEQUENCING||||CLINICAL RESEARCH ASSOCIATE|HEMATOLOGIST|NA|4|Visit_4|65|4|SCREENING|2021-03-17|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-31|P1Y2M10DT2H30M|COINCIDENT|2021-03-12|AFTER|2021-04-19
e|RS|d23cc47e-da96-4042-a69f-60097beaef0e|9|MRDIND|Minimal Residual Disease Indicator|SCHWARZ CERVICAL CANCER 2009|[?]|cd*s/m2|mCR|1|mg/day|MULTIPLE BREATH WASHOUT||||CAREGIVER|RATER|Y|5|Visit_5|90|3|SCREENING|2021-04-11|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-16|P1Y2M10DT2H30M|UNKNOWN|2021-02-04|COINCIDENT|2021-03-15
e|RS|d23cc47e-da96-4042-a69f-60097beaef0e|10|OVRLRESP|Overall Response|CHESON CLL 2012|[?]|mAnson U/mL|CMR|1|IU/g|CARDIAC THERMODILUTION||||INDEPENDENT ASSESSOR|OPHTHALMOLOGIST|NA|5|Visit_5|90|6|TREATMENT|2021-04-11|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-16|P1Y2M10DT2H30M|UNKNOWN|2021-03-28|BEFORE|2021-03-29
e|RS|b896c679-87d0-4e29-ad27-3944cf09b3ec|1|MRDRESP|Minimal Residual Disease Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|MPL U|pCR|1|nkat|HEMAGGLUTINATION ASSAY||||ADJUDICATION COMMITTEE|PHYSIOTHERAPIST|Y|1|Visit_1|10|4|TREATMENT|2021-01-02|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-08|P1Y2M10DT2H30M|BEFORE|2021-02-25|ONGOING|2021-02-26
e|RS|b896c679-87d0-4e29-ad27-3944cf09b3ec|2|SPLNRESP|Spleen Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|NEBULE|MR|1|ft2|INCISION-INDUCED BLEEDING METHOD|Y|||INDEPENDENT ASSESSOR|PATHOLOGIST 2|U|1|Visit_1|10|3|FOLLOW-UP|2021-01-02|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-08|P1Y2M10DT2H30M|AFTER|2021-02-08|AFTER|2021-02-16
e|RS|b896c679-87d0-4e29-ad27-3944cf09b3ec|3|NTLWIND|Non-Target Lesion Worsening Indicator|SHINDOH COLORECTAL CANCER 2013|[?]|Farad|iCPD|1|cd|CELL BASED BIOASSAY||||VENDOR|CLINICAL PATHOLOGIST|U|2|Visit_2|25|4|WASHOUT|2021-01-17|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-02|P1Y2M10DT2H30M|BEFORE|2021-01-01|AFTER|2021-03-29
e|RS|b896c679-87d0-4e29-ad27-3944cf09b3ec|4|NEWLWIND|New Lesion Worsening Indicator|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|SPRAY|nPR|1|10^12 IU/L|IODINE STAIN||||PARENT|HEMATOLOGIST|N|2|Visit_2|25|1|FOLLOW-UP|2021-01-17|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-02|P1Y2M10DT2H30M|AFTER|2021-03-14|BEFORE|2021-03-15
e|RS|b896c679-87d0-4e29-ad27-3944cf09b3ec|5|NTRGRESP|Non-target Response|UNSPECIFIED|[?]|oz|HI-P|1|um|SLOAN LETTER EYE CHART 1.25%||||PARENT|INTERNIST|NA|3|Visit_3|40|1|FOLLOW-UP|2021-02-01|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-12|P1Y2M10DT2H30M|COINCIDENT|2021-03-16|COINCIDENT|2021-03-17
e|RS|b896c679-87d0-4e29-ad27-3944cf09b3ec|6|LIVRRESP|Liver Response|NCIWG CHESON CLL 1996|[?]|DAgU/mL|PSEUDORESPONSE|1|uV*sec|PELLI-ROBSON EYE CHART||Y||PROXY|NEUROLOGIST 2|U|3|Visit_3|40|3|TREATMENT|2021-02-01|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-12|P1Y2M10DT2H30M|AFTER|2021-04-01|ONGOING|2021-04-02
e|RS|b896c679-87d0-4e29-ad27-3944cf09b3ec|7|NEWLWIND|New Lesion Worsening Indicator|WOLCHOK SOLID TUMORS 2009|[?]|umol/min|SD-CT|1|CAN|NUCLEIC ACID SEQUENCING|Y|||GUARDIAN|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|4|Visit_4|65|4|TREATMENT|2021-02-26|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-28|P1Y2M10DT2H30M|BEFORE|2021-03-09|COINCIDENT|2021-03-23
e|RS|b896c679-87d0-4e29-ad27-3944cf09b3ec|8|MRPHRESP|Morphologic Response|LUGANO CLASSIFICATION|[?]|cm2|HI-P|1|BLOCKS|CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY||Y||SIBLING|PATHOLOGIST 2|N|4|Visit_4|65|2|TREATMENT|2021-02-26|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-28|P1Y2M10DT2H30M|BEFORE|2021-02-03|AFTER|2021-03-20
e|RS|b896c679-87d0-4e29-ad27-3944cf09b3ec|9|STRUSTAT|Steroid Use Status|EBMT BLADE MYELOMA 1998|[?]|ELISA unit/dose|HI-P|1|BAU|PHOTOMETRY||||CAREGIVER|RATER|Y|5|Visit_5|90|2|FOLLOW-UP|2021-03-23|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-27|P1Y2M10DT2H30M|AFTER|2021-02-14|COINCIDENT|2021-03-24
e|RS|b896c679-87d0-4e29-ad27-3944cf09b3ec|10|LIVRRESP|Liver Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|10^6 IU/mL|MRD RELAPSE|1|mU|MICRONEUTRALIZATION ASSAY||||SPOUSE|ONCOLOGIST|Y|5|Visit_5|90|6|SCREENING|2021-03-23|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-27|P1Y2M10DT2H30M|COINCIDENT|2021-01-30|COINCIDENT|2021-02-07
e|RS|6d0ec221-6eb6-4fed-806e-2bc700968333|1|MJPTHIND|Major Pathological Response Indicator|MONTSERRAT CLL 1989|[?]|mL/min|RELAPSED DISEASE|1|mkat|CLINICAL EVALUATION|Y|Y||SIBLING|OPHTHALMOLOGIST|Y|1|Visit_1|10|4|FOLLOW-UP|2020-07-27|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-26|P1Y2M10DT2H30M|COINCIDENT|2020-07-28|ONGOING|2020-08-30
e|RS|6d0ec221-6eb6-4fed-806e-2bc700968333|2|PATHRESP|Pathologic Response|WOLCHOK SOLID TUMORS 2009|[?]|Hz/s|MOLECULAR CR|1|Watt|IN VITRO GENE EXPRESSION ASSAY||||CLINICAL STUDY SPONSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|1|Visit_1|10|5|FOLLOW-UP|2020-07-27|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-26|P1Y2M10DT2H30M|COINCIDENT|2020-08-13|COINCIDENT|2020-09-04
e|RS|6d0ec221-6eb6-4fed-806e-2bc700968333|3|LIVRRESP|Liver Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|kV|EQUIVOCAL|1|cmH2O/mL|EPSILOMETER||||DOMESTIC PARTNER|MICROSCOPIST 3|U|2|Visit_2|25|2|TREATMENT|2020-08-11|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-09|P1Y2M10DT2H30M|AFTER|2020-09-24|ONGOING|2020-10-22
e|RS|6d0ec221-6eb6-4fed-806e-2bc700968333|4|DRCRIND|Disease Recurrence Indicator|JACINTO CERVICAL CANCER 2007|||mCR|1|fmol/L/sec|CELL BASED BIOASSAY|Y||Y|PARENT|NEUROLOGIST 1|Y|2|Visit_2|25|3|WASHOUT|2020-08-11|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-09|P1Y2M10DT2H30M|COINCIDENT|2020-09-02|AFTER|2020-09-25
e|RS|6d0ec221-6eb6-4fed-806e-2bc700968333|5|MJPTHIND|Major Pathological Response Indicator|GUPPY OVARIAN CANCER 2002|[?]|L/kg|NR|1|RFU|TURBIDIMETRY||Y||INTERVIEWER|ADJUDICATOR 1|Y|3|Visit_3|40|4|TREATMENT|2020-08-26|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-17|P1Y2M10DT2H30M|UNKNOWN|2020-09-06|COINCIDENT|2020-10-15
e|RS|6d0ec221-6eb6-4fed-806e-2bc700968333|6|RDIORESP|Radiologic Response|RECIST 1.1|[?]|CIGARETTE|RELAPSED DISEASE FROM CR|1|g/day|CENTRIFUGATION||||PROXY|NEUROLOGIST 1|N|3|Visit_3|40|5|FOLLOW-UP|2020-08-26|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-17|P1Y2M10DT2H30M|COINCIDENT|2020-10-11|AFTER|2020-10-24
e|RS|6d0ec221-6eb6-4fed-806e-2bc700968333|7|NTRGRESP|Non-target Response|FAROOQUI SUPP CLL 2014|||iSD|1|nmol/g|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|||Y|PROXY|INTERNIST|N|4|Visit_4|65|5|WASHOUT|2020-09-20|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-04|P1Y2M10DT2H30M|BEFORE|2020-08-26|ONGOING|2020-10-17
e|RS|6d0ec221-6eb6-4fed-806e-2bc700968333|8|CLINRESP|Clinical Response|IWC HALLEK CLL 2008|[?]|mU/L|PD-CT|1|mmHg/sec|BRDU CELLULAR PROLIFERATION ASSAY||||ADJUDICATOR|ONCOLOGIST 1|N|4|Visit_4|65|3|TREATMENT|2020-09-20|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-04|P1Y2M10DT2H30M|AFTER|2020-08-20|BEFORE|2020-09-17
e|RS|6d0ec221-6eb6-4fed-806e-2bc700968333|9|MRPHRESP|Morphologic Response|PCWG SCHER PROSTATE CANCER 2008|[?]|PNU/mL|PR WITH LYMPHOCYTOSIS|1|CUP|DIGITAL PCR ARRAY||||CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 1|U|5|Visit_5|90|6|TREATMENT|2020-10-15|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-24|P1Y2M10DT2H30M|AFTER|2020-09-27|BEFORE|2020-10-09
e|RS|6d0ec221-6eb6-4fed-806e-2bc700968333|10|NTRGRESP|Non-target Response|DURIE MULTIPLE MYELOMA 2006|[?]|ug/g/h|NOT ALL EVALUATED|1|10^9 organisms|FUNCTIONAL MRI||Y||CLINICAL STUDY SPONSOR|PEDIATRIC NEUROLOGIST|Y|5|Visit_5|90|4|TREATMENT|2020-10-15|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-24|P1Y2M10DT2H30M|UNKNOWN|2020-08-05|ONGOING|2020-10-17
e|RS|1ba07712-d5a0-41a5-b5ee-636fa0bce22a|1|CYTORESP|Cytogenetic Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|MHz|iCPD|1|VOXEL|ELISPOT||||DOMESTIC PARTNER|ONCOLOGIST|N|1|Visit_1|10|3|TREATMENT|2020-10-03|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-28|P1Y2M10DT2H30M|UNKNOWN|2020-11-17|COINCIDENT|2020-12-23
e|RS|1ba07712-d5a0-41a5-b5ee-636fa0bce22a|2|MJPTHIND|Major Pathological Response Indicator|RECIST 1.1|[?]|umol/min|INDETERMINATE RESPONSE|1|mL/beat|INDIA INK STAIN|Y|||PARENT|RATER|NA|1|Visit_1|10|7|SCREENING|2020-10-03|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-28|P1Y2M10DT2H30M|UNKNOWN|2020-12-14|ONGOING|2020-12-22
e|RS|1ba07712-d5a0-41a5-b5ee-636fa0bce22a|3|CPRFSTAT|Clinical Performance Status|IWG CHESON AML 2003|[?]|nmol/mL/min|NON-CR/NON-PD|1|nmol|SCINTIGRAPHY|Y|||DOMESTIC PARTNER|RADIOLOGIST 2|U|2|Visit_2|25|4|SCREENING|2020-10-18|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-14|P1Y2M10DT2H30M|UNKNOWN|2020-10-09|AFTER|2020-12-17
e|RS|1ba07712-d5a0-41a5-b5ee-636fa0bce22a|4|PATHRESP|Pathologic Response|HARTMAN PANCREATIC CANCER 2012|[?]|g/g/day|PD FROM PR|1|100 IU/mL|ACCELERATOR MASS SPECTROMETRY|Y|||NON-HEALTH CARE PROFESSIONAL|READER|Y|2|Visit_2|25|3|WASHOUT|2020-10-18|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-14|P1Y2M10DT2H30M|AFTER|2020-12-11|ONGOING|2020-12-13
e|RS|1ba07712-d5a0-41a5-b5ee-636fa0bce22a|5|TMRESP|Tumor Marker Response|WHO BREAST CANCER 2006|[?]|kPa/L/sec|NR|1|MONTHS|HEMATOXYLIN AND EOSIN STAIN||||CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL PSYCHOLOGIST|NA|3|Visit_3|40|2|TREATMENT|2020-11-02|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-21|P1Y2M10DT2H30M|COINCIDENT|2020-10-04|COINCIDENT|2020-12-30
e|RS|1ba07712-d5a0-41a5-b5ee-636fa0bce22a|6|RDIORESP|Radiologic Response|SACT|[?]|ug/animal|PMR|1|Shock Wave|REAL-TIME POLYMERASE CHAIN REACTION ASSAY|Y|||FRIEND|RADIOLOGIST|U|3|Visit_3|40|6|TREATMENT|2020-11-02|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-21|P1Y2M10DT2H30M|AFTER|2020-11-27|AFTER|2020-12-02
e|RS|1ba07712-d5a0-41a5-b5ee-636fa0bce22a|7|TMRESP|Tumor Marker Response|GUILHOT CML 2007|[?]|uV2|CYTOGENETIC PR|1|log EID 50/dose|PULSE OXIMETRY|Y|||INTERVIEWER|NEUROLOGIST 2|N|4|Visit_4|65|6|TREATMENT|2020-11-27|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-01|P1Y2M10DT2H30M|AFTER|2020-11-10|BEFORE|2020-12-26
e|RS|1ba07712-d5a0-41a5-b5ee-636fa0bce22a|8|NEWLPROG|New Lesion Progression|LUGANO CLASSIFICATION|[?]|OI50|NED|1|mL/cage/day|PANENDOSCOPY||Y||ADJUDICATOR|ADJUDICATOR 3|U|4|Visit_4|65|5|WASHOUT|2020-11-27|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-01|P1Y2M10DT2H30M|UNKNOWN|2020-11-27|AFTER|2020-12-05
e|RS|1ba07712-d5a0-41a5-b5ee-636fa0bce22a|9|TMRESP|Tumor Marker Response|RANO ELLINGSON 2017|||MORPHOLOGIC CRi|1|PATCH|POLYMERASE CHAIN REACTION|Y||Y|HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|NA|5|Visit_5|90|7|SCREENING|2020-12-22|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-01|P1Y2M10DT2H30M|AFTER|2020-11-04|ONGOING|2020-12-24
e|RS|1ba07712-d5a0-41a5-b5ee-636fa0bce22a|10|BESTRESP|Best Overall Response|HARTMAN PANCREATIC CANCER 2012|[?]|Bq/kg|NON-PD|1|tuberculin unit|DIGITAL PCR ARRAY||||INTERVIEWER|RADIOLOGIST 2|NA|5|Visit_5|90|6|FOLLOW-UP|2020-12-22|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-01|P1Y2M10DT2H30M|BEFORE|2020-11-16|COINCIDENT|2020-12-22
e|RS|15e5e7ca-b832-450c-a20c-b21585086328|1|TRGRESP|Target Response|CHOI GIST 2008|[?]|mm2|PSEUDOPROGRESSION|1|cmH2O/mL|CONGO RED STAIN||Y||INDEPENDENT ASSESSOR|ADJUDICATOR 1|Y|1|Visit_1|10|3|TREATMENT|2021-01-05|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-01|P1Y2M10DT2H30M|UNKNOWN|2021-01-14|ONGOING|2021-03-18
e|RS|15e5e7ca-b832-450c-a20c-b21585086328|2|BONERESP|Bone Response|MURPHY PROSTATE CANCER 1980|[?]|MPL U/mL|VGPR|1|RNA copies/mL|TARGETED GENOME SEQUENCING||Y||VENDOR|MICROSCOPIST 3|U|1|Visit_1|10|3|SCREENING|2021-01-05|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-01|P1Y2M10DT2H30M|BEFORE|2021-01-09|ONGOING|2021-02-27
e|RS|15e5e7ca-b832-450c-a20c-b21585086328|3|ANATRESP|Anatomic Response|RECIST 1.1|||PD-CT|1|mmol/min/kPa/L|TELLER ACUITY CARDS|||Y|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST|N|2|Visit_2|25|3|FOLLOW-UP|2021-01-20|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-06|P1Y2M10DT2H30M|BEFORE|2021-01-14|ONGOING|2021-01-16
e|RS|15e5e7ca-b832-450c-a20c-b21585086328|4|HEMARESP|Hematologic Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|g/cm2|STABLE|1|L/s|TONOMETRY|Y|||PARENT|ONCOLOGIST 2|N|2|Visit_2|25|1|TREATMENT|2021-01-20|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-06|P1Y2M10DT2H30M|BEFORE|2021-02-27|AFTER|2021-03-09
e|RS|15e5e7ca-b832-450c-a20c-b21585086328|5|CPRFSTAT|Clinical Performance Status|MRECIST BYRNE MESOTHELIOMA 2004|[?]|mL/cm H2O|CYTOGENETIC NO RESPONSE|1|nmol BCE/nmol|OBSERVATION||Y||CLINICAL STUDY SPONSOR|PHYSIOTHERAPIST|U|3|Visit_3|40|7|WASHOUT|2021-02-04|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-12|P1Y2M10DT2H30M|UNKNOWN|2021-01-22|AFTER|2021-03-18
e|RS|15e5e7ca-b832-450c-a20c-b21585086328|6|CPRFSTAT|Clinical Performance Status|MACDONALD GLIOMA 1990|[?]|g/kg|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|U/m2|HPLC||||INTERVIEWER|RATER 1|NA|3|Visit_3|40|2|TREATMENT|2021-02-04|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-12|P1Y2M10DT2H30M|COINCIDENT|2021-02-27|BEFORE|2021-03-20
e|RS|15e5e7ca-b832-450c-a20c-b21585086328|7|CYTORESP|Cytogenetic Response|GUPPY OVARIAN CANCER 2002|[?]|Gravitational Unit|MR|1|days/wk|OPTICAL COHERENCE TOMOGRAPHY||Y||PARENT|PATHOLOGIST|Y|4|Visit_4|65|4|TREATMENT|2021-03-01|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-31|P1Y2M10DT2H30M|BEFORE|2021-01-20|BEFORE|2021-01-27
e|RS|15e5e7ca-b832-450c-a20c-b21585086328|8|RDIORESP|Radiologic Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|/10^4|QUANTIFIABLE MRD POSITIVITY|1|kN/cm2|HPLC-UV||Y||CLINICAL RESEARCH ASSOCIATE|CLINICAL PATHOLOGIST|U|4|Visit_4|65|2|TREATMENT|2021-03-01|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-31|P1Y2M10DT2H30M|AFTER|2021-03-03|ONGOING|2021-03-28
e|RS|15e5e7ca-b832-450c-a20c-b21585086328|9|OVRLRESP|Overall Response|WHO BREAST CANCER 2006|||cPR|1|mm/min|NUCLEIC ACID BASED METHOD|Y||Y|INDEPENDENT ASSESSOR|ADJUDICATOR 3|U|5|Visit_5|90|5|FOLLOW-UP|2021-03-26|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-28|P1Y2M10DT2H30M|BEFORE|2021-03-16|COINCIDENT|2021-03-30
e|RS|15e5e7ca-b832-450c-a20c-b21585086328|10|NEWLWIND|New Lesion Worsening Indicator|MRECIST BYRNE MESOTHELIOMA 2004|[?]|m3|PR WITH LYMPHOCYTOSIS|1|Bq/mL|STRESS ECHOCARDIOGRAPHY|Y|||CHILD|FORENSIC PATHOLOGIST|U|5|Visit_5|90|5|TREATMENT|2021-03-26|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-28|P1Y2M10DT2H30M|COINCIDENT|2021-01-19|COINCIDENT|2021-03-07
e|RS|b46ff3a2-f257-4803-8064-e29bd1114bfc|1|CYTORESP|Cytogenetic Response|MRECIST BYRNE MESOTHELIOMA 2004|||STABLE|1|APL U|COMPLEMENT FIXATION|||Y|ADJUDICATOR|PATHOLOGIST 1|Y|1|Visit_1|10|5|TREATMENT|2020-10-13|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-30|P1Y2M10DT2H30M|AFTER|2020-10-24|COINCIDENT|2020-11-13
e|RS|b46ff3a2-f257-4803-8064-e29bd1114bfc|2|SPLNRESP|Spleen Response|IWG CHESON MDS 2006|||HI-N|1|Log10 ELISA unit/dose|SLIT LAMP|||Y|STUDY SUBJECT|MICROSCOPIST|U|1|Visit_1|10|3|TREATMENT|2020-10-13|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-30|P1Y2M10DT2H30M|AFTER|2020-11-12|AFTER|2021-01-10
e|RS|b46ff3a2-f257-4803-8064-e29bd1114bfc|3|BONERESP|Bone Response|PRINCE TCELL LYMPHOMA 2010|||MRD PERSISTENCE|1|g/m2|FLOCCULATION, CHARCOAL ENHANCED|||Y|DOMESTIC PARTNER|CARDIOLOGIST|NA|2|Visit_2|25|7|SCREENING|2020-10-28|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-10|P1Y2M10DT2H30M|COINCIDENT|2021-01-03|ONGOING|2021-01-08
e|RS|b46ff3a2-f257-4803-8064-e29bd1114bfc|4|MRDRESP|Minimal Residual Disease Response|MONTSERRAT CLL 1989|||UNFAVORABLE RESPONSE|1|mAnson U/mL|KLEIHAUER-BETKE|||Y|DOMESTIC PARTNER|DERMATOLOGIST|Y|2|Visit_2|25|3|TREATMENT|2020-10-28|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-10|P1Y2M10DT2H30M|AFTER|2020-12-27|ONGOING|2021-01-04
e|RS|b46ff3a2-f257-4803-8064-e29bd1114bfc|5|SPLNRESP|Spleen Response|RAJKUMAR MYELOMA 2011|[?]|CIGAR|INCREASED|1|EID 50/mL|TELLER ACUITY CARDS|Y|Y||VENDOR|ADJUDICATOR 2|U|3|Visit_3|40|5|WASHOUT|2020-11-12|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-27|P1Y2M10DT2H30M|UNKNOWN|2021-01-02|COINCIDENT|2021-01-07
e|RS|b46ff3a2-f257-4803-8064-e29bd1114bfc|6|BESTRESP|Best Overall Response|DURIE MULTIPLE MYELOMA 2006|[?]|10^6 organisms/mg|iUPD|1|min/day|URANYL ACETATE STAIN|Y|||SPOUSE|RATER 2|N|3|Visit_3|40|2|TREATMENT|2020-11-12|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-27|P1Y2M10DT2H30M|UNKNOWN|2020-11-17|COINCIDENT|2020-12-01
e|RS|b46ff3a2-f257-4803-8064-e29bd1114bfc|7|SYMPTDTR|Symptomatic Deterioration|RECICL|[?]|MPS U|DECREASED|1|POINT|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY||||ADJUDICATION COMMITTEE|ONCOLOGIST|N|4|Visit_4|65|5|TREATMENT|2020-12-07|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-18|P1Y2M10DT2H30M|AFTER|2020-10-28|ONGOING|2020-11-04
e|RS|b46ff3a2-f257-4803-8064-e29bd1114bfc|8|MOLRESP|Molecular Response|SCHWARZ CERVICAL CANCER 2009|||RELAPSED DISEASE FROM CR OR PR|1|cpm|PHASE CONTRAST MICROSCOPY||Y|Y|CLINICAL RESEARCH ASSOCIATE|DERMATOLOGIST|Y|4|Visit_4|65|7|SCREENING|2020-12-07|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-18|P1Y2M10DT2H30M|UNKNOWN|2020-12-19|COINCIDENT|2021-01-09
e|RS|b46ff3a2-f257-4803-8064-e29bd1114bfc|9|NEWLWIND|New Lesion Worsening Indicator|EASL BRUIX LIVER CANCER 2001|[?]|psi|SD-CT|1|mL/cage/day|LIQUID SCINTILLATION COUNTING|Y|||CLINICAL RESEARCH ASSOCIATE|HEMATOLOGIST|Y|5|Visit_5|90|6|TREATMENT|2021-01-01|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-12|P1Y2M10DT2H30M|AFTER|2021-01-04|AFTER|2021-01-09
e|RS|b46ff3a2-f257-4803-8064-e29bd1114bfc|10|NEWLPROG|New Lesion Progression|FAROOQUI SUPP CLL 2014|||iCPD|1|Bq/mL|IN SITU HYBRIDIZATION|||Y|PROXY|ENDOCRINOLOGIST|Y|5|Visit_5|90|1|TREATMENT|2021-01-01|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-12|P1Y2M10DT2H30M|AFTER|2020-12-20|ONGOING|2021-01-04
e|RS|b269c0ea-d3db-4052-9dc7-a55ac59d82a6|1|BONERESP|Bone Response|MASS|[?]|g/animal|ABSENT MORPHOLOGIC RESPONSE|1|%/min|PHOTOMETRIC CLOT DETECTION||||STUDY SUBJECT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|1|Visit_1|10|3|TREATMENT|2020-12-06|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-30|P1Y2M10DT2H30M|AFTER|2021-01-11|ONGOING|2021-02-13
e|RS|b269c0ea-d3db-4052-9dc7-a55ac59d82a6|2|NEWLIND|New Lesion Indicator|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|POINT|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|mL/sec/1.73m2|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY||||ADJUDICATION COMMITTEE|MICROSCOPIST 2|U|1|Visit_1|10|6|WASHOUT|2020-12-06|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-30|P1Y2M10DT2H30M|UNKNOWN|2021-01-11|BEFORE|2021-02-21
e|RS|b269c0ea-d3db-4052-9dc7-a55ac59d82a6|3|ANATRESP|Anatomic Response|IWC HALLEK CLL 2008|[?]|BAR|MINOR PATHOLOGIC RESPONSE|1|ug/cm2|MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING||||INVESTIGATOR|RADIOLOGIST 1|N|2|Visit_2|25|3|WASHOUT|2020-12-21|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-21|P1Y2M10DT2H30M|AFTER|2021-02-21|AFTER|2021-02-28
e|RS|b269c0ea-d3db-4052-9dc7-a55ac59d82a6|4|CLINRESP|Clinical Response|AJCC V7|[?]|cd/m2|VGPR|1|mCi|MAGNETIC RESONANCE ELASTOGRAPHY||Y||CHILD|NEUROLOGIST 2|NA|2|Visit_2|25|5|WASHOUT|2020-12-21|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-21|P1Y2M10DT2H30M|UNKNOWN|2021-03-04|ONGOING|2021-03-05
e|RS|b269c0ea-d3db-4052-9dc7-a55ac59d82a6|5|SYMPTDTR|Symptomatic Deterioration|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|mm3/mm2/year|PR-CT|1|U/m2/h|MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY||||FAMILY MEMBER|RADIOLOGIST 1|U|3|Visit_3|40|3|SCREENING|2021-01-05|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-07|P1Y2M10DT2H30M|COINCIDENT|2021-02-26|ONGOING|2021-03-04
e|RS|b269c0ea-d3db-4052-9dc7-a55ac59d82a6|6|NEWLWIND|New Lesion Worsening Indicator|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|GBq/ug|CR|1|mol/mol|RADIOIMMUNOPRECIPITATION ASSAY||Y||SIGNIFICANT OTHER|READER 1|NA|3|Visit_3|40|6|SCREENING|2021-01-05|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-07|P1Y2M10DT2H30M|COINCIDENT|2020-12-05|COINCIDENT|2020-12-22
e|RS|b269c0ea-d3db-4052-9dc7-a55ac59d82a6|7|MNPTHIND|Minor Pathological Response Indicator|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|uV2|PMD|1|mmol/day|NUCLEAR RADIOLOGY||||INVESTIGATOR|ONCOLOGIST 2|U|4|Visit_4|65|2|WASHOUT|2021-01-30|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-03|P1Y2M10DT2H30M|BEFORE|2021-02-05|ONGOING|2021-02-14
e|RS|b269c0ea-d3db-4052-9dc7-a55ac59d82a6|8|NEWLWIND|New Lesion Worsening Indicator|PCWG BUBLEY PROSTATE CANCER 1999|[?]|%(v/v)|OPTIMAL MORPHOLOGIC RESPONSE|1|GBq|EEG|Y|||CLINICAL RESEARCH COORDINATOR|OPHTHALMOLOGIST|NA|4|Visit_4|65|5|FOLLOW-UP|2021-01-30|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-03|P1Y2M10DT2H30M|AFTER|2020-12-12|COINCIDENT|2021-01-27
e|RS|b269c0ea-d3db-4052-9dc7-a55ac59d82a6|9|BESTRESP|Best Overall Response|PERCIST|[?]|DPM|HI-N|1|g/animal|COULOMETRIC TITRATION||Y||CLINICAL RESEARCH ASSOCIATE|READER|N|5|Visit_5|90|2|SCREENING|2021-02-24|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-03|P1Y2M10DT2H30M|BEFORE|2021-02-08|ONGOING|2021-03-03
e|RS|b269c0ea-d3db-4052-9dc7-a55ac59d82a6|10|METBRESP|Metabolic Response|SHINDOH COLORECTAL CANCER 2013|[?]|mg/kg/day|FAVORABLE RESPONSE|1|m3|INTERRUPTER TECHNIQUE||Y||GUARDIAN|MICROSCOPIST 3|NA|5|Visit_5|90|4|FOLLOW-UP|2021-02-24|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-03|P1Y2M10DT2H30M|UNKNOWN|2021-01-24|BEFORE|2021-01-30
e|RS|a5c667d1-d2ac-49f7-ad44-bf9a44762025|1|METBRESP|Metabolic Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|10^12/L|SD|1|log10 TCID 50/dose|TEST STRIP|Y|||INVESTIGATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|1|Visit_1|10|3|WASHOUT|2020-10-06|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-28|P1Y2M10DT2H30M|COINCIDENT|2020-12-14|AFTER|2020-12-18
e|RS|a5c667d1-d2ac-49f7-ad44-bf9a44762025|2|BONERESP|Bone Response|CHESON CLL 2006|||INCREASED|1|cal|IMMUNORADIOMETRIC ASSAY||Y|Y|STUDY SUBJECT|OTOLARYNGOLOGIST|NA|1|Visit_1|10|1|WASHOUT|2020-10-06|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-28|P1Y2M10DT2H30M|BEFORE|2020-12-31|AFTER|2021-01-03
e|RS|a5c667d1-d2ac-49f7-ad44-bf9a44762025|3|NTNERESP|Non-Target Non-Enhancing Response|AJCC V8|[?]|mmol/g|cPR|1|ft|FORCED OSCILLATION TECHNIQUE|Y|Y||PARENT|PATHOLOGIST 1|U|2|Visit_2|25|5|SCREENING|2020-10-21|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-12|P1Y2M10DT2H30M|BEFORE|2020-10-16|BEFORE|2020-12-02
e|RS|a5c667d1-d2ac-49f7-ad44-bf9a44762025|4|NTRGRESP|Non-target Response|GUPPY OVARIAN CANCER 2002|[?]|10^3 organisms|iPR|1|mL/dL|POPULATION SEQUENCING||Y||NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|N|2|Visit_2|25|7|WASHOUT|2020-10-21|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-12|P1Y2M10DT2H30M|COINCIDENT|2020-12-28|BEFORE|2020-12-31
e|RS|a5c667d1-d2ac-49f7-ad44-bf9a44762025|5|MRDRESP|Minimal Residual Disease Response|RANO ELLINGSON 2017|[?]|nmol/L/h|MOLECULAR CR|1|L/s|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION||||ADJUDICATION COMMITTEE|READER 3|U|3|Visit_3|40|1|TREATMENT|2020-11-05|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-19|P1Y2M10DT2H30M|BEFORE|2020-11-15|ONGOING|2020-12-10
e|RS|a5c667d1-d2ac-49f7-ad44-bf9a44762025|6|NEWLIND|New Lesion Indicator|MRECIST LENCIONI LIVER CANCER 2010|[?]|Tbsp|TREATMENT FAILURE|1|10^6 U|TOTAL BODY IRRADIATION||||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 1|N|3|Visit_3|40|1|TREATMENT|2020-11-05|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-19|P1Y2M10DT2H30M|AFTER|2020-12-28|COINCIDENT|2021-01-03
e|RS|a5c667d1-d2ac-49f7-ad44-bf9a44762025|7|HEMARESP|Hematologic Response|RECICL|[?]|pmol/L/h|WORSENED|1|mol/mg|X-RAY FLUORESCENCE SPECTROMETRY||Y||INDEPENDENT ASSESSOR|NEUROLOGIST|N|4|Visit_4|65|7|WASHOUT|2020-11-30|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-15|P1Y2M10DT2H30M|UNKNOWN|2020-10-22|BEFORE|2020-10-28
e|RS|a5c667d1-d2ac-49f7-ad44-bf9a44762025|8|ANATRESP|Anatomic Response|JACINTO CERVICAL CANCER 2007|[?]|copies/uL|MINOR PATHOLOGIC RESPONSE|1|% INHIBITION|IMMUNODIFFUSION||||CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST|U|4|Visit_4|65|7|SCREENING|2020-11-30|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-15|P1Y2M10DT2H30M|UNKNOWN|2020-10-11|BEFORE|2020-12-20
e|RS|a5c667d1-d2ac-49f7-ad44-bf9a44762025|9|PATHRESP|Pathologic Response|AJCC V7|[?]|DNA copies/mL|NED|1|ugEq|SPIROMETRY|Y|||CLINICAL STUDY SPONSOR|CARDIOLOGIST|U|5|Visit_5|90|1|TREATMENT|2020-12-25|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-08|P1Y2M10DT2H30M|AFTER|2020-12-05|COINCIDENT|2020-12-06
e|RS|a5c667d1-d2ac-49f7-ad44-bf9a44762025|10|NEWLIND|New Lesion Indicator|FAROOQUI SUPP CLL 2014|[?]|%|INCREASED|1|pmol/day|LIGHT SCATTERING SPECTROSCOPY||Y||INDEPENDENT ASSESSOR|RATER 1|N|5|Visit_5|90|5|TREATMENT|2020-12-25|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-08|P1Y2M10DT2H30M|COINCIDENT|2020-10-23|ONGOING|2020-10-24
e|RS|944a2627-13f1-4ecf-9545-8819a1327138|1|ANATRESP|Anatomic Response|RANO ELLINGSON 2017|[?]|BISCUIT|CYTOGENETIC MINOR RESPONSE|1|mEq|ELECTROGASTROGRAPHY|Y|||HEALTH CARE PROFESSIONAL|UROLOGIST|NA|1|Visit_1|10|2|TREATMENT|2021-01-17|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-21|P1Y2M10DT2H30M|COINCIDENT|2021-04-02|ONGOING|2021-04-06
e|RS|944a2627-13f1-4ecf-9545-8819a1327138|2|METBRESP|Metabolic Response|SCHWARZ CERVICAL CANCER 2009|||pCR|1|Enzyme U/L|FLOCCULATION|Y||Y|INDEPENDENT ASSESSOR|OTOLARYNGOLOGIST|Y|1|Visit_1|10|4|WASHOUT|2021-01-17|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-21|P1Y2M10DT2H30M|UNKNOWN|2021-03-24|ONGOING|2021-04-16
e|RS|944a2627-13f1-4ecf-9545-8819a1327138|3|SYMPTDTR|Symptomatic Deterioration|SHINDOH COLORECTAL CANCER 2013|||PD FROM PR|1|L/s|DNA MICROARRAY|||Y|SIGNIFICANT OTHER|ADJUDICATOR|U|2|Visit_2|25|7|TREATMENT|2021-02-01|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-24|P1Y2M10DT2H30M|BEFORE|2021-03-15|ONGOING|2021-04-04
e|RS|944a2627-13f1-4ecf-9545-8819a1327138|4|NEWLIND|New Lesion Indicator|WHO BREAST CANCER 2006|[?]|pmol|PDu|1|CCID 50/dose|SLOAN LETTER EYE CHART 100%|Y|Y||FRIEND|ENDOCRINOLOGIST|NA|2|Visit_2|25|6|TREATMENT|2021-02-01|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-24|P1Y2M10DT2H30M|UNKNOWN|2021-01-31|ONGOING|2021-03-30
e|RS|944a2627-13f1-4ecf-9545-8819a1327138|5|METBRESP|Metabolic Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|ug/kg/min|MAJOR PATHOLOGIC RESPONSE|1|LB|REAL-TIME POLYMERASE CHAIN REACTION ASSAY|Y|||INDEPENDENT ASSESSOR|NEUROLOGIST 2|NA|3|Visit_3|40|2|WASHOUT|2021-02-16|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-27|P1Y2M10DT2H30M|UNKNOWN|2021-04-11|AFTER|2021-04-13
e|RS|944a2627-13f1-4ecf-9545-8819a1327138|6|OVRLRESP|Overall Response|SHINDOH COLORECTAL CANCER 2013|[?]|DIOPTER|CYTOGENETIC NO RESPONSE|1|cpm|PHYSICAL EXAMINATION||||NON-HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|NA|3|Visit_3|40|2|TREATMENT|2021-02-16|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-27|P1Y2M10DT2H30M|BEFORE|2021-02-14|AFTER|2021-03-02
e|RS|944a2627-13f1-4ecf-9545-8819a1327138|7|NTNERESP|Non-Target Non-Enhancing Response|IWG CHESON AML 2003|[?]|g|PD FROM PR|1|mPa|NO INFORMATION||Y||FAMILY MEMBER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|4|Visit_4|65|2|TREATMENT|2021-03-13|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-13|P1Y2M10DT2H30M|AFTER|2021-02-08|COINCIDENT|2021-03-22
e|RS|944a2627-13f1-4ecf-9545-8819a1327138|8|DRCRIND|Disease Recurrence Indicator|CHESON CLL 2012|[?]|SACHET|CYTOGENETIC MINIMAL RESPONSE|1|U|ACCELERATOR MASS SPECTROMETRY|Y|||CHILD|READER 2|U|4|Visit_4|65|6|SCREENING|2021-03-13|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-13|P1Y2M10DT2H30M|COINCIDENT|2021-01-21|BEFORE|2021-03-03
e|RS|944a2627-13f1-4ecf-9545-8819a1327138|9|MOLRESP|Molecular Response|HAMAOKA BREAST CANCER 2010|[?]|mL/100g/min|HI-N|1|PFU/animal|HPLC-FL||||SIBLING|ONCOLOGIST|N|5|Visit_5|90|2|TREATMENT|2021-04-07|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-12|P1Y2M10DT2H30M|BEFORE|2021-03-12|ONGOING|2021-04-11
e|RS|944a2627-13f1-4ecf-9545-8819a1327138|10|NTLWIND|Non-Target Lesion Worsening Indicator|PCWG SCHER PROSTATE CANCER 2016|[?]|U/mL|CYTOGENETIC MINOR RESPONSE|1|tsp eq|AUDIOMETRY||Y||VENDOR|RADIOLOGIST 2|NA|5|Visit_5|90|5|SCREENING|2021-04-07|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-12|P1Y2M10DT2H30M|COINCIDENT|2021-02-24|ONGOING|2021-04-09
e|RS|7902955a-6336-45e5-a15d-7c368a28ac4f|1|NTLWIND|Non-Target Lesion Worsening Indicator|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|PACK|HI-P|1|uL/dose|CARDIAC THERMODILUTION||||INDEPENDENT ASSESSOR|ONCOLOGIST|NA|1|Visit_1|10|1|TREATMENT|2020-06-01|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-22|P1Y2M10DT2H30M|UNKNOWN|2020-08-19|COINCIDENT|2020-08-20
e|RS|7902955a-6336-45e5-a15d-7c368a28ac4f|2|MRDRESP|Minimal Residual Disease Response|HAMAOKA BREAST CANCER 2010|||FAVORABLE RESPONSE|1|mg/kg/week|TEST STRIP|||Y|INDEPENDENT ASSESSOR|RADIOLOGIST|Y|1|Visit_1|10|2|TREATMENT|2020-06-01|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-22|P1Y2M10DT2H30M|COINCIDENT|2020-08-19|AFTER|2020-08-27
e|RS|7902955a-6336-45e5-a15d-7c368a28ac4f|3|MRPHRESP|Morphologic Response|NCIWG CHESON CLL 1996|[?]|kat|iUPD|1|h/wk|OBSERVATION||||PARENT|PATHOLOGIST|U|2|Visit_2|25|6|TREATMENT|2020-06-16|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-26|P1Y2M10DT2H30M|BEFORE|2020-07-18|BEFORE|2020-08-28
e|RS|7902955a-6336-45e5-a15d-7c368a28ac4f|4|CLINRESP|Clinical Response|LEE LUNG CANCER 2011|||NON-PD|1|/2000 RBC|REFLECTANCE SPECTROSCOPY|||Y|SPOUSE|NEUROLOGIST 2|Y|2|Visit_2|25|6|SCREENING|2020-06-16|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-26|P1Y2M10DT2H30M|COINCIDENT|2020-07-12|ONGOING|2020-08-28
e|RS|7902955a-6336-45e5-a15d-7c368a28ac4f|5|NEWLWIND|New Lesion Worsening Indicator|HARTMANN GERM CELL CANCER 2002|[?]|g/day|PD-CT|1|mL/animal|PET/CT SCAN|Y|||NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|Y|3|Visit_3|40|7|SCREENING|2020-07-01|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-21|P1Y2M10DT2H30M|BEFORE|2020-08-27|COINCIDENT|2020-08-29
e|RS|7902955a-6336-45e5-a15d-7c368a28ac4f|6|BESTRESP|Best Overall Response|RECIST 1.1|[?]|kg/cm|SD|1|mL/min|AUDIOMETRY|Y|||DOMESTIC PARTNER|ADJUDICATOR|N|3|Visit_3|40|2|TREATMENT|2020-07-01|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-21|P1Y2M10DT2H30M|COINCIDENT|2020-05-31|BEFORE|2020-07-16
e|RS|7902955a-6336-45e5-a15d-7c368a28ac4f|7|DRCRIND|Disease Recurrence Indicator|WHO BREAST CANCER 2006|||INDETERMINATE RESPONSE|1|mg/min|X-RAY|Y||Y|FAMILY MEMBER|READER 1|U|4|Visit_4|65|3|FOLLOW-UP|2020-07-26|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-21|P1Y2M10DT2H30M|BEFORE|2020-08-25|ONGOING|2020-08-27
e|RS|7902955a-6336-45e5-a15d-7c368a28ac4f|8|SFTSRESP|Soft Tissue Response|RECIST 1.1|[?]|km/h|SD|1|10^9/dose|WHOLE EXOME SEQUENCING|Y|||GUARDIAN|ADJUDICATOR 3|Y|4|Visit_4|65|1|WASHOUT|2020-07-26|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-21|P1Y2M10DT2H30M|COINCIDENT|2020-08-04|AFTER|2020-08-22
e|RS|7902955a-6336-45e5-a15d-7c368a28ac4f|9|CLINRESP|Clinical Response|MRANO VAN DEN BENT GLIOMA 2011|||HI-N|1|mgEq|TRICHROME STAIN|||Y|PROXY|ADJUDICATOR|U|5|Visit_5|90|4|TREATMENT|2020-08-20|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-07|P1Y2M10DT2H30M|AFTER|2020-06-28|COINCIDENT|2020-08-19
e|RS|7902955a-6336-45e5-a15d-7c368a28ac4f|10|RDIORESP|Radiologic Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|10^6 CFU/g|PD FROM PR|1|cmH2O/mL|KLEIHAUER-BETKE||Y||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 2|NA|5|Visit_5|90|1|TREATMENT|2020-08-20|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-07|P1Y2M10DT2H30M|COINCIDENT|2020-07-04|ONGOING|2020-08-06
e|RS|aeef8a2d-167c-41e7-baa6-a3dc756bbb49|1|CLINRESP|Clinical Response|BRUGGEMANN MRD 2010|||HI-N|1|Ci/mL|NEPHELOMETRY|||Y|SIGNIFICANT OTHER|DEVELOPMENTAL PSYCHOLOGIST|N|1|Visit_1|10|3|TREATMENT|2020-12-20|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-09|P1Y2M10DT2H30M|UNKNOWN|2021-01-24|COINCIDENT|2021-02-06
e|RS|aeef8a2d-167c-41e7-baa6-a3dc756bbb49|2|NTLWIND|Non-Target Lesion Worsening Indicator|PCWG BUBLEY PROSTATE CANCER 1999|[?]|Hz/s|CRi|1|mg2/dL2|FLUORESCENT SPOT TEST||||DOMESTIC PARTNER|MICROSCOPIST|Y|1|Visit_1|10|2|TREATMENT|2020-12-20|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-09|P1Y2M10DT2H30M|BEFORE|2021-02-04|COINCIDENT|2021-02-15
e|RS|aeef8a2d-167c-41e7-baa6-a3dc756bbb49|3|MJPTHIND|Major Pathological Response Indicator|IWG CHESON AML 2003|[?]|mL*cmH2O|MORPHOLOGIC CRi|1|ms2|OLIGO ACGH||||SIBLING|OTOLARYNGOLOGIST|Y|2|Visit_2|25|7|SCREENING|2021-01-04|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-02|P1Y2M10DT2H30M|COINCIDENT|2021-01-29|ONGOING|2021-02-03
e|RS|aeef8a2d-167c-41e7-baa6-a3dc756bbb49|4|CYTORESP|Cytogenetic Response|IRANO 2015|||NON-iCR/NON-iUPD|1|MHz|DIRECT SEQUENCING||Y|Y|FRIEND|UROLOGIST|U|2|Visit_2|25|4|FOLLOW-UP|2021-01-04|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-02|P1Y2M10DT2H30M|UNKNOWN|2021-01-31|AFTER|2021-02-20
e|RS|aeef8a2d-167c-41e7-baa6-a3dc756bbb49|5|MOLRESP|Molecular Response|IWG CHESON AML 2003|[?]|Absorbance U|MRD NEGATIVITY|1|Roentgen|PULMONARY ANGIOGRAPHY||Y||CLINICAL RESEARCH COORDINATOR|RATER 2|NA|3|Visit_3|40|2|TREATMENT|2021-01-19|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-21|P1Y2M10DT2H30M|AFTER|2021-01-28|ONGOING|2021-02-12
e|RS|aeef8a2d-167c-41e7-baa6-a3dc756bbb49|6|MNPTHIND|Minor Pathological Response Indicator|EASL BRUIX LIVER CANCER 2001|[?]|g/g/day|iCR|1|um/s|WESTERGREN||||SIBLING|FORENSIC PATHOLOGIST|U|3|Visit_3|40|4|TREATMENT|2021-01-19|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-21|P1Y2M10DT2H30M|UNKNOWN|2021-01-16|ONGOING|2021-02-12
e|RS|aeef8a2d-167c-41e7-baa6-a3dc756bbb49|7|MJPTHIND|Major Pathological Response Indicator|RECIST 1.1|||SD-CT|1|BOLUS|LISSAMINE GREEN STAIN|||Y|CHILD|READER 2|U|4|Visit_4|65|1|TREATMENT|2021-02-13|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-10|P1Y2M10DT2H30M|AFTER|2021-01-01|COINCIDENT|2021-02-02
e|RS|aeef8a2d-167c-41e7-baa6-a3dc756bbb49|8|OVRLRESP|Overall Response|NCCN ALL MRD 2014|[?]|mg/day|PR-CT|1|/10^3|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION||||FRIEND|RADIOLOGIST|U|4|Visit_4|65|7|TREATMENT|2021-02-13|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-10|P1Y2M10DT2H30M|UNKNOWN|2020-12-13|BEFORE|2021-02-22
e|RS|aeef8a2d-167c-41e7-baa6-a3dc756bbb49|9|MRDIND|Minimal Residual Disease Indicator|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|GBq/mg|CYTOGENETIC MINOR RESPONSE|1|Gy/min|MICRO BROTH DILUTION||||FRIEND|NEUROLOGIST|NA|5|Visit_5|90|7|FOLLOW-UP|2021-03-10|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-12|P1Y2M10DT2H30M|COINCIDENT|2020-12-15|ONGOING|2021-01-05
e|RS|aeef8a2d-167c-41e7-baa6-a3dc756bbb49|10|STRUSTAT|Steroid Use Status|MASS|[?]|cd*s/m2|RELAPSED DISEASE FROM CR|1|lx|CONTRAST ENHANCED MRI||||SIGNIFICANT OTHER|PEDIATRIC NEUROLOGIST|N|5|Visit_5|90|3|TREATMENT|2021-03-10|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-12|P1Y2M10DT2H30M|AFTER|2021-03-02|COINCIDENT|2021-03-08
e|RS|6071d81f-2f38-414f-90ca-4ad80c971054|1|BESTRESP|Best Overall Response|BLAZER COLORECTAL CANCER 2008|[?]|ppth|PD-CT|1|cs|PHASE CONTRAST MICROSCOPY||||VENDOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|1|Visit_1|10|6|WASHOUT|2020-09-07|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-01|P1Y2M10DT2H30M|AFTER|2020-09-05|COINCIDENT|2020-10-08
e|RS|6071d81f-2f38-414f-90ca-4ad80c971054|2|BMIVLIND|Bone Marrow Involvement Indicator|TSUKASAKI LEUKEMIA LYMPHOMA 2009|||iSD|1|EP U|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY|||Y|SPOUSE|FORENSIC PATHOLOGIST|N|1|Visit_1|10|4|FOLLOW-UP|2020-09-07|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-01|P1Y2M10DT2H30M|BEFORE|2020-11-30|COINCIDENT|2020-12-01
e|RS|6071d81f-2f38-414f-90ca-4ad80c971054|3|CPRFSTAT|Clinical Performance Status|SACT|[?]|10^7 PFU|TREATMENT FAILURE|1|kcal/day|HPLC||||DOMESTIC PARTNER|PATHOLOGIST 2|U|2|Visit_2|25|7|FOLLOW-UP|2020-09-22|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-13|P1Y2M10DT2H30M|UNKNOWN|2020-10-28|ONGOING|2020-12-03
e|RS|6071d81f-2f38-414f-90ca-4ad80c971054|4|MNPTHIND|Minor Pathological Response Indicator|AJCC V8|[?]|BOTTLE|MORPHOLOGIC LEUKEMIA-FREE STATE|1|STRIP|GRAM STAIN||Y||CLINICAL STUDY SPONSOR|READER 3|N|2|Visit_2|25|3|TREATMENT|2020-09-22|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-13|P1Y2M10DT2H30M|COINCIDENT|2020-10-12|BEFORE|2020-11-29
e|RS|6071d81f-2f38-414f-90ca-4ad80c971054|5|DRCRIND|Disease Recurrence Indicator|GUPPY OVARIAN CANCER 2002|||INDETERMINATE RESPONSE|1|10^6 CFU|RAJI CELL RIA|Y||Y|HEALTH CARE PROFESSIONAL|RATER|NA|3|Visit_3|40|3|TREATMENT|2020-10-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-20|P1Y2M10DT2H30M|AFTER|2020-11-11|ONGOING|2020-11-30
e|RS|6071d81f-2f38-414f-90ca-4ad80c971054|6|HEMARESP|Hematologic Response|RANO|[?]|mL/min/1.73m2|OPTIMAL MORPHOLOGIC RESPONSE|1|Farad|LISSAMINE GREEN STAIN||||GUARDIAN|OTOLARYNGOLOGIST|Y|3|Visit_3|40|4|FOLLOW-UP|2020-10-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-20|P1Y2M10DT2H30M|BEFORE|2020-09-18|BEFORE|2020-10-28
e|RS|6071d81f-2f38-414f-90ca-4ad80c971054|7|METBRESP|Metabolic Response|LUGANO CLASSIFICATION|||DISEASE TRANSFORMATION|1|pt_us|HEMAGGLUTINATION ASSAY|||Y|INDEPENDENT ASSESSOR|ADJUDICATOR 1|N|4|Visit_4|65|3|SCREENING|2020-11-01|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-28|P1Y2M10DT2H30M|BEFORE|2020-09-17|COINCIDENT|2020-11-30
e|RS|6071d81f-2f38-414f-90ca-4ad80c971054|8|CPRFSTAT|Clinical Performance Status|CHESON MALIGNANT LYMPHOMA 2007|[?]|kg/m2|MRD RELAPSE|1|genEq/mL|INFRARED SPECTROMETRY||||INTERVIEWER|FORENSIC PATHOLOGIST|N|4|Visit_4|65|3|TREATMENT|2020-11-01|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-28|P1Y2M10DT2H30M|UNKNOWN|2020-09-01|BEFORE|2020-09-23
e|RS|6071d81f-2f38-414f-90ca-4ad80c971054|9|SFTSRESP|Soft Tissue Response|MASS|[?]|mV/sec|cPR|1|DNA copies/mL|ZIEHL NEELSEN ACID FAST STAIN||Y||GUARDIAN|READER 2|N|5|Visit_5|90|7|WASHOUT|2020-11-26|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-12|P1Y2M10DT2H30M|BEFORE|2020-12-04|BEFORE|2020-12-05
e|RS|6071d81f-2f38-414f-90ca-4ad80c971054|10|SYMPTDTR|Symptomatic Deterioration|CHOLLET BREAST CANCER 2002|[?]|U/10^12 RBC|MRD PERSISTENCE|1|MBq|PET SCAN|Y|Y||FRIEND|INTERNIST|U|5|Visit_5|90|6|WASHOUT|2020-11-26|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-12|P1Y2M10DT2H30M|BEFORE|2020-10-06|COINCIDENT|2020-10-30
e|RS|22ffaa50-941f-4d52-b73b-84e13d2bb4bd|1|METBRESP|Metabolic Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|COAT|CYTOGENETIC CR|1|10^6 RNA copies/mL|DXA SCAN|Y|||SIBLING|MICROSCOPIST 2|Y|1|Visit_1|10|3|TREATMENT|2020-09-28|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-27|P1Y2M10DT2H30M|COINCIDENT|2020-10-18|ONGOING|2020-10-22
e|RS|22ffaa50-941f-4d52-b73b-84e13d2bb4bd|2|BESTRESP|Best Overall Response|RANO ELLINGSON 2017|[?]|mmHg/sec|CYTOGENETIC PR|1|TROCHE|REAL-TIME POLYMERASE CHAIN REACTION ASSAY|Y|Y||VENDOR|RATER 2|N|1|Visit_1|10|3|TREATMENT|2020-09-28|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-27|P1Y2M10DT2H30M|AFTER|2020-11-17|BEFORE|2020-12-25
e|RS|22ffaa50-941f-4d52-b73b-84e13d2bb4bd|3|ANATRESP|Anatomic Response|SCHER PROSTATE CANCER 2011|[?]|yd|MR|1|mg/m2/day|ERGOSPIROMETRY||||CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST|N|2|Visit_2|25|7|TREATMENT|2020-10-13|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-05|P1Y2M10DT2H30M|BEFORE|2020-10-18|COINCIDENT|2020-12-22
e|RS|22ffaa50-941f-4d52-b73b-84e13d2bb4bd|4|NTRGRESP|Non-target Response|AJCC V7|||PSEUDORESPONSE|1|kg/m2|MICROBIAL BIOCHEMICAL IDENTIFICATION|||Y|ADJUDICATOR|PEDIATRIC NEUROLOGIST|N|2|Visit_2|25|1|FOLLOW-UP|2020-10-13|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-05|P1Y2M10DT2H30M|AFTER|2020-10-31|COINCIDENT|2020-12-22
e|RS|22ffaa50-941f-4d52-b73b-84e13d2bb4bd|5|TMRESP|Tumor Marker Response|RECICL|||NON-PD|1|CAPSULE|FUNCTIONAL MRI|Y||Y|DOMESTIC PARTNER|RADIOLOGIST 1|Y|3|Visit_3|40|1|WASHOUT|2020-10-28|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-03|P1Y2M10DT2H30M|COINCIDENT|2020-11-12|BEFORE|2020-12-08
e|RS|22ffaa50-941f-4d52-b73b-84e13d2bb4bd|6|MOLRESP|Molecular Response|CHOI GIST 2008|[?]|BAG|DISEASE TRANSFORMATION|1|BEAM BREAKS|ACCELERATOR MASS SPECTROMETRY||||GUARDIAN|MICROSCOPIST 3|U|3|Visit_3|40|5|TREATMENT|2020-10-28|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-03|P1Y2M10DT2H30M|UNKNOWN|2020-11-05|COINCIDENT|2020-12-22
e|RS|22ffaa50-941f-4d52-b73b-84e13d2bb4bd|7|OVRLRESP|Overall Response|RECIST 1.1|[?]|nmol/L/min|pCR|1|mV|PYROSEQUENCING||||FRIEND|CARDIOLOGIST|NA|4|Visit_4|65|1|FOLLOW-UP|2020-11-22|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-16|P1Y2M10DT2H30M|COINCIDENT|2020-10-24|COINCIDENT|2020-11-09
e|RS|22ffaa50-941f-4d52-b73b-84e13d2bb4bd|8|MOLRESP|Molecular Response|SHINDOH COLORECTAL CANCER 2013|[?]|mol/mol|UNFAVORABLE RESPONSE|1|PFU/dose|FLUORESCENT LIFETIME IMAGING MICROSCOPY||||NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|4|Visit_4|65|2|TREATMENT|2020-11-22|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-16|P1Y2M10DT2H30M|COINCIDENT|2020-11-17|AFTER|2020-12-01
e|RS|22ffaa50-941f-4d52-b73b-84e13d2bb4bd|9|MRDRESP|Minimal Residual Disease Response|SACT|[?]|umol|PD|1|10^4 CFU/mL|BAC ACGH|Y|||NON-HEALTH CARE PROFESSIONAL|RATER 1|U|5|Visit_5|90|4|TREATMENT|2020-12-17|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-19|P1Y2M10DT2H30M|COINCIDENT|2020-12-10|BEFORE|2020-12-23
e|RS|22ffaa50-941f-4d52-b73b-84e13d2bb4bd|10|HEMARESP|Hematologic Response|KUKER LYMPHOMA 2005|||PSEUDORESPONSE|1|g/L|CALCULATION|Y|Y|Y|VENDOR|NEUROLOGIST|U|5|Visit_5|90|4|FOLLOW-UP|2020-12-17|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-19|P1Y2M10DT2H30M|AFTER|2020-11-12|ONGOING|2020-12-14
e|RS|a046d48d-b1fa-4d46-902e-3984aed00ec7|1|TRGRESP|Target Response|PETIT BREAST CANCER 2001|[?]|BOWL|INCREASED|1|mg/dose|CISH||Y||CAREGIVER|NEUROLOGIST 2|N|1|Visit_1|10|5|TREATMENT|2020-08-01|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-25|P1Y2M10DT2H30M|COINCIDENT|2020-07-25|COINCIDENT|2020-08-30
e|RS|a046d48d-b1fa-4d46-902e-3984aed00ec7|2|NEWLWIND|New Lesion Worsening Indicator|GUILHOT CML 2007|||ABSENT MORPHOLOGIC RESPONSE|1|kg|IMMUNOCHROMATOGRAPHY|Y||Y|VENDOR|UROLOGIST|Y|1|Visit_1|10|6|TREATMENT|2020-08-01|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-25|P1Y2M10DT2H30M|COINCIDENT|2020-09-24|ONGOING|2020-10-11
e|RS|a046d48d-b1fa-4d46-902e-3984aed00ec7|3|CPRFSTAT|Clinical Performance Status|HARTMANN GERM CELL CANCER 2002|||WORSENED|1|Pa|MANUAL COUNT|||Y|HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|U|2|Visit_2|25|7|WASHOUT|2020-08-16|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-24|P1Y2M10DT2H30M|BEFORE|2020-08-24|AFTER|2020-09-02
e|RS|a046d48d-b1fa-4d46-902e-3984aed00ec7|4|PATHRESP|Pathologic Response|CHESON LYMPHOMA 2008|||CA125 75% RESPONSE|1|Torr|VIRUS PLAQUE ASSAY|||Y|CAREGIVER|DEVELOPMENTAL PSYCHOLOGIST|Y|2|Visit_2|25|2|TREATMENT|2020-08-16|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-24|P1Y2M10DT2H30M|AFTER|2020-09-22|ONGOING|2020-10-24
e|RS|a046d48d-b1fa-4d46-902e-3984aed00ec7|5|LIVRRESP|Liver Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|grain|NON-QUANTIFIABLE MRD POSITIVITY|1|Gy/min|SICKLE CELL SOLUBILITY TEST||||FAMILY MEMBER|ADJUDICATOR 2|Y|3|Visit_3|40|7|SCREENING|2020-08-31|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-31|P1Y2M10DT2H30M|COINCIDENT|2020-08-25|BEFORE|2020-09-13
e|RS|a046d48d-b1fa-4d46-902e-3984aed00ec7|6|MJPTHIND|Major Pathological Response Indicator|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|DNA copies/ug|TREATMENT FAILURE|1|NFIU|SLOAN LETTER EYE CHART 2.5%|Y|||NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST|NA|3|Visit_3|40|7|WASHOUT|2020-08-31|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-31|P1Y2M10DT2H30M|AFTER|2020-08-25|BEFORE|2020-10-20
e|RS|a046d48d-b1fa-4d46-902e-3984aed00ec7|7|TRGRESP|Target Response|FAROOQUI SUPP CLL 2014|||PR WITH LYMPHOCYTOSIS|1|PUFF|IMMUNOPRECIPITATION|||Y|SIGNIFICANT OTHER|MICROSCOPIST 3|U|4|Visit_4|65|1|SCREENING|2020-09-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-09|P1Y2M10DT2H30M|UNKNOWN|2020-08-04|ONGOING|2020-08-06
e|RS|a046d48d-b1fa-4d46-902e-3984aed00ec7|8|ANATRESP|Anatomic Response|EASL BRUIX LIVER CANCER 2001|||NON-QUANTIFIABLE MRD POSITIVITY|1|mAmp|CLAUSS METHOD|||Y|FAMILY MEMBER|READER 1|N|4|Visit_4|65|1|TREATMENT|2020-09-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-09|P1Y2M10DT2H30M|COINCIDENT|2020-10-12|BEFORE|2020-10-20
e|RS|a046d48d-b1fa-4d46-902e-3984aed00ec7|9|STRUSTAT|Steroid Use Status|SHINDOH COLORECTAL CANCER 2013|||PARTIAL MORPHOLOGIC RESPONSE|1|umol/L/sec|MICROBIAL CULTURE|||Y|CAREGIVER|RADIOLOGIST 2|Y|5|Visit_5|90|7|SCREENING|2020-10-20|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-10|P1Y2M10DT2H30M|COINCIDENT|2020-08-19|ONGOING|2020-09-26
e|RS|a046d48d-b1fa-4d46-902e-3984aed00ec7|10|MOLRESP|Molecular Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|||CYTOGENETIC MINIMAL RESPONSE|1|um|QUANTITATIVE CORONARY ANGIOGRAPHY|||Y|INTERVIEWER|HEMATOLOGIST|U|5|Visit_5|90|3|SCREENING|2020-10-20|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-10|P1Y2M10DT2H30M|COINCIDENT|2020-10-17|ONGOING|2020-10-25
e|RS|8b60e1b0-2cd9-419d-b345-9006af042932|1|MOLRESP|Molecular Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|||RELAPSED DISEASE FROM CR OR PR|1|CIGARETTE|PERIODIC ACID SCHIFF STAIN|Y||Y|INVESTIGATOR|ENDOCRINOLOGIST|NA|1|Visit_1|10|7|TREATMENT|2020-12-16|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-08|P1Y2M10DT2H30M|BEFORE|2021-02-13|ONGOING|2021-03-08
e|RS|8b60e1b0-2cd9-419d-b345-9006af042932|2|MNPTHIND|Minor Pathological Response Indicator|PCWG SCHER PROSTATE CANCER 2016|[?]|nsec|MRD NEGATIVITY|1|genEq|MACRO BROTH DILUTION||Y||PARENT|ADJUDICATOR 1|N|1|Visit_1|10|6|TREATMENT|2020-12-16|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-08|P1Y2M10DT2H30M|BEFORE|2020-12-26|COINCIDENT|2021-01-12
e|RS|8b60e1b0-2cd9-419d-b345-9006af042932|3|NEWLWIND|New Lesion Worsening Indicator|WHO BREAST CANCER 2006|[?]|Bq/mg|CMR|1|kHz|TONOMETRY|Y|||INDEPENDENT ASSESSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|2|Visit_2|25|4|TREATMENT|2020-12-31|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-10|P1Y2M10DT2H30M|COINCIDENT|2021-01-27|AFTER|2021-03-13
e|RS|8b60e1b0-2cd9-419d-b345-9006af042932|4|MRPHRESP|Morphologic Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|% INHIBITION|CYTOGENETIC CR|1|cm|IMPEDANCE CONDUCTIVITY||||CHILD|RADIOLOGIST 1|N|2|Visit_2|25|4|TREATMENT|2020-12-31|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-10|P1Y2M10DT2H30M|BEFORE|2020-12-14|BEFORE|2021-01-09
e|RS|8b60e1b0-2cd9-419d-b345-9006af042932|5|NEWLIND|New Lesion Indicator|MRECIST LENCIONI LIVER CANCER 2010|||MRD PERSISTENCE|1|dmol|EEG||Y|Y|NON-HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|U|3|Visit_3|40|7|FOLLOW-UP|2021-01-15|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-11|P1Y2M10DT2H30M|UNKNOWN|2021-03-09|ONGOING|2021-03-12
e|RS|8b60e1b0-2cd9-419d-b345-9006af042932|6|MRPHRESP|Morphologic Response|SCHER PROSTATE CANCER 2011|||PR WITH LYMPHOCYTOSIS|1|CFU/mL|FREEZING POINT DEPRESSION|||Y|CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST|Y|3|Visit_3|40|1|WASHOUT|2021-01-15|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-11|P1Y2M10DT2H30M|UNKNOWN|2021-01-10|COINCIDENT|2021-01-18
e|RS|8b60e1b0-2cd9-419d-b345-9006af042932|7|BONERESP|Bone Response|KUMAR IMWG 2016|||PD FROM PR|1|Bq/mL|FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY||Y|Y|DOMESTIC PARTNER|NEUROLOGIST 1|U|4|Visit_4|65|2|TREATMENT|2021-02-09|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-05|P1Y2M10DT2H30M|UNKNOWN|2021-01-23|ONGOING|2021-02-26
e|RS|8b60e1b0-2cd9-419d-b345-9006af042932|8|NTLWIND|Non-Target Lesion Worsening Indicator|PCWG SCHER PROSTATE CANCER 2008|||COMPLETE MRD RESPONSE|1|mmol/L|PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY|||Y|FAMILY MEMBER|MICROSCOPIST 2|NA|4|Visit_4|65|3|SCREENING|2021-02-09|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-05|P1Y2M10DT2H30M|BEFORE|2020-12-26|COINCIDENT|2021-03-11
e|RS|8b60e1b0-2cd9-419d-b345-9006af042932|9|STRUSTAT|Steroid Use Status|SACT|[?]|/10^4|PD-CT|1|kg/mol|CELL CYTOTOXICITY NEUTRALIZATION ASSAY||||CLINICAL RESEARCH COORDINATOR|NEUROLOGIST|U|5|Visit_5|90|2|FOLLOW-UP|2021-03-06|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-25|P1Y2M10DT2H30M|UNKNOWN|2021-01-23|AFTER|2021-01-28
e|RS|8b60e1b0-2cd9-419d-b345-9006af042932|10|SYMPTDTR|Symptomatic Deterioration|PCWG SCHER PROSTATE CANCER 2008|[?]|TRANSDUCING UNIT|MAJOR PATHOLOGIC RESPONSE|1|10^6 copies/mL|FISH|Y|||VENDOR|READER 3|NA|5|Visit_5|90|3|TREATMENT|2021-03-06|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-25|P1Y2M10DT2H30M|UNKNOWN|2021-01-18|ONGOING|2021-03-06
e|RS|712029bc-471a-4e3d-9123-e38b3c38bc6c|1|MOLRESP|Molecular Response|RECIST 1.1|[?]|Enzyme U|IMPROVED|1|10^6 organisms/mg|PHYSICAL EXAMINATION||Y||CHILD|PATHOLOGIST 2|NA|1|Visit_1|10|6|TREATMENT|2021-01-24|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-19|P1Y2M10DT2H30M|AFTER|2021-03-26|BEFORE|2021-04-11
e|RS|712029bc-471a-4e3d-9123-e38b3c38bc6c|2|MRDRESP|Minimal Residual Disease Response|PCWG SCHER PROSTATE CANCER 2016|||CYTOGENETIC MINIMAL RESPONSE|1|ug/L/h|HEMAGGLUTINATION ASSAY|||Y|PARENT|READER 1|Y|1|Visit_1|10|4|TREATMENT|2021-01-24|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-19|P1Y2M10DT2H30M|AFTER|2021-02-10|COINCIDENT|2021-02-14
e|RS|712029bc-471a-4e3d-9123-e38b3c38bc6c|3|SYMPTDTR|Symptomatic Deterioration|BRUGGEMANN MRD 2010|||CRi|1|HOURS|BALLPOINT PEN TECHNIQUE|||Y|FAMILY MEMBER|CLINICAL PATHOLOGIST|Y|2|Visit_2|25|7|TREATMENT|2021-02-08|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-01|P1Y2M10DT2H30M|AFTER|2021-03-02|COINCIDENT|2021-03-05
e|RS|712029bc-471a-4e3d-9123-e38b3c38bc6c|4|STRUSTAT|Steroid Use Status|RECIST 1.1|||UNEQUIVOCAL|1|Torr|MICROBIAL CONCENTRATION|||Y|SIGNIFICANT OTHER|CLINICAL PATHOLOGIST|U|2|Visit_2|25|5|WASHOUT|2021-02-08|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-01|P1Y2M10DT2H30M|COINCIDENT|2021-02-03|ONGOING|2021-04-10
e|RS|712029bc-471a-4e3d-9123-e38b3c38bc6c|5|NEWLIND|New Lesion Indicator|KUMAR IMWG 2016|||MAJOR PATHOLOGIC RESPONSE|1|10^9 organisms/mg|CLINICAL EVALUATION|||Y|INDEPENDENT ASSESSOR|ONCOLOGIST 1|N|3|Visit_3|40|2|WASHOUT|2021-02-23|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-06|P1Y2M10DT2H30M|UNKNOWN|2021-04-14|COINCIDENT|2021-04-23
e|RS|712029bc-471a-4e3d-9123-e38b3c38bc6c|6|HEMARESP|Hematologic Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|PATCH|UNEQUIVOCAL|1|/mm|VIRUS PLAQUE ASSAY||||PROXY|DEVELOPMENTAL PSYCHOLOGIST|U|3|Visit_3|40|2|SCREENING|2021-02-23|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-06|P1Y2M10DT2H30M|COINCIDENT|2021-03-11|ONGOING|2021-03-28
e|RS|712029bc-471a-4e3d-9123-e38b3c38bc6c|7|PATHRESP|Pathologic Response|RAJKUMAR MYELOMA 2011|[?]|mg/min|iCR|1|IMPLANT|CONTRAST ENHANCED CT SCAN||||HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|Y|4|Visit_4|65|2|WASHOUT|2021-03-20|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-11|P1Y2M10DT2H30M|BEFORE|2021-03-31|AFTER|2021-04-21
e|RS|712029bc-471a-4e3d-9123-e38b3c38bc6c|8|PATHRESP|Pathologic Response|PERCIST|[?]|Tesla|iUPD|1|Gy/h|HEMOCYTOMETRY||||INDEPENDENT ASSESSOR|RADIOLOGIST|Y|4|Visit_4|65|1|FOLLOW-UP|2021-03-20|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-11|P1Y2M10DT2H30M|AFTER|2021-04-10|AFTER|2021-04-12
e|RS|712029bc-471a-4e3d-9123-e38b3c38bc6c|9|SPLNRESP|Spleen Response|SACT|[?]|%(w/v)|MORPHOLOGIC LEUKEMIA-FREE STATE|1|Ci/L|FLAME PHOTOMETRY|Y|||SPOUSE|CLINICAL PATHOLOGIST|N|5|Visit_5|90|4|SCREENING|2021-04-14|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-30|P1Y2M10DT2H30M|AFTER|2021-04-04|AFTER|2021-04-16
e|RS|712029bc-471a-4e3d-9123-e38b3c38bc6c|10|TMRESP|Tumor Marker Response|UNSPECIFIED|[?]|pmol/dL|ABSENT MORPHOLOGIC RESPONSE|1|RING|EIA||Y||GUARDIAN|ONCOLOGIST|N|5|Visit_5|90|6|TREATMENT|2021-04-14|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-30|P1Y2M10DT2H30M|UNKNOWN|2021-02-01|COINCIDENT|2021-03-15
e|RS|92c0183d-5704-45ad-9aec-e24bc5777b80|1|OVRLRESP|Overall Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|ug/g/day|cPR|1|mm/h|DUKE INCISION METHOD||Y||INTERVIEWER|PHYSIOTHERAPIST|NA|1|Visit_1|10|2|TREATMENT|2021-01-20|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-20|P1Y2M10DT2H30M|AFTER|2021-02-15|AFTER|2021-02-26
e|RS|92c0183d-5704-45ad-9aec-e24bc5777b80|2|BONERESP|Bone Response|LUGANO CLASSIFICATION|||nPR|1|cmol/L|CHROMATOGRAPHY|||Y|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST|U|1|Visit_1|10|6|TREATMENT|2021-01-20|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-20|P1Y2M10DT2H30M|AFTER|2021-01-25|ONGOING|2021-02-07
e|RS|92c0183d-5704-45ad-9aec-e24bc5777b80|3|MRDIND|Minimal Residual Disease Indicator|MRECIST BYRNE MESOTHELIOMA 2004|[?]|GBq|NR|1|Siemens|ETDRS EYE CHART||||INTERVIEWER|NEUROLOGIST|N|2|Visit_2|25|6|TREATMENT|2021-02-04|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-23|P1Y2M10DT2H30M|BEFORE|2021-04-02|ONGOING|2021-04-17
e|RS|92c0183d-5704-45ad-9aec-e24bc5777b80|4|LIVRRESP|Liver Response|AJCC V8|[?]|mL/animal|CR-CT|1|PACK|TURBIDIMETRY|Y|||FRIEND|READER|NA|2|Visit_2|25|7|TREATMENT|2021-02-04|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-23|P1Y2M10DT2H30M|COINCIDENT|2021-04-07|AFTER|2021-04-12
e|RS|92c0183d-5704-45ad-9aec-e24bc5777b80|5|NEWLIND|New Lesion Indicator|BRUGGEMANN MRD 2010|[?]|mg|OPTIMAL MORPHOLOGIC RESPONSE|1|CCID 50/mL|FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY|Y|||PROXY|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|3|Visit_3|40|4|WASHOUT|2021-02-19|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-07|P1Y2M10DT2H30M|COINCIDENT|2021-02-28|ONGOING|2021-03-12
e|RS|92c0183d-5704-45ad-9aec-e24bc5777b80|6|BESTRESP|Best Overall Response|MURPHY PROSTATE CANCER 1980|[?]|mol/mol|SD-CT|1|pg/dL|MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING||||SIGNIFICANT OTHER|RATER|NA|3|Visit_3|40|3|TREATMENT|2021-02-19|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-07|P1Y2M10DT2H30M|COINCIDENT|2021-04-14|BEFORE|2021-04-15
e|RS|92c0183d-5704-45ad-9aec-e24bc5777b80|7|TRGRESP|Target Response|IWG CHESON MDS 2006|[?]|mL/animal/day|RELAPSED DISEASE FROM CR|1|/VF|ENZYMATIC SPECTROPHOTOMETRY|Y|||NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|Y|4|Visit_4|65|1|FOLLOW-UP|2021-03-16|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-10|P1Y2M10DT2H30M|BEFORE|2021-03-21|ONGOING|2021-04-18
e|RS|92c0183d-5704-45ad-9aec-e24bc5777b80|8|HEMARESP|Hematologic Response|AJCC V8|[?]|umol/L|VGPR|1|cmol|PAP STAIN|Y|||SIBLING|RATER 1|U|4|Visit_4|65|3|TREATMENT|2021-03-16|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-10|P1Y2M10DT2H30M|COINCIDENT|2021-01-27|AFTER|2021-03-20
e|RS|92c0183d-5704-45ad-9aec-e24bc5777b80|9|NTLWIND|Non-Target Lesion Worsening Indicator|UNSPECIFIED|[?]|copies/uL|NE|1|PFU/animal|TRIPLE-PHASE MRI SCAN||||CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL PSYCHOLOGIST|U|5|Visit_5|90|5|TREATMENT|2021-04-10|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-25|P1Y2M10DT2H30M|UNKNOWN|2021-02-06|ONGOING|2021-04-10
e|RS|92c0183d-5704-45ad-9aec-e24bc5777b80|10|TRGRESP|Target Response|GUILHOT CML 2007|[?]|mg/L FEU|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|U/g/h|HIGH RESOLUTION CT||||ADJUDICATOR|RATER 1|Y|5|Visit_5|90|5|SCREENING|2021-04-10|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-25|P1Y2M10DT2H30M|AFTER|2021-03-13|AFTER|2021-04-05
e|RS|52ce3b1f-9500-4323-861d-73c8b96f59de|1|TRGRESP|Target Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|ug/dL|NON-PD|1|copies/uL|OPTICAL DENSITY MEASUREMENT||Y||CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 3|NA|1|Visit_1|10|3|FOLLOW-UP|2020-10-26|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-01|P1Y2M10DT2H30M|COINCIDENT|2020-12-22|BEFORE|2021-01-03
e|RS|52ce3b1f-9500-4323-861d-73c8b96f59de|2|CLINRESP|Clinical Response|DOHNER AML 2010|[?]|POUCH|cCR|1|INHALATION|WESTERGREN|Y|Y||SIBLING|RADIOLOGIST 1|Y|1|Visit_1|10|2|WASHOUT|2020-10-26|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-01|P1Y2M10DT2H30M|AFTER|2020-10-29|ONGOING|2020-11-24
e|RS|52ce3b1f-9500-4323-861d-73c8b96f59de|3|BMIVLIND|Bone Marrow Involvement Indicator|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|mg/kg|MINOR PATHOLOGIC RESPONSE|1|Ci/mg|ALCIAN BLUE STAIN||||SPOUSE|DEVELOPMENTAL PSYCHOLOGIST|U|2|Visit_2|25|6|TREATMENT|2020-11-10|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-05|P1Y2M10DT2H30M|BEFORE|2021-01-01|AFTER|2021-01-19
e|RS|52ce3b1f-9500-4323-861d-73c8b96f59de|4|SFTSRESP|Soft Tissue Response|IWG CHESON MDS 2006|[?]|ug/h|iPR|1|scm|ETDRS EYE CHART||||FRIEND|ADJUDICATOR 3|Y|2|Visit_2|25|1|WASHOUT|2020-11-10|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-05|P1Y2M10DT2H30M|COINCIDENT|2020-10-28|ONGOING|2020-12-20
e|RS|52ce3b1f-9500-4323-861d-73c8b96f59de|5|CLINRESP|Clinical Response|AJCC V7|[?]|umol/dL|NOT ALL EVALUATED|1|ug/day|CRYOSCOPY|Y|||SPOUSE|RADIOLOGIST 1|N|3|Visit_3|40|2|TREATMENT|2020-11-25|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-06|P1Y2M10DT2H30M|COINCIDENT|2020-11-01|BEFORE|2021-01-17
e|RS|52ce3b1f-9500-4323-861d-73c8b96f59de|6|DRCRIND|Disease Recurrence Indicator|PETIT BREAST CANCER 2001|||CA125 50% RESPONSE|1|dram|TEST STRIP|||Y|INDEPENDENT ASSESSOR|ADJUDICATOR|NA|3|Visit_3|40|3|WASHOUT|2020-11-25|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-06|P1Y2M10DT2H30M|COINCIDENT|2020-10-29|ONGOING|2020-11-05
e|RS|52ce3b1f-9500-4323-861d-73c8b96f59de|7|METSIND|Metastatic Indicator|NCIWG CHESON CLL 1996|||PSA PROGRESSION|1|m2|FREEZING POINT DEPRESSION||Y|Y|SIGNIFICANT OTHER|READER|N|4|Visit_4|65|1|TREATMENT|2020-12-20|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-25|P1Y2M10DT2H30M|BEFORE|2020-12-12|AFTER|2020-12-16
e|RS|52ce3b1f-9500-4323-861d-73c8b96f59de|8|RDIORESP|Radiologic Response|WHO BREAST CANCER 2006|[?]|g/kg|iSD|1|NFIU|LC/MS||||PARENT|RATER 1|N|4|Visit_4|65|1|FOLLOW-UP|2020-12-20|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-25|P1Y2M10DT2H30M|COINCIDENT|2021-01-09|AFTER|2021-01-17
e|RS|52ce3b1f-9500-4323-861d-73c8b96f59de|9|CPRFSTAT|Clinical Performance Status|MURPHY PROSTATE CANCER 1980|[?]|BOLUS|INCREASED|1|cd*s/m2|CELL BASED BIOASSAY||||CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 1|N|5|Visit_5|90|4|WASHOUT|2021-01-14|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-05|P1Y2M10DT2H30M|COINCIDENT|2020-10-19|AFTER|2020-11-13
e|RS|52ce3b1f-9500-4323-861d-73c8b96f59de|10|MNPTHIND|Minor Pathological Response Indicator|PCWG SCHER PROSTATE CANCER 2008|[?]|IU/dL|HI-P|1|TABLET|NUCLEIC ACID BASED METHOD||||SIGNIFICANT OTHER|READER 3|Y|5|Visit_5|90|7|TREATMENT|2021-01-14|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-05|P1Y2M10DT2H30M|UNKNOWN|2021-01-19|AFTER|2021-01-22
e|RS|3655d198-2e7e-419e-8337-d7eea7d795ca|1|NTRGRESP|Non-target Response|RANO|[?]|mg/kg/h|IMMUNOPHENOTYPIC CR|1|Bq/mg|QUANTITATIVE CORONARY ANGIOGRAPHY||||INVESTIGATOR|READER 3|N|1|Visit_1|10|7|WASHOUT|2020-11-23|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-10|P1Y2M10DT2H30M|BEFORE|2021-01-06|ONGOING|2021-01-17
e|RS|3655d198-2e7e-419e-8337-d7eea7d795ca|2|TMRESP|Tumor Marker Response|RAJKUMAR MYELOMA 2011|[?]|DAgU|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|F|DIGITAL PCR|Y|||PROXY|INTERNIST|Y|1|Visit_1|10|2|SCREENING|2020-11-23|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-10|P1Y2M10DT2H30M|BEFORE|2021-02-11|COINCIDENT|2021-02-16
e|RS|3655d198-2e7e-419e-8337-d7eea7d795ca|3|MRPHRESP|Morphologic Response|DOHNER AML 2010|[?]|anti-Xa IU|mCR|1|mL/kg|MULTIPLEXED BEAD BASED IMMUNOASSAY|Y|||HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|NA|2|Visit_2|25|7|TREATMENT|2020-12-08|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-28|P1Y2M10DT2H30M|AFTER|2020-12-03|ONGOING|2020-12-28
e|RS|3655d198-2e7e-419e-8337-d7eea7d795ca|4|NEWLIND|New Lesion Indicator|LEE LUNG CANCER 2011|[?]|fmol/g|PSEUDORESPONSE|1|10^3 RNA copies/mL|PHYSICAL EXAMINATION|Y|Y||INVESTIGATOR|READER 1|Y|2|Visit_2|25|3|SCREENING|2020-12-08|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-28|P1Y2M10DT2H30M|BEFORE|2021-01-01|AFTER|2021-01-10
e|RS|3655d198-2e7e-419e-8337-d7eea7d795ca|5|MRDRESP|Minimal Residual Disease Response|IRANO 2015|[?]|ng/L|NR|1|GBq/mg|LC/MS/MS||||CLINICAL RESEARCH ASSOCIATE|DERMATOLOGIST|NA|3|Visit_3|40|5|TREATMENT|2020-12-23|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-26|P1Y2M10DT2H30M|COINCIDENT|2021-01-02|COINCIDENT|2021-01-13
e|RS|3655d198-2e7e-419e-8337-d7eea7d795ca|6|LIVRRESP|Liver Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|days/wk|NED|1|CIGARETTE|SNELLEN EYE CHART||||SIGNIFICANT OTHER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|3|Visit_3|40|2|TREATMENT|2020-12-23|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-26|P1Y2M10DT2H30M|COINCIDENT|2020-12-10|ONGOING|2021-01-01
e|RS|3655d198-2e7e-419e-8337-d7eea7d795ca|7|CPRFSTAT|Clinical Performance Status|MRECIST LENCIONI LIVER CANCER 2010|[?]|log10 PFU/mL|MRD PERSISTENCE|1|vg/dose|NON-INVASIVE DIELECTRIC SENSING||||INTERVIEWER|RATER 1|NA|4|Visit_4|65|2|TREATMENT|2021-01-17|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-10|P1Y2M10DT2H30M|COINCIDENT|2021-02-19|AFTER|2021-02-20
e|RS|3655d198-2e7e-419e-8337-d7eea7d795ca|8|SPLNRESP|Spleen Response|SCHER PROSTATE CANCER 2011|[?]|ug/kg/day|PSA PROGRESSION|1|cmol/L|MICROBIAL CULTURE|Y|||GUARDIAN|RADIOLOGIST 2|N|4|Visit_4|65|1|TREATMENT|2021-01-17|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-10|P1Y2M10DT2H30M|BEFORE|2021-01-20|BEFORE|2021-01-22
e|RS|3655d198-2e7e-419e-8337-d7eea7d795ca|9|BONERESP|Bone Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|DISK|pCR|1|L/h|ANGIOGRAPHY|Y|Y||ADJUDICATION COMMITTEE|FORENSIC PATHOLOGIST|U|5|Visit_5|90|2|TREATMENT|2021-02-11|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-01|P1Y2M10DT2H30M|UNKNOWN|2021-01-07|BEFORE|2021-02-13
e|RS|3655d198-2e7e-419e-8337-d7eea7d795ca|10|MNPTHIND|Minor Pathological Response Indicator|MRECIST BYRNE MESOTHELIOMA 2004|[?]|QUANTITY SUFFICIENT|HI-P|1|uL/dose|HIGH LEVEL AMINOGLYCOSIDE SCREEN||||ADJUDICATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5|Visit_5|90|1|TREATMENT|2021-02-11|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-01|P1Y2M10DT2H30M|BEFORE|2021-01-22|BEFORE|2021-02-11
e|RS|d47da6bf-8abf-4b62-8bb8-797155981158|1|MRDRESP|Minimal Residual Disease Response|NCCN ALL MRD 2014|[?]|U/kg|IMPROVED|1|Mile|PHOTOGRAPHY|Y|||CAREGIVER|ONCOLOGIST 2|NA|1|Visit_1|10|5|SCREENING|2020-09-10|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-23|P1Y2M10DT2H30M|COINCIDENT|2020-11-18|ONGOING|2020-11-26
e|RS|d47da6bf-8abf-4b62-8bb8-797155981158|2|MJPTHIND|Major Pathological Response Indicator|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|umol/day|HI-N|1|gtt|ELISA||||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 2|U|1|Visit_1|10|3|FOLLOW-UP|2020-09-10|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-23|P1Y2M10DT2H30M|UNKNOWN|2020-09-13|AFTER|2020-10-31
e|RS|d47da6bf-8abf-4b62-8bb8-797155981158|3|SPLNRESP|Spleen Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|INHALATION|HI-P|1|pt_br|SPECT SCAN||||SIBLING|OPTOMETRIST|U|2|Visit_2|25|1|TREATMENT|2020-09-25|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-08|P1Y2M10DT2H30M|BEFORE|2020-12-08|AFTER|2020-12-09
e|RS|d47da6bf-8abf-4b62-8bb8-797155981158|4|OVRLRESP|Overall Response|MASS|[?]|AFU|IMPROVED|1|BEAM BREAKS|LIGHT MICROSCOPY||||DOMESTIC PARTNER|MICROSCOPIST 1|Y|2|Visit_2|25|1|SCREENING|2020-09-25|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-08|P1Y2M10DT2H30M|BEFORE|2020-10-17|ONGOING|2020-10-28
e|RS|d47da6bf-8abf-4b62-8bb8-797155981158|5|CYTORESP|Cytogenetic Response|CHOLLET BREAST CANCER 2002|[?]|GBq/g|CYTOGENETIC PR|1|%(w/v)|BIOPSY||||CAREGIVER|READER 3|N|3|Visit_3|40|4|SCREENING|2020-10-10|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-23|P1Y2M10DT2H30M|AFTER|2020-10-15|BEFORE|2020-11-20
e|RS|d47da6bf-8abf-4b62-8bb8-797155981158|6|CLINRESP|Clinical Response|RAJKUMAR MYELOMA 2011|[?]|VIAL|NR|1|kg/L|TOLUIDINE BLUE STAIN|Y|||PARENT|PHYSIOTHERAPIST|U|3|Visit_3|40|4|TREATMENT|2020-10-10|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-23|P1Y2M10DT2H30M|AFTER|2020-11-30|COINCIDENT|2020-12-06
e|RS|d47da6bf-8abf-4b62-8bb8-797155981158|7|MRDIND|Minimal Residual Disease Indicator|MONTSERRAT CLL 1989|[?]|nmol BCE/L|PD/RELAPSE AFTER HI|1|g/g/day|NUCLEIC ACID AMPLIFICATION TEST||||VENDOR|ENDOCRINOLOGIST|Y|4|Visit_4|65|7|FOLLOW-UP|2020-11-04|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-02|P1Y2M10DT2H30M|COINCIDENT|2020-10-28|COINCIDENT|2020-11-19
e|RS|d47da6bf-8abf-4b62-8bb8-797155981158|8|TMRESP|Tumor Marker Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|ft|NED|1|kV|MIGET||||CHILD|MICROSCOPIST|U|4|Visit_4|65|1|WASHOUT|2020-11-04|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-02|P1Y2M10DT2H30M|UNKNOWN|2020-09-19|AFTER|2020-10-11
e|RS|d47da6bf-8abf-4b62-8bb8-797155981158|9|NEWLIND|New Lesion Indicator|NCCN ALL MRD 2014|[?]|nmol/g|PSA PROGRESSION|1|ug/dL|PULMONARY ANGIOGRAPHY||||INDEPENDENT ASSESSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5|Visit_5|90|2|FOLLOW-UP|2020-11-29|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-25|P1Y2M10DT2H30M|AFTER|2020-11-16|AFTER|2020-11-23
e|RS|d47da6bf-8abf-4b62-8bb8-797155981158|10|CPRFSTAT|Clinical Performance Status|HARTMANN GERM CELL CANCER 2002|[?]|ug/mol|cCR|1|Absorbance U|ELECTROGASTROGRAPHY||||CLINICAL RESEARCH COORDINATOR|ONCOLOGIST|Y|5|Visit_5|90|5|FOLLOW-UP|2020-11-29|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-25|P1Y2M10DT2H30M|UNKNOWN|2020-10-21|COINCIDENT|2020-11-29
e|RS|25e81c81-8c23-4c9e-be79-35247384dd1f|1|MNPTHIND|Minor Pathological Response Indicator|PCWG BUBLEY PROSTATE CANCER 1999|[?]|MESF|CRi|1|DAYS|RAJI CELL RIA||||SPOUSE|CLINICAL PATHOLOGIST|Y|1|Visit_1|10|4|TREATMENT|2020-08-08|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-28|P1Y2M10DT2H30M|AFTER|2020-09-09|COINCIDENT|2020-09-10
e|RS|25e81c81-8c23-4c9e-be79-35247384dd1f|2|BESTRESP|Best Overall Response|BRUGGEMANN MRD 2010|[?]|MAC50|MR|1|10^3/L|ANALYTICAL ULTRACENTRIFUGATION||Y||INTERVIEWER|PATHOLOGIST|U|1|Visit_1|10|4|TREATMENT|2020-08-08|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-28|P1Y2M10DT2H30M|COINCIDENT|2020-09-26|AFTER|2020-10-25
e|RS|25e81c81-8c23-4c9e-be79-35247384dd1f|3|SYMPTDTR|Symptomatic Deterioration|IWC HALLEK CLL 2008|[?]|10^8 PFU|mCR|1|JAR|MICROBIAL BIOCHEMICAL IDENTIFICATION||||CHILD|ADJUDICATOR|NA|2|Visit_2|25|4|WASHOUT|2020-08-23|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-26|P1Y2M10DT2H30M|AFTER|2020-08-07|AFTER|2020-08-28
e|RS|25e81c81-8c23-4c9e-be79-35247384dd1f|4|NEWLWIND|New Lesion Worsening Indicator|PETIT BREAST CANCER 2001|||NON-QUANTIFIABLE MRD POSITIVITY|1|PACK|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|||Y|CLINICAL STUDY SPONSOR|RADIOLOGIST 2|NA|2|Visit_2|25|2|TREATMENT|2020-08-23|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-26|P1Y2M10DT2H30M|COINCIDENT|2020-09-03|BEFORE|2020-10-21
e|RS|25e81c81-8c23-4c9e-be79-35247384dd1f|5|SYMPTDTR|Symptomatic Deterioration|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|10^6/Ejaculate U|MOLECULAR CR|1|ug/kg/h|SPIRAL CT||||DOMESTIC PARTNER|FORENSIC PATHOLOGIST|Y|3|Visit_3|40|2|TREATMENT|2020-09-07|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-21|P1Y2M10DT2H30M|COINCIDENT|2020-09-04|BEFORE|2020-10-29
e|RS|25e81c81-8c23-4c9e-be79-35247384dd1f|6|NTRGRESP|Non-target Response|UNSPECIFIED|[?]|deg/mm|MR|1|anti-Xa IU|LUXOL FAST BLUE AND CRESYL VIOLET STAIN||||CHILD|ONCOLOGIST 2|NA|3|Visit_3|40|2|TREATMENT|2020-09-07|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-21|P1Y2M10DT2H30M|AFTER|2020-09-23|COINCIDENT|2020-09-30
e|RS|25e81c81-8c23-4c9e-be79-35247384dd1f|7|SPLNRESP|Spleen Response|DURIE MULTIPLE MYELOMA 2006|[?]|PIXELS/cm|CR-CT|1|vg/mL|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE||||SIGNIFICANT OTHER|READER 1|U|4|Visit_4|65|5|SCREENING|2020-10-02|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-26|P1Y2M10DT2H30M|UNKNOWN|2020-08-06|ONGOING|2020-09-07
e|RS|25e81c81-8c23-4c9e-be79-35247384dd1f|8|HEMARESP|Hematologic Response|UNSPECIFIED|||CRi|1|mg/L FEU|COLORIMETRY|||Y|INDEPENDENT ASSESSOR|OPTOMETRIST|Y|4|Visit_4|65|5|FOLLOW-UP|2020-10-02|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-26|P1Y2M10DT2H30M|BEFORE|2020-10-19|COINCIDENT|2020-11-04
e|RS|25e81c81-8c23-4c9e-be79-35247384dd1f|9|DRCRIND|Disease Recurrence Indicator|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|/mm|WORSENED|1|dpm/mg|CT SCAN||Y||DOMESTIC PARTNER|PATHOLOGIST 2|NA|5|Visit_5|90|6|FOLLOW-UP|2020-10-27|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-04|P1Y2M10DT2H30M|BEFORE|2020-08-19|AFTER|2020-09-03
e|RS|25e81c81-8c23-4c9e-be79-35247384dd1f|10|METBRESP|Metabolic Response|iRECIST|[?]|KALLIKREIN INHIBITOR UNIT|CHR|1|Ci/L|TRANSESOPHAGEAL ECHOCARDIOGRAPHY||Y||INTERVIEWER|MICROSCOPIST 2|U|5|Visit_5|90|4|SCREENING|2020-10-27|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-04|P1Y2M10DT2H30M|UNKNOWN|2020-09-15|COINCIDENT|2020-10-31
e|RS|4fd91c6c-3bc6-498a-a977-ee834c3bcb97|1|CLINRESP|Clinical Response|KUMAR IMWG 2016|[?]|U/g/min|HI-N|1|Ci/mg|LIGHT SCATTERING SPECTROSCOPY||||NON-HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|U|1|Visit_1|10|1|SCREENING|2020-07-27|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-07|P1Y2M10DT2H30M|BEFORE|2020-08-03|COINCIDENT|2020-10-04
e|RS|4fd91c6c-3bc6-498a-a977-ee834c3bcb97|2|NEWLWIND|New Lesion Worsening Indicator|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|TRANSDUCING UNIT|CYTOGENETIC CR|1|10^7 PFU|HPLC-UV||Y||STUDY SUBJECT|PATHOLOGIST 2|U|1|Visit_1|10|3|WASHOUT|2020-07-27|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-07|P1Y2M10DT2H30M|COINCIDENT|2020-09-08|COINCIDENT|2020-09-23
e|RS|4fd91c6c-3bc6-498a-a977-ee834c3bcb97|3|NTRGRESP|Non-target Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|ft2|EQUIVOCAL|1|mg/cm2|SPIRAL CT SCAN WITHOUT CONTRAST||||STUDY SUBJECT|PATHOLOGIST|U|2|Visit_2|25|2|FOLLOW-UP|2020-08-11|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-05|P1Y2M10DT2H30M|BEFORE|2020-08-03|AFTER|2020-08-27
e|RS|4fd91c6c-3bc6-498a-a977-ee834c3bcb97|4|PATHRESP|Pathologic Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|||IMMUNOPHENOTYPIC CR|1|GBq/ug|MRI WITHOUT CONTRAST||Y|Y|SIGNIFICANT OTHER|INTERNIST|NA|2|Visit_2|25|5|FOLLOW-UP|2020-08-11|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-05|P1Y2M10DT2H30M|BEFORE|2020-10-16|COINCIDENT|2020-10-23
e|RS|4fd91c6c-3bc6-498a-a977-ee834c3bcb97|5|LIVRRESP|Liver Response|RECIST 1.1|||SD-CT|1|mEq/mmol|MAGNETIC RESONANCE ENTEROGRAPHY|||Y|FRIEND|DEVELOPMENTAL PSYCHOLOGIST|Y|3|Visit_3|40|2|SCREENING|2020-08-26|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-31|P1Y2M10DT2H30M|UNKNOWN|2020-08-17|COINCIDENT|2020-09-19
e|RS|4fd91c6c-3bc6-498a-a977-ee834c3bcb97|6|BMIVLIND|Bone Marrow Involvement Indicator|AJCC V8|[?]|NEEDLE GAUGE|NON-QUANTIFIABLE MRD POSITIVITY|1|eq|FISH|Y|Y||SIBLING|RADIOLOGIST|NA|3|Visit_3|40|7|SCREENING|2020-08-26|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-31|P1Y2M10DT2H30M|AFTER|2020-08-21|AFTER|2020-09-11
e|RS|4fd91c6c-3bc6-498a-a977-ee834c3bcb97|7|STRUSTAT|Steroid Use Status|CHESON CLL 2012|[?]|gpELISA unit/mL|HI-N|1|mEq/ug|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY||||CHILD|OTOLARYNGOLOGIST|Y|4|Visit_4|65|7|TREATMENT|2020-09-20|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-15|P1Y2M10DT2H30M|UNKNOWN|2020-10-16|ONGOING|2020-10-21
e|RS|4fd91c6c-3bc6-498a-a977-ee834c3bcb97|8|BMIVLIND|Bone Marrow Involvement Indicator|RAJKUMAR MYELOMA 2011|[?]|STEPS|sCR|1|Coulomb|WHOLE EXOME SEQUENCING|Y|||CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 2|Y|4|Visit_4|65|2|TREATMENT|2020-09-20|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-15|P1Y2M10DT2H30M|UNKNOWN|2020-09-06|COINCIDENT|2020-10-16
e|RS|4fd91c6c-3bc6-498a-a977-ee834c3bcb97|9|NTNERESP|Non-Target Non-Enhancing Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|BAU|PSA PROGRESSION|1|Ci/g|DIGITAL PCR ARRAY||||CAREGIVER|CARDIOLOGIST|NA|5|Visit_5|90|1|TREATMENT|2020-10-15|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-23|P1Y2M10DT2H30M|COINCIDENT|2020-10-11|AFTER|2020-10-15
e|RS|4fd91c6c-3bc6-498a-a977-ee834c3bcb97|10|MJPTHIND|Major Pathological Response Indicator|CHESON CLL 2006|[?]|vg/kg|CYTOGENETIC MINOR RESPONSE|1|deg|ICC||Y||CLINICAL RESEARCH ASSOCIATE|READER 1|NA|5|Visit_5|90|3|TREATMENT|2020-10-15|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-23|P1Y2M10DT2H30M|BEFORE|2020-09-04|BEFORE|2020-10-04
e|RS|21d29ae6-bb12-4c5c-b32a-32ab4ddcf547|1|MRDRESP|Minimal Residual Disease Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|pmol/dL|MRD NEGATIVITY|1|nmol/mL/min|LEAD CITRATE STAIN||||PARENT|MICROSCOPIST 1|NA|1|Visit_1|10|1|WASHOUT|2020-11-12|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-14|P1Y2M10DT2H30M|BEFORE|2021-02-08|BEFORE|2021-02-09
e|RS|21d29ae6-bb12-4c5c-b32a-32ab4ddcf547|2|MRDIND|Minimal Residual Disease Indicator|CHESON LYMPHOMA 2008|[?]|mmol2/L2|CMR|1|mPa|TOTAL BODY RADIOGRAPHY||||GUARDIAN|NEUROLOGIST|Y|1|Visit_1|10|1|TREATMENT|2020-11-12|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-14|P1Y2M10DT2H30M|UNKNOWN|2020-12-10|ONGOING|2021-01-22
e|RS|21d29ae6-bb12-4c5c-b32a-32ab4ddcf547|3|STRUSTAT|Steroid Use Status|WOLCHOK SOLID TUMORS 2009|||iCR|1|10^3/L|GRADIENT DIFFUSION|Y||Y|CLINICAL STUDY SPONSOR|ADJUDICATOR 3|N|2|Visit_2|25|3|WASHOUT|2020-11-27|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-10|P1Y2M10DT2H30M|AFTER|2020-11-29|BEFORE|2021-01-27
e|RS|21d29ae6-bb12-4c5c-b32a-32ab4ddcf547|4|ANATRESP|Anatomic Response|WOLCHOK SOLID TUMORS 2009|[?]|pmol/L|EQUIVOCAL|1|ug/dose|MICROBIAL CONCENTRATION||||INTERVIEWER|CLINICAL PATHOLOGIST|NA|2|Visit_2|25|3|TREATMENT|2020-11-27|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-10|P1Y2M10DT2H30M|AFTER|2020-11-12|AFTER|2020-12-31
e|RS|21d29ae6-bb12-4c5c-b32a-32ab4ddcf547|5|MOLRESP|Molecular Response|IWG CHESON AML 2003|||MORPHOLOGIC LEUKEMIA-FREE STATE|1|pmol/day|FUNDUS PHOTOGRAPHY||Y|Y|STUDY SUBJECT|PHYSIOTHERAPIST|Y|3|Visit_3|40|2|TREATMENT|2020-12-12|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-11|P1Y2M10DT2H30M|BEFORE|2020-11-19|AFTER|2020-12-16
e|RS|21d29ae6-bb12-4c5c-b32a-32ab4ddcf547|6|METBRESP|Metabolic Response|MACDONALD GLIOMA 1990|||MORPHOLOGIC CR|1|m3|PET/CT SCAN|||Y|CLINICAL RESEARCH ASSOCIATE|OPHTHALMOLOGIST|NA|3|Visit_3|40|2|TREATMENT|2020-12-12|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-11|P1Y2M10DT2H30M|COINCIDENT|2020-12-08|BEFORE|2021-02-06
e|RS|21d29ae6-bb12-4c5c-b32a-32ab4ddcf547|7|SPLNRESP|Spleen Response|MASS|||OPTIMAL MORPHOLOGIC RESPONSE|1|um/day|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|Y||Y|FAMILY MEMBER|INTERNIST|Y|4|Visit_4|65|7|TREATMENT|2021-01-06|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-17|P1Y2M10DT2H30M|BEFORE|2021-01-19|AFTER|2021-01-23
e|RS|21d29ae6-bb12-4c5c-b32a-32ab4ddcf547|8|SPLNRESP|Spleen Response|RAJKUMAR MYELOMA 2011|[?]|BAU|MRD NEGATIVITY|1|min*mg/mL|LINE PROBE ASSAY||||FAMILY MEMBER|NEUROLOGIST 2|U|4|Visit_4|65|2|WASHOUT|2021-01-06|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-17|P1Y2M10DT2H30M|UNKNOWN|2021-01-10|COINCIDENT|2021-01-15
e|RS|21d29ae6-bb12-4c5c-b32a-32ab4ddcf547|9|METBRESP|Metabolic Response|KUKER LYMPHOMA 2005|[?]|mL/mmHg/min/L|INCREASED|1|g/m2/day|FREEZING POINT DEPRESSION||||ADJUDICATOR|PHYSIOTHERAPIST|U|5|Visit_5|90|3|FOLLOW-UP|2021-01-31|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-21|P1Y2M10DT2H30M|UNKNOWN|2020-12-09|AFTER|2021-01-06
e|RS|21d29ae6-bb12-4c5c-b32a-32ab4ddcf547|10|LIVRRESP|Liver Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|Enzyme U/g Hb|DECREASED|1|mg/animal|CENTRIFUGATION|Y|||INVESTIGATOR|ADJUDICATOR 2|N|5|Visit_5|90|3|WASHOUT|2021-01-31|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-21|P1Y2M10DT2H30M|UNKNOWN|2020-12-22|BEFORE|2021-01-22
e|RS|5ba70148-c29b-47af-9280-10d1a942380a|1|CLINRESP|Clinical Response|SACT|[?]|cmH2O*s/mL|CMR|1|/sec|LISSAMINE GREEN STAIN||||SIBLING|MICROSCOPIST 3|NA|1|Visit_1|10|3|WASHOUT|2020-11-28|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-10|P1Y2M10DT2H30M|COINCIDENT|2021-02-04|AFTER|2021-02-15
e|RS|5ba70148-c29b-47af-9280-10d1a942380a|2|NTERESP|Non-Target Enhancing Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|WEEKS|WORSENED|1|10^3 organisms/mL|RADIOGRAPHY||||FAMILY MEMBER|PHYSIOTHERAPIST|NA|1|Visit_1|10|7|SCREENING|2020-11-28|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-10|P1Y2M10DT2H30M|COINCIDENT|2021-01-04|ONGOING|2021-01-08
e|RS|5ba70148-c29b-47af-9280-10d1a942380a|3|CPRFSTAT|Clinical Performance Status|HARTMAN PANCREATIC CANCER 2012|[?]|PFU/mL|PSEUDORESPONSE|1|DPM|MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING|Y|||HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|U|2|Visit_2|25|6|SCREENING|2020-12-13|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-19|P1Y2M10DT2H30M|BEFORE|2021-01-03|AFTER|2021-02-09
e|RS|5ba70148-c29b-47af-9280-10d1a942380a|4|BESTRESP|Best Overall Response|GUPPY OVARIAN CANCER 2002|||STABLE|1|mL/breath|CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY||Y|Y|STUDY SUBJECT|ADJUDICATOR 3|N|2|Visit_2|25|7|FOLLOW-UP|2020-12-13|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-19|P1Y2M10DT2H30M|COINCIDENT|2021-01-15|AFTER|2021-02-20
e|RS|5ba70148-c29b-47af-9280-10d1a942380a|5|MJPTHIND|Major Pathological Response Indicator|PERCIST|[?]|BEAM BREAKS|cPR|1|ug/g/min|CLINICAL EVALUATION||||FRIEND|NEUROLOGIST|Y|3|Visit_3|40|3|TREATMENT|2020-12-28|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-27|P1Y2M10DT2H30M|BEFORE|2021-02-06|BEFORE|2021-02-18
e|RS|5ba70148-c29b-47af-9280-10d1a942380a|6|BMIVLIND|Bone Marrow Involvement Indicator|MRECIST BYRNE MESOTHELIOMA 2004|||MR|1|ug/dL|MICRODENSITOMETRY|Y|Y|Y|CAREGIVER|READER 3|NA|3|Visit_3|40|4|TREATMENT|2020-12-28|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-27|P1Y2M10DT2H30M|BEFORE|2021-02-05|ONGOING|2021-02-19
e|RS|5ba70148-c29b-47af-9280-10d1a942380a|7|SYMPTDTR|Symptomatic Deterioration|IWG CHESON MDS 2006|[?]|MBP|PD-CT|1|FIU|DIGITAL PCR ARRAY||||FAMILY MEMBER|ONCOLOGIST|Y|4|Visit_4|65|7|TREATMENT|2021-01-22|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-04|P1Y2M10DT2H30M|BEFORE|2021-01-18|BEFORE|2021-01-22
e|RS|5ba70148-c29b-47af-9280-10d1a942380a|8|MRDIND|Minimal Residual Disease Indicator|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|L|MRD RELAPSE|1|U/m2|RULER MEASUREMENT METHOD||||SIGNIFICANT OTHER|CLINICAL PATHOLOGIST|U|4|Visit_4|65|4|SCREENING|2021-01-22|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-04|P1Y2M10DT2H30M|BEFORE|2020-12-27|AFTER|2021-02-01
e|RS|5ba70148-c29b-47af-9280-10d1a942380a|9|SPLNRESP|Spleen Response|iRECIST|[?]|EIA unit|cPR|1|mg/mL/day|CELL BASED BIOASSAY||Y||NON-HEALTH CARE PROFESSIONAL|OPTOMETRIST|Y|5|Visit_5|90|1|WASHOUT|2021-02-16|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-20|P1Y2M10DT2H30M|BEFORE|2021-01-04|ONGOING|2021-02-24
e|RS|5ba70148-c29b-47af-9280-10d1a942380a|10|PATHRESP|Pathologic Response|BRUGGEMANN MRD 2010|[?]|kPa/L/sec|PR|1|mg/m2|PYROSEQUENCING||Y||INVESTIGATOR|READER 3|NA|5|Visit_5|90|7|FOLLOW-UP|2021-02-16|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-20|P1Y2M10DT2H30M|AFTER|2020-11-22|COINCIDENT|2021-01-27
e|RS|93b3c298-d81f-4d71-9c5d-ba5b4d4bdf42|1|NTRGRESP|Non-target Response|BRUGGEMANN MRD 2010|[?]|RATIO|INDETERMINATE RESPONSE|1|log10 CCID 50/dose|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS||||SIBLING|RADIOLOGIST 1|U|1|Visit_1|10|5|TREATMENT|2020-05-27|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-09|P1Y2M10DT2H30M|BEFORE|2020-06-22|COINCIDENT|2020-07-09
e|RS|93b3c298-d81f-4d71-9c5d-ba5b4d4bdf42|2|OVRLRESP|Overall Response|MACDONALD GLIOMA 1990|||MRD PERSISTENCE|1|CYLINDER|MASS SPECTROMETRY|Y||Y|FAMILY MEMBER|ONCOLOGIST 1|NA|1|Visit_1|10|5|FOLLOW-UP|2020-05-27|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-09|P1Y2M10DT2H30M|AFTER|2020-05-30|BEFORE|2020-08-20
e|RS|93b3c298-d81f-4d71-9c5d-ba5b4d4bdf42|3|NEWLPROG|New Lesion Progression|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|kcal/day|MR|1|BAR|THIN SMEAR||||SIGNIFICANT OTHER|INTERNIST|N|2|Visit_2|25|3|TREATMENT|2020-06-11|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-10|P1Y2M10DT2H30M|COINCIDENT|2020-07-10|AFTER|2020-07-21
e|RS|93b3c298-d81f-4d71-9c5d-ba5b4d4bdf42|4|MJPTHIND|Major Pathological Response Indicator|BURCOMBE BREAST CANCER 2005|[?]|SYRINGE|MOLECULAR CR|1|pmol/g|LC/MS/MS|Y|||VENDOR|RADIOLOGIST 2|Y|2|Visit_2|25|2|WASHOUT|2020-06-11|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-10|P1Y2M10DT2H30M|BEFORE|2020-08-24|COINCIDENT|2020-08-25
e|RS|93b3c298-d81f-4d71-9c5d-ba5b4d4bdf42|5|HEMARESP|Hematologic Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|IU|PARTIAL MORPHOLOGIC RESPONSE|1|Log10 ELISA unit|IVY INCISION METHOD|Y|||DOMESTIC PARTNER|PHYSIOTHERAPIST|NA|3|Visit_3|40|5|SCREENING|2020-06-26|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-04|P1Y2M10DT2H30M|BEFORE|2020-05-21|BEFORE|2020-05-25
e|RS|93b3c298-d81f-4d71-9c5d-ba5b4d4bdf42|6|NTNERESP|Non-Target Non-Enhancing Response|PRINCE TCELL LYMPHOMA 2010|||CMR|1|mL/kg/day|ELISA|Y||Y|CLINICAL STUDY SPONSOR|NEUROLOGIST 1|NA|3|Visit_3|40|2|TREATMENT|2020-06-26|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-04|P1Y2M10DT2H30M|AFTER|2020-07-06|AFTER|2020-07-31
e|RS|93b3c298-d81f-4d71-9c5d-ba5b4d4bdf42|7|NEWLPROG|New Lesion Progression|GCIG RUSTIN OVARIAN CANCER 2011|[?]|L/s|NON-iCR/NON-iUPD|1|kg/m2|CYSTOMETRY||||GUARDIAN|RATER 2|NA|4|Visit_4|65|7|WASHOUT|2020-07-21|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-10|P1Y2M10DT2H30M|AFTER|2020-07-15|BEFORE|2020-08-20
e|RS|93b3c298-d81f-4d71-9c5d-ba5b4d4bdf42|8|SYMPTDTR|Symptomatic Deterioration|MRANO VAN DEN BENT GLIOMA 2011|[?]|mol/g|iCPD|1|tuberculin unit|COMPUTERIZED CORNEAL TOPOGRAPHY|Y|Y||CLINICAL STUDY SPONSOR|RATER 2|Y|4|Visit_4|65|3|WASHOUT|2020-07-21|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-10|P1Y2M10DT2H30M|AFTER|2020-07-20|ONGOING|2020-07-28
e|RS|93b3c298-d81f-4d71-9c5d-ba5b4d4bdf42|9|TMRESP|Tumor Marker Response|BLAZER COLORECTAL CANCER 2008|[?]|steps/min|iUPD|1|MAC50|DNA MICROARRAY||||INVESTIGATOR|ONCOLOGIST|Y|5|Visit_5|90|4|FOLLOW-UP|2020-08-15|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-17|P1Y2M10DT2H30M|COINCIDENT|2020-06-21|COINCIDENT|2020-08-11
e|RS|93b3c298-d81f-4d71-9c5d-ba5b4d4bdf42|10|NTRGRESP|Non-target Response|RANO|[?]|WAFER|EQUIVOCAL|1|cmHg|MOUSE PROTECTION ASSAY||Y||CLINICAL RESEARCH COORDINATOR|RADIOLOGIST|U|5|Visit_5|90|7|TREATMENT|2020-08-15|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-17|P1Y2M10DT2H30M|AFTER|2020-07-25|AFTER|2020-07-31
e|RS|2d8f8b1e-7914-400b-afc5-8dc23a626d76|1|CLINRESP|Clinical Response|LEE LUNG CANCER 2011|[?]|CCID 50/dose|MR|1|10^6 copies/mL|SPECTROPHOTOMETRY||Y||SPOUSE|FORENSIC PATHOLOGIST|U|1|Visit_1|10|1|WASHOUT|2020-06-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-29|P1Y2M10DT2H30M|COINCIDENT|2020-08-25|BEFORE|2020-09-01
e|RS|2d8f8b1e-7914-400b-afc5-8dc23a626d76|2|STRUSTAT|Steroid Use Status|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|||CR|1|CCID 50/mL|DUKE INCISION METHOD||Y|Y|SPOUSE|CLINICAL PATHOLOGIST|N|1|Visit_1|10|6|SCREENING|2020-06-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-29|P1Y2M10DT2H30M|UNKNOWN|2020-07-31|ONGOING|2020-08-22
e|RS|2d8f8b1e-7914-400b-afc5-8dc23a626d76|3|LIVRRESP|Liver Response|DURIE MULTIPLE MYELOMA 2006|[?]|Bq/mg|MRD PERSISTENCE|1|/10^5|MICRONEUTRALIZATION ASSAY|Y|||STUDY SUBJECT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|2|Visit_2|25|2|TREATMENT|2020-07-04|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-07|P1Y2M10DT2H30M|COINCIDENT|2020-07-31|AFTER|2020-08-02
e|RS|2d8f8b1e-7914-400b-afc5-8dc23a626d76|4|TRGRESP|Target Response|SCHWARZ CERVICAL CANCER 2009|[?]|10^12/L|PSEUDOPROGRESSION|1|FFU|KNEMOMETRY||Y||SIBLING|PHYSIOTHERAPIST|N|2|Visit_2|25|3|SCREENING|2020-07-04|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-07|P1Y2M10DT2H30M|COINCIDENT|2020-08-16|COINCIDENT|2020-08-22
e|RS|2d8f8b1e-7914-400b-afc5-8dc23a626d76|5|BMIVLIND|Bone Marrow Involvement Indicator|IWG CHESON MDS 2006|[?]|g/animal/wk|PSEUDORESPONSE|1|mg/m2|ICP-MS||||CAREGIVER|RADIOLOGIST 1|Y|3|Visit_3|40|2|TREATMENT|2020-07-19|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-08|P1Y2M10DT2H30M|COINCIDENT|2020-08-14|AFTER|2020-08-30
e|RS|2d8f8b1e-7914-400b-afc5-8dc23a626d76|6|MNPTHIND|Minor Pathological Response Indicator|PALUMBO MULTIPLE MYELOMA 2009|[?]|mg/kg/h|MRD NEGATIVITY|1|m/sec|IMMUNO-PET SCAN||||NON-HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|NA|3|Visit_3|40|7|SCREENING|2020-07-19|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-08|P1Y2M10DT2H30M|COINCIDENT|2020-07-06|AFTER|2020-08-03
e|RS|2d8f8b1e-7914-400b-afc5-8dc23a626d76|7|LIVRRESP|Liver Response|BLAZER COLORECTAL CANCER 2008|[?]|mL/min/1.73m2|nPR|1|mm2|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION||Y||INDEPENDENT ASSESSOR|MICROSCOPIST|U|4|Visit_4|65|5|TREATMENT|2020-08-13|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-30|P1Y2M10DT2H30M|AFTER|2020-09-03|ONGOING|2020-09-12
e|RS|2d8f8b1e-7914-400b-afc5-8dc23a626d76|8|NTLWIND|Non-Target Lesion Worsening Indicator|SCHER PROSTATE CANCER 2011|[?]|mIU/L|PD|1|mL/m2/day|IMMUNOCHROMATOGRAPHY|Y|Y||PARENT|RATER 2|NA|4|Visit_4|65|6|TREATMENT|2020-08-13|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-30|P1Y2M10DT2H30M|AFTER|2020-09-02|ONGOING|2020-09-06
e|RS|2d8f8b1e-7914-400b-afc5-8dc23a626d76|9|LIVRRESP|Liver Response|KUKER LYMPHOMA 2005|[?]|mph|mCR|1|mCi/L|WHOLE TRANSCRIPTOME SEQUENCING|Y|||FRIEND|READER 1|Y|5|Visit_5|90|2|SCREENING|2020-09-07|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-07|P1Y2M10DT2H30M|COINCIDENT|2020-09-03|AFTER|2020-09-08
e|RS|2d8f8b1e-7914-400b-afc5-8dc23a626d76|10|MJPTHIND|Major Pathological Response Indicator|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|||UNFAVORABLE RESPONSE|1|VIAL|IMMUNOFIXATION ELECTROPHORESIS|||Y|INDEPENDENT ASSESSOR|PATHOLOGIST 2|Y|5|Visit_5|90|1|WASHOUT|2020-09-07|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-07|P1Y2M10DT2H30M|COINCIDENT|2020-08-08|ONGOING|2020-09-15
e|RS|9d3f5b5e-ebd4-4540-8b4d-14733497ed8e|1|PATHRESP|Pathologic Response|SCHER PROSTATE CANCER 2011|[?]|mg/kg/day|mCR|1|nmol/kg/day|KINETIC CHROMOGENIC ASSAY||||HEALTH CARE PROFESSIONAL|UROLOGIST|Y|1|Visit_1|10|3|TREATMENT|2020-08-20|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-29|P1Y2M10DT2H30M|AFTER|2020-09-17|COINCIDENT|2020-09-25
e|RS|9d3f5b5e-ebd4-4540-8b4d-14733497ed8e|2|CPRFSTAT|Clinical Performance Status|WHO BREAST CANCER 2006|||PDu|1|CAPLET|EEG|Y||Y|INTERVIEWER|ONCOLOGIST|N|1|Visit_1|10|2|TREATMENT|2020-08-20|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-29|P1Y2M10DT2H30M|AFTER|2020-10-13|BEFORE|2020-10-28
e|RS|9d3f5b5e-ebd4-4540-8b4d-14733497ed8e|3|MJPTHIND|Major Pathological Response Indicator|MRANO VAN DEN BENT GLIOMA 2011|[?]|Enzyme U/m2|CR-CT|1|Absorbance U/min|GEL ELECTROPHORESIS||||PROXY|HEMATOLOGIST|N|2|Visit_2|25|7|FOLLOW-UP|2020-09-04|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-23|P1Y2M10DT2H30M|COINCIDENT|2020-09-23|ONGOING|2020-10-01
e|RS|9d3f5b5e-ebd4-4540-8b4d-14733497ed8e|4|NTERESP|Non-Target Enhancing Response|AJCC V8|||NOT ALL EVALUATED|1|psec|DC SHEATH FLOW||Y|Y|PARENT|NEUROLOGIST 2|Y|2|Visit_2|25|2|TREATMENT|2020-09-04|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-23|P1Y2M10DT2H30M|UNKNOWN|2020-11-03|COINCIDENT|2020-11-07
e|RS|9d3f5b5e-ebd4-4540-8b4d-14733497ed8e|5|TRGRESP|Target Response|CHESON CLL 2006|[?]|mV2/Hz|HI-N|1|L/kg|QUANTITATIVE CORONARY ANGIOGRAPHY||||INTERVIEWER|READER 3|U|3|Visit_3|40|5|TREATMENT|2020-09-19|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-21|P1Y2M10DT2H30M|COINCIDENT|2020-10-06|COINCIDENT|2020-11-13
e|RS|9d3f5b5e-ebd4-4540-8b4d-14733497ed8e|6|MRDRESP|Minimal Residual Disease Response|CHOI GIST 2008|[?]|EIA unit|PSEUDOPROGRESSION|1|sec|CT SCAN|Y|Y||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 1|U|3|Visit_3|40|5|WASHOUT|2020-09-19|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-21|P1Y2M10DT2H30M|COINCIDENT|2020-09-12|COINCIDENT|2020-10-30
e|RS|9d3f5b5e-ebd4-4540-8b4d-14733497ed8e|7|PATHRESP|Pathologic Response|KEAM BREAST CANCER 2013|||PR-CT|1|nmol/day|VIRUS PLAQUE ASSAY|||Y|NON-HEALTH CARE PROFESSIONAL|UROLOGIST|Y|4|Visit_4|65|3|TREATMENT|2020-10-14|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-16|P1Y2M10DT2H30M|AFTER|2020-08-29|BEFORE|2020-10-23
e|RS|9d3f5b5e-ebd4-4540-8b4d-14733497ed8e|8|MRDRESP|Minimal Residual Disease Response|NCIWG CHESON CLL 1996|[?]|dB|DECREASED|1|mg/m2/day|QUANTITATIVE ULTRASOUND||||SIBLING|RADIOLOGIST 2|U|4|Visit_4|65|5|WASHOUT|2020-10-14|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-16|P1Y2M10DT2H30M|BEFORE|2020-09-09|ONGOING|2020-11-03
e|RS|9d3f5b5e-ebd4-4540-8b4d-14733497ed8e|9|MRPHRESP|Morphologic Response|KUMAR IMWG 2016|[?]|VIRTUAL PIXEL|SMD|1|SYRINGE|ACCELERATOR MASS SPECTROMETRY|Y|||CAREGIVER|RATER 1|U|5|Visit_5|90|1|FOLLOW-UP|2020-11-08|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-04|P1Y2M10DT2H30M|BEFORE|2020-08-20|AFTER|2020-09-24
e|RS|9d3f5b5e-ebd4-4540-8b4d-14733497ed8e|10|BESTRESP|Best Overall Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|/LSQN|CYTOGENETIC MINIMAL RESPONSE|1|Gy/h|SLOAN LETTER EYE CHART 1.25%||||NON-HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|N|5|Visit_5|90|7|SCREENING|2020-11-08|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-04|P1Y2M10DT2H30M|AFTER|2020-09-07|COINCIDENT|2020-11-09
e|RS|a73142e4-e34b-4144-b95f-7a5562574c1b|1|NTERESP|Non-Target Enhancing Response|IWG CHESON AML 2003|[?]|h*%|PSEUDORESPONSE|1|damol/L|ARTERIAL SPIN LABELING FUNCTIONAL MRI||||FAMILY MEMBER|CARDIOLOGIST|Y|1|Visit_1|10|6|FOLLOW-UP|2020-08-08|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-13|P1Y2M10DT2H30M|UNKNOWN|2020-09-22|COINCIDENT|2020-10-05
e|RS|a73142e4-e34b-4144-b95f-7a5562574c1b|2|NTRGRESP|Non-target Response|HAMAOKA BREAST CANCER 2010|[?]|MET|FAVORABLE RESPONSE|1|Absorbance U/min|PHOTOMETRIC CLOT DETECTION||||FRIEND|PATHOLOGIST 2|Y|1|Visit_1|10|7|TREATMENT|2020-08-08|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-13|P1Y2M10DT2H30M|BEFORE|2020-08-11|ONGOING|2020-09-02
e|RS|a73142e4-e34b-4144-b95f-7a5562574c1b|3|SPLNRESP|Spleen Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|anti-Xa IU/mL|ABSENT MORPHOLOGIC RESPONSE|1|mg/dose|SLIT LAMP|Y|||INVESTIGATOR|RATER 1|Y|2|Visit_2|25|3|FOLLOW-UP|2020-08-23|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-28|P1Y2M10DT2H30M|BEFORE|2020-09-25|BEFORE|2020-10-23
e|RS|a73142e4-e34b-4144-b95f-7a5562574c1b|4|LIVRRESP|Liver Response|IWG CHESON MDS 2000|[?]|U/L|nPR|1|10^8/L|WESTERGREN|Y|Y||CLINICAL STUDY SPONSOR|ADJUDICATOR 3|U|2|Visit_2|25|1|SCREENING|2020-08-23|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-28|P1Y2M10DT2H30M|UNKNOWN|2020-10-02|AFTER|2020-10-11
e|RS|a73142e4-e34b-4144-b95f-7a5562574c1b|5|MRDIND|Minimal Residual Disease Indicator|HARTMANN GERM CELL CANCER 2002|[?]|g/animal|CRi|1|Ci/g|EEG||||CLINICAL STUDY SPONSOR|RADIOLOGIST|N|3|Visit_3|40|6|WASHOUT|2020-09-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-05|P1Y2M10DT2H30M|BEFORE|2020-09-02|ONGOING|2020-09-06
e|RS|a73142e4-e34b-4144-b95f-7a5562574c1b|6|RDIORESP|Radiologic Response|MASS|[?]|TROCHE|EQUIVOCAL|1|Tbsp|RADIAL IMMUNODIFFUSION||||CLINICAL STUDY SPONSOR|OPHTHALMOLOGIST|NA|3|Visit_3|40|4|TREATMENT|2020-09-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-05|P1Y2M10DT2H30M|COINCIDENT|2020-09-06|ONGOING|2020-10-18
e|RS|a73142e4-e34b-4144-b95f-7a5562574c1b|7|ANATRESP|Anatomic Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|s^-1(%O2)^-1|iUPD|1|10^11/L|VENTILATION PERFUSION LUNG SCAN||Y||STUDY SUBJECT|NEUROLOGIST|NA|4|Visit_4|65|7|SCREENING|2020-10-02|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-13|P1Y2M10DT2H30M|BEFORE|2020-09-17|COINCIDENT|2020-10-26
e|RS|a73142e4-e34b-4144-b95f-7a5562574c1b|8|HEMARESP|Hematologic Response|RANO ELLINGSON 2017|[?]|mL/animal|MOLECULAR CR|1|uIU/L|THICK SMEAR||||CHILD|PATHOLOGIST 2|U|4|Visit_4|65|6|TREATMENT|2020-10-02|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-13|P1Y2M10DT2H30M|AFTER|2020-08-18|ONGOING|2020-08-23
e|RS|a73142e4-e34b-4144-b95f-7a5562574c1b|9|CLINRESP|Clinical Response|RANO ELLINGSON 2017|[?]|tuberculin unit|PD-CT|1|pm|IMPEDANCE CONDUCTIVITY||||CAREGIVER|PHYSIOTHERAPIST|N|5|Visit_5|90|2|SCREENING|2020-10-27|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-11|P1Y2M10DT2H30M|COINCIDENT|2020-10-01|BEFORE|2020-11-03
e|RS|a73142e4-e34b-4144-b95f-7a5562574c1b|10|CYTORESP|Cytogenetic Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|||CYTOGENETIC MINOR RESPONSE|1|v/v|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION||Y|Y|PARENT|PATHOLOGIST 2|Y|5|Visit_5|90|5|TREATMENT|2020-10-27|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-11|P1Y2M10DT2H30M|UNKNOWN|2020-08-27|COINCIDENT|2020-10-06
e|RS|a9bdb550-aa73-4194-a4b1-c69fa5dd2d4b|1|MOLRESP|Molecular Response|SCHER PROSTATE CANCER 2011|[?]|10^4 CFU|FAVORABLE RESPONSE|1|g/cage/wk|MULTI-SLICE SPIRAL CT|Y|||GUARDIAN|RATER 2|NA|1|Visit_1|10|5|WASHOUT|2020-06-03|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-15|P1Y2M10DT2H30M|COINCIDENT|2020-08-16|BEFORE|2020-08-19
e|RS|a9bdb550-aa73-4194-a4b1-c69fa5dd2d4b|2|ANATRESP|Anatomic Response|UNSPECIFIED|[?]|copies/ug|mCR|1|/200 HPFs|GIEMSA STAIN||||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 2|Y|1|Visit_1|10|5|FOLLOW-UP|2020-06-03|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-15|P1Y2M10DT2H30M|AFTER|2020-07-25|ONGOING|2020-08-01
e|RS|a9bdb550-aa73-4194-a4b1-c69fa5dd2d4b|3|TMRESP|Tumor Marker Response|PCWG SCHER PROSTATE CANCER 2008|[?]|SUPPOSITORY|SD|1|mg/mL/min|X-RAY FLUORESCENCE SPECTROMETRY||||VENDOR|OTOLARYNGOLOGIST|Y|2|Visit_2|25|7|WASHOUT|2020-06-18|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-17|P1Y2M10DT2H30M|AFTER|2020-07-15|ONGOING|2020-07-28
e|RS|a9bdb550-aa73-4194-a4b1-c69fa5dd2d4b|4|SYMPTDTR|Symptomatic Deterioration|DOHNER AML 2010|[?]|nmol/mol|SMD|1|MBq|THERMAL IONIZATION MASS SPECTROMETRY||||CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL PSYCHOLOGIST|N|2|Visit_2|25|5|TREATMENT|2020-06-18|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-17|P1Y2M10DT2H30M|UNKNOWN|2020-07-09|AFTER|2020-07-24
e|RS|a9bdb550-aa73-4194-a4b1-c69fa5dd2d4b|5|OVRLRESP|Overall Response|MONTSERRAT CLL 1989|||INCREASED|1|cmol|DIGITAL PCR ARRAY|||Y|PROXY|DERMATOLOGIST|N|3|Visit_3|40|1|TREATMENT|2020-07-03|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-18|P1Y2M10DT2H30M|UNKNOWN|2020-07-02|BEFORE|2020-08-01
e|RS|a9bdb550-aa73-4194-a4b1-c69fa5dd2d4b|6|SYMPTDTR|Symptomatic Deterioration|MURPHY PROSTATE CANCER 1980|[?]|STRIP|PR-CT|1|TUBE|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY||||SIGNIFICANT OTHER|CARDIOLOGIST|NA|3|Visit_3|40|4|TREATMENT|2020-07-03|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-18|P1Y2M10DT2H30M|BEFORE|2020-06-10|COINCIDENT|2020-07-19
e|RS|a9bdb550-aa73-4194-a4b1-c69fa5dd2d4b|7|BMIVLIND|Bone Marrow Involvement Indicator|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|||CA125 50% RESPONSE|1|MdFI|GEL ELECTROPHORESIS|||Y|VENDOR|PEDIATRIC NEUROLOGIST|NA|4|Visit_4|65|6|TREATMENT|2020-07-28|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-06|P1Y2M10DT2H30M|UNKNOWN|2020-07-28|AFTER|2020-08-31
e|RS|a9bdb550-aa73-4194-a4b1-c69fa5dd2d4b|8|NTLWIND|Non-Target Lesion Worsening Indicator|HARTMAN PANCREATIC CANCER 2012|[?]|MASK|iPR|1|mL/breath|ZIEHL NEELSEN ACID FAST STAIN||||DOMESTIC PARTNER|INTERNIST|Y|4|Visit_4|65|2|SCREENING|2020-07-28|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-06|P1Y2M10DT2H30M|BEFORE|2020-06-15|BEFORE|2020-07-31
e|RS|a9bdb550-aa73-4194-a4b1-c69fa5dd2d4b|9|MRDRESP|Minimal Residual Disease Response|PCWG SCHER PROSTATE CANCER 2008|[?]|m/sec|QUANTIFIABLE MRD POSITIVITY|1|mL/s/m2|IN SITU HYBRIDIZATION||||SPOUSE|MICROSCOPIST 3|Y|5|Visit_5|90|1|TREATMENT|2020-08-22|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-31|P1Y2M10DT2H30M|BEFORE|2020-07-30|ONGOING|2020-08-18
e|RS|a9bdb550-aa73-4194-a4b1-c69fa5dd2d4b|10|CYTORESP|Cytogenetic Response|WHO BREAST CANCER 2006|[?]|nmol/mL/min|PSA PROGRESSION|1|/LSQN|X-RAY||Y||GUARDIAN|ONCOLOGIST 2|NA|5|Visit_5|90|6|FOLLOW-UP|2020-08-22|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-31|P1Y2M10DT2H30M|COINCIDENT|2020-07-07|ONGOING|2020-08-20
e|RS|0f682806-b63c-4c3f-9fda-1e59befbd3a3|1|STRUSTAT|Steroid Use Status|CHESON LYMPHOMA 2008|[?]|mmol/kg|PR|1|10^9 organisms/g|CONTRAST ENHANCED X-RAY|Y|||GUARDIAN|PATHOLOGIST|Y|1|Visit_1|10|4|TREATMENT|2020-05-29|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-16|P1Y2M10DT2H30M|COINCIDENT|2020-06-01|BEFORE|2020-06-04
e|RS|0f682806-b63c-4c3f-9fda-1e59befbd3a3|2|SFTSRESP|Soft Tissue Response|PERCIST|[?]|APPLICATION|PD|1|BOTTLE|MACRO BROTH DILUTION||||PROXY|ONCOLOGIST 1|Y|1|Visit_1|10|2|SCREENING|2020-05-29|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-16|P1Y2M10DT2H30M|COINCIDENT|2020-07-12|AFTER|2020-07-15
e|RS|0f682806-b63c-4c3f-9fda-1e59befbd3a3|3|MRDRESP|Minimal Residual Disease Response|CHESON CLL 2006|[?]|PFU/mL|CR|1|cL|SCINTIGRAPHY|Y|Y||INTERVIEWER|OPHTHALMOLOGIST|U|2|Visit_2|25|1|SCREENING|2020-06-13|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-05|P1Y2M10DT2H30M|COINCIDENT|2020-07-05|AFTER|2020-07-10
e|RS|0f682806-b63c-4c3f-9fda-1e59befbd3a3|4|METSIND|Metastatic Indicator|IWG CHESON MDS 2000|[?]|CIGAR|MRD PERSISTENCE|1|nmol/L|CISH||||FAMILY MEMBER|ONCOLOGIST 1|NA|2|Visit_2|25|2|TREATMENT|2020-06-13|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-05|P1Y2M10DT2H30M|AFTER|2020-05-29|AFTER|2020-07-04
e|RS|0f682806-b63c-4c3f-9fda-1e59befbd3a3|5|RDIORESP|Radiologic Response|GUPPY OVARIAN CANCER 2002|||cPR|1|%|CONTRAST ENHANCED X-RAY||Y|Y|SIGNIFICANT OTHER|NEUROLOGIST 2|U|3|Visit_3|40|7|TREATMENT|2020-06-28|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-18|P1Y2M10DT2H30M|AFTER|2020-08-14|BEFORE|2020-08-19
e|RS|0f682806-b63c-4c3f-9fda-1e59befbd3a3|6|NTRGRESP|Non-target Response|CHESON CLL 2006|[?]|ELISA unit/mL|HI-N|1|cm/min|GC/MS||Y||CHILD|RATER 2|N|3|Visit_3|40|6|TREATMENT|2020-06-28|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-18|P1Y2M10DT2H30M|UNKNOWN|2020-05-22|ONGOING|2020-07-03
e|RS|0f682806-b63c-4c3f-9fda-1e59befbd3a3|7|OVRLRESP|Overall Response|PERCIST|[?]|bel|iUPD|1|mg/kg/day|GC/FID|Y|||CLINICAL STUDY SPONSOR|ADJUDICATOR 2|N|4|Visit_4|65|7|TREATMENT|2020-07-23|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-31|P1Y2M10DT2H30M|AFTER|2020-07-01|ONGOING|2020-08-02
e|RS|0f682806-b63c-4c3f-9fda-1e59befbd3a3|8|MNPTHIND|Minor Pathological Response Indicator|GUPPY OVARIAN CANCER 2002|[?]|CIGARETTE|CRi|1|nmol/L/min|HPLC/IEX||||INVESTIGATOR|ADJUDICATOR 1|U|4|Visit_4|65|2|SCREENING|2020-07-23|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-31|P1Y2M10DT2H30M|AFTER|2020-07-03|BEFORE|2020-07-16
e|RS|0f682806-b63c-4c3f-9fda-1e59befbd3a3|9|NTERESP|Non-Target Enhancing Response|AJCC V7|[?]|cup eq|iUPD|1|IU/g Hb|ENZYMATIC COLORIMETRY||||DOMESTIC PARTNER|PHYSIOTHERAPIST|U|5|Visit_5|90|6|TREATMENT|2020-08-17|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-25|P1Y2M10DT2H30M|COINCIDENT|2020-06-03|AFTER|2020-06-14
e|RS|0f682806-b63c-4c3f-9fda-1e59befbd3a3|10|METBRESP|Metabolic Response|HAMAOKA BREAST CANCER 2010|||PR-CT|1|Hz|LASER CAPTURE MICRODISSECTION|Y||Y|PROXY|RADIOLOGIST 1|NA|5|Visit_5|90|5|FOLLOW-UP|2020-08-17|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-25|P1Y2M10DT2H30M|COINCIDENT|2020-06-08|BEFORE|2020-07-09
e|RS|1d8aba56-f62e-4116-b447-899dedd3d4df|1|NTRGRESP|Non-target Response|BLAZER COLORECTAL CANCER 2008|[?]|gMFI|CYTOGENETIC CR|1|min|HPLC-UV||Y||INVESTIGATOR|PEDIATRIC NEUROLOGIST|Y|1|Visit_1|10|6|TREATMENT|2020-09-29|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-23|P1Y2M10DT2H30M|UNKNOWN|2020-12-16|AFTER|2020-12-27
e|RS|1d8aba56-f62e-4116-b447-899dedd3d4df|2|CLINRESP|Clinical Response|IWG CHESON AML 2003|[?]|mL/(min*100mL)|NR|1|ng/day|JAEGER EYE CHART||||CLINICAL STUDY SPONSOR|RATER 2|N|1|Visit_1|10|3|TREATMENT|2020-09-29|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-23|P1Y2M10DT2H30M|UNKNOWN|2020-12-10|AFTER|2020-12-14
e|RS|1d8aba56-f62e-4116-b447-899dedd3d4df|3|OVRLRESP|Overall Response|RANO ELLINGSON 2017|[?]|mV/sec|CR-CT|1|%/min|NEXT GENERATION SEQUENCING|Y|Y||FRIEND|PATHOLOGIST|N|2|Visit_2|25|4|TREATMENT|2020-10-14|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-04|P1Y2M10DT2H30M|UNKNOWN|2020-11-13|COINCIDENT|2020-12-13
e|RS|1d8aba56-f62e-4116-b447-899dedd3d4df|4|OVRLRESP|Overall Response|IWC HALLEK CLL 2008|[?]|dpm/mL|MINOR PATHOLOGIC RESPONSE|1|cL|ERGOSPIROMETRY||||CHILD|DERMATOLOGIST|NA|2|Visit_2|25|1|TREATMENT|2020-10-14|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-04|P1Y2M10DT2H30M|AFTER|2020-11-18|ONGOING|2020-12-13
e|RS|1d8aba56-f62e-4116-b447-899dedd3d4df|5|METBRESP|Metabolic Response|MRECIST LENCIONI LIVER CANCER 2010|||MINOR PATHOLOGIC RESPONSE|1|Antibody Unit|TOTAL BODY IRRADIATION|||Y|CLINICAL STUDY SPONSOR|READER|N|3|Visit_3|40|1|TREATMENT|2020-10-29|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-29|P1Y2M10DT2H30M|BEFORE|2020-12-10|AFTER|2020-12-26
e|RS|1d8aba56-f62e-4116-b447-899dedd3d4df|6|NTRGRESP|Non-target Response|BLAZER COLORECTAL CANCER 2008|[?]|ug/animal|NOT ALL EVALUATED|1|kN/cm2|HEMAGGLUTINATION ASSAY||||INDEPENDENT ASSESSOR|FORENSIC PATHOLOGIST|Y|3|Visit_3|40|1|TREATMENT|2020-10-29|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-29|P1Y2M10DT2H30M|COINCIDENT|2020-11-24|BEFORE|2020-12-08
e|RS|1d8aba56-f62e-4116-b447-899dedd3d4df|7|NTLWIND|Non-Target Lesion Worsening Indicator|CHESON MALIGNANT LYMPHOMA 2007|||PSA PROGRESSION|1|10^8/L|NO INFORMATION|||Y|PROXY|PEDIATRIC NEUROLOGIST|N|4|Visit_4|65|1|WASHOUT|2020-11-23|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-11|P1Y2M10DT2H30M|AFTER|2020-12-04|BEFORE|2020-12-11
e|RS|1d8aba56-f62e-4116-b447-899dedd3d4df|8|TMRESP|Tumor Marker Response|AJCC V8|[?]|mL/min/1.73m2|NON-iCR/NON-iUPD|1|PFU/mL|CONTRAST ENHANCED MRI||||ADJUDICATOR|PATHOLOGIST 1|U|4|Visit_4|65|3|WASHOUT|2020-11-23|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-11|P1Y2M10DT2H30M|UNKNOWN|2020-11-02|BEFORE|2020-12-22
e|RS|1d8aba56-f62e-4116-b447-899dedd3d4df|9|LIVRRESP|Liver Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|CCID 50/mL|CR-CT|1|uSiemens|DUCTOGRAPHY||||CLINICAL STUDY SPONSOR|ONCOLOGIST|Y|5|Visit_5|90|2|WASHOUT|2020-12-18|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-15|P1Y2M10DT2H30M|COINCIDENT|2020-12-19|COINCIDENT|2020-12-23
e|RS|1d8aba56-f62e-4116-b447-899dedd3d4df|10|BMIVLIND|Bone Marrow Involvement Indicator|BURCOMBE BREAST CANCER 2005|||nPR|1|U/m2|APPLANATION TONOMETRY||Y|Y|FRIEND|NEUROLOGIST|N|5|Visit_5|90|2|TREATMENT|2020-12-18|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-15|P1Y2M10DT2H30M|UNKNOWN|2020-11-06|AFTER|2020-11-11
e|RS|77bbd5c9-a7c4-43d1-a392-5dd44cfbfe4f|1|METBRESP|Metabolic Response|PETIT BREAST CANCER 2001|[?]|IMPLANT|CR|1|beats/min|COULOMETRIC TITRATION||Y||SPOUSE|ADJUDICATOR 2|Y|1|Visit_1|10|4|TREATMENT|2020-08-14|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-28|P1Y2M10DT2H30M|BEFORE|2020-11-03|AFTER|2020-11-05
e|RS|77bbd5c9-a7c4-43d1-a392-5dd44cfbfe4f|2|METSIND|Metastatic Indicator|PETIT BREAST CANCER 2001|[?]|deg|RELAPSED DISEASE FROM CR|1|mmol|MULTIPLEXED BEAD BASED IMMUNOASSAY||Y||ADJUDICATOR|NEUROLOGIST 2|NA|1|Visit_1|10|3|TREATMENT|2020-08-14|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-28|P1Y2M10DT2H30M|UNKNOWN|2020-09-11|COINCIDENT|2020-09-12
e|RS|77bbd5c9-a7c4-43d1-a392-5dd44cfbfe4f|3|HEMARESP|Hematologic Response|HARTMANN GERM CELL CANCER 2002|[?]|rpm|MOLECULAR CR|1|amol|RADIAL IMMUNODIFFUSION|Y|||SIBLING|MICROSCOPIST|N|2|Visit_2|25|3|SCREENING|2020-08-29|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-13|P1Y2M10DT2H30M|COINCIDENT|2020-08-11|COINCIDENT|2020-08-15
e|RS|77bbd5c9-a7c4-43d1-a392-5dd44cfbfe4f|4|MNPTHIND|Minor Pathological Response Indicator|PCWG SCHER PROSTATE CANCER 2016|||NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|Anson U|WRIGHT STAIN|||Y|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST|N|2|Visit_2|25|5|FOLLOW-UP|2020-08-29|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-13|P1Y2M10DT2H30M|UNKNOWN|2020-08-16|BEFORE|2020-10-07
e|RS|77bbd5c9-a7c4-43d1-a392-5dd44cfbfe4f|5|BESTRESP|Best Overall Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|kUSP|EQUIVOCAL|1|ng/mol|LIGHT MICROSCOPY|Y|||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|Y|3|Visit_3|40|2|TREATMENT|2020-09-13|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-03|P1Y2M10DT2H30M|COINCIDENT|2020-10-03|BEFORE|2020-10-20
e|RS|77bbd5c9-a7c4-43d1-a392-5dd44cfbfe4f|6|NEWLPROG|New Lesion Progression|BURCOMBE BREAST CANCER 2005|||PSEUDORESPONSE|1|V|SANGER SEQUENCING||Y|Y|ADJUDICATION COMMITTEE|PATHOLOGIST 1|NA|3|Visit_3|40|4|FOLLOW-UP|2020-09-13|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-03|P1Y2M10DT2H30M|UNKNOWN|2020-08-29|AFTER|2020-11-09
e|RS|77bbd5c9-a7c4-43d1-a392-5dd44cfbfe4f|7|STRUSTAT|Steroid Use Status|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|SBE/mL|ABSENT MORPHOLOGIC RESPONSE|1|pkat/L|ULTRASOUND|Y|Y||INDEPENDENT ASSESSOR|READER|Y|4|Visit_4|65|7|TREATMENT|2020-10-08|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-26|P1Y2M10DT2H30M|UNKNOWN|2020-09-08|COINCIDENT|2020-10-25
e|RS|77bbd5c9-a7c4-43d1-a392-5dd44cfbfe4f|8|CLINRESP|Clinical Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|||MRD RELAPSE|1|P|MRI WITHOUT CONTRAST|||Y|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST|Y|4|Visit_4|65|7|SCREENING|2020-10-08|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-26|P1Y2M10DT2H30M|BEFORE|2020-08-18|BEFORE|2020-10-22
e|RS|77bbd5c9-a7c4-43d1-a392-5dd44cfbfe4f|9|NEWLPROG|New Lesion Progression|SACT|[?]|/10^5|CA125 50% RESPONSE|1|/h|CONTRAST ENHANCED CT SCAN|Y|||ADJUDICATOR|CARDIOLOGIST|U|5|Visit_5|90|3|WASHOUT|2020-11-02|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-10|P1Y2M10DT2H30M|COINCIDENT|2020-11-02|BEFORE|2020-11-04
e|RS|77bbd5c9-a7c4-43d1-a392-5dd44cfbfe4f|10|MRDRESP|Minimal Residual Disease Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|ng/mol|SMD|1|mL/g/day|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY||||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 3|NA|5|Visit_5|90|4|SCREENING|2020-11-02|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-10|P1Y2M10DT2H30M|UNKNOWN|2020-10-14|COINCIDENT|2020-10-23
e|RS|383d3f30-14b7-48c3-b1a8-0f481ef37a50|1|ANATRESP|Anatomic Response|CHESON NON-HODGKINS LYMPHOMA 1999|||PARTIAL MORPHOLOGIC RESPONSE|1|Tbsp|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|||Y|FRIEND|INTERNIST|N|1|Visit_1|10|1|WASHOUT|2020-06-07|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-26|P1Y2M10DT2H30M|BEFORE|2020-06-03|ONGOING|2020-08-23
e|RS|383d3f30-14b7-48c3-b1a8-0f481ef37a50|2|MRDIND|Minimal Residual Disease Indicator|PCWG SCHER PROSTATE CANCER 2008|[?]|umol/day|PR WITH LYMPHOCYTOSIS|1|ohm|HEMAGGLUTINATION INHIBITION ASSAY|Y|Y||GUARDIAN|RATER|Y|1|Visit_1|10|1|FOLLOW-UP|2020-06-07|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-26|P1Y2M10DT2H30M|COINCIDENT|2020-08-09|AFTER|2020-08-22
e|RS|383d3f30-14b7-48c3-b1a8-0f481ef37a50|3|NEWLIND|New Lesion Indicator|DURIE MULTIPLE MYELOMA 2006|[?]|pt_br|pCR|1|U/kg/min|SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY||||CHILD|PATHOLOGIST 2|Y|2|Visit_2|25|2|TREATMENT|2020-06-22|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-27|P1Y2M10DT2H30M|AFTER|2020-06-09|COINCIDENT|2020-07-31
e|RS|383d3f30-14b7-48c3-b1a8-0f481ef37a50|4|STRUSTAT|Steroid Use Status|CHESON LYMPHOMA 2008|[?]|mU/L|PD-CT|1|CYLINDER|PHOTOMETRY||Y||SIGNIFICANT OTHER|NEUROLOGIST 1|NA|2|Visit_2|25|4|TREATMENT|2020-06-22|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-27|P1Y2M10DT2H30M|COINCIDENT|2020-08-30|BEFORE|2020-09-04
e|RS|383d3f30-14b7-48c3-b1a8-0f481ef37a50|5|RDIORESP|Radiologic Response|MACDONALD GLIOMA 1990|[?]|SQU/mL|PD-CT|1|IU/kg|ENZYMATIC COLORIMETRY|Y|||CAREGIVER|ADJUDICATOR|NA|3|Visit_3|40|3|FOLLOW-UP|2020-07-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-11|P1Y2M10DT2H30M|COINCIDENT|2020-06-19|BEFORE|2020-08-24
e|RS|383d3f30-14b7-48c3-b1a8-0f481ef37a50|6|NTLWIND|Non-Target Lesion Worsening Indicator|GUILHOT CML 2007|||RELAPSED DISEASE FROM CR|1|SUPPOSITORY|ROMANOWSKY STAIN|||Y|SIGNIFICANT OTHER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|3|Visit_3|40|4|WASHOUT|2020-07-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-11|P1Y2M10DT2H30M|COINCIDENT|2020-07-10|COINCIDENT|2020-08-07
e|RS|383d3f30-14b7-48c3-b1a8-0f481ef37a50|7|TMRESP|Tumor Marker Response|LUGANO CLASSIFICATION|[?]|CUP|WORSENED|1|mL*cmH2O|REFLECTANCE SPECTROSCOPY||Y||CLINICAL STUDY SPONSOR|CLINICAL PATHOLOGIST|U|4|Visit_4|65|5|FOLLOW-UP|2020-08-01|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-08|P1Y2M10DT2H30M|BEFORE|2020-07-03|COINCIDENT|2020-07-22
e|RS|383d3f30-14b7-48c3-b1a8-0f481ef37a50|8|STRUSTAT|Steroid Use Status|BRUGGEMANN MRD 2010|||CYTOGENETIC NO RESPONSE|1|Newton|FLUORESCENT LIFETIME IMAGING MICROSCOPY|||Y|SIBLING|MICROSCOPIST 3|NA|4|Visit_4|65|2|TREATMENT|2020-08-01|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-08|P1Y2M10DT2H30M|UNKNOWN|2020-07-07|COINCIDENT|2020-08-05
e|RS|383d3f30-14b7-48c3-b1a8-0f481ef37a50|9|HEMARESP|Hematologic Response|RECICL|[?]|L/L|MRD NEGATIVITY|1|nU/cL|URANYL ACETATE STAIN||||INTERVIEWER|FORENSIC PATHOLOGIST|Y|5|Visit_5|90|3|FOLLOW-UP|2020-08-26|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-31|P1Y2M10DT2H30M|UNKNOWN|2020-06-18|ONGOING|2020-07-25
e|RS|383d3f30-14b7-48c3-b1a8-0f481ef37a50|10|NTNERESP|Non-Target Non-Enhancing Response|GUPPY OVARIAN CANCER 2002|[?]|U/g/day|PDu|1|mL/h|CINEANGIOGRAPHY||||INVESTIGATOR|MICROSCOPIST 3|U|5|Visit_5|90|2|TREATMENT|2020-08-26|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-31|P1Y2M10DT2H30M|AFTER|2020-06-22|ONGOING|2020-07-03
e|RS|b4f81b74-fee9-4544-9404-206d931ed8e5|1|STRUSTAT|Steroid Use Status|KEAM BREAST CANCER 2013|[?]|mg/mol|PD-CT|1|10^3 organisms|LIGHT MICROSCOPY||||VENDOR|DERMATOLOGIST|Y|1|Visit_1|10|4|TREATMENT|2020-10-18|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-02|P1Y2M10DT2H30M|COINCIDENT|2020-10-30|ONGOING|2020-11-10
e|RS|b4f81b74-fee9-4544-9404-206d931ed8e5|2|PATHRESP|Pathologic Response|PCWG SCHER PROSTATE CANCER 2008|[?]|vg/dose|NOT ALL EVALUATED|1|PNU/mL|CALIPER MEASUREMENT METHOD||Y||FRIEND|MICROSCOPIST 3|NA|1|Visit_1|10|5|SCREENING|2020-10-18|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-02|P1Y2M10DT2H30M|COINCIDENT|2020-12-01|COINCIDENT|2021-01-08
e|RS|b4f81b74-fee9-4544-9404-206d931ed8e5|3|CLINRESP|Clinical Response|CHESON MALIGNANT LYMPHOMA 2007|||UNFAVORABLE RESPONSE|1|mmol/min/kPa|CALCULATION||Y|Y|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|Y|2|Visit_2|25|7|TREATMENT|2020-11-02|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-07|P1Y2M10DT2H30M|BEFORE|2020-11-19|AFTER|2020-11-20
e|RS|b4f81b74-fee9-4544-9404-206d931ed8e5|4|BONERESP|Bone Response|SCHER PROSTATE CANCER 2011|[?]|deg/mm|PSA PROGRESSION|1|10^6/Ejaculate U|FLUORESCENT SPOT TEST|Y|Y||DOMESTIC PARTNER|RATER 2|N|2|Visit_2|25|7|TREATMENT|2020-11-02|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-07|P1Y2M10DT2H30M|COINCIDENT|2020-11-05|ONGOING|2020-12-15
e|RS|b4f81b74-fee9-4544-9404-206d931ed8e5|5|SPLNRESP|Spleen Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|mg|MRD NEGATIVITY|1|um|LIGHT SCATTERING SPECTROSCOPY||||CLINICAL RESEARCH COORDINATOR|READER 1|NA|3|Visit_3|40|5|WASHOUT|2020-11-17|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-03|P1Y2M10DT2H30M|UNKNOWN|2020-12-09|BEFORE|2021-01-15
e|RS|b4f81b74-fee9-4544-9404-206d931ed8e5|6|ANATRESP|Anatomic Response|CHESON NON-HODGKINS LYMPHOMA 1999|||PD-CT|1|L/h/m2|CONTRAST ENHANCED PET SCAN||Y|Y|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 1|U|3|Visit_3|40|1|WASHOUT|2020-11-17|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-03|P1Y2M10DT2H30M|COINCIDENT|2020-12-17|COINCIDENT|2021-01-02
e|RS|b4f81b74-fee9-4544-9404-206d931ed8e5|7|DRCRIND|Disease Recurrence Indicator|MONTSERRAT CLL 1989|[?]|g|RELAPSED DISEASE FROM CR OR PR|1|CCID 50/dose|ECHOCARDIOGRAPHY||Y||HEALTH CARE PROFESSIONAL|READER 2|NA|4|Visit_4|65|4|SCREENING|2020-12-12|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-29|P1Y2M10DT2H30M|COINCIDENT|2020-10-16|AFTER|2020-12-11
e|RS|b4f81b74-fee9-4544-9404-206d931ed8e5|8|CPRFSTAT|Clinical Performance Status|RECICL|[?]|pL|CR-CT|1|CFU/mL|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS||||PARENT|READER 3|Y|4|Visit_4|65|7|TREATMENT|2020-12-12|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-29|P1Y2M10DT2H30M|UNKNOWN|2020-10-20|COINCIDENT|2020-12-27
e|RS|b4f81b74-fee9-4544-9404-206d931ed8e5|9|NTRGRESP|Non-target Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|ms/mmHg|CYTOGENETIC PR|1|ppb|COULOMETRIC TITRATION|Y|Y||SIBLING|RADIOLOGIST 1|Y|5|Visit_5|90|2|TREATMENT|2021-01-06|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-22|P1Y2M10DT2H30M|AFTER|2020-10-25|COINCIDENT|2020-11-13
e|RS|b4f81b74-fee9-4544-9404-206d931ed8e5|10|BONERESP|Bone Response|IWG CHESON MDS 2006|[?]|10^9 organisms/g|EQUIVOCAL|1|ug/kg/h|MICROPARTICLE ENZYME IMMUNOASSAY||||FAMILY MEMBER|ONCOLOGIST 1|N|5|Visit_5|90|7|TREATMENT|2021-01-06|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-22|P1Y2M10DT2H30M|UNKNOWN|2020-10-14|ONGOING|2020-12-23
e|RS|9e69b457-20db-45e5-a535-0cd8ac102fea|1|HEMARESP|Hematologic Response|DOHNER AML 2010|[?]|mmol/min/kPa|iCR|1|MESF|MAGNETIC RESONANCE ELASTOGRAPHY||||CHILD|OPHTHALMOLOGIST|U|1|Visit_1|10|5|TREATMENT|2020-06-07|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-23|P1Y2M10DT2H30M|UNKNOWN|2020-07-27|BEFORE|2020-08-16
e|RS|9e69b457-20db-45e5-a535-0cd8ac102fea|2|TRGRESP|Target Response|IWG CHESON MDS 2000|||QUANTIFIABLE MRD POSITIVITY|1|nmol|IMMUNE REPERTOIRE DEEP SEQUENCING|||Y|VENDOR|FORENSIC PATHOLOGIST|Y|1|Visit_1|10|2|WASHOUT|2020-06-07|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-23|P1Y2M10DT2H30M|UNKNOWN|2020-05-31|ONGOING|2020-06-23
e|RS|9e69b457-20db-45e5-a535-0cd8ac102fea|3|METBRESP|Metabolic Response|CHOI GIST 2008|[?]|mmol/mol|DECREASED|1|dmol|PANENDOSCOPY||||INVESTIGATOR|PEDIATRIC NEUROLOGIST|N|2|Visit_2|25|4|TREATMENT|2020-06-22|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-18|P1Y2M10DT2H30M|BEFORE|2020-08-20|ONGOING|2020-09-01
e|RS|9e69b457-20db-45e5-a535-0cd8ac102fea|4|MRDRESP|Minimal Residual Disease Response|RECIST 1.0|[?]|Hz/s|NON-iCR/NON-iUPD|1|APL U/mL|DARK FIELD MICROSCOPY|Y|||PROXY|READER 1|Y|2|Visit_2|25|5|TREATMENT|2020-06-22|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-18|P1Y2M10DT2H30M|AFTER|2020-07-28|COINCIDENT|2020-08-23
e|RS|9e69b457-20db-45e5-a535-0cd8ac102fea|5|BESTRESP|Best Overall Response|GUPPY OVARIAN CANCER 2002|[?]|deg/s|UNEQUIVOCAL|1|dpm/100mg|PERIPHERAL ANGIOGRAPHY|Y|Y||SPOUSE|RADIOLOGIST|N|3|Visit_3|40|5|TREATMENT|2020-07-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-20|P1Y2M10DT2H30M|AFTER|2020-08-10|AFTER|2020-08-18
e|RS|9e69b457-20db-45e5-a535-0cd8ac102fea|6|HEMARESP|Hematologic Response|CHESON CLL 2006|[?]|mL/sec/1.73m2|MAJOR PATHOLOGIC RESPONSE|1|10^9 organisms/g|PET SCAN||Y||SIBLING|ONCOLOGIST 2|NA|3|Visit_3|40|6|WASHOUT|2020-07-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-20|P1Y2M10DT2H30M|AFTER|2020-08-08|COINCIDENT|2020-08-23
e|RS|9e69b457-20db-45e5-a535-0cd8ac102fea|7|BONERESP|Bone Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|mg/L FEU|cCR|1|MdFI|AUSCULTATION||||ADJUDICATION COMMITTEE|NEUROLOGIST 1|NA|4|Visit_4|65|1|FOLLOW-UP|2020-08-01|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-04|P1Y2M10DT2H30M|BEFORE|2020-07-17|ONGOING|2020-07-29
e|RS|9e69b457-20db-45e5-a535-0cd8ac102fea|8|NTRGRESP|Non-target Response|JACINTO CERVICAL CANCER 2007|||FAVORABLE RESPONSE|1|CAN|SLOAN LETTER EYE CHART 100%|||Y|CAREGIVER|MICROSCOPIST 2|N|4|Visit_4|65|4|SCREENING|2020-08-01|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-04|P1Y2M10DT2H30M|UNKNOWN|2020-08-22|COINCIDENT|2020-08-28
e|RS|9e69b457-20db-45e5-a535-0cd8ac102fea|9|HEMARESP|Hematologic Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|IU/day|CHR|1|U/kg/day|CONGO RED STAIN|Y|||INDEPENDENT ASSESSOR|MICROSCOPIST|NA|5|Visit_5|90|6|SCREENING|2020-08-26|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-10|P1Y2M10DT2H30M|AFTER|2020-06-24|BEFORE|2020-07-03
e|RS|9e69b457-20db-45e5-a535-0cd8ac102fea|10|BONERESP|Bone Response|FAROOQUI SUPP CLL 2014|||NON-PD|1|Gy/h|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY||Y|Y|STUDY SUBJECT|UROLOGIST|Y|5|Visit_5|90|4|TREATMENT|2020-08-26|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-10|P1Y2M10DT2H30M|UNKNOWN|2020-06-10|AFTER|2020-08-07
e|RS|14211798-ddf6-47c8-bd9d-056d95bad8ff|1|CYTORESP|Cytogenetic Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|Siemens|CR|1|mL/cage/day|MICROSCOPY|Y|Y||SIGNIFICANT OTHER|PATHOLOGIST 2|N|1|Visit_1|10|2|SCREENING|2020-09-26|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-30|P1Y2M10DT2H30M|AFTER|2020-12-22|AFTER|2020-12-23
e|RS|14211798-ddf6-47c8-bd9d-056d95bad8ff|2|MRDRESP|Minimal Residual Disease Response|PETIT BREAST CANCER 2001|[?]|mL/cm|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|10^6 DNA copies/mL|PATHOLOGICAL EVALUATION||||ADJUDICATION COMMITTEE|READER 2|N|1|Visit_1|10|3|WASHOUT|2020-09-26|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-30|P1Y2M10DT2H30M|AFTER|2020-12-10|BEFORE|2020-12-17
e|RS|14211798-ddf6-47c8-bd9d-056d95bad8ff|3|OVRLRESP|Overall Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|ug/kg/min|PDu|1|msec|ELECTROCHEMILUMINESCENCE IMMUNOASSAY||Y||HEALTH CARE PROFESSIONAL|INTERNIST|U|2|Visit_2|25|2|TREATMENT|2020-10-11|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-10|P1Y2M10DT2H30M|BEFORE|2020-10-25|ONGOING|2020-12-05
e|RS|14211798-ddf6-47c8-bd9d-056d95bad8ff|4|MJPTHIND|Major Pathological Response Indicator|PCWG SCHER PROSTATE CANCER 2016|[?]|U.CARR|MOLECULAR CR|1|DAgU|KINETIC CHROMOGENIC ASSAY||||INTERVIEWER|ONCOLOGIST 1|Y|2|Visit_2|25|1|TREATMENT|2020-10-11|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-10|P1Y2M10DT2H30M|UNKNOWN|2020-10-06|ONGOING|2020-10-14
e|RS|14211798-ddf6-47c8-bd9d-056d95bad8ff|5|CYTORESP|Cytogenetic Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|mg/m2/day|CHR|1|Shock Wave|ATOMIC ABSORPTION SPECTROMETRY||||SIBLING|MICROSCOPIST 2|U|3|Visit_3|40|6|TREATMENT|2020-10-26|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-19|P1Y2M10DT2H30M|UNKNOWN|2020-12-13|BEFORE|2020-12-14
e|RS|14211798-ddf6-47c8-bd9d-056d95bad8ff|6|PATHRESP|Pathologic Response|NCCN ALL MRD 2014|[?]|ppb|PSEUDOPROGRESSION|1|uV2|NEXT GENERATION SEQUENCING||||HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|NA|3|Visit_3|40|1|TREATMENT|2020-10-26|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-19|P1Y2M10DT2H30M|COINCIDENT|2020-12-23|AFTER|2020-12-24
e|RS|14211798-ddf6-47c8-bd9d-056d95bad8ff|7|NTRGRESP|Non-target Response|RECICL|||PD-CT|1|mL/s/m2|DISK DIFFUSION||Y|Y|INTERVIEWER|ENDOCRINOLOGIST|NA|4|Visit_4|65|6|FOLLOW-UP|2020-11-20|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-22|P1Y2M10DT2H30M|AFTER|2020-12-05|ONGOING|2020-12-23
e|RS|14211798-ddf6-47c8-bd9d-056d95bad8ff|8|TMRESP|Tumor Marker Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|Bq/uL|CRi|1|mL|POLYGRAPHY||||CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 2|N|4|Visit_4|65|7|TREATMENT|2020-11-20|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-22|P1Y2M10DT2H30M|BEFORE|2020-10-25|BEFORE|2020-12-23
e|RS|14211798-ddf6-47c8-bd9d-056d95bad8ff|9|DRCRIND|Disease Recurrence Indicator|MRECIST LENCIONI LIVER CANCER 2010|[?]|ug/h|VGPR|1|Arbitrary U|NUCLEIC ACID SEQUENCING||||NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|Y|5|Visit_5|90|5|FOLLOW-UP|2020-12-15|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-03|P1Y2M10DT2H30M|COINCIDENT|2020-12-21|ONGOING|2020-12-22
e|RS|14211798-ddf6-47c8-bd9d-056d95bad8ff|10|CYTORESP|Cytogenetic Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|mmHg/sec|HI-N|1|nmol/L/h|PHASE CONTRAST MICROSCOPY||||VENDOR|ONCOLOGIST 2|Y|5|Visit_5|90|3|TREATMENT|2020-12-15|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-03|P1Y2M10DT2H30M|AFTER|2020-11-07|COINCIDENT|2020-12-03
e|RS|63f3194e-9b88-491a-9a68-19109ed86e2b|1|NEWLIND|New Lesion Indicator|IRANO 2015|||VGPR|1|ug/m2/h|RADIOIMMUNOPRECIPITATION ASSAY|||Y|ADJUDICATOR|NEUROLOGIST 1|Y|1|Visit_1|10|7|FOLLOW-UP|2020-06-10|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-18|P1Y2M10DT2H30M|UNKNOWN|2020-06-08|ONGOING|2020-07-04
e|RS|63f3194e-9b88-491a-9a68-19109ed86e2b|2|MRPHRESP|Morphologic Response|KUKER LYMPHOMA 2005|[?]|mL/s|IMPROVED|1|Bq/kg|COULOMETRIC TITRATION||Y||PARENT|OPHTHALMOLOGIST|U|1|Visit_1|10|5|TREATMENT|2020-06-10|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-18|P1Y2M10DT2H30M|UNKNOWN|2020-06-06|AFTER|2020-06-07
e|RS|63f3194e-9b88-491a-9a68-19109ed86e2b|3|MRDRESP|Minimal Residual Disease Response|HARTMAN PANCREATIC CANCER 2012|[?]|IU/kg/h|PD FROM PR|1|10^6 IU|AMSLER GRID||Y||CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 1|N|2|Visit_2|25|7|TREATMENT|2020-06-25|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-28|P1Y2M10DT2H30M|UNKNOWN|2020-06-13|ONGOING|2020-08-12
e|RS|63f3194e-9b88-491a-9a68-19109ed86e2b|4|TRGRESP|Target Response|PERCIST|[?]|ks|HI-P|1|CFU/g|OLIGO ACGH||||NON-HEALTH CARE PROFESSIONAL|HEMATOLOGIST|U|2|Visit_2|25|5|FOLLOW-UP|2020-06-25|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-28|P1Y2M10DT2H30M|AFTER|2020-07-23|ONGOING|2020-08-02
e|RS|63f3194e-9b88-491a-9a68-19109ed86e2b|5|METSIND|Metastatic Indicator|EBMT BLADE MYELOMA 1998|[?]|IU|ABSENT MORPHOLOGIC RESPONSE|1|MESF|NEXT GENERATION SEQUENCING|Y|||NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|Y|3|Visit_3|40|6|TREATMENT|2020-07-10|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-14|P1Y2M10DT2H30M|COINCIDENT|2020-09-04|AFTER|2020-09-06
e|RS|63f3194e-9b88-491a-9a68-19109ed86e2b|6|NEWLWIND|New Lesion Worsening Indicator|WHO BREAST CANCER 2006|[?]|mL/breath|sCR|1|pg/cell|GC/MS-EI|Y|||VENDOR|NEUROLOGIST 2|N|3|Visit_3|40|5|TREATMENT|2020-07-10|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-14|P1Y2M10DT2H30M|UNKNOWN|2020-07-15|BEFORE|2020-08-15
e|RS|63f3194e-9b88-491a-9a68-19109ed86e2b|7|NTNERESP|Non-Target Non-Enhancing Response|KEAM BREAST CANCER 2013|||NON-PD|1|10^4/hpf|KARYOTYPING|||Y|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 1|Y|4|Visit_4|65|5|WASHOUT|2020-08-04|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-05|P1Y2M10DT2H30M|AFTER|2020-08-05|COINCIDENT|2020-08-28
e|RS|63f3194e-9b88-491a-9a68-19109ed86e2b|8|LIVRRESP|Liver Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|MPL U|QUANTIFIABLE MRD POSITIVITY|1|mL/beat|NUCLEIC ACID SEQUENCING||Y||SIBLING|ONCOLOGIST 1|U|4|Visit_4|65|6|FOLLOW-UP|2020-08-04|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-05|P1Y2M10DT2H30M|COINCIDENT|2020-07-29|COINCIDENT|2020-08-07
e|RS|63f3194e-9b88-491a-9a68-19109ed86e2b|9|MJPTHIND|Major Pathological Response Indicator|HAMAOKA BREAST CANCER 2010|[?]|Osm|NON-iCR/NON-iUPD|1|log10 TCID 50/mL|FARNSWORTH-MUNSELL 100 HUE TEST||||PARENT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|5|Visit_5|90|1|TREATMENT|2020-08-29|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-03|P1Y2M10DT2H30M|BEFORE|2020-06-02|AFTER|2020-07-17
e|RS|63f3194e-9b88-491a-9a68-19109ed86e2b|10|BESTRESP|Best Overall Response|RANO|[?]|CUP|iSD|1|mL/day|PHOTOMETRY|Y|||VENDOR|ADJUDICATOR|U|5|Visit_5|90|4|WASHOUT|2020-08-29|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-03|P1Y2M10DT2H30M|BEFORE|2020-07-20|COINCIDENT|2020-09-05
e|RS|b6208258-d7c2-4dde-addf-4677946ab165|1|LIVRRESP|Liver Response|RECIST 1.0|||TREATMENT FAILURE|1|mmol/min/kPa/L|AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT|||Y|INTERVIEWER|RADIOLOGIST 1|N|1|Visit_1|10|4|TREATMENT|2020-09-20|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-05|P1Y2M10DT2H30M|BEFORE|2020-09-22|COINCIDENT|2020-10-28
e|RS|b6208258-d7c2-4dde-addf-4677946ab165|2|OVRLRESP|Overall Response|AJCC V8|[?]|mL/animal/day|PR-CT|1|mL/cm H2O|IMMUNOFLUORESCENT STAIN|Y|||VENDOR|ONCOLOGIST 2|N|1|Visit_1|10|2|TREATMENT|2020-09-20|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-05|P1Y2M10DT2H30M|COINCIDENT|2020-12-07|ONGOING|2020-12-09
e|RS|b6208258-d7c2-4dde-addf-4677946ab165|3|CPRFSTAT|Clinical Performance Status|SHINDOH COLORECTAL CANCER 2013|[?]|TRANSDUCING UNIT/mL|RELAPSED DISEASE FROM CR|1|TCID 50/dose|IMMUNOPRECIPITATION||||DOMESTIC PARTNER|INTERNIST|N|2|Visit_2|25|1|SCREENING|2020-10-05|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-25|P1Y2M10DT2H30M|UNKNOWN|2020-12-15|COINCIDENT|2020-12-18
e|RS|b6208258-d7c2-4dde-addf-4677946ab165|4|NEWLWIND|New Lesion Worsening Indicator|LUGANO CLASSIFICATION|||PSEUDORESPONSE|1|um2|GC/MS/MS|Y||Y|CHILD|ONCOLOGIST 1|N|2|Visit_2|25|2|WASHOUT|2020-10-05|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-25|P1Y2M10DT2H30M|UNKNOWN|2020-09-12|BEFORE|2020-09-27
e|RS|b6208258-d7c2-4dde-addf-4677946ab165|5|MRPHRESP|Morphologic Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|||IMMUNOPHENOTYPIC CR|1|10^9/g|NUCLEIC ACID AMPLIFICATION TEST|||Y|FAMILY MEMBER|RADIOLOGIST 1|N|3|Visit_3|40|6|TREATMENT|2020-10-20|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-19|P1Y2M10DT2H30M|UNKNOWN|2020-11-05|COINCIDENT|2020-12-13
e|RS|b6208258-d7c2-4dde-addf-4677946ab165|6|MRDIND|Minimal Residual Disease Indicator|HAMAOKA BREAST CANCER 2010|[?]|CCID 50/mL|iSD|1|Ci/mg|INTERRUPTER TECHNIQUE||||INDEPENDENT ASSESSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|3|Visit_3|40|2|SCREENING|2020-10-20|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-19|P1Y2M10DT2H30M|COINCIDENT|2020-12-10|AFTER|2020-12-11
e|RS|b6208258-d7c2-4dde-addf-4677946ab165|7|CLINRESP|Clinical Response|PRINCE TCELL LYMPHOMA 2010|[?]|nmol/kg/day|CR|1|ug/m2|U-HPLC/MS/MS||||STUDY SUBJECT|READER 2|Y|4|Visit_4|65|7|TREATMENT|2020-11-14|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-13|P1Y2M10DT2H30M|COINCIDENT|2020-09-13|COINCIDENT|2020-10-02
e|RS|b6208258-d7c2-4dde-addf-4677946ab165|8|NTNERESP|Non-Target Non-Enhancing Response|RECIST 1.1|||iCR|1|g/cage|NO INFORMATION|Y|Y|Y|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST|U|4|Visit_4|65|1|TREATMENT|2020-11-14|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-13|P1Y2M10DT2H30M|AFTER|2020-10-02|AFTER|2020-11-20
e|RS|b6208258-d7c2-4dde-addf-4677946ab165|9|NTRGRESP|Non-target Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|APL U|DECREASED|1|km|MYELOPEROXIDASE STAIN||||GUARDIAN|PHYSIOTHERAPIST|N|5|Visit_5|90|5|TREATMENT|2020-12-09|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-25|P1Y2M10DT2H30M|AFTER|2020-10-26|BEFORE|2020-12-06
e|RS|b6208258-d7c2-4dde-addf-4677946ab165|10|LIVRRESP|Liver Response|MASS|[?]|/10^3|NON-iCR/NON-iUPD|1|10^6 IU/mL|THIN SMEAR||||GUARDIAN|RADIOLOGIST 1|Y|5|Visit_5|90|3|TREATMENT|2020-12-09|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-25|P1Y2M10DT2H30M|AFTER|2020-09-19|COINCIDENT|2020-10-10
e|RS|a669a7b9-2034-4bca-aa80-0371c5fb46d3|1|BESTRESP|Best Overall Response|CHOI GIST 2008|[?]|Rad|SD-CT|1|ug/m2|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|Y|Y||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 3|U|1|Visit_1|10|5|TREATMENT|2021-01-26|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-03|P1Y2M10DT2H30M|UNKNOWN|2021-02-15|AFTER|2021-03-07
e|RS|a669a7b9-2034-4bca-aa80-0371c5fb46d3|2|TRGRESP|Target Response|IWG CHESON MDS 2006|[?]|aMFI|CR-CT|1|/min|WHOLE TRANSCRIPTOME SEQUENCING||||HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|U|1|Visit_1|10|2|SCREENING|2021-01-26|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-03|P1Y2M10DT2H30M|AFTER|2021-03-14|ONGOING|2021-04-03
e|RS|a669a7b9-2034-4bca-aa80-0371c5fb46d3|3|NTLWIND|Non-Target Lesion Worsening Indicator|HAMAOKA BREAST CANCER 2010|||QUANTIFIABLE MRD POSITIVITY|1|ukat/10^12 RBC|SPIRAL CT SCAN WITHOUT CONTRAST|||Y|HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|NA|2|Visit_2|25|1|SCREENING|2021-02-10|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-08|P1Y2M10DT2H30M|UNKNOWN|2021-03-28|COINCIDENT|2021-04-09
e|RS|a669a7b9-2034-4bca-aa80-0371c5fb46d3|4|LIVRRESP|Liver Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|||PMR|1|mg/mL/day|HIGH LEVEL AMINOGLYCOSIDE SCREEN|Y|Y|Y|INVESTIGATOR|NEUROLOGIST 1|NA|2|Visit_2|25|6|TREATMENT|2021-02-10|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-08|P1Y2M10DT2H30M|UNKNOWN|2021-03-02|BEFORE|2021-03-04
e|RS|a669a7b9-2034-4bca-aa80-0371c5fb46d3|5|NTRGRESP|Non-target Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|mV*min|CR-CT|1|Shock Wave|FISH||||FAMILY MEMBER|ADJUDICATOR|U|3|Visit_3|40|3|WASHOUT|2021-02-25|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-27|P1Y2M10DT2H30M|BEFORE|2021-03-30|AFTER|2021-04-07
e|RS|a669a7b9-2034-4bca-aa80-0371c5fb46d3|6|BONERESP|Bone Response|iRECIST|||SD|1|APS U|ORCHIDOMETERY|||Y|FRIEND|PATHOLOGIST 2|Y|3|Visit_3|40|6|WASHOUT|2021-02-25|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-27|P1Y2M10DT2H30M|AFTER|2021-02-18|ONGOING|2021-02-24
e|RS|a669a7b9-2034-4bca-aa80-0371c5fb46d3|7|HEMARESP|Hematologic Response|PCWG SCHER PROSTATE CANCER 2008|[?]|Hounsfield Unit|OPTIMAL MORPHOLOGIC RESPONSE|1|U/m2/day|AUTOMATED COUNT||Y||STUDY SUBJECT|NEUROLOGIST 2|Y|4|Visit_4|65|4|TREATMENT|2021-03-22|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-19|P1Y2M10DT2H30M|COINCIDENT|2021-03-16|COINCIDENT|2021-03-17
e|RS|a669a7b9-2034-4bca-aa80-0371c5fb46d3|8|NEWLPROG|New Lesion Progression|DOHNER AML 2010|[?]|CAN|IMMUNOPHENOTYPIC CR|1|cL|FLOW CYTOMETRY||||HEALTH CARE PROFESSIONAL|INTERNIST|NA|4|Visit_4|65|7|WASHOUT|2021-03-22|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-19|P1Y2M10DT2H30M|UNKNOWN|2021-01-26|ONGOING|2021-03-27
e|RS|a669a7b9-2034-4bca-aa80-0371c5fb46d3|9|NTNERESP|Non-Target Non-Enhancing Response|KUMAR IMWG 2016|[?]|Weber|cPR|1|cpm|NUCLEIC ACID AMPLIFICATION TEST||Y||FAMILY MEMBER|HEMATOLOGIST|U|5|Visit_5|90|5|TREATMENT|2021-04-16|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-08|P1Y2M10DT2H30M|BEFORE|2021-03-21|COINCIDENT|2021-04-23
e|RS|a669a7b9-2034-4bca-aa80-0371c5fb46d3|10|CYTORESP|Cytogenetic Response|CHESON CLL 2012|[?]|ft|MRD RELAPSE|1|Shock Wave|CONFOCAL MICROSCOPY||||INDEPENDENT ASSESSOR|ADJUDICATOR 3|U|5|Visit_5|90|4|TREATMENT|2021-04-16|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-08|P1Y2M10DT2H30M|COINCIDENT|2021-04-18|BEFORE|2021-04-21
e|RS|e148c13d-ee41-4503-a7e5-397dd6155f04|1|CYTORESP|Cytogenetic Response|MURPHY PROSTATE CANCER 1980|[?]|usec|INCREASED|1|IU/dL|TEST STRIP||Y||FRIEND|NEUROLOGIST 1|NA|1|Visit_1|10|2|TREATMENT|2020-07-18|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-14|P1Y2M10DT2H30M|UNKNOWN|2020-10-08|BEFORE|2020-10-11
e|RS|e148c13d-ee41-4503-a7e5-397dd6155f04|2|NEWLPROG|New Lesion Progression|PCWG SCHER PROSTATE CANCER 2016|[?]|mL|MORPHOLOGIC LEUKEMIA-FREE STATE|1|kBq/uL|DROPLET DIGITAL PCR||Y||CLINICAL STUDY SPONSOR|OPHTHALMOLOGIST|N|1|Visit_1|10|3|SCREENING|2020-07-18|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-14|P1Y2M10DT2H30M|BEFORE|2020-07-15|BEFORE|2020-08-18
e|RS|e148c13d-ee41-4503-a7e5-397dd6155f04|3|NTNERESP|Non-Target Non-Enhancing Response|PROTOCOL DEFINED RESPONSE CRITERIA|||CYTOGENETIC NO RESPONSE|1|pt_br|AUSCULTATION|||Y|INVESTIGATOR|RADIOLOGIST 2|N|2|Visit_2|25|5|FOLLOW-UP|2020-08-02|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-10|P1Y2M10DT2H30M|AFTER|2020-08-19|COINCIDENT|2020-10-02
e|RS|e148c13d-ee41-4503-a7e5-397dd6155f04|4|NEWLIND|New Lesion Indicator|PALUMBO MULTIPLE MYELOMA 2009|[?]|10^9 CFU/g|CR-CT|1|nkat|BAC ACGH||||ADJUDICATOR|MICROSCOPIST 2|U|2|Visit_2|25|4|WASHOUT|2020-08-02|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-10|P1Y2M10DT2H30M|BEFORE|2020-07-13|AFTER|2020-07-31
e|RS|e148c13d-ee41-4503-a7e5-397dd6155f04|5|MRDIND|Minimal Residual Disease Indicator|CHESON CLL 2006|[?]|Henry|mCR|1|%|SICKLE CELL SOLUBILITY TEST|Y|Y||SIBLING|NEUROLOGIST|N|3|Visit_3|40|6|TREATMENT|2020-08-17|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-20|P1Y2M10DT2H30M|BEFORE|2020-07-20|ONGOING|2020-08-10
e|RS|e148c13d-ee41-4503-a7e5-397dd6155f04|6|PATHRESP|Pathologic Response|BRUGGEMANN MRD 2010|[?]|ugEq|RELAPSED DISEASE FROM CR|1|log10 IU/mL|FLUORESCENT SPOT TEST||||ADJUDICATOR|MICROSCOPIST 1|Y|3|Visit_3|40|2|TREATMENT|2020-08-17|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-20|P1Y2M10DT2H30M|COINCIDENT|2020-08-27|ONGOING|2020-09-19
e|RS|e148c13d-ee41-4503-a7e5-397dd6155f04|7|MJPTHIND|Major Pathological Response Indicator|CHESON NON-HODGKINS LYMPHOMA 1999|||TREATMENT FAILURE|1|BAG|MEDIASTINOSCOPY|Y||Y|INDEPENDENT ASSESSOR|PATHOLOGIST|U|4|Visit_4|65|5|TREATMENT|2020-09-11|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-03|P1Y2M10DT2H30M|UNKNOWN|2020-07-17|ONGOING|2020-08-02
e|RS|e148c13d-ee41-4503-a7e5-397dd6155f04|8|RDIORESP|Radiologic Response|PETIT BREAST CANCER 2001|[?]|BAR|DECREASED|1|mmHg*min/L|IN VITRO GENE EXPRESSION ASSAY||Y||CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST|U|4|Visit_4|65|1|FOLLOW-UP|2020-09-11|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-03|P1Y2M10DT2H30M|UNKNOWN|2020-10-12|BEFORE|2020-10-13
e|RS|e148c13d-ee41-4503-a7e5-397dd6155f04|9|BONERESP|Bone Response|PCWG SCHER PROSTATE CANCER 2008|[?]|/wk|MOLECULAR CR|1|umol/mg/min|MRI WITHOUT CONTRAST||||CLINICAL RESEARCH ASSOCIATE|FORENSIC PATHOLOGIST|Y|5|Visit_5|90|5|TREATMENT|2020-10-06|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-29|P1Y2M10DT2H30M|UNKNOWN|2020-09-05|AFTER|2020-10-03
e|RS|e148c13d-ee41-4503-a7e5-397dd6155f04|10|PATHRESP|Pathologic Response|IWC HALLEK CLL 2008|[?]|IU/g|mCR|1|mm/2h|GEL ELECTROPHORESIS||||PROXY|ADJUDICATOR 1|NA|5|Visit_5|90|7|TREATMENT|2020-10-06|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-29|P1Y2M10DT2H30M|AFTER|2020-08-03|AFTER|2020-09-02
e|RS|815de94a-f259-41ee-8951-8df150184a25|1|SYMPTDTR|Symptomatic Deterioration|CHESON MALIGNANT LYMPHOMA 2007|[?]|bel|HI-P|1|10^6/g|CAPILLARY ELECTROPHORESIS||||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 3|NA|1|Visit_1|10|4|WASHOUT|2020-07-07|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-29|P1Y2M10DT2H30M|BEFORE|2020-09-16|ONGOING|2020-09-26
e|RS|815de94a-f259-41ee-8951-8df150184a25|2|METBRESP|Metabolic Response|RECICL|[?]|anti-Xa IU/mL|iCPD|1|Ci|DIGITAL PCR||||HEALTH CARE PROFESSIONAL|UROLOGIST|NA|1|Visit_1|10|5|TREATMENT|2020-07-07|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-29|P1Y2M10DT2H30M|UNKNOWN|2020-08-06|COINCIDENT|2020-08-11
e|RS|815de94a-f259-41ee-8951-8df150184a25|3|MOLRESP|Molecular Response|PETIT BREAST CANCER 2001|[?]|SYRINGE|CYTOGENETIC PR|1|10^12 IU/L|CELL CYTOTOXICITY NEUTRALIZATION ASSAY||||STUDY SUBJECT|NEUROLOGIST|U|2|Visit_2|25|5|TREATMENT|2020-07-22|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-10|P1Y2M10DT2H30M|UNKNOWN|2020-09-13|ONGOING|2020-09-15
e|RS|815de94a-f259-41ee-8951-8df150184a25|4|CPRFSTAT|Clinical Performance Status|SCHWARZ CERVICAL CANCER 2009|[?]|OD Unit|ABSENT MORPHOLOGIC RESPONSE|1|10^7 TCID 50/dose|SIZE EXCLUSION CHROMATOGRAPHY|Y|Y||FRIEND|RADIOLOGIST|N|2|Visit_2|25|3|WASHOUT|2020-07-22|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-10|P1Y2M10DT2H30M|UNKNOWN|2020-09-11|AFTER|2020-09-20
e|RS|815de94a-f259-41ee-8951-8df150184a25|5|NEWLPROG|New Lesion Progression|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|10^4 CFU|INCREASED|1|cP|PHASE CONTRAST MICROSCOPY|Y|||ADJUDICATION COMMITTEE|ADJUDICATOR 3|Y|3|Visit_3|40|6|TREATMENT|2020-08-06|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-14|P1Y2M10DT2H30M|UNKNOWN|2020-09-06|BEFORE|2020-09-28
e|RS|815de94a-f259-41ee-8951-8df150184a25|6|METBRESP|Metabolic Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|uIU/L|MRD RELAPSE|1|umol/L/min|MYELOPEROXIDASE STAIN||||FAMILY MEMBER|ADJUDICATOR 3|N|3|Visit_3|40|2|WASHOUT|2020-08-06|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-14|P1Y2M10DT2H30M|COINCIDENT|2020-07-08|AFTER|2020-09-15
e|RS|815de94a-f259-41ee-8951-8df150184a25|7|NEWLIND|New Lesion Indicator|EBMT BLADE MYELOMA 1998|[?]|sec|iUPD|1|%/s|REFLECTANCE SPECTROSCOPY||||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 1|N|4|Visit_4|65|4|TREATMENT|2020-08-31|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-23|P1Y2M10DT2H30M|BEFORE|2020-09-26|BEFORE|2020-10-04
e|RS|815de94a-f259-41ee-8951-8df150184a25|8|HEMARESP|Hematologic Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|||CR|1|mL/h|HPLC-UV|||Y|SIGNIFICANT OTHER|READER|NA|4|Visit_4|65|2|TREATMENT|2020-08-31|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-23|P1Y2M10DT2H30M|AFTER|2020-09-08|ONGOING|2020-09-10
e|RS|815de94a-f259-41ee-8951-8df150184a25|9|ANATRESP|Anatomic Response|CHESON LYMPHOMA 2008|[?]|MnFI|CHR|1|PIXELS/in|FREEZING POINT DEPRESSION||||INDEPENDENT ASSESSOR|ONCOLOGIST|U|5|Visit_5|90|5|TREATMENT|2020-09-25|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-08|P1Y2M10DT2H30M|BEFORE|2020-09-23|COINCIDENT|2020-09-25
e|RS|815de94a-f259-41ee-8951-8df150184a25|10|NTNERESP|Non-Target Non-Enhancing Response|NCIWG CHESON CLL 1996|[?]|copies/mL|pCR|1|SYRINGE|ISHIHARA COLOR PLATES||||SIGNIFICANT OTHER|OPTOMETRIST|N|5|Visit_5|90|1|TREATMENT|2020-09-25|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-08|P1Y2M10DT2H30M|AFTER|2020-08-16|COINCIDENT|2020-09-03
e|RS|c897cd09-0cbc-4a2f-a902-1c736a6c3a02|1|METBRESP|Metabolic Response|SCHER PROSTATE CANCER 2011|||cPR|1|10^7 CFU/mL|AUDIOMETRY|||Y|CLINICAL STUDY SPONSOR|ADJUDICATOR 3|N|1|Visit_1|10|3|WASHOUT|2020-05-16|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-19|P1Y2M10DT2H30M|COINCIDENT|2020-07-10|BEFORE|2020-08-08
e|RS|c897cd09-0cbc-4a2f-a902-1c736a6c3a02|2|MOLRESP|Molecular Response|NCIWG CHESON CLL 1996|[?]|mm/min|PD|1|fraction of 1|COULOMETRIC TITRATION||||INTERVIEWER|RADIOLOGIST|U|1|Visit_1|10|6|TREATMENT|2020-05-16|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-19|P1Y2M10DT2H30M|BEFORE|2020-05-12|BEFORE|2020-06-15
e|RS|c897cd09-0cbc-4a2f-a902-1c736a6c3a02|3|MRDIND|Minimal Residual Disease Indicator|LUGANO CLASSIFICATION|||OPTIMAL MORPHOLOGIC RESPONSE|1|mL/100g/min|ELLA|||Y|VENDOR|PATHOLOGIST|Y|2|Visit_2|25|5|TREATMENT|2020-05-31|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-09|P1Y2M10DT2H30M|UNKNOWN|2020-08-08|AFTER|2020-08-13
e|RS|c897cd09-0cbc-4a2f-a902-1c736a6c3a02|4|TMRESP|Tumor Marker Response|IWG CHESON AML 2003|[?]|C|PSA PROGRESSION|1|nU/cL|BALLPOINT PEN TECHNIQUE||||FAMILY MEMBER|OPHTHALMOLOGIST|U|2|Visit_2|25|4|TREATMENT|2020-05-31|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-09|P1Y2M10DT2H30M|UNKNOWN|2020-07-05|BEFORE|2020-08-07
e|RS|c897cd09-0cbc-4a2f-a902-1c736a6c3a02|5|NEWLWIND|New Lesion Worsening Indicator|DURIE MULTIPLE MYELOMA 2006|||PSA PROGRESSION|1|umol|CONTACT SPECULAR MICROSCOPY|||Y|SPOUSE|RATER|Y|3|Visit_3|40|4|TREATMENT|2020-06-15|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-03|P1Y2M10DT2H30M|BEFORE|2020-05-16|BEFORE|2020-06-16
e|RS|c897cd09-0cbc-4a2f-a902-1c736a6c3a02|6|CLINRESP|Clinical Response|IWC HALLEK CLL 2008|||IMMUNOPHENOTYPIC CR|1|umol/h/mmol|NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY||Y|Y|VENDOR|ENDOCRINOLOGIST|U|3|Visit_3|40|5|WASHOUT|2020-06-15|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-03|P1Y2M10DT2H30M|BEFORE|2020-06-08|AFTER|2020-07-07
e|RS|c897cd09-0cbc-4a2f-a902-1c736a6c3a02|7|BESTRESP|Best Overall Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|PFU/mL|WORSENED|1|uCi|MECHANICAL CLOT DETECTION||||CAREGIVER|ONCOLOGIST 1|Y|4|Visit_4|65|5|WASHOUT|2020-07-10|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-10|P1Y2M10DT2H30M|AFTER|2020-06-03|COINCIDENT|2020-07-13
e|RS|c897cd09-0cbc-4a2f-a902-1c736a6c3a02|8|NTERESP|Non-Target Enhancing Response|RANO|||MRD NEGATIVITY|1|eq|PALPATION|||Y|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 1|U|4|Visit_4|65|7|TREATMENT|2020-07-10|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-10|P1Y2M10DT2H30M|UNKNOWN|2020-06-10|AFTER|2020-07-19
e|RS|c897cd09-0cbc-4a2f-a902-1c736a6c3a02|9|BMIVLIND|Bone Marrow Involvement Indicator|AJCC V8|[?]|scm|MR|1|log10 IU/mL|MICROBIAL CONCENTRATION||Y||INTERVIEWER|HEMATOLOGIST|Y|5|Visit_5|90|6|SCREENING|2020-08-04|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-02|P1Y2M10DT2H30M|COINCIDENT|2020-05-18|BEFORE|2020-06-20
e|RS|c897cd09-0cbc-4a2f-a902-1c736a6c3a02|10|SPLNRESP|Spleen Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|||nPR|1|pmol/10^10 cells|CRYOSCOPY|||Y|STUDY SUBJECT|INTERNIST|U|5|Visit_5|90|4|SCREENING|2020-08-04|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-02|P1Y2M10DT2H30M|UNKNOWN|2020-07-25|COINCIDENT|2020-08-09
e|RS|d68e5fe0-ab34-4565-9e5d-6ff1f72217f1|1|LIVRRESP|Liver Response|WOLCHOK SOLID TUMORS 2009|[?]|lm|CYTOGENETIC PR|1|Bq|RAJI CELL RIA||Y||SPOUSE|MICROSCOPIST 1|N|1|Visit_1|10|4|FOLLOW-UP|2021-01-25|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-25|P1Y2M10DT2H30M|COINCIDENT|2021-02-14|BEFORE|2021-03-31
e|RS|d68e5fe0-ab34-4565-9e5d-6ff1f72217f1|2|ANATRESP|Anatomic Response|HARTMANN GERM CELL CANCER 2002|[?]|g/animal/day|SMD|1|mg/g/h|ENDPOINT DILUTION ASSAY|Y|||ADJUDICATION COMMITTEE|ADJUDICATOR|NA|1|Visit_1|10|3|WASHOUT|2021-01-25|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-25|P1Y2M10DT2H30M|UNKNOWN|2021-04-17|ONGOING|2021-04-18
e|RS|d68e5fe0-ab34-4565-9e5d-6ff1f72217f1|3|METSIND|Metastatic Indicator|PALUMBO MULTIPLE MYELOMA 2009|||PSEUDOPROGRESSION|1|lx|LUXOL FAST BLUE AND CRESYL VIOLET STAIN|Y|Y|Y|CLINICAL STUDY SPONSOR|MICROSCOPIST|U|2|Visit_2|25|4|SCREENING|2021-02-09|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-12|P1Y2M10DT2H30M|UNKNOWN|2021-04-22|AFTER|2021-04-24
e|RS|d68e5fe0-ab34-4565-9e5d-6ff1f72217f1|4|MNPTHIND|Minor Pathological Response Indicator|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|L/s|IMMUNOPHENOTYPIC CR|1|SACHET|INTRAVASCULAR ULTRASOUND|Y|||SIGNIFICANT OTHER|CLINICAL PATHOLOGIST|U|2|Visit_2|25|6|FOLLOW-UP|2021-02-09|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-12|P1Y2M10DT2H30M|UNKNOWN|2021-04-03|COINCIDENT|2021-04-10
e|RS|d68e5fe0-ab34-4565-9e5d-6ff1f72217f1|5|BONERESP|Bone Response|KEAM BREAST CANCER 2013|[?]|pmol/L|MRD RELAPSE|1|STEPS|NON-CONTACT SPECULAR MICROSCOPY||Y||FRIEND|ENDOCRINOLOGIST|Y|3|Visit_3|40|3|TREATMENT|2021-02-24|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-27|P1Y2M10DT2H30M|UNKNOWN|2021-03-06|AFTER|2021-04-06
e|RS|d68e5fe0-ab34-4565-9e5d-6ff1f72217f1|6|SFTSRESP|Soft Tissue Response|PERCIST|[?]|umol|PD FROM PR|1|10^7 CFU/mL|WESTERN BLOT|Y|||FRIEND|MICROSCOPIST 3|N|3|Visit_3|40|3|TREATMENT|2021-02-24|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-27|P1Y2M10DT2H30M|BEFORE|2021-03-18|BEFORE|2021-04-23
e|RS|d68e5fe0-ab34-4565-9e5d-6ff1f72217f1|7|TMRESP|Tumor Marker Response|PCWG SCHER PROSTATE CANCER 2016|||UNFAVORABLE RESPONSE|1|10^6 IU/mL|CORONARY ANGIOGRAPHY|Y||Y|ADJUDICATOR|PHYSIOTHERAPIST|U|4|Visit_4|65|4|TREATMENT|2021-03-21|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-18|P1Y2M10DT2H30M|UNKNOWN|2021-04-07|AFTER|2021-04-18
e|RS|d68e5fe0-ab34-4565-9e5d-6ff1f72217f1|8|RDIORESP|Radiologic Response|LEE LUNG CANCER 2011|[?]|nmol/L|MOLECULAR CR|1|mN|SLIT LAMP|Y|||PROXY|ONCOLOGIST|NA|4|Visit_4|65|2|WASHOUT|2021-03-21|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-18|P1Y2M10DT2H30M|BEFORE|2021-03-04|COINCIDENT|2021-03-05
e|RS|d68e5fe0-ab34-4565-9e5d-6ff1f72217f1|9|CLINRESP|Clinical Response|SACT|[?]|/cmH2O|CR-CT|1|ECL unit|HPLC/MS/MS||||STUDY SUBJECT|DERMATOLOGIST|U|5|Visit_5|90|2|FOLLOW-UP|2021-04-15|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-21|P1Y2M10DT2H30M|BEFORE|2021-02-05|COINCIDENT|2021-02-22
e|RS|d68e5fe0-ab34-4565-9e5d-6ff1f72217f1|10|SYMPTDTR|Symptomatic Deterioration|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|||HI-P|1|/200 HPFs|BALLPOINT PEN TECHNIQUE|||Y|FAMILY MEMBER|ADJUDICATOR 1|N|5|Visit_5|90|4|WASHOUT|2021-04-15|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-21|P1Y2M10DT2H30M|UNKNOWN|2021-01-26|AFTER|2021-04-24
e|RS|a616ef00-05d6-459a-8474-06ab3eb493b1|1|LIVRRESP|Liver Response|AJCC V8|[?]|mL/m2/min|iCR|1|CIGARETTE|RADIAL IMMUNODIFFUSION||||INVESTIGATOR|DERMATOLOGIST|U|1|Visit_1|10|6|FOLLOW-UP|2020-09-25|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-28|P1Y2M10DT2H30M|UNKNOWN|2020-11-17|AFTER|2020-12-21
e|RS|a616ef00-05d6-459a-8474-06ab3eb493b1|2|HEMARESP|Hematologic Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|% INHIBITION|IMMUNOPHENOTYPIC CR|1|mEq/g|FLOCCULATION, CHARCOAL ENHANCED||||VENDOR|HEMATOLOGIST|Y|1|Visit_1|10|7|FOLLOW-UP|2020-09-25|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-28|P1Y2M10DT2H30M|AFTER|2020-10-12|COINCIDENT|2020-12-07
e|RS|a616ef00-05d6-459a-8474-06ab3eb493b1|3|MJPTHIND|Major Pathological Response Indicator|SCHWARZ CERVICAL CANCER 2009|[?]|10^4 CFU/mL|PD|1|ug/m2/h|CELLULAR PROLIFERATION ASSAY|Y|Y||INDEPENDENT ASSESSOR|DEVELOPMENTAL PSYCHOLOGIST|NA|2|Visit_2|25|3|TREATMENT|2020-10-10|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-21|P1Y2M10DT2H30M|COINCIDENT|2020-12-07|BEFORE|2020-12-14
e|RS|a616ef00-05d6-459a-8474-06ab3eb493b1|4|NTRGRESP|Non-target Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|Bq|CA125 75% RESPONSE|1|Bq/g|FLOCCULATION||||ADJUDICATOR|RADIOLOGIST 1|Y|2|Visit_2|25|2|TREATMENT|2020-10-10|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-21|P1Y2M10DT2H30M|AFTER|2020-12-11|COINCIDENT|2020-12-18
e|RS|a616ef00-05d6-459a-8474-06ab3eb493b1|5|ANATRESP|Anatomic Response|IWG CHESON MDS 2006|[?]|mEq/day|iUPD|1|MAC50|PLETHYSMOGRAPHY||||INDEPENDENT ASSESSOR|ONCOLOGIST 1|N|3|Visit_3|40|4|TREATMENT|2020-10-25|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-28|P1Y2M10DT2H30M|AFTER|2020-11-21|AFTER|2020-12-09
e|RS|a616ef00-05d6-459a-8474-06ab3eb493b1|6|MRDRESP|Minimal Residual Disease Response|RECIST 1.1|[?]|mL/cm3/min|INDETERMINATE RESPONSE|1|P|LYMPHANGIOGRAPHY|Y|||CAREGIVER|READER|Y|3|Visit_3|40|5|TREATMENT|2020-10-25|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-28|P1Y2M10DT2H30M|AFTER|2020-09-27|AFTER|2020-10-22
e|RS|a616ef00-05d6-459a-8474-06ab3eb493b1|7|MRPHRESP|Morphologic Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|mL*cmH2O|DECREASED|1|100 IU/mL|WRIGHT STAIN||||PROXY|INTERNIST|Y|4|Visit_4|65|7|FOLLOW-UP|2020-11-19|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-09|P1Y2M10DT2H30M|BEFORE|2020-12-01|BEFORE|2020-12-07
e|RS|a616ef00-05d6-459a-8474-06ab3eb493b1|8|NEWLIND|New Lesion Indicator|SHINDOH COLORECTAL CANCER 2013|[?]|NEEDLE GAUGE|PARTIAL MORPHOLOGIC RESPONSE|1|m/sec2|CT SCAN WITHOUT CONTRAST||||INDEPENDENT ASSESSOR|MICROSCOPIST|N|4|Visit_4|65|5|TREATMENT|2020-11-19|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-09|P1Y2M10DT2H30M|COINCIDENT|2020-10-04|COINCIDENT|2020-12-08
e|RS|a616ef00-05d6-459a-8474-06ab3eb493b1|9|CYTORESP|Cytogenetic Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|Weber|CA125 75% RESPONSE|1|mm/sec|LANDOLT RING||||SIBLING|MICROSCOPIST 1|N|5|Visit_5|90|5|FOLLOW-UP|2020-12-14|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-18|P1Y2M10DT2H30M|BEFORE|2020-10-02|COINCIDENT|2020-12-16
e|RS|a616ef00-05d6-459a-8474-06ab3eb493b1|10|METBRESP|Metabolic Response|RECIST 1.1|||CYTOGENETIC CR|1|BAU|CLOT DETECTION|||Y|CHILD|PHYSIOTHERAPIST|N|5|Visit_5|90|4|SCREENING|2020-12-14|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-18|P1Y2M10DT2H30M|UNKNOWN|2020-12-08|ONGOING|2020-12-11
e|RS|a6cbce6b-ec22-4f4e-9990-b2c106a4554e|1|MOLRESP|Molecular Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|CAPLET|nPR|1|CUP|CORONARY ANGIOGRAPHY|Y|||CHILD|ONCOLOGIST 2|Y|1|Visit_1|10|4|TREATMENT|2020-08-20|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-11|P1Y2M10DT2H30M|BEFORE|2020-09-01|ONGOING|2020-10-26
e|RS|a6cbce6b-ec22-4f4e-9990-b2c106a4554e|2|SYMPTDTR|Symptomatic Deterioration|GUPPY OVARIAN CANCER 2002|[?]|Gauss|NON-CR/NON-PD|1|pg/dL|MEDIASTINOSCOPY||||PARENT|FORENSIC PATHOLOGIST|Y|1|Visit_1|10|3|WASHOUT|2020-08-20|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-11|P1Y2M10DT2H30M|BEFORE|2020-10-02|ONGOING|2020-10-22
e|RS|a6cbce6b-ec22-4f4e-9990-b2c106a4554e|3|NEWLIND|New Lesion Indicator|RANO ELLINGSON 2017|[?]|MAC50|OPTIMAL MORPHOLOGIC RESPONSE|1|mIU/L|ARTERIAL SPIN LABELING FUNCTIONAL MRI||||INTERVIEWER|OPHTHALMOLOGIST|N|2|Visit_2|25|1|TREATMENT|2020-09-04|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-16|P1Y2M10DT2H30M|AFTER|2020-10-28|COINCIDENT|2020-11-05
e|RS|a6cbce6b-ec22-4f4e-9990-b2c106a4554e|4|MNPTHIND|Minor Pathological Response Indicator|RANO ELLINGSON 2017|[?]|mPa|CA125 50% RESPONSE|1|MPS U|BIOPSY|Y|||INVESTIGATOR|OTOLARYNGOLOGIST|NA|2|Visit_2|25|6|TREATMENT|2020-09-04|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-16|P1Y2M10DT2H30M|COINCIDENT|2020-10-25|ONGOING|2020-11-06
e|RS|a6cbce6b-ec22-4f4e-9990-b2c106a4554e|5|SFTSRESP|Soft Tissue Response|LEE LUNG CANCER 2011|[?]|GBq/mg|PARTIAL MORPHOLOGIC RESPONSE|1|kcal|NON-INVASIVE DIELECTRIC SENSING||Y||HEALTH CARE PROFESSIONAL|CARDIOLOGIST|NA|3|Visit_3|40|3|WASHOUT|2020-09-19|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-02|P1Y2M10DT2H30M|AFTER|2020-10-26|BEFORE|2020-11-04
e|RS|a6cbce6b-ec22-4f4e-9990-b2c106a4554e|6|NTERESP|Non-Target Enhancing Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|foz_us|SD-CT|1|/h|RADIATION DOSIMETRY|Y|Y||CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST|U|3|Visit_3|40|6|WASHOUT|2020-09-19|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-02|P1Y2M10DT2H30M|AFTER|2020-10-24|AFTER|2020-11-01
e|RS|a6cbce6b-ec22-4f4e-9990-b2c106a4554e|7|MRPHRESP|Morphologic Response|WOLCHOK SOLID TUMORS 2009|[?]|cmHg|NR|1|MBq|SLIT LAMP||Y||CLINICAL STUDY SPONSOR|PATHOLOGIST 2|NA|4|Visit_4|65|1|FOLLOW-UP|2020-10-14|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-04|P1Y2M10DT2H30M|BEFORE|2020-11-04|ONGOING|2020-11-09
e|RS|a6cbce6b-ec22-4f4e-9990-b2c106a4554e|8|NTLWIND|Non-Target Lesion Worsening Indicator|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|ugEq|SD-CT|1|m/sec|MS/MS||||INDEPENDENT ASSESSOR|NEUROLOGIST 2|N|4|Visit_4|65|2|SCREENING|2020-10-14|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-04|P1Y2M10DT2H30M|UNKNOWN|2020-09-12|AFTER|2020-11-11
e|RS|a6cbce6b-ec22-4f4e-9990-b2c106a4554e|9|SFTSRESP|Soft Tissue Response|AJCC V8|||PR-CT|1|Enzyme U/g Hb|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI|||Y|INVESTIGATOR|ADJUDICATOR 1|NA|5|Visit_5|90|5|TREATMENT|2020-11-08|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-20|P1Y2M10DT2H30M|AFTER|2020-10-05|BEFORE|2020-11-15
e|RS|a6cbce6b-ec22-4f4e-9990-b2c106a4554e|10|DRCRIND|Disease Recurrence Indicator|RECICL|[?]|BP|UNFAVORABLE RESPONSE|1|10^9 CFU/g|WHOLE GENOME SEQUENCING|Y|||CHILD|ADJUDICATOR|U|5|Visit_5|90|5|WASHOUT|2020-11-08|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-20|P1Y2M10DT2H30M|BEFORE|2020-09-30|COINCIDENT|2020-11-13
e|RS|870f5f68-aa8a-4484-8d9d-febc7d5b83a2|1|RDIORESP|Radiologic Response|PRINCE TCELL LYMPHOMA 2010|||RELAPSED DISEASE|1|MAC50|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE||Y|Y|HEALTH CARE PROFESSIONAL|READER|NA|1|Visit_1|10|3|FOLLOW-UP|2020-10-21|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-22|P1Y2M10DT2H30M|AFTER|2020-10-31|ONGOING|2020-11-01
e|RS|870f5f68-aa8a-4484-8d9d-febc7d5b83a2|2|SFTSRESP|Soft Tissue Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|10^5/L|MORPHOLOGIC LEUKEMIA-FREE STATE|1|IU/L|WRIGHT-GIEMSA STAIN|Y|||CLINICAL STUDY SPONSOR|ENDOCRINOLOGIST|N|1|Visit_1|10|7|TREATMENT|2020-10-21|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-22|P1Y2M10DT2H30M|BEFORE|2020-12-12|BEFORE|2020-12-21
e|RS|870f5f68-aa8a-4484-8d9d-febc7d5b83a2|3|MRDRESP|Minimal Residual Disease Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|Frames/s|iCPD|1|Roentgen|FLUORESCENT ENZYME IMMUNOASSAY||||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|NA|2|Visit_2|25|4|FOLLOW-UP|2020-11-05|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-14|P1Y2M10DT2H30M|BEFORE|2020-12-22|AFTER|2021-01-12
e|RS|870f5f68-aa8a-4484-8d9d-febc7d5b83a2|4|TMRESP|Tumor Marker Response|IWC HALLEK CLL 2008|[?]|ug/g/day|UNEQUIVOCAL|1|CFU/g|HPLC/MS/MS||Y||INDEPENDENT ASSESSOR|HEMATOLOGIST|NA|2|Visit_2|25|3|TREATMENT|2020-11-05|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-14|P1Y2M10DT2H30M|BEFORE|2020-12-27|ONGOING|2020-12-29
e|RS|870f5f68-aa8a-4484-8d9d-febc7d5b83a2|5|TRGRESP|Target Response|SCHER PROSTATE CANCER 2011|[?]|ng|INDETERMINATE RESPONSE|1|kIU|CONFOCAL MICROSCOPY||||DOMESTIC PARTNER|NEUROLOGIST 2|U|3|Visit_3|40|7|WASHOUT|2020-11-20|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-01|P1Y2M10DT2H30M|AFTER|2020-12-30|BEFORE|2021-01-11
e|RS|870f5f68-aa8a-4484-8d9d-febc7d5b83a2|6|CLINRESP|Clinical Response|MURPHY PROSTATE CANCER 1980|[?]|CIGARETTE|DISEASE TRANSFORMATION|1|CAPFUL|AURAMINE STAIN||||STUDY SUBJECT|ONCOLOGIST 1|N|3|Visit_3|40|7|SCREENING|2020-11-20|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-01|P1Y2M10DT2H30M|BEFORE|2020-11-11|COINCIDENT|2020-11-29
e|RS|870f5f68-aa8a-4484-8d9d-febc7d5b83a2|7|BMIVLIND|Bone Marrow Involvement Indicator|MACDONALD GLIOMA 1990|[?]|cm2|sCR|1|kPa/L/sec|PANENDOSCOPY|Y|||INTERVIEWER|RATER|NA|4|Visit_4|65|2|FOLLOW-UP|2020-12-15|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-30|P1Y2M10DT2H30M|COINCIDENT|2020-12-05|ONGOING|2020-12-10
e|RS|870f5f68-aa8a-4484-8d9d-febc7d5b83a2|8|BMIVLIND|Bone Marrow Involvement Indicator|IWG CHESON MDS 2000|[?]|log10 CFU/mL|INDETERMINATE RESPONSE|1|dram|PEAK FLOWMETRY||||VENDOR|READER|N|4|Visit_4|65|4|SCREENING|2020-12-15|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-30|P1Y2M10DT2H30M|BEFORE|2020-10-18|ONGOING|2020-12-05
e|RS|870f5f68-aa8a-4484-8d9d-febc7d5b83a2|9|HEMARESP|Hematologic Response|WHO BREAST CANCER 2006|[?]|ug/L FEU|QUANTIFIABLE MRD POSITIVITY|1|NEBULE|HPLC/MS/MS||||HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|Y|5|Visit_5|90|4|TREATMENT|2021-01-09|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-01|P1Y2M10DT2H30M|UNKNOWN|2020-10-18|AFTER|2020-12-26
e|RS|870f5f68-aa8a-4484-8d9d-febc7d5b83a2|10|OVRLRESP|Overall Response|AJCC V7|[?]|mEq|CYTOGENETIC MINIMAL RESPONSE|1|MBq|DIGITAL PCR|Y|Y||SPOUSE|ADJUDICATOR|U|5|Visit_5|90|7|WASHOUT|2021-01-09|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-01|P1Y2M10DT2H30M|AFTER|2021-01-17|COINCIDENT|2021-01-18
e|RS|ffbb87da-c0a3-4acf-94e2-b1473cbd60e3|1|SPLNRESP|Spleen Response|SACT|[?]|L/h|HI-E|1|PIXELS/cm|STRESS ECHOCARDIOGRAPHY||Y||FAMILY MEMBER|ONCOLOGIST 1|U|1|Visit_1|10|5|TREATMENT|2020-07-04|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-28|P1Y2M10DT2H30M|BEFORE|2020-09-23|BEFORE|2020-09-26
e|RS|ffbb87da-c0a3-4acf-94e2-b1473cbd60e3|2|NTLWIND|Non-Target Lesion Worsening Indicator|DURIE MULTIPLE MYELOMA 2006|[?]|cL|SD|1|amol|GC/MS-CI||||CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 2|U|1|Visit_1|10|2|TREATMENT|2020-07-04|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-28|P1Y2M10DT2H30M|COINCIDENT|2020-08-22|COINCIDENT|2020-09-20
e|RS|ffbb87da-c0a3-4acf-94e2-b1473cbd60e3|3|CLINRESP|Clinical Response|IWC HALLEK CLL 2008|[?]|mV2/Hz|PSEUDOPROGRESSION|1|m3|MECHANICAL CLOT DETECTION||||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST|U|2|Visit_2|25|6|FOLLOW-UP|2020-07-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-13|P1Y2M10DT2H30M|AFTER|2020-08-18|BEFORE|2020-09-12
e|RS|ffbb87da-c0a3-4acf-94e2-b1473cbd60e3|4|STRUSTAT|Steroid Use Status|KUMAR IMWG 2016|[?]|Pack Year|OPTIMAL MORPHOLOGIC RESPONSE|1|s*kPa|FREEZING POINT DEPRESSION||||GUARDIAN|ONCOLOGIST 2|Y|2|Visit_2|25|4|FOLLOW-UP|2020-07-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-13|P1Y2M10DT2H30M|AFTER|2020-07-27|AFTER|2020-09-24
e|RS|ffbb87da-c0a3-4acf-94e2-b1473cbd60e3|5|PATHRESP|Pathologic Response|JACINTO CERVICAL CANCER 2007|[?]|DIOPTER|CA125 75% RESPONSE|1|kN/cm2|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY||||NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST|U|3|Visit_3|40|6|TREATMENT|2020-08-03|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-09|P1Y2M10DT2H30M|BEFORE|2020-07-02|BEFORE|2020-07-28
e|RS|ffbb87da-c0a3-4acf-94e2-b1473cbd60e3|6|MRDIND|Minimal Residual Disease Indicator|IWG CHESON MDS 2000|||CRi|1|mEq/uL|DYNAMIC CONTRAST ENHANCED MRI|||Y|DOMESTIC PARTNER|RADIOLOGIST|Y|3|Visit_3|40|1|WASHOUT|2020-08-03|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-09|P1Y2M10DT2H30M|UNKNOWN|2020-07-18|AFTER|2020-07-29
e|RS|ffbb87da-c0a3-4acf-94e2-b1473cbd60e3|7|MOLRESP|Molecular Response|CHESON LYMPHOMA 2008|[?]|STRIP|CYTOGENETIC NO RESPONSE|1|/LPF|FLOCCULATION|Y|||SIGNIFICANT OTHER|READER|Y|4|Visit_4|65|6|SCREENING|2020-08-28|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-02|P1Y2M10DT2H30M|UNKNOWN|2020-09-04|BEFORE|2020-09-19
e|RS|ffbb87da-c0a3-4acf-94e2-b1473cbd60e3|8|METSIND|Metastatic Indicator|KUMAR IMWG 2016|[?]|Farad|CMR|1|log10 TCID 50/dose|GC/MS/MS||||INTERVIEWER|INTERNIST|U|4|Visit_4|65|1|TREATMENT|2020-08-28|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-02|P1Y2M10DT2H30M|UNKNOWN|2020-07-05|AFTER|2020-08-23
e|RS|ffbb87da-c0a3-4acf-94e2-b1473cbd60e3|9|BONERESP|Bone Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|aMFI|nPR|1|/wk|BIOPSY||Y||CAREGIVER|NEUROLOGIST 1|N|5|Visit_5|90|1|TREATMENT|2020-09-22|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-06|P1Y2M10DT2H30M|UNKNOWN|2020-07-19|ONGOING|2020-08-31
e|RS|ffbb87da-c0a3-4acf-94e2-b1473cbd60e3|10|NEWLWIND|New Lesion Worsening Indicator|CHESON LYMPHOMA 2008|[?]|mEq/mmol|CRi|1|mg/mol|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI||Y||ADJUDICATION COMMITTEE|RATER 1|N|5|Visit_5|90|4|TREATMENT|2020-09-22|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-06|P1Y2M10DT2H30M|UNKNOWN|2020-08-14|BEFORE|2020-08-30
e|RS|2014bcd0-1430-4096-87f5-650a01dae626|1|METSIND|Metastatic Indicator|PERCIST|[?]|mEq|MORPHOLOGIC CRi|1|mmHg/sec|REFLECTANCE SPECTROSCOPY|Y|Y||INVESTIGATOR|OTOLARYNGOLOGIST|U|1|Visit_1|10|3|SCREENING|2020-05-31|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-19|P1Y2M10DT2H30M|AFTER|2020-05-27|BEFORE|2020-07-31
e|RS|2014bcd0-1430-4096-87f5-650a01dae626|2|CYTORESP|Cytogenetic Response|WOLCHOK SOLID TUMORS 2009|[?]|ms2|STABLE|1|Mile|FARNSWORTH-MUNSELL 100 HUE TEST||||INDEPENDENT ASSESSOR|READER 2|NA|1|Visit_1|10|7|TREATMENT|2020-05-31|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-19|P1Y2M10DT2H30M|BEFORE|2020-08-12|COINCIDENT|2020-08-14
e|RS|2014bcd0-1430-4096-87f5-650a01dae626|3|LIVRRESP|Liver Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|||PSEUDORESPONSE|1|pmol/g|IMMUNO-PET SCAN|||Y|FRIEND|ONCOLOGIST|U|2|Visit_2|25|1|TREATMENT|2020-06-15|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-15|P1Y2M10DT2H30M|BEFORE|2020-05-23|AFTER|2020-06-06
e|RS|2014bcd0-1430-4096-87f5-650a01dae626|4|DRCRIND|Disease Recurrence Indicator|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|||UNFAVORABLE RESPONSE|1|m|CYSTOMETRY||Y|Y|FAMILY MEMBER|NEUROLOGIST|N|2|Visit_2|25|2|WASHOUT|2020-06-15|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-15|P1Y2M10DT2H30M|BEFORE|2020-06-19|COINCIDENT|2020-08-14
e|RS|2014bcd0-1430-4096-87f5-650a01dae626|5|CLINRESP|Clinical Response|IWC HALLEK CLL 2008|||PMD|1|cmH2O*s/mL|HPLC/MS/MS|Y||Y|PARENT|CARDIOLOGIST|Y|3|Visit_3|40|2|TREATMENT|2020-06-30|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-12|P1Y2M10DT2H30M|COINCIDENT|2020-08-03|COINCIDENT|2020-08-17
e|RS|2014bcd0-1430-4096-87f5-650a01dae626|6|CLINRESP|Clinical Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|||NON-iCR/NON-iUPD|1|BP|CT SCAN||Y|Y|NON-HEALTH CARE PROFESSIONAL|CARDIOLOGIST|Y|3|Visit_3|40|6|SCREENING|2020-06-30|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-12|P1Y2M10DT2H30M|COINCIDENT|2020-08-02|ONGOING|2020-08-22
e|RS|2014bcd0-1430-4096-87f5-650a01dae626|7|MRDIND|Minimal Residual Disease Indicator|PRINCE TCELL LYMPHOMA 2010|[?]|mg/kg/h|HI-E|1|uSiemens|INTRAVASCULAR ULTRASOUND||||CLINICAL STUDY SPONSOR|ONCOLOGIST 1|U|4|Visit_4|65|6|TREATMENT|2020-07-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-02|P1Y2M10DT2H30M|AFTER|2020-08-02|BEFORE|2020-08-07
e|RS|2014bcd0-1430-4096-87f5-650a01dae626|8|NTLWIND|Non-Target Lesion Worsening Indicator|LUGANO CLASSIFICATION|||COMPLETE MRD RESPONSE|1|/200 HPFs|GRAM STAIN|||Y|HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|N|4|Visit_4|65|6|TREATMENT|2020-07-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-02|P1Y2M10DT2H30M|BEFORE|2020-05-31|COINCIDENT|2020-08-15
e|RS|2014bcd0-1430-4096-87f5-650a01dae626|9|TRGRESP|Target Response|IWG CHESON MDS 2006|[?]|mm/2h|QUANTIFIABLE MRD POSITIVITY|1|DNA copies/ug|CALCOFLUOR WHITE STAIN||||SIGNIFICANT OTHER|NEUROLOGIST 1|N|5|Visit_5|90|5|WASHOUT|2020-08-19|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-26|P1Y2M10DT2H30M|AFTER|2020-07-10|AFTER|2020-08-21
e|RS|2014bcd0-1430-4096-87f5-650a01dae626|10|BMIVLIND|Bone Marrow Involvement Indicator|CHOI GIST 2008|[?]|U/10^12 RBC|IMMUNOPHENOTYPIC CR|1|mV2/Hz|PHOTOMETRY||Y||CLINICAL STUDY SPONSOR|NEUROLOGIST 1|Y|5|Visit_5|90|4|TREATMENT|2020-08-19|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-26|P1Y2M10DT2H30M|AFTER|2020-06-14|ONGOING|2020-06-16
e|RS|e043f1b3-6b65-45c0-bdae-eb783406c263|1|MRPHRESP|Morphologic Response|CHOLLET BREAST CANCER 2002|[?]|MET*h|iCR|1|%(w/v)|NEPHELOMETRY||Y||CAREGIVER|READER 2|N|1|Visit_1|10|5|FOLLOW-UP|2020-11-11|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-09|P1Y2M10DT2H30M|UNKNOWN|2020-11-11|BEFORE|2020-12-11
e|RS|e043f1b3-6b65-45c0-bdae-eb783406c263|2|NEWLWIND|New Lesion Worsening Indicator|HAMAOKA BREAST CANCER 2010|[?]|mol/mol|CHR|1|mL/s/m2|FARNSWORTH-MUNSELL 100 HUE TEST||||ADJUDICATION COMMITTEE|INTERNIST|N|1|Visit_1|10|3|FOLLOW-UP|2020-11-11|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-09|P1Y2M10DT2H30M|BEFORE|2021-01-16|BEFORE|2021-01-20
e|RS|e043f1b3-6b65-45c0-bdae-eb783406c263|3|TMRESP|Tumor Marker Response|BRUGGEMANN MRD 2010|||CRi|1|CAPSULE|WEBER GREEN STAIN|||Y|INVESTIGATOR|ONCOLOGIST 1|NA|2|Visit_2|25|6|FOLLOW-UP|2020-11-26|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-02|P1Y2M10DT2H30M|BEFORE|2020-12-31|ONGOING|2021-01-16
e|RS|e043f1b3-6b65-45c0-bdae-eb783406c263|4|TRGRESP|Target Response|MONTSERRAT CLL 1989|||WORSENED|1|DRUM|HPLC/MS/MS||Y|Y|CHILD|ONCOLOGIST|N|2|Visit_2|25|7|FOLLOW-UP|2020-11-26|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-02|P1Y2M10DT2H30M|COINCIDENT|2020-11-15|ONGOING|2021-01-18
e|RS|e043f1b3-6b65-45c0-bdae-eb783406c263|5|CLINRESP|Clinical Response|WOLCHOK SOLID TUMORS 2009|[?]|gpELISA unit/mL|CHR|1|mg/m2|GC/FID|Y|Y||INVESTIGATOR|ONCOLOGIST|Y|3|Visit_3|40|6|FOLLOW-UP|2020-12-11|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-28|P1Y2M10DT2H30M|AFTER|2021-02-02|ONGOING|2021-02-03
e|RS|e043f1b3-6b65-45c0-bdae-eb783406c263|6|ANATRESP|Anatomic Response|RECICL|[?]|/2000 RBC|WORSENED|1|U/g/min|LINE PROBE ASSAY|Y|||FRIEND|ONCOLOGIST 1|Y|3|Visit_3|40|1|SCREENING|2020-12-11|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-28|P1Y2M10DT2H30M|UNKNOWN|2020-11-27|ONGOING|2020-12-13
e|RS|e043f1b3-6b65-45c0-bdae-eb783406c263|7|NTLWIND|Non-Target Lesion Worsening Indicator|RANO|[?]|log10 CFU/mL|cPR|1|mL/m2/min|ELISA||||CLINICAL RESEARCH COORDINATOR|RADIOLOGIST|N|4|Visit_4|65|2|WASHOUT|2021-01-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-12|P1Y2M10DT2H30M|AFTER|2021-01-09|COINCIDENT|2021-02-04
e|RS|e043f1b3-6b65-45c0-bdae-eb783406c263|8|MRPHRESP|Morphologic Response|IWC HALLEK CLL 2008|[?]|ug/animal|EQUIVOCAL|1|g/L|TRANSCRIPTION-MEDIATED AMPLIFICATION||||SIBLING|RADIOLOGIST|U|4|Visit_4|65|4|TREATMENT|2021-01-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-12|P1Y2M10DT2H30M|UNKNOWN|2020-12-16|BEFORE|2021-01-30
e|RS|e043f1b3-6b65-45c0-bdae-eb783406c263|9|TMRESP|Tumor Marker Response|IWG CHESON MDS 2000|[?]|ug/mL/h|MAJOR PATHOLOGIC RESPONSE|1|GLOBULE|COMPUTERIZED CORNEAL TOPOGRAPHY||||HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|U|5|Visit_5|90|2|TREATMENT|2021-01-30|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-19|P1Y2M10DT2H30M|AFTER|2020-11-03|AFTER|2021-02-04
e|RS|e043f1b3-6b65-45c0-bdae-eb783406c263|10|METBRESP|Metabolic Response|WHO BREAST CANCER 2006|[?]|dpm/mg|mCR|1|lm|QUANTITATIVE CORONARY ANGIOGRAPHY||||PARENT|PHYSIOTHERAPIST|U|5|Visit_5|90|2|TREATMENT|2021-01-30|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-19|P1Y2M10DT2H30M|BEFORE|2020-12-21|BEFORE|2021-02-01
e|RS|45623c39-86de-4b2f-bf2d-998d0e941e92|1|NTRGRESP|Non-target Response|PERCIST|[?]|YEARS|NED|1|ug/dL|MANUAL COUNT||||GUARDIAN|ADJUDICATOR 3|NA|1|Visit_1|10|4|WASHOUT|2020-07-22|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-16|P1Y2M10DT2H30M|BEFORE|2020-08-16|COINCIDENT|2020-10-02
e|RS|45623c39-86de-4b2f-bf2d-998d0e941e92|2|MRDIND|Minimal Residual Disease Indicator|CHESON CLL 2012|[?]|Gy/min|RELAPSED DISEASE|1|V|AUDIOMETRY||||HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|Y|1|Visit_1|10|7|WASHOUT|2020-07-22|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-16|P1Y2M10DT2H30M|COINCIDENT|2020-08-14|ONGOING|2020-08-22
e|RS|45623c39-86de-4b2f-bf2d-998d0e941e92|3|HEMARESP|Hematologic Response|RECIST 1.1|[?]|/wk|PARTIAL MORPHOLOGIC RESPONSE|1|U.CARR|IN SITU HYBRIDIZATION||||CHILD|OPTOMETRIST|U|2|Visit_2|25|7|FOLLOW-UP|2020-08-06|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-23|P1Y2M10DT2H30M|UNKNOWN|2020-08-06|AFTER|2020-10-01
e|RS|45623c39-86de-4b2f-bf2d-998d0e941e92|4|NTNERESP|Non-Target Non-Enhancing Response|CHESON LYMPHOMA 2008|||MRD PERSISTENCE|1|U/m2/min|CT SCAN|||Y|ADJUDICATOR|MICROSCOPIST 2|U|2|Visit_2|25|2|TREATMENT|2020-08-06|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-23|P1Y2M10DT2H30M|AFTER|2020-10-13|AFTER|2020-10-17
e|RS|45623c39-86de-4b2f-bf2d-998d0e941e92|5|MJPTHIND|Major Pathological Response Indicator|PCWG SCHER PROSTATE CANCER 2008|[?]|BAG|iPR|1|CFU/g|SPECT SCAN||||INDEPENDENT ASSESSOR|CLINICAL PATHOLOGIST|NA|3|Visit_3|40|2|TREATMENT|2020-08-21|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-07|P1Y2M10DT2H30M|AFTER|2020-07-26|ONGOING|2020-09-15
e|RS|45623c39-86de-4b2f-bf2d-998d0e941e92|6|OVRLRESP|Overall Response|SACT|[?]|ug/g/h|CYTOGENETIC MINOR RESPONSE|1|cycle/min|SANGER SEQUENCING||||CAREGIVER|MICROSCOPIST 3|U|3|Visit_3|40|1|FOLLOW-UP|2020-08-21|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-07|P1Y2M10DT2H30M|AFTER|2020-10-12|COINCIDENT|2020-10-14
e|RS|45623c39-86de-4b2f-bf2d-998d0e941e92|7|RDIORESP|Radiologic Response|RECIST 1.1|||UNEQUIVOCAL|1|nmol/mol|MAMMOGRAPHY|||Y|INVESTIGATOR|RADIOLOGIST 1|NA|4|Visit_4|65|3|WASHOUT|2020-09-15|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-25|P1Y2M10DT2H30M|BEFORE|2020-10-05|COINCIDENT|2020-10-09
e|RS|45623c39-86de-4b2f-bf2d-998d0e941e92|8|ANATRESP|Anatomic Response|BRUGGEMANN MRD 2010|[?]|10^4 CFU/mL|MRD PERSISTENCE|1|10^6/g|MICRO BROTH DILUTION||||SIBLING|READER 1|NA|4|Visit_4|65|2|FOLLOW-UP|2020-09-15|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-25|P1Y2M10DT2H30M|UNKNOWN|2020-08-01|AFTER|2020-09-18
e|RS|45623c39-86de-4b2f-bf2d-998d0e941e92|9|NTLWIND|Non-Target Lesion Worsening Indicator|DURIE MULTIPLE MYELOMA 2006|[?]|U/cL|DISEASE TRANSFORMATION|1|mL/min/mmHg|MULTIPLEXED BEAD BASED IMMUNOASSAY||||PROXY|ADJUDICATOR 2|NA|5|Visit_5|90|6|TREATMENT|2020-10-10|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-26|P1Y2M10DT2H30M|AFTER|2020-10-07|AFTER|2020-10-18
e|RS|45623c39-86de-4b2f-bf2d-998d0e941e92|10|NTNERESP|Non-Target Non-Enhancing Response|KEAM BREAST CANCER 2013|[?]|mCi|HI-E|1|m3|MICROBIAL CULTURE, SOLID||||INVESTIGATOR|INTERNIST|U|5|Visit_5|90|7|TREATMENT|2020-10-10|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-26|P1Y2M10DT2H30M|UNKNOWN|2020-07-26|COINCIDENT|2020-08-29
e|RS|a753f9c8-2f9a-4f54-80e0-b080e82dcb94|1|SFTSRESP|Soft Tissue Response|CHESON LYMPHOMA 2008|[?]|L/day|FAVORABLE RESPONSE|1|U/g|HPLC-UV||Y||CHILD|ADJUDICATOR 2|U|1|Visit_1|10|3|FOLLOW-UP|2020-10-18|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-07|P1Y2M10DT2H30M|COINCIDENT|2020-11-10|ONGOING|2020-11-25
e|RS|a753f9c8-2f9a-4f54-80e0-b080e82dcb94|2|RDIORESP|Radiologic Response|MACDONALD GLIOMA 1990|||NON-iCR/NON-iUPD|1|TRACE|SPIROMETRY|||Y|PROXY|OPHTHALMOLOGIST|NA|1|Visit_1|10|7|TREATMENT|2020-10-18|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-07|P1Y2M10DT2H30M|AFTER|2020-12-11|ONGOING|2021-01-08
e|RS|a753f9c8-2f9a-4f54-80e0-b080e82dcb94|3|HEMARESP|Hematologic Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|uL/kg/day|CHR|1|EU|MICRONEUTRALIZATION ASSAY|Y|||GUARDIAN|DEVELOPMENTAL PSYCHOLOGIST|NA|2|Visit_2|25|4|TREATMENT|2020-11-02|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-06|P1Y2M10DT2H30M|UNKNOWN|2020-11-14|ONGOING|2021-01-12
e|RS|a753f9c8-2f9a-4f54-80e0-b080e82dcb94|4|OVRLRESP|Overall Response|CHOI GIST 2008|||CRi|1|Bq/mL|CELLULOSE TAPE|||Y|CLINICAL RESEARCH ASSOCIATE|OTOLARYNGOLOGIST|N|2|Visit_2|25|1|SCREENING|2020-11-02|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-06|P1Y2M10DT2H30M|UNKNOWN|2020-11-29|COINCIDENT|2020-12-21
e|RS|a753f9c8-2f9a-4f54-80e0-b080e82dcb94|5|MRDIND|Minimal Residual Disease Indicator|DURIE MULTIPLE MYELOMA 2006|[?]|10^6 organisms|PSA PROGRESSION|1|kg/cm2|DIGITAL PCR ARRAY||||CAREGIVER|UROLOGIST|NA|3|Visit_3|40|1|SCREENING|2020-11-17|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-11|P1Y2M10DT2H30M|UNKNOWN|2020-10-28|AFTER|2020-11-02
e|RS|a753f9c8-2f9a-4f54-80e0-b080e82dcb94|6|DRCRIND|Disease Recurrence Indicator|NCCN ALL MRD 2014|||PSEUDOPROGRESSION|1|ug/L|STRESS ECHOCARDIOGRAPHY|||Y|HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|NA|3|Visit_3|40|7|TREATMENT|2020-11-17|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-11|P1Y2M10DT2H30M|COINCIDENT|2020-10-29|ONGOING|2020-11-24
e|RS|a753f9c8-2f9a-4f54-80e0-b080e82dcb94|7|RDIORESP|Radiologic Response|BURCOMBE BREAST CANCER 2005|[?]|Gy/min|CR|1|U/g|INDIRECT IMMUNOFLUORESCENCE||Y||ADJUDICATOR|PHYSIOTHERAPIST|N|4|Visit_4|65|4|TREATMENT|2020-12-12|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-04|P1Y2M10DT2H30M|UNKNOWN|2021-01-04|ONGOING|2021-01-15
e|RS|a753f9c8-2f9a-4f54-80e0-b080e82dcb94|8|CYTORESP|Cytogenetic Response|PCWG SCHER PROSTATE CANCER 2008|[?]|Shock Wave|PD|1|ELISA unit/dose|X-RAY FLUORESCENCE SPECTROMETRY||||PARENT|READER 1|U|4|Visit_4|65|5|TREATMENT|2020-12-12|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-04|P1Y2M10DT2H30M|COINCIDENT|2020-12-23|ONGOING|2020-12-26
e|RS|a753f9c8-2f9a-4f54-80e0-b080e82dcb94|9|MOLRESP|Molecular Response|PCWG SCHER PROSTATE CANCER 2016|[?]|mPa|ABSENT MORPHOLOGIC RESPONSE|1|mmol/min/kPa|ELECTROPHORESIS||||GUARDIAN|OTOLARYNGOLOGIST|NA|5|Visit_5|90|7|WASHOUT|2021-01-06|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-18|P1Y2M10DT2H30M|AFTER|2020-11-02|ONGOING|2020-12-31
e|RS|a753f9c8-2f9a-4f54-80e0-b080e82dcb94|10|MOLRESP|Molecular Response|GUPPY OVARIAN CANCER 2002|||iPR|1|Ci/kg|EEG||Y|Y|SPOUSE|ONCOLOGIST 1|U|5|Visit_5|90|3|SCREENING|2021-01-06|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-18|P1Y2M10DT2H30M|COINCIDENT|2020-11-13|AFTER|2021-01-06
e|RS|e5a105f7-38ac-4f19-aace-4149ed9b1100|1|ANATRESP|Anatomic Response|CHESON CLL 2012|[?]|pmol/dL|CA125 50% RESPONSE|1|mmol/mol|PHOTOMETRIC CLOT DETECTION||||HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|N|1|Visit_1|10|1|FOLLOW-UP|2020-09-03|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-06|P1Y2M10DT2H30M|UNKNOWN|2020-10-30|AFTER|2020-11-30
e|RS|e5a105f7-38ac-4f19-aace-4149ed9b1100|2|NEWLIND|New Lesion Indicator|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|U|iUPD|1|kBq|MACRO BROTH DILUTION|Y|||FRIEND|ONCOLOGIST|Y|1|Visit_1|10|1|SCREENING|2020-09-03|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-06|P1Y2M10DT2H30M|COINCIDENT|2020-09-23|ONGOING|2020-10-29
e|RS|e5a105f7-38ac-4f19-aace-4149ed9b1100|3|LIVRRESP|Liver Response|MURPHY PROSTATE CANCER 1980|[?]|m3|MRD RELAPSE|1|Ci|KINETIC MICROPARTICLE IMMUNOASSAY||||CLINICAL STUDY SPONSOR|HEMATOLOGIST|NA|2|Visit_2|25|2|WASHOUT|2020-09-18|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-16|P1Y2M10DT2H30M|AFTER|2020-09-12|ONGOING|2020-11-21
e|RS|e5a105f7-38ac-4f19-aace-4149ed9b1100|4|DRCRIND|Disease Recurrence Indicator|GUILHOT CML 2007|[?]|ukat/L|PMR|1|pkat/L|ACCELERATOR MASS SPECTROMETRY|Y|||HEALTH CARE PROFESSIONAL|RADIOLOGIST|NA|2|Visit_2|25|7|WASHOUT|2020-09-18|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-16|P1Y2M10DT2H30M|UNKNOWN|2020-09-25|ONGOING|2020-10-19
e|RS|e5a105f7-38ac-4f19-aace-4149ed9b1100|5|CLINRESP|Clinical Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|Enzyme U|DECREASED|1|POINT|BRDU CELLULAR PROLIFERATION ASSAY||||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR|U|3|Visit_3|40|7|SCREENING|2020-10-03|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-03|P1Y2M10DT2H30M|AFTER|2020-10-18|BEFORE|2020-11-30
e|RS|e5a105f7-38ac-4f19-aace-4149ed9b1100|6|PATHRESP|Pathologic Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|cycle/min|iCPD|1|mAmp|IODINE STAIN||Y||SIGNIFICANT OTHER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|3|Visit_3|40|6|TREATMENT|2020-10-03|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-03|P1Y2M10DT2H30M|COINCIDENT|2020-10-31|AFTER|2020-11-27
e|RS|e5a105f7-38ac-4f19-aace-4149ed9b1100|7|METBRESP|Metabolic Response|DURIE MULTIPLE MYELOMA 2006|[?]|mmHg/L/min|MOLECULAR CR|1|DRUM|QUANTITATIVE PERIPHERAL ANGIOGRAPHY||||STUDY SUBJECT|RADIOLOGIST 1|Y|4|Visit_4|65|4|SCREENING|2020-10-28|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-09|P1Y2M10DT2H30M|BEFORE|2020-10-16|COINCIDENT|2020-11-05
e|RS|e5a105f7-38ac-4f19-aace-4149ed9b1100|8|MNPTHIND|Minor Pathological Response Indicator|WHO BREAST CANCER 2006|[?]|GPL U/mL|TREATMENT FAILURE|1|10^3 copies/mL|JAEGER EYE CHART||||CLINICAL STUDY SPONSOR|NEUROLOGIST 1|Y|4|Visit_4|65|1|FOLLOW-UP|2020-10-28|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-09|P1Y2M10DT2H30M|UNKNOWN|2020-09-13|ONGOING|2020-11-26
e|RS|e5a105f7-38ac-4f19-aace-4149ed9b1100|9|MNPTHIND|Minor Pathological Response Indicator|CHESON MALIGNANT LYMPHOMA 2007|||iCR|1|10^8/L|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY|||Y|SPOUSE|PHYSIOTHERAPIST|U|5|Visit_5|90|4|WASHOUT|2020-11-22|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-12|P1Y2M10DT2H30M|BEFORE|2020-11-13|AFTER|2020-11-15
e|RS|e5a105f7-38ac-4f19-aace-4149ed9b1100|10|ANATRESP|Anatomic Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|10^3 organisms/g|COMPLETE MRD RESPONSE|1|days/month|IMMUNODIFFUSION||Y||CHILD|ADJUDICATOR|Y|5|Visit_5|90|5|TREATMENT|2020-11-22|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-12|P1Y2M10DT2H30M|COINCIDENT|2020-09-05|COINCIDENT|2020-10-13
e|RS|c568ab93-8e7f-4e4e-9685-f0c13f293606|1|SFTSRESP|Soft Tissue Response|CHESON LYMPHOMA 2008|[?]|kDa|sCR|1|ppm|ACID FAST STAIN|Y|||STUDY SUBJECT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|1|Visit_1|10|3|TREATMENT|2021-01-14|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-06|P1Y2M10DT2H30M|AFTER|2021-01-20|ONGOING|2021-03-15
e|RS|c568ab93-8e7f-4e4e-9685-f0c13f293606|2|NTRGRESP|Non-target Response|AJCC V8|[?]|pkat|CRi|1|CIGARETTE|PHASE-CONTRAST MRI||||NON-HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|NA|1|Visit_1|10|6|TREATMENT|2021-01-14|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-06|P1Y2M10DT2H30M|UNKNOWN|2021-01-26|AFTER|2021-02-12
e|RS|c568ab93-8e7f-4e4e-9685-f0c13f293606|3|SPLNRESP|Spleen Response|PERCIST|[?]|DNA copies/mL|MORPHOLOGIC LEUKEMIA-FREE STATE|1|10^9/dose|FLUORESCENT SPOT TEST||Y||SIBLING|MICROSCOPIST 1|Y|2|Visit_2|25|1|FOLLOW-UP|2021-01-29|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-01|P1Y2M10DT2H30M|BEFORE|2021-01-31|COINCIDENT|2021-03-18
e|RS|c568ab93-8e7f-4e4e-9685-f0c13f293606|4|DRCRIND|Disease Recurrence Indicator|KUKER LYMPHOMA 2005|[?]|mL*cmH2O|NON-iCR/NON-iUPD|1|kBq/uL|REFRACTOMETRY||||DOMESTIC PARTNER|ADJUDICATOR|Y|2|Visit_2|25|6|TREATMENT|2021-01-29|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-01|P1Y2M10DT2H30M|UNKNOWN|2021-01-20|BEFORE|2021-03-19
e|RS|c568ab93-8e7f-4e4e-9685-f0c13f293606|5|HEMARESP|Hematologic Response|HARTMAN PANCREATIC CANCER 2012|[?]|g/L|RELAPSED DISEASE FROM CR OR PR|1|cm|IODINE STAIN||Y||ADJUDICATION COMMITTEE|HEMATOLOGIST|U|3|Visit_3|40|3|WASHOUT|2021-02-13|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-17|P1Y2M10DT2H30M|AFTER|2021-04-08|ONGOING|2021-04-10
e|RS|c568ab93-8e7f-4e4e-9685-f0c13f293606|6|MOLRESP|Molecular Response|PROTOCOL DEFINED RESPONSE CRITERIA|||PARTIAL MORPHOLOGIC RESPONSE|1|PELLET|FLAME PHOTOMETRY|||Y|PROXY|RADIOLOGIST 2|U|3|Visit_3|40|2|TREATMENT|2021-02-13|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-17|P1Y2M10DT2H30M|COINCIDENT|2021-01-13|BEFORE|2021-01-24
e|RS|c568ab93-8e7f-4e4e-9685-f0c13f293606|7|MRDIND|Minimal Residual Disease Indicator|MRECIST LENCIONI LIVER CANCER 2010|[?]|umol/h/mmol|TREATMENT FAILURE|1|Mile|INDIRECT IMMUNOFLUORESCENCE||Y||INVESTIGATOR|RATER 2|NA|4|Visit_4|65|5|FOLLOW-UP|2021-03-10|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-06|P1Y2M10DT2H30M|BEFORE|2021-02-22|AFTER|2021-04-06
e|RS|c568ab93-8e7f-4e4e-9685-f0c13f293606|8|MNPTHIND|Minor Pathological Response Indicator|PRINCE TCELL LYMPHOMA 2010|[?]|mL/animal/day|NON-PD|1|umol/L/sec|MICROSCOPY||||CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 3|Y|4|Visit_4|65|6|SCREENING|2021-03-10|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-06|P1Y2M10DT2H30M|UNKNOWN|2021-01-08|BEFORE|2021-04-07
e|RS|c568ab93-8e7f-4e4e-9685-f0c13f293606|9|SFTSRESP|Soft Tissue Response|RECICL|[?]|cmHg|EQUIVOCAL|1|pptr|GIEMSA STAIN||||CLINICAL RESEARCH COORDINATOR|PHYSIOTHERAPIST|Y|5|Visit_5|90|4|FOLLOW-UP|2021-04-04|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-04|P1Y2M10DT2H30M|UNKNOWN|2021-02-14|BEFORE|2021-03-14
e|RS|c568ab93-8e7f-4e4e-9685-f0c13f293606|10|NTLWIND|Non-Target Lesion Worsening Indicator|CHOLLET BREAST CANCER 2002|[?]|/100 WBC|WORSENED|1|cy/cm|WHOLE GENOME SEQUENCING||Y||VENDOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5|Visit_5|90|7|TREATMENT|2021-04-04|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-04|P1Y2M10DT2H30M|AFTER|2021-04-09|ONGOING|2021-04-10
e|RS|bccd8af0-2ecf-4091-92e4-681597b57ca4|1|MRPHRESP|Morphologic Response|PCWG SCHER PROSTATE CANCER 2016|[?]|10^6/Ejaculate U|cCR|1|gMFI|PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY||||CAREGIVER|MICROSCOPIST 3|U|1|Visit_1|10|7|TREATMENT|2020-09-30|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-25|P1Y2M10DT2H30M|COINCIDENT|2020-12-24|BEFORE|2020-12-28
e|RS|bccd8af0-2ecf-4091-92e4-681597b57ca4|2|MJPTHIND|Major Pathological Response Indicator|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|lx|VGPR|1|Joule|GRADIENT DIFFUSION|Y|||CLINICAL RESEARCH COORDINATOR|HEMATOLOGIST|Y|1|Visit_1|10|6|FOLLOW-UP|2020-09-30|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-25|P1Y2M10DT2H30M|AFTER|2020-11-26|AFTER|2020-12-07
e|RS|bccd8af0-2ecf-4091-92e4-681597b57ca4|3|ANATRESP|Anatomic Response|KUKER LYMPHOMA 2005|[?]|10^3 CFU|UNEQUIVOCAL|1|oz eq|CALIPER MEASUREMENT METHOD|Y|Y||ADJUDICATION COMMITTEE|RATER 2|NA|2|Visit_2|25|2|WASHOUT|2020-10-15|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-08|P1Y2M10DT2H30M|AFTER|2020-11-12|COINCIDENT|2020-12-09
e|RS|bccd8af0-2ecf-4091-92e4-681597b57ca4|4|SPLNRESP|Spleen Response|PERCIST|[?]|TRANSDUCING UNIT|UNEQUIVOCAL|1|uIU/dL|HPLC-FL||||PARENT|HEMATOLOGIST|N|2|Visit_2|25|1|WASHOUT|2020-10-15|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-08|P1Y2M10DT2H30M|UNKNOWN|2020-12-08|AFTER|2020-12-16
e|RS|bccd8af0-2ecf-4091-92e4-681597b57ca4|5|DRCRIND|Disease Recurrence Indicator|CHOLLET BREAST CANCER 2002|[?]|atm|NON-PD|1|APL U|CYSTOSCOPY|Y|Y||HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|U|3|Visit_3|40|4|TREATMENT|2020-10-30|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-19|P1Y2M10DT2H30M|UNKNOWN|2020-10-27|ONGOING|2020-11-30
e|RS|bccd8af0-2ecf-4091-92e4-681597b57ca4|6|NEWLWIND|New Lesion Worsening Indicator|iRECIST|[?]|ms/mmHg|CYTOGENETIC CR|1|U/dL|LIGHT MICROSCOPY||||ADJUDICATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|3|Visit_3|40|1|TREATMENT|2020-10-30|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-19|P1Y2M10DT2H30M|AFTER|2020-12-18|AFTER|2020-12-26
e|RS|bccd8af0-2ecf-4091-92e4-681597b57ca4|7|DRCRIND|Disease Recurrence Indicator|CHESON CLL 2012|||PD|1|ug/m2/h|SPECTROPHOTOMETRY||Y|Y|CLINICAL RESEARCH ASSOCIATE|RATER 1|U|4|Visit_4|65|6|TREATMENT|2020-11-24|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-04|P1Y2M10DT2H30M|AFTER|2020-11-12|BEFORE|2020-11-15
e|RS|bccd8af0-2ecf-4091-92e4-681597b57ca4|8|SFTSRESP|Soft Tissue Response|NCCN ALL MRD 2014|[?]|nkat|WORSENED|1|MHz|ELISA|Y|||CLINICAL STUDY SPONSOR|DERMATOLOGIST|Y|4|Visit_4|65|4|SCREENING|2020-11-24|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-04|P1Y2M10DT2H30M|UNKNOWN|2020-10-17|AFTER|2020-11-29
e|RS|bccd8af0-2ecf-4091-92e4-681597b57ca4|9|NTLWIND|Non-Target Lesion Worsening Indicator|PALUMBO MULTIPLE MYELOMA 2009|[?]|vg/dose|iPR|1|Coulomb|MAMMOGRAPHY||||PARENT|DEVELOPMENTAL PSYCHOLOGIST|N|5|Visit_5|90|6|FOLLOW-UP|2020-12-19|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-03|P1Y2M10DT2H30M|BEFORE|2020-10-11|AFTER|2020-12-15
e|RS|bccd8af0-2ecf-4091-92e4-681597b57ca4|10|CYTORESP|Cytogenetic Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|10^9/g|CRi|1|ug/kg/h|FUNDUS PHOTOGRAPHY||Y||ADJUDICATOR|OPTOMETRIST|N|5|Visit_5|90|3|SCREENING|2020-12-19|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-03|P1Y2M10DT2H30M|COINCIDENT|2020-11-11|BEFORE|2020-12-25
e|RS|bf069a02-03a6-4013-b16d-d7c954a6cc3d|1|BONERESP|Bone Response|GUPPY OVARIAN CANCER 2002|[?]|nsec|MORPHOLOGIC LEUKEMIA-FREE STATE|1|ug/kg/h|LEAD CITRATE STAIN|Y|||FRIEND|RATER 2|NA|1|Visit_1|10|4|SCREENING|2020-08-06|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-01|P1Y2M10DT2H30M|UNKNOWN|2020-09-19|ONGOING|2020-10-05
e|RS|bf069a02-03a6-4013-b16d-d7c954a6cc3d|2|BONERESP|Bone Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|/LPF|PR|1|mV*min|LISSAMINE GREEN STAIN||Y||CLINICAL STUDY SPONSOR|READER 2|NA|1|Visit_1|10|4|WASHOUT|2020-08-06|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-01|P1Y2M10DT2H30M|AFTER|2020-10-16|COINCIDENT|2020-10-28
e|RS|bf069a02-03a6-4013-b16d-d7c954a6cc3d|3|NEWLIND|New Lesion Indicator|MRANO VAN DEN BENT GLIOMA 2011|[?]|APPLICATION|STABLE|1|Roentgen|SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|Y|||SPOUSE|PHYSIOTHERAPIST|N|2|Visit_2|25|7|FOLLOW-UP|2020-08-21|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-23|P1Y2M10DT2H30M|BEFORE|2020-10-16|ONGOING|2020-10-28
e|RS|bf069a02-03a6-4013-b16d-d7c954a6cc3d|4|METBRESP|Metabolic Response|RAJKUMAR MYELOMA 2011|||iSD|1|Tbsp|REFRACTOMETRY|Y||Y|SIGNIFICANT OTHER|MICROSCOPIST 1|U|2|Visit_2|25|4|TREATMENT|2020-08-21|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-23|P1Y2M10DT2H30M|AFTER|2020-10-13|BEFORE|2020-10-26
e|RS|bf069a02-03a6-4013-b16d-d7c954a6cc3d|5|ANATRESP|Anatomic Response|PCWG SCHER PROSTATE CANCER 2008|[?]|PHERESIS UNIT|iCPD|1|L/s/kPa|ACCELERATOR MASS SPECTROMETRY|Y|||ADJUDICATION COMMITTEE|ADJUDICATOR 2|U|3|Visit_3|40|5|TREATMENT|2020-09-05|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-18|P1Y2M10DT2H30M|AFTER|2020-09-28|AFTER|2020-10-24
e|RS|bf069a02-03a6-4013-b16d-d7c954a6cc3d|6|BONERESP|Bone Response|IWG CHESON MDS 2000|[?]|U/animal|PDu|1|10^9/g|THIN SMEAR|Y|||SPOUSE|READER 1|U|3|Visit_3|40|3|WASHOUT|2020-09-05|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-18|P1Y2M10DT2H30M|AFTER|2020-08-09|COINCIDENT|2020-10-27
e|RS|bf069a02-03a6-4013-b16d-d7c954a6cc3d|7|CPRFSTAT|Clinical Performance Status|UNSPECIFIED|[?]|mg/m2/min|CYTOGENETIC NO RESPONSE|1|mL/animal|NEURAMINIDASE INHIBITION ASSAY||||INVESTIGATOR|PATHOLOGIST|U|4|Visit_4|65|5|FOLLOW-UP|2020-09-30|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-02|P1Y2M10DT2H30M|UNKNOWN|2020-10-16|BEFORE|2020-10-30
e|RS|bf069a02-03a6-4013-b16d-d7c954a6cc3d|8|MRDIND|Minimal Residual Disease Indicator|AJCC V7|[?]|Anson U|OPTIMAL MORPHOLOGIC RESPONSE|1|mMU/mL|POTENTIOMETRY||||SIBLING|ADJUDICATOR 3|Y|4|Visit_4|65|7|TREATMENT|2020-09-30|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-02|P1Y2M10DT2H30M|BEFORE|2020-10-06|BEFORE|2020-10-18
e|RS|bf069a02-03a6-4013-b16d-d7c954a6cc3d|9|MOLRESP|Molecular Response|iRECIST|[?]|kPa/L/sec|PSA PROGRESSION|1|BAR|HIGH RESOLUTION MELT ANALYSIS||Y||FRIEND|OPTOMETRIST|Y|5|Visit_5|90|3|TREATMENT|2020-10-25|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-29|P1Y2M10DT2H30M|AFTER|2020-10-28|BEFORE|2020-10-30
e|RS|bf069a02-03a6-4013-b16d-d7c954a6cc3d|10|BESTRESP|Best Overall Response|AJCC V7|||CMR|1|mL/cm H2O|ACCELERATOR MASS SPECTROMETRY|Y||Y|INVESTIGATOR|PATHOLOGIST 2|U|5|Visit_5|90|4|TREATMENT|2020-10-25|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-29|P1Y2M10DT2H30M|UNKNOWN|2020-08-14|AFTER|2020-08-21
e|RS|c40fc52b-2668-4fab-b051-5b258da72f2c|1|MRDIND|Minimal Residual Disease Indicator|GUPPY OVARIAN CANCER 2002|[?]|GPL U|PMR|1|yd|CONFOCAL MICROSCOPY||||CHILD|MICROSCOPIST 2|U|1|Visit_1|10|1|TREATMENT|2020-10-11|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-01|P1Y2M10DT2H30M|UNKNOWN|2020-10-15|AFTER|2020-10-20
e|RS|c40fc52b-2668-4fab-b051-5b258da72f2c|2|METSIND|Metastatic Indicator|WHO BREAST CANCER 2006|||MORPHOLOGIC LEUKEMIA-FREE STATE|1|psi|SINGLE-MOLECULE ARRAY|||Y|INTERVIEWER|HEMATOLOGIST|NA|1|Visit_1|10|7|SCREENING|2020-10-11|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-01|P1Y2M10DT2H30M|UNKNOWN|2020-10-21|BEFORE|2020-12-15
e|RS|c40fc52b-2668-4fab-b051-5b258da72f2c|3|CPRFSTAT|Clinical Performance Status|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|||MORPHOLOGIC CR|1|ukat|SINGLE-SLICE SPIRAL CT|||Y|HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|U|2|Visit_2|25|2|SCREENING|2020-10-26|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-13|P1Y2M10DT2H30M|BEFORE|2020-12-05|BEFORE|2020-12-18
e|RS|c40fc52b-2668-4fab-b051-5b258da72f2c|4|MRDIND|Minimal Residual Disease Indicator|RANO|[?]|s^-1(%O2)^-1|MORPHOLOGIC CR|1|/40 HPFs|AMSLER GRID||||HEALTH CARE PROFESSIONAL|PATHOLOGIST|Y|2|Visit_2|25|2|SCREENING|2020-10-26|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-13|P1Y2M10DT2H30M|BEFORE|2020-11-07|ONGOING|2020-11-09
e|RS|c40fc52b-2668-4fab-b051-5b258da72f2c|5|ANATRESP|Anatomic Response|CHESON CLL 2006|||INCREASED|1|JAR|ELASTOGRAPHY|||Y|SIGNIFICANT OTHER|ONCOLOGIST 1|Y|3|Visit_3|40|6|TREATMENT|2020-11-10|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-03|P1Y2M10DT2H30M|UNKNOWN|2021-01-05|AFTER|2021-01-08
e|RS|c40fc52b-2668-4fab-b051-5b258da72f2c|6|TMRESP|Tumor Marker Response|UNSPECIFIED|[?]|PACKET|DECREASED|1|um/day|WRIGHT STAIN||Y||FRIEND|HEMATOLOGIST|NA|3|Visit_3|40|1|SCREENING|2020-11-10|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-03|P1Y2M10DT2H30M|COINCIDENT|2020-10-13|ONGOING|2020-12-16
e|RS|c40fc52b-2668-4fab-b051-5b258da72f2c|7|TMRESP|Tumor Marker Response|UNSPECIFIED|||PD|1|10^9 organisms/mg|APPLANATION TONOMETRY||Y|Y|PROXY|INTERNIST|U|4|Visit_4|65|2|TREATMENT|2020-12-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-30|P1Y2M10DT2H30M|UNKNOWN|2020-10-31|COINCIDENT|2020-11-08
e|RS|c40fc52b-2668-4fab-b051-5b258da72f2c|8|MNPTHIND|Minor Pathological Response Indicator|BLAZER COLORECTAL CANCER 2008|||WORSENED|1|nmol/mL/min|QUANTITATIVE ULTRASOUND|Y||Y|CLINICAL RESEARCH ASSOCIATE|RATER 2|NA|4|Visit_4|65|7|TREATMENT|2020-12-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-30|P1Y2M10DT2H30M|BEFORE|2020-11-19|COINCIDENT|2020-11-23
e|RS|c40fc52b-2668-4fab-b051-5b258da72f2c|9|MNPTHIND|Minor Pathological Response Indicator|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|Ci/L|UNEQUIVOCAL|1|/LSQN|CALIPER MEASUREMENT METHOD||||FAMILY MEMBER|ONCOLOGIST 1|N|5|Visit_5|90|1|FOLLOW-UP|2020-12-30|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-13|P1Y2M10DT2H30M|BEFORE|2020-11-10|BEFORE|2020-11-19
e|RS|c40fc52b-2668-4fab-b051-5b258da72f2c|10|METSIND|Metastatic Indicator|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|||CYTOGENETIC NO RESPONSE|1|10^6 organisms/mL|ANGIOGRAPHY|||Y|NON-HEALTH CARE PROFESSIONAL|OPTOMETRIST|U|5|Visit_5|90|4|SCREENING|2020-12-30|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-13|P1Y2M10DT2H30M|AFTER|2020-12-05|AFTER|2020-12-22
e|RS|d7c792d8-fc98-41ab-8a9e-59de1e186a06|1|CYTORESP|Cytogenetic Response|NCIWG CHESON CLL 1996|[?]|10^3 CFU/g|NOT ALL EVALUATED|1|GBq/mg|ANGIOGRAPHY||||DOMESTIC PARTNER|ADJUDICATOR 1|U|1|Visit_1|10|3|TREATMENT|2020-07-28|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-22|P1Y2M10DT2H30M|COINCIDENT|2020-09-27|BEFORE|2020-10-14
e|RS|d7c792d8-fc98-41ab-8a9e-59de1e186a06|2|METBRESP|Metabolic Response|MONTSERRAT CLL 1989|||PR WITH LYMPHOCYTOSIS|1|Siemens|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|Y||Y|ADJUDICATION COMMITTEE|MICROSCOPIST 2|Y|1|Visit_1|10|5|TREATMENT|2020-07-28|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-22|P1Y2M10DT2H30M|BEFORE|2020-09-16|COINCIDENT|2020-09-20
e|RS|d7c792d8-fc98-41ab-8a9e-59de1e186a06|3|RDIORESP|Radiologic Response|MASS|||cPR|1|mL/min/1.73m2|MS/MS||Y|Y|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST|U|2|Visit_2|25|5|TREATMENT|2020-08-12|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-01|P1Y2M10DT2H30M|UNKNOWN|2020-07-29|ONGOING|2020-10-17
e|RS|d7c792d8-fc98-41ab-8a9e-59de1e186a06|4|HEMARESP|Hematologic Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|||CYTOGENETIC PR|1|mU|ULTRASOUND|||Y|CLINICAL STUDY SPONSOR|PHYSIOTHERAPIST|NA|2|Visit_2|25|7|TREATMENT|2020-08-12|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-01|P1Y2M10DT2H30M|COINCIDENT|2020-08-28|AFTER|2020-09-15
e|RS|d7c792d8-fc98-41ab-8a9e-59de1e186a06|5|CYTORESP|Cytogenetic Response|KEAM BREAST CANCER 2013|[?]|CONTAINER|iCPD|1|g/m2|MAMMOGRAPHY|Y|||PROXY|RADIOLOGIST 2|Y|3|Visit_3|40|1|TREATMENT|2020-08-27|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-19|P1Y2M10DT2H30M|BEFORE|2020-10-03|AFTER|2020-10-10
e|RS|d7c792d8-fc98-41ab-8a9e-59de1e186a06|6|CYTORESP|Cytogenetic Response|PRINCE TCELL LYMPHOMA 2010|[?]|mL/s/m2|mCR|1|mPa|ELLA|Y|||DOMESTIC PARTNER|DEVELOPMENTAL PSYCHOLOGIST|NA|3|Visit_3|40|5|TREATMENT|2020-08-27|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-19|P1Y2M10DT2H30M|COINCIDENT|2020-08-08|ONGOING|2020-09-27
e|RS|d7c792d8-fc98-41ab-8a9e-59de1e186a06|7|HEMARESP|Hematologic Response|PETIT BREAST CANCER 2001|||CR-CT|1|BLOCKS|MICRODENSITOMETRY|||Y|PARENT|CLINICAL PATHOLOGIST|U|4|Visit_4|65|6|WASHOUT|2020-09-21|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-25|P1Y2M10DT2H30M|AFTER|2020-09-01|BEFORE|2020-10-01
e|RS|d7c792d8-fc98-41ab-8a9e-59de1e186a06|8|MRPHRESP|Morphologic Response|IWG CHESON MDS 2006|||HI-N|1|mmol/min/kPa/L|FUNCTIONAL MRI|Y||Y|ADJUDICATION COMMITTEE|ADJUDICATOR 1|Y|4|Visit_4|65|2|FOLLOW-UP|2020-09-21|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-25|P1Y2M10DT2H30M|UNKNOWN|2020-08-01|COINCIDENT|2020-10-09
e|RS|d7c792d8-fc98-41ab-8a9e-59de1e186a06|9|NEWLIND|New Lesion Indicator|BRUGGEMANN MRD 2010|[?]|mg/dose|OPTIMAL MORPHOLOGIC RESPONSE|1|mU|LC-FL||||CLINICAL STUDY SPONSOR|ONCOLOGIST 1|N|5|Visit_5|90|1|SCREENING|2020-10-16|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-15|P1Y2M10DT2H30M|BEFORE|2020-09-06|COINCIDENT|2020-09-25
e|RS|d7c792d8-fc98-41ab-8a9e-59de1e186a06|10|TMRESP|Tumor Marker Response|UNSPECIFIED|[?]|umol/L|UNFAVORABLE RESPONSE|1|g/cm2|AUDIOMETRY||||INTERVIEWER|RATER|Y|5|Visit_5|90|6|WASHOUT|2020-10-16|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-15|P1Y2M10DT2H30M|AFTER|2020-08-11|COINCIDENT|2020-09-17
e|RS|f7773659-f207-4b29-8389-3aa766a6337a|1|CLINRESP|Clinical Response|SHINDOH COLORECTAL CANCER 2013|||iPR|1|g/animal/wk|MICROPARTICLE ENZYME IMMUNOASSAY|||Y|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST|NA|1|Visit_1|10|6|TREATMENT|2020-10-19|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-04|P1Y2M10DT2H30M|UNKNOWN|2020-12-30|BEFORE|2021-01-06
e|RS|f7773659-f207-4b29-8389-3aa766a6337a|2|SYMPTDTR|Symptomatic Deterioration|WHO BREAST CANCER 2006|[?]|g/dL|PR WITH LYMPHOCYTOSIS|1|IMPLANT|PHOROPTER|Y|||FAMILY MEMBER|RADIOLOGIST 2|NA|1|Visit_1|10|1|TREATMENT|2020-10-19|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-04|P1Y2M10DT2H30M|BEFORE|2020-11-01|ONGOING|2021-01-06
e|RS|f7773659-f207-4b29-8389-3aa766a6337a|3|MRDRESP|Minimal Residual Disease Response|CHESON CLL 2012|[?]|/4.0 mL|iCR|1|m2|RYAN BLUE STAIN||Y||ADJUDICATION COMMITTEE|OTOLARYNGOLOGIST|N|2|Visit_2|25|7|SCREENING|2020-11-03|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-10|P1Y2M10DT2H30M|UNKNOWN|2020-12-07|BEFORE|2021-01-06
e|RS|f7773659-f207-4b29-8389-3aa766a6337a|4|ANATRESP|Anatomic Response|BURCOMBE BREAST CANCER 2005|[?]|10^7 CFU/mL|CR-CT|1|umol/day|MANUAL CLOT DETECTION|Y|||CLINICAL RESEARCH ASSOCIATE|OPHTHALMOLOGIST|Y|2|Visit_2|25|7|TREATMENT|2020-11-03|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-10|P1Y2M10DT2H30M|BEFORE|2020-11-25|AFTER|2020-12-10
e|RS|f7773659-f207-4b29-8389-3aa766a6337a|5|NTRGRESP|Non-target Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|mg/m2/h|IMMUNOPHENOTYPIC CR|1|ug/m2/day|ICC||||VENDOR|ONCOLOGIST|Y|3|Visit_3|40|7|TREATMENT|2020-11-18|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-13|P1Y2M10DT2H30M|AFTER|2020-12-30|AFTER|2021-01-10
e|RS|f7773659-f207-4b29-8389-3aa766a6337a|6|ANATRESP|Anatomic Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|TROCHE|DISEASE TRANSFORMATION|1|mg/mL/min|AURAMINE STAIN|Y|||NON-HEALTH CARE PROFESSIONAL|INTERNIST|N|3|Visit_3|40|6|SCREENING|2020-11-18|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-13|P1Y2M10DT2H30M|BEFORE|2021-01-13|BEFORE|2021-01-16
e|RS|f7773659-f207-4b29-8389-3aa766a6337a|7|HEMARESP|Hematologic Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|HOMEOPATHIC DILUTION|CYTOGENETIC NO RESPONSE|1|mL/(min*100mL)|ULTRASOUND||||ADJUDICATION COMMITTEE|READER 2|N|4|Visit_4|65|6|TREATMENT|2020-12-13|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-23|P1Y2M10DT2H30M|UNKNOWN|2020-12-18|AFTER|2020-12-30
e|RS|f7773659-f207-4b29-8389-3aa766a6337a|8|BONERESP|Bone Response|PERCIST|[?]|Log10 ELISA unit|NR|1|mL/animal/wk|LC-FL||||SIBLING|PEDIATRIC NEUROLOGIST|N|4|Visit_4|65|1|SCREENING|2020-12-13|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-23|P1Y2M10DT2H30M|AFTER|2020-10-12|COINCIDENT|2020-10-24
e|RS|f7773659-f207-4b29-8389-3aa766a6337a|9|PATHRESP|Pathologic Response|HAMAOKA BREAST CANCER 2010|[?]|Bq/mg|HI-P|1|CIGARETTE|ELECTROCHEMILUMINESCENCE||||SIBLING|READER 2|Y|5|Visit_5|90|3|SCREENING|2021-01-07|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-15|P1Y2M10DT2H30M|UNKNOWN|2020-12-15|COINCIDENT|2021-01-08
e|RS|f7773659-f207-4b29-8389-3aa766a6337a|10|CYTORESP|Cytogenetic Response|SCHER PROSTATE CANCER 2011|[?]|GLOBULE|UNEQUIVOCAL|1|foz_br|POLYSOMNOGRAPHY||||FAMILY MEMBER|ONCOLOGIST 2|U|5|Visit_5|90|3|SCREENING|2021-01-07|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-15|P1Y2M10DT2H30M|BEFORE|2020-12-14|COINCIDENT|2021-01-07
e|RS|9fa8c7af-c759-420d-a548-cc24c7ddbcdf|1|NEWLIND|New Lesion Indicator|NCCN ALL MRD 2014|[?]|RING|CRi|1|kg/cm2|ACRIDINE ORANGE STAIN||Y||STUDY SUBJECT|RADIOLOGIST 1|Y|1|Visit_1|10|5|SCREENING|2021-01-07|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-23|P1Y2M10DT2H30M|COINCIDENT|2021-03-28|BEFORE|2021-03-29
e|RS|9fa8c7af-c759-420d-a548-cc24c7ddbcdf|2|NTNERESP|Non-Target Non-Enhancing Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|||PR WITH LYMPHOCYTOSIS|1|U/g/day|LYMPHANGIOGRAPHY|Y||Y|VENDOR|RATER 2|Y|1|Visit_1|10|3|WASHOUT|2021-01-07|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-23|P1Y2M10DT2H30M|UNKNOWN|2021-03-17|ONGOING|2021-04-04
e|RS|9fa8c7af-c759-420d-a548-cc24c7ddbcdf|3|CYTORESP|Cytogenetic Response|WOLCHOK SOLID TUMORS 2009|[?]|Gy|NON-QUANTIFIABLE MRD POSITIVITY|1|mL/min|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS||Y||STUDY SUBJECT|MICROSCOPIST 1|N|2|Visit_2|25|1|SCREENING|2021-01-22|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-03|P1Y2M10DT2H30M|COINCIDENT|2021-01-02|AFTER|2021-03-14
e|RS|9fa8c7af-c759-420d-a548-cc24c7ddbcdf|4|METSIND|Metastatic Indicator|IWG CHESON AML 2003|||HI-P|1|mMU/mL|DYNAMIC CONTRAST ENHANCED MRI|Y||Y|VENDOR|NEUROLOGIST 2|Y|2|Visit_2|25|7|WASHOUT|2021-01-22|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-03|P1Y2M10DT2H30M|AFTER|2021-01-03|AFTER|2021-03-23
e|RS|9fa8c7af-c759-420d-a548-cc24c7ddbcdf|5|NEWLWIND|New Lesion Worsening Indicator|GCIG RUSTIN OVARIAN CANCER 2011|[?]|m/sec2|HI-E|1|uV|MICROBIAL CULTURE, LIQUID||Y||INVESTIGATOR|ONCOLOGIST|N|3|Visit_3|40|1|TREATMENT|2021-02-06|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-24|P1Y2M10DT2H30M|AFTER|2021-03-08|COINCIDENT|2021-03-27
e|RS|9fa8c7af-c759-420d-a548-cc24c7ddbcdf|6|METSIND|Metastatic Indicator|CHOI GIST 2008|[?]|10^3 organisms/mL|MINOR PATHOLOGIC RESPONSE|1|Absorbance U/mL|JAEGER EYE CHART|Y|||INDEPENDENT ASSESSOR|DERMATOLOGIST|U|3|Visit_3|40|5|FOLLOW-UP|2021-02-06|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-24|P1Y2M10DT2H30M|BEFORE|2021-04-03|BEFORE|2021-04-05
e|RS|9fa8c7af-c759-420d-a548-cc24c7ddbcdf|7|MRDIND|Minimal Residual Disease Indicator|RECIST 1.0|[?]|mEq/dL|STABLE|1|vp/mL|FLUOROSCOPY||||FRIEND|RADIOLOGIST 1|U|4|Visit_4|65|3|WASHOUT|2021-03-03|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-15|P1Y2M10DT2H30M|COINCIDENT|2021-01-17|ONGOING|2021-02-03
e|RS|9fa8c7af-c759-420d-a548-cc24c7ddbcdf|8|HEMARESP|Hematologic Response|BRUGGEMANN MRD 2010|[?]|Enzyme U|MOLECULAR MAJOR RESPONSE|1|mL/m2|LYMPHANGIOGRAPHY||Y||SIGNIFICANT OTHER|CARDIOLOGIST|NA|4|Visit_4|65|2|SCREENING|2021-03-03|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-15|P1Y2M10DT2H30M|BEFORE|2021-02-04|AFTER|2021-02-28
e|RS|9fa8c7af-c759-420d-a548-cc24c7ddbcdf|9|NTRGRESP|Non-target Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|RATIO|IMPROVED|1|ug/day|IN VITRO GENE EXPRESSION ASSAY||Y||VENDOR|RATER 2|NA|5|Visit_5|90|3|TREATMENT|2021-03-28|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-23|P1Y2M10DT2H30M|AFTER|2021-01-14|COINCIDENT|2021-03-18
e|RS|9fa8c7af-c759-420d-a548-cc24c7ddbcdf|10|METBRESP|Metabolic Response|PCWG BUBLEY PROSTATE CANCER 1999|||CR|1|BEAM BREAKS|LIGHT SCATTERING SPECTROSCOPY|||Y|INTERVIEWER|ADJUDICATOR 1|N|5|Visit_5|90|6|FOLLOW-UP|2021-03-28|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-23|P1Y2M10DT2H30M|UNKNOWN|2021-01-30|BEFORE|2021-03-06
e|RS|c0b85664-0ef6-4f93-8f84-ee87e1ca9f0f|1|BMIVLIND|Bone Marrow Involvement Indicator|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|U/m2/min|PR-CT|1|mV/sec|SEQUENCING||||DOMESTIC PARTNER|DEVELOPMENTAL PSYCHOLOGIST|NA|1|Visit_1|10|4|TREATMENT|2021-01-26|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-14|P1Y2M10DT2H30M|BEFORE|2021-03-08|BEFORE|2021-03-17
e|RS|c0b85664-0ef6-4f93-8f84-ee87e1ca9f0f|2|ANATRESP|Anatomic Response|LUGANO CLASSIFICATION|[?]|mL/cage/day|NOT ALL EVALUATED|1|mL/m2|HPLC-FL||Y||INTERVIEWER|ONCOLOGIST 1|Y|1|Visit_1|10|6|SCREENING|2021-01-26|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-14|P1Y2M10DT2H30M|COINCIDENT|2021-04-09|AFTER|2021-04-14
e|RS|c0b85664-0ef6-4f93-8f84-ee87e1ca9f0f|3|NTRGRESP|Non-target Response|LUGANO CLASSIFICATION|[?]|DAgU/mL|FAVORABLE RESPONSE|1|TRACE|SLIT LAMP||||GUARDIAN|FORENSIC PATHOLOGIST|U|2|Visit_2|25|6|FOLLOW-UP|2021-02-10|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-01|P1Y2M10DT2H30M|UNKNOWN|2021-01-27|BEFORE|2021-04-24
e|RS|c0b85664-0ef6-4f93-8f84-ee87e1ca9f0f|4|RDIORESP|Radiologic Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|PIPE|UNEQUIVOCAL|1|% INHIBITION|CONTRAST ENHANCED CT SCAN||||CHILD|DEVELOPMENTAL PSYCHOLOGIST|N|2|Visit_2|25|5|FOLLOW-UP|2021-02-10|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-01|P1Y2M10DT2H30M|COINCIDENT|2021-02-18|BEFORE|2021-03-26
e|RS|c0b85664-0ef6-4f93-8f84-ee87e1ca9f0f|5|CYTORESP|Cytogenetic Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|mg/kg|ABSENT MORPHOLOGIC RESPONSE|1|mEq/mL|FLUORESCENT IMMUNOASSAY||||CAREGIVER|RATER 2|N|3|Visit_3|40|5|TREATMENT|2021-02-25|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-23|P1Y2M10DT2H30M|AFTER|2021-03-07|COINCIDENT|2021-03-22
e|RS|c0b85664-0ef6-4f93-8f84-ee87e1ca9f0f|6|MNPTHIND|Minor Pathological Response Indicator|SCHER PROSTATE CANCER 2011|[?]|10^6 CFU/mL|pCR|1|umol/mg/min|CONGO RED STAIN|Y|||SIBLING|UROLOGIST|N|3|Visit_3|40|1|TREATMENT|2021-02-25|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-23|P1Y2M10DT2H30M|COINCIDENT|2021-02-27|BEFORE|2021-04-02
e|RS|c0b85664-0ef6-4f93-8f84-ee87e1ca9f0f|7|NTERESP|Non-Target Enhancing Response|EBMT BLADE MYELOMA 1998|[?]|L/h|DECREASED|1|10^9 organisms/mg|BRDU CELLULAR PROLIFERATION ASSAY||||INTERVIEWER|PEDIATRIC NEUROLOGIST|N|4|Visit_4|65|5|TREATMENT|2021-03-22|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-21|P1Y2M10DT2H30M|UNKNOWN|2021-04-20|BEFORE|2021-04-22
e|RS|c0b85664-0ef6-4f93-8f84-ee87e1ca9f0f|8|METBRESP|Metabolic Response|CHESON CLL 2012|||MRD NEGATIVITY|1|ug/cm2|JAFFE REACTION|||Y|GUARDIAN|READER 1|Y|4|Visit_4|65|1|TREATMENT|2021-03-22|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-21|P1Y2M10DT2H30M|BEFORE|2021-03-05|BEFORE|2021-04-07
e|RS|c0b85664-0ef6-4f93-8f84-ee87e1ca9f0f|9|TMRESP|Tumor Marker Response|PERCIST|||CYTOGENETIC NO RESPONSE|1|Ci/mL|ICC|Y||Y|PARENT|OPHTHALMOLOGIST|Y|5|Visit_5|90|6|TREATMENT|2021-04-16|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-15|P1Y2M10DT2H30M|UNKNOWN|2021-04-22|AFTER|2021-04-25
e|RS|c0b85664-0ef6-4f93-8f84-ee87e1ca9f0f|10|METBRESP|Metabolic Response|IWG CHESON AML 2003|||CHR|1|mU/L|LAPAROSCOPY||Y|Y|DOMESTIC PARTNER|ONCOLOGIST|Y|5|Visit_5|90|2|WASHOUT|2021-04-16|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-15|P1Y2M10DT2H30M|BEFORE|2021-01-20|AFTER|2021-02-08
e|RS|700049a2-ef66-466b-b1d8-f0800bcfde43|1|SYMPTDTR|Symptomatic Deterioration|KUMAR IMWG 2016|||MRD NEGATIVITY|1|10^4/L|TRANSESOPHAGEAL ECHOCARDIOGRAPHY||Y|Y|SIBLING|PATHOLOGIST 1|NA|1|Visit_1|10|6|WASHOUT|2020-06-27|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-12|P1Y2M10DT2H30M|BEFORE|2020-09-17|AFTER|2020-09-21
e|RS|700049a2-ef66-466b-b1d8-f0800bcfde43|2|NTERESP|Non-Target Enhancing Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|MPL U|MR|1|ng|LIGHT SCATTERING SPECTROSCOPY||||SIGNIFICANT OTHER|READER 2|NA|1|Visit_1|10|1|SCREENING|2020-06-27|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-12|P1Y2M10DT2H30M|BEFORE|2020-07-07|ONGOING|2020-07-18
e|RS|700049a2-ef66-466b-b1d8-f0800bcfde43|3|MRDIND|Minimal Residual Disease Indicator|PRINCE TCELL LYMPHOMA 2010|[?]|uL/dose|CYTOGENETIC MINOR RESPONSE|1|ug/dL|MAGNETIC RESONANCE ELASTOGRAPHY||Y||CHILD|NEUROLOGIST 2|U|2|Visit_2|25|5|SCREENING|2020-07-12|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-20|P1Y2M10DT2H30M|COINCIDENT|2020-08-19|AFTER|2020-09-19
e|RS|700049a2-ef66-466b-b1d8-f0800bcfde43|4|METSIND|Metastatic Indicator|CHOLLET BREAST CANCER 2002|[?]|cm2|SD|1|10^4/L|PAP STAIN|Y|Y||FAMILY MEMBER|NEUROLOGIST 2|U|2|Visit_2|25|2|WASHOUT|2020-07-12|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-20|P1Y2M10DT2H30M|COINCIDENT|2020-08-30|ONGOING|2020-09-09
e|RS|700049a2-ef66-466b-b1d8-f0800bcfde43|5|TMRESP|Tumor Marker Response|MASS|||NON-iCR/NON-iUPD|1|kg/cm2|MICRO BROTH DILUTION|||Y|SIBLING|FORENSIC PATHOLOGIST|NA|3|Visit_3|40|2|WASHOUT|2020-07-27|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-30|P1Y2M10DT2H30M|COINCIDENT|2020-07-03|ONGOING|2020-08-23
e|RS|700049a2-ef66-466b-b1d8-f0800bcfde43|6|MOLRESP|Molecular Response|UNSPECIFIED|[?]|umol/kg/min|UNEQUIVOCAL|1|10^7 TCID 50/dose|THICK SMEAR||||ADJUDICATION COMMITTEE|PEDIATRIC NEUROLOGIST|N|3|Visit_3|40|1|FOLLOW-UP|2020-07-27|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-30|P1Y2M10DT2H30M|BEFORE|2020-09-19|BEFORE|2020-09-20
e|RS|700049a2-ef66-466b-b1d8-f0800bcfde43|7|MJPTHIND|Major Pathological Response Indicator|PCWG SCHER PROSTATE CANCER 2016|[?]|VOXEL|MRD NEGATIVITY|1|mV|LYMPHANGIOGRAPHY|Y|||PROXY|READER|U|4|Visit_4|65|1|WASHOUT|2020-08-21|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-18|P1Y2M10DT2H30M|BEFORE|2020-07-13|COINCIDENT|2020-08-29
e|RS|700049a2-ef66-466b-b1d8-f0800bcfde43|8|BONERESP|Bone Response|SCHWARZ CERVICAL CANCER 2009|[?]|HOURS|CYTOGENETIC MINIMAL RESPONSE|1|TRANSDUCING UNIT|HIGH RESOLUTION CT|Y|||INTERVIEWER|DEVELOPMENTAL PSYCHOLOGIST|Y|4|Visit_4|65|2|TREATMENT|2020-08-21|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-18|P1Y2M10DT2H30M|UNKNOWN|2020-07-14|BEFORE|2020-09-17
e|RS|700049a2-ef66-466b-b1d8-f0800bcfde43|9|CYTORESP|Cytogenetic Response|DURIE MULTIPLE MYELOMA 2006|||MORPHOLOGIC CRi|1|mg/kg|MICROBIAL BIOCHEMICAL IDENTIFICATION|Y||Y|DOMESTIC PARTNER|CARDIOLOGIST|Y|5|Visit_5|90|5|WASHOUT|2020-09-15|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-25|P1Y2M10DT2H30M|UNKNOWN|2020-07-04|COINCIDENT|2020-08-12
e|RS|700049a2-ef66-466b-b1d8-f0800bcfde43|10|CPRFSTAT|Clinical Performance Status|BURCOMBE BREAST CANCER 2005|[?]|10^6 CFU/mL|CA125 75% RESPONSE|1|ppb|PHOTOMETRIC CLOT DETECTION||||CAREGIVER|READER 3|NA|5|Visit_5|90|2|FOLLOW-UP|2020-09-15|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-25|P1Y2M10DT2H30M|BEFORE|2020-08-20|COINCIDENT|2020-09-11
e|RS|00d906a6-2d14-4199-aff9-524388c5117f|1|OVRLRESP|Overall Response|CHESON CLL 2006|[?]|min*mg/mL|FAVORABLE RESPONSE|1|cmHg|TRIPLE-PHASE SPIRAL CT SCAN||Y||CLINICAL STUDY SPONSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|1|Visit_1|10|1|WASHOUT|2020-11-24|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-12|P1Y2M10DT2H30M|BEFORE|2021-01-06|BEFORE|2021-02-03
e|RS|00d906a6-2d14-4199-aff9-524388c5117f|2|NEWLPROG|New Lesion Progression|PETIT BREAST CANCER 2001|||IMPROVED|1|mg/mL/day|FLAME PHOTOMETRY||Y|Y|SIGNIFICANT OTHER|MICROSCOPIST|NA|1|Visit_1|10|6|FOLLOW-UP|2020-11-24|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-12|P1Y2M10DT2H30M|BEFORE|2021-01-11|BEFORE|2021-01-19
e|RS|00d906a6-2d14-4199-aff9-524388c5117f|3|NEWLPROG|New Lesion Progression|EBMT BLADE MYELOMA 1998|[?]|LENS|INCREASED|1|BAU/mL|SPIROMETRY||||INDEPENDENT ASSESSOR|OPHTHALMOLOGIST|Y|2|Visit_2|25|4|TREATMENT|2020-12-09|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-20|P1Y2M10DT2H30M|BEFORE|2020-11-26|ONGOING|2021-02-05
e|RS|00d906a6-2d14-4199-aff9-524388c5117f|4|LIVRRESP|Liver Response|IWG CHESON AML 2003|[?]|ug/dL|CYTOGENETIC MINOR RESPONSE|1|kg|INTERRUPTER TECHNIQUE||Y||CAREGIVER|MICROSCOPIST 2|NA|2|Visit_2|25|3|TREATMENT|2020-12-09|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-20|P1Y2M10DT2H30M|COINCIDENT|2020-12-25|BEFORE|2021-01-21
e|RS|00d906a6-2d14-4199-aff9-524388c5117f|5|METSIND|Metastatic Indicator|CHESON CLL 2012|[?]|nkat|COMPLETE MRD RESPONSE|1|mL/s/m2|FARNSWORTH-MUNSELL 100 HUE TEST||||CLINICAL STUDY SPONSOR|HEMATOLOGIST|N|3|Visit_3|40|4|TREATMENT|2020-12-24|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-28|P1Y2M10DT2H30M|COINCIDENT|2020-11-27|COINCIDENT|2021-01-26
e|RS|00d906a6-2d14-4199-aff9-524388c5117f|6|NTRGRESP|Non-target Response|RECICL|[?]|pg/dL|CYTOGENETIC PR|1|EP U|MICROPARTICLE ENZYME IMMUNOASSAY||||SPOUSE|RATER 1|U|3|Visit_3|40|1|TREATMENT|2020-12-24|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-28|P1Y2M10DT2H30M|AFTER|2021-01-06|ONGOING|2021-01-07
e|RS|00d906a6-2d14-4199-aff9-524388c5117f|7|CLINRESP|Clinical Response|DURIE MULTIPLE MYELOMA 2006|[?]|10^6 CFU|UNEQUIVOCAL|1|min*mg/mL|CISH||Y||SPOUSE|ADJUDICATOR 2|N|4|Visit_4|65|5|SCREENING|2021-01-18|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-17|P1Y2M10DT2H30M|COINCIDENT|2021-02-11|AFTER|2021-02-18
e|RS|00d906a6-2d14-4199-aff9-524388c5117f|8|HEMARESP|Hematologic Response|IWG CHESON MDS 2000|[?]|gtt|cCR|1|uL|PHOROPTER||||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 1|NA|4|Visit_4|65|4|TREATMENT|2021-01-18|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-17|P1Y2M10DT2H30M|BEFORE|2021-01-31|COINCIDENT|2021-02-10
e|RS|00d906a6-2d14-4199-aff9-524388c5117f|9|STRUSTAT|Steroid Use Status|MACDONALD GLIOMA 1990|[?]|FEU|COMPLETE MRD RESPONSE|1|gMFI|HILLMEN COLOR CHART||||CHILD|PEDIATRIC NEUROLOGIST|NA|5|Visit_5|90|6|TREATMENT|2021-02-12|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-30|P1Y2M10DT2H30M|UNKNOWN|2021-01-09|AFTER|2021-01-16
e|RS|00d906a6-2d14-4199-aff9-524388c5117f|10|ANATRESP|Anatomic Response|MACDONALD GLIOMA 1990|||CR|1|Enzyme U|IMMUNOBLOT|||Y|CAREGIVER|MICROSCOPIST|N|5|Visit_5|90|4|WASHOUT|2021-02-12|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-30|P1Y2M10DT2H30M|AFTER|2021-01-15|BEFORE|2021-02-16
e|RS|2fcc5910-bce0-4510-b17e-3925850d6d32|1|BESTRESP|Best Overall Response|SCHER PROSTATE CANCER 2011|[?]|mEq/dL|MOLECULAR CR|1|genEq/mL|DOPPLER ULTRASOUND||||FAMILY MEMBER|RATER 2|U|1|Visit_1|10|1|SCREENING|2020-12-16|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-12|P1Y2M10DT2H30M|AFTER|2021-02-10|BEFORE|2021-03-01
e|RS|2fcc5910-bce0-4510-b17e-3925850d6d32|2|MJPTHIND|Major Pathological Response Indicator|IRANO 2015|[?]|kPa|OPTIMAL MORPHOLOGIC RESPONSE|1|mmol/mol|NEPHELOMETRY||Y||SIBLING|ONCOLOGIST 1|Y|1|Visit_1|10|2|WASHOUT|2020-12-16|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-12|P1Y2M10DT2H30M|UNKNOWN|2021-03-13|AFTER|2021-03-15
e|RS|2fcc5910-bce0-4510-b17e-3925850d6d32|3|TRGRESP|Target Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|mL/g/min|CRi|1|msec|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY||||ADJUDICATION COMMITTEE|OPTOMETRIST|Y|2|Visit_2|25|2|SCREENING|2020-12-31|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-17|P1Y2M10DT2H30M|AFTER|2021-02-25|COINCIDENT|2021-03-03
e|RS|2fcc5910-bce0-4510-b17e-3925850d6d32|4|HEMARESP|Hematologic Response|SCHER PROSTATE CANCER 2011|||RELAPSED DISEASE FROM CR OR PR|1|m/sec|WESTERGREN|||Y|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 1|Y|2|Visit_2|25|3|SCREENING|2020-12-31|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-17|P1Y2M10DT2H30M|BEFORE|2021-01-31|BEFORE|2021-03-06
e|RS|2fcc5910-bce0-4510-b17e-3925850d6d32|5|NEWLPROG|New Lesion Progression|BURCOMBE BREAST CANCER 2005|[?]|Bq/g|PSEUDORESPONSE|1|nmol/L/min|ELECTROMYOGRAPHY||Y||FAMILY MEMBER|RATER 2|N|3|Visit_3|40|4|SCREENING|2021-01-15|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-02|P1Y2M10DT2H30M|AFTER|2021-03-04|AFTER|2021-03-07
e|RS|2fcc5910-bce0-4510-b17e-3925850d6d32|6|NTNERESP|Non-Target Non-Enhancing Response|HARTMAN PANCREATIC CANCER 2012|[?]|mL/kg/day|NON-PD|1|10^3 DNA copies/mL|MICROBIAL CULTURE, LIQUID||||SPOUSE|MICROSCOPIST 2|N|3|Visit_3|40|7|TREATMENT|2021-01-15|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-02|P1Y2M10DT2H30M|UNKNOWN|2021-01-25|AFTER|2021-02-24
e|RS|2fcc5910-bce0-4510-b17e-3925850d6d32|7|DRCRIND|Disease Recurrence Indicator|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|U|RELAPSED DISEASE FROM CR|1|umol/mg/min|MICROPARTICLE ENZYME IMMUNOASSAY|Y|||DOMESTIC PARTNER|ENDOCRINOLOGIST|Y|4|Visit_4|65|3|FOLLOW-UP|2021-02-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-20|P1Y2M10DT2H30M|UNKNOWN|2020-12-23|BEFORE|2021-01-22
e|RS|2fcc5910-bce0-4510-b17e-3925850d6d32|8|METSIND|Metastatic Indicator|RAJKUMAR MYELOMA 2011|[?]|m2|MR|1|mL/animal/day|GEL ELECTROPHORESIS||||DOMESTIC PARTNER|ONCOLOGIST 1|U|4|Visit_4|65|3|WASHOUT|2021-02-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-20|P1Y2M10DT2H30M|BEFORE|2020-12-29|COINCIDENT|2021-01-14
e|RS|2fcc5910-bce0-4510-b17e-3925850d6d32|9|NEWLWIND|New Lesion Worsening Indicator|KUMAR IMWG 2016|[?]|cmH2O*s2/mL|CYTOGENETIC NO RESPONSE|1|VIRTUAL PIXEL|SPIROMETRY|Y|||CLINICAL RESEARCH ASSOCIATE|DERMATOLOGIST|N|5|Visit_5|90|7|FOLLOW-UP|2021-03-06|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-17|P1Y2M10DT2H30M|BEFORE|2020-12-16|BEFORE|2021-02-17
e|RS|2fcc5910-bce0-4510-b17e-3925850d6d32|10|MRDIND|Minimal Residual Disease Indicator|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|lx|iUPD|1|Weber|DUKE INCISION METHOD|Y|Y||CLINICAL RESEARCH ASSOCIATE|FORENSIC PATHOLOGIST|Y|5|Visit_5|90|4|TREATMENT|2021-03-06|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-17|P1Y2M10DT2H30M|BEFORE|2021-03-01|COINCIDENT|2021-03-15
e|RS|a17fa9ed-b1fa-451c-8f51-ed1ab1b75366|1|NEWLWIND|New Lesion Worsening Indicator|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|dram|PD-CT|1|mm/h|PET/MRI SCAN|Y|Y||INVESTIGATOR|MICROSCOPIST|U|1|Visit_1|10|4|TREATMENT|2020-08-31|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-27|P1Y2M10DT2H30M|BEFORE|2020-11-01|BEFORE|2020-11-26
e|RS|a17fa9ed-b1fa-451c-8f51-ed1ab1b75366|2|NEWLPROG|New Lesion Progression|AJCC V8|[?]|copies/ug|cPR|1|gMFI|ICP-MS||||GUARDIAN|PHYSIOTHERAPIST|U|1|Visit_1|10|6|WASHOUT|2020-08-31|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-27|P1Y2M10DT2H30M|UNKNOWN|2020-09-23|BEFORE|2020-11-03
e|RS|a17fa9ed-b1fa-451c-8f51-ed1ab1b75366|3|CYTORESP|Cytogenetic Response|HARTMANN GERM CELL CANCER 2002|[?]|BAR|CYTOGENETIC MINIMAL RESPONSE|1|kcal/day|MANUAL CLOT DETECTION||||GUARDIAN|NEUROLOGIST 2|N|2|Visit_2|25|4|TREATMENT|2020-09-15|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-09|P1Y2M10DT2H30M|AFTER|2020-11-06|ONGOING|2020-11-26
e|RS|a17fa9ed-b1fa-451c-8f51-ed1ab1b75366|4|CYTORESP|Cytogenetic Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|g/animal|INCREASED|1|fg|NEXT GENERATION SEQUENCING|Y|||VENDOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|2|Visit_2|25|1|TREATMENT|2020-09-15|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-09|P1Y2M10DT2H30M|UNKNOWN|2020-09-17|AFTER|2020-10-05
e|RS|a17fa9ed-b1fa-451c-8f51-ed1ab1b75366|5|MNPTHIND|Minor Pathological Response Indicator|KUMAR IMWG 2016|[?]|in|SD|1|mg/mol|TRIPLE-PHASE SPIRAL CT SCAN||||PROXY|MICROSCOPIST 2|U|3|Visit_3|40|7|SCREENING|2020-09-30|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-03|P1Y2M10DT2H30M|COINCIDENT|2020-09-29|AFTER|2020-11-02
e|RS|a17fa9ed-b1fa-451c-8f51-ed1ab1b75366|6|NEWLWIND|New Lesion Worsening Indicator|RAJKUMAR MYELOMA 2011|[?]|cmH2O*s/mL|NON-QUANTIFIABLE MRD POSITIVITY|1|h*%|MAGNETIC RESONANCE ELASTOGRAPHY||||INVESTIGATOR|ADJUDICATOR 1|N|3|Visit_3|40|4|FOLLOW-UP|2020-09-30|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-03|P1Y2M10DT2H30M|UNKNOWN|2020-09-26|AFTER|2020-10-23
e|RS|a17fa9ed-b1fa-451c-8f51-ed1ab1b75366|7|MJPTHIND|Major Pathological Response Indicator|PRINCE TCELL LYMPHOMA 2010|[?]|kV|NON-QUANTIFIABLE MRD POSITIVITY|1|PIPE|MRS|Y|||GUARDIAN|RATER 2|NA|4|Visit_4|65|7|TREATMENT|2020-10-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-14|P1Y2M10DT2H30M|AFTER|2020-10-09|COINCIDENT|2020-11-03
e|RS|a17fa9ed-b1fa-451c-8f51-ed1ab1b75366|8|SFTSRESP|Soft Tissue Response|KEAM BREAST CANCER 2013|[?]|10^6/Ejaculate U|CR-CT|1|m2|SPIROMETRY|Y|||CLINICAL RESEARCH COORDINATOR|RATER 2|NA|4|Visit_4|65|4|WASHOUT|2020-10-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-14|P1Y2M10DT2H30M|AFTER|2020-10-08|BEFORE|2020-11-02
e|RS|a17fa9ed-b1fa-451c-8f51-ed1ab1b75366|9|BMIVLIND|Bone Marrow Involvement Indicator|IWC HALLEK CLL 2008|[?]|cs|CHR|1|MPS U|IMMUNE REPERTOIRE DEEP SEQUENCING||||FAMILY MEMBER|FORENSIC PATHOLOGIST|Y|5|Visit_5|90|7|TREATMENT|2020-11-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-15|P1Y2M10DT2H30M|BEFORE|2020-10-30|BEFORE|2020-11-25
e|RS|a17fa9ed-b1fa-451c-8f51-ed1ab1b75366|10|RDIORESP|Radiologic Response|GCIG RUSTIN OVARIAN CANCER 2011|||DISEASE TRANSFORMATION|1|C|ELECTROCHEMILUMINESCENCE|Y|Y|Y|STUDY SUBJECT|RADIOLOGIST 1|U|5|Visit_5|90|6|TREATMENT|2020-11-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-15|P1Y2M10DT2H30M|COINCIDENT|2020-11-24|ONGOING|2020-11-28
e|RS|6020ccb5-0bbe-4318-b99f-7a69b10b85a4|1|BMIVLIND|Bone Marrow Involvement Indicator|DOHNER AML 2010|||cCR|1|BOX|ACCELERATOR MASS SPECTROMETRY|Y||Y|PARENT|OPTOMETRIST|Y|1|Visit_1|10|2|TREATMENT|2020-07-26|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-11|P1Y2M10DT2H30M|BEFORE|2020-07-23|ONGOING|2020-10-21
e|RS|6020ccb5-0bbe-4318-b99f-7a69b10b85a4|2|MJPTHIND|Major Pathological Response Indicator|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|ug/kg/min|CRi|1|mL/100g/min|CHROMATOGRAPHY||||PROXY|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|1|Visit_1|10|4|TREATMENT|2020-07-26|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-11|P1Y2M10DT2H30M|BEFORE|2020-10-16|ONGOING|2020-10-21
e|RS|6020ccb5-0bbe-4318-b99f-7a69b10b85a4|3|METSIND|Metastatic Indicator|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|||DECREASED|1|Hz|ELECTROGASTROGRAPHY|||Y|GUARDIAN|RADIOLOGIST|N|2|Visit_2|25|3|TREATMENT|2020-08-10|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-17|P1Y2M10DT2H30M|BEFORE|2020-10-13|ONGOING|2020-10-16
e|RS|6020ccb5-0bbe-4318-b99f-7a69b10b85a4|4|METBRESP|Metabolic Response|WOLCHOK SOLID TUMORS 2009|[?]|mOsm/L|IMMUNOPHENOTYPIC CR|1|mm3/mm2/year|TARGETED TRANSCRIPTOME SEQUENCING||Y||CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 3|N|2|Visit_2|25|1|WASHOUT|2020-08-10|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-17|P1Y2M10DT2H30M|COINCIDENT|2020-09-30|BEFORE|2020-10-20
e|RS|6020ccb5-0bbe-4318-b99f-7a69b10b85a4|5|METSIND|Metastatic Indicator|RANO ELLINGSON 2017|[?]|%|iUPD|1|mEq/uL|SXA SCAN||||VENDOR|ONCOLOGIST|N|3|Visit_3|40|4|FOLLOW-UP|2020-08-25|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-23|P1Y2M10DT2H30M|COINCIDENT|2020-09-22|COINCIDENT|2020-10-23
e|RS|6020ccb5-0bbe-4318-b99f-7a69b10b85a4|6|DRCRIND|Disease Recurrence Indicator|IWC HALLEK CLL 2008|[?]|m/sec|NON-QUANTIFIABLE MRD POSITIVITY|1|fL|MALDI-TOF|Y|||CAREGIVER|ADJUDICATOR 3|N|3|Visit_3|40|7|WASHOUT|2020-08-25|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-23|P1Y2M10DT2H30M|UNKNOWN|2020-08-07|AFTER|2020-08-10
e|RS|6020ccb5-0bbe-4318-b99f-7a69b10b85a4|7|BESTRESP|Best Overall Response|CHESON CLL 2006|[?]|Bq|NOT ALL EVALUATED|1|10^12/L|IHC||Y||DOMESTIC PARTNER|NEUROLOGIST 2|Y|4|Visit_4|65|5|TREATMENT|2020-09-19|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-25|P1Y2M10DT2H30M|BEFORE|2020-08-12|AFTER|2020-10-23
e|RS|6020ccb5-0bbe-4318-b99f-7a69b10b85a4|8|DRCRIND|Disease Recurrence Indicator|HARTMANN GERM CELL CANCER 2002|[?]|/40 HPFs|PSEUDORESPONSE|1|copies/ug|PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY||||SPOUSE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|4|Visit_4|65|2|TREATMENT|2020-09-19|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-25|P1Y2M10DT2H30M|AFTER|2020-09-23|ONGOING|2020-09-30
e|RS|6020ccb5-0bbe-4318-b99f-7a69b10b85a4|9|HEMARESP|Hematologic Response|LEE LUNG CANCER 2011|[?]|ug/L DDU|INCREASED|1|ug/g/min|FLOCCULATION||||SIBLING|PEDIATRIC NEUROLOGIST|Y|5|Visit_5|90|5|TREATMENT|2020-10-14|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-23|P1Y2M10DT2H30M|COINCIDENT|2020-08-24|COINCIDENT|2020-09-28
e|RS|6020ccb5-0bbe-4318-b99f-7a69b10b85a4|10|NEWLPROG|New Lesion Progression|iRECIST|[?]|EID 50/mL|RELAPSED DISEASE|1|SPRAY|FLUORESCENT LIFETIME IMAGING MICROSCOPY||Y||INDEPENDENT ASSESSOR|ENDOCRINOLOGIST|NA|5|Visit_5|90|3|TREATMENT|2020-10-14|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-23|P1Y2M10DT2H30M|COINCIDENT|2020-09-03|AFTER|2020-10-07
e|RS|b6e22f6b-25a9-4d18-8de1-2bb4c261e4c9|1|SYMPTDTR|Symptomatic Deterioration|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|mL/cm|FAVORABLE RESPONSE|1|g|HIGH RESOLUTION CT|Y|||CHILD|NEUROLOGIST 1|N|1|Visit_1|10|6|TREATMENT|2020-10-28|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-20|P1Y2M10DT2H30M|UNKNOWN|2020-12-01|COINCIDENT|2020-12-16
e|RS|b6e22f6b-25a9-4d18-8de1-2bb4c261e4c9|2|NTLWIND|Non-Target Lesion Worsening Indicator|PALUMBO MULTIPLE MYELOMA 2009|[?]|pmol/L|CYTOGENETIC MINIMAL RESPONSE|1|GBq/g|MYELOPEROXIDASE STAIN||||CLINICAL STUDY SPONSOR|PATHOLOGIST 1|Y|1|Visit_1|10|4|TREATMENT|2020-10-28|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-20|P1Y2M10DT2H30M|COINCIDENT|2021-01-25|COINCIDENT|2021-01-26
e|RS|b6e22f6b-25a9-4d18-8de1-2bb4c261e4c9|3|MRDIND|Minimal Residual Disease Indicator|GUPPY OVARIAN CANCER 2002|[?]|/5x10^4 WBC|RELAPSED DISEASE FROM CR OR PR|1|kat|MRI WITHOUT CONTRAST||||CHILD|HEMATOLOGIST|U|2|Visit_2|25|6|WASHOUT|2020-11-12|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-17|P1Y2M10DT2H30M|UNKNOWN|2020-12-05|AFTER|2021-01-03
e|RS|b6e22f6b-25a9-4d18-8de1-2bb4c261e4c9|4|SYMPTDTR|Symptomatic Deterioration|MASS|[?]|PLUG|MRD PERSISTENCE|1|/LPF|PHOTOGRAPHY||||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|Y|2|Visit_2|25|4|FOLLOW-UP|2020-11-12|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-17|P1Y2M10DT2H30M|COINCIDENT|2021-01-21|ONGOING|2021-01-22
e|RS|b6e22f6b-25a9-4d18-8de1-2bb4c261e4c9|5|MRDRESP|Minimal Residual Disease Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|kg|CMR|1|mEq/g|DIFFUSION WEIGHTED MRI||||PROXY|READER 2|NA|3|Visit_3|40|2|WASHOUT|2020-11-27|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-26|P1Y2M10DT2H30M|AFTER|2020-10-20|BEFORE|2021-01-22
e|RS|b6e22f6b-25a9-4d18-8de1-2bb4c261e4c9|6|BONERESP|Bone Response|IWG CHESON AML 2003|[?]|IU/dL|NON-PD|1|100 IU/mL|MACRO BROTH DILUTION|Y|||GUARDIAN|RADIOLOGIST 1|NA|3|Visit_3|40|6|TREATMENT|2020-11-27|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-26|P1Y2M10DT2H30M|AFTER|2021-01-23|COINCIDENT|2021-01-25
e|RS|b6e22f6b-25a9-4d18-8de1-2bb4c261e4c9|7|HEMARESP|Hematologic Response|BLAZER COLORECTAL CANCER 2008|[?]|mU/g|HI-P|1|g/day|IMMUNODIFFUSION||||CLINICAL RESEARCH ASSOCIATE|READER 2|Y|4|Visit_4|65|6|TREATMENT|2020-12-22|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-23|P1Y2M10DT2H30M|BEFORE|2020-12-31|ONGOING|2021-01-15
e|RS|b6e22f6b-25a9-4d18-8de1-2bb4c261e4c9|8|NTRGRESP|Non-target Response|BURCOMBE BREAST CANCER 2005|[?]|nmol/L|iPR|1|/min|COULOMETRIC TITRATION||||CAREGIVER|ADJUDICATOR 1|U|4|Visit_4|65|1|TREATMENT|2020-12-22|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-23|P1Y2M10DT2H30M|AFTER|2020-11-07|ONGOING|2020-11-29
e|RS|b6e22f6b-25a9-4d18-8de1-2bb4c261e4c9|9|MNPTHIND|Minor Pathological Response Indicator|BRUGGEMANN MRD 2010|||CYTOGENETIC CR|1|pg/cell|SCANNING ELECTRON MICROSCOPY|||Y|INVESTIGATOR|NEUROLOGIST|NA|5|Visit_5|90|3|SCREENING|2021-01-16|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-03|P1Y2M10DT2H30M|COINCIDENT|2020-10-21|BEFORE|2020-12-16
e|RS|b6e22f6b-25a9-4d18-8de1-2bb4c261e4c9|10|LIVRRESP|Liver Response|IRANO 2015|[?]|U/mg|RELAPSED DISEASE FROM CR|1|/mm2|LEAD CITRATE STAIN||||CLINICAL STUDY SPONSOR|READER 1|Y|5|Visit_5|90|7|TREATMENT|2021-01-16|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-03|P1Y2M10DT2H30M|BEFORE|2020-11-13|BEFORE|2020-12-23
e|RS|ff163542-abec-4260-b257-f15a11e580ee|1|METBRESP|Metabolic Response|RAJKUMAR MYELOMA 2011|[?]|cs|CYTOGENETIC MINOR RESPONSE|1|nkat|ENZYMATIC SPECTROPHOTOMETRY||||CLINICAL RESEARCH ASSOCIATE|OPTOMETRIST|Y|1|Visit_1|10|1|TREATMENT|2020-08-16|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-17|P1Y2M10DT2H30M|UNKNOWN|2020-10-24|COINCIDENT|2020-11-06
e|RS|ff163542-abec-4260-b257-f15a11e580ee|2|OVRLRESP|Overall Response|RECIST 1.0|[?]|in|IMPROVED|1|pptr|MICROSCOPY||||FAMILY MEMBER|ADJUDICATOR 3|NA|1|Visit_1|10|7|SCREENING|2020-08-16|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-17|P1Y2M10DT2H30M|COINCIDENT|2020-11-13|BEFORE|2020-11-14
e|RS|ff163542-abec-4260-b257-f15a11e580ee|3|RDIORESP|Radiologic Response|PERCIST|[?]|umol/L|HI-N|1|log10 PFU/mL|SINGLE-MOLECULE ARRAY|Y|||FRIEND|MICROSCOPIST 1|Y|2|Visit_2|25|4|SCREENING|2020-08-31|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-23|P1Y2M10DT2H30M|AFTER|2020-08-13|ONGOING|2020-10-04
e|RS|ff163542-abec-4260-b257-f15a11e580ee|4|CYTORESP|Cytogenetic Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|/LSQN|CMR|1|mol/g|TRANSTHORACIC ECHOCARDIOGRAPHY||||INDEPENDENT ASSESSOR|READER|NA|2|Visit_2|25|7|FOLLOW-UP|2020-08-31|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-23|P1Y2M10DT2H30M|BEFORE|2020-10-25|ONGOING|2020-11-05
e|RS|ff163542-abec-4260-b257-f15a11e580ee|5|NTRGRESP|Non-target Response|UNSPECIFIED|[?]|mL/g/h|DISEASE TRANSFORMATION|1|hr/day|SLIT LAMP|Y|||SIGNIFICANT OTHER|INTERNIST|Y|3|Visit_3|40|3|FOLLOW-UP|2020-09-15|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-19|P1Y2M10DT2H30M|BEFORE|2020-10-03|BEFORE|2020-10-23
e|RS|ff163542-abec-4260-b257-f15a11e580ee|6|TRGRESP|Target Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|10^6 organisms|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|10^9 CFU|CALIPER MEASUREMENT METHOD|Y|Y||SPOUSE|CLINICAL PATHOLOGIST|Y|3|Visit_3|40|1|SCREENING|2020-09-15|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-19|P1Y2M10DT2H30M|BEFORE|2020-09-18|ONGOING|2020-10-27
e|RS|ff163542-abec-4260-b257-f15a11e580ee|7|OVRLRESP|Overall Response|NCCN ALL MRD 2014|[?]|mg/kg|INCREASED|1|umol/kg/min|DYNAMOMETRY||||PARENT|CLINICAL PATHOLOGIST|U|4|Visit_4|65|3|TREATMENT|2020-10-10|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-07|P1Y2M10DT2H30M|UNKNOWN|2020-11-04|ONGOING|2020-11-05
e|RS|ff163542-abec-4260-b257-f15a11e580ee|8|OVRLRESP|Overall Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|IU/mL|CYTOGENETIC MINOR RESPONSE|1|V/sec|INDIRECT IMMUNOFLUORESCENCE||||CLINICAL RESEARCH COORDINATOR|PHYSIOTHERAPIST|N|4|Visit_4|65|4|SCREENING|2020-10-10|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-07|P1Y2M10DT2H30M|COINCIDENT|2020-09-25|ONGOING|2020-11-04
e|RS|ff163542-abec-4260-b257-f15a11e580ee|9|PATHRESP|Pathologic Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|BP|MRD PERSISTENCE|1|Frames/s|LIQUID SCINTILLATION COUNTING|Y|||CAREGIVER|UROLOGIST|U|5|Visit_5|90|4|TREATMENT|2020-11-04|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-30|P1Y2M10DT2H30M|COINCIDENT|2020-10-03|AFTER|2020-11-01
e|RS|ff163542-abec-4260-b257-f15a11e580ee|10|SFTSRESP|Soft Tissue Response|HARTMANN GERM CELL CANCER 2002|[?]|10^3/L|DECREASED|1|cpm|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY||||SIBLING|MICROSCOPIST 1|U|5|Visit_5|90|3|TREATMENT|2020-11-04|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-30|P1Y2M10DT2H30M|BEFORE|2020-10-27|COINCIDENT|2020-10-30
e|RS|bb73f732-a52f-4013-9ae6-60ff23b9c224|1|SYMPTDTR|Symptomatic Deterioration|CHOLLET BREAST CANCER 2002|[?]|Ejaculate U|PSA PROGRESSION|1|TRACE|MAMMOGRAPHY||||SPOUSE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|1|Visit_1|10|3|FOLLOW-UP|2020-08-05|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-17|P1Y2M10DT2H30M|COINCIDENT|2020-10-21|ONGOING|2020-10-27
e|RS|bb73f732-a52f-4013-9ae6-60ff23b9c224|2|BMIVLIND|Bone Marrow Involvement Indicator|BRUGGEMANN MRD 2010|[?]|%(w/w)|MOLECULAR MAJOR RESPONSE|1|10^4/L|CLIP|Y|||SIGNIFICANT OTHER|ADJUDICATOR 3|Y|1|Visit_1|10|7|WASHOUT|2020-08-05|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-17|P1Y2M10DT2H30M|UNKNOWN|2020-10-24|AFTER|2020-10-28
e|RS|bb73f732-a52f-4013-9ae6-60ff23b9c224|3|NEWLPROG|New Lesion Progression|CHOLLET BREAST CANCER 2002|[?]|uU/L|SD|1|mol/g|DIFFUSION TENSOR MRI|Y|||INVESTIGATOR|MICROSCOPIST 1|N|2|Visit_2|25|7|FOLLOW-UP|2020-08-20|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-30|P1Y2M10DT2H30M|BEFORE|2020-10-07|ONGOING|2020-10-12
e|RS|bb73f732-a52f-4013-9ae6-60ff23b9c224|4|MRDRESP|Minimal Residual Disease Response|HARTMANN GERM CELL CANCER 2002|[?]|rpm|CYTOGENETIC CR|1|mmHg|HPLC/IEX|Y|||CLINICAL STUDY SPONSOR|DERMATOLOGIST|Y|2|Visit_2|25|5|SCREENING|2020-08-20|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-30|P1Y2M10DT2H30M|UNKNOWN|2020-09-29|COINCIDENT|2020-10-16
e|RS|bb73f732-a52f-4013-9ae6-60ff23b9c224|5|TMRESP|Tumor Marker Response|IWG CHESON AML 2003|[?]|BOTTLE|iSD|1|g|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY||||GUARDIAN|READER 2|Y|3|Visit_3|40|3|TREATMENT|2020-09-04|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-22|P1Y2M10DT2H30M|UNKNOWN|2020-10-26|BEFORE|2020-10-28
e|RS|bb73f732-a52f-4013-9ae6-60ff23b9c224|6|NTERESP|Non-Target Enhancing Response|SHINDOH COLORECTAL CANCER 2013|[?]|AU/mL|CA125 50% RESPONSE|1|TRACE|TOTAL BODY RADIOGRAPHY|Y|||NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|U|3|Visit_3|40|2|TREATMENT|2020-09-04|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-22|P1Y2M10DT2H30M|BEFORE|2020-09-04|ONGOING|2020-10-11
e|RS|bb73f732-a52f-4013-9ae6-60ff23b9c224|7|METSIND|Metastatic Indicator|NCIWG CHESON CLL 1996|||CR|1|PIPE|OPTICAL COHERENCE TOMOGRAPHY|||Y|INDEPENDENT ASSESSOR|UROLOGIST|NA|4|Visit_4|65|5|SCREENING|2020-09-29|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-10|P1Y2M10DT2H30M|AFTER|2020-10-30|COINCIDENT|2020-11-02
e|RS|bb73f732-a52f-4013-9ae6-60ff23b9c224|8|TRGRESP|Target Response|DURIE MULTIPLE MYELOMA 2006|||WORSENED|1|AMPULE|PLETHYSMOGRAPHY||Y|Y|CLINICAL STUDY SPONSOR|INTERNIST|Y|4|Visit_4|65|7|SCREENING|2020-09-29|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-10|P1Y2M10DT2H30M|AFTER|2020-09-24|AFTER|2020-10-07
e|RS|bb73f732-a52f-4013-9ae6-60ff23b9c224|9|MNPTHIND|Minor Pathological Response Indicator|NCCN ALL MRD 2014|[?]|ukat/L|iCR|1|pptr|MAGNETIC RESONANCE ENTEROGRAPHY|Y|||INDEPENDENT ASSESSOR|OPHTHALMOLOGIST|Y|5|Visit_5|90|2|TREATMENT|2020-10-24|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-03|P1Y2M10DT2H30M|AFTER|2020-08-03|ONGOING|2020-08-24
e|RS|bb73f732-a52f-4013-9ae6-60ff23b9c224|10|NTNERESP|Non-Target Non-Enhancing Response|IWC HALLEK CLL 2008|[?]|Anson U|MRD RELAPSE|1|mg/mL/day|ZIEHL NEELSEN ACID FAST STAIN||Y||HEALTH CARE PROFESSIONAL|RATER 1|N|5|Visit_5|90|6|WASHOUT|2020-10-24|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-03|P1Y2M10DT2H30M|UNKNOWN|2020-08-27|COINCIDENT|2020-09-09
e|RS|56fd91d0-502c-4e19-b7df-1e7dd2ad3cd5|1|LIVRRESP|Liver Response|PRINCE TCELL LYMPHOMA 2010|[?]|ms2|CMR|1|log10 IU/mL|TRANSMISSION ELECTRON MICROSCOPY||||DOMESTIC PARTNER|HEMATOLOGIST|NA|1|Visit_1|10|6|SCREENING|2020-07-21|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-13|P1Y2M10DT2H30M|UNKNOWN|2020-08-27|COINCIDENT|2020-09-16
e|RS|56fd91d0-502c-4e19-b7df-1e7dd2ad3cd5|2|MRDIND|Minimal Residual Disease Indicator|GCIG RUSTIN OVARIAN CANCER 2011|[?]|mEq/mmol|IMMUNOPHENOTYPIC CR|1|SBE/mL|PET/SPECT SCAN|Y|||FRIEND|NEUROLOGIST 2|N|1|Visit_1|10|1|TREATMENT|2020-07-21|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-13|P1Y2M10DT2H30M|BEFORE|2020-09-14|AFTER|2020-09-24
e|RS|56fd91d0-502c-4e19-b7df-1e7dd2ad3cd5|3|CPRFSTAT|Clinical Performance Status|KUMAR IMWG 2016|[?]|mg/cm2|PMD|1|mol/day|MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY||Y||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 1|N|2|Visit_2|25|2|TREATMENT|2020-08-05|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-19|P1Y2M10DT2H30M|UNKNOWN|2020-09-17|AFTER|2020-10-06
e|RS|56fd91d0-502c-4e19-b7df-1e7dd2ad3cd5|4|TRGRESP|Target Response|SHINDOH COLORECTAL CANCER 2013|[?]|hPa|CHR|1|mm/min|FLUORESCENT IMMUNOASSAY||||INDEPENDENT ASSESSOR|ENDOCRINOLOGIST|Y|2|Visit_2|25|5|WASHOUT|2020-08-05|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-19|P1Y2M10DT2H30M|UNKNOWN|2020-08-31|BEFORE|2020-09-17
e|RS|56fd91d0-502c-4e19-b7df-1e7dd2ad3cd5|5|HEMARESP|Hematologic Response|IWG CHESON MDS 2000|[?]|h*%|PMD|1|mEq/kg|APPLANATION TONOMETRY||||SIGNIFICANT OTHER|DERMATOLOGIST|U|3|Visit_3|40|2|TREATMENT|2020-08-20|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-15|P1Y2M10DT2H30M|UNKNOWN|2020-10-09|BEFORE|2020-10-13
e|RS|56fd91d0-502c-4e19-b7df-1e7dd2ad3cd5|6|RDIORESP|Radiologic Response|HAMAOKA BREAST CANCER 2010|||FAVORABLE RESPONSE|1|mg/animal|BETA LACTAMASE|Y|Y|Y|NON-HEALTH CARE PROFESSIONAL|CARDIOLOGIST|NA|3|Visit_3|40|2|TREATMENT|2020-08-20|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-15|P1Y2M10DT2H30M|UNKNOWN|2020-10-03|ONGOING|2020-10-10
e|RS|56fd91d0-502c-4e19-b7df-1e7dd2ad3cd5|7|BONERESP|Bone Response|SHINDOH COLORECTAL CANCER 2013|[?]|PUFF|mCR|1|mm/min|GC/MS/MS|Y|||SIBLING|PATHOLOGIST 1|N|4|Visit_4|65|3|SCREENING|2020-09-14|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-09|P1Y2M10DT2H30M|BEFORE|2020-07-22|COINCIDENT|2020-08-26
e|RS|56fd91d0-502c-4e19-b7df-1e7dd2ad3cd5|8|DRCRIND|Disease Recurrence Indicator|CHESON CLL 2006|[?]|POINT|NON-PD|1|um2|CONGO RED STAIN||Y||FRIEND|RADIOLOGIST 2|Y|4|Visit_4|65|4|TREATMENT|2020-09-14|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-09|P1Y2M10DT2H30M|UNKNOWN|2020-08-28|ONGOING|2020-10-18
e|RS|56fd91d0-502c-4e19-b7df-1e7dd2ad3cd5|9|PATHRESP|Pathologic Response|IWC HALLEK CLL 2008|[?]|Torr|PD-CT|1|nmol/g|WRIGHT STAIN||Y||INVESTIGATOR|OTOLARYNGOLOGIST|U|5|Visit_5|90|5|TREATMENT|2020-10-09|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-28|P1Y2M10DT2H30M|BEFORE|2020-09-16|ONGOING|2020-09-23
e|RS|56fd91d0-502c-4e19-b7df-1e7dd2ad3cd5|10|CYTORESP|Cytogenetic Response|AJCC V7|[?]|mmol/L|CYTOGENETIC CR|1|GLOBULE|HPLC|Y|Y||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 1|U|5|Visit_5|90|1|TREATMENT|2020-10-09|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-28|P1Y2M10DT2H30M|BEFORE|2020-09-12|ONGOING|2020-09-26
e|RS|8e056558-ffd2-4c43-bbfa-40914b38af34|1|CYTORESP|Cytogenetic Response|PRINCE TCELL LYMPHOMA 2010|||MOLECULAR MAJOR RESPONSE|1|U.CARR|URANYL ACETATE STAIN|||Y|CAREGIVER|OTOLARYNGOLOGIST|Y|1|Visit_1|10|2|WASHOUT|2021-01-29|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-08|P1Y2M10DT2H30M|AFTER|2021-03-27|ONGOING|2021-04-22
e|RS|8e056558-ffd2-4c43-bbfa-40914b38af34|2|CPRFSTAT|Clinical Performance Status|PCWG SCHER PROSTATE CANCER 2008|||RELAPSED DISEASE|1|EIA unit|ELECTROGASTROGRAPHY|||Y|PARENT|MICROSCOPIST 2|NA|1|Visit_1|10|3|TREATMENT|2021-01-29|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-08|P1Y2M10DT2H30M|UNKNOWN|2021-03-30|COINCIDENT|2021-04-25
e|RS|8e056558-ffd2-4c43-bbfa-40914b38af34|3|MNPTHIND|Minor Pathological Response Indicator|IWG CHESON MDS 2000|[?]|kPa/L/sec|iUPD|1|U/mL|PERFUSION MRI||Y||FRIEND|RATER 1|N|2|Visit_2|25|6|WASHOUT|2021-02-13|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-26|P1Y2M10DT2H30M|BEFORE|2021-03-08|AFTER|2021-04-27
e|RS|8e056558-ffd2-4c43-bbfa-40914b38af34|4|PATHRESP|Pathologic Response|AJCC V7|[?]|mEq/uL|iPR|1|kPa|ELECTROMYOGRAPHY||Y||INTERVIEWER|RADIOLOGIST 2|Y|2|Visit_2|25|7|TREATMENT|2021-02-13|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-26|P1Y2M10DT2H30M|UNKNOWN|2021-02-04|AFTER|2021-02-16
e|RS|8e056558-ffd2-4c43-bbfa-40914b38af34|5|SPLNRESP|Spleen Response|NCIWG CHESON CLL 1996|[?]|mg/mL/day|NON-CR/NON-PD|1|mEq|POTENTIOMETRY||||ADJUDICATION COMMITTEE|MICROSCOPIST 1|N|3|Visit_3|40|7|SCREENING|2021-02-28|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-22|P1Y2M10DT2H30M|BEFORE|2021-02-27|BEFORE|2021-04-24
e|RS|8e056558-ffd2-4c43-bbfa-40914b38af34|6|CPRFSTAT|Clinical Performance Status|NCCN ALL MRD 2014|[?]|Siemens|NR|1|cycle/min|MECHANICAL CLOT DETECTION||||CAREGIVER|ADJUDICATOR 1|Y|3|Visit_3|40|1|FOLLOW-UP|2021-02-28|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-22|P1Y2M10DT2H30M|BEFORE|2021-02-09|ONGOING|2021-04-25
e|RS|8e056558-ffd2-4c43-bbfa-40914b38af34|7|NTNERESP|Non-Target Non-Enhancing Response|HARTMAN PANCREATIC CANCER 2012|[?]|pg|NOT ALL EVALUATED|1|U/cL|ENZYMATIC ULTRACENTRIFUGATION||||PROXY|ENDOCRINOLOGIST|U|4|Visit_4|65|3|SCREENING|2021-03-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-22|P1Y2M10DT2H30M|BEFORE|2021-03-11|BEFORE|2021-03-27
e|RS|8e056558-ffd2-4c43-bbfa-40914b38af34|8|METSIND|Metastatic Indicator|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|ukat/L|CR|1|/2500 WBC|THIN SMEAR||||SIBLING|MICROSCOPIST|N|4|Visit_4|65|4|TREATMENT|2021-03-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-22|P1Y2M10DT2H30M|BEFORE|2021-02-15|COINCIDENT|2021-04-05
e|RS|8e056558-ffd2-4c43-bbfa-40914b38af34|9|NEWLIND|New Lesion Indicator|EUROPEAN LEUKEMIANET BACCARANI CML 2006|||NON-PD|1|uV2|NEXT GENERATION TARGETED SEQUENCING|||Y|INDEPENDENT ASSESSOR|RATER|Y|5|Visit_5|90|4|TREATMENT|2021-04-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-30|P1Y2M10DT2H30M|COINCIDENT|2021-03-09|AFTER|2021-04-10
e|RS|8e056558-ffd2-4c43-bbfa-40914b38af34|10|HEMARESP|Hematologic Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|COAT|MORPHOLOGIC CRi|1|Shock Wave|INTRAVASCULAR ULTRASOUND||||SIGNIFICANT OTHER|ADJUDICATOR|Y|5|Visit_5|90|1|TREATMENT|2021-04-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-30|P1Y2M10DT2H30M|BEFORE|2021-02-17|BEFORE|2021-02-18
e|RS|b7ffe7f2-7eb9-42a1-a548-9f26ee72799b|1|STRUSTAT|Steroid Use Status|DOHNER AML 2010|[?]|/100 HPFs|PD-CT|1|ngEq/L|CLIP||||SIGNIFICANT OTHER|RADIOLOGIST 2|N|1|Visit_1|10|5|FOLLOW-UP|2020-05-29|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-22|P1Y2M10DT2H30M|UNKNOWN|2020-06-18|COINCIDENT|2020-08-23
e|RS|b7ffe7f2-7eb9-42a1-a548-9f26ee72799b|2|NEWLWIND|New Lesion Worsening Indicator|CHESON CLL 2012|[?]|nL|NR|1|pm|FREEZING POINT DEPRESSION|Y|Y||GUARDIAN|READER 1|U|1|Visit_1|10|5|FOLLOW-UP|2020-05-29|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-22|P1Y2M10DT2H30M|UNKNOWN|2020-07-15|AFTER|2020-08-04
e|RS|b7ffe7f2-7eb9-42a1-a548-9f26ee72799b|3|MJPTHIND|Major Pathological Response Indicator|EBMT BLADE MYELOMA 1998|[?]|ug/h|NON-QUANTIFIABLE MRD POSITIVITY|1|Bq/kg|LIQUID SCINTILLATION COUNTING|Y|Y||HEALTH CARE PROFESSIONAL|ADJUDICATOR|Y|2|Visit_2|25|4|TREATMENT|2020-06-13|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-02|P1Y2M10DT2H30M|AFTER|2020-06-24|ONGOING|2020-08-24
e|RS|b7ffe7f2-7eb9-42a1-a548-9f26ee72799b|4|NEWLPROG|New Lesion Progression|EUROPEAN LEUKEMIANET BACCARANI CML 2006|||MOLECULAR CR|1|nmol BCE/L|DC SHEATH FLOW|Y||Y|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 3|Y|2|Visit_2|25|4|TREATMENT|2020-06-13|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-02|P1Y2M10DT2H30M|BEFORE|2020-06-08|ONGOING|2020-07-22
e|RS|b7ffe7f2-7eb9-42a1-a548-9f26ee72799b|5|HEMARESP|Hematologic Response|JACINTO CERVICAL CANCER 2007|[?]|mg/kg/week|NON-iCR/NON-iUPD|1|mmol/day|NON-INVASIVE DIELECTRIC SENSING||||DOMESTIC PARTNER|NEUROLOGIST 1|Y|3|Visit_3|40|4|TREATMENT|2020-06-28|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-26|P1Y2M10DT2H30M|COINCIDENT|2020-07-09|COINCIDENT|2020-07-19
e|RS|b7ffe7f2-7eb9-42a1-a548-9f26ee72799b|6|RDIORESP|Radiologic Response|BRUGGEMANN MRD 2010|[?]|ngEq/L|WORSENED|1|%/s|PUPILLOMETRY||||HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|N|3|Visit_3|40|5|TREATMENT|2020-06-28|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-26|P1Y2M10DT2H30M|AFTER|2020-06-27|BEFORE|2020-06-30
e|RS|b7ffe7f2-7eb9-42a1-a548-9f26ee72799b|7|PATHRESP|Pathologic Response|NCCN ALL MRD 2014|||UNFAVORABLE RESPONSE|1|IU/kg|ENZYMATIC SPECTROPHOTOMETRY|Y||Y|NON-HEALTH CARE PROFESSIONAL|UROLOGIST|Y|4|Visit_4|65|3|FOLLOW-UP|2020-07-23|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-22|P1Y2M10DT2H30M|BEFORE|2020-08-22|AFTER|2020-08-23
e|RS|b7ffe7f2-7eb9-42a1-a548-9f26ee72799b|8|CYTORESP|Cytogenetic Response|HARTMANN GERM CELL CANCER 2002|[?]|10^3 organisms|MAJOR PATHOLOGIC RESPONSE|1|10^9 organisms/mg|OSCILLOMETRY||Y||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 1|Y|4|Visit_4|65|4|TREATMENT|2020-07-23|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-22|P1Y2M10DT2H30M|AFTER|2020-08-24|ONGOING|2020-08-26
e|RS|b7ffe7f2-7eb9-42a1-a548-9f26ee72799b|9|OVRLRESP|Overall Response|IWG CHESON MDS 2006|||ABSENT MORPHOLOGIC RESPONSE|1|IU/day|IMMUNORADIOMETRIC ASSAY|Y||Y|VENDOR|NEUROLOGIST|U|5|Visit_5|90|3|TREATMENT|2020-08-17|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-25|P1Y2M10DT2H30M|COINCIDENT|2020-07-19|ONGOING|2020-07-28
e|RS|b7ffe7f2-7eb9-42a1-a548-9f26ee72799b|10|SFTSRESP|Soft Tissue Response|MURPHY PROSTATE CANCER 1980|[?]|log10 CFU/g|PMR|1|kg/cm|HANSEL STAIN||||INVESTIGATOR|PATHOLOGIST 1|N|5|Visit_5|90|4|TREATMENT|2020-08-17|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-25|P1Y2M10DT2H30M|AFTER|2020-08-02|ONGOING|2020-08-23
e|RS|624c1353-347a-417d-9aab-7f1e7077ba7f|1|MJPTHIND|Major Pathological Response Indicator|LUGANO CLASSIFICATION|[?]|mAnson U/mL|PSA PROGRESSION|1|Ci/uL|FLAME PHOTOMETRY||Y||CHILD|PHYSIOTHERAPIST|U|1|Visit_1|10|1|FOLLOW-UP|2020-08-28|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-06|P1Y2M10DT2H30M|UNKNOWN|2020-09-29|ONGOING|2020-10-08
e|RS|624c1353-347a-417d-9aab-7f1e7077ba7f|2|NTLWIND|Non-Target Lesion Worsening Indicator|RAJKUMAR MYELOMA 2011|[?]|mg/L|CYTOGENETIC CR|1|10^6/L|ENZYMATIC COLORIMETRY||||CHILD|DERMATOLOGIST|NA|1|Visit_1|10|3|TREATMENT|2020-08-28|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-06|P1Y2M10DT2H30M|BEFORE|2020-08-23|ONGOING|2020-09-27
e|RS|624c1353-347a-417d-9aab-7f1e7077ba7f|3|SPLNRESP|Spleen Response|AJCC V8|[?]|uV|FAVORABLE RESPONSE|1|L/kg|SLIT LAMP||||CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 3|N|2|Visit_2|25|6|SCREENING|2020-09-12|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-16|P1Y2M10DT2H30M|COINCIDENT|2020-08-25|AFTER|2020-09-23
e|RS|624c1353-347a-417d-9aab-7f1e7077ba7f|4|MOLRESP|Molecular Response|CHOLLET BREAST CANCER 2002|[?]|log10 CFU/mL|PSEUDORESPONSE|1|deg/s|HPLC/MS|Y|Y||CHILD|OPHTHALMOLOGIST|NA|2|Visit_2|25|1|TREATMENT|2020-09-12|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-16|P1Y2M10DT2H30M|UNKNOWN|2020-09-12|ONGOING|2020-11-10
e|RS|624c1353-347a-417d-9aab-7f1e7077ba7f|5|BMIVLIND|Bone Marrow Involvement Indicator|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|U/kg/h|iCR|1|deg/mm|CALCULATION||||NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|N|3|Visit_3|40|1|TREATMENT|2020-09-27|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-29|P1Y2M10DT2H30M|COINCIDENT|2020-09-08|COINCIDENT|2020-11-19
e|RS|624c1353-347a-417d-9aab-7f1e7077ba7f|6|SYMPTDTR|Symptomatic Deterioration|KUMAR IMWG 2016|[?]|PFU/animal|PSA PROGRESSION|1|Tesla|NUCLEIC ACID HYBRIDIZATION||Y||STUDY SUBJECT|READER 3|N|3|Visit_3|40|2|TREATMENT|2020-09-27|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-29|P1Y2M10DT2H30M|BEFORE|2020-10-25|ONGOING|2020-11-16
e|RS|624c1353-347a-417d-9aab-7f1e7077ba7f|7|CPRFSTAT|Clinical Performance Status|IWC HALLEK CLL 2008|[?]|Weber|DECREASED|1|Antibody Unit|EPSILOMETER|Y|||CLINICAL RESEARCH ASSOCIATE|OPTOMETRIST|NA|4|Visit_4|65|3|WASHOUT|2020-10-22|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-14|P1Y2M10DT2H30M|BEFORE|2020-09-29|AFTER|2020-11-24
e|RS|624c1353-347a-417d-9aab-7f1e7077ba7f|8|OVRLRESP|Overall Response|KEAM BREAST CANCER 2013|[?]|ug/dL|CA125 50% RESPONSE|1|pmol/10^9 cells|PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY||||NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST|NA|4|Visit_4|65|3|FOLLOW-UP|2020-10-22|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-14|P1Y2M10DT2H30M|BEFORE|2020-11-16|AFTER|2020-11-19
e|RS|624c1353-347a-417d-9aab-7f1e7077ba7f|9|MRDIND|Minimal Residual Disease Indicator|HARTMAN PANCREATIC CANCER 2012|||MINOR PATHOLOGIC RESPONSE|1|mV|LANDOLT RING|||Y|SIBLING|RADIOLOGIST 2|NA|5|Visit_5|90|7|SCREENING|2020-11-16|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-24|P1Y2M10DT2H30M|COINCIDENT|2020-10-25|ONGOING|2020-11-20
e|RS|624c1353-347a-417d-9aab-7f1e7077ba7f|10|NTRGRESP|Non-target Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|Bq|iUPD|1|U/m2/min|ANTIMICROBIAL COMBINATION TESTING||||DOMESTIC PARTNER|ADJUDICATOR 2|U|5|Visit_5|90|7|TREATMENT|2020-11-16|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-24|P1Y2M10DT2H30M|COINCIDENT|2020-10-03|COINCIDENT|2020-10-31
e|RS|ef1cddb8-f4ce-45c4-8671-32fe95f00993|1|NTERESP|Non-Target Enhancing Response|SHINDOH COLORECTAL CANCER 2013|[?]|PUFF|CRi|1|AMPULE|CLINICAL EVALUATION||||INDEPENDENT ASSESSOR|PEDIATRIC NEUROLOGIST|N|1|Visit_1|10|4|TREATMENT|2020-08-02|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-06|P1Y2M10DT2H30M|AFTER|2020-10-15|ONGOING|2020-10-21
e|RS|ef1cddb8-f4ce-45c4-8671-32fe95f00993|2|TMRESP|Tumor Marker Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|kPa/L/sec|iUPD|1|ng/L|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS||||CLINICAL RESEARCH COORDINATOR|OPHTHALMOLOGIST|N|1|Visit_1|10|6|SCREENING|2020-08-02|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-06|P1Y2M10DT2H30M|AFTER|2020-10-25|COINCIDENT|2020-10-29
e|RS|ef1cddb8-f4ce-45c4-8671-32fe95f00993|3|SPLNRESP|Spleen Response|AJCC V7|||sCR|1|deg/s|TEST STRIP|Y||Y|SIGNIFICANT OTHER|NEUROLOGIST 2|N|2|Visit_2|25|5|TREATMENT|2020-08-17|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-03|P1Y2M10DT2H30M|BEFORE|2020-09-15|BEFORE|2020-10-30
e|RS|ef1cddb8-f4ce-45c4-8671-32fe95f00993|4|METBRESP|Metabolic Response|CHOLLET BREAST CANCER 2002|[?]|nmol/g|FAVORABLE RESPONSE|1|10^7 CFU/mL|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS|Y|Y||CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST|Y|2|Visit_2|25|3|FOLLOW-UP|2020-08-17|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-03|P1Y2M10DT2H30M|BEFORE|2020-08-30|COINCIDENT|2020-10-03
e|RS|ef1cddb8-f4ce-45c4-8671-32fe95f00993|5|RDIORESP|Radiologic Response|NCIWG CHESON CLL 1996|[?]|mL/mmHg|NOT ALL EVALUATED|1|mL/cage/wk|MICROBIAL BIOCHEMICAL IDENTIFICATION||||HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|U|3|Visit_3|40|1|FOLLOW-UP|2020-09-01|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-02|P1Y2M10DT2H30M|AFTER|2020-08-04|AFTER|2020-10-21
e|RS|ef1cddb8-f4ce-45c4-8671-32fe95f00993|6|PATHRESP|Pathologic Response|HARTMANN GERM CELL CANCER 2002|[?]|mEq|iSD|1|mol|PHOTOMETRY|Y|||FAMILY MEMBER|INTERNIST|Y|3|Visit_3|40|6|TREATMENT|2020-09-01|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-02|P1Y2M10DT2H30M|UNKNOWN|2020-09-05|ONGOING|2020-10-08
e|RS|ef1cddb8-f4ce-45c4-8671-32fe95f00993|7|SPLNRESP|Spleen Response|CHESON CLL 2012|[?]|Gy/min|SMD|1|msec|ACRIDINE ORANGE STAIN||||CHILD|ENDOCRINOLOGIST|Y|4|Visit_4|65|1|FOLLOW-UP|2020-09-26|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-03|P1Y2M10DT2H30M|BEFORE|2020-08-07|COINCIDENT|2020-09-05
e|RS|ef1cddb8-f4ce-45c4-8671-32fe95f00993|8|LIVRRESP|Liver Response|SHINDOH COLORECTAL CANCER 2013|[?]|/HPF|MRD PERSISTENCE|1|10^12/L|COLORIMETRY||||ADJUDICATION COMMITTEE|HEMATOLOGIST|U|4|Visit_4|65|4|TREATMENT|2020-09-26|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-03|P1Y2M10DT2H30M|UNKNOWN|2020-08-14|COINCIDENT|2020-08-26
e|RS|ef1cddb8-f4ce-45c4-8671-32fe95f00993|9|DRCRIND|Disease Recurrence Indicator|KUKER LYMPHOMA 2005|[?]|TCID 50/dose|iUPD|1|mL/min|HEMAGGLUTINATION INHIBITION ASSAY||||CHILD|OPHTHALMOLOGIST|U|5|Visit_5|90|3|TREATMENT|2020-10-21|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-21|P1Y2M10DT2H30M|BEFORE|2020-10-21|AFTER|2020-10-24
e|RS|ef1cddb8-f4ce-45c4-8671-32fe95f00993|10|BESTRESP|Best Overall Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|log10 CFU/mL|cCR|1|IU/mg|CORONARY ANGIOGRAPHY||Y||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|NA|5|Visit_5|90|4|TREATMENT|2020-10-21|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-21|P1Y2M10DT2H30M|AFTER|2020-10-29|ONGOING|2020-10-30
e|RS|da6294b5-de91-4bf7-b160-55d22fefcb07|1|RDIORESP|Radiologic Response|HAMAOKA BREAST CANCER 2010|||MORPHOLOGIC CR|1|10^4/L|OPTICAL MAPPING|||Y|CLINICAL STUDY SPONSOR|PHYSIOTHERAPIST|N|1|Visit_1|10|6|TREATMENT|2020-06-28|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-14|P1Y2M10DT2H30M|AFTER|2020-07-08|AFTER|2020-09-04
e|RS|da6294b5-de91-4bf7-b160-55d22fefcb07|2|METSIND|Metastatic Indicator|RECIST 1.0|[?]|BLOCKS|NOT ALL EVALUATED|1|ft|IMMUNOFLUORESCENT STAIN|Y|||SIGNIFICANT OTHER|DEVELOPMENTAL PSYCHOLOGIST|U|1|Visit_1|10|6|SCREENING|2020-06-28|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-14|P1Y2M10DT2H30M|BEFORE|2020-06-30|AFTER|2020-08-29
e|RS|da6294b5-de91-4bf7-b160-55d22fefcb07|3|MOLRESP|Molecular Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|gtt|MRD NEGATIVITY|1|breaths/30s|SPECT SCAN||Y||DOMESTIC PARTNER|READER 3|NA|2|Visit_2|25|3|WASHOUT|2020-07-13|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-09|P1Y2M10DT2H30M|UNKNOWN|2020-07-05|AFTER|2020-08-16
e|RS|da6294b5-de91-4bf7-b160-55d22fefcb07|4|MRPHRESP|Morphologic Response|DURIE MULTIPLE MYELOMA 2006|||PD-CT|1|mL/kg/h|ENZYMATIC SPECTROPHOTOMETRY|||Y|INDEPENDENT ASSESSOR|PATHOLOGIST 1|Y|2|Visit_2|25|6|SCREENING|2020-07-13|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-09|P1Y2M10DT2H30M|UNKNOWN|2020-08-04|COINCIDENT|2020-08-07
e|RS|da6294b5-de91-4bf7-b160-55d22fefcb07|5|BESTRESP|Best Overall Response|IRANO 2015|[?]|L/s|PD FROM PR|1|RFU|IMMUNO-PET SCAN||||SIBLING|CARDIOLOGIST|N|3|Visit_3|40|6|TREATMENT|2020-07-28|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-11|P1Y2M10DT2H30M|COINCIDENT|2020-09-08|ONGOING|2020-09-19
e|RS|da6294b5-de91-4bf7-b160-55d22fefcb07|6|NEWLWIND|New Lesion Worsening Indicator|GCIG RUSTIN OVARIAN CANCER 2011|||NE|1|g/animal|FLUORESCEIN STAIN|||Y|PARENT|MICROSCOPIST 1|Y|3|Visit_3|40|6|WASHOUT|2020-07-28|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-11|P1Y2M10DT2H30M|BEFORE|2020-09-09|ONGOING|2020-09-15
e|RS|da6294b5-de91-4bf7-b160-55d22fefcb07|7|NTLWIND|Non-Target Lesion Worsening Indicator|DURIE MULTIPLE MYELOMA 2006|[?]|Mile|sCR|1|NEBULE|FUNCTIONAL MRI||||HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|N|4|Visit_4|65|7|SCREENING|2020-08-22|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-17|P1Y2M10DT2H30M|UNKNOWN|2020-07-17|ONGOING|2020-09-08
e|RS|da6294b5-de91-4bf7-b160-55d22fefcb07|8|CLINRESP|Clinical Response|IWG CHESON AML 2003|[?]|kat|RELAPSED DISEASE FROM CR OR PR|1|mAnson U/mL|DOUBLE IMMUNODIFFUSION||||SPOUSE|PHYSIOTHERAPIST|U|4|Visit_4|65|6|TREATMENT|2020-08-22|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-17|P1Y2M10DT2H30M|BEFORE|2020-08-14|ONGOING|2020-09-10
e|RS|da6294b5-de91-4bf7-b160-55d22fefcb07|9|NTRGRESP|Non-target Response|EBMT BLADE MYELOMA 1998|[?]|NEEDLE GAUGE|ABSENT MORPHOLOGIC RESPONSE|1|/2000 RBC|GC/MS-EI||||FAMILY MEMBER|NEUROLOGIST 2|U|5|Visit_5|90|5|TREATMENT|2020-09-16|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-11|P1Y2M10DT2H30M|BEFORE|2020-06-27|ONGOING|2020-07-20
e|RS|da6294b5-de91-4bf7-b160-55d22fefcb07|10|STRUSTAT|Steroid Use Status|IWG CHESON MDS 2000|||MOLECULAR CR|1|Gy/min|ATOMIC ABSORPTION SPECTROMETRY|||Y|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST|NA|5|Visit_5|90|1|SCREENING|2020-09-16|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-11|P1Y2M10DT2H30M|BEFORE|2020-07-17|BEFORE|2020-09-10
e|RS|c01c16d4-7a37-421d-9191-1874eba6a1e3|1|NTRGRESP|Non-target Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|MET*min|COMPLETE MRD RESPONSE|1|ugEq|LC/MS||Y||HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|Y|1|Visit_1|10|2|TREATMENT|2020-10-09|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-04|P1Y2M10DT2H30M|COINCIDENT|2021-01-06|COINCIDENT|2021-01-07
e|RS|c01c16d4-7a37-421d-9191-1874eba6a1e3|2|METBRESP|Metabolic Response|SCHER PROSTATE CANCER 2011|[?]|Gy/min|CA125 75% RESPONSE|1|10^3 DNA copies/mL|HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY|Y|Y||CLINICAL RESEARCH COORDINATOR|RATER 1|N|1|Visit_1|10|1|TREATMENT|2020-10-09|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-04|P1Y2M10DT2H30M|COINCIDENT|2020-11-23|ONGOING|2021-01-03
e|RS|c01c16d4-7a37-421d-9191-1874eba6a1e3|3|CPRFSTAT|Clinical Performance Status|CHOLLET BREAST CANCER 2002|[?]|cd*s/m2|CYTOGENETIC PR|1|Log10 ELISA unit/dose|ENZYMATIC SPECTROPHOTOMETRY||||HEALTH CARE PROFESSIONAL|UROLOGIST|Y|2|Visit_2|25|5|TREATMENT|2020-10-24|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-25|P1Y2M10DT2H30M|BEFORE|2020-10-22|COINCIDENT|2020-10-27
e|RS|c01c16d4-7a37-421d-9191-1874eba6a1e3|4|MRDIND|Minimal Residual Disease Indicator|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|BOLUS|DECREASED|1|MHz|DIFFUSION WEIGHTED MRI|Y|||NON-HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|N|2|Visit_2|25|7|FOLLOW-UP|2020-10-24|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-25|P1Y2M10DT2H30M|BEFORE|2020-10-24|AFTER|2020-11-30
e|RS|c01c16d4-7a37-421d-9191-1874eba6a1e3|5|NTRGRESP|Non-target Response|RECIST 1.1|[?]|RFU|nPR|1|ks|POLYMERASE CHAIN REACTION||Y||SIGNIFICANT OTHER|MICROSCOPIST 1|N|3|Visit_3|40|1|TREATMENT|2020-11-08|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-18|P1Y2M10DT2H30M|BEFORE|2020-11-16|ONGOING|2020-12-17
e|RS|c01c16d4-7a37-421d-9191-1874eba6a1e3|6|METBRESP|Metabolic Response|MACDONALD GLIOMA 1990|||pCR|1|hPa|ROMANOWSKY STAIN|Y||Y|CAREGIVER|ONCOLOGIST 1|Y|3|Visit_3|40|1|WASHOUT|2020-11-08|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-18|P1Y2M10DT2H30M|BEFORE|2020-12-20|BEFORE|2021-01-05
e|RS|c01c16d4-7a37-421d-9191-1874eba6a1e3|7|CPRFSTAT|Clinical Performance Status|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|mEq/g|UNEQUIVOCAL|1|ug/L FEU|ISHIHARA COLOR PLATES||||INVESTIGATOR|READER|NA|4|Visit_4|65|5|TREATMENT|2020-12-03|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-01|P1Y2M10DT2H30M|COINCIDENT|2020-11-20|BEFORE|2020-12-24
e|RS|c01c16d4-7a37-421d-9191-1874eba6a1e3|8|NTNERESP|Non-Target Non-Enhancing Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|||CYTOGENETIC PR|1|mg/m2/h|ACRIDINE ORANGE STAIN|||Y|PARENT|READER 2|Y|4|Visit_4|65|2|TREATMENT|2020-12-03|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-01|P1Y2M10DT2H30M|AFTER|2020-10-26|AFTER|2020-11-23
e|RS|c01c16d4-7a37-421d-9191-1874eba6a1e3|9|NEWLPROG|New Lesion Progression|BURCOMBE BREAST CANCER 2005|[?]|Ci/uL|CYTOGENETIC MINOR RESPONSE|1|LENS|PET/CT SCAN WITHOUT CONTRAST||Y||SIGNIFICANT OTHER|RADIOLOGIST 2|N|5|Visit_5|90|6|FOLLOW-UP|2020-12-28|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-22|P1Y2M10DT2H30M|UNKNOWN|2020-11-13|BEFORE|2020-12-19
e|RS|c01c16d4-7a37-421d-9191-1874eba6a1e3|10|SFTSRESP|Soft Tissue Response|KEAM BREAST CANCER 2013|[?]|Hz/s|VGPR|1|cmH2O*s2/mL|GC/MS-EI||||FAMILY MEMBER|HEMATOLOGIST|Y|5|Visit_5|90|3|FOLLOW-UP|2020-12-28|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-22|P1Y2M10DT2H30M|COINCIDENT|2020-11-04|ONGOING|2020-12-02
e|RS|6036407d-5ac8-400d-91f7-afd63f3cab88|1|NTRGRESP|Non-target Response|LUGANO CLASSIFICATION|[?]|U/L|DECREASED|1|DNA copies/mL|REFLECTANCE SPECTROSCOPY||||ADJUDICATION COMMITTEE|RATER|N|1|Visit_1|10|7|WASHOUT|2020-06-22|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-16|P1Y2M10DT2H30M|BEFORE|2020-06-24|AFTER|2020-07-24
e|RS|6036407d-5ac8-400d-91f7-afd63f3cab88|2|NEWLIND|New Lesion Indicator|CHESON MALIGNANT LYMPHOMA 2007|||PD-CT|1|mMU/mL|PALM METHOD||Y|Y|CLINICAL STUDY SPONSOR|READER 2|NA|1|Visit_1|10|2|WASHOUT|2020-06-22|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-16|P1Y2M10DT2H30M|BEFORE|2020-06-19|AFTER|2020-09-03
e|RS|6036407d-5ac8-400d-91f7-afd63f3cab88|3|MRPHRESP|Morphologic Response|HAMAOKA BREAST CANCER 2010|[?]|CCID 50/mL|MRD PERSISTENCE|1|nm|POLYSOMNOGRAPHY||||FRIEND|MICROSCOPIST 3|Y|2|Visit_2|25|3|TREATMENT|2020-07-07|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-19|P1Y2M10DT2H30M|BEFORE|2020-06-17|ONGOING|2020-06-20
e|RS|6036407d-5ac8-400d-91f7-afd63f3cab88|4|MNPTHIND|Minor Pathological Response Indicator|FAROOQUI SUPP CLL 2014|[?]|mL/s/m2|CYTOGENETIC CR|1|cmol/L|DIFFUSION WEIGHTED MRI||Y||INDEPENDENT ASSESSOR|MICROSCOPIST|U|2|Visit_2|25|4|TREATMENT|2020-07-07|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-19|P1Y2M10DT2H30M|COINCIDENT|2020-08-27|AFTER|2020-09-02
e|RS|6036407d-5ac8-400d-91f7-afd63f3cab88|5|BESTRESP|Best Overall Response|RAJKUMAR MYELOMA 2011|[?]|Ci/kg|MORPHOLOGIC LEUKEMIA-FREE STATE|1|HOURS|THIN SMEAR|Y|||SPOUSE|RATER 1|U|3|Visit_3|40|5|TREATMENT|2020-07-22|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-01|P1Y2M10DT2H30M|BEFORE|2020-06-15|ONGOING|2020-08-22
e|RS|6036407d-5ac8-400d-91f7-afd63f3cab88|6|CYTORESP|Cytogenetic Response|KUMAR IMWG 2016|[?]|/mm|CYTOGENETIC CR|1|CONTAINER|CONTRAST ENHANCED MRI||Y||FAMILY MEMBER|ADJUDICATOR 1|N|3|Visit_3|40|7|TREATMENT|2020-07-22|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-01|P1Y2M10DT2H30M|COINCIDENT|2020-06-29|ONGOING|2020-08-06
e|RS|6036407d-5ac8-400d-91f7-afd63f3cab88|7|METBRESP|Metabolic Response|CHESON CLL 2012|||MORPHOLOGIC LEUKEMIA-FREE STATE|1|umol/h/mmol|WESTERN BLOT|Y|Y|Y|SIBLING|OPHTHALMOLOGIST|NA|4|Visit_4|65|4|FOLLOW-UP|2020-08-16|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-03|P1Y2M10DT2H30M|AFTER|2020-06-14|COINCIDENT|2020-08-24
e|RS|6036407d-5ac8-400d-91f7-afd63f3cab88|8|SYMPTDTR|Symptomatic Deterioration|MACDONALD GLIOMA 1990|[?]|100 IU/mL|MORPHOLOGIC CR|1|g/cm2|COULOMETRIC TITRATION||||SIBLING|OPHTHALMOLOGIST|NA|4|Visit_4|65|7|TREATMENT|2020-08-16|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-03|P1Y2M10DT2H30M|COINCIDENT|2020-07-15|BEFORE|2020-08-30
e|RS|6036407d-5ac8-400d-91f7-afd63f3cab88|9|MJPTHIND|Major Pathological Response Indicator|EBMT BLADE MYELOMA 1998|||MOLECULAR CR|1|HOMEOPATHIC DILUTION|PHOTOMETRIC CLOT DETECTION|Y||Y|PROXY|RADIOLOGIST 2|NA|5|Visit_5|90|5|WASHOUT|2020-09-10|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-18|P1Y2M10DT2H30M|BEFORE|2020-09-17|COINCIDENT|2020-09-19
e|RS|6036407d-5ac8-400d-91f7-afd63f3cab88|10|NEWLIND|New Lesion Indicator|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|||VGPR|1|/HPF|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION||Y|Y|SIBLING|RATER|N|5|Visit_5|90|1|FOLLOW-UP|2020-09-10|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-18|P1Y2M10DT2H30M|AFTER|2020-07-24|COINCIDENT|2020-08-15
e|RS|69cf0c4b-13f6-4955-8046-72a333059d6e|1|DRCRIND|Disease Recurrence Indicator|GUILHOT CML 2007|[?]|mol/mol|iPR|1|nmol|NEPHELOMETRY||||VENDOR|PATHOLOGIST|N|1|Visit_1|10|1|TREATMENT|2020-12-16|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-14|P1Y2M10DT2H30M|COINCIDENT|2021-01-24|BEFORE|2021-01-25
e|RS|69cf0c4b-13f6-4955-8046-72a333059d6e|2|PATHRESP|Pathologic Response|CHESON MALIGNANT LYMPHOMA 2007|||sCR|1|CCID 50/dose|ISHIHARA COLOR PLATES|||Y|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR|NA|1|Visit_1|10|5|TREATMENT|2020-12-16|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-14|P1Y2M10DT2H30M|UNKNOWN|2021-01-04|COINCIDENT|2021-02-08
e|RS|69cf0c4b-13f6-4955-8046-72a333059d6e|3|NEWLPROG|New Lesion Progression|PETIT BREAST CANCER 2001|[?]|mg/mol|HI-N|1|uV*sec|INCISION-INDUCED BLEEDING METHOD||||CAREGIVER|NEUROLOGIST 1|Y|2|Visit_2|25|4|TREATMENT|2020-12-31|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-31|P1Y2M10DT2H30M|BEFORE|2020-12-26|COINCIDENT|2021-02-18
e|RS|69cf0c4b-13f6-4955-8046-72a333059d6e|4|MJPTHIND|Major Pathological Response Indicator|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|dyn|FAVORABLE RESPONSE|1|U/m2/min|CHROMOGENIC ASSAY|Y|||INVESTIGATOR|RATER 2|Y|2|Visit_2|25|3|FOLLOW-UP|2020-12-31|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-31|P1Y2M10DT2H30M|COINCIDENT|2021-03-12|BEFORE|2021-03-14
e|RS|69cf0c4b-13f6-4955-8046-72a333059d6e|5|SFTSRESP|Soft Tissue Response|SHINDOH COLORECTAL CANCER 2013|[?]|GBq|INCREASED|1|BU|FLUORESCENT ENZYME IMMUNOASSAY||||CHILD|ONCOLOGIST 1|NA|3|Visit_3|40|6|TREATMENT|2021-01-15|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-14|P1Y2M10DT2H30M|COINCIDENT|2021-03-02|ONGOING|2021-03-03
e|RS|69cf0c4b-13f6-4955-8046-72a333059d6e|6|MOLRESP|Molecular Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|Ejaculate U|MORPHOLOGIC CR|1|U/mg|SEQUENCING||||VENDOR|RADIOLOGIST|Y|3|Visit_3|40|2|TREATMENT|2021-01-15|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-14|P1Y2M10DT2H30M|COINCIDENT|2021-02-26|BEFORE|2021-03-14
e|RS|69cf0c4b-13f6-4955-8046-72a333059d6e|7|SYMPTDTR|Symptomatic Deterioration|PALUMBO MULTIPLE MYELOMA 2009|[?]|%|HI-E|1|ELISA unit/mL|SPECULAR MICROSCOPY||Y||DOMESTIC PARTNER|PATHOLOGIST 1|U|4|Visit_4|65|1|SCREENING|2021-02-09|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-09|P1Y2M10DT2H30M|COINCIDENT|2020-12-21|BEFORE|2021-03-01
e|RS|69cf0c4b-13f6-4955-8046-72a333059d6e|8|TMRESP|Tumor Marker Response|RANO|[?]|nmol/L/min|sCR|1|mL/kg/day|KINETIC CHROMOGENIC ASSAY|Y|Y||STUDY SUBJECT|HEMATOLOGIST|N|4|Visit_4|65|4|FOLLOW-UP|2021-02-09|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-09|P1Y2M10DT2H30M|AFTER|2021-02-17|ONGOING|2021-03-01
e|RS|69cf0c4b-13f6-4955-8046-72a333059d6e|9|STRUSTAT|Steroid Use Status|BURCOMBE BREAST CANCER 2005|[?]|mg/g/h|PMD|1|oz|GRADIENT DIFFUSION|Y|||HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|N|5|Visit_5|90|1|SCREENING|2021-03-06|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-08|P1Y2M10DT2H30M|UNKNOWN|2020-12-12|COINCIDENT|2021-03-12
e|RS|69cf0c4b-13f6-4955-8046-72a333059d6e|10|NEWLWIND|New Lesion Worsening Indicator|GUPPY OVARIAN CANCER 2002|[?]|mL/beat|RELAPSED DISEASE FROM CR OR PR|1|anti-Xa IU/mL|MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING||Y||GUARDIAN|MICROSCOPIST 1|NA|5|Visit_5|90|4|WASHOUT|2021-03-06|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-08|P1Y2M10DT2H30M|AFTER|2020-12-27|BEFORE|2021-02-07
e|RS|19829028-595c-4811-90e3-0ca696a04ba3|1|MRDRESP|Minimal Residual Disease Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|g|SMD|1|IU/mg|MIGET||Y||STUDY SUBJECT|MICROSCOPIST|U|1|Visit_1|10|7|TREATMENT|2020-07-15|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-14|P1Y2M10DT2H30M|BEFORE|2020-09-14|AFTER|2020-09-26
e|RS|19829028-595c-4811-90e3-0ca696a04ba3|2|CPRFSTAT|Clinical Performance Status|RECIST 1.1|[?]|mg/g/h|iCR|1|10^3 organisms/g|LIQUID SCINTILLATION COUNTING|Y|||CAREGIVER|OPTOMETRIST|N|1|Visit_1|10|3|WASHOUT|2020-07-15|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-14|P1Y2M10DT2H30M|BEFORE|2020-08-25|BEFORE|2020-10-11
e|RS|19829028-595c-4811-90e3-0ca696a04ba3|3|NTNERESP|Non-Target Non-Enhancing Response|CHESON CLL 2006|[?]|Antibody Unit|NE|1|EID 50/mL|FLUORIMETRY||||CAREGIVER|PATHOLOGIST 2|Y|2|Visit_2|25|4|WASHOUT|2020-07-30|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-12|P1Y2M10DT2H30M|AFTER|2020-08-31|AFTER|2020-09-08
e|RS|19829028-595c-4811-90e3-0ca696a04ba3|4|CLINRESP|Clinical Response|LEE LUNG CANCER 2011|||WORSENED|1|kg/cm|DUKE INCISION METHOD|||Y|CAREGIVER|RATER 2|N|2|Visit_2|25|7|TREATMENT|2020-07-30|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-12|P1Y2M10DT2H30M|BEFORE|2020-10-06|BEFORE|2020-10-12
e|RS|19829028-595c-4811-90e3-0ca696a04ba3|5|PATHRESP|Pathologic Response|AJCC V7|[?]|/month|cCR|1|mL/kg/day|ULTRASONOGRAPHIC ELASTOGRAPHY|Y|Y||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 3|NA|3|Visit_3|40|4|WASHOUT|2020-08-14|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-14|P1Y2M10DT2H30M|AFTER|2020-10-05|BEFORE|2020-10-06
e|RS|19829028-595c-4811-90e3-0ca696a04ba3|6|DRCRIND|Disease Recurrence Indicator|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|Bq/ug|sCR|1|gpELISA unit/mL|WHOLE TRANSCRIPTOME SEQUENCING||||DOMESTIC PARTNER|HEMATOLOGIST|N|3|Visit_3|40|5|FOLLOW-UP|2020-08-14|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-14|P1Y2M10DT2H30M|BEFORE|2020-08-24|COINCIDENT|2020-10-11
e|RS|19829028-595c-4811-90e3-0ca696a04ba3|7|HEMARESP|Hematologic Response|MRECIST LENCIONI LIVER CANCER 2010|||ABSENT MORPHOLOGIC RESPONSE|1|kV|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY|||Y|NON-HEALTH CARE PROFESSIONAL|OPTOMETRIST|U|4|Visit_4|65|3|TREATMENT|2020-09-08|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-08|P1Y2M10DT2H30M|COINCIDENT|2020-10-08|BEFORE|2020-10-10
e|RS|19829028-595c-4811-90e3-0ca696a04ba3|8|STRUSTAT|Steroid Use Status|GUPPY OVARIAN CANCER 2002|||CHR|1|Joule|ELECTROCHEMILUMINESCENCE IMMUNOASSAY|||Y|CAREGIVER|ADJUDICATOR 2|N|4|Visit_4|65|1|FOLLOW-UP|2020-09-08|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-08|P1Y2M10DT2H30M|AFTER|2020-08-29|AFTER|2020-10-08
e|RS|19829028-595c-4811-90e3-0ca696a04ba3|9|ANATRESP|Anatomic Response|CHOI GIST 2008|[?]|MPL U/mL|MOLECULAR CR|1|vp/dose|CONGO RED STAIN||Y||PROXY|CLINICAL PATHOLOGIST|N|5|Visit_5|90|6|SCREENING|2020-10-03|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-29|P1Y2M10DT2H30M|UNKNOWN|2020-09-28|BEFORE|2020-10-03
e|RS|19829028-595c-4811-90e3-0ca696a04ba3|10|BONERESP|Bone Response|HAMAOKA BREAST CANCER 2010|[?]|CARTRIDGE|MR|1|cycle/min|OPTICAL DENSITY MEASUREMENT|Y|Y||CHILD|NEUROLOGIST 2|U|5|Visit_5|90|3|WASHOUT|2020-10-03|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-29|P1Y2M10DT2H30M|BEFORE|2020-10-09|AFTER|2020-10-10
e|RS|562a8182-8e9b-4a68-9b95-bc52df58ed46|1|TRGRESP|Target Response|AJCC V8|||MRD NEGATIVITY|1|umol/L/min|SICKLE CELL SOLUBILITY TEST|||Y|VENDOR|PATHOLOGIST 1|N|1|Visit_1|10|3|FOLLOW-UP|2020-09-05|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-03|P1Y2M10DT2H30M|COINCIDENT|2020-10-07|AFTER|2020-10-18
e|RS|562a8182-8e9b-4a68-9b95-bc52df58ed46|2|MNPTHIND|Minor Pathological Response Indicator|PETIT BREAST CANCER 2001|[?]|AFU|PARTIAL MORPHOLOGIC RESPONSE|1|MnFI|SLOAN LETTER EYE CHART 100%||||ADJUDICATION COMMITTEE|ADJUDICATOR 2|N|1|Visit_1|10|4|TREATMENT|2020-09-05|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-03|P1Y2M10DT2H30M|BEFORE|2020-09-11|ONGOING|2020-11-27
e|RS|562a8182-8e9b-4a68-9b95-bc52df58ed46|3|TMRESP|Tumor Marker Response|BURCOMBE BREAST CANCER 2005|[?]|ug/kg/day|FAVORABLE RESPONSE|1|uCi|MRI||||DOMESTIC PARTNER|READER|N|2|Visit_2|25|5|TREATMENT|2020-09-20|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-05|P1Y2M10DT2H30M|UNKNOWN|2020-10-09|BEFORE|2020-11-13
e|RS|562a8182-8e9b-4a68-9b95-bc52df58ed46|4|MJPTHIND|Major Pathological Response Indicator|BRUGGEMANN MRD 2010|[?]|Absorbance U|NON-CR/NON-PD|1|GPS U|MICRONEUTRALIZATION ASSAY||Y||ADJUDICATOR|READER 1|NA|2|Visit_2|25|4|TREATMENT|2020-09-20|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-05|P1Y2M10DT2H30M|UNKNOWN|2020-11-08|ONGOING|2020-11-27
e|RS|562a8182-8e9b-4a68-9b95-bc52df58ed46|5|MJPTHIND|Major Pathological Response Indicator|IWC HALLEK CLL 2008|[?]|mCi/L|CHR|1|BP|CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY||||CLINICAL RESEARCH COORDINATOR|RATER 2|NA|3|Visit_3|40|7|TREATMENT|2020-10-05|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-17|P1Y2M10DT2H30M|COINCIDENT|2020-09-16|ONGOING|2020-10-12
e|RS|562a8182-8e9b-4a68-9b95-bc52df58ed46|6|SFTSRESP|Soft Tissue Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|nsec|MR|1|BAU|MYELOPEROXIDASE STAIN|Y|||INVESTIGATOR|PATHOLOGIST 2|Y|3|Visit_3|40|6|TREATMENT|2020-10-05|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-17|P1Y2M10DT2H30M|UNKNOWN|2020-11-30|COINCIDENT|2020-12-01
e|RS|562a8182-8e9b-4a68-9b95-bc52df58ed46|7|DRCRIND|Disease Recurrence Indicator|HAMAOKA BREAST CANCER 2010|[?]|kHz|PD/RELAPSE AFTER HI|1|mV|DIFFUSION TENSOR MRI|Y|||INVESTIGATOR|MICROSCOPIST 2|U|4|Visit_4|65|3|SCREENING|2020-10-30|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-21|P1Y2M10DT2H30M|COINCIDENT|2020-10-19|ONGOING|2020-11-04
e|RS|562a8182-8e9b-4a68-9b95-bc52df58ed46|8|OVRLRESP|Overall Response|iRECIST|[?]|/day|NON-PD|1|10^3 DNA copies/mL|PERIODIC ACID SCHIFF STAIN||||STUDY SUBJECT|RATER 2|U|4|Visit_4|65|2|SCREENING|2020-10-30|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-21|P1Y2M10DT2H30M|AFTER|2020-10-31|BEFORE|2020-11-27
e|RS|562a8182-8e9b-4a68-9b95-bc52df58ed46|9|PATHRESP|Pathologic Response|NCCN ALL MRD 2014|[?]|mOsm/L|INCREASED|1|K|RYAN BLUE STAIN||Y||SIBLING|ADJUDICATOR|N|5|Visit_5|90|3|FOLLOW-UP|2020-11-24|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-27|P1Y2M10DT2H30M|BEFORE|2020-09-24|ONGOING|2020-11-07
e|RS|562a8182-8e9b-4a68-9b95-bc52df58ed46|10|MOLRESP|Molecular Response|LEE LUNG CANCER 2011|||iCPD|1|Anson U|MRI|Y|Y|Y|INVESTIGATOR|RADIOLOGIST|NA|5|Visit_5|90|6|TREATMENT|2020-11-24|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-27|P1Y2M10DT2H30M|BEFORE|2020-10-14|AFTER|2020-11-29
e|RS|b29e6912-42f4-471b-ad90-1ec446f89ac0|1|ANATRESP|Anatomic Response|HAMAOKA BREAST CANCER 2010|[?]|kg/mol|pCR|1|pt_us|REAL-TIME POLYMERASE CHAIN REACTION ASSAY||||CLINICAL RESEARCH COORDINATOR|NEUROLOGIST|Y|1|Visit_1|10|1|SCREENING|2021-01-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-19|P1Y2M10DT2H30M|COINCIDENT|2021-02-10|COINCIDENT|2021-02-16
e|RS|b29e6912-42f4-471b-ad90-1ec446f89ac0|2|METBRESP|Metabolic Response|SCHER PROSTATE CANCER 2011|[?]|genEq|PD|1|mMU/mL|FREEZING POINT DEPRESSION|Y|||SIBLING|OTOLARYNGOLOGIST|Y|1|Visit_1|10|6|TREATMENT|2021-01-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-19|P1Y2M10DT2H30M|UNKNOWN|2021-02-03|COINCIDENT|2021-04-07
e|RS|b29e6912-42f4-471b-ad90-1ec446f89ac0|3|NTERESP|Non-Target Enhancing Response|AJCC V7|[?]|mmol/L|iUPD|1|Watt|BAC ACGH|Y|||INVESTIGATOR|RADIOLOGIST 1|Y|2|Visit_2|25|3|TREATMENT|2021-02-03|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-02|P1Y2M10DT2H30M|BEFORE|2021-04-04|AFTER|2021-04-12
e|RS|b29e6912-42f4-471b-ad90-1ec446f89ac0|4|RDIORESP|Radiologic Response|RANO|[?]|nm|mCR|1|tsp|PHASE CONTRAST MICROSCOPY||||CHILD|READER 2|NA|2|Visit_2|25|6|TREATMENT|2021-02-03|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-02|P1Y2M10DT2H30M|COINCIDENT|2021-03-21|ONGOING|2021-04-04
e|RS|b29e6912-42f4-471b-ad90-1ec446f89ac0|5|MRPHRESP|Morphologic Response|LEE LUNG CANCER 2011|[?]|mL/min/1.73m2|MORPHOLOGIC CR|1|min/day|ELECTRICAL IMPEDANCE MYOGRAPHY||||PARENT|RATER 2|N|3|Visit_3|40|4|TREATMENT|2021-02-18|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-31|P1Y2M10DT2H30M|BEFORE|2021-04-10|AFTER|2021-04-16
e|RS|b29e6912-42f4-471b-ad90-1ec446f89ac0|6|PATHRESP|Pathologic Response|UNSPECIFIED|[?]|PIXELS/in|CYTOGENETIC MINIMAL RESPONSE|1|mm/2h|KLEIHAUER-BETKE|Y|||DOMESTIC PARTNER|READER|N|3|Visit_3|40|1|TREATMENT|2021-02-18|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-31|P1Y2M10DT2H30M|AFTER|2021-01-26|AFTER|2021-02-13
e|RS|b29e6912-42f4-471b-ad90-1ec446f89ac0|7|TMRESP|Tumor Marker Response|BRUGGEMANN MRD 2010|[?]|10^6 CFU/g|cPR|1|cal|GEL ELECTROPHORESIS||||CAREGIVER|MICROSCOPIST 3|N|4|Visit_4|65|6|WASHOUT|2021-03-15|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-07|P1Y2M10DT2H30M|BEFORE|2021-03-30|COINCIDENT|2021-04-07
e|RS|b29e6912-42f4-471b-ad90-1ec446f89ac0|8|OVRLRESP|Overall Response|PERCIST|||FAVORABLE RESPONSE|1|uU/dL|SLOAN LETTER EYE CHART 100%|||Y|INVESTIGATOR|RADIOLOGIST 1|U|4|Visit_4|65|7|WASHOUT|2021-03-15|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-07|P1Y2M10DT2H30M|UNKNOWN|2021-03-03|BEFORE|2021-04-11
e|RS|b29e6912-42f4-471b-ad90-1ec446f89ac0|9|MNPTHIND|Minor Pathological Response Indicator|GUILHOT CML 2007|||PR|1|log10 TCID 50/uL|ATOMIC ABSORPTION SPECTROMETRY|Y||Y|STUDY SUBJECT|MICROSCOPIST 3|N|5|Visit_5|90|4|TREATMENT|2021-04-09|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-14|P1Y2M10DT2H30M|UNKNOWN|2021-04-01|ONGOING|2021-04-15
e|RS|b29e6912-42f4-471b-ad90-1ec446f89ac0|10|DRCRIND|Disease Recurrence Indicator|GUILHOT CML 2007|||NR|1|TUBE|TURBIDIMETRY|Y||Y|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST|NA|5|Visit_5|90|4|FOLLOW-UP|2021-04-09|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-14|P1Y2M10DT2H30M|AFTER|2021-01-27|AFTER|2021-03-04
e|RS|2cb58751-c0c4-432c-8f60-22dba6e1ec9a|1|TMRESP|Tumor Marker Response|SHINDOH COLORECTAL CANCER 2013|||ABSENT MORPHOLOGIC RESPONSE|1|mmol/L|PALPATION|||Y|PARENT|MICROSCOPIST 3|U|1|Visit_1|10|2|TREATMENT|2020-06-09|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-14|P1Y2M10DT2H30M|AFTER|2020-09-06|BEFORE|2020-09-07
e|RS|2cb58751-c0c4-432c-8f60-22dba6e1ec9a|2|MRPHRESP|Morphologic Response|KUMAR IMWG 2016|||NOT ALL EVALUATED|1|mU/g|AUTOREFRACTION|Y||Y|GUARDIAN|ONCOLOGIST|U|1|Visit_1|10|5|TREATMENT|2020-06-09|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-14|P1Y2M10DT2H30M|BEFORE|2020-07-26|AFTER|2020-09-03
e|RS|2cb58751-c0c4-432c-8f60-22dba6e1ec9a|3|STRUSTAT|Steroid Use Status|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|SPRAY|pCR|1|/500 WBC|CELLULAR PROLIFERATION ASSAY||||CAREGIVER|CARDIOLOGIST|U|2|Visit_2|25|7|TREATMENT|2020-06-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-15|P1Y2M10DT2H30M|COINCIDENT|2020-07-24|COINCIDENT|2020-08-27
e|RS|2cb58751-c0c4-432c-8f60-22dba6e1ec9a|4|BONERESP|Bone Response|WHO BREAST CANCER 2006|||CMR|1|pptr|VIRUS PLAQUE ASSAY|||Y|INDEPENDENT ASSESSOR|READER|NA|2|Visit_2|25|2|TREATMENT|2020-06-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-15|P1Y2M10DT2H30M|AFTER|2020-07-24|COINCIDENT|2020-08-07
e|RS|2cb58751-c0c4-432c-8f60-22dba6e1ec9a|5|NTERESP|Non-Target Enhancing Response|CHESON LYMPHOMA 2008|[?]|min|PD|1|foz_us|REFLECTANCE SPECTROSCOPY||||PROXY|NEUROLOGIST 1|N|3|Visit_3|40|3|TREATMENT|2020-07-09|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-14|P1Y2M10DT2H30M|BEFORE|2020-06-15|AFTER|2020-08-31
e|RS|2cb58751-c0c4-432c-8f60-22dba6e1ec9a|6|CPRFSTAT|Clinical Performance Status|KEAM BREAST CANCER 2013|[?]|POINT|CHR|1|pmol/L|SPECTROPHOTOMETRY||Y||HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|N|3|Visit_3|40|2|TREATMENT|2020-07-09|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-14|P1Y2M10DT2H30M|COINCIDENT|2020-08-22|AFTER|2020-08-30
e|RS|2cb58751-c0c4-432c-8f60-22dba6e1ec9a|7|NEWLPROG|New Lesion Progression|CHESON CLL 2012|[?]|ug/h|CMR|1|10^6 CFU/mL|EIA||||DOMESTIC PARTNER|RATER 2|NA|4|Visit_4|65|4|WASHOUT|2020-08-03|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-14|P1Y2M10DT2H30M|COINCIDENT|2020-07-30|COINCIDENT|2020-09-05
e|RS|2cb58751-c0c4-432c-8f60-22dba6e1ec9a|8|NTRGRESP|Non-target Response|FAROOQUI SUPP CLL 2014|[?]|TAMPON|MOLECULAR CR|1|/ms|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|Y|||SIGNIFICANT OTHER|NEUROLOGIST 1|U|4|Visit_4|65|5|WASHOUT|2020-08-03|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-14|P1Y2M10DT2H30M|UNKNOWN|2020-08-03|ONGOING|2020-08-23
e|RS|2cb58751-c0c4-432c-8f60-22dba6e1ec9a|9|CYTORESP|Cytogenetic Response|BLAZER COLORECTAL CANCER 2008|[?]|vg/kg|CA125 75% RESPONSE|1|/10^3|IN SITU HYBRIDIZATION||Y||VENDOR|RADIOLOGIST|NA|5|Visit_5|90|7|TREATMENT|2020-08-28|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-01|P1Y2M10DT2H30M|AFTER|2020-07-29|ONGOING|2020-08-29
e|RS|2cb58751-c0c4-432c-8f60-22dba6e1ec9a|10|NTERESP|Non-Target Enhancing Response|NCCN ALL MRD 2014|[?]|CUP|PDu|1|mL/kg/min|DC SHEATH FLOW|Y|Y||INDEPENDENT ASSESSOR|MICROSCOPIST 2|NA|5|Visit_5|90|7|WASHOUT|2020-08-28|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-01|P1Y2M10DT2H30M|AFTER|2020-06-26|ONGOING|2020-07-29
e|RS|396295ba-9f4c-4689-88c2-f80cb28b567a|1|NEWLPROG|New Lesion Progression|IRANO 2015|[?]|BISCUIT|cCR|1|APS U|LUXOL FAST BLUE AND CRESYL VIOLET STAIN|Y|Y||CHILD|RATER 2|NA|1|Visit_1|10|7|WASHOUT|2020-12-31|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-27|P1Y2M10DT2H30M|UNKNOWN|2021-03-02|BEFORE|2021-03-22
e|RS|396295ba-9f4c-4689-88c2-f80cb28b567a|2|HEMARESP|Hematologic Response|IWC HALLEK CLL 2008|||MORPHOLOGIC LEUKEMIA-FREE STATE|1|Pack Year|WEBER GREEN STAIN|||Y|SPOUSE|INTERNIST|NA|1|Visit_1|10|7|TREATMENT|2020-12-31|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-27|P1Y2M10DT2H30M|BEFORE|2021-02-10|AFTER|2021-03-16
e|RS|396295ba-9f4c-4689-88c2-f80cb28b567a|3|TRGRESP|Target Response|IWG CHESON MDS 2006|[?]|mL/cm H2O|PDu|1|ug/g/h|SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|Y|||SIBLING|ADJUDICATOR 3|N|2|Visit_2|25|2|TREATMENT|2021-01-15|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-14|P1Y2M10DT2H30M|UNKNOWN|2021-01-11|AFTER|2021-03-28
e|RS|396295ba-9f4c-4689-88c2-f80cb28b567a|4|RDIORESP|Radiologic Response|BURCOMBE BREAST CANCER 2005|||NOT ALL EVALUATED|1|10^3 CFU|QUANTITATIVE PERIPHERAL ANGIOGRAPHY|||Y|DOMESTIC PARTNER|UROLOGIST|U|2|Visit_2|25|1|SCREENING|2021-01-15|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-14|P1Y2M10DT2H30M|AFTER|2021-02-17|BEFORE|2021-03-01
e|RS|396295ba-9f4c-4689-88c2-f80cb28b567a|5|SFTSRESP|Soft Tissue Response|BURCOMBE BREAST CANCER 2005|[?]|mV*min|IMMUNOPHENOTYPIC CR|1|mm/2h|PANENDOSCOPY||||DOMESTIC PARTNER|ONCOLOGIST 1|U|3|Visit_3|40|6|TREATMENT|2021-01-30|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-26|P1Y2M10DT2H30M|AFTER|2020-12-24|AFTER|2021-01-03
e|RS|396295ba-9f4c-4689-88c2-f80cb28b567a|6|MJPTHIND|Major Pathological Response Indicator|MONTSERRAT CLL 1989|[?]|10^3/hpf|PSEUDOPROGRESSION|1|log10 copies/mL|DISK DIFFUSION||Y||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 1|Y|3|Visit_3|40|2|TREATMENT|2021-01-30|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-26|P1Y2M10DT2H30M|BEFORE|2021-02-11|BEFORE|2021-03-19
e|RS|396295ba-9f4c-4689-88c2-f80cb28b567a|7|BMIVLIND|Bone Marrow Involvement Indicator|LEE LUNG CANCER 2011|[?]|mg/mL/day|UNFAVORABLE RESPONSE|1|QUANTITY SUFFICIENT|TEST STRIP||||GUARDIAN|READER|U|4|Visit_4|65|5|SCREENING|2021-02-24|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-21|P1Y2M10DT2H30M|AFTER|2021-03-25|AFTER|2021-03-26
e|RS|396295ba-9f4c-4689-88c2-f80cb28b567a|8|DRCRIND|Disease Recurrence Indicator|FAROOQUI SUPP CLL 2014|[?]|PFU/animal|CYTOGENETIC MINOR RESPONSE|1|/4.0 mL|ICC||||DOMESTIC PARTNER|PHYSIOTHERAPIST|NA|4|Visit_4|65|5|TREATMENT|2021-02-24|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-21|P1Y2M10DT2H30M|COINCIDENT|2021-02-03|COINCIDENT|2021-03-04
e|RS|396295ba-9f4c-4689-88c2-f80cb28b567a|9|NEWLIND|New Lesion Indicator|IWC HALLEK CLL 2008|[?]|CAPLET|UNEQUIVOCAL|1|STEPS|DXA SCAN|Y|||PARENT|MICROSCOPIST 1|NA|5|Visit_5|90|6|WASHOUT|2021-03-21|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-04|P1Y2M10DT2H30M|COINCIDENT|2021-01-08|ONGOING|2021-03-03
e|RS|396295ba-9f4c-4689-88c2-f80cb28b567a|10|MRDRESP|Minimal Residual Disease Response|CHESON LYMPHOMA 2008|[?]|cycle/min|PD FROM PR|1|breaths/min|SINGLE-MOLECULE ARRAY||||PROXY|INTERNIST|U|5|Visit_5|90|2|FOLLOW-UP|2021-03-21|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-04|P1Y2M10DT2H30M|BEFORE|2021-01-30|AFTER|2021-02-01
e|RS|56072c44-67c3-4c93-8db7-2d1570b2bbbc|1|MRDRESP|Minimal Residual Disease Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|AFU|iPR|1|nsec|ANTIMICROBIAL COMBINATION TESTING||||PROXY|PATHOLOGIST 1|N|1|Visit_1|10|3|TREATMENT|2020-08-26|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-10|P1Y2M10DT2H30M|BEFORE|2020-09-27|COINCIDENT|2020-10-09
e|RS|56072c44-67c3-4c93-8db7-2d1570b2bbbc|2|METSIND|Metastatic Indicator|WHO BREAST CANCER 2006|[?]|PATCH|HI-E|1|10^6/L|HEMAGGLUTINATION INHIBITION ASSAY|Y|||PARENT|ONCOLOGIST 2|NA|1|Visit_1|10|3|SCREENING|2020-08-26|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-10|P1Y2M10DT2H30M|COINCIDENT|2020-08-20|BEFORE|2020-08-29
e|RS|56072c44-67c3-4c93-8db7-2d1570b2bbbc|3|MRDIND|Minimal Residual Disease Indicator|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|mCi/L|CYTOGENETIC MINIMAL RESPONSE|1|ugEq/L|CLAUSS METHOD|Y|||HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|NA|2|Visit_2|25|5|TREATMENT|2020-09-10|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-19|P1Y2M10DT2H30M|UNKNOWN|2020-09-21|ONGOING|2020-11-15
e|RS|56072c44-67c3-4c93-8db7-2d1570b2bbbc|4|NTERESP|Non-Target Enhancing Response|MRECIST BYRNE MESOTHELIOMA 2004|||PR|1|uEq|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|Y|Y|Y|ADJUDICATION COMMITTEE|PATHOLOGIST 1|NA|2|Visit_2|25|2|TREATMENT|2020-09-10|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-19|P1Y2M10DT2H30M|UNKNOWN|2020-08-21|COINCIDENT|2020-08-24
e|RS|56072c44-67c3-4c93-8db7-2d1570b2bbbc|5|TRGRESP|Target Response|HAMAOKA BREAST CANCER 2010|||NE|1|CFU/g|CELL BASED BIOASSAY||Y|Y|SPOUSE|OPTOMETRIST|Y|3|Visit_3|40|4|TREATMENT|2020-09-25|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-04|P1Y2M10DT2H30M|COINCIDENT|2020-09-21|COINCIDENT|2020-10-14
e|RS|56072c44-67c3-4c93-8db7-2d1570b2bbbc|6|CLINRESP|Clinical Response|MACDONALD GLIOMA 1990|||SD|1|ugEq|FLOCCULATION, CHARCOAL ENHANCED|Y||Y|CLINICAL RESEARCH ASSOCIATE|RATER 2|NA|3|Visit_3|40|2|TREATMENT|2020-09-25|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-04|P1Y2M10DT2H30M|COINCIDENT|2020-11-12|BEFORE|2020-11-16
e|RS|56072c44-67c3-4c93-8db7-2d1570b2bbbc|7|MRDRESP|Minimal Residual Disease Response|DOHNER AML 2010|||ABSENT MORPHOLOGIC RESPONSE|1|s^-1(%O2)^-1|SLOAN LETTER EYE CHART 2.5%|||Y|INTERVIEWER|CLINICAL PATHOLOGIST|N|4|Visit_4|65|4|TREATMENT|2020-10-20|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-01|P1Y2M10DT2H30M|UNKNOWN|2020-09-28|AFTER|2020-11-09
e|RS|56072c44-67c3-4c93-8db7-2d1570b2bbbc|8|SYMPTDTR|Symptomatic Deterioration|PROTOCOL DEFINED RESPONSE CRITERIA|||UNEQUIVOCAL|1|mL/g/min|IMMUNODIFFUSION|Y|Y|Y|NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|N|4|Visit_4|65|6|FOLLOW-UP|2020-10-20|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-01|P1Y2M10DT2H30M|COINCIDENT|2020-09-04|COINCIDENT|2020-11-10
e|RS|56072c44-67c3-4c93-8db7-2d1570b2bbbc|9|BMIVLIND|Bone Marrow Involvement Indicator|IWG CHESON MDS 2000|||DISEASE TRANSFORMATION|1|LENS|BETA LACTAMASE|Y||Y|INVESTIGATOR|PATHOLOGIST|Y|5|Visit_5|90|1|FOLLOW-UP|2020-11-14|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-05|P1Y2M10DT2H30M|COINCIDENT|2020-11-11|BEFORE|2020-11-23
e|RS|56072c44-67c3-4c93-8db7-2d1570b2bbbc|10|NTNERESP|Non-Target Non-Enhancing Response|IWC HALLEK CLL 2008|||CYTOGENETIC MINIMAL RESPONSE|1|Hz|PET SCAN|||Y|INVESTIGATOR|READER 2|N|5|Visit_5|90|1|TREATMENT|2020-11-14|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-05|P1Y2M10DT2H30M|BEFORE|2020-10-18|COINCIDENT|2020-11-15
e|RS|55b23180-01f2-498e-a0af-cb9cd7d81750|1|BONERESP|Bone Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|ug/L/h|MORPHOLOGIC LEUKEMIA-FREE STATE|1|ug/dL|LC-FL||||INDEPENDENT ASSESSOR|OPHTHALMOLOGIST|Y|1|Visit_1|10|2|FOLLOW-UP|2020-07-01|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-15|P1Y2M10DT2H30M|BEFORE|2020-09-03|COINCIDENT|2020-09-23
e|RS|55b23180-01f2-498e-a0af-cb9cd7d81750|2|SPLNRESP|Spleen Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|CFU/g|INDETERMINATE RESPONSE|1|log10 CFU/g|IHC|Y|||CLINICAL RESEARCH COORDINATOR|OTOLARYNGOLOGIST|N|1|Visit_1|10|2|TREATMENT|2020-07-01|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-15|P1Y2M10DT2H30M|UNKNOWN|2020-09-23|BEFORE|2020-09-25
e|RS|55b23180-01f2-498e-a0af-cb9cd7d81750|3|BESTRESP|Best Overall Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|kcal|CYTOGENETIC PR|1|mEq/dL|PERFUSION MRI||Y||FRIEND|PATHOLOGIST|Y|2|Visit_2|25|7|TREATMENT|2020-07-16|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-18|P1Y2M10DT2H30M|AFTER|2020-07-11|AFTER|2020-09-26
e|RS|55b23180-01f2-498e-a0af-cb9cd7d81750|4|METSIND|Metastatic Indicator|AJCC V8|[?]|OD Unit|NON-iCR/NON-iUPD|1|Log10 ELISA unit/dose|TRANSESOPHAGEAL ECHOCARDIOGRAPHY||||GUARDIAN|ADJUDICATOR 3|U|2|Visit_2|25|3|TREATMENT|2020-07-16|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-18|P1Y2M10DT2H30M|COINCIDENT|2020-09-20|AFTER|2020-09-23
e|RS|55b23180-01f2-498e-a0af-cb9cd7d81750|5|CPRFSTAT|Clinical Performance Status|PALUMBO MULTIPLE MYELOMA 2009|[?]|GPL U/mL|NON-PD|1|mmHg*min/L|AMSLER GRID||||INVESTIGATOR|RADIOLOGIST 2|Y|3|Visit_3|40|2|TREATMENT|2020-07-31|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-26|P1Y2M10DT2H30M|UNKNOWN|2020-09-02|BEFORE|2020-09-18
e|RS|55b23180-01f2-498e-a0af-cb9cd7d81750|6|BONERESP|Bone Response|WHO BREAST CANCER 2006|||PMD|1|10^3 CFU/g|IMMUNOCHROMATOGRAPHY|||Y|CLINICAL RESEARCH COORDINATOR|OTOLARYNGOLOGIST|Y|3|Visit_3|40|7|TREATMENT|2020-07-31|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-26|P1Y2M10DT2H30M|BEFORE|2020-06-23|ONGOING|2020-09-12
e|RS|55b23180-01f2-498e-a0af-cb9cd7d81750|7|NEWLWIND|New Lesion Worsening Indicator|CHESON CLL 2006|[?]|/mm|CYTOGENETIC NO RESPONSE|1|uCi/L|INTERRUPTER TECHNIQUE||||CLINICAL STUDY SPONSOR|READER 2|Y|4|Visit_4|65|7|WASHOUT|2020-08-25|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-16|P1Y2M10DT2H30M|COINCIDENT|2020-08-30|ONGOING|2020-09-09
e|RS|55b23180-01f2-498e-a0af-cb9cd7d81750|8|MOLRESP|Molecular Response|RECICL|||HI-E|1|ug/day|BIOPSY|||Y|STUDY SUBJECT|MICROSCOPIST|U|4|Visit_4|65|1|SCREENING|2020-08-25|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-16|P1Y2M10DT2H30M|UNKNOWN|2020-07-18|AFTER|2020-09-03
e|RS|55b23180-01f2-498e-a0af-cb9cd7d81750|9|BMIVLIND|Bone Marrow Involvement Indicator|JACINTO CERVICAL CANCER 2007|[?]|IU/L|PARTIAL MORPHOLOGIC RESPONSE|1|copies/ug|HPLC/IEX||||NON-HEALTH CARE PROFESSIONAL|HEMATOLOGIST|U|5|Visit_5|90|6|FOLLOW-UP|2020-09-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-05|P1Y2M10DT2H30M|BEFORE|2020-08-23|ONGOING|2020-09-11
e|RS|55b23180-01f2-498e-a0af-cb9cd7d81750|10|BONERESP|Bone Response|PERCIST|[?]|pmol/day|CMR|1|mEq/uL|SIZE EXCLUSION CHROMATOGRAPHY||||SIGNIFICANT OTHER|RATER 2|Y|5|Visit_5|90|1|TREATMENT|2020-09-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-05|P1Y2M10DT2H30M|COINCIDENT|2020-06-25|AFTER|2020-07-22
e|RS|22e2b674-dc3f-476d-b3d7-2b1f4ddeea1a|1|CLINRESP|Clinical Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|mOsm/L|MRD PERSISTENCE|1|uL/dose|WESTERGREN||||ADJUDICATOR|DEVELOPMENTAL PSYCHOLOGIST|U|1|Visit_1|10|6|SCREENING|2020-11-09|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-26|P1Y2M10DT2H30M|COINCIDENT|2021-02-04|COINCIDENT|2021-02-06
e|RS|22e2b674-dc3f-476d-b3d7-2b1f4ddeea1a|2|NEWLWIND|New Lesion Worsening Indicator|RECIST 1.1|[?]|Newton|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|U/10^12 RBC|HANSEL STAIN||||FRIEND|READER 2|NA|1|Visit_1|10|3|WASHOUT|2020-11-09|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-26|P1Y2M10DT2H30M|BEFORE|2020-12-02|BEFORE|2021-01-05
e|RS|22e2b674-dc3f-476d-b3d7-2b1f4ddeea1a|3|PATHRESP|Pathologic Response|CHESON CLL 2006|||ABSENT MORPHOLOGIC RESPONSE|1|U/cL|HIGH RESOLUTION MELT ANALYSIS|||Y|VENDOR|HEMATOLOGIST|Y|2|Visit_2|25|2|WASHOUT|2020-11-24|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-26|P1Y2M10DT2H30M|UNKNOWN|2020-11-16|AFTER|2021-02-04
e|RS|22e2b674-dc3f-476d-b3d7-2b1f4ddeea1a|4|NTLWIND|Non-Target Lesion Worsening Indicator|SACT|||STABLE|1|umol/kg/min|CONTACT SPECULAR MICROSCOPY||Y|Y|FAMILY MEMBER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|2|Visit_2|25|4|SCREENING|2020-11-24|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-26|P1Y2M10DT2H30M|AFTER|2020-12-20|ONGOING|2021-01-02
e|RS|22e2b674-dc3f-476d-b3d7-2b1f4ddeea1a|5|BMIVLIND|Bone Marrow Involvement Indicator|WOLCHOK SOLID TUMORS 2009|[?]|oz eq|RELAPSED DISEASE FROM CR|1|mol|SURFACE PLASMON RESONANCE||||CLINICAL STUDY SPONSOR|HEMATOLOGIST|N|3|Visit_3|40|2|SCREENING|2020-12-09|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-02|P1Y2M10DT2H30M|AFTER|2021-01-15|AFTER|2021-01-19
e|RS|22e2b674-dc3f-476d-b3d7-2b1f4ddeea1a|6|SPLNRESP|Spleen Response|MURPHY PROSTATE CANCER 1980|[?]|HEP|RELAPSED DISEASE FROM CR OR PR|1|ft|BETA LACTAMASE||||SPOUSE|RATER 2|N|3|Visit_3|40|3|FOLLOW-UP|2020-12-09|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-02|P1Y2M10DT2H30M|AFTER|2021-01-15|ONGOING|2021-01-29
e|RS|22e2b674-dc3f-476d-b3d7-2b1f4ddeea1a|7|NTRGRESP|Non-target Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|Ci/mL|NR|1|mOsm/kg|PHYSICAL EXAMINATION||||ADJUDICATOR|UROLOGIST|U|4|Visit_4|65|4|FOLLOW-UP|2021-01-03|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-25|P1Y2M10DT2H30M|COINCIDENT|2021-01-21|BEFORE|2021-01-27
e|RS|22e2b674-dc3f-476d-b3d7-2b1f4ddeea1a|8|NTLWIND|Non-Target Lesion Worsening Indicator|WHO BREAST CANCER 2006|||CRi|1|Coulomb|REAL-TIME POLYMERASE CHAIN REACTION ASSAY|||Y|ADJUDICATOR|RATER 2|N|4|Visit_4|65|7|SCREENING|2021-01-03|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-25|P1Y2M10DT2H30M|BEFORE|2021-01-23|BEFORE|2021-01-26
e|RS|22e2b674-dc3f-476d-b3d7-2b1f4ddeea1a|9|LIVRRESP|Liver Response|LEE LUNG CANCER 2011|||MOLECULAR MAJOR RESPONSE|1|uOsm|MICROBIAL CONCENTRATION|||Y|NON-HEALTH CARE PROFESSIONAL|RATER 2|U|5|Visit_5|90|5|TREATMENT|2021-01-28|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-04|P1Y2M10DT2H30M|UNKNOWN|2020-12-22|AFTER|2021-01-07
e|RS|22e2b674-dc3f-476d-b3d7-2b1f4ddeea1a|10|METSIND|Metastatic Indicator|NCCN ALL MRD 2014|[?]|DAgU/mL|WORSENED|1|10^9/L|JAEGER EYE CHART||Y||DOMESTIC PARTNER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|5|Visit_5|90|6|WASHOUT|2021-01-28|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-04|P1Y2M10DT2H30M|AFTER|2020-12-23|BEFORE|2021-01-24
e|RS|940e4aef-5648-46b3-9c3e-7c40f7930030|1|METBRESP|Metabolic Response|CHESON LYMPHOMA 2008|||MAJOR PATHOLOGIC RESPONSE|1|ng/mol|CONFOCAL MICROSCOPY|Y|Y|Y|SIGNIFICANT OTHER|NEUROLOGIST|NA|1|Visit_1|10|2|SCREENING|2020-11-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-15|P1Y2M10DT2H30M|AFTER|2021-01-08|AFTER|2021-02-04
e|RS|940e4aef-5648-46b3-9c3e-7c40f7930030|2|MJPTHIND|Major Pathological Response Indicator|MACDONALD GLIOMA 1990|[?]|U/kg/day|CA125 50% RESPONSE|1|mg/g/min|CELL CYTOTOXICITY NEUTRALIZATION ASSAY||||PROXY|ENDOCRINOLOGIST|N|1|Visit_1|10|2|TREATMENT|2020-11-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-15|P1Y2M10DT2H30M|COINCIDENT|2021-01-27|AFTER|2021-02-08
e|RS|940e4aef-5648-46b3-9c3e-7c40f7930030|3|MRDIND|Minimal Residual Disease Indicator|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|min|CYTOGENETIC NO RESPONSE|1|CCID 50/dose|ICP-MS||Y||CHILD|PHYSIOTHERAPIST|U|2|Visit_2|25|1|TREATMENT|2020-11-30|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-30|P1Y2M10DT2H30M|AFTER|2020-12-17|COINCIDENT|2021-01-14
e|RS|940e4aef-5648-46b3-9c3e-7c40f7930030|4|BONERESP|Bone Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|g/cm2|nPR|1|ft|CT SCAN WITHOUT CONTRAST||Y||CAREGIVER|HEMATOLOGIST|Y|2|Visit_2|25|1|FOLLOW-UP|2020-11-30|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-30|P1Y2M10DT2H30M|AFTER|2021-01-11|COINCIDENT|2021-01-13
e|RS|940e4aef-5648-46b3-9c3e-7c40f7930030|5|BESTRESP|Best Overall Response|BLAZER COLORECTAL CANCER 2008|||MRD RELAPSE|1|Osm|OLIGO ACGH|||Y|GUARDIAN|UROLOGIST|U|3|Visit_3|40|2|SCREENING|2020-12-15|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-02|P1Y2M10DT2H30M|BEFORE|2021-01-16|BEFORE|2021-01-23
e|RS|940e4aef-5648-46b3-9c3e-7c40f7930030|6|MRDIND|Minimal Residual Disease Indicator|GCIG RUSTIN OVARIAN CANCER 2011|||VGPR|1|EID 50/dose|LASER CAPTURE MICRODISSECTION|||Y|PARENT|OTOLARYNGOLOGIST|N|3|Visit_3|40|7|FOLLOW-UP|2020-12-15|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-02|P1Y2M10DT2H30M|AFTER|2021-01-13|AFTER|2021-01-14
e|RS|940e4aef-5648-46b3-9c3e-7c40f7930030|7|NEWLPROG|New Lesion Progression|CHOLLET BREAST CANCER 2002|[?]|uCi|mCR|1|tuberculin unit/mL|SPIRAL CT||||INTERVIEWER|OTOLARYNGOLOGIST|NA|4|Visit_4|65|6|TREATMENT|2021-01-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-28|P1Y2M10DT2H30M|AFTER|2020-12-22|AFTER|2021-01-30
e|RS|940e4aef-5648-46b3-9c3e-7c40f7930030|8|NTLWIND|Non-Target Lesion Worsening Indicator|IWG CHESON MDS 2006|||EQUIVOCAL|1|psec|ELLA||Y|Y|ADJUDICATOR|ADJUDICATOR 3|NA|4|Visit_4|65|2|WASHOUT|2021-01-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-28|P1Y2M10DT2H30M|BEFORE|2021-01-06|COINCIDENT|2021-02-03
e|RS|940e4aef-5648-46b3-9c3e-7c40f7930030|9|MOLRESP|Molecular Response|AJCC V7|[?]|PACKET|HI-N|1|mAnson U/mL|TONOMETRY||Y||CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR|U|5|Visit_5|90|4|WASHOUT|2021-02-03|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-26|P1Y2M10DT2H30M|UNKNOWN|2020-11-21|ONGOING|2021-01-15
e|RS|940e4aef-5648-46b3-9c3e-7c40f7930030|10|MRPHRESP|Morphologic Response|GUPPY OVARIAN CANCER 2002|||PMD|1|g/kg/day|SEQUENCING||Y|Y|VENDOR|ONCOLOGIST 2|Y|5|Visit_5|90|6|TREATMENT|2021-02-03|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-26|P1Y2M10DT2H30M|COINCIDENT|2020-12-05|AFTER|2021-01-05
e|RS|e4bece1e-6672-4b55-824f-56aa923e60f9|1|NTERESP|Non-Target Enhancing Response|PCWG SCHER PROSTATE CANCER 2008|[?]|GPL U|NR|1|ug/kg/min|TOTAL BODY RADIOGRAPHY||||SPOUSE|MICROSCOPIST 2|Y|1|Visit_1|10|2|TREATMENT|2020-06-22|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-24|P1Y2M10DT2H30M|UNKNOWN|2020-08-01|BEFORE|2020-09-10
e|RS|e4bece1e-6672-4b55-824f-56aa923e60f9|2|METSIND|Metastatic Indicator|IRANO 2015|[?]|PA|HI-N|1|Bq/kg|HPLC/MS||||CAREGIVER|ADJUDICATOR 1|Y|1|Visit_1|10|6|FOLLOW-UP|2020-06-22|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-24|P1Y2M10DT2H30M|AFTER|2020-06-19|AFTER|2020-08-24
e|RS|e4bece1e-6672-4b55-824f-56aa923e60f9|3|CYTORESP|Cytogenetic Response|HARTMANN GERM CELL CANCER 2002|[?]|OD Unit|MRD PERSISTENCE|1|MPL U/mL|ELISPOT||Y||FAMILY MEMBER|RADIOLOGIST|U|2|Visit_2|25|1|TREATMENT|2020-07-07|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-21|P1Y2M10DT2H30M|AFTER|2020-08-13|AFTER|2020-09-04
e|RS|e4bece1e-6672-4b55-824f-56aa923e60f9|4|METBRESP|Metabolic Response|CHESON LYMPHOMA 2008|[?]|mmol/kg|PDu|1|ugEq/L|RADIOGRAPHY||||STUDY SUBJECT|UROLOGIST|U|2|Visit_2|25|6|TREATMENT|2020-07-07|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-21|P1Y2M10DT2H30M|COINCIDENT|2020-08-25|ONGOING|2020-08-30
e|RS|e4bece1e-6672-4b55-824f-56aa923e60f9|5|NEWLIND|New Lesion Indicator|GUILHOT CML 2007|[?]|DAgU|INDETERMINATE RESPONSE|1|ELISA unit|NUCLEIC ACID AMPLIFICATION TEST|Y|||CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 1|Y|3|Visit_3|40|2|TREATMENT|2020-07-22|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-29|P1Y2M10DT2H30M|COINCIDENT|2020-08-04|AFTER|2020-08-16
e|RS|e4bece1e-6672-4b55-824f-56aa923e60f9|6|DRCRIND|Disease Recurrence Indicator|CHOI GIST 2008|[?]|mL/(min*100mL)|UNFAVORABLE RESPONSE|1|ugEq|MAMMOGRAPHY||Y||INTERVIEWER|READER 3|Y|3|Visit_3|40|7|TREATMENT|2020-07-22|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-29|P1Y2M10DT2H30M|UNKNOWN|2020-06-30|COINCIDENT|2020-07-29
e|RS|e4bece1e-6672-4b55-824f-56aa923e60f9|7|METBRESP|Metabolic Response|KUKER LYMPHOMA 2005|[?]|mL/day|CYTOGENETIC PR|1|ELISA unit/mL|NEXT GENERATION SEQUENCING||Y||DOMESTIC PARTNER|DERMATOLOGIST|NA|4|Visit_4|65|3|TREATMENT|2020-08-16|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-28|P1Y2M10DT2H30M|COINCIDENT|2020-06-28|COINCIDENT|2020-08-28
e|RS|e4bece1e-6672-4b55-824f-56aa923e60f9|8|OVRLRESP|Overall Response|MURPHY PROSTATE CANCER 1980|[?]|umol/dL|CHR|1|cP|ELECTROCHEMILUMINESCENCE IMMUNOASSAY||||GUARDIAN|ADJUDICATOR 2|NA|4|Visit_4|65|5|SCREENING|2020-08-16|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-28|P1Y2M10DT2H30M|UNKNOWN|2020-08-05|ONGOING|2020-09-14
e|RS|e4bece1e-6672-4b55-824f-56aa923e60f9|9|TRGRESP|Target Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|Bq/mL|CRi|1|U/10^12 RBC|FLOCCULATION, CHARCOAL ENHANCED|Y|||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 1|U|5|Visit_5|90|7|SCREENING|2020-09-10|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-25|P1Y2M10DT2H30M|AFTER|2020-07-01|ONGOING|2020-07-14
e|RS|e4bece1e-6672-4b55-824f-56aa923e60f9|10|DRCRIND|Disease Recurrence Indicator|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|/40 HPFs|CYTOGENETIC NO RESPONSE|1|m|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION|Y|||SIBLING|ONCOLOGIST|N|5|Visit_5|90|7|SCREENING|2020-09-10|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-25|P1Y2M10DT2H30M|UNKNOWN|2020-07-20|BEFORE|2020-08-31
e|RS|12e607da-f53c-4078-9742-23a111db6f54|1|NTLWIND|Non-Target Lesion Worsening Indicator|CHESON CLL 2006|||DECREASED|1|cP|FLUORESCENT ENZYME IMMUNOASSAY|||Y|PARENT|ENDOCRINOLOGIST|NA|1|Visit_1|10|6|FOLLOW-UP|2020-10-03|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-14|P1Y2M10DT2H30M|AFTER|2020-10-06|COINCIDENT|2020-11-28
e|RS|12e607da-f53c-4078-9742-23a111db6f54|2|MRPHRESP|Morphologic Response|SCHWARZ CERVICAL CANCER 2009|[?]|RNA copies/mL|NED|1|g/cage/day|DYNAMOMETRY||||ADJUDICATOR|MICROSCOPIST 3|N|1|Visit_1|10|7|TREATMENT|2020-10-03|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-14|P1Y2M10DT2H30M|AFTER|2020-11-16|ONGOING|2020-11-21
e|RS|12e607da-f53c-4078-9742-23a111db6f54|3|MNPTHIND|Minor Pathological Response Indicator|iRECIST|||PD-CT|1|g/U|LC-FL||Y|Y|INDEPENDENT ASSESSOR|ONCOLOGIST|Y|2|Visit_2|25|2|FOLLOW-UP|2020-10-18|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-08|P1Y2M10DT2H30M|AFTER|2020-12-05|BEFORE|2020-12-07
e|RS|12e607da-f53c-4078-9742-23a111db6f54|4|BONERESP|Bone Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|/cmH2O|PARTIAL MORPHOLOGIC RESPONSE|1|mL/g/min|CELL OF ORIGIN ASSAY||||ADJUDICATOR|UROLOGIST|N|2|Visit_2|25|3|WASHOUT|2020-10-18|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-08|P1Y2M10DT2H30M|BEFORE|2020-12-12|BEFORE|2020-12-19
e|RS|12e607da-f53c-4078-9742-23a111db6f54|5|MJPTHIND|Major Pathological Response Indicator|IRANO 2015|[?]|MBq/uL|PMD|1|lm|ICC||||ADJUDICATOR|PATHOLOGIST 2|U|3|Visit_3|40|4|TREATMENT|2020-11-02|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-26|P1Y2M10DT2H30M|COINCIDENT|2020-10-19|COINCIDENT|2020-12-01
e|RS|12e607da-f53c-4078-9742-23a111db6f54|6|NEWLWIND|New Lesion Worsening Indicator|CHOLLET BREAST CANCER 2002|||CYTOGENETIC MINIMAL RESPONSE|1|cm/min|MICRONEUTRALIZATION ASSAY|Y||Y|PARENT|ONCOLOGIST 1|N|3|Visit_3|40|7|TREATMENT|2020-11-02|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-26|P1Y2M10DT2H30M|AFTER|2020-10-13|BEFORE|2020-10-14
e|RS|12e607da-f53c-4078-9742-23a111db6f54|7|MNPTHIND|Minor Pathological Response Indicator|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|||nPR|1|U/g/min|INTRAVASCULAR ULTRASOUND|||Y|FRIEND|RADIOLOGIST 1|U|4|Visit_4|65|2|TREATMENT|2020-11-27|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-16|P1Y2M10DT2H30M|UNKNOWN|2020-11-12|AFTER|2020-12-24
e|RS|12e607da-f53c-4078-9742-23a111db6f54|8|MRPHRESP|Morphologic Response|PALUMBO MULTIPLE MYELOMA 2009|||CRi|1|m3|HPLC|Y||Y|CHILD|PATHOLOGIST 2|Y|4|Visit_4|65|2|TREATMENT|2020-11-27|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-16|P1Y2M10DT2H30M|BEFORE|2020-12-28|ONGOING|2020-12-29
e|RS|12e607da-f53c-4078-9742-23a111db6f54|9|NTRGRESP|Non-target Response|HARTMANN GERM CELL CANCER 2002|||CYTOGENETIC CR|1|CIGARETTE|DYNAMIC LIGHT SCATTERING|||Y|SIGNIFICANT OTHER|PHYSIOTHERAPIST|NA|5|Visit_5|90|1|WASHOUT|2020-12-22|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-10|P1Y2M10DT2H30M|AFTER|2020-11-03|AFTER|2020-11-14
e|RS|12e607da-f53c-4078-9742-23a111db6f54|10|MJPTHIND|Major Pathological Response Indicator|MONTSERRAT CLL 1989|[?]|mL/100g/min|NR|1|uV|INDIRECT IMMUNOFLUORESCENCE||||CHILD|INTERNIST|Y|5|Visit_5|90|4|TREATMENT|2020-12-22|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-10|P1Y2M10DT2H30M|UNKNOWN|2020-10-04|ONGOING|2020-10-18
e|RS|ca763b7f-2e60-4423-a7a8-b5fad4a74b25|1|NEWLIND|New Lesion Indicator|IWG CHESON MDS 2000|[?]|TABLET|INDETERMINATE RESPONSE|1|mL/100g/min|FLOW MICROSCOPY||||SIBLING|READER|U|1|Visit_1|10|6|TREATMENT|2021-01-26|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-19|P1Y2M10DT2H30M|COINCIDENT|2021-02-22|COINCIDENT|2021-03-30
e|RS|ca763b7f-2e60-4423-a7a8-b5fad4a74b25|2|CPRFSTAT|Clinical Performance Status|GUPPY OVARIAN CANCER 2002|[?]|ug/m2|MOLECULAR MAJOR RESPONSE|1|pmol/10^10 cells|X-RAY||||SIGNIFICANT OTHER|CLINICAL PATHOLOGIST|U|1|Visit_1|10|4|TREATMENT|2021-01-26|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-19|P1Y2M10DT2H30M|COINCIDENT|2021-01-20|AFTER|2021-03-30
e|RS|ca763b7f-2e60-4423-a7a8-b5fad4a74b25|3|RDIORESP|Radiologic Response|CHESON CLL 2006|[?]|10^3 organisms|iUPD|1|ft3|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN||Y||GUARDIAN|ADJUDICATOR 2|NA|2|Visit_2|25|7|SCREENING|2021-02-10|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-22|P1Y2M10DT2H30M|BEFORE|2021-02-23|COINCIDENT|2021-03-13
e|RS|ca763b7f-2e60-4423-a7a8-b5fad4a74b25|4|MRDRESP|Minimal Residual Disease Response|LEE LUNG CANCER 2011|[?]|USP U|CMR|1|BOX|OPTICAL COHERENCE TOMOGRAPHY||||VENDOR|READER 2|U|2|Visit_2|25|4|FOLLOW-UP|2021-02-10|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-22|P1Y2M10DT2H30M|BEFORE|2021-02-07|AFTER|2021-04-09
e|RS|ca763b7f-2e60-4423-a7a8-b5fad4a74b25|5|METBRESP|Metabolic Response|CHESON LYMPHOMA 2008|[?]|10^3 CFU/mL|iCPD|1|mg/m2|LC-FL||||CLINICAL STUDY SPONSOR|ADJUDICATOR 2|NA|3|Visit_3|40|1|WASHOUT|2021-02-25|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-17|P1Y2M10DT2H30M|COINCIDENT|2021-04-11|AFTER|2021-04-23
e|RS|ca763b7f-2e60-4423-a7a8-b5fad4a74b25|6|RDIORESP|Radiologic Response|RECIST 1.0|||CYTOGENETIC MINOR RESPONSE|1|km|ELLA|||Y|CAREGIVER|READER 2|Y|3|Visit_3|40|2|TREATMENT|2021-02-25|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-17|P1Y2M10DT2H30M|UNKNOWN|2021-04-12|BEFORE|2021-04-13
e|RS|ca763b7f-2e60-4423-a7a8-b5fad4a74b25|7|NEWLPROG|New Lesion Progression|BURCOMBE BREAST CANCER 2005|[?]|RING|TREATMENT FAILURE|1|ft3|MAGNETIC RESONANCE ENTEROGRAPHY|Y|||CHILD|RADIOLOGIST 1|U|4|Visit_4|65|5|TREATMENT|2021-03-22|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-14|P1Y2M10DT2H30M|AFTER|2021-03-16|ONGOING|2021-04-14
e|RS|ca763b7f-2e60-4423-a7a8-b5fad4a74b25|8|NTRGRESP|Non-target Response|MRECIST BYRNE MESOTHELIOMA 2004|||PSA PROGRESSION|1|MnFI|BAC ACGH|||Y|CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|4|Visit_4|65|5|TREATMENT|2021-03-22|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-14|P1Y2M10DT2H30M|AFTER|2021-03-08|BEFORE|2021-03-26
e|RS|ca763b7f-2e60-4423-a7a8-b5fad4a74b25|9|TRGRESP|Target Response|BLAZER COLORECTAL CANCER 2008|[?]|IU/L|HI-P|1|g/day|GC/MS||||DOMESTIC PARTNER|ONCOLOGIST 2|NA|5|Visit_5|90|1|TREATMENT|2021-04-16|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-20|P1Y2M10DT2H30M|BEFORE|2021-03-03|BEFORE|2021-03-07
e|RS|ca763b7f-2e60-4423-a7a8-b5fad4a74b25|10|NEWLPROG|New Lesion Progression|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|mL/kg/min|CYTOGENETIC PR|1|TABLET|ULTRASONOGRAPHIC ELASTOGRAPHY||||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 3|N|5|Visit_5|90|7|TREATMENT|2021-04-16|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-20|P1Y2M10DT2H30M|COINCIDENT|2021-03-28|COINCIDENT|2021-04-07
e|RS|1f6b4ff8-fc33-46c7-8298-fe2e9ea62d60|1|CYTORESP|Cytogenetic Response|IWC HALLEK CLL 2008|[?]|mph|PMD|1|PACKAGE|CALCULATION||Y||ADJUDICATION COMMITTEE|ONCOLOGIST 2|U|1|Visit_1|10|3|TREATMENT|2020-07-16|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-09|P1Y2M10DT2H30M|COINCIDENT|2020-08-25|COINCIDENT|2020-10-06
e|RS|1f6b4ff8-fc33-46c7-8298-fe2e9ea62d60|2|SPLNRESP|Spleen Response|HARTMANN GERM CELL CANCER 2002|[?]|mol/g|CRi|1|Watt|MAGNETIC RESONANCE ELASTOGRAPHY||Y||PARENT|FORENSIC PATHOLOGIST|Y|1|Visit_1|10|7|SCREENING|2020-07-16|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-09|P1Y2M10DT2H30M|AFTER|2020-08-22|AFTER|2020-09-09
e|RS|1f6b4ff8-fc33-46c7-8298-fe2e9ea62d60|3|MJPTHIND|Major Pathological Response Indicator|SHINDOH COLORECTAL CANCER 2013|[?]|PUFF|PSA PROGRESSION|1|U/L|MIGET|Y|||CHILD|RATER 2|U|2|Visit_2|25|7|WASHOUT|2020-07-31|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-20|P1Y2M10DT2H30M|UNKNOWN|2020-09-27|AFTER|2020-10-13
e|RS|1f6b4ff8-fc33-46c7-8298-fe2e9ea62d60|4|METBRESP|Metabolic Response|MONTSERRAT CLL 1989|[?]|kg/cm|MINOR PATHOLOGIC RESPONSE|1|mol|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI||||INVESTIGATOR|PATHOLOGIST 1|NA|2|Visit_2|25|7|TREATMENT|2020-07-31|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-20|P1Y2M10DT2H30M|COINCIDENT|2020-09-09|AFTER|2020-09-20
e|RS|1f6b4ff8-fc33-46c7-8298-fe2e9ea62d60|5|CYTORESP|Cytogenetic Response|JACINTO CERVICAL CANCER 2007|[?]|IU/kg|HI-N|1|mmol2/L2|MANUAL CLOT DETECTION||||CAREGIVER|RADIOLOGIST 2|Y|3|Visit_3|40|4|TREATMENT|2020-08-15|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-01|P1Y2M10DT2H30M|AFTER|2020-10-04|ONGOING|2020-10-06
e|RS|1f6b4ff8-fc33-46c7-8298-fe2e9ea62d60|6|NTLWIND|Non-Target Lesion Worsening Indicator|CHESON NON-HODGKINS LYMPHOMA 1999|||CR-CT|1|mEq/day|GIEMSA STAIN|||Y|INTERVIEWER|CLINICAL PATHOLOGIST|NA|3|Visit_3|40|4|FOLLOW-UP|2020-08-15|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-01|P1Y2M10DT2H30M|BEFORE|2020-09-10|COINCIDENT|2020-09-17
e|RS|1f6b4ff8-fc33-46c7-8298-fe2e9ea62d60|7|NTNERESP|Non-Target Non-Enhancing Response|MRECIST LENCIONI LIVER CANCER 2010|||FAVORABLE RESPONSE|1|U|MAMMOGRAPHY||Y|Y|CAREGIVER|PATHOLOGIST 2|Y|4|Visit_4|65|3|TREATMENT|2020-09-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-20|P1Y2M10DT2H30M|COINCIDENT|2020-08-20|COINCIDENT|2020-09-30
e|RS|1f6b4ff8-fc33-46c7-8298-fe2e9ea62d60|8|TRGRESP|Target Response|AJCC V7|||QUANTIFIABLE MRD POSITIVITY|1|fL|IMMUNOCHROMATOGRAPHY|||Y|SIBLING|MICROSCOPIST 2|NA|4|Visit_4|65|7|FOLLOW-UP|2020-09-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-20|P1Y2M10DT2H30M|UNKNOWN|2020-07-26|ONGOING|2020-09-06
e|RS|1f6b4ff8-fc33-46c7-8298-fe2e9ea62d60|9|SPLNRESP|Spleen Response|RAJKUMAR MYELOMA 2011|[?]|log10 copies/mL|ABSENT MORPHOLOGIC RESPONSE|1|cmol/L|X-RAY FLUORESCENCE SPECTROMETRY||Y||STUDY SUBJECT|ONCOLOGIST 2|NA|5|Visit_5|90|4|FOLLOW-UP|2020-10-04|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-03|P1Y2M10DT2H30M|COINCIDENT|2020-08-14|AFTER|2020-09-07
e|RS|1f6b4ff8-fc33-46c7-8298-fe2e9ea62d60|10|SFTSRESP|Soft Tissue Response|MACDONALD GLIOMA 1990|[?]|nmol BCE/L|HI-N|1|Joule|CONTRAST ENHANCED SPIRAL CT SCAN||||CLINICAL STUDY SPONSOR|PATHOLOGIST|Y|5|Visit_5|90|1|FOLLOW-UP|2020-10-04|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-03|P1Y2M10DT2H30M|AFTER|2020-10-04|AFTER|2020-10-13
e|RS|3260122d-3bf4-45ff-a026-2379158721d0|1|TRGRESP|Target Response|CHOI GIST 2008|[?]|v/v|sCR|1|log10 copies/mL|CALCOFLUOR WHITE STAIN||Y||CLINICAL STUDY SPONSOR|NEUROLOGIST 2|N|1|Visit_1|10|1|TREATMENT|2020-06-04|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-10|P1Y2M10DT2H30M|COINCIDENT|2020-07-08|COINCIDENT|2020-08-19
e|RS|3260122d-3bf4-45ff-a026-2379158721d0|2|SFTSRESP|Soft Tissue Response|PROTOCOL DEFINED RESPONSE CRITERIA|||nPR|1|Enzyme U/m2|SPIROMETRY|Y||Y|SIBLING|OPHTHALMOLOGIST|NA|1|Visit_1|10|1|TREATMENT|2020-06-04|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-10|P1Y2M10DT2H30M|BEFORE|2020-07-29|AFTER|2020-08-06
e|RS|3260122d-3bf4-45ff-a026-2379158721d0|3|ANATRESP|Anatomic Response|UNSPECIFIED|||pCR|1|fmol/g|LINE PROBE ASSAY|||Y|SIBLING|OPTOMETRIST|N|2|Visit_2|25|5|TREATMENT|2020-06-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-30|P1Y2M10DT2H30M|AFTER|2020-08-23|COINCIDENT|2020-08-31
e|RS|3260122d-3bf4-45ff-a026-2379158721d0|4|NTLWIND|Non-Target Lesion Worsening Indicator|EASL BRUIX LIVER CANCER 2001|||PSEUDORESPONSE|1|10^10/L|SLOAN LETTER EYE CHART 1.25%|Y||Y|PARENT|RATER 1|Y|2|Visit_2|25|2|WASHOUT|2020-06-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-30|P1Y2M10DT2H30M|BEFORE|2020-06-13|BEFORE|2020-07-07
e|RS|3260122d-3bf4-45ff-a026-2379158721d0|5|SFTSRESP|Soft Tissue Response|AJCC V8|[?]|g/cage/wk|SMD|1|mg/kg/day|QUANTITATIVE PERIPHERAL ANGIOGRAPHY|Y|||CHILD|ADJUDICATOR|U|3|Visit_3|40|3|TREATMENT|2020-07-04|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-01|P1Y2M10DT2H30M|COINCIDENT|2020-08-11|COINCIDENT|2020-08-14
e|RS|3260122d-3bf4-45ff-a026-2379158721d0|6|NEWLPROG|New Lesion Progression|PALUMBO MULTIPLE MYELOMA 2009|[?]|ug/day|cPR|1|cs|INTRAVASCULAR ULTRASOUND||||VENDOR|READER 2|U|3|Visit_3|40|4|WASHOUT|2020-07-04|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-01|P1Y2M10DT2H30M|COINCIDENT|2020-07-10|ONGOING|2020-08-31
e|RS|3260122d-3bf4-45ff-a026-2379158721d0|7|NTLWIND|Non-Target Lesion Worsening Indicator|SCHER PROSTATE CANCER 2011|[?]|/day|NE|1|L/min|VIRUS PLAQUE ASSAY||||STUDY SUBJECT|MICROSCOPIST 1|NA|4|Visit_4|65|1|WASHOUT|2020-07-29|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-24|P1Y2M10DT2H30M|BEFORE|2020-08-04|AFTER|2020-08-30
e|RS|3260122d-3bf4-45ff-a026-2379158721d0|8|BONERESP|Bone Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|||CR-CT|1|mV/sec|ANALYTICAL ULTRACENTRIFUGATION|||Y|FRIEND|READER 2|N|4|Visit_4|65|2|FOLLOW-UP|2020-07-29|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-24|P1Y2M10DT2H30M|BEFORE|2020-06-12|COINCIDENT|2020-08-19
e|RS|3260122d-3bf4-45ff-a026-2379158721d0|9|HEMARESP|Hematologic Response|GUPPY OVARIAN CANCER 2002|[?]|umol|iCPD|1|mV/sec|OSCILLOMETRY|Y|||NON-HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|U|5|Visit_5|90|1|TREATMENT|2020-08-23|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-27|P1Y2M10DT2H30M|BEFORE|2020-06-17|BEFORE|2020-07-30
e|RS|3260122d-3bf4-45ff-a026-2379158721d0|10|DRCRIND|Disease Recurrence Indicator|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|ngEq/L|UNFAVORABLE RESPONSE|1|nU/cL|OPTICAL MAPPING|Y|||CLINICAL STUDY SPONSOR|READER 2|NA|5|Visit_5|90|4|TREATMENT|2020-08-23|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-27|P1Y2M10DT2H30M|UNKNOWN|2020-05-31|AFTER|2020-07-10
e|RS|05eb4e29-887e-4cdb-8854-49939a8a13d1|1|PATHRESP|Pathologic Response|KUMAR IMWG 2016|[?]|K|PSEUDOPROGRESSION|1|umol/min|FLUORESCENT MICROSCOPY||||CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 3|U|1|Visit_1|10|3|SCREENING|2020-11-05|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-27|P1Y2M10DT2H30M|AFTER|2020-11-29|AFTER|2020-12-06
e|RS|05eb4e29-887e-4cdb-8854-49939a8a13d1|2|BESTRESP|Best Overall Response|CHOLLET BREAST CANCER 2002|[?]|deg2|MORPHOLOGIC CRi|1|deg/mm|GC/FID||||SIGNIFICANT OTHER|MICROSCOPIST 2|NA|1|Visit_1|10|6|TREATMENT|2020-11-05|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-27|P1Y2M10DT2H30M|UNKNOWN|2020-12-24|COINCIDENT|2021-01-06
e|RS|05eb4e29-887e-4cdb-8854-49939a8a13d1|3|SYMPTDTR|Symptomatic Deterioration|BURCOMBE BREAST CANCER 2005|[?]|Enzyme U/m2|MORPHOLOGIC CR|1|umol/kg/min|WEBER GREEN STAIN||||FRIEND|ONCOLOGIST 1|NA|2|Visit_2|25|5|TREATMENT|2020-11-20|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-02|P1Y2M10DT2H30M|BEFORE|2020-12-04|BEFORE|2020-12-08
e|RS|05eb4e29-887e-4cdb-8854-49939a8a13d1|4|CPRFSTAT|Clinical Performance Status|RANO|[?]|nmol BCE/mmol|PSA PROGRESSION|1|mOsm/kg|OPTICAL MAPPING||Y||DOMESTIC PARTNER|MICROSCOPIST 3|NA|2|Visit_2|25|1|TREATMENT|2020-11-20|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-02|P1Y2M10DT2H30M|COINCIDENT|2021-01-12|ONGOING|2021-01-30
e|RS|05eb4e29-887e-4cdb-8854-49939a8a13d1|5|METSIND|Metastatic Indicator|IWG CHESON MDS 2006|[?]|ms/mmHg|CRi|1|NEBULE|LEAD CITRATE STAIN||Y||CLINICAL STUDY SPONSOR|ADJUDICATOR 3|Y|3|Visit_3|40|6|FOLLOW-UP|2020-12-05|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-15|P1Y2M10DT2H30M|BEFORE|2020-12-25|ONGOING|2021-01-13
e|RS|05eb4e29-887e-4cdb-8854-49939a8a13d1|6|SPLNRESP|Spleen Response|MASS|[?]|U/m2/day|PMR|1|mU/g|PERIPHERAL ANGIOGRAPHY||||SIGNIFICANT OTHER|NEUROLOGIST|U|3|Visit_3|40|1|TREATMENT|2020-12-05|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-15|P1Y2M10DT2H30M|COINCIDENT|2021-01-25|AFTER|2021-01-31
e|RS|05eb4e29-887e-4cdb-8854-49939a8a13d1|7|MNPTHIND|Minor Pathological Response Indicator|GUPPY OVARIAN CANCER 2002|[?]|g/g|QUANTIFIABLE MRD POSITIVITY|1|LB|TWO-COLOR MICROARRAY||Y||GUARDIAN|PEDIATRIC NEUROLOGIST|Y|4|Visit_4|65|4|TREATMENT|2020-12-30|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-04|P1Y2M10DT2H30M|UNKNOWN|2021-01-29|ONGOING|2021-02-01
e|RS|05eb4e29-887e-4cdb-8854-49939a8a13d1|8|CPRFSTAT|Clinical Performance Status|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|mg/L FEU|PDu|1|DISK|REFRACTOMETRY|Y|Y||VENDOR|READER 3|N|4|Visit_4|65|2|WASHOUT|2020-12-30|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-04|P1Y2M10DT2H30M|UNKNOWN|2020-12-03|COINCIDENT|2020-12-19
e|RS|05eb4e29-887e-4cdb-8854-49939a8a13d1|9|OVRLRESP|Overall Response|RECIST 1.0|[?]|pt_br|CA125 75% RESPONSE|1|g/animal|IMMUNOBLOT|Y|||CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 2|NA|5|Visit_5|90|1|TREATMENT|2021-01-24|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-12|P1Y2M10DT2H30M|BEFORE|2020-11-27|AFTER|2021-01-26
e|RS|05eb4e29-887e-4cdb-8854-49939a8a13d1|10|CLINRESP|Clinical Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|umol/kg/min|SMD|1|fmol/g|EPSILOMETER||||SPOUSE|MICROSCOPIST 2|NA|5|Visit_5|90|2|WASHOUT|2021-01-24|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-12|P1Y2M10DT2H30M|AFTER|2020-12-18|COINCIDENT|2021-01-17
e|RS|c8390c70-766d-4252-9356-39591651bcdf|1|DRCRIND|Disease Recurrence Indicator|GUPPY OVARIAN CANCER 2002|[?]|mmol/mol|QUANTIFIABLE MRD POSITIVITY|1|umol/L|MALDI||||NON-HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|Y|1|Visit_1|10|2|TREATMENT|2020-08-11|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-04|P1Y2M10DT2H30M|BEFORE|2020-08-28|COINCIDENT|2020-08-29
e|RS|c8390c70-766d-4252-9356-39591651bcdf|2|PATHRESP|Pathologic Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|||SD|1|mg/kg|HIGH RESOLUTION CT|Y||Y|INVESTIGATOR|RADIOLOGIST 1|U|1|Visit_1|10|4|TREATMENT|2020-08-11|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-04|P1Y2M10DT2H30M|COINCIDENT|2020-09-26|BEFORE|2020-10-07
e|RS|c8390c70-766d-4252-9356-39591651bcdf|3|RDIORESP|Radiologic Response|GUPPY OVARIAN CANCER 2002|[?]|cd|NR|1|mAmp|AUTOREFRACTION|Y|Y||VENDOR|OPHTHALMOLOGIST|NA|2|Visit_2|25|7|SCREENING|2020-08-26|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-27|P1Y2M10DT2H30M|UNKNOWN|2020-09-10|COINCIDENT|2020-09-20
e|RS|c8390c70-766d-4252-9356-39591651bcdf|4|SYMPTDTR|Symptomatic Deterioration|RANO|[?]|mmol/kg|CYTOGENETIC PR|1|PA|FLUORESCENT IMMUNOASSAY||||PROXY|PATHOLOGIST 2|NA|2|Visit_2|25|2|TREATMENT|2020-08-26|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-27|P1Y2M10DT2H30M|BEFORE|2020-08-21|BEFORE|2020-10-10
e|RS|c8390c70-766d-4252-9356-39591651bcdf|5|NEWLPROG|New Lesion Progression|CHOI GIST 2008|[?]|mm/h|PD-CT|1|Hounsfield Unit|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE||||CAREGIVER|ADJUDICATOR 2|NA|3|Visit_3|40|3|FOLLOW-UP|2020-09-10|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-03|P1Y2M10DT2H30M|UNKNOWN|2020-10-09|ONGOING|2020-11-04
e|RS|c8390c70-766d-4252-9356-39591651bcdf|6|LIVRRESP|Liver Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|MHz|FAVORABLE RESPONSE|1|kV|EEG|Y|Y||SIGNIFICANT OTHER|FORENSIC PATHOLOGIST|U|3|Visit_3|40|5|TREATMENT|2020-09-10|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-03|P1Y2M10DT2H30M|COINCIDENT|2020-10-04|AFTER|2020-10-31
e|RS|c8390c70-766d-4252-9356-39591651bcdf|7|SYMPTDTR|Symptomatic Deterioration|CHOI GIST 2008|[?]|mol/mol|CYTOGENETIC NO RESPONSE|1|nmol BCE/mmol|CELL BASED BIOASSAY||||STUDY SUBJECT|DERMATOLOGIST|U|4|Visit_4|65|7|WASHOUT|2020-10-05|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-13|P1Y2M10DT2H30M|BEFORE|2020-10-22|ONGOING|2020-10-26
e|RS|c8390c70-766d-4252-9356-39591651bcdf|8|RDIORESP|Radiologic Response|PERCIST|[?]|10^7 CFU|SD-CT|1|m2|MOUSE PROTECTION ASSAY||Y||GUARDIAN|READER 3|U|4|Visit_4|65|1|TREATMENT|2020-10-05|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-13|P1Y2M10DT2H30M|BEFORE|2020-10-24|COINCIDENT|2020-10-25
e|RS|c8390c70-766d-4252-9356-39591651bcdf|9|NTERESP|Non-Target Enhancing Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|mm/sec|MOLECULAR MAJOR RESPONSE|1|mL/cage|TELLER ACUITY CARDS||||VENDOR|INTERNIST|N|5|Visit_5|90|7|TREATMENT|2020-10-30|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-19|P1Y2M10DT2H30M|UNKNOWN|2020-09-22|ONGOING|2020-11-05
e|RS|c8390c70-766d-4252-9356-39591651bcdf|10|NTLWIND|Non-Target Lesion Worsening Indicator|LEE LUNG CANCER 2011|[?]|/VF|CYTOGENETIC MINIMAL RESPONSE|1|vp/mL|REAL-TIME POLYMERASE CHAIN REACTION ASSAY||||INDEPENDENT ASSESSOR|FORENSIC PATHOLOGIST|U|5|Visit_5|90|4|TREATMENT|2020-10-30|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-19|P1Y2M10DT2H30M|AFTER|2020-08-22|AFTER|2020-10-04
e|RS|a40bf877-c070-40b3-89df-d566b942246e|1|OVRLRESP|Overall Response|CHOLLET BREAST CANCER 2002|[?]|s^-1(%O2)^-1|iPR|1|uL/kg/day|CONGO RED STAIN||||NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|1|Visit_1|10|6|FOLLOW-UP|2020-06-16|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-03|P1Y2M10DT2H30M|BEFORE|2020-07-14|ONGOING|2020-08-09
e|RS|a40bf877-c070-40b3-89df-d566b942246e|2|SPLNRESP|Spleen Response|SHINDOH COLORECTAL CANCER 2013|[?]|/2500 WBC|CRi|1|mg/g/min|CELLULOSE TAPE||||CAREGIVER|MICROSCOPIST|U|1|Visit_1|10|3|SCREENING|2020-06-16|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-03|P1Y2M10DT2H30M|COINCIDENT|2020-08-04|ONGOING|2020-08-24
e|RS|a40bf877-c070-40b3-89df-d566b942246e|3|SPLNRESP|Spleen Response|UNSPECIFIED|[?]|pkat|NE|1|10^3/L|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION||Y||ADJUDICATOR|RADIOLOGIST 1|Y|2|Visit_2|25|5|TREATMENT|2020-07-01|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-04|P1Y2M10DT2H30M|AFTER|2020-08-10|ONGOING|2020-08-23
e|RS|a40bf877-c070-40b3-89df-d566b942246e|4|NEWLIND|New Lesion Indicator|RAJKUMAR MYELOMA 2011|[?]|mEq/L|iCR|1|mMU/mL|FLUORESCENT MICROSCOPY||||NON-HEALTH CARE PROFESSIONAL|DERMATOLOGIST|U|2|Visit_2|25|6|TREATMENT|2020-07-01|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-04|P1Y2M10DT2H30M|BEFORE|2020-07-11|BEFORE|2020-07-27
e|RS|a40bf877-c070-40b3-89df-d566b942246e|5|TMRESP|Tumor Marker Response|HARTMANN GERM CELL CANCER 2002|[?]|min*mg/mL|CYTOGENETIC MINIMAL RESPONSE|1|%/min|ELECTROMYOGRAPHY||Y||CLINICAL RESEARCH ASSOCIATE|UROLOGIST|N|3|Visit_3|40|2|TREATMENT|2020-07-16|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-10|P1Y2M10DT2H30M|BEFORE|2020-09-03|ONGOING|2020-09-06
e|RS|a40bf877-c070-40b3-89df-d566b942246e|6|MRDRESP|Minimal Residual Disease Response|DURIE MULTIPLE MYELOMA 2006|[?]|U/mmol|NED|1|10^9/dose|REFLECTANCE SPECTROSCOPY||Y||HEALTH CARE PROFESSIONAL|READER 2|NA|3|Visit_3|40|7|TREATMENT|2020-07-16|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-10|P1Y2M10DT2H30M|BEFORE|2020-08-06|ONGOING|2020-08-21
e|RS|a40bf877-c070-40b3-89df-d566b942246e|7|BMIVLIND|Bone Marrow Involvement Indicator|RECIST 1.1|[?]|mmHg/sec|CYTOGENETIC CR|1|umol/dL|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION||||FRIEND|INTERNIST|Y|4|Visit_4|65|7|FOLLOW-UP|2020-08-10|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-05|P1Y2M10DT2H30M|UNKNOWN|2020-09-06|BEFORE|2020-09-10
e|RS|a40bf877-c070-40b3-89df-d566b942246e|8|MJPTHIND|Major Pathological Response Indicator|RECICL|[?]|TRACE|RELAPSED DISEASE FROM CR|1|Pack Year|REBOUND TONOMETRY||||ADJUDICATOR|ENDOCRINOLOGIST|U|4|Visit_4|65|7|TREATMENT|2020-08-10|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-05|P1Y2M10DT2H30M|COINCIDENT|2020-07-31|AFTER|2020-09-10
e|RS|a40bf877-c070-40b3-89df-d566b942246e|9|NTNERESP|Non-Target Non-Enhancing Response|SACT|[?]|pmol/g|RELAPSED DISEASE|1|mL/cm H2O|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION||Y||CLINICAL STUDY SPONSOR|ADJUDICATOR|Y|5|Visit_5|90|1|SCREENING|2020-09-04|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-24|P1Y2M10DT2H30M|COINCIDENT|2020-06-09|COINCIDENT|2020-08-01
e|RS|a40bf877-c070-40b3-89df-d566b942246e|10|MOLRESP|Molecular Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|mL/dL|SD|1|U/dL|AUTOMATED COUNT||||SIBLING|MICROSCOPIST 2|NA|5|Visit_5|90|1|TREATMENT|2020-09-04|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-24|P1Y2M10DT2H30M|AFTER|2020-08-27|ONGOING|2020-08-28
e|RS|e9633621-3d08-4b47-b394-5bd3fa47c07f|1|STRUSTAT|Steroid Use Status|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|MPL U/mL|PR|1|ug/mL/h|LIGHT SCATTERING SPECTROSCOPY||Y||HEALTH CARE PROFESSIONAL|INTERNIST|NA|1|Visit_1|10|7|SCREENING|2021-01-16|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-23|P1Y2M10DT2H30M|BEFORE|2021-02-03|AFTER|2021-04-10
e|RS|e9633621-3d08-4b47-b394-5bd3fa47c07f|2|MNPTHIND|Minor Pathological Response Indicator|PCWG SCHER PROSTATE CANCER 2008|[?]|bel|MOLECULAR CR|1|PFU/dose|IN SITU HYBRIDIZATION|Y|||HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|U|1|Visit_1|10|4|TREATMENT|2021-01-16|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-23|P1Y2M10DT2H30M|BEFORE|2021-02-26|AFTER|2021-03-31
e|RS|e9633621-3d08-4b47-b394-5bd3fa47c07f|3|BONERESP|Bone Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|Anson U|cCR|1|CAPFUL|HEMAGGLUTINATION ASSAY||||CHILD|ADJUDICATOR 2|U|2|Visit_2|25|5|TREATMENT|2021-01-31|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-21|P1Y2M10DT2H30M|AFTER|2021-01-26|BEFORE|2021-03-04
e|RS|e9633621-3d08-4b47-b394-5bd3fa47c07f|4|MJPTHIND|Major Pathological Response Indicator|RECIST 1.0|[?]|ELISA unit/mL|cCR|1|100 IU/mL|MALDI|Y|||INDEPENDENT ASSESSOR|CLINICAL PATHOLOGIST|NA|2|Visit_2|25|7|WASHOUT|2021-01-31|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-21|P1Y2M10DT2H30M|BEFORE|2021-03-03|ONGOING|2021-03-30
e|RS|e9633621-3d08-4b47-b394-5bd3fa47c07f|5|SPLNRESP|Spleen Response|iRECIST|[?]|min|WORSENED|1|nmol BCE/L|TRANSCRIPTION-MEDIATED AMPLIFICATION||Y||CLINICAL STUDY SPONSOR|ADJUDICATOR|NA|3|Visit_3|40|7|SCREENING|2021-02-15|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-04|P1Y2M10DT2H30M|AFTER|2021-03-31|AFTER|2021-04-11
e|RS|e9633621-3d08-4b47-b394-5bd3fa47c07f|6|LIVRRESP|Liver Response|KEAM BREAST CANCER 2013|[?]|10^7/L|MORPHOLOGIC CRi|1|GPL U|FUNDUS PHOTOGRAPHY||||VENDOR|PEDIATRIC NEUROLOGIST|Y|3|Visit_3|40|4|TREATMENT|2021-02-15|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-04|P1Y2M10DT2H30M|AFTER|2021-02-17|COINCIDENT|2021-02-22
e|RS|e9633621-3d08-4b47-b394-5bd3fa47c07f|7|PATHRESP|Pathologic Response|LEE LUNG CANCER 2011|[?]|foz_us|COMPLETE MRD RESPONSE|1|Bq/mg|SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY||Y||NON-HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|NA|4|Visit_4|65|1|TREATMENT|2021-03-12|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-05|P1Y2M10DT2H30M|COINCIDENT|2021-02-14|COINCIDENT|2021-02-19
e|RS|e9633621-3d08-4b47-b394-5bd3fa47c07f|8|ANATRESP|Anatomic Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|PFU|pCR|1|Osm|HPLC-UV||||CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 1|Y|4|Visit_4|65|2|TREATMENT|2021-03-12|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-05|P1Y2M10DT2H30M|BEFORE|2021-03-11|ONGOING|2021-03-28
e|RS|e9633621-3d08-4b47-b394-5bd3fa47c07f|9|TMRESP|Tumor Marker Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|nkat|CA125 50% RESPONSE|1|m/sec2|LC/MS/MS||||PARENT|CLINICAL PATHOLOGIST|NA|5|Visit_5|90|2|SCREENING|2021-04-06|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-01|P1Y2M10DT2H30M|BEFORE|2021-02-01|ONGOING|2021-02-10
e|RS|e9633621-3d08-4b47-b394-5bd3fa47c07f|10|CYTORESP|Cytogenetic Response|LUGANO CLASSIFICATION|[?]|USP U|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|Torr|NUCLEIC ACID AMPLIFICATION TEST|Y|||INVESTIGATOR|MICROSCOPIST 3|NA|5|Visit_5|90|4|TREATMENT|2021-04-06|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-01|P1Y2M10DT2H30M|COINCIDENT|2021-02-11|ONGOING|2021-03-29
e|RS|ff56cb6e-b6c4-49cc-ad21-9a4d20aad7ee|1|NTRGRESP|Non-target Response|UNSPECIFIED|[?]|cm H2O|DISEASE TRANSFORMATION|1|QUANTITY SUFFICIENT|IMMUNOCHROMATOGRAPHY||||NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST|NA|1|Visit_1|10|2|TREATMENT|2020-06-08|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-08|P1Y2M10DT2H30M|BEFORE|2020-06-24|BEFORE|2020-07-24
e|RS|ff56cb6e-b6c4-49cc-ad21-9a4d20aad7ee|2|MRDIND|Minimal Residual Disease Indicator|PETIT BREAST CANCER 2001|[?]|%/min|PR-CT|1|BAG|IMMUNOFLUORESCENT STAIN||Y||SIGNIFICANT OTHER|READER 1|U|1|Visit_1|10|7|FOLLOW-UP|2020-06-08|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-08|P1Y2M10DT2H30M|UNKNOWN|2020-06-30|BEFORE|2020-07-31
e|RS|ff56cb6e-b6c4-49cc-ad21-9a4d20aad7ee|3|NTLWIND|Non-Target Lesion Worsening Indicator|KUMAR IMWG 2016|[?]|BAU|PR-CT|1|U/m2/min|ELASTOGRAPHY||Y||FRIEND|PATHOLOGIST|NA|2|Visit_2|25|4|FOLLOW-UP|2020-06-23|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-25|P1Y2M10DT2H30M|COINCIDENT|2020-08-03|ONGOING|2020-08-17
e|RS|ff56cb6e-b6c4-49cc-ad21-9a4d20aad7ee|4|CLINRESP|Clinical Response|BRUGGEMANN MRD 2010|[?]|U.CARR|pCR|1|U/kg|DUKE INCISION METHOD||||INVESTIGATOR|DERMATOLOGIST|Y|2|Visit_2|25|3|TREATMENT|2020-06-23|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-25|P1Y2M10DT2H30M|COINCIDENT|2020-06-06|COINCIDENT|2020-07-18
e|RS|ff56cb6e-b6c4-49cc-ad21-9a4d20aad7ee|5|METBRESP|Metabolic Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|Bq/uL|NOT ALL EVALUATED|1|mEq/day|CALCULATION||||INTERVIEWER|ADJUDICATOR 3|U|3|Visit_3|40|4|FOLLOW-UP|2020-07-08|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-08|P1Y2M10DT2H30M|COINCIDENT|2020-08-17|COINCIDENT|2020-08-25
e|RS|ff56cb6e-b6c4-49cc-ad21-9a4d20aad7ee|6|MRDIND|Minimal Residual Disease Indicator|PRINCE TCELL LYMPHOMA 2010|[?]|s/h|NON-PD|1|nmol/L|MICRODENSITOMETRY||Y||FRIEND|OPTOMETRIST|Y|3|Visit_3|40|2|WASHOUT|2020-07-08|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-08|P1Y2M10DT2H30M|BEFORE|2020-08-21|BEFORE|2020-08-30
e|RS|ff56cb6e-b6c4-49cc-ad21-9a4d20aad7ee|7|BMIVLIND|Bone Marrow Involvement Indicator|AJCC V7|[?]|mL/cage/day|CYTOGENETIC CR|1|nkat|NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY||||PARENT|CARDIOLOGIST|Y|4|Visit_4|65|6|WASHOUT|2020-08-02|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-07|P1Y2M10DT2H30M|UNKNOWN|2020-06-05|ONGOING|2020-06-17
e|RS|ff56cb6e-b6c4-49cc-ad21-9a4d20aad7ee|8|BMIVLIND|Bone Marrow Involvement Indicator|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|cg|VGPR|1|Ci/mg|MICROBIAL CONCENTRATION||Y||VENDOR|NEUROLOGIST 1|N|4|Visit_4|65|6|SCREENING|2020-08-02|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-07|P1Y2M10DT2H30M|BEFORE|2020-08-16|ONGOING|2020-08-22
e|RS|ff56cb6e-b6c4-49cc-ad21-9a4d20aad7ee|9|ANATRESP|Anatomic Response|CHESON CLL 2012|[?]|kcal|cCR|1|10^7 CFU/mL|DXA SCAN||||FAMILY MEMBER|READER 3|NA|5|Visit_5|90|3|TREATMENT|2020-08-27|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-08|P1Y2M10DT2H30M|COINCIDENT|2020-08-08|BEFORE|2020-08-18
e|RS|ff56cb6e-b6c4-49cc-ad21-9a4d20aad7ee|10|BONERESP|Bone Response|iRECIST|[?]|uL/kg/day|PSEUDOPROGRESSION|1|Ejaculate U|HIGH LEVEL AMINOGLYCOSIDE SCREEN||||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 1|Y|5|Visit_5|90|4|SCREENING|2020-08-27|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-08|P1Y2M10DT2H30M|COINCIDENT|2020-06-30|ONGOING|2020-09-01
e|RS|ee525e77-38dd-4b0b-88f4-69759d5dbfd9|1|ANATRESP|Anatomic Response|RECIST 1.1|[?]|g/L|HI-N|1|DRINK|FLUORESCENT MICROSCOPY|Y|Y||SPOUSE|ADJUDICATOR 3|NA|1|Visit_1|10|5|SCREENING|2020-07-16|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-31|P1Y2M10DT2H30M|COINCIDENT|2020-09-20|AFTER|2020-10-01
e|RS|ee525e77-38dd-4b0b-88f4-69759d5dbfd9|2|BESTRESP|Best Overall Response|PCWG SCHER PROSTATE CANCER 2016|[?]|CAPLET|iSD|1|CAPSULE|FREEZING POINT DEPRESSION||||CLINICAL RESEARCH ASSOCIATE|READER 2|N|1|Visit_1|10|6|TREATMENT|2020-07-16|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-31|P1Y2M10DT2H30M|AFTER|2020-09-27|AFTER|2020-10-06
e|RS|ee525e77-38dd-4b0b-88f4-69759d5dbfd9|3|NTRGRESP|Non-target Response|DOHNER AML 2010|[?]|mm/min|UNEQUIVOCAL|1|10^6/L|CINEANGIOGRAPHY|Y|||INVESTIGATOR|ADJUDICATOR 1|N|2|Visit_2|25|4|TREATMENT|2020-07-31|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-27|P1Y2M10DT2H30M|COINCIDENT|2020-10-10|BEFORE|2020-10-11
e|RS|ee525e77-38dd-4b0b-88f4-69759d5dbfd9|4|NTRGRESP|Non-target Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|umol/day|OPTIMAL MORPHOLOGIC RESPONSE|1|USP U|DC SHEATH FLOW||||CLINICAL RESEARCH ASSOCIATE|OPHTHALMOLOGIST|Y|2|Visit_2|25|7|WASHOUT|2020-07-31|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-27|P1Y2M10DT2H30M|UNKNOWN|2020-08-10|COINCIDENT|2020-09-17
e|RS|ee525e77-38dd-4b0b-88f4-69759d5dbfd9|5|TMRESP|Tumor Marker Response|CHESON CLL 2012|[?]|g/day|iUPD|1|U/L|EIA||||SIGNIFICANT OTHER|ONCOLOGIST|N|3|Visit_3|40|2|TREATMENT|2020-08-15|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-02|P1Y2M10DT2H30M|COINCIDENT|2020-10-12|ONGOING|2020-10-13
e|RS|ee525e77-38dd-4b0b-88f4-69759d5dbfd9|6|NTERESP|Non-Target Enhancing Response|RECIST 1.1|[?]|mmol/g|PD FROM PR|1|FEU|ENDPOINT DILUTION ASSAY||||SIBLING|ADJUDICATOR|Y|3|Visit_3|40|5|TREATMENT|2020-08-15|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-02|P1Y2M10DT2H30M|AFTER|2020-08-15|BEFORE|2020-09-14
e|RS|ee525e77-38dd-4b0b-88f4-69759d5dbfd9|7|RDIORESP|Radiologic Response|HARTMANN GERM CELL CANCER 2002|[?]|um|CR-CT|1|ukat/10^12 RBC|FLUORESCENT LIFETIME IMAGING MICROSCOPY||||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 3|Y|4|Visit_4|65|2|FOLLOW-UP|2020-09-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-27|P1Y2M10DT2H30M|UNKNOWN|2020-07-21|BEFORE|2020-09-27
e|RS|ee525e77-38dd-4b0b-88f4-69759d5dbfd9|8|SYMPTDTR|Symptomatic Deterioration|iRECIST|[?]|AMPULE|PMR|1|ug/m2|PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY|Y|||GUARDIAN|READER|N|4|Visit_4|65|1|WASHOUT|2020-09-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-27|P1Y2M10DT2H30M|AFTER|2020-09-09|AFTER|2020-10-09
e|RS|ee525e77-38dd-4b0b-88f4-69759d5dbfd9|9|MOLRESP|Molecular Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|mg/m2/h|iUPD|1|ug/m2/min|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY||Y||CAREGIVER|ADJUDICATOR 3|U|5|Visit_5|90|7|WASHOUT|2020-10-04|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-07|P1Y2M10DT2H30M|BEFORE|2020-08-10|ONGOING|2020-10-01
e|RS|ee525e77-38dd-4b0b-88f4-69759d5dbfd9|10|NEWLIND|New Lesion Indicator|LEE LUNG CANCER 2011|[?]|RNA copies/mL|MINOR PATHOLOGIC RESPONSE|1|kg/cm|BIOPSY||||ADJUDICATION COMMITTEE|RADIOLOGIST|N|5|Visit_5|90|1|SCREENING|2020-10-04|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-07|P1Y2M10DT2H30M|AFTER|2020-07-24|BEFORE|2020-09-19
e|RS|63f43990-e56e-440c-a445-76e7d114cf26|1|BESTRESP|Best Overall Response|IWG CHESON AML 2003|[?]|Log10 ELISA unit|WORSENED|1|mmHg*min/L|COMPUTERIZED CORNEAL TOPOGRAPHY||||VENDOR|DERMATOLOGIST|Y|1|Visit_1|10|7|WASHOUT|2020-10-02|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-30|P1Y2M10DT2H30M|UNKNOWN|2020-11-08|COINCIDENT|2020-11-20
e|RS|63f43990-e56e-440c-a445-76e7d114cf26|2|LIVRRESP|Liver Response|HARTMANN GERM CELL CANCER 2002|[?]|PIXELS/cm|CMR|1|pm|BALLPOINT PEN TECHNIQUE||||FAMILY MEMBER|OPTOMETRIST|Y|1|Visit_1|10|1|TREATMENT|2020-10-02|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-30|P1Y2M10DT2H30M|AFTER|2020-12-25|AFTER|2020-12-29
e|RS|63f43990-e56e-440c-a445-76e7d114cf26|3|SYMPTDTR|Symptomatic Deterioration|GUILHOT CML 2007|[?]|cmH2O*s/mL|DISEASE TRANSFORMATION|1|/500 WBC|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY|Y|||INVESTIGATOR|NEUROLOGIST|N|2|Visit_2|25|2|SCREENING|2020-10-17|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-20|P1Y2M10DT2H30M|UNKNOWN|2020-10-18|COINCIDENT|2020-11-14
e|RS|63f43990-e56e-440c-a445-76e7d114cf26|4|DRCRIND|Disease Recurrence Indicator|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|||pCR|1|mmHg*min/L|IMMUNOFIXATION ELECTROPHORESIS|Y||Y|HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|N|2|Visit_2|25|2|TREATMENT|2020-10-17|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-20|P1Y2M10DT2H30M|UNKNOWN|2020-10-17|AFTER|2020-11-07
e|RS|63f43990-e56e-440c-a445-76e7d114cf26|5|HEMARESP|Hematologic Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|uL|MORPHOLOGIC CRi|1|Siemens|HEMATOXYLIN AND EOSIN STAIN||||PROXY|RADIOLOGIST 1|N|3|Visit_3|40|6|SCREENING|2020-11-01|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-20|P1Y2M10DT2H30M|AFTER|2020-10-21|BEFORE|2020-11-23
e|RS|63f43990-e56e-440c-a445-76e7d114cf26|6|MRPHRESP|Morphologic Response|RECIST 1.0|[?]|CUP|MORPHOLOGIC CR|1|log10 IU/mL|MICROBIAL CULTURE, LIQUID||||FAMILY MEMBER|OPHTHALMOLOGIST|Y|3|Visit_3|40|6|TREATMENT|2020-11-01|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-20|P1Y2M10DT2H30M|AFTER|2020-10-13|AFTER|2020-11-04
e|RS|63f43990-e56e-440c-a445-76e7d114cf26|7|OVRLRESP|Overall Response|GCIG RUSTIN OVARIAN CANCER 2011|||PD|1|nmol|BRDU CELLULAR PROLIFERATION ASSAY|||Y|SIGNIFICANT OTHER|NEUROLOGIST 2|Y|4|Visit_4|65|1|WASHOUT|2020-11-26|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-15|P1Y2M10DT2H30M|COINCIDENT|2020-10-23|AFTER|2020-11-17
e|RS|63f43990-e56e-440c-a445-76e7d114cf26|8|PATHRESP|Pathologic Response|IWC HALLEK CLL 2008|[?]|deg/s|SD|1|cd/m2|EPSILOMETER||||HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|N|4|Visit_4|65|7|TREATMENT|2020-11-26|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-15|P1Y2M10DT2H30M|COINCIDENT|2020-11-14|AFTER|2020-12-23
e|RS|63f43990-e56e-440c-a445-76e7d114cf26|9|PATHRESP|Pathologic Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|% INHIBITION|INDETERMINATE RESPONSE|1|ug/m2|SINGLE-MOLECULE ARRAY||||INDEPENDENT ASSESSOR|ONCOLOGIST|Y|5|Visit_5|90|3|TREATMENT|2020-12-21|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-12|P1Y2M10DT2H30M|UNKNOWN|2020-12-23|BEFORE|2020-12-27
e|RS|63f43990-e56e-440c-a445-76e7d114cf26|10|MOLRESP|Molecular Response|EBMT BLADE MYELOMA 1998|||PARTIAL MORPHOLOGIC RESPONSE|1|mgEq|MICROBIAL CULTURE|||Y|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 2|Y|5|Visit_5|90|6|WASHOUT|2020-12-21|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-12|P1Y2M10DT2H30M|COINCIDENT|2020-12-01|ONGOING|2020-12-27
e|RS|380c89f4-2650-4a54-92f5-5e1278b9a91e|1|MNPTHIND|Minor Pathological Response Indicator|MURPHY PROSTATE CANCER 1980|[?]|mph|EQUIVOCAL|1|mL/cage|MECHANICAL CLOT DETECTION|Y|||ADJUDICATOR|RATER|N|1|Visit_1|10|2|TREATMENT|2020-10-22|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-01|P1Y2M10DT2H30M|COINCIDENT|2020-11-02|COINCIDENT|2020-12-22
e|RS|380c89f4-2650-4a54-92f5-5e1278b9a91e|2|MJPTHIND|Major Pathological Response Indicator|PCWG BUBLEY PROSTATE CANCER 1999|[?]|pmol/10^10 cells|CRi|1|ug/g/h|SXA SCAN|Y|Y||VENDOR|MICROSCOPIST 1|U|1|Visit_1|10|1|TREATMENT|2020-10-22|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-01|P1Y2M10DT2H30M|COINCIDENT|2020-11-21|AFTER|2020-12-23
e|RS|380c89f4-2650-4a54-92f5-5e1278b9a91e|3|DRCRIND|Disease Recurrence Indicator|KUKER LYMPHOMA 2005|[?]|/2500 WBC|STABLE|1|BAU/mL|ELECTRONEUROGRAPHY||||SIGNIFICANT OTHER|NEUROLOGIST 1|NA|2|Visit_2|25|3|SCREENING|2020-11-06|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-14|P1Y2M10DT2H30M|BEFORE|2021-01-09|ONGOING|2021-01-19
e|RS|380c89f4-2650-4a54-92f5-5e1278b9a91e|4|SFTSRESP|Soft Tissue Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|PACK|PMR|1|umol/dL|KINYOUN STAIN||||CAREGIVER|MICROSCOPIST 3|NA|2|Visit_2|25|7|WASHOUT|2020-11-06|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-14|P1Y2M10DT2H30M|BEFORE|2020-12-03|BEFORE|2020-12-25
e|RS|380c89f4-2650-4a54-92f5-5e1278b9a91e|5|NEWLPROG|New Lesion Progression|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|||SD|1|10^9 organisms/mL|DIFFUSION TENSOR MRI|||Y|CHILD|ADJUDICATOR|Y|3|Visit_3|40|2|TREATMENT|2020-11-21|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-28|P1Y2M10DT2H30M|UNKNOWN|2020-11-18|ONGOING|2020-12-26
e|RS|380c89f4-2650-4a54-92f5-5e1278b9a91e|6|SPLNRESP|Spleen Response|MONTSERRAT CLL 1989|[?]|%(w/w)|SMD|1|Enzyme U/L|PELLI-ROBSON EYE CHART||Y||SPOUSE|MICROSCOPIST 1|Y|3|Visit_3|40|2|TREATMENT|2020-11-21|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-28|P1Y2M10DT2H30M|COINCIDENT|2020-11-05|COINCIDENT|2020-11-23
e|RS|380c89f4-2650-4a54-92f5-5e1278b9a91e|7|METBRESP|Metabolic Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|10^9 organisms/g|PMD|1|V/sec|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY||||INTERVIEWER|OPTOMETRIST|U|4|Visit_4|65|4|TREATMENT|2020-12-16|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-11|P1Y2M10DT2H30M|BEFORE|2020-10-28|ONGOING|2021-01-13
e|RS|380c89f4-2650-4a54-92f5-5e1278b9a91e|8|SPLNRESP|Spleen Response|HAMAOKA BREAST CANCER 2010|[?]|Ci/ug|nPR|1|nmol|NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY||Y||PARENT|MICROSCOPIST|Y|4|Visit_4|65|1|TREATMENT|2020-12-16|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-11|P1Y2M10DT2H30M|BEFORE|2020-11-10|COINCIDENT|2021-01-05
e|RS|380c89f4-2650-4a54-92f5-5e1278b9a91e|9|OVRLRESP|Overall Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|PACKAGE|HI-P|1|10^7 TCID 50/dose|ORCHIDOMETERY|Y|||CAREGIVER|PATHOLOGIST 2|N|5|Visit_5|90|3|WASHOUT|2021-01-10|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-14|P1Y2M10DT2H30M|UNKNOWN|2021-01-05|AFTER|2021-01-10
e|RS|380c89f4-2650-4a54-92f5-5e1278b9a91e|10|NTRGRESP|Non-target Response|WOLCHOK SOLID TUMORS 2009|[?]|EVENTS|PR-CT|1|CAPSULE|REAL-TIME POLYMERASE CHAIN REACTION ASSAY|Y|||CLINICAL RESEARCH ASSOCIATE|READER 3|N|5|Visit_5|90|4|SCREENING|2021-01-10|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-14|P1Y2M10DT2H30M|AFTER|2020-10-30|COINCIDENT|2021-01-14
e|RS|84c1f5f4-6415-49d8-b854-22e7529d65b6|1|NTNERESP|Non-Target Non-Enhancing Response|PCWG SCHER PROSTATE CANCER 2016|[?]|log10 copies/mL|QUANTIFIABLE MRD POSITIVITY|1|INHALATION|AUDIOMETRY|Y|||NON-HEALTH CARE PROFESSIONAL|READER|U|1|Visit_1|10|2|SCREENING|2020-12-05|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-05|P1Y2M10DT2H30M|UNKNOWN|2020-12-26|COINCIDENT|2021-01-17
e|RS|84c1f5f4-6415-49d8-b854-22e7529d65b6|2|HEMARESP|Hematologic Response|SCHWARZ CERVICAL CANCER 2009|||RELAPSED DISEASE FROM CR OR PR|1|mEq/ug|FLUORESCENT ENZYME IMMUNOASSAY|||Y|GUARDIAN|PHYSIOTHERAPIST|N|1|Visit_1|10|7|FOLLOW-UP|2020-12-05|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-05|P1Y2M10DT2H30M|AFTER|2020-12-08|BEFORE|2021-02-28
e|RS|84c1f5f4-6415-49d8-b854-22e7529d65b6|3|STRUSTAT|Steroid Use Status|RANO ELLINGSON 2017|[?]|ukat|MRD RELAPSE|1|Enzyme U/L|RADIOGRAPHY|Y|||ADJUDICATOR|PATHOLOGIST|NA|2|Visit_2|25|3|TREATMENT|2020-12-20|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-17|P1Y2M10DT2H30M|AFTER|2021-01-01|COINCIDENT|2021-01-23
e|RS|84c1f5f4-6415-49d8-b854-22e7529d65b6|4|TMRESP|Tumor Marker Response|GUILHOT CML 2007|[?]|ft|MRD RELAPSE|1|dpm/mL|TOTAL BODY IRRADIATION||||FRIEND|OPHTHALMOLOGIST|Y|2|Visit_2|25|1|WASHOUT|2020-12-20|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-17|P1Y2M10DT2H30M|COINCIDENT|2021-02-24|AFTER|2021-02-27
e|RS|84c1f5f4-6415-49d8-b854-22e7529d65b6|5|NEWLPROG|New Lesion Progression|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|log10 PFU|PARTIAL MORPHOLOGIC RESPONSE|1|mg/animal|CYSTOMETRY||Y||SIGNIFICANT OTHER|RATER|N|3|Visit_3|40|6|FOLLOW-UP|2021-01-04|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-12|P1Y2M10DT2H30M|BEFORE|2021-02-09|COINCIDENT|2021-02-20
e|RS|84c1f5f4-6415-49d8-b854-22e7529d65b6|6|MOLRESP|Molecular Response|MONTSERRAT CLL 1989|[?]|ft2|iSD|1|/cmH2O|ISHIHARA COLOR PLATES||||INDEPENDENT ASSESSOR|ENDOCRINOLOGIST|N|3|Visit_3|40|2|TREATMENT|2021-01-04|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-12|P1Y2M10DT2H30M|UNKNOWN|2021-01-14|BEFORE|2021-01-29
e|RS|84c1f5f4-6415-49d8-b854-22e7529d65b6|7|NTLWIND|Non-Target Lesion Worsening Indicator|MRECIST LENCIONI LIVER CANCER 2010|[?]|MHz|cCR|1|CAPFUL|CT SCAN WITHOUT CONTRAST||Y||GUARDIAN|HEMATOLOGIST|N|4|Visit_4|65|5|WASHOUT|2021-01-29|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-07|P1Y2M10DT2H30M|AFTER|2021-02-03|AFTER|2021-02-11
e|RS|84c1f5f4-6415-49d8-b854-22e7529d65b6|8|CYTORESP|Cytogenetic Response|RANO|[?]|pt_br|PR-CT|1|g/mol|U-HPLC/MS/MS||Y||DOMESTIC PARTNER|CARDIOLOGIST|Y|4|Visit_4|65|5|TREATMENT|2021-01-29|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-07|P1Y2M10DT2H30M|BEFORE|2021-01-05|COINCIDENT|2021-02-01
e|RS|84c1f5f4-6415-49d8-b854-22e7529d65b6|9|NTRGRESP|Non-target Response|PCWG SCHER PROSTATE CANCER 2016|[?]|Tesla|FAVORABLE RESPONSE|1|CFU/g|HEMAGGLUTINATION INHIBITION ASSAY|Y|||SIGNIFICANT OTHER|ONCOLOGIST 1|Y|5|Visit_5|90|6|WASHOUT|2021-02-23|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-01|P1Y2M10DT2H30M|COINCIDENT|2021-01-20|BEFORE|2021-02-01
e|RS|84c1f5f4-6415-49d8-b854-22e7529d65b6|10|HEMARESP|Hematologic Response|BRUGGEMANN MRD 2010|[?]|10^3 organisms/mL|CR-CT|1|Hz|DIGITAL PCR||||NON-HEALTH CARE PROFESSIONAL|OPTOMETRIST|N|5|Visit_5|90|6|SCREENING|2021-02-23|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-01|P1Y2M10DT2H30M|COINCIDENT|2020-11-27|BEFORE|2020-12-11
e|RS|77c26a0c-0c84-44d7-8351-a50f3236e59a|1|OVRLRESP|Overall Response|RECICL|[?]|10^9 organisms/g|NON-iCR/NON-iUPD|1|10^6 copies/mL|AMSLER GRID|Y|Y||ADJUDICATION COMMITTEE|CARDIOLOGIST|U|1|Visit_1|10|2|WASHOUT|2020-05-14|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-05|P1Y2M10DT2H30M|AFTER|2020-07-29|AFTER|2020-08-04
e|RS|77c26a0c-0c84-44d7-8351-a50f3236e59a|2|MRDRESP|Minimal Residual Disease Response|PRINCE TCELL LYMPHOMA 2010|[?]|INHALATION|QUANTIFIABLE MRD POSITIVITY|1|mg/m2/day|COULOMETRIC TITRATION|Y|||STUDY SUBJECT|DERMATOLOGIST|NA|1|Visit_1|10|4|TREATMENT|2020-05-14|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-05|P1Y2M10DT2H30M|AFTER|2020-07-03|BEFORE|2020-07-21
e|RS|77c26a0c-0c84-44d7-8351-a50f3236e59a|3|CLINRESP|Clinical Response|AJCC V8|[?]|kUSP|mCR|1|tuberculin unit/mL|DXA SCAN|Y|||VENDOR|PATHOLOGIST|N|2|Visit_2|25|2|SCREENING|2020-05-29|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-23|P1Y2M10DT2H30M|COINCIDENT|2020-06-15|AFTER|2020-08-06
e|RS|77c26a0c-0c84-44d7-8351-a50f3236e59a|4|METBRESP|Metabolic Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|U/m2/min|PARTIAL MORPHOLOGIC RESPONSE|1|SYRINGE|IMMUNOBLOT||||CLINICAL STUDY SPONSOR|RADIOLOGIST 1|N|2|Visit_2|25|2|WASHOUT|2020-05-29|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-23|P1Y2M10DT2H30M|BEFORE|2020-07-14|BEFORE|2020-08-05
e|RS|77c26a0c-0c84-44d7-8351-a50f3236e59a|5|RDIORESP|Radiologic Response|KUMAR IMWG 2016|[?]|MnFI|cCR|1|fmol/g|ECHOCARDIOGRAPHY|Y|Y||CHILD|ADJUDICATOR|N|3|Visit_3|40|5|TREATMENT|2020-06-13|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-28|P1Y2M10DT2H30M|UNKNOWN|2020-07-27|COINCIDENT|2020-08-03
e|RS|77c26a0c-0c84-44d7-8351-a50f3236e59a|6|NEWLIND|New Lesion Indicator|EBMT BLADE MYELOMA 1998|[?]|ug/kg|CA125 50% RESPONSE|1|mEq/ug|PLAQUE REDUCTION NEUTRALIZATION ASSAY||||INTERVIEWER|MICROSCOPIST 1|U|3|Visit_3|40|5|TREATMENT|2020-06-13|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-28|P1Y2M10DT2H30M|UNKNOWN|2020-05-24|ONGOING|2020-07-23
e|RS|77c26a0c-0c84-44d7-8351-a50f3236e59a|7|HEMARESP|Hematologic Response|SCHWARZ CERVICAL CANCER 2009|[?]|mm/2h|PR WITH LYMPHOCYTOSIS|1|s/h|REVERSE TRANSCRIPTASE PCR||||INTERVIEWER|ENDOCRINOLOGIST|N|4|Visit_4|65|4|TREATMENT|2020-07-08|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-04|P1Y2M10DT2H30M|AFTER|2020-05-15|ONGOING|2020-06-03
e|RS|77c26a0c-0c84-44d7-8351-a50f3236e59a|8|MRDIND|Minimal Residual Disease Indicator|SACT|[?]|ugEq/L|HI-E|1|BISCUIT|NUCLEIC ACID BASED METHOD||Y||FAMILY MEMBER|RADIOLOGIST|NA|4|Visit_4|65|5|TREATMENT|2020-07-08|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-04|P1Y2M10DT2H30M|COINCIDENT|2020-07-22|AFTER|2020-07-29
e|RS|77c26a0c-0c84-44d7-8351-a50f3236e59a|9|RDIORESP|Radiologic Response|PRINCE TCELL LYMPHOMA 2010|[?]|uCi|cCR|1|BEAM BREAKS|ECHOCARDIOGRAPHY||||CHILD|READER 1|Y|5|Visit_5|90|2|FOLLOW-UP|2020-08-02|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-16|P1Y2M10DT2H30M|BEFORE|2020-05-17|BEFORE|2020-06-29
e|RS|77c26a0c-0c84-44d7-8351-a50f3236e59a|10|ANATRESP|Anatomic Response|NCIWG CHESON CLL 1996|||SD-CT|1|uOsm|ALCIAN BLUE STAIN|||Y|INDEPENDENT ASSESSOR|PATHOLOGIST 2|U|5|Visit_5|90|4|FOLLOW-UP|2020-08-02|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-16|P1Y2M10DT2H30M|BEFORE|2020-06-26|BEFORE|2020-07-06
e|RS|a201c78a-e826-4f42-a997-7c6a019e2c91|1|BESTRESP|Best Overall Response|NCCN ALL MRD 2014|[?]|mmHg/L/min|pCR|1|ELISA unit/dose|ELECTROCHEMILUMINESCENCE||||ADJUDICATION COMMITTEE|PATHOLOGIST|N|1|Visit_1|10|7|WASHOUT|2020-08-03|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-29|P1Y2M10DT2H30M|BEFORE|2020-08-14|COINCIDENT|2020-08-17
e|RS|a201c78a-e826-4f42-a997-7c6a019e2c91|2|MRDRESP|Minimal Residual Disease Response|MURPHY PROSTATE CANCER 1980|[?]|mg/mL/day|cPR|1|MASK|FARR ASSAY||||SPOUSE|FORENSIC PATHOLOGIST|NA|1|Visit_1|10|2|WASHOUT|2020-08-03|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-29|P1Y2M10DT2H30M|BEFORE|2020-10-19|COINCIDENT|2020-10-27
e|RS|a201c78a-e826-4f42-a997-7c6a019e2c91|3|METBRESP|Metabolic Response|PCWG SCHER PROSTATE CANCER 2016|||iCPD|1|kPa|INFRARED SPECTROMETRY|Y||Y|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST|N|2|Visit_2|25|5|TREATMENT|2020-08-18|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-25|P1Y2M10DT2H30M|COINCIDENT|2020-10-29|AFTER|2020-10-30
e|RS|a201c78a-e826-4f42-a997-7c6a019e2c91|4|HEMARESP|Hematologic Response|UNSPECIFIED|[?]|10^11/L|MORPHOLOGIC CRi|1|%|AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT||||CAREGIVER|MICROSCOPIST 3|NA|2|Visit_2|25|4|TREATMENT|2020-08-18|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-25|P1Y2M10DT2H30M|AFTER|2020-08-30|BEFORE|2020-09-20
e|RS|a201c78a-e826-4f42-a997-7c6a019e2c91|5|NTNERESP|Non-Target Non-Enhancing Response|MASS|[?]|kN/cm2|COMPLETE MRD RESPONSE|1|kcal/day|RADIOIMMUNOPRECIPITATION ASSAY||||INTERVIEWER|RATER 2|N|3|Visit_3|40|6|FOLLOW-UP|2020-09-02|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-15|P1Y2M10DT2H30M|UNKNOWN|2020-08-08|ONGOING|2020-10-07
e|RS|a201c78a-e826-4f42-a997-7c6a019e2c91|6|STRUSTAT|Steroid Use Status|IWG CHESON MDS 2006|||COMPLETE MRD RESPONSE|1|/sec|CRYOSCOPY|||Y|CHILD|OPHTHALMOLOGIST|Y|3|Visit_3|40|4|SCREENING|2020-09-02|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-15|P1Y2M10DT2H30M|AFTER|2020-10-29|BEFORE|2020-10-31
e|RS|a201c78a-e826-4f42-a997-7c6a019e2c91|7|NTLWIND|Non-Target Lesion Worsening Indicator|AJCC V7|[?]|mAmp|PR|1|anti-Xa IU|MUGA||||CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 2|NA|4|Visit_4|65|7|FOLLOW-UP|2020-09-27|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-03|P1Y2M10DT2H30M|AFTER|2020-10-04|COINCIDENT|2020-10-21
e|RS|a201c78a-e826-4f42-a997-7c6a019e2c91|8|SFTSRESP|Soft Tissue Response|RANO ELLINGSON 2017|||UNEQUIVOCAL|1|L/min/m2|MASS SPECTROMETRY|Y||Y|PROXY|HEMATOLOGIST|U|4|Visit_4|65|6|TREATMENT|2020-09-27|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-03|P1Y2M10DT2H30M|BEFORE|2020-09-03|ONGOING|2020-10-16
e|RS|a201c78a-e826-4f42-a997-7c6a019e2c91|9|TRGRESP|Target Response|GCIG RUSTIN OVARIAN CANCER 2011|||PD-CT|1|PFU/animal|ZIEHL NEELSEN ACID FAST STAIN||Y|Y|PROXY|RADIOLOGIST 1|N|5|Visit_5|90|4|SCREENING|2020-10-22|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-18|P1Y2M10DT2H30M|UNKNOWN|2020-10-04|ONGOING|2020-10-30
e|RS|a201c78a-e826-4f42-a997-7c6a019e2c91|10|CLINRESP|Clinical Response|WOLCHOK SOLID TUMORS 2009|[?]|/VF|PSEUDOPROGRESSION|1|pkat/L|MAGNETIC RESONANCE ENTEROGRAPHY||||SIBLING|CLINICAL PATHOLOGIST|N|5|Visit_5|90|2|FOLLOW-UP|2020-10-22|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-18|P1Y2M10DT2H30M|COINCIDENT|2020-08-23|ONGOING|2020-09-01
e|RS|c41880bd-1e29-4961-b74d-bb0d979ab00f|1|SFTSRESP|Soft Tissue Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|mm/2h|PD|1|pg|PATHOLOGICAL EVALUATION||||VENDOR|INTERNIST|NA|1|Visit_1|10|3|TREATMENT|2020-09-11|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-24|P1Y2M10DT2H30M|BEFORE|2020-10-31|BEFORE|2020-11-18
e|RS|c41880bd-1e29-4961-b74d-bb0d979ab00f|2|SPLNRESP|Spleen Response|CHOI GIST 2008|[?]|GPS U|MRD NEGATIVITY|1|IU/g Hb|ETDRS EYE CHART||||CAREGIVER|CARDIOLOGIST|NA|1|Visit_1|10|3|FOLLOW-UP|2020-09-11|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-24|P1Y2M10DT2H30M|BEFORE|2020-10-14|AFTER|2020-11-02
e|RS|c41880bd-1e29-4961-b74d-bb0d979ab00f|3|SPLNRESP|Spleen Response|CHESON CLL 2012|[?]|ELISA unit/mL|IMMUNOPHENOTYPIC CR|1|Gauss|TARGETED TRANSCRIPTOME SEQUENCING|Y|||ADJUDICATION COMMITTEE|NEUROLOGIST|NA|2|Visit_2|25|3|TREATMENT|2020-09-26|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-05|P1Y2M10DT2H30M|AFTER|2020-09-18|AFTER|2020-10-20
e|RS|c41880bd-1e29-4961-b74d-bb0d979ab00f|4|HEMARESP|Hematologic Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|m/sec|mCR|1|mmHg|URANYL ACETATE STAIN||Y||HEALTH CARE PROFESSIONAL|RATER 1|U|2|Visit_2|25|5|TREATMENT|2020-09-26|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-05|P1Y2M10DT2H30M|AFTER|2020-12-06|COINCIDENT|2020-12-07
e|RS|c41880bd-1e29-4961-b74d-bb0d979ab00f|5|OVRLRESP|Overall Response|WHO BREAST CANCER 2006|||HI-E|1|/7.5 mL|PHOTOGRAPHY|Y||Y|STUDY SUBJECT|MICROSCOPIST 1|NA|3|Visit_3|40|6|TREATMENT|2020-10-11|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-09|P1Y2M10DT2H30M|BEFORE|2020-11-08|COINCIDENT|2020-11-13
e|RS|c41880bd-1e29-4961-b74d-bb0d979ab00f|6|TMRESP|Tumor Marker Response|RECIST 1.1|[?]|COAT|sCR|1|kDa|SNP ARRAY||||CLINICAL STUDY SPONSOR|INTERNIST|U|3|Visit_3|40|3|FOLLOW-UP|2020-10-11|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-09|P1Y2M10DT2H30M|AFTER|2020-12-04|ONGOING|2020-12-08
e|RS|c41880bd-1e29-4961-b74d-bb0d979ab00f|7|MRDIND|Minimal Residual Disease Indicator|SACT|[?]|kg/L|PD-CT|1|mmol/s|TWO-COLOR MICROARRAY||Y||INDEPENDENT ASSESSOR|CLINICAL PATHOLOGIST|Y|4|Visit_4|65|4|WASHOUT|2020-11-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-19|P1Y2M10DT2H30M|AFTER|2020-09-07|BEFORE|2020-10-28
e|RS|c41880bd-1e29-4961-b74d-bb0d979ab00f|8|MRPHRESP|Morphologic Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|||nPR|1|nmol/L|CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|||Y|FAMILY MEMBER|CARDIOLOGIST|N|4|Visit_4|65|2|FOLLOW-UP|2020-11-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-19|P1Y2M10DT2H30M|BEFORE|2020-11-23|BEFORE|2020-11-30
e|RS|c41880bd-1e29-4961-b74d-bb0d979ab00f|9|BONERESP|Bone Response|RANO|||sCR|1|mmol/s|DUCTOGRAPHY|Y|Y|Y|INDEPENDENT ASSESSOR|DEVELOPMENTAL PSYCHOLOGIST|NA|5|Visit_5|90|4|FOLLOW-UP|2020-11-30|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-31|P1Y2M10DT2H30M|BEFORE|2020-10-21|AFTER|2020-12-04
e|RS|c41880bd-1e29-4961-b74d-bb0d979ab00f|10|DRCRIND|Disease Recurrence Indicator|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|ug/animal|CYTOGENETIC CR|1|10^6 CFU|CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|Y|||CLINICAL RESEARCH ASSOCIATE|OPHTHALMOLOGIST|NA|5|Visit_5|90|7|TREATMENT|2020-11-30|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-31|P1Y2M10DT2H30M|BEFORE|2020-10-23|ONGOING|2020-11-10
e|RS|7de60015-fa9d-4a39-bd19-51c718a624e6|1|TMRESP|Tumor Marker Response|IWG CHESON MDS 2000|[?]|OI50|IMPROVED|1|umol/mol|WRIGHT STAIN||||INVESTIGATOR|MICROSCOPIST 1|N|1|Visit_1|10|4|TREATMENT|2020-10-24|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-01|P1Y2M10DT2H30M|AFTER|2020-11-30|COINCIDENT|2020-12-11
e|RS|7de60015-fa9d-4a39-bd19-51c718a624e6|2|TMRESP|Tumor Marker Response|WHO BREAST CANCER 2006|[?]|TAMPON|NED|1|10^9 organisms/mg|DISK DIFFUSION|Y|||CLINICAL STUDY SPONSOR|FORENSIC PATHOLOGIST|U|1|Visit_1|10|7|SCREENING|2020-10-24|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-01|P1Y2M10DT2H30M|AFTER|2020-12-08|BEFORE|2020-12-28
e|RS|7de60015-fa9d-4a39-bd19-51c718a624e6|3|NTRGRESP|Non-target Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|ECL unit|MORPHOLOGIC CRi|1|log10 TCID 50/mL|MAGNETIC RESONANCE ENTEROGRAPHY||Y||SPOUSE|OPTOMETRIST|NA|2|Visit_2|25|6|SCREENING|2020-11-08|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-10|P1Y2M10DT2H30M|BEFORE|2020-12-31|COINCIDENT|2021-01-08
e|RS|7de60015-fa9d-4a39-bd19-51c718a624e6|4|CPRFSTAT|Clinical Performance Status|MRANO VAN DEN BENT GLIOMA 2011|[?]|Enzyme U/m2|CYTOGENETIC MINIMAL RESPONSE|1|nmol BCE/mmol|DIGITAL PCR ARRAY|Y|Y||INVESTIGATOR|ENDOCRINOLOGIST|Y|2|Visit_2|25|2|TREATMENT|2020-11-08|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-10|P1Y2M10DT2H30M|COINCIDENT|2020-12-24|AFTER|2020-12-26
e|RS|7de60015-fa9d-4a39-bd19-51c718a624e6|5|METBRESP|Metabolic Response|AJCC V7|[?]|nmol/L/h|HI-E|1|EID 50/mL|REFRACTOMETRY||||ADJUDICATOR|READER 1|N|3|Visit_3|40|5|WASHOUT|2020-11-23|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-07|P1Y2M10DT2H30M|BEFORE|2020-11-22|AFTER|2020-12-11
e|RS|7de60015-fa9d-4a39-bd19-51c718a624e6|6|NTERESP|Non-Target Enhancing Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|gpELISA unit/mL|MAJOR PATHOLOGIC RESPONSE|1|beats/min|DROPLET DIGITAL PCR||Y||HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|N|3|Visit_3|40|3|TREATMENT|2020-11-23|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-07|P1Y2M10DT2H30M|BEFORE|2021-01-13|ONGOING|2021-01-21
e|RS|7de60015-fa9d-4a39-bd19-51c718a624e6|7|BONERESP|Bone Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|deg|CYTOGENETIC MINIMAL RESPONSE|1|dB|APPLANATION TONOMETRY|Y|Y||INVESTIGATOR|OTOLARYNGOLOGIST|Y|4|Visit_4|65|7|FOLLOW-UP|2020-12-18|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-14|P1Y2M10DT2H30M|BEFORE|2020-12-12|AFTER|2020-12-15
e|RS|7de60015-fa9d-4a39-bd19-51c718a624e6|8|SYMPTDTR|Symptomatic Deterioration|HARTMAN PANCREATIC CANCER 2012|||STABLE|1|mL/s/m2|OPHTHALMOSCOPY|||Y|CAREGIVER|MICROSCOPIST 3|N|4|Visit_4|65|7|TREATMENT|2020-12-18|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-14|P1Y2M10DT2H30M|BEFORE|2020-12-13|ONGOING|2020-12-24
e|RS|7de60015-fa9d-4a39-bd19-51c718a624e6|9|SPLNRESP|Spleen Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|IMPLANT|MINOR PATHOLOGIC RESPONSE|1|INHALATION|LUXOL FAST BLUE AND CRESYL VIOLET STAIN||||INTERVIEWER|NEUROLOGIST 2|U|5|Visit_5|90|2|TREATMENT|2021-01-12|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-16|P1Y2M10DT2H30M|BEFORE|2020-11-02|AFTER|2021-01-15
e|RS|7de60015-fa9d-4a39-bd19-51c718a624e6|10|NEWLWIND|New Lesion Worsening Indicator|CHOI GIST 2008|[?]|cd*s/m2|PD/RELAPSE AFTER HI|1|MET|SINGLE-SLICE SPIRAL CT||||FRIEND|READER 2|NA|5|Visit_5|90|7|FOLLOW-UP|2021-01-12|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-16|P1Y2M10DT2H30M|COINCIDENT|2020-12-24|COINCIDENT|2021-01-10
e|RS|34d03f58-155a-4908-bba3-aa979be84610|1|MRDRESP|Minimal Residual Disease Response|PETIT BREAST CANCER 2001|[?]|U/kg/min|iCPD|1|FINGERTIP UNIT|TRICHROME STAIN||Y||CAREGIVER|CLINICAL PATHOLOGIST|Y|1|Visit_1|10|1|FOLLOW-UP|2020-06-29|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-07|P1Y2M10DT2H30M|COINCIDENT|2020-08-18|BEFORE|2020-08-29
e|RS|34d03f58-155a-4908-bba3-aa979be84610|2|LIVRRESP|Liver Response|CHOLLET BREAST CANCER 2002|[?]|mOsm/kg|PR WITH LYMPHOCYTOSIS|1|10^3 DNA copies/mL|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION||||CAREGIVER|ONCOLOGIST|Y|1|Visit_1|10|6|SCREENING|2020-06-29|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-07|P1Y2M10DT2H30M|BEFORE|2020-07-08|COINCIDENT|2020-08-07
e|RS|34d03f58-155a-4908-bba3-aa979be84610|3|HEMARESP|Hematologic Response|HARTMANN GERM CELL CANCER 2002|[?]|ug/g/h|RELAPSED DISEASE|1|mg/day|ATOMIC ABSORPTION SPECTROMETRY||Y||CHILD|ADJUDICATOR 3|U|2|Visit_2|25|2|TREATMENT|2020-07-14|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-06|P1Y2M10DT2H30M|COINCIDENT|2020-06-24|AFTER|2020-08-30
e|RS|34d03f58-155a-4908-bba3-aa979be84610|4|METSIND|Metastatic Indicator|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|hr/day|MOLECULAR MAJOR RESPONSE|1|mL/animal/wk|DC SHEATH FLOW||Y||CLINICAL STUDY SPONSOR|FORENSIC PATHOLOGIST|NA|2|Visit_2|25|2|WASHOUT|2020-07-14|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-06|P1Y2M10DT2H30M|BEFORE|2020-07-21|COINCIDENT|2020-09-20
e|RS|34d03f58-155a-4908-bba3-aa979be84610|5|ANATRESP|Anatomic Response|UNSPECIFIED|||DECREASED|1|nmol/day|DXA SCAN|||Y|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 2|N|3|Visit_3|40|3|SCREENING|2020-07-29|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-27|P1Y2M10DT2H30M|AFTER|2020-07-24|COINCIDENT|2020-08-03
e|RS|34d03f58-155a-4908-bba3-aa979be84610|6|MRDIND|Minimal Residual Disease Indicator|HARTMAN PANCREATIC CANCER 2012|||HI-P|1|Linear ft*LB|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|||Y|STUDY SUBJECT|ENDOCRINOLOGIST|U|3|Visit_3|40|1|WASHOUT|2020-07-29|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-27|P1Y2M10DT2H30M|COINCIDENT|2020-09-01|AFTER|2020-09-16
e|RS|34d03f58-155a-4908-bba3-aa979be84610|7|TRGRESP|Target Response|CHOLLET BREAST CANCER 2002|||RELAPSED DISEASE FROM CR|1|Bq/mL|CENTRIFUGATION|||Y|INDEPENDENT ASSESSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|4|Visit_4|65|3|TREATMENT|2020-08-23|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-29|P1Y2M10DT2H30M|UNKNOWN|2020-08-03|ONGOING|2020-09-08
e|RS|34d03f58-155a-4908-bba3-aa979be84610|8|STRUSTAT|Steroid Use Status|CHESON LYMPHOMA 2008|[?]|MET*h|MR|1|U/g/h|PHASE CONTRAST MICROSCOPY||Y||CAREGIVER|READER 1|N|4|Visit_4|65|1|TREATMENT|2020-08-23|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-29|P1Y2M10DT2H30M|COINCIDENT|2020-06-28|COINCIDENT|2020-08-22
e|RS|34d03f58-155a-4908-bba3-aa979be84610|9|BONERESP|Bone Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|vp/dose|iCR|1|/min|TWO-COLOR MICROARRAY||||SPOUSE|MICROSCOPIST 3|Y|5|Visit_5|90|6|TREATMENT|2020-09-17|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-21|P1Y2M10DT2H30M|AFTER|2020-07-16|ONGOING|2020-08-08
e|RS|34d03f58-155a-4908-bba3-aa979be84610|10|METSIND|Metastatic Indicator|SCHWARZ CERVICAL CANCER 2009|[?]|L/h|iPR|1|GBq|IMMUNOASSAY||||CLINICAL STUDY SPONSOR|INTERNIST|N|5|Visit_5|90|6|TREATMENT|2020-09-17|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-21|P1Y2M10DT2H30M|AFTER|2020-07-30|COINCIDENT|2020-08-25
e|RS|3818424f-cbc9-4e79-94b8-7edbc706bdbc|1|BONERESP|Bone Response|NCCN ALL MRD 2014|[?]|grain|iCR|1|mEq/mL|WHOLE TRANSCRIPTOME SEQUENCING||||SPOUSE|RADIOLOGIST 1|NA|1|Visit_1|10|5|WASHOUT|2020-08-23|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-02|P1Y2M10DT2H30M|COINCIDENT|2020-10-12|BEFORE|2020-11-20
e|RS|3818424f-cbc9-4e79-94b8-7edbc706bdbc|2|MOLRESP|Molecular Response|KUMAR IMWG 2016|||nPR|1|pkat|HIGH LEVEL AMINOGLYCOSIDE SCREEN|Y||Y|FRIEND|ADJUDICATOR 1|Y|1|Visit_1|10|5|TREATMENT|2020-08-23|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-02|P1Y2M10DT2H30M|COINCIDENT|2020-10-09|ONGOING|2020-11-18
e|RS|3818424f-cbc9-4e79-94b8-7edbc706bdbc|3|MRDIND|Minimal Residual Disease Indicator|BURCOMBE BREAST CANCER 2005|[?]|BAU/mL|CYTOGENETIC MINOR RESPONSE|1|10^11/L|FLUORESCENT MICROSCOPY||Y||DOMESTIC PARTNER|RADIOLOGIST 1|NA|2|Visit_2|25|7|SCREENING|2020-09-07|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-24|P1Y2M10DT2H30M|COINCIDENT|2020-10-21|COINCIDENT|2020-11-04
e|RS|3818424f-cbc9-4e79-94b8-7edbc706bdbc|4|ANATRESP|Anatomic Response|NCIWG CHESON CLL 1996|[?]|10^9 organisms/mg|NON-PD|1|rpm|PHOTOMETRY||||ADJUDICATION COMMITTEE|HEMATOLOGIST|N|2|Visit_2|25|3|SCREENING|2020-09-07|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-24|P1Y2M10DT2H30M|UNKNOWN|2020-08-16|AFTER|2020-08-21
e|RS|3818424f-cbc9-4e79-94b8-7edbc706bdbc|5|MJPTHIND|Major Pathological Response Indicator|IWC HALLEK CLL 2008|[?]|pL|MRD PERSISTENCE|1|Tbsp|MALDI||||PROXY|CARDIOLOGIST|N|3|Visit_3|40|6|FOLLOW-UP|2020-09-22|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-21|P1Y2M10DT2H30M|COINCIDENT|2020-09-29|AFTER|2020-11-10
e|RS|3818424f-cbc9-4e79-94b8-7edbc706bdbc|6|SPLNRESP|Spleen Response|MACDONALD GLIOMA 1990|||NON-iCR/NON-iUPD|1|g/cage/wk|MIGET|Y||Y|SIBLING|ADJUDICATOR 2|Y|3|Visit_3|40|5|TREATMENT|2020-09-22|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-21|P1Y2M10DT2H30M|BEFORE|2020-08-30|AFTER|2020-10-10
e|RS|3818424f-cbc9-4e79-94b8-7edbc706bdbc|7|TMRESP|Tumor Marker Response|iRECIST|||PSEUDORESPONSE|1|mmol/mol|CAPILLARY ELECTROPHORESIS|||Y|GUARDIAN|NEUROLOGIST 2|N|4|Visit_4|65|3|WASHOUT|2020-10-17|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-26|P1Y2M10DT2H30M|AFTER|2020-11-11|BEFORE|2020-11-20
e|RS|3818424f-cbc9-4e79-94b8-7edbc706bdbc|8|RDIORESP|Radiologic Response|EBMT BLADE MYELOMA 1998|[?]|/month|CYTOGENETIC NO RESPONSE|1|TCID 50/dose|CT SCAN||||GUARDIAN|PATHOLOGIST|NA|4|Visit_4|65|2|FOLLOW-UP|2020-10-17|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-26|P1Y2M10DT2H30M|AFTER|2020-10-17|COINCIDENT|2020-10-31
e|RS|3818424f-cbc9-4e79-94b8-7edbc706bdbc|9|METBRESP|Metabolic Response|CHOI GIST 2008|[?]|kcal/day|WORSENED|1|/day|OSCILLOMETRY||||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR|Y|5|Visit_5|90|2|SCREENING|2020-11-11|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-03|P1Y2M10DT2H30M|UNKNOWN|2020-10-01|AFTER|2020-10-10
e|RS|3818424f-cbc9-4e79-94b8-7edbc706bdbc|10|PATHRESP|Pathologic Response|UNSPECIFIED|[?]|/40 HPFs|FAVORABLE RESPONSE|1|mEq|MRI||||ADJUDICATION COMMITTEE|NEUROLOGIST 1|Y|5|Visit_5|90|3|TREATMENT|2020-11-11|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-03|P1Y2M10DT2H30M|UNKNOWN|2020-10-07|BEFORE|2020-10-21
e|RS|4191788e-b2dc-4885-87d8-da9feb6deea5|1|MNPTHIND|Minor Pathological Response Indicator|AJCC V7|[?]|grain|MINOR PATHOLOGIC RESPONSE|1|log10 CCID 50/dose|BRDU CELLULAR PROLIFERATION ASSAY|Y|||INDEPENDENT ASSESSOR|READER 1|N|1|Visit_1|10|7|TREATMENT|2020-09-11|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-28|P1Y2M10DT2H30M|BEFORE|2020-11-15|ONGOING|2020-11-29
e|RS|4191788e-b2dc-4885-87d8-da9feb6deea5|2|MRDRESP|Minimal Residual Disease Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|L/min/m2|MRD PERSISTENCE|1|U/cL|REAL-TIME POLYMERASE CHAIN REACTION ASSAY||Y||PARENT|MICROSCOPIST|U|1|Visit_1|10|6|SCREENING|2020-09-11|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-28|P1Y2M10DT2H30M|UNKNOWN|2020-10-13|COINCIDENT|2020-10-26
e|RS|4191788e-b2dc-4885-87d8-da9feb6deea5|3|LIVRRESP|Liver Response|RAJKUMAR MYELOMA 2011|[?]|Linear ft*LB|RELAPSED DISEASE FROM CR OR PR|1|g/kg/day|MANUAL CLOT DETECTION||||FRIEND|ENDOCRINOLOGIST|U|2|Visit_2|25|4|TREATMENT|2020-09-26|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-06|P1Y2M10DT2H30M|UNKNOWN|2020-11-02|BEFORE|2020-11-19
e|RS|4191788e-b2dc-4885-87d8-da9feb6deea5|4|NEWLWIND|New Lesion Worsening Indicator|RECICL|[?]|mL/animal/day|CHR|1|cmol|INTERRUPTER TECHNIQUE||||ADJUDICATOR|DEVELOPMENTAL PSYCHOLOGIST|N|2|Visit_2|25|7|WASHOUT|2020-09-26|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-06|P1Y2M10DT2H30M|BEFORE|2020-10-06|AFTER|2020-11-08
e|RS|4191788e-b2dc-4885-87d8-da9feb6deea5|5|METBRESP|Metabolic Response|HAMAOKA BREAST CANCER 2010|[?]|mg/m2|NON-CR/NON-PD|1|GPL U/mL|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|Y|||NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|Y|3|Visit_3|40|1|FOLLOW-UP|2020-10-11|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-04|P1Y2M10DT2H30M|AFTER|2020-11-21|COINCIDENT|2020-11-28
e|RS|4191788e-b2dc-4885-87d8-da9feb6deea5|6|MNPTHIND|Minor Pathological Response Indicator|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|TRANSDUCING UNIT|MINOR PATHOLOGIC RESPONSE|1|mm2|EIA||||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 3|Y|3|Visit_3|40|1|TREATMENT|2020-10-11|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-04|P1Y2M10DT2H30M|BEFORE|2020-10-25|COINCIDENT|2020-11-29
e|RS|4191788e-b2dc-4885-87d8-da9feb6deea5|7|OVRLRESP|Overall Response|iRECIST|[?]|Joule|HI-P|1|% INHIBITION|EEG||||CLINICAL RESEARCH COORDINATOR|UROLOGIST|Y|4|Visit_4|65|3|TREATMENT|2020-11-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-14|P1Y2M10DT2H30M|BEFORE|2020-10-31|BEFORE|2020-12-02
e|RS|4191788e-b2dc-4885-87d8-da9feb6deea5|8|SYMPTDTR|Symptomatic Deterioration|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|nmol/kg/day|FAVORABLE RESPONSE|1|Newton|IHC||||HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|N|4|Visit_4|65|1|FOLLOW-UP|2020-11-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-14|P1Y2M10DT2H30M|COINCIDENT|2020-11-21|COINCIDENT|2020-11-26
e|RS|4191788e-b2dc-4885-87d8-da9feb6deea5|9|NEWLIND|New Lesion Indicator|MRECIST LENCIONI LIVER CANCER 2010|||FAVORABLE RESPONSE|1|RATIO|FLUORESCENT IMMUNOASSAY||Y|Y|INVESTIGATOR|NEUROLOGIST 1|N|5|Visit_5|90|6|TREATMENT|2020-11-30|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-04|P1Y2M10DT2H30M|COINCIDENT|2020-09-05|ONGOING|2020-12-01
e|RS|4191788e-b2dc-4885-87d8-da9feb6deea5|10|PATHRESP|Pathologic Response|DURIE MULTIPLE MYELOMA 2006|[?]|BP|MAJOR PATHOLOGIC RESPONSE|1|g/U|NUCLEIC ACID AMPLIFICATION TEST||||CAREGIVER|DEVELOPMENTAL PSYCHOLOGIST|N|5|Visit_5|90|2|TREATMENT|2020-11-30|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-04|P1Y2M10DT2H30M|UNKNOWN|2020-11-22|BEFORE|2020-12-05
e|RS|8572a9c4-eb87-4745-81b9-8316bc8de69e|1|MJPTHIND|Major Pathological Response Indicator|RANO ELLINGSON 2017|[?]|TRANSDUCING UNIT|MRD PERSISTENCE|1|GBq/g|MICRODENSITOMETRY|Y|Y||INVESTIGATOR|OTOLARYNGOLOGIST|NA|1|Visit_1|10|7|SCREENING|2020-12-24|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-16|P1Y2M10DT2H30M|COINCIDENT|2020-12-16|COINCIDENT|2021-01-27
e|RS|8572a9c4-eb87-4745-81b9-8316bc8de69e|2|HEMARESP|Hematologic Response|RECIST 1.1|[?]|copies/ug|CYTOGENETIC MINIMAL RESPONSE|1|cd|ENZYMATIC COLORIMETRY||||HEALTH CARE PROFESSIONAL|READER 2|U|1|Visit_1|10|1|TREATMENT|2020-12-24|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-16|P1Y2M10DT2H30M|UNKNOWN|2021-02-07|ONGOING|2021-03-09
e|RS|8572a9c4-eb87-4745-81b9-8316bc8de69e|3|MOLRESP|Molecular Response|AJCC V7|[?]|deg/s|HI-N|1|mEq/uL|FARNSWORTH-MUNSELL 100 HUE TEST|Y|||INDEPENDENT ASSESSOR|ONCOLOGIST|Y|2|Visit_2|25|4|TREATMENT|2021-01-08|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-30|P1Y2M10DT2H30M|COINCIDENT|2020-12-23|ONGOING|2021-01-19
e|RS|8572a9c4-eb87-4745-81b9-8316bc8de69e|4|SPLNRESP|Spleen Response|IWG CHESON MDS 2006|[?]|mL/cm|CYTOGENETIC MINOR RESPONSE|1|log EID 50/dose|CELL BASED BIOASSAY||Y||HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|U|2|Visit_2|25|5|TREATMENT|2021-01-08|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-30|P1Y2M10DT2H30M|AFTER|2021-01-03|COINCIDENT|2021-02-01
e|RS|8572a9c4-eb87-4745-81b9-8316bc8de69e|5|RDIORESP|Radiologic Response|EBMT BLADE MYELOMA 1998|[?]|Ci/ug|MORPHOLOGIC CR|1|10^3 copies/mL|CELLULAR PROLIFERATION ASSAY|Y|||SIGNIFICANT OTHER|OTOLARYNGOLOGIST|NA|3|Visit_3|40|4|SCREENING|2021-01-23|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-21|P1Y2M10DT2H30M|UNKNOWN|2021-03-02|COINCIDENT|2021-03-07
e|RS|8572a9c4-eb87-4745-81b9-8316bc8de69e|6|DRCRIND|Disease Recurrence Indicator|HAMAOKA BREAST CANCER 2010|[?]|vg/dose|pCR|1|ug/min|NON-CONTACT SPECULAR MICROSCOPY||Y||INTERVIEWER|RADIOLOGIST 1|NA|3|Visit_3|40|3|WASHOUT|2021-01-23|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-21|P1Y2M10DT2H30M|COINCIDENT|2021-03-07|BEFORE|2021-03-10
e|RS|8572a9c4-eb87-4745-81b9-8316bc8de69e|7|BONERESP|Bone Response|SACT|[?]|mL/cm3/min|NON-QUANTIFIABLE MRD POSITIVITY|1|Hz|MICRO BROTH DILUTION|Y|||CAREGIVER|UROLOGIST|U|4|Visit_4|65|1|WASHOUT|2021-02-17|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-14|P1Y2M10DT2H30M|BEFORE|2021-02-24|AFTER|2021-03-01
e|RS|8572a9c4-eb87-4745-81b9-8316bc8de69e|8|METBRESP|Metabolic Response|RANO|||MOLECULAR CR|1|ft3|MRS|Y||Y|CLINICAL STUDY SPONSOR|ONCOLOGIST 1|Y|4|Visit_4|65|3|FOLLOW-UP|2021-02-17|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-14|P1Y2M10DT2H30M|AFTER|2020-12-17|AFTER|2021-03-01
e|RS|8572a9c4-eb87-4745-81b9-8316bc8de69e|9|MNPTHIND|Minor Pathological Response Indicator|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|umol/min|CA125 75% RESPONSE|1|mOsm/L|U-HPLC/MS/MS||||ADJUDICATION COMMITTEE|READER 3|U|5|Visit_5|90|7|FOLLOW-UP|2021-03-14|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-12|P1Y2M10DT2H30M|COINCIDENT|2021-02-25|BEFORE|2021-03-07
e|RS|8572a9c4-eb87-4745-81b9-8316bc8de69e|10|SYMPTDTR|Symptomatic Deterioration|IWG CHESON MDS 2000|[?]|mU|SMD|1|mL/cage|OPTICAL DENSITY MEASUREMENT||||CHILD|OPTOMETRIST|Y|5|Visit_5|90|2|WASHOUT|2021-03-14|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-12|P1Y2M10DT2H30M|BEFORE|2020-12-16|COINCIDENT|2021-01-19
e|RS|74c9d1b3-6466-43c1-95b0-b720a0dd6e37|1|BMIVLIND|Bone Marrow Involvement Indicator|MONTSERRAT CLL 1989|||COMPLETE MRD RESPONSE|1|10^4/hpf|ENZYMATIC COLORIMETRY|Y|Y|Y|HEALTH CARE PROFESSIONAL|PATHOLOGIST|Y|1|Visit_1|10|7|SCREENING|2020-11-26|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-20|P1Y2M10DT2H30M|UNKNOWN|2021-02-21|COINCIDENT|2021-02-23
e|RS|74c9d1b3-6466-43c1-95b0-b720a0dd6e37|2|MRPHRESP|Morphologic Response|CHESON CLL 2012|[?]|m/sec|UNEQUIVOCAL|1|pmol/day|CELLULOSE TAPE|Y|||HEALTH CARE PROFESSIONAL|HEMATOLOGIST|U|1|Visit_1|10|4|WASHOUT|2020-11-26|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-20|P1Y2M10DT2H30M|UNKNOWN|2021-02-19|COINCIDENT|2021-02-23
e|RS|74c9d1b3-6466-43c1-95b0-b720a0dd6e37|3|TMRESP|Tumor Marker Response|IRANO 2015|||PD/RELAPSE AFTER HI|1|pL|PATHOLOGICAL EVALUATION|||Y|CLINICAL STUDY SPONSOR|NEUROLOGIST 1|N|2|Visit_2|25|1|TREATMENT|2020-12-11|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-16|P1Y2M10DT2H30M|COINCIDENT|2021-01-01|BEFORE|2021-02-06
e|RS|74c9d1b3-6466-43c1-95b0-b720a0dd6e37|4|MNPTHIND|Minor Pathological Response Indicator|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|/wk|MOLECULAR MAJOR RESPONSE|1|Torr|FLUORESCENT IMMUNOASSAY|Y|||FAMILY MEMBER|READER|Y|2|Visit_2|25|6|TREATMENT|2020-12-11|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-16|P1Y2M10DT2H30M|UNKNOWN|2020-11-29|ONGOING|2020-12-16
e|RS|74c9d1b3-6466-43c1-95b0-b720a0dd6e37|5|BMIVLIND|Bone Marrow Involvement Indicator|HARTMANN GERM CELL CANCER 2002|[?]|uU/dL|CYTOGENETIC MINIMAL RESPONSE|1|mL/cm|GC/MS|Y|||GUARDIAN|PATHOLOGIST|NA|3|Visit_3|40|1|FOLLOW-UP|2020-12-26|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-14|P1Y2M10DT2H30M|UNKNOWN|2020-12-23|BEFORE|2021-01-23
e|RS|74c9d1b3-6466-43c1-95b0-b720a0dd6e37|6|MOLRESP|Molecular Response|IWC HALLEK CLL 2008|[?]|umol/L/min|IMPROVED|1|log EID 50/dose|STATIC PERIMETRY||||ADJUDICATOR|OTOLARYNGOLOGIST|Y|3|Visit_3|40|6|TREATMENT|2020-12-26|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-14|P1Y2M10DT2H30M|UNKNOWN|2021-02-20|COINCIDENT|2021-02-23
e|RS|74c9d1b3-6466-43c1-95b0-b720a0dd6e37|7|NTERESP|Non-Target Enhancing Response|HAMAOKA BREAST CANCER 2010|[?]|gpELISA unit/mL|PD-CT|1|/kg|KINETIC CHROMOGENIC ASSAY|Y|||SIGNIFICANT OTHER|ADJUDICATOR 3|Y|4|Visit_4|65|3|FOLLOW-UP|2021-01-20|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-02|P1Y2M10DT2H30M|UNKNOWN|2020-12-25|AFTER|2021-01-10
e|RS|74c9d1b3-6466-43c1-95b0-b720a0dd6e37|8|MRDRESP|Minimal Residual Disease Response|RANO ELLINGSON 2017|[?]|dL|PD FROM PR|1|vg/mL|MULTIPLE BREATH WASHOUT|Y|||INDEPENDENT ASSESSOR|NEUROLOGIST 1|U|4|Visit_4|65|2|FOLLOW-UP|2021-01-20|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-02|P1Y2M10DT2H30M|BEFORE|2021-01-01|ONGOING|2021-02-14
e|RS|74c9d1b3-6466-43c1-95b0-b720a0dd6e37|9|BESTRESP|Best Overall Response|WOLCHOK SOLID TUMORS 2009|||PSEUDORESPONSE|1|U/g/min|LC/MS/MS|||Y|HEALTH CARE PROFESSIONAL|RATER 2|NA|5|Visit_5|90|3|WASHOUT|2021-02-14|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-31|P1Y2M10DT2H30M|COINCIDENT|2021-02-05|BEFORE|2021-02-08
e|RS|74c9d1b3-6466-43c1-95b0-b720a0dd6e37|10|NTRGRESP|Non-target Response|NCCN ALL MRD 2014|[?]|GBq/ug|HI-P|1|s^-1(%O2)^-1|MIGET||||DOMESTIC PARTNER|READER|U|5|Visit_5|90|2|TREATMENT|2021-02-14|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-31|P1Y2M10DT2H30M|AFTER|2021-02-21|COINCIDENT|2021-02-23
e|RS|3eceae61-a4a0-49fd-964b-9f142e0da067|1|CLINRESP|Clinical Response|WOLCHOK SOLID TUMORS 2009|[?]|copies/mL|sCR|1|ngEq/L|PET SCAN||||ADJUDICATOR|NEUROLOGIST 2|N|1|Visit_1|10|3|FOLLOW-UP|2020-08-28|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-13|P1Y2M10DT2H30M|AFTER|2020-09-11|AFTER|2020-11-18
e|RS|3eceae61-a4a0-49fd-964b-9f142e0da067|2|TRGRESP|Target Response|PALUMBO MULTIPLE MYELOMA 2009|||FAVORABLE RESPONSE|1|ukat/10^12 RBC|WESTERN BLOT|||Y|INDEPENDENT ASSESSOR|OTOLARYNGOLOGIST|N|1|Visit_1|10|4|WASHOUT|2020-08-28|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-13|P1Y2M10DT2H30M|COINCIDENT|2020-09-15|AFTER|2020-10-14
e|RS|3eceae61-a4a0-49fd-964b-9f142e0da067|3|CYTORESP|Cytogenetic Response|PERCIST|[?]|Pa|iUPD|1|ECL unit|FLUORESCENT IMMUNOASSAY|Y|||ADJUDICATOR|RADIOLOGIST 2|N|2|Visit_2|25|5|SCREENING|2020-09-12|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-25|P1Y2M10DT2H30M|UNKNOWN|2020-11-24|COINCIDENT|2020-11-25
e|RS|3eceae61-a4a0-49fd-964b-9f142e0da067|4|CPRFSTAT|Clinical Performance Status|SHINDOH COLORECTAL CANCER 2013|[?]|ng/dL|WORSENED|1|10^7/L|FLUORESCENT LIFETIME IMAGING MICROSCOPY||||INTERVIEWER|PATHOLOGIST|NA|2|Visit_2|25|2|SCREENING|2020-09-12|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-25|P1Y2M10DT2H30M|BEFORE|2020-09-07|ONGOING|2020-09-26
e|RS|3eceae61-a4a0-49fd-964b-9f142e0da067|5|TRGRESP|Target Response|WHO BREAST CANCER 2006|[?]|Ci/L|CRi|1|/LSQN|SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY||||VENDOR|READER 3|NA|3|Visit_3|40|3|FOLLOW-UP|2020-09-27|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-03|P1Y2M10DT2H30M|UNKNOWN|2020-08-25|COINCIDENT|2020-09-12
e|RS|3eceae61-a4a0-49fd-964b-9f142e0da067|6|CYTORESP|Cytogenetic Response|BURCOMBE BREAST CANCER 2005|||OPTIMAL MORPHOLOGIC RESPONSE|1|copies/mL|DNA MICROARRAY|||Y|FRIEND|RATER 2|Y|3|Visit_3|40|1|TREATMENT|2020-09-27|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-03|P1Y2M10DT2H30M|COINCIDENT|2020-11-24|ONGOING|2020-11-25
e|RS|3eceae61-a4a0-49fd-964b-9f142e0da067|7|STRUSTAT|Steroid Use Status|PRINCE TCELL LYMPHOMA 2010|[?]|cmH2O/mL|MOLECULAR MAJOR RESPONSE|1|Ci/uL|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION||Y||VENDOR|RATER 1|N|4|Visit_4|65|1|SCREENING|2020-10-22|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-22|P1Y2M10DT2H30M|AFTER|2020-11-10|COINCIDENT|2020-11-13
e|RS|3eceae61-a4a0-49fd-964b-9f142e0da067|8|MJPTHIND|Major Pathological Response Indicator|SACT|||PSA PROGRESSION|1|ug/L|ELECTROCHEMILUMINESCENCE IMMUNOASSAY|||Y|FAMILY MEMBER|RATER 1|U|4|Visit_4|65|7|TREATMENT|2020-10-22|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-22|P1Y2M10DT2H30M|AFTER|2020-11-15|BEFORE|2020-11-25
e|RS|3eceae61-a4a0-49fd-964b-9f142e0da067|9|OVRLRESP|Overall Response|HAMAOKA BREAST CANCER 2010|||HI-E|1|L/min/m2|ICP-MS||Y|Y|FAMILY MEMBER|ADJUDICATOR|U|5|Visit_5|90|1|TREATMENT|2020-11-16|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-31|P1Y2M10DT2H30M|AFTER|2020-09-11|ONGOING|2020-09-21
e|RS|3eceae61-a4a0-49fd-964b-9f142e0da067|10|DRCRIND|Disease Recurrence Indicator|CHOLLET BREAST CANCER 2002|[?]|nCi|CYTOGENETIC PR|1|mm/min|CONTRAST ENHANCED MRI|Y|||ADJUDICATOR|NEUROLOGIST 2|NA|5|Visit_5|90|2|WASHOUT|2020-11-16|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-31|P1Y2M10DT2H30M|BEFORE|2020-08-30|AFTER|2020-09-07
e|RS|fe7ad71c-601d-4909-b56a-401c9a10f00c|1|NTLWIND|Non-Target Lesion Worsening Indicator|RANO|||MOLECULAR CR|1|DNA copies/mL|CARDIAC THERMODILUTION|||Y|SIGNIFICANT OTHER|PEDIATRIC NEUROLOGIST|Y|1|Visit_1|10|6|TREATMENT|2020-05-21|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-01|P1Y2M10DT2H30M|AFTER|2020-06-23|BEFORE|2020-07-18
e|RS|fe7ad71c-601d-4909-b56a-401c9a10f00c|2|METBRESP|Metabolic Response|JUWEID NON-HODGKINS LYMPHOMA 2005|||PMR|1|Gravitational Unit|PYROSEQUENCING|||Y|DOMESTIC PARTNER|ONCOLOGIST 2|U|1|Visit_1|10|6|TREATMENT|2020-05-21|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-01|P1Y2M10DT2H30M|BEFORE|2020-05-18|COINCIDENT|2020-07-09
e|RS|fe7ad71c-601d-4909-b56a-401c9a10f00c|3|HEMARESP|Hematologic Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|Anson U|CMR|1|mL/min/1.73m2|CELL BASED BIOASSAY|Y|Y||GUARDIAN|RATER 1|U|2|Visit_2|25|5|TREATMENT|2020-06-05|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-16|P1Y2M10DT2H30M|AFTER|2020-05-27|COINCIDENT|2020-06-22
e|RS|fe7ad71c-601d-4909-b56a-401c9a10f00c|4|MRDRESP|Minimal Residual Disease Response|CHOI GIST 2008|||MOLECULAR MAJOR RESPONSE|1|CFU/mL|DROPLET DIGITAL PCR|Y||Y|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 3|NA|2|Visit_2|25|3|TREATMENT|2020-06-05|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-16|P1Y2M10DT2H30M|AFTER|2020-05-28|COINCIDENT|2020-08-10
e|RS|fe7ad71c-601d-4909-b56a-401c9a10f00c|5|MRPHRESP|Morphologic Response|PERCIST|[?]|pkat|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|/sec|DC SHEATH FLOW||||ADJUDICATION COMMITTEE|PEDIATRIC NEUROLOGIST|NA|3|Visit_3|40|3|TREATMENT|2020-06-20|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-24|P1Y2M10DT2H30M|BEFORE|2020-06-29|AFTER|2020-07-27
e|RS|fe7ad71c-601d-4909-b56a-401c9a10f00c|6|CPRFSTAT|Clinical Performance Status|EBMT BLADE MYELOMA 1998|[?]|Anson U|MINOR PATHOLOGIC RESPONSE|1|ug/day|MALDI-TOF||||INVESTIGATOR|PHYSIOTHERAPIST|N|3|Visit_3|40|2|SCREENING|2020-06-20|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-24|P1Y2M10DT2H30M|UNKNOWN|2020-05-31|COINCIDENT|2020-07-15
e|RS|fe7ad71c-601d-4909-b56a-401c9a10f00c|7|MNPTHIND|Minor Pathological Response Indicator|IWC HALLEK CLL 2008|[?]|tuberculin unit/mL|PSA PROGRESSION|1|pm|PERFUSION MRI||||CHILD|ONCOLOGIST 2|Y|4|Visit_4|65|7|TREATMENT|2020-07-15|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-04|P1Y2M10DT2H30M|BEFORE|2020-07-20|BEFORE|2020-07-30
e|RS|fe7ad71c-601d-4909-b56a-401c9a10f00c|8|NEWLPROG|New Lesion Progression|NCIWG CHESON CLL 1996|[?]|%(v/v)|PSEUDORESPONSE|1|nmol/L/h|PHOTOMETRY|Y|Y||SIBLING|NEUROLOGIST 1|N|4|Visit_4|65|1|TREATMENT|2020-07-15|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-04|P1Y2M10DT2H30M|COINCIDENT|2020-06-25|AFTER|2020-07-16
e|RS|fe7ad71c-601d-4909-b56a-401c9a10f00c|9|TMRESP|Tumor Marker Response|RECIST 1.0|||CYTOGENETIC CR|1|Log10 ELISA unit|SPECULAR MICROSCOPY|||Y|SIBLING|RADIOLOGIST 2|U|5|Visit_5|90|3|TREATMENT|2020-08-09|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-13|P1Y2M10DT2H30M|UNKNOWN|2020-07-16|ONGOING|2020-08-15
e|RS|fe7ad71c-601d-4909-b56a-401c9a10f00c|10|BONERESP|Bone Response|RECICL|[?]|mCi/L|EQUIVOCAL|1|APS U|PULMONARY ANGIOGRAPHY||Y||GUARDIAN|RATER|Y|5|Visit_5|90|1|TREATMENT|2020-08-09|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-13|P1Y2M10DT2H30M|COINCIDENT|2020-06-23|AFTER|2020-07-07
e|RS|cc52d895-5819-46c0-b8e6-b948f1cd2408|1|MNPTHIND|Minor Pathological Response Indicator|RANO ELLINGSON 2017|[?]|cmH2O/mL|HI-N|1|PIXELS/cm|FLUOROSCOPY||||FAMILY MEMBER|OPHTHALMOLOGIST|N|1|Visit_1|10|3|SCREENING|2020-07-06|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-11|P1Y2M10DT2H30M|BEFORE|2020-07-30|ONGOING|2020-09-21
e|RS|cc52d895-5819-46c0-b8e6-b948f1cd2408|2|SYMPTDTR|Symptomatic Deterioration|RAJKUMAR MYELOMA 2011|[?]|ug/dose|CYTOGENETIC NO RESPONSE|1|10^4 CFU/mL|TRICHROME STAIN||||ADJUDICATOR|READER|NA|1|Visit_1|10|7|TREATMENT|2020-07-06|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-11|P1Y2M10DT2H30M|UNKNOWN|2020-08-10|AFTER|2020-10-01
e|RS|cc52d895-5819-46c0-b8e6-b948f1cd2408|3|SYMPTDTR|Symptomatic Deterioration|RECIST 1.1|[?]|mol/day|PR-CT|1|/7.5 mL|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|Y|||FAMILY MEMBER|NEUROLOGIST 2|Y|2|Visit_2|25|1|WASHOUT|2020-07-21|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-01|P1Y2M10DT2H30M|AFTER|2020-07-31|BEFORE|2020-09-27
e|RS|cc52d895-5819-46c0-b8e6-b948f1cd2408|4|BMIVLIND|Bone Marrow Involvement Indicator|UNSPECIFIED|||HI-P|1|nsec|AUDIOMETRY|||Y|SIGNIFICANT OTHER|RATER 2|U|2|Visit_2|25|2|WASHOUT|2020-07-21|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-01|P1Y2M10DT2H30M|AFTER|2020-08-30|BEFORE|2020-09-26
e|RS|cc52d895-5819-46c0-b8e6-b948f1cd2408|5|OVRLRESP|Overall Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|10^6 CFU/g|PR|1|umol/dL|HEMAGGLUTINATION INHIBITION ASSAY||||FAMILY MEMBER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|3|Visit_3|40|7|FOLLOW-UP|2020-08-05|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-23|P1Y2M10DT2H30M|BEFORE|2020-07-15|ONGOING|2020-09-24
e|RS|cc52d895-5819-46c0-b8e6-b948f1cd2408|6|NTRGRESP|Non-target Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|m/sec|sCR|1|/10^4|TRANSVAGINAL ULTRASOUND||||NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|Y|3|Visit_3|40|3|FOLLOW-UP|2020-08-05|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-23|P1Y2M10DT2H30M|AFTER|2020-07-24|COINCIDENT|2020-09-24
e|RS|cc52d895-5819-46c0-b8e6-b948f1cd2408|7|TMRESP|Tumor Marker Response|iRECIST|||MAJOR PATHOLOGIC RESPONSE|1|amu|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI|||Y|INTERVIEWER|PHYSIOTHERAPIST|NA|4|Visit_4|65|4|TREATMENT|2020-08-30|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-25|P1Y2M10DT2H30M|BEFORE|2020-07-13|COINCIDENT|2020-09-21
e|RS|cc52d895-5819-46c0-b8e6-b948f1cd2408|8|MRPHRESP|Morphologic Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|Ci/ug|CYTOGENETIC NO RESPONSE|1|mmol/day|MS/MS||||INTERVIEWER|DEVELOPMENTAL PSYCHOLOGIST|NA|4|Visit_4|65|1|SCREENING|2020-08-30|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-25|P1Y2M10DT2H30M|UNKNOWN|2020-07-19|BEFORE|2020-08-29
e|RS|cc52d895-5819-46c0-b8e6-b948f1cd2408|9|NEWLWIND|New Lesion Worsening Indicator|NCIWG CHESON CLL 1996|[?]|OI50|NON-PD|1|mL/h|FREEZING POINT DEPRESSION||||CHILD|MICROSCOPIST 1|Y|5|Visit_5|90|3|TREATMENT|2020-09-24|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-26|P1Y2M10DT2H30M|BEFORE|2020-07-27|BEFORE|2020-08-22
e|RS|cc52d895-5819-46c0-b8e6-b948f1cd2408|10|CLINRESP|Clinical Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|/100 WBC|MOLECULAR MAJOR RESPONSE|1|log EID 50/dose|TEST STRIP||Y||ADJUDICATION COMMITTEE|FORENSIC PATHOLOGIST|NA|5|Visit_5|90|5|SCREENING|2020-09-24|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-26|P1Y2M10DT2H30M|AFTER|2020-08-04|BEFORE|2020-09-27
e|RS|b56a5fe6-1191-4e36-ad30-2f9fc0a2fb72|1|PATHRESP|Pathologic Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|10^3 DNA copies/mL|PSEUDOPROGRESSION|1|DIOPTER|MICROSCOPY||||FAMILY MEMBER|MICROSCOPIST 1|Y|1|Visit_1|10|6|WASHOUT|2021-01-29|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-05|P1Y2M10DT2H30M|BEFORE|2021-02-08|BEFORE|2021-02-19
e|RS|b56a5fe6-1191-4e36-ad30-2f9fc0a2fb72|2|RDIORESP|Radiologic Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|NEEDLE GAUGE|RELAPSED DISEASE FROM CR|1|MET|MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY||||SIGNIFICANT OTHER|ENDOCRINOLOGIST|N|1|Visit_1|10|3|FOLLOW-UP|2021-01-29|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-05|P1Y2M10DT2H30M|COINCIDENT|2021-03-27|AFTER|2021-04-26
e|RS|b56a5fe6-1191-4e36-ad30-2f9fc0a2fb72|3|NEWLWIND|New Lesion Worsening Indicator|CHOI GIST 2008|[?]|nmol|iSD|1|ppm|IMMUNOCHROMATOGRAPHY|Y|Y||PROXY|ONCOLOGIST|NA|2|Visit_2|25|2|WASHOUT|2021-02-13|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-13|P1Y2M10DT2H30M|AFTER|2021-04-25|ONGOING|2021-04-26
e|RS|b56a5fe6-1191-4e36-ad30-2f9fc0a2fb72|4|MRDIND|Minimal Residual Disease Indicator|BURCOMBE BREAST CANCER 2005|||pCR|1|MET|RYAN BLUE STAIN||Y|Y|INTERVIEWER|UROLOGIST|NA|2|Visit_2|25|1|FOLLOW-UP|2021-02-13|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-13|P1Y2M10DT2H30M|COINCIDENT|2021-04-07|COINCIDENT|2021-04-24
e|RS|b56a5fe6-1191-4e36-ad30-2f9fc0a2fb72|5|CPRFSTAT|Clinical Performance Status|KEAM BREAST CANCER 2013|||CYTOGENETIC MINIMAL RESPONSE|1|100 IU/mL|MULTIPLEXED BEAD BASED IMMUNOASSAY|||Y|CHILD|ADJUDICATOR 1|Y|3|Visit_3|40|4|SCREENING|2021-02-28|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-06|P1Y2M10DT2H30M|COINCIDENT|2021-01-27|AFTER|2021-02-13
e|RS|b56a5fe6-1191-4e36-ad30-2f9fc0a2fb72|6|OVRLRESP|Overall Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|log10 PFU/mL|CYTOGENETIC MINIMAL RESPONSE|1|DAgU|DXA SCAN||||VENDOR|PHYSIOTHERAPIST|N|3|Visit_3|40|5|FOLLOW-UP|2021-02-28|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-06|P1Y2M10DT2H30M|AFTER|2021-03-05|ONGOING|2021-04-23
e|RS|b56a5fe6-1191-4e36-ad30-2f9fc0a2fb72|7|NEWLWIND|New Lesion Worsening Indicator|CHESON CLL 2012|[?]|mg/day|NON-CR/NON-PD|1|mOsm/kg|SANGER SEQUENCING||||STUDY SUBJECT|READER 3|NA|4|Visit_4|65|3|TREATMENT|2021-03-25|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-11|P1Y2M10DT2H30M|COINCIDENT|2021-01-23|ONGOING|2021-02-11
e|RS|b56a5fe6-1191-4e36-ad30-2f9fc0a2fb72|8|HEMARESP|Hematologic Response|WHO BREAST CANCER 2006|[?]|yd|CYTOGENETIC CR|1|MnFI|CORONARY ANGIOGRAPHY||||STUDY SUBJECT|OTOLARYNGOLOGIST|NA|4|Visit_4|65|2|TREATMENT|2021-03-25|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-11|P1Y2M10DT2H30M|AFTER|2021-04-12|AFTER|2021-04-28
e|RS|b56a5fe6-1191-4e36-ad30-2f9fc0a2fb72|9|BONERESP|Bone Response|IWG CHESON MDS 2000|[?]|%(w/w)|PARTIAL MORPHOLOGIC RESPONSE|1|ppth|DUKE INCISION METHOD|Y|||CAREGIVER|DEVELOPMENTAL PSYCHOLOGIST|N|5|Visit_5|90|1|WASHOUT|2021-04-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-31|P1Y2M10DT2H30M|UNKNOWN|2021-02-24|BEFORE|2021-03-31
e|RS|b56a5fe6-1191-4e36-ad30-2f9fc0a2fb72|10|RDIORESP|Radiologic Response|PRINCE TCELL LYMPHOMA 2010|[?]|cm H2O|PSEUDORESPONSE|1|g/mol|WRIGHT STAIN||||NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|Y|5|Visit_5|90|6|SCREENING|2021-04-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-31|P1Y2M10DT2H30M|UNKNOWN|2021-03-08|BEFORE|2021-04-12
e|RS|1409edea-a372-4938-889b-df6ee93b8543|1|BESTRESP|Best Overall Response|RECIST 1.1|[?]|nmol/L/h|iUPD|1|mm|MRI||||STUDY SUBJECT|FORENSIC PATHOLOGIST|Y|1|Visit_1|10|6|FOLLOW-UP|2020-08-27|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-25|P1Y2M10DT2H30M|AFTER|2020-10-27|AFTER|2020-11-03
e|RS|1409edea-a372-4938-889b-df6ee93b8543|2|DRCRIND|Disease Recurrence Indicator|WOLCHOK SOLID TUMORS 2009|[?]|mL/min/1.73m2|MAJOR PATHOLOGIC RESPONSE|1|C|MRI WITHOUT CONTRAST|Y|Y||FAMILY MEMBER|RATER 2|Y|1|Visit_1|10|7|SCREENING|2020-08-27|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-25|P1Y2M10DT2H30M|COINCIDENT|2020-08-22|BEFORE|2020-09-02
e|RS|1409edea-a372-4938-889b-df6ee93b8543|3|NTERESP|Non-Target Enhancing Response|HARTMAN PANCREATIC CANCER 2012|[?]|SACHET|STABLE|1|g/m2/day|CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|Y|Y||INTERVIEWER|DERMATOLOGIST|U|2|Visit_2|25|7|TREATMENT|2020-09-11|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-30|P1Y2M10DT2H30M|UNKNOWN|2020-09-26|COINCIDENT|2020-10-17
e|RS|1409edea-a372-4938-889b-df6ee93b8543|4|MRDIND|Minimal Residual Disease Indicator|CHESON MALIGNANT LYMPHOMA 2007|[?]|g/animal/wk|DECREASED|1|min*mg/mL|COULOMETRIC TITRATION||||PROXY|MICROSCOPIST|Y|2|Visit_2|25|5|WASHOUT|2020-09-11|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-30|P1Y2M10DT2H30M|UNKNOWN|2020-09-16|ONGOING|2020-10-14
e|RS|1409edea-a372-4938-889b-df6ee93b8543|5|NTERESP|Non-Target Enhancing Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|mmol/min/kPa/L|iUPD|1|LENS|SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY||||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST|Y|3|Visit_3|40|3|WASHOUT|2020-09-26|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-08|P1Y2M10DT2H30M|COINCIDENT|2020-10-25|COINCIDENT|2020-10-29
e|RS|1409edea-a372-4938-889b-df6ee93b8543|6|TRGRESP|Target Response|GUPPY OVARIAN CANCER 2002|||PR-CT|1|ppm|ACCELERATOR MASS SPECTROMETRY|||Y|ADJUDICATION COMMITTEE|MICROSCOPIST 1|Y|3|Visit_3|40|3|WASHOUT|2020-09-26|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-08|P1Y2M10DT2H30M|AFTER|2020-08-28|COINCIDENT|2020-10-11
e|RS|1409edea-a372-4938-889b-df6ee93b8543|7|STRUSTAT|Steroid Use Status|CHESON CLL 2006|||STABLE|1|mm/2h|SLIT LAMP PHOTOGRAPHY|||Y|FRIEND|RATER 1|U|4|Visit_4|65|3|TREATMENT|2020-10-21|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-22|P1Y2M10DT2H30M|AFTER|2020-11-10|BEFORE|2020-11-11
e|RS|1409edea-a372-4938-889b-df6ee93b8543|8|OVRLRESP|Overall Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|10^9/g|CMR|1|mL/sec/1.73m2|FLUORESCENT LIFETIME IMAGING MICROSCOPY||||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST|NA|4|Visit_4|65|7|TREATMENT|2020-10-21|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-22|P1Y2M10DT2H30M|COINCIDENT|2020-10-19|BEFORE|2020-11-02
e|RS|1409edea-a372-4938-889b-df6ee93b8543|9|NEWLWIND|New Lesion Worsening Indicator|CHESON LYMPHOMA 2008|[?]|ELISA unit/dose|CR-CT|1|mol/mL|CALIPER MEASUREMENT METHOD|Y|||VENDOR|UROLOGIST|N|5|Visit_5|90|7|WASHOUT|2020-11-15|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-18|P1Y2M10DT2H30M|COINCIDENT|2020-11-11|ONGOING|2020-11-12
e|RS|1409edea-a372-4938-889b-df6ee93b8543|10|NEWLIND|New Lesion Indicator|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|mCi|PR WITH LYMPHOCYTOSIS|1|L/h|DROPLET DIGITAL PCR|Y|||PARENT|NEUROLOGIST|Y|5|Visit_5|90|6|TREATMENT|2020-11-15|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-18|P1Y2M10DT2H30M|BEFORE|2020-09-03|AFTER|2020-11-24
e|RS|3dc16ad2-d49d-4fad-9823-d0197fb57a42|1|ANATRESP|Anatomic Response|PRINCE TCELL LYMPHOMA 2010|[?]|mL/min|PR WITH LYMPHOCYTOSIS|1|DIP|FREEZING POINT DEPRESSION||||HEALTH CARE PROFESSIONAL|MICROSCOPIST|U|1|Visit_1|10|4|TREATMENT|2020-09-04|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-31|P1Y2M10DT2H30M|BEFORE|2020-11-01|BEFORE|2020-11-07
e|RS|3dc16ad2-d49d-4fad-9823-d0197fb57a42|2|NTRGRESP|Non-target Response|MURPHY PROSTATE CANCER 1980|||NON-CR/NON-PD|1|g/kg/day|INFRARED SPECTROMETRY|Y||Y|GUARDIAN|READER 2|Y|1|Visit_1|10|4|FOLLOW-UP|2020-09-04|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-31|P1Y2M10DT2H30M|BEFORE|2020-09-26|BEFORE|2020-10-19
e|RS|3dc16ad2-d49d-4fad-9823-d0197fb57a42|3|NEWLWIND|New Lesion Worsening Indicator|GUPPY OVARIAN CANCER 2002|[?]|10^8 PFU|iCR|1|DIOPTER|QUANTITATIVE CORONARY ANGIOGRAPHY||||STUDY SUBJECT|ADJUDICATOR|Y|2|Visit_2|25|2|TREATMENT|2020-09-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-05|P1Y2M10DT2H30M|UNKNOWN|2020-10-07|AFTER|2020-11-04
e|RS|3dc16ad2-d49d-4fad-9823-d0197fb57a42|4|TMRESP|Tumor Marker Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|BE/mL|CR|1|pm|MALDI||||FRIEND|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|2|Visit_2|25|4|SCREENING|2020-09-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-05|P1Y2M10DT2H30M|AFTER|2020-08-30|AFTER|2020-11-08
e|RS|3dc16ad2-d49d-4fad-9823-d0197fb57a42|5|MOLRESP|Molecular Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|JAR|UNFAVORABLE RESPONSE|1|fraction of 1|WEBER GREEN STAIN||||CAREGIVER|MICROSCOPIST 1|N|3|Visit_3|40|7|WASHOUT|2020-10-04|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-12|P1Y2M10DT2H30M|UNKNOWN|2020-09-06|AFTER|2020-09-12
e|RS|3dc16ad2-d49d-4fad-9823-d0197fb57a42|6|CPRFSTAT|Clinical Performance Status|DOHNER AML 2010|[?]|pmol/L/h|NOT ALL EVALUATED|1|km/h|PHOROPTER||Y||STUDY SUBJECT|DEVELOPMENTAL PSYCHOLOGIST|U|3|Visit_3|40|3|SCREENING|2020-10-04|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-12|P1Y2M10DT2H30M|COINCIDENT|2020-11-21|ONGOING|2020-11-28
e|RS|3dc16ad2-d49d-4fad-9823-d0197fb57a42|7|NEWLIND|New Lesion Indicator|RANO|[?]|APS U|MINOR PATHOLOGIC RESPONSE|1|cmH2O/mL|LUXOL FAST BLUE AND CRESYL VIOLET STAIN||||HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|Y|4|Visit_4|65|4|WASHOUT|2020-10-29|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-31|P1Y2M10DT2H30M|UNKNOWN|2020-09-15|BEFORE|2020-11-13
e|RS|3dc16ad2-d49d-4fad-9823-d0197fb57a42|8|MRDIND|Minimal Residual Disease Indicator|EBMT BLADE MYELOMA 1998|[?]|ka_u/dL|MOLECULAR CR|1|eq|MULTI-SLICE SPIRAL CT|Y|||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|U|4|Visit_4|65|4|WASHOUT|2020-10-29|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-31|P1Y2M10DT2H30M|AFTER|2020-12-01|ONGOING|2020-12-02
e|RS|3dc16ad2-d49d-4fad-9823-d0197fb57a42|9|PATHRESP|Pathologic Response|SHINDOH COLORECTAL CANCER 2013|[?]|AFU|PR|1|pmol/L|IODINE STAIN||Y||CLINICAL RESEARCH ASSOCIATE|PEDIATRIC NEUROLOGIST|U|5|Visit_5|90|5|SCREENING|2020-11-23|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-11|P1Y2M10DT2H30M|BEFORE|2020-11-18|ONGOING|2020-11-26
e|RS|3dc16ad2-d49d-4fad-9823-d0197fb57a42|10|HEMARESP|Hematologic Response|GUPPY OVARIAN CANCER 2002|[?]|MET*h|HI-P|1|/2000 RBC|FLUORESCENT ENZYME IMMUNOASSAY||Y||CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 1|N|5|Visit_5|90|3|TREATMENT|2020-11-23|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-11|P1Y2M10DT2H30M|UNKNOWN|2020-11-02|AFTER|2020-11-10
e|RS|7c244128-0508-422f-88ba-ecce68cec054|1|MOLRESP|Molecular Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|ug/kg/min|RELAPSED DISEASE FROM CR|1|10^6 RNA copies/mL|SPECTROPHOTOMETRY||||INDEPENDENT ASSESSOR|RADIOLOGIST|U|1|Visit_1|10|4|TREATMENT|2020-08-05|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-30|P1Y2M10DT2H30M|BEFORE|2020-09-16|ONGOING|2020-10-15
e|RS|7c244128-0508-422f-88ba-ecce68cec054|2|NTRGRESP|Non-target Response|MRANO VAN DEN BENT GLIOMA 2011|||MAJOR PATHOLOGIC RESPONSE|1|cGy|IN VITRO GENE EXPRESSION ASSAY|Y||Y|VENDOR|NEUROLOGIST 1|NA|1|Visit_1|10|2|FOLLOW-UP|2020-08-05|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-30|P1Y2M10DT2H30M|BEFORE|2020-10-29|AFTER|2020-10-31
e|RS|7c244128-0508-422f-88ba-ecce68cec054|3|CLINRESP|Clinical Response|AJCC V8|[?]|fmol/g|DISEASE TRANSFORMATION|1|kat|PHOROPTER|Y|||PARENT|ONCOLOGIST 1|Y|2|Visit_2|25|4|TREATMENT|2020-08-20|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-25|P1Y2M10DT2H30M|COINCIDENT|2020-09-03|ONGOING|2020-09-19
e|RS|7c244128-0508-422f-88ba-ecce68cec054|4|HEMARESP|Hematologic Response|MASS|[?]|mL/g/min|PR WITH LYMPHOCYTOSIS|1|ng/dL|BALLPOINT PEN TECHNIQUE|Y|Y||ADJUDICATION COMMITTEE|MICROSCOPIST|Y|2|Visit_2|25|2|TREATMENT|2020-08-20|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-25|P1Y2M10DT2H30M|COINCIDENT|2020-09-18|COINCIDENT|2020-10-12
e|RS|7c244128-0508-422f-88ba-ecce68cec054|5|TMRESP|Tumor Marker Response|GUPPY OVARIAN CANCER 2002|||PR-CT|1|in2|OSCILLOMETRY||Y|Y|INVESTIGATOR|DERMATOLOGIST|NA|3|Visit_3|40|4|TREATMENT|2020-09-04|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-23|P1Y2M10DT2H30M|AFTER|2020-08-14|BEFORE|2020-11-01
e|RS|7c244128-0508-422f-88ba-ecce68cec054|6|MOLRESP|Molecular Response|CHOI GIST 2008|[?]|CARTRIDGE|MORPHOLOGIC CRi|1|m/sec|WRIGHT-GIEMSA STAIN||Y||HEALTH CARE PROFESSIONAL|DERMATOLOGIST|NA|3|Visit_3|40|1|WASHOUT|2020-09-04|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-23|P1Y2M10DT2H30M|AFTER|2020-08-31|BEFORE|2020-09-27
e|RS|7c244128-0508-422f-88ba-ecce68cec054|7|NEWLIND|New Lesion Indicator|BLAZER COLORECTAL CANCER 2008|[?]|mL/kg/day|PD/RELAPSE AFTER HI|1|PA|ENZYMATIC SPECTROPHOTOMETRY||Y||ADJUDICATOR|PHYSIOTHERAPIST|U|4|Visit_4|65|5|FOLLOW-UP|2020-09-29|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-13|P1Y2M10DT2H30M|UNKNOWN|2020-10-10|COINCIDENT|2020-10-16
e|RS|7c244128-0508-422f-88ba-ecce68cec054|8|CPRFSTAT|Clinical Performance Status|RAJKUMAR MYELOMA 2011|[?]|mEq/g|HI-N|1|ug/m2/min|HPLC/MS|Y|||CHILD|NEUROLOGIST 2|N|4|Visit_4|65|5|FOLLOW-UP|2020-09-29|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-13|P1Y2M10DT2H30M|AFTER|2020-08-28|AFTER|2020-09-14
e|RS|7c244128-0508-422f-88ba-ecce68cec054|9|BMIVLIND|Bone Marrow Involvement Indicator|CHOLLET BREAST CANCER 2002|[?]|DPM|IMMUNOPHENOTYPIC CR|1|/LPF|FLOCCULATION, CHARCOAL ENHANCED||||CAREGIVER|OTOLARYNGOLOGIST|N|5|Visit_5|90|2|TREATMENT|2020-10-24|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-02|P1Y2M10DT2H30M|AFTER|2020-08-06|AFTER|2020-09-09
e|RS|7c244128-0508-422f-88ba-ecce68cec054|10|CPRFSTAT|Clinical Performance Status|RECICL|[?]|RNA copies/mL|MORPHOLOGIC LEUKEMIA-FREE STATE|1|ug/kg|IMMUNOASSAY|Y|Y||CAREGIVER|NEUROLOGIST 1|Y|5|Visit_5|90|6|TREATMENT|2020-10-24|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-02|P1Y2M10DT2H30M|COINCIDENT|2020-08-16|AFTER|2020-09-09
e|RS|247814c7-9fb3-43f2-9e0a-db70b27b3d95|1|NEWLPROG|New Lesion Progression|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|10^12 IU/L|STABLE|1|/mm|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS|Y|||SPOUSE|READER 3|Y|1|Visit_1|10|7|SCREENING|2020-12-16|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-15|P1Y2M10DT2H30M|AFTER|2021-01-20|BEFORE|2021-01-28
e|RS|247814c7-9fb3-43f2-9e0a-db70b27b3d95|2|TMRESP|Tumor Marker Response|PRINCE TCELL LYMPHOMA 2010|||MRD PERSISTENCE|1|L/min/m2|NUCLEIC ACID AMPLIFICATION TEST|Y||Y|NON-HEALTH CARE PROFESSIONAL|READER|N|1|Visit_1|10|3|TREATMENT|2020-12-16|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-15|P1Y2M10DT2H30M|AFTER|2021-03-15|ONGOING|2021-03-16
e|RS|247814c7-9fb3-43f2-9e0a-db70b27b3d95|3|NTRGRESP|Non-target Response|IWG CHESON MDS 2000|[?]|ohm|NON-PD|1|U/mL|JAFFE REACTION||||PROXY|HEMATOLOGIST|Y|2|Visit_2|25|2|TREATMENT|2020-12-31|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-01|P1Y2M10DT2H30M|AFTER|2020-12-31|COINCIDENT|2021-02-11
e|RS|247814c7-9fb3-43f2-9e0a-db70b27b3d95|4|MRDRESP|Minimal Residual Disease Response|RANO|||RELAPSED DISEASE FROM CR OR PR|1|/HPF|CELL OF ORIGIN ASSAY|||Y|SIBLING|OTOLARYNGOLOGIST|NA|2|Visit_2|25|5|SCREENING|2020-12-31|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-01|P1Y2M10DT2H30M|COINCIDENT|2021-02-14|ONGOING|2021-02-20
e|RS|247814c7-9fb3-43f2-9e0a-db70b27b3d95|5|CPRFSTAT|Clinical Performance Status|MURPHY PROSTATE CANCER 1980|[?]|EID 50/dose|CYTOGENETIC MINOR RESPONSE|1|cm/s|SPIRAL CT|Y|||ADJUDICATOR|OPHTHALMOLOGIST|N|3|Visit_3|40|6|TREATMENT|2021-01-15|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-13|P1Y2M10DT2H30M|BEFORE|2021-03-14|BEFORE|2021-03-15
e|RS|247814c7-9fb3-43f2-9e0a-db70b27b3d95|6|METSIND|Metastatic Indicator|MRECIST BYRNE MESOTHELIOMA 2004|||MRD NEGATIVITY|1|%(w/v)|DYNAMIC CONTRAST ENHANCED MRI|||Y|DOMESTIC PARTNER|READER|N|3|Visit_3|40|2|WASHOUT|2021-01-15|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-13|P1Y2M10DT2H30M|COINCIDENT|2020-12-24|ONGOING|2020-12-28
e|RS|247814c7-9fb3-43f2-9e0a-db70b27b3d95|7|NTRGRESP|Non-target Response|DURIE MULTIPLE MYELOMA 2006|[?]|mL/cage|MRD NEGATIVITY|1|10^6/g|CALIPER MEASUREMENT METHOD|Y|||ADJUDICATOR|READER 1|U|4|Visit_4|65|5|WASHOUT|2021-02-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-17|P1Y2M10DT2H30M|BEFORE|2021-01-29|COINCIDENT|2021-02-16
e|RS|247814c7-9fb3-43f2-9e0a-db70b27b3d95|8|NEWLPROG|New Lesion Progression|PCWG SCHER PROSTATE CANCER 2016|[?]|GBq/ug|FAVORABLE RESPONSE|1|10^9/dose|PERIPHERAL ANGIOGRAPHY||Y||ADJUDICATION COMMITTEE|RADIOLOGIST 2|N|4|Visit_4|65|5|TREATMENT|2021-02-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-17|P1Y2M10DT2H30M|BEFORE|2021-03-08|BEFORE|2021-03-10
e|RS|247814c7-9fb3-43f2-9e0a-db70b27b3d95|9|SYMPTDTR|Symptomatic Deterioration|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|dpm/100mg|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|TROCHE|ATOMIC ABSORPTION SPECTROMETRY||||STUDY SUBJECT|MICROSCOPIST 1|Y|5|Visit_5|90|2|WASHOUT|2021-03-06|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-28|P1Y2M10DT2H30M|COINCIDENT|2021-01-17|AFTER|2021-03-01
e|RS|247814c7-9fb3-43f2-9e0a-db70b27b3d95|10|NTERESP|Non-Target Enhancing Response|AJCC V7|[?]|anti-Xa IU|MORPHOLOGIC CRi|1|Absorbance U/min|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|Y|Y||CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 1|Y|5|Visit_5|90|4|TREATMENT|2021-03-06|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-28|P1Y2M10DT2H30M|BEFORE|2021-02-24|COINCIDENT|2021-03-06
e|RS|e870fe2f-b08c-41d9-a672-07da09fe2b99|1|NTNERESP|Non-Target Non-Enhancing Response|SCHER PROSTATE CANCER 2011|||MR|1|nmol BCE/mmol|DC SHEATH FLOW|Y||Y|CHILD|PATHOLOGIST|NA|1|Visit_1|10|5|SCREENING|2020-08-12|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-04|P1Y2M10DT2H30M|AFTER|2020-09-17|AFTER|2020-10-15
e|RS|e870fe2f-b08c-41d9-a672-07da09fe2b99|2|SYMPTDTR|Symptomatic Deterioration|FAROOQUI SUPP CLL 2014|[?]|mmHg/sec|PD/RELAPSE AFTER HI|1|nmol/L|NEXT GENERATION SEQUENCING|Y|||INTERVIEWER|NEUROLOGIST|NA|1|Visit_1|10|3|SCREENING|2020-08-12|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-04|P1Y2M10DT2H30M|BEFORE|2020-09-14|COINCIDENT|2020-10-09
e|RS|e870fe2f-b08c-41d9-a672-07da09fe2b99|3|SPLNRESP|Spleen Response|KUKER LYMPHOMA 2005|[?]|APL U|SD-CT|1|CYLINDER|ELLA||Y||SIBLING|PEDIATRIC NEUROLOGIST|Y|2|Visit_2|25|5|TREATMENT|2020-08-27|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-16|P1Y2M10DT2H30M|AFTER|2020-09-16|AFTER|2020-11-09
e|RS|e870fe2f-b08c-41d9-a672-07da09fe2b99|4|BONERESP|Bone Response|HARTMAN PANCREATIC CANCER 2012|||MORPHOLOGIC LEUKEMIA-FREE STATE|1|mmol/L|NUCLEIC ACID BASED METHOD||Y|Y|VENDOR|UROLOGIST|Y|2|Visit_2|25|7|WASHOUT|2020-08-27|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-16|P1Y2M10DT2H30M|COINCIDENT|2020-08-29|ONGOING|2020-09-26
e|RS|e870fe2f-b08c-41d9-a672-07da09fe2b99|5|MRDIND|Minimal Residual Disease Indicator|AJCC V8|[?]|g/cage/wk|mCR|1|BISCUIT|MICROSCOPY||Y||GUARDIAN|ONCOLOGIST 1|N|3|Visit_3|40|4|TREATMENT|2020-09-11|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-30|P1Y2M10DT2H30M|COINCIDENT|2020-09-14|AFTER|2020-10-12
e|RS|e870fe2f-b08c-41d9-a672-07da09fe2b99|6|MOLRESP|Molecular Response|WOLCHOK SOLID TUMORS 2009|[?]|mg/animal|PMR|1|GBq|FUNDUS PHOTOGRAPHY||||CLINICAL STUDY SPONSOR|FORENSIC PATHOLOGIST|Y|3|Visit_3|40|3|TREATMENT|2020-09-11|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-30|P1Y2M10DT2H30M|COINCIDENT|2020-10-11|ONGOING|2020-10-18
e|RS|e870fe2f-b08c-41d9-a672-07da09fe2b99|7|NEWLWIND|New Lesion Worsening Indicator|LUGANO CLASSIFICATION|[?]|/200 HPFs|CHR|1|GBq|RADIAL IMMUNODIFFUSION||Y||SPOUSE|MICROSCOPIST 3|NA|4|Visit_4|65|2|TREATMENT|2020-10-06|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-16|P1Y2M10DT2H30M|BEFORE|2020-10-12|COINCIDENT|2020-11-06
e|RS|e870fe2f-b08c-41d9-a672-07da09fe2b99|8|BONERESP|Bone Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|PATCH|CYTOGENETIC MINIMAL RESPONSE|1|10^3/hpf|CLAUSS METHOD|Y|||ADJUDICATION COMMITTEE|READER 3|N|4|Visit_4|65|6|FOLLOW-UP|2020-10-06|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-16|P1Y2M10DT2H30M|BEFORE|2020-08-06|ONGOING|2020-10-24
e|RS|e870fe2f-b08c-41d9-a672-07da09fe2b99|9|BESTRESP|Best Overall Response|CHESON CLL 2012|[?]|10^8/L|CYTOGENETIC NO RESPONSE|1|uCi|FUNDUS PHOTOGRAPHY||||NON-HEALTH CARE PROFESSIONAL|UROLOGIST|U|5|Visit_5|90|4|TREATMENT|2020-10-31|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-05|P1Y2M10DT2H30M|BEFORE|2020-11-06|COINCIDENT|2020-11-07
e|RS|e870fe2f-b08c-41d9-a672-07da09fe2b99|10|NTRGRESP|Non-target Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|IU/g|iPR|1|APS U|ENZYMATIC SPECTROPHOTOMETRY||||PROXY|RATER 1|NA|5|Visit_5|90|2|TREATMENT|2020-10-31|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-05|P1Y2M10DT2H30M|AFTER|2020-09-25|BEFORE|2020-10-29
e|RS|32979638-fb88-4cbb-a110-a4d2016e9bc5|1|TRGRESP|Target Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|km/h|HI-E|1|fmol/g|MICROARRAY||||STUDY SUBJECT|UROLOGIST|U|1|Visit_1|10|4|TREATMENT|2020-07-15|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-04|P1Y2M10DT2H30M|UNKNOWN|2020-07-13|ONGOING|2020-08-01
e|RS|32979638-fb88-4cbb-a110-a4d2016e9bc5|2|CLINRESP|Clinical Response|RANO ELLINGSON 2017|||MR|1|steps/min|THERMAL IONIZATION MASS SPECTROMETRY|||Y|CHILD|HEMATOLOGIST|NA|1|Visit_1|10|3|FOLLOW-UP|2020-07-15|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-04|P1Y2M10DT2H30M|COINCIDENT|2020-09-18|COINCIDENT|2020-09-24
e|RS|32979638-fb88-4cbb-a110-a4d2016e9bc5|3|BMIVLIND|Bone Marrow Involvement Indicator|CHESON LYMPHOMA 2008|||CYTOGENETIC PR|1|km/h|CONTRAST ENHANCED PET SCAN|||Y|ADJUDICATION COMMITTEE|DERMATOLOGIST|U|2|Visit_2|25|6|TREATMENT|2020-07-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-03|P1Y2M10DT2H30M|BEFORE|2020-09-19|ONGOING|2020-10-03
e|RS|32979638-fb88-4cbb-a110-a4d2016e9bc5|4|MRDRESP|Minimal Residual Disease Response|CHESON MALIGNANT LYMPHOMA 2007|||CA125 50% RESPONSE|1|mph|TURBIDIMETRY|Y||Y|PARENT|READER|Y|2|Visit_2|25|4|SCREENING|2020-07-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-03|P1Y2M10DT2H30M|AFTER|2020-07-08|ONGOING|2020-07-09
e|RS|32979638-fb88-4cbb-a110-a4d2016e9bc5|5|TMRESP|Tumor Marker Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|min/day|CYTOGENETIC MINOR RESPONSE|1|Hz/s|OPTICAL COHERENCE TOMOGRAPHY||Y||SIBLING|READER 1|Y|3|Visit_3|40|3|FOLLOW-UP|2020-08-14|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-28|P1Y2M10DT2H30M|AFTER|2020-07-13|BEFORE|2020-09-06
e|RS|32979638-fb88-4cbb-a110-a4d2016e9bc5|6|NTLWIND|Non-Target Lesion Worsening Indicator|EASL BRUIX LIVER CANCER 2001|[?]|ft3|EQUIVOCAL|1|USP U|SURFACE PLASMON RESONANCE||||PARENT|CLINICAL PATHOLOGIST|Y|3|Visit_3|40|6|TREATMENT|2020-08-14|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-28|P1Y2M10DT2H30M|COINCIDENT|2020-07-20|COINCIDENT|2020-09-13
e|RS|32979638-fb88-4cbb-a110-a4d2016e9bc5|7|NTRGRESP|Non-target Response|AJCC V8|[?]|mU|nPR|1|AFU|CELLULAR PROLIFERATION ASSAY||||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 3|Y|4|Visit_4|65|3|TREATMENT|2020-09-08|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-24|P1Y2M10DT2H30M|COINCIDENT|2020-07-23|BEFORE|2020-09-03
e|RS|32979638-fb88-4cbb-a110-a4d2016e9bc5|8|CLINRESP|Clinical Response|AJCC V8|[?]|FINGERTIP UNIT|PARTIAL MORPHOLOGIC RESPONSE|1|PUFF|MIGET||||FRIEND|MICROSCOPIST 2|Y|4|Visit_4|65|5|TREATMENT|2020-09-08|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-24|P1Y2M10DT2H30M|COINCIDENT|2020-08-24|AFTER|2020-10-03
e|RS|32979638-fb88-4cbb-a110-a4d2016e9bc5|9|TRGRESP|Target Response|GUPPY OVARIAN CANCER 2002|[?]|ag|PMR|1|umol/L/h|LINE PROBE ASSAY||||GUARDIAN|CLINICAL PATHOLOGIST|NA|5|Visit_5|90|3|TREATMENT|2020-10-03|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-04|P1Y2M10DT2H30M|UNKNOWN|2020-07-28|ONGOING|2020-08-09
e|RS|32979638-fb88-4cbb-a110-a4d2016e9bc5|10|BMIVLIND|Bone Marrow Involvement Indicator|RAJKUMAR MYELOMA 2011|||TREATMENT FAILURE|1|POINT|THIN SMEAR|Y||Y|PROXY|PHYSIOTHERAPIST|N|5|Visit_5|90|7|SCREENING|2020-10-03|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-04|P1Y2M10DT2H30M|AFTER|2020-08-07|BEFORE|2020-09-13
e|RS|39b8db88-810b-4402-9ca3-c2bab1939c1c|1|SFTSRESP|Soft Tissue Response|PROTOCOL DEFINED RESPONSE CRITERIA|||MR|1|mL/kg/h|MICRONEUTRALIZATION ASSAY|Y||Y|STUDY SUBJECT|CARDIOLOGIST|NA|1|Visit_1|10|2|TREATMENT|2020-11-15|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-31|P1Y2M10DT2H30M|UNKNOWN|2021-01-03|COINCIDENT|2021-02-08
e|RS|39b8db88-810b-4402-9ca3-c2bab1939c1c|2|NTLWIND|Non-Target Lesion Worsening Indicator|PCWG BUBLEY PROSTATE CANCER 1999|[?]|U/kg|ABSENT MORPHOLOGIC RESPONSE|1|CARTRIDGE|RIA||Y||CLINICAL RESEARCH ASSOCIATE|READER|U|1|Visit_1|10|3|TREATMENT|2020-11-15|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-31|P1Y2M10DT2H30M|AFTER|2021-01-12|COINCIDENT|2021-02-06
e|RS|39b8db88-810b-4402-9ca3-c2bab1939c1c|3|ANATRESP|Anatomic Response|AJCC V8|||DISEASE TRANSFORMATION|1|vg/kg|TRYPAN BLUE STAIN|||Y|CHILD|ONCOLOGIST|U|2|Visit_2|25|4|TREATMENT|2020-11-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-01|P1Y2M10DT2H30M|UNKNOWN|2020-12-18|COINCIDENT|2021-01-19
e|RS|39b8db88-810b-4402-9ca3-c2bab1939c1c|4|TRGRESP|Target Response|IWG CHESON MDS 2000|[?]|U/kg/min|INDETERMINATE RESPONSE|1|Gy|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY||||GUARDIAN|NEUROLOGIST 2|Y|2|Visit_2|25|1|TREATMENT|2020-11-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-01|P1Y2M10DT2H30M|AFTER|2021-02-01|BEFORE|2021-02-09
e|RS|39b8db88-810b-4402-9ca3-c2bab1939c1c|5|OVRLRESP|Overall Response|PCWG SCHER PROSTATE CANCER 2016|[?]|APL U/mL|CRi|1|mmol|AURAMINE STAIN||||GUARDIAN|READER 2|NA|3|Visit_3|40|6|FOLLOW-UP|2020-12-15|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-27|P1Y2M10DT2H30M|BEFORE|2021-01-12|BEFORE|2021-02-05
e|RS|39b8db88-810b-4402-9ca3-c2bab1939c1c|6|NTERESP|Non-Target Enhancing Response|RECIST 1.0|[?]|BOX|VGPR|1|CIGAR|LYMPHANGIOGRAPHY|Y|Y||GUARDIAN|CLINICAL PATHOLOGIST|NA|3|Visit_3|40|5|SCREENING|2020-12-15|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-27|P1Y2M10DT2H30M|UNKNOWN|2020-11-24|AFTER|2021-01-21
e|RS|39b8db88-810b-4402-9ca3-c2bab1939c1c|7|CLINRESP|Clinical Response|IWG CHESON MDS 2000|[?]|/200 HPFs|CYTOGENETIC CR|1|Bq/mg|IMMUNE REPERTOIRE DEEP SEQUENCING||||PARENT|READER 2|N|4|Visit_4|65|5|TREATMENT|2021-01-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-12|P1Y2M10DT2H30M|AFTER|2021-02-07|COINCIDENT|2021-02-12
e|RS|39b8db88-810b-4402-9ca3-c2bab1939c1c|8|METBRESP|Metabolic Response|RECICL|[?]|BOX|PSA PROGRESSION|1|10^6 organisms|SNELLEN EYE CHART||||CAREGIVER|ADJUDICATOR|N|4|Visit_4|65|2|TREATMENT|2021-01-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-12|P1Y2M10DT2H30M|COINCIDENT|2021-02-05|COINCIDENT|2021-02-12
e|RS|39b8db88-810b-4402-9ca3-c2bab1939c1c|9|MNPTHIND|Minor Pathological Response Indicator|MACDONALD GLIOMA 1990|||NON-QUANTIFIABLE MRD POSITIVITY|1|DPM|COLORIMETRY||Y|Y|PROXY|RADIOLOGIST 2|Y|5|Visit_5|90|2|TREATMENT|2021-02-03|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-29|P1Y2M10DT2H30M|UNKNOWN|2020-11-21|BEFORE|2020-12-29
e|RS|39b8db88-810b-4402-9ca3-c2bab1939c1c|10|NTRGRESP|Non-target Response|MACDONALD GLIOMA 1990|||iPR|1|MASK|HPLC/IEX||Y|Y|DOMESTIC PARTNER|RATER|Y|5|Visit_5|90|2|TREATMENT|2021-02-03|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-29|P1Y2M10DT2H30M|COINCIDENT|2021-01-22|COINCIDENT|2021-01-29
e|RS|b6cce9a5-9b5d-4dd2-80ad-0c6a5b1ed640|1|MNPTHIND|Minor Pathological Response Indicator|IWG CHESON AML 2003|[?]|10^6 CFU|NON-CR/NON-PD|1|Anson U|GC/MS/MS|Y|||STUDY SUBJECT|ADJUDICATOR|U|1|Visit_1|10|2|WASHOUT|2020-07-27|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-30|P1Y2M10DT2H30M|COINCIDENT|2020-09-01|BEFORE|2020-09-11
e|RS|b6cce9a5-9b5d-4dd2-80ad-0c6a5b1ed640|2|NEWLPROG|New Lesion Progression|SCHER PROSTATE CANCER 2011|[?]|mL/animal/wk|MOLECULAR CR|1|umol/L|ENZYMATIC COLORIMETRY||Y||VENDOR|RADIOLOGIST 2|U|1|Visit_1|10|3|TREATMENT|2020-07-27|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-30|P1Y2M10DT2H30M|AFTER|2020-08-15|BEFORE|2020-10-13
e|RS|b6cce9a5-9b5d-4dd2-80ad-0c6a5b1ed640|3|LIVRRESP|Liver Response|HARTMANN GERM CELL CANCER 2002|||VGPR|1|PFU/dose|CONTRAST ENHANCED SPIRAL CT SCAN|||Y|ADJUDICATION COMMITTEE|NEUROLOGIST 1|U|2|Visit_2|25|1|TREATMENT|2020-08-11|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-24|P1Y2M10DT2H30M|BEFORE|2020-08-09|COINCIDENT|2020-09-28
e|RS|b6cce9a5-9b5d-4dd2-80ad-0c6a5b1ed640|4|MNPTHIND|Minor Pathological Response Indicator|PCWG SCHER PROSTATE CANCER 2008|[?]|mL/beat|MR|1|mmol2/L2|CLOT DETECTION|Y|||INTERVIEWER|INTERNIST|Y|2|Visit_2|25|4|TREATMENT|2020-08-11|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-24|P1Y2M10DT2H30M|BEFORE|2020-09-05|ONGOING|2020-09-13
e|RS|b6cce9a5-9b5d-4dd2-80ad-0c6a5b1ed640|5|NEWLIND|New Lesion Indicator|AJCC V7|||ABSENT MORPHOLOGIC RESPONSE|1|dmol|LASER CAPTURE MICRODISSECTION|||Y|ADJUDICATION COMMITTEE|PEDIATRIC NEUROLOGIST|U|3|Visit_3|40|2|TREATMENT|2020-08-26|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-26|P1Y2M10DT2H30M|COINCIDENT|2020-08-23|COINCIDENT|2020-09-04
e|RS|b6cce9a5-9b5d-4dd2-80ad-0c6a5b1ed640|6|NTRGRESP|Non-target Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|nmol BCE/nmol|mCR|1|/wk|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY||Y||SIGNIFICANT OTHER|ADJUDICATOR 3|U|3|Visit_3|40|7|TREATMENT|2020-08-26|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-26|P1Y2M10DT2H30M|UNKNOWN|2020-08-31|AFTER|2020-09-19
e|RS|b6cce9a5-9b5d-4dd2-80ad-0c6a5b1ed640|7|MRPHRESP|Morphologic Response|WHO BREAST CANCER 2006|[?]|10^3 organisms/mL|NON-iCR/NON-iUPD|1|deg/s|LEAD CITRATE STAIN|Y|||PARENT|ADJUDICATOR 2|U|4|Visit_4|65|3|SCREENING|2020-09-20|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-25|P1Y2M10DT2H30M|BEFORE|2020-07-22|AFTER|2020-09-18
e|RS|b6cce9a5-9b5d-4dd2-80ad-0c6a5b1ed640|8|PATHRESP|Pathologic Response|MRANO VAN DEN BENT GLIOMA 2011|||MINOR PATHOLOGIC RESPONSE|1|K|FLOCCULATION, CHARCOAL ENHANCED||Y|Y|PROXY|READER|NA|4|Visit_4|65|2|TREATMENT|2020-09-20|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-25|P1Y2M10DT2H30M|BEFORE|2020-09-16|AFTER|2020-09-18
e|RS|b6cce9a5-9b5d-4dd2-80ad-0c6a5b1ed640|9|METBRESP|Metabolic Response|KUMAR IMWG 2016|[?]|km|IMMUNOPHENOTYPIC CR|1|cd*s/m2|FLUORESCENT SPOT TEST|Y|||CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 2|N|5|Visit_5|90|2|SCREENING|2020-10-15|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-18|P1Y2M10DT2H30M|BEFORE|2020-08-14|AFTER|2020-09-28
e|RS|b6cce9a5-9b5d-4dd2-80ad-0c6a5b1ed640|10|HEMARESP|Hematologic Response|IWG CHESON MDS 2006|[?]|ug/L DDU|CYTOGENETIC MINOR RESPONSE|1|mL/kg/h|SPIRAL CT||||SPOUSE|MICROSCOPIST 2|N|5|Visit_5|90|4|TREATMENT|2020-10-15|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-18|P1Y2M10DT2H30M|UNKNOWN|2020-08-31|AFTER|2020-10-20
e|RS|bca1f50d-04e6-46f5-afb3-e48aaea1069d|1|NTERESP|Non-Target Enhancing Response|RECICL|||MINOR PATHOLOGIC RESPONSE|1|10^11/L|FLUORESCENT MICROSCOPY||Y|Y|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 2|N|1|Visit_1|10|5|SCREENING|2020-11-03|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-10|P1Y2M10DT2H30M|BEFORE|2020-12-17|COINCIDENT|2021-01-14
e|RS|bca1f50d-04e6-46f5-afb3-e48aaea1069d|2|NEWLPROG|New Lesion Progression|EASL BRUIX LIVER CANCER 2001|[?]|g/cm2|STABLE|1|fL|FLUORESCENT IMMUNOASSAY||||SPOUSE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|1|Visit_1|10|2|WASHOUT|2020-11-03|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-10|P1Y2M10DT2H30M|BEFORE|2021-01-06|AFTER|2021-01-15
e|RS|bca1f50d-04e6-46f5-afb3-e48aaea1069d|3|TMRESP|Tumor Marker Response|BLAZER COLORECTAL CANCER 2008|[?]|nL|MRD PERSISTENCE|1|10^8/L|MS/MS|Y|||INVESTIGATOR|RATER|NA|2|Visit_2|25|6|TREATMENT|2020-11-18|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-08|P1Y2M10DT2H30M|COINCIDENT|2021-01-07|AFTER|2021-01-17
e|RS|bca1f50d-04e6-46f5-afb3-e48aaea1069d|4|HEMARESP|Hematologic Response|DURIE MULTIPLE MYELOMA 2006|[?]|CAPFUL|PD-CT|1|mU/g|X-RAY FLUORESCENCE SPECTROMETRY|Y|||SIBLING|PATHOLOGIST 2|U|2|Visit_2|25|1|TREATMENT|2020-11-18|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-08|P1Y2M10DT2H30M|COINCIDENT|2021-01-16|ONGOING|2021-01-22
e|RS|bca1f50d-04e6-46f5-afb3-e48aaea1069d|5|NEWLWIND|New Lesion Worsening Indicator|iRECIST|[?]|ug/kg/h|ABSENT MORPHOLOGIC RESPONSE|1|AU/mL|DYNAMOMETRY||||SPOUSE|ONCOLOGIST 2|NA|3|Visit_3|40|6|TREATMENT|2020-12-03|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-28|P1Y2M10DT2H30M|UNKNOWN|2021-01-14|ONGOING|2021-01-20
e|RS|bca1f50d-04e6-46f5-afb3-e48aaea1069d|6|MOLRESP|Molecular Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|K|NR|1|mL/g/h|CYSTOSCOPY|Y|||PARENT|READER 2|Y|3|Visit_3|40|2|TREATMENT|2020-12-03|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-28|P1Y2M10DT2H30M|COINCIDENT|2021-01-30|BEFORE|2021-01-31
e|RS|bca1f50d-04e6-46f5-afb3-e48aaea1069d|7|RDIORESP|Radiologic Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|STRIP|QUANTIFIABLE MRD POSITIVITY|1|U/g/day|MICROBIAL CONCENTRATION||||ADJUDICATOR|CARDIOLOGIST|N|4|Visit_4|65|3|SCREENING|2020-12-28|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-13|P1Y2M10DT2H30M|COINCIDENT|2020-12-09|BEFORE|2020-12-27
e|RS|bca1f50d-04e6-46f5-afb3-e48aaea1069d|8|MOLRESP|Molecular Response|CHOI GIST 2008|[?]|m|pCR|1|damol/L|CELLULAR PROLIFERATION ASSAY||Y||DOMESTIC PARTNER|FORENSIC PATHOLOGIST|N|4|Visit_4|65|5|SCREENING|2020-12-28|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-13|P1Y2M10DT2H30M|AFTER|2021-01-27|AFTER|2021-01-29
e|RS|bca1f50d-04e6-46f5-afb3-e48aaea1069d|9|NTNERESP|Non-Target Non-Enhancing Response|JACINTO CERVICAL CANCER 2007|[?]|KIT|PMD|1|mg/dose|MAGNETIC RESONANCE ENTEROGRAPHY||||PARENT|RADIOLOGIST 2|N|5|Visit_5|90|5|TREATMENT|2021-01-22|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-29|P1Y2M10DT2H30M|COINCIDENT|2020-12-19|ONGOING|2020-12-26
e|RS|bca1f50d-04e6-46f5-afb3-e48aaea1069d|10|CLINRESP|Clinical Response|RECIST 1.0|[?]|10^9 organisms/mg|PD-CT|1|ngEq/L|OLIGO ACGH||||PROXY|READER 1|U|5|Visit_5|90|7|FOLLOW-UP|2021-01-22|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-29|P1Y2M10DT2H30M|UNKNOWN|2020-10-29|ONGOING|2021-01-23
e|RS|6bddadef-13fb-4fab-b281-aa33aa97aa8f|1|BMIVLIND|Bone Marrow Involvement Indicator|PCWG BUBLEY PROSTATE CANCER 1999|||sCR|1|vg/mL|MRI||Y|Y|PARENT|ADJUDICATOR 3|Y|1|Visit_1|10|1|TREATMENT|2020-05-24|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-17|P1Y2M10DT2H30M|AFTER|2020-07-06|AFTER|2020-08-09
e|RS|6bddadef-13fb-4fab-b281-aa33aa97aa8f|2|SPLNRESP|Spleen Response|SHINDOH COLORECTAL CANCER 2013|[?]|/10^5|CYTOGENETIC CR|1|Ci/mL|TRANSCRIPTION-MEDIATED AMPLIFICATION||||FRIEND|OPTOMETRIST|N|1|Visit_1|10|4|SCREENING|2020-05-24|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-17|P1Y2M10DT2H30M|AFTER|2020-05-28|AFTER|2020-06-19
e|RS|6bddadef-13fb-4fab-b281-aa33aa97aa8f|3|ANATRESP|Anatomic Response|IRANO 2015|||iCR|1|DAYS|LASER CAPTURE MICRODISSECTION|||Y|ADJUDICATION COMMITTEE|CLINICAL PATHOLOGIST|Y|2|Visit_2|25|4|TREATMENT|2020-06-08|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-19|P1Y2M10DT2H30M|COINCIDENT|2020-05-16|AFTER|2020-06-16
e|RS|6bddadef-13fb-4fab-b281-aa33aa97aa8f|4|TRGRESP|Target Response|LUGANO CLASSIFICATION|[?]|cGy|iSD|1|PFU/mL|EPSILOMETER||||SIBLING|CARDIOLOGIST|N|2|Visit_2|25|5|SCREENING|2020-06-08|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-19|P1Y2M10DT2H30M|BEFORE|2020-07-17|BEFORE|2020-08-12
e|RS|6bddadef-13fb-4fab-b281-aa33aa97aa8f|5|DRCRIND|Disease Recurrence Indicator|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|||NR|1|cd|SPECULAR MICROSCOPY|||Y|GUARDIAN|PATHOLOGIST 2|NA|3|Visit_3|40|1|TREATMENT|2020-06-23|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-26|P1Y2M10DT2H30M|COINCIDENT|2020-06-10|BEFORE|2020-07-27
e|RS|6bddadef-13fb-4fab-b281-aa33aa97aa8f|6|BMIVLIND|Bone Marrow Involvement Indicator|DURIE MULTIPLE MYELOMA 2006|||PSEUDOPROGRESSION|1|IU/g|LC-FL|||Y|FAMILY MEMBER|PATHOLOGIST 1|U|3|Visit_3|40|6|WASHOUT|2020-06-23|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-26|P1Y2M10DT2H30M|COINCIDENT|2020-07-07|COINCIDENT|2020-08-06
e|RS|6bddadef-13fb-4fab-b281-aa33aa97aa8f|7|OVRLRESP|Overall Response|KUKER LYMPHOMA 2005|[?]|mPa|MORPHOLOGIC CRi|1|ug/h|ELECTROMYOGRAPHY|Y|Y||HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|U|4|Visit_4|65|5|WASHOUT|2020-07-18|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-29|P1Y2M10DT2H30M|COINCIDENT|2020-06-06|BEFORE|2020-06-25
e|RS|6bddadef-13fb-4fab-b281-aa33aa97aa8f|8|BMIVLIND|Bone Marrow Involvement Indicator|CHESON CLL 2012|[?]|VOXEL|UNFAVORABLE RESPONSE|1|um/s|X-RAY FLUORESCENCE SPECTROMETRY||||INDEPENDENT ASSESSOR|RATER 2|N|4|Visit_4|65|7|WASHOUT|2020-07-18|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-29|P1Y2M10DT2H30M|AFTER|2020-05-31|AFTER|2020-08-01
e|RS|6bddadef-13fb-4fab-b281-aa33aa97aa8f|9|ANATRESP|Anatomic Response|IWC HALLEK CLL 2008|[?]|ft3|MORPHOLOGIC LEUKEMIA-FREE STATE|1|PFU/animal|HILLMEN COLOR CHART||||CLINICAL STUDY SPONSOR|READER 3|N|5|Visit_5|90|6|WASHOUT|2020-08-12|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-21|P1Y2M10DT2H30M|COINCIDENT|2020-06-23|ONGOING|2020-08-10
e|RS|6bddadef-13fb-4fab-b281-aa33aa97aa8f|10|CPRFSTAT|Clinical Performance Status|MURPHY PROSTATE CANCER 1980|[?]|mL/m2/h|FAVORABLE RESPONSE|1|mg/h|CT SCAN WITHOUT CONTRAST||||ADJUDICATOR|MICROSCOPIST 1|NA|5|Visit_5|90|4|WASHOUT|2020-08-12|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-21|P1Y2M10DT2H30M|BEFORE|2020-06-25|BEFORE|2020-06-27
e|RS|6edb7414-d8f4-44da-8483-504b93a7e705|1|MRDIND|Minimal Residual Disease Indicator|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|10^6 CFU/g|CMR|1|kBq|HPLC-FL||||SIBLING|RADIOLOGIST|U|1|Visit_1|10|1|TREATMENT|2020-06-07|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-08|P1Y2M10DT2H30M|COINCIDENT|2020-05-30|AFTER|2020-07-02
e|RS|6edb7414-d8f4-44da-8483-504b93a7e705|2|RDIORESP|Radiologic Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|kBq/uL|ABSENT MORPHOLOGIC RESPONSE|1|mEq|ROMANOWSKY STAIN||||ADJUDICATION COMMITTEE|ADJUDICATOR 1|U|1|Visit_1|10|1|WASHOUT|2020-06-07|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-08|P1Y2M10DT2H30M|UNKNOWN|2020-08-22|AFTER|2020-08-28
e|RS|6edb7414-d8f4-44da-8483-504b93a7e705|3|DRCRIND|Disease Recurrence Indicator|IWG CHESON AML 2003|||MORPHOLOGIC CR|1|CAN|SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|||Y|INVESTIGATOR|ADJUDICATOR 2|NA|2|Visit_2|25|7|SCREENING|2020-06-22|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-11|P1Y2M10DT2H30M|BEFORE|2020-07-20|COINCIDENT|2020-08-24
e|RS|6edb7414-d8f4-44da-8483-504b93a7e705|4|CYTORESP|Cytogenetic Response|EASL BRUIX LIVER CANCER 2001|||SMD|1|deg2|MRI WITHOUT CONTRAST|||Y|CLINICAL STUDY SPONSOR|ADJUDICATOR 3|Y|2|Visit_2|25|1|TREATMENT|2020-06-22|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-11|P1Y2M10DT2H30M|COINCIDENT|2020-07-03|COINCIDENT|2020-08-19
e|RS|6edb7414-d8f4-44da-8483-504b93a7e705|5|STRUSTAT|Steroid Use Status|HARTMANN GERM CELL CANCER 2002|||CYTOGENETIC MINIMAL RESPONSE|1|DAgU|DIGITAL PCR ARRAY||Y|Y|GUARDIAN|PHYSIOTHERAPIST|U|3|Visit_3|40|5|WASHOUT|2020-07-07|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-21|P1Y2M10DT2H30M|UNKNOWN|2020-07-20|COINCIDENT|2020-08-13
e|RS|6edb7414-d8f4-44da-8483-504b93a7e705|6|CPRFSTAT|Clinical Performance Status|IWG CHESON MDS 2006|[?]|RNA copies/mL|QUANTIFIABLE MRD POSITIVITY|1|ohm|TRICHROME STAIN||||CHILD|PATHOLOGIST 2|U|3|Visit_3|40|4|SCREENING|2020-07-07|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-21|P1Y2M10DT2H30M|AFTER|2020-08-16|ONGOING|2020-08-26
e|RS|6edb7414-d8f4-44da-8483-504b93a7e705|7|NTRGRESP|Non-target Response|KUKER LYMPHOMA 2005|||iPR|1|10^3 CFU|DIFFUSION WEIGHTED MRI|Y|Y|Y|FRIEND|RADIOLOGIST|Y|4|Visit_4|65|3|TREATMENT|2020-08-01|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-29|P1Y2M10DT2H30M|COINCIDENT|2020-07-20|AFTER|2020-08-15
e|RS|6edb7414-d8f4-44da-8483-504b93a7e705|8|STRUSTAT|Steroid Use Status|HARTMANN GERM CELL CANCER 2002|[?]|ag|MR|1|uL/dose|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION||Y||INTERVIEWER|PATHOLOGIST 2|U|4|Visit_4|65|5|FOLLOW-UP|2020-08-01|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-29|P1Y2M10DT2H30M|UNKNOWN|2020-07-12|BEFORE|2020-08-04
e|RS|6edb7414-d8f4-44da-8483-504b93a7e705|9|CYTORESP|Cytogenetic Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|BOWL|NON-PD|1|nkat|MASS SPECTROMETRY||||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 2|U|5|Visit_5|90|1|SCREENING|2020-08-26|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-16|P1Y2M10DT2H30M|BEFORE|2020-06-16|ONGOING|2020-09-01
e|RS|6edb7414-d8f4-44da-8483-504b93a7e705|10|CLINRESP|Clinical Response|UNSPECIFIED|[?]|YEARS|CYTOGENETIC PR|1|MPS U|GEL ELECTROPHORESIS||||SPOUSE|OTOLARYNGOLOGIST|Y|5|Visit_5|90|2|TREATMENT|2020-08-26|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-16|P1Y2M10DT2H30M|AFTER|2020-06-11|AFTER|2020-08-14
e|RS|3fd8445d-f3b1-46ac-b5ae-a0e5a7f32210|1|NTLWIND|Non-Target Lesion Worsening Indicator|PCWG BUBLEY PROSTATE CANCER 1999|[?]|10^10/L|mCR|1|U.CARR|RAJI CELL EIA||Y||VENDOR|PEDIATRIC NEUROLOGIST|NA|1|Visit_1|10|5|SCREENING|2020-05-16|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-29|P1Y2M10DT2H30M|BEFORE|2020-06-29|COINCIDENT|2020-08-06
e|RS|3fd8445d-f3b1-46ac-b5ae-a0e5a7f32210|2|NEWLPROG|New Lesion Progression|KEAM BREAST CANCER 2013|||IMMUNOPHENOTYPIC CR|1|vp/dose|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS||Y|Y|HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|N|1|Visit_1|10|7|TREATMENT|2020-05-16|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-29|P1Y2M10DT2H30M|AFTER|2020-07-27|BEFORE|2020-08-05
e|RS|3fd8445d-f3b1-46ac-b5ae-a0e5a7f32210|3|MOLRESP|Molecular Response|PROTOCOL DEFINED RESPONSE CRITERIA|||CYTOGENETIC NO RESPONSE|1|mL/s|INCISION-INDUCED BLEEDING METHOD|||Y|DOMESTIC PARTNER|ADJUDICATOR 2|N|2|Visit_2|25|4|FOLLOW-UP|2020-05-31|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-21|P1Y2M10DT2H30M|AFTER|2020-05-23|COINCIDENT|2020-08-06
e|RS|3fd8445d-f3b1-46ac-b5ae-a0e5a7f32210|4|TRGRESP|Target Response|CHOLLET BREAST CANCER 2002|||FAVORABLE RESPONSE|1|nmol/g|COMPLEMENT FIXATION|||Y|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 2|Y|2|Visit_2|25|2|TREATMENT|2020-05-31|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-21|P1Y2M10DT2H30M|COINCIDENT|2020-07-21|ONGOING|2020-08-10
e|RS|3fd8445d-f3b1-46ac-b5ae-a0e5a7f32210|5|MRPHRESP|Morphologic Response|SACT|[?]|10^3/hpf|MINOR PATHOLOGIC RESPONSE|1|10^5/L|RYAN BLUE STAIN||||HEALTH CARE PROFESSIONAL|CARDIOLOGIST|Y|3|Visit_3|40|3|TREATMENT|2020-06-15|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-14|P1Y2M10DT2H30M|AFTER|2020-08-12|AFTER|2020-08-13
e|RS|3fd8445d-f3b1-46ac-b5ae-a0e5a7f32210|6|BONERESP|Bone Response|HAMAOKA BREAST CANCER 2010|||MR|1|PFU/animal|TRANSESOPHAGEAL ECHOCARDIOGRAPHY|||Y|SIBLING|FORENSIC PATHOLOGIST|N|3|Visit_3|40|3|SCREENING|2020-06-15|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-14|P1Y2M10DT2H30M|BEFORE|2020-05-09|COINCIDENT|2020-07-17
e|RS|3fd8445d-f3b1-46ac-b5ae-a0e5a7f32210|7|TMRESP|Tumor Marker Response|PCWG BUBLEY PROSTATE CANCER 1999|||DECREASED|1|cm H2O|CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY||Y|Y|CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 1|N|4|Visit_4|65|5|TREATMENT|2020-07-10|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-27|P1Y2M10DT2H30M|UNKNOWN|2020-06-05|BEFORE|2020-07-09
e|RS|3fd8445d-f3b1-46ac-b5ae-a0e5a7f32210|8|MOLRESP|Molecular Response|BRUGGEMANN MRD 2010|[?]|BAU|MRD NEGATIVITY|1|HOMEOPATHIC DILUTION|MAPH||||INDEPENDENT ASSESSOR|PATHOLOGIST 2|N|4|Visit_4|65|6|TREATMENT|2020-07-10|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-27|P1Y2M10DT2H30M|UNKNOWN|2020-05-10|COINCIDENT|2020-07-19
e|RS|3fd8445d-f3b1-46ac-b5ae-a0e5a7f32210|9|MNPTHIND|Minor Pathological Response Indicator|MACDONALD GLIOMA 1990|[?]|BOLUS|HI-E|1|mg/kg/min|ENZYMATIC ULTRACENTRIFUGATION|Y|||ADJUDICATOR|DERMATOLOGIST|U|5|Visit_5|90|6|TREATMENT|2020-08-04|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-25|P1Y2M10DT2H30M|UNKNOWN|2020-07-28|AFTER|2020-08-04
e|RS|3fd8445d-f3b1-46ac-b5ae-a0e5a7f32210|10|NTLWIND|Non-Target Lesion Worsening Indicator|RECIST 1.0|[?]|mL/cm H2O|CYTOGENETIC MINIMAL RESPONSE|1|vg/mL|WESTERGREN||Y||SIGNIFICANT OTHER|READER 2|N|5|Visit_5|90|4|TREATMENT|2020-08-04|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-25|P1Y2M10DT2H30M|COINCIDENT|2020-07-07|COINCIDENT|2020-07-25
e|RS|b005dec4-0aed-484d-b20a-bb18cf8ddbe6|1|SYMPTDTR|Symptomatic Deterioration|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|100 IU/mL|iCR|1|umol|IMMUNOTURBIDIMETRY||Y||SIGNIFICANT OTHER|RATER 2|NA|1|Visit_1|10|4|TREATMENT|2020-05-18|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-22|P1Y2M10DT2H30M|BEFORE|2020-06-18|COINCIDENT|2020-08-15
e|RS|b005dec4-0aed-484d-b20a-bb18cf8ddbe6|2|DRCRIND|Disease Recurrence Indicator|MASS|[?]|vg/dose|iUPD|1|mg|MICROARRAY||||CLINICAL RESEARCH COORDINATOR|RATER|Y|1|Visit_1|10|5|FOLLOW-UP|2020-05-18|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-22|P1Y2M10DT2H30M|COINCIDENT|2020-06-15|ONGOING|2020-06-25
e|RS|b005dec4-0aed-484d-b20a-bb18cf8ddbe6|3|METSIND|Metastatic Indicator|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|mol|CYTOGENETIC NO RESPONSE|1|IU/g|PHOTOMETRY||||CLINICAL STUDY SPONSOR|UROLOGIST|NA|2|Visit_2|25|6|TREATMENT|2020-06-02|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-05|P1Y2M10DT2H30M|UNKNOWN|2020-05-10|COINCIDENT|2020-07-03
e|RS|b005dec4-0aed-484d-b20a-bb18cf8ddbe6|4|CPRFSTAT|Clinical Performance Status|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|ug/m2|CYTOGENETIC NO RESPONSE|1|ug/m2/min|MRI||||CLINICAL RESEARCH COORDINATOR|CLINICAL PATHOLOGIST|NA|2|Visit_2|25|1|WASHOUT|2020-06-02|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-05|P1Y2M10DT2H30M|AFTER|2020-06-10|BEFORE|2020-06-15
e|RS|b005dec4-0aed-484d-b20a-bb18cf8ddbe6|5|RDIORESP|Radiologic Response|CHESON CLL 2012|||iSD|1|Bq/mg|STRESS ECHOCARDIOGRAPHY|||Y|FRIEND|UROLOGIST|Y|3|Visit_3|40|1|TREATMENT|2020-06-17|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-21|P1Y2M10DT2H30M|BEFORE|2020-05-27|AFTER|2020-05-29
e|RS|b005dec4-0aed-484d-b20a-bb18cf8ddbe6|6|MOLRESP|Molecular Response|PETIT BREAST CANCER 2001|[?]|Linear ft*LB|PD|1|Roentgen|KINYOUN STAIN||||INVESTIGATOR|CLINICAL PATHOLOGIST|U|3|Visit_3|40|4|TREATMENT|2020-06-17|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-21|P1Y2M10DT2H30M|AFTER|2020-05-20|ONGOING|2020-06-27
e|RS|b005dec4-0aed-484d-b20a-bb18cf8ddbe6|7|NTERESP|Non-Target Enhancing Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|mL/kg/min|nPR|1|10^6 organisms/g|PERIPHERAL ANGIOGRAPHY||||HEALTH CARE PROFESSIONAL|READER 1|N|4|Visit_4|65|5|FOLLOW-UP|2020-07-12|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-27|P1Y2M10DT2H30M|COINCIDENT|2020-07-11|COINCIDENT|2020-07-19
e|RS|b005dec4-0aed-484d-b20a-bb18cf8ddbe6|8|MRDIND|Minimal Residual Disease Indicator|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|||MOLECULAR MAJOR RESPONSE|1|U/kg/min|INTRAVASCULAR ULTRASOUND|||Y|PARENT|READER 3|U|4|Visit_4|65|5|SCREENING|2020-07-12|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-27|P1Y2M10DT2H30M|AFTER|2020-06-26|BEFORE|2020-08-13
e|RS|b005dec4-0aed-484d-b20a-bb18cf8ddbe6|9|METBRESP|Metabolic Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|AMPULE|HI-P|1|GBq/ug|ANGIOGRAPHY||||NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST|U|5|Visit_5|90|3|TREATMENT|2020-08-06|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-05|P1Y2M10DT2H30M|COINCIDENT|2020-07-11|ONGOING|2020-07-18
e|RS|b005dec4-0aed-484d-b20a-bb18cf8ddbe6|10|HEMARESP|Hematologic Response|PRINCE TCELL LYMPHOMA 2010|||MORPHOLOGIC LEUKEMIA-FREE STATE|1|/mm|WHOLE TRANSCRIPTOME SEQUENCING|||Y|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST|NA|5|Visit_5|90|7|TREATMENT|2020-08-06|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-05|P1Y2M10DT2H30M|COINCIDENT|2020-05-14|BEFORE|2020-06-20
e|RS|47d55e87-e559-424d-a6ad-d533a0d77f39|1|MJPTHIND|Major Pathological Response Indicator|LUGANO CLASSIFICATION|[?]|AMPULE|MORPHOLOGIC LEUKEMIA-FREE STATE|1|s/h|LIGHT MICROSCOPY||Y||CLINICAL STUDY SPONSOR|RADIOLOGIST 1|U|1|Visit_1|10|6|WASHOUT|2021-01-12|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-27|P1Y2M10DT2H30M|BEFORE|2021-03-01|ONGOING|2021-03-17
e|RS|47d55e87-e559-424d-a6ad-d533a0d77f39|2|BONERESP|Bone Response|IWG CHESON MDS 2000|||WORSENED|1|PFU/animal|HEMAGGLUTINATION ASSAY|||Y|INDEPENDENT ASSESSOR|MICROSCOPIST 1|Y|1|Visit_1|10|7|TREATMENT|2021-01-12|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-27|P1Y2M10DT2H30M|COINCIDENT|2021-02-11|COINCIDENT|2021-02-19
e|RS|47d55e87-e559-424d-a6ad-d533a0d77f39|3|DRCRIND|Disease Recurrence Indicator|MURPHY PROSTATE CANCER 1980|||PD/RELAPSE AFTER HI|1|IU/day|NUCLEIC ACID AMPLIFICATION TEST|Y||Y|INDEPENDENT ASSESSOR|MICROSCOPIST|Y|2|Visit_2|25|3|SCREENING|2021-01-27|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-17|P1Y2M10DT2H30M|UNKNOWN|2021-01-19|ONGOING|2021-02-15
e|RS|47d55e87-e559-424d-a6ad-d533a0d77f39|4|MRDRESP|Minimal Residual Disease Response|KUMAR IMWG 2016|[?]|keV|NE|1|mmol|FLUOROSCOPY||||INTERVIEWER|READER 1|NA|2|Visit_2|25|2|SCREENING|2021-01-27|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-17|P1Y2M10DT2H30M|UNKNOWN|2021-03-07|BEFORE|2021-03-25
e|RS|47d55e87-e559-424d-a6ad-d533a0d77f39|5|SPLNRESP|Spleen Response|IWC HALLEK CLL 2008|[?]|mAnson U/mL|STABLE|1|%|JAEGER EYE CHART|Y|||ADJUDICATION COMMITTEE|NEUROLOGIST|Y|3|Visit_3|40|4|TREATMENT|2021-02-11|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-01|P1Y2M10DT2H30M|AFTER|2021-02-03|ONGOING|2021-02-21
e|RS|47d55e87-e559-424d-a6ad-d533a0d77f39|6|MOLRESP|Molecular Response|HARTMANN GERM CELL CANCER 2002|||MOLECULAR MAJOR RESPONSE|1|/MBP|MICROPARTICLE ENZYME IMMUNOASSAY|||Y|SIBLING|ENDOCRINOLOGIST|U|3|Visit_3|40|3|TREATMENT|2021-02-11|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-01|P1Y2M10DT2H30M|BEFORE|2021-03-23|AFTER|2021-03-31
e|RS|47d55e87-e559-424d-a6ad-d533a0d77f39|7|MRDIND|Minimal Residual Disease Indicator|iRECIST|[?]|uCi|IMPROVED|1|s^-1(%O2)^-1|DC SHEATH FLOW||||INTERVIEWER|CLINICAL PATHOLOGIST|U|4|Visit_4|65|4|WASHOUT|2021-03-08|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-16|P1Y2M10DT2H30M|BEFORE|2021-02-14|BEFORE|2021-04-07
e|RS|47d55e87-e559-424d-a6ad-d533a0d77f39|8|MRPHRESP|Morphologic Response|AJCC V7|[?]|ug/cm2|HI-P|1|APL U/mL|REFLECTANCE SPECTROSCOPY|Y|Y||HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|N|4|Visit_4|65|3|FOLLOW-UP|2021-03-08|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-16|P1Y2M10DT2H30M|UNKNOWN|2021-04-10|BEFORE|2021-04-11
e|RS|47d55e87-e559-424d-a6ad-d533a0d77f39|9|BMIVLIND|Bone Marrow Involvement Indicator|HARTMANN GERM CELL CANCER 2002|||NON-iCR/NON-iUPD|1|10^12/L|MAPH||Y|Y|CLINICAL STUDY SPONSOR|MICROSCOPIST|NA|5|Visit_5|90|1|SCREENING|2021-04-02|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-20|P1Y2M10DT2H30M|AFTER|2021-03-23|COINCIDENT|2021-03-27
e|RS|47d55e87-e559-424d-a6ad-d533a0d77f39|10|BESTRESP|Best Overall Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|MPL U|CMR|1|COAT|MRI WITHOUT CONTRAST||||SIBLING|NEUROLOGIST 2|Y|5|Visit_5|90|5|TREATMENT|2021-04-02|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-20|P1Y2M10DT2H30M|COINCIDENT|2021-02-10|ONGOING|2021-03-07
e|RS|f89c08df-2e24-4c97-a451-1980cecebf14|1|NTNERESP|Non-Target Non-Enhancing Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|||CRi|1|kg/cm|TOTAL BODY IRRADIATION|||Y|INVESTIGATOR|MICROSCOPIST 2|U|1|Visit_1|10|2|TREATMENT|2020-12-18|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-13|P1Y2M10DT2H30M|COINCIDENT|2020-12-26|BEFORE|2021-03-08
e|RS|f89c08df-2e24-4c97-a451-1980cecebf14|2|MRPHRESP|Morphologic Response|MACDONALD GLIOMA 1990|[?]|BOWL|NON-CR/NON-PD|1|Enzyme U|IMMUNOBLOT|Y|||DOMESTIC PARTNER|ADJUDICATOR 1|Y|1|Visit_1|10|5|WASHOUT|2020-12-18|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-13|P1Y2M10DT2H30M|AFTER|2020-12-21|AFTER|2021-03-16
e|RS|f89c08df-2e24-4c97-a451-1980cecebf14|3|BMIVLIND|Bone Marrow Involvement Indicator|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|ug/min|CA125 75% RESPONSE|1|AU/mL|FARR ASSAY|Y|||HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|U|2|Visit_2|25|5|WASHOUT|2021-01-02|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-25|P1Y2M10DT2H30M|BEFORE|2021-02-05|AFTER|2021-03-16
e|RS|f89c08df-2e24-4c97-a451-1980cecebf14|4|BESTRESP|Best Overall Response|PERCIST|[?]|nmol BCE/nmol|INDETERMINATE RESPONSE|1|/40 HPFs|INCISION-INDUCED BLEEDING METHOD||||CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL PSYCHOLOGIST|N|2|Visit_2|25|4|SCREENING|2021-01-02|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-25|P1Y2M10DT2H30M|AFTER|2021-02-18|ONGOING|2021-02-20
e|RS|f89c08df-2e24-4c97-a451-1980cecebf14|5|NTERESP|Non-Target Enhancing Response|HARTMAN PANCREATIC CANCER 2012|||STABLE|1|PFU|GRAM STAIN|||Y|SIGNIFICANT OTHER|OTOLARYNGOLOGIST|NA|3|Visit_3|40|2|FOLLOW-UP|2021-01-17|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-22|P1Y2M10DT2H30M|AFTER|2021-03-02|ONGOING|2021-03-07
e|RS|f89c08df-2e24-4c97-a451-1980cecebf14|6|SPLNRESP|Spleen Response|MURPHY PROSTATE CANCER 1980|[?]|SQU/mL|MRD RELAPSE|1|uSiemens|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI||Y||SPOUSE|RADIOLOGIST|U|3|Visit_3|40|2|TREATMENT|2021-01-17|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-22|P1Y2M10DT2H30M|UNKNOWN|2021-02-09|BEFORE|2021-02-16
e|RS|f89c08df-2e24-4c97-a451-1980cecebf14|7|TRGRESP|Target Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|||MR|1|CFU/g|EPSILOMETER||Y|Y|PARENT|RATER|U|4|Visit_4|65|2|FOLLOW-UP|2021-02-11|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-24|P1Y2M10DT2H30M|COINCIDENT|2021-02-15|ONGOING|2021-02-16
e|RS|f89c08df-2e24-4c97-a451-1980cecebf14|8|MRPHRESP|Morphologic Response|RECICL|[?]|SPRAY|NR|1|mEq/dL|PULMONARY ANGIOGRAPHY||||GUARDIAN|CLINICAL PATHOLOGIST|U|4|Visit_4|65|2|FOLLOW-UP|2021-02-11|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-24|P1Y2M10DT2H30M|BEFORE|2020-12-18|ONGOING|2021-03-12
e|RS|f89c08df-2e24-4c97-a451-1980cecebf14|9|MNPTHIND|Minor Pathological Response Indicator|DOHNER AML 2010|[?]|mL/g/h|PD FROM PR|1|10^9 CFU/g|MIGET||||INTERVIEWER|OTOLARYNGOLOGIST|NA|5|Visit_5|90|2|SCREENING|2021-03-08|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-28|P1Y2M10DT2H30M|AFTER|2021-01-27|BEFORE|2021-03-09
e|RS|f89c08df-2e24-4c97-a451-1980cecebf14|10|NTLWIND|Non-Target Lesion Worsening Indicator|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|oz|EQUIVOCAL|1|Bq/mL|LISSAMINE GREEN STAIN|Y|||CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 3|Y|5|Visit_5|90|3|FOLLOW-UP|2021-03-08|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-28|P1Y2M10DT2H30M|AFTER|2021-01-31|ONGOING|2021-02-01
e|RS|dbb225ed-e322-4946-a60a-0fafd7e22953|1|SPLNRESP|Spleen Response|JACINTO CERVICAL CANCER 2007|[?]|eq|HI-P|1|uIU/L|INCISION-INDUCED BLEEDING METHOD||||STUDY SUBJECT|HEMATOLOGIST|N|1|Visit_1|10|7|SCREENING|2021-01-24|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-20|P1Y2M10DT2H30M|UNKNOWN|2021-02-12|ONGOING|2021-02-16
e|RS|dbb225ed-e322-4946-a60a-0fafd7e22953|2|TMRESP|Tumor Marker Response|SHINDOH COLORECTAL CANCER 2013|||PMR|1|BU|SCINTIGRAPHY|Y||Y|PARENT|OPTOMETRIST|Y|1|Visit_1|10|2|TREATMENT|2021-01-24|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-20|P1Y2M10DT2H30M|AFTER|2021-01-25|AFTER|2021-01-29
e|RS|dbb225ed-e322-4946-a60a-0fafd7e22953|3|MRPHRESP|Morphologic Response|MONTSERRAT CLL 1989|[?]|kBq|EQUIVOCAL|1|mL/beat|NUCLEIC ACID AMPLIFICATION TEST||||ADJUDICATION COMMITTEE|MICROSCOPIST 3|N|2|Visit_2|25|6|WASHOUT|2021-02-08|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-26|P1Y2M10DT2H30M|BEFORE|2021-02-02|COINCIDENT|2021-03-29
e|RS|dbb225ed-e322-4946-a60a-0fafd7e22953|4|MRPHRESP|Morphologic Response|IWC HALLEK CLL 2008|||MRD RELAPSE|1|USP U|KNEMOMETRY|Y|Y|Y|CAREGIVER|DERMATOLOGIST|NA|2|Visit_2|25|1|WASHOUT|2021-02-08|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-26|P1Y2M10DT2H30M|BEFORE|2021-02-13|ONGOING|2021-04-01
e|RS|dbb225ed-e322-4946-a60a-0fafd7e22953|5|MNPTHIND|Minor Pathological Response Indicator|DOHNER AML 2010|[?]|OD Unit|CR|1|Bq|GC/FID||||FRIEND|READER 1|Y|3|Visit_3|40|1|TREATMENT|2021-02-23|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-20|P1Y2M10DT2H30M|UNKNOWN|2021-01-16|BEFORE|2021-04-09
e|RS|dbb225ed-e322-4946-a60a-0fafd7e22953|6|NTLWIND|Non-Target Lesion Worsening Indicator|IWG CHESON MDS 2000|[?]|g/U|MOLECULAR CR|1|mg/kg/h|SPECULAR MICROSCOPY||Y||SPOUSE|CARDIOLOGIST|U|3|Visit_3|40|4|TREATMENT|2021-02-23|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-20|P1Y2M10DT2H30M|COINCIDENT|2021-03-28|COINCIDENT|2021-03-29
e|RS|dbb225ed-e322-4946-a60a-0fafd7e22953|7|MRPHRESP|Morphologic Response|RANO ELLINGSON 2017|[?]|mmol/min/kPa/L|PMR|1|days/month|CHROMOGENIC ASSAY||Y||PROXY|ADJUDICATOR 1|NA|4|Visit_4|65|3|TREATMENT|2021-03-20|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-04|P1Y2M10DT2H30M|UNKNOWN|2021-03-27|BEFORE|2021-04-11
e|RS|dbb225ed-e322-4946-a60a-0fafd7e22953|8|MRDIND|Minimal Residual Disease Indicator|MRECIST BYRNE MESOTHELIOMA 2004|[?]|BP|HI-P|1|copies/uL|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE||||DOMESTIC PARTNER|ADJUDICATOR 3|U|4|Visit_4|65|4|TREATMENT|2021-03-20|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-04|P1Y2M10DT2H30M|AFTER|2021-03-01|AFTER|2021-03-08
e|RS|dbb225ed-e322-4946-a60a-0fafd7e22953|9|RDIORESP|Radiologic Response|PCWG SCHER PROSTATE CANCER 2008|||SD-CT|1|ms2|QUANTITATIVE ULTRASOUND|||Y|HEALTH CARE PROFESSIONAL|READER 2|N|5|Visit_5|90|7|TREATMENT|2021-04-14|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-12|P1Y2M10DT2H30M|BEFORE|2021-02-16|COINCIDENT|2021-03-21
e|RS|dbb225ed-e322-4946-a60a-0fafd7e22953|10|MOLRESP|Molecular Response|KEAM BREAST CANCER 2013|[?]|BP|NON-QUANTIFIABLE MRD POSITIVITY|1|mL/mmHg/min/L|FISH||Y||FAMILY MEMBER|MICROSCOPIST|U|5|Visit_5|90|7|WASHOUT|2021-04-14|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-12|P1Y2M10DT2H30M|COINCIDENT|2021-04-23|ONGOING|2021-04-24
e|RS|95e61698-43f7-4cc5-aafa-06dac7870743|1|ANATRESP|Anatomic Response|IWG CHESON MDS 2000|||DECREASED|1|CAPFUL|PULMONARY ANGIOGRAPHY|||Y|SIBLING|DERMATOLOGIST|Y|1|Visit_1|10|5|SCREENING|2020-12-25|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-15|P1Y2M10DT2H30M|AFTER|2021-01-14|COINCIDENT|2021-02-13
e|RS|95e61698-43f7-4cc5-aafa-06dac7870743|2|MRDIND|Minimal Residual Disease Indicator|MRECIST BYRNE MESOTHELIOMA 2004|[?]|HEP|UNFAVORABLE RESPONSE|1|U/mg|GRADIENT DIFFUSION||||STUDY SUBJECT|DERMATOLOGIST|Y|1|Visit_1|10|1|TREATMENT|2020-12-25|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-15|P1Y2M10DT2H30M|AFTER|2021-01-29|ONGOING|2021-03-18
e|RS|95e61698-43f7-4cc5-aafa-06dac7870743|3|NTERESP|Non-Target Enhancing Response|BRUGGEMANN MRD 2010|[?]|L/day|PARTIAL MORPHOLOGIC RESPONSE|1|ugEq|DYNAMIC CONTRAST ENHANCED MRI||||CAREGIVER|DERMATOLOGIST|Y|2|Visit_2|25|1|TREATMENT|2021-01-09|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-08|P1Y2M10DT2H30M|UNKNOWN|2021-02-20|ONGOING|2021-02-28
e|RS|95e61698-43f7-4cc5-aafa-06dac7870743|4|MNPTHIND|Minor Pathological Response Indicator|RAJKUMAR MYELOMA 2011|[?]|USP U|iCR|1|/2500 WBC|WESTERGREN|Y|Y||INDEPENDENT ASSESSOR|HEMATOLOGIST|N|2|Visit_2|25|1|FOLLOW-UP|2021-01-09|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-08|P1Y2M10DT2H30M|AFTER|2021-01-08|AFTER|2021-01-24
e|RS|95e61698-43f7-4cc5-aafa-06dac7870743|5|SYMPTDTR|Symptomatic Deterioration|IWG CHESON MDS 2000|||WORSENED|1|NEEDLE GAUGE|CONTACT SPECULAR MICROSCOPY|Y||Y|INTERVIEWER|UROLOGIST|N|3|Visit_3|40|5|SCREENING|2021-01-24|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-10|P1Y2M10DT2H30M|AFTER|2021-02-18|ONGOING|2021-03-11
e|RS|95e61698-43f7-4cc5-aafa-06dac7870743|6|OVRLRESP|Overall Response|MRECIST BYRNE MESOTHELIOMA 2004|||UNFAVORABLE RESPONSE|1|umol/L/sec|ULTRASONOGRAPHIC ELASTOGRAPHY|||Y|SIBLING|ADJUDICATOR|NA|3|Visit_3|40|7|WASHOUT|2021-01-24|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-10|P1Y2M10DT2H30M|COINCIDENT|2021-03-20|ONGOING|2021-03-23
e|RS|95e61698-43f7-4cc5-aafa-06dac7870743|7|NTNERESP|Non-Target Non-Enhancing Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|||QUANTIFIABLE MRD POSITIVITY|1|/4.0 mL|ICP-MS|||Y|INTERVIEWER|NEUROLOGIST 2|N|4|Visit_4|65|6|FOLLOW-UP|2021-02-18|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-08|P1Y2M10DT2H30M|AFTER|2021-02-02|COINCIDENT|2021-02-10
e|RS|95e61698-43f7-4cc5-aafa-06dac7870743|8|NTRGRESP|Non-target Response|PETIT BREAST CANCER 2001|[?]|kUSP|iPR|1|Pack Year|LINE PROBE ASSAY||||PARENT|FORENSIC PATHOLOGIST|N|4|Visit_4|65|1|FOLLOW-UP|2021-02-18|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-08|P1Y2M10DT2H30M|COINCIDENT|2021-01-07|AFTER|2021-02-21
e|RS|95e61698-43f7-4cc5-aafa-06dac7870743|9|MNPTHIND|Minor Pathological Response Indicator|PRINCE TCELL LYMPHOMA 2010|[?]|10^3 RNA copies/mL|PARTIAL MORPHOLOGIC RESPONSE|1|10^6/L|SEQUENCING||Y||CHILD|INTERNIST|U|5|Visit_5|90|4|TREATMENT|2021-03-15|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-13|P1Y2M10DT2H30M|BEFORE|2021-02-06|COINCIDENT|2021-02-21
e|RS|95e61698-43f7-4cc5-aafa-06dac7870743|10|ANATRESP|Anatomic Response|MURPHY PROSTATE CANCER 1980|[?]|mEq/L|ABSENT MORPHOLOGIC RESPONSE|1|mmol2/L2|FORCED OSCILLATION TECHNIQUE||||INDEPENDENT ASSESSOR|MICROSCOPIST 3|NA|5|Visit_5|90|3|TREATMENT|2021-03-15|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-13|P1Y2M10DT2H30M|AFTER|2021-01-22|ONGOING|2021-02-09
e|RS|151308c7-03aa-4a0b-b13f-9838edb218ef|1|MRPHRESP|Morphologic Response|MACDONALD GLIOMA 1990|[?]|copies/ug|CA125 75% RESPONSE|1|kBq/uL|MICRODENSITOMETRY|Y|Y||FRIEND|READER 1|Y|1|Visit_1|10|3|TREATMENT|2020-09-13|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-09|P1Y2M10DT2H30M|AFTER|2020-09-27|AFTER|2020-11-01
e|RS|151308c7-03aa-4a0b-b13f-9838edb218ef|2|MJPTHIND|Major Pathological Response Indicator|CHOLLET BREAST CANCER 2002|||INCREASED|1|pptr|CELLULOSE TAPE|||Y|FRIEND|INTERNIST|U|1|Visit_1|10|1|WASHOUT|2020-09-13|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-09|P1Y2M10DT2H30M|AFTER|2020-10-22|COINCIDENT|2020-11-21
e|RS|151308c7-03aa-4a0b-b13f-9838edb218ef|3|BESTRESP|Best Overall Response|PCWG SCHER PROSTATE CANCER 2016|||TREATMENT FAILURE|1|L/s|LYMPHANGIOGRAPHY||Y|Y|CLINICAL STUDY SPONSOR|OPTOMETRIST|Y|2|Visit_2|25|7|TREATMENT|2020-09-28|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-31|P1Y2M10DT2H30M|BEFORE|2020-11-06|ONGOING|2020-11-22
e|RS|151308c7-03aa-4a0b-b13f-9838edb218ef|4|SYMPTDTR|Symptomatic Deterioration|WHO BREAST CANCER 2006|[?]|Arbitrary U|CYTOGENETIC NO RESPONSE|1|ng/L|CELL CYTOTOXICITY NEUTRALIZATION ASSAY||||SIBLING|NEUROLOGIST 1|N|2|Visit_2|25|4|SCREENING|2020-09-28|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-31|P1Y2M10DT2H30M|BEFORE|2020-10-15|BEFORE|2020-11-09
e|RS|151308c7-03aa-4a0b-b13f-9838edb218ef|5|MRDIND|Minimal Residual Disease Indicator|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|bel|PDu|1|ELISA unit|BRDU CELLULAR PROLIFERATION ASSAY||||CLINICAL RESEARCH COORDINATOR|CARDIOLOGIST|N|3|Visit_3|40|2|WASHOUT|2020-10-13|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-04|P1Y2M10DT2H30M|BEFORE|2020-09-14|AFTER|2020-11-25
e|RS|151308c7-03aa-4a0b-b13f-9838edb218ef|6|CPRFSTAT|Clinical Performance Status|GCIG RUSTIN OVARIAN CANCER 2011|||PR|1|ppm|HPLC/MS/MS|||Y|DOMESTIC PARTNER|DERMATOLOGIST|N|3|Visit_3|40|5|TREATMENT|2020-10-13|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-04|P1Y2M10DT2H30M|COINCIDENT|2020-11-30|ONGOING|2020-12-05
e|RS|151308c7-03aa-4a0b-b13f-9838edb218ef|7|METBRESP|Metabolic Response|MASS|[?]|damol/L|MRD RELAPSE|1|Ci/L|FLAME PHOTOMETRY|Y|Y||SIGNIFICANT OTHER|RADIOLOGIST 2|NA|4|Visit_4|65|3|SCREENING|2020-11-07|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-02|P1Y2M10DT2H30M|COINCIDENT|2020-10-12|BEFORE|2020-11-22
e|RS|151308c7-03aa-4a0b-b13f-9838edb218ef|8|OVRLRESP|Overall Response|HARTMANN GERM CELL CANCER 2002|||CYTOGENETIC CR|1|BE/mL|MRI WITHOUT CONTRAST|||Y|GUARDIAN|RADIOLOGIST 1|NA|4|Visit_4|65|2|SCREENING|2020-11-07|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-02|P1Y2M10DT2H30M|UNKNOWN|2020-10-16|AFTER|2020-12-06
e|RS|151308c7-03aa-4a0b-b13f-9838edb218ef|9|NEWLPROG|New Lesion Progression|SCHER PROSTATE CANCER 2011|[?]|g/animal/day|NON-CR/NON-PD|1|%(w/w)|CONFOCAL MICROSCOPY||||CHILD|DERMATOLOGIST|Y|5|Visit_5|90|3|SCREENING|2020-12-02|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-06|P1Y2M10DT2H30M|AFTER|2020-12-10|COINCIDENT|2020-12-11
e|RS|151308c7-03aa-4a0b-b13f-9838edb218ef|10|METSIND|Metastatic Indicator|PCWG SCHER PROSTATE CANCER 2008|[?]|in2|MORPHOLOGIC CR|1|g/animal/day|HPLC-UV||||SIBLING|CARDIOLOGIST|U|5|Visit_5|90|5|TREATMENT|2020-12-02|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-06|P1Y2M10DT2H30M|BEFORE|2020-09-09|AFTER|2020-10-23
e|RS|f38e0fff-e3f9-4687-b35b-f11f58b2b5f5|1|MJPTHIND|Major Pathological Response Indicator|WHO BREAST CANCER 2006|[?]|nmol/mL/min|CMR|1|umol/L|IMMUNOCHEMILUMINOMETRIC ASSAY|Y|||ADJUDICATION COMMITTEE|READER 1|U|1|Visit_1|10|2|TREATMENT|2020-06-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-15|P1Y2M10DT2H30M|BEFORE|2020-08-20|AFTER|2020-08-26
e|RS|f38e0fff-e3f9-4687-b35b-f11f58b2b5f5|2|BONERESP|Bone Response|CHESON CLL 2012|[?]|grain|NED|1|days/month|HANSEL STAIN||||GUARDIAN|OPHTHALMOLOGIST|Y|1|Visit_1|10|5|TREATMENT|2020-06-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-15|P1Y2M10DT2H30M|AFTER|2020-08-07|COINCIDENT|2020-08-22
e|RS|f38e0fff-e3f9-4687-b35b-f11f58b2b5f5|3|CLINRESP|Clinical Response|CHESON CLL 2012|[?]|10^6 IU/mL|CYTOGENETIC MINIMAL RESPONSE|1|CFU/g|PULMONARY ANGIOGRAPHY||||GUARDIAN|UROLOGIST|Y|2|Visit_2|25|2|FOLLOW-UP|2020-06-30|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-08|P1Y2M10DT2H30M|UNKNOWN|2020-09-01|BEFORE|2020-09-09
e|RS|f38e0fff-e3f9-4687-b35b-f11f58b2b5f5|4|LIVRRESP|Liver Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|cP|CA125 50% RESPONSE|1|10^6 CFU/mL|TRIPLE-PHASE MRI SCAN||||CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 1|N|2|Visit_2|25|4|SCREENING|2020-06-30|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-08|P1Y2M10DT2H30M|BEFORE|2020-07-12|ONGOING|2020-08-28
e|RS|f38e0fff-e3f9-4687-b35b-f11f58b2b5f5|5|BESTRESP|Best Overall Response|FAROOQUI SUPP CLL 2014|[?]|breaths/30s|SD|1|nU/cL|PLAQUE REDUCTION NEUTRALIZATION ASSAY||||CLINICAL RESEARCH ASSOCIATE|HEMATOLOGIST|NA|3|Visit_3|40|6|SCREENING|2020-07-15|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-26|P1Y2M10DT2H30M|AFTER|2020-07-06|ONGOING|2020-08-15
e|RS|f38e0fff-e3f9-4687-b35b-f11f58b2b5f5|6|BMIVLIND|Bone Marrow Involvement Indicator|UNSPECIFIED|||CR|1|TROCHE|LASER CAPTURE MICRODISSECTION|||Y|STUDY SUBJECT|MICROSCOPIST 3|Y|3|Visit_3|40|5|TREATMENT|2020-07-15|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-26|P1Y2M10DT2H30M|UNKNOWN|2020-07-31|ONGOING|2020-08-11
e|RS|f38e0fff-e3f9-4687-b35b-f11f58b2b5f5|7|TMRESP|Tumor Marker Response|CHESON CLL 2012|[?]|10^7 TCID 50/dose|NR|1|Bq/g|CINEANGIOGRAPHY||||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR|N|4|Visit_4|65|3|TREATMENT|2020-08-09|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-27|P1Y2M10DT2H30M|BEFORE|2020-07-12|COINCIDENT|2020-08-07
e|RS|f38e0fff-e3f9-4687-b35b-f11f58b2b5f5|8|MNPTHIND|Minor Pathological Response Indicator|GCIG RUSTIN OVARIAN CANCER 2011|||NE|1|eq|IMMUNOPRECIPITATION|||Y|CLINICAL STUDY SPONSOR|RATER 2|Y|4|Visit_4|65|7|FOLLOW-UP|2020-08-09|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-27|P1Y2M10DT2H30M|BEFORE|2020-08-01|BEFORE|2020-08-05
e|RS|f38e0fff-e3f9-4687-b35b-f11f58b2b5f5|9|CPRFSTAT|Clinical Performance Status|IWG CHESON MDS 2000|[?]|V|SMD|1|ug/h|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN||||INVESTIGATOR|ONCOLOGIST|NA|5|Visit_5|90|6|SCREENING|2020-09-03|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-01|P1Y2M10DT2H30M|AFTER|2020-07-02|BEFORE|2020-08-28
e|RS|f38e0fff-e3f9-4687-b35b-f11f58b2b5f5|10|MOLRESP|Molecular Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|ppm|CHR|1|PATCH|OPTICAL MAPPING||||ADJUDICATOR|CARDIOLOGIST|Y|5|Visit_5|90|2|TREATMENT|2020-09-03|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-01|P1Y2M10DT2H30M|UNKNOWN|2020-08-27|ONGOING|2020-08-31
e|RS|23605586-1b30-4f05-bb15-417dd3a79994|1|ANATRESP|Anatomic Response|DURIE MULTIPLE MYELOMA 2006|[?]|10^9 CFU|CMR|1|10^9 organisms|CONGO RED STAIN||||VENDOR|MICROSCOPIST|U|1|Visit_1|10|2|SCREENING|2020-10-31|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-23|P1Y2M10DT2H30M|UNKNOWN|2021-01-07|BEFORE|2021-01-19
e|RS|23605586-1b30-4f05-bb15-417dd3a79994|2|STRUSTAT|Steroid Use Status|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|||STABLE|1|Roentgen|FLUORESCEIN STAIN|||Y|CLINICAL RESEARCH ASSOCIATE|INTERNIST|NA|1|Visit_1|10|5|SCREENING|2020-10-31|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-23|P1Y2M10DT2H30M|COINCIDENT|2020-12-26|ONGOING|2020-12-28
e|RS|23605586-1b30-4f05-bb15-417dd3a79994|3|SYMPTDTR|Symptomatic Deterioration|PCWG SCHER PROSTATE CANCER 2016|[?]|10^6/hpf|PR-CT|1|deg|SPIROMETRY||||DOMESTIC PARTNER|MICROSCOPIST|NA|2|Visit_2|25|4|TREATMENT|2020-11-15|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-28|P1Y2M10DT2H30M|UNKNOWN|2020-12-09|ONGOING|2021-01-12
e|RS|23605586-1b30-4f05-bb15-417dd3a79994|4|NEWLWIND|New Lesion Worsening Indicator|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|/VF|RELAPSED DISEASE|1|Log10 ELISA unit/dose|VENTILATION PERFUSION LUNG SCAN||Y||CAREGIVER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|2|Visit_2|25|7|TREATMENT|2020-11-15|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-28|P1Y2M10DT2H30M|BEFORE|2020-11-09|ONGOING|2021-01-04
e|RS|23605586-1b30-4f05-bb15-417dd3a79994|5|DRCRIND|Disease Recurrence Indicator|CHESON CLL 2012|[?]|F|MORPHOLOGIC CR|1|F|MICROBIAL CULTURE||Y||INVESTIGATOR|PATHOLOGIST 2|Y|3|Visit_3|40|6|FOLLOW-UP|2020-11-30|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-26|P1Y2M10DT2H30M|BEFORE|2020-12-05|ONGOING|2020-12-19
e|RS|23605586-1b30-4f05-bb15-417dd3a79994|6|LIVRRESP|Liver Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|CAPSULE|VGPR|1|10^6 organisms/g|SPECT/CT SCAN||||FAMILY MEMBER|RATER|NA|3|Visit_3|40|7|TREATMENT|2020-11-30|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-26|P1Y2M10DT2H30M|COINCIDENT|2020-12-19|ONGOING|2021-01-10
e|RS|23605586-1b30-4f05-bb15-417dd3a79994|7|METSIND|Metastatic Indicator|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|cup eq|INDETERMINATE RESPONSE|1|g/m2|CELL OF ORIGIN ASSAY|Y|||INVESTIGATOR|RADIOLOGIST 1|U|4|Visit_4|65|6|SCREENING|2020-12-25|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-30|P1Y2M10DT2H30M|AFTER|2021-01-28|COINCIDENT|2021-01-29
e|RS|23605586-1b30-4f05-bb15-417dd3a79994|8|NTERESP|Non-Target Enhancing Response|DOHNER AML 2010|[?]|gpELISA unit/mL|ABSENT MORPHOLOGIC RESPONSE|1|ukat/10^12 RBC|WHOLE GENOME SEQUENCING||||ADJUDICATION COMMITTEE|ENDOCRINOLOGIST|N|4|Visit_4|65|4|FOLLOW-UP|2020-12-25|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-30|P1Y2M10DT2H30M|UNKNOWN|2020-12-15|COINCIDENT|2021-01-10
e|RS|23605586-1b30-4f05-bb15-417dd3a79994|9|ANATRESP|Anatomic Response|HAMAOKA BREAST CANCER 2010|[?]|h*%|PSA PROGRESSION|1|CIGAR|EPSILOMETER||Y||VENDOR|READER 3|NA|5|Visit_5|90|7|TREATMENT|2021-01-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-28|P1Y2M10DT2H30M|BEFORE|2020-11-27|BEFORE|2021-01-18
e|RS|23605586-1b30-4f05-bb15-417dd3a79994|10|ANATRESP|Anatomic Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|fraction of 1|CYTOGENETIC MINIMAL RESPONSE|1|Ci/g|INTERRUPTER TECHNIQUE|Y|||INDEPENDENT ASSESSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|5|Visit_5|90|6|SCREENING|2021-01-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-28|P1Y2M10DT2H30M|COINCIDENT|2020-11-27|BEFORE|2020-12-24
e|RS|57d15ac0-06a6-40e0-9201-4d947651c9b0|1|MRPHRESP|Morphologic Response|iRECIST|[?]|/MBP|UNEQUIVOCAL|1|mCi/kg|VIRUS PLAQUE ASSAY||||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 2|Y|1|Visit_1|10|6|FOLLOW-UP|2020-08-28|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-28|P1Y2M10DT2H30M|UNKNOWN|2020-10-09|COINCIDENT|2020-10-18
e|RS|57d15ac0-06a6-40e0-9201-4d947651c9b0|2|MRDRESP|Minimal Residual Disease Response|GUILHOT CML 2007|[?]|gpELISA unit/mL|PD-CT|1|m|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|Y|Y||CAREGIVER|OPTOMETRIST|N|1|Visit_1|10|5|WASHOUT|2020-08-28|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-28|P1Y2M10DT2H30M|BEFORE|2020-11-23|ONGOING|2020-11-24
e|RS|57d15ac0-06a6-40e0-9201-4d947651c9b0|3|MRDRESP|Minimal Residual Disease Response|NCIWG CHESON CLL 1996|[?]|10^9 organisms|EQUIVOCAL|1|mEq/ug|PULMONARY ANGIOGRAPHY|Y|Y||INTERVIEWER|RADIOLOGIST 1|NA|2|Visit_2|25|7|SCREENING|2020-09-12|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-04|P1Y2M10DT2H30M|BEFORE|2020-11-25|AFTER|2020-11-26
e|RS|57d15ac0-06a6-40e0-9201-4d947651c9b0|4|NTERESP|Non-Target Enhancing Response|PRINCE TCELL LYMPHOMA 2010|[?]|10^6 organisms/mL|HI-N|1|uL/mL|ROMANOWSKY STAIN||||ADJUDICATOR|PATHOLOGIST|U|2|Visit_2|25|3|TREATMENT|2020-09-12|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-04|P1Y2M10DT2H30M|UNKNOWN|2020-08-24|BEFORE|2020-11-13
e|RS|57d15ac0-06a6-40e0-9201-4d947651c9b0|5|BMIVLIND|Bone Marrow Involvement Indicator|CHESON MALIGNANT LYMPHOMA 2007|[?]|g/L|NON-PD|1|cycle/min|GC/MS/MS||||CAREGIVER|RADIOLOGIST 1|NA|3|Visit_3|40|4|SCREENING|2020-09-27|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-28|P1Y2M10DT2H30M|COINCIDENT|2020-10-01|BEFORE|2020-11-19
e|RS|57d15ac0-06a6-40e0-9201-4d947651c9b0|6|NTRGRESP|Non-target Response|HARTMAN PANCREATIC CANCER 2012|[?]|AMPULE|PR-CT|1|vg/mL|CELLULAR PROLIFERATION ASSAY||||GUARDIAN|ADJUDICATOR 2|NA|3|Visit_3|40|1|FOLLOW-UP|2020-09-27|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-28|P1Y2M10DT2H30M|UNKNOWN|2020-11-03|BEFORE|2020-11-25
e|RS|57d15ac0-06a6-40e0-9201-4d947651c9b0|7|LIVRRESP|Liver Response|PETIT BREAST CANCER 2001|[?]|vp/dose|PSEUDORESPONSE|1|dmol|OSCILLOMETRY||||SPOUSE|ONCOLOGIST 2|NA|4|Visit_4|65|5|WASHOUT|2020-10-22|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-12|P1Y2M10DT2H30M|COINCIDENT|2020-10-12|BEFORE|2020-11-15
e|RS|57d15ac0-06a6-40e0-9201-4d947651c9b0|8|MOLRESP|Molecular Response|CHESON CLL 2012|[?]|L/kg|MOLECULAR MAJOR RESPONSE|1|Mile|ELECTROCHEMILUMINESCENCE IMMUNOASSAY|Y|Y||INDEPENDENT ASSESSOR|READER 2|U|4|Visit_4|65|5|WASHOUT|2020-10-22|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-12|P1Y2M10DT2H30M|COINCIDENT|2020-10-14|COINCIDENT|2020-10-30
e|RS|57d15ac0-06a6-40e0-9201-4d947651c9b0|9|MJPTHIND|Major Pathological Response Indicator|EBMT BLADE MYELOMA 1998|[?]|mg/dL|MORPHOLOGIC CRi|1|/10^5|GC/MS|Y|||ADJUDICATION COMMITTEE|PATHOLOGIST 2|U|5|Visit_5|90|5|TREATMENT|2020-11-16|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-18|P1Y2M10DT2H30M|AFTER|2020-11-09|BEFORE|2020-11-25
e|RS|57d15ac0-06a6-40e0-9201-4d947651c9b0|10|NTERESP|Non-Target Enhancing Response|DURIE MULTIPLE MYELOMA 2006|[?]|cm2|PSA PROGRESSION|1|L/s/kPa|HPLC/IEX||||CLINICAL STUDY SPONSOR|ONCOLOGIST 1|NA|5|Visit_5|90|5|WASHOUT|2020-11-16|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-18|P1Y2M10DT2H30M|UNKNOWN|2020-11-11|AFTER|2020-11-12
e|RS|7dbd7e4e-12c2-48c2-9ac2-4d9176922722|1|NEWLIND|New Lesion Indicator|WOLCHOK SOLID TUMORS 2009|[?]|ug/L/h|EQUIVOCAL|1|MESF|AUTOREFRACTION||Y||SIGNIFICANT OTHER|OPTOMETRIST|Y|1|Visit_1|10|3|WASHOUT|2020-08-12|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-16|P1Y2M10DT2H30M|BEFORE|2020-10-30|AFTER|2020-11-05
e|RS|7dbd7e4e-12c2-48c2-9ac2-4d9176922722|2|MRPHRESP|Morphologic Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|||MOLECULAR MAJOR RESPONSE|1|10^4/hpf|HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY|||Y|CHILD|UROLOGIST|Y|1|Visit_1|10|6|SCREENING|2020-08-12|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-16|P1Y2M10DT2H30M|COINCIDENT|2020-09-19|ONGOING|2020-09-22
e|RS|7dbd7e4e-12c2-48c2-9ac2-4d9176922722|3|OVRLRESP|Overall Response|DURIE MULTIPLE MYELOMA 2006|[?]|DISK|INDETERMINATE RESPONSE|1|STRIP|WRIGHT STAIN||||SIBLING|CARDIOLOGIST|Y|2|Visit_2|25|6|WASHOUT|2020-08-27|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-24|P1Y2M10DT2H30M|AFTER|2020-09-28|AFTER|2020-10-18
e|RS|7dbd7e4e-12c2-48c2-9ac2-4d9176922722|4|STRUSTAT|Steroid Use Status|WHO BREAST CANCER 2006|||pCR|1|mL/dose|INCISION-INDUCED BLEEDING METHOD|||Y|CLINICAL STUDY SPONSOR|READER|NA|2|Visit_2|25|1|SCREENING|2020-08-27|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-24|P1Y2M10DT2H30M|COINCIDENT|2020-10-07|ONGOING|2020-10-23
e|RS|7dbd7e4e-12c2-48c2-9ac2-4d9176922722|5|RDIORESP|Radiologic Response|GUILHOT CML 2007|[?]|PACK|PARTIAL MORPHOLOGIC RESPONSE|1|kcal/day|WESTERGREN||Y||HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|NA|3|Visit_3|40|5|TREATMENT|2020-09-11|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-15|P1Y2M10DT2H30M|COINCIDENT|2020-10-26|COINCIDENT|2020-11-06
e|RS|7dbd7e4e-12c2-48c2-9ac2-4d9176922722|6|MNPTHIND|Minor Pathological Response Indicator|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|NEBULE|RELAPSED DISEASE FROM CR OR PR|1|Bq/g|SLIT LAMP||||VENDOR|ONCOLOGIST 1|Y|3|Visit_3|40|1|TREATMENT|2020-09-11|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-15|P1Y2M10DT2H30M|BEFORE|2020-09-11|COINCIDENT|2020-09-19
e|RS|7dbd7e4e-12c2-48c2-9ac2-4d9176922722|7|MRDRESP|Minimal Residual Disease Response|RANO ELLINGSON 2017|[?]|Newton|MORPHOLOGIC CRi|1|DIOPTER|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI|Y|||ADJUDICATOR|READER|NA|4|Visit_4|65|4|TREATMENT|2020-10-06|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-08|P1Y2M10DT2H30M|UNKNOWN|2020-09-26|BEFORE|2020-11-09
e|RS|7dbd7e4e-12c2-48c2-9ac2-4d9176922722|8|OVRLRESP|Overall Response|PERCIST|[?]|10^9 CFU/mL|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|ng/mol|FLOW CYTOMETRY|Y|||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 3|N|4|Visit_4|65|3|FOLLOW-UP|2020-10-06|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-08|P1Y2M10DT2H30M|AFTER|2020-10-11|ONGOING|2020-11-08
e|RS|7dbd7e4e-12c2-48c2-9ac2-4d9176922722|9|NEWLWIND|New Lesion Worsening Indicator|GUILHOT CML 2007|||PR-CT|1|uV2|GRADIENT DIFFUSION|||Y|CAREGIVER|ADJUDICATOR|U|5|Visit_5|90|6|TREATMENT|2020-10-31|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-26|P1Y2M10DT2H30M|BEFORE|2020-09-24|COINCIDENT|2020-11-01
e|RS|7dbd7e4e-12c2-48c2-9ac2-4d9176922722|10|PATHRESP|Pathologic Response|CHESON LYMPHOMA 2008|[?]|tsp|ABSENT MORPHOLOGIC RESPONSE|1|mg/min|CENTRIFUGATION||||VENDOR|RATER 2|NA|5|Visit_5|90|7|TREATMENT|2020-10-31|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-26|P1Y2M10DT2H30M|COINCIDENT|2020-10-15|ONGOING|2020-10-21
e|RS|5dbb73e4-6e14-45c4-bcaa-2c571199c74f|1|BONERESP|Bone Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|LB|PR WITH LYMPHOCYTOSIS|1|ng/L|CT SCAN||||FRIEND|FORENSIC PATHOLOGIST|U|1|Visit_1|10|3|TREATMENT|2020-08-31|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-11|P1Y2M10DT2H30M|UNKNOWN|2020-09-17|BEFORE|2020-11-27
e|RS|5dbb73e4-6e14-45c4-bcaa-2c571199c74f|2|MRDIND|Minimal Residual Disease Indicator|CHESON CLL 2012|[?]|oz|PARTIAL MORPHOLOGIC RESPONSE|1|log10 TCID 50/uL|IMMUNOCHROMATOGRAPHY||||INDEPENDENT ASSESSOR|RATER 2|NA|1|Visit_1|10|5|TREATMENT|2020-08-31|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-11|P1Y2M10DT2H30M|BEFORE|2020-09-18|COINCIDENT|2020-09-20
e|RS|5dbb73e4-6e14-45c4-bcaa-2c571199c74f|3|TMRESP|Tumor Marker Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|Tesla|QUANTIFIABLE MRD POSITIVITY|1|mmol/kg|CRYOSCOPY||||CLINICAL RESEARCH ASSOCIATE|HEMATOLOGIST|N|2|Visit_2|25|5|SCREENING|2020-09-15|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-24|P1Y2M10DT2H30M|BEFORE|2020-11-18|AFTER|2020-11-28
e|RS|5dbb73e4-6e14-45c4-bcaa-2c571199c74f|4|TMRESP|Tumor Marker Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|ukat/10^12 RBC|iUPD|1|PUFF|KINETIC CHROMOGENIC ASSAY|Y|||CAREGIVER|RADIOLOGIST 1|U|2|Visit_2|25|5|WASHOUT|2020-09-15|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-24|P1Y2M10DT2H30M|COINCIDENT|2020-11-01|BEFORE|2020-11-10
e|RS|5dbb73e4-6e14-45c4-bcaa-2c571199c74f|5|OVRLRESP|Overall Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|FEU|NE|1|nmol/L/min|FLUORESCENT MICROSCOPY||||ADJUDICATOR|NEUROLOGIST 2|U|3|Visit_3|40|5|TREATMENT|2020-09-30|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-23|P1Y2M10DT2H30M|AFTER|2020-11-18|COINCIDENT|2020-11-27
e|RS|5dbb73e4-6e14-45c4-bcaa-2c571199c74f|6|ANATRESP|Anatomic Response|NCCN ALL MRD 2014|[?]|EVENTS|RELAPSED DISEASE FROM CR|1|cm/s|LC/MS/MS||||CAREGIVER|FORENSIC PATHOLOGIST|N|3|Visit_3|40|5|SCREENING|2020-09-30|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-23|P1Y2M10DT2H30M|UNKNOWN|2020-10-18|COINCIDENT|2020-11-08
e|RS|5dbb73e4-6e14-45c4-bcaa-2c571199c74f|7|MRDIND|Minimal Residual Disease Indicator|PRINCE TCELL LYMPHOMA 2010|[?]|dyn|VGPR|1|L/s|HIGH RESOLUTION CT||||CAREGIVER|DEVELOPMENTAL PSYCHOLOGIST|NA|4|Visit_4|65|6|SCREENING|2020-10-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-23|P1Y2M10DT2H30M|AFTER|2020-11-03|COINCIDENT|2020-11-08
e|RS|5dbb73e4-6e14-45c4-bcaa-2c571199c74f|8|SYMPTDTR|Symptomatic Deterioration|BRUGGEMANN MRD 2010|||MR|1|PA|TELLER ACUITY CARDS||Y|Y|FAMILY MEMBER|READER 3|N|4|Visit_4|65|3|TREATMENT|2020-10-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-23|P1Y2M10DT2H30M|AFTER|2020-10-08|ONGOING|2020-10-12
e|RS|5dbb73e4-6e14-45c4-bcaa-2c571199c74f|9|HEMARESP|Hematologic Response|CHESON LYMPHOMA 2008|[?]|EID 50/dose|PDu|1|msec|IMMUNOFIXATION ELECTROPHORESIS|Y|Y||PARENT|OPHTHALMOLOGIST|Y|5|Visit_5|90|5|WASHOUT|2020-11-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-10|P1Y2M10DT2H30M|BEFORE|2020-09-14|ONGOING|2020-11-09
e|RS|5dbb73e4-6e14-45c4-bcaa-2c571199c74f|10|NTNERESP|Non-Target Non-Enhancing Response|LUGANO CLASSIFICATION|[?]|pmol/day|CR-CT|1|ug/h|CONTACT SPECULAR MICROSCOPY||||PROXY|OPHTHALMOLOGIST|N|5|Visit_5|90|4|TREATMENT|2020-11-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-10|P1Y2M10DT2H30M|UNKNOWN|2020-09-29|AFTER|2020-10-31
e|RS|ec2c7d40-5bcb-408d-bf6c-77667a92e2d1|1|NTERESP|Non-Target Enhancing Response|PETIT BREAST CANCER 2001|[?]|ug/g/day|UNEQUIVOCAL|1|umol/L/h|VENTILATION PERFUSION LUNG SCAN||||HEALTH CARE PROFESSIONAL|MICROSCOPIST|U|1|Visit_1|10|7|SCREENING|2020-12-24|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-16|P1Y2M10DT2H30M|BEFORE|2021-03-03|AFTER|2021-03-07
e|RS|ec2c7d40-5bcb-408d-bf6c-77667a92e2d1|2|HEMARESP|Hematologic Response|SHINDOH COLORECTAL CANCER 2013|[?]|mg/mol|sCR|1|GBq/mg|APPLANATION TONOMETRY||||NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|Y|1|Visit_1|10|3|SCREENING|2020-12-24|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-16|P1Y2M10DT2H30M|BEFORE|2021-02-24|ONGOING|2021-03-16
e|RS|ec2c7d40-5bcb-408d-bf6c-77667a92e2d1|3|PATHRESP|Pathologic Response|NCIWG CHESON CLL 1996|[?]|TAMPON|CA125 75% RESPONSE|1|log10 PFU|TURBIDIMETRY||||SIBLING|DERMATOLOGIST|NA|2|Visit_2|25|7|TREATMENT|2021-01-08|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-23|P1Y2M10DT2H30M|COINCIDENT|2021-03-13|ONGOING|2021-03-20
e|RS|ec2c7d40-5bcb-408d-bf6c-77667a92e2d1|4|PATHRESP|Pathologic Response|JACINTO CERVICAL CANCER 2007|[?]|AgU/mL|CYTOGENETIC MINIMAL RESPONSE|1|mmHg/L/min|IMMUNOASSAY||||CAREGIVER|PATHOLOGIST 2|U|2|Visit_2|25|7|TREATMENT|2021-01-08|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-23|P1Y2M10DT2H30M|BEFORE|2021-02-05|COINCIDENT|2021-03-03
e|RS|ec2c7d40-5bcb-408d-bf6c-77667a92e2d1|5|OVRLRESP|Overall Response|PCWG SCHER PROSTATE CANCER 2008|||NED|1|mCi/L|IVY INCISION METHOD|||Y|CLINICAL RESEARCH COORDINATOR|HEMATOLOGIST|NA|3|Visit_3|40|5|WASHOUT|2021-01-23|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-04|P1Y2M10DT2H30M|BEFORE|2021-01-10|AFTER|2021-02-13
e|RS|ec2c7d40-5bcb-408d-bf6c-77667a92e2d1|6|OVRLRESP|Overall Response|KUKER LYMPHOMA 2005|[?]|kat|INDETERMINATE RESPONSE|1|Tesla|MAPH||||NON-HEALTH CARE PROFESSIONAL|OPTOMETRIST|NA|3|Visit_3|40|6|FOLLOW-UP|2021-01-23|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-04|P1Y2M10DT2H30M|BEFORE|2021-03-06|COINCIDENT|2021-03-23
e|RS|ec2c7d40-5bcb-408d-bf6c-77667a92e2d1|7|PATHRESP|Pathologic Response|HARTMAN PANCREATIC CANCER 2012|[?]|GBq|PMR|1|umol/L/sec|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|Y|||INDEPENDENT ASSESSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|4|Visit_4|65|3|WASHOUT|2021-02-17|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-09|P1Y2M10DT2H30M|AFTER|2021-01-04|ONGOING|2021-02-12
e|RS|ec2c7d40-5bcb-408d-bf6c-77667a92e2d1|8|TMRESP|Tumor Marker Response|CHESON CLL 2006|||CYTOGENETIC PR|1|RFU|NON-CONTACT SPECULAR MICROSCOPY|Y||Y|FAMILY MEMBER|RADIOLOGIST|Y|4|Visit_4|65|7|TREATMENT|2021-02-17|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-09|P1Y2M10DT2H30M|BEFORE|2021-01-02|AFTER|2021-01-21
e|RS|ec2c7d40-5bcb-408d-bf6c-77667a92e2d1|9|CYTORESP|Cytogenetic Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|usec|iCR|1|umol/min|NUCLEIC ACID SEQUENCING||||SIGNIFICANT OTHER|CARDIOLOGIST|N|5|Visit_5|90|2|SCREENING|2021-03-14|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-07|P1Y2M10DT2H30M|BEFORE|2021-01-18|ONGOING|2021-02-22
e|RS|ec2c7d40-5bcb-408d-bf6c-77667a92e2d1|10|SYMPTDTR|Symptomatic Deterioration|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|||QUANTIFIABLE MRD POSITIVITY|1|10^3 CFU/g|PET/MRI SCAN|Y||Y|CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|5|Visit_5|90|5|FOLLOW-UP|2021-03-14|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-07|P1Y2M10DT2H30M|UNKNOWN|2021-01-24|ONGOING|2021-01-27
e|RS|24c65d59-8d34-4d91-bf0b-6fc6aaaab8ae|1|TMRESP|Tumor Marker Response|JACINTO CERVICAL CANCER 2007|[?]|L/day|pCR|1|ms2|FLOW CYTOMETRY|Y|||PROXY|ENDOCRINOLOGIST|N|1|Visit_1|10|2|TREATMENT|2020-07-02|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-31|P1Y2M10DT2H30M|BEFORE|2020-07-20|COINCIDENT|2020-07-28
e|RS|24c65d59-8d34-4d91-bf0b-6fc6aaaab8ae|2|LIVRRESP|Liver Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|g|MOLECULAR MAJOR RESPONSE|1|pmol/day|SPIRAL CT SCAN WITHOUT CONTRAST||||SIGNIFICANT OTHER|PEDIATRIC NEUROLOGIST|N|1|Visit_1|10|6|TREATMENT|2020-07-02|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-31|P1Y2M10DT2H30M|AFTER|2020-08-10|ONGOING|2020-09-16
e|RS|24c65d59-8d34-4d91-bf0b-6fc6aaaab8ae|3|OVRLRESP|Overall Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|BAG|MOLECULAR MAJOR RESPONSE|1|AU/mL|ERGOSPIROMETRY|Y|||CLINICAL RESEARCH COORDINATOR|OTOLARYNGOLOGIST|N|2|Visit_2|25|5|WASHOUT|2020-07-17|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-21|P1Y2M10DT2H30M|BEFORE|2020-07-24|BEFORE|2020-08-04
e|RS|24c65d59-8d34-4d91-bf0b-6fc6aaaab8ae|4|NTERESP|Non-Target Enhancing Response|WOLCHOK SOLID TUMORS 2009|||MRD NEGATIVITY|1|g/U|ENZYMATIC COLORIMETRY|||Y|FAMILY MEMBER|PEDIATRIC NEUROLOGIST|N|2|Visit_2|25|6|FOLLOW-UP|2020-07-17|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-21|P1Y2M10DT2H30M|AFTER|2020-09-21|ONGOING|2020-09-23
e|RS|24c65d59-8d34-4d91-bf0b-6fc6aaaab8ae|5|NEWLWIND|New Lesion Worsening Indicator|MURPHY PROSTATE CANCER 1980|[?]|L/min/m2|INCREASED|1|BU|CYSTOSCOPY||||SIGNIFICANT OTHER|RADIOLOGIST|Y|3|Visit_3|40|3|TREATMENT|2020-08-01|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-08|P1Y2M10DT2H30M|AFTER|2020-09-02|ONGOING|2020-09-19
e|RS|24c65d59-8d34-4d91-bf0b-6fc6aaaab8ae|6|NEWLIND|New Lesion Indicator|EASL BRUIX LIVER CANCER 2001|||CA125 50% RESPONSE|1|tsp|FLOW MICROSCOPY|||Y|ADJUDICATION COMMITTEE|NEUROLOGIST 2|NA|3|Visit_3|40|2|FOLLOW-UP|2020-08-01|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-08|P1Y2M10DT2H30M|COINCIDENT|2020-07-01|AFTER|2020-07-07
e|RS|24c65d59-8d34-4d91-bf0b-6fc6aaaab8ae|7|MOLRESP|Molecular Response|LUGANO CLASSIFICATION|||CA125 50% RESPONSE|1|PATCH|WESTERGREN|Y||Y|SIBLING|OPTOMETRIST|NA|4|Visit_4|65|6|WASHOUT|2020-08-26|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-13|P1Y2M10DT2H30M|BEFORE|2020-06-28|AFTER|2020-07-22
e|RS|24c65d59-8d34-4d91-bf0b-6fc6aaaab8ae|8|METBRESP|Metabolic Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|Mile|iPR|1|ka_u/dL|COULOMETRIC TITRATION|Y|||INTERVIEWER|MICROSCOPIST 1|Y|4|Visit_4|65|5|TREATMENT|2020-08-26|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-13|P1Y2M10DT2H30M|BEFORE|2020-08-01|COINCIDENT|2020-08-26
e|RS|24c65d59-8d34-4d91-bf0b-6fc6aaaab8ae|9|NTRGRESP|Non-target Response|MASS|[?]|FFU|MR|1|ELISA unit|URANYL ACETATE STAIN||||STUDY SUBJECT|UROLOGIST|Y|5|Visit_5|90|2|TREATMENT|2020-09-20|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-17|P1Y2M10DT2H30M|AFTER|2020-07-17|BEFORE|2020-09-07
e|RS|24c65d59-8d34-4d91-bf0b-6fc6aaaab8ae|10|NTERESP|Non-Target Enhancing Response|PRINCE TCELL LYMPHOMA 2010|||EQUIVOCAL|1|pg/cell|CYSTOSCOPY|||Y|CHILD|PEDIATRIC NEUROLOGIST|Y|5|Visit_5|90|3|TREATMENT|2020-09-20|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-17|P1Y2M10DT2H30M|AFTER|2020-09-17|COINCIDENT|2020-09-20
e|RS|81f62132-123e-4888-abbe-8e289599e965|1|BMIVLIND|Bone Marrow Involvement Indicator|MRECIST LENCIONI LIVER CANCER 2010|||VGPR|1|mm/min|ANTIBIOTIC AGAR SCREEN|||Y|STUDY SUBJECT|RADIOLOGIST|Y|1|Visit_1|10|2|TREATMENT|2020-12-04|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-18|P1Y2M10DT2H30M|AFTER|2021-01-13|BEFORE|2021-01-24
e|RS|81f62132-123e-4888-abbe-8e289599e965|2|CYTORESP|Cytogenetic Response|BLAZER COLORECTAL CANCER 2008|||TREATMENT FAILURE|1|Bq/L|VIRUS PLAQUE ASSAY||Y|Y|INVESTIGATOR|RADIOLOGIST|Y|1|Visit_1|10|4|TREATMENT|2020-12-04|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-18|P1Y2M10DT2H30M|AFTER|2021-01-18|AFTER|2021-02-22
e|RS|81f62132-123e-4888-abbe-8e289599e965|3|BMIVLIND|Bone Marrow Involvement Indicator|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|/2000 RBC|PSEUDOPROGRESSION|1|umol/L|CINEANGIOGRAPHY||Y||PARENT|OTOLARYNGOLOGIST|NA|2|Visit_2|25|5|TREATMENT|2020-12-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-21|P1Y2M10DT2H30M|UNKNOWN|2021-02-02|ONGOING|2021-02-03
e|RS|81f62132-123e-4888-abbe-8e289599e965|4|BMIVLIND|Bone Marrow Involvement Indicator|BLAZER COLORECTAL CANCER 2008|||QUANTIFIABLE MRD POSITIVITY|1|LENS|OPTICAL COHERENCE TOMOGRAPHY|||Y|SIGNIFICANT OTHER|READER|Y|2|Visit_2|25|4|TREATMENT|2020-12-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-21|P1Y2M10DT2H30M|BEFORE|2020-12-29|BEFORE|2021-02-14
e|RS|81f62132-123e-4888-abbe-8e289599e965|5|MRPHRESP|Morphologic Response|SCHER PROSTATE CANCER 2011|[?]|L/L|CA125 75% RESPONSE|1|sec|CONTRAST ENHANCED X-RAY||||PARENT|ENDOCRINOLOGIST|NA|3|Visit_3|40|7|SCREENING|2021-01-03|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-26|P1Y2M10DT2H30M|AFTER|2021-02-24|BEFORE|2021-02-27
e|RS|81f62132-123e-4888-abbe-8e289599e965|6|STRUSTAT|Steroid Use Status|LEE LUNG CANCER 2011|[?]|oz eq|COMPLETE MRD RESPONSE|1|MBP|CT SCAN||||ADJUDICATION COMMITTEE|MICROSCOPIST|Y|3|Visit_3|40|6|TREATMENT|2021-01-03|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-26|P1Y2M10DT2H30M|COINCIDENT|2021-01-05|COINCIDENT|2021-02-26
e|RS|81f62132-123e-4888-abbe-8e289599e965|7|NEWLIND|New Lesion Indicator|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|mL/animal/wk|TREATMENT FAILURE|1|TRACE|TRIPLE-PHASE MRI SCAN||||CLINICAL STUDY SPONSOR|READER|U|4|Visit_4|65|2|TREATMENT|2021-01-28|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-26|P1Y2M10DT2H30M|AFTER|2021-02-13|COINCIDENT|2021-02-22
e|RS|81f62132-123e-4888-abbe-8e289599e965|8|MRDIND|Minimal Residual Disease Indicator|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|mL*cmH2O|MRD NEGATIVITY|1|mg/mL/day|OPTICAL DENSITY MEASUREMENT||||CLINICAL RESEARCH COORDINATOR|RATER 1|N|4|Visit_4|65|5|SCREENING|2021-01-28|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-26|P1Y2M10DT2H30M|COINCIDENT|2021-02-22|BEFORE|2021-02-25
e|RS|81f62132-123e-4888-abbe-8e289599e965|9|METBRESP|Metabolic Response|PERCIST|||VGPR|1|L/min|SANGER SEQUENCING|||Y|VENDOR|PATHOLOGIST 1|Y|5|Visit_5|90|1|FOLLOW-UP|2021-02-22|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-26|P1Y2M10DT2H30M|COINCIDENT|2020-12-23|COINCIDENT|2021-01-28
e|RS|81f62132-123e-4888-abbe-8e289599e965|10|MRPHRESP|Morphologic Response|BURCOMBE BREAST CANCER 2005|[?]|DAYS|QUANTIFIABLE MRD POSITIVITY|1|mEq|SPECT/CT SCAN||||FRIEND|RADIOLOGIST 2|U|5|Visit_5|90|1|FOLLOW-UP|2021-02-22|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-26|P1Y2M10DT2H30M|UNKNOWN|2021-02-24|BEFORE|2021-02-25
e|RS|c16c0dd1-8d1a-4be6-9017-457db68bb8e4|1|SFTSRESP|Soft Tissue Response|KEAM BREAST CANCER 2013|||PD/RELAPSE AFTER HI|1|vg/mL|FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY|Y||Y|ADJUDICATION COMMITTEE|ONCOLOGIST|N|1|Visit_1|10|2|WASHOUT|2020-05-16|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-22|P1Y2M10DT2H30M|AFTER|2020-06-23|BEFORE|2020-07-20
e|RS|c16c0dd1-8d1a-4be6-9017-457db68bb8e4|2|SPLNRESP|Spleen Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|nmol BCE/nmol|IMPROVED|1|Hz/s|CRYOSCOPY|Y|||VENDOR|OPTOMETRIST|NA|1|Visit_1|10|3|TREATMENT|2020-05-16|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-22|P1Y2M10DT2H30M|BEFORE|2020-06-08|COINCIDENT|2020-08-04
e|RS|c16c0dd1-8d1a-4be6-9017-457db68bb8e4|3|BESTRESP|Best Overall Response|EASL BRUIX LIVER CANCER 2001|[?]|g/day|HI-N|1|mL/min|BAC ACGH||||STUDY SUBJECT|RADIOLOGIST|U|2|Visit_2|25|6|TREATMENT|2020-05-31|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-01|P1Y2M10DT2H30M|COINCIDENT|2020-07-29|AFTER|2020-08-11
e|RS|c16c0dd1-8d1a-4be6-9017-457db68bb8e4|4|METBRESP|Metabolic Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|BAU|PSEUDORESPONSE|1|fmol/L/sec|DIFFUSION WEIGHTED MRI||||SPOUSE|ADJUDICATOR 3|NA|2|Visit_2|25|6|TREATMENT|2020-05-31|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-01|P1Y2M10DT2H30M|BEFORE|2020-05-15|ONGOING|2020-07-12
e|RS|c16c0dd1-8d1a-4be6-9017-457db68bb8e4|5|STRUSTAT|Steroid Use Status|IWG CHESON MDS 2000|[?]|mg/min|cPR|1|1/(s*kPa)|MS/MS||||ADJUDICATOR|RADIOLOGIST 2|NA|3|Visit_3|40|4|SCREENING|2020-06-15|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-13|P1Y2M10DT2H30M|UNKNOWN|2020-06-26|BEFORE|2020-07-16
e|RS|c16c0dd1-8d1a-4be6-9017-457db68bb8e4|6|NTNERESP|Non-Target Non-Enhancing Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|RNA copies/mL|FAVORABLE RESPONSE|1|U/dL|ELECTROPHORESIS||Y||DOMESTIC PARTNER|OTOLARYNGOLOGIST|Y|3|Visit_3|40|3|SCREENING|2020-06-15|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-13|P1Y2M10DT2H30M|BEFORE|2020-06-24|ONGOING|2020-08-13
e|RS|c16c0dd1-8d1a-4be6-9017-457db68bb8e4|7|TMRESP|Tumor Marker Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|||RELAPSED DISEASE FROM CR|1|BOWL|NUCLEAR RADIOLOGY||Y|Y|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 1|NA|4|Visit_4|65|4|TREATMENT|2020-07-10|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-24|P1Y2M10DT2H30M|COINCIDENT|2020-07-10|ONGOING|2020-07-31
e|RS|c16c0dd1-8d1a-4be6-9017-457db68bb8e4|8|NTERESP|Non-Target Enhancing Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|Hounsfield Unit|CMR|1|Bq|MAMMOGRAPHY||Y||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 1|N|4|Visit_4|65|6|FOLLOW-UP|2020-07-10|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-24|P1Y2M10DT2H30M|AFTER|2020-06-15|ONGOING|2020-07-12
e|RS|c16c0dd1-8d1a-4be6-9017-457db68bb8e4|9|NTERESP|Non-Target Enhancing Response|DOHNER AML 2010|[?]|Weber|HI-P|1|uV|PERIPHERAL ANGIOGRAPHY||||CHILD|INTERNIST|NA|5|Visit_5|90|1|TREATMENT|2020-08-04|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-06|P1Y2M10DT2H30M|AFTER|2020-07-09|ONGOING|2020-08-12
e|RS|c16c0dd1-8d1a-4be6-9017-457db68bb8e4|10|SFTSRESP|Soft Tissue Response|HARTMAN PANCREATIC CANCER 2012|[?]|nmol/L/min|PR-CT|1|mEq/mL|MICROBIAL CULTURE, SOLID||||GUARDIAN|OTOLARYNGOLOGIST|Y|5|Visit_5|90|1|TREATMENT|2020-08-04|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-06|P1Y2M10DT2H30M|BEFORE|2020-06-24|ONGOING|2020-08-07
e|RS|49282406-97ec-4108-adf9-e01c18ce59c6|1|MNPTHIND|Minor Pathological Response Indicator|PRINCE TCELL LYMPHOMA 2010|[?]|10^9/dose|PMR|1|um/s|GRAM STAIN||||GUARDIAN|MICROSCOPIST 2|Y|1|Visit_1|10|7|FOLLOW-UP|2020-05-17|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-17|P1Y2M10DT2H30M|AFTER|2020-05-19|AFTER|2020-08-01
e|RS|49282406-97ec-4108-adf9-e01c18ce59c6|2|LIVRRESP|Liver Response|CHESON CLL 2012|[?]|mL/mmHg|MORPHOLOGIC CRi|1|Log10 ELISA unit/dose|CONTRAST ENHANCED MRI|Y|Y||INVESTIGATOR|PHYSIOTHERAPIST|Y|1|Visit_1|10|4|TREATMENT|2020-05-17|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-17|P1Y2M10DT2H30M|UNKNOWN|2020-07-19|BEFORE|2020-07-20
e|RS|49282406-97ec-4108-adf9-e01c18ce59c6|3|NTLWIND|Non-Target Lesion Worsening Indicator|NCIWG CHESON CLL 1996|[?]|C|DISEASE TRANSFORMATION|1|APL U|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION||Y||FRIEND|RADIOLOGIST 1|N|2|Visit_2|25|7|TREATMENT|2020-06-01|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-03|P1Y2M10DT2H30M|UNKNOWN|2020-07-27|COINCIDENT|2020-07-28
e|RS|49282406-97ec-4108-adf9-e01c18ce59c6|4|MOLRESP|Molecular Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|ukat/10^12 RBC|PSEUDOPROGRESSION|1|DAgU/mL|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION|Y|||CHILD|DERMATOLOGIST|NA|2|Visit_2|25|5|TREATMENT|2020-06-01|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-03|P1Y2M10DT2H30M|COINCIDENT|2020-07-17|AFTER|2020-08-02
e|RS|49282406-97ec-4108-adf9-e01c18ce59c6|5|MRPHRESP|Morphologic Response|iRECIST|[?]|DAgU|PMR|1|mCi/kg|SPECTROPHOTOMETRY||||INDEPENDENT ASSESSOR|RADIOLOGIST|NA|3|Visit_3|40|5|SCREENING|2020-06-16|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-18|P1Y2M10DT2H30M|AFTER|2020-06-18|BEFORE|2020-08-04
e|RS|49282406-97ec-4108-adf9-e01c18ce59c6|6|NTERESP|Non-Target Enhancing Response|MACDONALD GLIOMA 1990|||WORSENED|1|L/min|PLAQUE REDUCTION NEUTRALIZATION ASSAY||Y|Y|PROXY|PHYSIOTHERAPIST|NA|3|Visit_3|40|3|WASHOUT|2020-06-16|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-18|P1Y2M10DT2H30M|UNKNOWN|2020-05-28|AFTER|2020-07-22
e|RS|49282406-97ec-4108-adf9-e01c18ce59c6|7|METSIND|Metastatic Indicator|IWG CHESON MDS 2000|[?]|dyn|DISEASE TRANSFORMATION|1|IU|HPLC/MS/MS||||FAMILY MEMBER|OTOLARYNGOLOGIST|NA|4|Visit_4|65|1|FOLLOW-UP|2020-07-11|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-16|P1Y2M10DT2H30M|BEFORE|2020-05-15|COINCIDENT|2020-07-09
e|RS|49282406-97ec-4108-adf9-e01c18ce59c6|8|BESTRESP|Best Overall Response|MACDONALD GLIOMA 1990|[?]|mph|COMPLETE MRD RESPONSE|1|Roentgen|MALDI||||HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|U|4|Visit_4|65|6|WASHOUT|2020-07-11|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-16|P1Y2M10DT2H30M|AFTER|2020-05-14|BEFORE|2020-06-21
e|RS|49282406-97ec-4108-adf9-e01c18ce59c6|9|METBRESP|Metabolic Response|WHO BREAST CANCER 2006|[?]|pmol/L/h|CYTOGENETIC PR|1|cGy|FLOCCULATION||||HEALTH CARE PROFESSIONAL|MICROSCOPIST|Y|5|Visit_5|90|1|TREATMENT|2020-08-05|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-16|P1Y2M10DT2H30M|BEFORE|2020-05-21|AFTER|2020-08-07
e|RS|49282406-97ec-4108-adf9-e01c18ce59c6|10|PATHRESP|Pathologic Response|HARTMAN PANCREATIC CANCER 2012|[?]|mEq/uL|PSA PROGRESSION|1|MET|PALPATION|Y|||STUDY SUBJECT|PEDIATRIC NEUROLOGIST|N|5|Visit_5|90|6|TREATMENT|2020-08-05|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-16|P1Y2M10DT2H30M|BEFORE|2020-06-21|BEFORE|2020-07-22
e|RS|310936c8-7d24-4eea-9892-1cd8bb675421|1|BMIVLIND|Bone Marrow Involvement Indicator|AJCC V7|[?]|mL|NON-iCR/NON-iUPD|1|L/L|ELECTROGASTROGRAPHY||||INVESTIGATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|1|Visit_1|10|2|TREATMENT|2020-07-06|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-09|P1Y2M10DT2H30M|COINCIDENT|2020-09-06|AFTER|2020-10-03
e|RS|310936c8-7d24-4eea-9892-1cd8bb675421|2|PATHRESP|Pathologic Response|PETIT BREAST CANCER 2001|[?]|mol/mL|PD/RELAPSE AFTER HI|1|FFU|HPLC-FL||||HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|NA|1|Visit_1|10|6|FOLLOW-UP|2020-07-06|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-09|P1Y2M10DT2H30M|UNKNOWN|2020-08-01|AFTER|2020-08-10
e|RS|310936c8-7d24-4eea-9892-1cd8bb675421|3|CLINRESP|Clinical Response|IWG CHESON AML 2003|[?]|Enzyme U/L|SD-CT|1|mEq|GC/MS-CI|Y|||NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST|Y|2|Visit_2|25|3|WASHOUT|2020-07-21|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-15|P1Y2M10DT2H30M|BEFORE|2020-09-05|ONGOING|2020-10-01
e|RS|310936c8-7d24-4eea-9892-1cd8bb675421|4|ANATRESP|Anatomic Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|U/kg/day|MR|1|h/wk|IMMUNOCHEMILUMINOMETRIC ASSAY||||DOMESTIC PARTNER|PEDIATRIC NEUROLOGIST|U|2|Visit_2|25|3|TREATMENT|2020-07-21|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-15|P1Y2M10DT2H30M|AFTER|2020-08-18|COINCIDENT|2020-09-21
e|RS|310936c8-7d24-4eea-9892-1cd8bb675421|5|METBRESP|Metabolic Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|mg/kg/day|MORPHOLOGIC CRi|1|nmol/L|GRADIENT DIFFUSION||||PROXY|ADJUDICATOR 1|NA|3|Visit_3|40|6|WASHOUT|2020-08-05|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-18|P1Y2M10DT2H30M|AFTER|2020-07-19|BEFORE|2020-08-04
e|RS|310936c8-7d24-4eea-9892-1cd8bb675421|6|NTLWIND|Non-Target Lesion Worsening Indicator|MURPHY PROSTATE CANCER 1980|[?]|IU/mmol|PD-CT|1|/VF|MAGNETIC RESONANCE ANGIOGRAPHY||Y||PROXY|ADJUDICATOR|N|3|Visit_3|40|5|FOLLOW-UP|2020-08-05|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-18|P1Y2M10DT2H30M|COINCIDENT|2020-07-06|BEFORE|2020-09-20
e|RS|310936c8-7d24-4eea-9892-1cd8bb675421|7|NEWLPROG|New Lesion Progression|DOHNER AML 2010|||NE|1|10^6 organisms/mL|SPIRAL CT|||Y|FAMILY MEMBER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|4|Visit_4|65|5|FOLLOW-UP|2020-08-30|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-08|P1Y2M10DT2H30M|COINCIDENT|2020-08-02|BEFORE|2020-08-28
e|RS|310936c8-7d24-4eea-9892-1cd8bb675421|8|CYTORESP|Cytogenetic Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|CAPSULE|iCR|1|Frames/s|MAGNETIC RESONANCE ENTEROGRAPHY||||FRIEND|DEVELOPMENTAL PSYCHOLOGIST|N|4|Visit_4|65|1|WASHOUT|2020-08-30|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-08|P1Y2M10DT2H30M|UNKNOWN|2020-09-13|ONGOING|2020-09-23
e|RS|310936c8-7d24-4eea-9892-1cd8bb675421|9|METBRESP|Metabolic Response|DURIE MULTIPLE MYELOMA 2006|||NE|1|pmol/L/h|MRI|Y||Y|PROXY|HEMATOLOGIST|U|5|Visit_5|90|2|TREATMENT|2020-09-24|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-09|P1Y2M10DT2H30M|AFTER|2020-08-21|AFTER|2020-09-26
e|RS|310936c8-7d24-4eea-9892-1cd8bb675421|10|MNPTHIND|Minor Pathological Response Indicator|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|ukat/L|DECREASED|1|m/sec|DIGITAL PCR|Y|||SPOUSE|INTERNIST|NA|5|Visit_5|90|3|TREATMENT|2020-09-24|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-09|P1Y2M10DT2H30M|UNKNOWN|2020-07-04|COINCIDENT|2020-07-22
e|RS|034e303b-5675-4188-bcea-fc2e53b155d6|1|METBRESP|Metabolic Response|RECIST 1.1|[?]|MONTHS|VGPR|1|DNA copies/ug|INFRARED SPECTROMETRY||||CLINICAL STUDY SPONSOR|NEUROLOGIST 1|Y|1|Visit_1|10|4|TREATMENT|2020-06-01|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-21|P1Y2M10DT2H30M|COINCIDENT|2020-06-16|ONGOING|2020-08-15
e|RS|034e303b-5675-4188-bcea-fc2e53b155d6|2|MRPHRESP|Morphologic Response|RECIST 1.0|[?]|FINGERTIP UNIT|NOT ALL EVALUATED|1|mmAL|REAL-TIME POLYMERASE CHAIN REACTION ASSAY|Y|Y||SIGNIFICANT OTHER|HEMATOLOGIST|Y|1|Visit_1|10|7|TREATMENT|2020-06-01|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-21|P1Y2M10DT2H30M|UNKNOWN|2020-06-16|AFTER|2020-08-15
e|RS|034e303b-5675-4188-bcea-fc2e53b155d6|3|MRDIND|Minimal Residual Disease Indicator|CHESON CLL 2012|[?]|kPa/L/sec|CRi|1|10^9 CFU|LIGHT SCATTERING SPECTROSCOPY||||GUARDIAN|PHYSIOTHERAPIST|NA|2|Visit_2|25|7|TREATMENT|2020-06-16|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-26|P1Y2M10DT2H30M|UNKNOWN|2020-07-24|COINCIDENT|2020-08-28
e|RS|034e303b-5675-4188-bcea-fc2e53b155d6|4|STRUSTAT|Steroid Use Status|IWG CHESON AML 2003|||iCPD|1|amol|POTENTIOMETRY|||Y|ADJUDICATOR|INTERNIST|NA|2|Visit_2|25|5|TREATMENT|2020-06-16|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-26|P1Y2M10DT2H30M|COINCIDENT|2020-07-17|BEFORE|2020-08-07
e|RS|034e303b-5675-4188-bcea-fc2e53b155d6|5|BONERESP|Bone Response|CHOI GIST 2008|[?]|mL/m2/day|NE|1|mL/kg/min|INCISION-INDUCED BLEEDING METHOD||||DOMESTIC PARTNER|ADJUDICATOR 2|N|3|Visit_3|40|6|TREATMENT|2020-07-01|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-31|P1Y2M10DT2H30M|UNKNOWN|2020-08-14|BEFORE|2020-08-16
e|RS|034e303b-5675-4188-bcea-fc2e53b155d6|6|MRPHRESP|Morphologic Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|cmH2O*s/mL|iUPD|1|mmHg/L/min|DYNAMIC CONTRAST ENHANCED MRI||||CAREGIVER|OTOLARYNGOLOGIST|U|3|Visit_3|40|1|FOLLOW-UP|2020-07-01|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-31|P1Y2M10DT2H30M|AFTER|2020-06-25|AFTER|2020-08-13
e|RS|034e303b-5675-4188-bcea-fc2e53b155d6|7|NTRGRESP|Non-target Response|JACINTO CERVICAL CANCER 2007|[?]|PFU/dose|CYTOGENETIC CR|1|psi|SINGLE-MOLECULE ARRAY||||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 2|N|4|Visit_4|65|4|TREATMENT|2020-07-26|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-01|P1Y2M10DT2H30M|COINCIDENT|2020-08-09|BEFORE|2020-08-23
e|RS|034e303b-5675-4188-bcea-fc2e53b155d6|8|MOLRESP|Molecular Response|NCCN ALL MRD 2014|[?]|MPL U/mL|INCREASED|1|nmol/mL/min|LASER CAPTURE MICRODISSECTION|Y|||INDEPENDENT ASSESSOR|PATHOLOGIST 1|Y|4|Visit_4|65|6|TREATMENT|2020-07-26|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-01|P1Y2M10DT2H30M|UNKNOWN|2020-07-15|AFTER|2020-07-22
e|RS|034e303b-5675-4188-bcea-fc2e53b155d6|9|MNPTHIND|Minor Pathological Response Indicator|GUPPY OVARIAN CANCER 2002|[?]|PA|NON-PD|1|Log10 ELISA unit/dose|X-RAY||||CLINICAL STUDY SPONSOR|MICROSCOPIST 2|U|5|Visit_5|90|6|WASHOUT|2020-08-20|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-09|P1Y2M10DT2H30M|BEFORE|2020-06-01|COINCIDENT|2020-07-18
e|RS|034e303b-5675-4188-bcea-fc2e53b155d6|10|SYMPTDTR|Symptomatic Deterioration|GCIG RUSTIN OVARIAN CANCER 2011|||NR|1|mg/mL/min|MULTIPLEXED BEAD BASED IMMUNOASSAY|||Y|ADJUDICATION COMMITTEE|ONCOLOGIST 1|Y|5|Visit_5|90|1|SCREENING|2020-08-20|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-09|P1Y2M10DT2H30M|AFTER|2020-06-08|BEFORE|2020-08-17
e|RS|b09e4a17-0a71-4cd9-bb8d-97e2cca0f649|1|BMIVLIND|Bone Marrow Involvement Indicator|IRANO 2015|[?]|cd/m2|CYTOGENETIC MINOR RESPONSE|1|DRINK|PERFUSION MRI||||NON-HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|U|1|Visit_1|10|5|WASHOUT|2020-07-07|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-28|P1Y2M10DT2H30M|COINCIDENT|2020-08-12|COINCIDENT|2020-08-31
e|RS|b09e4a17-0a71-4cd9-bb8d-97e2cca0f649|2|HEMARESP|Hematologic Response|GUPPY OVARIAN CANCER 2002|[?]|Siemens|NE|1|U/mg|KLEIHAUER-BETKE||Y||FAMILY MEMBER|CLINICAL PATHOLOGIST|Y|1|Visit_1|10|7|WASHOUT|2020-07-07|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-28|P1Y2M10DT2H30M|UNKNOWN|2020-08-20|ONGOING|2020-08-28
e|RS|b09e4a17-0a71-4cd9-bb8d-97e2cca0f649|3|ANATRESP|Anatomic Response|HARTMANN GERM CELL CANCER 2002|[?]|RNA copies/mL|UNEQUIVOCAL|1|pg/dL|COULOMETRIC TITRATION||||INVESTIGATOR|ADJUDICATOR 3|U|2|Visit_2|25|2|FOLLOW-UP|2020-07-22|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-20|P1Y2M10DT2H30M|AFTER|2020-09-24|AFTER|2020-09-26
e|RS|b09e4a17-0a71-4cd9-bb8d-97e2cca0f649|4|SFTSRESP|Soft Tissue Response|MACDONALD GLIOMA 1990|[?]|nL|DISEASE TRANSFORMATION|1|mmol|RAJI CELL RIA||||VENDOR|ADJUDICATOR|N|2|Visit_2|25|7|SCREENING|2020-07-22|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-20|P1Y2M10DT2H30M|AFTER|2020-08-12|BEFORE|2020-09-16
e|RS|b09e4a17-0a71-4cd9-bb8d-97e2cca0f649|5|STRUSTAT|Steroid Use Status|EBMT BLADE MYELOMA 1998|[?]|IU/mL|QUANTIFIABLE MRD POSITIVITY|1|IU/L|IMPEDANCE CONDUCTIVITY||||GUARDIAN|CLINICAL PATHOLOGIST|U|3|Visit_3|40|2|SCREENING|2020-08-06|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-18|P1Y2M10DT2H30M|UNKNOWN|2020-07-31|AFTER|2020-08-02
e|RS|b09e4a17-0a71-4cd9-bb8d-97e2cca0f649|6|NEWLPROG|New Lesion Progression|iRECIST|[?]|mg/mL/day|pCR|1|pg/dL|THERMAL IONIZATION MASS SPECTROMETRY||||ADJUDICATION COMMITTEE|MICROSCOPIST|U|3|Visit_3|40|7|SCREENING|2020-08-06|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-18|P1Y2M10DT2H30M|UNKNOWN|2020-08-24|AFTER|2020-09-04
e|RS|b09e4a17-0a71-4cd9-bb8d-97e2cca0f649|7|MOLRESP|Molecular Response|WHO BREAST CANCER 2006|[?]|BAU|SD|1|ugEq|CLAUSS METHOD||Y||PROXY|MICROSCOPIST|N|4|Visit_4|65|3|TREATMENT|2020-08-31|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-23|P1Y2M10DT2H30M|AFTER|2020-09-23|AFTER|2020-10-04
e|RS|b09e4a17-0a71-4cd9-bb8d-97e2cca0f649|8|LIVRRESP|Liver Response|CHOI GIST 2008|[?]|g/animal/day|IMPROVED|1|cL|MRI||||FAMILY MEMBER|PATHOLOGIST 1|NA|4|Visit_4|65|2|TREATMENT|2020-08-31|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-23|P1Y2M10DT2H30M|UNKNOWN|2020-10-01|ONGOING|2020-10-02
e|RS|b09e4a17-0a71-4cd9-bb8d-97e2cca0f649|9|BMIVLIND|Bone Marrow Involvement Indicator|HARTMANN GERM CELL CANCER 2002|[?]|min|CA125 50% RESPONSE|1|10^6/g|FARNSWORTH-MUNSELL 100 HUE TEST|Y|Y||CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 2|N|5|Visit_5|90|3|WASHOUT|2020-09-25|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-26|P1Y2M10DT2H30M|BEFORE|2020-09-01|BEFORE|2020-09-18
e|RS|b09e4a17-0a71-4cd9-bb8d-97e2cca0f649|10|MOLRESP|Molecular Response|JACINTO CERVICAL CANCER 2007|||IMMUNOPHENOTYPIC CR|1|mg/kg/day|ELECTROCHEMILUMINESCENCE IMMUNOASSAY|Y||Y|VENDOR|RATER 1|N|5|Visit_5|90|1|TREATMENT|2020-09-25|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-26|P1Y2M10DT2H30M|AFTER|2020-09-30|AFTER|2020-10-01
e|RS|c912affb-cbc2-4919-81b4-ecaa03908261|1|CLINRESP|Clinical Response|CHESON CLL 2012|[?]|BAU|NED|1|U/animal|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY||||PROXY|PATHOLOGIST 1|N|1|Visit_1|10|6|WASHOUT|2020-07-12|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-16|P1Y2M10DT2H30M|COINCIDENT|2020-07-19|ONGOING|2020-10-05
e|RS|c912affb-cbc2-4919-81b4-ecaa03908261|2|NTERESP|Non-Target Enhancing Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|% INHIBITION|CRi|1|NEBULE|PET SCAN|Y|||PARENT|OPTOMETRIST|N|1|Visit_1|10|4|WASHOUT|2020-07-12|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-16|P1Y2M10DT2H30M|AFTER|2020-09-08|ONGOING|2020-09-14
e|RS|c912affb-cbc2-4919-81b4-ecaa03908261|3|NEWLIND|New Lesion Indicator|BLAZER COLORECTAL CANCER 2008|[?]|Farad|NON-QUANTIFIABLE MRD POSITIVITY|1|Linear ft*LB|HPLC/MS/MS||||FRIEND|OTOLARYNGOLOGIST|U|2|Visit_2|25|6|TREATMENT|2020-07-27|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-25|P1Y2M10DT2H30M|UNKNOWN|2020-07-19|ONGOING|2020-09-18
e|RS|c912affb-cbc2-4919-81b4-ecaa03908261|4|BMIVLIND|Bone Marrow Involvement Indicator|SHINDOH COLORECTAL CANCER 2013|||CRi|1|uSiemens|DIRECT SEQUENCING|||Y|GUARDIAN|DERMATOLOGIST|U|2|Visit_2|25|4|TREATMENT|2020-07-27|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-25|P1Y2M10DT2H30M|COINCIDENT|2020-07-10|BEFORE|2020-08-26
e|RS|c912affb-cbc2-4919-81b4-ecaa03908261|5|NEWLPROG|New Lesion Progression|SCHWARZ CERVICAL CANCER 2009|||PMD|1|CCID 50/mL|CONFOCAL MICROSCOPY||Y|Y|ADJUDICATION COMMITTEE|ENDOCRINOLOGIST|U|3|Visit_3|40|4|TREATMENT|2020-08-11|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-05|P1Y2M10DT2H30M|UNKNOWN|2020-09-15|BEFORE|2020-09-20
e|RS|c912affb-cbc2-4919-81b4-ecaa03908261|6|BONERESP|Bone Response|RANO ELLINGSON 2017|[?]|mmol/L|INCREASED|1|log EID 50/dose|PLETHYSMOGRAPHY|Y|||CLINICAL RESEARCH ASSOCIATE|PHYSIOTHERAPIST|U|3|Visit_3|40|7|TREATMENT|2020-08-11|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-05|P1Y2M10DT2H30M|BEFORE|2020-08-14|ONGOING|2020-10-08
e|RS|c912affb-cbc2-4919-81b4-ecaa03908261|7|CLINRESP|Clinical Response|SCHER PROSTATE CANCER 2011|[?]|LB|cCR|1|U/kg/day|SLIT LAMP|Y|||SIBLING|ADJUDICATOR|U|4|Visit_4|65|6|TREATMENT|2020-09-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-22|P1Y2M10DT2H30M|COINCIDENT|2020-08-03|ONGOING|2020-08-26
e|RS|c912affb-cbc2-4919-81b4-ecaa03908261|8|OVRLRESP|Overall Response|RANO|||CA125 50% RESPONSE|1|pg/L|CAPILLARY ELECTROPHORESIS||Y|Y|SIGNIFICANT OTHER|NEUROLOGIST 1|N|4|Visit_4|65|7|TREATMENT|2020-09-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-22|P1Y2M10DT2H30M|BEFORE|2020-09-04|ONGOING|2020-09-29
e|RS|c912affb-cbc2-4919-81b4-ecaa03908261|9|BESTRESP|Best Overall Response|NCIWG CHESON CLL 1996|||CYTOGENETIC CR|1|g/mol|ELECTROPHORESIS||Y|Y|PARENT|ADJUDICATOR 2|Y|5|Visit_5|90|5|TREATMENT|2020-09-30|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-24|P1Y2M10DT2H30M|COINCIDENT|2020-07-19|AFTER|2020-09-30
e|RS|c912affb-cbc2-4919-81b4-ecaa03908261|10|BONERESP|Bone Response|EASL BRUIX LIVER CANCER 2001|||PSEUDORESPONSE|1|mV2/Hz|MICROARRAY|||Y|FRIEND|MICROSCOPIST 2|NA|5|Visit_5|90|7|TREATMENT|2020-09-30|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-24|P1Y2M10DT2H30M|AFTER|2020-07-11|ONGOING|2020-07-29
e|RS|5af817f0-5dfb-4046-ac7c-4bae16a90036|1|METSIND|Metastatic Indicator|JACINTO CERVICAL CANCER 2007|[?]|cmol|iCR|1|K|IMMUNE REPERTOIRE DEEP SEQUENCING||||ADJUDICATION COMMITTEE|FORENSIC PATHOLOGIST|U|1|Visit_1|10|7|TREATMENT|2020-07-06|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-18|P1Y2M10DT2H30M|UNKNOWN|2020-07-21|BEFORE|2020-09-11
e|RS|5af817f0-5dfb-4046-ac7c-4bae16a90036|2|OVRLRESP|Overall Response|MASS|[?]|mCi|DISEASE TRANSFORMATION|1|hr/day|MICROBIAL CONCENTRATION|Y|||FAMILY MEMBER|UROLOGIST|N|1|Visit_1|10|1|FOLLOW-UP|2020-07-06|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-18|P1Y2M10DT2H30M|AFTER|2020-09-22|ONGOING|2020-09-29
e|RS|5af817f0-5dfb-4046-ac7c-4bae16a90036|3|NEWLWIND|New Lesion Worsening Indicator|KEAM BREAST CANCER 2013|[?]|10^9 CFU/g|RELAPSED DISEASE|1|10^11/L|DISK DIFFUSION||||SPOUSE|DERMATOLOGIST|Y|2|Visit_2|25|4|FOLLOW-UP|2020-07-21|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-02|P1Y2M10DT2H30M|BEFORE|2020-08-26|AFTER|2020-09-21
e|RS|5af817f0-5dfb-4046-ac7c-4bae16a90036|4|SPLNRESP|Spleen Response|RANO|[?]|/VF|PR-CT|1|10^7 TCID 50/dose|BAC ACGH||||SIBLING|RADIOLOGIST 1|U|2|Visit_2|25|4|TREATMENT|2020-07-21|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-02|P1Y2M10DT2H30M|UNKNOWN|2020-09-27|ONGOING|2020-10-03
e|RS|5af817f0-5dfb-4046-ac7c-4bae16a90036|5|MOLRESP|Molecular Response|SHINDOH COLORECTAL CANCER 2013|[?]|MAC50|CRi|1|/200 HPFs|ELISA||||GUARDIAN|INTERNIST|NA|3|Visit_3|40|4|TREATMENT|2020-08-05|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-20|P1Y2M10DT2H30M|AFTER|2020-08-02|ONGOING|2020-08-31
e|RS|5af817f0-5dfb-4046-ac7c-4bae16a90036|6|CPRFSTAT|Clinical Performance Status|AJCC V8|[?]|ft2|MAJOR PATHOLOGIC RESPONSE|1|KALLIKREIN INHIBITOR UNIT|BAC ACGH|Y|||SIGNIFICANT OTHER|READER 3|Y|3|Visit_3|40|5|TREATMENT|2020-08-05|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-20|P1Y2M10DT2H30M|BEFORE|2020-08-26|AFTER|2020-09-30
e|RS|5af817f0-5dfb-4046-ac7c-4bae16a90036|7|STRUSTAT|Steroid Use Status|CHESON CLL 2012|[?]|dpm/100mg|CA125 50% RESPONSE|1|EVENTS|RAJI CELL RIA|Y|||CAREGIVER|OPHTHALMOLOGIST|Y|4|Visit_4|65|1|TREATMENT|2020-08-30|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-28|P1Y2M10DT2H30M|UNKNOWN|2020-09-28|ONGOING|2020-09-30
e|RS|5af817f0-5dfb-4046-ac7c-4bae16a90036|8|MRDRESP|Minimal Residual Disease Response|RANO ELLINGSON 2017|[?]|mL/beat|CYTOGENETIC MINIMAL RESPONSE|1|kN/cm2|FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY||Y||PARENT|PATHOLOGIST 2|Y|4|Visit_4|65|7|WASHOUT|2020-08-30|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-28|P1Y2M10DT2H30M|UNKNOWN|2020-08-04|COINCIDENT|2020-10-03
e|RS|5af817f0-5dfb-4046-ac7c-4bae16a90036|9|ANATRESP|Anatomic Response|HARTMAN PANCREATIC CANCER 2012|[?]|mol/mL|mCR|1|umol/kg/min|KINETIC CHROMOGENIC ASSAY||Y||CLINICAL STUDY SPONSOR|CARDIOLOGIST|Y|5|Visit_5|90|2|TREATMENT|2020-09-24|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-05|P1Y2M10DT2H30M|BEFORE|2020-09-08|COINCIDENT|2020-09-27
e|RS|5af817f0-5dfb-4046-ac7c-4bae16a90036|10|METBRESP|Metabolic Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|%(v/v)|iUPD|1|psec|ANTIBIOTIC AGAR SCREEN|Y|||CHILD|PATHOLOGIST|N|5|Visit_5|90|4|TREATMENT|2020-09-24|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-05|P1Y2M10DT2H30M|UNKNOWN|2020-08-05|AFTER|2020-09-06
e|RS|dcefd656-a59a-4b71-9260-efcbcecd2132|1|HEMARESP|Hematologic Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|10^7/L|NON-iCR/NON-iUPD|1|s/h|MAGNETIC RESONANCE ENTEROGRAPHY||Y||CAREGIVER|INTERNIST|NA|1|Visit_1|10|5|WASHOUT|2020-06-04|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-26|P1Y2M10DT2H30M|BEFORE|2020-07-15|BEFORE|2020-08-17
e|RS|dcefd656-a59a-4b71-9260-efcbcecd2132|2|MOLRESP|Molecular Response|IWC HALLEK CLL 2008|[?]|IU/L|PR|1|DISK|PET SCAN||||INVESTIGATOR|NEUROLOGIST 1|N|1|Visit_1|10|4|TREATMENT|2020-06-04|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-26|P1Y2M10DT2H30M|UNKNOWN|2020-08-11|BEFORE|2020-08-19
e|RS|dcefd656-a59a-4b71-9260-efcbcecd2132|3|TMRESP|Tumor Marker Response|SCHER PROSTATE CANCER 2011|||NON-iCR/NON-iUPD|1|/HPF|U-HPLC/MS/MS||Y|Y|INDEPENDENT ASSESSOR|PATHOLOGIST|N|2|Visit_2|25|6|TREATMENT|2020-06-19|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-18|P1Y2M10DT2H30M|AFTER|2020-05-30|BEFORE|2020-06-07
e|RS|dcefd656-a59a-4b71-9260-efcbcecd2132|4|MNPTHIND|Minor Pathological Response Indicator|SHINDOH COLORECTAL CANCER 2013|||PR|1|MPS U|TOLUIDINE BLUE STAIN||Y|Y|INTERVIEWER|HEMATOLOGIST|Y|2|Visit_2|25|7|WASHOUT|2020-06-19|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-18|P1Y2M10DT2H30M|UNKNOWN|2020-07-31|AFTER|2020-08-27
e|RS|dcefd656-a59a-4b71-9260-efcbcecd2132|5|CPRFSTAT|Clinical Performance Status|IWG CHESON MDS 2006|[?]|L/min|iPR|1|%(w/w)|QUANTITATIVE ULTRASOUND||||CLINICAL RESEARCH ASSOCIATE|OPHTHALMOLOGIST|NA|3|Visit_3|40|6|FOLLOW-UP|2020-07-04|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-13|P1Y2M10DT2H30M|COINCIDENT|2020-06-08|COINCIDENT|2020-08-10
e|RS|dcefd656-a59a-4b71-9260-efcbcecd2132|6|NEWLIND|New Lesion Indicator|PERCIST|[?]|uIU/L|mCR|1|mm/h|CINEANGIOGRAPHY||||FAMILY MEMBER|OPTOMETRIST|NA|3|Visit_3|40|2|TREATMENT|2020-07-04|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-13|P1Y2M10DT2H30M|BEFORE|2020-06-17|ONGOING|2020-07-08
e|RS|dcefd656-a59a-4b71-9260-efcbcecd2132|7|BESTRESP|Best Overall Response|SHINDOH COLORECTAL CANCER 2013|[?]|U.CARR|TREATMENT FAILURE|1|ag|ULTRASOUND|Y|||NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|N|4|Visit_4|65|7|TREATMENT|2020-07-29|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-15|P1Y2M10DT2H30M|AFTER|2020-08-17|BEFORE|2020-08-26
e|RS|dcefd656-a59a-4b71-9260-efcbcecd2132|8|NEWLPROG|New Lesion Progression|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|lx|iUPD|1|g/mol|CONFOCAL MICROSCOPY|Y|||PROXY|DERMATOLOGIST|Y|4|Visit_4|65|4|WASHOUT|2020-07-29|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-15|P1Y2M10DT2H30M|BEFORE|2020-08-04|AFTER|2020-08-27
e|RS|dcefd656-a59a-4b71-9260-efcbcecd2132|9|BESTRESP|Best Overall Response|IWG CHESON AML 2003|[?]|mol|UNEQUIVOCAL|1|nkat/g Hb|CELL CYTOTOXICITY NEUTRALIZATION ASSAY||Y||STUDY SUBJECT|RADIOLOGIST 2|NA|5|Visit_5|90|3|SCREENING|2020-08-23|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-01|P1Y2M10DT2H30M|COINCIDENT|2020-08-31|ONGOING|2020-09-01
e|RS|dcefd656-a59a-4b71-9260-efcbcecd2132|10|LIVRRESP|Liver Response|RECICL|[?]|GBq/ug|PD/RELAPSE AFTER HI|1|pmol/10^10 cells|HPLC-UV||Y||GUARDIAN|NEUROLOGIST 2|NA|5|Visit_5|90|3|TREATMENT|2020-08-23|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-01|P1Y2M10DT2H30M|BEFORE|2020-05-27|BEFORE|2020-07-14
e|RS|641c8067-941a-4f1a-a7b1-4eea0242f1d7|1|NEWLIND|New Lesion Indicator|BRUGGEMANN MRD 2010|[?]|mEq/mmol|SMD|1|cs|CELL CYTOTOXICITY NEUTRALIZATION ASSAY||Y||SIBLING|OPTOMETRIST|Y|1|Visit_1|10|4|SCREENING|2020-12-22|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-14|P1Y2M10DT2H30M|COINCIDENT|2020-12-14|BEFORE|2021-03-02
e|RS|641c8067-941a-4f1a-a7b1-4eea0242f1d7|2|METSIND|Metastatic Indicator|CHESON LYMPHOMA 2008|[?]|mJoule/cm2|MRD NEGATIVITY|1|Ci|PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY||||PARENT|ADJUDICATOR 3|N|1|Visit_1|10|7|SCREENING|2020-12-22|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-14|P1Y2M10DT2H30M|BEFORE|2021-02-27|ONGOING|2021-03-19
e|RS|641c8067-941a-4f1a-a7b1-4eea0242f1d7|3|NEWLPROG|New Lesion Progression|GCIG RUSTIN OVARIAN CANCER 2011|[?]|ng/day|MORPHOLOGIC CR|1|mg/kg/week|KINETIC CHROMOGENIC ASSAY|Y|||INVESTIGATOR|FORENSIC PATHOLOGIST|Y|2|Visit_2|25|5|FOLLOW-UP|2021-01-06|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-31|P1Y2M10DT2H30M|COINCIDENT|2021-01-20|AFTER|2021-02-07
e|RS|641c8067-941a-4f1a-a7b1-4eea0242f1d7|4|NTNERESP|Non-Target Non-Enhancing Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|umol/L|PMD|1|nL|IVY INCISION METHOD|Y|||INTERVIEWER|READER 1|NA|2|Visit_2|25|3|WASHOUT|2021-01-06|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-31|P1Y2M10DT2H30M|UNKNOWN|2020-12-17|COINCIDENT|2021-01-21
e|RS|641c8067-941a-4f1a-a7b1-4eea0242f1d7|5|OVRLRESP|Overall Response|PCWG SCHER PROSTATE CANCER 2008|[?]|nsec|PR-CT|1|fg|IMMUNOCHEMILUMINOMETRIC ASSAY||||VENDOR|MICROSCOPIST 3|N|3|Visit_3|40|4|TREATMENT|2021-01-21|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-18|P1Y2M10DT2H30M|BEFORE|2021-01-14|AFTER|2021-03-19
e|RS|641c8067-941a-4f1a-a7b1-4eea0242f1d7|6|CYTORESP|Cytogenetic Response|WHO BREAST CANCER 2006|[?]|kg/m2|PD/RELAPSE AFTER HI|1|PIXELS/in|MS/MS||||PARENT|READER 3|NA|3|Visit_3|40|4|TREATMENT|2021-01-21|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-18|P1Y2M10DT2H30M|UNKNOWN|2021-01-02|BEFORE|2021-01-27
e|RS|641c8067-941a-4f1a-a7b1-4eea0242f1d7|7|MRPHRESP|Morphologic Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|mV*min|CYTOGENETIC MINIMAL RESPONSE|1|10^3/L|ENZYMATIC ULTRACENTRIFUGATION||||GUARDIAN|MICROSCOPIST|N|4|Visit_4|65|6|TREATMENT|2021-02-15|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-31|P1Y2M10DT2H30M|COINCIDENT|2021-03-01|ONGOING|2021-03-15
e|RS|641c8067-941a-4f1a-a7b1-4eea0242f1d7|8|NEWLWIND|New Lesion Worsening Indicator|RAJKUMAR MYELOMA 2011|[?]|U/m2/day|NON-CR/NON-PD|1|cP|CLIP SEQUENCING||Y||INTERVIEWER|RADIOLOGIST 1|Y|4|Visit_4|65|6|TREATMENT|2021-02-15|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-31|P1Y2M10DT2H30M|COINCIDENT|2021-03-12|BEFORE|2021-03-13
e|RS|641c8067-941a-4f1a-a7b1-4eea0242f1d7|9|BONERESP|Bone Response|KUMAR IMWG 2016|[?]|INHALATION|SD|1|mMU/mL|WRIGHT STAIN|Y|Y||INDEPENDENT ASSESSOR|MICROSCOPIST 2|N|5|Visit_5|90|3|SCREENING|2021-03-12|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-05|P1Y2M10DT2H30M|AFTER|2021-03-15|ONGOING|2021-03-21
e|RS|641c8067-941a-4f1a-a7b1-4eea0242f1d7|10|NEWLIND|New Lesion Indicator|EUROPEAN LEUKEMIANET BACCARANI CML 2006|||MORPHOLOGIC CRi|1|VIRTUAL PIXEL|NUCLEIC ACID SEQUENCING|||Y|FRIEND|RATER 2|N|5|Visit_5|90|5|FOLLOW-UP|2021-03-12|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-05|P1Y2M10DT2H30M|AFTER|2021-01-14|COINCIDENT|2021-02-01
e|RS|ab6fb8ca-d455-4141-82f7-cdb7eaf7dfda|1|STRUSTAT|Steroid Use Status|GUILHOT CML 2007|[?]|ks|CRi|1|um|PHOROPTER|Y|||INDEPENDENT ASSESSOR|READER 2|NA|1|Visit_1|10|2|TREATMENT|2020-09-24|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-28|P1Y2M10DT2H30M|BEFORE|2020-11-11|BEFORE|2020-12-04
e|RS|ab6fb8ca-d455-4141-82f7-cdb7eaf7dfda|2|STRUSTAT|Steroid Use Status|PCWG SCHER PROSTATE CANCER 2016|||iUPD|1|mEq/mmol|SCINTIGRAPHY|Y||Y|SPOUSE|RATER 2|Y|1|Visit_1|10|5|SCREENING|2020-09-24|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-28|P1Y2M10DT2H30M|BEFORE|2020-11-26|COINCIDENT|2020-12-20
e|RS|ab6fb8ca-d455-4141-82f7-cdb7eaf7dfda|3|STRUSTAT|Steroid Use Status|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|mL/h|PMR|1|JAR|WESTERGREN|Y|||HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|N|2|Visit_2|25|4|TREATMENT|2020-10-09|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-10|P1Y2M10DT2H30M|UNKNOWN|2020-10-28|BEFORE|2020-11-18
e|RS|ab6fb8ca-d455-4141-82f7-cdb7eaf7dfda|4|TMRESP|Tumor Marker Response|BRUGGEMANN MRD 2010|[?]|keV|PSEUDOPROGRESSION|1|ft3|CELLULOSE TAPE||||PROXY|READER|N|2|Visit_2|25|5|FOLLOW-UP|2020-10-09|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-10|P1Y2M10DT2H30M|AFTER|2020-09-30|ONGOING|2020-10-02
e|RS|ab6fb8ca-d455-4141-82f7-cdb7eaf7dfda|5|ANATRESP|Anatomic Response|KUKER LYMPHOMA 2005|[?]|mg2/dL2|iCR|1|BOWL|HPLC-FL||Y||ADJUDICATOR|ONCOLOGIST 1|N|3|Visit_3|40|3|TREATMENT|2020-10-24|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-27|P1Y2M10DT2H30M|COINCIDENT|2020-11-02|COINCIDENT|2020-11-19
e|RS|ab6fb8ca-d455-4141-82f7-cdb7eaf7dfda|6|CYTORESP|Cytogenetic Response|GUPPY OVARIAN CANCER 2002|[?]|ks|iSD|1|ka_u/dL|DYNAMIC CONTRAST ENHANCED MRI||||CAREGIVER|ADJUDICATOR|N|3|Visit_3|40|1|SCREENING|2020-10-24|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-27|P1Y2M10DT2H30M|BEFORE|2020-10-08|AFTER|2020-12-08
e|RS|ab6fb8ca-d455-4141-82f7-cdb7eaf7dfda|7|RDIORESP|Radiologic Response|MURPHY PROSTATE CANCER 1980|||CYTOGENETIC CR|1|Ci/kg|QUANTITATIVE PERIPHERAL ANGIOGRAPHY|||Y|CLINICAL RESEARCH ASSOCIATE|READER 1|U|4|Visit_4|65|3|SCREENING|2020-11-18|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-12|P1Y2M10DT2H30M|BEFORE|2020-10-18|COINCIDENT|2020-11-23
e|RS|ab6fb8ca-d455-4141-82f7-cdb7eaf7dfda|8|HEMARESP|Hematologic Response|EBMT BLADE MYELOMA 1998|[?]|Ci/mg|PSEUDOPROGRESSION|1|IU/g Hb|IMMUNOTURBIDIMETRY||Y||HEALTH CARE PROFESSIONAL|READER|Y|4|Visit_4|65|5|TREATMENT|2020-11-18|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-12|P1Y2M10DT2H30M|AFTER|2020-09-16|AFTER|2020-10-27
e|RS|ab6fb8ca-d455-4141-82f7-cdb7eaf7dfda|9|NEWLIND|New Lesion Indicator|CHESON CLL 2012|||PR-CT|1|DDU|RADIOIMMUNOPRECIPITATION ASSAY|||Y|PROXY|PEDIATRIC NEUROLOGIST|U|5|Visit_5|90|6|FOLLOW-UP|2020-12-13|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-24|P1Y2M10DT2H30M|UNKNOWN|2020-12-15|AFTER|2020-12-19
e|RS|ab6fb8ca-d455-4141-82f7-cdb7eaf7dfda|10|ANATRESP|Anatomic Response|PERCIST|[?]|mL/g/h|CYTOGENETIC PR|1|%/min|JAFFE REACTION||||STUDY SUBJECT|CLINICAL PATHOLOGIST|NA|5|Visit_5|90|7|SCREENING|2020-12-13|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-24|P1Y2M10DT2H30M|AFTER|2020-11-04|AFTER|2020-12-07
e|RS|b7a9c5a6-98ed-4ca1-98ea-4cfc03749c0f|1|MRPHRESP|Morphologic Response|MRECIST BYRNE MESOTHELIOMA 2004|||DECREASED|1|ug/L DDU|MICROARRAY|Y|Y|Y|INVESTIGATOR|READER|NA|1|Visit_1|10|5|TREATMENT|2020-10-31|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-14|P1Y2M10DT2H30M|BEFORE|2020-11-13|BEFORE|2020-11-25
e|RS|b7a9c5a6-98ed-4ca1-98ea-4cfc03749c0f|2|MJPTHIND|Major Pathological Response Indicator|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|EP U|PR WITH LYMPHOCYTOSIS|1|h/wk|SISH||||DOMESTIC PARTNER|PATHOLOGIST 2|N|1|Visit_1|10|5|SCREENING|2020-10-31|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-14|P1Y2M10DT2H30M|BEFORE|2021-01-12|ONGOING|2021-01-28
e|RS|b7a9c5a6-98ed-4ca1-98ea-4cfc03749c0f|3|NEWLPROG|New Lesion Progression|IWG CHESON MDS 2006|||NON-QUANTIFIABLE MRD POSITIVITY|1|/200 HPFs|ELISA|||Y|FAMILY MEMBER|ADJUDICATOR 2|NA|2|Visit_2|25|5|FOLLOW-UP|2020-11-15|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-27|P1Y2M10DT2H30M|AFTER|2020-12-21|ONGOING|2021-01-21
e|RS|b7a9c5a6-98ed-4ca1-98ea-4cfc03749c0f|4|BESTRESP|Best Overall Response|IRANO 2015|[?]|Bq/kg|PSEUDORESPONSE|1|PIXELS/cm|CALCULATION||Y||DOMESTIC PARTNER|PATHOLOGIST 1|NA|2|Visit_2|25|1|TREATMENT|2020-11-15|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-27|P1Y2M10DT2H30M|COINCIDENT|2020-12-10|AFTER|2020-12-15
e|RS|b7a9c5a6-98ed-4ca1-98ea-4cfc03749c0f|5|MNPTHIND|Minor Pathological Response Indicator|PCWG SCHER PROSTATE CANCER 2008|[?]|10^3 organisms/mL|TREATMENT FAILURE|1|10^9 CFU/g|FLUORESCENCE ANGIOGRAPHY||||SPOUSE|RADIOLOGIST 1|NA|3|Visit_3|40|6|TREATMENT|2020-11-30|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-05|P1Y2M10DT2H30M|AFTER|2020-12-31|AFTER|2021-01-27
e|RS|b7a9c5a6-98ed-4ca1-98ea-4cfc03749c0f|6|PATHRESP|Pathologic Response|MACDONALD GLIOMA 1990|[?]|log10 copies/mL|PMD|1|/5x10^4 WBC|POLYGRAPHY||Y||GUARDIAN|OTOLARYNGOLOGIST|U|3|Visit_3|40|4|TREATMENT|2020-11-30|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-05|P1Y2M10DT2H30M|UNKNOWN|2020-12-03|BEFORE|2021-01-26
e|RS|b7a9c5a6-98ed-4ca1-98ea-4cfc03749c0f|7|SYMPTDTR|Symptomatic Deterioration|MRANO VAN DEN BENT GLIOMA 2011|[?]|ukat/10^12 RBC|nPR|1|log10 TCID 50/mL|PUPILLOMETRY||Y||CLINICAL RESEARCH COORDINATOR|INTERNIST|NA|4|Visit_4|65|7|TREATMENT|2020-12-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-18|P1Y2M10DT2H30M|AFTER|2020-11-22|COINCIDENT|2020-12-14
e|RS|b7a9c5a6-98ed-4ca1-98ea-4cfc03749c0f|8|ANATRESP|Anatomic Response|CHESON CLL 2006|||iCPD|1|mCi/L|COMPUTERIZED CORNEAL TOPOGRAPHY|||Y|CHILD|RATER|NA|4|Visit_4|65|4|FOLLOW-UP|2020-12-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-18|P1Y2M10DT2H30M|COINCIDENT|2020-12-11|ONGOING|2020-12-21
e|RS|b7a9c5a6-98ed-4ca1-98ea-4cfc03749c0f|9|STRUSTAT|Steroid Use Status|PCWG SCHER PROSTATE CANCER 2008|||MORPHOLOGIC LEUKEMIA-FREE STATE|1|vg/dose|IMMUNE REPERTOIRE DEEP SEQUENCING|||Y|ADJUDICATOR|PATHOLOGIST 1|N|5|Visit_5|90|4|TREATMENT|2021-01-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-01|P1Y2M10DT2H30M|AFTER|2020-11-10|AFTER|2021-01-08
e|RS|b7a9c5a6-98ed-4ca1-98ea-4cfc03749c0f|10|MJPTHIND|Major Pathological Response Indicator|EUROPEAN LEUKEMIANET BACCARANI CML 2006|||PMR|1|TABLET|TRANSESOPHAGEAL ECHOCARDIOGRAPHY|||Y|ADJUDICATOR|OTOLARYNGOLOGIST|U|5|Visit_5|90|1|TREATMENT|2021-01-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-01|P1Y2M10DT2H30M|AFTER|2021-01-12|ONGOING|2021-01-18
e|RS|46304edd-0b05-4819-8fcb-35cf9c02764d|1|BMIVLIND|Bone Marrow Involvement Indicator|AJCC V7|[?]|fmol|PMR|1|Antibody Unit|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY||Y||CAREGIVER|ENDOCRINOLOGIST|NA|1|Visit_1|10|6|WASHOUT|2020-12-03|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-02|P1Y2M10DT2H30M|UNKNOWN|2020-11-29|COINCIDENT|2020-12-08
e|RS|46304edd-0b05-4819-8fcb-35cf9c02764d|2|RDIORESP|Radiologic Response|PCWG SCHER PROSTATE CANCER 2008|[?]|WAFER|MRD PERSISTENCE|1|TABLET|MECHANICAL CLOT DETECTION||Y||SPOUSE|READER 2|Y|1|Visit_1|10|4|TREATMENT|2020-12-03|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-02|P1Y2M10DT2H30M|UNKNOWN|2021-01-29|AFTER|2021-02-14
e|RS|46304edd-0b05-4819-8fcb-35cf9c02764d|3|TMRESP|Tumor Marker Response|iRECIST|[?]|cm/min|CA125 75% RESPONSE|1|U/m2/day|POTENTIOMETRY||||DOMESTIC PARTNER|PATHOLOGIST|Y|2|Visit_2|25|3|TREATMENT|2020-12-18|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-29|P1Y2M10DT2H30M|AFTER|2020-12-27|COINCIDENT|2020-12-29
e|RS|46304edd-0b05-4819-8fcb-35cf9c02764d|4|MNPTHIND|Minor Pathological Response Indicator|SCHWARZ CERVICAL CANCER 2009|[?]|mL/s|QUANTIFIABLE MRD POSITIVITY|1|uV|DIFFUSION TENSOR MRI||||ADJUDICATOR|PEDIATRIC NEUROLOGIST|N|2|Visit_2|25|3|TREATMENT|2020-12-18|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-29|P1Y2M10DT2H30M|COINCIDENT|2021-01-26|BEFORE|2021-02-28
e|RS|46304edd-0b05-4819-8fcb-35cf9c02764d|5|SPLNRESP|Spleen Response|MACDONALD GLIOMA 1990|[?]|10^10/L|EQUIVOCAL|1|mEq/ug|LUXOL FAST BLUE AND CRESYL VIOLET STAIN||||INVESTIGATOR|READER 3|Y|3|Visit_3|40|2|TREATMENT|2021-01-02|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-12|P1Y2M10DT2H30M|UNKNOWN|2021-02-21|ONGOING|2021-02-23
e|RS|46304edd-0b05-4819-8fcb-35cf9c02764d|6|MRPHRESP|Morphologic Response|WOLCHOK SOLID TUMORS 2009|||CYTOGENETIC MINIMAL RESPONSE|1|GBq/mg|ELECTRONEUROGRAPHY|||Y|CLINICAL STUDY SPONSOR|UROLOGIST|N|3|Visit_3|40|5|TREATMENT|2021-01-02|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-12|P1Y2M10DT2H30M|AFTER|2021-02-12|ONGOING|2021-02-23
e|RS|46304edd-0b05-4819-8fcb-35cf9c02764d|7|MRDIND|Minimal Residual Disease Indicator|CHOI GIST 2008|||INDETERMINATE RESPONSE|1|mEq|DYNAMIC CONTRAST ENHANCED MRI||Y|Y|INVESTIGATOR|PATHOLOGIST 1|N|4|Visit_4|65|3|TREATMENT|2021-01-27|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-17|P1Y2M10DT2H30M|COINCIDENT|2020-11-26|COINCIDENT|2021-02-11
e|RS|46304edd-0b05-4819-8fcb-35cf9c02764d|8|CYTORESP|Cytogenetic Response|RAJKUMAR MYELOMA 2011|[?]|PATCH|COMPLETE MRD RESPONSE|1|MET*h|FUNDUS PHOTOGRAPHY||||INDEPENDENT ASSESSOR|ONCOLOGIST 2|N|4|Visit_4|65|4|TREATMENT|2021-01-27|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-17|P1Y2M10DT2H30M|COINCIDENT|2021-01-01|ONGOING|2021-01-06
e|RS|46304edd-0b05-4819-8fcb-35cf9c02764d|9|NEWLWIND|New Lesion Worsening Indicator|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|h*%|CYTOGENETIC MINIMAL RESPONSE|1|umol|FLUORESCENT LIFETIME IMAGING MICROSCOPY||||CLINICAL STUDY SPONSOR|ADJUDICATOR|U|5|Visit_5|90|2|FOLLOW-UP|2021-02-21|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-20|P1Y2M10DT2H30M|BEFORE|2021-02-06|BEFORE|2021-02-15
e|RS|46304edd-0b05-4819-8fcb-35cf9c02764d|10|CYTORESP|Cytogenetic Response|KUKER LYMPHOMA 2005|[?]|MESF|FAVORABLE RESPONSE|1|DROP|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS||||CAREGIVER|MICROSCOPIST|U|5|Visit_5|90|1|TREATMENT|2021-02-21|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-20|P1Y2M10DT2H30M|BEFORE|2021-02-05|BEFORE|2021-02-13
e|RS|3fd6dab2-b35f-4cc5-88dd-b507583d9539|1|CPRFSTAT|Clinical Performance Status|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|beats/min|iPR|1|ms2|FLAME PHOTOMETRY|Y|||PARENT|RADIOLOGIST 2|NA|1|Visit_1|10|2|TREATMENT|2020-05-26|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-14|P1Y2M10DT2H30M|AFTER|2020-08-11|ONGOING|2020-08-13
e|RS|3fd6dab2-b35f-4cc5-88dd-b507583d9539|2|MOLRESP|Molecular Response|MONTSERRAT CLL 1989|||PDu|1|nU/cL|HPLC|||Y|GUARDIAN|UROLOGIST|N|1|Visit_1|10|4|TREATMENT|2020-05-26|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-14|P1Y2M10DT2H30M|UNKNOWN|2020-07-08|ONGOING|2020-08-10
e|RS|3fd6dab2-b35f-4cc5-88dd-b507583d9539|3|NEWLWIND|New Lesion Worsening Indicator|IWG CHESON AML 2003|||iUPD|1|ug/dose|FLOW MICROSCOPY|||Y|INTERVIEWER|ADJUDICATOR 2|Y|2|Visit_2|25|2|WASHOUT|2020-06-10|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-05|P1Y2M10DT2H30M|BEFORE|2020-05-20|ONGOING|2020-06-06
e|RS|3fd6dab2-b35f-4cc5-88dd-b507583d9539|4|CLINRESP|Clinical Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|mg/kg/day|EQUIVOCAL|1|10^6 U|IMMUNOCHROMATOGRAPHY|Y|||VENDOR|RADIOLOGIST 2|N|2|Visit_2|25|5|FOLLOW-UP|2020-06-10|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-05|P1Y2M10DT2H30M|COINCIDENT|2020-05-31|AFTER|2020-07-12
e|RS|3fd6dab2-b35f-4cc5-88dd-b507583d9539|5|NEWLPROG|New Lesion Progression|WOLCHOK SOLID TUMORS 2009|[?]|g/animal|MR|1|mg/h|OLIGO ACGH||||CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 2|N|3|Visit_3|40|2|TREATMENT|2020-06-25|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-17|P1Y2M10DT2H30M|COINCIDENT|2020-07-30|COINCIDENT|2020-08-19
e|RS|3fd6dab2-b35f-4cc5-88dd-b507583d9539|6|RDIORESP|Radiologic Response|HAMAOKA BREAST CANCER 2010|||RELAPSED DISEASE FROM CR OR PR|1|/2500 WBC|ANTIMICROBIAL COMBINATION TESTING|||Y|FRIEND|UROLOGIST|N|3|Visit_3|40|4|FOLLOW-UP|2020-06-25|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-17|P1Y2M10DT2H30M|BEFORE|2020-07-04|COINCIDENT|2020-08-08
e|RS|3fd6dab2-b35f-4cc5-88dd-b507583d9539|7|SFTSRESP|Soft Tissue Response|CHESON CLL 2006|[?]|m|HI-E|1|TABLET|COLORIMETRY|Y|Y||PARENT|PHYSIOTHERAPIST|N|4|Visit_4|65|2|SCREENING|2020-07-20|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-09|P1Y2M10DT2H30M|AFTER|2020-07-08|BEFORE|2020-08-21
e|RS|3fd6dab2-b35f-4cc5-88dd-b507583d9539|8|METBRESP|Metabolic Response|DURIE MULTIPLE MYELOMA 2006|||MR|1|ukat/10^12 RBC|CELL BASED BIOASSAY|Y||Y|NON-HEALTH CARE PROFESSIONAL|CARDIOLOGIST|U|4|Visit_4|65|2|TREATMENT|2020-07-20|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-09|P1Y2M10DT2H30M|AFTER|2020-05-20|AFTER|2020-08-08
e|RS|3fd6dab2-b35f-4cc5-88dd-b507583d9539|9|NTERESP|Non-Target Enhancing Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|fmol/g|NON-QUANTIFIABLE MRD POSITIVITY|1|mg/g/min|LC-FL||||CAREGIVER|READER|N|5|Visit_5|90|2|FOLLOW-UP|2020-08-14|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-08|P1Y2M10DT2H30M|AFTER|2020-06-19|BEFORE|2020-07-18
e|RS|3fd6dab2-b35f-4cc5-88dd-b507583d9539|10|NTNERESP|Non-Target Non-Enhancing Response|IWC HALLEK CLL 2008|[?]|ppb|CA125 50% RESPONSE|1|CFU/mL|DXA SCAN||||HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|NA|5|Visit_5|90|3|SCREENING|2020-08-14|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-08|P1Y2M10DT2H30M|AFTER|2020-08-01|COINCIDENT|2020-08-17
e|RS|daa3b89e-637a-43de-86c1-d0db93f00430|1|NEWLPROG|New Lesion Progression|SCHWARZ CERVICAL CANCER 2009|[?]|oz|iPR|1|DRINK|MICROBIAL CULTURE, LIQUID||||SIGNIFICANT OTHER|DEVELOPMENTAL PSYCHOLOGIST|Y|1|Visit_1|10|7|TREATMENT|2020-10-11|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-30|P1Y2M10DT2H30M|COINCIDENT|2020-12-27|BEFORE|2021-01-04
e|RS|daa3b89e-637a-43de-86c1-d0db93f00430|2|MJPTHIND|Major Pathological Response Indicator|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|10^6/hpf|CYTOGENETIC MINIMAL RESPONSE|1|L/min/m2|AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT||||CAREGIVER|ENDOCRINOLOGIST|U|1|Visit_1|10|1|TREATMENT|2020-10-11|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-30|P1Y2M10DT2H30M|AFTER|2021-01-01|ONGOING|2021-01-08
e|RS|daa3b89e-637a-43de-86c1-d0db93f00430|3|BONERESP|Bone Response|IRANO 2015|[?]|mL/m2/day|iCPD|1|ug/L/h|LIQUID SCINTILLATION COUNTING||||INTERVIEWER|OPHTHALMOLOGIST|N|2|Visit_2|25|1|WASHOUT|2020-10-26|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-23|P1Y2M10DT2H30M|UNKNOWN|2020-11-27|AFTER|2021-01-01
e|RS|daa3b89e-637a-43de-86c1-d0db93f00430|4|BONERESP|Bone Response|JACINTO CERVICAL CANCER 2007|[?]|mL/sec/1.73m2|MRD PERSISTENCE|1|mmol|MAPH||||VENDOR|PHYSIOTHERAPIST|Y|2|Visit_2|25|3|TREATMENT|2020-10-26|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-23|P1Y2M10DT2H30M|AFTER|2020-11-09|ONGOING|2020-11-16
e|RS|daa3b89e-637a-43de-86c1-d0db93f00430|5|NEWLPROG|New Lesion Progression|iRECIST|[?]|mL/animal/day|cPR|1|U/10^12 RBC|DROPLET DIGITAL PCR||||STUDY SUBJECT|PEDIATRIC NEUROLOGIST|U|3|Visit_3|40|4|TREATMENT|2020-11-10|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-25|P1Y2M10DT2H30M|AFTER|2020-10-30|COINCIDENT|2020-11-22
e|RS|daa3b89e-637a-43de-86c1-d0db93f00430|6|METBRESP|Metabolic Response|HAMAOKA BREAST CANCER 2010|[?]|atm|MR|1|ukat|ENDOSCOPY|Y|||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|U|3|Visit_3|40|2|SCREENING|2020-11-10|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-25|P1Y2M10DT2H30M|BEFORE|2020-10-07|BEFORE|2020-12-01
e|RS|daa3b89e-637a-43de-86c1-d0db93f00430|7|CPRFSTAT|Clinical Performance Status|NCIWG CHESON CLL 1996|[?]|10^4/hpf|NON-CR/NON-PD|1|keV|ENDPOINT DILUTION ASSAY|Y|||HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|N|4|Visit_4|65|4|FOLLOW-UP|2020-12-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-25|P1Y2M10DT2H30M|AFTER|2020-12-15|ONGOING|2020-12-16
e|RS|daa3b89e-637a-43de-86c1-d0db93f00430|8|NEWLIND|New Lesion Indicator|RECIST 1.1|[?]|mIU/L|nPR|1|/2500 WBC|GC/MS-CI|Y|||INVESTIGATOR|ENDOCRINOLOGIST|NA|4|Visit_4|65|7|WASHOUT|2020-12-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-25|P1Y2M10DT2H30M|BEFORE|2020-10-14|AFTER|2020-12-03
e|RS|daa3b89e-637a-43de-86c1-d0db93f00430|9|NTNERESP|Non-Target Non-Enhancing Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|BAG|QUANTIFIABLE MRD POSITIVITY|1|Arbitrary U|HEMOCYTOMETRY||||HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|NA|5|Visit_5|90|2|SCREENING|2020-12-30|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-06|P1Y2M10DT2H30M|COINCIDENT|2020-11-01|ONGOING|2020-12-13
e|RS|daa3b89e-637a-43de-86c1-d0db93f00430|10|CLINRESP|Clinical Response|RAJKUMAR MYELOMA 2011|[?]|PACKET|INCREASED|1|uV*sec|TRIPLE-PHASE SPIRAL CT SCAN||||SPOUSE|ENDOCRINOLOGIST|N|5|Visit_5|90|4|TREATMENT|2020-12-30|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-06|P1Y2M10DT2H30M|COINCIDENT|2020-12-05|ONGOING|2020-12-30
e|RS|14e9cde0-92f5-48d4-82ec-cc72f07ba40b|1|HEMARESP|Hematologic Response|AJCC V7|[?]|kat|PMD|1|mL/kg/min|BIOPSY||||INVESTIGATOR|CARDIOLOGIST|U|1|Visit_1|10|7|FOLLOW-UP|2020-07-04|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-29|P1Y2M10DT2H30M|COINCIDENT|2020-08-15|ONGOING|2020-08-22
e|RS|14e9cde0-92f5-48d4-82ec-cc72f07ba40b|2|BONERESP|Bone Response|MONTSERRAT CLL 1989|[?]|EP U|RELAPSED DISEASE FROM CR OR PR|1|10^9 CFU/mL|ANGIOGRAPHY|Y|||CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST|NA|1|Visit_1|10|5|WASHOUT|2020-07-04|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-29|P1Y2M10DT2H30M|BEFORE|2020-08-17|AFTER|2020-09-30
e|RS|14e9cde0-92f5-48d4-82ec-cc72f07ba40b|3|RDIORESP|Radiologic Response|KUMAR IMWG 2016|[?]|NEBULE|CHR|1|g/animal/day|PELLI-ROBSON EYE CHART|Y|||PROXY|MICROSCOPIST|Y|2|Visit_2|25|4|SCREENING|2020-07-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-17|P1Y2M10DT2H30M|UNKNOWN|2020-07-14|BEFORE|2020-09-04
e|RS|14e9cde0-92f5-48d4-82ec-cc72f07ba40b|4|MOLRESP|Molecular Response|PCWG SCHER PROSTATE CANCER 2008|[?]|atm|VGPR|1|kg/mol|PATHOLOGICAL EVALUATION||||SPOUSE|ONCOLOGIST|U|2|Visit_2|25|4|SCREENING|2020-07-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-17|P1Y2M10DT2H30M|AFTER|2020-08-29|AFTER|2020-08-30
e|RS|14e9cde0-92f5-48d4-82ec-cc72f07ba40b|5|MNPTHIND|Minor Pathological Response Indicator|MONTSERRAT CLL 1989|||EQUIVOCAL|1|pmol/L|PET/SPECT SCAN|||Y|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 1|NA|3|Visit_3|40|5|TREATMENT|2020-08-03|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-28|P1Y2M10DT2H30M|BEFORE|2020-09-02|COINCIDENT|2020-09-23
e|RS|14e9cde0-92f5-48d4-82ec-cc72f07ba40b|6|TMRESP|Tumor Marker Response|IWG CHESON MDS 2006|[?]|JAR|RELAPSED DISEASE|1|ng/mol|FLUOROSCOPY|Y|Y||CLINICAL STUDY SPONSOR|RATER 1|U|3|Visit_3|40|5|TREATMENT|2020-08-03|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-28|P1Y2M10DT2H30M|AFTER|2020-07-28|ONGOING|2020-09-12
e|RS|14e9cde0-92f5-48d4-82ec-cc72f07ba40b|7|SPLNRESP|Spleen Response|BRUGGEMANN MRD 2010|[?]|NFIU|PD FROM PR|1|L/h/m2|LIGHT MICROSCOPY|Y|||SIBLING|HEMATOLOGIST|N|4|Visit_4|65|6|TREATMENT|2020-08-28|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-17|P1Y2M10DT2H30M|COINCIDENT|2020-09-30|AFTER|2020-10-01
e|RS|14e9cde0-92f5-48d4-82ec-cc72f07ba40b|8|NEWLWIND|New Lesion Worsening Indicator|SHINDOH COLORECTAL CANCER 2013|[?]|PIXELS/cm|CYTOGENETIC MINIMAL RESPONSE|1|Ci/g|SINGLE-MOLECULE ARRAY|Y|Y||STUDY SUBJECT|READER 3|NA|4|Visit_4|65|7|WASHOUT|2020-08-28|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-17|P1Y2M10DT2H30M|UNKNOWN|2020-07-01|AFTER|2020-08-17
e|RS|14e9cde0-92f5-48d4-82ec-cc72f07ba40b|9|SYMPTDTR|Symptomatic Deterioration|LEE LUNG CANCER 2011|[?]|nmol/L/min|PSEUDOPROGRESSION|1|NFIU|ISHIHARA COLOR PLATES||Y||STUDY SUBJECT|OPTOMETRIST|U|5|Visit_5|90|1|TREATMENT|2020-09-22|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-02|P1Y2M10DT2H30M|BEFORE|2020-08-24|COINCIDENT|2020-09-25
e|RS|14e9cde0-92f5-48d4-82ec-cc72f07ba40b|10|LIVRRESP|Liver Response|SHINDOH COLORECTAL CANCER 2013|[?]|10^6 CFU|PD/RELAPSE AFTER HI|1|mm3/mm2/year|MICRONEUTRALIZATION ASSAY||||HEALTH CARE PROFESSIONAL|READER 1|U|5|Visit_5|90|3|TREATMENT|2020-09-22|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-02|P1Y2M10DT2H30M|AFTER|2020-09-20|AFTER|2020-09-23
e|RS|c22014f2-2d7b-4897-8ad5-e46785e51837|1|MNPTHIND|Minor Pathological Response Indicator|MONTSERRAT CLL 1989|[?]|PFU/animal|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|MPL U/mL|QUANTITATIVE COMPUTED TOMOGRAPHY||Y||INDEPENDENT ASSESSOR|RATER|Y|1|Visit_1|10|5|TREATMENT|2020-08-13|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-09|P1Y2M10DT2H30M|UNKNOWN|2020-09-29|COINCIDENT|2020-11-08
e|RS|c22014f2-2d7b-4897-8ad5-e46785e51837|2|ANATRESP|Anatomic Response|AJCC V8|[?]|mmol/g|CYTOGENETIC PR|1|mL/h|MS/MS||||FRIEND|RATER|N|1|Visit_1|10|2|TREATMENT|2020-08-13|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-09|P1Y2M10DT2H30M|AFTER|2020-09-19|BEFORE|2020-09-30
e|RS|c22014f2-2d7b-4897-8ad5-e46785e51837|3|ANATRESP|Anatomic Response|NCIWG CHESON CLL 1996|||SD-CT|1|mmol/L|KARYOTYPING|Y||Y|FRIEND|READER 2|N|2|Visit_2|25|3|TREATMENT|2020-08-28|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-17|P1Y2M10DT2H30M|UNKNOWN|2020-09-17|BEFORE|2020-09-19
e|RS|c22014f2-2d7b-4897-8ad5-e46785e51837|4|MRDIND|Minimal Residual Disease Indicator|HAMAOKA BREAST CANCER 2010|[?]|10^6 IU|CYTOGENETIC PR|1|PA|WESTERN BLOT|Y|||SPOUSE|FORENSIC PATHOLOGIST|NA|2|Visit_2|25|3|FOLLOW-UP|2020-08-28|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-17|P1Y2M10DT2H30M|AFTER|2020-10-02|BEFORE|2020-10-14
e|RS|c22014f2-2d7b-4897-8ad5-e46785e51837|5|MRDIND|Minimal Residual Disease Indicator|MRECIST LENCIONI LIVER CANCER 2010|[?]|10^6/hpf|PARTIAL MORPHOLOGIC RESPONSE|1|/10^4|IMMUNORADIOMETRIC ASSAY|Y|||CLINICAL STUDY SPONSOR|ONCOLOGIST 2|NA|3|Visit_3|40|3|FOLLOW-UP|2020-09-12|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-10|P1Y2M10DT2H30M|AFTER|2020-11-04|COINCIDENT|2020-11-10
e|RS|c22014f2-2d7b-4897-8ad5-e46785e51837|6|SPLNRESP|Spleen Response|IWG CHESON AML 2003|[?]|U/kg/h|MRD NEGATIVITY|1|PFU/mL|IRON HEMATOXYLIN STAIN||Y||HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|U|3|Visit_3|40|1|TREATMENT|2020-09-12|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-10|P1Y2M10DT2H30M|UNKNOWN|2020-08-07|COINCIDENT|2020-10-01
e|RS|c22014f2-2d7b-4897-8ad5-e46785e51837|7|MRPHRESP|Morphologic Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|mU/L|iSD|1|MET*min|CELL BASED BIOASSAY|Y|Y||GUARDIAN|PHYSIOTHERAPIST|U|4|Visit_4|65|5|FOLLOW-UP|2020-10-07|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-05|P1Y2M10DT2H30M|AFTER|2020-09-29|ONGOING|2020-10-31
e|RS|c22014f2-2d7b-4897-8ad5-e46785e51837|8|METBRESP|Metabolic Response|PETIT BREAST CANCER 2001|||CYTOGENETIC NO RESPONSE|1|IU/L|INCISION-INDUCED BLEEDING METHOD|||Y|PROXY|OPTOMETRIST|N|4|Visit_4|65|5|TREATMENT|2020-10-07|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-05|P1Y2M10DT2H30M|COINCIDENT|2020-10-13|BEFORE|2020-10-30
e|RS|c22014f2-2d7b-4897-8ad5-e46785e51837|9|MRDIND|Minimal Residual Disease Indicator|GCIG RUSTIN OVARIAN CANCER 2011|[?]|g/cm2|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|CCID 50/mL|PALPATION||||CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 2|U|5|Visit_5|90|4|WASHOUT|2020-11-01|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-07|P1Y2M10DT2H30M|COINCIDENT|2020-09-22|ONGOING|2020-11-06
e|RS|c22014f2-2d7b-4897-8ad5-e46785e51837|10|BESTRESP|Best Overall Response|NCIWG CHESON CLL 1996|[?]|10^7 CFU/mL|PSEUDORESPONSE|1|PFU/dose|GC/MS/MS||||CLINICAL STUDY SPONSOR|ONCOLOGIST 2|Y|5|Visit_5|90|6|WASHOUT|2020-11-01|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-07|P1Y2M10DT2H30M|AFTER|2020-11-08|ONGOING|2020-11-10
e|RS|987102b2-fe2f-4d72-b8dc-14a71bf034b5|1|BMIVLIND|Bone Marrow Involvement Indicator|PETIT BREAST CANCER 2001|[?]|dram|PSEUDOPROGRESSION|1|10^3 DNA copies/mL|CORONARY ANGIOGRAPHY||||SIBLING|MICROSCOPIST 1|N|1|Visit_1|10|7|FOLLOW-UP|2020-10-11|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-17|P1Y2M10DT2H30M|BEFORE|2020-10-09|COINCIDENT|2020-10-28
e|RS|987102b2-fe2f-4d72-b8dc-14a71bf034b5|2|CLINRESP|Clinical Response|SCHER PROSTATE CANCER 2011|[?]|/mm2|QUANTIFIABLE MRD POSITIVITY|1|mEq/day|IMPULSE OSCILLOMETRY||||INVESTIGATOR|UROLOGIST|U|1|Visit_1|10|1|SCREENING|2020-10-11|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-17|P1Y2M10DT2H30M|UNKNOWN|2020-11-20|AFTER|2020-12-24
e|RS|987102b2-fe2f-4d72-b8dc-14a71bf034b5|3|NEWLWIND|New Lesion Worsening Indicator|NCCN ALL MRD 2014|||UNFAVORABLE RESPONSE|1|VOXEL|X-RAY FLUORESCENCE SPECTROMETRY|||Y|CAREGIVER|FORENSIC PATHOLOGIST|Y|2|Visit_2|25|5|TREATMENT|2020-10-26|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-11|P1Y2M10DT2H30M|UNKNOWN|2020-11-03|AFTER|2020-11-30
e|RS|987102b2-fe2f-4d72-b8dc-14a71bf034b5|4|MOLRESP|Molecular Response|LEE LUNG CANCER 2011|||MINOR PATHOLOGIC RESPONSE|1|deg|MICROBIAL CONCENTRATION||Y|Y|FAMILY MEMBER|CLINICAL PATHOLOGIST|NA|2|Visit_2|25|1|TREATMENT|2020-10-26|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-11|P1Y2M10DT2H30M|BEFORE|2020-12-22|BEFORE|2020-12-27
e|RS|987102b2-fe2f-4d72-b8dc-14a71bf034b5|5|NTLWIND|Non-Target Lesion Worsening Indicator|WHO BREAST CANCER 2006|[?]|10^6/L|PMD|1|BAU/mL|RADIAL IMMUNODIFFUSION||||NON-HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|Y|3|Visit_3|40|6|TREATMENT|2020-11-10|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-03|P1Y2M10DT2H30M|AFTER|2020-10-13|ONGOING|2020-11-10
e|RS|987102b2-fe2f-4d72-b8dc-14a71bf034b5|6|NTLWIND|Non-Target Lesion Worsening Indicator|iRECIST|||CHR|1|% INHIBITION|POLYMERASE CHAIN REACTION|||Y|PARENT|OTOLARYNGOLOGIST|N|3|Visit_3|40|4|WASHOUT|2020-11-10|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-03|P1Y2M10DT2H30M|COINCIDENT|2020-12-08|BEFORE|2020-12-19
e|RS|987102b2-fe2f-4d72-b8dc-14a71bf034b5|7|CLINRESP|Clinical Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|||PD-CT|1|Ci/g|MICRONEUTRALIZATION ASSAY|||Y|PARENT|READER 3|Y|4|Visit_4|65|5|SCREENING|2020-12-05|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-14|P1Y2M10DT2H30M|UNKNOWN|2021-01-04|ONGOING|2021-01-05
e|RS|987102b2-fe2f-4d72-b8dc-14a71bf034b5|8|NTNERESP|Non-Target Non-Enhancing Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|1/(s*kPa)|SD|1|ug/dL|CALCULATION||Y||PARENT|RADIOLOGIST|U|4|Visit_4|65|1|SCREENING|2020-12-05|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-14|P1Y2M10DT2H30M|AFTER|2020-12-12|ONGOING|2020-12-25
e|RS|987102b2-fe2f-4d72-b8dc-14a71bf034b5|9|CYTORESP|Cytogenetic Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|mEq/day|NE|1|RATIO|ANALYTICAL ULTRACENTRIFUGATION||||FRIEND|FORENSIC PATHOLOGIST|N|5|Visit_5|90|1|SCREENING|2020-12-30|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-20|P1Y2M10DT2H30M|AFTER|2020-11-17|BEFORE|2020-12-02
e|RS|987102b2-fe2f-4d72-b8dc-14a71bf034b5|10|HEMARESP|Hematologic Response|JACINTO CERVICAL CANCER 2007|[?]|umol/min|cCR|1|steps/min|MICROSCOPY|Y|||CHILD|PATHOLOGIST 1|U|5|Visit_5|90|3|WASHOUT|2020-12-30|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-20|P1Y2M10DT2H30M|UNKNOWN|2020-11-03|COINCIDENT|2020-12-31
e|RS|24ce0c77-1921-4b87-91da-3627e2afd399|1|BESTRESP|Best Overall Response|CHOI GIST 2008|[?]|IU/g Hb|MORPHOLOGIC LEUKEMIA-FREE STATE|1|RFU|MOUSE PROTECTION ASSAY||||VENDOR|ENDOCRINOLOGIST|NA|1|Visit_1|10|1|TREATMENT|2021-01-29|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-25|P1Y2M10DT2H30M|COINCIDENT|2021-02-18|AFTER|2021-04-16
e|RS|24ce0c77-1921-4b87-91da-3627e2afd399|2|CYTORESP|Cytogenetic Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|g|EQUIVOCAL|1|EP U|COULOMETRIC TITRATION||||SIGNIFICANT OTHER|RADIOLOGIST 1|N|1|Visit_1|10|5|TREATMENT|2021-01-29|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-25|P1Y2M10DT2H30M|COINCIDENT|2021-03-30|ONGOING|2021-04-01
e|RS|24ce0c77-1921-4b87-91da-3627e2afd399|3|NTNERESP|Non-Target Non-Enhancing Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|PIXELS/cm|PSA PROGRESSION|1|MASK|IMMUNORADIOMETRIC ASSAY||Y||INVESTIGATOR|PEDIATRIC NEUROLOGIST|NA|2|Visit_2|25|6|SCREENING|2021-02-13|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-24|P1Y2M10DT2H30M|UNKNOWN|2021-03-30|ONGOING|2021-04-04
e|RS|24ce0c77-1921-4b87-91da-3627e2afd399|4|HEMARESP|Hematologic Response|CHOLLET BREAST CANCER 2002|[?]|cP|PSEUDORESPONSE|1|ELISA unit|REAL-TIME POLYMERASE CHAIN REACTION ASSAY|Y|Y||SIBLING|INTERNIST|Y|2|Visit_2|25|7|WASHOUT|2021-02-13|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-24|P1Y2M10DT2H30M|COINCIDENT|2021-03-20|AFTER|2021-03-29
e|RS|24ce0c77-1921-4b87-91da-3627e2afd399|5|MRPHRESP|Morphologic Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|||MRD NEGATIVITY|1|pmol/10^9 cells|TEST STRIP||Y|Y|SIBLING|ADJUDICATOR 2|Y|3|Visit_3|40|7|TREATMENT|2021-02-28|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-10|P1Y2M10DT2H30M|UNKNOWN|2021-04-11|ONGOING|2021-04-23
e|RS|24ce0c77-1921-4b87-91da-3627e2afd399|6|OVRLRESP|Overall Response|IWG CHESON MDS 2006|[?]|mOsm/kg|STABLE|1|%(v/v)|PERIPHERAL ANGIOGRAPHY||||GUARDIAN|MICROSCOPIST|N|3|Visit_3|40|5|TREATMENT|2021-02-28|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-10|P1Y2M10DT2H30M|AFTER|2021-03-07|ONGOING|2021-04-18
e|RS|24ce0c77-1921-4b87-91da-3627e2afd399|7|DRCRIND|Disease Recurrence Indicator|DURIE MULTIPLE MYELOMA 2006|[?]|GPL U|nPR|1|ug/mol|PET SCAN||||ADJUDICATOR|ADJUDICATOR 2|N|4|Visit_4|65|4|SCREENING|2021-03-25|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-05|P1Y2M10DT2H30M|UNKNOWN|2021-04-25|COINCIDENT|2021-04-27
e|RS|24ce0c77-1921-4b87-91da-3627e2afd399|8|TMRESP|Tumor Marker Response|MRECIST LENCIONI LIVER CANCER 2010|||UNEQUIVOCAL|1|cd|DIGITAL PCR||Y|Y|INVESTIGATOR|CARDIOLOGIST|Y|4|Visit_4|65|1|WASHOUT|2021-03-25|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-05|P1Y2M10DT2H30M|AFTER|2021-02-12|COINCIDENT|2021-04-20
e|RS|24ce0c77-1921-4b87-91da-3627e2afd399|9|OVRLRESP|Overall Response|HARTMAN PANCREATIC CANCER 2012|||CYTOGENETIC MINIMAL RESPONSE|1|uIU/L|HEMOCYTOMETRY|||Y|PARENT|MICROSCOPIST 3|U|5|Visit_5|90|3|TREATMENT|2021-04-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-23|P1Y2M10DT2H30M|BEFORE|2021-02-14|AFTER|2021-04-09
e|RS|24ce0c77-1921-4b87-91da-3627e2afd399|10|NTRGRESP|Non-target Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|10^4 CFU/mL|PSEUDORESPONSE|1|cmH2O/mL|ELISA|Y|||PARENT|READER 1|Y|5|Visit_5|90|4|SCREENING|2021-04-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-23|P1Y2M10DT2H30M|COINCIDENT|2021-03-21|ONGOING|2021-03-23
e|RS|097351a3-9bb2-4af7-8e96-6d4d9d8ccf87|1|MOLRESP|Molecular Response|CHOI GIST 2008|[?]|L/kg|RELAPSED DISEASE|1|ft3|CISH||||CHILD|READER 2|NA|1|Visit_1|10|1|TREATMENT|2020-08-20|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-13|P1Y2M10DT2H30M|COINCIDENT|2020-09-03|COINCIDENT|2020-10-04
e|RS|097351a3-9bb2-4af7-8e96-6d4d9d8ccf87|2|MRDRESP|Minimal Residual Disease Response|SCHER PROSTATE CANCER 2011|[?]|g/animal/day|OPTIMAL MORPHOLOGIC RESPONSE|1|mEq/day|DNA MICROARRAY|Y|||INTERVIEWER|OPHTHALMOLOGIST|N|1|Visit_1|10|5|SCREENING|2020-08-20|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-13|P1Y2M10DT2H30M|COINCIDENT|2020-09-18|AFTER|2020-10-06
e|RS|097351a3-9bb2-4af7-8e96-6d4d9d8ccf87|3|SPLNRESP|Spleen Response|GUILHOT CML 2007|[?]|g/animal|PSEUDORESPONSE|1|10^3 CFU/g|REFRACTOMETRY|Y|||CLINICAL RESEARCH ASSOCIATE|FORENSIC PATHOLOGIST|Y|2|Visit_2|25|2|FOLLOW-UP|2020-09-04|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-19|P1Y2M10DT2H30M|COINCIDENT|2020-11-06|COINCIDENT|2020-11-08
e|RS|097351a3-9bb2-4af7-8e96-6d4d9d8ccf87|4|NEWLWIND|New Lesion Worsening Indicator|MONTSERRAT CLL 1989|[?]|TRANSDUCING UNIT/mL|UNFAVORABLE RESPONSE|1|km|MRS|Y|||FRIEND|MICROSCOPIST 3|N|2|Visit_2|25|6|TREATMENT|2020-09-04|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-19|P1Y2M10DT2H30M|BEFORE|2020-09-15|COINCIDENT|2020-11-04
e|RS|097351a3-9bb2-4af7-8e96-6d4d9d8ccf87|5|SPLNRESP|Spleen Response|CHESON LYMPHOMA 2008|[?]|TABLET|MORPHOLOGIC LEUKEMIA-FREE STATE|1|/10^3|TRICHROME STAIN|Y|||CAREGIVER|RADIOLOGIST 1|NA|3|Visit_3|40|4|SCREENING|2020-09-19|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-07|P1Y2M10DT2H30M|UNKNOWN|2020-11-14|ONGOING|2020-11-15
e|RS|097351a3-9bb2-4af7-8e96-6d4d9d8ccf87|6|NEWLWIND|New Lesion Worsening Indicator|NCCN ALL MRD 2014|||CR-CT|1|FIU|CELLULAR PROLIFERATION ASSAY|Y||Y|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|N|3|Visit_3|40|2|TREATMENT|2020-09-19|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-07|P1Y2M10DT2H30M|AFTER|2020-10-26|BEFORE|2020-11-03
e|RS|097351a3-9bb2-4af7-8e96-6d4d9d8ccf87|7|NTERESP|Non-Target Enhancing Response|UNSPECIFIED|||MORPHOLOGIC CRi|1|IU/mmol|IN SITU HYBRIDIZATION|Y||Y|ADJUDICATION COMMITTEE|DEVELOPMENTAL PSYCHOLOGIST|N|4|Visit_4|65|5|TREATMENT|2020-10-14|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-12|P1Y2M10DT2H30M|UNKNOWN|2020-11-13|COINCIDENT|2020-11-14
e|RS|097351a3-9bb2-4af7-8e96-6d4d9d8ccf87|8|CYTORESP|Cytogenetic Response|AJCC V8|[?]|km/h|PMD|1|cs|ISHIHARA COLOR PLATES||||CAREGIVER|RATER 2|N|4|Visit_4|65|3|SCREENING|2020-10-14|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-12|P1Y2M10DT2H30M|COINCIDENT|2020-10-06|BEFORE|2020-11-02
e|RS|097351a3-9bb2-4af7-8e96-6d4d9d8ccf87|9|NEWLPROG|New Lesion Progression|RECIST 1.1|||HI-P|1|tuberculin unit/mL|REFRACTOMETRY|Y||Y|GUARDIAN|RADIOLOGIST 2|N|5|Visit_5|90|6|WASHOUT|2020-11-08|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-23|P1Y2M10DT2H30M|UNKNOWN|2020-09-23|AFTER|2020-11-02
e|RS|097351a3-9bb2-4af7-8e96-6d4d9d8ccf87|10|NTLWIND|Non-Target Lesion Worsening Indicator|IWG CHESON MDS 2006|[?]|mJoule/cm2|MORPHOLOGIC CRi|1|/kg|DIGITAL PCR ARRAY||Y||ADJUDICATOR|NEUROLOGIST|U|5|Visit_5|90|7|TREATMENT|2020-11-08|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-23|P1Y2M10DT2H30M|BEFORE|2020-10-23|COINCIDENT|2020-10-25
e|RS|f4b83a72-7cde-4e02-8883-05e789c617a8|1|ANATRESP|Anatomic Response|GUPPY OVARIAN CANCER 2002|[?]|mgEq|RELAPSED DISEASE|1|10^6 IU|CLINICAL EVALUATION|Y|Y||SIBLING|NEUROLOGIST 2|N|1|Visit_1|10|4|FOLLOW-UP|2020-12-25|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-19|P1Y2M10DT2H30M|COINCIDENT|2020-12-30|COINCIDENT|2021-01-28
e|RS|f4b83a72-7cde-4e02-8883-05e789c617a8|2|CLINRESP|Clinical Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|||PD/RELAPSE AFTER HI|1|10^4 CFU|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION|||Y|CHILD|PATHOLOGIST 2|Y|1|Visit_1|10|7|FOLLOW-UP|2020-12-25|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-19|P1Y2M10DT2H30M|AFTER|2021-02-13|ONGOING|2021-03-17
e|RS|f4b83a72-7cde-4e02-8883-05e789c617a8|3|METBRESP|Metabolic Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|PIXELS/cm|HI-P|1|10^12 IU/L|DIFFUSION TENSOR MRI||||PROXY|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|2|Visit_2|25|5|TREATMENT|2021-01-09|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-22|P1Y2M10DT2H30M|BEFORE|2021-03-08|ONGOING|2021-03-23
e|RS|f4b83a72-7cde-4e02-8883-05e789c617a8|4|TMRESP|Tumor Marker Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|genEq/mL|NR|1|ug/L DDU|PLETHYSMOGRAPHY||Y||INDEPENDENT ASSESSOR|ENDOCRINOLOGIST|U|2|Visit_2|25|5|FOLLOW-UP|2021-01-09|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-22|P1Y2M10DT2H30M|BEFORE|2021-02-19|ONGOING|2021-03-02
e|RS|f4b83a72-7cde-4e02-8883-05e789c617a8|5|HEMARESP|Hematologic Response|RANO|[?]|GBq/g|CYTOGENETIC MINIMAL RESPONSE|1|10^9 CFU|POLYSOMNOGRAPHY||||VENDOR|OPHTHALMOLOGIST|Y|3|Visit_3|40|5|SCREENING|2021-01-24|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-18|P1Y2M10DT2H30M|AFTER|2021-03-08|COINCIDENT|2021-03-13
e|RS|f4b83a72-7cde-4e02-8883-05e789c617a8|6|TMRESP|Tumor Marker Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|||CA125 75% RESPONSE|1|ug/L|IMMUNO-PET SCAN|||Y|FRIEND|NEUROLOGIST 1|U|3|Visit_3|40|6|WASHOUT|2021-01-24|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-18|P1Y2M10DT2H30M|COINCIDENT|2021-02-07|ONGOING|2021-03-20
e|RS|f4b83a72-7cde-4e02-8883-05e789c617a8|7|MRDRESP|Minimal Residual Disease Response|FAROOQUI SUPP CLL 2014|[?]|s*kPa|SD-CT|1|U/kg/min|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY||||FAMILY MEMBER|INTERNIST|N|4|Visit_4|65|6|TREATMENT|2021-02-18|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-08|P1Y2M10DT2H30M|COINCIDENT|2021-03-03|ONGOING|2021-03-10
e|RS|f4b83a72-7cde-4e02-8883-05e789c617a8|8|CLINRESP|Clinical Response|AJCC V8|[?]|U/m2/day|PSEUDORESPONSE|1|Enzyme U|TURBIDIMETRY||||ADJUDICATION COMMITTEE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|4|Visit_4|65|1|TREATMENT|2021-02-18|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-08|P1Y2M10DT2H30M|UNKNOWN|2021-03-01|COINCIDENT|2021-03-24
e|RS|f4b83a72-7cde-4e02-8883-05e789c617a8|9|LIVRRESP|Liver Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|USP U|CA125 50% RESPONSE|1|ug/mol|IMMUNODIFFUSION|Y|||SIBLING|READER 3|NA|5|Visit_5|90|2|TREATMENT|2021-03-15|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-19|P1Y2M10DT2H30M|UNKNOWN|2021-01-06|COINCIDENT|2021-03-09
e|RS|f4b83a72-7cde-4e02-8883-05e789c617a8|10|PATHRESP|Pathologic Response|PCWG SCHER PROSTATE CANCER 2008|[?]|BU|pCR|1|pm|SISH||||NON-HEALTH CARE PROFESSIONAL|READER 3|Y|5|Visit_5|90|4|TREATMENT|2021-03-15|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-19|P1Y2M10DT2H30M|COINCIDENT|2021-01-15|ONGOING|2021-03-17
e|RS|c4087538-422a-4bcf-af25-ed4aab36ed4b|1|HEMARESP|Hematologic Response|FAROOQUI SUPP CLL 2014|||UNEQUIVOCAL|1|mEq/day|AUDIOMETRY||Y|Y|FAMILY MEMBER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|1|Visit_1|10|7|TREATMENT|2021-01-09|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-30|P1Y2M10DT2H30M|AFTER|2021-01-17|ONGOING|2021-02-18
e|RS|c4087538-422a-4bcf-af25-ed4aab36ed4b|2|SYMPTDTR|Symptomatic Deterioration|SCHER PROSTATE CANCER 2011|[?]|mL/mmHg/min/L|iSD|1|10^9 organisms/mL|URANYL ACETATE STAIN||||FAMILY MEMBER|PATHOLOGIST 2|NA|1|Visit_1|10|2|WASHOUT|2021-01-09|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-30|P1Y2M10DT2H30M|COINCIDENT|2021-03-26|BEFORE|2021-03-30
e|RS|c4087538-422a-4bcf-af25-ed4aab36ed4b|3|NTERESP|Non-Target Enhancing Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|ug/m2/day|PR|1|mm/h|TOLUIDINE BLUE STAIN||||GUARDIAN|ONCOLOGIST 2|N|2|Visit_2|25|6|TREATMENT|2021-01-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-31|P1Y2M10DT2H30M|BEFORE|2021-02-06|BEFORE|2021-03-28
e|RS|c4087538-422a-4bcf-af25-ed4aab36ed4b|4|LIVRRESP|Liver Response|HARTMANN GERM CELL CANCER 2002|[?]|CYLINDER|HI-N|1|Ci|OSCILLOMETRY||Y||INTERVIEWER|PATHOLOGIST|U|2|Visit_2|25|6|TREATMENT|2021-01-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-31|P1Y2M10DT2H30M|AFTER|2021-02-14|BEFORE|2021-02-25
e|RS|c4087538-422a-4bcf-af25-ed4aab36ed4b|5|NEWLWIND|New Lesion Worsening Indicator|PETIT BREAST CANCER 2001|||PARTIAL MORPHOLOGIC RESPONSE|1|log10 TCID 50/uL|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|||Y|FAMILY MEMBER|ENDOCRINOLOGIST|U|3|Visit_3|40|4|WASHOUT|2021-02-08|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-02|P1Y2M10DT2H30M|AFTER|2021-03-08|BEFORE|2021-03-31
e|RS|c4087538-422a-4bcf-af25-ed4aab36ed4b|6|RDIORESP|Radiologic Response|LUGANO CLASSIFICATION|[?]|GPL U|PSEUDORESPONSE|1|DAgU/mL|SICKLE CELL SOLUBILITY TEST||||CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 1|U|3|Visit_3|40|5|SCREENING|2021-02-08|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-02|P1Y2M10DT2H30M|AFTER|2021-01-29|COINCIDENT|2021-02-09
e|RS|c4087538-422a-4bcf-af25-ed4aab36ed4b|7|HEMARESP|Hematologic Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|VIAL|iUPD|1|g/L|TRICHROME STAIN||||GUARDIAN|RATER|U|4|Visit_4|65|6|TREATMENT|2021-03-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-28|P1Y2M10DT2H30M|AFTER|2021-01-22|AFTER|2021-03-01
e|RS|c4087538-422a-4bcf-af25-ed4aab36ed4b|8|NEWLPROG|New Lesion Progression|HARTMAN PANCREATIC CANCER 2012|[?]|atm|PR|1|cycle/min|AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT||||FRIEND|ADJUDICATOR 3|U|4|Visit_4|65|1|WASHOUT|2021-03-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-28|P1Y2M10DT2H30M|AFTER|2021-02-17|ONGOING|2021-04-08
e|RS|c4087538-422a-4bcf-af25-ed4aab36ed4b|9|OVRLRESP|Overall Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|CCID 50/mL|NED|1|10^3 organisms/mL|X-RAY FLUORESCENCE SPECTROMETRY||Y||GUARDIAN|ADJUDICATOR 3|NA|5|Visit_5|90|4|TREATMENT|2021-03-30|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-12|P1Y2M10DT2H30M|AFTER|2021-02-26|COINCIDENT|2021-03-15
e|RS|c4087538-422a-4bcf-af25-ed4aab36ed4b|10|DRCRIND|Disease Recurrence Indicator|DOHNER AML 2010|||SD-CT|1|PATCH|AUDIOMETRY|||Y|STUDY SUBJECT|OTOLARYNGOLOGIST|Y|5|Visit_5|90|2|TREATMENT|2021-03-30|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-12|P1Y2M10DT2H30M|BEFORE|2021-03-24|COINCIDENT|2021-03-25
e|RS|947aefaf-20c7-47fc-ac56-140f9b6f38f3|1|MRDRESP|Minimal Residual Disease Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|g/cage|INDETERMINATE RESPONSE|1|mJoule/cm2|FLUORESCENT LIFETIME IMAGING MICROSCOPY||Y||FRIEND|INTERNIST|NA|1|Visit_1|10|4|FOLLOW-UP|2020-11-06|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-07|P1Y2M10DT2H30M|BEFORE|2021-02-03|COINCIDENT|2021-02-04
e|RS|947aefaf-20c7-47fc-ac56-140f9b6f38f3|2|METSIND|Metastatic Indicator|PCWG SCHER PROSTATE CANCER 2008|||CRi|1|U/mL|DXA SCAN|||Y|HEALTH CARE PROFESSIONAL|NEUROLOGIST|Y|1|Visit_1|10|3|WASHOUT|2020-11-06|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-07|P1Y2M10DT2H30M|COINCIDENT|2020-12-30|ONGOING|2021-01-19
e|RS|947aefaf-20c7-47fc-ac56-140f9b6f38f3|3|STRUSTAT|Steroid Use Status|PERCIST|[?]|lm|RELAPSED DISEASE FROM CR|1|atm|WRIGHT STAIN||||CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST|Y|2|Visit_2|25|2|FOLLOW-UP|2020-11-21|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-12|P1Y2M10DT2H30M|AFTER|2020-11-04|AFTER|2021-01-25
e|RS|947aefaf-20c7-47fc-ac56-140f9b6f38f3|4|PATHRESP|Pathologic Response|NCIWG CHESON CLL 1996|[?]|EID 50/dose|RELAPSED DISEASE FROM CR OR PR|1|10^12/L|AURAMINE STAIN||Y||CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 2|Y|2|Visit_2|25|2|TREATMENT|2020-11-21|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-12|P1Y2M10DT2H30M|COINCIDENT|2020-11-22|COINCIDENT|2020-12-07
e|RS|947aefaf-20c7-47fc-ac56-140f9b6f38f3|5|NTNERESP|Non-Target Non-Enhancing Response|PCWG SCHER PROSTATE CANCER 2016|[?]|U/m2/min|HI-P|1|yd|EPSILOMETER||||SIBLING|CLINICAL PATHOLOGIST|Y|3|Visit_3|40|2|WASHOUT|2020-12-06|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-14|P1Y2M10DT2H30M|COINCIDENT|2020-11-21|COINCIDENT|2021-01-12
e|RS|947aefaf-20c7-47fc-ac56-140f9b6f38f3|6|NTNERESP|Non-Target Non-Enhancing Response|PCWG SCHER PROSTATE CANCER 2016|[?]|mEq/dL|iCR|1|mm|MRI||Y||CLINICAL STUDY SPONSOR|PATHOLOGIST|NA|3|Visit_3|40|7|TREATMENT|2020-12-06|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-14|P1Y2M10DT2H30M|BEFORE|2020-10-30|BEFORE|2020-11-30
e|RS|947aefaf-20c7-47fc-ac56-140f9b6f38f3|7|LIVRRESP|Liver Response|PETIT BREAST CANCER 2001|[?]|mol/g|cCR|1|CONTAINER|NUCLEIC ACID SEQUENCING||||FAMILY MEMBER|RATER 1|N|4|Visit_4|65|6|TREATMENT|2020-12-31|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-22|P1Y2M10DT2H30M|AFTER|2020-11-27|AFTER|2021-01-25
e|RS|947aefaf-20c7-47fc-ac56-140f9b6f38f3|8|CPRFSTAT|Clinical Performance Status|MRECIST BYRNE MESOTHELIOMA 2004|[?]|g/cage/day|INCREASED|1|tuberculin unit|HILLMEN COLOR CHART|Y|||STUDY SUBJECT|READER|N|4|Visit_4|65|2|TREATMENT|2020-12-31|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-22|P1Y2M10DT2H30M|UNKNOWN|2020-11-05|BEFORE|2020-12-23
e|RS|947aefaf-20c7-47fc-ac56-140f9b6f38f3|9|MRPHRESP|Morphologic Response|CHESON CLL 2012|[?]|dpm/mg|STABLE|1|nmol|SNP ARRAY||||INTERVIEWER|PHYSIOTHERAPIST|N|5|Visit_5|90|1|SCREENING|2021-01-25|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-08|P1Y2M10DT2H30M|COINCIDENT|2020-11-17|AFTER|2021-01-29
e|RS|947aefaf-20c7-47fc-ac56-140f9b6f38f3|10|NTLWIND|Non-Target Lesion Worsening Indicator|EBMT BLADE MYELOMA 1998|[?]|10^4/L|NON-CR/NON-PD|1|10^6 U|HPLC-FL|Y|||INVESTIGATOR|READER 1|NA|5|Visit_5|90|3|WASHOUT|2021-01-25|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-08|P1Y2M10DT2H30M|UNKNOWN|2020-11-17|COINCIDENT|2021-01-10
e|RS|3a0c00eb-5614-4053-844d-6bdb71efb1cd|1|LIVRRESP|Liver Response|RANO ELLINGSON 2017|[?]|yd|CYTOGENETIC MINIMAL RESPONSE|1|/LPF|CLIP||||CHILD|READER|NA|1|Visit_1|10|3|TREATMENT|2020-08-11|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-05|P1Y2M10DT2H30M|UNKNOWN|2020-09-23|BEFORE|2020-10-29
e|RS|3a0c00eb-5614-4053-844d-6bdb71efb1cd|2|NTNERESP|Non-Target Non-Enhancing Response|KUMAR IMWG 2016|[?]|nmol/L/min|WORSENED|1|V/sec|CELLULOSE TAPE||||INDEPENDENT ASSESSOR|NEUROLOGIST 2|Y|1|Visit_1|10|4|TREATMENT|2020-08-11|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-05|P1Y2M10DT2H30M|AFTER|2020-10-05|BEFORE|2020-10-17
e|RS|3a0c00eb-5614-4053-844d-6bdb71efb1cd|3|MNPTHIND|Minor Pathological Response Indicator|RECIST 1.0|[?]|CCID 50/dose|DECREASED|1|ug/kg/min|ELISPOT||||INTERVIEWER|OPTOMETRIST|NA|2|Visit_2|25|2|TREATMENT|2020-08-26|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-12|P1Y2M10DT2H30M|COINCIDENT|2020-09-02|ONGOING|2020-09-29
e|RS|3a0c00eb-5614-4053-844d-6bdb71efb1cd|4|OVRLRESP|Overall Response|AJCC V7|||NON-QUANTIFIABLE MRD POSITIVITY|1|10^6 CFU/g|LIGHT MICROSCOPY|||Y|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 1|Y|2|Visit_2|25|3|TREATMENT|2020-08-26|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-12|P1Y2M10DT2H30M|BEFORE|2020-09-19|BEFORE|2020-09-23
e|RS|3a0c00eb-5614-4053-844d-6bdb71efb1cd|5|RDIORESP|Radiologic Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|h/wk|cPR|1|mL/h|ENDPOINT DILUTION ASSAY||||SIBLING|INTERNIST|NA|3|Visit_3|40|6|SCREENING|2020-09-10|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-01|P1Y2M10DT2H30M|BEFORE|2020-08-11|AFTER|2020-08-30
e|RS|3a0c00eb-5614-4053-844d-6bdb71efb1cd|6|BESTRESP|Best Overall Response|IWG CHESON MDS 2006|[?]|Joule|EQUIVOCAL|1|mV|SPECT/CT SCAN||||PROXY|RADIOLOGIST|U|3|Visit_3|40|3|TREATMENT|2020-09-10|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-01|P1Y2M10DT2H30M|AFTER|2020-10-14|COINCIDENT|2020-11-07
e|RS|3a0c00eb-5614-4053-844d-6bdb71efb1cd|7|NEWLIND|New Lesion Indicator|IRANO 2015|[?]|mmol/min/kPa|RELAPSED DISEASE|1|ft3|WHOLE EXOME SEQUENCING||||SIGNIFICANT OTHER|PATHOLOGIST 1|Y|4|Visit_4|65|2|SCREENING|2020-10-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-08|P1Y2M10DT2H30M|BEFORE|2020-08-13|AFTER|2020-08-21
e|RS|3a0c00eb-5614-4053-844d-6bdb71efb1cd|8|MJPTHIND|Major Pathological Response Indicator|BLAZER COLORECTAL CANCER 2008|[?]|PUFF|MR|1|Bq/ug|TONOMETRY|Y|||SIGNIFICANT OTHER|RADIOLOGIST|U|4|Visit_4|65|3|FOLLOW-UP|2020-10-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-08|P1Y2M10DT2H30M|UNKNOWN|2020-10-04|COINCIDENT|2020-10-19
e|RS|3a0c00eb-5614-4053-844d-6bdb71efb1cd|9|NTLWIND|Non-Target Lesion Worsening Indicator|KUMAR IMWG 2016|[?]|10^9 CFU/mL|MORPHOLOGIC CRi|1|mg/h|SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY||||PROXY|READER 2|N|5|Visit_5|90|5|FOLLOW-UP|2020-10-30|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-26|P1Y2M10DT2H30M|COINCIDENT|2020-08-06|ONGOING|2020-09-12
e|RS|3a0c00eb-5614-4053-844d-6bdb71efb1cd|10|OVRLRESP|Overall Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|dpm/100mg|HI-P|1|mEq/day|MULTIPLEXED BEAD BASED IMMUNOASSAY|Y|||INDEPENDENT ASSESSOR|PEDIATRIC NEUROLOGIST|NA|5|Visit_5|90|6|TREATMENT|2020-10-30|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-26|P1Y2M10DT2H30M|AFTER|2020-10-09|BEFORE|2020-10-17
e|RS|dc3ce247-24dd-4255-85a8-ec7a58d30c86|1|NTNERESP|Non-Target Non-Enhancing Response|SCHER PROSTATE CANCER 2011|[?]|DRINK|PR-CT|1|cm|ZIEHL NEELSEN ACID FAST STAIN|Y|||CAREGIVER|HEMATOLOGIST|U|1|Visit_1|10|1|TREATMENT|2020-10-11|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-24|P1Y2M10DT2H30M|COINCIDENT|2020-12-14|AFTER|2020-12-27
e|RS|dc3ce247-24dd-4255-85a8-ec7a58d30c86|2|NEWLPROG|New Lesion Progression|MRECIST BYRNE MESOTHELIOMA 2004|[?]|Ci/ug|HI-P|1|SBE/mL|PERCUSSION|Y|Y||CAREGIVER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|1|Visit_1|10|5|TREATMENT|2020-10-11|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-24|P1Y2M10DT2H30M|BEFORE|2020-11-10|ONGOING|2020-11-22
e|RS|dc3ce247-24dd-4255-85a8-ec7a58d30c86|3|STRUSTAT|Steroid Use Status|BLAZER COLORECTAL CANCER 2008|[?]|U.CARR|HI-N|1|MAC50|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION||||FAMILY MEMBER|ONCOLOGIST 2|Y|2|Visit_2|25|1|TREATMENT|2020-10-26|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-31|P1Y2M10DT2H30M|COINCIDENT|2020-10-19|BEFORE|2020-10-30
e|RS|dc3ce247-24dd-4255-85a8-ec7a58d30c86|4|MRPHRESP|Morphologic Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|||PARTIAL MORPHOLOGIC RESPONSE|1|10^9 CFU/g|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|Y|Y|Y|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 2|NA|2|Visit_2|25|7|TREATMENT|2020-10-26|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-31|P1Y2M10DT2H30M|COINCIDENT|2020-10-16|AFTER|2020-11-28
e|RS|dc3ce247-24dd-4255-85a8-ec7a58d30c86|5|NEWLPROG|New Lesion Progression|EASL BRUIX LIVER CANCER 2001|[?]|ug/g/min|INDETERMINATE RESPONSE|1|/LPF|SISH||||SPOUSE|PHYSIOTHERAPIST|NA|3|Visit_3|40|6|TREATMENT|2020-11-10|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-01|P1Y2M10DT2H30M|AFTER|2020-11-11|ONGOING|2020-12-28
e|RS|dc3ce247-24dd-4255-85a8-ec7a58d30c86|6|HEMARESP|Hematologic Response|SHINDOH COLORECTAL CANCER 2013|[?]|mEq/g|INCREASED|1|sec|ANTIBIOTIC AGAR SCREEN||Y||INDEPENDENT ASSESSOR|ADJUDICATOR 2|NA|3|Visit_3|40|2|TREATMENT|2020-11-10|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-01|P1Y2M10DT2H30M|UNKNOWN|2020-11-04|BEFORE|2020-11-17
e|RS|dc3ce247-24dd-4255-85a8-ec7a58d30c86|7|TMRESP|Tumor Marker Response|RECIST 1.1|[?]|RATIO|iPR|1|10^9 organisms|ENDPOINT DILUTION ASSAY|Y|||GUARDIAN|ADJUDICATOR 1|U|4|Visit_4|65|5|TREATMENT|2020-12-05|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-04|P1Y2M10DT2H30M|COINCIDENT|2020-11-14|ONGOING|2020-12-04
e|RS|dc3ce247-24dd-4255-85a8-ec7a58d30c86|8|METBRESP|Metabolic Response|MURPHY PROSTATE CANCER 1980|[?]|mL/beat|NON-iCR/NON-iUPD|1|LENS|PATHOLOGICAL EVALUATION||||PARENT|ENDOCRINOLOGIST|NA|4|Visit_4|65|1|WASHOUT|2020-12-05|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-04|P1Y2M10DT2H30M|AFTER|2020-11-27|BEFORE|2021-01-02
e|RS|dc3ce247-24dd-4255-85a8-ec7a58d30c86|9|SPLNRESP|Spleen Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|pg/cell|VGPR|1|L/s/kPa|CONTRAST ENHANCED PET SCAN|Y|Y||INVESTIGATOR|DEVELOPMENTAL PSYCHOLOGIST|Y|5|Visit_5|90|6|TREATMENT|2020-12-30|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-10|P1Y2M10DT2H30M|AFTER|2020-10-23|AFTER|2020-11-09
e|RS|dc3ce247-24dd-4255-85a8-ec7a58d30c86|10|NEWLPROG|New Lesion Progression|MRANO VAN DEN BENT GLIOMA 2011|[?]|BEAM BREAKS|RELAPSED DISEASE FROM CR OR PR|1|Coulomb|QUANTITATIVE CORONARY ANGIOGRAPHY||||CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 2|Y|5|Visit_5|90|4|TREATMENT|2020-12-30|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-10|P1Y2M10DT2H30M|AFTER|2020-10-12|COINCIDENT|2020-11-24
e|RS|61c19f94-bdfc-456d-ba7a-c9097ca1c645|1|SYMPTDTR|Symptomatic Deterioration|iRECIST|||EQUIVOCAL|1|BAU|COULOMETRIC TITRATION||Y|Y|INDEPENDENT ASSESSOR|ADJUDICATOR 3|N|1|Visit_1|10|3|WASHOUT|2020-07-04|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-24|P1Y2M10DT2H30M|COINCIDENT|2020-07-05|ONGOING|2020-08-14
e|RS|61c19f94-bdfc-456d-ba7a-c9097ca1c645|2|OVRLRESP|Overall Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|mL/cage|NON-QUANTIFIABLE MRD POSITIVITY|1|pt_us|PERIPHERAL ANGIOGRAPHY||Y||FRIEND|OTOLARYNGOLOGIST|NA|1|Visit_1|10|4|TREATMENT|2020-07-04|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-24|P1Y2M10DT2H30M|BEFORE|2020-09-10|AFTER|2020-09-30
e|RS|61c19f94-bdfc-456d-ba7a-c9097ca1c645|3|MRDRESP|Minimal Residual Disease Response|IWC HALLEK CLL 2008|||PDu|1|pmol/day|ANALYTICAL ULTRACENTRIFUGATION|||Y|CLINICAL RESEARCH COORDINATOR|READER 2|N|2|Visit_2|25|5|TREATMENT|2020-07-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-29|P1Y2M10DT2H30M|UNKNOWN|2020-08-17|ONGOING|2020-09-08
e|RS|61c19f94-bdfc-456d-ba7a-c9097ca1c645|4|SYMPTDTR|Symptomatic Deterioration|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|10^12/L|iPR|1|uU/L|CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|Y|||FRIEND|PATHOLOGIST|N|2|Visit_2|25|3|TREATMENT|2020-07-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-29|P1Y2M10DT2H30M|COINCIDENT|2020-07-08|AFTER|2020-09-28
e|RS|61c19f94-bdfc-456d-ba7a-c9097ca1c645|5|NTNERESP|Non-Target Non-Enhancing Response|DURIE MULTIPLE MYELOMA 2006|[?]|deg/mm|IMMUNOPHENOTYPIC CR|1|mg/m2/h|CORONARY ANGIOGRAPHY|Y|||INVESTIGATOR|NEUROLOGIST|U|3|Visit_3|40|5|TREATMENT|2020-08-03|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-06|P1Y2M10DT2H30M|AFTER|2020-08-14|ONGOING|2020-09-03
e|RS|61c19f94-bdfc-456d-ba7a-c9097ca1c645|6|BONERESP|Bone Response|MASS|||DECREASED|1|gtt|MOUSE PROTECTION ASSAY|||Y|FRIEND|DEVELOPMENTAL PSYCHOLOGIST|Y|3|Visit_3|40|3|SCREENING|2020-08-03|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-06|P1Y2M10DT2H30M|BEFORE|2020-07-16|COINCIDENT|2020-08-16
e|RS|61c19f94-bdfc-456d-ba7a-c9097ca1c645|7|NTRGRESP|Non-target Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|mL/s/m2|DISEASE TRANSFORMATION|1|nmol|PHYSICAL EXAMINATION|Y|||DOMESTIC PARTNER|ONCOLOGIST 1|Y|4|Visit_4|65|6|WASHOUT|2020-08-28|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-07|P1Y2M10DT2H30M|BEFORE|2020-09-10|AFTER|2020-09-13
e|RS|61c19f94-bdfc-456d-ba7a-c9097ca1c645|8|MRDIND|Minimal Residual Disease Indicator|iRECIST|[?]|FIU|RELAPSED DISEASE|1|10^12 IU/L|NEURAMINIDASE INHIBITION ASSAY||||CLINICAL RESEARCH ASSOCIATE|OPHTHALMOLOGIST|NA|4|Visit_4|65|2|SCREENING|2020-08-28|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-07|P1Y2M10DT2H30M|COINCIDENT|2020-08-13|AFTER|2020-08-21
e|RS|61c19f94-bdfc-456d-ba7a-c9097ca1c645|9|ANATRESP|Anatomic Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|Log10 ELISA unit|FAVORABLE RESPONSE|1|fmol/L|TRANSTHORACIC ECHOCARDIOGRAPHY|Y|Y||SPOUSE|ONCOLOGIST 2|N|5|Visit_5|90|4|SCREENING|2020-09-22|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-25|P1Y2M10DT2H30M|AFTER|2020-07-23|AFTER|2020-09-17
e|RS|61c19f94-bdfc-456d-ba7a-c9097ca1c645|10|MRDIND|Minimal Residual Disease Indicator|WOLCHOK SOLID TUMORS 2009|[?]|pt_us|CMR|1|U/g/day|MANUAL CLOT DETECTION||Y||CLINICAL STUDY SPONSOR|CLINICAL PATHOLOGIST|NA|5|Visit_5|90|4|TREATMENT|2020-09-22|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-25|P1Y2M10DT2H30M|COINCIDENT|2020-09-16|BEFORE|2020-09-22
e|RS|1e577f2d-2c45-477d-b74f-af24b81d6d20|1|BMIVLIND|Bone Marrow Involvement Indicator|GCIG RUSTIN OVARIAN CANCER 2011|[?]|ug/L|PD/RELAPSE AFTER HI|1|dyn|KARYOTYPING||||CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 1|NA|1|Visit_1|10|6|TREATMENT|2020-09-23|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-23|P1Y2M10DT2H30M|BEFORE|2020-09-21|COINCIDENT|2020-11-03
e|RS|1e577f2d-2c45-477d-b74f-af24b81d6d20|2|NTRGRESP|Non-target Response|IRANO 2015|[?]|mol/L|PR|1|foz_br|FLUORIMETRY|Y|||GUARDIAN|NEUROLOGIST 1|Y|1|Visit_1|10|1|TREATMENT|2020-09-23|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-23|P1Y2M10DT2H30M|UNKNOWN|2020-12-03|AFTER|2020-12-12
e|RS|1e577f2d-2c45-477d-b74f-af24b81d6d20|3|BESTRESP|Best Overall Response|JACINTO CERVICAL CANCER 2007|[?]|/40 HPFs|PMD|1|mm/h|COULOMETRIC TITRATION|Y|Y||DOMESTIC PARTNER|DERMATOLOGIST|U|2|Visit_2|25|5|FOLLOW-UP|2020-10-08|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-14|P1Y2M10DT2H30M|BEFORE|2020-10-09|BEFORE|2020-12-15
e|RS|1e577f2d-2c45-477d-b74f-af24b81d6d20|4|MRPHRESP|Morphologic Response|RANO|||PSEUDORESPONSE|1|mg/mL/min|HPLC/MS/MS|||Y|FAMILY MEMBER|ONCOLOGIST 1|NA|2|Visit_2|25|7|FOLLOW-UP|2020-10-08|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-14|P1Y2M10DT2H30M|COINCIDENT|2020-09-29|COINCIDENT|2020-10-23
e|RS|1e577f2d-2c45-477d-b74f-af24b81d6d20|5|MRDRESP|Minimal Residual Disease Response|IWG CHESON MDS 2006|[?]|Arbitrary U|INCREASED|1|foz_br|ELECTROCHEMILUMINESCENCE||||SIBLING|NEUROLOGIST 1|N|3|Visit_3|40|5|WASHOUT|2020-10-23|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-08|P1Y2M10DT2H30M|COINCIDENT|2020-10-19|BEFORE|2020-10-30
e|RS|1e577f2d-2c45-477d-b74f-af24b81d6d20|6|PATHRESP|Pathologic Response|BRUGGEMANN MRD 2010|[?]|SACHET|NON-CR/NON-PD|1|mL/min/mmHg|NUCLEAR RADIOLOGY|Y|Y||INDEPENDENT ASSESSOR|READER 3|Y|3|Visit_3|40|7|TREATMENT|2020-10-23|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-08|P1Y2M10DT2H30M|BEFORE|2020-12-12|BEFORE|2020-12-16
e|RS|1e577f2d-2c45-477d-b74f-af24b81d6d20|7|METSIND|Metastatic Indicator|MASS|[?]|CFU/g|MOLECULAR MAJOR RESPONSE|1|pmol/day|TONOMETRY||||ADJUDICATOR|PATHOLOGIST|Y|4|Visit_4|65|7|FOLLOW-UP|2020-11-17|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-19|P1Y2M10DT2H30M|UNKNOWN|2020-11-05|ONGOING|2020-12-02
e|RS|1e577f2d-2c45-477d-b74f-af24b81d6d20|8|CPRFSTAT|Clinical Performance Status|IWG CHESON AML 2003|[?]|/month|PD-CT|1|10^3/L|IMMUNO-PET SCAN|Y|||ADJUDICATOR|PATHOLOGIST 1|U|4|Visit_4|65|3|TREATMENT|2020-11-17|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-19|P1Y2M10DT2H30M|BEFORE|2020-11-21|COINCIDENT|2020-12-12
e|RS|1e577f2d-2c45-477d-b74f-af24b81d6d20|9|NEWLWIND|New Lesion Worsening Indicator|MACDONALD GLIOMA 1990|[?]|CIGARETTE|PSEUDOPROGRESSION|1|/LSQN|JAFFE REACTION|Y|Y||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|N|5|Visit_5|90|7|FOLLOW-UP|2020-12-12|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-19|P1Y2M10DT2H30M|UNKNOWN|2020-10-09|BEFORE|2020-11-28
e|RS|1e577f2d-2c45-477d-b74f-af24b81d6d20|10|MRPHRESP|Morphologic Response|RECIST 1.1|[?]|ug/L DDU|MRD NEGATIVITY|1|pg/L|FLUORESCEIN STAIN||Y||INDEPENDENT ASSESSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|5|Visit_5|90|5|FOLLOW-UP|2020-12-12|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-19|P1Y2M10DT2H30M|BEFORE|2020-10-16|AFTER|2020-12-10
e|RS|f845101e-c057-4f84-94b3-6043afb42ac7|1|MNPTHIND|Minor Pathological Response Indicator|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|mg/h|PR|1|mPa|DIGITAL PCR ARRAY||||INTERVIEWER|ENDOCRINOLOGIST|U|1|Visit_1|10|5|FOLLOW-UP|2020-10-27|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-25|P1Y2M10DT2H30M|COINCIDENT|2020-12-26|BEFORE|2021-01-15
e|RS|f845101e-c057-4f84-94b3-6043afb42ac7|2|CPRFSTAT|Clinical Performance Status|BURCOMBE BREAST CANCER 2005|[?]|Henry|WORSENED|1|vp/mL|DIRECT SEQUENCING|Y|||FAMILY MEMBER|ADJUDICATOR 1|N|1|Visit_1|10|1|TREATMENT|2020-10-27|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-25|P1Y2M10DT2H30M|COINCIDENT|2020-12-06|BEFORE|2020-12-27
e|RS|f845101e-c057-4f84-94b3-6043afb42ac7|3|TRGRESP|Target Response|UNSPECIFIED|[?]|kg/m2|PD FROM PR|1|PACK|QUANTITATIVE PERIPHERAL ANGIOGRAPHY||||VENDOR|READER 3|NA|2|Visit_2|25|7|TREATMENT|2020-11-11|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-16|P1Y2M10DT2H30M|AFTER|2020-11-27|ONGOING|2020-12-31
e|RS|f845101e-c057-4f84-94b3-6043afb42ac7|4|MRPHRESP|Morphologic Response|CHESON CLL 2006|[?]|DRINK|EQUIVOCAL|1|pt_us|OPTICAL MAPPING||||INTERVIEWER|PATHOLOGIST|Y|2|Visit_2|25|6|SCREENING|2020-11-11|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-16|P1Y2M10DT2H30M|AFTER|2021-01-15|BEFORE|2021-01-24
e|RS|f845101e-c057-4f84-94b3-6043afb42ac7|5|CYTORESP|Cytogenetic Response|SHINDOH COLORECTAL CANCER 2013|[?]|Ci/kg|MORPHOLOGIC LEUKEMIA-FREE STATE|1|/10^3|NUCLEAR RADIOLOGY||||INDEPENDENT ASSESSOR|READER 1|U|3|Visit_3|40|3|TREATMENT|2020-11-26|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-22|P1Y2M10DT2H30M|AFTER|2021-01-21|AFTER|2021-01-23
e|RS|f845101e-c057-4f84-94b3-6043afb42ac7|6|STRUSTAT|Steroid Use Status|IWG CHESON AML 2003|||iUPD|1|ppm|DISK DIFFUSION|||Y|CAREGIVER|ENDOCRINOLOGIST|N|3|Visit_3|40|2|FOLLOW-UP|2020-11-26|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-22|P1Y2M10DT2H30M|BEFORE|2020-10-21|ONGOING|2020-12-25
e|RS|f845101e-c057-4f84-94b3-6043afb42ac7|7|SFTSRESP|Soft Tissue Response|DOHNER AML 2010|[?]|min*mg/mL|TREATMENT FAILURE|1|mV2/Hz|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY||Y||SIGNIFICANT OTHER|ADJUDICATOR 2|N|4|Visit_4|65|2|SCREENING|2020-12-21|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-19|P1Y2M10DT2H30M|BEFORE|2021-01-22|COINCIDENT|2021-01-24
e|RS|f845101e-c057-4f84-94b3-6043afb42ac7|8|METBRESP|Metabolic Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|GPS U|MAJOR PATHOLOGIC RESPONSE|1|mL/min/mmHg|DYNAMIC CONTRAST ENHANCED MRI||||PARENT|READER 2|N|4|Visit_4|65|4|SCREENING|2020-12-21|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-19|P1Y2M10DT2H30M|COINCIDENT|2020-11-13|COINCIDENT|2020-11-18
e|RS|f845101e-c057-4f84-94b3-6043afb42ac7|9|LIVRRESP|Liver Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|mmHg/L/min|NON-QUANTIFIABLE MRD POSITIVITY|1|OI50|ZIEHL NEELSEN ACID FAST STAIN||||INDEPENDENT ASSESSOR|ONCOLOGIST 1|U|5|Visit_5|90|5|SCREENING|2021-01-15|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-30|P1Y2M10DT2H30M|UNKNOWN|2020-11-17|BEFORE|2020-11-18
e|RS|f845101e-c057-4f84-94b3-6043afb42ac7|10|SFTSRESP|Soft Tissue Response|WOLCHOK SOLID TUMORS 2009|[?]|ug/cm2|WORSENED|1|/day|STRESS ECHOCARDIOGRAPHY||||NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST|Y|5|Visit_5|90|1|WASHOUT|2021-01-15|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-30|P1Y2M10DT2H30M|UNKNOWN|2020-11-27|BEFORE|2020-12-09
e|RS|4ddb2076-6837-4028-81bc-3e8057475977|1|CYTORESP|Cytogenetic Response|AJCC V8|[?]|mm/2h|SMD|1|IU/mg|PALPATION||Y||PROXY|RADIOLOGIST 1|Y|1|Visit_1|10|3|SCREENING|2020-12-27|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-16|P1Y2M10DT2H30M|BEFORE|2021-02-14|BEFORE|2021-03-07
e|RS|4ddb2076-6837-4028-81bc-3e8057475977|2|PATHRESP|Pathologic Response|LEE LUNG CANCER 2011|[?]|MASK|MOLECULAR CR|1|uV2|PULMONARY ANGIOGRAPHY|Y|||CLINICAL RESEARCH COORDINATOR|UROLOGIST|N|1|Visit_1|10|1|WASHOUT|2020-12-27|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-16|P1Y2M10DT2H30M|UNKNOWN|2021-02-05|ONGOING|2021-03-05
e|RS|4ddb2076-6837-4028-81bc-3e8057475977|3|MRDIND|Minimal Residual Disease Indicator|NCIWG CHESON CLL 1996|[?]|MESF|RELAPSED DISEASE FROM CR OR PR|1|mL/breath|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION||||SIGNIFICANT OTHER|PATHOLOGIST 1|Y|2|Visit_2|25|4|FOLLOW-UP|2021-01-11|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-23|P1Y2M10DT2H30M|COINCIDENT|2021-02-07|BEFORE|2021-02-12
e|RS|4ddb2076-6837-4028-81bc-3e8057475977|4|BESTRESP|Best Overall Response|CHOLLET BREAST CANCER 2002|[?]|Pack Year|NR|1|mm3/mm2/year|MS/MS|Y|||SPOUSE|OPTOMETRIST|N|2|Visit_2|25|3|WASHOUT|2021-01-11|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-23|P1Y2M10DT2H30M|BEFORE|2021-01-21|ONGOING|2021-01-22
e|RS|4ddb2076-6837-4028-81bc-3e8057475977|5|MOLRESP|Molecular Response|CHESON CLL 2012|[?]|cg|PD FROM PR|1|uV|IN SITU HYBRIDIZATION||Y||DOMESTIC PARTNER|PATHOLOGIST 1|U|3|Visit_3|40|3|WASHOUT|2021-01-26|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-13|P1Y2M10DT2H30M|AFTER|2021-03-25|COINCIDENT|2021-03-26
e|RS|4ddb2076-6837-4028-81bc-3e8057475977|6|SFTSRESP|Soft Tissue Response|RECIST 1.0|||cCR|1|mCi/kg|FLOW MICROSCOPY|||Y|INTERVIEWER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|3|Visit_3|40|3|SCREENING|2021-01-26|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-13|P1Y2M10DT2H30M|AFTER|2021-02-01|COINCIDENT|2021-02-05
e|RS|4ddb2076-6837-4028-81bc-3e8057475977|7|HEMARESP|Hematologic Response|MONTSERRAT CLL 1989|[?]|log EID 50/dose|MRD RELAPSE|1|SBE/mL|QUANTITATIVE COMPUTED TOMOGRAPHY||||PARENT|UROLOGIST|N|4|Visit_4|65|3|WASHOUT|2021-02-20|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-29|P1Y2M10DT2H30M|AFTER|2021-01-19|ONGOING|2021-03-16
e|RS|4ddb2076-6837-4028-81bc-3e8057475977|8|NTNERESP|Non-Target Non-Enhancing Response|KUMAR IMWG 2016|[?]|copies/mL|RELAPSED DISEASE FROM CR|1|mmol/g|PHOTOGRAPHY|Y|Y||ADJUDICATION COMMITTEE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|4|Visit_4|65|2|WASHOUT|2021-02-20|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-29|P1Y2M10DT2H30M|BEFORE|2021-01-27|COINCIDENT|2021-02-14
e|RS|4ddb2076-6837-4028-81bc-3e8057475977|9|BESTRESP|Best Overall Response|WHO BREAST CANCER 2006|[?]|umol/kg/min|CR|1|tsp eq|HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY||||INDEPENDENT ASSESSOR|READER 1|Y|5|Visit_5|90|5|SCREENING|2021-03-17|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-01|P1Y2M10DT2H30M|COINCIDENT|2020-12-29|ONGOING|2021-01-24
e|RS|4ddb2076-6837-4028-81bc-3e8057475977|10|NTRGRESP|Non-target Response|RANO|[?]|Bq/uL|MINOR PATHOLOGIC RESPONSE|1|mU/L|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION||Y||FAMILY MEMBER|RATER 2|Y|5|Visit_5|90|6|TREATMENT|2021-03-17|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-01|P1Y2M10DT2H30M|COINCIDENT|2021-01-10|COINCIDENT|2021-03-04
e|RS|c165c69c-2ab2-495c-a190-e32d1204bc4e|1|MRDIND|Minimal Residual Disease Indicator|BLAZER COLORECTAL CANCER 2008|[?]|ng|MAJOR PATHOLOGIC RESPONSE|1|10^12/L|FLUORESCENT SPOT TEST||||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 2|NA|1|Visit_1|10|5|WASHOUT|2021-01-01|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-10|P1Y2M10DT2H30M|COINCIDENT|2021-01-14|ONGOING|2021-03-22
e|RS|c165c69c-2ab2-495c-a190-e32d1204bc4e|2|MRPHRESP|Morphologic Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|MET*h|NON-QUANTIFIABLE MRD POSITIVITY|1|/100 HPFs|MALDI-TOF||Y||ADJUDICATOR|READER 1|N|1|Visit_1|10|1|SCREENING|2021-01-01|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-10|P1Y2M10DT2H30M|AFTER|2020-12-27|BEFORE|2021-01-31
e|RS|c165c69c-2ab2-495c-a190-e32d1204bc4e|3|MRDRESP|Minimal Residual Disease Response|IWG CHESON AML 2003|||RELAPSED DISEASE FROM CR OR PR|1|BOTTLE|CINEANGIOGRAPHY|||Y|INTERVIEWER|ADJUDICATOR 1|NA|2|Visit_2|25|4|TREATMENT|2021-01-16|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-27|P1Y2M10DT2H30M|COINCIDENT|2021-03-15|AFTER|2021-03-23
e|RS|c165c69c-2ab2-495c-a190-e32d1204bc4e|4|RDIORESP|Radiologic Response|BURCOMBE BREAST CANCER 2005|||RELAPSED DISEASE FROM CR OR PR|1|pt_us|ELECTROCHEMILUMINESCENCE|||Y|SIBLING|ONCOLOGIST 1|NA|2|Visit_2|25|3|TREATMENT|2021-01-16|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-27|P1Y2M10DT2H30M|BEFORE|2021-02-28|BEFORE|2021-03-13
e|RS|c165c69c-2ab2-495c-a190-e32d1204bc4e|5|MRPHRESP|Morphologic Response|SCHER PROSTATE CANCER 2011|[?]|mL/min/mmHg|CYTOGENETIC MINIMAL RESPONSE|1|IU/kg/h|FLUORIMETRY|Y|||PROXY|RATER|N|3|Visit_3|40|3|TREATMENT|2021-01-31|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-24|P1Y2M10DT2H30M|BEFORE|2021-01-13|BEFORE|2021-01-30
e|RS|c165c69c-2ab2-495c-a190-e32d1204bc4e|6|NTNERESP|Non-Target Non-Enhancing Response|CHESON LYMPHOMA 2008|||IMPROVED|1|uIU/dL|PHYSICAL EXAMINATION|||Y|GUARDIAN|MICROSCOPIST 3|U|3|Visit_3|40|5|FOLLOW-UP|2021-01-31|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-24|P1Y2M10DT2H30M|AFTER|2021-01-15|ONGOING|2021-02-01
e|RS|c165c69c-2ab2-495c-a190-e32d1204bc4e|7|BMIVLIND|Bone Marrow Involvement Indicator|KUKER LYMPHOMA 2005|[?]|HOMEOPATHIC DILUTION|PDu|1|MET*h|DIRECT SEQUENCING|Y|||PARENT|PATHOLOGIST 2|NA|4|Visit_4|65|3|TREATMENT|2021-02-25|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-20|P1Y2M10DT2H30M|AFTER|2021-01-11|ONGOING|2021-03-03
e|RS|c165c69c-2ab2-495c-a190-e32d1204bc4e|8|HEMARESP|Hematologic Response|GUILHOT CML 2007|||iCPD|1|log10 PFU|FREEZING POINT DEPRESSION|||Y|CLINICAL STUDY SPONSOR|ADJUDICATOR 3|N|4|Visit_4|65|4|TREATMENT|2021-02-25|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-20|P1Y2M10DT2H30M|AFTER|2021-03-14|AFTER|2021-03-18
e|RS|c165c69c-2ab2-495c-a190-e32d1204bc4e|9|BONERESP|Bone Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|COAT|NR|1|nmol|HPLC-FL||||NON-HEALTH CARE PROFESSIONAL|UROLOGIST|N|5|Visit_5|90|6|TREATMENT|2021-03-22|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-02|P1Y2M10DT2H30M|AFTER|2021-02-18|ONGOING|2021-03-31
e|RS|c165c69c-2ab2-495c-a190-e32d1204bc4e|10|NEWLPROG|New Lesion Progression|IWG CHESON AML 2003|||TREATMENT FAILURE|1|IMPLANT|OLIGO ACGH|||Y|HEALTH CARE PROFESSIONAL|MICROSCOPIST|N|5|Visit_5|90|7|SCREENING|2021-03-22|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-02|P1Y2M10DT2H30M|UNKNOWN|2021-02-01|AFTER|2021-02-28
e|RS|fa6801a8-544d-44d7-a3e4-e8e18b2f2f69|1|CPRFSTAT|Clinical Performance Status|MURPHY PROSTATE CANCER 1980|||ABSENT MORPHOLOGIC RESPONSE|1|uL|MICROARRAY|Y|Y|Y|CLINICAL STUDY SPONSOR|NEUROLOGIST 1|NA|1|Visit_1|10|1|FOLLOW-UP|2020-12-29|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-05|P1Y2M10DT2H30M|AFTER|2021-01-17|COINCIDENT|2021-03-23
e|RS|fa6801a8-544d-44d7-a3e4-e8e18b2f2f69|2|SFTSRESP|Soft Tissue Response|PERCIST|[?]|LOZENGE|CMR|1|PUFF|MICRODENSITOMETRY||||ADJUDICATOR|ENDOCRINOLOGIST|NA|1|Visit_1|10|3|TREATMENT|2020-12-29|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-05|P1Y2M10DT2H30M|UNKNOWN|2021-02-06|COINCIDENT|2021-03-01
e|RS|fa6801a8-544d-44d7-a3e4-e8e18b2f2f69|3|BONERESP|Bone Response|PERCIST|||NON-iCR/NON-iUPD|1|mEq/mL|SPIROMETRY|||Y|INTERVIEWER|MICROSCOPIST|NA|2|Visit_2|25|2|TREATMENT|2021-01-13|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-07|P1Y2M10DT2H30M|UNKNOWN|2021-02-16|COINCIDENT|2021-02-21
e|RS|fa6801a8-544d-44d7-a3e4-e8e18b2f2f69|4|DRCRIND|Disease Recurrence Indicator|MASS|[?]|MET*min|CR-CT|1|mL/cage|MAPH||||PARENT|ADJUDICATOR 1|N|2|Visit_2|25|7|TREATMENT|2021-01-13|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-07|P1Y2M10DT2H30M|BEFORE|2021-02-25|BEFORE|2021-03-27
e|RS|fa6801a8-544d-44d7-a3e4-e8e18b2f2f69|5|NTNERESP|Non-Target Non-Enhancing Response|HARTMANN GERM CELL CANCER 2002|[?]|U/kg/day|UNFAVORABLE RESPONSE|1|10^6 organisms/mL|ULTRASONOGRAPHIC ELASTOGRAPHY||||PROXY|ADJUDICATOR 1|U|3|Visit_3|40|4|FOLLOW-UP|2021-01-28|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-05|P1Y2M10DT2H30M|BEFORE|2021-01-17|ONGOING|2021-03-27
e|RS|fa6801a8-544d-44d7-a3e4-e8e18b2f2f69|6|LIVRRESP|Liver Response|UNSPECIFIED|||STABLE|1|mmol/kg|KNEMOMETRY|||Y|INTERVIEWER|ADJUDICATOR 1|N|3|Visit_3|40|2|TREATMENT|2021-01-28|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-05|P1Y2M10DT2H30M|UNKNOWN|2021-02-21|ONGOING|2021-02-22
e|RS|fa6801a8-544d-44d7-a3e4-e8e18b2f2f69|7|NTLWIND|Non-Target Lesion Worsening Indicator|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|Siemens|STABLE|1|mL/animal|HPLC-UV||Y||ADJUDICATION COMMITTEE|ONCOLOGIST 2|Y|4|Visit_4|65|1|WASHOUT|2021-02-22|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-10|P1Y2M10DT2H30M|BEFORE|2021-03-16|BEFORE|2021-03-28
e|RS|fa6801a8-544d-44d7-a3e4-e8e18b2f2f69|8|CPRFSTAT|Clinical Performance Status|WHO BREAST CANCER 2006|||NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|ppth|CELL CYTOTOXICITY NEUTRALIZATION ASSAY||Y|Y|INTERVIEWER|ADJUDICATOR 1|NA|4|Visit_4|65|7|TREATMENT|2021-02-22|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-10|P1Y2M10DT2H30M|AFTER|2021-02-11|AFTER|2021-03-11
e|RS|fa6801a8-544d-44d7-a3e4-e8e18b2f2f69|9|BESTRESP|Best Overall Response|DURIE MULTIPLE MYELOMA 2006|||NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|ug/m2|AGAR DILUTION|Y||Y|VENDOR|CLINICAL PATHOLOGIST|Y|5|Visit_5|90|6|TREATMENT|2021-03-19|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-13|P1Y2M10DT2H30M|UNKNOWN|2021-01-15|COINCIDENT|2021-03-27
e|RS|fa6801a8-544d-44d7-a3e4-e8e18b2f2f69|10|METBRESP|Metabolic Response|PETIT BREAST CANCER 2001|[?]|mm3/mm2/year|MORPHOLOGIC CRi|1|mol|THIN SMEAR||||CLINICAL RESEARCH COORDINATOR|OPTOMETRIST|N|5|Visit_5|90|1|SCREENING|2021-03-19|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-13|P1Y2M10DT2H30M|UNKNOWN|2021-03-15|ONGOING|2021-03-26
e|RS|024a9f6d-4ff1-4673-8617-3790f831fce7|1|NEWLPROG|New Lesion Progression|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|VOXEL|WORSENED|1|mg/mL/day|KARYOTYPING||||INVESTIGATOR|MICROSCOPIST 1|NA|1|Visit_1|10|5|WASHOUT|2020-06-13|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-28|P1Y2M10DT2H30M|AFTER|2020-06-09|BEFORE|2020-07-29
e|RS|024a9f6d-4ff1-4673-8617-3790f831fce7|2|TRGRESP|Target Response|JUWEID NON-HODGKINS LYMPHOMA 2005|||UNFAVORABLE RESPONSE|1|v/v|PULSE OXIMETRY|Y|Y|Y|INTERVIEWER|MICROSCOPIST 2|Y|1|Visit_1|10|5|TREATMENT|2020-06-13|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-28|P1Y2M10DT2H30M|BEFORE|2020-08-28|ONGOING|2020-09-07
e|RS|024a9f6d-4ff1-4673-8617-3790f831fce7|3|DRCRIND|Disease Recurrence Indicator|PERCIST|[?]|IU/mL|NON-QUANTIFIABLE MRD POSITIVITY|1|DAgU|APPLANATION TONOMETRY|Y|Y||PROXY|FORENSIC PATHOLOGIST|Y|2|Visit_2|25|2|TREATMENT|2020-06-28|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-07|P1Y2M10DT2H30M|COINCIDENT|2020-07-21|BEFORE|2020-08-07
e|RS|024a9f6d-4ff1-4673-8617-3790f831fce7|4|ANATRESP|Anatomic Response|AJCC V7|[?]|V/sec|NOT ALL EVALUATED|1|anti-Xa IU|MIGET||Y||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 2|U|2|Visit_2|25|7|FOLLOW-UP|2020-06-28|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-07|P1Y2M10DT2H30M|UNKNOWN|2020-07-16|COINCIDENT|2020-09-03
e|RS|024a9f6d-4ff1-4673-8617-3790f831fce7|5|MRPHRESP|Morphologic Response|UNSPECIFIED|[?]|10^5/hpf|NED|1|dram|DROPLET DIGITAL PCR||Y||INTERVIEWER|MICROSCOPIST 1|U|3|Visit_3|40|1|TREATMENT|2020-07-13|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-17|P1Y2M10DT2H30M|AFTER|2020-06-20|ONGOING|2020-08-03
e|RS|024a9f6d-4ff1-4673-8617-3790f831fce7|6|MRDIND|Minimal Residual Disease Indicator|PALUMBO MULTIPLE MYELOMA 2009|[?]|PELLET|CYTOGENETIC CR|1|kcal/day|AGAR DILUTION||||CLINICAL RESEARCH COORDINATOR|OPTOMETRIST|U|3|Visit_3|40|7|TREATMENT|2020-07-13|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-17|P1Y2M10DT2H30M|UNKNOWN|2020-07-23|ONGOING|2020-09-04
e|RS|024a9f6d-4ff1-4673-8617-3790f831fce7|7|NTNERESP|Non-Target Non-Enhancing Response|WOLCHOK SOLID TUMORS 2009|[?]|ng/L|PSEUDOPROGRESSION|1|uOsm|DIRECT SEQUENCING||Y||INTERVIEWER|ONCOLOGIST|U|4|Visit_4|65|3|TREATMENT|2020-08-07|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-04|P1Y2M10DT2H30M|AFTER|2020-07-03|COINCIDENT|2020-08-14
e|RS|024a9f6d-4ff1-4673-8617-3790f831fce7|8|LIVRRESP|Liver Response|RAJKUMAR MYELOMA 2011|[?]|umol/mol|RELAPSED DISEASE|1|pptr|FORCED OSCILLATION TECHNIQUE||||ADJUDICATION COMMITTEE|NEUROLOGIST 2|NA|4|Visit_4|65|1|TREATMENT|2020-08-07|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-04|P1Y2M10DT2H30M|UNKNOWN|2020-08-22|COINCIDENT|2020-08-26
e|RS|024a9f6d-4ff1-4673-8617-3790f831fce7|9|MOLRESP|Molecular Response|MRECIST BYRNE MESOTHELIOMA 2004|||STABLE|1|MET*h|IMMUNOASSAY|Y||Y|PARENT|UROLOGIST|Y|5|Visit_5|90|5|SCREENING|2020-09-01|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-28|P1Y2M10DT2H30M|BEFORE|2020-07-16|AFTER|2020-07-30
e|RS|024a9f6d-4ff1-4673-8617-3790f831fce7|10|CYTORESP|Cytogenetic Response|HARTMANN GERM CELL CANCER 2002|[?]|kPa/L/sec|DISEASE TRANSFORMATION|1|Ejaculate U|PYROSEQUENCING|Y|Y||HEALTH CARE PROFESSIONAL|RADIOLOGIST|U|5|Visit_5|90|2|TREATMENT|2020-09-01|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-28|P1Y2M10DT2H30M|COINCIDENT|2020-06-17|BEFORE|2020-09-08
e|RS|40936fc6-251d-4a17-ae9d-3bd1150f8d20|1|MOLRESP|Molecular Response|CHESON LYMPHOMA 2008|||COMPLETE MRD RESPONSE|1|10^4/hpf|MICROPARTICLE ENZYME IMMUNOASSAY|Y|Y|Y|PARENT|HEMATOLOGIST|N|1|Visit_1|10|1|FOLLOW-UP|2020-11-18|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-16|P1Y2M10DT2H30M|UNKNOWN|2020-11-13|ONGOING|2021-02-13
e|RS|40936fc6-251d-4a17-ae9d-3bd1150f8d20|2|MOLRESP|Molecular Response|AJCC V7|[?]|CCID 50/mL|RELAPSED DISEASE FROM CR|1|DRINK|CLIP SEQUENCING||||FRIEND|READER 1|N|1|Visit_1|10|5|TREATMENT|2020-11-18|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-16|P1Y2M10DT2H30M|UNKNOWN|2021-02-02|AFTER|2021-02-09
e|RS|40936fc6-251d-4a17-ae9d-3bd1150f8d20|3|TMRESP|Tumor Marker Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|BOLUS|QUANTIFIABLE MRD POSITIVITY|1|L/L|ALCIAN BLUE STAIN||Y||INDEPENDENT ASSESSOR|FORENSIC PATHOLOGIST|U|2|Visit_2|25|1|WASHOUT|2020-12-03|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-12|P1Y2M10DT2H30M|COINCIDENT|2021-01-03|ONGOING|2021-01-15
e|RS|40936fc6-251d-4a17-ae9d-3bd1150f8d20|4|BMIVLIND|Bone Marrow Involvement Indicator|CHOI GIST 2008|[?]|F|MRD NEGATIVITY|1|mL/dose|NUCLEIC ACID BASED METHOD|Y|||CLINICAL RESEARCH COORDINATOR|RATER 1|U|2|Visit_2|25|6|SCREENING|2020-12-03|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-12|P1Y2M10DT2H30M|BEFORE|2020-12-01|COINCIDENT|2021-01-16
e|RS|40936fc6-251d-4a17-ae9d-3bd1150f8d20|5|NTNERESP|Non-Target Non-Enhancing Response|AJCC V7|||DECREASED|1|uCi/L|THERMAL IONIZATION MASS SPECTROMETRY|||Y|INTERVIEWER|READER 3|Y|3|Visit_3|40|1|TREATMENT|2020-12-18|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-16|P1Y2M10DT2H30M|COINCIDENT|2021-01-30|ONGOING|2021-02-03
e|RS|40936fc6-251d-4a17-ae9d-3bd1150f8d20|6|BMIVLIND|Bone Marrow Involvement Indicator|WOLCHOK SOLID TUMORS 2009|||WORSENED|1|ppb|IMMUNO-PET SCAN|||Y|SIBLING|RATER|Y|3|Visit_3|40|4|FOLLOW-UP|2020-12-18|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-16|P1Y2M10DT2H30M|UNKNOWN|2020-11-20|COINCIDENT|2021-01-14
e|RS|40936fc6-251d-4a17-ae9d-3bd1150f8d20|7|SPLNRESP|Spleen Response|RAJKUMAR MYELOMA 2011|[?]|Pa|CHR|1|umol/L/h|ERGOSPIROMETRY|Y|||ADJUDICATION COMMITTEE|NEUROLOGIST|U|4|Visit_4|65|2|TREATMENT|2021-01-12|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-16|P1Y2M10DT2H30M|BEFORE|2020-12-07|ONGOING|2021-01-29
e|RS|40936fc6-251d-4a17-ae9d-3bd1150f8d20|8|MRPHRESP|Morphologic Response|EASL BRUIX LIVER CANCER 2001|||HI-E|1|LB|MIGET|||Y|SIGNIFICANT OTHER|INTERNIST|Y|4|Visit_4|65|5|SCREENING|2021-01-12|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-16|P1Y2M10DT2H30M|BEFORE|2021-02-04|AFTER|2021-02-11
e|RS|40936fc6-251d-4a17-ae9d-3bd1150f8d20|9|DRCRIND|Disease Recurrence Indicator|HAMAOKA BREAST CANCER 2010|[?]|%/min|INCREASED|1|lx|PET/CT SCAN||||ADJUDICATOR|MICROSCOPIST 1|NA|5|Visit_5|90|2|TREATMENT|2021-02-06|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-07|P1Y2M10DT2H30M|UNKNOWN|2020-11-16|BEFORE|2020-11-28
e|RS|40936fc6-251d-4a17-ae9d-3bd1150f8d20|10|CPRFSTAT|Clinical Performance Status|DOHNER AML 2010|[?]|mOsm|ABSENT MORPHOLOGIC RESPONSE|1|PA|IMMUNO-PET SCAN||||FAMILY MEMBER|RATER 1|U|5|Visit_5|90|7|TREATMENT|2021-02-06|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-07|P1Y2M10DT2H30M|COINCIDENT|2021-01-29|ONGOING|2021-02-04
e|RS|17b9fa7a-f15d-423a-9671-99cd0cbbd362|1|ANATRESP|Anatomic Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|ELISA unit|MORPHOLOGIC CR|1|FINGERTIP UNIT|TEST STRIP|Y|||DOMESTIC PARTNER|PEDIATRIC NEUROLOGIST|Y|1|Visit_1|10|3|TREATMENT|2020-11-11|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-16|P1Y2M10DT2H30M|COINCIDENT|2021-01-30|AFTER|2021-02-02
e|RS|17b9fa7a-f15d-423a-9671-99cd0cbbd362|2|ANATRESP|Anatomic Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|mL/h|CA125 50% RESPONSE|1|10^6 CFU|CARDIAC THERMODILUTION||||PROXY|ADJUDICATOR 3|U|1|Visit_1|10|3|TREATMENT|2020-11-11|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-16|P1Y2M10DT2H30M|BEFORE|2020-11-29|BEFORE|2021-01-24
e|RS|17b9fa7a-f15d-423a-9671-99cd0cbbd362|3|OVRLRESP|Overall Response|HARTMAN PANCREATIC CANCER 2012|[?]|pg/L|CA125 50% RESPONSE|1|TAMPON|RAJI CELL RIA|Y|||CLINICAL STUDY SPONSOR|READER 1|U|2|Visit_2|25|1|TREATMENT|2020-11-26|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-14|P1Y2M10DT2H30M|COINCIDENT|2020-12-10|AFTER|2021-01-30
e|RS|17b9fa7a-f15d-423a-9671-99cd0cbbd362|4|METBRESP|Metabolic Response|HARTMANN GERM CELL CANCER 2002|[?]|mm/min|SD|1|U/mL|FARNSWORTH-MUNSELL 100 HUE TEST||||GUARDIAN|MICROSCOPIST 1|N|2|Visit_2|25|4|TREATMENT|2020-11-26|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-14|P1Y2M10DT2H30M|UNKNOWN|2021-01-14|COINCIDENT|2021-01-22
e|RS|17b9fa7a-f15d-423a-9671-99cd0cbbd362|5|MOLRESP|Molecular Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|||CYTOGENETIC CR|1|MHz|NEXT GENERATION TARGETED SEQUENCING|Y||Y|NON-HEALTH CARE PROFESSIONAL|READER 2|NA|3|Visit_3|40|7|TREATMENT|2020-12-11|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-04|P1Y2M10DT2H30M|AFTER|2020-11-12|COINCIDENT|2020-11-25
e|RS|17b9fa7a-f15d-423a-9671-99cd0cbbd362|6|MRPHRESP|Morphologic Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|Bq/ug|CR|1|CAN|BIOPSY|Y|Y||HEALTH CARE PROFESSIONAL|READER|NA|3|Visit_3|40|1|FOLLOW-UP|2020-12-11|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-04|P1Y2M10DT2H30M|AFTER|2020-12-31|BEFORE|2021-01-11
e|RS|17b9fa7a-f15d-423a-9671-99cd0cbbd362|7|NEWLPROG|New Lesion Progression|IWC HALLEK CLL 2008|||CA125 75% RESPONSE|1|NEEDLE GAUGE|MODIFIED ACID FAST STAIN|||Y|NON-HEALTH CARE PROFESSIONAL|INTERNIST|NA|4|Visit_4|65|7|TREATMENT|2021-01-05|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-03|P1Y2M10DT2H30M|BEFORE|2020-12-10|COINCIDENT|2021-01-30
e|RS|17b9fa7a-f15d-423a-9671-99cd0cbbd362|8|LIVRRESP|Liver Response|LEE LUNG CANCER 2011|[?]|g/cm2|MRD PERSISTENCE|1|PATCH|ICP-MS|Y|||INTERVIEWER|ONCOLOGIST 2|N|4|Visit_4|65|4|TREATMENT|2021-01-05|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-03|P1Y2M10DT2H30M|COINCIDENT|2021-01-12|ONGOING|2021-02-07
e|RS|17b9fa7a-f15d-423a-9671-99cd0cbbd362|9|MRPHRESP|Morphologic Response|PCWG SCHER PROSTATE CANCER 2016|||FAVORABLE RESPONSE|1|g/kg/day|NEURAMINIDASE INHIBITION ASSAY|||Y|SIBLING|ADJUDICATOR 2|N|5|Visit_5|90|2|TREATMENT|2021-01-30|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-06|P1Y2M10DT2H30M|UNKNOWN|2020-12-04|ONGOING|2020-12-22
e|RS|17b9fa7a-f15d-423a-9671-99cd0cbbd362|10|MNPTHIND|Minor Pathological Response Indicator|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|ug/cm2|CMR|1|umol|INTERRUPTER TECHNIQUE||||FAMILY MEMBER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5|Visit_5|90|2|FOLLOW-UP|2021-01-30|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-06|P1Y2M10DT2H30M|UNKNOWN|2021-01-24|BEFORE|2021-01-31
e|RS|95c4465b-162a-433d-83c9-6d67dd729c9e|1|MNPTHIND|Minor Pathological Response Indicator|IWG CHESON MDS 2000|[?]|amol|MINOR PATHOLOGIC RESPONSE|1|g/cage/wk|DISK DIFFUSION||||DOMESTIC PARTNER|HEMATOLOGIST|N|1|Visit_1|10|4|TREATMENT|2020-10-22|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-30|P1Y2M10DT2H30M|AFTER|2020-11-30|COINCIDENT|2020-12-23
e|RS|95c4465b-162a-433d-83c9-6d67dd729c9e|2|TRGRESP|Target Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|kIU|TREATMENT FAILURE|1|MBq|HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY|Y|||FRIEND|READER 1|U|1|Visit_1|10|4|WASHOUT|2020-10-22|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-30|P1Y2M10DT2H30M|BEFORE|2020-10-17|AFTER|2021-01-16
e|RS|95c4465b-162a-433d-83c9-6d67dd729c9e|3|CPRFSTAT|Clinical Performance Status|CHOI GIST 2008|[?]|ms2|MRD PERSISTENCE|1|uU/dL|CARDIAC THERMODILUTION|Y|||INVESTIGATOR|NEUROLOGIST 1|Y|2|Visit_2|25|4|TREATMENT|2020-11-06|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-02|P1Y2M10DT2H30M|COINCIDENT|2020-10-16|COINCIDENT|2021-01-09
e|RS|95c4465b-162a-433d-83c9-6d67dd729c9e|4|TRGRESP|Target Response|KUMAR IMWG 2016|[?]|mL/min|PD FROM PR|1|10^5/hpf|LIGHT MICROSCOPY|Y|Y||CAREGIVER|NEUROLOGIST|Y|2|Visit_2|25|6|SCREENING|2020-11-06|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-02|P1Y2M10DT2H30M|BEFORE|2021-01-05|BEFORE|2021-01-11
e|RS|95c4465b-162a-433d-83c9-6d67dd729c9e|5|SPLNRESP|Spleen Response|AJCC V7|[?]|pt_br|DECREASED|1|nmol/day|IMMUNODIFFUSION||||FAMILY MEMBER|DEVELOPMENTAL PSYCHOLOGIST|NA|3|Visit_3|40|2|WASHOUT|2020-11-21|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-11|P1Y2M10DT2H30M|UNKNOWN|2020-11-30|COINCIDENT|2021-01-11
e|RS|95c4465b-162a-433d-83c9-6d67dd729c9e|6|PATHRESP|Pathologic Response|IWG CHESON MDS 2006|[?]|ELISA unit/mL|PD-CT|1|dpm/mL|MECHANICAL CLOT DETECTION||||GUARDIAN|ENDOCRINOLOGIST|N|3|Visit_3|40|2|FOLLOW-UP|2020-11-21|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-11|P1Y2M10DT2H30M|AFTER|2020-12-23|COINCIDENT|2021-01-16
e|RS|95c4465b-162a-433d-83c9-6d67dd729c9e|7|CYTORESP|Cytogenetic Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|C|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|10^6 organisms/mg|PYROSEQUENCING||||STUDY SUBJECT|OPTOMETRIST|U|4|Visit_4|65|3|SCREENING|2020-12-16|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-25|P1Y2M10DT2H30M|UNKNOWN|2020-12-18|ONGOING|2021-01-12
e|RS|95c4465b-162a-433d-83c9-6d67dd729c9e|8|CPRFSTAT|Clinical Performance Status|CHESON MALIGNANT LYMPHOMA 2007|[?]|lm|NED|1|mL/min/mmHg|PHYSICAL EXAMINATION||||NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|U|4|Visit_4|65|5|TREATMENT|2020-12-16|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-25|P1Y2M10DT2H30M|UNKNOWN|2020-11-24|BEFORE|2020-12-17
e|RS|95c4465b-162a-433d-83c9-6d67dd729c9e|9|NTNERESP|Non-Target Non-Enhancing Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|mL/(min*100mL)|PR|1|nmol/day|GC/MS/MS|Y|Y||CAREGIVER|ADJUDICATOR 3|U|5|Visit_5|90|4|TREATMENT|2021-01-10|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-15|P1Y2M10DT2H30M|BEFORE|2020-10-16|COINCIDENT|2021-01-13
e|RS|95c4465b-162a-433d-83c9-6d67dd729c9e|10|SYMPTDTR|Symptomatic Deterioration|CHOLLET BREAST CANCER 2002|[?]|mEq/ug|INDETERMINATE RESPONSE|1|pmol/10^9 cells|PERIPHERAL ANGIOGRAPHY||||ADJUDICATOR|ONCOLOGIST|N|5|Visit_5|90|1|TREATMENT|2021-01-10|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-15|P1Y2M10DT2H30M|AFTER|2020-12-06|COINCIDENT|2020-12-31
e|RS|9a205b50-21a9-4fbc-9ca9-a9378aadd5de|1|HEMARESP|Hematologic Response|WHO BREAST CANCER 2006|[?]|GBq/ug|iSD|1|F|ELECTROMYOGRAPHY||Y||INVESTIGATOR|FORENSIC PATHOLOGIST|Y|1|Visit_1|10|2|FOLLOW-UP|2020-06-27|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-24|P1Y2M10DT2H30M|BEFORE|2020-09-01|AFTER|2020-09-20
e|RS|9a205b50-21a9-4fbc-9ca9-a9378aadd5de|2|TRGRESP|Target Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|||PD FROM PR|1|Anson U|CONGO RED STAIN|Y||Y|ADJUDICATOR|CLINICAL PATHOLOGIST|N|1|Visit_1|10|6|WASHOUT|2020-06-27|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-24|P1Y2M10DT2H30M|COINCIDENT|2020-08-09|COINCIDENT|2020-08-17
e|RS|9a205b50-21a9-4fbc-9ca9-a9378aadd5de|3|MOLRESP|Molecular Response|PETIT BREAST CANCER 2001|[?]|Bq/mL|CYTOGENETIC MINOR RESPONSE|1|pkat/L|PATHOLOGICAL EVALUATION||||GUARDIAN|READER|U|2|Visit_2|25|3|FOLLOW-UP|2020-07-12|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-16|P1Y2M10DT2H30M|UNKNOWN|2020-09-13|BEFORE|2020-09-14
e|RS|9a205b50-21a9-4fbc-9ca9-a9378aadd5de|4|BESTRESP|Best Overall Response|IWC HALLEK CLL 2008|[?]|kcal|CRi|1|log10 IU/mL|TRICHROME STAIN||||NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|2|Visit_2|25|4|WASHOUT|2020-07-12|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-16|P1Y2M10DT2H30M|BEFORE|2020-08-29|AFTER|2020-09-08
e|RS|9a205b50-21a9-4fbc-9ca9-a9378aadd5de|5|PATHRESP|Pathologic Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|K|MOLECULAR MAJOR RESPONSE|1|10^7/L|PHOROPTER|Y|||INDEPENDENT ASSESSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|3|Visit_3|40|6|FOLLOW-UP|2020-07-27|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-18|P1Y2M10DT2H30M|BEFORE|2020-08-10|ONGOING|2020-08-26
e|RS|9a205b50-21a9-4fbc-9ca9-a9378aadd5de|6|MRDRESP|Minimal Residual Disease Response|IWG CHESON AML 2003|||INDETERMINATE RESPONSE|1|mL/day|MICROBIAL CULTURE, SOLID|||Y|STUDY SUBJECT|DERMATOLOGIST|N|3|Visit_3|40|3|WASHOUT|2020-07-27|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-18|P1Y2M10DT2H30M|AFTER|2020-07-26|BEFORE|2020-09-24
e|RS|9a205b50-21a9-4fbc-9ca9-a9378aadd5de|7|TRGRESP|Target Response|KUMAR IMWG 2016|[?]|ppm|CYTOGENETIC CR|1|Frames/s|GC/MS-CI||||CLINICAL STUDY SPONSOR|READER 2|N|4|Visit_4|65|2|WASHOUT|2020-08-21|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-22|P1Y2M10DT2H30M|AFTER|2020-08-28|COINCIDENT|2020-09-08
e|RS|9a205b50-21a9-4fbc-9ca9-a9378aadd5de|8|NEWLIND|New Lesion Indicator|DURIE MULTIPLE MYELOMA 2006|||CYTOGENETIC PR|1|cd|GC/MS-EI|Y||Y|SIBLING|READER 1|NA|4|Visit_4|65|3|FOLLOW-UP|2020-08-21|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-22|P1Y2M10DT2H30M|UNKNOWN|2020-08-13|COINCIDENT|2020-09-04
e|RS|9a205b50-21a9-4fbc-9ca9-a9378aadd5de|9|MOLRESP|Molecular Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|U/m2/h|CR|1|mg/kg/day|BIOIMPEDANCE SPECTROSCOPY||||SIGNIFICANT OTHER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|5|Visit_5|90|7|SCREENING|2020-09-15|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-20|P1Y2M10DT2H30M|COINCIDENT|2020-09-07|BEFORE|2020-09-19
e|RS|9a205b50-21a9-4fbc-9ca9-a9378aadd5de|10|MRDRESP|Minimal Residual Disease Response|FAROOQUI SUPP CLL 2014|[?]|/ms|MOLECULAR MAJOR RESPONSE|1|/LSQN|SANGER SEQUENCING||||INDEPENDENT ASSESSOR|OPTOMETRIST|NA|5|Visit_5|90|7|WASHOUT|2020-09-15|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-20|P1Y2M10DT2H30M|COINCIDENT|2020-08-14|BEFORE|2020-08-22
e|RS|beb6b1ab-1264-456a-bf2b-81e28493301d|1|CLINRESP|Clinical Response|AJCC V7|[?]|kat|EQUIVOCAL|1|dmol|MICRODENSITOMETRY||Y||INTERVIEWER|OPTOMETRIST|Y|1|Visit_1|10|3|TREATMENT|2020-06-10|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-02|P1Y2M10DT2H30M|AFTER|2020-06-20|BEFORE|2020-07-27
e|RS|beb6b1ab-1264-456a-bf2b-81e28493301d|2|BONERESP|Bone Response|KUKER LYMPHOMA 2005|[?]|mL/cm|MOLECULAR MAJOR RESPONSE|1|kBq|X-RAY FLUORESCENCE SPECTROMETRY||||SPOUSE|PATHOLOGIST 1|Y|1|Visit_1|10|1|TREATMENT|2020-06-10|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-02|P1Y2M10DT2H30M|BEFORE|2020-08-13|COINCIDENT|2020-08-20
e|RS|beb6b1ab-1264-456a-bf2b-81e28493301d|3|MJPTHIND|Major Pathological Response Indicator|NCIWG CHESON CLL 1996|[?]|BOTTLE|PARTIAL MORPHOLOGIC RESPONSE|1|MBq/uL|PUPILLOMETRY|Y|Y||CHILD|OPTOMETRIST|NA|2|Visit_2|25|5|TREATMENT|2020-06-25|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-28|P1Y2M10DT2H30M|BEFORE|2020-08-26|BEFORE|2020-08-29
e|RS|beb6b1ab-1264-456a-bf2b-81e28493301d|4|NTNERESP|Non-Target Non-Enhancing Response|UNSPECIFIED|[?]|nmol/L|UNFAVORABLE RESPONSE|1|g/cage/wk|RADIATION DOSIMETRY||Y||CLINICAL STUDY SPONSOR|PATHOLOGIST|U|2|Visit_2|25|4|TREATMENT|2020-06-25|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-28|P1Y2M10DT2H30M|BEFORE|2020-08-24|BEFORE|2020-08-26
e|RS|beb6b1ab-1264-456a-bf2b-81e28493301d|5|HEMARESP|Hematologic Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|g/kg|sCR|1|Ci/L|VENTILATION PERFUSION LUNG SCAN||||PROXY|READER 1|NA|3|Visit_3|40|5|TREATMENT|2020-07-10|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-09|P1Y2M10DT2H30M|AFTER|2020-07-13|ONGOING|2020-07-14
e|RS|beb6b1ab-1264-456a-bf2b-81e28493301d|6|TRGRESP|Target Response|AJCC V7|[?]|L/min|CYTOGENETIC NO RESPONSE|1|kg/cm|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION||Y||CLINICAL RESEARCH ASSOCIATE|INTERNIST|Y|3|Visit_3|40|7|FOLLOW-UP|2020-07-10|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-09|P1Y2M10DT2H30M|AFTER|2020-08-24|ONGOING|2020-09-01
e|RS|beb6b1ab-1264-456a-bf2b-81e28493301d|7|HEMARESP|Hematologic Response|PROTOCOL DEFINED RESPONSE CRITERIA|||DISEASE TRANSFORMATION|1|rpm|ROMANOWSKY STAIN||Y|Y|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 2|N|4|Visit_4|65|3|TREATMENT|2020-08-04|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-02|P1Y2M10DT2H30M|AFTER|2020-07-06|AFTER|2020-09-07
e|RS|beb6b1ab-1264-456a-bf2b-81e28493301d|8|ANATRESP|Anatomic Response|EASL BRUIX LIVER CANCER 2001|[?]|cmol|WORSENED|1|mmAL|HEMOCYTOMETRY||Y||STUDY SUBJECT|ADJUDICATOR 1|N|4|Visit_4|65|5|TREATMENT|2020-08-04|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-02|P1Y2M10DT2H30M|COINCIDENT|2020-06-11|BEFORE|2020-06-25
e|RS|beb6b1ab-1264-456a-bf2b-81e28493301d|9|MOLRESP|Molecular Response|MASS|[?]|cd|CA125 75% RESPONSE|1|mOsm/kg|REFRACTOMETRY||Y||ADJUDICATOR|HEMATOLOGIST|U|5|Visit_5|90|2|TREATMENT|2020-08-29|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-02|P1Y2M10DT2H30M|BEFORE|2020-07-20|COINCIDENT|2020-09-04
e|RS|beb6b1ab-1264-456a-bf2b-81e28493301d|10|CYTORESP|Cytogenetic Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|RNA copies/mL|QUANTIFIABLE MRD POSITIVITY|1|g/mol|HPLC/MS/MS||Y||CLINICAL STUDY SPONSOR|PATHOLOGIST|U|5|Visit_5|90|6|TREATMENT|2020-08-29|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-02|P1Y2M10DT2H30M|COINCIDENT|2020-08-08|ONGOING|2020-09-02
e|RS|4292c06d-044e-4dff-aea0-830178a6e220|1|NTERESP|Non-Target Enhancing Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|pkat|MRD NEGATIVITY|1|PUFF|RAJI CELL RIA||||INDEPENDENT ASSESSOR|READER 1|U|1|Visit_1|10|1|TREATMENT|2020-12-02|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-25|P1Y2M10DT2H30M|AFTER|2020-12-15|COINCIDENT|2020-12-28
e|RS|4292c06d-044e-4dff-aea0-830178a6e220|2|NTNERESP|Non-Target Non-Enhancing Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|IU/L|IMPROVED|1|ug/animal|IMMUNO-PET SCAN||||VENDOR|OPTOMETRIST|Y|1|Visit_1|10|2|WASHOUT|2020-12-02|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-25|P1Y2M10DT2H30M|AFTER|2020-12-31|ONGOING|2021-02-15
e|RS|4292c06d-044e-4dff-aea0-830178a6e220|3|ANATRESP|Anatomic Response|AJCC V7|[?]|fL|COMPLETE MRD RESPONSE|1|nCi|MAGNETIC RESONANCE ENTEROGRAPHY||||VENDOR|NEUROLOGIST 2|Y|2|Visit_2|25|2|TREATMENT|2020-12-17|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-18|P1Y2M10DT2H30M|UNKNOWN|2021-01-29|BEFORE|2021-02-12
e|RS|4292c06d-044e-4dff-aea0-830178a6e220|4|MJPTHIND|Major Pathological Response Indicator|MRECIST LENCIONI LIVER CANCER 2010|[?]|nsec|CMR|1|MET|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION||||FRIEND|MICROSCOPIST|N|2|Visit_2|25|6|FOLLOW-UP|2020-12-17|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-18|P1Y2M10DT2H30M|UNKNOWN|2021-03-01|ONGOING|2021-03-02
e|RS|4292c06d-044e-4dff-aea0-830178a6e220|5|MRPHRESP|Morphologic Response|SACT|[?]|/HPF|MAJOR PATHOLOGIC RESPONSE|1|ms2|IMMUNOBLOT||||CAREGIVER|DEVELOPMENTAL PSYCHOLOGIST|N|3|Visit_3|40|2|WASHOUT|2021-01-01|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-05|P1Y2M10DT2H30M|COINCIDENT|2021-02-09|AFTER|2021-02-11
e|RS|4292c06d-044e-4dff-aea0-830178a6e220|6|NTNERESP|Non-Target Non-Enhancing Response|MURPHY PROSTATE CANCER 1980|[?]|pmol|SMD|1|eq|NUCLEIC ACID BASED METHOD||||INTERVIEWER|RATER|N|3|Visit_3|40|1|WASHOUT|2021-01-01|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-05|P1Y2M10DT2H30M|UNKNOWN|2020-12-19|AFTER|2021-01-28
e|RS|4292c06d-044e-4dff-aea0-830178a6e220|7|BESTRESP|Best Overall Response|BURCOMBE BREAST CANCER 2005|[?]|g|sCR|1|BOTTLE|DC SHEATH FLOW||Y||SPOUSE|ENDOCRINOLOGIST|N|4|Visit_4|65|5|TREATMENT|2021-01-26|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-17|P1Y2M10DT2H30M|UNKNOWN|2021-01-21|COINCIDENT|2021-02-01
e|RS|4292c06d-044e-4dff-aea0-830178a6e220|8|BONERESP|Bone Response|EBMT BLADE MYELOMA 1998|[?]|U/L|PDu|1|pkat|PHYSICAL EXAMINATION||||NON-HEALTH CARE PROFESSIONAL|HEMATOLOGIST|U|4|Visit_4|65|1|TREATMENT|2021-01-26|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-17|P1Y2M10DT2H30M|UNKNOWN|2020-12-05|ONGOING|2021-02-12
e|RS|4292c06d-044e-4dff-aea0-830178a6e220|9|LIVRRESP|Liver Response|GUPPY OVARIAN CANCER 2002|[?]|mEq/kg|MORPHOLOGIC CRi|1|L/h|MRS||||CHILD|OPHTHALMOLOGIST|NA|5|Visit_5|90|1|FOLLOW-UP|2021-02-20|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-28|P1Y2M10DT2H30M|COINCIDENT|2021-01-01|COINCIDENT|2021-01-31
e|RS|4292c06d-044e-4dff-aea0-830178a6e220|10|SYMPTDTR|Symptomatic Deterioration|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|Ci/uL|NOT ALL EVALUATED|1|breaths/min|CONTRAST ENHANCED PET/CT SCAN||||PROXY|PATHOLOGIST 2|U|5|Visit_5|90|3|TREATMENT|2021-02-20|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-28|P1Y2M10DT2H30M|AFTER|2021-01-23|BEFORE|2021-01-28
e|RS|050c12d2-cf9f-402b-9332-d6a9771ed115|1|DRCRIND|Disease Recurrence Indicator|BURCOMBE BREAST CANCER 2005|[?]|umol/mg/min|NR|1|10^6 organisms|ELLA||||SIGNIFICANT OTHER|PATHOLOGIST 1|Y|1|Visit_1|10|7|TREATMENT|2020-08-18|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-02|P1Y2M10DT2H30M|UNKNOWN|2020-11-11|ONGOING|2020-11-13
e|RS|050c12d2-cf9f-402b-9332-d6a9771ed115|2|BESTRESP|Best Overall Response|SACT|||CMR|1|nU/cL|FLOW CYTOMETRY|Y|Y|Y|FAMILY MEMBER|MICROSCOPIST 3|NA|1|Visit_1|10|1|FOLLOW-UP|2020-08-18|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-02|P1Y2M10DT2H30M|UNKNOWN|2020-09-19|COINCIDENT|2020-11-15
e|RS|050c12d2-cf9f-402b-9332-d6a9771ed115|3|MJPTHIND|Major Pathological Response Indicator|NCCN ALL MRD 2014|[?]|mL/animal/wk|RELAPSED DISEASE FROM CR OR PR|1|mU/L|FLUOROSCOPY||||INDEPENDENT ASSESSOR|ADJUDICATOR 3|NA|2|Visit_2|25|5|FOLLOW-UP|2020-09-02|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-11|P1Y2M10DT2H30M|AFTER|2020-08-14|ONGOING|2020-10-18
e|RS|050c12d2-cf9f-402b-9332-d6a9771ed115|4|TMRESP|Tumor Marker Response|JACINTO CERVICAL CANCER 2007|[?]|hPa|CR|1|mmol/s|ELECTROCHEMILUMINESCENCE IMMUNOASSAY|Y|||GUARDIAN|DEVELOPMENTAL PSYCHOLOGIST|Y|2|Visit_2|25|2|FOLLOW-UP|2020-09-02|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-11|P1Y2M10DT2H30M|UNKNOWN|2020-11-11|BEFORE|2020-11-14
e|RS|050c12d2-cf9f-402b-9332-d6a9771ed115|5|CLINRESP|Clinical Response|MASS|[?]|mg/cm2|MOLECULAR MAJOR RESPONSE|1|PUFF|IMMUNE REPERTOIRE DEEP SEQUENCING||||SPOUSE|OTOLARYNGOLOGIST|NA|3|Visit_3|40|5|TREATMENT|2020-09-17|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-09|P1Y2M10DT2H30M|COINCIDENT|2020-10-15|COINCIDENT|2020-10-22
e|RS|050c12d2-cf9f-402b-9332-d6a9771ed115|6|TRGRESP|Target Response|AJCC V7|||MOLECULAR CR|1|log10 CFU/mL|MIGET|Y|Y|Y|INDEPENDENT ASSESSOR|READER 3|NA|3|Visit_3|40|3|TREATMENT|2020-09-17|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-09|P1Y2M10DT2H30M|BEFORE|2020-09-14|ONGOING|2020-10-30
e|RS|050c12d2-cf9f-402b-9332-d6a9771ed115|7|MOLRESP|Molecular Response|RANO|||MOLECULAR CR|1|uSiemens|MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY||Y|Y|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|NA|4|Visit_4|65|3|TREATMENT|2020-10-12|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-26|P1Y2M10DT2H30M|BEFORE|2020-08-19|BEFORE|2020-08-25
e|RS|050c12d2-cf9f-402b-9332-d6a9771ed115|8|PATHRESP|Pathologic Response|HAMAOKA BREAST CANCER 2010|||INDETERMINATE RESPONSE|1|kg/cm|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|||Y|SIGNIFICANT OTHER|UROLOGIST|U|4|Visit_4|65|3|SCREENING|2020-10-12|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-26|P1Y2M10DT2H30M|AFTER|2020-10-09|BEFORE|2020-11-07
e|RS|050c12d2-cf9f-402b-9332-d6a9771ed115|9|PATHRESP|Pathologic Response|MONTSERRAT CLL 1989|[?]|kg|RELAPSED DISEASE|1|mmHg/L/min|MAPH||||DOMESTIC PARTNER|RADIOLOGIST 1|N|5|Visit_5|90|7|FOLLOW-UP|2020-11-06|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-19|P1Y2M10DT2H30M|AFTER|2020-09-25|ONGOING|2020-11-05
e|RS|050c12d2-cf9f-402b-9332-d6a9771ed115|10|CYTORESP|Cytogenetic Response|RAJKUMAR MYELOMA 2011|[?]|uL|COMPLETE MRD RESPONSE|1|V|PLAQUE REDUCTION NEUTRALIZATION ASSAY||||INVESTIGATOR|DEVELOPMENTAL PSYCHOLOGIST|NA|5|Visit_5|90|1|WASHOUT|2020-11-06|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-19|P1Y2M10DT2H30M|BEFORE|2020-09-26|COINCIDENT|2020-10-20
e|RS|2f1073e4-607f-423f-a5de-f531b828e2d3|1|NEWLWIND|New Lesion Worsening Indicator|GUILHOT CML 2007|[?]|mOsm/kg|PD FROM PR|1|BP|BIOIMPEDANCE SPECTROSCOPY|Y|||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 1|NA|1|Visit_1|10|6|TREATMENT|2020-10-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-11|P1Y2M10DT2H30M|COINCIDENT|2020-12-14|BEFORE|2021-01-09
e|RS|2f1073e4-607f-423f-a5de-f531b828e2d3|2|METBRESP|Metabolic Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|psi|CA125 75% RESPONSE|1|mAnson U/mL|NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY||Y||CLINICAL STUDY SPONSOR|RADIOLOGIST 2|NA|1|Visit_1|10|5|WASHOUT|2020-10-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-11|P1Y2M10DT2H30M|BEFORE|2020-10-25|ONGOING|2020-12-07
e|RS|2f1073e4-607f-423f-a5de-f531b828e2d3|3|TRGRESP|Target Response|WHO BREAST CANCER 2006|||NON-QUANTIFIABLE MRD POSITIVITY|1|uEq/L|CONTRAST ENHANCED MRI|Y||Y|NON-HEALTH CARE PROFESSIONAL|READER|N|2|Visit_2|25|3|TREATMENT|2020-10-30|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-07|P1Y2M10DT2H30M|AFTER|2020-11-22|COINCIDENT|2020-12-09
e|RS|2f1073e4-607f-423f-a5de-f531b828e2d3|4|NEWLPROG|New Lesion Progression|BRUGGEMANN MRD 2010|[?]|fL|RELAPSED DISEASE|1|mV*min|IMMUNOBLOT|Y|||ADJUDICATION COMMITTEE|PATHOLOGIST|N|2|Visit_2|25|6|TREATMENT|2020-10-30|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-07|P1Y2M10DT2H30M|BEFORE|2020-12-30|BEFORE|2021-01-07
e|RS|2f1073e4-607f-423f-a5de-f531b828e2d3|5|LIVRRESP|Liver Response|CHOI GIST 2008|[?]|/h|NON-PD|1|min*mg/mL|FLUORESCENT SPOT TEST||||VENDOR|NEUROLOGIST|Y|3|Visit_3|40|6|TREATMENT|2020-11-14|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-28|P1Y2M10DT2H30M|BEFORE|2020-11-15|AFTER|2021-01-01
e|RS|2f1073e4-607f-423f-a5de-f531b828e2d3|6|DRCRIND|Disease Recurrence Indicator|NCCN ALL MRD 2014|[?]|Shock Wave|OPTIMAL MORPHOLOGIC RESPONSE|1|umol/mol|HPLC/IEX|Y|||ADJUDICATOR|UROLOGIST|N|3|Visit_3|40|6|WASHOUT|2020-11-14|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-28|P1Y2M10DT2H30M|UNKNOWN|2020-11-16|ONGOING|2021-01-05
e|RS|2f1073e4-607f-423f-a5de-f531b828e2d3|7|DRCRIND|Disease Recurrence Indicator|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|10^9 CFU|PMR|1|mg/m2|REBOUND TONOMETRY|Y|||STUDY SUBJECT|OPHTHALMOLOGIST|Y|4|Visit_4|65|4|TREATMENT|2020-12-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-14|P1Y2M10DT2H30M|BEFORE|2020-10-18|COINCIDENT|2020-11-07
e|RS|2f1073e4-607f-423f-a5de-f531b828e2d3|8|OVRLRESP|Overall Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|%(v/v)|PSEUDORESPONSE|1|uV*sec|MAGNETIC RESONANCE ANGIOGRAPHY||||GUARDIAN|PATHOLOGIST 2|U|4|Visit_4|65|1|TREATMENT|2020-12-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-14|P1Y2M10DT2H30M|AFTER|2020-12-13|AFTER|2020-12-21
e|RS|2f1073e4-607f-423f-a5de-f531b828e2d3|9|BONERESP|Bone Response|PETIT BREAST CANCER 2001|[?]|log10 PFU/mL|iPR|1|10^3 organisms/g|ICP-MS|Y|||ADJUDICATOR|PATHOLOGIST 1|NA|5|Visit_5|90|7|TREATMENT|2021-01-03|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-26|P1Y2M10DT2H30M|BEFORE|2020-10-10|ONGOING|2020-11-08
e|RS|2f1073e4-607f-423f-a5de-f531b828e2d3|10|NTERESP|Non-Target Enhancing Response|PCWG SCHER PROSTATE CANCER 2016|[?]|g/m2|UNFAVORABLE RESPONSE|1|Henry|POTENTIOMETRY||||SPOUSE|MICROSCOPIST|NA|5|Visit_5|90|5|TREATMENT|2021-01-03|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-26|P1Y2M10DT2H30M|UNKNOWN|2020-11-29|COINCIDENT|2021-01-10
e|RS|df466903-3212-4e73-bff0-a183447c7408|1|PATHRESP|Pathologic Response|MURPHY PROSTATE CANCER 1980|[?]|dpm/mg|pCR|1|10^6 organisms/mg|ELECTROMYOGRAPHY||||CLINICAL STUDY SPONSOR|RADIOLOGIST 2|Y|1|Visit_1|10|3|FOLLOW-UP|2020-11-01|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-13|P1Y2M10DT2H30M|UNKNOWN|2021-01-09|AFTER|2021-01-29
e|RS|df466903-3212-4e73-bff0-a183447c7408|2|HEMARESP|Hematologic Response|iRECIST|[?]|ug/mol|NON-PD|1|vg/dose|BIOPSY||Y||STUDY SUBJECT|MICROSCOPIST 3|Y|1|Visit_1|10|7|TREATMENT|2020-11-01|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-13|P1Y2M10DT2H30M|COINCIDENT|2020-11-22|BEFORE|2020-12-05
e|RS|df466903-3212-4e73-bff0-a183447c7408|3|MOLRESP|Molecular Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|uV2|QUANTIFIABLE MRD POSITIVITY|1|mmol/min/kPa|BALLPOINT PEN TECHNIQUE|Y|||VENDOR|RADIOLOGIST|NA|2|Visit_2|25|1|TREATMENT|2020-11-16|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-18|P1Y2M10DT2H30M|BEFORE|2020-12-29|COINCIDENT|2021-01-15
e|RS|df466903-3212-4e73-bff0-a183447c7408|4|BESTRESP|Best Overall Response|MURPHY PROSTATE CANCER 1980|||CYTOGENETIC CR|1|TROCHE|SXA SCAN|Y||Y|CLINICAL STUDY SPONSOR|RATER|Y|2|Visit_2|25|4|TREATMENT|2020-11-16|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-18|P1Y2M10DT2H30M|BEFORE|2021-01-05|AFTER|2021-01-13
e|RS|df466903-3212-4e73-bff0-a183447c7408|5|MRDIND|Minimal Residual Disease Indicator|DOHNER AML 2010|||NON-PD|1|cmH2O*s/mL|HPLC|||Y|CHILD|ENDOCRINOLOGIST|N|3|Visit_3|40|6|SCREENING|2020-12-01|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-17|P1Y2M10DT2H30M|AFTER|2020-12-09|COINCIDENT|2021-01-12
e|RS|df466903-3212-4e73-bff0-a183447c7408|6|ANATRESP|Anatomic Response|CHOLLET BREAST CANCER 2002|[?]|cal|NON-CR/NON-PD|1|mL/cage/day|HEMATOXYLIN AND EOSIN STAIN||||CAREGIVER|ADJUDICATOR 1|NA|3|Visit_3|40|3|FOLLOW-UP|2020-12-01|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-17|P1Y2M10DT2H30M|AFTER|2020-12-02|COINCIDENT|2021-01-21
e|RS|df466903-3212-4e73-bff0-a183447c7408|7|STRUSTAT|Steroid Use Status|NCIWG CHESON CLL 1996|[?]|mg/mL/day|NE|1|ug/kg/h|WHOLE EXOME SEQUENCING||||CHILD|READER|Y|4|Visit_4|65|5|TREATMENT|2020-12-26|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-02|P1Y2M10DT2H30M|COINCIDENT|2020-11-12|AFTER|2020-12-25
e|RS|df466903-3212-4e73-bff0-a183447c7408|8|ANATRESP|Anatomic Response|NCCN ALL MRD 2014|[?]|umol/L/h|CYTOGENETIC PR|1|IU/kg|FUNCTIONAL MRI||||FRIEND|OPHTHALMOLOGIST|U|4|Visit_4|65|6|WASHOUT|2020-12-26|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-02|P1Y2M10DT2H30M|BEFORE|2020-12-31|ONGOING|2021-01-13
e|RS|df466903-3212-4e73-bff0-a183447c7408|9|STRUSTAT|Steroid Use Status|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|||PSEUDORESPONSE|1|KALLIKREIN INHIBITOR UNIT|QUANTITATIVE PERIPHERAL ANGIOGRAPHY|||Y|ADJUDICATION COMMITTEE|OPTOMETRIST|Y|5|Visit_5|90|1|TREATMENT|2021-01-20|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-03|P1Y2M10DT2H30M|AFTER|2020-12-23|COINCIDENT|2021-01-27
e|RS|df466903-3212-4e73-bff0-a183447c7408|10|NEWLIND|New Lesion Indicator|GUILHOT CML 2007|[?]|FFU|SD-CT|1|ug/L DDU|RULER MEASUREMENT METHOD||||CLINICAL RESEARCH COORDINATOR|RATER|NA|5|Visit_5|90|1|TREATMENT|2021-01-20|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-03|P1Y2M10DT2H30M|AFTER|2020-12-28|BEFORE|2021-01-11
e|RS|4eeb68ac-cd3a-4d3c-8381-2d715c8fa442|1|NTERESP|Non-Target Enhancing Response|SACT|[?]|g/kg|PD/RELAPSE AFTER HI|1|v/v|NEXT GENERATION SEQUENCING||||ADJUDICATION COMMITTEE|MICROSCOPIST 2|N|1|Visit_1|10|2|TREATMENT|2020-07-13|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-20|P1Y2M10DT2H30M|UNKNOWN|2020-09-28|COINCIDENT|2020-10-10
e|RS|4eeb68ac-cd3a-4d3c-8381-2d715c8fa442|2|OVRLRESP|Overall Response|KUMAR IMWG 2016|[?]|HEP|RELAPSED DISEASE|1|mL/animal/wk|GC/FID||||HEALTH CARE PROFESSIONAL|RATER|U|1|Visit_1|10|5|FOLLOW-UP|2020-07-13|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-20|P1Y2M10DT2H30M|BEFORE|2020-09-08|ONGOING|2020-09-17
e|RS|4eeb68ac-cd3a-4d3c-8381-2d715c8fa442|3|MRDIND|Minimal Residual Disease Indicator|IWG CHESON MDS 2000|[?]|Gauss|NON-CR/NON-PD|1|PELLET|GRAM STAIN||||SIBLING|PHYSIOTHERAPIST|U|2|Visit_2|25|2|SCREENING|2020-07-28|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-06|P1Y2M10DT2H30M|COINCIDENT|2020-07-29|BEFORE|2020-08-06
e|RS|4eeb68ac-cd3a-4d3c-8381-2d715c8fa442|4|NEWLWIND|New Lesion Worsening Indicator|MRECIST BYRNE MESOTHELIOMA 2004|[?]|umol/mg/min|CA125 75% RESPONSE|1|ug/dL|ETDRS EYE CHART|Y|||CLINICAL STUDY SPONSOR|ADJUDICATOR 2|U|2|Visit_2|25|4|TREATMENT|2020-07-28|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-06|P1Y2M10DT2H30M|COINCIDENT|2020-09-26|BEFORE|2020-10-06
e|RS|4eeb68ac-cd3a-4d3c-8381-2d715c8fa442|5|METSIND|Metastatic Indicator|CHESON MALIGNANT LYMPHOMA 2007|||NED|1|nmol/g|REVERSE TRANSCRIPTASE PCR||Y|Y|STUDY SUBJECT|PATHOLOGIST 2|U|3|Visit_3|40|4|TREATMENT|2020-08-12|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-22|P1Y2M10DT2H30M|COINCIDENT|2020-10-04|COINCIDENT|2020-10-06
e|RS|4eeb68ac-cd3a-4d3c-8381-2d715c8fa442|6|NTRGRESP|Non-target Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|mL/g/h|RELAPSED DISEASE FROM CR OR PR|1|uIU/L|GC/FID||||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 1|Y|3|Visit_3|40|6|SCREENING|2020-08-12|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-22|P1Y2M10DT2H30M|AFTER|2020-08-11|AFTER|2020-09-07
e|RS|4eeb68ac-cd3a-4d3c-8381-2d715c8fa442|7|STRUSTAT|Steroid Use Status|DURIE MULTIPLE MYELOMA 2006|[?]|aMFI|MORPHOLOGIC CRi|1|L/day|LANDOLT RING||||GUARDIAN|INTERNIST|Y|4|Visit_4|65|1|WASHOUT|2020-09-06|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-31|P1Y2M10DT2H30M|UNKNOWN|2020-07-25|COINCIDENT|2020-07-27
e|RS|4eeb68ac-cd3a-4d3c-8381-2d715c8fa442|8|NEWLWIND|New Lesion Worsening Indicator|KUKER LYMPHOMA 2005|[?]|HOMEOPATHIC DILUTION|HI-E|1|Ci/kg|EPSILOMETER||||PARENT|READER|Y|4|Visit_4|65|7|WASHOUT|2020-09-06|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-31|P1Y2M10DT2H30M|UNKNOWN|2020-07-31|COINCIDENT|2020-09-19
e|RS|4eeb68ac-cd3a-4d3c-8381-2d715c8fa442|9|MRPHRESP|Morphologic Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|mm3/mm2/year|CYTOGENETIC CR|1|ng/L|HPLC-UV||Y||DOMESTIC PARTNER|ADJUDICATOR 2|NA|5|Visit_5|90|5|WASHOUT|2020-10-01|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-04|P1Y2M10DT2H30M|COINCIDENT|2020-09-03|AFTER|2020-10-06
e|RS|4eeb68ac-cd3a-4d3c-8381-2d715c8fa442|10|OVRLRESP|Overall Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|Gy|sCR|1|psi|COMPUTERIZED CORNEAL TOPOGRAPHY||||SPOUSE|ADJUDICATOR 3|N|5|Visit_5|90|3|TREATMENT|2020-10-01|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-04|P1Y2M10DT2H30M|COINCIDENT|2020-10-06|AFTER|2020-10-08
e|RS|c37df2f6-be8a-4709-b97d-061ab9754e0d|1|METBRESP|Metabolic Response|LUGANO CLASSIFICATION|[?]|pmol|PD FROM PR|1|10^6 CFU|SLOAN LETTER EYE CHART 2.5%||||CLINICAL STUDY SPONSOR|PATHOLOGIST|U|1|Visit_1|10|3|TREATMENT|2020-08-01|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-04|P1Y2M10DT2H30M|COINCIDENT|2020-08-13|ONGOING|2020-10-24
e|RS|c37df2f6-be8a-4709-b97d-061ab9754e0d|2|BONERESP|Bone Response|DOHNER AML 2010|||CYTOGENETIC PR|1|DNA copies/ug|ELECTROCHEMILUMINESCENCE|||Y|ADJUDICATION COMMITTEE|MICROSCOPIST|U|1|Visit_1|10|3|WASHOUT|2020-08-01|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-04|P1Y2M10DT2H30M|AFTER|2020-09-05|AFTER|2020-09-14
e|RS|c37df2f6-be8a-4709-b97d-061ab9754e0d|3|LIVRRESP|Liver Response|GUILHOT CML 2007|[?]|LB|CYTOGENETIC NO RESPONSE|1|TRACE|IMMUNOFIXATION ELECTROPHORESIS||Y||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 3|NA|2|Visit_2|25|7|FOLLOW-UP|2020-08-16|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-25|P1Y2M10DT2H30M|COINCIDENT|2020-09-07|BEFORE|2020-10-26
e|RS|c37df2f6-be8a-4709-b97d-061ab9754e0d|4|RDIORESP|Radiologic Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|||iCR|1|PIPE|POPULATION SEQUENCING|Y|Y|Y|ADJUDICATION COMMITTEE|MICROSCOPIST|NA|2|Visit_2|25|6|TREATMENT|2020-08-16|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-25|P1Y2M10DT2H30M|COINCIDENT|2020-08-22|ONGOING|2020-10-13
e|RS|c37df2f6-be8a-4709-b97d-061ab9754e0d|5|SYMPTDTR|Symptomatic Deterioration|iRECIST|||CRi|1|min*mg/mL|FLUORESCENT MICROSCOPY|||Y|PROXY|UROLOGIST|U|3|Visit_3|40|2|TREATMENT|2020-08-31|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-19|P1Y2M10DT2H30M|AFTER|2020-09-21|ONGOING|2020-10-16
e|RS|c37df2f6-be8a-4709-b97d-061ab9754e0d|6|MRDRESP|Minimal Residual Disease Response|RANO ELLINGSON 2017|||CA125 75% RESPONSE|1|copies/ug|ORCHIDOMETERY|Y|Y|Y|ADJUDICATOR|INTERNIST|N|3|Visit_3|40|3|WASHOUT|2020-08-31|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-19|P1Y2M10DT2H30M|BEFORE|2020-10-09|AFTER|2020-10-20
e|RS|c37df2f6-be8a-4709-b97d-061ab9754e0d|7|NTLWIND|Non-Target Lesion Worsening Indicator|AJCC V7|[?]|BISCUIT|DISEASE TRANSFORMATION|1|MAC50|FLUORESCENT ENZYME IMMUNOASSAY|Y|||DOMESTIC PARTNER|RADIOLOGIST 1|NA|4|Visit_4|65|5|WASHOUT|2020-09-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-21|P1Y2M10DT2H30M|COINCIDENT|2020-08-22|AFTER|2020-10-26
e|RS|c37df2f6-be8a-4709-b97d-061ab9754e0d|8|NEWLWIND|New Lesion Worsening Indicator|PCWG SCHER PROSTATE CANCER 2008|[?]|Shock Wave|PR-CT|1|mmol/g|REBOUND TONOMETRY||||PARENT|ONCOLOGIST|N|4|Visit_4|65|2|TREATMENT|2020-09-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-21|P1Y2M10DT2H30M|COINCIDENT|2020-10-19|ONGOING|2020-10-26
e|RS|c37df2f6-be8a-4709-b97d-061ab9754e0d|9|MRDIND|Minimal Residual Disease Indicator|PETIT BREAST CANCER 2001|||UNEQUIVOCAL|1|10^4 CFU/mL|LIGHT SCATTERING SPECTROSCOPY|Y||Y|SPOUSE|PATHOLOGIST|N|5|Visit_5|90|1|SCREENING|2020-10-20|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-10|P1Y2M10DT2H30M|UNKNOWN|2020-09-18|ONGOING|2020-10-12
e|RS|c37df2f6-be8a-4709-b97d-061ab9754e0d|10|NTNERESP|Non-Target Non-Enhancing Response|KUKER LYMPHOMA 2005|[?]|km/h|PD/RELAPSE AFTER HI|1|VIRTUAL PIXEL|ELECTROMYOGRAPHY||Y||INDEPENDENT ASSESSOR|ADJUDICATOR 3|NA|5|Visit_5|90|5|SCREENING|2020-10-20|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-10|P1Y2M10DT2H30M|UNKNOWN|2020-08-21|ONGOING|2020-09-20
e|RS|c0120c9e-c421-4a2e-a85b-170f2d1c0f3f|1|NEWLPROG|New Lesion Progression|PALUMBO MULTIPLE MYELOMA 2009|||MORPHOLOGIC CRi|1|L/h|MRI WITHOUT CONTRAST|Y||Y|HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|Y|1|Visit_1|10|2|TREATMENT|2020-05-13|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-07|P1Y2M10DT2H30M|UNKNOWN|2020-06-18|COINCIDENT|2020-06-21
e|RS|c0120c9e-c421-4a2e-a85b-170f2d1c0f3f|2|OVRLRESP|Overall Response|EASL BRUIX LIVER CANCER 2001|[?]|ug/cm2|NR|1|DPM|GIEMSA STAIN||||SIGNIFICANT OTHER|ADJUDICATOR|Y|1|Visit_1|10|6|FOLLOW-UP|2020-05-13|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-07|P1Y2M10DT2H30M|UNKNOWN|2020-06-10|COINCIDENT|2020-07-07
e|RS|c0120c9e-c421-4a2e-a85b-170f2d1c0f3f|3|TMRESP|Tumor Marker Response|BURCOMBE BREAST CANCER 2005|[?]|DRUM|QUANTIFIABLE MRD POSITIVITY|1|nmol BCE/mmol|NEURAMINIDASE INHIBITION ASSAY|Y|||SIGNIFICANT OTHER|DEVELOPMENTAL PSYCHOLOGIST|NA|2|Visit_2|25|3|WASHOUT|2020-05-28|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-22|P1Y2M10DT2H30M|COINCIDENT|2020-05-09|COINCIDENT|2020-05-30
e|RS|c0120c9e-c421-4a2e-a85b-170f2d1c0f3f|4|MJPTHIND|Major Pathological Response Indicator|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|V/sec|SMD|1|mL/animal/wk|AUDIOMETRY||||NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST|Y|2|Visit_2|25|4|TREATMENT|2020-05-28|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-22|P1Y2M10DT2H30M|BEFORE|2020-07-27|ONGOING|2020-08-01
e|RS|c0120c9e-c421-4a2e-a85b-170f2d1c0f3f|5|LIVRRESP|Liver Response|IWG CHESON MDS 2006|[?]|MBq|NON-iCR/NON-iUPD|1|sec|SLOAN LETTER EYE CHART 1.25%||||PROXY|PATHOLOGIST 1|N|3|Visit_3|40|3|TREATMENT|2020-06-12|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-07|P1Y2M10DT2H30M|UNKNOWN|2020-05-18|ONGOING|2020-08-03
e|RS|c0120c9e-c421-4a2e-a85b-170f2d1c0f3f|6|NTRGRESP|Non-target Response|SACT|[?]|% INHIBITION|iPR|1|U/10^12 RBC|U-HPLC/MS/MS|Y|||PROXY|HEMATOLOGIST|N|3|Visit_3|40|6|TREATMENT|2020-06-12|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-07|P1Y2M10DT2H30M|AFTER|2020-07-08|COINCIDENT|2020-07-28
e|RS|c0120c9e-c421-4a2e-a85b-170f2d1c0f3f|7|RDIORESP|Radiologic Response|CHESON CLL 2006|||CRi|1|MBq|EIA|||Y|CHILD|RADIOLOGIST 1|NA|4|Visit_4|65|7|TREATMENT|2020-07-07|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-24|P1Y2M10DT2H30M|AFTER|2020-05-30|ONGOING|2020-07-13
e|RS|c0120c9e-c421-4a2e-a85b-170f2d1c0f3f|8|NTLWIND|Non-Target Lesion Worsening Indicator|RECICL|[?]|ELISA unit/mL|iUPD|1|ug/cm2|NEURAMINIDASE INHIBITION ASSAY||||INVESTIGATOR|NEUROLOGIST 2|Y|4|Visit_4|65|2|TREATMENT|2020-07-07|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-24|P1Y2M10DT2H30M|BEFORE|2020-07-22|AFTER|2020-07-27
e|RS|c0120c9e-c421-4a2e-a85b-170f2d1c0f3f|9|STRUSTAT|Steroid Use Status|AJCC V8|[?]|mEq/dL|INCREASED|1|ng/mol|RAJI CELL RIA|Y|||SIGNIFICANT OTHER|RADIOLOGIST 2|Y|5|Visit_5|90|3|FOLLOW-UP|2020-08-01|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-18|P1Y2M10DT2H30M|BEFORE|2020-07-09|AFTER|2020-08-09
e|RS|c0120c9e-c421-4a2e-a85b-170f2d1c0f3f|10|METBRESP|Metabolic Response|PCWG SCHER PROSTATE CANCER 2016|||SD-CT|1|anti-Xa IU|IRON HEMATOXYLIN STAIN|||Y|ADJUDICATION COMMITTEE|ONCOLOGIST 2|U|5|Visit_5|90|6|TREATMENT|2020-08-01|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-18|P1Y2M10DT2H30M|COINCIDENT|2020-05-06|ONGOING|2020-05-15
e|RS|cec9e0ce-4d09-470c-9c26-df661d316a69|1|NTLWIND|Non-Target Lesion Worsening Indicator|CHOLLET BREAST CANCER 2002|[?]|Ci/mg|CR|1|L/min|SLOAN LETTER EYE CHART 2.5%||||DOMESTIC PARTNER|READER 1|N|1|Visit_1|10|7|TREATMENT|2021-01-05|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-23|P1Y2M10DT2H30M|UNKNOWN|2021-03-10|BEFORE|2021-03-12
e|RS|cec9e0ce-4d09-470c-9c26-df661d316a69|2|MJPTHIND|Major Pathological Response Indicator|CHOLLET BREAST CANCER 2002|[?]|/10^4|CMR|1|HOURS|HIGH LEVEL AMINOGLYCOSIDE SCREEN||||GUARDIAN|CARDIOLOGIST|U|1|Visit_1|10|3|FOLLOW-UP|2021-01-05|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-23|P1Y2M10DT2H30M|UNKNOWN|2021-03-24|AFTER|2021-03-29
e|RS|cec9e0ce-4d09-470c-9c26-df661d316a69|3|BESTRESP|Best Overall Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|PHERESIS UNIT|NE|1|scm|OBSERVATION||Y||SPOUSE|ADJUDICATOR 3|Y|2|Visit_2|25|7|FOLLOW-UP|2021-01-20|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-04|P1Y2M10DT2H30M|BEFORE|2021-02-04|COINCIDENT|2021-03-15
e|RS|cec9e0ce-4d09-470c-9c26-df661d316a69|4|HEMARESP|Hematologic Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|10^3 RNA copies/mL|HI-E|1|mL/m2/h|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION||Y||CLINICAL RESEARCH ASSOCIATE|FORENSIC PATHOLOGIST|NA|2|Visit_2|25|6|FOLLOW-UP|2021-01-20|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-04|P1Y2M10DT2H30M|BEFORE|2021-02-08|BEFORE|2021-02-10
e|RS|cec9e0ce-4d09-470c-9c26-df661d316a69|5|STRUSTAT|Steroid Use Status|TSUKASAKI LEUKEMIA LYMPHOMA 2009|||NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|10^3/hpf|CHROMATOGRAPHY|Y|Y|Y|CAREGIVER|ADJUDICATOR|N|3|Visit_3|40|1|SCREENING|2021-02-04|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-07|P1Y2M10DT2H30M|BEFORE|2021-03-24|AFTER|2021-04-02
e|RS|cec9e0ce-4d09-470c-9c26-df661d316a69|6|NTERESP|Non-Target Enhancing Response|CHOI GIST 2008|[?]|DNA copies/mL|PMD|1|Gauss|CONTRAST ENHANCED CT SCAN||Y||VENDOR|CLINICAL PATHOLOGIST|N|3|Visit_3|40|2|TREATMENT|2021-02-04|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-07|P1Y2M10DT2H30M|BEFORE|2021-03-27|COINCIDENT|2021-04-02
e|RS|cec9e0ce-4d09-470c-9c26-df661d316a69|7|LIVRRESP|Liver Response|RECICL|[?]|mg|PR WITH LYMPHOCYTOSIS|1|10^6 DNA copies/mL|FLUOROSCOPY|Y|||PROXY|PATHOLOGIST 2|U|4|Visit_4|65|7|TREATMENT|2021-03-01|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-18|P1Y2M10DT2H30M|UNKNOWN|2021-01-14|BEFORE|2021-02-07
e|RS|cec9e0ce-4d09-470c-9c26-df661d316a69|8|RDIORESP|Radiologic Response|MASS|[?]|log EID 50/dose|iCPD|1|10^9/L|TEMPLATE INCISION METHOD||||STUDY SUBJECT|NEUROLOGIST 2|Y|4|Visit_4|65|7|TREATMENT|2021-03-01|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-18|P1Y2M10DT2H30M|BEFORE|2021-03-17|BEFORE|2021-03-24
e|RS|cec9e0ce-4d09-470c-9c26-df661d316a69|9|OVRLRESP|Overall Response|BLAZER COLORECTAL CANCER 2008|||MOLECULAR MAJOR RESPONSE|1|pmol|NON-CONTACT SPECULAR MICROSCOPY||Y|Y|INDEPENDENT ASSESSOR|OTOLARYNGOLOGIST|N|5|Visit_5|90|1|WASHOUT|2021-03-26|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-15|P1Y2M10DT2H30M|UNKNOWN|2021-03-08|COINCIDENT|2021-03-31
e|RS|cec9e0ce-4d09-470c-9c26-df661d316a69|10|RDIORESP|Radiologic Response|UNSPECIFIED|||NOT ALL EVALUATED|1|APS U|HIGH RESOLUTION MELT ANALYSIS|Y||Y|STUDY SUBJECT|ONCOLOGIST 2|U|5|Visit_5|90|2|SCREENING|2021-03-26|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-15|P1Y2M10DT2H30M|BEFORE|2021-01-23|AFTER|2021-02-03
e|RS|b98b4e19-51ac-40cc-80d5-cb6d8000c112|1|SFTSRESP|Soft Tissue Response|JACINTO CERVICAL CANCER 2007|||HI-N|1|10^4 CFU|FLAME PHOTOMETRY|||Y|SPOUSE|OTOLARYNGOLOGIST|N|1|Visit_1|10|6|WASHOUT|2021-01-17|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-07|P1Y2M10DT2H30M|BEFORE|2021-03-23|ONGOING|2021-04-11
e|RS|b98b4e19-51ac-40cc-80d5-cb6d8000c112|2|HEMARESP|Hematologic Response|CHOLLET BREAST CANCER 2002|[?]|nmol/L/h|PSA PROGRESSION|1|1/(s*kPa)|TRICHROME STAIN||Y||ADJUDICATOR|RADIOLOGIST|NA|1|Visit_1|10|7|TREATMENT|2021-01-17|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-07|P1Y2M10DT2H30M|BEFORE|2021-03-25|AFTER|2021-04-14
e|RS|b98b4e19-51ac-40cc-80d5-cb6d8000c112|3|HEMARESP|Hematologic Response|KUMAR IMWG 2016|[?]|g/animal|NON-CR/NON-PD|1|ug/L FEU|FUNDUS PHOTOGRAPHY||Y||SIBLING|OPTOMETRIST|Y|2|Visit_2|25|7|SCREENING|2021-02-01|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-14|P1Y2M10DT2H30M|COINCIDENT|2021-02-04|AFTER|2021-03-09
e|RS|b98b4e19-51ac-40cc-80d5-cb6d8000c112|4|TMRESP|Tumor Marker Response|PALUMBO MULTIPLE MYELOMA 2009|||DECREASED|1|10^3 RNA copies/mL|FLUORESCENT MICROSCOPY||Y|Y|CAREGIVER|ENDOCRINOLOGIST|NA|2|Visit_2|25|7|WASHOUT|2021-02-01|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-14|P1Y2M10DT2H30M|COINCIDENT|2021-01-29|BEFORE|2021-04-07
e|RS|b98b4e19-51ac-40cc-80d5-cb6d8000c112|5|CLINRESP|Clinical Response|PERCIST|||PD-CT|1|AMPULE|INTRAVASCULAR ULTRASOUND|Y||Y|FRIEND|NEUROLOGIST 2|NA|3|Visit_3|40|3|TREATMENT|2021-02-16|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-22|P1Y2M10DT2H30M|AFTER|2021-01-11|ONGOING|2021-04-02
e|RS|b98b4e19-51ac-40cc-80d5-cb6d8000c112|6|BESTRESP|Best Overall Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|||iCPD|1|CCID 50/mL|NEURAMINIDASE INHIBITION ASSAY||Y|Y|INVESTIGATOR|RADIOLOGIST 2|N|3|Visit_3|40|4|WASHOUT|2021-02-16|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-22|P1Y2M10DT2H30M|AFTER|2021-04-12|BEFORE|2021-04-16
e|RS|b98b4e19-51ac-40cc-80d5-cb6d8000c112|7|BESTRESP|Best Overall Response|AJCC V7|[?]|mol/mg|CR-CT|1|10^3 copies/mL|LIGHT MICROSCOPY||||ADJUDICATOR|READER 3|NA|4|Visit_4|65|2|TREATMENT|2021-03-13|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-31|P1Y2M10DT2H30M|COINCIDENT|2021-03-31|AFTER|2021-04-15
e|RS|b98b4e19-51ac-40cc-80d5-cb6d8000c112|8|RDIORESP|Radiologic Response|EBMT BLADE MYELOMA 1998|[?]|mL/cm H2O|RELAPSED DISEASE FROM CR OR PR|1|cg|SPECT/CT SCAN||||INTERVIEWER|RADIOLOGIST|U|4|Visit_4|65|4|TREATMENT|2021-03-13|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-31|P1Y2M10DT2H30M|COINCIDENT|2021-01-23|COINCIDENT|2021-04-01
e|RS|b98b4e19-51ac-40cc-80d5-cb6d8000c112|9|RDIORESP|Radiologic Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|/cmH2O|CMR|1|pL|BALLPOINT PEN TECHNIQUE||Y||ADJUDICATOR|PEDIATRIC NEUROLOGIST|Y|5|Visit_5|90|6|WASHOUT|2021-04-07|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-19|P1Y2M10DT2H30M|UNKNOWN|2021-03-02|COINCIDENT|2021-04-02
e|RS|b98b4e19-51ac-40cc-80d5-cb6d8000c112|10|BMIVLIND|Bone Marrow Involvement Indicator|GUILHOT CML 2007|[?]|kUSP|NON-PD|1|/MBP|ISHIHARA COLOR PLATES||||CLINICAL RESEARCH ASSOCIATE|PHYSIOTHERAPIST|N|5|Visit_5|90|2|FOLLOW-UP|2021-04-07|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-19|P1Y2M10DT2H30M|BEFORE|2021-01-10|BEFORE|2021-02-25
e|RS|525e8b0c-b2cf-46b0-a1e1-9f5368ba97df|1|NTRGRESP|Non-target Response|PRINCE TCELL LYMPHOMA 2010|||QUANTIFIABLE MRD POSITIVITY|1|ag|IMMUNOASSAY|||Y|INVESTIGATOR|MICROSCOPIST 3|Y|1|Visit_1|10|7|TREATMENT|2020-07-07|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-05|P1Y2M10DT2H30M|AFTER|2020-08-21|COINCIDENT|2020-09-24
e|RS|525e8b0c-b2cf-46b0-a1e1-9f5368ba97df|2|RDIORESP|Radiologic Response|BRUGGEMANN MRD 2010|[?]|ug/mL/h|MR|1|10^4 CFU|ENZYMATIC COLORIMETRY||Y||CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 1|N|1|Visit_1|10|6|TREATMENT|2020-07-07|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-05|P1Y2M10DT2H30M|AFTER|2020-07-19|COINCIDENT|2020-09-04
e|RS|525e8b0c-b2cf-46b0-a1e1-9f5368ba97df|3|MRPHRESP|Morphologic Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|mg/dose|UNEQUIVOCAL|1|L/s/kPa|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY|Y|||HEALTH CARE PROFESSIONAL|RATER 1|Y|2|Visit_2|25|7|WASHOUT|2020-07-22|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-04|P1Y2M10DT2H30M|AFTER|2020-09-29|ONGOING|2020-10-01
e|RS|525e8b0c-b2cf-46b0-a1e1-9f5368ba97df|4|BMIVLIND|Bone Marrow Involvement Indicator|MASS|[?]|mEq/mL|NR|1|ukat/L|LINE PROBE ASSAY||||NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|NA|2|Visit_2|25|5|WASHOUT|2020-07-22|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-04|P1Y2M10DT2H30M|COINCIDENT|2020-08-21|AFTER|2020-09-05
e|RS|525e8b0c-b2cf-46b0-a1e1-9f5368ba97df|5|SFTSRESP|Soft Tissue Response|MACDONALD GLIOMA 1990|[?]|ppb|PR-CT|1|BU|FLUORESCEIN STAIN|Y|Y||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 3|N|3|Visit_3|40|3|WASHOUT|2020-08-06|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-09|P1Y2M10DT2H30M|UNKNOWN|2020-07-24|ONGOING|2020-09-04
e|RS|525e8b0c-b2cf-46b0-a1e1-9f5368ba97df|6|MJPTHIND|Major Pathological Response Indicator|IWC HALLEK CLL 2008|[?]|mEq/kg|CA125 75% RESPONSE|1|mg/kg/dose|X-RAY FLUORESCENCE SPECTROMETRY||||NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|3|Visit_3|40|4|WASHOUT|2020-08-06|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-09|P1Y2M10DT2H30M|BEFORE|2020-09-01|BEFORE|2020-09-13
e|RS|525e8b0c-b2cf-46b0-a1e1-9f5368ba97df|7|LIVRRESP|Liver Response|WHO BREAST CANCER 2006|||CA125 75% RESPONSE|1|TRANSDUCING UNIT|LANDOLT RING|Y|Y|Y|STUDY SUBJECT|OPTOMETRIST|NA|4|Visit_4|65|2|FOLLOW-UP|2020-08-31|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-02|P1Y2M10DT2H30M|AFTER|2020-07-07|AFTER|2020-09-05
e|RS|525e8b0c-b2cf-46b0-a1e1-9f5368ba97df|8|MRPHRESP|Morphologic Response|AJCC V7|[?]|mgEq|IMMUNOPHENOTYPIC CR|1|10^6/L|ULTRASONOGRAPHIC ELASTOGRAPHY||Y||NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST|NA|4|Visit_4|65|4|TREATMENT|2020-08-31|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-02|P1Y2M10DT2H30M|UNKNOWN|2020-08-08|ONGOING|2020-09-28
e|RS|525e8b0c-b2cf-46b0-a1e1-9f5368ba97df|9|PATHRESP|Pathologic Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|POINT|PMD|1|Bq/mg|DYNAMIC CONTRAST ENHANCED MRI|Y|||GUARDIAN|ONCOLOGIST 2|N|5|Visit_5|90|5|TREATMENT|2020-09-25|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-25|P1Y2M10DT2H30M|AFTER|2020-07-26|ONGOING|2020-08-07
e|RS|525e8b0c-b2cf-46b0-a1e1-9f5368ba97df|10|BONERESP|Bone Response|HAMAOKA BREAST CANCER 2010|||CHR|1|mL/mmHg/min/L|SXA SCAN|Y|Y|Y|HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|Y|5|Visit_5|90|3|TREATMENT|2020-09-25|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-25|P1Y2M10DT2H30M|BEFORE|2020-07-11|ONGOING|2020-08-30
e|RS|4bc30b18-c8d8-41a3-91d5-33b8b064087b|1|SYMPTDTR|Symptomatic Deterioration|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|titer|TREATMENT FAILURE|1|10^7 CFU|CONTRAST ENHANCED MRI||||DOMESTIC PARTNER|PATHOLOGIST 1|NA|1|Visit_1|10|7|TREATMENT|2020-07-12|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-21|P1Y2M10DT2H30M|AFTER|2020-08-31|AFTER|2020-09-23
e|RS|4bc30b18-c8d8-41a3-91d5-33b8b064087b|2|MRDRESP|Minimal Residual Disease Response|GUILHOT CML 2007|[?]|FINGERTIP UNIT|VGPR|1|EID 50/mL|ANGIOGRAPHY||||SIBLING|RADIOLOGIST|N|1|Visit_1|10|3|SCREENING|2020-07-12|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-21|P1Y2M10DT2H30M|AFTER|2020-09-17|ONGOING|2020-10-05
e|RS|4bc30b18-c8d8-41a3-91d5-33b8b064087b|3|NEWLWIND|New Lesion Worsening Indicator|MASS|[?]|10^9 CFU/mL|NED|1|mL/beat|WHOLE TRANSCRIPTOME SEQUENCING|Y|Y||CLINICAL RESEARCH COORDINATOR|HEMATOLOGIST|N|2|Visit_2|25|6|TREATMENT|2020-07-27|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-10|P1Y2M10DT2H30M|BEFORE|2020-09-10|COINCIDENT|2020-09-11
e|RS|4bc30b18-c8d8-41a3-91d5-33b8b064087b|4|HEMARESP|Hematologic Response|iRECIST|[?]|EID 50/dose|CRi|1|/mm|TARGETED GENOME SEQUENCING||||CLINICAL RESEARCH ASSOCIATE|READER 1|NA|2|Visit_2|25|6|TREATMENT|2020-07-27|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-10|P1Y2M10DT2H30M|UNKNOWN|2020-07-26|COINCIDENT|2020-08-19
e|RS|4bc30b18-c8d8-41a3-91d5-33b8b064087b|5|SPLNRESP|Spleen Response|CHOLLET BREAST CANCER 2002|[?]|/mm|NR|1|ug/h|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY||||STUDY SUBJECT|ENDOCRINOLOGIST|U|3|Visit_3|40|3|FOLLOW-UP|2020-08-11|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-22|P1Y2M10DT2H30M|UNKNOWN|2020-07-23|BEFORE|2020-08-18
e|RS|4bc30b18-c8d8-41a3-91d5-33b8b064087b|6|METBRESP|Metabolic Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|Gravitational Unit|CYTOGENETIC NO RESPONSE|1|genEq|NUCLEAR RADIOLOGY||||FAMILY MEMBER|ONCOLOGIST|NA|3|Visit_3|40|5|FOLLOW-UP|2020-08-11|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-22|P1Y2M10DT2H30M|BEFORE|2020-07-13|BEFORE|2020-08-22
e|RS|4bc30b18-c8d8-41a3-91d5-33b8b064087b|7|MJPTHIND|Major Pathological Response Indicator|CHESON CLL 2006|||SMD|1|10^3 RNA copies/mL|TRANSMISSION ELECTRON MICROSCOPY|||Y|DOMESTIC PARTNER|RADIOLOGIST 2|U|4|Visit_4|65|1|TREATMENT|2020-09-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-23|P1Y2M10DT2H30M|BEFORE|2020-07-07|COINCIDENT|2020-08-21
e|RS|4bc30b18-c8d8-41a3-91d5-33b8b064087b|8|CLINRESP|Clinical Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|mg/h|HI-P|1|IMPLANT|COULOMETRIC TITRATION||||PROXY|DEVELOPMENTAL PSYCHOLOGIST|U|4|Visit_4|65|5|TREATMENT|2020-09-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-23|P1Y2M10DT2H30M|COINCIDENT|2020-08-13|COINCIDENT|2020-08-23
e|RS|4bc30b18-c8d8-41a3-91d5-33b8b064087b|9|LIVRRESP|Liver Response|IRANO 2015|[?]|in2|HI-N|1|U/g/min|LIGHT SCATTERING SPECTROSCOPY||Y||INDEPENDENT ASSESSOR|ADJUDICATOR 1|NA|5|Visit_5|90|1|SCREENING|2020-09-30|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-27|P1Y2M10DT2H30M|COINCIDENT|2020-10-07|BEFORE|2020-10-09
e|RS|4bc30b18-c8d8-41a3-91d5-33b8b064087b|10|DRCRIND|Disease Recurrence Indicator|GCIG RUSTIN OVARIAN CANCER 2011|[?]|Enzyme U/g Hb|PARTIAL MORPHOLOGIC RESPONSE|1|mg/m2/day|GC/MS-EI||||STUDY SUBJECT|RATER 2|NA|5|Visit_5|90|2|WASHOUT|2020-09-30|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-27|P1Y2M10DT2H30M|BEFORE|2020-10-01|AFTER|2020-10-08
e|RS|7ff27a70-0472-4cc1-b057-6b161ab29568|1|SYMPTDTR|Symptomatic Deterioration|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|ft|NON-PD|1|ng/mol|IMMUNOTURBIDIMETRY||||STUDY SUBJECT|NEUROLOGIST|U|1|Visit_1|10|3|TREATMENT|2020-11-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-01|P1Y2M10DT2H30M|AFTER|2021-01-04|AFTER|2021-01-29
e|RS|7ff27a70-0472-4cc1-b057-6b161ab29568|2|METBRESP|Metabolic Response|EBMT BLADE MYELOMA 1998|[?]|kg/m2|ABSENT MORPHOLOGIC RESPONSE|1|log10 TCID 50/dose|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY||||HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|N|1|Visit_1|10|1|TREATMENT|2020-11-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-01|P1Y2M10DT2H30M|COINCIDENT|2021-01-28|AFTER|2021-02-02
e|RS|7ff27a70-0472-4cc1-b057-6b161ab29568|3|SPLNRESP|Spleen Response|RANO ELLINGSON 2017|[?]|10^9 CFU/mL|iSD|1|PIPE|MULTIPLEXED BEAD BASED IMMUNOASSAY|Y|Y||CAREGIVER|OPTOMETRIST|U|2|Visit_2|25|6|SCREENING|2020-12-04|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-04|P1Y2M10DT2H30M|COINCIDENT|2021-02-14|BEFORE|2021-02-16
e|RS|7ff27a70-0472-4cc1-b057-6b161ab29568|4|HEMARESP|Hematologic Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|HOURS|HI-P|1|mol/mg|JAEGER EYE CHART||||INDEPENDENT ASSESSOR|OTOLARYNGOLOGIST|U|2|Visit_2|25|5|TREATMENT|2020-12-04|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-04|P1Y2M10DT2H30M|AFTER|2020-12-07|COINCIDENT|2020-12-23
e|RS|7ff27a70-0472-4cc1-b057-6b161ab29568|5|MNPTHIND|Minor Pathological Response Indicator|GUPPY OVARIAN CANCER 2002|[?]|10^12 IU/L|MRD NEGATIVITY|1|lm|ANGIOGRAPHY||||CLINICAL STUDY SPONSOR|RADIOLOGIST 2|N|3|Visit_3|40|4|TREATMENT|2020-12-19|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-04|P1Y2M10DT2H30M|AFTER|2020-11-19|COINCIDENT|2020-11-20
e|RS|7ff27a70-0472-4cc1-b057-6b161ab29568|6|BONERESP|Bone Response|KEAM BREAST CANCER 2013|[?]|mL/breath|iCPD|1|fg|MECHANICAL CLOT DETECTION||Y||ADJUDICATOR|MICROSCOPIST 3|U|3|Visit_3|40|7|TREATMENT|2020-12-19|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-04|P1Y2M10DT2H30M|COINCIDENT|2020-12-11|BEFORE|2021-01-11
e|RS|7ff27a70-0472-4cc1-b057-6b161ab29568|7|TMRESP|Tumor Marker Response|EBMT BLADE MYELOMA 1998|[?]|kPa|STABLE|1|10^9 CFU/mL|DYNAMIC LIGHT SCATTERING||||SPOUSE|MICROSCOPIST 3|U|4|Visit_4|65|2|SCREENING|2021-01-13|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-22|P1Y2M10DT2H30M|COINCIDENT|2021-01-29|COINCIDENT|2021-02-02
e|RS|7ff27a70-0472-4cc1-b057-6b161ab29568|8|LIVRRESP|Liver Response|KUKER LYMPHOMA 2005|[?]|mL/s/m2|NED|1|tsp eq|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|Y|||FRIEND|PATHOLOGIST 1|Y|4|Visit_4|65|7|TREATMENT|2021-01-13|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-22|P1Y2M10DT2H30M|BEFORE|2020-12-15|AFTER|2021-01-15
e|RS|7ff27a70-0472-4cc1-b057-6b161ab29568|9|METSIND|Metastatic Indicator|CHESON LYMPHOMA 2008|||MRD RELAPSE|1|/h|MEDIASTINOSCOPY|Y||Y|INDEPENDENT ASSESSOR|MICROSCOPIST 1|U|5|Visit_5|90|7|FOLLOW-UP|2021-02-07|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-25|P1Y2M10DT2H30M|BEFORE|2020-12-17|ONGOING|2020-12-29
e|RS|7ff27a70-0472-4cc1-b057-6b161ab29568|10|MOLRESP|Molecular Response|PCWG SCHER PROSTATE CANCER 2008|[?]|PACKET|MRD NEGATIVITY|1|psec|WHOLE GENOME SEQUENCING|Y|||STUDY SUBJECT|CLINICAL PATHOLOGIST|NA|5|Visit_5|90|2|TREATMENT|2021-02-07|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-25|P1Y2M10DT2H30M|UNKNOWN|2020-11-14|BEFORE|2021-02-11
e|RS|40529b01-9a80-4ada-a8df-96eec0e65043|1|SPLNRESP|Spleen Response|IWG CHESON AML 2003|||PMD|1|ug/L DDU|SLOAN LETTER EYE CHART 1.25%|Y||Y|INDEPENDENT ASSESSOR|OTOLARYNGOLOGIST|NA|1|Visit_1|10|1|TREATMENT|2020-06-17|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-14|P1Y2M10DT2H30M|AFTER|2020-08-13|COINCIDENT|2020-08-27
e|RS|40529b01-9a80-4ada-a8df-96eec0e65043|2|NEWLWIND|New Lesion Worsening Indicator|IWC HALLEK CLL 2008|[?]|APS U|CYTOGENETIC MINIMAL RESPONSE|1|OD Unit|SISH||||CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 2|N|1|Visit_1|10|3|FOLLOW-UP|2020-06-17|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-14|P1Y2M10DT2H30M|AFTER|2020-07-02|AFTER|2020-08-11
e|RS|40529b01-9a80-4ada-a8df-96eec0e65043|3|BESTRESP|Best Overall Response|BLAZER COLORECTAL CANCER 2008|[?]|ug/kg/day|SD-CT|1|TAMPON|PHASE CONTRAST MICROSCOPY|Y|Y||ADJUDICATION COMMITTEE|UROLOGIST|Y|2|Visit_2|25|3|SCREENING|2020-07-02|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-14|P1Y2M10DT2H30M|UNKNOWN|2020-07-17|COINCIDENT|2020-07-26
e|RS|40529b01-9a80-4ada-a8df-96eec0e65043|4|NEWLIND|New Lesion Indicator|iRECIST|[?]|cP|iSD|1|tuberculin unit|FISH||Y||CLINICAL RESEARCH COORDINATOR|INTERNIST|N|2|Visit_2|25|2|FOLLOW-UP|2020-07-02|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-14|P1Y2M10DT2H30M|UNKNOWN|2020-07-14|ONGOING|2020-07-27
e|RS|40529b01-9a80-4ada-a8df-96eec0e65043|5|DRCRIND|Disease Recurrence Indicator|PCWG BUBLEY PROSTATE CANCER 1999|||UNEQUIVOCAL|1|mL/s/m2|MICROBIAL BIOCHEMICAL IDENTIFICATION|Y|Y|Y|INTERVIEWER|DERMATOLOGIST|N|3|Visit_3|40|6|SCREENING|2020-07-17|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-06|P1Y2M10DT2H30M|UNKNOWN|2020-07-03|AFTER|2020-08-31
e|RS|40529b01-9a80-4ada-a8df-96eec0e65043|6|MJPTHIND|Major Pathological Response Indicator|SHINDOH COLORECTAL CANCER 2013|[?]|ppb|NOT ALL EVALUATED|1|MBP|PERCUSSION|Y|||SPOUSE|DEVELOPMENTAL PSYCHOLOGIST|U|3|Visit_3|40|1|FOLLOW-UP|2020-07-17|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-06|P1Y2M10DT2H30M|AFTER|2020-08-10|COINCIDENT|2020-08-25
e|RS|40529b01-9a80-4ada-a8df-96eec0e65043|7|ANATRESP|Anatomic Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|||IMPROVED|1|10^4/L|ELLA|||Y|GUARDIAN|PATHOLOGIST|U|4|Visit_4|65|1|SCREENING|2020-08-11|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-05|P1Y2M10DT2H30M|COINCIDENT|2020-08-14|COINCIDENT|2020-08-30
e|RS|40529b01-9a80-4ada-a8df-96eec0e65043|8|SYMPTDTR|Symptomatic Deterioration|KEAM BREAST CANCER 2013|[?]|mm2|CR|1|mg/L FEU|MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING||Y||STUDY SUBJECT|MICROSCOPIST|NA|4|Visit_4|65|5|SCREENING|2020-08-11|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-05|P1Y2M10DT2H30M|UNKNOWN|2020-07-24|AFTER|2020-07-29
e|RS|40529b01-9a80-4ada-a8df-96eec0e65043|9|NTRGRESP|Non-target Response|BURCOMBE BREAST CANCER 2005|[?]|AFU|CYTOGENETIC CR|1|10^7 TCID 50/dose|ORCHIDOMETERY|Y|||VENDOR|MICROSCOPIST 2|U|5|Visit_5|90|3|SCREENING|2020-09-05|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-04|P1Y2M10DT2H30M|COINCIDENT|2020-06-17|AFTER|2020-08-28
e|RS|40529b01-9a80-4ada-a8df-96eec0e65043|10|MRPHRESP|Morphologic Response|PETIT BREAST CANCER 2001|[?]|kV|CRi|1|breaths/min|ENDOSCOPY|Y|||FAMILY MEMBER|READER 2|U|5|Visit_5|90|7|TREATMENT|2020-09-05|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-04|P1Y2M10DT2H30M|COINCIDENT|2020-06-15|AFTER|2020-06-28
e|RS|f3e22efc-0948-4c6e-9173-8e284d342d33|1|NTRGRESP|Non-target Response|BURCOMBE BREAST CANCER 2005|[?]|mEq|NR|1|CCID 50/dose|CONFOCAL MICROSCOPY|Y|||FAMILY MEMBER|INTERNIST|Y|1|Visit_1|10|6|TREATMENT|2020-12-06|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-13|P1Y2M10DT2H30M|BEFORE|2021-02-13|ONGOING|2021-02-24
e|RS|f3e22efc-0948-4c6e-9173-8e284d342d33|2|TMRESP|Tumor Marker Response|EASL BRUIX LIVER CANCER 2001|[?]|ug/L/h|FAVORABLE RESPONSE|1|100 IU/mL|CONTRAST ENHANCED X-RAY|Y|||CLINICAL RESEARCH ASSOCIATE|OPTOMETRIST|N|1|Visit_1|10|2|WASHOUT|2020-12-06|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-13|P1Y2M10DT2H30M|AFTER|2020-12-30|BEFORE|2021-02-01
e|RS|f3e22efc-0948-4c6e-9173-8e284d342d33|3|DRCRIND|Disease Recurrence Indicator|PCWG SCHER PROSTATE CANCER 2016|[?]|10^6 CFU/mL|CMR|1|OD Unit|NUCLEIC ACID HYBRIDIZATION||||NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|NA|2|Visit_2|25|5|WASHOUT|2020-12-21|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-19|P1Y2M10DT2H30M|COINCIDENT|2021-01-10|BEFORE|2021-02-08
e|RS|f3e22efc-0948-4c6e-9173-8e284d342d33|4|STRUSTAT|Steroid Use Status|GUPPY OVARIAN CANCER 2002|[?]|mg/m2|CA125 50% RESPONSE|1|SFC/10^6 PBMC|MICROBIAL CULTURE, LIQUID||||STUDY SUBJECT|CLINICAL PATHOLOGIST|NA|2|Visit_2|25|4|TREATMENT|2020-12-21|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-19|P1Y2M10DT2H30M|UNKNOWN|2021-02-05|BEFORE|2021-02-24
e|RS|f3e22efc-0948-4c6e-9173-8e284d342d33|5|METBRESP|Metabolic Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|Antibody Unit|NED|1|vg/kg|TARGETED TRANSCRIPTOME SEQUENCING||Y||STUDY SUBJECT|RATER|U|3|Visit_3|40|6|SCREENING|2021-01-05|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-08|P1Y2M10DT2H30M|BEFORE|2021-01-21|COINCIDENT|2021-02-08
e|RS|f3e22efc-0948-4c6e-9173-8e284d342d33|6|MNPTHIND|Minor Pathological Response Indicator|HARTMAN PANCREATIC CANCER 2012|||DECREASED|1|ng/dL|SINGLE-SLICE SPIRAL CT|Y||Y|INDEPENDENT ASSESSOR|MICROSCOPIST|NA|3|Visit_3|40|5|TREATMENT|2021-01-05|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-08|P1Y2M10DT2H30M|BEFORE|2021-01-03|COINCIDENT|2021-01-05
e|RS|f3e22efc-0948-4c6e-9173-8e284d342d33|7|STRUSTAT|Steroid Use Status|NCCN ALL MRD 2014|||NOT ALL EVALUATED|1|mol/mol|STATIC PERIMETRY|||Y|CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL PSYCHOLOGIST|Y|4|Visit_4|65|4|TREATMENT|2021-01-30|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-08|P1Y2M10DT2H30M|BEFORE|2020-12-20|COINCIDENT|2021-01-29
e|RS|f3e22efc-0948-4c6e-9173-8e284d342d33|8|SFTSRESP|Soft Tissue Response|IRANO 2015|||PSEUDORESPONSE|1|Siemens|HEMATOXYLIN AND EOSIN STAIN|||Y|PARENT|PHYSIOTHERAPIST|Y|4|Visit_4|65|2|FOLLOW-UP|2021-01-30|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-08|P1Y2M10DT2H30M|BEFORE|2021-02-21|BEFORE|2021-02-26
e|RS|f3e22efc-0948-4c6e-9173-8e284d342d33|9|NTERESP|Non-Target Enhancing Response|CHOLLET BREAST CANCER 2002|||HI-N|1|uV2|INDIA INK STAIN||Y|Y|ADJUDICATOR|PATHOLOGIST 1|U|5|Visit_5|90|2|FOLLOW-UP|2021-02-24|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-30|P1Y2M10DT2H30M|COINCIDENT|2021-02-07|COINCIDENT|2021-03-05
e|RS|f3e22efc-0948-4c6e-9173-8e284d342d33|10|SYMPTDTR|Symptomatic Deterioration|BRUGGEMANN MRD 2010|||MAJOR PATHOLOGIC RESPONSE|1|yd|REFLECTANCE SPECTROSCOPY||Y|Y|ADJUDICATOR|PATHOLOGIST 1|U|5|Visit_5|90|5|SCREENING|2021-02-24|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-30|P1Y2M10DT2H30M|COINCIDENT|2021-03-01|AFTER|2021-03-03
e|RS|919eb5b4-a3df-41c6-86f7-c78501bb4335|1|CYTORESP|Cytogenetic Response|IWG CHESON MDS 2006|[?]|oz|CYTOGENETIC MINIMAL RESPONSE|1|mL/kg|RADIOIMMUNOPRECIPITATION ASSAY|Y|Y||CLINICAL RESEARCH ASSOCIATE|READER|U|1|Visit_1|10|2|TREATMENT|2020-10-01|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-10|P1Y2M10DT2H30M|COINCIDENT|2020-11-22|ONGOING|2020-12-03
e|RS|919eb5b4-a3df-41c6-86f7-c78501bb4335|2|SYMPTDTR|Symptomatic Deterioration|CHESON LYMPHOMA 2008|[?]|ug/m2/day|VGPR|1|CFU/mL|CLAUSS METHOD||||CLINICAL RESEARCH ASSOCIATE|READER|NA|1|Visit_1|10|1|WASHOUT|2020-10-01|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-10|P1Y2M10DT2H30M|AFTER|2020-12-14|BEFORE|2020-12-19
e|RS|919eb5b4-a3df-41c6-86f7-c78501bb4335|3|MRPHRESP|Morphologic Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|mg/dL|CYTOGENETIC MINOR RESPONSE|1|nmol/L/min|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY||||PROXY|RADIOLOGIST|NA|2|Visit_2|25|7|TREATMENT|2020-10-16|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-02|P1Y2M10DT2H30M|AFTER|2020-09-24|ONGOING|2020-10-15
e|RS|919eb5b4-a3df-41c6-86f7-c78501bb4335|4|PATHRESP|Pathologic Response|CHESON LYMPHOMA 2008|[?]|IU/g|PARTIAL MORPHOLOGIC RESPONSE|1|um2|HPLC/MS/MS||||INVESTIGATOR|ONCOLOGIST 1|NA|2|Visit_2|25|4|WASHOUT|2020-10-16|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-02|P1Y2M10DT2H30M|AFTER|2020-12-04|ONGOING|2020-12-24
e|RS|919eb5b4-a3df-41c6-86f7-c78501bb4335|5|CPRFSTAT|Clinical Performance Status|SCHER PROSTATE CANCER 2011|[?]|10^6 CFU/g|PSA PROGRESSION|1|mAnson U/mL|ACID FAST STAIN|Y|Y||CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 1|Y|3|Visit_3|40|6|WASHOUT|2020-10-31|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-18|P1Y2M10DT2H30M|AFTER|2020-09-25|AFTER|2020-12-27
e|RS|919eb5b4-a3df-41c6-86f7-c78501bb4335|6|MRDRESP|Minimal Residual Disease Response|CHOLLET BREAST CANCER 2002|[?]|MET*min|EQUIVOCAL|1|Sv|LUXOL FAST BLUE AND CRESYL VIOLET STAIN||||HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|N|3|Visit_3|40|1|FOLLOW-UP|2020-10-31|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-18|P1Y2M10DT2H30M|COINCIDENT|2020-10-21|COINCIDENT|2020-11-06
e|RS|919eb5b4-a3df-41c6-86f7-c78501bb4335|7|TMRESP|Tumor Marker Response|CHOLLET BREAST CANCER 2002|[?]|CAN|SD|1|kDa|CLIP||Y||DOMESTIC PARTNER|NEUROLOGIST 2|Y|4|Visit_4|65|1|TREATMENT|2020-11-25|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-03|P1Y2M10DT2H30M|COINCIDENT|2020-12-14|COINCIDENT|2020-12-21
e|RS|919eb5b4-a3df-41c6-86f7-c78501bb4335|8|MNPTHIND|Minor Pathological Response Indicator|JACINTO CERVICAL CANCER 2007|[?]|dyn|sCR|1|titer|FLUORESCEIN STAIN|Y|Y||NON-HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|NA|4|Visit_4|65|4|TREATMENT|2020-11-25|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-03|P1Y2M10DT2H30M|COINCIDENT|2020-11-24|BEFORE|2020-12-02
e|RS|919eb5b4-a3df-41c6-86f7-c78501bb4335|9|BMIVLIND|Bone Marrow Involvement Indicator|SCHER PROSTATE CANCER 2011|||NON-PD|1|U/g/min|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION|||Y|ADJUDICATOR|ADJUDICATOR 3|N|5|Visit_5|90|5|WASHOUT|2020-12-20|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-19|P1Y2M10DT2H30M|UNKNOWN|2020-12-24|COINCIDENT|2020-12-26
e|RS|919eb5b4-a3df-41c6-86f7-c78501bb4335|10|RDIORESP|Radiologic Response|RECICL|||INCREASED|1|ELISA unit/dose|WHOLE EXOME SEQUENCING|||Y|ADJUDICATION COMMITTEE|OPTOMETRIST|Y|5|Visit_5|90|3|TREATMENT|2020-12-20|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-19|P1Y2M10DT2H30M|COINCIDENT|2020-12-01|BEFORE|2020-12-13
e|RS|f918d6e0-6fc2-4303-b323-521c5d531773|1|PATHRESP|Pathologic Response|MACDONALD GLIOMA 1990|||MRD RELAPSE|1|10^8/L|FLOW CYTOMETRY|Y||Y|ADJUDICATOR|ADJUDICATOR|NA|1|Visit_1|10|2|TREATMENT|2020-07-31|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-12|P1Y2M10DT2H30M|COINCIDENT|2020-08-11|ONGOING|2020-08-28
e|RS|f918d6e0-6fc2-4303-b323-521c5d531773|2|NEWLWIND|New Lesion Worsening Indicator|BLAZER COLORECTAL CANCER 2008|[?]|mL/kg/day|cCR|1|ug/kg|KARYOTYPING|Y|||INTERVIEWER|PATHOLOGIST 1|U|1|Visit_1|10|3|WASHOUT|2020-07-31|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-12|P1Y2M10DT2H30M|AFTER|2020-10-06|BEFORE|2020-10-25
e|RS|f918d6e0-6fc2-4303-b323-521c5d531773|3|CYTORESP|Cytogenetic Response|PCWG BUBLEY PROSTATE CANCER 1999|||MAJOR PATHOLOGIC RESPONSE|1|oz|NUCLEIC ACID SEQUENCING||Y|Y|INTERVIEWER|PATHOLOGIST 2|N|2|Visit_2|25|2|FOLLOW-UP|2020-08-15|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-26|P1Y2M10DT2H30M|COINCIDENT|2020-10-07|COINCIDENT|2020-10-12
e|RS|f918d6e0-6fc2-4303-b323-521c5d531773|4|LIVRRESP|Liver Response|BLAZER COLORECTAL CANCER 2008|[?]|JDF Unit|MRD NEGATIVITY|1|scm|RULER MEASUREMENT METHOD||||CLINICAL RESEARCH ASSOCIATE|PHYSIOTHERAPIST|U|2|Visit_2|25|2|SCREENING|2020-08-15|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-26|P1Y2M10DT2H30M|BEFORE|2020-10-15|COINCIDENT|2020-10-28
e|RS|f918d6e0-6fc2-4303-b323-521c5d531773|5|MJPTHIND|Major Pathological Response Indicator|PALUMBO MULTIPLE MYELOMA 2009|[?]|m/sec2|MORPHOLOGIC CRi|1|Torr|GRAM STAIN|Y|Y||FRIEND|HEMATOLOGIST|U|3|Visit_3|40|1|TREATMENT|2020-08-30|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-19|P1Y2M10DT2H30M|UNKNOWN|2020-08-26|COINCIDENT|2020-10-25
e|RS|f918d6e0-6fc2-4303-b323-521c5d531773|6|METSIND|Metastatic Indicator|NCCN ALL MRD 2014|[?]|mL/m2/day|pCR|1|pmol/L/h|GIEMSA STAIN|Y|||CLINICAL RESEARCH ASSOCIATE|HEMATOLOGIST|N|3|Visit_3|40|1|SCREENING|2020-08-30|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-19|P1Y2M10DT2H30M|UNKNOWN|2020-10-19|BEFORE|2020-10-27
e|RS|f918d6e0-6fc2-4303-b323-521c5d531773|7|ANATRESP|Anatomic Response|RANO|||HI-N|1|uOsm|CISH||Y|Y|CHILD|INTERNIST|U|4|Visit_4|65|3|WASHOUT|2020-09-24|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-31|P1Y2M10DT2H30M|COINCIDENT|2020-09-28|AFTER|2020-09-30
e|RS|f918d6e0-6fc2-4303-b323-521c5d531773|8|MRDIND|Minimal Residual Disease Indicator|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|mEq/L|PSEUDOPROGRESSION|1|Frames/s|MACRO BROTH DILUTION||Y||INVESTIGATOR|PEDIATRIC NEUROLOGIST|N|4|Visit_4|65|5|WASHOUT|2020-09-24|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-31|P1Y2M10DT2H30M|BEFORE|2020-10-17|COINCIDENT|2020-10-20
e|RS|f918d6e0-6fc2-4303-b323-521c5d531773|9|MNPTHIND|Minor Pathological Response Indicator|WOLCHOK SOLID TUMORS 2009|[?]|APL U/mL|PMR|1|MET|SPECULAR MICROSCOPY|Y|||DOMESTIC PARTNER|FORENSIC PATHOLOGIST|U|5|Visit_5|90|3|TREATMENT|2020-10-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-22|P1Y2M10DT2H30M|COINCIDENT|2020-08-23|COINCIDENT|2020-09-11
e|RS|f918d6e0-6fc2-4303-b323-521c5d531773|10|BONERESP|Bone Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|cg|NON-PD|1|mg/mL/min|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|Y|||CHILD|MICROSCOPIST|NA|5|Visit_5|90|6|TREATMENT|2020-10-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-22|P1Y2M10DT2H30M|BEFORE|2020-10-12|BEFORE|2020-10-22
e|RS|1d9bccfd-ab01-460f-b1b5-9d1859ee7f66|1|NEWLIND|New Lesion Indicator|BLAZER COLORECTAL CANCER 2008|[?]|dL|CMR|1|PIXELS/cm|CAPILLARY ELECTROPHORESIS||||INVESTIGATOR|PHYSIOTHERAPIST|N|1|Visit_1|10|2|TREATMENT|2020-11-24|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-16|P1Y2M10DT2H30M|AFTER|2021-01-27|AFTER|2021-02-19
e|RS|1d9bccfd-ab01-460f-b1b5-9d1859ee7f66|2|SYMPTDTR|Symptomatic Deterioration|LEE LUNG CANCER 2011|||pCR|1|g/U|RADIAL IMMUNODIFFUSION|Y||Y|FRIEND|RATER 2|N|1|Visit_1|10|3|FOLLOW-UP|2020-11-24|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-16|P1Y2M10DT2H30M|UNKNOWN|2021-01-28|COINCIDENT|2021-02-19
e|RS|1d9bccfd-ab01-460f-b1b5-9d1859ee7f66|3|NEWLWIND|New Lesion Worsening Indicator|PALUMBO MULTIPLE MYELOMA 2009|[?]|V/sec|CYTOGENETIC NO RESPONSE|1|BAR|AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT|Y|Y||CHILD|UROLOGIST|N|2|Visit_2|25|6|SCREENING|2020-12-09|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-26|P1Y2M10DT2H30M|AFTER|2021-01-30|ONGOING|2021-02-10
e|RS|1d9bccfd-ab01-460f-b1b5-9d1859ee7f66|4|BMIVLIND|Bone Marrow Involvement Indicator|CHOLLET BREAST CANCER 2002|||MORPHOLOGIC CRi|1|ug|ACCELERATOR MASS SPECTROMETRY|||Y|DOMESTIC PARTNER|MICROSCOPIST|U|2|Visit_2|25|4|SCREENING|2020-12-09|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-26|P1Y2M10DT2H30M|COINCIDENT|2021-01-22|ONGOING|2021-02-19
e|RS|1d9bccfd-ab01-460f-b1b5-9d1859ee7f66|5|SYMPTDTR|Symptomatic Deterioration|CHESON CLL 2012|[?]|mV*min|PSEUDOPROGRESSION|1|Osm|AUTOREFRACTION||Y||FRIEND|ADJUDICATOR 2|Y|3|Visit_3|40|7|FOLLOW-UP|2020-12-24|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-13|P1Y2M10DT2H30M|AFTER|2021-02-14|BEFORE|2021-02-19
e|RS|1d9bccfd-ab01-460f-b1b5-9d1859ee7f66|6|SFTSRESP|Soft Tissue Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|||NON-PD|1|m3|FLUORESCENT SPOT TEST|Y||Y|CLINICAL STUDY SPONSOR|CARDIOLOGIST|N|3|Visit_3|40|6|TREATMENT|2020-12-24|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-13|P1Y2M10DT2H30M|UNKNOWN|2020-12-02|COINCIDENT|2020-12-24
e|RS|1d9bccfd-ab01-460f-b1b5-9d1859ee7f66|7|CYTORESP|Cytogenetic Response|MACDONALD GLIOMA 1990|[?]|mL/dL|RELAPSED DISEASE|1|Bq|ELECTROGASTROGRAPHY||||FRIEND|PATHOLOGIST 1|NA|4|Visit_4|65|1|TREATMENT|2021-01-18|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-13|P1Y2M10DT2H30M|AFTER|2020-12-06|ONGOING|2021-01-01
e|RS|1d9bccfd-ab01-460f-b1b5-9d1859ee7f66|8|HEMARESP|Hematologic Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|ft2|IMPROVED|1|/month|CYSTOSCOPY||||PARENT|NEUROLOGIST 1|NA|4|Visit_4|65|5|WASHOUT|2021-01-18|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-13|P1Y2M10DT2H30M|AFTER|2021-02-18|BEFORE|2021-02-20
e|RS|1d9bccfd-ab01-460f-b1b5-9d1859ee7f66|9|MJPTHIND|Major Pathological Response Indicator|IWC HALLEK CLL 2008|[?]|pmol/10^10 cells|STABLE|1|ug/g/h|IMMUNOBLOT||||INTERVIEWER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|5|Visit_5|90|3|TREATMENT|2021-02-12|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-19|P1Y2M10DT2H30M|BEFORE|2020-12-02|AFTER|2021-01-03
e|RS|1d9bccfd-ab01-460f-b1b5-9d1859ee7f66|10|RDIORESP|Radiologic Response|NCCN ALL MRD 2014|[?]|ug/m2|OPTIMAL MORPHOLOGIC RESPONSE|1|log10 TCID 50/mL|GC/MS-CI||||PROXY|NEUROLOGIST 1|U|5|Visit_5|90|4|TREATMENT|2021-02-12|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-19|P1Y2M10DT2H30M|AFTER|2020-12-04|ONGOING|2021-01-24
e|RS|4b1e011f-a16d-4ff6-902d-451d5d13ee97|1|NTRGRESP|Non-target Response|HARTMANN GERM CELL CANCER 2002|[?]|WEEKS|iSD|1|Pack Year|COLORIMETRY||||INTERVIEWER|PATHOLOGIST|N|1|Visit_1|10|2|WASHOUT|2020-06-21|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-07|P1Y2M10DT2H30M|BEFORE|2020-09-16|BEFORE|2020-09-17
e|RS|4b1e011f-a16d-4ff6-902d-451d5d13ee97|2|ANATRESP|Anatomic Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|U/L|CA125 75% RESPONSE|1|cmH2O*s2/mL|BALLPOINT PEN TECHNIQUE|Y|||INDEPENDENT ASSESSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|1|Visit_1|10|3|TREATMENT|2020-06-21|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-07|P1Y2M10DT2H30M|BEFORE|2020-09-03|BEFORE|2020-09-15
e|RS|4b1e011f-a16d-4ff6-902d-451d5d13ee97|3|LIVRRESP|Liver Response|LEE LUNG CANCER 2011|[?]|mL/min/mmHg|HI-N|1|umol/dL|DROPLET DIGITAL PCR||Y||FAMILY MEMBER|RATER 2|N|2|Visit_2|25|4|FOLLOW-UP|2020-07-06|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-02|P1Y2M10DT2H30M|UNKNOWN|2020-07-23|AFTER|2020-08-27
e|RS|4b1e011f-a16d-4ff6-902d-451d5d13ee97|4|MNPTHIND|Minor Pathological Response Indicator|RECIST 1.1|[?]|Gy|PD|1|10^9 organisms/g|CISH||||FAMILY MEMBER|OPHTHALMOLOGIST|U|2|Visit_2|25|6|FOLLOW-UP|2020-07-06|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-02|P1Y2M10DT2H30M|UNKNOWN|2020-06-25|ONGOING|2020-09-18
e|RS|4b1e011f-a16d-4ff6-902d-451d5d13ee97|5|SPLNRESP|Spleen Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|mEq/mL|iCR|1|cL|FARNSWORTH-MUNSELL 100 HUE TEST||||FRIEND|MICROSCOPIST|N|3|Visit_3|40|2|FOLLOW-UP|2020-07-21|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-01|P1Y2M10DT2H30M|COINCIDENT|2020-09-04|BEFORE|2020-09-11
e|RS|4b1e011f-a16d-4ff6-902d-451d5d13ee97|6|NEWLWIND|New Lesion Worsening Indicator|iRECIST|[?]|BE/mL|PMD|1|mOsm|MECHANICAL CLOT DETECTION|Y|||NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|U|3|Visit_3|40|5|TREATMENT|2020-07-21|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-01|P1Y2M10DT2H30M|COINCIDENT|2020-08-09|ONGOING|2020-08-28
e|RS|4b1e011f-a16d-4ff6-902d-451d5d13ee97|7|DRCRIND|Disease Recurrence Indicator|JACINTO CERVICAL CANCER 2007|[?]|Ci/g|PSEUDORESPONSE|1|um2|MAMMOGRAPHY|Y|Y||CLINICAL STUDY SPONSOR|ADJUDICATOR 3|U|4|Visit_4|65|4|FOLLOW-UP|2020-08-15|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-21|P1Y2M10DT2H30M|COINCIDENT|2020-09-01|COINCIDENT|2020-09-03
e|RS|4b1e011f-a16d-4ff6-902d-451d5d13ee97|8|CPRFSTAT|Clinical Performance Status|SCHWARZ CERVICAL CANCER 2009|[?]|vp/dose|DISEASE TRANSFORMATION|1|DISK|WESTERGREN||Y||FRIEND|ONCOLOGIST 1|NA|4|Visit_4|65|2|TREATMENT|2020-08-15|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-21|P1Y2M10DT2H30M|BEFORE|2020-06-30|ONGOING|2020-08-18
e|RS|4b1e011f-a16d-4ff6-902d-451d5d13ee97|9|NEWLPROG|New Lesion Progression|IWG CHESON MDS 2000|[?]|ug/m2/h|iCPD|1|Frames/s|ELECTROCHEMILUMINESCENCE||||ADJUDICATION COMMITTEE|ENDOCRINOLOGIST|Y|5|Visit_5|90|2|TREATMENT|2020-09-09|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-07|P1Y2M10DT2H30M|UNKNOWN|2020-06-19|BEFORE|2020-09-10
e|RS|4b1e011f-a16d-4ff6-902d-451d5d13ee97|10|PATHRESP|Pathologic Response|KUMAR IMWG 2016|[?]|log10 TCID 50/uL|CMR|1|mph|PUPILLOMETRY||Y||SPOUSE|NEUROLOGIST 2|N|5|Visit_5|90|3|TREATMENT|2020-09-09|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-07|P1Y2M10DT2H30M|AFTER|2020-08-11|BEFORE|2020-08-27
e|RS|d6d26e31-eaa0-4d4b-9df3-3c3d6b38f571|1|MRDIND|Minimal Residual Disease Indicator|SCHWARZ CERVICAL CANCER 2009|[?]|cm/min|MORPHOLOGIC LEUKEMIA-FREE STATE|1|KIT|FLAME PHOTOMETRY||||DOMESTIC PARTNER|MICROSCOPIST|Y|1|Visit_1|10|7|TREATMENT|2020-07-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-29|P1Y2M10DT2H30M|UNKNOWN|2020-08-11|BEFORE|2020-09-28
e|RS|d6d26e31-eaa0-4d4b-9df3-3c3d6b38f571|2|MRDRESP|Minimal Residual Disease Response|CHOLLET BREAST CANCER 2002|[?]|10^6 CFU/mL|CA125 50% RESPONSE|1|pkat/L|IN VITRO GENE EXPRESSION ASSAY||Y||CAREGIVER|ENDOCRINOLOGIST|Y|1|Visit_1|10|1|TREATMENT|2020-07-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-29|P1Y2M10DT2H30M|AFTER|2020-09-21|BEFORE|2020-09-29
e|RS|d6d26e31-eaa0-4d4b-9df3-3c3d6b38f571|3|TRGRESP|Target Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|mg/L|UNFAVORABLE RESPONSE|1|mm/min|INTERRUPTER TECHNIQUE||||FRIEND|PATHOLOGIST 2|NA|2|Visit_2|25|2|FOLLOW-UP|2020-08-03|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-11|P1Y2M10DT2H30M|COINCIDENT|2020-09-10|ONGOING|2020-10-13
e|RS|d6d26e31-eaa0-4d4b-9df3-3c3d6b38f571|4|HEMARESP|Hematologic Response|SCHWARZ CERVICAL CANCER 2009|[?]|MAC50|NON-iCR/NON-iUPD|1|mg/dL|ACCELERATOR MASS SPECTROMETRY||||FAMILY MEMBER|RADIOLOGIST 1|Y|2|Visit_2|25|2|WASHOUT|2020-08-03|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-11|P1Y2M10DT2H30M|COINCIDENT|2020-07-13|AFTER|2020-08-19
e|RS|d6d26e31-eaa0-4d4b-9df3-3c3d6b38f571|5|METBRESP|Metabolic Response|EBMT BLADE MYELOMA 1998|[?]|amp|HI-E|1|/7.5 mL|STATIC PERIMETRY|Y|||INVESTIGATOR|PATHOLOGIST 1|N|3|Visit_3|40|4|TREATMENT|2020-08-18|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-01|P1Y2M10DT2H30M|BEFORE|2020-07-19|AFTER|2020-08-04
e|RS|d6d26e31-eaa0-4d4b-9df3-3c3d6b38f571|6|MOLRESP|Molecular Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|L/day|PMD|1|10^6 copies/mL|FISH||||CLINICAL RESEARCH COORDINATOR|DERMATOLOGIST|U|3|Visit_3|40|3|FOLLOW-UP|2020-08-18|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-01|P1Y2M10DT2H30M|COINCIDENT|2020-10-15|AFTER|2020-10-16
e|RS|d6d26e31-eaa0-4d4b-9df3-3c3d6b38f571|7|CPRFSTAT|Clinical Performance Status|PRINCE TCELL LYMPHOMA 2010|[?]|kcal|UNFAVORABLE RESPONSE|1|cmH2O*s2/mL|FLAME PHOTOMETRY||||SPOUSE|CLINICAL PATHOLOGIST|Y|4|Visit_4|65|7|SCREENING|2020-09-12|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-28|P1Y2M10DT2H30M|COINCIDENT|2020-08-26|COINCIDENT|2020-09-03
e|RS|d6d26e31-eaa0-4d4b-9df3-3c3d6b38f571|8|HEMARESP|Hematologic Response|PCWG SCHER PROSTATE CANCER 2008|||NE|1|ug/mol|JAEGER EYE CHART||Y|Y|CLINICAL STUDY SPONSOR|FORENSIC PATHOLOGIST|Y|4|Visit_4|65|7|TREATMENT|2020-09-12|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-28|P1Y2M10DT2H30M|BEFORE|2020-08-16|BEFORE|2020-08-29
e|RS|d6d26e31-eaa0-4d4b-9df3-3c3d6b38f571|9|CPRFSTAT|Clinical Performance Status|PCWG BUBLEY PROSTATE CANCER 1999|[?]|ng/mol|CRi|1|CUP|PALM METHOD||||FRIEND|ADJUDICATOR 1|N|5|Visit_5|90|3|FOLLOW-UP|2020-10-07|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-12|P1Y2M10DT2H30M|UNKNOWN|2020-08-27|COINCIDENT|2020-09-03
e|RS|d6d26e31-eaa0-4d4b-9df3-3c3d6b38f571|10|NTRGRESP|Non-target Response|AJCC V8|[?]|copies/uL|ABSENT MORPHOLOGIC RESPONSE|1|nmol/day|SNP ARRAY||||DOMESTIC PARTNER|RADIOLOGIST 1|NA|5|Visit_5|90|7|FOLLOW-UP|2020-10-07|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-12|P1Y2M10DT2H30M|AFTER|2020-08-18|ONGOING|2020-09-16
e|RS|b49e6f4b-862e-4ad5-8964-51c94d2a03ec|1|MOLRESP|Molecular Response|CHESON CLL 2006|[?]|U/kg|INDETERMINATE RESPONSE|1|ug/day|MODIFIED ACID FAST STAIN||Y||FAMILY MEMBER|PATHOLOGIST|U|1|Visit_1|10|7|TREATMENT|2020-11-27|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-25|P1Y2M10DT2H30M|AFTER|2020-12-10|BEFORE|2021-02-13
e|RS|b49e6f4b-862e-4ad5-8964-51c94d2a03ec|2|METSIND|Metastatic Indicator|CHOLLET BREAST CANCER 2002|||NON-iCR/NON-iUPD|1|nsec|TWO-COLOR MICROARRAY|||Y|VENDOR|RADIOLOGIST 1|Y|1|Visit_1|10|2|TREATMENT|2020-11-27|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-25|P1Y2M10DT2H30M|AFTER|2021-02-13|AFTER|2021-02-16
e|RS|b49e6f4b-862e-4ad5-8964-51c94d2a03ec|3|CYTORESP|Cytogenetic Response|IWG CHESON MDS 2006|[?]|uL/mL|MORPHOLOGIC CRi|1|10^7 PFU|MAGNETIC RESONANCE ELASTOGRAPHY||||CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|2|Visit_2|25|2|TREATMENT|2020-12-12|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-20|P1Y2M10DT2H30M|BEFORE|2021-01-30|BEFORE|2021-02-10
e|RS|b49e6f4b-862e-4ad5-8964-51c94d2a03ec|4|MNPTHIND|Minor Pathological Response Indicator|BRUGGEMANN MRD 2010|[?]|gtt|PD-CT|1|TAMPON|MICROBIAL CULTURE||Y||DOMESTIC PARTNER|DERMATOLOGIST|N|2|Visit_2|25|1|SCREENING|2020-12-12|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-20|P1Y2M10DT2H30M|AFTER|2021-01-24|AFTER|2021-02-12
e|RS|b49e6f4b-862e-4ad5-8964-51c94d2a03ec|5|NEWLWIND|New Lesion Worsening Indicator|GUILHOT CML 2007|[?]|tsp|MORPHOLOGIC LEUKEMIA-FREE STATE|1|TAMPON|NUCLEAR RADIOLOGY||||INTERVIEWER|RADIOLOGIST 1|NA|3|Visit_3|40|2|TREATMENT|2020-12-27|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-20|P1Y2M10DT2H30M|UNKNOWN|2020-11-30|AFTER|2021-02-07
e|RS|b49e6f4b-862e-4ad5-8964-51c94d2a03ec|6|CPRFSTAT|Clinical Performance Status|GCIG RUSTIN OVARIAN CANCER 2011|[?]|10^6/Ejaculate U|CR|1|mL/cage/day|POPULATION SEQUENCING|Y|Y||GUARDIAN|NEUROLOGIST 2|Y|3|Visit_3|40|4|SCREENING|2020-12-27|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-20|P1Y2M10DT2H30M|AFTER|2021-01-13|BEFORE|2021-02-10
e|RS|b49e6f4b-862e-4ad5-8964-51c94d2a03ec|7|MRPHRESP|Morphologic Response|SCHER PROSTATE CANCER 2011|[?]|Ci|CMR|1|Bq/mg|ORCHIDOMETERY||Y||HEALTH CARE PROFESSIONAL|ADJUDICATOR 1|Y|4|Visit_4|65|2|TREATMENT|2021-01-21|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-08|P1Y2M10DT2H30M|AFTER|2021-02-17|ONGOING|2021-02-19
e|RS|b49e6f4b-862e-4ad5-8964-51c94d2a03ec|8|METSIND|Metastatic Indicator|BURCOMBE BREAST CANCER 2005|[?]|v/v|IMPROVED|1|Joule|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY||||FAMILY MEMBER|PHYSIOTHERAPIST|N|4|Visit_4|65|4|SCREENING|2021-01-21|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-08|P1Y2M10DT2H30M|COINCIDENT|2021-02-10|AFTER|2021-02-13
e|RS|b49e6f4b-862e-4ad5-8964-51c94d2a03ec|9|CPRFSTAT|Clinical Performance Status|PCWG SCHER PROSTATE CANCER 2016|[?]|uOsm|iSD|1|msec|EPSILOMETER||||FAMILY MEMBER|OPHTHALMOLOGIST|Y|5|Visit_5|90|5|SCREENING|2021-02-15|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-10|P1Y2M10DT2H30M|BEFORE|2020-12-20|ONGOING|2021-01-05
e|RS|b49e6f4b-862e-4ad5-8964-51c94d2a03ec|10|TRGRESP|Target Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|nmol/mL/min|DECREASED|1|WAFER|FLUORESCENT LIFETIME IMAGING MICROSCOPY|Y|||CLINICAL RESEARCH ASSOCIATE|OTOLARYNGOLOGIST|N|5|Visit_5|90|7|SCREENING|2021-02-15|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-10|P1Y2M10DT2H30M|BEFORE|2021-01-13|ONGOING|2021-01-30
e|RS|5c7645b5-5b4c-4280-878b-f5bd0e4349a7|1|CLINRESP|Clinical Response|AJCC V8|[?]|cd*s/m2|EQUIVOCAL|1|log10 PFU|TRANSTHORACIC ECHOCARDIOGRAPHY||||CAREGIVER|CARDIOLOGIST|NA|1|Visit_1|10|4|TREATMENT|2020-12-09|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-06|P1Y2M10DT2H30M|UNKNOWN|2021-02-04|AFTER|2021-02-26
e|RS|5c7645b5-5b4c-4280-878b-f5bd0e4349a7|2|SFTSRESP|Soft Tissue Response|PERCIST|[?]|rpm|NON-CR/NON-PD|1|cmH2O*s/mL|IMMUNORADIOMETRIC ASSAY||||NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST|U|1|Visit_1|10|7|WASHOUT|2020-12-09|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-06|P1Y2M10DT2H30M|BEFORE|2021-01-27|AFTER|2021-02-14
e|RS|5c7645b5-5b4c-4280-878b-f5bd0e4349a7|3|SPLNRESP|Spleen Response|PRINCE TCELL LYMPHOMA 2010|[?]|mol|CYTOGENETIC MINIMAL RESPONSE|1|/100 HPFs|PLETHYSMOGRAPHY||Y||VENDOR|RATER|N|2|Visit_2|25|6|FOLLOW-UP|2020-12-24|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-20|P1Y2M10DT2H30M|BEFORE|2021-02-25|ONGOING|2021-02-28
e|RS|5c7645b5-5b4c-4280-878b-f5bd0e4349a7|4|SPLNRESP|Spleen Response|AJCC V7|[?]|MdFI|PR WITH LYMPHOCYTOSIS|1|LENS|NUCLEIC ACID HYBRIDIZATION||||NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|NA|2|Visit_2|25|5|TREATMENT|2020-12-24|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-20|P1Y2M10DT2H30M|COINCIDENT|2021-01-22|ONGOING|2021-03-03
e|RS|5c7645b5-5b4c-4280-878b-f5bd0e4349a7|5|CLINRESP|Clinical Response|IWG CHESON MDS 2000|[?]|mEq/day|NON-CR/NON-PD|1|mL/m2/day|SPECT SCAN||||CAREGIVER|READER 1|Y|3|Visit_3|40|4|FOLLOW-UP|2021-01-08|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-13|P1Y2M10DT2H30M|AFTER|2021-01-28|BEFORE|2021-02-22
e|RS|5c7645b5-5b4c-4280-878b-f5bd0e4349a7|6|TMRESP|Tumor Marker Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|||MOLECULAR MAJOR RESPONSE|1|log10 CCID 50/dose|TRANSTHORACIC ECHOCARDIOGRAPHY|||Y|SIGNIFICANT OTHER|ADJUDICATOR 2|Y|3|Visit_3|40|6|TREATMENT|2021-01-08|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-13|P1Y2M10DT2H30M|COINCIDENT|2021-01-22|BEFORE|2021-02-14
e|RS|5c7645b5-5b4c-4280-878b-f5bd0e4349a7|7|NTNERESP|Non-Target Non-Enhancing Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|HOMEOPATHIC DILUTION|COMPLETE MRD RESPONSE|1|L/L|PERCUSSION||||CAREGIVER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|4|Visit_4|65|3|TREATMENT|2021-02-02|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-18|P1Y2M10DT2H30M|AFTER|2021-02-17|COINCIDENT|2021-02-19
e|RS|5c7645b5-5b4c-4280-878b-f5bd0e4349a7|8|NEWLPROG|New Lesion Progression|iRECIST|[?]|PATCH|CYTOGENETIC MINIMAL RESPONSE|1|mEq/kg|IHC|Y|||CLINICAL STUDY SPONSOR|ENDOCRINOLOGIST|NA|4|Visit_4|65|3|FOLLOW-UP|2021-02-02|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-18|P1Y2M10DT2H30M|BEFORE|2021-01-05|COINCIDENT|2021-02-26
e|RS|5c7645b5-5b4c-4280-878b-f5bd0e4349a7|9|TRGRESP|Target Response|GUILHOT CML 2007|[?]|msec|PD|1|g/mol|ANTIMICROBIAL COMBINATION TESTING|Y|||SIGNIFICANT OTHER|CLINICAL PATHOLOGIST|NA|5|Visit_5|90|2|WASHOUT|2021-02-27|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-09|P1Y2M10DT2H30M|BEFORE|2021-03-05|BEFORE|2021-03-06
e|RS|5c7645b5-5b4c-4280-878b-f5bd0e4349a7|10|MRDRESP|Minimal Residual Disease Response|KEAM BREAST CANCER 2013|[?]|Hz|nPR|1|mL/s/m2|EIA||||ADJUDICATOR|RADIOLOGIST|Y|5|Visit_5|90|1|FOLLOW-UP|2021-02-27|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-09|P1Y2M10DT2H30M|AFTER|2021-02-06|AFTER|2021-02-09
e|RS|87cd5d40-3ece-4e63-8f8f-13761cc94a2b|1|NTLWIND|Non-Target Lesion Worsening Indicator|AJCC V7|[?]|h*%|CA125 50% RESPONSE|1|mg/dL|TOTAL BODY IRRADIATION||||CLINICAL STUDY SPONSOR|ONCOLOGIST 2|Y|1|Visit_1|10|3|FOLLOW-UP|2020-07-06|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-07|P1Y2M10DT2H30M|COINCIDENT|2020-08-17|AFTER|2020-08-20
e|RS|87cd5d40-3ece-4e63-8f8f-13761cc94a2b|2|MJPTHIND|Major Pathological Response Indicator|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|ELISA unit|PSEUDORESPONSE|1|cmol|ROMANOWSKY STAIN||||CLINICAL RESEARCH COORDINATOR|HEMATOLOGIST|NA|1|Visit_1|10|6|SCREENING|2020-07-06|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-07|P1Y2M10DT2H30M|UNKNOWN|2020-08-24|COINCIDENT|2020-09-28
e|RS|87cd5d40-3ece-4e63-8f8f-13761cc94a2b|3|HEMARESP|Hematologic Response|SCHER PROSTATE CANCER 2011|[?]|C|IMPROVED|1|copies/uL|REFRACTOMETRY|Y|Y||HEALTH CARE PROFESSIONAL|READER 1|U|2|Visit_2|25|6|TREATMENT|2020-07-21|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-12|P1Y2M10DT2H30M|AFTER|2020-08-19|ONGOING|2020-09-14
e|RS|87cd5d40-3ece-4e63-8f8f-13761cc94a2b|4|DRCRIND|Disease Recurrence Indicator|UNSPECIFIED|[?]|U/kg|CA125 50% RESPONSE|1|EID 50/mL|CHROMATOGRAPHY|Y|||VENDOR|RATER|NA|2|Visit_2|25|7|WASHOUT|2020-07-21|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-12|P1Y2M10DT2H30M|COINCIDENT|2020-09-08|AFTER|2020-09-20
e|RS|87cd5d40-3ece-4e63-8f8f-13761cc94a2b|5|SYMPTDTR|Symptomatic Deterioration|IWC HALLEK CLL 2008|[?]|L/s/kPa|CR|1|Tbsp|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY||||INDEPENDENT ASSESSOR|READER 3|N|3|Visit_3|40|5|FOLLOW-UP|2020-08-05|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-06|P1Y2M10DT2H30M|BEFORE|2020-09-29|AFTER|2020-10-01
e|RS|87cd5d40-3ece-4e63-8f8f-13761cc94a2b|6|CPRFSTAT|Clinical Performance Status|PCWG BUBLEY PROSTATE CANCER 1999|||MINOR PATHOLOGIC RESPONSE|1|GBq/g|TOTAL BODY IRRADIATION|||Y|SIGNIFICANT OTHER|READER 2|Y|3|Visit_3|40|6|SCREENING|2020-08-05|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-06|P1Y2M10DT2H30M|COINCIDENT|2020-08-12|AFTER|2020-09-05
e|RS|87cd5d40-3ece-4e63-8f8f-13761cc94a2b|7|OVRLRESP|Overall Response|RECIST 1.0|[?]|Absorbance U/min|HI-N|1|BOLUS|INDIRECT IMMUNOFLUORESCENCE|Y|||SIGNIFICANT OTHER|RATER 1|NA|4|Visit_4|65|6|SCREENING|2020-08-30|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-12|P1Y2M10DT2H30M|COINCIDENT|2020-07-03|ONGOING|2020-07-05
e|RS|87cd5d40-3ece-4e63-8f8f-13761cc94a2b|8|NTRGRESP|Non-target Response|BURCOMBE BREAST CANCER 2005|[?]|lx|HI-E|1|/40 HPFs|FARR ASSAY||Y||ADJUDICATOR|RATER 1|U|4|Visit_4|65|1|TREATMENT|2020-08-30|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-12|P1Y2M10DT2H30M|BEFORE|2020-08-16|AFTER|2020-09-07
e|RS|87cd5d40-3ece-4e63-8f8f-13761cc94a2b|9|HEMARESP|Hematologic Response|BLAZER COLORECTAL CANCER 2008|[?]|fraction of 1|DISEASE TRANSFORMATION|1|Antibody Unit|FLUORIMETRY||||DOMESTIC PARTNER|NEUROLOGIST 1|Y|5|Visit_5|90|7|WASHOUT|2020-09-24|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-26|P1Y2M10DT2H30M|COINCIDENT|2020-07-14|BEFORE|2020-08-29
e|RS|87cd5d40-3ece-4e63-8f8f-13761cc94a2b|10|NTNERESP|Non-Target Non-Enhancing Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|cm/s|NON-iCR/NON-iUPD|1|mCi/L|EIA|Y|||HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|Y|5|Visit_5|90|1|TREATMENT|2020-09-24|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-26|P1Y2M10DT2H30M|UNKNOWN|2020-08-23|BEFORE|2020-08-31
e|RS|7f1e0661-ebbd-4abd-9031-cb6b424977e2|1|METBRESP|Metabolic Response|SCHWARZ CERVICAL CANCER 2009|[?]|mV2/Hz|CYTOGENETIC CR|1|uV2|ELLA||||SPOUSE|RATER 1|NA|1|Visit_1|10|7|TREATMENT|2020-12-13|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-31|P1Y2M10DT2H30M|BEFORE|2021-01-02|COINCIDENT|2021-02-07
e|RS|7f1e0661-ebbd-4abd-9031-cb6b424977e2|2|NTLWIND|Non-Target Lesion Worsening Indicator|JUWEID NON-HODGKINS LYMPHOMA 2005|||ABSENT MORPHOLOGIC RESPONSE|1|mL/s|IODINE STAIN|||Y|INVESTIGATOR|INTERNIST|NA|1|Visit_1|10|5|TREATMENT|2020-12-13|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-31|P1Y2M10DT2H30M|UNKNOWN|2020-12-05|AFTER|2021-01-18
e|RS|7f1e0661-ebbd-4abd-9031-cb6b424977e2|3|CYTORESP|Cytogenetic Response|SACT|[?]|/cmH2O|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|Ci/mg|WESTERGREN||||FAMILY MEMBER|FORENSIC PATHOLOGIST|NA|2|Visit_2|25|6|TREATMENT|2020-12-28|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-29|P1Y2M10DT2H30M|COINCIDENT|2021-01-10|BEFORE|2021-02-19
e|RS|7f1e0661-ebbd-4abd-9031-cb6b424977e2|4|HEMARESP|Hematologic Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|cm2|MORPHOLOGIC LEUKEMIA-FREE STATE|1|g/day|FREEZING POINT DEPRESSION||||CLINICAL RESEARCH ASSOCIATE|RATER 1|NA|2|Visit_2|25|3|WASHOUT|2020-12-28|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-29|P1Y2M10DT2H30M|BEFORE|2021-01-02|ONGOING|2021-02-14
e|RS|7f1e0661-ebbd-4abd-9031-cb6b424977e2|5|MJPTHIND|Major Pathological Response Indicator|GUILHOT CML 2007|||FAVORABLE RESPONSE|1|/wk|MULTIPLE BREATH WASHOUT|||Y|STUDY SUBJECT|PATHOLOGIST 1|U|3|Visit_3|40|2|TREATMENT|2021-01-12|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-12|P1Y2M10DT2H30M|BEFORE|2020-12-10|ONGOING|2021-02-22
e|RS|7f1e0661-ebbd-4abd-9031-cb6b424977e2|6|BMIVLIND|Bone Marrow Involvement Indicator|SCHWARZ CERVICAL CANCER 2009|[?]|log10 PFU|CYTOGENETIC PR|1|ug/cm2|PET/CT SCAN|Y|Y||SIGNIFICANT OTHER|HEMATOLOGIST|Y|3|Visit_3|40|2|TREATMENT|2021-01-12|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-12|P1Y2M10DT2H30M|AFTER|2020-12-19|BEFORE|2021-01-21
e|RS|7f1e0661-ebbd-4abd-9031-cb6b424977e2|7|MRPHRESP|Morphologic Response|CHESON LYMPHOMA 2008|[?]|umol/min|CYTOGENETIC PR|1|mV*min|TRIPLE-PHASE MRI SCAN|Y|||GUARDIAN|MICROSCOPIST 3|NA|4|Visit_4|65|2|TREATMENT|2021-02-06|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-14|P1Y2M10DT2H30M|BEFORE|2021-02-13|COINCIDENT|2021-02-14
e|RS|7f1e0661-ebbd-4abd-9031-cb6b424977e2|8|MRPHRESP|Morphologic Response|KUKER LYMPHOMA 2005|[?]|BU/mL|iCPD|1|Gy|MICROBIAL CULTURE, LIQUID||||PROXY|FORENSIC PATHOLOGIST|Y|4|Visit_4|65|6|FOLLOW-UP|2021-02-06|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-14|P1Y2M10DT2H30M|AFTER|2020-12-08|ONGOING|2021-01-16
e|RS|7f1e0661-ebbd-4abd-9031-cb6b424977e2|9|CLINRESP|Clinical Response|RAJKUMAR MYELOMA 2011|[?]|Ci/L|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|10^7 PFU|MANUAL CLOT DETECTION||||INTERVIEWER|MICROSCOPIST 3|Y|5|Visit_5|90|6|WASHOUT|2021-03-03|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-16|P1Y2M10DT2H30M|BEFORE|2021-03-12|BEFORE|2021-03-13
e|RS|7f1e0661-ebbd-4abd-9031-cb6b424977e2|10|NTRGRESP|Non-target Response|HARTMAN PANCREATIC CANCER 2012|[?]|%(v/v)|CMR|1|Roentgen|DARK FIELD MICROSCOPY||Y||DOMESTIC PARTNER|MICROSCOPIST 3|Y|5|Visit_5|90|3|TREATMENT|2021-03-03|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-16|P1Y2M10DT2H30M|UNKNOWN|2021-01-21|ONGOING|2021-02-04
e|RS|324a2c67-4802-4806-aff2-04fb9c7394d4|1|HEMARESP|Hematologic Response|BURCOMBE BREAST CANCER 2005|[?]|U/animal|EQUIVOCAL|1|BOLUS|ORCHIDOMETERY||Y||FRIEND|ONCOLOGIST|NA|1|Visit_1|10|4|WASHOUT|2020-05-27|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-27|P1Y2M10DT2H30M|AFTER|2020-07-20|COINCIDENT|2020-08-17
e|RS|324a2c67-4802-4806-aff2-04fb9c7394d4|2|NTLWIND|Non-Target Lesion Worsening Indicator|FAROOQUI SUPP CLL 2014|[?]|anti-Xa IU/mL|NED|1|mg/m2|RADIOIMMUNOPRECIPITATION ASSAY||||SIBLING|RATER 1|U|1|Visit_1|10|2|TREATMENT|2020-05-27|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-27|P1Y2M10DT2H30M|AFTER|2020-06-03|BEFORE|2020-06-17
e|RS|324a2c67-4802-4806-aff2-04fb9c7394d4|3|NTNERESP|Non-Target Non-Enhancing Response|EASL BRUIX LIVER CANCER 2001|[?]|SUPPOSITORY|NE|1|IU/mL|CYSTOMETRY||||FAMILY MEMBER|CLINICAL PATHOLOGIST|NA|2|Visit_2|25|6|TREATMENT|2020-06-11|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-31|P1Y2M10DT2H30M|COINCIDENT|2020-05-19|COINCIDENT|2020-06-06
e|RS|324a2c67-4802-4806-aff2-04fb9c7394d4|4|MRDRESP|Minimal Residual Disease Response|BRUGGEMANN MRD 2010|[?]|msec|NR|1|/100 WBC|IODINE STAIN|Y|||INVESTIGATOR|RATER 2|Y|2|Visit_2|25|7|TREATMENT|2020-06-11|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-31|P1Y2M10DT2H30M|COINCIDENT|2020-05-21|COINCIDENT|2020-06-09
e|RS|324a2c67-4802-4806-aff2-04fb9c7394d4|5|SYMPTDTR|Symptomatic Deterioration|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|uV|RELAPSED DISEASE FROM CR|1|mL/cage/day|QUANTITATIVE COMPUTED TOMOGRAPHY||||CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|3|Visit_3|40|7|TREATMENT|2020-06-26|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-06|P1Y2M10DT2H30M|COINCIDENT|2020-07-15|BEFORE|2020-08-19
e|RS|324a2c67-4802-4806-aff2-04fb9c7394d4|6|TRGRESP|Target Response|PETIT BREAST CANCER 2001|[?]|vg/mL|MRD PERSISTENCE|1|umol/kg/min|SLOAN LETTER EYE CHART 2.5%||||INVESTIGATOR|RATER 2|Y|3|Visit_3|40|4|WASHOUT|2020-06-26|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-06|P1Y2M10DT2H30M|COINCIDENT|2020-07-09|COINCIDENT|2020-07-25
e|RS|324a2c67-4802-4806-aff2-04fb9c7394d4|7|SPLNRESP|Spleen Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|U/dL|PMR|1|/day|OPTICAL DENSITY MEASUREMENT||Y||PARENT|MICROSCOPIST 3|NA|4|Visit_4|65|6|WASHOUT|2020-07-21|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-12|P1Y2M10DT2H30M|BEFORE|2020-06-21|COINCIDENT|2020-08-17
e|RS|324a2c67-4802-4806-aff2-04fb9c7394d4|8|SFTSRESP|Soft Tissue Response|RAJKUMAR MYELOMA 2011|[?]|BU|UNFAVORABLE RESPONSE|1|ft3|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY||||CAREGIVER|RADIOLOGIST 1|U|4|Visit_4|65|2|TREATMENT|2020-07-21|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-12|P1Y2M10DT2H30M|AFTER|2020-06-30|BEFORE|2020-07-16
e|RS|324a2c67-4802-4806-aff2-04fb9c7394d4|9|ANATRESP|Anatomic Response|PCWG SCHER PROSTATE CANCER 2016|[?]|10^9 organisms/mg|COMPLETE MRD RESPONSE|1|uCi/L|ULTRASOUND||||DOMESTIC PARTNER|RADIOLOGIST 1|N|5|Visit_5|90|5|TREATMENT|2020-08-15|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-24|P1Y2M10DT2H30M|COINCIDENT|2020-08-15|AFTER|2020-08-21
e|RS|324a2c67-4802-4806-aff2-04fb9c7394d4|10|CLINRESP|Clinical Response|PRINCE TCELL LYMPHOMA 2010|[?]|DAYS|RELAPSED DISEASE FROM CR|1|mU/g|TARGETED TRANSCRIPTOME SEQUENCING|Y|Y||INVESTIGATOR|READER 2|Y|5|Visit_5|90|2|TREATMENT|2020-08-15|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-24|P1Y2M10DT2H30M|AFTER|2020-07-30|COINCIDENT|2020-08-04
e|RS|9e6a2b90-c6ec-4d7d-96a3-8445f34ad4e7|1|CLINRESP|Clinical Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|mg/dose|PR|1|g/animal/wk|PUPILLOMETRY||||VENDOR|DEVELOPMENTAL PSYCHOLOGIST|U|1|Visit_1|10|4|TREATMENT|2020-12-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-22|P1Y2M10DT2H30M|COINCIDENT|2021-01-20|COINCIDENT|2021-02-01
e|RS|9e6a2b90-c6ec-4d7d-96a3-8445f34ad4e7|2|NTLWIND|Non-Target Lesion Worsening Indicator|GCIG RUSTIN OVARIAN CANCER 2011|[?]|BOWL|DISEASE TRANSFORMATION|1|tsp|TURBIDIMETRY||||PROXY|READER|U|1|Visit_1|10|5|SCREENING|2020-12-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-22|P1Y2M10DT2H30M|AFTER|2021-02-16|AFTER|2021-02-22
e|RS|9e6a2b90-c6ec-4d7d-96a3-8445f34ad4e7|3|TRGRESP|Target Response|UNSPECIFIED|[?]|pkat|OPTIMAL MORPHOLOGIC RESPONSE|1|days/wk|NUCLEIC ACID BASED METHOD|Y|||SIBLING|RADIOLOGIST|U|2|Visit_2|25|4|WASHOUT|2021-01-03|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-09|P1Y2M10DT2H30M|UNKNOWN|2020-12-19|COINCIDENT|2021-03-10
e|RS|9e6a2b90-c6ec-4d7d-96a3-8445f34ad4e7|4|NTLWIND|Non-Target Lesion Worsening Indicator|RECIST 1.0|[?]|Gy/min|PR WITH LYMPHOCYTOSIS|1|mm|MACRO BROTH DILUTION||Y||ADJUDICATION COMMITTEE|NEUROLOGIST 2|U|2|Visit_2|25|6|WASHOUT|2021-01-03|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-09|P1Y2M10DT2H30M|AFTER|2021-02-03|ONGOING|2021-03-14
e|RS|9e6a2b90-c6ec-4d7d-96a3-8445f34ad4e7|5|MJPTHIND|Major Pathological Response Indicator|HARTMAN PANCREATIC CANCER 2012|[?]|APPLICATION|CYTOGENETIC PR|1|ug/kg|BAC ACGH||Y||INTERVIEWER|READER 2|U|3|Visit_3|40|1|SCREENING|2021-01-18|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-12|P1Y2M10DT2H30M|UNKNOWN|2021-03-16|ONGOING|2021-03-18
e|RS|9e6a2b90-c6ec-4d7d-96a3-8445f34ad4e7|6|NEWLPROG|New Lesion Progression|RECICL|[?]|breaths/30s|iPR|1|mV/sec|CLAUSS METHOD||||CAREGIVER|OPTOMETRIST|U|3|Visit_3|40|5|TREATMENT|2021-01-18|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-12|P1Y2M10DT2H30M|AFTER|2021-02-18|BEFORE|2021-03-07
e|RS|9e6a2b90-c6ec-4d7d-96a3-8445f34ad4e7|7|BESTRESP|Best Overall Response|RECIST 1.1|[?]|U/10^12 RBC|NON-iCR/NON-iUPD|1|uIU/dL|FUNCTIONAL MRI|Y|||CLINICAL STUDY SPONSOR|UROLOGIST|U|4|Visit_4|65|1|TREATMENT|2021-02-12|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-20|P1Y2M10DT2H30M|UNKNOWN|2021-01-09|COINCIDENT|2021-03-06
e|RS|9e6a2b90-c6ec-4d7d-96a3-8445f34ad4e7|8|NEWLWIND|New Lesion Worsening Indicator|NCCN ALL MRD 2014|[?]|mEq|iSD|1|V|MACRO BROTH DILUTION|Y|||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 3|N|4|Visit_4|65|2|FOLLOW-UP|2021-02-12|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-20|P1Y2M10DT2H30M|COINCIDENT|2021-02-09|AFTER|2021-03-02
e|RS|9e6a2b90-c6ec-4d7d-96a3-8445f34ad4e7|9|NEWLPROG|New Lesion Progression|CHESON CLL 2012|[?]|g/kg|iCPD|1|CARTRIDGE|IMMUNOTURBIDIMETRY||||CLINICAL STUDY SPONSOR|MICROSCOPIST 1|Y|5|Visit_5|90|4|TREATMENT|2021-03-09|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-20|P1Y2M10DT2H30M|UNKNOWN|2021-01-03|COINCIDENT|2021-01-21
e|RS|9e6a2b90-c6ec-4d7d-96a3-8445f34ad4e7|10|LIVRRESP|Liver Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|TCID 50/dose|MOLECULAR CR|1|umol/min|COULOMETRIC TITRATION||||VENDOR|PHYSIOTHERAPIST|N|5|Visit_5|90|7|TREATMENT|2021-03-09|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-20|P1Y2M10DT2H30M|BEFORE|2021-02-09|ONGOING|2021-03-11
e|RS|f00837ad-bf06-4fbc-a50b-289ac5c5dc03|1|NTRGRESP|Non-target Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|U/mL|NOT ALL EVALUATED|1|beats/min|CELLULAR PROLIFERATION ASSAY|Y|||PROXY|OPHTHALMOLOGIST|NA|1|Visit_1|10|2|WASHOUT|2020-08-24|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-27|P1Y2M10DT2H30M|BEFORE|2020-11-02|AFTER|2020-11-12
e|RS|f00837ad-bf06-4fbc-a50b-289ac5c5dc03|2|PATHRESP|Pathologic Response|MRANO VAN DEN BENT GLIOMA 2011|||ABSENT MORPHOLOGIC RESPONSE|1|fraction of 1|TONOMETRY|Y|Y|Y|VENDOR|READER 2|N|1|Visit_1|10|4|SCREENING|2020-08-24|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-27|P1Y2M10DT2H30M|AFTER|2020-08-29|COINCIDENT|2020-09-20
e|RS|f00837ad-bf06-4fbc-a50b-289ac5c5dc03|3|SPLNRESP|Spleen Response|AJCC V8|[?]|10^9/dose|VGPR|1|ohm|WESTERN BLOT||Y||CAREGIVER|ADJUDICATOR 1|U|2|Visit_2|25|2|SCREENING|2020-09-08|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-12|P1Y2M10DT2H30M|COINCIDENT|2020-08-21|BEFORE|2020-11-19
e|RS|f00837ad-bf06-4fbc-a50b-289ac5c5dc03|4|MOLRESP|Molecular Response|IWC HALLEK CLL 2008|||SD|1|copies/mL|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION||Y|Y|PROXY|OTOLARYNGOLOGIST|Y|2|Visit_2|25|4|TREATMENT|2020-09-08|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-12|P1Y2M10DT2H30M|UNKNOWN|2020-11-11|AFTER|2020-11-17
e|RS|f00837ad-bf06-4fbc-a50b-289ac5c5dc03|5|TMRESP|Tumor Marker Response|PRINCE TCELL LYMPHOMA 2010|[?]|mCi/kg|CYTOGENETIC MINIMAL RESPONSE|1|Ejaculate U|TARGETED TRANSCRIPTOME SEQUENCING||||PROXY|DERMATOLOGIST|N|3|Visit_3|40|1|SCREENING|2020-09-23|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-17|P1Y2M10DT2H30M|COINCIDENT|2020-11-06|AFTER|2020-11-13
e|RS|f00837ad-bf06-4fbc-a50b-289ac5c5dc03|6|NTERESP|Non-Target Enhancing Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|PACK|PMR|1|cm/min|NO INFORMATION||||PROXY|CARDIOLOGIST|Y|3|Visit_3|40|3|WASHOUT|2020-09-23|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-17|P1Y2M10DT2H30M|UNKNOWN|2020-09-24|AFTER|2020-09-27
e|RS|f00837ad-bf06-4fbc-a50b-289ac5c5dc03|7|MRDRESP|Minimal Residual Disease Response|NCIWG CHESON CLL 1996|[?]|v/v|HI-E|1|mEq/ug|MRS||Y||CLINICAL RESEARCH COORDINATOR|READER 1|NA|4|Visit_4|65|6|WASHOUT|2020-10-18|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-29|P1Y2M10DT2H30M|BEFORE|2020-09-02|COINCIDENT|2020-11-17
e|RS|f00837ad-bf06-4fbc-a50b-289ac5c5dc03|8|TRGRESP|Target Response|IWC HALLEK CLL 2008|[?]|nkat|MOLECULAR CR|1|U/g|MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY||||FRIEND|RATER 1|N|4|Visit_4|65|5|TREATMENT|2020-10-18|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-29|P1Y2M10DT2H30M|BEFORE|2020-09-21|AFTER|2020-10-27
e|RS|f00837ad-bf06-4fbc-a50b-289ac5c5dc03|9|STRUSTAT|Steroid Use Status|KUMAR IMWG 2016|[?]|U/mg|MRD NEGATIVITY|1|EVENTS|CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|Y|Y||NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|N|5|Visit_5|90|5|TREATMENT|2020-11-12|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-03|P1Y2M10DT2H30M|COINCIDENT|2020-08-29|BEFORE|2020-10-25
e|RS|f00837ad-bf06-4fbc-a50b-289ac5c5dc03|10|METBRESP|Metabolic Response|RECIST 1.1|||MAJOR PATHOLOGIC RESPONSE|1|pt_br|THICK SMEAR|||Y|FRIEND|ONCOLOGIST 1|U|5|Visit_5|90|1|TREATMENT|2020-11-12|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-03|P1Y2M10DT2H30M|AFTER|2020-10-06|COINCIDENT|2020-10-12
e|RS|911dc297-91cb-42b1-8a26-18f6c83c32a6|1|BESTRESP|Best Overall Response|DOHNER AML 2010|[?]|FINGERTIP UNIT|WORSENED|1|Enzyme U/g Hb|DYNAMIC CONTRAST ENHANCED MRI||||FRIEND|RADIOLOGIST|NA|1|Visit_1|10|7|TREATMENT|2020-12-01|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-12|P1Y2M10DT2H30M|UNKNOWN|2021-01-02|AFTER|2021-02-25
e|RS|911dc297-91cb-42b1-8a26-18f6c83c32a6|2|NEWLIND|New Lesion Indicator|SCHER PROSTATE CANCER 2011|[?]|mg/day|PR WITH LYMPHOCYTOSIS|1|mU/g|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI||||CHILD|ENDOCRINOLOGIST|U|1|Visit_1|10|1|SCREENING|2020-12-01|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-12|P1Y2M10DT2H30M|UNKNOWN|2021-02-25|AFTER|2021-02-26
e|RS|911dc297-91cb-42b1-8a26-18f6c83c32a6|3|ANATRESP|Anatomic Response|IWG CHESON MDS 2000|[?]|10^4/hpf|CA125 50% RESPONSE|1|mL/cage/day|EEG||||INDEPENDENT ASSESSOR|PATHOLOGIST 1|Y|2|Visit_2|25|5|WASHOUT|2020-12-16|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-29|P1Y2M10DT2H30M|AFTER|2021-01-07|COINCIDENT|2021-02-22
e|RS|911dc297-91cb-42b1-8a26-18f6c83c32a6|4|HEMARESP|Hematologic Response|MASS|||NOT ALL EVALUATED|1|mg/dose|THIN SMEAR|Y||Y|NON-HEALTH CARE PROFESSIONAL|READER 3|NA|2|Visit_2|25|7|TREATMENT|2020-12-16|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-29|P1Y2M10DT2H30M|COINCIDENT|2021-01-06|ONGOING|2021-02-28
e|RS|911dc297-91cb-42b1-8a26-18f6c83c32a6|5|METBRESP|Metabolic Response|HARTMAN PANCREATIC CANCER 2012|[?]|uSiemens|IMMUNOPHENOTYPIC CR|1|RFU|QUANTITATIVE COMPUTED TOMOGRAPHY|Y|||INTERVIEWER|MICROSCOPIST 3|U|3|Visit_3|40|2|FOLLOW-UP|2020-12-31|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-26|P1Y2M10DT2H30M|BEFORE|2020-11-25|ONGOING|2021-01-02
e|RS|911dc297-91cb-42b1-8a26-18f6c83c32a6|6|METBRESP|Metabolic Response|CHESON LYMPHOMA 2008|[?]|mEq/kg|OPTIMAL MORPHOLOGIC RESPONSE|1|ppb|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY||Y||PARENT|READER 2|U|3|Visit_3|40|4|TREATMENT|2020-12-31|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-26|P1Y2M10DT2H30M|UNKNOWN|2021-01-15|COINCIDENT|2021-01-19
e|RS|911dc297-91cb-42b1-8a26-18f6c83c32a6|7|NTNERESP|Non-Target Non-Enhancing Response|EASL BRUIX LIVER CANCER 2001|[?]|mm/sec|OPTIMAL MORPHOLOGIC RESPONSE|1|CCID 50/dose|CINEANGIOGRAPHY||||NON-HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|Y|4|Visit_4|65|6|TREATMENT|2021-01-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-14|P1Y2M10DT2H30M|COINCIDENT|2020-12-25|BEFORE|2021-01-29
e|RS|911dc297-91cb-42b1-8a26-18f6c83c32a6|8|NEWLIND|New Lesion Indicator|MASS|[?]|/2000 RBC|iPR|1|10^8 PFU|FUNCTIONAL MRI||||PROXY|HEMATOLOGIST|Y|4|Visit_4|65|7|SCREENING|2021-01-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-14|P1Y2M10DT2H30M|UNKNOWN|2021-01-16|AFTER|2021-01-19
e|RS|911dc297-91cb-42b1-8a26-18f6c83c32a6|9|LIVRRESP|Liver Response|KUKER LYMPHOMA 2005|[?]|uSiemens|iPR|1|DIOPTER|FLOW MICROSCOPY||||INVESTIGATOR|READER|U|5|Visit_5|90|1|WASHOUT|2021-02-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-04|P1Y2M10DT2H30M|BEFORE|2021-02-25|ONGOING|2021-02-27
e|RS|911dc297-91cb-42b1-8a26-18f6c83c32a6|10|MNPTHIND|Minor Pathological Response Indicator|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|Gy/h|DISEASE TRANSFORMATION|1|mU|HIGH LEVEL AMINOGLYCOSIDE SCREEN|Y|Y||CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST|NA|5|Visit_5|90|5|TREATMENT|2021-02-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-04|P1Y2M10DT2H30M|AFTER|2020-11-24|AFTER|2021-01-20
e|RS|d87b795c-d158-4429-bdc6-1a2db7dc1a7d|1|SPLNRESP|Spleen Response|MASS|[?]|TRACE|MRD RELAPSE|1|SACHET|MS/MS||||INTERVIEWER|RADIOLOGIST 1|N|1|Visit_1|10|1|FOLLOW-UP|2020-11-25|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-06|P1Y2M10DT2H30M|COINCIDENT|2020-12-05|AFTER|2021-02-09
e|RS|d87b795c-d158-4429-bdc6-1a2db7dc1a7d|2|MNPTHIND|Minor Pathological Response Indicator|HARTMAN PANCREATIC CANCER 2012|[?]|nmol/L/min|RELAPSED DISEASE|1|U/animal|PHOTOMETRY||||NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 1|Y|1|Visit_1|10|2|WASHOUT|2020-11-25|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-06|P1Y2M10DT2H30M|COINCIDENT|2020-11-22|COINCIDENT|2021-01-05
e|RS|d87b795c-d158-4429-bdc6-1a2db7dc1a7d|3|ANATRESP|Anatomic Response|RANO ELLINGSON 2017|[?]|cP|DECREASED|1|EU|GEL ELECTROPHORESIS||Y||VENDOR|ADJUDICATOR 1|Y|2|Visit_2|25|7|TREATMENT|2020-12-10|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-30|P1Y2M10DT2H30M|UNKNOWN|2020-12-27|BEFORE|2020-12-30
e|RS|d87b795c-d158-4429-bdc6-1a2db7dc1a7d|4|BONERESP|Bone Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|uCi/L|PD FROM PR|1|/ms|SPECULAR MICROSCOPY||||FRIEND|PHYSIOTHERAPIST|Y|2|Visit_2|25|7|TREATMENT|2020-12-10|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-30|P1Y2M10DT2H30M|COINCIDENT|2020-12-28|COINCIDENT|2021-01-31
e|RS|d87b795c-d158-4429-bdc6-1a2db7dc1a7d|5|ANATRESP|Anatomic Response|GCIG RUSTIN OVARIAN CANCER 2011|||PR|1|CUP|TRANSCRIPTION-MEDIATED AMPLIFICATION|Y||Y|CAREGIVER|RADIOLOGIST 2|Y|3|Visit_3|40|7|TREATMENT|2020-12-25|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-12|P1Y2M10DT2H30M|BEFORE|2020-11-28|BEFORE|2021-01-11
e|RS|d87b795c-d158-4429-bdc6-1a2db7dc1a7d|6|RDIORESP|Radiologic Response|NCIWG CHESON CLL 1996|[?]|cL|NON-PD|1|/mm2|INFRARED SPECTROMETRY|Y|||STUDY SUBJECT|CLINICAL PATHOLOGIST|U|3|Visit_3|40|3|TREATMENT|2020-12-25|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-12|P1Y2M10DT2H30M|UNKNOWN|2021-01-14|BEFORE|2021-02-06
e|RS|d87b795c-d158-4429-bdc6-1a2db7dc1a7d|7|NEWLPROG|New Lesion Progression|MONTSERRAT CLL 1989|[?]|10^6 IU/mL|iCPD|1|g/animal/day|INCISION-INDUCED BLEEDING METHOD||||CLINICAL STUDY SPONSOR|MICROSCOPIST 3|U|4|Visit_4|65|3|SCREENING|2021-01-19|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-04|P1Y2M10DT2H30M|UNKNOWN|2020-11-23|COINCIDENT|2021-01-05
e|RS|d87b795c-d158-4429-bdc6-1a2db7dc1a7d|8|DRCRIND|Disease Recurrence Indicator|MONTSERRAT CLL 1989|||PR|1|IU|KARYOTYPING|Y||Y|INDEPENDENT ASSESSOR|NEUROLOGIST 1|N|4|Visit_4|65|5|TREATMENT|2021-01-19|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-04|P1Y2M10DT2H30M|AFTER|2020-12-18|COINCIDENT|2021-01-15
e|RS|d87b795c-d158-4429-bdc6-1a2db7dc1a7d|9|SFTSRESP|Soft Tissue Response|BRUGGEMANN MRD 2010|[?]|mmol/s|RELAPSED DISEASE FROM CR|1|PIXELS/in|SCINTIGRAPHY||Y||PROXY|UROLOGIST|U|5|Visit_5|90|4|FOLLOW-UP|2021-02-13|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-19|P1Y2M10DT2H30M|AFTER|2021-01-13|BEFORE|2021-02-16
e|RS|d87b795c-d158-4429-bdc6-1a2db7dc1a7d|10|HEMARESP|Hematologic Response|SACT|[?]|mMU/mL|QUANTIFIABLE MRD POSITIVITY|1|kPa/L/sec|NUCLEIC ACID SEQUENCING||Y||INDEPENDENT ASSESSOR|READER 2|U|5|Visit_5|90|4|TREATMENT|2021-02-13|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-19|P1Y2M10DT2H30M|AFTER|2020-12-03|BEFORE|2021-01-22
e|RS|9bfcd733-2233-4e54-a6cd-641a59fc8a01|1|LIVRRESP|Liver Response|PERCIST|||MOLECULAR MAJOR RESPONSE|1|PLUG|IMMUNOPRECIPITATION|Y|Y|Y|INVESTIGATOR|CLINICAL PATHOLOGIST|N|1|Visit_1|10|5|SCREENING|2020-08-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-20|P1Y2M10DT2H30M|COINCIDENT|2020-11-07|BEFORE|2020-11-12
e|RS|9bfcd733-2233-4e54-a6cd-641a59fc8a01|2|MRDIND|Minimal Residual Disease Indicator|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|ppb|OPTIMAL MORPHOLOGIC RESPONSE|1|mL/s|INDIRECT IMMUNOFLUORESCENCE||||INVESTIGATOR|ADJUDICATOR 2|U|1|Visit_1|10|4|TREATMENT|2020-08-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-20|P1Y2M10DT2H30M|COINCIDENT|2020-08-12|AFTER|2020-11-12
e|RS|9bfcd733-2233-4e54-a6cd-641a59fc8a01|3|MNPTHIND|Minor Pathological Response Indicator|AJCC V7|[?]|mmol/s|NON-PD|1|ug/m2/h|NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY||Y||SPOUSE|HEMATOLOGIST|NA|2|Visit_2|25|3|TREATMENT|2020-08-30|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-03|P1Y2M10DT2H30M|COINCIDENT|2020-09-20|ONGOING|2020-11-05
e|RS|9bfcd733-2233-4e54-a6cd-641a59fc8a01|4|MOLRESP|Molecular Response|JACINTO CERVICAL CANCER 2007|[?]|tsp|RELAPSED DISEASE|1|mEq/day|OPHTHALMOSCOPY||||GUARDIAN|CLINICAL PATHOLOGIST|U|2|Visit_2|25|5|TREATMENT|2020-08-30|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-03|P1Y2M10DT2H30M|BEFORE|2020-10-27|BEFORE|2020-11-06
e|RS|9bfcd733-2233-4e54-a6cd-641a59fc8a01|5|DRCRIND|Disease Recurrence Indicator|KEAM BREAST CANCER 2013|[?]|hr/day|STABLE|1|SYRINGE|LC/MS/MS||||CLINICAL RESEARCH COORDINATOR|RADIOLOGIST|N|3|Visit_3|40|6|SCREENING|2020-09-14|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-31|P1Y2M10DT2H30M|BEFORE|2020-08-28|AFTER|2020-09-20
e|RS|9bfcd733-2233-4e54-a6cd-641a59fc8a01|6|TRGRESP|Target Response|GUPPY OVARIAN CANCER 2002|[?]|umol/day|MOLECULAR MAJOR RESPONSE|1|DIOPTER|HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY||||VENDOR|ADJUDICATOR 1|NA|3|Visit_3|40|7|SCREENING|2020-09-14|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-31|P1Y2M10DT2H30M|COINCIDENT|2020-09-27|AFTER|2020-11-10
e|RS|9bfcd733-2233-4e54-a6cd-641a59fc8a01|7|NEWLWIND|New Lesion Worsening Indicator|JACINTO CERVICAL CANCER 2007|[?]|mg/L FEU|sCR|1|MBq/uL|RADIOGRAPHY||||SIGNIFICANT OTHER|DEVELOPMENTAL PSYCHOLOGIST|Y|4|Visit_4|65|3|TREATMENT|2020-10-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-13|P1Y2M10DT2H30M|COINCIDENT|2020-10-03|COINCIDENT|2020-10-31
e|RS|9bfcd733-2233-4e54-a6cd-641a59fc8a01|8|MOLRESP|Molecular Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|ks|PD/RELAPSE AFTER HI|1|cP|TOTAL BODY RADIOGRAPHY||||ADJUDICATION COMMITTEE|CLINICAL PATHOLOGIST|NA|4|Visit_4|65|3|TREATMENT|2020-10-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-13|P1Y2M10DT2H30M|AFTER|2020-10-06|BEFORE|2020-10-22
e|RS|9bfcd733-2233-4e54-a6cd-641a59fc8a01|9|LIVRRESP|Liver Response|AJCC V8|[?]|DROP|INDETERMINATE RESPONSE|1|Absorbance U|BETA LACTAMASE||||SIBLING|RADIOLOGIST 1|Y|5|Visit_5|90|6|SCREENING|2020-11-03|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-14|P1Y2M10DT2H30M|AFTER|2020-09-26|ONGOING|2020-10-13
e|RS|9bfcd733-2233-4e54-a6cd-641a59fc8a01|10|NTERESP|Non-Target Enhancing Response|PETIT BREAST CANCER 2001|[?]|ft2|PR|1|log EID 50/dose|SPIROMETRY||||INTERVIEWER|PEDIATRIC NEUROLOGIST|U|5|Visit_5|90|2|TREATMENT|2020-11-03|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-14|P1Y2M10DT2H30M|BEFORE|2020-10-21|AFTER|2020-10-28
e|RS|7eb97152-173c-4923-8604-5dad3140cc25|1|LIVRRESP|Liver Response|MACDONALD GLIOMA 1990|[?]|kg/cm|ABSENT MORPHOLOGIC RESPONSE|1|kV|CONGO RED STAIN|Y|||PARENT|UROLOGIST|NA|1|Visit_1|10|3|WASHOUT|2020-09-05|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-14|P1Y2M10DT2H30M|UNKNOWN|2020-11-14|COINCIDENT|2020-11-19
e|RS|7eb97152-173c-4923-8604-5dad3140cc25|2|ANATRESP|Anatomic Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|HEP|CR|1|mg/m2|IMMUNOPRECIPITATION||||HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|U|1|Visit_1|10|2|SCREENING|2020-09-05|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-14|P1Y2M10DT2H30M|AFTER|2020-10-06|AFTER|2020-10-13
e|RS|7eb97152-173c-4923-8604-5dad3140cc25|3|SYMPTDTR|Symptomatic Deterioration|iRECIST|[?]|dB|UNEQUIVOCAL|1|uL/mL|REFRACTOMETRY||||NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 1|NA|2|Visit_2|25|2|TREATMENT|2020-09-20|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-05|P1Y2M10DT2H30M|COINCIDENT|2020-11-28|ONGOING|2020-11-29
e|RS|7eb97152-173c-4923-8604-5dad3140cc25|4|HEMARESP|Hematologic Response|JACINTO CERVICAL CANCER 2007|[?]|nmol/day|iSD|1|RATIO|FLUORESCENT IMMUNOASSAY||||ADJUDICATION COMMITTEE|RATER|Y|2|Visit_2|25|5|WASHOUT|2020-09-20|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-05|P1Y2M10DT2H30M|COINCIDENT|2020-11-25|ONGOING|2020-12-03
e|RS|7eb97152-173c-4923-8604-5dad3140cc25|5|MRPHRESP|Morphologic Response|KEAM BREAST CANCER 2013|||PD FROM PR|1|mg/dose|INFRARED SPECTROMETRY|Y||Y|PROXY|NEUROLOGIST 2|NA|3|Visit_3|40|6|TREATMENT|2020-10-05|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-03|P1Y2M10DT2H30M|COINCIDENT|2020-11-06|AFTER|2020-11-10
e|RS|7eb97152-173c-4923-8604-5dad3140cc25|6|NEWLPROG|New Lesion Progression|PRINCE TCELL LYMPHOMA 2010|||MORPHOLOGIC LEUKEMIA-FREE STATE|1|ukat|FLUORESCENT MICROSCOPY|||Y|INTERVIEWER|ADJUDICATOR 1|Y|3|Visit_3|40|4|TREATMENT|2020-10-05|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-03|P1Y2M10DT2H30M|BEFORE|2020-11-05|BEFORE|2020-11-14
e|RS|7eb97152-173c-4923-8604-5dad3140cc25|7|TRGRESP|Target Response|DOHNER AML 2010|[?]|GPL U|iUPD|1|lm|MICROPARTICLE ENZYME IMMUNOASSAY|Y|Y||FRIEND|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|4|Visit_4|65|6|TREATMENT|2020-10-30|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-08|P1Y2M10DT2H30M|AFTER|2020-11-07|AFTER|2020-11-08
e|RS|7eb97152-173c-4923-8604-5dad3140cc25|8|NEWLIND|New Lesion Indicator|CHESON NON-HODGKINS LYMPHOMA 1999|||UNFAVORABLE RESPONSE|1|PIXEL|IMMUNORADIOMETRIC ASSAY|Y|Y|Y|PROXY|FORENSIC PATHOLOGIST|Y|4|Visit_4|65|3|SCREENING|2020-10-30|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-08|P1Y2M10DT2H30M|COINCIDENT|2020-12-03|COINCIDENT|2020-12-04
e|RS|7eb97152-173c-4923-8604-5dad3140cc25|9|DRCRIND|Disease Recurrence Indicator|HAMAOKA BREAST CANCER 2010|[?]|PIXELS/cm|NON-iCR/NON-iUPD|1|Absorbance U/min|WHOLE GENOME SEQUENCING||||FRIEND|ADJUDICATOR|N|5|Visit_5|90|4|WASHOUT|2020-11-24|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-16|P1Y2M10DT2H30M|UNKNOWN|2020-10-15|AFTER|2020-11-05
e|RS|7eb97152-173c-4923-8604-5dad3140cc25|10|NEWLIND|New Lesion Indicator|IWG CHESON AML 2003|[?]|mm/sec|PMD|1|/kg|LIGHT SCATTERING SPECTROSCOPY||Y||NON-HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|N|5|Visit_5|90|5|SCREENING|2020-11-24|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-16|P1Y2M10DT2H30M|COINCIDENT|2020-10-04|ONGOING|2020-11-24
e|RS|0b2104d0-e1e3-4516-8c4b-de5d42f82784|1|NEWLPROG|New Lesion Progression|PALUMBO MULTIPLE MYELOMA 2009|[?]|mol/mg|iPR|1|10^7 TCID 50/dose|MACRO BROTH DILUTION|Y|Y||STUDY SUBJECT|FORENSIC PATHOLOGIST|NA|1|Visit_1|10|1|SCREENING|2020-08-08|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-26|P1Y2M10DT2H30M|BEFORE|2020-08-25|BEFORE|2020-09-25
e|RS|0b2104d0-e1e3-4516-8c4b-de5d42f82784|2|MNPTHIND|Minor Pathological Response Indicator|KUMAR IMWG 2016|[?]|mL/animal/wk|RELAPSED DISEASE FROM CR OR PR|1|L/kg|FLOW CYTOMETRY||||SIGNIFICANT OTHER|READER|U|1|Visit_1|10|5|WASHOUT|2020-08-08|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-26|P1Y2M10DT2H30M|UNKNOWN|2020-08-14|COINCIDENT|2020-09-18
e|RS|0b2104d0-e1e3-4516-8c4b-de5d42f82784|3|SYMPTDTR|Symptomatic Deterioration|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|/100 WBC|pCR|1|10^3 RNA copies/mL|IVY INCISION METHOD||||INVESTIGATOR|INTERNIST|U|2|Visit_2|25|7|FOLLOW-UP|2020-08-23|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-14|P1Y2M10DT2H30M|AFTER|2020-09-06|AFTER|2020-10-02
e|RS|0b2104d0-e1e3-4516-8c4b-de5d42f82784|4|MJPTHIND|Major Pathological Response Indicator|MRANO VAN DEN BENT GLIOMA 2011|[?]|/7.5 mL|MRD PERSISTENCE|1|MET*h|IMMUNOPRECIPITATION|Y|||VENDOR|READER|NA|2|Visit_2|25|5|WASHOUT|2020-08-23|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-14|P1Y2M10DT2H30M|AFTER|2020-10-04|BEFORE|2020-11-02
e|RS|0b2104d0-e1e3-4516-8c4b-de5d42f82784|5|NTLWIND|Non-Target Lesion Worsening Indicator|SCHER PROSTATE CANCER 2011|[?]|U/g|ABSENT MORPHOLOGIC RESPONSE|1|mEq/uL|HPLC-UV|Y|||CLINICAL RESEARCH COORDINATOR|READER|NA|3|Visit_3|40|2|TREATMENT|2020-09-07|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-17|P1Y2M10DT2H30M|AFTER|2020-09-05|COINCIDENT|2020-09-29
e|RS|0b2104d0-e1e3-4516-8c4b-de5d42f82784|6|METSIND|Metastatic Indicator|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|U.CARR|CR|1|/200 HPFs|HEMAGGLUTINATION INHIBITION ASSAY||||NON-HEALTH CARE PROFESSIONAL|OPTOMETRIST|U|3|Visit_3|40|3|SCREENING|2020-09-07|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-17|P1Y2M10DT2H30M|BEFORE|2020-09-08|AFTER|2020-10-09
e|RS|0b2104d0-e1e3-4516-8c4b-de5d42f82784|7|OVRLRESP|Overall Response|UNSPECIFIED|[?]|mg/day|UNFAVORABLE RESPONSE|1|U/g/h|MAGNETIC RESONANCE ENTEROGRAPHY||||NON-HEALTH CARE PROFESSIONAL|READER 3|N|4|Visit_4|65|3|TREATMENT|2020-10-02|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-21|P1Y2M10DT2H30M|BEFORE|2020-09-24|BEFORE|2020-10-17
e|RS|0b2104d0-e1e3-4516-8c4b-de5d42f82784|8|DRCRIND|Disease Recurrence Indicator|RANO|[?]|SYRINGE|PR WITH LYMPHOCYTOSIS|1|mL/breath|GC/MS-CI||||GUARDIAN|ADJUDICATOR 1|N|4|Visit_4|65|3|TREATMENT|2020-10-02|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-21|P1Y2M10DT2H30M|UNKNOWN|2020-08-14|AFTER|2020-09-30
e|RS|0b2104d0-e1e3-4516-8c4b-de5d42f82784|9|SYMPTDTR|Symptomatic Deterioration|JACINTO CERVICAL CANCER 2007|[?]|10^5/L|MAJOR PATHOLOGIC RESPONSE|1|10^9/g|CONTRAST ENHANCED PET/CT SCAN||Y||PARENT|ONCOLOGIST|U|5|Visit_5|90|1|TREATMENT|2020-10-27|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-14|P1Y2M10DT2H30M|BEFORE|2020-08-30|AFTER|2020-09-27
e|RS|0b2104d0-e1e3-4516-8c4b-de5d42f82784|10|SPLNRESP|Spleen Response|KEAM BREAST CANCER 2013|||HI-N|1|nmol BCE/nmol|CELL BASED BIOASSAY|||Y|GUARDIAN|ONCOLOGIST 1|Y|5|Visit_5|90|2|TREATMENT|2020-10-27|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-14|P1Y2M10DT2H30M|UNKNOWN|2020-10-16|AFTER|2020-10-28
e|RS|96f68979-6869-403b-a8bd-78c8f965f98a|1|BESTRESP|Best Overall Response|BRUGGEMANN MRD 2010|[?]|mV*min|PR|1|AMPULE|DISK DIFFUSION||||FAMILY MEMBER|ONCOLOGIST 2|Y|1|Visit_1|10|2|WASHOUT|2020-05-26|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-28|P1Y2M10DT2H30M|UNKNOWN|2020-08-23|AFTER|2020-08-24
e|RS|96f68979-6869-403b-a8bd-78c8f965f98a|2|SYMPTDTR|Symptomatic Deterioration|RECICL|[?]|MESF|sCR|1|mJoule/cm2|CONGO RED STAIN||||PARENT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|1|Visit_1|10|5|TREATMENT|2020-05-26|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-28|P1Y2M10DT2H30M|UNKNOWN|2020-06-03|COINCIDENT|2020-06-04
e|RS|96f68979-6869-403b-a8bd-78c8f965f98a|3|NTLWIND|Non-Target Lesion Worsening Indicator|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|cg|FAVORABLE RESPONSE|1|Antibody Unit|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION|Y|||SIBLING|RADIOLOGIST 2|U|2|Visit_2|25|3|TREATMENT|2020-06-10|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-05|P1Y2M10DT2H30M|COINCIDENT|2020-08-22|BEFORE|2020-08-23
e|RS|96f68979-6869-403b-a8bd-78c8f965f98a|4|MOLRESP|Molecular Response|NCIWG CHESON CLL 1996|||cCR|1|IU/kg/h|IMMUNOFLUORESCENT STAIN|||Y|CLINICAL STUDY SPONSOR|ADJUDICATOR 2|U|2|Visit_2|25|1|TREATMENT|2020-06-10|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-05|P1Y2M10DT2H30M|AFTER|2020-07-30|AFTER|2020-08-20
e|RS|96f68979-6869-403b-a8bd-78c8f965f98a|5|NTERESP|Non-Target Enhancing Response|RAJKUMAR MYELOMA 2011|[?]|mm/sec|PD-CT|1|/2500 WBC|JAEGER EYE CHART|Y|Y||FRIEND|MICROSCOPIST|U|3|Visit_3|40|3|TREATMENT|2020-06-25|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-18|P1Y2M10DT2H30M|COINCIDENT|2020-05-27|AFTER|2020-08-07
e|RS|96f68979-6869-403b-a8bd-78c8f965f98a|6|TRGRESP|Target Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|10^7/L|MORPHOLOGIC LEUKEMIA-FREE STATE|1|10^3 organisms/mL|IN SITU HYBRIDIZATION||||INDEPENDENT ASSESSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|3|Visit_3|40|7|TREATMENT|2020-06-25|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-18|P1Y2M10DT2H30M|AFTER|2020-05-22|COINCIDENT|2020-06-13
e|RS|96f68979-6869-403b-a8bd-78c8f965f98a|7|SFTSRESP|Soft Tissue Response|LUGANO CLASSIFICATION|[?]|/100 WBC|SD|1|/10^3|PET/CT SCAN WITHOUT CONTRAST|Y|||INVESTIGATOR|ONCOLOGIST|U|4|Visit_4|65|4|TREATMENT|2020-07-20|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-14|P1Y2M10DT2H30M|BEFORE|2020-06-06|AFTER|2020-08-09
e|RS|96f68979-6869-403b-a8bd-78c8f965f98a|8|LIVRRESP|Liver Response|RANO ELLINGSON 2017|[?]|MBP|WORSENED|1|BEAM BREAKS|X-RAY FLUORESCENCE SPECTROMETRY||||PROXY|RATER 1|NA|4|Visit_4|65|7|WASHOUT|2020-07-20|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-14|P1Y2M10DT2H30M|COINCIDENT|2020-08-09|ONGOING|2020-08-19
e|RS|96f68979-6869-403b-a8bd-78c8f965f98a|9|NTLWIND|Non-Target Lesion Worsening Indicator|MRECIST LENCIONI LIVER CANCER 2010|[?]|ug/kg|EQUIVOCAL|1|mmHg*min/L|DIGITAL PCR ARRAY||||SPOUSE|PATHOLOGIST 2|Y|5|Visit_5|90|4|FOLLOW-UP|2020-08-14|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-13|P1Y2M10DT2H30M|COINCIDENT|2020-08-16|AFTER|2020-08-21
e|RS|96f68979-6869-403b-a8bd-78c8f965f98a|10|MNPTHIND|Minor Pathological Response Indicator|MACDONALD GLIOMA 1990|||MOLECULAR CR|1|CYLINDER|NUCLEIC ACID SEQUENCING||Y|Y|NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|U|5|Visit_5|90|4|FOLLOW-UP|2020-08-14|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-13|P1Y2M10DT2H30M|BEFORE|2020-06-13|ONGOING|2020-08-07
e|RS|e0f67610-b86a-4f5a-88eb-905b1e0aa609|1|MRPHRESP|Morphologic Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|Hz|CA125 75% RESPONSE|1|ug/min|SPIRAL CT||||HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|N|1|Visit_1|10|7|TREATMENT|2020-10-16|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-18|P1Y2M10DT2H30M|COINCIDENT|2020-10-09|AFTER|2020-11-01
e|RS|e0f67610-b86a-4f5a-88eb-905b1e0aa609|2|CYTORESP|Cytogenetic Response|CHESON LYMPHOMA 2008|[?]|USP U|HI-P|1|BAG|FLUOROSCOPY||||PARENT|READER 2|NA|1|Visit_1|10|6|TREATMENT|2020-10-16|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-18|P1Y2M10DT2H30M|COINCIDENT|2021-01-05|BEFORE|2021-01-09
e|RS|e0f67610-b86a-4f5a-88eb-905b1e0aa609|3|METBRESP|Metabolic Response|MONTSERRAT CLL 1989|[?]|Hz/s|CRi|1|mol/L|JAEGER EYE CHART||Y||NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST|Y|2|Visit_2|25|6|FOLLOW-UP|2020-10-31|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-13|P1Y2M10DT2H30M|AFTER|2020-11-20|AFTER|2021-01-04
e|RS|e0f67610-b86a-4f5a-88eb-905b1e0aa609|4|CLINRESP|Clinical Response|MRECIST LENCIONI LIVER CANCER 2010|||NR|1|POUCH|CHROMOGENIC ASSAY|Y||Y|CAREGIVER|ADJUDICATOR 1|NA|2|Visit_2|25|5|TREATMENT|2020-10-31|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-13|P1Y2M10DT2H30M|COINCIDENT|2021-01-01|BEFORE|2021-01-10
e|RS|e0f67610-b86a-4f5a-88eb-905b1e0aa609|5|MRDIND|Minimal Residual Disease Indicator|HARTMANN GERM CELL CANCER 2002|[?]|10^6 organisms/mL|NOT ALL EVALUATED|1|10^12/L|ANGIOGRAPHY||||ADJUDICATOR|READER 3|Y|3|Visit_3|40|4|TREATMENT|2020-11-15|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-09|P1Y2M10DT2H30M|UNKNOWN|2021-01-11|COINCIDENT|2021-01-13
e|RS|e0f67610-b86a-4f5a-88eb-905b1e0aa609|6|BESTRESP|Best Overall Response|RECICL|||INDETERMINATE RESPONSE|1|10^6 organisms/mL|KNEMOMETRY|||Y|STUDY SUBJECT|ADJUDICATOR 1|N|3|Visit_3|40|1|WASHOUT|2020-11-15|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-09|P1Y2M10DT2H30M|BEFORE|2020-12-24|AFTER|2021-01-01
e|RS|e0f67610-b86a-4f5a-88eb-905b1e0aa609|7|NEWLWIND|New Lesion Worsening Indicator|MRANO VAN DEN BENT GLIOMA 2011|[?]|10^7 CFU/mL|iSD|1|mU|VIRUS PLAQUE ASSAY|Y|Y||INDEPENDENT ASSESSOR|READER|U|4|Visit_4|65|4|WASHOUT|2020-12-10|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-08|P1Y2M10DT2H30M|COINCIDENT|2020-11-24|BEFORE|2020-12-28
e|RS|e0f67610-b86a-4f5a-88eb-905b1e0aa609|8|CPRFSTAT|Clinical Performance Status|GCIG RUSTIN OVARIAN CANCER 2011|[?]|TROCHE|NON-PD|1|10^6 DNA copies/mL|MICROBIAL BIOCHEMICAL IDENTIFICATION||||STUDY SUBJECT|DERMATOLOGIST|NA|4|Visit_4|65|4|TREATMENT|2020-12-10|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-08|P1Y2M10DT2H30M|AFTER|2020-12-09|AFTER|2020-12-31
e|RS|e0f67610-b86a-4f5a-88eb-905b1e0aa609|9|OVRLRESP|Overall Response|RANO ELLINGSON 2017|[?]|BU|CYTOGENETIC MINOR RESPONSE|1|ug|IMPULSE OSCILLOMETRY||||INVESTIGATOR|PEDIATRIC NEUROLOGIST|NA|5|Visit_5|90|3|TREATMENT|2021-01-04|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-25|P1Y2M10DT2H30M|AFTER|2020-12-15|COINCIDENT|2020-12-19
e|RS|e0f67610-b86a-4f5a-88eb-905b1e0aa609|10|NTNERESP|Non-Target Non-Enhancing Response|KUMAR IMWG 2016|||CHR|1|ug/L/h|CT SCAN|Y||Y|VENDOR|RATER 2|Y|5|Visit_5|90|1|TREATMENT|2021-01-04|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-25|P1Y2M10DT2H30M|COINCIDENT|2020-10-14|BEFORE|2020-10-22
e|RS|d62dc655-8865-4592-af0b-744524d9a24c|1|MNPTHIND|Minor Pathological Response Indicator|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|10^8 PFU|NR|1|U/m2|MALDI-TOF||||SIBLING|OPTOMETRIST|NA|1|Visit_1|10|7|WASHOUT|2020-09-29|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-05|P1Y2M10DT2H30M|BEFORE|2020-10-19|COINCIDENT|2020-12-19
e|RS|d62dc655-8865-4592-af0b-744524d9a24c|2|METBRESP|Metabolic Response|IWG CHESON MDS 2006|[?]|nkat|MRD RELAPSE|1|L/h/m2|TEMPLATE INCISION METHOD||Y||HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|1|Visit_1|10|1|WASHOUT|2020-09-29|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-05|P1Y2M10DT2H30M|UNKNOWN|2020-11-30|AFTER|2020-12-06
e|RS|d62dc655-8865-4592-af0b-744524d9a24c|3|SFTSRESP|Soft Tissue Response|MACDONALD GLIOMA 1990|[?]|mL/s|MORPHOLOGIC LEUKEMIA-FREE STATE|1|U/g|SNP ARRAY||||SPOUSE|ONCOLOGIST 2|N|2|Visit_2|25|5|TREATMENT|2020-10-14|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-01|P1Y2M10DT2H30M|BEFORE|2020-10-28|BEFORE|2020-11-05
e|RS|d62dc655-8865-4592-af0b-744524d9a24c|4|NTERESP|Non-Target Enhancing Response|MURPHY PROSTATE CANCER 1980|[?]|U/dL|CYTOGENETIC NO RESPONSE|1|GPL U/mL|RAJI CELL RIA||Y||FAMILY MEMBER|PHYSIOTHERAPIST|U|2|Visit_2|25|7|TREATMENT|2020-10-14|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-01|P1Y2M10DT2H30M|COINCIDENT|2020-09-28|COINCIDENT|2020-10-07
e|RS|d62dc655-8865-4592-af0b-744524d9a24c|5|HEMARESP|Hematologic Response|GUPPY OVARIAN CANCER 2002|[?]|mL/kg|CYTOGENETIC CR|1|breaths/30s|NUCLEIC ACID BASED METHOD||||DOMESTIC PARTNER|HEMATOLOGIST|NA|3|Visit_3|40|6|TREATMENT|2020-10-29|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-13|P1Y2M10DT2H30M|BEFORE|2020-11-14|BEFORE|2020-11-16
e|RS|d62dc655-8865-4592-af0b-744524d9a24c|6|STRUSTAT|Steroid Use Status|SCHWARZ CERVICAL CANCER 2009|||cPR|1|mEq/dL|FLOCCULATION|||Y|INDEPENDENT ASSESSOR|READER 3|N|3|Visit_3|40|3|SCREENING|2020-10-29|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-13|P1Y2M10DT2H30M|BEFORE|2020-11-16|BEFORE|2020-11-23
e|RS|d62dc655-8865-4592-af0b-744524d9a24c|7|TMRESP|Tumor Marker Response|MURPHY PROSTATE CANCER 1980|[?]|cmol|CYTOGENETIC PR|1|damol/L|DC SHEATH FLOW|Y|||ADJUDICATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|4|Visit_4|65|5|WASHOUT|2020-11-23|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-28|P1Y2M10DT2H30M|AFTER|2020-09-29|ONGOING|2020-11-10
e|RS|d62dc655-8865-4592-af0b-744524d9a24c|8|NEWLPROG|New Lesion Progression|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|||CR|1|nmol/mol|EEG|||Y|CLINICAL RESEARCH ASSOCIATE|PEDIATRIC NEUROLOGIST|Y|4|Visit_4|65|6|TREATMENT|2020-11-23|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-28|P1Y2M10DT2H30M|AFTER|2020-12-01|COINCIDENT|2020-12-10
e|RS|d62dc655-8865-4592-af0b-744524d9a24c|9|MNPTHIND|Minor Pathological Response Indicator|PALUMBO MULTIPLE MYELOMA 2009|[?]|mEq/uL|NED|1|C|MANUAL COUNT||||HEALTH CARE PROFESSIONAL|READER|U|5|Visit_5|90|7|TREATMENT|2020-12-18|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-06|P1Y2M10DT2H30M|COINCIDENT|2020-10-30|COINCIDENT|2020-12-27
e|RS|d62dc655-8865-4592-af0b-744524d9a24c|10|CYTORESP|Cytogenetic Response|PCWG SCHER PROSTATE CANCER 2016|[?]|cg|iPR|1|yd|SPECULAR MICROSCOPY|Y|||HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|U|5|Visit_5|90|6|TREATMENT|2020-12-18|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-06|P1Y2M10DT2H30M|UNKNOWN|2020-12-20|AFTER|2020-12-27
e|RS|6f2a59ba-1a8e-475f-b8c7-d8c6a9bf8b63|1|METSIND|Metastatic Indicator|CHOLLET BREAST CANCER 2002|[?]|mOsm|QUANTIFIABLE MRD POSITIVITY|1|cP|REBOUND TONOMETRY||||NON-HEALTH CARE PROFESSIONAL|READER 3|N|1|Visit_1|10|1|TREATMENT|2021-01-08|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-14|P1Y2M10DT2H30M|BEFORE|2021-01-15|ONGOING|2021-01-26
e|RS|6f2a59ba-1a8e-475f-b8c7-d8c6a9bf8b63|2|DRCRIND|Disease Recurrence Indicator|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|uIU/dL|RELAPSED DISEASE|1|log10 CCID 50/dose|MICROPARTICLE ENZYME IMMUNOASSAY||||SIBLING|PATHOLOGIST 1|U|1|Visit_1|10|6|SCREENING|2021-01-08|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-14|P1Y2M10DT2H30M|BEFORE|2021-01-18|AFTER|2021-02-14
e|RS|6f2a59ba-1a8e-475f-b8c7-d8c6a9bf8b63|3|CLINRESP|Clinical Response|BLAZER COLORECTAL CANCER 2008|[?]|pmol/10^9 cells|nPR|1|g/cage/day|THICK SMEAR||||CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 1|Y|2|Visit_2|25|6|WASHOUT|2021-01-23|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-27|P1Y2M10DT2H30M|UNKNOWN|2021-02-24|BEFORE|2021-04-02
e|RS|6f2a59ba-1a8e-475f-b8c7-d8c6a9bf8b63|4|SPLNRESP|Spleen Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|mph|STABLE|1|ug/h|AURAMINE STAIN||Y||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 3|U|2|Visit_2|25|6|FOLLOW-UP|2021-01-23|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-27|P1Y2M10DT2H30M|UNKNOWN|2021-03-27|ONGOING|2021-04-02
e|RS|6f2a59ba-1a8e-475f-b8c7-d8c6a9bf8b63|5|CPRFSTAT|Clinical Performance Status|DURIE MULTIPLE MYELOMA 2006|[?]|ug/g/h|MAJOR PATHOLOGIC RESPONSE|1|mL/m2|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION||||INTERVIEWER|CARDIOLOGIST|Y|3|Visit_3|40|7|WASHOUT|2021-02-07|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-24|P1Y2M10DT2H30M|BEFORE|2021-03-15|AFTER|2021-03-23
e|RS|6f2a59ba-1a8e-475f-b8c7-d8c6a9bf8b63|6|BMIVLIND|Bone Marrow Involvement Indicator|JACINTO CERVICAL CANCER 2007|[?]|U/dL|IMPROVED|1|10^9 organisms|NON-CONTACT SPECULAR MICROSCOPY|Y|Y||PARENT|MICROSCOPIST 1|Y|3|Visit_3|40|7|FOLLOW-UP|2021-02-07|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-24|P1Y2M10DT2H30M|AFTER|2021-02-18|COINCIDENT|2021-03-16
e|RS|6f2a59ba-1a8e-475f-b8c7-d8c6a9bf8b63|7|CLINRESP|Clinical Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|||CA125 75% RESPONSE|1|mg/h|SEQUENCING|||Y|FAMILY MEMBER|ONCOLOGIST|U|4|Visit_4|65|2|TREATMENT|2021-03-04|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-30|P1Y2M10DT2H30M|COINCIDENT|2021-01-20|AFTER|2021-03-10
e|RS|6f2a59ba-1a8e-475f-b8c7-d8c6a9bf8b63|8|NEWLPROG|New Lesion Progression|PETIT BREAST CANCER 2001|[?]|Absorbance U|NON-PD|1|STRIP|CELLULAR PROLIFERATION ASSAY||||ADJUDICATION COMMITTEE|ENDOCRINOLOGIST|NA|4|Visit_4|65|4|TREATMENT|2021-03-04|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-30|P1Y2M10DT2H30M|UNKNOWN|2021-03-02|ONGOING|2021-03-07
e|RS|6f2a59ba-1a8e-475f-b8c7-d8c6a9bf8b63|9|SPLNRESP|Spleen Response|HARTMANN GERM CELL CANCER 2002|[?]|mg/day|MORPHOLOGIC LEUKEMIA-FREE STATE|1|psec|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION||||CLINICAL STUDY SPONSOR|FORENSIC PATHOLOGIST|Y|5|Visit_5|90|2|TREATMENT|2021-03-29|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-06|P1Y2M10DT2H30M|COINCIDENT|2021-02-23|COINCIDENT|2021-03-23
e|RS|6f2a59ba-1a8e-475f-b8c7-d8c6a9bf8b63|10|HEMARESP|Hematologic Response|MACDONALD GLIOMA 1990|[?]|10^3/hpf|MORPHOLOGIC CRi|1|MBP|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|Y|Y||CLINICAL RESEARCH COORDINATOR|OTOLARYNGOLOGIST|U|5|Visit_5|90|3|TREATMENT|2021-03-29|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-06|P1Y2M10DT2H30M|COINCIDENT|2021-02-11|AFTER|2021-02-16
e|RS|8005bd56-3bd6-477a-a466-b9a3bd189770|1|NTRGRESP|Non-target Response|EASL BRUIX LIVER CANCER 2001|[?]|mph|MRD PERSISTENCE|1|deg2|CALCULATION|Y|||PROXY|FORENSIC PATHOLOGIST|NA|1|Visit_1|10|5|WASHOUT|2020-12-23|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-16|P1Y2M10DT2H30M|UNKNOWN|2021-03-19|COINCIDENT|2021-03-21
e|RS|8005bd56-3bd6-477a-a466-b9a3bd189770|2|METBRESP|Metabolic Response|HAMAOKA BREAST CANCER 2010|||MINOR PATHOLOGIC RESPONSE|1|Ci/g|BIOIMPEDANCE SPECTROSCOPY|||Y|PROXY|PHYSIOTHERAPIST|U|1|Visit_1|10|7|SCREENING|2020-12-23|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-16|P1Y2M10DT2H30M|COINCIDENT|2021-01-30|ONGOING|2021-02-16
e|RS|8005bd56-3bd6-477a-a466-b9a3bd189770|3|METSIND|Metastatic Indicator|RANO|||iCPD|1|uV*sec|SNELLEN EYE CHART|||Y|STUDY SUBJECT|NEUROLOGIST|N|2|Visit_2|25|7|TREATMENT|2021-01-07|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-22|P1Y2M10DT2H30M|UNKNOWN|2021-01-23|ONGOING|2021-03-01
e|RS|8005bd56-3bd6-477a-a466-b9a3bd189770|4|NTERESP|Non-Target Enhancing Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|mL/cage/day|CYTOGENETIC CR|1|kDa|PULMONARY ANGIOGRAPHY|Y|Y||SPOUSE|OPHTHALMOLOGIST|NA|2|Visit_2|25|6|TREATMENT|2021-01-07|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-22|P1Y2M10DT2H30M|COINCIDENT|2021-03-08|ONGOING|2021-03-15
e|RS|8005bd56-3bd6-477a-a466-b9a3bd189770|5|NTNERESP|Non-Target Non-Enhancing Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|uV2|WORSENED|1|IMPLANT|IN VITRO GENE EXPRESSION ASSAY||||PROXY|PHYSIOTHERAPIST|Y|3|Visit_3|40|6|WASHOUT|2021-01-22|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-20|P1Y2M10DT2H30M|COINCIDENT|2021-01-17|AFTER|2021-03-02
e|RS|8005bd56-3bd6-477a-a466-b9a3bd189770|6|TRGRESP|Target Response|RANO ELLINGSON 2017|[?]|ug/dose|MAJOR PATHOLOGIC RESPONSE|1|mkat|PATHOLOGICAL EVALUATION|Y|||PARENT|READER 1|Y|3|Visit_3|40|7|WASHOUT|2021-01-22|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-20|P1Y2M10DT2H30M|UNKNOWN|2021-01-07|ONGOING|2021-03-13
e|RS|8005bd56-3bd6-477a-a466-b9a3bd189770|7|MNPTHIND|Minor Pathological Response Indicator|MRECIST BYRNE MESOTHELIOMA 2004|[?]|10^7 CFU/mL|CYTOGENETIC MINOR RESPONSE|1|mL/dose|MACRO BROTH DILUTION||||CLINICAL RESEARCH COORDINATOR|PHYSIOTHERAPIST|NA|4|Visit_4|65|1|TREATMENT|2021-02-16|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-04|P1Y2M10DT2H30M|COINCIDENT|2021-02-08|BEFORE|2021-02-23
e|RS|8005bd56-3bd6-477a-a466-b9a3bd189770|8|NTNERESP|Non-Target Non-Enhancing Response|PERCIST|||NED|1|%/s|NEURAMINIDASE INHIBITION ASSAY|||Y|HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|NA|4|Visit_4|65|3|WASHOUT|2021-02-16|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-04|P1Y2M10DT2H30M|BEFORE|2021-03-02|BEFORE|2021-03-20
e|RS|8005bd56-3bd6-477a-a466-b9a3bd189770|9|OVRLRESP|Overall Response|BURCOMBE BREAST CANCER 2005|[?]|kUSP|MRD PERSISTENCE|1|WEEKS|MANUAL COUNT||Y||SIBLING|DEVELOPMENTAL PSYCHOLOGIST|NA|5|Visit_5|90|4|TREATMENT|2021-03-13|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-31|P1Y2M10DT2H30M|BEFORE|2021-02-02|ONGOING|2021-02-10
e|RS|8005bd56-3bd6-477a-a466-b9a3bd189770|10|TMRESP|Tumor Marker Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|Enzyme U|PD|1|cy/cm|PHOTOMETRY||||INTERVIEWER|OPTOMETRIST|Y|5|Visit_5|90|6|WASHOUT|2021-03-13|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-31|P1Y2M10DT2H30M|AFTER|2020-12-23|BEFORE|2021-01-05
e|RS|078ea33d-4114-4320-9116-740b8385a94e|1|CPRFSTAT|Clinical Performance Status|CHESON MALIGNANT LYMPHOMA 2007|[?]|kV|iCPD|1|Bq/uL|TONOMETRY||||PROXY|PATHOLOGIST 1|Y|1|Visit_1|10|6|TREATMENT|2020-07-26|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-18|P1Y2M10DT2H30M|BEFORE|2020-09-08|AFTER|2020-09-20
e|RS|078ea33d-4114-4320-9116-740b8385a94e|2|OVRLRESP|Overall Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|Coulomb|cCR|1|SFC/10^6 PBMC|CLINICAL EVALUATION||||CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|1|Visit_1|10|6|WASHOUT|2020-07-26|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-18|P1Y2M10DT2H30M|BEFORE|2020-09-16|BEFORE|2020-10-02
e|RS|078ea33d-4114-4320-9116-740b8385a94e|3|METSIND|Metastatic Indicator|RAJKUMAR MYELOMA 2011|[?]|mmol/mol|cCR|1|mm|PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY|Y|Y||HEALTH CARE PROFESSIONAL|READER 2|NA|2|Visit_2|25|7|WASHOUT|2020-08-10|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-13|P1Y2M10DT2H30M|UNKNOWN|2020-09-09|ONGOING|2020-09-29
e|RS|078ea33d-4114-4320-9116-740b8385a94e|4|NEWLPROG|New Lesion Progression|KEAM BREAST CANCER 2013|[?]|BU/mL|PR-CT|1|mL|NUCLEIC ACID AMPLIFICATION TEST||||INVESTIGATOR|PATHOLOGIST|N|2|Visit_2|25|5|WASHOUT|2020-08-10|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-13|P1Y2M10DT2H30M|COINCIDENT|2020-08-23|BEFORE|2020-09-23
e|RS|078ea33d-4114-4320-9116-740b8385a94e|5|MRDRESP|Minimal Residual Disease Response|WOLCHOK SOLID TUMORS 2009|[?]|mkat|iUPD|1|kV|DUKE INCISION METHOD||||ADJUDICATION COMMITTEE|NEUROLOGIST 2|N|3|Visit_3|40|7|FOLLOW-UP|2020-08-25|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-31|P1Y2M10DT2H30M|UNKNOWN|2020-08-07|AFTER|2020-09-16
e|RS|078ea33d-4114-4320-9116-740b8385a94e|6|CPRFSTAT|Clinical Performance Status|CHOI GIST 2008|||SD|1|oz|ANALYTICAL ULTRACENTRIFUGATION|||Y|SIGNIFICANT OTHER|RATER 2|U|3|Visit_3|40|6|TREATMENT|2020-08-25|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-31|P1Y2M10DT2H30M|COINCIDENT|2020-09-06|COINCIDENT|2020-09-15
e|RS|078ea33d-4114-4320-9116-740b8385a94e|7|NTERESP|Non-Target Enhancing Response|PCWG BUBLEY PROSTATE CANCER 1999|||DECREASED|1|DISK|IMMUNOTURBIDIMETRY|||Y|HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|U|4|Visit_4|65|1|SCREENING|2020-09-19|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-30|P1Y2M10DT2H30M|BEFORE|2020-09-20|ONGOING|2020-10-02
e|RS|078ea33d-4114-4320-9116-740b8385a94e|8|ANATRESP|Anatomic Response|LUGANO CLASSIFICATION|[?]|copies/uL|IMPROVED|1|ug/m2/min|CINEANGIOGRAPHY||||FAMILY MEMBER|OTOLARYNGOLOGIST|NA|4|Visit_4|65|3|FOLLOW-UP|2020-09-19|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-30|P1Y2M10DT2H30M|UNKNOWN|2020-09-18|BEFORE|2020-10-05
e|RS|078ea33d-4114-4320-9116-740b8385a94e|9|MRDIND|Minimal Residual Disease Indicator|PCWG SCHER PROSTATE CANCER 2016|[?]|pmol/10^10 cells|RELAPSED DISEASE FROM CR OR PR|1|kcal/day|MULTIPLEXED BEAD BASED IMMUNOASSAY|Y|||ADJUDICATOR|PHYSIOTHERAPIST|N|5|Visit_5|90|2|WASHOUT|2020-10-14|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-20|P1Y2M10DT2H30M|UNKNOWN|2020-09-27|COINCIDENT|2020-10-18
e|RS|078ea33d-4114-4320-9116-740b8385a94e|10|SYMPTDTR|Symptomatic Deterioration|GCIG RUSTIN OVARIAN CANCER 2011|[?]|ng/L|PD-CT|1|g/cage|IMMUNOFLUORESCENT STAIN|Y|Y||FAMILY MEMBER|MICROSCOPIST|N|5|Visit_5|90|4|TREATMENT|2020-10-14|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-20|P1Y2M10DT2H30M|COINCIDENT|2020-09-19|BEFORE|2020-09-29
e|RS|1ca91975-9a42-4f4d-9c55-53f7561d82fa|1|HEMARESP|Hematologic Response|EASL BRUIX LIVER CANCER 2001|||PSEUDOPROGRESSION|1|mL/cage|SISH|||Y|SIBLING|ONCOLOGIST 1|Y|1|Visit_1|10|7|TREATMENT|2020-06-03|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-08|P1Y2M10DT2H30M|UNKNOWN|2020-07-08|COINCIDENT|2020-07-25
e|RS|1ca91975-9a42-4f4d-9c55-53f7561d82fa|2|MRPHRESP|Morphologic Response|SHINDOH COLORECTAL CANCER 2013|||NE|1|mmol/g|ELECTRONEUROGRAPHY|Y|Y|Y|CAREGIVER|PHYSIOTHERAPIST|U|1|Visit_1|10|1|TREATMENT|2020-06-03|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-08|P1Y2M10DT2H30M|UNKNOWN|2020-07-25|COINCIDENT|2020-08-04
e|RS|1ca91975-9a42-4f4d-9c55-53f7561d82fa|3|SFTSRESP|Soft Tissue Response|CHOI GIST 2008|[?]|kg/cm2|OPTIMAL MORPHOLOGIC RESPONSE|1|ug/m2/min|SNELLEN EYE CHART|Y|Y||SPOUSE|HEMATOLOGIST|N|2|Visit_2|25|3|SCREENING|2020-06-18|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-20|P1Y2M10DT2H30M|BEFORE|2020-05-27|ONGOING|2020-05-30
e|RS|1ca91975-9a42-4f4d-9c55-53f7561d82fa|4|TRGRESP|Target Response|UNSPECIFIED|[?]|ug|PD/RELAPSE AFTER HI|1|10^9 CFU/g|HEMOCYTOMETRY||||ADJUDICATOR|OPHTHALMOLOGIST|U|2|Visit_2|25|2|WASHOUT|2020-06-18|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-20|P1Y2M10DT2H30M|BEFORE|2020-06-21|COINCIDENT|2020-07-18
e|RS|1ca91975-9a42-4f4d-9c55-53f7561d82fa|5|MNPTHIND|Minor Pathological Response Indicator|BURCOMBE BREAST CANCER 2005|[?]|uL|MOLECULAR MAJOR RESPONSE|1|BU/mL|PERIPHERAL ANGIOGRAPHY||||CAREGIVER|MICROSCOPIST|NA|3|Visit_3|40|5|WASHOUT|2020-07-03|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-29|P1Y2M10DT2H30M|AFTER|2020-06-09|ONGOING|2020-07-16
e|RS|1ca91975-9a42-4f4d-9c55-53f7561d82fa|6|METBRESP|Metabolic Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|mL/g/min|PR|1|pmol/10^10 cells|RADIATION DOSIMETRY||||PARENT|PEDIATRIC NEUROLOGIST|U|3|Visit_3|40|7|FOLLOW-UP|2020-07-03|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-29|P1Y2M10DT2H30M|BEFORE|2020-08-21|AFTER|2020-08-28
e|RS|1ca91975-9a42-4f4d-9c55-53f7561d82fa|7|NTLWIND|Non-Target Lesion Worsening Indicator|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|ug/g/min|FAVORABLE RESPONSE|1|DRINK|FARNSWORTH-MUNSELL 100 HUE TEST||||ADJUDICATION COMMITTEE|OPTOMETRIST|N|4|Visit_4|65|6|TREATMENT|2020-07-28|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-15|P1Y2M10DT2H30M|BEFORE|2020-08-05|ONGOING|2020-08-14
e|RS|1ca91975-9a42-4f4d-9c55-53f7561d82fa|8|BONERESP|Bone Response|LUGANO CLASSIFICATION|[?]|%(v/v)|DISEASE TRANSFORMATION|1|APL U|DIFFUSION TENSOR MRI||Y||INDEPENDENT ASSESSOR|OPHTHALMOLOGIST|Y|4|Visit_4|65|5|WASHOUT|2020-07-28|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-15|P1Y2M10DT2H30M|BEFORE|2020-07-14|AFTER|2020-08-25
e|RS|1ca91975-9a42-4f4d-9c55-53f7561d82fa|9|MNPTHIND|Minor Pathological Response Indicator|MRECIST LENCIONI LIVER CANCER 2010|[?]|CAPSULE|SD|1|mm3/mm2/year|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY||Y||ADJUDICATOR|READER 3|U|5|Visit_5|90|7|TREATMENT|2020-08-22|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-27|P1Y2M10DT2H30M|BEFORE|2020-07-17|ONGOING|2020-08-30
e|RS|1ca91975-9a42-4f4d-9c55-53f7561d82fa|10|BMIVLIND|Bone Marrow Involvement Indicator|SCHER PROSTATE CANCER 2011|||PMD|1|10^9 organisms/mL|URANYL ACETATE STAIN|Y||Y|GUARDIAN|ONCOLOGIST 1|U|5|Visit_5|90|6|TREATMENT|2020-08-22|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-27|P1Y2M10DT2H30M|COINCIDENT|2020-06-22|BEFORE|2020-07-22
e|RS|c5f292ad-1729-402b-820f-83ecd29ba00d|1|SPLNRESP|Spleen Response|HARTMAN PANCREATIC CANCER 2012|||ABSENT MORPHOLOGIC RESPONSE|1|uU/dL|PYROSEQUENCING|||Y|GUARDIAN|RATER 2|N|1|Visit_1|10|3|TREATMENT|2020-06-08|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-24|P1Y2M10DT2H30M|UNKNOWN|2020-08-29|ONGOING|2020-09-02
e|RS|c5f292ad-1729-402b-820f-83ecd29ba00d|2|CPRFSTAT|Clinical Performance Status|DOHNER AML 2010|[?]|DIP|CR|1|MBP|SPECTROPHOTOMETRY||Y||NON-HEALTH CARE PROFESSIONAL|READER|N|1|Visit_1|10|2|TREATMENT|2020-06-08|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-24|P1Y2M10DT2H30M|AFTER|2020-08-12|AFTER|2020-08-15
e|RS|c5f292ad-1729-402b-820f-83ecd29ba00d|3|MRDRESP|Minimal Residual Disease Response|SHINDOH COLORECTAL CANCER 2013|||INDETERMINATE RESPONSE|1|g/cage/wk|CLIP||Y|Y|FAMILY MEMBER|RATER 2|U|2|Visit_2|25|5|TREATMENT|2020-06-23|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-24|P1Y2M10DT2H30M|UNKNOWN|2020-07-06|AFTER|2020-08-04
e|RS|c5f292ad-1729-402b-820f-83ecd29ba00d|4|SYMPTDTR|Symptomatic Deterioration|RECICL|[?]|IU/mmol|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|uU/L|MRI WITHOUT CONTRAST||||FAMILY MEMBER|RADIOLOGIST 2|Y|2|Visit_2|25|6|SCREENING|2020-06-23|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-24|P1Y2M10DT2H30M|AFTER|2020-08-20|COINCIDENT|2020-08-27
e|RS|c5f292ad-1729-402b-820f-83ecd29ba00d|5|BMIVLIND|Bone Marrow Involvement Indicator|BRUGGEMANN MRD 2010|[?]|vg/dose|mCR|1|mMU/mL|NEXT GENERATION TARGETED SEQUENCING||Y||CHILD|PATHOLOGIST 1|U|3|Visit_3|40|6|FOLLOW-UP|2020-07-08|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-22|P1Y2M10DT2H30M|BEFORE|2020-08-11|BEFORE|2020-09-04
e|RS|c5f292ad-1729-402b-820f-83ecd29ba00d|6|MRDRESP|Minimal Residual Disease Response|DOHNER AML 2010|[?]|uIU/L|PR|1|mol|WESTERN BLOT||Y||ADJUDICATOR|READER 3|Y|3|Visit_3|40|5|WASHOUT|2020-07-08|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-22|P1Y2M10DT2H30M|AFTER|2020-06-10|COINCIDENT|2020-07-24
e|RS|c5f292ad-1729-402b-820f-83ecd29ba00d|7|NEWLWIND|New Lesion Worsening Indicator|EBMT BLADE MYELOMA 1998|||RELAPSED DISEASE FROM CR OR PR|1|mmol/min/kPa|DIRECT SEQUENCING|Y||Y|NON-HEALTH CARE PROFESSIONAL|RATER 1|NA|4|Visit_4|65|4|TREATMENT|2020-08-02|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-30|P1Y2M10DT2H30M|BEFORE|2020-08-23|ONGOING|2020-08-25
e|RS|c5f292ad-1729-402b-820f-83ecd29ba00d|8|NTRGRESP|Non-target Response|KUMAR IMWG 2016|||NON-PD|1|Ci/L|IMMUNOBLOT||Y|Y|PROXY|CLINICAL PATHOLOGIST|NA|4|Visit_4|65|4|TREATMENT|2020-08-02|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-30|P1Y2M10DT2H30M|UNKNOWN|2020-06-08|AFTER|2020-06-22
e|RS|c5f292ad-1729-402b-820f-83ecd29ba00d|9|MRDRESP|Minimal Residual Disease Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|ngEq/L|NED|1|ELISA unit/dose|HEMATOXYLIN AND EOSIN STAIN||Y||NON-HEALTH CARE PROFESSIONAL|READER 1|U|5|Visit_5|90|5|TREATMENT|2020-08-27|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-02|P1Y2M10DT2H30M|AFTER|2020-06-04|ONGOING|2020-06-20
e|RS|c5f292ad-1729-402b-820f-83ecd29ba00d|10|TMRESP|Tumor Marker Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|L/h|nPR|1|TRANSDUCING UNIT|ENDOSCOPY|Y|||DOMESTIC PARTNER|ADJUDICATOR 3|NA|5|Visit_5|90|5|TREATMENT|2020-08-27|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-02|P1Y2M10DT2H30M|AFTER|2020-06-03|COINCIDENT|2020-07-05
e|RS|a746aefb-16c8-43db-a0c4-8e9a4efdb244|1|HEMARESP|Hematologic Response|RAJKUMAR MYELOMA 2011|[?]|cP|IMPROVED|1|GPL U|FLUORIMETRY||||STUDY SUBJECT|RADIOLOGIST|U|1|Visit_1|10|1|TREATMENT|2020-06-27|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-04|P1Y2M10DT2H30M|AFTER|2020-07-07|BEFORE|2020-09-06
e|RS|a746aefb-16c8-43db-a0c4-8e9a4efdb244|2|ANATRESP|Anatomic Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|m/sec|DISEASE TRANSFORMATION|1|PHERESIS UNIT|IMMUNORADIOMETRIC ASSAY|Y|Y||DOMESTIC PARTNER|NEUROLOGIST|U|1|Visit_1|10|7|TREATMENT|2020-06-27|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-04|P1Y2M10DT2H30M|UNKNOWN|2020-07-22|ONGOING|2020-07-31
e|RS|a746aefb-16c8-43db-a0c4-8e9a4efdb244|3|LIVRRESP|Liver Response|CHOI GIST 2008|||UNFAVORABLE RESPONSE|1|ng/day|TOTAL BODY RADIOGRAPHY|||Y|FAMILY MEMBER|READER|Y|2|Visit_2|25|4|WASHOUT|2020-07-12|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-17|P1Y2M10DT2H30M|BEFORE|2020-07-01|COINCIDENT|2020-09-14
e|RS|a746aefb-16c8-43db-a0c4-8e9a4efdb244|4|NTNERESP|Non-Target Non-Enhancing Response|DURIE MULTIPLE MYELOMA 2006|[?]|mEq/g|MRD PERSISTENCE|1|vg/mL|SPIRAL CT||||FRIEND|PEDIATRIC NEUROLOGIST|Y|2|Visit_2|25|5|TREATMENT|2020-07-12|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-17|P1Y2M10DT2H30M|BEFORE|2020-07-08|COINCIDENT|2020-07-31
e|RS|a746aefb-16c8-43db-a0c4-8e9a4efdb244|5|MRPHRESP|Morphologic Response|KUKER LYMPHOMA 2005|[?]|IU/day|PR|1|scm|TRANSTHORACIC ECHOCARDIOGRAPHY||Y||CLINICAL STUDY SPONSOR|READER 3|NA|3|Visit_3|40|2|TREATMENT|2020-07-27|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-19|P1Y2M10DT2H30M|AFTER|2020-09-16|COINCIDENT|2020-09-20
e|RS|a746aefb-16c8-43db-a0c4-8e9a4efdb244|6|MOLRESP|Molecular Response|BLAZER COLORECTAL CANCER 2008|[?]|kBq/uL|CR-CT|1|mIU/L|MAGNETIC RESONANCE ANGIOGRAPHY||||CAREGIVER|ADJUDICATOR|Y|3|Visit_3|40|6|TREATMENT|2020-07-27|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-19|P1Y2M10DT2H30M|UNKNOWN|2020-07-07|COINCIDENT|2020-08-24
e|RS|a746aefb-16c8-43db-a0c4-8e9a4efdb244|7|CPRFSTAT|Clinical Performance Status|JACINTO CERVICAL CANCER 2007|[?]|g/mol|cPR|1|Pack Year|CYSTOMETRY||||INDEPENDENT ASSESSOR|DERMATOLOGIST|Y|4|Visit_4|65|2|WASHOUT|2020-08-21|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-19|P1Y2M10DT2H30M|BEFORE|2020-09-19|AFTER|2020-09-22
e|RS|a746aefb-16c8-43db-a0c4-8e9a4efdb244|8|MJPTHIND|Major Pathological Response Indicator|WOLCHOK SOLID TUMORS 2009|[?]|cmol/L|CYTOGENETIC MINIMAL RESPONSE|1|/mm2|CALCOFLUOR WHITE STAIN|Y|Y||ADJUDICATOR|CARDIOLOGIST|N|4|Visit_4|65|1|WASHOUT|2020-08-21|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-19|P1Y2M10DT2H30M|UNKNOWN|2020-08-28|BEFORE|2020-08-31
e|RS|a746aefb-16c8-43db-a0c4-8e9a4efdb244|9|STRUSTAT|Steroid Use Status|HARTMANN GERM CELL CANCER 2002|[?]|mL/cm H2O|MR|1|IU/mL|ECHOCARDIOGRAPHY|Y|||SPOUSE|UROLOGIST|Y|5|Visit_5|90|6|FOLLOW-UP|2020-09-15|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-05|P1Y2M10DT2H30M|BEFORE|2020-06-21|ONGOING|2020-07-16
e|RS|a746aefb-16c8-43db-a0c4-8e9a4efdb244|10|LIVRRESP|Liver Response|RECIST 1.0|[?]|mol|MAJOR PATHOLOGIC RESPONSE|1|U/mmol|DIGITAL PCR||||VENDOR|INTERNIST|N|5|Visit_5|90|2|TREATMENT|2020-09-15|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-05|P1Y2M10DT2H30M|COINCIDENT|2020-07-01|ONGOING|2020-07-21
e|RS|7f95b9c0-3b77-4c60-8890-ecc955f97122|1|NTRGRESP|Non-target Response|FAROOQUI SUPP CLL 2014|[?]|BISCUIT|MORPHOLOGIC CRi|1|10^3 organisms/g|ICC||Y||VENDOR|UROLOGIST|U|1|Visit_1|10|1|TREATMENT|2020-09-25|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-16|P1Y2M10DT2H30M|COINCIDENT|2020-12-18|BEFORE|2020-12-19
e|RS|7f95b9c0-3b77-4c60-8890-ecc955f97122|2|MNPTHIND|Minor Pathological Response Indicator|MRANO VAN DEN BENT GLIOMA 2011|[?]|cpm|PSEUDORESPONSE|1|/min|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION||||PROXY|READER 1|Y|1|Visit_1|10|3|FOLLOW-UP|2020-09-25|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-16|P1Y2M10DT2H30M|COINCIDENT|2020-10-22|ONGOING|2020-11-14
e|RS|7f95b9c0-3b77-4c60-8890-ecc955f97122|3|TRGRESP|Target Response|PERCIST|[?]|PFU/mL|HI-E|1|mmol/day|SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY||Y||SIGNIFICANT OTHER|ADJUDICATOR 1|U|2|Visit_2|25|2|TREATMENT|2020-10-10|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-24|P1Y2M10DT2H30M|COINCIDENT|2020-11-10|BEFORE|2020-12-18
e|RS|7f95b9c0-3b77-4c60-8890-ecc955f97122|4|LIVRRESP|Liver Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|/day|sCR|1|ugEq|KINYOUN STAIN||||GUARDIAN|CARDIOLOGIST|U|2|Visit_2|25|2|TREATMENT|2020-10-10|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-24|P1Y2M10DT2H30M|UNKNOWN|2020-11-15|AFTER|2020-12-16
e|RS|7f95b9c0-3b77-4c60-8890-ecc955f97122|5|SFTSRESP|Soft Tissue Response|PRINCE TCELL LYMPHOMA 2010|||HI-P|1|breaths/30s|TURBIDIMETRY|||Y|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 2|N|3|Visit_3|40|7|TREATMENT|2020-10-25|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-03|P1Y2M10DT2H30M|AFTER|2020-10-23|COINCIDENT|2020-11-21
e|RS|7f95b9c0-3b77-4c60-8890-ecc955f97122|6|SPLNRESP|Spleen Response|NCCN ALL MRD 2014|[?]|cg|STABLE|1|U/m2/h|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY|Y|||FRIEND|INTERNIST|Y|3|Visit_3|40|4|TREATMENT|2020-10-25|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-03|P1Y2M10DT2H30M|AFTER|2020-12-17|BEFORE|2020-12-18
e|RS|7f95b9c0-3b77-4c60-8890-ecc955f97122|7|METSIND|Metastatic Indicator|MACDONALD GLIOMA 1990|[?]|10^7 TCID 50/dose|DISEASE TRANSFORMATION|1|/kg|ISHIHARA COLOR PLATES||||DOMESTIC PARTNER|ADJUDICATOR|N|4|Visit_4|65|2|FOLLOW-UP|2020-11-19|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-18|P1Y2M10DT2H30M|COINCIDENT|2020-09-23|COINCIDENT|2020-12-16
e|RS|7f95b9c0-3b77-4c60-8890-ecc955f97122|8|METSIND|Metastatic Indicator|CHESON LYMPHOMA 2008|||NED|1|/200 HPFs|DC SHEATH FLOW|Y||Y|PARENT|MICROSCOPIST 1|U|4|Visit_4|65|6|FOLLOW-UP|2020-11-19|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-18|P1Y2M10DT2H30M|COINCIDENT|2020-11-20|ONGOING|2020-12-03
e|RS|7f95b9c0-3b77-4c60-8890-ecc955f97122|9|SPLNRESP|Spleen Response|IRANO 2015|[?]|10^9 CFU/g|PR-CT|1|ugEq|CONTRAST ENHANCED SPIRAL CT SCAN||||INVESTIGATOR|PATHOLOGIST 1|N|5|Visit_5|90|3|TREATMENT|2020-12-14|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-04|P1Y2M10DT2H30M|BEFORE|2020-09-22|BEFORE|2020-11-18
e|RS|7f95b9c0-3b77-4c60-8890-ecc955f97122|10|MNPTHIND|Minor Pathological Response Indicator|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|rpm|iCPD|1|anti-Xa IU/mL|RADIAL IMMUNODIFFUSION||Y||VENDOR|MICROSCOPIST 1|N|5|Visit_5|90|6|FOLLOW-UP|2020-12-14|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-04|P1Y2M10DT2H30M|COINCIDENT|2020-09-29|COINCIDENT|2020-12-02
e|RS|2be43c56-83f3-4148-9cb1-97c6d191d20e|1|MJPTHIND|Major Pathological Response Indicator|PERCIST|||RELAPSED DISEASE FROM CR|1|dyn|NEPHELOMETRY|Y|Y|Y|INDEPENDENT ASSESSOR|NEUROLOGIST|Y|1|Visit_1|10|5|FOLLOW-UP|2020-10-03|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-05|P1Y2M10DT2H30M|COINCIDENT|2020-10-28|BEFORE|2020-12-11
e|RS|2be43c56-83f3-4148-9cb1-97c6d191d20e|2|NTNERESP|Non-Target Non-Enhancing Response|RAJKUMAR MYELOMA 2011|||WORSENED|1|gMFI|FLUORESCENCE ANGIOGRAPHY|||Y|CLINICAL RESEARCH COORDINATOR|RATER 2|U|1|Visit_1|10|5|SCREENING|2020-10-03|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-05|P1Y2M10DT2H30M|COINCIDENT|2020-09-30|ONGOING|2020-10-26
e|RS|2be43c56-83f3-4148-9cb1-97c6d191d20e|3|MRDRESP|Minimal Residual Disease Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|QUANTITY SUFFICIENT|mCR|1|LENS|LIQUID SCINTILLATION COUNTING|Y|||CLINICAL STUDY SPONSOR|MICROSCOPIST|N|2|Visit_2|25|1|TREATMENT|2020-10-18|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-24|P1Y2M10DT2H30M|BEFORE|2020-11-17|ONGOING|2020-11-26
e|RS|2be43c56-83f3-4148-9cb1-97c6d191d20e|4|NTERESP|Non-Target Enhancing Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|10^4 CFU/mL|CYTOGENETIC MINIMAL RESPONSE|1|DNA copies/mL|ELECTROGASTROGRAPHY|Y|||GUARDIAN|OPHTHALMOLOGIST|NA|2|Visit_2|25|2|TREATMENT|2020-10-18|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-24|P1Y2M10DT2H30M|COINCIDENT|2020-10-16|BEFORE|2020-12-06
e|RS|2be43c56-83f3-4148-9cb1-97c6d191d20e|5|TMRESP|Tumor Marker Response|FAROOQUI SUPP CLL 2014|[?]|mL/m2/min|nPR|1|pmol|MANUAL CLOT DETECTION||||VENDOR|READER 2|Y|3|Visit_3|40|7|TREATMENT|2020-11-02|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-25|P1Y2M10DT2H30M|AFTER|2020-12-04|BEFORE|2020-12-18
e|RS|2be43c56-83f3-4148-9cb1-97c6d191d20e|6|NTRGRESP|Non-target Response|HARTMAN PANCREATIC CANCER 2012|||RELAPSED DISEASE|1|gpELISA unit/mL|TRANSMISSION ELECTRON MICROSCOPY||Y|Y|SIGNIFICANT OTHER|MICROSCOPIST 3|U|3|Visit_3|40|3|TREATMENT|2020-11-02|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-25|P1Y2M10DT2H30M|COINCIDENT|2020-10-03|COINCIDENT|2020-12-20
e|RS|2be43c56-83f3-4148-9cb1-97c6d191d20e|7|NTERESP|Non-Target Enhancing Response|CHESON CLL 2006|||MRD PERSISTENCE|1|KALLIKREIN INHIBITOR UNIT|JAFFE REACTION|||Y|PROXY|MICROSCOPIST 3|U|4|Visit_4|65|1|TREATMENT|2020-11-27|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-18|P1Y2M10DT2H30M|BEFORE|2020-10-12|AFTER|2020-10-21
e|RS|2be43c56-83f3-4148-9cb1-97c6d191d20e|8|OVRLRESP|Overall Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|gMFI|MORPHOLOGIC CRi|1|nkat|RAJI CELL EIA||||INTERVIEWER|DEVELOPMENTAL PSYCHOLOGIST|N|4|Visit_4|65|7|TREATMENT|2020-11-27|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-18|P1Y2M10DT2H30M|AFTER|2020-10-03|AFTER|2020-10-19
e|RS|2be43c56-83f3-4148-9cb1-97c6d191d20e|9|SYMPTDTR|Symptomatic Deterioration|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|cycle/min|NE|1|/day|SIZE EXCLUSION CHROMATOGRAPHY|Y|||VENDOR|OPHTHALMOLOGIST|N|5|Visit_5|90|6|WASHOUT|2020-12-22|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-29|P1Y2M10DT2H30M|AFTER|2020-11-20|AFTER|2020-12-26
e|RS|2be43c56-83f3-4148-9cb1-97c6d191d20e|10|NTNERESP|Non-Target Non-Enhancing Response|CHESON CLL 2006|||NON-PD|1|IU/L|SLIT LAMP|||Y|FRIEND|DEVELOPMENTAL PSYCHOLOGIST|N|5|Visit_5|90|2|FOLLOW-UP|2020-12-22|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-29|P1Y2M10DT2H30M|AFTER|2020-10-06|COINCIDENT|2020-12-12
e|RS|e27e0325-5fbe-46c0-8264-982d83124203|1|METSIND|Metastatic Indicator|RECIST 1.0|[?]|mmol2/L2|INCREASED|1|10^9 organisms/g|MICROBIAL CULTURE, SOLID|Y|||ADJUDICATION COMMITTEE|UROLOGIST|U|1|Visit_1|10|7|TREATMENT|2020-07-07|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-28|P1Y2M10DT2H30M|AFTER|2020-07-28|BEFORE|2020-08-16
e|RS|e27e0325-5fbe-46c0-8264-982d83124203|2|CPRFSTAT|Clinical Performance Status|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|Rad|PR|1|mg/kg/day|IMMUNOFLUORESCENT STAIN||||SPOUSE|ONCOLOGIST 2|U|1|Visit_1|10|7|FOLLOW-UP|2020-07-07|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-28|P1Y2M10DT2H30M|AFTER|2020-07-25|BEFORE|2020-09-13
e|RS|e27e0325-5fbe-46c0-8264-982d83124203|3|METSIND|Metastatic Indicator|PCWG SCHER PROSTATE CANCER 2008|[?]|mL|PMD|1|NEBULE|FLUOROSCOPY|Y|||INTERVIEWER|PEDIATRIC NEUROLOGIST|N|2|Visit_2|25|1|FOLLOW-UP|2020-07-22|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-31|P1Y2M10DT2H30M|UNKNOWN|2020-09-14|COINCIDENT|2020-09-24
e|RS|e27e0325-5fbe-46c0-8264-982d83124203|4|MOLRESP|Molecular Response|IWG CHESON MDS 2000|[?]|mmol/kg|NE|1|cm2|DARK FIELD MICROSCOPY||||GUARDIAN|RADIOLOGIST|Y|2|Visit_2|25|4|SCREENING|2020-07-22|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-31|P1Y2M10DT2H30M|COINCIDENT|2020-07-23|ONGOING|2020-10-02
e|RS|e27e0325-5fbe-46c0-8264-982d83124203|5|TRGRESP|Target Response|NCCN ALL MRD 2014|||EQUIVOCAL|1|ft|LASER CAPTURE MICRODISSECTION|Y||Y|ADJUDICATION COMMITTEE|PATHOLOGIST 1|Y|3|Visit_3|40|5|SCREENING|2020-08-06|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-31|P1Y2M10DT2H30M|BEFORE|2020-08-22|AFTER|2020-10-02
e|RS|e27e0325-5fbe-46c0-8264-982d83124203|6|TRGRESP|Target Response|KUKER LYMPHOMA 2005|[?]|/10^4|HI-N|1|COAT|CLIP||||PARENT|OPTOMETRIST|Y|3|Visit_3|40|4|TREATMENT|2020-08-06|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-31|P1Y2M10DT2H30M|UNKNOWN|2020-08-30|ONGOING|2020-09-08
e|RS|e27e0325-5fbe-46c0-8264-982d83124203|7|MRDRESP|Minimal Residual Disease Response|EASL BRUIX LIVER CANCER 2001|[?]|mm3/mm2/year|MOLECULAR CR|1|Coulomb|ECHOCARDIOGRAPHY||Y||NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 1|U|4|Visit_4|65|4|TREATMENT|2020-08-31|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-02|P1Y2M10DT2H30M|BEFORE|2020-10-03|ONGOING|2020-10-04
e|RS|e27e0325-5fbe-46c0-8264-982d83124203|8|NTNERESP|Non-Target Non-Enhancing Response|MURPHY PROSTATE CANCER 1980|||IMPROVED|1|usec|TOLUIDINE BLUE STAIN||Y|Y|SPOUSE|PHYSIOTHERAPIST|U|4|Visit_4|65|1|WASHOUT|2020-08-31|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-02|P1Y2M10DT2H30M|UNKNOWN|2020-08-01|AFTER|2020-09-08
e|RS|e27e0325-5fbe-46c0-8264-982d83124203|9|BMIVLIND|Bone Marrow Involvement Indicator|KUKER LYMPHOMA 2005|[?]|/10^3|OPTIMAL MORPHOLOGIC RESPONSE|1|10^9 organisms/mg|FLUORESCENT SPOT TEST||Y||DOMESTIC PARTNER|READER|NA|5|Visit_5|90|2|FOLLOW-UP|2020-09-25|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-27|P1Y2M10DT2H30M|BEFORE|2020-06-29|COINCIDENT|2020-07-11
e|RS|e27e0325-5fbe-46c0-8264-982d83124203|10|METBRESP|Metabolic Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|ms/mmHg|DISEASE TRANSFORMATION|1|PELLET|PUPILLOMETRY|Y|||VENDOR|MICROSCOPIST|NA|5|Visit_5|90|4|FOLLOW-UP|2020-09-25|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-27|P1Y2M10DT2H30M|COINCIDENT|2020-08-29|COINCIDENT|2020-09-06
e|RS|9ff51377-d75c-4c9a-aa45-f2f8d6f4ffbf|1|NTLWIND|Non-Target Lesion Worsening Indicator|EBMT BLADE MYELOMA 1998|[?]|ppth|PD-CT|1|GPL U|DC SHEATH FLOW|Y|||CLINICAL RESEARCH ASSOCIATE|DERMATOLOGIST|Y|1|Visit_1|10|4|TREATMENT|2020-12-19|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-30|P1Y2M10DT2H30M|COINCIDENT|2021-02-04|ONGOING|2021-03-11
e|RS|9ff51377-d75c-4c9a-aa45-f2f8d6f4ffbf|2|CPRFSTAT|Clinical Performance Status|PETIT BREAST CANCER 2001|[?]|BAU|MRD PERSISTENCE|1|mg/L|KINYOUN STAIN||||ADJUDICATOR|DEVELOPMENTAL PSYCHOLOGIST|NA|1|Visit_1|10|4|WASHOUT|2020-12-19|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-30|P1Y2M10DT2H30M|UNKNOWN|2020-12-20|BEFORE|2021-01-24
e|RS|9ff51377-d75c-4c9a-aa45-f2f8d6f4ffbf|3|MRPHRESP|Morphologic Response|RAJKUMAR MYELOMA 2011|[?]|10^4/hpf|MINOR PATHOLOGIC RESPONSE|1|Watt|OPTICAL DENSITY MEASUREMENT||Y||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|N|2|Visit_2|25|6|WASHOUT|2021-01-03|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-16|P1Y2M10DT2H30M|COINCIDENT|2021-01-24|AFTER|2021-02-03
e|RS|9ff51377-d75c-4c9a-aa45-f2f8d6f4ffbf|4|TRGRESP|Target Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|mol/mg|PD/RELAPSE AFTER HI|1|vp/dose|KLEIHAUER-BETKE||Y||PARENT|INTERNIST|N|2|Visit_2|25|5|TREATMENT|2021-01-03|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-16|P1Y2M10DT2H30M|AFTER|2021-02-02|ONGOING|2021-02-12
e|RS|9ff51377-d75c-4c9a-aa45-f2f8d6f4ffbf|5|MRPHRESP|Morphologic Response|RAJKUMAR MYELOMA 2011|[?]|g/m2|WORSENED|1|U/cL|ELECTRICAL IMPEDANCE MYOGRAPHY||||VENDOR|READER|U|3|Visit_3|40|5|TREATMENT|2021-01-18|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-25|P1Y2M10DT2H30M|BEFORE|2020-12-18|COINCIDENT|2021-01-26
e|RS|9ff51377-d75c-4c9a-aa45-f2f8d6f4ffbf|6|CPRFSTAT|Clinical Performance Status|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|PFU/dose|CMR|1|AU/mL|TRANSMISSION ELECTRON MICROSCOPY||||ADJUDICATION COMMITTEE|PEDIATRIC NEUROLOGIST|U|3|Visit_3|40|4|TREATMENT|2021-01-18|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-25|P1Y2M10DT2H30M|COINCIDENT|2021-03-11|AFTER|2021-03-14
e|RS|9ff51377-d75c-4c9a-aa45-f2f8d6f4ffbf|7|NTRGRESP|Non-target Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|U/mg|iSD|1|mg/g/h|OBSERVATION|Y|Y||CLINICAL STUDY SPONSOR|ADJUDICATOR 3|N|4|Visit_4|65|7|WASHOUT|2021-02-12|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-19|P1Y2M10DT2H30M|BEFORE|2021-01-11|BEFORE|2021-01-25
e|RS|9ff51377-d75c-4c9a-aa45-f2f8d6f4ffbf|8|BESTRESP|Best Overall Response|EBMT BLADE MYELOMA 1998|||PMD|1|mL/sec/1.73m2|TRANSVAGINAL ULTRASOUND|||Y|STUDY SUBJECT|RATER|Y|4|Visit_4|65|3|TREATMENT|2021-02-12|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-19|P1Y2M10DT2H30M|COINCIDENT|2020-12-14|BEFORE|2021-03-01
e|RS|9ff51377-d75c-4c9a-aa45-f2f8d6f4ffbf|9|NTERESP|Non-Target Enhancing Response|IWG CHESON MDS 2006|[?]|Bq/g|iSD|1|in2|MODIFIED ACID FAST STAIN||||DOMESTIC PARTNER|INTERNIST|N|5|Visit_5|90|4|TREATMENT|2021-03-09|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-08|P1Y2M10DT2H30M|COINCIDENT|2021-02-28|AFTER|2021-03-15
e|RS|9ff51377-d75c-4c9a-aa45-f2f8d6f4ffbf|10|NEWLWIND|New Lesion Worsening Indicator|KUMAR IMWG 2016|[?]|PUFF|sCR|1|CAPLET|PET/MRI SCAN||||HEALTH CARE PROFESSIONAL|READER 2|N|5|Visit_5|90|1|WASHOUT|2021-03-09|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-08|P1Y2M10DT2H30M|BEFORE|2020-12-12|COINCIDENT|2020-12-30
e|RS|29e08650-9eae-461f-981e-f2a20d8d4492|1|LIVRRESP|Liver Response|MRECIST LENCIONI LIVER CANCER 2010|||COMPLETE MRD RESPONSE|1|fg|MICRODENSITOMETRY||Y|Y|SIBLING|RADIOLOGIST 2|NA|1|Visit_1|10|6|SCREENING|2020-11-17|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-15|P1Y2M10DT2H30M|AFTER|2021-02-02|BEFORE|2021-02-08
e|RS|29e08650-9eae-461f-981e-f2a20d8d4492|2|METBRESP|Metabolic Response|RECIST 1.0|||MORPHOLOGIC CR|1|KIT|POPULATION SEQUENCING||Y|Y|FRIEND|READER 2|U|1|Visit_1|10|3|SCREENING|2020-11-17|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-15|P1Y2M10DT2H30M|COINCIDENT|2020-11-30|BEFORE|2021-02-05
e|RS|29e08650-9eae-461f-981e-f2a20d8d4492|3|NEWLIND|New Lesion Indicator|JACINTO CERVICAL CANCER 2007|||PSEUDOPROGRESSION|1|ugEq|THIN SMEAR|Y|Y|Y|PARENT|UROLOGIST|NA|2|Visit_2|25|7|SCREENING|2020-12-02|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-01|P1Y2M10DT2H30M|AFTER|2021-01-10|BEFORE|2021-02-04
e|RS|29e08650-9eae-461f-981e-f2a20d8d4492|4|ANATRESP|Anatomic Response|SCHWARZ CERVICAL CANCER 2009|[?]|uOsm|CR|1|ms2|NO INFORMATION||Y||CHILD|ADJUDICATOR 2|N|2|Visit_2|25|2|TREATMENT|2020-12-02|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-01|P1Y2M10DT2H30M|AFTER|2020-11-30|AFTER|2021-01-13
e|RS|29e08650-9eae-461f-981e-f2a20d8d4492|5|NTLWIND|Non-Target Lesion Worsening Indicator|MASS|[?]|Roentgen|PR-CT|1|10^6 CFU/g|QUANTITATIVE PERIPHERAL ANGIOGRAPHY||||FRIEND|ONCOLOGIST 2|Y|3|Visit_3|40|4|TREATMENT|2020-12-17|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-14|P1Y2M10DT2H30M|UNKNOWN|2020-12-21|AFTER|2021-02-06
e|RS|29e08650-9eae-461f-981e-f2a20d8d4492|6|NEWLWIND|New Lesion Worsening Indicator|JACINTO CERVICAL CANCER 2007|[?]|Ci/mg|HI-E|1|um/day|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION||||SIGNIFICANT OTHER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|3|Visit_3|40|1|FOLLOW-UP|2020-12-17|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-14|P1Y2M10DT2H30M|UNKNOWN|2021-02-03|COINCIDENT|2021-02-14
e|RS|29e08650-9eae-461f-981e-f2a20d8d4492|7|SPLNRESP|Spleen Response|MRECIST BYRNE MESOTHELIOMA 2004|||NR|1|U/animal|HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY|||Y|SIGNIFICANT OTHER|RADIOLOGIST 1|NA|4|Visit_4|65|6|TREATMENT|2021-01-11|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-22|P1Y2M10DT2H30M|AFTER|2020-11-17|COINCIDENT|2020-12-10
e|RS|29e08650-9eae-461f-981e-f2a20d8d4492|8|CYTORESP|Cytogenetic Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|Arbitrary U|RELAPSED DISEASE FROM CR OR PR|1|dB|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN||||SIGNIFICANT OTHER|PHYSIOTHERAPIST|Y|4|Visit_4|65|3|SCREENING|2021-01-11|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-22|P1Y2M10DT2H30M|BEFORE|2021-01-05|COINCIDENT|2021-01-30
e|RS|29e08650-9eae-461f-981e-f2a20d8d4492|9|OVRLRESP|Overall Response|IWC HALLEK CLL 2008|[?]|m|VGPR|1|kPa/L/sec|SPIRAL CT SCAN WITHOUT CONTRAST||||CHILD|ADJUDICATOR|U|5|Visit_5|90|4|TREATMENT|2021-02-05|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-27|P1Y2M10DT2H30M|COINCIDENT|2021-01-11|COINCIDENT|2021-02-03
e|RS|29e08650-9eae-461f-981e-f2a20d8d4492|10|NTLWIND|Non-Target Lesion Worsening Indicator|IWC HALLEK CLL 2008|[?]|ug/cm2|iCPD|1|mL/g/h|ELECTROMYOGRAPHY||||STUDY SUBJECT|PEDIATRIC NEUROLOGIST|NA|5|Visit_5|90|6|TREATMENT|2021-02-05|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-27|P1Y2M10DT2H30M|AFTER|2021-02-07|BEFORE|2021-02-13
e|RS|2b944a62-10bc-475e-a90d-da3f07a2c4df|1|DRCRIND|Disease Recurrence Indicator|MURPHY PROSTATE CANCER 1980|[?]|Hounsfield Unit|PDu|1|kDa|CELLULOSE TAPE|Y|||NON-HEALTH CARE PROFESSIONAL|OPTOMETRIST|NA|1|Visit_1|10|1|SCREENING|2020-09-01|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-26|P1Y2M10DT2H30M|AFTER|2020-10-29|COINCIDENT|2020-11-14
e|RS|2b944a62-10bc-475e-a90d-da3f07a2c4df|2|TRGRESP|Target Response|BURCOMBE BREAST CANCER 2005|[?]|mU/L|sCR|1|mL/kg/day|TOTAL BODY IRRADIATION||||ADJUDICATOR|MICROSCOPIST 1|Y|1|Visit_1|10|1|FOLLOW-UP|2020-09-01|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-26|P1Y2M10DT2H30M|UNKNOWN|2020-09-22|COINCIDENT|2020-11-18
e|RS|2b944a62-10bc-475e-a90d-da3f07a2c4df|3|NEWLWIND|New Lesion Worsening Indicator|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|mmol/min/kPa|MOLECULAR MAJOR RESPONSE|1|ng/dL|LIGHT MICROSCOPY||||GUARDIAN|READER 3|U|2|Visit_2|25|3|SCREENING|2020-09-16|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-07|P1Y2M10DT2H30M|UNKNOWN|2020-09-25|ONGOING|2020-11-01
e|RS|2b944a62-10bc-475e-a90d-da3f07a2c4df|4|MNPTHIND|Minor Pathological Response Indicator|MRECIST BYRNE MESOTHELIOMA 2004|[?]|mg/mL/min|NON-CR/NON-PD|1|mL/beat|EEG|Y|||GUARDIAN|OPHTHALMOLOGIST|Y|2|Visit_2|25|6|WASHOUT|2020-09-16|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-07|P1Y2M10DT2H30M|UNKNOWN|2020-09-23|AFTER|2020-11-11
e|RS|2b944a62-10bc-475e-a90d-da3f07a2c4df|5|BONERESP|Bone Response|GUILHOT CML 2007|[?]|Bq/L|TREATMENT FAILURE|1|Ci/uL|NEURAMINIDASE INHIBITION ASSAY||||DOMESTIC PARTNER|RADIOLOGIST 2|NA|3|Visit_3|40|1|TREATMENT|2020-10-01|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-24|P1Y2M10DT2H30M|BEFORE|2020-11-02|AFTER|2020-11-21
e|RS|2b944a62-10bc-475e-a90d-da3f07a2c4df|6|CPRFSTAT|Clinical Performance Status|KUKER LYMPHOMA 2005|[?]|g/day|CMR|1|umol|NEURAMINIDASE INHIBITION ASSAY|Y|||INTERVIEWER|ONCOLOGIST 1|Y|3|Visit_3|40|1|WASHOUT|2020-10-01|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-24|P1Y2M10DT2H30M|COINCIDENT|2020-09-29|ONGOING|2020-10-31
e|RS|2b944a62-10bc-475e-a90d-da3f07a2c4df|7|DRCRIND|Disease Recurrence Indicator|CHOI GIST 2008|[?]|IU/g|INCREASED|1|nU/cL|DIRECT SEQUENCING||||SIGNIFICANT OTHER|OPTOMETRIST|NA|4|Visit_4|65|4|SCREENING|2020-10-26|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-13|P1Y2M10DT2H30M|UNKNOWN|2020-11-19|COINCIDENT|2020-11-26
e|RS|2b944a62-10bc-475e-a90d-da3f07a2c4df|8|SYMPTDTR|Symptomatic Deterioration|HARTMAN PANCREATIC CANCER 2012|[?]|CCID 50/dose|CR-CT|1|POINT|KINYOUN STAIN|Y|||SIGNIFICANT OTHER|ENDOCRINOLOGIST|U|4|Visit_4|65|5|SCREENING|2020-10-26|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-13|P1Y2M10DT2H30M|BEFORE|2020-09-28|ONGOING|2020-11-09
e|RS|2b944a62-10bc-475e-a90d-da3f07a2c4df|9|CLINRESP|Clinical Response|RANO ELLINGSON 2017|[?]|10^9 organisms/mg|CHR|1|mmol/day|ACID FAST STAIN||||SIBLING|READER 3|Y|5|Visit_5|90|7|TREATMENT|2020-11-20|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-07|P1Y2M10DT2H30M|BEFORE|2020-10-09|BEFORE|2020-10-11
e|RS|2b944a62-10bc-475e-a90d-da3f07a2c4df|10|STRUSTAT|Steroid Use Status|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|||OPTIMAL MORPHOLOGIC RESPONSE|1|g/mol|CONFOCAL MICROSCOPY|||Y|CAREGIVER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|5|Visit_5|90|3|FOLLOW-UP|2020-11-20|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-07|P1Y2M10DT2H30M|AFTER|2020-08-30|BEFORE|2020-09-13
e|RS|d6e51edb-0983-4ffb-b5a6-59afc2696ce8|1|ANATRESP|Anatomic Response|KUMAR IMWG 2016|[?]|mmol2/L2|NON-PD|1|PIXELS/in|OLIGO ACGH|Y|||ADJUDICATOR|PEDIATRIC NEUROLOGIST|N|1|Visit_1|10|3|FOLLOW-UP|2020-09-09|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-24|P1Y2M10DT2H30M|UNKNOWN|2020-12-03|BEFORE|2020-12-04
e|RS|d6e51edb-0983-4ffb-b5a6-59afc2696ce8|2|CYTORESP|Cytogenetic Response|DOHNER AML 2010|[?]|EID 50/dose|NED|1|PHERESIS UNIT|ELASTOGRAPHY||Y||CHILD|ONCOLOGIST|Y|1|Visit_1|10|7|SCREENING|2020-09-09|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-24|P1Y2M10DT2H30M|UNKNOWN|2020-11-24|ONGOING|2020-11-28
e|RS|d6e51edb-0983-4ffb-b5a6-59afc2696ce8|3|DRCRIND|Disease Recurrence Indicator|SACT|||NON-CR/NON-PD|1|BOLUS|WESTERN BLOT|||Y|ADJUDICATOR|UROLOGIST|NA|2|Visit_2|25|4|WASHOUT|2020-09-24|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-31|P1Y2M10DT2H30M|COINCIDENT|2020-11-17|AFTER|2020-11-23
e|RS|d6e51edb-0983-4ffb-b5a6-59afc2696ce8|4|NTLWIND|Non-Target Lesion Worsening Indicator|DOHNER AML 2010|||CMR|1|kN/cm2|OSCILLOMETRY|||Y|STUDY SUBJECT|MICROSCOPIST 2|N|2|Visit_2|25|3|FOLLOW-UP|2020-09-24|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-31|P1Y2M10DT2H30M|COINCIDENT|2020-12-05|COINCIDENT|2020-12-07
e|RS|d6e51edb-0983-4ffb-b5a6-59afc2696ce8|5|NTERESP|Non-Target Enhancing Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|/LSQN|pCR|1|Ci|ULTRASONOGRAPHIC ELASTOGRAPHY|Y|||SPOUSE|MICROSCOPIST 3|Y|3|Visit_3|40|3|TREATMENT|2020-10-09|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-05|P1Y2M10DT2H30M|BEFORE|2020-09-18|COINCIDENT|2020-09-25
e|RS|d6e51edb-0983-4ffb-b5a6-59afc2696ce8|6|BONERESP|Bone Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|||PD-CT|1|mmol/kg|HANSEL STAIN|Y||Y|INVESTIGATOR|FORENSIC PATHOLOGIST|U|3|Visit_3|40|6|TREATMENT|2020-10-09|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-05|P1Y2M10DT2H30M|COINCIDENT|2020-10-04|COINCIDENT|2020-12-02
e|RS|d6e51edb-0983-4ffb-b5a6-59afc2696ce8|7|CPRFSTAT|Clinical Performance Status|FAROOQUI SUPP CLL 2014|[?]|lx|ABSENT MORPHOLOGIC RESPONSE|1|mph|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI||||SIBLING|RADIOLOGIST 1|N|4|Visit_4|65|4|TREATMENT|2020-11-03|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-20|P1Y2M10DT2H30M|BEFORE|2020-09-28|BEFORE|2020-10-04
e|RS|d6e51edb-0983-4ffb-b5a6-59afc2696ce8|8|ANATRESP|Anatomic Response|IWG CHESON AML 2003|[?]|mV|MRD RELAPSE|1|hr/day|WESTERN BLOT||||CLINICAL RESEARCH ASSOCIATE|CLINICAL PATHOLOGIST|N|4|Visit_4|65|2|WASHOUT|2020-11-03|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-20|P1Y2M10DT2H30M|AFTER|2020-10-08|ONGOING|2020-12-06
e|RS|d6e51edb-0983-4ffb-b5a6-59afc2696ce8|9|MNPTHIND|Minor Pathological Response Indicator|KUMAR IMWG 2016|[?]|uSiemens|OPTIMAL MORPHOLOGIC RESPONSE|1|deg/s|DYNAMIC LIGHT SCATTERING||||INVESTIGATOR|OPTOMETRIST|Y|5|Visit_5|90|1|SCREENING|2020-11-28|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-04|P1Y2M10DT2H30M|BEFORE|2020-11-18|ONGOING|2020-11-28
e|RS|d6e51edb-0983-4ffb-b5a6-59afc2696ce8|10|ANATRESP|Anatomic Response|RECIST 1.1|[?]|nmol/L/h|NON-iCR/NON-iUPD|1|10^7 CFU|ENZYMATIC SPECTROPHOTOMETRY||Y||NON-HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|NA|5|Visit_5|90|5|FOLLOW-UP|2020-11-28|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-04|P1Y2M10DT2H30M|UNKNOWN|2020-10-05|BEFORE|2020-11-07
e|RS|8aa77db3-b078-4073-a7f3-9b9a7fb14570|1|MNPTHIND|Minor Pathological Response Indicator|RANO|[?]|MASK|NON-CR/NON-PD|1|umol/h/mmol|RADIATION DOSIMETRY||||ADJUDICATOR|CLINICAL PATHOLOGIST|NA|1|Visit_1|10|5|SCREENING|2020-11-12|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-30|P1Y2M10DT2H30M|BEFORE|2020-12-23|BEFORE|2021-01-29
e|RS|8aa77db3-b078-4073-a7f3-9b9a7fb14570|2|ANATRESP|Anatomic Response|BLAZER COLORECTAL CANCER 2008|[?]|mL/s/m2|CYTOGENETIC PR|1|U/animal|CELL BASED BIOASSAY||Y||CLINICAL RESEARCH ASSOCIATE|HEMATOLOGIST|NA|1|Visit_1|10|2|TREATMENT|2020-11-12|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-30|P1Y2M10DT2H30M|BEFORE|2020-11-17|BEFORE|2020-11-29
e|RS|8aa77db3-b078-4073-a7f3-9b9a7fb14570|3|LIVRRESP|Liver Response|DURIE MULTIPLE MYELOMA 2006|[?]|foz_us|VGPR|1|10^3 CFU/g|IMMUNOTURBIDIMETRY||Y||ADJUDICATOR|RATER 1|Y|2|Visit_2|25|1|TREATMENT|2020-11-27|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-31|P1Y2M10DT2H30M|COINCIDENT|2020-11-09|COINCIDENT|2021-01-22
e|RS|8aa77db3-b078-4073-a7f3-9b9a7fb14570|4|CYTORESP|Cytogenetic Response|PETIT BREAST CANCER 2001|[?]|10^12 IU/L|nPR|1|FIU|FLOW MICROSCOPY||||SIBLING|PATHOLOGIST 1|N|2|Visit_2|25|1|TREATMENT|2020-11-27|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-31|P1Y2M10DT2H30M|AFTER|2020-12-30|COINCIDENT|2021-01-09
e|RS|8aa77db3-b078-4073-a7f3-9b9a7fb14570|5|MNPTHIND|Minor Pathological Response Indicator|AJCC V7|[?]|/5x10^4 WBC|MINOR PATHOLOGIC RESPONSE|1|mol/day|HPLC/MS/MS|Y|||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 1|Y|3|Visit_3|40|6|SCREENING|2020-12-12|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-08|P1Y2M10DT2H30M|BEFORE|2020-12-15|COINCIDENT|2021-02-06
e|RS|8aa77db3-b078-4073-a7f3-9b9a7fb14570|6|TRGRESP|Target Response|BRUGGEMANN MRD 2010|[?]|m2|cPR|1|Hounsfield Unit|COULOMETRIC TITRATION||Y||INDEPENDENT ASSESSOR|FORENSIC PATHOLOGIST|Y|3|Visit_3|40|7|SCREENING|2020-12-12|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-08|P1Y2M10DT2H30M|AFTER|2020-12-18|BEFORE|2021-01-16
e|RS|8aa77db3-b078-4073-a7f3-9b9a7fb14570|7|MRPHRESP|Morphologic Response|IWG CHESON MDS 2000|[?]|AgU/mL|MR|1|mV2/Hz|EPSILOMETER||||CAREGIVER|OTOLARYNGOLOGIST|N|4|Visit_4|65|7|TREATMENT|2021-01-06|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-08|P1Y2M10DT2H30M|AFTER|2021-01-17|COINCIDENT|2021-01-29
e|RS|8aa77db3-b078-4073-a7f3-9b9a7fb14570|8|MRPHRESP|Morphologic Response|LUGANO CLASSIFICATION|[?]|cmH2O*s2/mL|NE|1|GBq/g|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY||||HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|N|4|Visit_4|65|3|TREATMENT|2021-01-06|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-08|P1Y2M10DT2H30M|UNKNOWN|2020-12-23|AFTER|2020-12-24
e|RS|8aa77db3-b078-4073-a7f3-9b9a7fb14570|9|NEWLPROG|New Lesion Progression|NCCN ALL MRD 2014|||CYTOGENETIC PR|1|10^9/dose|ANTIBIOTIC AGAR SCREEN|Y||Y|ADJUDICATION COMMITTEE|ADJUDICATOR|NA|5|Visit_5|90|1|TREATMENT|2021-01-31|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-11|P1Y2M10DT2H30M|BEFORE|2020-11-22|BEFORE|2021-01-24
e|RS|8aa77db3-b078-4073-a7f3-9b9a7fb14570|10|MJPTHIND|Major Pathological Response Indicator|WOLCHOK SOLID TUMORS 2009|[?]|foz_br|COMPLETE MRD RESPONSE|1|keV|FARR ASSAY||||INTERVIEWER|HEMATOLOGIST|U|5|Visit_5|90|2|WASHOUT|2021-01-31|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-11|P1Y2M10DT2H30M|COINCIDENT|2020-11-18|COINCIDENT|2021-01-08
e|RS|1fce031b-680b-414f-9b74-d6383e10091d|1|LIVRRESP|Liver Response|PERCIST|[?]|K|MOLECULAR CR|1|mol/mg|WRIGHT-GIEMSA STAIN||||CLINICAL STUDY SPONSOR|PATHOLOGIST 1|Y|1|Visit_1|10|4|TREATMENT|2020-05-31|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-01|P1Y2M10DT2H30M|COINCIDENT|2020-08-06|BEFORE|2020-08-07
e|RS|1fce031b-680b-414f-9b74-d6383e10091d|2|SFTSRESP|Soft Tissue Response|AJCC V7|[?]|ng/dL|ABSENT MORPHOLOGIC RESPONSE|1|CAPFUL|FORCED OSCILLATION TECHNIQUE|Y|||ADJUDICATOR|OPTOMETRIST|NA|1|Visit_1|10|7|TREATMENT|2020-05-31|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-01|P1Y2M10DT2H30M|UNKNOWN|2020-08-14|AFTER|2020-08-20
e|RS|1fce031b-680b-414f-9b74-d6383e10091d|3|PATHRESP|Pathologic Response|KUKER LYMPHOMA 2005|[?]|deg/s|MRD NEGATIVITY|1|MET*min|DIGITAL PCR ARRAY|Y|||ADJUDICATOR|UROLOGIST|U|2|Visit_2|25|2|TREATMENT|2020-06-15|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-02|P1Y2M10DT2H30M|AFTER|2020-06-11|ONGOING|2020-06-23
e|RS|1fce031b-680b-414f-9b74-d6383e10091d|4|MOLRESP|Molecular Response|SACT|[?]|PHERESIS UNIT|NOT ALL EVALUATED|1|L/s|SLOAN LETTER EYE CHART 100%||||SIGNIFICANT OTHER|PHYSIOTHERAPIST|U|2|Visit_2|25|4|TREATMENT|2020-06-15|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-02|P1Y2M10DT2H30M|BEFORE|2020-06-28|COINCIDENT|2020-07-12
e|RS|1fce031b-680b-414f-9b74-d6383e10091d|5|ANATRESP|Anatomic Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|IU/g Hb|SD-CT|1|10^6 CFU|PELLI-ROBSON EYE CHART||Y||PARENT|MICROSCOPIST 1|N|3|Visit_3|40|1|FOLLOW-UP|2020-06-30|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-21|P1Y2M10DT2H30M|COINCIDENT|2020-07-13|BEFORE|2020-07-24
e|RS|1fce031b-680b-414f-9b74-d6383e10091d|6|ANATRESP|Anatomic Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|v/v|RELAPSED DISEASE|1|g/animal|MRI WITHOUT CONTRAST||||INTERVIEWER|NEUROLOGIST 1|NA|3|Visit_3|40|1|TREATMENT|2020-06-30|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-21|P1Y2M10DT2H30M|AFTER|2020-05-28|BEFORE|2020-07-05
e|RS|1fce031b-680b-414f-9b74-d6383e10091d|7|MNPTHIND|Minor Pathological Response Indicator|IWC HALLEK CLL 2008|||HI-E|1|Pa|ICP-MS|||Y|PROXY|NEUROLOGIST 2|Y|4|Visit_4|65|3|SCREENING|2020-07-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-27|P1Y2M10DT2H30M|AFTER|2020-07-20|AFTER|2020-08-28
e|RS|1fce031b-680b-414f-9b74-d6383e10091d|8|NEWLWIND|New Lesion Worsening Indicator|SCHWARZ CERVICAL CANCER 2009|||sCR|1|10^3 CFU|FLOW CYTOMETRY|||Y|CAREGIVER|NEUROLOGIST|Y|4|Visit_4|65|4|TREATMENT|2020-07-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-27|P1Y2M10DT2H30M|AFTER|2020-07-08|BEFORE|2020-08-13
e|RS|1fce031b-680b-414f-9b74-d6383e10091d|9|NTERESP|Non-Target Enhancing Response|BURCOMBE BREAST CANCER 2005|[?]|kg/L|MINOR PATHOLOGIC RESPONSE|1|log10 PFU/mL|HIGH RESOLUTION CT||Y||FAMILY MEMBER|FORENSIC PATHOLOGIST|NA|5|Visit_5|90|6|SCREENING|2020-08-19|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-18|P1Y2M10DT2H30M|COINCIDENT|2020-08-07|AFTER|2020-08-19
e|RS|1fce031b-680b-414f-9b74-d6383e10091d|10|NEWLWIND|New Lesion Worsening Indicator|NCCN ALL MRD 2014|[?]|/kg|IMPROVED|1|kg/mol|AMSLER GRID|Y|||GUARDIAN|CLINICAL PATHOLOGIST|U|5|Visit_5|90|2|WASHOUT|2020-08-19|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-18|P1Y2M10DT2H30M|BEFORE|2020-06-29|AFTER|2020-08-24
e|RS|dcc67696-e91a-4cef-81dd-f2d2711363ae|1|SFTSRESP|Soft Tissue Response|RECIST 1.1|[?]|g/kg/day|IMMUNOPHENOTYPIC CR|1|msec|POPULATION SEQUENCING||||PROXY|ADJUDICATOR 1|U|1|Visit_1|10|7|WASHOUT|2020-12-28|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-26|P1Y2M10DT2H30M|UNKNOWN|2021-02-04|ONGOING|2021-02-21
e|RS|dcc67696-e91a-4cef-81dd-f2d2711363ae|2|NTLWIND|Non-Target Lesion Worsening Indicator|EBMT BLADE MYELOMA 1998|[?]|genEq/mL|sCR|1|cm H2O|NEURAMINIDASE INHIBITION ASSAY||||VENDOR|NEUROLOGIST|Y|1|Visit_1|10|6|TREATMENT|2020-12-28|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-26|P1Y2M10DT2H30M|AFTER|2020-12-21|AFTER|2021-03-02
e|RS|dcc67696-e91a-4cef-81dd-f2d2711363ae|3|MOLRESP|Molecular Response|BURCOMBE BREAST CANCER 2005|[?]|ka_u/dL|IMMUNOPHENOTYPIC CR|1|nmol BCE/mmol|WHOLE GENOME SEQUENCING|Y|||SIGNIFICANT OTHER|CARDIOLOGIST|U|2|Visit_2|25|1|WASHOUT|2021-01-12|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-05|P1Y2M10DT2H30M|COINCIDENT|2021-02-26|ONGOING|2021-03-10
e|RS|dcc67696-e91a-4cef-81dd-f2d2711363ae|4|SFTSRESP|Soft Tissue Response|HAMAOKA BREAST CANCER 2010|[?]|CCID 50/dose|NR|1|mL/kg/day|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI||||NON-HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|N|2|Visit_2|25|4|TREATMENT|2021-01-12|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-05|P1Y2M10DT2H30M|COINCIDENT|2020-12-31|AFTER|2021-01-31
e|RS|dcc67696-e91a-4cef-81dd-f2d2711363ae|5|CLINRESP|Clinical Response|IWG CHESON MDS 2000|[?]|DAYS|CYTOGENETIC PR|1|10^7 PFU|HEMAGGLUTINATION INHIBITION ASSAY||||CLINICAL STUDY SPONSOR|READER|NA|3|Visit_3|40|4|TREATMENT|2021-01-27|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-02|P1Y2M10DT2H30M|AFTER|2021-03-15|ONGOING|2021-03-27
e|RS|dcc67696-e91a-4cef-81dd-f2d2711363ae|6|METSIND|Metastatic Indicator|AJCC V7|[?]|mph|NON-QUANTIFIABLE MRD POSITIVITY|1|GBq/ug|IMMUNOFIXATION ELECTROPHORESIS|Y|||DOMESTIC PARTNER|CLINICAL PATHOLOGIST|Y|3|Visit_3|40|6|WASHOUT|2021-01-27|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-02|P1Y2M10DT2H30M|AFTER|2021-01-14|ONGOING|2021-03-01
e|RS|dcc67696-e91a-4cef-81dd-f2d2711363ae|7|SPLNRESP|Spleen Response|RANO ELLINGSON 2017|||CR-CT|1|fraction of 1|FLUORESCENCE ANGIOGRAPHY|||Y|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST|Y|4|Visit_4|65|4|TREATMENT|2021-02-21|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-19|P1Y2M10DT2H30M|BEFORE|2021-01-08|AFTER|2021-02-26
e|RS|dcc67696-e91a-4cef-81dd-f2d2711363ae|8|TRGRESP|Target Response|RANO ELLINGSON 2017|||DISEASE TRANSFORMATION|1|g/cage/wk|MICROBIAL BIOCHEMICAL IDENTIFICATION|||Y|INVESTIGATOR|READER 1|N|4|Visit_4|65|7|TREATMENT|2021-02-21|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-19|P1Y2M10DT2H30M|UNKNOWN|2020-12-27|COINCIDENT|2020-12-29
e|RS|dcc67696-e91a-4cef-81dd-f2d2711363ae|9|BMIVLIND|Bone Marrow Involvement Indicator|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|||NON-iCR/NON-iUPD|1|kg/L|SXA SCAN|||Y|INVESTIGATOR|PEDIATRIC NEUROLOGIST|NA|5|Visit_5|90|6|TREATMENT|2021-03-18|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-22|P1Y2M10DT2H30M|BEFORE|2021-01-28|BEFORE|2021-01-31
e|RS|dcc67696-e91a-4cef-81dd-f2d2711363ae|10|CYTORESP|Cytogenetic Response|MACDONALD GLIOMA 1990|[?]|nL|iSD|1|nm|RAJI CELL RIA|Y|Y||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|NA|5|Visit_5|90|1|FOLLOW-UP|2021-03-18|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-22|P1Y2M10DT2H30M|COINCIDENT|2021-01-03|COINCIDENT|2021-02-17
e|RS|91e83d7a-186a-4fed-8750-af796d77d356|1|NTRGRESP|Non-target Response|IWG CHESON AML 2003|||CYTOGENETIC CR|1|uCi/L|HIGH RESOLUTION MELT ANALYSIS|Y||Y|PARENT|MICROSCOPIST 2|N|1|Visit_1|10|5|WASHOUT|2020-06-02|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-20|P1Y2M10DT2H30M|COINCIDENT|2020-07-12|COINCIDENT|2020-08-29
e|RS|91e83d7a-186a-4fed-8750-af796d77d356|2|NTLWIND|Non-Target Lesion Worsening Indicator|LEE LUNG CANCER 2011|[?]|Gy|CYTOGENETIC MINOR RESPONSE|1|L/kg|PULMONARY ANGIOGRAPHY||||FAMILY MEMBER|OPTOMETRIST|NA|1|Visit_1|10|1|TREATMENT|2020-06-02|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-20|P1Y2M10DT2H30M|COINCIDENT|2020-06-21|ONGOING|2020-07-05
e|RS|91e83d7a-186a-4fed-8750-af796d77d356|3|NEWLIND|New Lesion Indicator|CHOLLET BREAST CANCER 2002|||sCR|1|mm2|LC/MS|||Y|SIBLING|PATHOLOGIST|NA|2|Visit_2|25|1|WASHOUT|2020-06-17|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-19|P1Y2M10DT2H30M|UNKNOWN|2020-05-30|ONGOING|2020-06-24
e|RS|91e83d7a-186a-4fed-8750-af796d77d356|4|TRGRESP|Target Response|HAMAOKA BREAST CANCER 2010|[?]|breaths/30s|HI-N|1|mEq/uL|CALCOFLUOR WHITE STAIN||||HEALTH CARE PROFESSIONAL|UROLOGIST|NA|2|Visit_2|25|2|FOLLOW-UP|2020-06-17|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-19|P1Y2M10DT2H30M|UNKNOWN|2020-08-02|AFTER|2020-08-08
e|RS|91e83d7a-186a-4fed-8750-af796d77d356|5|NEWLPROG|New Lesion Progression|CHESON CLL 2006|[?]|%/s|SD-CT|1|POINT|MYELOPEROXIDASE STAIN||Y||CLINICAL STUDY SPONSOR|NEUROLOGIST|NA|3|Visit_3|40|4|FOLLOW-UP|2020-07-02|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-14|P1Y2M10DT2H30M|BEFORE|2020-08-11|COINCIDENT|2020-08-22
e|RS|91e83d7a-186a-4fed-8750-af796d77d356|6|METSIND|Metastatic Indicator|KEAM BREAST CANCER 2013|[?]|deg/mm|PARTIAL MORPHOLOGIC RESPONSE|1|cm H2O|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION|Y|||NON-HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|NA|3|Visit_3|40|2|WASHOUT|2020-07-02|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-14|P1Y2M10DT2H30M|BEFORE|2020-07-05|ONGOING|2020-07-08
e|RS|91e83d7a-186a-4fed-8750-af796d77d356|7|MRDRESP|Minimal Residual Disease Response|PERCIST|[?]|/LPF|iSD|1|dL|PLETHYSMOGRAPHY|Y|||INTERVIEWER|PEDIATRIC NEUROLOGIST|N|4|Visit_4|65|6|TREATMENT|2020-07-27|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-26|P1Y2M10DT2H30M|COINCIDENT|2020-05-29|AFTER|2020-06-15
e|RS|91e83d7a-186a-4fed-8750-af796d77d356|8|STRUSTAT|Steroid Use Status|PETIT BREAST CANCER 2001|||FAVORABLE RESPONSE|1|IU/mL|LIGHT MICROSCOPY|Y|Y|Y|FRIEND|DEVELOPMENTAL PSYCHOLOGIST|NA|4|Visit_4|65|6|SCREENING|2020-07-27|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-26|P1Y2M10DT2H30M|AFTER|2020-07-28|ONGOING|2020-08-22
e|RS|91e83d7a-186a-4fed-8750-af796d77d356|9|OVRLRESP|Overall Response|SCHER PROSTATE CANCER 2011|||HI-N|1|/200 HPFs|GRAM STAIN|||Y|NON-HEALTH CARE PROFESSIONAL|READER 1|U|5|Visit_5|90|2|SCREENING|2020-08-21|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-01|P1Y2M10DT2H30M|AFTER|2020-06-16|BEFORE|2020-06-25
e|RS|91e83d7a-186a-4fed-8750-af796d77d356|10|RDIORESP|Radiologic Response|IWC HALLEK CLL 2008|[?]|mL/100g/min|MINOR PATHOLOGIC RESPONSE|1|U/mg|MRI|Y|||STUDY SUBJECT|PATHOLOGIST|NA|5|Visit_5|90|2|WASHOUT|2020-08-21|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-01|P1Y2M10DT2H30M|UNKNOWN|2020-08-01|ONGOING|2020-08-26
e|RS|fdd8b4e9-8499-45ad-bd93-9de5992faf1e|1|SPLNRESP|Spleen Response|NCCN ALL MRD 2014|||CA125 75% RESPONSE|1|mL/g/day|ECHOCARDIOGRAPHY|||Y|CLINICAL STUDY SPONSOR|CLINICAL PATHOLOGIST|NA|1|Visit_1|10|1|TREATMENT|2020-05-13|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-10|P1Y2M10DT2H30M|AFTER|2020-05-16|COINCIDENT|2020-07-11
e|RS|fdd8b4e9-8499-45ad-bd93-9de5992faf1e|2|NTNERESP|Non-Target Non-Enhancing Response|MACDONALD GLIOMA 1990|||SD-CT|1|Frames/s|CLINICAL EVALUATION||Y|Y|FAMILY MEMBER|RATER 2|Y|1|Visit_1|10|3|SCREENING|2020-05-13|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-10|P1Y2M10DT2H30M|COINCIDENT|2020-05-15|AFTER|2020-07-09
e|RS|fdd8b4e9-8499-45ad-bd93-9de5992faf1e|3|TMRESP|Tumor Marker Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|kg/m2|DISEASE TRANSFORMATION|1|/LPF|DROPLET DIGITAL PCR||||PARENT|MICROSCOPIST 3|N|2|Visit_2|25|1|TREATMENT|2020-05-28|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-15|P1Y2M10DT2H30M|UNKNOWN|2020-05-09|BEFORE|2020-07-06
e|RS|fdd8b4e9-8499-45ad-bd93-9de5992faf1e|4|RDIORESP|Radiologic Response|EASL BRUIX LIVER CANCER 2001|[?]|mU|NON-PD|1|GBq/ug|THICK SMEAR||||STUDY SUBJECT|READER 2|N|2|Visit_2|25|3|TREATMENT|2020-05-28|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-15|P1Y2M10DT2H30M|COINCIDENT|2020-06-07|AFTER|2020-06-27
e|RS|fdd8b4e9-8499-45ad-bd93-9de5992faf1e|5|NEWLIND|New Lesion Indicator|AJCC V7|[?]|SQU/mL|SD-CT|1|TRACE|INTERRUPTER TECHNIQUE||||ADJUDICATION COMMITTEE|ADJUDICATOR|Y|3|Visit_3|40|2|TREATMENT|2020-06-12|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-27|P1Y2M10DT2H30M|BEFORE|2020-06-01|ONGOING|2020-08-04
e|RS|fdd8b4e9-8499-45ad-bd93-9de5992faf1e|6|OVRLRESP|Overall Response|SCHER PROSTATE CANCER 2011|[?]|/day|CYTOGENETIC CR|1|mL/h|SURFACE PLASMON RESONANCE||||PARENT|OTOLARYNGOLOGIST|U|3|Visit_3|40|3|TREATMENT|2020-06-12|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-27|P1Y2M10DT2H30M|BEFORE|2020-07-19|ONGOING|2020-07-31
e|RS|fdd8b4e9-8499-45ad-bd93-9de5992faf1e|7|STRUSTAT|Steroid Use Status|IWG CHESON MDS 2000|||IMMUNOPHENOTYPIC CR|1|Rad|BIOIMPEDANCE SPECTROSCOPY||Y|Y|FRIEND|INTERNIST|NA|4|Visit_4|65|6|WASHOUT|2020-07-07|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-14|P1Y2M10DT2H30M|BEFORE|2020-07-24|ONGOING|2020-07-28
e|RS|fdd8b4e9-8499-45ad-bd93-9de5992faf1e|8|SYMPTDTR|Symptomatic Deterioration|PALUMBO MULTIPLE MYELOMA 2009|||sCR|1|CAPSULE|SPIRAL CT SCAN WITHOUT CONTRAST|||Y|DOMESTIC PARTNER|RATER 2|NA|4|Visit_4|65|4|TREATMENT|2020-07-07|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-14|P1Y2M10DT2H30M|COINCIDENT|2020-07-18|ONGOING|2020-08-06
e|RS|fdd8b4e9-8499-45ad-bd93-9de5992faf1e|9|MRDRESP|Minimal Residual Disease Response|MONTSERRAT CLL 1989|||RELAPSED DISEASE|1|msec|SLOAN LETTER EYE CHART 2.5%|||Y|CHILD|READER 2|NA|5|Visit_5|90|1|TREATMENT|2020-08-01|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-04|P1Y2M10DT2H30M|BEFORE|2020-08-03|AFTER|2020-08-08
e|RS|fdd8b4e9-8499-45ad-bd93-9de5992faf1e|10|NTLWIND|Non-Target Lesion Worsening Indicator|MRANO VAN DEN BENT GLIOMA 2011|[?]|U/g/h|PARTIAL MORPHOLOGIC RESPONSE|1|mL/breath|CELL BASED BIOASSAY||||CLINICAL STUDY SPONSOR|PATHOLOGIST|NA|5|Visit_5|90|2|TREATMENT|2020-08-01|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-04|P1Y2M10DT2H30M|BEFORE|2020-05-08|AFTER|2020-07-10
e|RS|0145dfac-a107-4368-b358-bcd136e1ecb3|1|TMRESP|Tumor Marker Response|UNSPECIFIED|[?]|mL/animal/wk|CYTOGENETIC NO RESPONSE|1|GBq|SCANNING ELECTRON MICROSCOPY||Y||CLINICAL RESEARCH ASSOCIATE|PHYSIOTHERAPIST|NA|1|Visit_1|10|2|TREATMENT|2021-01-08|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-20|P1Y2M10DT2H30M|AFTER|2021-01-30|AFTER|2021-03-26
e|RS|0145dfac-a107-4368-b358-bcd136e1ecb3|2|CLINRESP|Clinical Response|SACT|[?]|mmol2/L2|NED|1|s*kPa|NON-INVASIVE DIELECTRIC SENSING|Y|||FAMILY MEMBER|ONCOLOGIST 1|Y|1|Visit_1|10|1|FOLLOW-UP|2021-01-08|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-20|P1Y2M10DT2H30M|UNKNOWN|2021-03-18|COINCIDENT|2021-04-04
e|RS|0145dfac-a107-4368-b358-bcd136e1ecb3|3|SPLNRESP|Spleen Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|TRANSDUCING UNIT|cPR|1|mOsm/L|NEXT GENERATION SEQUENCING|Y|||ADJUDICATION COMMITTEE|ENDOCRINOLOGIST|N|2|Visit_2|25|2|TREATMENT|2021-01-23|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-13|P1Y2M10DT2H30M|COINCIDENT|2021-01-28|COINCIDENT|2021-03-11
e|RS|0145dfac-a107-4368-b358-bcd136e1ecb3|4|LIVRRESP|Liver Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|ug/dL|EQUIVOCAL|1|10^3 DNA copies/mL|NUCLEIC ACID AMPLIFICATION TEST||||HEALTH CARE PROFESSIONAL|UROLOGIST|U|2|Visit_2|25|3|SCREENING|2021-01-23|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-13|P1Y2M10DT2H30M|COINCIDENT|2021-03-04|ONGOING|2021-04-07
e|RS|0145dfac-a107-4368-b358-bcd136e1ecb3|5|NEWLIND|New Lesion Indicator|PCWG SCHER PROSTATE CANCER 2008|[?]|sec|HI-N|1|ug/m2|MAGNETIC RESONANCE ENTEROGRAPHY|Y|||INVESTIGATOR|PHYSIOTHERAPIST|NA|3|Visit_3|40|3|FOLLOW-UP|2021-02-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-28|P1Y2M10DT2H30M|UNKNOWN|2021-03-26|BEFORE|2021-03-31
e|RS|0145dfac-a107-4368-b358-bcd136e1ecb3|6|BESTRESP|Best Overall Response|HARTMAN PANCREATIC CANCER 2012|||TREATMENT FAILURE|1|CAPSULE|CONTRAST ENHANCED PET/CT SCAN|||Y|CLINICAL RESEARCH ASSOCIATE|ENDOCRINOLOGIST|Y|3|Visit_3|40|5|TREATMENT|2021-02-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-28|P1Y2M10DT2H30M|AFTER|2021-01-19|ONGOING|2021-01-21
e|RS|0145dfac-a107-4368-b358-bcd136e1ecb3|7|PATHRESP|Pathologic Response|AJCC V8|[?]|APL U/mL|CRi|1|uCi/kg|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION||Y||SIGNIFICANT OTHER|RADIOLOGIST 1|NA|4|Visit_4|65|5|SCREENING|2021-03-04|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-21|P1Y2M10DT2H30M|AFTER|2021-01-20|BEFORE|2021-02-10
e|RS|0145dfac-a107-4368-b358-bcd136e1ecb3|8|DRCRIND|Disease Recurrence Indicator|DOHNER AML 2010|[?]|%/s|UNEQUIVOCAL|1|mPa|INCISION-INDUCED BLEEDING METHOD||Y||CLINICAL STUDY SPONSOR|MICROSCOPIST 2|U|4|Visit_4|65|1|TREATMENT|2021-03-04|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-21|P1Y2M10DT2H30M|BEFORE|2021-04-05|AFTER|2021-04-07
e|RS|0145dfac-a107-4368-b358-bcd136e1ecb3|9|MJPTHIND|Major Pathological Response Indicator|CHESON CLL 2006|[?]|HOURS|SD-CT|1|mg/kg/min|CALCULATION||||CLINICAL RESEARCH ASSOCIATE|RATER 2|U|5|Visit_5|90|1|TREATMENT|2021-03-29|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-27|P1Y2M10DT2H30M|AFTER|2021-02-06|COINCIDENT|2021-02-08
e|RS|0145dfac-a107-4368-b358-bcd136e1ecb3|10|BONERESP|Bone Response|DURIE MULTIPLE MYELOMA 2006|[?]|days/month|OPTIMAL MORPHOLOGIC RESPONSE|1|mmol/mol|WEBER GREEN STAIN||Y||INVESTIGATOR|NEUROLOGIST 1|N|5|Visit_5|90|6|TREATMENT|2021-03-29|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-27|P1Y2M10DT2H30M|AFTER|2020-12-31|ONGOING|2021-03-04
e|RS|cfbbaa65-9742-4682-9ec0-4d503bca0bb1|1|HEMARESP|Hematologic Response|CHESON LYMPHOMA 2008|[?]|U/g/day|PR|1|ug/animal|ELECTRONEUROGRAPHY|Y|||CAREGIVER|DERMATOLOGIST|U|1|Visit_1|10|7|WASHOUT|2020-12-29|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-13|P1Y2M10DT2H30M|BEFORE|2021-01-03|ONGOING|2021-02-04
e|RS|cfbbaa65-9742-4682-9ec0-4d503bca0bb1|2|MRDRESP|Minimal Residual Disease Response|NCIWG CHESON CLL 1996|[?]|ag|NE|1|titer|CARDIAC THERMODILUTION||||CAREGIVER|READER 2|NA|1|Visit_1|10|6|WASHOUT|2020-12-29|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-13|P1Y2M10DT2H30M|BEFORE|2021-01-06|ONGOING|2021-02-12
e|RS|cfbbaa65-9742-4682-9ec0-4d503bca0bb1|3|NTERESP|Non-Target Enhancing Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|min*mg/mL|CHR|1|pmol/10^9 cells|PHASE-CONTRAST MRI|Y|||FRIEND|INTERNIST|N|2|Visit_2|25|6|TREATMENT|2021-01-13|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-31|P1Y2M10DT2H30M|BEFORE|2021-02-01|AFTER|2021-03-10
e|RS|cfbbaa65-9742-4682-9ec0-4d503bca0bb1|4|MRDIND|Minimal Residual Disease Indicator|BRUGGEMANN MRD 2010|||pCR|1|mL/g/h|CARDIAC THERMODILUTION|||Y|NON-HEALTH CARE PROFESSIONAL|READER 3|U|2|Visit_2|25|2|TREATMENT|2021-01-13|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-31|P1Y2M10DT2H30M|BEFORE|2021-02-14|ONGOING|2021-02-20
e|RS|cfbbaa65-9742-4682-9ec0-4d503bca0bb1|5|CLINRESP|Clinical Response|HARTMANN GERM CELL CANCER 2002|||NE|1|nm|SIZE EXCLUSION CHROMATOGRAPHY||Y|Y|PROXY|RATER 1|N|3|Visit_3|40|4|TREATMENT|2021-01-28|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-20|P1Y2M10DT2H30M|BEFORE|2021-01-15|AFTER|2021-03-26
e|RS|cfbbaa65-9742-4682-9ec0-4d503bca0bb1|6|ANATRESP|Anatomic Response|CHESON NON-HODGKINS LYMPHOMA 1999|||PD/RELAPSE AFTER HI|1|CCID 50/mL|PYROSEQUENCING|Y||Y|INVESTIGATOR|MICROSCOPIST 2|U|3|Visit_3|40|4|TREATMENT|2021-01-28|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-20|P1Y2M10DT2H30M|COINCIDENT|2021-03-17|BEFORE|2021-03-19
e|RS|cfbbaa65-9742-4682-9ec0-4d503bca0bb1|7|MJPTHIND|Major Pathological Response Indicator|RANO ELLINGSON 2017|||NON-CR/NON-PD|1|10^3 organisms|KLEIHAUER-BETKE|Y||Y|FAMILY MEMBER|RADIOLOGIST 1|N|4|Visit_4|65|3|TREATMENT|2021-02-22|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-07|P1Y2M10DT2H30M|COINCIDENT|2021-01-12|AFTER|2021-02-17
e|RS|cfbbaa65-9742-4682-9ec0-4d503bca0bb1|8|RDIORESP|Radiologic Response|CHESON CLL 2012|||NOT ALL EVALUATED|1|nkat/g Hb|FLUORESCENT SPOT TEST|||Y|STUDY SUBJECT|READER 1|NA|4|Visit_4|65|7|TREATMENT|2021-02-22|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-07|P1Y2M10DT2H30M|UNKNOWN|2020-12-23|AFTER|2021-03-06
e|RS|cfbbaa65-9742-4682-9ec0-4d503bca0bb1|9|METBRESP|Metabolic Response|HARTMAN PANCREATIC CANCER 2012|[?]|cm|MRD PERSISTENCE|1|g/cm2|WRIGHT-GIEMSA STAIN||Y||FRIEND|ADJUDICATOR 3|NA|5|Visit_5|90|1|SCREENING|2021-03-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-26|P1Y2M10DT2H30M|BEFORE|2021-01-02|COINCIDENT|2021-03-07
e|RS|cfbbaa65-9742-4682-9ec0-4d503bca0bb1|10|LIVRRESP|Liver Response|CHESON CLL 2012|[?]|kUSP|COMPLETE MRD RESPONSE|1|m|DIRECT SEQUENCING||||STUDY SUBJECT|CLINICAL PATHOLOGIST|Y|5|Visit_5|90|7|WASHOUT|2021-03-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-26|P1Y2M10DT2H30M|UNKNOWN|2021-02-22|ONGOING|2021-02-26
e|RS|d4d79f6a-ba90-4503-934b-8a86286d83d3|1|CLINRESP|Clinical Response|JACINTO CERVICAL CANCER 2007|||MORPHOLOGIC CRi|1|mL/min/1.73m2|KINETIC MICROPARTICLE IMMUNOASSAY|||Y|VENDOR|PATHOLOGIST 1|NA|1|Visit_1|10|1|FOLLOW-UP|2020-11-17|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-13|P1Y2M10DT2H30M|BEFORE|2021-01-27|AFTER|2021-02-12
e|RS|d4d79f6a-ba90-4503-934b-8a86286d83d3|2|TRGRESP|Target Response|MACDONALD GLIOMA 1990|[?]|IU/mL|CYTOGENETIC CR|1|CARTRIDGE|U-HPLC/MS/MS||||PARENT|OTOLARYNGOLOGIST|Y|1|Visit_1|10|7|WASHOUT|2020-11-17|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-13|P1Y2M10DT2H30M|AFTER|2020-12-28|ONGOING|2020-12-29
e|RS|d4d79f6a-ba90-4503-934b-8a86286d83d3|3|MRPHRESP|Morphologic Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|mJoule/cm2|NON-iCR/NON-iUPD|1|U/L|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY|Y|Y||DOMESTIC PARTNER|OPHTHALMOLOGIST|Y|2|Visit_2|25|7|FOLLOW-UP|2020-12-02|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-26|P1Y2M10DT2H30M|AFTER|2021-01-30|AFTER|2021-02-06
e|RS|d4d79f6a-ba90-4503-934b-8a86286d83d3|4|LIVRRESP|Liver Response|FAROOQUI SUPP CLL 2014|[?]|deg/s|PD FROM PR|1|nmol/L/h|ELECTROGASTROGRAPHY||||PARENT|MICROSCOPIST 3|NA|2|Visit_2|25|4|TREATMENT|2020-12-02|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-26|P1Y2M10DT2H30M|BEFORE|2021-01-02|BEFORE|2021-01-23
e|RS|d4d79f6a-ba90-4503-934b-8a86286d83d3|5|NTERESP|Non-Target Enhancing Response|MURPHY PROSTATE CANCER 1980|[?]|uIU/L|HI-N|1|mOsm/kg|MAMMOGRAPHY||||GUARDIAN|READER 3|Y|3|Visit_3|40|7|TREATMENT|2020-12-17|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-22|P1Y2M10DT2H30M|COINCIDENT|2020-11-28|AFTER|2020-12-14
e|RS|d4d79f6a-ba90-4503-934b-8a86286d83d3|6|METBRESP|Metabolic Response|DOHNER AML 2010|[?]|mL/s/m2|NR|1|SQU/mL|CLAUSS METHOD||Y||HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|NA|3|Visit_3|40|4|TREATMENT|2020-12-17|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-22|P1Y2M10DT2H30M|AFTER|2021-02-10|AFTER|2021-02-13
e|RS|d4d79f6a-ba90-4503-934b-8a86286d83d3|7|SPLNRESP|Spleen Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|GBq|PARTIAL MORPHOLOGIC RESPONSE|1|deg|HPLC/IEX||||FAMILY MEMBER|NEUROLOGIST 1|N|4|Visit_4|65|6|TREATMENT|2021-01-11|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-12|P1Y2M10DT2H30M|BEFORE|2021-01-23|ONGOING|2021-02-09
e|RS|d4d79f6a-ba90-4503-934b-8a86286d83d3|8|NTRGRESP|Non-target Response|GUILHOT CML 2007|[?]|TRACE|PD/RELAPSE AFTER HI|1|um/day|IRON HEMATOXYLIN STAIN||||CLINICAL RESEARCH COORDINATOR|PHYSIOTHERAPIST|U|4|Visit_4|65|3|TREATMENT|2021-01-11|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-12|P1Y2M10DT2H30M|UNKNOWN|2021-01-13|BEFORE|2021-01-18
e|RS|d4d79f6a-ba90-4503-934b-8a86286d83d3|9|BMIVLIND|Bone Marrow Involvement Indicator|IRANO 2015|||nPR|1|log10 TCID 50/uL|IMPEDANCE CONDUCTIVITY|||Y|INTERVIEWER|READER 3|NA|5|Visit_5|90|7|TREATMENT|2021-02-05|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-12|P1Y2M10DT2H30M|COINCIDENT|2021-01-07|COINCIDENT|2021-02-12
e|RS|d4d79f6a-ba90-4503-934b-8a86286d83d3|10|STRUSTAT|Steroid Use Status|MRECIST BYRNE MESOTHELIOMA 2004|[?]|Ci/ug|PDu|1|U.CARR|MS/MS||||NON-HEALTH CARE PROFESSIONAL|UROLOGIST|NA|5|Visit_5|90|5|TREATMENT|2021-02-05|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-12|P1Y2M10DT2H30M|AFTER|2020-12-08|ONGOING|2021-02-09
e|RS|a329c350-49e2-415d-ba3c-e1ee929aec86|1|RDIORESP|Radiologic Response|IRANO 2015|[?]|PFU/dose|PDu|1|psi|BIOIMPEDANCE SPECTROSCOPY||||FAMILY MEMBER|RATER|NA|1|Visit_1|10|3|TREATMENT|2020-08-15|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-29|P1Y2M10DT2H30M|BEFORE|2020-08-25|AFTER|2020-09-22
e|RS|a329c350-49e2-415d-ba3c-e1ee929aec86|2|TMRESP|Tumor Marker Response|DURIE MULTIPLE MYELOMA 2006|[?]|IU/dL|PR-CT|1|Gy/h|PYROSEQUENCING|Y|Y||INTERVIEWER|RADIOLOGIST 1|NA|1|Visit_1|10|4|WASHOUT|2020-08-15|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-29|P1Y2M10DT2H30M|UNKNOWN|2020-10-07|BEFORE|2020-10-30
e|RS|a329c350-49e2-415d-ba3c-e1ee929aec86|3|TRGRESP|Target Response|CHOI GIST 2008|[?]|DROP|INCREASED|1|/LPF|TRANSESOPHAGEAL ECHOCARDIOGRAPHY|Y|||CLINICAL RESEARCH ASSOCIATE|CARDIOLOGIST|NA|2|Visit_2|25|6|WASHOUT|2020-08-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-25|P1Y2M10DT2H30M|UNKNOWN|2020-11-08|AFTER|2020-11-09
e|RS|a329c350-49e2-415d-ba3c-e1ee929aec86|4|CLINRESP|Clinical Response|WHO BREAST CANCER 2006|[?]|scm|MINOR PATHOLOGIC RESPONSE|1|U/m2|DUKE INCISION METHOD||||INVESTIGATOR|PATHOLOGIST 2|Y|2|Visit_2|25|2|TREATMENT|2020-08-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-25|P1Y2M10DT2H30M|BEFORE|2020-11-01|BEFORE|2020-11-06
e|RS|a329c350-49e2-415d-ba3c-e1ee929aec86|5|BMIVLIND|Bone Marrow Involvement Indicator|GUPPY OVARIAN CANCER 2002|||MOLECULAR MAJOR RESPONSE|1|mg/h|EEG|||Y|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 2|U|3|Visit_3|40|7|TREATMENT|2020-09-14|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-31|P1Y2M10DT2H30M|AFTER|2020-09-18|COINCIDENT|2020-09-29
e|RS|a329c350-49e2-415d-ba3c-e1ee929aec86|6|CLINRESP|Clinical Response|PCWG SCHER PROSTATE CANCER 2016|||PMD|1|BU|WESTERN BLOT|Y||Y|STUDY SUBJECT|ONCOLOGIST 2|Y|3|Visit_3|40|3|TREATMENT|2020-09-14|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-31|P1Y2M10DT2H30M|AFTER|2020-09-24|COINCIDENT|2020-09-28
e|RS|a329c350-49e2-415d-ba3c-e1ee929aec86|7|MRDRESP|Minimal Residual Disease Response|IRANO 2015|[?]|mEq/ug|DECREASED|1|h*%|REVERSE TRANSCRIPTASE PCR|Y|||FRIEND|NEUROLOGIST 1|U|4|Visit_4|65|7|SCREENING|2020-10-09|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-23|P1Y2M10DT2H30M|COINCIDENT|2020-08-21|COINCIDENT|2020-10-03
e|RS|a329c350-49e2-415d-ba3c-e1ee929aec86|8|METSIND|Metastatic Indicator|MRECIST LENCIONI LIVER CANCER 2010|||IMPROVED|1|ka_u/dL|AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT|||Y|ADJUDICATOR|READER 1|U|4|Visit_4|65|5|TREATMENT|2020-10-09|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-23|P1Y2M10DT2H30M|BEFORE|2020-09-15|COINCIDENT|2020-10-13
e|RS|a329c350-49e2-415d-ba3c-e1ee929aec86|9|NTRGRESP|Non-target Response|CHOLLET BREAST CANCER 2002|||CR|1|mAmp|ACCELERATOR MASS SPECTROMETRY|||Y|SPOUSE|OPTOMETRIST|U|5|Visit_5|90|1|TREATMENT|2020-11-03|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-09|P1Y2M10DT2H30M|COINCIDENT|2020-10-27|ONGOING|2020-10-30
e|RS|a329c350-49e2-415d-ba3c-e1ee929aec86|10|OVRLRESP|Overall Response|RAJKUMAR MYELOMA 2011|[?]|mm/min|NON-CR/NON-PD|1|g/L|IMMUNORADIOMETRIC ASSAY||||CLINICAL STUDY SPONSOR|CARDIOLOGIST|N|5|Visit_5|90|2|TREATMENT|2020-11-03|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-09|P1Y2M10DT2H30M|AFTER|2020-08-27|AFTER|2020-10-11
e|RS|ff0e3543-c1f3-47f8-987f-7b00a4a33704|1|NEWLWIND|New Lesion Worsening Indicator|BLAZER COLORECTAL CANCER 2008|[?]|mL/m2/day|SMD|1|C|ANALYTICAL ULTRACENTRIFUGATION||Y||FRIEND|MICROSCOPIST|U|1|Visit_1|10|4|TREATMENT|2020-10-01|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-28|P1Y2M10DT2H30M|COINCIDENT|2020-11-11|AFTER|2020-11-14
e|RS|ff0e3543-c1f3-47f8-987f-7b00a4a33704|2|METSIND|Metastatic Indicator|SHINDOH COLORECTAL CANCER 2013|||iPR|1|L/h/m2|MICROSCOPY|||Y|GUARDIAN|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|1|Visit_1|10|6|WASHOUT|2020-10-01|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-28|P1Y2M10DT2H30M|UNKNOWN|2020-11-08|AFTER|2020-12-09
e|RS|ff0e3543-c1f3-47f8-987f-7b00a4a33704|3|TRGRESP|Target Response|NCCN ALL MRD 2014|[?]|ng|CMR|1|GPL U/mL|KINYOUN STAIN||Y||CHILD|RADIOLOGIST 1|U|2|Visit_2|25|7|TREATMENT|2020-10-16|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-14|P1Y2M10DT2H30M|UNKNOWN|2020-10-21|COINCIDENT|2020-11-11
e|RS|ff0e3543-c1f3-47f8-987f-7b00a4a33704|4|NEWLPROG|New Lesion Progression|PCWG SCHER PROSTATE CANCER 2016|[?]|/5x10^4 WBC|DECREASED|1|nkat/g Hb|CHROMATOGRAPHY|Y|Y||PROXY|ENDOCRINOLOGIST|Y|2|Visit_2|25|1|TREATMENT|2020-10-16|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-14|P1Y2M10DT2H30M|UNKNOWN|2020-11-18|AFTER|2020-11-29
e|RS|ff0e3543-c1f3-47f8-987f-7b00a4a33704|5|CPRFSTAT|Clinical Performance Status|PERCIST|||iPR|1|ug/day|AGAR PROPORTION|||Y|HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|N|3|Visit_3|40|5|WASHOUT|2020-10-31|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-05|P1Y2M10DT2H30M|AFTER|2020-11-27|BEFORE|2020-12-28
e|RS|ff0e3543-c1f3-47f8-987f-7b00a4a33704|6|CLINRESP|Clinical Response|iRECIST|[?]|F|NR|1|mm/sec|POTENTIOMETRY||||INVESTIGATOR|ADJUDICATOR 3|N|3|Visit_3|40|3|TREATMENT|2020-10-31|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-05|P1Y2M10DT2H30M|BEFORE|2020-12-25|ONGOING|2020-12-26
e|RS|ff0e3543-c1f3-47f8-987f-7b00a4a33704|7|CPRFSTAT|Clinical Performance Status|WHO BREAST CANCER 2006|||IMPROVED|1|g/cm2|MYELOPEROXIDASE STAIN|Y|Y|Y|INVESTIGATOR|RATER 2|NA|4|Visit_4|65|5|WASHOUT|2020-11-25|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-25|P1Y2M10DT2H30M|AFTER|2020-11-02|BEFORE|2020-12-18
e|RS|ff0e3543-c1f3-47f8-987f-7b00a4a33704|8|OVRLRESP|Overall Response|IRANO 2015|[?]|mmol/mol|NON-iCR/NON-iUPD|1|mmHg|SPIROMETRY||||ADJUDICATOR|UROLOGIST|U|4|Visit_4|65|6|SCREENING|2020-11-25|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-25|P1Y2M10DT2H30M|BEFORE|2020-12-04|ONGOING|2020-12-17
e|RS|ff0e3543-c1f3-47f8-987f-7b00a4a33704|9|BMIVLIND|Bone Marrow Involvement Indicator|CHESON CLL 2012|||NON-PD|1|kat|CALCOFLUOR WHITE STAIN|||Y|PARENT|PATHOLOGIST|U|5|Visit_5|90|2|TREATMENT|2020-12-20|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-12|P1Y2M10DT2H30M|AFTER|2020-10-12|AFTER|2020-11-03
e|RS|ff0e3543-c1f3-47f8-987f-7b00a4a33704|10|TMRESP|Tumor Marker Response|MONTSERRAT CLL 1989|[?]|kg/cm|OPTIMAL MORPHOLOGIC RESPONSE|1|ug/kg/min|ATOMIC ABSORPTION SPECTROMETRY||Y||CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 3|U|5|Visit_5|90|2|FOLLOW-UP|2020-12-20|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-12|P1Y2M10DT2H30M|UNKNOWN|2020-12-26|AFTER|2020-12-28
e|RS|128153ce-7bee-4f8d-bb60-fb1776370b6d|1|PATHRESP|Pathologic Response|NCIWG CHESON CLL 1996|||CR|1|KIT|ELECTROCHEMILUMINESCENCE|||Y|CHILD|RATER|NA|1|Visit_1|10|4|TREATMENT|2021-01-11|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-09|P1Y2M10DT2H30M|UNKNOWN|2021-04-08|ONGOING|2021-04-09
e|RS|128153ce-7bee-4f8d-bb60-fb1776370b6d|2|TMRESP|Tumor Marker Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|umol/L/sec|SD-CT|1|10^6/Ejaculate U|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI||Y||CLINICAL STUDY SPONSOR|NEUROLOGIST 1|NA|1|Visit_1|10|4|WASHOUT|2021-01-11|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-09|P1Y2M10DT2H30M|AFTER|2021-01-21|ONGOING|2021-02-08
e|RS|128153ce-7bee-4f8d-bb60-fb1776370b6d|3|MJPTHIND|Major Pathological Response Indicator|PCWG SCHER PROSTATE CANCER 2008|[?]|mL/100g/min|VGPR|1|STRIP|MULTI-SLICE SPIRAL CT|Y|||CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 1|Y|2|Visit_2|25|6|TREATMENT|2021-01-26|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-07|P1Y2M10DT2H30M|UNKNOWN|2021-03-26|ONGOING|2021-04-07
e|RS|128153ce-7bee-4f8d-bb60-fb1776370b6d|4|OVRLRESP|Overall Response|PCWG SCHER PROSTATE CANCER 2016|[?]|Ci/uL|QUANTIFIABLE MRD POSITIVITY|1|log10 CCID 50/dose|LIGHT MICROSCOPY||||CAREGIVER|READER|Y|2|Visit_2|25|5|WASHOUT|2021-01-26|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-07|P1Y2M10DT2H30M|COINCIDENT|2021-03-23|AFTER|2021-04-01
e|RS|128153ce-7bee-4f8d-bb60-fb1776370b6d|5|CLINRESP|Clinical Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|titer|CYTOGENETIC CR|1|%/s|CALCOFLUOR WHITE STAIN||Y||NON-HEALTH CARE PROFESSIONAL|READER 1|N|3|Visit_3|40|1|FOLLOW-UP|2021-02-10|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-06|P1Y2M10DT2H30M|AFTER|2021-03-11|AFTER|2021-04-08
e|RS|128153ce-7bee-4f8d-bb60-fb1776370b6d|6|HEMARESP|Hematologic Response|RAJKUMAR MYELOMA 2011|[?]|Ejaculate U|PSA PROGRESSION|1|ohm|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE||||VENDOR|NEUROLOGIST|Y|3|Visit_3|40|2|TREATMENT|2021-02-10|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-06|P1Y2M10DT2H30M|COINCIDENT|2021-02-04|COINCIDENT|2021-03-03
e|RS|128153ce-7bee-4f8d-bb60-fb1776370b6d|7|MRDIND|Minimal Residual Disease Indicator|PERCIST|[?]|umol/mol|IMPROVED|1|umol/dL|FARNSWORTH-MUNSELL 100 HUE TEST||Y||INDEPENDENT ASSESSOR|PHYSIOTHERAPIST|U|4|Visit_4|65|6|TREATMENT|2021-03-07|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-09|P1Y2M10DT2H30M|COINCIDENT|2021-02-02|ONGOING|2021-04-10
e|RS|128153ce-7bee-4f8d-bb60-fb1776370b6d|8|NEWLWIND|New Lesion Worsening Indicator|IWC HALLEK CLL 2008|||MORPHOLOGIC CRi|1|ag|FLUORESCENT MICROSCOPY|||Y|SIGNIFICANT OTHER|RATER|U|4|Visit_4|65|3|FOLLOW-UP|2021-03-07|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-09|P1Y2M10DT2H30M|BEFORE|2021-01-11|ONGOING|2021-03-27
e|RS|128153ce-7bee-4f8d-bb60-fb1776370b6d|9|BMIVLIND|Bone Marrow Involvement Indicator|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|U/g|VGPR|1|ug/dL|LIGHT SCATTERING SPECTROSCOPY||||PARENT|NEUROLOGIST 2|U|5|Visit_5|90|4|TREATMENT|2021-04-01|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-10|P1Y2M10DT2H30M|BEFORE|2021-01-25|ONGOING|2021-03-26
e|RS|128153ce-7bee-4f8d-bb60-fb1776370b6d|10|TMRESP|Tumor Marker Response|MASS|[?]|P|DECREASED|1|cycle/min|HIGH RESOLUTION MELT ANALYSIS||||SIBLING|CLINICAL PATHOLOGIST|N|5|Visit_5|90|5|WASHOUT|2021-04-01|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-10|P1Y2M10DT2H30M|UNKNOWN|2021-03-18|ONGOING|2021-04-04
e|RS|22ee2f20-4a66-458f-a153-9d7e871e1db2|1|METSIND|Metastatic Indicator|RANO|[?]|hPa|NE|1|mg|REAL-TIME POLYMERASE CHAIN REACTION ASSAY||||FAMILY MEMBER|ONCOLOGIST|Y|1|Visit_1|10|2|TREATMENT|2020-06-17|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-04|P1Y2M10DT2H30M|COINCIDENT|2020-07-28|ONGOING|2020-08-19
e|RS|22ee2f20-4a66-458f-a153-9d7e871e1db2|2|HEMARESP|Hematologic Response|PRINCE TCELL LYMPHOMA 2010|[?]|mm2|CRi|1|Arbitrary U|LC/MS/MS|Y|||DOMESTIC PARTNER|ADJUDICATOR 3|Y|1|Visit_1|10|6|TREATMENT|2020-06-17|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-04|P1Y2M10DT2H30M|COINCIDENT|2020-08-17|AFTER|2020-09-13
e|RS|22ee2f20-4a66-458f-a153-9d7e871e1db2|3|BMIVLIND|Bone Marrow Involvement Indicator|FAROOQUI SUPP CLL 2014|||MORPHOLOGIC LEUKEMIA-FREE STATE|1|kg/mol|SLIT LAMP PHOTOGRAPHY|||Y|CAREGIVER|DEVELOPMENTAL PSYCHOLOGIST|Y|2|Visit_2|25|4|TREATMENT|2020-07-02|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-05|P1Y2M10DT2H30M|BEFORE|2020-08-26|COINCIDENT|2020-08-29
e|RS|22ee2f20-4a66-458f-a153-9d7e871e1db2|4|TRGRESP|Target Response|KEAM BREAST CANCER 2013|[?]|BOLUS|MRD RELAPSE|1|/cmH2O|SPIRAL CT||Y||INDEPENDENT ASSESSOR|RATER 1|N|2|Visit_2|25|4|TREATMENT|2020-07-02|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-05|P1Y2M10DT2H30M|BEFORE|2020-08-28|ONGOING|2020-09-12
e|RS|22ee2f20-4a66-458f-a153-9d7e871e1db2|5|TMRESP|Tumor Marker Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|APL U|NED|1|U/L|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION||||VENDOR|UROLOGIST|Y|3|Visit_3|40|3|TREATMENT|2020-07-17|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-12|P1Y2M10DT2H30M|COINCIDENT|2020-07-26|AFTER|2020-07-27
e|RS|22ee2f20-4a66-458f-a153-9d7e871e1db2|6|PATHRESP|Pathologic Response|CHOLLET BREAST CANCER 2002|[?]|uEq/L|CR-CT|1|cm H2O|SCANNING ELECTRON MICROSCOPY|Y|||SPOUSE|UROLOGIST|NA|3|Visit_3|40|5|FOLLOW-UP|2020-07-17|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-12|P1Y2M10DT2H30M|AFTER|2020-09-12|ONGOING|2020-09-13
e|RS|22ee2f20-4a66-458f-a153-9d7e871e1db2|7|NTLWIND|Non-Target Lesion Worsening Indicator|PCWG SCHER PROSTATE CANCER 2008|[?]|PFU/animal|MORPHOLOGIC LEUKEMIA-FREE STATE|1|pptr|CRYOSCOPY||||INTERVIEWER|RATER|U|4|Visit_4|65|6|SCREENING|2020-08-11|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-15|P1Y2M10DT2H30M|BEFORE|2020-09-08|BEFORE|2020-09-11
e|RS|22ee2f20-4a66-458f-a153-9d7e871e1db2|8|SPLNRESP|Spleen Response|MASS|[?]|Enzyme U|MORPHOLOGIC LEUKEMIA-FREE STATE|1|mL/kg/min|ALCIAN BLUE STAIN||||CHILD|ONCOLOGIST 2|N|4|Visit_4|65|1|WASHOUT|2020-08-11|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-15|P1Y2M10DT2H30M|BEFORE|2020-09-11|ONGOING|2020-09-12
e|RS|22ee2f20-4a66-458f-a153-9d7e871e1db2|9|TRGRESP|Target Response|IWG CHESON AML 2003|[?]|pg/L|COMPLETE MRD RESPONSE|1|mg/day|MAMMOGRAPHY||||CLINICAL RESEARCH ASSOCIATE|RATER 2|U|5|Visit_5|90|6|WASHOUT|2020-09-05|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-17|P1Y2M10DT2H30M|UNKNOWN|2020-07-07|BEFORE|2020-08-24
e|RS|22ee2f20-4a66-458f-a153-9d7e871e1db2|10|MOLRESP|Molecular Response|PCWG SCHER PROSTATE CANCER 2016|||MAJOR PATHOLOGIC RESPONSE|1|mm/min|FARNSWORTH-MUNSELL 100 HUE TEST|||Y|SPOUSE|NEUROLOGIST 2|Y|5|Visit_5|90|1|TREATMENT|2020-09-05|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-17|P1Y2M10DT2H30M|UNKNOWN|2020-09-01|AFTER|2020-09-06
e|RS|b7caaa04-bcc7-4350-ad98-85670a19778f|1|NTNERESP|Non-Target Non-Enhancing Response|SHINDOH COLORECTAL CANCER 2013|[?]|10^9 organisms/g|COMPLETE MRD RESPONSE|1|ug/kg/h|JAEGER EYE CHART||||FAMILY MEMBER|RATER|NA|1|Visit_1|10|2|WASHOUT|2020-07-06|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-18|P1Y2M10DT2H30M|BEFORE|2020-08-08|AFTER|2020-08-15
e|RS|b7caaa04-bcc7-4350-ad98-85670a19778f|2|ANATRESP|Anatomic Response|NCIWG CHESON CLL 1996|[?]|uL|PDu|1|mol/day|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION||||DOMESTIC PARTNER|INTERNIST|U|1|Visit_1|10|7|FOLLOW-UP|2020-07-06|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-18|P1Y2M10DT2H30M|COINCIDENT|2020-09-30|AFTER|2020-10-03
e|RS|b7caaa04-bcc7-4350-ad98-85670a19778f|3|MJPTHIND|Major Pathological Response Indicator|GCIG RUSTIN OVARIAN CANCER 2011|[?]|foz_br|DISEASE TRANSFORMATION|1|PIXELS/in|CYSTOMETRY||Y||VENDOR|ONCOLOGIST|N|2|Visit_2|25|1|TREATMENT|2020-07-21|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-19|P1Y2M10DT2H30M|COINCIDENT|2020-07-30|BEFORE|2020-08-19
e|RS|b7caaa04-bcc7-4350-ad98-85670a19778f|4|ANATRESP|Anatomic Response|IRANO 2015|[?]|cd|NON-CR/NON-PD|1|uU/L|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION||||STUDY SUBJECT|NEUROLOGIST 1|NA|2|Visit_2|25|4|TREATMENT|2020-07-21|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-19|P1Y2M10DT2H30M|AFTER|2020-08-30|BEFORE|2020-09-10
e|RS|b7caaa04-bcc7-4350-ad98-85670a19778f|5|PATHRESP|Pathologic Response|MACDONALD GLIOMA 1990|||HI-P|1|CCID 50/mL|SPECULAR MICROSCOPY|||Y|ADJUDICATOR|CARDIOLOGIST|N|3|Visit_3|40|1|TREATMENT|2020-08-05|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-29|P1Y2M10DT2H30M|AFTER|2020-07-16|AFTER|2020-09-09
e|RS|b7caaa04-bcc7-4350-ad98-85670a19778f|6|HEMARESP|Hematologic Response|FAROOQUI SUPP CLL 2014|[?]|kUSP|NON-iCR/NON-iUPD|1|PLUG|QUANTITATIVE COMPUTED TOMOGRAPHY|Y|Y||FAMILY MEMBER|MICROSCOPIST|Y|3|Visit_3|40|1|FOLLOW-UP|2020-08-05|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-29|P1Y2M10DT2H30M|UNKNOWN|2020-08-28|AFTER|2020-09-22
e|RS|b7caaa04-bcc7-4350-ad98-85670a19778f|7|SYMPTDTR|Symptomatic Deterioration|FAROOQUI SUPP CLL 2014|[?]|mmAL|NOT ALL EVALUATED|1|pt_us|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION||Y||VENDOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|4|Visit_4|65|2|TREATMENT|2020-08-30|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-06|P1Y2M10DT2H30M|COINCIDENT|2020-08-13|BEFORE|2020-09-23
e|RS|b7caaa04-bcc7-4350-ad98-85670a19778f|8|NEWLWIND|New Lesion Worsening Indicator|EUROPEAN LEUKEMIANET BACCARANI CML 2006|||MORPHOLOGIC CRi|1|vp/dose|MAGNETIC RESONANCE ELASTOGRAPHY||Y|Y|INVESTIGATOR|UROLOGIST|NA|4|Visit_4|65|6|TREATMENT|2020-08-30|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-06|P1Y2M10DT2H30M|BEFORE|2020-07-24|COINCIDENT|2020-08-25
e|RS|b7caaa04-bcc7-4350-ad98-85670a19778f|9|NEWLPROG|New Lesion Progression|EASL BRUIX LIVER CANCER 2001|[?]|10^4/hpf|DISEASE TRANSFORMATION|1|POINT|GIEMSA STAIN||Y||DOMESTIC PARTNER|MICROSCOPIST 3|U|5|Visit_5|90|1|TREATMENT|2020-09-24|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-23|P1Y2M10DT2H30M|UNKNOWN|2020-08-16|BEFORE|2020-09-15
e|RS|b7caaa04-bcc7-4350-ad98-85670a19778f|10|BMIVLIND|Bone Marrow Involvement Indicator|CHESON CLL 2012|[?]|mmHg|DISEASE TRANSFORMATION|1|TCID 50/dose|MODIFIED ACID FAST STAIN||||CHILD|RATER|N|5|Visit_5|90|6|FOLLOW-UP|2020-09-24|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-23|P1Y2M10DT2H30M|AFTER|2020-08-08|BEFORE|2020-08-27
e|RS|2b58d5fd-3ec8-415b-bb53-a252049f228a|1|MOLRESP|Molecular Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|mg/m2/min|RELAPSED DISEASE FROM CR|1|/40 HPFs|COMPLEMENT FIXATION||||FAMILY MEMBER|ENDOCRINOLOGIST|Y|1|Visit_1|10|5|TREATMENT|2020-12-17|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-02|P1Y2M10DT2H30M|UNKNOWN|2021-02-02|COINCIDENT|2021-03-15
e|RS|2b58d5fd-3ec8-415b-bb53-a252049f228a|2|NEWLIND|New Lesion Indicator|IWG CHESON AML 2003|[?]|Henry|OPTIMAL MORPHOLOGIC RESPONSE|1|m/sec|TRANSTHORACIC ECHOCARDIOGRAPHY||||FAMILY MEMBER|CLINICAL PATHOLOGIST|U|1|Visit_1|10|7|WASHOUT|2020-12-17|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-02|P1Y2M10DT2H30M|COINCIDENT|2021-01-25|COINCIDENT|2021-02-07
e|RS|2b58d5fd-3ec8-415b-bb53-a252049f228a|3|DRCRIND|Disease Recurrence Indicator|PALUMBO MULTIPLE MYELOMA 2009|[?]|mg/mL/day|PARTIAL MORPHOLOGIC RESPONSE|1|g/L|MICROPARTICLE ENZYME IMMUNOASSAY||||SPOUSE|CLINICAL PATHOLOGIST|NA|2|Visit_2|25|1|WASHOUT|2021-01-01|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-17|P1Y2M10DT2H30M|AFTER|2021-01-13|COINCIDENT|2021-02-22
e|RS|2b58d5fd-3ec8-415b-bb53-a252049f228a|4|NEWLIND|New Lesion Indicator|LUGANO CLASSIFICATION|||UNEQUIVOCAL|1|/10^5|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION||Y|Y|ADJUDICATOR|READER 1|U|2|Visit_2|25|6|TREATMENT|2021-01-01|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-17|P1Y2M10DT2H30M|UNKNOWN|2021-03-12|BEFORE|2021-03-16
e|RS|2b58d5fd-3ec8-415b-bb53-a252049f228a|5|BESTRESP|Best Overall Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|genEq/mL|CMR|1|10^6 organisms/mL|RYAN BLUE STAIN||||STUDY SUBJECT|NEUROLOGIST 2|NA|3|Visit_3|40|6|WASHOUT|2021-01-16|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-18|P1Y2M10DT2H30M|BEFORE|2020-12-17|COINCIDENT|2021-03-12
e|RS|2b58d5fd-3ec8-415b-bb53-a252049f228a|6|MJPTHIND|Major Pathological Response Indicator|CHESON MALIGNANT LYMPHOMA 2007|[?]|pkat|mCR|1|nmol/g|IMMUNOFIXATION ELECTROPHORESIS||||NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|NA|3|Visit_3|40|4|TREATMENT|2021-01-16|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-18|P1Y2M10DT2H30M|COINCIDENT|2021-01-03|ONGOING|2021-02-25
e|RS|2b58d5fd-3ec8-415b-bb53-a252049f228a|7|NTERESP|Non-Target Enhancing Response|JACINTO CERVICAL CANCER 2007|[?]|10^9/dose|CR|1|Bq/kg|URANYL ACETATE STAIN||||PROXY|MICROSCOPIST 2|Y|4|Visit_4|65|1|WASHOUT|2021-02-10|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-31|P1Y2M10DT2H30M|AFTER|2020-12-22|COINCIDENT|2020-12-24
e|RS|2b58d5fd-3ec8-415b-bb53-a252049f228a|8|CPRFSTAT|Clinical Performance Status|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|mV/sec|WORSENED|1|titer|CISH|Y|||SPOUSE|RATER 1|U|4|Visit_4|65|7|WASHOUT|2021-02-10|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-31|P1Y2M10DT2H30M|AFTER|2021-03-01|COINCIDENT|2021-03-13
e|RS|2b58d5fd-3ec8-415b-bb53-a252049f228a|9|NEWLWIND|New Lesion Worsening Indicator|MRECIST LENCIONI LIVER CANCER 2010|||CR-CT|1|BOX|SINGLE-SLICE SPIRAL CT|||Y|GUARDIAN|ADJUDICATOR 1|N|5|Visit_5|90|5|FOLLOW-UP|2021-03-07|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-07|P1Y2M10DT2H30M|AFTER|2020-12-20|BEFORE|2021-03-01
e|RS|2b58d5fd-3ec8-415b-bb53-a252049f228a|10|CPRFSTAT|Clinical Performance Status|RECICL|[?]|mg/mL/day|MRD PERSISTENCE|1|RNA copies/mL|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS||||PROXY|HEMATOLOGIST|U|5|Visit_5|90|3|TREATMENT|2021-03-07|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-07|P1Y2M10DT2H30M|BEFORE|2021-01-07|ONGOING|2021-02-01
e|RS|60b23345-43f6-42eb-9225-5a674456c9b9|1|CYTORESP|Cytogenetic Response|MONTSERRAT CLL 1989|[?]|nmol/mol|NOT ALL EVALUATED|1|titer|SISH||||PROXY|CLINICAL PATHOLOGIST|NA|1|Visit_1|10|3|SCREENING|2021-01-15|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-03|P1Y2M10DT2H30M|UNKNOWN|2021-04-13|BEFORE|2021-04-14
e|RS|60b23345-43f6-42eb-9225-5a674456c9b9|2|MRPHRESP|Morphologic Response|WOLCHOK SOLID TUMORS 2009|[?]|kIU|PD|1|DAgU|LISSAMINE GREEN STAIN||||CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|1|Visit_1|10|1|TREATMENT|2021-01-15|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-03|P1Y2M10DT2H30M|AFTER|2021-01-08|BEFORE|2021-03-09
e|RS|60b23345-43f6-42eb-9225-5a674456c9b9|3|BONERESP|Bone Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|||NON-QUANTIFIABLE MRD POSITIVITY|1|mL/m2/day|PET/CT SCAN WITHOUT CONTRAST|||Y|CAREGIVER|ONCOLOGIST 1|U|2|Visit_2|25|7|SCREENING|2021-01-30|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-11|P1Y2M10DT2H30M|AFTER|2021-01-19|AFTER|2021-03-01
e|RS|60b23345-43f6-42eb-9225-5a674456c9b9|4|NEWLIND|New Lesion Indicator|CHOLLET BREAST CANCER 2002|[?]|nsec|UNEQUIVOCAL|1|ugEq/L|TEMPLATE INCISION METHOD||||CLINICAL RESEARCH COORDINATOR|READER 2|NA|2|Visit_2|25|1|TREATMENT|2021-01-30|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-11|P1Y2M10DT2H30M|AFTER|2021-02-16|ONGOING|2021-03-08
e|RS|60b23345-43f6-42eb-9225-5a674456c9b9|5|NTRGRESP|Non-target Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|cGy|PARTIAL MORPHOLOGIC RESPONSE|1|m/sec2|CRYOSCOPY||||SIBLING|ONCOLOGIST 2|NA|3|Visit_3|40|3|TREATMENT|2021-02-14|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-05|P1Y2M10DT2H30M|AFTER|2021-02-13|BEFORE|2021-04-07
e|RS|60b23345-43f6-42eb-9225-5a674456c9b9|6|CPRFSTAT|Clinical Performance Status|RECICL|[?]|U/mmol|CYTOGENETIC MINOR RESPONSE|1|anti-Xa IU|FARR ASSAY||||SPOUSE|ONCOLOGIST|NA|3|Visit_3|40|7|TREATMENT|2021-02-14|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-05|P1Y2M10DT2H30M|BEFORE|2021-01-07|AFTER|2021-02-13
e|RS|60b23345-43f6-42eb-9225-5a674456c9b9|7|TMRESP|Tumor Marker Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|U/kg/day|pCR|1|foz_br|BRDU CELLULAR PROLIFERATION ASSAY||||STUDY SUBJECT|OPHTHALMOLOGIST|N|4|Visit_4|65|2|FOLLOW-UP|2021-03-11|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-30|P1Y2M10DT2H30M|UNKNOWN|2021-03-21|BEFORE|2021-04-08
e|RS|60b23345-43f6-42eb-9225-5a674456c9b9|8|LIVRRESP|Liver Response|EASL BRUIX LIVER CANCER 2001|[?]|days/wk|CMR|1|NEBULE|INCISION-INDUCED BLEEDING METHOD||Y||NON-HEALTH CARE PROFESSIONAL|RATER 2|U|4|Visit_4|65|4|SCREENING|2021-03-11|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-30|P1Y2M10DT2H30M|UNKNOWN|2021-02-06|BEFORE|2021-03-19
e|RS|60b23345-43f6-42eb-9225-5a674456c9b9|9|TRGRESP|Target Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|L/s/kPa|QUANTIFIABLE MRD POSITIVITY|1|mEq/ug|TEST STRIP||Y||INTERVIEWER|MICROSCOPIST 3|NA|5|Visit_5|90|3|SCREENING|2021-04-05|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-04|P1Y2M10DT2H30M|COINCIDENT|2021-03-28|BEFORE|2021-04-09
e|RS|60b23345-43f6-42eb-9225-5a674456c9b9|10|BMIVLIND|Bone Marrow Involvement Indicator|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|mL/dL|DECREASED|1|TRANSDUCING UNIT/mL|PULSE OXIMETRY||||ADJUDICATION COMMITTEE|ONCOLOGIST 1|Y|5|Visit_5|90|3|TREATMENT|2021-04-05|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-04|P1Y2M10DT2H30M|UNKNOWN|2021-01-08|AFTER|2021-03-26
e|RS|7979239e-2a6b-48e3-9d11-41c97b33d229|1|CYTORESP|Cytogenetic Response|PCWG SCHER PROSTATE CANCER 2008|||PD|1|/cmH2O|HPLC|||Y|STUDY SUBJECT|ONCOLOGIST 2|NA|1|Visit_1|10|6|TREATMENT|2021-01-15|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-20|P1Y2M10DT2H30M|UNKNOWN|2021-02-12|ONGOING|2021-04-12
e|RS|7979239e-2a6b-48e3-9d11-41c97b33d229|2|PATHRESP|Pathologic Response|CHESON LYMPHOMA 2008|||CR-CT|1|PACKAGE|U-HPLC/MS/MS|||Y|ADJUDICATOR|OPTOMETRIST|NA|1|Visit_1|10|3|FOLLOW-UP|2021-01-15|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-20|P1Y2M10DT2H30M|UNKNOWN|2021-01-11|BEFORE|2021-03-05
e|RS|7979239e-2a6b-48e3-9d11-41c97b33d229|3|SFTSRESP|Soft Tissue Response|CHOI GIST 2008|||RELAPSED DISEASE|1|/2000 RBC|TRANSVAGINAL ULTRASOUND||Y|Y|DOMESTIC PARTNER|FORENSIC PATHOLOGIST|U|2|Visit_2|25|6|FOLLOW-UP|2021-01-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-11|P1Y2M10DT2H30M|AFTER|2021-02-27|AFTER|2021-03-18
e|RS|7979239e-2a6b-48e3-9d11-41c97b33d229|4|DRCRIND|Disease Recurrence Indicator|AJCC V7|[?]|g/m2/day|iUPD|1|mg/kg/day|REBOUND TONOMETRY||||DOMESTIC PARTNER|MICROSCOPIST|U|2|Visit_2|25|1|TREATMENT|2021-01-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-11|P1Y2M10DT2H30M|BEFORE|2021-01-14|AFTER|2021-03-16
e|RS|7979239e-2a6b-48e3-9d11-41c97b33d229|5|NTRGRESP|Non-target Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|cmol/L|PSEUDOPROGRESSION|1|/2500 WBC|LANDOLT RING||||ADJUDICATION COMMITTEE|MICROSCOPIST 3|U|3|Visit_3|40|3|TREATMENT|2021-02-14|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-27|P1Y2M10DT2H30M|AFTER|2021-03-25|BEFORE|2021-04-09
e|RS|7979239e-2a6b-48e3-9d11-41c97b33d229|6|ANATRESP|Anatomic Response|FAROOQUI SUPP CLL 2014|[?]|mg/m2/h|MRD NEGATIVITY|1|U/m2/day|TEMPLATE INCISION METHOD|Y|||INDEPENDENT ASSESSOR|ADJUDICATOR 3|U|3|Visit_3|40|5|TREATMENT|2021-02-14|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-27|P1Y2M10DT2H30M|COINCIDENT|2021-01-22|BEFORE|2021-03-28
e|RS|7979239e-2a6b-48e3-9d11-41c97b33d229|7|BMIVLIND|Bone Marrow Involvement Indicator|DOHNER AML 2010|[?]|nsec|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|Gravitational Unit|OLIGO ACGH||||CHILD|MICROSCOPIST 3|U|4|Visit_4|65|3|FOLLOW-UP|2021-03-11|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-08|P1Y2M10DT2H30M|COINCIDENT|2021-03-27|AFTER|2021-04-14
e|RS|7979239e-2a6b-48e3-9d11-41c97b33d229|8|METSIND|Metastatic Indicator|MONTSERRAT CLL 1989|||NE|1|uL/kg/day|TRIPLE-PHASE SPIRAL CT SCAN|||Y|SIGNIFICANT OTHER|ADJUDICATOR 2|N|4|Visit_4|65|4|WASHOUT|2021-03-11|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-08|P1Y2M10DT2H30M|COINCIDENT|2021-01-07|AFTER|2021-03-08
e|RS|7979239e-2a6b-48e3-9d11-41c97b33d229|9|NTNERESP|Non-Target Non-Enhancing Response|RANO|[?]|nCi|cPR|1|mg/m2/h|PLETHYSMOGRAPHY|Y|||INDEPENDENT ASSESSOR|MICROSCOPIST 3|N|5|Visit_5|90|3|TREATMENT|2021-04-05|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-07|P1Y2M10DT2H30M|AFTER|2021-01-25|AFTER|2021-03-28
e|RS|7979239e-2a6b-48e3-9d11-41c97b33d229|10|SYMPTDTR|Symptomatic Deterioration|MRANO VAN DEN BENT GLIOMA 2011|[?]|um/day|PR|1|GBq/ug|KINETIC CHROMOGENIC ASSAY||||CAREGIVER|NEUROLOGIST 1|U|5|Visit_5|90|5|WASHOUT|2021-04-05|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-07|P1Y2M10DT2H30M|UNKNOWN|2021-04-14|BEFORE|2021-04-15
e|RS|027cd2f5-6bb8-41b2-8fb7-16ebff6155f1|1|NTERESP|Non-Target Enhancing Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|mL/breath|iCPD|1|10^9/g|CONTRAST ENHANCED PET SCAN||||CLINICAL RESEARCH ASSOCIATE|DERMATOLOGIST|N|1|Visit_1|10|1|WASHOUT|2020-08-06|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-31|P1Y2M10DT2H30M|AFTER|2020-09-28|AFTER|2020-10-01
e|RS|027cd2f5-6bb8-41b2-8fb7-16ebff6155f1|2|NEWLIND|New Lesion Indicator|WHO BREAST CANCER 2006|[?]|uCi|IMPROVED|1|g/mol|ENZYMATIC SPECTROPHOTOMETRY||Y||ADJUDICATOR|INTERNIST|U|1|Visit_1|10|2|TREATMENT|2020-08-06|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-31|P1Y2M10DT2H30M|AFTER|2020-07-30|AFTER|2020-08-23
e|RS|027cd2f5-6bb8-41b2-8fb7-16ebff6155f1|3|MNPTHIND|Minor Pathological Response Indicator|JACINTO CERVICAL CANCER 2007|[?]|mL/g/day|PD|1|m/sec2|MALDI||Y||INDEPENDENT ASSESSOR|PATHOLOGIST 2|U|2|Visit_2|25|5|TREATMENT|2020-08-21|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-13|P1Y2M10DT2H30M|AFTER|2020-09-14|AFTER|2020-10-26
e|RS|027cd2f5-6bb8-41b2-8fb7-16ebff6155f1|4|NTRGRESP|Non-target Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|ug/L|NON-CR/NON-PD|1|mgEq|SLIT LAMP PHOTOGRAPHY||||VENDOR|OTOLARYNGOLOGIST|Y|2|Visit_2|25|7|WASHOUT|2020-08-21|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-13|P1Y2M10DT2H30M|UNKNOWN|2020-08-09|ONGOING|2020-08-10
e|RS|027cd2f5-6bb8-41b2-8fb7-16ebff6155f1|5|NTERESP|Non-Target Enhancing Response|IWG CHESON MDS 2000|[?]|EID 50/dose|NOT ALL EVALUATED|1|10^3 organisms/g|OPTICAL DENSITY MEASUREMENT||||ADJUDICATOR|RATER 1|N|3|Visit_3|40|7|SCREENING|2020-09-05|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-28|P1Y2M10DT2H30M|COINCIDENT|2020-08-09|BEFORE|2020-10-05
e|RS|027cd2f5-6bb8-41b2-8fb7-16ebff6155f1|6|SYMPTDTR|Symptomatic Deterioration|EASL BRUIX LIVER CANCER 2001|[?]|nkat/g Hb|MR|1|grain|DYNAMOMETRY||||DOMESTIC PARTNER|PEDIATRIC NEUROLOGIST|Y|3|Visit_3|40|2|TREATMENT|2020-09-05|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-28|P1Y2M10DT2H30M|AFTER|2020-09-30|BEFORE|2020-10-12
e|RS|027cd2f5-6bb8-41b2-8fb7-16ebff6155f1|7|PATHRESP|Pathologic Response|BRUGGEMANN MRD 2010|[?]|Bq/ug|DISEASE TRANSFORMATION|1|h*%|IHC|Y|||FRIEND|PEDIATRIC NEUROLOGIST|N|4|Visit_4|65|2|TREATMENT|2020-09-30|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-25|P1Y2M10DT2H30M|BEFORE|2020-11-02|AFTER|2020-11-03
e|RS|027cd2f5-6bb8-41b2-8fb7-16ebff6155f1|8|CPRFSTAT|Clinical Performance Status|PERCIST|[?]|BOLUS|HI-P|1|10^9/L|STATIC PERIMETRY|Y|||CAREGIVER|RATER 2|NA|4|Visit_4|65|3|SCREENING|2020-09-30|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-25|P1Y2M10DT2H30M|UNKNOWN|2020-09-02|ONGOING|2020-10-21
e|RS|027cd2f5-6bb8-41b2-8fb7-16ebff6155f1|9|NEWLWIND|New Lesion Worsening Indicator|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|IU/kg|PSA PROGRESSION|1|10^6 organisms/g|MICROSCOPY||Y||CLINICAL RESEARCH ASSOCIATE|READER|Y|5|Visit_5|90|2|TREATMENT|2020-10-25|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-15|P1Y2M10DT2H30M|BEFORE|2020-08-09|ONGOING|2020-08-18
e|RS|027cd2f5-6bb8-41b2-8fb7-16ebff6155f1|10|DRCRIND|Disease Recurrence Indicator|KUMAR IMWG 2016|[?]|kHz|MRD NEGATIVITY|1|mm/sec|VENTILATION PERFUSION LUNG SCAN||||ADJUDICATOR|PATHOLOGIST|Y|5|Visit_5|90|5|TREATMENT|2020-10-25|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-15|P1Y2M10DT2H30M|AFTER|2020-08-31|ONGOING|2020-09-11
e|RS|3107cfa6-4eb9-433c-9cc6-79ec64f916f9|1|DRCRIND|Disease Recurrence Indicator|PCWG SCHER PROSTATE CANCER 2008|[?]|OD Unit|RELAPSED DISEASE FROM CR|1|g/cage/wk|MRI WITHOUT CONTRAST|Y|||SIBLING|HEMATOLOGIST|NA|1|Visit_1|10|1|TREATMENT|2021-01-05|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-21|P1Y2M10DT2H30M|BEFORE|2021-03-29|ONGOING|2021-04-03
e|RS|3107cfa6-4eb9-433c-9cc6-79ec64f916f9|2|SFTSRESP|Soft Tissue Response|DOHNER AML 2010|[?]|Shock Wave|nPR|1|mL/kg/min|LC-FL||||HEALTH CARE PROFESSIONAL|READER 3|NA|1|Visit_1|10|2|TREATMENT|2021-01-05|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-21|P1Y2M10DT2H30M|AFTER|2021-03-08|COINCIDENT|2021-03-10
e|RS|3107cfa6-4eb9-433c-9cc6-79ec64f916f9|3|TMRESP|Tumor Marker Response|LUGANO CLASSIFICATION|[?]|in|iSD|1|g/cage/wk|CARDIAC THERMODILUTION||||INVESTIGATOR|UROLOGIST|U|2|Visit_2|25|7|SCREENING|2021-01-20|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-11|P1Y2M10DT2H30M|AFTER|2021-03-03|COINCIDENT|2021-04-03
e|RS|3107cfa6-4eb9-433c-9cc6-79ec64f916f9|4|DRCRIND|Disease Recurrence Indicator|WHO BREAST CANCER 2006|||MRD PERSISTENCE|1|10^9/dose|PET SCAN||Y|Y|PROXY|NEUROLOGIST 2|Y|2|Visit_2|25|5|WASHOUT|2021-01-20|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-11|P1Y2M10DT2H30M|COINCIDENT|2021-03-04|COINCIDENT|2021-03-22
e|RS|3107cfa6-4eb9-433c-9cc6-79ec64f916f9|5|NEWLPROG|New Lesion Progression|RECICL|[?]|V/sec|PD/RELAPSE AFTER HI|1|FEU|NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY||||FRIEND|NEUROLOGIST 2|Y|3|Visit_3|40|2|SCREENING|2021-02-04|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-12|P1Y2M10DT2H30M|COINCIDENT|2021-03-15|BEFORE|2021-03-23
e|RS|3107cfa6-4eb9-433c-9cc6-79ec64f916f9|6|METBRESP|Metabolic Response|CHESON CLL 2012|[?]|10^8 PFU|PSA PROGRESSION|1|cL|HPLC-FL||||CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 3|N|3|Visit_3|40|7|TREATMENT|2021-02-04|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-12|P1Y2M10DT2H30M|UNKNOWN|2021-03-16|COINCIDENT|2021-03-27
e|RS|3107cfa6-4eb9-433c-9cc6-79ec64f916f9|7|CYTORESP|Cytogenetic Response|JACINTO CERVICAL CANCER 2007|||mCR|1|SBE/mL|LANDOLT RING|||Y|INDEPENDENT ASSESSOR|UROLOGIST|N|4|Visit_4|65|1|TREATMENT|2021-03-01|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-29|P1Y2M10DT2H30M|BEFORE|2021-01-18|COINCIDENT|2021-02-18
e|RS|3107cfa6-4eb9-433c-9cc6-79ec64f916f9|8|NEWLIND|New Lesion Indicator|LEE LUNG CANCER 2011|[?]|mOsm/L|NE|1|bel|MICROBIAL CULTURE, LIQUID||Y||CHILD|ADJUDICATOR|Y|4|Visit_4|65|2|TREATMENT|2021-03-01|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-29|P1Y2M10DT2H30M|UNKNOWN|2021-02-03|COINCIDENT|2021-03-31
e|RS|3107cfa6-4eb9-433c-9cc6-79ec64f916f9|9|MRDRESP|Minimal Residual Disease Response|MACDONALD GLIOMA 1990|||NON-iCR/NON-iUPD|1|mL/m2/h|TRANSESOPHAGEAL ECHOCARDIOGRAPHY|||Y|SIGNIFICANT OTHER|MICROSCOPIST|N|5|Visit_5|90|6|SCREENING|2021-03-26|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-27|P1Y2M10DT2H30M|COINCIDENT|2021-01-08|ONGOING|2021-01-30
e|RS|3107cfa6-4eb9-433c-9cc6-79ec64f916f9|10|CPRFSTAT|Clinical Performance Status|iRECIST|[?]|ugEq|NON-QUANTIFIABLE MRD POSITIVITY|1|Ci/g|PHOTOMETRIC CLOT DETECTION|Y|||GUARDIAN|MICROSCOPIST 2|NA|5|Visit_5|90|1|WASHOUT|2021-03-26|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-27|P1Y2M10DT2H30M|UNKNOWN|2021-02-18|ONGOING|2021-03-04
e|RS|da35fc01-4258-4e4d-99d9-4172e84c46e8|1|TRGRESP|Target Response|IWG CHESON AML 2003|[?]|dpm/mL|OPTIMAL MORPHOLOGIC RESPONSE|1|uIU/dL|PET/CT SCAN WITHOUT CONTRAST||||FAMILY MEMBER|READER 2|NA|1|Visit_1|10|2|TREATMENT|2020-07-22|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-16|P1Y2M10DT2H30M|AFTER|2020-09-27|AFTER|2020-09-28
e|RS|da35fc01-4258-4e4d-99d9-4172e84c46e8|2|BESTRESP|Best Overall Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|mV/sec|RELAPSED DISEASE FROM CR|1|/40 HPFs|CYSTOMETRY|Y|||STUDY SUBJECT|ADJUDICATOR 1|N|1|Visit_1|10|1|SCREENING|2020-07-22|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-16|P1Y2M10DT2H30M|BEFORE|2020-08-15|BEFORE|2020-09-04
e|RS|da35fc01-4258-4e4d-99d9-4172e84c46e8|3|NEWLIND|New Lesion Indicator|TSUKASAKI LEUKEMIA LYMPHOMA 2009|||CYTOGENETIC MINOR RESPONSE|1|mmol/day|WESTERGREN|Y||Y|CLINICAL RESEARCH COORDINATOR|DERMATOLOGIST|NA|2|Visit_2|25|4|SCREENING|2020-08-06|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-23|P1Y2M10DT2H30M|AFTER|2020-07-30|ONGOING|2020-09-27
e|RS|da35fc01-4258-4e4d-99d9-4172e84c46e8|4|TMRESP|Tumor Marker Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|mCi/kg|PMR|1|10^3 DNA copies/mL|TEMPLATE INCISION METHOD|Y|||CLINICAL STUDY SPONSOR|READER 3|N|2|Visit_2|25|2|TREATMENT|2020-08-06|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-23|P1Y2M10DT2H30M|BEFORE|2020-08-22|BEFORE|2020-09-13
e|RS|da35fc01-4258-4e4d-99d9-4172e84c46e8|5|MRDIND|Minimal Residual Disease Indicator|DOHNER AML 2010|[?]|10^6/g|CR|1|mL/cage/wk|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY||||HEALTH CARE PROFESSIONAL|OPTOMETRIST|N|3|Visit_3|40|5|TREATMENT|2020-08-21|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-09|P1Y2M10DT2H30M|BEFORE|2020-09-07|ONGOING|2020-09-17
e|RS|da35fc01-4258-4e4d-99d9-4172e84c46e8|6|CLINRESP|Clinical Response|EBMT BLADE MYELOMA 1998|[?]|ug/g/day|MR|1|mL/m2|THICK SMEAR|Y|||CLINICAL STUDY SPONSOR|ENDOCRINOLOGIST|N|3|Visit_3|40|3|SCREENING|2020-08-21|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-09|P1Y2M10DT2H30M|AFTER|2020-08-05|BEFORE|2020-09-25
e|RS|da35fc01-4258-4e4d-99d9-4172e84c46e8|7|MRDRESP|Minimal Residual Disease Response|RECICL|[?]|ug/g/day|cPR|1|Log10 ELISA unit|CONTRAST ENHANCED PET SCAN||||FRIEND|RATER|NA|4|Visit_4|65|2|FOLLOW-UP|2020-09-15|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-15|P1Y2M10DT2H30M|AFTER|2020-09-16|BEFORE|2020-09-18
e|RS|da35fc01-4258-4e4d-99d9-4172e84c46e8|8|DRCRIND|Disease Recurrence Indicator|PALUMBO MULTIPLE MYELOMA 2009|||CMR|1|SQU/mL|DISK DIFFUSION|Y||Y|ADJUDICATOR|RATER|NA|4|Visit_4|65|3|FOLLOW-UP|2020-09-15|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-15|P1Y2M10DT2H30M|BEFORE|2020-09-30|COINCIDENT|2020-10-12
e|RS|da35fc01-4258-4e4d-99d9-4172e84c46e8|9|BMIVLIND|Bone Marrow Involvement Indicator|IWG CHESON AML 2003|||DISEASE TRANSFORMATION|1|mL/day|FLUORESCENT LIFETIME IMAGING MICROSCOPY||Y|Y|FRIEND|PATHOLOGIST 1|N|5|Visit_5|90|6|SCREENING|2020-10-10|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-22|P1Y2M10DT2H30M|AFTER|2020-10-11|AFTER|2020-10-15
e|RS|da35fc01-4258-4e4d-99d9-4172e84c46e8|10|DRCRIND|Disease Recurrence Indicator|RANO ELLINGSON 2017|[?]|GBq/mg|SD-CT|1|FINGERTIP UNIT|DYNAMOMETRY||||GUARDIAN|RADIOLOGIST 1|NA|5|Visit_5|90|3|WASHOUT|2020-10-10|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-22|P1Y2M10DT2H30M|BEFORE|2020-10-14|ONGOING|2020-10-16
e|RS|bd163bba-f977-4f1a-8baf-5b6e7ecd94d9|1|MOLRESP|Molecular Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|%(w/w)|TREATMENT FAILURE|1|ppm|TWO-COLOR MICROARRAY||||STUDY SUBJECT|ONCOLOGIST|Y|1|Visit_1|10|4|WASHOUT|2020-08-04|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-13|P1Y2M10DT2H30M|BEFORE|2020-10-03|ONGOING|2020-10-20
e|RS|bd163bba-f977-4f1a-8baf-5b6e7ecd94d9|2|TMRESP|Tumor Marker Response|LUGANO CLASSIFICATION|[?]|GBq/ug|HI-P|1|MPS U|AUTOMATED COUNT||||INVESTIGATOR|DERMATOLOGIST|NA|1|Visit_1|10|7|WASHOUT|2020-08-04|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-13|P1Y2M10DT2H30M|UNKNOWN|2020-08-20|AFTER|2020-10-26
e|RS|bd163bba-f977-4f1a-8baf-5b6e7ecd94d9|3|ANATRESP|Anatomic Response|LEE LUNG CANCER 2011|||CA125 75% RESPONSE|1|10^4/hpf|OPHTHALMOSCOPY|||Y|CLINICAL STUDY SPONSOR|RADIOLOGIST 2|U|2|Visit_2|25|3|TREATMENT|2020-08-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-16|P1Y2M10DT2H30M|BEFORE|2020-09-24|AFTER|2020-10-10
e|RS|bd163bba-f977-4f1a-8baf-5b6e7ecd94d9|4|BONERESP|Bone Response|HAMAOKA BREAST CANCER 2010|[?]|STEPS|ABSENT MORPHOLOGIC RESPONSE|1|mph|HEMAGGLUTINATION INHIBITION ASSAY||||DOMESTIC PARTNER|MICROSCOPIST 2|NA|2|Visit_2|25|7|SCREENING|2020-08-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-16|P1Y2M10DT2H30M|BEFORE|2020-08-23|COINCIDENT|2020-09-16
e|RS|bd163bba-f977-4f1a-8baf-5b6e7ecd94d9|5|TRGRESP|Target Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|cm/min|NON-QUANTIFIABLE MRD POSITIVITY|1|HOMEOPATHIC DILUTION|THIN SMEAR||||HEALTH CARE PROFESSIONAL|RATER 2|NA|3|Visit_3|40|5|FOLLOW-UP|2020-09-03|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-29|P1Y2M10DT2H30M|UNKNOWN|2020-10-02|ONGOING|2020-10-24
e|RS|bd163bba-f977-4f1a-8baf-5b6e7ecd94d9|6|ANATRESP|Anatomic Response|PERCIST|[?]|uEq/L|iCR|1|U/mL|FLUORESCEIN STAIN|Y|Y||DOMESTIC PARTNER|RADIOLOGIST 1|Y|3|Visit_3|40|6|WASHOUT|2020-09-03|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-29|P1Y2M10DT2H30M|COINCIDENT|2020-09-02|AFTER|2020-10-06
e|RS|bd163bba-f977-4f1a-8baf-5b6e7ecd94d9|7|SYMPTDTR|Symptomatic Deterioration|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|||PDu|1|nmol/mol|KINETIC CHROMOGENIC ASSAY|Y||Y|FAMILY MEMBER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|4|Visit_4|65|6|TREATMENT|2020-09-28|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-08|P1Y2M10DT2H30M|AFTER|2020-08-30|ONGOING|2020-10-24
e|RS|bd163bba-f977-4f1a-8baf-5b6e7ecd94d9|8|NTERESP|Non-Target Enhancing Response|IWG CHESON MDS 2000|[?]|log10 CFU/mL|HI-P|1|pm|FARNSWORTH-MUNSELL 100 HUE TEST||||HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|N|4|Visit_4|65|7|WASHOUT|2020-09-28|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-08|P1Y2M10DT2H30M|BEFORE|2020-09-01|BEFORE|2020-09-25
e|RS|bd163bba-f977-4f1a-8baf-5b6e7ecd94d9|9|CLINRESP|Clinical Response|BRUGGEMANN MRD 2010|[?]|mm|QUANTIFIABLE MRD POSITIVITY|1|cmHg|DOPPLER ULTRASOUND||||FRIEND|INTERNIST|NA|5|Visit_5|90|4|SCREENING|2020-10-23|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-08|P1Y2M10DT2H30M|UNKNOWN|2020-09-16|AFTER|2020-10-26
e|RS|bd163bba-f977-4f1a-8baf-5b6e7ecd94d9|10|CYTORESP|Cytogenetic Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|kg/L|OPTIMAL MORPHOLOGIC RESPONSE|1|mV/sec|COLORIMETRY||||CLINICAL RESEARCH COORDINATOR|READER 2|U|5|Visit_5|90|7|TREATMENT|2020-10-23|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-08|P1Y2M10DT2H30M|AFTER|2020-08-30|BEFORE|2020-10-05
e|RS|ddcd6b0e-ca09-4693-bdfc-33e7d7979a6f|1|SFTSRESP|Soft Tissue Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|10^6/Ejaculate U|RELAPSED DISEASE FROM CR OR PR|1|MBq/uL|FLUORESCENT MICROSCOPY||Y||HEALTH CARE PROFESSIONAL|ADJUDICATOR|Y|1|Visit_1|10|2|TREATMENT|2020-12-14|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-30|P1Y2M10DT2H30M|AFTER|2021-02-05|COINCIDENT|2021-02-13
e|RS|ddcd6b0e-ca09-4693-bdfc-33e7d7979a6f|2|BESTRESP|Best Overall Response|RECICL|[?]|copies/mL|CRi|1|CAPLET|QUANTITATIVE ULTRASOUND|Y|||CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 1|Y|1|Visit_1|10|2|TREATMENT|2020-12-14|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-30|P1Y2M10DT2H30M|BEFORE|2021-02-19|COINCIDENT|2021-03-02
e|RS|ddcd6b0e-ca09-4693-bdfc-33e7d7979a6f|3|TRGRESP|Target Response|SHINDOH COLORECTAL CANCER 2013|[?]|amp|CYTOGENETIC NO RESPONSE|1|ug|CLAUSS METHOD||||VENDOR|OPHTHALMOLOGIST|N|2|Visit_2|25|1|WASHOUT|2020-12-29|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-04|P1Y2M10DT2H30M|COINCIDENT|2020-12-24|COINCIDENT|2021-01-02
e|RS|ddcd6b0e-ca09-4693-bdfc-33e7d7979a6f|4|NTRGRESP|Non-target Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|||INDETERMINATE RESPONSE|1|ft|ACID FAST STAIN|||Y|CAREGIVER|READER 2|Y|2|Visit_2|25|7|TREATMENT|2020-12-29|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-04|P1Y2M10DT2H30M|BEFORE|2020-12-15|COINCIDENT|2021-02-08
e|RS|ddcd6b0e-ca09-4693-bdfc-33e7d7979a6f|5|TMRESP|Tumor Marker Response|PCWG SCHER PROSTATE CANCER 2016|[?]|/LSQN|CYTOGENETIC NO RESPONSE|1|PACKET|IMMUNE REPERTOIRE DEEP SEQUENCING|Y|Y||SIGNIFICANT OTHER|RATER|NA|3|Visit_3|40|4|FOLLOW-UP|2021-01-13|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-04|P1Y2M10DT2H30M|UNKNOWN|2020-12-09|COINCIDENT|2021-01-29
e|RS|ddcd6b0e-ca09-4693-bdfc-33e7d7979a6f|6|MRPHRESP|Morphologic Response|CHESON CLL 2006|[?]|hPa|PD/RELAPSE AFTER HI|1|uU/L|ACRIDINE ORANGE STAIN|Y|||CLINICAL RESEARCH COORDINATOR|READER 1|N|3|Visit_3|40|1|SCREENING|2021-01-13|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-04|P1Y2M10DT2H30M|COINCIDENT|2021-01-01|COINCIDENT|2021-01-30
e|RS|ddcd6b0e-ca09-4693-bdfc-33e7d7979a6f|7|ANATRESP|Anatomic Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|||HI-P|1|pm|FUNDUS PHOTOGRAPHY|||Y|GUARDIAN|ONCOLOGIST 2|N|4|Visit_4|65|1|FOLLOW-UP|2021-02-07|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-12|P1Y2M10DT2H30M|UNKNOWN|2021-01-14|COINCIDENT|2021-02-06
e|RS|ddcd6b0e-ca09-4693-bdfc-33e7d7979a6f|8|OVRLRESP|Overall Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|||cCR|1|mmol|IMMUNE REPERTOIRE DEEP SEQUENCING||Y|Y|GUARDIAN|CARDIOLOGIST|U|4|Visit_4|65|3|TREATMENT|2021-02-07|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-12|P1Y2M10DT2H30M|UNKNOWN|2021-02-03|BEFORE|2021-02-18
e|RS|ddcd6b0e-ca09-4693-bdfc-33e7d7979a6f|9|MNPTHIND|Minor Pathological Response Indicator|KUKER LYMPHOMA 2005|[?]|mL|HI-P|1|cm|TRANSCRIPTION-MEDIATED AMPLIFICATION||||INTERVIEWER|READER 1|Y|5|Visit_5|90|5|WASHOUT|2021-03-04|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-03|P1Y2M10DT2H30M|UNKNOWN|2021-02-20|BEFORE|2021-02-23
e|RS|ddcd6b0e-ca09-4693-bdfc-33e7d7979a6f|10|NTERESP|Non-Target Enhancing Response|DOHNER AML 2010|[?]|IU/g|CRi|1|10^8 PFU|ULTRASONOGRAPHIC ELASTOGRAPHY|Y|Y||SIGNIFICANT OTHER|MICROSCOPIST|Y|5|Visit_5|90|7|FOLLOW-UP|2021-03-04|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-03|P1Y2M10DT2H30M|COINCIDENT|2021-01-08|ONGOING|2021-02-26
e|RS|31b865ec-cf8f-499f-85e9-931dbfa2cf1c|1|NEWLWIND|New Lesion Worsening Indicator|WOLCHOK SOLID TUMORS 2009|[?]|nmol BCE/L|UNEQUIVOCAL|1|cmH2O*s/mL|IMMUNOCHEMILUMINOMETRIC ASSAY||||ADJUDICATION COMMITTEE|ADJUDICATOR 1|Y|1|Visit_1|10|2|FOLLOW-UP|2020-06-09|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-23|P1Y2M10DT2H30M|COINCIDENT|2020-06-01|AFTER|2020-09-04
e|RS|31b865ec-cf8f-499f-85e9-931dbfa2cf1c|2|RDIORESP|Radiologic Response|CHOI GIST 2008|[?]|pptr|RELAPSED DISEASE|1|mL/mmHg|MALDI-TOF||Y||CLINICAL STUDY SPONSOR|RATER 1|U|1|Visit_1|10|4|WASHOUT|2020-06-09|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-23|P1Y2M10DT2H30M|UNKNOWN|2020-09-05|BEFORE|2020-09-06
e|RS|31b865ec-cf8f-499f-85e9-931dbfa2cf1c|3|CYTORESP|Cytogenetic Response|RECIST 1.1|||PD/RELAPSE AFTER HI|1|10^6/g|TOTAL BODY IRRADIATION||Y|Y|SIGNIFICANT OTHER|PHYSIOTHERAPIST|U|2|Visit_2|25|2|TREATMENT|2020-06-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-29|P1Y2M10DT2H30M|UNKNOWN|2020-06-04|AFTER|2020-08-19
e|RS|31b865ec-cf8f-499f-85e9-931dbfa2cf1c|4|SFTSRESP|Soft Tissue Response|GUPPY OVARIAN CANCER 2002|[?]|U/animal|HI-P|1|g/cage/wk|PALPATION|Y|||NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|NA|2|Visit_2|25|2|SCREENING|2020-06-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-29|P1Y2M10DT2H30M|COINCIDENT|2020-08-22|COINCIDENT|2020-08-31
e|RS|31b865ec-cf8f-499f-85e9-931dbfa2cf1c|5|METBRESP|Metabolic Response|GUILHOT CML 2007|[?]|10^9 organisms|RELAPSED DISEASE FROM CR|1|DAYS|ENZYMATIC COLORIMETRY||||ADJUDICATOR|CARDIOLOGIST|N|3|Visit_3|40|5|TREATMENT|2020-07-09|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-05|P1Y2M10DT2H30M|UNKNOWN|2020-06-20|BEFORE|2020-07-03
e|RS|31b865ec-cf8f-499f-85e9-931dbfa2cf1c|6|NEWLPROG|New Lesion Progression|EASL BRUIX LIVER CANCER 2001|[?]|hr/day|SD-CT|1|ugEq/L|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY||||FRIEND|OTOLARYNGOLOGIST|Y|3|Visit_3|40|3|WASHOUT|2020-07-09|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-05|P1Y2M10DT2H30M|BEFORE|2020-06-14|COINCIDENT|2020-06-29
e|RS|31b865ec-cf8f-499f-85e9-931dbfa2cf1c|7|NTERESP|Non-Target Enhancing Response|IWC HALLEK CLL 2008|[?]|um/s|CYTOGENETIC PR|1|10^6 organisms/mg|SPECT/CT SCAN||||STUDY SUBJECT|NEUROLOGIST|NA|4|Visit_4|65|4|WASHOUT|2020-08-03|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-15|P1Y2M10DT2H30M|BEFORE|2020-07-10|COINCIDENT|2020-08-01
e|RS|31b865ec-cf8f-499f-85e9-931dbfa2cf1c|8|HEMARESP|Hematologic Response|SCHER PROSTATE CANCER 2011|[?]|GBq|SD|1|amol|LC/MS||||FRIEND|MICROSCOPIST 3|N|4|Visit_4|65|7|WASHOUT|2020-08-03|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-15|P1Y2M10DT2H30M|BEFORE|2020-07-26|BEFORE|2020-07-28
e|RS|31b865ec-cf8f-499f-85e9-931dbfa2cf1c|9|BESTRESP|Best Overall Response|SCHER PROSTATE CANCER 2011|||RELAPSED DISEASE|1|10^6 IU/mL|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY||Y|Y|DOMESTIC PARTNER|READER|Y|5|Visit_5|90|4|TREATMENT|2020-08-28|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-18|P1Y2M10DT2H30M|COINCIDENT|2020-07-18|COINCIDENT|2020-08-05
e|RS|31b865ec-cf8f-499f-85e9-931dbfa2cf1c|10|ANATRESP|Anatomic Response|BRUGGEMANN MRD 2010|[?]|mL/mmHg|PSA PROGRESSION|1|EVENTS|MICROBIAL BIOCHEMICAL IDENTIFICATION||||SPOUSE|ENDOCRINOLOGIST|U|5|Visit_5|90|2|WASHOUT|2020-08-28|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-18|P1Y2M10DT2H30M|UNKNOWN|2020-08-07|AFTER|2020-08-15
e|RS|3f5d82c3-eb6c-4b9a-8fb7-10cf59e6d4bd|1|METBRESP|Metabolic Response|BLAZER COLORECTAL CANCER 2008|[?]|mmol2/L2|MOLECULAR CR|1|nkat/L|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY||||FAMILY MEMBER|NEUROLOGIST 2|N|1|Visit_1|10|7|FOLLOW-UP|2020-05-24|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-03|P1Y2M10DT2H30M|BEFORE|2020-07-17|ONGOING|2020-07-26
e|RS|3f5d82c3-eb6c-4b9a-8fb7-10cf59e6d4bd|2|NTNERESP|Non-Target Non-Enhancing Response|MURPHY PROSTATE CANCER 1980|[?]|EIA unit|INCREASED|1|vg/dose|SLOAN LETTER EYE CHART 100%||||INTERVIEWER|NEUROLOGIST 1|U|1|Visit_1|10|6|SCREENING|2020-05-24|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-03|P1Y2M10DT2H30M|AFTER|2020-06-07|ONGOING|2020-07-30
e|RS|3f5d82c3-eb6c-4b9a-8fb7-10cf59e6d4bd|3|NEWLWIND|New Lesion Worsening Indicator|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|SFC/10^6 PBMC|CYTOGENETIC PR|1|cm/min|LISSAMINE GREEN STAIN||Y||SPOUSE|PATHOLOGIST 2|U|2|Visit_2|25|7|TREATMENT|2020-06-08|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-02|P1Y2M10DT2H30M|BEFORE|2020-07-17|BEFORE|2020-07-27
e|RS|3f5d82c3-eb6c-4b9a-8fb7-10cf59e6d4bd|4|DRCRIND|Disease Recurrence Indicator|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|U/g/day|CR|1|CUP|IMMUNORADIOMETRIC ASSAY||||HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|U|2|Visit_2|25|2|TREATMENT|2020-06-08|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-02|P1Y2M10DT2H30M|COINCIDENT|2020-07-23|AFTER|2020-08-04
e|RS|3f5d82c3-eb6c-4b9a-8fb7-10cf59e6d4bd|5|MRPHRESP|Morphologic Response|RECIST 1.1|[?]|PA|pCR|1|vg/mL|SEQUENCING||Y||INDEPENDENT ASSESSOR|READER 2|U|3|Visit_3|40|2|TREATMENT|2020-06-23|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-14|P1Y2M10DT2H30M|COINCIDENT|2020-07-22|ONGOING|2020-08-17
e|RS|3f5d82c3-eb6c-4b9a-8fb7-10cf59e6d4bd|6|CLINRESP|Clinical Response|AJCC V8|[?]|log EID 50/dose|iCR|1|ug/min|IMMUNODIFFUSION|Y|||CLINICAL RESEARCH ASSOCIATE|READER 1|Y|3|Visit_3|40|3|TREATMENT|2020-06-23|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-14|P1Y2M10DT2H30M|UNKNOWN|2020-08-07|COINCIDENT|2020-08-11
e|RS|3f5d82c3-eb6c-4b9a-8fb7-10cf59e6d4bd|7|CPRFSTAT|Clinical Performance Status|MURPHY PROSTATE CANCER 1980|[?]|uV*sec|PD-CT|1|BOWL|TOLUIDINE BLUE STAIN||||CAREGIVER|ADJUDICATOR 2|U|4|Visit_4|65|7|TREATMENT|2020-07-18|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-10|P1Y2M10DT2H30M|COINCIDENT|2020-07-06|AFTER|2020-08-10
e|RS|3f5d82c3-eb6c-4b9a-8fb7-10cf59e6d4bd|8|DRCRIND|Disease Recurrence Indicator|LEE LUNG CANCER 2011|[?]|PACK|FAVORABLE RESPONSE|1|10^8/L|CELL BASED BIOASSAY|Y|||HEALTH CARE PROFESSIONAL|NEUROLOGIST|N|4|Visit_4|65|4|TREATMENT|2020-07-18|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-10|P1Y2M10DT2H30M|AFTER|2020-08-04|AFTER|2020-08-14
e|RS|3f5d82c3-eb6c-4b9a-8fb7-10cf59e6d4bd|9|SYMPTDTR|Symptomatic Deterioration|EUROPEAN LEUKEMIANET BACCARANI CML 2006|||PDu|1|Siemens|NON-CONTACT SPECULAR MICROSCOPY||Y|Y|SPOUSE|MICROSCOPIST 2|U|5|Visit_5|90|1|WASHOUT|2020-08-12|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-16|P1Y2M10DT2H30M|BEFORE|2020-08-17|AFTER|2020-08-19
e|RS|3f5d82c3-eb6c-4b9a-8fb7-10cf59e6d4bd|10|ANATRESP|Anatomic Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|APL U|HI-E|1|mL/h|THERMAL IONIZATION MASS SPECTROMETRY||||PARENT|ONCOLOGIST|NA|5|Visit_5|90|3|WASHOUT|2020-08-12|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-16|P1Y2M10DT2H30M|UNKNOWN|2020-07-28|ONGOING|2020-08-20
e|RS|136d59c6-9645-447a-a047-68d33dbb708e|1|CLINRESP|Clinical Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|Rad|DISEASE TRANSFORMATION|1|mg/mL/min|HEMAGGLUTINATION ASSAY||||FAMILY MEMBER|PATHOLOGIST|Y|1|Visit_1|10|3|SCREENING|2020-09-24|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-12|P1Y2M10DT2H30M|BEFORE|2020-10-22|BEFORE|2020-10-25
e|RS|136d59c6-9645-447a-a047-68d33dbb708e|2|HEMARESP|Hematologic Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|MPL U|PR WITH LYMPHOCYTOSIS|1|cg|PHOTOGRAPHY||||VENDOR|PHYSIOTHERAPIST|Y|1|Visit_1|10|3|TREATMENT|2020-09-24|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-12|P1Y2M10DT2H30M|UNKNOWN|2020-10-21|BEFORE|2020-12-18
e|RS|136d59c6-9645-447a-a047-68d33dbb708e|3|BMIVLIND|Bone Marrow Involvement Indicator|FAROOQUI SUPP CLL 2014|[?]|EP U|CYTOGENETIC CR|1|kg/m2|MAGNETIC RESONANCE ENTEROGRAPHY||||ADJUDICATOR|READER 1|N|2|Visit_2|25|2|TREATMENT|2020-10-09|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-22|P1Y2M10DT2H30M|COINCIDENT|2020-10-26|COINCIDENT|2020-11-20
e|RS|136d59c6-9645-447a-a047-68d33dbb708e|4|HEMARESP|Hematologic Response|SCHWARZ CERVICAL CANCER 2009|[?]|ug/kg/h|mCR|1|copies/ug|IVY INCISION METHOD|Y|||CHILD|MICROSCOPIST 3|NA|2|Visit_2|25|6|FOLLOW-UP|2020-10-09|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-22|P1Y2M10DT2H30M|BEFORE|2020-10-15|ONGOING|2020-12-02
e|RS|136d59c6-9645-447a-a047-68d33dbb708e|5|LIVRRESP|Liver Response|KUMAR IMWG 2016|[?]|DAgU/mL|DISEASE TRANSFORMATION|1|ug/g/h|REBOUND TONOMETRY|Y|||SIBLING|RADIOLOGIST|Y|3|Visit_3|40|6|TREATMENT|2020-10-24|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-21|P1Y2M10DT2H30M|COINCIDENT|2020-10-14|BEFORE|2020-11-06
e|RS|136d59c6-9645-447a-a047-68d33dbb708e|6|CYTORESP|Cytogenetic Response|GCIG RUSTIN OVARIAN CANCER 2011|||MORPHOLOGIC LEUKEMIA-FREE STATE|1|Enzyme U/L|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|Y||Y|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 2|NA|3|Visit_3|40|1|FOLLOW-UP|2020-10-24|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-21|P1Y2M10DT2H30M|COINCIDENT|2020-11-20|COINCIDENT|2020-12-19
e|RS|136d59c6-9645-447a-a047-68d33dbb708e|7|STRUSTAT|Steroid Use Status|PALUMBO MULTIPLE MYELOMA 2009|[?]|Tbsp|PR-CT|1|pmol/10^9 cells|ELLA||||INDEPENDENT ASSESSOR|ONCOLOGIST 2|NA|4|Visit_4|65|6|TREATMENT|2020-11-18|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-07|P1Y2M10DT2H30M|AFTER|2020-10-23|ONGOING|2020-11-01
e|RS|136d59c6-9645-447a-a047-68d33dbb708e|8|NTNERESP|Non-Target Non-Enhancing Response|LUGANO CLASSIFICATION|||MRD RELAPSE|1|mg/g/h|COLORIMETRY|||Y|PROXY|PATHOLOGIST|N|4|Visit_4|65|6|SCREENING|2020-11-18|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-07|P1Y2M10DT2H30M|UNKNOWN|2020-10-18|ONGOING|2020-12-04
e|RS|136d59c6-9645-447a-a047-68d33dbb708e|9|NTLWIND|Non-Target Lesion Worsening Indicator|GUILHOT CML 2007|[?]|/100 WBC|PR WITH LYMPHOCYTOSIS|1|vg/kg|CLIP SEQUENCING|Y|Y||NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|NA|5|Visit_5|90|7|TREATMENT|2020-12-13|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-30|P1Y2M10DT2H30M|BEFORE|2020-10-08|AFTER|2020-11-25
e|RS|136d59c6-9645-447a-a047-68d33dbb708e|10|SYMPTDTR|Symptomatic Deterioration|PALUMBO MULTIPLE MYELOMA 2009|[?]|mU/g|IMMUNOPHENOTYPIC CR|1|mmol/g|MICROBIAL CULTURE, SOLID||||CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 3|N|5|Visit_5|90|7|FOLLOW-UP|2020-12-13|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-30|P1Y2M10DT2H30M|COINCIDENT|2020-10-17|BEFORE|2020-12-07
e|RS|2e393b90-213c-4661-ad55-cabb2008bf14|1|BESTRESP|Best Overall Response|HARTMANN GERM CELL CANCER 2002|[?]|TROCHE|ABSENT MORPHOLOGIC RESPONSE|1|mmHg*min/L|GC/FID|Y|||SIBLING|OPHTHALMOLOGIST|N|1|Visit_1|10|3|FOLLOW-UP|2020-06-26|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-17|P1Y2M10DT2H30M|COINCIDENT|2020-09-07|BEFORE|2020-09-11
e|RS|2e393b90-213c-4661-ad55-cabb2008bf14|2|BONERESP|Bone Response|UNSPECIFIED|[?]|mol/mg|IMPROVED|1|uEq|CONTRAST ENHANCED X-RAY||||CAREGIVER|OPTOMETRIST|U|1|Visit_1|10|1|FOLLOW-UP|2020-06-26|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-17|P1Y2M10DT2H30M|UNKNOWN|2020-08-07|ONGOING|2020-08-30
e|RS|2e393b90-213c-4661-ad55-cabb2008bf14|3|METBRESP|Metabolic Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|mol/mol|STABLE|1|CIGARETTE|MICROARRAY|Y|||INDEPENDENT ASSESSOR|RATER|NA|2|Visit_2|25|2|FOLLOW-UP|2020-07-11|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-13|P1Y2M10DT2H30M|UNKNOWN|2020-07-15|BEFORE|2020-08-15
e|RS|2e393b90-213c-4661-ad55-cabb2008bf14|4|NEWLWIND|New Lesion Worsening Indicator|CHOI GIST 2008|[?]|mg/g/h|SD|1|fg|IMMUNOCHROMATOGRAPHY||Y||CLINICAL RESEARCH COORDINATOR|NEUROLOGIST|Y|2|Visit_2|25|1|TREATMENT|2020-07-11|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-13|P1Y2M10DT2H30M|UNKNOWN|2020-07-30|BEFORE|2020-08-23
e|RS|2e393b90-213c-4661-ad55-cabb2008bf14|5|PATHRESP|Pathologic Response|NCIWG CHESON CLL 1996|[?]|/LSQN|CA125 50% RESPONSE|1|kat|IRON HEMATOXYLIN STAIN||||SIBLING|READER 2|N|3|Visit_3|40|6|TREATMENT|2020-07-26|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-26|P1Y2M10DT2H30M|BEFORE|2020-08-04|BEFORE|2020-08-24
e|RS|2e393b90-213c-4661-ad55-cabb2008bf14|6|SFTSRESP|Soft Tissue Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|uL/mL|PSEUDORESPONSE|1|yd|RYAN BLUE STAIN||||GUARDIAN|ADJUDICATOR 1|N|3|Visit_3|40|3|SCREENING|2020-07-26|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-26|P1Y2M10DT2H30M|COINCIDENT|2020-07-20|BEFORE|2020-07-25
e|RS|2e393b90-213c-4661-ad55-cabb2008bf14|7|NTRGRESP|Non-target Response|IWG CHESON MDS 2006|||PMD|1|LB|SMEAR|||Y|PARENT|OPHTHALMOLOGIST|NA|4|Visit_4|65|7|FOLLOW-UP|2020-08-20|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-26|P1Y2M10DT2H30M|COINCIDENT|2020-09-13|ONGOING|2020-09-14
e|RS|2e393b90-213c-4661-ad55-cabb2008bf14|8|NTERESP|Non-Target Enhancing Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|U/g/min|iUPD|1|dpm/mg|OSCILLOMETRY||||ADJUDICATOR|ONCOLOGIST|Y|4|Visit_4|65|3|TREATMENT|2020-08-20|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-26|P1Y2M10DT2H30M|COINCIDENT|2020-08-31|ONGOING|2020-09-02
e|RS|2e393b90-213c-4661-ad55-cabb2008bf14|9|BMIVLIND|Bone Marrow Involvement Indicator|HARTMANN GERM CELL CANCER 2002|[?]|10^10/L|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|PELLET|CONTRAST ENHANCED X-RAY||Y||NON-HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|N|5|Visit_5|90|4|FOLLOW-UP|2020-09-14|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-19|P1Y2M10DT2H30M|AFTER|2020-06-23|ONGOING|2020-08-16
e|RS|2e393b90-213c-4661-ad55-cabb2008bf14|10|OVRLRESP|Overall Response|WOLCHOK SOLID TUMORS 2009|[?]|dpm/0.5 mL|HI-E|1|yd|CONTACT SPECULAR MICROSCOPY||||PROXY|HEMATOLOGIST|U|5|Visit_5|90|1|TREATMENT|2020-09-14|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-19|P1Y2M10DT2H30M|UNKNOWN|2020-07-31|BEFORE|2020-08-22
e|RS|f72002d8-262b-49da-84a4-42e6011286f0|1|HEMARESP|Hematologic Response|PERCIST|[?]|LB|MRD PERSISTENCE|1|mEq/L|ANGIOGRAPHY||||PARENT|OTOLARYNGOLOGIST|Y|1|Visit_1|10|2|TREATMENT|2020-10-14|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-12|P1Y2M10DT2H30M|BEFORE|2020-11-07|BEFORE|2020-12-07
e|RS|f72002d8-262b-49da-84a4-42e6011286f0|2|MRDRESP|Minimal Residual Disease Response|LUGANO CLASSIFICATION|[?]|Ci/L|CMR|1|/7.5 mL|WESTERN BLOT||||CLINICAL RESEARCH ASSOCIATE|DERMATOLOGIST|U|1|Visit_1|10|3|TREATMENT|2020-10-14|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-12|P1Y2M10DT2H30M|AFTER|2020-11-02|ONGOING|2020-12-18
e|RS|f72002d8-262b-49da-84a4-42e6011286f0|3|CYTORESP|Cytogenetic Response|SACT|[?]|mOsm/kg|SD-CT|1|amol|DIFFUSION WEIGHTED MRI||||CLINICAL RESEARCH ASSOCIATE|PEDIATRIC NEUROLOGIST|U|2|Visit_2|25|2|TREATMENT|2020-10-29|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-23|P1Y2M10DT2H30M|AFTER|2020-11-03|BEFORE|2020-11-28
e|RS|f72002d8-262b-49da-84a4-42e6011286f0|4|ANATRESP|Anatomic Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|vg/mL|iCPD|1|psi|INTERRUPTER TECHNIQUE||||SIBLING|READER 2|Y|2|Visit_2|25|7|TREATMENT|2020-10-29|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-23|P1Y2M10DT2H30M|UNKNOWN|2020-10-29|BEFORE|2020-12-03
e|RS|f72002d8-262b-49da-84a4-42e6011286f0|5|LIVRRESP|Liver Response|CHESON LYMPHOMA 2008|[?]|nmol|NED|1|uV2|PULSE OXIMETRY||||SIGNIFICANT OTHER|RADIOLOGIST|U|3|Visit_3|40|3|TREATMENT|2020-11-13|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-25|P1Y2M10DT2H30M|COINCIDENT|2021-01-04|BEFORE|2021-01-11
e|RS|f72002d8-262b-49da-84a4-42e6011286f0|6|BMIVLIND|Bone Marrow Involvement Indicator|PRINCE TCELL LYMPHOMA 2010|[?]|mm3/mm2/year|iPR|1|FFU|HIGH LEVEL AMINOGLYCOSIDE SCREEN|Y|||CLINICAL RESEARCH ASSOCIATE|HEMATOLOGIST|N|3|Visit_3|40|1|FOLLOW-UP|2020-11-13|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-25|P1Y2M10DT2H30M|AFTER|2020-11-13|ONGOING|2020-11-19
e|RS|f72002d8-262b-49da-84a4-42e6011286f0|7|ANATRESP|Anatomic Response|NCIWG CHESON CLL 1996|[?]|uL/mL|MORPHOLOGIC CRi|1|U/g|MULTI-SLICE SPIRAL CT||Y||CLINICAL STUDY SPONSOR|RADIOLOGIST|Y|4|Visit_4|65|2|TREATMENT|2020-12-08|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-11|P1Y2M10DT2H30M|BEFORE|2020-11-26|COINCIDENT|2020-12-23
e|RS|f72002d8-262b-49da-84a4-42e6011286f0|8|CPRFSTAT|Clinical Performance Status|MASS|||iUPD|1|ug/day|DISK DIFFUSION|||Y|INDEPENDENT ASSESSOR|MICROSCOPIST 2|Y|4|Visit_4|65|4|FOLLOW-UP|2020-12-08|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-11|P1Y2M10DT2H30M|UNKNOWN|2020-11-06|COINCIDENT|2021-01-05
e|RS|f72002d8-262b-49da-84a4-42e6011286f0|9|MJPTHIND|Major Pathological Response Indicator|AJCC V7|[?]|Bq/L|NON-QUANTIFIABLE MRD POSITIVITY|1|Siemens|HPLC-UV|Y|||INDEPENDENT ASSESSOR|NEUROLOGIST 2|Y|5|Visit_5|90|7|TREATMENT|2021-01-02|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-27|P1Y2M10DT2H30M|COINCIDENT|2020-10-10|AFTER|2020-11-06
e|RS|f72002d8-262b-49da-84a4-42e6011286f0|10|MRDRESP|Minimal Residual Disease Response|BURCOMBE BREAST CANCER 2005|[?]|mL/sec/1.73m2|sCR|1|10^3 DNA copies/mL|PHOROPTER|Y|Y||CHILD|INTERNIST|U|5|Visit_5|90|7|SCREENING|2021-01-02|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-27|P1Y2M10DT2H30M|AFTER|2020-11-16|BEFORE|2020-12-24
e|RS|68869dda-531d-4218-b2b0-4f5f46825569|1|SPLNRESP|Spleen Response|BRUGGEMANN MRD 2010|[?]|pmol/10^10 cells|COMPLETE MRD RESPONSE|1|mV2/Hz|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY||||CLINICAL RESEARCH COORDINATOR|READER 1|NA|1|Visit_1|10|6|FOLLOW-UP|2020-12-08|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-11|P1Y2M10DT2H30M|AFTER|2021-01-30|ONGOING|2021-02-07
e|RS|68869dda-531d-4218-b2b0-4f5f46825569|2|SPLNRESP|Spleen Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|mJoule/cm2|CA125 75% RESPONSE|1|Ci/kg|HEMAGGLUTINATION ASSAY||||CHILD|OPHTHALMOLOGIST|NA|1|Visit_1|10|2|FOLLOW-UP|2020-12-08|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-11|P1Y2M10DT2H30M|COINCIDENT|2021-03-04|BEFORE|2021-03-05
e|RS|68869dda-531d-4218-b2b0-4f5f46825569|3|NTRGRESP|Non-target Response|CHESON CLL 2012|||MINOR PATHOLOGIC RESPONSE|1|m2|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY|Y||Y|CHILD|PATHOLOGIST|N|2|Visit_2|25|5|SCREENING|2020-12-23|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-12|P1Y2M10DT2H30M|UNKNOWN|2021-01-27|BEFORE|2021-02-28
e|RS|68869dda-531d-4218-b2b0-4f5f46825569|4|NEWLIND|New Lesion Indicator|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|dpm/0.5 mL|PD FROM PR|1|Farad|MUGA||Y||CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 2|NA|2|Visit_2|25|1|TREATMENT|2020-12-23|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-12|P1Y2M10DT2H30M|COINCIDENT|2021-01-10|AFTER|2021-02-27
e|RS|68869dda-531d-4218-b2b0-4f5f46825569|5|STRUSTAT|Steroid Use Status|PERCIST|[?]|Siemens|PR-CT|1|/200 HPFs|TWO-COLOR MICROARRAY|Y|Y||SIGNIFICANT OTHER|ONCOLOGIST 2|U|3|Visit_3|40|5|WASHOUT|2021-01-07|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-19|P1Y2M10DT2H30M|COINCIDENT|2021-02-15|COINCIDENT|2021-02-17
e|RS|68869dda-531d-4218-b2b0-4f5f46825569|6|STRUSTAT|Steroid Use Status|IWG CHESON MDS 2006|||NE|1|mOsm/kg|MODIFIED ACID FAST STAIN|||Y|GUARDIAN|ADJUDICATOR|Y|3|Visit_3|40|5|WASHOUT|2021-01-07|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-19|P1Y2M10DT2H30M|UNKNOWN|2020-12-21|AFTER|2021-02-28
e|RS|68869dda-531d-4218-b2b0-4f5f46825569|7|SFTSRESP|Soft Tissue Response|EBMT BLADE MYELOMA 1998|[?]|mm/2h|IMMUNOPHENOTYPIC CR|1|kHz|INDIRECT IMMUNOFLUORESCENCE||||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|NA|4|Visit_4|65|2|TREATMENT|2021-02-01|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-16|P1Y2M10DT2H30M|UNKNOWN|2020-12-27|COINCIDENT|2021-01-15
e|RS|68869dda-531d-4218-b2b0-4f5f46825569|8|NEWLPROG|New Lesion Progression|UNSPECIFIED|||PR WITH LYMPHOCYTOSIS|1|mg/m2|HPLC-UV|||Y|STUDY SUBJECT|ENDOCRINOLOGIST|N|4|Visit_4|65|5|TREATMENT|2021-02-01|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-16|P1Y2M10DT2H30M|BEFORE|2021-02-24|AFTER|2021-02-25
e|RS|68869dda-531d-4218-b2b0-4f5f46825569|9|NEWLPROG|New Lesion Progression|BLAZER COLORECTAL CANCER 2008|||PSEUDOPROGRESSION|1|CARTRIDGE|CONGO RED STAIN|Y||Y|FAMILY MEMBER|CLINICAL PATHOLOGIST|U|5|Visit_5|90|7|TREATMENT|2021-02-26|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-26|P1Y2M10DT2H30M|BEFORE|2020-12-13|COINCIDENT|2021-01-29
e|RS|68869dda-531d-4218-b2b0-4f5f46825569|10|NTNERESP|Non-Target Non-Enhancing Response|CHESON CLL 2006|[?]|ug/m2|UNFAVORABLE RESPONSE|1|nsec|QUANTITATIVE COMPUTED TOMOGRAPHY||||SPOUSE|FORENSIC PATHOLOGIST|NA|5|Visit_5|90|2|SCREENING|2021-02-26|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-26|P1Y2M10DT2H30M|COINCIDENT|2020-12-04|COINCIDENT|2020-12-17
e|RS|68888445-1819-4f4c-bd0c-a445906476fb|1|CPRFSTAT|Clinical Performance Status|IWG CHESON MDS 2006|[?]|Enzyme U/m2|PD FROM PR|1|mmHg|CELLULOSE TAPE||||FRIEND|READER|U|1|Visit_1|10|5|TREATMENT|2021-01-14|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-10|P1Y2M10DT2H30M|COINCIDENT|2021-04-07|AFTER|2021-04-12
e|RS|68888445-1819-4f4c-bd0c-a445906476fb|2|BONERESP|Bone Response|AJCC V7|[?]|Bq/L|CRi|1|ug/day|MAMMOGRAPHY||||ADJUDICATOR|READER 1|N|1|Visit_1|10|3|TREATMENT|2021-01-14|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-10|P1Y2M10DT2H30M|UNKNOWN|2021-03-17|COINCIDENT|2021-03-30
e|RS|68888445-1819-4f4c-bd0c-a445906476fb|3|PATHRESP|Pathologic Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|||sCR|1|mg/cm2|LC/MS/MS|||Y|CLINICAL RESEARCH COORDINATOR|OPTOMETRIST|Y|2|Visit_2|25|6|FOLLOW-UP|2021-01-29|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-01|P1Y2M10DT2H30M|COINCIDENT|2021-01-10|ONGOING|2021-03-27
e|RS|68888445-1819-4f4c-bd0c-a445906476fb|4|MRPHRESP|Morphologic Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|uV*sec|NON-QUANTIFIABLE MRD POSITIVITY|1|U|NUCLEAR RADIOLOGY|Y|||SIGNIFICANT OTHER|RADIOLOGIST 2|Y|2|Visit_2|25|4|TREATMENT|2021-01-29|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-01|P1Y2M10DT2H30M|COINCIDENT|2021-04-08|AFTER|2021-04-11
e|RS|68888445-1819-4f4c-bd0c-a445906476fb|5|SYMPTDTR|Symptomatic Deterioration|RECICL|[?]|V/sec|PR-CT|1|10^6 organisms/g|ZIEHL NEELSEN ACID FAST STAIN||Y||VENDOR|ADJUDICATOR 2|Y|3|Visit_3|40|5|TREATMENT|2021-02-13|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-11|P1Y2M10DT2H30M|COINCIDENT|2021-02-14|COINCIDENT|2021-03-17
e|RS|68888445-1819-4f4c-bd0c-a445906476fb|6|MNPTHIND|Minor Pathological Response Indicator|AJCC V8|[?]|mMU/mL|RELAPSED DISEASE FROM CR|1|10^9/dose|IN SITU HYBRIDIZATION||||FAMILY MEMBER|ADJUDICATOR 1|NA|3|Visit_3|40|4|TREATMENT|2021-02-13|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-11|P1Y2M10DT2H30M|AFTER|2021-03-27|COINCIDENT|2021-04-11
e|RS|68888445-1819-4f4c-bd0c-a445906476fb|7|METSIND|Metastatic Indicator|PETIT BREAST CANCER 2001|||cCR|1|mg/mL/day|QUANTITATIVE PERIPHERAL ANGIOGRAPHY|Y||Y|CAREGIVER|CARDIOLOGIST|Y|4|Visit_4|65|7|TREATMENT|2021-03-10|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-21|P1Y2M10DT2H30M|AFTER|2021-03-24|BEFORE|2021-03-31
e|RS|68888445-1819-4f4c-bd0c-a445906476fb|8|NTLWIND|Non-Target Lesion Worsening Indicator|KEAM BREAST CANCER 2013|[?]|mL/s/m2|DISEASE TRANSFORMATION|1|FIU|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY||||PROXY|ADJUDICATOR 3|Y|4|Visit_4|65|2|TREATMENT|2021-03-10|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-21|P1Y2M10DT2H30M|UNKNOWN|2021-04-08|AFTER|2021-04-10
e|RS|68888445-1819-4f4c-bd0c-a445906476fb|9|ANATRESP|Anatomic Response|RECIST 1.1|[?]|CIGAR|ABSENT MORPHOLOGIC RESPONSE|1|m/sec|TRANSCRIPTION-MEDIATED AMPLIFICATION|Y|||CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 1|U|5|Visit_5|90|6|TREATMENT|2021-04-04|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-19|P1Y2M10DT2H30M|COINCIDENT|2021-04-03|AFTER|2021-04-11
e|RS|68888445-1819-4f4c-bd0c-a445906476fb|10|METSIND|Metastatic Indicator|PCWG SCHER PROSTATE CANCER 2008|[?]|pkat/L|PSEUDORESPONSE|1|10^4/hpf|IRON HEMATOXYLIN STAIN||Y||DOMESTIC PARTNER|ADJUDICATOR|Y|5|Visit_5|90|4|SCREENING|2021-04-04|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-19|P1Y2M10DT2H30M|AFTER|2021-03-09|COINCIDENT|2021-03-29
e|RS|b2ce31a0-513a-449a-aa2c-7c9668fde275|1|SYMPTDTR|Symptomatic Deterioration|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|amol|MRD RELAPSE|1|mL/(min*100mL)|MANUAL COUNT||||CLINICAL RESEARCH COORDINATOR|RATER 1|U|1|Visit_1|10|4|SCREENING|2020-06-24|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-14|P1Y2M10DT2H30M|UNKNOWN|2020-07-14|BEFORE|2020-07-20
e|RS|b2ce31a0-513a-449a-aa2c-7c9668fde275|2|PATHRESP|Pathologic Response|RECIST 1.0|[?]|mg2/dL2|NE|1|mL/kg/h|DIRECT SEQUENCING|Y|||FAMILY MEMBER|OPHTHALMOLOGIST|NA|1|Visit_1|10|1|SCREENING|2020-06-24|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-14|P1Y2M10DT2H30M|COINCIDENT|2020-07-16|AFTER|2020-07-20
e|RS|b2ce31a0-513a-449a-aa2c-7c9668fde275|3|SFTSRESP|Soft Tissue Response|JACINTO CERVICAL CANCER 2007|||DISEASE TRANSFORMATION|1|mm3/mm2/year|EEG||Y|Y|CLINICAL RESEARCH COORDINATOR|DERMATOLOGIST|Y|2|Visit_2|25|3|SCREENING|2020-07-09|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-23|P1Y2M10DT2H30M|COINCIDENT|2020-09-07|COINCIDENT|2020-09-10
e|RS|b2ce31a0-513a-449a-aa2c-7c9668fde275|4|PATHRESP|Pathologic Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|||PMR|1|vp/dose|TRANSTHORACIC ECHOCARDIOGRAPHY||Y|Y|FAMILY MEMBER|READER|NA|2|Visit_2|25|2|TREATMENT|2020-07-09|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-23|P1Y2M10DT2H30M|COINCIDENT|2020-08-28|COINCIDENT|2020-09-16
e|RS|b2ce31a0-513a-449a-aa2c-7c9668fde275|5|NEWLWIND|New Lesion Worsening Indicator|KEAM BREAST CANCER 2013|[?]|fraction of 1|MORPHOLOGIC CRi|1|10^9 organisms/mL|ENDPOINT DILUTION ASSAY||Y||NON-HEALTH CARE PROFESSIONAL|OPTOMETRIST|Y|3|Visit_3|40|2|FOLLOW-UP|2020-07-24|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-13|P1Y2M10DT2H30M|COINCIDENT|2020-09-03|BEFORE|2020-09-05
e|RS|b2ce31a0-513a-449a-aa2c-7c9668fde275|6|BESTRESP|Best Overall Response|GUILHOT CML 2007|[?]|nmol BCE/L|MRD RELAPSE|1|Ci/ug|MULTIPLEXED BEAD BASED IMMUNOASSAY||Y||PARENT|FORENSIC PATHOLOGIST|Y|3|Visit_3|40|2|TREATMENT|2020-07-24|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-13|P1Y2M10DT2H30M|AFTER|2020-07-04|ONGOING|2020-07-31
e|RS|b2ce31a0-513a-449a-aa2c-7c9668fde275|7|BESTRESP|Best Overall Response|UNSPECIFIED|[?]|IU/g|PMR|1|nkat/L|ATOMIC ABSORPTION SPECTROMETRY||||PROXY|NEUROLOGIST 2|NA|4|Visit_4|65|6|FOLLOW-UP|2020-08-18|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-10|P1Y2M10DT2H30M|BEFORE|2020-07-16|ONGOING|2020-08-03
e|RS|b2ce31a0-513a-449a-aa2c-7c9668fde275|8|NTLWIND|Non-Target Lesion Worsening Indicator|MONTSERRAT CLL 1989|[?]|ms2|CHR|1|mmol|ELECTROCHEMILUMINESCENCE IMMUNOASSAY|Y|||ADJUDICATION COMMITTEE|READER 2|N|4|Visit_4|65|4|TREATMENT|2020-08-18|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-10|P1Y2M10DT2H30M|COINCIDENT|2020-09-20|AFTER|2020-09-21
e|RS|b2ce31a0-513a-449a-aa2c-7c9668fde275|9|RDIORESP|Radiologic Response|KEAM BREAST CANCER 2013|[?]|10^3/hpf|CMR|1|kN/cm2|BIOPSY||Y||HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|Y|5|Visit_5|90|6|TREATMENT|2020-09-12|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-04|P1Y2M10DT2H30M|BEFORE|2020-08-28|BEFORE|2020-08-31
e|RS|b2ce31a0-513a-449a-aa2c-7c9668fde275|10|MRDRESP|Minimal Residual Disease Response|AJCC V8|[?]|ug/day|NON-CR/NON-PD|1|BU/mL|ANTIMICROBIAL COMBINATION TESTING|Y|||FRIEND|READER 1|N|5|Visit_5|90|5|WASHOUT|2020-09-12|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-04|P1Y2M10DT2H30M|AFTER|2020-06-23|COINCIDENT|2020-08-19
e|RS|6c1d481b-985a-4be0-97ca-ecd06a81b456|1|TMRESP|Tumor Marker Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|||MRD NEGATIVITY|1|m/sec|PHOROPTER|||Y|SPOUSE|NEUROLOGIST 2|NA|1|Visit_1|10|6|TREATMENT|2020-10-05|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-18|P1Y2M10DT2H30M|AFTER|2020-12-13|COINCIDENT|2020-12-27
e|RS|6c1d481b-985a-4be0-97ca-ecd06a81b456|2|BONERESP|Bone Response|HARTMAN PANCREATIC CANCER 2012|[?]|10^3 RNA copies/mL|MORPHOLOGIC CR|1|10^3 CFU|HEMATOXYLIN AND EOSIN STAIN|Y|||CAREGIVER|PATHOLOGIST 2|U|1|Visit_1|10|6|TREATMENT|2020-10-05|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-18|P1Y2M10DT2H30M|COINCIDENT|2020-10-03|AFTER|2020-11-24
e|RS|6c1d481b-985a-4be0-97ca-ecd06a81b456|3|NTERESP|Non-Target Enhancing Response|BURCOMBE BREAST CANCER 2005|||CR|1|FINGERTIP UNIT|INDIA INK STAIN|||Y|CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 1|Y|2|Visit_2|25|1|TREATMENT|2020-10-20|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-29|P1Y2M10DT2H30M|COINCIDENT|2020-12-02|AFTER|2020-12-17
e|RS|6c1d481b-985a-4be0-97ca-ecd06a81b456|4|METBRESP|Metabolic Response|SHINDOH COLORECTAL CANCER 2013|||CMR|1|KALLIKREIN INHIBITOR UNIT|BALLPOINT PEN TECHNIQUE|||Y|CHILD|PATHOLOGIST 2|Y|2|Visit_2|25|4|TREATMENT|2020-10-20|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-29|P1Y2M10DT2H30M|COINCIDENT|2020-12-20|COINCIDENT|2020-12-26
e|RS|6c1d481b-985a-4be0-97ca-ecd06a81b456|5|TMRESP|Tumor Marker Response|BRUGGEMANN MRD 2010|[?]|mL/breath|NOT ALL EVALUATED|1|RATIO|FLOW MICROSCOPY||Y||SIGNIFICANT OTHER|DERMATOLOGIST|U|3|Visit_3|40|7|TREATMENT|2020-11-04|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-14|P1Y2M10DT2H30M|BEFORE|2020-12-24|COINCIDENT|2020-12-31
e|RS|6c1d481b-985a-4be0-97ca-ecd06a81b456|6|METBRESP|Metabolic Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|fmol/g|PSEUDORESPONSE|1|mL/cm3/min|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI||Y||ADJUDICATOR|RATER|N|3|Visit_3|40|1|TREATMENT|2020-11-04|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-14|P1Y2M10DT2H30M|BEFORE|2020-12-01|ONGOING|2020-12-26
e|RS|6c1d481b-985a-4be0-97ca-ecd06a81b456|7|OVRLRESP|Overall Response|iRECIST|||MR|1|mg/cm2|SXA SCAN|Y||Y|SPOUSE|OPHTHALMOLOGIST|NA|4|Visit_4|65|5|SCREENING|2020-11-29|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-12|P1Y2M10DT2H30M|COINCIDENT|2020-12-16|AFTER|2021-01-02
e|RS|6c1d481b-985a-4be0-97ca-ecd06a81b456|8|PATHRESP|Pathologic Response|IWC HALLEK CLL 2008|[?]|mol/mL|CA125 75% RESPONSE|1|WEEKS|AUTOMATED COUNT||||NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST|Y|4|Visit_4|65|7|TREATMENT|2020-11-29|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-12|P1Y2M10DT2H30M|UNKNOWN|2020-10-25|BEFORE|2020-12-27
e|RS|6c1d481b-985a-4be0-97ca-ecd06a81b456|9|NEWLWIND|New Lesion Worsening Indicator|CHOLLET BREAST CANCER 2002|[?]|PIXELS/in|FAVORABLE RESPONSE|1|GPL U/mL|NUCLEAR RADIOLOGY||||VENDOR|FORENSIC PATHOLOGIST|NA|5|Visit_5|90|1|WASHOUT|2020-12-24|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-13|P1Y2M10DT2H30M|BEFORE|2020-09-27|COINCIDENT|2020-12-05
e|RS|6c1d481b-985a-4be0-97ca-ecd06a81b456|10|NEWLPROG|New Lesion Progression|BRUGGEMANN MRD 2010|||CHR|1|mL/m2/min|MANUAL CLOT DETECTION|||Y|ADJUDICATOR|ADJUDICATOR 2|N|5|Visit_5|90|7|WASHOUT|2020-12-24|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-13|P1Y2M10DT2H30M|AFTER|2020-12-13|BEFORE|2020-12-27
e|RS|645a9247-efcb-4641-9514-58d6e28560e0|1|BONERESP|Bone Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|gMFI|sCR|1|uL/dose|REBOUND TONOMETRY|Y|||SIGNIFICANT OTHER|OPTOMETRIST|N|1|Visit_1|10|5|TREATMENT|2020-12-21|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-29|P1Y2M10DT2H30M|COINCIDENT|2021-03-04|BEFORE|2021-03-18
e|RS|645a9247-efcb-4641-9514-58d6e28560e0|2|NTERESP|Non-Target Enhancing Response|EASL BRUIX LIVER CANCER 2001|[?]|copies/ug|INCREASED|1|Log10 ELISA unit/dose|ANALYTICAL ULTRACENTRIFUGATION||Y||SPOUSE|NEUROLOGIST|NA|1|Visit_1|10|4|TREATMENT|2020-12-21|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-29|P1Y2M10DT2H30M|BEFORE|2020-12-14|AFTER|2021-03-17
e|RS|645a9247-efcb-4641-9514-58d6e28560e0|3|LIVRRESP|Liver Response|GUILHOT CML 2007|[?]|genEq|nPR|1|cm/min|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION||||FRIEND|PATHOLOGIST|U|2|Visit_2|25|1|WASHOUT|2021-01-05|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-10|P1Y2M10DT2H30M|BEFORE|2021-02-23|ONGOING|2021-03-10
e|RS|645a9247-efcb-4641-9514-58d6e28560e0|4|STRUSTAT|Steroid Use Status|EBMT BLADE MYELOMA 1998|||PSEUDOPROGRESSION|1|/10^5|CELLULOSE TAPE|||Y|ADJUDICATOR|PATHOLOGIST 2|Y|2|Visit_2|25|5|WASHOUT|2021-01-05|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-10|P1Y2M10DT2H30M|AFTER|2021-02-24|ONGOING|2021-03-09
e|RS|645a9247-efcb-4641-9514-58d6e28560e0|5|CYTORESP|Cytogenetic Response|CHESON CLL 2006|[?]|ngEq/L|NON-PD|1|log10 TCID 50/uL|SINGLE-SLICE SPIRAL CT|Y|Y||GUARDIAN|RATER 2|NA|3|Visit_3|40|1|TREATMENT|2021-01-20|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-05|P1Y2M10DT2H30M|UNKNOWN|2021-03-06|AFTER|2021-03-15
e|RS|645a9247-efcb-4641-9514-58d6e28560e0|6|CPRFSTAT|Clinical Performance Status|CHOLLET BREAST CANCER 2002|[?]|copies/ug|COMPLETE MRD RESPONSE|1|umol/h/mmol|ANTIMICROBIAL COMBINATION TESTING||Y||ADJUDICATOR|RATER|NA|3|Visit_3|40|6|WASHOUT|2021-01-20|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-05|P1Y2M10DT2H30M|AFTER|2020-12-22|BEFORE|2021-01-05
e|RS|645a9247-efcb-4641-9514-58d6e28560e0|7|MRDIND|Minimal Residual Disease Indicator|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|mL/animal/day|CMR|1|U/g|TRANSMISSION ELECTRON MICROSCOPY||Y||CLINICAL RESEARCH COORDINATOR|NEUROLOGIST|Y|4|Visit_4|65|3|TREATMENT|2021-02-14|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-14|P1Y2M10DT2H30M|UNKNOWN|2021-02-15|BEFORE|2021-03-12
e|RS|645a9247-efcb-4641-9514-58d6e28560e0|8|NTERESP|Non-Target Enhancing Response|RECIST 1.0|[?]|Osm|NON-PD|1|mOsm/kg|ELECTRONEUROGRAPHY||Y||ADJUDICATION COMMITTEE|NEUROLOGIST|Y|4|Visit_4|65|3|TREATMENT|2021-02-14|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-14|P1Y2M10DT2H30M|UNKNOWN|2020-12-22|ONGOING|2021-01-14
e|RS|645a9247-efcb-4641-9514-58d6e28560e0|9|MNPTHIND|Minor Pathological Response Indicator|RECIST 1.0|[?]|mm2|NON-CR/NON-PD|1|cmol|CELL CYTOTOXICITY NEUTRALIZATION ASSAY||||FRIEND|MICROSCOPIST|U|5|Visit_5|90|3|TREATMENT|2021-03-11|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-25|P1Y2M10DT2H30M|COINCIDENT|2021-02-27|COINCIDENT|2021-03-17
e|RS|645a9247-efcb-4641-9514-58d6e28560e0|10|MJPTHIND|Major Pathological Response Indicator|BURCOMBE BREAST CANCER 2005|[?]|mg/L FEU|CRi|1|10^3 CFU|POLYSOMNOGRAPHY||||CHILD|MICROSCOPIST 2|Y|5|Visit_5|90|7|TREATMENT|2021-03-11|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-25|P1Y2M10DT2H30M|AFTER|2021-01-25|BEFORE|2021-03-15
e|RS|9e2164c8-0f5b-4951-83b8-487ed7b2d0a7|1|PATHRESP|Pathologic Response|KUKER LYMPHOMA 2005|[?]|gMFI|RELAPSED DISEASE|1|mEq/g|MOUSE PROTECTION ASSAY||||SPOUSE|ADJUDICATOR 2|U|1|Visit_1|10|2|FOLLOW-UP|2020-09-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-24|P1Y2M10DT2H30M|AFTER|2020-10-06|ONGOING|2020-11-03
e|RS|9e2164c8-0f5b-4951-83b8-487ed7b2d0a7|2|METBRESP|Metabolic Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|OD Unit|NED|1|10^6 CFU/g|LIQUID SCINTILLATION COUNTING||||PARENT|UROLOGIST|Y|1|Visit_1|10|7|TREATMENT|2020-09-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-24|P1Y2M10DT2H30M|COINCIDENT|2020-12-12|BEFORE|2020-12-13
e|RS|9e2164c8-0f5b-4951-83b8-487ed7b2d0a7|3|HEMARESP|Hematologic Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|GBq/ug|NED|1|uL/dose|WHOLE GENOME SEQUENCING||||FAMILY MEMBER|ONCOLOGIST|NA|2|Visit_2|25|7|FOLLOW-UP|2020-09-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-10|P1Y2M10DT2H30M|COINCIDENT|2020-09-19|BEFORE|2020-11-08
e|RS|9e2164c8-0f5b-4951-83b8-487ed7b2d0a7|4|MNPTHIND|Minor Pathological Response Indicator|UNSPECIFIED|||sCR|1|PHERESIS UNIT|BIOIMPEDANCE SPECTROSCOPY|||Y|VENDOR|ONCOLOGIST|U|2|Visit_2|25|2|SCREENING|2020-09-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-10|P1Y2M10DT2H30M|AFTER|2020-12-13|AFTER|2020-12-14
e|RS|9e2164c8-0f5b-4951-83b8-487ed7b2d0a7|5|OVRLRESP|Overall Response|DURIE MULTIPLE MYELOMA 2006|[?]|ug/kg/h|NE|1|kV|TRANSVAGINAL ULTRASOUND||||PROXY|DERMATOLOGIST|U|3|Visit_3|40|4|SCREENING|2020-10-15|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-05|P1Y2M10DT2H30M|UNKNOWN|2020-11-30|BEFORE|2020-12-13
e|RS|9e2164c8-0f5b-4951-83b8-487ed7b2d0a7|6|MRDRESP|Minimal Residual Disease Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|mmAL|IMMUNOPHENOTYPIC CR|1|fmol/L|BALLPOINT PEN TECHNIQUE||Y||FRIEND|ADJUDICATOR|NA|3|Visit_3|40|5|SCREENING|2020-10-15|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-05|P1Y2M10DT2H30M|UNKNOWN|2020-12-03|ONGOING|2020-12-06
e|RS|9e2164c8-0f5b-4951-83b8-487ed7b2d0a7|7|TMRESP|Tumor Marker Response|EBMT BLADE MYELOMA 1998|||DISEASE TRANSFORMATION|1|v/v|SURFACE PLASMON RESONANCE|Y||Y|ADJUDICATOR|INTERNIST|U|4|Visit_4|65|4|SCREENING|2020-11-09|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-20|P1Y2M10DT2H30M|COINCIDENT|2020-12-13|ONGOING|2020-12-14
e|RS|9e2164c8-0f5b-4951-83b8-487ed7b2d0a7|8|BONERESP|Bone Response|EBMT BLADE MYELOMA 1998|[?]|uV|PMD|1|DAYS|TELLER ACUITY CARDS||||STUDY SUBJECT|OPHTHALMOLOGIST|NA|4|Visit_4|65|2|WASHOUT|2020-11-09|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-20|P1Y2M10DT2H30M|AFTER|2020-09-14|AFTER|2020-10-02
e|RS|9e2164c8-0f5b-4951-83b8-487ed7b2d0a7|9|NTERESP|Non-Target Enhancing Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|mg/m2/min|ABSENT MORPHOLOGIC RESPONSE|1|mL/h|RADIOIMMUNOPRECIPITATION ASSAY||||CLINICAL STUDY SPONSOR|ADJUDICATOR|U|5|Visit_5|90|6|TREATMENT|2020-12-04|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-26|P1Y2M10DT2H30M|UNKNOWN|2020-11-10|BEFORE|2020-12-06
e|RS|9e2164c8-0f5b-4951-83b8-487ed7b2d0a7|10|ANATRESP|Anatomic Response|DOHNER AML 2010|[?]|MESF|CYTOGENETIC NO RESPONSE|1|genEq|LANDOLT RING||||PARENT|RATER 2|N|5|Visit_5|90|5|WASHOUT|2020-12-04|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-26|P1Y2M10DT2H30M|COINCIDENT|2020-10-31|COINCIDENT|2020-11-02
e|RS|05b05951-b1ba-4c51-b50f-9c842532bc4e|1|NEWLPROG|New Lesion Progression|CHOI GIST 2008|[?]|g/animal/wk|VGPR|1|GBq|MRI WITHOUT CONTRAST||||HEALTH CARE PROFESSIONAL|MICROSCOPIST|N|1|Visit_1|10|5|TREATMENT|2020-07-28|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-07|P1Y2M10DT2H30M|COINCIDENT|2020-09-17|BEFORE|2020-10-22
e|RS|05b05951-b1ba-4c51-b50f-9c842532bc4e|2|HEMARESP|Hematologic Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|||DISEASE TRANSFORMATION|1|kg|FLUORESCEIN STAIN|||Y|ADJUDICATOR|CLINICAL PATHOLOGIST|NA|1|Visit_1|10|7|TREATMENT|2020-07-28|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-07|P1Y2M10DT2H30M|AFTER|2020-10-15|ONGOING|2020-10-18
e|RS|05b05951-b1ba-4c51-b50f-9c842532bc4e|3|MRDRESP|Minimal Residual Disease Response|NCCN ALL MRD 2014|[?]|fmol/L|SMD|1|10^9 CFU/g|MANUAL COUNT|Y|||PROXY|NEUROLOGIST|U|2|Visit_2|25|3|TREATMENT|2020-08-12|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-30|P1Y2M10DT2H30M|COINCIDENT|2020-10-12|BEFORE|2020-10-15
e|RS|05b05951-b1ba-4c51-b50f-9c842532bc4e|4|CYTORESP|Cytogenetic Response|RECIST 1.0|[?]|10^6 DNA copies/mL|UNEQUIVOCAL|1|Pa|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY|Y|||GUARDIAN|PATHOLOGIST|NA|2|Visit_2|25|2|SCREENING|2020-08-12|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-30|P1Y2M10DT2H30M|AFTER|2020-09-07|AFTER|2020-09-21
e|RS|05b05951-b1ba-4c51-b50f-9c842532bc4e|5|RDIORESP|Radiologic Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|KIT|PD/RELAPSE AFTER HI|1|ks|MASS SPECTROMETRY|Y|Y||INDEPENDENT ASSESSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|3|Visit_3|40|6|TREATMENT|2020-08-27|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-06|P1Y2M10DT2H30M|BEFORE|2020-10-10|BEFORE|2020-10-22
e|RS|05b05951-b1ba-4c51-b50f-9c842532bc4e|6|OVRLRESP|Overall Response|SCHER PROSTATE CANCER 2011|||NON-CR/NON-PD|1|/10^5|BALLPOINT PEN TECHNIQUE|Y||Y|SIGNIFICANT OTHER|NEUROLOGIST|N|3|Visit_3|40|1|WASHOUT|2020-08-27|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-06|P1Y2M10DT2H30M|AFTER|2020-10-16|COINCIDENT|2020-10-18
e|RS|05b05951-b1ba-4c51-b50f-9c842532bc4e|7|BESTRESP|Best Overall Response|LUGANO CLASSIFICATION|[?]|10^6 organisms/g|CR|1|mmol/kg|QUANTITATIVE CORONARY ANGIOGRAPHY|Y|||GUARDIAN|RADIOLOGIST 2|U|4|Visit_4|65|2|FOLLOW-UP|2020-09-21|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-25|P1Y2M10DT2H30M|COINCIDENT|2020-09-11|BEFORE|2020-10-02
e|RS|05b05951-b1ba-4c51-b50f-9c842532bc4e|8|MRPHRESP|Morphologic Response|MASS|[?]|pg|nPR|1|ug/dL|RAJI CELL EIA||Y||FRIEND|CLINICAL PATHOLOGIST|NA|4|Visit_4|65|5|FOLLOW-UP|2020-09-21|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-25|P1Y2M10DT2H30M|UNKNOWN|2020-08-23|ONGOING|2020-10-18
e|RS|05b05951-b1ba-4c51-b50f-9c842532bc4e|9|PATHRESP|Pathologic Response|SCHER PROSTATE CANCER 2011|[?]|copies/ug|PD-CT|1|PELLET|SLIT LAMP PHOTOGRAPHY||||CLINICAL RESEARCH COORDINATOR|ENDOCRINOLOGIST|Y|5|Visit_5|90|1|FOLLOW-UP|2020-10-16|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-07|P1Y2M10DT2H30M|BEFORE|2020-07-31|AFTER|2020-08-27
e|RS|05b05951-b1ba-4c51-b50f-9c842532bc4e|10|METSIND|Metastatic Indicator|BRUGGEMANN MRD 2010|[?]|mg|SD|1|/LSQN|SNELLEN EYE CHART||||STUDY SUBJECT|RADIOLOGIST 2|Y|5|Visit_5|90|6|TREATMENT|2020-10-16|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-07|P1Y2M10DT2H30M|COINCIDENT|2020-09-11|ONGOING|2020-09-24
e|RS|ab38e976-8c2b-48ff-bdba-5a056637ecdd|1|NEWLWIND|New Lesion Worsening Indicator|WOLCHOK SOLID TUMORS 2009|[?]|km|DECREASED|1|scm|ERGOSPIROMETRY|Y|||PROXY|MICROSCOPIST|Y|1|Visit_1|10|1|WASHOUT|2020-10-23|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-30|P1Y2M10DT2H30M|AFTER|2021-01-10|ONGOING|2021-01-18
e|RS|ab38e976-8c2b-48ff-bdba-5a056637ecdd|2|NEWLIND|New Lesion Indicator|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|10^6 CFU/mL|WORSENED|1|Bq|MRS||||CAREGIVER|OTOLARYNGOLOGIST|N|1|Visit_1|10|2|TREATMENT|2020-10-23|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-30|P1Y2M10DT2H30M|UNKNOWN|2020-11-26|AFTER|2021-01-07
e|RS|ab38e976-8c2b-48ff-bdba-5a056637ecdd|3|BONERESP|Bone Response|RANO ELLINGSON 2017|[?]|PUFF|PDu|1|BOWL|SICKLE CELL SOLUBILITY TEST|Y|Y||SIGNIFICANT OTHER|HEMATOLOGIST|U|2|Visit_2|25|6|TREATMENT|2020-11-07|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-23|P1Y2M10DT2H30M|UNKNOWN|2020-12-05|COINCIDENT|2021-01-05
e|RS|ab38e976-8c2b-48ff-bdba-5a056637ecdd|4|STRUSTAT|Steroid Use Status|LUGANO CLASSIFICATION|[?]|ug/mol|CR|1|g/dL|BAC ACGH|Y|Y||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 3|NA|2|Visit_2|25|5|WASHOUT|2020-11-07|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-23|P1Y2M10DT2H30M|UNKNOWN|2020-12-28|AFTER|2020-12-30
e|RS|ab38e976-8c2b-48ff-bdba-5a056637ecdd|5|PATHRESP|Pathologic Response|CHOI GIST 2008|[?]|mgEq|PD-CT|1|DIOPTER|CONFOCAL MICROSCOPY||||INTERVIEWER|OTOLARYNGOLOGIST|Y|3|Visit_3|40|2|TREATMENT|2020-11-22|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-22|P1Y2M10DT2H30M|COINCIDENT|2020-11-10|COINCIDENT|2020-12-21
e|RS|ab38e976-8c2b-48ff-bdba-5a056637ecdd|6|ANATRESP|Anatomic Response|RANO ELLINGSON 2017|[?]|kDa|MRD RELAPSE|1|Ci/ug|MULTI-SLICE SPIRAL CT||||INTERVIEWER|PEDIATRIC NEUROLOGIST|U|3|Visit_3|40|5|WASHOUT|2020-11-22|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-22|P1Y2M10DT2H30M|BEFORE|2020-11-20|COINCIDENT|2020-12-13
e|RS|ab38e976-8c2b-48ff-bdba-5a056637ecdd|7|MNPTHIND|Minor Pathological Response Indicator|SCHER PROSTATE CANCER 2011|[?]|mol/day|EQUIVOCAL|1|g/mol|MAMMOGRAPHY||Y||INDEPENDENT ASSESSOR|INTERNIST|Y|4|Visit_4|65|2|TREATMENT|2020-12-17|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-04|P1Y2M10DT2H30M|BEFORE|2021-01-13|AFTER|2021-01-15
e|RS|ab38e976-8c2b-48ff-bdba-5a056637ecdd|8|NEWLIND|New Lesion Indicator|iRECIST|[?]|GPL U/mL|SD|1|g/animal/day|ORCHIDOMETERY|Y|||ADJUDICATION COMMITTEE|PHYSIOTHERAPIST|N|4|Visit_4|65|5|TREATMENT|2020-12-17|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-04|P1Y2M10DT2H30M|AFTER|2020-10-25|ONGOING|2020-11-21
e|RS|ab38e976-8c2b-48ff-bdba-5a056637ecdd|9|NTLWIND|Non-Target Lesion Worsening Indicator|MASS|[?]|mol|EQUIVOCAL|1|U/m2|DNA MICROARRAY||||CLINICAL STUDY SPONSOR|RATER|NA|5|Visit_5|90|5|TREATMENT|2021-01-11|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-05|P1Y2M10DT2H30M|BEFORE|2020-10-15|ONGOING|2020-11-18
e|RS|ab38e976-8c2b-48ff-bdba-5a056637ecdd|10|NEWLWIND|New Lesion Worsening Indicator|PALUMBO MULTIPLE MYELOMA 2009|[?]|mL/dL|CHR|1|vp/mL|MICROBIAL CONCENTRATION|Y|||INVESTIGATOR|UROLOGIST|N|5|Visit_5|90|5|TREATMENT|2021-01-11|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-05|P1Y2M10DT2H30M|BEFORE|2020-11-01|COINCIDENT|2020-12-27
e|RS|f19cb801-34fc-42fd-8691-ccfb6c5f8bb6|1|CLINRESP|Clinical Response|RECIST 1.0|||CYTOGENETIC MINIMAL RESPONSE|1|psi|SCINTIGRAPHY||Y|Y|DOMESTIC PARTNER|READER|Y|1|Visit_1|10|6|TREATMENT|2020-08-31|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-27|P1Y2M10DT2H30M|AFTER|2020-11-16|COINCIDENT|2020-11-25
e|RS|f19cb801-34fc-42fd-8691-ccfb6c5f8bb6|2|NTLWIND|Non-Target Lesion Worsening Indicator|NCCN ALL MRD 2014|[?]|L/h|MOLECULAR CR|1|10^3 organisms/g|MRS||||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 1|NA|1|Visit_1|10|6|TREATMENT|2020-08-31|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-27|P1Y2M10DT2H30M|BEFORE|2020-09-18|ONGOING|2020-09-30
e|RS|f19cb801-34fc-42fd-8691-ccfb6c5f8bb6|3|MOLRESP|Molecular Response|AJCC V7|||NR|1|ft|COMPLEMENT FIXATION|||Y|CHILD|DEVELOPMENTAL PSYCHOLOGIST|N|2|Visit_2|25|7|FOLLOW-UP|2020-09-15|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-06|P1Y2M10DT2H30M|BEFORE|2020-11-16|ONGOING|2020-11-18
e|RS|f19cb801-34fc-42fd-8691-ccfb6c5f8bb6|4|SYMPTDTR|Symptomatic Deterioration|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|/4.0 mL|pCR|1|STEPS|CELL OF ORIGIN ASSAY||||NON-HEALTH CARE PROFESSIONAL|READER 2|Y|2|Visit_2|25|2|TREATMENT|2020-09-15|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-06|P1Y2M10DT2H30M|UNKNOWN|2020-11-24|AFTER|2020-11-28
e|RS|f19cb801-34fc-42fd-8691-ccfb6c5f8bb6|5|HEMARESP|Hematologic Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|mL/dL|MRD PERSISTENCE|1|deg/s|KLEIHAUER-BETKE|Y|||INTERVIEWER|PATHOLOGIST 1|Y|3|Visit_3|40|4|TREATMENT|2020-09-30|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-09|P1Y2M10DT2H30M|BEFORE|2020-10-19|AFTER|2020-11-19
e|RS|f19cb801-34fc-42fd-8691-ccfb6c5f8bb6|6|SPLNRESP|Spleen Response|NCIWG CHESON CLL 1996|||CYTOGENETIC NO RESPONSE|1|mg2/dL2|SPIRAL CT|||Y|CLINICAL STUDY SPONSOR|READER 2|NA|3|Visit_3|40|6|TREATMENT|2020-09-30|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-09|P1Y2M10DT2H30M|BEFORE|2020-11-26|ONGOING|2020-11-28
e|RS|f19cb801-34fc-42fd-8691-ccfb6c5f8bb6|7|LIVRRESP|Liver Response|NCCN ALL MRD 2014|[?]|s*kPa|UNEQUIVOCAL|1|bel|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY||||FRIEND|INTERNIST|Y|4|Visit_4|65|6|TREATMENT|2020-10-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-18|P1Y2M10DT2H30M|UNKNOWN|2020-09-29|COINCIDENT|2020-10-16
e|RS|f19cb801-34fc-42fd-8691-ccfb6c5f8bb6|8|MOLRESP|Molecular Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|L/h/m2|PD|1|mmol/min/kPa|IMMUNOPRECIPITATION||||ADJUDICATION COMMITTEE|RATER|Y|4|Visit_4|65|1|SCREENING|2020-10-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-18|P1Y2M10DT2H30M|COINCIDENT|2020-10-12|AFTER|2020-11-05
e|RS|f19cb801-34fc-42fd-8691-ccfb6c5f8bb6|9|SPLNRESP|Spleen Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|DPM|RELAPSED DISEASE FROM CR OR PR|1|yd|ETDRS EYE CHART||||INTERVIEWER|FORENSIC PATHOLOGIST|NA|5|Visit_5|90|3|TREATMENT|2020-11-19|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-26|P1Y2M10DT2H30M|AFTER|2020-11-13|BEFORE|2020-11-17
e|RS|f19cb801-34fc-42fd-8691-ccfb6c5f8bb6|10|SYMPTDTR|Symptomatic Deterioration|EBMT BLADE MYELOMA 1998|||NON-PD|1|ft3|AUSCULTATION|||Y|CAREGIVER|ADJUDICATOR 2|N|5|Visit_5|90|1|FOLLOW-UP|2020-11-19|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-26|P1Y2M10DT2H30M|AFTER|2020-11-22|ONGOING|2020-11-28
e|RS|51a49847-6405-4842-b549-0e2ab99f61b2|1|TRGRESP|Target Response|IWC HALLEK CLL 2008|[?]|mL/g/day|iCPD|1|Enzyme U/g Hb|CELL BASED BIOASSAY||||SIBLING|ADJUDICATOR 3|U|1|Visit_1|10|4|TREATMENT|2021-01-16|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-27|P1Y2M10DT2H30M|COINCIDENT|2021-04-01|COINCIDENT|2021-04-13
e|RS|51a49847-6405-4842-b549-0e2ab99f61b2|2|SFTSRESP|Soft Tissue Response|SCHER PROSTATE CANCER 2011|[?]|/VF|CA125 75% RESPONSE|1|PUFF|DYNAMIC LIGHT SCATTERING|Y|||CLINICAL STUDY SPONSOR|CLINICAL PATHOLOGIST|N|1|Visit_1|10|5|TREATMENT|2021-01-16|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-27|P1Y2M10DT2H30M|UNKNOWN|2021-02-23|AFTER|2021-03-05
e|RS|51a49847-6405-4842-b549-0e2ab99f61b2|3|NTERESP|Non-Target Enhancing Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|mg/kg/dose|PR|1|ELISA unit/dose|SINGLE-SLICE SPIRAL CT||||FRIEND|PATHOLOGIST 2|U|2|Visit_2|25|5|SCREENING|2021-01-31|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-06|P1Y2M10DT2H30M|AFTER|2021-02-19|COINCIDENT|2021-02-27
e|RS|51a49847-6405-4842-b549-0e2ab99f61b2|4|BESTRESP|Best Overall Response|CHESON LYMPHOMA 2008|[?]|Ci/mg|HI-P|1|ms2|MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING||||FRIEND|ONCOLOGIST 1|U|2|Visit_2|25|6|TREATMENT|2021-01-31|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-06|P1Y2M10DT2H30M|UNKNOWN|2021-02-18|COINCIDENT|2021-04-09
e|RS|51a49847-6405-4842-b549-0e2ab99f61b2|5|NEWLPROG|New Lesion Progression|JUWEID NON-HODGKINS LYMPHOMA 2005|||NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|mL/h|OLIGO ACGH|Y||Y|FAMILY MEMBER|READER 1|U|3|Visit_3|40|4|TREATMENT|2021-02-15|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-16|P1Y2M10DT2H30M|BEFORE|2021-03-07|AFTER|2021-03-18
e|RS|51a49847-6405-4842-b549-0e2ab99f61b2|6|SYMPTDTR|Symptomatic Deterioration|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|pmol|MRD RELAPSE|1|Tbsp|GRADIENT DIFFUSION||||ADJUDICATOR|NEUROLOGIST 2|U|3|Visit_3|40|2|TREATMENT|2021-02-15|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-16|P1Y2M10DT2H30M|BEFORE|2021-04-13|BEFORE|2021-04-14
e|RS|51a49847-6405-4842-b549-0e2ab99f61b2|7|MNPTHIND|Minor Pathological Response Indicator|RECICL|||PD-CT|1|nkat/g Hb|MICROBIAL CONCENTRATION||Y|Y|HEALTH CARE PROFESSIONAL|ADJUDICATOR 1|N|4|Visit_4|65|7|SCREENING|2021-03-12|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-29|P1Y2M10DT2H30M|AFTER|2021-02-17|BEFORE|2021-04-14
e|RS|51a49847-6405-4842-b549-0e2ab99f61b2|8|STRUSTAT|Steroid Use Status|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|tuberculin unit|INCREASED|1|g/cage/day|MAGNETIC RESONANCE ELASTOGRAPHY||||SIGNIFICANT OTHER|DERMATOLOGIST|NA|4|Visit_4|65|4|TREATMENT|2021-03-12|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-29|P1Y2M10DT2H30M|AFTER|2021-03-12|COINCIDENT|2021-03-22
e|RS|51a49847-6405-4842-b549-0e2ab99f61b2|9|MRDIND|Minimal Residual Disease Indicator|MRANO VAN DEN BENT GLIOMA 2011|[?]|genEq/mL|MRD PERSISTENCE|1|IU/mg|JAFFE REACTION||Y||HEALTH CARE PROFESSIONAL|CARDIOLOGIST|NA|5|Visit_5|90|6|TREATMENT|2021-04-06|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-02|P1Y2M10DT2H30M|UNKNOWN|2021-04-06|AFTER|2021-04-11
e|RS|51a49847-6405-4842-b549-0e2ab99f61b2|10|NTLWIND|Non-Target Lesion Worsening Indicator|PCWG SCHER PROSTATE CANCER 2008|[?]|/month|PD-CT|1|VIRTUAL PIXEL|POLYMERASE CHAIN REACTION|Y|Y||SIBLING|ONCOLOGIST 2|Y|5|Visit_5|90|2|SCREENING|2021-04-06|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-02|P1Y2M10DT2H30M|UNKNOWN|2021-03-27|ONGOING|2021-04-08
e|RS|44dcfb9a-c590-4826-a28c-b5e9f83129d5|1|CYTORESP|Cytogenetic Response|PROTOCOL DEFINED RESPONSE CRITERIA|||MRD RELAPSE|1|PELLET|ELECTRONEUROGRAPHY||Y|Y|NON-HEALTH CARE PROFESSIONAL|DERMATOLOGIST|Y|1|Visit_1|10|4|TREATMENT|2020-05-21|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-08|P1Y2M10DT2H30M|BEFORE|2020-06-30|AFTER|2020-07-03
e|RS|44dcfb9a-c590-4826-a28c-b5e9f83129d5|2|NTERESP|Non-Target Enhancing Response|MASS|[?]|L/min/m2|PR-CT|1|mCi/L|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION||||NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|NA|1|Visit_1|10|2|TREATMENT|2020-05-21|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-08|P1Y2M10DT2H30M|AFTER|2020-05-30|BEFORE|2020-06-30
e|RS|44dcfb9a-c590-4826-a28c-b5e9f83129d5|3|ANATRESP|Anatomic Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|AMPULE|MORPHOLOGIC LEUKEMIA-FREE STATE|1|kN/cm2|FLOW MICROSCOPY||Y||PROXY|RATER 2|NA|2|Visit_2|25|3|WASHOUT|2020-06-05|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-18|P1Y2M10DT2H30M|UNKNOWN|2020-06-03|ONGOING|2020-07-30
e|RS|44dcfb9a-c590-4826-a28c-b5e9f83129d5|4|MRDRESP|Minimal Residual Disease Response|IWG CHESON MDS 2006|[?]|mg/m2/min|IMMUNOPHENOTYPIC CR|1|PLUG|OLIGO ACGH||||FAMILY MEMBER|NEUROLOGIST 2|N|2|Visit_2|25|4|TREATMENT|2020-06-05|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-18|P1Y2M10DT2H30M|BEFORE|2020-05-17|COINCIDENT|2020-07-22
e|RS|44dcfb9a-c590-4826-a28c-b5e9f83129d5|5|CYTORESP|Cytogenetic Response|DOHNER AML 2010|||PMD|1|AgU/mL|RAJI CELL EIA|||Y|DOMESTIC PARTNER|RATER 1|NA|3|Visit_3|40|2|WASHOUT|2020-06-20|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-06|P1Y2M10DT2H30M|BEFORE|2020-07-27|ONGOING|2020-08-03
e|RS|44dcfb9a-c590-4826-a28c-b5e9f83129d5|6|METBRESP|Metabolic Response|HAMAOKA BREAST CANCER 2010|[?]|/ms|DECREASED|1|ug/g/h|MICROBIAL CONCENTRATION||Y||NON-HEALTH CARE PROFESSIONAL|READER 2|Y|3|Visit_3|40|2|TREATMENT|2020-06-20|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-06|P1Y2M10DT2H30M|BEFORE|2020-06-22|COINCIDENT|2020-08-02
e|RS|44dcfb9a-c590-4826-a28c-b5e9f83129d5|7|MJPTHIND|Major Pathological Response Indicator|CHESON CLL 2006|[?]|nkat|PDu|1|/2500 WBC|IODINE STAIN||||FAMILY MEMBER|PEDIATRIC NEUROLOGIST|Y|4|Visit_4|65|1|TREATMENT|2020-07-15|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-12|P1Y2M10DT2H30M|COINCIDENT|2020-08-06|AFTER|2020-08-18
e|RS|44dcfb9a-c590-4826-a28c-b5e9f83129d5|8|CLINRESP|Clinical Response|IWC HALLEK CLL 2008|[?]|DNA copies/ug|iCR|1|um|MAMMOGRAPHY||Y||STUDY SUBJECT|OTOLARYNGOLOGIST|Y|4|Visit_4|65|2|FOLLOW-UP|2020-07-15|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-12|P1Y2M10DT2H30M|BEFORE|2020-08-14|BEFORE|2020-08-17
e|RS|44dcfb9a-c590-4826-a28c-b5e9f83129d5|9|BONERESP|Bone Response|RAJKUMAR MYELOMA 2011|[?]|uL/mL|CHR|1|cpm|HPLC-FL|Y|||CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 1|Y|5|Visit_5|90|7|SCREENING|2020-08-09|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-27|P1Y2M10DT2H30M|COINCIDENT|2020-08-04|BEFORE|2020-08-15
e|RS|44dcfb9a-c590-4826-a28c-b5e9f83129d5|10|BONERESP|Bone Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|L/day|CA125 75% RESPONSE|1|nkat/L|FLUORESCEIN STAIN||||HEALTH CARE PROFESSIONAL|READER 1|Y|5|Visit_5|90|7|SCREENING|2020-08-09|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-27|P1Y2M10DT2H30M|UNKNOWN|2020-06-02|AFTER|2020-07-23
e|RS|98166d74-caa7-4693-a817-b2cbae947ff8|1|NTNERESP|Non-Target Non-Enhancing Response|FAROOQUI SUPP CLL 2014|[?]|10^10/L|CR-CT|1|tsp eq|DUKE INCISION METHOD||||CAREGIVER|ADJUDICATOR 2|U|1|Visit_1|10|2|TREATMENT|2021-01-11|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-03|P1Y2M10DT2H30M|COINCIDENT|2021-03-27|ONGOING|2021-04-03
e|RS|98166d74-caa7-4693-a817-b2cbae947ff8|2|DRCRIND|Disease Recurrence Indicator|LUGANO CLASSIFICATION|[?]|L/day|CYTOGENETIC NO RESPONSE|1|Bq/mg|MAGNETIC RESONANCE ELASTOGRAPHY||||DOMESTIC PARTNER|MICROSCOPIST 2|NA|1|Visit_1|10|6|TREATMENT|2021-01-11|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-03|P1Y2M10DT2H30M|AFTER|2021-01-19|BEFORE|2021-02-23
e|RS|98166d74-caa7-4693-a817-b2cbae947ff8|3|HEMARESP|Hematologic Response|MASS|[?]|/VF|MRD NEGATIVITY|1|kBq/uL|INDIA INK STAIN||||CHILD|HEMATOLOGIST|N|2|Visit_2|25|4|TREATMENT|2021-01-26|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-06|P1Y2M10DT2H30M|COINCIDENT|2021-03-12|ONGOING|2021-04-01
e|RS|98166d74-caa7-4693-a817-b2cbae947ff8|4|MRDIND|Minimal Residual Disease Indicator|PRINCE TCELL LYMPHOMA 2010|[?]|mL/min/1.73m2|MOLECULAR CR|1|10^7 TCID 50/dose|CRYOSCOPY||||ADJUDICATION COMMITTEE|PATHOLOGIST|N|2|Visit_2|25|4|SCREENING|2021-01-26|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-06|P1Y2M10DT2H30M|COINCIDENT|2021-01-12|COINCIDENT|2021-03-25
e|RS|98166d74-caa7-4693-a817-b2cbae947ff8|5|TMRESP|Tumor Marker Response|CHESON CLL 2012|[?]|mmHg|MOLECULAR CR|1|BAR|INTERRUPTER TECHNIQUE||||ADJUDICATOR|PATHOLOGIST|U|3|Visit_3|40|4|TREATMENT|2021-02-10|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-18|P1Y2M10DT2H30M|UNKNOWN|2021-04-03|ONGOING|2021-04-04
e|RS|98166d74-caa7-4693-a817-b2cbae947ff8|6|SYMPTDTR|Symptomatic Deterioration|BRUGGEMANN MRD 2010|[?]|10^3 organisms|NON-PD|1|/4.0 mL|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY||||NON-HEALTH CARE PROFESSIONAL|INTERNIST|N|3|Visit_3|40|1|TREATMENT|2021-02-10|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-18|P1Y2M10DT2H30M|BEFORE|2021-03-27|AFTER|2021-04-07
e|RS|98166d74-caa7-4693-a817-b2cbae947ff8|7|METBRESP|Metabolic Response|JACINTO CERVICAL CANCER 2007|[?]|Roentgen|CA125 75% RESPONSE|1|mL/animal/wk|TARGETED GENOME SEQUENCING||||SIGNIFICANT OTHER|PEDIATRIC NEUROLOGIST|NA|4|Visit_4|65|4|TREATMENT|2021-03-07|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-03|P1Y2M10DT2H30M|COINCIDENT|2021-03-01|COINCIDENT|2021-03-19
e|RS|98166d74-caa7-4693-a817-b2cbae947ff8|8|MRPHRESP|Morphologic Response|CHOLLET BREAST CANCER 2002|[?]|/wk|pCR|1|1/(s*kPa)|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY||||CLINICAL STUDY SPONSOR|CARDIOLOGIST|NA|4|Visit_4|65|5|TREATMENT|2021-03-07|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-03|P1Y2M10DT2H30M|AFTER|2021-03-25|ONGOING|2021-03-26
e|RS|98166d74-caa7-4693-a817-b2cbae947ff8|9|DRCRIND|Disease Recurrence Indicator|MRECIST BYRNE MESOTHELIOMA 2004|[?]|/min|QUANTIFIABLE MRD POSITIVITY|1|STEPS|ICP-MS|Y|||VENDOR|UROLOGIST|N|5|Visit_5|90|1|TREATMENT|2021-04-01|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-18|P1Y2M10DT2H30M|BEFORE|2021-03-10|BEFORE|2021-03-16
e|RS|98166d74-caa7-4693-a817-b2cbae947ff8|10|BONERESP|Bone Response|iRECIST|[?]|HEP|NON-iCR/NON-iUPD|1|kUSP|FLUORESCENCE ANGIOGRAPHY|Y|Y||SIGNIFICANT OTHER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|5|Visit_5|90|1|TREATMENT|2021-04-01|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-18|P1Y2M10DT2H30M|AFTER|2021-03-28|AFTER|2021-03-31
e|RS|cb07675a-2042-44da-a1f9-8b7783347e88|1|TRGRESP|Target Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|anti-Xa IU/mL|CA125 50% RESPONSE|1|L/L|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION|Y|Y||DOMESTIC PARTNER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|1|Visit_1|10|3|FOLLOW-UP|2020-12-05|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-28|P1Y2M10DT2H30M|UNKNOWN|2020-12-22|ONGOING|2021-03-02
e|RS|cb07675a-2042-44da-a1f9-8b7783347e88|2|NTRGRESP|Non-target Response|HARTMAN PANCREATIC CANCER 2012|[?]|log10 CFU/mL|DECREASED|1|U/m2/h|ETDRS EYE CHART||Y||SIBLING|ADJUDICATOR 1|NA|1|Visit_1|10|6|TREATMENT|2020-12-05|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-28|P1Y2M10DT2H30M|COINCIDENT|2021-01-09|COINCIDENT|2021-01-13
e|RS|cb07675a-2042-44da-a1f9-8b7783347e88|3|RDIORESP|Radiologic Response|PERCIST|[?]|yd|MOLECULAR MAJOR RESPONSE|1|ug/m2/min|ANGIOGRAPHY|Y|||ADJUDICATION COMMITTEE|RATER|N|2|Visit_2|25|5|TREATMENT|2020-12-20|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-29|P1Y2M10DT2H30M|COINCIDENT|2020-12-11|BEFORE|2021-01-28
e|RS|cb07675a-2042-44da-a1f9-8b7783347e88|4|SPLNRESP|Spleen Response|WHO BREAST CANCER 2006|||MR|1|Gauss|STATIC PERIMETRY||Y|Y|SIBLING|PATHOLOGIST 1|Y|2|Visit_2|25|2|FOLLOW-UP|2020-12-20|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-29|P1Y2M10DT2H30M|AFTER|2021-02-05|AFTER|2021-02-11
e|RS|cb07675a-2042-44da-a1f9-8b7783347e88|5|NEWLWIND|New Lesion Worsening Indicator|BURCOMBE BREAST CANCER 2005|||CA125 75% RESPONSE|1|DAgU/mL|WEBER GREEN STAIN|||Y|HEALTH CARE PROFESSIONAL|OPTOMETRIST|U|3|Visit_3|40|2|TREATMENT|2021-01-04|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-05|P1Y2M10DT2H30M|BEFORE|2021-02-28|ONGOING|2021-03-04
e|RS|cb07675a-2042-44da-a1f9-8b7783347e88|6|HEMARESP|Hematologic Response|IRANO 2015|||ABSENT MORPHOLOGIC RESPONSE|1|10^6 CFU|GRADIENT DIFFUSION||Y|Y|INDEPENDENT ASSESSOR|ADJUDICATOR 3|NA|3|Visit_3|40|7|TREATMENT|2021-01-04|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-05|P1Y2M10DT2H30M|BEFORE|2020-12-08|BEFORE|2021-02-17
e|RS|cb07675a-2042-44da-a1f9-8b7783347e88|7|DRCRIND|Disease Recurrence Indicator|DOHNER AML 2010|[?]|ft2|MORPHOLOGIC CR|1|BOWL|THERMAL IONIZATION MASS SPECTROMETRY|Y|||VENDOR|CLINICAL PATHOLOGIST|N|4|Visit_4|65|6|TREATMENT|2021-01-29|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-19|P1Y2M10DT2H30M|COINCIDENT|2020-12-28|COINCIDENT|2020-12-31
e|RS|cb07675a-2042-44da-a1f9-8b7783347e88|8|METSIND|Metastatic Indicator|SHINDOH COLORECTAL CANCER 2013|[?]|hPa|UNEQUIVOCAL|1|g/kg/day|KINYOUN STAIN|Y|||PROXY|CLINICAL PATHOLOGIST|N|4|Visit_4|65|5|TREATMENT|2021-01-29|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-19|P1Y2M10DT2H30M|AFTER|2021-02-16|COINCIDENT|2021-02-25
e|RS|cb07675a-2042-44da-a1f9-8b7783347e88|9|NEWLIND|New Lesion Indicator|EUROPEAN LEUKEMIANET BACCARANI CML 2006|||MORPHOLOGIC CR|1|uIU/L|CYSTOSCOPY||Y|Y|SPOUSE|PATHOLOGIST 1|U|5|Visit_5|90|3|TREATMENT|2021-02-23|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-21|P1Y2M10DT2H30M|COINCIDENT|2020-12-17|COINCIDENT|2020-12-25
e|RS|cb07675a-2042-44da-a1f9-8b7783347e88|10|MRDIND|Minimal Residual Disease Indicator|GUPPY OVARIAN CANCER 2002|[?]|10^8/L|INDETERMINATE RESPONSE|1|mL/cm|CELL BASED BIOASSAY||||SIGNIFICANT OTHER|UROLOGIST|U|5|Visit_5|90|5|WASHOUT|2021-02-23|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-21|P1Y2M10DT2H30M|COINCIDENT|2021-01-18|COINCIDENT|2021-03-03
e|RS|a8a14aa1-4484-4bbc-86bf-c44257146a26|1|DRCRIND|Disease Recurrence Indicator|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|kV|TREATMENT FAILURE|1|psec|TEMPLATE INCISION METHOD|Y|Y||PARENT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|1|Visit_1|10|4|WASHOUT|2020-07-01|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-03|P1Y2M10DT2H30M|BEFORE|2020-07-08|AFTER|2020-07-17
e|RS|a8a14aa1-4484-4bbc-86bf-c44257146a26|2|LIVRRESP|Liver Response|NCCN ALL MRD 2014|[?]|mL/sec/1.73m2|FAVORABLE RESPONSE|1|nsec|SICKLE CELL SOLUBILITY TEST||||DOMESTIC PARTNER|RADIOLOGIST|N|1|Visit_1|10|5|TREATMENT|2020-07-01|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-03|P1Y2M10DT2H30M|BEFORE|2020-08-12|ONGOING|2020-08-18
e|RS|a8a14aa1-4484-4bbc-86bf-c44257146a26|3|NTNERESP|Non-Target Non-Enhancing Response|PETIT BREAST CANCER 2001|[?]|mL/animal/day|PD/RELAPSE AFTER HI|1|/100 WBC|NUCLEAR RADIOLOGY|Y|Y||INVESTIGATOR|RADIOLOGIST|U|2|Visit_2|25|5|FOLLOW-UP|2020-07-16|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-23|P1Y2M10DT2H30M|UNKNOWN|2020-08-28|COINCIDENT|2020-09-09
e|RS|a8a14aa1-4484-4bbc-86bf-c44257146a26|4|LIVRRESP|Liver Response|PCWG SCHER PROSTATE CANCER 2008|[?]|g/cage|NED|1|um|PLETHYSMOGRAPHY||||GUARDIAN|HEMATOLOGIST|U|2|Visit_2|25|7|TREATMENT|2020-07-16|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-23|P1Y2M10DT2H30M|AFTER|2020-08-08|ONGOING|2020-09-11
e|RS|a8a14aa1-4484-4bbc-86bf-c44257146a26|5|NTERESP|Non-Target Enhancing Response|SACT|[?]|L/min|PSEUDOPROGRESSION|1|mV|REFLECTANCE SPECTROSCOPY||Y||INDEPENDENT ASSESSOR|NEUROLOGIST|NA|3|Visit_3|40|1|SCREENING|2020-07-31|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-22|P1Y2M10DT2H30M|COINCIDENT|2020-08-30|ONGOING|2020-09-22
e|RS|a8a14aa1-4484-4bbc-86bf-c44257146a26|6|METSIND|Metastatic Indicator|HAMAOKA BREAST CANCER 2010|[?]|AgU/mL|PDu|1|mU|TOLUIDINE BLUE STAIN||||INVESTIGATOR|OTOLARYNGOLOGIST|N|3|Visit_3|40|1|TREATMENT|2020-07-31|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-22|P1Y2M10DT2H30M|AFTER|2020-09-05|AFTER|2020-09-18
e|RS|a8a14aa1-4484-4bbc-86bf-c44257146a26|7|MOLRESP|Molecular Response|GUILHOT CML 2007|[?]|vg/dose|HI-E|1|mU/g|TEMPLATE INCISION METHOD||||VENDOR|HEMATOLOGIST|N|4|Visit_4|65|6|TREATMENT|2020-08-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-28|P1Y2M10DT2H30M|BEFORE|2020-08-15|BEFORE|2020-09-05
e|RS|a8a14aa1-4484-4bbc-86bf-c44257146a26|8|MRPHRESP|Morphologic Response|RECIST 1.1|[?]|PACKET|HI-N|1|m/sec2|CELLULAR PROLIFERATION ASSAY|Y|Y||FRIEND|RATER 2|U|4|Visit_4|65|3|TREATMENT|2020-08-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-28|P1Y2M10DT2H30M|BEFORE|2020-08-03|COINCIDENT|2020-09-27
e|RS|a8a14aa1-4484-4bbc-86bf-c44257146a26|9|BMIVLIND|Bone Marrow Involvement Indicator|CHOLLET BREAST CANCER 2002|[?]|MET*min|STABLE|1|mL/cm|COMPLEMENT FIXATION|Y|||CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR|N|5|Visit_5|90|1|TREATMENT|2020-09-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-09|P1Y2M10DT2H30M|COINCIDENT|2020-09-18|COINCIDENT|2020-09-20
e|RS|a8a14aa1-4484-4bbc-86bf-c44257146a26|10|NTRGRESP|Non-target Response|DURIE MULTIPLE MYELOMA 2006|[?]|ppth|CRi|1|10^3 copies/mL|CALCULATION||||STUDY SUBJECT|HEMATOLOGIST|N|5|Visit_5|90|2|WASHOUT|2020-09-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-09|P1Y2M10DT2H30M|AFTER|2020-08-13|AFTER|2020-08-29
e|RS|dfa4c661-9317-4bec-b307-a31eeadcaba6|1|NTNERESP|Non-Target Non-Enhancing Response|LUGANO CLASSIFICATION|[?]|KIT|MAJOR PATHOLOGIC RESPONSE|1|sec|CLIP|Y|||ADJUDICATION COMMITTEE|CARDIOLOGIST|NA|1|Visit_1|10|4|TREATMENT|2020-06-04|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-29|P1Y2M10DT2H30M|UNKNOWN|2020-06-22|BEFORE|2020-08-21
e|RS|dfa4c661-9317-4bec-b307-a31eeadcaba6|2|MOLRESP|Molecular Response|DOHNER AML 2010|[?]|Absorbance U/mL|sCR|1|mL/m2/h|MULTI-SLICE SPIRAL CT||Y||CLINICAL RESEARCH COORDINATOR|RATER 2|N|1|Visit_1|10|1|SCREENING|2020-06-04|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-29|P1Y2M10DT2H30M|COINCIDENT|2020-08-23|BEFORE|2020-08-26
e|RS|dfa4c661-9317-4bec-b307-a31eeadcaba6|3|RDIORESP|Radiologic Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|CCID 50/mL|QUANTIFIABLE MRD POSITIVITY|1|uCi/L|REAL-TIME POLYMERASE CHAIN REACTION ASSAY||||GUARDIAN|RADIOLOGIST|U|2|Visit_2|25|3|WASHOUT|2020-06-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-09|P1Y2M10DT2H30M|AFTER|2020-08-18|COINCIDENT|2020-08-29
e|RS|dfa4c661-9317-4bec-b307-a31eeadcaba6|4|MNPTHIND|Minor Pathological Response Indicator|RANO ELLINGSON 2017|[?]|10^3 CFU/mL|iCR|1|cL|MICROBIAL CULTURE||||CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 1|Y|2|Visit_2|25|6|SCREENING|2020-06-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-09|P1Y2M10DT2H30M|UNKNOWN|2020-06-10|BEFORE|2020-07-22
e|RS|dfa4c661-9317-4bec-b307-a31eeadcaba6|5|RDIORESP|Radiologic Response|LUGANO CLASSIFICATION|||PD-CT|1|mL/g/h|MACRO BROTH DILUTION||Y|Y|SIGNIFICANT OTHER|RATER 2|U|3|Visit_3|40|4|TREATMENT|2020-07-04|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-08|P1Y2M10DT2H30M|AFTER|2020-06-22|COINCIDENT|2020-08-25
e|RS|dfa4c661-9317-4bec-b307-a31eeadcaba6|6|NTLWIND|Non-Target Lesion Worsening Indicator|CHESON CLL 2006|[?]|10^6/g|iUPD|1|pt_us|QUANTITATIVE CORONARY ANGIOGRAPHY|Y|Y||VENDOR|READER 1|NA|3|Visit_3|40|7|SCREENING|2020-07-04|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-08|P1Y2M10DT2H30M|COINCIDENT|2020-05-28|COINCIDENT|2020-08-14
e|RS|dfa4c661-9317-4bec-b307-a31eeadcaba6|7|NTERESP|Non-Target Enhancing Response|JACINTO CERVICAL CANCER 2007|[?]|uIU/dL|HI-N|1|TAMPON|PERIPHERAL ANGIOGRAPHY||Y||VENDOR|PEDIATRIC NEUROLOGIST|U|4|Visit_4|65|5|SCREENING|2020-07-29|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-08|P1Y2M10DT2H30M|BEFORE|2020-06-12|BEFORE|2020-08-30
e|RS|dfa4c661-9317-4bec-b307-a31eeadcaba6|8|BESTRESP|Best Overall Response|KUKER LYMPHOMA 2005|[?]|IU/mg|CA125 50% RESPONSE|1|mg/g/h|PET/MRI SCAN|Y|||INTERVIEWER|ENDOCRINOLOGIST|Y|4|Visit_4|65|2|TREATMENT|2020-07-29|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-08|P1Y2M10DT2H30M|BEFORE|2020-06-09|AFTER|2020-07-18
e|RS|dfa4c661-9317-4bec-b307-a31eeadcaba6|9|CYTORESP|Cytogenetic Response|PETIT BREAST CANCER 2001|[?]|LOZENGE|DISEASE TRANSFORMATION|1|psec|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS||||FAMILY MEMBER|RATER 2|N|5|Visit_5|90|5|TREATMENT|2020-08-23|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-24|P1Y2M10DT2H30M|UNKNOWN|2020-07-29|BEFORE|2020-08-09
e|RS|dfa4c661-9317-4bec-b307-a31eeadcaba6|10|BMIVLIND|Bone Marrow Involvement Indicator|IWG CHESON MDS 2000|||iCR|1|gpELISA unit/mL|FLOW CYTOMETRY|||Y|VENDOR|ADJUDICATOR 2|N|5|Visit_5|90|6|SCREENING|2020-08-23|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-24|P1Y2M10DT2H30M|COINCIDENT|2020-08-27|AFTER|2020-08-30
e|RS|9ed984a9-c153-4729-9dc9-3bb3d9059919|1|PATHRESP|Pathologic Response|NCCN ALL MRD 2014|[?]|10^8 PFU|UNEQUIVOCAL|1|Bq/kg|FLOCCULATION|Y|||CHILD|MICROSCOPIST 1|NA|1|Visit_1|10|7|WASHOUT|2020-09-01|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-18|P1Y2M10DT2H30M|COINCIDENT|2020-11-13|COINCIDENT|2020-11-29
e|RS|9ed984a9-c153-4729-9dc9-3bb3d9059919|2|NEWLPROG|New Lesion Progression|RECIST 1.1|[?]|usec|HI-N|1|U/mmol|ANTIBIOTIC AGAR SCREEN||||CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 2|N|1|Visit_1|10|3|TREATMENT|2020-09-01|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-18|P1Y2M10DT2H30M|AFTER|2020-10-22|BEFORE|2020-10-31
e|RS|9ed984a9-c153-4729-9dc9-3bb3d9059919|3|METBRESP|Metabolic Response|RECICL|[?]|fmol/g|EQUIVOCAL|1|s*kPa|GIEMSA STAIN|Y|Y||SIBLING|PATHOLOGIST 1|U|2|Visit_2|25|6|SCREENING|2020-09-16|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-27|P1Y2M10DT2H30M|UNKNOWN|2020-11-13|AFTER|2020-11-15
e|RS|9ed984a9-c153-4729-9dc9-3bb3d9059919|4|MOLRESP|Molecular Response|PROTOCOL DEFINED RESPONSE CRITERIA|||iCPD|1|10^6 IU|PULSE OXIMETRY||Y|Y|SIGNIFICANT OTHER|MICROSCOPIST 2|NA|2|Visit_2|25|4|TREATMENT|2020-09-16|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-27|P1Y2M10DT2H30M|AFTER|2020-10-25|BEFORE|2020-11-04
e|RS|9ed984a9-c153-4729-9dc9-3bb3d9059919|5|METSIND|Metastatic Indicator|GCIG RUSTIN OVARIAN CANCER 2011|[?]|MBP|CR-CT|1|mL/m2/h|CLOT DETECTION|Y|Y||SIBLING|READER 2|U|3|Visit_3|40|6|TREATMENT|2020-10-01|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-24|P1Y2M10DT2H30M|COINCIDENT|2020-10-30|ONGOING|2020-11-19
e|RS|9ed984a9-c153-4729-9dc9-3bb3d9059919|6|BESTRESP|Best Overall Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|/40 HPFs|ABSENT MORPHOLOGIC RESPONSE|1|ms/mmHg|MACRO BROTH DILUTION||||CAREGIVER|RADIOLOGIST 1|U|3|Visit_3|40|5|FOLLOW-UP|2020-10-01|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-24|P1Y2M10DT2H30M|COINCIDENT|2020-08-29|COINCIDENT|2020-09-02
e|RS|9ed984a9-c153-4729-9dc9-3bb3d9059919|7|NTNERESP|Non-Target Non-Enhancing Response|IWC HALLEK CLL 2008|[?]|10^6 RNA copies/mL|PSA PROGRESSION|1|breaths/min|KNEMOMETRY|Y|||FAMILY MEMBER|UROLOGIST|N|4|Visit_4|65|6|TREATMENT|2020-10-26|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-01|P1Y2M10DT2H30M|UNKNOWN|2020-11-04|COINCIDENT|2020-11-12
e|RS|9ed984a9-c153-4729-9dc9-3bb3d9059919|8|NTNERESP|Non-Target Non-Enhancing Response|RANO ELLINGSON 2017|[?]|PFU/mL|UNFAVORABLE RESPONSE|1|SACHET|COULOMETRIC TITRATION||||SIBLING|MICROSCOPIST 2|NA|4|Visit_4|65|6|WASHOUT|2020-10-26|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-01|P1Y2M10DT2H30M|UNKNOWN|2020-09-07|ONGOING|2020-11-17
e|RS|9ed984a9-c153-4729-9dc9-3bb3d9059919|9|LIVRRESP|Liver Response|RANO|[?]|1/(s*kPa)|CYTOGENETIC MINOR RESPONSE|1|in|SLIT LAMP||Y||ADJUDICATOR|ENDOCRINOLOGIST|NA|5|Visit_5|90|4|TREATMENT|2020-11-20|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-04|P1Y2M10DT2H30M|AFTER|2020-09-01|AFTER|2020-10-30
e|RS|9ed984a9-c153-4729-9dc9-3bb3d9059919|10|LIVRRESP|Liver Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|in2|CR-CT|1|IU/day|GRADIENT DIFFUSION||||HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|NA|5|Visit_5|90|2|TREATMENT|2020-11-20|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-04|P1Y2M10DT2H30M|COINCIDENT|2020-10-06|BEFORE|2020-10-25
e|RS|fb234b67-3c81-4d55-bc63-2389a23d67b2|1|MRDRESP|Minimal Residual Disease Response|HARTMAN PANCREATIC CANCER 2012|[?]|/7.5 mL|NR|1|cpm|HPLC/MS/MS||||ADJUDICATOR|NEUROLOGIST 1|U|1|Visit_1|10|6|TREATMENT|2021-01-11|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-02|P1Y2M10DT2H30M|UNKNOWN|2021-02-08|BEFORE|2021-02-09
e|RS|fb234b67-3c81-4d55-bc63-2389a23d67b2|2|MJPTHIND|Major Pathological Response Indicator|IWC HALLEK CLL 2008|[?]|Pack Year|IMPROVED|1|pt_br|EIA||Y||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR|NA|1|Visit_1|10|5|TREATMENT|2021-01-11|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-02|P1Y2M10DT2H30M|BEFORE|2021-03-05|BEFORE|2021-04-07
e|RS|fb234b67-3c81-4d55-bc63-2389a23d67b2|3|BESTRESP|Best Overall Response|AJCC V7|[?]|AFU|MRD PERSISTENCE|1|ft3|CT SCAN||||CLINICAL STUDY SPONSOR|ONCOLOGIST 1|U|2|Visit_2|25|1|TREATMENT|2021-01-26|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-13|P1Y2M10DT2H30M|UNKNOWN|2021-01-25|AFTER|2021-02-24
e|RS|fb234b67-3c81-4d55-bc63-2389a23d67b2|4|NTNERESP|Non-Target Non-Enhancing Response|CHOI GIST 2008|[?]|/2000 RBC|MORPHOLOGIC LEUKEMIA-FREE STATE|1|pmol/day|WESTERN BLOT||||CAREGIVER|ADJUDICATOR|N|2|Visit_2|25|1|TREATMENT|2021-01-26|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-13|P1Y2M10DT2H30M|AFTER|2021-03-25|BEFORE|2021-04-10
e|RS|fb234b67-3c81-4d55-bc63-2389a23d67b2|5|LIVRRESP|Liver Response|JACINTO CERVICAL CANCER 2007|[?]|mCi|iSD|1|mm/min|ENZYMATIC ULTRACENTRIFUGATION||||INDEPENDENT ASSESSOR|UROLOGIST|Y|3|Visit_3|40|6|SCREENING|2021-02-10|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-31|P1Y2M10DT2H30M|AFTER|2021-01-21|BEFORE|2021-02-28
e|RS|fb234b67-3c81-4d55-bc63-2389a23d67b2|6|PATHRESP|Pathologic Response|BRUGGEMANN MRD 2010|[?]|U/g/h|RELAPSED DISEASE FROM CR OR PR|1|g/L|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY|Y|||CAREGIVER|ONCOLOGIST 1|U|3|Visit_3|40|7|TREATMENT|2021-02-10|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-31|P1Y2M10DT2H30M|COINCIDENT|2021-04-04|BEFORE|2021-04-05
e|RS|fb234b67-3c81-4d55-bc63-2389a23d67b2|7|RDIORESP|Radiologic Response|BLAZER COLORECTAL CANCER 2008|[?]|Tbsp|iSD|1|V/sec|LISSAMINE GREEN STAIN||Y||SPOUSE|ADJUDICATOR 1|Y|4|Visit_4|65|2|TREATMENT|2021-03-07|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-06|P1Y2M10DT2H30M|COINCIDENT|2021-03-10|AFTER|2021-04-05
e|RS|fb234b67-3c81-4d55-bc63-2389a23d67b2|8|BMIVLIND|Bone Marrow Involvement Indicator|AJCC V7|||CHR|1|Ci/L|APPLANATION TONOMETRY|||Y|INTERVIEWER|ADJUDICATOR|Y|4|Visit_4|65|5|FOLLOW-UP|2021-03-07|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-06|P1Y2M10DT2H30M|COINCIDENT|2021-03-30|BEFORE|2021-04-08
e|RS|fb234b67-3c81-4d55-bc63-2389a23d67b2|9|METBRESP|Metabolic Response|RECICL|[?]|cmol/L|HI-E|1|Ci/mL|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION|Y|||CLINICAL STUDY SPONSOR|RADIOLOGIST 1|Y|5|Visit_5|90|3|TREATMENT|2021-04-01|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-23|P1Y2M10DT2H30M|COINCIDENT|2021-03-30|BEFORE|2021-04-03
e|RS|fb234b67-3c81-4d55-bc63-2389a23d67b2|10|PATHRESP|Pathologic Response|BURCOMBE BREAST CANCER 2005|[?]|GPL U|PDu|1|10^5/L|PET/CT SCAN WITHOUT CONTRAST||||ADJUDICATOR|DERMATOLOGIST|Y|5|Visit_5|90|4|WASHOUT|2021-04-01|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-23|P1Y2M10DT2H30M|UNKNOWN|2021-03-06|BEFORE|2021-03-29
e|RS|84d7ff44-cbe2-446f-b667-5bc539de519b|1|ANATRESP|Anatomic Response|RECIST 1.1|||STABLE|1|ppm|PLAQUE REDUCTION NEUTRALIZATION ASSAY|||Y|ADJUDICATOR|NEUROLOGIST|NA|1|Visit_1|10|4|SCREENING|2020-07-06|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-10|P1Y2M10DT2H30M|UNKNOWN|2020-07-02|BEFORE|2020-07-13
e|RS|84d7ff44-cbe2-446f-b667-5bc539de519b|2|METSIND|Metastatic Indicator|UNSPECIFIED|||cPR|1|MET*h|SCANNING ELECTRON MICROSCOPY|||Y|DOMESTIC PARTNER|CLINICAL PATHOLOGIST|N|1|Visit_1|10|7|TREATMENT|2020-07-06|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-10|P1Y2M10DT2H30M|UNKNOWN|2020-08-21|ONGOING|2020-09-26
e|RS|84d7ff44-cbe2-446f-b667-5bc539de519b|3|DRCRIND|Disease Recurrence Indicator|IRANO 2015|[?]|mL/sec/1.73m2|NED|1|eq|MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING||||FRIEND|RATER 1|U|2|Visit_2|25|7|TREATMENT|2020-07-21|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-13|P1Y2M10DT2H30M|AFTER|2020-07-02|COINCIDENT|2020-07-05
e|RS|84d7ff44-cbe2-446f-b667-5bc539de519b|4|CYTORESP|Cytogenetic Response|AJCC V7|||PSEUDORESPONSE|1|GBq|DYNAMOMETRY|||Y|STUDY SUBJECT|NEUROLOGIST|Y|2|Visit_2|25|6|TREATMENT|2020-07-21|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-13|P1Y2M10DT2H30M|COINCIDENT|2020-09-20|ONGOING|2020-09-24
e|RS|84d7ff44-cbe2-446f-b667-5bc539de519b|5|SPLNRESP|Spleen Response|NCCN ALL MRD 2014|[?]|mm/min|CYTOGENETIC PR|1|L/h|HPLC-FL||||FRIEND|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|3|Visit_3|40|7|TREATMENT|2020-08-05|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-25|P1Y2M10DT2H30M|COINCIDENT|2020-09-10|COINCIDENT|2020-09-17
e|RS|84d7ff44-cbe2-446f-b667-5bc539de519b|6|MJPTHIND|Major Pathological Response Indicator|CHOLLET BREAST CANCER 2002|[?]|copies/uL|PSEUDORESPONSE|1|ppb|CELL OF ORIGIN ASSAY||||INDEPENDENT ASSESSOR|PATHOLOGIST|NA|3|Visit_3|40|6|TREATMENT|2020-08-05|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-25|P1Y2M10DT2H30M|AFTER|2020-07-22|BEFORE|2020-09-12
e|RS|84d7ff44-cbe2-446f-b667-5bc539de519b|7|SYMPTDTR|Symptomatic Deterioration|MACDONALD GLIOMA 1990|[?]|IU/day|NON-CR/NON-PD|1|g/U|MALDI|Y|Y||DOMESTIC PARTNER|READER|N|4|Visit_4|65|2|TREATMENT|2020-08-30|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-21|P1Y2M10DT2H30M|COINCIDENT|2020-07-17|COINCIDENT|2020-08-25
e|RS|84d7ff44-cbe2-446f-b667-5bc539de519b|8|SPLNRESP|Spleen Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|||iUPD|1|/7.5 mL|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY||Y|Y|SPOUSE|READER|N|4|Visit_4|65|2|SCREENING|2020-08-30|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-21|P1Y2M10DT2H30M|UNKNOWN|2020-07-14|BEFORE|2020-09-23
e|RS|84d7ff44-cbe2-446f-b667-5bc539de519b|9|PATHRESP|Pathologic Response|IRANO 2015|[?]|L/day|NON-iCR/NON-iUPD|1|mg/L|WRIGHT STAIN|Y|||FAMILY MEMBER|DERMATOLOGIST|N|5|Visit_5|90|3|TREATMENT|2020-09-24|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-23|P1Y2M10DT2H30M|COINCIDENT|2020-09-21|AFTER|2020-09-29
e|RS|84d7ff44-cbe2-446f-b667-5bc539de519b|10|NEWLWIND|New Lesion Worsening Indicator|LUGANO CLASSIFICATION|[?]|L/h|NOT ALL EVALUATED|1|Farad|WRIGHT-GIEMSA STAIN||||VENDOR|ADJUDICATOR 3|U|5|Visit_5|90|1|WASHOUT|2020-09-24|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-23|P1Y2M10DT2H30M|COINCIDENT|2020-08-12|COINCIDENT|2020-09-27
e|RS|c96e4485-4aff-4c18-9c65-5f1a800cc6db|1|MRPHRESP|Morphologic Response|AJCC V8|[?]|10^6/g|iCR|1|lx|CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY||||INDEPENDENT ASSESSOR|ADJUDICATOR 1|U|1|Visit_1|10|1|TREATMENT|2020-09-24|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-18|P1Y2M10DT2H30M|COINCIDENT|2020-11-29|COINCIDENT|2020-12-07
e|RS|c96e4485-4aff-4c18-9c65-5f1a800cc6db|2|ANATRESP|Anatomic Response|RECIST 1.1|[?]|copies/mL|FAVORABLE RESPONSE|1|mmol/kg|CONFOCAL MICROSCOPY||Y||PROXY|UROLOGIST|NA|1|Visit_1|10|1|FOLLOW-UP|2020-09-24|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-18|P1Y2M10DT2H30M|BEFORE|2020-09-19|BEFORE|2020-10-01
e|RS|c96e4485-4aff-4c18-9c65-5f1a800cc6db|3|RDIORESP|Radiologic Response|NCCN ALL MRD 2014|||PMD|1|10^7 TCID 50/dose|PERIPHERAL ANGIOGRAPHY||Y|Y|HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|NA|2|Visit_2|25|6|WASHOUT|2020-10-09|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-21|P1Y2M10DT2H30M|AFTER|2020-10-16|AFTER|2020-12-21
e|RS|c96e4485-4aff-4c18-9c65-5f1a800cc6db|4|DRCRIND|Disease Recurrence Indicator|IWC HALLEK CLL 2008|||PD|1|/10^3|SEQUENCING|||Y|STUDY SUBJECT|PEDIATRIC NEUROLOGIST|NA|2|Visit_2|25|2|WASHOUT|2020-10-09|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-21|P1Y2M10DT2H30M|BEFORE|2020-11-27|AFTER|2020-12-10
e|RS|c96e4485-4aff-4c18-9c65-5f1a800cc6db|5|MRDIND|Minimal Residual Disease Indicator|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|PFU/dose|QUANTIFIABLE MRD POSITIVITY|1|10^6 organisms/g|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION|Y|||ADJUDICATION COMMITTEE|UROLOGIST|Y|3|Visit_3|40|2|TREATMENT|2020-10-24|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-17|P1Y2M10DT2H30M|UNKNOWN|2020-11-16|COINCIDENT|2020-12-18
e|RS|c96e4485-4aff-4c18-9c65-5f1a800cc6db|6|NEWLWIND|New Lesion Worsening Indicator|WOLCHOK SOLID TUMORS 2009|[?]|ugEq/L|NON-CR/NON-PD|1|10^7 CFU|EEG|Y|||CLINICAL RESEARCH COORDINATOR|PHYSIOTHERAPIST|U|3|Visit_3|40|1|FOLLOW-UP|2020-10-24|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-17|P1Y2M10DT2H30M|BEFORE|2020-10-23|COINCIDENT|2020-12-22
e|RS|c96e4485-4aff-4c18-9c65-5f1a800cc6db|7|METBRESP|Metabolic Response|SHINDOH COLORECTAL CANCER 2013|[?]|MPL U/mL|CYTOGENETIC NO RESPONSE|1|tsp eq|TRANSMISSION ELECTRON MICROSCOPY|Y|||PROXY|RATER|U|4|Visit_4|65|5|TREATMENT|2020-11-18|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-11|P1Y2M10DT2H30M|COINCIDENT|2020-12-06|COINCIDENT|2020-12-14
e|RS|c96e4485-4aff-4c18-9c65-5f1a800cc6db|8|TMRESP|Tumor Marker Response|BRUGGEMANN MRD 2010|||CRi|1|min|QUANTITATIVE PERIPHERAL ANGIOGRAPHY|Y||Y|INTERVIEWER|ADJUDICATOR|Y|4|Visit_4|65|4|TREATMENT|2020-11-18|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-11|P1Y2M10DT2H30M|BEFORE|2020-10-30|AFTER|2020-12-11
e|RS|c96e4485-4aff-4c18-9c65-5f1a800cc6db|9|MRDIND|Minimal Residual Disease Indicator|UNSPECIFIED|||UNEQUIVOCAL|1|Pa|CONTRAST ENHANCED PET SCAN|||Y|FRIEND|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5|Visit_5|90|4|SCREENING|2020-12-13|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-20|P1Y2M10DT2H30M|BEFORE|2020-09-20|COINCIDENT|2020-10-30
e|RS|c96e4485-4aff-4c18-9c65-5f1a800cc6db|10|MNPTHIND|Minor Pathological Response Indicator|MRECIST BYRNE MESOTHELIOMA 2004|[?]|CFU/mL|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|10^4 CFU/mL|PET/SPECT SCAN||Y||INTERVIEWER|READER 1|U|5|Visit_5|90|7|TREATMENT|2020-12-13|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-20|P1Y2M10DT2H30M|AFTER|2020-09-26|COINCIDENT|2020-11-12
e|RS|955188f1-b434-40ab-94c8-0c0fb7f23e84|1|PATHRESP|Pathologic Response|WHO BREAST CANCER 2006|[?]|s^-1(%O2)^-1|CRi|1|v/v|KINYOUN STAIN||Y||CLINICAL STUDY SPONSOR|RADIOLOGIST|NA|1|Visit_1|10|4|TREATMENT|2020-12-14|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-15|P1Y2M10DT2H30M|COINCIDENT|2021-03-10|ONGOING|2021-03-13
e|RS|955188f1-b434-40ab-94c8-0c0fb7f23e84|2|CLINRESP|Clinical Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|mL/animal|UNFAVORABLE RESPONSE|1|uV|STATIC PERIMETRY||Y||FAMILY MEMBER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|1|Visit_1|10|1|TREATMENT|2020-12-14|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-15|P1Y2M10DT2H30M|BEFORE|2021-03-10|BEFORE|2021-03-13
e|RS|955188f1-b434-40ab-94c8-0c0fb7f23e84|3|MJPTHIND|Major Pathological Response Indicator|CHESON MALIGNANT LYMPHOMA 2007|[?]|Hz|SD-CT|1|ppb|DYNAMIC LIGHT SCATTERING||Y||INTERVIEWER|DEVELOPMENTAL PSYCHOLOGIST|NA|2|Visit_2|25|3|SCREENING|2020-12-29|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-19|P1Y2M10DT2H30M|UNKNOWN|2021-01-13|AFTER|2021-03-09
e|RS|955188f1-b434-40ab-94c8-0c0fb7f23e84|4|BONERESP|Bone Response|RECIST 1.0|[?]|LB|nPR|1|m|TRANSMISSION ELECTRON MICROSCOPY||Y||ADJUDICATOR|ONCOLOGIST|N|2|Visit_2|25|3|TREATMENT|2020-12-29|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-19|P1Y2M10DT2H30M|COINCIDENT|2021-01-13|AFTER|2021-03-04
e|RS|955188f1-b434-40ab-94c8-0c0fb7f23e84|5|SFTSRESP|Soft Tissue Response|GUILHOT CML 2007|[?]|ug/mL/h|RELAPSED DISEASE FROM CR OR PR|1|mU/L|NUCLEAR RADIOLOGY||||FRIEND|PATHOLOGIST 2|NA|3|Visit_3|40|2|TREATMENT|2021-01-13|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-22|P1Y2M10DT2H30M|BEFORE|2021-02-21|AFTER|2021-03-07
e|RS|955188f1-b434-40ab-94c8-0c0fb7f23e84|6|RDIORESP|Radiologic Response|CHOLLET BREAST CANCER 2002|[?]|YEARS|MRD RELAPSE|1|BOLUS|VIRUS PLAQUE ASSAY||||INTERVIEWER|PHYSIOTHERAPIST|N|3|Visit_3|40|1|WASHOUT|2021-01-13|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-22|P1Y2M10DT2H30M|BEFORE|2021-02-28|AFTER|2021-03-06
e|RS|955188f1-b434-40ab-94c8-0c0fb7f23e84|7|METBRESP|Metabolic Response|PCWG SCHER PROSTATE CANCER 2008|[?]|mg/g/min|SMD|1|CUP|TARGETED GENOME SEQUENCING||||HEALTH CARE PROFESSIONAL|MICROSCOPIST|Y|4|Visit_4|65|2|TREATMENT|2021-02-07|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-08|P1Y2M10DT2H30M|UNKNOWN|2021-01-26|ONGOING|2021-02-28
e|RS|955188f1-b434-40ab-94c8-0c0fb7f23e84|8|TMRESP|Tumor Marker Response|RECIST 1.0|||COMPLETE MRD RESPONSE|1|g/U|FREEZING POINT DEPRESSION||Y|Y|GUARDIAN|PATHOLOGIST 1|U|4|Visit_4|65|5|TREATMENT|2021-02-07|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-08|P1Y2M10DT2H30M|COINCIDENT|2021-02-15|AFTER|2021-02-18
e|RS|955188f1-b434-40ab-94c8-0c0fb7f23e84|9|BONERESP|Bone Response|IWG CHESON MDS 2006|[?]|IU/mL|RELAPSED DISEASE FROM CR|1|ug/L DDU|INCISION-INDUCED BLEEDING METHOD||||PROXY|INTERNIST|U|5|Visit_5|90|5|SCREENING|2021-03-04|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-26|P1Y2M10DT2H30M|COINCIDENT|2020-12-17|COINCIDENT|2021-03-08
e|RS|955188f1-b434-40ab-94c8-0c0fb7f23e84|10|MJPTHIND|Major Pathological Response Indicator|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|||VGPR|1|V/sec|PULSE OXIMETRY|||Y|ADJUDICATOR|READER 2|N|5|Visit_5|90|4|SCREENING|2021-03-04|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-26|P1Y2M10DT2H30M|BEFORE|2020-12-30|AFTER|2021-03-04
e|RS|5a384b5e-954c-4af9-bd60-96aadc72ca44|1|BMIVLIND|Bone Marrow Involvement Indicator|BURCOMBE BREAST CANCER 2005|||NON-PD|1|ng/dL|MRI|Y|Y|Y|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST|U|1|Visit_1|10|7|TREATMENT|2020-10-09|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-25|P1Y2M10DT2H30M|COINCIDENT|2020-11-26|ONGOING|2020-12-27
e|RS|5a384b5e-954c-4af9-bd60-96aadc72ca44|2|BONERESP|Bone Response|PERCIST|||PSA PROGRESSION|1|DISK|KNEMOMETRY|Y||Y|PARENT|READER 3|N|1|Visit_1|10|5|WASHOUT|2020-10-09|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-25|P1Y2M10DT2H30M|AFTER|2020-11-29|COINCIDENT|2020-12-05
e|RS|5a384b5e-954c-4af9-bd60-96aadc72ca44|3|CLINRESP|Clinical Response|HARTMANN GERM CELL CANCER 2002|||CYTOGENETIC PR|1|dpm/0.5 mL|SCANNING ELECTRON MICROSCOPY|Y|Y|Y|SIBLING|UROLOGIST|Y|2|Visit_2|25|4|TREATMENT|2020-10-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-29|P1Y2M10DT2H30M|UNKNOWN|2020-10-21|AFTER|2020-11-30
e|RS|5a384b5e-954c-4af9-bd60-96aadc72ca44|4|DRCRIND|Disease Recurrence Indicator|JACINTO CERVICAL CANCER 2007|[?]|BEAM BREAKS|EQUIVOCAL|1|ug/kg|PET SCAN||||CHILD|CARDIOLOGIST|U|2|Visit_2|25|4|SCREENING|2020-10-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-29|P1Y2M10DT2H30M|BEFORE|2020-12-26|ONGOING|2020-12-31
e|RS|5a384b5e-954c-4af9-bd60-96aadc72ca44|5|METBRESP|Metabolic Response|IWC HALLEK CLL 2008|[?]|mL/animal/wk|CA125 75% RESPONSE|1|psec|PET/CT SCAN||Y||CLINICAL RESEARCH ASSOCIATE|PHYSIOTHERAPIST|Y|3|Visit_3|40|1|TREATMENT|2020-11-08|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-03|P1Y2M10DT2H30M|BEFORE|2020-11-02|COINCIDENT|2020-12-23
e|RS|5a384b5e-954c-4af9-bd60-96aadc72ca44|6|MRPHRESP|Morphologic Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|||PD-CT|1|nmol/g|JAFFE REACTION|Y||Y|INDEPENDENT ASSESSOR|NEUROLOGIST 2|Y|3|Visit_3|40|3|FOLLOW-UP|2020-11-08|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-03|P1Y2M10DT2H30M|UNKNOWN|2021-01-05|COINCIDENT|2021-01-06
e|RS|5a384b5e-954c-4af9-bd60-96aadc72ca44|7|NTERESP|Non-Target Enhancing Response|CHESON LYMPHOMA 2008|[?]|10^3 RNA copies/mL|INDETERMINATE RESPONSE|1|IU/g|FLUORESCENT MICROSCOPY||||PROXY|ONCOLOGIST 1|N|4|Visit_4|65|3|SCREENING|2020-12-03|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-06|P1Y2M10DT2H30M|AFTER|2020-10-04|COINCIDENT|2020-12-23
e|RS|5a384b5e-954c-4af9-bd60-96aadc72ca44|8|CYTORESP|Cytogenetic Response|PCWG SCHER PROSTATE CANCER 2016|||QUANTIFIABLE MRD POSITIVITY|1|Bq/g|IMPEDANCE CONDUCTIVITY|Y||Y|HEALTH CARE PROFESSIONAL|DERMATOLOGIST|N|4|Visit_4|65|1|SCREENING|2020-12-03|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-06|P1Y2M10DT2H30M|COINCIDENT|2021-01-02|ONGOING|2021-01-04
e|RS|5a384b5e-954c-4af9-bd60-96aadc72ca44|9|NTERESP|Non-Target Enhancing Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|||PARTIAL MORPHOLOGIC RESPONSE|1|grain|TRICHROME STAIN||Y|Y|DOMESTIC PARTNER|RATER 1|Y|5|Visit_5|90|4|TREATMENT|2020-12-28|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-26|P1Y2M10DT2H30M|BEFORE|2020-10-24|ONGOING|2020-12-16
e|RS|5a384b5e-954c-4af9-bd60-96aadc72ca44|10|NTLWIND|Non-Target Lesion Worsening Indicator|GCIG RUSTIN OVARIAN CANCER 2011|[?]|cy/cm|OPTIMAL MORPHOLOGIC RESPONSE|1|Bq/g|IMMUNOTURBIDIMETRY||||CHILD|ADJUDICATOR|N|5|Visit_5|90|3|TREATMENT|2020-12-28|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-26|P1Y2M10DT2H30M|AFTER|2020-11-08|COINCIDENT|2020-12-22
e|RS|2c2d4104-35dd-4f81-ac31-ab1f84c2bc35|1|NTRGRESP|Non-target Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|Farad|CYTOGENETIC MINOR RESPONSE|1|umol/mg/min|MICROBIAL BIOCHEMICAL IDENTIFICATION|Y|||PROXY|ONCOLOGIST 1|N|1|Visit_1|10|2|TREATMENT|2020-07-02|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-12|P1Y2M10DT2H30M|BEFORE|2020-07-08|BEFORE|2020-07-16
e|RS|2c2d4104-35dd-4f81-ac31-ab1f84c2bc35|2|NEWLWIND|New Lesion Worsening Indicator|AJCC V8|||CHR|1|BOLUS|FARNSWORTH-MUNSELL 100 HUE TEST|||Y|FAMILY MEMBER|PEDIATRIC NEUROLOGIST|Y|1|Visit_1|10|4|FOLLOW-UP|2020-07-02|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-12|P1Y2M10DT2H30M|UNKNOWN|2020-07-20|COINCIDENT|2020-08-21
e|RS|2c2d4104-35dd-4f81-ac31-ab1f84c2bc35|3|DRCRIND|Disease Recurrence Indicator|DURIE MULTIPLE MYELOMA 2006|||SMD|1|days/month|PALM METHOD|||Y|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 2|NA|2|Visit_2|25|2|TREATMENT|2020-07-17|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-31|P1Y2M10DT2H30M|BEFORE|2020-09-20|ONGOING|2020-09-24
e|RS|2c2d4104-35dd-4f81-ac31-ab1f84c2bc35|4|NTERESP|Non-Target Enhancing Response|CHESON NON-HODGKINS LYMPHOMA 1999|||QUANTIFIABLE MRD POSITIVITY|1|CCID 50/dose|HIGH RESOLUTION CT|Y|Y|Y|SIBLING|PEDIATRIC NEUROLOGIST|U|2|Visit_2|25|6|WASHOUT|2020-07-17|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-31|P1Y2M10DT2H30M|BEFORE|2020-07-01|BEFORE|2020-07-09
e|RS|2c2d4104-35dd-4f81-ac31-ab1f84c2bc35|5|TMRESP|Tumor Marker Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|days/wk|MORPHOLOGIC CRi|1|Newton|CONFOCAL MICROSCOPY||||ADJUDICATION COMMITTEE|MICROSCOPIST 1|U|3|Visit_3|40|3|FOLLOW-UP|2020-08-01|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-22|P1Y2M10DT2H30M|COINCIDENT|2020-09-19|AFTER|2020-09-27
e|RS|2c2d4104-35dd-4f81-ac31-ab1f84c2bc35|6|MRPHRESP|Morphologic Response|GUPPY OVARIAN CANCER 2002|[?]|mU/g|MRD PERSISTENCE|1|IU/kg/h|CRYOSCOPY||||CLINICAL STUDY SPONSOR|READER|Y|3|Visit_3|40|6|FOLLOW-UP|2020-08-01|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-22|P1Y2M10DT2H30M|BEFORE|2020-09-07|COINCIDENT|2020-09-12
e|RS|2c2d4104-35dd-4f81-ac31-ab1f84c2bc35|7|MNPTHIND|Minor Pathological Response Indicator|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|USP U|CR|1|mg/m2|COULOMETRIC TITRATION||||GUARDIAN|MICROSCOPIST 1|U|4|Visit_4|65|7|SCREENING|2020-08-26|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-28|P1Y2M10DT2H30M|BEFORE|2020-08-25|BEFORE|2020-09-13
e|RS|2c2d4104-35dd-4f81-ac31-ab1f84c2bc35|8|MRPHRESP|Morphologic Response|AJCC V7|[?]|mL/cm3/min|PR-CT|1|mL/dL|RYAN BLUE STAIN||||STUDY SUBJECT|ONCOLOGIST|N|4|Visit_4|65|3|TREATMENT|2020-08-26|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-28|P1Y2M10DT2H30M|AFTER|2020-08-17|AFTER|2020-09-15
e|RS|2c2d4104-35dd-4f81-ac31-ab1f84c2bc35|9|SPLNRESP|Spleen Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|||CRi|1|GPS U|LEAD CITRATE STAIN||Y|Y|SIGNIFICANT OTHER|ADJUDICATOR 2|U|5|Visit_5|90|1|SCREENING|2020-09-20|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-06|P1Y2M10DT2H30M|UNKNOWN|2020-08-14|ONGOING|2020-09-23
e|RS|2c2d4104-35dd-4f81-ac31-ab1f84c2bc35|10|DRCRIND|Disease Recurrence Indicator|BURCOMBE BREAST CANCER 2005|||PARTIAL MORPHOLOGIC RESPONSE|1|10^3 copies/mL|SICKLE CELL SOLUBILITY TEST|||Y|GUARDIAN|READER 1|Y|5|Visit_5|90|7|SCREENING|2020-09-20|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-06|P1Y2M10DT2H30M|COINCIDENT|2020-08-15|AFTER|2020-08-17
e|RS|f9432d72-f7d7-4cdf-a173-2e2029258474|1|BMIVLIND|Bone Marrow Involvement Indicator|RECIST 1.0|[?]|MASK|TREATMENT FAILURE|1|ka_u/dL|CYSTOSCOPY||||NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|N|1|Visit_1|10|7|WASHOUT|2020-11-20|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-19|P1Y2M10DT2H30M|UNKNOWN|2020-12-30|ONGOING|2021-01-26
e|RS|f9432d72-f7d7-4cdf-a173-2e2029258474|2|PATHRESP|Pathologic Response|IWG CHESON AML 2003|||RELAPSED DISEASE FROM CR OR PR|1|mg/cm2|DXA SCAN|||Y|CAREGIVER|RATER|NA|1|Visit_1|10|4|WASHOUT|2020-11-20|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-19|P1Y2M10DT2H30M|BEFORE|2021-01-17|ONGOING|2021-02-04
e|RS|f9432d72-f7d7-4cdf-a173-2e2029258474|3|ANATRESP|Anatomic Response|IWG CHESON AML 2003|[?]|copies/ug|cCR|1|SYRINGE|POLYGRAPHY|Y|||CAREGIVER|MICROSCOPIST 2|Y|2|Visit_2|25|3|WASHOUT|2020-12-05|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-15|P1Y2M10DT2H30M|COINCIDENT|2020-12-16|AFTER|2021-01-03
e|RS|f9432d72-f7d7-4cdf-a173-2e2029258474|4|CLINRESP|Clinical Response|RAJKUMAR MYELOMA 2011|[?]|hr/day|MRD PERSISTENCE|1|mL/g/h|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN||||ADJUDICATOR|HEMATOLOGIST|NA|2|Visit_2|25|7|SCREENING|2020-12-05|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-15|P1Y2M10DT2H30M|COINCIDENT|2020-12-14|AFTER|2021-01-29
e|RS|f9432d72-f7d7-4cdf-a173-2e2029258474|5|CPRFSTAT|Clinical Performance Status|IWG CHESON MDS 2000|||HI-N|1|10^6 RNA copies/mL|DYNAMIC LIGHT SCATTERING|||Y|SIGNIFICANT OTHER|PEDIATRIC NEUROLOGIST|NA|3|Visit_3|40|3|SCREENING|2020-12-20|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-12|P1Y2M10DT2H30M|COINCIDENT|2021-01-29|AFTER|2021-02-12
e|RS|f9432d72-f7d7-4cdf-a173-2e2029258474|6|PATHRESP|Pathologic Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|pt_us|IMMUNOPHENOTYPIC CR|1|umol/kg/min|MAPH||Y||INDEPENDENT ASSESSOR|ADJUDICATOR|NA|3|Visit_3|40|7|TREATMENT|2020-12-20|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-12|P1Y2M10DT2H30M|AFTER|2021-01-01|COINCIDENT|2021-01-24
e|RS|f9432d72-f7d7-4cdf-a173-2e2029258474|7|MRDRESP|Minimal Residual Disease Response|EASL BRUIX LIVER CANCER 2001|[?]|MHz|UNFAVORABLE RESPONSE|1|ks|LEAD CITRATE STAIN||||FAMILY MEMBER|ADJUDICATOR|U|4|Visit_4|65|2|SCREENING|2021-01-14|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-16|P1Y2M10DT2H30M|UNKNOWN|2021-02-16|AFTER|2021-02-17
e|RS|f9432d72-f7d7-4cdf-a173-2e2029258474|8|STRUSTAT|Steroid Use Status|MASS|[?]|Bq/mL|CYTOGENETIC PR|1|MHz|SEQUENCING||||FAMILY MEMBER|ONCOLOGIST 1|U|4|Visit_4|65|7|WASHOUT|2021-01-14|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-16|P1Y2M10DT2H30M|BEFORE|2020-12-09|ONGOING|2020-12-28
e|RS|f9432d72-f7d7-4cdf-a173-2e2029258474|9|CYTORESP|Cytogenetic Response|SCHWARZ CERVICAL CANCER 2009|[?]|10^6 U|OPTIMAL MORPHOLOGIC RESPONSE|1|foz_us|FLOCCULATION|Y|||GUARDIAN|RATER|U|5|Visit_5|90|5|TREATMENT|2021-02-08|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-08|P1Y2M10DT2H30M|AFTER|2020-12-08|ONGOING|2021-01-25
e|RS|f9432d72-f7d7-4cdf-a173-2e2029258474|10|BMIVLIND|Bone Marrow Involvement Indicator|MONTSERRAT CLL 1989|[?]|mg/L FEU|TREATMENT FAILURE|1|mL/breath|PYROSEQUENCING||||ADJUDICATION COMMITTEE|ADJUDICATOR|Y|5|Visit_5|90|7|TREATMENT|2021-02-08|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-08|P1Y2M10DT2H30M|COINCIDENT|2020-11-28|ONGOING|2021-01-18
e|RS|1382c3ff-89fd-48e2-b64d-56c8ca9c71d3|1|NTLWIND|Non-Target Lesion Worsening Indicator|CHOLLET BREAST CANCER 2002|||SD|1|v/v|POTENTIOMETRY|Y||Y|INTERVIEWER|READER 2|Y|1|Visit_1|10|7|TREATMENT|2020-12-19|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-09|P1Y2M10DT2H30M|COINCIDENT|2021-01-23|COINCIDENT|2021-02-04
e|RS|1382c3ff-89fd-48e2-b64d-56c8ca9c71d3|2|MOLRESP|Molecular Response|MACDONALD GLIOMA 1990|[?]|foz_us|OPTIMAL MORPHOLOGIC RESPONSE|1|mL/dL|OSCILLOMETRY||Y||GUARDIAN|PEDIATRIC NEUROLOGIST|U|1|Visit_1|10|3|FOLLOW-UP|2020-12-19|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-09|P1Y2M10DT2H30M|UNKNOWN|2020-12-29|AFTER|2021-01-13
e|RS|1382c3ff-89fd-48e2-b64d-56c8ca9c71d3|3|MRPHRESP|Morphologic Response|EASL BRUIX LIVER CANCER 2001|[?]|nkat|CYTOGENETIC PR|1|log10 IU/mL|SLOAN LETTER EYE CHART 2.5%||||PROXY|MICROSCOPIST 1|Y|2|Visit_2|25|2|TREATMENT|2021-01-03|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-07|P1Y2M10DT2H30M|UNKNOWN|2021-01-07|COINCIDENT|2021-02-01
e|RS|1382c3ff-89fd-48e2-b64d-56c8ca9c71d3|4|BMIVLIND|Bone Marrow Involvement Indicator|BRUGGEMANN MRD 2010|[?]|in2|NON-QUANTIFIABLE MRD POSITIVITY|1|POUCH|MYELOPEROXIDASE STAIN|Y|||FAMILY MEMBER|ONCOLOGIST 1|NA|2|Visit_2|25|6|WASHOUT|2021-01-03|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-07|P1Y2M10DT2H30M|UNKNOWN|2021-02-28|COINCIDENT|2021-03-18
e|RS|1382c3ff-89fd-48e2-b64d-56c8ca9c71d3|5|PATHRESP|Pathologic Response|EBMT BLADE MYELOMA 1998|||mCR|1|ugEq/L|ATOMIC ABSORPTION SPECTROMETRY|||Y|VENDOR|MICROSCOPIST 1|Y|3|Visit_3|40|3|FOLLOW-UP|2021-01-18|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-18|P1Y2M10DT2H30M|UNKNOWN|2021-01-03|ONGOING|2021-01-31
e|RS|1382c3ff-89fd-48e2-b64d-56c8ca9c71d3|6|NTNERESP|Non-Target Non-Enhancing Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|/ms|HI-N|1|dyn|FUNDUS PHOTOGRAPHY||||INTERVIEWER|ADJUDICATOR 2|Y|3|Visit_3|40|7|SCREENING|2021-01-18|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-18|P1Y2M10DT2H30M|BEFORE|2021-02-05|BEFORE|2021-02-28
e|RS|1382c3ff-89fd-48e2-b64d-56c8ca9c71d3|7|METBRESP|Metabolic Response|CHESON CLL 2006|||INDETERMINATE RESPONSE|1|CAPLET|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY|||Y|INDEPENDENT ASSESSOR|ADJUDICATOR|Y|4|Visit_4|65|4|TREATMENT|2021-02-12|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-15|P1Y2M10DT2H30M|BEFORE|2021-03-03|BEFORE|2021-03-04
e|RS|1382c3ff-89fd-48e2-b64d-56c8ca9c71d3|8|METSIND|Metastatic Indicator|JACINTO CERVICAL CANCER 2007|||NOT ALL EVALUATED|1|ft2|MULTIPLEXED BEAD BASED IMMUNOASSAY|Y|Y|Y|INTERVIEWER|HEMATOLOGIST|N|4|Visit_4|65|3|SCREENING|2021-02-12|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-15|P1Y2M10DT2H30M|UNKNOWN|2021-01-29|AFTER|2021-02-10
e|RS|1382c3ff-89fd-48e2-b64d-56c8ca9c71d3|9|BMIVLIND|Bone Marrow Involvement Indicator|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|Ci/L|MOLECULAR MAJOR RESPONSE|1|MPL U|ELISPOT||||INTERVIEWER|PATHOLOGIST|U|5|Visit_5|90|6|TREATMENT|2021-03-09|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-08|P1Y2M10DT2H30M|AFTER|2021-01-11|BEFORE|2021-01-13
e|RS|1382c3ff-89fd-48e2-b64d-56c8ca9c71d3|10|NTNERESP|Non-Target Non-Enhancing Response|RANO ELLINGSON 2017|[?]|DIP|cCR|1|10^9/L|ISHIHARA COLOR PLATES|Y|||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 3|N|5|Visit_5|90|3|TREATMENT|2021-03-09|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-08|P1Y2M10DT2H30M|BEFORE|2021-03-04|ONGOING|2021-03-05
e|RS|0fc0650f-ed95-422d-b407-dcee93178780|1|METBRESP|Metabolic Response|MRECIST LENCIONI LIVER CANCER 2010|||IMMUNOPHENOTYPIC CR|1|EIA unit|AUSCULTATION|||Y|NON-HEALTH CARE PROFESSIONAL|DERMATOLOGIST|U|1|Visit_1|10|1|TREATMENT|2020-08-23|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-06|P1Y2M10DT2H30M|UNKNOWN|2020-08-20|AFTER|2020-10-17
e|RS|0fc0650f-ed95-422d-b407-dcee93178780|2|SYMPTDTR|Symptomatic Deterioration|DOHNER AML 2010|||NON-PD|1|g/g/day|ERGOSPIROMETRY|||Y|PROXY|RADIOLOGIST|N|1|Visit_1|10|1|SCREENING|2020-08-23|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-06|P1Y2M10DT2H30M|COINCIDENT|2020-09-20|AFTER|2020-10-23
e|RS|0fc0650f-ed95-422d-b407-dcee93178780|3|METBRESP|Metabolic Response|SCHWARZ CERVICAL CANCER 2009|[?]|mmAL|PR|1|IU/kg|CONTRAST ENHANCED MRI|Y|||FAMILY MEMBER|ADJUDICATOR|U|2|Visit_2|25|3|TREATMENT|2020-09-07|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-24|P1Y2M10DT2H30M|BEFORE|2020-08-21|BEFORE|2020-09-29
e|RS|0fc0650f-ed95-422d-b407-dcee93178780|4|DRCRIND|Disease Recurrence Indicator|LUGANO CLASSIFICATION|[?]|mL/dose|SMD|1|mL/(min*100mL)|ECHOCARDIOGRAPHY||||CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 1|Y|2|Visit_2|25|1|TREATMENT|2020-09-07|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-24|P1Y2M10DT2H30M|AFTER|2020-11-16|AFTER|2020-11-19
e|RS|0fc0650f-ed95-422d-b407-dcee93178780|5|NEWLIND|New Lesion Indicator|TSUKASAKI LEUKEMIA LYMPHOMA 2009|||UNEQUIVOCAL|1|mg/dose|MICRODENSITOMETRY||Y|Y|ADJUDICATOR|ADJUDICATOR 2|NA|3|Visit_3|40|5|TREATMENT|2020-09-22|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-27|P1Y2M10DT2H30M|BEFORE|2020-09-30|AFTER|2020-10-18
e|RS|0fc0650f-ed95-422d-b407-dcee93178780|6|BMIVLIND|Bone Marrow Involvement Indicator|PERCIST|||DECREASED|1|mEq|CALCOFLUOR WHITE STAIN|||Y|SIGNIFICANT OTHER|DEVELOPMENTAL PSYCHOLOGIST|Y|3|Visit_3|40|1|FOLLOW-UP|2020-09-22|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-27|P1Y2M10DT2H30M|UNKNOWN|2020-09-16|BEFORE|2020-11-16
e|RS|0fc0650f-ed95-422d-b407-dcee93178780|7|MNPTHIND|Minor Pathological Response Indicator|RAJKUMAR MYELOMA 2011|[?]|g/cm2|NON-CR/NON-PD|1|10^4/hpf|CONTRAST ENHANCED PET/CT SCAN||||INVESTIGATOR|RATER|N|4|Visit_4|65|1|TREATMENT|2020-10-17|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-26|P1Y2M10DT2H30M|UNKNOWN|2020-10-31|ONGOING|2020-11-02
e|RS|0fc0650f-ed95-422d-b407-dcee93178780|8|LIVRRESP|Liver Response|IWG CHESON MDS 2006|[?]|10^3 DNA copies/mL|PDu|1|hPa|FLUORESCENT IMMUNOASSAY|Y|||SIGNIFICANT OTHER|RATER 2|NA|4|Visit_4|65|1|SCREENING|2020-10-17|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-26|P1Y2M10DT2H30M|COINCIDENT|2020-09-02|BEFORE|2020-09-29
e|RS|0fc0650f-ed95-422d-b407-dcee93178780|9|CLINRESP|Clinical Response|IWG CHESON AML 2003|[?]|SCOOPFUL|VGPR|1|U/cL|GC/MS-EI|Y|||FAMILY MEMBER|NEUROLOGIST 2|NA|5|Visit_5|90|2|TREATMENT|2020-11-11|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-30|P1Y2M10DT2H30M|UNKNOWN|2020-10-23|COINCIDENT|2020-11-18
e|RS|0fc0650f-ed95-422d-b407-dcee93178780|10|NTERESP|Non-Target Enhancing Response|iRECIST|[?]|mCi/L|MORPHOLOGIC CR|1|anti-Xa IU|CHROMOGENIC ASSAY|Y|||FAMILY MEMBER|MICROSCOPIST|Y|5|Visit_5|90|1|SCREENING|2020-11-11|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-30|P1Y2M10DT2H30M|UNKNOWN|2020-09-02|AFTER|2020-10-21
e|RS|3b5e8a1c-1174-4f60-8a95-b2cf413f7e39|1|TMRESP|Tumor Marker Response|PCWG SCHER PROSTATE CANCER 2008|[?]|s/h|CR-CT|1|10^9/g|SCINTIGRAPHY||||ADJUDICATION COMMITTEE|UROLOGIST|N|1|Visit_1|10|3|FOLLOW-UP|2020-06-03|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-06|P1Y2M10DT2H30M|BEFORE|2020-06-09|COINCIDENT|2020-08-27
e|RS|3b5e8a1c-1174-4f60-8a95-b2cf413f7e39|2|ANATRESP|Anatomic Response|LEE LUNG CANCER 2011|[?]|PELLET|CYTOGENETIC MINIMAL RESPONSE|1|PNU/mL|PLETHYSMOGRAPHY|Y|Y||ADJUDICATION COMMITTEE|DEVELOPMENTAL PSYCHOLOGIST|NA|1|Visit_1|10|3|TREATMENT|2020-06-03|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-06|P1Y2M10DT2H30M|UNKNOWN|2020-07-13|BEFORE|2020-08-08
e|RS|3b5e8a1c-1174-4f60-8a95-b2cf413f7e39|3|OVRLRESP|Overall Response|PERCIST|[?]|breaths/30s|PMR|1|mmHg/sec|QUANTITATIVE COMPUTED TOMOGRAPHY||||INVESTIGATOR|CARDIOLOGIST|U|2|Visit_2|25|3|TREATMENT|2020-06-18|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-05|P1Y2M10DT2H30M|COINCIDENT|2020-07-18|COINCIDENT|2020-08-29
e|RS|3b5e8a1c-1174-4f60-8a95-b2cf413f7e39|4|NTERESP|Non-Target Enhancing Response|JACINTO CERVICAL CANCER 2007|[?]|K|MORPHOLOGIC LEUKEMIA-FREE STATE|1|umol/kg/min|MICROPARTICLE ENZYME IMMUNOASSAY||||CLINICAL STUDY SPONSOR|READER 3|N|2|Visit_2|25|1|SCREENING|2020-06-18|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-05|P1Y2M10DT2H30M|UNKNOWN|2020-07-19|ONGOING|2020-08-13
e|RS|3b5e8a1c-1174-4f60-8a95-b2cf413f7e39|5|TMRESP|Tumor Marker Response|DOHNER AML 2010|[?]|AgU/mL|pCR|1|log10 CFU/g|TRYPAN BLUE STAIN||||SPOUSE|MICROSCOPIST 3|Y|3|Visit_3|40|7|TREATMENT|2020-07-03|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-12|P1Y2M10DT2H30M|UNKNOWN|2020-06-15|BEFORE|2020-07-28
e|RS|3b5e8a1c-1174-4f60-8a95-b2cf413f7e39|6|BMIVLIND|Bone Marrow Involvement Indicator|EBMT BLADE MYELOMA 1998|[?]|U/kg|TREATMENT FAILURE|1|BAU/mL|OPTICAL MAPPING||||FRIEND|ADJUDICATOR|NA|3|Visit_3|40|2|SCREENING|2020-07-03|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-12|P1Y2M10DT2H30M|BEFORE|2020-08-02|BEFORE|2020-08-03
e|RS|3b5e8a1c-1174-4f60-8a95-b2cf413f7e39|7|CLINRESP|Clinical Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|mL/min/1.73m2|PARTIAL MORPHOLOGIC RESPONSE|1|mg/L FEU|ELECTROGASTROGRAPHY|Y|Y||PARENT|RADIOLOGIST 2|NA|4|Visit_4|65|4|TREATMENT|2020-07-28|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-17|P1Y2M10DT2H30M|AFTER|2020-07-20|BEFORE|2020-08-15
e|RS|3b5e8a1c-1174-4f60-8a95-b2cf413f7e39|8|MRDRESP|Minimal Residual Disease Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|PFU/mL|MORPHOLOGIC CR|1|mL/day|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION||||GUARDIAN|RADIOLOGIST 2|NA|4|Visit_4|65|2|SCREENING|2020-07-28|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-17|P1Y2M10DT2H30M|BEFORE|2020-06-18|COINCIDENT|2020-08-15
e|RS|3b5e8a1c-1174-4f60-8a95-b2cf413f7e39|9|TMRESP|Tumor Marker Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|mmol/s|MINOR PATHOLOGIC RESPONSE|1|ukat/10^12 RBC|INFRARED SPECTROMETRY||||FRIEND|MICROSCOPIST|U|5|Visit_5|90|4|TREATMENT|2020-08-22|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-28|P1Y2M10DT2H30M|UNKNOWN|2020-07-04|ONGOING|2020-08-27
e|RS|3b5e8a1c-1174-4f60-8a95-b2cf413f7e39|10|STRUSTAT|Steroid Use Status|KUKER LYMPHOMA 2005|||PARTIAL MORPHOLOGIC RESPONSE|1|GPL U/mL|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|Y||Y|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST|U|5|Visit_5|90|3|WASHOUT|2020-08-22|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-28|P1Y2M10DT2H30M|UNKNOWN|2020-07-29|AFTER|2020-08-08
e|RS|a6f48290-787a-46ad-bee1-ae263ad3c121|1|METSIND|Metastatic Indicator|EBMT BLADE MYELOMA 1998|||iSD|1|mL/day|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|||Y|FAMILY MEMBER|READER 1|U|1|Visit_1|10|1|WASHOUT|2021-01-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-18|P1Y2M10DT2H30M|AFTER|2021-04-12|AFTER|2021-04-16
e|RS|a6f48290-787a-46ad-bee1-ae263ad3c121|2|MRDRESP|Minimal Residual Disease Response|IWC HALLEK CLL 2008|[?]|Torr|DISEASE TRANSFORMATION|1|10^4 CFU|LASER CAPTURE MICRODISSECTION||||CHILD|DEVELOPMENTAL PSYCHOLOGIST|N|1|Visit_1|10|2|FOLLOW-UP|2021-01-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-18|P1Y2M10DT2H30M|UNKNOWN|2021-03-13|COINCIDENT|2021-04-07
e|RS|a6f48290-787a-46ad-bee1-ae263ad3c121|3|BESTRESP|Best Overall Response|HAMAOKA BREAST CANCER 2010|[?]|10^11/L|CYTOGENETIC MINIMAL RESPONSE|1|10^6/Ejaculate U|MANUAL COUNT|Y|Y||ADJUDICATOR|RATER|U|2|Visit_2|25|2|WASHOUT|2021-02-03|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-26|P1Y2M10DT2H30M|AFTER|2021-02-09|BEFORE|2021-03-19
e|RS|a6f48290-787a-46ad-bee1-ae263ad3c121|4|PATHRESP|Pathologic Response|UNSPECIFIED|[?]|BLOCKS|PD FROM PR|1|SACHET|HEMAGGLUTINATION ASSAY||||CLINICAL STUDY SPONSOR|DERMATOLOGIST|U|2|Visit_2|25|6|SCREENING|2021-02-03|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-26|P1Y2M10DT2H30M|AFTER|2021-03-14|BEFORE|2021-03-31
e|RS|a6f48290-787a-46ad-bee1-ae263ad3c121|5|MOLRESP|Molecular Response|PERCIST|||HI-E|1|10^9/dose|CORONARY ANGIOGRAPHY|||Y|FAMILY MEMBER|OTOLARYNGOLOGIST|N|3|Visit_3|40|3|TREATMENT|2021-02-18|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-20|P1Y2M10DT2H30M|UNKNOWN|2021-02-05|AFTER|2021-02-13
e|RS|a6f48290-787a-46ad-bee1-ae263ad3c121|6|METBRESP|Metabolic Response|PCWG BUBLEY PROSTATE CANCER 1999|||SMD|1|HEP|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN|Y||Y|ADJUDICATION COMMITTEE|NEUROLOGIST 2|NA|3|Visit_3|40|3|FOLLOW-UP|2021-02-18|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-20|P1Y2M10DT2H30M|AFTER|2021-03-02|COINCIDENT|2021-03-08
e|RS|a6f48290-787a-46ad-bee1-ae263ad3c121|7|STRUSTAT|Steroid Use Status|UNSPECIFIED|[?]|Tbsp|IMPROVED|1|kBq/uL|CLAUSS METHOD||||INTERVIEWER|ADJUDICATOR|Y|4|Visit_4|65|4|TREATMENT|2021-03-15|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-23|P1Y2M10DT2H30M|COINCIDENT|2021-02-19|ONGOING|2021-03-19
e|RS|a6f48290-787a-46ad-bee1-ae263ad3c121|8|SYMPTDTR|Symptomatic Deterioration|AJCC V8|[?]|rpm|iSD|1|mg/L FEU|PAP STAIN||||FRIEND|OPTOMETRIST|N|4|Visit_4|65|5|FOLLOW-UP|2021-03-15|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-23|P1Y2M10DT2H30M|AFTER|2021-03-04|BEFORE|2021-04-13
e|RS|a6f48290-787a-46ad-bee1-ae263ad3c121|9|CLINRESP|Clinical Response|GCIG RUSTIN OVARIAN CANCER 2011|||mCR|1|mOsm/L|CHROMATOGRAPHY|||Y|INTERVIEWER|FORENSIC PATHOLOGIST|NA|5|Visit_5|90|5|WASHOUT|2021-04-09|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-06|P1Y2M10DT2H30M|BEFORE|2021-01-12|COINCIDENT|2021-01-20
e|RS|a6f48290-787a-46ad-bee1-ae263ad3c121|10|BONERESP|Bone Response|NCCN ALL MRD 2014|[?]|ng|RELAPSED DISEASE FROM CR OR PR|1|mg/h|MIGET||||ADJUDICATION COMMITTEE|RATER 1|N|5|Visit_5|90|5|TREATMENT|2021-04-09|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-06|P1Y2M10DT2H30M|UNKNOWN|2021-03-23|AFTER|2021-04-12
e|RS|565e5c83-9c67-4718-bd54-af34be936427|1|NEWLPROG|New Lesion Progression|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|||MOLECULAR MAJOR RESPONSE|1|ug/kg/min|ANGIOGRAPHY|Y||Y|SIGNIFICANT OTHER|CLINICAL PATHOLOGIST|Y|1|Visit_1|10|1|FOLLOW-UP|2020-06-09|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-07|P1Y2M10DT2H30M|UNKNOWN|2020-08-07|COINCIDENT|2020-09-06
e|RS|565e5c83-9c67-4718-bd54-af34be936427|2|METSIND|Metastatic Indicator|WHO BREAST CANCER 2006|[?]|10^9 organisms/mg|RELAPSED DISEASE FROM CR|1|/5x10^4 WBC|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|Y|Y||VENDOR|NEUROLOGIST 1|Y|1|Visit_1|10|2|TREATMENT|2020-06-09|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-07|P1Y2M10DT2H30M|BEFORE|2020-06-15|AFTER|2020-08-07
e|RS|565e5c83-9c67-4718-bd54-af34be936427|3|CLINRESP|Clinical Response|BURCOMBE BREAST CANCER 2005|[?]|mL/day|VGPR|1|L/min|ELECTRICAL IMPEDANCE MYOGRAPHY||Y||ADJUDICATOR|DEVELOPMENTAL PSYCHOLOGIST|N|2|Visit_2|25|5|WASHOUT|2020-06-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-13|P1Y2M10DT2H30M|AFTER|2020-08-31|AFTER|2020-09-02
e|RS|565e5c83-9c67-4718-bd54-af34be936427|4|MJPTHIND|Major Pathological Response Indicator|IRANO 2015|[?]|10^3 CFU/g|NOT ALL EVALUATED|1|INHALATION|IMMUNOFLUORESCENT STAIN|Y|Y||CAREGIVER|PATHOLOGIST 1|U|2|Visit_2|25|4|FOLLOW-UP|2020-06-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-13|P1Y2M10DT2H30M|AFTER|2020-06-26|COINCIDENT|2020-08-29
e|RS|565e5c83-9c67-4718-bd54-af34be936427|5|LIVRRESP|Liver Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|mL/mmHg|CRi|1|MET*h|NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY||||CAREGIVER|READER|N|3|Visit_3|40|7|TREATMENT|2020-07-09|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-13|P1Y2M10DT2H30M|UNKNOWN|2020-07-29|BEFORE|2020-08-28
e|RS|565e5c83-9c67-4718-bd54-af34be936427|6|NEWLWIND|New Lesion Worsening Indicator|MURPHY PROSTATE CANCER 1980|||PMR|1|TUBE|MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY||Y|Y|HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|Y|3|Visit_3|40|5|SCREENING|2020-07-09|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-13|P1Y2M10DT2H30M|AFTER|2020-09-06|BEFORE|2020-09-07
e|RS|565e5c83-9c67-4718-bd54-af34be936427|7|SFTSRESP|Soft Tissue Response|LEE LUNG CANCER 2011|[?]|pt_br|NON-CR/NON-PD|1|DAgU|MAGNETIC RESONANCE ANGIOGRAPHY|Y|Y||SIGNIFICANT OTHER|OTOLARYNGOLOGIST|Y|4|Visit_4|65|4|FOLLOW-UP|2020-08-03|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-16|P1Y2M10DT2H30M|AFTER|2020-08-18|AFTER|2020-08-28
e|RS|565e5c83-9c67-4718-bd54-af34be936427|8|BESTRESP|Best Overall Response|CHESON CLL 2006|||CYTOGENETIC CR|1|log10 TCID 50/dose|OLIGO ACGH|||Y|PROXY|PATHOLOGIST 2|N|4|Visit_4|65|2|TREATMENT|2020-08-03|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-16|P1Y2M10DT2H30M|BEFORE|2020-06-03|ONGOING|2020-08-10
e|RS|565e5c83-9c67-4718-bd54-af34be936427|9|NTERESP|Non-Target Enhancing Response|AJCC V7|[?]|U/mmol|MOLECULAR MAJOR RESPONSE|1|titer|PET/MRI SCAN||||VENDOR|INTERNIST|N|5|Visit_5|90|7|FOLLOW-UP|2020-08-28|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-07|P1Y2M10DT2H30M|BEFORE|2020-09-01|BEFORE|2020-09-02
e|RS|565e5c83-9c67-4718-bd54-af34be936427|10|CPRFSTAT|Clinical Performance Status|EBMT BLADE MYELOMA 1998|||RELAPSED DISEASE|1|/LSQN|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE|Y|Y|Y|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|U|5|Visit_5|90|3|WASHOUT|2020-08-28|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-07|P1Y2M10DT2H30M|UNKNOWN|2020-08-15|AFTER|2020-08-17
e|RS|b238304c-15ef-4c6e-a32c-9cd583a233a9|1|NTRGRESP|Non-target Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|||NON-QUANTIFIABLE MRD POSITIVITY|1|V/sec|QUANTITATIVE CORONARY ANGIOGRAPHY|||Y|STUDY SUBJECT|ADJUDICATOR 1|NA|1|Visit_1|10|5|SCREENING|2021-01-07|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-29|P1Y2M10DT2H30M|COINCIDENT|2021-04-03|AFTER|2021-04-05
e|RS|b238304c-15ef-4c6e-a32c-9cd583a233a9|2|MNPTHIND|Minor Pathological Response Indicator|MRANO VAN DEN BENT GLIOMA 2011|||cCR|1|/mm|MEDIASTINOSCOPY|Y|Y|Y|STUDY SUBJECT|DERMATOLOGIST|Y|1|Visit_1|10|2|TREATMENT|2021-01-07|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-29|P1Y2M10DT2H30M|UNKNOWN|2021-01-06|AFTER|2021-01-26
e|RS|b238304c-15ef-4c6e-a32c-9cd583a233a9|3|MNPTHIND|Minor Pathological Response Indicator|PCWG BUBLEY PROSTATE CANCER 1999|[?]|DDU|PSEUDORESPONSE|1|CYLINDER|KINETIC MICROPARTICLE IMMUNOASSAY||||PARENT|ENDOCRINOLOGIST|NA|2|Visit_2|25|4|TREATMENT|2021-01-22|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-07|P1Y2M10DT2H30M|UNKNOWN|2021-02-28|AFTER|2021-03-12
e|RS|b238304c-15ef-4c6e-a32c-9cd583a233a9|4|RDIORESP|Radiologic Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|||IMMUNOPHENOTYPIC CR|1|cd/m2|CHROMOGENIC ASSAY|||Y|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|N|2|Visit_2|25|6|TREATMENT|2021-01-22|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-07|P1Y2M10DT2H30M|UNKNOWN|2021-03-30|COINCIDENT|2021-04-04
e|RS|b238304c-15ef-4c6e-a32c-9cd583a233a9|5|TMRESP|Tumor Marker Response|RANO|[?]|mL/s/m2|MRD RELAPSE|1|cmHg|ELECTROCHEMILUMINESCENCE IMMUNOASSAY||||FRIEND|ADJUDICATOR 3|U|3|Visit_3|40|2|TREATMENT|2021-02-06|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-05|P1Y2M10DT2H30M|BEFORE|2021-02-14|AFTER|2021-03-31
e|RS|b238304c-15ef-4c6e-a32c-9cd583a233a9|6|SYMPTDTR|Symptomatic Deterioration|IRANO 2015|[?]|Coulomb|UNFAVORABLE RESPONSE|1|AMPULE|LANDOLT RING||||INDEPENDENT ASSESSOR|DEVELOPMENTAL PSYCHOLOGIST|NA|3|Visit_3|40|7|TREATMENT|2021-02-06|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-05|P1Y2M10DT2H30M|AFTER|2021-01-07|ONGOING|2021-01-15
e|RS|b238304c-15ef-4c6e-a32c-9cd583a233a9|7|METBRESP|Metabolic Response|PCWG SCHER PROSTATE CANCER 2016|||CYTOGENETIC MINIMAL RESPONSE|1|umol/h/mmol|TRANSESOPHAGEAL ECHOCARDIOGRAPHY|Y||Y|CLINICAL RESEARCH COORDINATOR|HEMATOLOGIST|NA|4|Visit_4|65|2|WASHOUT|2021-03-03|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-20|P1Y2M10DT2H30M|UNKNOWN|2021-01-15|AFTER|2021-03-29
e|RS|b238304c-15ef-4c6e-a32c-9cd583a233a9|8|STRUSTAT|Steroid Use Status|GUPPY OVARIAN CANCER 2002|[?]|Sv|CA125 75% RESPONSE|1|nmol/L/min|HPLC/MS||||SIBLING|READER 3|U|4|Visit_4|65|1|FOLLOW-UP|2021-03-03|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-20|P1Y2M10DT2H30M|BEFORE|2021-03-24|COINCIDENT|2021-04-01
e|RS|b238304c-15ef-4c6e-a32c-9cd583a233a9|9|NEWLWIND|New Lesion Worsening Indicator|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|ppth|RELAPSED DISEASE FROM CR|1|Tbsp|SPECULAR MICROSCOPY|Y|||FAMILY MEMBER|OPHTHALMOLOGIST|Y|5|Visit_5|90|1|WASHOUT|2021-03-28|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-09|P1Y2M10DT2H30M|BEFORE|2021-03-09|ONGOING|2021-03-13
e|RS|b238304c-15ef-4c6e-a32c-9cd583a233a9|10|LIVRRESP|Liver Response|LUGANO CLASSIFICATION|[?]|lm|UNEQUIVOCAL|1|scm|RAJI CELL EIA||||FRIEND|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|5|Visit_5|90|7|SCREENING|2021-03-28|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-09|P1Y2M10DT2H30M|UNKNOWN|2021-02-04|BEFORE|2021-03-26
e|RS|c273f039-bca9-4d55-8620-5c5db32a6c4b|1|NTERESP|Non-Target Enhancing Response|DOHNER AML 2010|[?]|uU/dL|RELAPSED DISEASE FROM CR|1|bel|HIGH RESOLUTION CT||||VENDOR|CLINICAL PATHOLOGIST|N|1|Visit_1|10|7|TREATMENT|2020-09-23|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-09|P1Y2M10DT2H30M|COINCIDENT|2020-10-30|BEFORE|2020-11-28
e|RS|c273f039-bca9-4d55-8620-5c5db32a6c4b|2|NTERESP|Non-Target Enhancing Response|CHESON CLL 2012|[?]|dpm/mg|NOT ALL EVALUATED|1|MET*h|PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY||||DOMESTIC PARTNER|RADIOLOGIST 2|Y|1|Visit_1|10|6|SCREENING|2020-09-23|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-09|P1Y2M10DT2H30M|AFTER|2020-11-25|COINCIDENT|2020-11-28
e|RS|c273f039-bca9-4d55-8620-5c5db32a6c4b|3|BMIVLIND|Bone Marrow Involvement Indicator|RANO|[?]|GPL U/mL|UNEQUIVOCAL|1|foz_br|HPLC-FL||||PROXY|PEDIATRIC NEUROLOGIST|N|2|Visit_2|25|3|FOLLOW-UP|2020-10-08|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-10|P1Y2M10DT2H30M|AFTER|2020-11-08|ONGOING|2020-11-24
e|RS|c273f039-bca9-4d55-8620-5c5db32a6c4b|4|MRPHRESP|Morphologic Response|IWG CHESON MDS 2000|||IMMUNOPHENOTYPIC CR|1|ngEq/L|CRYOSCOPY|||Y|HEALTH CARE PROFESSIONAL|RATER 1|NA|2|Visit_2|25|5|FOLLOW-UP|2020-10-08|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-10|P1Y2M10DT2H30M|UNKNOWN|2020-12-05|ONGOING|2020-12-21
e|RS|c273f039-bca9-4d55-8620-5c5db32a6c4b|5|TRGRESP|Target Response|BLAZER COLORECTAL CANCER 2008|[?]|10^11/L|STABLE|1|Hounsfield Unit|CONTRAST ENHANCED X-RAY|Y|Y||FRIEND|READER 3|N|3|Visit_3|40|6|FOLLOW-UP|2020-10-23|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-19|P1Y2M10DT2H30M|BEFORE|2020-11-03|ONGOING|2020-11-17
e|RS|c273f039-bca9-4d55-8620-5c5db32a6c4b|6|TRGRESP|Target Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|mEq/kg|NON-CR/NON-PD|1|oz|ENDOSCOPY||||HEALTH CARE PROFESSIONAL|NEUROLOGIST|NA|3|Visit_3|40|7|WASHOUT|2020-10-23|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-19|P1Y2M10DT2H30M|AFTER|2020-10-22|COINCIDENT|2020-10-26
e|RS|c273f039-bca9-4d55-8620-5c5db32a6c4b|7|LIVRRESP|Liver Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|10^6 IU/mL|CYTOGENETIC MINIMAL RESPONSE|1|mEq/g|OPTICAL MAPPING||||SPOUSE|RADIOLOGIST 2|NA|4|Visit_4|65|2|FOLLOW-UP|2020-11-17|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-29|P1Y2M10DT2H30M|UNKNOWN|2020-11-05|AFTER|2020-11-29
e|RS|c273f039-bca9-4d55-8620-5c5db32a6c4b|8|LIVRRESP|Liver Response|CHESON MALIGNANT LYMPHOMA 2007|||PARTIAL MORPHOLOGIC RESPONSE|1|U/m2/h|IMPEDANCE CONDUCTIVITY||Y|Y|INVESTIGATOR|DEVELOPMENTAL PSYCHOLOGIST|N|4|Visit_4|65|6|FOLLOW-UP|2020-11-17|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-29|P1Y2M10DT2H30M|UNKNOWN|2020-11-24|BEFORE|2020-12-01
e|RS|c273f039-bca9-4d55-8620-5c5db32a6c4b|9|MNPTHIND|Minor Pathological Response Indicator|BRUGGEMANN MRD 2010|[?]|log10 TCID 50/dose|NON-CR/NON-PD|1|dmol|MEDIASTINOSCOPY||||SIBLING|RATER 1|NA|5|Visit_5|90|4|WASHOUT|2020-12-12|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-24|P1Y2M10DT2H30M|BEFORE|2020-10-02|ONGOING|2020-10-28
e|RS|c273f039-bca9-4d55-8620-5c5db32a6c4b|10|PATHRESP|Pathologic Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|IU|PD/RELAPSE AFTER HI|1|mkat|IMPEDANCE CONDUCTIVITY||Y||SIGNIFICANT OTHER|NEUROLOGIST 2|N|5|Visit_5|90|2|SCREENING|2020-12-12|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-24|P1Y2M10DT2H30M|BEFORE|2020-11-10|AFTER|2020-12-03
e|RS|2cdb5053-2108-4f50-8906-8afabc855a36|1|NTNERESP|Non-Target Non-Enhancing Response|RECIST 1.0|[?]|nCi|mCR|1|PACKET|NUCLEAR RADIOLOGY|Y|||INVESTIGATOR|RADIOLOGIST 2|U|1|Visit_1|10|4|FOLLOW-UP|2020-08-28|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-25|P1Y2M10DT2H30M|UNKNOWN|2020-09-06|COINCIDENT|2020-10-20
e|RS|2cdb5053-2108-4f50-8906-8afabc855a36|2|NTLWIND|Non-Target Lesion Worsening Indicator|PERCIST|[?]|CIGARETTE|NOT ALL EVALUATED|1|CYLINDER|PHOTOMETRY||||GUARDIAN|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|1|Visit_1|10|6|SCREENING|2020-08-28|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-25|P1Y2M10DT2H30M|UNKNOWN|2020-11-24|AFTER|2020-11-25
e|RS|2cdb5053-2108-4f50-8906-8afabc855a36|3|MOLRESP|Molecular Response|LUGANO CLASSIFICATION|[?]|bel|NON-QUANTIFIABLE MRD POSITIVITY|1|ukat|JAFFE REACTION||Y||DOMESTIC PARTNER|DEVELOPMENTAL PSYCHOLOGIST|U|2|Visit_2|25|5|WASHOUT|2020-09-12|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-14|P1Y2M10DT2H30M|BEFORE|2020-10-06|AFTER|2020-10-26
e|RS|2cdb5053-2108-4f50-8906-8afabc855a36|4|NEWLIND|New Lesion Indicator|MACDONALD GLIOMA 1990|||nPR|1|cmH2O*s/mL|FLUORESCENT LIFETIME IMAGING MICROSCOPY||Y|Y|CLINICAL RESEARCH COORDINATOR|PHYSIOTHERAPIST|NA|2|Visit_2|25|2|TREATMENT|2020-09-12|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-14|P1Y2M10DT2H30M|AFTER|2020-10-19|COINCIDENT|2020-10-23
e|RS|2cdb5053-2108-4f50-8906-8afabc855a36|5|MOLRESP|Molecular Response|MACDONALD GLIOMA 1990|||iCR|1|U/kg/h|SMEAR||Y|Y|SPOUSE|INTERNIST|Y|3|Visit_3|40|7|WASHOUT|2020-09-27|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-20|P1Y2M10DT2H30M|UNKNOWN|2020-10-13|COINCIDENT|2020-10-14
e|RS|2cdb5053-2108-4f50-8906-8afabc855a36|6|SPLNRESP|Spleen Response|RANO|[?]|g/cage/wk|HI-E|1|cm H2O|NON-INVASIVE DIELECTRIC SENSING|Y|||GUARDIAN|PEDIATRIC NEUROLOGIST|N|3|Visit_3|40|6|TREATMENT|2020-09-27|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-20|P1Y2M10DT2H30M|UNKNOWN|2020-08-31|AFTER|2020-09-09
e|RS|2cdb5053-2108-4f50-8906-8afabc855a36|7|METBRESP|Metabolic Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|cm|sCR|1|10^3 organisms/g|CONTRAST ENHANCED SPIRAL CT SCAN||||CHILD|CLINICAL PATHOLOGIST|U|4|Visit_4|65|2|SCREENING|2020-10-22|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-25|P1Y2M10DT2H30M|AFTER|2020-10-17|COINCIDENT|2020-11-14
e|RS|2cdb5053-2108-4f50-8906-8afabc855a36|8|METBRESP|Metabolic Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|pL|MORPHOLOGIC CR|1|mL/dose|ENZYMATIC SPECTROPHOTOMETRY||Y||SIGNIFICANT OTHER|RATER 2|NA|4|Visit_4|65|5|SCREENING|2020-10-22|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-25|P1Y2M10DT2H30M|UNKNOWN|2020-10-11|COINCIDENT|2020-11-10
e|RS|2cdb5053-2108-4f50-8906-8afabc855a36|9|NTLWIND|Non-Target Lesion Worsening Indicator|KUKER LYMPHOMA 2005|[?]|10^9/dose|CA125 50% RESPONSE|1|10^6 organisms/g|DARK FIELD MICROSCOPY||||CLINICAL RESEARCH COORDINATOR|PEDIATRIC NEUROLOGIST|NA|5|Visit_5|90|6|FOLLOW-UP|2020-11-16|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-14|P1Y2M10DT2H30M|COINCIDENT|2020-10-24|ONGOING|2020-10-27
e|RS|2cdb5053-2108-4f50-8906-8afabc855a36|10|HEMARESP|Hematologic Response|FAROOQUI SUPP CLL 2014|[?]|mEq|cPR|1|MPL U/mL|ICP-MS||Y||PROXY|READER 1|N|5|Visit_5|90|3|FOLLOW-UP|2020-11-16|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-14|P1Y2M10DT2H30M|AFTER|2020-11-08|COINCIDENT|2020-11-15
e|RS|fce7149a-503e-4209-8c62-8044a2ad1c1c|1|CLINRESP|Clinical Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|%(w/w)|PD-CT|1|YEARS|IMMUNOCHEMILUMINOMETRIC ASSAY||||CLINICAL RESEARCH COORDINATOR|PHYSIOTHERAPIST|N|1|Visit_1|10|7|SCREENING|2020-08-06|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-04|P1Y2M10DT2H30M|UNKNOWN|2020-08-04|BEFORE|2020-08-27
e|RS|fce7149a-503e-4209-8c62-8044a2ad1c1c|2|STRUSTAT|Steroid Use Status|MRANO VAN DEN BENT GLIOMA 2011|[?]|10^5/hpf|STABLE|1|v/v|FLOW MICROSCOPY||||FRIEND|OPTOMETRIST|NA|1|Visit_1|10|4|TREATMENT|2020-08-06|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-04|P1Y2M10DT2H30M|BEFORE|2020-10-15|ONGOING|2020-10-19
e|RS|fce7149a-503e-4209-8c62-8044a2ad1c1c|3|BESTRESP|Best Overall Response|BURCOMBE BREAST CANCER 2005|[?]|MET*h|RELAPSED DISEASE FROM CR|1|msec|POTENTIOMETRY||||PROXY|READER 1|Y|2|Visit_2|25|2|TREATMENT|2020-08-21|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-15|P1Y2M10DT2H30M|COINCIDENT|2020-10-05|BEFORE|2020-10-31
e|RS|fce7149a-503e-4209-8c62-8044a2ad1c1c|4|DRCRIND|Disease Recurrence Indicator|NCIWG CHESON CLL 1996|||MORPHOLOGIC CRi|1|nkat/g Hb|ELECTROMYOGRAPHY||Y|Y|ADJUDICATION COMMITTEE|OTOLARYNGOLOGIST|NA|2|Visit_2|25|6|TREATMENT|2020-08-21|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-15|P1Y2M10DT2H30M|COINCIDENT|2020-09-30|COINCIDENT|2020-10-14
e|RS|fce7149a-503e-4209-8c62-8044a2ad1c1c|5|NEWLWIND|New Lesion Worsening Indicator|KUMAR IMWG 2016|[?]|BEAM BREAKS|PDu|1|dpm/mg|SLIT LAMP PHOTOGRAPHY|Y|||CLINICAL RESEARCH ASSOCIATE|READER|NA|3|Visit_3|40|4|SCREENING|2020-09-05|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-23|P1Y2M10DT2H30M|UNKNOWN|2020-10-06|BEFORE|2020-11-01
e|RS|fce7149a-503e-4209-8c62-8044a2ad1c1c|6|NTRGRESP|Non-target Response|UNSPECIFIED|[?]|deg/s|cPR|1|10^6 RNA copies/mL|ACID FAST STAIN||||CHILD|OPHTHALMOLOGIST|NA|3|Visit_3|40|2|TREATMENT|2020-09-05|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-23|P1Y2M10DT2H30M|BEFORE|2020-10-04|BEFORE|2020-11-01
e|RS|fce7149a-503e-4209-8c62-8044a2ad1c1c|7|STRUSTAT|Steroid Use Status|BLAZER COLORECTAL CANCER 2008|[?]|10^9 organisms/mL|CYTOGENETIC CR|1|CUP|NO INFORMATION|Y|||INVESTIGATOR|NEUROLOGIST 2|Y|4|Visit_4|65|4|TREATMENT|2020-09-30|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-16|P1Y2M10DT2H30M|COINCIDENT|2020-08-17|BEFORE|2020-08-19
e|RS|fce7149a-503e-4209-8c62-8044a2ad1c1c|8|MRDRESP|Minimal Residual Disease Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|uL/mL|PD/RELAPSE AFTER HI|1|INHALATION|KARYOTYPING||Y||CHILD|ADJUDICATOR 3|Y|4|Visit_4|65|4|TREATMENT|2020-09-30|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-16|P1Y2M10DT2H30M|BEFORE|2020-10-14|BEFORE|2020-10-19
e|RS|fce7149a-503e-4209-8c62-8044a2ad1c1c|9|ANATRESP|Anatomic Response|MONTSERRAT CLL 1989|[?]|10^6 CFU/mL|DISEASE TRANSFORMATION|1|atm|WHOLE TRANSCRIPTOME SEQUENCING|Y|||CLINICAL RESEARCH COORDINATOR|FORENSIC PATHOLOGIST|Y|5|Visit_5|90|6|FOLLOW-UP|2020-10-25|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-30|P1Y2M10DT2H30M|COINCIDENT|2020-08-12|COINCIDENT|2020-10-23
e|RS|fce7149a-503e-4209-8c62-8044a2ad1c1c|10|CYTORESP|Cytogenetic Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|gtt|MOLECULAR MAJOR RESPONSE|1|amp|MICROBIAL CULTURE||Y||VENDOR|FORENSIC PATHOLOGIST|U|5|Visit_5|90|5|WASHOUT|2020-10-25|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-30|P1Y2M10DT2H30M|AFTER|2020-10-29|BEFORE|2020-11-01
e|RS|c8aad550-11a1-4473-8b35-79b7dfb08122|1|MRDRESP|Minimal Residual Disease Response|RECIST 1.0|[?]|nCi|SMD|1|ug/L|DIFFUSION TENSOR MRI||||HEALTH CARE PROFESSIONAL|ADJUDICATOR|Y|1|Visit_1|10|5|TREATMENT|2020-06-09|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-04|P1Y2M10DT2H30M|COINCIDENT|2020-07-14|AFTER|2020-07-19
e|RS|c8aad550-11a1-4473-8b35-79b7dfb08122|2|NEWLIND|New Lesion Indicator|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|||CR-CT|1|CFU/mL|HPLC|||Y|INDEPENDENT ASSESSOR|ADJUDICATOR 3|NA|1|Visit_1|10|4|FOLLOW-UP|2020-06-09|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-04|P1Y2M10DT2H30M|AFTER|2020-08-17|ONGOING|2020-08-25
e|RS|c8aad550-11a1-4473-8b35-79b7dfb08122|3|SYMPTDTR|Symptomatic Deterioration|DURIE MULTIPLE MYELOMA 2006|[?]|U/m2/h|MORPHOLOGIC CR|1|keV|MAPH||||FRIEND|RADIOLOGIST 2|Y|2|Visit_2|25|7|SCREENING|2020-06-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-12|P1Y2M10DT2H30M|UNKNOWN|2020-06-11|AFTER|2020-07-04
e|RS|c8aad550-11a1-4473-8b35-79b7dfb08122|4|NEWLIND|New Lesion Indicator|IWC HALLEK CLL 2008|||PMR|1|mU/g|ALCIAN BLUE STAIN|||Y|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 1|U|2|Visit_2|25|2|WASHOUT|2020-06-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-12|P1Y2M10DT2H30M|BEFORE|2020-09-01|COINCIDENT|2020-09-03
e|RS|c8aad550-11a1-4473-8b35-79b7dfb08122|5|TRGRESP|Target Response|IWC HALLEK CLL 2008|[?]|Joule|NON-QUANTIFIABLE MRD POSITIVITY|1|mg/mL/day|WESTERN BLOT||||ADJUDICATOR|READER 3|NA|3|Visit_3|40|7|FOLLOW-UP|2020-07-09|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-10|P1Y2M10DT2H30M|UNKNOWN|2020-06-17|COINCIDENT|2020-07-29
e|RS|c8aad550-11a1-4473-8b35-79b7dfb08122|6|MNPTHIND|Minor Pathological Response Indicator|AJCC V7|[?]|PRESSOR UNITS|PR-CT|1|mEq/L|TOTAL BODY RADIOGRAPHY|Y|||CLINICAL RESEARCH COORDINATOR|OPHTHALMOLOGIST|NA|3|Visit_3|40|5|FOLLOW-UP|2020-07-09|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-10|P1Y2M10DT2H30M|BEFORE|2020-08-02|BEFORE|2020-08-10
e|RS|c8aad550-11a1-4473-8b35-79b7dfb08122|7|BONERESP|Bone Response|MONTSERRAT CLL 1989|[?]|GPL U/mL|PARTIAL MORPHOLOGIC RESPONSE|1|mL/min|U-HPLC/MS/MS||Y||GUARDIAN|PATHOLOGIST|Y|4|Visit_4|65|4|FOLLOW-UP|2020-08-03|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-09|P1Y2M10DT2H30M|COINCIDENT|2020-06-24|AFTER|2020-08-04
e|RS|c8aad550-11a1-4473-8b35-79b7dfb08122|8|SPLNRESP|Spleen Response|CHESON CLL 2012|[?]|cL|CR|1|INHALATION|CONTACT SPECULAR MICROSCOPY||||ADJUDICATOR|HEMATOLOGIST|Y|4|Visit_4|65|3|TREATMENT|2020-08-03|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-09|P1Y2M10DT2H30M|COINCIDENT|2020-06-30|AFTER|2020-08-26
e|RS|c8aad550-11a1-4473-8b35-79b7dfb08122|9|METBRESP|Metabolic Response|SACT|||COMPLETE MRD RESPONSE|1|U/dL|CONTRAST ENHANCED MRI||Y|Y|VENDOR|ONCOLOGIST|Y|5|Visit_5|90|1|SCREENING|2020-08-28|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-06|P1Y2M10DT2H30M|COINCIDENT|2020-09-02|COINCIDENT|2020-09-06
e|RS|c8aad550-11a1-4473-8b35-79b7dfb08122|10|NTRGRESP|Non-target Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|||SD-CT|1|ug/dose|MICRO BROTH DILUTION|Y||Y|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|U|5|Visit_5|90|1|TREATMENT|2020-08-28|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-06|P1Y2M10DT2H30M|AFTER|2020-07-24|BEFORE|2020-09-06
e|RS|f1967c6e-c520-4482-be7e-01ada4380d87|1|NTRGRESP|Non-target Response|DURIE MULTIPLE MYELOMA 2006|[?]|CAPSULE|PMR|1|uCi|ROMANOWSKY STAIN|Y|||INVESTIGATOR|FORENSIC PATHOLOGIST|U|1|Visit_1|10|5|TREATMENT|2021-01-05|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-15|P1Y2M10DT2H30M|BEFORE|2021-02-06|AFTER|2021-03-31
e|RS|f1967c6e-c520-4482-be7e-01ada4380d87|2|NEWLIND|New Lesion Indicator|RAJKUMAR MYELOMA 2011|[?]|ohm|CMR|1|ug/m2/min|SEQUENCING|Y|Y||CHILD|ADJUDICATOR 1|NA|1|Visit_1|10|4|TREATMENT|2021-01-05|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-15|P1Y2M10DT2H30M|COINCIDENT|2021-02-28|BEFORE|2021-03-07
e|RS|f1967c6e-c520-4482-be7e-01ada4380d87|3|HEMARESP|Hematologic Response|LUGANO CLASSIFICATION|[?]|MONTHS|CR-CT|1|kHz|ELISPOT||||INDEPENDENT ASSESSOR|MICROSCOPIST 3|N|2|Visit_2|25|1|TREATMENT|2021-01-20|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-16|P1Y2M10DT2H30M|AFTER|2021-03-29|ONGOING|2021-03-31
e|RS|f1967c6e-c520-4482-be7e-01ada4380d87|4|NTLWIND|Non-Target Lesion Worsening Indicator|MURPHY PROSTATE CANCER 1980|||NE|1|umol/day|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|||Y|CAREGIVER|ENDOCRINOLOGIST|Y|2|Visit_2|25|2|TREATMENT|2021-01-20|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-16|P1Y2M10DT2H30M|UNKNOWN|2021-01-28|ONGOING|2021-03-14
e|RS|f1967c6e-c520-4482-be7e-01ada4380d87|5|LIVRRESP|Liver Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|||CYTOGENETIC CR|1|kHz|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION|||Y|PARENT|FORENSIC PATHOLOGIST|N|3|Visit_3|40|1|TREATMENT|2021-02-04|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-10|P1Y2M10DT2H30M|UNKNOWN|2021-01-03|AFTER|2021-02-22
e|RS|f1967c6e-c520-4482-be7e-01ada4380d87|6|STRUSTAT|Steroid Use Status|RECIST 1.1|[?]|ug/g/min|nPR|1|vp/dose|CRYOSCOPY|Y|Y||CAREGIVER|PEDIATRIC NEUROLOGIST|U|3|Visit_3|40|3|TREATMENT|2021-02-04|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-10|P1Y2M10DT2H30M|AFTER|2021-03-11|ONGOING|2021-03-18
e|RS|f1967c6e-c520-4482-be7e-01ada4380d87|7|NEWLIND|New Lesion Indicator|SACT|[?]|kat|COMPLETE MRD RESPONSE|1|cGy|OPTICAL COHERENCE TOMOGRAPHY||||VENDOR|RATER 2|Y|4|Visit_4|65|5|TREATMENT|2021-03-01|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-28|P1Y2M10DT2H30M|COINCIDENT|2021-03-18|ONGOING|2021-04-04
e|RS|f1967c6e-c520-4482-be7e-01ada4380d87|8|NEWLPROG|New Lesion Progression|SACT|[?]|min/day|PR|1|/sec|LEAD CITRATE STAIN|Y|||ADJUDICATION COMMITTEE|RATER 1|U|4|Visit_4|65|4|WASHOUT|2021-03-01|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-28|P1Y2M10DT2H30M|COINCIDENT|2021-02-10|ONGOING|2021-03-13
e|RS|f1967c6e-c520-4482-be7e-01ada4380d87|9|DRCRIND|Disease Recurrence Indicator|KEAM BREAST CANCER 2013|[?]|ft3|NON-iCR/NON-iUPD|1|mL/m2/h|MRI WITHOUT CONTRAST||||HEALTH CARE PROFESSIONAL|INTERNIST|U|5|Visit_5|90|4|SCREENING|2021-03-26|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-03|P1Y2M10DT2H30M|UNKNOWN|2021-01-10|BEFORE|2021-03-24
e|RS|f1967c6e-c520-4482-be7e-01ada4380d87|10|TRGRESP|Target Response|KEAM BREAST CANCER 2013|[?]|GPL U|NON-iCR/NON-iUPD|1|vg/dose|NEPHELOMETRY||||DOMESTIC PARTNER|INTERNIST|N|5|Visit_5|90|5|SCREENING|2021-03-26|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-03|P1Y2M10DT2H30M|COINCIDENT|2021-03-08|ONGOING|2021-03-29
e|RS|2a5a1c03-f54e-47da-8dda-2104c9423e94|1|NEWLPROG|New Lesion Progression|RANO|[?]|TROCHE|CYTOGENETIC NO RESPONSE|1|IU/mmol|IMMUNE REPERTOIRE DEEP SEQUENCING||||INTERVIEWER|DEVELOPMENTAL PSYCHOLOGIST|U|1|Visit_1|10|6|TREATMENT|2021-01-01|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-01|P1Y2M10DT2H30M|AFTER|2021-03-04|ONGOING|2021-03-19
e|RS|2a5a1c03-f54e-47da-8dda-2104c9423e94|2|METBRESP|Metabolic Response|HAMAOKA BREAST CANCER 2010|[?]|10^8 PFU|PSEUDOPROGRESSION|1|10^3 organisms|SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY||Y||GUARDIAN|ONCOLOGIST 1|NA|1|Visit_1|10|2|FOLLOW-UP|2021-01-01|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-01|P1Y2M10DT2H30M|AFTER|2021-01-13|BEFORE|2021-03-25
e|RS|2a5a1c03-f54e-47da-8dda-2104c9423e94|3|CLINRESP|Clinical Response|MRECIST BYRNE MESOTHELIOMA 2004|||CYTOGENETIC CR|1|eq|IMMUNE REPERTOIRE DEEP SEQUENCING|||Y|FRIEND|ONCOLOGIST 1|NA|2|Visit_2|25|1|SCREENING|2021-01-16|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-17|P1Y2M10DT2H30M|UNKNOWN|2021-01-10|BEFORE|2021-02-28
e|RS|2a5a1c03-f54e-47da-8dda-2104c9423e94|4|NTLWIND|Non-Target Lesion Worsening Indicator|NCCN ALL MRD 2014|[?]|g/kg|MRD RELAPSE|1|10^9 organisms|AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT|Y|||CHILD|PATHOLOGIST 2|NA|2|Visit_2|25|4|TREATMENT|2021-01-16|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-17|P1Y2M10DT2H30M|AFTER|2021-02-16|AFTER|2021-03-26
e|RS|2a5a1c03-f54e-47da-8dda-2104c9423e94|5|MJPTHIND|Major Pathological Response Indicator|RANO ELLINGSON 2017|[?]|MBq/uL|sCR|1|min/day|ETDRS EYE CHART||Y||STUDY SUBJECT|PATHOLOGIST 1|U|3|Visit_3|40|6|TREATMENT|2021-01-31|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-24|P1Y2M10DT2H30M|AFTER|2021-03-31|ONGOING|2021-04-01
e|RS|2a5a1c03-f54e-47da-8dda-2104c9423e94|6|METBRESP|Metabolic Response|RANO ELLINGSON 2017|[?]|Absorbance U/min|RELAPSED DISEASE FROM CR|1|tuberculin unit/mL|PHASE CONTRAST MICROSCOPY||||SIBLING|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|3|Visit_3|40|3|TREATMENT|2021-01-31|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-24|P1Y2M10DT2H30M|BEFORE|2020-12-24|ONGOING|2020-12-29
e|RS|2a5a1c03-f54e-47da-8dda-2104c9423e94|7|BONERESP|Bone Response|PCWG SCHER PROSTATE CANCER 2016|[?]|nmol/kg/day|PSEUDORESPONSE|1|ugEq|IMMUNO-PET SCAN|Y|||FAMILY MEMBER|HEMATOLOGIST|N|4|Visit_4|65|1|TREATMENT|2021-02-25|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-24|P1Y2M10DT2H30M|BEFORE|2021-01-05|COINCIDENT|2021-02-25
e|RS|2a5a1c03-f54e-47da-8dda-2104c9423e94|8|OVRLRESP|Overall Response|RANO|[?]|cd/m2|PR|1|mmol2/L2|IMMUNOFIXATION ELECTROPHORESIS||||DOMESTIC PARTNER|INTERNIST|U|4|Visit_4|65|2|WASHOUT|2021-02-25|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-24|P1Y2M10DT2H30M|COINCIDENT|2021-01-23|BEFORE|2021-03-16
e|RS|2a5a1c03-f54e-47da-8dda-2104c9423e94|9|MRDRESP|Minimal Residual Disease Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|||MRD NEGATIVITY|1|OI50|SLOAN LETTER EYE CHART 2.5%|||Y|GUARDIAN|MICROSCOPIST 3|Y|5|Visit_5|90|3|FOLLOW-UP|2021-03-22|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-17|P1Y2M10DT2H30M|BEFORE|2021-01-15|BEFORE|2021-03-14
e|RS|2a5a1c03-f54e-47da-8dda-2104c9423e94|10|SFTSRESP|Soft Tissue Response|BURCOMBE BREAST CANCER 2005|[?]|foz_us|EQUIVOCAL|1|eq|SNELLEN EYE CHART||||FRIEND|CLINICAL PATHOLOGIST|N|5|Visit_5|90|6|SCREENING|2021-03-22|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-17|P1Y2M10DT2H30M|UNKNOWN|2021-03-13|ONGOING|2021-03-18
e|RS|8f98bac3-8010-4902-8ae1-783dc5fea72d|1|PATHRESP|Pathologic Response|IWG CHESON AML 2003|[?]|mmHg/sec|NON-CR/NON-PD|1|L/h/m2|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY||||SPOUSE|RATER|NA|1|Visit_1|10|7|FOLLOW-UP|2020-06-29|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-23|P1Y2M10DT2H30M|COINCIDENT|2020-09-22|COINCIDENT|2020-09-23
e|RS|8f98bac3-8010-4902-8ae1-783dc5fea72d|2|MOLRESP|Molecular Response|BLAZER COLORECTAL CANCER 2008|||PARTIAL MORPHOLOGIC RESPONSE|1|ft|GC/MS|Y||Y|INDEPENDENT ASSESSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|1|Visit_1|10|1|WASHOUT|2020-06-29|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-23|P1Y2M10DT2H30M|AFTER|2020-09-22|BEFORE|2020-09-24
e|RS|8f98bac3-8010-4902-8ae1-783dc5fea72d|3|MRPHRESP|Morphologic Response|CHESON CLL 2006|[?]|ug/kg/h|CYTOGENETIC MINOR RESPONSE|1|%(w/v)|SPECTROPHOTOMETRY||||STUDY SUBJECT|ONCOLOGIST 2|N|2|Visit_2|25|4|WASHOUT|2020-07-14|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-02|P1Y2M10DT2H30M|UNKNOWN|2020-06-29|ONGOING|2020-08-08
e|RS|8f98bac3-8010-4902-8ae1-783dc5fea72d|4|NEWLWIND|New Lesion Worsening Indicator|SCHER PROSTATE CANCER 2011|[?]|/4.0 mL|NON-QUANTIFIABLE MRD POSITIVITY|1|POUCH|PHYSICAL EXAMINATION||||PARENT|ADJUDICATOR 2|N|2|Visit_2|25|4|TREATMENT|2020-07-14|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-02|P1Y2M10DT2H30M|COINCIDENT|2020-08-16|AFTER|2020-08-23
e|RS|8f98bac3-8010-4902-8ae1-783dc5fea72d|5|CPRFSTAT|Clinical Performance Status|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|GLOBULE|NED|1|ug/L|FORCED OSCILLATION TECHNIQUE|Y|||CLINICAL STUDY SPONSOR|RADIOLOGIST 2|U|3|Visit_3|40|1|TREATMENT|2020-07-29|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-27|P1Y2M10DT2H30M|COINCIDENT|2020-08-08|BEFORE|2020-08-30
e|RS|8f98bac3-8010-4902-8ae1-783dc5fea72d|6|CYTORESP|Cytogenetic Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|||CA125 75% RESPONSE|1|MPS U|PERIPHERAL ANGIOGRAPHY|||Y|SIGNIFICANT OTHER|RATER 1|U|3|Visit_3|40|5|SCREENING|2020-07-29|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-27|P1Y2M10DT2H30M|AFTER|2020-08-07|ONGOING|2020-08-22
e|RS|8f98bac3-8010-4902-8ae1-783dc5fea72d|7|DRCRIND|Disease Recurrence Indicator|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|um2|CMR|1|10^12 IU/L|MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING||Y||GUARDIAN|NEUROLOGIST|U|4|Visit_4|65|4|SCREENING|2020-08-23|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-22|P1Y2M10DT2H30M|UNKNOWN|2020-08-31|BEFORE|2020-09-23
e|RS|8f98bac3-8010-4902-8ae1-783dc5fea72d|8|SFTSRESP|Soft Tissue Response|UNSPECIFIED|[?]|Hz/s|UNFAVORABLE RESPONSE|1|BOTTLE|OSCILLOMETRY||Y||SIBLING|FORENSIC PATHOLOGIST|N|4|Visit_4|65|6|TREATMENT|2020-08-23|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-22|P1Y2M10DT2H30M|AFTER|2020-08-29|BEFORE|2020-09-14
e|RS|8f98bac3-8010-4902-8ae1-783dc5fea72d|9|CLINRESP|Clinical Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|deg|iUPD|1|Bq|FLUORESCEIN STAIN||||SIBLING|MICROSCOPIST 1|NA|5|Visit_5|90|1|TREATMENT|2020-09-17|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-09|P1Y2M10DT2H30M|COINCIDENT|2020-07-21|BEFORE|2020-08-25
e|RS|8f98bac3-8010-4902-8ae1-783dc5fea72d|10|NTRGRESP|Non-target Response|PERCIST|[?]|TROCHE|PARTIAL MORPHOLOGIC RESPONSE|1|ug/m2/h|CALCULATION||Y||SPOUSE|READER 3|NA|5|Visit_5|90|6|TREATMENT|2020-09-17|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-09|P1Y2M10DT2H30M|COINCIDENT|2020-09-01|ONGOING|2020-09-06
e|RS|0fd7cece-4d9d-4d8c-82e0-df0c75613888|1|METBRESP|Metabolic Response|PCWG BUBLEY PROSTATE CANCER 1999|||FAVORABLE RESPONSE|1|U/m2|ELECTROGASTROGRAPHY|||Y|SPOUSE|PEDIATRIC NEUROLOGIST|Y|1|Visit_1|10|2|TREATMENT|2020-12-11|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-26|P1Y2M10DT2H30M|UNKNOWN|2021-01-02|ONGOING|2021-01-09
e|RS|0fd7cece-4d9d-4d8c-82e0-df0c75613888|2|TRGRESP|Target Response|MURPHY PROSTATE CANCER 1980|||PR|1|/2500 WBC|ELECTROCHEMILUMINESCENCE||Y|Y|PARENT|UROLOGIST|NA|1|Visit_1|10|2|SCREENING|2020-12-11|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-26|P1Y2M10DT2H30M|AFTER|2021-01-23|AFTER|2021-02-21
e|RS|0fd7cece-4d9d-4d8c-82e0-df0c75613888|3|NTLWIND|Non-Target Lesion Worsening Indicator|BLAZER COLORECTAL CANCER 2008|[?]|mV/sec|SD|1|copies/mL|JAFFE REACTION||Y||CLINICAL STUDY SPONSOR|ONCOLOGIST 2|U|2|Visit_2|25|5|SCREENING|2020-12-26|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-09|P1Y2M10DT2H30M|COINCIDENT|2021-02-28|ONGOING|2021-03-10
e|RS|0fd7cece-4d9d-4d8c-82e0-df0c75613888|4|TMRESP|Tumor Marker Response|IWG CHESON MDS 2000|[?]|10^4/hpf|CR|1|mmol/L|TEMPLATE INCISION METHOD||||NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|NA|2|Visit_2|25|3|WASHOUT|2020-12-26|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-09|P1Y2M10DT2H30M|COINCIDENT|2020-12-28|BEFORE|2021-02-06
e|RS|0fd7cece-4d9d-4d8c-82e0-df0c75613888|5|STRUSTAT|Steroid Use Status|PRINCE TCELL LYMPHOMA 2010|[?]|Osm|nPR|1|GBq/mg|MICROSCOPY||||PROXY|OPTOMETRIST|NA|3|Visit_3|40|1|TREATMENT|2021-01-10|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-04|P1Y2M10DT2H30M|BEFORE|2020-12-15|AFTER|2021-01-11
e|RS|0fd7cece-4d9d-4d8c-82e0-df0c75613888|6|SFTSRESP|Soft Tissue Response|EBMT BLADE MYELOMA 1998|[?]|uCi|MOLECULAR CR|1|g/cm2|BRDU CELLULAR PROLIFERATION ASSAY||||HEALTH CARE PROFESSIONAL|DERMATOLOGIST|NA|3|Visit_3|40|2|WASHOUT|2021-01-10|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-04|P1Y2M10DT2H30M|UNKNOWN|2021-02-28|COINCIDENT|2021-03-10
e|RS|0fd7cece-4d9d-4d8c-82e0-df0c75613888|7|SFTSRESP|Soft Tissue Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|g/cage|PD-CT|1|/10^4|IMMUNORADIOMETRIC ASSAY||Y||DOMESTIC PARTNER|PATHOLOGIST 2|NA|4|Visit_4|65|4|WASHOUT|2021-02-04|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-11|P1Y2M10DT2H30M|BEFORE|2020-12-19|ONGOING|2021-01-05
e|RS|0fd7cece-4d9d-4d8c-82e0-df0c75613888|8|LIVRRESP|Liver Response|HARTMAN PANCREATIC CANCER 2012|[?]|mEq/mL|PSEUDOPROGRESSION|1|10^5/hpf|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE|Y|Y||FAMILY MEMBER|INTERNIST|Y|4|Visit_4|65|1|WASHOUT|2021-02-04|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-11|P1Y2M10DT2H30M|BEFORE|2021-01-22|ONGOING|2021-02-03
e|RS|0fd7cece-4d9d-4d8c-82e0-df0c75613888|9|MNPTHIND|Minor Pathological Response Indicator|FAROOQUI SUPP CLL 2014|[?]|mL/animal/wk|TREATMENT FAILURE|1|ng/mol|HPLC||||CLINICAL STUDY SPONSOR|ONCOLOGIST 2|NA|5|Visit_5|90|1|SCREENING|2021-03-01|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-06|P1Y2M10DT2H30M|COINCIDENT|2021-02-26|ONGOING|2021-02-28
e|RS|0fd7cece-4d9d-4d8c-82e0-df0c75613888|10|BESTRESP|Best Overall Response|CHOLLET BREAST CANCER 2002|[?]|mL/breath|SD|1|kg/mol|CINEANGIOGRAPHY||||SIBLING|MICROSCOPIST 3|NA|5|Visit_5|90|7|TREATMENT|2021-03-01|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-06|P1Y2M10DT2H30M|UNKNOWN|2021-02-09|AFTER|2021-02-12
e|RS|1ade93f5-35f2-4bcc-9b9b-519c3f13baf9|1|SYMPTDTR|Symptomatic Deterioration|RECIST 1.1|[?]|CARTRIDGE|NR|1|/VF|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI||||VENDOR|DERMATOLOGIST|NA|1|Visit_1|10|1|TREATMENT|2020-06-13|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-07|P1Y2M10DT2H30M|UNKNOWN|2020-06-28|AFTER|2020-07-01
e|RS|1ade93f5-35f2-4bcc-9b9b-519c3f13baf9|2|NTNERESP|Non-Target Non-Enhancing Response|MURPHY PROSTATE CANCER 1980|||UNEQUIVOCAL|1|mL/min/1.73m2|FLUORESCENT IMMUNOASSAY|||Y|INTERVIEWER|RADIOLOGIST|N|1|Visit_1|10|4|FOLLOW-UP|2020-06-13|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-07|P1Y2M10DT2H30M|BEFORE|2020-08-07|AFTER|2020-08-14
e|RS|1ade93f5-35f2-4bcc-9b9b-519c3f13baf9|3|NEWLIND|New Lesion Indicator|SCHER PROSTATE CANCER 2011|[?]|MPL U/mL|TREATMENT FAILURE|1|cmH2O/mL|FARNSWORTH-MUNSELL 100 HUE TEST||Y||INVESTIGATOR|PATHOLOGIST 1|Y|2|Visit_2|25|3|TREATMENT|2020-06-28|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-27|P1Y2M10DT2H30M|UNKNOWN|2020-06-24|COINCIDENT|2020-07-28
e|RS|1ade93f5-35f2-4bcc-9b9b-519c3f13baf9|4|MJPTHIND|Major Pathological Response Indicator|LUGANO CLASSIFICATION|[?]|DRUM|MRD NEGATIVITY|1|RNA copies/mL|BALLPOINT PEN TECHNIQUE||||PARENT|READER|Y|2|Visit_2|25|2|TREATMENT|2020-06-28|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-27|P1Y2M10DT2H30M|AFTER|2020-06-21|COINCIDENT|2020-07-19
e|RS|1ade93f5-35f2-4bcc-9b9b-519c3f13baf9|5|NTLWIND|Non-Target Lesion Worsening Indicator|SACT|||WORSENED|1|cg|OPHTHALMOSCOPY||Y|Y|CAREGIVER|DEVELOPMENTAL PSYCHOLOGIST|NA|3|Visit_3|40|4|TREATMENT|2020-07-13|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-12|P1Y2M10DT2H30M|UNKNOWN|2020-07-20|ONGOING|2020-08-14
e|RS|1ade93f5-35f2-4bcc-9b9b-519c3f13baf9|6|NTRGRESP|Non-target Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|USP U|RELAPSED DISEASE FROM CR OR PR|1|copies/uL|PHOTOMETRY||||SPOUSE|RATER 1|Y|3|Visit_3|40|1|TREATMENT|2020-07-13|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-12|P1Y2M10DT2H30M|AFTER|2020-06-06|ONGOING|2020-07-10
e|RS|1ade93f5-35f2-4bcc-9b9b-519c3f13baf9|7|HEMARESP|Hematologic Response|MACDONALD GLIOMA 1990|[?]|umol/L|pCR|1|L/h|KARYOTYPING|Y|||INVESTIGATOR|READER 3|NA|4|Visit_4|65|3|SCREENING|2020-08-07|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-10|P1Y2M10DT2H30M|UNKNOWN|2020-07-27|AFTER|2020-08-19
e|RS|1ade93f5-35f2-4bcc-9b9b-519c3f13baf9|8|NTRGRESP|Non-target Response|PCWG SCHER PROSTATE CANCER 2016|[?]|APS U|CMR|1|mL/sec/1.73m2|NUCLEIC ACID AMPLIFICATION TEST||Y||DOMESTIC PARTNER|READER|U|4|Visit_4|65|1|TREATMENT|2020-08-07|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-10|P1Y2M10DT2H30M|COINCIDENT|2020-08-16|BEFORE|2020-08-18
e|RS|1ade93f5-35f2-4bcc-9b9b-519c3f13baf9|9|OVRLRESP|Overall Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|10^8/L|MR|1|10^3 CFU|EPSILOMETER||||SIBLING|MICROSCOPIST 1|U|5|Visit_5|90|6|TREATMENT|2020-09-01|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-30|P1Y2M10DT2H30M|AFTER|2020-08-25|COINCIDENT|2020-09-07
e|RS|1ade93f5-35f2-4bcc-9b9b-519c3f13baf9|10|BMIVLIND|Bone Marrow Involvement Indicator|SCHER PROSTATE CANCER 2011|[?]|10^9/dose|NOT ALL EVALUATED|1|PFU/mL|RAJI CELL EIA||Y||INDEPENDENT ASSESSOR|MICROSCOPIST 2|NA|5|Visit_5|90|5|TREATMENT|2020-09-01|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-30|P1Y2M10DT2H30M|BEFORE|2020-07-16|ONGOING|2020-08-07
e|RS|4be1ea69-9baf-45b4-873b-13a879544d9c|1|RDIORESP|Radiologic Response|HAMAOKA BREAST CANCER 2010|[?]|mol/mL|SD|1|umol|MRS||||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|U|1|Visit_1|10|3|TREATMENT|2021-01-26|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-09|P1Y2M10DT2H30M|AFTER|2021-04-09|AFTER|2021-04-17
e|RS|4be1ea69-9baf-45b4-873b-13a879544d9c|2|ANATRESP|Anatomic Response|MURPHY PROSTATE CANCER 1980|||HI-N|1|BEAM BREAKS|PHASE CONTRAST MICROSCOPY|||Y|INDEPENDENT ASSESSOR|RATER|N|1|Visit_1|10|5|SCREENING|2021-01-26|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-09|P1Y2M10DT2H30M|BEFORE|2021-03-16|ONGOING|2021-03-19
e|RS|4be1ea69-9baf-45b4-873b-13a879544d9c|3|MOLRESP|Molecular Response|MACDONALD GLIOMA 1990|[?]|psi|MORPHOLOGIC CRi|1|uL|MYELOPEROXIDASE STAIN||Y||CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST|Y|2|Visit_2|25|6|SCREENING|2021-02-10|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-11|P1Y2M10DT2H30M|AFTER|2021-02-08|ONGOING|2021-02-19
e|RS|4be1ea69-9baf-45b4-873b-13a879544d9c|4|BMIVLIND|Bone Marrow Involvement Indicator|CHOI GIST 2008|[?]|um/day|CA125 50% RESPONSE|1|mm/h|CELLULAR PROLIFERATION ASSAY||||NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST|Y|2|Visit_2|25|4|SCREENING|2021-02-10|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-11|P1Y2M10DT2H30M|AFTER|2021-02-28|BEFORE|2021-03-25
e|RS|4be1ea69-9baf-45b4-873b-13a879544d9c|5|MRPHRESP|Morphologic Response|EBMT BLADE MYELOMA 1998|||PMR|1|mg/kg/day|CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|Y|Y|Y|CHILD|RATER 1|N|3|Visit_3|40|3|FOLLOW-UP|2021-02-25|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-17|P1Y2M10DT2H30M|AFTER|2021-03-02|ONGOING|2021-03-15
e|RS|4be1ea69-9baf-45b4-873b-13a879544d9c|6|SYMPTDTR|Symptomatic Deterioration|BURCOMBE BREAST CANCER 2005|[?]|ELISA unit|mCR|1|nmol/mol|KLEIHAUER-BETKE||Y||CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 2|NA|3|Visit_3|40|3|SCREENING|2021-02-25|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-17|P1Y2M10DT2H30M|COINCIDENT|2021-01-30|BEFORE|2021-03-15
e|RS|4be1ea69-9baf-45b4-873b-13a879544d9c|7|RDIORESP|Radiologic Response|IWG CHESON MDS 2006|[?]|mL/animal|iPR|1|mg/m2/h|FLUORESCEIN STAIN||||INVESTIGATOR|RATER 1|U|4|Visit_4|65|3|SCREENING|2021-03-22|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-13|P1Y2M10DT2H30M|UNKNOWN|2021-03-14|COINCIDENT|2021-04-09
e|RS|4be1ea69-9baf-45b4-873b-13a879544d9c|8|TMRESP|Tumor Marker Response|IRANO 2015|[?]|nmol/L/h|SD-CT|1|g/U|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY||||SIBLING|RATER|U|4|Visit_4|65|5|TREATMENT|2021-03-22|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-13|P1Y2M10DT2H30M|BEFORE|2021-03-29|BEFORE|2021-04-21
e|RS|4be1ea69-9baf-45b4-873b-13a879544d9c|9|HEMARESP|Hematologic Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|||CR|1|pmol/g|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION||Y|Y|PROXY|DEVELOPMENTAL PSYCHOLOGIST|Y|5|Visit_5|90|5|TREATMENT|2021-04-16|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-04|P1Y2M10DT2H30M|AFTER|2021-02-12|COINCIDENT|2021-03-21
e|RS|4be1ea69-9baf-45b4-873b-13a879544d9c|10|BESTRESP|Best Overall Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|mL/dose|EQUIVOCAL|1|dyn|INDIRECT IMMUNOFLUORESCENCE||||SIGNIFICANT OTHER|RATER 2|NA|5|Visit_5|90|4|FOLLOW-UP|2021-04-16|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-04|P1Y2M10DT2H30M|COINCIDENT|2021-04-06|COINCIDENT|2021-04-24
e|RS|7480ca7e-bffc-455b-a08e-c732ac6c8b4e|1|ANATRESP|Anatomic Response|IWC HALLEK CLL 2008|||iCR|1|mm/min|MRI|Y||Y|ADJUDICATOR|RATER|N|1|Visit_1|10|1|TREATMENT|2020-10-29|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-22|P1Y2M10DT2H30M|UNKNOWN|2020-11-04|AFTER|2021-01-13
e|RS|7480ca7e-bffc-455b-a08e-c732ac6c8b4e|2|CPRFSTAT|Clinical Performance Status|GUPPY OVARIAN CANCER 2002|[?]|mol/mL|pCR|1|pg|SPIRAL CT SCAN WITHOUT CONTRAST|Y|||STUDY SUBJECT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|1|Visit_1|10|1|TREATMENT|2020-10-29|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-22|P1Y2M10DT2H30M|UNKNOWN|2021-01-07|BEFORE|2021-01-14
e|RS|7480ca7e-bffc-455b-a08e-c732ac6c8b4e|3|BMIVLIND|Bone Marrow Involvement Indicator|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|BISCUIT|QUANTIFIABLE MRD POSITIVITY|1|PIXELS/in|SMEAR|Y|||SIBLING|NEUROLOGIST|Y|2|Visit_2|25|5|SCREENING|2020-11-13|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-25|P1Y2M10DT2H30M|BEFORE|2020-11-15|AFTER|2021-01-14
e|RS|7480ca7e-bffc-455b-a08e-c732ac6c8b4e|4|CPRFSTAT|Clinical Performance Status|MONTSERRAT CLL 1989|||cPR|1|10^7 TCID 50/dose|DYNAMIC LIGHT SCATTERING|||Y|INDEPENDENT ASSESSOR|READER 2|U|2|Visit_2|25|3|WASHOUT|2020-11-13|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-25|P1Y2M10DT2H30M|AFTER|2020-11-20|BEFORE|2021-01-11
e|RS|7480ca7e-bffc-455b-a08e-c732ac6c8b4e|5|NEWLIND|New Lesion Indicator|MURPHY PROSTATE CANCER 1980|[?]|tsp eq|OPTIMAL MORPHOLOGIC RESPONSE|1|mN|PUPILLOMETRY|Y|||CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 1|U|3|Visit_3|40|6|TREATMENT|2020-11-28|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-03|P1Y2M10DT2H30M|UNKNOWN|2021-01-22|BEFORE|2021-01-25
e|RS|7480ca7e-bffc-455b-a08e-c732ac6c8b4e|6|NEWLPROG|New Lesion Progression|UNSPECIFIED|[?]|mg/mL/day|CYTOGENETIC MINOR RESPONSE|1|vg/kg|SPIROMETRY||||PARENT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|3|Visit_3|40|4|TREATMENT|2020-11-28|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-03|P1Y2M10DT2H30M|AFTER|2020-11-18|BEFORE|2020-12-15
e|RS|7480ca7e-bffc-455b-a08e-c732ac6c8b4e|7|DRCRIND|Disease Recurrence Indicator|MRECIST BYRNE MESOTHELIOMA 2004|||SD-CT|1|kDa|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|||Y|INVESTIGATOR|PATHOLOGIST 2|Y|4|Visit_4|65|4|WASHOUT|2020-12-23|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-21|P1Y2M10DT2H30M|COINCIDENT|2021-01-14|ONGOING|2021-01-23
e|RS|7480ca7e-bffc-455b-a08e-c732ac6c8b4e|8|BONERESP|Bone Response|DURIE MULTIPLE MYELOMA 2006|[?]|cmol|HI-P|1|mEq/day|ENZYMATIC ULTRACENTRIFUGATION||||CHILD|RATER 1|N|4|Visit_4|65|3|TREATMENT|2020-12-23|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-21|P1Y2M10DT2H30M|AFTER|2020-10-21|ONGOING|2020-11-04
e|RS|7480ca7e-bffc-455b-a08e-c732ac6c8b4e|9|NEWLPROG|New Lesion Progression|RANO ELLINGSON 2017|[?]|pg|DECREASED|1|copies/uL|SPIROMETRY|Y|||CAREGIVER|RATER 1|Y|5|Visit_5|90|2|FOLLOW-UP|2021-01-17|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-28|P1Y2M10DT2H30M|COINCIDENT|2020-12-01|AFTER|2021-01-25
e|RS|7480ca7e-bffc-455b-a08e-c732ac6c8b4e|10|CPRFSTAT|Clinical Performance Status|SACT|[?]|cm/min|QUANTIFIABLE MRD POSITIVITY|1|kg/cm|MAPH|Y|||VENDOR|NEUROLOGIST 1|U|5|Visit_5|90|4|TREATMENT|2021-01-17|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-28|P1Y2M10DT2H30M|BEFORE|2020-10-22|ONGOING|2020-11-05
e|RS|16720f71-55b5-478f-b041-00b61ae19ac9|1|PATHRESP|Pathologic Response|HAMAOKA BREAST CANCER 2010|[?]|10^5/hpf|CYTOGENETIC PR|1|min|IMMUNORADIOMETRIC ASSAY||||CLINICAL RESEARCH COORDINATOR|READER 1|Y|1|Visit_1|10|4|FOLLOW-UP|2021-01-10|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-14|P1Y2M10DT2H30M|BEFORE|2021-02-21|BEFORE|2021-02-23
e|RS|16720f71-55b5-478f-b041-00b61ae19ac9|2|NTRGRESP|Non-target Response|CHOI GIST 2008|||CYTOGENETIC CR|1|10^9 CFU|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY|Y||Y|SIBLING|ADJUDICATOR 2|NA|1|Visit_1|10|4|WASHOUT|2021-01-10|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-14|P1Y2M10DT2H30M|COINCIDENT|2021-02-02|BEFORE|2021-02-22
e|RS|16720f71-55b5-478f-b041-00b61ae19ac9|3|BESTRESP|Best Overall Response|IWG CHESON MDS 2000|[?]|vp/dose|MRD PERSISTENCE|1|mAnson U/mL|MICRONEUTRALIZATION ASSAY|Y|Y||SIGNIFICANT OTHER|RADIOLOGIST 1|N|2|Visit_2|25|6|TREATMENT|2021-01-25|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-06|P1Y2M10DT2H30M|UNKNOWN|2021-04-06|ONGOING|2021-04-08
e|RS|16720f71-55b5-478f-b041-00b61ae19ac9|4|LIVRRESP|Liver Response|MURPHY PROSTATE CANCER 1980|||PR|1|Henry|CONTRAST ENHANCED SPIRAL CT SCAN|||Y|VENDOR|READER 3|Y|2|Visit_2|25|2|WASHOUT|2021-01-25|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-06|P1Y2M10DT2H30M|UNKNOWN|2021-02-03|COINCIDENT|2021-03-18
e|RS|16720f71-55b5-478f-b041-00b61ae19ac9|5|MRDRESP|Minimal Residual Disease Response|DOHNER AML 2010|[?]|log EID 50/dose|PMD|1|deg/mm|HEMOCYTOMETRY||Y||CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 2|N|3|Visit_3|40|1|FOLLOW-UP|2021-02-09|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-14|P1Y2M10DT2H30M|AFTER|2021-02-09|BEFORE|2021-02-27
e|RS|16720f71-55b5-478f-b041-00b61ae19ac9|6|MNPTHIND|Minor Pathological Response Indicator|MURPHY PROSTATE CANCER 1980|[?]|GBq/ug|ABSENT MORPHOLOGIC RESPONSE|1|10^9 CFU|QUANTITATIVE COMPUTED TOMOGRAPHY||Y||CAREGIVER|READER 2|N|3|Visit_3|40|4|TREATMENT|2021-02-09|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-14|P1Y2M10DT2H30M|AFTER|2021-03-31|ONGOING|2021-04-01
e|RS|16720f71-55b5-478f-b041-00b61ae19ac9|7|OVRLRESP|Overall Response|RANO|[?]|mAnson U/mL|cCR|1|GBq/ug|LANDOLT RING||||FRIEND|CLINICAL PATHOLOGIST|NA|4|Visit_4|65|4|SCREENING|2021-03-06|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-25|P1Y2M10DT2H30M|UNKNOWN|2021-01-18|BEFORE|2021-02-28
e|RS|16720f71-55b5-478f-b041-00b61ae19ac9|8|METSIND|Metastatic Indicator|BRUGGEMANN MRD 2010|||CYTOGENETIC MINIMAL RESPONSE|1|BP|PULSE OXIMETRY|||Y|CLINICAL RESEARCH ASSOCIATE|HEMATOLOGIST|N|4|Visit_4|65|4|TREATMENT|2021-03-06|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-25|P1Y2M10DT2H30M|UNKNOWN|2021-01-21|COINCIDENT|2021-02-07
e|RS|16720f71-55b5-478f-b041-00b61ae19ac9|9|ANATRESP|Anatomic Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|g|MOLECULAR CR|1|Rad|URANYL ACETATE STAIN||Y||ADJUDICATOR|READER 3|N|5|Visit_5|90|6|FOLLOW-UP|2021-03-31|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-09|P1Y2M10DT2H30M|COINCIDENT|2021-03-29|BEFORE|2021-03-31
e|RS|16720f71-55b5-478f-b041-00b61ae19ac9|10|ANATRESP|Anatomic Response|AJCC V8|[?]|dpm/mg|MRD RELAPSE|1|mg/m2/day|IMMUNOCHROMATOGRAPHY||||GUARDIAN|MICROSCOPIST|N|5|Visit_5|90|6|SCREENING|2021-03-31|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-09|P1Y2M10DT2H30M|COINCIDENT|2021-04-05|BEFORE|2021-04-06
e|RS|4349f45e-f18b-4606-9a72-fd45e64e17dc|1|CPRFSTAT|Clinical Performance Status|IWG CHESON MDS 2000|[?]|1/(s*kPa)|NON-PD|1|ug/kg/day|CLOT DETECTION|Y|Y||INDEPENDENT ASSESSOR|OPHTHALMOLOGIST|NA|1|Visit_1|10|1|WASHOUT|2021-01-11|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-23|P1Y2M10DT2H30M|AFTER|2021-02-01|COINCIDENT|2021-02-07
e|RS|4349f45e-f18b-4606-9a72-fd45e64e17dc|2|NTERESP|Non-Target Enhancing Response|PETIT BREAST CANCER 2001|[?]|mL/h|iCPD|1|mg/mol|ARTERIAL SPIN LABELING FUNCTIONAL MRI||Y||SIGNIFICANT OTHER|PATHOLOGIST 1|U|1|Visit_1|10|6|WASHOUT|2021-01-11|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-23|P1Y2M10DT2H30M|UNKNOWN|2021-03-20|AFTER|2021-03-24
e|RS|4349f45e-f18b-4606-9a72-fd45e64e17dc|3|HEMARESP|Hematologic Response|CHESON LYMPHOMA 2008|[?]|mL/g/min|PR WITH LYMPHOCYTOSIS|1|10^9 organisms/g|TONOMETRY||Y||FAMILY MEMBER|ONCOLOGIST|NA|2|Visit_2|25|2|WASHOUT|2021-01-26|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-03|P1Y2M10DT2H30M|BEFORE|2021-01-28|ONGOING|2021-02-24
e|RS|4349f45e-f18b-4606-9a72-fd45e64e17dc|4|RDIORESP|Radiologic Response|CHESON CLL 2006|||NR|1|mEq/mmol|NEXT GENERATION TARGETED SEQUENCING|Y||Y|HEALTH CARE PROFESSIONAL|READER 1|N|2|Visit_2|25|6|SCREENING|2021-01-26|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-03|P1Y2M10DT2H30M|COINCIDENT|2021-03-27|COINCIDENT|2021-04-08
e|RS|4349f45e-f18b-4606-9a72-fd45e64e17dc|5|ANATRESP|Anatomic Response|DOHNER AML 2010|[?]|Frames/s|MINOR PATHOLOGIC RESPONSE|1|mmol/kg|CLAUSS METHOD||Y||PARENT|RADIOLOGIST|NA|3|Visit_3|40|1|TREATMENT|2021-02-10|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-24|P1Y2M10DT2H30M|BEFORE|2021-02-17|COINCIDENT|2021-02-27
e|RS|4349f45e-f18b-4606-9a72-fd45e64e17dc|6|SYMPTDTR|Symptomatic Deterioration|BRUGGEMANN MRD 2010|[?]|10^6 copies/mL|UNEQUIVOCAL|1|Hz/s|MRI WITHOUT CONTRAST||||INDEPENDENT ASSESSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|3|Visit_3|40|4|TREATMENT|2021-02-10|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-24|P1Y2M10DT2H30M|COINCIDENT|2021-03-27|AFTER|2021-04-05
e|RS|4349f45e-f18b-4606-9a72-fd45e64e17dc|7|BONERESP|Bone Response|HAMAOKA BREAST CANCER 2010|[?]|hPa|PR|1|Log10 ELISA unit/dose|FLOW MICROSCOPY||||SIBLING|OPHTHALMOLOGIST|Y|4|Visit_4|65|1|FOLLOW-UP|2021-03-07|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-03|P1Y2M10DT2H30M|COINCIDENT|2021-03-27|BEFORE|2021-03-29
e|RS|4349f45e-f18b-4606-9a72-fd45e64e17dc|8|DRCRIND|Disease Recurrence Indicator|DURIE MULTIPLE MYELOMA 2006|[?]|10^7 TCID 50/dose|NR|1|g/g|MICROBIAL CONCENTRATION||||CAREGIVER|INTERNIST|U|4|Visit_4|65|2|TREATMENT|2021-03-07|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-03|P1Y2M10DT2H30M|BEFORE|2021-03-28|ONGOING|2021-04-04
e|RS|4349f45e-f18b-4606-9a72-fd45e64e17dc|9|NTNERESP|Non-Target Non-Enhancing Response|NCIWG CHESON CLL 1996|[?]|mEq/kg|IMMUNOPHENOTYPIC CR|1|fL|TRYPAN BLUE STAIN|Y|Y||CAREGIVER|MICROSCOPIST|NA|5|Visit_5|90|4|WASHOUT|2021-04-01|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-12|P1Y2M10DT2H30M|BEFORE|2021-03-10|BEFORE|2021-03-11
e|RS|4349f45e-f18b-4606-9a72-fd45e64e17dc|10|ANATRESP|Anatomic Response|IWC HALLEK CLL 2008|[?]|10^9/dose|CRi|1|ug/m2/day|RADIATION DOSIMETRY|Y|||SIGNIFICANT OTHER|HEMATOLOGIST|U|5|Visit_5|90|4|WASHOUT|2021-04-01|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-12|P1Y2M10DT2H30M|COINCIDENT|2021-04-01|AFTER|2021-04-10
e|RS|32e36ec1-6895-42ff-bf33-52977e72b338|1|NTLWIND|Non-Target Lesion Worsening Indicator|RECIST 1.0|[?]|Bq/ug|CHR|1|cg|OPTICAL DENSITY MEASUREMENT||||STUDY SUBJECT|MICROSCOPIST|NA|1|Visit_1|10|6|TREATMENT|2020-09-05|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-02|P1Y2M10DT2H30M|BEFORE|2020-09-14|COINCIDENT|2020-11-11
e|RS|32e36ec1-6895-42ff-bf33-52977e72b338|2|NTERESP|Non-Target Enhancing Response|BLAZER COLORECTAL CANCER 2008|||iPR|1|uV*sec|MYELOPEROXIDASE STAIN|||Y|FAMILY MEMBER|NEUROLOGIST 1|NA|1|Visit_1|10|4|TREATMENT|2020-09-05|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-02|P1Y2M10DT2H30M|UNKNOWN|2020-11-11|BEFORE|2020-12-01
e|RS|32e36ec1-6895-42ff-bf33-52977e72b338|3|SFTSRESP|Soft Tissue Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|||PD/RELAPSE AFTER HI|1|umol/min|ORCHIDOMETERY|||Y|PARENT|OPTOMETRIST|N|2|Visit_2|25|2|FOLLOW-UP|2020-09-20|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-31|P1Y2M10DT2H30M|BEFORE|2020-12-02|ONGOING|2020-12-03
e|RS|32e36ec1-6895-42ff-bf33-52977e72b338|4|SYMPTDTR|Symptomatic Deterioration|IWG CHESON MDS 2000|[?]|mg/min|STABLE|1|atm|OSCILLOMETRY||||SIBLING|NEUROLOGIST 1|U|2|Visit_2|25|7|TREATMENT|2020-09-20|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-31|P1Y2M10DT2H30M|COINCIDENT|2020-11-05|ONGOING|2020-11-16
e|RS|32e36ec1-6895-42ff-bf33-52977e72b338|5|NTLWIND|Non-Target Lesion Worsening Indicator|RECIST 1.1|||NED|1|SPRAY|TRIPLE-PHASE MRI SCAN||Y|Y|SPOUSE|ADJUDICATOR 1|U|3|Visit_3|40|4|SCREENING|2020-10-05|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-18|P1Y2M10DT2H30M|BEFORE|2020-10-30|COINCIDENT|2020-11-07
e|RS|32e36ec1-6895-42ff-bf33-52977e72b338|6|SFTSRESP|Soft Tissue Response|SACT|[?]|/day|PMD|1|breaths/min|TEMPLATE INCISION METHOD||||INDEPENDENT ASSESSOR|MICROSCOPIST 3|Y|3|Visit_3|40|2|TREATMENT|2020-10-05|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-18|P1Y2M10DT2H30M|AFTER|2020-09-12|AFTER|2020-11-03
e|RS|32e36ec1-6895-42ff-bf33-52977e72b338|7|SPLNRESP|Spleen Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|10^6/hpf|MOLECULAR MAJOR RESPONSE|1|mg/m2/h|DISK DIFFUSION||||FAMILY MEMBER|NEUROLOGIST 2|Y|4|Visit_4|65|6|TREATMENT|2020-10-30|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-13|P1Y2M10DT2H30M|BEFORE|2020-10-21|AFTER|2020-11-16
e|RS|32e36ec1-6895-42ff-bf33-52977e72b338|8|CPRFSTAT|Clinical Performance Status|WHO BREAST CANCER 2006|[?]|umol/mg/min|CR-CT|1|ppth|FUNDUS PHOTOGRAPHY||||PROXY|READER|NA|4|Visit_4|65|2|TREATMENT|2020-10-30|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-13|P1Y2M10DT2H30M|COINCIDENT|2020-09-02|BEFORE|2020-11-22
e|RS|32e36ec1-6895-42ff-bf33-52977e72b338|9|METSIND|Metastatic Indicator|IWG CHESON MDS 2006|[?]|pmol/10^10 cells|cCR|1|mg/g/h|CHROMATOGRAPHY|Y|||GUARDIAN|ADJUDICATOR|U|5|Visit_5|90|4|FOLLOW-UP|2020-11-24|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-30|P1Y2M10DT2H30M|BEFORE|2020-10-05|BEFORE|2020-11-23
e|RS|32e36ec1-6895-42ff-bf33-52977e72b338|10|NEWLWIND|New Lesion Worsening Indicator|BRUGGEMANN MRD 2010|[?]|dyn|SMD|1|msec|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION||Y||SPOUSE|CARDIOLOGIST|Y|5|Visit_5|90|4|FOLLOW-UP|2020-11-24|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-30|P1Y2M10DT2H30M|AFTER|2020-10-11|BEFORE|2020-11-18
e|RS|e546f2d8-baea-4a6e-93cb-c7ec7292b423|1|SYMPTDTR|Symptomatic Deterioration|EASL BRUIX LIVER CANCER 2001|||PARTIAL MORPHOLOGIC RESPONSE|1|mg/min|SXA SCAN|Y|Y|Y|CLINICAL STUDY SPONSOR|ADJUDICATOR 3|N|1|Visit_1|10|2|WASHOUT|2020-10-25|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-25|P1Y2M10DT2H30M|AFTER|2020-10-26|AFTER|2020-12-11
e|RS|e546f2d8-baea-4a6e-93cb-c7ec7292b423|2|SFTSRESP|Soft Tissue Response|HARTMAN PANCREATIC CANCER 2012|[?]|mmHg|MRD RELAPSE|1|log10 CFU/mL|MICROBIAL CULTURE||||CHILD|PATHOLOGIST|U|1|Visit_1|10|4|TREATMENT|2020-10-25|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-25|P1Y2M10DT2H30M|UNKNOWN|2021-01-16|ONGOING|2021-01-17
e|RS|e546f2d8-baea-4a6e-93cb-c7ec7292b423|3|MJPTHIND|Major Pathological Response Indicator|CHESON CLL 2012|[?]|Log10 ELISA unit|CA125 50% RESPONSE|1|kBq|RULER MEASUREMENT METHOD||Y||SPOUSE|CARDIOLOGIST|U|2|Visit_2|25|4|TREATMENT|2020-11-09|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-16|P1Y2M10DT2H30M|UNKNOWN|2021-01-15|BEFORE|2021-01-20
e|RS|e546f2d8-baea-4a6e-93cb-c7ec7292b423|4|SYMPTDTR|Symptomatic Deterioration|DURIE MULTIPLE MYELOMA 2006|[?]|U/10^12 RBC|MOLECULAR MAJOR RESPONSE|1|tuberculin unit/mL|PERFUSION MRI||Y||CLINICAL STUDY SPONSOR|CARDIOLOGIST|N|2|Visit_2|25|6|TREATMENT|2020-11-09|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-16|P1Y2M10DT2H30M|UNKNOWN|2020-12-11|COINCIDENT|2021-01-06
e|RS|e546f2d8-baea-4a6e-93cb-c7ec7292b423|5|MRPHRESP|Morphologic Response|SCHER PROSTATE CANCER 2011|||NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|Gy/min|ERGOSPIROMETRY|Y||Y|DOMESTIC PARTNER|NEUROLOGIST 1|N|3|Visit_3|40|5|TREATMENT|2020-11-24|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-20|P1Y2M10DT2H30M|BEFORE|2020-11-08|BEFORE|2020-11-17
e|RS|e546f2d8-baea-4a6e-93cb-c7ec7292b423|6|METBRESP|Metabolic Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|POUCH|PDu|1|10^5/L|GEL ELECTROPHORESIS||||DOMESTIC PARTNER|ADJUDICATOR|NA|3|Visit_3|40|5|FOLLOW-UP|2020-11-24|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-20|P1Y2M10DT2H30M|AFTER|2020-11-29|COINCIDENT|2020-12-25
e|RS|e546f2d8-baea-4a6e-93cb-c7ec7292b423|7|OVRLRESP|Overall Response|LUGANO CLASSIFICATION|[?]|10^6 organisms/mL|VGPR|1|cs|LC/MS/MS||||ADJUDICATOR|INTERNIST|N|4|Visit_4|65|3|TREATMENT|2020-12-19|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-04|P1Y2M10DT2H30M|BEFORE|2020-10-30|AFTER|2020-12-31
e|RS|e546f2d8-baea-4a6e-93cb-c7ec7292b423|8|NTERESP|Non-Target Enhancing Response|HAMAOKA BREAST CANCER 2010|[?]|U/g/min|PSEUDOPROGRESSION|1|Newton|APPLANATION TONOMETRY||Y||STUDY SUBJECT|RATER 2|NA|4|Visit_4|65|5|TREATMENT|2020-12-19|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-04|P1Y2M10DT2H30M|BEFORE|2020-11-13|ONGOING|2021-01-22
e|RS|e546f2d8-baea-4a6e-93cb-c7ec7292b423|9|SFTSRESP|Soft Tissue Response|MONTSERRAT CLL 1989|||MORPHOLOGIC LEUKEMIA-FREE STATE|1|PATCH|CINEANGIOGRAPHY|||Y|GUARDIAN|OPTOMETRIST|N|5|Visit_5|90|5|TREATMENT|2021-01-13|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-25|P1Y2M10DT2H30M|AFTER|2020-12-09|AFTER|2021-01-18
e|RS|e546f2d8-baea-4a6e-93cb-c7ec7292b423|10|MRPHRESP|Morphologic Response|LEE LUNG CANCER 2011|[?]|10^9 CFU/mL|INDETERMINATE RESPONSE|1|ug/dose|PLETHYSMOGRAPHY||Y||CLINICAL RESEARCH ASSOCIATE|CARDIOLOGIST|NA|5|Visit_5|90|2|WASHOUT|2021-01-13|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-25|P1Y2M10DT2H30M|BEFORE|2020-11-23|COINCIDENT|2020-12-17
e|RS|0329de16-fc7a-4941-900c-b390dac637aa|1|MRPHRESP|Morphologic Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|nmol BCE/mmol|PMD|1|mg/mL/day|FREEZING POINT DEPRESSION||||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST|Y|1|Visit_1|10|5|TREATMENT|2020-09-27|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-11|P1Y2M10DT2H30M|UNKNOWN|2020-10-09|AFTER|2020-12-21
e|RS|0329de16-fc7a-4941-900c-b390dac637aa|2|BESTRESP|Best Overall Response|LEE LUNG CANCER 2011|[?]|s^-1(%O2)^-1|CMR|1|ppb|OLIGO ACGH||||VENDOR|MICROSCOPIST|NA|1|Visit_1|10|1|TREATMENT|2020-09-27|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-11|P1Y2M10DT2H30M|COINCIDENT|2020-10-18|AFTER|2020-10-22
e|RS|0329de16-fc7a-4941-900c-b390dac637aa|3|NTERESP|Non-Target Enhancing Response|RECICL|[?]|ag|UNEQUIVOCAL|1|anti-Xa IU|IMPEDANCE CONDUCTIVITY||||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR|Y|2|Visit_2|25|7|TREATMENT|2020-10-12|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-27|P1Y2M10DT2H30M|COINCIDENT|2020-11-23|BEFORE|2020-12-21
e|RS|0329de16-fc7a-4941-900c-b390dac637aa|4|ANATRESP|Anatomic Response|JACINTO CERVICAL CANCER 2007|||DECREASED|1|U.CARR|SPECTROPHOTOMETRY|||Y|INVESTIGATOR|MICROSCOPIST 1|NA|2|Visit_2|25|6|SCREENING|2020-10-12|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-27|P1Y2M10DT2H30M|COINCIDENT|2020-10-31|COINCIDENT|2020-12-16
e|RS|0329de16-fc7a-4941-900c-b390dac637aa|5|BMIVLIND|Bone Marrow Involvement Indicator|FAROOQUI SUPP CLL 2014|[?]|NEEDLE GAUGE|UNEQUIVOCAL|1|pmol/L|DUKE INCISION METHOD|Y|||HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|NA|3|Visit_3|40|6|SCREENING|2020-10-27|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-04|P1Y2M10DT2H30M|AFTER|2020-11-21|COINCIDENT|2020-12-20
e|RS|0329de16-fc7a-4941-900c-b390dac637aa|6|METBRESP|Metabolic Response|LUGANO CLASSIFICATION|[?]|cpm|HI-E|1|/5x10^4 WBC|SPECTROPHOTOMETRY||||PARENT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|3|Visit_3|40|2|WASHOUT|2020-10-27|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-04|P1Y2M10DT2H30M|AFTER|2020-11-15|AFTER|2020-12-24
e|RS|0329de16-fc7a-4941-900c-b390dac637aa|7|SYMPTDTR|Symptomatic Deterioration|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|10^6 CFU/mL|VGPR|1|uL/kg/day|MAMMOGRAPHY|Y|||CAREGIVER|RATER 1|U|4|Visit_4|65|1|WASHOUT|2020-11-21|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-22|P1Y2M10DT2H30M|UNKNOWN|2020-11-14|ONGOING|2020-12-09
e|RS|0329de16-fc7a-4941-900c-b390dac637aa|8|CYTORESP|Cytogenetic Response|IWC HALLEK CLL 2008|[?]|pg/L|PD FROM PR|1|IU/dL|SPECT SCAN||||CLINICAL STUDY SPONSOR|RADIOLOGIST 1|Y|4|Visit_4|65|3|TREATMENT|2020-11-21|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-22|P1Y2M10DT2H30M|COINCIDENT|2020-12-24|COINCIDENT|2020-12-25
e|RS|0329de16-fc7a-4941-900c-b390dac637aa|9|HEMARESP|Hematologic Response|RECIST 1.1|[?]|mAnson U/mL|PD/RELAPSE AFTER HI|1|10^10/L|PHOTOMETRY||||SPOUSE|PATHOLOGIST 1|N|5|Visit_5|90|4|TREATMENT|2020-12-16|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-21|P1Y2M10DT2H30M|UNKNOWN|2020-10-01|AFTER|2020-12-21
e|RS|0329de16-fc7a-4941-900c-b390dac637aa|10|NTRGRESP|Non-target Response|LUGANO CLASSIFICATION|[?]|SBE/mL|CA125 75% RESPONSE|1|RFU|DYNAMOMETRY||||DOMESTIC PARTNER|RADIOLOGIST 1|Y|5|Visit_5|90|3|TREATMENT|2020-12-16|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-21|P1Y2M10DT2H30M|UNKNOWN|2020-12-12|AFTER|2020-12-14
e|RS|89d364c9-1338-472b-af0b-19280e45508b|1|MOLRESP|Molecular Response|PALUMBO MULTIPLE MYELOMA 2009|||FAVORABLE RESPONSE|1|10^5/hpf|CRYOSCOPY|Y||Y|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|N|1|Visit_1|10|4|TREATMENT|2020-10-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-06|P1Y2M10DT2H30M|COINCIDENT|2021-01-10|COINCIDENT|2021-01-12
e|RS|89d364c9-1338-472b-af0b-19280e45508b|2|BMIVLIND|Bone Marrow Involvement Indicator|iRECIST|[?]|OD Unit|NED|1|umol/h/mmol|U-HPLC/MS/MS||||PROXY|MICROSCOPIST|Y|1|Visit_1|10|2|TREATMENT|2020-10-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-06|P1Y2M10DT2H30M|BEFORE|2021-01-05|AFTER|2021-01-07
e|RS|89d364c9-1338-472b-af0b-19280e45508b|3|NEWLWIND|New Lesion Worsening Indicator|SHINDOH COLORECTAL CANCER 2013|[?]|DPM|MAJOR PATHOLOGIC RESPONSE|1|g/animal/wk|CLINICAL EVALUATION||||VENDOR|ENDOCRINOLOGIST|N|2|Visit_2|25|6|TREATMENT|2020-10-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-23|P1Y2M10DT2H30M|AFTER|2020-11-08|AFTER|2020-12-08
e|RS|89d364c9-1338-472b-af0b-19280e45508b|4|MRDIND|Minimal Residual Disease Indicator|PCWG SCHER PROSTATE CANCER 2008|[?]|g/kg/day|NED|1|in|OPTICAL COHERENCE TOMOGRAPHY||||CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 1|Y|2|Visit_2|25|3|FOLLOW-UP|2020-10-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-23|P1Y2M10DT2H30M|BEFORE|2020-12-30|BEFORE|2021-01-12
e|RS|89d364c9-1338-472b-af0b-19280e45508b|5|NTLWIND|Non-Target Lesion Worsening Indicator|EASL BRUIX LIVER CANCER 2001|[?]|mg/cm2|MOLECULAR CR|1|copies/ug|CARDIAC THERMODILUTION||||PARENT|INTERNIST|Y|3|Visit_3|40|1|SCREENING|2020-11-14|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-24|P1Y2M10DT2H30M|COINCIDENT|2020-10-21|COINCIDENT|2020-12-04
e|RS|89d364c9-1338-472b-af0b-19280e45508b|6|DRCRIND|Disease Recurrence Indicator|DOHNER AML 2010|[?]|Pa|PR|1|mEq|MICROSCOPY||||DOMESTIC PARTNER|MICROSCOPIST|N|3|Visit_3|40|7|SCREENING|2020-11-14|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-24|P1Y2M10DT2H30M|AFTER|2020-11-30|ONGOING|2020-12-27
e|RS|89d364c9-1338-472b-af0b-19280e45508b|7|NEWLIND|New Lesion Indicator|HAMAOKA BREAST CANCER 2010|[?]|ug/kg|RELAPSED DISEASE FROM CR OR PR|1|breaths/min|DIGITAL PCR||||SIBLING|DEVELOPMENTAL PSYCHOLOGIST|U|4|Visit_4|65|2|SCREENING|2020-12-09|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-14|P1Y2M10DT2H30M|AFTER|2020-10-27|BEFORE|2020-11-01
e|RS|89d364c9-1338-472b-af0b-19280e45508b|8|BMIVLIND|Bone Marrow Involvement Indicator|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|PIXEL|UNFAVORABLE RESPONSE|1|mm/sec|ACCELERATOR MASS SPECTROMETRY|Y|Y||CHILD|ADJUDICATOR 3|Y|4|Visit_4|65|2|TREATMENT|2020-12-09|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-14|P1Y2M10DT2H30M|AFTER|2021-01-06|AFTER|2021-01-11
e|RS|89d364c9-1338-472b-af0b-19280e45508b|9|TMRESP|Tumor Marker Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|oz|SD|1|mV*min|KARYOTYPING||Y||STUDY SUBJECT|DERMATOLOGIST|U|5|Visit_5|90|4|TREATMENT|2021-01-03|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-22|P1Y2M10DT2H30M|COINCIDENT|2020-11-09|COINCIDENT|2020-12-01
e|RS|89d364c9-1338-472b-af0b-19280e45508b|10|BONERESP|Bone Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|||INDETERMINATE RESPONSE|1|msec|CYSTOMETRY|||Y|CHILD|RADIOLOGIST 2|NA|5|Visit_5|90|4|TREATMENT|2021-01-03|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-22|P1Y2M10DT2H30M|AFTER|2020-10-19|ONGOING|2020-12-04
e|RS|ecd8ff7b-9c30-4b74-ad95-f8555c59ab5e|1|MRDIND|Minimal Residual Disease Indicator|GUPPY OVARIAN CANCER 2002|[?]|ug|PD-CT|1|GPL U/mL|HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY|Y|||INVESTIGATOR|MICROSCOPIST 3|U|1|Visit_1|10|2|TREATMENT|2020-05-27|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-18|P1Y2M10DT2H30M|UNKNOWN|2020-07-01|ONGOING|2020-08-01
e|RS|ecd8ff7b-9c30-4b74-ad95-f8555c59ab5e|2|NTNERESP|Non-Target Non-Enhancing Response|RANO ELLINGSON 2017|[?]|uIU/L|mCR|1|nmol/kg/day|HEMAGGLUTINATION ASSAY||Y||FAMILY MEMBER|ADJUDICATOR 3|Y|1|Visit_1|10|4|TREATMENT|2020-05-27|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-18|P1Y2M10DT2H30M|AFTER|2020-07-20|AFTER|2020-07-25
e|RS|ecd8ff7b-9c30-4b74-ad95-f8555c59ab5e|3|NTLWIND|Non-Target Lesion Worsening Indicator|GUILHOT CML 2007|||NOT ALL EVALUATED|1|10^8/L|APPLANATION TONOMETRY|||Y|HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|NA|2|Visit_2|25|6|FOLLOW-UP|2020-06-11|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-28|P1Y2M10DT2H30M|UNKNOWN|2020-06-09|COINCIDENT|2020-06-25
e|RS|ecd8ff7b-9c30-4b74-ad95-f8555c59ab5e|4|NEWLWIND|New Lesion Worsening Indicator|SCHER PROSTATE CANCER 2011|[?]|mg/mL/min|NED|1|dB|PATHOLOGICAL EVALUATION|Y|||HEALTH CARE PROFESSIONAL|DERMATOLOGIST|N|2|Visit_2|25|6|TREATMENT|2020-06-11|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-28|P1Y2M10DT2H30M|UNKNOWN|2020-05-27|COINCIDENT|2020-08-15
e|RS|ecd8ff7b-9c30-4b74-ad95-f8555c59ab5e|5|NEWLPROG|New Lesion Progression|CHESON NON-HODGKINS LYMPHOMA 1999|||CA125 50% RESPONSE|1|DAgU/mL|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI||Y|Y|DOMESTIC PARTNER|MICROSCOPIST 2|N|3|Visit_3|40|5|TREATMENT|2020-06-26|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-21|P1Y2M10DT2H30M|AFTER|2020-08-24|ONGOING|2020-08-25
e|RS|ecd8ff7b-9c30-4b74-ad95-f8555c59ab5e|6|MNPTHIND|Minor Pathological Response Indicator|MRANO VAN DEN BENT GLIOMA 2011|[?]|mg/h|PMD|1|10^3 copies/mL|SLOAN LETTER EYE CHART 2.5%||||CHILD|CLINICAL PATHOLOGIST|NA|3|Visit_3|40|1|FOLLOW-UP|2020-06-26|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-21|P1Y2M10DT2H30M|COINCIDENT|2020-06-24|BEFORE|2020-08-22
e|RS|ecd8ff7b-9c30-4b74-ad95-f8555c59ab5e|7|DRCRIND|Disease Recurrence Indicator|KEAM BREAST CANCER 2013|[?]|ag|nPR|1|IU/g Hb|PHOTOGRAPHY||||CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST|Y|4|Visit_4|65|6|TREATMENT|2020-07-21|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-07|P1Y2M10DT2H30M|AFTER|2020-07-18|AFTER|2020-07-22
e|RS|ecd8ff7b-9c30-4b74-ad95-f8555c59ab5e|8|METSIND|Metastatic Indicator|RAJKUMAR MYELOMA 2011|||PSEUDOPROGRESSION|1|ug/m2/h|HPLC/IEX|||Y|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR|N|4|Visit_4|65|5|TREATMENT|2020-07-21|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-07|P1Y2M10DT2H30M|AFTER|2020-08-02|ONGOING|2020-08-04
e|RS|ecd8ff7b-9c30-4b74-ad95-f8555c59ab5e|9|TRGRESP|Target Response|HARTMAN PANCREATIC CANCER 2012|||mCR|1|cd|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE|||Y|CLINICAL STUDY SPONSOR|ONCOLOGIST 2|U|5|Visit_5|90|6|SCREENING|2020-08-15|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-25|P1Y2M10DT2H30M|UNKNOWN|2020-08-03|AFTER|2020-08-04
e|RS|ecd8ff7b-9c30-4b74-ad95-f8555c59ab5e|10|NEWLIND|New Lesion Indicator|LUGANO CLASSIFICATION|[?]|TABLET|CYTOGENETIC PR|1|mL/cm H2O|MAPH||||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR|Y|5|Visit_5|90|1|TREATMENT|2020-08-15|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-25|P1Y2M10DT2H30M|UNKNOWN|2020-06-28|BEFORE|2020-07-02
e|RS|f53c6f33-e2a6-4153-b1d6-9073f4ddefd1|1|DRCRIND|Disease Recurrence Indicator|SHINDOH COLORECTAL CANCER 2013|||TREATMENT FAILURE|1|ng|SXA SCAN|||Y|CLINICAL STUDY SPONSOR|MICROSCOPIST|NA|1|Visit_1|10|5|TREATMENT|2020-10-12|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-02|P1Y2M10DT2H30M|BEFORE|2020-11-04|COINCIDENT|2020-12-14
e|RS|f53c6f33-e2a6-4153-b1d6-9073f4ddefd1|2|ANATRESP|Anatomic Response|MONTSERRAT CLL 1989|[?]|KALLIKREIN INHIBITOR UNIT|IMPROVED|1|fmol/g|ANTIBIOTIC AGAR SCREEN||||STUDY SUBJECT|MICROSCOPIST 1|Y|1|Visit_1|10|6|TREATMENT|2020-10-12|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-02|P1Y2M10DT2H30M|COINCIDENT|2020-12-04|COINCIDENT|2021-01-01
e|RS|f53c6f33-e2a6-4153-b1d6-9073f4ddefd1|3|MJPTHIND|Major Pathological Response Indicator|KEAM BREAST CANCER 2013|[?]|mL/min/mmHg|PSEUDORESPONSE|1|mol/day|LIGHT SCATTERING SPECTROSCOPY|Y|||CAREGIVER|CLINICAL PATHOLOGIST|N|2|Visit_2|25|5|SCREENING|2020-10-27|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-21|P1Y2M10DT2H30M|COINCIDENT|2020-11-23|BEFORE|2020-12-07
e|RS|f53c6f33-e2a6-4153-b1d6-9073f4ddefd1|4|BESTRESP|Best Overall Response|KUKER LYMPHOMA 2005|[?]|JDF Unit|PARTIAL MORPHOLOGIC RESPONSE|1|DIP|IN SITU HYBRIDIZATION||||CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 2|NA|2|Visit_2|25|7|TREATMENT|2020-10-27|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-21|P1Y2M10DT2H30M|UNKNOWN|2020-12-29|ONGOING|2021-01-03
e|RS|f53c6f33-e2a6-4153-b1d6-9073f4ddefd1|5|TRGRESP|Target Response|SHINDOH COLORECTAL CANCER 2013|||SD|1|APS U|LASER CAPTURE MICRODISSECTION|||Y|FAMILY MEMBER|OPHTHALMOLOGIST|Y|3|Visit_3|40|4|TREATMENT|2020-11-11|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-08|P1Y2M10DT2H30M|AFTER|2020-12-06|ONGOING|2021-01-06
e|RS|f53c6f33-e2a6-4153-b1d6-9073f4ddefd1|6|SYMPTDTR|Symptomatic Deterioration|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|ELISA unit|cCR|1|kHz|LC-FL||||CLINICAL RESEARCH COORDINATOR|DEVELOPMENTAL PSYCHOLOGIST|U|3|Visit_3|40|7|SCREENING|2020-11-11|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-08|P1Y2M10DT2H30M|AFTER|2020-10-24|ONGOING|2020-12-06
e|RS|f53c6f33-e2a6-4153-b1d6-9073f4ddefd1|7|MNPTHIND|Minor Pathological Response Indicator|CHESON LYMPHOMA 2008|||EQUIVOCAL|1|umol/min|MASS SPECTROMETRY|||Y|INDEPENDENT ASSESSOR|PEDIATRIC NEUROLOGIST|N|4|Visit_4|65|2|TREATMENT|2020-12-06|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-13|P1Y2M10DT2H30M|UNKNOWN|2020-11-12|AFTER|2020-11-25
e|RS|f53c6f33-e2a6-4153-b1d6-9073f4ddefd1|8|MRPHRESP|Morphologic Response|KEAM BREAST CANCER 2013|[?]|cL|INDETERMINATE RESPONSE|1|nmol BCE/mmol|DXA SCAN||Y||INVESTIGATOR|CLINICAL PATHOLOGIST|NA|4|Visit_4|65|4|SCREENING|2020-12-06|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-13|P1Y2M10DT2H30M|UNKNOWN|2020-12-06|ONGOING|2020-12-21
e|RS|f53c6f33-e2a6-4153-b1d6-9073f4ddefd1|9|MNPTHIND|Minor Pathological Response Indicator|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|||PR-CT|1|dmol|SPIRAL CT SCAN WITHOUT CONTRAST|Y||Y|GUARDIAN|PEDIATRIC NEUROLOGIST|Y|5|Visit_5|90|1|FOLLOW-UP|2020-12-31|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-28|P1Y2M10DT2H30M|UNKNOWN|2020-11-15|AFTER|2020-12-15
e|RS|f53c6f33-e2a6-4153-b1d6-9073f4ddefd1|10|NEWLIND|New Lesion Indicator|MRANO VAN DEN BENT GLIOMA 2011|||NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|ng/dL|LIGHT MICROSCOPY||Y|Y|INTERVIEWER|PATHOLOGIST 2|U|5|Visit_5|90|4|TREATMENT|2020-12-31|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-28|P1Y2M10DT2H30M|AFTER|2020-11-25|BEFORE|2020-12-25
e|RS|0c103005-efae-48ed-91e3-35d38fa1d359|1|NTNERESP|Non-Target Non-Enhancing Response|EBMT BLADE MYELOMA 1998|[?]|scm|NE|1|g/kg|TRANSVAGINAL ULTRASOUND||||CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 2|NA|1|Visit_1|10|5|FOLLOW-UP|2020-05-28|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-12|P1Y2M10DT2H30M|BEFORE|2020-08-21|BEFORE|2020-08-22
e|RS|0c103005-efae-48ed-91e3-35d38fa1d359|2|MRDIND|Minimal Residual Disease Indicator|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|DRUM|PSEUDORESPONSE|1|ug/g/h|DYNAMIC LIGHT SCATTERING||||VENDOR|OPTOMETRIST|Y|1|Visit_1|10|3|SCREENING|2020-05-28|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-12|P1Y2M10DT2H30M|COINCIDENT|2020-06-19|ONGOING|2020-07-01
e|RS|0c103005-efae-48ed-91e3-35d38fa1d359|3|LIVRRESP|Liver Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|mg/cm2|PMR|1|mEq/mL|IMMUNOBLOT||Y||DOMESTIC PARTNER|MICROSCOPIST|NA|2|Visit_2|25|1|FOLLOW-UP|2020-06-12|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-25|P1Y2M10DT2H30M|COINCIDENT|2020-05-25|AFTER|2020-05-27
e|RS|0c103005-efae-48ed-91e3-35d38fa1d359|4|CLINRESP|Clinical Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|||DISEASE TRANSFORMATION|1|10^7 PFU|NON-CONTACT SPECULAR MICROSCOPY|Y||Y|SIGNIFICANT OTHER|OPHTHALMOLOGIST|Y|2|Visit_2|25|5|TREATMENT|2020-06-12|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-25|P1Y2M10DT2H30M|COINCIDENT|2020-07-17|AFTER|2020-08-21
e|RS|0c103005-efae-48ed-91e3-35d38fa1d359|5|METBRESP|Metabolic Response|MACDONALD GLIOMA 1990|[?]|mol/g|MORPHOLOGIC LEUKEMIA-FREE STATE|1|NEBULE|ENDPOINT DILUTION ASSAY||Y||NON-HEALTH CARE PROFESSIONAL|RATER 1|Y|3|Visit_3|40|5|TREATMENT|2020-06-27|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-04|P1Y2M10DT2H30M|BEFORE|2020-07-11|AFTER|2020-07-20
e|RS|0c103005-efae-48ed-91e3-35d38fa1d359|6|METSIND|Metastatic Indicator|GCIG RUSTIN OVARIAN CANCER 2011|||MR|1|SYRINGE|KNEMOMETRY|||Y|STUDY SUBJECT|DERMATOLOGIST|NA|3|Visit_3|40|4|WASHOUT|2020-06-27|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-04|P1Y2M10DT2H30M|AFTER|2020-05-20|BEFORE|2020-08-24
e|RS|0c103005-efae-48ed-91e3-35d38fa1d359|7|BMIVLIND|Bone Marrow Involvement Indicator|PERCIST|||MOLECULAR CR|1|atm|LIQUID SCINTILLATION COUNTING|||Y|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|NA|4|Visit_4|65|6|SCREENING|2020-07-22|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-19|P1Y2M10DT2H30M|UNKNOWN|2020-08-12|AFTER|2020-08-19
e|RS|0c103005-efae-48ed-91e3-35d38fa1d359|8|NTRGRESP|Non-target Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|hr/day|PMD|1|mL/m2/day|DYNAMIC LIGHT SCATTERING|Y|||CLINICAL STUDY SPONSOR|ADJUDICATOR 2|Y|4|Visit_4|65|2|SCREENING|2020-07-22|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-19|P1Y2M10DT2H30M|AFTER|2020-07-24|ONGOING|2020-08-06
e|RS|0c103005-efae-48ed-91e3-35d38fa1d359|9|TMRESP|Tumor Marker Response|PRINCE TCELL LYMPHOMA 2010|[?]|ft2|MOLECULAR CR|1|U/m2/day|KARYOTYPING||||INVESTIGATOR|CLINICAL PATHOLOGIST|U|5|Visit_5|90|4|WASHOUT|2020-08-16|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-23|P1Y2M10DT2H30M|AFTER|2020-06-06|AFTER|2020-07-14
e|RS|0c103005-efae-48ed-91e3-35d38fa1d359|10|NTNERESP|Non-Target Non-Enhancing Response|SCHWARZ CERVICAL CANCER 2009|[?]|mL/100g/min|ABSENT MORPHOLOGIC RESPONSE|1|EU|DOUBLE IMMUNODIFFUSION||||CLINICAL RESEARCH COORDINATOR|RADIOLOGIST|Y|5|Visit_5|90|4|TREATMENT|2020-08-16|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-23|P1Y2M10DT2H30M|AFTER|2020-07-22|BEFORE|2020-08-09
e|RS|c9808184-3432-448c-a5e5-50176715effa|1|DRCRIND|Disease Recurrence Indicator|IWG CHESON MDS 2006|[?]|10^9/dose|PDu|1|CUP|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION|Y|||SIGNIFICANT OTHER|MICROSCOPIST 1|N|1|Visit_1|10|2|TREATMENT|2020-12-29|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-15|P1Y2M10DT2H30M|BEFORE|2021-02-20|AFTER|2021-02-27
e|RS|c9808184-3432-448c-a5e5-50176715effa|2|LIVRRESP|Liver Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|||MRD NEGATIVITY|1|nmol/L|TRANSTHORACIC ECHOCARDIOGRAPHY|Y||Y|INTERVIEWER|PATHOLOGIST|Y|1|Visit_1|10|3|WASHOUT|2020-12-29|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-15|P1Y2M10DT2H30M|BEFORE|2021-02-02|BEFORE|2021-03-07
e|RS|c9808184-3432-448c-a5e5-50176715effa|3|NEWLPROG|New Lesion Progression|MURPHY PROSTATE CANCER 1980|[?]|Linear ft*LB|mCR|1|nmol/L|MULTIPLEXED BEAD BASED IMMUNOASSAY||||INTERVIEWER|ADJUDICATOR|NA|2|Visit_2|25|3|WASHOUT|2021-01-13|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-02|P1Y2M10DT2H30M|COINCIDENT|2021-03-17|AFTER|2021-03-20
e|RS|c9808184-3432-448c-a5e5-50176715effa|4|MRDIND|Minimal Residual Disease Indicator|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|hr/day|MOLECULAR CR|1|U/kg|ELISA||||PARENT|HEMATOLOGIST|NA|2|Visit_2|25|7|TREATMENT|2021-01-13|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-02|P1Y2M10DT2H30M|AFTER|2021-01-02|BEFORE|2021-01-08
e|RS|c9808184-3432-448c-a5e5-50176715effa|5|SFTSRESP|Soft Tissue Response|GUILHOT CML 2007|[?]|days/month|WORSENED|1|BP|LC/MS|Y|||CHILD|OPHTHALMOLOGIST|Y|3|Visit_3|40|2|TREATMENT|2021-01-28|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-02|P1Y2M10DT2H30M|COINCIDENT|2021-03-06|COINCIDENT|2021-03-07
e|RS|c9808184-3432-448c-a5e5-50176715effa|6|CLINRESP|Clinical Response|HARTMANN GERM CELL CANCER 2002|[?]|mAmp|iCPD|1|m/sec|ARTERIAL SPIN LABELING FUNCTIONAL MRI||||ADJUDICATION COMMITTEE|MICROSCOPIST|N|3|Visit_3|40|7|SCREENING|2021-01-28|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-02|P1Y2M10DT2H30M|UNKNOWN|2021-02-20|BEFORE|2021-03-14
e|RS|c9808184-3432-448c-a5e5-50176715effa|7|BMIVLIND|Bone Marrow Involvement Indicator|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|BU/mL|SD|1|g/g/day|HIGH RESOLUTION CT|Y|||DOMESTIC PARTNER|CLINICAL PATHOLOGIST|NA|4|Visit_4|65|4|SCREENING|2021-02-22|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-06|P1Y2M10DT2H30M|AFTER|2021-02-10|BEFORE|2021-02-26
e|RS|c9808184-3432-448c-a5e5-50176715effa|8|MJPTHIND|Major Pathological Response Indicator|PCWG SCHER PROSTATE CANCER 2008|||MRD PERSISTENCE|1|mEq/mmol|FORCED OSCILLATION TECHNIQUE||Y|Y|DOMESTIC PARTNER|ADJUDICATOR|NA|4|Visit_4|65|5|TREATMENT|2021-02-22|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-06|P1Y2M10DT2H30M|AFTER|2021-01-13|BEFORE|2021-03-09
e|RS|c9808184-3432-448c-a5e5-50176715effa|9|BMIVLIND|Bone Marrow Involvement Indicator|IWC HALLEK CLL 2008|[?]|titer|mCR|1|pmol/dL|HEMATOXYLIN AND EOSIN STAIN||Y||INTERVIEWER|OPTOMETRIST|N|5|Visit_5|90|3|FOLLOW-UP|2021-03-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-26|P1Y2M10DT2H30M|AFTER|2021-02-06|ONGOING|2021-02-13
e|RS|c9808184-3432-448c-a5e5-50176715effa|10|SYMPTDTR|Symptomatic Deterioration|PCWG BUBLEY PROSTATE CANCER 1999|||HI-P|1|kUSP|HPLC/MS/MS|||Y|SIBLING|DERMATOLOGIST|Y|5|Visit_5|90|4|TREATMENT|2021-03-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-26|P1Y2M10DT2H30M|UNKNOWN|2021-01-12|COINCIDENT|2021-03-17
e|RS|c3d7d293-975f-44de-bd35-0168eec40ac9|1|MJPTHIND|Major Pathological Response Indicator|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|HOURS|TREATMENT FAILURE|1|steps/min|BIOIMPEDANCE SPECTROSCOPY||||VENDOR|NEUROLOGIST 2|Y|1|Visit_1|10|5|FOLLOW-UP|2021-01-04|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-02|P1Y2M10DT2H30M|BEFORE|2021-02-12|COINCIDENT|2021-03-15
e|RS|c3d7d293-975f-44de-bd35-0168eec40ac9|2|MRDIND|Minimal Residual Disease Indicator|PCWG BUBLEY PROSTATE CANCER 1999|||CYTOGENETIC PR|1|ug/min|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY||Y|Y|SPOUSE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|1|Visit_1|10|5|FOLLOW-UP|2021-01-04|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-02|P1Y2M10DT2H30M|AFTER|2021-02-15|ONGOING|2021-02-17
e|RS|c3d7d293-975f-44de-bd35-0168eec40ac9|3|NEWLPROG|New Lesion Progression|RANO|[?]|DIP|VGPR|1|uIU/dL|SLOAN LETTER EYE CHART 2.5%||||PROXY|OPTOMETRIST|Y|2|Visit_2|25|7|TREATMENT|2021-01-19|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-15|P1Y2M10DT2H30M|BEFORE|2021-03-19|COINCIDENT|2021-04-02
e|RS|c3d7d293-975f-44de-bd35-0168eec40ac9|4|MRDRESP|Minimal Residual Disease Response|IWG CHESON AML 2003|[?]|U/cL|RELAPSED DISEASE|1|s/h|MULTI-SLICE SPIRAL CT|Y|||SPOUSE|RATER|U|2|Visit_2|25|4|TREATMENT|2021-01-19|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-15|P1Y2M10DT2H30M|UNKNOWN|2021-01-16|COINCIDENT|2021-01-22
e|RS|c3d7d293-975f-44de-bd35-0168eec40ac9|5|STRUSTAT|Steroid Use Status|SCHWARZ CERVICAL CANCER 2009|[?]|log10 CFU/mL|COMPLETE MRD RESPONSE|1|uL/kg/day|PLAQUE REDUCTION NEUTRALIZATION ASSAY||||ADJUDICATION COMMITTEE|RATER 1|N|3|Visit_3|40|4|FOLLOW-UP|2021-02-03|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-23|P1Y2M10DT2H30M|BEFORE|2021-02-22|COINCIDENT|2021-03-24
e|RS|c3d7d293-975f-44de-bd35-0168eec40ac9|6|NTNERESP|Non-Target Non-Enhancing Response|HAMAOKA BREAST CANCER 2010|[?]|AMPULE|VGPR|1|mol/day|CRYOSCOPY||||SIBLING|READER 1|N|3|Visit_3|40|1|TREATMENT|2021-02-03|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-23|P1Y2M10DT2H30M|AFTER|2021-03-11|ONGOING|2021-03-28
e|RS|c3d7d293-975f-44de-bd35-0168eec40ac9|7|MNPTHIND|Minor Pathological Response Indicator|KEAM BREAST CANCER 2013|||SD-CT|1|FIU|PHYSICAL EXAMINATION|||Y|GUARDIAN|INTERNIST|N|4|Visit_4|65|7|WASHOUT|2021-02-28|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-25|P1Y2M10DT2H30M|BEFORE|2021-02-03|COINCIDENT|2021-03-12
e|RS|c3d7d293-975f-44de-bd35-0168eec40ac9|8|NTNERESP|Non-Target Non-Enhancing Response|HARTMANN GERM CELL CANCER 2002|[?]|EU|STABLE|1|steps/min|MICROPARTICLE ENZYME IMMUNOASSAY||||SIGNIFICANT OTHER|ONCOLOGIST 1|NA|4|Visit_4|65|3|WASHOUT|2021-02-28|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-25|P1Y2M10DT2H30M|UNKNOWN|2020-12-28|BEFORE|2021-01-19
e|RS|c3d7d293-975f-44de-bd35-0168eec40ac9|9|MRDRESP|Minimal Residual Disease Response|MONTSERRAT CLL 1989|||RELAPSED DISEASE|1|DIP|LANDOLT RING|||Y|PROXY|NEUROLOGIST|Y|5|Visit_5|90|7|TREATMENT|2021-03-25|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-21|P1Y2M10DT2H30M|COINCIDENT|2021-02-22|COINCIDENT|2021-03-30
e|RS|c3d7d293-975f-44de-bd35-0168eec40ac9|10|METSIND|Metastatic Indicator|CHESON LYMPHOMA 2008|[?]|Torr|ABSENT MORPHOLOGIC RESPONSE|1|mOsm|OPTICAL DENSITY MEASUREMENT||Y||NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 1|NA|5|Visit_5|90|2|TREATMENT|2021-03-25|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-21|P1Y2M10DT2H30M|BEFORE|2021-01-26|AFTER|2021-03-20
e|RS|2db1f07d-a7db-4cc3-8943-536e24378f08|1|SFTSRESP|Soft Tissue Response|IWG CHESON AML 2003|[?]|IU/g Hb|QUANTIFIABLE MRD POSITIVITY|1|kg/cm|CELL CYTOTOXICITY NEUTRALIZATION ASSAY||||INVESTIGATOR|ADJUDICATOR 1|Y|1|Visit_1|10|2|TREATMENT|2020-06-12|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-30|P1Y2M10DT2H30M|AFTER|2020-08-28|AFTER|2020-08-29
e|RS|2db1f07d-a7db-4cc3-8943-536e24378f08|2|SFTSRESP|Soft Tissue Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|cd*s/m2|MOLECULAR CR|1|m2|STRESS ECHOCARDIOGRAPHY||||FRIEND|MICROSCOPIST 3|NA|1|Visit_1|10|6|WASHOUT|2020-06-12|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-30|P1Y2M10DT2H30M|COINCIDENT|2020-07-20|COINCIDENT|2020-07-30
e|RS|2db1f07d-a7db-4cc3-8943-536e24378f08|3|MRDRESP|Minimal Residual Disease Response|IWC HALLEK CLL 2008|[?]|U/kg/min|PD/RELAPSE AFTER HI|1|Ci/L|SPECTROPHOTOMETRY||||FAMILY MEMBER|CLINICAL PATHOLOGIST|N|2|Visit_2|25|7|FOLLOW-UP|2020-06-27|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-28|P1Y2M10DT2H30M|BEFORE|2020-06-04|COINCIDENT|2020-07-23
e|RS|2db1f07d-a7db-4cc3-8943-536e24378f08|4|METSIND|Metastatic Indicator|MRECIST LENCIONI LIVER CANCER 2010|[?]|DIOPTER|iSD|1|grain|LAPAROSCOPY||||DOMESTIC PARTNER|RATER|N|2|Visit_2|25|2|TREATMENT|2020-06-27|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-28|P1Y2M10DT2H30M|BEFORE|2020-07-05|COINCIDENT|2020-08-16
e|RS|2db1f07d-a7db-4cc3-8943-536e24378f08|5|DRCRIND|Disease Recurrence Indicator|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|Siemens|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|BLOCKS|BALLPOINT PEN TECHNIQUE||Y||CLINICAL RESEARCH COORDINATOR|UROLOGIST|U|3|Visit_3|40|5|WASHOUT|2020-07-12|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-09|P1Y2M10DT2H30M|BEFORE|2020-07-21|BEFORE|2020-09-08
e|RS|2db1f07d-a7db-4cc3-8943-536e24378f08|6|NTRGRESP|Non-target Response|EASL BRUIX LIVER CANCER 2001|[?]|Ci/ug|CHR|1|uL/kg/day|DNA MICROARRAY|Y|||PARENT|PHYSIOTHERAPIST|N|3|Visit_3|40|1|FOLLOW-UP|2020-07-12|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-09|P1Y2M10DT2H30M|COINCIDENT|2020-07-29|COINCIDENT|2020-08-22
e|RS|2db1f07d-a7db-4cc3-8943-536e24378f08|7|NEWLPROG|New Lesion Progression|RANO|[?]|PA|CMR|1|km|URANYL ACETATE STAIN||||SPOUSE|NEUROLOGIST 2|N|4|Visit_4|65|5|TREATMENT|2020-08-06|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-06|P1Y2M10DT2H30M|AFTER|2020-06-24|ONGOING|2020-07-21
e|RS|2db1f07d-a7db-4cc3-8943-536e24378f08|8|BESTRESP|Best Overall Response|SHINDOH COLORECTAL CANCER 2013|[?]|cd|CYTOGENETIC CR|1|100 IU/mL|SNP ARRAY||Y||SIBLING|READER|NA|4|Visit_4|65|5|FOLLOW-UP|2020-08-06|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-06|P1Y2M10DT2H30M|UNKNOWN|2020-06-27|BEFORE|2020-08-21
e|RS|2db1f07d-a7db-4cc3-8943-536e24378f08|9|MRDRESP|Minimal Residual Disease Response|SCHWARZ CERVICAL CANCER 2009|[?]|PFU/animal|cPR|1|ELISA unit/mL|TOTAL BODY IRRADIATION|Y|||NON-HEALTH CARE PROFESSIONAL|READER 3|U|5|Visit_5|90|7|TREATMENT|2020-08-31|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-28|P1Y2M10DT2H30M|BEFORE|2020-07-25|COINCIDENT|2020-08-24
e|RS|2db1f07d-a7db-4cc3-8943-536e24378f08|10|MRPHRESP|Morphologic Response|RANO ELLINGSON 2017|[?]|mL/dL|PDu|1|PIXEL|ULTRASOUND||Y||CLINICAL STUDY SPONSOR|MICROSCOPIST|U|5|Visit_5|90|2|WASHOUT|2020-08-31|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-28|P1Y2M10DT2H30M|UNKNOWN|2020-06-23|COINCIDENT|2020-08-13
e|RS|c343ba98-87d7-40bc-b0e8-b866e42d3a21|1|CYTORESP|Cytogenetic Response|MURPHY PROSTATE CANCER 1980|[?]|BU/mL|iUPD|1|/mm|NUCLEIC ACID BASED METHOD||Y||NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|NA|1|Visit_1|10|1|TREATMENT|2020-12-15|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-09|P1Y2M10DT2H30M|BEFORE|2021-01-07|BEFORE|2021-01-23
e|RS|c343ba98-87d7-40bc-b0e8-b866e42d3a21|2|NTLWIND|Non-Target Lesion Worsening Indicator|SACT|||PSEUDOPROGRESSION|1|/200 HPFs|SPECT/CT SCAN|||Y|INVESTIGATOR|ADJUDICATOR 3|U|1|Visit_1|10|5|TREATMENT|2020-12-15|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-09|P1Y2M10DT2H30M|COINCIDENT|2020-12-30|BEFORE|2021-01-02
e|RS|c343ba98-87d7-40bc-b0e8-b866e42d3a21|3|MRDIND|Minimal Residual Disease Indicator|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|VIRTUAL PIXEL|MRD RELAPSE|1|/200 HPFs|WEBER GREEN STAIN||||SIGNIFICANT OTHER|CLINICAL PATHOLOGIST|U|2|Visit_2|25|1|SCREENING|2020-12-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-02|P1Y2M10DT2H30M|AFTER|2021-01-16|COINCIDENT|2021-01-17
e|RS|c343ba98-87d7-40bc-b0e8-b866e42d3a21|4|MNPTHIND|Minor Pathological Response Indicator|DOHNER AML 2010|[?]|mg/L FEU|IMMUNOPHENOTYPIC CR|1|ng/day|FLAME PHOTOMETRY||Y||FAMILY MEMBER|UROLOGIST|U|2|Visit_2|25|3|TREATMENT|2020-12-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-02|P1Y2M10DT2H30M|BEFORE|2021-03-12|AFTER|2021-03-13
e|RS|c343ba98-87d7-40bc-b0e8-b866e42d3a21|5|MNPTHIND|Minor Pathological Response Indicator|CHESON CLL 2012|||iSD|1|DISK|CT SCAN|||Y|CLINICAL STUDY SPONSOR|DEVELOPMENTAL PSYCHOLOGIST|N|3|Visit_3|40|3|TREATMENT|2021-01-14|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-23|P1Y2M10DT2H30M|AFTER|2021-02-18|BEFORE|2021-03-11
e|RS|c343ba98-87d7-40bc-b0e8-b866e42d3a21|6|LIVRRESP|Liver Response|PCWG SCHER PROSTATE CANCER 2016|||iUPD|1|vg/mL|CONTRAST ENHANCED PET SCAN||Y|Y|HEALTH CARE PROFESSIONAL|RATER 2|Y|3|Visit_3|40|7|SCREENING|2021-01-14|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-23|P1Y2M10DT2H30M|COINCIDENT|2021-01-18|ONGOING|2021-01-21
e|RS|c343ba98-87d7-40bc-b0e8-b866e42d3a21|7|BESTRESP|Best Overall Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|pmol|CYTOGENETIC PR|1|mL/cage/wk|IMMUNOFIXATION ELECTROPHORESIS||Y||CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 1|Y|4|Visit_4|65|6|SCREENING|2021-02-08|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-05|P1Y2M10DT2H30M|UNKNOWN|2021-01-07|BEFORE|2021-02-24
e|RS|c343ba98-87d7-40bc-b0e8-b866e42d3a21|8|MOLRESP|Molecular Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|||MINOR PATHOLOGIC RESPONSE|1|/wk|BAC ACGH|||Y|PROXY|PATHOLOGIST 1|U|4|Visit_4|65|3|WASHOUT|2021-02-08|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-05|P1Y2M10DT2H30M|BEFORE|2021-02-26|AFTER|2021-03-05
e|RS|c343ba98-87d7-40bc-b0e8-b866e42d3a21|9|TMRESP|Tumor Marker Response|JACINTO CERVICAL CANCER 2007|[?]|U/mg|iCR|1|mL/s|PHASE-CONTRAST MRI||||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|Y|5|Visit_5|90|5|WASHOUT|2021-03-05|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-14|P1Y2M10DT2H30M|BEFORE|2021-02-18|COINCIDENT|2021-03-05
e|RS|c343ba98-87d7-40bc-b0e8-b866e42d3a21|10|BMIVLIND|Bone Marrow Involvement Indicator|SHINDOH COLORECTAL CANCER 2013|||MR|1|U/g Hb|THICK SMEAR|||Y|NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|5|Visit_5|90|2|FOLLOW-UP|2021-03-05|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-14|P1Y2M10DT2H30M|BEFORE|2021-02-13|BEFORE|2021-03-06
e|RS|d2b31ba9-9718-43ce-82ca-3276c28ac42a|1|CYTORESP|Cytogenetic Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|FEU|TREATMENT FAILURE|1|g/cage/day|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY||Y||ADJUDICATOR|RADIOLOGIST 2|N|1|Visit_1|10|5|SCREENING|2020-12-04|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-17|P1Y2M10DT2H30M|COINCIDENT|2021-01-26|AFTER|2021-02-13
e|RS|d2b31ba9-9718-43ce-82ca-3276c28ac42a|2|MRDIND|Minimal Residual Disease Indicator|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|um/day|cPR|1|L/min|ULTRASOUND||Y||NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|NA|1|Visit_1|10|4|TREATMENT|2020-12-04|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-17|P1Y2M10DT2H30M|COINCIDENT|2020-12-07|COINCIDENT|2021-01-15
e|RS|d2b31ba9-9718-43ce-82ca-3276c28ac42a|3|CYTORESP|Cytogenetic Response|WHO BREAST CANCER 2006|[?]|BAG|CYTOGENETIC MINOR RESPONSE|1|Ci/L|POPULATION SEQUENCING||||ADJUDICATOR|MICROSCOPIST 3|NA|2|Visit_2|25|6|FOLLOW-UP|2020-12-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-06|P1Y2M10DT2H30M|AFTER|2021-01-15|BEFORE|2021-01-28
e|RS|d2b31ba9-9718-43ce-82ca-3276c28ac42a|4|NEWLIND|New Lesion Indicator|WHO BREAST CANCER 2006|[?]|mmol/g|iSD|1|CIGAR|PYROSEQUENCING|Y|||FAMILY MEMBER|MICROSCOPIST 3|N|2|Visit_2|25|6|SCREENING|2020-12-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-06|P1Y2M10DT2H30M|BEFORE|2020-12-06|ONGOING|2021-01-07
e|RS|d2b31ba9-9718-43ce-82ca-3276c28ac42a|5|ANATRESP|Anatomic Response|AJCC V7|[?]|uOsm|INCREASED|1|amol|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI||||SIBLING|MICROSCOPIST 2|Y|3|Visit_3|40|5|FOLLOW-UP|2021-01-03|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-04|P1Y2M10DT2H30M|AFTER|2020-12-05|AFTER|2021-02-23
e|RS|d2b31ba9-9718-43ce-82ca-3276c28ac42a|6|MRDRESP|Minimal Residual Disease Response|RANO|[?]|Ci/mg|MR|1|ka_u/dL|PHOTOMETRIC CLOT DETECTION||||SPOUSE|HEMATOLOGIST|NA|3|Visit_3|40|3|TREATMENT|2021-01-03|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-04|P1Y2M10DT2H30M|UNKNOWN|2021-01-30|BEFORE|2021-02-08
e|RS|d2b31ba9-9718-43ce-82ca-3276c28ac42a|7|BESTRESP|Best Overall Response|MONTSERRAT CLL 1989|[?]|mU/L|iUPD|1|nmol/L/h|GIEMSA STAIN||||STUDY SUBJECT|RATER 1|U|4|Visit_4|65|1|SCREENING|2021-01-28|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-13|P1Y2M10DT2H30M|AFTER|2021-01-21|AFTER|2021-02-20
e|RS|d2b31ba9-9718-43ce-82ca-3276c28ac42a|8|MNPTHIND|Minor Pathological Response Indicator|AJCC V7|[?]|uV|MINOR PATHOLOGIC RESPONSE|1|pg|SCANNING ELECTRON MICROSCOPY||||VENDOR|ENDOCRINOLOGIST|N|4|Visit_4|65|5|SCREENING|2021-01-28|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-13|P1Y2M10DT2H30M|COINCIDENT|2021-02-21|COINCIDENT|2021-02-24
e|RS|d2b31ba9-9718-43ce-82ca-3276c28ac42a|9|BMIVLIND|Bone Marrow Involvement Indicator|BLAZER COLORECTAL CANCER 2008|[?]|mg/L FEU|CYTOGENETIC PR|1|AMPULE|MICROBIAL CULTURE, LIQUID|Y|Y||FAMILY MEMBER|READER 1|NA|5|Visit_5|90|5|SCREENING|2021-02-22|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-24|P1Y2M10DT2H30M|AFTER|2021-02-09|COINCIDENT|2021-02-11
e|RS|d2b31ba9-9718-43ce-82ca-3276c28ac42a|10|NTLWIND|Non-Target Lesion Worsening Indicator|AJCC V8|[?]|tsp eq|INDETERMINATE RESPONSE|1|uOsm|ELECTRICAL IMPEDANCE MYOGRAPHY|Y|||CLINICAL STUDY SPONSOR|PATHOLOGIST 1|NA|5|Visit_5|90|4|TREATMENT|2021-02-22|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-24|P1Y2M10DT2H30M|BEFORE|2021-03-02|ONGOING|2021-03-03
e|RS|4aa77a8a-bbbe-4b7f-91fb-1edb3b61b711|1|RDIORESP|Radiologic Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|SFC/10^6 PBMC|iUPD|1|BAG|EEG|Y|||SIBLING|CARDIOLOGIST|Y|1|Visit_1|10|4|TREATMENT|2020-07-23|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-20|P1Y2M10DT2H30M|COINCIDENT|2020-07-28|ONGOING|2020-08-07
e|RS|4aa77a8a-bbbe-4b7f-91fb-1edb3b61b711|2|SFTSRESP|Soft Tissue Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|||iUPD|1|YEARS|NEURAMINIDASE INHIBITION ASSAY|Y||Y|SIGNIFICANT OTHER|ADJUDICATOR 3|U|1|Visit_1|10|1|TREATMENT|2020-07-23|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-20|P1Y2M10DT2H30M|AFTER|2020-09-19|COINCIDENT|2020-10-10
e|RS|4aa77a8a-bbbe-4b7f-91fb-1edb3b61b711|3|TMRESP|Tumor Marker Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|pptr|SD|1|EVENTS|CELL BASED BIOASSAY||||STUDY SUBJECT|FORENSIC PATHOLOGIST|NA|2|Visit_2|25|5|TREATMENT|2020-08-07|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-13|P1Y2M10DT2H30M|AFTER|2020-10-12|COINCIDENT|2020-10-17
e|RS|4aa77a8a-bbbe-4b7f-91fb-1edb3b61b711|4|RDIORESP|Radiologic Response|PRINCE TCELL LYMPHOMA 2010|[?]|ks|WORSENED|1|kg/L|CALCULATION||||FAMILY MEMBER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|2|Visit_2|25|2|TREATMENT|2020-08-07|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-13|P1Y2M10DT2H30M|BEFORE|2020-08-26|COINCIDENT|2020-09-12
e|RS|4aa77a8a-bbbe-4b7f-91fb-1edb3b61b711|5|CYTORESP|Cytogenetic Response|EASL BRUIX LIVER CANCER 2001|[?]|psi|CR|1|JAR|ELISPOT||Y||HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|NA|3|Visit_3|40|5|WASHOUT|2020-08-22|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-14|P1Y2M10DT2H30M|UNKNOWN|2020-09-23|AFTER|2020-09-26
e|RS|4aa77a8a-bbbe-4b7f-91fb-1edb3b61b711|6|CPRFSTAT|Clinical Performance Status|SHINDOH COLORECTAL CANCER 2013|[?]|vg/kg|MOLECULAR CR|1|g/m2/day|PLAQUE REDUCTION NEUTRALIZATION ASSAY|Y|Y||FRIEND|HEMATOLOGIST|N|3|Visit_3|40|3|TREATMENT|2020-08-22|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-14|P1Y2M10DT2H30M|COINCIDENT|2020-08-19|ONGOING|2020-10-06
e|RS|4aa77a8a-bbbe-4b7f-91fb-1edb3b61b711|7|LIVRRESP|Liver Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|g/cage/day|NOT ALL EVALUATED|1|Absorbance U|HEMAGGLUTINATION INHIBITION ASSAY||||FRIEND|ENDOCRINOLOGIST|U|4|Visit_4|65|6|SCREENING|2020-09-16|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-30|P1Y2M10DT2H30M|AFTER|2020-10-17|BEFORE|2020-10-18
e|RS|4aa77a8a-bbbe-4b7f-91fb-1edb3b61b711|8|MRDIND|Minimal Residual Disease Indicator|UNSPECIFIED|||IMMUNOPHENOTYPIC CR|1|log EID 50/dose|MRI|Y|Y|Y|GUARDIAN|MICROSCOPIST|N|4|Visit_4|65|2|SCREENING|2020-09-16|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-30|P1Y2M10DT2H30M|BEFORE|2020-10-19|AFTER|2020-10-20
e|RS|4aa77a8a-bbbe-4b7f-91fb-1edb3b61b711|9|NTNERESP|Non-Target Non-Enhancing Response|IRANO 2015|[?]|mmHg*min/L|SMD|1|10^6/g|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY||||STUDY SUBJECT|MICROSCOPIST 1|U|5|Visit_5|90|2|SCREENING|2020-10-11|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-19|P1Y2M10DT2H30M|UNKNOWN|2020-09-01|ONGOING|2020-09-27
e|RS|4aa77a8a-bbbe-4b7f-91fb-1edb3b61b711|10|CLINRESP|Clinical Response|WHO BREAST CANCER 2006|[?]|uIU/L|RELAPSED DISEASE FROM CR OR PR|1|LOZENGE|LUXOL FAST BLUE AND CRESYL VIOLET STAIN||||PARENT|OPHTHALMOLOGIST|NA|5|Visit_5|90|2|TREATMENT|2020-10-11|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-19|P1Y2M10DT2H30M|AFTER|2020-09-24|COINCIDENT|2020-09-29
e|RS|0a42f96a-49c3-492f-a272-bf9989e53e9d|1|NEWLWIND|New Lesion Worsening Indicator|DOHNER AML 2010|[?]|IU/g|STABLE|1|mV2/Hz|SPIRAL CT||||HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|U|1|Visit_1|10|4|TREATMENT|2021-01-26|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-16|P1Y2M10DT2H30M|AFTER|2021-02-11|AFTER|2021-02-28
e|RS|0a42f96a-49c3-492f-a272-bf9989e53e9d|2|ANATRESP|Anatomic Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|mCi/kg|STABLE|1|ug/kg|CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY||||INVESTIGATOR|INTERNIST|NA|1|Visit_1|10|4|TREATMENT|2021-01-26|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-16|P1Y2M10DT2H30M|AFTER|2021-02-06|ONGOING|2021-03-29
e|RS|0a42f96a-49c3-492f-a272-bf9989e53e9d|3|METBRESP|Metabolic Response|IWG CHESON AML 2003|||FAVORABLE RESPONSE|1|mg/kg/dose|HEMAGGLUTINATION ASSAY|||Y|CLINICAL STUDY SPONSOR|MICROSCOPIST|U|2|Visit_2|25|6|SCREENING|2021-02-10|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-22|P1Y2M10DT2H30M|AFTER|2021-02-04|AFTER|2021-04-14
e|RS|0a42f96a-49c3-492f-a272-bf9989e53e9d|4|MJPTHIND|Major Pathological Response Indicator|JACINTO CERVICAL CANCER 2007|[?]|Ci/g|IMPROVED|1|10^3 CFU/mL|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY||||CLINICAL RESEARCH COORDINATOR|HEMATOLOGIST|U|2|Visit_2|25|4|FOLLOW-UP|2021-02-10|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-22|P1Y2M10DT2H30M|AFTER|2021-04-16|COINCIDENT|2021-04-18
e|RS|0a42f96a-49c3-492f-a272-bf9989e53e9d|5|SPLNRESP|Spleen Response|GUILHOT CML 2007|[?]|10^6 copies/mL|RELAPSED DISEASE FROM CR|1|log10 CFU/mL|SLIT LAMP PHOTOGRAPHY||||INDEPENDENT ASSESSOR|PATHOLOGIST 2|N|3|Visit_3|40|7|SCREENING|2021-02-25|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-19|P1Y2M10DT2H30M|COINCIDENT|2021-03-07|ONGOING|2021-03-10
e|RS|0a42f96a-49c3-492f-a272-bf9989e53e9d|6|LIVRRESP|Liver Response|EASL BRUIX LIVER CANCER 2001|[?]|FFU|RELAPSED DISEASE FROM CR|1|PHERESIS UNIT|TEST STRIP||Y||VENDOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|3|Visit_3|40|3|TREATMENT|2021-02-25|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-19|P1Y2M10DT2H30M|COINCIDENT|2021-02-04|AFTER|2021-03-27
e|RS|0a42f96a-49c3-492f-a272-bf9989e53e9d|7|NTERESP|Non-Target Enhancing Response|KEAM BREAST CANCER 2013|||OPTIMAL MORPHOLOGIC RESPONSE|1|uL/dose|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION|||Y|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 1|U|4|Visit_4|65|4|SCREENING|2021-03-22|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-14|P1Y2M10DT2H30M|AFTER|2021-04-16|ONGOING|2021-04-19
e|RS|0a42f96a-49c3-492f-a272-bf9989e53e9d|8|MRPHRESP|Morphologic Response|CHESON NON-HODGKINS LYMPHOMA 1999|||DISEASE TRANSFORMATION|1|MnFI|EEG|Y||Y|INDEPENDENT ASSESSOR|READER|N|4|Visit_4|65|7|TREATMENT|2021-03-22|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-14|P1Y2M10DT2H30M|AFTER|2021-02-18|ONGOING|2021-03-08
e|RS|0a42f96a-49c3-492f-a272-bf9989e53e9d|9|SYMPTDTR|Symptomatic Deterioration|IWG CHESON MDS 2000|[?]|%/min|PD|1|YEARS|GRADIENT DIFFUSION||||CLINICAL STUDY SPONSOR|ADJUDICATOR 2|U|5|Visit_5|90|7|TREATMENT|2021-04-16|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-13|P1Y2M10DT2H30M|BEFORE|2021-02-23|BEFORE|2021-04-06
e|RS|0a42f96a-49c3-492f-a272-bf9989e53e9d|10|MOLRESP|Molecular Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|10^9/g|MOLECULAR MAJOR RESPONSE|1|ug/g/min|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION||||INTERVIEWER|NEUROLOGIST|U|5|Visit_5|90|4|FOLLOW-UP|2021-04-16|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-13|P1Y2M10DT2H30M|AFTER|2021-03-25|ONGOING|2021-04-06
e|RS|a78e7287-581c-4bf2-b3ca-ad2476c010cd|1|MRPHRESP|Morphologic Response|LUGANO CLASSIFICATION|||PD/RELAPSE AFTER HI|1|mL/mmHg|SICKLE CELL SOLUBILITY TEST||Y|Y|GUARDIAN|ONCOLOGIST 2|U|1|Visit_1|10|3|TREATMENT|2021-01-08|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-22|P1Y2M10DT2H30M|BEFORE|2021-03-09|COINCIDENT|2021-03-11
e|RS|a78e7287-581c-4bf2-b3ca-ad2476c010cd|2|CPRFSTAT|Clinical Performance Status|PCWG SCHER PROSTATE CANCER 2016|[?]|RING|iSD|1|BP|CLAUSS METHOD||||HEALTH CARE PROFESSIONAL|RADIOLOGIST|U|1|Visit_1|10|5|WASHOUT|2021-01-08|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-22|P1Y2M10DT2H30M|BEFORE|2021-03-30|AFTER|2021-04-07
e|RS|a78e7287-581c-4bf2-b3ca-ad2476c010cd|3|SPLNRESP|Spleen Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|kg/mol|cCR|1|mL/kg/h|ERGOSPIROMETRY||Y||ADJUDICATOR|NEUROLOGIST|U|2|Visit_2|25|5|TREATMENT|2021-01-23|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-11|P1Y2M10DT2H30M|UNKNOWN|2021-04-05|COINCIDENT|2021-04-07
e|RS|a78e7287-581c-4bf2-b3ca-ad2476c010cd|4|RDIORESP|Radiologic Response|PERCIST|[?]|pkat|MRD NEGATIVITY|1|beats/min|OPHTHALMOSCOPY|Y|Y||FAMILY MEMBER|NEUROLOGIST|Y|2|Visit_2|25|1|SCREENING|2021-01-23|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-11|P1Y2M10DT2H30M|AFTER|2021-01-26|AFTER|2021-04-02
e|RS|a78e7287-581c-4bf2-b3ca-ad2476c010cd|5|MRPHRESP|Morphologic Response|PERCIST|[?]|mm3/mm2/year|DECREASED|1|DRINK|RULER MEASUREMENT METHOD|Y|||CHILD|READER|NA|3|Visit_3|40|6|TREATMENT|2021-02-07|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-08|P1Y2M10DT2H30M|UNKNOWN|2021-01-11|BEFORE|2021-01-19
e|RS|a78e7287-581c-4bf2-b3ca-ad2476c010cd|6|CYTORESP|Cytogenetic Response|LUGANO CLASSIFICATION|[?]|L/h/m2|NON-CR/NON-PD|1|ug/mL/h|ANTIBIOTIC AGAR SCREEN||||STUDY SUBJECT|ONCOLOGIST 1|U|3|Visit_3|40|2|TREATMENT|2021-02-07|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-08|P1Y2M10DT2H30M|UNKNOWN|2021-03-22|ONGOING|2021-04-07
e|RS|a78e7287-581c-4bf2-b3ca-ad2476c010cd|7|ANATRESP|Anatomic Response|MACDONALD GLIOMA 1990|||SMD|1|10^9/g|IN SITU HYBRIDIZATION|||Y|SIBLING|ONCOLOGIST 2|NA|4|Visit_4|65|5|TREATMENT|2021-03-04|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-09|P1Y2M10DT2H30M|UNKNOWN|2021-02-08|BEFORE|2021-03-04
e|RS|a78e7287-581c-4bf2-b3ca-ad2476c010cd|8|CYTORESP|Cytogenetic Response|HARTMANN GERM CELL CANCER 2002|[?]|mg/kg/min|MAJOR PATHOLOGIC RESPONSE|1|cd|LINE PROBE ASSAY||||CLINICAL RESEARCH ASSOCIATE|PEDIATRIC NEUROLOGIST|Y|4|Visit_4|65|1|TREATMENT|2021-03-04|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-09|P1Y2M10DT2H30M|AFTER|2021-02-23|ONGOING|2021-02-26
e|RS|a78e7287-581c-4bf2-b3ca-ad2476c010cd|9|MRDIND|Minimal Residual Disease Indicator|MRANO VAN DEN BENT GLIOMA 2011|[?]|kHz|OPTIMAL MORPHOLOGIC RESPONSE|1|mL/kg|SNP ARRAY||||SIGNIFICANT OTHER|ONCOLOGIST 1|Y|5|Visit_5|90|7|TREATMENT|2021-03-29|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-09|P1Y2M10DT2H30M|UNKNOWN|2021-03-10|AFTER|2021-03-27
e|RS|a78e7287-581c-4bf2-b3ca-ad2476c010cd|10|RDIORESP|Radiologic Response|CHOI GIST 2008|[?]|nm|CYTOGENETIC CR|1|/7.5 mL|THIN SMEAR||||FAMILY MEMBER|RATER 1|NA|5|Visit_5|90|4|TREATMENT|2021-03-29|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-09|P1Y2M10DT2H30M|BEFORE|2021-03-16|BEFORE|2021-04-03
e|RS|d3651e5f-bc38-4c96-afbf-5a65873ff306|1|CPRFSTAT|Clinical Performance Status|MACDONALD GLIOMA 1990|[?]|CIGAR|SMD|1|mm/2h|RYAN BLUE STAIN||||HEALTH CARE PROFESSIONAL|RADIOLOGIST|NA|1|Visit_1|10|5|SCREENING|2020-07-28|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-07|P1Y2M10DT2H30M|BEFORE|2020-10-08|COINCIDENT|2020-10-21
e|RS|d3651e5f-bc38-4c96-afbf-5a65873ff306|2|METSIND|Metastatic Indicator|EBMT BLADE MYELOMA 1998|[?]|Bq/L|CYTOGENETIC MINOR RESPONSE|1|10^6 copies/mL|LANDOLT RING||||INTERVIEWER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|1|Visit_1|10|4|SCREENING|2020-07-28|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-07|P1Y2M10DT2H30M|COINCIDENT|2020-10-04|BEFORE|2020-10-23
e|RS|d3651e5f-bc38-4c96-afbf-5a65873ff306|3|CPRFSTAT|Clinical Performance Status|IRANO 2015|[?]|h*%|RELAPSED DISEASE|1|s/h|FLUORESCENCE ANGIOGRAPHY||||HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|Y|2|Visit_2|25|6|FOLLOW-UP|2020-08-12|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-22|P1Y2M10DT2H30M|AFTER|2020-08-31|AFTER|2020-10-18
e|RS|d3651e5f-bc38-4c96-afbf-5a65873ff306|4|SPLNRESP|Spleen Response|JACINTO CERVICAL CANCER 2007|||PSA PROGRESSION|1|g/animal/wk|PET/CT SCAN WITHOUT CONTRAST||Y|Y|INDEPENDENT ASSESSOR|READER 3|N|2|Visit_2|25|7|SCREENING|2020-08-12|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-22|P1Y2M10DT2H30M|BEFORE|2020-09-14|COINCIDENT|2020-09-30
e|RS|d3651e5f-bc38-4c96-afbf-5a65873ff306|5|CYTORESP|Cytogenetic Response|LUGANO CLASSIFICATION|[?]|uV|iCPD|1|mV|FLOW CYTOMETRY||||INTERVIEWER|READER|N|3|Visit_3|40|2|WASHOUT|2020-08-27|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-21|P1Y2M10DT2H30M|UNKNOWN|2020-10-12|COINCIDENT|2020-10-19
e|RS|d3651e5f-bc38-4c96-afbf-5a65873ff306|6|CYTORESP|Cytogenetic Response|PCWG SCHER PROSTATE CANCER 2016|||CMR|1|/5x10^4 WBC|INDIA INK STAIN|Y||Y|DOMESTIC PARTNER|ONCOLOGIST 2|U|3|Visit_3|40|2|TREATMENT|2020-08-27|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-21|P1Y2M10DT2H30M|UNKNOWN|2020-09-25|BEFORE|2020-10-10
e|RS|d3651e5f-bc38-4c96-afbf-5a65873ff306|7|TMRESP|Tumor Marker Response|HAMAOKA BREAST CANCER 2010|[?]|10^6/Ejaculate U|WORSENED|1|CARTRIDGE|TOTAL BODY RADIOGRAPHY||||INTERVIEWER|PHYSIOTHERAPIST|NA|4|Visit_4|65|4|TREATMENT|2020-09-21|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-11|P1Y2M10DT2H30M|UNKNOWN|2020-08-05|ONGOING|2020-08-10
e|RS|d3651e5f-bc38-4c96-afbf-5a65873ff306|8|BONERESP|Bone Response|BURCOMBE BREAST CANCER 2005|||PD FROM PR|1|U/g/min|PHYSICAL EXAMINATION||Y|Y|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 2|NA|4|Visit_4|65|7|TREATMENT|2020-09-21|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-11|P1Y2M10DT2H30M|BEFORE|2020-10-06|BEFORE|2020-10-14
e|RS|d3651e5f-bc38-4c96-afbf-5a65873ff306|9|SYMPTDTR|Symptomatic Deterioration|MONTSERRAT CLL 1989|[?]|mg/g/h|PSEUDOPROGRESSION|1|ppth|IHC||Y||SIBLING|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5|Visit_5|90|2|FOLLOW-UP|2020-10-16|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-28|P1Y2M10DT2H30M|BEFORE|2020-07-24|AFTER|2020-10-24
e|RS|d3651e5f-bc38-4c96-afbf-5a65873ff306|10|SPLNRESP|Spleen Response|IRANO 2015|[?]|YEARS|NED|1|mol/day|ENDOSCOPY|Y|||ADJUDICATOR|ONCOLOGIST 2|U|5|Visit_5|90|1|WASHOUT|2020-10-16|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-28|P1Y2M10DT2H30M|UNKNOWN|2020-09-01|COINCIDENT|2020-09-20
e|RS|4dca1d91-f6fe-4ee7-b4c3-062972eb5f37|1|CLINRESP|Clinical Response|IWG CHESON AML 2003|[?]|ukat/L|iCR|1|10^9 organisms/mL|MICROARRAY|Y|||INTERVIEWER|RADIOLOGIST|NA|1|Visit_1|10|7|WASHOUT|2020-06-11|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-08|P1Y2M10DT2H30M|COINCIDENT|2020-06-05|ONGOING|2020-08-05
e|RS|4dca1d91-f6fe-4ee7-b4c3-062972eb5f37|2|NTERESP|Non-Target Enhancing Response|NCIWG CHESON CLL 1996|[?]|pt_us|CYTOGENETIC PR|1|mg/animal|DUKE INCISION METHOD|Y|||PARENT|RATER|Y|1|Visit_1|10|3|TREATMENT|2020-06-11|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-08|P1Y2M10DT2H30M|BEFORE|2020-08-14|AFTER|2020-09-01
e|RS|4dca1d91-f6fe-4ee7-b4c3-062972eb5f37|3|MRDIND|Minimal Residual Disease Indicator|KUMAR IMWG 2016|||MRD PERSISTENCE|1|/100 WBC|CALCOFLUOR WHITE STAIN|||Y|CLINICAL STUDY SPONSOR|RATER 2|U|2|Visit_2|25|6|SCREENING|2020-06-26|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-08|P1Y2M10DT2H30M|BEFORE|2020-06-16|COINCIDENT|2020-07-07
e|RS|4dca1d91-f6fe-4ee7-b4c3-062972eb5f37|4|PATHRESP|Pathologic Response|RECIST 1.0|[?]|m|RELAPSED DISEASE FROM CR|1|kUSP|OSCILLOMETRY|Y|||SIBLING|ONCOLOGIST 1|N|2|Visit_2|25|2|FOLLOW-UP|2020-06-26|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-08|P1Y2M10DT2H30M|AFTER|2020-08-09|ONGOING|2020-08-12
e|RS|4dca1d91-f6fe-4ee7-b4c3-062972eb5f37|5|BMIVLIND|Bone Marrow Involvement Indicator|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|g/m2/day|PMR|1|/h|MICROBIAL CULTURE||||PROXY|MICROSCOPIST 3|NA|3|Visit_3|40|6|SCREENING|2020-07-11|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-07|P1Y2M10DT2H30M|COINCIDENT|2020-07-28|AFTER|2020-08-26
e|RS|4dca1d91-f6fe-4ee7-b4c3-062972eb5f37|6|DRCRIND|Disease Recurrence Indicator|RANO ELLINGSON 2017|[?]|log10 CCID 50/dose|CR|1|mg/kg/h|OBSERVATION|Y|||PROXY|RADIOLOGIST 1|U|3|Visit_3|40|6|TREATMENT|2020-07-11|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-07|P1Y2M10DT2H30M|AFTER|2020-09-07|ONGOING|2020-09-08
e|RS|4dca1d91-f6fe-4ee7-b4c3-062972eb5f37|7|STRUSTAT|Steroid Use Status|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|mL/kg|MOLECULAR MAJOR RESPONSE|1|uCi/L|REFRACTOMETRY||||INTERVIEWER|MICROSCOPIST|U|4|Visit_4|65|3|TREATMENT|2020-08-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-19|P1Y2M10DT2H30M|UNKNOWN|2020-07-07|ONGOING|2020-09-01
e|RS|4dca1d91-f6fe-4ee7-b4c3-062972eb5f37|8|NEWLIND|New Lesion Indicator|HARTMAN PANCREATIC CANCER 2012|[?]|Bq/kg|DECREASED|1|SQU/mL|HPLC/MS/MS||||CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 1|N|4|Visit_4|65|3|TREATMENT|2020-08-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-19|P1Y2M10DT2H30M|UNKNOWN|2020-08-11|COINCIDENT|2020-08-19
e|RS|4dca1d91-f6fe-4ee7-b4c3-062972eb5f37|9|METBRESP|Metabolic Response|RANO|[?]|fL|cPR|1|U/m2/min|SCINTIGRAPHY||Y||INTERVIEWER|PATHOLOGIST 1|N|5|Visit_5|90|4|TREATMENT|2020-08-30|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-29|P1Y2M10DT2H30M|COINCIDENT|2020-07-09|AFTER|2020-08-06
e|RS|4dca1d91-f6fe-4ee7-b4c3-062972eb5f37|10|METSIND|Metastatic Indicator|NCIWG CHESON CLL 1996|[?]|10^6 IU/mL|UNEQUIVOCAL|1|Absorbance U/mL|NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY||||STUDY SUBJECT|READER 3|Y|5|Visit_5|90|6|TREATMENT|2020-08-30|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-29|P1Y2M10DT2H30M|AFTER|2020-08-11|BEFORE|2020-08-15
e|RS|f50537d2-e098-4dae-8f91-16f2357d709c|1|MRDRESP|Minimal Residual Disease Response|KEAM BREAST CANCER 2013|[?]|mPa|CR|1|log10 IU/mL|VENTILATION PERFUSION LUNG SCAN||||GUARDIAN|MICROSCOPIST 3|Y|1|Visit_1|10|5|WASHOUT|2020-12-07|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-04|P1Y2M10DT2H30M|COINCIDENT|2021-02-17|COINCIDENT|2021-02-26
e|RS|f50537d2-e098-4dae-8f91-16f2357d709c|2|BONERESP|Bone Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|mL/g/h|HI-N|1|10^6 U|THIN SMEAR||Y||CAREGIVER|DERMATOLOGIST|U|1|Visit_1|10|7|WASHOUT|2020-12-07|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-04|P1Y2M10DT2H30M|BEFORE|2021-02-20|ONGOING|2021-03-05
e|RS|f50537d2-e098-4dae-8f91-16f2357d709c|3|CPRFSTAT|Clinical Performance Status|EASL BRUIX LIVER CANCER 2001|[?]|mL/cage/wk|PSEUDORESPONSE|1|MESF|QUANTITATIVE ULTRASOUND||||CHILD|ADJUDICATOR 2|U|2|Visit_2|25|4|TREATMENT|2020-12-22|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-27|P1Y2M10DT2H30M|UNKNOWN|2021-02-23|ONGOING|2021-02-28
e|RS|f50537d2-e098-4dae-8f91-16f2357d709c|4|NTNERESP|Non-Target Non-Enhancing Response|IWG CHESON MDS 2006|||PSA PROGRESSION|1|10^9 organisms/mL|ATOMIC ABSORPTION SPECTROMETRY||Y|Y|PARENT|ADJUDICATOR|NA|2|Visit_2|25|1|SCREENING|2020-12-22|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-27|P1Y2M10DT2H30M|UNKNOWN|2020-11-30|COINCIDENT|2021-02-06
e|RS|f50537d2-e098-4dae-8f91-16f2357d709c|5|BMIVLIND|Bone Marrow Involvement Indicator|KUKER LYMPHOMA 2005|[?]|cs|CYTOGENETIC PR|1|10^6 copies/mL|VENTILATION PERFUSION LUNG SCAN||||PROXY|ADJUDICATOR 1|Y|3|Visit_3|40|2|SCREENING|2021-01-06|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-16|P1Y2M10DT2H30M|BEFORE|2020-12-20|BEFORE|2020-12-25
e|RS|f50537d2-e098-4dae-8f91-16f2357d709c|6|MRDIND|Minimal Residual Disease Indicator|HAMAOKA BREAST CANCER 2010|[?]|mm|UNEQUIVOCAL|1|mmol/kg|PALPATION|Y|||CLINICAL STUDY SPONSOR|ADJUDICATOR 3|N|3|Visit_3|40|2|TREATMENT|2021-01-06|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-16|P1Y2M10DT2H30M|AFTER|2021-02-20|BEFORE|2021-03-05
e|RS|f50537d2-e098-4dae-8f91-16f2357d709c|7|HEMARESP|Hematologic Response|PCWG SCHER PROSTATE CANCER 2016|[?]|mL/h|NON-CR/NON-PD|1|gtt|PERFUSION MRI||||CLINICAL STUDY SPONSOR|RATER 1|Y|4|Visit_4|65|1|TREATMENT|2021-01-31|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-28|P1Y2M10DT2H30M|BEFORE|2021-02-28|BEFORE|2021-03-01
e|RS|f50537d2-e098-4dae-8f91-16f2357d709c|8|LIVRRESP|Liver Response|CHESON MALIGNANT LYMPHOMA 2007|||NON-iCR/NON-iUPD|1|U/g/day|TRIPLE-PHASE SPIRAL CT SCAN|||Y|CLINICAL RESEARCH ASSOCIATE|CLINICAL PATHOLOGIST|NA|4|Visit_4|65|1|SCREENING|2021-01-31|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-28|P1Y2M10DT2H30M|UNKNOWN|2020-12-16|COINCIDENT|2020-12-31
e|RS|f50537d2-e098-4dae-8f91-16f2357d709c|9|HEMARESP|Hematologic Response|SHINDOH COLORECTAL CANCER 2013|[?]|mg/h|MRD PERSISTENCE|1|Bq/ug|ORCHIDOMETERY||||VENDOR|ADJUDICATOR 2|Y|5|Visit_5|90|4|TREATMENT|2021-02-25|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-02|P1Y2M10DT2H30M|BEFORE|2021-02-22|AFTER|2021-03-04
e|RS|f50537d2-e098-4dae-8f91-16f2357d709c|10|TMRESP|Tumor Marker Response|PRINCE TCELL LYMPHOMA 2010|||MINOR PATHOLOGIC RESPONSE|1|/VF|MICROARRAY|||Y|ADJUDICATION COMMITTEE|NEUROLOGIST|N|5|Visit_5|90|3|TREATMENT|2021-02-25|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-02|P1Y2M10DT2H30M|UNKNOWN|2021-03-05|COINCIDENT|2021-03-06
e|RS|7fedb0fd-d2ff-434c-9208-ffabb26d1a98|1|NEWLWIND|New Lesion Worsening Indicator|RANO|||sCR|1|CUP|EIA|||Y|HEALTH CARE PROFESSIONAL|RADIOLOGIST|U|1|Visit_1|10|2|TREATMENT|2020-07-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-02|P1Y2M10DT2H30M|COINCIDENT|2020-07-28|AFTER|2020-08-11
e|RS|7fedb0fd-d2ff-434c-9208-ffabb26d1a98|2|MNPTHIND|Minor Pathological Response Indicator|CHOI GIST 2008|[?]|pg/cell|NON-QUANTIFIABLE MRD POSITIVITY|1|mL/100g/min|ENZYMATIC ULTRACENTRIFUGATION||||DOMESTIC PARTNER|ADJUDICATOR 3|N|1|Visit_1|10|6|WASHOUT|2020-07-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-02|P1Y2M10DT2H30M|UNKNOWN|2020-08-12|COINCIDENT|2020-08-16
e|RS|7fedb0fd-d2ff-434c-9208-ffabb26d1a98|3|MRDIND|Minimal Residual Disease Indicator|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|/mm2|cPR|1|U/kg/min|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN||||CHILD|FORENSIC PATHOLOGIST|Y|2|Visit_2|25|4|TREATMENT|2020-08-03|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-25|P1Y2M10DT2H30M|AFTER|2020-08-27|COINCIDENT|2020-10-06
e|RS|7fedb0fd-d2ff-434c-9208-ffabb26d1a98|4|BESTRESP|Best Overall Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|DDU|MORPHOLOGIC LEUKEMIA-FREE STATE|1|Osm|NUCLEAR RADIOLOGY|Y|||INVESTIGATOR|NEUROLOGIST 2|NA|2|Visit_2|25|1|TREATMENT|2020-08-03|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-25|P1Y2M10DT2H30M|COINCIDENT|2020-08-29|AFTER|2020-09-21
e|RS|7fedb0fd-d2ff-434c-9208-ffabb26d1a98|5|HEMARESP|Hematologic Response|BURCOMBE BREAST CANCER 2005|[?]|TRACE|NON-QUANTIFIABLE MRD POSITIVITY|1|POINT|IRON HEMATOXYLIN STAIN|Y|||ADJUDICATION COMMITTEE|READER 1|Y|3|Visit_3|40|4|TREATMENT|2020-08-18|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-30|P1Y2M10DT2H30M|BEFORE|2020-07-23|AFTER|2020-07-26
e|RS|7fedb0fd-d2ff-434c-9208-ffabb26d1a98|6|PATHRESP|Pathologic Response|PCWG SCHER PROSTATE CANCER 2016|[?]|mPa|SMD|1|10^6 organisms|OSCILLOMETRY||||INVESTIGATOR|PATHOLOGIST|NA|3|Visit_3|40|3|TREATMENT|2020-08-18|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-30|P1Y2M10DT2H30M|UNKNOWN|2020-09-07|ONGOING|2020-09-09
e|RS|7fedb0fd-d2ff-434c-9208-ffabb26d1a98|7|HEMARESP|Hematologic Response|iRECIST|||SD|1|ug/mL/h|CONTRAST ENHANCED MRI||Y|Y|DOMESTIC PARTNER|PATHOLOGIST 1|Y|4|Visit_4|65|3|FOLLOW-UP|2020-09-12|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-21|P1Y2M10DT2H30M|UNKNOWN|2020-09-27|COINCIDENT|2020-10-16
e|RS|7fedb0fd-d2ff-434c-9208-ffabb26d1a98|8|TRGRESP|Target Response|IRANO 2015|[?]|BAG|iPR|1|log EID 50/dose|MASS SPECTROMETRY||||INTERVIEWER|RATER|NA|4|Visit_4|65|1|WASHOUT|2020-09-12|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-21|P1Y2M10DT2H30M|UNKNOWN|2020-08-05|BEFORE|2020-09-19
e|RS|7fedb0fd-d2ff-434c-9208-ffabb26d1a98|9|CPRFSTAT|Clinical Performance Status|HARTMANN GERM CELL CANCER 2002|[?]|10^6 organisms/mL|COMPLETE MRD RESPONSE|1|umol/day|ELLA||||STUDY SUBJECT|CARDIOLOGIST|Y|5|Visit_5|90|4|TREATMENT|2020-10-07|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-20|P1Y2M10DT2H30M|COINCIDENT|2020-08-04|AFTER|2020-09-22
e|RS|7fedb0fd-d2ff-434c-9208-ffabb26d1a98|10|MOLRESP|Molecular Response|LEE LUNG CANCER 2011|[?]|Bq/kg|IMMUNOPHENOTYPIC CR|1|POUCH|ATOMIC ABSORPTION SPECTROMETRY|Y|Y||GUARDIAN|PHYSIOTHERAPIST|Y|5|Visit_5|90|4|TREATMENT|2020-10-07|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-20|P1Y2M10DT2H30M|UNKNOWN|2020-10-15|COINCIDENT|2020-10-16
e|RS|489870ed-9da5-4df6-a5ef-17821c449c84|1|DRCRIND|Disease Recurrence Indicator|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|||cPR|1|cs|ZIEHL NEELSEN ACID FAST STAIN|||Y|GUARDIAN|MICROSCOPIST 1|N|1|Visit_1|10|6|TREATMENT|2020-07-30|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-12|P1Y2M10DT2H30M|BEFORE|2020-08-18|AFTER|2020-10-01
e|RS|489870ed-9da5-4df6-a5ef-17821c449c84|2|CLINRESP|Clinical Response|CHESON CLL 2006|[?]|ELISA unit/dose|PD FROM PR|1|IU/dL|ECHOCARDIOGRAPHY||||NON-HEALTH CARE PROFESSIONAL|READER 3|Y|1|Visit_1|10|7|FOLLOW-UP|2020-07-30|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-12|P1Y2M10DT2H30M|COINCIDENT|2020-08-20|BEFORE|2020-10-09
e|RS|489870ed-9da5-4df6-a5ef-17821c449c84|3|DRCRIND|Disease Recurrence Indicator|RECIST 1.0|[?]|umol|TREATMENT FAILURE|1|GBq/g|PHASE CONTRAST MICROSCOPY||||INTERVIEWER|RATER 2|Y|2|Visit_2|25|2|SCREENING|2020-08-14|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-20|P1Y2M10DT2H30M|COINCIDENT|2020-08-28|ONGOING|2020-09-10
e|RS|489870ed-9da5-4df6-a5ef-17821c449c84|4|DRCRIND|Disease Recurrence Indicator|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|g/m2|MORPHOLOGIC CRi|1|Sv|ACID FAST STAIN||||INTERVIEWER|ADJUDICATOR 3|U|2|Visit_2|25|3|SCREENING|2020-08-14|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-20|P1Y2M10DT2H30M|BEFORE|2020-08-14|ONGOING|2020-09-19
e|RS|489870ed-9da5-4df6-a5ef-17821c449c84|5|STRUSTAT|Steroid Use Status|RECIST 1.0|[?]|rpm|HI-E|1|kg/mol|ICP-MS||||PARENT|ADJUDICATOR 3|NA|3|Visit_3|40|7|TREATMENT|2020-08-29|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-16|P1Y2M10DT2H30M|BEFORE|2020-07-22|ONGOING|2020-08-12
e|RS|489870ed-9da5-4df6-a5ef-17821c449c84|6|NTLWIND|Non-Target Lesion Worsening Indicator|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|||cCR|1|mEq/L|SINGLE-SLICE SPIRAL CT|||Y|GUARDIAN|ONCOLOGIST 2|NA|3|Visit_3|40|3|TREATMENT|2020-08-29|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-16|P1Y2M10DT2H30M|AFTER|2020-10-17|BEFORE|2020-10-19
e|RS|489870ed-9da5-4df6-a5ef-17821c449c84|7|METBRESP|Metabolic Response|AJCC V7|[?]|um2|HI-E|1|fL|PEAK FLOWMETRY||Y||PARENT|NEUROLOGIST 1|Y|4|Visit_4|65|2|TREATMENT|2020-09-23|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-01|P1Y2M10DT2H30M|UNKNOWN|2020-09-11|ONGOING|2020-09-20
e|RS|489870ed-9da5-4df6-a5ef-17821c449c84|8|LIVRRESP|Liver Response|BRUGGEMANN MRD 2010|[?]|10^7/L|PSA PROGRESSION|1|mEq/day|NUCLEAR RADIOLOGY|Y|||PARENT|PATHOLOGIST|Y|4|Visit_4|65|4|FOLLOW-UP|2020-09-23|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-01|P1Y2M10DT2H30M|AFTER|2020-10-01|COINCIDENT|2020-10-17
e|RS|489870ed-9da5-4df6-a5ef-17821c449c84|9|NEWLIND|New Lesion Indicator|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|/10^5|NE|1|nsec|JAFFE REACTION||||SIBLING|ADJUDICATOR 1|U|5|Visit_5|90|2|WASHOUT|2020-10-18|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-22|P1Y2M10DT2H30M|AFTER|2020-08-19|BEFORE|2020-10-16
e|RS|489870ed-9da5-4df6-a5ef-17821c449c84|10|TMRESP|Tumor Marker Response|DOHNER AML 2010|[?]|kg/cm2|CYTOGENETIC NO RESPONSE|1|PA|IMPULSE OSCILLOMETRY||Y||INTERVIEWER|RATER 1|N|5|Visit_5|90|6|SCREENING|2020-10-18|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-22|P1Y2M10DT2H30M|BEFORE|2020-08-31|COINCIDENT|2020-09-18
e|RS|90fe992f-5a11-4829-b3b0-1c8314f53012|1|MOLRESP|Molecular Response|IRANO 2015|[?]|L/min|NE|1|INHALATION|CHROMOGENIC ASSAY||Y||CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 1|Y|1|Visit_1|10|3|TREATMENT|2020-09-23|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-17|P1Y2M10DT2H30M|COINCIDENT|2020-10-30|AFTER|2020-12-03
e|RS|90fe992f-5a11-4829-b3b0-1c8314f53012|2|NTRGRESP|Non-target Response|HARTMANN GERM CELL CANCER 2002|[?]|10^3 copies/mL|PDu|1|nmol|SLIT LAMP PHOTOGRAPHY||||DOMESTIC PARTNER|UROLOGIST|N|1|Visit_1|10|1|SCREENING|2020-09-23|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-17|P1Y2M10DT2H30M|UNKNOWN|2020-09-27|ONGOING|2020-10-18
e|RS|90fe992f-5a11-4829-b3b0-1c8314f53012|3|BONERESP|Bone Response|HAMAOKA BREAST CANCER 2010|||CHR|1|mL/breath|PERIPHERAL ANGIOGRAPHY|||Y|ADJUDICATOR|PHYSIOTHERAPIST|NA|2|Visit_2|25|5|TREATMENT|2020-10-08|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-12|P1Y2M10DT2H30M|UNKNOWN|2020-11-22|BEFORE|2020-12-11
e|RS|90fe992f-5a11-4829-b3b0-1c8314f53012|4|SPLNRESP|Spleen Response|GUILHOT CML 2007|[?]|FFU|CRi|1|cL|IMMUNODIFFUSION||Y||FRIEND|ADJUDICATOR|N|2|Visit_2|25|2|TREATMENT|2020-10-08|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-12|P1Y2M10DT2H30M|AFTER|2020-12-09|ONGOING|2020-12-21
e|RS|90fe992f-5a11-4829-b3b0-1c8314f53012|5|METSIND|Metastatic Indicator|SCHWARZ CERVICAL CANCER 2009|[?]|10^8/L|OPTIMAL MORPHOLOGIC RESPONSE|1|100 IU/mL|RADIOGRAPHY||||SPOUSE|INTERNIST|U|3|Visit_3|40|5|TREATMENT|2020-10-23|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-04|P1Y2M10DT2H30M|UNKNOWN|2020-09-19|ONGOING|2020-11-09
e|RS|90fe992f-5a11-4829-b3b0-1c8314f53012|6|PATHRESP|Pathologic Response|RANO ELLINGSON 2017|[?]|kBq/uL|CA125 75% RESPONSE|1|10^6 CFU/g|NEURAMINIDASE INHIBITION ASSAY||||INDEPENDENT ASSESSOR|OPHTHALMOLOGIST|N|3|Visit_3|40|6|TREATMENT|2020-10-23|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-04|P1Y2M10DT2H30M|BEFORE|2020-11-08|ONGOING|2020-11-23
e|RS|90fe992f-5a11-4829-b3b0-1c8314f53012|7|BMIVLIND|Bone Marrow Involvement Indicator|PALUMBO MULTIPLE MYELOMA 2009|||iPR|1|MPL U|JAEGER EYE CHART|Y||Y|SIGNIFICANT OTHER|ADJUDICATOR|U|4|Visit_4|65|2|FOLLOW-UP|2020-11-17|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-04|P1Y2M10DT2H30M|BEFORE|2020-11-18|COINCIDENT|2020-11-19
e|RS|90fe992f-5a11-4829-b3b0-1c8314f53012|8|MRPHRESP|Morphologic Response|RANO|[?]|L/s/kPa|COMPLETE MRD RESPONSE|1|titer|ELISA|Y|||CLINICAL RESEARCH COORDINATOR|HEMATOLOGIST|Y|4|Visit_4|65|1|FOLLOW-UP|2020-11-17|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-04|P1Y2M10DT2H30M|UNKNOWN|2020-11-06|BEFORE|2020-12-17
e|RS|90fe992f-5a11-4829-b3b0-1c8314f53012|9|NEWLWIND|New Lesion Worsening Indicator|WOLCHOK SOLID TUMORS 2009|[?]|10^6 organisms/mg|COMPLETE MRD RESPONSE|1|10^3 organisms/g|MACRO BROTH DILUTION||Y||PROXY|CLINICAL PATHOLOGIST|NA|5|Visit_5|90|6|SCREENING|2020-12-12|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-06|P1Y2M10DT2H30M|COINCIDENT|2020-12-06|BEFORE|2020-12-21
e|RS|90fe992f-5a11-4829-b3b0-1c8314f53012|10|MJPTHIND|Major Pathological Response Indicator|EBMT BLADE MYELOMA 1998|[?]|umol/L/min|PR WITH LYMPHOCYTOSIS|1|Ci/kg|FUNCTIONAL MRI|Y|||CLINICAL RESEARCH COORDINATOR|CARDIOLOGIST|NA|5|Visit_5|90|4|TREATMENT|2020-12-12|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-06|P1Y2M10DT2H30M|COINCIDENT|2020-11-09|COINCIDENT|2020-12-10
e|RS|74be8de0-3307-4cc3-9044-05068b60f7e0|1|TMRESP|Tumor Marker Response|CHOI GIST 2008|[?]|RATIO|CR|1|IU/mL|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION||||INVESTIGATOR|MICROSCOPIST 2|N|1|Visit_1|10|7|WASHOUT|2020-10-20|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-17|P1Y2M10DT2H30M|COINCIDENT|2020-11-10|BEFORE|2020-12-27
e|RS|74be8de0-3307-4cc3-9044-05068b60f7e0|2|NEWLWIND|New Lesion Worsening Indicator|GUILHOT CML 2007|||QUANTIFIABLE MRD POSITIVITY|1|DAgU|ICP-MS|Y|Y|Y|CLINICAL STUDY SPONSOR|MICROSCOPIST 2|U|1|Visit_1|10|4|TREATMENT|2020-10-20|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-17|P1Y2M10DT2H30M|AFTER|2020-11-16|BEFORE|2020-12-14
e|RS|74be8de0-3307-4cc3-9044-05068b60f7e0|3|METSIND|Metastatic Indicator|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|||NON-iCR/NON-iUPD|1|ELISA unit|SICKLE CELL SOLUBILITY TEST|||Y|INDEPENDENT ASSESSOR|READER 2|U|2|Visit_2|25|6|TREATMENT|2020-11-04|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-16|P1Y2M10DT2H30M|BEFORE|2021-01-01|COINCIDENT|2021-01-05
e|RS|74be8de0-3307-4cc3-9044-05068b60f7e0|4|DRCRIND|Disease Recurrence Indicator|AJCC V7|[?]|dB|OPTIMAL MORPHOLOGIC RESPONSE|1|POINT|CRYOSCOPY||Y||PROXY|RADIOLOGIST|Y|2|Visit_2|25|6|TREATMENT|2020-11-04|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-16|P1Y2M10DT2H30M|UNKNOWN|2020-12-06|ONGOING|2020-12-18
e|RS|74be8de0-3307-4cc3-9044-05068b60f7e0|5|CLINRESP|Clinical Response|MASS|[?]|mL/min/mmHg|RELAPSED DISEASE FROM CR|1|uL|PERFUSION MRI|Y|||PROXY|RADIOLOGIST 2|N|3|Visit_3|40|1|SCREENING|2020-11-19|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-15|P1Y2M10DT2H30M|COINCIDENT|2020-11-19|COINCIDENT|2020-11-20
e|RS|74be8de0-3307-4cc3-9044-05068b60f7e0|6|NEWLIND|New Lesion Indicator|CHESON LYMPHOMA 2008|[?]|IU/kg|PR WITH LYMPHOCYTOSIS|1|scm|TRYPAN BLUE STAIN||||SIGNIFICANT OTHER|INTERNIST|Y|3|Visit_3|40|7|TREATMENT|2020-11-19|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-15|P1Y2M10DT2H30M|COINCIDENT|2020-11-30|ONGOING|2020-12-10
e|RS|74be8de0-3307-4cc3-9044-05068b60f7e0|7|SYMPTDTR|Symptomatic Deterioration|EUROPEAN LEUKEMIANET BACCARANI CML 2006|||CA125 75% RESPONSE|1|sec|GIEMSA STAIN|Y||Y|GUARDIAN|PHYSIOTHERAPIST|Y|4|Visit_4|65|5|TREATMENT|2020-12-14|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-19|P1Y2M10DT2H30M|AFTER|2020-12-13|COINCIDENT|2021-01-04
e|RS|74be8de0-3307-4cc3-9044-05068b60f7e0|8|MRDRESP|Minimal Residual Disease Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|mCi/L|INDETERMINATE RESPONSE|1|SPRAY|NUCLEIC ACID AMPLIFICATION TEST||Y||FRIEND|RADIOLOGIST 2|Y|4|Visit_4|65|3|FOLLOW-UP|2020-12-14|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-19|P1Y2M10DT2H30M|COINCIDENT|2020-12-24|COINCIDENT|2020-12-31
e|RS|74be8de0-3307-4cc3-9044-05068b60f7e0|9|NTNERESP|Non-Target Non-Enhancing Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|log10 copies/mL|CHR|1|10^7 CFU/mL|NUCLEAR RADIOLOGY|Y|||DOMESTIC PARTNER|OPTOMETRIST|NA|5|Visit_5|90|1|WASHOUT|2021-01-08|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-15|P1Y2M10DT2H30M|UNKNOWN|2020-11-22|ONGOING|2021-01-07
e|RS|74be8de0-3307-4cc3-9044-05068b60f7e0|10|BONERESP|Bone Response|JACINTO CERVICAL CANCER 2007|||PR WITH LYMPHOCYTOSIS|1|ug/dose|HIGH RESOLUTION CT||Y|Y|VENDOR|MICROSCOPIST 2|NA|5|Visit_5|90|4|TREATMENT|2021-01-08|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-15|P1Y2M10DT2H30M|BEFORE|2020-10-28|COINCIDENT|2020-12-16
e|RS|b95317e6-0acc-4be7-9525-4f6ca6cfe0fc|1|DRCRIND|Disease Recurrence Indicator|IWG CHESON AML 2003|[?]|foz_br|MAJOR PATHOLOGIC RESPONSE|1|kBq|LAPAROSCOPY||||HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|U|1|Visit_1|10|6|TREATMENT|2020-06-11|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-20|P1Y2M10DT2H30M|AFTER|2020-06-06|AFTER|2020-06-10
e|RS|b95317e6-0acc-4be7-9525-4f6ca6cfe0fc|2|LIVRRESP|Liver Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|10^6/hpf|MOLECULAR CR|1|ukat|NUCLEIC ACID BASED METHOD||||NON-HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|Y|1|Visit_1|10|4|FOLLOW-UP|2020-06-11|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-20|P1Y2M10DT2H30M|UNKNOWN|2020-07-26|COINCIDENT|2020-08-10
e|RS|b95317e6-0acc-4be7-9525-4f6ca6cfe0fc|3|PATHRESP|Pathologic Response|LEE LUNG CANCER 2011|[?]|mkat|NE|1|uIU/L|ATOMIC ABSORPTION SPECTROMETRY||||SIGNIFICANT OTHER|ONCOLOGIST|N|2|Visit_2|25|4|FOLLOW-UP|2020-06-26|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-07|P1Y2M10DT2H30M|BEFORE|2020-09-04|BEFORE|2020-09-07
e|RS|b95317e6-0acc-4be7-9525-4f6ca6cfe0fc|4|NTLWIND|Non-Target Lesion Worsening Indicator|CHOI GIST 2008|[?]|pmol|NON-QUANTIFIABLE MRD POSITIVITY|1|mL/cage|CT SCAN||||INVESTIGATOR|RADIOLOGIST 1|NA|2|Visit_2|25|1|TREATMENT|2020-06-26|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-07|P1Y2M10DT2H30M|COINCIDENT|2020-06-07|COINCIDENT|2020-07-08
e|RS|b95317e6-0acc-4be7-9525-4f6ca6cfe0fc|5|CYTORESP|Cytogenetic Response|RANO|[?]|ppth|PDu|1|%/min|FLUORESCEIN STAIN||Y||CHILD|READER 1|NA|3|Visit_3|40|4|TREATMENT|2020-07-11|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-06|P1Y2M10DT2H30M|AFTER|2020-07-28|AFTER|2020-08-19
e|RS|b95317e6-0acc-4be7-9525-4f6ca6cfe0fc|6|SFTSRESP|Soft Tissue Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|/h|SD|1|log10 copies/mL|CLAUSS METHOD||Y||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 3|Y|3|Visit_3|40|1|FOLLOW-UP|2020-07-11|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-06|P1Y2M10DT2H30M|AFTER|2020-06-03|BEFORE|2020-06-05
e|RS|b95317e6-0acc-4be7-9525-4f6ca6cfe0fc|7|MRPHRESP|Morphologic Response|RANO ELLINGSON 2017|||CR|1|mol/mol|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY|||Y|STUDY SUBJECT|READER|NA|4|Visit_4|65|1|TREATMENT|2020-08-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-03|P1Y2M10DT2H30M|AFTER|2020-08-19|ONGOING|2020-08-25
e|RS|b95317e6-0acc-4be7-9525-4f6ca6cfe0fc|8|MRDIND|Minimal Residual Disease Indicator|AJCC V8|[?]|dram|MINOR PATHOLOGIC RESPONSE|1|g/g/day|MALDI||||ADJUDICATOR|DERMATOLOGIST|NA|4|Visit_4|65|1|TREATMENT|2020-08-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-03|P1Y2M10DT2H30M|BEFORE|2020-07-06|BEFORE|2020-07-14
e|RS|b95317e6-0acc-4be7-9525-4f6ca6cfe0fc|9|SFTSRESP|Soft Tissue Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|10^9/L|NE|1|genEq/mL|VIRUS PLAQUE ASSAY||||FAMILY MEMBER|ADJUDICATOR 2|Y|5|Visit_5|90|3|FOLLOW-UP|2020-08-30|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-03|P1Y2M10DT2H30M|AFTER|2020-07-23|AFTER|2020-08-25
e|RS|b95317e6-0acc-4be7-9525-4f6ca6cfe0fc|10|NEWLIND|New Lesion Indicator|RECICL|[?]|Ci/g|iCPD|1|DDU|MUGA||Y||PROXY|INTERNIST|Y|5|Visit_5|90|6|FOLLOW-UP|2020-08-30|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-03|P1Y2M10DT2H30M|UNKNOWN|2020-07-27|COINCIDENT|2020-08-26
e|RS|8825b806-fa76-49d7-b281-d36fc42fee1e|1|METBRESP|Metabolic Response|PCWG SCHER PROSTATE CANCER 2016|||cPR|1|kcal|COLORIMETRY|||Y|ADJUDICATOR|ADJUDICATOR 3|N|1|Visit_1|10|1|FOLLOW-UP|2020-08-29|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-26|P1Y2M10DT2H30M|COINCIDENT|2020-10-13|ONGOING|2020-11-03
e|RS|8825b806-fa76-49d7-b281-d36fc42fee1e|2|STRUSTAT|Steroid Use Status|CHESON MALIGNANT LYMPHOMA 2007|[?]|IU/day|RELAPSED DISEASE FROM CR OR PR|1|Gy/h|CELL BASED BIOASSAY|Y|||CAREGIVER|MICROSCOPIST 1|U|1|Visit_1|10|2|TREATMENT|2020-08-29|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-26|P1Y2M10DT2H30M|AFTER|2020-08-21|AFTER|2020-09-14
e|RS|8825b806-fa76-49d7-b281-d36fc42fee1e|3|CLINRESP|Clinical Response|MACDONALD GLIOMA 1990|[?]|vg/dose|WORSENED|1|oz|MICROBIAL CONCENTRATION||||CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 2|N|2|Visit_2|25|1|TREATMENT|2020-09-13|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-11|P1Y2M10DT2H30M|UNKNOWN|2020-10-08|AFTER|2020-11-19
e|RS|8825b806-fa76-49d7-b281-d36fc42fee1e|4|CPRFSTAT|Clinical Performance Status|BLAZER COLORECTAL CANCER 2008|||FAVORABLE RESPONSE|1|log10 copies/mL|MAGNETIC RESONANCE ENTEROGRAPHY|Y||Y|FAMILY MEMBER|ONCOLOGIST 1|N|2|Visit_2|25|1|SCREENING|2020-09-13|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-11|P1Y2M10DT2H30M|COINCIDENT|2020-08-23|ONGOING|2020-09-28
e|RS|8825b806-fa76-49d7-b281-d36fc42fee1e|5|CYTORESP|Cytogenetic Response|MONTSERRAT CLL 1989|[?]|POUCH|MORPHOLOGIC LEUKEMIA-FREE STATE|1|tuberculin unit|POLYMERASE CHAIN REACTION||||DOMESTIC PARTNER|RADIOLOGIST 1|N|3|Visit_3|40|2|TREATMENT|2020-09-28|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-16|P1Y2M10DT2H30M|UNKNOWN|2020-10-16|AFTER|2020-11-01
e|RS|8825b806-fa76-49d7-b281-d36fc42fee1e|6|NTERESP|Non-Target Enhancing Response|CHESON CLL 2012|[?]|nmol/mL/min|NON-PD|1|TRANSDUCING UNIT|MEDIASTINOSCOPY|Y|||ADJUDICATION COMMITTEE|READER 3|U|3|Visit_3|40|4|SCREENING|2020-09-28|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-16|P1Y2M10DT2H30M|BEFORE|2020-09-01|AFTER|2020-10-04
e|RS|8825b806-fa76-49d7-b281-d36fc42fee1e|7|ANATRESP|Anatomic Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|||PD-CT|1|DRINK|CELLULOSE TAPE|||Y|GUARDIAN|MICROSCOPIST|N|4|Visit_4|65|5|WASHOUT|2020-10-23|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-23|P1Y2M10DT2H30M|AFTER|2020-09-27|AFTER|2020-10-29
e|RS|8825b806-fa76-49d7-b281-d36fc42fee1e|8|NEWLPROG|New Lesion Progression|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|Gauss|CMR|1|mm|IMPEDANCE CONDUCTIVITY||Y||FRIEND|ENDOCRINOLOGIST|N|4|Visit_4|65|5|SCREENING|2020-10-23|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-23|P1Y2M10DT2H30M|AFTER|2020-09-23|ONGOING|2020-11-12
e|RS|8825b806-fa76-49d7-b281-d36fc42fee1e|9|NEWLIND|New Lesion Indicator|GUILHOT CML 2007|[?]|kg|HI-P|1|copies/ug|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY||||FAMILY MEMBER|READER|U|5|Visit_5|90|1|FOLLOW-UP|2020-11-17|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-22|P1Y2M10DT2H30M|AFTER|2020-10-20|ONGOING|2020-11-11
e|RS|8825b806-fa76-49d7-b281-d36fc42fee1e|10|PATHRESP|Pathologic Response|RECICL|||CMR|1|IU/g|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY|||Y|PARENT|PATHOLOGIST 2|U|5|Visit_5|90|3|TREATMENT|2020-11-17|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-22|P1Y2M10DT2H30M|AFTER|2020-11-25|BEFORE|2020-11-26
e|RS|c075ec99-ae16-4a7d-b5da-d0f1db78bbac|1|CPRFSTAT|Clinical Performance Status|GUILHOT CML 2007|||cPR|1|fmol|MANUAL COUNT|||Y|VENDOR|RATER 2|N|1|Visit_1|10|7|SCREENING|2020-05-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-05|P1Y2M10DT2H30M|COINCIDENT|2020-06-20|ONGOING|2020-06-30
e|RS|c075ec99-ae16-4a7d-b5da-d0f1db78bbac|2|METBRESP|Metabolic Response|SHINDOH COLORECTAL CANCER 2013|[?]|BEAM BREAKS|CYTOGENETIC PR|1|BLOCKS|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI||Y||INDEPENDENT ASSESSOR|MICROSCOPIST 3|U|1|Visit_1|10|4|TREATMENT|2020-05-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-05|P1Y2M10DT2H30M|UNKNOWN|2020-06-08|ONGOING|2020-08-02
e|RS|c075ec99-ae16-4a7d-b5da-d0f1db78bbac|3|SPLNRESP|Spleen Response|HARTMANN GERM CELL CANCER 2002|[?]|Log10 ELISA unit|CRi|1|/h|TOTAL BODY RADIOGRAPHY||||SIBLING|ENDOCRINOLOGIST|NA|2|Visit_2|25|4|FOLLOW-UP|2020-06-03|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-25|P1Y2M10DT2H30M|UNKNOWN|2020-06-13|ONGOING|2020-07-19
e|RS|c075ec99-ae16-4a7d-b5da-d0f1db78bbac|4|NTERESP|Non-Target Enhancing Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|10^9 CFU/mL|MR|1|mL/kg/min|FLUORESCENCE ANGIOGRAPHY||Y||STUDY SUBJECT|NEUROLOGIST|U|2|Visit_2|25|1|TREATMENT|2020-06-03|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-25|P1Y2M10DT2H30M|UNKNOWN|2020-07-20|COINCIDENT|2020-07-29
e|RS|c075ec99-ae16-4a7d-b5da-d0f1db78bbac|5|SPLNRESP|Spleen Response|LEE LUNG CANCER 2011|[?]|pL|DECREASED|1|uOsm|COLORIMETRY||||NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|Y|3|Visit_3|40|4|FOLLOW-UP|2020-06-18|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-06|P1Y2M10DT2H30M|UNKNOWN|2020-05-27|AFTER|2020-08-14
e|RS|c075ec99-ae16-4a7d-b5da-d0f1db78bbac|6|CPRFSTAT|Clinical Performance Status|KUKER LYMPHOMA 2005|[?]|IU/kg|HI-N|1|mg/cm2|JAFFE REACTION|Y|||CLINICAL RESEARCH COORDINATOR|RATER 1|NA|3|Visit_3|40|1|FOLLOW-UP|2020-06-18|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-06|P1Y2M10DT2H30M|BEFORE|2020-07-12|COINCIDENT|2020-08-05
e|RS|c075ec99-ae16-4a7d-b5da-d0f1db78bbac|7|SFTSRESP|Soft Tissue Response|PETIT BREAST CANCER 2001|[?]|dyn|MOLECULAR MAJOR RESPONSE|1|uOsm|FLUORESCENT SPOT TEST||||CAREGIVER|MICROSCOPIST 1|NA|4|Visit_4|65|4|TREATMENT|2020-07-13|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-29|P1Y2M10DT2H30M|UNKNOWN|2020-06-01|ONGOING|2020-06-21
e|RS|c075ec99-ae16-4a7d-b5da-d0f1db78bbac|8|LIVRRESP|Liver Response|iRECIST|||CA125 75% RESPONSE|1|mL/(min*100mL)|PHASE CONTRAST MICROSCOPY||Y|Y|DOMESTIC PARTNER|ENDOCRINOLOGIST|NA|4|Visit_4|65|6|SCREENING|2020-07-13|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-29|P1Y2M10DT2H30M|COINCIDENT|2020-06-27|AFTER|2020-07-21
e|RS|c075ec99-ae16-4a7d-b5da-d0f1db78bbac|9|METSIND|Metastatic Indicator|BRUGGEMANN MRD 2010|[?]|Frames/s|CA125 50% RESPONSE|1|L/h|BETA LACTAMASE||||INDEPENDENT ASSESSOR|MICROSCOPIST 3|NA|5|Visit_5|90|4|TREATMENT|2020-08-07|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-30|P1Y2M10DT2H30M|UNKNOWN|2020-07-27|COINCIDENT|2020-08-11
e|RS|c075ec99-ae16-4a7d-b5da-d0f1db78bbac|10|OVRLRESP|Overall Response|LUGANO CLASSIFICATION|||NON-QUANTIFIABLE MRD POSITIVITY|1|titer|DNA MICROARRAY|||Y|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 3|U|5|Visit_5|90|7|WASHOUT|2020-08-07|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-30|P1Y2M10DT2H30M|AFTER|2020-05-19|BEFORE|2020-08-08
e|RS|def2ec82-35be-4ef5-a1fd-a7212b2d1a1e|1|CLINRESP|Clinical Response|WHO BREAST CANCER 2006|[?]|/2000 RBC|NON-PD|1|log10 TCID 50/dose|TOTAL BODY RADIOGRAPHY||||GUARDIAN|ADJUDICATOR 3|U|1|Visit_1|10|4|TREATMENT|2021-01-14|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-08|P1Y2M10DT2H30M|BEFORE|2021-03-03|COINCIDENT|2021-03-16
e|RS|def2ec82-35be-4ef5-a1fd-a7212b2d1a1e|2|OVRLRESP|Overall Response|PETIT BREAST CANCER 2001|[?]|m3|CA125 50% RESPONSE|1|pg|IMMUNOFIXATION ELECTROPHORESIS||||INTERVIEWER|RADIOLOGIST 1|NA|1|Visit_1|10|3|TREATMENT|2021-01-14|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-08|P1Y2M10DT2H30M|COINCIDENT|2021-01-24|AFTER|2021-04-10
e|RS|def2ec82-35be-4ef5-a1fd-a7212b2d1a1e|3|BMIVLIND|Bone Marrow Involvement Indicator|MRECIST LENCIONI LIVER CANCER 2010|||PD FROM PR|1|umol/mol|CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY||Y|Y|HEALTH CARE PROFESSIONAL|RATER 2|U|2|Visit_2|25|4|TREATMENT|2021-01-29|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-08|P1Y2M10DT2H30M|BEFORE|2021-04-11|ONGOING|2021-04-12
e|RS|def2ec82-35be-4ef5-a1fd-a7212b2d1a1e|4|METBRESP|Metabolic Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|Ci/L|MORPHOLOGIC CR|1|mg/kg/h|DC SHEATH FLOW||Y||FRIEND|PHYSIOTHERAPIST|NA|2|Visit_2|25|5|FOLLOW-UP|2021-01-29|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-08|P1Y2M10DT2H30M|UNKNOWN|2021-02-07|ONGOING|2021-03-24
e|RS|def2ec82-35be-4ef5-a1fd-a7212b2d1a1e|5|MRDRESP|Minimal Residual Disease Response|LEE LUNG CANCER 2011|[?]|umol/h/mmol|MR|1|copies/ug|KINETIC CHROMOGENIC ASSAY||||SIBLING|OTOLARYNGOLOGIST|Y|3|Visit_3|40|4|SCREENING|2021-02-13|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-17|P1Y2M10DT2H30M|COINCIDENT|2021-01-23|AFTER|2021-04-06
e|RS|def2ec82-35be-4ef5-a1fd-a7212b2d1a1e|6|NTNERESP|Non-Target Non-Enhancing Response|RECIST 1.1|||PSEUDORESPONSE|1|10^3 CFU|LASER CAPTURE MICRODISSECTION|Y||Y|PROXY|READER 1|NA|3|Visit_3|40|3|TREATMENT|2021-02-13|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-17|P1Y2M10DT2H30M|UNKNOWN|2021-01-31|AFTER|2021-03-02
e|RS|def2ec82-35be-4ef5-a1fd-a7212b2d1a1e|7|NTNERESP|Non-Target Non-Enhancing Response|CHESON CLL 2006|||CHR|1|mm2|DIFFUSION WEIGHTED MRI|||Y|STUDY SUBJECT|RATER|U|4|Visit_4|65|6|WASHOUT|2021-03-10|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-24|P1Y2M10DT2H30M|COINCIDENT|2021-01-09|BEFORE|2021-03-03
e|RS|def2ec82-35be-4ef5-a1fd-a7212b2d1a1e|8|HEMARESP|Hematologic Response|MASS|[?]|10^7 PFU|CYTOGENETIC PR|1|um|FREEZING POINT DEPRESSION||||GUARDIAN|PATHOLOGIST|U|4|Visit_4|65|2|TREATMENT|2021-03-10|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-24|P1Y2M10DT2H30M|UNKNOWN|2021-04-08|COINCIDENT|2021-04-11
e|RS|def2ec82-35be-4ef5-a1fd-a7212b2d1a1e|9|HEMARESP|Hematologic Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|mgEq|COMPLETE MRD RESPONSE|1|mU|ALCIAN BLUE STAIN||||CAREGIVER|ONCOLOGIST|U|5|Visit_5|90|3|TREATMENT|2021-04-04|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-13|P1Y2M10DT2H30M|BEFORE|2021-01-24|COINCIDENT|2021-02-11
e|RS|def2ec82-35be-4ef5-a1fd-a7212b2d1a1e|10|MJPTHIND|Major Pathological Response Indicator|PRINCE TCELL LYMPHOMA 2010|[?]|mol/mol|CYTOGENETIC PR|1|Linear ft*LB|LC/MS/MS||||GUARDIAN|MICROSCOPIST|N|5|Visit_5|90|3|SCREENING|2021-04-04|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-13|P1Y2M10DT2H30M|BEFORE|2021-02-17|COINCIDENT|2021-04-13
e|RS|b36220d8-c129-48bf-8c41-542a954b819a|1|CLINRESP|Clinical Response|LEE LUNG CANCER 2011|[?]|g/day|NON-QUANTIFIABLE MRD POSITIVITY|1|dB|ZIEHL NEELSEN ACID FAST STAIN||Y||INTERVIEWER|MICROSCOPIST 1|U|1|Visit_1|10|6|FOLLOW-UP|2020-05-24|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-21|P1Y2M10DT2H30M|UNKNOWN|2020-07-13|COINCIDENT|2020-07-18
e|RS|b36220d8-c129-48bf-8c41-542a954b819a|2|OVRLRESP|Overall Response|IWC HALLEK CLL 2008|||UNFAVORABLE RESPONSE|1|RNA copies/mL|LANDOLT RING||Y|Y|ADJUDICATOR|DEVELOPMENTAL PSYCHOLOGIST|NA|1|Visit_1|10|7|TREATMENT|2020-05-24|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-21|P1Y2M10DT2H30M|UNKNOWN|2020-07-08|AFTER|2020-08-05
e|RS|b36220d8-c129-48bf-8c41-542a954b819a|3|TMRESP|Tumor Marker Response|MACDONALD GLIOMA 1990|[?]|mL/kg/h|CYTOGENETIC NO RESPONSE|1|sec|CONTRAST ENHANCED PET/CT SCAN|Y|Y||NON-HEALTH CARE PROFESSIONAL|RATER 2|Y|2|Visit_2|25|2|WASHOUT|2020-06-08|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-26|P1Y2M10DT2H30M|AFTER|2020-07-19|AFTER|2020-07-25
e|RS|b36220d8-c129-48bf-8c41-542a954b819a|4|STRUSTAT|Steroid Use Status|SCHER PROSTATE CANCER 2011|[?]|m3|MOLECULAR CR|1|g/g/day|CONGO RED STAIN|Y|||PROXY|ADJUDICATOR 3|U|2|Visit_2|25|5|TREATMENT|2020-06-08|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-26|P1Y2M10DT2H30M|UNKNOWN|2020-08-15|ONGOING|2020-08-19
e|RS|b36220d8-c129-48bf-8c41-542a954b819a|5|METSIND|Metastatic Indicator|MASS|[?]|Ci|HI-P|1|MHz|PH METER MEASUREMENT METHOD||||SIBLING|MICROSCOPIST|N|3|Visit_3|40|1|TREATMENT|2020-06-23|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-17|P1Y2M10DT2H30M|BEFORE|2020-07-28|BEFORE|2020-08-12
e|RS|b36220d8-c129-48bf-8c41-542a954b819a|6|STRUSTAT|Steroid Use Status|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|KIT|COMPLETE MRD RESPONSE|1|Siemens|ATOMIC ABSORPTION SPECTROMETRY||||FRIEND|READER 1|Y|3|Visit_3|40|2|TREATMENT|2020-06-23|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-17|P1Y2M10DT2H30M|UNKNOWN|2020-07-14|ONGOING|2020-08-20
e|RS|b36220d8-c129-48bf-8c41-542a954b819a|7|MNPTHIND|Minor Pathological Response Indicator|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|/LSQN|PR-CT|1|umol/mg/min|DIGITAL PCR|Y|Y||PROXY|PEDIATRIC NEUROLOGIST|Y|4|Visit_4|65|3|WASHOUT|2020-07-18|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-22|P1Y2M10DT2H30M|UNKNOWN|2020-07-25|ONGOING|2020-07-29
e|RS|b36220d8-c129-48bf-8c41-542a954b819a|8|NEWLWIND|New Lesion Worsening Indicator|AJCC V8|[?]|copies/uL|RELAPSED DISEASE FROM CR|1|pmol/10^10 cells|SEQUENCING|Y|||DOMESTIC PARTNER|PEDIATRIC NEUROLOGIST|Y|4|Visit_4|65|1|SCREENING|2020-07-18|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-22|P1Y2M10DT2H30M|AFTER|2020-07-24|BEFORE|2020-07-25
e|RS|b36220d8-c129-48bf-8c41-542a954b819a|9|TMRESP|Tumor Marker Response|LEE LUNG CANCER 2011|[?]|mPa|HI-N|1|U/10^12 RBC|JAFFE REACTION||||SIBLING|RATER|N|5|Visit_5|90|5|TREATMENT|2020-08-12|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-03|P1Y2M10DT2H30M|AFTER|2020-05-31|ONGOING|2020-06-15
e|RS|b36220d8-c129-48bf-8c41-542a954b819a|10|CPRFSTAT|Clinical Performance Status|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|/kg|INDETERMINATE RESPONSE|1|s/h|IODINE STAIN|Y|||DOMESTIC PARTNER|ENDOCRINOLOGIST|N|5|Visit_5|90|7|WASHOUT|2020-08-12|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-03|P1Y2M10DT2H30M|BEFORE|2020-08-14|COINCIDENT|2020-08-18
e|RS|92d3477b-7460-4ce8-b237-38ca4c55fc91|1|STRUSTAT|Steroid Use Status|FAROOQUI SUPP CLL 2014|[?]|U/m2/day|CA125 75% RESPONSE|1|TAMPON|DROPLET DIGITAL PCR||||CLINICAL STUDY SPONSOR|ADJUDICATOR 1|NA|1|Visit_1|10|7|SCREENING|2020-08-14|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-27|P1Y2M10DT2H30M|AFTER|2020-09-03|AFTER|2020-09-28
e|RS|92d3477b-7460-4ce8-b237-38ca4c55fc91|2|NTRGRESP|Non-target Response|RANO ELLINGSON 2017|[?]|U/cL|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|mL/kg/min|PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY||||PROXY|PHYSIOTHERAPIST|NA|1|Visit_1|10|1|FOLLOW-UP|2020-08-14|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-27|P1Y2M10DT2H30M|AFTER|2020-10-09|BEFORE|2020-10-11
e|RS|92d3477b-7460-4ce8-b237-38ca4c55fc91|3|STRUSTAT|Steroid Use Status|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|um/s|OPTIMAL MORPHOLOGIC RESPONSE|1|PRESSOR UNITS|MICRONEUTRALIZATION ASSAY||||INTERVIEWER|ADJUDICATOR 1|NA|2|Visit_2|25|2|FOLLOW-UP|2020-08-29|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-06|P1Y2M10DT2H30M|AFTER|2020-08-29|AFTER|2020-11-10
e|RS|92d3477b-7460-4ce8-b237-38ca4c55fc91|4|SFTSRESP|Soft Tissue Response|BRUGGEMANN MRD 2010|[?]|ug/g/h|PD/RELAPSE AFTER HI|1|mL/dose|KINETIC MICROPARTICLE IMMUNOASSAY||Y||NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|Y|2|Visit_2|25|6|TREATMENT|2020-08-29|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-06|P1Y2M10DT2H30M|COINCIDENT|2020-08-30|COINCIDENT|2020-09-12
e|RS|92d3477b-7460-4ce8-b237-38ca4c55fc91|5|BMIVLIND|Bone Marrow Involvement Indicator|BLAZER COLORECTAL CANCER 2008|||INDETERMINATE RESPONSE|1|uL|DROPLET DIGITAL PCR|Y||Y|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|Y|3|Visit_3|40|3|TREATMENT|2020-09-13|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-10|P1Y2M10DT2H30M|AFTER|2020-10-14|COINCIDENT|2020-10-21
e|RS|92d3477b-7460-4ce8-b237-38ca4c55fc91|6|NEWLIND|New Lesion Indicator|IWC HALLEK CLL 2008|[?]|10^5/L|MORPHOLOGIC LEUKEMIA-FREE STATE|1|U/kg/day|CYSTOSCOPY||||VENDOR|READER 3|Y|3|Visit_3|40|6|TREATMENT|2020-09-13|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-10|P1Y2M10DT2H30M|COINCIDENT|2020-10-02|COINCIDENT|2020-11-11
e|RS|92d3477b-7460-4ce8-b237-38ca4c55fc91|7|NEWLIND|New Lesion Indicator|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|mL/g/h|nPR|1|keV|DNA MICROARRAY||||INVESTIGATOR|PATHOLOGIST 1|Y|4|Visit_4|65|5|TREATMENT|2020-10-08|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-11|P1Y2M10DT2H30M|UNKNOWN|2020-09-22|AFTER|2020-10-02
e|RS|92d3477b-7460-4ce8-b237-38ca4c55fc91|8|BESTRESP|Best Overall Response|MRECIST LENCIONI LIVER CANCER 2010|||NED|1|deg2|CONTRAST ENHANCED X-RAY||Y|Y|CLINICAL STUDY SPONSOR|OPHTHALMOLOGIST|Y|4|Visit_4|65|5|TREATMENT|2020-10-08|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-11|P1Y2M10DT2H30M|BEFORE|2020-08-12|BEFORE|2020-11-01
e|RS|92d3477b-7460-4ce8-b237-38ca4c55fc91|9|STRUSTAT|Steroid Use Status|UNSPECIFIED|||MOLECULAR MAJOR RESPONSE|1|LOZENGE|PET/MRI SCAN|||Y|GUARDIAN|READER|U|5|Visit_5|90|4|TREATMENT|2020-11-02|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-07|P1Y2M10DT2H30M|BEFORE|2020-09-15|ONGOING|2020-09-22
e|RS|92d3477b-7460-4ce8-b237-38ca4c55fc91|10|MOLRESP|Molecular Response|FAROOQUI SUPP CLL 2014|[?]|pmol/g|VGPR|1|steps/min|MEDIASTINOSCOPY|Y|||CAREGIVER|CARDIOLOGIST|N|5|Visit_5|90|4|FOLLOW-UP|2020-11-02|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-07|P1Y2M10DT2H30M|COINCIDENT|2020-09-15|BEFORE|2020-10-01
e|RS|62b4fc8f-517b-4fa2-ac96-2420934bfd7d|1|BONERESP|Bone Response|HARTMAN PANCREATIC CANCER 2012|||NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|uV*sec|CELL CYTOTOXICITY NEUTRALIZATION ASSAY|||Y|SPOUSE|RATER 1|U|1|Visit_1|10|1|SCREENING|2020-12-16|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-10|P1Y2M10DT2H30M|UNKNOWN|2021-02-16|COINCIDENT|2021-02-27
e|RS|62b4fc8f-517b-4fa2-ac96-2420934bfd7d|2|SFTSRESP|Soft Tissue Response|FAROOQUI SUPP CLL 2014|[?]|Ci/mL|MR|1|ug/m2/day|CORONARY ANGIOGRAPHY|Y|||SPOUSE|MICROSCOPIST 3|Y|1|Visit_1|10|4|TREATMENT|2020-12-16|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-10|P1Y2M10DT2H30M|BEFORE|2021-02-13|ONGOING|2021-02-21
e|RS|62b4fc8f-517b-4fa2-ac96-2420934bfd7d|3|OVRLRESP|Overall Response|MONTSERRAT CLL 1989|||PARTIAL MORPHOLOGIC RESPONSE|1|cup eq|HIGH RESOLUTION CT|||Y|CHILD|ADJUDICATOR 1|NA|2|Visit_2|25|5|TREATMENT|2020-12-31|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-13|P1Y2M10DT2H30M|UNKNOWN|2021-02-28|COINCIDENT|2021-03-10
e|RS|62b4fc8f-517b-4fa2-ac96-2420934bfd7d|4|METSIND|Metastatic Indicator|SHINDOH COLORECTAL CANCER 2013|[?]|MET*h|PSA PROGRESSION|1|mmHg|IMMUNORADIOMETRIC ASSAY||||CHILD|ONCOLOGIST|Y|2|Visit_2|25|5|TREATMENT|2020-12-31|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-13|P1Y2M10DT2H30M|BEFORE|2020-12-18|BEFORE|2021-01-09
e|RS|62b4fc8f-517b-4fa2-ac96-2420934bfd7d|5|METBRESP|Metabolic Response|RECIST 1.1|||pCR|1|cg|ACCELERATOR MASS SPECTROMETRY|||Y|FAMILY MEMBER|CARDIOLOGIST|Y|3|Visit_3|40|3|TREATMENT|2021-01-15|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-14|P1Y2M10DT2H30M|BEFORE|2021-03-11|COINCIDENT|2021-03-12
e|RS|62b4fc8f-517b-4fa2-ac96-2420934bfd7d|6|NEWLWIND|New Lesion Worsening Indicator|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|anti-Xa IU|CYTOGENETIC PR|1|cL|AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT||||CLINICAL RESEARCH ASSOCIATE|FORENSIC PATHOLOGIST|NA|3|Visit_3|40|3|TREATMENT|2021-01-15|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-14|P1Y2M10DT2H30M|UNKNOWN|2020-12-10|COINCIDENT|2021-02-26
e|RS|62b4fc8f-517b-4fa2-ac96-2420934bfd7d|7|NEWLIND|New Lesion Indicator|MRECIST LENCIONI LIVER CANCER 2010|[?]|vg/mL|CR|1|IU/g Hb|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY||||CAREGIVER|UROLOGIST|N|4|Visit_4|65|4|SCREENING|2021-02-09|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-26|P1Y2M10DT2H30M|UNKNOWN|2021-01-10|COINCIDENT|2021-02-22
e|RS|62b4fc8f-517b-4fa2-ac96-2420934bfd7d|8|CLINRESP|Clinical Response|CHOLLET BREAST CANCER 2002|[?]|usec|PD FROM PR|1|ka_u/dL|PATHOLOGICAL EVALUATION||||CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST|NA|4|Visit_4|65|7|TREATMENT|2021-02-09|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-26|P1Y2M10DT2H30M|BEFORE|2021-01-29|ONGOING|2021-03-15
e|RS|62b4fc8f-517b-4fa2-ac96-2420934bfd7d|9|NEWLPROG|New Lesion Progression|PRINCE TCELL LYMPHOMA 2010|[?]|PACKAGE|UNEQUIVOCAL|1|msec|ANALYTICAL ULTRACENTRIFUGATION||||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST|N|5|Visit_5|90|2|FOLLOW-UP|2021-03-06|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-25|P1Y2M10DT2H30M|COINCIDENT|2021-03-03|ONGOING|2021-03-05
e|RS|62b4fc8f-517b-4fa2-ac96-2420934bfd7d|10|RDIORESP|Radiologic Response|EBMT BLADE MYELOMA 1998|[?]|mL/m2/min|NON-CR/NON-PD|1|Ci/g|SINGLE-SLICE SPIRAL CT||||PROXY|PATHOLOGIST 2|N|5|Visit_5|90|2|TREATMENT|2021-03-06|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-25|P1Y2M10DT2H30M|BEFORE|2021-03-15|COINCIDENT|2021-03-16
e|RS|db13afe0-14f6-445b-869a-b0d9fe87e5b9|1|ANATRESP|Anatomic Response|HAMAOKA BREAST CANCER 2010|||MAJOR PATHOLOGIC RESPONSE|1|mL/breath|RAJI CELL RIA|||Y|INVESTIGATOR|MICROSCOPIST 1|N|1|Visit_1|10|4|SCREENING|2020-08-22|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-18|P1Y2M10DT2H30M|COINCIDENT|2020-10-21|BEFORE|2020-11-13
e|RS|db13afe0-14f6-445b-869a-b0d9fe87e5b9|2|LIVRRESP|Liver Response|HAMAOKA BREAST CANCER 2010|[?]|STEPS|COMPLETE MRD RESPONSE|1|ECL unit|KINETIC CHROMOGENIC ASSAY||||INVESTIGATOR|UROLOGIST|U|1|Visit_1|10|1|FOLLOW-UP|2020-08-22|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-18|P1Y2M10DT2H30M|COINCIDENT|2020-11-18|ONGOING|2020-11-19
e|RS|db13afe0-14f6-445b-869a-b0d9fe87e5b9|3|MNPTHIND|Minor Pathological Response Indicator|MASS|||QUANTIFIABLE MRD POSITIVITY|1|Ci/mL|X-RAY FLUORESCENCE SPECTROMETRY|||Y|ADJUDICATOR|ENDOCRINOLOGIST|N|2|Visit_2|25|1|TREATMENT|2020-09-06|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-07|P1Y2M10DT2H30M|COINCIDENT|2020-09-12|COINCIDENT|2020-10-23
e|RS|db13afe0-14f6-445b-869a-b0d9fe87e5b9|4|RDIORESP|Radiologic Response|EASL BRUIX LIVER CANCER 2001|[?]|U/g/min|iPR|1|10^7 PFU|POPULATION SEQUENCING|Y|||ADJUDICATION COMMITTEE|CLINICAL PATHOLOGIST|Y|2|Visit_2|25|6|FOLLOW-UP|2020-09-06|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-07|P1Y2M10DT2H30M|UNKNOWN|2020-08-29|COINCIDENT|2020-11-13
e|RS|db13afe0-14f6-445b-869a-b0d9fe87e5b9|5|RDIORESP|Radiologic Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|mL/breath|cPR|1|10^7 TCID 50/dose|NUCLEAR RADIOLOGY|Y|||VENDOR|FORENSIC PATHOLOGIST|U|3|Visit_3|40|2|TREATMENT|2020-09-21|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-10|P1Y2M10DT2H30M|BEFORE|2020-09-12|BEFORE|2020-11-03
e|RS|db13afe0-14f6-445b-869a-b0d9fe87e5b9|6|LIVRRESP|Liver Response|PCWG BUBLEY PROSTATE CANCER 1999|||INCREASED|1|kg|LAPAROSCOPY|Y||Y|HEALTH CARE PROFESSIONAL|RADIOLOGIST|N|3|Visit_3|40|5|TREATMENT|2020-09-21|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-10|P1Y2M10DT2H30M|BEFORE|2020-08-23|COINCIDENT|2020-10-29
e|RS|db13afe0-14f6-445b-869a-b0d9fe87e5b9|7|METBRESP|Metabolic Response|RECIST 1.0|[?]|GPL U/mL|CA125 75% RESPONSE|1|YEARS|IODINE STAIN||||ADJUDICATION COMMITTEE|ADJUDICATOR 1|N|4|Visit_4|65|3|TREATMENT|2020-10-16|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-10|P1Y2M10DT2H30M|BEFORE|2020-10-20|COINCIDENT|2020-10-29
e|RS|db13afe0-14f6-445b-869a-b0d9fe87e5b9|8|ANATRESP|Anatomic Response|CHOI GIST 2008|[?]|U/g/min|pCR|1|breaths/min|HPLC||Y||HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|N|4|Visit_4|65|3|FOLLOW-UP|2020-10-16|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-10|P1Y2M10DT2H30M|BEFORE|2020-10-19|COINCIDENT|2020-10-22
e|RS|db13afe0-14f6-445b-869a-b0d9fe87e5b9|9|NTERESP|Non-Target Enhancing Response|HAMAOKA BREAST CANCER 2010|[?]|ug/m2/min|FAVORABLE RESPONSE|1|um2|HEMOCYTOMETRY|Y|||CHILD|CARDIOLOGIST|NA|5|Visit_5|90|1|WASHOUT|2020-11-10|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-23|P1Y2M10DT2H30M|UNKNOWN|2020-08-24|AFTER|2020-11-14
e|RS|db13afe0-14f6-445b-869a-b0d9fe87e5b9|10|MRDIND|Minimal Residual Disease Indicator|CHESON CLL 2012|[?]|g/day|MRD RELAPSE|1|APL U/mL|TOTAL BODY IRRADIATION||||CLINICAL STUDY SPONSOR|NEUROLOGIST 1|U|5|Visit_5|90|7|TREATMENT|2020-11-10|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-23|P1Y2M10DT2H30M|UNKNOWN|2020-11-03|COINCIDENT|2020-11-13
e|RS|3f75a463-1348-4c7f-8b29-7472d29628c8|1|SPLNRESP|Spleen Response|RAJKUMAR MYELOMA 2011|[?]|VIRTUAL PIXEL|CYTOGENETIC MINOR RESPONSE|1|mJoule/cm2|PH METER MEASUREMENT METHOD||||FAMILY MEMBER|ADJUDICATOR|U|1|Visit_1|10|3|TREATMENT|2020-07-12|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-06|P1Y2M10DT2H30M|AFTER|2020-08-23|ONGOING|2020-09-20
e|RS|3f75a463-1348-4c7f-8b29-7472d29628c8|2|MRDIND|Minimal Residual Disease Indicator|WHO BREAST CANCER 2006|[?]|10^9 CFU/g|HI-N|1|TRANSDUCING UNIT|FLOCCULATION, CHARCOAL ENHANCED||||FRIEND|ADJUDICATOR|N|1|Visit_1|10|2|TREATMENT|2020-07-12|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-06|P1Y2M10DT2H30M|BEFORE|2020-08-26|AFTER|2020-09-23
e|RS|3f75a463-1348-4c7f-8b29-7472d29628c8|3|NEWLIND|New Lesion Indicator|LEE LUNG CANCER 2011|||CRi|1|ng/dL|MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING|Y||Y|GUARDIAN|MICROSCOPIST|Y|2|Visit_2|25|3|SCREENING|2020-07-27|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-15|P1Y2M10DT2H30M|AFTER|2020-08-02|BEFORE|2020-09-06
e|RS|3f75a463-1348-4c7f-8b29-7472d29628c8|4|NEWLIND|New Lesion Indicator|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|log10 TCID 50/uL|PD/RELAPSE AFTER HI|1|ka_u/dL|ICC|Y|||ADJUDICATION COMMITTEE|MICROSCOPIST 3|N|2|Visit_2|25|1|SCREENING|2020-07-27|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-15|P1Y2M10DT2H30M|BEFORE|2020-10-03|COINCIDENT|2020-10-09
e|RS|3f75a463-1348-4c7f-8b29-7472d29628c8|5|NEWLPROG|New Lesion Progression|SCHWARZ CERVICAL CANCER 2009|[?]|mEq/mmol|HI-N|1|/7.5 mL|POLYGRAPHY||||PARENT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|3|Visit_3|40|1|WASHOUT|2020-08-11|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-22|P1Y2M10DT2H30M|BEFORE|2020-10-03|COINCIDENT|2020-10-07
e|RS|3f75a463-1348-4c7f-8b29-7472d29628c8|6|NEWLWIND|New Lesion Worsening Indicator|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|APL U|PR|1|PATCH|PET/CT SCAN||||INDEPENDENT ASSESSOR|CARDIOLOGIST|N|3|Visit_3|40|1|WASHOUT|2020-08-11|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-22|P1Y2M10DT2H30M|UNKNOWN|2020-07-22|BEFORE|2020-08-27
e|RS|3f75a463-1348-4c7f-8b29-7472d29628c8|7|CYTORESP|Cytogenetic Response|RAJKUMAR MYELOMA 2011|[?]|Bq/L|CHR|1|Watt|MICROBIAL BIOCHEMICAL IDENTIFICATION||||INVESTIGATOR|PATHOLOGIST 1|Y|4|Visit_4|65|3|TREATMENT|2020-09-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-12|P1Y2M10DT2H30M|COINCIDENT|2020-08-13|AFTER|2020-09-07
e|RS|3f75a463-1348-4c7f-8b29-7472d29628c8|8|STRUSTAT|Steroid Use Status|RAJKUMAR MYELOMA 2011|[?]|dpm/0.5 mL|STABLE|1|deg/s|HEMOCYTOMETRY||||CHILD|MICROSCOPIST 1|NA|4|Visit_4|65|2|TREATMENT|2020-09-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-12|P1Y2M10DT2H30M|AFTER|2020-07-19|COINCIDENT|2020-09-15
e|RS|3f75a463-1348-4c7f-8b29-7472d29628c8|9|METSIND|Metastatic Indicator|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|tsp|DISEASE TRANSFORMATION|1|mL/cm3/min|HPLC/IEX||||CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 1|N|5|Visit_5|90|2|TREATMENT|2020-09-30|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-15|P1Y2M10DT2H30M|UNKNOWN|2020-07-28|AFTER|2020-08-31
e|RS|3f75a463-1348-4c7f-8b29-7472d29628c8|10|PATHRESP|Pathologic Response|PCWG SCHER PROSTATE CANCER 2016|||CYTOGENETIC CR|1|IU/day|POLYSOMNOGRAPHY|Y||Y|STUDY SUBJECT|NEUROLOGIST 2|Y|5|Visit_5|90|5|SCREENING|2020-09-30|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-15|P1Y2M10DT2H30M|AFTER|2020-07-11|ONGOING|2020-07-30
e|RS|d1644413-1ed4-4ac9-b68f-f7ccb3cf6e42|1|BESTRESP|Best Overall Response|RECIST 1.1|||MORPHOLOGIC LEUKEMIA-FREE STATE|1|PNU/mL|CRYOSCOPY|||Y|SIBLING|RADIOLOGIST|NA|1|Visit_1|10|1|TREATMENT|2021-01-30|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-15|P1Y2M10DT2H30M|UNKNOWN|2021-04-17|ONGOING|2021-04-25
e|RS|d1644413-1ed4-4ac9-b68f-f7ccb3cf6e42|2|MNPTHIND|Minor Pathological Response Indicator|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|Gy/h|iSD|1|U/cL|HPLC/MS||||SPOUSE|CLINICAL PATHOLOGIST|U|1|Visit_1|10|4|WASHOUT|2021-01-30|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-15|P1Y2M10DT2H30M|UNKNOWN|2021-04-15|ONGOING|2021-04-18
e|RS|d1644413-1ed4-4ac9-b68f-f7ccb3cf6e42|3|BMIVLIND|Bone Marrow Involvement Indicator|JACINTO CERVICAL CANCER 2007|[?]|umol/mol|NON-PD|1|tsp eq|PHOTOMETRY||||PROXY|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|2|Visit_2|25|4|TREATMENT|2021-02-14|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-23|P1Y2M10DT2H30M|COINCIDENT|2021-02-24|ONGOING|2021-04-26
e|RS|d1644413-1ed4-4ac9-b68f-f7ccb3cf6e42|4|RDIORESP|Radiologic Response|DURIE MULTIPLE MYELOMA 2006|||CYTOGENETIC NO RESPONSE|1|IU/mL|BALLPOINT PEN TECHNIQUE|Y||Y|CLINICAL RESEARCH COORDINATOR|FORENSIC PATHOLOGIST|NA|2|Visit_2|25|6|TREATMENT|2021-02-14|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-23|P1Y2M10DT2H30M|BEFORE|2021-03-04|AFTER|2021-03-05
e|RS|d1644413-1ed4-4ac9-b68f-f7ccb3cf6e42|5|MRDRESP|Minimal Residual Disease Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|mL/mmHg/min/L|PD-CT|1|nmol/g|MICROSCOPY||||PROXY|READER 2|Y|3|Visit_3|40|2|SCREENING|2021-03-01|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-06|P1Y2M10DT2H30M|UNKNOWN|2021-02-09|COINCIDENT|2021-03-19
e|RS|d1644413-1ed4-4ac9-b68f-f7ccb3cf6e42|6|DRCRIND|Disease Recurrence Indicator|PETIT BREAST CANCER 2001|||NR|1|Newton|IMMUNOASSAY|Y||Y|CHILD|FORENSIC PATHOLOGIST|N|3|Visit_3|40|3|SCREENING|2021-03-01|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-06|P1Y2M10DT2H30M|UNKNOWN|2021-03-16|ONGOING|2021-03-24
e|RS|d1644413-1ed4-4ac9-b68f-f7ccb3cf6e42|7|METSIND|Metastatic Indicator|NCIWG CHESON CLL 1996|[?]|/sec|PSA PROGRESSION|1|/10^5|MASS SPECTROMETRY||||INVESTIGATOR|NEUROLOGIST 2|NA|4|Visit_4|65|4|TREATMENT|2021-03-26|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-09|P1Y2M10DT2H30M|UNKNOWN|2021-02-28|BEFORE|2021-04-17
e|RS|d1644413-1ed4-4ac9-b68f-f7ccb3cf6e42|8|RDIORESP|Radiologic Response|AJCC V7|[?]|Enzyme U/m2|UNEQUIVOCAL|1|DAgU|STRESS ECHOCARDIOGRAPHY||||PROXY|PATHOLOGIST|N|4|Visit_4|65|3|FOLLOW-UP|2021-03-26|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-09|P1Y2M10DT2H30M|UNKNOWN|2021-04-16|BEFORE|2021-04-26
e|RS|d1644413-1ed4-4ac9-b68f-f7ccb3cf6e42|9|LIVRRESP|Liver Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|Siemens|NON-iCR/NON-iUPD|1|IU|FISH|Y|||PARENT|READER 1|NA|5|Visit_5|90|5|FOLLOW-UP|2021-04-20|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-27|P1Y2M10DT2H30M|COINCIDENT|2021-04-23|AFTER|2021-04-25
e|RS|d1644413-1ed4-4ac9-b68f-f7ccb3cf6e42|10|OVRLRESP|Overall Response|KUMAR IMWG 2016|[?]|uL/kg/day|iCPD|1|pm|IVY INCISION METHOD||||CLINICAL STUDY SPONSOR|PATHOLOGIST 1|N|5|Visit_5|90|7|WASHOUT|2021-04-20|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-27|P1Y2M10DT2H30M|BEFORE|2021-02-16|COINCIDENT|2021-04-25
e|RS|4b00b9ef-ddc3-4669-8a73-f69c73743bce|1|MRDIND|Minimal Residual Disease Indicator|EASL BRUIX LIVER CANCER 2001|||mCR|1|NEEDLE GAUGE|IMMUNOBLOT|||Y|ADJUDICATION COMMITTEE|ADJUDICATOR|NA|1|Visit_1|10|1|FOLLOW-UP|2020-07-23|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-25|P1Y2M10DT2H30M|BEFORE|2020-07-22|AFTER|2020-08-08
e|RS|4b00b9ef-ddc3-4669-8a73-f69c73743bce|2|SFTSRESP|Soft Tissue Response|PRINCE TCELL LYMPHOMA 2010|||RELAPSED DISEASE FROM CR OR PR|1|m|FUNCTIONAL MRI|Y||Y|VENDOR|OPHTHALMOLOGIST|NA|1|Visit_1|10|1|TREATMENT|2020-07-23|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-25|P1Y2M10DT2H30M|UNKNOWN|2020-10-03|BEFORE|2020-10-09
e|RS|4b00b9ef-ddc3-4669-8a73-f69c73743bce|3|RDIORESP|Radiologic Response|WOLCHOK SOLID TUMORS 2009|||UNEQUIVOCAL|1|Gauss|CAPILLARY ELECTROPHORESIS|||Y|NON-HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|N|2|Visit_2|25|6|FOLLOW-UP|2020-08-07|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-26|P1Y2M10DT2H30M|BEFORE|2020-08-31|ONGOING|2020-10-20
e|RS|4b00b9ef-ddc3-4669-8a73-f69c73743bce|4|LIVRRESP|Liver Response|UNSPECIFIED|[?]|10^3 CFU/mL|INCREASED|1|POINT|PHASE CONTRAST MICROSCOPY||||ADJUDICATION COMMITTEE|OPHTHALMOLOGIST|U|2|Visit_2|25|1|FOLLOW-UP|2020-08-07|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-26|P1Y2M10DT2H30M|UNKNOWN|2020-08-14|AFTER|2020-10-18
e|RS|4b00b9ef-ddc3-4669-8a73-f69c73743bce|5|DRCRIND|Disease Recurrence Indicator|DURIE MULTIPLE MYELOMA 2006|[?]|Bq/mL|RELAPSED DISEASE|1|kg/mol|SINGLE-MOLECULE ARRAY|Y|||FAMILY MEMBER|RATER 2|Y|3|Visit_3|40|1|TREATMENT|2020-08-22|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-05|P1Y2M10DT2H30M|AFTER|2020-10-08|ONGOING|2020-10-20
e|RS|4b00b9ef-ddc3-4669-8a73-f69c73743bce|6|MRDIND|Minimal Residual Disease Indicator|SCHER PROSTATE CANCER 2011|||iSD|1|mL/cage/day|CLAUSS METHOD||Y|Y|PARENT|RADIOLOGIST 1|N|3|Visit_3|40|6|WASHOUT|2020-08-22|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-05|P1Y2M10DT2H30M|COINCIDENT|2020-08-08|COINCIDENT|2020-08-23
e|RS|4b00b9ef-ddc3-4669-8a73-f69c73743bce|7|METSIND|Metastatic Indicator|RANO|[?]|pmol|COMPLETE MRD RESPONSE|1|kcal|FLUORIMETRY|Y|Y||FRIEND|ADJUDICATOR 2|Y|4|Visit_4|65|7|FOLLOW-UP|2020-09-16|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-01|P1Y2M10DT2H30M|UNKNOWN|2020-07-29|ONGOING|2020-09-22
e|RS|4b00b9ef-ddc3-4669-8a73-f69c73743bce|8|BONERESP|Bone Response|RANO ELLINGSON 2017|[?]|10^6 U|MR|1|SFC/10^6 PBMC|TOLUIDINE BLUE STAIN||Y||STUDY SUBJECT|ADJUDICATOR 3|U|4|Visit_4|65|7|TREATMENT|2020-09-16|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-01|P1Y2M10DT2H30M|AFTER|2020-10-01|AFTER|2020-10-10
e|RS|4b00b9ef-ddc3-4669-8a73-f69c73743bce|9|MNPTHIND|Minor Pathological Response Indicator|RECIST 1.0|||PSEUDOPROGRESSION|1|ug/kg/day|HPLC/IEX|||Y|VENDOR|NEUROLOGIST 2|U|5|Visit_5|90|7|SCREENING|2020-10-11|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-06|P1Y2M10DT2H30M|BEFORE|2020-08-09|COINCIDENT|2020-10-09
e|RS|4b00b9ef-ddc3-4669-8a73-f69c73743bce|10|BONERESP|Bone Response|MRANO VAN DEN BENT GLIOMA 2011|||PD|1|oz eq|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY|||Y|ADJUDICATION COMMITTEE|CARDIOLOGIST|NA|5|Visit_5|90|6|TREATMENT|2020-10-11|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-06|P1Y2M10DT2H30M|UNKNOWN|2020-10-19|BEFORE|2020-10-20
e|RS|a125efdf-aec8-47a1-b492-cdaf8b619a78|1|NTNERESP|Non-Target Non-Enhancing Response|CHESON CLL 2012|||SD-CT|1|Hz/s|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|||Y|PROXY|ADJUDICATOR 2|U|1|Visit_1|10|3|SCREENING|2020-09-30|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-20|P1Y2M10DT2H30M|COINCIDENT|2020-11-23|COINCIDENT|2020-12-19
e|RS|a125efdf-aec8-47a1-b492-cdaf8b619a78|2|NEWLWIND|New Lesion Worsening Indicator|RAJKUMAR MYELOMA 2011|[?]|log10 PFU|VGPR|1|Bq|SLOAN LETTER EYE CHART 1.25%||Y||SPOUSE|ADJUDICATOR 3|NA|1|Visit_1|10|1|WASHOUT|2020-09-30|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-20|P1Y2M10DT2H30M|AFTER|2020-12-06|BEFORE|2020-12-26
e|RS|a125efdf-aec8-47a1-b492-cdaf8b619a78|3|SPLNRESP|Spleen Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|mEq/dL|RELAPSED DISEASE|1|10^9/g|OPTICAL MAPPING||||ADJUDICATOR|MICROSCOPIST 1|Y|2|Visit_2|25|1|TREATMENT|2020-10-15|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-10|P1Y2M10DT2H30M|UNKNOWN|2020-12-06|AFTER|2020-12-20
e|RS|a125efdf-aec8-47a1-b492-cdaf8b619a78|4|NTLWIND|Non-Target Lesion Worsening Indicator|SHINDOH COLORECTAL CANCER 2013|[?]|MdFI|RELAPSED DISEASE|1|10^6/g|ERGOSPIROMETRY||||ADJUDICATION COMMITTEE|INTERNIST|N|2|Visit_2|25|5|TREATMENT|2020-10-15|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-10|P1Y2M10DT2H30M|AFTER|2020-10-07|BEFORE|2020-11-09
e|RS|a125efdf-aec8-47a1-b492-cdaf8b619a78|5|OVRLRESP|Overall Response|PCWG SCHER PROSTATE CANCER 2008|||NED|1|10^6/g|IMMUNOPRECIPITATION|||Y|VENDOR|MICROSCOPIST 3|NA|3|Visit_3|40|1|TREATMENT|2020-10-30|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-18|P1Y2M10DT2H30M|BEFORE|2020-10-08|AFTER|2020-10-21
e|RS|a125efdf-aec8-47a1-b492-cdaf8b619a78|6|RDIORESP|Radiologic Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|IU/mg|STABLE|1|nmol/L/h|KINETIC MICROPARTICLE IMMUNOASSAY||||INVESTIGATOR|HEMATOLOGIST|U|3|Visit_3|40|4|TREATMENT|2020-10-30|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-18|P1Y2M10DT2H30M|AFTER|2020-10-31|AFTER|2020-12-01
e|RS|a125efdf-aec8-47a1-b492-cdaf8b619a78|7|NTRGRESP|Non-target Response|BURCOMBE BREAST CANCER 2005|||PSEUDOPROGRESSION|1|STEPS|RAJI CELL RIA|||Y|INDEPENDENT ASSESSOR|RADIOLOGIST 2|U|4|Visit_4|65|5|FOLLOW-UP|2020-11-24|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-09|P1Y2M10DT2H30M|UNKNOWN|2020-10-29|COINCIDENT|2020-11-27
e|RS|a125efdf-aec8-47a1-b492-cdaf8b619a78|8|BONERESP|Bone Response|HARTMANN GERM CELL CANCER 2002|[?]|mEq/L|MINOR PATHOLOGIC RESPONSE|1|PATCH|CONGO RED STAIN|Y|||FRIEND|MICROSCOPIST|N|4|Visit_4|65|1|TREATMENT|2020-11-24|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-09|P1Y2M10DT2H30M|COINCIDENT|2020-11-03|AFTER|2020-11-21
e|RS|a125efdf-aec8-47a1-b492-cdaf8b619a78|9|MJPTHIND|Major Pathological Response Indicator|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|CFU/g|CRi|1|m/sec|LC-FL||Y||GUARDIAN|HEMATOLOGIST|N|5|Visit_5|90|6|SCREENING|2020-12-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-21|P1Y2M10DT2H30M|AFTER|2020-09-30|AFTER|2020-12-27
e|RS|a125efdf-aec8-47a1-b492-cdaf8b619a78|10|DRCRIND|Disease Recurrence Indicator|NCIWG CHESON CLL 1996|[?]|/day|PSA PROGRESSION|1|mAnson U/mL|OPTICAL DENSITY MEASUREMENT|Y|||INDEPENDENT ASSESSOR|UROLOGIST|U|5|Visit_5|90|4|TREATMENT|2020-12-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-21|P1Y2M10DT2H30M|BEFORE|2020-09-26|BEFORE|2020-12-07
e|RS|9171362e-0166-46f2-ab2d-2748d8c291d5|1|METBRESP|Metabolic Response|PROTOCOL DEFINED RESPONSE CRITERIA|||QUANTIFIABLE MRD POSITIVITY|1|LENS|MICROBIAL CULTURE, LIQUID|Y|Y|Y|ADJUDICATION COMMITTEE|DEVELOPMENTAL PSYCHOLOGIST|Y|1|Visit_1|10|4|SCREENING|2021-01-12|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-16|P1Y2M10DT2H30M|AFTER|2021-02-03|COINCIDENT|2021-04-07
e|RS|9171362e-0166-46f2-ab2d-2748d8c291d5|2|NTERESP|Non-Target Enhancing Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|mL/g/min|QUANTIFIABLE MRD POSITIVITY|1|FFU|PULSE OXIMETRY||Y||STUDY SUBJECT|RADIOLOGIST|N|1|Visit_1|10|1|WASHOUT|2021-01-12|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-16|P1Y2M10DT2H30M|AFTER|2021-02-25|AFTER|2021-03-11
e|RS|9171362e-0166-46f2-ab2d-2748d8c291d5|3|PATHRESP|Pathologic Response|KUMAR IMWG 2016|[?]|EP U|PSEUDORESPONSE|1|OI50|DUKE INCISION METHOD||||SIGNIFICANT OTHER|FORENSIC PATHOLOGIST|Y|2|Visit_2|25|1|TREATMENT|2021-01-27|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-23|P1Y2M10DT2H30M|COINCIDENT|2021-03-05|COINCIDENT|2021-03-23
e|RS|9171362e-0166-46f2-ab2d-2748d8c291d5|4|PATHRESP|Pathologic Response|GUILHOT CML 2007|[?]|ug/m2/day|OPTIMAL MORPHOLOGIC RESPONSE|1|mg/dose|SINGLE-MOLECULE ARRAY|Y|||FAMILY MEMBER|MICROSCOPIST 1|Y|2|Visit_2|25|2|SCREENING|2021-01-27|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-23|P1Y2M10DT2H30M|UNKNOWN|2021-04-11|BEFORE|2021-04-12
e|RS|9171362e-0166-46f2-ab2d-2748d8c291d5|5|PATHRESP|Pathologic Response|FAROOQUI SUPP CLL 2014|[?]|ug/L DDU|QUANTIFIABLE MRD POSITIVITY|1|PACKET|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY||||STUDY SUBJECT|READER 1|Y|3|Visit_3|40|3|WASHOUT|2021-02-11|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-06|P1Y2M10DT2H30M|COINCIDENT|2021-01-28|ONGOING|2021-04-09
e|RS|9171362e-0166-46f2-ab2d-2748d8c291d5|6|SPLNRESP|Spleen Response|PCWG SCHER PROSTATE CANCER 2016|[?]|L/min|iCPD|1|g/day|ETDRS EYE CHART|Y|Y||SPOUSE|CARDIOLOGIST|NA|3|Visit_3|40|2|TREATMENT|2021-02-11|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-06|P1Y2M10DT2H30M|COINCIDENT|2021-03-10|BEFORE|2021-03-25
e|RS|9171362e-0166-46f2-ab2d-2748d8c291d5|7|OVRLRESP|Overall Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|Log10 ELISA unit|CA125 50% RESPONSE|1|anti-Xa IU/mL|ACID FAST STAIN||Y||ADJUDICATION COMMITTEE|RATER|NA|4|Visit_4|65|5|TREATMENT|2021-03-08|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-27|P1Y2M10DT2H30M|COINCIDENT|2021-02-08|ONGOING|2021-04-01
e|RS|9171362e-0166-46f2-ab2d-2748d8c291d5|8|CYTORESP|Cytogenetic Response|PCWG SCHER PROSTATE CANCER 2008|[?]|msec|PMD|1|TAMPON|TRYPAN BLUE STAIN|Y|||NON-HEALTH CARE PROFESSIONAL|READER 1|NA|4|Visit_4|65|1|TREATMENT|2021-03-08|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-27|P1Y2M10DT2H30M|AFTER|2021-02-22|ONGOING|2021-02-27
e|RS|9171362e-0166-46f2-ab2d-2748d8c291d5|9|NTLWIND|Non-Target Lesion Worsening Indicator|MRECIST BYRNE MESOTHELIOMA 2004|[?]|mCi|SMD|1|/200 HPFs|TOTAL BODY RADIOGRAPHY||||HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|U|5|Visit_5|90|4|TREATMENT|2021-04-02|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-05|P1Y2M10DT2H30M|UNKNOWN|2021-02-16|COINCIDENT|2021-03-11
e|RS|9171362e-0166-46f2-ab2d-2748d8c291d5|10|METBRESP|Metabolic Response|FAROOQUI SUPP CLL 2014|[?]|mL/m2/day|INDETERMINATE RESPONSE|1|uIU/dL|RAJI CELL RIA|Y|||ADJUDICATOR|PHYSIOTHERAPIST|U|5|Visit_5|90|1|WASHOUT|2021-04-02|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-05|P1Y2M10DT2H30M|AFTER|2021-01-30|AFTER|2021-03-18
e|RS|9b150e38-dc85-4a28-aad3-43f7620be460|1|HEMARESP|Hematologic Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|CCID 50/mL|iPR|1|10^8/L|GIEMSA STAIN||||CAREGIVER|ADJUDICATOR 3|N|1|Visit_1|10|3|SCREENING|2020-07-22|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-21|P1Y2M10DT2H30M|BEFORE|2020-09-03|AFTER|2020-09-12
e|RS|9b150e38-dc85-4a28-aad3-43f7620be460|2|OVRLRESP|Overall Response|SCHER PROSTATE CANCER 2011|||MORPHOLOGIC CR|1|10^11/L|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY||Y|Y|CLINICAL STUDY SPONSOR|MICROSCOPIST|NA|1|Visit_1|10|1|FOLLOW-UP|2020-07-22|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-21|P1Y2M10DT2H30M|UNKNOWN|2020-07-17|AFTER|2020-08-20
e|RS|9b150e38-dc85-4a28-aad3-43f7620be460|3|SYMPTDTR|Symptomatic Deterioration|CHOI GIST 2008|[?]|mm|COMPLETE MRD RESPONSE|1|g/g/day|SMEAR||||CAREGIVER|NEUROLOGIST 1|NA|2|Visit_2|25|2|SCREENING|2020-08-06|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-06|P1Y2M10DT2H30M|AFTER|2020-10-12|COINCIDENT|2020-10-17
e|RS|9b150e38-dc85-4a28-aad3-43f7620be460|4|HEMARESP|Hematologic Response|IWG CHESON AML 2003|||NON-CR/NON-PD|1|Ci/g|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION|||Y|VENDOR|ADJUDICATOR 2|N|2|Visit_2|25|5|WASHOUT|2020-08-06|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-06|P1Y2M10DT2H30M|COINCIDENT|2020-10-02|AFTER|2020-10-19
e|RS|9b150e38-dc85-4a28-aad3-43f7620be460|5|NEWLPROG|New Lesion Progression|CHESON LYMPHOMA 2008|[?]|ppth|PSA PROGRESSION|1|mEq/dL|IMMUNOCHROMATOGRAPHY||||CLINICAL RESEARCH COORDINATOR|OPTOMETRIST|U|3|Visit_3|40|1|FOLLOW-UP|2020-08-21|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-20|P1Y2M10DT2H30M|BEFORE|2020-09-17|ONGOING|2020-10-10
e|RS|9b150e38-dc85-4a28-aad3-43f7620be460|6|METSIND|Metastatic Indicator|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|cd/m2|RELAPSED DISEASE FROM CR|1|GBq|DARK FIELD MICROSCOPY||Y||PARENT|RATER 1|N|3|Visit_3|40|5|TREATMENT|2020-08-21|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-20|P1Y2M10DT2H30M|AFTER|2020-08-17|ONGOING|2020-09-24
e|RS|9b150e38-dc85-4a28-aad3-43f7620be460|7|NEWLIND|New Lesion Indicator|WOLCHOK SOLID TUMORS 2009|||RELAPSED DISEASE FROM CR|1|pkat/L|FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY|||Y|PARENT|ONCOLOGIST 2|N|4|Visit_4|65|6|SCREENING|2020-09-15|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-27|P1Y2M10DT2H30M|UNKNOWN|2020-08-10|ONGOING|2020-10-16
e|RS|9b150e38-dc85-4a28-aad3-43f7620be460|8|TRGRESP|Target Response|HAMAOKA BREAST CANCER 2010|[?]|mmol/day|PSEUDORESPONSE|1|uCi|RAJI CELL EIA|Y|||INVESTIGATOR|ONCOLOGIST|NA|4|Visit_4|65|3|TREATMENT|2020-09-15|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-27|P1Y2M10DT2H30M|AFTER|2020-10-03|ONGOING|2020-10-19
e|RS|9b150e38-dc85-4a28-aad3-43f7620be460|9|MRDIND|Minimal Residual Disease Indicator|BURCOMBE BREAST CANCER 2005|[?]|U/cL|CMR|1|IU/L|RADIOGRAPHY||||CHILD|NEUROLOGIST|Y|5|Visit_5|90|1|WASHOUT|2020-10-10|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-26|P1Y2M10DT2H30M|BEFORE|2020-08-08|BEFORE|2020-08-24
e|RS|9b150e38-dc85-4a28-aad3-43f7620be460|10|PATHRESP|Pathologic Response|RECICL|[?]|BAR|cCR|1|10^6 CFU/mL|LAPAROSCOPY||||VENDOR|MICROSCOPIST 3|U|5|Visit_5|90|4|TREATMENT|2020-10-10|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-26|P1Y2M10DT2H30M|COINCIDENT|2020-09-09|BEFORE|2020-10-05
e|RS|2a595fc0-7621-4ec9-bd77-74444886052e|1|BMIVLIND|Bone Marrow Involvement Indicator|WHO BREAST CANCER 2006|[?]|Log10 ELISA unit|HI-E|1|IU/g|DUCTOGRAPHY||||CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 1|NA|1|Visit_1|10|3|TREATMENT|2020-10-25|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-27|P1Y2M10DT2H30M|BEFORE|2021-01-08|COINCIDENT|2021-01-21
e|RS|2a595fc0-7621-4ec9-bd77-74444886052e|2|NTERESP|Non-Target Enhancing Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|m/sec2|UNFAVORABLE RESPONSE|1|cmHg|FLAME PHOTOMETRY||||CLINICAL RESEARCH ASSOCIATE|READER 1|N|1|Visit_1|10|4|WASHOUT|2020-10-25|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-27|P1Y2M10DT2H30M|UNKNOWN|2020-11-27|ONGOING|2020-12-08
e|RS|2a595fc0-7621-4ec9-bd77-74444886052e|3|DRCRIND|Disease Recurrence Indicator|KUMAR IMWG 2016|||HI-P|1|V/sec|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|||Y|DOMESTIC PARTNER|MICROSCOPIST|N|2|Visit_2|25|5|SCREENING|2020-11-09|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-20|P1Y2M10DT2H30M|UNKNOWN|2020-10-30|AFTER|2020-11-29
e|RS|2a595fc0-7621-4ec9-bd77-74444886052e|4|BONERESP|Bone Response|PROTOCOL DEFINED RESPONSE CRITERIA|||NON-CR/NON-PD|1|/100 HPFs|NEURAMINIDASE INHIBITION ASSAY|Y||Y|NON-HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|Y|2|Visit_2|25|7|TREATMENT|2020-11-09|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-20|P1Y2M10DT2H30M|BEFORE|2021-01-08|BEFORE|2021-01-13
e|RS|2a595fc0-7621-4ec9-bd77-74444886052e|5|CLINRESP|Clinical Response|RECIST 1.0|[?]|TCID 50/dose|CA125 50% RESPONSE|1|Ci/g|ELLA||Y||HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|NA|3|Visit_3|40|7|TREATMENT|2020-11-24|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-18|P1Y2M10DT2H30M|BEFORE|2021-01-20|COINCIDENT|2021-01-21
e|RS|2a595fc0-7621-4ec9-bd77-74444886052e|6|BONERESP|Bone Response|CHESON LYMPHOMA 2008|[?]|10^7/L|VGPR|1|BEAM BREAKS|IMPEDANCE CONDUCTIVITY||||FRIEND|OTOLARYNGOLOGIST|N|3|Visit_3|40|7|TREATMENT|2020-11-24|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-18|P1Y2M10DT2H30M|BEFORE|2021-01-10|AFTER|2021-01-16
e|RS|2a595fc0-7621-4ec9-bd77-74444886052e|7|BONERESP|Bone Response|BLAZER COLORECTAL CANCER 2008|[?]|mg/kg/dose|MRD RELAPSE|1|kg|RADIAL IMMUNODIFFUSION||||FAMILY MEMBER|ENDOCRINOLOGIST|NA|4|Visit_4|65|3|SCREENING|2020-12-19|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-11|P1Y2M10DT2H30M|BEFORE|2020-11-11|ONGOING|2020-11-12
e|RS|2a595fc0-7621-4ec9-bd77-74444886052e|8|MJPTHIND|Major Pathological Response Indicator|BLAZER COLORECTAL CANCER 2008|[?]|/200 HPFs|PSEUDOPROGRESSION|1|U/animal|SINGLE-MOLECULE ARRAY||||CHILD|MICROSCOPIST|Y|4|Visit_4|65|3|WASHOUT|2020-12-19|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-11|P1Y2M10DT2H30M|BEFORE|2020-12-09|ONGOING|2020-12-29
e|RS|2a595fc0-7621-4ec9-bd77-74444886052e|9|METSIND|Metastatic Indicator|PETIT BREAST CANCER 2001|[?]|10^3 organisms/mL|CYTOGENETIC PR|1|Enzyme U|JAFFE REACTION||Y||STUDY SUBJECT|ONCOLOGIST 1|Y|5|Visit_5|90|2|WASHOUT|2021-01-13|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-04|P1Y2M10DT2H30M|COINCIDENT|2020-12-27|AFTER|2021-01-05
e|RS|2a595fc0-7621-4ec9-bd77-74444886052e|10|METBRESP|Metabolic Response|BRUGGEMANN MRD 2010|[?]|L|CYTOGENETIC MINIMAL RESPONSE|1|OI50|DARK FIELD MICROSCOPY||||GUARDIAN|PATHOLOGIST 1|N|5|Visit_5|90|7|SCREENING|2021-01-13|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-04|P1Y2M10DT2H30M|UNKNOWN|2020-11-15|BEFORE|2021-01-13
e|RS|0bab89c8-cf57-4d19-9b95-884a2e9da523|1|SYMPTDTR|Symptomatic Deterioration|PERCIST|[?]|lx|IMMUNOPHENOTYPIC CR|1|msec|WHOLE GENOME SEQUENCING||Y||ADJUDICATION COMMITTEE|FORENSIC PATHOLOGIST|NA|1|Visit_1|10|7|TREATMENT|2020-12-20|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-11|P1Y2M10DT2H30M|BEFORE|2021-01-07|ONGOING|2021-01-24
e|RS|0bab89c8-cf57-4d19-9b95-884a2e9da523|2|ANATRESP|Anatomic Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|kat|iCPD|1|mL/beat|ORCHIDOMETERY||||PROXY|READER 3|NA|1|Visit_1|10|4|TREATMENT|2020-12-20|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-11|P1Y2M10DT2H30M|UNKNOWN|2021-03-04|BEFORE|2021-03-13
e|RS|0bab89c8-cf57-4d19-9b95-884a2e9da523|3|MRPHRESP|Morphologic Response|CHOI GIST 2008|||MRD PERSISTENCE|1|L/min|KNEMOMETRY||Y|Y|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 2|NA|2|Visit_2|25|2|TREATMENT|2021-01-04|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-01|P1Y2M10DT2H30M|BEFORE|2021-02-03|BEFORE|2021-03-14
e|RS|0bab89c8-cf57-4d19-9b95-884a2e9da523|4|PATHRESP|Pathologic Response|RECIST 1.1|[?]|GBq/g|PD-CT|1|genEq|KINETIC CHROMOGENIC ASSAY|Y|Y||VENDOR|PEDIATRIC NEUROLOGIST|NA|2|Visit_2|25|4|TREATMENT|2021-01-04|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-01|P1Y2M10DT2H30M|AFTER|2021-03-12|BEFORE|2021-03-16
e|RS|0bab89c8-cf57-4d19-9b95-884a2e9da523|5|RDIORESP|Radiologic Response|KUMAR IMWG 2016|[?]|nkat/g Hb|iPR|1|uCi|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION||||CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 1|N|3|Visit_3|40|4|FOLLOW-UP|2021-01-19|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-17|P1Y2M10DT2H30M|AFTER|2021-03-07|AFTER|2021-03-14
e|RS|0bab89c8-cf57-4d19-9b95-884a2e9da523|6|TMRESP|Tumor Marker Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|VIRTUAL PIXEL|MORPHOLOGIC LEUKEMIA-FREE STATE|1|Ci/uL|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY||||GUARDIAN|READER 1|NA|3|Visit_3|40|2|TREATMENT|2021-01-19|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-17|P1Y2M10DT2H30M|AFTER|2021-01-26|BEFORE|2021-02-17
e|RS|0bab89c8-cf57-4d19-9b95-884a2e9da523|7|CLINRESP|Clinical Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|mL/sec/1.73m2|MRD NEGATIVITY|1|ngEq/L|SPECT SCAN||Y||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR|N|4|Visit_4|65|1|TREATMENT|2021-02-13|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-20|P1Y2M10DT2H30M|AFTER|2021-02-01|ONGOING|2021-02-07
e|RS|0bab89c8-cf57-4d19-9b95-884a2e9da523|8|CPRFSTAT|Clinical Performance Status|IWG CHESON AML 2003|||WORSENED|1|/10^3|PALM METHOD|Y|Y|Y|DOMESTIC PARTNER|RATER 2|Y|4|Visit_4|65|7|TREATMENT|2021-02-13|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-20|P1Y2M10DT2H30M|BEFORE|2021-03-07|COINCIDENT|2021-03-15
e|RS|0bab89c8-cf57-4d19-9b95-884a2e9da523|9|ANATRESP|Anatomic Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|||INDETERMINATE RESPONSE|1|mg/min|ELASTOGRAPHY|||Y|SIGNIFICANT OTHER|RATER 1|NA|5|Visit_5|90|4|SCREENING|2021-03-10|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-10|P1Y2M10DT2H30M|BEFORE|2021-02-07|ONGOING|2021-03-14
e|RS|0bab89c8-cf57-4d19-9b95-884a2e9da523|10|TMRESP|Tumor Marker Response|WOLCHOK SOLID TUMORS 2009|[?]|SYRINGE|PSEUDOPROGRESSION|1|/100 WBC|ANALYTICAL ULTRACENTRIFUGATION||||INTERVIEWER|ONCOLOGIST 1|N|5|Visit_5|90|6|FOLLOW-UP|2021-03-10|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-10|P1Y2M10DT2H30M|COINCIDENT|2021-02-20|COINCIDENT|2021-02-25
e|RS|84edaa9d-ce48-4866-ab43-af91bee126ae|1|PATHRESP|Pathologic Response|HARTMANN GERM CELL CANCER 2002|[?]|Ejaculate U|CYTOGENETIC NO RESPONSE|1|L/s|MICROBIAL CULTURE|Y|||CAREGIVER|FORENSIC PATHOLOGIST|U|1|Visit_1|10|4|TREATMENT|2020-05-11|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-03|P1Y2M10DT2H30M|COINCIDENT|2020-08-04|BEFORE|2020-08-05
e|RS|84edaa9d-ce48-4866-ab43-af91bee126ae|2|SYMPTDTR|Symptomatic Deterioration|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|km/h|PD|1|Bq/mL|SINGLE-SLICE SPIRAL CT||||CLINICAL RESEARCH COORDINATOR|DERMATOLOGIST|NA|1|Visit_1|10|6|TREATMENT|2020-05-11|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-03|P1Y2M10DT2H30M|BEFORE|2020-05-04|ONGOING|2020-06-16
e|RS|84edaa9d-ce48-4866-ab43-af91bee126ae|3|CLINRESP|Clinical Response|CHESON MALIGNANT LYMPHOMA 2007|||PR-CT|1|CIGARETTE|ROMANOWSKY STAIN||Y|Y|SIGNIFICANT OTHER|RATER|Y|2|Visit_2|25|1|WASHOUT|2020-05-26|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-14|P1Y2M10DT2H30M|AFTER|2020-07-11|AFTER|2020-08-07
e|RS|84edaa9d-ce48-4866-ab43-af91bee126ae|4|TMRESP|Tumor Marker Response|RANO ELLINGSON 2017|[?]|10^6 RNA copies/mL|CRi|1|tsp eq|MAGNETIC RESONANCE ENTEROGRAPHY|Y|||GUARDIAN|ADJUDICATOR 2|Y|2|Visit_2|25|7|TREATMENT|2020-05-26|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-14|P1Y2M10DT2H30M|COINCIDENT|2020-08-07|AFTER|2020-08-08
e|RS|84edaa9d-ce48-4866-ab43-af91bee126ae|5|CPRFSTAT|Clinical Performance Status|MURPHY PROSTATE CANCER 1980|[?]|min|RELAPSED DISEASE FROM CR|1|mmol/mol|COULOMETRIC TITRATION||Y||GUARDIAN|ONCOLOGIST 1|U|3|Visit_3|40|1|TREATMENT|2020-06-10|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-05|P1Y2M10DT2H30M|COINCIDENT|2020-07-15|AFTER|2020-07-25
e|RS|84edaa9d-ce48-4866-ab43-af91bee126ae|6|MJPTHIND|Major Pathological Response Indicator|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|kat|WORSENED|1|tsp|ETDRS EYE CHART||||STUDY SUBJECT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|3|Visit_3|40|7|TREATMENT|2020-06-10|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-05|P1Y2M10DT2H30M|COINCIDENT|2020-07-13|BEFORE|2020-07-16
e|RS|84edaa9d-ce48-4866-ab43-af91bee126ae|7|CPRFSTAT|Clinical Performance Status|PERCIST|[?]|WAFER|ABSENT MORPHOLOGIC RESPONSE|1|L/L|URANYL ACETATE STAIN||||INDEPENDENT ASSESSOR|RATER 2|N|4|Visit_4|65|5|SCREENING|2020-07-05|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-29|P1Y2M10DT2H30M|BEFORE|2020-05-31|ONGOING|2020-07-12
e|RS|84edaa9d-ce48-4866-ab43-af91bee126ae|8|CPRFSTAT|Clinical Performance Status|HARTMANN GERM CELL CANCER 2002|[?]|pmol/L|CYTOGENETIC CR|1|pkat|AURAMINE STAIN||||DOMESTIC PARTNER|READER 1|U|4|Visit_4|65|6|TREATMENT|2020-07-05|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-29|P1Y2M10DT2H30M|AFTER|2020-06-17|ONGOING|2020-07-21
e|RS|84edaa9d-ce48-4866-ab43-af91bee126ae|9|RDIORESP|Radiologic Response|MURPHY PROSTATE CANCER 1980|[?]|mm/min|CYTOGENETIC CR|1|SUPPOSITORY|PHOTOMETRIC CLOT DETECTION||||ADJUDICATOR|READER 2|NA|5|Visit_5|90|7|SCREENING|2020-07-30|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-17|P1Y2M10DT2H30M|AFTER|2020-06-17|BEFORE|2020-08-02
e|RS|84edaa9d-ce48-4866-ab43-af91bee126ae|10|MJPTHIND|Major Pathological Response Indicator|EBMT BLADE MYELOMA 1998|[?]|GBq|PSEUDOPROGRESSION|1|pmol/L|PET/SPECT SCAN||||PARENT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|5|Visit_5|90|7|FOLLOW-UP|2020-07-30|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-17|P1Y2M10DT2H30M|UNKNOWN|2020-06-24|AFTER|2020-07-18
e|RS|0a955f0d-058a-49ac-bc7f-4f8ef9690f5a|1|LIVRRESP|Liver Response|CHOLLET BREAST CANCER 2002|[?]|U/m2/h|cPR|1|Hz/s|REFLECTANCE SPECTROSCOPY||||SIGNIFICANT OTHER|OPHTHALMOLOGIST|N|1|Visit_1|10|7|FOLLOW-UP|2020-08-03|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-27|P1Y2M10DT2H30M|AFTER|2020-09-01|BEFORE|2020-10-27
e|RS|0a955f0d-058a-49ac-bc7f-4f8ef9690f5a|2|NTLWIND|Non-Target Lesion Worsening Indicator|BRUGGEMANN MRD 2010|[?]|kPa|CYTOGENETIC PR|1|g/m2/day|HPLC-FL||Y||ADJUDICATOR|CLINICAL PATHOLOGIST|N|1|Visit_1|10|3|SCREENING|2020-08-03|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-27|P1Y2M10DT2H30M|UNKNOWN|2020-09-24|ONGOING|2020-09-27
e|RS|0a955f0d-058a-49ac-bc7f-4f8ef9690f5a|3|TRGRESP|Target Response|NCCN ALL MRD 2014|[?]|/HPF|NE|1|Ci/uL|ANGIOGRAPHY||Y||FAMILY MEMBER|PATHOLOGIST 2|U|2|Visit_2|25|7|FOLLOW-UP|2020-08-18|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-13|P1Y2M10DT2H30M|COINCIDENT|2020-09-17|BEFORE|2020-09-18
e|RS|0a955f0d-058a-49ac-bc7f-4f8ef9690f5a|4|RDIORESP|Radiologic Response|IWG CHESON MDS 2006|[?]|RING|RELAPSED DISEASE FROM CR OR PR|1|APL U|WESTERGREN||||STUDY SUBJECT|ADJUDICATOR 1|N|2|Visit_2|25|1|TREATMENT|2020-08-18|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-13|P1Y2M10DT2H30M|COINCIDENT|2020-09-13|BEFORE|2020-10-14
e|RS|0a955f0d-058a-49ac-bc7f-4f8ef9690f5a|5|ANATRESP|Anatomic Response|CHOLLET BREAST CANCER 2002|[?]|U.CARR|CMR|1|PFU|SNP ARRAY|Y|Y||HEALTH CARE PROFESSIONAL|RATER 1|NA|3|Visit_3|40|5|FOLLOW-UP|2020-09-02|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-19|P1Y2M10DT2H30M|COINCIDENT|2020-09-08|BEFORE|2020-09-12
e|RS|0a955f0d-058a-49ac-bc7f-4f8ef9690f5a|6|NEWLPROG|New Lesion Progression|PALUMBO MULTIPLE MYELOMA 2009|[?]|SBE/mL|HI-N|1|foz_br|IMMUNOPRECIPITATION||Y||CHILD|ONCOLOGIST 2|U|3|Visit_3|40|2|TREATMENT|2020-09-02|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-19|P1Y2M10DT2H30M|BEFORE|2020-10-23|AFTER|2020-10-28
e|RS|0a955f0d-058a-49ac-bc7f-4f8ef9690f5a|7|NTRGRESP|Non-target Response|SACT|[?]|genEq/mL|HI-N|1|/day|CRYOSCOPY||||STUDY SUBJECT|ENDOCRINOLOGIST|N|4|Visit_4|65|2|FOLLOW-UP|2020-09-27|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-30|P1Y2M10DT2H30M|COINCIDENT|2020-09-16|AFTER|2020-10-13
e|RS|0a955f0d-058a-49ac-bc7f-4f8ef9690f5a|8|MOLRESP|Molecular Response|MASS|[?]|mEq/mL|MAJOR PATHOLOGIC RESPONSE|1|U/mL|MULTIPLEXED BEAD BASED IMMUNOASSAY||||INDEPENDENT ASSESSOR|NEUROLOGIST 2|NA|4|Visit_4|65|4|TREATMENT|2020-09-27|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-30|P1Y2M10DT2H30M|COINCIDENT|2020-10-12|BEFORE|2020-10-18
e|RS|0a955f0d-058a-49ac-bc7f-4f8ef9690f5a|9|TMRESP|Tumor Marker Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|mL/kg/h|iPR|1|ELISA unit/mL|EEG||||PARENT|UROLOGIST|NA|5|Visit_5|90|2|TREATMENT|2020-10-22|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-21|P1Y2M10DT2H30M|AFTER|2020-10-02|COINCIDENT|2020-10-19
e|RS|0a955f0d-058a-49ac-bc7f-4f8ef9690f5a|10|NTRGRESP|Non-target Response|RANO|[?]|Coulomb|MRD NEGATIVITY|1|NFIU|OPTICAL COHERENCE TOMOGRAPHY||Y||NON-HEALTH CARE PROFESSIONAL|UROLOGIST|N|5|Visit_5|90|3|TREATMENT|2020-10-22|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-21|P1Y2M10DT2H30M|COINCIDENT|2020-09-20|ONGOING|2020-09-30
e|RS|9734ec2a-d06b-43e1-82a5-37764af17890|1|NTNERESP|Non-Target Non-Enhancing Response|KEAM BREAST CANCER 2013|[?]|MBq|PDu|1|U|EIA||||INVESTIGATOR|PATHOLOGIST|NA|1|Visit_1|10|4|SCREENING|2020-09-29|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-15|P1Y2M10DT2H30M|BEFORE|2020-10-30|ONGOING|2020-11-08
e|RS|9734ec2a-d06b-43e1-82a5-37764af17890|2|MNPTHIND|Minor Pathological Response Indicator|PRINCE TCELL LYMPHOMA 2010|[?]|CAN|FAVORABLE RESPONSE|1|ppb|EIA||Y||PROXY|ENDOCRINOLOGIST|Y|1|Visit_1|10|3|WASHOUT|2020-09-29|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-15|P1Y2M10DT2H30M|UNKNOWN|2020-11-14|COINCIDENT|2020-12-03
e|RS|9734ec2a-d06b-43e1-82a5-37764af17890|3|MJPTHIND|Major Pathological Response Indicator|RANO ELLINGSON 2017|[?]|mOsm/kg|EQUIVOCAL|1|ELISA unit/dose|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS||||SIGNIFICANT OTHER|PATHOLOGIST 2|NA|2|Visit_2|25|7|FOLLOW-UP|2020-10-14|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-27|P1Y2M10DT2H30M|UNKNOWN|2020-10-22|ONGOING|2020-11-01
e|RS|9734ec2a-d06b-43e1-82a5-37764af17890|4|NTLWIND|Non-Target Lesion Worsening Indicator|RAJKUMAR MYELOMA 2011|||DECREASED|1|uCi/kg|ORCHIDOMETERY|||Y|STUDY SUBJECT|UROLOGIST|N|2|Visit_2|25|6|TREATMENT|2020-10-14|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-27|P1Y2M10DT2H30M|COINCIDENT|2020-12-20|AFTER|2020-12-21
e|RS|9734ec2a-d06b-43e1-82a5-37764af17890|5|METBRESP|Metabolic Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|||WORSENED|1|mg/kg|CONGO RED STAIN|Y|Y|Y|GUARDIAN|RATER|N|3|Visit_3|40|7|TREATMENT|2020-10-29|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-12|P1Y2M10DT2H30M|BEFORE|2020-10-20|ONGOING|2020-12-08
e|RS|9734ec2a-d06b-43e1-82a5-37764af17890|6|BESTRESP|Best Overall Response|SHINDOH COLORECTAL CANCER 2013|[?]|nkat|CYTOGENETIC MINOR RESPONSE|1|RING|FUNDUS PHOTOGRAPHY||||CAREGIVER|RATER 1|NA|3|Visit_3|40|5|WASHOUT|2020-10-29|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-12|P1Y2M10DT2H30M|COINCIDENT|2020-10-27|COINCIDENT|2020-11-03
e|RS|9734ec2a-d06b-43e1-82a5-37764af17890|7|MJPTHIND|Major Pathological Response Indicator|LUGANO CLASSIFICATION|[?]|uU/L|PR-CT|1|U/cL|JAEGER EYE CHART||||PARENT|OPHTHALMOLOGIST|N|4|Visit_4|65|7|SCREENING|2020-11-23|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-18|P1Y2M10DT2H30M|UNKNOWN|2020-11-02|ONGOING|2020-11-09
e|RS|9734ec2a-d06b-43e1-82a5-37764af17890|8|NTNERESP|Non-Target Non-Enhancing Response|MONTSERRAT CLL 1989|[?]|kDa|EQUIVOCAL|1|nmol/L|TOLUIDINE BLUE STAIN||Y||INVESTIGATOR|READER|N|4|Visit_4|65|3|TREATMENT|2020-11-23|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-18|P1Y2M10DT2H30M|AFTER|2020-12-13|ONGOING|2020-12-23
e|RS|9734ec2a-d06b-43e1-82a5-37764af17890|9|ANATRESP|Anatomic Response|BRUGGEMANN MRD 2010|[?]|%/s|NON-PD|1|U/kg|VIRUS PLAQUE ASSAY||Y||INVESTIGATOR|ENDOCRINOLOGIST|NA|5|Visit_5|90|6|TREATMENT|2020-12-18|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-22|P1Y2M10DT2H30M|BEFORE|2020-12-15|BEFORE|2020-12-26
e|RS|9734ec2a-d06b-43e1-82a5-37764af17890|10|SPLNRESP|Spleen Response|MACDONALD GLIOMA 1990|[?]|mmAL|COMPLETE MRD RESPONSE|1|kg|INTERRUPTER TECHNIQUE||||FRIEND|RATER|Y|5|Visit_5|90|3|TREATMENT|2020-12-18|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-22|P1Y2M10DT2H30M|BEFORE|2020-11-02|AFTER|2020-12-24
e|RS|9a0ce525-7f10-4651-885a-f64bd9c8925e|1|METBRESP|Metabolic Response|MASS|[?]|pt_us|ABSENT MORPHOLOGIC RESPONSE|1|amol|SLOAN LETTER EYE CHART 1.25%||Y||HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|N|1|Visit_1|10|6|TREATMENT|2020-11-28|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-11|P1Y2M10DT2H30M|BEFORE|2021-01-22|ONGOING|2021-01-25
e|RS|9a0ce525-7f10-4651-885a-f64bd9c8925e|2|CPRFSTAT|Clinical Performance Status|SHINDOH COLORECTAL CANCER 2013|[?]|log EID 50/dose|CYTOGENETIC MINIMAL RESPONSE|1|mV2/Hz|IMMUNE REPERTOIRE DEEP SEQUENCING||Y||ADJUDICATION COMMITTEE|PATHOLOGIST|Y|1|Visit_1|10|2|SCREENING|2020-11-28|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-11|P1Y2M10DT2H30M|BEFORE|2021-01-20|COINCIDENT|2021-02-18
e|RS|9a0ce525-7f10-4651-885a-f64bd9c8925e|3|MRPHRESP|Morphologic Response|MURPHY PROSTATE CANCER 1980|||NON-QUANTIFIABLE MRD POSITIVITY|1|F|GC/MS-EI|||Y|CAREGIVER|CLINICAL PATHOLOGIST|NA|2|Visit_2|25|6|TREATMENT|2020-12-13|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-13|P1Y2M10DT2H30M|COINCIDENT|2021-01-23|AFTER|2021-02-17
e|RS|9a0ce525-7f10-4651-885a-f64bd9c8925e|4|MRDRESP|Minimal Residual Disease Response|NCIWG CHESON CLL 1996|[?]|Enzyme U/L|ABSENT MORPHOLOGIC RESPONSE|1|oz eq|MULTIPLE BREATH WASHOUT||||INTERVIEWER|ADJUDICATOR 3|Y|2|Visit_2|25|7|TREATMENT|2020-12-13|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-13|P1Y2M10DT2H30M|UNKNOWN|2021-01-10|BEFORE|2021-01-25
e|RS|9a0ce525-7f10-4651-885a-f64bd9c8925e|5|TRGRESP|Target Response|PALUMBO MULTIPLE MYELOMA 2009|||PD/RELAPSE AFTER HI|1|10^9/g|CYSTOSCOPY|||Y|CHILD|MICROSCOPIST 1|U|3|Visit_3|40|2|WASHOUT|2020-12-28|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-03|P1Y2M10DT2H30M|COINCIDENT|2020-12-06|BEFORE|2020-12-21
e|RS|9a0ce525-7f10-4651-885a-f64bd9c8925e|6|METSIND|Metastatic Indicator|iRECIST|[?]|Rad|SD|1|uV*sec|REFRACTOMETRY||||INTERVIEWER|MICROSCOPIST|Y|3|Visit_3|40|4|TREATMENT|2020-12-28|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-03|P1Y2M10DT2H30M|UNKNOWN|2020-12-19|BEFORE|2021-02-17
e|RS|9a0ce525-7f10-4651-885a-f64bd9c8925e|7|MNPTHIND|Minor Pathological Response Indicator|UNSPECIFIED|[?]|Antibody Unit|PD FROM PR|1|DAYS|FLAME PHOTOMETRY||||CAREGIVER|DEVELOPMENTAL PSYCHOLOGIST|N|4|Visit_4|65|6|WASHOUT|2021-01-22|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-10|P1Y2M10DT2H30M|COINCIDENT|2021-02-20|AFTER|2021-02-23
e|RS|9a0ce525-7f10-4651-885a-f64bd9c8925e|8|CLINRESP|Clinical Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|Ci/g|CYTOGENETIC NO RESPONSE|1|CAPFUL|DYNAMOMETRY||||CLINICAL RESEARCH ASSOCIATE|READER|U|4|Visit_4|65|2|SCREENING|2021-01-22|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-10|P1Y2M10DT2H30M|UNKNOWN|2020-11-23|COINCIDENT|2020-12-08
e|RS|9a0ce525-7f10-4651-885a-f64bd9c8925e|9|PATHRESP|Pathologic Response|MASS|||INDETERMINATE RESPONSE|1|10^10/L|SPECT/CT SCAN||Y|Y|INVESTIGATOR|HEMATOLOGIST|U|5|Visit_5|90|1|TREATMENT|2021-02-16|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-12|P1Y2M10DT2H30M|AFTER|2021-01-15|AFTER|2021-01-21
e|RS|9a0ce525-7f10-4651-885a-f64bd9c8925e|10|DRCRIND|Disease Recurrence Indicator|PALUMBO MULTIPLE MYELOMA 2009|[?]|TROCHE|FAVORABLE RESPONSE|1|10^3 CFU/mL|MICRONEUTRALIZATION ASSAY||Y||CAREGIVER|MICROSCOPIST 2|U|5|Visit_5|90|3|TREATMENT|2021-02-16|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-12|P1Y2M10DT2H30M|UNKNOWN|2021-02-10|AFTER|2021-02-24
e|RS|f2cd01c4-b765-4ac5-8e8d-c9fef7366720|1|MRDRESP|Minimal Residual Disease Response|CHESON CLL 2006|[?]|ug/L FEU|NE|1|/100 HPFs|ORCHIDOMETERY||||CLINICAL STUDY SPONSOR|READER 3|NA|1|Visit_1|10|1|FOLLOW-UP|2020-07-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-27|P1Y2M10DT2H30M|AFTER|2020-08-25|ONGOING|2020-09-23
e|RS|f2cd01c4-b765-4ac5-8e8d-c9fef7366720|2|METSIND|Metastatic Indicator|NCCN ALL MRD 2014|||NON-iCR/NON-iUPD|1|kHz|TONOMETRY|||Y|CHILD|RATER 1|Y|1|Visit_1|10|7|WASHOUT|2020-07-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-27|P1Y2M10DT2H30M|BEFORE|2020-08-03|BEFORE|2020-09-02
e|RS|f2cd01c4-b765-4ac5-8e8d-c9fef7366720|3|MRDRESP|Minimal Residual Disease Response|DOHNER AML 2010|[?]|in2|MORPHOLOGIC CR|1|mOsm/kg|CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY||Y||FAMILY MEMBER|ENDOCRINOLOGIST|N|2|Visit_2|25|4|WASHOUT|2020-07-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-14|P1Y2M10DT2H30M|COINCIDENT|2020-07-11|ONGOING|2020-09-30
e|RS|f2cd01c4-b765-4ac5-8e8d-c9fef7366720|4|MRPHRESP|Morphologic Response|IWG CHESON AML 2003|||cPR|1|g/cm2|DIFFUSION WEIGHTED MRI|Y||Y|FRIEND|RATER 2|NA|2|Visit_2|25|7|TREATMENT|2020-07-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-14|P1Y2M10DT2H30M|BEFORE|2020-08-06|AFTER|2020-08-22
e|RS|f2cd01c4-b765-4ac5-8e8d-c9fef7366720|5|STRUSTAT|Steroid Use Status|WHO BREAST CANCER 2006|||MRD NEGATIVITY|1|ug/m2/day|JAFFE REACTION|Y|Y|Y|SIBLING|MICROSCOPIST 1|NA|3|Visit_3|40|2|SCREENING|2020-08-14|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-17|P1Y2M10DT2H30M|BEFORE|2020-08-06|ONGOING|2020-08-13
e|RS|f2cd01c4-b765-4ac5-8e8d-c9fef7366720|6|MJPTHIND|Major Pathological Response Indicator|MONTSERRAT CLL 1989|[?]|umol/kg/min|DECREASED|1|10^8 PFU|FLUORESCENT SPOT TEST|Y|||PARENT|NEUROLOGIST|U|3|Visit_3|40|1|TREATMENT|2020-08-14|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-17|P1Y2M10DT2H30M|BEFORE|2020-08-02|ONGOING|2020-10-07
e|RS|f2cd01c4-b765-4ac5-8e8d-c9fef7366720|7|SPLNRESP|Spleen Response|IWG CHESON AML 2003|[?]|K|MRD PERSISTENCE|1|Ejaculate U|SMEAR||Y||PROXY|FORENSIC PATHOLOGIST|N|4|Visit_4|65|5|WASHOUT|2020-09-08|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-14|P1Y2M10DT2H30M|UNKNOWN|2020-08-05|COINCIDENT|2020-08-28
e|RS|f2cd01c4-b765-4ac5-8e8d-c9fef7366720|8|NTERESP|Non-Target Enhancing Response|IWC HALLEK CLL 2008|[?]|SYRINGE|EQUIVOCAL|1|log10 copies/mL|DYNAMIC LIGHT SCATTERING||||CHILD|CLINICAL PATHOLOGIST|NA|4|Visit_4|65|5|FOLLOW-UP|2020-09-08|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-14|P1Y2M10DT2H30M|UNKNOWN|2020-09-14|BEFORE|2020-10-02
e|RS|f2cd01c4-b765-4ac5-8e8d-c9fef7366720|9|RDIORESP|Radiologic Response|RECICL|[?]|mm/min|cPR|1|Arbitrary U|CELL CYTOTOXICITY NEUTRALIZATION ASSAY||||FRIEND|UROLOGIST|U|5|Visit_5|90|1|WASHOUT|2020-10-03|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-14|P1Y2M10DT2H30M|UNKNOWN|2020-08-20|COINCIDENT|2020-10-02
e|RS|f2cd01c4-b765-4ac5-8e8d-c9fef7366720|10|CPRFSTAT|Clinical Performance Status|MASS|[?]|Bq/kg|EQUIVOCAL|1|pg|ELECTROMYOGRAPHY||||ADJUDICATOR|ONCOLOGIST 1|N|5|Visit_5|90|3|SCREENING|2020-10-03|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-14|P1Y2M10DT2H30M|UNKNOWN|2020-08-12|ONGOING|2020-10-04
e|RS|4ba88073-0003-461a-a950-4504ef7680e7|1|RDIORESP|Radiologic Response|IRANO 2015|||INDETERMINATE RESPONSE|1|JAR|INTRAVASCULAR ULTRASOUND|||Y|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|U|1|Visit_1|10|2|SCREENING|2020-09-02|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-06|P1Y2M10DT2H30M|AFTER|2020-09-25|ONGOING|2020-11-03
e|RS|4ba88073-0003-461a-a950-4504ef7680e7|2|SYMPTDTR|Symptomatic Deterioration|PCWG SCHER PROSTATE CANCER 2008|[?]|10^9 CFU|DECREASED|1|mL/g/min|PHOROPTER||Y||CAREGIVER|OPTOMETRIST|U|1|Visit_1|10|4|WASHOUT|2020-09-02|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-06|P1Y2M10DT2H30M|BEFORE|2020-08-25|BEFORE|2020-11-27
e|RS|4ba88073-0003-461a-a950-4504ef7680e7|3|RDIORESP|Radiologic Response|MONTSERRAT CLL 1989|[?]|mm|mCR|1|kIU|IMMUNODIFFUSION||||PARENT|CLINICAL PATHOLOGIST|N|2|Visit_2|25|1|SCREENING|2020-09-17|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-16|P1Y2M10DT2H30M|BEFORE|2020-11-08|AFTER|2020-11-20
e|RS|4ba88073-0003-461a-a950-4504ef7680e7|4|NEWLWIND|New Lesion Worsening Indicator|iRECIST|[?]|fmol|NON-iCR/NON-iUPD|1|umol|SPIRAL CT SCAN WITHOUT CONTRAST||Y||DOMESTIC PARTNER|OPHTHALMOLOGIST|Y|2|Visit_2|25|3|SCREENING|2020-09-17|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-16|P1Y2M10DT2H30M|COINCIDENT|2020-11-21|ONGOING|2020-11-29
e|RS|4ba88073-0003-461a-a950-4504ef7680e7|5|TRGRESP|Target Response|DOHNER AML 2010|[?]|U/10^12 RBC|NON-iCR/NON-iUPD|1|kDa|TWO-COLOR MICROARRAY|Y|||HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|NA|3|Visit_3|40|2|SCREENING|2020-10-02|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-12|P1Y2M10DT2H30M|COINCIDENT|2020-08-30|ONGOING|2020-09-12
e|RS|4ba88073-0003-461a-a950-4504ef7680e7|6|METSIND|Metastatic Indicator|CHOI GIST 2008|||STABLE|1|umol/L/min|NON-INVASIVE DIELECTRIC SENSING|Y||Y|INVESTIGATOR|MICROSCOPIST|N|3|Visit_3|40|3|TREATMENT|2020-10-02|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-12|P1Y2M10DT2H30M|BEFORE|2020-10-05|BEFORE|2020-10-26
e|RS|4ba88073-0003-461a-a950-4504ef7680e7|7|NTERESP|Non-Target Enhancing Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|||nPR|1|SUPPOSITORY|IMMUNOPRECIPITATION||Y|Y|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|U|4|Visit_4|65|1|TREATMENT|2020-10-27|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-21|P1Y2M10DT2H30M|BEFORE|2020-11-10|AFTER|2020-11-21
e|RS|4ba88073-0003-461a-a950-4504ef7680e7|8|CPRFSTAT|Clinical Performance Status|GUPPY OVARIAN CANCER 2002|||RELAPSED DISEASE|1|10^6 CFU/g|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY||Y|Y|CLINICAL RESEARCH COORDINATOR|READER 2|N|4|Visit_4|65|6|TREATMENT|2020-10-27|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-21|P1Y2M10DT2H30M|COINCIDENT|2020-10-28|COINCIDENT|2020-11-07
e|RS|4ba88073-0003-461a-a950-4504ef7680e7|9|SPLNRESP|Spleen Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|L/kg|VGPR|1|/10^4|SPIRAL CT||||PROXY|RATER 1|NA|5|Visit_5|90|3|TREATMENT|2020-11-21|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-21|P1Y2M10DT2H30M|UNKNOWN|2020-10-23|COINCIDENT|2020-11-07
e|RS|4ba88073-0003-461a-a950-4504ef7680e7|10|NEWLPROG|New Lesion Progression|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|kV|RELAPSED DISEASE|1|10^9 organisms/mg|CLINICAL EVALUATION||||ADJUDICATION COMMITTEE|MICROSCOPIST|N|5|Visit_5|90|6|SCREENING|2020-11-21|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-21|P1Y2M10DT2H30M|AFTER|2020-09-21|COINCIDENT|2020-10-03
e|RS|a0079507-0ad8-45e3-94f9-bfe0a80c7c4d|1|LIVRRESP|Liver Response|NCIWG CHESON CLL 1996|[?]|pt_br|CYTOGENETIC MINIMAL RESPONSE|1|mol|AMSLER GRID||||DOMESTIC PARTNER|MICROSCOPIST 2|N|1|Visit_1|10|6|FOLLOW-UP|2020-09-01|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-23|P1Y2M10DT2H30M|UNKNOWN|2020-09-08|COINCIDENT|2020-09-15
e|RS|a0079507-0ad8-45e3-94f9-bfe0a80c7c4d|2|NTERESP|Non-Target Enhancing Response|HARTMANN GERM CELL CANCER 2002|[?]|nmol BCE/mmol|pCR|1|DRINK|FLUORESCENT LIFETIME IMAGING MICROSCOPY||||FAMILY MEMBER|READER|Y|1|Visit_1|10|5|TREATMENT|2020-09-01|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-23|P1Y2M10DT2H30M|UNKNOWN|2020-11-16|ONGOING|2020-11-20
e|RS|a0079507-0ad8-45e3-94f9-bfe0a80c7c4d|3|NTNERESP|Non-Target Non-Enhancing Response|EBMT BLADE MYELOMA 1998|[?]|U/g|MORPHOLOGIC CR|1|IU/mg|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY||||CLINICAL STUDY SPONSOR|OPHTHALMOLOGIST|U|2|Visit_2|25|2|TREATMENT|2020-09-16|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-20|P1Y2M10DT2H30M|COINCIDENT|2020-09-20|BEFORE|2020-11-01
e|RS|a0079507-0ad8-45e3-94f9-bfe0a80c7c4d|4|SFTSRESP|Soft Tissue Response|IWG CHESON AML 2003|[?]|DAgU/mL|ABSENT MORPHOLOGIC RESPONSE|1|U/mL|IMPULSE OSCILLOMETRY||||HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|U|2|Visit_2|25|5|FOLLOW-UP|2020-09-16|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-20|P1Y2M10DT2H30M|AFTER|2020-11-08|BEFORE|2020-11-13
e|RS|a0079507-0ad8-45e3-94f9-bfe0a80c7c4d|5|OVRLRESP|Overall Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|MPL U|PSEUDOPROGRESSION|1|SBE/mL|GEL ELECTROPHORESIS||||PARENT|NEUROLOGIST 2|U|3|Visit_3|40|3|FOLLOW-UP|2020-10-01|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-27|P1Y2M10DT2H30M|BEFORE|2020-09-11|AFTER|2020-11-15
e|RS|a0079507-0ad8-45e3-94f9-bfe0a80c7c4d|6|RDIORESP|Radiologic Response|IWG CHESON MDS 2006|[?]|10^6/Ejaculate U|MORPHOLOGIC LEUKEMIA-FREE STATE|1|mol/mg|GIEMSA STAIN||||ADJUDICATOR|MICROSCOPIST 1|U|3|Visit_3|40|2|TREATMENT|2020-10-01|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-27|P1Y2M10DT2H30M|AFTER|2020-10-29|AFTER|2020-10-31
e|RS|a0079507-0ad8-45e3-94f9-bfe0a80c7c4d|7|NTLWIND|Non-Target Lesion Worsening Indicator|WHO BREAST CANCER 2006|||ABSENT MORPHOLOGIC RESPONSE|1|GBq|PHASE CONTRAST MICROSCOPY||Y|Y|VENDOR|MICROSCOPIST 1|NA|4|Visit_4|65|3|SCREENING|2020-10-26|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-26|P1Y2M10DT2H30M|BEFORE|2020-11-23|AFTER|2020-11-26
e|RS|a0079507-0ad8-45e3-94f9-bfe0a80c7c4d|8|NTNERESP|Non-Target Non-Enhancing Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|pg/L|NON-iCR/NON-iUPD|1|mm/min|GC/MS-EI|Y|||VENDOR|NEUROLOGIST 1|N|4|Visit_4|65|5|FOLLOW-UP|2020-10-26|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-26|P1Y2M10DT2H30M|BEFORE|2020-09-24|AFTER|2020-10-15
e|RS|a0079507-0ad8-45e3-94f9-bfe0a80c7c4d|9|TMRESP|Tumor Marker Response|DURIE MULTIPLE MYELOMA 2006|[?]|ng/mol|RELAPSED DISEASE|1|C|DUKE INCISION METHOD|Y|Y||ADJUDICATION COMMITTEE|ADJUDICATOR|NA|5|Visit_5|90|4|FOLLOW-UP|2020-11-20|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-29|P1Y2M10DT2H30M|UNKNOWN|2020-11-12|AFTER|2020-11-15
e|RS|a0079507-0ad8-45e3-94f9-bfe0a80c7c4d|10|MJPTHIND|Major Pathological Response Indicator|CHESON LYMPHOMA 2008|[?]|Bq/L|OPTIMAL MORPHOLOGIC RESPONSE|1|dpm/100mg|DYNAMIC LIGHT SCATTERING||||GUARDIAN|ADJUDICATOR 2|N|5|Visit_5|90|2|TREATMENT|2020-11-20|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-29|P1Y2M10DT2H30M|BEFORE|2020-11-22|AFTER|2020-11-27
e|RS|f552fa78-d78f-44c5-9590-30a737e6652d|1|MRDIND|Minimal Residual Disease Indicator|HARTMANN GERM CELL CANCER 2002|[?]|ug/g/day|IMMUNOPHENOTYPIC CR|1|mg/m2/h|QUANTITATIVE CORONARY ANGIOGRAPHY||||INVESTIGATOR|NEUROLOGIST|NA|1|Visit_1|10|5|TREATMENT|2020-10-05|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-11|P1Y2M10DT2H30M|COINCIDENT|2020-12-09|ONGOING|2020-12-22
e|RS|f552fa78-d78f-44c5-9590-30a737e6652d|2|MRDRESP|Minimal Residual Disease Response|PCWG SCHER PROSTATE CANCER 2008|||RELAPSED DISEASE|1|SACHET|POPULATION SEQUENCING|||Y|CLINICAL STUDY SPONSOR|ONCOLOGIST|N|1|Visit_1|10|5|SCREENING|2020-10-05|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-11|P1Y2M10DT2H30M|AFTER|2021-01-02|COINCIDENT|2021-01-03
e|RS|f552fa78-d78f-44c5-9590-30a737e6652d|3|LIVRRESP|Liver Response|GUPPY OVARIAN CANCER 2002|[?]|U/m2/min|IMMUNOPHENOTYPIC CR|1|steps/min|CONTACT SPECULAR MICROSCOPY||||GUARDIAN|OTOLARYNGOLOGIST|NA|2|Visit_2|25|1|TREATMENT|2020-10-20|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-11|P1Y2M10DT2H30M|BEFORE|2020-11-28|COINCIDENT|2020-12-10
e|RS|f552fa78-d78f-44c5-9590-30a737e6652d|4|METBRESP|Metabolic Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|DIOPTER|COMPLETE MRD RESPONSE|1|/MBP|VIRUS PLAQUE ASSAY|Y|Y||SIBLING|ADJUDICATOR 1|U|2|Visit_2|25|5|TREATMENT|2020-10-20|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-11|P1Y2M10DT2H30M|COINCIDENT|2020-10-20|ONGOING|2020-12-24
e|RS|f552fa78-d78f-44c5-9590-30a737e6652d|5|NEWLIND|New Lesion Indicator|IWC HALLEK CLL 2008|||iSD|1|SCOOPFUL|HILLMEN COLOR CHART|Y||Y|VENDOR|NEUROLOGIST 2|NA|3|Visit_3|40|7|SCREENING|2020-11-04|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-01|P1Y2M10DT2H30M|UNKNOWN|2020-10-07|COINCIDENT|2020-12-15
e|RS|f552fa78-d78f-44c5-9590-30a737e6652d|6|DRCRIND|Disease Recurrence Indicator|BURCOMBE BREAST CANCER 2005|[?]|Pa|QUANTIFIABLE MRD POSITIVITY|1|mL/g/min|IMMUNODIFFUSION||Y||SPOUSE|PEDIATRIC NEUROLOGIST|NA|3|Visit_3|40|6|TREATMENT|2020-11-04|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-01|P1Y2M10DT2H30M|BEFORE|2020-12-20|COINCIDENT|2020-12-29
e|RS|f552fa78-d78f-44c5-9590-30a737e6652d|7|BONERESP|Bone Response|EASL BRUIX LIVER CANCER 2001|[?]|10^3 CFU/g|mCR|1|10^9 CFU/g|GC/MS/MS|Y|||SIBLING|RADIOLOGIST|N|4|Visit_4|65|3|TREATMENT|2020-11-29|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-14|P1Y2M10DT2H30M|UNKNOWN|2020-12-27|ONGOING|2020-12-31
e|RS|f552fa78-d78f-44c5-9590-30a737e6652d|8|BESTRESP|Best Overall Response|MURPHY PROSTATE CANCER 1980|[?]|ug/m2/day|CMR|1|mmol2/L2|DIFFUSION WEIGHTED MRI||||INVESTIGATOR|MICROSCOPIST 3|Y|4|Visit_4|65|4|WASHOUT|2020-11-29|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-14|P1Y2M10DT2H30M|UNKNOWN|2020-12-10|BEFORE|2020-12-24
e|RS|f552fa78-d78f-44c5-9590-30a737e6652d|9|MOLRESP|Molecular Response|KUMAR IMWG 2016|[?]|ppm|PARTIAL MORPHOLOGIC RESPONSE|1|SPRAY|NON-CONTACT SPECULAR MICROSCOPY||Y||DOMESTIC PARTNER|HEMATOLOGIST|N|5|Visit_5|90|6|TREATMENT|2020-12-24|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-29|P1Y2M10DT2H30M|COINCIDENT|2020-10-14|COINCIDENT|2020-12-10
e|RS|f552fa78-d78f-44c5-9590-30a737e6652d|10|NEWLWIND|New Lesion Worsening Indicator|BRUGGEMANN MRD 2010|[?]|mmol/L|CYTOGENETIC PR|1|mOsm/kg|GC/MS-EI||Y||DOMESTIC PARTNER|INTERNIST|N|5|Visit_5|90|1|TREATMENT|2020-12-24|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-29|P1Y2M10DT2H30M|UNKNOWN|2020-12-05|AFTER|2020-12-09
e|RS|38d83f86-d8ce-461a-a288-95aebe498d22|1|MOLRESP|Molecular Response|HAMAOKA BREAST CANCER 2010|[?]|Gravitational Unit|NON-iCR/NON-iUPD|1|dL|PYROSEQUENCING||||INDEPENDENT ASSESSOR|FORENSIC PATHOLOGIST|U|1|Visit_1|10|6|TREATMENT|2020-08-25|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-23|P1Y2M10DT2H30M|AFTER|2020-09-15|AFTER|2020-11-08
e|RS|38d83f86-d8ce-461a-a288-95aebe498d22|2|MRPHRESP|Morphologic Response|CHOI GIST 2008|||PMD|1|L/min|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY|||Y|SIBLING|ENDOCRINOLOGIST|Y|1|Visit_1|10|4|FOLLOW-UP|2020-08-25|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-23|P1Y2M10DT2H30M|UNKNOWN|2020-10-19|AFTER|2020-11-07
e|RS|38d83f86-d8ce-461a-a288-95aebe498d22|3|MRPHRESP|Morphologic Response|AJCC V7|[?]|mN|CYTOGENETIC PR|1|MONTHS|CONTRAST ENHANCED X-RAY|Y|||SPOUSE|READER 3|U|2|Visit_2|25|2|TREATMENT|2020-09-09|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-18|P1Y2M10DT2H30M|UNKNOWN|2020-08-29|COINCIDENT|2020-10-12
e|RS|38d83f86-d8ce-461a-a288-95aebe498d22|4|RDIORESP|Radiologic Response|RECIST 1.1|[?]|P|CA125 75% RESPONSE|1|usec|GC/MS-EI||||STUDY SUBJECT|NEUROLOGIST 1|U|2|Visit_2|25|2|SCREENING|2020-09-09|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-18|P1Y2M10DT2H30M|UNKNOWN|2020-08-26|COINCIDENT|2020-09-18
e|RS|38d83f86-d8ce-461a-a288-95aebe498d22|5|SYMPTDTR|Symptomatic Deterioration|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|10^3 CFU|NE|1|CAPLET|THERMAL IONIZATION MASS SPECTROMETRY||||FAMILY MEMBER|DERMATOLOGIST|Y|3|Visit_3|40|7|TREATMENT|2020-09-24|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-02|P1Y2M10DT2H30M|UNKNOWN|2020-09-12|ONGOING|2020-10-21
e|RS|38d83f86-d8ce-461a-a288-95aebe498d22|6|HEMARESP|Hematologic Response|PALUMBO MULTIPLE MYELOMA 2009|||CYTOGENETIC NO RESPONSE|1|PLUG|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY|Y||Y|FAMILY MEMBER|PHYSIOTHERAPIST|U|3|Visit_3|40|1|WASHOUT|2020-09-24|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-02|P1Y2M10DT2H30M|UNKNOWN|2020-08-23|ONGOING|2020-08-24
e|RS|38d83f86-d8ce-461a-a288-95aebe498d22|7|NTRGRESP|Non-target Response|FAROOQUI SUPP CLL 2014|[?]|cy/cm|NE|1|BP|CALCULATION|Y|||ADJUDICATION COMMITTEE|ENDOCRINOLOGIST|N|4|Visit_4|65|2|TREATMENT|2020-10-19|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-06|P1Y2M10DT2H30M|UNKNOWN|2020-10-12|BEFORE|2020-11-01
e|RS|38d83f86-d8ce-461a-a288-95aebe498d22|8|METSIND|Metastatic Indicator|PALUMBO MULTIPLE MYELOMA 2009|[?]|10^5/hpf|NON-iCR/NON-iUPD|1|ELISA unit/dose|QUANTITATIVE ULTRASOUND||Y||ADJUDICATION COMMITTEE|MICROSCOPIST|U|4|Visit_4|65|7|TREATMENT|2020-10-19|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-06|P1Y2M10DT2H30M|AFTER|2020-11-15|BEFORE|2020-11-17
e|RS|38d83f86-d8ce-461a-a288-95aebe498d22|9|PATHRESP|Pathologic Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|Rad|PSA PROGRESSION|1|uCi/kg|MOUSE PROTECTION ASSAY||||CHILD|READER 3|Y|5|Visit_5|90|7|WASHOUT|2020-11-13|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-01|P1Y2M10DT2H30M|UNKNOWN|2020-10-24|BEFORE|2020-11-07
e|RS|38d83f86-d8ce-461a-a288-95aebe498d22|10|NTLWIND|Non-Target Lesion Worsening Indicator|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|RFU|COMPLETE MRD RESPONSE|1|10^3/L|FREEZING POINT DEPRESSION|Y|||PARENT|RADIOLOGIST|NA|5|Visit_5|90|3|SCREENING|2020-11-13|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-01|P1Y2M10DT2H30M|UNKNOWN|2020-11-05|BEFORE|2020-11-14
e|RS|b31e8820-cc17-4ce5-af30-358dbeb12ba2|1|METSIND|Metastatic Indicator|SCHWARZ CERVICAL CANCER 2009|[?]|mL|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|uEq/L|ELECTROCHEMILUMINESCENCE|Y|Y||GUARDIAN|RATER|Y|1|Visit_1|10|6|TREATMENT|2020-08-13|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-19|P1Y2M10DT2H30M|AFTER|2020-10-16|AFTER|2020-10-18
e|RS|b31e8820-cc17-4ce5-af30-358dbeb12ba2|2|BMIVLIND|Bone Marrow Involvement Indicator|RANO|[?]|10^6 IU|EQUIVOCAL|1|kUSP|GIEMSA STAIN||Y||INVESTIGATOR|PATHOLOGIST 2|U|1|Visit_1|10|6|TREATMENT|2020-08-13|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-19|P1Y2M10DT2H30M|UNKNOWN|2020-10-27|BEFORE|2020-11-09
e|RS|b31e8820-cc17-4ce5-af30-358dbeb12ba2|3|NTNERESP|Non-Target Non-Enhancing Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|mmol|NON-QUANTIFIABLE MRD POSITIVITY|1|kHz|HEMAGGLUTINATION ASSAY||||DOMESTIC PARTNER|READER 2|Y|2|Visit_2|25|4|FOLLOW-UP|2020-08-28|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-15|P1Y2M10DT2H30M|COINCIDENT|2020-08-18|BEFORE|2020-10-28
e|RS|b31e8820-cc17-4ce5-af30-358dbeb12ba2|4|SFTSRESP|Soft Tissue Response|RECICL|[?]|MdFI|NON-CR/NON-PD|1|mL/100g/min|ANTIBIOTIC AGAR SCREEN|Y|||PARENT|PATHOLOGIST|NA|2|Visit_2|25|6|TREATMENT|2020-08-28|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-15|P1Y2M10DT2H30M|COINCIDENT|2020-10-01|AFTER|2020-11-05
e|RS|b31e8820-cc17-4ce5-af30-358dbeb12ba2|5|SFTSRESP|Soft Tissue Response|WOLCHOK SOLID TUMORS 2009|[?]|L|CYTOGENETIC MINIMAL RESPONSE|1|gpELISA unit/mL|MACRO BROTH DILUTION||||CAREGIVER|MICROSCOPIST|N|3|Visit_3|40|3|WASHOUT|2020-09-12|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-16|P1Y2M10DT2H30M|BEFORE|2020-10-28|BEFORE|2020-11-07
e|RS|b31e8820-cc17-4ce5-af30-358dbeb12ba2|6|HEMARESP|Hematologic Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|MnFI|MAJOR PATHOLOGIC RESPONSE|1|mL/mmHg/min/L|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY||Y||INVESTIGATOR|NEUROLOGIST 1|Y|3|Visit_3|40|2|TREATMENT|2020-09-12|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-16|P1Y2M10DT2H30M|UNKNOWN|2020-10-28|ONGOING|2020-10-29
e|RS|b31e8820-cc17-4ce5-af30-358dbeb12ba2|7|MRDIND|Minimal Residual Disease Indicator|IWG CHESON AML 2003|||iSD|1|cm2|INTRAVASCULAR ULTRASOUND|||Y|INDEPENDENT ASSESSOR|MICROSCOPIST 3|NA|4|Visit_4|65|3|WASHOUT|2020-10-07|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-07|P1Y2M10DT2H30M|BEFORE|2020-09-13|ONGOING|2020-10-11
e|RS|b31e8820-cc17-4ce5-af30-358dbeb12ba2|8|MOLRESP|Molecular Response|PCWG SCHER PROSTATE CANCER 2008|[?]|/10^5|CA125 75% RESPONSE|1|Gy/min|CORONARY ANGIOGRAPHY||||SIGNIFICANT OTHER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|4|Visit_4|65|4|SCREENING|2020-10-07|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-07|P1Y2M10DT2H30M|COINCIDENT|2020-10-02|BEFORE|2020-10-30
e|RS|b31e8820-cc17-4ce5-af30-358dbeb12ba2|9|MRPHRESP|Morphologic Response|SACT|[?]|scm|PD FROM PR|1|10^9 organisms/mL|CONTRAST ENHANCED SPIRAL CT SCAN||||SPOUSE|NEUROLOGIST 1|U|5|Visit_5|90|7|TREATMENT|2020-11-01|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-13|P1Y2M10DT2H30M|COINCIDENT|2020-09-28|COINCIDENT|2020-10-29
e|RS|b31e8820-cc17-4ce5-af30-358dbeb12ba2|10|CLINRESP|Clinical Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|Mile|PMD|1|mol/mL|THICK SMEAR||||SPOUSE|OPHTHALMOLOGIST|N|5|Visit_5|90|4|TREATMENT|2020-11-01|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-13|P1Y2M10DT2H30M|BEFORE|2020-09-19|BEFORE|2020-10-10
e|RS|cf39d5bd-7682-4546-8495-5bcf48600a69|1|MRDRESP|Minimal Residual Disease Response|MURPHY PROSTATE CANCER 1980|[?]|mg2/dL2|MRD NEGATIVITY|1|/mm2|EEG||||NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST|N|1|Visit_1|10|6|TREATMENT|2021-01-20|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-24|P1Y2M10DT2H30M|AFTER|2021-03-17|AFTER|2021-03-18
e|RS|cf39d5bd-7682-4546-8495-5bcf48600a69|2|SYMPTDTR|Symptomatic Deterioration|WOLCHOK SOLID TUMORS 2009|[?]|BAG|PSEUDOPROGRESSION|1|mL/beat|DIFFUSION WEIGHTED MRI|Y|||FRIEND|MICROSCOPIST 2|Y|1|Visit_1|10|4|FOLLOW-UP|2021-01-20|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-24|P1Y2M10DT2H30M|BEFORE|2021-03-07|AFTER|2021-03-25
e|RS|cf39d5bd-7682-4546-8495-5bcf48600a69|3|METSIND|Metastatic Indicator|RANO ELLINGSON 2017|[?]|pt_us|INCREASED|1|IMPLANT|CONTRAST ENHANCED X-RAY|Y|||SPOUSE|PEDIATRIC NEUROLOGIST|NA|2|Visit_2|25|3|TREATMENT|2021-02-04|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-05|P1Y2M10DT2H30M|UNKNOWN|2021-03-17|COINCIDENT|2021-04-14
e|RS|cf39d5bd-7682-4546-8495-5bcf48600a69|4|TRGRESP|Target Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|ug/kg/h|CR-CT|1|U/g|TRIPLE-PHASE MRI SCAN|Y|Y||FAMILY MEMBER|UROLOGIST|Y|2|Visit_2|25|3|FOLLOW-UP|2021-02-04|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-05|P1Y2M10DT2H30M|COINCIDENT|2021-03-30|COINCIDENT|2021-04-12
e|RS|cf39d5bd-7682-4546-8495-5bcf48600a69|5|MJPTHIND|Major Pathological Response Indicator|BLAZER COLORECTAL CANCER 2008|[?]|VOXEL|pCR|1|/ms|ICP-MS|Y|||CLINICAL STUDY SPONSOR|RATER|U|3|Visit_3|40|4|SCREENING|2021-02-19|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-10|P1Y2M10DT2H30M|UNKNOWN|2021-04-11|COINCIDENT|2021-04-14
e|RS|cf39d5bd-7682-4546-8495-5bcf48600a69|6|NTNERESP|Non-Target Non-Enhancing Response|IRANO 2015|[?]|umol/h/mmol|CYTOGENETIC MINOR RESPONSE|1|10^7/L|MICROBIAL BIOCHEMICAL IDENTIFICATION||Y||CAREGIVER|UROLOGIST|U|3|Visit_3|40|3|TREATMENT|2021-02-19|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-10|P1Y2M10DT2H30M|AFTER|2021-03-09|COINCIDENT|2021-04-18
e|RS|cf39d5bd-7682-4546-8495-5bcf48600a69|7|DRCRIND|Disease Recurrence Indicator|KUKER LYMPHOMA 2005|[?]|ug/g/h|iCR|1|10^3 CFU/g|MICROBIAL CONCENTRATION||||SPOUSE|PHYSIOTHERAPIST|U|4|Visit_4|65|7|TREATMENT|2021-03-16|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-18|P1Y2M10DT2H30M|UNKNOWN|2021-04-16|AFTER|2021-04-17
e|RS|cf39d5bd-7682-4546-8495-5bcf48600a69|8|MRDRESP|Minimal Residual Disease Response|SCHWARZ CERVICAL CANCER 2009|[?]|cL|PMR|1|U/m2/min|ELECTRICAL IMPEDANCE MYOGRAPHY||Y||SPOUSE|READER 2|NA|4|Visit_4|65|5|SCREENING|2021-03-16|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-18|P1Y2M10DT2H30M|UNKNOWN|2021-03-19|BEFORE|2021-03-20
e|RS|cf39d5bd-7682-4546-8495-5bcf48600a69|9|DRCRIND|Disease Recurrence Indicator|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|kg/cm2|NON-PD|1|mg2/dL2|TOTAL BODY IRRADIATION|Y|||SIGNIFICANT OTHER|RATER|U|5|Visit_5|90|5|TREATMENT|2021-04-10|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-27|P1Y2M10DT2H30M|BEFORE|2021-02-17|COINCIDENT|2021-03-19
e|RS|cf39d5bd-7682-4546-8495-5bcf48600a69|10|RDIORESP|Radiologic Response|IWG CHESON MDS 2000|[?]|cal|NON-CR/NON-PD|1|mU/g|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS||||FAMILY MEMBER|READER 1|N|5|Visit_5|90|7|FOLLOW-UP|2021-04-10|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-27|P1Y2M10DT2H30M|COINCIDENT|2021-01-28|COINCIDENT|2021-03-11
e|RS|84c17e7b-8d56-4726-96a5-9ca41fb9d894|1|NTNERESP|Non-Target Non-Enhancing Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|uU/L|CR-CT|1|keV|FLAME PHOTOMETRY||||HEALTH CARE PROFESSIONAL|READER 3|N|1|Visit_1|10|3|TREATMENT|2020-11-24|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-13|P1Y2M10DT2H30M|AFTER|2020-12-30|ONGOING|2021-02-19
e|RS|84c17e7b-8d56-4726-96a5-9ca41fb9d894|2|METBRESP|Metabolic Response|KUKER LYMPHOMA 2005|||CA125 50% RESPONSE|1|10^6/g|CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY|||Y|HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|N|1|Visit_1|10|7|TREATMENT|2020-11-24|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-13|P1Y2M10DT2H30M|AFTER|2021-01-31|COINCIDENT|2021-02-21
e|RS|84c17e7b-8d56-4726-96a5-9ca41fb9d894|3|MRPHRESP|Morphologic Response|SCHWARZ CERVICAL CANCER 2009|[?]|Linear ft*LB|DISEASE TRANSFORMATION|1|JAR|TRANSTHORACIC ECHOCARDIOGRAPHY|Y|||DOMESTIC PARTNER|INTERNIST|NA|2|Visit_2|25|1|SCREENING|2020-12-09|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-16|P1Y2M10DT2H30M|UNKNOWN|2020-11-24|BEFORE|2021-02-03
e|RS|84c17e7b-8d56-4726-96a5-9ca41fb9d894|4|NTRGRESP|Non-target Response|iRECIST|[?]|1/(s*kPa)|MRD NEGATIVITY|1|oz|EEG|Y|Y||CAREGIVER|ADJUDICATOR|N|2|Visit_2|25|3|TREATMENT|2020-12-09|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-16|P1Y2M10DT2H30M|AFTER|2021-01-04|ONGOING|2021-02-20
e|RS|84c17e7b-8d56-4726-96a5-9ca41fb9d894|5|ANATRESP|Anatomic Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|cmH2O*s/mL|iCPD|1|ag|ISHIHARA COLOR PLATES|Y|Y||CAREGIVER|MICROSCOPIST 1|N|3|Visit_3|40|4|TREATMENT|2020-12-24|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-18|P1Y2M10DT2H30M|BEFORE|2021-02-20|AFTER|2021-02-21
e|RS|84c17e7b-8d56-4726-96a5-9ca41fb9d894|6|RDIORESP|Radiologic Response|RANO ELLINGSON 2017|||NOT ALL EVALUATED|1|pt_us|GRAM STAIN|Y||Y|INVESTIGATOR|MICROSCOPIST 3|NA|3|Visit_3|40|7|TREATMENT|2020-12-24|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-18|P1Y2M10DT2H30M|BEFORE|2021-02-12|BEFORE|2021-02-15
e|RS|84c17e7b-8d56-4726-96a5-9ca41fb9d894|7|HEMARESP|Hematologic Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|mg/mL/day|RELAPSED DISEASE FROM CR|1|MBq/uL|LAPAROSCOPY|Y|||SIGNIFICANT OTHER|PATHOLOGIST 2|NA|4|Visit_4|65|6|TREATMENT|2021-01-18|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-01|P1Y2M10DT2H30M|BEFORE|2021-02-04|COINCIDENT|2021-02-05
e|RS|84c17e7b-8d56-4726-96a5-9ca41fb9d894|8|BESTRESP|Best Overall Response|BURCOMBE BREAST CANCER 2005|||PR|1|/5x10^4 WBC|DYNAMIC CONTRAST ENHANCED MRI|||Y|NON-HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|Y|4|Visit_4|65|5|TREATMENT|2021-01-18|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-01|P1Y2M10DT2H30M|COINCIDENT|2020-12-19|AFTER|2021-01-13
e|RS|84c17e7b-8d56-4726-96a5-9ca41fb9d894|9|NEWLPROG|New Lesion Progression|SCHER PROSTATE CANCER 2011|[?]|CARTRIDGE|MAJOR PATHOLOGIC RESPONSE|1|bel|NEURAMINIDASE INHIBITION ASSAY||||STUDY SUBJECT|ADJUDICATOR 1|U|5|Visit_5|90|7|TREATMENT|2021-02-12|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-20|P1Y2M10DT2H30M|COINCIDENT|2021-02-09|AFTER|2021-02-17
e|RS|84c17e7b-8d56-4726-96a5-9ca41fb9d894|10|NTRGRESP|Non-target Response|MURPHY PROSTATE CANCER 1980|||CYTOGENETIC PR|1|TAMPON|MICRONEUTRALIZATION ASSAY|||Y|CAREGIVER|UROLOGIST|U|5|Visit_5|90|1|TREATMENT|2021-02-12|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-20|P1Y2M10DT2H30M|AFTER|2020-11-23|COINCIDENT|2021-02-02
e|RS|6e557fd7-efaf-4c86-806d-9bd66c7de7da|1|BMIVLIND|Bone Marrow Involvement Indicator|RAJKUMAR MYELOMA 2011|||iCPD|1|mL/kg/day|LEAD CITRATE STAIN||Y|Y|FRIEND|OPHTHALMOLOGIST|U|1|Visit_1|10|3|WASHOUT|2021-01-27|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-07|P1Y2M10DT2H30M|COINCIDENT|2021-03-07|ONGOING|2021-04-24
e|RS|6e557fd7-efaf-4c86-806d-9bd66c7de7da|2|NEWLWIND|New Lesion Worsening Indicator|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|pm|CA125 75% RESPONSE|1|Pa|RYAN BLUE STAIN||||STUDY SUBJECT|MICROSCOPIST|N|1|Visit_1|10|3|TREATMENT|2021-01-27|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-07|P1Y2M10DT2H30M|UNKNOWN|2021-01-21|AFTER|2021-02-15
e|RS|6e557fd7-efaf-4c86-806d-9bd66c7de7da|3|MRPHRESP|Morphologic Response|PETIT BREAST CANCER 2001|[?]|HEP|MRD RELAPSE|1|dpm/mg|PET/CT SCAN||||GUARDIAN|OPHTHALMOLOGIST|N|2|Visit_2|25|3|FOLLOW-UP|2021-02-11|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-08|P1Y2M10DT2H30M|BEFORE|2021-04-13|ONGOING|2021-04-24
e|RS|6e557fd7-efaf-4c86-806d-9bd66c7de7da|4|BMIVLIND|Bone Marrow Involvement Indicator|MASS|[?]|ug/mL/h|nPR|1|mg/m2/h|ETDRS EYE CHART|Y|Y||CAREGIVER|PATHOLOGIST 2|N|2|Visit_2|25|7|FOLLOW-UP|2021-02-11|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-08|P1Y2M10DT2H30M|AFTER|2021-03-05|COINCIDENT|2021-04-01
e|RS|6e557fd7-efaf-4c86-806d-9bd66c7de7da|5|NTRGRESP|Non-target Response|LUGANO CLASSIFICATION|||pCR|1|KALLIKREIN INHIBITOR UNIT|POTENTIOMETRY|||Y|FRIEND|READER|N|3|Visit_3|40|7|SCREENING|2021-02-26|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-25|P1Y2M10DT2H30M|UNKNOWN|2021-03-27|BEFORE|2021-04-17
e|RS|6e557fd7-efaf-4c86-806d-9bd66c7de7da|6|BMIVLIND|Bone Marrow Involvement Indicator|EASL BRUIX LIVER CANCER 2001|[?]|ft3|STABLE|1|gtt|IMMUNOCHROMATOGRAPHY||||CLINICAL STUDY SPONSOR|READER 2|Y|3|Visit_3|40|4|TREATMENT|2021-02-26|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-25|P1Y2M10DT2H30M|COINCIDENT|2021-04-14|ONGOING|2021-04-17
e|RS|6e557fd7-efaf-4c86-806d-9bd66c7de7da|7|ANATRESP|Anatomic Response|RECICL|[?]|QUANTITY SUFFICIENT|iUPD|1|POUCH|TOLUIDINE BLUE STAIN|Y|||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 1|NA|4|Visit_4|65|7|TREATMENT|2021-03-23|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-21|P1Y2M10DT2H30M|AFTER|2021-04-25|BEFORE|2021-04-26
e|RS|6e557fd7-efaf-4c86-806d-9bd66c7de7da|8|METBRESP|Metabolic Response|PERCIST|||HI-N|1|Antibody Unit|ALCIAN BLUE STAIN|Y||Y|INDEPENDENT ASSESSOR|PATHOLOGIST 2|Y|4|Visit_4|65|7|TREATMENT|2021-03-23|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-21|P1Y2M10DT2H30M|BEFORE|2021-03-27|COINCIDENT|2021-04-26
e|RS|6e557fd7-efaf-4c86-806d-9bd66c7de7da|9|OVRLRESP|Overall Response|JACINTO CERVICAL CANCER 2007|||iPR|1|ug/L FEU|NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY|||Y|CAREGIVER|RADIOLOGIST 2|NA|5|Visit_5|90|7|TREATMENT|2021-04-17|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-28|P1Y2M10DT2H30M|UNKNOWN|2021-03-05|BEFORE|2021-04-16
e|RS|6e557fd7-efaf-4c86-806d-9bd66c7de7da|10|CLINRESP|Clinical Response|HAMAOKA BREAST CANCER 2010|[?]|PFU/animal|CYTOGENETIC MINIMAL RESPONSE|1|m3|IMMUNOFIXATION ELECTROPHORESIS|Y|||ADJUDICATION COMMITTEE|CARDIOLOGIST|U|5|Visit_5|90|4|TREATMENT|2021-04-17|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-28|P1Y2M10DT2H30M|UNKNOWN|2021-03-25|ONGOING|2021-04-23
e|RS|2b25e1f9-929c-4bdc-8758-79f33b832026|1|SFTSRESP|Soft Tissue Response|RECIST 1.1|[?]|/100 HPFs|cCR|1|FIU|ACID FAST STAIN|Y|||CHILD|MICROSCOPIST 3|NA|1|Visit_1|10|3|FOLLOW-UP|2020-10-19|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-23|P1Y2M10DT2H30M|AFTER|2020-11-12|AFTER|2020-11-14
e|RS|2b25e1f9-929c-4bdc-8758-79f33b832026|2|SFTSRESP|Soft Tissue Response|IRANO 2015|[?]|uL/dose|MRD NEGATIVITY|1|10^9/L|FUNDUS PHOTOGRAPHY||||INVESTIGATOR|RATER 1|N|1|Visit_1|10|6|WASHOUT|2020-10-19|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-23|P1Y2M10DT2H30M|AFTER|2020-12-03|BEFORE|2020-12-20
e|RS|2b25e1f9-929c-4bdc-8758-79f33b832026|3|METSIND|Metastatic Indicator|AJCC V7|||INCREASED|1|Gravitational Unit|ACID FAST STAIN|||Y|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST|U|2|Visit_2|25|3|TREATMENT|2020-11-03|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-16|P1Y2M10DT2H30M|BEFORE|2020-12-10|AFTER|2020-12-25
e|RS|2b25e1f9-929c-4bdc-8758-79f33b832026|4|TMRESP|Tumor Marker Response|UNSPECIFIED|[?]|mL/min/mmHg|MINOR PATHOLOGIC RESPONSE|1|SUPPOSITORY|HEMATOXYLIN AND EOSIN STAIN|Y|||GUARDIAN|ADJUDICATOR 3|U|2|Visit_2|25|4|TREATMENT|2020-11-03|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-16|P1Y2M10DT2H30M|COINCIDENT|2020-11-06|AFTER|2020-11-08
e|RS|2b25e1f9-929c-4bdc-8758-79f33b832026|5|SPLNRESP|Spleen Response|KUMAR IMWG 2016|||MORPHOLOGIC CRi|1|log10 PFU/mL|LIQUID SCINTILLATION COUNTING|||Y|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 3|NA|3|Visit_3|40|2|TREATMENT|2020-11-18|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-29|P1Y2M10DT2H30M|COINCIDENT|2020-12-31|ONGOING|2021-01-06
e|RS|2b25e1f9-929c-4bdc-8758-79f33b832026|6|METSIND|Metastatic Indicator|LEE LUNG CANCER 2011|[?]|mEq/dL|SMD|1|nU/cL|LIGHT SCATTERING SPECTROSCOPY||Y||NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|U|3|Visit_3|40|1|SCREENING|2020-11-18|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-29|P1Y2M10DT2H30M|UNKNOWN|2020-12-28|AFTER|2021-01-09
e|RS|2b25e1f9-929c-4bdc-8758-79f33b832026|7|PATHRESP|Pathologic Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|kBq/uL|SD-CT|1|FINGERTIP UNIT|MALDI||||NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST|Y|4|Visit_4|65|3|TREATMENT|2020-12-13|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-11|P1Y2M10DT2H30M|BEFORE|2021-01-07|COINCIDENT|2021-01-08
e|RS|2b25e1f9-929c-4bdc-8758-79f33b832026|8|CLINRESP|Clinical Response|IWG CHESON MDS 2000|[?]|BOTTLE|NON-iCR/NON-iUPD|1|log10 CCID 50/dose|COMPUTERIZED CORNEAL TOPOGRAPHY||||PARENT|ADJUDICATOR 1|Y|4|Visit_4|65|5|TREATMENT|2020-12-13|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-11|P1Y2M10DT2H30M|BEFORE|2021-01-09|BEFORE|2021-01-13
e|RS|2b25e1f9-929c-4bdc-8758-79f33b832026|9|MRPHRESP|Morphologic Response|NCIWG CHESON CLL 1996|||STABLE|1|PUFF|ALCIAN BLUE STAIN||Y|Y|SIBLING|UROLOGIST|NA|5|Visit_5|90|2|TREATMENT|2021-01-07|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-12|P1Y2M10DT2H30M|AFTER|2020-10-29|COINCIDENT|2020-12-03
e|RS|2b25e1f9-929c-4bdc-8758-79f33b832026|10|NEWLIND|New Lesion Indicator|RANO|[?]|RATIO|NOT ALL EVALUATED|1|/HPF|BALLPOINT PEN TECHNIQUE|Y|Y||HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|Y|5|Visit_5|90|2|TREATMENT|2021-01-07|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-12|P1Y2M10DT2H30M|BEFORE|2020-12-10|COINCIDENT|2021-01-04
e|RS|d02c7553-17f5-44ec-8c24-469234d080e8|1|SFTSRESP|Soft Tissue Response|BURCOMBE BREAST CANCER 2005|[?]|beats/min|MOLECULAR MAJOR RESPONSE|1|PIXEL|PERFUSION MRI||||NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|1|Visit_1|10|3|WASHOUT|2021-01-26|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-20|P1Y2M10DT2H30M|AFTER|2021-03-28|BEFORE|2021-04-08
e|RS|d02c7553-17f5-44ec-8c24-469234d080e8|2|NEWLPROG|New Lesion Progression|SCHER PROSTATE CANCER 2011|[?]|CAPSULE|PMR|1|m/sec2|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY||||ADJUDICATION COMMITTEE|READER 3|NA|1|Visit_1|10|3|WASHOUT|2021-01-26|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-20|P1Y2M10DT2H30M|BEFORE|2021-02-11|COINCIDENT|2021-02-24
e|RS|d02c7553-17f5-44ec-8c24-469234d080e8|3|MJPTHIND|Major Pathological Response Indicator|MONTSERRAT CLL 1989|[?]|10^3 DNA copies/mL|PD FROM PR|1|mOsm|ANALYTICAL ULTRACENTRIFUGATION||||CLINICAL RESEARCH COORDINATOR|RATER 2|NA|2|Visit_2|25|7|TREATMENT|2021-02-10|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-23|P1Y2M10DT2H30M|COINCIDENT|2021-04-23|BEFORE|2021-04-24
e|RS|d02c7553-17f5-44ec-8c24-469234d080e8|4|PATHRESP|Pathologic Response|CHESON CLL 2006|[?]|Tesla|MAJOR PATHOLOGIC RESPONSE|1|mL/m2/h|CALIPER MEASUREMENT METHOD||Y||HEALTH CARE PROFESSIONAL|INTERNIST|NA|2|Visit_2|25|7|SCREENING|2021-02-10|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-23|P1Y2M10DT2H30M|AFTER|2021-03-10|ONGOING|2021-03-26
e|RS|d02c7553-17f5-44ec-8c24-469234d080e8|5|LIVRRESP|Liver Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|% INHIBITION|CYTOGENETIC CR|1|IU/L|MALDI||||CLINICAL STUDY SPONSOR|READER 1|U|3|Visit_3|40|4|TREATMENT|2021-02-25|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-23|P1Y2M10DT2H30M|BEFORE|2021-03-21|COINCIDENT|2021-04-24
e|RS|d02c7553-17f5-44ec-8c24-469234d080e8|6|HEMARESP|Hematologic Response|MACDONALD GLIOMA 1990|||PR|1|PACKET|REBOUND TONOMETRY|||Y|CLINICAL STUDY SPONSOR|RADIOLOGIST 1|U|3|Visit_3|40|1|SCREENING|2021-02-25|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-23|P1Y2M10DT2H30M|UNKNOWN|2021-02-25|BEFORE|2021-04-11
e|RS|d02c7553-17f5-44ec-8c24-469234d080e8|7|NEWLPROG|New Lesion Progression|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|IU/g|PD-CT|1|GBq/g|CYSTOMETRY||||DOMESTIC PARTNER|RATER 2|N|4|Visit_4|65|4|SCREENING|2021-03-22|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-25|P1Y2M10DT2H30M|BEFORE|2021-04-20|BEFORE|2021-04-21
e|RS|d02c7553-17f5-44ec-8c24-469234d080e8|8|NTLWIND|Non-Target Lesion Worsening Indicator|CHOLLET BREAST CANCER 2002|||PDu|1|genEq/mL|EPSILOMETER|||Y|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 2|NA|4|Visit_4|65|2|TREATMENT|2021-03-22|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-25|P1Y2M10DT2H30M|COINCIDENT|2021-03-29|ONGOING|2021-03-31
e|RS|d02c7553-17f5-44ec-8c24-469234d080e8|9|MOLRESP|Molecular Response|BRUGGEMANN MRD 2010|[?]|L/day|nPR|1|SCOOPFUL|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS||Y||SPOUSE|RATER|NA|5|Visit_5|90|6|TREATMENT|2021-04-16|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-22|P1Y2M10DT2H30M|AFTER|2021-02-02|AFTER|2021-03-28
e|RS|d02c7553-17f5-44ec-8c24-469234d080e8|10|TRGRESP|Target Response|IWC HALLEK CLL 2008|[?]|pg|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|mL/m2|MRI||||PROXY|UROLOGIST|NA|5|Visit_5|90|2|SCREENING|2021-04-16|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-22|P1Y2M10DT2H30M|UNKNOWN|2021-02-08|COINCIDENT|2021-03-04
e|RS|e819939e-548d-4e05-83e3-7976790de7e1|1|MRDIND|Minimal Residual Disease Indicator|MRANO VAN DEN BENT GLIOMA 2011|||nPR|1|U/m2/day|INTRAVASCULAR ULTRASOUND|||Y|SIBLING|READER|N|1|Visit_1|10|5|FOLLOW-UP|2020-09-07|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-29|P1Y2M10DT2H30M|COINCIDENT|2020-11-04|ONGOING|2020-11-10
e|RS|e819939e-548d-4e05-83e3-7976790de7e1|2|MRDRESP|Minimal Residual Disease Response|KEAM BREAST CANCER 2013|[?]|%(v/v)|NON-QUANTIFIABLE MRD POSITIVITY|1|MONTHS|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|Y|Y||INVESTIGATOR|UROLOGIST|Y|1|Visit_1|10|2|WASHOUT|2020-09-07|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-29|P1Y2M10DT2H30M|UNKNOWN|2020-11-17|BEFORE|2020-11-19
e|RS|e819939e-548d-4e05-83e3-7976790de7e1|3|METSIND|Metastatic Indicator|iRECIST|[?]|mL/cage/day|iCPD|1|Enzyme U/g Hb|INDIA INK STAIN|Y|||CAREGIVER|RADIOLOGIST 1|N|2|Visit_2|25|1|TREATMENT|2020-09-22|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-24|P1Y2M10DT2H30M|COINCIDENT|2020-11-07|ONGOING|2020-11-15
e|RS|e819939e-548d-4e05-83e3-7976790de7e1|4|NEWLWIND|New Lesion Worsening Indicator|IRANO 2015|[?]|cg|OPTIMAL MORPHOLOGIC RESPONSE|1|mL/sec/1.73m2|NON-CONTACT SPECULAR MICROSCOPY||||CAREGIVER|RATER 2|U|2|Visit_2|25|2|TREATMENT|2020-09-22|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-24|P1Y2M10DT2H30M|AFTER|2020-11-06|COINCIDENT|2020-11-11
e|RS|e819939e-548d-4e05-83e3-7976790de7e1|5|MRDRESP|Minimal Residual Disease Response|SACT|[?]|10^7/L|PMD|1|uCi/kg|CONTRAST ENHANCED PET/CT SCAN|Y|||DOMESTIC PARTNER|ENDOCRINOLOGIST|U|3|Visit_3|40|2|SCREENING|2020-10-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-07|P1Y2M10DT2H30M|UNKNOWN|2020-11-26|COINCIDENT|2020-11-29
e|RS|e819939e-548d-4e05-83e3-7976790de7e1|6|NEWLIND|New Lesion Indicator|IWG CHESON MDS 2000|[?]|pmol/10^10 cells|RELAPSED DISEASE|1|CAPLET|NUCLEIC ACID BASED METHOD||Y||INTERVIEWER|OTOLARYNGOLOGIST|U|3|Visit_3|40|2|WASHOUT|2020-10-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-07|P1Y2M10DT2H30M|UNKNOWN|2020-11-28|ONGOING|2020-11-30
e|RS|e819939e-548d-4e05-83e3-7976790de7e1|7|NTNERESP|Non-Target Non-Enhancing Response|DURIE MULTIPLE MYELOMA 2006|[?]|mL/dose|MRD NEGATIVITY|1|log10 TCID 50/mL|CLINICAL EVALUATION||||VENDOR|PATHOLOGIST 1|Y|4|Visit_4|65|3|WASHOUT|2020-11-01|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-02|P1Y2M10DT2H30M|BEFORE|2020-11-10|BEFORE|2020-12-01
e|RS|e819939e-548d-4e05-83e3-7976790de7e1|8|TRGRESP|Target Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|||UNEQUIVOCAL|1|Henry|RIA|||Y|VENDOR|MICROSCOPIST 1|Y|4|Visit_4|65|6|TREATMENT|2020-11-01|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-02|P1Y2M10DT2H30M|AFTER|2020-11-06|BEFORE|2020-11-26
e|RS|e819939e-548d-4e05-83e3-7976790de7e1|9|MJPTHIND|Major Pathological Response Indicator|KEAM BREAST CANCER 2013|[?]|/100 WBC|pCR|1|umol/kg/min|FLOCCULATION, CHARCOAL ENHANCED||||ADJUDICATOR|RADIOLOGIST|N|5|Visit_5|90|7|TREATMENT|2020-11-26|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-20|P1Y2M10DT2H30M|AFTER|2020-09-28|COINCIDENT|2020-10-18
e|RS|e819939e-548d-4e05-83e3-7976790de7e1|10|NTRGRESP|Non-target Response|CHOLLET BREAST CANCER 2002|[?]|U/mg|MRD RELAPSE|1|WAFER|PALPATION||||INVESTIGATOR|READER 2|NA|5|Visit_5|90|6|TREATMENT|2020-11-26|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-20|P1Y2M10DT2H30M|AFTER|2020-10-04|BEFORE|2020-11-02
e|RS|3b35f16c-38c8-45a2-8872-fe0f0f30b0d9|1|NEWLPROG|New Lesion Progression|MONTSERRAT CLL 1989|[?]|log10 copies/mL|PR WITH LYMPHOCYTOSIS|1|YEARS|DROPLET DIGITAL PCR|Y|||VENDOR|UROLOGIST|U|1|Visit_1|10|7|TREATMENT|2020-08-18|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-13|P1Y2M10DT2H30M|COINCIDENT|2020-10-02|COINCIDENT|2020-11-14
e|RS|3b35f16c-38c8-45a2-8872-fe0f0f30b0d9|2|SFTSRESP|Soft Tissue Response|SHINDOH COLORECTAL CANCER 2013|[?]|hr/day|PSEUDOPROGRESSION|1|/cmH2O|KLEIHAUER-BETKE||||STUDY SUBJECT|OPHTHALMOLOGIST|Y|1|Visit_1|10|4|TREATMENT|2020-08-18|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-13|P1Y2M10DT2H30M|UNKNOWN|2020-08-30|AFTER|2020-11-07
e|RS|3b35f16c-38c8-45a2-8872-fe0f0f30b0d9|3|TRGRESP|Target Response|PCWG SCHER PROSTATE CANCER 2016|[?]|BOWL|PR WITH LYMPHOCYTOSIS|1|%(w/w)|RULER MEASUREMENT METHOD|Y|||CLINICAL STUDY SPONSOR|ADJUDICATOR 1|Y|2|Visit_2|25|2|FOLLOW-UP|2020-09-02|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-30|P1Y2M10DT2H30M|AFTER|2020-08-31|AFTER|2020-09-25
e|RS|3b35f16c-38c8-45a2-8872-fe0f0f30b0d9|4|BESTRESP|Best Overall Response|AJCC V7|[?]|m3|cPR|1|ug/L FEU|SMEAR|Y|||CHILD|OPHTHALMOLOGIST|NA|2|Visit_2|25|4|TREATMENT|2020-09-02|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-30|P1Y2M10DT2H30M|BEFORE|2020-10-08|COINCIDENT|2020-10-18
e|RS|3b35f16c-38c8-45a2-8872-fe0f0f30b0d9|5|NTLWIND|Non-Target Lesion Worsening Indicator|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|AU/mL|CYTOGENETIC MINOR RESPONSE|1|mg/kg/h|PHOROPTER||||CHILD|OPHTHALMOLOGIST|U|3|Visit_3|40|2|WASHOUT|2020-09-17|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-15|P1Y2M10DT2H30M|COINCIDENT|2020-08-24|COINCIDENT|2020-09-02
e|RS|3b35f16c-38c8-45a2-8872-fe0f0f30b0d9|6|BMIVLIND|Bone Marrow Involvement Indicator|EASL BRUIX LIVER CANCER 2001|[?]|BU|CA125 50% RESPONSE|1|uEq|DNA MICROARRAY||Y||VENDOR|NEUROLOGIST 2|Y|3|Visit_3|40|7|TREATMENT|2020-09-17|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-15|P1Y2M10DT2H30M|AFTER|2020-08-12|AFTER|2020-11-13
e|RS|3b35f16c-38c8-45a2-8872-fe0f0f30b0d9|7|LIVRRESP|Liver Response|IWG CHESON AML 2003|[?]|uOsm|OPTIMAL MORPHOLOGIC RESPONSE|1|mmHg*min/L|ORCHIDOMETERY||||CLINICAL RESEARCH COORDINATOR|RATER 1|U|4|Visit_4|65|5|TREATMENT|2020-10-12|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-07|P1Y2M10DT2H30M|UNKNOWN|2020-11-03|COINCIDENT|2020-11-08
e|RS|3b35f16c-38c8-45a2-8872-fe0f0f30b0d9|8|MNPTHIND|Minor Pathological Response Indicator|HARTMAN PANCREATIC CANCER 2012|[?]|mL/s|NON-PD|1|PELLET|AGAR PROPORTION|Y|||CAREGIVER|NEUROLOGIST 1|NA|4|Visit_4|65|1|WASHOUT|2020-10-12|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-07|P1Y2M10DT2H30M|AFTER|2020-10-17|AFTER|2020-11-07
e|RS|3b35f16c-38c8-45a2-8872-fe0f0f30b0d9|9|METSIND|Metastatic Indicator|PCWG BUBLEY PROSTATE CANCER 1999|||MRD RELAPSE|1|min/day|CONTRAST ENHANCED PET SCAN|||Y|ADJUDICATOR|PATHOLOGIST 1|N|5|Visit_5|90|6|WASHOUT|2020-11-06|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-11|P1Y2M10DT2H30M|COINCIDENT|2020-10-05|COINCIDENT|2020-11-10
e|RS|3b35f16c-38c8-45a2-8872-fe0f0f30b0d9|10|NTNERESP|Non-Target Non-Enhancing Response|NCCN ALL MRD 2014|[?]|pptr|cCR|1|amu|MULTIPLE BREATH WASHOUT||Y||CLINICAL RESEARCH ASSOCIATE|CLINICAL PATHOLOGIST|N|5|Visit_5|90|5|TREATMENT|2020-11-06|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-11|P1Y2M10DT2H30M|AFTER|2020-09-16|BEFORE|2020-11-13
e|RS|ea5229ad-6469-4147-be40-546d27c04c4c|1|TMRESP|Tumor Marker Response|IWG CHESON AML 2003|||WORSENED|1|kDa|CELL BASED BIOASSAY|||Y|CLINICAL STUDY SPONSOR|PATHOLOGIST|U|1|Visit_1|10|7|SCREENING|2020-06-09|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-06|P1Y2M10DT2H30M|UNKNOWN|2020-06-29|COINCIDENT|2020-07-15
e|RS|ea5229ad-6469-4147-be40-546d27c04c4c|2|MRDRESP|Minimal Residual Disease Response|SCHWARZ CERVICAL CANCER 2009|[?]|/2500 WBC|CYTOGENETIC MINOR RESPONSE|1|PA|BRDU CELLULAR PROLIFERATION ASSAY||||ADJUDICATION COMMITTEE|HEMATOLOGIST|U|1|Visit_1|10|5|FOLLOW-UP|2020-06-09|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-06|P1Y2M10DT2H30M|AFTER|2020-07-30|COINCIDENT|2020-08-22
e|RS|ea5229ad-6469-4147-be40-546d27c04c4c|3|NEWLWIND|New Lesion Worsening Indicator|MACDONALD GLIOMA 1990|[?]|HEP|CYTOGENETIC MINOR RESPONSE|1|ug/dL|MALDI||Y||VENDOR|PATHOLOGIST 2|N|2|Visit_2|25|7|TREATMENT|2020-06-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-10|P1Y2M10DT2H30M|AFTER|2020-06-04|ONGOING|2020-06-21
e|RS|ea5229ad-6469-4147-be40-546d27c04c4c|4|SFTSRESP|Soft Tissue Response|PRINCE TCELL LYMPHOMA 2010|[?]|L/min|PD|1|mOsm/kg|PERCUSSION||||CHILD|READER|NA|2|Visit_2|25|3|TREATMENT|2020-06-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-10|P1Y2M10DT2H30M|COINCIDENT|2020-08-08|ONGOING|2020-09-02
e|RS|ea5229ad-6469-4147-be40-546d27c04c4c|5|NEWLIND|New Lesion Indicator|GCIG RUSTIN OVARIAN CANCER 2011|[?]|PRESSOR UNITS|PMR|1|pmol|AUSCULTATION||||INTERVIEWER|MICROSCOPIST|U|3|Visit_3|40|2|FOLLOW-UP|2020-07-09|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-25|P1Y2M10DT2H30M|BEFORE|2020-06-14|COINCIDENT|2020-08-26
e|RS|ea5229ad-6469-4147-be40-546d27c04c4c|6|NEWLWIND|New Lesion Worsening Indicator|BURCOMBE BREAST CANCER 2005|[?]|HEP|MOLECULAR MAJOR RESPONSE|1|pkat/L|CYSTOMETRY||||HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|NA|3|Visit_3|40|5|TREATMENT|2020-07-09|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-25|P1Y2M10DT2H30M|AFTER|2020-07-12|BEFORE|2020-08-02
e|RS|ea5229ad-6469-4147-be40-546d27c04c4c|7|RDIORESP|Radiologic Response|AJCC V8|[?]|fraction of 1|ABSENT MORPHOLOGIC RESPONSE|1|mEq/dL|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY||||FAMILY MEMBER|DEVELOPMENTAL PSYCHOLOGIST|N|4|Visit_4|65|4|TREATMENT|2020-08-03|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-14|P1Y2M10DT2H30M|BEFORE|2020-08-23|BEFORE|2020-08-29
e|RS|ea5229ad-6469-4147-be40-546d27c04c4c|8|OVRLRESP|Overall Response|LEE LUNG CANCER 2011|[?]|/100 WBC|HI-N|1|PIXELS/cm|DISK DIFFUSION||||SPOUSE|READER 3|U|4|Visit_4|65|5|TREATMENT|2020-08-03|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-14|P1Y2M10DT2H30M|COINCIDENT|2020-09-03|BEFORE|2020-09-06
e|RS|ea5229ad-6469-4147-be40-546d27c04c4c|9|CPRFSTAT|Clinical Performance Status|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|1/(s*kPa)|PR WITH LYMPHOCYTOSIS|1|mL/s|EIA||||SPOUSE|FORENSIC PATHOLOGIST|Y|5|Visit_5|90|6|FOLLOW-UP|2020-08-28|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-22|P1Y2M10DT2H30M|COINCIDENT|2020-06-06|ONGOING|2020-07-12
e|RS|ea5229ad-6469-4147-be40-546d27c04c4c|10|TMRESP|Tumor Marker Response|GUILHOT CML 2007|[?]|g/cm2|CYTOGENETIC NO RESPONSE|1|MnFI|ANGIOGRAPHY||||GUARDIAN|ONCOLOGIST 1|U|5|Visit_5|90|1|TREATMENT|2020-08-28|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-22|P1Y2M10DT2H30M|BEFORE|2020-06-27|COINCIDENT|2020-08-07
e|RS|0a566742-0f71-4603-85f0-875e2c3395e7|1|NTNERESP|Non-Target Non-Enhancing Response|MASS|||UNFAVORABLE RESPONSE|1|vg/dose|ENZYMATIC COLORIMETRY|Y||Y|ADJUDICATION COMMITTEE|FORENSIC PATHOLOGIST|N|1|Visit_1|10|1|TREATMENT|2021-01-08|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-06|P1Y2M10DT2H30M|AFTER|2021-01-09|COINCIDENT|2021-01-26
e|RS|0a566742-0f71-4603-85f0-875e2c3395e7|2|MJPTHIND|Major Pathological Response Indicator|GUILHOT CML 2007|||WORSENED|1|CIGAR|CT SCAN|||Y|ADJUDICATION COMMITTEE|RATER 2|Y|1|Visit_1|10|7|SCREENING|2021-01-08|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-06|P1Y2M10DT2H30M|AFTER|2021-03-24|AFTER|2021-03-31
e|RS|0a566742-0f71-4603-85f0-875e2c3395e7|3|BMIVLIND|Bone Marrow Involvement Indicator|GCIG RUSTIN OVARIAN CANCER 2011|[?]|g/cage/wk|PR|1|RING|IMMUNOASSAY|Y|||CLINICAL RESEARCH ASSOCIATE|HEMATOLOGIST|U|2|Visit_2|25|1|TREATMENT|2021-01-23|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-29|P1Y2M10DT2H30M|UNKNOWN|2021-02-10|AFTER|2021-03-28
e|RS|0a566742-0f71-4603-85f0-875e2c3395e7|4|BMIVLIND|Bone Marrow Involvement Indicator|SACT|||MR|1|BP|TOTAL BODY RADIOGRAPHY|||Y|SIBLING|ENDOCRINOLOGIST|N|2|Visit_2|25|6|TREATMENT|2021-01-23|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-29|P1Y2M10DT2H30M|COINCIDENT|2021-02-01|BEFORE|2021-03-23
e|RS|0a566742-0f71-4603-85f0-875e2c3395e7|5|MNPTHIND|Minor Pathological Response Indicator|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|mm/2h|HI-E|1|Tesla|GC/FID||||SPOUSE|DEVELOPMENTAL PSYCHOLOGIST|U|3|Visit_3|40|1|TREATMENT|2021-02-07|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-18|P1Y2M10DT2H30M|BEFORE|2021-01-04|AFTER|2021-02-10
e|RS|0a566742-0f71-4603-85f0-875e2c3395e7|6|MOLRESP|Molecular Response|CHESON CLL 2012|[?]|mU/g|UNEQUIVOCAL|1|mol/day|KNEMOMETRY|Y|||HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|Y|3|Visit_3|40|4|WASHOUT|2021-02-07|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-18|P1Y2M10DT2H30M|COINCIDENT|2021-01-07|BEFORE|2021-03-07
e|RS|0a566742-0f71-4603-85f0-875e2c3395e7|7|MJPTHIND|Major Pathological Response Indicator|HAMAOKA BREAST CANCER 2010|[?]|U/mL|PR-CT|1|Gy/h|SNELLEN EYE CHART||||CHILD|DERMATOLOGIST|NA|4|Visit_4|65|2|TREATMENT|2021-03-04|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-20|P1Y2M10DT2H30M|COINCIDENT|2021-02-19|ONGOING|2021-02-26
e|RS|0a566742-0f71-4603-85f0-875e2c3395e7|8|BESTRESP|Best Overall Response|SACT|[?]|dpm/100mg|CYTOGENETIC MINOR RESPONSE|1|mAnson U/mL|IMPEDANCE CONDUCTIVITY||Y||CHILD|DERMATOLOGIST|NA|4|Visit_4|65|7|WASHOUT|2021-03-04|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-20|P1Y2M10DT2H30M|COINCIDENT|2021-04-02|AFTER|2021-04-06
e|RS|0a566742-0f71-4603-85f0-875e2c3395e7|9|CPRFSTAT|Clinical Performance Status|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|||HI-N|1|uSiemens|QUANTITATIVE PERIPHERAL ANGIOGRAPHY|Y||Y|PROXY|MICROSCOPIST 1|NA|5|Visit_5|90|6|WASHOUT|2021-03-29|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-19|P1Y2M10DT2H30M|UNKNOWN|2021-03-28|BEFORE|2021-04-04
e|RS|0a566742-0f71-4603-85f0-875e2c3395e7|10|HEMARESP|Hematologic Response|EBMT BLADE MYELOMA 1998|[?]|%(w/v)|UNEQUIVOCAL|1|STRIP|COMPUTERIZED CORNEAL TOPOGRAPHY||Y||PARENT|ADJUDICATOR 1|Y|5|Visit_5|90|5|SCREENING|2021-03-29|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-19|P1Y2M10DT2H30M|UNKNOWN|2021-01-28|AFTER|2021-02-04
e|RS|fdcd8f25-f7bd-477e-a7f6-4a279380d98f|1|NEWLPROG|New Lesion Progression|AJCC V7|[?]|ng/day|COMPLETE MRD RESPONSE|1|ug/L DDU|MAGNETIC RESONANCE ELASTOGRAPHY||||PROXY|MICROSCOPIST 2|NA|1|Visit_1|10|1|SCREENING|2020-05-14|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-02|P1Y2M10DT2H30M|BEFORE|2020-06-25|BEFORE|2020-08-03
e|RS|fdcd8f25-f7bd-477e-a7f6-4a279380d98f|2|BONERESP|Bone Response|PCWG SCHER PROSTATE CANCER 2016|[?]|mg/m2/h|WORSENED|1|10^7/L|INDIA INK STAIN||||INDEPENDENT ASSESSOR|ADJUDICATOR 2|N|1|Visit_1|10|3|FOLLOW-UP|2020-05-14|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-02|P1Y2M10DT2H30M|BEFORE|2020-05-07|AFTER|2020-06-01
e|RS|fdcd8f25-f7bd-477e-a7f6-4a279380d98f|3|NTNERESP|Non-Target Non-Enhancing Response|RECIST 1.1|||NON-CR/NON-PD|1|uV*sec|CT SCAN WITHOUT CONTRAST|||Y|SIGNIFICANT OTHER|READER 2|U|2|Visit_2|25|3|TREATMENT|2020-05-29|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-22|P1Y2M10DT2H30M|COINCIDENT|2020-06-14|BEFORE|2020-07-28
e|RS|fdcd8f25-f7bd-477e-a7f6-4a279380d98f|4|NEWLWIND|New Lesion Worsening Indicator|iRECIST|[?]|gpELISA unit/mL|CYTOGENETIC PR|1|nmol|ELASTOGRAPHY||Y||CHILD|READER 3|U|2|Visit_2|25|7|TREATMENT|2020-05-29|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-22|P1Y2M10DT2H30M|UNKNOWN|2020-05-30|COINCIDENT|2020-06-17
e|RS|fdcd8f25-f7bd-477e-a7f6-4a279380d98f|5|PATHRESP|Pathologic Response|MURPHY PROSTATE CANCER 1980|||CR-CT|1|kIU|MYELOPEROXIDASE STAIN|||Y|VENDOR|PATHOLOGIST|Y|3|Visit_3|40|3|TREATMENT|2020-06-13|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-11|P1Y2M10DT2H30M|AFTER|2020-06-14|BEFORE|2020-07-15
e|RS|fdcd8f25-f7bd-477e-a7f6-4a279380d98f|6|CPRFSTAT|Clinical Performance Status|GCIG RUSTIN OVARIAN CANCER 2011|||NON-iCR/NON-iUPD|1|mPa|OPTICAL MAPPING|Y|Y|Y|PARENT|UROLOGIST|Y|3|Visit_3|40|2|TREATMENT|2020-06-13|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-11|P1Y2M10DT2H30M|UNKNOWN|2020-08-11|BEFORE|2020-08-12
e|RS|fdcd8f25-f7bd-477e-a7f6-4a279380d98f|7|CLINRESP|Clinical Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|log10 PFU|PSEUDOPROGRESSION|1|uL|REBOUND TONOMETRY||||GUARDIAN|READER 1|N|4|Visit_4|65|2|TREATMENT|2020-07-08|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-02|P1Y2M10DT2H30M|UNKNOWN|2020-06-16|AFTER|2020-06-19
e|RS|fdcd8f25-f7bd-477e-a7f6-4a279380d98f|8|LIVRRESP|Liver Response|CHESON CLL 2012|[?]|Gauss|mCR|1|POUCH|HEMAGGLUTINATION ASSAY||Y||SIBLING|ENDOCRINOLOGIST|N|4|Visit_4|65|5|FOLLOW-UP|2020-07-08|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-02|P1Y2M10DT2H30M|BEFORE|2020-06-29|COINCIDENT|2020-08-02
e|RS|fdcd8f25-f7bd-477e-a7f6-4a279380d98f|9|DRCRIND|Disease Recurrence Indicator|AJCC V7|[?]|ug/kg/h|MORPHOLOGIC CRi|1|mol/mg|KNEMOMETRY||||INDEPENDENT ASSESSOR|PATHOLOGIST|N|5|Visit_5|90|1|TREATMENT|2020-08-02|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-13|P1Y2M10DT2H30M|BEFORE|2020-05-12|COINCIDENT|2020-06-21
e|RS|fdcd8f25-f7bd-477e-a7f6-4a279380d98f|10|ANATRESP|Anatomic Response|HAMAOKA BREAST CANCER 2010|[?]|m2|STABLE|1|cmH2O*s/mL|REFLECTANCE SPECTROSCOPY|Y|||SIBLING|PATHOLOGIST|N|5|Visit_5|90|5|TREATMENT|2020-08-02|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-13|P1Y2M10DT2H30M|UNKNOWN|2020-06-30|COINCIDENT|2020-08-08
e|RS|48103500-0f3d-4108-9167-6afee1098773|1|BONERESP|Bone Response|PERCIST|[?]|pmol/10^10 cells|DISEASE TRANSFORMATION|1|gtt|QUANTITATIVE CORONARY ANGIOGRAPHY|Y|||ADJUDICATOR|HEMATOLOGIST|NA|1|Visit_1|10|2|TREATMENT|2020-05-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-28|P1Y2M10DT2H30M|UNKNOWN|2020-06-14|BEFORE|2020-08-11
e|RS|48103500-0f3d-4108-9167-6afee1098773|2|STRUSTAT|Steroid Use Status|MRECIST LENCIONI LIVER CANCER 2010|[?]|mL|CA125 50% RESPONSE|1|mL/(min*100mL)|ANTIMICROBIAL COMBINATION TESTING||||CLINICAL STUDY SPONSOR|ONCOLOGIST|Y|1|Visit_1|10|5|SCREENING|2020-05-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-28|P1Y2M10DT2H30M|UNKNOWN|2020-05-20|COINCIDENT|2020-06-18
e|RS|48103500-0f3d-4108-9167-6afee1098773|3|NTERESP|Non-Target Enhancing Response|KUMAR IMWG 2016|||nPR|1|vg/dose|TRANSTHORACIC ECHOCARDIOGRAPHY|Y||Y|CHILD|OPTOMETRIST|NA|2|Visit_2|25|2|TREATMENT|2020-05-30|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-01|P1Y2M10DT2H30M|BEFORE|2020-06-27|AFTER|2020-06-30
e|RS|48103500-0f3d-4108-9167-6afee1098773|4|MNPTHIND|Minor Pathological Response Indicator|RAJKUMAR MYELOMA 2011|[?]|umol/day|pCR|1|m3|RADIATION DOSIMETRY||||CLINICAL RESEARCH ASSOCIATE|FORENSIC PATHOLOGIST|NA|2|Visit_2|25|2|TREATMENT|2020-05-30|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-01|P1Y2M10DT2H30M|BEFORE|2020-05-23|BEFORE|2020-06-06
e|RS|48103500-0f3d-4108-9167-6afee1098773|5|MRDRESP|Minimal Residual Disease Response|DOHNER AML 2010|[?]|APPLICATION|INDETERMINATE RESPONSE|1|10^7 CFU|SCANNING ELECTRON MICROSCOPY|Y|Y||ADJUDICATION COMMITTEE|FORENSIC PATHOLOGIST|N|3|Visit_3|40|2|TREATMENT|2020-06-14|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-10|P1Y2M10DT2H30M|BEFORE|2020-08-08|AFTER|2020-08-09
e|RS|48103500-0f3d-4108-9167-6afee1098773|6|MNPTHIND|Minor Pathological Response Indicator|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|copies/mL|NON-iCR/NON-iUPD|1|mol/L|DYNAMIC CONTRAST ENHANCED MRI||||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST|NA|3|Visit_3|40|7|FOLLOW-UP|2020-06-14|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-10|P1Y2M10DT2H30M|AFTER|2020-06-28|BEFORE|2020-07-20
e|RS|48103500-0f3d-4108-9167-6afee1098773|7|METSIND|Metastatic Indicator|RECIST 1.1|[?]|Bq/kg|MORPHOLOGIC LEUKEMIA-FREE STATE|1|Newton|PULMONARY ANGIOGRAPHY||||CLINICAL RESEARCH ASSOCIATE|FORENSIC PATHOLOGIST|U|4|Visit_4|65|4|SCREENING|2020-07-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-10|P1Y2M10DT2H30M|AFTER|2020-07-06|ONGOING|2020-08-05
e|RS|48103500-0f3d-4108-9167-6afee1098773|8|NTERESP|Non-Target Enhancing Response|AJCC V8|[?]|U/kg/h|MRD NEGATIVITY|1|nmol/L/h|CONTRAST ENHANCED PET/CT SCAN||||CAREGIVER|ADJUDICATOR 1|Y|4|Visit_4|65|7|SCREENING|2020-07-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-10|P1Y2M10DT2H30M|BEFORE|2020-08-07|AFTER|2020-08-09
e|RS|48103500-0f3d-4108-9167-6afee1098773|9|ANATRESP|Anatomic Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|Frames/s|MRD PERSISTENCE|1|Frames/s|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS||||CLINICAL RESEARCH COORDINATOR|READER 3|N|5|Visit_5|90|6|TREATMENT|2020-08-03|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-27|P1Y2M10DT2H30M|BEFORE|2020-06-11|COINCIDENT|2020-07-04
e|RS|48103500-0f3d-4108-9167-6afee1098773|10|MRDRESP|Minimal Residual Disease Response|CHESON LYMPHOMA 2008|[?]|/mm2|iPR|1|NEEDLE GAUGE|LINE PROBE ASSAY||Y||PROXY|PEDIATRIC NEUROLOGIST|NA|5|Visit_5|90|2|TREATMENT|2020-08-03|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-27|P1Y2M10DT2H30M|COINCIDENT|2020-08-12|COINCIDENT|2020-08-13
e|RS|9855fc59-f162-48ba-8c51-e8c6c54b72f3|1|MRPHRESP|Morphologic Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|Bq|MRD NEGATIVITY|1|g/g|AURAMINE STAIN||||PROXY|MICROSCOPIST|N|1|Visit_1|10|3|TREATMENT|2020-07-25|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-25|P1Y2M10DT2H30M|BEFORE|2020-09-23|ONGOING|2020-10-08
e|RS|9855fc59-f162-48ba-8c51-e8c6c54b72f3|2|DRCRIND|Disease Recurrence Indicator|CHESON MALIGNANT LYMPHOMA 2007|||cCR|1|U/cL|FLUORESCENT IMMUNOASSAY|Y||Y|FRIEND|ONCOLOGIST 1|Y|1|Visit_1|10|7|TREATMENT|2020-07-25|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-25|P1Y2M10DT2H30M|UNKNOWN|2020-08-20|BEFORE|2020-10-18
e|RS|9855fc59-f162-48ba-8c51-e8c6c54b72f3|3|ANATRESP|Anatomic Response|NCCN ALL MRD 2014|[?]|mL/animal/wk|CYTOGENETIC MINIMAL RESPONSE|1|10^9 organisms/mg|FUNDUS PHOTOGRAPHY|Y|||CHILD|CLINICAL PATHOLOGIST|NA|2|Visit_2|25|5|SCREENING|2020-08-09|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-19|P1Y2M10DT2H30M|AFTER|2020-10-02|ONGOING|2020-10-17
e|RS|9855fc59-f162-48ba-8c51-e8c6c54b72f3|4|TRGRESP|Target Response|MRECIST BYRNE MESOTHELIOMA 2004|||NON-CR/NON-PD|1|kcal/day|PERFUSION MRI|||Y|FRIEND|ONCOLOGIST|Y|2|Visit_2|25|7|FOLLOW-UP|2020-08-09|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-19|P1Y2M10DT2H30M|AFTER|2020-07-25|ONGOING|2020-09-04
e|RS|9855fc59-f162-48ba-8c51-e8c6c54b72f3|5|MRPHRESP|Morphologic Response|NCIWG CHESON CLL 1996|[?]|FEU|SD-CT|1|GBq|SICKLE CELL SOLUBILITY TEST|Y|||SPOUSE|MICROSCOPIST 3|U|3|Visit_3|40|1|TREATMENT|2020-08-24|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-16|P1Y2M10DT2H30M|UNKNOWN|2020-09-29|AFTER|2020-10-17
e|RS|9855fc59-f162-48ba-8c51-e8c6c54b72f3|6|BMIVLIND|Bone Marrow Involvement Indicator|KEAM BREAST CANCER 2013|||MRD RELAPSE|1|mL/kg|BIOIMPEDANCE SPECTROSCOPY||Y|Y|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST|N|3|Visit_3|40|2|TREATMENT|2020-08-24|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-16|P1Y2M10DT2H30M|UNKNOWN|2020-08-06|AFTER|2020-09-24
e|RS|9855fc59-f162-48ba-8c51-e8c6c54b72f3|7|TRGRESP|Target Response|CHESON CLL 2012|[?]|DNA copies/ug|CA125 50% RESPONSE|1|Osm|PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY||Y||CAREGIVER|INTERNIST|U|4|Visit_4|65|4|TREATMENT|2020-09-18|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-10|P1Y2M10DT2H30M|COINCIDENT|2020-08-04|ONGOING|2020-08-30
e|RS|9855fc59-f162-48ba-8c51-e8c6c54b72f3|8|MRDIND|Minimal Residual Disease Indicator|BRUGGEMANN MRD 2010|[?]|U/g Hb|COMPLETE MRD RESPONSE|1|PFU|RAJI CELL RIA||||SPOUSE|INTERNIST|NA|4|Visit_4|65|7|TREATMENT|2020-09-18|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-10|P1Y2M10DT2H30M|AFTER|2020-10-03|AFTER|2020-10-11
e|RS|9855fc59-f162-48ba-8c51-e8c6c54b72f3|9|BONERESP|Bone Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|Osm|UNEQUIVOCAL|1|PELLET|DC SHEATH FLOW|Y|||CLINICAL STUDY SPONSOR|RATER 2|Y|5|Visit_5|90|6|SCREENING|2020-10-13|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-19|P1Y2M10DT2H30M|COINCIDENT|2020-10-22|AFTER|2020-10-23
e|RS|9855fc59-f162-48ba-8c51-e8c6c54b72f3|10|SYMPTDTR|Symptomatic Deterioration|JACINTO CERVICAL CANCER 2007|||CRi|1|mol/L|FLUORESCENT MICROSCOPY|||Y|GUARDIAN|OPHTHALMOLOGIST|U|5|Visit_5|90|7|TREATMENT|2020-10-13|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-19|P1Y2M10DT2H30M|BEFORE|2020-08-03|ONGOING|2020-09-20
e|RS|ceab42b0-3a7e-4aad-b599-5da311398148|1|NEWLIND|New Lesion Indicator|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|||cPR|1|ug/L|CHROMOGENIC ASSAY|||Y|PROXY|OPHTHALMOLOGIST|U|1|Visit_1|10|1|SCREENING|2020-06-21|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-05|P1Y2M10DT2H30M|COINCIDENT|2020-08-26|ONGOING|2020-09-11
e|RS|ceab42b0-3a7e-4aad-b599-5da311398148|2|OVRLRESP|Overall Response|RANO ELLINGSON 2017|||iCR|1|cmH2O*s/mL|REVERSE TRANSCRIPTASE PCR|Y||Y|ADJUDICATION COMMITTEE|RATER 1|NA|1|Visit_1|10|6|TREATMENT|2020-06-21|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-05|P1Y2M10DT2H30M|UNKNOWN|2020-08-31|COINCIDENT|2020-09-12
e|RS|ceab42b0-3a7e-4aad-b599-5da311398148|3|SPLNRESP|Spleen Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|10^4/L|HI-N|1|cs|NEPHELOMETRY||Y||GUARDIAN|FORENSIC PATHOLOGIST|Y|2|Visit_2|25|7|WASHOUT|2020-07-06|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-28|P1Y2M10DT2H30M|UNKNOWN|2020-06-25|AFTER|2020-08-23
e|RS|ceab42b0-3a7e-4aad-b599-5da311398148|4|MOLRESP|Molecular Response|LEE LUNG CANCER 2011|[?]|SBE/mL|iCR|1|10^7 TCID 50/dose|SEQUENCING||||HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|NA|2|Visit_2|25|7|SCREENING|2020-07-06|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-28|P1Y2M10DT2H30M|BEFORE|2020-06-13|COINCIDENT|2020-06-14
e|RS|ceab42b0-3a7e-4aad-b599-5da311398148|5|SYMPTDTR|Symptomatic Deterioration|LEE LUNG CANCER 2011|[?]|mg/day|cCR|1|Frames/s|CELL BASED BIOASSAY|Y|||FAMILY MEMBER|RATER 1|NA|3|Visit_3|40|2|WASHOUT|2020-07-21|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-16|P1Y2M10DT2H30M|AFTER|2020-07-13|AFTER|2020-08-16
e|RS|ceab42b0-3a7e-4aad-b599-5da311398148|6|NEWLIND|New Lesion Indicator|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|IU|SMD|1|in|ENZYMATIC COLORIMETRY||||INTERVIEWER|PATHOLOGIST 2|Y|3|Visit_3|40|4|TREATMENT|2020-07-21|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-16|P1Y2M10DT2H30M|COINCIDENT|2020-08-17|BEFORE|2020-09-12
e|RS|ceab42b0-3a7e-4aad-b599-5da311398148|7|BESTRESP|Best Overall Response|BRUGGEMANN MRD 2010|[?]|MET|NE|1|Ci/uL|GRAM STAIN||||INDEPENDENT ASSESSOR|MICROSCOPIST 1|NA|4|Visit_4|65|3|FOLLOW-UP|2020-08-15|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-22|P1Y2M10DT2H30M|COINCIDENT|2020-08-19|BEFORE|2020-08-27
e|RS|ceab42b0-3a7e-4aad-b599-5da311398148|8|CPRFSTAT|Clinical Performance Status|EASL BRUIX LIVER CANCER 2001|[?]|mkat|MINOR PATHOLOGIC RESPONSE|1|KIT|LIGHT MICROSCOPY||||CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 3|U|4|Visit_4|65|6|SCREENING|2020-08-15|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-22|P1Y2M10DT2H30M|COINCIDENT|2020-08-16|ONGOING|2020-09-16
e|RS|ceab42b0-3a7e-4aad-b599-5da311398148|9|BESTRESP|Best Overall Response|SCHWARZ CERVICAL CANCER 2009|[?]|mL/mmHg|PR WITH LYMPHOCYTOSIS|1|/month|AGAR DILUTION|Y|||CHILD|PHYSIOTHERAPIST|U|5|Visit_5|90|4|FOLLOW-UP|2020-09-09|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-01|P1Y2M10DT2H30M|UNKNOWN|2020-08-17|AFTER|2020-08-31
e|RS|ceab42b0-3a7e-4aad-b599-5da311398148|10|BESTRESP|Best Overall Response|BLAZER COLORECTAL CANCER 2008|||RELAPSED DISEASE FROM CR OR PR|1|10^6 CFU/g|THERMAL IONIZATION MASS SPECTROMETRY||Y|Y|INDEPENDENT ASSESSOR|MICROSCOPIST 3|N|5|Visit_5|90|2|TREATMENT|2020-09-09|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-01|P1Y2M10DT2H30M|COINCIDENT|2020-09-17|BEFORE|2020-09-18
e|RS|c6fed210-d4a7-41f9-b3ff-ece262a91a5f|1|TRGRESP|Target Response|IWG CHESON MDS 2000|[?]|mOsm/L|MRD RELAPSE|1|U/g/day|SLOAN LETTER EYE CHART 1.25%||Y||ADJUDICATOR|ADJUDICATOR 1|U|1|Visit_1|10|7|TREATMENT|2020-07-09|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-25|P1Y2M10DT2H30M|BEFORE|2020-09-25|ONGOING|2020-09-27
e|RS|c6fed210-d4a7-41f9-b3ff-ece262a91a5f|2|NEWLWIND|New Lesion Worsening Indicator|PCWG SCHER PROSTATE CANCER 2008|[?]|10^10/L|CA125 50% RESPONSE|1|TRANSDUCING UNIT/mL|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION|Y|||STUDY SUBJECT|OTOLARYNGOLOGIST|Y|1|Visit_1|10|7|TREATMENT|2020-07-09|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-25|P1Y2M10DT2H30M|COINCIDENT|2020-09-14|ONGOING|2020-10-06
e|RS|c6fed210-d4a7-41f9-b3ff-ece262a91a5f|3|STRUSTAT|Steroid Use Status|IWG CHESON MDS 2000|[?]|ppm|PR WITH LYMPHOCYTOSIS|1|Tesla|MANUAL COUNT|Y|Y||DOMESTIC PARTNER|RATER 2|NA|2|Visit_2|25|5|TREATMENT|2020-07-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-27|P1Y2M10DT2H30M|UNKNOWN|2020-10-06|COINCIDENT|2020-10-07
e|RS|c6fed210-d4a7-41f9-b3ff-ece262a91a5f|4|MJPTHIND|Major Pathological Response Indicator|HARTMAN PANCREATIC CANCER 2012|[?]|/sec|MR|1|umol/kg/min|OBSERVATION||||VENDOR|READER|U|2|Visit_2|25|3|TREATMENT|2020-07-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-27|P1Y2M10DT2H30M|COINCIDENT|2020-08-30|AFTER|2020-09-22
e|RS|c6fed210-d4a7-41f9-b3ff-ece262a91a5f|5|METBRESP|Metabolic Response|PRINCE TCELL LYMPHOMA 2010|[?]|Frames/s|MAJOR PATHOLOGIC RESPONSE|1|uCi/kg|ELECTROMYOGRAPHY||||VENDOR|CARDIOLOGIST|N|3|Visit_3|40|3|FOLLOW-UP|2020-08-08|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-25|P1Y2M10DT2H30M|BEFORE|2020-08-18|ONGOING|2020-09-04
e|RS|c6fed210-d4a7-41f9-b3ff-ece262a91a5f|6|OVRLRESP|Overall Response|CHESON MALIGNANT LYMPHOMA 2007|||MRD NEGATIVITY|1|anti-Xa IU/mL|HEMOCYTOMETRY|||Y|INVESTIGATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|3|Visit_3|40|2|FOLLOW-UP|2020-08-08|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-25|P1Y2M10DT2H30M|AFTER|2020-10-02|AFTER|2020-10-04
e|RS|c6fed210-d4a7-41f9-b3ff-ece262a91a5f|7|MRPHRESP|Morphologic Response|PERCIST|[?]|U/m2/h|PMD|1|mmol/mol|DYNAMIC LIGHT SCATTERING||Y||VENDOR|DERMATOLOGIST|NA|4|Visit_4|65|6|TREATMENT|2020-09-02|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-03|P1Y2M10DT2H30M|BEFORE|2020-09-10|COINCIDENT|2020-09-17
e|RS|c6fed210-d4a7-41f9-b3ff-ece262a91a5f|8|SPLNRESP|Spleen Response|MRANO VAN DEN BENT GLIOMA 2011|||CYTOGENETIC NO RESPONSE|1|cL|NON-INVASIVE DIELECTRIC SENSING|||Y|VENDOR|MICROSCOPIST 3|Y|4|Visit_4|65|5|FOLLOW-UP|2020-09-02|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-03|P1Y2M10DT2H30M|UNKNOWN|2020-07-09|COINCIDENT|2020-08-12
e|RS|c6fed210-d4a7-41f9-b3ff-ece262a91a5f|9|LIVRRESP|Liver Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|mg/dL|HI-E|1|RNA copies/mL|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY|Y|||INVESTIGATOR|READER 2|N|5|Visit_5|90|6|FOLLOW-UP|2020-09-27|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-01|P1Y2M10DT2H30M|BEFORE|2020-07-12|AFTER|2020-08-19
e|RS|c6fed210-d4a7-41f9-b3ff-ece262a91a5f|10|MNPTHIND|Minor Pathological Response Indicator|RANO ELLINGSON 2017|[?]|s*kPa|MRD RELAPSE|1|ug/day|APPLANATION TONOMETRY||||ADJUDICATOR|PATHOLOGIST|N|5|Visit_5|90|3|TREATMENT|2020-09-27|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-01|P1Y2M10DT2H30M|UNKNOWN|2020-07-03|AFTER|2020-08-04
e|RS|6fdbc6f3-431d-48ca-b51b-992f2340b9f5|1|ANATRESP|Anatomic Response|SCHER PROSTATE CANCER 2011|||CHR|1|pmol/L/h|FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY|||Y|CAREGIVER|RATER 1|NA|1|Visit_1|10|3|FOLLOW-UP|2020-07-10|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-15|P1Y2M10DT2H30M|UNKNOWN|2020-09-20|BEFORE|2020-09-25
e|RS|6fdbc6f3-431d-48ca-b51b-992f2340b9f5|2|TRGRESP|Target Response|DOHNER AML 2010|[?]|mmol/kg|MINOR PATHOLOGIC RESPONSE|1|SUPPOSITORY|FLUORESCENCE ANGIOGRAPHY||Y||CAREGIVER|READER 2|U|1|Visit_1|10|3|TREATMENT|2020-07-10|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-15|P1Y2M10DT2H30M|UNKNOWN|2020-08-12|AFTER|2020-09-07
e|RS|6fdbc6f3-431d-48ca-b51b-992f2340b9f5|3|METSIND|Metastatic Indicator|HAMAOKA BREAST CANCER 2010|[?]|mL/min|MR|1|PFU/animal|GRAM STAIN||||ADJUDICATOR|NEUROLOGIST 2|NA|2|Visit_2|25|4|TREATMENT|2020-07-25|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-04|P1Y2M10DT2H30M|AFTER|2020-07-29|AFTER|2020-09-14
e|RS|6fdbc6f3-431d-48ca-b51b-992f2340b9f5|4|TMRESP|Tumor Marker Response|MURPHY PROSTATE CANCER 1980|[?]|10^7 TCID 50/dose|STABLE|1|vg/dose|CAPILLARY ELECTROPHORESIS||||HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|NA|2|Visit_2|25|6|TREATMENT|2020-07-25|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-04|P1Y2M10DT2H30M|AFTER|2020-08-26|COINCIDENT|2020-10-03
e|RS|6fdbc6f3-431d-48ca-b51b-992f2340b9f5|5|PATHRESP|Pathologic Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|log10 IU/mL|NED|1|nL|MYELOPEROXIDASE STAIN||Y||CLINICAL RESEARCH ASSOCIATE|CLINICAL PATHOLOGIST|U|3|Visit_3|40|2|TREATMENT|2020-08-09|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-15|P1Y2M10DT2H30M|UNKNOWN|2020-09-24|AFTER|2020-09-26
e|RS|6fdbc6f3-431d-48ca-b51b-992f2340b9f5|6|OVRLRESP|Overall Response|iRECIST|||INCREASED|1|BP|LYMPHANGIOGRAPHY||Y|Y|INVESTIGATOR|ADJUDICATOR 1|NA|3|Visit_3|40|4|TREATMENT|2020-08-09|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-15|P1Y2M10DT2H30M|BEFORE|2020-08-12|ONGOING|2020-09-09
e|RS|6fdbc6f3-431d-48ca-b51b-992f2340b9f5|7|BMIVLIND|Bone Marrow Involvement Indicator|MRECIST BYRNE MESOTHELIOMA 2004|||ABSENT MORPHOLOGIC RESPONSE|1|IU/mL|SPIRAL CT|Y||Y|CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL PSYCHOLOGIST|Y|4|Visit_4|65|6|TREATMENT|2020-09-03|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-02|P1Y2M10DT2H30M|UNKNOWN|2020-08-17|ONGOING|2020-09-25
e|RS|6fdbc6f3-431d-48ca-b51b-992f2340b9f5|8|CPRFSTAT|Clinical Performance Status|RANO ELLINGSON 2017|[?]|uEq|RELAPSED DISEASE FROM CR OR PR|1|kPa|ACCELERATOR MASS SPECTROMETRY|Y|||FRIEND|NEUROLOGIST 2|Y|4|Visit_4|65|2|TREATMENT|2020-09-03|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-02|P1Y2M10DT2H30M|AFTER|2020-08-24|BEFORE|2020-09-07
e|RS|6fdbc6f3-431d-48ca-b51b-992f2340b9f5|9|HEMARESP|Hematologic Response|HARTMAN PANCREATIC CANCER 2012|[?]|mL/mmHg/min/L|EQUIVOCAL|1|kg/L|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY||||FAMILY MEMBER|ADJUDICATOR 3|U|5|Visit_5|90|5|TREATMENT|2020-09-28|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-31|P1Y2M10DT2H30M|COINCIDENT|2020-08-31|ONGOING|2020-09-28
e|RS|6fdbc6f3-431d-48ca-b51b-992f2340b9f5|10|METBRESP|Metabolic Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|IU/L|CYTOGENETIC CR|1|PIXELS/cm|NEXT GENERATION TARGETED SEQUENCING||||CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 1|Y|5|Visit_5|90|3|TREATMENT|2020-09-28|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-31|P1Y2M10DT2H30M|COINCIDENT|2020-09-12|COINCIDENT|2020-09-29
e|RS|36a54b72-6368-460e-ab4c-952923e0fd14|1|NEWLWIND|New Lesion Worsening Indicator|SACT|[?]|pL|HI-N|1|g/animal|MAPH|Y|Y||PARENT|RATER|Y|1|Visit_1|10|5|TREATMENT|2020-05-15|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-19|P1Y2M10DT2H30M|AFTER|2020-07-20|AFTER|2020-08-09
e|RS|36a54b72-6368-460e-ab4c-952923e0fd14|2|NEWLWIND|New Lesion Worsening Indicator|HARTMANN GERM CELL CANCER 2002|[?]|pmol/L|PD-CT|1|10^9 CFU/g|MICROBIAL BIOCHEMICAL IDENTIFICATION||||INDEPENDENT ASSESSOR|RADIOLOGIST 2|U|1|Visit_1|10|7|FOLLOW-UP|2020-05-15|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-19|P1Y2M10DT2H30M|UNKNOWN|2020-08-11|COINCIDENT|2020-08-12
e|RS|36a54b72-6368-460e-ab4c-952923e0fd14|3|STRUSTAT|Steroid Use Status|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|10^9/L|PMD|1|pkat|ELECTRICAL IMPEDANCE MYOGRAPHY||||SIGNIFICANT OTHER|ONCOLOGIST|U|2|Visit_2|25|3|FOLLOW-UP|2020-05-30|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-10|P1Y2M10DT2H30M|COINCIDENT|2020-07-24|BEFORE|2020-08-02
e|RS|36a54b72-6368-460e-ab4c-952923e0fd14|4|LIVRRESP|Liver Response|iRECIST|[?]|U/mL|iCR|1|PACKET|GC/MS||||INDEPENDENT ASSESSOR|MICROSCOPIST 1|Y|2|Visit_2|25|5|SCREENING|2020-05-30|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-10|P1Y2M10DT2H30M|BEFORE|2020-06-21|AFTER|2020-08-05
e|RS|36a54b72-6368-460e-ab4c-952923e0fd14|5|ANATRESP|Anatomic Response|GUPPY OVARIAN CANCER 2002|||RELAPSED DISEASE|1|U/m2/min|TOTAL BODY RADIOGRAPHY|Y||Y|CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 2|NA|3|Visit_3|40|6|TREATMENT|2020-06-14|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-14|P1Y2M10DT2H30M|UNKNOWN|2020-07-13|BEFORE|2020-07-15
e|RS|36a54b72-6368-460e-ab4c-952923e0fd14|6|MRDIND|Minimal Residual Disease Indicator|PETIT BREAST CANCER 2001|[?]|mU/g|PMD|1|Absorbance U/mL|COLORIMETRY||Y||PARENT|ONCOLOGIST 1|Y|3|Visit_3|40|6|SCREENING|2020-06-14|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-14|P1Y2M10DT2H30M|BEFORE|2020-07-19|ONGOING|2020-07-20
e|RS|36a54b72-6368-460e-ab4c-952923e0fd14|7|NEWLPROG|New Lesion Progression|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|||CA125 50% RESPONSE|1|tuberculin unit/mL|BETA LACTAMASE|||Y|ADJUDICATOR|PHYSIOTHERAPIST|NA|4|Visit_4|65|1|FOLLOW-UP|2020-07-09|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-28|P1Y2M10DT2H30M|AFTER|2020-05-21|COINCIDENT|2020-08-04
e|RS|36a54b72-6368-460e-ab4c-952923e0fd14|8|MRDRESP|Minimal Residual Disease Response|RECIST 1.1|[?]|DPM|EQUIVOCAL|1|km/h|RAJI CELL EIA|Y|||INDEPENDENT ASSESSOR|RATER|U|4|Visit_4|65|4|TREATMENT|2020-07-09|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-28|P1Y2M10DT2H30M|BEFORE|2020-08-10|ONGOING|2020-08-11
e|RS|36a54b72-6368-460e-ab4c-952923e0fd14|9|STRUSTAT|Steroid Use Status|IRANO 2015|[?]|mL/(min*100mL)|CYTOGENETIC MINIMAL RESPONSE|1|mm/h|ALCIAN BLUE STAIN||||NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|N|5|Visit_5|90|5|WASHOUT|2020-08-03|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-11|P1Y2M10DT2H30M|BEFORE|2020-07-31|AFTER|2020-08-09
e|RS|36a54b72-6368-460e-ab4c-952923e0fd14|10|CPRFSTAT|Clinical Performance Status|RANO ELLINGSON 2017|[?]|GPL U|CYTOGENETIC MINIMAL RESPONSE|1|DNA copies/mL|KINETIC CHROMOGENIC ASSAY||||ADJUDICATOR|FORENSIC PATHOLOGIST|NA|5|Visit_5|90|4|TREATMENT|2020-08-03|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-11|P1Y2M10DT2H30M|UNKNOWN|2020-05-15|BEFORE|2020-08-01
e|RS|84e56692-9a33-472a-9ddc-545d3342da34|1|RDIORESP|Radiologic Response|GUPPY OVARIAN CANCER 2002|||RELAPSED DISEASE FROM CR OR PR|1|INHALATION|SLOAN LETTER EYE CHART 1.25%|||Y|INVESTIGATOR|PHYSIOTHERAPIST|NA|1|Visit_1|10|1|TREATMENT|2020-12-19|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-26|P1Y2M10DT2H30M|BEFORE|2021-01-14|BEFORE|2021-02-07
e|RS|84e56692-9a33-472a-9ddc-545d3342da34|2|MNPTHIND|Minor Pathological Response Indicator|WOLCHOK SOLID TUMORS 2009|[?]|IU/mmol|COMPLETE MRD RESPONSE|1|/sec|SPECTROPHOTOMETRY||||SPOUSE|UROLOGIST|NA|1|Visit_1|10|3|TREATMENT|2020-12-19|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-26|P1Y2M10DT2H30M|COINCIDENT|2021-03-04|ONGOING|2021-03-15
e|RS|84e56692-9a33-472a-9ddc-545d3342da34|3|RDIORESP|Radiologic Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|||PSEUDORESPONSE|1|IU/kg|OSCILLOMETRY|||Y|INDEPENDENT ASSESSOR|ADJUDICATOR|N|2|Visit_2|25|7|TREATMENT|2021-01-03|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-16|P1Y2M10DT2H30M|BEFORE|2021-01-24|BEFORE|2021-03-18
e|RS|84e56692-9a33-472a-9ddc-545d3342da34|4|METBRESP|Metabolic Response|CHOLLET BREAST CANCER 2002|[?]|vg/mL|mCR|1|IU/g|AURAMINE STAIN||Y||HEALTH CARE PROFESSIONAL|RATER|Y|2|Visit_2|25|4|SCREENING|2021-01-03|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-16|P1Y2M10DT2H30M|BEFORE|2021-01-27|COINCIDENT|2021-01-28
e|RS|84e56692-9a33-472a-9ddc-545d3342da34|5|MRPHRESP|Morphologic Response|AJCC V8|[?]|cm/s|mCR|1|genEq/mL|ANALYTICAL ULTRACENTRIFUGATION||||ADJUDICATION COMMITTEE|READER 2|Y|3|Visit_3|40|3|TREATMENT|2021-01-18|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-05|P1Y2M10DT2H30M|UNKNOWN|2021-01-13|COINCIDENT|2021-03-02
e|RS|84e56692-9a33-472a-9ddc-545d3342da34|6|NEWLIND|New Lesion Indicator|MONTSERRAT CLL 1989|||MOLECULAR CR|1|m/sec2|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY|||Y|ADJUDICATOR|ENDOCRINOLOGIST|Y|3|Visit_3|40|6|TREATMENT|2021-01-18|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-05|P1Y2M10DT2H30M|UNKNOWN|2020-12-26|COINCIDENT|2021-02-12
e|RS|84e56692-9a33-472a-9ddc-545d3342da34|7|BMIVLIND|Bone Marrow Involvement Indicator|EBMT BLADE MYELOMA 1998|||UNFAVORABLE RESPONSE|1|mol/day|FLUORESCEIN STAIN|Y|Y|Y|SPOUSE|RATER 2|NA|4|Visit_4|65|2|TREATMENT|2021-02-12|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-15|P1Y2M10DT2H30M|AFTER|2020-12-21|COINCIDENT|2021-03-16
e|RS|84e56692-9a33-472a-9ddc-545d3342da34|8|MRPHRESP|Morphologic Response|WOLCHOK SOLID TUMORS 2009|[?]|mL/s|NOT ALL EVALUATED|1|sec|NUCLEIC ACID SEQUENCING||||DOMESTIC PARTNER|RATER 2|N|4|Visit_4|65|2|FOLLOW-UP|2021-02-12|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-15|P1Y2M10DT2H30M|AFTER|2021-03-17|ONGOING|2021-03-18
e|RS|84e56692-9a33-472a-9ddc-545d3342da34|9|MJPTHIND|Major Pathological Response Indicator|MACDONALD GLIOMA 1990|[?]|L/h/m2|ABSENT MORPHOLOGIC RESPONSE|1|10^7 TCID 50/dose|KINYOUN STAIN|Y|||PARENT|ADJUDICATOR 1|U|5|Visit_5|90|3|FOLLOW-UP|2021-03-09|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-16|P1Y2M10DT2H30M|COINCIDENT|2020-12-13|BEFORE|2021-02-26
e|RS|84e56692-9a33-472a-9ddc-545d3342da34|10|LIVRRESP|Liver Response|GUILHOT CML 2007|[?]|DPM|TREATMENT FAILURE|1|PFU|BIOPSY||||ADJUDICATION COMMITTEE|PATHOLOGIST 2|N|5|Visit_5|90|5|TREATMENT|2021-03-09|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-16|P1Y2M10DT2H30M|COINCIDENT|2021-01-17|BEFORE|2021-01-31
e|RS|d917a86c-f13b-4ed8-aa0a-cc36ac57647e|1|MNPTHIND|Minor Pathological Response Indicator|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|||ABSENT MORPHOLOGIC RESPONSE|1|ohm|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY|Y||Y|CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST|N|1|Visit_1|10|4|WASHOUT|2020-05-31|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-01|P1Y2M10DT2H30M|BEFORE|2020-05-23|BEFORE|2020-06-17
e|RS|d917a86c-f13b-4ed8-aa0a-cc36ac57647e|2|TRGRESP|Target Response|HARTMANN GERM CELL CANCER 2002|[?]|Hounsfield Unit|PSEUDOPROGRESSION|1|10^7 TCID 50/dose|LC/MS/MS|Y|||SIBLING|PHYSIOTHERAPIST|N|1|Visit_1|10|6|SCREENING|2020-05-31|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-01|P1Y2M10DT2H30M|AFTER|2020-05-26|BEFORE|2020-07-02
e|RS|d917a86c-f13b-4ed8-aa0a-cc36ac57647e|3|NEWLIND|New Lesion Indicator|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|mL/min/1.73m2|VGPR|1|ug/L|TRANSCRIPTION-MEDIATED AMPLIFICATION||||PARENT|ONCOLOGIST|Y|2|Visit_2|25|7|SCREENING|2020-06-15|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-01|P1Y2M10DT2H30M|UNKNOWN|2020-07-23|BEFORE|2020-08-04
e|RS|d917a86c-f13b-4ed8-aa0a-cc36ac57647e|4|CPRFSTAT|Clinical Performance Status|PRINCE TCELL LYMPHOMA 2010|[?]|mPa|QUANTIFIABLE MRD POSITIVITY|1|kg/L|THICK SMEAR|Y|||SIGNIFICANT OTHER|MICROSCOPIST 2|Y|2|Visit_2|25|5|TREATMENT|2020-06-15|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-01|P1Y2M10DT2H30M|AFTER|2020-08-19|BEFORE|2020-08-25
e|RS|d917a86c-f13b-4ed8-aa0a-cc36ac57647e|5|MNPTHIND|Minor Pathological Response Indicator|MURPHY PROSTATE CANCER 1980|||COMPLETE MRD RESPONSE|1|/mm2|ANALYTICAL ULTRACENTRIFUGATION|||Y|PROXY|OTOLARYNGOLOGIST|U|3|Visit_3|40|5|TREATMENT|2020-06-30|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-01|P1Y2M10DT2H30M|COINCIDENT|2020-06-18|ONGOING|2020-07-15
e|RS|d917a86c-f13b-4ed8-aa0a-cc36ac57647e|6|RDIORESP|Radiologic Response|DURIE MULTIPLE MYELOMA 2006|[?]|U/kg/h|iPR|1|Frames/s|ACID FAST STAIN||||FRIEND|MICROSCOPIST 2|Y|3|Visit_3|40|7|TREATMENT|2020-06-30|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-01|P1Y2M10DT2H30M|COINCIDENT|2020-08-19|ONGOING|2020-08-26
e|RS|d917a86c-f13b-4ed8-aa0a-cc36ac57647e|7|DRCRIND|Disease Recurrence Indicator|PCWG BUBLEY PROSTATE CANCER 1999|||HI-E|1|nL|GC/MS-CI|||Y|ADJUDICATION COMMITTEE|ADJUDICATOR 1|N|4|Visit_4|65|3|TREATMENT|2020-07-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-06|P1Y2M10DT2H30M|COINCIDENT|2020-07-09|BEFORE|2020-08-14
e|RS|d917a86c-f13b-4ed8-aa0a-cc36ac57647e|8|MRDRESP|Minimal Residual Disease Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|nkat/L|MORPHOLOGIC CRi|1|amu|AUSCULTATION|Y|||SPOUSE|MICROSCOPIST|N|4|Visit_4|65|6|TREATMENT|2020-07-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-06|P1Y2M10DT2H30M|COINCIDENT|2020-06-12|BEFORE|2020-07-14
e|RS|d917a86c-f13b-4ed8-aa0a-cc36ac57647e|9|NEWLIND|New Lesion Indicator|BRUGGEMANN MRD 2010|[?]|Tbsp|MR|1|Ejaculate U|FLUOROSCOPY|Y|Y||PARENT|PATHOLOGIST 1|Y|5|Visit_5|90|7|WASHOUT|2020-08-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-16|P1Y2M10DT2H30M|BEFORE|2020-06-11|BEFORE|2020-06-12
e|RS|d917a86c-f13b-4ed8-aa0a-cc36ac57647e|10|SYMPTDTR|Symptomatic Deterioration|RANO|||UNEQUIVOCAL|1|NEEDLE GAUGE|POLYGRAPHY|Y||Y|SIGNIFICANT OTHER|RADIOLOGIST|NA|5|Visit_5|90|7|SCREENING|2020-08-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-16|P1Y2M10DT2H30M|AFTER|2020-05-31|BEFORE|2020-06-22
e|RS|917f909f-fd5d-47ad-9e2a-f7c6953cfbd1|1|METBRESP|Metabolic Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|ug/kg/min|QUANTIFIABLE MRD POSITIVITY|1|cL|FARNSWORTH-MUNSELL 100 HUE TEST||||NON-HEALTH CARE PROFESSIONAL|READER 1|NA|1|Visit_1|10|2|WASHOUT|2020-06-10|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-29|P1Y2M10DT2H30M|COINCIDENT|2020-08-21|COINCIDENT|2020-08-25
e|RS|917f909f-fd5d-47ad-9e2a-f7c6953cfbd1|2|CYTORESP|Cytogenetic Response|SCHER PROSTATE CANCER 2011|||STABLE|1|Linear ft*LB|INDIRECT IMMUNOFLUORESCENCE|||Y|CLINICAL RESEARCH COORDINATOR|OTOLARYNGOLOGIST|NA|1|Visit_1|10|2|TREATMENT|2020-06-10|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-29|P1Y2M10DT2H30M|AFTER|2020-09-06|BEFORE|2020-09-07
e|RS|917f909f-fd5d-47ad-9e2a-f7c6953cfbd1|3|MNPTHIND|Minor Pathological Response Indicator|CHOLLET BREAST CANCER 2002|||CRi|1|mmHg|ARTERIAL SPIN LABELING FUNCTIONAL MRI|||Y|HEALTH CARE PROFESSIONAL|DERMATOLOGIST|Y|2|Visit_2|25|5|SCREENING|2020-06-25|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-21|P1Y2M10DT2H30M|UNKNOWN|2020-08-17|ONGOING|2020-08-19
e|RS|917f909f-fd5d-47ad-9e2a-f7c6953cfbd1|4|MOLRESP|Molecular Response|PETIT BREAST CANCER 2001|[?]|g/g/day|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|g/animal/wk|ELISPOT||||ADJUDICATION COMMITTEE|ONCOLOGIST 2|N|2|Visit_2|25|5|TREATMENT|2020-06-25|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-21|P1Y2M10DT2H30M|AFTER|2020-08-01|AFTER|2020-08-03
e|RS|917f909f-fd5d-47ad-9e2a-f7c6953cfbd1|5|NTERESP|Non-Target Enhancing Response|LEE LUNG CANCER 2011|[?]|mg|NON-PD|1|/100 HPFs|PET SCAN|Y|||NON-HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|NA|3|Visit_3|40|5|TREATMENT|2020-07-10|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-31|P1Y2M10DT2H30M|UNKNOWN|2020-06-11|AFTER|2020-07-23
e|RS|917f909f-fd5d-47ad-9e2a-f7c6953cfbd1|6|METSIND|Metastatic Indicator|EBMT BLADE MYELOMA 1998|[?]|nCi|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|DISK|DUKE INCISION METHOD|Y|||FAMILY MEMBER|PEDIATRIC NEUROLOGIST|NA|3|Visit_3|40|4|TREATMENT|2020-07-10|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-31|P1Y2M10DT2H30M|AFTER|2020-09-06|BEFORE|2020-09-07
e|RS|917f909f-fd5d-47ad-9e2a-f7c6953cfbd1|7|BONERESP|Bone Response|JACINTO CERVICAL CANCER 2007|||sCR|1|Roentgen|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|||Y|FRIEND|MICROSCOPIST 3|N|4|Visit_4|65|5|TREATMENT|2020-08-04|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-13|P1Y2M10DT2H30M|COINCIDENT|2020-07-09|BEFORE|2020-09-01
e|RS|917f909f-fd5d-47ad-9e2a-f7c6953cfbd1|8|HEMARESP|Hematologic Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|YEARS|PSA PROGRESSION|1|ohm|SPECT SCAN||||CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR|NA|4|Visit_4|65|6|SCREENING|2020-08-04|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-13|P1Y2M10DT2H30M|BEFORE|2020-09-05|AFTER|2020-09-06
e|RS|917f909f-fd5d-47ad-9e2a-f7c6953cfbd1|9|METBRESP|Metabolic Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|damol/L|PR|1|dL|ENZYMATIC COLORIMETRY|Y|||SIBLING|CLINICAL PATHOLOGIST|U|5|Visit_5|90|2|SCREENING|2020-08-29|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-20|P1Y2M10DT2H30M|UNKNOWN|2020-06-28|AFTER|2020-08-04
e|RS|917f909f-fd5d-47ad-9e2a-f7c6953cfbd1|10|HEMARESP|Hematologic Response|NCCN ALL MRD 2014|||iUPD|1|mL/m2/day|ACID FAST STAIN||Y|Y|FAMILY MEMBER|OPHTHALMOLOGIST|NA|5|Visit_5|90|4|TREATMENT|2020-08-29|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-20|P1Y2M10DT2H30M|COINCIDENT|2020-06-20|AFTER|2020-08-26
e|RS|ae0e05c1-3953-4406-bfae-299295c1fa4c|1|LIVRRESP|Liver Response|RECIST 1.0|[?]|kV|PD/RELAPSE AFTER HI|1|fmol/L/sec|CENTRIFUGATION||||ADJUDICATOR|ADJUDICATOR 3|N|1|Visit_1|10|2|TREATMENT|2021-01-12|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-25|P1Y2M10DT2H30M|UNKNOWN|2021-03-25|COINCIDENT|2021-03-31
e|RS|ae0e05c1-3953-4406-bfae-299295c1fa4c|2|BMIVLIND|Bone Marrow Involvement Indicator|PCWG SCHER PROSTATE CANCER 2008|[?]|10^6 organisms/mL|iUPD|1|mEq|HPLC-FL|Y|||ADJUDICATOR|NEUROLOGIST 2|Y|1|Visit_1|10|2|TREATMENT|2021-01-12|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-25|P1Y2M10DT2H30M|COINCIDENT|2021-02-23|AFTER|2021-03-10
e|RS|ae0e05c1-3953-4406-bfae-299295c1fa4c|3|MRDIND|Minimal Residual Disease Indicator|SCHER PROSTATE CANCER 2011|||DISEASE TRANSFORMATION|1|g/animal/day|POLYGRAPHY|||Y|PARENT|MICROSCOPIST 2|NA|2|Visit_2|25|4|TREATMENT|2021-01-27|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-09|P1Y2M10DT2H30M|BEFORE|2021-01-16|COINCIDENT|2021-02-16
e|RS|ae0e05c1-3953-4406-bfae-299295c1fa4c|4|TRGRESP|Target Response|BLAZER COLORECTAL CANCER 2008|[?]|ug/m2/day|MRD NEGATIVITY|1|EID 50/mL|EEG||||CLINICAL RESEARCH ASSOCIATE|PHYSIOTHERAPIST|U|2|Visit_2|25|6|TREATMENT|2021-01-27|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-09|P1Y2M10DT2H30M|AFTER|2021-03-28|ONGOING|2021-04-08
e|RS|ae0e05c1-3953-4406-bfae-299295c1fa4c|5|NTRGRESP|Non-target Response|JACINTO CERVICAL CANCER 2007|[?]|EU|TREATMENT FAILURE|1|log10 CCID 50/dose|SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY||Y||GUARDIAN|MICROSCOPIST 1|Y|3|Visit_3|40|4|TREATMENT|2021-02-11|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-28|P1Y2M10DT2H30M|UNKNOWN|2021-02-10|BEFORE|2021-02-27
e|RS|ae0e05c1-3953-4406-bfae-299295c1fa4c|6|TMRESP|Tumor Marker Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|U/dL|HI-E|1|LENS|FISH||||SIBLING|READER 2|Y|3|Visit_3|40|5|TREATMENT|2021-02-11|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-28|P1Y2M10DT2H30M|UNKNOWN|2021-01-06|AFTER|2021-03-01
e|RS|ae0e05c1-3953-4406-bfae-299295c1fa4c|7|CLINRESP|Clinical Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|/200 HPFs|CMR|1|APPLICATION|MIGET||||CAREGIVER|HEMATOLOGIST|N|4|Visit_4|65|6|WASHOUT|2021-03-08|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-24|P1Y2M10DT2H30M|UNKNOWN|2021-02-11|COINCIDENT|2021-03-28
e|RS|ae0e05c1-3953-4406-bfae-299295c1fa4c|8|CPRFSTAT|Clinical Performance Status|SACT|[?]|GLOBULE|PR|1|ug/min|INFRARED SPECTROMETRY|Y|||GUARDIAN|ADJUDICATOR|NA|4|Visit_4|65|5|SCREENING|2021-03-08|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-24|P1Y2M10DT2H30M|AFTER|2021-02-14|COINCIDENT|2021-04-01
e|RS|ae0e05c1-3953-4406-bfae-299295c1fa4c|9|SYMPTDTR|Symptomatic Deterioration|NCCN ALL MRD 2014|||CMR|1|ug/kg/h|IN VITRO GENE EXPRESSION ASSAY|||Y|HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|N|5|Visit_5|90|2|TREATMENT|2021-04-02|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-24|P1Y2M10DT2H30M|COINCIDENT|2021-01-18|AFTER|2021-02-15
e|RS|ae0e05c1-3953-4406-bfae-299295c1fa4c|10|MNPTHIND|Minor Pathological Response Indicator|GUPPY OVARIAN CANCER 2002|[?]|TRANSDUCING UNIT|MORPHOLOGIC CRi|1|mL/100g/min|MANUAL COUNT||Y||CAREGIVER|READER|Y|5|Visit_5|90|3|TREATMENT|2021-04-02|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-24|P1Y2M10DT2H30M|UNKNOWN|2021-01-25|BEFORE|2021-02-15
e|RS|7bbe20e7-3dcc-41ea-bba8-fc03ff83a28b|1|MJPTHIND|Major Pathological Response Indicator|HARTMANN GERM CELL CANCER 2002|[?]|IU/g Hb|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|SPRAY|CONTRAST ENHANCED X-RAY||||SPOUSE|MICROSCOPIST 3|U|1|Visit_1|10|6|FOLLOW-UP|2021-01-16|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-29|P1Y2M10DT2H30M|UNKNOWN|2021-01-31|AFTER|2021-03-18
e|RS|7bbe20e7-3dcc-41ea-bba8-fc03ff83a28b|2|ANATRESP|Anatomic Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|||PD|1|ug/L/h|CONGO RED STAIN|Y||Y|INVESTIGATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|1|Visit_1|10|1|TREATMENT|2021-01-16|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-29|P1Y2M10DT2H30M|COINCIDENT|2021-02-11|BEFORE|2021-02-17
e|RS|7bbe20e7-3dcc-41ea-bba8-fc03ff83a28b|3|MOLRESP|Molecular Response|RAJKUMAR MYELOMA 2011|[?]|INHALATION|PSA PROGRESSION|1|amp|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN||Y||PARENT|PHYSIOTHERAPIST|N|2|Visit_2|25|2|TREATMENT|2021-01-31|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-18|P1Y2M10DT2H30M|COINCIDENT|2021-01-25|ONGOING|2021-04-12
e|RS|7bbe20e7-3dcc-41ea-bba8-fc03ff83a28b|4|TMRESP|Tumor Marker Response|DOHNER AML 2010|[?]|10^6 DNA copies/mL|PARTIAL MORPHOLOGIC RESPONSE|1|cycle/min|DYNAMIC LIGHT SCATTERING|Y|||INVESTIGATOR|RADIOLOGIST|NA|2|Visit_2|25|6|SCREENING|2021-01-31|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-18|P1Y2M10DT2H30M|BEFORE|2021-02-04|BEFORE|2021-02-26
e|RS|7bbe20e7-3dcc-41ea-bba8-fc03ff83a28b|5|NEWLWIND|New Lesion Worsening Indicator|IWG CHESON AML 2003|[?]|SCOOPFUL|HI-P|1|10^3 CFU/mL|TONOMETRY||||SIGNIFICANT OTHER|HEMATOLOGIST|NA|3|Visit_3|40|6|TREATMENT|2021-02-15|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-29|P1Y2M10DT2H30M|COINCIDENT|2021-02-11|ONGOING|2021-03-17
e|RS|7bbe20e7-3dcc-41ea-bba8-fc03ff83a28b|6|NTNERESP|Non-Target Non-Enhancing Response|PCWG SCHER PROSTATE CANCER 2008|[?]|nmol BCE/L|CMR|1|mL/m2/day|CONTRAST ENHANCED PET SCAN|Y|||PARENT|ENDOCRINOLOGIST|N|3|Visit_3|40|4|TREATMENT|2021-02-15|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-29|P1Y2M10DT2H30M|BEFORE|2021-03-04|AFTER|2021-03-22
e|RS|7bbe20e7-3dcc-41ea-bba8-fc03ff83a28b|7|MNPTHIND|Minor Pathological Response Indicator|SACT|||PD-CT|1|kg/mol|POLYMERASE CHAIN REACTION|||Y|CLINICAL RESEARCH ASSOCIATE|RATER 2|N|4|Visit_4|65|1|TREATMENT|2021-03-12|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-07|P1Y2M10DT2H30M|COINCIDENT|2021-02-13|ONGOING|2021-03-11
e|RS|7bbe20e7-3dcc-41ea-bba8-fc03ff83a28b|8|MRDRESP|Minimal Residual Disease Response|CHOLLET BREAST CANCER 2002|||RELAPSED DISEASE|1|amp|DIFFUSION TENSOR MRI|Y||Y|SIBLING|NEUROLOGIST|Y|4|Visit_4|65|3|TREATMENT|2021-03-12|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-07|P1Y2M10DT2H30M|COINCIDENT|2021-02-02|COINCIDENT|2021-03-13
e|RS|7bbe20e7-3dcc-41ea-bba8-fc03ff83a28b|9|BESTRESP|Best Overall Response|BLAZER COLORECTAL CANCER 2008|[?]|mg/kg/h|PSEUDORESPONSE|1|uIU/L|OPTICAL DENSITY MEASUREMENT|Y|||CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 1|Y|5|Visit_5|90|5|TREATMENT|2021-04-06|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-21|P1Y2M10DT2H30M|BEFORE|2021-01-25|BEFORE|2021-02-12
e|RS|7bbe20e7-3dcc-41ea-bba8-fc03ff83a28b|10|LIVRRESP|Liver Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|10^6 organisms|PD|1|ohm|WHOLE GENOME SEQUENCING||||FRIEND|NEUROLOGIST 1|NA|5|Visit_5|90|4|FOLLOW-UP|2021-04-06|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-21|P1Y2M10DT2H30M|AFTER|2021-02-15|AFTER|2021-03-13
e|RS|ab09e76d-8bbf-4126-a60d-08d6b5292836|1|OVRLRESP|Overall Response|GUILHOT CML 2007|||UNFAVORABLE RESPONSE|1|10^9/g|ENDPOINT DILUTION ASSAY|Y||Y|SPOUSE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|1|Visit_1|10|3|TREATMENT|2020-12-25|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-30|P1Y2M10DT2H30M|COINCIDENT|2021-01-28|AFTER|2021-03-12
e|RS|ab09e76d-8bbf-4126-a60d-08d6b5292836|2|METBRESP|Metabolic Response|NCCN ALL MRD 2014|||CR-CT|1|mg/kg/min|ENDPOINT DILUTION ASSAY|Y|Y|Y|SIBLING|RADIOLOGIST 2|U|1|Visit_1|10|3|TREATMENT|2020-12-25|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-30|P1Y2M10DT2H30M|UNKNOWN|2021-03-11|AFTER|2021-03-18
e|RS|ab09e76d-8bbf-4126-a60d-08d6b5292836|3|MNPTHIND|Minor Pathological Response Indicator|IWC HALLEK CLL 2008|[?]|kg|iSD|1|NEEDLE GAUGE|SURFACE PLASMON RESONANCE||||SIGNIFICANT OTHER|READER 2|N|2|Visit_2|25|4|FOLLOW-UP|2021-01-09|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-10|P1Y2M10DT2H30M|COINCIDENT|2021-01-17|BEFORE|2021-02-15
e|RS|ab09e76d-8bbf-4126-a60d-08d6b5292836|4|NEWLPROG|New Lesion Progression|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|mg/kg/day|SD|1|cd|ENDOSCOPY||||PARENT|NEUROLOGIST|Y|2|Visit_2|25|6|TREATMENT|2021-01-09|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-10|P1Y2M10DT2H30M|UNKNOWN|2021-02-04|AFTER|2021-02-16
e|RS|ab09e76d-8bbf-4126-a60d-08d6b5292836|5|BMIVLIND|Bone Marrow Involvement Indicator|MACDONALD GLIOMA 1990|[?]|BOTTLE|CYTOGENETIC NO RESPONSE|1|gpELISA unit/mL|DISK DIFFUSION||Y||INVESTIGATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|3|Visit_3|40|7|TREATMENT|2021-01-24|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-20|P1Y2M10DT2H30M|BEFORE|2021-01-03|COINCIDENT|2021-01-25
e|RS|ab09e76d-8bbf-4126-a60d-08d6b5292836|6|SFTSRESP|Soft Tissue Response|FAROOQUI SUPP CLL 2014|[?]|BAU|VGPR|1|beats/min|MICRONEUTRALIZATION ASSAY||||INDEPENDENT ASSESSOR|RATER 2|N|3|Visit_3|40|1|FOLLOW-UP|2021-01-24|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-20|P1Y2M10DT2H30M|BEFORE|2021-01-27|AFTER|2021-02-04
e|RS|ab09e76d-8bbf-4126-a60d-08d6b5292836|7|BONERESP|Bone Response|FAROOQUI SUPP CLL 2014|[?]|Bq/mL|CYTOGENETIC PR|1|ng/mol|ANTIBIOTIC AGAR SCREEN||||CLINICAL RESEARCH COORDINATOR|RADIOLOGIST|U|4|Visit_4|65|5|TREATMENT|2021-02-18|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-15|P1Y2M10DT2H30M|COINCIDENT|2021-01-23|BEFORE|2021-01-31
e|RS|ab09e76d-8bbf-4126-a60d-08d6b5292836|8|PATHRESP|Pathologic Response|CHESON CLL 2012|[?]|10^9 CFU/mL|PD|1|10^3 RNA copies/mL|NON-CONTACT SPECULAR MICROSCOPY|Y|||ADJUDICATOR|ONCOLOGIST 2|NA|4|Visit_4|65|5|TREATMENT|2021-02-18|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-15|P1Y2M10DT2H30M|AFTER|2021-03-16|AFTER|2021-03-20
e|RS|ab09e76d-8bbf-4126-a60d-08d6b5292836|9|MRPHRESP|Morphologic Response|SHINDOH COLORECTAL CANCER 2013|||iUPD|1|mg/kg/min|ELISPOT|Y||Y|FRIEND|MICROSCOPIST 3|Y|5|Visit_5|90|1|TREATMENT|2021-03-15|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-14|P1Y2M10DT2H30M|BEFORE|2021-03-21|COINCIDENT|2021-03-23
e|RS|ab09e76d-8bbf-4126-a60d-08d6b5292836|10|METSIND|Metastatic Indicator|IWG CHESON MDS 2006|||CR-CT|1|Linear ft*LB|NUCLEIC ACID AMPLIFICATION TEST||Y|Y|FRIEND|ADJUDICATOR|N|5|Visit_5|90|7|TREATMENT|2021-03-15|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-14|P1Y2M10DT2H30M|AFTER|2020-12-27|COINCIDENT|2021-03-06
e|RS|8b7e3909-4115-4736-b07a-e0b6c382aa7e|1|STRUSTAT|Steroid Use Status|PROTOCOL DEFINED RESPONSE CRITERIA|||PD/RELAPSE AFTER HI|1|10^6 organisms|FLUORESCENT ENZYME IMMUNOASSAY|||Y|ADJUDICATION COMMITTEE|CARDIOLOGIST|NA|1|Visit_1|10|7|SCREENING|2020-07-11|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-20|P1Y2M10DT2H30M|COINCIDENT|2020-08-02|BEFORE|2020-08-16
e|RS|8b7e3909-4115-4736-b07a-e0b6c382aa7e|2|TMRESP|Tumor Marker Response|LUGANO CLASSIFICATION|[?]|log10 TCID 50/mL|iPR|1|g/day|CELL BASED BIOASSAY||Y||CAREGIVER|ADJUDICATOR 1|Y|1|Visit_1|10|3|TREATMENT|2020-07-11|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-20|P1Y2M10DT2H30M|AFTER|2020-09-27|COINCIDENT|2020-10-04
e|RS|8b7e3909-4115-4736-b07a-e0b6c382aa7e|3|MJPTHIND|Major Pathological Response Indicator|PCWG SCHER PROSTATE CANCER 2016|[?]|mL/cage/wk|MR|1|L/kg|CELL BASED BIOASSAY||||DOMESTIC PARTNER|CARDIOLOGIST|U|2|Visit_2|25|4|TREATMENT|2020-07-26|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-07|P1Y2M10DT2H30M|UNKNOWN|2020-10-05|COINCIDENT|2020-10-07
e|RS|8b7e3909-4115-4736-b07a-e0b6c382aa7e|4|BONERESP|Bone Response|NCCN ALL MRD 2014|||MORPHOLOGIC CR|1|nmol/kg/day|LUXOL FAST BLUE AND CRESYL VIOLET STAIN||Y|Y|STUDY SUBJECT|NEUROLOGIST 1|N|2|Visit_2|25|4|SCREENING|2020-07-26|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-07|P1Y2M10DT2H30M|COINCIDENT|2020-07-19|COINCIDENT|2020-08-30
e|RS|8b7e3909-4115-4736-b07a-e0b6c382aa7e|5|MRDIND|Minimal Residual Disease Indicator|CHOLLET BREAST CANCER 2002|[?]|SYRINGE|MORPHOLOGIC CRi|1|breaths/min|LAPAROSCOPY|Y|||ADJUDICATION COMMITTEE|NEUROLOGIST|NA|3|Visit_3|40|3|SCREENING|2020-08-10|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-06|P1Y2M10DT2H30M|COINCIDENT|2020-07-17|ONGOING|2020-08-02
e|RS|8b7e3909-4115-4736-b07a-e0b6c382aa7e|6|METBRESP|Metabolic Response|BURCOMBE BREAST CANCER 2005|[?]|10^8/L|MOLECULAR MAJOR RESPONSE|1|nmol/kg/day|GRADIENT DIFFUSION||||CLINICAL RESEARCH ASSOCIATE|CLINICAL PATHOLOGIST|N|3|Visit_3|40|3|SCREENING|2020-08-10|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-06|P1Y2M10DT2H30M|BEFORE|2020-09-24|AFTER|2020-09-30
e|RS|8b7e3909-4115-4736-b07a-e0b6c382aa7e|7|SYMPTDTR|Symptomatic Deterioration|PETIT BREAST CANCER 2001|[?]|kUSP|STABLE|1|um/s|GRAM STAIN||Y||SIBLING|PHYSIOTHERAPIST|Y|4|Visit_4|65|4|TREATMENT|2020-09-04|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-02|P1Y2M10DT2H30M|BEFORE|2020-07-09|AFTER|2020-07-18
e|RS|8b7e3909-4115-4736-b07a-e0b6c382aa7e|8|MRDIND|Minimal Residual Disease Indicator|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|fL|SMD|1|mm|CELLULAR PROLIFERATION ASSAY|Y|||SIBLING|PEDIATRIC NEUROLOGIST|NA|4|Visit_4|65|3|TREATMENT|2020-09-04|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-02|P1Y2M10DT2H30M|BEFORE|2020-09-10|ONGOING|2020-09-27
e|RS|8b7e3909-4115-4736-b07a-e0b6c382aa7e|9|OVRLRESP|Overall Response|BURCOMBE BREAST CANCER 2005|[?]|PFU/dose|WORSENED|1|10^11/L|ANGIOGRAPHY||Y||STUDY SUBJECT|OPTOMETRIST|NA|5|Visit_5|90|4|TREATMENT|2020-09-29|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-13|P1Y2M10DT2H30M|COINCIDENT|2020-08-03|COINCIDENT|2020-09-22
e|RS|8b7e3909-4115-4736-b07a-e0b6c382aa7e|10|CPRFSTAT|Clinical Performance Status|MURPHY PROSTATE CANCER 1980|||UNFAVORABLE RESPONSE|1|BP|PLETHYSMOGRAPHY||Y|Y|ADJUDICATOR|RADIOLOGIST 1|N|5|Visit_5|90|4|TREATMENT|2020-09-29|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-13|P1Y2M10DT2H30M|UNKNOWN|2020-08-20|ONGOING|2020-09-05
e|RS|187b2279-526f-4978-89d4-d2da56cc2257|1|STRUSTAT|Steroid Use Status|AJCC V8|[?]|vg/mL|pCR|1|GPL U/mL|X-RAY||||SIBLING|ADJUDICATOR 1|N|1|Visit_1|10|6|TREATMENT|2020-06-21|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-25|P1Y2M10DT2H30M|UNKNOWN|2020-08-12|AFTER|2020-08-17
e|RS|187b2279-526f-4978-89d4-d2da56cc2257|2|SPLNRESP|Spleen Response|LUGANO CLASSIFICATION|[?]|kUSP|mCR|1|Ci/uL|RADIOGRAPHY||Y||ADJUDICATOR|OTOLARYNGOLOGIST|N|1|Visit_1|10|2|TREATMENT|2020-06-21|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-25|P1Y2M10DT2H30M|AFTER|2020-06-14|ONGOING|2020-08-14
e|RS|187b2279-526f-4978-89d4-d2da56cc2257|3|NEWLWIND|New Lesion Worsening Indicator|GCIG RUSTIN OVARIAN CANCER 2011|[?]|pg|CYTOGENETIC PR|1|mg2/dL2|ELECTROGASTROGRAPHY||||GUARDIAN|ENDOCRINOLOGIST|U|2|Visit_2|25|7|TREATMENT|2020-07-06|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-29|P1Y2M10DT2H30M|COINCIDENT|2020-08-18|COINCIDENT|2020-08-22
e|RS|187b2279-526f-4978-89d4-d2da56cc2257|4|BONERESP|Bone Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|CONTAINER|NON-PD|1|pL|STRESS ECHOCARDIOGRAPHY||Y||CLINICAL RESEARCH COORDINATOR|CLINICAL PATHOLOGIST|U|2|Visit_2|25|7|FOLLOW-UP|2020-07-06|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-29|P1Y2M10DT2H30M|COINCIDENT|2020-08-04|COINCIDENT|2020-08-29
e|RS|187b2279-526f-4978-89d4-d2da56cc2257|5|SFTSRESP|Soft Tissue Response|DOHNER AML 2010|[?]|ug/kg|CYTOGENETIC MINOR RESPONSE|1|10^9 organisms/mL|MS/MS|Y|Y||ADJUDICATION COMMITTEE|READER 1|Y|3|Visit_3|40|6|TREATMENT|2020-07-21|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-06|P1Y2M10DT2H30M|UNKNOWN|2020-09-02|ONGOING|2020-09-18
e|RS|187b2279-526f-4978-89d4-d2da56cc2257|6|NTLWIND|Non-Target Lesion Worsening Indicator|MRECIST BYRNE MESOTHELIOMA 2004|[?]|NEEDLE GAUGE|CHR|1|mmHg*min/L|X-RAY FLUORESCENCE SPECTROMETRY||||CLINICAL RESEARCH ASSOCIATE|DERMATOLOGIST|NA|3|Visit_3|40|4|TREATMENT|2020-07-21|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-06|P1Y2M10DT2H30M|COINCIDENT|2020-09-03|ONGOING|2020-09-13
e|RS|187b2279-526f-4978-89d4-d2da56cc2257|7|OVRLRESP|Overall Response|iRECIST|[?]|vg/dose|NR|1|DNA copies/mL|WEBER GREEN STAIN||||INTERVIEWER|NEUROLOGIST|NA|4|Visit_4|65|2|TREATMENT|2020-08-15|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-04|P1Y2M10DT2H30M|COINCIDENT|2020-07-02|BEFORE|2020-09-05
e|RS|187b2279-526f-4978-89d4-d2da56cc2257|8|METBRESP|Metabolic Response|GUILHOT CML 2007|[?]|deg2|EQUIVOCAL|1|GPL U/mL|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE||Y||INTERVIEWER|OPHTHALMOLOGIST|Y|4|Visit_4|65|6|TREATMENT|2020-08-15|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-04|P1Y2M10DT2H30M|COINCIDENT|2020-08-18|COINCIDENT|2020-09-09
e|RS|187b2279-526f-4978-89d4-d2da56cc2257|9|CYTORESP|Cytogenetic Response|PRINCE TCELL LYMPHOMA 2010|[?]|SUPPOSITORY|EQUIVOCAL|1|DDU|NEURAMINIDASE INHIBITION ASSAY||||CAREGIVER|DERMATOLOGIST|U|5|Visit_5|90|5|WASHOUT|2020-09-09|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-19|P1Y2M10DT2H30M|COINCIDENT|2020-06-23|COINCIDENT|2020-08-01
e|RS|187b2279-526f-4978-89d4-d2da56cc2257|10|RDIORESP|Radiologic Response|RECIST 1.1|[?]|m2|CR|1|fraction of 1|SPIRAL CT SCAN WITHOUT CONTRAST||Y||SPOUSE|FORENSIC PATHOLOGIST|U|5|Visit_5|90|3|WASHOUT|2020-09-09|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-19|P1Y2M10DT2H30M|UNKNOWN|2020-09-05|BEFORE|2020-09-09
e|RS|53506a04-dedb-495b-8e35-0576cdf1b323|1|OVRLRESP|Overall Response|LEE LUNG CANCER 2011|[?]|1/(s*kPa)|iPR|1|g|FLUORESCENT MICROSCOPY||||SIGNIFICANT OTHER|CLINICAL PATHOLOGIST|Y|1|Visit_1|10|7|SCREENING|2020-11-07|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-15|P1Y2M10DT2H30M|COINCIDENT|2021-01-25|BEFORE|2021-01-26
e|RS|53506a04-dedb-495b-8e35-0576cdf1b323|2|SFTSRESP|Soft Tissue Response|NCIWG CHESON CLL 1996|[?]|BOTTLE|HI-P|1|vg/dose|FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY|Y|Y||CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 1|N|1|Visit_1|10|2|TREATMENT|2020-11-07|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-15|P1Y2M10DT2H30M|COINCIDENT|2020-11-21|COINCIDENT|2021-01-09
e|RS|53506a04-dedb-495b-8e35-0576cdf1b323|3|OVRLRESP|Overall Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|F|PR|1|AU/mL|SINGLE-SLICE SPIRAL CT||||FRIEND|INTERNIST|N|2|Visit_2|25|2|SCREENING|2020-11-22|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-10|P1Y2M10DT2H30M|BEFORE|2020-11-23|AFTER|2021-01-22
e|RS|53506a04-dedb-495b-8e35-0576cdf1b323|4|MJPTHIND|Major Pathological Response Indicator|CHESON MALIGNANT LYMPHOMA 2007|[?]|PELLET|FAVORABLE RESPONSE|1|U|ENDPOINT DILUTION ASSAY||||STUDY SUBJECT|PATHOLOGIST|Y|2|Visit_2|25|4|TREATMENT|2020-11-22|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-10|P1Y2M10DT2H30M|COINCIDENT|2020-12-11|COINCIDENT|2020-12-17
e|RS|53506a04-dedb-495b-8e35-0576cdf1b323|5|MJPTHIND|Major Pathological Response Indicator|PRINCE TCELL LYMPHOMA 2010|||STABLE|1|g/g/day|MULTIPLEXED BEAD BASED IMMUNOASSAY|||Y|PARENT|READER 1|N|3|Visit_3|40|4|FOLLOW-UP|2020-12-07|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-02|P1Y2M10DT2H30M|UNKNOWN|2020-11-20|AFTER|2021-01-14
e|RS|53506a04-dedb-495b-8e35-0576cdf1b323|6|LIVRRESP|Liver Response|RANO ELLINGSON 2017|[?]|gMFI|RELAPSED DISEASE|1|uU/dL|STATIC PERIMETRY|Y|||FRIEND|RATER|U|3|Visit_3|40|1|WASHOUT|2020-12-07|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-02|P1Y2M10DT2H30M|UNKNOWN|2021-02-01|ONGOING|2021-02-03
e|RS|53506a04-dedb-495b-8e35-0576cdf1b323|7|SPLNRESP|Spleen Response|MONTSERRAT CLL 1989|[?]|10^9 CFU/g|MRD PERSISTENCE|1|Ci/mg|HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY||Y||SPOUSE|ADJUDICATOR|NA|4|Visit_4|65|6|FOLLOW-UP|2021-01-01|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-03|P1Y2M10DT2H30M|COINCIDENT|2020-12-25|ONGOING|2021-01-02
e|RS|53506a04-dedb-495b-8e35-0576cdf1b323|8|NTRGRESP|Non-target Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|mmol/min/kPa|NED|1|CCID 50/mL|IMMUNOFLUORESCENT STAIN||||GUARDIAN|HEMATOLOGIST|Y|4|Visit_4|65|4|WASHOUT|2021-01-01|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-03|P1Y2M10DT2H30M|AFTER|2020-12-14|AFTER|2021-01-29
e|RS|53506a04-dedb-495b-8e35-0576cdf1b323|9|RDIORESP|Radiologic Response|MURPHY PROSTATE CANCER 1980|[?]|ng/L|UNFAVORABLE RESPONSE|1|mCi/L|HIGH RESOLUTION MELT ANALYSIS|Y|Y||PROXY|READER 3|NA|5|Visit_5|90|6|FOLLOW-UP|2021-01-26|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-01|P1Y2M10DT2H30M|BEFORE|2021-01-14|AFTER|2021-01-27
e|RS|53506a04-dedb-495b-8e35-0576cdf1b323|10|MJPTHIND|Major Pathological Response Indicator|HAMAOKA BREAST CANCER 2010|[?]|kUSP|nPR|1|pm|CALIPER MEASUREMENT METHOD|Y|Y||SIGNIFICANT OTHER|DERMATOLOGIST|Y|5|Visit_5|90|5|TREATMENT|2021-01-26|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-01|P1Y2M10DT2H30M|BEFORE|2021-01-13|ONGOING|2021-01-18
e|RS|defa600c-4205-476e-a40c-690cb16769b3|1|MRDIND|Minimal Residual Disease Indicator|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|RATIO|VGPR|1|mol/L|CLINICAL EVALUATION||||PARENT|UROLOGIST|Y|1|Visit_1|10|3|TREATMENT|2021-01-24|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-20|P1Y2M10DT2H30M|UNKNOWN|2021-02-27|AFTER|2021-04-13
e|RS|defa600c-4205-476e-a40c-690cb16769b3|2|MRDRESP|Minimal Residual Disease Response|RANO|||IMMUNOPHENOTYPIC CR|1|IU/g|HANSEL STAIN|||Y|INDEPENDENT ASSESSOR|READER|U|1|Visit_1|10|4|TREATMENT|2021-01-24|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-20|P1Y2M10DT2H30M|COINCIDENT|2021-01-20|BEFORE|2021-03-16
e|RS|defa600c-4205-476e-a40c-690cb16769b3|3|MRPHRESP|Morphologic Response|PERCIST|[?]|10^3 organisms|PSEUDORESPONSE|1|mL/kg/min|KINYOUN STAIN||Y||PARENT|RADIOLOGIST|U|2|Visit_2|25|6|TREATMENT|2021-02-08|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-12|P1Y2M10DT2H30M|UNKNOWN|2021-04-08|AFTER|2021-04-21
e|RS|defa600c-4205-476e-a40c-690cb16769b3|4|CPRFSTAT|Clinical Performance Status|PERCIST|[?]|copies/uL|INDETERMINATE RESPONSE|1|IU/day|HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY||||ADJUDICATION COMMITTEE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|2|Visit_2|25|2|TREATMENT|2021-02-08|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-12|P1Y2M10DT2H30M|UNKNOWN|2021-02-11|BEFORE|2021-03-29
e|RS|defa600c-4205-476e-a40c-690cb16769b3|5|BONERESP|Bone Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|mL/min/mmHg|UNEQUIVOCAL|1|Joule|JAFFE REACTION||Y||CAREGIVER|INTERNIST|U|3|Visit_3|40|2|SCREENING|2021-02-23|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-08|P1Y2M10DT2H30M|COINCIDENT|2021-04-21|BEFORE|2021-04-23
e|RS|defa600c-4205-476e-a40c-690cb16769b3|6|LIVRRESP|Liver Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|L|PR WITH LYMPHOCYTOSIS|1|CUP|CLIP|Y|||INDEPENDENT ASSESSOR|RADIOLOGIST 2|Y|3|Visit_3|40|1|SCREENING|2021-02-23|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-08|P1Y2M10DT2H30M|BEFORE|2021-02-11|AFTER|2021-03-25
e|RS|defa600c-4205-476e-a40c-690cb16769b3|7|SPLNRESP|Spleen Response|GUILHOT CML 2007|[?]|10^6 organisms/mL|iCPD|1|copies/ug|SPIRAL CT SCAN WITHOUT CONTRAST||||PROXY|PATHOLOGIST 1|NA|4|Visit_4|65|7|SCREENING|2021-03-20|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-08|P1Y2M10DT2H30M|AFTER|2021-04-01|BEFORE|2021-04-13
e|RS|defa600c-4205-476e-a40c-690cb16769b3|8|METSIND|Metastatic Indicator|SACT|[?]|uIU/dL|HI-P|1|ug/L|ELASTOGRAPHY||||CHILD|ONCOLOGIST|Y|4|Visit_4|65|5|TREATMENT|2021-03-20|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-08|P1Y2M10DT2H30M|COINCIDENT|2021-01-27|COINCIDENT|2021-03-02
e|RS|defa600c-4205-476e-a40c-690cb16769b3|9|NEWLPROG|New Lesion Progression|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|ug/m2/min|MORPHOLOGIC CR|1|Coulomb|TWO-COLOR MICROARRAY|Y|||NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|U|5|Visit_5|90|6|TREATMENT|2021-04-14|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-10|P1Y2M10DT2H30M|AFTER|2021-03-11|BEFORE|2021-04-11
e|RS|defa600c-4205-476e-a40c-690cb16769b3|10|SFTSRESP|Soft Tissue Response|CHOI GIST 2008|[?]|kPa|SD-CT|1|pt_us|ULTRASONOGRAPHIC ELASTOGRAPHY||||SIGNIFICANT OTHER|NEUROLOGIST|N|5|Visit_5|90|4|SCREENING|2021-04-14|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-10|P1Y2M10DT2H30M|BEFORE|2021-01-25|ONGOING|2021-03-14
e|RS|e5092583-4259-40ba-a6a2-eeef6607263b|1|LIVRRESP|Liver Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|mg/m2/day|NON-iCR/NON-iUPD|1|dL|LC-FL||||CHILD|FORENSIC PATHOLOGIST|N|1|Visit_1|10|1|SCREENING|2020-09-16|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-12|P1Y2M10DT2H30M|BEFORE|2020-10-21|AFTER|2020-11-10
e|RS|e5092583-4259-40ba-a6a2-eeef6607263b|2|SFTSRESP|Soft Tissue Response|IWC HALLEK CLL 2008|[?]|10^3 RNA copies/mL|PMR|1|DNA copies/ug|LISSAMINE GREEN STAIN||||ADJUDICATION COMMITTEE|ADJUDICATOR 3|NA|1|Visit_1|10|6|TREATMENT|2020-09-16|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-12|P1Y2M10DT2H30M|BEFORE|2020-11-10|COINCIDENT|2020-11-17
e|RS|e5092583-4259-40ba-a6a2-eeef6607263b|3|ANATRESP|Anatomic Response|MONTSERRAT CLL 1989|||PR WITH LYMPHOCYTOSIS|1|%(w/v)|INFRARED SPECTROMETRY||Y|Y|CAREGIVER|READER 1|N|2|Visit_2|25|5|TREATMENT|2020-10-01|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-07|P1Y2M10DT2H30M|UNKNOWN|2020-11-08|BEFORE|2020-12-14
e|RS|e5092583-4259-40ba-a6a2-eeef6607263b|4|RDIORESP|Radiologic Response|RECICL|[?]|BAG|PD FROM PR|1|COAT|LIGHT MICROSCOPY|Y|Y||ADJUDICATOR|PATHOLOGIST 2|Y|2|Visit_2|25|5|FOLLOW-UP|2020-10-01|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-07|P1Y2M10DT2H30M|AFTER|2020-10-31|COINCIDENT|2020-11-12
e|RS|e5092583-4259-40ba-a6a2-eeef6607263b|5|SFTSRESP|Soft Tissue Response|MRECIST BYRNE MESOTHELIOMA 2004|||RELAPSED DISEASE FROM CR OR PR|1|BU/mL|SIZE EXCLUSION CHROMATOGRAPHY|||Y|HEALTH CARE PROFESSIONAL|RATER|U|3|Visit_3|40|3|SCREENING|2020-10-16|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-08|P1Y2M10DT2H30M|UNKNOWN|2020-12-10|AFTER|2020-12-14
e|RS|e5092583-4259-40ba-a6a2-eeef6607263b|6|MRPHRESP|Morphologic Response|EBMT BLADE MYELOMA 1998|[?]|L/s/kPa|PD FROM PR|1|mmol/mol|PELLI-ROBSON EYE CHART||||CLINICAL STUDY SPONSOR|INTERNIST|U|3|Visit_3|40|3|FOLLOW-UP|2020-10-16|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-08|P1Y2M10DT2H30M|BEFORE|2020-10-29|ONGOING|2020-12-12
e|RS|e5092583-4259-40ba-a6a2-eeef6607263b|7|MRDRESP|Minimal Residual Disease Response|MRECIST LENCIONI LIVER CANCER 2010|||SD|1|DNA copies/ug|COMPUTERIZED CORNEAL TOPOGRAPHY|||Y|SIGNIFICANT OTHER|RATER 1|Y|4|Visit_4|65|5|TREATMENT|2020-11-10|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-24|P1Y2M10DT2H30M|BEFORE|2020-10-27|AFTER|2020-11-08
e|RS|e5092583-4259-40ba-a6a2-eeef6607263b|8|ANATRESP|Anatomic Response|LEE LUNG CANCER 2011|[?]|/5x10^4 WBC|PD/RELAPSE AFTER HI|1|mL/min/1.73m2|FISH||||SIBLING|RATER 2|NA|4|Visit_4|65|1|SCREENING|2020-11-10|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-24|P1Y2M10DT2H30M|BEFORE|2020-10-13|BEFORE|2020-10-30
e|RS|e5092583-4259-40ba-a6a2-eeef6607263b|9|CLINRESP|Clinical Response|SACT|[?]|NFIU|HI-P|1|mg/kg/day|BETA LACTAMASE||||SIBLING|DEVELOPMENTAL PSYCHOLOGIST|NA|5|Visit_5|90|2|SCREENING|2020-12-05|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-11|P1Y2M10DT2H30M|COINCIDENT|2020-12-07|AFTER|2020-12-13
e|RS|e5092583-4259-40ba-a6a2-eeef6607263b|10|MJPTHIND|Major Pathological Response Indicator|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|PACKAGE|VGPR|1|Frames/s|AUTOMATED COUNT||||PARENT|READER 3|N|5|Visit_5|90|1|TREATMENT|2020-12-05|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-11|P1Y2M10DT2H30M|BEFORE|2020-09-21|ONGOING|2020-11-04
e|RS|461196d1-1213-4e5f-9bac-71f097b6cfdb|1|TMRESP|Tumor Marker Response|LUGANO CLASSIFICATION|[?]|mm2|NON-CR/NON-PD|1|Newton|MULTI-SLICE SPIRAL CT|Y|||VENDOR|ADJUDICATOR 2|U|1|Visit_1|10|6|FOLLOW-UP|2020-11-13|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-27|P1Y2M10DT2H30M|BEFORE|2021-01-16|ONGOING|2021-01-26
e|RS|461196d1-1213-4e5f-9bac-71f097b6cfdb|2|NEWLPROG|New Lesion Progression|SACT|[?]|Bq|iPR|1|Anson U|SLOAN LETTER EYE CHART 2.5%||||CLINICAL RESEARCH COORDINATOR|RADIOLOGIST|NA|1|Visit_1|10|5|TREATMENT|2020-11-13|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-27|P1Y2M10DT2H30M|COINCIDENT|2021-01-21|ONGOING|2021-02-03
e|RS|461196d1-1213-4e5f-9bac-71f097b6cfdb|3|NTERESP|Non-Target Enhancing Response|PETIT BREAST CANCER 2001|[?]|TRANSDUCING UNIT|INDETERMINATE RESPONSE|1|pptr|ANTIBIOTIC AGAR SCREEN|Y|||STUDY SUBJECT|CLINICAL PATHOLOGIST|NA|2|Visit_2|25|7|TREATMENT|2020-11-28|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-12|P1Y2M10DT2H30M|AFTER|2021-01-18|BEFORE|2021-02-03
e|RS|461196d1-1213-4e5f-9bac-71f097b6cfdb|4|METSIND|Metastatic Indicator|NCCN ALL MRD 2014|[?]|IU/kg/h|NON-QUANTIFIABLE MRD POSITIVITY|1|ug/kg/h|CALIPER MEASUREMENT METHOD||||GUARDIAN|PATHOLOGIST 2|NA|2|Visit_2|25|1|FOLLOW-UP|2020-11-28|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-12|P1Y2M10DT2H30M|AFTER|2021-01-26|ONGOING|2021-02-10
e|RS|461196d1-1213-4e5f-9bac-71f097b6cfdb|5|NTLWIND|Non-Target Lesion Worsening Indicator|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|TUBE|iSD|1|AU/mL|REFRACTOMETRY||||FAMILY MEMBER|OTOLARYNGOLOGIST|Y|3|Visit_3|40|4|TREATMENT|2020-12-13|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-22|P1Y2M10DT2H30M|AFTER|2020-12-08|AFTER|2020-12-09
e|RS|461196d1-1213-4e5f-9bac-71f097b6cfdb|6|NTERESP|Non-Target Enhancing Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|RNA copies/mL|IMPROVED|1|mL|DYNAMIC LIGHT SCATTERING||Y||CHILD|HEMATOLOGIST|U|3|Visit_3|40|7|SCREENING|2020-12-13|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-22|P1Y2M10DT2H30M|COINCIDENT|2020-12-22|AFTER|2020-12-29
e|RS|461196d1-1213-4e5f-9bac-71f097b6cfdb|7|MNPTHIND|Minor Pathological Response Indicator|SCHER PROSTATE CANCER 2011|||UNEQUIVOCAL|1|mL/cage/wk|SEQUENCING|||Y|CHILD|READER 3|NA|4|Visit_4|65|6|WASHOUT|2021-01-07|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-29|P1Y2M10DT2H30M|UNKNOWN|2021-01-09|COINCIDENT|2021-01-26
e|RS|461196d1-1213-4e5f-9bac-71f097b6cfdb|8|TMRESP|Tumor Marker Response|KEAM BREAST CANCER 2013|[?]|mg/kg|PD FROM PR|1|MONTHS|TARGETED TRANSCRIPTOME SEQUENCING||Y||FAMILY MEMBER|ADJUDICATOR 2|NA|4|Visit_4|65|7|WASHOUT|2021-01-07|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-29|P1Y2M10DT2H30M|UNKNOWN|2021-01-22|BEFORE|2021-02-07
e|RS|461196d1-1213-4e5f-9bac-71f097b6cfdb|9|CPRFSTAT|Clinical Performance Status|PCWG SCHER PROSTATE CANCER 2008|[?]|%/min|CA125 75% RESPONSE|1|uOsm|ENDOSCOPY||Y||CLINICAL RESEARCH ASSOCIATE|PEDIATRIC NEUROLOGIST|Y|5|Visit_5|90|5|TREATMENT|2021-02-01|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-20|P1Y2M10DT2H30M|BEFORE|2021-01-29|BEFORE|2021-02-06
e|RS|461196d1-1213-4e5f-9bac-71f097b6cfdb|10|ANATRESP|Anatomic Response|SHINDOH COLORECTAL CANCER 2013|[?]|10^6 IU|PSEUDORESPONSE|1|10^5/L|LIQUID SCINTILLATION COUNTING||||GUARDIAN|OTOLARYNGOLOGIST|NA|5|Visit_5|90|4|SCREENING|2021-02-01|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-20|P1Y2M10DT2H30M|AFTER|2020-12-17|COINCIDENT|2020-12-26
e|RS|4c82922a-55d0-45b9-a7bb-4edac32b0f68|1|TRGRESP|Target Response|IWC HALLEK CLL 2008|[?]|Osm|COMPLETE MRD RESPONSE|1|Absorbance U/min|SCANNING ELECTRON MICROSCOPY|Y|||GUARDIAN|PATHOLOGIST|NA|1|Visit_1|10|4|TREATMENT|2020-12-09|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-20|P1Y2M10DT2H30M|AFTER|2021-01-03|BEFORE|2021-01-23
e|RS|4c82922a-55d0-45b9-a7bb-4edac32b0f68|2|TMRESP|Tumor Marker Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|g/dL|ABSENT MORPHOLOGIC RESPONSE|1|EID 50/mL|AUSCULTATION||||ADJUDICATOR|PEDIATRIC NEUROLOGIST|U|1|Visit_1|10|2|TREATMENT|2020-12-09|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-20|P1Y2M10DT2H30M|AFTER|2021-02-25|ONGOING|2021-03-02
e|RS|4c82922a-55d0-45b9-a7bb-4edac32b0f68|3|NEWLWIND|New Lesion Worsening Indicator|SCHWARZ CERVICAL CANCER 2009|[?]|mU/L|DISEASE TRANSFORMATION|1|hr/day|SPECTROPHOTOMETRY|Y|||SPOUSE|RADIOLOGIST|Y|2|Visit_2|25|6|WASHOUT|2020-12-24|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-12|P1Y2M10DT2H30M|BEFORE|2021-02-27|BEFORE|2021-03-05
e|RS|4c82922a-55d0-45b9-a7bb-4edac32b0f68|4|PATHRESP|Pathologic Response|WHO BREAST CANCER 2006|[?]|MAC50|MOLECULAR MAJOR RESPONSE|1|APPLICATION|SPIROMETRY||||GUARDIAN|RADIOLOGIST 1|U|2|Visit_2|25|6|SCREENING|2020-12-24|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-12|P1Y2M10DT2H30M|UNKNOWN|2020-12-12|COINCIDENT|2021-03-05
e|RS|4c82922a-55d0-45b9-a7bb-4edac32b0f68|5|MNPTHIND|Minor Pathological Response Indicator|KEAM BREAST CANCER 2013|[?]|pg/cell|PR|1|cd/m2|U-HPLC/MS/MS||||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST|N|3|Visit_3|40|3|TREATMENT|2021-01-08|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-06|P1Y2M10DT2H30M|COINCIDENT|2021-02-02|COINCIDENT|2021-02-20
e|RS|4c82922a-55d0-45b9-a7bb-4edac32b0f68|6|PATHRESP|Pathologic Response|CHOI GIST 2008|||NON-CR/NON-PD|1|Bq/ug|WEBER GREEN STAIN|||Y|STUDY SUBJECT|ONCOLOGIST 2|NA|3|Visit_3|40|6|TREATMENT|2021-01-08|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-06|P1Y2M10DT2H30M|UNKNOWN|2020-12-02|COINCIDENT|2021-02-03
e|RS|4c82922a-55d0-45b9-a7bb-4edac32b0f68|7|TRGRESP|Target Response|WHO BREAST CANCER 2006|[?]|kHz|SMD|1|mmol|NEPHELOMETRY||||PROXY|RATER|Y|4|Visit_4|65|1|TREATMENT|2021-02-02|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-22|P1Y2M10DT2H30M|UNKNOWN|2021-01-05|ONGOING|2021-02-05
e|RS|4c82922a-55d0-45b9-a7bb-4edac32b0f68|8|NEWLPROG|New Lesion Progression|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|WAFER|MRD RELAPSE|1|U/m2/day|POLYMERASE CHAIN REACTION|Y|||INTERVIEWER|ONCOLOGIST|Y|4|Visit_4|65|7|WASHOUT|2021-02-02|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-22|P1Y2M10DT2H30M|AFTER|2021-01-12|COINCIDENT|2021-03-02
e|RS|4c82922a-55d0-45b9-a7bb-4edac32b0f68|9|NTRGRESP|Non-target Response|KEAM BREAST CANCER 2013|[?]|WEEKS|RELAPSED DISEASE|1|Ci|COULOMETRIC TITRATION||Y||CHILD|ONCOLOGIST 2|U|5|Visit_5|90|4|TREATMENT|2021-02-27|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-15|P1Y2M10DT2H30M|BEFORE|2021-02-22|AFTER|2021-03-06
e|RS|4c82922a-55d0-45b9-a7bb-4edac32b0f68|10|MJPTHIND|Major Pathological Response Indicator|GCIG RUSTIN OVARIAN CANCER 2011|[?]|Hz|PSEUDORESPONSE|1|mV|IN SITU HYBRIDIZATION||Y||INTERVIEWER|RATER 1|U|5|Visit_5|90|4|FOLLOW-UP|2021-02-27|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-15|P1Y2M10DT2H30M|BEFORE|2021-02-06|ONGOING|2021-03-08
e|RS|57971bdc-14df-4d9e-a59a-2665703c12ab|1|SYMPTDTR|Symptomatic Deterioration|PCWG BUBLEY PROSTATE CANCER 1999|||CYTOGENETIC MINOR RESPONSE|1|CAPSULE|DARK FIELD MICROSCOPY|Y||Y|GUARDIAN|RADIOLOGIST|NA|1|Visit_1|10|5|TREATMENT|2020-05-30|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-25|P1Y2M10DT2H30M|BEFORE|2020-06-23|AFTER|2020-06-24
e|RS|57971bdc-14df-4d9e-a59a-2665703c12ab|2|TMRESP|Tumor Marker Response|UNSPECIFIED|[?]|U/dL|SD-CT|1|ug/L/h|CHROMOGENIC ASSAY||||PROXY|PATHOLOGIST 2|N|1|Visit_1|10|6|FOLLOW-UP|2020-05-30|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-25|P1Y2M10DT2H30M|BEFORE|2020-08-22|AFTER|2020-08-26
e|RS|57971bdc-14df-4d9e-a59a-2665703c12ab|3|CLINRESP|Clinical Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|beats/min|MINOR PATHOLOGIC RESPONSE|1|Watt|WESTERGREN||Y||NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|NA|2|Visit_2|25|5|TREATMENT|2020-06-14|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-22|P1Y2M10DT2H30M|COINCIDENT|2020-06-16|AFTER|2020-07-31
e|RS|57971bdc-14df-4d9e-a59a-2665703c12ab|4|BONERESP|Bone Response|IWG CHESON MDS 2000|||MORPHOLOGIC LEUKEMIA-FREE STATE|1|10^8/L|PLAQUE REDUCTION NEUTRALIZATION ASSAY|||Y|FAMILY MEMBER|NEUROLOGIST 2|N|2|Visit_2|25|6|TREATMENT|2020-06-14|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-22|P1Y2M10DT2H30M|AFTER|2020-08-15|ONGOING|2020-08-22
e|RS|57971bdc-14df-4d9e-a59a-2665703c12ab|5|PATHRESP|Pathologic Response|LUGANO CLASSIFICATION|[?]|g/g|NED|1|/10^4|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY||||CLINICAL STUDY SPONSOR|HEMATOLOGIST|U|3|Visit_3|40|4|TREATMENT|2020-06-29|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-21|P1Y2M10DT2H30M|UNKNOWN|2020-07-17|BEFORE|2020-07-29
e|RS|57971bdc-14df-4d9e-a59a-2665703c12ab|6|MRDIND|Minimal Residual Disease Indicator|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|PUFF|MORPHOLOGIC LEUKEMIA-FREE STATE|1|10^9 CFU|IMPULSE OSCILLOMETRY|Y|Y||SPOUSE|RADIOLOGIST 2|NA|3|Visit_3|40|6|SCREENING|2020-06-29|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-21|P1Y2M10DT2H30M|BEFORE|2020-06-13|COINCIDENT|2020-08-12
e|RS|57971bdc-14df-4d9e-a59a-2665703c12ab|7|HEMARESP|Hematologic Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|Gy/h|CYTOGENETIC CR|1|fraction of 1|LISSAMINE GREEN STAIN||||CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 2|NA|4|Visit_4|65|1|WASHOUT|2020-07-24|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-22|P1Y2M10DT2H30M|COINCIDENT|2020-08-01|AFTER|2020-08-18
e|RS|57971bdc-14df-4d9e-a59a-2665703c12ab|8|BMIVLIND|Bone Marrow Involvement Indicator|JUWEID NON-HODGKINS LYMPHOMA 2005|||cPR|1|DAYS|BETA LACTAMASE|||Y|CLINICAL STUDY SPONSOR|ONCOLOGIST 2|Y|4|Visit_4|65|1|TREATMENT|2020-07-24|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-22|P1Y2M10DT2H30M|BEFORE|2020-05-27|COINCIDENT|2020-06-02
e|RS|57971bdc-14df-4d9e-a59a-2665703c12ab|9|OVRLRESP|Overall Response|RANO ELLINGSON 2017|[?]|Henry|NE|1|oz eq|HIGH RESOLUTION CT||||CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 1|U|5|Visit_5|90|7|FOLLOW-UP|2020-08-18|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-05|P1Y2M10DT2H30M|AFTER|2020-06-23|COINCIDENT|2020-06-24
e|RS|57971bdc-14df-4d9e-a59a-2665703c12ab|10|MRDRESP|Minimal Residual Disease Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|keV|OPTIMAL MORPHOLOGIC RESPONSE|1|EID 50/mL|CAPILLARY ELECTROPHORESIS|Y|||DOMESTIC PARTNER|RADIOLOGIST|N|5|Visit_5|90|1|TREATMENT|2020-08-18|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-05|P1Y2M10DT2H30M|COINCIDENT|2020-06-13|BEFORE|2020-08-02
e|RS|dacea2da-9101-41e9-97aa-1cb8445b1320|1|RDIORESP|Radiologic Response|SCHER PROSTATE CANCER 2011|||MORPHOLOGIC CR|1|SYRINGE|HANSEL STAIN|Y||Y|CLINICAL RESEARCH COORDINATOR|PEDIATRIC NEUROLOGIST|Y|1|Visit_1|10|1|SCREENING|2020-10-09|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-06|P1Y2M10DT2H30M|UNKNOWN|2020-12-11|AFTER|2020-12-25
e|RS|dacea2da-9101-41e9-97aa-1cb8445b1320|2|BMIVLIND|Bone Marrow Involvement Indicator|MASS|[?]|U/g/day|MOLECULAR MAJOR RESPONSE|1|mL/min/1.73m2|GRADIENT DIFFUSION||Y||SIBLING|RADIOLOGIST|N|1|Visit_1|10|6|SCREENING|2020-10-09|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-06|P1Y2M10DT2H30M|UNKNOWN|2020-11-14|BEFORE|2020-11-30
e|RS|dacea2da-9101-41e9-97aa-1cb8445b1320|3|NTERESP|Non-Target Enhancing Response|RECIST 1.0|[?]|10^6 U|PSEUDORESPONSE|1|ug/m2/h|EEG||||DOMESTIC PARTNER|RATER 2|N|2|Visit_2|25|7|SCREENING|2020-10-24|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-23|P1Y2M10DT2H30M|UNKNOWN|2020-12-31|ONGOING|2021-01-02
e|RS|dacea2da-9101-41e9-97aa-1cb8445b1320|4|SYMPTDTR|Symptomatic Deterioration|CHESON LYMPHOMA 2008|[?]|uV2|CA125 50% RESPONSE|1|BU|SMEAR||||CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 1|Y|2|Visit_2|25|1|SCREENING|2020-10-24|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-23|P1Y2M10DT2H30M|UNKNOWN|2020-11-24|COINCIDENT|2020-12-18
e|RS|dacea2da-9101-41e9-97aa-1cb8445b1320|5|NEWLWIND|New Lesion Worsening Indicator|SHINDOH COLORECTAL CANCER 2013|[?]|mg/g/min|nPR|1|EID 50/mL|PERIPHERAL ANGIOGRAPHY||||INVESTIGATOR|CARDIOLOGIST|NA|3|Visit_3|40|6|TREATMENT|2020-11-08|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-07|P1Y2M10DT2H30M|COINCIDENT|2020-10-30|BEFORE|2020-12-17
e|RS|dacea2da-9101-41e9-97aa-1cb8445b1320|6|MRDRESP|Minimal Residual Disease Response|PETIT BREAST CANCER 2001|[?]|ELISA unit|PSEUDOPROGRESSION|1|kg/cm2|HIGH LEVEL AMINOGLYCOSIDE SCREEN||||INDEPENDENT ASSESSOR|OPTOMETRIST|Y|3|Visit_3|40|6|TREATMENT|2020-11-08|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-07|P1Y2M10DT2H30M|BEFORE|2020-10-11|COINCIDENT|2020-10-26
e|RS|dacea2da-9101-41e9-97aa-1cb8445b1320|7|LIVRRESP|Liver Response|RANO|[?]|IU/kg/h|VGPR|1|cmHg|NEXT GENERATION SEQUENCING||||SIGNIFICANT OTHER|NEUROLOGIST 1|NA|4|Visit_4|65|7|TREATMENT|2020-12-03|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-16|P1Y2M10DT2H30M|UNKNOWN|2020-11-14|COINCIDENT|2020-11-16
e|RS|dacea2da-9101-41e9-97aa-1cb8445b1320|8|SYMPTDTR|Symptomatic Deterioration|iRECIST|[?]|10^4 CFU/mL|WORSENED|1|pkat|LIGHT SCATTERING SPECTROSCOPY||Y||CAREGIVER|RATER|U|4|Visit_4|65|2|FOLLOW-UP|2020-12-03|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-16|P1Y2M10DT2H30M|AFTER|2020-11-25|ONGOING|2020-11-29
e|RS|dacea2da-9101-41e9-97aa-1cb8445b1320|9|CPRFSTAT|Clinical Performance Status|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|U/mmol|cPR|1|PLUG|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|Y|||SPOUSE|NEUROLOGIST 2|N|5|Visit_5|90|3|SCREENING|2020-12-28|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-13|P1Y2M10DT2H30M|AFTER|2021-01-03|ONGOING|2021-01-05
e|RS|dacea2da-9101-41e9-97aa-1cb8445b1320|10|TRGRESP|Target Response|LUGANO CLASSIFICATION|[?]|ukat|MR|1|cd/m2|NO INFORMATION||||SPOUSE|UROLOGIST|Y|5|Visit_5|90|2|TREATMENT|2020-12-28|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-13|P1Y2M10DT2H30M|AFTER|2021-01-03|AFTER|2021-01-06
e|RS|cbf5d05e-e934-4946-b991-5fef63a01888|1|MRDRESP|Minimal Residual Disease Response|PETIT BREAST CANCER 2001|[?]|cd*s/m2|mCR|1|10^6 IU|DISK DIFFUSION|Y|Y||CLINICAL RESEARCH ASSOCIATE|READER 1|Y|1|Visit_1|10|4|FOLLOW-UP|2020-11-06|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-12|P1Y2M10DT2H30M|AFTER|2021-01-12|BEFORE|2021-01-13
e|RS|cbf5d05e-e934-4946-b991-5fef63a01888|2|METSIND|Metastatic Indicator|NCIWG CHESON CLL 1996|||MINOR PATHOLOGIC RESPONSE|1|uSiemens|CINEANGIOGRAPHY|||Y|SPOUSE|MICROSCOPIST 3|N|1|Visit_1|10|7|SCREENING|2020-11-06|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-12|P1Y2M10DT2H30M|AFTER|2021-01-01|BEFORE|2021-01-05
e|RS|cbf5d05e-e934-4946-b991-5fef63a01888|3|NEWLIND|New Lesion Indicator|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|pkat|CRi|1|10^7 TCID 50/dose|MICROBIAL CONCENTRATION|Y|||NON-HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|U|2|Visit_2|25|2|TREATMENT|2020-11-21|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-01|P1Y2M10DT2H30M|AFTER|2020-11-04|BEFORE|2020-12-03
e|RS|cbf5d05e-e934-4946-b991-5fef63a01888|4|MOLRESP|Molecular Response|CHOI GIST 2008|[?]|PRESSOR UNITS|sCR|1|10^6 organisms/g|TELLER ACUITY CARDS||Y||CHILD|PATHOLOGIST 2|Y|2|Visit_2|25|4|TREATMENT|2020-11-21|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-01|P1Y2M10DT2H30M|COINCIDENT|2020-11-19|AFTER|2021-02-03
e|RS|cbf5d05e-e934-4946-b991-5fef63a01888|5|NTERESP|Non-Target Enhancing Response|RECICL|||PR-CT|1|min*mg/mL|DXA SCAN|||Y|STUDY SUBJECT|NEUROLOGIST 2|N|3|Visit_3|40|1|TREATMENT|2020-12-06|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-01|P1Y2M10DT2H30M|COINCIDENT|2020-12-25|ONGOING|2020-12-30
e|RS|cbf5d05e-e934-4946-b991-5fef63a01888|6|OVRLRESP|Overall Response|CHESON LYMPHOMA 2008|[?]|mg/m2/min|MOLECULAR CR|1|PLUG|HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY||||SIGNIFICANT OTHER|PATHOLOGIST|U|3|Visit_3|40|3|SCREENING|2020-12-06|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-01|P1Y2M10DT2H30M|BEFORE|2021-02-01|AFTER|2021-02-02
e|RS|cbf5d05e-e934-4946-b991-5fef63a01888|7|TMRESP|Tumor Marker Response|MURPHY PROSTATE CANCER 1980|[?]|GPL U|iPR|1|10^6 organisms/mL|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY|Y|||ADJUDICATION COMMITTEE|PATHOLOGIST|Y|4|Visit_4|65|6|SCREENING|2020-12-31|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-19|P1Y2M10DT2H30M|BEFORE|2021-01-15|COINCIDENT|2021-01-27
e|RS|cbf5d05e-e934-4946-b991-5fef63a01888|8|ANATRESP|Anatomic Response|RECICL|[?]|mmol/L|TREATMENT FAILURE|1|10^10/L|SLIT LAMP||||SPOUSE|OTOLARYNGOLOGIST|NA|4|Visit_4|65|4|TREATMENT|2020-12-31|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-19|P1Y2M10DT2H30M|BEFORE|2020-11-15|COINCIDENT|2020-12-15
e|RS|cbf5d05e-e934-4946-b991-5fef63a01888|9|NEWLWIND|New Lesion Worsening Indicator|BURCOMBE BREAST CANCER 2005|[?]|Osm|RELAPSED DISEASE|1|TRACE|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY||||PROXY|OPTOMETRIST|N|5|Visit_5|90|7|TREATMENT|2021-01-25|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-21|P1Y2M10DT2H30M|AFTER|2020-11-26|ONGOING|2020-12-19
e|RS|cbf5d05e-e934-4946-b991-5fef63a01888|10|CLINRESP|Clinical Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|mL/cm|RELAPSED DISEASE|1|10^7 CFU/mL|CISH||||CLINICAL STUDY SPONSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|5|Visit_5|90|6|SCREENING|2021-01-25|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-21|P1Y2M10DT2H30M|COINCIDENT|2021-01-14|BEFORE|2021-01-30
e|RS|be18633c-0ff9-4775-9737-dc8a9524fd2c|1|NEWLIND|New Lesion Indicator|PRINCE TCELL LYMPHOMA 2010|[?]|10^6 RNA copies/mL|INCREASED|1|ms/mmHg|CYSTOMETRY||||FAMILY MEMBER|ONCOLOGIST 2|N|1|Visit_1|10|7|SCREENING|2020-10-18|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-17|P1Y2M10DT2H30M|UNKNOWN|2020-12-11|AFTER|2020-12-28
e|RS|be18633c-0ff9-4775-9737-dc8a9524fd2c|2|CPRFSTAT|Clinical Performance Status|WHO BREAST CANCER 2006|[?]|tuberculin unit/mL|PSEUDORESPONSE|1|MBq/uL|ENZYMATIC ULTRACENTRIFUGATION||||CLINICAL RESEARCH COORDINATOR|INTERNIST|U|1|Visit_1|10|5|TREATMENT|2020-10-18|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-17|P1Y2M10DT2H30M|UNKNOWN|2020-11-29|ONGOING|2020-12-25
e|RS|be18633c-0ff9-4775-9737-dc8a9524fd2c|3|NTERESP|Non-Target Enhancing Response|EASL BRUIX LIVER CANCER 2001|||CR-CT|1|MHz|PULSE OXIMETRY|||Y|SIGNIFICANT OTHER|OTOLARYNGOLOGIST|U|2|Visit_2|25|5|WASHOUT|2020-11-02|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-23|P1Y2M10DT2H30M|UNKNOWN|2020-12-12|BEFORE|2021-01-06
e|RS|be18633c-0ff9-4775-9737-dc8a9524fd2c|4|MNPTHIND|Minor Pathological Response Indicator|NCIWG CHESON CLL 1996|||iPR|1|PRESSOR UNITS|TOLUIDINE BLUE STAIN|||Y|FAMILY MEMBER|RATER|Y|2|Visit_2|25|7|FOLLOW-UP|2020-11-02|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-23|P1Y2M10DT2H30M|AFTER|2020-11-20|AFTER|2020-12-11
e|RS|be18633c-0ff9-4775-9737-dc8a9524fd2c|5|RDIORESP|Radiologic Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|cm/min|NON-QUANTIFIABLE MRD POSITIVITY|1|mL/animal|CYSTOSCOPY||Y||CLINICAL RESEARCH COORDINATOR|RATER 2|Y|3|Visit_3|40|2|FOLLOW-UP|2020-11-17|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-14|P1Y2M10DT2H30M|BEFORE|2020-11-01|COINCIDENT|2021-01-03
e|RS|be18633c-0ff9-4775-9737-dc8a9524fd2c|6|MRDIND|Minimal Residual Disease Indicator|MACDONALD GLIOMA 1990|||NE|1|cm/min|ACCELERATOR MASS SPECTROMETRY||Y|Y|SIBLING|RADIOLOGIST|NA|3|Visit_3|40|1|WASHOUT|2020-11-17|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-14|P1Y2M10DT2H30M|COINCIDENT|2020-10-28|AFTER|2020-11-22
e|RS|be18633c-0ff9-4775-9737-dc8a9524fd2c|7|MNPTHIND|Minor Pathological Response Indicator|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|Bq/ug|CA125 75% RESPONSE|1|Pack Year|INDIRECT IMMUNOFLUORESCENCE||||CLINICAL RESEARCH ASSOCIATE|READER 3|NA|4|Visit_4|65|2|SCREENING|2020-12-12|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-11|P1Y2M10DT2H30M|UNKNOWN|2020-10-12|ONGOING|2020-12-04
e|RS|be18633c-0ff9-4775-9737-dc8a9524fd2c|8|CPRFSTAT|Clinical Performance Status|PCWG SCHER PROSTATE CANCER 2008|[?]|DDU|IMPROVED|1|SACHET|AGAR PROPORTION||||FRIEND|ADJUDICATOR|N|4|Visit_4|65|3|TREATMENT|2020-12-12|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-11|P1Y2M10DT2H30M|AFTER|2020-12-04|COINCIDENT|2021-01-13
e|RS|be18633c-0ff9-4775-9737-dc8a9524fd2c|9|CPRFSTAT|Clinical Performance Status|PALUMBO MULTIPLE MYELOMA 2009|||MRD NEGATIVITY|1|g/m2/day|FLUORESCENT LIFETIME IMAGING MICROSCOPY|||Y|CHILD|READER|NA|5|Visit_5|90|6|TREATMENT|2021-01-06|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-29|P1Y2M10DT2H30M|UNKNOWN|2020-11-05|BEFORE|2020-11-08
e|RS|be18633c-0ff9-4775-9737-dc8a9524fd2c|10|PATHRESP|Pathologic Response|CHESON CLL 2006|[?]|/200 HPFs|HI-E|1|mol/mL|STATIC PERIMETRY|Y|||CHILD|UROLOGIST|U|5|Visit_5|90|5|TREATMENT|2021-01-06|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-29|P1Y2M10DT2H30M|COINCIDENT|2020-11-10|AFTER|2020-11-20
e|RS|f7eba9b8-94fb-46b8-842a-0322eb68a355|1|TRGRESP|Target Response|PCWG SCHER PROSTATE CANCER 2016|[?]|10^8/L|PD-CT|1|U/m2/h|PET/MRI SCAN||||FRIEND|READER 1|U|1|Visit_1|10|4|SCREENING|2020-05-12|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-06|P1Y2M10DT2H30M|COINCIDENT|2020-05-20|COINCIDENT|2020-07-07
e|RS|f7eba9b8-94fb-46b8-842a-0322eb68a355|2|NEWLIND|New Lesion Indicator|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|10^3 RNA copies/mL|NON-iCR/NON-iUPD|1|TABLET|SPECTROPHOTOMETRY|Y|||INVESTIGATOR|PHYSIOTHERAPIST|Y|1|Visit_1|10|5|FOLLOW-UP|2020-05-12|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-06|P1Y2M10DT2H30M|COINCIDENT|2020-05-30|ONGOING|2020-07-06
e|RS|f7eba9b8-94fb-46b8-842a-0322eb68a355|3|TRGRESP|Target Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|||DECREASED|1|nL|LIGHT SCATTERING SPECTROSCOPY|||Y|ADJUDICATOR|NEUROLOGIST 1|Y|2|Visit_2|25|4|WASHOUT|2020-05-27|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-28|P1Y2M10DT2H30M|BEFORE|2020-06-11|BEFORE|2020-07-29
e|RS|f7eba9b8-94fb-46b8-842a-0322eb68a355|4|METBRESP|Metabolic Response|HARTMAN PANCREATIC CANCER 2012|[?]|pg|UNEQUIVOCAL|1|mCi/kg|WESTERN BLOT||||INVESTIGATOR|MICROSCOPIST 1|N|2|Visit_2|25|2|TREATMENT|2020-05-27|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-28|P1Y2M10DT2H30M|BEFORE|2020-08-02|ONGOING|2020-08-08
e|RS|f7eba9b8-94fb-46b8-842a-0322eb68a355|5|HEMARESP|Hematologic Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|anti-Xa IU|EQUIVOCAL|1|Shock Wave|GC/MS||||VENDOR|HEMATOLOGIST|NA|3|Visit_3|40|5|TREATMENT|2020-06-11|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-15|P1Y2M10DT2H30M|COINCIDENT|2020-06-30|COINCIDENT|2020-08-05
e|RS|f7eba9b8-94fb-46b8-842a-0322eb68a355|6|BMIVLIND|Bone Marrow Involvement Indicator|GUILHOT CML 2007|[?]|10^3 organisms|CRi|1|mL/(min*100mL)|DIFFUSION WEIGHTED MRI||||FRIEND|ONCOLOGIST 1|Y|3|Visit_3|40|6|WASHOUT|2020-06-11|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-15|P1Y2M10DT2H30M|UNKNOWN|2020-08-05|BEFORE|2020-08-06
e|RS|f7eba9b8-94fb-46b8-842a-0322eb68a355|7|MRPHRESP|Morphologic Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|SPRAY|MRD RELAPSE|1|uL/dose|FORCED OSCILLATION TECHNIQUE||||INDEPENDENT ASSESSOR|ADJUDICATOR|NA|4|Visit_4|65|5|WASHOUT|2020-07-06|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-10|P1Y2M10DT2H30M|BEFORE|2020-07-25|COINCIDENT|2020-08-05
e|RS|f7eba9b8-94fb-46b8-842a-0322eb68a355|8|METSIND|Metastatic Indicator|GUILHOT CML 2007|||NON-CR/NON-PD|1|cup eq|MICROPARTICLE ENZYME IMMUNOASSAY|||Y|FRIEND|MICROSCOPIST|N|4|Visit_4|65|7|TREATMENT|2020-07-06|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-10|P1Y2M10DT2H30M|BEFORE|2020-07-14|ONGOING|2020-08-04
e|RS|f7eba9b8-94fb-46b8-842a-0322eb68a355|9|RDIORESP|Radiologic Response|LEE LUNG CANCER 2011|[?]|mL/dL|STABLE|1|mL/dose|MYELOPEROXIDASE STAIN||||CLINICAL RESEARCH COORDINATOR|PATHOLOGIST|U|5|Visit_5|90|2|TREATMENT|2020-07-31|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-06|P1Y2M10DT2H30M|AFTER|2020-08-06|ONGOING|2020-08-07
e|RS|f7eba9b8-94fb-46b8-842a-0322eb68a355|10|MOLRESP|Molecular Response|CHOI GIST 2008|[?]|uL|mCR|1|mg2/dL2|IMMUNORADIOMETRIC ASSAY||||CLINICAL RESEARCH ASSOCIATE|OTOLARYNGOLOGIST|U|5|Visit_5|90|3|TREATMENT|2020-07-31|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-06|P1Y2M10DT2H30M|UNKNOWN|2020-06-26|ONGOING|2020-07-16
e|RS|903199e2-56e1-41e4-8904-d33cc6846ee3|1|SFTSRESP|Soft Tissue Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|SYRINGE|cCR|1|nmol BCE/mmol|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY||||ADJUDICATION COMMITTEE|ADJUDICATOR 2|N|1|Visit_1|10|6|FOLLOW-UP|2021-01-18|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-13|P1Y2M10DT2H30M|AFTER|2021-03-09|AFTER|2021-04-06
e|RS|903199e2-56e1-41e4-8904-d33cc6846ee3|2|SFTSRESP|Soft Tissue Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|/100 HPFs|MORPHOLOGIC CRi|1|U.CARR|FLOCCULATION, CHARCOAL ENHANCED||||STUDY SUBJECT|MICROSCOPIST 3|NA|1|Visit_1|10|1|SCREENING|2021-01-18|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-13|P1Y2M10DT2H30M|BEFORE|2021-02-14|AFTER|2021-03-13
e|RS|903199e2-56e1-41e4-8904-d33cc6846ee3|3|METSIND|Metastatic Indicator|CHESON CLL 2006|[?]|VIRTUAL PIXEL|FAVORABLE RESPONSE|1|mCi/kg|SURFACE PLASMON RESONANCE||||ADJUDICATION COMMITTEE|ONCOLOGIST 2|NA|2|Visit_2|25|3|TREATMENT|2021-02-02|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-28|P1Y2M10DT2H30M|BEFORE|2021-03-17|ONGOING|2021-03-25
e|RS|903199e2-56e1-41e4-8904-d33cc6846ee3|4|TMRESP|Tumor Marker Response|KEAM BREAST CANCER 2013|[?]|L/min/m2|PD|1|mmol/day|OPTICAL DENSITY MEASUREMENT|Y|||ADJUDICATOR|PEDIATRIC NEUROLOGIST|Y|2|Visit_2|25|5|TREATMENT|2021-02-02|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-28|P1Y2M10DT2H30M|AFTER|2021-01-16|ONGOING|2021-02-18
e|RS|903199e2-56e1-41e4-8904-d33cc6846ee3|5|METBRESP|Metabolic Response|NCIWG CHESON CLL 1996|||DISEASE TRANSFORMATION|1|IU/day|FLUORESCENT SPOT TEST|||Y|GUARDIAN|RADIOLOGIST 1|NA|3|Visit_3|40|3|TREATMENT|2021-02-17|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-07|P1Y2M10DT2H30M|BEFORE|2021-01-27|COINCIDENT|2021-03-30
e|RS|903199e2-56e1-41e4-8904-d33cc6846ee3|6|MRDRESP|Minimal Residual Disease Response|PETIT BREAST CANCER 2001|[?]|ug/kg/min|NON-QUANTIFIABLE MRD POSITIVITY|1|cmH2O/mL|CONTRAST ENHANCED SPIRAL CT SCAN|Y|||CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 2|U|3|Visit_3|40|4|TREATMENT|2021-02-17|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-07|P1Y2M10DT2H30M|UNKNOWN|2021-01-28|BEFORE|2021-04-09
e|RS|903199e2-56e1-41e4-8904-d33cc6846ee3|7|SYMPTDTR|Symptomatic Deterioration|FAROOQUI SUPP CLL 2014|||MRD NEGATIVITY|1|10^9 CFU|IHC|||Y|STUDY SUBJECT|RATER|N|4|Visit_4|65|7|FOLLOW-UP|2021-03-14|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-04|P1Y2M10DT2H30M|COINCIDENT|2021-01-17|ONGOING|2021-03-24
e|RS|903199e2-56e1-41e4-8904-d33cc6846ee3|8|SYMPTDTR|Symptomatic Deterioration|SCHWARZ CERVICAL CANCER 2009|[?]|10^6 U|sCR|1|kcal/day|PERCUSSION||||PARENT|READER|N|4|Visit_4|65|2|TREATMENT|2021-03-14|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-04|P1Y2M10DT2H30M|COINCIDENT|2021-03-15|BEFORE|2021-04-17
e|RS|903199e2-56e1-41e4-8904-d33cc6846ee3|9|NTLWIND|Non-Target Lesion Worsening Indicator|IWG CHESON AML 2003|[?]|10^9 organisms/mg|CHR|1|mL/animal/day|CALCULATION||||ADJUDICATION COMMITTEE|READER 1|N|5|Visit_5|90|6|WASHOUT|2021-04-08|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-09|P1Y2M10DT2H30M|BEFORE|2021-01-14|BEFORE|2021-01-29
e|RS|903199e2-56e1-41e4-8904-d33cc6846ee3|10|SYMPTDTR|Symptomatic Deterioration|SCHWARZ CERVICAL CANCER 2009|[?]|10^3 organisms/g|CYTOGENETIC MINOR RESPONSE|1|kUSP|DARK FIELD MICROSCOPY||||HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|U|5|Visit_5|90|6|TREATMENT|2021-04-08|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-09|P1Y2M10DT2H30M|COINCIDENT|2021-03-29|COINCIDENT|2021-04-04
e|RS|32567f8d-e746-44e1-a269-d95ba3bb0b11|1|BONERESP|Bone Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|U/kg/min|sCR|1|yd|DXA SCAN||||CHILD|ENDOCRINOLOGIST|N|1|Visit_1|10|7|TREATMENT|2020-11-02|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-16|P1Y2M10DT2H30M|UNKNOWN|2021-01-13|COINCIDENT|2021-01-26
e|RS|32567f8d-e746-44e1-a269-d95ba3bb0b11|2|HEMARESP|Hematologic Response|NCIWG CHESON CLL 1996|[?]|PIXELS/in|PR-CT|1|mmol/mol|DIGITAL PCR ARRAY|Y|||DOMESTIC PARTNER|DEVELOPMENTAL PSYCHOLOGIST|U|1|Visit_1|10|4|SCREENING|2020-11-02|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-16|P1Y2M10DT2H30M|UNKNOWN|2021-01-25|AFTER|2021-01-29
e|RS|32567f8d-e746-44e1-a269-d95ba3bb0b11|3|RDIORESP|Radiologic Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|GBq|MOLECULAR CR|1|kPa/L/sec|IMMUNE REPERTOIRE DEEP SEQUENCING||||INTERVIEWER|NEUROLOGIST 2|NA|2|Visit_2|25|1|FOLLOW-UP|2020-11-17|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-05|P1Y2M10DT2H30M|BEFORE|2020-11-10|BEFORE|2020-11-14
e|RS|32567f8d-e746-44e1-a269-d95ba3bb0b11|4|MJPTHIND|Major Pathological Response Indicator|MONTSERRAT CLL 1989|[?]|V/sec|IMPROVED|1|mEq/day|PHASE-CONTRAST MRI||||SIGNIFICANT OTHER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|2|Visit_2|25|5|TREATMENT|2020-11-17|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-05|P1Y2M10DT2H30M|BEFORE|2021-01-03|COINCIDENT|2021-01-09
e|RS|32567f8d-e746-44e1-a269-d95ba3bb0b11|5|TMRESP|Tumor Marker Response|KUMAR IMWG 2016|[?]|mol/mol|MRD PERSISTENCE|1|CCID 50/mL|HPLC-UV|Y|||FRIEND|ONCOLOGIST|Y|3|Visit_3|40|3|TREATMENT|2020-12-02|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-25|P1Y2M10DT2H30M|AFTER|2021-01-29|ONGOING|2021-01-30
e|RS|32567f8d-e746-44e1-a269-d95ba3bb0b11|6|MRDIND|Minimal Residual Disease Indicator|MURPHY PROSTATE CANCER 1980|[?]|10^9/g|COMPLETE MRD RESPONSE|1|MAC50|NUCLEAR RADIOLOGY||||CLINICAL STUDY SPONSOR|CLINICAL PATHOLOGIST|U|3|Visit_3|40|7|TREATMENT|2020-12-02|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-25|P1Y2M10DT2H30M|COINCIDENT|2021-01-08|ONGOING|2021-01-11
e|RS|32567f8d-e746-44e1-a269-d95ba3bb0b11|7|MOLRESP|Molecular Response|IRANO 2015|[?]|ug/m2/h|TREATMENT FAILURE|1|ug/m2/min|PHOTOMETRY|Y|||INDEPENDENT ASSESSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|4|Visit_4|65|1|WASHOUT|2020-12-27|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-13|P1Y2M10DT2H30M|AFTER|2021-01-27|BEFORE|2021-01-30
e|RS|32567f8d-e746-44e1-a269-d95ba3bb0b11|8|STRUSTAT|Steroid Use Status|DOHNER AML 2010|[?]|IU/g Hb|EQUIVOCAL|1|CIGAR|AMSLER GRID||Y||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 2|NA|4|Visit_4|65|1|FOLLOW-UP|2020-12-27|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-13|P1Y2M10DT2H30M|UNKNOWN|2021-01-08|ONGOING|2021-01-21
e|RS|32567f8d-e746-44e1-a269-d95ba3bb0b11|9|TMRESP|Tumor Marker Response|RAJKUMAR MYELOMA 2011|[?]|/wk|iUPD|1|Bq/mg|MULTIPLE BREATH WASHOUT|Y|||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 2|NA|5|Visit_5|90|7|TREATMENT|2021-01-21|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-14|P1Y2M10DT2H30M|COINCIDENT|2021-01-10|AFTER|2021-01-26
e|RS|32567f8d-e746-44e1-a269-d95ba3bb0b11|10|SYMPTDTR|Symptomatic Deterioration|HARTMAN PANCREATIC CANCER 2012|||DECREASED|1|uV|ELISA|||Y|SIGNIFICANT OTHER|RATER 2|N|5|Visit_5|90|2|FOLLOW-UP|2021-01-21|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-14|P1Y2M10DT2H30M|BEFORE|2020-12-01|AFTER|2020-12-18
e|RS|ecdc54eb-c02f-4112-8e85-8a3352470b3b|1|BONERESP|Bone Response|LEE LUNG CANCER 2011|||PSA PROGRESSION|1|APS U|AUDIOMETRY|||Y|ADJUDICATOR|MICROSCOPIST 3|N|1|Visit_1|10|2|TREATMENT|2020-11-11|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-10|P1Y2M10DT2H30M|COINCIDENT|2020-11-05|COINCIDENT|2021-02-02
e|RS|ecdc54eb-c02f-4112-8e85-8a3352470b3b|2|MRPHRESP|Morphologic Response|JACINTO CERVICAL CANCER 2007|[?]|Ci/uL|SD|1|10^9 organisms/mL|STATIC PERIMETRY||||SIGNIFICANT OTHER|ADJUDICATOR 2|U|1|Visit_1|10|3|SCREENING|2020-11-11|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-10|P1Y2M10DT2H30M|COINCIDENT|2020-12-05|AFTER|2020-12-31
e|RS|ecdc54eb-c02f-4112-8e85-8a3352470b3b|3|METBRESP|Metabolic Response|RANO|||PSA PROGRESSION|1|ugEq/L|SPECULAR MICROSCOPY|||Y|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST|N|2|Visit_2|25|4|FOLLOW-UP|2020-11-26|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-03|P1Y2M10DT2H30M|COINCIDENT|2020-12-20|COINCIDENT|2021-01-15
e|RS|ecdc54eb-c02f-4112-8e85-8a3352470b3b|4|MRDIND|Minimal Residual Disease Indicator|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|breaths/min|MRD RELAPSE|1|/day|ELECTROCHEMILUMINESCENCE||||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 3|U|2|Visit_2|25|2|WASHOUT|2020-11-26|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-03|P1Y2M10DT2H30M|AFTER|2020-12-13|ONGOING|2021-01-01
e|RS|ecdc54eb-c02f-4112-8e85-8a3352470b3b|5|NEWLWIND|New Lesion Worsening Indicator|LEE LUNG CANCER 2011|[?]|/day|NED|1|ks|DXA SCAN||||CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 1|NA|3|Visit_3|40|6|TREATMENT|2020-12-11|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-17|P1Y2M10DT2H30M|UNKNOWN|2021-02-06|BEFORE|2021-02-08
e|RS|ecdc54eb-c02f-4112-8e85-8a3352470b3b|6|SYMPTDTR|Symptomatic Deterioration|MASS|||WORSENED|1|10^6 IU|HPLC/MS|||Y|INDEPENDENT ASSESSOR|DEVELOPMENTAL PSYCHOLOGIST|U|3|Visit_3|40|4|TREATMENT|2020-12-11|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-17|P1Y2M10DT2H30M|COINCIDENT|2021-01-21|AFTER|2021-01-27
e|RS|ecdc54eb-c02f-4112-8e85-8a3352470b3b|7|STRUSTAT|Steroid Use Status|SACT|[?]|g/kg/day|VGPR|1|mL/min/mmHg|OSCILLOMETRY||||ADJUDICATION COMMITTEE|MICROSCOPIST|NA|4|Visit_4|65|5|TREATMENT|2021-01-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-03|P1Y2M10DT2H30M|COINCIDENT|2021-01-30|ONGOING|2021-02-04
e|RS|ecdc54eb-c02f-4112-8e85-8a3352470b3b|8|CYTORESP|Cytogenetic Response|IWG CHESON AML 2003|||IMMUNOPHENOTYPIC CR|1|ukat/L|RULER MEASUREMENT METHOD|||Y|SIGNIFICANT OTHER|PHYSIOTHERAPIST|N|4|Visit_4|65|1|WASHOUT|2021-01-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-03|P1Y2M10DT2H30M|COINCIDENT|2021-01-01|BEFORE|2021-01-31
e|RS|ecdc54eb-c02f-4112-8e85-8a3352470b3b|9|DRCRIND|Disease Recurrence Indicator|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|Arbitrary U|sCR|1|EID 50/mL|SLIT LAMP PHOTOGRAPHY|Y|Y||VENDOR|ADJUDICATOR 2|Y|5|Visit_5|90|3|FOLLOW-UP|2021-01-30|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-28|P1Y2M10DT2H30M|BEFORE|2021-01-20|ONGOING|2021-02-01
e|RS|ecdc54eb-c02f-4112-8e85-8a3352470b3b|10|SFTSRESP|Soft Tissue Response|RECIST 1.1|||pCR|1|deg/s|HIGH LEVEL AMINOGLYCOSIDE SCREEN|||Y|SIGNIFICANT OTHER|PATHOLOGIST 1|N|5|Visit_5|90|4|TREATMENT|2021-01-30|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-28|P1Y2M10DT2H30M|BEFORE|2020-11-03|COINCIDENT|2020-11-20
e|RS|6885a3d0-5bd9-4f2f-a126-35b8030ad1b8|1|METSIND|Metastatic Indicator|IWG CHESON MDS 2000|||nPR|1|10^3 organisms/mL|SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY||Y|Y|DOMESTIC PARTNER|DERMATOLOGIST|NA|1|Visit_1|10|1|TREATMENT|2020-07-09|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-07|P1Y2M10DT2H30M|BEFORE|2020-09-05|AFTER|2020-09-24
e|RS|6885a3d0-5bd9-4f2f-a126-35b8030ad1b8|2|LIVRRESP|Liver Response|PERCIST|[?]|PHERESIS UNIT|SMD|1|lx|MICROBIAL CULTURE, SOLID||||CHILD|MICROSCOPIST 2|Y|1|Visit_1|10|3|TREATMENT|2020-07-09|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-07|P1Y2M10DT2H30M|BEFORE|2020-09-01|COINCIDENT|2020-09-11
e|RS|6885a3d0-5bd9-4f2f-a126-35b8030ad1b8|3|NTERESP|Non-Target Enhancing Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|10^7/L|iUPD|1|mm/h|LC/MS||||INVESTIGATOR|ADJUDICATOR|U|2|Visit_2|25|3|TREATMENT|2020-07-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-07|P1Y2M10DT2H30M|COINCIDENT|2020-08-10|ONGOING|2020-09-17
e|RS|6885a3d0-5bd9-4f2f-a126-35b8030ad1b8|4|MOLRESP|Molecular Response|RAJKUMAR MYELOMA 2011|||PDu|1|cg|LIQUID SCINTILLATION COUNTING||Y|Y|CHILD|CLINICAL PATHOLOGIST|NA|2|Visit_2|25|7|TREATMENT|2020-07-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-07|P1Y2M10DT2H30M|BEFORE|2020-09-27|ONGOING|2020-09-28
e|RS|6885a3d0-5bd9-4f2f-a126-35b8030ad1b8|5|PATHRESP|Pathologic Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|Frames/s|MORPHOLOGIC CR|1|100 IU/mL|PERIODIC ACID SCHIFF STAIN||||CLINICAL RESEARCH COORDINATOR|READER 1|U|3|Visit_3|40|6|TREATMENT|2020-08-08|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-29|P1Y2M10DT2H30M|COINCIDENT|2020-09-12|BEFORE|2020-10-05
e|RS|6885a3d0-5bd9-4f2f-a126-35b8030ad1b8|6|NTLWIND|Non-Target Lesion Worsening Indicator|RANO ELLINGSON 2017|||SD|1|Anson U|REAL-TIME POLYMERASE CHAIN REACTION ASSAY||Y|Y|ADJUDICATOR|READER 2|N|3|Visit_3|40|6|SCREENING|2020-08-08|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-29|P1Y2M10DT2H30M|UNKNOWN|2020-09-19|AFTER|2020-10-05
e|RS|6885a3d0-5bd9-4f2f-a126-35b8030ad1b8|7|SYMPTDTR|Symptomatic Deterioration|HARTMANN GERM CELL CANCER 2002|||NED|1|NFIU|DYNAMIC LIGHT SCATTERING|||Y|SPOUSE|ADJUDICATOR 2|Y|4|Visit_4|65|2|FOLLOW-UP|2020-09-02|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-12|P1Y2M10DT2H30M|UNKNOWN|2020-07-11|ONGOING|2020-08-19
e|RS|6885a3d0-5bd9-4f2f-a126-35b8030ad1b8|8|OVRLRESP|Overall Response|RECIST 1.1|[?]|ug/L DDU|HI-N|1|fmol|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION||||NON-HEALTH CARE PROFESSIONAL|UROLOGIST|N|4|Visit_4|65|4|FOLLOW-UP|2020-09-02|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-12|P1Y2M10DT2H30M|COINCIDENT|2020-09-11|BEFORE|2020-09-24
e|RS|6885a3d0-5bd9-4f2f-a126-35b8030ad1b8|9|METSIND|Metastatic Indicator|GUPPY OVARIAN CANCER 2002|[?]|cL|PR WITH LYMPHOCYTOSIS|1|kg/cm|MICROBIAL BIOCHEMICAL IDENTIFICATION||||STUDY SUBJECT|CARDIOLOGIST|U|5|Visit_5|90|5|TREATMENT|2020-09-27|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-21|P1Y2M10DT2H30M|BEFORE|2020-08-23|ONGOING|2020-09-09
e|RS|6885a3d0-5bd9-4f2f-a126-35b8030ad1b8|10|TMRESP|Tumor Marker Response|WHO BREAST CANCER 2006|[?]|umol|MRD RELAPSE|1|mN|MICROBIAL BIOCHEMICAL IDENTIFICATION||Y||SPOUSE|ENDOCRINOLOGIST|U|5|Visit_5|90|3|FOLLOW-UP|2020-09-27|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-21|P1Y2M10DT2H30M|UNKNOWN|2020-07-29|ONGOING|2020-09-18
e|RS|5d7241ec-120d-486d-ab39-b9e14ab4ce90|1|RDIORESP|Radiologic Response|RAJKUMAR MYELOMA 2011|||MRD PERSISTENCE|1|mL/sec/1.73m2|WRIGHT STAIN|Y||Y|FRIEND|RADIOLOGIST 1|N|1|Visit_1|10|6|WASHOUT|2020-08-01|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-24|P1Y2M10DT2H30M|BEFORE|2020-09-30|ONGOING|2020-10-27
e|RS|5d7241ec-120d-486d-ab39-b9e14ab4ce90|2|MOLRESP|Molecular Response|AJCC V8|||sCR|1|Log10 ELISA unit/dose|CONTRAST ENHANCED CT SCAN|||Y|STUDY SUBJECT|ADJUDICATOR 1|U|1|Visit_1|10|7|TREATMENT|2020-08-01|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-24|P1Y2M10DT2H30M|COINCIDENT|2020-09-26|ONGOING|2020-10-20
e|RS|5d7241ec-120d-486d-ab39-b9e14ab4ce90|3|LIVRRESP|Liver Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|ks|HI-P|1|/100 HPFs|GC/MS||||INDEPENDENT ASSESSOR|ONCOLOGIST 2|U|2|Visit_2|25|3|TREATMENT|2020-08-16|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-02|P1Y2M10DT2H30M|UNKNOWN|2020-08-12|ONGOING|2020-10-05
e|RS|5d7241ec-120d-486d-ab39-b9e14ab4ce90|4|OVRLRESP|Overall Response|LUGANO CLASSIFICATION|[?]|log10 PFU|iSD|1|mL/beat|FLAME PHOTOMETRY||||DOMESTIC PARTNER|MICROSCOPIST 1|NA|2|Visit_2|25|4|TREATMENT|2020-08-16|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-02|P1Y2M10DT2H30M|AFTER|2020-09-04|BEFORE|2020-09-12
e|RS|5d7241ec-120d-486d-ab39-b9e14ab4ce90|5|BONERESP|Bone Response|BRUGGEMANN MRD 2010|[?]|pg|CA125 75% RESPONSE|1|mol/day|ELECTRICAL IMPEDANCE MYOGRAPHY||||ADJUDICATION COMMITTEE|ONCOLOGIST|N|3|Visit_3|40|7|SCREENING|2020-08-31|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-22|P1Y2M10DT2H30M|AFTER|2020-09-27|AFTER|2020-10-04
e|RS|5d7241ec-120d-486d-ab39-b9e14ab4ce90|6|NEWLPROG|New Lesion Progression|IWG CHESON MDS 2000|||PR-CT|1|nmol/L/h|PERIPHERAL ANGIOGRAPHY|Y||Y|CLINICAL RESEARCH ASSOCIATE|FORENSIC PATHOLOGIST|N|3|Visit_3|40|6|TREATMENT|2020-08-31|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-22|P1Y2M10DT2H30M|AFTER|2020-08-14|COINCIDENT|2020-10-12
e|RS|5d7241ec-120d-486d-ab39-b9e14ab4ce90|7|METBRESP|Metabolic Response|DURIE MULTIPLE MYELOMA 2006|[?]|mL/kg/day|MRD NEGATIVITY|1|umol/L/h|SEQUENCING|Y|||HEALTH CARE PROFESSIONAL|READER 3|U|4|Visit_4|65|7|TREATMENT|2020-09-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-26|P1Y2M10DT2H30M|COINCIDENT|2020-10-17|ONGOING|2020-10-29
e|RS|5d7241ec-120d-486d-ab39-b9e14ab4ce90|8|NEWLPROG|New Lesion Progression|PCWG SCHER PROSTATE CANCER 2008|[?]|nmol/kg/day|CA125 50% RESPONSE|1|deg2|PYROSEQUENCING||||ADJUDICATOR|PATHOLOGIST|U|4|Visit_4|65|1|FOLLOW-UP|2020-09-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-26|P1Y2M10DT2H30M|BEFORE|2020-09-08|ONGOING|2020-10-11
e|RS|5d7241ec-120d-486d-ab39-b9e14ab4ce90|9|BMIVLIND|Bone Marrow Involvement Indicator|CHOI GIST 2008|||CA125 50% RESPONSE|1|TABLET|SPECTROPHOTOMETRY|||Y|GUARDIAN|MICROSCOPIST 1|N|5|Visit_5|90|2|TREATMENT|2020-10-20|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-09|P1Y2M10DT2H30M|AFTER|2020-08-07|AFTER|2020-08-31
e|RS|5d7241ec-120d-486d-ab39-b9e14ab4ce90|10|SFTSRESP|Soft Tissue Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|anti-Xa IU/mL|CYTOGENETIC PR|1|10^6 DNA copies/mL|ORCHIDOMETERY||Y||NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR|Y|5|Visit_5|90|5|SCREENING|2020-10-20|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-09|P1Y2M10DT2H30M|COINCIDENT|2020-10-11|AFTER|2020-10-25
e|RS|17fdb337-01e4-42ce-b3f0-1f4beeafc26c|1|PATHRESP|Pathologic Response|DURIE MULTIPLE MYELOMA 2006|[?]|CAPLET|pCR|1|kDa|RAJI CELL EIA||||CLINICAL STUDY SPONSOR|OPTOMETRIST|N|1|Visit_1|10|3|SCREENING|2020-06-01|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-23|P1Y2M10DT2H30M|AFTER|2020-08-26|AFTER|2020-08-27
e|RS|17fdb337-01e4-42ce-b3f0-1f4beeafc26c|2|OVRLRESP|Overall Response|iRECIST|[?]|mL/cage/day|PARTIAL MORPHOLOGIC RESPONSE|1|BLOCKS|PELLI-ROBSON EYE CHART||||VENDOR|PATHOLOGIST 1|Y|1|Visit_1|10|3|SCREENING|2020-06-01|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-23|P1Y2M10DT2H30M|UNKNOWN|2020-07-29|AFTER|2020-08-16
e|RS|17fdb337-01e4-42ce-b3f0-1f4beeafc26c|3|STRUSTAT|Steroid Use Status|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|10^7 CFU/mL|MOLECULAR MAJOR RESPONSE|1|EU|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY||||SIBLING|ADJUDICATOR 1|N|2|Visit_2|25|6|TREATMENT|2020-06-16|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-27|P1Y2M10DT2H30M|AFTER|2020-06-19|ONGOING|2020-08-04
e|RS|17fdb337-01e4-42ce-b3f0-1f4beeafc26c|4|NTERESP|Non-Target Enhancing Response|SCHWARZ CERVICAL CANCER 2009|[?]|ELISA unit/dose|CRi|1|10^6 organisms|IODINE STAIN|Y|||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST|N|2|Visit_2|25|2|TREATMENT|2020-06-16|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-27|P1Y2M10DT2H30M|BEFORE|2020-06-30|AFTER|2020-07-28
e|RS|17fdb337-01e4-42ce-b3f0-1f4beeafc26c|5|NTLWIND|Non-Target Lesion Worsening Indicator|iRECIST|[?]|MPL U|pCR|1|BISCUIT|IVY INCISION METHOD||||DOMESTIC PARTNER|MICROSCOPIST 2|Y|3|Visit_3|40|6|TREATMENT|2020-07-01|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-09|P1Y2M10DT2H30M|UNKNOWN|2020-07-30|AFTER|2020-08-11
e|RS|17fdb337-01e4-42ce-b3f0-1f4beeafc26c|6|RDIORESP|Radiologic Response|BRUGGEMANN MRD 2010|[?]|mg/m2/day|WORSENED|1|dB|HIGH RESOLUTION CT||||SPOUSE|MICROSCOPIST 3|N|3|Visit_3|40|6|TREATMENT|2020-07-01|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-09|P1Y2M10DT2H30M|UNKNOWN|2020-07-25|AFTER|2020-08-23
e|RS|17fdb337-01e4-42ce-b3f0-1f4beeafc26c|7|BONERESP|Bone Response|iRECIST|||PSEUDOPROGRESSION|1|Osm|CINEANGIOGRAPHY|||Y|INTERVIEWER|OPTOMETRIST|U|4|Visit_4|65|1|FOLLOW-UP|2020-07-26|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-19|P1Y2M10DT2H30M|BEFORE|2020-06-02|COINCIDENT|2020-08-09
e|RS|17fdb337-01e4-42ce-b3f0-1f4beeafc26c|8|SYMPTDTR|Symptomatic Deterioration|BRUGGEMANN MRD 2010|[?]|nkat|VGPR|1|Rad|TRYPAN BLUE STAIN|Y|||INDEPENDENT ASSESSOR|ADJUDICATOR 2|U|4|Visit_4|65|4|SCREENING|2020-07-26|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-19|P1Y2M10DT2H30M|BEFORE|2020-07-06|BEFORE|2020-08-03
e|RS|17fdb337-01e4-42ce-b3f0-1f4beeafc26c|9|NEWLIND|New Lesion Indicator|RANO|[?]|ukat/L|PSEUDOPROGRESSION|1|kDa|RYAN BLUE STAIN||Y||ADJUDICATOR|ENDOCRINOLOGIST|U|5|Visit_5|90|4|WASHOUT|2020-08-20|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-26|P1Y2M10DT2H30M|COINCIDENT|2020-07-16|AFTER|2020-08-28
e|RS|17fdb337-01e4-42ce-b3f0-1f4beeafc26c|10|NEWLPROG|New Lesion Progression|HAMAOKA BREAST CANCER 2010|[?]|VIAL|CYTOGENETIC NO RESPONSE|1|10^6/Ejaculate U|WEBER GREEN STAIN||||CHILD|OPTOMETRIST|U|5|Visit_5|90|3|FOLLOW-UP|2020-08-20|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-26|P1Y2M10DT2H30M|UNKNOWN|2020-08-10|BEFORE|2020-08-20
e|RS|8efc2f2c-fa89-4ceb-a43c-c77bc2ff6319|1|MRPHRESP|Morphologic Response|CHOLLET BREAST CANCER 2002|||PD/RELAPSE AFTER HI|1|Bq/uL|SPECULAR MICROSCOPY||Y|Y|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 1|N|1|Visit_1|10|3|FOLLOW-UP|2020-07-04|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-20|P1Y2M10DT2H30M|AFTER|2020-09-17|BEFORE|2020-09-23
e|RS|8efc2f2c-fa89-4ceb-a43c-c77bc2ff6319|2|NTNERESP|Non-Target Non-Enhancing Response|WHO BREAST CANCER 2006|[?]|mL/100g/min|PSA PROGRESSION|1|kBq/uL|ELECTROCHEMILUMINESCENCE|Y|||ADJUDICATION COMMITTEE|MICROSCOPIST 2|NA|1|Visit_1|10|3|WASHOUT|2020-07-04|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-20|P1Y2M10DT2H30M|AFTER|2020-07-06|AFTER|2020-09-24
e|RS|8efc2f2c-fa89-4ceb-a43c-c77bc2ff6319|3|METBRESP|Metabolic Response|SHINDOH COLORECTAL CANCER 2013|[?]|mph|EQUIVOCAL|1|genEq/mL|DNA MICROARRAY||||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR|Y|2|Visit_2|25|1|TREATMENT|2020-07-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-05|P1Y2M10DT2H30M|BEFORE|2020-08-12|ONGOING|2020-09-12
e|RS|8efc2f2c-fa89-4ceb-a43c-c77bc2ff6319|4|MRDIND|Minimal Residual Disease Indicator|DURIE MULTIPLE MYELOMA 2006|||NON-iCR/NON-iUPD|1|mmol/day|ANGIOGRAPHY|||Y|SIGNIFICANT OTHER|PATHOLOGIST 2|U|2|Visit_2|25|3|WASHOUT|2020-07-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-05|P1Y2M10DT2H30M|BEFORE|2020-08-19|BEFORE|2020-10-01
e|RS|8efc2f2c-fa89-4ceb-a43c-c77bc2ff6319|5|CPRFSTAT|Clinical Performance Status|IRANO 2015|[?]|Bq/mL|MAJOR PATHOLOGIC RESPONSE|1|CONTAINER|REFLECTANCE SPECTROSCOPY||||INDEPENDENT ASSESSOR|PHYSIOTHERAPIST|NA|3|Visit_3|40|7|TREATMENT|2020-08-03|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-09|P1Y2M10DT2H30M|BEFORE|2020-08-07|COINCIDENT|2020-09-27
e|RS|8efc2f2c-fa89-4ceb-a43c-c77bc2ff6319|6|BESTRESP|Best Overall Response|IWG CHESON MDS 2006|||cPR|1|BAU|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN|Y||Y|FAMILY MEMBER|ONCOLOGIST 2|Y|3|Visit_3|40|1|WASHOUT|2020-08-03|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-09|P1Y2M10DT2H30M|UNKNOWN|2020-07-23|BEFORE|2020-08-01
e|RS|8efc2f2c-fa89-4ceb-a43c-c77bc2ff6319|7|ANATRESP|Anatomic Response|PCWG SCHER PROSTATE CANCER 2008|||CYTOGENETIC CR|1|10^3 organisms|DYNAMIC CONTRAST ENHANCED MRI|Y|Y|Y|FAMILY MEMBER|ADJUDICATOR 3|N|4|Visit_4|65|1|TREATMENT|2020-08-28|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-28|P1Y2M10DT2H30M|UNKNOWN|2020-08-11|ONGOING|2020-08-19
e|RS|8efc2f2c-fa89-4ceb-a43c-c77bc2ff6319|8|CLINRESP|Clinical Response|RECICL|[?]|MPL U/mL|STABLE|1|cup eq|CLINICAL EVALUATION||Y||STUDY SUBJECT|MICROSCOPIST 3|N|4|Visit_4|65|6|SCREENING|2020-08-28|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-28|P1Y2M10DT2H30M|AFTER|2020-09-16|BEFORE|2020-09-28
e|RS|8efc2f2c-fa89-4ceb-a43c-c77bc2ff6319|9|TRGRESP|Target Response|IWG CHESON AML 2003|[?]|Watt|PMD|1|10^3 organisms/g|ULTRASONOGRAPHIC ELASTOGRAPHY|Y|||CAREGIVER|RADIOLOGIST 2|N|5|Visit_5|90|4|TREATMENT|2020-09-22|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-08|P1Y2M10DT2H30M|AFTER|2020-08-04|ONGOING|2020-09-27
e|RS|8efc2f2c-fa89-4ceb-a43c-c77bc2ff6319|10|MRPHRESP|Morphologic Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|||HI-E|1|ELISA unit|INTERRUPTER TECHNIQUE|||Y|PROXY|CARDIOLOGIST|N|5|Visit_5|90|2|FOLLOW-UP|2020-09-22|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-08|P1Y2M10DT2H30M|COINCIDENT|2020-07-24|BEFORE|2020-09-02
e|RS|a69c6182-9c35-4365-b732-b238e0584ba7|1|MRDIND|Minimal Residual Disease Indicator|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|Osm|MORPHOLOGIC CRi|1|L/min|DIGITAL PCR||Y||CLINICAL STUDY SPONSOR|READER 1|U|1|Visit_1|10|2|SCREENING|2020-08-07|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-03|P1Y2M10DT2H30M|AFTER|2020-10-24|COINCIDENT|2020-10-28
e|RS|a69c6182-9c35-4365-b732-b238e0584ba7|2|BONERESP|Bone Response|MRECIST BYRNE MESOTHELIOMA 2004|||UNEQUIVOCAL|1|lx|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN|||Y|ADJUDICATOR|HEMATOLOGIST|U|1|Visit_1|10|3|TREATMENT|2020-08-07|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-03|P1Y2M10DT2H30M|UNKNOWN|2020-08-25|AFTER|2020-10-21
e|RS|a69c6182-9c35-4365-b732-b238e0584ba7|3|LIVRRESP|Liver Response|IWG CHESON MDS 2000|[?]|cmHg|iSD|1|U/m2|TURBIDIMETRY|Y|Y||FRIEND|OTOLARYNGOLOGIST|N|2|Visit_2|25|7|FOLLOW-UP|2020-08-22|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-30|P1Y2M10DT2H30M|UNKNOWN|2020-08-13|BEFORE|2020-10-25
e|RS|a69c6182-9c35-4365-b732-b238e0584ba7|4|CLINRESP|Clinical Response|WHO BREAST CANCER 2006|||CRi|1|anti-Xa IU|IN VITRO GENE EXPRESSION ASSAY|||Y|ADJUDICATION COMMITTEE|PEDIATRIC NEUROLOGIST|Y|2|Visit_2|25|5|TREATMENT|2020-08-22|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-30|P1Y2M10DT2H30M|BEFORE|2020-09-16|ONGOING|2020-10-20
e|RS|a69c6182-9c35-4365-b732-b238e0584ba7|5|BMIVLIND|Bone Marrow Involvement Indicator|AJCC V8|[?]|APL U|CYTOGENETIC PR|1|10^6 organisms|DC SHEATH FLOW|Y|Y||HEALTH CARE PROFESSIONAL|RATER 1|NA|3|Visit_3|40|4|SCREENING|2020-09-06|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-13|P1Y2M10DT2H30M|BEFORE|2020-09-05|BEFORE|2020-10-30
e|RS|a69c6182-9c35-4365-b732-b238e0584ba7|6|MRPHRESP|Morphologic Response|NCCN ALL MRD 2014|[?]|mL/day|PD|1|JDF Unit|PHOROPTER||||CAREGIVER|ADJUDICATOR 3|U|3|Visit_3|40|2|TREATMENT|2020-09-06|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-13|P1Y2M10DT2H30M|UNKNOWN|2020-08-30|AFTER|2020-10-06
e|RS|a69c6182-9c35-4365-b732-b238e0584ba7|7|ANATRESP|Anatomic Response|DURIE MULTIPLE MYELOMA 2006|[?]|L/s/kPa|CYTOGENETIC MINOR RESPONSE|1|PIXELS/cm|FLUORIMETRY||||NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|U|4|Visit_4|65|3|TREATMENT|2020-10-01|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-28|P1Y2M10DT2H30M|AFTER|2020-10-12|COINCIDENT|2020-10-29
e|RS|a69c6182-9c35-4365-b732-b238e0584ba7|8|MRPHRESP|Morphologic Response|PERCIST|||TREATMENT FAILURE|1|mg/mL/day|OSCILLOMETRY|||Y|HEALTH CARE PROFESSIONAL|READER 1|Y|4|Visit_4|65|1|TREATMENT|2020-10-01|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-28|P1Y2M10DT2H30M|AFTER|2020-08-02|ONGOING|2020-09-14
e|RS|a69c6182-9c35-4365-b732-b238e0584ba7|9|SYMPTDTR|Symptomatic Deterioration|KUKER LYMPHOMA 2005|[?]|YEARS|NR|1|10^6 CFU/g|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|Y|||FAMILY MEMBER|CARDIOLOGIST|U|5|Visit_5|90|1|WASHOUT|2020-10-26|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-21|P1Y2M10DT2H30M|BEFORE|2020-11-01|COINCIDENT|2020-11-03
e|RS|a69c6182-9c35-4365-b732-b238e0584ba7|10|NTERESP|Non-Target Enhancing Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|10^3/L|NON-QUANTIFIABLE MRD POSITIVITY|1|10^6 IU/mL|DIFFUSION WEIGHTED MRI||Y||SIGNIFICANT OTHER|OPHTHALMOLOGIST|NA|5|Visit_5|90|2|TREATMENT|2020-10-26|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-21|P1Y2M10DT2H30M|COINCIDENT|2020-10-17|ONGOING|2020-10-25
e|RS|1b9896cf-160e-4a56-8737-9759cd83e784|1|SPLNRESP|Spleen Response|MASS|[?]|uV2|VGPR|1|Roentgen|PUPILLOMETRY||||GUARDIAN|ADJUDICATOR 1|Y|1|Visit_1|10|5|TREATMENT|2020-12-11|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-29|P1Y2M10DT2H30M|COINCIDENT|2021-01-12|BEFORE|2021-02-28
e|RS|1b9896cf-160e-4a56-8737-9759cd83e784|2|STRUSTAT|Steroid Use Status|GUPPY OVARIAN CANCER 2002|[?]|DNA copies/ug|RELAPSED DISEASE FROM CR|1|CAPLET|GC/MS-EI||Y||DOMESTIC PARTNER|ADJUDICATOR 2|Y|1|Visit_1|10|6|FOLLOW-UP|2020-12-11|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-29|P1Y2M10DT2H30M|UNKNOWN|2021-02-01|ONGOING|2021-02-03
e|RS|1b9896cf-160e-4a56-8737-9759cd83e784|3|MRDIND|Minimal Residual Disease Indicator|DOHNER AML 2010|[?]|Ci/L|NE|1|mm/h|PLAQUE REDUCTION NEUTRALIZATION ASSAY||||HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|NA|2|Visit_2|25|6|WASHOUT|2020-12-26|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-08|P1Y2M10DT2H30M|COINCIDENT|2020-12-12|COINCIDENT|2021-02-12
e|RS|1b9896cf-160e-4a56-8737-9759cd83e784|4|MJPTHIND|Major Pathological Response Indicator|IRANO 2015|[?]|dmol|PSA PROGRESSION|1|cm H2O|ELISA||||HEALTH CARE PROFESSIONAL|RATER|NA|2|Visit_2|25|4|WASHOUT|2020-12-26|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-08|P1Y2M10DT2H30M|COINCIDENT|2021-02-21|ONGOING|2021-03-01
e|RS|1b9896cf-160e-4a56-8737-9759cd83e784|5|NEWLWIND|New Lesion Worsening Indicator|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|||CYTOGENETIC NO RESPONSE|1|mg/animal|NUCLEIC ACID SEQUENCING|Y||Y|INTERVIEWER|OPTOMETRIST|Y|3|Visit_3|40|4|TREATMENT|2021-01-10|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-08|P1Y2M10DT2H30M|UNKNOWN|2020-12-26|ONGOING|2021-03-07
e|RS|1b9896cf-160e-4a56-8737-9759cd83e784|6|CLINRESP|Clinical Response|AJCC V8|[?]|cycle/min|DISEASE TRANSFORMATION|1|EP U|GC/MS||Y||FRIEND|PEDIATRIC NEUROLOGIST|Y|3|Visit_3|40|5|FOLLOW-UP|2021-01-10|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-08|P1Y2M10DT2H30M|UNKNOWN|2021-02-08|ONGOING|2021-03-08
e|RS|1b9896cf-160e-4a56-8737-9759cd83e784|7|NEWLPROG|New Lesion Progression|HARTMANN GERM CELL CANCER 2002|[?]|Ci/kg|MORPHOLOGIC CR|1|C|IMPEDANCE CONDUCTIVITY||Y||FRIEND|HEMATOLOGIST|U|4|Visit_4|65|2|TREATMENT|2021-02-04|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-23|P1Y2M10DT2H30M|COINCIDENT|2021-02-07|BEFORE|2021-02-27
e|RS|1b9896cf-160e-4a56-8737-9759cd83e784|8|TRGRESP|Target Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|||SD-CT|1|pmol/10^9 cells|CONTRAST ENHANCED MRI|||Y|PARENT|PATHOLOGIST 1|Y|4|Visit_4|65|5|SCREENING|2021-02-04|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-23|P1Y2M10DT2H30M|UNKNOWN|2020-12-30|COINCIDENT|2021-02-15
e|RS|1b9896cf-160e-4a56-8737-9759cd83e784|9|NTERESP|Non-Target Enhancing Response|EBMT BLADE MYELOMA 1998|[?]|10^4 CFU|MOLECULAR MAJOR RESPONSE|1|ELISA unit|TRANSTHORACIC ECHOCARDIOGRAPHY||||DOMESTIC PARTNER|NEUROLOGIST|N|5|Visit_5|90|7|TREATMENT|2021-03-01|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-10|P1Y2M10DT2H30M|COINCIDENT|2021-02-02|COINCIDENT|2021-03-10
e|RS|1b9896cf-160e-4a56-8737-9759cd83e784|10|MNPTHIND|Minor Pathological Response Indicator|JACINTO CERVICAL CANCER 2007|[?]|MBq/uL|MRD NEGATIVITY|1|mV2/Hz|SLIT LAMP PHOTOGRAPHY|Y|Y||DOMESTIC PARTNER|HEMATOLOGIST|Y|5|Visit_5|90|5|WASHOUT|2021-03-01|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-10|P1Y2M10DT2H30M|UNKNOWN|2020-12-08|BEFORE|2021-01-01
e|RS|ea87b553-e331-40cf-bd86-d2bd22694476|1|MRDIND|Minimal Residual Disease Indicator|NCIWG CHESON CLL 1996|||MR|1|umol/min|PERCUSSION||Y|Y|GUARDIAN|RATER 1|N|1|Visit_1|10|3|TREATMENT|2020-08-05|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-29|P1Y2M10DT2H30M|AFTER|2020-10-11|ONGOING|2020-10-22
e|RS|ea87b553-e331-40cf-bd86-d2bd22694476|2|BESTRESP|Best Overall Response|BRUGGEMANN MRD 2010|||CA125 75% RESPONSE|1|ukat/L|CONTRAST ENHANCED X-RAY||Y|Y|CLINICAL STUDY SPONSOR|DEVELOPMENTAL PSYCHOLOGIST|U|1|Visit_1|10|7|WASHOUT|2020-08-05|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-29|P1Y2M10DT2H30M|COINCIDENT|2020-08-11|AFTER|2020-10-03
e|RS|ea87b553-e331-40cf-bd86-d2bd22694476|3|MRPHRESP|Morphologic Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|pg|CMR|1|DAYS|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS|Y|Y||SPOUSE|CLINICAL PATHOLOGIST|N|2|Visit_2|25|4|TREATMENT|2020-08-20|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-19|P1Y2M10DT2H30M|COINCIDENT|2020-10-25|BEFORE|2020-10-26
e|RS|ea87b553-e331-40cf-bd86-d2bd22694476|4|NTLWIND|Non-Target Lesion Worsening Indicator|KUMAR IMWG 2016|[?]|g/g|iCPD|1|Torr|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY|Y|||INTERVIEWER|MICROSCOPIST 2|Y|2|Visit_2|25|2|SCREENING|2020-08-20|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-19|P1Y2M10DT2H30M|AFTER|2020-08-07|BEFORE|2020-09-23
e|RS|ea87b553-e331-40cf-bd86-d2bd22694476|5|OVRLRESP|Overall Response|iRECIST|||RELAPSED DISEASE FROM CR OR PR|1|ng/day|PERIODIC ACID SCHIFF STAIN|Y||Y|CAREGIVER|MICROSCOPIST 3|NA|3|Visit_3|40|5|FOLLOW-UP|2020-09-04|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-18|P1Y2M10DT2H30M|COINCIDENT|2020-07-28|BEFORE|2020-09-06
e|RS|ea87b553-e331-40cf-bd86-d2bd22694476|6|CYTORESP|Cytogenetic Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|mJoule/cm2|MORPHOLOGIC CR|1|/2000 RBC|CLIP||Y||CAREGIVER|HEMATOLOGIST|Y|3|Visit_3|40|5|TREATMENT|2020-09-04|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-18|P1Y2M10DT2H30M|AFTER|2020-07-30|ONGOING|2020-08-18
e|RS|ea87b553-e331-40cf-bd86-d2bd22694476|7|PATHRESP|Pathologic Response|WHO BREAST CANCER 2006|[?]|mEq/ug|HI-P|1|nmol/L|HANSEL STAIN||Y||VENDOR|RATER 1|Y|4|Visit_4|65|6|TREATMENT|2020-09-29|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-04|P1Y2M10DT2H30M|BEFORE|2020-08-02|BEFORE|2020-08-03
e|RS|ea87b553-e331-40cf-bd86-d2bd22694476|8|RDIORESP|Radiologic Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|mg/m2|STABLE|1|umol/h/mmol|MASS SPECTROMETRY||Y||INDEPENDENT ASSESSOR|PATHOLOGIST 1|U|4|Visit_4|65|3|TREATMENT|2020-09-29|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-04|P1Y2M10DT2H30M|BEFORE|2020-10-10|BEFORE|2020-10-14
e|RS|ea87b553-e331-40cf-bd86-d2bd22694476|9|CLINRESP|Clinical Response|PRINCE TCELL LYMPHOMA 2010|[?]|gMFI|INCREASED|1|ohm|DIGITAL PCR ARRAY|Y|||INDEPENDENT ASSESSOR|ONCOLOGIST 1|U|5|Visit_5|90|5|FOLLOW-UP|2020-10-24|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-22|P1Y2M10DT2H30M|UNKNOWN|2020-09-15|ONGOING|2020-10-17
e|RS|ea87b553-e331-40cf-bd86-d2bd22694476|10|SPLNRESP|Spleen Response|EASL BRUIX LIVER CANCER 2001|[?]|umol/dL|PR WITH LYMPHOCYTOSIS|1|U/m2/day|AUTOMATED COUNT||||HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|Y|5|Visit_5|90|2|WASHOUT|2020-10-24|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-22|P1Y2M10DT2H30M|AFTER|2020-08-18|ONGOING|2020-09-11
e|RS|7aebcf72-ac09-4814-ade2-0c0b2add2d8c|1|LIVRRESP|Liver Response|MACDONALD GLIOMA 1990|[?]|%(w/w)|SMD|1|nU/cL|POPULATION SEQUENCING||Y||ADJUDICATOR|RADIOLOGIST 1|Y|1|Visit_1|10|1|TREATMENT|2020-07-30|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-23|P1Y2M10DT2H30M|UNKNOWN|2020-08-28|ONGOING|2020-10-07
e|RS|7aebcf72-ac09-4814-ade2-0c0b2add2d8c|2|STRUSTAT|Steroid Use Status|CHESON LYMPHOMA 2008|[?]|ppm|NON-iCR/NON-iUPD|1|MHz|CONTRAST ENHANCED PET SCAN||||STUDY SUBJECT|RADIOLOGIST|NA|1|Visit_1|10|7|SCREENING|2020-07-30|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-23|P1Y2M10DT2H30M|UNKNOWN|2020-07-23|COINCIDENT|2020-09-21
e|RS|7aebcf72-ac09-4814-ade2-0c0b2add2d8c|3|MRPHRESP|Morphologic Response|RECIST 1.0|||VGPR|1|PUFF|PUPILLOMETRY|||Y|PROXY|READER 1|Y|2|Visit_2|25|4|TREATMENT|2020-08-14|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-26|P1Y2M10DT2H30M|BEFORE|2020-09-05|BEFORE|2020-09-20
e|RS|7aebcf72-ac09-4814-ade2-0c0b2add2d8c|4|DRCRIND|Disease Recurrence Indicator|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|||CMR|1|WEEKS|HANSEL STAIN|||Y|INDEPENDENT ASSESSOR|NEUROLOGIST 1|U|2|Visit_2|25|7|TREATMENT|2020-08-14|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-26|P1Y2M10DT2H30M|COINCIDENT|2020-07-22|COINCIDENT|2020-08-18
e|RS|7aebcf72-ac09-4814-ade2-0c0b2add2d8c|5|NEWLIND|New Lesion Indicator|SCHER PROSTATE CANCER 2011|[?]|Ci/kg|PSA PROGRESSION|1|dpm/0.5 mL|KARYOTYPING||||CLINICAL RESEARCH ASSOCIATE|INTERNIST|N|3|Visit_3|40|7|TREATMENT|2020-08-29|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-03|P1Y2M10DT2H30M|AFTER|2020-08-10|AFTER|2020-10-19
e|RS|7aebcf72-ac09-4814-ade2-0c0b2add2d8c|6|BMIVLIND|Bone Marrow Involvement Indicator|HAMAOKA BREAST CANCER 2010|[?]|CAN|DISEASE TRANSFORMATION|1|10^8/L|CT SCAN|Y|||CHILD|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|3|Visit_3|40|3|WASHOUT|2020-08-29|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-03|P1Y2M10DT2H30M|UNKNOWN|2020-10-02|BEFORE|2020-10-13
e|RS|7aebcf72-ac09-4814-ade2-0c0b2add2d8c|7|NTRGRESP|Non-target Response|CHOI GIST 2008|[?]|uL/dose|NR|1|fmol/L/sec|IMMUNODIFFUSION||||ADJUDICATOR|READER 2|Y|4|Visit_4|65|5|TREATMENT|2020-09-23|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-30|P1Y2M10DT2H30M|COINCIDENT|2020-10-21|BEFORE|2020-10-27
e|RS|7aebcf72-ac09-4814-ade2-0c0b2add2d8c|8|METSIND|Metastatic Indicator|CHESON LYMPHOMA 2008|[?]|pkat/L|MRD NEGATIVITY|1|Weber|OLIGO ACGH||||CLINICAL STUDY SPONSOR|RADIOLOGIST 1|NA|4|Visit_4|65|3|SCREENING|2020-09-23|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-30|P1Y2M10DT2H30M|UNKNOWN|2020-09-12|BEFORE|2020-09-14
e|RS|7aebcf72-ac09-4814-ade2-0c0b2add2d8c|9|SFTSRESP|Soft Tissue Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|mL/cage/day|PR WITH LYMPHOCYTOSIS|1|fg|FLOCCULATION||||FRIEND|RATER|N|5|Visit_5|90|1|WASHOUT|2020-10-18|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-04|P1Y2M10DT2H30M|BEFORE|2020-10-22|BEFORE|2020-10-25
e|RS|7aebcf72-ac09-4814-ade2-0c0b2add2d8c|10|SPLNRESP|Spleen Response|HARTMAN PANCREATIC CANCER 2012|||PR-CT|1|mg/L FEU|MRI|||Y|SPOUSE|NEUROLOGIST 2|U|5|Visit_5|90|1|TREATMENT|2020-10-18|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-04|P1Y2M10DT2H30M|UNKNOWN|2020-10-12|ONGOING|2020-10-14
e|RS|051dc064-be6f-43eb-aa51-7ed8634d6e23|1|PATHRESP|Pathologic Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|umol/min|NON-QUANTIFIABLE MRD POSITIVITY|1|/7.5 mL|SPECULAR MICROSCOPY|Y|||STUDY SUBJECT|RADIOLOGIST 1|Y|1|Visit_1|10|4|WASHOUT|2020-07-08|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-21|P1Y2M10DT2H30M|AFTER|2020-09-09|BEFORE|2020-09-22
e|RS|051dc064-be6f-43eb-aa51-7ed8634d6e23|2|SYMPTDTR|Symptomatic Deterioration|LUGANO CLASSIFICATION|||MORPHOLOGIC CRi|1|BAR|RULER MEASUREMENT METHOD|Y||Y|HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|U|1|Visit_1|10|7|TREATMENT|2020-07-08|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-21|P1Y2M10DT2H30M|UNKNOWN|2020-07-24|AFTER|2020-08-02
e|RS|051dc064-be6f-43eb-aa51-7ed8634d6e23|3|CPRFSTAT|Clinical Performance Status|WOLCHOK SOLID TUMORS 2009|[?]|min|STABLE|1|mL/dL|MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING||||CHILD|RADIOLOGIST 1|U|2|Visit_2|25|7|TREATMENT|2020-07-23|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-22|P1Y2M10DT2H30M|BEFORE|2020-08-29|ONGOING|2020-10-03
e|RS|051dc064-be6f-43eb-aa51-7ed8634d6e23|4|RDIORESP|Radiologic Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|USP U|DISEASE TRANSFORMATION|1|Absorbance U|MICROBIAL CULTURE||||SIBLING|DEVELOPMENTAL PSYCHOLOGIST|Y|2|Visit_2|25|3|TREATMENT|2020-07-23|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-22|P1Y2M10DT2H30M|UNKNOWN|2020-07-04|BEFORE|2020-09-03
e|RS|051dc064-be6f-43eb-aa51-7ed8634d6e23|5|NEWLIND|New Lesion Indicator|PETIT BREAST CANCER 2001|[?]|PIPE|CMR|1|Log10 ELISA unit|NEXT GENERATION TARGETED SEQUENCING||||PROXY|READER|N|3|Visit_3|40|1|WASHOUT|2020-08-07|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-26|P1Y2M10DT2H30M|AFTER|2020-08-06|COINCIDENT|2020-10-03
e|RS|051dc064-be6f-43eb-aa51-7ed8634d6e23|6|CLINRESP|Clinical Response|HAMAOKA BREAST CANCER 2010|[?]|U/g Hb|NON-CR/NON-PD|1|ug/kg/h|LC/MS/MS|Y|Y||INDEPENDENT ASSESSOR|ONCOLOGIST 2|U|3|Visit_3|40|1|WASHOUT|2020-08-07|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-26|P1Y2M10DT2H30M|COINCIDENT|2020-09-09|ONGOING|2020-09-10
e|RS|051dc064-be6f-43eb-aa51-7ed8634d6e23|7|LIVRRESP|Liver Response|MRANO VAN DEN BENT GLIOMA 2011|||DISEASE TRANSFORMATION|1|10^6/L|RADIAL IMMUNODIFFUSION|||Y|SPOUSE|ONCOLOGIST|NA|4|Visit_4|65|4|TREATMENT|2020-09-01|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-11|P1Y2M10DT2H30M|UNKNOWN|2020-08-06|AFTER|2020-09-22
e|RS|051dc064-be6f-43eb-aa51-7ed8634d6e23|8|MNPTHIND|Minor Pathological Response Indicator|CHESON CLL 2006|[?]|mL/m2/day|iUPD|1|OD Unit|TRIPLE-PHASE SPIRAL CT SCAN||||INDEPENDENT ASSESSOR|HEMATOLOGIST|Y|4|Visit_4|65|7|TREATMENT|2020-09-01|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-11|P1Y2M10DT2H30M|BEFORE|2020-07-21|BEFORE|2020-08-19
e|RS|051dc064-be6f-43eb-aa51-7ed8634d6e23|9|PATHRESP|Pathologic Response|RECIST 1.0|[?]|TRACE|IMMUNOPHENOTYPIC CR|1|APS U|INFRARED SPECTROMETRY|Y|||INTERVIEWER|ADJUDICATOR 1|U|5|Visit_5|90|1|TREATMENT|2020-09-26|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-14|P1Y2M10DT2H30M|AFTER|2020-09-24|ONGOING|2020-09-30
e|RS|051dc064-be6f-43eb-aa51-7ed8634d6e23|10|NTERESP|Non-Target Enhancing Response|CHESON LYMPHOMA 2008|[?]|VIRTUAL PIXEL|PD|1|/4.0 mL|EIA||Y||CHILD|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|5|Visit_5|90|3|TREATMENT|2020-09-26|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-14|P1Y2M10DT2H30M|BEFORE|2020-08-26|COINCIDENT|2020-09-10
e|RS|9d85acbf-5a26-4bcd-aee8-e1ab2834a2f9|1|BESTRESP|Best Overall Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|Rad|EQUIVOCAL|1|TRANSDUCING UNIT|JAEGER EYE CHART||Y||HEALTH CARE PROFESSIONAL|DERMATOLOGIST|Y|1|Visit_1|10|2|TREATMENT|2020-06-03|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-18|P1Y2M10DT2H30M|COINCIDENT|2020-06-06|COINCIDENT|2020-08-18
e|RS|9d85acbf-5a26-4bcd-aee8-e1ab2834a2f9|2|LIVRRESP|Liver Response|IRANO 2015|[?]|MASK|MOLECULAR MAJOR RESPONSE|1|gMFI|DIGITAL PCR ARRAY||Y||SIBLING|RADIOLOGIST 2|N|1|Visit_1|10|1|TREATMENT|2020-06-03|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-18|P1Y2M10DT2H30M|BEFORE|2020-06-28|ONGOING|2020-08-12
e|RS|9d85acbf-5a26-4bcd-aee8-e1ab2834a2f9|3|NTNERESP|Non-Target Non-Enhancing Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|gtt|iPR|1|10^3 CFU|PH METER MEASUREMENT METHOD||||PARENT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|2|Visit_2|25|1|SCREENING|2020-06-18|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-30|P1Y2M10DT2H30M|AFTER|2020-06-07|BEFORE|2020-07-02
e|RS|9d85acbf-5a26-4bcd-aee8-e1ab2834a2f9|4|MNPTHIND|Minor Pathological Response Indicator|JACINTO CERVICAL CANCER 2007|[?]|mV2/Hz|STABLE|1|10^4 CFU|SPECT SCAN|Y|||INTERVIEWER|PHYSIOTHERAPIST|U|2|Visit_2|25|3|TREATMENT|2020-06-18|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-30|P1Y2M10DT2H30M|UNKNOWN|2020-08-11|COINCIDENT|2020-08-31
e|RS|9d85acbf-5a26-4bcd-aee8-e1ab2834a2f9|5|BESTRESP|Best Overall Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|BU|NON-QUANTIFIABLE MRD POSITIVITY|1|/LSQN|PULMONARY ANGIOGRAPHY||||SPOUSE|RATER 1|U|3|Visit_3|40|4|FOLLOW-UP|2020-07-03|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-18|P1Y2M10DT2H30M|AFTER|2020-08-01|BEFORE|2020-08-04
e|RS|9d85acbf-5a26-4bcd-aee8-e1ab2834a2f9|6|STRUSTAT|Steroid Use Status|CHESON MALIGNANT LYMPHOMA 2007|||PR|1|kcal/day|WHOLE EXOME SEQUENCING|Y|Y|Y|SIGNIFICANT OTHER|FORENSIC PATHOLOGIST|N|3|Visit_3|40|4|FOLLOW-UP|2020-07-03|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-18|P1Y2M10DT2H30M|UNKNOWN|2020-06-20|ONGOING|2020-08-04
e|RS|9d85acbf-5a26-4bcd-aee8-e1ab2834a2f9|7|NEWLIND|New Lesion Indicator|RAJKUMAR MYELOMA 2011|[?]|h/wk|nPR|1|tuberculin unit|FLUOROSCOPY||Y||DOMESTIC PARTNER|ADJUDICATOR 2|U|4|Visit_4|65|1|SCREENING|2020-07-28|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-02|P1Y2M10DT2H30M|BEFORE|2020-06-13|COINCIDENT|2020-06-19
e|RS|9d85acbf-5a26-4bcd-aee8-e1ab2834a2f9|8|BMIVLIND|Bone Marrow Involvement Indicator|NCIWG CHESON CLL 1996|||STABLE|1|g/cm2|PYROSEQUENCING|||Y|SIBLING|ADJUDICATOR 3|Y|4|Visit_4|65|6|TREATMENT|2020-07-28|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-02|P1Y2M10DT2H30M|COINCIDENT|2020-07-01|COINCIDENT|2020-08-06
e|RS|9d85acbf-5a26-4bcd-aee8-e1ab2834a2f9|9|BMIVLIND|Bone Marrow Involvement Indicator|AJCC V7|[?]|ft2|DISEASE TRANSFORMATION|1|ft|IMMUNO-PET SCAN||||INTERVIEWER|NEUROLOGIST|U|5|Visit_5|90|7|TREATMENT|2020-08-22|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-15|P1Y2M10DT2H30M|AFTER|2020-08-17|COINCIDENT|2020-08-19
e|RS|9d85acbf-5a26-4bcd-aee8-e1ab2834a2f9|10|SPLNRESP|Spleen Response|BRUGGEMANN MRD 2010|[?]|uL/dose|PD-CT|1|fg|OPTICAL DENSITY MEASUREMENT||||ADJUDICATOR|ONCOLOGIST|NA|5|Visit_5|90|2|SCREENING|2020-08-22|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-15|P1Y2M10DT2H30M|UNKNOWN|2020-06-18|AFTER|2020-07-09
e|RS|7a17fe21-b640-4bc5-bf19-b1bceb393dab|1|BESTRESP|Best Overall Response|CHOLLET BREAST CANCER 2002|[?]|pg/cell|CR-CT|1|mph|DYNAMIC CONTRAST ENHANCED MRI||Y||INTERVIEWER|RADIOLOGIST|Y|1|Visit_1|10|3|TREATMENT|2020-09-02|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-28|P1Y2M10DT2H30M|BEFORE|2020-11-04|ONGOING|2020-11-30
e|RS|7a17fe21-b640-4bc5-bf19-b1bceb393dab|2|NEWLPROG|New Lesion Progression|CHESON CLL 2006|[?]|mg/m2/min|INCREASED|1|OD Unit|SPECT/CT SCAN||||DOMESTIC PARTNER|READER 3|N|1|Visit_1|10|3|TREATMENT|2020-09-02|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-28|P1Y2M10DT2H30M|AFTER|2020-10-02|COINCIDENT|2020-11-29
e|RS|7a17fe21-b640-4bc5-bf19-b1bceb393dab|3|NTRGRESP|Non-target Response|PRINCE TCELL LYMPHOMA 2010|[?]|LENS|PD FROM PR|1|pt_us|LIQUID SCINTILLATION COUNTING|Y|||SIGNIFICANT OTHER|READER 1|U|2|Visit_2|25|3|SCREENING|2020-09-17|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-15|P1Y2M10DT2H30M|BEFORE|2020-11-09|COINCIDENT|2020-11-20
e|RS|7a17fe21-b640-4bc5-bf19-b1bceb393dab|4|CLINRESP|Clinical Response|EBMT BLADE MYELOMA 1998|||NOT ALL EVALUATED|1|cd|IMMUNOCHEMILUMINOMETRIC ASSAY|||Y|FAMILY MEMBER|RADIOLOGIST|NA|2|Visit_2|25|3|TREATMENT|2020-09-17|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-15|P1Y2M10DT2H30M|COINCIDENT|2020-11-01|ONGOING|2020-11-14
e|RS|7a17fe21-b640-4bc5-bf19-b1bceb393dab|5|ANATRESP|Anatomic Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|IU/kg|CYTOGENETIC CR|1|copies/ug|MICROBIAL CULTURE, LIQUID||Y||CHILD|MICROSCOPIST 3|NA|3|Visit_3|40|5|TREATMENT|2020-10-02|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-23|P1Y2M10DT2H30M|AFTER|2020-10-29|COINCIDENT|2020-11-14
e|RS|7a17fe21-b640-4bc5-bf19-b1bceb393dab|6|NTRGRESP|Non-target Response|CHESON LYMPHOMA 2008|||CYTOGENETIC PR|1|CONTAINER|FLUORESCENT MICROSCOPY||Y|Y|INVESTIGATOR|HEMATOLOGIST|NA|3|Visit_3|40|3|FOLLOW-UP|2020-10-02|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-23|P1Y2M10DT2H30M|BEFORE|2020-09-03|AFTER|2020-10-02
e|RS|7a17fe21-b640-4bc5-bf19-b1bceb393dab|7|TRGRESP|Target Response|NCCN ALL MRD 2014|[?]|cd*s/m2|PD-CT|1|m/sec|CELLULAR PROLIFERATION ASSAY||||SIGNIFICANT OTHER|NEUROLOGIST|N|4|Visit_4|65|3|TREATMENT|2020-10-27|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-06|P1Y2M10DT2H30M|BEFORE|2020-09-30|BEFORE|2020-10-11
e|RS|7a17fe21-b640-4bc5-bf19-b1bceb393dab|8|NTNERESP|Non-Target Non-Enhancing Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|Ci|cCR|1|10^9 organisms/g|MACRO BROTH DILUTION||||CHILD|READER 3|Y|4|Visit_4|65|5|TREATMENT|2020-10-27|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-06|P1Y2M10DT2H30M|AFTER|2020-10-14|AFTER|2020-11-06
e|RS|7a17fe21-b640-4bc5-bf19-b1bceb393dab|9|NEWLIND|New Lesion Indicator|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|BOWL|pCR|1|m/sec|ANTIMICROBIAL COMBINATION TESTING|Y|Y||INDEPENDENT ASSESSOR|RADIOLOGIST 2|NA|5|Visit_5|90|6|TREATMENT|2020-11-21|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-26|P1Y2M10DT2H30M|BEFORE|2020-09-16|COINCIDENT|2020-10-04
e|RS|7a17fe21-b640-4bc5-bf19-b1bceb393dab|10|PATHRESP|Pathologic Response|IWG CHESON MDS 2000|[?]|g/animal|INDETERMINATE RESPONSE|1|ECL unit|BETA LACTAMASE||Y||CLINICAL RESEARCH COORDINATOR|OPHTHALMOLOGIST|Y|5|Visit_5|90|4|TREATMENT|2020-11-21|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-26|P1Y2M10DT2H30M|UNKNOWN|2020-09-10|COINCIDENT|2020-09-25
e|RS|d2080dd2-03ad-4c43-be69-eeb8151cc9b5|1|MOLRESP|Molecular Response|CHOI GIST 2008|||MINOR PATHOLOGIC RESPONSE|1|log10 TCID 50/mL|AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT|||Y|INDEPENDENT ASSESSOR|FORENSIC PATHOLOGIST|U|1|Visit_1|10|7|FOLLOW-UP|2021-01-20|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-10|P1Y2M10DT2H30M|UNKNOWN|2021-04-10|ONGOING|2021-04-11
e|RS|d2080dd2-03ad-4c43-be69-eeb8151cc9b5|2|NEWLIND|New Lesion Indicator|FAROOQUI SUPP CLL 2014|[?]|cg|HI-P|1|WEEKS|ENZYMATIC COLORIMETRY||||SIBLING|MICROSCOPIST|NA|1|Visit_1|10|6|TREATMENT|2021-01-20|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-10|P1Y2M10DT2H30M|AFTER|2021-02-04|AFTER|2021-03-10
e|RS|d2080dd2-03ad-4c43-be69-eeb8151cc9b5|3|MNPTHIND|Minor Pathological Response Indicator|SCHER PROSTATE CANCER 2011|[?]|Absorbance U|CR|1|10^6 CFU/mL|MICROBIAL CONCENTRATION||Y||CAREGIVER|RATER 1|NA|2|Visit_2|25|1|TREATMENT|2021-02-04|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-20|P1Y2M10DT2H30M|AFTER|2021-04-11|BEFORE|2021-04-19
e|RS|d2080dd2-03ad-4c43-be69-eeb8151cc9b5|4|HEMARESP|Hematologic Response|RANO ELLINGSON 2017|[?]|titer|MRD RELAPSE|1|Tbsp|SPECT/CT SCAN||Y||FAMILY MEMBER|PEDIATRIC NEUROLOGIST|Y|2|Visit_2|25|3|TREATMENT|2021-02-04|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-20|P1Y2M10DT2H30M|BEFORE|2021-03-23|BEFORE|2021-04-07
e|RS|d2080dd2-03ad-4c43-be69-eeb8151cc9b5|5|RDIORESP|Radiologic Response|MURPHY PROSTATE CANCER 1980|||iUPD|1|ukat/L|CARDIAC THERMODILUTION|||Y|SPOUSE|READER|U|3|Visit_3|40|6|TREATMENT|2021-02-19|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-12|P1Y2M10DT2H30M|COINCIDENT|2021-04-17|ONGOING|2021-04-18
e|RS|d2080dd2-03ad-4c43-be69-eeb8151cc9b5|6|TMRESP|Tumor Marker Response|NCCN ALL MRD 2014|[?]|mmAL|iSD|1|CAPSULE|GRADIENT DIFFUSION||||NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|NA|3|Visit_3|40|5|TREATMENT|2021-02-19|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-12|P1Y2M10DT2H30M|AFTER|2021-03-17|COINCIDENT|2021-03-20
e|RS|d2080dd2-03ad-4c43-be69-eeb8151cc9b5|7|METBRESP|Metabolic Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|Tbsp|nPR|1|mL/min/mmHg|BIOPSY|Y|Y||STUDY SUBJECT|OTOLARYNGOLOGIST|NA|4|Visit_4|65|6|TREATMENT|2021-03-16|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-17|P1Y2M10DT2H30M|BEFORE|2021-04-11|BEFORE|2021-04-12
e|RS|d2080dd2-03ad-4c43-be69-eeb8151cc9b5|8|SPLNRESP|Spleen Response|IRANO 2015|[?]|/100 HPFs|STABLE|1|nU/cL|HPLC/IEX||||SPOUSE|MICROSCOPIST 1|N|4|Visit_4|65|5|WASHOUT|2021-03-16|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-17|P1Y2M10DT2H30M|COINCIDENT|2021-02-12|BEFORE|2021-03-14
e|RS|d2080dd2-03ad-4c43-be69-eeb8151cc9b5|9|MRDRESP|Minimal Residual Disease Response|PCWG SCHER PROSTATE CANCER 2008|||CYTOGENETIC PR|1|Bq/uL|DNA MICROARRAY|||Y|STUDY SUBJECT|RADIOLOGIST 2|N|5|Visit_5|90|4|TREATMENT|2021-04-10|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-17|P1Y2M10DT2H30M|COINCIDENT|2021-04-15|COINCIDENT|2021-04-18
e|RS|d2080dd2-03ad-4c43-be69-eeb8151cc9b5|10|METBRESP|Metabolic Response|RECIST 1.0|[?]|U/kg/day|pCR|1|g/mol|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|Y|||PROXY|RADIOLOGIST 1|N|5|Visit_5|90|5|TREATMENT|2021-04-10|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-17|P1Y2M10DT2H30M|COINCIDENT|2021-03-20|ONGOING|2021-04-17
e|RS|f1d0daec-aa97-4838-9c53-e16dae3e17b2|1|METBRESP|Metabolic Response|IWG CHESON MDS 2000|[?]|nmol/g|MORPHOLOGIC CR|1|10^9/L|PLETHYSMOGRAPHY|Y|Y||HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|N|1|Visit_1|10|4|TREATMENT|2020-06-23|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-18|P1Y2M10DT2H30M|AFTER|2020-06-28|COINCIDENT|2020-09-09
e|RS|f1d0daec-aa97-4838-9c53-e16dae3e17b2|2|MRDIND|Minimal Residual Disease Indicator|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|Arbitrary U|iCR|1|fmol/g|LIGHT SCATTERING SPECTROSCOPY||||GUARDIAN|ONCOLOGIST 2|NA|1|Visit_1|10|2|SCREENING|2020-06-23|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-18|P1Y2M10DT2H30M|COINCIDENT|2020-07-30|BEFORE|2020-08-19
e|RS|f1d0daec-aa97-4838-9c53-e16dae3e17b2|3|SYMPTDTR|Symptomatic Deterioration|CHOLLET BREAST CANCER 2002|||MRD NEGATIVITY|1|10^9 organisms/mL|FLUORESCENCE ANGIOGRAPHY|||Y|CHILD|CLINICAL PATHOLOGIST|NA|2|Visit_2|25|5|TREATMENT|2020-07-08|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-18|P1Y2M10DT2H30M|AFTER|2020-07-22|ONGOING|2020-08-27
e|RS|f1d0daec-aa97-4838-9c53-e16dae3e17b2|4|PATHRESP|Pathologic Response|EBMT BLADE MYELOMA 1998|||MORPHOLOGIC CRi|1|kN/cm2|ELECTROGASTROGRAPHY|||Y|SPOUSE|MICROSCOPIST 1|U|2|Visit_2|25|3|SCREENING|2020-07-08|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-18|P1Y2M10DT2H30M|BEFORE|2020-08-28|ONGOING|2020-09-07
e|RS|f1d0daec-aa97-4838-9c53-e16dae3e17b2|5|CLINRESP|Clinical Response|CHOI GIST 2008|||MINOR PATHOLOGIC RESPONSE|1|log10 PFU|CALCOFLUOR WHITE STAIN|||Y|HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|N|3|Visit_3|40|7|WASHOUT|2020-07-23|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-18|P1Y2M10DT2H30M|BEFORE|2020-09-04|AFTER|2020-09-15
e|RS|f1d0daec-aa97-4838-9c53-e16dae3e17b2|6|CYTORESP|Cytogenetic Response|GUILHOT CML 2007|||INCREASED|1|U/g/day|IMMUNOTURBIDIMETRY|||Y|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 1|Y|3|Visit_3|40|3|TREATMENT|2020-07-23|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-18|P1Y2M10DT2H30M|BEFORE|2020-07-19|AFTER|2020-08-28
e|RS|f1d0daec-aa97-4838-9c53-e16dae3e17b2|7|CLINRESP|Clinical Response|LEE LUNG CANCER 2011|[?]|m|CA125 50% RESPONSE|1|umol/L/h|FLOCCULATION, CHARCOAL ENHANCED||||INTERVIEWER|INTERNIST|U|4|Visit_4|65|3|TREATMENT|2020-08-17|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-13|P1Y2M10DT2H30M|COINCIDENT|2020-07-22|ONGOING|2020-09-20
e|RS|f1d0daec-aa97-4838-9c53-e16dae3e17b2|8|SFTSRESP|Soft Tissue Response|RANO|[?]|cd|SMD|1|mmol/min/kPa|PAP STAIN|Y|Y||CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 1|Y|4|Visit_4|65|5|SCREENING|2020-08-17|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-13|P1Y2M10DT2H30M|AFTER|2020-08-28|ONGOING|2020-09-04
e|RS|f1d0daec-aa97-4838-9c53-e16dae3e17b2|9|LIVRRESP|Liver Response|LEE LUNG CANCER 2011|||NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|Tbsp|COULOMETRIC TITRATION||Y|Y|VENDOR|DEVELOPMENTAL PSYCHOLOGIST|N|5|Visit_5|90|7|FOLLOW-UP|2020-09-11|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-25|P1Y2M10DT2H30M|COINCIDENT|2020-08-18|BEFORE|2020-08-22
e|RS|f1d0daec-aa97-4838-9c53-e16dae3e17b2|10|NEWLPROG|New Lesion Progression|UNSPECIFIED|[?]|kg/L|HI-E|1|L|OBSERVATION||||CAREGIVER|PATHOLOGIST|U|5|Visit_5|90|6|TREATMENT|2020-09-11|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-25|P1Y2M10DT2H30M|UNKNOWN|2020-08-20|BEFORE|2020-09-19
e|RS|835594ab-e93c-402b-8129-6af659be5ae1|1|NEWLWIND|New Lesion Worsening Indicator|CHESON CLL 2012|||VGPR|1|Ci/uL|ISHIHARA COLOR PLATES|||Y|SIBLING|PHYSIOTHERAPIST|NA|1|Visit_1|10|1|WASHOUT|2020-11-01|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-07|P1Y2M10DT2H30M|UNKNOWN|2021-01-26|BEFORE|2021-01-27
e|RS|835594ab-e93c-402b-8129-6af659be5ae1|2|NTRGRESP|Non-target Response|MASS|[?]|hPa|CR|1|10^3 organisms|DC SHEATH FLOW||||SPOUSE|RATER|Y|1|Visit_1|10|4|TREATMENT|2020-11-01|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-07|P1Y2M10DT2H30M|COINCIDENT|2020-10-26|COINCIDENT|2020-12-17
e|RS|835594ab-e93c-402b-8129-6af659be5ae1|3|NTNERESP|Non-Target Non-Enhancing Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|deg/mm|RELAPSED DISEASE FROM CR|1|nmol/L|HEMOCYTOMETRY||||ADJUDICATOR|RATER 2|NA|2|Visit_2|25|2|FOLLOW-UP|2020-11-16|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-12|P1Y2M10DT2H30M|BEFORE|2020-11-30|ONGOING|2021-01-29
e|RS|835594ab-e93c-402b-8129-6af659be5ae1|4|MOLRESP|Molecular Response|CHESON CLL 2012|[?]|h*%|HI-P|1|DRINK|MAPH||||CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 2|U|2|Visit_2|25|7|TREATMENT|2020-11-16|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-12|P1Y2M10DT2H30M|COINCIDENT|2020-12-23|ONGOING|2021-01-06
e|RS|835594ab-e93c-402b-8129-6af659be5ae1|5|MRDRESP|Minimal Residual Disease Response|PCWG SCHER PROSTATE CANCER 2016|[?]|PACK|PD/RELAPSE AFTER HI|1|kHz|HANSEL STAIN|Y|||INVESTIGATOR|PATHOLOGIST 1|N|3|Visit_3|40|2|WASHOUT|2020-12-01|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-06|P1Y2M10DT2H30M|BEFORE|2020-11-12|COINCIDENT|2021-01-01
e|RS|835594ab-e93c-402b-8129-6af659be5ae1|6|STRUSTAT|Steroid Use Status|HAMAOKA BREAST CANCER 2010|[?]|tuberculin unit/mL|QUANTIFIABLE MRD POSITIVITY|1|IU/mL|KNEMOMETRY|Y|||FAMILY MEMBER|OPTOMETRIST|U|3|Visit_3|40|5|TREATMENT|2020-12-01|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-06|P1Y2M10DT2H30M|COINCIDENT|2020-12-21|BEFORE|2021-01-21
e|RS|835594ab-e93c-402b-8129-6af659be5ae1|7|SYMPTDTR|Symptomatic Deterioration|RECIST 1.0|[?]|IU/g|PR-CT|1|mV*min|DYNAMOMETRY|Y|||FAMILY MEMBER|RATER|NA|4|Visit_4|65|2|SCREENING|2020-12-26|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-05|P1Y2M10DT2H30M|COINCIDENT|2020-11-27|AFTER|2021-01-11
e|RS|835594ab-e93c-402b-8129-6af659be5ae1|8|NEWLIND|New Lesion Indicator|IRANO 2015|||PR WITH LYMPHOCYTOSIS|1|DNA copies/mL|RADIAL IMMUNODIFFUSION|Y||Y|SPOUSE|READER 1|NA|4|Visit_4|65|4|TREATMENT|2020-12-26|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-05|P1Y2M10DT2H30M|COINCIDENT|2020-11-08|ONGOING|2020-12-14
e|RS|835594ab-e93c-402b-8129-6af659be5ae1|9|NTLWIND|Non-Target Lesion Worsening Indicator|HAMAOKA BREAST CANCER 2010|[?]|Shock Wave|RELAPSED DISEASE FROM CR OR PR|1|ka_u/dL|IMMUNOBLOT||||ADJUDICATOR|DERMATOLOGIST|Y|5|Visit_5|90|6|WASHOUT|2021-01-20|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-04|P1Y2M10DT2H30M|COINCIDENT|2021-01-25|AFTER|2021-01-27
e|RS|835594ab-e93c-402b-8129-6af659be5ae1|10|BESTRESP|Best Overall Response|RECICL|[?]|lx|QUANTIFIABLE MRD POSITIVITY|1|10^5/L|IHC|Y|||INDEPENDENT ASSESSOR|NEUROLOGIST 2|Y|5|Visit_5|90|6|TREATMENT|2021-01-20|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-04|P1Y2M10DT2H30M|BEFORE|2020-12-13|AFTER|2020-12-29
e|RS|c3c85786-d24b-4620-9ee0-c13b1cc4f951|1|MOLRESP|Molecular Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|CAPSULE|PSEUDOPROGRESSION|1|nmol BCE/L|TRANSESOPHAGEAL ECHOCARDIOGRAPHY|Y|||NON-HEALTH CARE PROFESSIONAL|RATER 1|N|1|Visit_1|10|2|FOLLOW-UP|2020-10-07|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-20|P1Y2M10DT2H30M|AFTER|2020-10-30|ONGOING|2020-12-18
e|RS|c3c85786-d24b-4620-9ee0-c13b1cc4f951|2|MOLRESP|Molecular Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|/VF|DECREASED|1|mol/day|NUCLEIC ACID HYBRIDIZATION||||PROXY|MICROSCOPIST 1|U|1|Visit_1|10|3|TREATMENT|2020-10-07|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-20|P1Y2M10DT2H30M|COINCIDENT|2020-12-21|AFTER|2020-12-30
e|RS|c3c85786-d24b-4620-9ee0-c13b1cc4f951|3|BONERESP|Bone Response|PRINCE TCELL LYMPHOMA 2010|[?]|Hz/s|NED|1|mV2/Hz|NON-CONTACT SPECULAR MICROSCOPY||||SIGNIFICANT OTHER|RATER|NA|2|Visit_2|25|5|SCREENING|2020-10-22|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-01|P1Y2M10DT2H30M|AFTER|2020-10-30|BEFORE|2020-12-30
e|RS|c3c85786-d24b-4620-9ee0-c13b1cc4f951|4|METBRESP|Metabolic Response|IWG CHESON AML 2003|[?]|mg/g/h|INDETERMINATE RESPONSE|1|NEEDLE GAUGE|CYSTOSCOPY||||FRIEND|PHYSIOTHERAPIST|N|2|Visit_2|25|3|TREATMENT|2020-10-22|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-01|P1Y2M10DT2H30M|COINCIDENT|2020-10-16|ONGOING|2020-12-08
e|RS|c3c85786-d24b-4620-9ee0-c13b1cc4f951|5|RDIORESP|Radiologic Response|RANO|[?]|dpm/0.5 mL|CRi|1|HOURS|ERGOSPIROMETRY|Y|||GUARDIAN|RATER 1|N|3|Visit_3|40|4|TREATMENT|2020-11-06|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-07|P1Y2M10DT2H30M|BEFORE|2020-12-30|COINCIDENT|2021-01-02
e|RS|c3c85786-d24b-4620-9ee0-c13b1cc4f951|6|CPRFSTAT|Clinical Performance Status|BRUGGEMANN MRD 2010|[?]|/h|PSEUDOPROGRESSION|1|titer|PATHOLOGICAL EVALUATION||||ADJUDICATION COMMITTEE|ONCOLOGIST 1|Y|3|Visit_3|40|4|SCREENING|2020-11-06|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-07|P1Y2M10DT2H30M|COINCIDENT|2020-11-20|COINCIDENT|2020-12-10
e|RS|c3c85786-d24b-4620-9ee0-c13b1cc4f951|7|NTRGRESP|Non-target Response|EASL BRUIX LIVER CANCER 2001|[?]|g/mol|NON-iCR/NON-iUPD|1|nsec|SMEAR||||DOMESTIC PARTNER|MICROSCOPIST 2|U|4|Visit_4|65|7|TREATMENT|2020-12-01|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-28|P1Y2M10DT2H30M|AFTER|2020-10-04|ONGOING|2020-10-28
e|RS|c3c85786-d24b-4620-9ee0-c13b1cc4f951|8|BESTRESP|Best Overall Response|JACINTO CERVICAL CANCER 2007|[?]|vp/dose|HI-N|1|CFU/mL|HEMOCYTOMETRY||||FAMILY MEMBER|RADIOLOGIST 2|NA|4|Visit_4|65|4|FOLLOW-UP|2020-12-01|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-28|P1Y2M10DT2H30M|AFTER|2020-11-23|ONGOING|2020-12-29
e|RS|c3c85786-d24b-4620-9ee0-c13b1cc4f951|9|NTLWIND|Non-Target Lesion Worsening Indicator|CHOI GIST 2008|[?]|MBP|SMD|1|uL|PALPATION|Y|||SPOUSE|ONCOLOGIST 1|Y|5|Visit_5|90|3|WASHOUT|2020-12-26|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-31|P1Y2M10DT2H30M|BEFORE|2020-12-16|AFTER|2020-12-19
e|RS|c3c85786-d24b-4620-9ee0-c13b1cc4f951|10|PATHRESP|Pathologic Response|RAJKUMAR MYELOMA 2011|[?]|BOX|iPR|1|cd*s/m2|FUNCTIONAL MRI||Y||DOMESTIC PARTNER|PEDIATRIC NEUROLOGIST|Y|5|Visit_5|90|5|TREATMENT|2020-12-26|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-31|P1Y2M10DT2H30M|AFTER|2020-11-04|ONGOING|2020-11-13
e|RS|5354e3c4-4106-4e4c-85c3-2dbbd001688c|1|CPRFSTAT|Clinical Performance Status|MRECIST LENCIONI LIVER CANCER 2010|||PSEUDORESPONSE|1|Mile|NEPHELOMETRY|||Y|CHILD|READER|Y|1|Visit_1|10|3|TREATMENT|2020-11-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-22|P1Y2M10DT2H30M|BEFORE|2020-11-30|AFTER|2021-02-04
e|RS|5354e3c4-4106-4e4c-85c3-2dbbd001688c|2|NTRGRESP|Non-target Response|SCHWARZ CERVICAL CANCER 2009|[?]|10^6 IU/mL|EQUIVOCAL|1|cmHg|AMSLER GRID|Y|||VENDOR|RATER|NA|1|Visit_1|10|2|FOLLOW-UP|2020-11-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-22|P1Y2M10DT2H30M|BEFORE|2020-12-05|COINCIDENT|2020-12-27
e|RS|5354e3c4-4106-4e4c-85c3-2dbbd001688c|3|CYTORESP|Cytogenetic Response|PRINCE TCELL LYMPHOMA 2010|||CR|1|mkat|MAPH|||Y|SIGNIFICANT OTHER|PATHOLOGIST|NA|2|Visit_2|25|4|TREATMENT|2020-11-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-21|P1Y2M10DT2H30M|COINCIDENT|2021-01-20|ONGOING|2021-02-05
e|RS|5354e3c4-4106-4e4c-85c3-2dbbd001688c|4|METSIND|Metastatic Indicator|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|fraction of 1|iSD|1|CARTRIDGE|IMMUNOTURBIDIMETRY||||VENDOR|READER 1|N|2|Visit_2|25|6|TREATMENT|2020-11-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-21|P1Y2M10DT2H30M|AFTER|2020-12-13|ONGOING|2021-01-24
e|RS|5354e3c4-4106-4e4c-85c3-2dbbd001688c|5|BMIVLIND|Bone Marrow Involvement Indicator|PCWG SCHER PROSTATE CANCER 2016|||EQUIVOCAL|1|cal|OPTICAL MAPPING|||Y|FAMILY MEMBER|ONCOLOGIST 2|NA|3|Visit_3|40|4|TREATMENT|2020-12-15|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-06|P1Y2M10DT2H30M|BEFORE|2021-02-04|AFTER|2021-02-08
e|RS|5354e3c4-4106-4e4c-85c3-2dbbd001688c|6|BONERESP|Bone Response|EBMT BLADE MYELOMA 1998|[?]|DIP|iCPD|1|Absorbance U/min|LIGHT SCATTERING SPECTROSCOPY||||CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 1|Y|3|Visit_3|40|4|FOLLOW-UP|2020-12-15|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-06|P1Y2M10DT2H30M|BEFORE|2020-11-17|BEFORE|2020-12-13
e|RS|5354e3c4-4106-4e4c-85c3-2dbbd001688c|7|HEMARESP|Hematologic Response|GCIG RUSTIN OVARIAN CANCER 2011|||mCR|1|g/animal/wk|LC/MS/MS|||Y|DOMESTIC PARTNER|READER 3|U|4|Visit_4|65|1|TREATMENT|2021-01-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-15|P1Y2M10DT2H30M|AFTER|2020-12-10|ONGOING|2020-12-31
e|RS|5354e3c4-4106-4e4c-85c3-2dbbd001688c|8|SPLNRESP|Spleen Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|/7.5 mL|INDETERMINATE RESPONSE|1|Gy/min|KINETIC CHROMOGENIC ASSAY|Y|||SIGNIFICANT OTHER|PATHOLOGIST 1|N|4|Visit_4|65|3|SCREENING|2021-01-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-15|P1Y2M10DT2H30M|AFTER|2021-01-30|COINCIDENT|2021-02-03
e|RS|5354e3c4-4106-4e4c-85c3-2dbbd001688c|9|CPRFSTAT|Clinical Performance Status|DOHNER AML 2010|[?]|IU/day|RELAPSED DISEASE FROM CR|1|10^4/L|GC/MS-CI||Y||GUARDIAN|FORENSIC PATHOLOGIST|NA|5|Visit_5|90|2|TREATMENT|2021-02-03|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-02|P1Y2M10DT2H30M|BEFORE|2020-11-17|ONGOING|2020-11-18
e|RS|5354e3c4-4106-4e4c-85c3-2dbbd001688c|10|STRUSTAT|Steroid Use Status|RECICL|[?]|nmol/L/h|MRD RELAPSE|1|RFU|LC-FL||Y||CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 1|U|5|Visit_5|90|7|TREATMENT|2021-02-03|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-02|P1Y2M10DT2H30M|UNKNOWN|2020-12-10|ONGOING|2021-01-28
e|RS|f10e9188-ef7b-46f9-a80a-0669436eb4dd|1|ANATRESP|Anatomic Response|CHESON MALIGNANT LYMPHOMA 2007|||cCR|1|ngEq/L|CT SCAN|||Y|STUDY SUBJECT|RATER 1|N|1|Visit_1|10|4|SCREENING|2020-06-24|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-13|P1Y2M10DT2H30M|COINCIDENT|2020-09-12|ONGOING|2020-09-16
e|RS|f10e9188-ef7b-46f9-a80a-0669436eb4dd|2|CPRFSTAT|Clinical Performance Status|PCWG BUBLEY PROSTATE CANCER 1999|[?]|CYLINDER|NE|1|mol/mg|ENZYMATIC ULTRACENTRIFUGATION|Y|||INDEPENDENT ASSESSOR|ONCOLOGIST 1|Y|1|Visit_1|10|7|TREATMENT|2020-06-24|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-13|P1Y2M10DT2H30M|UNKNOWN|2020-07-27|COINCIDENT|2020-08-16
e|RS|f10e9188-ef7b-46f9-a80a-0669436eb4dd|3|MJPTHIND|Major Pathological Response Indicator|SACT|||cCR|1|pmol|IMMUNO-PET SCAN|||Y|INDEPENDENT ASSESSOR|READER 3|N|2|Visit_2|25|3|FOLLOW-UP|2020-07-09|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-13|P1Y2M10DT2H30M|UNKNOWN|2020-09-09|AFTER|2020-09-13
e|RS|f10e9188-ef7b-46f9-a80a-0669436eb4dd|4|NEWLIND|New Lesion Indicator|AJCC V7|||ABSENT MORPHOLOGIC RESPONSE|1|10^4/L|ROMANOWSKY STAIN|Y||Y|SIGNIFICANT OTHER|OPHTHALMOLOGIST|U|2|Visit_2|25|6|FOLLOW-UP|2020-07-09|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-13|P1Y2M10DT2H30M|BEFORE|2020-06-17|BEFORE|2020-08-02
e|RS|f10e9188-ef7b-46f9-a80a-0669436eb4dd|5|NEWLPROG|New Lesion Progression|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|titer|MRD RELAPSE|1|MPL U/mL|ELISPOT||Y||CLINICAL RESEARCH ASSOCIATE|CARDIOLOGIST|U|3|Visit_3|40|1|TREATMENT|2020-07-24|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-06|P1Y2M10DT2H30M|AFTER|2020-06-23|ONGOING|2020-07-09
e|RS|f10e9188-ef7b-46f9-a80a-0669436eb4dd|6|NEWLWIND|New Lesion Worsening Indicator|CHESON CLL 2006|||MOLECULAR MAJOR RESPONSE|1|ug/m2/min|IMMUNE REPERTOIRE DEEP SEQUENCING|||Y|GUARDIAN|RADIOLOGIST|NA|3|Visit_3|40|7|TREATMENT|2020-07-24|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-06|P1Y2M10DT2H30M|UNKNOWN|2020-07-19|COINCIDENT|2020-08-29
e|RS|f10e9188-ef7b-46f9-a80a-0669436eb4dd|7|NTLWIND|Non-Target Lesion Worsening Indicator|PCWG SCHER PROSTATE CANCER 2008|[?]|nmol/L/min|RELAPSED DISEASE FROM CR|1|L/L|REFLECTANCE SPECTROSCOPY||||INTERVIEWER|RADIOLOGIST 2|U|4|Visit_4|65|1|TREATMENT|2020-08-18|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-26|P1Y2M10DT2H30M|BEFORE|2020-08-09|AFTER|2020-08-11
e|RS|f10e9188-ef7b-46f9-a80a-0669436eb4dd|8|CLINRESP|Clinical Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|pg/L|PD|1|kIU|HEMAGGLUTINATION ASSAY||Y||SIBLING|INTERNIST|NA|4|Visit_4|65|4|TREATMENT|2020-08-18|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-26|P1Y2M10DT2H30M|BEFORE|2020-07-26|BEFORE|2020-09-07
e|RS|f10e9188-ef7b-46f9-a80a-0669436eb4dd|9|DRCRIND|Disease Recurrence Indicator|MASS|[?]|/ms|PD/RELAPSE AFTER HI|1|10^9/dose|MICROARRAY||||CAREGIVER|READER 3|N|5|Visit_5|90|2|SCREENING|2020-09-12|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-31|P1Y2M10DT2H30M|COINCIDENT|2020-07-22|COINCIDENT|2020-09-05
e|RS|f10e9188-ef7b-46f9-a80a-0669436eb4dd|10|MNPTHIND|Minor Pathological Response Indicator|RAJKUMAR MYELOMA 2011|[?]|cd|NON-PD|1|Gravitational Unit|ISHIHARA COLOR PLATES||||FAMILY MEMBER|MICROSCOPIST|NA|5|Visit_5|90|1|TREATMENT|2020-09-12|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-31|P1Y2M10DT2H30M|AFTER|2020-08-05|AFTER|2020-08-18
e|RS|f5c49bb8-c1c4-42fc-a5a0-4a39d95604eb|1|BONERESP|Bone Response|iRECIST|[?]|EU|IMMUNOPHENOTYPIC CR|1|log10 TCID 50/mL|CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY||||CHILD|NEUROLOGIST 1|U|1|Visit_1|10|5|TREATMENT|2020-08-13|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-05|P1Y2M10DT2H30M|AFTER|2020-08-31|BEFORE|2020-09-25
e|RS|f5c49bb8-c1c4-42fc-a5a0-4a39d95604eb|2|LIVRRESP|Liver Response|GCIG RUSTIN OVARIAN CANCER 2011|||PARTIAL MORPHOLOGIC RESPONSE|1|umol/kg/min|DXA SCAN|||Y|DOMESTIC PARTNER|ADJUDICATOR 1|N|1|Visit_1|10|3|TREATMENT|2020-08-13|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-05|P1Y2M10DT2H30M|COINCIDENT|2020-10-17|BEFORE|2020-10-26
e|RS|f5c49bb8-c1c4-42fc-a5a0-4a39d95604eb|3|HEMARESP|Hematologic Response|MACDONALD GLIOMA 1990|[?]|mL/cm|CA125 75% RESPONSE|1|dpm/mL|CONFOCAL MICROSCOPY||Y||DOMESTIC PARTNER|READER 1|Y|2|Visit_2|25|6|WASHOUT|2020-08-28|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-21|P1Y2M10DT2H30M|BEFORE|2020-09-07|ONGOING|2020-09-13
e|RS|f5c49bb8-c1c4-42fc-a5a0-4a39d95604eb|4|NTERESP|Non-Target Enhancing Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|umol/mol|HI-N|1|umol/mg/min|COULOMETRIC TITRATION|Y|||FRIEND|MICROSCOPIST 3|NA|2|Visit_2|25|4|FOLLOW-UP|2020-08-28|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-21|P1Y2M10DT2H30M|BEFORE|2020-10-12|ONGOING|2020-11-03
e|RS|f5c49bb8-c1c4-42fc-a5a0-4a39d95604eb|5|TMRESP|Tumor Marker Response|IWG CHESON MDS 2000|[?]|mL/cage/day|CMR|1|10^7 PFU|PHOROPTER||||DOMESTIC PARTNER|DEVELOPMENTAL PSYCHOLOGIST|Y|3|Visit_3|40|5|TREATMENT|2020-09-12|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-24|P1Y2M10DT2H30M|COINCIDENT|2020-08-11|ONGOING|2020-10-20
e|RS|f5c49bb8-c1c4-42fc-a5a0-4a39d95604eb|6|NTERESP|Non-Target Enhancing Response|CHESON LYMPHOMA 2008|[?]|kg/L|MORPHOLOGIC CRi|1|10^9/L|PARTICLE-ENHANCED TURBIDIMETRIC IMMUNOASSAY||Y||CLINICAL RESEARCH ASSOCIATE|INTERNIST|NA|3|Visit_3|40|4|TREATMENT|2020-09-12|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-24|P1Y2M10DT2H30M|BEFORE|2020-08-09|COINCIDENT|2020-11-02
e|RS|f5c49bb8-c1c4-42fc-a5a0-4a39d95604eb|7|MRDIND|Minimal Residual Disease Indicator|AJCC V7|[?]|cm|PD|1|STEPS|PHOROPTER||||INDEPENDENT ASSESSOR|ADJUDICATOR 2|U|4|Visit_4|65|5|TREATMENT|2020-10-07|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-18|P1Y2M10DT2H30M|BEFORE|2020-10-14|BEFORE|2020-11-05
e|RS|f5c49bb8-c1c4-42fc-a5a0-4a39d95604eb|8|TRGRESP|Target Response|BRUGGEMANN MRD 2010|[?]|mJoule/cm2|DECREASED|1|mol/day|AUTOMATED COUNT|Y|Y||HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|N|4|Visit_4|65|4|TREATMENT|2020-10-07|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-18|P1Y2M10DT2H30M|AFTER|2020-08-06|AFTER|2020-08-08
e|RS|f5c49bb8-c1c4-42fc-a5a0-4a39d95604eb|9|CPRFSTAT|Clinical Performance Status|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|||CHR|1|BAU|IMMUNOCHROMATOGRAPHY|||Y|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 1|N|5|Visit_5|90|6|TREATMENT|2020-11-01|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-16|P1Y2M10DT2H30M|BEFORE|2020-09-23|COINCIDENT|2020-10-15
e|RS|f5c49bb8-c1c4-42fc-a5a0-4a39d95604eb|10|MRDRESP|Minimal Residual Disease Response|IWG CHESON MDS 2000|[?]|Linear ft*LB|CYTOGENETIC MINOR RESPONSE|1|L|HPLC-UV||||SIBLING|MICROSCOPIST 1|NA|5|Visit_5|90|6|TREATMENT|2020-11-01|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-16|P1Y2M10DT2H30M|COINCIDENT|2020-09-08|AFTER|2020-10-12
e|RS|000b5b99-a92d-4c84-9edc-ee08930d8a2e|1|MNPTHIND|Minor Pathological Response Indicator|NCIWG CHESON CLL 1996|||MRD PERSISTENCE|1|kIU|IN VITRO GENE EXPRESSION ASSAY|Y|Y|Y|INTERVIEWER|READER 2|Y|1|Visit_1|10|5|SCREENING|2020-10-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-01|P1Y2M10DT2H30M|COINCIDENT|2020-10-09|COINCIDENT|2020-10-17
e|RS|000b5b99-a92d-4c84-9edc-ee08930d8a2e|2|STRUSTAT|Steroid Use Status|CHESON CLL 2006|||mCR|1|mL/s/m2|VENTILATION PERFUSION LUNG SCAN|||Y|DOMESTIC PARTNER|MICROSCOPIST|NA|1|Visit_1|10|1|TREATMENT|2020-10-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-01|P1Y2M10DT2H30M|BEFORE|2020-10-27|AFTER|2021-01-04
e|RS|000b5b99-a92d-4c84-9edc-ee08930d8a2e|3|MRDIND|Minimal Residual Disease Indicator|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|kcal|PDu|1|10^8/L|CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|Y|||GUARDIAN|RADIOLOGIST 2|U|2|Visit_2|25|1|WASHOUT|2020-10-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-25|P1Y2M10DT2H30M|BEFORE|2020-11-24|ONGOING|2020-12-12
e|RS|000b5b99-a92d-4c84-9edc-ee08930d8a2e|4|NTLWIND|Non-Target Lesion Worsening Indicator|MASS|||CR|1|kV|ENZYMATIC ULTRACENTRIFUGATION|||Y|STUDY SUBJECT|NEUROLOGIST 1|U|2|Visit_2|25|5|SCREENING|2020-10-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-25|P1Y2M10DT2H30M|AFTER|2020-12-23|COINCIDENT|2021-01-01
e|RS|000b5b99-a92d-4c84-9edc-ee08930d8a2e|5|CPRFSTAT|Clinical Performance Status|KUMAR IMWG 2016|||SD|1|kg/cm|DARK FIELD MICROSCOPY|Y||Y|SIBLING|OPHTHALMOLOGIST|U|3|Visit_3|40|2|SCREENING|2020-11-14|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-07|P1Y2M10DT2H30M|UNKNOWN|2020-11-12|COINCIDENT|2020-11-17
e|RS|000b5b99-a92d-4c84-9edc-ee08930d8a2e|6|CYTORESP|Cytogenetic Response|IWG CHESON MDS 2006|||iCR|1|kPa/L/sec|HEMOCYTOMETRY|Y||Y|INTERVIEWER|UROLOGIST|U|3|Visit_3|40|6|TREATMENT|2020-11-14|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-07|P1Y2M10DT2H30M|AFTER|2020-12-17|COINCIDENT|2021-01-08
e|RS|000b5b99-a92d-4c84-9edc-ee08930d8a2e|7|SFTSRESP|Soft Tissue Response|WOLCHOK SOLID TUMORS 2009|[?]|PIXEL|PR|1|mU|NON-CONTACT SPECULAR MICROSCOPY|Y|||ADJUDICATOR|ADJUDICATOR 2|N|4|Visit_4|65|3|TREATMENT|2020-12-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-23|P1Y2M10DT2H30M|UNKNOWN|2020-11-04|AFTER|2020-12-17
e|RS|000b5b99-a92d-4c84-9edc-ee08930d8a2e|8|LIVRRESP|Liver Response|SACT|[?]|dpm/mg|DISEASE TRANSFORMATION|1|uV*sec|RAJI CELL EIA||||PROXY|MICROSCOPIST|U|4|Visit_4|65|4|TREATMENT|2020-12-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-23|P1Y2M10DT2H30M|UNKNOWN|2020-12-19|AFTER|2020-12-24
e|RS|000b5b99-a92d-4c84-9edc-ee08930d8a2e|9|HEMARESP|Hematologic Response|MRECIST BYRNE MESOTHELIOMA 2004|||NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|10^9 organisms/mg|U-HPLC/MS/MS|||Y|SPOUSE|ADJUDICATOR 1|NA|5|Visit_5|90|5|TREATMENT|2021-01-03|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-04|P1Y2M10DT2H30M|COINCIDENT|2020-10-07|BEFORE|2021-01-07
e|RS|000b5b99-a92d-4c84-9edc-ee08930d8a2e|10|CYTORESP|Cytogenetic Response|WHO BREAST CANCER 2006|||CYTOGENETIC PR|1|umol/L/sec|ETDRS EYE CHART|Y||Y|INDEPENDENT ASSESSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|5|Visit_5|90|4|FOLLOW-UP|2021-01-03|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-04|P1Y2M10DT2H30M|AFTER|2020-12-01|COINCIDENT|2020-12-23
e|RS|4f919ad0-fdb4-49d8-ba63-bb9e1680bca5|1|CYTORESP|Cytogenetic Response|SCHER PROSTATE CANCER 2011|||nPR|1|cm2|DYNAMIC LIGHT SCATTERING|||Y|CHILD|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|1|Visit_1|10|5|FOLLOW-UP|2020-06-01|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-26|P1Y2M10DT2H30M|BEFORE|2020-06-11|ONGOING|2020-08-25
e|RS|4f919ad0-fdb4-49d8-ba63-bb9e1680bca5|2|NEWLWIND|New Lesion Worsening Indicator|PCWG SCHER PROSTATE CANCER 2016|[?]|g/animal/day|PARTIAL MORPHOLOGIC RESPONSE|1|10^7 PFU|ULTRASONOGRAPHIC ELASTOGRAPHY||||PROXY|MICROSCOPIST|NA|1|Visit_1|10|3|SCREENING|2020-06-01|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-26|P1Y2M10DT2H30M|AFTER|2020-07-23|AFTER|2020-07-25
e|RS|4f919ad0-fdb4-49d8-ba63-bb9e1680bca5|3|OVRLRESP|Overall Response|MURPHY PROSTATE CANCER 1980|[?]|U/m2|MR|1|RATIO|PHOTOGRAPHY|Y|||CLINICAL STUDY SPONSOR|MICROSCOPIST 1|U|2|Visit_2|25|6|TREATMENT|2020-06-16|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-29|P1Y2M10DT2H30M|UNKNOWN|2020-07-19|ONGOING|2020-08-17
e|RS|4f919ad0-fdb4-49d8-ba63-bb9e1680bca5|4|BMIVLIND|Bone Marrow Involvement Indicator|CHESON CLL 2006|[?]|nU/cL|mCR|1|bel|LC/MS/MS||||PROXY|PEDIATRIC NEUROLOGIST|NA|2|Visit_2|25|5|WASHOUT|2020-06-16|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-29|P1Y2M10DT2H30M|BEFORE|2020-06-05|AFTER|2020-06-25
e|RS|4f919ad0-fdb4-49d8-ba63-bb9e1680bca5|5|MJPTHIND|Major Pathological Response Indicator|MURPHY PROSTATE CANCER 1980|||MRD PERSISTENCE|1|ug|KINETIC MICROPARTICLE IMMUNOASSAY||Y|Y|HEALTH CARE PROFESSIONAL|ADJUDICATOR 3|U|3|Visit_3|40|2|WASHOUT|2020-07-01|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-12|P1Y2M10DT2H30M|BEFORE|2020-08-11|COINCIDENT|2020-08-29
e|RS|4f919ad0-fdb4-49d8-ba63-bb9e1680bca5|6|DRCRIND|Disease Recurrence Indicator|BLAZER COLORECTAL CANCER 2008|||NON-PD|1|mmol/min/kPa|ROMANOWSKY STAIN||Y|Y|VENDOR|PATHOLOGIST 1|N|3|Visit_3|40|2|WASHOUT|2020-07-01|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-12|P1Y2M10DT2H30M|COINCIDENT|2020-05-30|ONGOING|2020-07-27
e|RS|4f919ad0-fdb4-49d8-ba63-bb9e1680bca5|7|MRPHRESP|Morphologic Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|uIU/L|CHR|1|in2|FLUORESCENT IMMUNOASSAY||||FRIEND|DEVELOPMENTAL PSYCHOLOGIST|NA|4|Visit_4|65|6|TREATMENT|2020-07-26|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-14|P1Y2M10DT2H30M|UNKNOWN|2020-08-11|BEFORE|2020-08-16
e|RS|4f919ad0-fdb4-49d8-ba63-bb9e1680bca5|8|NEWLIND|New Lesion Indicator|RECIST 1.1|[?]|mAnson U/mL|PDu|1|umol/L|ROMANOWSKY STAIN||||CHILD|NEUROLOGIST 2|Y|4|Visit_4|65|2|TREATMENT|2020-07-26|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-14|P1Y2M10DT2H30M|UNKNOWN|2020-07-26|AFTER|2020-08-29
e|RS|4f919ad0-fdb4-49d8-ba63-bb9e1680bca5|9|NTERESP|Non-Target Enhancing Response|PCWG SCHER PROSTATE CANCER 2008|[?]|CONTAINER|mCR|1|U/g/h|COMPUTERIZED CORNEAL TOPOGRAPHY||||INDEPENDENT ASSESSOR|ONCOLOGIST 1|N|5|Visit_5|90|2|WASHOUT|2020-08-20|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-28|P1Y2M10DT2H30M|AFTER|2020-06-20|COINCIDENT|2020-08-19
e|RS|4f919ad0-fdb4-49d8-ba63-bb9e1680bca5|10|TRGRESP|Target Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|mg/L FEU|MAJOR PATHOLOGIC RESPONSE|1|COAT|TRANSMISSION ELECTRON MICROSCOPY||||VENDOR|DERMATOLOGIST|NA|5|Visit_5|90|6|FOLLOW-UP|2020-08-20|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-28|P1Y2M10DT2H30M|COINCIDENT|2020-06-05|ONGOING|2020-08-11
e|RS|11b2b359-d4a1-411d-a676-075b26e1453c|1|ANATRESP|Anatomic Response|LUGANO CLASSIFICATION|[?]|km|PD/RELAPSE AFTER HI|1|mL/day|IN VITRO GENE EXPRESSION ASSAY|Y|||CAREGIVER|MICROSCOPIST 1|Y|1|Visit_1|10|6|WASHOUT|2020-09-20|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-14|P1Y2M10DT2H30M|BEFORE|2020-12-12|BEFORE|2020-12-15
e|RS|11b2b359-d4a1-411d-a676-075b26e1453c|2|NEWLPROG|New Lesion Progression|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|amol|RELAPSED DISEASE|1|log10 PFU/mL|IMMUNOCHROMATOGRAPHY||Y||PARENT|RADIOLOGIST 2|NA|1|Visit_1|10|7|FOLLOW-UP|2020-09-20|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-14|P1Y2M10DT2H30M|COINCIDENT|2020-11-06|BEFORE|2020-11-09
e|RS|11b2b359-d4a1-411d-a676-075b26e1453c|3|METBRESP|Metabolic Response|RECIST 1.0|||DECREASED|1|BAG|DC SHEATH FLOW|||Y|ADJUDICATOR|PATHOLOGIST 1|Y|2|Visit_2|25|2|WASHOUT|2020-10-05|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-10|P1Y2M10DT2H30M|BEFORE|2020-11-16|ONGOING|2020-12-07
e|RS|11b2b359-d4a1-411d-a676-075b26e1453c|4|PATHRESP|Pathologic Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|cm|NR|1|LENS|THIN SMEAR|Y|||PARENT|CARDIOLOGIST|Y|2|Visit_2|25|2|SCREENING|2020-10-05|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-10|P1Y2M10DT2H30M|COINCIDENT|2020-11-10|AFTER|2020-11-30
e|RS|11b2b359-d4a1-411d-a676-075b26e1453c|5|NEWLPROG|New Lesion Progression|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|||FAVORABLE RESPONSE|1|U.CARR|CLAUSS METHOD|||Y|CAREGIVER|RATER 2|Y|3|Visit_3|40|1|WASHOUT|2020-10-20|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-13|P1Y2M10DT2H30M|COINCIDENT|2020-10-17|ONGOING|2020-12-11
e|RS|11b2b359-d4a1-411d-a676-075b26e1453c|6|METSIND|Metastatic Indicator|DURIE MULTIPLE MYELOMA 2006|[?]|/mm|ABSENT MORPHOLOGIC RESPONSE|1|BOWL|LYMPHANGIOGRAPHY||||PARENT|ADJUDICATOR 1|NA|3|Visit_3|40|3|FOLLOW-UP|2020-10-20|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-13|P1Y2M10DT2H30M|BEFORE|2020-11-20|ONGOING|2020-11-25
e|RS|11b2b359-d4a1-411d-a676-075b26e1453c|7|NTNERESP|Non-Target Non-Enhancing Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|pmol|WORSENED|1|Gauss|FREEZING POINT DEPRESSION||Y||FAMILY MEMBER|RADIOLOGIST 2|U|4|Visit_4|65|6|TREATMENT|2020-11-14|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-09|P1Y2M10DT2H30M|COINCIDENT|2020-12-09|COINCIDENT|2020-12-11
e|RS|11b2b359-d4a1-411d-a676-075b26e1453c|8|NTRGRESP|Non-target Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|10^9 CFU|DISEASE TRANSFORMATION|1|10^9/g|PANENDOSCOPY||||SIBLING|NEUROLOGIST|U|4|Visit_4|65|4|SCREENING|2020-11-14|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-09|P1Y2M10DT2H30M|BEFORE|2020-10-07|BEFORE|2020-10-21
e|RS|11b2b359-d4a1-411d-a676-075b26e1453c|9|SFTSRESP|Soft Tissue Response|GUPPY OVARIAN CANCER 2002|[?]|APS U|MORPHOLOGIC CR|1|PFU/animal|MICROBIAL CULTURE, LIQUID||Y||SPOUSE|ADJUDICATOR|U|5|Visit_5|90|5|TREATMENT|2020-12-09|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-08|P1Y2M10DT2H30M|UNKNOWN|2020-12-18|COINCIDENT|2020-12-19
e|RS|11b2b359-d4a1-411d-a676-075b26e1453c|10|MJPTHIND|Major Pathological Response Indicator|CHESON LYMPHOMA 2008|[?]|pg|HI-E|1|genEq/mL|LAPAROSCOPY|Y|Y||SIBLING|RADIOLOGIST 2|NA|5|Visit_5|90|4|TREATMENT|2020-12-09|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-08|P1Y2M10DT2H30M|UNKNOWN|2020-09-12|AFTER|2020-11-12
e|RS|293f673d-af6a-473e-8bce-118bb85bbd9e|1|MNPTHIND|Minor Pathological Response Indicator|IWG CHESON MDS 2006|||NON-PD|1|U|ELASTOGRAPHY|Y||Y|INDEPENDENT ASSESSOR|READER 1|N|1|Visit_1|10|5|TREATMENT|2020-10-19|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-05|P1Y2M10DT2H30M|AFTER|2020-12-05|BEFORE|2020-12-27
e|RS|293f673d-af6a-473e-8bce-118bb85bbd9e|2|LIVRRESP|Liver Response|NCIWG CHESON CLL 1996|[?]|DISK|FAVORABLE RESPONSE|1|BAR|BALLPOINT PEN TECHNIQUE|Y|||FRIEND|READER 3|NA|1|Visit_1|10|2|FOLLOW-UP|2020-10-19|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-05|P1Y2M10DT2H30M|AFTER|2020-11-26|ONGOING|2021-01-16
e|RS|293f673d-af6a-473e-8bce-118bb85bbd9e|3|MRDIND|Minimal Residual Disease Indicator|PCWG BUBLEY PROSTATE CANCER 1999|||ABSENT MORPHOLOGIC RESPONSE|1|EP U|OPTICAL DENSITY MEASUREMENT|||Y|NON-HEALTH CARE PROFESSIONAL|RATER|U|2|Visit_2|25|3|FOLLOW-UP|2020-11-03|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-05|P1Y2M10DT2H30M|BEFORE|2020-10-17|ONGOING|2020-10-27
e|RS|293f673d-af6a-473e-8bce-118bb85bbd9e|4|MRDRESP|Minimal Residual Disease Response|PCWG SCHER PROSTATE CANCER 2008|[?]|10^6 IU|UNFAVORABLE RESPONSE|1|mL|POLYMERASE CHAIN REACTION|Y|Y||PARENT|NEUROLOGIST 1|Y|2|Visit_2|25|5|TREATMENT|2020-11-03|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-05|P1Y2M10DT2H30M|AFTER|2021-01-08|ONGOING|2021-01-15
e|RS|293f673d-af6a-473e-8bce-118bb85bbd9e|5|NEWLPROG|New Lesion Progression|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|mg2/dL2|PMR|1|mL/mmHg|AGAR DILUTION||||FAMILY MEMBER|FORENSIC PATHOLOGIST|N|3|Visit_3|40|3|TREATMENT|2020-11-18|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-10|P1Y2M10DT2H30M|AFTER|2021-01-03|AFTER|2021-01-13
e|RS|293f673d-af6a-473e-8bce-118bb85bbd9e|6|MRPHRESP|Morphologic Response|NCIWG CHESON CLL 1996|[?]|ug/m2/day|CMR|1|cmol/L|CLOT DETECTION||Y||CLINICAL STUDY SPONSOR|MICROSCOPIST 3|Y|3|Visit_3|40|2|TREATMENT|2020-11-18|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-10|P1Y2M10DT2H30M|BEFORE|2020-10-30|BEFORE|2020-11-23
e|RS|293f673d-af6a-473e-8bce-118bb85bbd9e|7|SFTSRESP|Soft Tissue Response|CHESON CLL 2012|||SD-CT|1|DRINK|ELECTRONEUROGRAPHY||Y|Y|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 2|U|4|Visit_4|65|6|SCREENING|2020-12-13|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-20|P1Y2M10DT2H30M|UNKNOWN|2021-01-15|AFTER|2021-01-16
e|RS|293f673d-af6a-473e-8bce-118bb85bbd9e|8|ANATRESP|Anatomic Response|GUPPY OVARIAN CANCER 2002|[?]|Bq/L|IMPROVED|1|cy/cm|PHYSICAL EXAMINATION|Y|||INDEPENDENT ASSESSOR|ADJUDICATOR 1|Y|4|Visit_4|65|7|FOLLOW-UP|2020-12-13|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-20|P1Y2M10DT2H30M|UNKNOWN|2020-12-24|AFTER|2021-01-02
e|RS|293f673d-af6a-473e-8bce-118bb85bbd9e|9|BMIVLIND|Bone Marrow Involvement Indicator|PALUMBO MULTIPLE MYELOMA 2009|[?]|psec|UNEQUIVOCAL|1|mmol2/L2|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|Y|||ADJUDICATOR|ONCOLOGIST|Y|5|Visit_5|90|2|FOLLOW-UP|2021-01-07|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-14|P1Y2M10DT2H30M|UNKNOWN|2021-01-10|COINCIDENT|2021-01-16
e|RS|293f673d-af6a-473e-8bce-118bb85bbd9e|10|CYTORESP|Cytogenetic Response|PCWG SCHER PROSTATE CANCER 2008|[?]|log10 CCID 50/dose|CYTOGENETIC CR|1|mAmp|EEG||||NON-HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|Y|5|Visit_5|90|1|TREATMENT|2021-01-07|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-14|P1Y2M10DT2H30M|COINCIDENT|2020-11-08|BEFORE|2020-12-14
e|RS|0f60ab31-ee13-4846-93d2-6bcac139006f|1|NTERESP|Non-Target Enhancing Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|mL/min/1.73m2|CHR|1|ag|MALDI|Y|||ADJUDICATOR|OPTOMETRIST|Y|1|Visit_1|10|4|TREATMENT|2020-07-02|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-06|P1Y2M10DT2H30M|UNKNOWN|2020-09-19|COINCIDENT|2020-09-22
e|RS|0f60ab31-ee13-4846-93d2-6bcac139006f|2|METSIND|Metastatic Indicator|RECICL|[?]|SCOOPFUL|INCREASED|1|mL/animal/day|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE||Y||FRIEND|RATER 1|N|1|Visit_1|10|7|TREATMENT|2020-07-02|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-06|P1Y2M10DT2H30M|UNKNOWN|2020-07-27|AFTER|2020-08-08
e|RS|0f60ab31-ee13-4846-93d2-6bcac139006f|3|MRPHRESP|Morphologic Response|AJCC V7|||OPTIMAL MORPHOLOGIC RESPONSE|1|LB|SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|||Y|NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST|U|2|Visit_2|25|2|TREATMENT|2020-07-17|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-22|P1Y2M10DT2H30M|COINCIDENT|2020-07-18|BEFORE|2020-09-13
e|RS|0f60ab31-ee13-4846-93d2-6bcac139006f|4|MRDIND|Minimal Residual Disease Indicator|GCIG RUSTIN OVARIAN CANCER 2011|[?]|PFU/animal|SD-CT|1|AFU|IMPULSE OSCILLOMETRY||||GUARDIAN|ONCOLOGIST 1|N|2|Visit_2|25|2|WASHOUT|2020-07-17|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-22|P1Y2M10DT2H30M|AFTER|2020-09-22|ONGOING|2020-09-25
e|RS|0f60ab31-ee13-4846-93d2-6bcac139006f|5|NEWLPROG|New Lesion Progression|EASL BRUIX LIVER CANCER 2001|[?]|mg/g/h|COMPLETE MRD RESPONSE|1|SYRINGE|MICROBIAL CULTURE||||GUARDIAN|RATER|NA|3|Visit_3|40|5|WASHOUT|2020-08-01|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-17|P1Y2M10DT2H30M|UNKNOWN|2020-09-21|BEFORE|2020-09-22
e|RS|0f60ab31-ee13-4846-93d2-6bcac139006f|6|MOLRESP|Molecular Response|AJCC V7|[?]|CAPSULE|CA125 50% RESPONSE|1|L/L|IMMUNE REPERTOIRE DEEP SEQUENCING||||VENDOR|DEVELOPMENTAL PSYCHOLOGIST|NA|3|Visit_3|40|1|FOLLOW-UP|2020-08-01|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-17|P1Y2M10DT2H30M|AFTER|2020-09-03|BEFORE|2020-09-16
e|RS|0f60ab31-ee13-4846-93d2-6bcac139006f|7|ANATRESP|Anatomic Response|CHOLLET BREAST CANCER 2002|[?]|Ci|iCPD|1|10^6 organisms/g|DC SHEATH FLOW|Y|Y||VENDOR|READER 2|N|4|Visit_4|65|5|TREATMENT|2020-08-26|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-18|P1Y2M10DT2H30M|UNKNOWN|2020-09-19|ONGOING|2020-09-27
e|RS|0f60ab31-ee13-4846-93d2-6bcac139006f|8|TRGRESP|Target Response|UNSPECIFIED|[?]|/100 HPFs|nPR|1|IU/kg/h|OBSERVATION||Y||GUARDIAN|NEUROLOGIST|N|4|Visit_4|65|3|SCREENING|2020-08-26|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-18|P1Y2M10DT2H30M|AFTER|2020-09-29|BEFORE|2020-09-30
e|RS|0f60ab31-ee13-4846-93d2-6bcac139006f|9|MRDIND|Minimal Residual Disease Indicator|BURCOMBE BREAST CANCER 2005|||MORPHOLOGIC CRi|1|U/g|CLIP SEQUENCING|||Y|FAMILY MEMBER|ENDOCRINOLOGIST|N|5|Visit_5|90|2|FOLLOW-UP|2020-09-20|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-01|P1Y2M10DT2H30M|COINCIDENT|2020-08-20|ONGOING|2020-09-02
e|RS|0f60ab31-ee13-4846-93d2-6bcac139006f|10|HEMARESP|Hematologic Response|KEAM BREAST CANCER 2013|[?]|IU/mg|PR-CT|1|mV/sec|PATHOLOGICAL EVALUATION||Y||CHILD|OTOLARYNGOLOGIST|N|5|Visit_5|90|7|TREATMENT|2020-09-20|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-01|P1Y2M10DT2H30M|BEFORE|2020-08-18|ONGOING|2020-08-29
e|RS|d49f37ce-2d6e-4ebb-91af-7ed32322f824|1|NTRGRESP|Non-target Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|||DECREASED|1|cL|COLORIMETRY|Y||Y|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|N|1|Visit_1|10|2|TREATMENT|2020-08-31|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-22|P1Y2M10DT2H30M|BEFORE|2020-11-17|COINCIDENT|2020-11-23
e|RS|d49f37ce-2d6e-4ebb-91af-7ed32322f824|2|MNPTHIND|Minor Pathological Response Indicator|PCWG SCHER PROSTATE CANCER 2008|||cCR|1|HOURS|ACRIDINE ORANGE STAIN|Y|Y|Y|ADJUDICATOR|MICROSCOPIST 1|Y|1|Visit_1|10|7|TREATMENT|2020-08-31|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-22|P1Y2M10DT2H30M|AFTER|2020-10-24|BEFORE|2020-11-17
e|RS|d49f37ce-2d6e-4ebb-91af-7ed32322f824|3|BONERESP|Bone Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|BEAM BREAKS|TREATMENT FAILURE|1|L/s|NUCLEIC ACID HYBRIDIZATION||||ADJUDICATOR|PATHOLOGIST 2|NA|2|Visit_2|25|3|TREATMENT|2020-09-15|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-04|P1Y2M10DT2H30M|UNKNOWN|2020-11-04|AFTER|2020-11-10
e|RS|d49f37ce-2d6e-4ebb-91af-7ed32322f824|4|MNPTHIND|Minor Pathological Response Indicator|SACT|[?]|Hz/s|SD-CT|1|mL/kg/day|BAC ACGH|Y|||GUARDIAN|INTERNIST|N|2|Visit_2|25|3|TREATMENT|2020-09-15|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-04|P1Y2M10DT2H30M|AFTER|2020-11-01|BEFORE|2020-11-02
e|RS|d49f37ce-2d6e-4ebb-91af-7ed32322f824|5|ANATRESP|Anatomic Response|EASL BRUIX LIVER CANCER 2001|[?]|HOURS|SD-CT|1|mL/animal|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|Y|||CLINICAL RESEARCH ASSOCIATE|HEMATOLOGIST|N|3|Visit_3|40|7|TREATMENT|2020-09-30|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-07|P1Y2M10DT2H30M|BEFORE|2020-10-21|ONGOING|2020-11-27
e|RS|d49f37ce-2d6e-4ebb-91af-7ed32322f824|6|NEWLIND|New Lesion Indicator|RECIST 1.1|[?]|mL/dose|PSEUDOPROGRESSION|1|cm|NUCLEIC ACID AMPLIFICATION TEST|Y|||NON-HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|NA|3|Visit_3|40|1|TREATMENT|2020-09-30|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-07|P1Y2M10DT2H30M|BEFORE|2020-08-28|ONGOING|2020-09-01
e|RS|d49f37ce-2d6e-4ebb-91af-7ed32322f824|7|CLINRESP|Clinical Response|SACT|||CR|1|ms/mmHg|MAGNETIC RESONANCE ENTEROGRAPHY|Y||Y|CHILD|PATHOLOGIST 2|U|4|Visit_4|65|6|FOLLOW-UP|2020-10-25|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-30|P1Y2M10DT2H30M|BEFORE|2020-10-10|BEFORE|2020-11-25
e|RS|d49f37ce-2d6e-4ebb-91af-7ed32322f824|8|NTERESP|Non-Target Enhancing Response|MRANO VAN DEN BENT GLIOMA 2011|||NON-CR/NON-PD|1|Gy/min|CHROMATOGRAPHY|Y||Y|DOMESTIC PARTNER|RATER 1|N|4|Visit_4|65|4|TREATMENT|2020-10-25|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-30|P1Y2M10DT2H30M|AFTER|2020-08-27|ONGOING|2020-10-18
e|RS|d49f37ce-2d6e-4ebb-91af-7ed32322f824|9|TMRESP|Tumor Marker Response|LUGANO CLASSIFICATION|[?]|BOX|CA125 50% RESPONSE|1|gtt|CLAUSS METHOD||||FAMILY MEMBER|OPHTHALMOLOGIST|NA|5|Visit_5|90|4|TREATMENT|2020-11-19|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-08|P1Y2M10DT2H30M|COINCIDENT|2020-11-14|COINCIDENT|2020-11-21
e|RS|d49f37ce-2d6e-4ebb-91af-7ed32322f824|10|STRUSTAT|Steroid Use Status|RECIST 1.1|[?]|C|PARTIAL MORPHOLOGIC RESPONSE|1|mEq/mL|KNEMOMETRY|Y|Y||CLINICAL RESEARCH COORDINATOR|READER 1|NA|5|Visit_5|90|7|TREATMENT|2020-11-19|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-08|P1Y2M10DT2H30M|AFTER|2020-11-01|AFTER|2020-11-08
e|RS|76dd2fe2-bc9e-48e4-870c-af7ece70009a|1|SPLNRESP|Spleen Response|MONTSERRAT CLL 1989|[?]|nmol/mL/min|NON-CR/NON-PD|1|usec|IMMUNODIFFUSION||Y||CLINICAL RESEARCH COORDINATOR|PEDIATRIC NEUROLOGIST|Y|1|Visit_1|10|1|TREATMENT|2020-07-06|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-09|P1Y2M10DT2H30M|COINCIDENT|2020-07-05|BEFORE|2020-07-15
e|RS|76dd2fe2-bc9e-48e4-870c-af7ece70009a|2|RDIORESP|Radiologic Response|KUKER LYMPHOMA 2005|[?]|foz_br|CA125 75% RESPONSE|1|steps/min|SLIT LAMP PHOTOGRAPHY||Y||INTERVIEWER|INTERNIST|U|1|Visit_1|10|3|TREATMENT|2020-07-06|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-09|P1Y2M10DT2H30M|COINCIDENT|2020-07-28|ONGOING|2020-08-16
e|RS|76dd2fe2-bc9e-48e4-870c-af7ece70009a|3|HEMARESP|Hematologic Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|CUP|PR WITH LYMPHOCYTOSIS|1|ug/L/h|NO INFORMATION|Y|||SIGNIFICANT OTHER|ADJUDICATOR 2|U|2|Visit_2|25|1|TREATMENT|2020-07-21|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-13|P1Y2M10DT2H30M|COINCIDENT|2020-09-23|COINCIDENT|2020-09-26
e|RS|76dd2fe2-bc9e-48e4-870c-af7ece70009a|4|CPRFSTAT|Clinical Performance Status|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|VOXEL|CYTOGENETIC CR|1|APL U/mL|ENZYME MULTIPLIED IMMUNOASSAY TECHNIQUE||Y||HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|NA|2|Visit_2|25|4|WASHOUT|2020-07-21|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-13|P1Y2M10DT2H30M|COINCIDENT|2020-09-15|ONGOING|2020-09-20
e|RS|76dd2fe2-bc9e-48e4-870c-af7ece70009a|5|CYTORESP|Cytogenetic Response|PALUMBO MULTIPLE MYELOMA 2009|||OPTIMAL MORPHOLOGIC RESPONSE|1|umol/mg/min|INDIA INK STAIN|||Y|GUARDIAN|ONCOLOGIST|N|3|Visit_3|40|6|WASHOUT|2020-08-05|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-13|P1Y2M10DT2H30M|UNKNOWN|2020-07-19|ONGOING|2020-09-14
e|RS|76dd2fe2-bc9e-48e4-870c-af7ece70009a|6|OVRLRESP|Overall Response|MACDONALD GLIOMA 1990|[?]|log10 TCID 50/uL|PDu|1|/500 WBC|IMMUNOBLOT||Y||FAMILY MEMBER|CARDIOLOGIST|U|3|Visit_3|40|4|TREATMENT|2020-08-05|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-13|P1Y2M10DT2H30M|UNKNOWN|2020-09-13|COINCIDENT|2020-09-24
e|RS|76dd2fe2-bc9e-48e4-870c-af7ece70009a|7|SFTSRESP|Soft Tissue Response|IWG CHESON AML 2003|||QUANTIFIABLE MRD POSITIVITY|1|MET|ACRIDINE ORANGE STAIN|||Y|CAREGIVER|READER|Y|4|Visit_4|65|3|WASHOUT|2020-08-30|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-06|P1Y2M10DT2H30M|AFTER|2020-09-27|BEFORE|2020-09-30
e|RS|76dd2fe2-bc9e-48e4-870c-af7ece70009a|8|DRCRIND|Disease Recurrence Indicator|FAROOQUI SUPP CLL 2014|[?]|Hz|IMMUNOPHENOTYPIC CR|1|mEq|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION||||GUARDIAN|DERMATOLOGIST|Y|4|Visit_4|65|3|WASHOUT|2020-08-30|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-06|P1Y2M10DT2H30M|COINCIDENT|2020-07-07|BEFORE|2020-08-08
e|RS|76dd2fe2-bc9e-48e4-870c-af7ece70009a|9|NTLWIND|Non-Target Lesion Worsening Indicator|HARTMAN PANCREATIC CANCER 2012|[?]|pmol/day|MORPHOLOGIC CR|1|/10^4|TWO-COLOR MICROARRAY|Y|||SIBLING|ADJUDICATOR|U|5|Visit_5|90|2|SCREENING|2020-09-24|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-29|P1Y2M10DT2H30M|BEFORE|2020-08-19|AFTER|2020-09-26
e|RS|76dd2fe2-bc9e-48e4-870c-af7ece70009a|10|RDIORESP|Radiologic Response|CHOLLET BREAST CANCER 2002|[?]|mMU/mL|PDu|1|nmol/mL/min|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY||||SIBLING|UROLOGIST|U|5|Visit_5|90|5|TREATMENT|2020-09-24|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-29|P1Y2M10DT2H30M|COINCIDENT|2020-08-28|AFTER|2020-09-03
e|RS|5ac0fe16-cde1-41ea-9948-0b79e72fd8ad|1|DRCRIND|Disease Recurrence Indicator|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|C|nPR|1|Absorbance U/mL|PATHOLOGICAL EVALUATION|Y|Y||NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|NA|1|Visit_1|10|4|TREATMENT|2020-11-24|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-30|P1Y2M10DT2H30M|AFTER|2021-01-23|ONGOING|2021-01-26
e|RS|5ac0fe16-cde1-41ea-9948-0b79e72fd8ad|2|BESTRESP|Best Overall Response|RANO ELLINGSON 2017|[?]|TAMPON|MAJOR PATHOLOGIC RESPONSE|1|hPa|HILLMEN COLOR CHART||||FAMILY MEMBER|CLINICAL PATHOLOGIST|U|1|Visit_1|10|3|WASHOUT|2020-11-24|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-30|P1Y2M10DT2H30M|UNKNOWN|2020-11-24|BEFORE|2021-01-06
e|RS|5ac0fe16-cde1-41ea-9948-0b79e72fd8ad|3|NEWLPROG|New Lesion Progression|BRUGGEMANN MRD 2010|[?]|mmol/min/kPa|CYTOGENETIC MINOR RESPONSE|1|mg/m2/day|CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY||||FAMILY MEMBER|ONCOLOGIST|N|2|Visit_2|25|1|TREATMENT|2020-12-09|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-03|P1Y2M10DT2H30M|COINCIDENT|2021-02-02|BEFORE|2021-02-12
e|RS|5ac0fe16-cde1-41ea-9948-0b79e72fd8ad|4|BMIVLIND|Bone Marrow Involvement Indicator|GUPPY OVARIAN CANCER 2002|[?]|cup eq|NON-PD|1|/VF|MACRO BROTH DILUTION||||INTERVIEWER|OPTOMETRIST|NA|2|Visit_2|25|7|TREATMENT|2020-12-09|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-03|P1Y2M10DT2H30M|UNKNOWN|2020-12-24|AFTER|2021-01-12
e|RS|5ac0fe16-cde1-41ea-9948-0b79e72fd8ad|5|LIVRRESP|Liver Response|RANO|[?]|foz_br|ABSENT MORPHOLOGIC RESPONSE|1|sec|TOLUIDINE BLUE STAIN||||CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 1|U|3|Visit_3|40|1|TREATMENT|2020-12-24|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-17|P1Y2M10DT2H30M|BEFORE|2021-01-11|ONGOING|2021-01-15
e|RS|5ac0fe16-cde1-41ea-9948-0b79e72fd8ad|6|MNPTHIND|Minor Pathological Response Indicator|FAROOQUI SUPP CLL 2014|[?]|cy/cm|WORSENED|1|g/L|CYSTOMETRY|Y|Y||FRIEND|PHYSIOTHERAPIST|NA|3|Visit_3|40|6|WASHOUT|2020-12-24|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-17|P1Y2M10DT2H30M|BEFORE|2021-01-06|BEFORE|2021-01-12
e|RS|5ac0fe16-cde1-41ea-9948-0b79e72fd8ad|7|CYTORESP|Cytogenetic Response|PROTOCOL DEFINED RESPONSE CRITERIA|||SD|1|ECL unit|ELECTROGASTROGRAPHY||Y|Y|SPOUSE|HEMATOLOGIST|N|4|Visit_4|65|3|TREATMENT|2021-01-18|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-28|P1Y2M10DT2H30M|UNKNOWN|2021-02-06|BEFORE|2021-02-11
e|RS|5ac0fe16-cde1-41ea-9948-0b79e72fd8ad|8|PATHRESP|Pathologic Response|EASL BRUIX LIVER CANCER 2001|[?]|PACKAGE|MR|1|cpm|MAMMOGRAPHY|Y|||VENDOR|INTERNIST|U|4|Visit_4|65|1|TREATMENT|2021-01-18|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-28|P1Y2M10DT2H30M|AFTER|2021-01-17|BEFORE|2021-02-02
e|RS|5ac0fe16-cde1-41ea-9948-0b79e72fd8ad|9|NTLWIND|Non-Target Lesion Worsening Indicator|HARTMAN PANCREATIC CANCER 2012|[?]|dpm/0.5 mL|PD|1|mL/min/mmHg|VIRUS PLAQUE ASSAY||||CLINICAL STUDY SPONSOR|PHYSIOTHERAPIST|U|5|Visit_5|90|2|TREATMENT|2021-02-12|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-18|P1Y2M10DT2H30M|BEFORE|2020-12-23|BEFORE|2021-02-05
e|RS|5ac0fe16-cde1-41ea-9948-0b79e72fd8ad|10|NTRGRESP|Non-target Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|/200 HPFs|MRD NEGATIVITY|1|BOX|IN SITU HYBRIDIZATION||||CLINICAL RESEARCH COORDINATOR|RATER|NA|5|Visit_5|90|6|SCREENING|2021-02-12|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-18|P1Y2M10DT2H30M|BEFORE|2021-01-20|COINCIDENT|2021-02-14
e|RS|78778706-6b5b-4ad8-90af-f56d602863ae|1|PATHRESP|Pathologic Response|CHESON CLL 2006|[?]|eq|MORPHOLOGIC LEUKEMIA-FREE STATE|1|PUFF|TRICHROME STAIN||||SIBLING|UROLOGIST|U|1|Visit_1|10|4|FOLLOW-UP|2020-05-13|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-20|P1Y2M10DT2H30M|BEFORE|2020-08-01|ONGOING|2020-08-05
e|RS|78778706-6b5b-4ad8-90af-f56d602863ae|2|LIVRRESP|Liver Response|BURCOMBE BREAST CANCER 2005|[?]|ka_u/dL|COMPLETE MRD RESPONSE|1|umol/h/mmol|SLIT LAMP PHOTOGRAPHY||||CLINICAL STUDY SPONSOR|ADJUDICATOR 3|Y|1|Visit_1|10|5|WASHOUT|2020-05-13|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-20|P1Y2M10DT2H30M|UNKNOWN|2020-07-19|AFTER|2020-07-23
e|RS|78778706-6b5b-4ad8-90af-f56d602863ae|3|NTNERESP|Non-Target Non-Enhancing Response|CHESON CLL 2012|[?]|uV*sec|EQUIVOCAL|1|10^6 organisms|NEXT GENERATION TARGETED SEQUENCING||||CHILD|PATHOLOGIST|NA|2|Visit_2|25|4|TREATMENT|2020-05-28|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-17|P1Y2M10DT2H30M|COINCIDENT|2020-07-02|COINCIDENT|2020-07-08
e|RS|78778706-6b5b-4ad8-90af-f56d602863ae|4|MNPTHIND|Minor Pathological Response Indicator|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|uU/L|IMPROVED|1|fmol/L/sec|RADIOGRAPHY|Y|Y||DOMESTIC PARTNER|ONCOLOGIST|Y|2|Visit_2|25|1|TREATMENT|2020-05-28|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-17|P1Y2M10DT2H30M|BEFORE|2020-07-01|AFTER|2020-08-10
e|RS|78778706-6b5b-4ad8-90af-f56d602863ae|5|LIVRRESP|Liver Response|PCWG SCHER PROSTATE CANCER 2008|||iCR|1|mL/g/min|OPTICAL MAPPING|||Y|VENDOR|CARDIOLOGIST|Y|3|Visit_3|40|2|WASHOUT|2020-06-12|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-06|P1Y2M10DT2H30M|COINCIDENT|2020-07-10|ONGOING|2020-07-26
e|RS|78778706-6b5b-4ad8-90af-f56d602863ae|6|ANATRESP|Anatomic Response|MONTSERRAT CLL 1989|[?]|/wk|CA125 50% RESPONSE|1|10^4 CFU|OSCILLOMETRY|Y|||ADJUDICATION COMMITTEE|ADJUDICATOR 2|NA|3|Visit_3|40|1|WASHOUT|2020-06-12|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-06|P1Y2M10DT2H30M|AFTER|2020-05-24|BEFORE|2020-05-27
e|RS|78778706-6b5b-4ad8-90af-f56d602863ae|7|MOLRESP|Molecular Response|BURCOMBE BREAST CANCER 2005|[?]|IU/kg|MOLECULAR MAJOR RESPONSE|1|/h|CAPILLARY ELECTROPHORESIS||||SIGNIFICANT OTHER|NEUROLOGIST|U|4|Visit_4|65|4|SCREENING|2020-07-07|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-29|P1Y2M10DT2H30M|UNKNOWN|2020-07-02|ONGOING|2020-07-03
e|RS|78778706-6b5b-4ad8-90af-f56d602863ae|8|HEMARESP|Hematologic Response|BLAZER COLORECTAL CANCER 2008|[?]|nkat/g Hb|RELAPSED DISEASE|1|g/m2|QUANTITATIVE COMPUTED TOMOGRAPHY||||CLINICAL STUDY SPONSOR|ADJUDICATOR 2|N|4|Visit_4|65|3|SCREENING|2020-07-07|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-29|P1Y2M10DT2H30M|AFTER|2020-07-24|BEFORE|2020-08-06
e|RS|78778706-6b5b-4ad8-90af-f56d602863ae|9|ANATRESP|Anatomic Response|KEAM BREAST CANCER 2013|[?]|Watt|RELAPSED DISEASE|1|mm3/mm2/year|QUANTITATIVE CORONARY ANGIOGRAPHY||||INTERVIEWER|INTERNIST|N|5|Visit_5|90|7|TREATMENT|2020-08-01|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-20|P1Y2M10DT2H30M|AFTER|2020-08-06|ONGOING|2020-08-10
e|RS|78778706-6b5b-4ad8-90af-f56d602863ae|10|MNPTHIND|Minor Pathological Response Indicator|WOLCHOK SOLID TUMORS 2009|||RELAPSED DISEASE FROM CR|1|IU/g|GC/MS-EI|Y||Y|INTERVIEWER|RATER 2|U|5|Visit_5|90|7|WASHOUT|2020-08-01|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-20|P1Y2M10DT2H30M|COINCIDENT|2020-05-07|BEFORE|2020-05-31
e|RS|a6954aa1-4860-412a-b988-7f708aca2ab2|1|METBRESP|Metabolic Response|LUGANO CLASSIFICATION|||RELAPSED DISEASE FROM CR|1|g|IMMUNOPRECIPITATION|||Y|CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 2|Y|1|Visit_1|10|3|WASHOUT|2020-09-17|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-08|P1Y2M10DT2H30M|UNKNOWN|2020-12-09|ONGOING|2020-12-12
e|RS|a6954aa1-4860-412a-b988-7f708aca2ab2|2|LIVRRESP|Liver Response|BRUGGEMANN MRD 2010|[?]|PACKET|COMPLETE MRD RESPONSE|1|DAgU/mL|PLETHYSMOGRAPHY|Y|Y||CHILD|OTOLARYNGOLOGIST|NA|1|Visit_1|10|2|FOLLOW-UP|2020-09-17|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-08|P1Y2M10DT2H30M|BEFORE|2020-10-14|COINCIDENT|2020-10-28
e|RS|a6954aa1-4860-412a-b988-7f708aca2ab2|3|OVRLRESP|Overall Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|||HI-N|1|ug/animal|NUCLEIC ACID HYBRIDIZATION||Y|Y|HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|NA|2|Visit_2|25|1|TREATMENT|2020-10-02|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-15|P1Y2M10DT2H30M|AFTER|2020-12-08|ONGOING|2020-12-09
e|RS|a6954aa1-4860-412a-b988-7f708aca2ab2|4|MNPTHIND|Minor Pathological Response Indicator|SCHWARZ CERVICAL CANCER 2009|[?]|uOsm|TREATMENT FAILURE|1|log10 PFU|COMPUTERIZED CORNEAL TOPOGRAPHY||||PARENT|RATER|NA|2|Visit_2|25|3|FOLLOW-UP|2020-10-02|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-15|P1Y2M10DT2H30M|AFTER|2020-11-19|COINCIDENT|2020-12-06
e|RS|a6954aa1-4860-412a-b988-7f708aca2ab2|5|SPLNRESP|Spleen Response|RECIST 1.1|[?]|mm/h|FAVORABLE RESPONSE|1|L/kg|HEMATOXYLIN AND EOSIN STAIN|Y|||FRIEND|INTERNIST|Y|3|Visit_3|40|6|TREATMENT|2020-10-17|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-09|P1Y2M10DT2H30M|COINCIDENT|2020-12-10|ONGOING|2020-12-15
e|RS|a6954aa1-4860-412a-b988-7f708aca2ab2|6|SFTSRESP|Soft Tissue Response|IWG CHESON MDS 2006|[?]|kN/cm2|PMD|1|mOsm/kg|DOUBLE IMMUNODIFFUSION||Y||ADJUDICATOR|READER|N|3|Visit_3|40|7|FOLLOW-UP|2020-10-17|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-09|P1Y2M10DT2H30M|AFTER|2020-11-17|BEFORE|2020-12-02
e|RS|a6954aa1-4860-412a-b988-7f708aca2ab2|7|NEWLWIND|New Lesion Worsening Indicator|PROTOCOL DEFINED RESPONSE CRITERIA|||PSA PROGRESSION|1|ug/L/h|SLIT LAMP PHOTOGRAPHY|||Y|FAMILY MEMBER|NEUROLOGIST 2|NA|4|Visit_4|65|6|TREATMENT|2020-11-11|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-28|P1Y2M10DT2H30M|BEFORE|2020-10-02|AFTER|2020-12-11
e|RS|a6954aa1-4860-412a-b988-7f708aca2ab2|8|MNPTHIND|Minor Pathological Response Indicator|FAROOQUI SUPP CLL 2014|[?]|NEEDLE GAUGE|IMPROVED|1|mL/min|PHASE-CONTRAST MRI||||GUARDIAN|RATER|Y|4|Visit_4|65|1|WASHOUT|2020-11-11|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-28|P1Y2M10DT2H30M|BEFORE|2020-10-05|ONGOING|2020-10-30
e|RS|a6954aa1-4860-412a-b988-7f708aca2ab2|9|METBRESP|Metabolic Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|mg/m2/min|VGPR|1|genEq|FLUORESCENT MICROSCOPY||||SIGNIFICANT OTHER|ADJUDICATOR 3|Y|5|Visit_5|90|5|TREATMENT|2020-12-06|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-06|P1Y2M10DT2H30M|COINCIDENT|2020-11-04|BEFORE|2020-12-14
e|RS|a6954aa1-4860-412a-b988-7f708aca2ab2|10|TRGRESP|Target Response|GUILHOT CML 2007|[?]|log10 TCID 50/mL|iSD|1|uV*sec|CT SCAN WITHOUT CONTRAST||Y||CLINICAL RESEARCH COORDINATOR|OPHTHALMOLOGIST|U|5|Visit_5|90|4|WASHOUT|2020-12-06|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-06|P1Y2M10DT2H30M|COINCIDENT|2020-11-16|AFTER|2020-12-06
e|RS|0a970eb4-f958-42ad-ad8b-60bb427c9cba|1|NTRGRESP|Non-target Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|mg/g/h|RELAPSED DISEASE FROM CR OR PR|1|mg2/dL2|NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY||||INTERVIEWER|PATHOLOGIST 1|N|1|Visit_1|10|5|TREATMENT|2020-05-14|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-07|P1Y2M10DT2H30M|UNKNOWN|2020-07-05|COINCIDENT|2020-07-26
e|RS|0a970eb4-f958-42ad-ad8b-60bb427c9cba|2|CYTORESP|Cytogenetic Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|IU/mmol|COMPLETE MRD RESPONSE|1|mg/kg/dose|HIGH LEVEL AMINOGLYCOSIDE SCREEN||Y||INDEPENDENT ASSESSOR|MICROSCOPIST 1|U|1|Visit_1|10|6|TREATMENT|2020-05-14|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-07|P1Y2M10DT2H30M|UNKNOWN|2020-07-01|COINCIDENT|2020-08-08
e|RS|0a970eb4-f958-42ad-ad8b-60bb427c9cba|3|NTRGRESP|Non-target Response|JACINTO CERVICAL CANCER 2007|[?]|K|PSEUDOPROGRESSION|1|mmHg*min/L|HPLC-FL|Y|||INDEPENDENT ASSESSOR|RATER 1|N|2|Visit_2|25|3|WASHOUT|2020-05-29|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-31|P1Y2M10DT2H30M|UNKNOWN|2020-05-16|BEFORE|2020-07-13
e|RS|0a970eb4-f958-42ad-ad8b-60bb427c9cba|4|CLINRESP|Clinical Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|Bq/mg|DISEASE TRANSFORMATION|1|BAG|MICROBIAL CULTURE||||DOMESTIC PARTNER|PHYSIOTHERAPIST|N|2|Visit_2|25|5|TREATMENT|2020-05-29|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-31|P1Y2M10DT2H30M|AFTER|2020-06-29|BEFORE|2020-07-13
e|RS|0a970eb4-f958-42ad-ad8b-60bb427c9cba|5|MNPTHIND|Minor Pathological Response Indicator|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|||PDu|1|scm|COULOMETRIC TITRATION|Y||Y|INVESTIGATOR|DEVELOPMENTAL PSYCHOLOGIST|U|3|Visit_3|40|4|FOLLOW-UP|2020-06-13|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-28|P1Y2M10DT2H30M|BEFORE|2020-05-22|BEFORE|2020-08-02
e|RS|0a970eb4-f958-42ad-ad8b-60bb427c9cba|6|ANATRESP|Anatomic Response|UNSPECIFIED|||iPR|1|10^6 IU/mL|FLAME PHOTOMETRY||Y|Y|PROXY|OPTOMETRIST|U|3|Visit_3|40|6|TREATMENT|2020-06-13|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-28|P1Y2M10DT2H30M|COINCIDENT|2020-05-08|COINCIDENT|2020-06-29
e|RS|0a970eb4-f958-42ad-ad8b-60bb427c9cba|7|TRGRESP|Target Response|SHINDOH COLORECTAL CANCER 2013|||SMD|1|ug/kg/min|CONTRAST ENHANCED CT SCAN|Y|Y|Y|PROXY|READER 1|NA|4|Visit_4|65|1|TREATMENT|2020-07-08|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-13|P1Y2M10DT2H30M|AFTER|2020-06-03|BEFORE|2020-06-08
e|RS|0a970eb4-f958-42ad-ad8b-60bb427c9cba|8|SYMPTDTR|Symptomatic Deterioration|AJCC V7|[?]|MBq/uL|MRD NEGATIVITY|1|L/s/kPa|FISH|Y|||GUARDIAN|RATER|N|4|Visit_4|65|7|TREATMENT|2020-07-08|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-13|P1Y2M10DT2H30M|AFTER|2020-08-08|AFTER|2020-08-11
e|RS|0a970eb4-f958-42ad-ad8b-60bb427c9cba|9|MOLRESP|Molecular Response|LEE LUNG CANCER 2011|||PSA PROGRESSION|1|EIA unit|QUANTITATIVE PERIPHERAL ANGIOGRAPHY|Y||Y|SIBLING|UROLOGIST|U|5|Visit_5|90|2|FOLLOW-UP|2020-08-02|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-06|P1Y2M10DT2H30M|COINCIDENT|2020-07-08|AFTER|2020-07-29
e|RS|0a970eb4-f958-42ad-ad8b-60bb427c9cba|10|MNPTHIND|Minor Pathological Response Indicator|RANO ELLINGSON 2017|||NED|1|INHALATION|MICROARRAY|||Y|SPOUSE|NEUROLOGIST 1|NA|5|Visit_5|90|7|FOLLOW-UP|2020-08-02|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-06|P1Y2M10DT2H30M|BEFORE|2020-06-23|AFTER|2020-06-27
e|RS|dd6179f5-d2f5-4258-ac74-cf8e7a2d8673|1|METBRESP|Metabolic Response|KUKER LYMPHOMA 2005|[?]|g/kg|NON-iCR/NON-iUPD|1|mEq/uL|SPECTROPHOTOMETRY|Y|Y||INTERVIEWER|MICROSCOPIST 2|U|1|Visit_1|10|3|TREATMENT|2021-01-26|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-07|P1Y2M10DT2H30M|AFTER|2021-02-28|BEFORE|2021-03-15
e|RS|dd6179f5-d2f5-4258-ac74-cf8e7a2d8673|2|SFTSRESP|Soft Tissue Response|HARTMANN GERM CELL CANCER 2002|||MOLECULAR CR|1|cm|MICROBIAL CONCENTRATION|||Y|ADJUDICATION COMMITTEE|CARDIOLOGIST|Y|1|Visit_1|10|4|FOLLOW-UP|2021-01-26|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-07|P1Y2M10DT2H30M|BEFORE|2021-04-25|ONGOING|2021-04-26
e|RS|dd6179f5-d2f5-4258-ac74-cf8e7a2d8673|3|DRCRIND|Disease Recurrence Indicator|WHO BREAST CANCER 2006|[?]|mg/kg/h|COMPLETE MRD RESPONSE|1|IU/L|PALM METHOD||||NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|NA|2|Visit_2|25|3|WASHOUT|2021-02-10|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-19|P1Y2M10DT2H30M|AFTER|2021-02-14|AFTER|2021-03-24
e|RS|dd6179f5-d2f5-4258-ac74-cf8e7a2d8673|4|NTNERESP|Non-Target Non-Enhancing Response|RANO ELLINGSON 2017|[?]|/4.0 mL|PR-CT|1|g/animal/wk|SNP ARRAY||||CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 1|N|2|Visit_2|25|4|SCREENING|2021-02-10|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-19|P1Y2M10DT2H30M|COINCIDENT|2021-02-26|ONGOING|2021-04-22
e|RS|dd6179f5-d2f5-4258-ac74-cf8e7a2d8673|5|BMIVLIND|Bone Marrow Involvement Indicator|MURPHY PROSTATE CANCER 1980|||SMD|1|L/min/m2|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY|||Y|PARENT|ADJUDICATOR 3|U|3|Visit_3|40|6|TREATMENT|2021-02-25|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-19|P1Y2M10DT2H30M|AFTER|2021-03-14|AFTER|2021-04-15
e|RS|dd6179f5-d2f5-4258-ac74-cf8e7a2d8673|6|METBRESP|Metabolic Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|U/kg/min|mCR|1|PFU/animal|CELLULAR PROLIFERATION ASSAY||Y||GUARDIAN|OPHTHALMOLOGIST|Y|3|Visit_3|40|5|TREATMENT|2021-02-25|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-19|P1Y2M10DT2H30M|BEFORE|2021-04-15|BEFORE|2021-04-21
e|RS|dd6179f5-d2f5-4258-ac74-cf8e7a2d8673|7|HEMARESP|Hematologic Response|KUKER LYMPHOMA 2005|[?]|steps/min|UNEQUIVOCAL|1|AU/mL|INTERRUPTER TECHNIQUE|Y|||INVESTIGATOR|ADJUDICATOR 3|NA|4|Visit_4|65|6|FOLLOW-UP|2021-03-22|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-25|P1Y2M10DT2H30M|BEFORE|2021-01-23|ONGOING|2021-03-01
e|RS|dd6179f5-d2f5-4258-ac74-cf8e7a2d8673|8|OVRLRESP|Overall Response|PRINCE TCELL LYMPHOMA 2010|[?]|LOZENGE|FAVORABLE RESPONSE|1|10^6/hpf|CONTRAST ENHANCED X-RAY||Y||NON-HEALTH CARE PROFESSIONAL|DERMATOLOGIST|N|4|Visit_4|65|4|WASHOUT|2021-03-22|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-25|P1Y2M10DT2H30M|UNKNOWN|2021-03-20|AFTER|2021-04-22
e|RS|dd6179f5-d2f5-4258-ac74-cf8e7a2d8673|9|MRPHRESP|Morphologic Response|CHESON CLL 2012|[?]|Log10 ELISA unit|IMMUNOPHENOTYPIC CR|1|PUFF|BIOPSY||||INVESTIGATOR|OTOLARYNGOLOGIST|U|5|Visit_5|90|7|TREATMENT|2021-04-16|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-16|P1Y2M10DT2H30M|AFTER|2021-02-27|COINCIDENT|2021-04-25
e|RS|dd6179f5-d2f5-4258-ac74-cf8e7a2d8673|10|SFTSRESP|Soft Tissue Response|MACDONALD GLIOMA 1990|[?]|mCi/kg|CA125 75% RESPONSE|1|nCi|AUDIOMETRY||Y||INVESTIGATOR|RADIOLOGIST 2|NA|5|Visit_5|90|6|TREATMENT|2021-04-16|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-16|P1Y2M10DT2H30M|BEFORE|2021-02-27|ONGOING|2021-03-16
e|RS|fae58cd9-1ff0-47dc-9ecb-916fb9f4187b|1|MRDIND|Minimal Residual Disease Indicator|RANO|[?]|%/min|iSD|1|MET*h|FLUORESCEIN STAIN||||STUDY SUBJECT|OPHTHALMOLOGIST|NA|1|Visit_1|10|3|SCREENING|2020-08-24|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-21|P1Y2M10DT2H30M|UNKNOWN|2020-10-06|BEFORE|2020-10-16
e|RS|fae58cd9-1ff0-47dc-9ecb-916fb9f4187b|2|LIVRRESP|Liver Response|DURIE MULTIPLE MYELOMA 2006|[?]|mL/kg|sCR|1|aMFI|NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY||||PROXY|RADIOLOGIST 1|Y|1|Visit_1|10|4|SCREENING|2020-08-24|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-21|P1Y2M10DT2H30M|UNKNOWN|2020-08-28|ONGOING|2020-09-24
e|RS|fae58cd9-1ff0-47dc-9ecb-916fb9f4187b|3|SFTSRESP|Soft Tissue Response|PERCIST|||QUANTIFIABLE MRD POSITIVITY|1|mMU/mL|TRANSESOPHAGEAL ECHOCARDIOGRAPHY|||Y|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 1|NA|2|Visit_2|25|1|TREATMENT|2020-09-08|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-22|P1Y2M10DT2H30M|COINCIDENT|2020-11-15|COINCIDENT|2020-11-16
e|RS|fae58cd9-1ff0-47dc-9ecb-916fb9f4187b|4|NTERESP|Non-Target Enhancing Response|BRUGGEMANN MRD 2010|[?]|CUP|PSA PROGRESSION|1|mL/kg/h|POLYMERASE CHAIN REACTION||||DOMESTIC PARTNER|HEMATOLOGIST|N|2|Visit_2|25|4|TREATMENT|2020-09-08|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-22|P1Y2M10DT2H30M|COINCIDENT|2020-09-04|BEFORE|2020-10-26
e|RS|fae58cd9-1ff0-47dc-9ecb-916fb9f4187b|5|CPRFSTAT|Clinical Performance Status|CHESON CLL 2012|[?]|mL/animal/day|CYTOGENETIC NO RESPONSE|1|10^9 CFU|TEMPLATE INCISION METHOD|Y|||INVESTIGATOR|RATER|N|3|Visit_3|40|3|TREATMENT|2020-09-23|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-20|P1Y2M10DT2H30M|UNKNOWN|2020-11-12|BEFORE|2020-11-16
e|RS|fae58cd9-1ff0-47dc-9ecb-916fb9f4187b|6|RDIORESP|Radiologic Response|WOLCHOK SOLID TUMORS 2009|[?]|mEq/ug|MR|1|kPa/L/sec|COMPUTERIZED CORNEAL TOPOGRAPHY||Y||HEALTH CARE PROFESSIONAL|NEUROLOGIST|NA|3|Visit_3|40|7|TREATMENT|2020-09-23|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-20|P1Y2M10DT2H30M|BEFORE|2020-09-28|COINCIDENT|2020-10-26
e|RS|fae58cd9-1ff0-47dc-9ecb-916fb9f4187b|7|CLINRESP|Clinical Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|EVENTS|HI-E|1|ug/dL|INFRARED SPECTROMETRY||Y||CLINICAL STUDY SPONSOR|CLINICAL PATHOLOGIST|Y|4|Visit_4|65|4|FOLLOW-UP|2020-10-18|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-01|P1Y2M10DT2H30M|UNKNOWN|2020-09-27|AFTER|2020-11-09
e|RS|fae58cd9-1ff0-47dc-9ecb-916fb9f4187b|8|LIVRRESP|Liver Response|EBMT BLADE MYELOMA 1998|[?]|ugEq|VGPR|1|mg/mL/day|FLUOROSCOPY||||VENDOR|OTOLARYNGOLOGIST|NA|4|Visit_4|65|1|TREATMENT|2020-10-18|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-01|P1Y2M10DT2H30M|COINCIDENT|2020-08-22|ONGOING|2020-10-03
e|RS|fae58cd9-1ff0-47dc-9ecb-916fb9f4187b|9|PATHRESP|Pathologic Response|CHOI GIST 2008|[?]|g/kg|IMPROVED|1|Log10 ELISA unit|ELECTRICAL IMPEDANCE MYOGRAPHY||||ADJUDICATION COMMITTEE|DEVELOPMENTAL PSYCHOLOGIST|NA|5|Visit_5|90|4|TREATMENT|2020-11-12|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-07|P1Y2M10DT2H30M|COINCIDENT|2020-09-21|BEFORE|2020-10-23
e|RS|fae58cd9-1ff0-47dc-9ecb-916fb9f4187b|10|LIVRRESP|Liver Response|IWG CHESON AML 2003|[?]|L/L|SMD|1|uV|CELLULAR PROLIFERATION ASSAY||Y||PROXY|CLINICAL PATHOLOGIST|NA|5|Visit_5|90|7|WASHOUT|2020-11-12|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-07|P1Y2M10DT2H30M|COINCIDENT|2020-09-04|COINCIDENT|2020-09-06
e|RS|9b268a13-dc40-4eb6-8729-c131ac302dd3|1|CYTORESP|Cytogenetic Response|HAMAOKA BREAST CANCER 2010|[?]|mU/g|PMD|1|APL U|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS||||CAREGIVER|ADJUDICATOR|U|1|Visit_1|10|2|WASHOUT|2020-05-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-26|P1Y2M10DT2H30M|COINCIDENT|2020-05-21|COINCIDENT|2020-06-13
e|RS|9b268a13-dc40-4eb6-8729-c131ac302dd3|2|NEWLIND|New Lesion Indicator|PALUMBO MULTIPLE MYELOMA 2009|||SMD|1|nmol/kg/day|RADIOIMMUNOPRECIPITATION ASSAY|||Y|INVESTIGATOR|FORENSIC PATHOLOGIST|Y|1|Visit_1|10|6|TREATMENT|2020-05-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-26|P1Y2M10DT2H30M|BEFORE|2020-08-12|ONGOING|2020-08-13
e|RS|9b268a13-dc40-4eb6-8729-c131ac302dd3|3|NEWLIND|New Lesion Indicator|KEAM BREAST CANCER 2013|||PSEUDOPROGRESSION|1|mU/g|THIN SMEAR|Y||Y|SPOUSE|ADJUDICATOR 1|N|2|Visit_2|25|4|TREATMENT|2020-05-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-28|P1Y2M10DT2H30M|UNKNOWN|2020-07-14|BEFORE|2020-07-29
e|RS|9b268a13-dc40-4eb6-8729-c131ac302dd3|4|METBRESP|Metabolic Response|JACINTO CERVICAL CANCER 2007|||CRi|1|kPa/L/sec|CALCOFLUOR WHITE STAIN|Y||Y|SIBLING|READER 1|NA|2|Visit_2|25|2|SCREENING|2020-05-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-28|P1Y2M10DT2H30M|BEFORE|2020-07-10|ONGOING|2020-07-16
e|RS|9b268a13-dc40-4eb6-8729-c131ac302dd3|5|MOLRESP|Molecular Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|mL/sec/1.73m2|PMR|1|IU/dL|MICROSCOPY||Y||ADJUDICATION COMMITTEE|RATER|N|3|Visit_3|40|2|TREATMENT|2020-06-14|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-01|P1Y2M10DT2H30M|AFTER|2020-05-28|COINCIDENT|2020-08-08
e|RS|9b268a13-dc40-4eb6-8729-c131ac302dd3|6|NEWLWIND|New Lesion Worsening Indicator|PCWG SCHER PROSTATE CANCER 2016|[?]|/VF|PMD|1|kcal|MULTIPLEX REAL-TIME POLYMERASE CHAIN REACTION ASSAY||||ADJUDICATION COMMITTEE|RADIOLOGIST 1|NA|3|Visit_3|40|5|WASHOUT|2020-06-14|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-01|P1Y2M10DT2H30M|BEFORE|2020-07-27|ONGOING|2020-08-02
e|RS|9b268a13-dc40-4eb6-8729-c131ac302dd3|7|SFTSRESP|Soft Tissue Response|KUMAR IMWG 2016|[?]|USP U|CYTOGENETIC CR|1|mm/h|ENZYMATIC COLORIMETRY||||DOMESTIC PARTNER|READER|Y|4|Visit_4|65|7|SCREENING|2020-07-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-29|P1Y2M10DT2H30M|AFTER|2020-08-04|AFTER|2020-08-11
e|RS|9b268a13-dc40-4eb6-8729-c131ac302dd3|8|NTLWIND|Non-Target Lesion Worsening Indicator|LEE LUNG CANCER 2011|[?]|mL/m2|QUANTIFIABLE MRD POSITIVITY|1|uEq/L|IMMUNOCHEMILUMINOMETRIC ASSAY||||SIGNIFICANT OTHER|MICROSCOPIST 2|NA|4|Visit_4|65|1|TREATMENT|2020-07-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-29|P1Y2M10DT2H30M|COINCIDENT|2020-06-10|COINCIDENT|2020-08-06
e|RS|9b268a13-dc40-4eb6-8729-c131ac302dd3|9|TMRESP|Tumor Marker Response|CHOLLET BREAST CANCER 2002|[?]|mg/g/h|PR-CT|1|ug/m2/day|ENZYMATIC COLORIMETRY||||PROXY|MICROSCOPIST 3|NA|5|Visit_5|90|1|SCREENING|2020-08-03|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-01|P1Y2M10DT2H30M|AFTER|2020-07-19|AFTER|2020-08-10
e|RS|9b268a13-dc40-4eb6-8729-c131ac302dd3|10|NTLWIND|Non-Target Lesion Worsening Indicator|RECICL|[?]|L/s|QUANTIFIABLE MRD POSITIVITY|1|ng/dL|CONTRAST ENHANCED PET SCAN||||INVESTIGATOR|ONCOLOGIST 2|U|5|Visit_5|90|2|TREATMENT|2020-08-03|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-01|P1Y2M10DT2H30M|BEFORE|2020-07-30|COINCIDENT|2020-08-08
e|RS|fa11534a-92f9-4887-828b-25b7637b8f57|1|NTLWIND|Non-Target Lesion Worsening Indicator|PCWG SCHER PROSTATE CANCER 2016|[?]|uL/kg/day|PSEUDOPROGRESSION|1|s/h|AUDIOMETRY||||SPOUSE|ENDOCRINOLOGIST|U|1|Visit_1|10|4|TREATMENT|2020-12-13|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-16|P1Y2M10DT2H30M|BEFORE|2020-12-22|BEFORE|2021-03-12
e|RS|fa11534a-92f9-4887-828b-25b7637b8f57|2|NEWLWIND|New Lesion Worsening Indicator|MRECIST BYRNE MESOTHELIOMA 2004|[?]|10^3 RNA copies/mL|PR WITH LYMPHOCYTOSIS|1|psi|HPLC/IEX||Y||CLINICAL STUDY SPONSOR|READER 2|Y|1|Visit_1|10|1|WASHOUT|2020-12-13|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-16|P1Y2M10DT2H30M|BEFORE|2020-12-31|COINCIDENT|2021-03-01
e|RS|fa11534a-92f9-4887-828b-25b7637b8f57|3|SPLNRESP|Spleen Response|PCWG SCHER PROSTATE CANCER 2016|[?]|FIU|PSEUDOPROGRESSION|1|fL|GC/FID|Y|||VENDOR|UROLOGIST|NA|2|Visit_2|25|3|TREATMENT|2020-12-28|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-22|P1Y2M10DT2H30M|COINCIDENT|2021-02-08|ONGOING|2021-02-09
e|RS|fa11534a-92f9-4887-828b-25b7637b8f57|4|BONERESP|Bone Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|Ci/L|MOLECULAR CR|1|g/day|KINYOUN STAIN||||PROXY|RADIOLOGIST|U|2|Visit_2|25|6|TREATMENT|2020-12-28|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-22|P1Y2M10DT2H30M|AFTER|2021-01-06|AFTER|2021-01-16
e|RS|fa11534a-92f9-4887-828b-25b7637b8f57|5|CYTORESP|Cytogenetic Response|AJCC V7|[?]|L/min/m2|iPR|1|CCID 50/mL|CLOT DETECTION||||NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 1|N|3|Visit_3|40|5|TREATMENT|2021-01-12|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-12|P1Y2M10DT2H30M|AFTER|2020-12-16|COINCIDENT|2021-01-16
e|RS|fa11534a-92f9-4887-828b-25b7637b8f57|6|CLINRESP|Clinical Response|UNSPECIFIED|[?]|pmol/g|EQUIVOCAL|1|/kg|AUTOREFRACTION|Y|Y||STUDY SUBJECT|PHYSIOTHERAPIST|N|3|Visit_3|40|2|TREATMENT|2021-01-12|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-12|P1Y2M10DT2H30M|UNKNOWN|2021-01-17|ONGOING|2021-02-04
e|RS|fa11534a-92f9-4887-828b-25b7637b8f57|7|DRCRIND|Disease Recurrence Indicator|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|pmol/10^10 cells|INDETERMINATE RESPONSE|1|QUANTITY SUFFICIENT|CAPILLARY ELECTROPHORESIS||Y||CLINICAL STUDY SPONSOR|HEMATOLOGIST|U|4|Visit_4|65|3|WASHOUT|2021-02-06|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-05|P1Y2M10DT2H30M|BEFORE|2021-02-26|COINCIDENT|2021-03-06
e|RS|fa11534a-92f9-4887-828b-25b7637b8f57|8|LIVRRESP|Liver Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|copies/uL|iSD|1|kHz|MALDI|Y|Y||SIGNIFICANT OTHER|READER|U|4|Visit_4|65|7|SCREENING|2021-02-06|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-05|P1Y2M10DT2H30M|COINCIDENT|2021-02-27|ONGOING|2021-03-03
e|RS|fa11534a-92f9-4887-828b-25b7637b8f57|9|OVRLRESP|Overall Response|MONTSERRAT CLL 1989|[?]|usec|iCR|1|ukat/L|NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY||||FAMILY MEMBER|NEUROLOGIST 2|NA|5|Visit_5|90|3|SCREENING|2021-03-03|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-01|P1Y2M10DT2H30M|AFTER|2021-02-01|BEFORE|2021-02-21
e|RS|fa11534a-92f9-4887-828b-25b7637b8f57|10|PATHRESP|Pathologic Response|MURPHY PROSTATE CANCER 1980|[?]|ELISA unit/dose|PR-CT|1|KIT|EPSILOMETER||||PARENT|ENDOCRINOLOGIST|NA|5|Visit_5|90|5|FOLLOW-UP|2021-03-03|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-01|P1Y2M10DT2H30M|BEFORE|2021-01-24|BEFORE|2021-03-10
e|RS|f305f7a3-8c8b-4eca-afb2-4a376f811170|1|NTLWIND|Non-Target Lesion Worsening Indicator|BRUGGEMANN MRD 2010|[?]|APL U/mL|PMR|1|Hz/s|ROMANOWSKY STAIN||Y||PARENT|NEUROLOGIST 2|NA|1|Visit_1|10|7|FOLLOW-UP|2020-10-04|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-06|P1Y2M10DT2H30M|UNKNOWN|2020-12-09|AFTER|2020-12-31
e|RS|f305f7a3-8c8b-4eca-afb2-4a376f811170|2|SFTSRESP|Soft Tissue Response|MONTSERRAT CLL 1989|||SD-CT|1|TROCHE|INCISION-INDUCED BLEEDING METHOD|Y||Y|STUDY SUBJECT|FORENSIC PATHOLOGIST|NA|1|Visit_1|10|2|WASHOUT|2020-10-04|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-06|P1Y2M10DT2H30M|UNKNOWN|2020-11-14|AFTER|2020-11-24
e|RS|f305f7a3-8c8b-4eca-afb2-4a376f811170|3|NEWLWIND|New Lesion Worsening Indicator|TSUKASAKI LEUKEMIA LYMPHOMA 2009|||PR WITH LYMPHOCYTOSIS|1|IU/g|SLIT LAMP|||Y|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 1|U|2|Visit_2|25|1|WASHOUT|2020-10-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-25|P1Y2M10DT2H30M|AFTER|2020-11-03|COINCIDENT|2020-12-31
e|RS|f305f7a3-8c8b-4eca-afb2-4a376f811170|4|STRUSTAT|Steroid Use Status|GUPPY OVARIAN CANCER 2002|||HI-E|1|umol/L/sec|IMMUNOCHROMATOGRAPHY|||Y|FRIEND|PATHOLOGIST 1|NA|2|Visit_2|25|6|TREATMENT|2020-10-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-25|P1Y2M10DT2H30M|AFTER|2020-11-25|AFTER|2020-12-23
e|RS|f305f7a3-8c8b-4eca-afb2-4a376f811170|5|CPRFSTAT|Clinical Performance Status|LUGANO CLASSIFICATION|[?]|PIPE|MOLECULAR MAJOR RESPONSE|1|g/cage/day|LIGHT SCATTERING SPECTROSCOPY|Y|||CAREGIVER|UROLOGIST|NA|3|Visit_3|40|6|TREATMENT|2020-11-03|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-07|P1Y2M10DT2H30M|AFTER|2020-12-01|ONGOING|2020-12-24
e|RS|f305f7a3-8c8b-4eca-afb2-4a376f811170|6|MRDRESP|Minimal Residual Disease Response|KUMAR IMWG 2016|[?]|mOsm/kg|nPR|1|pmol/dL|PERIODIC ACID SCHIFF STAIN||Y||INDEPENDENT ASSESSOR|PATHOLOGIST|NA|3|Visit_3|40|5|TREATMENT|2020-11-03|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-07|P1Y2M10DT2H30M|AFTER|2020-12-04|BEFORE|2020-12-13
e|RS|f305f7a3-8c8b-4eca-afb2-4a376f811170|7|NTNERESP|Non-Target Non-Enhancing Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|mg/kg/day|VGPR|1|10^6/g|OPTICAL MAPPING||||SIGNIFICANT OTHER|RADIOLOGIST 1|NA|4|Visit_4|65|6|TREATMENT|2020-11-28|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-09|P1Y2M10DT2H30M|UNKNOWN|2020-10-14|AFTER|2020-12-30
e|RS|f305f7a3-8c8b-4eca-afb2-4a376f811170|8|BONERESP|Bone Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|||PD FROM PR|1|tuberculin unit/mL|ULTRASONOGRAPHIC ELASTOGRAPHY|Y||Y|SIBLING|ONCOLOGIST|Y|4|Visit_4|65|6|TREATMENT|2020-11-28|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-09|P1Y2M10DT2H30M|UNKNOWN|2020-10-02|ONGOING|2020-12-31
e|RS|f305f7a3-8c8b-4eca-afb2-4a376f811170|9|SYMPTDTR|Symptomatic Deterioration|HARTMANN GERM CELL CANCER 2002|[?]|OD Unit|COMPLETE MRD RESPONSE|1|mL/sec/1.73m2|ELECTROPHORESIS||||GUARDIAN|MICROSCOPIST 1|U|5|Visit_5|90|1|TREATMENT|2020-12-23|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-14|P1Y2M10DT2H30M|UNKNOWN|2020-10-21|COINCIDENT|2020-11-06
e|RS|f305f7a3-8c8b-4eca-afb2-4a376f811170|10|SPLNRESP|Spleen Response|SCHER PROSTATE CANCER 2011|[?]|pt_br|iCPD|1|ug/cm2|MACRO BROTH DILUTION||||DOMESTIC PARTNER|MICROSCOPIST 2|U|5|Visit_5|90|7|TREATMENT|2020-12-23|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-14|P1Y2M10DT2H30M|AFTER|2020-09-26|COINCIDENT|2020-10-31
e|RS|6e4ed6b3-e419-464c-a40e-f100a6894baa|1|ANATRESP|Anatomic Response|GUILHOT CML 2007|[?]|DIP|CA125 50% RESPONSE|1|mg/L FEU|SLIT LAMP||||INTERVIEWER|MICROSCOPIST 2|U|1|Visit_1|10|3|FOLLOW-UP|2020-06-07|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-05|P1Y2M10DT2H30M|COINCIDENT|2020-08-05|AFTER|2020-09-04
e|RS|6e4ed6b3-e419-464c-a40e-f100a6894baa|2|SPLNRESP|Spleen Response|LUGANO CLASSIFICATION|||iCR|1|cg|MICRONEUTRALIZATION ASSAY|||Y|CLINICAL STUDY SPONSOR|NEUROLOGIST 2|Y|1|Visit_1|10|6|TREATMENT|2020-06-07|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-05|P1Y2M10DT2H30M|AFTER|2020-08-29|AFTER|2020-09-04
e|RS|6e4ed6b3-e419-464c-a40e-f100a6894baa|3|METBRESP|Metabolic Response|IWG CHESON AML 2003|[?]|fmol/L|PD/RELAPSE AFTER HI|1|/wk|SINGLE-MOLECULE ARRAY||||CHILD|MICROSCOPIST 2|Y|2|Visit_2|25|7|FOLLOW-UP|2020-06-22|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-23|P1Y2M10DT2H30M|BEFORE|2020-09-02|AFTER|2020-09-03
e|RS|6e4ed6b3-e419-464c-a40e-f100a6894baa|4|MJPTHIND|Major Pathological Response Indicator|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|mmol2/L2|PR WITH LYMPHOCYTOSIS|1|cd*s/m2|NUCLEIC ACID BASED METHOD|Y|||GUARDIAN|NEUROLOGIST|U|2|Visit_2|25|1|WASHOUT|2020-06-22|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-23|P1Y2M10DT2H30M|BEFORE|2020-08-13|ONGOING|2020-08-22
e|RS|6e4ed6b3-e419-464c-a40e-f100a6894baa|5|NEWLIND|New Lesion Indicator|SCHER PROSTATE CANCER 2011|[?]|TRANSDUCING UNIT/mL|PSA PROGRESSION|1|log10 TCID 50/mL|NEPHELOMETRY||||CLINICAL RESEARCH COORDINATOR|CLINICAL PATHOLOGIST|N|3|Visit_3|40|2|TREATMENT|2020-07-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-25|P1Y2M10DT2H30M|UNKNOWN|2020-08-20|BEFORE|2020-08-23
e|RS|6e4ed6b3-e419-464c-a40e-f100a6894baa|6|NTRGRESP|Non-target Response|PCWG BUBLEY PROSTATE CANCER 1999|||CA125 75% RESPONSE|1|/kg|PERIODIC ACID SCHIFF STAIN|||Y|INDEPENDENT ASSESSOR|ADJUDICATOR|NA|3|Visit_3|40|7|FOLLOW-UP|2020-07-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-25|P1Y2M10DT2H30M|UNKNOWN|2020-07-12|COINCIDENT|2020-08-11
e|RS|6e4ed6b3-e419-464c-a40e-f100a6894baa|7|MRDRESP|Minimal Residual Disease Response|CHOI GIST 2008|[?]|uL/kg/day|PD-CT|1|USP U|PERIODIC ACID SCHIFF STAIN|Y|||DOMESTIC PARTNER|NEUROLOGIST 2|U|4|Visit_4|65|3|TREATMENT|2020-08-01|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-11|P1Y2M10DT2H30M|BEFORE|2020-08-22|ONGOING|2020-08-30
e|RS|6e4ed6b3-e419-464c-a40e-f100a6894baa|8|NTNERESP|Non-Target Non-Enhancing Response|iRECIST|||IMPROVED|1|DPM|NO INFORMATION||Y|Y|PARENT|READER 3|NA|4|Visit_4|65|7|WASHOUT|2020-08-01|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-11|P1Y2M10DT2H30M|BEFORE|2020-09-02|BEFORE|2020-09-03
e|RS|6e4ed6b3-e419-464c-a40e-f100a6894baa|9|CYTORESP|Cytogenetic Response|SHINDOH COLORECTAL CANCER 2013|||iCR|1|mmol/L|COLORIMETRY|||Y|FAMILY MEMBER|MICROSCOPIST 2|NA|5|Visit_5|90|1|SCREENING|2020-08-26|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-19|P1Y2M10DT2H30M|COINCIDENT|2020-08-11|ONGOING|2020-08-31
e|RS|6e4ed6b3-e419-464c-a40e-f100a6894baa|10|BMIVLIND|Bone Marrow Involvement Indicator|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|ug/mol|CYTOGENETIC MINIMAL RESPONSE|1|vg/dose|HIGH RESOLUTION MELT ANALYSIS||||HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|U|5|Visit_5|90|7|FOLLOW-UP|2020-08-26|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-19|P1Y2M10DT2H30M|COINCIDENT|2020-06-17|ONGOING|2020-09-02
e|RS|1e5e6ccc-a4b2-4aec-8048-988d1708caf0|1|TMRESP|Tumor Marker Response|LUGANO CLASSIFICATION|[?]|PNU/mL|UNFAVORABLE RESPONSE|1|copies/mL|ELECTROPHORESIS|Y|||INTERVIEWER|PATHOLOGIST 1|N|1|Visit_1|10|7|TREATMENT|2020-08-08|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-09|P1Y2M10DT2H30M|AFTER|2020-08-16|AFTER|2020-09-06
e|RS|1e5e6ccc-a4b2-4aec-8048-988d1708caf0|2|NTRGRESP|Non-target Response|IWG CHESON AML 2003|[?]|U/g/day|PDu|1|ug|PERFUSION MRI||||FRIEND|MICROSCOPIST 3|NA|1|Visit_1|10|3|WASHOUT|2020-08-08|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-09|P1Y2M10DT2H30M|AFTER|2020-08-09|COINCIDENT|2020-11-03
e|RS|1e5e6ccc-a4b2-4aec-8048-988d1708caf0|3|PATHRESP|Pathologic Response|IWG CHESON AML 2003|[?]|BOTTLE|FAVORABLE RESPONSE|1|U/m2|CELL BASED BIOASSAY||||SIGNIFICANT OTHER|INTERNIST|Y|2|Visit_2|25|2|TREATMENT|2020-08-23|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-09|P1Y2M10DT2H30M|AFTER|2020-08-06|ONGOING|2020-09-04
e|RS|1e5e6ccc-a4b2-4aec-8048-988d1708caf0|4|BESTRESP|Best Overall Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|pmol/dL|MRD RELAPSE|1|mol/mL|GC/FID||||FAMILY MEMBER|PATHOLOGIST 2|Y|2|Visit_2|25|2|TREATMENT|2020-08-23|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-09|P1Y2M10DT2H30M|AFTER|2020-10-16|BEFORE|2020-10-20
e|RS|1e5e6ccc-a4b2-4aec-8048-988d1708caf0|5|MOLRESP|Molecular Response|CHESON LYMPHOMA 2008|[?]|ug/L FEU|CA125 50% RESPONSE|1|umol/h/mmol|WRIGHT STAIN||||PROXY|READER|NA|3|Visit_3|40|6|TREATMENT|2020-09-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-16|P1Y2M10DT2H30M|AFTER|2020-08-09|ONGOING|2020-09-26
e|RS|1e5e6ccc-a4b2-4aec-8048-988d1708caf0|6|MRDIND|Minimal Residual Disease Indicator|RANO ELLINGSON 2017|[?]|IMPLANT|INCREASED|1|Ci/ug|IN VITRO GENE EXPRESSION ASSAY||||CHILD|NEUROLOGIST 2|NA|3|Visit_3|40|2|SCREENING|2020-09-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-16|P1Y2M10DT2H30M|AFTER|2020-08-04|ONGOING|2020-08-16
e|RS|1e5e6ccc-a4b2-4aec-8048-988d1708caf0|7|NTLWIND|Non-Target Lesion Worsening Indicator|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|U/g Hb|NON-QUANTIFIABLE MRD POSITIVITY|1|breaths/min|JAEGER EYE CHART||||FRIEND|MICROSCOPIST|N|4|Visit_4|65|6|TREATMENT|2020-10-02|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-01|P1Y2M10DT2H30M|BEFORE|2020-10-05|BEFORE|2020-11-04
e|RS|1e5e6ccc-a4b2-4aec-8048-988d1708caf0|8|MNPTHIND|Minor Pathological Response Indicator|RECIST 1.0|||ABSENT MORPHOLOGIC RESPONSE|1|ug/animal|OPTICAL DENSITY MEASUREMENT||Y|Y|CHILD|UROLOGIST|N|4|Visit_4|65|3|TREATMENT|2020-10-02|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-01|P1Y2M10DT2H30M|COINCIDENT|2020-09-15|AFTER|2020-10-24
e|RS|1e5e6ccc-a4b2-4aec-8048-988d1708caf0|9|BMIVLIND|Bone Marrow Involvement Indicator|RANO|[?]|10^10/L|CA125 50% RESPONSE|1|/LSQN|REBOUND TONOMETRY||Y||VENDOR|OPTOMETRIST|Y|5|Visit_5|90|7|TREATMENT|2020-10-27|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-27|P1Y2M10DT2H30M|BEFORE|2020-08-20|AFTER|2020-10-09
e|RS|1e5e6ccc-a4b2-4aec-8048-988d1708caf0|10|METBRESP|Metabolic Response|AJCC V8|[?]|DPM|EQUIVOCAL|1|/40 HPFs|TRANSMISSION ELECTRON MICROSCOPY||Y||CLINICAL STUDY SPONSOR|RATER|U|5|Visit_5|90|3|TREATMENT|2020-10-27|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-27|P1Y2M10DT2H30M|COINCIDENT|2020-08-13|COINCIDENT|2020-11-03
e|RS|5d25ac6d-428d-41eb-9549-c23df035a54e|1|TMRESP|Tumor Marker Response|IWC HALLEK CLL 2008|||MORPHOLOGIC CRi|1|/LPF|NON-CONTACT SPECULAR MICROSCOPY|Y||Y|INDEPENDENT ASSESSOR|FORENSIC PATHOLOGIST|U|1|Visit_1|10|4|WASHOUT|2020-05-13|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-12|P1Y2M10DT2H30M|COINCIDENT|2020-05-05|AFTER|2020-06-08
e|RS|5d25ac6d-428d-41eb-9549-c23df035a54e|2|METSIND|Metastatic Indicator|LEE LUNG CANCER 2011|[?]|ugEq/L|NON-PD|1|DAgU/mL|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY||||ADJUDICATOR|ENDOCRINOLOGIST|NA|1|Visit_1|10|6|FOLLOW-UP|2020-05-13|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-12|P1Y2M10DT2H30M|COINCIDENT|2020-06-30|ONGOING|2020-07-01
e|RS|5d25ac6d-428d-41eb-9549-c23df035a54e|3|TRGRESP|Target Response|RAJKUMAR MYELOMA 2011|[?]|log EID 50/dose|OPTIMAL MORPHOLOGIC RESPONSE|1|U/g/min|NEXT GENERATION TARGETED SEQUENCING||||ADJUDICATOR|UROLOGIST|Y|2|Visit_2|25|4|SCREENING|2020-05-28|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-11|P1Y2M10DT2H30M|UNKNOWN|2020-07-01|BEFORE|2020-07-10
e|RS|5d25ac6d-428d-41eb-9549-c23df035a54e|4|NEWLIND|New Lesion Indicator|IWG CHESON MDS 2006|[?]|log10 IU/mL|RELAPSED DISEASE FROM CR OR PR|1|cal|IMMUNOTURBIDIMETRY|Y|||PARENT|UROLOGIST|NA|2|Visit_2|25|2|TREATMENT|2020-05-28|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-11|P1Y2M10DT2H30M|BEFORE|2020-07-20|BEFORE|2020-07-21
e|RS|5d25ac6d-428d-41eb-9549-c23df035a54e|5|NTERESP|Non-Target Enhancing Response|KUKER LYMPHOMA 2005|[?]|mL/min/mmHg|PMR|1|JDF Unit|HIGH LEVEL AMINOGLYCOSIDE SCREEN||||INDEPENDENT ASSESSOR|READER 2|Y|3|Visit_3|40|6|SCREENING|2020-06-12|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-21|P1Y2M10DT2H30M|BEFORE|2020-06-14|BEFORE|2020-08-04
e|RS|5d25ac6d-428d-41eb-9549-c23df035a54e|6|TRGRESP|Target Response|EBMT BLADE MYELOMA 1998|[?]|RNA copies/mL|PD|1|mmol2/L2|DOUBLE IMMUNODIFFUSION|Y|||SPOUSE|NEUROLOGIST 1|Y|3|Visit_3|40|1|TREATMENT|2020-06-12|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-21|P1Y2M10DT2H30M|COINCIDENT|2020-06-17|ONGOING|2020-07-30
e|RS|5d25ac6d-428d-41eb-9549-c23df035a54e|7|NEWLPROG|New Lesion Progression|MACDONALD GLIOMA 1990|[?]|EID 50/dose|CR-CT|1|mL/m2/day|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY|Y|||VENDOR|PHYSIOTHERAPIST|NA|4|Visit_4|65|1|TREATMENT|2020-07-07|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-01|P1Y2M10DT2H30M|BEFORE|2020-05-27|ONGOING|2020-06-20
e|RS|5d25ac6d-428d-41eb-9549-c23df035a54e|8|NTRGRESP|Non-target Response|PCWG BUBLEY PROSTATE CANCER 1999|||CR|1|COAT|SXA SCAN|||Y|INTERVIEWER|ONCOLOGIST 2|Y|4|Visit_4|65|3|FOLLOW-UP|2020-07-07|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-01|P1Y2M10DT2H30M|COINCIDENT|2020-06-18|COINCIDENT|2020-06-21
e|RS|5d25ac6d-428d-41eb-9549-c23df035a54e|9|ANATRESP|Anatomic Response|KEAM BREAST CANCER 2013|[?]|Bq|CR|1|10^6 CFU/g|MECHANICAL CLOT DETECTION||||INDEPENDENT ASSESSOR|MICROSCOPIST 1|U|5|Visit_5|90|4|TREATMENT|2020-08-01|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-06|P1Y2M10DT2H30M|AFTER|2020-07-12|COINCIDENT|2020-07-27
e|RS|5d25ac6d-428d-41eb-9549-c23df035a54e|10|SPLNRESP|Spleen Response|LUGANO CLASSIFICATION|||PSEUDOPROGRESSION|1|mg/dose|LISSAMINE GREEN STAIN|||Y|SPOUSE|RATER|Y|5|Visit_5|90|2|TREATMENT|2020-08-01|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-06|P1Y2M10DT2H30M|COINCIDENT|2020-05-25|AFTER|2020-08-06
e|RS|7d7dde17-c060-4ad3-9821-6faa49ddd1b2|1|ANATRESP|Anatomic Response|MASS|[?]|10^4/hpf|HI-E|1|ug/dL|ARTERIAL SPIN LABELING FUNCTIONAL MRI|Y|Y||FAMILY MEMBER|PATHOLOGIST 2|Y|1|Visit_1|10|2|TREATMENT|2020-10-30|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-04|P1Y2M10DT2H30M|UNKNOWN|2021-01-13|COINCIDENT|2021-01-25
e|RS|7d7dde17-c060-4ad3-9821-6faa49ddd1b2|2|NTERESP|Non-Target Enhancing Response|DOHNER AML 2010|[?]|um2|MORPHOLOGIC CR|1|RFU|OPTICAL DENSITY MEASUREMENT||Y||SPOUSE|ONCOLOGIST|NA|1|Visit_1|10|3|TREATMENT|2020-10-30|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-04|P1Y2M10DT2H30M|BEFORE|2021-01-22|ONGOING|2021-01-24
e|RS|7d7dde17-c060-4ad3-9821-6faa49ddd1b2|3|PATHRESP|Pathologic Response|DURIE MULTIPLE MYELOMA 2006|[?]|g/animal|MORPHOLOGIC LEUKEMIA-FREE STATE|1|min|FLUORESCENT MICROSCOPY||||INDEPENDENT ASSESSOR|RADIOLOGIST 1|U|2|Visit_2|25|1|TREATMENT|2020-11-14|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-23|P1Y2M10DT2H30M|AFTER|2020-11-11|ONGOING|2021-01-20
e|RS|7d7dde17-c060-4ad3-9821-6faa49ddd1b2|4|MNPTHIND|Minor Pathological Response Indicator|IRANO 2015|[?]|cm/min|sCR|1|ohm|BRDU CELLULAR PROLIFERATION ASSAY||||CAREGIVER|ONCOLOGIST 2|N|2|Visit_2|25|5|FOLLOW-UP|2020-11-14|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-23|P1Y2M10DT2H30M|COINCIDENT|2020-12-31|ONGOING|2021-01-24
e|RS|7d7dde17-c060-4ad3-9821-6faa49ddd1b2|5|NEWLPROG|New Lesion Progression|AJCC V8|[?]|cm2|CYTOGENETIC MINIMAL RESPONSE|1|BISCUIT|MICRONEUTRALIZATION ASSAY||Y||CAREGIVER|PEDIATRIC NEUROLOGIST|NA|3|Visit_3|40|4|SCREENING|2020-11-29|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-29|P1Y2M10DT2H30M|AFTER|2020-11-28|ONGOING|2020-12-04
e|RS|7d7dde17-c060-4ad3-9821-6faa49ddd1b2|6|STRUSTAT|Steroid Use Status|RECIST 1.1|||NON-iCR/NON-iUPD|1|ft3|QUANTITATIVE ULTRASOUND||Y|Y|VENDOR|UROLOGIST|Y|3|Visit_3|40|4|TREATMENT|2020-11-29|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-29|P1Y2M10DT2H30M|AFTER|2020-11-08|AFTER|2021-01-21
e|RS|7d7dde17-c060-4ad3-9821-6faa49ddd1b2|7|NEWLWIND|New Lesion Worsening Indicator|iRECIST|[?]|%(w/w)|PARTIAL MORPHOLOGIC RESPONSE|1|mol/g|IMMUNOTURBIDIMETRY||Y||CHILD|RATER 2|NA|4|Visit_4|65|5|SCREENING|2020-12-24|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-18|P1Y2M10DT2H30M|BEFORE|2020-11-13|ONGOING|2020-12-16
e|RS|7d7dde17-c060-4ad3-9821-6faa49ddd1b2|8|TMRESP|Tumor Marker Response|WOLCHOK SOLID TUMORS 2009|[?]|AFU|HI-E|1|g/animal/wk|POLYMERASE CHAIN REACTION|Y|||INTERVIEWER|DERMATOLOGIST|NA|4|Visit_4|65|3|TREATMENT|2020-12-24|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-18|P1Y2M10DT2H30M|BEFORE|2021-01-18|ONGOING|2021-01-22
e|RS|7d7dde17-c060-4ad3-9821-6faa49ddd1b2|9|SYMPTDTR|Symptomatic Deterioration|MRECIST LENCIONI LIVER CANCER 2010|[?]|g|CR-CT|1|/mm|NEPHELOMETRY|Y|||NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST 2|NA|5|Visit_5|90|7|TREATMENT|2021-01-18|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-16|P1Y2M10DT2H30M|AFTER|2020-12-08|AFTER|2020-12-19
e|RS|7d7dde17-c060-4ad3-9821-6faa49ddd1b2|10|OVRLRESP|Overall Response|WHO BREAST CANCER 2006|[?]|HOMEOPATHIC DILUTION|NON-iCR/NON-iUPD|1|Bq/L|U-HPLC/MS/MS||||INVESTIGATOR|ONCOLOGIST|N|5|Visit_5|90|3|SCREENING|2021-01-18|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-16|P1Y2M10DT2H30M|AFTER|2020-12-23|AFTER|2020-12-25
e|RS|173aea61-964d-4f4a-8d48-56a1a58de6d8|1|NTRGRESP|Non-target Response|RANO|[?]|dpm/0.5 mL|CRi|1|U/m2/min|TONOMETRY||||HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|U|1|Visit_1|10|2|WASHOUT|2020-10-13|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-18|P1Y2M10DT2H30M|COINCIDENT|2021-01-07|ONGOING|2021-01-08
e|RS|173aea61-964d-4f4a-8d48-56a1a58de6d8|2|MRDIND|Minimal Residual Disease Indicator|LEE LUNG CANCER 2011|[?]|DAgU|EQUIVOCAL|1|uL/mL|MICRONEUTRALIZATION ASSAY||||ADJUDICATION COMMITTEE|PATHOLOGIST 2|U|1|Visit_1|10|6|SCREENING|2020-10-13|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-18|P1Y2M10DT2H30M|BEFORE|2020-10-14|COINCIDENT|2020-10-17
e|RS|173aea61-964d-4f4a-8d48-56a1a58de6d8|3|TMRESP|Tumor Marker Response|WOLCHOK SOLID TUMORS 2009|[?]|IU/mg|DECREASED|1|10^9 organisms/mL|OBSERVATION||||ADJUDICATOR|OTOLARYNGOLOGIST|N|2|Visit_2|25|6|FOLLOW-UP|2020-10-28|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-08|P1Y2M10DT2H30M|AFTER|2020-12-07|BEFORE|2020-12-15
e|RS|173aea61-964d-4f4a-8d48-56a1a58de6d8|4|CYTORESP|Cytogenetic Response|RANO ELLINGSON 2017|[?]|mOsm/kg|HI-N|1|/sec|LIGHT MICROSCOPY|Y|||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|U|2|Visit_2|25|7|TREATMENT|2020-10-28|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-08|P1Y2M10DT2H30M|BEFORE|2020-12-09|BEFORE|2020-12-12
e|RS|173aea61-964d-4f4a-8d48-56a1a58de6d8|5|NEWLWIND|New Lesion Worsening Indicator|IRANO 2015|||pCR|1|GPL U/mL|ISHIHARA COLOR PLATES|||Y|ADJUDICATION COMMITTEE|INTERNIST|NA|3|Visit_3|40|6|FOLLOW-UP|2020-11-12|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-11|P1Y2M10DT2H30M|BEFORE|2020-11-22|BEFORE|2020-12-12
e|RS|173aea61-964d-4f4a-8d48-56a1a58de6d8|6|BMIVLIND|Bone Marrow Involvement Indicator|MONTSERRAT CLL 1989|||PD|1|mL/min/mmHg|GRADIENT DIFFUSION|||Y|PROXY|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|3|Visit_3|40|5|TREATMENT|2020-11-12|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-11|P1Y2M10DT2H30M|COINCIDENT|2020-10-27|COINCIDENT|2020-11-25
e|RS|173aea61-964d-4f4a-8d48-56a1a58de6d8|7|NTNERESP|Non-Target Non-Enhancing Response|GUPPY OVARIAN CANCER 2002|||CYTOGENETIC PR|1|Bq/mg|MICROBIAL CONCENTRATION|Y||Y|CLINICAL RESEARCH ASSOCIATE|ONCOLOGIST 2|U|4|Visit_4|65|5|FOLLOW-UP|2020-12-07|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-10|P1Y2M10DT2H30M|AFTER|2020-11-14|ONGOING|2021-01-10
e|RS|173aea61-964d-4f4a-8d48-56a1a58de6d8|8|NTRGRESP|Non-target Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|10^6 CFU/mL|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|Henry|SNELLEN EYE CHART|Y|||DOMESTIC PARTNER|ONCOLOGIST 1|U|4|Visit_4|65|4|FOLLOW-UP|2020-12-07|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-10|P1Y2M10DT2H30M|UNKNOWN|2020-12-21|BEFORE|2021-01-03
e|RS|173aea61-964d-4f4a-8d48-56a1a58de6d8|9|DRCRIND|Disease Recurrence Indicator|CHESON CLL 2006|[?]|mg/dL|PR WITH LYMPHOCYTOSIS|1|mL/min|GC/MS-EI|Y|Y||CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 1|NA|5|Visit_5|90|1|FOLLOW-UP|2021-01-01|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-05|P1Y2M10DT2H30M|BEFORE|2020-12-16|BEFORE|2020-12-21
e|RS|173aea61-964d-4f4a-8d48-56a1a58de6d8|10|MRDIND|Minimal Residual Disease Indicator|CHESON LYMPHOMA 2008|||cCR|1|Ci/g|TRANSMISSION ELECTRON MICROSCOPY||Y|Y|HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|Y|5|Visit_5|90|4|TREATMENT|2021-01-01|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-05|P1Y2M10DT2H30M|AFTER|2020-12-30|AFTER|2021-01-02
e|RS|45d1adb8-9b3b-4f06-87cb-740205448680|1|SFTSRESP|Soft Tissue Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|mL/animal/day|PSA PROGRESSION|1|mOsm/kg|EIA||||NON-HEALTH CARE PROFESSIONAL|HEMATOLOGIST|Y|1|Visit_1|10|6|WASHOUT|2020-07-17|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-09|P1Y2M10DT2H30M|AFTER|2020-08-02|COINCIDENT|2020-09-23
e|RS|45d1adb8-9b3b-4f06-87cb-740205448680|2|NEWLIND|New Lesion Indicator|HARTMAN PANCREATIC CANCER 2012|[?]|PIXELS/in|MAJOR PATHOLOGIC RESPONSE|1|%|LASER CAPTURE MICRODISSECTION||||STUDY SUBJECT|CARDIOLOGIST|Y|1|Visit_1|10|6|WASHOUT|2020-07-17|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-09|P1Y2M10DT2H30M|UNKNOWN|2020-09-21|BEFORE|2020-10-10
e|RS|45d1adb8-9b3b-4f06-87cb-740205448680|3|CLINRESP|Clinical Response|RECIST 1.0|[?]|BAU|CYTOGENETIC PR|1|fmol/g|CONTRAST ENHANCED X-RAY||||CLINICAL RESEARCH ASSOCIATE|FORENSIC PATHOLOGIST|N|2|Visit_2|25|4|FOLLOW-UP|2020-08-01|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-16|P1Y2M10DT2H30M|UNKNOWN|2020-10-08|ONGOING|2020-10-12
e|RS|45d1adb8-9b3b-4f06-87cb-740205448680|4|SPLNRESP|Spleen Response|MASS|[?]|cup eq|DECREASED|1|NFIU|KINETIC CHROMOGENIC ASSAY||Y||SIGNIFICANT OTHER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|2|Visit_2|25|1|WASHOUT|2020-08-01|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-16|P1Y2M10DT2H30M|UNKNOWN|2020-07-16|COINCIDENT|2020-08-12
e|RS|45d1adb8-9b3b-4f06-87cb-740205448680|5|METBRESP|Metabolic Response|PALUMBO MULTIPLE MYELOMA 2009|||PSEUDOPROGRESSION|1|mL/h|RAJI CELL EIA|||Y|ADJUDICATION COMMITTEE|READER 1|U|3|Visit_3|40|1|WASHOUT|2020-08-16|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-29|P1Y2M10DT2H30M|UNKNOWN|2020-09-15|COINCIDENT|2020-09-17
e|RS|45d1adb8-9b3b-4f06-87cb-740205448680|6|NTRGRESP|Non-target Response|SCHER PROSTATE CANCER 2011|[?]|10^9 organisms/mg|PMR|1|mL/cm3/min|COMPLEMENT FIXATION|Y|||FAMILY MEMBER|MICROSCOPIST 3|N|3|Visit_3|40|2|TREATMENT|2020-08-16|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-29|P1Y2M10DT2H30M|UNKNOWN|2020-09-08|COINCIDENT|2020-10-03
e|RS|45d1adb8-9b3b-4f06-87cb-740205448680|7|NEWLWIND|New Lesion Worsening Indicator|MRANO VAN DEN BENT GLIOMA 2011|||NON-QUANTIFIABLE MRD POSITIVITY|1|BP|TARGETED TRANSCRIPTOME SEQUENCING|||Y|INDEPENDENT ASSESSOR|RATER 1|U|4|Visit_4|65|3|WASHOUT|2020-09-10|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-25|P1Y2M10DT2H30M|COINCIDENT|2020-08-24|ONGOING|2020-09-03
e|RS|45d1adb8-9b3b-4f06-87cb-740205448680|8|SFTSRESP|Soft Tissue Response|CHESON CLL 2012|[?]|10^7 CFU|PSEUDORESPONSE|1|cd*s/m2|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY||||CHILD|ADJUDICATOR 1|U|4|Visit_4|65|3|FOLLOW-UP|2020-09-10|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-25|P1Y2M10DT2H30M|UNKNOWN|2020-08-24|AFTER|2020-09-12
e|RS|45d1adb8-9b3b-4f06-87cb-740205448680|9|OVRLRESP|Overall Response|SCHWARZ CERVICAL CANCER 2009|[?]|mL/sec/1.73m2|INCREASED|1|cy/cm|RIA||||CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 2|Y|5|Visit_5|90|6|TREATMENT|2020-10-05|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-14|P1Y2M10DT2H30M|COINCIDENT|2020-07-11|COINCIDENT|2020-09-13
e|RS|45d1adb8-9b3b-4f06-87cb-740205448680|10|HEMARESP|Hematologic Response|NCCN ALL MRD 2014|||PD|1|lm|CALCULATION||Y|Y|PROXY|ONCOLOGIST 2|N|5|Visit_5|90|5|WASHOUT|2020-10-05|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-14|P1Y2M10DT2H30M|UNKNOWN|2020-08-01|COINCIDENT|2020-08-28
e|RS|7403ad67-7ed5-4716-a874-c360429845bc|1|SYMPTDTR|Symptomatic Deterioration|PERCIST|||SD-CT|1|log10 TCID 50/dose|CELL CYTOTOXICITY NEUTRALIZATION ASSAY|||Y|INDEPENDENT ASSESSOR|ADJUDICATOR 2|U|1|Visit_1|10|4|TREATMENT|2020-05-30|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-07|P1Y2M10DT2H30M|UNKNOWN|2020-07-10|BEFORE|2020-08-23
e|RS|7403ad67-7ed5-4716-a874-c360429845bc|2|SPLNRESP|Spleen Response|BLAZER COLORECTAL CANCER 2008|[?]|Mile|EQUIVOCAL|1|10^6 CFU/mL|STATIC PERIMETRY|Y|||CHILD|ADJUDICATOR 2|N|1|Visit_1|10|3|FOLLOW-UP|2020-05-30|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-07|P1Y2M10DT2H30M|COINCIDENT|2020-08-14|ONGOING|2020-08-17
e|RS|7403ad67-7ed5-4716-a874-c360429845bc|3|SPLNRESP|Spleen Response|MONTSERRAT CLL 1989|[?]|cg|NON-PD|1|deg|NO INFORMATION||||VENDOR|ADJUDICATOR 2|N|2|Visit_2|25|3|WASHOUT|2020-06-14|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-29|P1Y2M10DT2H30M|COINCIDENT|2020-06-15|BEFORE|2020-08-09
e|RS|7403ad67-7ed5-4716-a874-c360429845bc|4|TMRESP|Tumor Marker Response|FAROOQUI SUPP CLL 2014|[?]|mg/m2/day|NON-CR/NON-PD|1|copies/mL|IVY INCISION METHOD||Y||STUDY SUBJECT|RADIOLOGIST|NA|2|Visit_2|25|5|TREATMENT|2020-06-14|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-29|P1Y2M10DT2H30M|BEFORE|2020-06-14|ONGOING|2020-08-09
e|RS|7403ad67-7ed5-4716-a874-c360429845bc|5|MOLRESP|Molecular Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|mkat|HI-N|1|MONTHS|THICK SMEAR|Y|||INVESTIGATOR|RATER|NA|3|Visit_3|40|5|FOLLOW-UP|2020-06-29|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-21|P1Y2M10DT2H30M|BEFORE|2020-07-14|COINCIDENT|2020-08-10
e|RS|7403ad67-7ed5-4716-a874-c360429845bc|6|LIVRRESP|Liver Response|PCWG SCHER PROSTATE CANCER 2016|||MAJOR PATHOLOGIC RESPONSE|1|SCOOPFUL|FLUORIMETRY|||Y|ADJUDICATOR|ONCOLOGIST|Y|3|Visit_3|40|4|TREATMENT|2020-06-29|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-21|P1Y2M10DT2H30M|AFTER|2020-07-31|AFTER|2020-08-18
e|RS|7403ad67-7ed5-4716-a874-c360429845bc|7|NTNERESP|Non-Target Non-Enhancing Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|pmol/10^9 cells|STABLE|1|pmol/L|TEMPLATE INCISION METHOD||||STUDY SUBJECT|PATHOLOGIST|Y|4|Visit_4|65|6|TREATMENT|2020-07-24|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-28|P1Y2M10DT2H30M|AFTER|2020-06-23|COINCIDENT|2020-07-06
e|RS|7403ad67-7ed5-4716-a874-c360429845bc|8|NEWLWIND|New Lesion Worsening Indicator|BURCOMBE BREAST CANCER 2005|[?]|10^9 organisms/g|PD|1|g/kg|ETDRS EYE CHART|Y|Y||STUDY SUBJECT|MICROSCOPIST|N|4|Visit_4|65|4|TREATMENT|2020-07-24|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-28|P1Y2M10DT2H30M|AFTER|2020-06-22|AFTER|2020-08-02
e|RS|7403ad67-7ed5-4716-a874-c360429845bc|9|TMRESP|Tumor Marker Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|mol/mL|INCREASED|1|%/s|IMMUNOFIXATION ELECTROPHORESIS|Y|||GUARDIAN|OPTOMETRIST|NA|5|Visit_5|90|2|SCREENING|2020-08-18|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-02|P1Y2M10DT2H30M|UNKNOWN|2020-07-29|BEFORE|2020-08-18
e|RS|7403ad67-7ed5-4716-a874-c360429845bc|10|MJPTHIND|Major Pathological Response Indicator|GCIG RUSTIN OVARIAN CANCER 2011|||EQUIVOCAL|1|PELLET|FUNCTIONAL MRI||Y|Y|ADJUDICATOR|MICROSCOPIST 3|N|5|Visit_5|90|5|TREATMENT|2020-08-18|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-02|P1Y2M10DT2H30M|AFTER|2020-07-22|ONGOING|2020-08-19
e|RS|8be919ce-34da-4e49-ac7a-3679c7af632d|1|MOLRESP|Molecular Response|GUILHOT CML 2007|[?]|LENS|pCR|1|kBq/uL|WHOLE TRANSCRIPTOME SEQUENCING|Y|||FAMILY MEMBER|DEVELOPMENTAL PSYCHOLOGIST|N|1|Visit_1|10|7|TREATMENT|2021-01-13|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-21|P1Y2M10DT2H30M|UNKNOWN|2021-02-03|ONGOING|2021-03-28
e|RS|8be919ce-34da-4e49-ac7a-3679c7af632d|2|NTRGRESP|Non-target Response|iRECIST|[?]|log10 CFU/mL|INDETERMINATE RESPONSE|1|m/sec2|SPIRAL CT SCAN WITHOUT CONTRAST||Y||FAMILY MEMBER|DERMATOLOGIST|U|1|Visit_1|10|1|TREATMENT|2021-01-13|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-21|P1Y2M10DT2H30M|AFTER|2021-03-05|BEFORE|2021-04-10
e|RS|8be919ce-34da-4e49-ac7a-3679c7af632d|3|LIVRRESP|Liver Response|iRECIST|[?]|mL/beat|HI-N|1|DRINK|TRIPLE-PHASE SPIRAL CT SCAN||||STUDY SUBJECT|RADIOLOGIST 1|U|2|Visit_2|25|5|TREATMENT|2021-01-28|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-12|P1Y2M10DT2H30M|COINCIDENT|2021-02-08|COINCIDENT|2021-02-14
e|RS|8be919ce-34da-4e49-ac7a-3679c7af632d|4|NEWLIND|New Lesion Indicator|KUKER LYMPHOMA 2005|[?]|BEAM BREAKS|CYTOGENETIC MINIMAL RESPONSE|1|/10^5|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI||||SIBLING|ONCOLOGIST|N|2|Visit_2|25|3|FOLLOW-UP|2021-01-28|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-12|P1Y2M10DT2H30M|AFTER|2021-02-02|ONGOING|2021-02-23
e|RS|8be919ce-34da-4e49-ac7a-3679c7af632d|5|NTNERESP|Non-Target Non-Enhancing Response|RAJKUMAR MYELOMA 2011|[?]|kV|SD-CT|1|PRESSOR UNITS|SPECT SCAN||||NON-HEALTH CARE PROFESSIONAL|HEMATOLOGIST|Y|3|Visit_3|40|4|TREATMENT|2021-02-12|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-27|P1Y2M10DT2H30M|COINCIDENT|2021-03-07|ONGOING|2021-04-10
e|RS|8be919ce-34da-4e49-ac7a-3679c7af632d|6|TMRESP|Tumor Marker Response|GUPPY OVARIAN CANCER 2002|[?]|mg/mL/day|MORPHOLOGIC CR|1|mOsm/L|FUNCTIONAL MRI|Y|||CHILD|PEDIATRIC NEUROLOGIST|N|3|Visit_3|40|5|WASHOUT|2021-02-12|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-27|P1Y2M10DT2H30M|AFTER|2021-02-02|BEFORE|2021-02-15
e|RS|8be919ce-34da-4e49-ac7a-3679c7af632d|7|PATHRESP|Pathologic Response|BRUGGEMANN MRD 2010|[?]|mL/animal/day|FAVORABLE RESPONSE|1|tuberculin unit|QUANTITATIVE CORONARY ANGIOGRAPHY||||STUDY SUBJECT|NEUROLOGIST 1|U|4|Visit_4|65|3|WASHOUT|2021-03-09|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-10|P1Y2M10DT2H30M|UNKNOWN|2021-01-26|BEFORE|2021-04-09
e|RS|8be919ce-34da-4e49-ac7a-3679c7af632d|8|LIVRRESP|Liver Response|RECIST 1.0|||PD FROM PR|1|PNU/mL|CLINICAL EVALUATION|||Y|CAREGIVER|RATER 2|NA|4|Visit_4|65|1|WASHOUT|2021-03-09|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-10|P1Y2M10DT2H30M|COINCIDENT|2021-01-08|BEFORE|2021-02-28
e|RS|8be919ce-34da-4e49-ac7a-3679c7af632d|9|METSIND|Metastatic Indicator|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|Torr|NON-PD|1|mL/cm3/min|MACRO BROTH DILUTION|Y|Y||SIGNIFICANT OTHER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5|Visit_5|90|4|TREATMENT|2021-04-03|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-19|P1Y2M10DT2H30M|COINCIDENT|2021-02-21|AFTER|2021-03-21
e|RS|8be919ce-34da-4e49-ac7a-3679c7af632d|10|TRGRESP|Target Response|WHO BREAST CANCER 2006|[?]|ohm|PR|1|log10 TCID 50/mL|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI||Y||HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|NA|5|Visit_5|90|1|TREATMENT|2021-04-03|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-19|P1Y2M10DT2H30M|BEFORE|2021-01-09|BEFORE|2021-01-26
e|RS|9c44967b-914e-43d5-be1e-6829804e04ab|1|NTRGRESP|Non-target Response|JACINTO CERVICAL CANCER 2007|[?]|pmol/10^10 cells|CHR|1|EID 50/mL|THERMAL IONIZATION MASS SPECTROMETRY||Y||FAMILY MEMBER|INTERNIST|Y|1|Visit_1|10|4|TREATMENT|2021-01-24|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-28|P1Y2M10DT2H30M|BEFORE|2021-01-27|BEFORE|2021-04-22
e|RS|9c44967b-914e-43d5-be1e-6829804e04ab|2|SYMPTDTR|Symptomatic Deterioration|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|100 IU/mL|MRD RELAPSE|1|U/kg/day|IVY INCISION METHOD|Y|||NON-HEALTH CARE PROFESSIONAL|CARDIOLOGIST|Y|1|Visit_1|10|1|WASHOUT|2021-01-24|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-28|P1Y2M10DT2H30M|BEFORE|2021-02-07|COINCIDENT|2021-04-02
e|RS|9c44967b-914e-43d5-be1e-6829804e04ab|3|CYTORESP|Cytogenetic Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|U/kg/min|PD FROM PR|1|PHERESIS UNIT|NON-INVASIVE DIELECTRIC SENSING|Y|||INVESTIGATOR|FORENSIC PATHOLOGIST|Y|2|Visit_2|25|1|FOLLOW-UP|2021-02-08|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-23|P1Y2M10DT2H30M|COINCIDENT|2021-01-30|BEFORE|2021-04-03
e|RS|9c44967b-914e-43d5-be1e-6829804e04ab|4|NTLWIND|Non-Target Lesion Worsening Indicator|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|uL/kg/day|NON-CR/NON-PD|1|uOsm|THIN SMEAR|Y|||CLINICAL RESEARCH COORDINATOR|RATER|U|2|Visit_2|25|1|SCREENING|2021-02-08|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-23|P1Y2M10DT2H30M|AFTER|2021-03-10|COINCIDENT|2021-03-15
e|RS|9c44967b-914e-43d5-be1e-6829804e04ab|5|MRDRESP|Minimal Residual Disease Response|BRUGGEMANN MRD 2010|||PSEUDORESPONSE|1|nkat/L|CONTRAST ENHANCED MRI|Y||Y|PROXY|RATER|U|3|Visit_3|40|2|TREATMENT|2021-02-23|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-28|P1Y2M10DT2H30M|COINCIDENT|2021-02-24|COINCIDENT|2021-03-06
e|RS|9c44967b-914e-43d5-be1e-6829804e04ab|6|NEWLWIND|New Lesion Worsening Indicator|WOLCHOK SOLID TUMORS 2009|||PD|1|U/cL|RIA|||Y|HEALTH CARE PROFESSIONAL|ADJUDICATOR 1|N|3|Visit_3|40|5|TREATMENT|2021-02-23|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-28|P1Y2M10DT2H30M|BEFORE|2021-04-04|AFTER|2021-04-07
e|RS|9c44967b-914e-43d5-be1e-6829804e04ab|7|MOLRESP|Molecular Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|||SMD|1|copies/uL|CISH|||Y|FRIEND|NEUROLOGIST 2|U|4|Visit_4|65|5|WASHOUT|2021-03-20|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-29|P1Y2M10DT2H30M|BEFORE|2021-01-27|ONGOING|2021-02-16
e|RS|9c44967b-914e-43d5-be1e-6829804e04ab|8|LIVRRESP|Liver Response|BLAZER COLORECTAL CANCER 2008|[?]|nsec|NON-PD|1|TCID 50/dose|DYNAMOMETRY||||VENDOR|DERMATOLOGIST|U|4|Visit_4|65|1|FOLLOW-UP|2021-03-20|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-29|P1Y2M10DT2H30M|AFTER|2021-02-17|ONGOING|2021-04-08
e|RS|9c44967b-914e-43d5-be1e-6829804e04ab|9|NEWLPROG|New Lesion Progression|BLAZER COLORECTAL CANCER 2008|||PARTIAL MORPHOLOGIC RESPONSE|1|MdFI|TEMPLATE INCISION METHOD||Y|Y|INVESTIGATOR|ONCOLOGIST 1|N|5|Visit_5|90|1|TREATMENT|2021-04-14|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-22|P1Y2M10DT2H30M|BEFORE|2021-03-14|BEFORE|2021-03-27
e|RS|9c44967b-914e-43d5-be1e-6829804e04ab|10|RDIORESP|Radiologic Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|oz eq|IMPROVED|1|mL/day|HIGH LEVEL AMINOGLYCOSIDE SCREEN||||SIGNIFICANT OTHER|MICROSCOPIST|Y|5|Visit_5|90|4|FOLLOW-UP|2021-04-14|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-22|P1Y2M10DT2H30M|COINCIDENT|2021-03-20|ONGOING|2021-04-10
e|RS|36b6c36e-3cba-4d15-85e2-9f9bfc4c05e1|1|NEWLWIND|New Lesion Worsening Indicator|RAJKUMAR MYELOMA 2011|[?]|PFU/mL|MOLECULAR CR|1|Ci/L|MICROBIAL BIOCHEMICAL IDENTIFICATION||Y||ADJUDICATOR|PEDIATRIC NEUROLOGIST|NA|1|Visit_1|10|7|FOLLOW-UP|2020-07-31|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-25|P1Y2M10DT2H30M|UNKNOWN|2020-08-22|AFTER|2020-09-01
e|RS|36b6c36e-3cba-4d15-85e2-9f9bfc4c05e1|2|BESTRESP|Best Overall Response|IWG CHESON MDS 2006|[?]|BAU|VGPR|1|NFIU|DUKE INCISION METHOD||||FRIEND|RATER 1|U|1|Visit_1|10|4|SCREENING|2020-07-31|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-25|P1Y2M10DT2H30M|UNKNOWN|2020-08-16|ONGOING|2020-09-28
e|RS|36b6c36e-3cba-4d15-85e2-9f9bfc4c05e1|3|METSIND|Metastatic Indicator|MURPHY PROSTATE CANCER 1980|[?]|PA|IMPROVED|1|mL/g/min|ELECTROCHEMILUMINESCENCE||||ADJUDICATOR|MICROSCOPIST 3|NA|2|Visit_2|25|4|FOLLOW-UP|2020-08-15|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-23|P1Y2M10DT2H30M|COINCIDENT|2020-08-27|ONGOING|2020-10-15
e|RS|36b6c36e-3cba-4d15-85e2-9f9bfc4c05e1|4|NTRGRESP|Non-target Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|genEq/mL|INCREASED|1|/100 WBC|RIA||||STUDY SUBJECT|ADJUDICATOR 3|NA|2|Visit_2|25|1|SCREENING|2020-08-15|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-23|P1Y2M10DT2H30M|BEFORE|2020-08-16|AFTER|2020-10-25
e|RS|36b6c36e-3cba-4d15-85e2-9f9bfc4c05e1|5|BESTRESP|Best Overall Response|PCWG SCHER PROSTATE CANCER 2016|||MORPHOLOGIC CRi|1|pg|GIEMSA STAIN|||Y|SPOUSE|RADIOLOGIST 2|N|3|Visit_3|40|2|SCREENING|2020-08-30|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-24|P1Y2M10DT2H30M|COINCIDENT|2020-08-25|AFTER|2020-10-25
e|RS|36b6c36e-3cba-4d15-85e2-9f9bfc4c05e1|6|NTNERESP|Non-Target Non-Enhancing Response|PRINCE TCELL LYMPHOMA 2010|[?]|DNA copies/mL|MAJOR PATHOLOGIC RESPONSE|1|umol/h/mmol|TRIPLE-PHASE SPIRAL CT SCAN|Y|||INVESTIGATOR|RATER 2|N|3|Visit_3|40|4|WASHOUT|2020-08-30|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-24|P1Y2M10DT2H30M|UNKNOWN|2020-08-20|AFTER|2020-09-14
e|RS|36b6c36e-3cba-4d15-85e2-9f9bfc4c05e1|7|LIVRRESP|Liver Response|IWG CHESON MDS 2006|[?]|U/mL|CHR|1|mol|OPTICAL MAPPING||||INDEPENDENT ASSESSOR|NEUROLOGIST|U|4|Visit_4|65|7|WASHOUT|2020-09-24|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-21|P1Y2M10DT2H30M|BEFORE|2020-07-23|BEFORE|2020-10-27
e|RS|36b6c36e-3cba-4d15-85e2-9f9bfc4c05e1|8|MRPHRESP|Morphologic Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|10^7 CFU|MRD RELAPSE|1|IU|WEBER GREEN STAIN|Y|Y||FAMILY MEMBER|READER|N|4|Visit_4|65|6|WASHOUT|2020-09-24|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-21|P1Y2M10DT2H30M|AFTER|2020-09-07|ONGOING|2020-10-10
e|RS|36b6c36e-3cba-4d15-85e2-9f9bfc4c05e1|9|BMIVLIND|Bone Marrow Involvement Indicator|HAMAOKA BREAST CANCER 2010|||NON-PD|1|umol/L/sec|GC/FID|Y||Y|INDEPENDENT ASSESSOR|ENDOCRINOLOGIST|Y|5|Visit_5|90|1|FOLLOW-UP|2020-10-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-05|P1Y2M10DT2H30M|COINCIDENT|2020-08-15|ONGOING|2020-09-17
e|RS|36b6c36e-3cba-4d15-85e2-9f9bfc4c05e1|10|NEWLPROG|New Lesion Progression|WHO BREAST CANCER 2006|[?]|kat|CMR|1|10^12/L|FLUORESCENT MICROSCOPY||Y||FRIEND|MICROSCOPIST|N|5|Visit_5|90|6|TREATMENT|2020-10-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-05|P1Y2M10DT2H30M|BEFORE|2020-08-06|BEFORE|2020-10-23
e|RS|cad8c553-739f-4046-a898-d939eb286dba|1|DRCRIND|Disease Recurrence Indicator|MRECIST BYRNE MESOTHELIOMA 2004|[?]|mmHg*min/L|HI-N|1|10^3 organisms/mL|OLIGO ACGH||||HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|Y|1|Visit_1|10|4|SCREENING|2020-05-17|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-01|P1Y2M10DT2H30M|UNKNOWN|2020-07-08|COINCIDENT|2020-07-12
e|RS|cad8c553-739f-4046-a898-d939eb286dba|2|ANATRESP|Anatomic Response|PCWG SCHER PROSTATE CANCER 2008|[?]|mL/s/m2|INCREASED|1|mL/kg/day|AUTOMATED COUNT||||SIGNIFICANT OTHER|CLINICAL PATHOLOGIST|U|1|Visit_1|10|1|TREATMENT|2020-05-17|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-01|P1Y2M10DT2H30M|UNKNOWN|2020-07-06|COINCIDENT|2020-07-21
e|RS|cad8c553-739f-4046-a898-d939eb286dba|3|METSIND|Metastatic Indicator|PETIT BREAST CANCER 2001|[?]|msec|PD FROM PR|1|mmol/day|SLIT LAMP||Y||INTERVIEWER|INTERNIST|U|2|Visit_2|25|4|FOLLOW-UP|2020-06-01|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-17|P1Y2M10DT2H30M|UNKNOWN|2020-07-17|ONGOING|2020-07-25
e|RS|cad8c553-739f-4046-a898-d939eb286dba|4|NEWLIND|New Lesion Indicator|iRECIST|[?]|cm/s|MORPHOLOGIC CRi|1|mL/g/day|INTRAVASCULAR ULTRASOUND|Y|||VENDOR|NEUROLOGIST 1|Y|2|Visit_2|25|6|FOLLOW-UP|2020-06-01|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-17|P1Y2M10DT2H30M|COINCIDENT|2020-06-19|COINCIDENT|2020-08-03
e|RS|cad8c553-739f-4046-a898-d939eb286dba|5|NTNERESP|Non-Target Non-Enhancing Response|MONTSERRAT CLL 1989|||cPR|1|days/wk|FLAME PHOTOMETRY|||Y|CHILD|ADJUDICATOR 1|U|3|Visit_3|40|5|FOLLOW-UP|2020-06-16|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-13|P1Y2M10DT2H30M|UNKNOWN|2020-05-26|AFTER|2020-07-03
e|RS|cad8c553-739f-4046-a898-d939eb286dba|6|NTRGRESP|Non-target Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|||MRD PERSISTENCE|1|ug/h|MRS|Y||Y|VENDOR|ADJUDICATOR|U|3|Visit_3|40|7|FOLLOW-UP|2020-06-16|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-13|P1Y2M10DT2H30M|COINCIDENT|2020-06-18|AFTER|2020-08-01
e|RS|cad8c553-739f-4046-a898-d939eb286dba|7|TRGRESP|Target Response|CHOI GIST 2008|||MRD NEGATIVITY|1|EIA unit|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY||Y|Y|SIGNIFICANT OTHER|CARDIOLOGIST|Y|4|Visit_4|65|7|TREATMENT|2020-07-11|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-25|P1Y2M10DT2H30M|UNKNOWN|2020-07-17|ONGOING|2020-08-11
e|RS|cad8c553-739f-4046-a898-d939eb286dba|8|NEWLWIND|New Lesion Worsening Indicator|CHESON LYMPHOMA 2008|||PD|1|POINT|NEXT GENERATION SEQUENCING||Y|Y|SPOUSE|OPTOMETRIST|NA|4|Visit_4|65|7|TREATMENT|2020-07-11|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-25|P1Y2M10DT2H30M|BEFORE|2020-05-22|COINCIDENT|2020-05-23
e|RS|cad8c553-739f-4046-a898-d939eb286dba|9|NTRGRESP|Non-target Response|GUPPY OVARIAN CANCER 2002|[?]|ug/min|PR WITH LYMPHOCYTOSIS|1|nmol/kg/day|PHOTOMETRY||||GUARDIAN|MICROSCOPIST|U|5|Visit_5|90|4|WASHOUT|2020-08-05|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-01|P1Y2M10DT2H30M|BEFORE|2020-07-15|AFTER|2020-07-27
e|RS|cad8c553-739f-4046-a898-d939eb286dba|10|NTLWIND|Non-Target Lesion Worsening Indicator|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|||PR WITH LYMPHOCYTOSIS|1|Enzyme U|QUANTITATIVE ULTRASOUND|||Y|INDEPENDENT ASSESSOR|ONCOLOGIST 1|N|5|Visit_5|90|5|FOLLOW-UP|2020-08-05|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-01|P1Y2M10DT2H30M|AFTER|2020-07-06|COINCIDENT|2020-08-04
e|RS|0bd95d1b-a993-4ae6-9ed0-3e3256ee1648|1|MJPTHIND|Major Pathological Response Indicator|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|fmol/L/sec|MOLECULAR MAJOR RESPONSE|1|log10 copies/mL|PALM METHOD|Y|Y||INVESTIGATOR|READER 1|N|1|Visit_1|10|4|WASHOUT|2020-09-11|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-03|P1Y2M10DT2H30M|COINCIDENT|2020-11-05|ONGOING|2020-11-19
e|RS|0bd95d1b-a993-4ae6-9ed0-3e3256ee1648|2|RDIORESP|Radiologic Response|CHOI GIST 2008|[?]|PUFF|RELAPSED DISEASE FROM CR OR PR|1|Ci/uL|IMMUNOPRECIPITATION||Y||VENDOR|OPTOMETRIST|NA|1|Visit_1|10|3|TREATMENT|2020-09-11|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-03|P1Y2M10DT2H30M|BEFORE|2020-11-04|BEFORE|2020-11-08
e|RS|0bd95d1b-a993-4ae6-9ed0-3e3256ee1648|3|LIVRRESP|Liver Response|RECIST 1.1|||PD|1|kUSP|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION|||Y|INTERVIEWER|HEMATOLOGIST|U|2|Visit_2|25|3|TREATMENT|2020-09-26|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-28|P1Y2M10DT2H30M|BEFORE|2020-11-30|ONGOING|2020-12-07
e|RS|0bd95d1b-a993-4ae6-9ed0-3e3256ee1648|4|BONERESP|Bone Response|CHESON CLL 2012|||CR-CT|1|vp/dose|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|Y||Y|INVESTIGATOR|READER|NA|2|Visit_2|25|2|TREATMENT|2020-09-26|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-28|P1Y2M10DT2H30M|UNKNOWN|2020-12-05|ONGOING|2020-12-06
e|RS|0bd95d1b-a993-4ae6-9ed0-3e3256ee1648|5|NTRGRESP|Non-target Response|RECIST 1.0|||CRi|1|Pack Year|POLYGRAPHY|||Y|SIGNIFICANT OTHER|NEUROLOGIST|U|3|Visit_3|40|7|WASHOUT|2020-10-11|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-04|P1Y2M10DT2H30M|COINCIDENT|2020-09-20|ONGOING|2020-11-25
e|RS|0bd95d1b-a993-4ae6-9ed0-3e3256ee1648|6|NEWLWIND|New Lesion Worsening Indicator|RECICL|[?]|pmol/10^9 cells|CA125 50% RESPONSE|1|EIA unit|DOPPLER ULTRASOUND||Y||SIBLING|INTERNIST|N|3|Visit_3|40|3|TREATMENT|2020-10-11|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-04|P1Y2M10DT2H30M|BEFORE|2020-11-17|BEFORE|2020-12-04
e|RS|0bd95d1b-a993-4ae6-9ed0-3e3256ee1648|7|MNPTHIND|Minor Pathological Response Indicator|CHESON LYMPHOMA 2008|||QUANTIFIABLE MRD POSITIVITY|1|GLOBULE|X-RAY|Y||Y|DOMESTIC PARTNER|PATHOLOGIST 1|NA|4|Visit_4|65|3|FOLLOW-UP|2020-11-05|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-16|P1Y2M10DT2H30M|AFTER|2020-10-01|AFTER|2020-10-20
e|RS|0bd95d1b-a993-4ae6-9ed0-3e3256ee1648|8|OVRLRESP|Overall Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|fmol/L/sec|PD-CT|1|mL/s/m2|FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY||||VENDOR|READER|U|4|Visit_4|65|4|TREATMENT|2020-11-05|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-16|P1Y2M10DT2H30M|AFTER|2020-11-22|ONGOING|2020-11-25
e|RS|0bd95d1b-a993-4ae6-9ed0-3e3256ee1648|9|BMIVLIND|Bone Marrow Involvement Indicator|SCHWARZ CERVICAL CANCER 2009|[?]|s^-1(%O2)^-1|PD FROM PR|1|Ci|NO INFORMATION||Y||FRIEND|READER 1|U|5|Visit_5|90|6|FOLLOW-UP|2020-11-30|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-22|P1Y2M10DT2H30M|BEFORE|2020-12-07|COINCIDENT|2020-12-08
e|RS|0bd95d1b-a993-4ae6-9ed0-3e3256ee1648|10|PATHRESP|Pathologic Response|SACT|[?]|10^7 PFU|SMD|1|in2|SCANNING ELECTRON MICROSCOPY|Y|||NON-HEALTH CARE PROFESSIONAL|RATER|U|5|Visit_5|90|7|FOLLOW-UP|2020-11-30|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-22|P1Y2M10DT2H30M|COINCIDENT|2020-10-16|BEFORE|2020-10-31
e|RS|81e934f8-7bcc-48d2-8d15-5270e51f2870|1|NEWLWIND|New Lesion Worsening Indicator|NCIWG CHESON CLL 1996|[?]|IU/mg|MORPHOLOGIC LEUKEMIA-FREE STATE|1|mV|MEDIASTINOSCOPY|Y|||CHILD|READER 1|N|1|Visit_1|10|4|TREATMENT|2021-01-24|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-16|P1Y2M10DT2H30M|AFTER|2021-03-18|AFTER|2021-03-31
e|RS|81e934f8-7bcc-48d2-8d15-5270e51f2870|2|BESTRESP|Best Overall Response|PRINCE TCELL LYMPHOMA 2010|||HI-N|1|EIA unit|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS||Y|Y|DOMESTIC PARTNER|MICROSCOPIST 1|NA|1|Visit_1|10|1|TREATMENT|2021-01-24|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-16|P1Y2M10DT2H30M|AFTER|2021-01-25|ONGOING|2021-04-20
e|RS|81e934f8-7bcc-48d2-8d15-5270e51f2870|3|BESTRESP|Best Overall Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|umol/h/mmol|RELAPSED DISEASE|1|nmol/day|PET/CT SCAN||||GUARDIAN|READER 2|NA|2|Visit_2|25|3|WASHOUT|2021-02-08|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-09|P1Y2M10DT2H30M|COINCIDENT|2021-04-20|AFTER|2021-04-22
e|RS|81e934f8-7bcc-48d2-8d15-5270e51f2870|4|STRUSTAT|Steroid Use Status|WHO BREAST CANCER 2006|||PMR|1|PNU/mL|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS||Y|Y|CHILD|PATHOLOGIST|Y|2|Visit_2|25|3|WASHOUT|2021-02-08|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-09|P1Y2M10DT2H30M|UNKNOWN|2021-01-21|ONGOING|2021-01-30
e|RS|81e934f8-7bcc-48d2-8d15-5270e51f2870|5|METSIND|Metastatic Indicator|NCIWG CHESON CLL 1996|[?]|ug/min|CYTOGENETIC MINOR RESPONSE|1|mL/day|SPECTROPHOTOMETRY||Y||INTERVIEWER|RADIOLOGIST|NA|3|Visit_3|40|3|TREATMENT|2021-02-23|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-02|P1Y2M10DT2H30M|BEFORE|2021-04-11|BEFORE|2021-04-17
e|RS|81e934f8-7bcc-48d2-8d15-5270e51f2870|6|SYMPTDTR|Symptomatic Deterioration|MRECIST LENCIONI LIVER CANCER 2010|[?]|CFU/mL|CYTOGENETIC MINIMAL RESPONSE|1|10^6 U|AUTOMATED COUNT|Y|Y||FAMILY MEMBER|NEUROLOGIST 2|NA|3|Visit_3|40|5|TREATMENT|2021-02-23|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-02|P1Y2M10DT2H30M|COINCIDENT|2021-04-04|AFTER|2021-04-12
e|RS|81e934f8-7bcc-48d2-8d15-5270e51f2870|7|BONERESP|Bone Response|CHOI GIST 2008|[?]|mm/h|NON-iCR/NON-iUPD|1|Ci/ug|KARYOTYPING||||STUDY SUBJECT|ADJUDICATOR 2|NA|4|Visit_4|65|4|SCREENING|2021-03-20|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-04|P1Y2M10DT2H30M|BEFORE|2021-03-26|AFTER|2021-04-19
e|RS|81e934f8-7bcc-48d2-8d15-5270e51f2870|8|TMRESP|Tumor Marker Response|RAJKUMAR MYELOMA 2011|[?]|mL/min/1.73m2|PR WITH LYMPHOCYTOSIS|1|mL/m2/min|PHOTOMETRY||Y||SIGNIFICANT OTHER|NEUROLOGIST 1|U|4|Visit_4|65|5|WASHOUT|2021-03-20|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-04|P1Y2M10DT2H30M|AFTER|2021-04-07|AFTER|2021-04-10
e|RS|81e934f8-7bcc-48d2-8d15-5270e51f2870|9|MRPHRESP|Morphologic Response|GUPPY OVARIAN CANCER 2002|||PDu|1|ohm|GC/MS|||Y|STUDY SUBJECT|PEDIATRIC NEUROLOGIST|N|5|Visit_5|90|6|WASHOUT|2021-04-14|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-22|P1Y2M10DT2H30M|BEFORE|2021-02-01|ONGOING|2021-03-12
e|RS|81e934f8-7bcc-48d2-8d15-5270e51f2870|10|METBRESP|Metabolic Response|BLAZER COLORECTAL CANCER 2008|||sCR|1|kHz|INTRAVASCULAR ULTRASOUND|||Y|CHILD|READER 3|N|5|Visit_5|90|4|WASHOUT|2021-04-14|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-22|P1Y2M10DT2H30M|BEFORE|2021-01-28|AFTER|2021-02-17
e|RS|5713cabe-4d79-4f77-8ddc-daad1242a837|1|NTERESP|Non-Target Enhancing Response|SCHER PROSTATE CANCER 2011|||cCR|1|10^6 CFU|CLOT DETECTION|||Y|INVESTIGATOR|ONCOLOGIST|N|1|Visit_1|10|4|SCREENING|2020-09-09|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-14|P1Y2M10DT2H30M|COINCIDENT|2020-11-22|AFTER|2020-11-27
e|RS|5713cabe-4d79-4f77-8ddc-daad1242a837|2|MRDRESP|Minimal Residual Disease Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|EID 50/mL|NON-CR/NON-PD|1|/4.0 mL|SANGER SEQUENCING|Y|||FRIEND|READER 3|N|1|Visit_1|10|6|WASHOUT|2020-09-09|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-14|P1Y2M10DT2H30M|UNKNOWN|2020-11-09|BEFORE|2020-11-26
e|RS|5713cabe-4d79-4f77-8ddc-daad1242a837|3|STRUSTAT|Steroid Use Status|RECIST 1.1|[?]|ugEq/L|INCREASED|1|mg/mL/min|MOUSE PROTECTION ASSAY||||DOMESTIC PARTNER|PHYSIOTHERAPIST|NA|2|Visit_2|25|3|TREATMENT|2020-09-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-16|P1Y2M10DT2H30M|COINCIDENT|2020-09-18|AFTER|2020-10-15
e|RS|5713cabe-4d79-4f77-8ddc-daad1242a837|4|SFTSRESP|Soft Tissue Response|iRECIST|[?]|V|ABSENT MORPHOLOGIC RESPONSE|1|mmol/L|VENTILATION PERFUSION LUNG SCAN|Y|||INDEPENDENT ASSESSOR|OTOLARYNGOLOGIST|U|2|Visit_2|25|2|FOLLOW-UP|2020-09-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-16|P1Y2M10DT2H30M|COINCIDENT|2020-10-24|COINCIDENT|2020-12-04
e|RS|5713cabe-4d79-4f77-8ddc-daad1242a837|5|MOLRESP|Molecular Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|CFU/mL|iCR|1|10^6 U|HIGH LEVEL AMINOGLYCOSIDE SCREEN||||STUDY SUBJECT|OPHTHALMOLOGIST|N|3|Visit_3|40|7|SCREENING|2020-10-09|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-20|P1Y2M10DT2H30M|AFTER|2020-11-07|AFTER|2020-12-01
e|RS|5713cabe-4d79-4f77-8ddc-daad1242a837|6|BONERESP|Bone Response|IWG CHESON AML 2003|||QUANTIFIABLE MRD POSITIVITY|1|TRACE|QUANTITATIVE PERIPHERAL ANGIOGRAPHY|||Y|PARENT|READER 2|U|3|Visit_3|40|3|FOLLOW-UP|2020-10-09|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-20|P1Y2M10DT2H30M|UNKNOWN|2020-09-02|ONGOING|2020-09-09
e|RS|5713cabe-4d79-4f77-8ddc-daad1242a837|7|NEWLPROG|New Lesion Progression|FAROOQUI SUPP CLL 2014|||PR|1|IMPLANT|PH METER MEASUREMENT METHOD||Y|Y|GUARDIAN|OTOLARYNGOLOGIST|Y|4|Visit_4|65|5|FOLLOW-UP|2020-11-03|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-13|P1Y2M10DT2H30M|UNKNOWN|2020-09-28|AFTER|2020-11-01
e|RS|5713cabe-4d79-4f77-8ddc-daad1242a837|8|BONERESP|Bone Response|GUPPY OVARIAN CANCER 2002|[?]|ug/g/h|NE|1|pmol/L/h|CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY||||ADJUDICATOR|MICROSCOPIST 2|NA|4|Visit_4|65|5|FOLLOW-UP|2020-11-03|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-13|P1Y2M10DT2H30M|AFTER|2020-10-22|COINCIDENT|2020-11-17
e|RS|5713cabe-4d79-4f77-8ddc-daad1242a837|9|SYMPTDTR|Symptomatic Deterioration|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|IU/L|CYTOGENETIC MINOR RESPONSE|1|MPL U/mL|HEMAGGLUTINATION INHIBITION ASSAY||||CLINICAL RESEARCH ASSOCIATE|INTERNIST|U|5|Visit_5|90|1|TREATMENT|2020-11-28|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-07|P1Y2M10DT2H30M|UNKNOWN|2020-11-11|COINCIDENT|2020-11-19
e|RS|5713cabe-4d79-4f77-8ddc-daad1242a837|10|MRDIND|Minimal Residual Disease Indicator|MRECIST BYRNE MESOTHELIOMA 2004|[?]|g/g|ABSENT MORPHOLOGIC RESPONSE|1|IU/g Hb|IRON HEMATOXYLIN STAIN||Y||ADJUDICATION COMMITTEE|FORENSIC PATHOLOGIST|NA|5|Visit_5|90|6|TREATMENT|2020-11-28|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-07|P1Y2M10DT2H30M|UNKNOWN|2020-09-03|ONGOING|2020-09-30
e|RS|414d20c7-8dc8-49ad-8ae9-f113b9610109|1|PATHRESP|Pathologic Response|IWG CHESON MDS 2006|[?]|EVENTS|CA125 50% RESPONSE|1|cd|PLAQUE REDUCTION NEUTRALIZATION ASSAY||||PARENT|OTOLARYNGOLOGIST|NA|1|Visit_1|10|1|TREATMENT|2020-07-10|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-08|P1Y2M10DT2H30M|BEFORE|2020-07-21|COINCIDENT|2020-09-21
e|RS|414d20c7-8dc8-49ad-8ae9-f113b9610109|2|DRCRIND|Disease Recurrence Indicator|RANO ELLINGSON 2017|[?]|Bq/kg|STABLE|1|mEq/mL|POTENTIOMETRY||Y||INTERVIEWER|RATER|NA|1|Visit_1|10|2|WASHOUT|2020-07-10|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-08|P1Y2M10DT2H30M|UNKNOWN|2020-09-14|ONGOING|2020-09-16
e|RS|414d20c7-8dc8-49ad-8ae9-f113b9610109|3|NTNERESP|Non-Target Non-Enhancing Response|KUKER LYMPHOMA 2005|[?]|fL|SD-CT|1|m3|ELISPOT||||FRIEND|CLINICAL PATHOLOGIST|Y|2|Visit_2|25|2|SCREENING|2020-07-25|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-23|P1Y2M10DT2H30M|UNKNOWN|2020-08-05|BEFORE|2020-09-14
e|RS|414d20c7-8dc8-49ad-8ae9-f113b9610109|4|MRDIND|Minimal Residual Disease Indicator|IWG CHESON MDS 2000|[?]|breaths/min|CHR|1|kg/m2|SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY||||SIGNIFICANT OTHER|ENDOCRINOLOGIST|U|2|Visit_2|25|7|SCREENING|2020-07-25|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-23|P1Y2M10DT2H30M|AFTER|2020-08-02|BEFORE|2020-08-17
e|RS|414d20c7-8dc8-49ad-8ae9-f113b9610109|5|NTLWIND|Non-Target Lesion Worsening Indicator|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|||CYTOGENETIC PR|1|10^3 organisms/mL|QUANTITATIVE ULTRASOUND|Y||Y|GUARDIAN|PATHOLOGIST 1|U|3|Visit_3|40|1|FOLLOW-UP|2020-08-09|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-20|P1Y2M10DT2H30M|COINCIDENT|2020-08-23|ONGOING|2020-09-20
e|RS|414d20c7-8dc8-49ad-8ae9-f113b9610109|6|NEWLWIND|New Lesion Worsening Indicator|NCIWG CHESON CLL 1996|[?]|psec|MOLECULAR CR|1|g/cage/wk|IMMUNOCHROMATOGRAPHY|Y|||NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST|Y|3|Visit_3|40|7|WASHOUT|2020-08-09|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-20|P1Y2M10DT2H30M|AFTER|2020-08-11|COINCIDENT|2020-09-11
e|RS|414d20c7-8dc8-49ad-8ae9-f113b9610109|7|MRDIND|Minimal Residual Disease Indicator|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|g/U|CA125 75% RESPONSE|1|mg/g/h|CELLULOSE TAPE||||CLINICAL RESEARCH COORDINATOR|ONCOLOGIST|U|4|Visit_4|65|2|TREATMENT|2020-09-03|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-29|P1Y2M10DT2H30M|UNKNOWN|2020-07-31|AFTER|2020-08-03
e|RS|414d20c7-8dc8-49ad-8ae9-f113b9610109|8|MRPHRESP|Morphologic Response|iRECIST|[?]|m3|CYTOGENETIC PR|1|mmHg/sec|SLIT LAMP PHOTOGRAPHY|Y|Y||ADJUDICATOR|NEUROLOGIST|N|4|Visit_4|65|4|TREATMENT|2020-09-03|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-29|P1Y2M10DT2H30M|BEFORE|2020-09-10|COINCIDENT|2020-10-02
e|RS|414d20c7-8dc8-49ad-8ae9-f113b9610109|9|DRCRIND|Disease Recurrence Indicator|PERCIST|||RELAPSED DISEASE|1|mL/m2|ISHIHARA COLOR PLATES|||Y|VENDOR|RADIOLOGIST 1|N|5|Visit_5|90|2|TREATMENT|2020-09-28|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-21|P1Y2M10DT2H30M|COINCIDENT|2020-08-24|ONGOING|2020-09-18
e|RS|414d20c7-8dc8-49ad-8ae9-f113b9610109|10|NEWLPROG|New Lesion Progression|SCHER PROSTATE CANCER 2011|||PSEUDORESPONSE|1|Siemens|CALCOFLUOR WHITE STAIN|||Y|FAMILY MEMBER|CARDIOLOGIST|U|5|Visit_5|90|5|SCREENING|2020-09-28|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-21|P1Y2M10DT2H30M|COINCIDENT|2020-10-02|BEFORE|2020-10-05
e|RS|21e16094-23bd-4d20-b5f8-10d45858160e|1|CLINRESP|Clinical Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|10^6/hpf|PD|1|uL|HILLMEN COLOR CHART||||HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|NA|1|Visit_1|10|7|WASHOUT|2020-09-17|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-01|P1Y2M10DT2H30M|COINCIDENT|2020-09-18|ONGOING|2020-11-23
e|RS|21e16094-23bd-4d20-b5f8-10d45858160e|2|DRCRIND|Disease Recurrence Indicator|MRECIST LENCIONI LIVER CANCER 2010|[?]|RNA copies/mL|HI-E|1|L/kg|DROPLET DIGITAL PCR||||INVESTIGATOR|NEUROLOGIST 2|U|1|Visit_1|10|7|TREATMENT|2020-09-17|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-01|P1Y2M10DT2H30M|COINCIDENT|2020-12-13|ONGOING|2020-12-14
e|RS|21e16094-23bd-4d20-b5f8-10d45858160e|3|NTNERESP|Non-Target Non-Enhancing Response|MONTSERRAT CLL 1989|[?]|g/g|MINOR PATHOLOGIC RESPONSE|1|GPS U|PULSE OXIMETRY|Y|||INDEPENDENT ASSESSOR|NEUROLOGIST 1|N|2|Visit_2|25|6|TREATMENT|2020-10-02|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-22|P1Y2M10DT2H30M|UNKNOWN|2020-11-08|COINCIDENT|2020-12-02
e|RS|21e16094-23bd-4d20-b5f8-10d45858160e|4|LIVRRESP|Liver Response|LEE LUNG CANCER 2011|||SD|1|ug/kg/day|SICKLE CELL SOLUBILITY TEST|||Y|HEALTH CARE PROFESSIONAL|HEMATOLOGIST|N|2|Visit_2|25|3|WASHOUT|2020-10-02|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-22|P1Y2M10DT2H30M|AFTER|2020-10-10|COINCIDENT|2020-12-15
e|RS|21e16094-23bd-4d20-b5f8-10d45858160e|5|CLINRESP|Clinical Response|CHOI GIST 2008|[?]|ELISA unit/dose|IMMUNOPHENOTYPIC CR|1|mg/kg/dose|SEQUENCING||||DOMESTIC PARTNER|NEUROLOGIST 2|NA|3|Visit_3|40|4|WASHOUT|2020-10-17|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-12|P1Y2M10DT2H30M|BEFORE|2020-12-03|BEFORE|2020-12-11
e|RS|21e16094-23bd-4d20-b5f8-10d45858160e|6|METSIND|Metastatic Indicator|CHESON MALIGNANT LYMPHOMA 2007|[?]|/5x10^4 WBC|iCPD|1|10^10/L|IMMUNOTURBIDIMETRY||||INDEPENDENT ASSESSOR|NEUROLOGIST 1|NA|3|Visit_3|40|4|SCREENING|2020-10-17|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-12|P1Y2M10DT2H30M|AFTER|2020-10-26|ONGOING|2020-11-10
e|RS|21e16094-23bd-4d20-b5f8-10d45858160e|7|METSIND|Metastatic Indicator|DURIE MULTIPLE MYELOMA 2006|[?]|GBq/g|NE|1|U/dL|PHOROPTER||||VENDOR|MICROSCOPIST 1|N|4|Visit_4|65|5|TREATMENT|2020-11-11|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-07|P1Y2M10DT2H30M|UNKNOWN|2020-09-09|AFTER|2020-11-11
e|RS|21e16094-23bd-4d20-b5f8-10d45858160e|8|NTERESP|Non-Target Enhancing Response|CHESON LYMPHOMA 2008|||PD|1|Osm|FLUOROSCOPY|Y|Y|Y|PROXY|MICROSCOPIST 3|Y|4|Visit_4|65|6|FOLLOW-UP|2020-11-11|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-07|P1Y2M10DT2H30M|UNKNOWN|2020-10-29|COINCIDENT|2020-11-16
e|RS|21e16094-23bd-4d20-b5f8-10d45858160e|9|NEWLPROG|New Lesion Progression|MACDONALD GLIOMA 1990|[?]|km/h|MINOR PATHOLOGIC RESPONSE|1|PACKET|CHROMATOGRAPHY|Y|||INVESTIGATOR|ADJUDICATOR 2|Y|5|Visit_5|90|1|WASHOUT|2020-12-06|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-17|P1Y2M10DT2H30M|COINCIDENT|2020-12-09|BEFORE|2020-12-14
e|RS|21e16094-23bd-4d20-b5f8-10d45858160e|10|CYTORESP|Cytogenetic Response|CHOI GIST 2008|[?]|pkat|cPR|1|ug/mL/h|JAFFE REACTION||||ADJUDICATION COMMITTEE|MICROSCOPIST 2|Y|5|Visit_5|90|4|TREATMENT|2020-12-06|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-17|P1Y2M10DT2H30M|AFTER|2020-12-12|COINCIDENT|2020-12-14
e|RS|2346613e-6734-476a-a414-511606c2d753|1|MRDIND|Minimal Residual Disease Indicator|HARTMAN PANCREATIC CANCER 2012|[?]|m3|IMMUNOPHENOTYPIC CR|1|cmol/L|RADIOGRAPHY||Y||SPOUSE|CARDIOLOGIST|Y|1|Visit_1|10|6|WASHOUT|2020-09-22|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-15|P1Y2M10DT2H30M|BEFORE|2020-12-08|BEFORE|2020-12-12
e|RS|2346613e-6734-476a-a414-511606c2d753|2|STRUSTAT|Steroid Use Status|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|mm|DISEASE TRANSFORMATION|1|uU/L|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION||||FAMILY MEMBER|PATHOLOGIST|N|1|Visit_1|10|4|FOLLOW-UP|2020-09-22|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-15|P1Y2M10DT2H30M|UNKNOWN|2020-10-12|BEFORE|2020-10-13
e|RS|2346613e-6734-476a-a414-511606c2d753|3|MJPTHIND|Major Pathological Response Indicator|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|Farad|PSEUDOPROGRESSION|1|vg/kg|SPIROMETRY||||ADJUDICATOR|UROLOGIST|NA|2|Visit_2|25|2|TREATMENT|2020-10-07|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-18|P1Y2M10DT2H30M|UNKNOWN|2020-10-02|BEFORE|2020-11-07
e|RS|2346613e-6734-476a-a414-511606c2d753|4|METSIND|Metastatic Indicator|DOHNER AML 2010|[?]|nmol/kg/day|STABLE|1|vp/dose|IRON HEMATOXYLIN STAIN||||SPOUSE|MICROSCOPIST 3|NA|2|Visit_2|25|5|SCREENING|2020-10-07|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-18|P1Y2M10DT2H30M|AFTER|2020-11-24|BEFORE|2020-12-05
e|RS|2346613e-6734-476a-a414-511606c2d753|5|DRCRIND|Disease Recurrence Indicator|BURCOMBE BREAST CANCER 2005|||CYTOGENETIC NO RESPONSE|1|mL/kg/min|ALCIAN BLUE STAIN|||Y|PROXY|FORENSIC PATHOLOGIST|U|3|Visit_3|40|3|FOLLOW-UP|2020-10-22|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-18|P1Y2M10DT2H30M|COINCIDENT|2020-11-20|BEFORE|2020-11-30
e|RS|2346613e-6734-476a-a414-511606c2d753|6|PATHRESP|Pathologic Response|MACDONALD GLIOMA 1990|||UNEQUIVOCAL|1|umol/L/sec|CONGO RED STAIN|||Y|CLINICAL RESEARCH COORDINATOR|INTERNIST|NA|3|Visit_3|40|3|FOLLOW-UP|2020-10-22|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-18|P1Y2M10DT2H30M|AFTER|2020-11-21|AFTER|2020-11-24
e|RS|2346613e-6734-476a-a414-511606c2d753|7|BMIVLIND|Bone Marrow Involvement Indicator|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|umol/L|MORPHOLOGIC LEUKEMIA-FREE STATE|1|kUSP|PLAQUE REDUCTION NEUTRALIZATION ASSAY||||VENDOR|READER 1|N|4|Visit_4|65|2|SCREENING|2020-11-16|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-12|P1Y2M10DT2H30M|BEFORE|2020-10-20|BEFORE|2020-11-12
e|RS|2346613e-6734-476a-a414-511606c2d753|8|DRCRIND|Disease Recurrence Indicator|FAROOQUI SUPP CLL 2014|[?]|10^6/Ejaculate U|MOLECULAR CR|1|g/L|INTERRUPTER TECHNIQUE||||PROXY|ENDOCRINOLOGIST|N|4|Visit_4|65|2|TREATMENT|2020-11-16|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-12|P1Y2M10DT2H30M|UNKNOWN|2020-12-06|ONGOING|2020-12-17
e|RS|2346613e-6734-476a-a414-511606c2d753|9|NTERESP|Non-Target Enhancing Response|CHOI GIST 2008|[?]|/sec|pCR|1|g/cage/day|DYNAMIC CONTRAST ENHANCED MRI||||FRIEND|PATHOLOGIST|NA|5|Visit_5|90|1|WASHOUT|2020-12-11|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-26|P1Y2M10DT2H30M|COINCIDENT|2020-09-20|AFTER|2020-12-10
e|RS|2346613e-6734-476a-a414-511606c2d753|10|OVRLRESP|Overall Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|mmol/min/kPa/L|STABLE|1|cmol/L|ENDPOINT DILUTION ASSAY||Y||FAMILY MEMBER|ONCOLOGIST|U|5|Visit_5|90|4|TREATMENT|2020-12-11|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-26|P1Y2M10DT2H30M|AFTER|2020-09-18|COINCIDENT|2020-11-16
e|RS|6a8bda83-1b5a-481e-af4f-77fe74bc37be|1|HEMARESP|Hematologic Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|log10 CCID 50/dose|RELAPSED DISEASE FROM CR|1|mg/animal|HEPATITIS C VIRUS RECOMBINANT IMMUNOBLOT ASSAY||||SIBLING|PEDIATRIC NEUROLOGIST|U|1|Visit_1|10|2|TREATMENT|2020-11-26|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-19|P1Y2M10DT2H30M|AFTER|2021-01-17|BEFORE|2021-01-25
e|RS|6a8bda83-1b5a-481e-af4f-77fe74bc37be|2|CLINRESP|Clinical Response|AJCC V7|[?]|IMPLANT|TREATMENT FAILURE|1|mOsm|PULSE OXIMETRY||||CLINICAL RESEARCH COORDINATOR|INTERNIST|Y|1|Visit_1|10|1|TREATMENT|2020-11-26|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-19|P1Y2M10DT2H30M|COINCIDENT|2020-12-06|COINCIDENT|2020-12-14
e|RS|6a8bda83-1b5a-481e-af4f-77fe74bc37be|3|NEWLIND|New Lesion Indicator|EASL BRUIX LIVER CANCER 2001|||RELAPSED DISEASE FROM CR|1|hPa|ANTIBIOTIC AGAR SCREEN|Y||Y|VENDOR|ADJUDICATOR|U|2|Visit_2|25|2|WASHOUT|2020-12-11|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-27|P1Y2M10DT2H30M|UNKNOWN|2021-01-09|BEFORE|2021-01-12
e|RS|6a8bda83-1b5a-481e-af4f-77fe74bc37be|4|ANATRESP|Anatomic Response|MASS|[?]|/ms|NON-PD|1|/wk|PET/MRI SCAN||||CLINICAL STUDY SPONSOR|PATHOLOGIST 2|Y|2|Visit_2|25|3|FOLLOW-UP|2020-12-11|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-27|P1Y2M10DT2H30M|BEFORE|2020-12-04|ONGOING|2021-02-15
e|RS|6a8bda83-1b5a-481e-af4f-77fe74bc37be|5|SYMPTDTR|Symptomatic Deterioration|GUILHOT CML 2007|[?]|um/s|CYTOGENETIC CR|1|ug/cm2|X-RAY||||STUDY SUBJECT|INTERNIST|Y|3|Visit_3|40|5|TREATMENT|2020-12-26|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-04|P1Y2M10DT2H30M|UNKNOWN|2021-01-20|COINCIDENT|2021-02-12
e|RS|6a8bda83-1b5a-481e-af4f-77fe74bc37be|6|DRCRIND|Disease Recurrence Indicator|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|||IMPROVED|1|g/kg/day|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN|Y||Y|INTERVIEWER|READER 3|NA|3|Visit_3|40|1|SCREENING|2020-12-26|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-04|P1Y2M10DT2H30M|AFTER|2020-11-25|BEFORE|2021-01-21
e|RS|6a8bda83-1b5a-481e-af4f-77fe74bc37be|7|NEWLWIND|New Lesion Worsening Indicator|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|ug/day|NON-PD|1|10^7 PFU|WESTERN BLOT||||GUARDIAN|RADIOLOGIST 1|N|4|Visit_4|65|1|TREATMENT|2021-01-20|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-18|P1Y2M10DT2H30M|AFTER|2021-02-03|AFTER|2021-02-12
e|RS|6a8bda83-1b5a-481e-af4f-77fe74bc37be|8|TMRESP|Tumor Marker Response|BURCOMBE BREAST CANCER 2005|[?]|10^9 organisms/mL|PDu|1|tuberculin unit|DC SHEATH FLOW||Y||FRIEND|PHYSIOTHERAPIST|N|4|Visit_4|65|7|FOLLOW-UP|2021-01-20|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-18|P1Y2M10DT2H30M|COINCIDENT|2021-02-15|BEFORE|2021-02-19
e|RS|6a8bda83-1b5a-481e-af4f-77fe74bc37be|9|BESTRESP|Best Overall Response|WOLCHOK SOLID TUMORS 2009|[?]|in2|NON-PD|1|days/wk|MANUAL COUNT||||INVESTIGATOR|ONCOLOGIST 2|Y|5|Visit_5|90|4|TREATMENT|2021-02-14|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-16|P1Y2M10DT2H30M|BEFORE|2021-02-12|ONGOING|2021-02-17
e|RS|6a8bda83-1b5a-481e-af4f-77fe74bc37be|10|DRCRIND|Disease Recurrence Indicator|MONTSERRAT CLL 1989|[?]|DRINK|EQUIVOCAL|1|JAR|MEDIASTINOSCOPY|Y|Y||DOMESTIC PARTNER|HEMATOLOGIST|Y|5|Visit_5|90|1|FOLLOW-UP|2021-02-14|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-16|P1Y2M10DT2H30M|BEFORE|2020-12-11|COINCIDENT|2021-02-10
e|RS|748ef401-3def-4674-8d5e-4a198709d672|1|DRCRIND|Disease Recurrence Indicator|CHOLLET BREAST CANCER 2002|||NON-CR/NON-PD|1|tsp eq|FREEZING POINT DEPRESSION|Y||Y|INDEPENDENT ASSESSOR|PEDIATRIC NEUROLOGIST|U|1|Visit_1|10|7|TREATMENT|2020-06-08|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-13|P1Y2M10DT2H30M|AFTER|2020-09-05|COINCIDENT|2020-09-06
e|RS|748ef401-3def-4674-8d5e-4a198709d672|2|RDIORESP|Radiologic Response|AJCC V8|[?]|10^3 CFU/g|HI-P|1|uSiemens|MASS SPECTROMETRY|Y|||SPOUSE|PEDIATRIC NEUROLOGIST|Y|1|Visit_1|10|6|TREATMENT|2020-06-08|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-13|P1Y2M10DT2H30M|BEFORE|2020-09-05|COINCIDENT|2020-09-06
e|RS|748ef401-3def-4674-8d5e-4a198709d672|3|NEWLPROG|New Lesion Progression|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|BAU|sCR|1|PFU/dose|SPECULAR MICROSCOPY||||GUARDIAN|ONCOLOGIST 2|U|2|Visit_2|25|4|TREATMENT|2020-06-23|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-13|P1Y2M10DT2H30M|AFTER|2020-07-08|COINCIDENT|2020-08-13
e|RS|748ef401-3def-4674-8d5e-4a198709d672|4|ANATRESP|Anatomic Response|AJCC V8|||PD/RELAPSE AFTER HI|1|VIAL|PALPATION|||Y|SIGNIFICANT OTHER|MICROSCOPIST 1|NA|2|Visit_2|25|6|TREATMENT|2020-06-23|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-13|P1Y2M10DT2H30M|AFTER|2020-07-30|ONGOING|2020-08-17
e|RS|748ef401-3def-4674-8d5e-4a198709d672|5|BMIVLIND|Bone Marrow Involvement Indicator|CHESON CLL 2006|[?]|cmol/L|UNFAVORABLE RESPONSE|1|mg/h|AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT||||INVESTIGATOR|ADJUDICATOR 2|U|3|Visit_3|40|3|SCREENING|2020-07-08|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-26|P1Y2M10DT2H30M|BEFORE|2020-06-15|BEFORE|2020-08-14
e|RS|748ef401-3def-4674-8d5e-4a198709d672|6|BONERESP|Bone Response|DOHNER AML 2010|[?]|mL/g/min|CA125 50% RESPONSE|1|ug/h|DXA SCAN||||VENDOR|FORENSIC PATHOLOGIST|NA|3|Visit_3|40|6|TREATMENT|2020-07-08|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-26|P1Y2M10DT2H30M|AFTER|2020-06-13|BEFORE|2020-07-11
e|RS|748ef401-3def-4674-8d5e-4a198709d672|7|METSIND|Metastatic Indicator|PALUMBO MULTIPLE MYELOMA 2009|[?]|PFU/mL|ABSENT MORPHOLOGIC RESPONSE|1|SUPPOSITORY|VENTILATION PERFUSION LUNG SCAN|Y|||INTERVIEWER|DEVELOPMENTAL PSYCHOLOGIST|U|4|Visit_4|65|7|TREATMENT|2020-08-02|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-22|P1Y2M10DT2H30M|BEFORE|2020-08-14|AFTER|2020-08-24
e|RS|748ef401-3def-4674-8d5e-4a198709d672|8|LIVRRESP|Liver Response|GUPPY OVARIAN CANCER 2002|[?]|U.CARR|PMR|1|CYLINDER|AMSLER GRID||Y||CLINICAL RESEARCH ASSOCIATE|RATER 2|Y|4|Visit_4|65|7|SCREENING|2020-08-02|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-22|P1Y2M10DT2H30M|COINCIDENT|2020-06-10|BEFORE|2020-08-20
e|RS|748ef401-3def-4674-8d5e-4a198709d672|9|MRDRESP|Minimal Residual Disease Response|MACDONALD GLIOMA 1990|[?]|mEq/day|DECREASED|1|bel|ELECTROGASTROGRAPHY|Y|Y||ADJUDICATION COMMITTEE|PATHOLOGIST 2|NA|5|Visit_5|90|3|TREATMENT|2020-08-27|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-08|P1Y2M10DT2H30M|AFTER|2020-06-26|ONGOING|2020-08-23
e|RS|748ef401-3def-4674-8d5e-4a198709d672|10|RDIORESP|Radiologic Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|cm/s|HI-E|1|ms2|NUCLEAR RADIOLOGY|Y|||PARENT|RATER 2|NA|5|Visit_5|90|1|TREATMENT|2020-08-27|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-08|P1Y2M10DT2H30M|AFTER|2020-07-09|COINCIDENT|2020-09-03
e|RS|03c399c1-77b9-4879-a6e8-42ba58ca68d4|1|DRCRIND|Disease Recurrence Indicator|DOHNER AML 2010|||NON-CR/NON-PD|1|Hz|INTERRUPTER TECHNIQUE|Y||Y|INTERVIEWER|MICROSCOPIST 3|NA|1|Visit_1|10|5|TREATMENT|2020-07-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-22|P1Y2M10DT2H30M|AFTER|2020-09-08|BEFORE|2020-09-10
e|RS|03c399c1-77b9-4879-a6e8-42ba58ca68d4|2|BONERESP|Bone Response|HARTMANN GERM CELL CANCER 2002|||CYTOGENETIC NO RESPONSE|1|nCi|GC/FID|||Y|INDEPENDENT ASSESSOR|CARDIOLOGIST|Y|1|Visit_1|10|5|FOLLOW-UP|2020-07-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-22|P1Y2M10DT2H30M|AFTER|2020-08-24|ONGOING|2020-08-28
e|RS|03c399c1-77b9-4879-a6e8-42ba58ca68d4|3|TMRESP|Tumor Marker Response|LUGANO CLASSIFICATION|[?]|EU|PSEUDOPROGRESSION|1|/7.5 mL|PELLI-ROBSON EYE CHART||||FAMILY MEMBER|RADIOLOGIST 2|U|2|Visit_2|25|3|FOLLOW-UP|2020-07-30|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-25|P1Y2M10DT2H30M|BEFORE|2020-07-10|ONGOING|2020-10-09
e|RS|03c399c1-77b9-4879-a6e8-42ba58ca68d4|4|METBRESP|Metabolic Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|keV|cCR|1|BOTTLE|PALPATION|Y|||FRIEND|RATER 1|U|2|Visit_2|25|4|TREATMENT|2020-07-30|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-25|P1Y2M10DT2H30M|COINCIDENT|2020-08-03|BEFORE|2020-09-29
e|RS|03c399c1-77b9-4879-a6e8-42ba58ca68d4|5|NEWLIND|New Lesion Indicator|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|steps/min|UNFAVORABLE RESPONSE|1|pmol/dL|FORCED OSCILLATION TECHNIQUE|Y|||INTERVIEWER|INTERNIST|Y|3|Visit_3|40|6|TREATMENT|2020-08-14|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-18|P1Y2M10DT2H30M|AFTER|2020-07-23|ONGOING|2020-07-31
e|RS|03c399c1-77b9-4879-a6e8-42ba58ca68d4|6|NEWLWIND|New Lesion Worsening Indicator|CHESON CLL 2012|[?]|vp/mL|IMMUNOPHENOTYPIC CR|1|dpm/100mg|AUSCULTATION||||CHILD|PEDIATRIC NEUROLOGIST|Y|3|Visit_3|40|7|TREATMENT|2020-08-14|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-18|P1Y2M10DT2H30M|AFTER|2020-08-10|AFTER|2020-09-29
e|RS|03c399c1-77b9-4879-a6e8-42ba58ca68d4|7|BESTRESP|Best Overall Response|EBMT BLADE MYELOMA 1998|||MOLECULAR MAJOR RESPONSE|1|FINGERTIP UNIT|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|||Y|CLINICAL RESEARCH ASSOCIATE|CLINICAL PATHOLOGIST|N|4|Visit_4|65|2|TREATMENT|2020-09-08|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-30|P1Y2M10DT2H30M|COINCIDENT|2020-08-03|BEFORE|2020-09-01
e|RS|03c399c1-77b9-4879-a6e8-42ba58ca68d4|8|SPLNRESP|Spleen Response|GUILHOT CML 2007|[?]|nmol/mol|CYTOGENETIC MINOR RESPONSE|1|/200 HPFs|CONTRAST ENHANCED X-RAY||||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST|U|4|Visit_4|65|2|TREATMENT|2020-09-08|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-30|P1Y2M10DT2H30M|UNKNOWN|2020-07-27|ONGOING|2020-08-13
e|RS|03c399c1-77b9-4879-a6e8-42ba58ca68d4|9|BMIVLIND|Bone Marrow Involvement Indicator|GUPPY OVARIAN CANCER 2002|||nPR|1|um/s|EEG|||Y|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|Y|5|Visit_5|90|5|TREATMENT|2020-10-03|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-01|P1Y2M10DT2H30M|UNKNOWN|2020-09-08|AFTER|2020-10-01
e|RS|03c399c1-77b9-4879-a6e8-42ba58ca68d4|10|PATHRESP|Pathologic Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|mmHg/L/min|NON-CR/NON-PD|1|m3|THICK SMEAR||||INVESTIGATOR|RADIOLOGIST 1|NA|5|Visit_5|90|2|TREATMENT|2020-10-03|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-01|P1Y2M10DT2H30M|BEFORE|2020-10-10|ONGOING|2020-10-11
e|RS|b8afdaf1-5c4d-408f-b8ba-381461f15bde|1|MRDIND|Minimal Residual Disease Indicator|NCCN ALL MRD 2014|[?]|vp/dose|CR-CT|1|U/kg/h|PAP STAIN|Y|||GUARDIAN|OPHTHALMOLOGIST|U|1|Visit_1|10|6|TREATMENT|2020-11-13|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-19|P1Y2M10DT2H30M|AFTER|2021-01-31|ONGOING|2021-02-01
e|RS|b8afdaf1-5c4d-408f-b8ba-381461f15bde|2|BMIVLIND|Bone Marrow Involvement Indicator|HARTMAN PANCREATIC CANCER 2012|||SD-CT|1|Watt|TWO-COLOR MICROARRAY|||Y|HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|Y|1|Visit_1|10|2|TREATMENT|2020-11-13|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-19|P1Y2M10DT2H30M|COINCIDENT|2020-12-10|BEFORE|2020-12-16
e|RS|b8afdaf1-5c4d-408f-b8ba-381461f15bde|3|RDIORESP|Radiologic Response|KEAM BREAST CANCER 2013|[?]|/7.5 mL|CYTOGENETIC MINOR RESPONSE|1|nmol/day|AURAMINE STAIN||Y||CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 2|U|2|Visit_2|25|4|TREATMENT|2020-11-28|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-01|P1Y2M10DT2H30M|BEFORE|2020-12-09|ONGOING|2021-01-25
e|RS|b8afdaf1-5c4d-408f-b8ba-381461f15bde|4|NTNERESP|Non-Target Non-Enhancing Response|SCHWARZ CERVICAL CANCER 2009|||PR-CT|1|log10 TCID 50/uL|HILLMEN COLOR CHART||Y|Y|ADJUDICATOR|ONCOLOGIST|U|2|Visit_2|25|6|SCREENING|2020-11-28|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-01|P1Y2M10DT2H30M|AFTER|2020-12-07|ONGOING|2020-12-29
e|RS|b8afdaf1-5c4d-408f-b8ba-381461f15bde|5|CPRFSTAT|Clinical Performance Status|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|gMFI|MRD PERSISTENCE|1|kat|IMMUNOTURBIDIMETRY||||SIBLING|ENDOCRINOLOGIST|Y|3|Visit_3|40|1|TREATMENT|2020-12-13|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-08|P1Y2M10DT2H30M|BEFORE|2021-01-03|BEFORE|2021-01-13
e|RS|b8afdaf1-5c4d-408f-b8ba-381461f15bde|6|NTNERESP|Non-Target Non-Enhancing Response|IWG CHESON MDS 2006|||PMR|1|10^5/L|LAPAROSCOPY||Y|Y|DOMESTIC PARTNER|CLINICAL PATHOLOGIST|U|3|Visit_3|40|5|TREATMENT|2020-12-13|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-08|P1Y2M10DT2H30M|BEFORE|2020-11-08|COINCIDENT|2020-12-16
e|RS|b8afdaf1-5c4d-408f-b8ba-381461f15bde|7|STRUSTAT|Steroid Use Status|SCHWARZ CERVICAL CANCER 2009|||MORPHOLOGIC CRi|1|10^3 organisms|LEAD CITRATE STAIN|||Y|STUDY SUBJECT|PATHOLOGIST 2|NA|4|Visit_4|65|7|WASHOUT|2021-01-07|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-29|P1Y2M10DT2H30M|UNKNOWN|2020-12-01|COINCIDENT|2020-12-09
e|RS|b8afdaf1-5c4d-408f-b8ba-381461f15bde|8|SFTSRESP|Soft Tissue Response|DURIE MULTIPLE MYELOMA 2006|[?]|mg/m2/h|OPTIMAL MORPHOLOGIC RESPONSE|1|uCi|ECHOCARDIOGRAPHY||Y||CLINICAL RESEARCH ASSOCIATE|PEDIATRIC NEUROLOGIST|NA|4|Visit_4|65|6|TREATMENT|2021-01-07|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-29|P1Y2M10DT2H30M|BEFORE|2020-11-16|AFTER|2021-02-03
e|RS|b8afdaf1-5c4d-408f-b8ba-381461f15bde|9|BONERESP|Bone Response|SCHER PROSTATE CANCER 2011|[?]|cd/m2|WORSENED|1|JAR|WEBER GREEN STAIN||||FRIEND|CLINICAL PATHOLOGIST|U|5|Visit_5|90|6|SCREENING|2021-02-01|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-11|P1Y2M10DT2H30M|AFTER|2021-01-10|BEFORE|2021-01-16
e|RS|b8afdaf1-5c4d-408f-b8ba-381461f15bde|10|MOLRESP|Molecular Response|RANO|||PD/RELAPSE AFTER HI|1|10^3 organisms/g|CALCULATION||Y|Y|ADJUDICATOR|DERMATOLOGIST|U|5|Visit_5|90|4|SCREENING|2021-02-01|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-11|P1Y2M10DT2H30M|COINCIDENT|2021-02-03|AFTER|2021-02-08
e|RS|8115d6e8-0908-4491-a82a-08f43ccf1f0d|1|STRUSTAT|Steroid Use Status|JACINTO CERVICAL CANCER 2007|||nPR|1|Hounsfield Unit|PATHOLOGICAL EVALUATION||Y|Y|FAMILY MEMBER|RADIOLOGIST 2|Y|1|Visit_1|10|6|WASHOUT|2020-11-28|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-05|P1Y2M10DT2H30M|COINCIDENT|2020-11-22|BEFORE|2020-12-23
e|RS|8115d6e8-0908-4491-a82a-08f43ccf1f0d|2|NTERESP|Non-Target Enhancing Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|BAU/mL|sCR|1|nsec|FLUORIMETRY||Y||CLINICAL RESEARCH COORDINATOR|FORENSIC PATHOLOGIST|N|1|Visit_1|10|2|FOLLOW-UP|2020-11-28|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-05|P1Y2M10DT2H30M|BEFORE|2021-01-04|ONGOING|2021-01-20
e|RS|8115d6e8-0908-4491-a82a-08f43ccf1f0d|3|TMRESP|Tumor Marker Response|PETIT BREAST CANCER 2001|[?]|kg/L|sCR|1|mL/cm|LINE PROBE ASSAY||||DOMESTIC PARTNER|READER 1|N|2|Visit_2|25|6|TREATMENT|2020-12-13|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-20|P1Y2M10DT2H30M|BEFORE|2020-12-17|AFTER|2020-12-19
e|RS|8115d6e8-0908-4491-a82a-08f43ccf1f0d|4|SFTSRESP|Soft Tissue Response|SCHWARZ CERVICAL CANCER 2009|||cCR|1|cP|SLOAN LETTER EYE CHART 1.25%|||Y|PARENT|RADIOLOGIST 1|U|2|Visit_2|25|2|WASHOUT|2020-12-13|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-20|P1Y2M10DT2H30M|AFTER|2020-11-28|AFTER|2021-02-23
e|RS|8115d6e8-0908-4491-a82a-08f43ccf1f0d|5|SPLNRESP|Spleen Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|10^12/L|NE|1|nmol/L/h|SLIT LAMP|Y|||NON-HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|N|3|Visit_3|40|6|SCREENING|2020-12-28|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-29|P1Y2M10DT2H30M|BEFORE|2020-12-01|COINCIDENT|2021-01-08
e|RS|8115d6e8-0908-4491-a82a-08f43ccf1f0d|6|MRDIND|Minimal Residual Disease Indicator|EASL BRUIX LIVER CANCER 2001|||PMD|1|L/h|SANGER SEQUENCING|||Y|FRIEND|DEVELOPMENTAL PSYCHOLOGIST|U|3|Visit_3|40|2|TREATMENT|2020-12-28|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-29|P1Y2M10DT2H30M|BEFORE|2021-01-07|AFTER|2021-01-26
e|RS|8115d6e8-0908-4491-a82a-08f43ccf1f0d|7|NEWLIND|New Lesion Indicator|IWG CHESON MDS 2006|[?]|ms2|UNFAVORABLE RESPONSE|1|g/mol|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS||||PARENT|PATHOLOGIST 2|NA|4|Visit_4|65|1|TREATMENT|2021-01-22|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-19|P1Y2M10DT2H30M|BEFORE|2020-12-27|AFTER|2021-01-25
e|RS|8115d6e8-0908-4491-a82a-08f43ccf1f0d|8|LIVRRESP|Liver Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|uCi|SD-CT|1|DIOPTER|LIGHT SCATTERING SPECTROSCOPY||||SIBLING|ADJUDICATOR 2|NA|4|Visit_4|65|4|WASHOUT|2021-01-22|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-19|P1Y2M10DT2H30M|AFTER|2021-01-15|COINCIDENT|2021-02-14
e|RS|8115d6e8-0908-4491-a82a-08f43ccf1f0d|9|BMIVLIND|Bone Marrow Involvement Indicator|PCWG SCHER PROSTATE CANCER 2016|[?]|Arbitrary U|PMR|1|U/L|CYSTOMETRY||||CLINICAL STUDY SPONSOR|ONCOLOGIST|U|5|Visit_5|90|5|TREATMENT|2021-02-16|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-12|P1Y2M10DT2H30M|BEFORE|2021-02-21|BEFORE|2021-02-24
e|RS|8115d6e8-0908-4491-a82a-08f43ccf1f0d|10|MNPTHIND|Minor Pathological Response Indicator|IRANO 2015|[?]|10^4/L|NED|1|uCi/L|DXA SCAN||||HEALTH CARE PROFESSIONAL|READER|N|5|Visit_5|90|1|TREATMENT|2021-02-16|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-12|P1Y2M10DT2H30M|UNKNOWN|2021-01-19|COINCIDENT|2021-02-12
e|RS|fbd7ecb2-905f-40a9-babc-ebaf310cc372|1|SYMPTDTR|Symptomatic Deterioration|IRANO 2015|[?]|BEAM BREAKS|NON-QUANTIFIABLE MRD POSITIVITY|1|L/s|MICRODENSITOMETRY||||PARENT|PATHOLOGIST 1|NA|1|Visit_1|10|5|SCREENING|2020-06-30|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-09|P1Y2M10DT2H30M|COINCIDENT|2020-09-14|COINCIDENT|2020-09-20
e|RS|fbd7ecb2-905f-40a9-babc-ebaf310cc372|2|NTERESP|Non-Target Enhancing Response|FAROOQUI SUPP CLL 2014|||nPR|1|mL/100g/min|RAJI CELL EIA|||Y|ADJUDICATION COMMITTEE|CARDIOLOGIST|NA|1|Visit_1|10|6|SCREENING|2020-06-30|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-09|P1Y2M10DT2H30M|BEFORE|2020-09-25|COINCIDENT|2020-09-27
e|RS|fbd7ecb2-905f-40a9-babc-ebaf310cc372|3|MRPHRESP|Morphologic Response|iRECIST|[?]|/LPF|MORPHOLOGIC LEUKEMIA-FREE STATE|1|beats/min|LC-FL||||DOMESTIC PARTNER|ONCOLOGIST 2|U|2|Visit_2|25|3|TREATMENT|2020-07-15|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-13|P1Y2M10DT2H30M|COINCIDENT|2020-09-26|COINCIDENT|2020-09-27
e|RS|fbd7ecb2-905f-40a9-babc-ebaf310cc372|4|HEMARESP|Hematologic Response|CHESON LYMPHOMA 2008|[?]|h/wk|DECREASED|1|PIXEL|PET SCAN||||CAREGIVER|ADJUDICATOR 1|U|2|Visit_2|25|5|TREATMENT|2020-07-15|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-13|P1Y2M10DT2H30M|COINCIDENT|2020-08-17|AFTER|2020-08-20
e|RS|fbd7ecb2-905f-40a9-babc-ebaf310cc372|5|CYTORESP|Cytogenetic Response|BURCOMBE BREAST CANCER 2005|[?]|IU/kg/h|DISEASE TRANSFORMATION|1|ug/g/day|URANYL ACETATE STAIN||||CHILD|PATHOLOGIST|NA|3|Visit_3|40|2|TREATMENT|2020-07-30|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-13|P1Y2M10DT2H30M|AFTER|2020-08-02|BEFORE|2020-08-06
e|RS|fbd7ecb2-905f-40a9-babc-ebaf310cc372|6|SPLNRESP|Spleen Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|10^6/g|mCR|1|PACKET|PELLI-ROBSON EYE CHART||||DOMESTIC PARTNER|DEVELOPMENTAL PSYCHOLOGIST|U|3|Visit_3|40|6|TREATMENT|2020-07-30|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-13|P1Y2M10DT2H30M|COINCIDENT|2020-07-26|BEFORE|2020-08-29
e|RS|fbd7ecb2-905f-40a9-babc-ebaf310cc372|7|METSIND|Metastatic Indicator|EBMT BLADE MYELOMA 1998|||iUPD|1|nm|FREEZING POINT DEPRESSION|||Y|INVESTIGATOR|PATHOLOGIST|Y|4|Visit_4|65|3|TREATMENT|2020-08-24|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-29|P1Y2M10DT2H30M|COINCIDENT|2020-09-09|AFTER|2020-09-21
e|RS|fbd7ecb2-905f-40a9-babc-ebaf310cc372|8|NEWLWIND|New Lesion Worsening Indicator|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|Ci/mg|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|copies/uL|AGAR PROPORTION||||HEALTH CARE PROFESSIONAL|RADIOLOGIST|NA|4|Visit_4|65|3|TREATMENT|2020-08-24|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-29|P1Y2M10DT2H30M|UNKNOWN|2020-08-29|AFTER|2020-09-19
e|RS|fbd7ecb2-905f-40a9-babc-ebaf310cc372|9|SFTSRESP|Soft Tissue Response|IRANO 2015|[?]|GPS U|PSA PROGRESSION|1|COAT|MAMMOGRAPHY||||INTERVIEWER|MICROSCOPIST 1|NA|5|Visit_5|90|4|FOLLOW-UP|2020-09-18|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-17|P1Y2M10DT2H30M|BEFORE|2020-06-25|ONGOING|2020-07-02
e|RS|fbd7ecb2-905f-40a9-babc-ebaf310cc372|10|MOLRESP|Molecular Response|iRECIST|[?]|amu|RELAPSED DISEASE FROM CR|1|kPa/L/sec|QUANTITATIVE CORONARY ANGIOGRAPHY||||ADJUDICATION COMMITTEE|DERMATOLOGIST|U|5|Visit_5|90|6|TREATMENT|2020-09-18|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-17|P1Y2M10DT2H30M|BEFORE|2020-07-17|ONGOING|2020-07-26
e|RS|1a0e1a66-82dd-4945-9c9f-179fba9d781e|1|SYMPTDTR|Symptomatic Deterioration|SHINDOH COLORECTAL CANCER 2013|[?]|mg/kg/min|CR|1|Rad|TRICHROME STAIN||||SIBLING|MICROSCOPIST 1|Y|1|Visit_1|10|7|TREATMENT|2020-12-09|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-06|P1Y2M10DT2H30M|BEFORE|2021-02-20|AFTER|2021-02-28
e|RS|1a0e1a66-82dd-4945-9c9f-179fba9d781e|2|METBRESP|Metabolic Response|iRECIST|[?]|umol/min|EQUIVOCAL|1|mol/mL|EIA|Y|Y||GUARDIAN|ONCOLOGIST|U|1|Visit_1|10|2|TREATMENT|2020-12-09|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-06|P1Y2M10DT2H30M|UNKNOWN|2020-12-18|AFTER|2021-03-07
e|RS|1a0e1a66-82dd-4945-9c9f-179fba9d781e|3|NTLWIND|Non-Target Lesion Worsening Indicator|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|mol|RELAPSED DISEASE|1|HEP|HIGH RESOLUTION CT||||PARENT|UROLOGIST|NA|2|Visit_2|25|1|WASHOUT|2020-12-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-25|P1Y2M10DT2H30M|COINCIDENT|2021-01-04|ONGOING|2021-02-19
e|RS|1a0e1a66-82dd-4945-9c9f-179fba9d781e|4|TRGRESP|Target Response|RAJKUMAR MYELOMA 2011|[?]|BAU/mL|INDETERMINATE RESPONSE|1|fmol/L|ERGOSPIROMETRY||||ADJUDICATION COMMITTEE|MICROSCOPIST 3|U|2|Visit_2|25|3|WASHOUT|2020-12-24|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-25|P1Y2M10DT2H30M|AFTER|2021-02-11|ONGOING|2021-03-03
e|RS|1a0e1a66-82dd-4945-9c9f-179fba9d781e|5|NTERESP|Non-Target Enhancing Response|KUKER LYMPHOMA 2005|[?]|U/mg|iSD|1|CONTAINER|ZIEHL NEELSEN ACID FAST STAIN||Y||CLINICAL STUDY SPONSOR|CARDIOLOGIST|Y|3|Visit_3|40|2|WASHOUT|2021-01-08|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-08|P1Y2M10DT2H30M|AFTER|2021-02-08|BEFORE|2021-02-26
e|RS|1a0e1a66-82dd-4945-9c9f-179fba9d781e|6|PATHRESP|Pathologic Response|UNSPECIFIED|[?]|g/cage/wk|mCR|1|g/cage/wk|IMMUNOPRECIPITATION||||ADJUDICATION COMMITTEE|ADJUDICATOR|Y|3|Visit_3|40|5|WASHOUT|2021-01-08|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-08|P1Y2M10DT2H30M|BEFORE|2021-02-20|COINCIDENT|2021-03-03
e|RS|1a0e1a66-82dd-4945-9c9f-179fba9d781e|7|SFTSRESP|Soft Tissue Response|IWC HALLEK CLL 2008|[?]|g/cm2|sCR|1|h*%|LIQUID SCINTILLATION COUNTING||||CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST 1|N|4|Visit_4|65|1|TREATMENT|2021-02-02|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-01|P1Y2M10DT2H30M|UNKNOWN|2020-12-30|COINCIDENT|2021-01-15
e|RS|1a0e1a66-82dd-4945-9c9f-179fba9d781e|8|RDIORESP|Radiologic Response|CHESON CLL 2006|[?]|/500 WBC|NR|1|TABLET|GRAM STAIN||||FRIEND|READER 3|Y|4|Visit_4|65|1|WASHOUT|2021-02-02|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-01|P1Y2M10DT2H30M|UNKNOWN|2021-02-24|ONGOING|2021-02-27
e|RS|1a0e1a66-82dd-4945-9c9f-179fba9d781e|9|MJPTHIND|Major Pathological Response Indicator|IWG CHESON MDS 2006|[?]|mg/kg|PD/RELAPSE AFTER HI|1|ks|VENTILATION PERFUSION LUNG SCAN||||CAREGIVER|MICROSCOPIST|NA|5|Visit_5|90|6|TREATMENT|2021-02-27|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-22|P1Y2M10DT2H30M|UNKNOWN|2020-12-23|BEFORE|2021-02-07
e|RS|1a0e1a66-82dd-4945-9c9f-179fba9d781e|10|DRCRIND|Disease Recurrence Indicator|SCHER PROSTATE CANCER 2011|||CR|1|10^9 CFU/mL|MICRO BROTH DILUTION||Y|Y|VENDOR|PATHOLOGIST|NA|5|Visit_5|90|5|TREATMENT|2021-02-27|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-22|P1Y2M10DT2H30M|UNKNOWN|2021-03-04|COINCIDENT|2021-03-06
e|RS|b3ab1879-3dc7-41fa-be53-f4484af21fbd|1|HEMARESP|Hematologic Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|||OPTIMAL MORPHOLOGIC RESPONSE|1|10^7 CFU|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI|||Y|PROXY|MICROSCOPIST|U|1|Visit_1|10|3|TREATMENT|2020-11-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-17|P1Y2M10DT2H30M|UNKNOWN|2020-12-25|ONGOING|2021-01-09
e|RS|b3ab1879-3dc7-41fa-be53-f4484af21fbd|2|NEWLPROG|New Lesion Progression|MRECIST LENCIONI LIVER CANCER 2010|[?]|L|CYTOGENETIC CR|1|Hounsfield Unit|PLAQUE REDUCTION NEUTRALIZATION ASSAY||||NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|N|1|Visit_1|10|5|TREATMENT|2020-11-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-17|P1Y2M10DT2H30M|UNKNOWN|2020-12-07|AFTER|2021-02-15
e|RS|b3ab1879-3dc7-41fa-be53-f4484af21fbd|3|PATHRESP|Pathologic Response|LEE LUNG CANCER 2011|[?]|BAU/mL|MOLECULAR CR|1|ug/h|CALIPER MEASUREMENT METHOD||||FAMILY MEMBER|PATHOLOGIST 2|NA|2|Visit_2|25|1|FOLLOW-UP|2020-12-04|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-15|P1Y2M10DT2H30M|UNKNOWN|2021-01-13|AFTER|2021-02-02
e|RS|b3ab1879-3dc7-41fa-be53-f4484af21fbd|4|MRDRESP|Minimal Residual Disease Response|RANO|[?]|ng|EQUIVOCAL|1|mCi/L|HPLC/MS/MS|Y|||INVESTIGATOR|READER 3|Y|2|Visit_2|25|1|WASHOUT|2020-12-04|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-15|P1Y2M10DT2H30M|COINCIDENT|2020-12-13|ONGOING|2021-02-07
e|RS|b3ab1879-3dc7-41fa-be53-f4484af21fbd|5|MJPTHIND|Major Pathological Response Indicator|KEAM BREAST CANCER 2013|||iSD|1|mEq/mL|DXA SCAN|||Y|INVESTIGATOR|INTERNIST|U|3|Visit_3|40|6|WASHOUT|2020-12-19|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-12|P1Y2M10DT2H30M|COINCIDENT|2020-11-13|ONGOING|2021-02-13
e|RS|b3ab1879-3dc7-41fa-be53-f4484af21fbd|6|SPLNRESP|Spleen Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|pt_br|MOLECULAR MAJOR RESPONSE|1|10^6 CFU/mL|POTENTIOMETRY||||VENDOR|READER 1|NA|3|Visit_3|40|3|TREATMENT|2020-12-19|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-12|P1Y2M10DT2H30M|AFTER|2020-12-30|ONGOING|2021-01-10
e|RS|b3ab1879-3dc7-41fa-be53-f4484af21fbd|7|BMIVLIND|Bone Marrow Involvement Indicator|GUILHOT CML 2007|[?]|mEq/kg|RELAPSED DISEASE FROM CR|1|min/day|SPIRAL CT||||ADJUDICATION COMMITTEE|RADIOLOGIST 1|NA|4|Visit_4|65|7|TREATMENT|2021-01-13|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-05|P1Y2M10DT2H30M|AFTER|2020-11-13|AFTER|2021-02-09
e|RS|b3ab1879-3dc7-41fa-be53-f4484af21fbd|8|DRCRIND|Disease Recurrence Indicator|MACDONALD GLIOMA 1990|[?]|dpm/100mg|CA125 75% RESPONSE|1|PA|MULTI-SLICE SPIRAL CT|Y|||PROXY|RATER 1|Y|4|Visit_4|65|4|SCREENING|2021-01-13|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-05|P1Y2M10DT2H30M|COINCIDENT|2020-11-17|BEFORE|2021-01-18
e|RS|b3ab1879-3dc7-41fa-be53-f4484af21fbd|9|METBRESP|Metabolic Response|RECIST 1.1|||PMR|1|QUANTITY SUFFICIENT|THERMAL IONIZATION MASS SPECTROMETRY|||Y|DOMESTIC PARTNER|ADJUDICATOR|Y|5|Visit_5|90|1|SCREENING|2021-02-07|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-14|P1Y2M10DT2H30M|AFTER|2021-01-13|BEFORE|2021-02-07
e|RS|b3ab1879-3dc7-41fa-be53-f4484af21fbd|10|NEWLIND|New Lesion Indicator|SACT|[?]|cm2|ABSENT MORPHOLOGIC RESPONSE|1|cm2|MRI||||PARENT|DEVELOPMENTAL PSYCHOLOGIST|N|5|Visit_5|90|2|SCREENING|2021-02-07|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-14|P1Y2M10DT2H30M|UNKNOWN|2020-12-05|BEFORE|2021-01-13
e|RS|bc71ddfa-c71c-447b-9684-005e4c112172|1|MRDIND|Minimal Residual Disease Indicator|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|AFU|OPTIMAL MORPHOLOGIC RESPONSE|1|mPa|RADIOGRAPHY||||INTERVIEWER|MICROSCOPIST|NA|1|Visit_1|10|2|TREATMENT|2020-07-11|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-21|P1Y2M10DT2H30M|AFTER|2020-08-13|BEFORE|2020-09-22
e|RS|bc71ddfa-c71c-447b-9684-005e4c112172|2|MNPTHIND|Minor Pathological Response Indicator|MURPHY PROSTATE CANCER 1980|[?]|VIAL|sCR|1|mEq/day|CLIP||||SIGNIFICANT OTHER|READER|Y|1|Visit_1|10|3|TREATMENT|2020-07-11|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-21|P1Y2M10DT2H30M|UNKNOWN|2020-09-25|ONGOING|2020-10-08
e|RS|bc71ddfa-c71c-447b-9684-005e4c112172|3|NTERESP|Non-Target Enhancing Response|DOHNER AML 2010|||UNEQUIVOCAL|1|Arbitrary U|ANTIMICROBIAL COMBINATION TESTING|||Y|INVESTIGATOR|CARDIOLOGIST|Y|2|Visit_2|25|4|FOLLOW-UP|2020-07-26|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-12|P1Y2M10DT2H30M|UNKNOWN|2020-07-27|COINCIDENT|2020-09-24
e|RS|bc71ddfa-c71c-447b-9684-005e4c112172|4|OVRLRESP|Overall Response|RANO|[?]|vg/kg|CYTOGENETIC PR|1|10^4/hpf|HIGH LEVEL AMINOGLYCOSIDE SCREEN||||HEALTH CARE PROFESSIONAL|READER|Y|2|Visit_2|25|1|TREATMENT|2020-07-26|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-12|P1Y2M10DT2H30M|AFTER|2020-07-22|AFTER|2020-09-01
e|RS|bc71ddfa-c71c-447b-9684-005e4c112172|5|TRGRESP|Target Response|GCIG RUSTIN OVARIAN CANCER 2011|||PDu|1|Pa|PERIODIC ACID SCHIFF STAIN|||Y|INDEPENDENT ASSESSOR|RATER|NA|3|Visit_3|40|4|WASHOUT|2020-08-10|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-22|P1Y2M10DT2H30M|BEFORE|2020-08-23|ONGOING|2020-08-26
e|RS|bc71ddfa-c71c-447b-9684-005e4c112172|6|NEWLWIND|New Lesion Worsening Indicator|PCWG SCHER PROSTATE CANCER 2016|[?]|CYLINDER|CRi|1|damol/L|HPLC-FL||||PROXY|ONCOLOGIST 2|NA|3|Visit_3|40|4|WASHOUT|2020-08-10|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-22|P1Y2M10DT2H30M|BEFORE|2020-09-01|AFTER|2020-09-18
e|RS|bc71ddfa-c71c-447b-9684-005e4c112172|7|NEWLIND|New Lesion Indicator|RECIST 1.1|[?]|cmH2O*s/mL|MORPHOLOGIC CR|1|ug|WHOLE EXOME SEQUENCING||||INTERVIEWER|CARDIOLOGIST|Y|4|Visit_4|65|3|TREATMENT|2020-09-04|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-21|P1Y2M10DT2H30M|AFTER|2020-09-16|AFTER|2020-10-04
e|RS|bc71ddfa-c71c-447b-9684-005e4c112172|8|NEWLIND|New Lesion Indicator|EASL BRUIX LIVER CANCER 2001|||CMR|1|pm|OPTICAL MAPPING|||Y|CLINICAL RESEARCH ASSOCIATE|READER 3|N|4|Visit_4|65|6|SCREENING|2020-09-04|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-21|P1Y2M10DT2H30M|AFTER|2020-09-27|COINCIDENT|2020-10-06
e|RS|bc71ddfa-c71c-447b-9684-005e4c112172|9|MOLRESP|Molecular Response|GUPPY OVARIAN CANCER 2002|[?]|Enzyme U/L|CR|1|ug/dL|STRESS ECHOCARDIOGRAPHY||Y||HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|U|5|Visit_5|90|4|WASHOUT|2020-09-29|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-31|P1Y2M10DT2H30M|COINCIDENT|2020-07-26|AFTER|2020-07-31
e|RS|bc71ddfa-c71c-447b-9684-005e4c112172|10|SFTSRESP|Soft Tissue Response|NCCN ALL MRD 2014|[?]|GBq/ug|SMD|1|genEq|SINGLE-SLICE SPIRAL CT|Y|Y||INTERVIEWER|OTOLARYNGOLOGIST|U|5|Visit_5|90|3|WASHOUT|2020-09-29|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-31|P1Y2M10DT2H30M|UNKNOWN|2020-09-28|ONGOING|2020-10-08
e|RS|ed3ae3f4-892a-4e68-9f3d-e81b2f2e09c0|1|NTRGRESP|Non-target Response|MONTSERRAT CLL 1989|[?]|mL/dL|FAVORABLE RESPONSE|1|DPM|HEMAGGLUTINATION ASSAY||Y||STUDY SUBJECT|RATER 2|NA|1|Visit_1|10|1|SCREENING|2020-12-09|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-14|P1Y2M10DT2H30M|AFTER|2021-02-27|COINCIDENT|2021-03-08
e|RS|ed3ae3f4-892a-4e68-9f3d-e81b2f2e09c0|2|MNPTHIND|Minor Pathological Response Indicator|HAMAOKA BREAST CANCER 2010|[?]|Osm|PSEUDOPROGRESSION|1|pg/L|PHYSICAL EXAMINATION||||GUARDIAN|ADJUDICATOR|NA|1|Visit_1|10|5|WASHOUT|2020-12-09|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-14|P1Y2M10DT2H30M|COINCIDENT|2021-03-06|AFTER|2021-03-07
e|RS|ed3ae3f4-892a-4e68-9f3d-e81b2f2e09c0|3|NTNERESP|Non-Target Non-Enhancing Response|SCHWARZ CERVICAL CANCER 2009|||PD FROM PR|1|kg/L|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI||Y|Y|SPOUSE|CARDIOLOGIST|U|2|Visit_2|25|4|WASHOUT|2020-12-24|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-02|P1Y2M10DT2H30M|BEFORE|2021-01-20|COINCIDENT|2021-02-13
e|RS|ed3ae3f4-892a-4e68-9f3d-e81b2f2e09c0|4|SYMPTDTR|Symptomatic Deterioration|EASL BRUIX LIVER CANCER 2001|[?]|dyn|SMD|1|SQU/mL|MS/MS|Y|||CAREGIVER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|2|Visit_2|25|3|FOLLOW-UP|2020-12-24|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-02|P1Y2M10DT2H30M|BEFORE|2021-01-19|BEFORE|2021-02-21
e|RS|ed3ae3f4-892a-4e68-9f3d-e81b2f2e09c0|5|MRDIND|Minimal Residual Disease Indicator|IWG CHESON MDS 2000|[?]|mph|UNFAVORABLE RESPONSE|1|genEq/mL|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|Y|Y||CAREGIVER|READER 3|Y|3|Visit_3|40|2|WASHOUT|2021-01-08|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-17|P1Y2M10DT2H30M|BEFORE|2021-02-10|BEFORE|2021-03-05
e|RS|ed3ae3f4-892a-4e68-9f3d-e81b2f2e09c0|6|NTRGRESP|Non-target Response|MONTSERRAT CLL 1989|||FAVORABLE RESPONSE|1|min*mg/mL|ZIEHL NEELSEN ACID FAST STAIN|||Y|DOMESTIC PARTNER|READER 1|Y|3|Visit_3|40|4|TREATMENT|2021-01-08|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-17|P1Y2M10DT2H30M|UNKNOWN|2021-01-20|AFTER|2021-02-03
e|RS|ed3ae3f4-892a-4e68-9f3d-e81b2f2e09c0|7|LIVRRESP|Liver Response|UNSPECIFIED|[?]|U/m2/day|cPR|1|Bq/ug|REFLECTANCE SPECTROSCOPY||||PROXY|ONCOLOGIST 1|Y|4|Visit_4|65|5|WASHOUT|2021-02-02|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-09|P1Y2M10DT2H30M|BEFORE|2021-03-03|AFTER|2021-03-04
e|RS|ed3ae3f4-892a-4e68-9f3d-e81b2f2e09c0|8|MJPTHIND|Major Pathological Response Indicator|GCIG RUSTIN OVARIAN CANCER 2011|[?]|CARTRIDGE|DECREASED|1|mm/min|SURFACE PLASMON RESONANCE||||FRIEND|ONCOLOGIST 1|U|4|Visit_4|65|6|TREATMENT|2021-02-02|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-09|P1Y2M10DT2H30M|UNKNOWN|2020-12-31|COINCIDENT|2021-01-22
e|RS|ed3ae3f4-892a-4e68-9f3d-e81b2f2e09c0|9|SYMPTDTR|Symptomatic Deterioration|iRECIST|||PSA PROGRESSION|1|KIT|IMMUNOASSAY|||Y|PROXY|INTERNIST|Y|5|Visit_5|90|1|TREATMENT|2021-02-27|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-22|P1Y2M10DT2H30M|AFTER|2020-12-06|BEFORE|2021-02-09
e|RS|ed3ae3f4-892a-4e68-9f3d-e81b2f2e09c0|10|TRGRESP|Target Response|LEE LUNG CANCER 2011|||CYTOGENETIC CR|1|ug/cm2|GEL ELECTROPHORESIS||Y|Y|DOMESTIC PARTNER|NEUROLOGIST 1|N|5|Visit_5|90|6|TREATMENT|2021-02-27|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-22|P1Y2M10DT2H30M|AFTER|2021-02-09|AFTER|2021-03-02
e|RS|88d03ea3-dc55-4fb5-9296-3b94037a1aa6|1|NTNERESP|Non-Target Non-Enhancing Response|DOHNER AML 2010|||PSEUDOPROGRESSION|1|/10^3|QUANTITATIVE ULTRASOUND||Y|Y|HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|NA|1|Visit_1|10|2|TREATMENT|2020-09-06|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-02|P1Y2M10DT2H30M|BEFORE|2020-09-03|ONGOING|2020-10-12
e|RS|88d03ea3-dc55-4fb5-9296-3b94037a1aa6|2|NEWLWIND|New Lesion Worsening Indicator|GUILHOT CML 2007|||CYTOGENETIC MINIMAL RESPONSE|1|ft3|PULMONARY ANGIOGRAPHY|Y||Y|SPOUSE|NEUROLOGIST 1|NA|1|Visit_1|10|1|FOLLOW-UP|2020-09-06|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-02|P1Y2M10DT2H30M|AFTER|2020-10-09|ONGOING|2020-12-02
e|RS|88d03ea3-dc55-4fb5-9296-3b94037a1aa6|3|NTERESP|Non-Target Enhancing Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|%(w/v)|ABSENT MORPHOLOGIC RESPONSE|1|cm|PEAK FLOWMETRY||||CLINICAL RESEARCH ASSOCIATE|RATER 1|N|2|Visit_2|25|6|TREATMENT|2020-09-21|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-23|P1Y2M10DT2H30M|AFTER|2020-10-11|COINCIDENT|2020-11-28
e|RS|88d03ea3-dc55-4fb5-9296-3b94037a1aa6|4|BONERESP|Bone Response|PRINCE TCELL LYMPHOMA 2010|[?]|DIP|CA125 50% RESPONSE|1|dmol|BIOIMPEDANCE SPECTROSCOPY||||PARENT|RATER 2|U|2|Visit_2|25|6|SCREENING|2020-09-21|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-23|P1Y2M10DT2H30M|AFTER|2020-09-06|COINCIDENT|2020-09-18
e|RS|88d03ea3-dc55-4fb5-9296-3b94037a1aa6|5|METSIND|Metastatic Indicator|MASS|[?]|breaths/min|PR-CT|1|mEq/g|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY|Y|||STUDY SUBJECT|DERMATOLOGIST|U|3|Visit_3|40|5|SCREENING|2020-10-06|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-04|P1Y2M10DT2H30M|UNKNOWN|2020-11-24|COINCIDENT|2020-11-27
e|RS|88d03ea3-dc55-4fb5-9296-3b94037a1aa6|6|CYTORESP|Cytogenetic Response|HARTMAN PANCREATIC CANCER 2012|[?]|mL/animal/wk|CA125 75% RESPONSE|1|g/m2|CONFOCAL MICROSCOPY|Y|Y||INVESTIGATOR|READER|U|3|Visit_3|40|5|WASHOUT|2020-10-06|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-04|P1Y2M10DT2H30M|UNKNOWN|2020-12-01|ONGOING|2020-12-04
e|RS|88d03ea3-dc55-4fb5-9296-3b94037a1aa6|7|METBRESP|Metabolic Response|EASL BRUIX LIVER CANCER 2001|[?]|10^3 copies/mL|iUPD|1|nmol/L/min|AMSLER GRID||||SPOUSE|ONCOLOGIST|Y|4|Visit_4|65|1|FOLLOW-UP|2020-10-31|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-31|P1Y2M10DT2H30M|AFTER|2020-11-07|COINCIDENT|2020-11-30
e|RS|88d03ea3-dc55-4fb5-9296-3b94037a1aa6|8|TRGRESP|Target Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|mmol/min/kPa|QUANTIFIABLE MRD POSITIVITY|1|ug/m2/min|MICROARRAY|Y|||PARENT|MICROSCOPIST 1|Y|4|Visit_4|65|7|WASHOUT|2020-10-31|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-31|P1Y2M10DT2H30M|AFTER|2020-10-10|BEFORE|2020-11-07
e|RS|88d03ea3-dc55-4fb5-9296-3b94037a1aa6|9|RDIORESP|Radiologic Response|BURCOMBE BREAST CANCER 2005|[?]|mg/dL|MRD RELAPSE|1|oz eq|SLIT LAMP||||SIBLING|NEUROLOGIST 1|U|5|Visit_5|90|4|SCREENING|2020-11-25|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-10|P1Y2M10DT2H30M|UNKNOWN|2020-10-12|ONGOING|2020-11-26
e|RS|88d03ea3-dc55-4fb5-9296-3b94037a1aa6|10|NEWLWIND|New Lesion Worsening Indicator|CHOLLET BREAST CANCER 2002|||SD-CT|1|uV*sec|ZIEHL NEELSEN ACID FAST STAIN|||Y|NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST|N|5|Visit_5|90|5|WASHOUT|2020-11-25|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-10|P1Y2M10DT2H30M|BEFORE|2020-09-20|BEFORE|2020-11-25
e|RS|b1b3e113-8c73-4446-8095-3341f8912bd7|1|ANATRESP|Anatomic Response|BURCOMBE BREAST CANCER 2005|||PD-CT|1|ug/g/min|TRANSVAGINAL ULTRASOUND|||Y|STUDY SUBJECT|HEMATOLOGIST|NA|1|Visit_1|10|7|SCREENING|2021-01-27|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-31|P1Y2M10DT2H30M|BEFORE|2021-04-22|COINCIDENT|2021-04-26
e|RS|b1b3e113-8c73-4446-8095-3341f8912bd7|2|RDIORESP|Radiologic Response|DURIE MULTIPLE MYELOMA 2006|[?]|PA|PDu|1|Bq|AUTOMATED COUNT||||INTERVIEWER|ONCOLOGIST 2|N|1|Visit_1|10|5|FOLLOW-UP|2021-01-27|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-31|P1Y2M10DT2H30M|UNKNOWN|2021-02-28|COINCIDENT|2021-04-20
e|RS|b1b3e113-8c73-4446-8095-3341f8912bd7|3|METBRESP|Metabolic Response|AJCC V7|[?]|10^7 TCID 50/dose|NE|1|mL/dose|PALPATION|Y|||ADJUDICATOR|RATER|Y|2|Visit_2|25|5|WASHOUT|2021-02-11|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-27|P1Y2M10DT2H30M|UNKNOWN|2021-01-20|COINCIDENT|2021-04-10
e|RS|b1b3e113-8c73-4446-8095-3341f8912bd7|4|SYMPTDTR|Symptomatic Deterioration|PRINCE TCELL LYMPHOMA 2010|[?]|DAYS|HI-P|1|mIU/L|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY|Y|||SPOUSE|MICROSCOPIST 1|Y|2|Visit_2|25|7|FOLLOW-UP|2021-02-11|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-27|P1Y2M10DT2H30M|UNKNOWN|2021-02-08|ONGOING|2021-04-26
e|RS|b1b3e113-8c73-4446-8095-3341f8912bd7|5|HEMARESP|Hematologic Response|PRINCE TCELL LYMPHOMA 2010|[?]|vg/dose|cCR|1|BLOCKS|MS/MS||||GUARDIAN|PATHOLOGIST|NA|3|Visit_3|40|6|WASHOUT|2021-02-26|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-18|P1Y2M10DT2H30M|BEFORE|2021-04-25|BEFORE|2021-04-26
e|RS|b1b3e113-8c73-4446-8095-3341f8912bd7|6|STRUSTAT|Steroid Use Status|SCHER PROSTATE CANCER 2011|[?]|10^5/hpf|DISEASE TRANSFORMATION|1|nmol BCE/nmol|FLOCCULATION, CHARCOAL ENHANCED|Y|||PARENT|MICROSCOPIST 1|U|3|Visit_3|40|5|TREATMENT|2021-02-26|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-18|P1Y2M10DT2H30M|COINCIDENT|2021-03-14|COINCIDENT|2021-04-13
e|RS|b1b3e113-8c73-4446-8095-3341f8912bd7|7|OVRLRESP|Overall Response|IRANO 2015|[?]|mL/sec/1.73m2|MORPHOLOGIC LEUKEMIA-FREE STATE|1|ug/m2/h|IODINE STAIN||Y||CAREGIVER|MICROSCOPIST 3|NA|4|Visit_4|65|3|FOLLOW-UP|2021-03-23|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-20|P1Y2M10DT2H30M|UNKNOWN|2021-04-18|AFTER|2021-04-25
e|RS|b1b3e113-8c73-4446-8095-3341f8912bd7|8|LIVRRESP|Liver Response|MASS|[?]|mU/L|DISEASE TRANSFORMATION|1|ppb|CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY||||INVESTIGATOR|RATER|N|4|Visit_4|65|4|WASHOUT|2021-03-23|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-20|P1Y2M10DT2H30M|AFTER|2021-02-07|AFTER|2021-02-19
e|RS|b1b3e113-8c73-4446-8095-3341f8912bd7|9|CPRFSTAT|Clinical Performance Status|NCIWG CHESON CLL 1996|[?]|mph|PMR|1|L/h/m2|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION||||SIBLING|ADJUDICATOR 3|N|5|Visit_5|90|1|FOLLOW-UP|2021-04-17|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-09|P1Y2M10DT2H30M|COINCIDENT|2021-04-03|AFTER|2021-04-08
e|RS|b1b3e113-8c73-4446-8095-3341f8912bd7|10|NEWLPROG|New Lesion Progression|IWG CHESON MDS 2000|[?]|Enzyme U/g Hb|IMPROVED|1|Gy/h|STRESS ECHOCARDIOGRAPHY||||FRIEND|ONCOLOGIST 1|U|5|Visit_5|90|5|TREATMENT|2021-04-17|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-09|P1Y2M10DT2H30M|BEFORE|2021-02-20|COINCIDENT|2021-04-23
e|RS|caed12ff-3dfa-42cd-95e8-9a3dfd10184d|1|LIVRRESP|Liver Response|MURPHY PROSTATE CANCER 1980|[?]|%(w/v)|PD FROM PR|1|GBq/mg|ICP-MS||Y||FAMILY MEMBER|ONCOLOGIST|Y|1|Visit_1|10|2|TREATMENT|2020-11-22|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-30|P1Y2M10DT2H30M|COINCIDENT|2020-11-30|COINCIDENT|2021-01-24
e|RS|caed12ff-3dfa-42cd-95e8-9a3dfd10184d|2|LIVRRESP|Liver Response|WHO BREAST CANCER 2006|||sCR|1|kg/cm|TRIPLE-PHASE MRI SCAN|||Y|CLINICAL STUDY SPONSOR|UROLOGIST|U|1|Visit_1|10|2|TREATMENT|2020-11-22|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-30|P1Y2M10DT2H30M|COINCIDENT|2020-11-30|AFTER|2021-02-02
e|RS|caed12ff-3dfa-42cd-95e8-9a3dfd10184d|3|ANATRESP|Anatomic Response|NCCN ALL MRD 2014|||PR|1|ug/kg/h|LUXOL FAST BLUE AND CRESYL VIOLET STAIN||Y|Y|ADJUDICATION COMMITTEE|RADIOLOGIST|Y|2|Visit_2|25|6|TREATMENT|2020-12-07|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-22|P1Y2M10DT2H30M|AFTER|2020-12-22|AFTER|2021-02-16
e|RS|caed12ff-3dfa-42cd-95e8-9a3dfd10184d|4|MRDRESP|Minimal Residual Disease Response|SCHER PROSTATE CANCER 2011|[?]|PNU/mL|IMPROVED|1|ug/animal|IMPEDANCE CONDUCTIVITY||||CLINICAL RESEARCH COORDINATOR|READER 3|N|2|Visit_2|25|1|TREATMENT|2020-12-07|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-22|P1Y2M10DT2H30M|COINCIDENT|2020-11-30|AFTER|2020-12-25
e|RS|caed12ff-3dfa-42cd-95e8-9a3dfd10184d|5|MRDRESP|Minimal Residual Disease Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|MAC50|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|cd*s/m2|SPIROMETRY||||HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|NA|3|Visit_3|40|3|FOLLOW-UP|2020-12-22|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-09|P1Y2M10DT2H30M|COINCIDENT|2020-12-18|BEFORE|2021-02-11
e|RS|caed12ff-3dfa-42cd-95e8-9a3dfd10184d|6|RDIORESP|Radiologic Response|HARTMAN PANCREATIC CANCER 2012|[?]|CARTRIDGE|WORSENED|1|mL/day|ACID FAST STAIN|Y|||VENDOR|READER 3|U|3|Visit_3|40|5|TREATMENT|2020-12-22|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-09|P1Y2M10DT2H30M|COINCIDENT|2020-12-24|BEFORE|2021-02-06
e|RS|caed12ff-3dfa-42cd-95e8-9a3dfd10184d|7|OVRLRESP|Overall Response|LUGANO CLASSIFICATION|[?]|Torr|MRD PERSISTENCE|1|mmAL|GC/FID||||CAREGIVER|READER 1|NA|4|Visit_4|65|6|WASHOUT|2021-01-16|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-25|P1Y2M10DT2H30M|AFTER|2020-12-18|ONGOING|2021-02-03
e|RS|caed12ff-3dfa-42cd-95e8-9a3dfd10184d|8|TMRESP|Tumor Marker Response|CHESON CLL 2006|[?]|KIT|iCR|1|EIA unit|SLOAN LETTER EYE CHART 2.5%|Y|||ADJUDICATOR|ADJUDICATOR|N|4|Visit_4|65|1|TREATMENT|2021-01-16|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-25|P1Y2M10DT2H30M|BEFORE|2020-12-01|AFTER|2020-12-27
e|RS|caed12ff-3dfa-42cd-95e8-9a3dfd10184d|9|ANATRESP|Anatomic Response|KUMAR IMWG 2016|[?]|SACHET|MOLECULAR MAJOR RESPONSE|1|TROCHE|CLOT DETECTION||Y||STUDY SUBJECT|READER 1|Y|5|Visit_5|90|1|TREATMENT|2021-02-10|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-16|P1Y2M10DT2H30M|UNKNOWN|2021-01-15|BEFORE|2021-02-12
e|RS|caed12ff-3dfa-42cd-95e8-9a3dfd10184d|10|MRPHRESP|Morphologic Response|PETIT BREAST CANCER 2001|[?]|g/dL|SD-CT|1|pmol/10^9 cells|GEL ELECTROPHORESIS||||CHILD|OPHTHALMOLOGIST|Y|5|Visit_5|90|7|TREATMENT|2021-02-10|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-16|P1Y2M10DT2H30M|AFTER|2021-01-18|COINCIDENT|2021-02-18
e|RS|8ef3d6ea-49e3-4646-90ba-4b8b5b65e799|1|OVRLRESP|Overall Response|RANO|[?]|mL/m2/h|DECREASED|1|min*mg/mL|MICROPARTICLE ENZYME IMMUNOASSAY||||CLINICAL RESEARCH ASSOCIATE|CLINICAL PATHOLOGIST|Y|1|Visit_1|10|3|FOLLOW-UP|2020-08-06|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-19|P1Y2M10DT2H30M|UNKNOWN|2020-10-29|ONGOING|2020-10-31
e|RS|8ef3d6ea-49e3-4646-90ba-4b8b5b65e799|2|LIVRRESP|Liver Response|CHOI GIST 2008|[?]|ohm|RELAPSED DISEASE FROM CR OR PR|1|L/kg|IODINE STAIN|Y|||FRIEND|MICROSCOPIST 1|Y|1|Visit_1|10|7|TREATMENT|2020-08-06|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-19|P1Y2M10DT2H30M|BEFORE|2020-08-14|BEFORE|2020-10-02
e|RS|8ef3d6ea-49e3-4646-90ba-4b8b5b65e799|3|OVRLRESP|Overall Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|||PARTIAL MORPHOLOGIC RESPONSE|1|10^7 TCID 50/dose|WESTERGREN||Y|Y|NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST|N|2|Visit_2|25|2|WASHOUT|2020-08-21|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-03|P1Y2M10DT2H30M|COINCIDENT|2020-09-10|COINCIDENT|2020-10-17
e|RS|8ef3d6ea-49e3-4646-90ba-4b8b5b65e799|4|NEWLWIND|New Lesion Worsening Indicator|LUGANO CLASSIFICATION|[?]|g/mol|PSA PROGRESSION|1|DRUM|FLUORESCENT IMMUNOASSAY||||INDEPENDENT ASSESSOR|MICROSCOPIST 2|U|2|Visit_2|25|5|TREATMENT|2020-08-21|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-03|P1Y2M10DT2H30M|COINCIDENT|2020-10-26|BEFORE|2020-10-31
e|RS|8ef3d6ea-49e3-4646-90ba-4b8b5b65e799|5|METBRESP|Metabolic Response|SHINDOH COLORECTAL CANCER 2013|||UNFAVORABLE RESPONSE|1|/month|ALCIAN BLUE STAIN|||Y|PARENT|CLINICAL PATHOLOGIST|U|3|Visit_3|40|3|FOLLOW-UP|2020-09-05|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-13|P1Y2M10DT2H30M|COINCIDENT|2020-08-29|AFTER|2020-10-19
e|RS|8ef3d6ea-49e3-4646-90ba-4b8b5b65e799|6|DRCRIND|Disease Recurrence Indicator|EASL BRUIX LIVER CANCER 2001|[?]|PIPE|SD|1|mg/g/min|RAJI CELL EIA||Y||SIGNIFICANT OTHER|INTERNIST|N|3|Visit_3|40|4|WASHOUT|2020-09-05|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-13|P1Y2M10DT2H30M|COINCIDENT|2020-10-03|COINCIDENT|2020-10-12
e|RS|8ef3d6ea-49e3-4646-90ba-4b8b5b65e799|7|NTERESP|Non-Target Enhancing Response|MONTSERRAT CLL 1989|[?]|STRIP|iUPD|1|uEq/L|POLYMERASE CHAIN REACTION||||SIGNIFICANT OTHER|RATER 1|U|4|Visit_4|65|4|SCREENING|2020-09-30|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-10|P1Y2M10DT2H30M|AFTER|2020-11-03|BEFORE|2020-11-04
e|RS|8ef3d6ea-49e3-4646-90ba-4b8b5b65e799|8|DRCRIND|Disease Recurrence Indicator|RECICL|[?]|Anson U|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|FFU|CONFOCAL MICROSCOPY|Y|||INTERVIEWER|PHYSIOTHERAPIST|NA|4|Visit_4|65|7|SCREENING|2020-09-30|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-10|P1Y2M10DT2H30M|COINCIDENT|2020-09-22|COINCIDENT|2020-10-24
e|RS|8ef3d6ea-49e3-4646-90ba-4b8b5b65e799|9|MRPHRESP|Morphologic Response|iRECIST|[?]|m/sec2|CA125 50% RESPONSE|1|umol/mg/min|REBOUND TONOMETRY|Y|||STUDY SUBJECT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|5|Visit_5|90|1|TREATMENT|2020-10-25|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-29|P1Y2M10DT2H30M|AFTER|2020-11-01|AFTER|2020-11-02
e|RS|8ef3d6ea-49e3-4646-90ba-4b8b5b65e799|10|MNPTHIND|Minor Pathological Response Indicator|AJCC V8|[?]|uEq/L|HI-P|1|deg/s|DIGITAL PCR|Y|||SPOUSE|OPTOMETRIST|N|5|Visit_5|90|4|TREATMENT|2020-10-25|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-29|P1Y2M10DT2H30M|UNKNOWN|2020-10-11|AFTER|2020-10-14
e|RS|3b83c7a0-e22b-45b1-b065-71971f014039|1|ANATRESP|Anatomic Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|mmol/min/kPa|iUPD|1|10^9/L|MRI||||DOMESTIC PARTNER|ONCOLOGIST 1|Y|1|Visit_1|10|3|WASHOUT|2020-09-01|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-18|P1Y2M10DT2H30M|AFTER|2020-10-11|ONGOING|2020-11-09
e|RS|3b83c7a0-e22b-45b1-b065-71971f014039|2|NEWLWIND|New Lesion Worsening Indicator|FAROOQUI SUPP CLL 2014|[?]|ug/kg/h|STABLE|1|cm|SLOAN LETTER EYE CHART 100%||||CAREGIVER|ENDOCRINOLOGIST|N|1|Visit_1|10|4|TREATMENT|2020-09-01|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-18|P1Y2M10DT2H30M|UNKNOWN|2020-09-06|COINCIDENT|2020-11-18
e|RS|3b83c7a0-e22b-45b1-b065-71971f014039|3|MRDIND|Minimal Residual Disease Indicator|MRECIST LENCIONI LIVER CANCER 2010|[?]|ug/kg/day|PARTIAL MORPHOLOGIC RESPONSE|1|PFU/dose|MALDI||||STUDY SUBJECT|ONCOLOGIST 2|Y|2|Visit_2|25|7|WASHOUT|2020-09-16|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-31|P1Y2M10DT2H30M|AFTER|2020-09-23|AFTER|2020-10-26
e|RS|3b83c7a0-e22b-45b1-b065-71971f014039|4|MRDIND|Minimal Residual Disease Indicator|IRANO 2015|||PARTIAL MORPHOLOGIC RESPONSE|1|/day|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION|||Y|GUARDIAN|READER 1|U|2|Visit_2|25|2|TREATMENT|2020-09-16|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-31|P1Y2M10DT2H30M|BEFORE|2020-08-29|ONGOING|2020-11-15
e|RS|3b83c7a0-e22b-45b1-b065-71971f014039|5|METSIND|Metastatic Indicator|CHOI GIST 2008|||CYTOGENETIC MINOR RESPONSE|1|log10 CFU/mL|PERIPHERAL ANGIOGRAPHY|||Y|VENDOR|FORENSIC PATHOLOGIST|Y|3|Visit_3|40|7|SCREENING|2020-10-01|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-16|P1Y2M10DT2H30M|COINCIDENT|2020-09-21|ONGOING|2020-11-17
e|RS|3b83c7a0-e22b-45b1-b065-71971f014039|6|MNPTHIND|Minor Pathological Response Indicator|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|cpm|PSEUDORESPONSE|1|cd/m2|EPSILOMETER||||ADJUDICATOR|OTOLARYNGOLOGIST|U|3|Visit_3|40|2|FOLLOW-UP|2020-10-01|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-16|P1Y2M10DT2H30M|BEFORE|2020-11-13|COINCIDENT|2020-11-16
e|RS|3b83c7a0-e22b-45b1-b065-71971f014039|7|OVRLRESP|Overall Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|kcal|MRD NEGATIVITY|1|uSiemens|PERIPHERAL ANGIOGRAPHY|Y|||INVESTIGATOR|DEVELOPMENTAL PSYCHOLOGIST|N|4|Visit_4|65|3|FOLLOW-UP|2020-10-26|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-15|P1Y2M10DT2H30M|BEFORE|2020-09-15|ONGOING|2020-11-22
e|RS|3b83c7a0-e22b-45b1-b065-71971f014039|8|ANATRESP|Anatomic Response|RECIST 1.0|||PDu|1|kBq/uL|SCINTIGRAPHY|Y|Y|Y|PROXY|ADJUDICATOR 1|NA|4|Visit_4|65|3|WASHOUT|2020-10-26|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-15|P1Y2M10DT2H30M|BEFORE|2020-09-12|COINCIDENT|2020-09-18
e|RS|3b83c7a0-e22b-45b1-b065-71971f014039|9|HEMARESP|Hematologic Response|RECICL|[?]|log EID 50/dose|PSEUDORESPONSE|1|cmH2O*s/mL|ZIEHL NEELSEN ACID FAST STAIN|Y|Y||INVESTIGATOR|PATHOLOGIST|U|5|Visit_5|90|3|TREATMENT|2020-11-20|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-30|P1Y2M10DT2H30M|BEFORE|2020-10-07|BEFORE|2020-11-27
e|RS|3b83c7a0-e22b-45b1-b065-71971f014039|10|METBRESP|Metabolic Response|UNSPECIFIED|||DECREASED|1|cg|FISH||Y|Y|INTERVIEWER|NEUROLOGIST|NA|5|Visit_5|90|7|FOLLOW-UP|2020-11-20|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-30|P1Y2M10DT2H30M|AFTER|2020-11-28|BEFORE|2020-11-29
e|RS|92c849ce-12b8-4c38-baab-f91c44a007b9|1|DRCRIND|Disease Recurrence Indicator|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|ug/kg/day|INCREASED|1|VIAL|OPTICAL MAPPING||||ADJUDICATOR|READER 3|N|1|Visit_1|10|6|TREATMENT|2020-11-12|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-09|P1Y2M10DT2H30M|AFTER|2020-11-05|BEFORE|2020-12-08
e|RS|92c849ce-12b8-4c38-baab-f91c44a007b9|2|NTERESP|Non-Target Enhancing Response|EBMT BLADE MYELOMA 1998|[?]|ug|PD FROM PR|1|kg/cm2|FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY||||STUDY SUBJECT|HEMATOLOGIST|Y|1|Visit_1|10|6|FOLLOW-UP|2020-11-12|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-09|P1Y2M10DT2H30M|UNKNOWN|2021-01-17|ONGOING|2021-01-22
e|RS|92c849ce-12b8-4c38-baab-f91c44a007b9|3|MJPTHIND|Major Pathological Response Indicator|CHESON CLL 2006|[?]|mL/kg/day|WORSENED|1|C|SLOAN LETTER EYE CHART 100%|Y|||ADJUDICATOR|PATHOLOGIST 1|U|2|Visit_2|25|2|FOLLOW-UP|2020-11-27|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-08|P1Y2M10DT2H30M|UNKNOWN|2021-01-31|COINCIDENT|2021-02-03
e|RS|92c849ce-12b8-4c38-baab-f91c44a007b9|4|ANATRESP|Anatomic Response|RAJKUMAR MYELOMA 2011|[?]|g/cm2|CYTOGENETIC MINOR RESPONSE|1|10^3 organisms|MAGNETIC RESONANCE ELASTOGRAPHY||||ADJUDICATOR|MICROSCOPIST 1|U|2|Visit_2|25|6|FOLLOW-UP|2020-11-27|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-08|P1Y2M10DT2H30M|UNKNOWN|2020-12-05|AFTER|2021-01-18
e|RS|92c849ce-12b8-4c38-baab-f91c44a007b9|5|MNPTHIND|Minor Pathological Response Indicator|DURIE MULTIPLE MYELOMA 2006|[?]|copies/ug|CA125 50% RESPONSE|1|mEq/uL|CINEANGIOGRAPHY||||SPOUSE|FORENSIC PATHOLOGIST|Y|3|Visit_3|40|5|TREATMENT|2020-12-12|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-29|P1Y2M10DT2H30M|AFTER|2021-02-07|AFTER|2021-02-09
e|RS|92c849ce-12b8-4c38-baab-f91c44a007b9|6|NEWLWIND|New Lesion Worsening Indicator|MRANO VAN DEN BENT GLIOMA 2011|[?]|grain|MORPHOLOGIC LEUKEMIA-FREE STATE|1|nmol/L|WRIGHT STAIN||Y||CLINICAL RESEARCH ASSOCIATE|OPTOMETRIST|Y|3|Visit_3|40|1|WASHOUT|2020-12-12|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-29|P1Y2M10DT2H30M|AFTER|2020-11-06|BEFORE|2021-01-07
e|RS|92c849ce-12b8-4c38-baab-f91c44a007b9|7|CLINRESP|Clinical Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|||CMR|1|mEq/day|NO INFORMATION|Y|Y|Y|INDEPENDENT ASSESSOR|RATER|N|4|Visit_4|65|2|WASHOUT|2021-01-06|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-08|P1Y2M10DT2H30M|COINCIDENT|2021-01-31|ONGOING|2021-02-04
e|RS|92c849ce-12b8-4c38-baab-f91c44a007b9|8|NEWLWIND|New Lesion Worsening Indicator|MACDONALD GLIOMA 1990|||PD FROM PR|1|log10 PFU/mL|COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY||Y|Y|PROXY|PATHOLOGIST 2|NA|4|Visit_4|65|3|WASHOUT|2021-01-06|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-08|P1Y2M10DT2H30M|AFTER|2021-01-24|COINCIDENT|2021-02-06
e|RS|92c849ce-12b8-4c38-baab-f91c44a007b9|9|ANATRESP|Anatomic Response|RAJKUMAR MYELOMA 2011|[?]|Ejaculate U|EQUIVOCAL|1|mEq/mL|OBSERVATION||||FAMILY MEMBER|NEUROLOGIST 1|Y|5|Visit_5|90|4|WASHOUT|2021-01-31|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-01|P1Y2M10DT2H30M|BEFORE|2021-01-23|AFTER|2021-01-30
e|RS|92c849ce-12b8-4c38-baab-f91c44a007b9|10|BONERESP|Bone Response|MASS|||RELAPSED DISEASE FROM CR|1|10^6/L|MALDI|||Y|CLINICAL RESEARCH ASSOCIATE|READER 1|Y|5|Visit_5|90|1|TREATMENT|2021-01-31|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-01|P1Y2M10DT2H30M|UNKNOWN|2021-02-03|ONGOING|2021-02-08
e|RS|f2101018-c983-435e-a453-148f182388f7|1|NTRGRESP|Non-target Response|NCIWG CHESON CLL 1996|||MRD NEGATIVITY|1|um2|FLUORESCENT SPOT TEST|||Y|STUDY SUBJECT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|1|Visit_1|10|6|TREATMENT|2020-09-01|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-15|P1Y2M10DT2H30M|UNKNOWN|2020-11-02|BEFORE|2020-11-09
e|RS|f2101018-c983-435e-a453-148f182388f7|2|PATHRESP|Pathologic Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|ohm|HI-E|1|mg/mL/min|APPLANATION TONOMETRY||||CLINICAL STUDY SPONSOR|READER 2|Y|1|Visit_1|10|3|FOLLOW-UP|2020-09-01|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-15|P1Y2M10DT2H30M|COINCIDENT|2020-10-21|ONGOING|2020-11-01
e|RS|f2101018-c983-435e-a453-148f182388f7|3|MRDIND|Minimal Residual Disease Indicator|CHESON CLL 2012|[?]|days/month|CRi|1|10^4/hpf|TRANSCRIPTION-MEDIATED AMPLIFICATION||||CLINICAL STUDY SPONSOR|PATHOLOGIST 1|NA|2|Visit_2|25|6|SCREENING|2020-09-16|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-14|P1Y2M10DT2H30M|COINCIDENT|2020-11-20|ONGOING|2020-11-22
e|RS|f2101018-c983-435e-a453-148f182388f7|4|SPLNRESP|Spleen Response|PROTOCOL DEFINED RESPONSE CRITERIA|||UNFAVORABLE RESPONSE|1|pmol|HPLC-FL|Y||Y|NON-HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|NA|2|Visit_2|25|4|SCREENING|2020-09-16|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-14|P1Y2M10DT2H30M|UNKNOWN|2020-11-16|COINCIDENT|2020-11-24
e|RS|f2101018-c983-435e-a453-148f182388f7|5|NTLWIND|Non-Target Lesion Worsening Indicator|RANO ELLINGSON 2017|[?]|ug/mL/h|iCPD|1|U/mL|NUCLEAR RADIOLOGY|Y|||PROXY|RADIOLOGIST 2|NA|3|Visit_3|40|1|TREATMENT|2020-10-01|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-12|P1Y2M10DT2H30M|AFTER|2020-09-22|ONGOING|2020-10-29
e|RS|f2101018-c983-435e-a453-148f182388f7|6|NEWLPROG|New Lesion Progression|GUILHOT CML 2007|[?]|mL/animal/day|NE|1|10^10/L|CONTACT SPECULAR MICROSCOPY||||PARENT|RATER|U|3|Visit_3|40|4|WASHOUT|2020-10-01|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-12|P1Y2M10DT2H30M|UNKNOWN|2020-09-04|BEFORE|2020-10-31
e|RS|f2101018-c983-435e-a453-148f182388f7|7|NEWLIND|New Lesion Indicator|IWG CHESON MDS 2006|||UNFAVORABLE RESPONSE|1|mEq/L|CRYOSCOPY||Y|Y|SPOUSE|HEMATOLOGIST|N|4|Visit_4|65|6|FOLLOW-UP|2020-10-26|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-17|P1Y2M10DT2H30M|AFTER|2020-11-09|AFTER|2020-11-22
e|RS|f2101018-c983-435e-a453-148f182388f7|8|MRDIND|Minimal Residual Disease Indicator|BRUGGEMANN MRD 2010|[?]|mEq/day|PD|1|pmol/10^10 cells|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY|Y|||HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|U|4|Visit_4|65|7|TREATMENT|2020-10-26|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-17|P1Y2M10DT2H30M|COINCIDENT|2020-11-29|AFTER|2020-11-30
e|RS|f2101018-c983-435e-a453-148f182388f7|9|ANATRESP|Anatomic Response|IWG CHESON AML 2003|[?]|U/m2|MRD RELAPSE|1|FFU|TRANSVAGINAL ULTRASOUND||||INTERVIEWER|MICROSCOPIST 3|Y|5|Visit_5|90|7|TREATMENT|2020-11-20|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-14|P1Y2M10DT2H30M|AFTER|2020-11-24|COINCIDENT|2020-11-28
e|RS|f2101018-c983-435e-a453-148f182388f7|10|PATHRESP|Pathologic Response|WHO BREAST CANCER 2006|||PR|1|/5x10^4 WBC|NEPHELOMETRY|||Y|FAMILY MEMBER|ADJUDICATOR 3|NA|5|Visit_5|90|5|SCREENING|2020-11-20|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-14|P1Y2M10DT2H30M|AFTER|2020-09-29|AFTER|2020-10-07
e|RS|613284eb-edbe-446b-b4fe-f96f1510e626|1|MJPTHIND|Major Pathological Response Indicator|GCIG RUSTIN OVARIAN CANCER 2011|[?]|mEq/L|PARTIAL MORPHOLOGIC RESPONSE|1|/sec|IMPULSE OSCILLOMETRY|Y|||SIGNIFICANT OTHER|OTOLARYNGOLOGIST|NA|1|Visit_1|10|1|FOLLOW-UP|2020-11-07|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-08|P1Y2M10DT2H30M|BEFORE|2020-11-28|BEFORE|2020-12-20
e|RS|613284eb-edbe-446b-b4fe-f96f1510e626|2|TRGRESP|Target Response|JACINTO CERVICAL CANCER 2007|[?]|10^3 RNA copies/mL|FAVORABLE RESPONSE|1|ms/mmHg|FREEZING POINT DEPRESSION|Y|||FAMILY MEMBER|FORENSIC PATHOLOGIST|N|1|Visit_1|10|2|TREATMENT|2020-11-07|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-08|P1Y2M10DT2H30M|BEFORE|2021-01-09|BEFORE|2021-01-22
e|RS|613284eb-edbe-446b-b4fe-f96f1510e626|3|BMIVLIND|Bone Marrow Involvement Indicator|NCCN ALL MRD 2014|[?]|Bq/mg|iPR|1|ug/g/min|AUSCULTATION||||VENDOR|PATHOLOGIST|N|2|Visit_2|25|7|WASHOUT|2020-11-22|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-08|P1Y2M10DT2H30M|UNKNOWN|2021-01-04|ONGOING|2021-02-03
e|RS|613284eb-edbe-446b-b4fe-f96f1510e626|4|METBRESP|Metabolic Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|1/(s*kPa)|MOLECULAR MAJOR RESPONSE|1|um/s|ELASTOGRAPHY||||VENDOR|ONCOLOGIST 1|NA|2|Visit_2|25|4|TREATMENT|2020-11-22|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-08|P1Y2M10DT2H30M|AFTER|2020-12-27|AFTER|2021-01-07
e|RS|613284eb-edbe-446b-b4fe-f96f1510e626|5|METSIND|Metastatic Indicator|EASL BRUIX LIVER CANCER 2001|[?]|mL/cm H2O|DECREASED|1|log10 PFU/mL|PULSE OXIMETRY|Y|||INDEPENDENT ASSESSOR|READER 3|U|3|Visit_3|40|1|TREATMENT|2020-12-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-14|P1Y2M10DT2H30M|BEFORE|2020-12-18|AFTER|2021-01-15
e|RS|613284eb-edbe-446b-b4fe-f96f1510e626|6|PATHRESP|Pathologic Response|RANO ELLINGSON 2017|||NR|1|mL/kg/day|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|||Y|FRIEND|READER|Y|3|Visit_3|40|1|WASHOUT|2020-12-07|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-14|P1Y2M10DT2H30M|BEFORE|2020-11-16|AFTER|2021-01-12
e|RS|613284eb-edbe-446b-b4fe-f96f1510e626|7|MJPTHIND|Major Pathological Response Indicator|MRECIST BYRNE MESOTHELIOMA 2004|[?]|TAMPON|CR|1|mL/min/1.73m2|DUCTOGRAPHY||||CLINICAL RESEARCH ASSOCIATE|RATER 1|Y|4|Visit_4|65|7|FOLLOW-UP|2021-01-01|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-06|P1Y2M10DT2H30M|AFTER|2020-12-15|AFTER|2020-12-29
e|RS|613284eb-edbe-446b-b4fe-f96f1510e626|8|MOLRESP|Molecular Response|GUPPY OVARIAN CANCER 2002|||CR|1|MASK|FISH|||Y|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 2|U|4|Visit_4|65|6|TREATMENT|2021-01-01|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-06|P1Y2M10DT2H30M|AFTER|2020-12-22|AFTER|2020-12-23
e|RS|613284eb-edbe-446b-b4fe-f96f1510e626|9|CYTORESP|Cytogenetic Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|PIXELS/in|CYTOGENETIC PR|1|10^6 organisms/mL|CLIP SEQUENCING||Y||STUDY SUBJECT|PATHOLOGIST 1|NA|5|Visit_5|90|2|SCREENING|2021-01-26|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-19|P1Y2M10DT2H30M|BEFORE|2021-01-29|AFTER|2021-01-30
e|RS|613284eb-edbe-446b-b4fe-f96f1510e626|10|SPLNRESP|Spleen Response|IWC HALLEK CLL 2008|[?]|U/m2/min|SD-CT|1|ug/L FEU|REVERSE TRANSCRIPTASE PCR||||SIGNIFICANT OTHER|MICROSCOPIST|NA|5|Visit_5|90|7|WASHOUT|2021-01-26|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-19|P1Y2M10DT2H30M|AFTER|2021-01-26|AFTER|2021-02-03
e|RS|65e8391b-0c34-4687-a0ab-cb291a4cdf36|1|NTLWIND|Non-Target Lesion Worsening Indicator|NCCN ALL MRD 2014|[?]|mMU/mL|VGPR|1|10^8 PFU|PERIODIC ACID SCHIFF STAIN||Y||SIGNIFICANT OTHER|INTERNIST|U|1|Visit_1|10|2|WASHOUT|2020-07-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-05|P1Y2M10DT2H30M|COINCIDENT|2020-09-03|ONGOING|2020-10-10
e|RS|65e8391b-0c34-4687-a0ab-cb291a4cdf36|2|TRGRESP|Target Response|BURCOMBE BREAST CANCER 2005|[?]|K|DISEASE TRANSFORMATION|1|cd*s/m2|INCISION-INDUCED BLEEDING METHOD||||CHILD|RATER 2|NA|1|Visit_1|10|4|WASHOUT|2020-07-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-05|P1Y2M10DT2H30M|UNKNOWN|2020-09-01|COINCIDENT|2020-09-26
e|RS|65e8391b-0c34-4687-a0ab-cb291a4cdf36|3|NEWLWIND|New Lesion Worsening Indicator|UNSPECIFIED|[?]|mL/g/h|PSA PROGRESSION|1|100 IU/mL|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS||Y||CAREGIVER|INTERNIST|N|2|Visit_2|25|2|TREATMENT|2020-07-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-04|P1Y2M10DT2H30M|BEFORE|2020-07-17|BEFORE|2020-10-03
e|RS|65e8391b-0c34-4687-a0ab-cb291a4cdf36|4|ANATRESP|Anatomic Response|RAJKUMAR MYELOMA 2011|[?]|mL/dL|iUPD|1|kg/L|MYELOPEROXIDASE STAIN|Y|||GUARDIAN|NEUROLOGIST 1|U|2|Visit_2|25|3|TREATMENT|2020-07-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-04|P1Y2M10DT2H30M|AFTER|2020-07-30|BEFORE|2020-08-03
e|RS|65e8391b-0c34-4687-a0ab-cb291a4cdf36|5|MJPTHIND|Major Pathological Response Indicator|KEAM BREAST CANCER 2013|||FAVORABLE RESPONSE|1|Log10 ELISA unit|ICC|Y|Y|Y|CHILD|RADIOLOGIST 2|U|3|Visit_3|40|6|SCREENING|2020-08-14|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-16|P1Y2M10DT2H30M|AFTER|2020-07-19|COINCIDENT|2020-07-30
e|RS|65e8391b-0c34-4687-a0ab-cb291a4cdf36|6|TMRESP|Tumor Marker Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|||mCR|1|L/day|MICROBIAL CULTURE|||Y|CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 3|Y|3|Visit_3|40|7|TREATMENT|2020-08-14|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-16|P1Y2M10DT2H30M|AFTER|2020-07-09|COINCIDENT|2020-09-12
e|RS|65e8391b-0c34-4687-a0ab-cb291a4cdf36|7|SYMPTDTR|Symptomatic Deterioration|SACT|||pCR|1|DDU|CT SCAN|||Y|INDEPENDENT ASSESSOR|INTERNIST|U|4|Visit_4|65|3|FOLLOW-UP|2020-09-08|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-06|P1Y2M10DT2H30M|BEFORE|2020-07-15|COINCIDENT|2020-08-11
e|RS|65e8391b-0c34-4687-a0ab-cb291a4cdf36|8|NTRGRESP|Non-target Response|CHESON LYMPHOMA 2008|||FAVORABLE RESPONSE|1|mm/min|SNELLEN EYE CHART|||Y|ADJUDICATION COMMITTEE|OTOLARYNGOLOGIST|U|4|Visit_4|65|4|FOLLOW-UP|2020-09-08|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-06|P1Y2M10DT2H30M|COINCIDENT|2020-09-01|ONGOING|2020-09-26
e|RS|65e8391b-0c34-4687-a0ab-cb291a4cdf36|9|CLINRESP|Clinical Response|NCCN ALL MRD 2014|[?]|/MBP|QUANTIFIABLE MRD POSITIVITY|1|mg/kg/week|RULER MEASUREMENT METHOD|Y|Y||FAMILY MEMBER|ONCOLOGIST 2|U|5|Visit_5|90|7|TREATMENT|2020-10-03|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-03|P1Y2M10DT2H30M|AFTER|2020-09-08|AFTER|2020-10-02
e|RS|65e8391b-0c34-4687-a0ab-cb291a4cdf36|10|NTNERESP|Non-Target Non-Enhancing Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|SQU/mL|WORSENED|1|mg/dL|STRESS ECHOCARDIOGRAPHY||Y||NON-HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|N|5|Visit_5|90|5|TREATMENT|2020-10-03|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-03|P1Y2M10DT2H30M|BEFORE|2020-08-25|COINCIDENT|2020-09-29
e|RS|2350438a-0bc8-4da5-b6c9-99a6c012b454|1|STRUSTAT|Steroid Use Status|IRANO 2015|||ABSENT MORPHOLOGIC RESPONSE|1|dyn|DIRECT SEQUENCING|Y|Y|Y|CLINICAL STUDY SPONSOR|ADJUDICATOR 3|NA|1|Visit_1|10|1|FOLLOW-UP|2020-08-21|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-05|P1Y2M10DT2H30M|COINCIDENT|2020-10-27|AFTER|2020-11-18
e|RS|2350438a-0bc8-4da5-b6c9-99a6c012b454|2|SYMPTDTR|Symptomatic Deterioration|MRECIST LENCIONI LIVER CANCER 2010|[?]|mL/m2|MORPHOLOGIC LEUKEMIA-FREE STATE|1|ks|QUANTITATIVE CORONARY ANGIOGRAPHY||||PROXY|ENDOCRINOLOGIST|NA|1|Visit_1|10|4|SCREENING|2020-08-21|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-05|P1Y2M10DT2H30M|UNKNOWN|2020-10-09|AFTER|2020-10-27
e|RS|2350438a-0bc8-4da5-b6c9-99a6c012b454|3|CYTORESP|Cytogenetic Response|EASL BRUIX LIVER CANCER 2001|[?]|CYLINDER|iCR|1|%/s|MAGNETIC RESONANCE ELASTOGRAPHY||Y||NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST|U|2|Visit_2|25|7|TREATMENT|2020-09-05|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-19|P1Y2M10DT2H30M|COINCIDENT|2020-11-10|AFTER|2020-11-13
e|RS|2350438a-0bc8-4da5-b6c9-99a6c012b454|4|NTRGRESP|Non-target Response|PETIT BREAST CANCER 2001|[?]|mAnson U/mL|NE|1|pptr|CELLULOSE TAPE|Y|||CHILD|MICROSCOPIST 2|Y|2|Visit_2|25|3|TREATMENT|2020-09-05|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-19|P1Y2M10DT2H30M|UNKNOWN|2020-10-06|BEFORE|2020-11-10
e|RS|2350438a-0bc8-4da5-b6c9-99a6c012b454|5|MJPTHIND|Major Pathological Response Indicator|CHESON MALIGNANT LYMPHOMA 2007|[?]|nkat/L|CA125 75% RESPONSE|1|mV/sec|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN||Y||DOMESTIC PARTNER|ONCOLOGIST 1|Y|3|Visit_3|40|6|TREATMENT|2020-09-20|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-17|P1Y2M10DT2H30M|UNKNOWN|2020-10-09|COINCIDENT|2020-10-15
e|RS|2350438a-0bc8-4da5-b6c9-99a6c012b454|6|CYTORESP|Cytogenetic Response|LUGANO CLASSIFICATION|[?]|mol/g|QUANTIFIABLE MRD POSITIVITY|1|km/h|LISSAMINE GREEN STAIN||||ADJUDICATOR|READER|N|3|Visit_3|40|4|TREATMENT|2020-09-20|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-17|P1Y2M10DT2H30M|COINCIDENT|2020-11-18|BEFORE|2020-11-19
e|RS|2350438a-0bc8-4da5-b6c9-99a6c012b454|7|NTNERESP|Non-Target Non-Enhancing Response|EBMT BLADE MYELOMA 1998|[?]|fraction of 1|PDu|1|ug/g/h|POLYGRAPHY||Y||VENDOR|FORENSIC PATHOLOGIST|NA|4|Visit_4|65|7|FOLLOW-UP|2020-10-15|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-05|P1Y2M10DT2H30M|COINCIDENT|2020-08-26|AFTER|2020-09-05
e|RS|2350438a-0bc8-4da5-b6c9-99a6c012b454|8|PATHRESP|Pathologic Response|RECIST 1.1|||CA125 75% RESPONSE|1|PELLET|KNEMOMETRY|Y||Y|CLINICAL STUDY SPONSOR|MICROSCOPIST 1|Y|4|Visit_4|65|4|SCREENING|2020-10-15|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-05|P1Y2M10DT2H30M|BEFORE|2020-11-15|BEFORE|2020-11-17
e|RS|2350438a-0bc8-4da5-b6c9-99a6c012b454|9|MRPHRESP|Morphologic Response|PETIT BREAST CANCER 2001|||PDu|1|mmol/s|SNELLEN EYE CHART||Y|Y|FRIEND|ONCOLOGIST|N|5|Visit_5|90|1|TREATMENT|2020-11-09|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-25|P1Y2M10DT2H30M|AFTER|2020-08-26|AFTER|2020-09-05
e|RS|2350438a-0bc8-4da5-b6c9-99a6c012b454|10|CLINRESP|Clinical Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|mg/L FEU|PDu|1|mmHg/L/min|MAGNETIC RESONANCE ELASTOGRAPHY|Y|Y||PROXY|RATER 2|U|5|Visit_5|90|5|WASHOUT|2020-11-09|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-25|P1Y2M10DT2H30M|BEFORE|2020-08-16|ONGOING|2020-11-11
e|RS|ddfe1ae3-a8d4-4011-b2d0-753ef49d0bb8|1|MRDIND|Minimal Residual Disease Indicator|MURPHY PROSTATE CANCER 1980|[?]|mol|PD/RELAPSE AFTER HI|1|MPS U|PALM METHOD|Y|Y||INDEPENDENT ASSESSOR|PATHOLOGIST 1|U|1|Visit_1|10|2|TREATMENT|2020-11-16|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-09|P1Y2M10DT2H30M|BEFORE|2020-12-09|BEFORE|2021-02-04
e|RS|ddfe1ae3-a8d4-4011-b2d0-753ef49d0bb8|2|RDIORESP|Radiologic Response|LEE LUNG CANCER 2011|[?]|mol/mol|PD FROM PR|1|ng|SXA SCAN|Y|||NON-HEALTH CARE PROFESSIONAL|READER 3|N|1|Visit_1|10|4|SCREENING|2020-11-16|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-09|P1Y2M10DT2H30M|COINCIDENT|2020-11-10|ONGOING|2021-02-10
e|RS|ddfe1ae3-a8d4-4011-b2d0-753ef49d0bb8|3|RDIORESP|Radiologic Response|WOLCHOK SOLID TUMORS 2009|[?]|F|cPR|1|DNA copies/ug|SLIT LAMP PHOTOGRAPHY||||FAMILY MEMBER|RADIOLOGIST|N|2|Visit_2|25|1|WASHOUT|2020-12-01|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-16|P1Y2M10DT2H30M|BEFORE|2020-11-11|AFTER|2021-01-25
e|RS|ddfe1ae3-a8d4-4011-b2d0-753ef49d0bb8|4|MRPHRESP|Morphologic Response|UNSPECIFIED|[?]|breaths/min|MORPHOLOGIC LEUKEMIA-FREE STATE|1|ug/kg/min|RAJI CELL EIA||Y||HEALTH CARE PROFESSIONAL|RATER|NA|2|Visit_2|25|1|FOLLOW-UP|2020-12-01|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-16|P1Y2M10DT2H30M|BEFORE|2020-11-15|COINCIDENT|2020-12-23
e|RS|ddfe1ae3-a8d4-4011-b2d0-753ef49d0bb8|5|TMRESP|Tumor Marker Response|RECIST 1.0|[?]|ng|ABSENT MORPHOLOGIC RESPONSE|1|mmol|INTRAVASCULAR ULTRASOUND||||SPOUSE|PATHOLOGIST|N|3|Visit_3|40|2|SCREENING|2020-12-16|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-10|P1Y2M10DT2H30M|UNKNOWN|2021-02-09|COINCIDENT|2021-02-12
e|RS|ddfe1ae3-a8d4-4011-b2d0-753ef49d0bb8|6|BMIVLIND|Bone Marrow Involvement Indicator|KEAM BREAST CANCER 2013|[?]|umol|CYTOGENETIC PR|1|mIU/L|SEQUENCE-BASED TYPING POLYMERASE CHAIN REACTION|Y|||SIGNIFICANT OTHER|MICROSCOPIST|U|3|Visit_3|40|3|WASHOUT|2020-12-16|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-10|P1Y2M10DT2H30M|BEFORE|2020-11-28|BEFORE|2021-01-27
e|RS|ddfe1ae3-a8d4-4011-b2d0-753ef49d0bb8|7|ANATRESP|Anatomic Response|RANO ELLINGSON 2017|||RELAPSED DISEASE FROM CR OR PR|1|ug/m2/h|MRS|||Y|CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 3|Y|4|Visit_4|65|6|SCREENING|2021-01-10|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-26|P1Y2M10DT2H30M|BEFORE|2021-02-11|COINCIDENT|2021-02-13
e|RS|ddfe1ae3-a8d4-4011-b2d0-753ef49d0bb8|8|OVRLRESP|Overall Response|DURIE MULTIPLE MYELOMA 2006|[?]|BU|sCR|1|TRACE|SISH|Y|||PARENT|INTERNIST|U|4|Visit_4|65|5|WASHOUT|2021-01-10|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-26|P1Y2M10DT2H30M|COINCIDENT|2021-02-12|BEFORE|2021-02-13
e|RS|ddfe1ae3-a8d4-4011-b2d0-753ef49d0bb8|9|NTNERESP|Non-Target Non-Enhancing Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|s^-1(%O2)^-1|NON-PD|1|mol/mL|PULSE OXIMETRY||||INDEPENDENT ASSESSOR|ADJUDICATOR 3|N|5|Visit_5|90|5|TREATMENT|2021-02-04|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-22|P1Y2M10DT2H30M|UNKNOWN|2020-11-25|AFTER|2021-02-02
e|RS|ddfe1ae3-a8d4-4011-b2d0-753ef49d0bb8|10|CYTORESP|Cytogenetic Response|AJCC V7|||MORPHOLOGIC CRi|1|Bq/mL|REBOUND TONOMETRY|||Y|CHILD|READER 1|N|5|Visit_5|90|7|TREATMENT|2021-02-04|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-22|P1Y2M10DT2H30M|UNKNOWN|2020-11-16|BEFORE|2020-12-11
e|RS|416fe99b-1258-4e72-b1df-48b989f8f8ed|1|DRCRIND|Disease Recurrence Indicator|CHESON CLL 2012|[?]|/200 HPFs|PR-CT|1|Joule|CINEANGIOGRAPHY|Y|||CHILD|NEUROLOGIST 2|NA|1|Visit_1|10|1|TREATMENT|2020-08-28|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-31|P1Y2M10DT2H30M|BEFORE|2020-08-31|AFTER|2020-11-05
e|RS|416fe99b-1258-4e72-b1df-48b989f8f8ed|2|CLINRESP|Clinical Response|NCIWG CHESON CLL 1996|||UNEQUIVOCAL|1|mg/mL/day|POTENTIOMETRY|||Y|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST|NA|1|Visit_1|10|1|SCREENING|2020-08-28|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-31|P1Y2M10DT2H30M|AFTER|2020-09-01|COINCIDENT|2020-09-28
e|RS|416fe99b-1258-4e72-b1df-48b989f8f8ed|3|HEMARESP|Hematologic Response|PRINCE TCELL LYMPHOMA 2010|[?]|10^6 organisms|CYTOGENETIC MINIMAL RESPONSE|1|ukat|ELECTROPHORESIS|Y|||SPOUSE|CARDIOLOGIST|N|2|Visit_2|25|1|FOLLOW-UP|2020-09-12|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-10|P1Y2M10DT2H30M|COINCIDENT|2020-11-16|COINCIDENT|2020-11-17
e|RS|416fe99b-1258-4e72-b1df-48b989f8f8ed|4|METBRESP|Metabolic Response|SACT|[?]|cmH2O*s2/mL|MOLECULAR MAJOR RESPONSE|1|mL/min/1.73m2|CONFOCAL MICROSCOPY|Y|Y||STUDY SUBJECT|INTERNIST|U|2|Visit_2|25|2|TREATMENT|2020-09-12|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-10|P1Y2M10DT2H30M|UNKNOWN|2020-11-15|ONGOING|2020-11-21
e|RS|416fe99b-1258-4e72-b1df-48b989f8f8ed|5|ANATRESP|Anatomic Response|iRECIST|[?]|genEq/mL|CYTOGENETIC NO RESPONSE|1|COAT|MICROBIAL CONCENTRATION||Y||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 1|NA|3|Visit_3|40|1|TREATMENT|2020-09-27|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-03|P1Y2M10DT2H30M|UNKNOWN|2020-10-27|BEFORE|2020-11-04
e|RS|416fe99b-1258-4e72-b1df-48b989f8f8ed|6|SPLNRESP|Spleen Response|EBMT BLADE MYELOMA 1998|[?]|s^-1(%O2)^-1|HI-E|1|pg/cell|QUANTITATIVE COMPUTED TOMOGRAPHY||||SIBLING|READER 2|N|3|Visit_3|40|5|FOLLOW-UP|2020-09-27|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-03|P1Y2M10DT2H30M|COINCIDENT|2020-10-13|AFTER|2020-11-18
e|RS|416fe99b-1258-4e72-b1df-48b989f8f8ed|7|NTLWIND|Non-Target Lesion Worsening Indicator|MACDONALD GLIOMA 1990|[?]|CIGARETTE|nPR|1|uIU/L|TELLER ACUITY CARDS||||CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 2|Y|4|Visit_4|65|1|TREATMENT|2020-10-22|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-28|P1Y2M10DT2H30M|AFTER|2020-09-24|ONGOING|2020-11-14
e|RS|416fe99b-1258-4e72-b1df-48b989f8f8ed|8|MNPTHIND|Minor Pathological Response Indicator|JACINTO CERVICAL CANCER 2007|[?]|pt_br|mCR|1|/cmH2O|SPIROMETRY||||FAMILY MEMBER|MICROSCOPIST 1|U|4|Visit_4|65|7|TREATMENT|2020-10-22|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-28|P1Y2M10DT2H30M|BEFORE|2020-10-18|COINCIDENT|2020-10-20
e|RS|416fe99b-1258-4e72-b1df-48b989f8f8ed|9|METBRESP|Metabolic Response|LUGANO CLASSIFICATION|[?]|KALLIKREIN INHIBITOR UNIT|iCPD|1|PFU/mL|TRIPLE-PHASE MRI SCAN||||FAMILY MEMBER|RADIOLOGIST|U|5|Visit_5|90|2|FOLLOW-UP|2020-11-16|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-16|P1Y2M10DT2H30M|AFTER|2020-11-13|COINCIDENT|2020-11-18
e|RS|416fe99b-1258-4e72-b1df-48b989f8f8ed|10|RDIORESP|Radiologic Response|iRECIST|[?]|10^3 RNA copies/mL|NON-iCR/NON-iUPD|1|10^9 CFU/mL|INTRAVASCULAR ULTRASOUND|Y|||NON-HEALTH CARE PROFESSIONAL|CARDIOLOGIST|Y|5|Visit_5|90|7|FOLLOW-UP|2020-11-16|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-16|P1Y2M10DT2H30M|UNKNOWN|2020-10-04|BEFORE|2020-10-27
e|RS|16a9e070-3e5d-444c-9ac1-6a1abfac0370|1|SPLNRESP|Spleen Response|RECICL|[?]|10^9/g|PDu|1|ng|MS/MS|Y|Y||ADJUDICATOR|UROLOGIST|N|1|Visit_1|10|1|TREATMENT|2020-05-26|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-18|P1Y2M10DT2H30M|AFTER|2020-06-28|COINCIDENT|2020-07-10
e|RS|16a9e070-3e5d-444c-9ac1-6a1abfac0370|2|MRPHRESP|Morphologic Response|HARTMANN GERM CELL CANCER 2002|||cCR|1|ugEq/L|CLINICAL EVALUATION|||Y|CLINICAL STUDY SPONSOR|MICROSCOPIST 3|Y|1|Visit_1|10|2|WASHOUT|2020-05-26|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-18|P1Y2M10DT2H30M|COINCIDENT|2020-06-11|ONGOING|2020-08-14
e|RS|16a9e070-3e5d-444c-9ac1-6a1abfac0370|3|SFTSRESP|Soft Tissue Response|SCHWARZ CERVICAL CANCER 2009|||SMD|1|ug/g/min|TRANSMISSION ELECTRON MICROSCOPY||Y|Y|SIBLING|RADIOLOGIST|Y|2|Visit_2|25|1|TREATMENT|2020-06-10|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-08|P1Y2M10DT2H30M|AFTER|2020-08-04|AFTER|2020-08-11
e|RS|16a9e070-3e5d-444c-9ac1-6a1abfac0370|4|SYMPTDTR|Symptomatic Deterioration|SCHER PROSTATE CANCER 2011|[?]|10^3 DNA copies/mL|UNEQUIVOCAL|1|10^3 copies/mL|MICRONEUTRALIZATION ASSAY||||ADJUDICATION COMMITTEE|READER 2|NA|2|Visit_2|25|7|SCREENING|2020-06-10|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-08|P1Y2M10DT2H30M|COINCIDENT|2020-06-03|BEFORE|2020-06-04
e|RS|16a9e070-3e5d-444c-9ac1-6a1abfac0370|5|NEWLWIND|New Lesion Worsening Indicator|EASL BRUIX LIVER CANCER 2001|[?]|pkat/L|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|mm/h|FORCED OSCILLATION TECHNIQUE||||ADJUDICATOR|UROLOGIST|NA|3|Visit_3|40|4|SCREENING|2020-06-25|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-04|P1Y2M10DT2H30M|BEFORE|2020-07-04|ONGOING|2020-07-06
e|RS|16a9e070-3e5d-444c-9ac1-6a1abfac0370|6|MOLRESP|Molecular Response|JACINTO CERVICAL CANCER 2007|[?]|pmol/L/h|mCR|1|mg/g/min|CONTACT SPECULAR MICROSCOPY|Y|||CLINICAL STUDY SPONSOR|READER 1|NA|3|Visit_3|40|4|SCREENING|2020-06-25|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-04|P1Y2M10DT2H30M|BEFORE|2020-06-23|COINCIDENT|2020-08-11
e|RS|16a9e070-3e5d-444c-9ac1-6a1abfac0370|7|MRDIND|Minimal Residual Disease Indicator|GCIG RUSTIN OVARIAN CANCER 2011|||SD-CT|1|foz_br|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|||Y|INDEPENDENT ASSESSOR|READER 3|U|4|Visit_4|65|4|TREATMENT|2020-07-20|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-02|P1Y2M10DT2H30M|UNKNOWN|2020-07-11|COINCIDENT|2020-07-27
e|RS|16a9e070-3e5d-444c-9ac1-6a1abfac0370|8|NEWLPROG|New Lesion Progression|HARTMAN PANCREATIC CANCER 2012|||PR-CT|1|uCi/L|SINGLE-MOLECULE ARRAY|||Y|SIGNIFICANT OTHER|MICROSCOPIST|U|4|Visit_4|65|5|WASHOUT|2020-07-20|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-02|P1Y2M10DT2H30M|UNKNOWN|2020-07-22|ONGOING|2020-08-15
e|RS|16a9e070-3e5d-444c-9ac1-6a1abfac0370|9|NTERESP|Non-Target Enhancing Response|BURCOMBE BREAST CANCER 2005|[?]|U/m2/min|MAJOR PATHOLOGIC RESPONSE|1|ug/kg/min|IMPEDANCE CONDUCTIVITY||||FAMILY MEMBER|NEUROLOGIST 2|N|5|Visit_5|90|1|FOLLOW-UP|2020-08-14|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-26|P1Y2M10DT2H30M|AFTER|2020-08-23|COINCIDENT|2020-08-24
e|RS|16a9e070-3e5d-444c-9ac1-6a1abfac0370|10|NTRGRESP|Non-target Response|NCCN ALL MRD 2014|[?]|ukat/L|mCR|1|kUSP|SPECT SCAN||Y||ADJUDICATOR|NEUROLOGIST 2|U|5|Visit_5|90|2|FOLLOW-UP|2020-08-14|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-26|P1Y2M10DT2H30M|BEFORE|2020-07-10|ONGOING|2020-08-16
e|RS|1497a00d-55b1-4e02-a957-cf15e3d15512|1|STRUSTAT|Steroid Use Status|RECICL|[?]|DNA copies/mL|IMMUNOPHENOTYPIC CR|1|BAG|DUCTOGRAPHY||||ADJUDICATOR|RADIOLOGIST 1|N|1|Visit_1|10|2|SCREENING|2021-01-25|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-06|P1Y2M10DT2H30M|COINCIDENT|2021-01-30|COINCIDENT|2021-02-14
e|RS|1497a00d-55b1-4e02-a957-cf15e3d15512|2|NEWLPROG|New Lesion Progression|CHESON CLL 2006|[?]|lm|MAJOR PATHOLOGIC RESPONSE|1|10^6 organisms/mg|KINETIC MICROPARTICLE IMMUNOASSAY|Y|Y||PARENT|MICROSCOPIST 3|Y|1|Visit_1|10|6|SCREENING|2021-01-25|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-06|P1Y2M10DT2H30M|UNKNOWN|2021-03-05|AFTER|2021-03-23
e|RS|1497a00d-55b1-4e02-a957-cf15e3d15512|3|MOLRESP|Molecular Response|CHOLLET BREAST CANCER 2002|[?]|Absorbance U/mL|MORPHOLOGIC CRi|1|uV2|TWO-COLOR MICROARRAY||||FRIEND|MICROSCOPIST 3|U|2|Visit_2|25|1|WASHOUT|2021-02-09|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-22|P1Y2M10DT2H30M|UNKNOWN|2021-03-27|BEFORE|2021-04-03
e|RS|1497a00d-55b1-4e02-a957-cf15e3d15512|4|OVRLRESP|Overall Response|GUPPY OVARIAN CANCER 2002|[?]|mgEq|MRD RELAPSE|1|10^6 CFU/g|GC/MS-CI|Y|||SIGNIFICANT OTHER|ENDOCRINOLOGIST|U|2|Visit_2|25|6|FOLLOW-UP|2021-02-09|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-22|P1Y2M10DT2H30M|COINCIDENT|2021-02-12|AFTER|2021-02-23
e|RS|1497a00d-55b1-4e02-a957-cf15e3d15512|5|NEWLPROG|New Lesion Progression|CHOLLET BREAST CANCER 2002|[?]|mm/min|HI-N|1|cmol/L|SANGER SEQUENCING||Y||INTERVIEWER|MICROSCOPIST|Y|3|Visit_3|40|7|TREATMENT|2021-02-24|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-06|P1Y2M10DT2H30M|UNKNOWN|2021-04-02|COINCIDENT|2021-04-12
e|RS|1497a00d-55b1-4e02-a957-cf15e3d15512|6|TRGRESP|Target Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|ug/h|NR|1|DAgU/mL|QUANTITATIVE CORONARY ANGIOGRAPHY||||HEALTH CARE PROFESSIONAL|ONCOLOGIST|Y|3|Visit_3|40|7|FOLLOW-UP|2021-02-24|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-06|P1Y2M10DT2H30M|COINCIDENT|2021-03-06|COINCIDENT|2021-03-28
e|RS|1497a00d-55b1-4e02-a957-cf15e3d15512|7|NEWLWIND|New Lesion Worsening Indicator|HAMAOKA BREAST CANCER 2010|[?]|LENS|iUPD|1|%/min|CONTRAST ENHANCED PET SCAN||||CHILD|PATHOLOGIST 2|Y|4|Visit_4|65|4|FOLLOW-UP|2021-03-21|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-10|P1Y2M10DT2H30M|UNKNOWN|2021-02-13|COINCIDENT|2021-03-19
e|RS|1497a00d-55b1-4e02-a957-cf15e3d15512|8|BONERESP|Bone Response|JACINTO CERVICAL CANCER 2007|||FAVORABLE RESPONSE|1|g/animal/wk|AUDIOMETRY|||Y|FAMILY MEMBER|RATER|U|4|Visit_4|65|5|FOLLOW-UP|2021-03-21|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-10|P1Y2M10DT2H30M|AFTER|2021-04-21|COINCIDENT|2021-04-22
e|RS|1497a00d-55b1-4e02-a957-cf15e3d15512|9|MRDRESP|Minimal Residual Disease Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|mOsm|UNEQUIVOCAL|1|TRACE|AUDIOMETRY||||VENDOR|READER|NA|5|Visit_5|90|3|TREATMENT|2021-04-15|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-21|P1Y2M10DT2H30M|BEFORE|2021-02-17|AFTER|2021-03-12
e|RS|1497a00d-55b1-4e02-a957-cf15e3d15512|10|TRGRESP|Target Response|SCHER PROSTATE CANCER 2011|||PDu|1|10^7 CFU/mL|ANGIOGRAPHY|Y||Y|VENDOR|NEUROLOGIST 1|N|5|Visit_5|90|1|WASHOUT|2021-04-15|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-21|P1Y2M10DT2H30M|AFTER|2021-01-29|ONGOING|2021-03-02
e|RS|9c188f41-b137-4d5a-bfbf-1783b1e0d3df|1|MRPHRESP|Morphologic Response|HARTMANN GERM CELL CANCER 2002|[?]|ug/L/h|CYTOGENETIC CR|1|U/animal|MRI WITHOUT CONTRAST||||ADJUDICATOR|ADJUDICATOR 1|NA|1|Visit_1|10|1|WASHOUT|2020-07-21|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-13|P1Y2M10DT2H30M|AFTER|2020-08-02|AFTER|2020-08-26
e|RS|9c188f41-b137-4d5a-bfbf-1783b1e0d3df|2|NTRGRESP|Non-target Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|ug/L DDU|PMD|1|nmol/mol|GC/MS-CI||Y||SPOUSE|RATER|N|1|Visit_1|10|2|WASHOUT|2020-07-21|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-13|P1Y2M10DT2H30M|UNKNOWN|2020-08-02|COINCIDENT|2020-09-20
e|RS|9c188f41-b137-4d5a-bfbf-1783b1e0d3df|3|MOLRESP|Molecular Response|PCWG SCHER PROSTATE CANCER 2008|[?]|lm|cCR|1|ug/g/min|RULER MEASUREMENT METHOD||Y||PARENT|READER|N|2|Visit_2|25|1|TREATMENT|2020-08-05|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-20|P1Y2M10DT2H30M|BEFORE|2020-09-27|AFTER|2020-10-11
e|RS|9c188f41-b137-4d5a-bfbf-1783b1e0d3df|4|STRUSTAT|Steroid Use Status|BRUGGEMANN MRD 2010|[?]|g/day|MRD NEGATIVITY|1|ugEq/L|PHOTOMETRY||||CLINICAL RESEARCH ASSOCIATE|READER 3|N|2|Visit_2|25|1|WASHOUT|2020-08-05|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-20|P1Y2M10DT2H30M|BEFORE|2020-09-02|ONGOING|2020-09-17
e|RS|9c188f41-b137-4d5a-bfbf-1783b1e0d3df|5|TRGRESP|Target Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|||UNEQUIVOCAL|1|ug/L/h|MRI WITHOUT CONTRAST|||Y|SIBLING|RATER 1|N|3|Visit_3|40|1|FOLLOW-UP|2020-08-20|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-05|P1Y2M10DT2H30M|AFTER|2020-08-14|ONGOING|2020-09-17
e|RS|9c188f41-b137-4d5a-bfbf-1783b1e0d3df|6|MRDIND|Minimal Residual Disease Indicator|PERCIST|[?]|BOTTLE|mCR|1|pkat|FARR ASSAY||Y||INVESTIGATOR|CLINICAL PATHOLOGIST|U|3|Visit_3|40|7|FOLLOW-UP|2020-08-20|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-05|P1Y2M10DT2H30M|COINCIDENT|2020-07-22|AFTER|2020-10-14
e|RS|9c188f41-b137-4d5a-bfbf-1783b1e0d3df|7|OVRLRESP|Overall Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|DAgU|MOLECULAR MAJOR RESPONSE|1|Bq/ug|THIN SMEAR||Y||SIBLING|RATER 1|NA|4|Visit_4|65|5|SCREENING|2020-09-14|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-31|P1Y2M10DT2H30M|BEFORE|2020-08-03|ONGOING|2020-10-03
e|RS|9c188f41-b137-4d5a-bfbf-1783b1e0d3df|8|TRGRESP|Target Response|KEAM BREAST CANCER 2013|[?]|um/day|SMD|1|days/month|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION||||INDEPENDENT ASSESSOR|ADJUDICATOR 3|NA|4|Visit_4|65|1|WASHOUT|2020-09-14|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-31|P1Y2M10DT2H30M|UNKNOWN|2020-08-03|AFTER|2020-08-26
e|RS|9c188f41-b137-4d5a-bfbf-1783b1e0d3df|9|METBRESP|Metabolic Response|PROTOCOL DEFINED RESPONSE CRITERIA|||cPR|1|CUP|SMEAR|||Y|INTERVIEWER|ONCOLOGIST 2|N|5|Visit_5|90|1|SCREENING|2020-10-09|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-26|P1Y2M10DT2H30M|AFTER|2020-10-03|COINCIDENT|2020-10-17
e|RS|9c188f41-b137-4d5a-bfbf-1783b1e0d3df|10|HEMARESP|Hematologic Response|HARTMAN PANCREATIC CANCER 2012|[?]|ng|CYTOGENETIC NO RESPONSE|1|breaths/min|GC/FID|Y|||STUDY SUBJECT|RATER|U|5|Visit_5|90|4|TREATMENT|2020-10-09|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-26|P1Y2M10DT2H30M|AFTER|2020-10-17|ONGOING|2020-10-18
e|RS|b5e44703-e5e2-43b8-af6b-b74af0ae3ede|1|MJPTHIND|Major Pathological Response Indicator|CHESON CLL 2006|||CYTOGENETIC NO RESPONSE|1|Ci/kg|FLOW CYTOMETRY|Y||Y|PARENT|READER 1|Y|1|Visit_1|10|5|TREATMENT|2020-12-09|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-16|P1Y2M10DT2H30M|COINCIDENT|2021-02-15|ONGOING|2021-03-06
e|RS|b5e44703-e5e2-43b8-af6b-b74af0ae3ede|2|SPLNRESP|Spleen Response|MACDONALD GLIOMA 1990|[?]|kPa|MOLECULAR MAJOR RESPONSE|1|MPS U|PATHOLOGICAL EVALUATION||||PARENT|MICROSCOPIST 2|N|1|Visit_1|10|3|TREATMENT|2020-12-09|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-16|P1Y2M10DT2H30M|AFTER|2020-12-25|COINCIDENT|2020-12-29
e|RS|b5e44703-e5e2-43b8-af6b-b74af0ae3ede|3|TRGRESP|Target Response|PETIT BREAST CANCER 2001|[?]|IU/mg|PD-CT|1|%(w/v)|WEBER GREEN STAIN||Y||SIGNIFICANT OTHER|ONCOLOGIST 1|NA|2|Visit_2|25|7|TREATMENT|2020-12-24|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-11|P1Y2M10DT2H30M|AFTER|2021-01-08|BEFORE|2021-02-24
e|RS|b5e44703-e5e2-43b8-af6b-b74af0ae3ede|4|SPLNRESP|Spleen Response|CHOI GIST 2008|[?]|uOsm|CYTOGENETIC CR|1|DRUM|KINYOUN STAIN||||CLINICAL RESEARCH COORDINATOR|READER 3|U|2|Visit_2|25|3|FOLLOW-UP|2020-12-24|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-11|P1Y2M10DT2H30M|UNKNOWN|2020-12-03|AFTER|2020-12-13
e|RS|b5e44703-e5e2-43b8-af6b-b74af0ae3ede|5|LIVRRESP|Liver Response|DOHNER AML 2010|[?]|STEPS|CA125 50% RESPONSE|1|%|ETDRS EYE CHART|Y|||VENDOR|PATHOLOGIST 2|U|3|Visit_3|40|3|TREATMENT|2021-01-08|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-11|P1Y2M10DT2H30M|COINCIDENT|2021-01-27|BEFORE|2021-02-11
e|RS|b5e44703-e5e2-43b8-af6b-b74af0ae3ede|6|MJPTHIND|Major Pathological Response Indicator|PCWG SCHER PROSTATE CANCER 2016|[?]|RING|MR|1|CIGAR|NEURAMINIDASE INHIBITION ASSAY||||ADJUDICATION COMMITTEE|READER|U|3|Visit_3|40|2|WASHOUT|2021-01-08|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-11|P1Y2M10DT2H30M|BEFORE|2021-01-30|AFTER|2021-02-17
e|RS|b5e44703-e5e2-43b8-af6b-b74af0ae3ede|7|METSIND|Metastatic Indicator|HARTMANN GERM CELL CANCER 2002|||NON-iCR/NON-iUPD|1|uEq/L|SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY|||Y|CHILD|ADJUDICATOR|Y|4|Visit_4|65|5|TREATMENT|2021-02-02|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-13|P1Y2M10DT2H30M|COINCIDENT|2020-12-05|AFTER|2021-03-06
e|RS|b5e44703-e5e2-43b8-af6b-b74af0ae3ede|8|CPRFSTAT|Clinical Performance Status|CHOLLET BREAST CANCER 2002|[?]|log10 TCID 50/mL|pCR|1|U/mg|SNELLEN EYE CHART||||HEALTH CARE PROFESSIONAL|RADIOLOGIST 1|NA|4|Visit_4|65|2|SCREENING|2021-02-02|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-13|P1Y2M10DT2H30M|AFTER|2021-03-06|ONGOING|2021-03-07
e|RS|b5e44703-e5e2-43b8-af6b-b74af0ae3ede|9|DRCRIND|Disease Recurrence Indicator|BURCOMBE BREAST CANCER 2005|[?]|mmol/min/kPa/L|INCREASED|1|DDU|MULTI-SLICE SPIRAL CT||Y||CLINICAL STUDY SPONSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|5|Visit_5|90|6|WASHOUT|2021-02-27|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-22|P1Y2M10DT2H30M|BEFORE|2021-02-03|COINCIDENT|2021-02-11
e|RS|b5e44703-e5e2-43b8-af6b-b74af0ae3ede|10|NTLWIND|Non-Target Lesion Worsening Indicator|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|Weber|TREATMENT FAILURE|1|g/m2|TELLER ACUITY CARDS|Y|||DOMESTIC PARTNER|READER|NA|5|Visit_5|90|1|SCREENING|2021-02-27|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-22|P1Y2M10DT2H30M|COINCIDENT|2020-12-21|ONGOING|2021-01-15
e|RS|80f006d0-1a4f-4ee7-9492-3ab1f6d7caef|1|MRDRESP|Minimal Residual Disease Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|genEq|SD-CT|1|uU/L|REBOUND TONOMETRY||||SPOUSE|ONCOLOGIST 1|NA|1|Visit_1|10|7|FOLLOW-UP|2020-11-05|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-12|P1Y2M10DT2H30M|UNKNOWN|2021-01-14|ONGOING|2021-01-28
e|RS|80f006d0-1a4f-4ee7-9492-3ab1f6d7caef|2|CLINRESP|Clinical Response|SACT|[?]|/sec|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|ug/m2|HILLMEN COLOR CHART||||DOMESTIC PARTNER|MICROSCOPIST 1|N|1|Visit_1|10|4|FOLLOW-UP|2020-11-05|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-12|P1Y2M10DT2H30M|AFTER|2021-01-06|COINCIDENT|2021-01-20
e|RS|80f006d0-1a4f-4ee7-9492-3ab1f6d7caef|3|TMRESP|Tumor Marker Response|LUGANO CLASSIFICATION|[?]|10^3 RNA copies/mL|NON-CR/NON-PD|1|PIPE|LIQUID SCINTILLATION COUNTING||Y||STUDY SUBJECT|ADJUDICATOR|NA|2|Visit_2|25|5|TREATMENT|2020-11-20|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-01|P1Y2M10DT2H30M|COINCIDENT|2020-12-27|ONGOING|2021-01-20
e|RS|80f006d0-1a4f-4ee7-9492-3ab1f6d7caef|4|BMIVLIND|Bone Marrow Involvement Indicator|KUMAR IMWG 2016|[?]|10^3 organisms/g|RELAPSED DISEASE FROM CR|1|ug/kg/min|KNEMOMETRY||||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 3|N|2|Visit_2|25|6|WASHOUT|2020-11-20|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-01|P1Y2M10DT2H30M|COINCIDENT|2020-11-07|BEFORE|2020-11-19
e|RS|80f006d0-1a4f-4ee7-9492-3ab1f6d7caef|5|MRPHRESP|Morphologic Response|BLAZER COLORECTAL CANCER 2008|||ABSENT MORPHOLOGIC RESPONSE|1|10^3 CFU|BIOIMPEDANCE SPECTROSCOPY|||Y|FAMILY MEMBER|NEUROLOGIST|NA|3|Visit_3|40|3|TREATMENT|2020-12-05|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-19|P1Y2M10DT2H30M|COINCIDENT|2021-01-18|ONGOING|2021-01-25
e|RS|80f006d0-1a4f-4ee7-9492-3ab1f6d7caef|6|RDIORESP|Radiologic Response|IRANO 2015|[?]|10^6 RNA copies/mL|RELAPSED DISEASE|1|kg/cm|SCINTIGRAPHY||||NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|NA|3|Visit_3|40|2|TREATMENT|2020-12-05|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-19|P1Y2M10DT2H30M|BEFORE|2021-01-02|AFTER|2021-01-18
e|RS|80f006d0-1a4f-4ee7-9492-3ab1f6d7caef|7|SYMPTDTR|Symptomatic Deterioration|CHOLLET BREAST CANCER 2002|||cCR|1|Sv|FLUORESCENT ANTIBODY VIRUS NEUTRALIZATION ASSAY|||Y|HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|NA|4|Visit_4|65|6|FOLLOW-UP|2020-12-30|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-09|P1Y2M10DT2H30M|UNKNOWN|2020-11-15|AFTER|2020-12-15
e|RS|80f006d0-1a4f-4ee7-9492-3ab1f6d7caef|8|NEWLIND|New Lesion Indicator|SHINDOH COLORECTAL CANCER 2013|||PR WITH LYMPHOCYTOSIS|1|mIU/L|LC-FL|Y|Y|Y|CLINICAL RESEARCH COORDINATOR|CLINICAL PATHOLOGIST|Y|4|Visit_4|65|5|TREATMENT|2020-12-30|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-09|P1Y2M10DT2H30M|COINCIDENT|2020-12-02|COINCIDENT|2020-12-13
e|RS|80f006d0-1a4f-4ee7-9492-3ab1f6d7caef|9|CYTORESP|Cytogenetic Response|GUPPY OVARIAN CANCER 2002|||mCR|1|TRANSDUCING UNIT|DUCTOGRAPHY|||Y|CLINICAL STUDY SPONSOR|ENDOCRINOLOGIST|N|5|Visit_5|90|6|SCREENING|2021-01-24|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-07|P1Y2M10DT2H30M|AFTER|2021-01-13|BEFORE|2021-01-22
e|RS|80f006d0-1a4f-4ee7-9492-3ab1f6d7caef|10|CPRFSTAT|Clinical Performance Status|SACT|[?]|10^9 organisms|PD|1|umol/L/h|WRIGHT-GIEMSA STAIN||||ADJUDICATION COMMITTEE|READER 2|Y|5|Visit_5|90|4|WASHOUT|2021-01-24|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-07|P1Y2M10DT2H30M|COINCIDENT|2021-02-01|AFTER|2021-02-02
e|RS|8aa15baf-9164-4dc8-b7c2-30e435b9e6bd|1|BESTRESP|Best Overall Response|CHESON CLL 2012|[?]|nmol/L|PMD|1|%/s|PET/CT SCAN WITHOUT CONTRAST||Y||SIBLING|DEVELOPMENTAL PSYCHOLOGIST|U|1|Visit_1|10|4|SCREENING|2020-05-27|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-10|P1Y2M10DT2H30M|BEFORE|2020-06-07|ONGOING|2020-08-13
e|RS|8aa15baf-9164-4dc8-b7c2-30e435b9e6bd|2|DRCRIND|Disease Recurrence Indicator|HARTMAN PANCREATIC CANCER 2012|||ABSENT MORPHOLOGIC RESPONSE|1|nmol BCE/mmol|BETA LACTAMASE|Y|Y|Y|INTERVIEWER|CLINICAL PATHOLOGIST|NA|1|Visit_1|10|6|WASHOUT|2020-05-27|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-10|P1Y2M10DT2H30M|AFTER|2020-07-03|COINCIDENT|2020-07-14
e|RS|8aa15baf-9164-4dc8-b7c2-30e435b9e6bd|3|NTNERESP|Non-Target Non-Enhancing Response|RECICL|[?]|mL/beat|cPR|1|POUCH|JAEGER EYE CHART|Y|||INDEPENDENT ASSESSOR|ADJUDICATOR 2|Y|2|Visit_2|25|7|FOLLOW-UP|2020-06-11|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-14|P1Y2M10DT2H30M|COINCIDENT|2020-08-13|ONGOING|2020-08-19
e|RS|8aa15baf-9164-4dc8-b7c2-30e435b9e6bd|4|HEMARESP|Hematologic Response|WOLCHOK SOLID TUMORS 2009|[?]|ukat/L|RELAPSED DISEASE FROM CR|1|SFC/10^6 PBMC|MRI||||INDEPENDENT ASSESSOR|NEUROLOGIST 2|U|2|Visit_2|25|6|FOLLOW-UP|2020-06-11|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-14|P1Y2M10DT2H30M|COINCIDENT|2020-07-31|AFTER|2020-08-17
e|RS|8aa15baf-9164-4dc8-b7c2-30e435b9e6bd|5|MOLRESP|Molecular Response|EBMT BLADE MYELOMA 1998|||iSD|1|ug/cm2|PET/CT SCAN WITHOUT CONTRAST|||Y|PROXY|RATER 1|U|3|Visit_3|40|3|SCREENING|2020-06-26|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-21|P1Y2M10DT2H30M|COINCIDENT|2020-06-28|BEFORE|2020-07-23
e|RS|8aa15baf-9164-4dc8-b7c2-30e435b9e6bd|6|TRGRESP|Target Response|RECICL|[?]|10^6 CFU|cPR|1|U|COLORIMETRY||Y||PARENT|ENDOCRINOLOGIST|NA|3|Visit_3|40|3|TREATMENT|2020-06-26|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-21|P1Y2M10DT2H30M|COINCIDENT|2020-08-22|AFTER|2020-08-23
e|RS|8aa15baf-9164-4dc8-b7c2-30e435b9e6bd|7|NTNERESP|Non-Target Non-Enhancing Response|WHO BREAST CANCER 2006|[?]|10^6/g|nPR|1|ug/day|CALIPER MEASUREMENT METHOD||||CLINICAL STUDY SPONSOR|MICROSCOPIST 3|N|4|Visit_4|65|6|TREATMENT|2020-07-21|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-24|P1Y2M10DT2H30M|COINCIDENT|2020-06-29|COINCIDENT|2020-07-14
e|RS|8aa15baf-9164-4dc8-b7c2-30e435b9e6bd|8|TRGRESP|Target Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|umol/mg/min|iUPD|1|titer|OPTICAL MAPPING|Y|||FAMILY MEMBER|PATHOLOGIST 2|Y|4|Visit_4|65|2|TREATMENT|2020-07-21|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-24|P1Y2M10DT2H30M|UNKNOWN|2020-06-09|ONGOING|2020-06-30
e|RS|8aa15baf-9164-4dc8-b7c2-30e435b9e6bd|9|LIVRRESP|Liver Response|BLAZER COLORECTAL CANCER 2008|[?]|Ci|NON-iCR/NON-iUPD|1|mg/h|NUCLEIC ACID SEQUENCING||||SIBLING|NEUROLOGIST 1|N|5|Visit_5|90|2|TREATMENT|2020-08-15|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-24|P1Y2M10DT2H30M|AFTER|2020-08-20|BEFORE|2020-08-21
e|RS|8aa15baf-9164-4dc8-b7c2-30e435b9e6bd|10|NTERESP|Non-Target Enhancing Response|CHOLLET BREAST CANCER 2002|[?]|U/m2/h|DISEASE TRANSFORMATION|1|10^6 organisms/g|MULTIPLEXED BEAD BASED IMMUNOASSAY|Y|||NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|NA|5|Visit_5|90|4|TREATMENT|2020-08-15|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-24|P1Y2M10DT2H30M|AFTER|2020-06-19|ONGOING|2020-06-23
e|RS|2216086b-197e-4780-8e10-28123eb090c5|1|DRCRIND|Disease Recurrence Indicator|PCWG BUBLEY PROSTATE CANCER 1999|[?]|PELLET|iCPD|1|ng/dL|DROPLET DIGITAL PCR||||FAMILY MEMBER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|1|Visit_1|10|7|WASHOUT|2020-12-12|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-16|P1Y2M10DT2H30M|BEFORE|2021-01-27|BEFORE|2021-03-10
e|RS|2216086b-197e-4780-8e10-28123eb090c5|2|TMRESP|Tumor Marker Response|RAJKUMAR MYELOMA 2011|[?]|mCi/kg|NON-CR/NON-PD|1|nmol/L|SPIROMETRY||||FRIEND|NEUROLOGIST 1|NA|1|Visit_1|10|4|FOLLOW-UP|2020-12-12|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-16|P1Y2M10DT2H30M|UNKNOWN|2021-02-04|BEFORE|2021-02-22
e|RS|2216086b-197e-4780-8e10-28123eb090c5|3|NTLWIND|Non-Target Lesion Worsening Indicator|CHESON CLL 2006|[?]|IU/dL|DECREASED|1|g/animal/day|RYAN BLUE STAIN|Y|||GUARDIAN|ADJUDICATOR 2|NA|2|Visit_2|25|5|TREATMENT|2020-12-27|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-13|P1Y2M10DT2H30M|BEFORE|2021-02-17|COINCIDENT|2021-03-07
e|RS|2216086b-197e-4780-8e10-28123eb090c5|4|CPRFSTAT|Clinical Performance Status|GUILHOT CML 2007|[?]|10^9 CFU/g|HI-E|1|C|NEXT GENERATION TARGETED SEQUENCING||||ADJUDICATOR|READER 2|NA|2|Visit_2|25|2|TREATMENT|2020-12-27|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-13|P1Y2M10DT2H30M|AFTER|2020-12-24|COINCIDENT|2021-02-20
e|RS|2216086b-197e-4780-8e10-28123eb090c5|5|MOLRESP|Molecular Response|CHOLLET BREAST CANCER 2002|[?]|ug/L/h|MOLECULAR CR|1|deg2|WHOLE EXOME SEQUENCING||||DOMESTIC PARTNER|PATHOLOGIST|NA|3|Visit_3|40|7|TREATMENT|2021-01-11|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-02|P1Y2M10DT2H30M|UNKNOWN|2021-03-08|BEFORE|2021-03-09
e|RS|2216086b-197e-4780-8e10-28123eb090c5|6|CYTORESP|Cytogenetic Response|IWG CHESON MDS 2000|||NON-QUANTIFIABLE MRD POSITIVITY|1|mL/cm H2O|COMPUTERIZED CORNEAL TOPOGRAPHY||Y|Y|PARENT|DEVELOPMENTAL PSYCHOLOGIST|U|3|Visit_3|40|7|TREATMENT|2021-01-11|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-02|P1Y2M10DT2H30M|AFTER|2020-12-14|COINCIDENT|2021-02-28
e|RS|2216086b-197e-4780-8e10-28123eb090c5|7|TMRESP|Tumor Marker Response|RANO|[?]|Coulomb|PR|1|log10 TCID 50/mL|TRANSESOPHAGEAL ECHOCARDIOGRAPHY||||SPOUSE|PATHOLOGIST 2|Y|4|Visit_4|65|7|WASHOUT|2021-02-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-13|P1Y2M10DT2H30M|AFTER|2021-03-04|BEFORE|2021-03-10
e|RS|2216086b-197e-4780-8e10-28123eb090c5|8|MNPTHIND|Minor Pathological Response Indicator|MASS|[?]|cL|INDETERMINATE RESPONSE|1|/LPF|REBOUND TONOMETRY||||FRIEND|OTOLARYNGOLOGIST|N|4|Visit_4|65|2|TREATMENT|2021-02-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-13|P1Y2M10DT2H30M|COINCIDENT|2021-01-06|BEFORE|2021-01-24
e|RS|2216086b-197e-4780-8e10-28123eb090c5|9|NEWLIND|New Lesion Indicator|MRECIST BYRNE MESOTHELIOMA 2004|[?]|vp/dose|PD|1|cup eq|IMMUNOTURBIDIMETRY||||PARENT|RADIOLOGIST 2|U|5|Visit_5|90|1|TREATMENT|2021-03-02|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-10|P1Y2M10DT2H30M|AFTER|2020-12-30|COINCIDENT|2021-01-06
e|RS|2216086b-197e-4780-8e10-28123eb090c5|10|MRDIND|Minimal Residual Disease Indicator|JACINTO CERVICAL CANCER 2007|[?]|L/h/m2|EQUIVOCAL|1|NEBULE|PYROSEQUENCING||||FAMILY MEMBER|ONCOLOGIST 1|U|5|Visit_5|90|4|TREATMENT|2021-03-02|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-10|P1Y2M10DT2H30M|UNKNOWN|2021-01-05|BEFORE|2021-02-23
e|RS|7280f69c-a0f4-48b5-b714-1e272193168c|1|TRGRESP|Target Response|BLAZER COLORECTAL CANCER 2008|[?]|nCi|INCREASED|1|/40 HPFs|WRIGHT-GIEMSA STAIN||||CLINICAL STUDY SPONSOR|RATER|U|1|Visit_1|10|5|TREATMENT|2020-08-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-18|P1Y2M10DT2H30M|BEFORE|2020-09-14|BEFORE|2020-11-15
e|RS|7280f69c-a0f4-48b5-b714-1e272193168c|2|NEWLWIND|New Lesion Worsening Indicator|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|pmol/dL|HI-E|1|SUPPOSITORY|TRANSMISSION ELECTRON MICROSCOPY|Y|||STUDY SUBJECT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|1|Visit_1|10|5|TREATMENT|2020-08-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-18|P1Y2M10DT2H30M|UNKNOWN|2020-09-27|BEFORE|2020-11-08
e|RS|7280f69c-a0f4-48b5-b714-1e272193168c|3|NTNERESP|Non-Target Non-Enhancing Response|MACDONALD GLIOMA 1990|[?]|uV2|nPR|1|log EID 50/dose|CHROMOGENIC ASSAY||||CLINICAL RESEARCH ASSOCIATE|READER 2|Y|2|Visit_2|25|6|WASHOUT|2020-09-03|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-01|P1Y2M10DT2H30M|BEFORE|2020-10-25|BEFORE|2020-11-11
e|RS|7280f69c-a0f4-48b5-b714-1e272193168c|4|NTNERESP|Non-Target Non-Enhancing Response|CHESON CLL 2012|[?]|MBq/uL|CA125 75% RESPONSE|1|mL/animal/wk|SNP ARRAY||||CLINICAL STUDY SPONSOR|PATHOLOGIST 1|Y|2|Visit_2|25|1|FOLLOW-UP|2020-09-03|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-01|P1Y2M10DT2H30M|UNKNOWN|2020-10-01|AFTER|2020-11-11
e|RS|7280f69c-a0f4-48b5-b714-1e272193168c|5|METSIND|Metastatic Indicator|RAJKUMAR MYELOMA 2011|[?]|10^10/L|MRD NEGATIVITY|1|uU/L|RULER MEASUREMENT METHOD||||INVESTIGATOR|PEDIATRIC NEUROLOGIST|NA|3|Visit_3|40|1|TREATMENT|2020-09-18|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-30|P1Y2M10DT2H30M|COINCIDENT|2020-09-26|AFTER|2020-10-16
e|RS|7280f69c-a0f4-48b5-b714-1e272193168c|6|STRUSTAT|Steroid Use Status|AJCC V7|[?]|gMFI|EQUIVOCAL|1|mmol2/L2|TOTAL BODY RADIOGRAPHY|Y|Y||INTERVIEWER|READER|N|3|Visit_3|40|3|FOLLOW-UP|2020-09-18|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-30|P1Y2M10DT2H30M|COINCIDENT|2020-10-20|AFTER|2020-11-05
e|RS|7280f69c-a0f4-48b5-b714-1e272193168c|7|BMIVLIND|Bone Marrow Involvement Indicator|IWG CHESON MDS 2006|||PD-CT|1|mg/kg/day|EEG|||Y|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 1|NA|4|Visit_4|65|3|WASHOUT|2020-10-13|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-01|P1Y2M10DT2H30M|AFTER|2020-09-15|BEFORE|2020-10-15
e|RS|7280f69c-a0f4-48b5-b714-1e272193168c|8|NTRGRESP|Non-target Response|CHESON CLL 2012|[?]|umol/h/mmol|MORPHOLOGIC LEUKEMIA-FREE STATE|1|scm|SURFACE PLASMON RESONANCE||||HEALTH CARE PROFESSIONAL|READER|U|4|Visit_4|65|5|SCREENING|2020-10-13|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-01|P1Y2M10DT2H30M|BEFORE|2020-09-20|AFTER|2020-09-22
e|RS|7280f69c-a0f4-48b5-b714-1e272193168c|9|CYTORESP|Cytogenetic Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|CCID 50/mL|mCR|1|pmol/L/h|AUTOMATED CAPILLARY ELECTROPHORESIS WESTERN BLOT|Y|||INDEPENDENT ASSESSOR|RATER 1|NA|5|Visit_5|90|1|TREATMENT|2020-11-07|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-22|P1Y2M10DT2H30M|COINCIDENT|2020-10-22|ONGOING|2020-11-09
e|RS|7280f69c-a0f4-48b5-b714-1e272193168c|10|NTRGRESP|Non-target Response|RECICL|[?]|log10 TCID 50/uL|UNFAVORABLE RESPONSE|1|cpm|WESTERGREN||||FAMILY MEMBER|ADJUDICATOR 1|Y|5|Visit_5|90|1|FOLLOW-UP|2020-11-07|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-22|P1Y2M10DT2H30M|AFTER|2020-10-24|BEFORE|2020-11-04
e|RS|4ce0546d-d8d9-42cb-bf2a-8e002536dd65|1|STRUSTAT|Steroid Use Status|PRINCE TCELL LYMPHOMA 2010|[?]|mmol/s|QUANTIFIABLE MRD POSITIVITY|1|Arbitrary U|ICP-MS||||CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 2|U|1|Visit_1|10|6|TREATMENT|2020-08-01|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-27|P1Y2M10DT2H30M|COINCIDENT|2020-07-27|COINCIDENT|2020-08-08
e|RS|4ce0546d-d8d9-42cb-bf2a-8e002536dd65|2|NTERESP|Non-Target Enhancing Response|MASS|[?]|U/g Hb|CYTOGENETIC CR|1|STRIP|PHOROPTER||||CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 3|Y|1|Visit_1|10|3|FOLLOW-UP|2020-08-01|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-27|P1Y2M10DT2H30M|BEFORE|2020-09-18|ONGOING|2020-09-25
e|RS|4ce0546d-d8d9-42cb-bf2a-8e002536dd65|3|CPRFSTAT|Clinical Performance Status|CHESON LYMPHOMA 2008|[?]|nCi|MOLECULAR MAJOR RESPONSE|1|Tesla|IHC||||NON-HEALTH CARE PROFESSIONAL|DERMATOLOGIST|N|2|Visit_2|25|2|SCREENING|2020-08-16|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-30|P1Y2M10DT2H30M|BEFORE|2020-10-02|COINCIDENT|2020-10-26
e|RS|4ce0546d-d8d9-42cb-bf2a-8e002536dd65|4|CYTORESP|Cytogenetic Response|LUGANO CLASSIFICATION|||iSD|1|mmHg/sec|FORCED OSCILLATION TECHNIQUE|||Y|ADJUDICATION COMMITTEE|MICROSCOPIST 2|U|2|Visit_2|25|5|TREATMENT|2020-08-16|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-30|P1Y2M10DT2H30M|BEFORE|2020-08-13|COINCIDENT|2020-09-25
e|RS|4ce0546d-d8d9-42cb-bf2a-8e002536dd65|5|LIVRRESP|Liver Response|RANO ELLINGSON 2017|[?]|mU/g|CYTOGENETIC MINOR RESPONSE|1|mU/L|CONTRAST ENHANCED SPIRAL CT SCAN||||CHILD|MICROSCOPIST 1|U|3|Visit_3|40|1|TREATMENT|2020-08-31|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-24|P1Y2M10DT2H30M|UNKNOWN|2020-10-13|AFTER|2020-10-23
e|RS|4ce0546d-d8d9-42cb-bf2a-8e002536dd65|6|NEWLWIND|New Lesion Worsening Indicator|NCCN ALL MRD 2014|||iCR|1|IU/kg|MOUSE PROTECTION ASSAY|||Y|CAREGIVER|READER 1|N|3|Visit_3|40|3|TREATMENT|2020-08-31|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-24|P1Y2M10DT2H30M|UNKNOWN|2020-08-13|BEFORE|2020-08-24
e|RS|4ce0546d-d8d9-42cb-bf2a-8e002536dd65|7|MRDIND|Minimal Residual Disease Indicator|WHO BREAST CANCER 2006|||iSD|1|days/month|ATOMIC ABSORPTION SPECTROMETRY||Y|Y|CAREGIVER|RADIOLOGIST 2|NA|4|Visit_4|65|1|SCREENING|2020-09-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-29|P1Y2M10DT2H30M|COINCIDENT|2020-10-28|AFTER|2020-10-29
e|RS|4ce0546d-d8d9-42cb-bf2a-8e002536dd65|8|CPRFSTAT|Clinical Performance Status|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|Hounsfield Unit|PD-CT|1|L/s/kPa|TURBIDIMETRY||||SPOUSE|OPTOMETRIST|Y|4|Visit_4|65|7|TREATMENT|2020-09-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-29|P1Y2M10DT2H30M|UNKNOWN|2020-10-11|ONGOING|2020-10-18
e|RS|4ce0546d-d8d9-42cb-bf2a-8e002536dd65|9|CLINRESP|Clinical Response|MURPHY PROSTATE CANCER 1980|[?]|min*mg/mL|MRD PERSISTENCE|1|beats/min|CARDIAC THERMODILUTION||Y||CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR|Y|5|Visit_5|90|2|TREATMENT|2020-10-20|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-09|P1Y2M10DT2H30M|BEFORE|2020-10-07|ONGOING|2020-10-21
e|RS|4ce0546d-d8d9-42cb-bf2a-8e002536dd65|10|SPLNRESP|Spleen Response|LUGANO CLASSIFICATION|[?]|U.CARR|HI-E|1|U/g/day|GC/FID||||INVESTIGATOR|OPTOMETRIST|N|5|Visit_5|90|3|WASHOUT|2020-10-20|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-09|P1Y2M10DT2H30M|UNKNOWN|2020-08-30|COINCIDENT|2020-09-25
e|RS|25c6812b-9200-4dc4-a954-6879183a2c54|1|SPLNRESP|Spleen Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|mmol/min/kPa|MRD NEGATIVITY|1|/LSQN|POTENTIOMETRY|Y|||SPOUSE|PEDIATRIC NEUROLOGIST|U|1|Visit_1|10|5|TREATMENT|2020-12-24|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-08|P1Y2M10DT2H30M|BEFORE|2021-03-09|BEFORE|2021-03-15
e|RS|25c6812b-9200-4dc4-a954-6879183a2c54|2|MRDRESP|Minimal Residual Disease Response|EBMT BLADE MYELOMA 1998|[?]|amp|OPTIMAL MORPHOLOGIC RESPONSE|1|EID 50/mL|LIGHT MICROSCOPY||||CLINICAL STUDY SPONSOR|ONCOLOGIST 1|U|1|Visit_1|10|3|TREATMENT|2020-12-24|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-08|P1Y2M10DT2H30M|AFTER|2021-03-13|AFTER|2021-03-20
e|RS|25c6812b-9200-4dc4-a954-6879183a2c54|3|STRUSTAT|Steroid Use Status|iRECIST|[?]|nmol BCE/nmol|COMPLETE MRD RESPONSE|1|ppm|FLAME PHOTOMETRY||Y||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|U|2|Visit_2|25|6|WASHOUT|2021-01-08|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-05|P1Y2M10DT2H30M|UNKNOWN|2021-03-23|ONGOING|2021-03-24
e|RS|25c6812b-9200-4dc4-a954-6879183a2c54|4|CPRFSTAT|Clinical Performance Status|MRECIST BYRNE MESOTHELIOMA 2004|[?]|mL/m2/day|FAVORABLE RESPONSE|1|log10 CFU/g|MALDI||||GUARDIAN|RATER 1|Y|2|Visit_2|25|1|WASHOUT|2021-01-08|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-05|P1Y2M10DT2H30M|UNKNOWN|2021-01-06|COINCIDENT|2021-01-25
e|RS|25c6812b-9200-4dc4-a954-6879183a2c54|5|METSIND|Metastatic Indicator|FAROOQUI SUPP CLL 2014|[?]|CAPFUL|RELAPSED DISEASE FROM CR OR PR|1|IU/mmol|AUDIOMETRY||||NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|N|3|Visit_3|40|6|FOLLOW-UP|2021-01-23|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-10|P1Y2M10DT2H30M|BEFORE|2021-01-27|BEFORE|2021-03-22
e|RS|25c6812b-9200-4dc4-a954-6879183a2c54|6|CYTORESP|Cytogenetic Response|CHESON LYMPHOMA 2008|[?]|HEP|PD/RELAPSE AFTER HI|1|fmol/L/sec|LANDOLT RING||||CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 1|NA|3|Visit_3|40|3|FOLLOW-UP|2021-01-23|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-10|P1Y2M10DT2H30M|BEFORE|2021-01-18|BEFORE|2021-03-15
e|RS|25c6812b-9200-4dc4-a954-6879183a2c54|7|CLINRESP|Clinical Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|APL U/mL|RELAPSED DISEASE FROM CR OR PR|1|foz_us|MANUAL COUNT|Y|||CHILD|DERMATOLOGIST|NA|4|Visit_4|65|4|TREATMENT|2021-02-17|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-17|P1Y2M10DT2H30M|UNKNOWN|2021-03-22|BEFORE|2021-03-23
e|RS|25c6812b-9200-4dc4-a954-6879183a2c54|8|HEMARESP|Hematologic Response|NCCN ALL MRD 2014|||iSD|1|BOLUS|NO INFORMATION||Y|Y|SPOUSE|INTERNIST|NA|4|Visit_4|65|4|TREATMENT|2021-02-17|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-17|P1Y2M10DT2H30M|BEFORE|2021-01-09|COINCIDENT|2021-02-25
e|RS|25c6812b-9200-4dc4-a954-6879183a2c54|9|SFTSRESP|Soft Tissue Response|IWG CHESON AML 2003|[?]|ppth|MOLECULAR CR|1|BOLUS|TEMPLATE INCISION METHOD||Y||SIBLING|PHYSIOTHERAPIST|NA|5|Visit_5|90|4|FOLLOW-UP|2021-03-14|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-18|P1Y2M10DT2H30M|AFTER|2021-01-22|COINCIDENT|2021-01-28
e|RS|25c6812b-9200-4dc4-a954-6879183a2c54|10|SFTSRESP|Soft Tissue Response|PERCIST|[?]|Weber|SMD|1|/MBP|KARYOTYPING|Y|||ADJUDICATOR|DERMATOLOGIST|N|5|Visit_5|90|5|FOLLOW-UP|2021-03-14|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-18|P1Y2M10DT2H30M|AFTER|2021-01-25|COINCIDENT|2021-02-08
e|RS|10dca475-f364-42f3-9192-faf762832adf|1|NTNERESP|Non-Target Non-Enhancing Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|TRANSDUCING UNIT/mL|UNEQUIVOCAL|1|pm|GC/FID||||INDEPENDENT ASSESSOR|RATER 1|N|1|Visit_1|10|5|TREATMENT|2020-09-25|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-13|P1Y2M10DT2H30M|COINCIDENT|2020-11-07|ONGOING|2020-12-06
e|RS|10dca475-f364-42f3-9192-faf762832adf|2|TRGRESP|Target Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|10^10/L|MOLECULAR CR|1|V/sec|IMMUNOFIXATION ELECTROPHORESIS|Y|||VENDOR|ADJUDICATOR 2|NA|1|Visit_1|10|1|TREATMENT|2020-09-25|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-13|P1Y2M10DT2H30M|AFTER|2020-09-28|AFTER|2020-10-11
e|RS|10dca475-f364-42f3-9192-faf762832adf|3|TMRESP|Tumor Marker Response|RAJKUMAR MYELOMA 2011|||SD-CT|1|nmol/L/min|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY|||Y|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST|NA|2|Visit_2|25|4|SCREENING|2020-10-10|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-20|P1Y2M10DT2H30M|AFTER|2020-10-28|ONGOING|2020-12-16
e|RS|10dca475-f364-42f3-9192-faf762832adf|4|TRGRESP|Target Response|SHINDOH COLORECTAL CANCER 2013|[?]|days/wk|cPR|1|anti-Xa IU/mL|JAFFE REACTION||||SPOUSE|RADIOLOGIST 1|NA|2|Visit_2|25|1|TREATMENT|2020-10-10|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-20|P1Y2M10DT2H30M|AFTER|2020-11-19|AFTER|2020-11-24
e|RS|10dca475-f364-42f3-9192-faf762832adf|5|SFTSRESP|Soft Tissue Response|KUKER LYMPHOMA 2005|||PD-CT|1|yd|IRON HEMATOXYLIN STAIN|||Y|STUDY SUBJECT|PATHOLOGIST 1|U|3|Visit_3|40|7|TREATMENT|2020-10-25|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-12|P1Y2M10DT2H30M|BEFORE|2020-12-02|AFTER|2020-12-12
e|RS|10dca475-f364-42f3-9192-faf762832adf|6|TRGRESP|Target Response|SCHER PROSTATE CANCER 2011|[?]|10^3 DNA copies/mL|IMPROVED|1|/ms|NUCLEIC ACID HYBRIDIZATION||Y||FAMILY MEMBER|UROLOGIST|NA|3|Visit_3|40|3|SCREENING|2020-10-25|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-12|P1Y2M10DT2H30M|BEFORE|2020-10-22|COINCIDENT|2020-10-28
e|RS|10dca475-f364-42f3-9192-faf762832adf|7|CYTORESP|Cytogenetic Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|mg/animal|MOLECULAR CR|1|Frames/s|PERCUSSION||||ADJUDICATION COMMITTEE|DERMATOLOGIST|N|4|Visit_4|65|1|WASHOUT|2020-11-19|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-12|P1Y2M10DT2H30M|BEFORE|2020-11-20|BEFORE|2020-12-03
e|RS|10dca475-f364-42f3-9192-faf762832adf|8|NTRGRESP|Non-target Response|IWC HALLEK CLL 2008|[?]|Tbsp|DISEASE TRANSFORMATION|1|ng/day|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION||||STUDY SUBJECT|PATHOLOGIST 2|Y|4|Visit_4|65|5|TREATMENT|2020-11-19|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-12|P1Y2M10DT2H30M|COINCIDENT|2020-10-23|AFTER|2020-11-16
e|RS|10dca475-f364-42f3-9192-faf762832adf|9|SPLNRESP|Spleen Response|PERCIST|[?]|100 IU/mL|OPTIMAL MORPHOLOGIC RESPONSE|1|/day|THIN SMEAR||||INDEPENDENT ASSESSOR|RADIOLOGIST|Y|5|Visit_5|90|5|TREATMENT|2020-12-14|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-16|P1Y2M10DT2H30M|UNKNOWN|2020-11-06|AFTER|2020-12-04
e|RS|10dca475-f364-42f3-9192-faf762832adf|10|SYMPTDTR|Symptomatic Deterioration|WHO BREAST CANCER 2006|[?]|dpm/100mg|CMR|1|/10^3|ROMANOWSKY STAIN|Y|||PROXY|FORENSIC PATHOLOGIST|NA|5|Visit_5|90|3|FOLLOW-UP|2020-12-14|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-16|P1Y2M10DT2H30M|COINCIDENT|2020-11-14|AFTER|2020-12-06
e|RS|caf54095-56c3-428f-8342-ce45c6c9a287|1|NTNERESP|Non-Target Non-Enhancing Response|CHOI GIST 2008|||INCREASED|1|%/s|MUGA|||Y|CHILD|MICROSCOPIST|U|1|Visit_1|10|3|TREATMENT|2020-12-20|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-06|P1Y2M10DT2H30M|UNKNOWN|2021-01-21|BEFORE|2021-03-13
e|RS|caf54095-56c3-428f-8342-ce45c6c9a287|2|NTERESP|Non-Target Enhancing Response|LEE LUNG CANCER 2011|[?]|nmol/g|HI-E|1|L/day|TRANSESOPHAGEAL ECHOCARDIOGRAPHY||||CLINICAL RESEARCH ASSOCIATE|DERMATOLOGIST|U|1|Visit_1|10|7|TREATMENT|2020-12-20|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-06|P1Y2M10DT2H30M|BEFORE|2020-12-31|ONGOING|2021-01-02
e|RS|caf54095-56c3-428f-8342-ce45c6c9a287|3|NTNERESP|Non-Target Non-Enhancing Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|||TREATMENT FAILURE|1|Watt|MICROARRAY|Y|Y|Y|VENDOR|RATER 2|Y|2|Visit_2|25|2|TREATMENT|2021-01-04|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-07|P1Y2M10DT2H30M|BEFORE|2021-03-13|ONGOING|2021-03-17
e|RS|caf54095-56c3-428f-8342-ce45c6c9a287|4|NEWLWIND|New Lesion Worsening Indicator|JUWEID NON-HODGKINS LYMPHOMA 2005|||MRD PERSISTENCE|1|umol/L/sec|WESTERGREN||Y|Y|NON-HEALTH CARE PROFESSIONAL|READER 1|U|2|Visit_2|25|2|TREATMENT|2021-01-04|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-07|P1Y2M10DT2H30M|UNKNOWN|2021-02-26|AFTER|2021-03-14
e|RS|caf54095-56c3-428f-8342-ce45c6c9a287|5|NEWLWIND|New Lesion Worsening Indicator|BRUGGEMANN MRD 2010|[?]|10^3 CFU/g|PARTIAL MORPHOLOGIC RESPONSE|1|10^6 CFU/g|DISK DIFFUSION||Y||HEALTH CARE PROFESSIONAL|ADJUDICATOR|N|3|Visit_3|40|2|SCREENING|2021-01-19|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-22|P1Y2M10DT2H30M|COINCIDENT|2021-02-28|BEFORE|2021-03-11
e|RS|caf54095-56c3-428f-8342-ce45c6c9a287|6|DRCRIND|Disease Recurrence Indicator|GUPPY OVARIAN CANCER 2002|[?]|cd|CYTOGENETIC PR|1|U/kg/min|ETDRS EYE CHART||||SIGNIFICANT OTHER|MICROSCOPIST 3|NA|3|Visit_3|40|3|TREATMENT|2021-01-19|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-22|P1Y2M10DT2H30M|COINCIDENT|2021-02-12|BEFORE|2021-02-19
e|RS|caf54095-56c3-428f-8342-ce45c6c9a287|7|SPLNRESP|Spleen Response|IWG CHESON MDS 2006|||iUPD|1|pg/cell|CELL CYTOTOXICITY NEUTRALIZATION ASSAY||Y|Y|CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|4|Visit_4|65|3|TREATMENT|2021-02-13|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-18|P1Y2M10DT2H30M|BEFORE|2021-01-02|AFTER|2021-03-12
e|RS|caf54095-56c3-428f-8342-ce45c6c9a287|8|MRDRESP|Minimal Residual Disease Response|LEE LUNG CANCER 2011|||MINOR PATHOLOGIC RESPONSE|1|Antibody Unit|FUNDUS PHOTOGRAPHY||Y|Y|VENDOR|ADJUDICATOR 1|N|4|Visit_4|65|3|TREATMENT|2021-02-13|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-18|P1Y2M10DT2H30M|UNKNOWN|2021-02-20|BEFORE|2021-03-09
e|RS|caf54095-56c3-428f-8342-ce45c6c9a287|9|METBRESP|Metabolic Response|RANO|[?]|APL U/mL|DECREASED|1|amp|ANTIMICROBIAL COMBINATION TESTING|Y|Y||SPOUSE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|5|Visit_5|90|5|FOLLOW-UP|2021-03-10|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-13|P1Y2M10DT2H30M|COINCIDENT|2020-12-18|AFTER|2021-01-24
e|RS|caf54095-56c3-428f-8342-ce45c6c9a287|10|MOLRESP|Molecular Response|LUGANO CLASSIFICATION|[?]|U/dL|PD FROM PR|1|dram|PERIODIC ACID SCHIFF STAIN||Y||CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST|Y|5|Visit_5|90|1|FOLLOW-UP|2021-03-10|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-13|P1Y2M10DT2H30M|BEFORE|2021-03-04|AFTER|2021-03-11
e|RS|f833ca56-d426-420b-a6d3-fedeabc02734|1|METSIND|Metastatic Indicator|RAJKUMAR MYELOMA 2011|[?]|BOX|PR WITH LYMPHOCYTOSIS|1|U/kg/min|OBSERVATION||||INDEPENDENT ASSESSOR|RATER|Y|1|Visit_1|10|5|WASHOUT|2020-06-20|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-27|P1Y2M10DT2H30M|UNKNOWN|2020-06-25|ONGOING|2020-08-30
e|RS|f833ca56-d426-420b-a6d3-fedeabc02734|2|LIVRRESP|Liver Response|PCWG SCHER PROSTATE CANCER 2016|||NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|CONTAINER|MICROBIAL CULTURE, LIQUID|Y|Y|Y|SPOUSE|ADJUDICATOR 3|N|1|Visit_1|10|5|TREATMENT|2020-06-20|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-27|P1Y2M10DT2H30M|AFTER|2020-08-30|BEFORE|2020-09-03
e|RS|f833ca56-d426-420b-a6d3-fedeabc02734|3|BMIVLIND|Bone Marrow Involvement Indicator|DOHNER AML 2010|[?]|BP|TREATMENT FAILURE|1|log10 TCID 50/uL|SLOAN LETTER EYE CHART 100%||Y||FAMILY MEMBER|ADJUDICATOR 1|Y|2|Visit_2|25|4|WASHOUT|2020-07-05|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-21|P1Y2M10DT2H30M|UNKNOWN|2020-08-24|COINCIDENT|2020-08-26
e|RS|f833ca56-d426-420b-a6d3-fedeabc02734|4|CPRFSTAT|Clinical Performance Status|MRANO VAN DEN BENT GLIOMA 2011|[?]|cmol|PMR|1|FEU|CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|Y|||INDEPENDENT ASSESSOR|RADIOLOGIST 1|Y|2|Visit_2|25|1|WASHOUT|2020-07-05|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-21|P1Y2M10DT2H30M|UNKNOWN|2020-08-31|COINCIDENT|2020-09-09
e|RS|f833ca56-d426-420b-a6d3-fedeabc02734|5|NEWLIND|New Lesion Indicator|IWC HALLEK CLL 2008|[?]|log10 TCID 50/uL|cCR|1|mm/2h|FLUORESCENT ENZYME IMMUNOASSAY||||CAREGIVER|RADIOLOGIST 1|NA|3|Visit_3|40|5|TREATMENT|2020-07-20|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-03|P1Y2M10DT2H30M|BEFORE|2020-08-14|BEFORE|2020-09-08
e|RS|f833ca56-d426-420b-a6d3-fedeabc02734|6|NEWLPROG|New Lesion Progression|CHOLLET BREAST CANCER 2002|[?]|cmH2O/mL|CA125 50% RESPONSE|1|Gy/h|MEDIASTINOSCOPY||Y||INDEPENDENT ASSESSOR|MICROSCOPIST|N|3|Visit_3|40|4|TREATMENT|2020-07-20|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-03|P1Y2M10DT2H30M|COINCIDENT|2020-07-29|BEFORE|2020-09-11
e|RS|f833ca56-d426-420b-a6d3-fedeabc02734|7|MOLRESP|Molecular Response|KUKER LYMPHOMA 2005|[?]|TRANSDUCING UNIT|MORPHOLOGIC CR|1|mg/m2|ATOMIC ABSORPTION SPECTROMETRY|Y|||STUDY SUBJECT|MICROSCOPIST 2|Y|4|Visit_4|65|2|FOLLOW-UP|2020-08-14|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-24|P1Y2M10DT2H30M|AFTER|2020-08-29|BEFORE|2020-09-12
e|RS|f833ca56-d426-420b-a6d3-fedeabc02734|8|METSIND|Metastatic Indicator|GCIG RUSTIN OVARIAN CANCER 2011|[?]|mL/animal/wk|CYTOGENETIC CR|1|10^6 organisms/g|NUCLEAR RADIOLOGY||Y||ADJUDICATOR|ONCOLOGIST|U|4|Visit_4|65|1|SCREENING|2020-08-14|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-24|P1Y2M10DT2H30M|AFTER|2020-07-07|AFTER|2020-08-19
e|RS|f833ca56-d426-420b-a6d3-fedeabc02734|9|NTRGRESP|Non-target Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|mL/cm H2O|CRi|1|mg/h|AUTOREFRACTION||||PARENT|MICROSCOPIST 2|NA|5|Visit_5|90|4|FOLLOW-UP|2020-09-08|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-21|P1Y2M10DT2H30M|UNKNOWN|2020-07-11|BEFORE|2020-07-21
e|RS|f833ca56-d426-420b-a6d3-fedeabc02734|10|METBRESP|Metabolic Response|iRECIST|||MORPHOLOGIC CR|1|mL/kg/day|DROPLET DIGITAL PCR|||Y|SIGNIFICANT OTHER|RADIOLOGIST 1|Y|5|Visit_5|90|4|WASHOUT|2020-09-08|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-21|P1Y2M10DT2H30M|BEFORE|2020-09-10|BEFORE|2020-09-17
e|RS|03c8e2c7-b70d-4d46-8064-c99370eab232|1|NEWLPROG|New Lesion Progression|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|umol/L|PR|1|kg/cm|PALPATION||||CLINICAL RESEARCH COORDINATOR|OTOLARYNGOLOGIST|U|1|Visit_1|10|7|SCREENING|2020-11-29|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-24|P1Y2M10DT2H30M|BEFORE|2021-01-14|ONGOING|2021-01-26
e|RS|03c8e2c7-b70d-4d46-8064-c99370eab232|2|CPRFSTAT|Clinical Performance Status|GCIG RUSTIN OVARIAN CANCER 2011|[?]|pL|UNFAVORABLE RESPONSE|1|mPa|LC/MS||Y||VENDOR|OPTOMETRIST|U|1|Visit_1|10|2|SCREENING|2020-11-29|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-24|P1Y2M10DT2H30M|AFTER|2021-02-22|AFTER|2021-02-26
e|RS|03c8e2c7-b70d-4d46-8064-c99370eab232|3|NEWLPROG|New Lesion Progression|IRANO 2015|[?]|g/g/day|mCR|1|fmol|IMMUNORADIOMETRIC ASSAY||||SPOUSE|PATHOLOGIST 1|U|2|Visit_2|25|2|TREATMENT|2020-12-14|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-08|P1Y2M10DT2H30M|UNKNOWN|2021-01-16|COINCIDENT|2021-02-13
e|RS|03c8e2c7-b70d-4d46-8064-c99370eab232|4|CPRFSTAT|Clinical Performance Status|PERCIST|[?]|/2000 RBC|SD-CT|1|FFU|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY||Y||PARENT|READER|N|2|Visit_2|25|5|WASHOUT|2020-12-14|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-08|P1Y2M10DT2H30M|AFTER|2021-02-18|COINCIDENT|2021-02-24
e|RS|03c8e2c7-b70d-4d46-8064-c99370eab232|5|PATHRESP|Pathologic Response|NCIWG CHESON CLL 1996|[?]|log EID 50/dose|FAVORABLE RESPONSE|1|CFU/g|HANSEL STAIN||Y||SIGNIFICANT OTHER|MICROSCOPIST 1|U|3|Visit_3|40|1|TREATMENT|2020-12-29|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-25|P1Y2M10DT2H30M|AFTER|2020-12-02|ONGOING|2021-01-14
e|RS|03c8e2c7-b70d-4d46-8064-c99370eab232|6|MRPHRESP|Morphologic Response|WOLCHOK SOLID TUMORS 2009|[?]|DAgU|iUPD|1|pg|MEDIASTINOSCOPY|Y|||CLINICAL STUDY SPONSOR|CARDIOLOGIST|U|3|Visit_3|40|7|FOLLOW-UP|2020-12-29|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-25|P1Y2M10DT2H30M|BEFORE|2021-01-11|ONGOING|2021-01-21
e|RS|03c8e2c7-b70d-4d46-8064-c99370eab232|7|SPLNRESP|Spleen Response|CHOI GIST 2008|[?]|kg/L|NON-CR/NON-PD|1|ug/g/h|PHASE CONTRAST MICROSCOPY|Y|||INVESTIGATOR|OTOLARYNGOLOGIST|N|4|Visit_4|65|2|FOLLOW-UP|2021-01-23|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-30|P1Y2M10DT2H30M|AFTER|2021-02-13|AFTER|2021-02-24
e|RS|03c8e2c7-b70d-4d46-8064-c99370eab232|8|MRDRESP|Minimal Residual Disease Response|RAJKUMAR MYELOMA 2011|[?]|/500 WBC|NE|1|Frames/s|LEAD CITRATE STAIN|Y|||GUARDIAN|READER 3|N|4|Visit_4|65|3|TREATMENT|2021-01-23|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-30|P1Y2M10DT2H30M|COINCIDENT|2021-01-26|ONGOING|2021-02-18
e|RS|03c8e2c7-b70d-4d46-8064-c99370eab232|9|RDIORESP|Radiologic Response|FAROOQUI SUPP CLL 2014|[?]|10^6 CFU|EQUIVOCAL|1|umol/L/h|MOUSE PROTECTION ASSAY||Y||SPOUSE|ONCOLOGIST|Y|5|Visit_5|90|5|FOLLOW-UP|2021-02-17|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-15|P1Y2M10DT2H30M|UNKNOWN|2020-12-25|COINCIDENT|2021-01-18
e|RS|03c8e2c7-b70d-4d46-8064-c99370eab232|10|NTLWIND|Non-Target Lesion Worsening Indicator|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|10^12/L|PD-CT|1|EIA unit|CHROMATOGRAPHY||||INTERVIEWER|INTERNIST|U|5|Visit_5|90|2|FOLLOW-UP|2021-02-17|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-15|P1Y2M10DT2H30M|AFTER|2020-11-22|AFTER|2021-02-17
e|RS|944617c7-c5e6-4e06-b114-499c3020dbbd|1|BESTRESP|Best Overall Response|JACINTO CERVICAL CANCER 2007|[?]|log10 copies/mL|MOLECULAR CR|1|10^9/g|AGAR DILUTION||||FAMILY MEMBER|MICROSCOPIST 2|U|1|Visit_1|10|7|TREATMENT|2020-10-22|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-28|P1Y2M10DT2H30M|COINCIDENT|2020-12-12|BEFORE|2020-12-14
e|RS|944617c7-c5e6-4e06-b114-499c3020dbbd|2|NTERESP|Non-Target Enhancing Response|LUGANO CLASSIFICATION|[?]|10^9 organisms/g|PMD|1|MBP|ORCHIDOMETERY||Y||INTERVIEWER|RADIOLOGIST 2|NA|1|Visit_1|10|5|WASHOUT|2020-10-22|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-28|P1Y2M10DT2H30M|COINCIDENT|2020-12-13|AFTER|2020-12-19
e|RS|944617c7-c5e6-4e06-b114-499c3020dbbd|3|MRPHRESP|Morphologic Response|IWG CHESON MDS 2000|[?]|damol/L|iPR|1|g/day|CISH||Y||ADJUDICATOR|RATER 1|U|2|Visit_2|25|1|TREATMENT|2020-11-06|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-05|P1Y2M10DT2H30M|AFTER|2020-11-24|AFTER|2021-01-09
e|RS|944617c7-c5e6-4e06-b114-499c3020dbbd|4|CLINRESP|Clinical Response|WHO BREAST CANCER 2006|[?]|Frames/s|pCR|1|EID 50/mL|SINGLE-MOLECULE ARRAY||Y||ADJUDICATION COMMITTEE|ADJUDICATOR|U|2|Visit_2|25|5|TREATMENT|2020-11-06|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-05|P1Y2M10DT2H30M|BEFORE|2020-11-24|BEFORE|2020-12-06
e|RS|944617c7-c5e6-4e06-b114-499c3020dbbd|5|BONERESP|Bone Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|g/g|CRi|1|10^9 organisms/g|CHROMOGENIC ASSAY||||NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|NA|3|Visit_3|40|5|TREATMENT|2020-11-21|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-27|P1Y2M10DT2H30M|COINCIDENT|2020-12-30|BEFORE|2021-01-19
e|RS|944617c7-c5e6-4e06-b114-499c3020dbbd|6|ANATRESP|Anatomic Response|PRINCE TCELL LYMPHOMA 2010|[?]|mg/min|OPTIMAL MORPHOLOGIC RESPONSE|1|NFIU|SPIRAL CT||||DOMESTIC PARTNER|OPTOMETRIST|Y|3|Visit_3|40|5|WASHOUT|2020-11-21|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-27|P1Y2M10DT2H30M|UNKNOWN|2020-11-12|AFTER|2020-12-26
e|RS|944617c7-c5e6-4e06-b114-499c3020dbbd|7|CLINRESP|Clinical Response|NCIWG CHESON CLL 1996|[?]|Bq/mg|CYTOGENETIC PR|1|Pack Year|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY||||CLINICAL RESEARCH ASSOCIATE|READER 2|U|4|Visit_4|65|5|FOLLOW-UP|2020-12-16|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-21|P1Y2M10DT2H30M|BEFORE|2021-01-16|COINCIDENT|2021-01-18
e|RS|944617c7-c5e6-4e06-b114-499c3020dbbd|8|MJPTHIND|Major Pathological Response Indicator|KUMAR IMWG 2016|[?]|10^3 CFU/g|PARTIAL MORPHOLOGIC RESPONSE|1|10^9 organisms|NEXT GENERATION SEQUENCING||||SPOUSE|NEUROLOGIST 2|N|4|Visit_4|65|5|SCREENING|2020-12-16|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-21|P1Y2M10DT2H30M|COINCIDENT|2020-11-17|BEFORE|2020-11-22
e|RS|944617c7-c5e6-4e06-b114-499c3020dbbd|9|NEWLWIND|New Lesion Worsening Indicator|BLAZER COLORECTAL CANCER 2008|[?]|mL/cm H2O|NON-CR/NON-PD|1|log10 CCID 50/dose|NEXT GENERATION TARGETED SEQUENCING||||GUARDIAN|CARDIOLOGIST|N|5|Visit_5|90|1|FOLLOW-UP|2021-01-10|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-06|P1Y2M10DT2H30M|UNKNOWN|2021-01-03|COINCIDENT|2021-01-11
e|RS|944617c7-c5e6-4e06-b114-499c3020dbbd|10|SPLNRESP|Spleen Response|DURIE MULTIPLE MYELOMA 2006|[?]|SYRINGE|PARTIAL MORPHOLOGIC RESPONSE|1|ng/dL|SLIT LAMP|Y|||INTERVIEWER|HEMATOLOGIST|N|5|Visit_5|90|3|WASHOUT|2021-01-10|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-06|P1Y2M10DT2H30M|BEFORE|2021-01-07|AFTER|2021-01-14
e|RS|e4878c66-1e2b-49bb-838e-85139d160dd4|1|BONERESP|Bone Response|KEAM BREAST CANCER 2013|[?]|MnFI|IMPROVED|1|mgEq|WESTERN BLOT||||SIGNIFICANT OTHER|MICROSCOPIST 3|Y|1|Visit_1|10|5|TREATMENT|2020-10-21|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-14|P1Y2M10DT2H30M|UNKNOWN|2020-12-23|ONGOING|2021-01-09
e|RS|e4878c66-1e2b-49bb-838e-85139d160dd4|2|CYTORESP|Cytogenetic Response|IWG CHESON MDS 2000|[?]|K|NON-QUANTIFIABLE MRD POSITIVITY|1|IMPLANT|PHASE CONTRAST MICROSCOPY||||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 2|U|1|Visit_1|10|5|TREATMENT|2020-10-21|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-14|P1Y2M10DT2H30M|AFTER|2020-12-23|ONGOING|2020-12-31
e|RS|e4878c66-1e2b-49bb-838e-85139d160dd4|3|RDIORESP|Radiologic Response|CHESON CLL 2006|[?]|/MBP|NON-iCR/NON-iUPD|1|fmol|DYNAMOMETRY||Y||VENDOR|CARDIOLOGIST|N|2|Visit_2|25|6|TREATMENT|2020-11-05|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-23|P1Y2M10DT2H30M|UNKNOWN|2020-11-10|ONGOING|2021-01-04
e|RS|e4878c66-1e2b-49bb-838e-85139d160dd4|4|BONERESP|Bone Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|cd/m2|MR|1|L/h|MANUAL COUNT|Y|||FRIEND|UROLOGIST|N|2|Visit_2|25|6|WASHOUT|2020-11-05|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-23|P1Y2M10DT2H30M|UNKNOWN|2021-01-12|COINCIDENT|2021-01-17
e|RS|e4878c66-1e2b-49bb-838e-85139d160dd4|5|NTLWIND|Non-Target Lesion Worsening Indicator|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|KALLIKREIN INHIBITOR UNIT|MOLECULAR CR|1|10^8 PFU|MICROBIAL CONCENTRATION||||SPOUSE|ONCOLOGIST|Y|3|Visit_3|40|3|WASHOUT|2020-11-20|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-29|P1Y2M10DT2H30M|AFTER|2020-12-17|COINCIDENT|2020-12-21
e|RS|e4878c66-1e2b-49bb-838e-85139d160dd4|6|NTLWIND|Non-Target Lesion Worsening Indicator|iRECIST|[?]|ft3|iSD|1|Sv|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN|Y|||ADJUDICATOR|ONCOLOGIST 1|NA|3|Visit_3|40|1|TREATMENT|2020-11-20|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-29|P1Y2M10DT2H30M|COINCIDENT|2020-11-16|AFTER|2020-12-23
e|RS|e4878c66-1e2b-49bb-838e-85139d160dd4|7|BONERESP|Bone Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|MBq/uL|VGPR|1|umol/L/min|SURFACE PLASMON RESONANCE||||FRIEND|PEDIATRIC NEUROLOGIST|U|4|Visit_4|65|6|FOLLOW-UP|2020-12-15|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-11|P1Y2M10DT2H30M|COINCIDENT|2020-11-26|BEFORE|2020-12-18
e|RS|e4878c66-1e2b-49bb-838e-85139d160dd4|8|TMRESP|Tumor Marker Response|PETIT BREAST CANCER 2001|[?]|yd|PARTIAL MORPHOLOGIC RESPONSE|1|HOMEOPATHIC DILUTION|SICKLE CELL SOLUBILITY TEST||Y||DOMESTIC PARTNER|PATHOLOGIST|N|4|Visit_4|65|5|FOLLOW-UP|2020-12-15|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-11|P1Y2M10DT2H30M|COINCIDENT|2021-01-08|ONGOING|2021-01-18
e|RS|e4878c66-1e2b-49bb-838e-85139d160dd4|9|DRCRIND|Disease Recurrence Indicator|RANO ELLINGSON 2017|[?]|DNA copies/mL|QUANTIFIABLE MRD POSITIVITY|1|CAN|POLYMERASE CHAIN REACTION||||NON-HEALTH CARE PROFESSIONAL|CLINICAL PATHOLOGIST|Y|5|Visit_5|90|1|SCREENING|2021-01-09|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-09|P1Y2M10DT2H30M|COINCIDENT|2020-11-05|COINCIDENT|2020-11-07
e|RS|e4878c66-1e2b-49bb-838e-85139d160dd4|10|ANATRESP|Anatomic Response|EASL BRUIX LIVER CANCER 2001|[?]|SFC/10^6 PBMC|ABSENT MORPHOLOGIC RESPONSE|1|10^3 CFU/mL|DROPLET DIGITAL PCR|Y|||INTERVIEWER|MICROSCOPIST|N|5|Visit_5|90|1|TREATMENT|2021-01-09|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-09|P1Y2M10DT2H30M|BEFORE|2020-11-14|AFTER|2020-11-20
e|RS|6873e227-baef-4d6e-8600-0bb61d60fe49|1|SYMPTDTR|Symptomatic Deterioration|JUWEID NON-HODGKINS LYMPHOMA 2005|||iUPD|1|log10 CCID 50/dose|FLUORESCENT LIFETIME IMAGING MICROSCOPY||Y|Y|PARENT|NEUROLOGIST 1|U|1|Visit_1|10|7|TREATMENT|2020-06-06|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-18|P1Y2M10DT2H30M|BEFORE|2020-06-04|BEFORE|2020-08-13
e|RS|6873e227-baef-4d6e-8600-0bb61d60fe49|2|MJPTHIND|Major Pathological Response Indicator|CHESON NON-HODGKINS LYMPHOMA 1999|||INDETERMINATE RESPONSE|1|10^12 IU/L|CONFOCAL MICROSCOPY|||Y|INVESTIGATOR|ONCOLOGIST|N|1|Visit_1|10|6|TREATMENT|2020-06-06|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-18|P1Y2M10DT2H30M|AFTER|2020-08-31|BEFORE|2020-09-03
e|RS|6873e227-baef-4d6e-8600-0bb61d60fe49|3|CYTORESP|Cytogenetic Response|FAROOQUI SUPP CLL 2014|[?]|10^6 copies/mL|PD FROM PR|1|breaths/30s|INCISION-INDUCED BLEEDING METHOD|Y|||CHILD|RADIOLOGIST|NA|2|Visit_2|25|5|SCREENING|2020-06-21|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-06|P1Y2M10DT2H30M|AFTER|2020-07-27|AFTER|2020-08-03
e|RS|6873e227-baef-4d6e-8600-0bb61d60fe49|4|CYTORESP|Cytogenetic Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|steps/min|NED|1|mL/dose|HPLC/MS||||PARENT|MICROSCOPIST 1|U|2|Visit_2|25|4|TREATMENT|2020-06-21|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-06|P1Y2M10DT2H30M|AFTER|2020-07-10|BEFORE|2020-07-14
e|RS|6873e227-baef-4d6e-8600-0bb61d60fe49|5|ANATRESP|Anatomic Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|mEq/L|UNEQUIVOCAL|1|aMFI|CONTACT SPECULAR MICROSCOPY||||SIBLING|OTOLARYNGOLOGIST|NA|3|Visit_3|40|3|FOLLOW-UP|2020-07-06|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-08|P1Y2M10DT2H30M|BEFORE|2020-08-10|BEFORE|2020-08-31
e|RS|6873e227-baef-4d6e-8600-0bb61d60fe49|6|MJPTHIND|Major Pathological Response Indicator|JACINTO CERVICAL CANCER 2007|[?]|10^7 PFU|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|mmol/mol|MANUAL CLOT DETECTION|Y|Y||ADJUDICATION COMMITTEE|DEVELOPMENTAL PSYCHOLOGIST|Y|3|Visit_3|40|7|TREATMENT|2020-07-06|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-08|P1Y2M10DT2H30M|COINCIDENT|2020-08-16|COINCIDENT|2020-08-17
e|RS|6873e227-baef-4d6e-8600-0bb61d60fe49|7|BONERESP|Bone Response|IWG CHESON MDS 2006|[?]|mg/mL/min|CHR|1|AFU|PELLI-ROBSON EYE CHART|Y|||ADJUDICATOR|ONCOLOGIST 2|Y|4|Visit_4|65|2|WASHOUT|2020-07-31|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-07|P1Y2M10DT2H30M|COINCIDENT|2020-07-03|COINCIDENT|2020-08-20
e|RS|6873e227-baef-4d6e-8600-0bb61d60fe49|8|METBRESP|Metabolic Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|||NED|1|kDa|PELLI-ROBSON EYE CHART||Y|Y|CHILD|NEUROLOGIST|N|4|Visit_4|65|4|WASHOUT|2020-07-31|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-07|P1Y2M10DT2H30M|UNKNOWN|2020-08-10|BEFORE|2020-08-24
e|RS|6873e227-baef-4d6e-8600-0bb61d60fe49|9|CLINRESP|Clinical Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|ug/L DDU|iSD|1|nCi|RAJI CELL EIA||Y||CAREGIVER|PHYSIOTHERAPIST|Y|5|Visit_5|90|7|FOLLOW-UP|2020-08-25|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-16|P1Y2M10DT2H30M|UNKNOWN|2020-08-02|ONGOING|2020-08-05
e|RS|6873e227-baef-4d6e-8600-0bb61d60fe49|10|NTLWIND|Non-Target Lesion Worsening Indicator|BRUGGEMANN MRD 2010|||sCR|1|um/day|VENTILATION PERFUSION LUNG SCAN|||Y|FRIEND|PHYSIOTHERAPIST|U|5|Visit_5|90|2|TREATMENT|2020-08-25|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-16|P1Y2M10DT2H30M|COINCIDENT|2020-06-05|BEFORE|2020-08-17
e|RS|bad01879-9b97-4d9c-9eec-58871168bd57|1|CYTORESP|Cytogenetic Response|RANO ELLINGSON 2017|||UNFAVORABLE RESPONSE|1|Watt|TRIPLE-PHASE MRI SCAN|||Y|INDEPENDENT ASSESSOR|RADIOLOGIST 1|NA|1|Visit_1|10|7|WASHOUT|2020-10-15|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-22|P1Y2M10DT2H30M|COINCIDENT|2020-11-07|BEFORE|2020-12-22
e|RS|bad01879-9b97-4d9c-9eec-58871168bd57|2|NTLWIND|Non-Target Lesion Worsening Indicator|PCWG SCHER PROSTATE CANCER 2016|[?]|10^10/L|RELAPSED DISEASE|1|10^7 CFU/mL|BIOIMPEDANCE SPECTROSCOPY||Y||CLINICAL RESEARCH COORDINATOR|READER 1|Y|1|Visit_1|10|3|SCREENING|2020-10-15|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-22|P1Y2M10DT2H30M|COINCIDENT|2020-11-12|AFTER|2021-01-11
e|RS|bad01879-9b97-4d9c-9eec-58871168bd57|3|ANATRESP|Anatomic Response|CHOI GIST 2008|[?]|cm H2O|PMR|1|AFU|NEXT GENERATION SEQUENCING||||INDEPENDENT ASSESSOR|MICROSCOPIST|NA|2|Visit_2|25|2|TREATMENT|2020-10-30|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-18|P1Y2M10DT2H30M|BEFORE|2020-10-12|BEFORE|2020-11-19
e|RS|bad01879-9b97-4d9c-9eec-58871168bd57|4|CLINRESP|Clinical Response|GUILHOT CML 2007|[?]|mU/g|TREATMENT FAILURE|1|dmol|ORCHIDOMETERY||||INTERVIEWER|ENDOCRINOLOGIST|N|2|Visit_2|25|3|TREATMENT|2020-10-30|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-18|P1Y2M10DT2H30M|COINCIDENT|2020-12-27|AFTER|2021-01-08
e|RS|bad01879-9b97-4d9c-9eec-58871168bd57|5|NTRGRESP|Non-target Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|oz|iCPD|1|ng|EIA|Y|||INDEPENDENT ASSESSOR|NEUROLOGIST|NA|3|Visit_3|40|7|TREATMENT|2020-11-14|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-18|P1Y2M10DT2H30M|COINCIDENT|2020-12-19|AFTER|2020-12-24
e|RS|bad01879-9b97-4d9c-9eec-58871168bd57|6|TRGRESP|Target Response|RECIST 1.1|[?]|10^6 CFU/mL|SD|1|U/m2/min|PHOTOMETRY|Y|Y||INVESTIGATOR|OTOLARYNGOLOGIST|Y|3|Visit_3|40|5|SCREENING|2020-11-14|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-18|P1Y2M10DT2H30M|COINCIDENT|2020-11-23|ONGOING|2020-12-27
e|RS|bad01879-9b97-4d9c-9eec-58871168bd57|7|NEWLPROG|New Lesion Progression|LUGANO CLASSIFICATION|[?]|Torr|RELAPSED DISEASE FROM CR OR PR|1|g/cage/day|STATIC PERIMETRY||||PARENT|ADJUDICATOR 1|N|4|Visit_4|65|7|FOLLOW-UP|2020-12-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-21|P1Y2M10DT2H30M|BEFORE|2021-01-04|BEFORE|2021-01-11
e|RS|bad01879-9b97-4d9c-9eec-58871168bd57|8|MRDIND|Minimal Residual Disease Indicator|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|Roentgen|MAJOR PATHOLOGIC RESPONSE|1|dyn|TWO-COLOR MICROARRAY||||DOMESTIC PARTNER|RADIOLOGIST 2|N|4|Visit_4|65|7|FOLLOW-UP|2020-12-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-21|P1Y2M10DT2H30M|BEFORE|2020-11-27|AFTER|2020-12-30
e|RS|bad01879-9b97-4d9c-9eec-58871168bd57|9|SPLNRESP|Spleen Response|PETIT BREAST CANCER 2001|[?]|Hounsfield Unit|PARTIAL MORPHOLOGIC RESPONSE|1|km|SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY|Y|||CLINICAL RESEARCH COORDINATOR|NEUROLOGIST|NA|5|Visit_5|90|5|TREATMENT|2021-01-03|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-27|P1Y2M10DT2H30M|AFTER|2020-12-14|COINCIDENT|2020-12-22
e|RS|bad01879-9b97-4d9c-9eec-58871168bd57|10|BONERESP|Bone Response|AJCC V7|[?]|10^9/dose|STABLE|1|FIU|KINETIC MICROPARTICLE IMMUNOASSAY||||INTERVIEWER|PATHOLOGIST|NA|5|Visit_5|90|6|TREATMENT|2021-01-03|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-27|P1Y2M10DT2H30M|BEFORE|2020-10-20|AFTER|2020-10-21
e|RS|10d97d12-b3e9-4e58-87a2-d0c81ceeac17|1|CPRFSTAT|Clinical Performance Status|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|nmol/mL/min|WORSENED|1|IU|ENDOSCOPY|Y|||GUARDIAN|PATHOLOGIST|N|1|Visit_1|10|1|FOLLOW-UP|2020-11-05|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-04|P1Y2M10DT2H30M|AFTER|2021-01-01|AFTER|2021-01-26
e|RS|10d97d12-b3e9-4e58-87a2-d0c81ceeac17|2|SFTSRESP|Soft Tissue Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|kN/cm2|IMPROVED|1|VIRTUAL PIXEL|DUKE INCISION METHOD||||CLINICAL RESEARCH COORDINATOR|PEDIATRIC NEUROLOGIST|U|1|Visit_1|10|2|TREATMENT|2020-11-05|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-04|P1Y2M10DT2H30M|AFTER|2020-11-03|BEFORE|2020-11-15
e|RS|10d97d12-b3e9-4e58-87a2-d0c81ceeac17|3|NTRGRESP|Non-target Response|IWG CHESON AML 2003|||FAVORABLE RESPONSE|1|g/animal/wk|OPTICAL DENSITY MEASUREMENT|Y|Y|Y|INVESTIGATOR|ENDOCRINOLOGIST|N|2|Visit_2|25|2|TREATMENT|2020-11-20|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-30|P1Y2M10DT2H30M|COINCIDENT|2020-11-13|AFTER|2020-12-06
e|RS|10d97d12-b3e9-4e58-87a2-d0c81ceeac17|4|METSIND|Metastatic Indicator|RECIST 1.1|[?]|mg/g/min|QUANTIFIABLE MRD POSITIVITY|1|JDF Unit|NUCLEIC ACID BASED METHOD||Y||ADJUDICATION COMMITTEE|RATER 2|Y|2|Visit_2|25|7|FOLLOW-UP|2020-11-20|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-30|P1Y2M10DT2H30M|COINCIDENT|2020-11-04|BEFORE|2020-11-16
e|RS|10d97d12-b3e9-4e58-87a2-d0c81ceeac17|5|LIVRRESP|Liver Response|RANO|[?]|min|iCPD|1|AgU/mL|FLUORESCENCE ANGIOGRAPHY||||CLINICAL STUDY SPONSOR|RADIOLOGIST 2|NA|3|Visit_3|40|1|TREATMENT|2020-12-05|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-22|P1Y2M10DT2H30M|UNKNOWN|2020-12-24|BEFORE|2021-01-12
e|RS|10d97d12-b3e9-4e58-87a2-d0c81ceeac17|6|NTERESP|Non-Target Enhancing Response|EASL BRUIX LIVER CANCER 2001|[?]|damol/L|STABLE|1|10^12 IU/L|STATIC PERIMETRY|Y|||FAMILY MEMBER|DEVELOPMENTAL PSYCHOLOGIST|U|3|Visit_3|40|2|WASHOUT|2020-12-05|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-22|P1Y2M10DT2H30M|COINCIDENT|2021-01-01|AFTER|2021-01-23
e|RS|10d97d12-b3e9-4e58-87a2-d0c81ceeac17|7|MOLRESP|Molecular Response|CHESON MALIGNANT LYMPHOMA 2007|||IMPROVED|1|/month|HPLC/IEX||Y|Y|CAREGIVER|READER|U|4|Visit_4|65|7|TREATMENT|2020-12-30|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-12|P1Y2M10DT2H30M|BEFORE|2020-12-10|ONGOING|2021-01-31
e|RS|10d97d12-b3e9-4e58-87a2-d0c81ceeac17|8|RDIORESP|Radiologic Response|RECIST 1.0|[?]|NEEDLE GAUGE|MR|1|mg/g/h|SNELLEN EYE CHART|Y|||CAREGIVER|ADJUDICATOR|NA|4|Visit_4|65|2|WASHOUT|2020-12-30|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-12|P1Y2M10DT2H30M|BEFORE|2020-12-13|ONGOING|2021-01-23
e|RS|10d97d12-b3e9-4e58-87a2-d0c81ceeac17|9|NTNERESP|Non-Target Non-Enhancing Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|gpELISA unit/mL|PSEUDOPROGRESSION|1|uEq|PET/MRI SCAN||Y||FAMILY MEMBER|ONCOLOGIST 2|U|5|Visit_5|90|1|TREATMENT|2021-01-24|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-09|P1Y2M10DT2H30M|UNKNOWN|2020-12-12|BEFORE|2021-01-06
e|RS|10d97d12-b3e9-4e58-87a2-d0c81ceeac17|10|NEWLPROG|New Lesion Progression|DOHNER AML 2010|[?]|dpm/100mg|CR-CT|1|mg/kg/h|MICRODENSITOMETRY||||SIBLING|PHYSIOTHERAPIST|N|5|Visit_5|90|5|TREATMENT|2021-01-24|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-09|P1Y2M10DT2H30M|COINCIDENT|2021-01-05|COINCIDENT|2021-01-15
e|RS|0df77775-6e65-4f77-9f8f-7faaa1471141|1|OVRLRESP|Overall Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|Pa|HI-E|1|SPRAY|IMMUNOCHROMATOGRAPHY||Y||PARENT|READER 3|Y|1|Visit_1|10|4|TREATMENT|2020-08-24|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-15|P1Y2M10DT2H30M|UNKNOWN|2020-10-14|BEFORE|2020-11-01
e|RS|0df77775-6e65-4f77-9f8f-7faaa1471141|2|NEWLIND|New Lesion Indicator|SACT|||SD|1|pmol/g|GRADIENT DIFFUSION||Y|Y|SPOUSE|PATHOLOGIST|Y|1|Visit_1|10|2|TREATMENT|2020-08-24|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-15|P1Y2M10DT2H30M|AFTER|2020-09-14|COINCIDENT|2020-10-13
e|RS|0df77775-6e65-4f77-9f8f-7faaa1471141|3|NTLWIND|Non-Target Lesion Worsening Indicator|CHOLLET BREAST CANCER 2002|[?]|PA|MOLECULAR MAJOR RESPONSE|1|/10^3|RADIOGRAPHY|Y|||FAMILY MEMBER|RATER|U|2|Visit_2|25|3|TREATMENT|2020-09-08|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-04|P1Y2M10DT2H30M|AFTER|2020-08-19|AFTER|2020-10-26
e|RS|0df77775-6e65-4f77-9f8f-7faaa1471141|4|BESTRESP|Best Overall Response|AJCC V7|[?]|%(v/v)|INDETERMINATE RESPONSE|1|DISK|THICK SMEAR||||PARENT|PEDIATRIC NEUROLOGIST|N|2|Visit_2|25|7|FOLLOW-UP|2020-09-08|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-04|P1Y2M10DT2H30M|UNKNOWN|2020-08-29|AFTER|2020-10-06
e|RS|0df77775-6e65-4f77-9f8f-7faaa1471141|5|PATHRESP|Pathologic Response|GUILHOT CML 2007|[?]|IU/day|pCR|1|GBq/ug|FLOCCULATION||||INTERVIEWER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|3|Visit_3|40|2|TREATMENT|2020-09-23|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-01|P1Y2M10DT2H30M|AFTER|2020-09-15|AFTER|2020-09-24
e|RS|0df77775-6e65-4f77-9f8f-7faaa1471141|6|HEMARESP|Hematologic Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|/2000 RBC|NON-QUANTIFIABLE MRD POSITIVITY|1|10^4/L|MICRODENSITOMETRY||||SIGNIFICANT OTHER|RATER|NA|3|Visit_3|40|4|FOLLOW-UP|2020-09-23|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-01|P1Y2M10DT2H30M|COINCIDENT|2020-10-07|BEFORE|2020-10-24
e|RS|0df77775-6e65-4f77-9f8f-7faaa1471141|7|CYTORESP|Cytogenetic Response|EASL BRUIX LIVER CANCER 2001|[?]|/cmH2O|IMPROVED|1|BAU|ARTERIAL SPIN LABELING FUNCTIONAL MRI||||FRIEND|CARDIOLOGIST|Y|4|Visit_4|65|7|WASHOUT|2020-10-18|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-12|P1Y2M10DT2H30M|AFTER|2020-10-31|COINCIDENT|2020-11-19
e|RS|0df77775-6e65-4f77-9f8f-7faaa1471141|8|TMRESP|Tumor Marker Response|SCHER PROSTATE CANCER 2011|[?]|cmol/L|COMPLETE MRD RESPONSE|1|MHz|DIFFUSION TENSOR MRI||||HEALTH CARE PROFESSIONAL|HEMATOLOGIST|U|4|Visit_4|65|4|SCREENING|2020-10-18|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-12|P1Y2M10DT2H30M|COINCIDENT|2020-09-05|AFTER|2020-11-17
e|RS|0df77775-6e65-4f77-9f8f-7faaa1471141|9|OVRLRESP|Overall Response|CHESON CLL 2012|||CYTOGENETIC MINOR RESPONSE|1|L/L|QUANTITATIVE CORONARY ANGIOGRAPHY|Y||Y|SIGNIFICANT OTHER|MICROSCOPIST|N|5|Visit_5|90|3|TREATMENT|2020-11-12|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-06|P1Y2M10DT2H30M|COINCIDENT|2020-10-08|ONGOING|2020-11-18
e|RS|0df77775-6e65-4f77-9f8f-7faaa1471141|10|NTERESP|Non-Target Enhancing Response|RECIST 1.0|||SD-CT|1|kg|FLOCCULATION, CHARCOAL ENHANCED|||Y|HEALTH CARE PROFESSIONAL|RATER|N|5|Visit_5|90|4|FOLLOW-UP|2020-11-12|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-06|P1Y2M10DT2H30M|UNKNOWN|2020-09-18|BEFORE|2020-09-27
e|RS|adc5359a-f1d5-428b-97d8-fce67cfeeaea|1|BESTRESP|Best Overall Response|UNSPECIFIED|[?]|Hz/s|NON-iCR/NON-iUPD|1|ppth|CARDIAC THERMODILUTION||||HEALTH CARE PROFESSIONAL|ONCOLOGIST 2|U|1|Visit_1|10|7|TREATMENT|2020-08-22|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-09|P1Y2M10DT2H30M|AFTER|2020-09-12|COINCIDENT|2020-09-16
e|RS|adc5359a-f1d5-428b-97d8-fce67cfeeaea|2|TMRESP|Tumor Marker Response|SHINDOH COLORECTAL CANCER 2013|||INCREASED|1|10^3 CFU/mL|FLUORESCENT ENZYME IMMUNOASSAY|||Y|ADJUDICATION COMMITTEE|MICROSCOPIST 2|U|1|Visit_1|10|5|TREATMENT|2020-08-22|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-09|P1Y2M10DT2H30M|BEFORE|2020-10-09|BEFORE|2020-10-25
e|RS|adc5359a-f1d5-428b-97d8-fce67cfeeaea|3|SFTSRESP|Soft Tissue Response|BURCOMBE BREAST CANCER 2005|[?]|APPLICATION|PR-CT|1|STRIP|PHOROPTER|Y|||GUARDIAN|DERMATOLOGIST|Y|2|Visit_2|25|5|TREATMENT|2020-09-06|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-19|P1Y2M10DT2H30M|AFTER|2020-10-31|COINCIDENT|2020-11-08
e|RS|adc5359a-f1d5-428b-97d8-fce67cfeeaea|4|NEWLPROG|New Lesion Progression|SACT|[?]|cP|NON-PD|1|P|PULSE OXIMETRY||||SIBLING|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|2|Visit_2|25|7|TREATMENT|2020-09-06|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-19|P1Y2M10DT2H30M|BEFORE|2020-09-07|AFTER|2020-10-21
e|RS|adc5359a-f1d5-428b-97d8-fce67cfeeaea|5|NEWLIND|New Lesion Indicator|CHESON MALIGNANT LYMPHOMA 2007|[?]|dpm/0.5 mL|MOLECULAR MAJOR RESPONSE|1|Log10 ELISA unit/dose|GRADIENT DIFFUSION||Y||HEALTH CARE PROFESSIONAL|NEUROLOGIST 1|NA|3|Visit_3|40|4|TREATMENT|2020-09-21|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-06|P1Y2M10DT2H30M|COINCIDENT|2020-08-16|ONGOING|2020-10-03
e|RS|adc5359a-f1d5-428b-97d8-fce67cfeeaea|6|SPLNRESP|Spleen Response|BLAZER COLORECTAL CANCER 2008|[?]|PIXELS/in|COMPLETE MRD RESPONSE|1|kN/cm2|U-HPLC/MS/MS|Y|||FAMILY MEMBER|FORENSIC PATHOLOGIST|U|3|Visit_3|40|5|WASHOUT|2020-09-21|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-06|P1Y2M10DT2H30M|AFTER|2020-10-02|AFTER|2020-10-04
e|RS|adc5359a-f1d5-428b-97d8-fce67cfeeaea|7|CYTORESP|Cytogenetic Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|mg/g/min|CYTOGENETIC NO RESPONSE|1|Linear ft*LB|MRI WITHOUT CONTRAST||||SPOUSE|ONCOLOGIST|Y|4|Visit_4|65|2|WASHOUT|2020-10-16|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-31|P1Y2M10DT2H30M|AFTER|2020-11-09|BEFORE|2020-11-17
e|RS|adc5359a-f1d5-428b-97d8-fce67cfeeaea|8|MOLRESP|Molecular Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|HOURS|PR-CT|1|days/month|WRIGHT-GIEMSA STAIN||||VENDOR|ONCOLOGIST 1|U|4|Visit_4|65|5|TREATMENT|2020-10-16|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-31|P1Y2M10DT2H30M|UNKNOWN|2020-10-09|COINCIDENT|2020-10-13
e|RS|adc5359a-f1d5-428b-97d8-fce67cfeeaea|9|TRGRESP|Target Response|AJCC V7|[?]|mL/cm|CYTOGENETIC NO RESPONSE|1|nmol/L/min|FLUORESCENT SPOT TEST||||SIBLING|READER 1|NA|5|Visit_5|90|6|TREATMENT|2020-11-10|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-11|P1Y2M10DT2H30M|BEFORE|2020-09-25|ONGOING|2020-09-30
e|RS|adc5359a-f1d5-428b-97d8-fce67cfeeaea|10|BESTRESP|Best Overall Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|fmol/L/sec|CMR|1|cycle/min|CHROMATOGRAPHY||||CAREGIVER|RATER 2|NA|5|Visit_5|90|7|WASHOUT|2020-11-10|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-11|P1Y2M10DT2H30M|BEFORE|2020-09-20|BEFORE|2020-10-10
e|RS|cd68296c-95d4-489e-8b64-b2404f16316c|1|MNPTHIND|Minor Pathological Response Indicator|LEE LUNG CANCER 2011|[?]|Pack Year|CR-CT|1|ugEq/L|KNEMOMETRY||||CLINICAL STUDY SPONSOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|1|Visit_1|10|5|FOLLOW-UP|2020-12-20|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-27|P1Y2M10DT2H30M|BEFORE|2021-02-11|ONGOING|2021-02-12
e|RS|cd68296c-95d4-489e-8b64-b2404f16316c|2|BONERESP|Bone Response|BLAZER COLORECTAL CANCER 2008|[?]|DRUM|nPR|1|CFU/g|OPTICAL MAPPING||Y||CAREGIVER|UROLOGIST|U|1|Visit_1|10|3|SCREENING|2020-12-20|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-27|P1Y2M10DT2H30M|COINCIDENT|2021-01-12|COINCIDENT|2021-03-19
e|RS|cd68296c-95d4-489e-8b64-b2404f16316c|3|HEMARESP|Hematologic Response|SHINDOH COLORECTAL CANCER 2013|[?]|/100 WBC|CYTOGENETIC MINIMAL RESPONSE|1|cpm|MECHANICAL CLOT DETECTION||||STUDY SUBJECT|READER 3|NA|2|Visit_2|25|6|FOLLOW-UP|2021-01-04|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-09|P1Y2M10DT2H30M|BEFORE|2021-03-08|ONGOING|2021-03-19
e|RS|cd68296c-95d4-489e-8b64-b2404f16316c|4|NTRGRESP|Non-target Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|m|CR-CT|1|TABLET|SLOAN LETTER EYE CHART 100%||Y||FAMILY MEMBER|DEVELOPMENTAL PSYCHOLOGIST|U|2|Visit_2|25|7|SCREENING|2021-01-04|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-09|P1Y2M10DT2H30M|AFTER|2021-02-05|ONGOING|2021-02-15
e|RS|cd68296c-95d4-489e-8b64-b2404f16316c|5|TMRESP|Tumor Marker Response|LEE LUNG CANCER 2011|[?]|EVENTS|pCR|1|mol/mg|RIA||||FAMILY MEMBER|NEUROLOGIST|N|3|Visit_3|40|5|TREATMENT|2021-01-19|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-19|P1Y2M10DT2H30M|AFTER|2020-12-31|COINCIDENT|2021-01-03
e|RS|cd68296c-95d4-489e-8b64-b2404f16316c|6|NTRGRESP|Non-target Response|CHESON LYMPHOMA 2008|[?]|U/g Hb|PSA PROGRESSION|1|BOWL|PERIPHERAL ANGIOGRAPHY|Y|||HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|N|3|Visit_3|40|7|TREATMENT|2021-01-19|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-19|P1Y2M10DT2H30M|UNKNOWN|2021-01-17|AFTER|2021-03-08
e|RS|cd68296c-95d4-489e-8b64-b2404f16316c|7|MOLRESP|Molecular Response|PERCIST|[?]|Ci|DECREASED|1|STRIP|PHOTOMETRY||Y||GUARDIAN|PEDIATRIC NEUROLOGIST|U|4|Visit_4|65|6|TREATMENT|2021-02-13|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-05|P1Y2M10DT2H30M|COINCIDENT|2021-01-07|ONGOING|2021-02-19
e|RS|cd68296c-95d4-489e-8b64-b2404f16316c|8|MJPTHIND|Major Pathological Response Indicator|JACINTO CERVICAL CANCER 2007|||NON-CR/NON-PD|1|ug/m2/h|ATOMIC ABSORPTION SPECTROMETRY|Y||Y|FAMILY MEMBER|PATHOLOGIST 2|NA|4|Visit_4|65|5|FOLLOW-UP|2021-02-13|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-05|P1Y2M10DT2H30M|COINCIDENT|2021-01-10|AFTER|2021-03-04
e|RS|cd68296c-95d4-489e-8b64-b2404f16316c|9|LIVRRESP|Liver Response|JACINTO CERVICAL CANCER 2007|||COMPLETE MRD RESPONSE|1|ELISA unit/dose|MULTIPLEXED BEAD BASED IMMUNOASSAY|Y||Y|INVESTIGATOR|READER 1|N|5|Visit_5|90|1|WASHOUT|2021-03-10|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-16|P1Y2M10DT2H30M|AFTER|2021-01-27|BEFORE|2021-03-16
e|RS|cd68296c-95d4-489e-8b64-b2404f16316c|10|HEMARESP|Hematologic Response|NCCN ALL MRD 2014|[?]|FINGERTIP UNIT|NR|1|kIU|PET/MRI SCAN||||FAMILY MEMBER|FORENSIC PATHOLOGIST|Y|5|Visit_5|90|3|WASHOUT|2021-03-10|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-16|P1Y2M10DT2H30M|COINCIDENT|2021-01-02|ONGOING|2021-02-13
e|RS|fe137506-d1ce-4b08-a043-9366d86c421e|1|TMRESP|Tumor Marker Response|NCIWG CHESON CLL 1996|[?]|/wk|MORPHOLOGIC LEUKEMIA-FREE STATE|1|mL/breath|MIGET|Y|||CLINICAL RESEARCH COORDINATOR|PHYSIOTHERAPIST|N|1|Visit_1|10|4|SCREENING|2020-07-03|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-23|P1Y2M10DT2H30M|COINCIDENT|2020-09-27|ONGOING|2020-09-28
e|RS|fe137506-d1ce-4b08-a043-9366d86c421e|2|MNPTHIND|Minor Pathological Response Indicator|RECIST 1.1|||cPR|1|U/cL|CHEMILUMINESCENT MICROPARTICLE IMMUNOASSAY|||Y|ADJUDICATION COMMITTEE|RADIOLOGIST 2|Y|1|Visit_1|10|5|WASHOUT|2020-07-03|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-23|P1Y2M10DT2H30M|BEFORE|2020-07-24|ONGOING|2020-09-13
e|RS|fe137506-d1ce-4b08-a043-9366d86c421e|3|ANATRESP|Anatomic Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|||HI-E|1|Absorbance U/mL|WHOLE TRANSCRIPTOME SEQUENCING|Y||Y|SIGNIFICANT OTHER|ADJUDICATOR|U|2|Visit_2|25|1|SCREENING|2020-07-18|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-09|P1Y2M10DT2H30M|BEFORE|2020-09-18|ONGOING|2020-09-24
e|RS|fe137506-d1ce-4b08-a043-9366d86c421e|4|RDIORESP|Radiologic Response|LUGANO CLASSIFICATION|||INCREASED|1|10^7 CFU/mL|AGAR DILUTION|||Y|NON-HEALTH CARE PROFESSIONAL|RADIOLOGIST|N|2|Visit_2|25|7|WASHOUT|2020-07-18|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-09|P1Y2M10DT2H30M|COINCIDENT|2020-09-15|BEFORE|2020-09-18
e|RS|fe137506-d1ce-4b08-a043-9366d86c421e|5|SYMPTDTR|Symptomatic Deterioration|BRUGGEMANN MRD 2010|[?]|uV2|PR WITH LYMPHOCYTOSIS|1|kcal|IMMUNE REPERTOIRE DEEP SEQUENCING||||DOMESTIC PARTNER|ADJUDICATOR 3|Y|3|Visit_3|40|6|TREATMENT|2020-08-02|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-13|P1Y2M10DT2H30M|BEFORE|2020-07-21|BEFORE|2020-09-06
e|RS|fe137506-d1ce-4b08-a043-9366d86c421e|6|OVRLRESP|Overall Response|FAROOQUI SUPP CLL 2014|[?]|mm/min|pCR|1|BOLUS|FISH|Y|Y||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|Y|3|Visit_3|40|6|WASHOUT|2020-08-02|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-13|P1Y2M10DT2H30M|UNKNOWN|2020-08-02|ONGOING|2020-09-14
e|RS|fe137506-d1ce-4b08-a043-9366d86c421e|7|TMRESP|Tumor Marker Response|IWG CHESON MDS 2000|||CA125 50% RESPONSE|1|/2000 RBC|KINETIC CHROMOGENIC ASSAY|||Y|CAREGIVER|DEVELOPMENTAL PSYCHOLOGIST|N|4|Visit_4|65|6|TREATMENT|2020-08-27|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-23|P1Y2M10DT2H30M|BEFORE|2020-06-29|BEFORE|2020-07-26
e|RS|fe137506-d1ce-4b08-a043-9366d86c421e|8|ANATRESP|Anatomic Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|cy/cm|CYTOGENETIC PR|1|mL/min/mmHg|ICC||Y||STUDY SUBJECT|ONCOLOGIST 1|N|4|Visit_4|65|5|WASHOUT|2020-08-27|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-23|P1Y2M10DT2H30M|BEFORE|2020-07-07|COINCIDENT|2020-09-03
e|RS|fe137506-d1ce-4b08-a043-9366d86c421e|9|MRPHRESP|Morphologic Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|deg|PR|1|mL/cm H2O|CELL BASED BIOASSAY||||INVESTIGATOR|RADIOLOGIST|NA|5|Visit_5|90|2|TREATMENT|2020-09-21|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-17|P1Y2M10DT2H30M|BEFORE|2020-08-16|ONGOING|2020-09-14
e|RS|fe137506-d1ce-4b08-a043-9366d86c421e|10|NEWLIND|New Lesion Indicator|MRECIST BYRNE MESOTHELIOMA 2004|[?]|/HPF|PD/RELAPSE AFTER HI|1|Newton|CLINICAL EVALUATION||||SIGNIFICANT OTHER|DERMATOLOGIST|Y|5|Visit_5|90|7|TREATMENT|2020-09-21|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-17|P1Y2M10DT2H30M|UNKNOWN|2020-07-17|ONGOING|2020-08-07
e|RS|b112c524-42c8-4e9e-8699-209e739972a7|1|OVRLRESP|Overall Response|FAROOQUI SUPP CLL 2014|||iPR|1|mol/L|EIA|||Y|CLINICAL STUDY SPONSOR|PATHOLOGIST 2|N|1|Visit_1|10|6|WASHOUT|2021-01-03|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-29|P1Y2M10DT2H30M|COINCIDENT|2021-03-15|ONGOING|2021-03-21
e|RS|b112c524-42c8-4e9e-8699-209e739972a7|2|ANATRESP|Anatomic Response|JUWEID NON-HODGKINS LYMPHOMA 2005|||IMPROVED|1|g/animal/wk|FORCED OSCILLATION TECHNIQUE|||Y|ADJUDICATION COMMITTEE|RATER 2|Y|1|Visit_1|10|3|WASHOUT|2021-01-03|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-29|P1Y2M10DT2H30M|AFTER|2021-01-26|BEFORE|2021-02-02
e|RS|b112c524-42c8-4e9e-8699-209e739972a7|3|NTLWIND|Non-Target Lesion Worsening Indicator|iRECIST|||SD|1|PFU/dose|PANENDOSCOPY|||Y|HEALTH CARE PROFESSIONAL|NEUROLOGIST|Y|2|Visit_2|25|1|FOLLOW-UP|2021-01-18|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-17|P1Y2M10DT2H30M|UNKNOWN|2021-01-14|BEFORE|2021-01-24
e|RS|b112c524-42c8-4e9e-8699-209e739972a7|4|NTLWIND|Non-Target Lesion Worsening Indicator|iRECIST|[?]|BISCUIT|SMD|1|amu|DIFFUSION WEIGHTED MRI||||FRIEND|ADJUDICATOR 3|U|2|Visit_2|25|7|TREATMENT|2021-01-18|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-17|P1Y2M10DT2H30M|BEFORE|2021-01-29|ONGOING|2021-02-15
e|RS|b112c524-42c8-4e9e-8699-209e739972a7|5|BESTRESP|Best Overall Response|JACINTO CERVICAL CANCER 2007|[?]|nmol BCE/nmol|STABLE|1|HEP|SLIT LAMP||||CHILD|PATHOLOGIST 1|N|3|Visit_3|40|3|WASHOUT|2021-02-02|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-26|P1Y2M10DT2H30M|BEFORE|2021-03-11|BEFORE|2021-03-31
e|RS|b112c524-42c8-4e9e-8699-209e739972a7|6|HEMARESP|Hematologic Response|PCWG SCHER PROSTATE CANCER 2016|||INCREASED|1|mL/mmHg|MYELOPEROXIDASE STAIN|Y||Y|VENDOR|READER 2|U|3|Visit_3|40|5|TREATMENT|2021-02-02|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-26|P1Y2M10DT2H30M|BEFORE|2021-03-25|COINCIDENT|2021-03-26
e|RS|b112c524-42c8-4e9e-8699-209e739972a7|7|NTERESP|Non-Target Enhancing Response|HARTMANN GERM CELL CANCER 2002|[?]|FINGERTIP UNIT|CR-CT|1|mg/kg|TOTAL BODY RADIOGRAPHY||||INDEPENDENT ASSESSOR|READER|N|4|Visit_4|65|5|WASHOUT|2021-02-27|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-03|P1Y2M10DT2H30M|AFTER|2021-03-03|COINCIDENT|2021-03-07
e|RS|b112c524-42c8-4e9e-8699-209e739972a7|8|BONERESP|Bone Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|mg|CA125 50% RESPONSE|1|cal|CALCOFLUOR WHITE STAIN||||ADJUDICATION COMMITTEE|NEUROLOGIST 2|U|4|Visit_4|65|3|TREATMENT|2021-02-27|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-03|P1Y2M10DT2H30M|BEFORE|2021-02-27|COINCIDENT|2021-03-28
e|RS|b112c524-42c8-4e9e-8699-209e739972a7|9|NTERESP|Non-Target Enhancing Response|DOHNER AML 2010|||CR|1|h*%|IMMUNOPRECIPITATION|||Y|VENDOR|UROLOGIST|Y|5|Visit_5|90|6|WASHOUT|2021-03-24|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-17|P1Y2M10DT2H30M|UNKNOWN|2021-02-01|ONGOING|2021-03-02
e|RS|b112c524-42c8-4e9e-8699-209e739972a7|10|NEWLIND|New Lesion Indicator|RECIST 1.0|[?]|RATIO|UNFAVORABLE RESPONSE|1|Gy|PHOTOMETRY|Y|Y||CLINICAL RESEARCH ASSOCIATE|DEVELOPMENTAL PSYCHOLOGIST|U|5|Visit_5|90|2|TREATMENT|2021-03-24|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-17|P1Y2M10DT2H30M|AFTER|2021-02-19|ONGOING|2021-03-04
e|RS|e6e32df8-8b66-49a5-a626-fd385297dd6f|1|MNPTHIND|Minor Pathological Response Indicator|KUKER LYMPHOMA 2005|[?]|umol/h/mmol|PD/RELAPSE AFTER HI|1|in|RAJI CELL EIA||||ADJUDICATION COMMITTEE|ONCOLOGIST 2|N|1|Visit_1|10|2|WASHOUT|2020-09-02|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-12|P1Y2M10DT2H30M|COINCIDENT|2020-10-27|AFTER|2020-11-05
e|RS|e6e32df8-8b66-49a5-a626-fd385297dd6f|2|PATHRESP|Pathologic Response|RAJKUMAR MYELOMA 2011|[?]|mL/s/m2|sCR|1|/MBP|MICRO BROTH DILUTION|Y|||VENDOR|RADIOLOGIST 1|U|1|Visit_1|10|3|WASHOUT|2020-09-02|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-12|P1Y2M10DT2H30M|BEFORE|2020-11-16|ONGOING|2020-11-25
e|RS|e6e32df8-8b66-49a5-a626-fd385297dd6f|3|SFTSRESP|Soft Tissue Response|SCHER PROSTATE CANCER 2011|[?]|mL/sec/1.73m2|MRD RELAPSE|1|amol|SLOAN LETTER EYE CHART 100%|Y|||INTERVIEWER|NEUROLOGIST 2|U|2|Visit_2|25|4|FOLLOW-UP|2020-09-17|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-21|P1Y2M10DT2H30M|UNKNOWN|2020-09-17|AFTER|2020-10-27
e|RS|e6e32df8-8b66-49a5-a626-fd385297dd6f|4|SFTSRESP|Soft Tissue Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|||VGPR|1|umol/min|CAPILLARY ELECTROPHORESIS||Y|Y|VENDOR|MICROSCOPIST 3|Y|2|Visit_2|25|4|TREATMENT|2020-09-17|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-21|P1Y2M10DT2H30M|AFTER|2020-11-17|BEFORE|2020-11-28
e|RS|e6e32df8-8b66-49a5-a626-fd385297dd6f|5|CYTORESP|Cytogenetic Response|IWG CHESON MDS 2000|[?]|TUBE|HI-N|1|Ci/mL|COULOMETRIC TITRATION||||FRIEND|MICROSCOPIST 1|N|3|Visit_3|40|6|WASHOUT|2020-10-02|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-03|P1Y2M10DT2H30M|UNKNOWN|2020-11-08|COINCIDENT|2020-11-16
e|RS|e6e32df8-8b66-49a5-a626-fd385297dd6f|6|OVRLRESP|Overall Response|IWG CHESON AML 2003|||PDu|1|log10 CFU/mL|DYNAMIC CONTRAST ENHANCED MRI|Y||Y|CHILD|MICROSCOPIST 1|NA|3|Visit_3|40|4|FOLLOW-UP|2020-10-02|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-03|P1Y2M10DT2H30M|COINCIDENT|2020-10-08|AFTER|2020-11-16
e|RS|e6e32df8-8b66-49a5-a626-fd385297dd6f|7|STRUSTAT|Steroid Use Status|IRANO 2015|[?]|pm|NON-iCR/NON-iUPD|1|foz_us|MICRO BROTH DILUTION||Y||INTERVIEWER|OTOLARYNGOLOGIST|N|4|Visit_4|65|5|TREATMENT|2020-10-27|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-11|P1Y2M10DT2H30M|AFTER|2020-11-19|COINCIDENT|2020-11-28
e|RS|e6e32df8-8b66-49a5-a626-fd385297dd6f|8|BMIVLIND|Bone Marrow Involvement Indicator|HAMAOKA BREAST CANCER 2010|[?]|copies/mL|RELAPSED DISEASE|1|ms/mmHg|DYNAMOMETRY||||CAREGIVER|ADJUDICATOR 2|Y|4|Visit_4|65|3|WASHOUT|2020-10-27|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-11|P1Y2M10DT2H30M|COINCIDENT|2020-10-19|COINCIDENT|2020-10-25
e|RS|e6e32df8-8b66-49a5-a626-fd385297dd6f|9|NEWLPROG|New Lesion Progression|GCIG RUSTIN OVARIAN CANCER 2011|||INDETERMINATE RESPONSE|1|ngEq/L|PULMONARY ANGIOGRAPHY|Y||Y|SIGNIFICANT OTHER|PEDIATRIC NEUROLOGIST|U|5|Visit_5|90|1|TREATMENT|2020-11-21|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-13|P1Y2M10DT2H30M|UNKNOWN|2020-10-03|ONGOING|2020-11-01
e|RS|e6e32df8-8b66-49a5-a626-fd385297dd6f|10|MOLRESP|Molecular Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|||NON-QUANTIFIABLE MRD POSITIVITY|1|kHz|SANGER SEQUENCING|Y||Y|ADJUDICATOR|RATER|N|5|Visit_5|90|4|TREATMENT|2020-11-21|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-13|P1Y2M10DT2H30M|AFTER|2020-11-23|COINCIDENT|2020-11-27
e|RS|4dbfcc27-dc5a-4f04-a104-0eeb83561ab9|1|NTERESP|Non-Target Enhancing Response|CHESON LYMPHOMA 2008|[?]|OI50|PMR|1|10^4 CFU|SCANNING ELECTRON MICROSCOPY||||INVESTIGATOR|DERMATOLOGIST|NA|1|Visit_1|10|5|TREATMENT|2020-09-18|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-29|P1Y2M10DT2H30M|UNKNOWN|2020-11-27|AFTER|2020-12-13
e|RS|4dbfcc27-dc5a-4f04-a104-0eeb83561ab9|2|BMIVLIND|Bone Marrow Involvement Indicator|CHESON LYMPHOMA 2008|||NR|1|cd*s/m2|MICROPARTICLE ENZYME IMMUNOASSAY||Y|Y|PARENT|CLINICAL PATHOLOGIST|Y|1|Visit_1|10|7|TREATMENT|2020-09-18|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-29|P1Y2M10DT2H30M|BEFORE|2020-11-19|BEFORE|2020-11-25
e|RS|4dbfcc27-dc5a-4f04-a104-0eeb83561ab9|3|BMIVLIND|Bone Marrow Involvement Indicator|KEAM BREAST CANCER 2013|[?]|um|COMPLETE MRD RESPONSE|1|mkat|X-RAY||||CLINICAL STUDY SPONSOR|ONCOLOGIST 2|U|2|Visit_2|25|4|WASHOUT|2020-10-03|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-15|P1Y2M10DT2H30M|COINCIDENT|2020-10-22|ONGOING|2020-11-23
e|RS|4dbfcc27-dc5a-4f04-a104-0eeb83561ab9|4|SPLNRESP|Spleen Response|CHOLLET BREAST CANCER 2002|[?]|fmol/g|STABLE|1|10^6 organisms/mL|SLIT LAMP||||INTERVIEWER|NEUROLOGIST 2|U|2|Visit_2|25|7|WASHOUT|2020-10-03|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-15|P1Y2M10DT2H30M|BEFORE|2020-11-09|AFTER|2020-11-20
e|RS|4dbfcc27-dc5a-4f04-a104-0eeb83561ab9|5|MNPTHIND|Minor Pathological Response Indicator|DURIE MULTIPLE MYELOMA 2006|[?]|PNU/mL|PD/RELAPSE AFTER HI|1|pmol/10^10 cells|CONGO RED STAIN||Y||HEALTH CARE PROFESSIONAL|DERMATOLOGIST|Y|3|Visit_3|40|4|TREATMENT|2020-10-18|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-16|P1Y2M10DT2H30M|UNKNOWN|2020-12-07|AFTER|2020-12-13
e|RS|4dbfcc27-dc5a-4f04-a104-0eeb83561ab9|6|ANATRESP|Anatomic Response|SCHER PROSTATE CANCER 2011|[?]|IU/L|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|%|ULTRASOUND||||INTERVIEWER|RADIOLOGIST 2|NA|3|Visit_3|40|3|TREATMENT|2020-10-18|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-16|P1Y2M10DT2H30M|COINCIDENT|2020-12-16|COINCIDENT|2020-12-17
e|RS|4dbfcc27-dc5a-4f04-a104-0eeb83561ab9|7|ANATRESP|Anatomic Response|MASS|||DISEASE TRANSFORMATION|1|cmol|CONTRAST ENHANCED TRANSTHORACIC ECHOCARDIOGRAPHY||Y|Y|HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|Y|4|Visit_4|65|5|TREATMENT|2020-11-12|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-30|P1Y2M10DT2H30M|BEFORE|2020-09-14|AFTER|2020-11-01
e|RS|4dbfcc27-dc5a-4f04-a104-0eeb83561ab9|8|MOLRESP|Molecular Response|CHESON NON-HODGKINS LYMPHOMA 1999|||CA125 75% RESPONSE|1|IU/kg/h|MULTIPLEXED BEAD BASED IMMUNOASSAY||Y|Y|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST|U|4|Visit_4|65|6|SCREENING|2020-11-12|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-30|P1Y2M10DT2H30M|BEFORE|2020-10-27|AFTER|2020-11-24
e|RS|4dbfcc27-dc5a-4f04-a104-0eeb83561ab9|9|BMIVLIND|Bone Marrow Involvement Indicator|MRECIST LENCIONI LIVER CANCER 2010|[?]|kDa|UNFAVORABLE RESPONSE|1|BEAM BREAKS|SNELLEN EYE CHART|Y|||CAREGIVER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|5|Visit_5|90|4|SCREENING|2020-12-07|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-11|P1Y2M10DT2H30M|AFTER|2020-10-29|AFTER|2020-11-03
e|RS|4dbfcc27-dc5a-4f04-a104-0eeb83561ab9|10|MNPTHIND|Minor Pathological Response Indicator|PERCIST|[?]|PELLET|HI-P|1|AFU|GIEMSA STAIN||||INVESTIGATOR|MICROSCOPIST 1|NA|5|Visit_5|90|1|TREATMENT|2020-12-07|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-11|P1Y2M10DT2H30M|COINCIDENT|2020-09-22|COINCIDENT|2020-11-04
e|RS|5002de57-45df-4525-a6b7-b6cc33c22229|1|STRUSTAT|Steroid Use Status|MURPHY PROSTATE CANCER 1980|[?]|v/v|CYTOGENETIC MINIMAL RESPONSE|1|msec|RADIATION DOSIMETRY|Y|||DOMESTIC PARTNER|OPHTHALMOLOGIST|NA|1|Visit_1|10|5|TREATMENT|2021-01-12|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-06|P1Y2M10DT2H30M|AFTER|2021-04-11|ONGOING|2021-04-12
e|RS|5002de57-45df-4525-a6b7-b6cc33c22229|2|MJPTHIND|Major Pathological Response Indicator|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|sec|PMR|1|mL/g/day|DARK FIELD MICROSCOPY||||INTERVIEWER|INTERNIST|Y|1|Visit_1|10|2|WASHOUT|2021-01-12|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-06|P1Y2M10DT2H30M|AFTER|2021-03-13|AFTER|2021-03-24
e|RS|5002de57-45df-4525-a6b7-b6cc33c22229|3|HEMARESP|Hematologic Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|||NE|1|GBq|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|Y||Y|FAMILY MEMBER|ONCOLOGIST|U|2|Visit_2|25|3|SCREENING|2021-01-27|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-11|P1Y2M10DT2H30M|AFTER|2021-03-09|ONGOING|2021-03-20
e|RS|5002de57-45df-4525-a6b7-b6cc33c22229|4|BMIVLIND|Bone Marrow Involvement Indicator|MURPHY PROSTATE CANCER 1980|||CR-CT|1|mOsm/L|HIGH LEVEL AMINOGLYCOSIDE SCREEN|||Y|HEALTH CARE PROFESSIONAL|READER 1|N|2|Visit_2|25|5|TREATMENT|2021-01-27|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-11|P1Y2M10DT2H30M|COINCIDENT|2021-01-05|ONGOING|2021-01-30
e|RS|5002de57-45df-4525-a6b7-b6cc33c22229|5|MOLRESP|Molecular Response|LUGANO CLASSIFICATION|[?]|umol/L/min|iUPD|1|nmol BCE/mmol|FLUORESCENT IMMUNOASSAY||||FRIEND|ONCOLOGIST 1|NA|3|Visit_3|40|7|SCREENING|2021-02-11|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-02|P1Y2M10DT2H30M|AFTER|2021-01-24|AFTER|2021-03-28
e|RS|5002de57-45df-4525-a6b7-b6cc33c22229|6|ANATRESP|Anatomic Response|MACDONALD GLIOMA 1990|[?]|PFU|PD/RELAPSE AFTER HI|1|10^9 CFU|GC/FID||||PARENT|DEVELOPMENTAL PSYCHOLOGIST|N|3|Visit_3|40|6|SCREENING|2021-02-11|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-04-02|P1Y2M10DT2H30M|COINCIDENT|2021-03-04|BEFORE|2021-04-08
e|RS|5002de57-45df-4525-a6b7-b6cc33c22229|7|CPRFSTAT|Clinical Performance Status|PALUMBO MULTIPLE MYELOMA 2009|||DISEASE TRANSFORMATION|1|eq|BAC ACGH|||Y|FRIEND|UROLOGIST|U|4|Visit_4|65|3|SCREENING|2021-03-08|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-05|P1Y2M10DT2H30M|BEFORE|2021-03-30|AFTER|2021-04-10
e|RS|5002de57-45df-4525-a6b7-b6cc33c22229|8|HEMARESP|Hematologic Response|PCWG SCHER PROSTATE CANCER 2008|[?]|mL/100g/min|PMR|1|uV*sec|TARGETED GENOME SEQUENCING|Y|||CAREGIVER|RATER 2|NA|4|Visit_4|65|7|WASHOUT|2021-03-08|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-05|P1Y2M10DT2H30M|BEFORE|2021-01-24|AFTER|2021-01-29
e|RS|5002de57-45df-4525-a6b7-b6cc33c22229|9|NTERESP|Non-Target Enhancing Response|PERCIST|[?]|kN/cm2|MRD RELAPSE|1|RATIO|EPSILOMETER|Y|||PARENT|RADIOLOGIST 1|N|5|Visit_5|90|2|SCREENING|2021-04-02|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-09|P1Y2M10DT2H30M|UNKNOWN|2021-02-17|AFTER|2021-03-23
e|RS|5002de57-45df-4525-a6b7-b6cc33c22229|10|TMRESP|Tumor Marker Response|CHESON CLL 2012|[?]|log10 PFU/mL|nPR|1|umol/day|WRIGHT STAIN||Y||CLINICAL RESEARCH ASSOCIATE|OTOLARYNGOLOGIST|U|5|Visit_5|90|1|TREATMENT|2021-04-02|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-09|P1Y2M10DT2H30M|COINCIDENT|2021-01-07|AFTER|2021-01-28
e|RS|298f2081-bb11-4856-9e88-4be3b9b2250d|1|TRGRESP|Target Response|PCWG SCHER PROSTATE CANCER 2008|||RELAPSED DISEASE|1|mL/animal/wk|AMSLER GRID|||Y|DOMESTIC PARTNER|NEUROLOGIST 2|U|1|Visit_1|10|4|TREATMENT|2020-10-05|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-28|P1Y2M10DT2H30M|AFTER|2020-09-28|AFTER|2020-11-14
e|RS|298f2081-bb11-4856-9e88-4be3b9b2250d|2|BMIVLIND|Bone Marrow Involvement Indicator|AJCC V7|||CR|1|IU|IMMUNOCHROMATOGRAPHY|||Y|PROXY|MICROSCOPIST|U|1|Visit_1|10|4|FOLLOW-UP|2020-10-05|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-28|P1Y2M10DT2H30M|COINCIDENT|2020-09-28|BEFORE|2020-10-04
e|RS|298f2081-bb11-4856-9e88-4be3b9b2250d|3|STRUSTAT|Steroid Use Status|DOHNER AML 2010|||EQUIVOCAL|1|mL/g/h|NON-INVASIVE DIELECTRIC SENSING||Y|Y|ADJUDICATOR|PHYSIOTHERAPIST|Y|2|Visit_2|25|1|TREATMENT|2020-10-20|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-26|P1Y2M10DT2H30M|BEFORE|2020-11-30|ONGOING|2020-12-11
e|RS|298f2081-bb11-4856-9e88-4be3b9b2250d|4|MRPHRESP|Morphologic Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|10^9/dose|PDu|1|%/s|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY||Y||DOMESTIC PARTNER|ONCOLOGIST 2|U|2|Visit_2|25|4|FOLLOW-UP|2020-10-20|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-26|P1Y2M10DT2H30M|BEFORE|2020-12-02|BEFORE|2020-12-14
e|RS|298f2081-bb11-4856-9e88-4be3b9b2250d|5|MRDRESP|Minimal Residual Disease Response|PALUMBO MULTIPLE MYELOMA 2009|||CR-CT|1|/10^5|RADIAL IMMUNODIFFUSION|||Y|VENDOR|OTOLARYNGOLOGIST|Y|3|Visit_3|40|2|TREATMENT|2020-11-04|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-19|P1Y2M10DT2H30M|BEFORE|2020-10-14|ONGOING|2020-12-14
e|RS|298f2081-bb11-4856-9e88-4be3b9b2250d|6|CPRFSTAT|Clinical Performance Status|CHESON MALIGNANT LYMPHOMA 2007|[?]|%(w/v)|PD|1|cm/min|ELECTROGASTROGRAPHY||||ADJUDICATOR|ADJUDICATOR 2|U|3|Visit_3|40|5|SCREENING|2020-11-04|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-19|P1Y2M10DT2H30M|UNKNOWN|2020-10-17|BEFORE|2020-10-29
e|RS|298f2081-bb11-4856-9e88-4be3b9b2250d|7|TMRESP|Tumor Marker Response|CHESON CLL 2012|||VGPR|1|L/h|ENZYMATIC ULTRACENTRIFUGATION||Y|Y|PROXY|PATHOLOGIST 1|NA|4|Visit_4|65|6|TREATMENT|2020-11-29|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-14|P1Y2M10DT2H30M|COINCIDENT|2020-11-30|COINCIDENT|2020-12-25
e|RS|298f2081-bb11-4856-9e88-4be3b9b2250d|8|MJPTHIND|Major Pathological Response Indicator|PROTOCOL DEFINED RESPONSE CRITERIA|||PSA PROGRESSION|1|log10 IU/mL|SICKLE CELL SOLUBILITY TEST|Y|Y|Y|DOMESTIC PARTNER|OPTOMETRIST|U|4|Visit_4|65|3|TREATMENT|2020-11-29|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-14|P1Y2M10DT2H30M|UNKNOWN|2020-11-06|ONGOING|2020-12-16
e|RS|298f2081-bb11-4856-9e88-4be3b9b2250d|9|NEWLIND|New Lesion Indicator|PCWG SCHER PROSTATE CANCER 2008|[?]|GLOBULE|CYTOGENETIC PR|1|log10 TCID 50/mL|FARR ASSAY||Y||CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 1|NA|5|Visit_5|90|5|TREATMENT|2020-12-24|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-24|P1Y2M10DT2H30M|BEFORE|2020-10-16|COINCIDENT|2020-12-31
e|RS|298f2081-bb11-4856-9e88-4be3b9b2250d|10|MRPHRESP|Morphologic Response|PCWG SCHER PROSTATE CANCER 2008|[?]|mL/s|iCR|1|TRANSDUCING UNIT/mL|TURBIDIMETRY|Y|||SIBLING|READER 3|N|5|Visit_5|90|5|WASHOUT|2020-12-24|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-24|P1Y2M10DT2H30M|COINCIDENT|2020-11-02|AFTER|2020-11-07
e|RS|7c864bb9-ff9d-4e5f-ae93-6e32ad859ac2|1|MNPTHIND|Minor Pathological Response Indicator|PRINCE TCELL LYMPHOMA 2010|[?]|Sv|NON-QUANTIFIABLE MRD POSITIVITY|1|mmol/day|LC/MS/MS|Y|||SIBLING|CARDIOLOGIST|U|1|Visit_1|10|7|TREATMENT|2020-12-29|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-22|P1Y2M10DT2H30M|AFTER|2021-01-04|BEFORE|2021-01-30
e|RS|7c864bb9-ff9d-4e5f-ae93-6e32ad859ac2|2|MJPTHIND|Major Pathological Response Indicator|IWC HALLEK CLL 2008|[?]|Arbitrary U|iUPD|1|lm|PATHOLOGICAL EVALUATION||||CLINICAL RESEARCH ASSOCIATE|RATER 1|Y|1|Visit_1|10|7|FOLLOW-UP|2020-12-29|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-22|P1Y2M10DT2H30M|UNKNOWN|2021-01-19|COINCIDENT|2021-02-06
e|RS|7c864bb9-ff9d-4e5f-ae93-6e32ad859ac2|3|TMRESP|Tumor Marker Response|WHO BREAST CANCER 2006|||STABLE|1|mL/kg|DYNAMIC LIGHT SCATTERING|Y||Y|CAREGIVER|CLINICAL PATHOLOGIST|N|2|Visit_2|25|5|WASHOUT|2021-01-13|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-06|P1Y2M10DT2H30M|AFTER|2021-01-15|AFTER|2021-01-28
e|RS|7c864bb9-ff9d-4e5f-ae93-6e32ad859ac2|4|MNPTHIND|Minor Pathological Response Indicator|SCHER PROSTATE CANCER 2011|||NED|1|mg/mL/min|PARTICLE-ENHANCED NEPHELOMETRIC IMMUNOASSAY|||Y|CHILD|ONCOLOGIST|N|2|Visit_2|25|6|TREATMENT|2021-01-13|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-06|P1Y2M10DT2H30M|COINCIDENT|2021-02-27|AFTER|2021-03-23
e|RS|7c864bb9-ff9d-4e5f-ae93-6e32ad859ac2|5|RDIORESP|Radiologic Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|DISK|PDu|1|DIP|LIGHT SCATTERING SPECTROSCOPY||||SPOUSE|READER 3|Y|3|Visit_3|40|7|TREATMENT|2021-01-28|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-11|P1Y2M10DT2H30M|BEFORE|2021-02-15|AFTER|2021-02-23
e|RS|7c864bb9-ff9d-4e5f-ae93-6e32ad859ac2|6|NEWLWIND|New Lesion Worsening Indicator|EASL BRUIX LIVER CANCER 2001|[?]|aMFI|cCR|1|nmol/L/min|AMSLER GRID|Y|||FAMILY MEMBER|READER|Y|3|Visit_3|40|2|TREATMENT|2021-01-28|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-11|P1Y2M10DT2H30M|UNKNOWN|2020-12-29|BEFORE|2021-01-17
e|RS|7c864bb9-ff9d-4e5f-ae93-6e32ad859ac2|7|PATHRESP|Pathologic Response|iRECIST|[?]|cmol|MRD RELAPSE|1|/sec|RADIATION DOSIMETRY|Y|||FAMILY MEMBER|ONCOLOGIST|Y|4|Visit_4|65|2|TREATMENT|2021-02-22|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-02|P1Y2M10DT2H30M|BEFORE|2021-03-12|ONGOING|2021-03-16
e|RS|7c864bb9-ff9d-4e5f-ae93-6e32ad859ac2|8|STRUSTAT|Steroid Use Status|PALUMBO MULTIPLE MYELOMA 2009|[?]|IU/L|OPTIMAL MORPHOLOGIC RESPONSE|1|Bq/g|THERMAL IONIZATION MASS SPECTROMETRY||||SIBLING|OTOLARYNGOLOGIST|U|4|Visit_4|65|6|TREATMENT|2021-02-22|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-02|P1Y2M10DT2H30M|UNKNOWN|2021-01-16|ONGOING|2021-01-17
e|RS|7c864bb9-ff9d-4e5f-ae93-6e32ad859ac2|9|TMRESP|Tumor Marker Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|||WORSENED|1|dram|WEBER GREEN STAIN|||Y|SIBLING|OPHTHALMOLOGIST|Y|5|Visit_5|90|4|SCREENING|2021-03-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-03|P1Y2M10DT2H30M|AFTER|2021-02-02|AFTER|2021-03-09
e|RS|7c864bb9-ff9d-4e5f-ae93-6e32ad859ac2|10|METBRESP|Metabolic Response|HAMAOKA BREAST CANCER 2010|[?]|Ci/L|CYTOGENETIC MINOR RESPONSE|1|VIAL|ELISA||||DOMESTIC PARTNER|READER 3|Y|5|Visit_5|90|6|TREATMENT|2021-03-19|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-03|P1Y2M10DT2H30M|COINCIDENT|2021-01-13|BEFORE|2021-01-23
e|RS|a9e7f609-df5e-4a99-bf27-2a90cb7deebb|1|LIVRRESP|Liver Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|L/s/kPa|SMD|1|BAG|MANUAL COUNT||Y||FRIEND|ONCOLOGIST 2|Y|1|Visit_1|10|6|FOLLOW-UP|2020-05-12|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-13|P1Y2M10DT2H30M|UNKNOWN|2020-07-07|AFTER|2020-08-01
e|RS|a9e7f609-df5e-4a99-bf27-2a90cb7deebb|2|CLINRESP|Clinical Response|SCHWARZ CERVICAL CANCER 2009|[?]|%/s|CMR|1|Bq/kg|CHROMOGENIC ASSAY||||FAMILY MEMBER|OTOLARYNGOLOGIST|U|1|Visit_1|10|6|FOLLOW-UP|2020-05-12|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-13|P1Y2M10DT2H30M|AFTER|2020-07-24|ONGOING|2020-08-05
e|RS|a9e7f609-df5e-4a99-bf27-2a90cb7deebb|3|NTNERESP|Non-Target Non-Enhancing Response|PCWG SCHER PROSTATE CANCER 2008|||MRD PERSISTENCE|1|cg|AGAR PROPORTION|||Y|STUDY SUBJECT|ADJUDICATOR 2|U|2|Visit_2|25|4|TREATMENT|2020-05-27|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-28|P1Y2M10DT2H30M|AFTER|2020-07-05|COINCIDENT|2020-07-31
e|RS|a9e7f609-df5e-4a99-bf27-2a90cb7deebb|4|HEMARESP|Hematologic Response|RECIST 1.0|[?]|ug/L/h|PSEUDOPROGRESSION|1|/VF|PELLI-ROBSON EYE CHART||||CAREGIVER|RATER 2|N|2|Visit_2|25|7|SCREENING|2020-05-27|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-28|P1Y2M10DT2H30M|BEFORE|2020-06-22|BEFORE|2020-07-10
e|RS|a9e7f609-df5e-4a99-bf27-2a90cb7deebb|5|BONERESP|Bone Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|DIP|MOLECULAR MAJOR RESPONSE|1|lx|IMPEDANCE CONDUCTIVITY||||INVESTIGATOR|NEUROLOGIST 2|NA|3|Visit_3|40|1|TREATMENT|2020-06-11|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-29|P1Y2M10DT2H30M|AFTER|2020-06-05|COINCIDENT|2020-06-11
e|RS|a9e7f609-df5e-4a99-bf27-2a90cb7deebb|6|NTERESP|Non-Target Enhancing Response|LEE LUNG CANCER 2011|[?]|pmol/L/h|UNEQUIVOCAL|1|IU/kg|CLINICAL EVALUATION||||CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 1|NA|3|Visit_3|40|3|TREATMENT|2020-06-11|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-29|P1Y2M10DT2H30M|AFTER|2020-07-26|COINCIDENT|2020-08-04
e|RS|a9e7f609-df5e-4a99-bf27-2a90cb7deebb|7|MNPTHIND|Minor Pathological Response Indicator|PROTOCOL DEFINED RESPONSE CRITERIA|||sCR|1|ug/kg/h|SCANNING ELECTRON MICROSCOPY||Y|Y|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR 3|NA|4|Visit_4|65|3|WASHOUT|2020-07-06|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-08|P1Y2M10DT2H30M|COINCIDENT|2020-06-19|ONGOING|2020-06-20
e|RS|a9e7f609-df5e-4a99-bf27-2a90cb7deebb|8|NEWLWIND|New Lesion Worsening Indicator|KUMAR IMWG 2016|[?]|PUFF|DECREASED|1|pg|KINETIC CHROMOGENIC ASSAY||||CLINICAL STUDY SPONSOR|OPHTHALMOLOGIST|N|4|Visit_4|65|1|TREATMENT|2020-07-06|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-08|P1Y2M10DT2H30M|AFTER|2020-06-18|BEFORE|2020-08-08
e|RS|a9e7f609-df5e-4a99-bf27-2a90cb7deebb|9|RDIORESP|Radiologic Response|MACDONALD GLIOMA 1990|[?]|kg/cm|STABLE|1|10^9 organisms/g|INDIA INK STAIN||Y||FRIEND|RADIOLOGIST|U|5|Visit_5|90|6|WASHOUT|2020-07-31|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-17|P1Y2M10DT2H30M|UNKNOWN|2020-05-19|AFTER|2020-06-24
e|RS|a9e7f609-df5e-4a99-bf27-2a90cb7deebb|10|STRUSTAT|Steroid Use Status|KEAM BREAST CANCER 2013|[?]|10^4/L|NED|1|ug/L/h|NEPHELOMETRY||||CAREGIVER|PATHOLOGIST|N|5|Visit_5|90|7|FOLLOW-UP|2020-07-31|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-17|P1Y2M10DT2H30M|BEFORE|2020-07-11|BEFORE|2020-07-16
e|RS|18c21176-db5e-4650-a1af-beb2042c31d8|1|RDIORESP|Radiologic Response|DURIE MULTIPLE MYELOMA 2006|[?]|in|CMR|1|g/kg/day|SPECTROPHOTOMETRY||||PARENT|READER 1|Y|1|Visit_1|10|1|WASHOUT|2020-08-30|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-27|P1Y2M10DT2H30M|UNKNOWN|2020-11-26|ONGOING|2020-11-27
e|RS|18c21176-db5e-4650-a1af-beb2042c31d8|2|NEWLWIND|New Lesion Worsening Indicator|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|mg/kg/min|SD|1|IU/kg/h|TARGETED TRANSCRIPTOME SEQUENCING||||SPOUSE|RATER 1|N|1|Visit_1|10|7|TREATMENT|2020-08-30|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-27|P1Y2M10DT2H30M|COINCIDENT|2020-10-18|ONGOING|2020-11-14
e|RS|18c21176-db5e-4650-a1af-beb2042c31d8|3|SPLNRESP|Spleen Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|[?]|10^12 IU/L|MOLECULAR MAJOR RESPONSE|1|10^3 copies/mL|JAFFE REACTION||||PARENT|PATHOLOGIST|NA|2|Visit_2|25|4|TREATMENT|2020-09-14|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-07|P1Y2M10DT2H30M|COINCIDENT|2020-09-30|BEFORE|2020-10-10
e|RS|18c21176-db5e-4650-a1af-beb2042c31d8|4|NTLWIND|Non-Target Lesion Worsening Indicator|KUMAR IMWG 2016|[?]|mL/min/mmHg|pCR|1|U/kg|AUTOREFRACTION||||ADJUDICATOR|MICROSCOPIST 2|Y|2|Visit_2|25|1|SCREENING|2020-09-14|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-07|P1Y2M10DT2H30M|UNKNOWN|2020-08-26|AFTER|2020-10-26
e|RS|18c21176-db5e-4650-a1af-beb2042c31d8|5|MRDRESP|Minimal Residual Disease Response|WHO BREAST CANCER 2006|[?]|Bq/uL|CRi|1|lx|KINETIC MICROPARTICLE IMMUNOASSAY|Y|Y||STUDY SUBJECT|RATER 2|N|3|Visit_3|40|2|TREATMENT|2020-09-29|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-01|P1Y2M10DT2H30M|AFTER|2020-09-05|COINCIDENT|2020-11-27
e|RS|18c21176-db5e-4650-a1af-beb2042c31d8|6|NTLWIND|Non-Target Lesion Worsening Indicator|SCHWARZ CERVICAL CANCER 2009|[?]|mkat|SMD|1|mg2/dL2|MYELOPEROXIDASE STAIN||||INVESTIGATOR|ADJUDICATOR 1|N|3|Visit_3|40|7|WASHOUT|2020-09-29|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-01|P1Y2M10DT2H30M|BEFORE|2020-10-02|AFTER|2020-10-17
e|RS|18c21176-db5e-4650-a1af-beb2042c31d8|7|SPLNRESP|Spleen Response|HARTMAN PANCREATIC CANCER 2012|||MR|1|EP U|COLORIMETRY|||Y|CLINICAL STUDY SPONSOR|RADIOLOGIST 2|U|4|Visit_4|65|7|WASHOUT|2020-10-24|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-08|P1Y2M10DT2H30M|AFTER|2020-09-28|AFTER|2020-11-03
e|RS|18c21176-db5e-4650-a1af-beb2042c31d8|8|MJPTHIND|Major Pathological Response Indicator|MONTSERRAT CLL 1989|[?]|mL/g/min|NON-iCR/NON-iUPD|1|CAPLET|IN VITRO GENE EXPRESSION ASSAY||||DOMESTIC PARTNER|ONCOLOGIST 2|Y|4|Visit_4|65|7|WASHOUT|2020-10-24|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-08|P1Y2M10DT2H30M|UNKNOWN|2020-11-17|COINCIDENT|2020-11-20
e|RS|18c21176-db5e-4650-a1af-beb2042c31d8|9|BESTRESP|Best Overall Response|HARTMANN GERM CELL CANCER 2002|[?]|/500 WBC|CA125 75% RESPONSE|1|g/mol|TRANSESOPHAGEAL ECHOCARDIOGRAPHY||||CLINICAL RESEARCH COORDINATOR|PEDIATRIC NEUROLOGIST|U|5|Visit_5|90|2|TREATMENT|2020-11-18|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-17|P1Y2M10DT2H30M|UNKNOWN|2020-11-23|COINCIDENT|2020-11-27
e|RS|18c21176-db5e-4650-a1af-beb2042c31d8|10|PATHRESP|Pathologic Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|Anson U|NR|1|Tbsp|ECHOCARDIOGRAPHY||||VENDOR|DERMATOLOGIST|N|5|Visit_5|90|6|SCREENING|2020-11-18|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-17|P1Y2M10DT2H30M|COINCIDENT|2020-11-24|ONGOING|2020-11-26
e|RS|7808abd1-7d6f-4090-aa08-916a804c95f5|1|CPRFSTAT|Clinical Performance Status|JUWEID NON-HODGKINS LYMPHOMA 2005|||IMMUNOPHENOTYPIC CR|1|mm|TELLER ACUITY CARDS|Y||Y|SIBLING|ADJUDICATOR|Y|1|Visit_1|10|5|FOLLOW-UP|2020-06-20|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-21|P1Y2M10DT2H30M|AFTER|2020-07-31|BEFORE|2020-08-19
e|RS|7808abd1-7d6f-4090-aa08-916a804c95f5|2|NTNERESP|Non-Target Non-Enhancing Response|PETIT BREAST CANCER 2001|[?]|Osm|CYTOGENETIC CR|1|WEEKS|HPLC/IEX||||INVESTIGATOR|RADIOLOGIST 1|Y|1|Visit_1|10|6|TREATMENT|2020-06-20|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-21|P1Y2M10DT2H30M|UNKNOWN|2020-08-26|COINCIDENT|2020-08-28
e|RS|7808abd1-7d6f-4090-aa08-916a804c95f5|3|PATHRESP|Pathologic Response|LUGANO CLASSIFICATION|[?]|CCID 50/dose|CHR|1|km/h|IRON HEMATOXYLIN STAIN|Y|||FRIEND|PATHOLOGIST|N|2|Visit_2|25|2|TREATMENT|2020-07-05|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-05|P1Y2M10DT2H30M|COINCIDENT|2020-06-29|COINCIDENT|2020-08-27
e|RS|7808abd1-7d6f-4090-aa08-916a804c95f5|4|NTNERESP|Non-Target Non-Enhancing Response|HARTMANN GERM CELL CANCER 2002|[?]|/200 HPFs|cCR|1|ug/m2/h|PERFUSION MRI|Y|Y||VENDOR|DERMATOLOGIST|Y|2|Visit_2|25|4|TREATMENT|2020-07-05|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-05|P1Y2M10DT2H30M|BEFORE|2020-08-26|BEFORE|2020-08-31
e|RS|7808abd1-7d6f-4090-aa08-916a804c95f5|5|TRGRESP|Target Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|Pa|CYTOGENETIC NO RESPONSE|1|mg/animal|JAFFE REACTION||Y||ADJUDICATOR|ADJUDICATOR 2|U|3|Visit_3|40|6|TREATMENT|2020-07-20|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-10|P1Y2M10DT2H30M|COINCIDENT|2020-08-19|AFTER|2020-09-06
e|RS|7808abd1-7d6f-4090-aa08-916a804c95f5|6|CYTORESP|Cytogenetic Response|CHESON LYMPHOMA 2008|[?]|ug/kg|HI-N|1|CCID 50/dose|SPECT/CT SCAN|Y|||CAREGIVER|RATER 1|N|3|Visit_3|40|2|TREATMENT|2020-07-20|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-10|P1Y2M10DT2H30M|COINCIDENT|2020-06-19|COINCIDENT|2020-07-27
e|RS|7808abd1-7d6f-4090-aa08-916a804c95f5|7|NEWLWIND|New Lesion Worsening Indicator|JUWEID NON-HODGKINS LYMPHOMA 2005|||INCREASED|1|10^4/hpf|FLOCCULATION, CHARCOAL ENHANCED|Y||Y|CAREGIVER|INTERNIST|N|4|Visit_4|65|3|WASHOUT|2020-08-14|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-15|P1Y2M10DT2H30M|BEFORE|2020-08-12|ONGOING|2020-09-11
e|RS|7808abd1-7d6f-4090-aa08-916a804c95f5|8|SFTSRESP|Soft Tissue Response|CHESON CLL 2006|[?]|10^6 organisms|MRD NEGATIVITY|1|BAG|SPIRAL CT SCAN WITHOUT CONTRAST|Y|||HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|N|4|Visit_4|65|6|SCREENING|2020-08-14|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-15|P1Y2M10DT2H30M|AFTER|2020-07-15|ONGOING|2020-07-21
e|RS|7808abd1-7d6f-4090-aa08-916a804c95f5|9|OVRLRESP|Overall Response|IWG CHESON MDS 2000|||SMD|1|mg/kg/h|MULTI-SLICE SPIRAL CT|||Y|CHILD|HEMATOLOGIST|U|5|Visit_5|90|1|SCREENING|2020-09-08|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-20|P1Y2M10DT2H30M|UNKNOWN|2020-07-10|BEFORE|2020-08-15
e|RS|7808abd1-7d6f-4090-aa08-916a804c95f5|10|BONERESP|Bone Response|RAJKUMAR MYELOMA 2011|[?]|/MBP|MRD NEGATIVITY|1|mg/kg|COULOMETRIC TITRATION||||FRIEND|MICROSCOPIST 1|U|5|Visit_5|90|1|FOLLOW-UP|2020-09-08|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-20|P1Y2M10DT2H30M|AFTER|2020-07-07|ONGOING|2020-08-24
e|RS|57553b78-e761-4577-aae2-5c693a2dc303|1|NTERESP|Non-Target Enhancing Response|DOHNER AML 2010|[?]|mV|UNEQUIVOCAL|1|breaths/30s|AGAR PROPORTION||||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 3|N|1|Visit_1|10|5|FOLLOW-UP|2021-01-01|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-09|P1Y2M10DT2H30M|AFTER|2021-02-27|BEFORE|2021-03-12
e|RS|57553b78-e761-4577-aae2-5c693a2dc303|2|METSIND|Metastatic Indicator|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|U/cL|MOLECULAR CR|1|oz eq|PALM METHOD||||CHILD|CLINICAL PATHOLOGIST|Y|1|Visit_1|10|3|TREATMENT|2021-01-01|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-09|P1Y2M10DT2H30M|UNKNOWN|2021-03-18|BEFORE|2021-03-29
e|RS|57553b78-e761-4577-aae2-5c693a2dc303|3|PATHRESP|Pathologic Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|dpm/mg|COMPLETE MRD RESPONSE|1|Ci/kg|CONTRAST ENHANCED CT SCAN||||SIBLING|READER 3|U|2|Visit_2|25|5|TREATMENT|2021-01-16|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-13|P1Y2M10DT2H30M|UNKNOWN|2021-01-18|BEFORE|2021-03-24
e|RS|57553b78-e761-4577-aae2-5c693a2dc303|4|NTERESP|Non-Target Enhancing Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|mL/kg/min|MORPHOLOGIC CR|1|DDU|ORCHIDOMETERY||||PROXY|ADJUDICATOR 3|NA|2|Visit_2|25|6|TREATMENT|2021-01-16|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-13|P1Y2M10DT2H30M|COINCIDENT|2021-03-13|ONGOING|2021-03-20
e|RS|57553b78-e761-4577-aae2-5c693a2dc303|5|SFTSRESP|Soft Tissue Response|PETIT BREAST CANCER 2001|[?]|U.CARR|PSEUDORESPONSE|1|/2500 WBC|CONTRAST ENHANCED MRI||||VENDOR|MICROSCOPIST 1|NA|3|Visit_3|40|2|SCREENING|2021-01-31|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-21|P1Y2M10DT2H30M|COINCIDENT|2021-01-19|COINCIDENT|2021-03-07
e|RS|57553b78-e761-4577-aae2-5c693a2dc303|6|BESTRESP|Best Overall Response|KEAM BREAST CANCER 2013|[?]|uV2|MORPHOLOGIC CRi|1|Gy|CARDIAC THERMODILUTION||||HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|NA|3|Visit_3|40|6|TREATMENT|2021-01-31|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-21|P1Y2M10DT2H30M|AFTER|2021-02-10|ONGOING|2021-02-16
e|RS|57553b78-e761-4577-aae2-5c693a2dc303|7|TRGRESP|Target Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|ug/m2|iPR|1|uL/mL|IMMUNE REPERTOIRE DEEP SEQUENCING|Y|||INVESTIGATOR|PATHOLOGIST|Y|4|Visit_4|65|5|FOLLOW-UP|2021-02-25|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-18|P1Y2M10DT2H30M|COINCIDENT|2021-01-02|ONGOING|2021-02-17
e|RS|57553b78-e761-4577-aae2-5c693a2dc303|8|MRPHRESP|Morphologic Response|BURCOMBE BREAST CANCER 2005|[?]|SPRAY|NE|1|log10 CFU/g|IN VITRO GENE EXPRESSION ASSAY||||SIGNIFICANT OTHER|READER|NA|4|Visit_4|65|4|WASHOUT|2021-02-25|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-18|P1Y2M10DT2H30M|AFTER|2021-03-16|COINCIDENT|2021-03-26
e|RS|57553b78-e761-4577-aae2-5c693a2dc303|9|HEMARESP|Hematologic Response|MASS|||COMPLETE MRD RESPONSE|1|umol/mg/min|AURAMINE STAIN|||Y|CHILD|ONCOLOGIST 2|N|5|Visit_5|90|5|TREATMENT|2021-03-22|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-04|P1Y2M10DT2H30M|UNKNOWN|2021-03-15|BEFORE|2021-03-22
e|RS|57553b78-e761-4577-aae2-5c693a2dc303|10|MOLRESP|Molecular Response|RECICL|||PSEUDORESPONSE|1|mm3/mm2/year|INFRARED SPECTROMETRY||Y|Y|STUDY SUBJECT|OPTOMETRIST|Y|5|Visit_5|90|5|TREATMENT|2021-03-22|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-04|P1Y2M10DT2H30M|UNKNOWN|2021-03-07|COINCIDENT|2021-03-24
e|RS|40883550-4627-4f92-974a-7eeb5bde74c5|1|NEWLIND|New Lesion Indicator|FAROOQUI SUPP CLL 2014|[?]|mL/sec/1.73m2|MINOR PATHOLOGIC RESPONSE|1|APS U|ENZYMATIC SPECTROPHOTOMETRY||Y||INVESTIGATOR|ONCOLOGIST|U|1|Visit_1|10|3|WASHOUT|2020-10-13|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-04|P1Y2M10DT2H30M|AFTER|2020-10-15|ONGOING|2020-12-02
e|RS|40883550-4627-4f92-974a-7eeb5bde74c5|2|TRGRESP|Target Response|CHESON CLL 2012|[?]|/LPF|CYTOGENETIC CR|1|Enzyme U/m2|SPECULAR MICROSCOPY||||INDEPENDENT ASSESSOR|NEUROLOGIST 2|U|1|Visit_1|10|7|SCREENING|2020-10-13|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-04|P1Y2M10DT2H30M|COINCIDENT|2020-10-27|COINCIDENT|2020-11-17
e|RS|40883550-4627-4f92-974a-7eeb5bde74c5|3|MRDRESP|Minimal Residual Disease Response|CHESON CLL 2006|||NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|10^12 IU/L|OPTICAL DENSITY MEASUREMENT|Y||Y|HEALTH CARE PROFESSIONAL|MICROSCOPIST|Y|2|Visit_2|25|6|WASHOUT|2020-10-28|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-09|P1Y2M10DT2H30M|UNKNOWN|2020-11-28|ONGOING|2020-12-15
e|RS|40883550-4627-4f92-974a-7eeb5bde74c5|4|NTLWIND|Non-Target Lesion Worsening Indicator|MONTSERRAT CLL 1989|||PMD|1|deg|SANGER SEQUENCING|Y||Y|INDEPENDENT ASSESSOR|OTOLARYNGOLOGIST|NA|2|Visit_2|25|7|TREATMENT|2020-10-28|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-09|P1Y2M10DT2H30M|AFTER|2020-12-19|ONGOING|2020-12-25
e|RS|40883550-4627-4f92-974a-7eeb5bde74c5|5|NTERESP|Non-Target Enhancing Response|RECIST 1.0|[?]|Gauss|RELAPSED DISEASE FROM CR OR PR|1|pmol/g|TARGETED TRANSCRIPTOME SEQUENCING|Y|||PARENT|INTERNIST|NA|3|Visit_3|40|5|WASHOUT|2020-11-12|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-23|P1Y2M10DT2H30M|COINCIDENT|2020-11-02|ONGOING|2020-12-21
e|RS|40883550-4627-4f92-974a-7eeb5bde74c5|6|MJPTHIND|Major Pathological Response Indicator|CHESON MALIGNANT LYMPHOMA 2007|[?]|Bq/mL|OPTIMAL MORPHOLOGIC RESPONSE|1|mL/animal|PH METER MEASUREMENT METHOD||||ADJUDICATOR|PATHOLOGIST 2|NA|3|Visit_3|40|7|SCREENING|2020-11-12|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-23|P1Y2M10DT2H30M|UNKNOWN|2020-11-23|AFTER|2020-12-30
e|RS|40883550-4627-4f92-974a-7eeb5bde74c5|7|HEMARESP|Hematologic Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|tsp|MORPHOLOGIC CRi|1|psec|WHOLE GENOME SEQUENCING|Y|||GUARDIAN|RATER 1|NA|4|Visit_4|65|7|SCREENING|2020-12-07|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-17|P1Y2M10DT2H30M|BEFORE|2020-10-15|COINCIDENT|2021-01-08
e|RS|40883550-4627-4f92-974a-7eeb5bde74c5|8|HEMARESP|Hematologic Response|SACT|[?]|IU|SD|1|kIU|CONFOCAL MICROSCOPY||||VENDOR|OTOLARYNGOLOGIST|N|4|Visit_4|65|3|TREATMENT|2020-12-07|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-17|P1Y2M10DT2H30M|UNKNOWN|2020-11-18|BEFORE|2020-11-25
e|RS|40883550-4627-4f92-974a-7eeb5bde74c5|9|DRCRIND|Disease Recurrence Indicator|GUILHOT CML 2007|[?]|mPa|MRD RELAPSE|1|mL/cm|BALLPOINT PEN TECHNIQUE||||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST|N|5|Visit_5|90|4|TREATMENT|2021-01-01|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-24|P1Y2M10DT2H30M|BEFORE|2020-12-23|ONGOING|2020-12-30
e|RS|40883550-4627-4f92-974a-7eeb5bde74c5|10|HEMARESP|Hematologic Response|iRECIST|||SD|1|cm|MICROPARTICLE ENZYME IMMUNOASSAY|||Y|ADJUDICATION COMMITTEE|ENDOCRINOLOGIST|N|5|Visit_5|90|5|FOLLOW-UP|2021-01-01|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-24|P1Y2M10DT2H30M|UNKNOWN|2021-01-05|ONGOING|2021-01-09
e|RS|4199b549-d021-4bfd-97e6-95630d407183|1|SPLNRESP|Spleen Response|IRANO 2015|[?]|CFU/g|pCR|1|ug/m2/day|DIRECT SEQUENCING||||ADJUDICATION COMMITTEE|READER 3|U|1|Visit_1|10|5|TREATMENT|2020-12-02|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-27|P1Y2M10DT2H30M|AFTER|2021-02-01|ONGOING|2021-02-15
e|RS|4199b549-d021-4bfd-97e6-95630d407183|2|CPRFSTAT|Clinical Performance Status|LEE LUNG CANCER 2011|[?]|L/min/m2|CYTOGENETIC NO RESPONSE|1|/500 WBC|SISH||||HEALTH CARE PROFESSIONAL|PATHOLOGIST 2|N|1|Visit_1|10|2|TREATMENT|2020-12-02|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-27|P1Y2M10DT2H30M|BEFORE|2021-02-21|COINCIDENT|2021-02-27
e|RS|4199b549-d021-4bfd-97e6-95630d407183|3|BMIVLIND|Bone Marrow Involvement Indicator|MRANO VAN DEN BENT GLIOMA 2011|[?]|Pa|MORPHOLOGIC CRi|1|10^10/L|FLUOROSCOPY||Y||INDEPENDENT ASSESSOR|PATHOLOGIST|NA|2|Visit_2|25|2|TREATMENT|2020-12-17|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-16|P1Y2M10DT2H30M|BEFORE|2021-01-17|COINCIDENT|2021-02-27
e|RS|4199b549-d021-4bfd-97e6-95630d407183|4|MNPTHIND|Minor Pathological Response Indicator|MRECIST BYRNE MESOTHELIOMA 2004|[?]|mg/cm2|iPR|1|log10 TCID 50/dose|NON-INVASIVE DIELECTRIC SENSING||Y||STUDY SUBJECT|FORENSIC PATHOLOGIST|U|2|Visit_2|25|6|TREATMENT|2020-12-17|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-16|P1Y2M10DT2H30M|COINCIDENT|2020-12-31|AFTER|2021-01-07
e|RS|4199b549-d021-4bfd-97e6-95630d407183|5|TRGRESP|Target Response|MURPHY PROSTATE CANCER 1980|||CA125 50% RESPONSE|1|pL|POLYSOMNOGRAPHY|||Y|INDEPENDENT ASSESSOR|HEMATOLOGIST|Y|3|Visit_3|40|6|WASHOUT|2021-01-01|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-20|P1Y2M10DT2H30M|AFTER|2021-01-31|ONGOING|2021-02-02
e|RS|4199b549-d021-4bfd-97e6-95630d407183|6|DRCRIND|Disease Recurrence Indicator|JUWEID NON-HODGKINS LYMPHOMA 2005|||nPR|1|log10 CCID 50/dose|CLAUSS METHOD|||Y|HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|NA|3|Visit_3|40|1|FOLLOW-UP|2021-01-01|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-20|P1Y2M10DT2H30M|AFTER|2021-02-09|ONGOING|2021-02-10
e|RS|4199b549-d021-4bfd-97e6-95630d407183|7|SFTSRESP|Soft Tissue Response|JUWEID NON-HODGKINS LYMPHOMA 2005|||PARTIAL MORPHOLOGIC RESPONSE|1|AMPULE|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY|||Y|CAREGIVER|ADJUDICATOR 1|N|4|Visit_4|65|5|TREATMENT|2021-01-26|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-30|P1Y2M10DT2H30M|COINCIDENT|2021-01-24|ONGOING|2021-02-14
e|RS|4199b549-d021-4bfd-97e6-95630d407183|8|PATHRESP|Pathologic Response|RECIST 1.1|[?]|log10 IU/mL|CYTOGENETIC MINOR RESPONSE|1|nL|URANYL ACETATE STAIN||Y||CLINICAL RESEARCH COORDINATOR|PATHOLOGIST 2|N|4|Visit_4|65|6|TREATMENT|2021-01-26|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-30|P1Y2M10DT2H30M|UNKNOWN|2020-12-24|AFTER|2021-02-17
e|RS|4199b549-d021-4bfd-97e6-95630d407183|9|CPRFSTAT|Clinical Performance Status|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|pmol/dL|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|L/s|RAJI CELL EIA||Y||STUDY SUBJECT|MICROSCOPIST|Y|5|Visit_5|90|3|SCREENING|2021-02-20|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-29|P1Y2M10DT2H30M|AFTER|2021-01-25|ONGOING|2021-02-14
e|RS|4199b549-d021-4bfd-97e6-95630d407183|10|HEMARESP|Hematologic Response|CHESON CLL 2006|||MRD RELAPSE|1|g/m2|MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY|||Y|NON-HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|NA|5|Visit_5|90|2|TREATMENT|2021-02-20|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-29|P1Y2M10DT2H30M|BEFORE|2021-01-12|AFTER|2021-01-23
e|RS|6366647f-62fa-48dc-9d77-1677fce62fc7|1|MRDIND|Minimal Residual Disease Indicator|RANO|[?]|10^6 copies/mL|PD|1|mol/day|CONTRAST ENHANCED PET/CT SCAN||||PROXY|RATER 2|NA|1|Visit_1|10|4|TREATMENT|2020-07-14|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-17|P1Y2M10DT2H30M|AFTER|2020-08-24|BEFORE|2020-09-29
e|RS|6366647f-62fa-48dc-9d77-1677fce62fc7|2|SYMPTDTR|Symptomatic Deterioration|RECIST 1.1|[?]|breaths/30s|NED|1|Ci/mg|FLOW CYTOMETRY|Y|||ADJUDICATOR|ENDOCRINOLOGIST|NA|1|Visit_1|10|1|TREATMENT|2020-07-14|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-17|P1Y2M10DT2H30M|COINCIDENT|2020-09-06|BEFORE|2020-09-18
e|RS|6366647f-62fa-48dc-9d77-1677fce62fc7|3|NTRGRESP|Non-target Response|MRECIST LENCIONI LIVER CANCER 2010|||EQUIVOCAL|1|HOMEOPATHIC DILUTION|LAPAROSCOPY|Y||Y|PARENT|RADIOLOGIST|NA|2|Visit_2|25|3|FOLLOW-UP|2020-07-29|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-18|P1Y2M10DT2H30M|AFTER|2020-07-13|COINCIDENT|2020-09-20
e|RS|6366647f-62fa-48dc-9d77-1677fce62fc7|4|MRDRESP|Minimal Residual Disease Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|titer|MRD RELAPSE|1|U/m2/min|DIFFUSION TENSOR MRI|Y|Y||INTERVIEWER|MICROSCOPIST 3|N|2|Visit_2|25|1|SCREENING|2020-07-29|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-18|P1Y2M10DT2H30M|UNKNOWN|2020-09-26|ONGOING|2020-10-01
e|RS|6366647f-62fa-48dc-9d77-1677fce62fc7|5|CLINRESP|Clinical Response|SCHWARZ CERVICAL CANCER 2009|[?]|mmHg/sec|TREATMENT FAILURE|1|/100 WBC|ELECTROGASTROGRAPHY|Y|||VENDOR|RATER|Y|3|Visit_3|40|5|TREATMENT|2020-08-13|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-10|P1Y2M10DT2H30M|UNKNOWN|2020-09-26|ONGOING|2020-10-03
e|RS|6366647f-62fa-48dc-9d77-1677fce62fc7|6|MRDRESP|Minimal Residual Disease Response|AJCC V8|[?]|%|VGPR|1|g/animal/wk|VENTILATION PERFUSION LUNG SCAN||||CHILD|PHYSIOTHERAPIST|U|3|Visit_3|40|2|TREATMENT|2020-08-13|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-10|P1Y2M10DT2H30M|BEFORE|2020-09-26|ONGOING|2020-10-06
e|RS|6366647f-62fa-48dc-9d77-1677fce62fc7|7|NTERESP|Non-Target Enhancing Response|BURCOMBE BREAST CANCER 2005|||CA125 50% RESPONSE|1|PLUG|HPLC||Y|Y|INDEPENDENT ASSESSOR|PATHOLOGIST|NA|4|Visit_4|65|3|TREATMENT|2020-09-07|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-15|P1Y2M10DT2H30M|UNKNOWN|2020-09-25|COINCIDENT|2020-10-02
e|RS|6366647f-62fa-48dc-9d77-1677fce62fc7|8|SPLNRESP|Spleen Response|PCWG SCHER PROSTATE CANCER 2008|[?]|kg|MRD PERSISTENCE|1|ug/min|REVERSE TRANSCRIPTASE PCR||Y||PROXY|ENDOCRINOLOGIST|Y|4|Visit_4|65|5|TREATMENT|2020-09-07|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-15|P1Y2M10DT2H30M|AFTER|2020-08-18|ONGOING|2020-09-06
e|RS|6366647f-62fa-48dc-9d77-1677fce62fc7|9|SYMPTDTR|Symptomatic Deterioration|RECICL|[?]|Absorbance U/mL|CYTOGENETIC NO RESPONSE|1|CAPLET|CALCULATION||||INTERVIEWER|ONCOLOGIST 1|U|5|Visit_5|90|6|TREATMENT|2020-10-02|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-01|P1Y2M10DT2H30M|AFTER|2020-10-06|AFTER|2020-10-08
e|RS|6366647f-62fa-48dc-9d77-1677fce62fc7|10|OVRLRESP|Overall Response|RANO|||ABSENT MORPHOLOGIC RESPONSE|1|dB|U-HPLC/MS/MS|Y||Y|PARENT|PATHOLOGIST 1|N|5|Visit_5|90|1|WASHOUT|2020-10-02|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-01|P1Y2M10DT2H30M|UNKNOWN|2020-08-08|ONGOING|2020-09-06
e|RS|29fe31ae-bf22-4cfb-bdd3-f35ddf68cbc8|1|MJPTHIND|Major Pathological Response Indicator|MACDONALD GLIOMA 1990|[?]|umol/L|cCR|1|AFU|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY||||GUARDIAN|NEUROLOGIST 1|Y|1|Visit_1|10|2|TREATMENT|2020-05-13|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-08|P1Y2M10DT2H30M|UNKNOWN|2020-06-20|AFTER|2020-07-22
e|RS|29fe31ae-bf22-4cfb-bdd3-f35ddf68cbc8|2|ANATRESP|Anatomic Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|JDF Unit|IMPROVED|1|ug/g/min|MICRO BROTH DILUTION|Y|||INTERVIEWER|READER 2|NA|1|Visit_1|10|5|TREATMENT|2020-05-13|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-08|P1Y2M10DT2H30M|BEFORE|2020-07-09|ONGOING|2020-07-13
e|RS|29fe31ae-bf22-4cfb-bdd3-f35ddf68cbc8|3|MJPTHIND|Major Pathological Response Indicator|PRINCE TCELL LYMPHOMA 2010|[?]|L|MRD NEGATIVITY|1|tuberculin unit/mL|MICROPARTICLE ENZYME IMMUNOASSAY||||STUDY SUBJECT|OTOLARYNGOLOGIST|Y|2|Visit_2|25|4|SCREENING|2020-05-28|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-05|P1Y2M10DT2H30M|AFTER|2020-05-18|BEFORE|2020-06-30
e|RS|29fe31ae-bf22-4cfb-bdd3-f35ddf68cbc8|4|MRDIND|Minimal Residual Disease Indicator|PRINCE TCELL LYMPHOMA 2010|[?]|Bq/ug|CR-CT|1|mV/sec|PHOTOMETRIC CLOT DETECTION||||STUDY SUBJECT|READER 2|Y|2|Visit_2|25|2|TREATMENT|2020-05-28|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-05|P1Y2M10DT2H30M|UNKNOWN|2020-06-26|ONGOING|2020-07-05
e|RS|29fe31ae-bf22-4cfb-bdd3-f35ddf68cbc8|5|ANATRESP|Anatomic Response|NCIWG CHESON CLL 1996|[?]|mg/kg/dose|MINOR PATHOLOGIC RESPONSE|1|ukat/L|TRANSVAGINAL ULTRASOUND||||INVESTIGATOR|RADIOLOGIST 2|NA|3|Visit_3|40|6|TREATMENT|2020-06-12|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-30|P1Y2M10DT2H30M|UNKNOWN|2020-05-17|ONGOING|2020-07-25
e|RS|29fe31ae-bf22-4cfb-bdd3-f35ddf68cbc8|6|BESTRESP|Best Overall Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|log EID 50/dose|STABLE|1|10^3 organisms/g|DC SHEATH FLOW||||ADJUDICATION COMMITTEE|ENDOCRINOLOGIST|Y|3|Visit_3|40|1|TREATMENT|2020-06-12|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-30|P1Y2M10DT2H30M|BEFORE|2020-07-08|AFTER|2020-07-21
e|RS|29fe31ae-bf22-4cfb-bdd3-f35ddf68cbc8|7|NTLWIND|Non-Target Lesion Worsening Indicator|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|mm3/mm2/year|CYTOGENETIC CR|1|um/day|MAGNETIC RESONANCE ENTEROGRAPHY||||GUARDIAN|OTOLARYNGOLOGIST|U|4|Visit_4|65|4|SCREENING|2020-07-07|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-03|P1Y2M10DT2H30M|UNKNOWN|2020-07-29|AFTER|2020-08-01
e|RS|29fe31ae-bf22-4cfb-bdd3-f35ddf68cbc8|8|SPLNRESP|Spleen Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|BOTTLE|NR|1|mL/animal/day|FORCED OSCILLATION TECHNIQUE||||INTERVIEWER|MICROSCOPIST|N|4|Visit_4|65|3|WASHOUT|2020-07-07|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-03|P1Y2M10DT2H30M|COINCIDENT|2020-06-06|COINCIDENT|2020-07-26
e|RS|29fe31ae-bf22-4cfb-bdd3-f35ddf68cbc8|9|NEWLIND|New Lesion Indicator|RANO|||CR|1|ka_u/dL|MOUSE PROTECTION ASSAY||Y|Y|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST|U|5|Visit_5|90|6|WASHOUT|2020-08-01|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-12|P1Y2M10DT2H30M|UNKNOWN|2020-08-09|ONGOING|2020-08-10
e|RS|29fe31ae-bf22-4cfb-bdd3-f35ddf68cbc8|10|CPRFSTAT|Clinical Performance Status|RANO ELLINGSON 2017|[?]|mMU/mL|pCR|1|Bq/mg|SPECULAR MICROSCOPY|Y|||DOMESTIC PARTNER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|5|Visit_5|90|1|FOLLOW-UP|2020-08-01|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-05-12|P1Y2M10DT2H30M|COINCIDENT|2020-06-24|AFTER|2020-07-21
e|RS|637d7d5f-78d3-47fb-b6dc-d877d92b9001|1|CLINRESP|Clinical Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|vp/dose|STABLE|1|s^-1(%O2)^-1|LC/MS/MS||||CLINICAL STUDY SPONSOR|ONCOLOGIST|U|1|Visit_1|10|6|FOLLOW-UP|2020-06-03|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-02|P1Y2M10DT2H30M|UNKNOWN|2020-06-08|AFTER|2020-06-09
e|RS|637d7d5f-78d3-47fb-b6dc-d877d92b9001|2|MRDIND|Minimal Residual Disease Indicator|LUGANO CLASSIFICATION|||CYTOGENETIC MINOR RESPONSE|1|Antibody Unit|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|Y||Y|NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 3|Y|1|Visit_1|10|3|WASHOUT|2020-06-03|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-02|P1Y2M10DT2H30M|AFTER|2020-06-08|AFTER|2020-08-30
e|RS|637d7d5f-78d3-47fb-b6dc-d877d92b9001|3|BESTRESP|Best Overall Response|MASS|[?]|Ci/kg|HI-P|1|10^6/Ejaculate U|PULSE OXIMETRY|Y|Y||ADJUDICATION COMMITTEE|ENDOCRINOLOGIST|Y|2|Visit_2|25|7|SCREENING|2020-06-18|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-10|P1Y2M10DT2H30M|COINCIDENT|2020-07-07|ONGOING|2020-07-11
e|RS|637d7d5f-78d3-47fb-b6dc-d877d92b9001|4|SPLNRESP|Spleen Response|IWG CHESON MDS 2000|[?]|PRESSOR UNITS|MR|1|CAPFUL|WHOLE TRANSCRIPTOME SEQUENCING||||HEALTH CARE PROFESSIONAL|RATER 1|U|2|Visit_2|25|5|FOLLOW-UP|2020-06-18|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-10|P1Y2M10DT2H30M|AFTER|2020-08-26|AFTER|2020-08-29
e|RS|637d7d5f-78d3-47fb-b6dc-d877d92b9001|5|TRGRESP|Target Response|iRECIST|||MRD RELAPSE|1|ug/min|ELECTROCHEMILUMINESCENCE IMMUNOASSAY|||Y|INTERVIEWER|RATER 2|NA|3|Visit_3|40|3|FOLLOW-UP|2020-07-03|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-15|P1Y2M10DT2H30M|AFTER|2020-05-27|AFTER|2020-07-22
e|RS|637d7d5f-78d3-47fb-b6dc-d877d92b9001|6|HEMARESP|Hematologic Response|KUMAR IMWG 2016|[?]|NFIU|MORPHOLOGIC CR|1|/5x10^4 WBC|CT SCAN WITHOUT CONTRAST||||ADJUDICATION COMMITTEE|UROLOGIST|U|3|Visit_3|40|5|FOLLOW-UP|2020-07-03|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-15|P1Y2M10DT2H30M|AFTER|2020-08-10|BEFORE|2020-08-23
e|RS|637d7d5f-78d3-47fb-b6dc-d877d92b9001|7|TRGRESP|Target Response|WOLCHOK SOLID TUMORS 2009|||SMD|1|TAMPON|SPIROMETRY|Y||Y|ADJUDICATION COMMITTEE|MICROSCOPIST 1|NA|4|Visit_4|65|4|SCREENING|2020-07-28|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-20|P1Y2M10DT2H30M|COINCIDENT|2020-07-25|COINCIDENT|2020-07-30
e|RS|637d7d5f-78d3-47fb-b6dc-d877d92b9001|8|TRGRESP|Target Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|cup eq|PD FROM PR|1|MESF|KINETIC MICROPARTICLE IMMUNOASSAY|Y|||SIGNIFICANT OTHER|ONCOLOGIST 1|U|4|Visit_4|65|7|FOLLOW-UP|2020-07-28|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-20|P1Y2M10DT2H30M|AFTER|2020-08-28|AFTER|2020-08-30
e|RS|637d7d5f-78d3-47fb-b6dc-d877d92b9001|9|BESTRESP|Best Overall Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|pt_us|UNFAVORABLE RESPONSE|1|cs|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION||||CLINICAL RESEARCH ASSOCIATE|ADJUDICATOR 1|N|5|Visit_5|90|1|SCREENING|2020-08-22|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-27|P1Y2M10DT2H30M|COINCIDENT|2020-07-29|BEFORE|2020-08-19
e|RS|637d7d5f-78d3-47fb-b6dc-d877d92b9001|10|METBRESP|Metabolic Response|RAJKUMAR MYELOMA 2011|[?]|EID 50/dose|UNEQUIVOCAL|1|mg2/dL2|FLUOROSCOPY||||CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST 2|Y|5|Visit_5|90|1|FOLLOW-UP|2020-08-22|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-27|P1Y2M10DT2H30M|AFTER|2020-06-13|AFTER|2020-08-06
e|RS|696cd04a-cde7-4481-b5e2-fad1877ec284|1|CLINRESP|Clinical Response|GUILHOT CML 2007|[?]|mmol/day|NE|1|WAFER|OPTICAL COHERENCE TOMOGRAPHY||||VENDOR|ADJUDICATOR 3|Y|1|Visit_1|10|2|FOLLOW-UP|2020-08-31|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-18|P1Y2M10DT2H30M|COINCIDENT|2020-09-23|AFTER|2020-11-12
e|RS|696cd04a-cde7-4481-b5e2-fad1877ec284|2|MRDRESP|Minimal Residual Disease Response|HARTMAN PANCREATIC CANCER 2012|||PD-CT|1|Log10 ELISA unit/dose|PET/MRI SCAN|||Y|FRIEND|OPHTHALMOLOGIST|Y|1|Visit_1|10|2|TREATMENT|2020-08-31|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-18|P1Y2M10DT2H30M|BEFORE|2020-10-24|BEFORE|2020-11-19
e|RS|696cd04a-cde7-4481-b5e2-fad1877ec284|3|OVRLRESP|Overall Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|ug/mol|ABSENT MORPHOLOGIC RESPONSE|1|U/mmol|SPECULAR MICROSCOPY||||DOMESTIC PARTNER|CARDIOLOGIST|N|2|Visit_2|25|7|TREATMENT|2020-09-15|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-28|P1Y2M10DT2H30M|BEFORE|2020-11-10|ONGOING|2020-11-13
e|RS|696cd04a-cde7-4481-b5e2-fad1877ec284|4|MRDRESP|Minimal Residual Disease Response|PCWG SCHER PROSTATE CANCER 2008|[?]|grain|HI-E|1|TRACE|ETDRS EYE CHART||||HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|U|2|Visit_2|25|6|TREATMENT|2020-09-15|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-28|P1Y2M10DT2H30M|UNKNOWN|2020-09-19|ONGOING|2020-10-31
e|RS|696cd04a-cde7-4481-b5e2-fad1877ec284|5|MRDIND|Minimal Residual Disease Indicator|BURCOMBE BREAST CANCER 2005|[?]|atm|MORPHOLOGIC LEUKEMIA-FREE STATE|1|mg/dose|CLOT DETECTION||||SPOUSE|ONCOLOGIST|Y|3|Visit_3|40|7|SCREENING|2020-09-30|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-17|P1Y2M10DT2H30M|BEFORE|2020-10-27|BEFORE|2020-11-12
e|RS|696cd04a-cde7-4481-b5e2-fad1877ec284|6|RDIORESP|Radiologic Response|BRUGGEMANN MRD 2010|[?]|MBq/uL|SD-CT|1|mV*min|HIGH LEVEL AMINOGLYCOSIDE SCREEN||||SIBLING|HEMATOLOGIST|Y|3|Visit_3|40|4|WASHOUT|2020-09-30|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-17|P1Y2M10DT2H30M|UNKNOWN|2020-11-01|COINCIDENT|2020-11-13
e|RS|696cd04a-cde7-4481-b5e2-fad1877ec284|7|SFTSRESP|Soft Tissue Response|BLAZER COLORECTAL CANCER 2008|[?]|g/cage/day|DISEASE TRANSFORMATION|1|mIU/L|GEL ELECTROPHORESIS|Y|||NON-HEALTH CARE PROFESSIONAL|HEMATOLOGIST|N|4|Visit_4|65|5|TREATMENT|2020-10-25|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-16|P1Y2M10DT2H30M|BEFORE|2020-11-12|COINCIDENT|2020-11-14
e|RS|696cd04a-cde7-4481-b5e2-fad1877ec284|8|RDIORESP|Radiologic Response|MURPHY PROSTATE CANCER 1980|||CA125 75% RESPONSE|1|mg/animal|IN VITRO GENE EXPRESSION ASSAY||Y|Y|DOMESTIC PARTNER|DERMATOLOGIST|NA|4|Visit_4|65|5|WASHOUT|2020-10-25|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-16|P1Y2M10DT2H30M|AFTER|2020-10-02|ONGOING|2020-10-30
e|RS|696cd04a-cde7-4481-b5e2-fad1877ec284|9|NEWLWIND|New Lesion Worsening Indicator|IWG CHESON AML 2003|[?]|L/L|CHR|1|fg|CHROMOGENIC ASSAY||||FRIEND|RATER 2|N|5|Visit_5|90|4|FOLLOW-UP|2020-11-19|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-24|P1Y2M10DT2H30M|AFTER|2020-09-13|BEFORE|2020-10-13
e|RS|696cd04a-cde7-4481-b5e2-fad1877ec284|10|OVRLRESP|Overall Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|TABLET|CA125 50% RESPONSE|1|mMU/mL|X-RAY FLUORESCENCE SPECTROMETRY||||SIBLING|NEUROLOGIST|Y|5|Visit_5|90|6|TREATMENT|2020-11-19|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-24|P1Y2M10DT2H30M|UNKNOWN|2020-10-30|ONGOING|2020-11-05
e|RS|ce4699cb-66f1-4c13-8428-84064255b765|1|BMIVLIND|Bone Marrow Involvement Indicator|RECIST 1.1|[?]|mg/kg|nPR|1|GLOBULE|LC/MS||||CHILD|RADIOLOGIST|N|1|Visit_1|10|2|SCREENING|2020-12-02|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-24|P1Y2M10DT2H30M|BEFORE|2021-02-17|ONGOING|2021-02-22
e|RS|ce4699cb-66f1-4c13-8428-84064255b765|2|PATHRESP|Pathologic Response|SCHER PROSTATE CANCER 2011|[?]|IU|FAVORABLE RESPONSE|1|10^4 CFU/mL|TARGETED GENOME SEQUENCING||||FAMILY MEMBER|READER 3|U|1|Visit_1|10|5|WASHOUT|2020-12-02|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-24|P1Y2M10DT2H30M|COINCIDENT|2021-02-16|COINCIDENT|2021-02-20
e|RS|ce4699cb-66f1-4c13-8428-84064255b765|3|TMRESP|Tumor Marker Response|HAMAOKA BREAST CANCER 2010|||STABLE|1|QUANTITY SUFFICIENT|IMMUNOPRECIPITATION|Y|Y|Y|CAREGIVER|HEMATOLOGIST|NA|2|Visit_2|25|1|FOLLOW-UP|2020-12-17|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-21|P1Y2M10DT2H30M|UNKNOWN|2020-12-24|AFTER|2021-02-24
e|RS|ce4699cb-66f1-4c13-8428-84064255b765|4|CYTORESP|Cytogenetic Response|IRANO 2015|[?]|nmol/mol|OPTIMAL MORPHOLOGIC RESPONSE|1|DIP|WHOLE EXOME SEQUENCING||||PROXY|ADJUDICATOR 2|NA|2|Visit_2|25|7|WASHOUT|2020-12-17|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-21|P1Y2M10DT2H30M|AFTER|2021-02-11|COINCIDENT|2021-02-16
e|RS|ce4699cb-66f1-4c13-8428-84064255b765|5|MNPTHIND|Minor Pathological Response Indicator|RANO ELLINGSON 2017|[?]|mL/cage/wk|CA125 50% RESPONSE|1|hr/day|MS/MS||||NON-HEALTH CARE PROFESSIONAL|RATER 1|Y|3|Visit_3|40|6|TREATMENT|2021-01-01|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-10|P1Y2M10DT2H30M|BEFORE|2021-02-20|AFTER|2021-02-27
e|RS|ce4699cb-66f1-4c13-8428-84064255b765|6|DRCRIND|Disease Recurrence Indicator|BRUGGEMANN MRD 2010|||COMPLETE MRD RESPONSE|1|mg/day|RADIAL IMMUNODIFFUSION|Y||Y|FAMILY MEMBER|ADJUDICATOR 2|U|3|Visit_3|40|5|FOLLOW-UP|2021-01-01|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-10|P1Y2M10DT2H30M|BEFORE|2021-01-14|AFTER|2021-02-13
e|RS|ce4699cb-66f1-4c13-8428-84064255b765|7|METBRESP|Metabolic Response|KUMAR IMWG 2016|[?]|nCi|PMR|1|kg/L|CONTRAST ENHANCED SPIRAL CT SCAN|Y|||DOMESTIC PARTNER|ONCOLOGIST|Y|4|Visit_4|65|3|TREATMENT|2021-01-26|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-20|P1Y2M10DT2H30M|UNKNOWN|2021-02-23|BEFORE|2021-02-27
e|RS|ce4699cb-66f1-4c13-8428-84064255b765|8|NEWLWIND|New Lesion Worsening Indicator|KUKER LYMPHOMA 2005|||NON-CR/NON-PD|1|BE/mL|WHOLE GENOME SEQUENCING|||Y|CLINICAL RESEARCH ASSOCIATE|HEMATOLOGIST|U|4|Visit_4|65|3|SCREENING|2021-01-26|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-20|P1Y2M10DT2H30M|AFTER|2020-12-11|ONGOING|2021-02-05
e|RS|ce4699cb-66f1-4c13-8428-84064255b765|9|SYMPTDTR|Symptomatic Deterioration|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|MPS U|PR-CT|1|10^8 PFU|HPLC|Y|||NON-HEALTH CARE PROFESSIONAL|READER 3|N|5|Visit_5|90|1|FOLLOW-UP|2021-02-20|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-25|P1Y2M10DT2H30M|UNKNOWN|2021-01-25|COINCIDENT|2021-02-28
e|RS|ce4699cb-66f1-4c13-8428-84064255b765|10|NEWLWIND|New Lesion Worsening Indicator|PALUMBO MULTIPLE MYELOMA 2009|[?]|nU/cL|EQUIVOCAL|1|U/mmol|NUCLEIC ACID AMPLIFICATION TEST||||DOMESTIC PARTNER|MICROSCOPIST 3|N|5|Visit_5|90|1|TREATMENT|2021-02-20|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-25|P1Y2M10DT2H30M|BEFORE|2020-12-16|AFTER|2020-12-23
e|RS|015b391b-23c7-478d-b9d1-226d3cb9edcf|1|CPRFSTAT|Clinical Performance Status|MACDONALD GLIOMA 1990|||PSEUDOPROGRESSION|1|gMFI|ELECTROGASTROGRAPHY|Y||Y|SIBLING|READER 2|Y|1|Visit_1|10|4|TREATMENT|2020-11-29|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-24|P1Y2M10DT2H30M|AFTER|2021-02-12|BEFORE|2021-02-19
e|RS|015b391b-23c7-478d-b9d1-226d3cb9edcf|2|DRCRIND|Disease Recurrence Indicator|CHOLLET BREAST CANCER 2002|[?]|10^6 DNA copies/mL|UNFAVORABLE RESPONSE|1|vg/kg|GRADIENT DIFFUSION||||INDEPENDENT ASSESSOR|NEUROLOGIST 2|NA|1|Visit_1|10|6|TREATMENT|2020-11-29|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-24|P1Y2M10DT2H30M|UNKNOWN|2020-12-02|COINCIDENT|2020-12-22
e|RS|015b391b-23c7-478d-b9d1-226d3cb9edcf|3|SYMPTDTR|Symptomatic Deterioration|HARTMANN GERM CELL CANCER 2002|[?]|mL/(min*100mL)|HI-P|1|mg/mol|ALCIAN BLUE AND PERIODIC ACID SCHIFF STAIN||Y||CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST|Y|2|Visit_2|25|2|TREATMENT|2020-12-14|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-18|P1Y2M10DT2H30M|UNKNOWN|2021-01-05|COINCIDENT|2021-01-08
e|RS|015b391b-23c7-478d-b9d1-226d3cb9edcf|4|MRPHRESP|Morphologic Response|LEE LUNG CANCER 2011|[?]|MnFI|NED|1|CIGAR|ATOMIC ABSORPTION SPECTROMETRY|Y|||FAMILY MEMBER|OTOLARYNGOLOGIST|U|2|Visit_2|25|1|TREATMENT|2020-12-14|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-18|P1Y2M10DT2H30M|BEFORE|2020-12-12|BEFORE|2021-01-01
e|RS|015b391b-23c7-478d-b9d1-226d3cb9edcf|5|MJPTHIND|Major Pathological Response Indicator|AJCC V8|[?]|10^8/L|CYTOGENETIC CR|1|ppb|TEMPLATE INCISION METHOD||||INDEPENDENT ASSESSOR|PHYSIOTHERAPIST|U|3|Visit_3|40|6|TREATMENT|2020-12-29|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-17|P1Y2M10DT2H30M|COINCIDENT|2021-02-14|BEFORE|2021-02-19
e|RS|015b391b-23c7-478d-b9d1-226d3cb9edcf|6|CPRFSTAT|Clinical Performance Status|BURCOMBE BREAST CANCER 2005|[?]|BU/mL|TREATMENT FAILURE|1|Roentgen|WHOLE TRANSCRIPTOME SEQUENCING||||ADJUDICATION COMMITTEE|READER|Y|3|Visit_3|40|3|WASHOUT|2020-12-29|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-17|P1Y2M10DT2H30M|AFTER|2020-12-19|COINCIDENT|2021-01-29
e|RS|015b391b-23c7-478d-b9d1-226d3cb9edcf|7|TMRESP|Tumor Marker Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|psi|RELAPSED DISEASE FROM CR OR PR|1|uV|PHYSICAL EXAMINATION||||NON-HEALTH CARE PROFESSIONAL|PHYSIOTHERAPIST|N|4|Visit_4|65|6|WASHOUT|2021-01-23|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-30|P1Y2M10DT2H30M|AFTER|2020-12-15|AFTER|2020-12-27
e|RS|015b391b-23c7-478d-b9d1-226d3cb9edcf|8|BMIVLIND|Bone Marrow Involvement Indicator|AJCC V8|[?]|/wk|NON-CR/NON-PD|1|mL/min|CLIP SEQUENCING|Y|Y||CLINICAL STUDY SPONSOR|RATER 2|U|4|Visit_4|65|3|FOLLOW-UP|2021-01-23|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-30|P1Y2M10DT2H30M|AFTER|2021-01-08|ONGOING|2021-02-18
e|RS|015b391b-23c7-478d-b9d1-226d3cb9edcf|9|CYTORESP|Cytogenetic Response|RANO ELLINGSON 2017|[?]|um2|SD|1|nU/cL|FREEZING POINT DEPRESSION||||STUDY SUBJECT|MICROSCOPIST|Y|5|Visit_5|90|6|TREATMENT|2021-02-17|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-21|P1Y2M10DT2H30M|BEFORE|2020-12-31|AFTER|2021-02-16
e|RS|015b391b-23c7-478d-b9d1-226d3cb9edcf|10|RDIORESP|Radiologic Response|FAROOQUI SUPP CLL 2014|||CHR|1|IU/mL|ANTIMICROBIAL COMBINATION TESTING|Y||Y|VENDOR|PATHOLOGIST|Y|5|Visit_5|90|7|SCREENING|2021-02-17|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-21|P1Y2M10DT2H30M|BEFORE|2020-12-22|COINCIDENT|2020-12-30
e|RS|b510a277-c5ee-4a32-b111-b2dbc72c8a27|1|SPLNRESP|Spleen Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|pmol/L/h|MOLECULAR CR|1|CAPSULE|FLOW MICROSCOPY||Y||VENDOR|OPTOMETRIST|NA|1|Visit_1|10|4|FOLLOW-UP|2020-06-07|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-18|P1Y2M10DT2H30M|BEFORE|2020-08-09|BEFORE|2020-09-02
e|RS|b510a277-c5ee-4a32-b111-b2dbc72c8a27|2|NEWLIND|New Lesion Indicator|SCHER PROSTATE CANCER 2011|[?]|log10 PFU|NE|1|MPL U|AURAMINE STAIN||||GUARDIAN|ADJUDICATOR 3|U|1|Visit_1|10|1|FOLLOW-UP|2020-06-07|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-18|P1Y2M10DT2H30M|AFTER|2020-07-26|BEFORE|2020-08-14
e|RS|b510a277-c5ee-4a32-b111-b2dbc72c8a27|3|NTLWIND|Non-Target Lesion Worsening Indicator|PERCIST|[?]|genEq|iCR|1|10^4/L|GC/FID||||SIBLING|ONCOLOGIST 1|N|2|Visit_2|25|6|TREATMENT|2020-06-22|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-04|P1Y2M10DT2H30M|AFTER|2020-08-07|ONGOING|2020-08-13
e|RS|b510a277-c5ee-4a32-b111-b2dbc72c8a27|4|MNPTHIND|Minor Pathological Response Indicator|EASL BRUIX LIVER CANCER 2001|[?]|log10 PFU|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|SYRINGE|SLOAN LETTER EYE CHART 2.5%||||DOMESTIC PARTNER|NEUROLOGIST|U|2|Visit_2|25|6|TREATMENT|2020-06-22|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-04|P1Y2M10DT2H30M|BEFORE|2020-07-14|COINCIDENT|2020-07-23
e|RS|b510a277-c5ee-4a32-b111-b2dbc72c8a27|5|TRGRESP|Target Response|AJCC V7|[?]|cd/m2|VGPR|1|uIU/L|DIRECT SEQUENCING||||INTERVIEWER|ADJUDICATOR 3|U|3|Visit_3|40|7|TREATMENT|2020-07-07|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-10|P1Y2M10DT2H30M|BEFORE|2020-06-16|ONGOING|2020-08-21
e|RS|b510a277-c5ee-4a32-b111-b2dbc72c8a27|6|BONERESP|Bone Response|JACINTO CERVICAL CANCER 2007|[?]|SPRAY|MINOR PATHOLOGIC RESPONSE|1|mL/m2/min|MIGET|Y|||CLINICAL STUDY SPONSOR|PATHOLOGIST|U|3|Visit_3|40|3|TREATMENT|2020-07-07|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-10|P1Y2M10DT2H30M|AFTER|2020-07-21|AFTER|2020-08-15
e|RS|b510a277-c5ee-4a32-b111-b2dbc72c8a27|7|BESTRESP|Best Overall Response|GUILHOT CML 2007|[?]|anti-Xa IU/mL|CR-CT|1|10^9 CFU/g|IN VITRO GENE EXPRESSION ASSAY||||NON-HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|N|4|Visit_4|65|7|FOLLOW-UP|2020-08-01|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-06|P1Y2M10DT2H30M|UNKNOWN|2020-08-30|COINCIDENT|2020-09-04
e|RS|b510a277-c5ee-4a32-b111-b2dbc72c8a27|8|BONERESP|Bone Response|CHESON CLL 2012|[?]|umol/h/mmol|UNFAVORABLE RESPONSE|1|mEq/mL|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION||||PROXY|MICROSCOPIST|U|4|Visit_4|65|1|SCREENING|2020-08-01|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-06|P1Y2M10DT2H30M|COINCIDENT|2020-08-30|BEFORE|2020-08-31
e|RS|b510a277-c5ee-4a32-b111-b2dbc72c8a27|9|TRGRESP|Target Response|RAJKUMAR MYELOMA 2011|||CMR|1|ohm|STRESS ECHOCARDIOGRAPHY|||Y|STUDY SUBJECT|PATHOLOGIST 2|Y|5|Visit_5|90|5|TREATMENT|2020-08-26|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-05|P1Y2M10DT2H30M|UNKNOWN|2020-08-17|ONGOING|2020-09-02
e|RS|b510a277-c5ee-4a32-b111-b2dbc72c8a27|10|STRUSTAT|Steroid Use Status|CHOI GIST 2008|[?]|mL/g/min|PMD|1|mm2|PHASE CONTRAST MICROSCOPY||||FAMILY MEMBER|READER|U|5|Visit_5|90|7|TREATMENT|2020-08-26|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-05|P1Y2M10DT2H30M|AFTER|2020-08-02|ONGOING|2020-08-16
e|RS|9e9acf6b-d29a-4c11-96d6-b580c721f462|1|TMRESP|Tumor Marker Response|KEAM BREAST CANCER 2013|[?]|BE/mL|RELAPSED DISEASE FROM CR OR PR|1|nkat/L|SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY||||INVESTIGATOR|CARDIOLOGIST|N|1|Visit_1|10|2|TREATMENT|2020-08-20|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-17|P1Y2M10DT2H30M|BEFORE|2020-09-09|BEFORE|2020-11-02
e|RS|9e9acf6b-d29a-4c11-96d6-b580c721f462|2|LIVRRESP|Liver Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|mEq/mmol|PR-CT|1|nkat/g Hb|QUANTITATIVE PERIPHERAL ANGIOGRAPHY|Y|||INTERVIEWER|MICROSCOPIST|U|1|Visit_1|10|6|WASHOUT|2020-08-20|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-17|P1Y2M10DT2H30M|COINCIDENT|2020-11-01|ONGOING|2020-11-11
e|RS|9e9acf6b-d29a-4c11-96d6-b580c721f462|3|STRUSTAT|Steroid Use Status|LUGANO CLASSIFICATION|[?]|ug/day|CYTOGENETIC CR|1|/2000 RBC|NO INFORMATION||Y||ADJUDICATOR|PEDIATRIC NEUROLOGIST|NA|2|Visit_2|25|5|WASHOUT|2020-09-04|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-08|P1Y2M10DT2H30M|UNKNOWN|2020-10-04|ONGOING|2020-10-08
e|RS|9e9acf6b-d29a-4c11-96d6-b580c721f462|4|BONERESP|Bone Response|HAMAOKA BREAST CANCER 2010|[?]|MESF|PD|1|APPLICATION|BETA LACTAMASE||||CHILD|ONCOLOGIST 1|N|2|Visit_2|25|5|FOLLOW-UP|2020-09-04|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-08|P1Y2M10DT2H30M|UNKNOWN|2020-11-04|ONGOING|2020-11-09
e|RS|9e9acf6b-d29a-4c11-96d6-b580c721f462|5|CPRFSTAT|Clinical Performance Status|SACT|[?]|Ejaculate U|PDu|1|POINT|REBOUND TONOMETRY|Y|||CLINICAL STUDY SPONSOR|MICROSCOPIST 3|NA|3|Visit_3|40|4|SCREENING|2020-09-19|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-19|P1Y2M10DT2H30M|COINCIDENT|2020-09-16|AFTER|2020-10-01
e|RS|9e9acf6b-d29a-4c11-96d6-b580c721f462|6|ANATRESP|Anatomic Response|GUILHOT CML 2007|[?]|kV|cPR|1|mEq/ug|SLOAN LETTER EYE CHART 2.5%||||FAMILY MEMBER|RADIOLOGIST 2|N|3|Visit_3|40|6|TREATMENT|2020-09-19|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-19|P1Y2M10DT2H30M|UNKNOWN|2020-09-28|ONGOING|2020-10-29
e|RS|9e9acf6b-d29a-4c11-96d6-b580c721f462|7|PATHRESP|Pathologic Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|Ci/kg|PSEUDORESPONSE|1|fg|FARR ASSAY|Y|||GUARDIAN|DEVELOPMENTAL PSYCHOLOGIST|Y|4|Visit_4|65|4|WASHOUT|2020-10-14|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-18|P1Y2M10DT2H30M|BEFORE|2020-11-02|AFTER|2020-11-14
e|RS|9e9acf6b-d29a-4c11-96d6-b580c721f462|8|SFTSRESP|Soft Tissue Response|MASS|||NED|1|10^9 organisms/g|FLUORESCENT MICROSCOPY||Y|Y|CLINICAL RESEARCH COORDINATOR|RADIOLOGIST 1|U|4|Visit_4|65|2|FOLLOW-UP|2020-10-14|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-18|P1Y2M10DT2H30M|AFTER|2020-10-06|COINCIDENT|2020-10-20
e|RS|9e9acf6b-d29a-4c11-96d6-b580c721f462|9|CLINRESP|Clinical Response|PETIT BREAST CANCER 2001|[?]|umol/day|NED|1|dyn|FLUORESCENT IMMUNOASSAY||||SIBLING|RADIOLOGIST 1|U|5|Visit_5|90|5|TREATMENT|2020-11-08|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-07|P1Y2M10DT2H30M|COINCIDENT|2020-08-14|ONGOING|2020-09-09
e|RS|9e9acf6b-d29a-4c11-96d6-b580c721f462|10|METBRESP|Metabolic Response|CHOI GIST 2008|||WORSENED|1|U/m2/day|NUCLEIC ACID HYBRIDIZATION|Y||Y|DOMESTIC PARTNER|OTOLARYNGOLOGIST|NA|5|Visit_5|90|3|TREATMENT|2020-11-08|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-07|P1Y2M10DT2H30M|UNKNOWN|2020-10-29|ONGOING|2020-11-08
e|RS|da69b157-7dab-49c5-b8fb-bd312a21fcf0|1|CYTORESP|Cytogenetic Response|BURCOMBE BREAST CANCER 2005|[?]|U/g Hb|CHR|1|IU/L|IMMUNE REPERTOIRE DEEP SEQUENCING||Y||VENDOR|INTERNIST|U|1|Visit_1|10|4|TREATMENT|2020-07-18|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-15|P1Y2M10DT2H30M|AFTER|2020-09-16|COINCIDENT|2020-10-15
e|RS|da69b157-7dab-49c5-b8fb-bd312a21fcf0|2|MOLRESP|Molecular Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|mmol/min/kPa/L|pCR|1|PIXELS/cm|PET/SPECT SCAN||Y||CAREGIVER|CLINICAL PATHOLOGIST|NA|1|Visit_1|10|6|TREATMENT|2020-07-18|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-15|P1Y2M10DT2H30M|UNKNOWN|2020-07-16|AFTER|2020-09-14
e|RS|da69b157-7dab-49c5-b8fb-bd312a21fcf0|3|MNPTHIND|Minor Pathological Response Indicator|DURIE MULTIPLE MYELOMA 2006|[?]|mV*min|UNEQUIVOCAL|1|Gauss|FLUORESCENT MICROSCOPY||Y||ADJUDICATOR|DEVELOPMENTAL PSYCHOLOGIST|N|2|Visit_2|25|3|TREATMENT|2020-08-02|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-10|P1Y2M10DT2H30M|BEFORE|2020-10-03|COINCIDENT|2020-10-12
e|RS|da69b157-7dab-49c5-b8fb-bd312a21fcf0|4|METBRESP|Metabolic Response|WHO BREAST CANCER 2006|||MRD RELAPSE|1|pptr|HIGH RESOLUTION MELT ANALYSIS|Y||Y|INVESTIGATOR|OTOLARYNGOLOGIST|NA|2|Visit_2|25|2|SCREENING|2020-08-02|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-10|P1Y2M10DT2H30M|COINCIDENT|2020-09-21|BEFORE|2020-10-02
e|RS|da69b157-7dab-49c5-b8fb-bd312a21fcf0|5|CLINRESP|Clinical Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|SUPPOSITORY|VGPR|1|/7.5 mL|ELECTROPHORESIS||||FRIEND|ADJUDICATOR|N|3|Visit_3|40|2|WASHOUT|2020-08-17|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-19|P1Y2M10DT2H30M|AFTER|2020-08-20|COINCIDENT|2020-09-21
e|RS|da69b157-7dab-49c5-b8fb-bd312a21fcf0|6|PATHRESP|Pathologic Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|cup eq|QUANTIFIABLE MRD POSITIVITY|1|mL/g/day|AHG-ENHANCED COMPLEMENT-DEPENDENT LYMPHOCYTOTOXICITY ASSAY|Y|||SIBLING|DERMATOLOGIST|N|3|Visit_3|40|7|WASHOUT|2020-08-17|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-19|P1Y2M10DT2H30M|AFTER|2020-07-25|BEFORE|2020-08-29
e|RS|da69b157-7dab-49c5-b8fb-bd312a21fcf0|7|MRDIND|Minimal Residual Disease Indicator|CHESON CLL 2012|[?]|MAC50|PD/RELAPSE AFTER HI|1|dram|LISSAMINE GREEN STAIN||||FRIEND|NEUROLOGIST|U|4|Visit_4|65|2|TREATMENT|2020-09-11|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-05|P1Y2M10DT2H30M|BEFORE|2020-10-13|ONGOING|2020-10-15
e|RS|da69b157-7dab-49c5-b8fb-bd312a21fcf0|8|TMRESP|Tumor Marker Response|UNSPECIFIED|[?]|SQU/mL|MRD PERSISTENCE|1|10^9 organisms|TOTAL BODY IRRADIATION||||SIGNIFICANT OTHER|OTOLARYNGOLOGIST|U|4|Visit_4|65|2|TREATMENT|2020-09-11|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-05|P1Y2M10DT2H30M|BEFORE|2020-07-14|ONGOING|2020-09-21
e|RS|da69b157-7dab-49c5-b8fb-bd312a21fcf0|9|NEWLWIND|New Lesion Worsening Indicator|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|kN/cm2|MOLECULAR CR|1|mL/dL|QUANTITATIVE PERIPHERAL ANGIOGRAPHY|Y|||ADJUDICATION COMMITTEE|RADIOLOGIST|NA|5|Visit_5|90|3|FOLLOW-UP|2020-10-06|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-14|P1Y2M10DT2H30M|AFTER|2020-08-14|ONGOING|2020-09-09
e|RS|da69b157-7dab-49c5-b8fb-bd312a21fcf0|10|NTRGRESP|Non-target Response|MRANO VAN DEN BENT GLIOMA 2011|||CR|1|pg|RULER MEASUREMENT METHOD||Y|Y|VENDOR|OPHTHALMOLOGIST|U|5|Visit_5|90|4|TREATMENT|2020-10-06|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-14|P1Y2M10DT2H30M|AFTER|2020-07-16|BEFORE|2020-10-12
e|RS|0e94ec23-3ef8-4a1f-b6e0-72ce49abba5d|1|TRGRESP|Target Response|MASS|[?]|ug/L FEU|NON-QUANTIFIABLE MRD POSITIVITY|1|pmol/L|MICRONEUTRALIZATION ASSAY||||VENDOR|RADIOLOGIST 2|NA|1|Visit_1|10|1|TREATMENT|2020-05-29|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-06|P1Y2M10DT2H30M|COINCIDENT|2020-05-26|COINCIDENT|2020-07-13
e|RS|0e94ec23-3ef8-4a1f-b6e0-72ce49abba5d|2|NTRGRESP|Non-target Response|IWG CHESON MDS 2000|[?]|Gy/min|MAJOR PATHOLOGIC RESPONSE|1|umol/L/sec|CLINICAL EVALUATION||||NON-HEALTH CARE PROFESSIONAL|RATER|NA|1|Visit_1|10|3|WASHOUT|2020-05-29|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-06|P1Y2M10DT2H30M|AFTER|2020-08-06|ONGOING|2020-08-19
e|RS|0e94ec23-3ef8-4a1f-b6e0-72ce49abba5d|3|METBRESP|Metabolic Response|RANO ELLINGSON 2017|[?]|ug/g/day|MINOR PATHOLOGIC RESPONSE|1|ug/g/h|GC/MS-EI||||CLINICAL STUDY SPONSOR|PATHOLOGIST 2|NA|2|Visit_2|25|1|TREATMENT|2020-06-13|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-16|P1Y2M10DT2H30M|BEFORE|2020-07-16|BEFORE|2020-08-01
e|RS|0e94ec23-3ef8-4a1f-b6e0-72ce49abba5d|4|NTERESP|Non-Target Enhancing Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|umol|MORPHOLOGIC CRi|1|g/L|ORCHIDOMETERY||||FRIEND|CARDIOLOGIST|U|2|Visit_2|25|2|FOLLOW-UP|2020-06-13|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-16|P1Y2M10DT2H30M|UNKNOWN|2020-07-14|ONGOING|2020-08-09
e|RS|0e94ec23-3ef8-4a1f-b6e0-72ce49abba5d|5|NTERESP|Non-Target Enhancing Response|SHINDOH COLORECTAL CANCER 2013|||PMD|1|mg/m2/min|OPHTHALMOSCOPY|||Y|SIGNIFICANT OTHER|PHYSIOTHERAPIST|N|3|Visit_3|40|6|TREATMENT|2020-06-28|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-08|P1Y2M10DT2H30M|UNKNOWN|2020-06-27|COINCIDENT|2020-08-19
e|RS|0e94ec23-3ef8-4a1f-b6e0-72ce49abba5d|6|RDIORESP|Radiologic Response|SHINDOH COLORECTAL CANCER 2013|||iPR|1|L/kg|PLAQUE REDUCTION NEUTRALIZATION ASSAY|||Y|CLINICAL RESEARCH ASSOCIATE|PEDIATRIC NEUROLOGIST|U|3|Visit_3|40|5|TREATMENT|2020-06-28|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-08|P1Y2M10DT2H30M|AFTER|2020-07-16|ONGOING|2020-08-25
e|RS|0e94ec23-3ef8-4a1f-b6e0-72ce49abba5d|7|NTNERESP|Non-Target Non-Enhancing Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|||SD-CT|1|COAT|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS||Y|Y|SPOUSE|ADJUDICATOR|Y|4|Visit_4|65|7|WASHOUT|2020-07-23|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-10|P1Y2M10DT2H30M|COINCIDENT|2020-06-18|AFTER|2020-06-25
e|RS|0e94ec23-3ef8-4a1f-b6e0-72ce49abba5d|8|METSIND|Metastatic Indicator|KUMAR IMWG 2016|||NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|mEq|HPLC|Y|Y|Y|ADJUDICATOR|UROLOGIST|N|4|Visit_4|65|5|FOLLOW-UP|2020-07-23|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-10|P1Y2M10DT2H30M|COINCIDENT|2020-08-15|BEFORE|2020-08-26
e|RS|0e94ec23-3ef8-4a1f-b6e0-72ce49abba5d|9|MJPTHIND|Major Pathological Response Indicator|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|mmol/kg|PR-CT|1|mCi/L|GC/MS||||ADJUDICATION COMMITTEE|ONCOLOGIST 2|N|5|Visit_5|90|5|TREATMENT|2020-08-17|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-24|P1Y2M10DT2H30M|BEFORE|2020-08-08|ONGOING|2020-08-25
e|RS|0e94ec23-3ef8-4a1f-b6e0-72ce49abba5d|10|MRDRESP|Minimal Residual Disease Response|LEE LUNG CANCER 2011|[?]|kg|SD|1|kUSP|ACID FAST STAIN||||CAREGIVER|ADJUDICATOR 3|Y|5|Visit_5|90|1|TREATMENT|2020-08-17|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-24|P1Y2M10DT2H30M|UNKNOWN|2020-08-23|COINCIDENT|2020-08-26
e|RS|77c97d1e-e223-4485-b2de-59daa4e5b01f|1|BESTRESP|Best Overall Response|PRINCE TCELL LYMPHOMA 2010|[?]|PATCH|cPR|1|10^6/hpf|WRIGHT STAIN||||STUDY SUBJECT|DERMATOLOGIST|NA|1|Visit_1|10|1|TREATMENT|2020-06-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-12|P1Y2M10DT2H30M|AFTER|2020-07-22|COINCIDENT|2020-08-05
e|RS|77c97d1e-e223-4485-b2de-59daa4e5b01f|2|METBRESP|Metabolic Response|HARTMAN PANCREATIC CANCER 2012|[?]|amu|CYTOGENETIC PR|1|Ci/L|NUCLEIC ACID BASED METHOD||||SIBLING|PHYSIOTHERAPIST|U|1|Visit_1|10|6|TREATMENT|2020-06-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-12|P1Y2M10DT2H30M|COINCIDENT|2020-06-27|ONGOING|2020-07-28
e|RS|77c97d1e-e223-4485-b2de-59daa4e5b01f|3|NTERESP|Non-Target Enhancing Response|UNSPECIFIED|[?]|nkat/g Hb|PSEUDORESPONSE|1|AMPULE|PHENOTYPIC MULTIPLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY||||ADJUDICATOR|RADIOLOGIST|U|2|Visit_2|25|2|WASHOUT|2020-07-04|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-11|P1Y2M10DT2H30M|COINCIDENT|2020-09-06|COINCIDENT|2020-09-09
e|RS|77c97d1e-e223-4485-b2de-59daa4e5b01f|4|NTRGRESP|Non-target Response|RECIST 1.0|[?]|ug/dose|MRD PERSISTENCE|1|U/kg|GC/MS-EI||||INVESTIGATOR|READER|U|2|Visit_2|25|1|TREATMENT|2020-07-04|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-11|P1Y2M10DT2H30M|BEFORE|2020-08-07|AFTER|2020-09-04
e|RS|77c97d1e-e223-4485-b2de-59daa4e5b01f|5|CLINRESP|Clinical Response|RANO|[?]|ppm|ABSENT MORPHOLOGIC RESPONSE|1|kPa/L/sec|CHROMOGENIC ASSAY||||SPOUSE|READER 3|Y|3|Visit_3|40|6|TREATMENT|2020-07-19|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-06|P1Y2M10DT2H30M|COINCIDENT|2020-07-14|AFTER|2020-08-24
e|RS|77c97d1e-e223-4485-b2de-59daa4e5b01f|6|MRDRESP|Minimal Residual Disease Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|10^3 organisms|NOT ALL EVALUATED|1|SBE/mL|FLUORESCENT LIFETIME IMAGING MICROSCOPY|Y|Y||DOMESTIC PARTNER|PEDIATRIC NEUROLOGIST|Y|3|Visit_3|40|5|TREATMENT|2020-07-19|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-06|P1Y2M10DT2H30M|COINCIDENT|2020-06-21|COINCIDENT|2020-08-23
e|RS|77c97d1e-e223-4485-b2de-59daa4e5b01f|7|RDIORESP|Radiologic Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|mL/day|TREATMENT FAILURE|1|/200 HPFs|MASS SPECTROMETRY||||INTERVIEWER|ONCOLOGIST 1|NA|4|Visit_4|65|6|FOLLOW-UP|2020-08-13|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-08|P1Y2M10DT2H30M|COINCIDENT|2020-07-18|AFTER|2020-08-04
e|RS|77c97d1e-e223-4485-b2de-59daa4e5b01f|8|NEWLPROG|New Lesion Progression|IWG CHESON MDS 2006|[?]|mmol/mol|EQUIVOCAL|1|Enzyme U/m2|CHROMOGENIC ASSAY|Y|||CLINICAL RESEARCH ASSOCIATE|PHYSIOTHERAPIST|NA|4|Visit_4|65|4|TREATMENT|2020-08-13|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-08|P1Y2M10DT2H30M|UNKNOWN|2020-06-15|COINCIDENT|2020-08-27
e|RS|77c97d1e-e223-4485-b2de-59daa4e5b01f|9|NTNERESP|Non-Target Non-Enhancing Response|AJCC V8|||iCR|1|mg/day|TRANSESOPHAGEAL ECHOCARDIOGRAPHY|||Y|CLINICAL RESEARCH ASSOCIATE|READER 3|NA|5|Visit_5|90|7|TREATMENT|2020-09-07|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-09|P1Y2M10DT2H30M|AFTER|2020-08-11|BEFORE|2020-09-03
e|RS|77c97d1e-e223-4485-b2de-59daa4e5b01f|10|NEWLIND|New Lesion Indicator|GUILHOT CML 2007|||SMD|1|copies/mL|PET/CT SCAN WITHOUT CONTRAST||Y|Y|INDEPENDENT ASSESSOR|OTOLARYNGOLOGIST|U|5|Visit_5|90|7|WASHOUT|2020-09-07|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-09|P1Y2M10DT2H30M|UNKNOWN|2020-08-17|ONGOING|2020-08-20
e|RS|9ea26788-8e26-4cbf-9a5a-58cb49686fc6|1|BESTRESP|Best Overall Response|KUMAR IMWG 2016|[?]|GBq/ug|MRD NEGATIVITY|1|kg/cm|TEST STRIP||||CAREGIVER|CLINICAL PATHOLOGIST|U|1|Visit_1|10|7|SCREENING|2020-10-14|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-19|P1Y2M10DT2H30M|AFTER|2020-11-01|BEFORE|2020-11-09
e|RS|9ea26788-8e26-4cbf-9a5a-58cb49686fc6|2|MRPHRESP|Morphologic Response|RECIST 1.1|||CR-CT|1|IU/mmol|RYAN BLUE STAIN|Y||Y|STUDY SUBJECT|ADJUDICATOR 2|NA|1|Visit_1|10|7|SCREENING|2020-10-14|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-19|P1Y2M10DT2H30M|AFTER|2020-12-04|COINCIDENT|2020-12-06
e|RS|9ea26788-8e26-4cbf-9a5a-58cb49686fc6|3|CYTORESP|Cytogenetic Response|KEAM BREAST CANCER 2013|[?]|mV/sec|QUANTIFIABLE MRD POSITIVITY|1|10^3 organisms/mL|MICRO BROTH DILUTION||||STUDY SUBJECT|MICROSCOPIST 2|NA|2|Visit_2|25|1|TREATMENT|2020-10-29|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-14|P1Y2M10DT2H30M|BEFORE|2020-11-24|AFTER|2020-12-05
e|RS|9ea26788-8e26-4cbf-9a5a-58cb49686fc6|4|CLINRESP|Clinical Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|Gy/h|iUPD|1|pt_br|ENDOSCOPY|Y|||FAMILY MEMBER|OPTOMETRIST|NA|2|Visit_2|25|4|TREATMENT|2020-10-29|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-14|P1Y2M10DT2H30M|BEFORE|2020-10-11|AFTER|2020-10-12
e|RS|9ea26788-8e26-4cbf-9a5a-58cb49686fc6|5|SFTSRESP|Soft Tissue Response|BURCOMBE BREAST CANCER 2005|[?]|mJoule/cm2|INCREASED|1|GLOBULE|KARYOTYPING||||STUDY SUBJECT|NEUROLOGIST 2|NA|3|Visit_3|40|2|WASHOUT|2020-11-13|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-11|P1Y2M10DT2H30M|COINCIDENT|2020-11-24|BEFORE|2021-01-04
e|RS|9ea26788-8e26-4cbf-9a5a-58cb49686fc6|6|MRDRESP|Minimal Residual Disease Response|DOHNER AML 2010|[?]|mg/m2/min|INCREASED|1|dpm/0.5 mL|PET SCAN|Y|||VENDOR|ADJUDICATOR 3|Y|3|Visit_3|40|1|TREATMENT|2020-11-13|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-11|P1Y2M10DT2H30M|AFTER|2020-12-22|COINCIDENT|2020-12-23
e|RS|9ea26788-8e26-4cbf-9a5a-58cb49686fc6|7|ANATRESP|Anatomic Response|iRECIST|[?]|10^3 CFU|OPTIMAL MORPHOLOGIC RESPONSE|1|LENS|KINETIC CHROMOGENIC ASSAY||||VENDOR|READER 3|NA|4|Visit_4|65|3|SCREENING|2020-12-08|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-24|P1Y2M10DT2H30M|AFTER|2020-11-13|COINCIDENT|2020-12-22
e|RS|9ea26788-8e26-4cbf-9a5a-58cb49686fc6|8|HEMARESP|Hematologic Response|PCWG SCHER PROSTATE CANCER 2008|[?]|WEEKS|CYTOGENETIC PR|1|kg/cm2|FLUORESCENT LIFETIME IMAGING MICROSCOPY||Y||PROXY|RADIOLOGIST 2|NA|4|Visit_4|65|2|FOLLOW-UP|2020-12-08|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-24|P1Y2M10DT2H30M|UNKNOWN|2020-11-13|ONGOING|2020-12-05
e|RS|9ea26788-8e26-4cbf-9a5a-58cb49686fc6|9|SFTSRESP|Soft Tissue Response|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|/10^3|PMD|1|genEq|FLUORESCENT ENZYME IMMUNOASSAY||||SIBLING|NEUROLOGIST|Y|5|Visit_5|90|2|TREATMENT|2021-01-02|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-03|P1Y2M10DT2H30M|AFTER|2020-11-13|ONGOING|2021-01-03
e|RS|9ea26788-8e26-4cbf-9a5a-58cb49686fc6|10|OVRLRESP|Overall Response|LUGANO CLASSIFICATION|[?]|kDa|NED|1|s^-1(%O2)^-1|IHC||Y||CHILD|UROLOGIST|U|5|Visit_5|90|4|TREATMENT|2021-01-02|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-03|P1Y2M10DT2H30M|UNKNOWN|2020-11-13|AFTER|2021-01-08
e|RS|af049bb3-79a3-4a4c-8c2c-05d5b8c82967|1|RDIORESP|Radiologic Response|SHINDOH COLORECTAL CANCER 2013|[?]|uL/mL|PD-CT|1|mL*cmH2O|CONGO RED STAIN||||PROXY|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|Y|1|Visit_1|10|3|TREATMENT|2020-11-01|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-25|P1Y2M10DT2H30M|COINCIDENT|2020-12-16|AFTER|2021-01-19
e|RS|af049bb3-79a3-4a4c-8c2c-05d5b8c82967|2|NEWLWIND|New Lesion Worsening Indicator|SACT|||NON-CR/NON-PD|1|mCi/L|NUCLEIC ACID HYBRIDIZATION|||Y|FAMILY MEMBER|MICROSCOPIST 1|U|1|Visit_1|10|7|WASHOUT|2020-11-01|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-25|P1Y2M10DT2H30M|COINCIDENT|2020-11-13|BEFORE|2021-01-18
e|RS|af049bb3-79a3-4a4c-8c2c-05d5b8c82967|3|BONERESP|Bone Response|PERCIST|[?]|Antibody Unit|CYTOGENETIC PR|1|mOsm/kg|MASS SPECTROMETRY||||PROXY|FORENSIC PATHOLOGIST|N|2|Visit_2|25|5|TREATMENT|2020-11-16|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-14|P1Y2M10DT2H30M|AFTER|2020-12-22|ONGOING|2021-01-07
e|RS|af049bb3-79a3-4a4c-8c2c-05d5b8c82967|4|MOLRESP|Molecular Response|BURCOMBE BREAST CANCER 2005|[?]|sec|PD-CT|1|m2|QUANTITATIVE CORONARY ANGIOGRAPHY||||CLINICAL RESEARCH COORDINATOR|MICROSCOPIST 3|U|2|Visit_2|25|2|WASHOUT|2020-11-16|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-14|P1Y2M10DT2H30M|BEFORE|2021-01-17|COINCIDENT|2021-01-24
e|RS|af049bb3-79a3-4a4c-8c2c-05d5b8c82967|5|HEMARESP|Hematologic Response|BRUGGEMANN MRD 2010|||PSEUDORESPONSE|1|g|CONTRAST ENHANCED CT SCAN|Y|Y|Y|PARENT|OTOLARYNGOLOGIST|NA|3|Visit_3|40|1|WASHOUT|2020-12-01|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-07|P1Y2M10DT2H30M|UNKNOWN|2021-01-18|ONGOING|2021-01-26
e|RS|af049bb3-79a3-4a4c-8c2c-05d5b8c82967|6|PATHRESP|Pathologic Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|||nPR|1|gtt|MICROBIAL CULTURE|Y||Y|CLINICAL STUDY SPONSOR|UROLOGIST|U|3|Visit_3|40|7|TREATMENT|2020-12-01|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-07|P1Y2M10DT2H30M|COINCIDENT|2020-12-09|ONGOING|2021-01-07
e|RS|af049bb3-79a3-4a4c-8c2c-05d5b8c82967|7|PATHRESP|Pathologic Response|WOLCHOK SOLID TUMORS 2009|||PSEUDORESPONSE|1|U/g/day|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION||Y|Y|INTERVIEWER|DERMATOLOGIST|U|4|Visit_4|65|2|TREATMENT|2020-12-26|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-20|P1Y2M10DT2H30M|COINCIDENT|2020-11-04|BEFORE|2020-12-02
e|RS|af049bb3-79a3-4a4c-8c2c-05d5b8c82967|8|NTLWIND|Non-Target Lesion Worsening Indicator|UNSPECIFIED|[?]|mg/dose|PR|1|mmHg|FISH||Y||CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST 1|U|4|Visit_4|65|3|TREATMENT|2020-12-26|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-20|P1Y2M10DT2H30M|UNKNOWN|2020-12-13|COINCIDENT|2021-01-17
e|RS|af049bb3-79a3-4a4c-8c2c-05d5b8c82967|9|NEWLWIND|New Lesion Worsening Indicator|CHESON MALIGNANT LYMPHOMA 2007|||MAJOR PATHOLOGIC RESPONSE|1|Hz|ULTRASONOGRAPHIC ELASTOGRAPHY|||Y|ADJUDICATOR|RADIOLOGIST 1|NA|5|Visit_5|90|5|FOLLOW-UP|2021-01-20|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-03|P1Y2M10DT2H30M|UNKNOWN|2021-01-03|BEFORE|2021-01-26
e|RS|af049bb3-79a3-4a4c-8c2c-05d5b8c82967|10|DRCRIND|Disease Recurrence Indicator|MRECIST LENCIONI LIVER CANCER 2010|[?]|LB|iUPD|1|mkat|REAL-TIME POLYMERASE CHAIN REACTION ASSAY|Y|Y||CAREGIVER|MICROSCOPIST 2|NA|5|Visit_5|90|5|SCREENING|2021-01-20|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-03|P1Y2M10DT2H30M|COINCIDENT|2020-11-13|ONGOING|2021-01-05
e|RS|9eb6e591-d266-4e05-85b6-230e8a02d494|1|METSIND|Metastatic Indicator|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|Antibody Unit|iPR|1|mL/cage|BETA LACTAMASE||||INDEPENDENT ASSESSOR|UROLOGIST|N|1|Visit_1|10|3|SCREENING|2020-06-28|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-02|P1Y2M10DT2H30M|AFTER|2020-06-22|COINCIDENT|2020-07-10
e|RS|9eb6e591-d266-4e05-85b6-230e8a02d494|2|CLINRESP|Clinical Response|DOHNER AML 2010|[?]|mg/h|CR|1|mL/m2/h|AURAMINE STAIN||||ADJUDICATOR|READER 2|NA|1|Visit_1|10|1|SCREENING|2020-06-28|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-02|P1Y2M10DT2H30M|BEFORE|2020-07-28|BEFORE|2020-09-11
e|RS|9eb6e591-d266-4e05-85b6-230e8a02d494|3|NEWLWIND|New Lesion Worsening Indicator|SCHER PROSTATE CANCER 2011|[?]|cP|MORPHOLOGIC CRi|1|umol/L/min|RADIOGRAPHY|Y|||NON-HEALTH CARE PROFESSIONAL|READER 1|NA|2|Visit_2|25|6|SCREENING|2020-07-13|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-05|P1Y2M10DT2H30M|UNKNOWN|2020-07-29|BEFORE|2020-09-21
e|RS|9eb6e591-d266-4e05-85b6-230e8a02d494|4|TMRESP|Tumor Marker Response|NCIWG CHESON CLL 1996|||CYTOGENETIC MINOR RESPONSE|1|L/s|ANTIMICROBIAL COMBINATION TESTING|||Y|ADJUDICATOR|READER 1|U|2|Visit_2|25|6|TREATMENT|2020-07-13|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-05|P1Y2M10DT2H30M|AFTER|2020-08-08|COINCIDENT|2020-08-11
e|RS|9eb6e591-d266-4e05-85b6-230e8a02d494|5|TRGRESP|Target Response|MASS|[?]|VIAL|TREATMENT FAILURE|1|pg/L|PHASE-CONTRAST MRI||||CLINICAL STUDY SPONSOR|MICROSCOPIST 2|N|3|Visit_3|40|6|TREATMENT|2020-07-28|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-01|P1Y2M10DT2H30M|COINCIDENT|2020-09-03|COINCIDENT|2020-09-10
e|RS|9eb6e591-d266-4e05-85b6-230e8a02d494|6|CLINRESP|Clinical Response|RECIST 1.1|[?]|10^6/Ejaculate U|NON-CR/NON-PD|1|log10 CCID 50/dose|PHYSICAL EXAMINATION||||SPOUSE|OPTOMETRIST|U|3|Visit_3|40|4|WASHOUT|2020-07-28|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-01|P1Y2M10DT2H30M|COINCIDENT|2020-06-22|COINCIDENT|2020-07-31
e|RS|9eb6e591-d266-4e05-85b6-230e8a02d494|7|OVRLRESP|Overall Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|pptr|VGPR|1|mCi/L|PET/CT SCAN||||ADJUDICATOR|ADJUDICATOR 2|N|4|Visit_4|65|1|TREATMENT|2020-08-22|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-21|P1Y2M10DT2H30M|UNKNOWN|2020-08-27|ONGOING|2020-09-04
e|RS|9eb6e591-d266-4e05-85b6-230e8a02d494|8|NEWLIND|New Lesion Indicator|PRINCE TCELL LYMPHOMA 2010|||pCR|1|CFU/mL|PALM METHOD||Y|Y|CHILD|PATHOLOGIST|NA|4|Visit_4|65|2|SCREENING|2020-08-22|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-21|P1Y2M10DT2H30M|BEFORE|2020-09-01|ONGOING|2020-09-12
e|RS|9eb6e591-d266-4e05-85b6-230e8a02d494|9|NTRGRESP|Non-target Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|nm|cCR|1|TRANSDUCING UNIT/mL|THERMAL IONIZATION MASS SPECTROMETRY||||DOMESTIC PARTNER|DEVELOPMENTAL PSYCHOLOGIST|U|5|Visit_5|90|3|WASHOUT|2020-09-16|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-26|P1Y2M10DT2H30M|UNKNOWN|2020-09-12|AFTER|2020-09-20
e|RS|9eb6e591-d266-4e05-85b6-230e8a02d494|10|BONERESP|Bone Response|SCHWARZ CERVICAL CANCER 2009|[?]|nmol/L|CYTOGENETIC PR|1|Tesla|U-HPLC/MS/MS|Y|||PROXY|DERMATOLOGIST|U|5|Visit_5|90|5|FOLLOW-UP|2020-09-16|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-26|P1Y2M10DT2H30M|COINCIDENT|2020-08-12|ONGOING|2020-08-16
e|RS|6a6e040d-6a09-4004-9fab-f4f82ba00eae|1|NEWLPROG|New Lesion Progression|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|log10 TCID 50/dose|CMR|1|%(w/v)|TELLER ACUITY CARDS|Y|||PARENT|MICROSCOPIST 1|N|1|Visit_1|10|2|FOLLOW-UP|2020-06-30|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-16|P1Y2M10DT2H30M|BEFORE|2020-06-29|ONGOING|2020-08-25
e|RS|6a6e040d-6a09-4004-9fab-f4f82ba00eae|2|DRCRIND|Disease Recurrence Indicator|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|Frames/s|PR WITH LYMPHOCYTOSIS|1|dB|ICC||||HEALTH CARE PROFESSIONAL|RATER 2|NA|1|Visit_1|10|4|TREATMENT|2020-06-30|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-16|P1Y2M10DT2H30M|COINCIDENT|2020-07-08|COINCIDENT|2020-09-16
e|RS|6a6e040d-6a09-4004-9fab-f4f82ba00eae|3|RDIORESP|Radiologic Response|PRINCE TCELL LYMPHOMA 2010|[?]|U/g/min|CYTOGENETIC NO RESPONSE|1|pm|IMMUNE REPERTOIRE DEEP SEQUENCING||||SIGNIFICANT OTHER|RATER 1|U|2|Visit_2|25|2|WASHOUT|2020-07-15|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-28|P1Y2M10DT2H30M|AFTER|2020-07-04|COINCIDENT|2020-08-22
e|RS|6a6e040d-6a09-4004-9fab-f4f82ba00eae|4|BESTRESP|Best Overall Response|PETIT BREAST CANCER 2001|[?]|kcal|PR WITH LYMPHOCYTOSIS|1|pt_us|U-HPLC/MS/MS||||PROXY|ADJUDICATOR 3|Y|2|Visit_2|25|1|FOLLOW-UP|2020-07-15|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-28|P1Y2M10DT2H30M|UNKNOWN|2020-08-10|ONGOING|2020-08-27
e|RS|6a6e040d-6a09-4004-9fab-f4f82ba00eae|5|METSIND|Metastatic Indicator|GCIG RUSTIN OVARIAN CANCER 2011|[?]|ug/m2/day|DECREASED|1|tsp eq|LINE PROBE ASSAY|Y|||STUDY SUBJECT|RATER|U|3|Visit_3|40|4|WASHOUT|2020-07-30|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-03|P1Y2M10DT2H30M|COINCIDENT|2020-09-22|AFTER|2020-09-27
e|RS|6a6e040d-6a09-4004-9fab-f4f82ba00eae|6|CPRFSTAT|Clinical Performance Status|HARTMANN GERM CELL CANCER 2002|[?]|kg/m2|CR-CT|1|BOTTLE|GC/MS-CI||||PROXY|NEUROLOGIST 2|NA|3|Visit_3|40|2|SCREENING|2020-07-30|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-03|P1Y2M10DT2H30M|COINCIDENT|2020-09-09|BEFORE|2020-09-10
e|RS|6a6e040d-6a09-4004-9fab-f4f82ba00eae|7|SPLNRESP|Spleen Response|SCHWARZ CERVICAL CANCER 2009|[?]|mg/kg|iUPD|1|U/m2|ANALYTICAL ULTRACENTRIFUGATION|Y|||INTERVIEWER|ADJUDICATOR 3|N|4|Visit_4|65|5|SCREENING|2020-08-24|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-26|P1Y2M10DT2H30M|UNKNOWN|2020-09-22|BEFORE|2020-09-27
e|RS|6a6e040d-6a09-4004-9fab-f4f82ba00eae|8|NTERESP|Non-Target Enhancing Response|PETIT BREAST CANCER 2001|[?]|ug/L FEU|FAVORABLE RESPONSE|1|ng/day|VENTILATION PERFUSION LUNG SCAN||||PROXY|RADIOLOGIST|N|4|Visit_4|65|2|TREATMENT|2020-08-24|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-26|P1Y2M10DT2H30M|UNKNOWN|2020-08-12|BEFORE|2020-09-24
e|RS|6a6e040d-6a09-4004-9fab-f4f82ba00eae|9|TMRESP|Tumor Marker Response|IWG CHESON MDS 2000|[?]|GPL U/mL|RELAPSED DISEASE|1|hPa|LINE PROBE ASSAY||||INTERVIEWER|OPHTHALMOLOGIST|U|5|Visit_5|90|5|TREATMENT|2020-09-18|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-02|P1Y2M10DT2H30M|UNKNOWN|2020-08-12|COINCIDENT|2020-09-12
e|RS|6a6e040d-6a09-4004-9fab-f4f82ba00eae|10|CLINRESP|Clinical Response|PCWG SCHER PROSTATE CANCER 2008|[?]|mg/mL/min|cCR|1|mg/g/min|FLUORESCEIN STAIN||||CLINICAL RESEARCH COORDINATOR|HEMATOLOGIST|Y|5|Visit_5|90|7|WASHOUT|2020-09-18|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-02|P1Y2M10DT2H30M|COINCIDENT|2020-07-23|COINCIDENT|2020-07-29
e|RS|5d4845ae-b8b5-4a5d-91b9-bfd391e7829e|1|MRPHRESP|Morphologic Response|WOLCHOK SOLID TUMORS 2009|[?]|log10 TCID 50/dose|PSEUDOPROGRESSION|1|m3|NEXT GENERATION SEQUENCING||Y||NON-HEALTH CARE PROFESSIONAL|NEUROLOGIST|N|1|Visit_1|10|1|TREATMENT|2020-08-17|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-06|P1Y2M10DT2H30M|UNKNOWN|2020-08-28|ONGOING|2020-11-11
e|RS|5d4845ae-b8b5-4a5d-91b9-bfd391e7829e|2|NEWLPROG|New Lesion Progression|UNSPECIFIED|[?]|BU/mL|NED|1|ugEq/L|KINETIC MICROPARTICLE IMMUNOASSAY||||SIGNIFICANT OTHER|PATHOLOGIST 2|Y|1|Visit_1|10|6|TREATMENT|2020-08-17|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-06|P1Y2M10DT2H30M|AFTER|2020-10-21|ONGOING|2020-10-23
e|RS|5d4845ae-b8b5-4a5d-91b9-bfd391e7829e|3|NTRGRESP|Non-target Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|||QUANTIFIABLE MRD POSITIVITY|1|mg/m2/min|CONTRAST ENHANCED SPIRAL CT SCAN|||Y|CLINICAL RESEARCH COORDINATOR|RATER|N|2|Visit_2|25|3|SCREENING|2020-09-01|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-12|P1Y2M10DT2H30M|BEFORE|2020-09-13|AFTER|2020-10-06
e|RS|5d4845ae-b8b5-4a5d-91b9-bfd391e7829e|4|PATHRESP|Pathologic Response|MASS|[?]|Anson U|PD-CT|1|uU/L|ANALYTICAL ULTRACENTRIFUGATION||Y||CLINICAL RESEARCH ASSOCIATE|READER 1|Y|2|Visit_2|25|7|WASHOUT|2020-09-01|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-12|P1Y2M10DT2H30M|BEFORE|2020-08-16|ONGOING|2020-09-13
e|RS|5d4845ae-b8b5-4a5d-91b9-bfd391e7829e|5|LIVRRESP|Liver Response|MASS|[?]|10^3 CFU/mL|OPTIMAL MORPHOLOGIC RESPONSE|1|ft3|KLEIHAUER-BETKE|Y|||STUDY SUBJECT|CARDIOLOGIST|N|3|Visit_3|40|2|TREATMENT|2020-09-16|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-14|P1Y2M10DT2H30M|BEFORE|2020-10-11|ONGOING|2020-11-05
e|RS|5d4845ae-b8b5-4a5d-91b9-bfd391e7829e|6|OVRLRESP|Overall Response|IWG CHESON MDS 2006|[?]|Ejaculate U|OPTIMAL MORPHOLOGIC RESPONSE|1|Gauss|SINGLE ANTIGEN BEAD-BASED MULTIPLEX ASSAY||||STUDY SUBJECT|MICROSCOPIST 2|N|3|Visit_3|40|6|TREATMENT|2020-09-16|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-14|P1Y2M10DT2H30M|AFTER|2020-09-16|COINCIDENT|2020-09-26
e|RS|5d4845ae-b8b5-4a5d-91b9-bfd391e7829e|7|SYMPTDTR|Symptomatic Deterioration|GCIG RUSTIN OVARIAN CANCER 2011|||iCPD|1|mg|MULTIPLE-COMPLETE-DIGEST RESTRICTION FRAGMENT MAPPING|||Y|INTERVIEWER|ONCOLOGIST 1|U|4|Visit_4|65|6|WASHOUT|2020-10-11|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-22|P1Y2M10DT2H30M|COINCIDENT|2020-09-25|COINCIDENT|2020-10-21
e|RS|5d4845ae-b8b5-4a5d-91b9-bfd391e7829e|8|TMRESP|Tumor Marker Response|PROTOCOL DEFINED RESPONSE CRITERIA|||CMR|1|mol/L|MRS|||Y|DOMESTIC PARTNER|ONCOLOGIST|U|4|Visit_4|65|4|TREATMENT|2020-10-11|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-22|P1Y2M10DT2H30M|COINCIDENT|2020-10-01|ONGOING|2020-10-22
e|RS|5d4845ae-b8b5-4a5d-91b9-bfd391e7829e|9|RDIORESP|Radiologic Response|PALUMBO MULTIPLE MYELOMA 2009|[?]|fL|DISEASE TRANSFORMATION|1|copies/uL|SXA SCAN||||VENDOR|MICROSCOPIST 3|Y|5|Visit_5|90|4|TREATMENT|2020-11-05|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-23|P1Y2M10DT2H30M|COINCIDENT|2020-09-01|COINCIDENT|2020-10-08
e|RS|5d4845ae-b8b5-4a5d-91b9-bfd391e7829e|10|HEMARESP|Hematologic Response|MURPHY PROSTATE CANCER 1980|||NED|1|deg|COLORIMETRY|||Y|CLINICAL STUDY SPONSOR|RADIOLOGIST|U|5|Visit_5|90|2|SCREENING|2020-11-05|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-23|P1Y2M10DT2H30M|AFTER|2020-10-16|COINCIDENT|2020-11-03
e|RS|6c7d2865-ecfa-40fc-aae1-3d1083bc7e40|1|MJPTHIND|Major Pathological Response Indicator|HARTMANN GERM CELL CANCER 2002|[?]|mmHg|CR|1|CYLINDER|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY||||CAREGIVER|MICROSCOPIST 3|NA|1|Visit_1|10|6|FOLLOW-UP|2021-01-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-31|P1Y2M10DT2H30M|AFTER|2021-04-07|COINCIDENT|2021-04-17
e|RS|6c7d2865-ecfa-40fc-aae1-3d1083bc7e40|2|METSIND|Metastatic Indicator|CHOLLET BREAST CANCER 2002|[?]|BEAM BREAKS|MRD PERSISTENCE|1|deg/s|SPECT/CT SCAN||||SIBLING|ONCOLOGIST 1|Y|1|Visit_1|10|5|SCREENING|2021-01-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-31|P1Y2M10DT2H30M|COINCIDENT|2021-04-07|COINCIDENT|2021-04-18
e|RS|6c7d2865-ecfa-40fc-aae1-3d1083bc7e40|3|MRPHRESP|Morphologic Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|10^6 organisms/mL|MORPHOLOGIC LEUKEMIA-FREE STATE|1|PUFF|FORCED OSCILLATION TECHNIQUE|Y|Y||FAMILY MEMBER|CARDIOLOGIST|NA|2|Visit_2|25|4|TREATMENT|2021-02-03|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-02|P1Y2M10DT2H30M|BEFORE|2021-02-26|AFTER|2021-02-28
e|RS|6c7d2865-ecfa-40fc-aae1-3d1083bc7e40|4|NEWLWIND|New Lesion Worsening Indicator|LEE LUNG CANCER 2011|[?]|s/h|CA125 75% RESPONSE|1|BAR|WRIGHT STAIN||||VENDOR|DEVELOPMENTAL PSYCHOLOGIST|NA|2|Visit_2|25|7|TREATMENT|2021-02-03|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-02|P1Y2M10DT2H30M|BEFORE|2021-04-16|COINCIDENT|2021-04-18
e|RS|6c7d2865-ecfa-40fc-aae1-3d1083bc7e40|5|NTNERESP|Non-Target Non-Enhancing Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|||COMPLETE MRD RESPONSE|1|MPL U/mL|FLUORESCENT ENZYME IMMUNOASSAY||Y|Y|SPOUSE|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|3|Visit_3|40|2|WASHOUT|2021-02-18|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-28|P1Y2M10DT2H30M|AFTER|2021-03-10|ONGOING|2021-03-17
e|RS|6c7d2865-ecfa-40fc-aae1-3d1083bc7e40|6|TMRESP|Tumor Marker Response|JACINTO CERVICAL CANCER 2007|[?]|mL/cage/wk|MORPHOLOGIC LEUKEMIA-FREE STATE|1|log10 TCID 50/uL|JAEGER EYE CHART|Y|Y||PROXY|RADIOLOGIST 1|NA|3|Visit_3|40|6|TREATMENT|2021-02-18|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-28|P1Y2M10DT2H30M|AFTER|2021-03-27|AFTER|2021-04-06
e|RS|6c7d2865-ecfa-40fc-aae1-3d1083bc7e40|7|NEWLIND|New Lesion Indicator|FAROOQUI SUPP CLL 2014|[?]|CFU/g|CR-CT|1|mL/g/day|FARNSWORTH-MUNSELL 100 HUE TEST||Y||HEALTH CARE PROFESSIONAL|INTERNIST|NA|4|Visit_4|65|6|TREATMENT|2021-03-15|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-30|P1Y2M10DT2H30M|COINCIDENT|2021-01-19|COINCIDENT|2021-02-10
e|RS|6c7d2865-ecfa-40fc-aae1-3d1083bc7e40|8|TMRESP|Tumor Marker Response|IWG CHESON MDS 2006|||SD|1|IU/day|FARNSWORTH-MUNSELL 100 HUE TEST|||Y|HEALTH CARE PROFESSIONAL|FORENSIC PATHOLOGIST|NA|4|Visit_4|65|6|WASHOUT|2021-03-15|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-30|P1Y2M10DT2H30M|UNKNOWN|2021-02-28|COINCIDENT|2021-03-04
e|RS|6c7d2865-ecfa-40fc-aae1-3d1083bc7e40|9|PATHRESP|Pathologic Response|CHESON CLL 2012|[?]|SBE/mL|RELAPSED DISEASE FROM CR OR PR|1|mJoule/cm2|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY|Y|||CLINICAL STUDY SPONSOR|DEVELOPMENTAL PSYCHOLOGIST|N|5|Visit_5|90|7|TREATMENT|2021-04-09|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-05|P1Y2M10DT2H30M|AFTER|2021-02-13|AFTER|2021-04-13
e|RS|6c7d2865-ecfa-40fc-aae1-3d1083bc7e40|10|MRPHRESP|Morphologic Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|CFU/mL|NED|1|U/m2/h|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY||||PARENT|DEVELOPMENTAL PSYCHOLOGIST|U|5|Visit_5|90|2|FOLLOW-UP|2021-04-09|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-05|P1Y2M10DT2H30M|COINCIDENT|2021-01-11|COINCIDENT|2021-04-08
e|RS|81eefadb-c9b5-49c5-8bc0-3d243fc67e23|1|HEMARESP|Hematologic Response|SHINDOH COLORECTAL CANCER 2013|||MORPHOLOGIC LEUKEMIA-FREE STATE|1|APPLICATION|MICROPARTICLE ENZYME IMMUNOASSAY||Y|Y|INDEPENDENT ASSESSOR|OTOLARYNGOLOGIST|Y|1|Visit_1|10|6|TREATMENT|2020-05-12|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-26|P1Y2M10DT2H30M|BEFORE|2020-05-07|ONGOING|2020-07-30
e|RS|81eefadb-c9b5-49c5-8bc0-3d243fc67e23|2|MRDRESP|Minimal Residual Disease Response|MASS|[?]|DNA copies/mL|CMR|1|U/kg/min|RAJI CELL EIA|Y|||CAREGIVER|RATER 1|Y|1|Visit_1|10|7|SCREENING|2020-05-12|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-26|P1Y2M10DT2H30M|AFTER|2020-07-10|ONGOING|2020-07-20
e|RS|81eefadb-c9b5-49c5-8bc0-3d243fc67e23|3|NTNERESP|Non-Target Non-Enhancing Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|ng/mol|ABSENT MORPHOLOGIC RESPONSE|1|dpm/mL|NUCLEIC ACID AMPLIFICATION TEST||||HEALTH CARE PROFESSIONAL|ONCOLOGIST|NA|2|Visit_2|25|2|WASHOUT|2020-05-27|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-13|P1Y2M10DT2H30M|COINCIDENT|2020-06-06|COINCIDENT|2020-08-02
e|RS|81eefadb-c9b5-49c5-8bc0-3d243fc67e23|4|HEMARESP|Hematologic Response|JAPANESE CLASSIFICATION GASTRIC CANCER 2011|||CR-CT|1|Mile|INTERRUPTER TECHNIQUE|||Y|VENDOR|RATER 1|N|2|Visit_2|25|3|TREATMENT|2020-05-27|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-13|P1Y2M10DT2H30M|BEFORE|2020-07-12|BEFORE|2020-07-30
e|RS|81eefadb-c9b5-49c5-8bc0-3d243fc67e23|5|MRPHRESP|Morphologic Response|CHESON CLL 2006|[?]|Anson U|NON-QUANTIFIABLE MRD POSITIVITY|1|Gy|ENZYMATIC ULTRACENTRIFUGATION||||FRIEND|MICROSCOPIST 3|Y|3|Visit_3|40|7|SCREENING|2020-06-11|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-15|P1Y2M10DT2H30M|UNKNOWN|2020-07-01|BEFORE|2020-07-25
e|RS|81eefadb-c9b5-49c5-8bc0-3d243fc67e23|6|ANATRESP|Anatomic Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|USP U|PD/RELAPSE AFTER HI|1|Tbsp|TARGETED GENOME SEQUENCING|Y|||CLINICAL STUDY SPONSOR|PEDIATRIC NEUROLOGIST|N|3|Visit_3|40|6|WASHOUT|2020-06-11|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-15|P1Y2M10DT2H30M|AFTER|2020-08-05|AFTER|2020-08-07
e|RS|81eefadb-c9b5-49c5-8bc0-3d243fc67e23|7|METSIND|Metastatic Indicator|EASL BRUIX LIVER CANCER 2001|[?]|CONTAINER|MORPHOLOGIC LEUKEMIA-FREE STATE|1|/100 HPFs|OLIGO ACGH||Y||INTERVIEWER|READER|NA|4|Visit_4|65|4|TREATMENT|2020-07-06|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-29|P1Y2M10DT2H30M|COINCIDENT|2020-08-03|BEFORE|2020-08-08
e|RS|81eefadb-c9b5-49c5-8bc0-3d243fc67e23|8|RDIORESP|Radiologic Response|FAROOQUI SUPP CLL 2014|||iSD|1|10^6/Ejaculate U|X-RAY FLUORESCENCE SPECTROMETRY|Y|Y|Y|FAMILY MEMBER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|4|Visit_4|65|3|TREATMENT|2020-07-06|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-29|P1Y2M10DT2H30M|COINCIDENT|2020-06-05|COINCIDENT|2020-06-10
e|RS|81eefadb-c9b5-49c5-8bc0-3d243fc67e23|9|NTRGRESP|Non-target Response|IWG CHESON AML 2003|[?]|100 IU/mL|MRD NEGATIVITY|1|pg/dL|KINETIC CHROMOGENIC ASSAY|Y|||VENDOR|ONCOLOGIST 1|N|5|Visit_5|90|2|WASHOUT|2020-07-31|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-31|P1Y2M10DT2H30M|COINCIDENT|2020-07-04|ONGOING|2020-08-04
e|RS|81eefadb-c9b5-49c5-8bc0-3d243fc67e23|10|MOLRESP|Molecular Response|BRUGGEMANN MRD 2010|[?]|mU/g|iSD|1|SCOOPFUL|DIRECT SEQUENCING||Y||INVESTIGATOR|MICROSCOPIST|U|5|Visit_5|90|6|WASHOUT|2020-07-31|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-31|P1Y2M10DT2H30M|BEFORE|2020-07-13|BEFORE|2020-07-23
e|RS|ba99022a-d398-4c60-828c-876f119459e1|1|SPLNRESP|Spleen Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|mg/g/min|nPR|1|COAT|DOUBLE IMMUNODIFFUSION|Y|||DOMESTIC PARTNER|OPTOMETRIST|U|1|Visit_1|10|4|SCREENING|2020-12-01|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-14|P1Y2M10DT2H30M|COINCIDENT|2021-02-06|BEFORE|2021-02-19
e|RS|ba99022a-d398-4c60-828c-876f119459e1|2|DRCRIND|Disease Recurrence Indicator|PETIT BREAST CANCER 2001|||EQUIVOCAL|1|kPa/L/sec|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS||Y|Y|ADJUDICATOR|RADIOLOGIST 1|NA|1|Visit_1|10|5|TREATMENT|2020-12-01|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-14|P1Y2M10DT2H30M|COINCIDENT|2021-01-24|ONGOING|2021-02-06
e|RS|ba99022a-d398-4c60-828c-876f119459e1|3|CLINRESP|Clinical Response|RECICL|[?]|10^9 CFU/mL|FAVORABLE RESPONSE|1|10^3 copies/mL|TRANSCRIPTION-MEDIATED AMPLIFICATION||Y||CAREGIVER|ADJUDICATOR 3|U|2|Visit_2|25|5|TREATMENT|2020-12-16|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-05|P1Y2M10DT2H30M|BEFORE|2021-02-02|AFTER|2021-02-27
e|RS|ba99022a-d398-4c60-828c-876f119459e1|4|CLINRESP|Clinical Response|IRANO 2015|[?]|cd|IMMUNOPHENOTYPIC CR|1|Log10 ELISA unit|ACRIDINE ORANGE STAIN|Y|||SPOUSE|DERMATOLOGIST|NA|2|Visit_2|25|4|WASHOUT|2020-12-16|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-05|P1Y2M10DT2H30M|COINCIDENT|2021-02-28|COINCIDENT|2021-03-01
e|RS|ba99022a-d398-4c60-828c-876f119459e1|5|LIVRRESP|Liver Response|IWG CHESON MDS 2000|[?]|ELISA unit/mL|STABLE|1|TRANSDUCING UNIT/mL|PHYSICAL EXAMINATION||||FRIEND|ENDOCRINOLOGIST|NA|3|Visit_3|40|6|FOLLOW-UP|2020-12-31|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-16|P1Y2M10DT2H30M|AFTER|2021-02-07|BEFORE|2021-02-24
e|RS|ba99022a-d398-4c60-828c-876f119459e1|6|NTERESP|Non-Target Enhancing Response|RECIST 1.0|[?]|ELISA unit|SMD|1|eq|CLOT DETECTION|Y|||DOMESTIC PARTNER|RATER 2|Y|3|Visit_3|40|6|TREATMENT|2020-12-31|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-16|P1Y2M10DT2H30M|UNKNOWN|2020-12-14|ONGOING|2021-01-13
e|RS|ba99022a-d398-4c60-828c-876f119459e1|7|NEWLIND|New Lesion Indicator|JACINTO CERVICAL CANCER 2007|[?]|cm|PARTIAL MORPHOLOGIC RESPONSE|1|DISK|WESTERGREN||||HEALTH CARE PROFESSIONAL|RATER 1|NA|4|Visit_4|65|1|TREATMENT|2021-01-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-04|P1Y2M10DT2H30M|BEFORE|2020-12-23|AFTER|2021-01-27
e|RS|ba99022a-d398-4c60-828c-876f119459e1|8|BONERESP|Bone Response|EASL BRUIX LIVER CANCER 2001|[?]|mIU/L|NON-PD|1|EU|PUPILLOMETRY||||INTERVIEWER|UROLOGIST|U|4|Visit_4|65|1|TREATMENT|2021-01-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-04|P1Y2M10DT2H30M|BEFORE|2021-02-05|COINCIDENT|2021-02-06
e|RS|ba99022a-d398-4c60-828c-876f119459e1|9|MOLRESP|Molecular Response|IWG CHESON MDS 2006|||PSA PROGRESSION|1|ukat/L|ALCIAN BLUE STAIN|||Y|STUDY SUBJECT|OPTOMETRIST|NA|5|Visit_5|90|1|TREATMENT|2021-02-19|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-06|P1Y2M10DT2H30M|COINCIDENT|2021-02-12|COINCIDENT|2021-02-28
e|RS|ba99022a-d398-4c60-828c-876f119459e1|10|SFTSRESP|Soft Tissue Response|BRUGGEMANN MRD 2010|[?]|Log10 ELISA unit/dose|TREATMENT FAILURE|1|nmol/mL/min|PELLI-ROBSON EYE CHART||Y||INVESTIGATOR|FORENSIC PATHOLOGIST|NA|5|Visit_5|90|1|FOLLOW-UP|2021-02-19|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-06|P1Y2M10DT2H30M|AFTER|2021-01-15|AFTER|2021-01-22
e|RS|d713869e-061c-4e95-8a50-da2e1ec47b3c|1|ANATRESP|Anatomic Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|||PD|1|fmol/L|DIGITAL PCR|Y||Y|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 1|Y|1|Visit_1|10|7|SCREENING|2020-06-06|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-26|P1Y2M10DT2H30M|AFTER|2020-06-06|ONGOING|2020-06-15
e|RS|d713869e-061c-4e95-8a50-da2e1ec47b3c|2|MOLRESP|Molecular Response|EASL BRUIX LIVER CANCER 2001|[?]|g/cage/day|PSA PROGRESSION|1|Ci/mL|AURAMINE STAIN|Y|||SPOUSE|CLINICAL PATHOLOGIST|Y|1|Visit_1|10|1|FOLLOW-UP|2020-06-06|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-26|P1Y2M10DT2H30M|COINCIDENT|2020-06-18|BEFORE|2020-08-05
e|RS|d713869e-061c-4e95-8a50-da2e1ec47b3c|3|STRUSTAT|Steroid Use Status|DURIE MULTIPLE MYELOMA 2006|[?]|fmol/L/sec|MAJOR PATHOLOGIC RESPONSE|1|mm2|VENTILATION PERFUSION LUNG SCAN|Y|||CAREGIVER|MICROSCOPIST 1|NA|2|Visit_2|25|6|TREATMENT|2020-06-21|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-07|P1Y2M10DT2H30M|COINCIDENT|2020-06-11|ONGOING|2020-08-04
e|RS|d713869e-061c-4e95-8a50-da2e1ec47b3c|4|NEWLWIND|New Lesion Worsening Indicator|PALUMBO MULTIPLE MYELOMA 2009|[?]|10^12/L|CYTOGENETIC PR|1|cmol/L|ELISA|Y|Y||CAREGIVER|ONCOLOGIST 2|U|2|Visit_2|25|4|TREATMENT|2020-06-21|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-07|P1Y2M10DT2H30M|BEFORE|2020-07-29|COINCIDENT|2020-08-20
e|RS|d713869e-061c-4e95-8a50-da2e1ec47b3c|5|NEWLPROG|New Lesion Progression|RAJKUMAR MYELOMA 2011|[?]|%(w/w)|MRD PERSISTENCE|1|pg|QUANTITATIVE REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION||||SIBLING|PATHOLOGIST|NA|3|Visit_3|40|6|TREATMENT|2020-07-06|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-15|P1Y2M10DT2H30M|BEFORE|2020-07-10|COINCIDENT|2020-08-19
e|RS|d713869e-061c-4e95-8a50-da2e1ec47b3c|6|SPLNRESP|Spleen Response|WOLCHOK SOLID TUMORS 2009|||iCR|1|g|AUTOREFRACTION|||Y|STUDY SUBJECT|RATER|U|3|Visit_3|40|7|FOLLOW-UP|2020-07-06|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-15|P1Y2M10DT2H30M|UNKNOWN|2020-08-12|COINCIDENT|2020-08-13
e|RS|d713869e-061c-4e95-8a50-da2e1ec47b3c|7|NEWLIND|New Lesion Indicator|BOONSIRIKAMCHAI COLORECTAL CANCER 2011|[?]|mEq/ug|NON-PD|1|L/day|MYELOPEROXIDASE STAIN||Y||NON-HEALTH CARE PROFESSIONAL|PEDIATRIC NEUROLOGIST|Y|4|Visit_4|65|3|TREATMENT|2020-07-31|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-29|P1Y2M10DT2H30M|COINCIDENT|2020-06-30|AFTER|2020-08-05
e|RS|d713869e-061c-4e95-8a50-da2e1ec47b3c|8|ANATRESP|Anatomic Response|UNSPECIFIED|[?]|pmol/g|CYTOGENETIC CR|1|PIXEL|TOLUIDINE BLUE STAIN|Y|||FRIEND|NEUROLOGIST 2|NA|4|Visit_4|65|7|TREATMENT|2020-07-31|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-29|P1Y2M10DT2H30M|AFTER|2020-07-17|BEFORE|2020-07-31
e|RS|d713869e-061c-4e95-8a50-da2e1ec47b3c|9|HEMARESP|Hematologic Response|PCWG SCHER PROSTATE CANCER 2016|||MINOR PATHOLOGIC RESPONSE|1|SYRINGE|CYSTOSCOPY|||Y|PARENT|MICROSCOPIST 2|NA|5|Visit_5|90|2|WASHOUT|2020-08-25|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-23|P1Y2M10DT2H30M|BEFORE|2020-09-01|BEFORE|2020-09-02
e|RS|d713869e-061c-4e95-8a50-da2e1ec47b3c|10|NEWLPROG|New Lesion Progression|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|||RELAPSED DISEASE FROM CR|1|Ejaculate U|ELECTROPHORESIS|||Y|SIBLING|PEDIATRIC NEUROLOGIST|NA|5|Visit_5|90|5|SCREENING|2020-08-25|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-23|P1Y2M10DT2H30M|UNKNOWN|2020-08-03|ONGOING|2020-08-29
e|RS|fcebb64c-e0e6-4f29-9c52-15fa91f60018|1|RDIORESP|Radiologic Response|HARTMANN GERM CELL CANCER 2002|[?]|10^6/Ejaculate U|SD-CT|1|%|MICROBIAL CULTURE|Y|Y||CLINICAL RESEARCH ASSOCIATE|OTOLARYNGOLOGIST|Y|1|Visit_1|10|7|FOLLOW-UP|2020-07-11|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-22|P1Y2M10DT2H30M|UNKNOWN|2020-07-08|BEFORE|2020-09-16
e|RS|fcebb64c-e0e6-4f29-9c52-15fa91f60018|2|NEWLIND|New Lesion Indicator|RANO ELLINGSON 2017|[?]|cm2|MRD RELAPSE|1|mEq/uL|IMMUNE REPERTOIRE DEEP SEQUENCING||Y||DOMESTIC PARTNER|ADJUDICATOR 2|NA|1|Visit_1|10|5|TREATMENT|2020-07-11|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-22|P1Y2M10DT2H30M|UNKNOWN|2020-07-04|COINCIDENT|2020-08-13
e|RS|fcebb64c-e0e6-4f29-9c52-15fa91f60018|3|MJPTHIND|Major Pathological Response Indicator|RECICL|||SMD|1|deg/s|EPSILOMETER|||Y|CHILD|READER 1|U|2|Visit_2|25|4|FOLLOW-UP|2020-07-26|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-07|P1Y2M10DT2H30M|COINCIDENT|2020-08-24|BEFORE|2020-10-04
e|RS|fcebb64c-e0e6-4f29-9c52-15fa91f60018|4|LIVRRESP|Liver Response|MRANO VAN DEN BENT GLIOMA 2011|[?]|10^7 CFU/mL|CR|1|VIAL|PERIPHERAL ANGIOGRAPHY||||VENDOR|NEUROLOGIST 2|U|2|Visit_2|25|5|SCREENING|2020-07-26|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-07|P1Y2M10DT2H30M|BEFORE|2020-08-06|COINCIDENT|2020-08-24
e|RS|fcebb64c-e0e6-4f29-9c52-15fa91f60018|5|SPLNRESP|Spleen Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|Gy|MOLECULAR CR|1|10^11/L|CRYOSCOPY||Y||INDEPENDENT ASSESSOR|CARDIOLOGIST|N|3|Visit_3|40|5|WASHOUT|2020-08-10|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-14|P1Y2M10DT2H30M|COINCIDENT|2020-07-15|AFTER|2020-10-03
e|RS|fcebb64c-e0e6-4f29-9c52-15fa91f60018|6|SFTSRESP|Soft Tissue Response|GUILHOT CML 2007|[?]|Gy/h|PD-CT|1|/month|MICROBIAL BIOCHEMICAL IDENTIFICATION||||CAREGIVER|RADIOLOGIST 2|Y|3|Visit_3|40|5|TREATMENT|2020-08-10|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-14|P1Y2M10DT2H30M|AFTER|2020-08-10|BEFORE|2020-08-12
e|RS|fcebb64c-e0e6-4f29-9c52-15fa91f60018|7|NTRGRESP|Non-target Response|KUKER LYMPHOMA 2005|[?]|kV|MORPHOLOGIC CRi|1|ppth|WHOLE GENOME SEQUENCING||||PROXY|MICROSCOPIST|N|4|Visit_4|65|3|TREATMENT|2020-09-04|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-07|P1Y2M10DT2H30M|AFTER|2020-09-01|AFTER|2020-10-03
e|RS|fcebb64c-e0e6-4f29-9c52-15fa91f60018|8|ANATRESP|Anatomic Response|MASS|[?]|dB|SD-CT|1|PFU/mL|CYSTOMETRY|Y|||ADJUDICATION COMMITTEE|ADJUDICATOR 2|U|4|Visit_4|65|5|TREATMENT|2020-09-04|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-07|P1Y2M10DT2H30M|UNKNOWN|2020-08-14|AFTER|2020-08-19
e|RS|fcebb64c-e0e6-4f29-9c52-15fa91f60018|9|NTLWIND|Non-Target Lesion Worsening Indicator|RANO ELLINGSON 2017|[?]|Ci|MOLECULAR CR|1|10^11/L|TELLER ACUITY CARDS||Y||SIGNIFICANT OTHER|PATHOLOGIST|NA|5|Visit_5|90|1|TREATMENT|2020-09-29|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-06|P1Y2M10DT2H30M|UNKNOWN|2020-09-16|BEFORE|2020-10-02
e|RS|fcebb64c-e0e6-4f29-9c52-15fa91f60018|10|METSIND|Metastatic Indicator|MRECIST BYRNE MESOTHELIOMA 2004|[?]|pt_br|SD|1|ohm|CAPILLARY ELECTROPHORESIS||||PARENT|PHYSIOTHERAPIST|NA|5|Visit_5|90|6|TREATMENT|2020-09-29|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-06|P1Y2M10DT2H30M|UNKNOWN|2020-07-08|BEFORE|2020-08-29
e|RS|e443f82e-43a8-4710-bff4-fd2b2f4d512f|1|HEMARESP|Hematologic Response|SCHWARZ CERVICAL CANCER 2009|||PD-CT|1|MESF|ELISA||Y|Y|DOMESTIC PARTNER|DEVELOPMENTAL PSYCHOLOGIST|Y|1|Visit_1|10|4|WASHOUT|2021-01-01|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-23|P1Y2M10DT2H30M|BEFORE|2021-03-03|AFTER|2021-03-19
e|RS|e443f82e-43a8-4710-bff4-fd2b2f4d512f|2|MNPTHIND|Minor Pathological Response Indicator|DURIE MULTIPLE MYELOMA 2006|[?]|L|MORPHOLOGIC LEUKEMIA-FREE STATE|1|DISK|HPLC-UV|Y|Y||INVESTIGATOR|UROLOGIST|N|1|Visit_1|10|5|SCREENING|2021-01-01|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-23|P1Y2M10DT2H30M|UNKNOWN|2021-03-27|AFTER|2021-03-31
e|RS|e443f82e-43a8-4710-bff4-fd2b2f4d512f|3|CLINRESP|Clinical Response|HARTMANN GERM CELL CANCER 2002|[?]|PACK|HI-E|1|L/L|SIZE EXCLUSION CHROMATOGRAPHY||||STUDY SUBJECT|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|2|Visit_2|25|7|SCREENING|2021-01-16|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-22|P1Y2M10DT2H30M|AFTER|2021-02-05|AFTER|2021-02-14
e|RS|e443f82e-43a8-4710-bff4-fd2b2f4d512f|4|NTERESP|Non-Target Enhancing Response|CHOLLET BREAST CANCER 2002|[?]|10^6/Ejaculate U|ABSENT MORPHOLOGIC RESPONSE|1|mV2/Hz|CELL CYTOTOXICITY NEUTRALIZATION ASSAY||||ADJUDICATION COMMITTEE|MICROSCOPIST 2|Y|2|Visit_2|25|3|TREATMENT|2021-01-16|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-22|P1Y2M10DT2H30M|UNKNOWN|2021-03-24|BEFORE|2021-03-26
e|RS|e443f82e-43a8-4710-bff4-fd2b2f4d512f|5|BONERESP|Bone Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|L/day|NON-PD|1|g/day|HILLMEN COLOR CHART||||INTERVIEWER|UROLOGIST|NA|3|Visit_3|40|6|FOLLOW-UP|2021-01-31|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-19|P1Y2M10DT2H30M|AFTER|2021-03-03|COINCIDENT|2021-03-30
e|RS|e443f82e-43a8-4710-bff4-fd2b2f4d512f|6|MRPHRESP|Morphologic Response|SCHWARZ CERVICAL CANCER 2009|[?]|mg/m2|PD FROM PR|1|ug/day|LC/MS/MS|Y|||CLINICAL STUDY SPONSOR|UROLOGIST|Y|3|Visit_3|40|2|TREATMENT|2021-01-31|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-19|P1Y2M10DT2H30M|BEFORE|2021-02-18|COINCIDENT|2021-03-30
e|RS|e443f82e-43a8-4710-bff4-fd2b2f4d512f|7|NEWLPROG|New Lesion Progression|PERCIST|[?]|EIA unit|PDu|1|WAFER|PLETHYSMOGRAPHY||Y||HEALTH CARE PROFESSIONAL|UROLOGIST|Y|4|Visit_4|65|6|TREATMENT|2021-02-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-18|P1Y2M10DT2H30M|UNKNOWN|2021-02-21|COINCIDENT|2021-03-16
e|RS|e443f82e-43a8-4710-bff4-fd2b2f4d512f|8|HEMARESP|Hematologic Response|BLAZER COLORECTAL CANCER 2008|[?]|g/g|MOLECULAR MAJOR RESPONSE|1|mm/min|CHROMOGENIC ASSAY||||FRIEND|PATHOLOGIST|Y|4|Visit_4|65|7|FOLLOW-UP|2021-02-25|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-18|P1Y2M10DT2H30M|COINCIDENT|2021-03-27|BEFORE|2021-03-28
e|RS|e443f82e-43a8-4710-bff4-fd2b2f4d512f|9|NEWLIND|New Lesion Indicator|TSUKASAKI LEUKEMIA LYMPHOMA 2009|||CR|1|ugEq|MAGNETIC RESONANCE ELASTOGRAPHY|Y||Y|CLINICAL RESEARCH COORDINATOR|NEUROLOGIST 1|Y|5|Visit_5|90|3|TREATMENT|2021-03-22|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-15|P1Y2M10DT2H30M|AFTER|2020-12-26|AFTER|2021-02-15
e|RS|e443f82e-43a8-4710-bff4-fd2b2f4d512f|10|NEWLWIND|New Lesion Worsening Indicator|RANO ELLINGSON 2017|||RELAPSED DISEASE|1|Absorbance U/min|RADIOIMMUNOPRECIPITATION ASSAY|||Y|CLINICAL STUDY SPONSOR|PEDIATRIC NEUROLOGIST|NA|5|Visit_5|90|3|TREATMENT|2021-03-22|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-15|P1Y2M10DT2H30M|AFTER|2021-02-13|ONGOING|2021-03-08
e|RS|d9f6cfa7-1321-4e08-bf1c-8a4cba4fc57d|1|BONERESP|Bone Response|CHESON LYMPHOMA 2008|[?]|AU/mL|CYTOGENETIC CR|1|Roentgen|ERGOSPIROMETRY||Y||CLINICAL RESEARCH COORDINATOR|ONCOLOGIST 1|NA|1|Visit_1|10|7|TREATMENT|2020-06-22|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-18|P1Y2M10DT2H30M|UNKNOWN|2020-07-08|AFTER|2020-07-30
e|RS|d9f6cfa7-1321-4e08-bf1c-8a4cba4fc57d|2|HEMARESP|Hematologic Response|EASL BRUIX LIVER CANCER 2001|[?]|DPM|CHR|1|mgEq|OPTICAL COHERENCE TOMOGRAPHY||||CLINICAL STUDY SPONSOR|CLINICAL PATHOLOGIST|N|1|Visit_1|10|5|WASHOUT|2020-06-22|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-18|P1Y2M10DT2H30M|COINCIDENT|2020-08-17|AFTER|2020-09-06
e|RS|d9f6cfa7-1321-4e08-bf1c-8a4cba4fc57d|3|CLINRESP|Clinical Response|AJCC V7|[?]|COAT|CYTOGENETIC NO RESPONSE|1|ug/min|IMMUNOFLUORESCENT STAIN|Y|||GUARDIAN|ENDOCRINOLOGIST|NA|2|Visit_2|25|6|TREATMENT|2020-07-07|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-06|P1Y2M10DT2H30M|BEFORE|2020-09-11|COINCIDENT|2020-09-19
e|RS|d9f6cfa7-1321-4e08-bf1c-8a4cba4fc57d|4|NTNERESP|Non-Target Non-Enhancing Response|GUPPY OVARIAN CANCER 2002|||nPR|1|10^7 TCID 50/dose|SPIRAL CT SCAN WITHOUT CONTRAST|||Y|SIGNIFICANT OTHER|READER 1|U|2|Visit_2|25|5|SCREENING|2020-07-07|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-06|P1Y2M10DT2H30M|BEFORE|2020-07-29|BEFORE|2020-08-02
e|RS|d9f6cfa7-1321-4e08-bf1c-8a4cba4fc57d|5|MOLRESP|Molecular Response|MURPHY PROSTATE CANCER 1980|[?]|IU/kg/h|PD FROM PR|1|vg/kg|MICROBIAL CULTURE, LIQUID|Y|||CHILD|PEDIATRIC NEUROLOGIST|Y|3|Visit_3|40|1|WASHOUT|2020-07-22|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-26|P1Y2M10DT2H30M|AFTER|2020-08-02|BEFORE|2020-09-06
e|RS|d9f6cfa7-1321-4e08-bf1c-8a4cba4fc57d|6|MRDIND|Minimal Residual Disease Indicator|AJCC V8|[?]|um|PSEUDOPROGRESSION|1|g/cage/day|ELECTROMYOGRAPHY||Y||CHILD|READER 1|Y|3|Visit_3|40|5|WASHOUT|2020-07-22|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-26|P1Y2M10DT2H30M|COINCIDENT|2020-07-11|COINCIDENT|2020-08-24
e|RS|d9f6cfa7-1321-4e08-bf1c-8a4cba4fc57d|7|CYTORESP|Cytogenetic Response|BRUGGEMANN MRD 2010|[?]|Enzyme U|MINOR PATHOLOGIC RESPONSE|1|10^3 organisms/mL|RADIOGRAPHY||||FRIEND|RADIOLOGIST|NA|4|Visit_4|65|2|TREATMENT|2020-08-16|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-19|P1Y2M10DT2H30M|COINCIDENT|2020-08-23|COINCIDENT|2020-09-02
e|RS|d9f6cfa7-1321-4e08-bf1c-8a4cba4fc57d|8|NTNERESP|Non-Target Non-Enhancing Response|CHOI GIST 2008|[?]|100 IU/mL|NED|1|nL|MAMMOGRAPHY||||ADJUDICATOR|MICROSCOPIST|N|4|Visit_4|65|1|TREATMENT|2020-08-16|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-19|P1Y2M10DT2H30M|AFTER|2020-07-26|BEFORE|2020-09-08
e|RS|d9f6cfa7-1321-4e08-bf1c-8a4cba4fc57d|9|METBRESP|Metabolic Response|JACINTO CERVICAL CANCER 2007|[?]|mL/kg|CA125 50% RESPONSE|1|/HPF|MAGNETIC RESONANCE ANGIOGRAPHY||||ADJUDICATION COMMITTEE|NEUROLOGIST|Y|5|Visit_5|90|5|WASHOUT|2020-09-10|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-17|P1Y2M10DT2H30M|UNKNOWN|2020-08-20|BEFORE|2020-09-16
e|RS|d9f6cfa7-1321-4e08-bf1c-8a4cba4fc57d|10|NTNERESP|Non-Target Non-Enhancing Response|IRANO 2015|[?]|nmol/L/min|NON-iCR/NON-iUPD|1|mEq/L|CHROMOGENIC ASSAY||||GUARDIAN|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|U|5|Visit_5|90|4|WASHOUT|2020-09-10|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-17|P1Y2M10DT2H30M|COINCIDENT|2020-07-12|AFTER|2020-07-28
e|RS|8a2147b1-2deb-410e-a298-d028a5efc555|1|OVRLRESP|Overall Response|WHO BREAST CANCER 2006|[?]|nmol/L|mCR|1|CCID 50/mL|FUNDUS PHOTOGRAPHY||||ADJUDICATION COMMITTEE|READER 1|U|1|Visit_1|10|1|WASHOUT|2020-10-30|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-11|P1Y2M10DT2H30M|COINCIDENT|2020-12-04|BEFORE|2021-01-21
e|RS|8a2147b1-2deb-410e-a298-d028a5efc555|2|TMRESP|Tumor Marker Response|MONTSERRAT CLL 1989|[?]|ELISA unit/mL|DECREASED|1|ELISA unit|COMPLEMENT FIXATION||||CLINICAL RESEARCH COORDINATOR|HEMATOLOGIST|NA|1|Visit_1|10|7|TREATMENT|2020-10-30|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-11|P1Y2M10DT2H30M|COINCIDENT|2020-10-29|AFTER|2021-01-01
e|RS|8a2147b1-2deb-410e-a298-d028a5efc555|3|DRCRIND|Disease Recurrence Indicator|MRECIST BYRNE MESOTHELIOMA 2004|||CHR|1|HEP|CHROMATOGRAPHY||Y|Y|INVESTIGATOR|NEUROLOGIST|U|2|Visit_2|25|7|TREATMENT|2020-11-14|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-09|P1Y2M10DT2H30M|UNKNOWN|2020-10-27|BEFORE|2020-10-30
e|RS|8a2147b1-2deb-410e-a298-d028a5efc555|4|SPLNRESP|Spleen Response|WHO BREAST CANCER 2006|[?]|ECL unit|DECREASED|1|CIGAR|PHOTOGRAPHY|Y|Y||SIBLING|RATER 2|N|2|Visit_2|25|3|FOLLOW-UP|2020-11-14|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-11-09|P1Y2M10DT2H30M|UNKNOWN|2021-01-05|AFTER|2021-01-12
e|RS|8a2147b1-2deb-410e-a298-d028a5efc555|5|MJPTHIND|Major Pathological Response Indicator|RECIST 1.0|||SD-CT|1|FINGERTIP UNIT|MICROBIAL CONCENTRATION|Y|Y|Y|PROXY|UROLOGIST|U|3|Visit_3|40|6|TREATMENT|2020-11-29|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-17|P1Y2M10DT2H30M|BEFORE|2020-11-30|BEFORE|2020-12-12
e|RS|8a2147b1-2deb-410e-a298-d028a5efc555|6|NEWLWIND|New Lesion Worsening Indicator|iRECIST|[?]|DRINK|CMR|1|10^9 CFU/g|MAMMOGRAPHY|Y|Y||CLINICAL RESEARCH COORDINATOR|DERMATOLOGIST|Y|3|Visit_3|40|4|FOLLOW-UP|2020-11-29|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-17|P1Y2M10DT2H30M|BEFORE|2020-11-27|COINCIDENT|2020-12-02
e|RS|8a2147b1-2deb-410e-a298-d028a5efc555|7|NEWLWIND|New Lesion Worsening Indicator|MRECIST LENCIONI LIVER CANCER 2010|[?]|/100 HPFs|CYTOGENETIC MINIMAL RESPONSE|1|mL/min|JAEGER EYE CHART|Y|Y||INVESTIGATOR|READER 3|N|4|Visit_4|65|6|WASHOUT|2020-12-24|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-08|P1Y2M10DT2H30M|BEFORE|2020-12-01|BEFORE|2020-12-10
e|RS|8a2147b1-2deb-410e-a298-d028a5efc555|8|MRPHRESP|Morphologic Response|IWG CHESON MDS 2000|[?]|hr/day|iCPD|1|AgU/mL|ELECTRICAL IMPEDANCE MYOGRAPHY||||STUDY SUBJECT|RATER 2|U|4|Visit_4|65|1|TREATMENT|2020-12-24|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-08|P1Y2M10DT2H30M|AFTER|2020-11-04|ONGOING|2020-12-30
e|RS|8a2147b1-2deb-410e-a298-d028a5efc555|9|METBRESP|Metabolic Response|WHO BREAST CANCER 2006|[?]|DAgU/mL|MRD PERSISTENCE|1|/mm|CLAUSS METHOD||Y||PROXY|PATHOLOGIST 2|Y|5|Visit_5|90|5|SCREENING|2021-01-18|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-27|P1Y2M10DT2H30M|COINCIDENT|2020-11-10|ONGOING|2020-12-15
e|RS|8a2147b1-2deb-410e-a298-d028a5efc555|10|NEWLIND|New Lesion Indicator|WOLCHOK SOLID TUMORS 2009|[?]|log10 TCID 50/dose|NON-CR/NON-PD|1|CFU/mL|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY||Y||INTERVIEWER|READER 3|N|5|Visit_5|90|1|WASHOUT|2021-01-18|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-27|P1Y2M10DT2H30M|COINCIDENT|2021-01-16|ONGOING|2021-01-23
e|RS|033db3bf-17fb-4872-afdb-1eea3dac6d85|1|CLINRESP|Clinical Response|IWG CHESON MDS 2000|[?]|BOWL|NE|1|uV2|PYROSEQUENCING||||STUDY SUBJECT|PHYSIOTHERAPIST|NA|1|Visit_1|10|2|TREATMENT|2020-07-05|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-24|P1Y2M10DT2H30M|UNKNOWN|2020-07-06|BEFORE|2020-08-20
e|RS|033db3bf-17fb-4872-afdb-1eea3dac6d85|2|METSIND|Metastatic Indicator|NCCN ALL MRD 2014|[?]|mg/cm2|MOLECULAR MAJOR RESPONSE|1|ug/m2/h|PANENDOSCOPY||||CAREGIVER|ONCOLOGIST 2|NA|1|Visit_1|10|3|TREATMENT|2020-07-05|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-24|P1Y2M10DT2H30M|UNKNOWN|2020-08-19|AFTER|2020-09-17
e|RS|033db3bf-17fb-4872-afdb-1eea3dac6d85|3|CPRFSTAT|Clinical Performance Status|MRECIST LENCIONI LIVER CANCER 2010|[?]|umol|VGPR|1|ug/m2|SEQUENCE-SPECIFIC OLIGONUCLEOTIDE PROBE POLYMERASE CHAIN REACTION||||HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|Y|2|Visit_2|25|4|FOLLOW-UP|2020-07-20|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-23|P1Y2M10DT2H30M|UNKNOWN|2020-07-07|COINCIDENT|2020-09-26
e|RS|033db3bf-17fb-4872-afdb-1eea3dac6d85|4|NTLWIND|Non-Target Lesion Worsening Indicator|BURCOMBE BREAST CANCER 2005|[?]|days/wk|nPR|1|KALLIKREIN INHIBITOR UNIT|REBOUND TONOMETRY||||CAREGIVER|CLINICAL PATHOLOGIST|NA|2|Visit_2|25|6|SCREENING|2020-07-20|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-23|P1Y2M10DT2H30M|UNKNOWN|2020-09-05|AFTER|2020-10-01
e|RS|033db3bf-17fb-4872-afdb-1eea3dac6d85|5|SPLNRESP|Spleen Response|HARTMANN GERM CELL CANCER 2002|[?]|mg/animal|MR|1|mg/m2|MYELOPEROXIDASE STAIN|Y|||SIBLING|RADIOLOGIST 2|U|3|Visit_3|40|7|TREATMENT|2020-08-04|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-17|P1Y2M10DT2H30M|AFTER|2020-08-07|BEFORE|2020-08-21
e|RS|033db3bf-17fb-4872-afdb-1eea3dac6d85|6|BONERESP|Bone Response|MACDONALD GLIOMA 1990|[?]|AMPULE|CYTOGENETIC CR|1|APL U|IODINE STAIN||||INVESTIGATOR|DEVELOPMENTAL PSYCHOLOGIST|U|3|Visit_3|40|3|TREATMENT|2020-08-04|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-17|P1Y2M10DT2H30M|BEFORE|2020-09-01|COINCIDENT|2020-09-15
e|RS|033db3bf-17fb-4872-afdb-1eea3dac6d85|7|CLINRESP|Clinical Response|CHESON NON-HODGKINS LYMPHOMA 1999|[?]|AgU/mL|INDETERMINATE RESPONSE|1|mOsm|REPRESENTATIONAL OLIGONUCLEOTIDE MICROARRAY ANALYSIS||Y||INDEPENDENT ASSESSOR|OPTOMETRIST|Y|4|Visit_4|65|4|TREATMENT|2020-08-29|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-05|P1Y2M10DT2H30M|COINCIDENT|2020-08-30|COINCIDENT|2020-09-09
e|RS|033db3bf-17fb-4872-afdb-1eea3dac6d85|8|NTLWIND|Non-Target Lesion Worsening Indicator|IWG CHESON MDS 2000|[?]|ppb|STABLE|1|kN/cm2|FLUORESCENT SPOT TEST|Y|||INTERVIEWER|OPHTHALMOLOGIST|U|4|Visit_4|65|7|TREATMENT|2020-08-29|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-05|P1Y2M10DT2H30M|AFTER|2020-08-23|BEFORE|2020-09-27
e|RS|033db3bf-17fb-4872-afdb-1eea3dac6d85|9|BMIVLIND|Bone Marrow Involvement Indicator|MASS|[?]|fraction of 1|iCPD|1|cy/cm|CELL CYTOTOXICITY NEUTRALIZATION ASSAY||||STUDY SUBJECT|READER|Y|5|Visit_5|90|2|SCREENING|2020-09-23|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-06|P1Y2M10DT2H30M|UNKNOWN|2020-09-23|BEFORE|2020-09-27
e|RS|033db3bf-17fb-4872-afdb-1eea3dac6d85|10|RDIORESP|Radiologic Response|PETIT BREAST CANCER 2001|[?]|PFU/dose|RELAPSED DISEASE FROM CR OR PR|1|BAU|OPTICAL MAPPING|Y|||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST|NA|5|Visit_5|90|7|FOLLOW-UP|2020-09-23|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-06|P1Y2M10DT2H30M|UNKNOWN|2020-08-19|AFTER|2020-09-24
e|RS|e6bd8fdb-3af0-41c3-a23a-912ccd0cfce5|1|STRUSTAT|Steroid Use Status|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|TABLET|PSEUDOPROGRESSION|1|BOWL|PHOROPTER|Y|||PARENT|OPHTHALMOLOGIST|NA|1|Visit_1|10|3|WASHOUT|2020-06-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-01|P1Y2M10DT2H30M|BEFORE|2020-08-19|AFTER|2020-09-03
e|RS|e6bd8fdb-3af0-41c3-a23a-912ccd0cfce5|2|MRPHRESP|Morphologic Response|CHESON CLL 2012|||OPTIMAL MORPHOLOGIC RESPONSE|1|CIGAR|LAPAROSCOPY|||Y|ADJUDICATOR|DEVELOPMENTAL PSYCHOLOGIST|U|1|Visit_1|10|5|FOLLOW-UP|2020-06-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-01|P1Y2M10DT2H30M|UNKNOWN|2020-07-04|AFTER|2020-08-06
e|RS|e6bd8fdb-3af0-41c3-a23a-912ccd0cfce5|3|MNPTHIND|Minor Pathological Response Indicator|HARTMANN GERM CELL CANCER 2002|[?]|mV|CYTOGENETIC NO RESPONSE|1|RFU|COMPUTERIZED CORNEAL TOPOGRAPHY||||FAMILY MEMBER|OPTOMETRIST|Y|2|Visit_2|25|6|TREATMENT|2020-07-04|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-22|P1Y2M10DT2H30M|UNKNOWN|2020-07-10|ONGOING|2020-08-20
e|RS|e6bd8fdb-3af0-41c3-a23a-912ccd0cfce5|4|BESTRESP|Best Overall Response|DURIE MULTIPLE MYELOMA 2006|||PSEUDOPROGRESSION|1|PUFF|ELECTROPHORESIS|||Y|FRIEND|RATER 1|NA|2|Visit_2|25|1|FOLLOW-UP|2020-07-04|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-22|P1Y2M10DT2H30M|AFTER|2020-07-01|ONGOING|2020-07-05
e|RS|e6bd8fdb-3af0-41c3-a23a-912ccd0cfce5|5|TMRESP|Tumor Marker Response|iRECIST|[?]|g/kg/day|RELAPSED DISEASE FROM CR|1|ug/dL|SODIUM LAUREL SULFATE-METHEMOGLOBIN COMPLEX DETECTION PHOTOMETRY||||INDEPENDENT ASSESSOR|READER 1|U|3|Visit_3|40|7|TREATMENT|2020-07-19|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-24|P1Y2M10DT2H30M|UNKNOWN|2020-08-19|COINCIDENT|2020-09-12
e|RS|e6bd8fdb-3af0-41c3-a23a-912ccd0cfce5|6|CPRFSTAT|Clinical Performance Status|MURPHY PROSTATE CANCER 1980|||CYTOGENETIC PR|1|cm H2O|REBOUND TONOMETRY|||Y|GUARDIAN|MICROSCOPIST 2|N|3|Visit_3|40|3|TREATMENT|2020-07-19|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-24|P1Y2M10DT2H30M|BEFORE|2020-07-10|AFTER|2020-07-29
e|RS|e6bd8fdb-3af0-41c3-a23a-912ccd0cfce5|7|BONERESP|Bone Response|PCWG SCHER PROSTATE CANCER 2008|||CR|1|umol/min|X-RAY|||Y|SIBLING|FORENSIC PATHOLOGIST|Y|4|Visit_4|65|1|WASHOUT|2020-08-13|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-10|P1Y2M10DT2H30M|UNKNOWN|2020-08-01|COINCIDENT|2020-09-01
e|RS|e6bd8fdb-3af0-41c3-a23a-912ccd0cfce5|8|SFTSRESP|Soft Tissue Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|||HI-N|1|DRINK|DYNAMIC CONTRAST ENHANCED MRI|||Y|VENDOR|PATHOLOGIST 1|NA|4|Visit_4|65|1|TREATMENT|2020-08-13|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-10|P1Y2M10DT2H30M|COINCIDENT|2020-07-16|COINCIDENT|2020-07-23
e|RS|e6bd8fdb-3af0-41c3-a23a-912ccd0cfce5|9|ANATRESP|Anatomic Response|PCWG SCHER PROSTATE CANCER 2016|[?]|cycle/min|EQUIVOCAL|1|BU|RULER MEASUREMENT METHOD|Y|Y||INDEPENDENT ASSESSOR|ADJUDICATOR 2|U|5|Visit_5|90|4|SCREENING|2020-09-07|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-16|P1Y2M10DT2H30M|AFTER|2020-08-14|COINCIDENT|2020-08-31
e|RS|e6bd8fdb-3af0-41c3-a23a-912ccd0cfce5|10|TMRESP|Tumor Marker Response|LUGANO CLASSIFICATION|[?]|nm|PD FROM PR|1|atm|KLEIHAUER-BETKE||Y||ADJUDICATION COMMITTEE|NEUROLOGIST|Y|5|Visit_5|90|1|SCREENING|2020-09-07|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-16|P1Y2M10DT2H30M|AFTER|2020-07-09|ONGOING|2020-07-24
e|RS|8dd493b7-a892-4cab-8f69-701471c51d99|1|NEWLPROG|New Lesion Progression|SCHER PROSTATE CANCER 2011|||PSA PROGRESSION|1|vp/mL|NUCLEAR RADIOLOGY|Y|Y|Y|SIBLING|CLINICAL PATHOLOGIST|U|1|Visit_1|10|7|SCREENING|2021-01-12|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-28|P1Y2M10DT2H30M|AFTER|2021-02-18|BEFORE|2021-03-28
e|RS|8dd493b7-a892-4cab-8f69-701471c51d99|2|SYMPTDTR|Symptomatic Deterioration|MRECIST BYRNE MESOTHELIOMA 2004|[?]|cm H2O|CA125 75% RESPONSE|1|U/g Hb|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION||||GUARDIAN|ENDOCRINOLOGIST|NA|1|Visit_1|10|7|WASHOUT|2021-01-12|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-28|P1Y2M10DT2H30M|BEFORE|2021-01-31|COINCIDENT|2021-03-13
e|RS|8dd493b7-a892-4cab-8f69-701471c51d99|3|MRDRESP|Minimal Residual Disease Response|TSUKASAKI LEUKEMIA LYMPHOMA 2009|[?]|U/kg|PDu|1|amu|X-RAY FLUORESCENCE SPECTROMETRY||Y||PROXY|FORENSIC PATHOLOGIST|Y|2|Visit_2|25|2|TREATMENT|2021-01-27|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-15|P1Y2M10DT2H30M|BEFORE|2021-01-14|AFTER|2021-01-29
e|RS|8dd493b7-a892-4cab-8f69-701471c51d99|4|STRUSTAT|Steroid Use Status|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|BLOCKS|NON-PD|1|mL/cm H2O|DYNAMIC SUSCEPTIBILITY-CONTRAST MRI||||CLINICAL STUDY SPONSOR|ADJUDICATOR 1|N|2|Visit_2|25|7|SCREENING|2021-01-27|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-15|P1Y2M10DT2H30M|UNKNOWN|2021-02-24|COINCIDENT|2021-03-22
e|RS|8dd493b7-a892-4cab-8f69-701471c51d99|5|HEMARESP|Hematologic Response|IWG CHESON AML 2003|||pCR|1|mmHg|TARGETED GENOME SEQUENCING|Y|Y|Y|GUARDIAN|ONCOLOGIST 2|N|3|Visit_3|40|6|WASHOUT|2021-02-11|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-10|P1Y2M10DT2H30M|BEFORE|2021-04-02|BEFORE|2021-04-03
e|RS|8dd493b7-a892-4cab-8f69-701471c51d99|6|SFTSRESP|Soft Tissue Response|WOLCHOK SOLID TUMORS 2009|||CYTOGENETIC MINIMAL RESPONSE|1|log10 TCID 50/dose|DROPLET DIGITAL PCR|Y||Y|ADJUDICATION COMMITTEE|ADJUDICATOR 3|NA|3|Visit_3|40|5|FOLLOW-UP|2021-02-11|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-10|P1Y2M10DT2H30M|UNKNOWN|2021-02-14|COINCIDENT|2021-02-19
e|RS|8dd493b7-a892-4cab-8f69-701471c51d99|7|LIVRRESP|Liver Response|CHESON CLL 2006|||OPTIMAL MORPHOLOGIC RESPONSE|1|mCi/L|CONTRAST ENHANCED PET/CT SCAN|Y||Y|CAREGIVER|DERMATOLOGIST|Y|4|Visit_4|65|3|FOLLOW-UP|2021-03-08|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-06|P1Y2M10DT2H30M|UNKNOWN|2021-03-21|ONGOING|2021-03-24
e|RS|8dd493b7-a892-4cab-8f69-701471c51d99|8|RDIORESP|Radiologic Response|AJCC V8|[?]|Farad|RELAPSED DISEASE|1|mCi/L|FLAME PHOTOMETRY||||CHILD|READER 3|NA|4|Visit_4|65|2|SCREENING|2021-03-08|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-06|P1Y2M10DT2H30M|BEFORE|2021-01-22|ONGOING|2021-02-04
e|RS|8dd493b7-a892-4cab-8f69-701471c51d99|9|NTNERESP|Non-Target Non-Enhancing Response|WHO BREAST CANCER 2006|[?]|mL/s|IMPROVED|1|CAPLET|SCANNING ELECTRON MICROSCOPY||||CLINICAL STUDY SPONSOR|RATER 1|N|5|Visit_5|90|3|FOLLOW-UP|2021-04-02|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-10|P1Y2M10DT2H30M|UNKNOWN|2021-04-02|ONGOING|2021-04-03
e|RS|8dd493b7-a892-4cab-8f69-701471c51d99|10|MJPTHIND|Major Pathological Response Indicator|KUKER LYMPHOMA 2005|[?]|IU/kg|CA125 50% RESPONSE|1|ELISA unit|FLOCCULATION||||CLINICAL RESEARCH ASSOCIATE|CLINICAL PATHOLOGIST|NA|5|Visit_5|90|4|TREATMENT|2021-04-02|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-10|P1Y2M10DT2H30M|COINCIDENT|2021-01-21|AFTER|2021-04-03
e|RS|a13bbcb3-2c6d-4de3-a3ee-f5651042a9fa|1|BESTRESP|Best Overall Response|UNSPECIFIED|[?]|kg/m2|IMPROVED|1|pmol/10^10 cells|ATOMIC ABSORPTION SPECTROMETRY||Y||ADJUDICATION COMMITTEE|ONCOLOGIST|Y|1|Visit_1|10|1|TREATMENT|2020-11-07|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-18|P1Y2M10DT2H30M|AFTER|2020-12-11|ONGOING|2021-01-31
e|RS|a13bbcb3-2c6d-4de3-a3ee-f5651042a9fa|2|LIVRRESP|Liver Response|JACINTO CERVICAL CANCER 2007|[?]|cm/s|iUPD|1|mg/kg/dose|IMMUNO-PET SCAN|Y|||ADJUDICATOR|MICROSCOPIST 1|NA|1|Visit_1|10|2|FOLLOW-UP|2020-11-07|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-18|P1Y2M10DT2H30M|BEFORE|2020-12-25|ONGOING|2021-01-18
e|RS|a13bbcb3-2c6d-4de3-a3ee-f5651042a9fa|3|MNPTHIND|Minor Pathological Response Indicator|MRECIST BYRNE MESOTHELIOMA 2004|[?]|%/s|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|SPRAY|DYNAMIC LIGHT SCATTERING||Y||GUARDIAN|ADJUDICATOR 2|NA|2|Visit_2|25|3|TREATMENT|2020-11-22|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-12|P1Y2M10DT2H30M|AFTER|2020-12-20|COINCIDENT|2020-12-28
e|RS|a13bbcb3-2c6d-4de3-a3ee-f5651042a9fa|4|SPLNRESP|Spleen Response|CHESON MALIGNANT LYMPHOMA 2007|||MOLECULAR MAJOR RESPONSE|1|Antibody Unit|CLAUSS METHOD|Y||Y|CHILD|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|2|Visit_2|25|3|WASHOUT|2020-11-22|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-12|P1Y2M10DT2H30M|COINCIDENT|2020-11-04|BEFORE|2020-11-28
e|RS|a13bbcb3-2c6d-4de3-a3ee-f5651042a9fa|5|SFTSRESP|Soft Tissue Response|AJCC V8|[?]|BAG|INCREASED|1|ug/animal|PHASE CONTRAST MICROSCOPY||||FAMILY MEMBER|READER 1|Y|3|Visit_3|40|4|TREATMENT|2020-12-07|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-13|P1Y2M10DT2H30M|AFTER|2020-12-09|BEFORE|2020-12-31
e|RS|a13bbcb3-2c6d-4de3-a3ee-f5651042a9fa|6|METSIND|Metastatic Indicator|HARTMANN GERM CELL CANCER 2002|||MRD PERSISTENCE|1|/min|PERCUSSION|||Y|HEALTH CARE PROFESSIONAL|OPHTHALMOLOGIST|NA|3|Visit_3|40|4|WASHOUT|2020-12-07|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-13|P1Y2M10DT2H30M|UNKNOWN|2020-10-30|BEFORE|2020-11-24
e|RS|a13bbcb3-2c6d-4de3-a3ee-f5651042a9fa|7|BONERESP|Bone Response|WHO BREAST CANCER 2006|[?]|mg/kg/dose|NR|1|KIT|FUNDUS PHOTOGRAPHY|Y|Y||NON-HEALTH CARE PROFESSIONAL|PATHOLOGIST|Y|4|Visit_4|65|7|TREATMENT|2021-01-01|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-12|P1Y2M10DT2H30M|BEFORE|2020-12-18|ONGOING|2021-01-17
e|RS|a13bbcb3-2c6d-4de3-a3ee-f5651042a9fa|8|MJPTHIND|Major Pathological Response Indicator|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|||IMPROVED|1|mmol|TARGETED GENOME SEQUENCING|Y|Y|Y|INTERVIEWER|MICROSCOPIST 2|U|4|Visit_4|65|6|SCREENING|2021-01-01|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-12|P1Y2M10DT2H30M|BEFORE|2020-12-29|AFTER|2021-02-02
e|RS|a13bbcb3-2c6d-4de3-a3ee-f5651042a9fa|9|MJPTHIND|Major Pathological Response Indicator|KUKER LYMPHOMA 2005|[?]|Frames/s|PMR|1|deg/mm|PSEUDOVIRION-BASED NEUTRALIZATION ASSAY||Y||PARENT|ADJUDICATOR 2|Y|5|Visit_5|90|7|WASHOUT|2021-01-26|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-11|P1Y2M10DT2H30M|AFTER|2021-01-24|ONGOING|2021-02-01
e|RS|a13bbcb3-2c6d-4de3-a3ee-f5651042a9fa|10|ANATRESP|Anatomic Response|KUKER LYMPHOMA 2005|[?]|mEq/mL|PR-CT|1|mL/cm H2O|VIRUS PLAQUE ASSAY||||DOMESTIC PARTNER|RATER 2|N|5|Visit_5|90|2|FOLLOW-UP|2021-01-26|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-11|P1Y2M10DT2H30M|UNKNOWN|2020-11-12|ONGOING|2020-11-24
e|RS|a77d90cb-2f8e-49c7-aa09-ed432432ecc9|1|NTLWIND|Non-Target Lesion Worsening Indicator|PERCIST|[?]|10^6 CFU/g|CYTOGENETIC MINOR RESPONSE|1|nmol BCE/mmol|GEL ELECTROPHORESIS||||NON-HEALTH CARE PROFESSIONAL|ONCOLOGIST|NA|1|Visit_1|10|1|TREATMENT|2020-09-04|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-16|P1Y2M10DT2H30M|UNKNOWN|2020-10-15|COINCIDENT|2020-10-25
e|RS|a77d90cb-2f8e-49c7-aa09-ed432432ecc9|2|NTRGRESP|Non-target Response|HAMAOKA BREAST CANCER 2010|[?]|nmol/L|MORPHOLOGIC LEUKEMIA-FREE STATE|1|ug/h|IMMUNOCHEMILUMINOMETRIC ASSAY|Y|||CHILD|MICROSCOPIST 2|Y|1|Visit_1|10|3|TREATMENT|2020-09-04|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-16|P1Y2M10DT2H30M|AFTER|2020-09-16|ONGOING|2020-11-15
e|RS|a77d90cb-2f8e-49c7-aa09-ed432432ecc9|3|NTERESP|Non-Target Enhancing Response|RECIST 1.1|[?]|log10 TCID 50/dose|NON-CR/NON-PD|1|mL/sec/1.73m2|KARYOTYPING||||DOMESTIC PARTNER|READER 1|NA|2|Visit_2|25|5|SCREENING|2020-09-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-28|P1Y2M10DT2H30M|COINCIDENT|2020-09-30|ONGOING|2020-10-30
e|RS|a77d90cb-2f8e-49c7-aa09-ed432432ecc9|4|BONERESP|Bone Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|nmol/L/h|CYTOGENETIC NO RESPONSE|1|mL/cage/day|COLORIMETRY|Y|||FAMILY MEMBER|MICROSCOPIST 3|U|2|Visit_2|25|4|SCREENING|2020-09-19|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-28|P1Y2M10DT2H30M|AFTER|2020-09-05|ONGOING|2020-09-19
e|RS|a77d90cb-2f8e-49c7-aa09-ed432432ecc9|5|BONERESP|Bone Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|[?]|mkat|IMPROVED|1|MET|TARGETED TRANSCRIPTOME SEQUENCING||||FRIEND|ADJUDICATOR 3|N|3|Visit_3|40|4|SCREENING|2020-10-04|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-01|P1Y2M10DT2H30M|BEFORE|2020-10-21|AFTER|2020-11-27
e|RS|a77d90cb-2f8e-49c7-aa09-ed432432ecc9|6|MNPTHIND|Minor Pathological Response Indicator|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|||CYTOGENETIC CR|1|mmol/min/kPa|NUCLEIC ACID BASED METHOD|||Y|CLINICAL STUDY SPONSOR|OPTOMETRIST|U|3|Visit_3|40|2|WASHOUT|2020-10-04|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-01|P1Y2M10DT2H30M|COINCIDENT|2020-09-16|COINCIDENT|2020-11-12
e|RS|a77d90cb-2f8e-49c7-aa09-ed432432ecc9|7|BMIVLIND|Bone Marrow Involvement Indicator|EBMT BLADE MYELOMA 1998|[?]|EU|INDETERMINATE RESPONSE|1|/500 WBC|PET/MRI SCAN|Y|||VENDOR|PATHOLOGIST 1|N|4|Visit_4|65|7|FOLLOW-UP|2020-10-29|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-29|P1Y2M10DT2H30M|BEFORE|2020-09-02|AFTER|2020-10-18
e|RS|a77d90cb-2f8e-49c7-aa09-ed432432ecc9|8|SPLNRESP|Spleen Response|CHESON CLL 2012|[?]|SYRINGE|nPR|1|TRACE|CONTRAST ENHANCED PET SCAN||Y||INDEPENDENT ASSESSOR|ADJUDICATOR 3|N|4|Visit_4|65|1|TREATMENT|2020-10-29|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-29|P1Y2M10DT2H30M|BEFORE|2020-11-27|AFTER|2020-12-01
e|RS|a77d90cb-2f8e-49c7-aa09-ed432432ecc9|9|BMIVLIND|Bone Marrow Involvement Indicator|DURIE MULTIPLE MYELOMA 2006|[?]|MET*h|MRD RELAPSE|1|nmol BCE/mmol|PATHOLOGICAL EVALUATION||||INDEPENDENT ASSESSOR|CARDIOLOGIST|U|5|Visit_5|90|3|FOLLOW-UP|2020-11-23|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-25|P1Y2M10DT2H30M|UNKNOWN|2020-12-01|ONGOING|2020-12-02
e|RS|a77d90cb-2f8e-49c7-aa09-ed432432ecc9|10|SPLNRESP|Spleen Response|WOLCHOK SOLID TUMORS 2009|||MOLECULAR MAJOR RESPONSE|1|10^6 organisms/g|DYNAMOMETRY|||Y|FAMILY MEMBER|PEDIATRIC NEUROLOGIST|U|5|Visit_5|90|7|SCREENING|2020-11-23|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-25|P1Y2M10DT2H30M|COINCIDENT|2020-09-06|AFTER|2020-09-15
e|RS|40319f6b-5d5f-41d2-b96e-6bc8443b85e3|1|HEMARESP|Hematologic Response|PRINCE TCELL LYMPHOMA 2010|||TREATMENT FAILURE|1|ukat/L|OSCILLOMETRY|||Y|NON-HEALTH CARE PROFESSIONAL|RATER|U|1|Visit_1|10|1|TREATMENT|2020-11-20|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-13|P1Y2M10DT2H30M|AFTER|2021-01-02|ONGOING|2021-01-12
e|RS|40319f6b-5d5f-41d2-b96e-6bc8443b85e3|2|MRPHRESP|Morphologic Response|PCWG SCHER PROSTATE CANCER 2008|[?]|MASK|MORPHOLOGIC LEUKEMIA-FREE STATE|1|TRANSDUCING UNIT|GEL ELECTROPHORESIS||Y||CLINICAL STUDY SPONSOR|ADJUDICATOR 3|N|1|Visit_1|10|5|FOLLOW-UP|2020-11-20|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-13|P1Y2M10DT2H30M|AFTER|2021-01-06|BEFORE|2021-01-23
e|RS|40319f6b-5d5f-41d2-b96e-6bc8443b85e3|3|METSIND|Metastatic Indicator|MONTSERRAT CLL 1989|||CA125 50% RESPONSE|1|WEEKS|ERGOSPIROMETRY|||Y|PARENT|OPHTHALMOLOGIST|U|2|Visit_2|25|7|WASHOUT|2020-12-05|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-30|P1Y2M10DT2H30M|BEFORE|2021-01-03|COINCIDENT|2021-01-14
e|RS|40319f6b-5d5f-41d2-b96e-6bc8443b85e3|4|CPRFSTAT|Clinical Performance Status|CHESON CLL 2006|||NE|1|mL/cm3/min|PLAQUE REDUCTION NEUTRALIZATION ASSAY|Y|Y|Y|CLINICAL RESEARCH ASSOCIATE|PATHOLOGIST|U|2|Visit_2|25|3|TREATMENT|2020-12-05|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-30|P1Y2M10DT2H30M|AFTER|2021-02-16|ONGOING|2021-02-17
e|RS|40319f6b-5d5f-41d2-b96e-6bc8443b85e3|5|NTNERESP|Non-Target Non-Enhancing Response|CHOI GIST 2008|[?]|APL U/mL|INDETERMINATE RESPONSE|1|10^6/Ejaculate U|TEMPLATE INCISION METHOD||||CLINICAL RESEARCH ASSOCIATE|ENDOCRINOLOGIST|Y|3|Visit_3|40|4|SCREENING|2020-12-20|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-29|P1Y2M10DT2H30M|AFTER|2020-11-18|COINCIDENT|2020-12-11
e|RS|40319f6b-5d5f-41d2-b96e-6bc8443b85e3|6|DRCRIND|Disease Recurrence Indicator|CHOLLET BREAST CANCER 2002|[?]|mL/g/h|CYTOGENETIC CR|1|Mile|PAP STAIN|Y|||DOMESTIC PARTNER|RATER 1|N|3|Visit_3|40|4|FOLLOW-UP|2020-12-20|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-29|P1Y2M10DT2H30M|BEFORE|2021-01-31|BEFORE|2021-02-12
e|RS|40319f6b-5d5f-41d2-b96e-6bc8443b85e3|7|TMRESP|Tumor Marker Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|/month|FAVORABLE RESPONSE|1|mL/dL|IVY INCISION METHOD|Y|||SPOUSE|PATHOLOGIST|N|4|Visit_4|65|4|SCREENING|2021-01-14|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-30|P1Y2M10DT2H30M|AFTER|2021-02-04|AFTER|2021-02-15
e|RS|40319f6b-5d5f-41d2-b96e-6bc8443b85e3|8|TRGRESP|Target Response|PCWG BUBLEY PROSTATE CANCER 1999|||CR-CT|1|PELLET|PET SCAN||Y|Y|INTERVIEWER|ONCOLOGIST 2|NA|4|Visit_4|65|3|TREATMENT|2021-01-14|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-30|P1Y2M10DT2H30M|AFTER|2020-12-24|AFTER|2021-01-14
e|RS|40319f6b-5d5f-41d2-b96e-6bc8443b85e3|9|TMRESP|Tumor Marker Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|[?]|PHERESIS UNIT|HI-N|1|mmol/day|ANGIOGRAPHY||||SPOUSE|RATER|U|5|Visit_5|90|5|TREATMENT|2021-02-08|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-25|P1Y2M10DT2H30M|BEFORE|2020-11-22|COINCIDENT|2021-02-04
e|RS|40319f6b-5d5f-41d2-b96e-6bc8443b85e3|10|OVRLRESP|Overall Response|LEE LUNG CANCER 2011|||PD/RELAPSE AFTER HI|1|mL|IODINE STAIN|Y||Y|ADJUDICATION COMMITTEE|RADIOLOGIST|NA|5|Visit_5|90|1|WASHOUT|2021-02-08|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-25|P1Y2M10DT2H30M|BEFORE|2020-12-24|AFTER|2021-01-06
e|RS|b49ef90c-a17e-4554-9fa6-af72b4d56a06|1|SPLNRESP|Spleen Response|RAJKUMAR MYELOMA 2011|[?]|Frames/s|MORPHOLOGIC CRi|1|mg/kg/h|WHOLE TRANSCRIPTOME SEQUENCING||||ADJUDICATION COMMITTEE|PATHOLOGIST|Y|1|Visit_1|10|1|TREATMENT|2021-01-05|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-09|P1Y2M10DT2H30M|UNKNOWN|2021-01-01|AFTER|2021-03-28
e|RS|b49ef90c-a17e-4554-9fa6-af72b4d56a06|2|STRUSTAT|Steroid Use Status|MONTSERRAT CLL 1989|[?]|NFIU|CYTOGENETIC MINOR RESPONSE|1|genEq/mL|COMPLEMENT FIXATION||Y||DOMESTIC PARTNER|MICROSCOPIST 1|Y|1|Visit_1|10|3|WASHOUT|2021-01-05|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-09|P1Y2M10DT2H30M|BEFORE|2021-01-20|ONGOING|2021-01-24
e|RS|b49ef90c-a17e-4554-9fa6-af72b4d56a06|3|MJPTHIND|Major Pathological Response Indicator|RANO ELLINGSON 2017|[?]|Enzyme U/g Hb|iSD|1|DAYS|QUANTITATIVE ULTRASOUND||||CLINICAL RESEARCH COORDINATOR|DERMATOLOGIST|NA|2|Visit_2|25|1|FOLLOW-UP|2021-01-20|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-04|P1Y2M10DT2H30M|AFTER|2021-02-07|ONGOING|2021-03-09
e|RS|b49ef90c-a17e-4554-9fa6-af72b4d56a06|4|CLINRESP|Clinical Response|RAJKUMAR MYELOMA 2011|[?]|ug/mol|RELAPSED DISEASE FROM CR OR PR|1|uCi|EPSILOMETER||||CLINICAL STUDY SPONSOR|MICROSCOPIST 2|NA|2|Visit_2|25|5|FOLLOW-UP|2021-01-20|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-04|P1Y2M10DT2H30M|UNKNOWN|2021-01-22|AFTER|2021-01-28
e|RS|b49ef90c-a17e-4554-9fa6-af72b4d56a06|5|CYTORESP|Cytogenetic Response|FAROOQUI SUPP CLL 2014|[?]|g/mol|ABSENT MORPHOLOGIC RESPONSE|1|IU|BETA LACTAMASE|Y|Y||CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST|NA|3|Visit_3|40|2|TREATMENT|2021-02-04|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-24|P1Y2M10DT2H30M|COINCIDENT|2021-03-18|AFTER|2021-03-29
e|RS|b49ef90c-a17e-4554-9fa6-af72b4d56a06|6|RDIORESP|Radiologic Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|CONTAINER|PR|1|cm|PHOTOMETRIC CLOT DETECTION||||CHILD|PATHOLOGIST 2|U|3|Visit_3|40|4|TREATMENT|2021-02-04|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-24|P1Y2M10DT2H30M|AFTER|2021-03-18|COINCIDENT|2021-04-03
e|RS|b49ef90c-a17e-4554-9fa6-af72b4d56a06|7|BESTRESP|Best Overall Response|SHINDOH COLORECTAL CANCER 2013|||IMPROVED|1|mg/mL/day|WESTERN BLOT||Y|Y|HEALTH CARE PROFESSIONAL|RATER 2|U|4|Visit_4|65|4|TREATMENT|2021-03-01|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-28|P1Y2M10DT2H30M|BEFORE|2021-02-01|AFTER|2021-03-14
e|RS|b49ef90c-a17e-4554-9fa6-af72b4d56a06|8|NEWLWIND|New Lesion Worsening Indicator|WHO BREAST CANCER 2006|[?]|ug|CYTOGENETIC CR|1|ugEq|OPHTHALMOSCOPY||||INVESTIGATOR|CARDIOLOGIST|NA|4|Visit_4|65|5|TREATMENT|2021-03-01|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-28|P1Y2M10DT2H30M|UNKNOWN|2021-01-06|COINCIDENT|2021-01-07
e|RS|b49ef90c-a17e-4554-9fa6-af72b4d56a06|9|CYTORESP|Cytogenetic Response|LEE LUNG CANCER 2011|||mCR|1|/day|SXA SCAN|||Y|PROXY|PATHOLOGIST 1|NA|5|Visit_5|90|4|WASHOUT|2021-03-26|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-31|P1Y2M10DT2H30M|UNKNOWN|2021-01-12|BEFORE|2021-02-14
e|RS|b49ef90c-a17e-4554-9fa6-af72b4d56a06|10|RDIORESP|Radiologic Response|NCIWG CHESON CLL 1996|||CYTOGENETIC PR|1|TCID 50/dose|HEMOCYTOMETRY||Y|Y|GUARDIAN|ONCOLOGIST|U|5|Visit_5|90|6|TREATMENT|2021-03-26|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-31|P1Y2M10DT2H30M|BEFORE|2021-03-17|ONGOING|2021-04-01
e|RS|df041193-ee4e-4835-8db9-5be9b832ded0|1|RDIORESP|Radiologic Response|PERCIST|||PSEUDOPROGRESSION|1|Bq/ug|MULTIPLE BREATH WASHOUT|||Y|SPOUSE|ADJUDICATOR|N|1|Visit_1|10|7|TREATMENT|2020-11-25|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-17|P1Y2M10DT2H30M|UNKNOWN|2020-12-14|ONGOING|2021-02-01
e|RS|df041193-ee4e-4835-8db9-5be9b832ded0|2|OVRLRESP|Overall Response|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|[?]|genEq|UNEQUIVOCAL|1|m/sec|PYROSEQUENCING|Y|||CAREGIVER|MICROSCOPIST 1|Y|1|Visit_1|10|6|TREATMENT|2020-11-25|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-17|P1Y2M10DT2H30M|COINCIDENT|2021-01-01|COINCIDENT|2021-01-15
e|RS|df041193-ee4e-4835-8db9-5be9b832ded0|3|HEMARESP|Hematologic Response|GCIG RUSTIN OVARIAN CANCER 2011|[?]|uL|MRD RELAPSE|1|damol/L|PALPATION||||FAMILY MEMBER|PATHOLOGIST|U|2|Visit_2|25|7|TREATMENT|2020-12-10|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-31|P1Y2M10DT2H30M|UNKNOWN|2020-12-28|AFTER|2021-02-11
e|RS|df041193-ee4e-4835-8db9-5be9b832ded0|4|TMRESP|Tumor Marker Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|/sec|PSEUDOPROGRESSION|1|uCi|ANTIMICROBIAL COMBINATION TESTING||||INVESTIGATOR|NEUROLOGIST 1|N|2|Visit_2|25|3|TREATMENT|2020-12-10|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-12-31|P1Y2M10DT2H30M|AFTER|2021-02-12|ONGOING|2021-02-16
e|RS|df041193-ee4e-4835-8db9-5be9b832ded0|5|NEWLPROG|New Lesion Progression|iRECIST|[?]|JDF Unit|CHR|1|mol/mol|LC/MS/MS||||DOMESTIC PARTNER|ADJUDICATOR|U|3|Visit_3|40|5|TREATMENT|2020-12-25|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-08|P1Y2M10DT2H30M|BEFORE|2021-02-03|ONGOING|2021-02-05
e|RS|df041193-ee4e-4835-8db9-5be9b832ded0|6|CLINRESP|Clinical Response|iRECIST|[?]|umol/h/mmol|FAVORABLE RESPONSE|1|10^4/L|FARR ASSAY||||PARENT|UROLOGIST|Y|3|Visit_3|40|1|TREATMENT|2020-12-25|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-08|P1Y2M10DT2H30M|BEFORE|2020-12-22|AFTER|2021-01-07
e|RS|df041193-ee4e-4835-8db9-5be9b832ded0|7|BMIVLIND|Bone Marrow Involvement Indicator|MRANO VAN DEN BENT GLIOMA 2011|||MRD RELAPSE|1|U/g|HIGH RESOLUTION MELT ANALYSIS|||Y|INVESTIGATOR|DEVELOPMENTAL PSYCHOLOGIST|U|4|Visit_4|65|6|TREATMENT|2021-01-19|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-30|P1Y2M10DT2H30M|BEFORE|2020-12-10|BEFORE|2020-12-28
e|RS|df041193-ee4e-4835-8db9-5be9b832ded0|8|ANATRESP|Anatomic Response|CHOLLET BREAST CANCER 2002|[?]|BLOCKS|CYTOGENETIC NO RESPONSE|1|Henry|INTERRUPTER TECHNIQUE|Y|Y||INDEPENDENT ASSESSOR|NEUROLOGIST 1|N|4|Visit_4|65|1|FOLLOW-UP|2021-01-19|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-01-30|P1Y2M10DT2H30M|COINCIDENT|2020-11-29|COINCIDENT|2020-12-03
e|RS|df041193-ee4e-4835-8db9-5be9b832ded0|9|MRPHRESP|Morphologic Response|CHOLLET BREAST CANCER 2002|[?]|ug/m2/day|HI-E|1|/day|DOUBLE IMMUNODIFFUSION||Y||FRIEND|INTERNIST|N|5|Visit_5|90|5|WASHOUT|2021-02-13|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-25|P1Y2M10DT2H30M|AFTER|2020-12-27|COINCIDENT|2021-02-06
e|RS|df041193-ee4e-4835-8db9-5be9b832ded0|10|LIVRRESP|Liver Response|RANO ELLINGSON 2017|||SD-CT|1|10^12 IU/L|MICRO-LATEX PARTICLE-MEDIATED IMMUNOASSAY|||Y|VENDOR|HEMATOLOGIST|N|5|Visit_5|90|7|SCREENING|2021-02-13|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-25|P1Y2M10DT2H30M|COINCIDENT|2021-01-22|ONGOING|2021-01-29
e|RS|e41a4505-a5aa-4cac-895b-04fe85737ca9|1|LIVRRESP|Liver Response|SCHWARZ CERVICAL CANCER 2009|[?]|HEP|SD-CT|1|BU|WHOLE GENOME SEQUENCING||||CLINICAL RESEARCH ASSOCIATE|NEUROLOGIST|N|1|Visit_1|10|4|TREATMENT|2021-01-13|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-26|P1Y2M10DT2H30M|BEFORE|2021-01-22|AFTER|2021-01-31
e|RS|e41a4505-a5aa-4cac-895b-04fe85737ca9|2|STRUSTAT|Steroid Use Status|GCIG RUSTIN OVARIAN CANCER 2011|[?]|BLOCKS|MRD RELAPSE|1|CAPLET|APPLANATION TONOMETRY||||ADJUDICATION COMMITTEE|ONCOLOGIST|NA|1|Visit_1|10|4|TREATMENT|2021-01-13|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-26|P1Y2M10DT2H30M|COINCIDENT|2021-02-15|BEFORE|2021-02-18
e|RS|e41a4505-a5aa-4cac-895b-04fe85737ca9|3|SYMPTDTR|Symptomatic Deterioration|SCHER PROSTATE CANCER 2011|[?]|BOLUS|UNFAVORABLE RESPONSE|1|GBq/mg|BIOPSY||||ADJUDICATION COMMITTEE|READER 3|N|2|Visit_2|25|6|TREATMENT|2021-01-28|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-05|P1Y2M10DT2H30M|BEFORE|2021-04-11|COINCIDENT|2021-04-12
e|RS|e41a4505-a5aa-4cac-895b-04fe85737ca9|4|BMIVLIND|Bone Marrow Involvement Indicator|MONTSERRAT CLL 1989|||INCREASED|1|DPM|CONTRAST ENHANCED CT SCAN|Y|Y|Y|FRIEND|MICROSCOPIST|N|2|Visit_2|25|5|TREATMENT|2021-01-28|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-05|P1Y2M10DT2H30M|UNKNOWN|2021-01-27|BEFORE|2021-02-08
e|RS|e41a4505-a5aa-4cac-895b-04fe85737ca9|5|METBRESP|Metabolic Response|RECIST 1.1|||MORPHOLOGIC CR|1|MPL U|FUNCTIONAL MRI|||Y|CHILD|PHYSIOTHERAPIST|N|3|Visit_3|40|4|TREATMENT|2021-02-12|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-20|P1Y2M10DT2H30M|COINCIDENT|2021-01-12|AFTER|2021-04-09
e|RS|e41a4505-a5aa-4cac-895b-04fe85737ca9|6|NTERESP|Non-Target Enhancing Response|KEAM BREAST CANCER 2013|[?]|ng/dL|COMPLETE MRD RESPONSE|1|cy/cm|MICROBIAL CULTURE, SOLID||Y||HEALTH CARE PROFESSIONAL|MICROSCOPIST|N|3|Visit_3|40|7|TREATMENT|2021-02-12|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-20|P1Y2M10DT2H30M|BEFORE|2021-04-04|BEFORE|2021-04-10
e|RS|e41a4505-a5aa-4cac-895b-04fe85737ca9|7|BMIVLIND|Bone Marrow Involvement Indicator|SCHWARZ CERVICAL CANCER 2009|[?]|mmol/g|MORPHOLOGIC CRi|1|genEq|LISSAMINE GREEN STAIN||||FAMILY MEMBER|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|NA|4|Visit_4|65|4|FOLLOW-UP|2021-03-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-20|P1Y2M10DT2H30M|UNKNOWN|2021-02-04|AFTER|2021-02-08
e|RS|e41a4505-a5aa-4cac-895b-04fe85737ca9|8|NEWLIND|New Lesion Indicator|CHOI GIST 2008|[?]|10^6/g|CR-CT|1|10^6 CFU|PHOTOGRAPHY||Y||FAMILY MEMBER|RADIOLOGIST|N|4|Visit_4|65|5|SCREENING|2021-03-09|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-20|P1Y2M10DT2H30M|AFTER|2021-01-05|BEFORE|2021-02-25
e|RS|e41a4505-a5aa-4cac-895b-04fe85737ca9|9|ANATRESP|Anatomic Response|RECIST 1.1|[?]|SUPPOSITORY|QUANTIFIABLE MRD POSITIVITY|1|dyn|SISH||||DOMESTIC PARTNER|INTERNIST|N|5|Visit_5|90|2|WASHOUT|2021-04-03|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-19|P1Y2M10DT2H30M|COINCIDENT|2021-02-26|COINCIDENT|2021-04-08
e|RS|e41a4505-a5aa-4cac-895b-04fe85737ca9|10|MRDRESP|Minimal Residual Disease Response|CHESON CLL 2012|[?]|deg/mm|MOLECULAR MAJOR RESPONSE|1|mL/cm|RYAN BLUE STAIN|Y|||FAMILY MEMBER|RATER 1|N|5|Visit_5|90|2|FOLLOW-UP|2021-04-03|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-19|P1Y2M10DT2H30M|COINCIDENT|2021-02-13|ONGOING|2021-04-03
e|RS|64424aa7-ac36-4c85-bf35-44f8dca3ec4d|1|DRCRIND|Disease Recurrence Indicator|SACT|[?]|U/m2/min|nPR|1|cmH2O*s2/mL|SINGLE-SLICE SPIRAL CT||||INDEPENDENT ASSESSOR|ENDOCRINOLOGIST|N|1|Visit_1|10|3|SCREENING|2021-01-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-16|P1Y2M10DT2H30M|UNKNOWN|2021-01-07|BEFORE|2021-02-01
e|RS|64424aa7-ac36-4c85-bf35-44f8dca3ec4d|2|LIVRRESP|Liver Response|JUWEID NON-HODGKINS LYMPHOMA 2005|[?]|DNA copies/mL|NON-QUANTIFIABLE MRD POSITIVITY|1|Bq/kg|IMPEDANCE CONDUCTIVITY||||CHILD|PATHOLOGIST 2|N|1|Visit_1|10|4|TREATMENT|2021-01-15|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-16|P1Y2M10DT2H30M|AFTER|2021-03-16|AFTER|2021-03-28
e|RS|64424aa7-ac36-4c85-bf35-44f8dca3ec4d|3|NEWLIND|New Lesion Indicator|WHO BREAST CANCER 2006|[?]|cd|PD|1|10^6 IU/mL|IHC||Y||INVESTIGATOR|PATHOLOGIST 1|Y|2|Visit_2|25|2|FOLLOW-UP|2021-01-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-29|P1Y2M10DT2H30M|BEFORE|2021-02-21|BEFORE|2021-03-23
e|RS|64424aa7-ac36-4c85-bf35-44f8dca3ec4d|4|METSIND|Metastatic Indicator|HARTMAN PANCREATIC CANCER 2012|||COMPLETE MRD RESPONSE|1|nkat/L|KLEIHAUER-BETKE|||Y|INVESTIGATOR|ONCOLOGIST|U|2|Visit_2|25|4|TREATMENT|2021-01-30|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-29|P1Y2M10DT2H30M|BEFORE|2021-03-31|COINCIDENT|2021-04-09
e|RS|64424aa7-ac36-4c85-bf35-44f8dca3ec4d|5|NEWLWIND|New Lesion Worsening Indicator|iRECIST|||PD/RELAPSE AFTER HI|1|L/s/kPa|THICK SMEAR|||Y|ADJUDICATOR|PATHOLOGIST|N|3|Visit_3|40|3|FOLLOW-UP|2021-02-14|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-19|P1Y2M10DT2H30M|BEFORE|2021-02-22|BEFORE|2021-04-14
e|RS|64424aa7-ac36-4c85-bf35-44f8dca3ec4d|6|NTRGRESP|Non-target Response|CHESON CLL 2006|[?]|BOTTLE|SD-CT|1|kUSP|GC/MS||||FAMILY MEMBER|RADIOLOGIST 1|U|3|Visit_3|40|2|TREATMENT|2021-02-14|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-01-19|P1Y2M10DT2H30M|AFTER|2021-02-03|ONGOING|2021-02-16
e|RS|64424aa7-ac36-4c85-bf35-44f8dca3ec4d|7|TMRESP|Tumor Marker Response|EBMT BLADE MYELOMA 1998|[?]|mL/cage/day|UNFAVORABLE RESPONSE|1|Ci|KARYOTYPING|Y|||ADJUDICATION COMMITTEE|ADJUDICATOR|NA|4|Visit_4|65|1|TREATMENT|2021-03-11|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-06|P1Y2M10DT2H30M|AFTER|2021-04-06|AFTER|2021-04-14
e|RS|64424aa7-ac36-4c85-bf35-44f8dca3ec4d|8|BONERESP|Bone Response|CHESON CLL 2006|[?]|mU/g|ABSENT MORPHOLOGIC RESPONSE|1|/cmH2O|GC/MS/MS||||INDEPENDENT ASSESSOR|OPHTHALMOLOGIST|NA|4|Visit_4|65|1|TREATMENT|2021-03-11|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-04-06|P1Y2M10DT2H30M|BEFORE|2021-02-03|AFTER|2021-03-21
e|RS|64424aa7-ac36-4c85-bf35-44f8dca3ec4d|9|TMRESP|Tumor Marker Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|U/g/h|nPR|1|mL/h|PET/CT SCAN WITHOUT CONTRAST||Y||CLINICAL STUDY SPONSOR|ADJUDICATOR 3|Y|5|Visit_5|90|7|TREATMENT|2021-04-05|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-07|P1Y2M10DT2H30M|BEFORE|2021-04-07|COINCIDENT|2021-04-14
e|RS|64424aa7-ac36-4c85-bf35-44f8dca3ec4d|10|TRGRESP|Target Response|PETIT BREAST CANCER 2001|||PR|1|Ci/kg|ROMANOWSKY STAIN|||Y|CLINICAL RESEARCH COORDINATOR|ADJUDICATOR|Y|5|Visit_5|90|1|TREATMENT|2021-04-05|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-07|P1Y2M10DT2H30M|AFTER|2021-02-06|AFTER|2021-02-10
e|RS|8d572dcc-917b-463d-b8f6-2e3e888c5fb6|1|MJPTHIND|Major Pathological Response Indicator|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|||NON-QUANTIFIABLE MRD POSITIVITY|1|BAU|TRYPAN BLUE STAIN|Y||Y|CHILD|PHYSIOTHERAPIST|N|1|Visit_1|10|3|WASHOUT|2020-12-12|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-07|P1Y2M10DT2H30M|COINCIDENT|2020-12-31|COINCIDENT|2021-02-22
e|RS|8d572dcc-917b-463d-b8f6-2e3e888c5fb6|2|SPLNRESP|Spleen Response|NCCN ALL MRD 2014|||INCREASED|1|BU|INCISION-INDUCED BLEEDING METHOD|||Y|ADJUDICATOR|PEDIATRIC NEUROLOGIST|N|1|Visit_1|10|7|FOLLOW-UP|2020-12-12|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-07|P1Y2M10DT2H30M|BEFORE|2021-02-09|ONGOING|2021-02-16
e|RS|8d572dcc-917b-463d-b8f6-2e3e888c5fb6|3|CLINRESP|Clinical Response|BLAZER COLORECTAL CANCER 2008|||STABLE|1|Osm|SINGLE-SLICE SPIRAL CT|Y||Y|CHILD|NEUROLOGIST|Y|2|Visit_2|25|7|FOLLOW-UP|2020-12-27|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-22|P1Y2M10DT2H30M|BEFORE|2021-02-04|BEFORE|2021-02-12
e|RS|8d572dcc-917b-463d-b8f6-2e3e888c5fb6|4|NTLWIND|Non-Target Lesion Worsening Indicator|AJCC V7|[?]|mL/mmHg|RELAPSED DISEASE|1|mmol/L|MICRONEUTRALIZATION ASSAY||||SPOUSE|MICROSCOPIST 1|U|2|Visit_2|25|2|TREATMENT|2020-12-27|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-22|P1Y2M10DT2H30M|AFTER|2020-12-24|AFTER|2021-02-22
e|RS|8d572dcc-917b-463d-b8f6-2e3e888c5fb6|5|METBRESP|Metabolic Response|SCHER PROSTATE CANCER 2011|[?]|mg/L|CYTOGENETIC MINOR RESPONSE|1|DRINK|MULTIPLEXED OPSONOPHAGOCYTIC KILLING ASSAY||||INDEPENDENT ASSESSOR|PEDIATRIC NEUROLOGIST|N|3|Visit_3|40|5|TREATMENT|2021-01-11|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-20|P1Y2M10DT2H30M|BEFORE|2020-12-13|ONGOING|2021-03-09
e|RS|8d572dcc-917b-463d-b8f6-2e3e888c5fb6|6|TMRESP|Tumor Marker Response|EORTC OLSEN MYCOSIS FUNGOIDES AND SEZARY SYNDROME 2011|[?]|pmol/10^9 cells|CRi|1|10^11/L|ELISPOT||||DOMESTIC PARTNER|PATHOLOGIST|U|3|Visit_3|40|2|FOLLOW-UP|2021-01-11|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-12-20|P1Y2M10DT2H30M|UNKNOWN|2021-03-07|AFTER|2021-03-10
e|RS|8d572dcc-917b-463d-b8f6-2e3e888c5fb6|7|ANATRESP|Anatomic Response|WHO BREAST CANCER 2006|[?]|mg/kg/dose|RELAPSED DISEASE FROM CR OR PR|1|USP U|LIQUID SCINTILLATION COUNTING||Y||CHILD|DEVELOPMENTAL PSYCHOLOGIST|Y|4|Visit_4|65|5|WASHOUT|2021-02-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-09|P1Y2M10DT2H30M|BEFORE|2021-01-29|AFTER|2021-03-10
e|RS|8d572dcc-917b-463d-b8f6-2e3e888c5fb6|8|CYTORESP|Cytogenetic Response|iRECIST|[?]|Pack Year|HI-E|1|Watt|WHOLE GENOME SEQUENCING||||CAREGIVER|NEUROLOGIST 1|N|4|Visit_4|65|6|TREATMENT|2021-02-05|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-03-09|P1Y2M10DT2H30M|AFTER|2021-01-18|ONGOING|2021-02-12
e|RS|8d572dcc-917b-463d-b8f6-2e3e888c5fb6|9|SFTSRESP|Soft Tissue Response|PCWG BUBLEY PROSTATE CANCER 1999|[?]|g/kg|MOLECULAR CR|1|PA|JAEGER EYE CHART|Y|Y||PARENT|ADJUDICATOR 3|N|5|Visit_5|90|2|TREATMENT|2021-03-02|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-13|P1Y2M10DT2H30M|AFTER|2021-01-16|ONGOING|2021-02-07
e|RS|8d572dcc-917b-463d-b8f6-2e3e888c5fb6|10|SPLNRESP|Spleen Response|LUGANO CLASSIFICATION|[?]|pg/dL|UNEQUIVOCAL|1|ag|PANENDOSCOPY|Y|||ADJUDICATOR|ONCOLOGIST|Y|5|Visit_5|90|2|WASHOUT|2021-03-02|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-13|P1Y2M10DT2H30M|UNKNOWN|2021-03-10|BEFORE|2021-03-11
e|RS|5abbbb78-2eeb-4d21-85ac-f5d18294c603|1|MJPTHIND|Major Pathological Response Indicator|NCIWG CHESON CLL 1996|||CYTOGENETIC NO RESPONSE|1|mol/g|IMMUNOBLOT||Y|Y|CAREGIVER|INTERNIST|Y|1|Visit_1|10|6|TREATMENT|2021-01-25|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-04|P1Y2M10DT2H30M|BEFORE|2021-04-14|ONGOING|2021-04-23
e|RS|5abbbb78-2eeb-4d21-85ac-f5d18294c603|2|NEWLWIND|New Lesion Worsening Indicator|AJCC V8|[?]|WEEKS|OPTIMAL MORPHOLOGIC RESPONSE|1|hPa|WRIGHT STAIN|Y|||CHILD|NEUROLOGIST 1|NA|1|Visit_1|10|1|SCREENING|2021-01-25|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-04|P1Y2M10DT2H30M|AFTER|2021-04-06|COINCIDENT|2021-04-24
e|RS|5abbbb78-2eeb-4d21-85ac-f5d18294c603|3|MNPTHIND|Minor Pathological Response Indicator|BRUGGEMANN MRD 2010|[?]|kBq|INCREASED|1|mg|MAMMOGRAPHY||||HEALTH CARE PROFESSIONAL|READER 2|Y|2|Visit_2|25|5|SCREENING|2021-02-09|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-12|P1Y2M10DT2H30M|UNKNOWN|2021-01-27|COINCIDENT|2021-02-22
e|RS|5abbbb78-2eeb-4d21-85ac-f5d18294c603|4|TMRESP|Tumor Marker Response|PERCIST|||MR|1|/500 WBC|NUCLEAR RADIOLOGY|||Y|INDEPENDENT ASSESSOR|RADIOLOGIST 1|NA|2|Visit_2|25|3|TREATMENT|2021-02-09|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-12|P1Y2M10DT2H30M|AFTER|2021-02-04|COINCIDENT|2021-04-08
e|RS|5abbbb78-2eeb-4d21-85ac-f5d18294c603|5|SYMPTDTR|Symptomatic Deterioration|RECIST 1.1|[?]|EVENTS|UNEQUIVOCAL|1|10^9 organisms/mL|QUANTITATIVE PERIPHERAL ANGIOGRAPHY|Y|Y||FAMILY MEMBER|FORENSIC PATHOLOGIST|Y|3|Visit_3|40|6|TREATMENT|2021-02-24|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-26|P1Y2M10DT2H30M|AFTER|2021-03-19|ONGOING|2021-04-16
e|RS|5abbbb78-2eeb-4d21-85ac-f5d18294c603|6|NTERESP|Non-Target Enhancing Response|FAROOQUI SUPP CLL 2014|[?]|fg|SD|1|uEq/L|MICROBIAL CONCENTRATION|Y|||FAMILY MEMBER|FORENSIC PATHOLOGIST|N|3|Visit_3|40|5|SCREENING|2021-02-24|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2021-02-26|P1Y2M10DT2H30M|AFTER|2021-03-07|ONGOING|2021-03-28
e|RS|5abbbb78-2eeb-4d21-85ac-f5d18294c603|7|NEWLPROG|New Lesion Progression|EASL BRUIX LIVER CANCER 2001|||MOLECULAR CR|1|mL/h|OPTICAL MAPPING||Y|Y|SPOUSE|ONCOLOGIST 1|N|4|Visit_4|65|2|TREATMENT|2021-03-21|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-14|P1Y2M10DT2H30M|UNKNOWN|2021-03-18|ONGOING|2021-04-09
e|RS|5abbbb78-2eeb-4d21-85ac-f5d18294c603|8|SPLNRESP|Spleen Response|DURIE MULTIPLE MYELOMA 2006|[?]|SQU/mL|IMPROVED|1|INHALATION|DOUBLE IMMUNODIFFUSION|Y|||INTERVIEWER|RATER|Y|4|Visit_4|65|4|SCREENING|2021-03-21|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-03-14|P1Y2M10DT2H30M|BEFORE|2021-01-27|BEFORE|2021-04-01
e|RS|5abbbb78-2eeb-4d21-85ac-f5d18294c603|9|TRGRESP|Target Response|MRECIST BYRNE MESOTHELIOMA 2004|||nPR|1|anti-Xa IU/mL|POLYGRAPHY|Y||Y|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|Y|5|Visit_5|90|5|TREATMENT|2021-04-15|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-04|P1Y2M10DT2H30M|AFTER|2021-02-12|COINCIDENT|2021-02-22
e|RS|5abbbb78-2eeb-4d21-85ac-f5d18294c603|10|OVRLRESP|Overall Response|BLAZER COLORECTAL CANCER 2008|[?]|uV*sec|iCPD|1|Gy/h|HIGH LEVEL AMINOGLYCOSIDE SCREEN||Y||CLINICAL STUDY SPONSOR|RADIOLOGIST 1|U|5|Visit_5|90|4|SCREENING|2021-04-15|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2021-02-04|P1Y2M10DT2H30M|AFTER|2021-03-27|COINCIDENT|2021-04-14
e|RS|109fe46d-ac1f-47fe-8ecb-6049a577d38c|1|SYMPTDTR|Symptomatic Deterioration|GCIG RUSTIN OVARIAN CANCER 2011|[?]|BAU|UNEQUIVOCAL|1|CIGAR|MICRODENSITOMETRY||||INVESTIGATOR|PATHOLOGIST 2|U|1|Visit_1|10|1|TREATMENT|2020-05-20|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-06|P1Y2M10DT2H30M|COINCIDENT|2020-07-23|BEFORE|2020-08-08
e|RS|109fe46d-ac1f-47fe-8ecb-6049a577d38c|2|STRUSTAT|Steroid Use Status|AJCC V7|[?]|dmol|PSA PROGRESSION|1|cmH2O*s2/mL|NO INFORMATION||||DOMESTIC PARTNER|PATHOLOGIST|N|1|Visit_1|10|4|SCREENING|2020-05-20|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-06|P1Y2M10DT2H30M|UNKNOWN|2020-07-29|COINCIDENT|2020-08-14
e|RS|109fe46d-ac1f-47fe-8ecb-6049a577d38c|3|OVRLRESP|Overall Response|LUGANO CLASSIFICATION|[?]|dmol|cCR|1|cup eq|MAGNETIC RESONANCE CHOLANGIOPANCREATOGRAPHY||Y||ADJUDICATION COMMITTEE|ONCOLOGIST|Y|2|Visit_2|25|7|SCREENING|2020-06-04|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-28|P1Y2M10DT2H30M|COINCIDENT|2020-05-22|COINCIDENT|2020-05-30
e|RS|109fe46d-ac1f-47fe-8ecb-6049a577d38c|4|NEWLPROG|New Lesion Progression|IWG CHESON MDS 2000|[?]|L/s|PMD|1|ng|IMMUNOBLOT|Y|||INVESTIGATOR|PHYSIOTHERAPIST|N|2|Visit_2|25|7|FOLLOW-UP|2020-06-04|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-28|P1Y2M10DT2H30M|COINCIDENT|2020-06-04|BEFORE|2020-08-08
e|RS|109fe46d-ac1f-47fe-8ecb-6049a577d38c|5|NTERESP|Non-Target Enhancing Response|MINKOV LANGERHANS CELL HISTIOCYTOSIS 2009|||PD-CT|1|10^9 organisms/mL|MALDI|Y|Y|Y|FRIEND|PATHOLOGIST 1|N|3|Visit_3|40|2|TREATMENT|2020-06-19|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-07|P1Y2M10DT2H30M|COINCIDENT|2020-08-10|BEFORE|2020-08-14
e|RS|109fe46d-ac1f-47fe-8ecb-6049a577d38c|6|SYMPTDTR|Symptomatic Deterioration|WHO BREAST CANCER 2006|[?]|mg/kg|DECREASED|1|mL/g/h|MEDIASTINOSCOPY||||CLINICAL STUDY SPONSOR|MICROSCOPIST 3|N|3|Visit_3|40|1|TREATMENT|2020-06-19|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-08-07|P1Y2M10DT2H30M|AFTER|2020-06-28|ONGOING|2020-07-07
e|RS|109fe46d-ac1f-47fe-8ecb-6049a577d38c|7|METSIND|Metastatic Indicator|WHO BREAST CANCER 2006|[?]|nmol/L/min|UNFAVORABLE RESPONSE|1|lm|NEXT GENERATION SEQUENCING||||INVESTIGATOR|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|4|Visit_4|65|1|TREATMENT|2020-07-14|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-23|P1Y2M10DT2H30M|AFTER|2020-07-01|ONGOING|2020-08-07
e|RS|109fe46d-ac1f-47fe-8ecb-6049a577d38c|8|NEWLPROG|New Lesion Progression|AJCC V7|||NR|1|mmol2/L2|MULTIPLEX LIGATION-DEPENDENT PROBE AMPLIFICATION|Y||Y|CLINICAL RESEARCH COORDINATOR|RATER|Y|4|Visit_4|65|5|WASHOUT|2020-07-14|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-23|P1Y2M10DT2H30M|UNKNOWN|2020-07-15|COINCIDENT|2020-07-23
e|RS|109fe46d-ac1f-47fe-8ecb-6049a577d38c|9|MJPTHIND|Major Pathological Response Indicator|MRANO VAN DEN BENT GLIOMA 2011|[?]|10^6 CFU/mL|IMMUNOPHENOTYPIC CR|1|% INHIBITION|MULTIPLEXED DIGITAL GENE EXPRESSION ANALYSIS|Y|||FRIEND|RATER 1|N|5|Visit_5|90|5|TREATMENT|2020-08-08|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-22|P1Y2M10DT2H30M|COINCIDENT|2020-06-13|AFTER|2020-08-01
e|RS|109fe46d-ac1f-47fe-8ecb-6049a577d38c|10|NTNERESP|Non-Target Non-Enhancing Response|KUKER LYMPHOMA 2005|[?]|g/animal/day|WORSENED|1|BOWL|PERCUSSION||||CHILD|DERMATOLOGIST|U|5|Visit_5|90|1|WASHOUT|2020-08-08|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-22|P1Y2M10DT2H30M|AFTER|2020-07-18|AFTER|2020-08-06
e|RS|cdb18d0a-5fca-4437-9b6e-0e46b0930521|1|NTLWIND|Non-Target Lesion Worsening Indicator|KEAM BREAST CANCER 2013|[?]|cP|OPTIMAL MORPHOLOGIC RESPONSE|1|hPa|NUCLEAR RADIOLOGY||||SPOUSE|RATER 2|Y|1|Visit_1|10|3|WASHOUT|2020-09-03|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-06|P1Y2M10DT2H30M|UNKNOWN|2020-09-26|BEFORE|2020-11-17
e|RS|cdb18d0a-5fca-4437-9b6e-0e46b0930521|2|MRDRESP|Minimal Residual Disease Response|BURCOMBE BREAST CANCER 2005|[?]|mEq/kg|OPTIMAL MORPHOLOGIC RESPONSE|1|CONTAINER|PET/CT SCAN||||INTERVIEWER|ONCOLOGIST 1|Y|1|Visit_1|10|4|TREATMENT|2020-09-03|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-11-06|P1Y2M10DT2H30M|AFTER|2020-09-21|ONGOING|2020-11-07
e|RS|cdb18d0a-5fca-4437-9b6e-0e46b0930521|3|CPRFSTAT|Clinical Performance Status|KEAM BREAST CANCER 2013|[?]|mL/m2/min|MR|1|WEEKS|MICROBIAL CULTURE, LIQUID||||SIBLING|OPTOMETRIST|N|2|Visit_2|25|3|WASHOUT|2020-09-18|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-04|P1Y2M10DT2H30M|COINCIDENT|2020-10-16|COINCIDENT|2020-11-13
e|RS|cdb18d0a-5fca-4437-9b6e-0e46b0930521|4|MRPHRESP|Morphologic Response|JACINTO CERVICAL CANCER 2007|[?]|fmol/L/sec|MOLECULAR CR|1|mEq/L|IMMUNOASSAY||Y||INVESTIGATOR|ADJUDICATOR|U|2|Visit_2|25|2|TREATMENT|2020-09-18|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-04|P1Y2M10DT2H30M|COINCIDENT|2020-09-16|ONGOING|2020-10-01
e|RS|cdb18d0a-5fca-4437-9b6e-0e46b0930521|5|RDIORESP|Radiologic Response|PROTOCOL DEFINED RESPONSE CRITERIA|[?]|PFU/dose|DISEASE TRANSFORMATION|1|10^6/Ejaculate U|GEL ELECTROPHORESIS|Y|||SIGNIFICANT OTHER|RADIOLOGIST 2|Y|3|Visit_3|40|4|TREATMENT|2020-10-03|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-19|P1Y2M10DT2H30M|COINCIDENT|2020-10-06|COINCIDENT|2020-11-23
e|RS|cdb18d0a-5fca-4437-9b6e-0e46b0930521|6|MJPTHIND|Major Pathological Response Indicator|KUKER LYMPHOMA 2005|[?]|10^5/hpf|MORPHOLOGIC CR|1|nkat|PET/CT SCAN||||PARENT|ONCOLOGIST|N|3|Visit_3|40|4|TREATMENT|2020-10-03|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-19|P1Y2M10DT2H30M|BEFORE|2020-09-29|ONGOING|2020-11-28
e|RS|cdb18d0a-5fca-4437-9b6e-0e46b0930521|7|SFTSRESP|Soft Tissue Response|BLAZER COLORECTAL CANCER 2008|[?]|L/day|WORSENED|1|mg|CONTRAST ENHANCED CT SCAN||Y||FRIEND|RADIOLOGIST 2|Y|4|Visit_4|65|3|TREATMENT|2020-10-28|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-17|P1Y2M10DT2H30M|UNKNOWN|2020-11-08|BEFORE|2020-11-19
e|RS|cdb18d0a-5fca-4437-9b6e-0e46b0930521|8|MNPTHIND|Minor Pathological Response Indicator|KIMBY WALDENSTROMS MACROGLOBULINEMIA 2006|||TREATMENT FAILURE|1|mL/g/min|LIQUID SCINTILLATION COUNTING|||Y|INVESTIGATOR|PHYSIOTHERAPIST|Y|4|Visit_4|65|6|FOLLOW-UP|2020-10-28|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-17|P1Y2M10DT2H30M|UNKNOWN|2020-11-14|ONGOING|2020-11-29
e|RS|cdb18d0a-5fca-4437-9b6e-0e46b0930521|9|CLINRESP|Clinical Response|CHESON CLL 2006|||SD-CT|1|Absorbance U/mL|AMSLER GRID|||Y|INTERVIEWER|READER 3|NA|5|Visit_5|90|2|TREATMENT|2020-11-22|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-15|P1Y2M10DT2H30M|BEFORE|2020-09-09|AFTER|2020-11-22
e|RS|cdb18d0a-5fca-4437-9b6e-0e46b0930521|10|MJPTHIND|Major Pathological Response Indicator|CHOI GIST 2008|||CYTOGENETIC MINOR RESPONSE|1|mL|PHOTOMETRIC CLOT DETECTION|||Y|FAMILY MEMBER|PEDIATRIC NEUROLOGIST|NA|5|Visit_5|90|1|SCREENING|2020-11-22|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-15|P1Y2M10DT2H30M|COINCIDENT|2020-10-21|BEFORE|2020-11-20
e|RS|e515b916-5d28-4236-8835-2ff43b498ab3|1|METSIND|Metastatic Indicator|HARTMANN GERM CELL CANCER 2002|[?]|PLUG|MORPHOLOGIC LEUKEMIA-FREE STATE|1|Siemens|IMPULSE OSCILLOMETRY||||GUARDIAN|INTERNIST|NA|1|Visit_1|10|4|TREATMENT|2020-05-23|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-01|P1Y2M10DT2H30M|UNKNOWN|2020-05-24|ONGOING|2020-06-19
e|RS|e515b916-5d28-4236-8835-2ff43b498ab3|2|NTLWIND|Non-Target Lesion Worsening Indicator|TSUKASAKI LEUKEMIA LYMPHOMA 2009|||SD|1|ug/kg/h|LISSAMINE GREEN STAIN|||Y|HEALTH CARE PROFESSIONAL|ONCOLOGIST 1|U|1|Visit_1|10|3|TREATMENT|2020-05-23|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-01|P1Y2M10DT2H30M|AFTER|2020-05-30|COINCIDENT|2020-07-21
e|RS|e515b916-5d28-4236-8835-2ff43b498ab3|3|NTRGRESP|Non-target Response|CHESON NON-HODGKINS HODGKINS LYMPHOMA 1993|[?]|LB|PARTIAL MORPHOLOGIC RESPONSE|1|mEq/mmol|KINETIC CHROMOGENIC ASSAY||||CLINICAL STUDY SPONSOR|ADJUDICATOR 3|Y|2|Visit_2|25|5|SCREENING|2020-06-07|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-29|P1Y2M10DT2H30M|UNKNOWN|2020-06-28|ONGOING|2020-07-05
e|RS|e515b916-5d28-4236-8835-2ff43b498ab3|4|METBRESP|Metabolic Response|WOLCHOK SOLID TUMORS 2009|[?]|MESF|CYTOGENETIC MINIMAL RESPONSE|1|fmol/g|ELECTRONEUROGRAPHY|Y|Y||SIBLING|RADIOLOGIST 1|U|2|Visit_2|25|6|TREATMENT|2020-06-07|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-29|P1Y2M10DT2H30M|BEFORE|2020-05-16|ONGOING|2020-07-29
e|RS|e515b916-5d28-4236-8835-2ff43b498ab3|5|NEWLPROG|New Lesion Progression|EBMT BLADE MYELOMA 1998|[?]|Bq/L|DISEASE TRANSFORMATION|1|GBq/ug|DOUBLE IMMUNODIFFUSION||||SPOUSE|MICROSCOPIST 2|U|3|Visit_3|40|3|TREATMENT|2020-06-22|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-21|P1Y2M10DT2H30M|COINCIDENT|2020-06-17|COINCIDENT|2020-07-11
e|RS|e515b916-5d28-4236-8835-2ff43b498ab3|6|BESTRESP|Best Overall Response|EASL BRUIX LIVER CANCER 2001|[?]|mEq/g|PR WITH LYMPHOCYTOSIS|1|IU|CONTRAST ENHANCED X-RAY||||CHILD|DERMATOLOGIST|U|3|Visit_3|40|4|TREATMENT|2020-06-22|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-21|P1Y2M10DT2H30M|BEFORE|2020-06-21|ONGOING|2020-08-11
e|RS|e515b916-5d28-4236-8835-2ff43b498ab3|7|MNPTHIND|Minor Pathological Response Indicator|RANO ELLINGSON 2017|[?]|mEq/g|UNFAVORABLE RESPONSE|1|mol|RADIOIMMUNOPRECIPITATION ASSAY|Y|||CHILD|RATER 2|NA|4|Visit_4|65|3|TREATMENT|2020-07-17|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-11|P1Y2M10DT2H30M|COINCIDENT|2020-05-19|ONGOING|2020-06-27
e|RS|e515b916-5d28-4236-8835-2ff43b498ab3|8|TMRESP|Tumor Marker Response|PALUMBO MULTIPLE MYELOMA 2009|||MOLECULAR CR|1|10^3 CFU|CT SCAN WITHOUT CONTRAST|||Y|DOMESTIC PARTNER|ONCOLOGIST|U|4|Visit_4|65|1|TREATMENT|2020-07-17|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-11|P1Y2M10DT2H30M|BEFORE|2020-08-11|COINCIDENT|2020-08-19
e|RS|e515b916-5d28-4236-8835-2ff43b498ab3|9|MJPTHIND|Major Pathological Response Indicator|KUKER LYMPHOMA 2005|[?]|g/cage|pCR|1|pptr|IMMUNOMAGNETIC FLUORESCENCE MICROSCOPY|Y|||ADJUDICATION COMMITTEE|PATHOLOGIST 1|N|5|Visit_5|90|7|WASHOUT|2020-08-11|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-17|P1Y2M10DT2H30M|UNKNOWN|2020-06-21|COINCIDENT|2020-07-02
e|RS|e515b916-5d28-4236-8835-2ff43b498ab3|10|SPLNRESP|Spleen Response|PRINCE TCELL LYMPHOMA 2010|[?]|NFIU|IMMUNOPHENOTYPIC CR|1|IU/mg|PET/CT SCAN WITHOUT CONTRAST||||FRIEND|ADJUDICATOR 3|NA|5|Visit_5|90|5|TREATMENT|2020-08-11|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-06-17|P1Y2M10DT2H30M|COINCIDENT|2020-05-28|AFTER|2020-06-10
e|RS|158af2a8-d447-45e5-8c58-3b950f1bd889|1|NTLWIND|Non-Target Lesion Worsening Indicator|IWG CHESON MDS 2000|||iCPD|1|cy/cm|MALDI-TOF|Y||Y|FAMILY MEMBER|PATHOLOGIST|N|1|Visit_1|10|4|SCREENING|2020-05-30|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-27|P1Y2M10DT2H30M|BEFORE|2020-06-26|ONGOING|2020-08-08
e|RS|158af2a8-d447-45e5-8c58-3b950f1bd889|2|METBRESP|Metabolic Response|BRUGGEMANN MRD 2010|||PSEUDORESPONSE|1|IU|IVY INCISION METHOD|||Y|GUARDIAN|RADIOLOGIST 2|NA|1|Visit_1|10|6|TREATMENT|2020-05-30|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-27|P1Y2M10DT2H30M|AFTER|2020-06-02|BEFORE|2020-08-25
e|RS|158af2a8-d447-45e5-8c58-3b950f1bd889|3|LIVRRESP|Liver Response|MRECIST BYRNE MESOTHELIOMA 2004|[?]|ug/kg|STABLE|1|Tesla|CLINICAL EVALUATION||||PARENT|READER 1|NA|2|Visit_2|25|3|FOLLOW-UP|2020-06-14|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-12|P1Y2M10DT2H30M|COINCIDENT|2020-06-10|BEFORE|2020-08-27
e|RS|158af2a8-d447-45e5-8c58-3b950f1bd889|4|LIVRRESP|Liver Response|HAMAOKA BREAST CANCER 2010|[?]|nU/cL|CR-CT|1|mL/kg/h|REVERSE TRANSCRIPTASE PCR||Y||ADJUDICATOR|PATHOLOGIST|U|2|Visit_2|25|3|TREATMENT|2020-06-14|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-12|P1Y2M10DT2H30M|UNKNOWN|2020-06-16|COINCIDENT|2020-08-22
e|RS|158af2a8-d447-45e5-8c58-3b950f1bd889|5|ANATRESP|Anatomic Response|PCWG SCHER PROSTATE CANCER 2008|[?]|mm2|CA125 75% RESPONSE|1|amol|BALLPOINT PEN TECHNIQUE||||SIBLING|ONCOLOGIST 1|Y|3|Visit_3|40|4|TREATMENT|2020-06-29|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-26|P1Y2M10DT2H30M|COINCIDENT|2020-07-13|AFTER|2020-08-01
e|RS|158af2a8-d447-45e5-8c58-3b950f1bd889|6|SYMPTDTR|Symptomatic Deterioration|GUILHOT CML 2007|[?]|log10 copies/mL|cPR|1|g/animal|LASER CAPTURE MICRODISSECTION|Y|||DOMESTIC PARTNER|ONCOLOGIST|N|3|Visit_3|40|1|TREATMENT|2020-06-29|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-05-26|P1Y2M10DT2H30M|AFTER|2020-08-23|BEFORE|2020-08-26
e|RS|158af2a8-d447-45e5-8c58-3b950f1bd889|7|TMRESP|Tumor Marker Response|EBMT BLADE MYELOMA 1998|||PMD|1|GPS U|IMMUNOTURBIDIMETRY|Y||Y|INDEPENDENT ASSESSOR|ONCOLOGIST 2|NA|4|Visit_4|65|4|TREATMENT|2020-07-24|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-31|P1Y2M10DT2H30M|COINCIDENT|2020-07-22|AFTER|2020-08-21
e|RS|158af2a8-d447-45e5-8c58-3b950f1bd889|8|PATHRESP|Pathologic Response|MACDONALD GLIOMA 1990|||iPR|1|mol/mol|QUANTITATIVE PERIPHERAL ANGIOGRAPHY|||Y|NON-HEALTH CARE PROFESSIONAL|ADJUDICATOR 2|U|4|Visit_4|65|1|SCREENING|2020-07-24|65|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-31|P1Y2M10DT2H30M|COINCIDENT|2020-08-03|AFTER|2020-08-12
e|RS|158af2a8-d447-45e5-8c58-3b950f1bd889|9|DRCRIND|Disease Recurrence Indicator|CHOLLET BREAST CANCER 2002|[?]|mol/day|INDETERMINATE RESPONSE|1|mU/L|COULOMETRIC TITRATION||||NON-HEALTH CARE PROFESSIONAL|DERMATOLOGIST|U|5|Visit_5|90|4|TREATMENT|2020-08-18|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-24|P1Y2M10DT2H30M|BEFORE|2020-07-03|AFTER|2020-08-15
e|RS|158af2a8-d447-45e5-8c58-3b950f1bd889|10|BMIVLIND|Bone Marrow Involvement Indicator|AJCC V7|||SMD|1|HEP|WRIGHT STAIN|||Y|FAMILY MEMBER|FORENSIC PATHOLOGIST|Y|5|Visit_5|90|5|TREATMENT|2020-08-18|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-06-24|P1Y2M10DT2H30M|AFTER|2020-06-13|AFTER|2020-06-19
e|RS|e9a930d5-ca57-4069-8251-c164273df082|1|CLINRESP|Clinical Response|JACINTO CERVICAL CANCER 2007|[?]|100 IU/mL|VGPR|1|LOZENGE|X-RAY FLUORESCENCE SPECTROMETRY||Y||VENDOR|MICROSCOPIST 1|U|1|Visit_1|10|3|SCREENING|2020-05-21|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-07|P1Y2M10DT2H30M|COINCIDENT|2020-07-21|ONGOING|2020-08-14
e|RS|e9a930d5-ca57-4069-8251-c164273df082|2|MRDIND|Minimal Residual Disease Indicator|CHESON CLL 2006|[?]|ppm|COMPLETE MRD RESPONSE|1|mCi|JAFFE REACTION||||PROXY|DEVELOPMENTAL PSYCHOLOGIST|U|1|Visit_1|10|6|SCREENING|2020-05-21|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-07|P1Y2M10DT2H30M|UNKNOWN|2020-06-27|AFTER|2020-07-15
e|RS|e9a930d5-ca57-4069-8251-c164273df082|3|TRGRESP|Target Response|MRECIST LENCIONI LIVER CANCER 2010|[?]|1/(s*kPa)|mCR|1|nCi|MUGA||Y||HEALTH CARE PROFESSIONAL|ENDOCRINOLOGIST|N|2|Visit_2|25|6|TREATMENT|2020-06-05|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-27|P1Y2M10DT2H30M|COINCIDENT|2020-08-13|COINCIDENT|2020-08-15
e|RS|e9a930d5-ca57-4069-8251-c164273df082|4|MRPHRESP|Morphologic Response|SCHER PROSTATE CANCER 2011|[?]|keV|CMR|1|SUPPOSITORY|IMMUNOCHEMILUMINOMETRIC ASSAY||||INDEPENDENT ASSESSOR|CARDIOLOGIST|U|2|Visit_2|25|7|TREATMENT|2020-06-05|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-27|P1Y2M10DT2H30M|COINCIDENT|2020-06-16|COINCIDENT|2020-06-24
e|RS|e9a930d5-ca57-4069-8251-c164273df082|5|TRGRESP|Target Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|mg2/dL2|iCPD|1|U/mmol|DISK DIFFUSION|Y|Y||INTERVIEWER|MICROSCOPIST 2|NA|3|Visit_3|40|7|TREATMENT|2020-06-20|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-09|P1Y2M10DT2H30M|UNKNOWN|2020-06-09|BEFORE|2020-06-12
e|RS|e9a930d5-ca57-4069-8251-c164273df082|6|CLINRESP|Clinical Response|HAMAOKA BREAST CANCER 2010|[?]|TABLET|PSEUDORESPONSE|1|10^4 CFU/mL|WESTERGREN||||SIGNIFICANT OTHER|INTERNIST|NA|3|Visit_3|40|3|SCREENING|2020-06-20|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-09|P1Y2M10DT2H30M|COINCIDENT|2020-07-23|BEFORE|2020-08-08
e|RS|e9a930d5-ca57-4069-8251-c164273df082|7|NEWLIND|New Lesion Indicator|SCHER PROSTATE CANCER 2011|[?]|g/L|MINOR PATHOLOGIC RESPONSE|1|ug/L FEU|MULTIPLE BREATH WASHOUT||||INDEPENDENT ASSESSOR|CLINICAL PATHOLOGIST|N|4|Visit_4|65|6|TREATMENT|2020-07-15|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-12|P1Y2M10DT2H30M|COINCIDENT|2020-07-26|AFTER|2020-07-29
e|RS|e9a930d5-ca57-4069-8251-c164273df082|8|METSIND|Metastatic Indicator|PROTOCOL DEFINED RESPONSE CRITERIA|||PD-CT|1|BAG|CORONARY ANGIOGRAPHY|Y||Y|SIGNIFICANT OTHER|ONCOLOGIST 1|NA|4|Visit_4|65|5|TREATMENT|2020-07-15|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-12|P1Y2M10DT2H30M|UNKNOWN|2020-06-24|AFTER|2020-07-11
e|RS|e9a930d5-ca57-4069-8251-c164273df082|9|LIVRRESP|Liver Response|GUILHOT CML 2007|[?]|ug/g/min|cPR|1|10^5/L|CONTRAST ENHANCED TRANSESOPHAGEAL ECHOCARDIOGRAPHY|Y|||ADJUDICATOR|ADJUDICATOR|NA|5|Visit_5|90|4|TREATMENT|2020-08-09|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-10|P1Y2M10DT2H30M|COINCIDENT|2020-08-11|COINCIDENT|2020-08-16
e|RS|e9a930d5-ca57-4069-8251-c164273df082|10|CPRFSTAT|Clinical Performance Status|IWG CHESON MDS 2000|[?]|umol/h/mmol|MORPHOLOGIC CRi|1|in|PET/MRI SCAN||||FAMILY MEMBER|RADIOLOGIST 2|Y|5|Visit_5|90|7|FOLLOW-UP|2020-08-09|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-10|P1Y2M10DT2H30M|BEFORE|2020-06-05|COINCIDENT|2020-07-04
e|RS|e654e37e-1c95-4f25-83b1-9233186626c6|1|HEMARESP|Hematologic Response|IRANO 2015|[?]|mL/min/1.73m2|ABSENT MORPHOLOGIC RESPONSE|1|mL/kg|EIA|Y|||CHILD|RADIOLOGIST 2|NA|1|Visit_1|10|3|TREATMENT|2020-08-04|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-26|P1Y2M10DT2H30M|COINCIDENT|2020-09-02|BEFORE|2020-10-12
e|RS|e654e37e-1c95-4f25-83b1-9233186626c6|2|SYMPTDTR|Symptomatic Deterioration|CHESON LYMPHOMA 2008|[?]|genEq/mL|UNFAVORABLE RESPONSE|1|CFU/g|ENZYMATIC COLORIMETRY|Y|Y||HEALTH CARE PROFESSIONAL|DEVELOPMENTAL BEHAVIORAL PEDIATRICIAN|N|1|Visit_1|10|2|FOLLOW-UP|2020-08-04|10|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-09-26|P1Y2M10DT2H30M|BEFORE|2020-07-27|ONGOING|2020-09-02
e|RS|e654e37e-1c95-4f25-83b1-9233186626c6|3|DRCRIND|Disease Recurrence Indicator|BRUGGEMANN MRD 2010|[?]|Bq/mL|MOLECULAR MAJOR RESPONSE|1|TAMPON|OPTICAL DENSITY MEASUREMENT||Y||HEALTH CARE PROFESSIONAL|DEVELOPMENTAL PSYCHOLOGIST|U|2|Visit_2|25|7|TREATMENT|2020-08-19|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-02|P1Y2M10DT2H30M|BEFORE|2020-08-23|BEFORE|2020-09-24
e|RS|e654e37e-1c95-4f25-83b1-9233186626c6|4|BMIVLIND|Bone Marrow Involvement Indicator|BURCOMBE BREAST CANCER 2005|[?]|FFU|CA125 75% RESPONSE|1|oz eq|PERIPHERAL ANGIOGRAPHY||Y||PROXY|RADIOLOGIST 2|NA|2|Visit_2|25|7|TREATMENT|2020-08-19|25|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-02|P1Y2M10DT2H30M|AFTER|2020-09-13|BEFORE|2020-09-23
e|RS|e654e37e-1c95-4f25-83b1-9233186626c6|5|TRGRESP|Target Response|AJCC V8|[?]|mL*cmH2O|PMD|1|DAgU|NEURAMINIDASE INHIBITION ASSAY||Y||STUDY SUBJECT|NEUROLOGIST|Y|3|Visit_3|40|1|WASHOUT|2020-09-03|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-23|P1Y2M10DT2H30M|COINCIDENT|2020-08-28|COINCIDENT|2020-10-23
e|RS|e654e37e-1c95-4f25-83b1-9233186626c6|6|CLINRESP|Clinical Response|MRANO VAN DEN BENT GLIOMA 2011|||NED|1|nm|ENZYMATIC SPECTROPHOTOMETRY|||Y|PARENT|PEDIATRIC NEUROLOGIST|NA|3|Visit_3|40|6|TREATMENT|2020-09-03|40|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-23|P1Y2M10DT2H30M|UNKNOWN|2020-08-26|BEFORE|2020-10-08
e|RS|e654e37e-1c95-4f25-83b1-9233186626c6|7|BMIVLIND|Bone Marrow Involvement Indicator|KUKER LYMPHOMA 2005|[?]|Bq/L|PMR|1|U/mmol|FARNSWORTH-MUNSELL 100 HUE TEST|Y|Y||SIBLING|NEUROLOGIST|Y|4|Visit_4|65|1|TREATMENT|2020-09-28|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-30|P1Y2M10DT2H30M|UNKNOWN|2020-09-19|ONGOING|2020-10-14
e|RS|e654e37e-1c95-4f25-83b1-9233186626c6|8|OVRLRESP|Overall Response|UNSPECIFIED|[?]|beats/min|HI-N|1|U/g Hb|RADIAL IMMUNODIFFUSION|Y|||NON-HEALTH CARE PROFESSIONAL|MICROSCOPIST 1|N|4|Visit_4|65|5|SCREENING|2020-09-28|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-10-30|P1Y2M10DT2H30M|AFTER|2020-08-08|ONGOING|2020-09-30
e|RS|e654e37e-1c95-4f25-83b1-9233186626c6|9|SPLNRESP|Spleen Response|AJCC V8|[?]|/wk|NONE BEYOND PHYSIOLOGIC REPLACEMENT DOSE|1|anti-Xa IU/mL|SINGLE-STRAND CONFORMATION POLYMERASE CHAIN REACTION||||FRIEND|NEUROLOGIST|N|5|Visit_5|90|6|FOLLOW-UP|2020-10-23|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-03|P1Y2M10DT2H30M|UNKNOWN|2020-08-12|ONGOING|2020-08-18
e|RS|e654e37e-1c95-4f25-83b1-9233186626c6|10|OVRLRESP|Overall Response|DURIE MULTIPLE MYELOMA 2006|||CMR|1|100 IU/mL|MIGET||Y|Y|PROXY|READER 1|U|5|Visit_5|90|5|TREATMENT|2020-10-23|90|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-10-03|P1Y2M10DT2H30M|AFTER|2020-09-22|AFTER|2020-10-14
e|RS|808ee0ac-e668-4e8e-aa0a-889476cbe631|1|SFTSRESP|Soft Tissue Response|LEE LUNG CANCER 2011|[?]|kPa/L/sec|mCR|1|Roentgen|IVY INCISION METHOD|Y|||INVESTIGATOR|RADIOLOGIST|U|1|Visit_1|10|4|TREATMENT|2020-06-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-04|P1Y2M10DT2H30M|UNKNOWN|2020-06-28|ONGOING|2020-07-24
e|RS|808ee0ac-e668-4e8e-aa0a-889476cbe631|2|BONERESP|Bone Response|BRUGGEMANN MRD 2010|[?]|kg/cm|MOLECULAR CR|1|GLOBULE|LOOP-MEDIATED ISOTHERMAL AMPLIFICATION||||HEALTH CARE PROFESSIONAL|ONCOLOGIST|U|1|Visit_1|10|6|SCREENING|2020-06-19|10|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-09-04|P1Y2M10DT2H30M|BEFORE|2020-06-23|COINCIDENT|2020-08-25
e|RS|808ee0ac-e668-4e8e-aa0a-889476cbe631|3|NTERESP|Non-Target Enhancing Response|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|10^9 organisms/mg|DISEASE TRANSFORMATION|1|mL*cmH2O|PANENDOSCOPY||Y||HEALTH CARE PROFESSIONAL|OTOLARYNGOLOGIST|N|2|Visit_2|25|1|TREATMENT|2020-07-04|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-13|P1Y2M10DT2H30M|AFTER|2020-09-03|BEFORE|2020-09-05
e|RS|808ee0ac-e668-4e8e-aa0a-889476cbe631|4|TRGRESP|Target Response|CHESON MALIGNANT LYMPHOMA 2007|[?]|cup eq|MORPHOLOGIC CR|1|/LSQN|HPLC/IEX||||INTERVIEWER|RADIOLOGIST 1|NA|2|Visit_2|25|1|SCREENING|2020-07-04|25|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-13|P1Y2M10DT2H30M|BEFORE|2020-06-28|ONGOING|2020-07-21
e|RS|808ee0ac-e668-4e8e-aa0a-889476cbe631|5|CPRFSTAT|Clinical Performance Status|EUROPEAN LEUKEMIANET BACCARANI CML 2006|[?]|Watt|MORPHOLOGIC LEUKEMIA-FREE STATE|1|foz_br|AUSCULTATION||||INDEPENDENT ASSESSOR|ENDOCRINOLOGIST|NA|3|Visit_3|40|4|TREATMENT|2020-07-19|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-18|P1Y2M10DT2H30M|AFTER|2020-06-19|ONGOING|2020-08-12
e|RS|808ee0ac-e668-4e8e-aa0a-889476cbe631|6|METSIND|Metastatic Indicator|LUGANO CLASSIFICATION|[?]|10^6 copies/mL|INCREASED|1|GPS U|PERCUSSION||||INVESTIGATOR|NEUROLOGIST 2|U|3|Visit_3|40|7|FOLLOW-UP|2020-07-19|40|PREVIOUS MEAL|2|P1Y2M10DT2H30M|PREVIOUS MEAL|2020-07-18|P1Y2M10DT2H30M|COINCIDENT|2020-08-01|BEFORE|2020-08-17
e|RS|808ee0ac-e668-4e8e-aa0a-889476cbe631|7|MRPHRESP|Morphologic Response|LUGANO CLASSIFICATION|[?]|DAgU/mL|MAJOR PATHOLOGIC RESPONSE|1|mm2|PHOTOMETRY||||FAMILY MEMBER|OTOLARYNGOLOGIST|NA|4|Visit_4|65|7|TREATMENT|2020-08-13|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-31|P1Y2M10DT2H30M|COINCIDENT|2020-09-15|ONGOING|2020-09-16
e|RS|808ee0ac-e668-4e8e-aa0a-889476cbe631|8|TMRESP|Tumor Marker Response|CHESON HODGKINS NON-HODGKINS LYMPHOMA 2008|||ABSENT MORPHOLOGIC RESPONSE|1|Rad|INFRARED SPECTROMETRY|||Y|SIBLING|RADIOLOGIST 1|N|4|Visit_4|65|6|TREATMENT|2020-08-13|65|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-07-31|P1Y2M10DT2H30M|UNKNOWN|2020-08-24|AFTER|2020-09-13
e|RS|808ee0ac-e668-4e8e-aa0a-889476cbe631|9|METBRESP|Metabolic Response|CHOI GIST 2008|||PMR|1|mL/m2|SLOAN LETTER EYE CHART 100%|||Y|CLINICAL RESEARCH ASSOCIATE|RADIOLOGIST 2|N|5|Visit_5|90|3|TREATMENT|2020-09-07|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-22|P1Y2M10DT2H30M|UNKNOWN|2020-07-07|AFTER|2020-08-11
e|RS|808ee0ac-e668-4e8e-aa0a-889476cbe631|10|NEWLWIND|New Lesion Worsening Indicator|PCWG SCHER PROSTATE CANCER 2008|||MRD RELAPSE|1|copies/ug|WRIGHT STAIN|||Y|CLINICAL RESEARCH ASSOCIATE|MICROSCOPIST|U|5|Visit_5|90|6|SCREENING|2020-09-07|90|PREVIUOUS DOSE|1|P1Y2M10DT2H30M|PREVIOUS DOSE|2020-08-22|P1Y2M10DT2H30M|BEFORE|2020-07-23|BEFORE|2020-08-14
